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P0001 ALTERATIONS OF THE NO-CGMP PATHWAY IN
THIOACETAMIDE-INDUCED LIVER FIBROSIS/CIRRHOSIS IN
RATS
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Introduction: Liver cirrhosis is associated with an imbalance between vasodilation
and vasoconstriction in the sinusoids. Therefore the investigation of the nitric
oxide - cyclic guanosine monophosphate (NO-cGMP) pathway, a key regulator
of vascular smooth muscle tone, is essential.
Aims & Methods: The rat model of thioacetamide (TAA) was used to induce liver
fibrosis/cirrhosis and alterations of the NO-cGMP pathway and subsequent liver
damage were assessed. 25 male Wistar rats were studied (11 untreated controls
and 14 TAA treated animals [0.03 g TAA/100ml drinking water for 16 weeks]).
TAA dosage was adjusted weekly based on body weight changes. Hepatic gene
expression of endothelial and inducible NO synthase (eNOS and iNOS), phos-
phodiesterase 5 (PDE5), soluble guanylate cyclase subunit a1 and b1 (sGCa1 and
sGCb1) was determined by qRT-PCR. Serum cGMP concentrations were mea-
sured by ELISA using blood samples taken from the carotid artery. Likewise
liver damage was assessed by liver chemistry (i.e. alanine- and aspartate-amino-
transferase (ALAT and ASAT), alkaline phosphatase (AP), albumin and bilir-
ubin). The degree of fibrosis was estimated by histological criteria (i.e. Desmet
scores). PDE5-expression was determined by immunohistochemistry. Kruskal-
Wallis test was used for statistical analysis of group differences.
Results: 43% (6/14) of TAA-treated rats developed liver fibrosis (Desmet score of
1–3) while 57% (8/14) developed liver cirrhosis (Desmet score of 4). No major
differences in ALAT, ASAT, and AP serum concentrations were observed in
either group. However, bilirubin was significantly elevated in TAA-treated
rats, while albumin concentrations were significantly reduced. Gene expression
analysis revealed significantly increased expression of eNOS (1.5fold), PDE5
(7.7fold), and sGCb1 (2.1fold) in fibrotic livers compared to controls. cGMP
concentrations in fibrotic animals were slightly decreased (-34%). Significantly
increased expression of eNOS (2.2fold), PDE5 (11fold), sGCa1 (1.7fold) and
sGCb1 (3fold) was observed in cirrhotic livers compared to controls, while
cGMP concentrations were significantly decreased (-40%). iNOS expression
was only detected in fibrotic and cirrhotic livers, but absent in controls.
Immunohistochemistry revealed markedly increased PDE5-expression in cirrho-
tic livers, which was predominantly localized in hepatic stellate cells.
Conclusion: The analysis of the animal model of TAA-induced liver fibrosis/
cirrhosis revealed alterations of the NO-cGMP pathway, characterized by
reduced concentrations of cGMP, a key mediator of vasodilation, due to
increased PDE5-expression. These changes reinforce the hypothesis that sinu-
soids remain in a contractile state in cirrhotic livers, thereby contributing to
portal hypertension. Thus, administration of PDE5-inhibitors, possibly com-
bined with sGC-activators, should be further studied in clinical trials as a pro-
mising therapeutic approach to target portal hypertension.
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Introduction:Mesenchymal stem cell (MSC) therapy is a promising approach that
may preclude the need for liver transplantation. Natural killer cells (NK cells)
have critical antifibrotic effect in part through killing the activated hepatic stel-
late cells (HSCs); and the role of NK cells in fibrotic liver treated with MSCs is
not thoroughly understood.
Aims & Methods: To investigate the effects of bone marrow MSC transplantation
in rats having hepatic fibrosis produced by common bile duct ligation (CBDL)
model with a special focus on the changes of NK population in liver and the
supernatant of splenocyte culture. Rats were divided into three groups: 1- CBDL
rats that were given MSCs (CBDLþMSC), 2- CBDL rats given phosphate-
buffered saline (PBS) (CBDLþPBS), 3- Healthy rats that were sham operated
and given MSCs (HealthyþMSC). MSCs or PBS were injected via the tail vein
of the rats. MSCs were labeled with GFP to check the localization of stem cells
and to get idea for the regenerative capacity in the injured liver. Splenocytes were
isolated from spleen and cultured with Anti-CD3 and Anti CD28. Immunologic
parameters were analysed with flowcytometry.
Results: Histologically, liver fibrosis developed in CBDL rats while the healthy
rats group did not show any alteration in liver architecture. Bilirubin levels were
as follows: Grp 1: 6.80 (5.97–8.01), Grp 2: 6.77 (5.95–7.44), Grp 3: 0.15 (0.11-.14)
mg/dl. T-lymphocyte proliferation was suppressed significantly more in
CBDLþMSC compared to CBDLþPBS group. By measuring the cytokine
levels in supernatants of cultured lymphocytes, we found that CBDLþPBS
group had significantly higher IL-1, TNF- and IFN- levels than health
MSCs. Treatment of those rats with MSCs tended to decrease IL-1, TNF-
and IFN- levels compared to CBDLþPBS group. The splenocyte supernatants
of CBDLþMSC rats showed a tendency towards higher CD4þCD25þ cell and
CD161a cell counts compared to CBDLþPBS. On pathological examination,
liver fibrosis was significantly higher in CBDLþPBS compared to
CBDLþMSC group. The NK distribution was evaluated both in portal and
parenchymal areas of liver. We have found that in the whole liver the NK cells
were depressed significantly in CBDLþPBS group compared to healthyþMSC
group and furthermore in the CBDLþMSC group, NK cells were significantly
increased compared to CBDLþPBS group.
Conclusion: Our findings suggest bone marrow MSCs may be effective in alleviat-
ing the hepatic injury by suppressing the T cell proliferation, increasing the
circulating peripheral NK cell population and CD4þCD25þ and suppressing
the proinflammatory cytokines in rats. Beneficial effects of MSC treatment is
accompanied with significantly alleviated hepatic fibrosis and the significant NK
recruitment to liver parenchyme. Thus, MSC injection treatment may appear
promising in liver injury and future clinical therapies are warranted.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: In chronic HCV infection disease progression is maintained by
sustained necroinflammation and fibrosis in the liver. Upon macrophage activa-
tion, the soluble marker CD163 (sCD163) is released in serum and its levels
correlate with fibrosis and NASH in the liver. The serin protease inhibitor
SerpinB3 (or SCCA1), has been shown to be involved in liver fibrogenesis and
the circulating SCCA-IgM complex has been depicted as a marker of liver disease
progression and of NASH in patients with chronic hepatitis C. Preliminary data
suggest that SerpinB3 activates primary monocytes through the Wnt canonical
pathway. The purpose of this study was to evaluate the relationship between
SCCA-IgM and sCD163 in serum and the possible effect of SerpinB3 on
sCD163 and on pro-inflammatory cytokines expression, in primary monocytes.
Aims & Methods: In 91 patients with biopsy-proven chronic hepatitis C, serum
samples were tested for sCD163 (ng/ml) and SCCA-IgM (AU/ml) by ELISA.
The results were analyzed in relation with clinical and histological parameters.
Primary monocytes were isolated from healthy donors, treated with recombinant
SerpinB3 (200 ng/ml) and supernatants analyzed after 2 and 7 days. Expression
of sCD163 secreted in the supernatant was evaluated by ELISA. In primary
monocytes mRNA expression of IL-12, CXCL-10 and TNF-alpha were also
analyzed by PCR at different time points.
Results: In patients with chronic hepatitis C sCD163 was found correlated with
inflammatory and metabolic alterations (AST, ALT, GGT, HOMA-IR, trigly-
cerides), and was significantly elevated in patients with more advanced histolo-
gical fibrosis stage (F1-F2 vs. F3-F4 sec. Metavir: p5 0.04). Patients with levels
of SCCA-IgM4 200 AU/ml had more elevated serum levels of sCD163
(p5 0.05). In primary monocytes stimulated with recombinant SerpinB3
‘‘in vitro’’, sCD163 expression increased of 2.5 times and this finding was parallel
to an up-regulation of the inflammatory cytokines IL-12, CXCL-10 and TNF-
alpha.
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Conclusion: In chronic hepatitis C SerpinB3 is involved in monocyte activation,
leading to the release of sCD163. These results support the correlation of these
two molecules in serum of patients with more severe liver fibrosis and metabolic
alterations.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0004 THE PROTECTIVE EFFECTS OF GROUP 3 INNATE
LYMPHOID CELLS ON HEPATITIS B VIRUS RELATED LIVER
FIBROSIS COULD BE IMPAIRED BY TH17 CELLS
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Introduction: Th17 cells have been proved to contribute to hepatitis B virus
(HBV) associated liver fibrosis. Group 3 innate lymphoid cells (ILC3s), which
have similar profiles of transcription factor and cytokines to that of Th17 cells,
were also suggested to be involved in the progression of liver fibrosis.
Aims & Methods: The study was designed to explore the functions of ILC3s and
the relationships between ILC3s and Th17 cells in liver fibrosis. Peripheral blood
samples were collected from 60 patients with chronic hepatitis B (CHB), and 50
patients with HBV related liver cirrhosis (LC) as well as 30 healthy controls
(HC). The percentages and cytokines secretion of ILC3s
(LinCD127þCD117þCD294) and Th17 cells (CD4þIL-17þ) were detected by
flow cytometry. Peripheral blood mononuclear cells (PBMCs) and PBMCs with-
out ILC3s co-cultured with hepatic stellate cells (HSCs)-LX2 in contact and non-
contact manners. Then Th17 cells, which were induced from naı̈ve CD4þT cells
in vitro, were transferred into Rag1/ mice with carbon tetrachloride (CCl4)
related liver fibrosis. In addition, ILC3s in Rag1/ mice were depleted by inject-
ing with anti-CD90.2 antibody.
Results: Compared with HC, the percentage of ILC3s increased in CHB group.
The anti-inflammation cytokines secreted by ILC3s such as IL-22 increased,
whereas pro-inflammation cytokines of ILC3s such as IL-17A, TNF-, IFN-
decreased in CHB patients. However, ILC3s decreased in LC patients with
reduced cytokines secretion. Th17 cells frequencies significantly increased both
in CHB and LC groups compared with HC. PBMCs without ILC3s, which were
collected from CHB and LC patients, promoted the proliferation and activation
of HSCs because of less IL-22 secretion. Similarly, compared with wild type mice,
ILC3s in spleens and livers of C57BL/6 mice with liver fibrosis increased sequen-
tially at time point of week 2 and week 4 following drug injection. Intriguingly, at
week 6, ILC3s decreased compared with previous. However, Th17 cells increased
gradually with CCl4 administration, even at week 6. Transferring Th17 cells into
Rag1/mice with liver fibrosis made the ILC3s in spleens and livers decrease
significantly, and the degree of mice liver fibrosis become more severe than
control. Furthermore, ILC3s depletion correlated with reduced expression of
IL-22 and more severe liver fibrosis. Transferring purified liver ILC3s into reci-
pient mice could alleviate liver inflammation and reverse liver fibrosis.
Conclusion: Our study has uncovered the protective role of ILC3s in liver fibrosis,
which is through secrete IL-22 to reduce proliferation and activation of HSCs.
However, the protective functions of ILC3s could be impaired by Th17 cells.
Disclosure of Interest: All authors have declared no conflicts of interest.
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RECEPTOR AND TLR4/NOD2 IN MICE WITH OBSTRUCTIVE
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Introduction: Internal biliary drainage has been confirmed better than external
biliary drainage in alleviating the damage of intestinal mucosa barrier caused by
obstructive jaundice, but the relevant mechanism is still unclear.
Aims & Methods: We aimed to investigate the potential relation between the
expressions of bile acid receptor and TLR4/NOD2 in intestinal mucosa and its
influence on the intestinal mucosal barrier with obstructive jaundice. In this
study, we mainly study the expression between FXR and TLR4, TGR5 and
NOD2. Sixty male adult Kunming mice were randomly assigned to four
groups: SH (shame operation), OJ (obstructive jaundice), ID (internal drainage),
ED (external drainage) (n¼ 15 in each group). On the 7th day from the first
operation, the OJ and SH mice were executed and specimens of blood and ileal
tissue of groups were collected. ED and ID were reoperated on day 8 for biliary
drainage procedure. Blood was drawn from heart for liver function test. The
terminal ileum specimen was collected for test of histology using haematoxylin-
eosin (HE) staining. Western blot (WB) and real-time polymerase chain reaction
(RT-PCR) were used to detect the expression of protein and mRNA Kof
FXRTGR5 KTLR4 and NOD2 in intestinal mucosa.
Results: We have successfully established the animal models. The histopatholo-
gical examination revealed notable inflammatory infiltration and hyperplasia
disruption at terminal ileum in OJ mice; significant alleviation of above injures
by ID while little improvement by ED. FXR-TLR4: After biliary obstruction, the
expression of protein and mRNA of FXR were significantly increased, while the
expression of protein and mRNA of TLR4 were significantly decreased com-
pared with SH group’s (P5 0.001). After ED, compared with OJ group’s, the
expression of protein of FXR was decreased while TLR4 were increased. The
mRNA of both FXR and TLR4 were increased. After ID, the expression of
protein and mRNA of FXR were significantly decreased compared with OJ
group’s but were still higher than that in SH group and were better than ED
group’s. And the expression of protein and mRNA of TLR4 were significantly
increased compared with OJ group’s (P5 0.001), but were still lower than that in
SH group and were better than ED group’s. The trend of TLR4 expression was
almost the same between vehicle group and no gavage group. After gavage with
FXR agonist, the differences of TLR4 expression of four groups disappeared
(P4 0.05). TGR5-NOD2: IHC and WB suggested that after OJ surgery, the
protein expression of both TGR5 and NOD2 increased obviously compared to
that of SH mice; then the level of TGR5 and NOD2 protein fell remarkably after
ID surgery close to SH level while in ED group there was only a slightly reduc-
tion form OJ level and still with a high expression of TGR5 and NOD2 protein.
Detection of RT-PCR found that TGR5 mRNA and NOD2 mRNA level in OJ
group increased several times as that of the SH group; after ID surgery, the
expression of TGR5 mRNA significantly reduced, NOD2 mRNA level also
fell down consistently, but the effect was not observed in ED mice.
Conclusion: The expression of intestinal FXR and TLR4, TGR5 and NOD2
could be one of the critical mechanism why internal drainage is better than
external drainage in restore intestinal barrier function of obstructive jaundice
mice.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Alterations in the gut microbiota have been correlated to a wide
variety of diseases, including liver diseases. Used as probiotics, several strains of
Lactobacillus have been associated not only to modulation of intestinal tight
junctions but also to amelioration of liver fibrosis. Common bile duct ligation
(BDL) results in acute cholestatic injury and secondary biliary fibrosis, associated
with early increased intestinal permeability and disturbed bile acid homeostasis.
We have demonstrated that the oncogenic microRNA-21 (miR-21) is upregu-
lated in BDL mouse liver, mediating liver fibrosis. We aimed to investigate the
role of miR-21 in the response of the small intestinal microbiota to BDL that
may explain miR-21 effects in acute liver injury and fibrosis.
Aims & Methods: Three-month-old C57BL/6 wildtype (WT) and miR-21 whole
body knockout (KO) mice were submitted to sham or BDL surgeries. After three
days, animals were sacrificed and small intestine and its luminal content were
carefully removed and preserved. mRNA expression was analysed by qRT-PCR.
Bacterial DNA was purified from the small intestinal lumen samples and ana-
lysed by next generation sequencing – metagenome analysis. Liver tissue and
serum were also collected for biochemical analysis of hepatic damage and
fibrosis.
Results: TNF- and IL-1-bmRNA levels increased in the small intestine of BDL-
miR-21 KO mice, compared to WT. TLR-4 and TGF-b expression was increased
in both sham- and BDL-miR-21 KO mice which is in accordance with the higher
LPS in blood plasma observed. Zona occludens (ZO-1) and occludin mRNA
levels were decreased in WT mice after BDL. Strikingly, miR-21 KO reverted
mRNA of tight junction proteins to control levels. BDL miR-21 KO mice
showed decreased circulating levels of hepatic enzymes, concomitant with
decreased fibrogenic gene expression in the liver, in comparison with WT mice,
suggesting that miR-21 contributes to BDL-induced liver injury and fibrosis.
Further, mir-21 KO not only show a decreased small intestine permeability
through a ZO-1 and occludin pathway, as it is associated with development of
beneficial strains of Lactobacillaceae that may also contribute to liver protection.
Conclusion: These data suggest that miR-21 depletion is associated with increased
inflammatory markers in the small intestine and better immune response to
bacterial dysbiosis provoked by the BDL surgery, thus halting liver injury and
promoting gut microbiota homeostasis. (Supported by PTDC/BIM-MEC/
089572014, FCT)
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Sorafenib is the only approved systemic therapy for advanced hepa-
tocellular carcinoma (HCC). However, the application of Sorafenib in therapy
has faced increasing challenges due to drug resistance. Drug resistance is known
to be associated with cancer stem cells (CSC). The transcription factor ZBP-89
was reported to be involved in cell growth and apoptosis in tumor and acts as a
potential tumor suppressor in HCC. It has shown that high levels of ZBP-89
expression were statistically associated with better survival of HCC patients.
Unfortunately, the mechanism of ZBP-89 in modulating sensitivity of
Sorafenib in CSC remains unknown.
Aims & Methods: In this study, we investigated the mechanism of Sorafenib
resistance in HCC cancer stem cells, and how ZBP-89 reduced drug resistance.
The sensitivity of Huh7 and Hep3B parental and sphere-forming cells to
Sorafenib was measured by MTT assay. We then examined the expression pat-
terns of Notch1 and liver CSC markers in Huh7 and Hep3B CSC after the
treatment with Sorafenib. MTT assay was also used to measure the effects of
ZBP-89 overexpression on the sensitivity of Sorafenib in sphere-forming cells.
The levels of ZBP-89 and CD44 were measured using q-PCR in human HCC
tissue samples. The regulatory effects of ZBP-89 on CSC phenotype were
explored by various methods including q-PCR, immunoblotting, tumor sphere
formation assay, soft agar formation assay and colony formation assay. Gene
expressions and protein interaction in stemness signaling pathways were
analyzed.
Results: We found that sphere-forming HCC cells had significant higher resis-
tance to Sorafenib, compared with their parental cells. The expression of Notch1
and EpCAM was increased along with the treatment of low dose of Sorafenib,
suggesting that the activation of Notch1 pathway was associated with the drug
resistance in liver CSC. Studies further indicated that ZBP-89 overexpression was
able to improve the sensitivity of Sorafenib on sphere-forming HCC cells.
Furthermore, we found that ZBP-89 expression was negatively correlated with
CSC marker CD44 in human HCC tissues. In vitro study indicated that tumor
sphere formation capacity was impaired upon stable overexpression of ZBP-89,
suggesting that ZBP-89 was involved in suppression of CSC phenotype. Detailed
investigation against control cells showed that overexpression of ZBP-89 resulted
in reduced expression of CSC markers EpCAM, CD133, Sox2 and c-myc at both
mRNA and protein levels. In addition, the overexpression of ZBP-89 or silencing
of Notch1 reduced the number of colonies formed by sphere-forming HCC cells,
demonstrating opposite effects of these two proteins. Mechanistic studies
revealed that ZBP-89 was able to repress the expression of Notch1 and reported
Notch1 target genes including HES1, HES6, HEY1 and NRARP. Amino acids
6–180 of ZBP-89 could directly bind to the activated Notch1 in the nucleus,
resulting in a negative regulation of CSCs and overcome of Sorafenib resistance.
Conclusion: Sphere-forming HCC cells, which contained high levels of Notch1
and EpCAM, were resistant to Sorafenib. The overexpression of ZBP-89 was
found to result in the loss of CSC phenotype and improve the sensitivity to
Sorafenib in CSC through its interaction with activated Notch1. In conclusion,
we believe that targeting ZBP-89 is likely to be a new therapeutic strategy to
overcome the resistance to Sorafenib in HCC.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Accumulating evidence indicates that gut microbiota participates in
the pathogenesis and progression of liver diseases. The severity of immune-
mediated liver injury is associated with different microbial communities.
Akkermansia muciniphila can regulate immunologic and metabolic functions.
However, little is known about its effects on gut microbiota structure and
function.
Aims & Methods: This study investigated the effect of A. muciniphila on immune-
mediated hepatitis and potential underlying mechanisms. Twenty-two C57BL/6
mice were assigned to three groups (N¼ 7–8 per group) and continuously admi-
nistrated A. muciniphila MucT (ATTC BAA-835) or PBS by oral gavage for 10
days. Mouse feces were collected for gut microbiota analysis on the eleventh day,
and acute hepatitis was induced by Concanavalin A (Con A, 15mg/kg) injection
through the tail vein. Samples (blood, liver, ileum, colon) were assessed for liver
injury, systemic inflammation, and intestinal barrier function.
Results: We found that oral administration of A. muciniphila (Akk) decreased
serum ALT and AST and alleviated liver histopathological damage induced by
Con A. Serum levels of pro-inflammatory cytokines (IL-2, IFN-, IL-12p40,
MCP-1, MIP-1a, MIP-1b) were substantially attenuated. Akk significantly
decreased hepatic cell apoptosis; Bcl-2 expression increased, but Fas and DR5
decreased. Further investigation showed that Akk enhanced Occludin and Tjp-1,
two proteins related to strengthened intestinal barriers. Fecal 16S rRNA
sequence analysis indicated that Akk increased microbial richness and diversity.
The community structure of the Akk group clustered distinctly from that of the
Control and Normal groups. Relative abundance of Firmicutes increased, and
Bacteroidetes abundance decreased. Correlation analysis showed that injury-
related factors (IL-12p40, IFN-g, DR5) were negatively associated with specific
genera (Ruminococcaceae_UCG009, Lachnospiraceae_UCG001,
Akkermansia), which were enriched in mice pretreated with Akk.
Conclusion: Our results suggested that A. muciniphila MucT (ATTC BAA-835)
had beneficial effects on immune-mediated liver injury by alleviating inflamma-
tion and hepatocellular death. These effects may be driven by the protective
profile of the intestinal community induced by the bacteria. The results provide
a new perspective on the immune function of gut microbiota in host diseases.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: With the improvement of living standards, obesity, the prevalence
of insulin resistance (IR), hyperlipidemia and diabetes and other metabolic dis-
orders in nonalcoholic fatty liver (NAFLD) in China had increased. NAFLD
refers to the factors caused by exclusion of alcohol and other clear liver damage,
clinical pathological syndrome, and genetic liver steatosis as the main feature of
the link between insulin resistance and other factors closely for acute liver injury
of metabolism. Serious illness can develop into liver cancer. NAFLD has become
the leading cause of chronic liver disease in developed countries and China.
Chronic liver disease is often accompanied by intestinal micro ecological imbal-
ance; studies have shown that the imbalance of intestinal micro ecology led to the
transfer of intestinal endotoxin into the blood, and stimulate the production of
inflammatory factors aggravate liver damage, thus chronic liver disease. A series
of studies show that changes of intestinal microflora, intestinal bacterial over-
growth (small intestinal bacterial over growth, SIBO) and intestinal endotoxemia
in the occurrence and development of NAFLD plays an important role, and the
recovery of intestinal micro ecological balance may have assisted treatment of
NAFLD. A series of studies show that changes of intestinal microflora, intestinal
bacterial overgrowth (SIBO) and intestinal endotoxemia in the occurrence and
development of NAFLD plays an important role, and the recovery of intestinal
micro ecological balance may have assisted treatment of NAFLD.
Aims & Methods: We aimed to study the clinical effect of probiotics in the
treatment of nonalcoholic fatty liver disease. 200 cases of patients with nonalco-
holic fatty liver disease were randomly divided into routine treatment group (A
group) and combined treatment 3 groups (B, C, D). All 50 cases were given orally
Polyene Phosphatidylcholine Capsules, 456mg, TID; The combination therapy
group B was given orally the Live Combined Bifidobacterium Lactobacillus and
Enterococcus Powder, 420mg. TID; group C, two live combined Bacillus subtilis
Enterococcus, 500mg, TID; D group was given orally the both probiotics above.
The course was 1 month. All patients were respectively examined before treat-
ment and seven days and thirty days after treatment, for cholesterol (TC), trigly-
ceride (TG), high density lipoprotein cholesterol (HDL-L), low density
lipoprotein cholesterol (LDL-L), alanine aminotransferase (ALT), aspartate ami-
notransferase (AST), fasting blood glucose (FPG), serum high molecular weight
adiponectin (HMW APN) and serum TNF-a. The 4 groups were collected faeces
samples, that were tested routine detection, bacterial culture. At the same time all
patients were checked with liver ultrasound scan.
Results: In terms of blood lipids and blood glucose, each group improved than
before, only HDL-Lwas not statistically significant, D group showed significant
differences in triglyceride. In liver function, blood ALT, AST were significantly
lower in D group than A group. TNF-a levels were decreased after treatment,
combined treatment D group was statistically significant; group D more than the
group A; serum HMW APN increased after treatment, combined treatment
group D comparing with routine treatment group A was significant difference.
Conclusion: Intestinal probiotics can regulate the intestinal micro ecological
imbalance in NAFLD patients, and reduce the level of serum TNF-a, improve
the level of adiponectin, which can further improve the blood glucose, lipid
metabolism, and then improve the liver injury of non-alcoholic fatty liver disease.
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Introduction: Despite evidence that the microbiota is involved in the pathogenesis
of obesity, the microbiota of patients with nonalcoholic fatty liver disease
(NAFLD) has not been well characterized. NAFLD is considered a hepatic
manifestation of metabolic syndrome and is particularly associated with insulin
resistance, obesity, and gut-driven endotoxin.
Aims & Methods: The aim of our study is to assess if there are any differences in
the microbiota of patients with biopsy-proven NAFLD and healthy controls
(HC). In addition, peripheral blood endotoxin (ET) and gut-permeability was
analyzed in NAFLD (mild fibrosis vs severe fibrosis) and HC patients. A total of
201 patients were enrolled in this study: 68 HC and 143 biopsy-proven NAFLD
(77 mild fibrosis [F0–2] and 56 severe fibrosis [F3–4]). One stool sample was
collected from each participant. All NAFLD patients included in this study
underwent percutaneous liver biopsy. Healthy controls were volunteers. The
composition of gut bacterial communities was determined by 16S rDNA sequen-
cing. In addition, peripheral blood ET was determined using by endotoxin activ-
ity assay (EAA). Gut-permeability was assessed by Lactulose mannitol ratio
(LMR). Trial registration: This trial has been registered in the University
Hospital Medical Information Network (UMIN) Clinical Trials Registry as
UMIN000020917.
Results: Among those taxa with greater than 1% representation in any of the
disease groups, it was significantly decrease in Bacteroidetes at phylum level in
NAFLD compared with HC. At genus level, Faecalibacterium prausnitzii (F.P)
was significantly decreased in NAFLD compared with HC. F.P is significantly
decreased in NAFLD with severe fibrosis compared with those with mild fibrosis
patients. In addition, endotoxin levels were increased in NAFLD with severe
fibrosis than those with mild fibrosis. Furthermore, occupation ratio of F.P
was negative correlation with blood ET levels (R2¼ 0.327, P5 0.0001).
Additionally, it showed a significant correlation among three items of F.B,
EAA and LMR (F.B vs EAA: P5 0.0001, LMR vs EAA: P5 0.0001, LMR
vs F.B: P5 0.0025).
Conclusion: Our study indicated that the change of the gut microbiota and patho-
logic connection were suggested in acknowledgment of the decrease on F.P in the
NAFLD patients. The decreased abundance of F.B in NASH with severe fibrosis,
elevated blood-endotoxin in NAFLD with severe fibrosis patients suggests a role
for ET in the pathogenesis of fibrosis. Moreover, our study showed that the
mechanism of fibrotic progression via the endotoxin in NAFLD may relate
strongly gut-permeability. We postulate that the distinct composition of the
gut microbiota among NAFLD and HC could offer a target for intervention
or a marker for disease.
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Introduction: Non-alcoholic fatty liver disease (NAFLD) has become the most
common liver disease worldwide, and is thought to be strongly associated with
gut microbiota. Several diet models were therefore built in mice to try to clarify
the molecular mechanisms. However, how and to what extent these diet models
alter the composition of the gut microbiota have not yet been clearly elucidated.
Aims & Methods: In this study, we developed three mouse models of NAFLD
using methionine-choline-deficient (MCD) diet, high-fat (HF) diet, and choline-
deficient- high-fat (CD-HF) diet, evaluated the severity of steatohepatitis, and
sequenced the fecal bacteria by targeting 16S V4-V6 regions on Illumina MiSeq
using PE 300 reagents.
Results: Histological scores showed that MCD induced the severest steatohepa-
titis, followed by HF and CD-HF diets. Based on OTUs at cutoff of 97%
similarity, there were significant (PERMANOVA, P¼ 0.001) differences in over-
all gut bacterial communities among MCD, HF, CD-HFD, and the Control,
forming three major clusters in PCA ordination with HF and CD-HF groups
more similar. Furthermore, -diversity of HF and CD-HF groups, including
observed OTU numbers, Shannon index, and Pielou evenness were significantly
(ANOVA, P5 0.05) higher than the Control and MCD group. Overall, mouse
gut bacteria were mainly composed of Fimicutes (Ruminococcaceae,
Lachnospiraceae, Clostridiaceae) and Bacteroidetes (S24-7,
Porphyromonadaceae). More specifically, Ruminococcus was significantly
reduced in the three NAFLD models than the Control, and was identified as
the biomarker of NAFLD in LEfSe analysis. More biomarkers at genus level
(Lachnospira, S24-7, etc.) were identified in pairwise comparison of one mouse
model with the Control.
Conclusion: In summary, the composition of gut microbiota varied remarkably
between mice administrated different experimental diets to induce non-alcoholic
fatty liver disease.
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Introduction: Aproximately 25% of adult population in western countries have
metabolic syndrome (MS). Hyperferritinemia (HF) is frequently present in
patients with MS (dysmetabolic hyperferritinemia). Liver steatosis is often sus-
pected in patients with MS.
Aims & Methods: To study the prevalence of hepatic steatosis determined by
MRI in these patients. A prospective study of 312 consecutive with HF
(4200 mg/L women; 300 mg/L men) and/or TSI4 45%, confirmed in two deter-
minations, was conducted from December 2010 to April 2013. The MS was
defined by the presence of three of the following factors: waist circumference
94 cm men/80 cm women; Triglycerides 150mg/dL or treatment for this
dislipidemia; HDL 540mg/dL women/550mg/dL men or treatment for this
dislipidemia; glucose 100mg/dL or Type 2 diabetes; hypertension: blood pres-
sure 130mmHg/85mmHg or treatment for arterial hypertension (1). LIC was
determined by MRI 1.5 Tesla system (SIR method) (2). We systematically per-
formed T1-weighted in-phase and opposed-phase imaging to determine the pre-
sence or not of liver steatosis.
Results: 312 patients (272 men/40 women) were included. Mean age 55 (SD 13.5);
Mean ferritin 729, 6 (SD 449.6), mean TSI 40, 8 (SD 15.8); 276 patients have all
the required criteria to determine the MS presence: 115/240 men (48%) and 20/36
women (55.6%) presented MS: 135 patients with MS (49%); 141 without MS
(NMS) (51%). In 286 patients a MR study for the presence of liver steatosis was
performed: 196 no steatosis; 90 liver steatosis. 251 patients with MS criteria and
MR for steatosis: NMS group (128): no steatosis 103; steatosis 25; MS group
(123): no steatosis 72, steatosis 51 (total: no steatosis 175, steatosis 76). When we
study if the presence of liver steatosis was more frequent in the MS group, the
results obtained were statistically significant, p¼ 0.000.
Conclusion: Nearly 50% of the patients referred for hyperferritinemia to the
hospitals of our country had MS; the patients with MS had more frequently
liver steatosis than the patients without MS.
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Introduction: In a previous study from our group (1), in a secondary hospital, we
did not find differences in the liver iron concentration (LIC) of the different
groups, and we can not predict liver iron overload for hyperferritinemia (HF)
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patients with HFE mutations and (transferrin saturation index (TSI) values
alone. But we did not have C282Y/C282Y patients in the series.
Aims & Methods: To study the relevance of HFE mutations and TSI in determin-
ing LIC for HF patients attending the outpatient clinic at 6 hospitals in the
Basque country. Prospective study of 312 consecutive patients with HF.
Olynyk et al.(2) described three different groups according to HFE mutations
and TSI (Group A: no predisposing mutations (PM) for HH and TSI4 45 %,
Group B: PM for HH: C282Y/C282Y; C282Y/H63D, H63D/H63D, and
TSI4 45 %; Group C: no PM for HH and normal TSI);Group D: PM and
normal TSI. In the Basque country, hereditary hemochromatosis (HH) predis-
posing mutations differ, with relevance of the H63D/H63D mutation. The LIC
was measured by MRI.
Results: In all the patients HFE study was available: C282Y/C282Y 14 (4.49%);
C282Y/H63D 25 (8.01%); H63D/H63D 47 (15.06%); H63D/wt 99 (31.73%); wt/
wt 98 (31.41%); C282Y/S65C 1 (0.32%); H63D/S65C 2 (0.64%); C282Y/wt 16
(5.13%); S65C/wt 10 (3.21%). LIC was obtained from all the patients by MR.
Mean age: 55 13.5, 272 men and 40 women. Group A: 54, Group B: 32 Group
C:160. Group D: 54. The mean LIC in Group A: 37.21 27.89, group B:
70.53 58.67, group C: 35.23 22.62. Group D: 42.67 22.98. We compared
the LIC mean values of the 4 groups (bonferroni) with significant differences
(p¼ 0.0000).
Conclusion: The LIC in different groups of patients referred for HF are signifi-
cantly different with different predisposition to HH.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
1. Castiella A, Zapata E, Zubiaurre L, et al. Liver iron concentration (LIC) in
patients referred for hyperferritinemia (HF) to a secondary hospital: analysis
of the different groups according to HFE mutations and transferrin satura-
tion index (TSI). UEG journal 2014;2: A293. (P584).
2. Olynyk JP, Gan E, Tan T. Predicting iron overload in hyperferritinemia. Clin
Gastroenterol Hepatol 2009; 7: 359–362.
P0014 LIVER IRON CONCENTRATION IN THE METABOLIC
SYNDROME WITH HYPERFERRITINEMIA (DYSMETABOLIC
HYPERFERRITINEMIA). RESULTS FROM A PROSPECTIVE
COHORT OF 312 PATIENTS
A. Castiella Eguzkiza1, E. Zapata1, I. Urreta2, L. Zubiaurre1, P. Otazua3, J.
M. Alustiza4, E. Salvador4, G. Letamendi5, B. Arrizabalaga6, L. Mendibil1, J.
I. Emparanza2
1Gastroenterology, Mendaro Hospital, Mendaro/Spain
2Clinical Epidemiology, Donostia University Hospital, Donostia/Spain
3Gastroenterology, Mondragon Hospital, Mondragon/Spain
4Radiology, Osatek Donostia, Donostia/Spain
5Hematology, Galdakao Hospital, Galdakao/Spain
6Hematology, Hospital de Cruces, Barakaldo/Spain
Contact E-mail Address: agustincastiella@yahoo.es
Introduction: Aproximately 25% of adult population in western countries have
metabolic syndrome (MS). Hyperferritinemia (HF) is frequently present in
patients with MS (dysmetabolic hyperferritinemia). There are some publications
that support that HF is associated with a raised liver iron concentration (LIC) in
these patients, but some doubts persist about this subject.
Aims & Methods: To study the LIC in patients referred for hyperferritinemia to
six different hospitals in the Basque Country (multicenter study), Spain, and
determine if there are differences between patients with or without metabolic
syndrome. A prospective study of 312 consecutive patients with HF (4200mg/
L women, 4300mg/L men) was conducted from December 2010 to April 2013.
The Metabolic syndrome was defined by the presence of three of the following
factors: waist circumference 94 cm men/80 cm women; Triglycerides 150mg/
dL or treatment for this dislipidemia; HDL 540mg/dL women/550mg/dL men
or treatment for this dislipidemia; glucose 100mg/dL or Type 2 diabetes; hyper-
tension: blood pressure 130mmHg/85mmHg or treatment for arterial hyper-
tension (1). LIC was determined by MRI (SIR method) (2).
Results: In 276 of 312 patients we have all the data to determine the MS presence:
115/240 men (48%) and 20/36 women (55.6%), 135 patients, presented MS. In all
276 patients MRI for LIC determination (mean SD) was performed. (We have
LIC results (mmol/g) from the 276 patients). The mean LIC was 30.83 19.38
(women) and 38.84 25.50(men), with 37.66 24.79 (CI 95%; 33, 44 to 41, 88)
for all the MS group. In 141 patients MS was not diagnosed (NMS): 125/240
were men (52%), and 16/36 women (44.4%). The mean LIC was 34.88 16.18 in
women, and 44.48 38.16 in men, with 43.39 36.43(CI 95%, 37, 32 to 49, 46)
for all the NMS group. We compare the mean values of LIC from both groups
(MS vs NMS) by Pearson’s Chi square test and Fisher’s exact test: no significant
differences were seen (p¼ 0.12).
Conclusion: Patients with HF and MS (dysmetabolic hyperferritinemia) present a
mean LIC near normal values and their values do not differ from those of
patients with HF and without MS.
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Introduction: Alternatively activated anti-inflammatory macrophage (also termed
M2 Kupffer cell) is important for prevention of the development of steatosis and
liver injury in non-alcoholic fatty liver disease (NAFLD). Our previous studies
demonstrated that interleukin (IL)-25 was downregulated in NAFLD mice and
exogenous IL-25 protected against NAFLD by inducing M2 Kupffer cells.
Aims & Methods: We aimed to explore the intracellular signaling pathways of IL-
25 to regulate macrophage polarization and direct effects of IL-25 on Kupffer
cells. Mouse model of NAFLD was induced by feeding a high-fat diet (HFD);
In vitro expansion of mouse Kupffer cells, IL-10 and IL-25 were used to induce
M2a Kupffer cells; specific siRNAs were used to knockdown IL-25 receptor
mRNA for assessing the direct and specific effect of IL-25 on Kupffer cells;
IL-25 induced M2a Kupffer cells were back transfusion into the abdomen of
NAFLD mouse to assess the efficacy; Dual-luciferase reporter assays and
Chromatin immunoprecipitation assays were used to determine the transcription
factor of IL-25 promoter.
Results: Exogenous IL-25 induced expression of type 2 cytokine and alternative
activation of Kupffer cell in vivo. It could also promote hepatic macrophages to
differentiate into M2a Kupffer cells in vitro. Interestingly, IL-25 recovered the
expression of IL-25 mRNA in the liver of NAFLD mice. Furthermore, IL-25
could induce the expression of IL-25 in cultured hepatocytes by activation of
STAT6, rather than MZF1, AP1 or NF-B. STAT6 was sufficient and necessary
for IL-25 expression. Deletion and site-directed mutagenesis of the IL-25 pro-
moter revealed that IL-25 transcriptional activation depended primarily on a
putative STAT-binding sequence between nucleotides 682/674 upstream of
the start site. STAT6 binding to this sequence increased in response to IL-25
treatment in vitro and in vivo. Finally, IL-25 induced M2a Kupffer cells could
ameliorate HFD-induced hepatic steatosis by reducing M1 Kupffer cells.
Conclusion: Our results elucidate the molecular mechanisms of IL-25 during
amelioration of hepatic steatosis and provide the scientific basis of direct IL-25
treatment or macrophage transfusion therapy for NAFLD.
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Introduction: NASH is considered an important risk factor for liver fibrosis.
Although literature data indicates that statins may be beneficial when given for
NASH treatment, recent reports are controversial 1.
Aims & Methods: To evaluate if statins independently influence the evolution of
fibrosis accompanying NASH using the scales of FibroMax, 120 patients with
NASH and metabolic syndrome were followed-up for a period of 3 years. We
excluded patients taking a serie of drugs, with genetic metabolic disorders or
impaired intestinal absorption (celiac disease) or alcoholics. Steatosis, fibrosis
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and NASH were quantified by using the FibroMax scales at baseline and after
three years of statin treatment. Patients were randomized in two groups: the
active group of 60 patients receiving low-dose hydrophilic statin (rosuvastatin
5mg/day) and the witness group of 60 patients, matched by age, gender and sex,
receiving placebo.
Results: 97% of subjects fulfilled the follow-up period. The FibroMax staging at
baseline showed the following results in the active group: S1–29%, S2–41% and
S3–30%; F1–50%, F2–30%, F3–13% and F4–7% of patients, respectively N1–
31% and N2–69%. The staging according to FibroTest, SteatoTest and
NashTest was similar in placebo group. After 2 years of low-dose hydrophilic
statin, the mean ALT level from active group decreased from 72.22 IU/L to
32.80 IU/L, p5 0.05 (ss); in the witness group no significant ALT decrease
was noticed (69.34 IU/L to 58.17 IU/L, p4 0.5). The FibroMax showed an
important improvement of steatosis and fibrosis in active group, compared
with the witness group. After three years of statins, our active group was strati-
fied as follows: S0–27%, S1–46%, S2–25%, respectively S3–2% of patients,
respectively F0–38%, F1–32%, F2–28%, F3–2%; F4–0% of patients.
NashTest also proved a positive evolution under statin treatment, compared
with placebo (N0–36%, N1–40% respectively N2–26%, p4 0.001, ss) After
adjusting for age, BMI, diabetes, LDL-cholesterol and triglyceride levels, statin
therapy showed a significant correlation with the steatosis, fibrosis and NASH
stages improvement in the active group (r¼ 0.92, r¼ 0.87, respectively r¼ 0.95,
p5 0.005, ss).
Conclusion: While statins proved to be safe and efficient for the treatment of
NASH in our series, larger cohort studies are needed to further demonstrate this
potential positive effect on liver fibrosis.
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Introduction: Methylenetetrahydrofolate reductase (MTHFR) is the key enzyme
in homocysteine metabolism. It is thought that MTHFR A1298C and C677T
gene polymorphisms contribute to etiopathogenesis of NASH because of their
effects in homocysteine metabolism.
Aims & Methods: Our aim in this study is to determine the relationship between
the NASH and MTHFR C677T and A1298C gene polymorphisms, especially in
non-obese NASH patients. Eighty-eight NASH patients whose diagnoses were
confirmed by liver biopsies and 90 healthy volunteers as control group were
included in the study. We investigated MTHFR A1298C and C677T gene poly-
morphisms and compared NASH patients and controls. NASH patients were
assigned to two groups according to whether they are obese.
Results: Eighty-eight NASH patients (52M, 36F, mean age 45 years), and 90
healthy controls (53M, 37F, mean age 41 years) were included in the study.
According to BMI values of NASH patients, 55 patients were non-obese and
33 patients were obese. There was no statistically significant difference between
distribution of MTHFR A1298C polymorphism of NASH patients and controls
(p4 0.05). The proportion of TT genotype of MTHFR C677T polymorphism of
NASH patients was significantly higher than that of controls (p5 0.01). Also the
proportion of TT genotype of MTHFR C677T polymorphism of non-obese
NASH patients was significantly higher than that of controls (p5 0.01).
However, the proportion of TT genotype of MTHFR C677T polymorphism of
obese NASH patients was not significantly different than the control group
(p4 0.05). MTHFR C677T CC (wild) genotype was significantly lower in
non-obese NASH patients than controls (p5 0.05).
Conclusion: This study revealed that TT genotype of MTHFR C677T poly-
morphism is more frequent, especially in non-obese NASH patients than in
healthy controls. This finding shows that genetic factors are particularly more
important in non-obese NASH patients.
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Introduction: The importance of subclinical inflammation and hyperhomocystei-
nemia in the development of nonalcoholic fatty liver disease (NAFLD) needs
further study.1 Recent studies have shown that the development of hyperhomo-
cysteinemia and an increase in the level of C-reactive protein contributes to
increased oxidative stress, influences the development of metabolic disorders,
which makes it possible to consider these indicators as additional markers for
the development of NAFLD in patients with abdominal obesity (AO).
Aims & Methods: We aimed to study the relationship between CRP and homo-
cysteine (HC) levels with pathological changes in the liver, determined with the
non-invasive bioprognostic test Steatoscreen in patients with AO. The study
included 60 patients aged 18 to 59 years with joints with a waist circumferen-
ce480 cm for women, over 94 cm for men. All patients underwent a bio-prog-
nostic test Steatoscreen. Depending on the severity of the pathological changes in
the liver, the Steatoskrin scale divided all the patients into 3 groups: steatosis,
fibrosis and steato- fibrosis. Depending on the presence or absence of cytolysis
syndrome, 2 subgroups were distinguished in each group: subgroups of non-
alcoholic steatohepatitis (ALT values, AST above the norm more than 2
times), and steatosis. In all patients, the levels of CRP and GC were studied.
Results: In groups of patients with fibrosis and steato-fibrosis, the levels of CRP
and HC were significantly higher than in patients in the steatosis group, and the
highest values of these parameters were recorded in patients in subgroups with
non-alcoholic steatohepatitis. In the process of correlation analysis, significantly
positive interrelations between the levels of CRP and HC were obtained with the
levels of severity of pathological changes in the liver on the Steatoscrin scale:
r¼ 0.6 h o5 0.001; r¼ 0.85 h p5 0.0016 for CRP and HQ, respectively.
Conclusion: NAFLD in patients with AO is characterized by the development of
a complex of metabolic disorders associated with chronic vascular inflammation.
This fact can influence the risk of developing the pathology of not only the liver,
but also atherosclerosis and proves the need for a more thorough examination of
patients with AO and NAFLD for the purpose of early detection and correction
of existing metabolic disorders.
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Introduction: In the last decade, the notion of non-alcoholic fatty liver disease
(NAFLD) has undergone noticeable changes. It is shown that in the liver with
fatty hepatosis, insulin and glucose utilization is disrupted, conditions are created
for the synthesis of atherogenic fractions of cholesterol and triglycerides. This
contributes to the development of violations of carbohydrate and lipid metabo-
lism, the early appearance of atherosclerosis and associated cardiovascular com-
plications. Thus, NAFLD can be considered as an independent, additional risk
factor for the development of atherosclerosis. Obviously, the studies devoted to
clarifying the nature of the relationship between NAFLD and the early manifes-
tations of atherosclerotic vascular wall lesions are relevant.
Aims & Methods: Study of changes in the vascular wall of the common carotid
artery (IMT CCA) and in patients with abdominal obesity (AO) and different
forms of nonalcoholic fatty liver disease (NAFLD). The study involved 60
patients with AO between the ages of 18 to 59 years (waist circumference
(WC) 480 cm in women and 494 cm in men), and NAFLD, in the absence of
clinical manifestations, provided written informed consent to participate in the
study. All patients underwent an ultrasound examination of the abdominal cavity
to determine the size of the liver and signs of steatosis. The level of severity of
pathological changes in the liver tissue (fibrosis, steatosis and steatofibrosis) was
assessed by non-invasive diagnostic method Steatoskreen. (Biopredictive labora-
tory, France). Measurement of the CCA IMT was performed according to stan-
dard procedures on the machine Voluson 730 Expert, equipped with a linear
transducer phased array with a frequency of 7.5 MHz. The presence of early
signs of atherosclerosis was defined as a local thickening of the IMT CCA more
than 0.9mm in any point of the carotid artery (CCA IMT max). Depending on
the severity of the pathological changes in the liver, the Steatoskreen scale
divided all the patients into 3 groups: steatosis, fibrosis and steatofibrosis.
Depending on the presence or absence of cytolysis syndrome, 2 subgroups
were distinguished in each group: subgroups of non-alcoholic steatohepatitis
(ALT values, AST above the norm more than 2 times), and steatosis. In the
future, comparative and correlation analysis of the data was carried out.
Results: Signs of early atherosclerosis, in the form of the IMT CCA, were
detected in the majority of the patients (52%) and differed between the observed
groups. The average thickness of the IMT CCA was significantly higher in
patients with abdominal obesity and pathological changes in the liver in the
form of severe steatofibrosis on the Steatoscreen scale than in groups of patients
with less severe changes in hepatic tissue (0.83mm for the steatosis group, 0.89
and 0.97mm for fibrosis and steatofibrosis groups respectively, p5 0.001). At
the same time, the maximum thickness of the IMT CCA was recorded in the
group of patients with non-alcoholic steatohepatitis in the fibrosis group
(1.14mm, p¼ 0.002). In the process of regression analysis, a direct significantly
relationship was found between the thickness of the carotid intima-media
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complex and pathological changes in the liver, determined by the test
Steatoscreen (r¼ 0.76; p5 0.0001). The dependence obtained is confirmed by
the equation of simple linear regression.
Conclusion: In patients with AO, there is a direct relationship between the pre-
sence of pathological changes in the liver and the initial manifestations of ather-
osclerosis. The results obtained make it possible to evaluate the individual risk of
atherosclerosis in this category of patients. Clinical significance of the results is
the need for a more thorough examination of patients with AO and suspicion of
liver pathology to assess the development of not only the disease of the liver itself,
but also cardiovascular complications.
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Introduction: Insulin resistance is the main pathogenic determinant of both
NAFLD and diabetes, and it can facilitate triglyceride accumulation in the
liver. Overexpression of hepassocin (HPS) increased hepatic lipid accumulation
and NAFLD activity scores (NAS), whereas deletion of HPS improved high fat
diet-induced hepatic steatosis and decreased NAS in mice.
Aims & Methods: The aim of this study was to explore the relationship between
hepassocin and diabetic patients with or without NAFLD. The study included 80
patients that were divided into 4 groups: Group I: included 20 patients who were
diagnosed as diabetes mellitus type 2, Group II: included 20 patients who were
diagnosed as non alcoholic fatty liver disease, Group III: included 20 patients
who were diagnosed as diabetes type 2 and non alcoholic fatty liver disease,
Group IV (control group): included 20 healthy person who were matched in
age and sex with patients group.
Results: There was stastically significant decrease in mean value of serum hepas-
socin of group 1 and IV on comparing with group II and group III. For group III
there was stastically significant increase in mean value of serum hepassocin on
comparing with other groups. There was a significant serum hepassocin up reg-
ulation in patients with type 2 diabetes and non alcoholic fatty liver diseased
patients (Group 3) mostly than diabetic patients (Group 1) and even than non
alcoholic fatty liver disease (Group 2).
Conclusion: The present study provides evidence that overexpression of HPS may
facilitate increased hepatic lipid accumulation with NAFLD and Type 2 Diabetes
mellitus.
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Introduction: Visceral adipose tissue (VAT) and gut are thought to be the main
two sources of damage factors promoting non-alcoholic fatty liver disease
(NAFLD). As one part of VAT, mesenteric adipose tissue (MAT) may be
unique in VAT for it can affect liver directly via portal vein. However, the
relationship of MAT status with different stages of NAFLD is not clear, as
well as the role of inflamed MAT in NAFLD.
Aims & Methods: Mice fed with high fat diet or normal diet were sacrificed in
time gradients (4w, 8w, 12w). Then, MAT in high fat diet feeding mice was
removed or not at 8th week and mice were sacrificed by 12th week.
Results: Mice have developed hepatic steatosis at 8th week and progressed to
steatohepatitis by 12th week. Among four parts (mesenteric, epididymal, perire-
nal and retroperitoneal) of VAT, merely MAT became inflamed (mRNA
expression of TNF- increased, P5 0.01 and IL-10 decreased, P5 0.05) by
8th week, which happened to coincide with the presence of hepatic steatosis.
Removal of inflamed MAT significantly worsened liver pathology, as well as
resulted in hepatic inflammation (mRNA expression of MCP-1 increased,
P5 0.01 and IL-10 decreased, P5 0.01) and lipid accumulation (mRNA expres-
sion of ACC1 increased, P5 0.01 and PPAR- decreased, P5 0.01). Meanwhile,
intestinal permeability was higher in the MAT removal group than that in the
Sham group, which was supported by higher lipopolysaccharide (P5 0.05) in
serum and lower mRNA expression of ZO-1 (P5 0.01) and occludin (P5 0.05)
in small intestine.
Conclusion: These results suggest MAT inflammation arises at the early stage of
NAFLD. Removal of inflamed MAT promotes the development of NAFLD and
injures the intestinal barrier. Thus, we propose that MAT inflammation seems to
be a compensatory response, on the fact that inflamed MAT protects the liver
from the gut-derived damage factors via confining them within MAT, rather than
aggravates NAFLD.
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Introduction: Non alcoholic fatty liver disease (NAFLD) is a broad term descrip-
ing simple steatosis, non alcoholic steatohepatitis (NASH), NASH cirrhosis and
NASH-induced hepatocellular carcinoma (1). Incidence increased in patients
with type 2 diabetes mellitus (DM) (2). Different diagnostic modalities have
great limitations in differentiating simple staetosis from steatohepatitis (3).
Liver biopsy remains the gold standard for diagnosis of NASH, however, it is
invasive with potential severe complications (4). Several ultrasound elastography
techniques have been descriped incluing transient elastography, acoustic radia-
tion force impulse elastography and shear wave elastography(5). Shear wave
elastography shows a stepwise increase of liver stiffness as the severity of liver
inflammation increases(6).
Aims & Methods: We aimed to evaluate the accuracy of shear wave ultrasound
elastography in differntiating simple steatosis from steatohepatitis in patients
with type 2 DM. This was a prospective study including 60 patients 30 males
and 30 females who visited our outpatient clinic or inpatient department at
Specialized Medical Hospital. These patients were diabetic aged more than 30
years old with ultrasound showing fatty liver. Significant alcohol consumption,
drugs causing steatosis and hepatic diseases were excluded by history, laboratory
investigations and liver biopsy. All patients underwent full detailed history,
examination, laboratory investigations (complete blood count, liver functions,
kidney functions, random blood sugar, lipid profile, serology for hepatitis B
and C viruses). Shear wave elastography was performed to all patients and stiff-
ness of the liver was measured from different areas in kilopascal (kPa) then
average stiffness by elastography was calculated. Liver biopsy was done and
histopathological examination by Hematoxlin, Eosin and Masson Trichrome
stains, then NAFLD activity score (NAS) was calculated.
Roc curve for diagnosis of definitive NASH versus no NASH and probable NASH
Variable Criterion AUC CI P. Senstivity Specificity PPV NPV
Average
stiffness by
elastography
8.45 0.936 0.871–1 50.001 90% 90% 81% 94%
Results: Correlation between results of stiffness by elastography and NAS by
biopsy revealed that: There was a significant positive association between average
stiffness by elastography and definitive NASH (NAS 5 and 6) in patients with
type 2 DM. At a level of 8.45 kPa by shear wave elastography, we can differntiate
simple steatosis from steatohepatitis (Area Under Curve 0.936, senstivity 90%,
specificity 90%, positive predictive value 81%, negative predictive value 49%).
Conclusion: Shear wave ultrasound elastography is a promising non invasive
technique to diffferntiate simple steatosis from steatohepatitis in patients with
type 2 DM.
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Introduction: Nonalcoholic fatty liver disease is a main cause of chronic liver
disease worldwide. A quantitative, non-invasive assessment of hepatic steatosis
is desirable. Throughout the path of ultrasound (US), attenuation by liver par-
enchyma is uneven. This is the basis of the controlled attenuation parameter
(CAP). However, further accumulation of data is needed to assess the role of
CAP in the diagnosis of steatosis1). We investigated the diagnostic performance
of B-mode image-guided ultrasound attenuation imaging and quantification for
assessing hepatic steatosis by a liver biopsy (LB, reference standard). It was
compared with the liver-to-spleen ratio (L/S ratio) from computed tomography
(CT) and CAP.
Aims & Methods: We prospectively analyzed 112 consecutive patients with
chronic liver disease who underwent ultrasound attenuation imaging, CT, and
liver biopsy. Ultrasound attenuation imaging was performed using the LOGIQ
E9 scanner (GE Healthcare) with a C1-6-D convex array probe (frequency, 4
MHz). We acquired a B-mode image of liver parenchyma. RF signals corre-
sponding to the images were compensated by the reference signal previously
measured from the uniform phantom (known attenuation, 0.5 dB/cm/MHz)2).
The attenuation coefficient (AC) was calculated from the signals’ decay slope.
Steatosis, liver fibrosis, and necroinflammatory activity were staged and graded
during pathological analysis. The steatosis grade was categorised as follows: S0,
55%; S1, 5–33%; S2, 34–66%; or S3, 67%. The diagnostic performance of AC
for steatosis prediction was assessed using area under the curve (AUC) analysis;
it was compared with the L/S ratio or CAP. Univariate and multivariate regres-
sion analyses were used to identify variables correlated with AC values.
Results: Patients (51% men; 42% had non-alcoholic fatty liver disease, 58% had
hepatitis C virus) had a median body mass index of 26 kg/m2. Median AC values
for grades S0 (n¼ 38), S1 (n¼ 47), S2 (n¼ 18), and S3 (n¼ 9) were 0.49, 0.55,
0.66, and 0.72, respectively, demonstrating a stepwise increase with increasing
steatosis severity (P5 0.0001). AC was significantly correlated with the steatosis
percentage (r¼ 0.800, P5 0.0001), L/S ratio (r¼ -0.670, P5 0.0001), and CAP
(r¼ 0.639, P5 0.001). AUCs of AC vs. the L/S ratio for identifying grades S1,
S2, and S3 were 0.919 vs. 0.856, 0.957 vs. 0.902, and 0.960 vs. 0.919, respec-
tively, showing significantly better results than those for the L/S ratio and CAP.
For the sensitivity and specificity of AC 85%, cut-off values were 0.53 dB/cm/
MHz for S1, 0.60 dB/cm/MHz for S2, and 0.64 dB/cm/MHz for S3.
Steatosis was the only factor independently affecting AC values.
Conclusion: Ultrasound attenuation imaging had a high diagnostic accuracy for
detecting hepatic steatosis.
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Introduction: Individuals with chronic liver diseases may have a mild to moderate
iron overload, but the mechanism is not fully understood. Increased contents of
iron have been attributed to the progression of liver cirrhosis caused by HCV
infection, non-alcoholic fatty liver disease, or alcoholic liver disease. Serum fer-
ritin concentration can be increased in iron overload and shows hepatic necro-
inflammation. Recently, raised serum ferritin concentration was shown to predict
mortality in patients awaiting liver transplantation in decompensated liver cir-
rhosis, but according to latest research plasma ferritin levels can help to predict
the early mortality of patients with alcoholic liver cirrhosis (ALC).
Aims & Methods: The aim of this study was to determine the association between
serum ferritin concentration and the outcomes of patients with ALC. The study
included 72 patients with ALC. The diagnosis and etiology of ALC was con-
firmed by laboratory tests, clinical features, radiological imaging, and percuta-
neous or tranjugular liver biopsy. Alcoholic liver disease was confirmed when
daily consumption of alcohol was 4 30 g/20 g/day for males/females, respec-
tively, as confirmed by at least 1 family member of affected individual. All
patients were divided into three groups by serum ferritin concentration: below
200 mg/l, 200–400 mg/l and above 400mg/l. Statistical analysis was performed
using statistical software SPSS 23.0. ROC (Receiver operating characteristic)
scale was used to estimate serum ferritin specificity in predicting early mortality.
If the area under the curve (AUC) is greater than 0.5, the test is specific.
Results: The first group consisted of 44 patients, the second group 13 patients, the
third group 15 patients. The average age was 57.5 11.7 years. Serum ferritin
concentration in first group was 58.2 45.9mg/l, second 293.5 63.5mg/l, third
599.5 221.1 mg/l. AST concentration in first group was 90.8 70.2 IU/l,
second – 96.7 58.3 IU/l, third – 133.8 95.5 IU/l. ALT concentration in first
group was 66.7 66.8 IU/l, second – 64.5 75.5 IU/l, third – 60.1 49.5 IU/l.
Bilirubin concentration in first group was 90.52 85.7mmol/l, second –
111.9 72.3mmol/l, third – 140.9 195.0mmol/l. The biggest mortality rate was
in third group – 13 of 15 patients (86.67 %) (p5 0.00001). ROC scale shows a
77% specificity of serum ferritin concentration predicting early mortality in
patients with toxic cirrhosis (AUC 0.838, p5 0.0001).
Conclusion: Serum ferritin level above 400 mg/l, elevated liver enzymes and bilir-
ubin concentration shows a poor outcome of patients with ALC (p5 0.0001).
Serum ferritin level is a specific indicator for predicting early mortality in ALC.
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Introduction: Reticulon 4 (RTN4) protein was first described as a potent neurite
growth inhibitor in the central nervous system1. However, according to recent
research, the protein expression is not limited to the cells of nervous system as it
was found in various other tissues, including endothelial cells, fibroblasts, muscle
cells, hepatocytes1, 2, 3. The diverse location of the protein accounts for various
functions, such as vascular remodeling, inflammation and oxidative stress, cell
proliferation, carcinogenesis and atherogenesis2, 3, 4, 5, 6. The function and
expression of the protein in liver disease is still not clear.
Aims & Methods: In this study we aimed to evaluate plasma levels of RTN4
protein in cirrhotic patients and associate them with clinical parameters and
portal hypertension. The pilot study included 72 patients with hepatitis C or
alcoholic liver cirrhosis and 22 healthy controls. Liver cirrhosis was diagnosed
by laboratory tests, radiological imaging and/or liver biopsy. Portal pressure was
assessed by hepatic venous pressure gradient (HVPG) measurement. Plasma
levels of RTN4 were determined by enzyme-linked immunosorbent assay.
Association of RTN4 with biochemical parameters, Child-Turcotte-Pugh and
Model of End Stage liver disease (MELD) score, transient elastography values,
esophagogastric varices, HVPG, clinically significant portal hypertension
(CSPH; HVPG 10 mHg) and severe portal hypertension (SPH; HVPG 12)
was assessed.
Results: Plasma RTN4 levels were significantly lower in cirrhotic patients than in
healthy controls (p5 0.0001). Significant negative correlation was observed
between RTN4 and Child-Pugh score (r¼ -0.301; p¼ 0.015), MELD score
(r¼ -0.311; p¼ 0.026), transient elastography values (r¼ -331; p¼ 0.006). There
was significant correlation between RTN4 and AST (r¼ -0.307, p¼ 0.005), ALP
(r¼ -0.396; p¼ 0.001), total bilirubin (r¼ -0.426; p5 0.0001), thrombocytes
(r¼ 0.534, p5 0.0001), INR (r¼ -0.357, p¼ 0.002) concentrations. RTN4 corre-
lated with HVPG (r¼ -0.298; p¼ 0.011) and predicted CSPH (p5 0.001) as well
as SPH (p5 0.0001). Using a RTN 4 cut-off value of 1.7 ng/ml, the AUC for
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detection of CSPH was 0.71, with positive predictive value of 75% and negative
predictive value of 63%, sensitivity 70% and specificity 71%. RTN4 value of
1.1 ng/ml was associated with esophagogastric varices (odds ratio [OR]¼ 3, 63;
p5 0.022).
Conclusion: Low levels of RTN4 are associated with liver cirrhosis and portal
hypertension. RTN4 correlates with liver function. It may be a surrogate marker
of CSPH and presence of esophagogastric varices.
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Introduction: Peritoneal carcinomatosis (PCA) has a prognostic role in patients
with gastrointestinal cancers. Despite the low sensitivity, cytology remains the
gold standard in differential diagnosis of PCA to peritonitis (for example spon-
taneous bacterial peritonitis, SBP) or uncomplicated ascites due to portal hyper-
tension (no SBP/PCA). MicroRNAs (miRNAs) are considered as promising
biomarkers and are commonly dysregulated in cancer.
Aims & Methods: In this proof-of-principle study, we systematically evaluated
preanalytical factors and potential of miRNAs as ascites biomarkers. We pro-
spectively examined samples from patients with ascites with benign and malig-
nant conditions including: PCA (n¼ 15), SBP (n¼ 15) and portal hypertension
(no SBP/PCA, n¼ 15). Various extraction kits were used to compare the total
RNA extraction. Furthermore, we systematically evaluated the influence of sto-
rage, stability and sample processing (uncentifuged, pelleted etc.) on miRNA
expression in ascites. MiRNA expression profiling using TaqMan Low Density
Array (TLDA) and quantitative RT-PCR (TaqMan/SYBRgreen) were used to
evaluate the expression.
Results: Systematic analysis of miRNAs stability confirms that miRNAs in
ascites are well preserved from degradation with good short- (0 h, 12 h, 24 h,
and 48 h) and long-term stability (-30C, 80C for 2 years). Several miRNAs
that were selected for the proof-of-principle analysis (miR-21 and miR-16) were
reproducibly detectable in ascites samples. MiRNA expression profiling in
patients with PCA compared to those with uncomplicated portal hypertension
revealed miR-21, miR-186, miR-222 and miR-483-5p to be up-regulated and
miR-26b to be down-regulated. MiRNA expression validation analysis con-
firmed higher expression of miR-21 (mean delta CTSD; 11.11 1.2 vs.
8.46 3.46 vs. 9.65 2.55 for no SBP/PCA, PCA and SBP, respectively,
ANOVA, p¼ 0.026; posttest no SBP/PCA vs. PCA p5 0.05) and miR-186 in
patients with PCA compared to no SBP/PCA groups, while miR-223 was sig-
nificantly upregulated in SBP (meanSD; 12.16 1.56 vs. 10.05 3.19 vs.
6.95 3.56 for no SBP/PCA, PCA and SBP, respectively, ANOVA,
p5 0.0001; posttest SBP vs no SBP/PCA and vs. PCA p5 0.05).
Conclusion: Our data provide novel evidence for the differential expression of
miRNAs in ascites in patients with PCA and SBP. Evaluation of ascites-miRNAs
may offer an alternative approach for diagnosis of peritoneal carcinomatosis and
create an avenue for therapeutic application as well.
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Introduction: Pathological bacterial translocation (PBT) in liver cirrhosis (LC) is
the pathophysiological hallmark for spontaneous bacterial infections increasing
mortality several-fold. Factors known to contribute to PBT in LC are among
others an increased intestinal permeability.
Aims & Methods: A clear route of translocation for luminal intestinal bacteria is
yet to be defined but we hypothesize that the recently described gut vascular
barrier (GVB) is impaired in experimental portal hypertension leading to protein
loss and increased accessibility of the vascular compartment for translocating
bacteria. For this purpose two different models of experimental portal hyperten-
sion, namely partial portal vein ligation (PPVL) and bile duct ligation (BDL)
were used in mice under standardized gnotobiotic conditions (sDMDM2). A
novel in vivo confocal endomicroscopy technique was established in order to
visualize the intestinal vascular leakage. Briefly, 70 kDa FITC-marked dextran
was injected intravenously and confocal probe was placed in the intestinal lumen
(terminal ileum) to visualize villus-capillaries. Leakage was measured over time
(10 minutes) as a ratio between the mean fluorescent intensity outside the vessel
(lamina propria) and inside the vessel. Immunofluorescence (IF) stains of the
fenestral diaphragms marker plasmalemma vesicle-associated protein-1 (PV-1)
were performed for GVB analysis.
Results: Confocal endomicroscopy data revealed an earlier and significantly
increased leakage of 70kDA through the intestinal vasculature in both BDL
and PPVL mice. FITC-70kDA-dextran did only leak in BDL and PPVL but
not in control (sham operated) mice. Interestingly GVB stains showed increased
expression of PV1 in intestinal vessels (CD34þ) of BDL but not PPVL.
Conclusion: Portal hypertension per se has an impact on the GVB increasing
FITC-70 kDa-dextran leakage from intestinal capillaries to the lamina propria
in both BDL and PPVL. However, the IF showed only in BDL an increased PV-1
expression indicative of a wider opening of the fenestral diaphragms than in
PPVL. Therefore, different mechanisms appear to be involved in alterations of
the gut-vascular barrier in pre-hepatic portal hypertension and biliary cirrhosis.
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Introduction: Splenomegaly is a common finding in liver cirrhosis. However, the
precise underlying mechanisms behind this phenomenon have not been eluci-
dated, and its effective therapies are limited.
Aims & Methods: We aimed to investigate whether cyclooxygenase-2 (COX-2) is
involved as a contributing factor in the pathological process of splenomegaly in
cirrhotic rats. Thirty-six male Sprague-Dawley rats weighing 200–250 g were
randomized into 3 groups with 12 rats in each group. The control group received
intraperitoneal injection of normal saline (1ml, twice a week); the TAA group
received intraperitoneal injection of thioacetamide (TAA, 200mg/kg, twice a
week for 16 weeks); the TAAþ celecoxib group received TAA intraperitoneally
and celecoxib via gastric gavage (20mg/kg/day). The portal pressure was mea-
sured by portal venous catheterization. Sections from paraffin-embedded spleens
were stained with hematoxylin and eosin and Sirius Red, and immunostained
with VEGF and CD31. The protein expressions of COX-2, VEGF, PI3K, p-
AKT, and AKT in the spleen were assessed by Western blot. The enzyme-
linked immunosorbent assay was performed to evaluate the expression of
TNF-a and IL-1b in the spleen.
Results: The ratio of splenic weight to body weight increased by 73.9% in TAA
group, while in rats treated with celecoxib, the ratio was significantly reduced.
While determined by H&E staining, areas of splenic white pulp in the TAA group
enlarged by 27.9%. Yet, compared with that in TAA group, celecoxib obviously
decreased the area of splenic white pulp by 37.6%. Besides, the portal pressure
elevated by 79.1% in the TAA group; while significant reduction of the portal
pressure was observed in the TAAþ celecoxib group (by 28.8%). In addition, a
considerable amount of collagen was visualized with Sirius Red staining in the
splenic red pulp of TAA group. Decreased splenic fibrosis was found in
TAAþ celecoxib group. Increased COX-2 protein was detected in the spleen of
the TAA group compared with that in the control group. However, celecoxib
significantly reduced the expression of COX-2 in the TAAþ celecoxib group.
Besides, compared with the control group, TNF-a and IL-1b, the two proinflam-
matory cytokines were found to be greatly increased in the TAA group. On the
contrary, in TAAþ celecoxib group, the protein expression of TNF-a and IL-1b
was obviously reduced. We also found that the expression of proangiogenic
factor VEGF and the neovascular marker CD31 increased in TAA group by
Western blot and immunohistology, which indicated a role of angiogenesis in
the pathophysiology of splenomegaly. Furthermore, up-regulation of PI3K and
p-AKT protein expression was detected in the spleen of TAA group compared
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with that of the control group, demonstrating that PI3K/AKT signal pathway
was involved in the development of pathological angiogenesis. However, the
treatment with celecoxib strongly decreased the protein expression of VEGF,
CD31, PI3K and AKT in the spleen of cirrhotic rats.
Conclusion: The present study indicates that COX-2 contributes to splenomegaly
by facilitating angiogenesis, fibrosis and inflammation in the spleen. Moreover,
inhibition of COX-2 by celecoxib could ameliorate portal hypertension and
splenomegaly
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Introduction: Spontaneous bacterial peritonitis (SBP) is a life-threatening com-
plication in advancing liver cirrhosis. Translocation of intestinal bacteria or
bacterial products from the gut to mesenteric lymph nodes is crucial for SBP,
with Escherichia coli (E. coli), Klebsiella pneumoniae being the most common
germs. Small intestinal bacterial overgrowth and a altered microbiota are so
far known as risk factors for SBP. However, the exact mechanisms of bacterial
translocation need to be identified as they are supposed to contribute to the
development of early recognition systems and initiation of antibiosis.
Aims & Methods: With regard to the development of early recognition systems,
pathomechanisms and signaling pathways of bacterial translocation in SPB were
explored. These insights might lead to an initiation of antibiosis on time and
reduced mortality in SBP.
Monolayers of human intestinal epithelial cell lines Caco-2 (p53 mutant) and
HCT-116 (p53 wildtyp) were cocultured with E. coli with different MOI (MOI
0, 1, 5 and 10) for 2 to 4 hours post confluence. Experiments with heat inactivated
E. coli were performed as controls. Effects of microbial metabolic products were
tested by using the supernatant of an overnight culture. qPCR and Western Blot
analysis were performed to analyze changes in mRNA and protein levels of
Occludin, E-cadherin and the p53 family including p53 and p73.
Results: E. coli stimulation of HCT-116 cells resulted in a strong decrease of
Occludin, E-cadherin, p53 and p73 protein levels. These changes were dependent
on incubation time and bacterial concentration. Following bacterial infection,
marginal to no effects were detected on mRNA levels of cellular junctions and
p53. Caco-2 cells displayed less reduction of Occludin and E-cadherin protein
levels compared to p53-wildtyp HCT-116 cells.
Conclusion: By using an in vitro model, we demonstrate destabilizing effects of E.
coli on intestinal cell junctions, p53 and p73. As far as these effects are dependent
on incubation time, microbial concentration and living bacteria, these effects
might represent a mechanism to protect bacteria from intestinal immune
responses and therefore to promote bacterial translocation in SBP.
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Introduction: Pathological bacterial translocation (PBT) in liver cirrhosis (LC) is
the pathophysiological hallmark for spontaneous bacterial infections increasing
mortality several-fold. Factors known to contribute to PBT in LC are among
others an increased intestinal epithelial permeability.
Aims & Methods: Since mucus represents one of the major components of this
barrier we hypothesize that i) gut mucus is altered in LC and ii) bile could be a
modulator of its production. Two different models of experimental LC –namely
bile duct ligation (BDL) and the chronic treatment with carbon tetrachloride
(CCl4) – as well as partial portal vein ligation (PPVL) and sham-operated mice
were used. Finally the farnesoid X receptor (FXR) agonist obeticholic acid
(OCA) was used as treatment in CCl4-LC and control-animals. Mucus thickness
measurement on gut explants and PAS (Periodic acid–Schiff) staining to visualize
and count goblet cells (GC) were utilized.
Results: We have observed a significant reduction in mucus thickness in ileum
and colon (Control 101.34 mm 9.54 vs BDL 77.49 mm 14.31 in Ileum; control
154.38mm 12.51 vs BDL 100.74mm 0.6 in proximal colon) and goblet cell
numbers in ileum (Control 0.47 GC/100mm of villus 0.07 vs BDL 0.29 GC/
100 mm of villus 0.04) of mice following BDL but not PPVL (Control 0.27 GC/
100 mm of villus 0.11 vs PPVL 0.30 GC/100 mm of villus 0.04). Moreover we
have seen that farnesoid X receptor (FXR) agonist obeticholic acid (OCA) par-
tially restored GC loss in CCl4 treated animals (Control 0.63 GC/100 mm of
villus 0.08 vs Control OCA 0.65 GC/100mm of villus 0.07 vs CCl4 0.49
GC/100mm of villus 0.18 CCl4 OCA 0.57 GC/100 mm of villus 0.09).
Conclusion: All these results suggest that a reduced bile production by the cir-
rhotic liver and not portal hypertension per se interfere in the goblet cell devel-
opment and/or maturation. In addition, this effect can be, at least partially, be
restored by the FXR agonist OCA. Our study opens the possibility to a, so far,
unknown effect of bile salts in the intestinal epithelium development in the con-
text of liver cirrhosis being a clear candidate for mucus layer regulation and
hence protective effect against bacterial translocation.
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Introduction: Liver fibrosis refers to the excessive accumulation of extracellular
matrix (ECM) following a chronic liver injury. It is characterised by an increase
in gene expression of proinflammatory molecules such as TGF-b1, IL-1 b, IL-6
and TNF-a, as well as excess synthesis in of ECM components such as COL-1.
Capsaicin (CAP) is a pungent compound found in chilli peppers which has shown
anticarconogenic, antiinflammatory and antifibrotic properties. Moreover, sul-
foraphane (SFN) is an isothiocyanate which is in cruciferous such as broccoli and
it has exhibit an antioxidant effect in several in vitro and in vivo models.
Aims & Methods: The objective of this project was to evaluate the antifibrogenic
and antiinflammatory effects of a daily supplementation with CAP and SFN in a
rat model of liver fibrosis due to carbon tetrachloride (CCl4) intoxication. 35
male Wistar rats were included (n¼ 7/group); animals were administrated intra-
peritoneally 3 times per week during 8 weeks with a mix of CCl4:mineral oil (1:5/
week 1, 1:4 week 2 and 1:3 week 3–8). Healthy and CCl4-fibrotic controls
received only supplementation vehicle (Tween 2% in PBS). Treated groups
receive SFN 5ug/kg, or CAP 2mg/kg, or both supplements daily by oral
gavage since the beginning of CCl4-intoxication regimen until sacrifice. Masson
staining and PCR was performed in liver samples. Hepatic enzymes were ana-
lysed in serum.
Results: Groups treated with CAP and SFN showed a decrease of 30points in
percentage of liver fibrosis according to Masson staining (p5 0.05), hepatic
function improve since AST and ALT serum levels diminish (p5 0.01) also a
lower gene expression of TGF-b1, Col-1, TNF-a, IL-1 b and IL-6 was detected in
treated animals when compared with fibrotic controls (p5 0.01).
Conclusion: Thus, CAP and SFN seem to exert a hepatoprotective effect in this
model of chronic-induced liver damage. These findings suggest that dietary
sources of CAP and SFN might be included in dietetic guidelines for the preven-
tion of liver fibrosis.
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Introduction: Gastric variceal bleeding is common complication, and it is asso-
ciated with higher morbidity and mortality rates than hemorrhage from esopha-
geal varices. Oesophagogastroduodenoscopy is usually the initial investigation in
patients with portal hypertension for the purpose of the distinction between
gastric varices and gastric folds. The aim of this study was to investigate endo-
scopic color Doppler ultrasonography (ECDUS) findings of gastric varices.
Aims & Methods: Two hundred-fifteen patients with gastric varices were evalu-
ated with ECDUS. To begin with, identification of gastric varices was performed
with B-mode scanning and then, color flow mapping was done. On B-mode
scanning, submucosal gastric varices, and para-gastric collateral veins were
obtained as hypoechoic vessels within gastric wall or in the tissue and spaces
exterior to the adventitia of gastric wall. ECDUS provides a color display of
blood flow and evaluates the flow pattern using fast Fourier transform (FFT)
analysis. FFT analysis can indicate the flow pattern and calculate the velocity of
blood flow. We monitored the color flow images of gastric varices, and para-
gastric or peri-gastric collateral veins. Endoscopic findings of gastric varices were
evaluated according to the grading system outlined in The General Rules for
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Recording Endoscopic Findings of Esophago-gastric Varices devised by the
Japanese Research Committee on Portal Hypertension.
Results: The color flow images of gastric varices and peri-gastric veins were
delineated in all 215 patients with ECDUS. Evaluation of blood flow velocity
in the 215 gastric varices revealed velocities of 7.7–35.7 cm/s (mean,
18.2 6.0 cm/s). Mean velocity of large, coil-shaped (F3) type gastric varices
was 23.7 6.2 cm/s (n¼ 52), while the mean velocity of enlarged tortuous (F2)
type gastric varices was 16.7 5.0 cm/s (n¼ 163). The velocities of F3 type gastric
varices were significantly higher than those of F2 type (P5 0.0001). Next, we
evaluated the wall thickness to submucosal gastric varices. Two hundred-fifteen
of the gastric varices were 1.0–2.2mm (1.6 0.4mm) in gastric wall thickness.
Mean thickness of red color (RC) or erosion positive varices was 1.2 0.2mm
(n¼ 42), while the mean thickness of RC or erosion negative varices was
1.7 0.3mm (n¼ 173). The thickness of RC or erosion positive varices was sig-
nificantly thinner than that of the negative cases (P5 0.0001). Seven cases of the
215 patients had the current history of gastric variceal bleeding, and the other
three cases had experienced variceal rupture on follow up (bleeding cases, n¼ 10),
and mean thickness of these bleeding cases were 1.2 0.2mm.
Conclusion: ECDUS is a useful modality for the diagnosis of hemodynamics of
gastric varices and may allow the stratification of patients into low, high risk for
hemorrhage.
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Introduction: Liver cirrhosis and portal hypertension are associated with esopha-
geal varices, gastric varices, small and large intestinal enteropathies.
Aims &Methods:We aimed to study the prevalence of colopathy and ileopathy in
patients with portal hypertension secondary to liver cirrhosis. Chronic hepatitis C
patients with portal hypertension secondary to liver cirrhosis were enrolled. The
severity of cirrhosis was classified by the Child-Pugh score. All patients were
evaluated by upper endoscopy and colonoscopy for screening of portal hyper-
tensive complications. Esophageal varices were graded as small, moderate and
big varices. Portal hypertensive gastropathy was classified as absent or present,
and, if present, it was sub-classified as mild or severe. Colonoscopy was done up
to terminal ileum in all patients.
Results: Our study included sixty chronic hepatitis C patients with portal hyper-
tension secondary to liver cirrhosis (53.33% females) their mean age (SD) was
54.75 (13.13) years. Child-Pugh class was A for 2 (3.4%), B for 33 (55.9%) and
C for 24 (40.7%). 53 (88.33%) patients had esophageal varices (23 patients had
small esophageal varices, 15 had moderate, and 8 had big varices, 2 post-band
ligation and 5 obliterated varices). Gastric varices were present in 3 patients
(5%). Portal hypertensive gastropathy was noted in 43 patients (71.6 %) and
was mild in 38 and severe in 5 patients. Colonoscopy finding up to the terminal
ileum revealed that portal hypertensive colopathy was present in 16 patients
(26.7%). portal hypertensive ileopathy was noted only in one case (1.7%). No
colonic or ileal varices were noted.
Conclusion: Portal hypertensive colopathy but not ileopathy is common in
Egyptians with liver cirrhosis. Ileal varices and ileopathy are not common in
patients with cirrhosis and PHT.
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Introduction: Acute-on-chronic liver failure (ACLF) is a specific clinical form of
liver failure in patients with liver cirrhosis, referred as acute deterioration of liver
function associated with an acute specific complication of liver cirrhosis. ACLF
is defined by the presence of renal failure or 2 organ failures according to
European Association for the Study of the Liver-International Chronic Liver
Failure consortium: 1) circulatory- need for vasopressor support; 2) renal-
serum creatinine value 2mg/dL; 3) cerebral- Grade III or IV hepatic encepha-
lopathy; 4) respiratory- SpO2/FiO2 214.
Aims & Methods: We aimed to identify predictive factors for ACLF development
in cirrhotic patients admitted for variceal gastrointestinal bleeding. All patients
admitted with gastrointestinal bleeding in the Institute of Gastroenterology and
Hepatology Iasi (consisting of 8 secondary hepatology centers) between June and
December 2016 were evaluated for ACLF (we excluded from the study the
patients presenting ACLF diagnosis criteria on admission). We compared cirrho-
tic patients who developed ACLF after 12 hours of admission with those who did
not.
Results: 99 cirrhotic patients with gastrointestinal bleeding were evaluated.
48.5% of patients admitted with variceal bleeding developed ACLF.
Demographic data were similar in patients with ACLF vs. no ACLF in age
(54.2 7.3 vs. 56.6 9.5 years), male sex (54 vs. 45), and diabetes (56 vs. 43)
and significant difference was found in alcohol consumption (72 vs. 27). In
patients with ACLF, the grade 1 was the most frequent (56.3%); grade 2
(33.3%) and 3 (10.4%) of ACLF were more rare and no significant differences
between the ACLF subgroups was observed. The patients with ACLF were more
likely to be admitted with infections and alcohol consumption, when compared
to patients without ACLF. Independent predictors for ACLF development
included a high admission MELD (p5 0.05), presence of infection and alcohol
abuse (p5 0.001), hospitalization in the last 6 months (p5 0.05). Inhospital and
30-day mortality were significantly higher in patients with ACLF (p5 0.0001).
Conclusion: Patients admitted with variceal bleeding, with alcohol consumption,
high MELD on admission, previous admission in 56 months are more likely to
develop ACLF and need to be monitored closely for the development of ACLF.
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Introduction: Cirrhosis is characterized by both bleeding and thrombotic compli-
cations due to underlying procoagulative haemostatic imbalance [1]. Among
thrombotic events, portal vein thrombosis (PVT) is the most common with
annual incidence ranging between 4.6% and 12.8% [2, 3]. Demonstrated asso-
ciated risk factors are severity of portal hypertension and slowed portal flow [4].
However, data regarding haemostasis in the portal venous system of cirrhotics
are lacking.
Aims & Methods: To evaluate peripheral and portal venous haemocoagulative
state in patients with cirrhosis in comparison with controls, through thrombin
generation test (TGT), rotational-thrombelastometry (ROTEM) along with eva-
luation of endothelial dysfunction by quantification of circulating endothelial-
microparticles (MP). Correlate these results with activity levels of local pro and
anticoagulant factors. Compare peripheral and portal venous districts in cirrho-
tics in terms of haemostatic balance. We consecutively enrolled adult patients
with liver cirrhosis undergoing liver transplantation (LT) or transjugular intra-
hepatic portosystemic shunt (TIPS). Patients without liver disease awaiting liver
surgery or deceased liver donors were enrolled as controls. The following labora-
tory tests were performed on citrated peripheral and portal venous blood sam-
ples: TGT with and without thrombomodulin (TM), ROTEM, dosage of main
pro and anticoagulants factors activity and analysis of circulating endothelial
MP.
Results: 25 cirrhotics (15 LT and 10 TIPS) and 6 controls (2 undergoing hepatic
resection for benign liver lesions and 4 liver donors) were enrolled. Peripheral
blood in cirrhotics showed resistance to activation of PC-pathway at TGT (ETP
with/without TM 0.89 (0.78–0.92) vs 0.6 (0.3–0.74), p5 0.001), lower clot stabi-
lity at ROTEM (MCF-NATEM mm: 43.5 (36–51) vs 63 (53–69), p¼ 0.042), and
significant increase of endothelial-MP (CD62EMP/L: 1391 (651–2301) vs 582
(380–1161), p¼ 0.046), indicative of higher endothelial damage compared to
controls. Similar results were obtained comparing portal blood of cirrhotics
and controls (ETP with/without TM 0.89 (0.78–0.92) vs 0.63 (0.33–0.75),
p¼ 0.001; MCF-NATEM mm: 46 (39–51) vs 62 (49–66), p¼ 0.056; CD62E-
MP/L: 1606.5 (680–1885) vs 529.5 (266–781), p¼ 0.069). There was a significant
correlation between diminished levels of PC, PS, AT, FII and either TGT or
ROTEM parameters. Comparing portal and peripheral blood of cirrhotics, we
detected endogenous heparinoids in portal blood (-angle NATEM 51 (46–57) vs
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HEPTEM 57 (50–59), p¼ 0.05). This finding, together with a decreased concen-
tration of endothelial-MP carrying TM (TM-MP/L: 232 (190–287) vs 377 (218–
493), p¼ 0.002) and endothelial-PC receptor (EPCR/CD65E-MP/L: 16 (14–25)
vs 37 (24–70), p5 0.001), demonstrated a local greater endothelial damage in
cirrhotics.
Conclusion: In cirrhotics, venous hypercoagulability and portal site specific
endothelial damage, associated with hampered antithrombotic properties, may
be important local risk factors in the pathogenesis of PVT along with the docu-
mented venous stasis.
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Introduction: In clinical trials rifaximin- (RFX) has been shown to reduce recur-
rence of episodes of overt hepatic encephalopathy (HE) and HE-related hospi-
talisations. UK real-world data confirmed reductions in hospital admissions and
length of stay with RFX use; however, data on use of emergency department
(ED; A&E in UK) resources are still scarce. This study assessed the impact of
RFX on utilisation of ED resources.
Aims & Methods: Patients from 11 UK hospitals who were prescribed RFX for
HE between July-2008 and May-2014 were included in this retrospective obser-
vational study. Patient records were reviewed; details of demographic and clinical
characteristics, and all-cause ED attendances and admissions were collected in
the 6 and 12 months pre- and post-RFX initiation. The analysis included only
patients who were alive at the end of the study periods.
Results: Of the 145 patients included, 114 (79%) were alive at 6 months and 102
(70%) at 12 months post-RFX initiation. At RFX start, mean age was 61 years,
63% were male; 67% had alcohol-related liver disease; for patients with available
MELD score (70%), the mean was 16; 78% were on lactulose. Use of ED
resources in the 6 and 12 months pre- and post-RFX initiation is shown in
Table 1. Six patients developed adverse events, none serious.
Conclusion: In UK clinical practice, treatment with RFX for HE is well-tolerated
and associated with significant reductions in ED attendances, with or without
admission, both within 6 and 12 months of RFX initiation.
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Introduction: Hepatic encephalopathy (HE) is a frequent complication of liver
cirrhosis, with necessity of hospital admission in many cases. The economic
burden of HE is substantial. After ascites, HE is the second most common
reason for hospitalization of cirrhotic patients. HE is also the most common,
possibly preventable, cause for readmission.
Aims & Methods: We aimed to assess the factors associated with the increased
likelihood of hospital readmission for HE after the onset episode.
We completed a retrospective Retrospective analysis of admissions for HE of
patients with liver cirrhosis, between October 2010 and October 2015. Only the
onset episode was included. Patients were followed for 1 year or until readmis-
sion for HE. All payients were discharged under lactulose therapy. Descriptive
statistics, uni and multivariate analysis, logistic regression, and ROC curves
analysis were performed using IBM SPSS Statistics 22 with p5 0.05 deemed
to be statistically significant.
Results: In this study 119 patients were included: 78% men with a mean age of
59 13 years; 8% had hepatocellular carcinoma, and 45% had Child-Pugh C.
The most frequent cirrhosis etiologies were alcoholic disease (60%) and HCV
infection (12%). The precipitating factors, for the onset episode, more frequently
detected were diuretic overdose (36%) and infection (31%). All patients were
treated with standard therapy, with an adequate lactulose dose. The readmission
rate after the first episode of HE was 72% (75% men). The estimated average
time to relapse was 18 weeks. The most frequent causes of readmission were also
diuretics overdose (31%) and infection (30%). The patients who were readmitted
had a higher MELD score than patients without recurrence (13.9 vs. 11.6 points;
p¼ 0.015). This association was verified in the multivariate analysis (OR¼ 1.1,
p¼ 0.044).
Conclusion: In this cohort, there was a high rate of readmission for HE after the
inaugural episode, which carries a great impact on individual health and high
socio-economic costs. A higher MELD score was independently associated with a
high probability of readmission for HE.
Disclosure of Interest: All authors have declared no conflicts of interest.
Reference
1. Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital readmissions
among patients with decompensated cirrhosis. Am J Gastroenterol. 2012.
107(2):247–52
Abstract No: P0037
Table 1: All-cause ED attendances, with and without admission, pre- and post-RFX initiation
6 Months (N¼ 114) 12 Months (N¼ 102)
Resource use parameter* n# Pre-RFX initiation Post-RFX initiation Py n# Pre-RFX initiation Post-RFX initiation Py
ED attendances with or without admission 81 264 118 – 82 325 217 –
ED attendances with or without admission/patient 81 2.3 (0.3) 1.0 (0.2) 50.001 82 3.2 (0.5) 2.1 (0.4) 0.023
ED attendances without admission 61 118 60 – 62 151 114 –
ED attendances without admission/patient 61 1.0 (0.2) 0.5 (0.1) 50.001 62 1.5 (0.3) 1.1 (0.2) 0.116
Admissions via ED 74 146 58 – 76 174 103 –
Admissions via ED/patient 74 1.3 (0.2) 0.5 (0.1) 50.001 76 1.7 (0.3) 1.0 (0.2) 0.009
Bed days/patient admitted via ED 74 18.2 (2.6) 7.2 (2.0) 50.001 76 23.2 (3.4) 11.4 (2.7) 0.002
*Data are presented for all surviving patients at the end of the 6 months (N¼ 114) or 12 months (N¼ 102) as mean (standard error of the mean, SEM) per patient
Number of patients with 1 ED attendance/admission in the observed periods yPaired t-test
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Introduction: The regulations for prescribing interferon-free treatment for
patients infected with hepatitis C virus in Romania comprised only patients
with F3/F4 fibrosis so the risk of hepatic decompensation and complications
was higher compared to other cohorts. In previous interferon-based regimens,
thrombocytopenia and hypoalbuminemia as markers for portal hypertension and
hepatic synthetic dysfunction, respectively, have been shown to reduce the like-
lihood of sustained virological response and to increase the rates of serious
adverse events.
Aims & Methods: The aim of this study was to evaluate the impact of thrombo-
cytopenia and hypoalbuminemia on treatment outcome and disease complica-
tions. We included in this study 855 HCV-infected cirrhotic patients treated with
ombitasvir/paritaprevir/rþdasabuvirþribavirin for 12 weeks in 10 university hos-
pitals in Romania. The following groups were studied: 151 patients (17.7%) with
albumin 53.5 g/dl, 239 (28%) with thrombocytopenia (a cutoff of 100000/mmc
was used) and 71 patients (8.3%) with both hypoalbuminemia and thrombocy-
topenia before initiating antiviral treatment. Safety (as AE in 45% and SAE),
efficacy (defined as HCV RNA undetectable at week 12 post-therapy and com-
plication rate were evaluated using Pearson’s correlation, multivariate analysis
and Chi-Square test.
Results: Main patient characteristics were: 100% genotype 1 b, a median age of
60 yo, 466 women (54.57%), high rate of previous interferon based-treatment
(36.1%). End-of-treatment and sustained virological response rate were both
499% and there was no correlation with the presence of thrombocytopenia or
hypoalbuminemia. The rate of adverse events in the whole cohort was 17.5% at 2
weeks reaching 18% at the end of treatment with only 0.8% severe adverse events
with no statistical association with the presence of thrombocytopenia and
hypoalbuminemia. The multivariate analysis showed significant asscociation of
thrombocytopenia (5100000/mmc) with higher (41) degree of oesophageal
varices (p5 0.001), onset of upper digestive hemorrhage during treatment
(p¼ 0.011), and prior exposure to interferon based regimens (p¼ 0.025). Low
albumin (53.5 g/dl) also correlated with higher (41) degree of oesophageal
varices (p5 0.001) and onset of upper digestive hemorrhage during treatment
(p¼ 0.002)
Conclusion: The efficacy and safety of the ombitasvir/paritaprevir/
rþdasabuvirþribavirin (as recomended by national regulations) was not different
in cirrhotic patients with hypoalbuminemia and thrombocytopenia, but compli-
cations rate was higher so close follow-up and profilactic measures should be
recommended, especially if previously exposed to interferom containing
regimens.
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Introduction: In the UK multicentre, retrospective, real-world study, IMPRESS,
rifaximin- (RFX) use in patients with hepatic encephalopathy (HE) significantly
reduced hospitalisations and length of stay in the 6 and 12 months post-RFX
initiation compared to the respective periods pre-RFX initiation. This post-hoc
analysis of the IMPRESS data compared hospital resource use pre- and post-
RFX initiation in 2 sub-groups of difficult-to-treat HE patients: those with
advanced liver disease or ongoing alcohol misuse.
Aims & Methods: Medical records of patients from 11 UK hospitals who were
prescribed RFX for HE between July-2008 and May-2014 were retrospectively
reviewed; details of demographic and clinical characteristics, and all-cause hos-
pital admissions were collected in the 6 and 12 months pre- and post-RFX
initiation. Patients with baseline MELD score 15 or not abstinent at the end
of the study period were included in this analysis. Statistical significance of the
mean change (standard error of the mean, SEM) was calculated using paired t-
test or Wilcoxon test.
Results: Only patients alive at the end of the 6 and 12 months RFX-treatment
periods were included: 114 and 102, respectively. Amongst these, 33/114 (29%,
for the 6 months) and 26/102 (25%, for the 12 months) had baseline MELD 15;
mean age, 63 years; 70% were male; 66% had alcohol-related liver disease; mean
MELD 24. The mean (SEM) number of bed days/patient reduced from 25 (6.0)
in the 6 months pre- to 15 (5.5) in the 6 months post-RFX initiation, and from 36
(9.5) in the 12 months pre- to 20 (7.7) in the 12 months post-RFX initiation (p
value not significant). At 6 months post-RFX initiation, 15/114 (13%) patients
were still actively drinking. At RFX initiation, mean age was 56 years; 73% were
male, mean MELD was 19. Despite this, the mean (SEM) number of bed days/
patient decreased from 36 (7.9) in the 6 months pre- to 15 (5.4) in the 6 months
post-RFX initiation (p¼ 0.048), and the mean of hospitalisations/patient fell
from 2.8 (0.8) to 1.2 (0.4) (t-test p¼ 0.059; Wilcoxon test p¼ 0.029). Too few
patients with continued alcohol misuse were alive at 12 months to evaluate. Two
patients reported adverse events, none serious.
Conclusion: In UK clinical practice, treatment with RFX for HE for 6 or 12
months suggested trends in reduced hospital length of stay in patients with
advanced liver disease and in those with continued alcohol misuse. However,
larger studies are needed to strengthen these findings.
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Introduction: Bacterial infections are common in cirrhotic patients and the pro-
inflammatory response superimposed on the hemodynamic dysfunction of portal
hypertension predisposes to the development of complications. Some authors
suggest that the occurrence of infection should be considered a separate clinical
stage, since it alters the natural history of cirrhosis.
Aims & Methods: Retrospective assessment of patients with cirrhosis hospitalized
for first episode of decompensation between 2011–2015. The aim was to evaluate
the prognostic significance of bacterial infections regardless of the severity of the
underlying liver disease.
Results: Sixty-four patients (85% male, mean age 59 years, mean MELD 15, 72%
alcoholic cirrhosis) were included with a total of 197 hospitalizations. Hospitaĺs
admissions were more frequent due to variceal haemorrhage (42%) and encepha-
lopathy (37%). The incidence of bacterial infection was 25%: 41% respiratory,
31% spontaneous bacterial peritonitis and 24% urinary. Of these, 51% were
nosocomial and in 20% an infectious agent was isolated. The survival rates at
30 days, 3 months, 6 months and 1 year were 65%, 55%, 34% and 27% in
patients with infection and 97%, 90%, 85% and 78% in those without infection
(p5 0.001). In the multivariate analysis, survival was independently associated
with MELD (hazard ratio (HR) 1.073, p¼ 0.012), age (HR 1, 032, p¼ 0.012) and
infection (HR 3, 821, p5 0.001). Bacterial infection remained an independent
predictor of mortality, even when excluding patients with in-hospital mortality
and at 30 days (HR 3.093, p¼ 0.005).
Conclusion: Patients with cirrhosis exposed to a bacterial infection are at
increased risk of death. This risk remains in the long term when we exclude
patients with in-hospital mortality and at 30 days and regardless of the severity
of the underlying disease (MELD).
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Introduction: NASH progresses to cirrhosis and its complications including hepa-
tocellular carcinoma. It is possible that risk factors for NAFLD-associated cir-
rhosis and HCC in Eastern countries differ from those in the West. Thus, we
aimed to document the characteristics of patients with NAFLD-associated cir-
rhosis from Turkey, a European country sharing 97% of its borders with Asia.
Relative to other Europeans, the Turkish population exhibits a higher rate of
obesity that is comparable to that in the United States.
Aims & Methods: To characterize non-alcoholic fatty liver disease (NAFLD)
presentation with esophageal varices. METHODS: We have kept the records
of patients at our hepatology unit and affiliated liver center. Data were collected
for esophageal varices only at the advanced endoscopy unit. A cohort of patients
with esophageal varices from 2003 to 2014 was reviewed. Eligible patients were
18 years of age and have had esophageal varices diagnosed by upper gastro-
intestinal endoscopy examination. They had regular clinical follow-up and endo-
scopic examinations at our clinic. Efficacy data were based on the last evaluation.
Transplanted cases were excluded. The main inclusion criterion was the presence
of esophageal varices with or without gastric varices. Only 258 patients with
endoscopically defined high-risk varices had reliable data and were included in
this study. Each patient was evaluated for fundal varices, PVT, cirrhosis, HCC,
and mortality. After the first evaluation, patients were divided into 4 groups:
Those with hepatitis B, hepatitis C, NAFLD and others related to autoimmune
hepatitis, Wilson Disease, primary biliary cirrhosis, etc.
Results: Primary end-point of the study was to use this cohort of patients with
esophageal varices to evaluate the relationship between this disease and several
etiologies, including NAFLD, hepatitis B, hepatitis C or other liver-related dis-
eases. Second end-point was to draw this comparison in terms of PVT, HCC,
survival and mortality. Of the 258 patients with esophageal varices; NAFLD in
39.0% (101 patients), hepatitis B virus in 29.1% (75 patients) and HCV in 11.2%
(29 patients). The mean age of NAFLD was 56.4 16.0 years and 62% of these
patients were men. Moreover, 47.5% had PVT, 5.0% had HCC, and 45.5% had
fundic varices. The mortality rate was 47.5% during follow-up, but increased to
80% in the presence of HCC. PVT was observed in 47.5% of patients with
NAFLD, 29.3% of patients with hepatitis B, 17.2% of patients with hepatitis
C, and 62.3% of patients with other liver-related diseases (P5 0.0001). Of the
111 patients (43%) that died during the study period, 72 patients (64.9%) had no
PVT (P¼ 0.057). HCC was: 5.0% in patients with NAFLD, 26.7% in patients
with hepatitis B, 34.5% in patients with hepatitis C, and 5.7% in other diseases
(P5 0.0001). Of the 38 patients with HCC, 13% had PVT. Moreover, HCC
increased the mortality rate in almost all the groups. Of the patients, 50.0%
with NAFLD, 33.3% with hepatitis B, 26.3% with hepatitis C, and 58.3%
with other diseases were alive at the end of the 5-year period with a significant
difference according to the Kaplan-Meier log Rank test (P¼ 0.04). Risk for
mortality, measured by risk ratio (RR), did not change per gender (RR: male/
female¼ 43.3%/42.5%, P4 0.05) or with the occurrence of cirrhosis (RR:
44.8%/28.6%, P4 0.05). However, it changed with the existence of fundic
varices (RR: 49.3/35.3, P¼ 0.024 in favor of fundic varices development) and
HCC (RR: 78.9%/36.8%, P5 0.0001 in favor of HCC development).
Conclusion: Data revealed a proportionally greater rise in liver transplant candi-
dacy due to NAFLD-associated cirrhosis with portal vein thrombosis. The mor-
tality rate of patients with NAFLD-associated cirrhosis did not differ from that
in patients with virally caused cirrhosis. We confirmed that NAFLD was the
third leading cause of HCC on the transplantation waiting list. Older patients
were more prone to developing more cirrhosis, HCC and high mortality rates.
These findings should constitute a reliable guideline for evaluating patients at the
transplant center and for health policy makers to develop better strategic pre-
ventive measures against liver diseases.
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Introduction: Bacterial infections are a leading cause of mortality in patients with
decompensated cirrhosis.
Aims & Methods: The objective of this study was to evaluate the prevalence of
multiresistant bacterial infections, associated risk factors and their impact on
prognosis in hospitalized decompensated liver cirrhosis patients.
This was a retrospective Retrospective study that consecutively evaluated all
bacterial infections with confirmed microbiological isolation in patients with
decompensated liver cirrhosis admitted to the Gastroenterology ward between
January 2009 and May 2016.
Results: There were 308 infections with confirmed microbiological isolates, cor-
responding to 218 hospitalizations, in a total of 161 patients. The median age of
the patients was 63 years (IQR 55–71) and 67% of them were men. Alcoholic
liver disease was the major cause of cirrhosis (72%). Among the infections eval-
uated, 87% were nosocomial and 13% community-acquired. Urinary tract infec-
tion was the most common infection (57%). In 27% of patients there were at
least two concomitant bacterial infections. Multidrug resistant (MDR) bacteria
were isolated in over half of patients. In the multivariate analysis, prophylaxis for
spontaneous bacterial peritonitis (OR 2.3, p¼ 0.009), MELD score greater than
19 at admission (OR 1.7, p¼ 0.043), hospitalization in an Intensive/Intermediate
Care in the previous month (OR 2.8, p¼ 0.001) and antibiotic therapy for infec-
tion in the last 6 months (OR 2.4; p¼ 0.001) were independently associated with
MDR infection. From the variables identified in the multivariate analysis, a
predictive model of MDR bacterial infection was created. Assuming a sensitivity
of 66% and a specificity of 72%, we considered the cut-off of 0.0415 as clini-
cally relevant, regarding likelihood of developing a MDR bacterial infection
(AUROC 0.723; 95% CI [0.667–0.780]). The occurrence of a MDR infection
was associated with a longer duration of hospitalization (p¼ 0.017). In the multi-
variate analysis there was no independent association between MDR infection
and in-hospital mortality and one month after discharge.
Conclusion: The prevalence of MDR bacterial infections in cirrhotic patients is
significant and associated with a longer hospital stay. It is possible to identify
predictors of its occurrence in order to implement epidemiological strategies to
reduce the risk of these infections.
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Introduction: Hepatitis C virus (HCV) diminishes health related quality of life
(HRQOL). Currently, there is no published data on assessing of the impact of
treatment of chronic hepatitis C with the new antiviral drugs in old-aged patients.
Aims & Methods: The aim is to study the effect of treatment of chronic hepatitis
C with the new antiviral drugs in old-aged patients in HRQOL. About 132
patients with chronic hepatitis C (cirrhotic and non-cirrhotic) were enrolled in
the study. Age of patients was sixty years old and older. All patients were treated
with sofosbuvir/daclatasvir with or without ribavirin for three months. The
HRQOL was assessed with sickness impact profile scoring (SIP) before start of
treatment, at end of treatment and after three months of end of treatment.
Results: Old chronic hepatitis C patients who were treated achieved primary vir-
ological response (end of treatment) with percentage 100% and sustained virolo-
gical response (SVR) (after 3 months of end of treatment) in about 96% of treated
patients. Before treatment, patients with chronic hepatitis C had worse scores
especially in work, sleep, rest and recreation and pastimes categories. After treat-
ment, patients who received sofosbuvir/daclatasvir with or without ribavirin had
significant improve in work, sleep, rest and recreation and pastimes categories with
p- value 0.001. Numerical improvement was observed in total score, physical and
psychosocial dimension scores. In patients with SVR, the most improvement was
in work and psychosocial dimension scores. There was no significant difference in
SIP between scores after end of treatment and after 3 months of end of treatment.
Conclusion: Treatment of chronic hepatitis C in old-aged patients had a signifi-
cant improvement in HRQOL.
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Introduction: Accurate determination of the degree of hepatic-fibrosis is manda-
tory not only for the diagnosis and prognosis of disease, but also for deciding on
the antiviral treatment. Indeed, many studies have been dedicated to the search of
non-invasive fibrosis markers capable of providing an accurate information
about hepatic fibrosis stage in patients with chronic hepatitis C (CHC). Direct
and indirect markers of hepatic fibrosis are useful for prediction of liver cirrhosis
but have limited accuracy for the diagnosis of significant fibrosis. Therefore, the
development of more advanced scores combining both direct and indirect mar-
kers may improve their diagnostic accuracy.
Aims & Methods: This work is concerned with determining the levels of some of
fibrosis markers, which are directly involved in deposition and removal of extra-
cellular matrix (ECM), together with other indirect fibrosis markers so as to
construct a predictive score capable of identifying the presence of significant
fibrosis with a high degree of accuracy. Then, we aimed to estimate its perfor-
mance against that of the other simple noninvasive tests in chronic hepatitis C
patients.
Material and Methods: A total of 148 Egyptian HCV patients were subjected to
routine laboratory workup in addition to estimation of serum AFP, hyaluronic
acid (HA), platelet-derived growth factor (PDGF), tissue inhibitor of metallo-
proteinase-1 (TIMP-1) and collagen IV. According to fibroscan, patients were
classified into those with non-significant fibrosis (F5 2) and significant fibrosis
(F2).
Results: Based on univariate analysis, ten variables were signiEcantly higher in
patients with significant Ebrosis. Patients with F2-F4 had 2.08-fold, 2.14-fold,
1.80-fold and 1.90-fold increase in the concentrations of collagen IV, HA, PDGF
and TIMP-1, respectively. Multivariate regression demonstrated that only age,
AFP, PDGF, collagen IV and TIMP-1 retained signiEcance. Therefore, a five-
marker score named Egypt (EGY) Fibro-mark (FM) was developed. A signifi-
cant correlation was found between its candidate markers and liver fibrosis
progression. AFP was found to have highest correlation (r¼ 0.47, P5 0.0001)
followed by collagen IV (r¼ 0.46, P5 0.0001), Age (r¼ 0.43, P5 0.0001),
TIMP-1 (r¼ 0.40, P5 0.0001) and PDGF (r¼ 0.40, P5 0.0001). ROC curve
was used to estimate and compare the diagnostic accuracy of these candidate
variables. As a consequence, these markers were in a decreasing rank: AFP
(AUC 0.79), collagen IV (AUC 0.78), age (AUC 0.76), TIMP-1 and PDGF
(AUC 0.75). Additionally, Bivariate Spearman’s rank correlation coefficient
between EGY-FM and its candidate markers was determined for estimating
the impact of each marker on the predictive criteria. The diagnostic value of
Egy FM was then assessed by ROC curve showing an AUC of 0.89 for diagnos-
ing signiEcant Ebrosis at an optimal cut-off point of 4.05 with77% sensitivity,
83% specificity and 79% efficiency. Next, the area under the ROC curve (AUC)
was used as an index to evaluate and compare the performance characteristics of
different non-invasive scores. The AUC was greatest for Fibro-mark (0.89), then
BRC (0.83), followed by FRT and King’s score (0.82), APRI (0.80), Fibro-
(0.70) and finally FibroQ (0.63).
Table 1: The correlation of each score to hepatic fibrosis progression
Index AUC Cutoff Sensetivity Specificity Efficiency
Odds ratio
(95% CI)
Fibro-mark 0.89 44.05 77 83 79 16.18 (6.59–39.70)
BRC score a (37) 0.83 47.2 97 30 76 12.86 (3.44–48.13)
FRT a (38) 0.82 44.0 99 11 69 10.71 (1.21–94.60)
King’s score (41) 0.82 12.3 94 45 79 12.25 (4.39–34.19)
APRI a (42) 0.80 41.5 29 94 50 6.13 (1.76–21.30)
Fibro- score (43) 0.70 41.28 95 19 72 4.34 (1.33–14.17)
FibroQ(40) 0.63 41.6 93 13 69 1.80 (0.53–6.04)
Conclusion: Egy Fibro-mark (FM) score, a more sophisticated score combining
‘direct’ and ‘indirect’ markers, is a useful tool to improve the staging of liver
fibrosis in CHC patients and seems more efficient than BRC, FRT, King’s score,
APRI, Fibro- score and FibroQ in this group of Egyptian patients.
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Introduction: In patients with chronic hepatitis C, host genetics influence liver
fibrosis, particularly modifiers in genes controlling the inflammatory and
immune response pathways. In this context, interleukin 28B (IL-28B)
rs12979860 single-nucleotide polymorphisms (SNP) is considered the most
important. Controversial data suggests that IL-28B SNP relate to the severity
of hepatic histology. Some studies showed that rs12979860 C allele may be
associated with greater hepatic inflammation, higher alanine aminotransferase
levels and increased risk of worse clinical outcomes, other studies have not found
this association. Furthermore, other studies found that the T allele affects the
severity of liver fibrosis and had a mean staging score higher than other geno-
types. Else, none of the previous studies concerned the association between the
IL-28B SNP and signs of fibrosis severity.
Aims & Methods: We aimed to evaluate the cirrhotic development in C/T geno-
types using FibroScan, extracellular matrix (ECM) proteins and the model for
end-stage liver disease (MELD) in order to resolve conundrum regarding the
association between interleukin 28B (IL-28B) rs12979860 and disease severity
in chronic hepatitis C (CHC). So we assessed the allelic and genotypic frequencies
of IL-28B rs12979860 in in 272 HCV-infected Egyptian individuals; investigate
serum levels of ECM proteins, including hyaluronic acid (HA), laminin, collagen
type IV and the N-terminal pro-peptide of collagen type III (PIIINP) as well as
its association with liver fibrosis, as assessed by FibroScan, in different IL-28B
rs12979860 genotypes; From another view, if C allele has a protective role, we
need a precise confirmation, thus we decided to evaluate the difference in cirrho-
tic behavior using FibroScan, ECM proteins and the MELD score between C/T
IL-28B genotypes and evaluate the diagnostic performance of Fibroscan and
these ECM proteins in IL-28B rs12979860 genotypes.
Results: IL-28B rs12979860 CT genotype is the commonest genotype among
patients constituting 73% of the studied sample. The CC and TT genotypes
constituted 18% and 9% respectively. Liver cirrhosis percentage increased
with the increasing number of T alleles as it was 10%, 52% and 96% in CC, CT
and TT genotypes, respectively. FibroScan values (kPa) gave a strong positive
correlation (r¼ 0.6; P5 0.0001) with IL28B polymorphism. Similar to
FibroScan, HA (r¼ 0.5), laminin (r¼ 0.5), collagen IV (r¼ 0.4) and PIIINP
(r¼ 0.4) serum levels showed significant (P5 0.0001) positive associations with
IL28B polymorphism. There was stepwise increase in the values of fibroscan and
ECM protiens from CC to TT genotypes, so that elevated ECM proteins serum
levels were associated with the presence of IL-28B T allele. (Table). In compar-
ison with CC genotype, IL-28B rs12979860 T allele had a significant 2.4-fold
increase (in case of CT) and 4.7-fold increase (in case of TT) in Fibroscan score
values (kPa). The same was true for ECM proteins serum levels. Interestingly, the
characteristics of the cirrhotic patients with TT genotype were completely differ-
ent from the cirrhotic patients with CT genotype as assessed with FibroScan,
ECM proteins and MELD score. Among cirrhotic patients, liver stiffness
was31.13 2.28 kPa in TT genotype vs 20.96 0.74 kPa in CT genotype,
MELD was 9.6 0.73 in TT genotype vs 3.9 0.41 in CT genotype and ECM
proteins were significantly (P5 0.0001) higher in patients with TT than CT
genotype. AUC values for FibroScan, HA, laminin, collagen IV and PIIINP
serum levels to differentiate CC from other IL-28B genotypes were 0.91, 0.85,
0.84, 0.82 and 0.82, respectively. These values rise to 1.0, 0.97, 0.93, 0.98 and
0.93, respectively, when comparing CC to only TT genotype.
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Table 1: Distribution of different fibrosis markers in IL-28B CC, CT and TT
genotypes
Fibrosis marker
IL-28B genotypes
P valueCC CT TT
FibroScan (kPa) 6.6 0.4 15.6 0.6 31.1 2.3 0.0001
Hyaluronic acid (ng/mL) 74.6 5.2 147.8 8.2 419.4 95.2 0.0001
Laminin (ng/mL) 60.6 3.2 106.5 4.6 282.1 58.1 0.0001
Collagen IV (mg/mL) 6.1 0.4 11.8 0.9 30.1 6.2 0.0001
PIIINP (ng/mL) 13.3 0.7 25.6 1.7 55.4 10.4 0.0001
Conclusion: FibroScan and ECM proteins prove that the IL-28B rs12979860 T
allele affects the severity of liver disease. Coexistence of C allele with T allele
reduces cirrhosis severity. This study gives a good deduction that carriage of the
IL-28B C allele protects from unfavorable outcomes in CHC. This study shed the
light on using FibroScan and ECM proteins as good diagnostic options for liver
disease severity in IL-28B genotypes
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Introduction: Chronic hepatitis C virus (CHCV) patients with persistently normal
transaminases represent a category of patients with mild and slowly progressive
disease. Proper management of these patients with direct acting antivirals
(DAAs) needs to be investigated in real world treatment settings in Egypt to
further validate the accumulating data of the achieved high sustained virologic
response (SVR) rates with the use of these drugs in clinical trials.
Aims & Methods: We aimed to report the efficacy of 5 different DAAs regimens
for treatment of CHCV genotype 4 patients with persistently normal liver
enzymes in real-world Egyptian cohort. Data of CHCV genotype 4 patients
with normal liver enzymes who started treatment with different DAAs between
September 2014 and September 2016 in a single specialized viral hepatitis treat-
ment center in Egypt were retrieved. Treatment regimens included: Pegylated
interferon alpha 2b/Sofosbuvir/Ribavirin (PEG/SOF/RBV), Sofosbuvir/
Daclatasvir (SOF/DCV), Sofosbuvir/Daclatasvir/Ribavirin (SOF/DCV/RBV),
Sofosbuvir/Ribavirin (SOF/RBV) and Sofosbuvir/Simeprevir (SOF/SIM). All
regimens were given for 12 weeks except SOF/RBV which was given for 24
weeks. HCV RNA was tested at week 4 of treatment, and 12 weeks after treat-
ment cessation to check for SVR 12.
Results: Our cohort included 1149 patients (562 males and 587 females). 158
patients were treatment experienced (13.75%) and 146 patients (12.7%) had
liver cirrhosis. Regarding the used treatment regimens; 244 (21%) patients
were treated with PEG/SOF/RBV, 382 (33.5%) with SOF/DCV, 152 (13.5%)
with SOF/DCV/RBV, 117(10%) with SOF/RBV and 254 (22%) with SOF/SIM.
The overall SVR rate was 97.5% while the SVR rates for different regimens were:
94.7%, 99.7%, 100%, 91.5% and 98% for (PEG/SOF/RBV), (SOF/DCV),
(SOF/DCV/RBV), (SOF/RBV) and (SOF/SIM) respectively.
Conclusion: Different DAAs achieved high SVR rates in treating CHCV geno-
type 4 with normal liver enzymes in a real-world cohort from Egypt. SOF/DCV/
RBV combination was the most effective among the studied regimens.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0049 THE SAFETY AND EFFICACY OF THE COMBINATION OF
DACLATASVIR, ASUNAPREVIR, AND BECLABUVIR IN THE
TREATMENT OF CHRONIC HEPATITIS C VIRUS GENOTYPE 1
INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
A.M. Ahmed
1, M.F. Doheim2, O.M. Mattar3, N.A. Sherif4, D.H. Truong5,
P.T.L. Hoa6, K. Hirayama7, N.T. Huy8
1Faculty of Medicine, Al-Azhar University, Cairo/Egypt
2Faculty of Medicine, Alexandria University, Alexandria/Egypt
3Kasr Alainy Faculty of Medicine, Cairo/Egypt
4Faculty of Medicine, Mansoura University, Mansoura/Egypt
5Quang Binh Pharmaceutical Joint-Stock Company, Quang Binh/Viet Nam
6Department of Tropical Diseases, University of Medicine and Pharmacy, Ho Chi
Minh City/Viet Nam
7Institute of Tropical Medicine (NEKKEN), Leading Graduate School Program,
and Graduate School of Biomedical Sciences, Nagasaki University, Ngasaki/Japan
8Department Of Clinical Product Development, Institute of Tropical Medicine
(NEKKEN), Leading Graduate School Program, and Graduate School of
Biomedical Sciences, Nagasaki University, Nagasaki/Japan
Contact E-mail Address: med.b.dean@azhar.edu.eg
Introduction: Recently, new direct antiviral agents (DAAs) with different
mechanisms of action have been developed to provide much more efficacious
and better-tolerated therapeutic strategies for treatment patients with hepatitis C
virus (HCV) infection. Several clinical trials have investigated a 12-week therapy
with fixed dose of all-oral three-drug combination of daclatasvir (DCV), a potent
pan-genotypic nonstructural protein 5A [NS5A] inhibitor, in 60mg once daily;
asunaprevir (ASV), an NS3 protease inhibitor, in 200mg twice daily; and becla-
buvir (BCV), a non-nucleoside NS5B thumb-1 polymerase inhibitor, in 75mg
twice daily (BCV-TRIO) for treatment of patients with HCV genotype 1
infection.
Aims & Methods: This systematic review and meta-analysis aimed to investigate
the efficacy and safety outcomes of the three-drug combination of daclatasvir,
asunaprevir, and beclabuvir, in treatment of HCV genotype 1 infection. Eleven
electronic search engines/libraries, including PubMed, Scopus, Web of Science,
Google Scholar, Virtual Health Library (VHL), WHO Global Health Library
(GHL), ClinicalTrials, POPLINE, System for Information on Grey Literature in
Europe (SIGLE), Cochrane library, and the New York Academy of Medicine
(NYAM), were systematically searched for any clinical trial reporting the efficacy
and safety of BCV-TRIO for the treatment of HCV genotype 1 infection. Studies
were screened for eligibility and data was extracted by two independent
reviewers. Sustained virologic response rate after 12 weeks of treatment
(SVR12) and commonly reported outcomes were pooled as event rate and risk
ratio in the comparison meta-analysis (RR). The meta-analysis was conducted
using the Comprehensive Meta-analysis (CMA) platform. The protocol was
registered in PROSPERO (CRD42017054391).
Results: Among the included five studies, four studies, with low to moderate risk
of bias, were included for the meta-analysis (n¼ 1096). The BCV-TRIO showed a
high-response rate in naı̈ve patients (SVR12 rate¼ 95.5% (95%CI [93.5–96.9]).
This total population was sub-grouped to get SRV12 rates; 89.5% (95%CI [85.8–
92.4]), 96.2% (95% CI [93.0–98.0]), 93.5% (95%CI [89.2–96.1]), 91.1% (95%CI
[87.6–93.7]), 93.9% (95% CI [86.6–97.3]), and 91.9% (95%CI [89.1–94.0]) for
HCV genotype 1a, HCV genotype 1b, IL28B CC genotype, IL28B non-CC gen-
otype, cirrhotic, and non-cirrhotic respectively. The virologic failure occurred in
only 40 patients (7%) (95%CI [5.2–9.4]). There was no difference when adding
ribavirin to this combination (RR¼ 0.98, 95% confidence interval (95% CI)
[0.90, 1.08], P¼ 0.70), using this regimen on interferon-experienced patients
(RR¼ 1.03, 95% CI [0.98, 1.08], P¼ 0.30), or changing the dose of BCV from
75mg to 150mg regardless the genotype 1 subtypes or IL28B genotype.
Similarly, the minimal failure of treatment showed no difference regarding the
main two comparisons regardless the cause of this failure. Increasing the dose or
the duration did not show a significant increase in the efficacy. The rates of
serious adverse events (AEs) occurrence were; (3.4%, 95%CI [2.3–5.1]), (6.5%,
95%CI [3.2–12.7]), (2.3%, 95%CI [0.6–8.8]), and (2.9%, 95%CI [0.2–33.6]) for
BCV-TRIO, (BCV-TRIO þRBV) for 12 weeks, (DCVþASVþBCV-150mg)
for 12 weeks, and both (BCV-TRIO) and (DCVþASVþBCV-150mg) for 24
weeks respectively. For BCV-TRIO, the most-frequent AEs were headache, diar-
rhoea, fatigue, and nausea with rates; (21.2%, 95%CI [18.4–24.2]), (14.3%,
95%CI [12.0–16.9]), (13.8%, 95%CI [11.2–16.8]), and (13.4%, 95%CI [10.9–
16.4]) respectively.
Conclusion: This study reported a high SVR, minimal treatment failure rate, and
few AEs with fixed-dose three drug combination of daclatasvir, asunaprevir, and
beclabuvir for 12-week duration in HCV genotype 1-infected patients, without
adding ribavirin, prior interferon-based therapy, restriction on noncirrhotic
patients, restriction on certain IL28B genotype, restriction on baseline resis-
tance-associated variants, or expansion the duration of the treatment to 24
weeks.
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Introduction: Egypt has the highest prevalence of HCV worldwide. Prevalence of
HCV was reported to be 13.9% among healthy populations. Adults have higher
HCV prevalence (15.7%) than children (4.0%). Geographically, HCV is highly
prevalent in the Nile delta (15.8%) than in Upper Egypt (9.02%). The household
contacts of HCV seropositive patients had been shown to have a high risk of
HCV infection.
Aims & Methods: The aim of this study was to determine the prevalence of HCV
infection among household contacts of HCV seropositive index patients. We also
aimed to compare HCV genotyping distribution in upper and lower Egypt. In
this Multicentre hospital case control based study a total of 4894 Egyptian indi-
viduals were recruited to the hospitals from different Egyptian population in
Upper & lower Egypt (mainly from Dakahlia, Cairo and Assuit governorates).
The index HCV patients were 1106 cases whereas the families or close household
contacts of these index cases were 3788 cases. Ideally family was selected on the
basis of containing at least one positive HCV index, one positive HCV member
and other one negative HCV member with no history of any liver complications
or disorders(first and second degree consanguinity, living and sharing usual life
activity and having at least 15 years of exposure to the index case). The positive
cases (whether index or contact cases) in the family were selected with inclusion
criteria of 1-HCV positive by PCR RNA4 6 months, 2-Adults (above 18 years)
of both sexes 3-Any stage of HCV related liver diseases. While cases were diag-
nosed as spontaneously cleared the virus (SVC) based on the following criteria:
positive Anti-HCV but negative PCR HCV RNA in 2 successive samples at least
6 months apart with no prior history of antiviral therapy. Each participant was
subjected to routine clinical and laboratory investigations in addition to mole-
cular diagnosis and PCR HCV to confirm HCV infection. Sequencing analysis of
the 50 UTR of HCV was performed using an ABI Prism 310 Genetic Analyzer
(PE Applied Biosystems, Germany). The sequencing reaction was performed
using Big Dye Deoxy Terminator method as recommended by the manufacturer
(PE Applied Biosystems). Genotypes were determined according to the published
reference sequences.
Results: The prevalence of Anti-HCV þve cases among household contacts was
20.71% but when PCR HCV was performed only 17.83% were þve while 2.9%
were spontaneously cleared the virus (SVC). The HCV prevalence among house
hold contacts was 17.29% & 19.17% while the SVC was 2.49% & 1.55% in lower
& Upper Egypt respectively. When the genotyping of the positive cases were
performed it was found that the following pattern was noticed in the upper &
lower Egypt respectively: (genotype 4a (90.3% & 70.1%), 4m (4.8% & 11.8%) 4n
(0.5% & 3.2%) 4o (0.2% & 2.9%) 4i (0.5% & 1.9%) 4v (0.8% & 1.2%) & 1a
(2.9% & 8.3%) as shown in the following table.
HCV genotype Upper Egypt (%) Lower Egypt (%)
4a 90.3 70.1
4m 4.8 11.8
4 n 0.5 3.2
4o 0.2 2.9
4i 0.5 1.9
4v 0.8 1.2
1a 2.9 8.3
1 g 0.0 0.3
1b 0.0 0.3
Conclusion: The prevalence of HCV was found to be 18.5% among household
contacts of Egyptian families. The genotype 4 was predominant in upper Egypt
(97.1%) more than lower Egypt (91.7%). On the other hand genotype 1a was
higher in lower Egypt (8.3%) more than upper Egypt (2.9%).
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Introduction: Red blood cell distribution width (RDW) is a numerical measure of
the variability in size of red cell It reflects variability in the size of circulating
RBCs. RDW can be used as a prognostic marker in heart failure. In hepatic
patients it was approved to be an independent predictor of liver fibrosis in
patients with chronic HBV infection, and it is higher in patients with alcoholic
liver disease and non alcoholic liver cirrhosis. The gold standard for assessing the
histological out come of liver disease is liver biopsy. This procedure is costly and
carries a small risk of complications due to sampling error, invasiveness and
requires hospitalization of at least 6–18 h. These limitations have stimulated
the development of non- invasive techniques for assessing the presence and the
degree of liver fibrosis. Several laboratory scores composed of routine laboratory
markers that are readily available have been proposed for non-invasive predic-
tion of liver fibrosis in chronic hepatitis C (CHC) patients.
Aims & Methods: The aim of this work is to use RDW as a marker for non-
invasive prediction of the stage of hepatic fibrosis in patients with chronic hepa-
titis C genotype4. 100 patients with chronic hepatitis C were subjected to routine
laboratory & radiological investigations in addition to using KX-21 Sysmex
automated hematology analyzer to measure RDW& RPR (RDW%/Platelet
ratio). Comparing with other biomarkers of liver fibrosis like APRI (AST-to-
Platelet ratio index) FIB-4 equation (using platelet count, AST, ALT, age) to
perform this test. PCR HCV RNA, genotyping & liver biopsy (using METAVIR
scoring system where cases were classified into early fibrosis (F1þF2):68
patients & late fibrosis (F3þF4): 32 patients]were done.
Results: RDW & RPR were significantly higher in patients with late fibrosis 4
early fibrosis (P5 0.0001) while platelets count was significantly lower in late
fibrosis 4 early fibrosis (p5 0.001). By applying ROC curve it was found that
the cut off value of RDW was 16.5, with sensitivity 86.4% specificity 85.9% &
accuracy 86% & the cut off value of the platelets was 196.5 with sensitivity
81.8%, specificity 62.8% accuracy 67%, while RPR cut off value was 0.0897
with sensitivity 90.9%, specificity 85.9% & accuracy 87%. As regard APRI
test it was found that the cut off value was 40.5with sensitivity 72.7%, specificity
66.7% & accuracy 68% While FIB-4 equation showed cut off value 1.685 with
sensitivity 77.3%, specificity 66.7% and accuracy 69%. In conclusion the area
under the ROC curve for, RDW & RPR were excellent but for platelets, FIB-4 &
APRI were fair. When applying regression analysis it was found that the RDW
(OR:3.903, 95% CI: 1.538–9.904) & Platelets (OR:0953, 95% CI: 0.913–0.995),
so as the level of RDW increase by one unit the risk late fibrosis will increase by
3.9 on the other hand when the platelets increase by one unit the risk of late
fibrosis will decrease by 0.953.
Conclusion: RDW & RPR may be used as simple, non-invasive predictors of
advanced fibrosis in patients with with chronic HCV genotype-4.
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Introduction: The incidence of liver cancer and its recurrence have been reported
frequently at an early stage in patients who underwent interferon (IFN)-free
direct-acting antiviral (DAA) therapy [1]. The underlying mechanisms of
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cancer incidence following DAA therapy may include the rapid clearance of
hepatitis C virus, reconstitution of the immune system, and reduction of cancer
immunosurveillance [2]. These changes may in fact have an impact on the devel-
opment of cancer in other organs.
Aims & Methods: We conducted a retrospective analysis to compare the cancer
incidence in patients treated with IFN-free DAA therapy with those treated with
IFN therapy. All patients who achieved sustained viral response 12 following
antiviral therapy between 1992 and 2016 in our hospital were investigated retro-
spectively. Patient records were examined to identify new cases of cancer, as
diagnosed by pathology or medical imaging, in organs other than the liver fol-
lowing antiviral therapy. The date of diagnosis was determined based on the
records, and the cancer incidence was compared between patients treated with
DAA therapy and those treated with IFN therapy using the Kaplan-Meier
method and Cox regression analysis. Patients with recurrent cancer were
excluded from the analysis. Propensity score analysis followed by inverse prob-
ability of treatment weighting (IPTW) was used to correct for the effects of
confounding factors.
Results: There was a significant difference in the age and sex of the patients
treated with DAAs (n¼ 324, median age: 70, male: 41%) and those treated
with IFNs (n¼ 445, median age: 58, male: 60%). Median lengths of the observa-
tion period for the DAA and IFN groups were 1.3 and 6.2 years, respectively.
There were 12 and 22 cases of cancer occurring in organs other than the liver in
the DAA and IFN groups, respectively. These cancer cases occurred the most
frequently in the gastrointestinal tract, followed by the urinary organs, hemato-
poietic organs, biliary tract/pancreas, lungs, and others. The median periods
from the start of the antiviral therapy to the time of diagnosis were 0.9 and
6.8 years in the DAA and IFN groups, respectively. Cumulative rates of
cancer after 1 and 2 years were 3.0 and 5.0% for the DAA group, and 0.2 and
0.9% for the IFN group, respectively. The difference between the groups was
significant (p¼ 0.02) based on Cox regression analysis using IPTW.
Table: Cox regression analysis for cancer incidence other than the liver in IPTW
samples
Hazard Ratio 95% CI
Treatment
IFN (Ref.) 1
DAA 4.491 1.264–15.96
CI: confidence interval, IPTW: inverse probability of treatment weighting, IFN:
interferon, DAA: direct acting antiviral
Conclusion: Because cancer detection in organs other than the liver can be chal-
lenging in management of hepatitis, some cases with cancer found after the
treatment might have been diagnosable before the treatment, possibly leading
to an overestimation of the incidence after the treatment. The number of newly
diagnosed cancer cases was small in the present study, resulting in a low statis-
tical power. Nevertheless, the cancer incidence in organs other than the liver was
significantly higher in patients treated with DAA therapy than those treated with
IFN therapy. This difference persisted after correcting for possible confounding
factors including the age and sex of the patients. Our findings suggest that
patients need to be carefully examined after DAA therapy for the development
of cancer in various organs, including but not limited to the liver.
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Introduction: The shift from therapy with interferon to Direct antiviral agents
(DAAs) has been a watershed for the management of HCV-related chronic liver
diseases. In fact, treatment with second-generation DAAs cures the great major-
ity of subject with HCV chronic infectrion, with the exception on genotype 3
cirrhotic patietns
Aims & Methods: The present report focuses on HCV genotype 3 cirrhotic
patients treated with second-generation DAAs in order to identify which of the
several treatment schedules recommended for genotype 3 would constitute the
best option. Methods: 1. Twenty-four italian centers (ITAL-C consortium) were
involved in this real-life study where HCV genotype 3 patients treated with
DAAs. Eligible patients were418years-old with chronic HCV infection, either
naı̈ve or treatment-experienced. Patients with any of the following features were
excluded: infection with HCV genotypes other than 3, active HCC on imaging,
HIV and/or HBV co-infection, liver-transplant recipients, patients with an esti-
mated glomerular filtration rate 530ml/min. 2. With the intent to delineate a
treatment schedule with the new DAAs that would offer the higher chance of
SVR to patients with HCV genotype 3, a systematic search of the literature data
was implemented and the retrieved information was pooled and evaluated by a
meta-analytical approach. Electronic, systematic review of the available evidence
in the published literature was undertaken to identify all studies. The systematic
literature review was performed via Medline from 2012 to 2016 by the following
search keys: HCV Genotype 3 AND [(DAA)OR (sofosbuvir) OR (daclatasvir)
OR (Ledipasvir) OR (Velpatasvir)].
Results: 1. A total of 233 HCV genotype 3 patients were enrolled. In the entire
population, the SVR rate was achieved by 205 subjects (88.0%). A successful
treatment outcome was documented in 79.0% of patients treated with sofosbuvir
in combination with RBV, in 92.0% of those who received sofosbuvir/daclatasvir
with or without RBV, and in all 7 patients treated with sofosbuvir/ledipasvir with
or without RBV. At the univariate analysis, baseline predictors of the SVR12
were gender (female patients being more responsive than males), BMI5 30 and
the treatment schedule. Of relevance, age, stage of liver disease (whether
advanced fibrosis or cirrhosis), RBV use, and treatment length were irrelevant
to SVR12. At the stepwise logistic regression analysis, the only two factors
independently associated with SVR12 were regimens containing sofosbuvir in
combination with daclatasvir or ledipasvir (OR¼ 4.25; 95%CI: 1.81–9.97;
p¼ 0.001), and the BMI5 30 (OR¼ 2.64; 95%CI: 1.04–6.72; p¼ 0.041). 2.
The systematic review of literature provided data of 3311 patients from 17 full
text article and two abstracts. The mean weighted SVR12 rate was
84.4%(CI:80.4–87.8); the rates varied from 79.0%(CI:70.9–85.3) with sofosbu-
vir/ribavirin, to 83.7%(CI:66.2–93.1) with sofosbuvir/ledispavir, and to 88.2%
(CI:83.3–91.7) with sofosbuvir/daclatasvir.
Conclusion: HCV genotype 3-infected patients, and in particular those progressed
to cirrhosis, should be no more considered difficult-to-treat individuals, provided
that an optimal therapeutic schedule is applied. Patients without cirrhosis should
be treated with sofosbuvir and daclatasvir for 12 weeks. Patients with cirrhosis
should be treated with sofosbuvir and daclatasvir for 24 weeks with or without
ribavirin
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Introduction: The impact of the virological cure on the evolution of cirrhotic
patients treated with direct-acting antivirals (DAA) is not yet well established.
Recently, some papers reported an elevated incidence of recurrence of hepato-
cellular carcinoma (HCC)1–4 and others a possible rise on the de novo incidence
of HCC in the first year after treatment with DAA5–6, but not others7–9.
Aims & Methods: This is a prospective study of cirrhotic patients treated with
DAA between february/2015 and january/2017, under HCC screening with ultra-
sonography according to international guidelines. The main endpoint of the
study was to determine the incidence of ‘‘de novo’’ and recurrent HCC. The
second endpoint was to search for possible predictive factors associated with
the occurrence of HCC. Statistical analysis performed on SPSSv.24.
Results: 106 cirrhotics (73% mean; 54.5 8.8 years), MELD 7.3 2.6, 60% with
portal hypertension (n¼ 64) and 22% with decompensated cirrhosis (n¼ 23, 22
Child-Pugh B). Two patients with previous HCC, stage Barcelona Clinic Liver
Classification (BCLC) A, inviable after loco-regional treatment. The sustained
virological response at week 12 was 89.9% (71/79): 4 deaths, 1 relapse, 1 ther-
apeutic failure and 2 losses to follow-up (FU). In 11 7 months of FU, we
registred 5 HCC, 4 ‘‘de novo’’ and 1 recurrence, which corresponded to an
incidence of 3.8% of ‘‘de novo’’ HCC (13% in decompensated cirrhosis). The
BCLC staging was: 2 stage A, 2 stage B and the one with the recurrence was stage
D. A Child-Pugh B class (p¼ 0.004), low platelets level (p¼ 0.001) and hospita-
lization for decompensation (p¼ 0.045) were associated with the occurrence of
HCC; the genotype did not have association. The mean time to HCC develop-
ment was 7.5 months (2–14).
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Conclusion: In this cohort the ‘‘de novo’’ incidence of 3.8% of HCC after the
treatment with DAA occurred mainly in patients with decompensated cirrhosis,
not eligible for treatment with interferon in the past, and in a short interval of
time after treatment. These results alert for an eventual need to increase the
frequency of screening in the post-treatment period and carefully evaluate the
best timing for liver transplantation. We could not conclude about recurrence
due to the small number of patients.
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Introduction: Primary biliary cholangitis (PBC) is a chronic cholestatic liver dis-
ease associated with autoimmune phenomena targeting intrahepatic bile duct
cells (cholangiocytes). Although PBC etiopathogenesis remains still obscure,
development of anti-mitochondrial auto-antibodies against pyruvate dehydro-
genase complex-E2 (PDC-E2) is a common feature. MicroRNA (miR) dysregu-
lation occurs in liver and immune cells of PBC patients, but their functional
relevance is largely unknown. We previously reported that miR-506 is overex-
pressed in PBC cholangiocytes and directly targets both Cl–/HCO3
– anion
exchanger 2 (AE2) and type III inositol 1, 4, 5-trisphosphate receptor
(InsP3R3), leading to cholestasis.
Aims & Methods: The regulation of miR-506 gene expression and its role in
cholangiocyte pathophysiology and immune activation was studied. Different
sizes of miR-506 promoter were cloned in a luciferase expression vector, which
were transfected in human cholangiocytes (H69 cells) and the role of pro-
inflammatory cytokines, bile acids, estrogens and glucocorticoids was evaluated
on the promoter activities. MiR-506 or a negative control miRNA sequence were
also cloned in an expression vector under the regulation of the CMV promoter;
these constructs were stably transfected in H69 human cholangiocytes, and cho-
langiocyte pathophysiology and immune activation were evaluated.
Results: Several pro-inflammatory cytokines overexpressed in PBC livers [such as
IL-8, IL-12, IL-17, IL-18 and TNFa] stimulated miR-506 promoter activity in
human cholangiocytes, as revealed by luciferase reporter assays. Experimental
overexpression of miR-506 in cholangiocytes dysregulated the cell proteomic
profile (by mass spectrometry) affecting proteins involved in different biological
processes including mitochondrial metabolism. In cholangiocytes, miR-506: i)
induced dedifferentiation with downregulation of biliary and epithelial markers
together with upregulation of mesenchymal and pro-inflammatory markers; ii)
impaired cell proliferation and adhesion; iii) increased oxidative and endoplasmic
reticulum (ER) stress; iv) caused DNA damage; and v) sensitized to caspase-3-
dependent apoptosis induced by cytotoxic bile acids. These events were also
associated with impaired energy metabolism in mitochondria (proton leak and
less ATP production) and PDC-E2 overexpression. Co-culture of miR-506 over-
expressing cholangiocytes with PBC immunocytes induced activation and pro-
liferation of PBC immunocytes.
Conclusion: Different pro-inflammatory cytokines enhance the expression of
miR-506 in biliary epithelial cells. MiR-506 induces PBC-like features in cholan-
giocytes and promotes immune activation, representing a potential therapeutic
target for PBC patients.
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Introduction: Liver biopsy is recognized as the definitive diagnostic tool for the
diagnosis and treatment of liver diseases. The transjugular pathway (TJLB) is
commonly used in the presence of contraindications to the percutaneous route.
Aims & Methods: The objective was to report the current experience with this
technique, as well as its diagnostic acuity and impact in the approach to the
patient. Retrospective study of 265 consecutive patients submitted to TJLB
between 2010 and 2016.
Results: We included 265 patients with mean age 56 years (þ/12.4), with the
majority (60.1%) being male. One hundred and eleven patients (41.9%) were
hospitalized. In 40.1% of cases there was previously known liver disease, espe-
cially alcoholic disease, hepatitis C and non-alcoholic steatohepatitis. In 80.5%
of the cases the purpose of TJLB was for diagnosis and in the remaining cases for
staging liver disease. Eighty-five patients (32.1%) had cirrhosis prior to biopsy.
In a fourth of the cases the biopsy was performed in the context of acute hepa-
titis, being in 12.6% for diagnosis of alcoholic hepatitis. The reasons for the
percutaneous route included: coagulopathy/anticoagulation (32.2%), thrombo-
cytopenia (17.8%), ascites (17.8%), and failed percutaneous liver biopsy (13.6%).
The technical success was 92.4%. Sampling was considered adequate in 92.2% of
cases, which was associated with diagnostic purpose (94.9% vs. 80.4%, p¼ 0.001)
and evidence of acute hepatitis (98.4% vs. 89.8%, p¼ 0.03). Most patients
(60.4%) had histological criteria for cirrhosis. In 76.2% of patients TJLB allowed
a histological diagnosis, mainly alcoholic and non-alcoholic steatohepatitis.
Ability to provide a histological diagnosis was associated with adequate
sample (80.8% vs. 21.1%, p5 0.001), presence of cirrhosis (83.9% vs. 71.6%,
P¼ 0.023) and 41 passage (82.1% vs. 68.3%, p¼ 0.012). Findings were normal
in 4.8%. In 70.9% of the situations the TJLB was considered to have an impact
on the subsequent approach. No major complications were recorded.
Conclusion: TJLB is a safe diagnostic tool with high diagnostic acuity, allowing a
change in strategy in a high percentage of cases.
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Introduction: Real-time shear wave elastography (SWE) is an established method
of evaluating liver stiffness with excellent diagnostic accuracy. However, no con-
sensus exists on the number of measurements or whether mean or median value
should be used when reporting results.
Aims & Methods: In this study, we sought to estimate the most appropriate
reporting method for SWE results in practice. Overall, 200 consecutive patients
with hepatitis C virus infection who underwent liver biopsy between June 2015
and March 2017 were enrolled. Ten SWE measurements (GE Healthcare, USA)
and liver biopsies were performed on the same day. Fibrosis was staged from
liver biopsies based on METAVIR scores. SWE results were reported using eight
methods: (A) one measurement; (B) the mean of two measurements, (C) three,
(D) five, (E) ten; and (F) the median of three, (G) five, and (H) 10 measurements.
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Area under the curve and receiver operator characteristic (AUROC) compari-
sons were used to compare the diagnostic accuracy of the eight methods. The
interquartile range (IQR) and median of 10 SWE measurements using body mass
index (BMI) and age were analysed using the Mann-Whitney U test.
Results: The study population consisted of 106 men and 94 women with a mean
age of 64.7 10.8 years and mean BMI of 23.3 3.64 kg/m2. Fibrosis severity
was F0/F1/F2/F3/F4 in 7/50/33/24/23 patients, respectively. The median SWE
(m/s) of 10 measurements in patients with F0, F1, F2, F3, and F4 were 1.33, 1.57,
1.73, 1.95, 1.98, respectively. The median IQR/median was 0.21. Furthermore, we
found that obesity (BMI 25: 0.24, 5 25: 0.20, p¼ 0.124) and older patients (age
65: 0.22, 565: 0.20, p¼ 0.012) indicated significantly greater IQR/median.
There was no significant difference in the diagnostic accuracy between using
the median or mean of three, five, and 10 measurements. The AUROCs to
diagnose patients with significant fibrosis (F2) ranged from 0.778 (A) to
0.876 (H). AUROC increased based on the number of measurements. A signifi-
cant difference between 1 and 5 (p5 0.05), 1 and 10 (p5 0.01), 2 and 10
(p5 0.05) measurements was observed in pairwise comparison. Likewise,
AUROCs to diagnose patients with severe fibrosis (F3) ranged from 0.782
(A) to 0.923 (G). A significant difference (p5 0.05) was seen between one and
10 measurements. In the cohort of IQR/median 50.3, the diagnostic accuracy of
F2 and F3 ranged from 0.806 (A) to 0.877 (H), and from 0.832 (A) to 0.928
(H), respectively. In the cohort of obese (BMI 25) and old patients (age 65),
the diagnostic accuracy of F2 and F3 ranged from 0.752 (A) to 0.862 (D), and
from 0.735 (A) to 0.903 (H), respectively. Comparing the AUROC of one mea-
surement, IQR/median50.3 cohort showed greater AUROC than those of other
cohorts, however, the AUROCs of ten measurements were similar in each cohort.
Conclusion: No difference was found between reporting mean or median SWE
measurements. The diagnostic performance of SWE increased with the number
of measurements taken. Our results suggest that 10 measurements are recom-
mended to ensure the accuracy of SWE measurements in a practical setting.
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Introduction: Percutaneous radiofrequency ablation (RFA) is a commonly used
locoregional interventional procedure in treatment of hepatocellular carcinoma
(HCC). There is growing evidence that apparent diffusion coefficient (ADC)
value can be used in evaluating RFA therapeutic efficacy in treatment of HCC
and thus represent a reliable predictor of local HCC recurrence after treatment.
Aims & Methods: We aimed to determine the therapeutic efficacy RFA in
patients with hepatocellular carcinomas using ADC value. A total of 52 patients
with 58 HCCs were included, and were treated with RFA according to the
guidlines. All lesions were evaluated by diffusion weighted imaging (DWI) and
ADC value measurement before and after RFA treatment. DWI was obtained
using axial a single-shot echoplanar imaging with two b-values (500, 1000 mm2/s)
using 3 tesla MRI machine. Quantitative ADC maps were calculated using com-
mercially available software and an imaging workstation. Diagnosis of HCC
relied on triphasic CT and MRI, showing enhancement at the arterial phase of
dynamic contrast enhanced CT or MRI with rapid washout at the portal venous
& delayed phases. Follow-up post ablation by triphasic CT and/or MRI with
ADC value measurement was done after one and three months to determine
responsive cases (no residual tumoral activity) and non-responsive cases with
residual tumor activity.
Results: Forty-eight lesions responded to treatment and 10 lesions had shown no
response. ADC values were significantly higher in lesions that responded to RFA
than in non-responding lesions. The mean ADC value before treatment was
1.26 0.16	 103mm2/s (meanSD), while after treatment it was
1.46 0.12	 103mm2/s with a statistically significant difference (P¼ 0.003)
usingb value 500. The mean ADC of the lesions using b value 1000 before treat-
ment was 1.32 0.28	 103mm2/s, and increased after treatment in responding
lesions to reach 1.52 0.1	 103mm2/s with a statistically significant difference
(P¼ 0.003). Using b value 500, the mean ADC value before treatment didn’t
show significant difference between responding (1.26 0.16	 103mm2/s) and
non-responding lesions (1.26 0.12	 103mm2/s; P¼ 0.97). While using b
value 1000, there was a significant difference with higher mean ADC values
before RFA in responding lesions than in non-responding
(1.32 0.28	 103mm2/s in responding lesions and 1.09 0.14	 103mm2/s in
non-responding, respectively; P¼ 0.03) The change in ADC in responding lesions
is significantly higher than in non-responding lesions, and it was 19.6% vs. 6.2%,
respectively (P¼ 0.01) using b value 500 and was 23.7% vs. 21.2%, respectively
(P¼ 0.001) using b value 1000.
Conclusion: ADC is a good quantitative measurement allows effective evaluation
of the therapeutic efficacy of RFA for treatment of patients with HCC and can
be used as good non-contrast alternative to conventional imaging methods in
post ablation follow-up.
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Introduction: To study the effect of NAFLD on the results of shear wave elasto-
graphy (SWE) in patients with chronic diffuse liver disease.
Aims & Methods: We have performed outcome analysis in 100 patients with
diffuse hepatic disease which were treated from 2015 to 2016. There were 41
male patients (41%), and 59 female patients (59%), age Me (LQ-UQ) 49 (39–
56), minimal age was 18 years, maximal age was 77 years. All patients were found
to have chronic diffuse hepatic diseases and were hospitalized for morphological
assessment and diagnosis verification. All patients had shear wave elastography
(SWE) with quantitative measure tissue stiffness, Metavir score staging for
received results.
Results: Based on the obtained morphological results, we have formed the fol-
lowing subgroups of patients: F0 - F1–31 people, F2–9; F3–15 and F4–45
patients. Given that patients with a degree of fibrosis on the scale METAVIR
F0 and F1 do not require active conservative therapy, we combined the data of
the group into one F0-F1. The obtained results of shear wave elastography are
presented in the form of quantitative variables. Median stiffness with interquar-
tile range (25%-75%) in groups: F0 - F1–5, 4 (4, 8–7, 2) kPa, F2–8, 5 (8, 3–8, 9)
kPa, F3–13, 5 (10, 1–14, 8) kPa and F4–22, 0 (18, 2–28, 5) kPa. The parameters of
liver elastometry in the various groups on the METAVIR scale differed statisti-
cally significantly between p5 0.05. When carrying out a correlation analysis
between the stiffness indices of the liver parenchyma and the morphological stage
of fibrosis, a strong correlation was revealed: the Spearman coefficient was
r¼ 0.81 p5 0.1	10–6. Cutoff values in the general group were: for stage F2–7,
75; F3–13, 25; F4–14, 9 kPa. In 10 patients, results for SWE differed from mor-
phological conclusion. Analyzing reasons we observed that in 8 (80%) patients
there was NAFLD found and in 6 cases more than 66% was. To study fatty
degeneration impact on elastography outcomes we excluded patients with the
given disease (16 patients) from the secondary statistical processing. Stiffness
median in patients without fatty hepatic degeneration was: F0 - F1–5, 0 (4, 5–
6, 5) kPa, F2–8, 4 (7, 55–8, 7) kPa, F3 11, 7 (9, 8–14, 2) kPa and F4–22 (18, 0–
28, 5) kPa. According to ROC analyses threshold values were: for stages F2–7, 4;
F3–9, 8; F4–14, 85 kPa. However, stage correlation for hepatic fatty disease with
elastography results was none: r¼ 0.11 o¼ 0.246214.
Conclusion: Quantitative indicators of SWE in patients with diffuse liver disease
in combination with steatosis are higher than in patients without it. When inter-
preting the results of SWE in patients with diffuse liver disease, the possibility of
fatty dystrophy should be taken into account, since an underestimation of this
fact can lead to false-positive results in the staging of fibrosis by METAVIR. The
SWE method can’t be recommended for evaluation of the degree of hepatic
steatosis, in the absence of correlation with elastometry data.
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Introduction: The estimation of liver stiffness (LS) has recently been evaluating by
new elastographic techniques, such as Shear Wave Elastography (SWE), with a
wider applicability than transient elastography (1). No studies evaluated LS in
patients with alcoholic liver diseases (ALD) by using the elastographic methods.
Moreover, exploring the possibility to assess the elasticity of other tissues, few
studies evaluated the pancreatic stiffness (PS) by using transabdominal elasto-
graphy (2;3), observing that chronic pancreatitis and alcoholic etiology had
higher PS values (2).
Aims & Methods: The present study aimed at assessing the feasibility and repro-
ducibility of SWE at measuring LS and PS in a cohort of patients with alcohol
abuse and known ALD and investigating the possible correlation between LS or
PS with the some clinical and laboratory data. Over a 6-months period 86
patients undergoing LS and PS measurement by SWE were consecutively
enrolled. 65 healthy volunteers (HV) were also examined. SWE was blindly
performed by two different raters. Liver and pancreatic ultrasound were per-
formed by a single operator. The comparison of stiffness values between patients
and HV was performed. Interobserver agreement for SWE was assessed by
intraclass correlation coefficient (ICC). The effect of clinical and imaging data
was evaluated on log-transformed PS or LS, with univariate and multivariate
linear regression model, with PS or LS as dependent variable. P values 50.05
were considered statistically significant.
Results: LS and PS by SWE were obtained in all the patients and HV. No failure
was observed. LS and PS were significantly higher in patients than in HV:
22.1 kPa (95% CI, 16.9–36.2) vs 5.7 kPa (95% CI 5.2–6.4) for LS and 15.4 kPa
(95% CI 12.2–19.9) vs 12.4 kPa (95% CI 9.5–13.6) for PS, p5 0.001. ICC for LS
was good: 0.64 (95%CI, 0.50–0.45). ICC for PS was fair to good: 0.40 (95%CI,
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0.21–0.57). At univariate analysis LS was associated with: liver cirrhosis
(p5 0.0001), steatosis (p¼ 0.0003), liver surface nodularity (p¼ 0.0003), active
alcoholic consume (p¼ 0.015), alcohol consumption/day (p¼ 0.0134), diabetes
(p¼ 0.0223). At multivariate analysis cirrhosis (p5 0.0001) and steatosis
(p¼ 0.0073) were independently associated with LS. At both univariate and
multivariate analysis, PS was significantly correlated only with liver cirrhosis
(p¼ 0.0058).
Conclusion: The present is the first series assessing LS and PS in ALD patients by
using SWE. The feasibility of the technique was excellent. The reproducibility
was good for LS and fair for PS. SWE was a good predictor of liver fibrosis in the
ALD cohort. Liver cirrhosis was the only independent variable correlating with
PS, whose estimation could be useful to detect alcohol-related pancreatic damage
in patients with severe ALD.
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Introduction: miR-224 was found regulated progression of liver cancer in our
previous studies, IL-6/STAT3 pathway play key role, but the precise underlying
mechanism remains to be explored. It was found exosomes are the vesicles
released by the tumor cells into tumor microenvironment, they are a powerful
diagnostic tool due to relative stability and composition covering the whole range
of cancer-related biomarkers including proteins, metabolites, DNA, DNA mod-
ifications, coding and non coding RNA. Thus, study the roles of exosomic
miRNA could be usefull for therapy and prognosis prediction of hepatocellular
carcinoma (HCC).
Aims & Methods: The expression of miR-224, IL-6, STAT3 and SMAD4 in
tumor as well as adjacent tumor tissues of HCC were detected by RT-PCR.
Then the role of miR-224 in HCC progression was assessed in vitro as well as
in vivo, and the expression of miR-224 and genes related to HCC invasion and
migration were detected by RT-PCR and immunochemistry methods in the
transplantation tumor of nude mice. Furthermore, the supernatant exosome
from HCC cells was isolated and the translocation roles of exosome was studied
by confocal. Finally, the expression of miR-224 and genes in STAT3/SMAD4
pathway in the exosome isolated from the supernatant of HCC cells induced by
IL-6 were detected.
Conclusion: This study provides the novel mechanism of regulatory roles of miR-
224 in HCC, and from the study, exosomic miR-224 showed as the novel target
and predictor for HCC prevention and treatment in future clinic.
Results: It was found miR-224, IL-6 and STAT3 were up regulated in the tumor
tissues of HCC patients but the SMAD4 showed the down regulated when com-
pared with adjacent tumor tissues. Over expression of miR-224 can promote
growth, proliferation, migration and invasion capability of HCC cells in vitro.
Furthermore, in the vivo study, miR-224 was found accelerated transplantation
tumor growth in nude mice, and the up regulation of miR-224, IL-6/STAT3 and
down regulation of SMAD4 were also found in the transplantation tumors which
were induced by miR-224. The Exosome from the supernatant of HCC cells can
be found translocated into HCC cells conversely, when the HCC cells were
induced by IL-6, the overexpression of exosomic miR-224 and STAT3 and
decrease of exosomic SMAD4 were detected. It was speculated miR-224 can
regulated HCC progression through IL-6/STAT3/SMAD4 pathway by exosomic
way.
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Introduction: The prevalence of hepatocellular carcinoma (HCC) in Africa is
higher compared to the rest of the world due to the high incidence of chronic
infection with hepatitis C virus (HCV). In Egypt, HCV infection is the leading
cause for the high HCC incidence, which is usually diagnosed at late stages. Due
to the absence of reliable and accurate biomarkers for early detection of liver
cancer, circulating microRNAs have recently emerged as great candidates for
early diagnosis of HCC. These small non-coding RNA molecules are responsible
for regulating gene expression and RNA stability. Therefore, the aim of this
study is to investigate the potential of liver-specific circulating microRNAs as
an accurate non-invasive diagnostic tool for the early detection of HCV-induced
HCC.
Aims & Methods: Seven main miRNAs (miR-125a, miR-139, miR-34a, miR-221,
miR-16, miR-145 and miR-199a) were selected due to their expression patterns in
HCC as well as their contribution to the development of hepato-carcinogenesis.
A total of 165 patients were enrolled in this study, from which serum samples
were collected and categorized into four main patient groups: 42 chronic hepatitis
C (CHC) without cirrhosis, 45 CHC with cirrhosis (LC), 38 HCC with HCV
patients, and 40 healthy controls. The expression profile of the seven miRNAs
was analyzed using TaqMan real-time reverse transcription-polymerase chain
reaction. Additionally, the conventional markers for HCC -fetoprotein (AFP)
and des--carboxyprothrombin (DCP) were measured using commercial kits.
Results: Serum levels of miR-125a, miR-139, miR-145 and miR-199a were sig-
nificantly decreased (P5 0.01) in HCC than in the CHC and LC groups (Table
1). On the other hand, miR-16 and miR-34a were significantly increased
(P5 0.01) in HCC patients compared to the normal group. However, no signifi-
cant difference was shown in the expression of miR-16, miR-34a, and miR-221
between the CHC, LC, and HCC groups. As a single biomarker, miR-34a
showed the highest sensitivity and specificity among all miRNAs investigated,
followed by miR-221, miR-125a, miR-139, miR-145, and miR-199a.
Table 1: Expression levels of serum microRNAs of the patient groups
MicroRNAs Normal CHC LC HCC
miRNA-16 14.26 0.69 24.09 0.44** 23.29 0.46** 22.35 0.54**, a
miRNA-34a 27.32 0.19 32.69 0.34** 30.01 0.54**, b 32.50 0.94**
miRNA-221 22.82 0.38 27.17 1.44** 28.22 0.41** 28.51 0.46**
miRNA-125 20.57 0.54 96.01 4.36** 100.54 0.81** 29.96 0.57**, d
miRNA-139 29.96 0.57 94.63 0.38** 86.02 0.40**, e 30.03 0.43
miRNA-145 20.65 0.52 85.31 0.53** 80.74 0.59** 20.64 0.57
miRNA-199 80.23 0.72 330.38 0.74** 311.98 0.72** 66.16 0.44c, d
**p5 0.01 significant increase than control; ap5 0.01 significant decrease than
CHC; bp5 0.01 significant decrease than CHC and HCC; cp5 0.01 significant
decrease than control; dp5 0.01 significant decrease than CHC and LC; ep5 0.01
significant decrease than CHC
Conclusion: These results indicate that measuring the expression levels of liver-
specific circulating microRNAs can be used as a reliable diagnostic and prog-
nostic tool for HCC. Our results demonstrated that the up-regulation of miR-16,
miR-34a, and miR-221 can differentiate between normal individuals and patients
with liver disease ranging from fibrosis, cirrhosis, and HCC. Meanwhile, the
noticeable down-regulation of miR-125a, miR-139, miR-145 and miR-199a in
the HCC patient group indicates that these microRNAs can differentiate HCC
from CHC and LC.
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Introduction: Primary hepatocellular carcinoma (HCC) is one of the most
common malignancies all over the world. HCC is associated with poor prognosis.
However, the mechanism of HCC initiation and development remains unclear. In
our previous work, high-throughput microarray assay in collected clinical HCC
samples followed by bioinformatic analysis suggested that Metallothionein 1G
(MT1G) might be one of the key factors in HCC.
Aims & Methods: We detected the MT1G expression in paired HCC samples and
HCC cell lines by RT-qPCR and Western blot. Then MSP (Methylation specific
PCR) and BGS (Bisulfite genomic sequencing) were performed to evaluate
methylation status of MT1G in HCC. The functional significance of MT1G in
HCC was investigated by overexpression or knockdown in HCC cell lines. The
effects of MT1G re-expression were also determined by flow cytometry.
Results: MT1G was inactivated in all (6/6) HCC cell lines tested, but was readily
expressed in immortalized liver cell line LO2. The expression of MT1G was down
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regulated in cancer tissues compared with the adjacent non-tumor tissues
(P5 0.001). The gene expression level of MT1G in the liver cancer cell lines
was closely correlated to the promoter hypermethylation status. The MT1G
expression in silenced HCC cell lines could be restored by demethylation
agent. We generated HCC cell lines overexpressed MT1G. Ectopic re-expression
of MT1G by stable transfection in SMMC-7721 and Hep3B cells inhibited
colony formation (P5 0.001), suppressed cell motility and invasiveness
(P5 0.05), concomitant with up-regulation of E-cadherin; and down-regulation
of PCNA, MMP2, MMP13 and Vimentin. The in vivo growth of HCC cells in
nude mice was also markedly inhibited after stable expression of MT1G
(P5 0.001). MT1G over-expression in HCC cells induced the cell apoptosis
(P5 0.01).
Conclusion: Our results demonstrate that MT1G promoter methylation directly
mediates the transcription down-regulation and commonly occurs in HCC.
MT1G gene can act as a functional tumor suppressor in liver carcinogenesis
by playing an important role in depression of cell proliferation, migration, inva-
sion, and induction of cell apoptosis.
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Introduction: Hepatocellular adenoma (HCA) and focal nodular hyperplasia
(FNH) may be confused on medical imaging. Both tumours are not connected
to the biliary tree, however only FNH accumulates bile salts, suggesting that
hepatocellular uptake and secretion of bile constituents differs in FNH and
HCA. Therefore, one would anticipate changes in the Farnesoid X receptor
(FXR) expression. However, the expression of FXR and its targets in HCA
and FNH is relatively unknown. Targets of FXR regulate uptake and excretion
of hepatobiliary contrast agents, possibly altering the presentation of FNH and
HCA on medical imaging. We studied the expression of FXR and its targets in
HCA and FNH and compared this with the appearance of lesions on MRI.
Aims & Methods: Tumour tissue and normal tissue from 7 patients with HCA
and 7 patients with FNH was obtained. Diagnosis was confirmed by histopatho-
logical examination in all patients. Reverse transcription of the mRNA to cDNA
was performed, using random primers and MultiScribe Reverse Transcriptase
(Life Technologies, Carlsbad, Ca). The cDNA was used as template for PCR
amplification by Taqman assay analysis (Applied Biosystems, Foster City,
CA). The expression of all the target genes in the FXR pathway (SHP, NTCP,
OATP1B1, OATP1B3, BSEP, CYP7A1, CYP8B1, BAAT, SLC27A5, CYP3A4,
SSULT2A1, UGT2B4, FGFR4, MRP2, MRP3, MDR3) were compared to the
expression of UBC which functioned as internal reference in both normal and
tumour tissue. Matched case comparisons were made for tumour and normal
tissue. DNA expression of FNH and HCA was compared to MRI findings.
Results: FXR was downregulated in both HCA and FNH. NTCP was signifi-
cantly downregulated in FNH, and not significantly in HCA, although showing a
trend towards down regulation. Three patients (1 FNH 2 HCA) show aberrant
expression of NTCP compared to all the other patients. All these three patients
had also an unclear or incorrect diagnosis based on MRI scan with gadoxetic
acid as compared to final diagnosis by histopathological examination. OATP1B1
was downregulated in both HCA and FNH, except again for the three patients
with the aberrant imaging. Expression of OATP1B8 and SHP in HCA and FNH
did not significantly differ from expression in healthy liver tissue. MRP2 was
significantly downregulated in HCA, but not in FNH. However, this may again
be due to the patients with the aberrant expression pattern. OATP1B3 was sig-
nificantly downregulated in HCA. CYP3A4 and CYP2A1 were very strong
downregulated in HCA, but not in FNH. FGFR 4 was heavily downregulated
in HCA, but not in not FNH. BAAT was significantly downregulated in HCA.
Conclusion: Limited by sample size, this study suggests that misdiagnosis based
on medical imaging might actually correlate with aberrances on hepatocyte trans-
porter level. This seemed to account for NTCP (bile salt importer), OATP1B1
(bile salt importer) MRP2(efflux pump of conjugated compounds). Although
FXR itself was downregulated in both FNH and HCA, its downstream targets
differed in expression between tumours. FXR receptor activity might be altered
even though expression is not different, or downstream targets might be influ-
enced by factors outside the FXR pathway. Future research could provide a
more profound insight into this mechanism.
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Introduction: CUX1 (CUTL1) is a transcription factor able to promote the
expression of several genes implicated in cellular proliferation, differentiation
and demise. In normal adult cells, it preferentially favors the expression of proa-
poptotic genes. Its aberrant expression in tumor turns its role as foe.
Aims & Methods: Here, we analyze the role exerted by CUX1 during deacetylase
inhibitors mediated cell death in liver cancer cells. CUX1, endoplasmic reticulum
(ER) stress and autophagy markers were analyzed by RT-qPCR in two liver
cancer cell lines HepG2 and Hep3B. Protein level was measured by western
blotting. Cells were transfected with siRNA for CUX1 and furthermore treated
with deacetylase inhibitors panobinostat, SAHA and trichostatin A.
Thapsigargin, an endoplasmic reticulum stress inducer, served as positive
control.
Results: CUX1 knock down caused a suppression of ER stress and autophagy
markers BiP, CHOP, ATF4, ATF6, Beclin1, MAP1LC3B, UVRAG and TFEB
at early time point (6 hours) in both cell lines. Prolonged transfection did not
alter the expression of the above mentioned markers; BiP was the only one
suppressed in HepG2 after 24 hours. Interestingly, the deacetylase inhibitors
are able to promote CUX1 over-expression after 6 hours of treatment, whereas
they show to lose this ability after 24 hours. CUX1 knock-down reduced not
significantly its protein level after treatment with deacetylase inhibitors. CUX1
knock down counteracts the accumulation of BiP protein after 24 hours of
treatment with deacetylase inhibitors. Thapsigargin induced BiP independently
from CUX1.
Conclusion: ER stress and autophagy markers are under the control of CUX1.
The cell death induced by deacetylase inhibitors is strictly connected with CUX1
expression and activity. Further studies are needed to clarify the exact mechan-
ism exerted by CUX1 in this scenario.
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Introduction: CUX1 (CUTL1) is a transcription factor able to promote the
expression of several genes implicated in cellular proliferation, differentiation
and demise. In normal adult cells, it preferentially favors the expression of proa-
poptotic genes. Its aberrant expression in tumor turns its role as foe.
Aims & Methods: Here, we analyze CUX1 activity in TRAIL (Tumour necrosis
factor related apoptosis inducing ligand) mediated cell death in liver cancer cells.
CUX1 was knocked down in HepG2 and Hep3B cells. Cells were further treated
for 48 hours with a strong ligand (superkiller) binding DR4 and DR5 (TRAIL
death receptors). The cell death events were analyzed by FACS analysis. RT-
qPCR was performed to detect the expression of apoptotic markers. Caspase
activity was measured by luminescence. Apoptosis array was performed.
Western blotting was performed for caspase 8 and Flip detection
Results: Treatment with superkiller TRAIL, at 50 and 100 ng/ml, caused cell
death in HepG2 and Hep3B cells after 48 h proven by an accumulation of
40% of sub-G1 events. CUX1 knock down caused a sensitization of liver
cancer cells to TRAIL effect by increasing, significantly, the percentage of sub-
G1 events (60% with 100 ng/ml). CUX1 knock down did not change the expres-
sion of TP53, KRT18, CDKN1A and CDKN1B. Interestingly, silencing CUX1
increased the activity of caspase 3/7 after treatment with soluble TRAIL. The
effect was neutralized by pan-caspase inhibitor zVAD. Apoptosis array evi-
denced an increased protein level of un-/cleaved caspase 3 after CUX1 knock
down. Caspase 8 uncleaved form was down-regulated at protein level after CUX1
knock down and treatment with TRAIL. Its cleaved forms were up-regulated.
FlipL decreased in favor of FlipS also.
Conclusion: CUX1 mediates the resistance of liver cancer cells to TRAIL signal-
ing. Knock down of CUX1 restores the potential of TRAIL to trigger cell death.
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Introduction: Hepatocellular carcinoma (HCC) is a primary malignancy of the
liver. HCC is the fifth most common malignancy in the world and the third most
common cause of cancer-related deaths worldwide. It is a major health problem
in Egypt with the incidence expected to rise continuously in the next decade. [1–2]
The diagnosis of liver cancer depends on both screening with alpha-fetoprotein
(AFP) and radiological imaging studies. Generally, normal levels of AFP are
below 10 ng/ml but AFP greater than 200 ng/ml is suggestive of HCC . The
sensitivity of AFP for liver cancer is about 67%; therefore a normal AFP does
not exclude HCC. Searching another tumor marker, that together with AFP
could improve the diagnostic utility of HCC.[3]
Squamous cell carcinoma antigen (SCCA), a member of the high molecular
weight family of serine protease inhibitors named serpins which are physiologi-
cally found in the granular layers of normal squamous epithelium but found to be
typically expressed by neoplastic cells of epithelial origin in a number of different
cancers for example cancer cervix, lung, and head and neck cancers hence, it can
be used as a clinical marker of these malignancies. [4]
The structure of the serpin ovalbumin revealed the archetype native serpin fold
that typically have three b-sheets (termed A, B and C) and eight or nine -helices
(hA-hI). Serpins also possess an exposed region termed the reactive centre loop
(RCL) that includes the specificity determining region and forms the initial inter-
action with the target protease.
Recently much attention has been focused on the role of SCCA in HCV cirrhotic
patients suggesting that high levels of SCCA can assess HCC development. [5]
The aim of this study was to assess the serum level of squamous cell carcinoma
antigen (SCCA) in cirrhotic chronic HCV patients with and without hepatocel-
lular carcinoma in relation to alfa feto protein (AFP).
Aims &Methods: The aim of this study was to assess the serum level of squamous
cell carcinoma antigen (SCCA) in cirrhotic chronic HCV patients with hepato-
cellular carcinoma in relation to alfa feto protein (AFP). These groups were from
both sexes who are admitted to the inpatient ward and the outpatient clinic of
Tropical Medicine Department, Faculty of Medicine, Alexandria University.
This study was carried out on:
Group A: 100 cases of hepatocellular carcinoma without interventions.
Group B: same 100 cases of group A before and 3 months after successful
interventions.
Group C: 100 cases of established cirrhosis.
Group D: 100 cases with chronic hepatitis C virus infection without established
cirrhosis.
Group E: 100 healthy individuals as controls.
All patients in this study were subjected to: complete blood picture, liver bio-
chemical profile, serum alanine aminotransferase (ALT), serum aspartate amino-
transferase (AST), serum alkaline phosphatase, total and direct serum bilirubin,
prothrombin time and activity, serum albumin blood urea nitrogen (BUN),
serum creatinine. Fasting blood sugar. Serum alpha fetoprotein (AFP).
Determination of squamous cell carcinoma antigen (SCC-Ag) Sera from selected
patients and controls were used for estimation of SCC-Ag using CanAg SCC
EIA. The CanAg SCC EIA is a solid phase, non-competitive immunoassay based
upon the direct sandwich technique. Calibrators and patient samples are incu-
bated together with biotinylated Anti-SCC monoclonal antibody in Streptavidin
coated microstrips. After washing buffered Substrate/Chromogen reagent
(hydrogen peroxide and 3, 3’, 5, 5’ tetra-methylbenzidine) is added to each well
and the enzyme reaction is allowed to proceed. During the enzyme reaction a
blue colour will develop if antigen is present. The intensity of the colour is
proportional to the amount of SCC present in the samples. The colour intensity
is determined in a microplate spectrophotometer at 620 nm (or optionally at
405 nm after addition of Stop Solution). Calibration curves are constructed for
each calibrator. The SCC concentrations of patient samples are the read from the
calibration curve.
Results: Table 1 shows a statistical significant difference between different studied
groups regarding alpha feto protein (P¼ 0.000).
Table 1: Comparison Between Different Studied Groups Regarding Alpha Feto
Protein
Mean Std. deviation Minimum Maximum
Gp. A 263.0 96.02 150. 438
Gp. B 209.4 64.7 145. 380.
Gp. C 154.5 48.16 75. 210.
Gp. D 7 1.82574 5 9
Gp. E 1.22 0.27406 0.8 1.6
F 38.208
P 0.000*
Table 2 shows a statistical significant difference between different studied groups
regarding SCCA level (P¼ 0.000).
Table 2: Comparison Between Different Studied Groups Regarding SCCA
Score
Mean Std. deviation Minimum Maximum
Gp. A 5.53 2.16 2.5 10.
Gp. B 5.3 1.5 3.3 7.6
Gp. C 3.3 1.6 1.2 5.6
Gp. D 0.824 0.15897 0.6 1.05
Gp. E 0.646 0.23172 0.3 0.95
F 28.897
P 0.000*
Also, Positive significant correlation was found between AFP and SCCA in both
groups (Table 3).
Table 3: Correlation Between AFP and SCCA
AFP
HCC without intervention HCC with intervention
SCCA r 0.629* 0.525*
p 50.001 50.001
Note. r: Pearson coefficient, *: Statistically significant at p 0.05
When combined sensitivity of both markers were calculated in our study at the
best-chosen cutoff values (SCCA 3.2 ng/ml and AFP 200 ng/ml) sensitivity
improved to 93% (Table 4).
Table 4: AUC for AFP, SCCA and SCCAþAFP
AUC p
AFPþSCCA 0.930* 0.001
AFP 0.890* 0.003
SCCA 0.820* 0.016
Conclusion: In the present study patients with HCC either with or without ther-
apeutic intervention have significantly higher level of AFP in comparison to
chronic HCV, cirrhotic and control groups this is in agreement with
Awadallah et al.[6] who reported a statistically highly significant elevation in
the serum AFP in HCC group when compared with control group. Moreover,
the mean serum level of AFP in group A (HCC before intervention) was 263 ng/
ml that decreased to 209.4 ng/ml in group B after therapeutic intervention and
this agreed with Feng et al[7] and Molinari et al.[8] Also, at AFP level of 200 ng/
ml, the sensitivity was 90%, while the specificity was 60%.
Our results showed that SCCA level ranged from 2.5–10 with a mean of 5.53 in
HCC patients without interventions, 3.3–7.6 with a mean of 5.3 in patients with
HCC with therapeutic interventions, 1.2–5.6 with a mean of 3.3 in cirrhotic
group, 0.6–1.05 with a mean of 0.824 in chronic HCV group while healthy con-
trol group had much lower values ranging from 0.3–0.95 with a mean of 0.646.
Thus, a highly significant increase in serum SCCA level in patients with HCC
before and after therapeutic intervention when compared to cirrhotic, chronic
HCV and control groups (P5 0.001). These results were in accordance with
Hussein et al. [9] and El Ezawy et al.[10] SCCA was also higher among patients
with HCC before intervention compared to patients with HCC after intervention
as found by Bin et al.[11]
Applying the ROC curves analysis showed the best cut-off value to differentiate
HCC patients from cirrhotic patients was 3.2 ng/ml for SCCA yielded 80% sen-
sitivity and 90% specificity. These results were in agreement with Trevisani
et al.[12] Patients with HCC, in our study were none randomized selected as
BCLC stage B (either one HCC lesion 55 cm in size or 3 lesions 53 cms) so
no statistical correlation was done between serum AFP level and tumor size.
Our results showed a significant positive correlation between serum SCCA and
AFP among patients with HCC before and after therapeutic intervention. Our
data are in agreement with that of Hussein et al.[9] and El Ezawy et al.[10] who
detected that SCCA were positively significantly correlated with AFP level.
When combined sensitivity of both markers was calculated in our study at the
best-chosen cutoff values (SCCA 3.2 ng/ml and AFP 200 ng/ml) sensitivity
improved to 93%. Matching results were found by Gianluigi et al.[4]
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P0068 HEPATOCELLULAR CARCINOMA MULTIDISCIPLINARY
CLINIC – CAIRO UNIVERSITY (HMC-CU) SCORE; A NEW SIMPLE
SCORE FOR EARLY DIAGNOSIS OF HCC
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Introduction: Hepatocellular carcinoma (HCC) is the first most common primary
malignant tumor of the liver, the fifth common cancer and the third most
common cause of cancer-related death worldwide. (1) Early detection of HCC
provides the best chance for a curative treatment which in turn improves patients
survival. However, more than 60% of HCCs are diagnosed at a late stage (2).
This could be explained by poor compliance of cirrhotic patients to the surveil-
lance programs and lack of a sensitive and specific tumor marker. Serum AFP –
commonly used for HCC diagnosis has a low sensitivity, and specificity for HCC
detection(3).
Aims & Methods: The aim of this study was to develop Hepatocellular
Multidisciplinary clinic – Cairo University (MHC-CU) score and test its accuracy
in HCC detection in comparison to the widely used AFP In the current study, we
reviewed the data of 2363 Egyptian patients with HCV genotype-4 related
chronic liver disease CLD; 1291 patients were diagnosed to have HCC while
1072 patients were diagnosed to have HCV related liver cirrhosis with no HCC
on top. All the patients were recruited from the HCC multidisciplinary clinic,
Cairo University Focal hepatic lesions detected by abdominal ultrasound (US)
and/or rising AFP assays were further evaluated by tri- phasic multiphase com-
puted tomography (CT) or contrast-enhanced magnetic resonance imaging
(MRI). Lesions showing enhancement in the arterial phase were diagnosed as
HCC. Diagnosis of HCV related liver cirrhosis was based on clinical, laboratory
and imaging evidence of chronic liver disease in addition to detection of HCV
antibodies and HCV RNA by PCR technique. Each patient signed an Informed
consent and the study was carried out according to the ethical guide-lines of 1975
Helsinki Declaration.
Results: On bivariate analysis, the HCC patients were significantly elder, anemic
and showed significant thrombocytopenia, hyper- bilirubinemia, elevated serum
AST and AFP serum levels. Serum albumin was significantly lower in HCC
patients. Consequently, we entered these significant variables in a multivariate
regression model that demonstrated that only age, gender, hemoglobin, albumin,
AFP and INR were independently associated with HCC development.
Table: Multivariate analysis for calculation of the HMC-CU score.
OR
95% C.I.
P- valueLower Upper
Age Gender Hb INR
Alb AFP Constant
1.164 1.141 1.188 5.001
2.653 1.959 3.594 5.001
0.886 .819 .959 .003
0.498 .267 .931 .029
0.347 .268 .448 5.001
1.022 1.016 1.028 5.001
0.080 .010
The best overall formula that could best predict HCC was then constructed
Hepatocellular Multidisciplinary clinic – Cairo University (MHC-CU) score is
as following: Logit probability of HCC¼2.524þ 0.152 x age - 0.121 x Hb -
0.696 x INR – 1.059 x Albþ 0.022 x AFPþ 0.976 x Gender Gender Male¼ 1
Female¼ 0 The diagnostic value of HMC-CU was then assessed by ROC curve.
At a cutoff point of 0.56 HMC-CU enabled the correct identification of patients
with HCC with 90% sensitivity, 80.6% specificity. AUC was 0.93 and the 95%
confidence interval was 0.917–0.94. On comparing the diagnostic performance of
HMC-CU to the performance of serum AFP for early diagnosis of HCC, it was
found that serum AFP was able to diagnose HCC at cutoff value of 11.9 ng/ml
with sensitivity of 68% and specificity 66%. AUC was 0.76 and the 95% con-
fidence interval was 0.74–0.78
Conclusion: The HMC-CU score constructed from routine parameters is accurate
in early diagnosis of HCC in patients with HCV-related CLD. The elegancy of
our score is based on its simplicity, being based on routine laboratory parameters
and serum AFP which is being used for screening of patients in many centers all
over the world. Our score will not impose extra costs for the patients because it
utilizes only routine laboratory parameters. The HMC-CU score may be useful
during surveillance programs for HCC. Our study included large number of
HCC and non HCC patients all are Egyptians with a background of HCV
type 4 related CLD. A prospective validation study is being planned and further
studies are invited to validate this score on patients of other races infected with
other HCV genotypes.
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P0069 MULTIPLE BIPOLAR RADIOFREQUENCY ABLATION IN
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Introduction: Monopolar radiofrequency ablation (RFA) treatment for hepato-
mas has been unsatisfactory with local tumor recurrent rates of 8–40% in tumors
3 cm. Bipolar RFA devices have been developed to overcome the limitations of
monopolar RFA devices.
Aims & Methods: This study aimed to evaluate the therapeutic effect and long
term survival in medium and large hepatomas using multiple bipolar radiofre-
quency ablation system (Celon). The study subjects had a Child-Pugh classifica-
tion of A or B. The patients who were ineligible for surgical intervention or
preferred RFA over surgery were treated with percutaneous bipolar electrodes.
A total of 30 consecutive cirrhotic patients (48 tumors) with hepatomas 3 cm
were enrolled between January 2011 and November 2012. The follow-up period
was 30 months after RFA. The complete necrosis rate, tumor recurrence rate and
long-term survival rate were analyzed and compared between medium and large
hepatomas using Kaplan-Meier survival and the prognostic factors were using
multivariate analysis.
Results: 30 patients were divided equally into two groups with 15 patients in each
of medium and large hepatoma groups. 17 patients underwent artificial ascites
(56.3%). The complete necrosis rate after ablation was 93.3% (14/15 patients) for
either medium or large hepatomas. The local tumor progression rate and distant
tumor recurrence rate of 40% and 60% (p¼ 0.098) vs 73.3% and 80% (p¼ 0.652)
for medium and large hepatomas during 30 months follow up were not statisti-
cally significant. The overall survival rates of 80%, 66.7% vs 60%, 46.7% at 12
and 30 months, respectively, was not statistically significant (p¼ 0.390). By multi-
variate analysis, BCLC stage (HR¼ 3.904, p¼ 0.023), MELD score (HR¼ 1.220,
p¼ 0.021) and pre-treatment AST level (HR¼ 1.028, p¼ 0.019) were independent
prognostic factors for overall survival.
Conclusion: Multiple bipolar RFA system can achieve high complete tumor
necrosis rate and low complication rates in treating medium to large hepatomas
with shorter duration. Pre-treatment BCLC stage, MELD score and AST level
were independent prognostic factors for overall survival. The therapeutic effect
and long term survival for large hepatomas (5 cm) was not inferior to that of
medium hepatomas by multiple bipolar RFA.
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P0070 RECENT TRENDS IN HEPATOCELLULAR ADENOMAS:
CLINICAL FEATURES, DIAGNOSIS AND OUTCOMES
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Introduction: Hepatocellular adenomas (HCA) are rare, benign tumors of pre-
sumable epithelial origin, that occur predominantly, but not exclusively, in young
women taking oral contraceptives (OC) or other estrogens. The Bordeaux ade-
noma tumour markers are a promising method of identifying the high-risk HCA
of malignant transformation into hepatocellular carcinoma (HCC).
Aims & Methods: Aims: The authors propose to evaluate the demographics,
etiology, clinical manifestations and prognosis of HCA.
We undertook retrospective analysis of patients with HCA, histologically con-
firmed (by guided biopsy or surgical resection), between 2008 and 2016, in a
tertiary referral centre. When feasible, the subtype classification of HCA pro-
posed by the Bordeaux group, was performed. Descriptive statistics, uni and
multivariate analysis were performed using IBM SPSS Statistics 22, with
p5 0.05 deemed to be statistically significant.
Results: In this study 27 patients were included, 2 man and 25 women, with a
median age of 38 11 years, followed for a mean time of 78 36 weeks (lost
follow-up in 7 cases). Three cases of hepatic adenomatosis were included. Forty-
one percent of the women used OC and 38% of the patients had dyslipidemia.
The mean size of the HCA was 70 42mm; 63% of the patients had abnormal
liver tests at diagnosis, 46% were symptomatic and in 21% the diagnosis was
performed due to ruptured HCA. Surgical resection was performed in 88% of the
cases; complete resection was achieved in 75% of the cases. Of the 19 patients
who performed abdominal-CT scan or abdominal-MRI before histological con-
firmation, only 29% had an imagiological diagnosis of HCA. In 12 (44%) cases,
immunohistochemical analysis was performed. According to the Bordeaux clas-
sification of HCA, 8 (67%) cases were classified as inflammatory, 2 (17%) as
HNF-1-mutated, 1 (8%) as b-catenin mutated and 1 (8%) as unclassified.
During follow-up, 1 (4%) patient died due to hemorrhagic shock related with
HCA rupture and in 2 (10%) was necessary surgical revision due to incomplete
resection. There was no HCC cases diagnosed during the follow-up. The median
size of the HCA that weren’t completely resected and also of those presenting
with HCA rupture was significantly higher: (110 vs 55mm [p¼ 0.035] and 105 vs
47mm [p¼ 0.037], respectively). The 2 male patients had inflammatory HCA
(p¼ 0.011).
Conclusion: In this cohort, HCA were prevalent in female taking OC and the
inflammatory type HCA was the most common. In many cases, abdominal
imaging is insufficient for a correct diagnosis, and biopsy specimen or surgical
resection should be performed for a correct diagnosis. Lesion size was associated
with the risk of rupture and incomplete surgical resection.
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Introduction: Currently, the standard treatment using transarterial chemo-embo-
lisation (TACE) for patients showing solitary large (40mm) hepatocellular
carcinoma (HCC) is unsatisfactory with high rate of recurrence. Data from
literature suggest the alternative use of thermal ablation.
Aims & Methods: We aimed to evaluate the efficacy and safety of Laser Ablation
(LA) in comparison to TACE in patients with large tumor size HCC. Between
January 2009 and December 2012, 41 cirrhotic patients (29/12 M/F; median age
72 yrs, range 54–88, Child-Pugh A/B: 37/4) with a single nodule of HCC 40
(median size 46mm, range 40–75) were enrolled in this study. The patients were
treated with multifiber technique of LA. The control group consisting of 41
patients (29/12 M/F; mean age 72 yrs, range 49–86; Child-Pugh A/B: 34/7;
median size of the nodule 50mm, range 40–80, treated with TACE, was obtained
from the ITA.LI.CA database and observed in the same period of time. No
statistically significant difference between the 2 groups was observed. The diag-
nosis of HCC was done according to the international guidelines and patients
were staged according to BCLC Staging System (BCLC stage A/B: 27/14 and 18/
23, for LA and TACE, respectively). Response to therapy was evaluated accord-
ing to the mRECIST criteria. Survival was calculated from the time of cancer
diagnosis to death with values censored at the date of the last follow-up.
Results: Twenty-six (63.4%) patients of LA group and 8 (19.5%) patients of
TACE group showed a complete response after treatment (p5 0.001). The super-
ior efficacy of LA was confirmed in all categories, also after the stratification of
the nodules according to the nodules size (40–50mm, 51–60mm and 460mm).
Disease recurrence, during a meanSD period of follow-up of 37.4 20.7
months, was observed in 13 (24%) LA-treated patients (24%) and in 24
(58.5%) TACE-treated patients (p¼ 0.00515). Overall survival probability rate
at 1 and 3 years was 90.2% and 55.4% in LA group and 85.4 and 48.8. in TACE
group.
Conclusion: LA is a more efficacious therapeutic option than TACE in patients
with solitary large HCC.
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Introduction: Endoscopic ultrasound (EUS)-guided fine needle aspiration (EUS-
FNA) is one of the alternative methods for tissue sampling of liver solid mass.
However, the diagnostic efficacy using cytology alone was limited.
Aims & Methods: In this study, we evaluated the feasibility and diagnostic accu-
racy of EUS-guided fine needle biopsy (EUS-FNB) for hepatic solid masses in
patients with suspected malignancy. The EUS-FNB using 20G, 22G or 25G
ProCore needle (PCN) was performed to evaluate the patient with solid liver
mass. The primary outcome was the diagnostic accuracy of EUS-FNB for malig-
nancy, and adequacy of the specimen for histology. The secondary outcomes
were (1) the proportions of patients in whom immunohistochemical (IHC)
stain was possible, and (2) compared diagnostic yield of FNB according to the
needle size, and (3) safety of EUS-FNB
Results: Forty-one patients (13 women; mean age, 67.9 10.3 years [range, 46–
86]) underwent evaluation with EUS and identified hepatic lesions ranging in size
from 0.7 cm to 15 cm. EUS-FNB with 20G (n¼ 10), 22G (n¼ 24) or 25G PCN
(n¼ 7) was performed (right lobe: n¼ 10, left lobe: n¼ 31). The median number
of needle passes was 2.4 0.8 (range, 1–5). Technical success rates for tissue
acquisition were 97.6%, but both specimen adequacy for histology and available
IHC stain was 92.6%. Three (7.3%) were non-diagnostic and subsequently
proved to be malignant; 2 by smear cytology and 1 after surgical resection.
The diagnostic yield, sensitivity and specificity of EUS-FNB for the diagnosis
of malignancy were 92.6%, 92.6% and 100%, respectively. The diagnostic yield
in 20G PCN and 22G PCN was significantly superior to the 25 G PCN
(p¼ 0.045). There was one bleeding complication, but controlled with endo-
scopic hemostasis with endoclips.
Conclusion: EUS-FNB with core biopsy needle may be a safe and useful modality
in the management of patients with hepatic solid mass. Moreover, 20G and 22G
FNB may be adequate for liver biopsy.
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Introduction: Liver function is a key element in determining outcome of patients
with hepatocellular carcinoma (HCC). For HCC with ascites, estimation of liver
function is particularly important, as they already have decreased liver function.
Aims & Methods: We aimed to find out best method to predict outcome of HCC
patients with ascites. A total of 437 newly-diagnosed HCC patients with ascites
(mean age¼ 56.0 y, male¼ 74.8%, hepatitis B virus¼ 73.2%) were analyzed. We
compared Child-Pugh score, Model for End-Stage Liver Disease (MELD) score,
MELD-Na score, and the Albumin-bilirubin (ALBI) grade for overall survival.
Results: During a median 9.0 months of follow-up (range; 0.1 154.0), mortality
was observed in 373 (85.4%) patients. MELD-Na showed highest time-depen-
dent area under receiver-operating characteristics curves (AUROCs) at 1 year
(0.672) that was significantly higher than ALBI grade (0.605), MELD score
(0.580), and Child-Pugh score (0.580). The median survival was significantly
lower for those with MELD-Na 12 than MELD-Na5 12 (median: 13.6 vs.
3.7 months, p5 0.001). Overall, 350 patients received treatment, and most com-
monly used modality was transarterial chemoembolization (62.3%), followed by
radiofrequency ablation (15.7%) and resection (13.4%). Overall survival was
significantly different for those who received treatment than those who did not
(median survival: 13.3 vs. 2.4 months, p5 0.001). When patients were further
stratified by mUICC stage and MELD-Na score, treatment was not associated
with better outcome for mUICC stage IV patients with MELD-Na 12 (median
survival: 2.2 vs. 1.8 months for treatment vs. best supportive care, p¼ 0.15), while
treatment was associated with better outcome in other subgroups.
Conclusion: In HCC patients with ascites, treatment was associated with better
survival, except for subgroup with advanced tumor with decreased liver function,
indicating that ascites per se is not absolute contraindication for HCC treatment.
For these patients, MELD-Na showed better performance than MELD, Child-
Pugh score and ALBI score for predicting overall survival.
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Introduction: The ideal serological marker in hepatocellular carcinoma (HCC)
has not been identified yet since Alphafetoprotein (AFP) has unsatisfactory
characteristics. Squamous Cell Carcinoma Antigen (SCCA) is expressed in
tissue and serum of HCC patients and when determined immunocomplexed
with IgM (SCCA-IgM) has satisfactory diagnostic and prognostic performance.
Aims & Methods: Aim of our study was to evaluate, in HCC patients, the diag-
nostic and prognostic role of SCCA determination in tissue and in serum sam-
ples. SCCA-IgM levels were determined in 409 sera obtained from 196 HCC
patients and 213 cirrhotics. SCCA tissue expression was analyzed in a subgroup
of 62 patients with biopsy available at diagnosis. Sensitivity, specificity, correla-
tion with clinical and tumor parameters, response to treatment and survival were
evaluated.
Results: HCC patients had SCCA-IgM levels significantly higher than cirrhotics
(P5 0.0001). Sensitivity, specificity, positive and negative predictive values were
76%, 52%, 60% and 70%, respectively. In comparison, sensitivity and specificity
of AFP were 54% and 85%. SCCA-IgM values were correlated to HCC etiology
and size. A cut-off of 130 AU/mL (validated in literature) was used for the
prognostic analysis: patients with SCCA-IgM levels 5130 AU/mL showed a
slightly better survival (p¼ns); in long-term survivors (424 months) and in
Child A patients the difference in survival was statistically significant
(p¼ 0.036 and p¼ 0.01, respectively). A drop in SCCA-IgM levels after TACE
correlated with mRECIST response to treatment. Child-Pugh status was the only
independent predictor of survival at Cox multivariate analysis. A better survival
trend in HCC with low serpin tissue expression was documented (31 vs 24
months, p¼ns). No correlation was found between tissue and serum levels.
Stratifying patients by gender, SCCA-IgM levels showed an opposite behavior
in the prognostic prediction: in males a better survival was documented with
levels 5130 AU/mL while in females with SCCA-IgM 130 AU/mL. In
males, SCCA-IgM levels and Child-Pugh status were identified as independent
predictors of survival. SCCA-IgM levels were directly correlated with tumor size
and BCLC stage in females and with etiology in males.
Conclusion: SCCA-IgM is a sensitive marker of HCC but lacks in specificity. As
reported in literature, SCCA-IgM levels identify patients with better prognosis
(especially in long-term survivors) and the marker confirms its ability in detecting
treatment responders. Lower levels of tissue SCCA seem to be related with less
aggressive tumors, given that the longer survival of these patients. The gender-
based differences observed in our patients, especially with respect to the SCCA-
IgM prognostic role and correlation with clinical and tumor parameters, are
intriguing and focused studies on the point are needed.
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Introduction: The BCLC algorithm is the standard system for clinical manage-
ment of HCC. Data on adherence to this therapeutic paradigm are scarce. The
aim of this field-practice study is to provide a description of HCC patients in
Southern Italy, to evaluate the adherence to BCLC guidelines and its impact on
patients’ survival.
Aims & Methods: We analyzed the region-wide Italian database of Progetto
Epatocarcinoma Campania, which includes data of HCC patients, prospectively
collected from January 2013 to December 2015 in 16 regional centers.
Results: Overall 1008 HCC patients were enrolled: 70.6% patients received thera-
pies recommended by BCLC algorithm, while 29.4% underwent different treat-
ments. Among patients who were treated in adherence to guidelines, a higher rate
of diagnosis on surveillance programs, better liver function, lower rate of AFP
4200 ng/ml, more early stage and monofocal HCC, lower frequency of nodules
45cm, portal vein thrombosis and metastases were observed. The multivariate
analysis showed that non-adherence to treatment guidelines was independently
associated to the BCLC stage B, Child-Pugh classes B-C, and to the presence of
neoplastic thrombosis and metastases. The mean overall survival in patients
treated according to BCLC indications was 35.5months, while in patients man-
aged differently was 31.9 months (p5 0.0001).
Conclusion: Adherence to BCLC algorithm in field-practice was high in early and
end stage HCC patients, but it was poor in intermediate and advanced patients.
This may be due to the wide heterogeneity of intermediate-stage patients, and to
the limited use of sorafenib in advanced-stage patients. Strategies to improve
treatment and stratification of HCC patients are required.
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Introduction: Liver cirrhosis is a great public health burden for Chinese health
system. The most common causese are HBV, HCV, alcohol consumption and
non-alcoholic fatty liver disease, et al. The quality of life of liver cirrhosis patients
is impacted by the physical symptoms and psychological symptoms such as
anxiety as depression.
Aims & Methods: We aimed to investigate the quality of life of patients with
cirrhosis, as well as depression and anxiety. A questionnaire survey was carried
out in 95 patients in our gastroenterology department, Peking University
People’s Hospital from May to August in 2016. The patients were divided into
two groups, cirrhosis group and contral group. The patients in cirrhosis group
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were diagnosed liver cirrhosis without complications. The control group included
the digestive polyps patients without other diseases. The questionnaire included
the World Health Organization Quality of Life (WHOQOL)-BREF, Self-rating
Anxiety Scale (SAS) and Self-rating Depression Scale (SPS). The questionnaire
scores of the two groups were analysized.
Results: A total of 95 valid questionnaires were collected and divided into cir-
rhosis group (n¼ 40) and control group (n¼ 45). In the cirrhosis group, there
were 22 males and 18 females, average age 57.97 10.448 years. In the control
group, there were 45 males, 23 males and 22 females, with an average age of
61.47 13.081, showing no difference from cirrhosis group. WHOQOL includes
four domains: physiological domain, psychological domain, social relationship
domain, environment domain. The scores of liver cirrhosis group: physiological
field (22.23 3.312), psychological field (19.59 3.925), social relationship field
(9.64 2.497), environment domain (26.23 7.534) and control group
(22.96 3.275 in physiological field, 19.87 3.152 in psychological field,
10.58 2.061 in social relation field and 28.36 5.091 in environmental field),
they had no significant difference between the two groups (P4 0.05). The depres-
sion self-rating score of cirrhosis group (47.86 10.782) was significant higher
(P¼ 0.034) than that of control group (42.61 11.564). Meanwhile, there was no
significant difference between the Self-rating Anxiety Scale scores of the cirrhosis
group (38.46 11.917) and control group (37.00 12.521) (P4 0.05) (Table 1).
cirrhosis group control group P value
Age 57.97 10.448 23.85 7.406 0.196
Male(n) 22 18 0.808
Female(n) 23 22 0.736
WHOQOL-BREF
physiological domain 22.23 3.312 22.96 3.275 0.317
psychological domain 19.59 3.925 19.87 3.152 0.721
social relationship domain 9.64 2.497 10.58 2.061 0.063
enviroment domain 26.23 7.534 28.36 5.091 0.129
Self-rating Depression Scale(SDS) 47.86 10.782 42.61 11.564 0.034*
Self-rating Anxiety Scale(SAS) 38.46 11.917 37.00 12.521 0.584
*P50.05: cirrhosis group vs control group
Conclusion: The quality of life and anxiety score in cirrhosis group had no sig-
nificant difference from the control group, but the depression score was higher
than that of the control group.
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Introduction: At the present stage, the treatment of patients with non-alcoholic
fatty liver disease has insufficient effectiveness due to the simultaneous availabil-
ity of a number of recommendations and the lack of an individual approach. Not
enough attention is paid to the study of nutritional behavior and the role of
nutrietics, as additional risk factors for the development of non-alcoholic fatty
liver disease. While eating disorders are a modifiable risk factor.
Aims & Methods: We aimed to study the dynamics of metabolic parameters in
patients with non-alcoholic fatty liver disease (NAFLD) as a result of individual
correction of eating behavior (EB).
52 patients (22 men and 30 women) with NAFLD and visceral obesity were
examined. All patients studied EB (questionnaire DEBQ), physical activity
(PhA), were determined: waist circumference (WC), lipid and carbohydrate meta-
bolism studies were performed, a visceral obesity index (VOI) was calculated, the
body composition was monitored (determination of% visceral adipose tissue
(VAT)) and computed tomography of the abdominal cavity (CT AC) with mea-
surement of the area (S, cm2) of VAT and percutaneous adipose tissue (PAT).
Patients were divided into 2 reciprocal comparison groups (p4 0.05): 1st group.
(n¼ 26) was assigned individual correction of EB based on nutriogenetic exam-
ination (determination of nucleotide polymorphisms of PPARG2 and ADRB3
genes) taking into account the revealed features of EB and PhA, 2nd group
(n¼ 26) - standard non-drug treatment was prescribed according to the general
recommendations of the European Association For the Study of the Liver et al.
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-
alcoholic fatty liver disease (2016).
Results: It was found that after 6 months of compliance with individual recom-
mendations for EB in patients of the 1st group anthropometric and metabolic
parameters improved (p5 0.05): the WC was decreased by 8.9% [8.6; 9.1], the %
of VAT decreased to 8.0% [6.0; 9.0] and S of VAT -up to 84 [82;89] cm2, VOI -
up to 1, 7 [1, 3;2, 4], the lipidogram parameters improved (decreased TG, LDL
and HDL increased) (p5 0.05), the index of NOMA-IR (p5 0.05) was
decreased against the background of a 10.8% decrease in body weight [10.1;
11.2]. 100% compliance of patients of 1 group was noted to adhere to the
appointed recommendations. In the next 6 months in patients 1 st group
(P5 0.05) decrease in VAT/PAT (VAT/PAT5 0.6% in 96.2% of patients)
and VOI (VOI5 1 in 92.3% of patients), in contrast to the dynamics of the
corresponding parameters in the patients of the 2nd group.
Conclusion: Thus, the appointment of an individual correction of eating behavior
can increase the adherence of patients to treatment and achieve a reliable positive
dynamics of metabolic indicators.
With the purpose of increasing the effectiveness of non-drug therapy of patients
with non-alcoholic fatty liver disease, methods for studying the characteristics of
eating behavior should be applied more widely, which will allow timely appro-
priate correction. A more extensive study of nutrigenetics will make it possible to
designate a personified diet, taking into account the detected polymorphisms,
which will make it possible to achieve a significant improvement in metabolic
parameters in this category of patients.
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Introduction: HCV is highly endemic in Egypt with a prevalence of 12%. The
ministry of health through the national committee for hepatic viruses has done an
extra-ordinary effort since the beginning of the DAAs era which resulted in
treatment of almost one million infected patients till now. Still this looks as
the summit of the iceberg and there is still estimated more than 10 million
Egyptians infected with the virus, the majority of them are still undetected.
Aims & Methods: The aim of this work is to give an example of non-govern-
mental efforts which can be done to solve this tough national problem. A group
of young medical and non-medical volunteers all from El Salam village in
Mansoura, Dakahlia governorate, Egypt have worked together. They contacted
mosques and pharmacies in the village and distributed brochures to announce for
the free of charge screening for the virus in the village. They contacted business-
men in the village to sponsor the campaign. They contacted the laboratory of the
village to do the HCV Ab test with nonprofit price.
Results: A total of 2220 citizens have visited the referral lab to do the antibody
test. Only 419 persons proved positive. This gives an estimated prevalence in the
village of 19.0%. 119 patients were insurance patients and they went to treatment
and did not complete the study. The rest 300 Ab þve patients completed the
study. All patients were HBs Ag –ve. 132 PCR –ve (44%) patients from the 310
HCV Ab þve group. The rest 168 patients were þve for HCV RNA (56%). 18
patients of the HCV PCR –ve had previous HCV treatment (6.5%). Only 2
patients of the 168 HCV RNA þve. (1.2%) were previously treated. The PCR
–ve patients without previous treatment were 114 patients (38.0%). So only
62.0% of the HCV Ab þve in the community are PCR þve and require treat-
ment. The total cost for the screening of the 2220 patients was 40.000 L.E. which
means 18.0 L.E per person (almost one Dollar).
Conclusion: The screening costs for HCV Ab positivity can be markedly reduced
if it is done in each village depending on volunteers from the same village work-
ing in related fields like medical, pharmacists, laboratory and social jobs. Only
62.0% of the HCV Ab þve in the community are PCR þve and require
treatment.
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Introduction: Non-alcoholic fatty liver disease (NAFLD) is liver disease with
histological signs of accumulation of cholesterin excessive amount in hepatocyte
in the absence of alcohol consumption by the patient (due to causes other than).
The search for accessible, non-invasive and effective methods of screening for this
pathology, allowing to detect NAFLD at early, potentially reversible stages of
development is relevant. The purpose of the work was frequency estimation of
the prevalence steatosis according to elastometry with controlled attenuation
parameter (CAP) among young people and associated with them specific
body composition.
Aims & Methods: 59 volunteers (students of medical university) at the age of 19–
28 years (the median age of 20.5) have participated in research. There were 22
(37.3%) men and 33 (62.7%) women among them without verified liver diseases.
The survey was conducted in order to exclude or detect risk factors. Determining
the presence and degree of steatosis and the stage of liver fibrosis was performed
with the apparatus FibroScan 502 Touch. The final figures of elasticity of the
liver were estimated in kPa (METAVIR). The controlled attenuation parameter
(QAP) in dB/m was used for the severity of steatosis. Moreover, there was the
bioelectrical impedance analysis of body (BIA), evaluated: body mass index
(BMI), body fat.
Results: The signs of violations of the structure of the liver were diagnosed in 15
people out of 59 (25.4%). The signs of steatosis were founded in 12 (20.3%)
students (CAP4215 dB/m). The signs of liver fibrosis were recorded in 7
(11.9%) people (E4 5, 8 kPa). At the same time the combination of liver fibrosis
and steatosis was diagnosed in 4 (6.8%). After analyzing data of BIA it was
revealed that body weight above normal in 23 (40, 3%); wherein fat body com-
position above normal values in 19 (33, 4%). Results of binary regression ana-
lysis showed that the chance of development of hepatic steatosis in case of excess
adipose tissue increase 28 times (p¼ 0, 045), influence of BMI, gender, age was
statistically insignificant.
Conclusion: Based on the results obtained, it can be concluded that there is high
enough level of distribution of liver steatosis among young people. Transient
elastography (TE) with controlled attenuation parameter (CAP) is a fast, reli-
able, repeatable non-invasive method for the assessment of NAFLD. The devel-
opment of hepatic steatosis among practically healthy young persons validly
associated with the increase the amount of adipose tissue in the body.
Confirmed the importance of evaluation of body composition and lack of infor-
mation of using only BMI when evaluating the chances of development of
NAFLD.
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Introduction: Biliary cannulation is indispensable for therapeutic endoscopic ret-
rograde cholangiopancreatography (ERCP) in patients having biliary disease.
Selective biliary cannulation is often difficult due to anatomical constraints.
Numerous techniques have been attempted to overcome such problems.
Although a wire-guided selective cannulation technique into the bile duct is a
useful approach, conventional guidewires (0.025 or 0.035 inch) are relatively rigid
to pass through the long curved narrow distal segment (NDS) or malignant
stricture and sometimes get flicked off the NDS in such cases. It may be better
to use finer and more flexible guidewire. Hence, we developed a novel guidewire
technique (GTWt) using a micro guidewire (GT wire; 0.016 inch, 300 cm,
TERUMO, Japan) designed for super-selective angiography in difficult cases
of selective biliary cannulation.
Aims & Methods: We aimed to assess usefulness of GTWt for salvage technique
in biliary cannulation. We studied 240 consecutive ERCP-naı̈ve patients between
August 2014 and February 2017. We have tried to perform GTWt to ERCP-
difficult-cases that was defined as patients of unsuccessful cannulation despite
attempts over 15min with conventional techniques including wire-guided cannu-
lation or pancreatic guidewire placement with conventional guidewire (0.025 or
0.035 inch). Following the unsuccessful attempts, the guidewire was changed to
GT wire and selective biliary cannulation was performed under fluoroscopic
control. We assessed the number of patients who benefitted from GTWt and
whether overall success rate of biliary cannulation in ERCP was improved.
Results: Among 240 ERCP-naive patients, 40 were ERCP-difficult-cases (success
rate with conventional technique: 200/240; 83%). Among 40 ERCP-difficult
cases, GTWt was successful in 32 patients (success rate with GTWt: 32/40;
80%). Overall success rate of ERCP-naive patients improved from 80% to
97% (232/240 patients). After ERCP with GTWt, four patients developed mild
acute pancreatitis, which resolved in a few days. No serious procedural accidents
were reported. The 40 ERCP-difficult cases included 22 patients with a long
curved NDS, six patients with juxtapapillary duodenal diverticulum, six patients
with malignant stricture, and four patients with difficult front view of papilla.
Among eight patients who failed with GTWt, seven were successful performing
precut papillotomy or endoscopic ultrasound-guided biliary drainage and one
was interrupted because of developed serious condition.
Conclusion: GTWt as a salvage technique for unsuccessful selective biliary can-
nulation cases improves the success rate of ERCP, and could be attempted before
performing a precut papillotomy, endoscopic ultrasound-guided techniques or
other cumbersome procedures.
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Introduction: To evaluate the safety and effectiveness of this procedure (ERCP) in
patients age 85 years and older.
Aims & Methods: From first January 2010 until end of December 2016 in our
digestive endoscopic unit 3153 patients underwent ERCP, including 351
(11.13%) patients over 85. Characteristics of these patients: The mean age was
89 (range 85–99), 117 males and 234 females. 43 (12.2%) were in treatment with
antithrombotic drugs. The initial diagnosis in 218 patients (62.1%) was choledo-
cholithiasis, malignant CBD stenosis in 92 patients (25.9%), postoperative leak
in 11 patients (3, 13%) and unknown CBD stenosis in 31 patients (8.83%). All
patients underwent the following clinical evaluation before and after ERCP. 34
patients (9.4%) were sedated with Propofol and anesthetists assisted. The rest of
the patients 90.6% were sedated with the intravenous combination of midazolam
and Fentanyl with standardized monitoring (pulse oximetry, heart rate, non
invasive blood pressure measurements) during the procedure. Drug infusion
was performed by the nursing staff and an attending endoscopist.
Results: Deep biliary cannulation was successful in 330 patients (94%). In 127
patients (36.18%) Vater papilla was associated with duodenale diverticula. The
post-ERCP complication rates were as follows: Heperamilasemia in 28 patients
(7.9%), Mild pancreatitis in 12 patients (3.4%), Minor bleeding in 10 patients
(2.8%), Major bleeding in 2 patients (0, 56) and cholangitis in 6 patients (1, 7%).
Conclusion: ERCP is an acceptable procedure in patients of 85 or older in terms
of safety, success and complication rates.
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Introduction: Gallbladder stone (GBS) is a common gastrointestinal disease can
progress to severe cholecystitis and is a strong risk factor for gallbladder cancer
(GBC). Recently, clinical epidemiologic studies revealed that the alcohol con-
sumption has a preventive effect for development of gallstone diseases.
Aims & Methods: To evaluate the relative risks of alcohol consumption for the
gallbladder stone diseases development. Systematic searching was performed
using MEDLINE, EMBASE and Cochrane library from January 1st, 1996, to
December 31st, 2016 for studies assessed the relationship between alcohol con-
sumption and gallbladder stone diseases development risk. The eligibility criteria
was included: 1) studies involving the patients with gallbladder stone with or
without cholecystitis; 2) cohort or case-control studies investigated the associa-
tion between alcohol consumption and gallstone disease development.
Newcastle-Ottawa Scale was used to assess the methodologic quality of each
studies. Data was obtained from each selected studies regarding: 1) baseline
characteristics of the study (cohort, case-control); 2) number of participants; 3)
participants’ clinical features; 4) country; 5) publication year; 6) Risk or odds
ratio with confidence intervals for various levels of alcohol consumption and risk
of gallstone. The random effect model was used to estimate the pooled relative
risks (RR) with 95% confidence intervals (CIs).
Results: Twenty-five cohort and case-control studies were included, and total 12,
581 cases with gallstone diseases among those 172, 509 controls. Alcohol con-
sumption indicated a decreased risk of GSD development (Pooled RR¼ 0.84
[0.79–0.90], P5 0.001). Subgroup analyses according to the alcohol doses (g/d)
confirmed a gradual risk-reduction effect on GSD compared to non-drinkers
(Light: RR¼ 0.97 [0.94, 1.00], p¼ 0.864; Moderate: RR¼ 0.82 [0.79, 0.86],
p¼ 0.777; Heavy: RR¼ 0.70 [0.62, 0.80], p5 0.01).
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Conclusion: In this systematic review with meta-analysis, alcohol consumption
has dose-dependent negative co-relationship with the risk of gallstone disease
development.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: Cholelithiasis and
cancer. Gut and Liver 2012;6:172–187.
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. Int J Surg 2010; doi:10.1016/j.ijsu.2010.02.007
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The
Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised stu-
dies in meta-analyses. [cited March 2017].
Hamling J, Lee P, Weitkunat R, Ambuhl M (2008) Facilitating meta-analyses by
deriving relative effect and precision estimates for alternative comparisons from a
set of estimates presented by exposure level or disease category. Stat Med 27:
954–970.
P0083 ERCP WITH SHORT-TYPE SINGLE BALLOON
ENTEROSCOPE IN PATIENTS WITH SURGICALLY ALTERED
PATIENTS
M. Kida
1, H. Yamauchi1, Y. Kawaguchi1, E. Miyata1, R. Hasegawa1,
T. Kaneko1, K. Okuwaki1, T. Iwai1, H. Kikuchi1, H. Imaizumi1, W. Koizumi2
1Endoscopy & Gastroenterology, Kitasato University, Sagamihara/Japan
2Gastroenterology, Kitasato University School of Medicine, Sagamihara/Japan
Contact E-mail Address: m-kida@kitasato-u.ac.jp
Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) remains
challenging in patients who have undergone surgical reconstruction of the intes-
tine. In 2001, double-balloon enteroscope (DBE) was reported by Yamamoto
et al to be an effective procedure for the diagnosis and treatment of small intest-
inal lesions. In 2005, DBE-assisted ERCP was first successfully by Haruta et al
used to treat a late anastomotic stricture in a patient who undergone biliary
reconstruction by R-Y choledochojejunostomy after liver transplantation.
After that, several studies with long enteroscope have reported that balloon
enteroscope-assisted ERCP (BEA-ERCP) is a safe and effective procedure with
about 69–100% of reaching the blind end. However long type enteroscope allows
us to use limited number of ERCP devices because of its length 200 cm. Then
Olympus Co. introduce the prototype of short single balloon enteroscope (SBE)
with bigger channel 3.2mm in diameter was developed. We will present its use-
fulness and limitation.
Aims & Methods: In order to investigate the usefulness and limitation of short-
type SBE, we have performed totally 183 cases/302 procedures of ERCP with
short-type SBE in patients with B-II (24 cases, 30 procedures), R-Y gastrectomy
(RY; 94, 138), Hepatico-Jejunostomy without gastrectomy (HJ; 29, 58), and
Child/Whipple (CW; 36, 76) from 2009 to 2016. We have investigated its rate
of reaching blind end, time of procedure, success rate of therapeutic procedure,
complications and its limitations.
Results: Using short type SBE, the rate of reaching blind end is B-II: 97% (29/
30), RY: 91% (126/138), HJ: 72% (39/58), CW:93% (71/76), and 88% (totally).
Success rate of therapeutic procedure in reached blind end cases, is B-II: 100%
(27/27), RY: 96% (104/108), HJ: 94% (34/36), CW:100% (67/67), and 97% (232/
238) totally. The average time of procedure is B-II: 38.6min, RY: 47.2, HJ: 38.5,
and CW:44.3, respectively. The reason of unreached cases in HJ without gas-
trectomy group is not enough scope length: 68% (13/19), stricture: 21% (4/19),
adhesion: 11% (2/19). And using long-type SBE, it is practicable to do thera-
peutic procedure in 85% in not enough scope length group (11/13). Concerning
about complication, pancreatitis 3% (8/302), Perforation 1% (4/302), bleeding
0.8% (2/302), and cholangitis 0.8% (2/302).
Conclusion: ERCP with short-type SBE in patients with surgically anatomy is
practicable with high success rate, except for cases with HJ without gastrectomy.
However, even in these cases, most of cases can be performed with long-type
SBE.
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Introduction: Patients undergoing endoscopic retrograde cholangiopancreatogra-
phy (ERCP) and duct clearance for common bile duct stones (CBDS) should be
followed up with an early cholecystectomy to prevent recurrent biliary complica-
tions (1, 2) and acute gallstone pancreatitis. Recently the National Confidential
Enquiry into Patient Outcome and Death (NCEPOD) recommended that defi-
nitive eradication of gallstones by cholecystectomy prevents the risk of a recur-
rent attack of acute pancreatitis (AP). For patients with an episode of mild acute
pancreatitis, early definitive surgery should be undertaken, either during the
index admission or within two weeks (3, 4).
Aims & Methods: 1) To determine time frame between ERCP/duct clearance and
cholecystectomy (CCX) in non-pancreatitis group. 2) To determine time frame
between ERCP/duct clearance and CCX in pancreatitis group. 3) To determine
re-admission rate while awaiting CCX. All patients who underwent ERCP for
CBDS between 01/01/2014 to 31/12/2014 were included in the study. Patients
who had previously undergone CCX (de novo stones) were excluded. All patients
were followed up for a minimum period of 2 years following their ERCP.
Results: A total of 273 patients underwent ERCP for CBDS. Out of these 21.2%
(n¼ 58) had previously had CCX and were excluded. Out of the remaining 215
with gall bladder (GB) in situ, 87.4% (188/215) underwent successful duct clear-
ance at index or subsequent ERCP. Of these, 47.3% (89/188) underwent CCX
1% (2/188) patients are currently awaiting CCX and 51.6% (97/188) did not
undergo CCX. The outcomes in remaining 13.4% (n¼ 27) patients in whom
duct clearance was not achieved are discussed later. In the CCX group, the
median time between ERCP/duct clearance and CCX was 123 days (range 0–
820 days). In this group, 15 patients had gall stone pancreatitis (GSP) on pre-
sentation and the median time between ERCP and CCX in the GSP group was
136 days (range 35–287 days); 12 of these had mild pancreatitis with a median
time to CCX of 140 days (range 60–287 days). 4 patients re-presented with CBDS
while awaiting CCX after duct clearance; 1 had pancreatitis on readmission.
51.6% (97/188) patients who did not undergo CCX after duct clearance are
referred to as non-cholecystectomy (non-CCX) group. This was mainly second-
ary to high ASA grade. We compared patient demographics and presentation
with the CCX group and the results were as follows:
Value
CCX group
(n¼ 89)
Non-CCX group
(n¼ 97)
Median Age 61 years 79 years
Median ASA grade 1 2.8
Female patients 67% 56%
Male patients 33% 44%
Pancreatitis on presentation 17% 11.4%
Readmission with CBDS 4.5% 5.4%
In 27 patients duct clearance was not achieved; 26% (7/27) underwent surgical
management (CBD exploration/on table cholangiogram and CCX). The remain-
ing 74% (20/27) patients were deemed unsuitable for invasive intervention and
were either for symptomatic stent change only or conservative management.
Conclusion: The time period between duct clearance and CCX was longer than
anticipated, especially in patients with mild acute pancreatitis as none of them
underwent CCX during index admission or within 2 weeks of ERCP/duct clear-
ance. Some patients re-presented with CBDS while awaiting CCX. We looked
into potential causes of delay in CCX – delayed referral to surgery, long waiting
time for elective CCX and patient choice. We propose to develop a local pathway
for patients with CBDS and gallstones and induct a robust system for referring
patients for CCX following duct clearance. This would help to minimize read-
mission and potential complications.
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Introduction: The placement of self-expandable metallic stent has become the
treatment of choice to restore luminal patency in the palliative treatment of
unresectable malignant biliary stricture. Currently, drug-eluting stents (DESs)
are developed to prevent tumor invasion into the stent and to prolong stent
patency. However, the capacity of drug per unit area varies with the position
in membrane, and the control of drug release is impossible in current available
DESs.
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Aims & Methods: The aim of current study is to develop the multi-layer drug
eluting membrane using ultrasonic spray coating method, which have uniform
capacity of drug and be able to control the drug-release capacity.
Methods: The drug eluting membrane was made using ultrasonic spray coating
machine (MediCoat-2JX). The membrane consists with two kinds of coating
material. One is silicone (MED-6640), that was used to basic structure of mem-
brane and the other coating agent is polyurethane (tecophilic, tecothane,
Tecoflex and pellethane). The gemcitabine was used as antitumor drug, and
coated to membrane by mixed form with polyurethane (gemcitabine, 250ug/ml;
polyurethane, 500ug/ml). The thickness of membrane and the capacity of drug in
membrane were measured at the proximal and distal end, and mid portion. The
drug release capacity and duration was measured by using drug releasing test
in vitro for 3 days.
Results: The mean thickness of membrane was 50um. The mean capacity of drug
per unit area was 100 ug/cm2, and the amount was constant in all tested area
(Standard deviation, 5 ug/cm2). In drug release test, the capacity of releasing drug
was different depended on the kinds of polyurethane. The total amount of
released drug in 24 hours was 919 ug, 836 ug, 681 ug, and 580 ug in tecophilic
coating, tecothane coating, tecoflex coating, and pellethane coating. The total of
released drug amount depended on polyurethane was described in table 1.
Table 1: The total of releasing drug amount in 72 hours
Coating Polymer
Drug release amount
Gemcitbine (ug)
24 hrs 48 hrs 72 hrs
Tecophilic 919 927 933
Tecothane 836 859 868
Tecoflex 681 690 698
Pellethane 580 604 622
Conclusion: The ultrasonic spray coating technique could be applied to make
multi-layer drug eluting membrane with regular thickness. The membranes con-
tained the uniform capacity of drug in all tested area. The releasing drug capacity
is able to control by applying different kind of polyurethane.
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Introduction: Local treatment of primary bile duct cancer is a challenge and
endoscopic stent insertion is widely used to maintain the bile duct patency.
Drug eluting stent is currently developed to add the ability of antitumor effect.
Aims & Methods: We aimed to evaluate the antitumor effect of the paclitaxel,
gemcitabine, and mitomycin C-eluting polyurethane membrane in a tumor
model. Total of 24 mice were used in current study and divided into four
groups, each group had six mice. Membranes containing different antitumor
drugs (paclitaxel, gemcitabine, mitomycine C, 100mg/disc) were inserted beneath
the tumor mass in mouse models. Tumor size and body weight of the tumor
model were monitored for 22 days after insertion of the membrane. The results
were compared with the tumor model which was inserted only silicone membrane
(control).
Results: Tumor volumes on day 22 of membrane treatment were decreased in all
drugs, that were significantly different compared to those of control (paclitaxel,
291.77mm3, P value¼ 0.4116; gemcitabine, 63.38mm3, P value¼ 0.0001; mitomy-
cin C, 119.02 mm3, P value¼ 0.0029; control 1362.62mm3). The antitumor effect
of gemcitabine was tended to be superior compared to other drugs. However, it
was not statistically difference. No significant difference in body weight change
was observed among groups.
Membrane
only Paclitaxel Gemcitabine Mitomycin C
Mouse weight (g) 24.28 21.05 19.56 20.67
Tumor volume (mm3) 1362.62 291.77 63.38 119.02
Tumor weight (mg) 1025 524 496 443
Conclusion: The drug-eluting membrane showed significant antitumor activity.
However, the effect was not different according to kinds of the antitumor drugs.
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Introduction: Liquid-based sample preparations for cytology have improved the
cellular yield in pancreatico-biliary (PB) malignancy (1). The SurePath (SP) meth-
odology produces a pellet of concentrated cellular material which enables addi-
tional slides for immunohistochemical (IHC) staining for tumour markers Ki67,
p53 and CDX2. The presence of the mitosis-related marker, Ki67, in high con-
centration and with a specific pattern adds a level of confidence in diagnosing
malignancy using cytological preparations. The aim of this study was to assess
Ki67 staining in biliary epithelium obtained from patients with bile duct
obstruction.
Aims & Methods: Brushings were obtained from the common bile duct during
endoscopic retrograde cholangiopancreatography (ERCP) in patients presenting
with biliary obstruction. After collecting the sample, the brush was placed imme-
diately into a SurePath vial and shaken vigorously to fix and suspend the cells. In
the cytology laboratory, the vial (with brush included) was agitated on a platform
vortex for 10 minutes to shake the cells off the brush into the solution. The high
cellular content enabled the preparation of multiple slides for IHC and these
slides were reviewed independently by two senior cytopathologists.
Results: Thirty-four (34) consecutive patients with bile duct obstruction were
included in the study. The cohort had a mean age of 70.2; 41% were female.
Adenocarcinoma was identified in 19 (56%) and atypical/reactive cells in 9
(26%). Ki67 positive nuclei were present in 90–100% of the cells in malignant
cell clusters, while sheets of normal cells had positive nuclei in less than 20% of
cells. Atypical cells sheets had an intermediate percentage range.
Conclusion: SP is superior to conventional slide-based cytology preparations in
the diagnosis of malignant bile duct strictures. Advantages include ease of collec-
tion, no requirement for a cytology technician, a sizable pellet of intact cells for
the cytopathologist to examine and the ability to undertake IHC staining. Ki67 is
a marker of cell division and cells stained with Ki67 are increased significantly in
adenocarcinoma as confirmed by this study. The presence of a large number of
cells stained with Ki67 as well as the pattern of intracellular staining adds a level
of confidence for the cytopathologist to diagnose malignancy, particularly when
there is no clinical or scan evidence of a tumour mass. Early diagnosis is the key
for curative surgery and specific cell tumour markers &/or their pattern may
impact significantly on the outcome.
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Introduction: Palliative biliary drainage was used to improving obstructive jaun-
dice, nutritional status, quality of life along with survival rate in unresectable
distal malignant biliary stricture patients. The ERCP with biliary drainage with
or without systemic chemotherapy are mainstay of treatment in these patients.
The benefits of biliary stent type, which are different in cost on survival rate,
nutritional status and efficacy of biliary drainage in DMBS patients are still
questionable in limit health budget country.
Aims & Methods: We aimed to assess the impact of endoscopic palliative biliary
drainage stents on survival rate, nutritional status and efficacy of biliary drainage
of patients in distal biliary malignant stricture patients.
All of the computerized medical records of distal biliary malignant stricture
patients, who were undergoing to endoscopic biliary drainage from January
01, 2012 to December 30, 2015 in Songklanagarind hospital were retrospectively
review. ERCP with biliary drainage stents was undertaken at the discretion of
attending physicians. The overall survival rate, nutritional status (body weight),
efficacy of biliary drainage (level of total bilirubin) after biliary drainage between
the metal stent group, plastic stent group and plastic stent followed with metal
stent group were compared.
Results: Sixty eight patients (45 males, mean age 63.7 þ/14.8 years) were
enrolled, 35 patients were classified into the plastic stent group, 18 patients
were classified into the metal stent group and 15 patients were classified into
the plastic stent followed to metal stent group. Demographic data, primary
malignancy, tumor staging and ECOG score, initial total bilirubin and stricture
length were similar between 3 groups. The median survival time was 5.4 months
95%CI (3.2–8.5) and overall survival rate was lowest in the metal stent group
(median 3.2 months 95%CI 1.8–6.9). Mean weight reduction and the declining of
total biliary after biliary drainage were not significantly different between biliary
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stent types. The plastic stent group had lowest cost of total ERCP statistically
significance. The complications rate was not different between biliary stent types.
Conclusion: Palliative biliary drainage with plastic stent in unresectable distal
malignant biliary stricture was slightly better on survival rate and was not dif-
ferent in nutritional status, efficacy to drainage and complication rate compared
with metal stent or plastic followed with metal stent. But the plastic stent group
had lowest cost of total procedure.
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Introduction: The most widely used standard for determining the effectiveness of
chemotherapy is a set of rules called Response Evaluation Criteria in Solid
Tumors, or RECIST. However, it is often difficult to evaluate radiologic
response to chemotherapy especially in patients with biliary tract cancer (BTC)
mainly because of the pathognomonic tumor progression along bile duct and/or
inflammatory reaction induced by indwelling biliary drainage. Therefore, quan-
titative evaluation using tumor markers is expected to play complementary roles
to assess treatment efficacy, however, the prognostic value of carbohydrate anti-
gen 19-9 (CA 19-9) kinetics in patients with advanced or recurrent BTC receiving
chemotherapy remains to be elucidated.
Aims & Methods: Between January 2006 and March 2016, a total of 185
advanced or recurrent BTC patients receiving a first line systemic chemotherapy
for at least two cycles were retrospectively studied. Serum CA 19-9 was measured
at baseline (CA19-9_Pre) and after two cycles of chemotherapy, and patients
were categorized into three groups based on CA19-9 response: CA19-9 decrease
group (30% decrease), stable group (530% decrease and 20% increase) and
increase group (20% increase). The Cox proportional hazards model was used
to analyze the prognostic factors for OS and PFS, using the landmark method.
Results: The primary tumors were located as follows: 68 (37%) in intrahepatic
bile duct, 43 (23%) in extrahepatic bile duct, 64 (35%) in gallbladder and 10 (5%)
in ampulla. As for chemotherapeutic regimen, single-agent or combination ther-
apy was given in 49 (26%) or 136 (74%), respectively. After 2 cycles of che-
motherapy, partial response was achieved in 29 (16%) and stable disease in
112 (60%), giving response rate of 16% and disease control rate of 76%. The
median CA 19-9 levels at baseline and after two cycles were 264 IU/mL and
194 IU/mL, respectively. After 2 cycles of chemotherapy, CA19-9 decrease was
obtained in 77 (42%), stable in 56 (30%), and increase in 52 (28%). The median
PFS and OS were 5.62 months (95% confidence interval [CI], 5.29–13.28) and
13.71 months (95% CI, 11.38–22.06). There was a statistically significant trend
for CA 19-9 and RECIST responses (p¼ 0.05). Compared with CA19-9 decrease
group, hazard ratios for stable and increase groups were 1.22 (95% CI, 0.79–
1.87) and 2.42 (95% CI, 1.57–3.72) for PFS, respectively (p for trend 50.001),
and 1.04 (95% CI, 0.68–1.59) and 2.54 (95% CI, 1.68–3.85) for OS (p for trend
0.060). Multivariable analyses showed that CA19-9 response was prognostic both
for OS and PFS in addition to CA19-9_Pre and performance status.
Conclusion: CA 19-9 response after two cycles as well as baseline served as a
prognostic factor for OS and PFS in patients with advanced and recurrent BTC
on systemic chemotherapy.
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Introduction: Patients with unresectable perihilar cholangiocarcinoma (PHC)
typically present with obstructive jaundice. They require percutaneous or endo-
scopic biliary drainage for symptom relieve and eligibility for palliative systemic
chemotherapy. However, biliary drainage in unresectable PHC is complex with a
high failure and complication rate even in tertiary referral centers.
Aims & Methods: The aim of this study was to investigate the failure and com-
plication rate of the initial drainage procedure in patients with unresectable PHC.
Consecutive patients with unresectable PHC on imaging in two tertiary referral
centers between 2002 and 2014 were identified. Patients were included if a biliary
drainage procedure was performed. Baseline patient and tumor characteristics
Abstract No: P0088
Table1.: Demographic data
Variable Group 1 Plastic stent Group 2 Metal stent Group 3 Plastic – metal stent P value
Number 35 18 15
Gender (male), (%) 26 (74%) 9 (50%) 10 (66%) 0.209
Age (year) 61.2 71.3 60.7 0.04
Primary malignancy
Head of pancreas
Cholangiocarcinoma
Ampulla cancer
Neuroendocrine tumor
Hematologic malignancy Metastasis
16 (46%)
4 (11.4%)
10 (28.6%)
1 (2.9%)
2 (5.7%)
2 (5.7%)
11 (61%)
1 (5.6%)
4 (22.2%)
1 (5.6%)
1 (5.6%)
11 (73%)
1 (6.7%)
2 (13.3%)
1 (6.7%)
0.869
Stage of disease 1 2 3 4 6 (17.1%)
12 (34.3%)
6 (17.1%)
11 (31.4%)
5 (27.8%)
3 (16.7%)
2 (11.1%)
8 (44.4%)
3 (20%)
10 (66.7%)
2 (13.3%)
0.076
ECOG pre-treatment 1 2 3 20 (57.1%)
12 (34.3%)
3 (8.6%)
5 (27.8%)
9 (50%)
4 (22.2%)
11 (73.3%)
4 (26.7%)
0.062
Initial TB (mg/dL) 20 17.6 17.6 0.599
Body weight (kg) 51.8 (10.2) 46 (7.9) 53 (11.6) 0.082
Stricture length (mm) 23 20 17.8 0.481
CMT (yes, %) 6 (17.1%) 5 (27.8%) 4 (26.7%) 0.587
Complications ERCP Biliary stent 2 4 1 2 1 3 1
Cost of ERCP (bath) 26, 531 (9, 069) 22, 113 (7, 732) 38, 424 (10, 268) 50.01
Cost biliary stents (bath) 2, 480 (1, 495) 29, 539 (5, 564) 29, 965 (6, 382) 50.001
Cost of total procedure (bath) 28, 917 (10, 018) 55, 471 (14, 398) 69, 262 (12, 135) 50.001
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and data on the biliary drainage procedure were collected from medical records.
Definitions of failure of drainage or other severe drainage related complications
are shown in table 1.
Results: In total, 187 patients were included. Initial drainage was performed in a
non-referral center in 125 patients (66.8%). The initial drainage procedure was
endoscopic in 158 patients (84.5%) and percutaneous in 29 patients (15.5%). A
stent was placed in 91 patients (61.5%) at the initial drainage procedure. The
highest bilirubin level in the 2 weeks prior to drainage was 248 (IQR 138–377)
mmol/L. Only 14 (8.1%) patients had cholangitis prior to the initial drainage
procedure. Failure of drainage or other severe complications related to the initial
drainage procedure were noted in 117 (62.6%) patients. Failure of drainage or
reintervention was most common and was noted in 95 patients (50.8%). Bile duct
injury occurred in 3 (1.6%) patients, acute pancreatitis in 5 (2.7%) patients and
cholangitis in 11 (5.9%) patients. Two (1.1%) patients had cardiopulmonary
complications and 1 (0.5%) patient had a duodenal perforation. The median
period between the initial and second drainage procedure was 13 (5–31) days
and the bilirubin level dropped below 50 mmol/L in 27 patients (14.4%). After
initial drainage, 20 patients (10.7%) died within 30-days and 66 patients (35.3%)
within 90 days. The median OS after initial drainage was 6.6 (95% CI: 2.0–15.2)
months.
Conclusion: Patients with unresectable PHC on imaging have a very high failure
and complication rate after initial biliary drainage.
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Introduction: Endoscopic retrograde cholangiopancreatography (ERCP)-guided
brush cytology has become the most widely used method, although with limita-
tions, in the initial diagnostic evaluation of patients with biliary strictures.
Aims & Methods: The objective of the study was to evaluate if the systematic use
of 10 brush passages improves the diagnostic yield of brush cytology guided by
ERCP of bile strictures. ERCPs between 2012 and 2015 involving brush cytology
of bile strictures for suspected malignancy were included in the study. Cytologies
were obtained using the Brush Master V (Olympus Medical System). Histological
evaluation was performed by two experienced cytopathologists.
Results: In total, 62 patients underwent cytology of biliary strictures, with a
median age of 69 years (IRQ: 55–81). The cytological analysis was compatible
with adenocarcinoma in 30.6% of the cases, low grade dysplasia in 3.2%, high
grade dysplasia in 1.6% and adenoma in 1.6%. In 26 patients the cytology was
negative (41.9%) and in 13 cases it was considered inconclusive (21%). Fifteen
patients were subsequently submitted to surgery (24.2%). In 34 cases (54.8%)
there was a correlation between the cytology and the final diagnosis. In the
univariate analysis, previous history of cholecystectomy (73.7% vs. 26.3%,
p¼ 0.047), cytology suggestive of malignancy/adenocarcinoma (89.5% vs.
10.5%, p5 0.001) and final non-equivocal diagnosis (14.3% vs. 85.7%,
p¼ 0.002) were associated with positive correlation. If the cytology and final
diagnosis are coded as "malignant, " "benign, " or "inconclusive, " the correlation
increases to 67.7%. In this situation, the univariate analysis showed that the
presence of malignancy in cytology (87.5% vs. 10.5%, p¼ 0.009) and final
non-equivocal diagnosis (35.7% vs. 64.3%, p¼ 0.012) were associated with a
positive correlation. If the cases identified as undetermined cytology were
excluded, there was no increase in correlation with the final diagnosis (56.5%).
Conclusion: The systematic use of 10 passages in the cytology of the biliary tract
modestly increases the accuracy of the detection of malignant versus benign
situations.
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Introduction: Endoscopic biliary stenting is widely accepted as effective palliation
therapy for unresectable malignant hilar biliary obstruction (MHBO). Although
draining more than 50% of liver volume is associated with better outcomes,
insertion of multiple stents is technically difficult.
Aims & Methods: The aim of this study was to evaluate differences in technical
feasibility and clinical efficacy between unilateral and bilateral stent-in-stent
(SIS) placement of metal stents for MHBO. We retrospectively reviewed 23
consecutive patients with MHBO who underwent endoscopic biliary drainage
with self-expandable metal stents (SEMS) at our institution from March 2012
to March 2017. Unilateral metal stenting was performed in 15 patients (Uni
group) and bilateral metal stenting was performed in 18 patients (Bi group). In
the Uni group, we placed uncovered SEMS. In the Bi group, we placed cross-
wired metal stents with the SIS technique. Technical success rates, complication
rates and stent patency were compared between groups.
Results: There were no significant differences between the Uni group and the Bi
group in technical success rate (100% vs. 94%), complication rate (0% vs. 0%),
stent occlusion rate (15% vs. 18%) or median stent patency period (102.5 days vs.
98 days). There was no significant difference in cumulative stent patency between
the groups (p¼ 0.669).
Conclusion: Endoscopic bilateral SIS placement of metal stents for palliative
treatment of MHBO had a high technical success rate and low complication
rate, similar to those of unilateral placement.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The commonest indication for biliary stent is for the treatment of
obstructive jaundice and for the management of bile leak. The currently available
stents are made of either plastic or metal alloy. The stents can be inserted endos-
copically to provide internal drainage of the bile into the duodenum. Among the
disadvantages of plastic stents are recurrences of jaundice due to biofilms for-
mation, which require a repeat ERCP procedure to remove the stent before 3
months. We have embarked to study the safety and feasibility of a biodegradable
biliary stents (BBS), which can treat biliary obstruction without the need to
undergo a repeat endoscopic procedure to remove the stents.
Aims & Methods: This is a pilot study enrolling 30 subjects with symptomatic
jaundice and pruritus caused by either benign or malignant biliary obstructions
that were amenable to treatment by ERCP guided stenting. Primary objective
was technical success and safety. Procedural and technical successes were
assessed during the stenting procedure. Adverse events or complications were
monitored throughout the studies. The secondary endpoints were clinical success,
which was measured by a reduction of at least 20% of the initial serum bilirubin
level at Day 7 post stenting. A simple self-assessment scale from 0 to 10 was used
to assess quality of life before and after the stenting.
Results: 30 patients had the Biodegradable Biliary Stent (BBS) implanted, 18
patients (60%) were males, the mean age was 56.9 years, 26 patients (86.7%)
had benign biliary duct disease and 4 (13.3%) patients had malignant condition.
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Table 1.: Definitions of failure of drainage and other severe drainage related complications
Cholangitis Elevation in temperature more than 38, 5C and Leukocytes 10 *109/L, thought to have a biliary cause, without con-
comitant evidence of acute cholecystitis, requiring invasive intervention.
Acute cholecystitis Radiologic evidence of cholecystitis, elevation in temperature more than 38.5C and Leukocytes 10*109/L, and requirement
of percutaneous drainage or emergency cholecystectomy.
Failure of drainage or Reintervention Rising or steady bilirubin level after therapeutic success had initially been obtained, without signs of cholangitis or chole-
cystitis, requiring new cannulation of the tumor. Bilirubin levels 450 mmol/L within 14 days after the initial procedure
Unsuccessful cannulation during the initial drainage procedure.
Second drainage procedure 14 days after the initial procedure.
Acute pancreatitis Abdominal pain and a serum concentration of pancreatic enzymes (amylase or lipase) 3 times the upper limit of normal,
that requires 1 one night of hospitalization.
Biliary injury Injury to the bile duct documented by any radiographic technique requiring intervention.
Duodenal perforation Perforation of the duodenum documented by any radiographic technique requiring intervention.
Cardiopulmonary complications Any pulmonary or cardiac abnormality occurring during the drainage or in the post-intervention period that produces
identifiable disease or dysfunction which is clinically significant and adversely affects the clinical course.
A192 United European Gastroenterology Journal 5(5S)
Table 1: Patients’ Demography
n¼ 30 (%)
Gender: males, females 18 (60%), 12 (40%)
Indication: Benign Biliary
Obstruction, Malignant
Biliary Obstruction
26 (86.7%), 4 (13.3%)
Age (mean sd) 56.9 18.9
9 patients had the fast and medium degradation stents respectively and 12 had
the slow degradation stents implanted. All stents were 3.4mm in diameter and
the length ranges from 60 to 120mm depending on the level of obstruction. It
took an average of 29.6 minutes to complete each procedures, and the mean stent
deployment duration was 6.0 minutes. It ranges from 13.5 minutes in the initial
phase and improved to 1.5 minutes in the later phase. Biliary sphincterotomy was
not necessary for inserting single biodegradable stent, but however, all patients
with biliary stone had sphincterotomy to fascilitate retrival of the stones. Serum
bilirubin level (SBL) showed reduction of 52% from the mean SBL of 54.9mmol/
L prior to stenting to 26.2 mmol/L at Day 7. Quality of life score improved from
2.0 up to 8.5 after stenting. The BBS ranks high in terms of loadability, track-
ability over guide-wire, and pushability with push catheter. There was minimal
force required to implant it and it has good visibility by fluoroscopy. The BBS is
as flexible as the conventional plastic stents and can be accurately deployed under
fluoroscopy. Technical success or completion of the ERCP and stent deployment
was achieved in all 30 patients.
Conclusion: This pilot study has shown encouraging results. It benefit the patient
to avoid the burden of a second ERCP procedure for plastic stent removal.
However, these results should be interpreted with caution as this is a pilot
study to assess the safety and efficacy of the biodegradable stent on limited
number of volunteers with symptomatic jaundice. We plan to conduct a phase
2 study involving a larger number of cohorts with a more specific indication of
benign and malignant biliary stricture.
Disclosure of Interest: H. Othman: The Biodegradable Biliary Stents used for this
study is sponsored by amg International GmbH, Winsen, Germany. The authors
have no financial relationship with the company which could inappropriately
influence or bias the content of this presentation.
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Introduction: Stellate cells contribute significantly to the development of several
diseases. In particular, liver stellate cells are responsible for liver fibrogenesis and
further for cirrhosis that culminates into cancer development eventually. In pan-
creas, it is known that stellate cells sustain the tumor cells via autophagy
mechanism.
Aims & Methods: This study aimed to clarify the involvement of Toll-like recep-
tor 5 (TLR5) in the activation of human stellate cells. LX-2 liver stellate cells and
HPSC (human pancreatic stellate cells) were treated for 48 hours with 2.5 ng/ml
TGF-beta 1. The analysis of activation markers was performed by RT-qPCR,
western blotting and immunofluorescence. Real-time cell monitoring with
Incucyte was performed. TLRs PCR Array was performed. TLR5 knock down
was obtained with commercially validated siRNAs.
Results: Treatment with 2.5 ng/ml TGF-beta 1 caused the activation of both LX2
and HPSC cells. Over-expression of alpha smooth muscle actin (a-SMA) and
collagen 1 (COL1A1) transcripts was observed. The protein level of a-SMA and
COL1A1 significantly increased also. Interestingly, SNAIL 1, SLUG, TLR5 and
TLR3 transcripts were induced by treatment with TGF-beta 1 in both cell lines.
SNAIL 1 was over-expressed at protein level also. Knock down of TLR5 neu-
tralized the activity of TGF-beta 1 by keeping the expression of the above mar-
kers at basal level or even not expressed.
Conclusion: TLR5, for the first time, has been identified as key player of the
activation of stellate cells. Its contribution represents a new aspect in terms of
interaction between immune system and stellate cells and could represent a
potential new target for the diseases of the gastrointestinal tract involving the
activity of stellate cells. TLR5 and its natural agonist flagellin could be a key link
between impairment of microbiota and organo-fibrosis in the gastrointestinal
tract.
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Introduction: The cystic fibrosis transmembrane conductance regulator (CFTR)
has a major role in pancreatic ductal secretion and it’s genetic defects damage the
pancreas. It is known that intracellular Ca2þ homeostasis is disturbed in bron-
chial epithelial cells in cystic fibrosis (CF), but the connection of CFTR and the
intracellular Ca2þ signaling has never been suggested in pancreatic damage in CF
before.
Aims & Methods: Our aim was to characterize the Ca2þ homeostasis of CFTR-
deficient PDC. Wild type (WT) and CFTR knockout (KO) mouse pancreatic
ductal and acinar cells and iPSC (induced pluripotent stem cell) derived human
organoids from 2 CF patients and controls, human CF pancreatic cell line
(CFPAC-1; F508 mutant) were used for intracellular Ca2þ measurements.
Mitochondrial membrane potential (m) and mitochondrial morphology was
assessed in isolated pancreatic ducts. Immunofluorescent staining and quantita-
tive PCR measurements were performed to detect changes of mRNA and protein
expressions.
Results: The plateau phase of the agonist-induced Ca2þ signal was elevated in
CFTR-deficient PDC, which was caused by decreased function of the plasma
membrane Ca2þ pump (PMCA). The functional inhibition of CFTR had no
effect on the PMCA activity. Human CF organoids have shown decreased
PMCA function compared to control while the 24 h treatment of the CF orga-
noids with VX-809 have restored the PMCA function to the control level.
Similarly native CFPAC-1 cells and PDEC treated with siRNA to inhibit the
expression of CFTR showed the same PMCA dysfunction. Viral transfection of
CFPAC-1 with CFTR gene completely restored PMCA function. Sustained
[Ca2þ]i levels decreased m and induced cytochrome c release in CFTR KO
PDEC without significant alterations in mitochondrial morphology.
Conclusion: Dysfunction of PMCA leads to disturbed Ca2þ homeostasis in
CFTR-deficient PDC and the consequent cellular Ca2þ overload impairs mito-
chondrial function contributing to the pancreatic damage in CF.
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Introduction: Given their capability to differentiate to every cell type of the
human body, human induced pluripotent stem cells (hiPSCs) provide a unique
platform for developmental studies and regenerative medicine. The generation of
pancreatic progenitor (PP) cells from pluripotent stem cells follows the sequential
induction of virtually pure definitive endoderm (DE), foregut endoderm (GTE)
and pancreatic endoderm (PE). We have recently reported the generation of a
novel three-dimensional pancreatic organoid culture system that generates func-
tional acinar-/ductal-like structures from pluripotent stem cells (Hohwieler et al,
GUT, 2016).
Aims & Methods: In the current study we implemented this culture system to
understand the role of exocrine differentiation and proliferation factor (Exdpf), a
signalling molecule proposed to be involved pancreatic differentiation in zebra-
fish. CrisprCas9 technologies were used to ablate Expdf in human embryonic
stem cells, while a piggy bac engineering approach allowed us timed expression to
study the role of both loss and gain of Exdpf function during pancreatic
differentiation.
Results: First, a limited role of Expdf was observed until the PE stage, while PP
formation was strongly diminished. Moreover, a dramatically altered organoid
morphology was observed upon Expdf knock out leading to mostly cystic struc-
tures. Phenotyping for ductal and acinar lineage allowed to investigate these
United European Gastroenterology Journal 5(5S) A193
changes in more detail and genome wide expression profiling helped us to under-
stand the role of Expdf in more detail.
Conclusion: Thus, we report a novel signalling molecule playing a critical role
during human pancreas development based on a pluripotent stem cell differen-
tiation platform.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK), melatonin
metabolite, has been demonstrated recently as effective pancreatic protector
against acute inflammation. AFMK significantly attenuated acute pancreatitis;
however, its effect on pancreatic exocrine function has not been investigated yet.
Aims & Methods: 1. To investigate the effects of intraduodenal (i.d.) application
of AFMK on pancreatic enzyme secretion under basal conditions and following
the stimulation of this secretion with diversion of pancreato-biliary juice (DPBJ)
and to examine the role of CCK in this process. 2. To assess the effect of AFMK
on CCK receptor in pancreatic acinar cell line AR42J. Material and methods:
For in vivo study Wistar rats weighing 300 g were employed. Under pentobarbi-
tane anesthesia the animals were surgically equipped with silicone catheters,
inserted into pancreato-biliary duct, and into duodenum. AFMK (5.10mg/kg
i.d.) was given to the rats under basal conditions or following stimulation of
pancreatic secretion with DPBJ. Lorglumide, the CCK1 receptor antagonist
(1mg/kg i.d.) was administered 15 minutes prior to the application of AFMK.
Samples of pancreato-biliary juice were collected to measure the amylase outputs.
The blood samples were taken for determination of CCK by ELISA kit. For
in vitro study pancreatic acinar cells AR42J were incubated in presence of
AFMK alone or in combination with CCK. The protein signal of CCK receptor
was determined by Western blot.
Results: AFMK given i.d. produced the dose-dependent increases of pancreatic
amylase secretions both; unstimulated, as well as that induced by DPBJ. The rises
of pancreatic amylase outputs were accompanied by significant increase of CCK
plasma levels. Administration of lorglumide, a CCK1 receptor blocker, comple-
tely abolished the stimulation of pancreatic exocrine function induced by
AFMK. This melatonin metabolite failed to affect protein signal for CCK recep-
tor in AR42J cells.
Conclusion: The stimulatory effect of AFMK on pancreatic enzyme secretion in
the rats is indirect and dependent on the release of CCK by this melatonin
metabolite.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0099 INVESTIGATION OF THE FUNCTION OF TRPM2 INMOUSE
PANCREATIC ACINAR CELLS
J. Fanczal
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Introduction: Aberrant intracellular Ca2þ signaling is the hallmark of acute pan-
creatitis (AP) inducing mitochondrial damage, intraacinar digestive enzyme acti-
vation and cell death. Thus prevention of toxic cellular Ca2þ overload is a
promising therapeutic target. The transient receptor potential melastatin 2
(TRPM2) is a non-selective cation channel that plays major role in oxidative
stress induced cellular Ca2þ overload in different cell types. Although likely, its
role in pancreatic acinar cells and the pathogenesis of AP was not investigated
yet.
Aims & Methods: Our aim was to characterize the functional activity of TRPM2
in pancreatic acinar cells. In our experiments pancreatic acinar cells (PAC) were
isolated from wild type (WT) and TRPM2 knockout (KO) mice with enzymatic
digestion. The changes of the intracellular Ca2þ level was measured whit fluor-
escent microscopy using FURA2-AM.
Results: The intracellular Ca2þ signals evoked by 100 mM carbachol were not
different in WT and TRPM2 KO PAC. On the other hand, 1 mM H2O2 induced
significantly higher intracellular Ca2þ elevation in WT PAC compared to the
TRPM2 KO. In Ca2þ free extracellular solution the Ca2þ signal in response to
1 mM H2O2was markedly reduced in WT PAC confirming that H2O2 activates
dominantly extracellular Ca2þ influx.
Conclusion: Our result confirmed the functional activity of the TRPM2 channel
in pancreatic acinar cells. In our further investigations we aim to clarify the
pathogenetic role of TRPM2 in AP.
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Introduction: Pancreatic ductal fluid and HCO3
 secretion are crucially impor-
tant in the physiology and pathophysiology of the exocrine pancreas. However,
the study of human pancreatic secretory processes is great challenge due to the
limited access to human pancreatic ductal cells. The recently developed three-
dimensional pancreatic organoid cultures (OC) may help to overcome this lim-
itation. However, the ion secretory processes in pancreatic OC is not known.
Aims & Methods: Our aim was to characterize the ion transport processes in
mouse pancreatic OCs. Mouse pancreatic ductal fragments were isolated by
enzymatic digestion. The isolated ducts were grown in Matrigel on 37C for a
week in OC media. Changes of the intracellular pH was measured to characterize
the ion transporter activities of the epithelial cells in OC.
Results: Basolateral administration of 20mM NH4Cl in standard HEPES or
CO2/HCO3
 buffered solution resulted in rapid intracellular alkalization,
which was followed by a recovery phase. Removal of NH4Cl induced rapid
acidification followed by regeneration to the resting pH levels. The regeneration
phase was inhibited by the removal of extracellular Naþ. The administration of
10mM CFTRinh172, a selective inhibitor of cystic fibrosis transmembrane con-
ductance regulator decreased the regeneration from alkali load. Basolateral
administration of 20mM amiloride and 20mM H2DIDS decreased the intracel-
lular pH suggesting the activity of Naþ/Hþ exchanger and Naþ/HCO3
 cotran-
sporter on the basolateral membrane.
Conclusion: The ion transport activities in mouse OC are similar to those
observed in freshly isolated primary tissue. This suggest that OC will be suitable
to study human ductal epithelial ion transport.
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Introduction: Acute pancreatitis (AP) is the most common inflammatory disorder
in the gastrointestinal tract with an overall mortality of 20–30% in severe cases.
The treatment of AP is not resolved yet, urging the identification of novel drug
targets. Toxic cellular Ca2þ overload was highlighted as a key event in pancreatic
acinar and ductal cells during the pathogenesis of AP. In addition, the inhibition
of Orai1 in pancreatic acinar cells markedly decreased the Ca2þ toxicity and the
severity of AP. However, We have no information regarding the role of Orai1 in
pancreatic ductal physiology or pathophysiology.
Aims &Methods:Wild type FVB/N mice were used for the isolation of pancreatic
ductal fragments. The intracellular pH and Ca2þ level of the pancreatic ductal
cells (PDC) were measured by microfluorimetry. The effect of selective Orai1
inhibitors provided by CalciMedica was evaluated.
Results: The tested compounds dose-dependently inhibited Ca2þ influx during
the carbachol induced Ca2þ signal in PDC. Inhibition was complete at a con-
centration of 10mM (CM-B: 99.87%, CM-C: 95.29%). Next, endoplasmic reti-
culum Ca2þ stores were depleted with cyclopiazonic acid and the inhibition of
store-operated Ca2þ entry (SOCE) was investigated after the re-addition of extra-
cellular Ca2þ. Under these conditions CM-B and CM-C significantly, but not
completely, decreased SOCE in PDC (55.96% and 55.03% respectively). The
removal of extracellular Naþ to abolish activity of the Naþ/Ca2þ exchanger
had no effect on the inhibition of SOCE by CM-B or CM-C. We also showed
that the inhibition of Orai1 has no effect on the basal secretion of HCO3
 by
PDC, which is the main physiological function of these cells.
Conclusion: We showed that Orai1 has a significant role in the Ca2þ signaling of
PDC. In the next step we will evaluate the pathophysiological relevance of the
channel.
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Introduction: Acute pancreatitis (AP) is among the most difficult diseases faced
by gastroenterologists and surgeons. In some cases it is difficult to understand
etiology of AP. Hereditary pancreatitis (HP) is an autosomal dominant genetic
disorder characterized by recurrent attacks of acute pancreatitis.
Aims & Methods: We analyzed medical records of patients who were diagnosed
with juvenile pancreatitis and pancreatitis of unknown etiology (PUE) at the
Center for Digestive Diseases at Karolinska University Hospital from January
2008 to December 2016.
Results: During the observation period, 44 patients (17 male and 27 female) were
registered with the ICD code chronic or relapsing pancreatitis, and onset of
symptoms before the age of twenty. At time of first visit, the mean age was
36.726.9 years, range 24–57. The average period between the occurrence of
first symptoms and diagnosis was 14.6 years (range 1–39 years). All patients
(100%) clinically presented with recurrent acute pancreatitis. There were 28
(63.7%) patients with genetic mutations. Five out of 28 genetic positive patients
(17.9%) had a definitive diagnosis of genetic etiology of pancreatitis. Seven out
of 28 genetic positive patients (25%) had complications: in five patients endo-
scopic treatment due to pancreatic duct stenosis was performed; one patient had
pancreatic and bile duct stenosis and one patient (female, age 28, CFTR hetero-
zygous mutation) a pancreatic tumor (mucinous cystadenoma with high dyspla-
sia that was successfully surgically treated with R0 resection). One patient died
due to non-pancreatic related disease (kidney cancer). None of the patients
reported alcohol overconsumption. Four out of 28 genetic positive patients
(14.3%) were active smokers. Fecal elastase-1 (FE-1) was tested in 28 (63.6%)
patients: 16 (57.1%) in genetic positive and 12 (75%) in genetic negative group of
patients. Pancreatic exocrine insufficiency (PEI) was found in 5 out of 12 (41.7%)
of genetic negative patients and in 5 out of 16 (31.2%) genetic positive patients
Average age at onset of PEI was 38 years (range 27–53). Diabetes mellitus (DM)
was diagnosed in one patient in group with genetic alterations and 2 patients in
group without genetic alterations.
Conclusion: We found high proportion of genetic alterations in patients with
juvenile pancreatitis and PUE. In patients in whom pancreatitis remains unex-
plained after excluding of the most often etiologies and presence of genetic
alteration, hereditary pancreatitis seems as reasonable explanation even in
patients with mutations in other genes than PRSS1. Routine follow-up of
patients with regular testing on pancreatic exocrine insufficiency and diabetes
mellitus and pancreatic cancer surveillance is necessary.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0103 THE FACTORS FOR PREDICTING HOSPITAL MORTALITY
IN EARLY STAGE OF SEVERE ACUTE PANCREATITIS
M. Horibe1, M. Sasaki2, M. Sanui3, H. Sawano4, T. Goto5, T. Ikeura6,
T. Hamada7, E. Iwasaki1, T. Kanai1, T. Mayumi8
1Keio University School of Medicine, Tokyo/Japan
2National Cancer Center Hospital, Tokyo/Japan
3Jichi Medical University Saitama Medical Center, Saitama/Japan
4Osaka Saiseikai Senri Hospital, Osaka/Japan
5Hiroshima City Hiroshima Citizens Hospital, Hiroshima/Japan
6Kansai Medical University, Osaka/Japan
7Gastroenterology, The University of Tokyo, Tokyo/Japan
8School of Medicine University of Occupational and Environmental Health,
Fukuoka/Japan
Contact E-mail Address: aries24sirius@yahoo.co.jp
Introduction: Severe acute pancreatitis has high mortality and needs intensive
care. However it is difficult to stratify the severity of acute pancreatitis in early
stage because revised Atlanta classification requires persistent organ failure last-
ing at least 48 hours.
Aims & Methods: We searched factors to predict hospital mortality in early stage
of severe acute pancreatitis. This was a retrospective cohort study of all conse-
cutive patients with severe acute pancreatitis who admitted at 44 institutions
between June 1, 2009 and December 31, 2013. We evaluated ten factors which
associated with mortality in previous study.
Odds ratios and 95%
confidence intervals P value
Respiratory failure 3.13(2.01–4.89) 50.001
Advanced age 2.64(1.78–3.93) 50.001
Renal failure 2.02(1.29–3.15) 0.002
High lactate dehydrogenase 1.63(1.03–2.58) 0.04
Results: The mortality was 12.7% (142/1114 patients). All ten factors were asso-
ciated with mortality in univariable analysis. In multivariable analysis, four fac-
tors, namely " partial pressure of oxygen in blood 60mmHg (room air) or
mechanical ventilation", "age 70 years", " blood urea nitrogen 40mg/dL
(or creatinine 2.0mg/dL) or oliguria (daily urine output 5400mL even after
adequate intravenous fluid resuscitation)", and " lactate dehydrogenase 2 times
upper limit of the normal range" were associated with mortality. The other
factors, namely "base excess -3mEq/L", "platelet count 100, 000/mm3",
"serum calcium 7.5mg/dL", " c-reactive protein 15mg/dL", "number of posi-
tive measures in systemic inflammatory response syndrome criteria 3" and "
computed tomography grade" were not associated with mortality.
Conclusion: Advanced age, respiratory failure, renal failure and high lactate
dehydrogenase could predict mortality in early stage of severe acute pancreatitis.
The patients with these factors require transport to a hospital with intensive care
unit.
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Surgery, Luleå/Sweden
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Introduction: Cholecystectomy during the index admission may reduce risk of
recurrent biliary events but concerns have been raised about complications if
surgery is performed to early. The objectives of this study were to compare
gallstone- and cholecystectomy-related complications and patient reported qual-
ity-of-life and pain if cholecystectomy was performed before discharge or sched-
uled 6 weeks from the initial episode.
Aims & Methods: Patients admitted with biliary pancreatitis at the Karolinska
University Hospital were assessed for eligibility. Patients with mild pancreatitis
were enrolled into either index- or scheduled cholecystectomy (IC vs. SC). IC was
performed when patients showed recovery and within 48 hours from randomiza-
tion. SC was planned after 6 week from randomization. The primary outcome
was recurrent biliary events. Secondary endpoints were cholecystectomy compli-
cations within 1 months, the proportion of common bile duct stones at chole-
cystectomy requiring ERC and patientś reported quality-of-life and pain.
Results: Sixty-four patients between May 2009 and March 2017 were randomized
into IC (n¼ 31) or SC (n¼ 33). Recurrent pancreatitis occurred in one and six
patients in the IC and SC groups respectively (3.2% vs. 18.7%, P¼ 0.049).
Higher proportion of common bile duct stones were found in the IC group
during cholecystectomy requiring ERC (23.3% vs. 10.7%, P¼ 0.30). There was
no difference in pain measure between the groups at randomization and follow-
up.
Conclusion: Delaying cholecystectomy in mild gallstone pancreatitis is associated
with increased risk for recurrent gallstone-related events. Cholecystectomy per-
formed at the index admission is safe and feasible.
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Introduction: The course of acute pancreatitis (AP) ranges from life threatening to
mild disease, so accurately predicting its outcome is important. The revised
Atlanta classification breaks the previous mild/severe dichotomy, so the absence
of predictors of severity does not preclude a mild course. Studies designed
according to the new classification evaluating existing predictors are still scarce.
Aims & Methods: Our study aims at evaluating the diagnostic accuracy of easily
available prognostic scores to predict mortality, persistent organ failure (severe
AP) and mild AP. We analyzed a single-center retrospective cohort including all
adult patients admitted between 2010 and 2015. Patients with a previous episode
of AP in the six months before admission, with other primary diagnosis at dis-
charge and those partially attended at other institutions were excluded. Severity
and local complications were defined according to the 2012 Atlanta classification.
Four different scores (BISAP, SIRS, APACHE II and HAPS) and the following
predictors: C reactive protein (CPR) at 24 h, hematocrit and BUN at admission
United European Gastroenterology Journal 5(5S) A195
and their evolution after 24 h were evaluated. Accuracy was measured using
diagnostic tests and receiver operating characteristic analyses.
Results: Of the 817 eligible patients, 118 were excluded, most for a previous
episode before admission. We analyzed 699 patients with a median age of 57.5
years (IQR: 45.1–72.7), 57.4% males. Most frequent comorbidities were: diabetes
(16%), ischemic heart disease (8.6%) and COPD (7.7%). Median length of stay
was 7 (5–10) days. Most common causes were: biliary (53.9%), idiopathic
(21.8%) and alcoholic pancreatitis (14.3%). A CT scan was performed in
56.1% identifying local complications in 36.2% of them, acute fluid collections
in 30.1% and acute necrotic collections in 16.8%. There were 42 (6%) severe and
196 (28%) moderately severe cases. Overall mortality was 2.4% (1, 5–3, 9%),
35.7% (23–50.8%) among severe cases. BUN at admission AUC: 0.88 [0.85–
0.90]), BISAP score (AUC: 0.88 [0.85–0.90]) and APACHE II (AUC: 0.87
[0.83–0.90]) outperformed all other evaluators in predicting death. APACHE II
presented the highest sensitivity, 100% (81.6–100%), while the BISAP score pre-
sented the highest specificity, 93.1% (90.6–94.8%). BUN at admission (AUC: 0.89
[0.86–0.91]) and the BISAP score (AUC: 0.87 [0.84–0.89]) also presented the best
performance for severe AP. The BISAP score presented the highest specificity,
94.2% (92.2–95.8%), although with a low PPV, 32.1% (21.4–45.2%). On the other
hand, diagnostic accuracy for mild AP was poor, as all predictors presented an
AUC 50.7. The HAPS score reached the highest specificity, 87.8% (83–91.4%),
but presented a very poor sensitivity (28.9% [24.3–33.9%]).
Conclusion: The revised Atlanta classification accurately identifies those patients
at higher risk of death. Among the available predictors of severity, BISAP and
BUN at admission presented an excellent performance, with an AUC of nearly
0.9. New scores are needed to predict a mild course, as none of the available
indexes presented an AUC4 0.7.
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Introduction: Although uncommon in the West, Ascaris lumbricoides is a common
cause of acute pancreatitis in developing countries. The mechanism of
acute pancreatitis in ascariasis may be due to obstruction of papilla of Vater,
invasion of common bile duct (CBD), or pancreatic duct (PD). The invasion of
pancreatic duct occurs rarely owing to its smaller calibre. Ultrasonography
(USG) is an effective tool for the diagnosis of biliary and pancreatic ascariasis;
however, the diagnosis may be false negative in up to 30% of cases. Pancreatic
ascariasis is a rare entity. Only case reports has been described in literature. We
present our retrospective data of last 10 years of 15 cases of pancreatic ascariasis.
Aims & Methods: During a study period of 10 years, 15 cases of pancreatic
ascariasis were diagnosed by USG or endoscopic ultrasonogrpahy(EUS). EUS
was performed with a linear or radial echoendoscope. 13 patients presented with
symptoms of acute pancreatitis. Out of 13 patients, 9 presented with first episode
of idiopathic pancreatitis while 4 presented with idiopathic recurrent acute pan-
creatitis (IRAP). One patient had biliary colic and one patient presented with
acute cholangitis. 12 patients had mild pancreatitis while only one had moderate
pancreatitis. Patients were treated with parenteral Fuids, analgesics, antibiotics,
and albendazole. Only 2 cases were diagnosed with USG while 13 patients were
diagnosed with EUS. The patients underwent side viewing endoscopy/ERCP
under the same sedation after EUS if EUS revealed biliary/pancreatic ascariasis.
Out of 15 patients, 14 underwent side viewing endoscopy with removal of live
single/multiple worms with rat tooth forceps/biopsy forceps/dormia basket in 13
patients. 2 patients were managed conservatively with repeat USG showing
absence of ascariasis. There were no complications.
Results: The patient characteristics are described in table. 2 patients had asso-
ciated bile duct ascariasis. Sonographic characteristics of A. lumbricoides were
single or multiple echogenic nonshadowing linear, tubular structures and curved
strips with anechoic tubular central lines. EUS features were single or multiple
linear hyperechoic structure without acoustic shadowing in the PD or CBD
(‘‘single-tube sign’’ or ‘‘strip sign’’) or with central hypoechoic tube representing
alimentary canal of the worm (‘‘double tube sign’’ or ‘‘inner tube sign’’) and
movements of worms inside the duct. Live roundworms were removed from
PD without undertaking sphincterotomy. In endemic areas, sphincterotomy
facilitates the risk of migration of worms into the CBD or PD
Conclusion: Ascariasis-induced acute pancreatitis is usually mild and EUS is the
investigation of choice. The recurrence is rare and treatment is side viewing endo-
scopy with removal of worms. EUS significantly improves the diagnostic yield for
idiopathic acute pancreatitis (IAP). Our retrosceptive study shows that EUS is a
highly accurate method to diagnose the etiology of IAP with reference to biliopan-
creatic ascariasis.AlthoughUSG is quite sensitive for diagnosing BPA, its sensitivity
significantly falls when the worm is thin, in the PD, or the CBD is non-dilated. EUS
is more sensitive for diagnosis of ascariasis in the pancreatic duct than other radi-
ologic investigations. The probable reasons are excellent imaging of pancreas by
EUS and in and out movement of ascaris whichmight memissed by other investiga-
tions. Endoscopic retrograde cholangiopancreatography, considered the gold stan-
dard for diagnosis of biliary ascariasis, should be reserved for therapeutic rather
than diagnostic use as papillotomy can lead to reentry of theworm into the common
bile duct. EUS should be used early in the work-up of IAP after the first episode.We
propose EUS to be investigation of choice for PD ascariais.Most of the episodes are
of mild pancreatitis with no mortality.
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Introduction: The severity of acute pancreatitis varies widely, from a mild self-
limited disease to one with a severe clinical course complicated by multiple organ-
system failure1. No pharmacologic therapy has been shown to improve the prog-
nosis of patients with severe acute pancreatitis, while the quality of supportive
care including early fluid resuscitation is critically important1, 2. Fluid resuscita-
tion maintains adequate intravascular volume by compensating for fluid shifts to
the third space3. However, there is a lack of consensus regarding the details of
optimal fluid administration such as the type of fluid, infusion rate and volume of
administration, and the physiologic goals of fluid resuscitation4.
Aims & Methods: The aim of this study is to evaluate the association between the
volume of fluid administered and clinical outcomes in patients with severe acute
pancreatitis. We conducted a secondary analysis of data from a multi-centre
retrospective study of patients with severe acute pancreatitis in Japan, which
was registered with the University Hospital Medical Information Network
Clinical Trials Registry (Registry number 000012220) and approved by the
Institutional Review Board or the Medical Ethics Committee at each institution5.
The diagnosis of severe acute pancreatitis was based on criteria of the Japanese
Ministry of Health, Labour and Welfare (Japanese Severity Score)6. Patients
were stratified into two groups: administered fluid volume 56000ml and
6000ml in the first 24 hours. We evaluated the association between the two
groups and clinical outcomes using multivariable logistic regression analysis. The
primary outcome was in-hospital mortality. As a sensitivity analysis, we con-
ducted an identical analysis for subgroup patients with severe acute pancreatitis
diagnosed according to the revised Atlanta classification7.
Results: We analysed 1097 patients, and the mean fluid volume administered was
5618 3018ml (mean standard deviation), with 708 and 389 patients stratified
into the fluid 56000ml and fluid 6000ml groups, respectively. Overall in-hos-
pital mortality was 12.3%. The fluid 6000ml group had significantly higher
mortality than the fluid 56000ml group (15.9% vs. 10.3%, p5 0.05). However,
in multivariable logistic regression analysis, conversely fluid 6000ml within the
first 24 hours was significantly associated with reduced mortality (OR 0.58,
95%CI 0.34–0.98). We performed subgroup analyses for patients diagnosed
with severe acute pancreatitis based on the revised Atlanta classification7. One
hundred sixty-seven patients were classified in the fluid 56000ml group, and 201
patients classified in the fluid 6000ml group. There were no significant differ-
ences between the two groups with regard to in-hospital mortality (fluid
56000ml: 35.3% vs. fluid 6000ml: 28.4%, p¼ 0.18). In multivariable logistic
regression analysis, administered fluid 6000ml within the first 24 hours was
associated with significantly less mortality (OR 0.56, 95%CI 0.32–0.98).
Conclusion: In patients with severe acute pancreatitis, administration of fluid
6000ml within the first 24 hours is associated with decreased mortality.
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Introduction: There is no definite prognostic marker of post-endoscopic retro-
grade cholangiopancreatography (ERCP) pancreatitis (PEP). Previous animal
study reported that serum phosphate correlated with severity of acute
pancreatitis.
Aims & Methods: In this study, we aimed to evaluate the efficacy of serum
phosphate as a prognostic factor for PEP in human. Between January 2005
and December 2016, 176 patients who underwent serum phosphate test among
patients with PEP were included in the study. Serum phosphate was measured
between 12 and 24hours after ERCP. PEP was defined as new abdominal pain
with at least 3-fold increase in serum amylase or lipase levels. The severity of the
pancreatitis was determined according to consensus guidelines.
Results: A total of 176 patients with mild (n¼ 69; 39.2%), moderate (n¼ 80;
45.5%), or severe (n¼ 27; 15.3%) PEP were included. Serum phosphate was
associated with severity of PEP. Serum phosphate levels in mild, moderate and
severe PEP were 2.9, 3.0, and 3.3mg/dL, respectively (P¼ 0.035). In the linear
regression analysis, only the serum phosphate was associated with the duration of
hospitalization (P¼ 0.016). Hematocrit, blood urea nitrogen, and high sensitivity
C-reactive protein were not significantly associated with admission duration.
Conclusion: According to our retrospective data, serum phosphate is associated
with the severity of PEP, and its role as a prognostic factor for PEP can be
considered.
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Introduction: The 2012 revised Atlanta Classification in 2012 has established an
important change in Acute Pancreatitis (AP) definitions, comprising 3 grades of
severity depending on the presence and persistence of organic failure (1).
Thereby, patients with severe acute pancreatitis (SAP) include the vast majority
of mortality in this disease (2–4).
Aims & Methods: Our goal was to know the predicting ability of BISAP and
Ranson in a European cohort with the latest Atlanta Classification. Patients
diagnosed of AP in University Hospital Virgen de las Nieves from June 2010-
June 2012 were included. BISAP was calculated on admission and Ranson was
calculated with parameters of the first 48 hours. We assessed the presence of SAP
and mortality, receiving operating curves (ROC) and area under the curve (AUC)
were calculated, selecting the best cut-off value in terms of sensibility, specificity,
positive predictive value (VPP) and negative predictive value (NPV).
Results: 269 patients were included, 52.8% female and 47.2% male, 17 presented
SAP (6.3%), 8 deaths (3%). Etiology: 65% biliary, 10.4% alcoholic, post ERCP
3%, drugs related in 0.7%, metabolic in 1.1%, idiopathic 15.2%, mixed (alco-
holicþ biliary) 1.1% and others in 2.6% BISAP showed an AUC 0.9, with
sensitivity of 70%, specificity of 94%, PPV 41.4%, NPV 97.9% and overall
accuracy of 91.8% for the prediction of SAP. Regarding mortality prediction,
it exhibited an AUC of 0.97, sensitivity of 100%, specificity 92%, PPV 27.6%,
NPV 100% and accuracy 92.2% (Tables 1a and 1b) RANSON showed AUC
0.85, sensitivity of 88% and specificity of 79%, PPV 22.1%, NPV 99% and
accuracy of 79.6% for SAP prediction. With the respect of mortality prediction,
it presented an AUC of 0.94, sensitivity of 100% and specificity of 77%, PPV
11.8%, NPV 100% and accuracy of 77.7% for mortality prediction (Tables 1a
and 1b)
Conclusion: Our study analyzed the prediction ability of BISAP and Ranson in a
European cohort using de updated classification of Atlanta 2012 and showed
good results in terms of sensitivity and specificity in both scores when predicting
SAP and death. As they are low prevalent outcomes in our sample, PPVs are low
but it gives interesting information, since 41% of patients with BISAP 3 on
admission will develop SAP. On the other hand, NPVs are very high so in
patients with BISAP5 3 or Ranson5 4, SAP and mortality can be considered
very unlikely. Although both scores have similar results, Ranson needs more than
48 hours to be completed, so it does not provide enough information on admis-
sion to warrant the patient aggressive therapies or ICU admission in the earliest
stage of the disease. Multicenter studies in European cohorts are needed to
confirm our findings.
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Table 1a: AUC, sensitivity, specificity, positive predictive values and negative predictive values of scoring systems and biomarkers in predicting Severe Acute
Pancreatitis. (SAP: Severe acute pancreatitis. AUC: Area under the curve. PPV: positive predictive value. NPV: Negative predictive value.
SAP Cut-off values AUC (95% CI) Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
BISAP 3 0.9 (0.83–0.97) 70.6% (46.9%–86.7%) 93.3% (89.5%–95.7%) 41.4% (25%–59.3% 97.9% (95.3%99.1%)
RANSON 4 0.85 (0.76–0.95) 88.2 % (65.7–96.7%) 79% (73.5%–83.5%) 22.1% (13.8%–33.3%) 99% (96.4%–99.7%)
Table 1b AUC, sensitivity, specificity, positive predictive values and negative predictive values of scoring systems and biomarkers in predicting Mortality.
(AUC: Area under the curve. PPV: positive predictive value. NPV: Negative predictive value.
Mortality Cut-off values AUC (95% CI) Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
BISAP 3 0.97 (0.95–0.99) 100% (67.6%–100%) 92% (88%–94.7%) 27.6% (14.7%–45.7%) 100% (98.4%–100%)
RANSON 4 0.94 (0.89–0.99) 100% (67.6–100%) 77% (71.5%–81.7%) 11.8% (6.1%–21.5%) 100% (98.1%–100%)
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Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) is
increasingly used for therapeutic management of various biliary and pancreatic
diseases[1]. However, ERCP is not a procedure without morbidities[2]. Post-
ERCP pancreatitis (PEP) remains the most common and serious
complication after ERCP[3].
Aims & Methods: To detect risk factors for post-endoscopic retrograde cholan-
giopancreatography (ERCP) pancreatitis (PEP) and investigate the predictors of
its severity. This is a prospective cohort study of all patients who underwent
ERCP. Pre-ERCP data, intraoperative data, and post-ERCP data were collected
Results: The study population consisted of 996 patients. Their mean age at pre-
sentation was 58.42 (14.72) years, and there were 454 male and 442 female
patients. Overall, PEP occurred in 102 (10.2%) patients of the study population;
eighty (78.4%) cases were of mild to moderate degree, while severe pancreatitis
occurred in 22 (21.6%) patients. No hospital mortality was reported for any of
PEP patients during the study duration. Age less than 35 years (P¼ 0.001,
OR¼ 0.035), narrower common bile duct (CBD) diameter (P¼ 0.0001) and
increased number of pancreatic cannulations (P¼ 0.0001) were independent
risk factors for the occurrence of PEP.
Conclusion: In conclusion, PEP is the most frequent and devastating complica-
tion after ERCP. PEP is associated with higher morbidity and mortality beside its
effect in increasing the consumption of hospital resources. Age less than 35 years,
narrower median CBD diameter and increased number of pancreatic cannula-
tions are independent risk factors for the occurrence of PEP. Patients with these
risk factors are candidates for prophylactic and preventive measures
against PEP.
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Introduction: The revision of Atlanta Classification in 2012 has established an
important change in Acute Pancreatitis (AP) definitions, comprising 3 grades of
severity depending on the presence and persistence of organic failure (1).
Thereby, patients with severe acute pancreatitis (SAP) include the vast majority
of deaths in this disease (2–4).
Aims & Methods: Our aim was to know the predicting ability of lactate and other
single biomarkers in a European cohort with the revised Atlanta Classification in
terms of severe acute pancreatitis (SAP) and mortality. Patients diagnosed of AP
in the University Hospital ‘‘Virgen de las Nieves’’ from June 2010 to June 2012
were included. Blood sample including hematological parameters, biochemical
test, BUN, CRP and venous gasometry including lactate were performed on
admission. We assessed the presence of SAP and mortality during admission,
receiving operating curves (ROC) and area under the curve (AUC) were calcu-
lated, selecting the best cut-off value in terms of sensibility, specificity, positive
predictive value (VPP) and negative predictive value (NPV).
Results: 269 patients were included, 52.8% female and 47.2% male, 17 presented
SAP (6.3%), 8 (3%) patients died. Etiology: 65% biliary, 10.4% alcoholic, post
ERCP 3%, drugs related in 0.7%, metabolic in 1.1%, idiopathic 15.2%, mixed
(alcoholicþbiliary) 1.1% and other in 2.6% The results in terms of sensitivity,
specificity, PPV, NPV and AUC are summarized in Table 1a and 1b. BUN had
the highest AUC in terms of SAP predictions whereas Lactate had was the best in
terms of mortality prediction.
Conclusion: Biomarkers are quick but incomplete tools for SAP prediction, which
can be easily obtained at any moment throughout the disease. Our study shows
good values of specificity and AUC for BUN, Cr and lactate but not for CRP
concerning SAP and mortality prediction on admission, but since they are low
prevalent outcomes in our sample, PPVs are low and not very reliable. Although
many of these parameters has been analyzed in previous studies, we present
lactate as a new biomarker with similar performance than that of Cr and
BUN, suggesting a possible role for scores building or outcome monitoring.
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Table 1a. AUC, sensitivity, specificity, positive predictive values and negative predictive values of scoring systems and biomarkers in predicting Severe Acute
Pancreatitis. (SAP: Severe acute pancreatitis. AUC: Area under the curve. PPV: positive predictive value. NPV: Negative predictive value.
BUN: Blood urea nitrogen measured on admission. CRP: C-reactive protein measured on admission.
SAP Cut-off values AUC (95% CI) Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
Lactate 42.8mEq/L 0.79 (0.71–0.88) 58.8% (36%–78.4%) 83.3% (78.2%–87.4%) 19.2% (10.8%–31.9%) 96.8% (93.5%–98.4%)
Creatinine 41.4mg/Dl 0.82 (0.71–0.93) 64.7% (41.3%–82.7%) 86.1% (81.3%–89.8%) 23.9% (13.9%–37.9%) 97.3% (94.3%–98.8%)
BUN 428mg/dL 0.83 (0.73–0.93 64.7% (41.3%–82.7% 86.9% (82.2%–90.5%) 25% (14.6%–39.4%) 97.3% (94.3%–98.8%)
CRP CRP4 47mg/L 0.72 (0.60–0.83) 70.6% (46.9%–86.7%) 69.7% (63.8%–75.1%) 13.6% (8%–22.3%) 97.2% (93.7%–98.8%
Table 1b. AUC, sensitivity, specificity, positive predictive values and negative predictive values of scoring systems and biomarkers in predicting Mortality.
(AUC: Area under the curve. PPV: positive predictive value. NPV: Negative predictive value. BUN: Blood urea nitrogen measured on admission.
CRP: C-reactive protein measured on admission.
Mortality Cut-off values AUC (95% CI) Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
Lactate 42.8mEq/L 0.87 (0.78–0.96) 87.5% (52.9%–97.2%) 82.7% (77.6%–86.8%) 13.5% (6.7%–25.3%) 99.5% (97.4%–99.9%)
Creatinine 41.4mg/dL 0.85 (0.70–0.99) 75% (40.9%–92.9%) 84.7% (79.8%–88.5%) 13% (6.1%25.7%) 99.1% (96.8%–99.8%)
BUN 428mg/dL 0.83 (0.68–0.98) 75% (40.9%–92.9%) 85.4% (80.6%–89.2%) 13.6% (6.4%–26.7%) 99.1% (96.8%–99.8%)
CRP CRP4 47mg/L 0.62 (0.41–0.82) 62.5% (30.6%–86.3%) 68.1% (62.2%–73.4%) 5.7% (2.5%–12.6%) 98.3% (95.2%–99.4%)
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Introduction: The Cotton criteria (1) and the revised Atlanta classification (2) are
advocated to define post-endoscopic retrograde cholangiopancreatography
(ERCP) pancreatitis (PEP) severity (3). Whereas Cotton puts the emphasis on
length of hospitalisation, Atlanta focuses on the presence of local (necrosis) and
systemic (organ failure) complications. The number of hospitalization days may
not be a proper representation of PEP severity, because it is influenced by other
diagnoses such as ERCP complications and comorbidity. The goal of this retro-
spective cohort study is to compare the Cotton and Atlanta criteria for the
severity of PEP.
Aims & Methods: All ERCP procedures from a Dutch university medical centre
and a teaching hospital between 2012 and November 2016 were checked retro-
spectively for patients with PEP. Patients were eligible if they met the Cotton
criteria or Atlanta criteria for acute pancreatitis. All records were checked up to
48 hours after ERCP to capture delayed PEP. Patients were excluded if they had
acute pancreatitis prior to ERCP or had chronic pancreatitis. In the primary
analysis, mild/moderate and severe PEP were compared between Cotton and
Atlanta with Fischer’s exact test. Atlanta was regarded as the golden standard.
Secondarily, we compared the sensitivity and specificity of both definitions for
mortality.
Results: Out of a total 2156 ERCPs, 66 patients (3%) had PEP. Two patients
were excluded due to missing data for hospital stay. Of the 64 patients analysed,
39 (60.9%) were female, mean age was 60.6 years and the most common indica-
tion for ERCP was choledocholithiasis (n¼ 33, 51.6%). Four patients (6.3%)
developed organ failure, 3 patients (4.7%) died. The table below depicts the PEP
severity distribution according to Cotton and Atlanta. No significant differences
were found (p¼ 0.64). Of the 25 severe patients according to Cotton, 23 were
categorized due to hospital stay exceeding 10 days, but were mild according to
Atlanta. In 11 patients (44%), concomitant disease (syndrome of inappropriate
antidiuretic hormone secretion, cholangitis, pneumonia, perforation or biliary
leakage) was the cause for prolonged stay.
Severity of PEP according to Cotton and Atlanta
Atlanta Total
Mild-moderate Severe
Cotton Mild-moderate 37 (62%) 2 (50%) 39 (61%)
Severe 23 (38%) 2 (50% 25 (39%)
Total 60 (94%) 4 (6%) 64 (100%)
All 3 patients that died had severe PEP according to Atlanta due to persistent
organ failure. Cotton classified them as mild, moderate and severe based on
hospitalization. Two patients died within 10 days of early multiple organ failure.
No other Cotton criterion for severity was met. Thus, the Cotton criteria due not
capture early deaths due to multiple organ failure. The sensitivity and specificity
of Atlanta and Cotton for mortality were 100%, 98.4%, 33.3% and 60.7%,
respectively.
Conclusion: The Cotton criteria for PEP overestimate disease severity, but under-
estimate mortality. Therefore, the Atlanta criteria should be used for defining
PEP severity.
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Introduction: Acute pancreatitis (AP) is a common but potentially lethal pathol-
ogy due to the multiplicity and severity of its complications1. Infected pancreatic
necrosis (IPN) occurs in 30% of patients with necrotizing AP and is associated
with an increase in mortality ranging from 15% to 39%1. While interventional
drainage and/or removal of the infected tissue remain the mainstay of therapy of
IPN, important progresses have been achieved over the last decade and mini-
invasive interventional treatments have been developed. The aim of this study
was to identify factors associated with IPN and to describe outcomes and
management.
Aims & Methods: This was a retrospective study of collected data from all
patients admitted in Intensive Care Unit (ICU) in a single centre from 2012 to
2015 for a severe AP. Baseline characteristics of the overall population were
expressed as frequencies (percentages) for categorical variables, as mean stan-
dard deviation (SD) for continuous data. For the analysis of mortality, multi-
variate analysis with Cox proportional hazards regression modeling was used to
identify independent predictors. Association between IPN and patients’ charac-
teristics at baseline was evaluated using logistic regression.
Results: In total, 148 patients were included in this study. Overall mortality was
17%. Body mass Index, computed Tomography Severity Index (CTSI) ans per-
sistent (448H) organ failure (OF) were independently associated with overall
mortality. 4/16 patients died of documented mesenteric ischemia during the early
phase (8 days) and 3/10 patients during the late phase (48 days). IPN was
present in 62 patients (43%), all requiring an intervention (i.e. radiological,
endoscopical, and/or surgical). 35% of patients (22/62) had only one modality
of drainage (radiologic or transgastric) and did not required any necrosectomy.
For 30 patients (48%), additional necrosectomy was needed because of lack of
improvement after drainage alone. 10 patients (17%) had only necrosectomy
without prior drainage procedure. Complications such as hemorrhage and per-
foration of visceral organ occurred more frequently in the IPN group (1.4% vs
19.4%, p5 0.001 and 0% vs 8.5%, p¼ 0.02 respectively). The late phase mor-
tality (48 days) was significantly higher in the IPN group (14.5% vs 1.4%,
p5 0.01). In multivariate analysis, factors associated with IPN were number
of OF and portosplenomesenteric venous thrombosis (table 1). 39 patients
(68%) received anticoagulants with a median time of 6 [3–6] months and
among them. 25 patients developed cavernoma, irrespective of whether or not
they receive systemic anticoagulation(p¼ 0.31).
Table 1: Multivariate analysis of factors associated with infected pancreatic
necrosis
ORadjust [IC95%] p
Cause of pancreatitis
Alcohol abused Biliary Others 1 2.43[0.79–7.45]
5.36[1.59–18.12]
0.02
Number of organ failure (OF)
No OF 1 or 2 OF multiple OF (3) 1 4.44[1.07–18.40]
28.67[6.23–131.96]
50.001
Postosplenomesenteric vein thrombosis 8.16 [3.06–21.76] 50.001
Conclusion: In conclusion, this study performed in routine practice conditions
showed that IPN occurs in almost half of patients hospitalized in ICU for severe
AP, and is associated with increased mortality and complications rates. Overall
mortality was 17.6%, and factors associated with mortality were a high BMI,
CTSI and persistent OF. Those results are consistent with previous studies1, 2,
but we reported a high rate of mesenteric ischemia (7/26 patients deceased) while
this complication is occasionally described. IPN patients required an intervention
for drainage of infected tissue removal, which was performed using minimally
invasive techniques in the vast majority of cases, with no complication or severe
side effect. 35% of patients were treated with drainage alone without any addi-
tional necrosectomy. Finally, PSMVT and early OF appeared to be associated
with the risk of developing an IPN but anticoagulation for PSMVT did not
protect for cavernoma occurrence and can expose to intestinal bleeding. Our
results also suggest that the optimal and early management of OF and detection
of PVSMT might prevent IPN and/or its complications. Such hypothesis will
need to be tested in large multicentre prospective studies.
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Introduction: Although it is well known that some patients with AP have an
increased need for fluid therapy, it is not clear who should get fluids aggressively.
Changes in hematocrit, BUN and serum creatinine, has been documented to limit
necrosis and improve outcome. The early prediction of fluid sequestration may
help to select patients for more or less aggressive fluid resuscitation1.
Aims & Methods: 1) To determine early variables as predictors of fluid seques-
tration in the first 48 hours. 2) To determine outcome associated with fluid
sequestration. In this prospective cohort study 300 consecutive patients of
acute pancreatitis were included. Fluid sequestration was calculated by adding
the total amount of fluid administered and subtracting the total amount of fluid
lost in the first 48 hours of hospitalization. Local complications were defined
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according to the revised Atlanta classification. Univariate and multivariate ana-
lysis were performed.
Results: The median fluid sequestration in the first 48 h after hospitalization was
4.7 liter (2.8–6.8 L). It was 3.2 l (1.4–5 l), 6.4 l (3.6–9.5 l) in those without necrosis
and those with necrosis, and 7.5 l (4.4–12 l) in those with persistent organ failure.
The univariate and multivariate analysis showed that alcohol etiology, an
increasing number of SIRS criteria and Hematocrit were significantly associated
with increased fluid sequestration (Table). Body mass index, APACHE II score,
sodium, creatinine and blood urea nitrogen levels did not help predict fluid
sequestration. Patients with and without acute fluid collections had a median
sequestration of 7.2 and 4.2 L (p5 0.001), respectively. 22 patients died (7.33%);
median fluid sequestration in the patients who died was 6.5 L compared to 4.2L
among the patients who survived (p.0.05). Increased fluid sequestration was
associated with prolonged hospital stay (p5 0.01). (table) Association between
variables determined at admission and fluid sequestration.
Variable
Fluid
sequestration
(48 hours) (L)
Univariate
analysis,
p value
Multivariate
analysis,
p value
Age (years) 535 5.3 (2.7–8.9) 0.06 50.05
35–45 5.6 (2.9–7.6)
45–55 4.9 (3.1–7.9)
55–65 5.3 (2.7–6.9)
465 4.5 (2.7–6.2
Sex Male 5.1 (2.7–8.9) 50.01 40.05
Female 4.8 (2.8–7.4)
Etiology Alcohol 5.5 (2.7–8.8) 50.001 50.001
Biliary 5.2(2.4–8.1)
Idiopathic 4.8 (2.8–7.2)
Others 4.6 (2.7–6.4)
Hematocrit (%) 535 3.6 (2.7–4.9) 50.001 50.01
35–40 3.3 (2.7–5.1)
40–45 3.8 (3.1–7.5)
445 4.7 (3.8–8.9)
SIRS score 0 5.3 (2.7–4.1) 50.001 50.01
1 5.3 (2.2–4.4)
2 5.3 (2.9–6.5)
3 5.3 (3.1–7.2)
4 5.3 (3.8–8.9)
Conclusion: Alcohol etiology, increased number of SIRS criteria, hemoconcen-
tration and younger age were independent predictors of increased fluid loss.
Patients with increased sequestration of fluid are at higher risk of local complica-
tions and prolonged stay.
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Introduction: Post ERCP pancreatitis (PEP), that can potentially result in proce-
dure-related death is still great concern in pancreato-biliary endoscopists because
it may be a potentially preventable complication but it is difficult to prevent.
Among reported prophylactic procedures for PEP, placement of prophylactic
pancreatic stent (PPS) is known as a promising one to decrease the risk of
PEP in high-risk patients. It is, however, still unclear what high-risk patient is
a good candidate for PPS. We have previously reported the two predictive factors
for PEP; the cannulation time longer than 13min and 2-hour amylase level over
264 IU/L (World J Gastrointest Endosc 2016; 8: 777–784). In the present study,
we evaluated if PPS for PEP was useful in high-risk patients with using the
propensity score matching method.
Aims & Methods: This is a retrospective single center cohort study of consecutive
patients that underwent ERCP from January 2010 to December 2015. A total of
2298 patients (average age 73 11, female 41.2%) were enrolled. Of them, 174
cases with the following conditions were excluded: 1) gallstone pancreatitis, 2)
unreachable to papilla, 3) missing data of procedure time or serum amylase
levels. Finally, 2124 cases were analyzed. Overall, 86 of 2124 cases developed
PEP (4.0%). Pancreatic guidewire in addition to the cannulation time longer than
13min were revealed as significant high-risk factor of PEP using a univariate
analysis. There were a total of 216 patients with above two risk factors (HR
group). Of them, 30 patients developed PEP (13.9%). Using logistic regression,
propensity scores were used to prevent selection bias between with and without
PPS. The covariates entered in the propensity model were age, gender, native
papilla, endoscopic biliary stent, endoscopic metallic stent, pancreatic guidewire,
pancreatic injection, endoscopic sphincterotomy, precut, endoscopic papillary
balloon dilation, pancreatic duct brush. Subsequently, 1-to-1 matched PPS and
non-PPS group (each group N¼ 64) were extracted from the cohort using the
closet matching score.
Results: After matching, mean propensity matching score in PPS and non-PPS
group were 0.46 0.2 and 0.46 0.2 respectively. There were 62 female (48.4%)
with a mean age of 71 in each group. A total of 17 patients with HR developed
PEP (13.2%). The PEP rate in PPS group was significantly lower than in non-
PEP group (6.3% vs 20.0%: p¼ 0.019). Mean post-ERCP 2h amylase levels were
also lower in PPS group than non-PPS group (178 vs 352: p¼ 0.0214).
Conclusion:Using a propensity analysis revealed that PPS significantly reduce the
risk of developing PEP in high-risk patients with longer cannulation time and
pancreatic guidewire. Consequently, we considered patients with above two risk
factors be a good candidate for PPS.
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Introduction: Autoimmune pancreatitis (AIP) is a well-recognized fibro-inflam-
matory disease of the pancreas characterized by a drammatic response to steroid
therapy.(1) Three different types have been identified according to the
International Consensus Diagnostic Criteria: type 1, type 2 and type not-other-
wise specified (NOS).(2) Despite the significant number of studies published on
AIP type 1 and 2, (3, 4) no studies have been focused on AIP type NOS and
therefore very little is known about clinical features and long-term outcomes of
these patients.
Aims & Methods: Aim was to investigate clinical features, risk of other organ
involvement, risk of relapse and long-term outcomes of AIP type NOS-patients.
Patients classified by International Consensus Diagnostic Criteria (ICDC) as AIP
type NOS at clinical onset included in our database prospectively maintained
since 1995 have been evaluated. AIP type 1 (168 patients) and AIP type 2 (63
patients) were excluded. Epidemiological and clinical data have been collected
and analyzed.
Results: 47 patients fulfilled inclusion criteria. Symptoms at clinical onset were
mainly weight-loss (40, 5%), jaundice (34%) and pancreatitis (29.8%). Six
patients (12, 8%) had other organs involvement (5 proximal biliary involvement
and 1 salivary involvement) and only two (4, 3%) patients had serum IgG4 levels
4140mg/dL at clinical onset. Six patients (12, 8%) developed ulcerative colitis
(UC) during follow-up and were therefore reclassified as AIP type 2. The mean
time between the clinical onset of AIP-NOS and development of UC was 14
months (range 4–48). Eight patients (17%) experienced a relapse after steroid
treatment and two (4, 3%) needed immunosuppressive drugs (Azathioprine)
because of recurrent relapses. None underwent resective surgery despite 30
patients (63, 8%) had a focal pancreatic involvement of the pancreas at imaging.
Conclusion: Patients suffering from AIP type NOS have own clinical features.
The risk of relapse is low (17%) but not irrelevant, as well as the risk of devel-
oping UC (12, 8%) during follow-up switching the diagnosis to AIP type 2.
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Introduction: We started our original EPDBD (endoscopic pancreatic duct bal-
loon dilation) therapy for pancreatic diseases in 1996. In these 22 years, 698 cases
were treated by this method. We would like to show its usefulness and safety.
Aims & Methods: The balloon (6mm diameter, 15mm long -Boston Scientific)
was inflated in the stenotic portion of the pancreas duct at 6 atm. pressure for 1
minute several times. Then stone removal or EPS (endoscopic pancreatic stent-
ing) was done. Following were evaluated; 1. The stone free rate and stone relapse
rate in 568 pancreatic stone cases treated by EPDBD 2. The prognoses of 114
EPS-successful pseudocyst cases treated by EPDBD 3. The prognoses of 16 EPS-
successful divisum cases (complete type 6, incomplete type 10) trerated by
EPBDB respectively. Complications after these therapies are also evaluated.
Results: The purpose of EPDBD therapy for pancreatic stone was to ease endo-
scopic procedures in the pancreatic duct and stone removal, and to reduce stone
relapse rates. 568 cases of pancreatic stone were treated by EPDBD. They con-
sisted of 90 cases treated by endoscopic method alone (via major papilla 62,
minor papilla 28), and 478 cases treated by ESWLþ endoscopic method (via
major papilla 381, minor papilla 97). After EPDBD therapy, the stone free
rate was 75.3%, the pain free rate 97.1%. The stone relapse rate was 5.7% -
this is a much lower result compared to other reports. We think that EPDBD
contributes to this good result. Complications of EPDBD therapy were only
minor bleeding from orifice at the therapy and mild pancreatitis after therapy
for several days. Case A; 22 y/o male. idiopathic chronic pancreatitis, pancreas
stone: After 4th ESWL, small stones remained in the head duct which can’t be
removed by basket catheter and severe pain continued, so EPDBD was done
under good informed consent. After several dilation of the orifice and the head
duct, stones were removed easily. This is our first case of EPDBD. In our hospi-
tal, EPS and ENPD (endoscopic nasal pancreatic drainage) are the preferred
choice for pancreatic pseudocyst therpy after dilation of the stenotic duct. 114
cases were successfully treated without major complications, and their prognoses
were good. Case B; 29 y/o female. alchoholic chronic pancreatitis, pancreatic
stone: ERP via minor papilla revealed the duct rupture in the body portion
and contrast medium flowed out into thoracic and abdominal cavity. After dila-
tion of the stenotic duct in the body, EPS placement was done and she recovered
quickly. The 16 cases of divisum consisted of 6 complete and 10 incomplete type.
After EPDBD, EPS was successful in 2 cases via major papilla, and 14 cases via
minor papilla with good prognoses. Case C; 72 y/o male. alcoholic chronic
pancreatitis, pancreatic stone: ERP revealed type 2 incomplete divisum. After
ESWL and EPDBD, stones were removed via minor papilla, then EPS was
placed into minor papilla successfully.
Conclusion: By EPDBD therapy, the relapse rate of pancreatic stone decreased,
and the success rate of endoscopic drainage and stenting in pseudocyst and
divisum increased markedly with minor complications, and their prognoses
were good. EPDBD is a safe and favorable procedure for pancreatic diseases.
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Introduction: Pancreatic calculi (PC) are a sequelae of chronic pancreatitis (CP)
and may obstruct and produce ductal hypertension leading to pain, the cardinal
feature of CP. The rationale for endoscopic treatment of obstructing PC is based
on the observation that pain subsides when the stone(s) is removed and drainage
of pancreatic secretion is restored. Indications for endotherapy include stones
55mm size, stones in head of pancreas which are not impacted and absence of
downstream strictures. The assessment prior to the procedure is done by MRCP
or CT. However, problems are encountered during ERCP clearance which are
not anticipated despite MRCP/CT. The problems are, possible impacted stones,
hard stones, indeterminate stricture, and change of finding during ERCP. Hence,
controversy exists. EUS can help by providing concordance or discordance with
MRCP images and may help in further clarification.
Aims & Methods: We aimed to evaluate the role, feasibility and management
changes of EUS prior to ERCP in patients planned for endotherapy in CP.
Another objective was to evaluate whether EUS features of pancreatic duct
(PD) stones can serve as a predictor of successful removal during ERCP. The
data of 412 patients during the study period (2009–2016) with CP was retro-
spectively analysed. 143 were associated with stones in head/papillary region of
pancreas. Out of these, 75 were excluded and remaining 68 were evaluated by
EUS using a linear/radial echo endoscope prior to ERCP.
Results: Out of 68 cases, 48 were associated with hard stones with acoustic
shadowing while 20 were associated with soft stones without acoustic shadowing.
In 20 soft stones cases, ERCP was successful in 18 patients. In 48 patients with
hard stones, there was failure of endotherapy in 40 patients which required
ESWL/surgery. The remaining 8 patients required multiple sessions of ERCP
for successful removal. Three patients had ampullary/papillary stones which
were removed with precut sphincterotomy with immediate relief of pain. Four
patients had ventral duct obstruction by calculi and hence underwent ERCP
through minor papilla with successful removal of stones in 3 patients. In three
patients, there were calculi in pancreatic parenchyma and pancreatic duct simul-
taneously (ducto-parenchymal stones) and hence endotherapy was avoided.
Three patients had pancreas divisum diagnosed on EUS and hence underwent
minor papillotomy with stone removal. Three patients also had biliary obstruc-
tion with CBD stone/sludge and underwent biliary endotherapy. Four patients
had pancreatic mass in head and underwent EUS-FNA with two patients diag-
nosed with pancreatic cancer who were referred for surgery. The remaining two
were also referred for surgery. Four patients were found to have strictures on
EUS and hence were referred for surgery. The presence of large (5mm), hard,
immobile stones were negative predictors of successful endotherapy. Small
(55mm), ampullary/papillary stones were positive predictors.
Conclusion: Present study suggests that EUS can differentiate "soft PD stones’’
(without an acoustic shadow) from "hard PD stones"(with an acoustic shadow).
This differentiation can help in predicting successful removal during ERCP.
"Hard PD stones" diagnosed on EUS are better managed by ESWL. An EUS
can influence important therapeutic decisions before endotherapy and can pre-
vent unsuccessful attempts at ERCP and thus improve overall success/prognosis.
An EUS has an additional advantage of making a diagnosis of ampullary/papil-
lary stones and biliary obstruction which can be treated endoscopically. It can
guide whether endotherapy needs to be performed through major or minor
papilla. EUS by diagnosing pancreatic tumour/strictures missed on other ima-
ging modalities allows early surgical reference and hence improves long-term
prognosis. It can prevent unsuccesful attempts at endotherapy and its possible
risks/costs. We conclude that EUS before endotherapy plays an important role
regarding further management decisions in patients with CP.
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Introduction: IgG4-related disease (IgG4-RD) is characterized by the infiltration
of inflammatory cells, such as plasma cells and macrophages, and fibrosis in
tissues. We previously reported that apoptosis inhibitor of macrophage (AIM),
which is secreted by macrophages, is related to the progression of hepatic fibrosis
in chronic hepatitis C. Some studies have observed a relationship between IgG4-
RD and malignancy. IgG4-RD is considered to represent a premalignant state or
paraneoplastic condition.
Aims & Methods: To clarify the significance of the serum AIM levels in patients
with IgG4-RD, we measured these levels in 22 healthy controls, 32 patients with
IgG4-RD, and 36 patients with other pancreatic diseases (chronic pancreatitis
[CP], intraductal papillary mucinous neoplasm [IPMN], pancreatic cancer [PC]).
We also analyzed the prevalence of malignancy, the relationship between the
appearance of malignancy and the diagnosis of 42 IgG4-RD, the type of
cancer, and related factors, and we compared the age, gender, laboratory data,
and AIM level.
Results: Fifteen malignancies were seen in 12 of 42 patients (28.6%). These
diagnoses were made before the diagnosis of IgG4-RD for 10 malignancies in
8 patients (mean 4.8 years earlier, range 1–16 years), and after the diagnosis of
IgG4-RD for 3 malignancies in 2 patients (mean 2 years later, range 1–3 years).
Two malignancies in 2 patients were diagnosed at the same time as IgG4-RD.
The AIM level was significantly higher in the IgG4-RD patients with malignancy
than in those without malignancy. No significant differences were seen in the
mean age or gender between patients with and without malignancies. The IgG4-
RD group had significantly higher serum AIM levels than the healthy control or
IPMN groups, and the levels tended to be higher than in the PC group.
Conclusion: Macrophages are reportedly related to IgG4 class switching in B cells
and fibrosis in IgG4-RD. The serum level of AIM, which is secreted by macro-
phages, is considered a useful biomarker for evaluating the pathology and differ-
entiating IgG4-RD and malignant diseases.
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Introduction: Endosonography (EUS) is one of the main diagnostic tools for the
differential diagnosis of pancreatic masses. The aim of our study was to deter-
mine pitfalls of this technique in patients suspected of having pancreatic cancer.
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This was done in consideration of the current knowledge about lesions mimicking
cancer in the setting of a normal pancreatic parenchyma or existence of signs for
pancreatitis
Aims & Methods: Retrospective analysis of prospectively collected data in our
tertiary University center. From March 2007 to October 2015, 218 (124 men, 94
women; mean age 60 14 years) patients underwent EUS for suspected solid
pancreatic neoplasm because of cross sectional imaging results, idiopathic
acute pancreatitis, weight loss, pancreatic hyperenzymemia, painless jaundice
and elevated Ca 19-9 values. Cystic pancreatic lesions, pseudocysts and cystic
pancreatic neoplasms were excluded from the analysis.
Results: Malignant lesions were diagnosed in 98 (45%) patients. 54 patients
(24.8%) underwent surgery and 61 patients (28% of all patients) underwent
clinical follow-up (16.5 27.3 months, 18 needed surgery). 43 lesions not under-
going surgery needed EUS follow-up before achieving final diagnosis: pancreatic
cancer (n¼ 6, 9.8%), neuroendocrine tumor (NET) (n¼ 10, 16.4%), paraduode-
nal pancreatitis (n¼ 5, 8.9%), chronic pancreatitis (n¼ 13, 21.3%), necrosis
(n¼ 3, 4.9%), autoimmune pancreatitis (AIP) (n¼ 3, 4.9%), microcystic serous
neoplasia (n¼ 1), ventral/dorsal split (n¼ 1), lipomatosis (n¼ 1). EUS showed
sensitivity and specificity for malignancy of 91.4% and 97.7%, respectively, in
the non-pancreatitis group (n¼ 121) and 44% and 87.1% in the pancreatitis
group (n¼ 97). Ca 19-9 elevation, rapid onset jaundice, double duct sign are
useful indicators of malignancy both in the setting of normal and inflamed
pancreas. Patients without pancreatitis the presence of enlarged lymphnodes or
a mass in EUS, weight loss and worsening diabetes are predictor of malignancy.
In patients without pancreatitis and without jaundice Ca 19-9 sensitivity for
malignancy was 95% and specificity was 39%. In the pancreatitis group, Ca
19-9 sensitivity for malignancy (in patients without jaundice) was 45% and spe-
cificity was 86%. IgG4 elevation presented a sensitivity of 83.3% and a specificity
of 77.8% for AIP, where one false elevation was seen in a distal cholangiocellular
carcinoma.
Conclusion: Diagnostic accuracy of EUS is lower in the presence of pancreatitis.
Focal autoimmune pancreatitis and paraduodenal pancreatitis are still confused
with pancreatic cancer, also in the setting of a not inflamed pancreatic parench-
yma. EUS in the setting of a normal parenchyma is an excellent tool to exclude
pancreatic cancer. Tumor markers like Ca 19-9 and IgG4 values should be mea-
sured in the evaluation of pancreatic masses, also in the setting of chronic pan-
creatitis. In unclear cases, clinical and imaging follow-up with more than one
modality (usually EUS with CT) were necessary for achieving a definitive diag-
nosis. If there is a high clinical suspicion of pancreatic neoplasm in a patient that
does not undergo surgery and if EUS or other available imaging modalities are
negative, repeated EUS after 2–3 months may be useful for detecting an occult
pancreatic neoplasm.
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Introduction: Pancreatic cancer is characterized by a high density of stroma.
Interactions between tumor and stromal cells play a critical role in tumor pro-
gression and there is increasing evidence that pancreatic stellate cells (PSC), a
main component of the stroma, may participate in the development of pancreatic
cancer[1]. However, details of the mechanism underlying the interaction between
PSCs and pancreatic cancer cells (PCC) are poorly understood.
Stromal cell-derived factor-1 (SDF-1 or CXCL12) belongs to the CXC chemo-
kine family and is the ligand of CXCR4 [2]. It has been implicated in promoting
the metastatic potential of breast, gastric, ovarian, prostate, lung and pancreatic
cancer cells. Although SDF-1 reports of SDF-1 in pancreatic cancer cell lines are
rare, it has been identified in pancreatic cancer tissue samples [3], suggesting that
SDF-1 produced in activated PSCs may be an integral factor in tumor-stromal
interactions.
Galectin-1 mediates communication between cells by binding to glycol-conju-
gated proteins on the cell surface. Studies have shown that it is involved in
multiple cancer-related processes, including immunosuppression, angiogenesis
and metastasis [4]. We previously reported that Galectin-1 was highly expressed
in pancreatic cancer tissues; furthermore, the primary source of Galectin-1 was in
activated PSCs within the stroma of cancer cells [5]. It has previously been
hypothesized that Galectin-1 may also induce activation of PSCs and stimulate
secretion of chemokines [6]; however, the biological mechanism and its activities
in PCCs are unclear.
Aims & Methods: The purpose of this study was to identify the effect and eluci-
date the biological mechanism of Galectin-1 in PSCs and its role in tumor pro-
gression in pancreatic cancer.
Results: By conducting a chemokine antibody array assay and transwell invasion
and migration assays we were able to show that Galectin-1 induced secretion of
SDF-1 in PSCs leading to increased migration and invasion of PCCs. An NF-B
activity assay indicated that the mechanism involved activation of NF-B. These
observations were confirmed by qRT-PCR, ELISA and immunofluorescent
assays, and were further verified by knockdown of Galectin-1 through lentiviral
transfection and by employing inhibitors to block SDF-1, its ligand CXCR4 and
NF-B. The in vitro findings were supported in an in vivo mouse model. In
combination, our results demonstrated that Galectin-1 stimulated production
of SDF-1 in PSCs through activation of NF-B, and that SDF-1 promoted
invasion and migration of PCCs.
Conclusion: This study suggested that enhanced expression of Galectin-1 in stro-
mal PSCs promotes metastasis in PDAC, thereby offering a potential target in
the treatment of pancreatic cancer.
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Introduction: Intraductal papillary mucinous neoplasms (IPMN) are common
pancreatic cystic neoplasms often detected by chance, and are sometimes pre-
cursors to invasive pancreatic cancer, resulting in a poor prognosis. These neo-
plasms are distinct from pancreatic ductal adenocarcinoma (PDA), conventional
pancreatic cancer. In some IPMN cases, they cannot be detected before invasive
and metastatic carcinoma develops. Knowledge of genetic backgrounds may lead
to the discovery of IPMN with poor prognosis. Although whole-genome sequen-
cing by next-generation sequencing (NGS) has become popular, the use of
minute samples obtained by EUS-FNA is scarce. The value of NGS of pancreatic
cystic fluids or walls has not been clear relative to imaging impressions. On the
other hand, in some kinds of cancer, genetic analysis by NGS was used to select
the treatment method. In this study, we analysed whether minute clinical samples
from EUS-FNA are useful for genetic analysis and whether that aids in deciding
the adequate treatment.
Aims & Methods: We analysed IPMN or PDA tissues using NGS and assessed
the impact of NGS on clinical diagnosis. From January to December 2015, 14
tissue samples of undiagnosed pancreatic tumours (from 8 male patients, 6
female patients; mean age, 79.3 years; age range, 85–100 years; mean tumour
size, 29.6	 17.9mm; tumour size range, 10–66mm) were collected by EUS-FNA.
The locations of the tumours were the head (3), body (4), and tail (5); we
obtained their samples through the stomach or duodenum. EUS-FNA was per-
formed using a curvilinear echoendoscope (GF-UCT 260; Olympus Medical
Systems, Tokyo, Japan) and 22- or 25-gauge needles (ProCore; Cook Japan,
Tokyo, Japan/Expect; Boston Scientific, Tokyo, Japan). Both slow-pull and
negative pressure techniques were used to obtain specimens. We performed
whole-genome sequencing of DNA obtained from IPMN or PDA using the
Comprehensive Cancer panel, and compared their genetic mutations.
Additionaly, in the case of IPMN, we compared the differences in results between
mural nodules and cystic fluids or walls.
Results: Pathological diagnoses showed 2 adenocarcinomas, 3 intraductal papil-
lary mucinous carcinomas, 7 intraductal papillary mucinous adenomas; the
remaining 2 cases could not be diagnosed. We used minute specimens obtained
from EUS-FNA, and analysed genetic mutations of 10 cases using NGS.
Homogenous genetic mutations were approximately 18% and heterogenous
genetic mutations were approximately 25%. Five of the cases had mural nodules
inside the cysts. We could analyse genetic mutations of cystic fluids or walls by
the same way as of mural nodules. For the gradually growing IPMN without
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mural nodules, it is useful to analyse genetic mutations of cystic fluids or walls.
Currently, adequate samples from EUS-FNA were unavailable, and in some
cases, we could not make a pathological diagnosis. Even in such cases, genetic
analysis and the subsequent diagnoseis of malignant or benign tumours may be
possible. We could identify several cancer-related genes, such as GNAS, KRAS,
TP53, and BRAF.
Conclusion: In this study, we performed whole-genome sequencing of samples
obtained from IPMN or PDA using EUS-FNA. Consequently, genetic analysis
by NGS may be effective in addition to pathological diagnosis when deciding the
management of pancreatic tumours.
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Introduction: The ubiquitously expressed non-receptor protein tyrosine phospha-
tase SHP2, encoded by PTPN11, is involved in the regulation of multiple signal-
ing cascades. SHP2 was the first reported oncogenic tyrosine phosphatase,
although more recently demonstrated tumor suppressive properties as well.
SHP2 has been proven to be required for proper wild-type RAS activation, yet
studies addressing the relevance of SHP2 for mutated KRAS dependent cancers,
such as pancreatic and lung cancer are lacking.
Aims & Methods: Employing mutant KrasG12D driven genetically engineered
murine models (GEMM) of pancreatic ductal adenocarcinoma (PDAC) and
non-small cell lung cancer, CRISPR/Cas9 mediated gene knockout in vitro,
and patient derived tissue xenografts.
Results: In mutant KrasG12D driven genetically engineered murine models
(GEMM) of pancreatic ductal adenocarcinoma (PDAC) we detected a pivotal
requirement of Shp2 for pancreatic carcinogenesis. Spontaneous as well as cer-
ulein-triggered accelerated formation of premalignant lesions, and consequently
PDAC, was almost completely abrogated in GEMM lacking Ptpn11 in the pan-
creas. Even in Ink4a/Arf and Trp53 deficient mutant Kras-driven tumors PDAC
formation was dependent on Shp2 expression. Survival in these mice was sub-
stantially prolonged. Functional and transcriptional analyses revealed Shp2-
dependent regulation of Ras-activity and its main downstream effectors, and
of the mutant Kras related oncogenic transcriptional program. Importantly,
oncogenic transformation of the pancreas by constitutive active mutants of
Map2k1 or Pik3ca was not impaired by deletion of Ptpn11, confirming a striking
dependency of oncogenic Kras on Shp2 expression. These findings were corro-
borated in mutant Kras-driven lung adenocarcinoma GEMMs, in which the lack
of Ptpn11 significantly delayed carcinogenesis suggesting a central role for Shp2
across organs. In contrast, spatiotemporal genetic deletion or pharmacologic
inhibition of SHP2 in established Kras-mutant pancreatic and lung tumors or
tumor cells had limited effect on growth capacity indicating that SHP2 is dis-
pensable for tumor maintenance. However, focused pharmacologic screening
using various substances revealed synergistic effects of SHP2 and MEK-inhibi-
tors. In fact, co-inhibition of SHP2 and MEK prevented tumor relapse upon
MEK monotherapy in endogenous GEMM and demonstrated synergistic
potency in the treatment of patient-derived PDAC organoids and tissue
xenografts.
Conclusion: Thus, as an integrator of RTK-Ras-MEK-ERK signaling down-
stream of almost all RTKs, SHP2 may hold promise as a therapeutic target
not only in RTK-driven, but also in Kras-mutant tumors.
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Introduction: Circular RNAs (circRNAs) are a novel class of noncoding RNAs
that formed by a junction of the 5’ end and 3’end. Increasing reports have shown
that circRNA is dysfunction in neuro system diseases, cardiological heart dis-
eases, human cancers and many other diseases. CircRNA have been demon-
strated involving in tumorigenicity, proliferation, apoptosis, angiogenesis,
migration, invasion and metastasis in human carcinoma. CircRNA can act as
microRNA (miRNA) sponge and regulate the targets of miRNA. Circular RNA
HIPK3 (circHIPK3) is originated from second exon of HIPK3 gene, which is
upregulated in gastric, liver, esophageal. However, the mechanism remains
unclear. Previous studies revealed that signal transducer and activator of tran-
scription 3 (STAT3) as an oncogene that was activated in pancreatic carcinoma.
Phosphorylation of STAT3 (p-STAT3) is a downstream target of interleukin 6
receptor (IL6R). Activation of STAT3 leads to malignancy of tumorgenesis, cell
proliferation and migration. Knockdown STAT3 induces cell apoptosis by Bcl-
xL, c-Myc, cyclinD1, etc. CircHIPK3 regulates BxPC3 cell proliferation through
IL6R/STAT3 pathway. It may be a new target for the therapy of pancreatic
carcinoma.
Aims & Methods: Our research is to study whether circHIPK3 can promote
proliferation of pancreatic carcinoma cell line, BxPC3, and to explore the
mechanism of circHIPK3 in cell proliferation. Cell viability was determined by
cell counting kit-8 (CCK-8). Transient knockdown of circHIPK3 using specific
siRNA targeting the conjunction of circHIPK3. Overexpression of miR-124 was
transfected with synthetic miRNA mimic. Real-time quantitative reverse tran-
scription-polymerase chain reaction (qRT-PCR) was performed to detect
circHIPK3, miR-124 and mRNAs. The expressions of STAT3, p-STAT3, IL-
6R were measured by Western blot. Overexpression of STAT3 was transfected
with STAT3 plasmid. Dual-Luciferase Reporter Assay was performed to detect
the interaction of circHIPK3 and miR-124.
Results: CircHIPK3 was upregulated in BxPC3 compared to human pancreatic
duct epithelial cells (HPDE6-C7). Knockdown of circHIPK3, which didn’t affect
the linear transcript, significantly decreased cell viability of BxPC3.
Bioinformatical analysis and luciferase assay demonstrated that circHIPK3 inter-
acted with miR-124. QRT-PCR and Western blot confirmed that knockdown of
circHIPK3 caused decreasing of mRNA levels of STAT3 and IL-6R and protein
levels of STAT3, p-STAT3 and IL-6R. Previous studies confirmed that miR-124
negatively regulates STAT3, IL-6R via interacting with 3’-UTR (untranslated
region). Ectopic expression of miR-124 decreased the expression of STAT3, p-
STAT3, IL-6R. Indeed, miR-124 repressed BxPC3 cell proliferation which was
consistent with si-circHIPK3. In addition, overexpression STAT3 abolished the
si-circHIPK3 and miR-124 mimic induced cell suppression. QRT-PCR and
Western blot confirmed that circHIPK3 and both STAT3, p-STAT3 and IL-
6R were upregulated in BxPC3 cells than HPDE6-C7 cells while miR-124 was
downregulated. MiR-124 was negatively correlated with circHIPK3 and STAT3,
p-STAT3 and IL-6R.
Conclusion: In this study, we identified circHIPK3 promotes BxPC3 pancreatic
carcinoma cell proliferation by targeting miR-124 and its target genes STAT3
and IL-6R. We found that miR-124 was a negative regulator of proliferation in
BxPC3. And overexpression of STAT3 could attenuate the anti-proliferation of
si-circHIPK3 and miR-124. These results demonstrated that circHIPK3 regulates
BxPC3 cell proliferation by acting as miR-124 sponge.
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Introduction: Intraductal papillary mucinous neoplasms (IPMNs) are precursors
of pancreatic ductal adenocarcinoma (PDA) and are also associated with multi-
centric lesions (field defect), where concurrent de novo PDA, independent of
index IPMN lesion, can also develop. However, there are cases where PDAs
arise adjacent to the index IPMNs, and occasionaly they are pathologically
indistinguishable whether the carcinoma developed from IPMN or was coinci-
dental to the IPMN. A genetic approach can be useful to clarify the origin of
each tumor compartment to determine if they shared molecular signatures.
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Aims & Methods: Twenty concomitant PDAs and IPMNs (39 samples, including
cuncurrent lesions) from surgically resected patients were enrolled in this study.
Resected pancreata were sliced at 5-mm intervals for whole-section histological
analysis, and the distance between PDA and IPMNs was measured after precise
pathological mapping. Target amplicon sequencing that covers 18 PDA-asso-
ciated genes including KRAS, GNAS, TP53, SMAD4, CDKN2A/p16, CTNNB1
and RNF43, was performed using Ion PGMTM system (Thermo Fisher
Scientific). Protein expression of TP53, SMAD4, p16, b-catenin, and RNF43
was also analyzed immunohistochemically.
Results: KRAS mutations were detected in 19/20 (95%) of PDAs and in 38/39
(97%) of IPMNs. ‘‘Adjacent’’ concomitant PDAs, defined as those that are 5mm
or less away from the IPMN (n¼ 11), tended to harbor identical KRAS muta-
tions as the index IPMNs (KRAS identical; n¼ 8, 72%, KRAS different; n¼ 3,
27%). All three cases with contiguous neoplastic lesions via the main pancreatic
duct between PDAs and IPMNs had identical KRAS mutations. In contrast, 7 of
9 ‘‘distant’’ concomitant PDAs, defined as those greater than 5mm away from
the IPMN (n¼ 9), possessed distinct KRAS mutations from the index IPMNs
(78%). Mutations in GNAS were demonstrated in 14/20 (70%) of index IPMNs
and in 29/39 (74%) of all IPMNs, but not in PDAs, supporting de novo carci-
nogenesis rather than progression from the IPMNs. PDAs harboring identical
mutations in KRAS as IPMNs were significantly closer to the IPMNs (KRAS
identical n¼ 16, 0–35mm, average 9mm) relative to cases with distinct KRAS
mutations in the PDAs and IPMNs (n¼ 23, 0–75mm, average 20mm,
p¼ 0.0397). The KRAS identical group had a better prognosis than the KRAS
different group (disease-free survival p¼ 0.0245, overall survival p¼ 0.205).
Curiously, the molecular signature of 18 PDA-associated genes was not signifi-
cantly different between two groups.
Conclusion: Multiple clones with distinct KRAS mutations were identified in
pancreata during initiation and progression of IPMNs, and a subset of PDAs
arising within the field defect share the same KRAS mutation with index IPMN
lesions. Interestingly, PDAs adjacent to IPMN tend to have identical KRAS
mutations, suggesting PDAs and index IPMNs may arise from a common foun-
der. The KRAS identical group appears to have better prognosis relative to the
KRAS-different group, implying distinct molecular programs may govern their
biological behavior.
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Introduction: The pancreatic cancer is a leading cause of death in cancer carriers
worldwide.
Aims &Methods: To study the polymorphism of the TP53 gene on the suppressor
in the blood serum and to evaluate proinflammatory cytokines (IL-1b, TNF-),
insulin blood serum levels at patients with various pathologies of the pancreas
(cancer (PCa), acute and chronic pancreatitis (OP and CP)) with various geno-
types of TP53. 150 patients were followed in a one-stage clinical trial (42 patients
with OP, 81 with CP, and 27 with PCa). The diagnosis has been verified by clinic
methods, ultrasonography, CT. The mean age of patients with PCa was 63.6 4,
9 years. In patients with OP, blood sampling was carried out in the first 5 days
after admission to hospital, patients with CP were examined at the stage of
exacerbation. The concentration of IL-1b, TNF-, serum insulin was determined
by ELISA using the ELISA kit and Monobind Inc., USA. The frequencies of
genotypes and alleles of the TP53 gene by exon (exon 4, Arg72Pro) polymorph-
ism were studied by PCR.
Results: The incidence of Arg/Arg genotypes of the TP53 gene was 65% in
patients with PCa, 49% in the control group. In patients with PCa there was
no homozygotic genotype Pro/Pro, in the comparison group - 13%, p5 0.05.
The frequency of Arg/Pro genotypes was 35% in patients with PCa and 38% in
the comparison group. The frequency of alleles of the TP53 gene in patients with
PCa and in the comparison group was: Arg (82.5% and 68%), Pro (17.5% and
32%). The concentration of insulin in different genotypes in patients with PCa
did not differ significantly and was 7.5 2.2 mU/ml in Arg/Arg, Arg/Pro –
11.0 5.9mU/ml, p4 0.05. In the comparison group, the serum level of insulin
was 5.7 1.8 mU/ml. In patients with PCa, the glucose level was significantly
higher, compared with patients with OP and CP (8.5 1.4 mlMol/l, 5.4 0.3
and 5.1 0.1 mlMol/l, respectively, P5 0.05). The level of IL-1b was signifi-
cantly higher in patients with OP than in patients with CP and PCa (5.1 1.7,
2.0 0.3 and 1.3 0.2 pg/ml, respectively), p5 0.05. The level of TNF- in the
serum of patients with OP was 3.5 0.5 pg/ml, and did not significantly differ
from the serum level of patients with CP and PCa – 4.3 0.7 and 1.1 0.2 pg/ml,
respectively. In patients with PCa, the level of TNF- was significantly lower
than in patients with CP, p5 0.05. The levels of IL-1b in the serum of patients
with PCa with different genotypes of the TP53 gene did not differ significantly
and amounted to 1.1 0.2 pg/ml in patients with the Arg/Arg genotype, with
Arg/Pro genotypes of 1.2 0.3 pg/ml, p4 0.05. The level of TNF- in the serum
of patients with PC with the Arg/Arg genotype was – 1.2 0.2 pg/ml, and did not
significantly differ from the level in the serum of patients with the Arg/Pro
genotype - 1.3 0.1 pg/ml.
Conclusion: The Pro/Pro genotype of the TP53 gene was significantly more
common in the comparison group than in the patients with PCa. We detected
significant differences in serum insulin levels in the comparison group and in
patients with heterozygous genotypes, p5 0.05. The level of TNF- in patients
with PCa, CP was significantly lower than in patients with OP, and the level of
IL-1b was significantly lower in patients with PCa than in patients with CP.
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Introduction: Pancreatic cancer (PC) is one of the most lethal diseases due to the
difficulty of early detection. There is no effective blood biomarker for screening.
Recently metabolomics is considered to be a promising approach to discover
disease biomarkers. We previously reported that the serum/plasma levels of
some metabolites in PC patients were significantly changed compared with
those of healthy individuals.
Aims & Methods: The aim of this study is to confirm and develop our candidate
metabolomic biomarkers in blood of PC patients. Blood samples from PC
patients and healthy volunteers (HV) were collected by two independent
groups consisting of multiple institutions. The 1st set was included 55 PC in
stage I and II and 58 HV. The 2nd set was included 16 PC and 16 HV. Six-
teen candidate metabolites were selected from previous report. Quantitative ana-
lyses were performed by gas chromatography/tandem mass spectrometry (GC/
MS/MS) together with their corresponding stable isotopes. In the 1st set, diag-
nostic models were constructed via multivariate logistic regression analysis.
These results were validated using the 2nd set.
Results: In the 1st set, the levels of 11 metabolites differed significantly between
PC and HV. Model Y consisting of 2 metabolites; i.e., histidine and xylitol
showed high sensitivity (70.4%) than CA19-9. Furthermore, combination of
model Y with CA19-9 increased its sensitivity (90.7%) and specificity (89.5%).
In the 2ndset, combination of model Y with CA19-9 demonstrated high sensitivity
(81.3%) and specificity (93.8%). In particular, it displayed very high sensitivity
(100%) for PC in a resectable state.
Conclusion: Quantitative analysis using GC/MS/MS confirmed the possibility of
metabolomics-based screening methods for PC.
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Introduction: Diagnostic yield from EUS-FNAC (fine needle aspiration cytology)
has improved in the past few years with better tissue acquisition techniques. Core
biopsy needles are now available but are more expensive than FNAC needles. We
assessed the diagnostic yield and accuracy of FNAC samples processed for both
cytology and histology.
Aims & Methods: EUS-FNA samples of solid lesions (from September 2014 to
September 2016) were included in a prospective audit of practice. Between
September 2014 and January 2016 the standard practice was to send FNAC
samples for cytology only. After this date, FNAC samples were filtered through
a cassette. The solid material was sent in formalin to histology and the effluent to
cytology for cytospin and cell block as previously. Cellularity was graded as
adequate or inadequate. Final diagnosis was obtained from MDT outcomes.
Results: A total of 211 patients (118 male) were included. Samples were sent to
cytology (n¼ 135; 107 pancreas, 10 biliary, 7 lymph nodes, 11 other), or cytology
& histology (n¼ 76; 56 pancreas, 12 biliary, 5 lymph nodes, 3 other). Sample
adequacy was 80.7% and 98.7% (p¼ 0.0004). Diagnostic yield (64.4%, 94.7%)
and accuracy (81.3%, 96.1%) was significantly better in the combined (histology
& cytology) group (p5 0.0001, p¼ 0.003). Within the combined group, diagnos-
tic yield and accuracy improved by 20.5% (p¼ 0.007) and 26% (p¼ 0.0002)
respectively when the sample was processed for both cytology and histology.
Conclusion: Our study confirms significant improvement in diagnostic yield and
accuracy when samples were sent for both cytology and histology using standard
FNAC needles.
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Introduction: In the revised international consensus guidelines of 2012 for the
management of IPMN of the pancreas, resection is recommended for all main
pancreatic duct IPMN. While in branch pancreatic duct IPMN (BD-IPMN), the
indications for resection are more conservative. Cyst size 430mm without
‘‘high-risk stigmata’’ can be observed without immediate resection. And EUS
observation is recommended to decide a treatment strategy.
Aims & Methods: The present study was a retrospective investigation of surgical
indication for BD-IPMN with worrisome features (WF). 466 patients with IPMN
underwent pancreatic resection at 3 high volume centers in Japan between 1996
and 2014. Among them, 156 patients with BD-IPMN were enrolled this study.
The investigation of predictors of malignancy was done for 10 factors: age at time
of surgery, sex, presence or absence of symptoms, serum amylase, CA19-9, CEA,
tumor location, size of mural nodules (MN), diameter of main pancreatic duct
(MPD), and cyst size of branch pancreatic duct (BPD). In preoperative examina-
tion, endoscopic ultrasonography (EUS) and computed tomography (CT) were
considered to be essential. As for size of MN, EUS measurements were used in all
156 cases. For diameter of MPD and cyst size of BPD, the CT measurement
values were used in all cases. In this study, BD-IPMN was defined as cases with
cystic dilatation of BPD and the MPD diameter was considered 55mm
(International Consensus Guidelines 2012). According to the WHO histological
classification of IPMN (2000), pathological diagnosis is classified as adenoma
(IPMA), borderline (IPMB), and noninvasive and invasive carcinoma (IPMC). A
central review of pathological diagnosis was done in the cases of IPMB and
IPMC. Patients were categorized as benign (IPMA and IPMB) or malignant
(IPMC).
Results: Pathological diagnosis was benign IPMN in 91cases (58%) and malig-
nant in 65 (42%). In univariate analysis CA19-9, MPD diameter, the sizes of MN
and BPD cysts were significant factors. In multivariate analyses, size of MN
(p5 0.0001) and cyst size of BPDs (p¼ 0.0004) were independent predictors of
malignancy, and in ROC analysis AUC for these factors was 0.74 and 0.72,
respectively. Among 78 cases with WF (BPD cyst size=30mm), 45 cases (58%)
had malignant IPMN. The rate of malignancy was significantly higher than that
of patients without WF(26%) (p50.0001). Among 78 WF patients, 54 cases had
MN with EUS observation. The rate of malignancy in patients with MN was
significantly higher than that of WF patients without MN (69% vs 33%). With
7mm taken as the cutoff value for the size of MN, the diagnosis of malignant
IPMN had sensitivity of 76%, specificity of 73% and accuracy of 74%.
Carcinoma without MN was present in 8 patients (8/45¼ 17%) among 78 WF
patients. Pathological findings of these patients were noninvasive carcinoma in 6,
invasive carcinoma 2.
Conclusion: Algorithm for the management of BD-IPMN of International
Consensus Guidelines 2012 was acceptable. Mural nodules observed with EUS
showed high predictive ability in BD-IPMN patients with WF. However, about
15% of carcinoma patients did not have nodules, and the handling of the diag-
nosis in such cases is a problem for the future.
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Introduction: Cystic lesions of the pancreas represent a diagnostic dilemma as
some of the lesions are non-neoplastic or benign, whereas others are malignant or
have potential for malignant transformation. As indicated in a recent meta-ana-
lysis on diagnostic accuracy of endoscopic ultrasound (EUS) guided fine-needle
aspiration (FNA) cytology, it is often impossible to obtain sufficient cellular
material when diagnosing these lesions with current modalities [1]. Recently, a
novel biopsy forceps (MorayTM, US Endoscopy, Mentor, USA) has become
available. It can be introduced through a 19 G FNA-needle, enabling the endos-
copists to obtain histological specimens from the pancreatic cyst wall for the first
time [2].
Aims & Methods: The aim of this study was to evaluate the use of the novel
micro-forceps in a multicenter clinical setting. The patients referred for EUS
evaluation of pancreatic cysts were included retrospectively from five
European tertiary centers. Inclusion criteria were age of 18 or above and a
pancreatic cyst of a size that allowed for FNA puncture. Exclusion criteria
were pregnant or lactating females. A standardized data collection sheet includ-
ing the information about patient demographics, cyst size, EUS/FNA findings,
technical and clinical success, and the results of the biopsies taken was sent to the
collaborating centers. Technical success was defined by successful puncture of the
pancreatic cyst, subsequent successful mounting of the micro-biopsy forceps, and
extraction of at least one micro-biopsy. Clinical success was defined by obtaining
useful histological results.
Results: Twenty patients were included. There was a slight overrepresentation of
female patients (n¼ 12, 60%) and the median age was 65 (range: 41–80). The
patients had a median cyst size of 30mm (range: 15–130mm) and a median
procedural time was 30, 5min (range: 17–58min). We report a technical success
rate of 85% (n¼ 17) - technical failure was only seen in transduodenal puncture
(n¼ 3, 15%). Biopsies were generally of good quality and contributed to the
diagnosis in 14 patients (clinical success of 82%). Among these, there were ten
cases of intraductal papillary mucinous neoplasia, two serous cystic adenomas,
one mucinous cystic adenoma, one mucinous cystadenocarcinoma, and one pseu-
docyst. Two mild adverse events were recorded (10%), a case of re-admission due
to non-specific abdominal pain and a mild acute pancreatitis.
Conclusion: The use of micro-biopsy forceps was until now only reported in case
reports. This is a first larger-scale feasibility study. We conclude that the use of
the micro-forceps seems feasible and safe with acceptable rates of technical and
clinical success. However, prospective studies are needed in order to determine
diagnostic potential of this instrument compared to the other modalities cur-
rently used.
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Introduction: The diagnosis of pancreatic malignancy can be performed by brush
cytology of the common bile duct or main pancreatic duct (MPD) during endo-
scopic retrograde cholangiopancreatography (ERCP). Preliminary data suggest
that cytologic brushing of the MPD is safe and has a sensitivity equal to or
slightly higher to that of bile duct cytology, although its clinical application is
not defined.
Aims & Methods: In this work we report our experience in the execution of MPD
brush cytology. ERCPs between 2014 and 2015 that involved brush cytology of
pancreatic strictures were included. Cytologies were obtained using the Brush
Master V (Olympus Medical System). Histological evaluation was performed by
two experienced cytopathologists.
Results: Of the 18 patients evaluated, 16 were men and 2 women, with a median
age of 62 years (range: 43–89). All patients underwent abdominal computed
tomography and 3 patients had magnetic resonance imaging. In addition to
pancreatic strictures, abdominal CT revealed cephalopancreatic lesions in 61%,
findings suggestive of chronic pancreatitis in 28%, pancreas divisum in 6%, and
pancreatic inflammatory features in 6%. The distribution of the strictures was:
head - 16, head and body - 1, tail - 1. The pancreatic duct was dilated in 16
patients with a median of 7.5mm (IQR: 6–15). The diagnostic values of MPD
brush cytology for pancreatic cancer were: sensitivity - 81.8%, specificity - 100%,
positive predictive value - 100%, negative predictive value - 77.8%, acuity -
88.9%. Sixty-one percent (n¼ 11) of the patients had a final diagnosis of pan-
creatic adenocarcinoma, 5.6% (n¼ 1) of neuroendocrine tumor and 33.3%
(n¼ 6) inflammatory stricture. All the adenocarcinomas lead to strictures in
the head of the pancreas. The diagnosis of neuroendocrine tumor was made by
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endoscopic ultrasonography fine needle aspiration. One patient developed mild
pancreatitis (5.6%).
Conclusion: In patients with suspected cephalopancreatic adenocarcinoma
referred for ERCP, MPD brush cytology may be performed beyond biliary
cytology, as it may improve cytologic diagnosis of malignancy without increasing
complications rate.
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Introduction: Pancreatic metastases (PM) account for 1–2% of pancreatic
tumors. Several cancer types metastasize to the pancreas, but even recently devel-
oped cross-sectional imaging modalities have difficulties distinguishing PM from
primary pancreatic tumors. Moreover, their prognostic significance is poorly
defined.
Aims & Methods: The aims of this study were to clarify the incidence of primary
tumors leading to PM, the clinical characteristics, and prognoses, and to define
the prognostic factors for survival. A retrospective analysis was performed at 39
Japanese tertiary referral hospitals between January 2005 and August 2015, after
receiving approval from the institutional review board of each hospital. We
identified the patients based on data obtained from each institutional database,
and analyzed patient and tumor characteristics, and survival time. All the
patients enrolled in the analysis were histopathologically or cytopathologically
diagnosed with PM. Kaplan-Meier analysis and Cox’s proportional hazard
models were applied to evaluate overall survival and survival analysis,
respectively.
Results: We enrolled 159 patients (median age 74.5 years) with a pathologic
diagnosis of PM. The most common primary tumor was renal cell carcinoma
(38.4%, n¼ 61), followed by lung cancer (24.5%, n¼ 39), colorectal cancer
(11.3%, n¼ 18), sarcoma (6.3%, n¼ 10), breast cancer (6.3%, n¼ 10), and
other cancer (n¼ 21). At the time of the diagnosis of PM, 38 patients (24%)
had at least one tumor-related symptom. Additional extra-pancreatic metastases
were diagnosed in 94 patients (59%). Sixty-four patients (40%) underwent sur-
gical resection, and no surgical resection was performed in 95 patients (60%).
Additional therapies were chemotherapy (n¼ 69), chemoradiation (n¼ 4), radia-
tion (n¼ 3), palliative care, and unclear (n¼ 2). Eight patients were lost during
follow-up and 151 patients were included in the statistical analysis. All patients
with PM had a median overall survival of 43.0 months, with 3- and 5-year
survival rates of 52.5% and 42.6%, respectively. Among the five frequent pri-
mary sites of PM, prognoses of RCC, breast cancer, and colorectal were better
than those of lung cancer and sarcoma. Univariate Cox proportional regression
analysis identified four prognostic factors: pancreatic resection (hazard ratio
[HR] 0.31, 95% confidence interval [CI] 0.18–0.57, p5 0.001), extra-pancreatic
metastases (HR 3.07, 95%CI 1.71–5.51, p5 0.001), tumor-related symptoms at
PM diagnosis (HR 3.88, 95%CI 2.29–6.56; p5 0.001), and pathologic diagnosis
of primary tumors (p5 0.001). Multivariate Cox proportional regression analy-
sis identified three independent prognostic factors: extra-pancreatic metastases
(HR 2.13, 95%CI 1.11–4.07, p¼ 0.02), tumor-related symptoms at diagnosis (HR
5.39, 95%CI 2.92–9.91, p5 0.001), and pathologic diagnosis of primary tumors
(p5 0.001).
Conclusion: Treatment strategies and prognoses for PM completely differ accord-
ing to the primary tumor type. A definitive pathologic diagnosis of PM is essen-
tial for selecting the appropriate treatment.
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Introduction: National Comprehensive Cancer Network (NCCN) guidelines
recommend chest x-ray or chest computed tomography (CT) for the staging of
potential resectable pancreatic adenocarcinoma (PDA). However, there is limited
data supporting these guidelines, and the prevalence of lung metastasis is not well
defined on staging CT scans. We report our findings of patients with lung metas-
tasis during initial staging and follow-up of patients with PDA.
Aims & Methods: Data was prospectively collected from May 2013 to September
2016 for PDA patients who were presented at a multidisciplinary pancreas con-
ference (MDPC) at a large tertiary care center. All patients were staged with CT
pancreatic protocol, CT chest and Endoscopic Ultrasound. Patients with findings
of lung lesions on initial staging chest CT were followed prospectively. Metastatic
lung lesions were determined based on definite imaging characteristics with clin-
ical consensus or lung biopsy results.
Results: A total 278 PDA patients referred to MDPC were staged with CT chest
(Table 1). Out of these, 36 (12.6%) patients were found to have either malignant
(N¼ 6) or indeterminate (N¼ 30) lung lesions on initial staging CT chest. Out of
the six malignant lung lesions, 5 (1.8%) patients had metastatic PDA lesions, and
1 (0.35%) patient had incidental primary lung cancer. On a follow-up of 30
patients with indeterminate lung lesions, 8 patients (26.7%) were later determined
to be lung metastasis. The overall prevalence of definite lung metastasis was at
least 4.8% (13/278). The prevalence of lung metastasis in pancreatic head cancer
was 3.0%, while body and tail masses was 10.5%. Lung metastasis was almost
four times more likely in the body, and tail masses (OR¼ 3.83, CI 1.2–11.8,
p¼ 0.02) compared to head. Overall CT chest resulted in change in management
plan in 9 (2.9%) patients due to change in the stage to metastatic (8) and diag-
nosis primary lung cancer (1). Staging with CT chest changed otherwise resect-
able disease to unresectable/metastatic in 5 patients (1.8%) and borderline
resectable to metastatic disease in 2 (0.7%) patients. Prevalence of isolated
PDA lung metastasis without any other metastasis was 2.8% (8/278).
Table 1: Comparison of patient and tumor characteristics.
Characteristics
Patients without
Lung metastasis
N¼ 265
Patients with
LungMetastasis
N¼ 13 P value
Age (yrs), mean (S.D) 68.6 64.8 0.22
Male (%) 48.4 69.2 0.14
Race, Caucasian (%) 90.2 100 0.36
Mass size (mm), mean (S.D) 26.9 31.1 0.16
Mass Location
Head (%) 76.7 46.2 0.01
Body/Tail (%) 23.3 53.8
CA 19-9, mean (S.D) 899 (1528) 961 (482) 0.90
Conclusion: Our study showed that the prevalence of pulmonary metastasis in
PDA was clinically relevant to mandate routine staging with CT chest.
Prevalence was significantly higher for pancreatic body and tail cancers com-
pared to the head. Staging CT chest resulted in a change in the stage of PDA and
management decisions.
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Introduction: New lesions (metachronous pancreatic cancer) and recurrence may
develop in the remnant pancreas after initial resection for pancreatic cancer and
Intraductal Papillary Mucinous Neoplasm (IPMN). Endoscopic ultrasonogra-
phy (EUS) is proved as a more specific and sensitive method for pancreatic
lesion. However, there is no report about EUS after pancreatectomy. If it is
possible to observe from the anastomotic part to remnant pancreas under the
EUS, remnant pancreatic cancer may be pointed out an early stage.
Aims & Methods: The aim of this study was retrospectively to investigate the
observation ability of EUS for remnant pancreas. In this retrospective study, 44
patients who underwent EUS for remnant pancreas were enrollment. The defini-
tion of observation under the EUS for remnant pancreas was as follows, total
observation for remnant pancreas observed from liner white line (anastomotic
part) to opposite side pancreas, otherwise it was insufficient observation. We
compared the detection rate of EUS findings and that of CT or MRI findings.
Results: Among the 395 patients who underwent pancreatectomy at the JA
Onomichi General Hospital between December 2002 and March 2016, the
enrolled patients were 44 who underwent EUS for remnant pancreas. In the
surgical procedure, pancreaticoduodenectomy (PD) including pylorus-preserving
PD (PPPD) and subtotal stomach-preserving PD (SSPPD) was 20 cases and
distal pancreatectomy (DP) was 24 cases. Total observation of remnant pancreas
was possible in 41 cases (93%). Seven of 44 cases showed the lesion of recurrence
in the remnant pancreas. Although CT or MRI was able to point out it in only 2
cases, EUS was able to point out it in the remnant pancreas of all cases. Stage of
six cases were as follows, 1 case of stage 0, 2 cases of stage Ia, 3 cases of stage IIb.
The other case was IPMN. We were able to perform EUS-FNA for lesion in the
remnant pancreas in all cases. Pathological results were positive in 5 cases. One of
the other 2 cases was negative (class III), but it was a recurrence by surgery. The
other case was strongly suspected to recurrence by Positron emission tomogra-
phy (PET). Second pancreatectomy was performed in 4 out of 7 cases. The
sensitivity of EUS-FNA was 71.4% (5/7), the specificity was 85.7% (6/7) and
the accuracy was 71.4% (5/7). In addition, a comparison of detection ability of
EUS and CT or MRI findings showed that EUS was significantly superior to CT
or MRI (P5 0.01)
Conclusion: EUS was able to observe remnant pancreas in almost cases. We were
able to perform EUS-FNA for lesion in the remnant pancreas. In addition, the
detection ability of EUS was significantly superior to that of CT or MRI. We
believe that EUS and EUS-FNA should be underwent for lesion in remnant
pancreas, and that remnant pancreatic cancer may be pointed out an early stage.
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Introduction: Number of studies reported that patients with intraductal papillary
mucionous neoplasms of pancreas (IPMNs) are at the increased risk for occur-
rence of extrapancreatic malignancies (EPMs). We have conducted a study in
order to assess the prevalence and incidence of EPMs in a cohort of Italian
patients diagnosed with IMPN and to identify risk factor for their occurrence.
Aims & Methods: A hospital based single-centre study was conducted in hospital
Santa Maria della Misericordia, Udine, Italy. Hospital records were screened in
order to identify all new diagnosed IPMN cases in period January 1st 2009 –
December 31st 2015, as well as those seen during the follow-up. Data were
extracted for all the cases identified on demographics, clinical characteristics,
treatment and outcomes. Furthermore we searched for any EPMs diagnosed
previous, synchronous or metachronous in relation to IPMN diagnosis. We
compared the distribution of the demographics clinical characteristics, treatment
and outcomes among patients with and without EPMs by univariate analysis.
The ratio of the observed (O) number of patients with EPMs to the expected (E)
number was calculated along with 95% confidence interval (CI).
Results: Number of 198 patients with IPMN was included in the study. Patients
were predominantly female (59.1%) and age 70–79 (47.2%). IPMNs were pre-
dominantly brunch duct (79.2%), multifocal (66.2%) and were not subjected to
surgical treatment (89.9%). We identified 72 EPMs in 63 patients with IPMN
(31.8%). Eight patients have had 2 EPMs and 2 patients have had 3 EPMs.
Among identified EPMs, 51 (70.8%) were diagnosed previous to IPMN, 17
(23.6%) synchronous to IPMN and 4 (5.6%) metachronous to IPMN. Among
most frequently diagnosed were colorectal cancer (12 patients, 6.1%), breast
cancer (8 patients, 4.0%), renal cell cancer (8 patients, 4.0%) and prostate
cancer (7 patients, 3.5%). O/E ratios for EPMs were significantly increased for
cancer in general (3.66, CI 95%: 2.39–5.37) as well as for renal cell carcinoma
(9.62, CI 95%: 1.98–28.10) and prostate cancer (4.91, CI 95%: 1.59–11.45), while
borderline significance was observed for colorectal carcinoma (3.59, CI 95%:
0.98–9.19) and breast cancer (3.16, CI 95%: 1.03–7.37) (Table 1). We did not
identify any of the demographics and clinical characteristics to significantly
influence EPM occurrence among patients with IPMN.
Table 1: Observed and expected number of patients with extrapancreatic
malignancies in 60 patients with intraductal papillary mucinous neoplasms
Observed Expected O/E CI 95%
ALL 26 7, 096 3, 66 2.39–5.37
prostate cancer 5 1, 019 4, 91 1.59–11.45
breast cancera 5 1, 583 3, 16 1.03–7.37
colorectal cancer 4 1, 115 3, 59 0.98–9.19
renal cell cancer 3 0, 312 9, 62 1.98–28.10
aCalculated for females.
Conclusion: We report an increased prevalence of EPMs in Italian patients with
IPMN, especially for renal cell carcinoma, prostate, colorectal and breast cancer.
A systematic surveillance of IPMN cases for such cancer types would be advised.
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Introduction: Pancreatic ductal adenocarcinoma (PDAC) is known to have an
extremely poor prognosis. Several studies reported the increased risk of second
primary pancreatic ductal adenocarcinoma (2nd PDAC) in cancer survivors.
However, data on the characteristics of 2nd PDAC are insufficient. Studies of
PDAC in the setting of second primary cancer can provide etiologic clues to
understand PDAC.
Aims & Methods: The aim of this study was to investigate the clinical character-
istics of the patients with second primary PDAC compared to patients with first
primary PDAC. This retrospective cohort study included 1759 patients with
PDAC. They were classified as having 2nd PDAC or first primary PDAC (1st
PDAC) according to a prior diagnosed cancer that originated from different
organ and diagnosed at least 6 months before the diagnosis of PDAC.
Comparative analysis and multivariated survival analysis were used to evaluate
the characteristics of the 2nd PDAC.
Results: A total of 1759 patients with PDAC were included in the cohort. Forty-
three patients were classified as having synchronous 2nd PDAC and excluded
from the analysis. There were 110 patients (6.4%) with 2nd PDAC and 1606
(93.6%) patients with 1st PDAC. The median interval between the diagnosis of
the 2nd PDAC and the diagnosis of the prior cancer was 8.4 years (range 0.7–31.4
years) in the 2nd PDAC group. In the comparison of baseline characteristics
between the 1st PDAC and 2nd PDAC groups, patients with 2nd PDAC pre-
sented significantly older age at diagnosis (66.5 vs. 62.2 years, p5 0.001), lower
rate of alcohol consumption (25.5 vs. 36.8%, p¼ 0.017), higher rate of resect-
ability of PDAC (26.4 vs. 15.9%, p¼ 0.004), and higher rate of receiving surgery
as initial treatment (26.4 vs. 15.9%, p¼ 0.018) than patients with 1st PDAC. The
most common origin of prior cancers was the stomach (22 of 110, 20.0%),
followed by the thyroid (21 of 110, 19.1%), breast (19 of 110, 17.3%), colon
(12 of 110, 10.9%), and others. The overall survival (OS) was slightly longer in
patients with 2nd PDAC; however, the difference was not significant (11.8 vs.
12.3 months, p¼ 0.068). Multivariate analysis without resectable status showed
that 2nd PDAC (HR 0.73, 95% CI 0.56–0.94, p¼ 0.016), age at diagnosis (HR
1.02, 95% CI 1.01–1.02, p5 0.001), and alcohol consumption (HR 1.28, 95% CI
1.13–1.47, p5 0.001) were significantly related to OS (Table 1). When resectable
status was included in multivariate analysis, age at diagnosis (HR 1.02, 95% CI
1.01–1.02, p5 0.001), alcohol consumption (HR 1.25, 95% CI 1.11–1.42,
p¼ 0.001), and resectable status at diagnosis (HR 0.30, 95% CI 0.25–0.36,
p5 0.001) were significantly associated with OS. However, 2nd PDAC (HR
0.85, 95% CI 0.66–1.09, p¼ 0.198) was no longer significantly associated with
OS after adjusting for resectable status. This analysis suggested that the associa-
tion between 2nd PDAC and survival was owing to the higher resectability rate.
When subgroups were separately analyzed according to initial treatment mod-
ality, the effectiveness of surgery and chemotherapy were similar between 2nd
and 1st PDAC. In the subgroup of patients who received curative surgery, the
median OS was 28.5 months (95% CI, 23.0–34.1) in the 1st PDAC group com-
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pared with 33.1 months (95% CI, 9.0–27.2) in the 2nd PDAC group (N: 259 vs.
29, p¼ 0.860). In the subgroup of patients who received chemotherapy, the
median OS was 10.7 months (95% CI, 10.0–11.4) in 1st PDAC compared with
10.8 months (95% CI, 9.2–12.3) in 2nd PDAC (N: 1094 vs. 66, p¼ 0.952).
Table 1: Cox proportional analysis for the contribution of clinical factors to
overall survival
Univariate Multivariate Multivariate
HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value
Second
PDAC
0.81 (0.63–1.04) 0.093 0.73 (0.56–0.94) 0.016 0.85 (0.66–1.09) 0.198
Age, mean
(SD)
1.02 (1.01 1.02) 50.001 1.02 (1.01–1.02) 50.001 1.02(1.01–1.02) 50.001
Male sex 1.12 (0.991.27) 0.056 1.04 (0.90–1.19) 0.627 1.03(0.90–1.19) 0.645
Alcohol 1.23 (1.081.39) 0.001 1.28 (1.13–1.47) 50.001 1.25 (1.11–1.42) 50.001
Resectable
status
0.30 (0.25–0.35) 50.001 Not included 0.30 (0.25–0.36) 50.001
Abbreviations: PDAC, pancreatic ductal adenocarcinoma; SD, standard devia-
tion; HR, hazard ratio; CI, confidence interval.
Conclusion: Second primary pancreatic cancer had a higher rate of resectability,
and there was no difference in the effectiveness of curative surgery and che-
motherapy between 2nd and 1st PDAC. Therefore, when curative surgery for
2nd PDAC is possible, it should be conducted similarly to curative surgery for 1st
PDAC. Considering the increased risk of 2nd PDAC in cancer survivors and the
fact that surgery is the only curative treatment for this fatal cancer, more efforts
are needed to develop screening programs for second primary pancreatic cancer
in cancer survivors.
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Introduction: The development of new technology including next-generation
sequencing has accelerated seeking new biomarkers and implementation ‘‘pre-
cision medicine’’. Generally, formalin-fixed paraffin-embedded tumor tissues
obtained by surgery are used for molecular testing. The problem is that surgery
is invasive, therefore, acquisition of adequate specimen by less-invasive proce-
dure is getting significant factor. Endoscopic ultrasound-guided fine-needle
aspiration and biopsy (EUS-FNAB) is the standard technique for diagnosing
pancreatic solid tumor. There are several studies that have assessed the diagnostic
yield of EUS-FNAB, comparing different needle sizes. Whereas, few reports had
evaluated the sample volume of EUS-FNAB depends on the needle size.
Therefore, we investigated the accuracy and assessed the adequacy of sample
volume for ‘‘precision medicine’’, evaluating EUS-FNAB specimens obtained
by 22-gauge needles (22G) and 25-gauge needles (25G).
Aims & Methods: The aim of our study was to verify the accuracy and sample
volume obtained by EUS-FNAB using 22G and 25G, evaluating the feasibility
for immunohistochemistry (IHC) staining. This was a retrospective study in a
single tertiary referral center. Between October 2006 and November 2015, we
investigated 153 patients of pancreatic ductal adenocarcinoma (PDAC) under-
gone diagnostic EUS-FNAB before neoadjuvant gemcitabine-based chemora-
diotherapy. EUS-FNAB was performed with rapid on-site evaluation. We
reviewed the sampling rate, the accuracy rate, and the success rate of IHC stain-
ing between 22G and 25G.
Results: 153 patients underwent EUS-FNAB; 70 patients in 22G group and 83
patients in 25G group. The overall sampling rates on cytology and histology were
100% (153/153) and 98.0% (150/153), respectively. Both 22G and 25G groups
had high sampling rates on cytology and histology, and the sampling rate did not
differ between 22G and 25G groups. The overall diagnostic accuracy rates on
cytology and histology were 94.8% (145/153) and 79.7% (122/153), respectively.
The accuracy rates of 22G and 25G on cytology were 94.3% (66/70) and 95.2%
(79/83), whereas those on histology were 80.0% (56/70) and 79.5% (66/83),
respectively. The overall accuracy rate on combined analysis both cytology and
histology was 96.7% (148/153). The accuracy rates on combined analysis of 22G
and 25G were better than the accuracy rates on cytology or histology alone;
97.1% (68/70) for 22G and 96.4% (80/83) for 25G. The diagnostic accuracy
on cytology, histology and combined analysis did not differ significantly between
22G and 25G groups. We performed hENT1 IHC analysis using the remaining
cell blocks followed by cytological/histological diagnosis for PDAC. 69% (106/
153) of PDAC provided sufficient specimens for IHC staining. The success rate
of IHC staining did not differ significantly between 22G (67%, 47/70) and 25G
(71%, 59/83) (p¼ 0.60).
Conclusion: In the present study, both 22G and 25G diagnostic yields were high;
the accuracy rate on histology of 25G was equivalent to that of 22G. Moreover,
EUS-FNAB specimens obtained by both 22G and 25G can be adequate for IHC
analysis. Further investigations such as EUS-FNAB needle design and novel cell
block preparation are needed for acquiring of adequate material not only for
diagnosis, but for ‘‘precision medicine’’.
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Introduction: Endoscopic submucosal dissection (ESD) for gastric neoplasms
with continuous low-dose aspirin (LDA) is comparatively acceptable according
to recent guidelines [1–3]. This study aimed to evaluate risk factors for post-
operative bleeding after gastric ESD with continuous LDA for patients on
dual antiplatelet therapy (DAPT).
Aims & Methods: This retrospective study was conducted at New Tokyo
Hospital. A total of 597 gastric neoplasms (496 with early gastric cancers and
101 with gastric adenomas) in 571 consecutive patients were treated with gastric
ESD between January 2010 and October 2016. A total of 102 lesions were
excluded from this study: 51 lesions due to anticoagulation therapy; 25 lesions
in patients receiving antiplatelet therapy excluding single-LDA and DAPT; and
26 lesions in patients who underwent ESD for more than two lesions at the same
time. Thus, a total of 495 patients were enrolled in this study. The patients were
categorized according to antiplatelet therapy (APT). APT was defined as follows:
oral administration of single-LDA (aspirin [100 mg/day]) or DAPT (aspirin [100
mg/day] plus clopidogrel [75 mg/day]). Logistic regression analysis was per-
formed for risk factors of bleeding after gastric ESD.
Results: The patients were categorized into two groups: no APT (n¼ 370) and
APT (n¼ 125). APT included single-LDA (n¼ 74) and DAPT (LDA plus clopi-
dogrel; n¼ 51). Among them, 46 received continuous LDA on single-LDA and
40 received continuous LDA on DAPT. The postoperative bleeding rate in the
APT group was significantly higher than that in the no APT group (16.0% vs.
5.9%; P¼ 0.001). Postoperative bleeding occurred in seven and nine patients in
the continuous single-LDA group (15.2%) and the continuous LDA on DAPT
group (22.5%), respectively. In multivariate analysis, specimen size of 40mm
(odds ratio [OR] 3.19; 95% confidence interval [CI], 1.65–6.16; P5 0.001) was a
sole independent risk factor for postoperative bleeding (Table.1). In subgroup
univariate analysis among continuous LDA users, continuous single-LDA and
continuous LDA on DAPT were not related to postoperative bleeding.
Table.1 Multivariate analysis for postoperative bleeding after ESD.
Odds ratio 95% CI P-value
Coronary artery disease 1.52 0.61–3.78 0.370
CKD with hemodialysis 3.21 0.97–10.60 0.056
Continuous LDA 2.13 0.83–5.45 0.116
Specimen size 40mm 3.19 1.65–6.16 50.001
Conclusion: This study suggests that continuous LDA may be acceptable for
gastric ESD in patients on DAPT. However, patients with continuous LDA on
DAPT should be monitored carefully for postoperative bleeding after gastric
ESD because the rate of postoperative bleeding in the continuous LDA on
DAPT group was higher than that in the other groups.
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Introduction: Peroral endoscopic myotomy (POEM) has received wide acceptance
as a highly effective and safe treatment for esophageal achalasia. Short-term and
small-scale studies are ample but long-term large-scale studies are few.
Aims & Methods: The aim of this study was to systematically analyze our long-
term results of POEM, with particular emphasis on POEM failures and asso-
ciated risk factors. This is a single center study. Consecutive POEM patients
between Aug, 2010 and Dec, 2012 were included. Kaplan-Meier survival function
was used to estimate clinical success rate at each year. The Cox proportional
hazards model was used to analyze risk factors related to recurrence.
Results: A total of 564 patients were included. Mucosa injuries happened in 93
patients (16.5%) and 36 patients (6.4%) experienced major perioperative adverse
events. The Eckardt score and lower esophageal sphincter (LES) pressure were
significantly decreased after POEM (median Eckardt score 8 to 2, p5 0.05;
median LES pressure 29.7mm Hg to 11.9mm Hg, p5 0.05). During a median
follow-up period of 49 months (range 3–67 months), fifteen failures occurred
within 3 months, 23 between 3 months and 3 years, and 10 after 3 years. The
estimated clinical success rates at 1, 2, 3, 4, and 5 years were 94.2%, 92.2%,
91.1%, 88.6% and 87.1%, respectively. Multivariate Cox regression revealed
long disease duration ( 10 years) and history of prior interventions to be risk
factors for recurrence. Clinical reflux occurred in 37.3% (155/416) patients.
Conclusion: POEM is a highly safe and effective treatment for esophageal acha-
lasia with favorable long-term outcomes.
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Introduction: Chronic gastrointestinal ischemia (CGI) results of insufficient blood
supply to the gastrointestinal tract1. The majority of CGI patients has systemic
disorders of the circulatory system including hypertension, diabetes and other
cardiovascular risk factors2. Studies in patients with acute gastrointestinal ische-
mia found a correlation between intestinal ischemia and sublingual microcircu-
latory alterations3. However, little is known about microcirculatory alterations in
patients with CGI. We hypothesized that patients with CGI may reveal sublin-
gual microcirculation alterations. We further hypothesized that such alterations
will be amplified when challenging the patient to enteral caloric challenges. This
would provide a patient-friendly means to identify CGI.
Aims & Methods: Consecutive patients with CGI and healthy controls were pro-
spectively included between September 2014 and August 2015. All patients
received the standard work-up for CGI, consisting of assessment of medical
history and symptoms, radiological imaging of the gastrointestinal arteries,
and endoscopic visible light spectroscopy (VLS) for assessment of gastroduode-
nal mucosal oxygen saturation. The sublingual microcirculation was evaluated
before (T0) and 20 minutes after enteral feeding (T1). Total vessel density (TVD
(mm/mm2)), perfused vessel density (PVD (mm/mm2), proportion of perfused
vessels (PorPV (%)), and microvascular flow index (MFI (AU)) were assessed.
Results: We included 12 consecutive patients (63.2 (IQR 48.8–70.4) years, 67%
male) with CGI and 12 controls (32.7 (IQR 27.7–38.1) years, 42% male). At
baseline, patients with CGI had a decreased PORPV of the sublingual small
vessels (median 84.77% vs 95.70%, p¼ 0.006), PORPV of all vessels (median
85.38% vs 95.27%, p¼ 0.007) and MFI of all vessels (median 3.00 vs 2.80,
p¼ 0.039) compared to healthy controls. After caloric challenge, PVD increased
significantly in both in small (PVDs) vessels and all vessels (PVDa) in patients
with CGI (PVDs (T0) median 16.3 (IQR 13.3–22.1) mm/mm2 vs (T1) 19.9 (IQR
14.2–26.2) mm/mm2, p¼ 0.008; PVDa (T0) median 19.1 (IQR 16.2–23.6) mm/
mm2 vs (T1) 22.2 (16.5–28.9) mm/mm2, p¼ 0.02; PorPVs (T0) median 84.8%
(IQR 75.3–90.4) vs (T1) 91.0% (80.1–93.8), p¼ 0.01). In contrast, no significant
changes in microcirculatory parameters were observed after caloric challenge in
the healthy controls.
Conclusion: Patients with CGI have impaired sublingual microcirculation com-
pared to healthy controls. They also show significant alterations in the sublingual
microcirculation after oral caloric challenge compared to healthy controls.
Sublingual microcirculation visualization may offer a fast non-invasive diagnos-
tic opportunity to diagnose patients with CGI.
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Introduction: The operative link of gastritis assessment (OLGA) staging system is
widely used to assess the risk for gastric cancer on the basis of several biopsy
samples taken from the antrum and corpus.
Aims & Methods: In this study we attempted to evaluate whether gastritis staging
using conventional narrow band imaging (NBI) endoscopy is equivalent to that
determined by histopathology. Fifty (50) consecutive patients with Helicobacter
Pylori (H. Pylori) related gastric atrophy selected according to NBI endoscopic
findings 1. The diagnosis of H. Pylori based on direct detection of the organism
by histopathology assessment. The NBI grade of lower gastric atrophy scored
from 0 to 3. The histopathological assessment of lower gastric atrophy was based
on OLGA scoring system. Furthermore, we assessed the presence or absence of
antral intestinal metaplasia. The NBI and histology stages of gastric atrophy
were assessed using a combination of scores for the antrum and corpus. These
stages further classified into low risk (stage 0, I and II) and high risk (stage III
and IV). Finally the degree of correspondence between NBI and histopathology,
in prediction of gastric cancer risk, was assessed.
Results: The mean age of included patients was 38.7 15.6 years, they were 21
(42%) males and 29 (58%) females. 38 (76%) and 13 (26%) patients have pseu-
dopyloric and intestinal metaplasia respectively. Overall 41 (82%) and 9 (18%)
patients have low and high gastric cancer risk respectively. The sensitivity of NBI
in diagnosis of Helicobacter Pylori infection, gastric atrophy and intestinal meta-
plasia were 96% (n¼ 48/50). 100% and 61.5% (n¼ 8/13) respectively. The degree
of correspondence between the scores obtained by NBI and by histology was
58% (29/50) for the lower gastric body atrophy and 86% (n¼ 43/50) for the
antral intestinal metaplasia. The degree of correspondence between the high
risk and low risk groups determined on the basis of NBI endoscopy on one
hand and histopathology on the other hand was 80% (n¼ 40/50).
Conclusion: NBI is able to approximate histopathological staging of gastritis to
good extent. More studies and training will further improve the performance of
our suggested new staging method.
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Introduction: Endoscopic submucosal dissection (ESD) is a standard treatment
for early gastric cancer. Development of the ESD device has been conducted
recently. Splash M-Knife, the new multi-functional ESD device was invented
to achieve complete ESD with a single device. It achieves clear marking, better
hemostasis and smoother operation during a procedure without replacing the
knife.
Aims & Methods: The aim of this study was to investigate clinical outcome of
ESD for early gastric cancer with a new device (Splash M-knife). In total, early
gastric cancer treated by ESD with a needle-type knife between January 2012 and
August 2016 at Kitakyushu Municipal Medical Center were retrospectively
reviewed. Lesions treated by ESD with a conventional needle-knife (ESD-C,
n¼ 76) and by ESD with a new device (ESD-N, n¼ 73) were compared.
Multivariate analyses and propensity score matching were used to compensate
for the differences in age(75 years vs 575 years), sex (male vs female), under-
lying disease (none vs with cardiopathy or cirrhosis), antithrombotic drugs (not
receiving or discontinuation vs continuation), tumor size (=21mm vs 521mm),
lesion location (in the upper or middle third of the stomach vs in the lower
stomach), lesion position (in the lesser curvature of the stomach vs others),
macroscopic type (flat or depressed vs elevated), presence of ulceration (presence
vs absence) and operator level (experience of 50 vs experience550). As primary
endpoint, the rate of the lesions that need hemostatic forceps was compared
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among two groups. As sub-analyses, the cutting time, rate of en-block/complete
resection and rates of adverse events were evaluated among two groups.
Results: Propensity score matching analysis created 46 matched pairs. Adjusted
comparisons between two groups showed a significantly smaller usage rate of
hemostatic forceps in ESD-N than that in ESD-C (4.35% vs 84.8%, p5 0.001),
and similar treatment outcomes (en-block resection rate: 100% in both groups;
complete resection rate: 97.8% vs 100%, p¼ 1; cutting time: 84.6min vs 83.0min,
p¼ 0.89; perforation during ESD: 0% in both groups).
Conclusion: Splash M-Knife achieved better hemostasis and safer ESD for early
gastric cancer. It may contribute to reduce cost for ESD by reducing usage of
hemostatic forceps during ESD procedure.
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Introduction: Intubation failure (IF) occurs when a trained endoscopist is unable
to progress into the upper oesophagus via the oropharynx. The incidence is
unknown, but estimated at 1.8%.[1] There have been no studies exploring IF
and follow-up findings. We aimed to assess the incidence, causes of IF, predictors
of pathology in patients with IF, and follow-up findings.
Aims & Methods: We retrospectively identified all gastroscopies performed at a
district general hospital between August 2010–August 2016 from an endoscopy
database, and reviewed cases with IF. We excluded patients who had achieved
oesophageal intubation. Data on sedation use, endoscopist status, indications,
radiological and endoscopic findings were recorded. Procedural limitations were
classified into 2 groups: ‘failure to tolerate’ (e.g. pulling out scope, anxiety) and
‘failure to progress’. Statistical analyses were made using Pearson’s chi2 and
Wilcoxon signed rank test.
Results: The incidence of IF was 0.95% (248/26130). 238 patients were identified,
with a mean age of 63.2 (SD 16.1), with ‘failure to progress’ in 41 and ‘failure to
tolerate’ in 197. Subsequent investigations included barium radiology (59.7%,
n¼ 142), CT (21%, n¼ 50), repeat gastroscopy (29.4%, n¼ 70) and no further
investigations (19.7%, n¼ 47). Structural pharyngeal abnormalities were
detected in 41 (28.9%), comprising of cricopharyngeal hypertrophy (CPH)
[49%], Zenker’s diverticulum (ZD) [14.6%], pharyngeal web (12.2%), ZD with
CPH (9.8%), cervical spondylosis (7.3%) and other (7.3%). Endoscopist status
was a predictor of IF (OR for medical vs. non-medical endoscopist 0.7, 95% CI:
0.5–0.9, p¼ 0.007). Within the IF cohort, predictors of structural causes on
barium radiology included: dysphagia (OR 5.5, 95% CI: 2.5–11.8, p5 0.001),
failure to progress (OR 5.2, 95% CI: 2.3–12.0, p5 0.001) and age 65 (OR 4.0,
95% CI: 1.8–8.9, p5 0.001). Repeat gastroscopy was successful in 63/70 (2 using
nasendoscope) after increasing midazolam dosage (mean increase¼ 1.5mg, 95%
CI: 1.0–2.0mg, p5 0.001). Diagnostic yield for barium radiology, CT and repeat
gastroscopy were 69.0%, 54.0% and 64.3% respectively. The concordance of
endoscopic indication and pathology on further investigation for IF was 110/
192 (57.3%). In patients undergoing barium radiology and repeat gastroscopy,
the false negative rate for endoscopy was 17/30 (56.7%), consisting of pharyngeal
pathology (n¼ 9), dysmotility (n¼ 4) and significant reflux (n¼ 4).
Conclusion:We present novel data regarding IF, and report an incidence of 1%.
Patients should be investigated further owing to the high risk of underlying
pathology, particularly if associated with age 65, dysphagia, and failure of
endoscopic progression. Barium radiology is comparable to repeat gastroscopy
in terms of diagnostic yield, and may be more helpful in evaluating pharyngeal
and functional pathology.
Disclosure of Interest: All authors have declared no conflicts of interest.
Reference
1. Ponchon T, GIE, April 2000; 51(4): AB275
P0144 DIAGNOSTIC CAPABILITY OF ENDOSCOPY FOR
HELICOBACTER PYLORI INFECTION
Y. Shinji
1, K. Mabe2, M. Kato2, N. Sakamoto3
1Department Of Gastroenterology, Sapporo Medical Center Ntt Ec, Sapporo/
Japan
2Department Of Gastroenterology, Hakodate National Hospital, Hakodate/Japan
3Department Of Gastroenterology And Hepatology, Hokkaido University Hospital,
Sapporo/Japan
Contact E-mail Address: shinjiyoshii@yahoo.co.jp
Aims & Methods: The aim of this study was therefore to determine the usefulness
of the Kyoto classification for diagnosis of HP infection status. A total of 498
subjects were recruited during the period from January to October in 2015 for
this study after providing informed consent in writing. HP infection status was
determined by the presence of HP-IgG antibody (E-plate II H. pylori antibody,
Eiken Chemical Co., Ltd., Tokyo, Japan) and history of eradication therapy. HP
infection status was judged to be ‘‘eradicated’’ if there was a definite history of
eradication therapy. Without a history of eradication therapy, HP infection
status was judged to be ‘‘uninfected’’ for an HP antibody titer of less than 3
U/ml, ‘‘eradicated’’ for an HP antibody titer of 3–10 U/ml and ‘‘infected’’ for an
HP antibody titer of more than 10 U/ml. Seven endoscopists (5 well-experienced
endoscopists and 2 trainees) who were blinded to history of eradication therapy
performed the examinations. The following endoscopic findings were assessed
according to the Kyoto gastritis classification: diffuse redness, regular arrange-
ment of collecting venules (RAC), fundic gland polyp (FGP), atrophy,
xanthoma, hyperplastic polyp, map-like redness, intestinal metaplasia, nodular-
ity, mucosal swelling, white and flat elevated lesion, sticky mucus, depressive
erosion, raised erosion, red streak, and enlarged fold. HP infection status was
diagnosed on the basis of the findings. An Olympus H260 and Xp260NS were
used for endoscopy. The diagnostic accuracy rate of the Kyoto classification and
the sensitivity, specificity, positive predictive value (PPV), negative predictive
value (NPV) and diagnostic odds ratio (DOR) for endoscopic findings were
determined. This study was registered as a clinical trial in UMIN
(UMIN000016674) and was conducted with the approval of the ethics committee
in our institution.
Introduction: Since Helicobacter pylori (HP) eradication therapy is necessary to
prevent the development of gastric cancer, evaluation of HP infection status
(uninfected, infected, eradicated) by endoscopy has become important. For
that purpose, the Japan Gastroenterological Endoscopy Society proposed the
Kyoto classification for gastritis. However, the usefulness of the classification
in daily clinical practice has not been sufficiently evaluated.
Results: The 498 subjects included 376 males and 122 females with a mean age of
53.1 years. HP status was unaffected in 315 subjects, eradicated in 104 subjects
and infected in 79 subjects. The diagnostic accuracy rate was 82.9%. The sensi-
tivity, specificity, PPV, NPV and DOR were 88.3%, 92.9%, 95.5%, 82.1% and
98.6, respectively, for uninfected status, 78.8%, 90.0%, 69.5%, 94.2% and 37.0,
respectively, for eradicated status, and 67.1%, 91.4%, 59.6%, 93.6% and 21.7,
respectively, for infected status. High DORs were obtained for the following
endoscopic findings: 32.2 for RAC, 7.7 for FGP and 4.7 for red streak in subjects
with uninfected status, 12.9 for map-like redness in subjects with eradicated
status, and 26.8 for diffuse redness, 13.3 for mucosal swelling, 10.2 for sticky
mucus and 8.6 for enlarged fold in subjects with infected status.
Conclusion: The Kyoto classification is useful for diagnosis of HP infection
status. Particularly important findings are RAC, FGP and red streak for unin-
fected status, map-like redness for eradicated status, and diffuse redness, mucosal
swelling, sticky mucus and enlarged fold for infected status.
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Introduction: Balloon tamponade, such as with Sengstaken-Blakemore tubes
(SBT), remains the main immediate salvage therapy for acute variceal bleeding
uncontrolled by variceal ligation or injection therapy. Previous cohort studies
from the 1970–1980s report success rates of 40–94% for initial haemostasis but
high re-bleeding rates of 40–70% on removal [1–3]. Despite guidelines recom-
mending balloon tamponade as initial therapy in treating endoscopically
uncontrollable variceal bleeding, specialists and trainees feel uncomfortable
with SBT insertion [4] given the perceived difficulties and complications [5].
Aims & Methods: We aimed to describe the current practices surrounding inser-
tion of SBT for acute variceal bleeding, the outcomes and to identify areas
requiring improvement. A retrospective audit of all patients from 2008–2016
who required SBT insertion for control of acute variceal bleeding was undertaken
at Monash Health, a large tertiary Australian centre. These patients were identi-
fied from coding classifications. Details regarding their admission were obtained
via electronic records.
Results: Approximately 14% of all patients with variceal bleeding required inser-
tion of a SBT. Of these 42 patients, the majority were male (71%) with a median
age of 55 years (range 34–78). Alcohol was the most common aetiology for
cirrhosis (62%), with 65% actively drinking. Most patients had cirrhosis severity
scores of Child-Pugh B (67%) or Child-Pugh C (29%) and a median MELD
score of 16 (range 8–39). At the index variceal bleed, 67% were haemodynami-
cally unstable and 29% were encephalopathic. All received standard medical
therapy with octreotide or terlipressin, antibiotics and blood products as
required. The time to initial endoscopy from 1st onset bleeding was prompt
(median 6.62 hours). Most bleeding varices were oesophageal (90%). Initial liga-
tion/injection was performed in 64% with the remaining patients having such
large volumes of blood in the UGI tract that satisfactory views were unable to be
obtained. The current practice surrounding SBT insertion is shown in the table
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below. Re-look endoscopy post-SBT insertion was performed in 86% patients at
a median of 39 hours after insertion with further endoscopic therapy in 47%.
Complications of SBT insertion occurred in 31% and included minor oesopha-
geal ulceration (9), significant oesophageal ulceration (3), aspiration pneumonia
(4) and oesophageal perforation (1).
Current practice surrounding Sengstaken-Blakemore Tube insertion
Variable Results (n¼ 42)
Indication for SBT insertion Incomplete haemostasis
74%, poor view 50%
SBT insertion site Oral 32, nasal 8
Confirmation of position Direct endoscopic visualisation 13,
imaging 25, none 6
Volume of balloon inflation Gastric balloon - 306ml mean
(60–450ml) Oesophageal
balloon - 25–300ml (n¼ 15)
Duration of balloon
inflation (median hours)
Gastric balloon - 35.1 (1–140.3)
Oesophageal balloon - 16 (1–62.8)
Time to re-look endoscopy
after SBT (median hours)
39.3 (11.5–348.2)
Re-bleeding occurred in 45% patients during the admission despite SBT inser-
tion, of which 79% did not survive. Seven other patients subsequently underwent
a TIPS procedure but 4 of these still died. Survival at discharge and at 12 months
was 50% and 41% respectively. The median duration of hospitalisation, intensive
care and mechanical ventilation was 13 days (1–56), 6.2 days (0.3–36.2) and 120
hours (1–708) respectively.
Conclusion: Primary haemostasis was achieved in 93% of patients; however, re-
bleeding occurred in 45% and was associated with a poor survival rate of 20%.
Short and longer-term survival overall has not significantly improved since stu-
dies in the 1970s-1980s despite advances in pharmacological therapy. Current
practices surrounding SBT insertion are variable and would benefit from further
education. Rates of direct visualisation of balloon position prior to inflation with
endoscopy should be improved as with referrals for early TIPS.
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Introduction: To evaluate the feasibility and safety of the dexmedetomidine
(DEX) for conscious sedation during endoscopic submucosal dissection (ESD).
Aims & Methods: This study was a prospective trial, and was conducted at the
Yamashita Hospital in Japan. Between January 2016 and December 2016, all 50
patients were enrolled in this study. The inclusion criteria for the study was the
presence of esophageal, gastric or duodenal tumors. The criteria for exclusion
from this study is as follows: patients who were allergic to the drugs used, a base-
line heart rate less than 50 beats/minutes, patients who could not use anticholi-
nergic drugs, and lack of patient’s consent. A total 50 patients who underwent
ESD by using DEX for esophageal, gastric or duodenal tumor. The patients were
sedated with DEX (an initial bolus infusion of 3.0 mg/kg/hour intravenously over
10 minutes, followed by a continuous infusion at 0.4mg/kg/hour titrated). During
sedation, midazolam (0.03mg/kg) and pethidine (17.5mg) were added intrave-
nously as needed. If the level of sedation dropped to less than RASS -3, the
intravenous DEX injection rate was reduced by 0.1 mg/kg/hour. If heart rate
was less than 50 beats/minutes or systolic blood pressure was less than
80mmHg, the intravenous DEX injection rate was reduced by 0.1 mg/kg/hour.
If the patient’s heart rate was less than 50 beats/minutes, the patient was intra-
venously infused with atropine sulfate hydrate (0.125mg-0.25mg). During pro-
cedure, the following parameters were measured continuously, and recorded
every 5 minutes: heart rate, blood pressure, hemoglobin oxygen saturation
(SpO2), respiratory rate and RASS. As the achievement rate of conscious seda-
tion during procedure, the percentage of the time that the depth of sedation from
RASS 1 to 3 during procedure were evaluated. Body movement leading to the
interruption of ESD were recorded appropriately. After the procedure, all
patients were intravenously infused with flumazenil (0.3mg) and observed until
the Aldrete score reached 9 points.
Results: During this study period, 50 patients with esophageal, gastric and duo-
denal tumors were identified as potentially eligible for participation. There were
37 males and 13 females, and the mean age was 67.5 8.6 y. 27 patients regularly
consumed alcohol and 5 patients use sleeping drugs regularly. Tumors were
located in the following locations: 9 cases in the esophagus, 38 cases in the
stomach, 3 cases in the duodenum. The mean tumor size was 23.8 16.9mm
and the procedure time was 88.0 59.5 minutes. The histologic results of ESD
were squamous cell carcinoma (n¼ 9), adenoma (n¼ 17) and adenocarcinoma
(n¼ 24). ESD by using DEX were successfully performed in all 50 tumors. No
adverse events that were the results of procedures occurred. The mean achieve-
ment rate of conscious sedation during procedure was 84.7 16.5%. The median
frequency of disturbance by patient’s movement was 0 times (range 0–3 times). 33
cases reduced and 14 cases discontinued a continuous infusion of DEX. In 23
cases, there was a decreased heart rate less than 50 beats/minutes. In 16 cases, the
patient required an infusion of atropine sulfate hydrate. Thirteen cases of 16
cases required an infusion of atropine sulfate hydrate after the procedure and
3 cases required it during procedure. The median time that the final administra-
tion of an atropine sulfate hydrate was 35min (range 5–140min) after procedure.
There was no case in lowering of systolic blood pressure less than 80mmHg.
Although in 7 cases, the patient’s SpO2 level dropped to less than 90%, however,
they recovered after the administration of oxygen into the nasal cannula. The
mean time that the Aldrete score reached 9 or over 9 was 7 4 minutes. The
median endoscopist and patient’s satisfaction score was 9 points (range 2–10
points) and 8 points (range 2–10 points). There were 30 patients (60%) who
have a memory during procedure.
Conclusion: Conscious sedation with DEX is effective, safe and a high level of
satisfaction for endoscopists and patients for upper gastrointestinal ESD.
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Introduction: Preoperative diagnosis of invasion depth of superficial esophageal
squamous cell carcinoma (SESCC) is very important to select appropriate ther-
apeutic procedure. The Japan Esophageal Society (JES) classification using
narrow-band imaging with magnification (M-NBI) was efficient for predicting
invasion depth of SESCC1). Blue laser imaging (BLI) is an image enhanced
endoscopy consisted of two different lasers with wavelength 410 and 450 nm as
light source, which can enhance mucosal vascular and surface structure. In pre-
vious study, BLI with magnification (M-BLI) was useful for evaluating gastro-
intestinal neoplasms such as predicting invasion depth or tumor detection2).
Aims & Methods: We aim to investigate the diagnostic value of M-BLI by com-
paring that of M-NBI. Our study was single center retrospective study and
approved by the Ethical Review Committee of Kyoto Prefectural University of
Medicine, and performed in accordance with the World Medical Association’s
Declaration of Helsinki. All patients provided informed consent for undergoing
both M-NBI and M-BLI. Consecutive 166 patients underwent endoscopic sub-
mucosal dissection (ESD) for esophageal tumor at Kyoto Prefectural University
of Medicine between April 2014 and March 2016. Endoscopic images of SESCCs
were recorded by both M-BLI and M-NBI prior to ESD. SESCCs were patho-
logically diagnosed by ESD specimens. Three endoscopists with no information
of the lesions evaluated invasion depth of SESCCs using M-BLI and M-NBI
images according to JES classification. The diagnostic value of each procedure
was evaluated.
Results: 124 SESCCs were analyzed in this study. The numbers of male/female
were 104/20, respectively. Median age was 68.5 years old. Median size of tumor
was 17.6mm. The proportion of tumor location at Ut/Mt/Lt was 13/70/17(%),
respectively. The proportion of macroscopic type for 0-I/0-IIa/0-IIb/0-IIc was 1/
10/66/23(%), respectively. The proportion of invasion depth of the lesions sub-
classified as EP or LPM, MM or SM1, and SM2 were 80, 13 and 7(%) respec-
tively. The overall diagnostic accuracy of BLI and NBI were 88.7% and 83.9%
(P¼ 0.35), respectively. The interobsever variability of three endscopists with BLI
and NBI was 0.679/0.560/0.559 and 0.568/0.822/0.560, respectively. The intraob-
server variability with BLI and NBI was 0.839/0.718/0.531 and 0.517/0.514/
0.441, respectively.
Conclusion:M-BLI was efficient for diagnosing invasion depth of SESCC accord-
ing to JES classification, similar to M-NBI.
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Introduction: Endoscopic Ultrasound (EUS) has been found to be an effective
tool in diagnosing pancreatic cystic neoplasms (PCN). Carcinoembryonic antigen
(CEA) tumor marker has also been used to differentiate PCN and is the most
accurate marker of mucinous cystic neoplasms. Recently, needle-based conofocal
laser endomicroscopy (nCLE) has been increasingly used for the diagnosis of
PCN. nCLE allows for evaluation of pancreatic cysts with results similar to
that of a pathological diagnosis. In this study, we will compare our standard
of care, EUS, with combined CEA and nCLE to determine which combination of
diagnostic modalities is a better predictor of PCN.
Aims & Methods: In this retrospective chart review, 22 patients with pancreatic
cysts were evaluated. Specificity and Negative Predictive Value (NPV) of EUS
alone or EUS with CEA and nCLE combined were evaluated and diagnostic
accuracy was compared with pathology using McNemar’s test. Worrisome fea-
tures (increased cyst size, wall thickness, main pancreatic duct size, and presence
of non enhanced mural nodules, abrupt changes, distal atrophy and lymphade-
nopathy) were tested by determining dissimilar calculations using Euclidean dis-
tance and later were used in hierarchical clustering to create two clusters based on
Euclidean distance.
Results: Diagnosis of PCN using EUS alone had a specificity of 0.75 and a NPV
of 0.88. EUS and CEA combined had a specificity of 0.95 and a NPV of 0.90.
Finally, EUS with CEA and nCLE combined had a specificity of 0.80 and a NPV
of 0.94. Worrisome features clustering was able to predict pathology,
p¼ .000289.
Conclusion: We concluded that specificity and NPV of EUS predicting PCN are
positively impacted by the addition of CEA and nCLE. We also found that
clustering of worrisome factors predicts pathology, however, a larger cohort is
required for future studies.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Full-spectrum esophagogastroduodenoscopy (FUSE-EGD) pro-
vides a 245-degree field of view with double CCE imagers on the front and left
side of the endoscope.
Aims & Methods: The aim of this study is to determine the usefulness of FUSE-
EGD for upper gastrointestinal screening. The primary endpoint was comparison
of the success rates of entire visualization of the ampulla of Vater and the sec-
ondary endpoint was comparison of success rates of visualization of the anal side
of the pyloric ring between FUSE-EGD and conventional forward-viewing
EGD. The additional endopoint was possibility of close-up visualization of the
squamo-columnar junction (SCJ). Between April 2016 and September 2016, 88
healthy individuals (46 male and 42 women; median age of examination, 68 years;
range, 26–91) underwent FUSE-EGD, and 818 healthy individuals (423 male and
395 women; median age of examination, 67 years; range, 19–97) underwent
conventional EGD for upper gastrointestinal screening. Among them, 40 indivi-
duals who underwent FUSE-EGD with a previous history of conventional EGD
were interviewed about the degree of pain at insertion, during and after the
FUSE-EGD examinations using the visual analog scale (VAS) (0, comfort; 50,
equal to the last conventional EGD; and 100, painful). Furthermore, we evalu-
ated 3 patients with familial adenomatous polyposis (FAP) and 2 with the ampul-
lary tumors using FUSE-EGD.
Results: Entire visualization of the ampulla of Vater was successful at 90.4% (47/
52) with FUSE-EGD, compared to 41.2% (174/422) with conventional EGD
(P5 0.001). Visualization of the anal side of the pyloric ring was successful at
88.5% (46/52) with FUSE-EGD, compared to 8.5% (6/70) with conventional
EGD (P5 0.001). Close-up visualization of SCJ was successful at 92.0% (81/88)
with FUSE-EGD. VASs at insertion, during and after examinations were 51.2
(10–75), 46.9 (0–75), and 45.2 (10–50) points, respectively, which were equivalent
to conventional EGD. The ampullary adenoma was observed in all 3 patients
with FAP, and the openings of the biliary and pancreatic ducts of the ampulla of
Vater were observed in all 2 cases with the ampullary tumors with FUSE-EGD.
There were no adverse events associated with FUSE-EGD.
Conclusion: FUSE-EGD seems safe and effective for upper gastrointestinal
screening, especially when the precise observation of the ampulla of Vater and/
or the anal side of the pyloric ring is necessary.
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Introduction: Endoscopic submucosal dissection (ESD) is accepted as the treat-
ment of intestinal-type early-stage gastric cancer. However, ESD occasionally
results in unfavourable outcome due to technical difficulties. Therefore, predic-
tions of difficulties in ESD would preclude complications associated with ESD.
Aims & Methods: The aim of this study is to determine the predictive factors of
procedural difficulties in ESD. Between January 2009 and July 2016, 577 con-
secutive patients who underwent ESD for gastric neoplasms were enrolled. These
patients were classified into 3 groups: group S, group L, and others. Group S
comprised 30 patients who underwent ESD for the shortest duration (10–16min).
Group L comprised 30 patients who underwent ESD for the longest duration
(149–215min). Multivariate analysis was performed between Groups L and S
using the following factors: location (cardia, posterior wall of angle, lesser cur-
vature of lower gastric body and others), macroscopic type (protruded, depressed
or mixed), size of the resected specimen, preoperative scar, number of preopera-
tive biopsies, /others), and as predictor for submucosal fat tissue, body mass
index, waist circumference, visceral fat tissue measurements on CT, blood test
findings (glycated hemoglobin, triglyceride and total cholesterol), blood pressure,
and heart rate before ESD.
Results: Significant differences were found regarding the number of biopsies
(group L, 8.5; group S, 6.8, P¼ 0.0211), (group L, 616.7mm2; group S,
99.2mm2, P¼ 0.0286), biopsy diagnosis (P¼ 0.0292), and location (P¼ 0.0086).
Based on these factors and odds ratio, we prioritized sensitivity to avoid missing
cases with removal difficulties during ESD and suggested predictive factors for
removal difficulties during ESD. Preoperative scar: 3 points, the size of the
resected specimen 4800mm2: 3 points, difficult location: 2 points, the number
of biopsies 47 pieces: 1 point, Group 5 on biopsy diagnosis: 1 point. Cases of 6
points or more was regarded as difficult to remove that takes over 70 minutes.
When examining 43 patients who underwent ESD for gastric neoplasms between
August to November 2016 the sensitivity was 87.5% and the specificity was 80%.
Conclusion: Our results suggest that the number of biopsies, size of the resected
specimen, biopsy diagnosis, preoperative scar and biopsy location are predictive
factors for difficulties in ESD.
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Introduction: Timely detection of early gastric cancer (EGC) is important in
performing endoscopic submucosal dissection (ESD). We attempted to know
the location characteristics where EGC is frequently detected and analyzed
EGC characteristics associated with the location.
Aims & Methods: We retrospectively reviewed the medical records of patients
with EGC treated by ESD between November 2008 and August 2016. We retro-
spectively investigated and analyzed 647 EGC lesions.
Results: The patients’ mean age was 66.7 10.8 years. The patient population
was predominantly male (77.1%, 499/647). A well to moderately differentiated
carcinoma was observed in 97.2% of patients. The common site was the lower
part of the stomach (89.6%, 580/647). The highest percentage of EGC was found
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in the lesser curvature (43.9%, 284/647). Posterior EGC was more frequent in the
mid-to-upper part of the stomach than the anterior part (20.4%, 31/67 vs. 16.4%,
11/67, respectively). For EGC characteristics compared between the lower and
mid-to-upper parts, submucosal invasive EGC was found to be significantly
different (odds ratio, 1.919; confidence interval, 1.014–3.623; p¼ 0.045).
Conclusion: Most of the EGCs resectable with ESD were found in the lower part
of the stomach and lesser curvature of the stomach. The incidence of the poster-
ior part in the mid-to-upper part of the stomach was higher than that of anterior
part. The EGC located in the mid-to-upper part of the stomach was found to
have a higher incidence of invasive cancer.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The recognition of general images by machine learning (ML) with
the convolutional neural network (CNN) and deep learning (DL) is good.
However, the possibility of the recognition of endoscopic images by ML with
CNN and DL is undetermined.
Aims & Methods: The aim of this study was to clarify the possibility of the
recognition of endoscopic images by ML with CNN and DL.
We selected 816 endoscopic images of 8 categories which include laryngopharynx
(LP), thoracic esophagus (TE), abdominal esophagus (AE), gastric fundus (GF),
gastric body (GB), gastric antrum (GA), duodenal bulb (DB) and descending
part of the duodenum (DD). Each category had approximately 100 images.
These images were randomly separated into two groups, 60% (489 images) for
learning and 40% (327 images) for testing. We increased the learning group
images to 8313 by adding additionally rotated images of each five degrees.
We made an ML model with three CNN layers, three Activation Function layers,
two Max-Pooling layers and two Dens layers by TensorFlow and Keras.
We trained the ML model with the learning group images (n¼ 8313) and then
tested it with the testing group images (n¼ 327) to determine whether it can
recognize the endoscopic site. Two members of our hospital staff performed
the same test utilizing the same images.
Results: It took 73 minutes for the ML model to learn and 6 seconds to answer
the test. The percentage of correct answers of the ML model was 70.6% in all
categories (n¼ 327), 77.1% in LP (n¼ 48), 91.5% in TE (n¼ 47), 64.4% in AE
(n¼ 45), 73.7% in GF (n¼ 38), 61.5% in GB (n¼ 39), 52.8% in GA (n¼ 36),
65.6% in DB (n¼ 32) and 71.4% in DD (n¼ 42). The average percentage of
correct answers of humans was 95.4% in gastroenterologists (n¼ 5), 85.2% in
junior residents (n¼ 2), 81.2% in endoscopy nurses (n¼ 5), 54.4% in medical
clerks (n¼ 5) and 51.8% in floor nurses (n¼ 4).
The percentage of correct answers of the ML model was lower than those of
humans who have knowledge about endoscopic images. However, it was higher
than those of other humans who do not.
Conclusion: The results suggest the possibility of the recognition of endoscopic
images by ML with CNN and DL. Further study is necessary to confirm the
ability of it because this study was conducted in a simple ML model with three
CNN layers and a small number of images.
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Introduction: To clarify whether traction assist improves technical outcomes of
endoscopic submucosal dissection (ESD).
Aims & Methods: A superiority, randomized phase 3 trial was conducted at 14
institutions across Japan. Patients with single gastric neoplasm meeting the indi-
cation of the Japanese gastric treatment guidelines were enrolled and assigned to
conventional ESD or dental floss clip traction ESD (DFC-ESD) by a computer-
generated random sequence with stratification by institution, tumor location,
tumor size and operator’s proficiency. The primary endpoint was ESD procedure
time, which was defined as the time from the start of submucosal injection to the
end of tumor removal.
Results: Between July 2015 and September 2016, 640 patients underwent rando-
mization. 316 patients assigned to conventional ESD and 319 patients assigned to
DFC-ESD were included in the analysis set. Mean ESD procedure time was 60.7
minutes in the conventional ESD group and 58.1 minutes in the DFC-ESD group
(p¼ 0.45). Perforation was less frequent in the DFC-ESD group (conventional
ESD vs. DFC-ESD: 2.2% vs. 0.3%, p¼ 0.04). Among the lesions in the greater
curvature of the upper or middle stomach, mean procedure time in the DFC-
ESD group was shorter than the conventional ESD group (conventional ESD vs.
DFC-ESD: 104.1 vs. 57.2 minutes, p¼ 0.01).
Conclusion: This study reveals that traction-assisted ESD does not result in
quicker procedures in the entire population, but it can reduce the risk of perfora-
tion. Selectively applied to the lesions in the greater curvature of the upper or
middle third stomach, traction assist contributes to a remarkable reduction of
procedure time.
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Introduction: The vessel plus surface (VS) classification system proposed by Yao
is widely used for endoscopic diagnosis of early gastric cancer1. However, this
diagnosis is performed by visual observation and no quantitative index exists.
Aims & Methods: In this study, a method for automatically detecting early gastric
cancer lesions by narrow-band imaging (NBI) using a magnifying endoscopic
image in the stomach is proposed to support diagnosis. The proposed system
quantitatively shows the demarcation line (DL) of lesions in narrow-band
images. Machine learning is introduced into the VS classification and image
processing is performed. In the literature, texture analysis, which is a type of
image processing, is used to assess the mucosal surface2. In addition, the pro-
posed system uses a color feature that quantitatively expresses mucosal vessels.
Furthermore, the narrow-band image contained 200 superpixels, and each super-
pixel contained texture and color features; a superpixel is a collection of pixels
with similar features. Finally, lesions were identified by a support vector
machine, which is a model for machine learning, and DL was detected. In this
computational experiment, the utility of the system was verified by identifying 25
early-stage gastric cancer lesions (50 endoscopic images) using NBI-magnified
observation at the Department of Gastroenterology, Murakami Memorial
Hospital, Asahi University, Gifu.
Results: The average detection rate of the lesion area greatly improved to 63.0%
with the proposed method compared with 28.8% with the conventional method.
In addition, the obtained DL was similar to that indicated by an experienced
medical physician. Based on these results, the proposed system enabled the auto-
matic detection of early gastric cancer DL in narrow-band images, suggesting
that the proposed system is useful for the determination of DL.
Conclusion: In this study, a method to assess features of gastric lesions combined
with the use of superpixels was proposed. The average detection rate of the lesion
range using the proposed method greatly improved compared with that using the
existing method, enabling the detection of DL without depending on a physi-
cian’s experience.
Disclosure of Interest: All authors have declared no conflicts of interest.
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M. Barthet3
1Hopital Nord, Marseille/France
2Dept. De Gastroenterologie, APHM - North Hospital, Marseille/France
3Gastroenterology, Hopital Nord, Marseille/France
Contact E-mail Address: diane.lorenzo@gmail.com
Introduction: Post-sleeve gastrectomy fistulas (PSGF) are major complication of
bariatric surgery. Endoscopic management evolved from a fistula closure to an
internal drainage (ID) strategy within the 2013 year. The main objective of this
study was to evaluate these different endoscopic approaches.
Aims & Methods: This retrospective study included all patients treated for PSGF
in a referral center. "Closure" management was defined as: initial treatment using
covered-metal-stent and endoclips. ID management was defined as: initial treat-
ment by nasocystic drain and/or double-pigtail-stent. The failure was defined as:
need for surgery, or death.
Results: Between 2007 and 2015, 100 patients (women: N¼ 78; mean age:
42 12years) were included. The mean delay between SG and the first endoscopy
was 82 125 days. Overall success of endoscopic treatment was 86% within
6 27months. Two patients died. Primary success of ID and closure manage-
ment occurred in 19/22 (86%) and 49/77 (63%) patients, respectively. Among
patients in failure of closure management, 22 had secondary ID (18 being suc-
cessful). Success of initial management was significantly higher for ID (p5 0.05).
Factors associated with failure of closure management were in multivariate ana-
lysis: collection45 cm (p¼ 0.013, OR¼ 3.8 95%CI[1.3–10.9]). Factors associated
with duration of management over 6 months were in multivariate analysis: reo-
peration before endoscopy (p¼ 0.044, OR¼ 3.9 95%CI[1.0–14.9]) and purulent
flowing at endoscopy (p¼ 0.043, OR¼ 4.6 95%CI[1.0–20.4]). Factors associated
with post-2013 management were in multivariate analysis: first endoscopy within
30 days (p¼ 0.016), Clavien-Dindo-type 4 and 5 (p¼ 0.016), and absence of glue
sealing (p¼ 0.027).
Conclusion: Endoscopic management of PSGF healed in 86% of cases. In case of
collection greater than 5 cm, an internal drainage should be proposed first. A
second surgical procedure before endoscopy is associated with longer care.
Management in our center has changed over time with earlier first endoscopy
and management of more severe patients.
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Introduction: Endoscopic full-thickness resection (EFTR) is a mini-invasive tech-
nique for gastrointestinal subepithelial tumors, which enables a full-thickness
resection of tumors and can provide a complete basis for pathological diagnosis.
Gastrointestinal fistula closure after EFTR is a challenge for endoscopists. In this
study we introduced EFTR with fistula closure using the over-the-scope clip
(OTSC) system for gastrointestinal subepithelial tumors originating from the
muscularis propria.
Aims &Methods:We aimed to evaluate the feasibility and safety of fistula closure
with OTSC by a retrospective analysis on the cases of EFTR with defect closure
using OTSC for gastrointestinal subepithelial tumors in our hospital. The
patients were selected who underwent EFTR for gastrointestinal subepithelial
tumors originating from the muscularis propria (tumor diameter 3 cm) in our
hospital from May 2014 to December 2016. After a full-thickness resection of
tumors, one or two OTSCs were released to close the defect. The success rate of
defect closure with OTSC was observed and the endoscopic follow-up was per-
formed at 1 week, 1 month, 6 months, 24 months after operation to check OTSC
closure.
Results: In total 49 patients were included into the study. The full-thickness resec-
tion rate of gastrointestinal tumors in the muscularis propria was 100% (49/49), the
success rate of defect closure was 100%, and the average time of defect closure was
7.3min (range: 3–27min). All patients experienced no postoperative complications
such as bleeding and perforation. The postoperative follow-up time was 1–24
months (mean: 11 months), and no late complications was found.
Conclusion: OTSC can be used to perform EFTR with defect closure for gastro-
intestinal tumors in the muscularis propria (tumor diameter 3 cm). It is simple,
convenient, safe and effective.
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Introduction: ESD has been performed on many patients with early stage eso-
phageal cancer. However, postoperative stricture after2/3 circumferential ESD
is the most important issues for quality of life in patients which is drastically
decreased and repeat, periodic endoscopic balloon dilatation (EBD) is usually
required over long periods. It is well known that hormone for external use is
more easily absorbed in broken skin. Accordingly, We explore an innovative
strategy with oral mixture of hydrocortisone sodium succinate and Aluminum
phosphate gel for prevention of the stricture
Aims & Methods: To evaluate the efficacy of this mixture in single center of
Beijing, China.
Patients and Methods: In total, 13 patients who underwentmore than 2/3 circular or
complete circular ESD for esophageal superficial squamous cell carcinoma were
included in this study. They all received preventative strategy for stricture and
were divided into three groups chronologically. Four patients received systemic
steroid treatment (ST group), three patients received endoscopic intralesional ster-
oid (triamcinolone acetonide 80mg) injection accompanied with systemic steroid
treatment (ITþ ST group), six patients received oral mixture of hydrocortisone
sodium succinate and aluminum phosphate gel (OHA group). We compared the
two groups in terms of stricture rate and total number of endoscopic balloon dilata-
tion (EBD) sessions. ST groups started with 30mg/day prednisolone on the second
day post-ESD, and continued with a gradually tapering prednisolone dose, finally
discontinuing systemic steroid administration 8 weeks later. ITþ ST group started
with 80mg introlesional steroid at the end of ESD procedure, and 30mg/day pre-
dnisolone on the second day post-ESD which exactly was the same as ST group of
tapering process. OHA group started with mixture of hydrocortisone sodium succi-
nate 50mg and aluminum phosphate gel 20 g, qid for 2 weeks and continued with a
gradually tapering OHA dose on the second day post-ESD.
Esophagogastroduodenoscopy (EGD) was performed on demand whenever
patients complained of dysphagia. Among those cases, EBD was performed when
patients experienced persistent dysphagia. If the patient had no complaint of dys-
phagia, EGD was performed 8 weeks after ESD to evaluate any possible stricture.
The primary end point in this study was the stricture rate after ESD followed by oral
prednisolone. The secondary end point was the number of EBD sessions required to
resolve the stricture. A stricture was defined as a difficulty in swallowing solids or an
inability to pass an EGD (9.2mm diameter endoscope).
Results: There were two complete and two 75% circular ESD in ST group, one
complete and two 75% circular ESD cases in ITþ ST group, and one complete
and five 75% circular ESD cases in OHA group. 12 cases were resected en bloc
with tumor free lateral and basal margins. No complications were seen after this
procedure. The stricture rates of ST, ITþ ST, OHA group after ESD were 100%
(4 of 4 patients), 33.% (one of three patients), 0% (none of six patients), respec-
tively. One patient with stricture after ESD had lateral recurrence at the margin
of ulcer. One EBD was performed in three patients in ST group and one patient
in ITþST group with esophageal stricture. One patient in ST group underwent
operation in response to patient demand.
Conclusion: Short period, oral l mixture of hydrocortisone sodium succinate and
aluminum phosphate gel showed promising results for the prevention of stricture
after ESD for early stage esophageal cancers.
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Introduction: Endoscopic resection for superficial nonampullary duodenal epithe-
lial tumors (SNADETs) has a high incidence of complications such as perfora-
tion in endoscopic mucosal resection (EMR) as well as in endoscopic submucosal
dissection (ESD), compared with resection of other parts of the digestive tract.
We had written the first report on the safety and efficacy of cold polypectomy
(cold forceps polypectomy [CFP] and cold snare polypectomy [CSP]) for sporadic
SNADETs. However, there is no report on the long-term outcomes of cold
polypectomy for sporadic SNADETs. In this study, we aimed to assess the
long-term outcomes of cold polypectomy for sporadic SNADETs.
Aims & Methods: Patients without polyposis syndrome who underwent cold
polypectomy for one or more SNADETs 6mm in size and were diagnosed
with adenomas between March 2015 and November 2016, and were followed
up by endoscopy for more than 1 year were analyzed. All patients subsequently
underwent upper gastrointestinal endoscopy 3 months after the intervention. The
presence of residual tumors was evaluated by conducting endoscopic examina-
tions and histopathological tests with tissue samples obtained from the cold
polypectomy scars. Subsequently, patients underwent upper gastrointestinal
endoscopy annually, and when residual tumors could not be denied, biopsies
were taken from the scars.
Results: A total of 43 lesions in 33 patients were removed using cold polypect-
omy. Twenty-four lesions in 20 patients were followed up for more than 1 year.
The mean follow-up period by upper gastrointestinal endoscopy was 13.1 (12–18)
months. Of these 20 patients, 12 (60%) were men and the mean age of the
subjects was 63 11 years. The number of lesions were 5, 16, and 3 (21%,
67%, 13%) per lesion location (1st, 2nd, and 3rd portion), respectively, and 2,
3, 13, 4, and 2 (8%, 13%, 54%, 17%, 8%) per macroscopic appearance (Isp, Is,
IIa, IIaþ IIc, and IIc), respectively. Nine lesions in 8 patients were resected using
CFP, while 15 lesions in 12 patients were resected using CSP. Seven of 9 (78%)
and 14 of 15 (93%) lesions were removed en bloc using CFP and CSP, respec-
tively; the other 3 lesions were removed by piecemeal resection in 2 pieces. All
specimens resected using both CFP and CSP were successfully retrieved.
Histopathologic analysis showed that 21 of 24 lesions (88%) were low-grade
adenomas, and 3 (13%) were high-grade adenomas. The mean size of the ade-
nomatous lesions was 4.0 1.3mm (2–6mm). Eleven of 24 adenomas (46%) were
R0 resections; 3 of 9 (33%) and 8 of 15 (53%) were R0 resections using CFP and
CSP, respectively. Delayed bleeding and intraprocedural/delayed perforation
were not observed in any case. The scars were identified and biopsied at
follow-up endoscopy performed 3 months after cold polypectomy, and no resi-
dual or recurrent tumor was detected morphologically or histopathologically.
Although there was no recurrent case during the follow-up period, one patient
died 6 months after resection because of heart failure.
Conclusion: Cold polypectomy is a safe and effective treatment for diminutive
and small sporadic SNADETs that have been subjected to long-term follow-up.
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Introduction: Endoscopic Treatment of Boerhaave Syndrome: A Surprisingly
Quick Healing
Aims & Methods: A 48-year-old male was presented at the emergency room
complaining of severe chest pain, which began after several episodes of vomiting,
following a meal. Upon his arrival a severe episode of haematemesis was
reported. The electrocardiogram showed tachycardia with a ventricular rate of
128 bpm. The computed tomography of the chest demonstrated a hydrothorax,
as well as mediastinal free air. Due to the hemorrhage we performed an emer-
gency upper endoscopy after we obtained the patient’s consent. We observed an
esophageal opening, 11 cm long, with a Mallory-Weiss tear at the distal end. We
clipped the visible vessel and decided to close the opening with clips (Figure 1).
We used twelve clips and successfully stopped the bleeding while also closing the
esophageal opening. Thoracic surgeons placed a thoracic drainage tube. The
patient received a conservative therapy, complemented by a withdrawal of oral
intake and administration of broad spectrum antibiotics.
Results: The next day we performed a follow-up upper endoscopy to inspect the
closure and hemostasis. We observed an amazing healing (Figure 2). The chest
tube was removed at the fourth day and the patient started oral feeding on the
sixth day. The patient was discharged from the hospital with no complications on
the eight day. We performed an upper endoscopy after one month with no
strictures
Conclusion: Boerhaave syndrome has an estimated mortality rate of 20% to 40%.
The standard of care is multidisciplinary; surgical, endoscopic or conservative
approaches are acceptable. No consensus exists regarding the best strategy.
Endoscopic treatment consists of closure with endoscopic clips—the through-
the-scope (TTS) clip and the over the-scope clip (OTSC)—or stenting with remo-
vable stents. This paper explores the case of a spontaneous esophageal rupture
after vomiting, which was treated with TTS clips. We note the extremely fast rate
of healing of the wound.
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Introduction: Esophagogastroduodenoscopy (EGD) is of growing importance in
the diagnosis of Helicobacter pylori (HP) gastritis, because HP infection is
strongly associated with gastric carcinogenesis1). However, the accuracy of endo-
scopic diagnosis of HP infection may vary according to the experience and
technique of the attending endoscopist. Here, we challenged to establish a com-
puter aided endoscopic diagnosis system for HP infection using two novel tech-
nologies. First is a Linked color imaging (LCI). It is a new Image-enhanced
endoscopy (IEE) using a LASER light source to enhance slight differences in
mucosal color. Second is an Artificial Intelligence (AI) technology. Deep
Learning has attracted attention in diagnostic imaging. It is a type of AI which
imitates neural network in the brain.
Aims & Methods: The aim of this study was to establish an AI diagnosis of HP
infection using LCI. We designed a prospective study of all patients who under-
went EGD and were tested for serum anti-HP IgG antibodies at our medical
clinic. Subjects who had a history of HP eradication therapy were excluded in this
study. A total of 220 examinees were candidates who underwent EGD and serum
test of anti-HP IgG antibodies (HP-positive examinees were 112). The HP IgG
antibody titer of each subject was taken as the gold standard for HP infection
status for this study. During EGD an enodoscopist took 3 LCI pictures of the
lesser curvature, greater curvature and anturum of the stomach by EG-L580NW
(FUJIFILM Co., Japan). Finally, we used a total of 639 LCI pictures in the
study. The specifications of the AI used in this study were as follows: Operating
system: Linux (Ubuntu 14.04 LTS), Neural network: GoogLeNet2), Framework:
Caffe3), and Graphic processor unit: Geforce GTX TITAN X (NVIDIA Co.,
USA), and we used R (version 3. 3. 2.) for all statistical analyses.
Results: The area under the curve (AUC) of receiver operating characteristics
(ROC) was 0.95 for the lesser curvature. Compared to this, the AUC of the
greater curvature and anturum was 0.81 and 0.67, respectively. The AUCs
obtained in the lesser curvature was significantly larger than that in the greater
curvature and anturum (P5 0.01).
Conclusion: The results demonstrate that the AI has excellent ability to diagnose
HP infection using LCI in the lesser curvature. The authors believe that AI
technology with IEEs is likely to become a useful image diagnostic tool.
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Introduction: Current guidelines (MAPS) suggest that intestinal metaplasia (IM)
should be staged using OLGIM1 (Operative Link on Gastric Intestinal
Metaplasia) and that patients with stages OLGIM 3 and 4 should be followed-
up2. High-resolution narrow band imaging (HR-NBI) was previously shown to
be accurate to diagnose IM3. Recently a new endoscopic classification
(Endoscopic Grading of Gastric Intestinal Metaplasia - EGGIM) has been pro-
posed to assess the risk phenotype of patients by the evaluation of IM in the
antrum and in the corpus with the use of HR-NBI scopes4, 5.
Aims & Methods: We aimed at determining the accuracy of EGGIM classifica-
tion, compared with the pathological evaluation of gastric biopsies expressed
according to OLGIM classification. Two centers (Italy, Portugal) consecutively
included 78 adult patients (female 56%; median age 61 (20–84) years; 8 with 1st
degree family history of gastric cancer). All patients were evaluated by High-
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Resolution White Light Endoscopy (HR-WLE) followed by HR-NBI. A careful
evaluation of the antrum and corpus mucosa was performed and EGGIM score
was calculated. Five different areas were considered (lesser and greater curvature
in the antrum, lesser and greater curvature in the corpus and incisura) and in
each area 0 (no IM), 1 (focal IM, less or equal than 30% of the area) or 2 points
(extensive IM in that area, more than 30% of the area) were attributed for a total
of 10 points. Biopsies were taken where the endoscopists observed IM and, if IM
was not present, random biopsies were taken using the updated Sydney System
protocol. Biopsies from the different sites were sent for histopathologic evalua-
tion in separate jars. The diagnostic performance of EGGIM was then compared
to OLGIM (gold standard) and sensibility, specificity, positive predictive value
(PPV) and negative predictive value (NPV) were calculated.
Results: IM was staged as OLGIM 0, 2, 3 and 4, respectively: 32 (41.0%), 23
(29.5%), 17 (21.8%), and 6 (7.7%) pts (no patients with OLGIM 1 were found).
Table 1 shows detailed the EGGIM scores compared to OLGA. Compared to
OLGIM as gold standard for the evaluation of IM, sensitivity, specificity, PPV
and NPV of EGGIM classification were 97.8%, 81.2%, 88.2% and 96.3%,
respectively. Three of the 6 patients with false positive results using the
EGGIM classification were H. pylori positive. Analyzing the subgroup of
patients with OLGIM 3 and 4, the diagnostic performance of EGGIM was:
sensibility 95.6%, specificity 90.9%, PPV 81.5% and NPV 98.0%. Two of the
5 patients who resulted false positive using the EGGIM classification were H.
pylori positive. A high agreement between EGGIM and OLGIM scores was
observed (83.3%).
% of total (within
each OLGIM grade)
EGGIM
score
0 1–2 3–4 5–7 8–10
OLGIM 0
I
II
III
IV
33 (81)
0
1 (4)
0
0
5 (12)
0
8 (26)
0
0
3 (7)
0
14 (48)
1 (6)
0
0
0
4 (13)
17 (76)
4 (50)
0
0
3 (9)
4 (18)
4 (50)
Extent of intestinal
metaplasia
Absent Focal Moderate Extensive Extensive
Conclusion: The EGGIM classification showed a high diagnostic performance
compared to OLGIM, in particular in patients with OLGIM 3 and 4. A possible
confounding factor leading to overestimation of presence of intestinal metaplasia
might be the presence of H. pylori infection. This approach could be used to
simplify the surveillance of these patients.
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Introduction: Percutaneous transesophageal gastrotubing (PTEG) was developed
as an alternative route to access the gastrointestinal tract for the patients that
Percutaneous Endoscopic Gastrostomy was contraindicated with conditions such
as prior gastrectomy, gastric anterior wall malignancies, or massive ascites.
PTEG will be an ideal method as the palliative care for the patients with malig-
nant disease.
Aims & Methods: The aim of this study is to evaluate the clinical usefulness of
PTEG supported by endoscopy for the patients who need decompression from
gastrointestinal tract due to malignancies. A rupture-free balloon (RFB) catheter
is inserted into the upper esophagus. Percutaneous balloon puncture with a spe-
cialized needle is then performed from the left side of patient’s neck under ultra-
sonographic control. A guide wire is inserted through the needle into the RFB,
followed by a dilator and sheath. A placement tube is then inserted through the
sheath, and the sheath is removed. Double Balloons equipped Over tube type RFB
were used instead of primary RFB in five cases that the puncture needle is punc-
tured into the over tube trough the balloon. We perform PTEG in a total of 62
patients (37 men and 25 women, mean age 61.8 years) in whom PEG was not
feasible for decompression. Every patient suffered discomfort to the prior inser-
tion of nasal tube. Fifty-three patients had peritoneal dissemination and 7 patients
had gastrointestinal tract obstruction, and 2 patients need biliary drainage,
Results: Satisfactory results were achieved in all 62 patients. Median follow-up
was 60.5 days in patients who received decompression because of the obstruction
due to malignancies. All patients could free from nasal tube prior insertion. Oral
ingestion could be achieved in 48.6% and home care could achieved in 63.9% of
those patients. Complications were minor oozing bleeding in three patients that
did not require blood transfusion, thyroid puncture in three patients, which were
managed conservatively. No patient required surgical treatment or died after
PTEG.
Conclusion: PTEG is feasible, safe, and useful. PTEG could be an only procedure
to be free from a nasal tube especially for the patients with carcinomatous
peritonitis. PTEG is the ideal solution for the patients with malignant gastro-
intestinal obstruction. PTEG is one of the best tool in palliative care for the
patients with malignant disease.
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Introduction: Gastrostomy is the current method of choice for medium and long-
term enteral feeding. Available techniques include Percutaneous Endoscopic
Gastrostomy (PEG) and Percutaneous Radiologic Gastrostomy (PRG). Both
techniques are preferred over surgical gastrostomy. Previous studies that have
compared outcomes between PEG and PRG are limited due to small sample
sizes, high risk of confounding and selection bias. Our primary aim was to retro-
spectively analyse data from our centre with respect to complications and mor-
tality between PEG and PRG procedures in relation to indications. These data
may help to predict which technique is best for an individual patient.
Aims & Methods: A retrospective analysis including all adult patients receiving
initial PRG (January 2010 until April 2016) and PEG (January 2008 until April
2016) placement in our university hospital, was performed.
Outcomes were complications (early (30 days) and late), success rates and
mortality (procedure related, 30-day, and overall). Chi2, Fisher’s exact and t-
tests were used. Multivariate logistic regression and Cox proportional hazards
regression analysis were performed.
Results: A total of 760 initial procedures (469 PRG and 291 PEG) were included
in the analysis (62.9% male, mean age 62.8yrs [SD 12.64]). Most common indi-
cations were head and neck malignancy (HN, PEG 38.8%, PRG 69.9%,
p¼50.001), Cerebrovascular Accident (CVA, PEG 13.7%, PRG 2.1%,
p5 0.001) and Motor Neuron Disease (MND, PEG 2.7%, PRG 9.8%,
p¼50.001). Success rates for placement were 91.2% for PEG (failure mostly
due to absence of transillumination, n¼ 14) and 97.1% for PRG (p¼ 0.001).
Major complications (e.g. abscess, buried bumper, peritonitis) and infections
did not differ amongst groups, neither did procedure-related mortality, which
was 1.7% in PEG (n¼ 5) vs. 0.4% in PRG (n¼ 2, p¼ 0.113). One case of tumour
(HN) seeding occurred after PRG placement. Tube related complications
(including dislocation, obstruction, leak and tube defects) were lower in PEG
than PRG, both within 30 days (2.7% vs. 26.4% of patients, p¼50.001 and
after 30 days (8.6% vs. 31.5%, p¼50.001).
The 30-day mortality was higher in patients who received PEG (11.3%: 27 deaths
due to underlying conditions, 5 related to the procedure (1 massive bleeding, 4
aspiration pneumonia)) compared to those with PRG (4.48%, 19 deaths due to
underlying conditions, 2 related to the procedure (both aspiration pneumonia),
p¼50.001). The 30-day mortality was related more to the patients’ general
condition, than to the procedure itself
Overall survival was 46.7% vs. 44.1%(PEG vs. PRG; p¼ 0.049, OR 1.224[1.000–
1.498]). Positive predictive factors for overall survival were PEG, ALS and a
higher BMI before placement (adjusted OR for all three factors together
1.292[1.027–1.626]).
Conclusion: PRG appears favourable with respect to 30 day mortality while PEG
appears favourable over PRG in terms of complications (such as dislocation,
pain, and irritation). A higher initial success rate and the possibility of placement
in case of a narrow lumen favour PRG placement. More adequate patient selec-
tion and more thorough procedure selection prior to gastrostomy is therefore
required.
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Introduction: Peroral endoscopic myotomy (POEM) is being increasingly per-
formed worldwide. However, studies on its learning curve are limited. A com-
prehensive evaluation based on risk factors is needed.
Aims & Methods: This study was aimed to evaluate the impact of various factors
on the learning curve of POEM. From August 2010 to July 2015, 1346 POEM
performed in Zhongshan Hospital were analyzed. The primary outcome of the
study was a composite outcome of aborted procedures and complication. The
secondary outcomes included procedure time and hospital stay. The impact of
risk factors was assessed by backward conditional logistic regression on primary
and secondary outcomes. The risk-adjusted CUSUM and moving average meth-
ods were used to evaluate the outcomes.
Results: Fifty-four (4%) patients had the composite outcome with 10 aborted
procedures and 44 adverse events. The composite outcome was related to case
number, full-thickness myotomy and procedure time in the multivariate logistic
regression. Adjusted for these risk factors, the CUSUM analysis showed that the
composite outcome gradually decreased after 150 cases. The procedure time was
higher in the early stage and decreased after 71 cases. Case number, in represen-
tative of the operative experience, is also an independent risk factor for a longer
procedure time and hospital stay.
Conclusion: For POEM operators, seventy cases might be considered a threshold
for faster operation, i.e., technical proficiency. A hundred-and-fifty cases might
be considered a threshold for the decrease of aborted procedures and adverse
events, i.e., technical reliability.
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Introduction: Gastrointestinal stromal tumor (GIST) is one of the most common
tumors originating from mesenchymal tissue of gastrointestinal tract, which
accounts for about 0.2% of gastrointestinal tumors. Gastric stromal tumors
are more common, accounting for about 40% 70% of GIST. At present, the
endoscopic treatments of gastric stromal tumors includes endoscopic submucosal
dissection (ESD), endoscopic full-thickness resection (EFR) and combined endo-
scopic and laparoscopic surgery.
Aims & Methods: Our study is aimed to assess the safeness and effectiveness of
endoscopic treatments for gastric stromal tumor. Clinical data of 162 patients
with gastric stromal tumor who underwent endoscopic treatments from June 1st
2011 to July 31st 2015 were analyzed retrospectively. The mean diameter of the
tumors was 1.5 cm (0.3 5.0 cm). 104 patients received endoscopic submucosal
dissection, 58 patients received endoscopic full-thickness resection. Among them,
4 operations were completed under the monitor of laparoscopy.
Results: Complications were observed in 8 patients(4.9%): bleeding during opera-
tions: 3 patients, post-operation perforation: 3 patients, respiratory tract infec-
tion: 2 patients. The mean post-operation feeding time was 2.67 days (range 1–9
days) and post-operation hospital stays were 5.39 days (range 2–10 days). The
mean time of follow-up was 26.4 months (range 5–51months). The follow-up
showed that 6 patients kept on treating with oral administration of imatinib.
No patient was found recurrence or death.
Conclusion: Endoscopic treatments were demonstrated as safe and effective ways
to resect gastric stromal tumors in this study.
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Introduction: Much concern surrounds Gastroenterology Specialist Registrar
(StR) endoscopy training, especially in regards to endoscopic management of
Acute Upper Gastrointestinal Bleeding (AUGIB). Recent evidence suggests
there has been a decline in exposure and experience in AUGIB endoscopy1. In
July 2013 our University Hospital introduced a Consultant-led and Registrar-
supported Monday to Friday, 9 to 5 pm in-reach service. It comprises of a
morning visit to the acute medical units and a daily inpatient emergency list.
This study looked at registrar AUGIB endoscopy training after its
implementation.
Aims & Methods: Endoscopy reports of patients presenting with haematemesis,
melena or both who had undergone gastroscopy during the period of 1st of
March 2015 to 31st August 2015 were retrieved using the endoscopy reporting
tool Unisoft and analysed. Reports where StRs were the primary operator were
considered. Number of procedures, haemostatic intervention and nature of hae-
mostasis was analysed. This was then compared to data from the year before
implementation (01/03/2012 to 31/08/2012)
Results: A total of 7 StRs (5 Full Time and 2 Less than Full Time) performed
gastroscopies on AUGIB patients as first operators under Consultant super-
vision. Over the 6-month period a total of 166 gastroscopies were undertaken
(Mean 24). On 26 occasions, endoscopic intervention (EI) was performed
(Mean 4). On average, 16% of the AUGIB patients required EI. In cases
of Non Variceal Bleeding, Dual therapy was applied in 87.5% of the cases.
In the remaining cases Haemospray was used. On average each StR was able
to perform one case of oesophageal variceal banding and one case where
Haemospray was utilised. Data from the 2012 cohort in comparison showed
a total of 66 gastroscopies over 6 months with 13 EI. On average 13 proce-
dures and 2.6 EIs were performed by each StR. Dual therapy was applied in
only 28.5% of the cases
Conclusion: The introduction of the Registrar of the Week Service provides a
valuable opportunity for StRs to be trained in endoscopic haemostasis and
acquire exposure to AUGIB patients. As per this study each StR on an average
performed endoscopy on 24 AUGIB patients. If this is extrapolated, each StR
will be able to perform 48 procedures in 1 year and 240 procedures over 5 years.
In the case of EI, on average a StR can perform around 4 interventions over 6
months, which comes to 8 per year and 40 in a 5 year programme which is
significantly better than in the previous cohort and other centres1. Hospitals
should consider developing similar services not only to meet demands for 24/7
Consultant led AUGIB endoscopy service but provide adequate endoscopic
training provision for current specialist registrars in order to ensure future com-
petent and confident consultants.
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Introduction: Endoscopic recognition of dysplasia or early cancer in Barrett’s
esophagus (BE) is difficult. Experience in recognition of early neoplastic lesions
is thought to increase the detection of visible dysplastic lesions. A previous study
reported that endoscopists in community hospitals detect neoplastic lesions at a
significant lower rate than referral centres. The aim of the study we want to assess
the significance of dysplasia in random biopsies in BE, in the absence of reported
visible lesions as well as the final outcome of pathology.
Aims & Methods: We retrospectively analysed all patients referred from 19 com-
munity hospitals to our tertiary referral centre with the diagnosis of BE with
dysplasia or early adenocarcinoma (EAC) between February 2008 and April
2016. All patients underwent a dedicated imaging endoscopy with high-definition
endoscopy supplemented with virtual chromoendoscopy and/or acetic acid stain-
ing at the discretion of the endoscopist. All procedures were performed by an
endoscopist with extensive experience in the detection of early neoplastic lesions
in BE. During endoscopy all visible lesions were noted and biopsied and/or
removed by endoscopic resection (ER). Patients were included for analysis in
case of absence of reporting visible lesions at referral.
Results: In total 184 patients were referred with dysplasia or EAC of which 82
patient (80.5% male, age 42–81 years (median (68)) did not show a visible lesion
upon referral endoscopy. Referral diagnosis of these 82 patients was 32 low-grade
dysplasia (LGD), 43 high-grade dysplasia (HGD) and 7 EAC, In three of 32
patients (9.4%) referred with LGD, a visible lesion during imaging endoscopy
was detected. Two cases of histology proved EAC and one confirmed LGD. In
twenty-six of 43 patients (60.5%) referred with HGD, a visible lesion with his-
tology specimens corresponding to HGD (10) and EAC (16) were found,
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respectively. All cases of EAC were detected (7/7). In 18/75 (24%) patients
referred with dysplasia (LGD/HGD) without a visible lesion, the referral diag-
nosis was thus upstaged to EAC. Overall, 41/82 (50%) lesions were found
additionally.
Conclusion: The presence of any grade of dysplasia in random biopsies in BE
screening in community hospitals is a potential marker for more severe final
pathology after endoscopic work-up in an expert centre. Training in Barrett
imaging is mandatory for non-expert endoscopists.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Nonmalignant esophago-respiratory fistulas (ERF) are rare but
frightening clinical situations. They usually involve surgery, but the morbidity
and the mortality is high. The knowledges about the modalities and outcomes
after endoscopic management of ERF remain limited.
Aims & Methods: The aim of this study was to describe and assess the endoscopic
management of benign ERF in our center. This was a retrospective study invol-
ving patients manage for benign ERF in our tertiary center between July 2012
and December 2016. The inclusion criterion was the presence of communication
between esophagus and bronchial tree diagnosed confirmed and treated by endo-
scopy, and malignant ERFs were excluded. The ERFs were classified into three
groups of sizes: punctiform (if the orifice was no larger than a straight catheter),
medium and large (with visibility of bronchial tree). The primary endpoint was to
document the clinical success defined as the closure of the fistula confirmed by
endoscopy and persisting 46 months. The secondary endpoints were to docu-
ment the characteristics of endoscopic treatment, the functional success and
death, and to identify factors associated with success and death.
TABLE 1: - Demographics & Results
Clinical
failure
Clinical
success p value
Number of patients n¼ 22 n¼ 12 n¼ 10
Gender
Male/Female 6/6 7/3 0.342
Etiology
Post-surgery 7 6 0.665
Post-dilatation 0 3 0.062
Post-radiation 2 0 0.138
Post-invasive ventilation 3 2 0.534
Pulmonary location
Trachea 10 7 0.127
Right bronchus 2 1 0.534
Left bronchus 0 2 0.138
Orifice size
Punctiform 3 6 0.193
Medium 3 3 1
Large 6 1 0.17
Timing of closure
Resolution at 3 monts 0 7 510^-3
Resolution at 6 months 0 8 510^-3
No resolution at 6 months 12 2 510^-3
Endoscopic treatment
Mean number of esophageal stents 3.6 (3.9) 2.3 (2.7) 0.069
Mean number of OTSc 1.2 (1.8) 0.4 (0.7) 0.082
At least one esophageal stent 11 9 0.892
At least one OTSc 6 2 0.146
Results: A total of 22 patients were included and analyzed. The etiologies of ERF
were esophageal surgery in 12 patients (54.5%), esophageal dilatation in 3
(13.6%), invasive ventilation in 3 (13.6%), radiation therapy in 2 (9.1%) and
tracheostomy in 2 (9.1%). A total of 93 procedures were performed with a mean
of number of endoscopies of 4.2 4.5 per patient. At some point of the manage-
ment, twenty-one patients (95%) had esophageal stents placement, eight patients
(36%) had over the scope clips (OTSC) placement and seven had OTSC asso-
ciated with esophageal stent. The clinical success rate was 45.5% (n¼ 10), and
55% of the patients had a functional success (n¼ 12). Serious adverse events
occurred in 9 patients (40.9%) such as gastrointestinal bleeding (4 patients,
18.2%), stent migration (4 patients, 18.2%), thoracic spondylodiscitis (2 patients,
9.1%) alimentary esophageal impaction (1 patient, 4.5%), stent mucosal impac-
tion (1 patient, 4.5%), major chest pain (1 patient, 4.5%). Six patients died
(27%). Clinical success was reached for 67% of punctiform ERF (p¼ 0.193),
50% of medium ERF (p¼ 1) and 14% of large ERF (p¼ 0.17). The factor
associated with the failure of endoscopic treatment was the persistence of the
fistula after 6 months (OR¼ 44; IC95: 3.38–573, 4; p¼ 0.004 multivariate ana-
lysis). The orifice’s size was associated with the mortality with 71% of death
among large fistulas (p¼ 0.001 univariate analysis).
Conclusion: Conclusions: Endoscopic treatment of ERF can lead to 45.5% of
clinical success and 55.5% of functional success. However, this outcome appears
to depend on the size of the fistula. Moreover, the absence of resolution after 6
months of endoscopic treatment dramatically decreases the chance for ERF
healing. In conclusion, the endoscopic approach seems reasonable for small or
medium orifices, and has to be attempted during six months. After this time or
for larger orifices, surgery or palliative therapy should be considered.
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Introduction: Esophageal squamous cell carcinoma (ESCC) is common in Asia.
Predicting invasion depth of superficial ESCC is crucial in determining the pre-
cise treatment because the rate of lymph node metastasis increases in proportion
of the invasion depth of the carcinoma. According to Japanese guidelines for
diagnosis and treatment of esophageal cancer, superficial invasions are divided
into 5 categories: carcinoma in situ (EP), tumors invades lamina propria mucosa
(LPM), lamina muscularis mucosa (MM), the submucosa to a depth of 200 mm or
less from the muscularis mucosa (SM1), and the submucosa to a depth more than
200 mm (SM2). The rate of lymph node metastasis is extremely low in EP/LPM
tumors, and endoscopic resection (ER) is certified as precise treatment. On the
other hand, the rate of lymph node metastasis in MM/SM1 tumors are reported
to 10–20%, and both operation and ER are considered as their treatment.
Accurate pretherapeutic diagnosis of MM/SM1 tumor is very important for
selection of appropriate treatment and interests of patients. In this point, endo-
scopic diagnosis is very important diagnostic approach.
Aims & Methods: The purpose of this study is to investigate the utility of Narrow
Band Imaging (NBI) magnifying endoscopy for the diagnosis of MM/SM1
ESCC. From January 2011 to April 2017, 23 patients were diagnosed as patho-
logically MM/SM1 ESCC in our hospital. We retrospectively analyzed their
endoscopic findings and pathological findings. The depth of invasion was diag-
nosed by NBI magnifying endoscopy according to the Japan Esophageal Society
(JES) magnifying endoscopic classification1. Diagnostic criteria are based on the
degree of microvascular irregularity in the target lesion observed by NBI magni-
fying endoscopy. Microvessels are grouped into 2 types. Type A microvessels are
normal intrapapillary capillary loops or abnormal microvessels without severe
irregularity. Type B microvessels are abnormal vessels with severe irregularity or
highly dilated abnormal vessels, and subclassified into B1, B2, and B3 based on
the running pattern or degree of dilation of severely irregular microvessels. When
target lesions have B1 vessels, the invasion depth is predicted as EP or LPM.
When B2 or B3 vessels are seen, the invasion depth is predicted as MM or SM1
and SM2 or deeper, respectively.
Results: In 23 pathologically MM/SM1 cases, clinical type diagnosed by endo-
scopy was 0-IIc in 16 cases (70%), 0-IIa in 3 cases (13%), 0-IIb in 3cases (13%),
and 0-Ip in 1 case (4%). Predicted depth of invasion by NBI magnifying endo-
scopy based on the JES classification was EP in 2 cases (9%), LPM in 7 cases
(30%), MM in 10 cases (43%), SM1 in 3 cases (13%) and SM2 in 1 case (4%).
Total diagnostic accuracy of MM/SM1 was 57% (13/23). When the B2 vessels
were observed, diagnostic accuracy of MM/SM1 was 90% (9/10). In the cases
that MM or SM1 invasion remained pathologically quite localized, B2 vessels
could not be observed by NBI magnifying endoscopy. And also, in the cases with
inflammation or keratinizing epithelium, precise diagnosis of microvessels were
difficult.
Conclusion: Our data indicate that diagnosis of MM/SM1 ESCC by NBI magni-
fying endoscopy based on the JES classification is useful when the abnormal
microvessels are observable, and NBI magnifying endoscopy is essential
method for pretherapeutic examination.
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Introduction: Gastroparesis is a chronic, debilitating motility disorder. Effective
treatment is challenging especially in patients with severe symptoms. POEP is an
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emerging modality for refractory gastroparesis with promising preliminary
results.
Aims & Methods: The aim of this prospective case series was to assess our first
(single center) experience with POEP. Main outcomes were: 1) the efficacy
defined by improvement of GCSI score; 2) gastric emptying evolution and 3)
safety. Since Nov 2015, a total of 7 patients underwent POEP. The etiology of
gastroparesis was post-operative in 4, diabetic in 2 and idiopathic in 1 patient.
One patient underwent POEP for gastroparesis following a multivisceral trans-
plantation; one patient underwent both POEP and POEM (as a single procedure)
for coexisting refractory idiopathic gastroparesis and achalasia. All patients had
severe gastroparesis as defined by elevated GCSI score and delayed gastric emp-
tying scintigraphy. Follow visit at 3, 6, 12-months were completed in 7/7 (100%),
5/7 (71%) and 1/7 (14%) patients, respectively. Upper GI endoscopy and scinti-
graphy were performed 3 months after the procedure.
Results: POEP was successfully performed in all patients. Mean procedure time
was 70 minutes (range 63–106). After POEP, mean GCSI decreased from
3.0 1.2 to 0.8 0.7 (at 3-months) and 0.9 0.8 (at 6-months). One women
finished the 12-months follow maintaining excellent outcome. Treatment success
was reached in 6/7 (85%) of patient, one female patient with diabetic gastropar-
esis did not have a major symptomatic improvement despite normalisation of
gastric emptying study. Gastric scintigraphy normalized in all patients, mean half
emptying time decreased from 108 30min to 62 23min; and mean bolus
retention at 4 hours decreased from 17 9.2% to 2.0 2.0%. One patient devel-
oped bleeding ulcer 10 days after POEP, this adverse event was successfully
managed endoscopically (clips) and by parenteral proton pump inhibitor.
Conclusion: We report our first experiences with POEP for refractory gastropar-
esis, demonstrating its feasibility and safety with promising clinical efficacy.
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Introduction: Neoplasia in Barrett’s can be subtle and difficult to identify. Blue
light imaging (BLI) by Fujifilm is a novel advanced endoscopic technology that
provides high-intensity contrast imaging for superior visualisation of mucosal
surface and vessel patterns. This can improve the identification of Barrett’s neo-
plasia. To date there is no formal classification system that enables the charac-
terisation of neoplastic and non-neoplastic Barrett’s for BLI.
Aims & Methods: The aim of our study was to develop and validate a classifica-
tion to identify Barrett’s neoplasia using BLI. 3 expert endoscopists formed a
working group to identify criteria characterising neoplastic and non-neoplastic
Barrett’s on BLI using a modified Delphi method. A simple classification system
utilising pit, vessel pattern and colour was developed using a database of 40
images. 6 experienced endoscopists then assessed a library containing 45
images of neoplastic and non-neoplastic Barrett’s using the proposed criteria.
Sensitivity, specificity, positive (PPV) and negative predictive values (NPV)
were calculated to assess its performance. The same parameters were then eval-
uated for each component criteria.
Results: The BLINC classification descriptors are as follows: Non Neoplastic
Barrett’s: Pit pattern: circular, tubular or branching with normal density;
Vessel pattern: regular, pericryptal non dilated vessels with normal density;
Colour: pale Neoplastic Barrett’s: Pit pattern: irregular, crowded with increased
density; Vessel pattern: irregular, non cryptal, dilated vessels with increased den-
sity; Colour: focal darkness The overall sensitivity and specificity, negative and
positive predictive values with corresponding 95% confidence intervals are as
follows: 96.7 (92.4–98.9)%, 96.7 (91.2–99.1)%, 97.3 (93.3–99.0)% and 95.9
(90.7–98.2)% respectively in the classification of Barrett’s neoplasia. When
each category in the classification was analysed separately the predictive values
of pit and vessel pattern in neoplasia characterisation were high compared to
colour (as shown in the table below).
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV
(95% CI)
NPV
(95%CI)
Pit pattern 96.0 (91.5–98.5)% 98.3 (94.1–99.8)% 98.6 (94.8–99.7)% 95.2 (89.9–97.7)%
Vessel Pattern 94.7 (89.8–97.7)% 93.3 (87.3–97.1)% 94.7 (90.1–97.2)% 95.2 (89.9–97.7)%
Colour 86.7 (80.2–91.7)% 78.3 (69.9–85.3)% 83.3 (78.0–87.6)% 82.5 (75.6–87.7)%
Conclusion: We have developed the first internally validated simple classification
system for the diagnosis of Barrett’s neoplasia using BLI. The classification
criteria demonstrated high sensitivity and specificity particularly with regards
to mucosal pit and vessel patterns. We aim to use the proposed classification
in future studies for real time optical diagnosis of Barrett’s neoplasia.
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Introduction: Submucosal tunneling endoscopic resection (STER) is a novel tech-
nique to remove the gastrointestinal submucosal tumors. Previous studies mainly
focused on technical feasibility for patients with one single gastrointestinal sub-
mucosal tumor. No systematic studies about multiple upper gastrointestinal sub-
mucosal tumors synchronously removed by STER are addressed. The aim of this
study was to evaluate the safety and outcome of STER in treatment of multiple
gastrointestinal submucosal tumors.
Aims & Methods: From January 2011 to January 2017, 42 patients with multiple
gastrointestinal submucosal tumors undergoing STER were included. Variables
of each tumor and patient were analyzed. Detailed tumor characteristics included
max size, sum of max size and number of tumors, and longest distance of tumor.
While detailed technique information included number of tunnels, tunnel length,
hospital stay, procedure time, complication, follow-up, recurrence, and
metastasis.
Results: Among all the cases, 96 lesions of upper gastrointestinal submucosal
tumors were removed by STER. The median procedure time was 50min (range
13.6–84.9min). The median number of tumors was 2 (2–4). The median max size
of each tumor was 1.8 cm (range 0.7–3.5 cm) and the median sum of max size of
each tumor of each patient was 3 cm (range 1.3–8 cm). Six patients had perio-
perative complications (14.2%), with 3 pneumothorax/hydrothorax (7.2%), 1
mucosal injury (2.4%), 1 pneumonia (2.4%), and 1 major bleeding (2.4%).
Patients with different number of tunnels had similar tumor characteristics and
techniques. There were significant differences in longest distance of tumors com-
paring two groups (p5 0.001). No local recurrence or distant metastasis was
detected with a median follow-up of 33 months.
Conclusion: STER is a safety and feasible technique for multiple upper gastro-
intestinal submucosal tumors no matter in one tunnel or two tunnels resection.
Based on the longest distance of tumors, different number of tunnels can be
performed with similar procedure technique and prognosis.
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Introduction: LCI is a new imaging technique based on 4 independently acting
LEDs that is enhancing the mucosal vascular pattern and surface pattern mor-
phology. To date, chromoendoscopy with acetic acid is considered the gold
standard for diagnosis of Barrett’s esophagus.
Aims & Methods: The aim of this prospective study was to evaluate the recently
introduced LCI technique compared to conventional dye spraying with acetic
acid for diagnosis of Barrett’s esophagus. Therefore, consecutive patients with
Barrett’s esophagus were categorized according to the Prague classification and
prospectively included. All Barrett segments were carefully evaluated by using
high-definition white-light imaging, followed by LCI and acetic acid spraying. At
each examination targeted biopsies were taken from all visible lesions, followed
by random four-quadrant biopsies were applicable.
Results: The diagnostic yield of conventional dye spraying was significantly
higher for diagnosis of Barrett’s esophagus compared to high-definition white-
light endoscopy (P5 0.05). Of note, no significant difference for diagnosis of
Barrett’s esophagus was noted between acetic acid chromoendoscopy and the
LCI technique. LCI diagnosis was always consistent to traditional dye spraying
(100% concordance). The random four-quadrant biopsy protocol did not add
any new information to the one already obtained by using LCI.
Conclusion: The newly introduced LCI technique is superior to high-definition
white light endoscopy for diagnosis of Barrett’s esophagus and equally effective
to acetic acid dye spraying. Therefore, the LCI technique has the potential to
facilitate the diagnosis of Barrett’s esophagus and to overcome the limitations of
a random 4-quadrant biopsy protocol.
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Introduction: In Canada, gastroenterologists and general surgeons perform 97%
of the colonoscopies. There are a small number of rural Canadian Family
Physicians who perform colonoscopies. These endoscopists may improve access
for rural patients who require endoscopy and help improve provincial endoscopy
wait times. Although some studies demonstrate that adequately trained Family
Physicians are able to perform quality endoscopy, other studies question the
quality of colonoscopies performed by non-gastroenterologists.
Aims & Methods: The Alberta Family Physician Electronic Endoscopic (AFPEE)
study aimed to examine the quality of colonoscopies performed by Family
Physicians in Alberta, Canada. Primary outcomes include the proportion of
successful cecal intubations; proportion of patients 50 years and older having a
first time colonoscopy with an adenoma; and immediate complication rates.
Prospective, multi-centred observational study with real-time electronic data col-
lection and pathological reconciliation. Using IPADs, TM data was inputted in
real time into an REDCapTM based electronic record developed by the study
team. Individual physician and group results of key quality indicators were com-
pared to standard colonoscopy quality benchmarks.
Results: In this six-month study, 9 Family Physicians performed 1769 colonos-
copies in 11 rural Alberta sites. The proportion of successful cecal intubations
was 97.9% (95% CI: 97.2, 98.5). All physicians had over 90% successfully com-
pleted colonoscopies (ranging from 95.2 to 100%) The proportion of males and
females 50 years old with an adenoma on a first-time colonoscopy was 67.4%
(95% CI; 62.4, 72.7) and 51.1% (95% CI; 45.5, 56.7) respectively. All physicians
achieved benchmarks of 30% of males and 20% for females having at least one
adenoma. From all colonoscopies in the study there were 2099 pathologically
confirmed adenomas or SSAs, 628 advanced adenomas and 17 cancers. corre-
sponding to 120 adenomas, 36 advanced adenomas and 1 colon cancer per 100
colonoscopies. There were 2 post-polypectomy bleeds, no perforations and no
deaths.
Conclusion: Alberta Family Physician colonoscopists are meeting benchmarks in
colonoscopy quality. Ongoing electronic collection of endoscopy quality markers
should be encouraged. Supporting and training rural Family Physicians who
perform endoscopy may help alleviate current wait times and improve access
for rural Canadian patients.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
Hilsden RJ, Tepper J, Moayyedi P, Rabeneck L. Who provides gastrointestinal
endoscopy in Canada? Can J Gastroenterol 2007;21[12]:843–846.
Kolber MR, Wong CKW, Fedorak RN, Rowe BH, on behalf of the APC-Endo
Study Physicians. Prospective Study of the Quality of Colonoscopies Performed
by Primary Care Physicians: The Alberta Primary Care Endoscopy [APC-Endo]
Study. PLoS ONE 2013; 8[6]: e67017. doi:10.1371/journal.pone.0067017
Wilkins T, LeClair B, Smolkin M, Davies K, Thomas A, Taylor ML, et al.
Screening colonoscopies by primary care physicians: a meta-analysis. Ann Fam
Med 2009; 7: 56–62.
Rabeneck L, Paszat LF, Saskin R [2010] Endoscopist specialty is associated with
incident colorectal cancer after a negative colonoscopy. Clin Gastroenterol
Hepatol 8: 275–279.
Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, et al. Rates of new or
missed colorectal cancers after colonoscopy and their risk factors: a population-
based analysis. Gastroenterology 2007; 132: 96–102.
Rex DK, Schoenfeld PS, Cohen J, Pike IM, Adler DG, Fennerty MB et al, on
behalf of the American Society for Gastrointestinal Endoscopy. Quality
Indicators for Colonoscopy. Gastrointestinal Endoscopy 2015; 81 (1); 31–53
Valori R on behalf of the Joint Advisory Group. A guide to auditing quality and
safety items of Endoscopy Global Rating Scale. Available at: www.thejag.org.uk
P0176 PREDICTORS OF ADENOMA DETECTION AT
COLONOSCOPY AFTER BOWEL SCOPE SURVEILLANCE:
RESULTS FROM A UK PILOT SCREENING CENTRE
A. Yew1, K. Siau2, S. Jewes1, A. Veitch1, S. Ishaq3, M. Brookes1, B. Mckaig1,
A. Veitch1, S. Shetty3, A. Murugananthan1
1Department Of Gastroenterology, Royal Wolverhampton Hospitals NHS Trust,
Wolverhampton/United Kingdom
2Royal College Of Physicians, JAG Clinical Fellow, London/United Kingdom
3Gastroenterology, Dudley Group Hospitals NHS Foundation Trust, Dudley/
United Kingdom
Contact E-mail Address: keith@siau.org
Introduction: In a randomised controlled trial, flexible sigmoidoscopy (bowel
scope) reduced colorectal cancer incidence and mortality in a population aged
55–64.[1] Patients progressed to colonoscopy based on ‘high risk’ features (Table
1).[1] Based on these pivotal findings, the UK bowel scope (BS) surveillance
programme was introduced in 2013 to individuals aged 55. The
Wolverhampton Bowel Cancer Screening Centre was the first UK site to fully
roll out the programme. The correlation between BS findings and subsequent
colonoscopy has not previously been evaluated in this specific cohort.
Aims & Methods: We prospectively collated data from all BS patients at our
centre and identified those undergoing colonoscopy between August 2013–
2016. We assessed conversion rates, compliance with BS protocol and correlated
endoscopic and histological findings to identify predictors for detection of
pathology at colonoscopy. Univariate analysis was performed using Pearson’s
chi2.
Results: 11,711 bowel scopes were performed, with an adenoma detection rate
(ADR) of 8.5%, and conversion to colonoscopy in 421 patients (3.6%). 386 were
included for analysis after excluding incomplete colonoscopy/histology. All
patients were aged 55 (64.8% male). Additional ADR at colonoscopy was
35.2%, with malignant diagnoses in 1.5% (all detected at BS). The adenoma
miss rate at BS was 5.2%. On univariate analysis (Table 1), polyp 10mm was
the only indication associated with increased ADR at colonoscopy (OR 2.13,
p5 0.001). Additional predictors identified included villous (not tubulovillous)
histology (OR 4.41, p¼ 0.02), and male gender (OR 2.35, p5 0.001). These
factors also significantly predicted new 10mm adenoma. 57 (14.8%) underwent
colonoscopy outside protocol, which reduced ADR (OR 0.29, p¼ 0.03). After
excluding high risk indications, changing the conversion criteria from any villous
to villous only histology altered sensitivity from 27.2% to 83.3%, and specificity
from 84.5% to 80.5%.
Table 1: Indications for progression from BS to colonoscopy (in bold), [1] and
likelihood of new adenoma detection. *Patients in multiple categories are included
multiple times. **p5 0.05
Indication N* New adenoma OR (95% CI) p-value
At least 3 polyps 78 45 (57.7%) 1.46 (0.88–2.43) 0.14
Size at least 10mm 196 86 (43.9%) 2.13 (1.39–3.27) 50.001**
High grade dysplasia 16 5 (31.3%) 0.82 (0.28–2.41) 0.72
Any villous component 190 69 (36.3%) 1.09 (0.72–1.67) 0.66
420 hyperplastic polyps 3 0 NA NA
None of the above 57 9 (15.8%) 0.29 (0.14–0.62) 0.001**
Villous only histology 10 7 (70.0%) 4.41 (1.12–17.36) 0.02**
Conclusion: At BS, male gender, 10mm polyps, and villous histology are pre-
dictors of proximal colonic pathology. Further analyses are required to clarify
the benefits of converting low-risk tubulovillous adenomas at BS to colonoscopy.
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Introduction: Cold snare polypectomy is an established method for the resection
of small colorectal polyps (SCPs); however, significant incomplete resection rates
still leave room for improvement. We aimed to assess the efficacy of cold snare
polypectomy with submucosal lift (SL-CSP), compared to endoscopic mucosal
resection (EMR), for nonpedunculated polyps 6–10mm (ClinicalTrials.gov
NCT02678663).
Aims & Methods: Dual-center, randomized, noninferiority trial. Consecutive
adult patients with at least one nonpedunculated polyp 6–10mm were enrolled.
Eligible polyps were randomized (1:1) to be treated with either SL-CSP or EMR.
The primary noninferiority endpoint was histologic eradication, with a noninfer-
iority margin of 10%. Evaluation of histologic complete resection relied on a
postpolypectomy biopsy protocol (4 biopsies obtained in a 4-quadrant fashion
from the polypectomy site margins; 1 biopsy from the base). Secondary outcomes
included occurrence of intraprocedural bleeding (IPB; defined as any immediate
episode requiring endoscopic haemostasis), clinically-significant postprocedural
bleeding (CSPPB; any episode requiring emergency department presentation,
hospitalization, or reintervention within 30 days of the procedure) and
perforation.
Results: Among 689 patients screened, 155 patients with 164 eligible polyps (SL-
CSP; n¼ 83, EMR; n¼ 81) were included. The overall rate of histologic complete
resection was 92.8% (77/83) in the SL-CSP group and 96.3% (78/81) in the EMR
group (difference 3.5%; 95%CI, 4.15 to 11.56), showing noninferiority of SL-
CSP compared with EMR. The SL-CSP technique was noninferior to EMR both
for polyps measuring 6–7mm (SL-CSP, 93.3%; EMR, 100%; 95%CI, 7.95 to
21.3) and those 8–10mm (SL-CSP, 92.5%; EMR, 94.7%; 95%CI, 7.91 to
13.16). By multivariate analysis, female gender (OR, 0.15; 95%CI, 0.02–1.06;
P¼ 0.06) and Paris 0-IIa morphology (OR, 0.12; 95%CI, 0.01–1.19; P¼ 0.07)
were marginally significant predictors correlating negatively with complete resec-
tion. Rates of IPB were similar between the two groups (SL-CSP; 3.6%, EMR;
1.2%, p¼ 0.3). No CSPPB or perforation occurred in either group.
Conclusion: SL-CSP appears to be an effective modification of standard cold
snare technique, obviating the need to use diathermy for 6–10mm colorectal
polyps.
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Introduction: Colonoscopic polipectomy effectively reduce the incidence of colo-
rectal cancer. Variations in the technique have been implicated in the effective-
ness of the resection and in the complication rates. However, there is no
consensus regarding the optimal polypectomy technique for diminutive
(5mm) and small (6 to 9mm) polyps. There are scarce of data about polypect-
omy practices among European endoscopists
Aims & Methods: To determine the different techniques used by Spanish endos-
copists for resection of sessile or flat colorectal polyps smaller than 20mm.
A 70-item survey was sent by email to all Gastroenterology Departments in all
Spanish hospitals (1678 gastroenterologists). The survey was conducted from
December 2015 to February 2016.
Results: The rate of participation was 20.3% (341/1678). All physicians indicated
they were practicing gastroenterologist (none were trainees). Most respondents
(60%) were males and 50% had more than 14 years in practice. The mean
number of colonoscopies per week was 21 12.3. Half of participants performed
endoscopies for 3 days per week and 49.6% did not performed advanced
therapeutic endoscopy. The techniques used for the excision of polyps smaller
than 20mm by Spanish clinicians are summarized in Table 1. Significant differ-
ences were noted in the polypectomy techniques used for the resection of polyps
1–3mm, 6–9mm and 10–19mm in diameter; being cold forceps, hot snare and
endoscopic mucosal resection (EMR), the preferred techniques respectively for
the different sizes. However, for polyps 4–5mm in size, both the cold snare and
cold forceps were the most commonly used techniques, though no method was
use more often than the other. Years in practice, colonoscopy volume per week
and performing advanced therapeutic endoscopy were associated with different
choices of polypectomy technique. For polyps measuring 4–5mm, cold snare was
the favourite method among endoscopists who performed 20 colonoscopies per
week (20 colonoscopies/week vs. 520 colonoscopies/week, 42.4% vs. 26.6%,
p5 0.05), among those who performed endoscopies 3 days/week (3 days/
week vs. 53 days/week, 40% vs. 25.7%, p5 0.05) and among those who per-
formed advanced endoscopy (advanced endoscopy vs no advanced endoscopy,
40.4% vs. 29.2%, p5 0.05). However, cold forceps was the preferred technique
among endoscopists who performed endoscopies 53 days per week (38.9% vs.
29.2%, p5 0.05) and among those who did not perform advanced endoscopy
(37.3% vs. 28.1%, p5 0.05). For small polyps (6–9mm), cold snare polypectomy
was most frequent among endoscopists who performed more colonoscopies (20
colonoscopies/week vs. 520 colonoscopies/week, 28% vs. 13%, p5 0.05) and
among those with less than 10 years in practice (510 years vs. 10 years, 27.2%
vs. 17.7%, p5 0.05). However, hot snare polypectomy was most frequent among
endoscopists who performed less than 20 colonoscopies/week (520 colonosco-
pies/week vs. 20 colonoscopies/week, 56.7% vs. 44.7%, p5 0.05) and among
those with more than 10 years in practice (10 years vs. 510 years, 53.8% vs.
44.7%, p5 0.05).
Table 1: The techniques used for the excision of colorectal polyps smaller than
20mm
Resection Method 1–3mm 4–5mm 6–9mm 10–19mm
Standard cold biopsy forceps 70.5% 32.7% 3.3% 0.3%
Jumbo biopsy forceps 7.3% 6.8% 1.9% 0%
Hot biopsy forceps 1% 1.9% 2.5% 2%
Cold snare 16.2% 34.8% 21.2% 1.1%
Hot snare 4.1% 19.6% 50.4% 38.9%
Endoscopic mucosal resection 0.6% 3.9% 19.7% 57%
Conclusion: There is a remarkable heterogeneity in the techniques used for
removal of polyps 520mm among Spanish endoscopists. Cold forceps, hot
snare and EMR are the preferred methods for removing diminutive polyps,
small polyps and polyps measuring 10 to 19mm, respectively. The use of cold
snare for removing small and diminutive polyps is most frequent among gastro-
enterologists with a greater dedication to endoscopy (colonoscopy volume per
week and performing advanced endoscopy) and among endoscopists with less
than 10 years in practice.
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Introduction: Early diagnosis of colorectal cancer whether through a sympto-
matic or screening pathway results in better outcomes for patients. Various
studies have reported barriers to screening amongst non-responders as well as
delays in diagnostic pathways. Current constraints in the NHS in colonoscopy
capacity are a compounding factor and all these factors contribute to delays in
diagnosis. We hypothesise that changing the diagnostic paradigm through com-
munity or primary care based semi-automated robotic colonoscopy is a method
of improving access to and engagement with non-responders (1, 2).
Aims & Methods: This project forms part of the development of a training
programme with the use of a simulation based training model to understand
the specific training needs and methods of fulfilling these for the potential ulti-
mate users of community-based robotic colonoscopy. This study involved parti-
cipants with varying degree of skills and background knowledge in the field of
colonoscopy. We enrolled three expert endoscopists, three trainee endoscopists,
two novices and two experienced video gamers. All participants performed colo-
noscopies on a validated ‘colonoscopy suitcase’ model developed at Welsh
Institute for Minimal Access Therapy (WIMAT) centre. Before testing each
participant received both verbal and written instructions on the goals of the
study and information about the semi-automated robotic endoscope along
with a familiarisation period with the device. Quantitative parameters were
recorded related to procedure times and lesion detection during the procedure.
Afterwards participants filled out a questionnaire evaluating the robotic
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colonoscope. Some operators participated in a follow up session in order to
analyse the learning curve of the robotic endoscopy.
Results: On average, experts required the shortest time to reach the caecum,
followed by video gamers, trainees then novices. Polyp detection rate (as a pro-
portion of total number in the model simulator colon) was the highest in the
novice group (91.67%) followed by the experts (86.11%), then equally, trainees
and video gamers (79.17%). Four out of nine participants attended the second
session where they were asked to repeat the procedure from the first session. Each
participant had a lower caecal intubation time during session 2 in comparison
with session 1, with range of improvement between 30% and 70%. Each of the
participants also had the same or higher polyp detection rate with range of
improvement between 0% and 25%. Qualitative assessment of feedback from
all participants indicated that most operators felt that the role of the novel test
was likely to be greater as a diagnostic procedure in an out of hospital setting.
Expert operators felt that training in the device was easier but also provided less
ability to torque steer due to automated sequences.
Conclusion: This project is the first step in identifying specific training needs and
potential roles of robotics in early diagnosis of cancer. This study also shows a
potential to reduce the length of time for skills acquisition associated with stan-
dard colonoscopy training through the use of semi-automated robotic devices.
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Introduction: Yao et al. observed gastric epithelial neoplasms and chronic gas-
tritis mucosa using magnifying endoscopy with narrow-band imaging (M-NBI),
and reported a phenomenon in which a white opaque substance (WOS) present in
the epithelium did not allow passage of the projected light and obscured the
subepithelial microvasculature (1). Furthermore, the morphology of the WOS
is a useful marker for differentiating between adenoma and carcinoma in gastric
epithelial neoplasms (1). Recently, we reported for the first time that WOS is also
detected in colorectal epithelial neoplasms (2). However, it is unclear whether the
morphology of the WOS in colorectal epithelial neoplasms is useful in the differ-
ential diagnosis of adenoma and carcinoma. We, therefore, conducted a prospec-
tive observational study to determine whether it is possible to differentiate
between carcinoma and adenoma based on the morphology of the WOS in color-
ectal epithelial neoplasms (UMIN000021167).
Aims &Methods: The subjects were consecutive patients with colorectal epithelial
neoplasms (adenoma, early colorectal cancer) who underwent endoscopic or
surgical resection at Fukuoka University Chikushi Hospital from December
2015 to November 2016. Prior to treatment, the entire lesion was observed
using M-NBI, and endoscopic images were taken and recorded in a filing
system. After the endoscopy was completed, a determination was made regarding
the presence or absence of WOS on the endoscopic images. The morphology of
the WOS was determined for cases in which WOS was present and in whomWOS
was seen in more than half of the region before the results of histopathological
examination of the lesions were known. The morphological characteristics of the
WOS were classified as regular WOS or irregular WOS according to our previous
report (1). The primary endpoint was the diagnostic performance of morpholo-
gical analysis of the WOS (accuracy, sensitivity, specificity) for early colorectal
cancer taking irregular WOS as an indicator. The secondary endpoint was the
difference in the prevalence of irregular WOS between mucosal (M) or SM-s
cancer (the depth of submucosal invasion is limited 1000 micrometers) and
SM-m (the depth of submucosal invasion is over 1000 micrometers).
Results: Five hundred twenty-nine lesions in 296 patients were included in this
study. Of these lesions, 404 were excluded, according to the following conditions:
268 negative for WOS, 72 in which WOS was seen in less than half of the region
34 that were diagnosed histologically as hyperplastic polyp, and 30 that could not
be investigated because of rich mucus. The analysis was conducted using 125
lesions from 96 patients. Of these 125 lesions, 33 were determined to have irre-
gular WOS and 92 to have regular WOS. Of the 33 lesions showed irregular
WOS, 30 (90.9%) were early cancer and 3 (9.1%) were adenoma. Of the 92
lesions demonstated regular WOS, 13 (14.1%) were early cancer and 79
(85.9%) were adenoma. The prevalence of irregular WOS in early cancer was
significantly higher than that in adenoma (p5 0.001, chi-square test). The diag-
nostic accuracy for the differentiation between early cancer and adenoma using
irregular WOS as an indicator of cancer was 87%. The sensitivity was 91% and
specificity was 86%. The frequency of irregular WOS in M or SM-s cancer and
SM-m cancer was 67.8% (21/31) and 75% (9/12), respectively. There was no
significant difference in the prevalence between irregular WOS in M or SM-s
cancer and SM-m cancer (p¼ 0.727, chi-square test).
Conclusion: These findings suggest that in colorectal epithelial neoplasms in
which the microvasculature cannot be visualized because of WOS, the morphol-
ogy of the WOS may be a useful marker in the differential diagnosis of adenoma
and carcinoma using magnifying endoscopy.
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Introduction: To reduce costs of colorectal cancer screening, a resect and discard
strategy has been proposed for small polyps. The American Society of
Gastrointestinal Endoscopy (ASGE) recommends achieving a diagnostic accu-
racy 90%, before implementing it (1). Narrow band imaging (NBI) is increas-
ingly available and the NICE classification is frequently used to reach real time
histologic classification. Endoscopists usually rely on short sessions, online
courses or self-education for training in NBI, so we evaluated the learning
curve in subjects with no previous endoscopic experience and their subsequent
performance in patients with polyps 7mm.
Aims & Methods: Participants (4th or 5th year medical students) attended one
training session regarding NBI and NICE classification. Learning curves were
posteriorly evaluated employing LC-CUSUM curves, with each participant indi-
vidually assessing 100 lesions. Polyps were ordered by a computer-generated
random sequence and divided into 6 sets of images (presenting 2 sets every
week) consisting of 16–17 polyps. After evaluating each polyp, they received
the correct diagnosis and a short explanation. The main outcome was a correct
NICE diagnosis. A 90% accuracy defined an adequate performance and 80%
was considered inadequate. A virtual cohort of 15000 evaluators was used to
estimate a cut-off of 3, 45 for the LC-CUSUM curve. To assess the diagnostic
performance, consecutive patients with lesions 7mm were included. Patients
with polyps lacking histological assessment, polyps 47mm or incomplete poly-
pectomies were excluded. All participants received the same white light and NBI
still images from 10 patients every week, including all polyps excised.
Colonoscopies were presented in the same order as they were included in the
study. Histological results were available with a 2-week delay. Evaluators pre-
dicted each polyp’s histology, giving their level of confidence, and recommended
a surveillance interval for each patient. Diagnostic accuracy was evaluated at
polyp level and for follow-up intervals.
Results: Thirty-eight evaluators (median age: 22.1 years, 71.1% women) com-
pleted the study. Of the 100 lesions (8.5mm, IQR: 5–17.5) included in the learn-
ing curve evaluation 19 were NICE 1.71 were NICE 2 and 10 NICE 3. Median
diagnostic accuracy was 86% (IQR: 84–91%, range: 76–96%), increasing from
81.8% (IQR: 78.8–87.9%) in the first 33 lesions to 87.9% (IQR: 84.8–93.9%) in
the last 33. According to the LC-CUSUM curve, 20 evaluators (52.6%) reached
diagnostic competence. During the diagnostic performance assessment, a total of
180 patients were included, presenting 307 polyps (range: 1–8 polyps/patient),
with a median size of 3mm (IQR: 2–5); 71.3% were adenomas, 21.8% hyper-
plastic 2.6% serrated adenomas and 4.2% presented other diagnoses. Overall
diagnostic accuracy was 76.9% (76.2–77.7%), reaching 81.3% (80.5–82.1%) in
high-confidence diagnoses. Sensitivity for adenomas was 83% (82.2–83.8%),
while for hyperplastic polyps it was 62.6% (60.8–64.5%). Surveillance intervals
were correct in 78% (77–79%) of patients, 81.3% (80.2–82.4%) in those present-
ing highly confident diagnoses. Only 2 (5.3%) evaluators reached the 90%
recommended threshold. Larger polyp size was associated with higher accuracy
(p5 0.001), but neither competence according to the LC-CUSUM test (p¼ 0.99)
nor frequent review of the histological results (p¼ 0.74) improved the evaluators’
accuracy.
Conclusion: Self-formation after a single training session did not allow most
evaluators to reach the ASGE suggested thresholds, mainly due to the low sen-
sitivity for hyperplastic polyps. Further studies are required to address if specific
training for small polyps or different formation methods might make NBI
assisted optical diagnosis a plausible option for small polyps outside expert
centers.
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Introduction: Effective colonoscopy requires effective bowel cleansing.
Inadequate cleansing may decrease diagnostic sensitivity, necessitate repeat pro-
cedures and delay appropriate treatment. Successful colon cleansing is harder to
achieve in patients aged over 65 than in younger patients. NER1006 is the first 1L
polyethylene glycol (PEG) -based bowel preparation, a patented combination
optimised for effective bowel cleansing. Here, the efficacy of NER1006 at cleans-
ing the colon in preparation for colonoscopy is compared to three active com-
parators, with attention to their efficacies in patients aged 65 years and 465
years who had a readable colonoscopy.
Aims & Methods: Colon cleansing efficacy of NER1006 was compared to three
currently used bowel preparations in patients aged 65 years and in patients aged
465 years. NER1006 was compared to sodium picosulfateþmagnesium citrate
(NaPicþMgCit), trisulfate and 2L PEG with ascorbate (2L PEGþAsc), in three
multicentre randomised Phase 3 clinical trials: DAYB1, NOCT2 and MORA3,
respectively. 2L PEGþAsc was administered over 2 days and in the MORA
trial, the doses of NER1006 were administered either both in 1 day morning-
only (N1D) or, as with 2L PEGþAsc, split over 2 days (N2D). In the DAYB
study, NER1006 was administered evening-only the day before colonoscopy
(NDB). Treatment-blinded central readers rated colon cleansing according to
the Harefield Cleansing Scale. Following segmental scoring, overall colon cleans-
ing was graded from A to D. Grades A and B were judged as successful cleansing;
grades C and D were judged as failed cleansing.
Results: Pooling the data from the three trials to assess colon cleansing in the two
age groups showed successful cleansing in 80.5% (1158/1438) of patients aged
65 and in 79.6% (277/348) of patients aged 465 (difference of 0.9%; P¼ 0.698;
95% CI: 3.7–5.6%). Within each trial the difference in colon cleansing in the
age groups indicated that the effect of increased age on cleansing efficacy was
lesser in the NER1006-treated patients than in patients treated with the active
comparators (Table 1). For example, in patients treated with NER1006 the rate
of successful colon cleansing in patients aged 465 was 5.2% higher than in
patients aged 65, whereas in patients treated with NaPicþMgCit, there was
3.5% lower successful cleansing rate in patients aged 465 than in patients aged
65.
Conclusion: NER1006 was efficacious in successful colon cleansing in patients
aged 465 (in whom successful colon cleansing is harder to achieve) as well as in
patients aged 65. Statistical significance was not reached in these comparisons.
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Introduction: Effective colonoscopy requires effective bowel preparation. For
detection of polyps larger than 5mm, an ’adequate’ segmental cleansing level
has recently been defined as 2 or more on the Boston Bowel Preparation Scale
(BBPS).1 The Phase 3 trial MORA compared NER1006 as an evening/morning
split-dosing or a morning-only dosing regimen, against 2L PEG with ascorbate as
an evening/morning split-dosing regimen (2L PEGþAsc). Treatment-blinded
central readers assessed the bowel cleansing efficacy using both the Harefield
Cleansing Scale (HCS) and the BBPS. This post hoc analysis shows the BBPS
scores for the two primary endpoints, in those patients who had a readable
colonoscopy.
Aims & Methods: In the MORA trial, 2 849 patients aged 18–85 were randomised
to bowel preparation with morning-only or evening/morning split-dosing using
either NER1006 or 2L PEGþAsc. Adequate level cleansing success was assessed
according to the BBPS for both overall colon (all segments 2) and right colon
cleansing (segmental score 2). The analysis includes all subjects for whom
colonoscopy videos were available for assessment by central readers.
Results: A total of 792 patients were analysed. When using an evening/morning
split-dosing, 249/262 (95%) patients on NER1006 achieved adequate level overall
colon cleansing compared to 232/260 (89%) on 2L PEGþAsc (Table 1). Using
morning-only dosing, 243/270 (90%) patients on NER1006 achieved the same.
Using evening/morning split-dosing, 254/262 (97%) patients on NER1006
achieved adequate level right colon cleansing compared to 242/260 (93%) on
2L PEGþAsc. Using morning-only dosing, 253/270 (94%) patients on
NER1006 achieved adequate level right colon cleansing. Adequate level cleansing
success was achieved significantly more often with NER1006 evening/morning
split-dosing than 2L PEGþAsc, both in the overall colon (P¼ 0.013) and in the
right colon (P¼ 0.042). The slight improvement seen with NER1006 morning-
only dosing in the cleansing rate of the overall colon and right sided colon was
not statistically significant. Table 1: Adequate level cleansing of the overall colon
and right colon (BBPS segmental scores 2–3) as determined by treatment-blinded
central readers
Conclusion: NER1006 demonstrated an exceptionally high adequate level bowel
cleansing efficacy. A significant improvement was shown for both the overall
colon and the clinically relevant right sided colon versus 2L PEGþAsc when
administered using the same dosing regimen. The morning-only dosing regimen
of NER1006 delivered a very high success rate, similar to that of 2L PEGþAsc.
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Abstract No: P0183
Patients with successful cleansing, n (%)
DAYB (1:1) NOCT (1:1) MORA (1:1:1)
NER1006 (NDB) NaPicþMgCit NER1006 Trisulfate NER1006 (N1D) NER1006 (N2D) 2L PEGþAsc
Aged 65 N (%) 127/196 (64.8) 115/205 (56.1) 192/208 (92.3) 197/213 (92.5) 191/210 (90.9) 184/192 (95.8) 198/214 (92.5)
Aged4 65 N (%) 28/40 (70.0) 20/38 (52.6) 43/47 (91.4) 41/47 (87.2) 54/60 (90.0) 69/70 (98.6) 40/46 (86.9)
Difference (%) 5.2 3.5 0.9 5.3 0.9 2.8 5.6
P-value 0.522 0.699 0.856 0.320 0.828 0.179 0.301
95% CI (%) 21.4–11 14.4–21.3 8.1–9.8 5.2–15.7 7.7–9.6 6.7–1.2 5.1–16.2
N.B. successful cleansing defined here as a Harefield Cleansing Scale grade of A or B (overall colon)
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Introduction: The European Colonoscopy Quality Investigation (ECQI) Group
comprises expert colonoscopists and investigators from Europe and aims to raise
awareness of the need for improvement in colonoscopy standards across Europe.
Recently, the European Society of Gastrointestinal Endoscopy (ESGE) has
developed key performance measures for lower gastrointestinal colonoscopy.1
Aims &Methods: To assess the quality of colonoscopy in current clinical practice,
through the use of online questionnaires, compared with recently published
ESGE performance indicators. The development of the online practitioner and
procedure questionnaires has been previously described.2, 3 Data collection is an
ongoing process. We analysed data collected between 2/6/16 and 17/4/17 and
compared with the ESGE performance measures.
Results: 40 of 50 practitioners completed the practitioner questionnaire. 2094
colonoscopies were documented across 8 European countries by 47 practitioners.
The ESGE sets a minimum standard of 90% of patients with adequate bowel
preparation, defined as Boston Bowel Preparation Scale score 6. From our
data, 81% (n¼ 1692) of procedures had adequate bowel cleansing (data unavail-
able for 96.4.6%). The ESGE recommends a minimum standard of 90% of all
diagnostic and screening colonoscopies visualize the whole caecum (excluding
those that have no indication to reach the caecum). Only 55% of practitioners
routinely record caecal intubation rate. The caecum was the intended endpoint in
66% of procedures. For those diagnostic and screening colonoscopies where the
caecum was the intended endpoint (n¼ 1390), 93% reached the endpoint but
only 70% had this endpoint photo-documented. The ESGE recommends that
adenoma detection rate (ADR) should be used as a measure of adequate inspec-
tion at screening or diagnostic colonoscopy in patients aged 50 years or more.
ADR was routinely recorded by only 18% of practitioners. Polyp removal rate is
routinely recorded by 30% of practitioners, and polyp retrieval rate by 23%.
Conclusion: Our findings indicate that some important performance measures
recommended by ESGE are not currently being achieved in practice. By provid-
ing a self-assessment tool and as a next step, by individual consultations with
national Group members, ECQI hopes to improve clinical practice standards.
Further information on the ECQI Group initiative can be found on
www.ecqigroup.eu
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Introduction: When it comes to gastrointestinal endoscopy, considerable hetero-
geneity is observed between gastroenterologists regarding the use of sedation and
the preferred sedative agents. The sedation protocol used by a gastroenterologist
may have a significant effect on endoscopic quality, patient cooperation and both
the doctor’s and the patient’s satisfaction with the procedure.
Aims & Methods: The aim of this study was to document current endoscopic
practices of Greek gastroenterologists and investigate whether they use sedation
to perform gastrointestinal endoscopy and which pharmaceutical agents are
usually involved. A 39-item online questionnaire was devised, addressing demo-
graphic data, use of sedation in endoscopy and monitoring practices. It was
subsequently made available to 509 Greek gastroenterologists by e-mail.
Results: A total of 195 questionnaires were successfully completed (38.3%). 49
gastroenterologists did not use sedation to perform esophagogastroduodeno-
scopy (EGD) or colonoscopy (25.1%). The younger gastroenterologists were
more likely to use sedation (p¼ 0.005). Among those using sedation, midazolam
was the most frequently used agent in EGD (50%) and the combination of
midazolam/fentanyl was the most frequently used in colonoscopy (24.6%), fol-
lowed by midazolam (21.9%). Out of 137 physicians using benzodiazepines (mid-
azolam, diazepam) as part of their endoscopic sedation regimen, 91 (66.4%)
routinely used flumazenil to facilitate pharmacological antagonism after the
completion of the endoscopy. In total, 45 physicians, 23.1% of the participants
and 30.8% of those using sedation, used propofol or a combination of propofol
and other agents. 30 gastroenterologists routinely administered propofol without
the aid of an anesthesiologist (66.6%). Medicolegal issues (33%), inadequate
training in the use of propofol (26.4%) and risk of cardiopulmonary complica-
tions (23.6%) were cited as the main reasons for not using propofol. As far as
monitoring practices go, the majority of gastroenterologists observed heart rate
and oxygen saturation (96% and 97% respectively). Regarding the safety equip-
ment available to the gastroenterologists, 160 (82%) reported having access to
regimens of pharmaceutical resuscitation, 145 (74%) to oropharyngeal airway
devices or laryngeal airway masks, 92 (47%) to endotracheal intubation equip-
ment and 86 (44%) to a defibrillator. When asked to rate their level of satisfac-
tion with their preferred sedation regimen (or with not using sedation) in a scale
of 1 to 10, 72 physicians rated their satisfaction level as 9 or 10 (36.9%) and 92 as
7 or 8 (47.1%). While there was no significant difference in terms of satisfaction
between the doctors that used sedation and those who did not, there was a
statistically significant difference between the gastroenterologists that used pro-
pofol (alone or in combination with other agents) and those who used other
sedative agents (p¼ 0.003). When asked on their preferred method of sedation,
if they were themselves subjected to gastrointestinal endoscopy, 104 physicians
opted for propofol-based sedation regimens (53.3%).
Conclusion: Gastrointestinal endoscopy is performed with the use of sedation by
the majority of Greek gastroenterologists. Propofol-based regimens are seldom
used in everyday clinical practice, despite a vast number of Greek gastroenterol-
ogists identifying them as their preferred regimen, in case they themselves should
undergo endoscopy. Compared to a past survey, Greek gastroenterologists are
still hesitant about using propofol. However, an increasing tendency towards
administering propofol without the aid of an anesthesiologist is observed.
Also, physicians using propofol seem to be more satisfied with their sedation
practices than the doctors using other sedation regimens. Absence of a distinct
legal framework, inadequate training and fear of cardiopulmonary complications
are identified as the main reasons preventing Greek gastroenterologists from
using propofol.
Disclosure of Interest: All authors have declared no conflicts of interest.
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NER1006
evening/morning split dosing
NER1006
morning only dosing
2L PEGþ
Ascevening/morning split dosing
Patients (N) 262 270 260
Patients with an adequate level
cleansing success of the overall colon, n (%)
249 (95) 243 (90) 232 (89)
Patients with an adequate level cleansing
success of the right colon, n (%)
254 (97) 253 (94) 242 (93)
P vs. 2L PEGþAsc (overall colon) 0.013 0.772 –
P vs. 2L PEGþAsc (right colon) 0.042 0.772 –
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Brussels/Belgium
Contact E-mail Address: souazzan@ulb.ac.be
Introduction: Indicators for colonoscopy quality assessment were developed and
promoted during this last decade. However technical and human resources con-
straints limit local implementation of continuous recording of endoscopic quality
indicators (QI). Automatic system of data extraction and presentation could help
endoscopy units in their seek for quality improvement. We hereby report our
local experience in implementing colonoscopy QI record trough an automatic
data extraction from two separate databases (DB), and assess the colonoscopy
quality at unit and individual levels.
Aims & Methods: We locally adapted a company reporting system for colono-
scopy by adding in a dedicated tab, selected procedure indicators. Endoscopic QI
data from reporting system DB and pathological results from another DB were
extracted and merged together in a separated DB. On a regular period basis or on
request, key QI are calculated and extracted. It includes adenoma detection rate
(ADR), polyp detection rate, caecal intubation rate, quality of bowel preparation
(using the Boston bowel preparation scale) and type of sedation. During a first
period of 6 months starting in January 2016, endoscopists were encouraged to
fulfill the dedicated tab on a voluntary basis. In a second period, filling of QI was
turned to be mandatory. The completeness of QI recording was evaluated across
both periods, and results from second period are presented. Performance mea-
sures of all endoscopists were compared to global results of our department and
to published targets.
Results: During the 6 months "mandatory-filling" period (July-December 2016),
1802 colonoscopies were performed with a QI tab fully filled in 100% of cases
compared to 63.1% after the ‘‘free-filling period’’ (p5 0.0001). The global caecal
intubation rate for screening colonoscopy was 92.9%. Mean Boston bowel pre-
paration score was 7.2 0.76 with 86.9% of cases with adequate preparation
(Boston score 45; 89.9% among outpatients and 81.9% among inpatients).
Colonoscopies were performed under propofol sedation in 94.1%. During this
second period, the global ADR was 32.4% (range: 0%-55.7%). The polyp detec-
tion rate was 44.4% with a mean of 1.19 polyp removed by colonoscopy.
Conclusion: This study illustrates that quality indicators for colonoscopy assess-
ment in a Belgian tertiary hospital endoscopy unit could be easily implemented
with limited human resources by adapting a company reporting system and link
it to the pathology department database. Mandatory filling of QI items is the key
for system implementation success. Our results were consistent with goals
required by international guidelines. This system allows giving feedback to indi-
vidual endoscopists for self-performance assessment and might be easily adapted
in the future following guidelines updates.
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Introduction: Since the advent of screening colonoscopy we diagnose a lot more
asymptomatic large rectal polyps 45 cm in diameter. With the introduction of
EMR (endoscopic mucosal resection) and ESD (endoscopic submucosal dissec-
tion) we have now endoscopic means to resect those lesions effectively. It is
however still unclear whether EMR or ESD is superior in terms of complete
resection and safety.
Aims & Methods: We will compare the outcome (perforation, bleeding, complete
resection, recurrence rate) in two cohorts of patients with lateral spreading rectal
adenomas 45 cm who were either treated by EMR or ESD in our centre.
Results: 62 large laterally spreading rectal adenomas in consecutive patients (age
45–84 years) were completely resected endoscopically. ESD en-bloc resection was
performed in 23 patients. All other lesions were excised by piecemeal EMR. Prior
to resection a careful examination under white light and NBI was performed
using the Paris classification. In comparison ESD took about three times as
long as EMR (average procedure time 98min. vs 37min) with comparable
intra- and postoperative bleeding rates (5% in each group). No perforations
were encountered. All en-bloc ESD specimens were R0 on histology. In one
patient deep submucosal invasion of the submucosa (41000mm) was present.
The patient underwent surgical resection 6 weeks after the endoscopy without
evidence of remaining tumor or lymph node invasion. The most striking differ-
ence in the two groups was seen regarding recurrence of adenomas during 6
months follow-up: 0% in the ESD cohort and 12% in the piecemeal EMR
group. All recurrent adenomas after EMR could however be easily resected by
snare polypectomy without any further recurrence over the next 12 months. The
calculated average equipment cost for ESD (hook knife, dual knife, injectate,
transparent cap) was significantly higher compared to EMR (687$ vs. 39$).
Conclusion: EMR and ESD are equally effective in resecting large lateral spread-
ing adenomas of the rectum. The higher rate of post-EMR adenoma recurrence
did not impact the patients overall cure rate after one year. ESD is significantly
more time consuming and costly.
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Introduction: Colorectal cancer (CRC) is a significant cause of morbidity and
mortality; it is third in terms of incidence and cause of death among both men
and women in the United States. In Brazil, CRC incidence has reached 19–21
cases per 100,000 individuals. CRC has several precursory lesions, and patient
survival depends largely on disease stage at diagnosis. Thus, CRC screening is
vital for decreasing CRC incidence and disease-specific mortality. Optical colo-
noscopy (OC) is the first-choice investigation for colonic conditions and it is
excellent for CRC screening and surveillance. Newer technologies such as com-
puted tomography colonography (CTC) may also be useful in CRC screening.
Aims & Methods: This systematic review compares the benefits of CTC and OC
for CRC screening. This systematic review includes all available randomized
clinical trials available comparing CTC and OC for CRC screening in asympto-
matic patients. We assessed study quality using the revised version of the Quality
Assessment of Diagnostic Accuracy Studies. In this meta-analysis, we compared,
in the form of Forest Plots, patient participation rate and the detection rates for
advanced colorectal neoplasia (ACN) between the two methods. The positive
predictive value (PPV) of CTC in terms of the outcome ‘‘detection of ACN’’
was also calculated, comparisons were made after considering patients in all
included studies.
Results: A total of 386 articles were identified in the initial search. Of these, three
were included in the systematic review and submitted for meta-analysis. A total
of 16,592 patients were invited to undergo screening programs, but only 3881
underwent the procedures. In the analysis of participation rates, only 2333 of
8104 patients invited underwent CTC and only 1486 of the 7310 patients invited
underwent OC. The absolute risk difference in participation rate in the two
procedures was 0.1 (95% CI, 0.05–0.14) in favor of CTC. In the analysis of
ACN detection rates, 2357 patients undergoing CTC and 1524 patients under-
going OC were included. Of these, 135 patients who underwent a CTC and 130
patients who underwent an OC were diagnosed with ACN. The absolute risk
difference in ACN detection rate in the two procedure types was 0.02 (with a
95% CI between 0.04 and 0.00) in favor of OC.
Conclusion: CTC is an option for the exercise of CRC screening in asymptomatic
patients. However, as a CTC has proved inferior in detecting advanced colorectal
neoplasia, the method should not replace a OC, wich remains as gold standard.
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Introduction: High adenoma detection rates (ADRs) for colonoscopy are asso-
ciated with a lower risk of colorectal cancer. ADR is therefore treated as a quality
indicator of colonoscopy. However, ADR varied among endoscopists and
depend on their skill. To facilitate high-quality clinical practice that is not depen-
dent on endoscopists’ skill, we have been researching a computer-aided diagnosis
system1, 2. This time, we developed an automated polyp detection system based
on deep learning (one of the latest artificial intelligence technologies).
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Aims & Methods: The aim of this study was to develop a computer-aided detec-
tion (CAD) algorithm for colonoscopy using deep learning. To evaluate the
developed CAD algorithm, we retrospectively viewed colonoscopy videos from
a previous randomized controlled study (UMIN000017083) conducted from
April 2015 to October 2015. All examinations were performed using CF-
HQ290ZI (Olympus Corp., Tokyo, Japan). Each case was recorded with full
high-definition quality using HVO-1000MD (Sony Corp., Tokyo, Japan). In
this study, two endoscopists (M.M, Y.M.) manually annotated 43 colonoscopy
videos with 238min of 17,903,967 frames. These videos included 75 polyps (48
neoplasms, 27 non-neoplasms), and annotations were made on the presence or
absence of polyps in every frame. Forty-three videos were divided into 300 short
video for machine learning and validation process. Among 300 short videos, 246
were used for the machine-learning process. The remaining 54 (33 included a
lesion) were used to validate the CAD algorithm. A modified version of Caffe
with 3-Dimensional Convolutional Networks (a kind of deep learning) was used
for the CAD algorithm. The validation samples were analyzed using the CAD
algorithm and its output as the probability of the presence of a lesion in each
validation video. A receiver operating characteristic (ROC) analysis was per-
formed to evaluate the efficacy of the CAD algorithm.
Results: The mean probability of a polyp-positive video was 62.1 27.9%,
whereas that of a polyp-negative video was 18.1 24.6% (P5 0.001). The area
under the ROC curve was 0.887. If a cutoff probability was set at 20.4%, the
present CAD algorithm could detect a polyp with 90.9% sensitivity and 76.2%
specificity.
Conclusion: Our preliminary results showed that state-of-the-art artificial intelli-
gence has the potential for achieving automatic detection of colorectal polyps. A
prospective study is now planned after more machine-learning sessions.
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JP 17K15971.
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Introduction: Colonoscopy is widely accepted for the diagnosis and treatment of
colonic diseases. Accepted quality parameters for colonoscopy include a cecal
intubation rate of 4¼ 90%. 10% of all colonoscopies are difficult and intuba-
tion of the cecum can sometimes be impossible. The novel motorized endoscope
was recently developed (Olympus Medical Systems Corporation, Tokyo, Japan)
and represents a disruptive new technology in endoscopy. It is currently being
evaluated for anterograde enteroscopy. Spiral technique offers the potential to
overcome some of the limitations of standard colonoscopy with push technique
by actively pleating the bowel onto the endoscope with motorized rotation of the
spiral overtube. This may have advantages in cases of difficult standard colono-
scopy to facilitate cecal intubation on the one hand and in all colonoscopies in
terms of patients comfort, sedation and ease of use also in therapeutic situations.
Aims & Methods: To evaluate feasibility and safety of MSC for diagnostic colo-
noscopy. Secondary endpoints were ileum intubation rate, procedure time, need
for sedation and external compression, patients’ pain and satisfaction, adenoma
detection rate (ADR) and feasibility of therapeutic interventions. 30 consecutive
patients with indication for colonoscopy meeting the inclusion criteria at a single
tertiary referral center were enrolled in the trial between December 2016 and
January 2017. The study was conceived as proof of concept trial with the primary
aim to achieve a cecal intubation rate of at least 90% according to quality guide-
line recommendations.
Results: 13 male and 17 female patients were enrolled. Mean age was 68.9 years
(30–90), health status was ASA-1: 16.7%, ASA-2: 36.7% and ASA-3: 46.6%.
43.3% of the patients had diverticula. Indications for colonoscopy were clarifica-
tion of indeterminate iron deficiency anemia (IDA, n¼ 5), lower gastrointestinal
bleeding (GIB, n¼ 6), surveillance after previous polypectomy (n¼ 6), screening
for polyps and colorectal cancer (n¼ 11) and others (n¼ 2). Sedation level
(ESGE-Guideline, Level 1–3) in all patients was 3 (deep sedation). Mean
amount of propofol was 305 [130–880] mg. Mean procedure time was 20.8
[11.4–55.3] min. Cecal intubation rate (technical success) was 96.7% (29/30).
One incomplete colonoscopy occurred due to an unexpected postinflammatory
stricture of the sigmoid. All colonoscopies reaching the cecum also successfully
intubated the ileum (96.7%). Only in one case external compression was needed.
Adenoma detection rate was 46.7%. EMR was performed in 9 cases, 5 patients
had forceps polypectomy. One case of incidental finding of submucosal invasive
adenocarcinoma in EMR specimen was histologically proven to have R0 en-bloc
resection. All other therapeutic interventions could also successfully be con-
ducted (clip n¼ 3, argon plasma coagulation n¼ 1, tissue sampling n¼ 2). Two
mild adverse events were recorded (mild superficial mucosal lesions without
clinical symptoms). No severe adverse occured.
Conclusion: This study represents the first clinical evaluation of the novel motor-
ized spiral endoscope for examination of the colon. Our data show that it is
effective and safe for diagnostic and therapeutic colonoscopy. It may also have
potential advantages over standard colonoscopy technique in terms of effective-
ness and convenience of colonoscopy.
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Introduction: The results of the National Polyp Study are premised on the
removal of all adenomatous lesions. Cold forceps polypectomy (CFP) using
jumbo biopsy forceps is a simple and safe technique used for diminutive
polyps (5mm). The recurrence rate after CFP for patients with diminutive
polyps has not been elucidated.
Aims & Methods: We have prospectively enrolled patients with diminutive polyps
treated by CFP from June 2015 to March 2017. Magnifying colonoscopy was
used for all procedures. The location, size, endoscopic findings and procedures
were recorded. The patients who have undergone CFP had their follow-up colo-
noscopy in one year after CFP.
Results: CFP was performed for total 515 polyps from 277 patients. The size of
the polyps was 53mm/4mm/5mm¼379/101/35. The rate of one-bite polypect-
omy for adenoma was 53mm/4mm/5mm¼79%/54%/33%. There was no sig-
nificant difference in the one-bite rate between endoscopists’ experience. No
cancer was observed in histology. Rates of delayed bleeding after CFP was
0.19% (1/515). Concomitant use of anticoagulation use of antiplatelet drugs
was found in 14% (72/458), and none of them experienced delayed bleeding.
No perforation occurred. Seventy-five patients had their follow-up colonoscopy
so far. There are no polyps suspecting residual or recurrent lesions. Among 75
patients, 62 patients had less than two polyps removed at their first colonoscopy
(Group A). On the other hand, 13 patients had more than three polyps removed
at their first colonoscopy (Group B). Follow-up colonoscopy revealed that the
rates of newly discovered polyps in the same segment were 8% and 23% in
groups A and B, respectively. The rates of newly discovered polyps in the differ-
ent segment were 27% and 61% in groups A and B, respectively. When the initial
CFP was performed by the endoscopist with the experience of 55 years/5–9
years/more than ten years, the rates of newly discovered polyps found at
follow-up colonoscopy was 54% (14/26)/42% (8/18)/37% (11/30), respectively.
Conclusion: The rate of one-bite polypectomy was significantly higher for
diminutive polyps especially less than 3mm. Importantly there are no polyps
suspecting residual or recurrent lesions in the follow-up colonoscopy. CFP is a
safe and effective option for diminutive polyps (5mm). Although the rate of one-
bite polypectomy was not related to the endoscopists’ experience, adenoma detec-
tion rate is seemed to be low in young endoscopists. Since achievement of ‘‘clean
colon’’ is difficult with a single colonoscopy, multiple colonoscopic examinations
are necessary to achieve ‘‘clean colon’’ especially if the patients have more than
two polyps at the first examination.
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Introduction: Colonoscopy is the most effective method for preventing colorectal
cancer, as it offers easy detection and resection of polyps. Cimetropium bromide
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results in colonic spasmolysis and may improve polyp detection. We studied the
effect of cimetropium bromide on polyp detection during colonoscopic
withdrawal.
Aims & Methods: Patients undergoing colonoscopy for screening examinations
were included and randomized at cecal intubation to receive either 5mg cime-
tropium bromide or placebo. We evaluated the polyp detection rate (PDR),
adenoma detection rate (ADR), and advanced ADR (AADR) in the right side
colon as well as in the colorectum.
Results: A total of 181 patients were analyzed in this study. Cimetropium group
consisted of 91 patients, and control group consisted of 90 patients. PDR, ADR,
and AADR were not significantly different in cimetropium and control groups
(62.6% vs. 66.6%, P¼ 0.571; 51.6% vs. 47.7%, P¼ 0.603; 3.2% vs. 7.7%,
P¼ 0.187; respectively). Similarly, PDR and ADR in the right side colon were
not significantly different between the groups (46.1% vs. 47.7%, P¼ 0.827;
32.9% vs. 35.5%, P¼ 0.714; respectively).
Conclusion: Cimetropium bromide does not improve the PDR or ADR in the
right side colon or the colorectum. Thus, administration of cimetropium bromide
can be used selectively in screening colonoscopy.
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Introduction: Colorectal cancer (CRC) accounts for up to 11% of all cancers in
women and 14% of men in Ireland, and is the second most common cancer
across sexes. The adenoma-carcinoma sequence of colorectal carcinogenesis
lends itself to screening with the aim of complete excision of polyps. It has
been estimated that incomplete resections of polyps are involved in 19–31% of
interval cancers. ESGE guidelines state that polyps 5mm or greater should be
removed by snare resection. Previous studies report inappropriated resection
techniques employed in up to 46% of cases. The aim of this study was to inves-
tigate polypectomy techniques and to assess adherence to guidelines in a tertiary
referral, University teaching hospital in Dublin, Ireland. We also investigated the
differences between subspecialty and consultants versus trainees.
Aims & Methods: The study included all patients who underwent colonoscopy in
Tallaght Hospital (Dublin, Ireland) between January 2012 and December 2015 for
any indication. From this, a list of patients with colonic polyps was compiled.
Demographics and other information including number and site of polyps, resection
and retrieval rates, method of resection and specialty of endoscopist were included.
Results: 11,400 colonoscopies were performed during the study period. To date,
the records of approximately 7000 (61%) procedures have been reviewed. 2337
(22.5%) patients were identified with polyps, with 1027 females (43.4%), 1310
males (56.6%) and a mean age of 60.6 years. The indication for colonoscopy
included symptoms (47.2%), polyp surveillance (22.3%), CRC cancer screening
(9.2%), family history of CRC (4.4%) IBD surveillance (3.8%), with no indica-
tion noted in 12.95%. The mean number of polyps per patient was 2.2. 47.7% of
patients had one polyp identified. In 52.5% (n¼ 1227), polyps were left-sided,
and were right-sided in 23.1% (n¼ 540). In all 15.72% of polyps 45mm were
resected by forceps and not by snare resection. Non-adherence to guidelines was
observed in 17.56% and 17.3% of procedures completed by medical and surgical
trainees respectively. Medical (12.3%) and surgical (12.1%) consultants had a
higher adherence rate.
Conclusion: European guidelines have yet to be universally implemented.
Previous cohort studies report non-adherence rates of up to 46%. Our study
shows a non-adherence rate of 12–18% amongst trainees and Consultants. The
low polyp detection rate likely represents the varied case mix. A greater emphasis
on ESGE guidelines could improve awareness and enhance compliance which is
suboptimal. A follow up study to determine the effect on interval cancers in these
groups is planned.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Sedation for colonoscopy by using intravenous propofol has
become standard in many Western countries.
Aims & Methods: While gender-specific differences have been shown for general
anaesthesia used in dentistry, no such data exist as yet for gastrointestinal endo-
scopy. In a prospective observational study at an Academic teaching hospital of
Hannover Medical School 219 patients (108 women and 111 men) scheduled for
colonoscopy were included. Propofol sedation using EEG monitoring during a
constant level of sedation depth (D0 to D2) performed by trained nurses or
physicians after bodyweight adjusted loading-dose.
Main outcome measures: Primary endpoint was the presence of gender-specific
differences in wake-up time (time from end of sedation to eye - opening and the
complete orientation of the patient); secondary outcome parameters analysed
were total dose of propofol, sedation associated complications (bradycardia,
hypotension, hypoxia, apnoea), patient cooperation and patient satisfaction.
Multivariate analysis was performed to correct confounding factors such as
age and BMI.
Results: Women awake significantly faster compared to men with a time to eye
opening of 7.26 3.69 versus 8.39 3.43min. (p¼ 0.005) and time until complete
orientation 9.14 3.88 versus 10.4 13.71min (p¼ 0.008); propofol dosage was
not significantly different, with some trend towards more propofol per kg body
weight in women (3.98 1.81mg versus 3.72 1.75mg, p¼ 0.232, n.s.).
Conclusion: The effect of gender aspects should be taken into account upon
propofol induced sedation for gastrointestinal endoscopy. That includes ade-
quate dosing for female as well as cautiousness regarding potential overdosing
of male patients.
Trial registration: ClinicalTrials.gov (Identifier: NCT02687568). Data were pre-
sentet at a national meeting (DGEBV) in Germany.
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Introduction: Consensus guidelines suggest to assess at least 12 lymph nodes for
adequate staging of colorectal cancer and the correlation between number of
lymph nodes retrieved and the patient survival has been formerly reported. To
facilitate the retrieval of lymph nodes, preoperative endoscopic tattooing to mark
the site of the tumor has been proposed. In this study, we aimed to evaluate the
effect of preoperative colonoscopic tattooing (PCT) using indocyanine green
(ICG) for lymph node harvest in colorectal cancer. Additionally, we evaluated
the effect of both side injection of ICG for improving the rate of adequate lymph
node harvest.
Aims & Methods: 1023 patients who underwent curative resection for colorectal
cancer between Jan 2013 and Aug 2016 at the Pusan National University
Yangsan Hospital in Korea were retrospectively divided into the tattooing
group and the non-tattooing group depending on whether PCT using ICG was
done. Pathological findings and lymph node harvest were compared between the
two groups.
Results: The rate of adequate lymph node harvest (retrieval of more than 12
lymph nodes) was similar in tattooing group and non-tattooing group (91.9%
vs. 91.4%). However, when comparing the both side injection group and
United European Gastroenterology Journal 5(5S) A227
nontattooing group, both side injection group was better result (96.2% vs.
91.4%, OR 2.348, p-value 0.229). Most results did not have statistical association
with higher lymph node yield in colorectal cancer. But in T1 cancer, the rate of
adequate lymph node harvest was higher in the both side injection group, statis-
tically (94.7% vs. 81.0%, OR 4.235, pvalue 0.047)
Conclusion: PCT using ICG was associated with higher lymph node harvest in
colorectal cancer, especially in T1 cancer. And both side injection of ICG
increased the rate of adequate lymph node harvest. Further studies and methods
are needed to harvest adequate lymph nodes in colorectal cancer.
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Introduction: Cold snare polypectomy (CSP) has grown in popularity worldwide
due to its ease and safety with a low incidence of adverse events, such as hemor-
rhage and post-polypectomy syndrome1–3. However, there are concerns regard-
ing tumor residue with CSP because it does not use electrocautery, thereby
eliminating its burning effect. European Society of Gastrointestinal Endoscopy
(ESGE) clinical guideline suggests CSP for subcentimetre sessile polyps because
of its safety profile, despite lack of evidence for efficacy compared to HSP4. The
aim of this study was to investigate the success rate of CSP for complete resection
of subcentimetre colorectal adenomatous polyps compared to that of HSP.
Aims & Methods: This was a prospective, multicentre, randomised controlled,
non-inferiority trial conducted in 12 Japanese endoscopy units. Patients aged
20 years, undergoing elective colonoscopy/polypectomy, and who provided
written informed consent were included. Patients who were taking anti-throm-
botic agents and undergoing hemodialysis were excluded, as well as those with
inflammatory bowel diseases, polyposis, and pregnancy. Endoscopically diag-
nosed sessile adenomatous polyps, 4–9mm in size, were randomly assigned to
the CSP or HSP group. After complete removal of the polyp using the allocated
technique, biopsy specimens from the resection margin after polypectomy were
obtained. The primary endpoint was the complete resection rate, defined as no
evidence of adenomatous tissue in the biopsied specimens, among all patholo-
gically confirmed adenomatous polyps (full analysis set: FAS). Pre-planned
subgroup analyses for the size of polyp were also conducted. The sample size
was calculated according to the incomplete resection rate seen in previous arti-
cles and the required sample size was estimated at 780 lesions, including drop
out cases. The protocol was approved by the institutional review board in each
institution.
Results: A total of 796 eligible polyps were detected in 538 of 912 patients
screened for eligibility between September 2015 and August 2016. Three
hundred and ninety-four lesions were assigned to the CSP group and 402
lesions were assigned to the HSP group. One hundred and nine lesions (56 in
the CSP group and 53 in the HSP group) were excluded for FAS analysis.
Background characteristics of the lesions (size, location, morphology, and
institution) were similar in both groups. The complete resection rate for
CSP was 98.2%, compared to 97.4% for HSP. The between group difference
in complete resection rate was þ0.8%, favouring CSP (90% C.I. of 0.8.2.7;
p-5 0.0001). Resection time, overall, was significantly shorter with CSP than
with HSP (60 s versus 83 s, respectively; p5 0.001). Postoperative bleeding
requiring endoscopic haemostasis occurred only in the HSP group (0.5%, 2
of 402 cases). Subgroup analysis according to the size of the polyp (4–5mm
and 6–9mm) showed a comparable complete resection rate for CSP and HSP
for both subgroups of polyps.
Conclusion: The complete resection rate of CSP is not inferior to that of HSP.
CSP can be one of the standard techniques for subcentimetre colorectal polyps.
(Study registration: UMIN000018328)
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Introduction: Prevention of complications secondary to endoscopic resection
techniques (EMR or ESD) requires avoiding deep thermal damage and increase
mucosal healing. Platelet-rich plasma (PRP) has demonstrated efficacy in pre-
clinical endoscopic resection models [1]. The EndoPRP study was a prospective
single-center study to assess the efficacy of PRP on endoscopic resection of large
sessile lesions (larger than 35mm). (Study registered at ClinicalTrials.gov:
NCT02931149)
Aims &Methods: In the EndoPRP study 15 patients (males and females, aged 52–
80) were assigned to receive PRP (6–18mL): i) Endoscopic Shielding Technique
(EST, n¼ 4), applying PRP as a shield after standard resection technique, or ii)
Submucosal injection (SMI, n¼ 11), performing a submucosal injection of PRP
prior to EMR or ESD. Patients were informed and accepted to participate with a
written consent. PRP was obtained from a sample of patient’s blood (18–36mL)
drawn at the time of endoscopy. Patients underwent endoscopic follow-up at 4
weeks. The efficacy of PRP was assessed by the incidence of adverse events
(delayed bleeding or perforation). Mucosal healing rate (MHR) was defined as
a percentage of mucosal restoration after 4 weeks.
Results: Shielding technique with PRP was performed in 4 lesions at rectum (Æ
53.7 20.6mm, range 35–80mm). Submucosal injection of PRP was used in 11
lesions (2 at antrum, 3 at rectum, and 8 at colon) (Æ 41.6 9.6mm, range 35–
70mm). Delayed bleeding occurred after EMR of 1 lesion (no required blood
transfusion or endoscopic treatment; 6.6% of all lesions: 1 patient at EST group,
0 patients at SMI group). MHR was significantly higher in patients treated with
SMI than EST (87.5% vs. 78.6%; p¼ 0.03).
Conclusion: PRP applied as a shield over the scar or as submucosal fluid cushion
has proved clinical efficacy in endoscopic resection of large lesions. Submucosal
injection of PRP has showed better mucosal healing rate as comparison with
shielding technique.
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Introduction: Procedural sedation is commonly used during gastrointestinal endo-
scopy procedures to improve patient comfort. It comes, however, with the risk of
sedation-related adverse events (AEs) as defined by World SIVA.1 The cost of
AEs and their impact on healthcare resource use and efficiency is currently
unknown.
Aims & Methods: The aim of our study is to quantify and compare the costs of
AEs during procedural sedation in France, Germany, Italy, UK, and USA.
Online interviews were conducted with providers (nurses, physicians, and anaes-
thesiologists) and payers. Respondents were screened to ensure that they had the
expertise and experience to complete the survey. The provider survey covered
topics such as guidelines, sedation agents, monitoring, and patient outcomes
following AEs. Each provider reported on current clinical practice, the incidence
of AEs, and the standard treatment and outcomes for 100 hypothetical patients
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with a defined AE. Treatment options, including none required, were taken from
SIVA-defined lists. Outcomes examined included delayed procedures, unplanned
hospital admission, and death. Payers were surveyed about costs for interven-
tions, provider time, hospital administration, and admissions. Outliers were iden-
tified using Dixon’s Q test. The mean treatments and outcomes per AE per
country were calculated, with responses weighted by the AE frequency reported
by physicians and the outliers replaced by global means. Mean costs were calcu-
lated per intervention and outcome, with outliers removed.
Results: 101 providers and 26 payers completed the surveys, with a minimum of
20 providers and 5 payer responses per country. Over 62% of providers were
gastroenterologists and anaesthesiology nurses. Local guidelines determined
practice in most cases, and propofol and midazolam were the main sedation
agents employed. The most common AEs reported were hypotension and bra-
dycardia, with 9% and 4% of respondents, respectively, estimating each to occur
during 410% of procedures. Mean provider time required to treat AEs ranged
from 1.7 minutes for mild desaturation in Germany to 31.0 minutes for cardiac
arrest in the USA. Accounting for interventions and provider time, the mean
direct cost per AE ranged from EUR 12 for bradycardia in Germany to USD 3,
877 for cardiac arrest in the USA (Table). When costs were ‘‘fully loaded’’ these
became EUR 39 and USD 19, 722, respectively. Although of low direct cost,
bradycardia in Germany was reported to cause procedure termination or sub-
stantial delay in 3.8% of cases. In Euro countries, the median of mean direct
costs for an AE was EUR 40 (IQR: 29–67). When costs of outcomes of AEs were
included the median ‘‘fully loaded’’ cost reached EUR 301 (IQR: 115–738).
Table: Costs of select adverse events by country. FL: Fully-loaded (costs
including hospital administration, time, inpatient stays, delays, and cancellations,
but excluding legal costs)
Country,
currency Hypotension
Mild
desaturation
Severe
desaturation Bradycardia
Prolonged
apnoea
Cardiac
arrest
Direct; FL Direct; FL Direct; FL Direct; FL Direct; FL Direct; FL
France, EUR 32; 173 23; 471 79; 1994 17; 131 53; 490 137; 11,936
Germany,
EUR
23; 193 18; 212 92; 1268 12; 39 118; 807 274; 4765
Italy, EUR 41; 111 32; 98 59; 201 33; 93 43; 99 101; 1195
UK, GBP 69; 537 34; 606 93; 1258 35; 362 80; 631 658; 8984
US, USD 247; 841 463; 1456 529; 1715 83; 358 394; 1262 3877; 19,722
Conclusion: Costs of sedation-related AEs can be substantial regardless of coun-
try of origin. Disruption of patient flow and provider efficiency may add to the
cost burden. Even relatively minor events may prompt additional intervention,
increasing the overall cost of care.
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Introduction: Performing CR-ESD remains challenging in Western countries and
surveillance studies in this setting are not fully described. KAR has been advised
as a reasonable strategy for non-expert endoscopists and difficult lesions.
However, some KAR eventually requires a piecemeal resection (p-KAR). A
direct comparison between these two techniques is lacking. Additionally, when
the specimen is resected en bloc regardless of what procedure is used, and the only
pathological risk factor for recurrence is lateral margin (LM) involvement, its
implications concerning the recurrence rate should be assessed.
Aims & Methods: 1.) To compare the recurrence rate after R0 and R1/Rx endo-
scopic resection (ER), on an ESD ‘‘intention-to-treat’’ basis, in a Western
European setting where CR-ESD is performed by non-experts. 2.) To evaluate
the impact of LM involvement on local recurrence when neoplasms without risk
factors for lymph node metastasis are resected en bloc. We prospectively included
89 consecutive CR neoplasms planned for ESD from September 2008 to
December 2015. When technical difficulties arose or for patient’s safety reasons,
we performed a KAR. Kaplan-Meier survival curves were used to assess the
recurrence rate over time. The end of follow-up was considered when a local
recurrence occurred or at the end of the surveillance period in those patients who
did not develop the event. Comparisons were made using the log-rank test. The
recurrence rate during follow-up was stratified considering advanced histology,
en bloc resection and R0 resection.
Results: The ER was aborted in 5 cases (perforation n¼ 3; technical difficulties
n¼ 2). Surgical intervention was needed after ER because of submucosal or
linfovascular invasion in 4 patients. Five out of the remaining 80 cases, were
lost to follow-up. Finally, 75 CR neoplasms were included in 74 patients (43
male; 58.1%). Median age was 71 years (range: 37–93). Median size of the lesions
was 32mm (range 10–100). Histology was 26 (34.7%) Vienna category 3; 46
(61.3%) Vienna 4 and 3 (4%) sm1-Vienna 5. En bloc resections were obtained
in 44 cases (58.7%): 33 ESD (44%) and 11 KAR (14.7%). The ER finished as p-
KAR in the 31 remaining lesions (41.3%). R0 resections (n¼ 23; 30.7%) were
achieved in 18/33 ESD and 5/42 KAR [OR¼ 8.9 (CI 95%: 2.8–28.3);
p5 0.0001]. The median follow-up period was 16 months (1–91). Local recur-
rence occurred in 11 cases: 9 of the latter throughout the first year (81.8%). No
surgery was needed because of recurrence. The overall recurrence rate at 36
months was 15%. The recurrence rate at 3 years showed a statistical significant
difference when R0 resections were compared with R1/Rx: 0% vs. 21.5%
(p¼ 0.03). When results were stratified according to histology and en bloc resec-
tions, no significant differences were found in the recurrence rate. When en bloc
resections in pT1a/T1b (sm1); ly (-); v (-); pVM0 lesions (n¼ 44) were analysed
separately, LM distribution was: 23 LM0 (52.3%); 18 LM1 (40.9) and 3 LMx
(6.8). There was a non-significant trend concerning the recurrence rate when
LM0 (n¼ 23) lesions were compared with LM1/LMx (n¼ 21): 0% vs. 14.8%
at 3 years; p¼ 0.06.
Main characteristics of the resected lesions by procedure
ESD en bloc KAR p-KAR p
Mean tumor size, mm;
median (range)
28 (11–50) 20 (11–65) 42.1 (17–100) 0.002
Length of procedure, min;
median (range)
225 (62–340) 175 (60–300) 270 (75–400) 0.11
Rectal location; n (%) 22 (68.7) 5 (41.6) 21 (67.7) 0.38
Vienna category 4;
n (%)
23 (71.8) 6 (50) 20 (64.5) 0.66
Follow up - months;
median (range)
16.3 (2.6–62.7) 16.9 (8.0–91.3) 13.8 (1.1–44.6) 0.59
Conclusion: ESD R0 resections were 9 times greater than that of KAR on an ESD
‘‘intention-to-treat’’ basis. R0 resections were associated with lower recurrence
rates in comparison with R1/Rx resections. LM involvement increased the recur-
rence rate but without a statistical significance when it was the only pathological
risk factor for recurrence and the specimen was resected en bloc.
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Introduction: Laterally spreading tumors (LST) are important precursors of col-
orectal cancer (CRC)1. The endoscopic characteristics of the LSTs, such as size
and location, appear to correlate with the histological findings2,3, which is an
essential data for the decision of the best therapeutic procedure to be carried
out4,5.
Aims & Methods: To determine the association between size, location and the
histological characteristics of colorectal LSTs by reviewing of the colonoscopy
and histopathological reports of the LSTs endoscopically removed between
October 2013 and June 2015 at the digestive endoscopy department of a tertiary
hospital. The Vienna revised classification was used for the adenomatous
lesions6, and the World Health Organization (WHO) classification for the
‘‘sessile serrated adenomas’’ (SSA)7,8. The regions of the colon were referred to
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as either ‘‘proximal’’ or ‘‘distal’’ colon. Thereafter the division into six anatomi-
cal segments was considered (cecum, ascending, transversal, descending, sigmoid
and rectum).
Results: A total of 218 LSTs were included in this study. Most patients (59.4%)
were female. The mean age was 66.1 years, and the average size of the LSTs
included was 1.69 cm. The proximal colon was the most common site (73.4%) of
occurrence of the LSTs, with 34% being at the ascending colon. The most
common histological type was the low grade dysplasia adenoma (Vienna 3),
followed by the SSA without dysplasia with 21.6%. There was significant corre-
lation between size and histology (p5 0.005), where the adenomatous lesions
were found to be larger than the other categories. The SSAs, however, did not
show this association. We identified association between location and histologi-
cal type (p5 0.005): the adenomas with low grade dysplasia were most prevalent
in the proximal colon. However, when the subdivision of the colon into anato-
mical segments was considered, the SSA without dysplasia was the most common
type at the ascending colon.
Conclusion: There is association between the size and the histological character-
istics of colorectal LSTs. Adenomas with high grade dysplasia were found to be
larger than the other classifications. This association, however, is not observed
between SSAs lesions. There is association between location and histology; with
the SSAs without dysplasia being the predominant type at the ascending colon.
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Introduction: Endoscopic mucosal resection (EMR) and endoscopic submucosal
dissection (ESD) are well-established and effective techniques for the endoscopic
resection of mucosal neoplasms along the gastrointestinal (GI) tract. However,
these procedures are limited to superficial lesions. In the case of deeper ingrowth
into the gut wall as well as anatomic sites prone to perforation, the novel full-
thickness resection device (FTRD) opens a new dimension of possibilities for
endoscopic resection.
Aims & Methods: Sixty patients underwent therapeutic endoscopic full-thickness
resection (eFTR) at our institution. The procedures were carried out as follows:
First, the target lesion is marked with electrocautery and the endoscope is then
retracted. The full-thickness resection device (FTRD, Ovesco Endoscopy AG,
Tübingen), is fitted onto a therapeutic endoscope. The endoscope with the
FTRD is advanced to the previously marked lesion. Grasping forceps are
used to take hold of the target lesion and carefully pull it into the plastic cap
of the FTRD. Immediately after deployment of the OTSC, eFTR is per-
formed using the hyperthermic snare within the plastic cap. The full-thickness
specimen is retrieved and processed for histopathological examination. Safety,
learning curve, R0 resection rate and clinical outcome of all 60 interventions were
studied.
Results: EFTR was performed for the following indications: 1. Recurrent adeno-
mas (n¼ 22.37%) with a non-lifting sign after previous incomplete polypectomy
and adenomas with a primary non-lifting sign on saline injection (n¼ 2.3%). 2.
Non-lifting base after extensive piecemeal resection of a spreading adenoma
(n¼ 10.17%). 3. Polyps in a diverticulum (n¼ 2.3%). 4. Polyps the cecal appendix
(4.6.7%). 5. Submucosal lesions (n¼ 5.8.3%). 6. Early carcinoma (n¼ 7.12%). 7.
Follow-up resection of a malignant polyp (n¼ 6.10%) had. 8. EFTR over endoloop
resection (n¼ 2.3%). In 97% (58/60) of the interventions, the FTRD-mounted
endoscope reached the previously marked lesion and eFTR was performed (tech-
nical success). Full-thickness resection was achieved in 88% of the cases, with an
R0 resection on histological examination in 79%. The clinical success rate based
on follow-up histology was even higher (88%). The following adverse events
occurred: Appendicitis of the residual cecal appendix after eFTR of an appendi-
cular adenoma (1/58.2%). Minor bleeding at the eFTR site (2/58.3%). EFTR
performed accidently without proper prior deployment of the OTSC (1/58.2%).
There was no secondary perforation or eFTR-associated mortality.
Conclusion: In conclusion, after specific training, endoscopic full-thickness resec-
tion is a feasible, safe and promising resection technique. It allows complete
resection of lesions affecting layers of the gut wall beneath the mucosa, without
the risk of perforation. In the future, eFTR may become a valuable alternative to
a surgical approach in cases where endoscopic resection was previously thought
impossible.
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Introduction: Narrow Band Imaging (NBI) and chromoendoscopy with methy-
lene blue are enhancing techniques which are helpful in differentiating vascular
and pit patterns of colorectal neoplasms. Therefore, they have a key-role for the
adequate management of the lesions which might be candidates for endoscopic
resection.
Aims & Methods: The aim of our study was to measure the interobserver agree-
ment and the diagnostic accuracy in an endoscopy unit using methylene blue and
NBI for the evaluation of the pit and vascular pattern according to the Kudo,
Sano and NICE classifications of colo-rectal neoplasms, before and after an
image-based training program. We retrospectively collected consecutive endo-
scopic images (NBI and with methylene blue) of colo-rectal neoplasms from
the internal database. The image set was then evaluated by our gold standard
composed by two expert endoscopists. Their evaluation resulted confident with
histology reports in 88% of cases. The images set was then evaluated by the 9
endoscopists of the unit, before and after a 30-minutes image-based training
program on enhancing techniques and surface colorectal patterns. NBI and
colonic neoplasms’ surface and vascular patterns. Interobserver agreement was
calculated using the kappa statistic by Cohen. By using the gold standard evalua-
tion as criterion standard, the accuracy of colo-rectal neoplasms’ evaluation
before and after the training was also calculated using the McNemar test. A
value of p5 0.05 was considered statistically significative.
Results: A total of 30 images were obtained (see Table). Before the training
process, the interobserver agreement was minimal for Kudo (0.10 0.03) and
Sano (0.12 0.04), and poor for the NICE classification (0.24 0.05).
Diagnostic accuracy was 0.33 0.07, 0.54 0.12 and 0.60 0.10 for Kudo,
Sano and NICE classifications, respectively. After the image-based training pro-
gram, interobserver agreement moved to moderate for the Kudo classification
(p5 0.0001) and to good for Sano and NICE classifications (p5 0.0001).
Diagnostic accuracy increased significantly, too, with values of 0.60 0.05,
0.76 0.05, 0.80 0.05 for Kudo, Sano and NICE classifications, respectively
(p5 0.0001).
Classification Type N
Kudo I 0
II 2
III l 1
III s 6
IV 12
V i 5
V n 4
SANO I 2
II 19
III a 5
III b 4
NICE I 2
II 19
III 9
Conclusion: To the best of our knowledge, we present the first study on the ability
of an image-based training program in increasing the interobserver agreement
and diagnostic accuracy in differentiating pit and vascular patterns of colo-rectal
neoplasms using all the available endoscopic classifications (Kudo, Sano and
NICE classifications). Such training seems mandatory for endoscopists using
enhancing techniques especially when advanced lesions are planned to be treated
endoscopically.
Disclosure of Interest: All authors have declared no conflicts of interest.
A230 United European Gastroenterology Journal 5(5S)
References
1. Higashi R et al. Diagnostic accuracy of narrow-band imaging and pit pattern
analysis significantly improved for less-experienced endoscopists after an
expanded training program. Gastrointestinal endoscopy 2010; 72, 127–135
2. Ignjatovic A et al. Development and validation of a training module on the
use of narrow-band imaging in differentiation of small adenomas from
hyperplastic colorectal polyps. Gastrointestinal endoscopy 2011; 73, 128–133
3. McKill S et al. Endoscopists can sustain high performance for the optical
diagnosis of colorectal polyps following standardized and continued training.
Endoscopy 2015; 47: 200–206
4. Sikong Y et al. Effectiveness of systematic training in the application of
narrow-band imaging international colorectal endoscopic (NICE) classifica-
tion for optical diagnosis of colorectal polyps: experience from a single center
in China. Digestive Endoscopy 2016; 28: 583–591
P0204 YIELD OF 2ND SURVEILLANCE COLONOSCOPY IN
‘‘INTERMEDIATE RISK’’ PATIENTS. COULD SURVEILLANCE
INTERVALS BE REFINED?
M. Balakrishnan, B. Adeoti, S. Cerys, S. Catnach, A. King, B. Macfarlane,
J. Landy
Gastroenterology, West Hertfordshire Hospitals NHS Trust, Watford/United
Kingdom
Contact E-mail Address: jonathan.landy@whht.nhs.uk
Introduction: Data regarding the yield of 2nd surveillance colonoscopy after
index procedure findings of advanced colonic neoplasia (ACN) are limited.
The yield of ACN at 2nd surveillance is associated with high risk index or 1st
surveillance findings (1). However, previous studies are heterogenous and defini-
tions of ACN include characteristics of both "intermediate" (IR, 43 adenomas
or any adenoma 410mm) and "high risk" groups (HR, 45 adenomas or 43
adenomas with at least 1 410mm) as defined by BSG guidelines.
Aims & Methods: We aimed to evaluate the differences in yield of advanced
colonic neoplasia at 2nd surveillance colonoscopy (S2) between ‘‘intermediate’’
and ‘‘high’’ risk patients at index colonoscopy in our unit. ACN was defined as
5 adenomas, any adenoma 1 cm, tubulovillous histology or high grade dys-
plasia, or cancer. Patients with HR or IR index procedures undertaken by 3
experienced, accredited bowel cancer screening colonoscopists and at least 2
surveillance colonoscopies, were identified from our local database between
2008 and 2016. Findings at 1st and 2nd surveillance procedures were assessed
for the presence of ACN. Statistical analysis was undertaken using Graphpad
Prism 5 using Fisher’s exact test. All tests were two tailed and a p value of 0.05
was considered significant. ORs with a 95% CI were calculated for significant
findings.
Results: 218 patients meeting inclusion criteria were identified. 53% of patients
had IR index findings. The median time to S2 was 49 months (IQR 48–49m) for
HR index patients and 72m (IQR 70–73m) for IR index patients. 11% of all
patients had ACN at S2. 4% of IR patients v 18% of HR patients had ACN at
S2, OR 0.4 (95% CI 0.2–0.6). 3% of IR patients without ACN at S1 had ACN at
S2 v 15% of IR patients with ACN at S1 (ns). 11% of HR patients without ACN
at S1 v 37% with ACN at S1 had ACN at S2; OR 0.2 (95% CI 0.07–0.6).
Conclusion: Stratification of high-risk index findings into HR and IR groups as
per BSG guidelines differentiates a low-risk group at second surveillance colono-
scopy. The second surveillance interval for IR patients without ACN at first
surveillance might be increased as ACN is infrequently detected in this group.
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Introduction: Cold snare polypectomy (CSP) has been increasingly used in recent
years because post- polypectomy bleeding is less common with this technique
than with conventional polypectomy. According to the 2012 update of the
Japanese guideline for periprocedural management of antithrombotic medica-
tions issued by the Japan Gastroenterological Endoscopy Society, procedures
with a low risk of hemorrhage may be performed with a short interruption or
continuation of antithrombotic medication. However, the guideline does not
refer to periprocedural antithrombotic management for CSP.
Aims & Methods: The objective of this study was to determine the safety of CSP
in patients on antithrombotic medication. The subjects were patients who under-
went CSP at this hospital between April 2014 and March 2016. Post-CSP bleed-
ing rates were examined in relation to the use of antithrombotic medication. CSP
was indicated for non-pedunculated polyps smaller than 10mm, excluding lesions
with submucosal invasion and suspected of being cancerous at the preprocedural
diagnostic evaluation.
Results: CSP was performed to remove 2466 polyps in 1003 patients; cancerous
lesions accounted for 0.2% of them, but all had negative margins. There were 549
polyps (22.3%) in 186 patients who had been taking antithrombotic medication
before CSP (antithrombotic group), and 1917 (77.7%) in 817 patients not taking
antithrombotic medication (non-antithrombotic group). In the antithrombotic
group, 106 patients with 283 polyps continued taking the antithrombotic medi-
cation; specifically, aspirin in 41 patients with 113 polyps, clopidogrel in 13
patients with 17 polyps, dual antiplatelet therapy (DAPT) in 13 patients with
18 polyps, antiplatelet agents other than clopidogrel in 17 patients with 68
polyps, anticoagulant agents in 20 patients with 56 polyps, and antiplatelet
plus anticoagulant combination therapy in 2 patients with 11 polyps. Heparin
bridging was used in 13 patients with 38 polyps. Post-CSP bleeding occurred in
0.54% (3/549) of the interventions in the antithrombotic group and in 0.10% (2/
1917) of those in the non-antithrombotic group, showing no significant difference
(p¼ 0.08). Endoscopic hemostasis was successful in all cases of bleeding, without
requiring blood transfusion. As for the 3 cases of post-CSP bleeding in the
antithrombotic group, the specific antithrombotic medication being used was
aspirin in 1 patient with 1 polyp (0.88%, 1/113), and aspirin and clopidogrel a
patient with 2 polyps (11.1%, 2/18). No post-CSP bleeding occurred in patients
on other antiplatelet or anticoagulant agents, or on heparin bridging. Clipping
after CSP was more likely used in the antithrombotic group (i.e., 13.5% vs. 4.6%;
p5 0.01). No significant difference in post-CSP bleeding rate was observed
between lesions with and without clipping (0% with clipping vs. 0.34% without
clipping; p¼ 0.55)
Conclusion: CSP is a safe procedure even in patients on antithrombotic medica-
tion. The risk of bleeding after CSP was not high compared with that after biopsy
in patients on antithrombotic medication (post-procedural bleeding rate,
0.090.61%), suggesting that CSP can be virtually categorized as a procedure
with a low risk for hemorrhage in the guideline for periprocedural antithrombotic
management.
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Introduction: Diminutive polyps are a common finding among surveillance colo-
noscopies without having high prevalence of advanced histology, making their
standardized removal cost-, time- and risk-intensive. Based on these considera-
tions, the American Society of Gastrointestinal Endoscopy (ASGE) proposed the
so called PIVI statement, in which diagnostic thresholds are defined that new
technologies used for the real-time assessment of colorectal polyp histology
should meet. Optical enhancement (OE) is a novel endoscopic pre-processing
optical filter technology, in which the spectrum of the emitted wavelengths is
reduced, thereby leading to enhanced visualization of the mucosal and vascular
pattern.
Aims & Methods: In this study we aimed to assess whether OE can accurately
predict the histology of diminutive colorectal polyps according to the ASGE
PIVI criteria. A total of 106 colorectal polyps from 49 patients undergoing
diagnostic or surveillance colonoscopy were included. The in vivo histology pre-
diction using OE was compared to results of histopathology as a reference
standard.
Results: The overall accuracy of OE for real-time prediction of polyp histology
was 94.3% with a sensitivity, specificity, positive (PPV) and negative prediction
value (NPV) of 100%, 95.3%, 85.4% and 100%, respectively. When including
only high confidence (HC) predictions, the accuracy of OE increased to 96.5%.
Sensitivity, specificity, PPV and NPV were 100%, 94.5%, 91.2% and 100%,
respectively. In distal colorectal polyps the accuracy was 93.3% with sensitivity,
specificity, PPV and NPV being 100%, 91.3%, 80% and 100%, respectively. The
post-polypectomy colonoscopy surveillance intervals were predicted correctly in
90% of patients with OE.
Conclusion: Optical enhancement allows to accurately predict the histology of
diminutive colorectal polyps in vivo in real-time and meets the PIVI thresholds
for resecting and discarding diminutive polyps without histological assessment
and for leaving distal diminutive colorectal polyps in place. Hence, optical
enhancement can potentially reduce time, risk and costs associated with removal
and histopathological assessment of diminutive polyps.
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Introduction: Blue Laser Imaging (BLI) is a new image-enhanced endoscopic
technique, meant, in association with magnification endoscopy, to help differen-
tiating between neoplastic and non-neoplastic colorectal polyps. A variety of
endoscopic classifications have been developed to guide optical diagnosis of
colorectal polyps. The aim of our study was to evaluate NICE, WASP and
Sano classifications for the optical diagnosis of colorectal polyps using Blue
Laser Imaging and magnification.
Aims & Methods: Between May 2014 and December 2015, 181 colorectal polyps
in 65 patients were imaged and resected in our single center study. Each polyp
was evaluated using white light endoscopy, BLI with and without magnification.
An independant expert reviewed the pictures and the videos of the polyps and
staged them using NICE, Sano and WASP classifications: his conclusions were
compared with the actual histology of the polyps. Diagnostic performances of
BLI and magnification were calculated with each endoscopic classification.
Results: 181 polyps were studied, among which 125 adenomas, 24 sessile serrated
adenomas/polyps, 25 hyperplastic polyps, 2 adenocarcinomas and 11 normal
colorectal mucosal samples. The median polyp size was 7mm. Overall, the
NICE, Sano and WASP classifications were comparable in terms of diagnostic
performances for the optical diagnosis of colorectal adenomas (p¼ 0.7).
However, the WASP classification provided the best results with a sensitivity,
specificity, positive and negative predictive value, and diagnostic accuracy for the
diagnosis of adenoma of 0.93 (95% CI 0.86 to 0.97), 0.80 (95% CI 0.66 to 0.91),
0.93, 0.80 and 0.9. In the rectosigmoid, negative predictive values for the diag-
nosis of adenoma were 0.77; 0.91; and 1.0 using NICE, Sano and WASP
classifications.
Conclusion: Our work suggests that BLI with magnification is a promising tech-
nique for the optical diagnosis of colorectal polyps with a diagnostic accuracy of
86–90%. Our study did not establish significant difference between the three
classifications. However, the ASGE criteria for the implementation of the
"resect and discard" strategy were met for the classifications of Sano and
WASP with a negative predictive value for the diagnosis of adenoma beyond
90% in the rectosigmoid.
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Introduction: Colonoscopy is difficult procedure, largely due to unpredictable
looping during insertion. If the endoscopist is able to see the colonoscope on
the image display, fewer attempts are needed to straighten the shaft of the scope.
A prototype Fiber Brag Grating(FBG) scope guided endoscopy provides a facil-
ity for continuous viewing on a monitor of the position of the colonoscope during
examination.
Aims & Methods: The aim of this study was to evaluate the accuracy and feasi-
bility of the innovative 3D Colonoscope using FBG. In the first part of the study,
the FBG sensor was inserted into the working channel of a routine colonoscope
in the first 70 cm from the tip of the scope. Then, the scope was placed in front of
the monitor to confirm movement of the scope in all three dimensions. We
evaluated loop formation such as N loop, alpha loop, reverse alpha loop, with
the 3D imaging monitor. In the second part of the study, 5 patients underwent
colonoscopy with a FBG sensor, the colonoscope can be displayed in anteropos-
terior or lateral view, or in both positions together. Fluoroscopy was used in all
investigations for comparison.
Results: In the first part of the study, the results showed that the shape sensor was
reliable at a maximum bending curvature of 80mm-1. The average tip position
error was 1.722 1.678mm, which corresponds to 1.50 1.46% of the total
length of the sensor. Scope movement and loops were detected correctly in all
cases through the monitor. The prototype used in the second part of the study
showed a high correlation and little discrepancy with the comparative findings at
fluoroscopy.
Conclusion: Scope-guided endoscopy using FBG sensor can be successfully used
to display colonoscope configuration. This flexible, thin and almost weightless
shape sensor would be a novel technique for identification of colonoscope shape.
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Introduction: Irreversible electroporation (IRE) is a promising novel technique
for tumor ablation using energy current pulses. IRE can effectively remove
unwanted cells without thermally damaging surrounding tissues. We used multi-
photon microscopy for evaluated the response of cancer cell to IRE ablation and
found apoptotic process after applying IRE.
Aims & Methods: By using multi-photon (MP) probes, that is ABI-Nu for
nucleus and PMT for mitochondria, we were focusing on these two vital intra-
cellular organelles for examining the real-time phenomenon of IRE-induced
apoptosis. The study was conducted in three stages. Colon cancer cell lines
and normal colon mucosa and colon neoplasm tissues obtained during colono-
scopic biopsy from 10 patients were stained with multi-photon (MP) probes that
is ABI-Nu for nucleus and PMT for mitochondria. We evaluated the feasibility
of using multiphoton microscopy (MPM) to observe IRE response. First, the
IRE responses of colon cancer cell lines were compared before and after IRE.
Electrical pulses were administered with a Harvard apparatus, and the changes in
the intensity of the nucleus and mitochondria were observed with time. Second,
the IRE response of normal colon and colon cancer tissue obtained from same
patient were evaluated before and after IRE same with previous method. Also,
the 3-D images of the tissues co-labelled with ABI-Nu and PMT were recon-
structed. Third, to assess apoptosis, colon cancer cells were stained with the
fluorescent dye Annexin V or propidium iodide (PI) after applying electropora-
tion at the same energy used earlier. Also, in order to determine whether IRE
induce apoptosis, membrane blebbing of colon cancer cell lines were examined
after apply IRE.
Results: MPM images of cancer cells stained with MP probes revealed that ABI-
Nu stained quicker after IRE ablation. At the tissue level, nuclear staining was
present earlier and was more prominent after IRE was applied. In addition, IRE
had a relatively stronger effect on cancer than normal. We obtained MPM
images for each tissue slice, including four MP images for every 150 sections at
a depth of 90–150 mm along the z-direction. Using the same electroporation
energy, staining was positive for Annexin V and PI, providing the evidence of
apoptosis. Also, blebs, which are distinctive of apoptotic cells were developed
after IRE in the colon cancer cell. However, bleb formation was not appeared in
the control group.
Conclusion:Here, we observed using MPM that nuclear staining occurred quickly
due to increased cell membrane permeability and bleb was formed after electric
pulse exposure. These results are expected to challenge the understanding of the
A232 United European Gastroenterology Journal 5(5S)
permeability process after IRE by providing the real-time images. Additionally,
MPM can replace other apoptosis assessment methods, including Annexin V-
FITC and PI staining. This MP probe protocol would dramatically increase the
accuracy of diagnostic techniques by providing in vivo cell images.
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Introduction: Endoscopic mucosal resection (EMR) is an established therapeutic
option for large (430mm) colonic polyps. We aimed to assess characteristics and
outcomes of this cohort. Primary outcomes consisted of rates, predictors and
durability of EMR success, whilst secondary outcomes included complications,
malignant risk, and conversion to surgery.
Aims & Methods: We prospectively identified patients referred for large polyp
EMR from a polyp multidisciplinary team meeting between August 2008–2016)
in a district general hospital with tertiary EMR expertise. Data on demographics,
polyp site, morphology, size, accessibility (SMSA), histology and follow-up
endoscopy were retrospectively collected. Binary logistic regression modelling
was performed using SPSS, with components comprising of year, individual
SMSA components, and histology. The Kaplan-Meier approach was used to
measure durability of EMR success.
Results: Large polyp EMR was performed in 91 patients out of 125 MDT refer-
rals (73%). Patients had a median age of 72 (interquartile range [IQR] 14.4), and
were predominantly male (60%). Polyps were sessile (46%), flat (49%) or ped-
unculated 4 (4%), with a median size of 40mm (IQR 20.5mm), and were left-
colonic in 81%. Bleeding occurred in 16.5%, all of whom achieved haemostasis.
The 30-day complication rate was 1.1% (delayed bleeding in 1 patient). 54 (59%)
were fully resected in one session, with overall EMR successful in 75 (81.5%)
after an average of 1.5 sessions. On multivariable analysis, significant predictors
of complete resection at first attempt (Table 1) included: increasing year, sessile
vs. flat morphology, and non-malignant histology. Malignant histology
(p5 0.001) predicted overall EMR failure, but not age, gender, year of EMR,
SMSA score, or concomitant argon plasma coagulation. Of the EMR failure
group, 11/16 (69%) underwent surgical resection, of which 7/11 (64%) harboured
adenocarcinoma. Of the EMR success group, 4/80 were malignant polyps with
R0 endoscopic resection. The overall malignant histology rate in this cohort was
11/91 (12%). In this cohort, the R0 EMR success rates was 4/11 (36%), with no
recurrence after 60 months of follow-up. The overall 12-month recurrence rates
following complete EMR was 1.5%, with no significant factors affecting EMR
durability identified.
Table 1: Predictors of complete resection on first EMR attempt. p-values derived
from bivariate regression, with bold values significant if 50.05. *Increase in OR
for each increase in year. **p-value 50.05 considered statistically significant.
Factor Odds Ratio
95% Confidence
Interval p-value
Year 1.41* 1.04–1.90 0.048**
Size (3–3.9 cm vs. 44.0 cm) 2.96 0.85–10.3 0.088
Site (left vs. right colon) 0.46 0.09–2.48 0.367
Access (easy vs. difficult) 1.39 0.38–5.14 0.619
Morphology (sessile vs. flat) 3.38 1.04–11.0 0.043**
Non-malignant histology 41.5 3.74–461 0.002**
Conclusion: Large polyp EMR is a safe and effective alternative to surgical
resection of large polyps. Endoscopist experience, polyp morphology, and
benign histology predict complete resection at index EMR. Further data are
required to evaluate the longer-term outcomes of malignant polyps.
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Introduction: Though numerous research has enabled decrease of the bowel pre-
paration solution volume, it is still a major complaint of patients preparing
colonoscopy. There have been studied that additional administration of laxatives
could lessen the amount of aqueous formula with prokinetic effect. Prucalopride
is a serotonin (5-HT4) receptor agonist which stimulate colonic mass movements
and provide main propulsive force for defecation.
Aims & Methods: The aim of this study is to compare 2-L PEG-Asc and 1-L
PEG-Asc plus prucalopride for quality of bowel cleansing while preparing for
colonoscopy and patient compliance. Two hundred patients were prospectively
enrolled. Patients referred for colonoscopy were divided into group A (the split-
dose 2-L PEG-Asc) and group B (1-L PEG-Ascþprucalopride) randomly.
During colonoscopy, each patient’s bowel preparation quality was evaluated
with The Boston Bowel Preparation Scale (BBPS) and Aronchick Preparation
Scale (APS). The tolerability and satisfaction of patients was determined based
on a questionnaire-based survey.
Results: One hundred patients received either 2-L PEG-Asc or 1-L PEG-Asc with
prucalopride. Regarding colon cleansing outcome (BPPS and APS), the 1-L
PEG-Asc with prucalopride group showed similar, but non-inferior results com-
pared to the 2-L PEG-Asc group on both BBPS (7.65 1.27 vs 7.52 1.40,
p¼ 0.586) and APS scales (93.3% vs 95%, p¼ 0.717). Tolerability was similar
for both 1-L PEG-Asc with prucalopride and 2-L PEG-Asc.
Conclusion: 1-L PEG-Asc plus prucalopride preparation showed comparable
result to traditional 2-L PEG-Asc preparation. 1-L PEG-Asc plus prucalopride
preparation method could be an alternative method for bowel preparation which
can relieve patient discomfort.
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Introduction: Endoscopic mucosal resection (EMR) is an effective and safe treat-
ment for large (20mm) laterally spreading colorectal lesions. Although colon
EMR has been established as a minimally invasive technique for treatment of
large colorectal lesions, risk of adenoma recurrence is the main limitation.
Current guidelines recommend first follow-up at 3–6 months; however, there
are no well-designed prospective-studies published establishing an optimal
system to ensure SC1 (first surveillance colonoscopy after initial exam) is sched-
uled and executed in the appropriate timeline. Inadequate or absent scheduling of
SC1 can have an impact on the detection of recurrent adenomas, increasing
potential patient morbidity, adding unnecessary costs and potentially leading
to repeated and avoidable procedures. The aim of this study was to conduct a
quality improvement initiative aimed at increasing compliance in SC1 by under-
standing the current scheduling process and developing strategies to standardize
our endoscopy center practices.
Aims & Methods: Single tertiary referral center quality improvement project
started in January 2017 and currently still in progress. We present here the
interim data. Consecutive patients who had undergone or would have EMR of
lesions 20mm were eligible for inclusion. The process of following-up patients
after EMR was divided at two levels: A dedicated team member generated a
monthly report identifying patients who underwent colon EMR using our endo-
scopy procedure documentation program. The appropriate timeline for SC1 for
each patient that underwent colonoscopy EMR was identified and orders and
scheduling for the colonoscopy follow-up were carried out. Evaluation of follow-
up: A dedicated team member reviewed the status of patients who underwent
colon EMR six months prior to the start of the QI study. If patient did not show
up on their scheduled follow-up, phone calls were placed to contact the patients.
Patients who had followed-up with their local gastroenterologists were recorded.
All the data in intervention group was compared retrospectively with noninter-
vention group who were not tracked through quality improvement process.
Mean follow-up time and follow-up rate (%) at 6–9 months at SC1 after index
EMR was compared between the two groups.
Results: Per-protocol 25 patients included in intervention group were compared
to 60 patients in the nonintervention group. Mean age was 62 years in interven-
tion group and 66 years in non-intervention group (p¼ 0.04). There were no
differences in distribution in size of lesion, gender, EMR site, and polyp histology
between two groups (Table 1). The mean follow-up time in intervention group
was 8.2 months (2.6) and nonintervention group was 10.4 months (9.1). There
was increase in rate of 6–9 months follow-up in intervention group when com-
pared to the nonintervention group (88%, 95% CI [0.80%-0.94%] vs 64%, 95%
CI [0.54%-0.73%]) (Table 1).
Table 1: Demographic, clinical characteristics, follow up rates
Variables
Intervention
group (n¼ 25)
Non-intervention
group (n¼ 60)
Age, Mean (SD) 62 (8.7) 66 (10.5)
Sex, Male (%) 38% (10) 58% (35)
Size of polyp(mm),
Mean (SD)
35 (18) 30 (12)
(continued)
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Table 1 Continued
Variables
Intervention
group (n¼ 25)
Non-intervention
group (n¼ 60)
Site of polyp resection
Rectum 8% (2) 5% (3)
Sigmoid 4% (1) 7% (4)
Recto-sigmoid 0% 2% (1)
Descending colon 0% 3% (2)
Transverse colon 15% (4) 12%(7)
Hepatic flexure 15% (4) 8% (5)
Ascending colon 23% (6) 37%(22)
Mid ascending colon 0% 5% (3)
Cecum 23% (6) 13%(8)
Cecum with appendicle orifice 8% (2) 0%
Ileocecal valve 4% (1) 8% (5)
Polyp histology
Sessile serrated adenoma 23% (6) 30% (18)
Tubular adenoma 35% (9) 35% (21)
Tubular adenoma with HGD 8% (2) 2% (1)
Tubulovillous adenoma 31% (8) 32% (19)
Tubulovillous adenoma
with HGD
4% (1) 0%
Adenocarcinoma 0% 2% (1)
Follow-up Rates
Median(range) 7.3 months
(6–15 months)
7.3 months
(4–66 months)
Mean (SD) 8.2 months (2.6) 10.4 (9.1)
Colon EMR follow-up rate
of 6–9 months, % (n)
88%, 95%
CI [0.8%–0.94%],
(22)
64%, 95%
CI [0.54%–0.73%],
(35)
Conclusion: These preliminary results suggest significant improvement in SC1
compliance with our intervention. We believe that continuing these efforts and
further refining the intervention process, requiring less personnel resources, may
be helpful to improve the follow-up time until 3–6 months interval while also
enduring as a sustainable change for our practice.
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Introduction: Missed adenomas in the right colon are of major concern for inter-
val colon cancer (CRC) development. There is evidence from cohort and rando-
mized controlled studies (RCTs) that a second examination of the right colon –
either in direct view or in retroflexion- increases the diagnostic yield of the
procedure. However, data are not accepted unanimously.
Aims & Methods: The aim of this meta-analysis was to examine the effect of a
second, back-to-back mucosa inspection on the diagnostic yield of colonoscopy
in the cecum and the ascending colon. We performed literature searches in
MEDLINE to identify studies evaluating the effect of a second pass endoscopic
examination on adenoma detection rate (ADR) and advanced ADR (AADR) in
the right colon. Study outcomes effect sizes were calculated using RevMan 5.3
software fixed or random effect model, as appropriate, and they are presented as
OR[95%CI]. Heterogeneity was measured using the I2 statistics. Publication bias
was assessed by Funnel plots inspection and the quality of the meta-analyzed
studies was assessed using the Jadad criteria.
Results:We identified 8 studies (5 cohort and 3 RCT, with 9 sets of data and 5639
subjects – mixed CRC screening/surveillance and symptomatic population) that
reported on the aforementioned outcomes. Two sets of data examined the yield
of the second direct view as compared to that of a single inspection, one set
examined the cumulative yield of two passes compared to that of an extended
(timely) inspection of the right colon and six sets of data evaluated the yield of
the second examination of the right colon with scope retroflexion compared to
that of the single direct view. They were moderate risk of bias studies; suspicion
for publication bias was detected in the direct view arm of the analysis. As
compared to a single pass, the second right colon inspection significantly
increased ADR (1.31 [1.15–1.49], I2¼ 49%). The effect size of ADR was
higher in the direct view second pass arm (1.73 [1.41–2.12], I2¼ 0%) as compared
to the retroflexion arm (1.17 [1.06–1.29, I2¼ 0%). Sensitivity analysis with
removal of one study each time did not identify a single study responsible for
the detected heterogeneity. Our analysis did not show significant increase in right
colon AADR (1.5 [0.76–1.56], I2¼ 0%) after the second exam.
Conclusion: In comparison to a single pass, the second inspection of the right
colon either in direct view or with scope retroflection increases ADR in this colon
segment. However, results should be interpreted cautiously due to the small
number of meta-analyzed studies with mixed indications populations, and the
detected moderate levels of heterogeneity and risk for bias.
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Introduction: Endoscopic treatment of malignant colorectal polyps is often chal-
lenging, especially for early rectal cancer (ERC) localized close to the dentate
line. Conversely, the surgical approach may result in temporary or definitive
stoma and in frequent post-surgical complications [1–2]. Endoscopic Full
Thickness resection (EFTR) is a novel technique that, besides having other indi-
cations, appears to be promising for wall-thickness excision of intestinal T1
carcinoma following incomplete endoscopic resection [3–4].
Aims & Methods: Follow-up data on patients treated with this device are scarce,
particularly for ERC. We enrolled six consecutive patients with T1-ERC. They
were treated with the EFTR, after appropriate staging, and their long-term out-
comes were evaluated based on a detailed clinical and instrumental assessment.
Results: The endoscopic en bloc full-thickness resection was technically feasible in
all patients. The histopathologic analysis showed a complete endoscopic resec-
tion in all cases, and a full-thickness excision in four. Neither complication, nor
disease recurrence was observed during the one-year follow-up performed.
Conclusion: EFTR is a promising tool for treating ERC featuring a residual risk
of disease recurrence after incomplete endoscopic mucosal resection in patients
unfit for surgery or refusing surgical approach.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Colorectal Endoscopic Submucosal Dissection (CR-ESD) is tech-
nically difficult, time-consuming, and has a long learning curve for Western
endoscopists. Several factors related with greater difficulty while performing
this technique have been described. Generally, during the learning curve phase,
we select simple lessions while initiating the technique.
Aims & Methods: Our goal was to assess those factors associated with greater
difficulty during untutored DSE-CR without prior selection of less difficult les-
sions. All patients who attended the complex colorectal polyps consultation were
included consecutively. No polyps regardless of their size, morphology, location
or any characteristic of greater technical difficulty were ruled out. All CR-ESDs
were performed by an endoscopist with previous animal model experience. The
demographic and clinical characteristics of the patient, the morphology of the
lesion and factors related to the technique were collected. A complex technique
Abstract No:P0215.
Table 1: T1 early rectal cancer features, indications to endoscopic full-thickness resection, and follow-up.
# Rectal site Endoscopic features
Positive Ueno’s criteria
after en bloc EMR Indication to EFTR Pre-EFTR staging Histology following EFTR Follow-up after EFTR
1 Distal 30mm, Is, Kudo V,
negative lifting sign
Tumor budding, exci-
sion margin,
Kikuchi’s level,
width of submuco-
sal invasion
unfit for surgery (ASA
IV)
T0, N0 R0, full-thickness resection; histology
negative for residual disease
Endoscopy, EUS, and
CT negative at 3
and 12 months;
Endoscopy and
EUS negative at 18
months.
2 Distal 20mm, I sp, Kudo
IIIL, negative lift-
ing sign
Tumor budding,
Haggitt’s level,
excision margin,
depth and width of
submucosal
invasion
refusing surgery (ASA
II)
T0, N0 R0, full-thickness resection; histology
negative for residual disease
Endoscopy, EUS and
CT negative at 6
and 12 months
3 Distal 18mm, I sp, Kudo
IIIL, negative lift-
ing sign
Haggitt’s level, excision
margin, depth and
widht of submuco-
sal invasion
refusing surgery (ASA
III)
T0, N0 R0, complete submucosal resection
but no muscolaris propria layer
in the specimen; histology nega-
tive for residual disease
Endoscopy, EUS and
CT negative at 6
and 12 months
4 Proximal 0.6mm, I s, Kudo V,
negative lifting sign
Haggitt’s level, excision
margin
unfit for surgery (ASA
IV)
T1, N0 R0, full-thickness resection; histology
positive for adenocarcinoma
Endoscopy, EUS and
CT negative at 6
month. Patient
died for severe car-
diac disease at 8
follow-up month.
5 Distal 0.7mm, I s, Kudo IV,
negative lifting sign
Low tumor differentia-
tion grade, excision
margin
unfit for surgery (ASA
IV)
T0, N0 R0, full-thickness resection; histology
negative for residual disease
Endoscopy, EUS and
CT negative at 6
and 12 months
6 Distal 18mm, I s, Kudo IIIL,
negative lifting sign
Tumor budding, exci-
sion margin, width
of submucosal
invasion
refusing surgery (ASA
III)
T0, N0 R0, complete submucosal resection
but no muscolaris propria layer
in the specimen; histology nega-
tive for residual disease
Endoscopy, EUS and
CT negative at 6
and 12 months
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Complex(n¼ 27) No complex(n¼ 27) P Univ. Odds ratioUniv. PMultiv. Odds ratioMultiv.
SEX, n(%)
Male Female) 16 (59.2) 11 (40.8) 49 (60.4) 32 (39.6) 0.910 0.95 (0.39–2.31)
AGE, n(%)
570 years old 70 years old 17 (63) 10 (37) 51 (63) 30 (37) 1 1.00 (0.41–2.46)
SMOKER, n(%)
No Yes Former smoker 12 (44.4)
4 (14.8)
11 (40.8)
30 (37)
18 (22.2)
33 (40.8)
0,
362 0,
708
1 1,
8 (0.50–6.43) 1,
2 (0.46–3.12)
ANTICOAGULANT/ANTIAGGREGANT/
COAGULATION DEFICIT, n(%)
No
Yes
22 (81.4)
5 (18.6)
61 (75.3)
20 (24.7)
0,
510
0,
70 (0.23–2.07)
Body Mass Index (obese), n(%)
530 30 22 (81.4) 5 (18.6) 72 (88.9) 9 (11.1) 0.510 1.82 (0.55–6.00)
Body Mass Index (overweight), n(%)
525 25 10 (37) 17 (63) 36 (44.4) 45 (55.6) 0.500 1.36 (0.56–3.33)
ANESTHETIC RISK, n(%)
Low (ASA I-II) High (ASA III) 18 (66.6) 9 (33.3) 59 (72.9) 22 (27.1) 0.539 1.34 (0.53–3.43)
PREVIOUS COLORECTAL SURGERY, n(%)
No Yes 25 (92.6) 2 (7.4) 68 (84.0) 13 (16.0) 0.261 0.418 (0.09–1.99)
CO2 insufflation, n(%)
No Yes 15 (55.6) 12 (44.4) 16 (19.8) 65 (80.2) 50.001 5.08 (1.99–12.94) 0.030 6.34 (1.20–33.57)
Size, n(%)
535mm 35mm 10 (37) 17 (63) 59 (72.8) 22 (27.2) 0.001 4.56 (1.81–11.46) 0.025 5.74 (1.25–26.33)
LOCATION, n(%)
Right Colon Left Colon Rectum 17 (63) 5 (18.5) 5 (18.5) 55 (67.9)17 (21) 9 (11.1) 0.932 0.342 1 1.05 (0.3–3.2) 0.56 (0.1–1.8)
MORPHOLOGY, n(%)
LST-G LST-NG No LST 16 (59.3)9 (33.3)2 (7.4) 36 (44.4)43 (53.1)2 (2.5) 0.108 0.587 1 2.12 (0.8–5.3) 0.44 (0.06–3.4)
SEVERE FIBROSIS, n(%)
No Si 14 (51.9) 13 (48.1) 75 (92.6) 6 (7.4) 50.001 11.61 (3.78–35.69) 0.039 7.42 (1.11–49.65)
FATTY TISSUE, n(%)
No Si 11 (40.7) 16 (59.3) 63 (77.8) 18 (22.2) 50.001 5.09 (2.01–12.90) 0.035 5.78 (1.13–29.53)
Time dissection Mean, min (range) 180 (80–280) 131.9 (45–290) not applicable
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was defined as that dissection that is not done en block and/or had
complications.
Results: 112 lesions were selected, discarding 4 due to deep invasion. We evalu-
ated in this study 108 DSE-CR, 27 (25%) of which were compatible with our
definition of "complex’’ ESD. In Table 1 you can see the characteristics of each
group. Univariate analysis showed that variables such as size over 35mm [63%
vs. 27.2%; OR 4.56 (95% CI: 1.81–11.46); P¼ 0.001], absence of CO2 [55.6% vs.
19.8%; OR 5.08 (95% CI: 1.99–12.94); P5 0.001], presence of serious fibrosis in
the submucosa [48.1% vs. 7.4%; OR 11.61 (95% CI: 3.78–35.69); P5 0.001] and
presence of fatty tissue in the submucosa [59.3% vs. 22.2%; OR 5.09 (95% CI:
2.01–12.90); P5 0.001] were related to a "complex" ESD. Finally, in the multi-
variate analysis, those variables were associated with a complex technique with
an Odds Ratio of 7.42 for severe fibrosis (p¼ 0.039), 6.34 for non-CO2 insuffla-
tion (p¼ 0.030), 5.78 in the presence of fatty tissue in the submucosa (p¼ 0.035)
and 5.74 in size greater than 35mm (p¼ 0.025). There was no relation with the
complexity of the technique the demographic-clinical characteristics of the
patient, nor the location-morphology of the lesions. The duration of the techni-
que was an average of 48 minutes longer in cases of a complex technique.
Conclusion: In our series the difficulty of CR-ESD was associated with factors
described in other studies such as the size, the non-insufflation of CO2 and the
presence of severe fibrosis in the submucosa. Our results describe the presence of
fatty tissue in the submucosa as a new predictor of technical difficulty. In our
study, we did not select the location to begin the technique, and in our learning
curve we did not find significant differences in the performance of ESD in the
proximal colon, distal or rectum.
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Introduction: Endoscopic mucosal resection (EMR) of large (20mm) laterally
spreading colonic lesions (LSL) is safe, effective and superior to surgery. This
advantage is based on a day stay model of care; however, the most common
adverse event is abdominal pain and this is a major impediment to its efficiency.
No prospective data exist on the optimal selection of analgesics, the necessary
recovery period or the triggers that should alert the practitioner to a more serious
trajectory and the need for escalation of care.
Aims & Methods: We aimed to characterise potential predictors for PP and
develop a simple and effective management algorithm for patients with PP
based on the need for analgesics in recovery. Data on consecutive patients
with a LSL referred for EMR at a single, tertiary referral centre were included.
Patient and lesion characteristics and peri-procedural data were prospectively
collected. Standard post EMR care included 2 hours in first stage recovery
followed by 1 hour in 2nd stage recovery where clear fluids were given and
discharge after if the patients were well. Persistent post-procedural pain (PP)
was graded from 0 to 10 using a Visual Analogue Scale (VAS). If PP occurred
45 minutes, 1 gram of acetaminophen was administered parenterally and out-
comes were monitored. If pain settled the patient was transferred to second stage
recovery after medical review. PP 430 minutes lead to clinical review and
upgrade of analgesics to fentanyl, with a starting dose of 25 micrograms (mcg)
up to a maximum of 100mcg. Investigations, admission and interventions for PP
were recorded.
Results: 166 patients with 166 lesions were included between February and April
2017. 34/166 (20.5%) of patients had PP requiring intervention (median VAS 5,
IQR 3–6). 27/34 (79.4%) had resolution of pain with acetaminophen only and
were ultimately discharged without sequelae. 7/34 patients (20.6%) required fen-
tanyl (25 mcg of fentanyl in 3 patients, 50mcg in 1.75mcg in 1 and 100mcg in 2).
A CT scan was performed in the 2 patients requiring 100mcg of fentanyl, show-
ing serositis in 1 patient and no abnormalities in the other. Both patients were
admitted and managed conservatively (discharge day 6 and 2 respectively). The
other 5 patients were discharged home on the same day after extended recovery.
Predictors of PP were lesion size 45mm (P¼ .003), Paris classification
(P¼ .022) and intra-procedural bleeding requiring endoscopic control (IPB,
P¼ .042). Lesion size 45mm and IPB were also independent variables on multi-
variate analysis with an odds ratio of 2.8 (95% confidence interval 1.3–6.3,
p¼ .012) and 2.3 (95% confidence interval 1.0–5.2, p¼ .042 respectively (Table
1).
Conclusion: Pain after EMR occurs in 20% of patients and is associated with
larger lesion size and intraprocedural bleeding requiring endoscopic control in a
multivariate analysis. If pain subsides after parenteral acetaminophen and does
not recur the patient can be safely and confidently discharged to the step down
recovery area and after medical review allowed to leave hospital. PP despite
parenteral acetaminophen heralds a more serious scenario and imaging should
be considered when stronger analgesics do not relieve the pain.
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Introduction: Some high-quality, large-scale cohort studies proved removals of
colorectal neoplasms achieved prevention of colorectal cancer incidence and
deaths. We introduced a strategy of removing all neoplastic polyps in single
session colonoscopic examinations using cold polypectomy was started.
Aims & Methods: The aim of this retrospective study was to investigate about
achievement of colorectal polyp remove in our clinical practice setting. Scheduled
colonoscopic examinations for 40–79 years outpatients who had at least one
colorectal neoplasm between January 2015 and December 2016 were collected
from our endoscopic data base. Exclusion criteria were as follows; patients who
had colorectal neoplasm larger than 20mm, pre-examination of colorectal sur-
gery or endoscopic submucosal dissection, inflammatory bowel disease, familial
adenomatous polyposis, uncontrolled malignancies, by trainee endoscopists
(5500 colonoscopies), no agreements of polyp removal, and/or patients with
continuation of anti-thrombotic agents. Outcome measurements were polyp
removal rate (per-lesion analysis), complete polyp removal rate (per-patient ana-
lysis) and complications. Proportions of each endoscopic removal method
according to size were also analyzed.
Results: A total of 2527 patients (mean age 66.8 y, 799 females) with 8203 color-
ectal neoplasms (CRNs) (7675 adenomas, 423 serrated polyps and 105 Tis and T1
cancers) who met inclusion and exclusion criteria were analyzed. Mean number
of CRNs per patients was 3.2. Mean size was 4.7 (2.9) mm. Polyp removal rate
(per-lesion) and complete polyp removal rate (per-patient) were 97.0% (7955/
8203) and 94.7% (2394/2527), respectively. Post-polypectomy bleeding requiring
endoscopic hemostasis occurred in 7 patients (0.27%) and all origins of bleeding
were endoscopic mucosal resection (EMR) and hot snare polypectomy (HSP).
Post electrocoagulation syndrome requiring admission was occurred in one
patient (0.04%) after pre-cutting EMR. Mean procedure time was 27.4 (13.3)
min. Proportions of each endoscopic removal method according to size were
presented in an attached table. In 1–4 mm CRNs, both cold snare polypectomy
(CSP) (51.8%) and cold forceps polypectomy (CFP) (45.8%) for 1–4mm CRNs
were main methods. In 5–9m CRNs, CSP was a leading method (73.8%) and
EMR was the second one (24.1%). CRNs larger than 10mm were almost
removed by EMR (94.4%).
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Table 1.: Baseline and lesion characteristics. Comparison between the patients with and without pain post endoscopic mucosal resection of a large (20mm) laterally
spreading lesion. SD: standard deviation, IQR: interquartile range, *left colon: distal to hepatic flexure, #using thermal therapy.
No pain (n¼ 132) Pain (n¼ 34) P-value Multivariate
Baseline characteristics
Age (years, mean, SD) 69.2 (10.6) 69.6 (10.7) .944
Sex (%) Male Female 73 (55.3) 59 (44.7) 14 (41.2) 20 (58.8) .141
Lesion characteristics
Size (mm, %) 20–44mm 45mm 103 (78.0) 29 (22.0) 18 (52.9) 16 (47.1) .003 .012
Location (%) Left colon* Right colon 53 (40.2) 79 (59.8) 17 (50.0) 17 (50.0) .300
Paris classification (%) 0-Is 0-IIa 0-IIaþ Is Others 6 (4.5) 84 (63.6) 40 (30.3) 2 (1.5) 1 (2.9) 14 (41.2) 16 (47.1) 3 (8.8) .022
Procedural data
Submucosal fibrosis (%) 38 (28.8) 9 (26.5) .789
Intra-procedural bleeding requiring endoscopic control# (%) 59 (44.7) 23 (67.6) .017 0.042
Intra-procedural perforation (%) 6 (4.5%) 0 (0%) .348
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Proportions of each endoscopic removal method according to size
Size(mm) CFP CSP HSP EMR
1–4 (N¼ 5046) 45.8% 51.8% 0.5% 1.9%
5–9 (N¼ 2294) 0.6% 73.8% 1.5% 24.1%
10–20 (N¼ 612) 0% 4.9% 0.7% 94.4%
Conclusion: In our clinical practice setting, the polyp removal rates were satisfac-
tory level in single session colonoscopic examinations using cold polypectomy.
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Introduction: The transmural OTSC is used to achieve a full-thickness, serosa-to-
serosa apposition (emergency & elective cases) for closure of GI wall defects
(perforation, leak, fistula) with reported mean closure rates of 62–100% (range
0–100%), depending on the size of perforation, type and nature of lesion and the
endoscopists’ experience1–3. However, recto-urogenital fistula may arise from a
variety of etiologies and are mostly leaks or fistula of chronic nature, rarely acute
perforations with vital wound tissue. They may occur in Crohn’s disease, but can
also be a consequence of abdominal surgery, traumatic lesions or post-radiation
damage.
Aims & Methods: To further explore the role of the OTSC in this particular type
of fistula we analyzed own cases and 21 reports from the literature dealing with
any type of recto-urogenital fistula. In total, 25 patients. were identified with
closure of a recto-urogenital fistula using the OTSC, but there was considerable
heterogeneity, because of the fistula location (rectocutaneous n¼ 2, rectovaginal
n¼ 10, rectovesical n¼ 7, rectourethral n¼ 2, other rectal fistula n¼ 3).
Results: In most situations a previous interdisciplinary discussion was reported
before an OTSC attempt, or patients refused to undergo re-operation. However,
special characteristics of these leaks were reported to make more difficult the
OTSC procedure compared with other GI locations, e.g. the site of the fistula is
nearby located to L. dentata and anal sphincter, it includes a localization with
little space for endoscopic manipulation, fibrous and scarry tissue is around the
fistula in rectum or anastomosis and there may be sometimes suture material in
situ. Thus, the tissue is often fixed and there is not so much tissue for grasping
tissue into the OTSC.
The diagnosis of recto-urogenital fistula was usually made by endoscopic visua-
lization and radiologically documented extravastion of contrast media into the
vagina, urethra, bladder or into other adjacent tissue. For fistula closure trau-
matic OTSC was mostly used, but sometimes other adjuvant therapeutic mod-
alities were also combined locally (e.g. histoacryl injection, fibrin glue, argon
plasma coagulation, brushing etc) or systemically (e.g. ascorbic acid 7.5 g i.v.)
to stimulate wound healing. The procedural success of occluding various types of
recto-urogenital fistulae by the OTSC system was found to be successful in 71%
(0–100%) in the short-term, while a durable clinical success was found in only
52% (0–100%) of all 25 patients. The success rate was lower in cases of highly
fibrotic chronic fistulae, after dislocation of clips and when using the atraumatic
clip. Thus, even in this distal problematic site usage of a traumatic OTSC should
be tried in experienced hands before surgical repair.
Conclusion: In conclusion, recto-urogenital fistula may be a potential indication
for OTSC application, after interdisciplinary consensus, when re-operation is
avoided, deemed to be too risky or cumbersome. Although this type of fistula
carries some difficulties because of little space, tissue tension and fibrous or
postop changes, long-term success may be achieved in around half of all patients.
Further improvements should focus on increasing healing potency of the fistula
or better after performing anastomosis creation (ascorbic acid?), to avoid post-
operative recto-urogenital leaks.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Colonoscopy plays a key role in the prevention and diagnosis of
colorectal cancer (CRC), and the quality of it influences interval cancer.
However, we have little information on compliance with quality standards in
Spain.
Aims & Methods: Knowing quality indicators fulfillment may lead to apply
measures to improve the efficiency in the colonoscopy. Hence the aim of this
study was to know the quality indicators of colonoscopies in a sample of centers
in Spain. A total of 6912 colonoscopies performed between January and
November 2016 were prospectively included in the QUALISCOPIA project, an
observational, multicenter and prospective study, developed in 12 centers in
Spain. Patients between the ages of 40 and 80 years with indication for colono-
scopy due to digestive symptoms, post-polypectomy surveillance, positive fecal
immunochemical test (FITþ) and direct colonoscopy of colorectal cancer were
included. The exclusion criteria were patients with diagnosis of colorectal cancer
or adenomas in the last 6 months, incomplete excision or post-excised adenomas,
treatment of colon stenosis, abdominal or rectal mass, inflammatory bowel dis-
ease and hereditary cancer syndrome.
Results: 51.9% (3586) patients were men and the median age was 61 years.
Regarding the colonoscopies indications, thirty one percent (2971) of the patients
presented gastrointestinal symptoms, 20.3% (1398) were admited due to post-
polypectomy surveillance, 28.3% (1949) presented positive fecal inmmunochem-
ical test (FITþ), and 8.4% (578) due to direct screening. 70.4% (4869) of the
explorations were performed in the morning shift. Respecting the bowel prepara-
tion, 48.4% used polyetilenglycol (PEG) 2L, 27.5% (1902) used sodium picosul-
phate/magnesium citrate, and 19.5% (1347) PEG4L. Digital chromoendoscopy
was used for lesion seen in 4.7% (322) and panchrome in 0.1% (7). CO2 was used
in 42% (2906) of the procedures. Colon cleansing was good-excellent in 86.1%
(5512) and cecal intubation was performed in 95.8% (6590). 92.8% (6260) of the
colonoscopies were performed under sedation, and the gastroenterologist was
responsible for it in 80.1% (4995). The most used drugs for sedation were pro-
pofol in 63.9% (4417), midazolam in 44.1% (3045) and fentanyl in 31.1% (2149).
Olympus was used in 69.2% (4732), Pentax in 21.8% (1492) and Fuji in 8.3%
(569). Polyps were found in 50.9% (3515) of the procedures, and CRC was found
in 4.1% (281). The total number of adenomas was 6249, and the total number of
traditional and sessile serrated adenomas was 224. The adenomas detection rate
(ADR) was 39.6%. The sessile and traditional serrated polyps detection rate
(SDR) was 2.2%. And for advanced adenomas, detection rate (AADR) was
21.5% and for colorectal cancer 4.1%.
Conclusion: In Spain, there is good compliance with the quality indicators of
colonoscopies.
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Introduction: While ESD in the upper GI tract is well established, it is as yet not
standard of care in the colorectum. Contrary to Japan, western experience is
limited and only relatively few case series have been published in Europe (e.g.
Dessain et al. 2017).
Aims & Methods: For the period 5/2012–1/2017 the first fifty-one consecutive
patients with colorectal (n¼ 18/17/16 rectum/left/right hemicolon) neoplasias
(diameter 27 13mm, x SD; low grade dysplasia: n¼ 8/9/14 serrated/tubu-
lar/villous; high grade dysplasia: n¼ 12; malignant: n¼ 4) or hyperplastic
polyps (n¼ 4) receiving ESD according to a predefined protocol (hook or dual
knife, Olympus Medical Systems, Hamburg, Germany; procedure time
162 63min; xSD) are reported. ESD was performed by a single investigator
(G.K.) trained previously by Japanese experts and in experimental models. ESD
was complete (n¼ 22) or complemented by snare resection of a remaining stalk
(n¼ 25) or cancelled (n¼ 4) with subsequent alternative treatment.
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Results: According to endoscopic or pathologic judgment resection was complete
in 40 or 30 patients, respectively. During hospital follow-up (2–14; median 4
days) abdominal pain, fever or local peritonitis were noted in 6 and bleeding
in 3 patients (hypotension in 1) with antibiotics/transfusions/surgery needed in 4/
0/0 patients. There was no hospital mortality. Among those with histologic
incomplete resection (n¼ 21), surgery or FTR was performed in 5 patients, endo-
scopic follow-up is pending in 7 and revealed no residual neoplasia in 9. Among
those with cancelled ESD or endoscopic incomplete resection (n¼ 11), surgery or
FTR was performed in 5, endoscopic follow-up is pending in 2 and revealed no
residual neoplasia in 4.
Conclusion: After appropriate training, even in low volume European case series
ESD in the colorectum appears to be safe and partially effective.
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3Endoscopy Unit, Hospital Clı́nic, University of Barcelona, Barcelona/Spain
4Department Of Digestive Diseases, APHP Saint Antoine Hospital, Paris/France
Contact E-mail Address: aymeric.histace@ensea.fr
Introduction: Colorectal cancer is the second leading cause of cancer death in US
[1]. Its incidence can be mitigated by detecting its precursor lesion, the polyp,
before it develops into cancer. Coloscopy is still the gold standard for colon
screening though some polyps are still missed. This can be explained by technical
limitations of colonoscopes (camera orientation, field of view, etc.), but also by
human factors (such as experience). Several computational systems, being the
majority still-frame-based, have been proposed to assist clinicians in this task [2]
but, to the best of our knowledge, none of them is being used in the exploration
room due to not meeting real-time constraints (40ms max per image). In this
abstract, we present a methodology to adapt and evaluate a real-time still frame-
based method [3] to video analysis.
Aims & Methods: The still frame detection system used as reference [3] was based
on an active learning method. We base the adaptation to video analysis on two
aspects: (i) influence of the type of information used for polyp candidate char-
acterisation, and (ii) introduction of spatio-temporal coherence. The former stu-
dies whether the combination of different types of information may lead to
improve system performance whereas the latter fosters stability in the position
of the detector output between consecutive frames. The learning stage of the
method used a public still-frame database (CVC-Clinic, 612 images) whereas
the testing was done on a new set of 18 sequences with a polyp (10,294
images) collected with an Olympus colonoscope CIF-H190 at Hospital Clinic,
Barcelona. Performance was evaluated using two groups of metrics: (i) standard
image/video metrics: Precision, Recall and F1-Score (ii) ad-hoc clinical metrics
(assessing the clinical usability). Among the latter group we define: a) Polyp
Detection Rate (PDR), checking if a method is able to detect polyp at least in
10% of the sequence, b) Mean Processing Time per frame (MPT), c) Mean
Number of False Alarms per frame (MNFP), number of false alarms that can
disturb the physician and d) Reaction Time (RT), representing the delay between
first appearance of a polyp in the sequence and the first correct detection pro-
vided by the method.
Results: Table 1 shows the influence of local features on the overall performance
and how the combination of both types of features can lead to an overall
improvement in Recall and RT, which we interpret as local descriptors comple-
menting each other.
Method PDR MPT MNFP Prec Rec F1 RT
Texture
(Local Binary
Patterns [3])
100% 162ms 0.7 29.88% 34.96% 32.22% 45.9 [1.8 sec]
Shape (Haar
features [5])
100% 21ms 0.6 39.14% 42.56% 40.78% 27.3 [1.1 sec]
Combination 100% 185ms 1.0 30.72% 51.00% 38.34% 17.4 [0.7 sec]
Conclusion: Work presented in this abstract shows how a real-time still-frame-
based polyp detection method can be successfully adapted to video analysis.
Clinical usability metrics along with a new fully annotated video database were
introduced to completely assess method performance. Results show methodology
potential regarding clinical deployment as it detects all different polyps with a
small RT. Results show that the sole use of shape features allows to meet real-
time constraints but that a combination with a computationally efficient texture
descriptor might improve frame-based performance.
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Introduction: The use of Narrow Band Imaging (NBI) technology for in vivo
histological prediction of colorectal polyps presents high accuracy in Referral
Centers, particularly for diminutive polyps, which could be managed by the
‘‘resect and discard’’ strategy and, for sigmoid and rectum polyps, the ‘‘diagnose
and disregard’’ strategy. However, the applicability of this practice in
Community Hospitals still needs to be determined.
Aims & Methods: We aimed to determine the accuracy of NBI in predicting
histology, according to NICE and WASP classifications, in a Center without
previous NBI experience. This was a prospective study including patients sub-
mitted to colonoscopy between June 2016 and July 2017. Polyps characteristics:
location, size, morphology (Paris Classification), NICE/WASP classification
(hyperplastic, sessile serreated, adenoma, invasive carcinoma) and degree of con-
fidence (low:590% vs. high 90%). Comparison between NBI classification
and histology SPSS 23.
Results: 163 polyps included (71 patients); mean polyp dimension of 6.1mm
(61.3% 5mm); 91.4% sessile polyps; 62.6% on the left colon. Polyps classifica-
tion according to NICE/WASP vs. histology: hyperplastic 49.7vs 42.9%; sessile
serrated polyps 4.9vs 9.8%; adenoma 44.2 vs. 43.6%; carcinoma 1.2 vs. 0%;
inflammatory reaction on histology – 3.7%. Adenoma diagnosis using NICE/
WASP classification presents an accuracy, sensitivity, specificity, positive predic-
tive value and negative predictive value of 80.9%, 78.1%, 84.2%, 85% and
77.1%, respectively. For left polyps 5mm (n¼ 61) the accuracy and negative
predictive value were of 81.2% and 82.3%, respectively, with 79.4% high con-
fidence classifications. Multivariate analysis showed that high confidence predic-
tion and 3 polyps/exam had a significant association with correct NBI
classification (p5 0.05).
Conclusion: NBI utilization by inexperienced endoscopists presented moderate
acuity in histological prediction. Despite promising results, acuity and confidence
levels were lower than the thresholds recommended in guidelines (90%). These
results justify implementing additional training and monitoring.
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Introduction: Cold forceps polypectomy (CFP) is commonly used to remove
diminutive colorectal polyps (5mm). In addition, jumbo biopsy forceps are
superior to standard forceps for removing colorectal polyps. However, problems
remain for CFP with regard to residual adenomatous tissue on histological eva-
luation after a complete endoscopic cold forceps polyp resection.
Aims & Methods: The aim of this study was to evaluate the efficacy and safety of
jumbo forceps biopsy using narrow-band imaging endoscopy in patients with
diminutive polyps. In addition, we evaluated the factors related to one-bite resec-
tion. This is a multicenter, prospective, single-arm observational study conducted
at 11 institutes of the National Hospital Organization between January 2015 and
September 2016. Patients aged 20 to 75 years with diminutive polyps were
enrolled in this study. When lesions were found, we used magnification endo-
scopy with narrow-band imaging (NBI) in all the cases. CFP was performed until
no polyps were visible under magnified endoscopy with NBI. We evaluated the
patients’ characteristics, clinicopathological features of the polyps, adverse
events, and complete resection rates of the lesions. Additionally, we studied the
factors of one-bite resection using Cox’s regression model.
Results: A total of 503 patients were prospectively assessed, and 1015 polyps were
resected. The median age of the patients was 65 years. The patients comprised
329 men (65%) and 174 women (35%). The polyp morphologies were 0-Is lesions
in 886 cases (87.2%), 0-IIa lesions in 65 (6.4%), 0-Isp lesions in 63 (6.2%), and 0-
Ip lesion in 1 (0.1%). Polyps were most often resected in the ascending colon (289
lesions) or transverse colon (262 lesions). Of all the polyps, 88% (896 lesions)
were adenomas, 10% (100 lesions) were hyperplastic, and 0.3% were adenocar-
cinomas. The mean procedure and treatment times were 26.5 and 20.4min,
respectively. The complete resection rate was 99.3%. The rate of one-bite poly-
pectomy was 71.8%, which included rates of 100%, 91.5%, 81.8%, 56.9%, and
40.5% for lesions 1, 2, 3, 4, and 5mm in diameter, respectively. Delayed bleeding
that required endoscopic hemostasis occurred in only one case, but no other
adverse events occurred. The most important factor rerated to one-bite polypect-
omy was polyp size (53mm; OR: 5.58), followed by macroscopic type of polyps
(non-IIa; OR: 1.95).
Conclusion: In this large-scale multicenter prospective study, 99.3% of all diminu-
tive polyps were completely resected by using jumbo forceps biopsy and magni-
fied endoscopy with NBI. In addition, we was able to do one-bite polypectomy
for more smaller polyps (53mm). Jumbo forceps biopsy appears to be adequate
for resecting diminutive polyps if no residual tissue is visible by using magnified
endoscopy with NBI.
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Introduction: Heparin bridging therapy (HBT) is recommended for patients
administered anticoagulants who have a high thrombotic risk and who undergo
a high bleeding-risk procedure such as endoscopic submucosal dissection (ESD)
or endoscopic mucosal resection (EMR)1, 2). However, HBT is actually related to
a high frequency of delayed bleeding3, 4).
Aims & Methods: Our aim is to analyze bleeding and coagulation markers in the
management of anticoagulants without HBT during the perioperative periods of
ESD and EMR. Patients who underwent ESD or EMR and received warfarin or
a direct oral anticoagulant (DOAC) during the period from January 2013 to
March 2017 were analyzed. Generally, administration of warfarin was continued
within the therapeutic range of the international normalized ratio (INR) during
the perioperative periods and DOACs were not administered on the day of the
procedure. HBT was conducted only for patients who had a hypercoagulable
condition. The rates of delayed bleeding in patients who received warfarin and
patients who received DOACs were compared, and coagulation molecular mar-
kers including soluble fibrin (SF), thrombin-antithrombin complex (TAT), pro-
thrombin fragment 1þ 2 (F1þ 2) and D-dimer (DD) were compared before and
after the procedures in 13 patients who received DOACs.
Results: Among the patients who underwent ESD or EMR during the study
period, 51patients received warfarin and 49 received DOACs. Delayed bleeding
occurred in 6 patients (11.8%) in the warfarin group and in 8 patients (16.3%) in
the DOAC group, and there was no significant difference. Only one patient with
continued administration of antiplatelet agents had delayed bleeding among the
patients in whom administration of warfarin was continued within the therapeu-
tic range (5.3%, 1/19). Six (15%) of the 40 patients in the DOAC group for
whom the DOAC was not administered only on the day of the procedure had
delayed bleeding, and 23.8% (5/21) of the patients who received HBT had
delayed bleeding. No thrombotic events occurred from one month after the
procedures. One patient in whom the DOAC was not administered on the day
of the procedure became positive for TAT, F1þ 2 and DD after EMR and had a
hypercoagulable condition.
Conclusion: For perioperative management of anticoagulants in patients under-
going ESD or EMR, continuous use of warfarin within the therapeutic range is
better than HBT. However, DOACs should be carefully managed with attention
to hemorrhagic risk and coagulable condition.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Colorectal cancers are generally recognized to develop from‘‘po-
lyps’’. This ‘‘adenoma-carcinoma sequence’’ theory has been in the mainstream
of development of colorectal cancers. But recently the existence of many
depressed-type cancers has been revealed, which are considered to emerge
directly from normal epithelium, not through the adenomatous stage. This
theory is called ‘‘de novo’’ pathway. Now, it is possible to presume the histology
of colorectal lesions using magnifying endoscopy(pit pattern classification) and
endocytoscopy(EC classification). We can observe not only the structural atypia
but also the cellular atypia in living colorectal lesions.
Aims & Methods: The aim is to clarify the endoscopic characteristics of
depressed-type colorectal neoplasms, demonstrating the validity of pit pattern
diagnosis and EC classification. A total of 29,030 colorectal neoplasms excluding
advanced cancers were resected endoscopically or surgically in our unit from
April 2001 to December 2016. Of these, 17,761 lesions were low-grade dysplasia,
2922 were high-grade dysplasia and 1077 were submucosally invasive (T1) carci-
nomas. According to the developmental morphology classification, they were
divided into 3 types: depressed, flat and protruded-type. We investigated the
rate of T1 carcinomas and the characteristics of depressed- type neoplasms con-
cerning pit pattern and EC classification.
Results: The rate of T1 carcinomas in depressed-type lesions reached to 62.0%,
meanwhile that in flat-type and protruded-type lesions was 3.3% and 2.8%,
respectively. Within less than 5mm in diameter, that was 10.6%, 0% and
0.04%, respectivel. Most (93.0% and 93.1%) of the flat-type and protruded-
type lesions showed typeIIIL or IV pit pattern corresponding to adenomas,
whereas 91.3% of the depressed-type lesions were characterized by type IIIS,
VI or VN pit patterns correspondings to carcinomas. As for endocytoscopy,
most of the flat-and protruded-type lesions showed EC2 corresponding to ade-
nomas. In contrast, the depressed-type lesions were observed as EC3a (38.9%)
and EC3b (58.0%) corresponding to invasive carcinomas
Conclusion: This study revealed the diagnostic characteristics of depressed-type
lesions. They show typically type IIIS, VI or VN pit patterns in magnifying
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endoscopy and type EC3a or EC3b in endocytoscopy. These lesions tend to
invade the submucosal layer even when they are small. Therefore, it is important
to consider deeply and examine the developmental morphology of colorectal
neoplasms.
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Introduction: It remains unknown if colonic lesions detection rates as quality
indicators of the colonoscopy, behave in the same way in relation to colonoscopy
indication.
Aims & Methods: The aim of this study was to evaluate the adenoma detection
rate (ADR), serrated polyp detection rate (SDR), advanced adenoma detection
rate (AADR) and colorectal cancer detection rate (CRCDR) depending on the
colonoscopy indication. A total of 6912 colonoscopies have been prospectively
included in the QUALISCOPIA project, an observational, multicenter and pro-
spective study, developed in 12 centers in Spain. The ADR, SDR, AADR and
CRCDR have been calculated. These data were analysed according to the colo-
noscopy indication adjusted by sex, age, cecal intubation, adequate cleansing
(Boston scale score of 2–3 in all segments) and sedation use.
Results: The results can be seen in table 1. In colonoscopies performed due to
positive fecal immunochemical test (FITþ), the ADR was 54.0% (p5 0.001,
aOR 3.0, 95%CI 2.6–3.4). In those performed because of post-polypectomy
surveillance, was 49.3% (p5 0.001, aOR 2.2, 95%CI 1.9–2.5), and those due
to direct screening, the ADR was 31.6% (p5 0.005, aOR 1.4, 95%CI 1.1–1.7)
compared to 28% in patients with gastrointestinal symptoms. Regarding the
serrated polyps, in procedures performed due to FITþ, the SDR was 1.9%
(p¼ 0.094, aOR 1.5, 95%CI 0.9–2.5), 4.2% in surveillance colonoscopies
(p5 0.001, aOR 3.4, 95%CI 2.2–5.3), and 3.3% in direct screening (p5 0.001,
aOR 2.8, 95%CI 1.6–5.0), compared to 1.2% of patients with digestive symp-
toms. Moreover, the AADR in colonoscopies performed due to FITþ was 36.8%
(p5 0.001, aOR 3.9, 95%CI 3.3–4.6), compared to 23.1% in surveillance colo-
noscopies (p5 0.001, aOR 1.8, 95%CI 1.5–2.2), and 14.9% in direct screening
(p¼ 0.023, aOR 1.3, 95%CI 1.1–1.8). However, the SDR was 12.8% in patients
with digestive symptoms. Finally, the CRCDR was 5.8% in patients with gastro-
intestinal symptoms (p5 0.001, aOR 11.6, 95%CI 4.7–28.7), 4.8% in those with
FITþ (p5 0.001, aOR 13.4, 95%CI 5.4–33.2), and 1.8% in direct screening
(p¼ 0.005, aOR 5.1, 95%CI 1.6–15.6), compared to 0.5% in post-polypectomy
surveillance.
TABLE 1: DETECTION RATES BY INDICATION
ADR
% (n) OR (95%CI) p-value1 aOR2 (95% CI) p-value1
Post-polypectomy
surveillance
49.3 (629/1275) 2.5 (2.2–2.9) 50.001 2.2 (1.9–2.5) 50.001
FITþ 54.0 (928/1718) 3.0 (2.7–3.4) 50.001 3.0 (2.6–3.4) 0.001
Direct screening 31.6 (174/550) 1.2 (1.0–1.5) 0.085 1.4 (1.1–1.7) 0.005
Digestive symptoms 28.0 (793/2832) 1.0 1.0
SDR
Post-polypectomy
surveillance
4.2 (53/1275) 3.5 (2.6–5.3) 50.001 3.4 (2.2–5.3) 50.001
FITþ 1.9 (32/1718) 1.5 (0.9–2.5) 0.091 1.5 (0.9–2.5) 0.094
Direct screening 3.3 (18/550) 2.7 (1.5–4.8) 50.001 2.8 (1.6–5.0) 0.001
Digestive symptoms 1.2 (35/2832) 1.0 1.0
AADR
Post-polypectomy
surveillance
23.1 (294/1275) 2.0 (1.7–2.4) 50.001 1.8 (1.5–2.2) 50.001
FITþ 36.8 (632/1718) 4.0 (3.4–4.6) 50.001 3.9 (3.3–4.6) 50.001
Direct screening 14.9 (82/550) 1.2 (0.9–1.5) 0.177 1.3 (1.1–1.8) 0.023
Digestive symptoms 12.8 (362/2832) 1.0 1.0
CRCDR
Digestive symptoms 5.8 (165/2832) 13.1 (5.8–29.6) 50.001 11.6 (4.7–28.7) 50.001
(continued)
TABLE 1 Continued
ADR
% (n) OR (95%CI) p-value1 aOR2 (95% CI) p-value1
FITþ 4.8 (83/1718) 10.7 (4.7–24.7) 0.001 13.4 (5.4–33.2) 50.001
Direct screening 1.8 (10/550) 3.9 (1.4–10.8) 0.009 5.1 (1.6–15.6) 0.005
Post-polypectomy
surveillance
0.5 (6/1275) 1.0 1.0
1p-value: significance level; 2aOR: adjusted Odds Ratio
Conclusion: The indication of colonoscopy has a very important influence on the
different quality indicators such as detection rates of lesions.
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Introduction: Recently, we have performed therapeutic ERCP using a newly
developed short single-balloon enteroscope (sSBE) (working length of 152 cm,
working channel of 3.2mm) in patients with surgically altered anatomy.
Aims & Methods: We aimed to evaluate the usefulness and safety of sSBE for
therapeutic ERCP in patients with surgically altered anatomy. One hundred four
patients with surgically altered anatomy who underwent therapeutic ERCP using
a sSBE between August 2011 and February 2017 were included in this study.
Patient anatomy consisted of Roux-en-Y anastomosis (R-Y) (n¼ 82), hepatico-
jejunostomy (HJ) (n¼ 11), subtotal stomach-preserving pancreaticoduodenect-
omy (SSPPD) (n¼ 11). The indications for ERCP were choledocholithiasis (68:
R-Y cases), malignant biliary strictures (20: R-Y 14, HJ 7, SSPPD 4), intrahe-
patic stones (9: HJ 7, SSPPD 2), and anastomotic stenosis (7: SSPPD 5, HJ 2).
The success rate of reaching the target site, the technical success rate, and the
adverse event rate were retrospectively evaluated.
Results: The success rate of reaching the target site was 91% (95/104), and the
overall technical success rate was 79% (80/104). Biliary interventions included 64
stone extraction (R-Y 58, HJ 5, SSPPD 1), and 12 metallic biliary stent placement
(R-Y 7, HJ 1, SSPPD 4). Of 17 unsuccessful cases, nine with choledocholithiasis
underwent surgical operation (R-Y 6, HJ 2, SSPPD 1) and EUS-guided drainage
was successfully performed in six with anastomotic stenosis (SSPPD 3, R-Y 2, HJ
1). The remaing two with malignant bile duct stricture (R-Y) underwent PTCD.
The adverse event rate was 10% (10: cholangitis 4, mild pancreatitis 3, perfora-
tion 2, aspiration pneumonitis 1). The two perforation cases required urgent
operation but remaing eight cases were managed conservatively.
Conclusion: Therapeutic ERCP using a sSBE in patients with surgically altered
anatomy was considered to be safe and effective.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: SpyGlass single-operator peroral cholangioscopy (SOC) has been
designed to overcome some limitations of conventional cholangioscopy, and
demonstrated improved diagnostic and therapeutic abilities of complex pancrea-
ticobiliary disease.
Aims & Methods: To assess the clinical efficacy and safety of the SpyGlass system
for diagnosis and treatment of bile-duct disorders in a large-volume center. All
patients undergoing SOC in our department between January 2013 and May
2016 were retrospectively identified from a prospectively collected database.
The baseline characteristics, including age, gender, presenting symptoms, indica-
tion and others were recorded. Procedure-related parameters of SOC for detect-
ing malignant lesions and the stone clearance rate were calculated.
Results: During the study period, a total of 68 patients underwent 78 SOC
procedures: 26 (38.2%) with indeterminate strictures, 7 (10.3%) with indetermi-
nate filling defects, 31 (45.6%) with difficult bile stones, and 4 (5.9%) with cystic
lesions. SpyGlass was technically successful in 63 of 68 patients (92.6%). The
mean total SpyGlass procedure time was 12min. In patients with indeterminate
biliary strictures, 6 cases of definite diagnosis (stones, varices) was made by SOC
evaluation. Twenty patients underwent SOC-directed biopsy, and samples were
adequate for histological diagnosis in 17 patients (85%). The preliminary accu-
racy of SpyGlass-directed biopsy to diagnose malignancy were 76%. For the
patients with biliary stone, SpyGlass-guided holmium laser lithotripsy or electro-
hydraulic lithotripsy succeeded in 15 of 15 patients (100%). There were 6 proce-
dure-related adverse events occurred (8.8%), and resolved uneventfully.
A240 United European Gastroenterology Journal 5(5S)
Conclusion: SpyGlass cholangioscopy system can be safe and useful for definite
diagnosis with high accuracy in patients with indeterminate biliary lesions, and
successfully guided stone therapy. Further prospective multicenter trials of the
system are warranted in the future.
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Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) is
increasingly being used in the diagnosis and management of biliary and pancrea-
tic disorders in pediatric patients.
Aims & Methods: To evaluate the indications, success rate, diagnostic and ther-
apeutic yields, and complications of ERCP performed in Chinese children. A
retrospective study was conducted in an academic, tertiary care, medical
center, in which all children undergoing ERCP between 2005 to 2016 were iden-
tified from endoscopy databases. Data on demographics, indication, ERCP find-
ings, ERCP interventions performed and complications were collected.
Results: A total of 288 children (mean age 9.3 years, range 1 month to 18 years)
underwent 312 ERCP procedures. General anesthesia and sedation were per-
formed in 48% and 52% of procedures, respectively. Indications for ERCP
were common bile duct obstructions (n¼ 153, 54.2%), recurrent or chronic pan-
creatitis (n¼ 64, 22.2%) and others. ERCP was successfully performed in 267 of
288 cases (92.7%). The most common ERCP findings was choledocholithiasis
(n¼ 146, 50.7%). A therapeutic intervention was performed in 70.8% patients
(n¼ 204), including sphincterotomy (n¼ 97), stone extraction (n¼ 55), and stent
insertion (n¼ 52). Complications occurred for only 13 patients (4.5%), including
12 cases of post-ERCP pancreatitis and 1 case of bleeding. No severe pancrea-
titis, or perforation was noted.
Conclusion: Diagnostic and therapeutic ERCP is effective and safe in the children
population, with the high rates of technical success and low rates of
complication.
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Introduction: It is technically challenging to perform endoscopic retrograde cho-
langiopancreatography (ERCP) in patients with surgically altered gastrointest-
inal anatomy.
Aims &Methods: The aims of this study were to investigate the yield, efficacy and
safety of ERCP in surgically altered anatomy patients at a single tertiary-care
center with a high volume of endoscopy. All patients with altered surgical anat-
omy who underwent ERCP at our center from September 2005 to July 2016 were
retrospectively reviewed. Data regarding to patients baseline characteristics, pro-
cedure-related details and adverse events was recorded and analyzed.
Results: A total of 304 procedures were performed in 236 patients, including 108
cases (45.8%) with Billroth II gastrectomy, 45 cases (19.1%) with Billroth I
gastrectomy, 52 cases (22.0%) with hepaticoduodenostomy, 18 cases (7.6%)
with esophagogastrostomy and 13 cases (5.5%) with Roux-en-Y reconstruction.
The most common indication was cholelithiasis (58.1%, 137/236). The overall
technique success rate of reaching the papilla was 90.8% (276/304), including
91.3% (126/138) for Billroth II gastrectomy, 94.5% (52/55) for Billroth I gas-
trectomy, 89.9% (71/79) for hepaticoduodenostomy, 100% (19/19) for esopha-
gogastrostomy and 61.5% (8/13) for Roux-en-Y reconstruction. The clinical
success rate was 88.2% (268/304). Therapeutic interventions were performed in
194 patients successfully, including stone extraction (n¼ 146), sphincterotomy
(n¼ 44), stent placement (n¼ 57), papillary balloon dilatation (n¼ 27) and
mechanical lithotripsy (n¼ 25). The adverse event rate was 7.2% (17/236).
Mild pancreatitis occurred in 3% (7/236) of cases, perforation occurred in
2.5% (6/236) of cases, and asymptomatic hyperamylasemia occurred in 1.7%
(4/236) of cases.
Conclusion: ERCP can be performed in surgically altered anatomy patients with a
high success rate.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Risk factors for colorectal adenoma recurrence after Endoscopic
Mucosal Resection (EMR) such as size 20mm, high grade dysplasia, use of
argon plasma coagulation (APC) and intraprocedural bleeding (IPB), have been
well documented in literature. However, it is unknown if the latest generation
dual-focus (DF) colonoscopes ability to visualize subtle residual neoplasia, has
improved the rate of complete EMR.
Aims & Methods: We aimed to assess the efficacy of the newer 190 colonoscopes
versus standard 180 colonoscopes for complete resection of lateral spreading
lesions (LSL) 20mm. A secondary aim was to identify risk factors for recur-
rence and the applicability of the Sydney EMR recurrence tool (SERT score) in
our cohort.
This was a single-center retrospective study of patients who underwent EMR
with 180 or 190 colonoscope series from 2010 to 2016. Lesions 20mm resected
in a piecemeal fashion and patients with a surveillance colonoscopy after index
EMR were included. A propensity score approach with inverse probability
weighting (IPW) was used to control potential confounders affecting adenoma
recurrence. Each lesion was graded according to SERT score and associations
with recurrence were analyzed.
Results: 291 patients met inclusion criteria for the study. The rate of adenoma
recurrence at the EMR site was 23.3% for the 180 colonoscope cases and 25.2%
for the 190 colonoscope cases. Odds ratio (OR) for recurrence with 190 series was
1.06 (p¼ 0.85). Adenoma size (p¼ 0.002) and concomitant need for supplemental
APC (p5 0.001) were risk factors for recurrence. SERT4 0 lesions had a higher
risk of recurrence during follow-up (OR 1.71; 95% CI 1.00–2.92; p¼ 0.048) and a
higher cumulative incidence for recurrence. Conversely, SERT¼ 0 lesions
reached a plateau for recurrence after 12 and 18 months in Kaplan Meier curves.
Odds ratio estimates for 190 colonoscope effect on adenoma recurrence at dif-
ferent stages of adjustment.
Model Odds Ratio
Lower
95% CI
Upper
95% CI P-value
Unadjusted all-subject
(en-bloc and piecmeal)
1.58 0.94 2.65 0.08
Unadjusted-piecemeal
resection only
1.11 0.64 1.92 0.71
IPW adjustment-piecemeal
resection
1.06 0.60 1.86 0.85
Cumulative incidence of recurrence at SC1 by SERT score in 291 lesions.
Months
N-events
[SERT¼ 0]
Event rate,%
[SERT¼ 0]
N-events
[SERT4 0] Event rate,% [SERT4 0]
6
12
18
24
36
26
34
34
35
36
16.4%
23.3%
23.3%
25.4%
27.5%
21
32
35
36
37
21.9%
37.6%
43.6%
47.1%
51.5%
CI: Confidence intervals; IPW: Inverse probability weighting; SERT: Sydney
EMR recurrence tool; SC1: First surveillance colonoscopy.
Conclusion: In this study, recurrence was significantly associated with adenoma
size and complementary use of APC for EMR. The use of the latest generation
DF colonoscopes (CF-HQ190L/I) did not measurably affect adenoma recurrence
at the EMR site during first surveillance colonoscopy (SC1). Lesions with
SERT4 0 were associated with higher recurrence rates. In our cohort,
SERT¼ 0 lesions that remain negative for recurrence at 18 months, may
return to routine surveillance.
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Introduction: Post-endoscopic retrograde cholangiopancreatography (ERCP)
pancreatitis (PEP) is a potentially serious complication, and some risk factors
for PEP have been reported in general ERCP in previous studies. Emergency
ERCP is different from normal state ERCP, and the risk factors for PEP in
emergency ERCP are not clear.
Aims & Methods: This study aimed to identify the incidence and risk factors for
PEP in emergency ERCP. We performed a prospective study of 2078 cases under-
going diagnostic and therapeutic ERCP at five Japanese institutions between
April 2015 and May 2016. Exclusion criteria were active pancreatitis, choledo-
chojejunostomy, inability to approach a papilla, and inspection aimed at only the
pancreatic duct (PD). Emergency ERCP indicated unscheduled inspections per-
formed within and outside duty hours in this study. PEP was considered when
two of the following three conditions were met: (1) serum amylase level more
than three times the upper limit of the normal range in each institution, (2)
continuous abdominal pain for over 24 hours, and (3) presence of pancreatitis
findings on computed tomography. The first study involved comparison of the
incidence of PEP and its characteristics between emergency and elective ERCP.
The second study involved determining the predictive risk factors for PEP in
emergency ERCP using univariate and multivariate analyses.
Results: A total of 1677 cases were enrolled in this study. 5Study 14 PEP
developed in 20 of 429 cases (4.7%) from the emergency group and in 101 of
1248 cases (8.1%) from the elective group. The incidence of PEP was significantly
lower in the emergency group than in the elective group (odds ratio [OR]: 0.56,
95% confidence interval [CI]: 0.32–0.92, P¼ 0.017). Endoscopic sphincterotomy,
stone removal, papillary balloon dilatation, and intraductal ultrasound sonogra-
phy were performed significantly more often in the elective group than in the
emergency group (P5 0.001). Placement of a biliary stent was significantly more
common in the emergency group than in the elective group. In addition, the
procedure time was significantly longer (P5 0.001) and the number of endosco-
pists who had more than five years of experience was significantly higher
(P¼ 0.04) in the elective group than in the emergency group. 5Study 24
Cases with no naı̈ve papilla (n¼ 181) were excluded from the analysis of risk
factors for PEP because no PEP was observed in these cases. Only cases with
naı̈ve papilla (n¼ 248) were analyzed. Univariate analysis showed that contrast
injection into the PD (OR: 4.20, 95%CI: 1.64–10.80, P¼ 0.0028), more than four
cannulation attempts (OR: 2.85, 95%CI: 1.00–8.09, P5 0.05) increased and pla-
cement of a biliary stent (OR: 0.028, 95%CI: 0.11–0.88, P¼ 0.028) decreased the
risk of PEP in emergency ERCP. Multivariate analysis showed that contrast
injection into the PD (OR: 4.51, 95%CI: 1.64–12.40, P¼ 0.0035) increased the
risk of PEP in emergency ERCP.
Conclusion: The incidence of PEP was lower in emergency ERCP than in elective
ERCP, and it was largely unaffected by the endoscopist’s experience and the
procedure time. This may be associated with a tendency to avoid invasive pro-
cedures in emergency cases, and it is considered that only placement of a biliary
stent contributes to a decrease in the development of PEP. Close attention should
be paid for contrast injection into the PD, particularly when attempt of cannula-
tion for naı̈ve papilla are required.
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Introduction: Endoscopic necrosectomy (EN) in walled-off necrosis (WON) is a
labor intensive, high-risk, non-standardized technique that is associated with
significant morbidity and mortality.
Aims & Methods: We aimed to compare the clinical outcomes of patients with
WON treated by conventional EN versus an algorithmic approach that is tai-
lored to the extent and location of WON.
This observational study included 45 consecutive patients with WON who had
suboptimal treatment response to EUS-guided transluminal drainage and sub-
sequently underwent necrosectomy. The conventional technique using a diag-
nostic or therapeutic gastroscope involved removal of necrotic debris using
any 15–20mm polypectomy snare, 7.5mm rat tooth or tripod grasping forceps
and retrieval nets. Normal saline was used for intra-procedural irrigation and
lavage of the necrotic cavity. The algorithmic technique, using a cap-fitted
therapeutic gastroscope, was tailored to the extent and location of the
WON: While WON extending to the flanks and more proximate (520 cm)
to the abdominal wall were treated by percutaneous necrosectomy, those in
close proximity to the stomach and without extension to the flanks were
treated by transluminal EN. Adherent debris were removed using 15–25mm
round, braided-wire snares and non-adherent debris were removed using 15–
30mm oval snares. A large 14.9mm diameter, rat tooth forceps were used for
debridement when the necrotic debris were not amenable for snaring. The
necrotic cavity was evacuated by sucking the debris within the gastroscope
cap using snares and/or forceps. In order to avoid frothing that obscures
visibility, intra-procedural lavage of the necrotic cavity was performed using
normal saline mixed with 120mg gentamicin and irrigation with hydrogen
peroxide was reserved for sterilizing the cavity at the end of the procedure.
The primary outcome measure was to compare the treatment success and
number of reinterventions performed between the two groups. Treatment fail-
ure was defined as death from underlying disease or need for open surgical
necrosectomy.
Results: Of the 45 WON patients, 23 were treated using conventional techniques
and 22 using the algorithmic approach. Treatment success was significantly
higher for patients treated using the algorithmic approach, 100 vs. 69.6%,
p¼ 0.009. Of the 7 patients who had treatment failure in the conventional tech-
nique cohort, 6 required open necrosectomy and 1 died of multi-organ failure.
The median number of reinterventions required to achieve treatment success was
significantly lower for the algorithmic approach, 1 (IQR¼ 1–1) vs. 2 (IQR¼ 1–
2), p¼ 0.003. Multivariable logistic regression analysis revealed that the algorith-
mic approach was the only variable associated with treatment success
(OR¼ 60.4, p¼ 0.02) when adjusted for patient demographics, lab parameters
and disease/WON characteristics.
Conclusion: A structured, algorithmic approach to endoscopic necrosectomy
results in successful treatment outcomes.
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Introduction: Pancreas divisum( PD) is the most common congenital anomaly of
the pancreas. Most PD individuals are asymptomatic, but a few may present
symptoms in the form of recurrent acute pancreatitis (RAP), chronic pancreatitis
(CP) or pancreatic-type pain. It is imperative to treat PD associated with RAP as
early as possible to prevent it from developing CP. Unfortunately, to date, most
PD-related studies have been concentrated on adults. Researches of PD in chil-
dren is rare.
Aims & Methods: To evaluate the safety and efficacy of endoscopic retrograde
cholangiopancreatography (ERCP) for the treatment of pancreas divisum
(PD) associated with recurrent acute pancreatitis (RAP) in children. We retro-
spectively analyzed patients of PD associated with RAP who were younger
than 18 years old from January 2011 to December 2015 in our center. All the
patients were diagnosed and treated with ERCP. Patients of complete PD
associated with RAP underwent endoscopic minor sphincterotomy combined
with dorsal duct stenting (ESCS). Patients of incomplete PD underwent bi-
papilla endoscopic sphincterotomy combined with dorsal duct stenting (Bi-
ESCS). ERCP-related data, complications and other relevant data were col-
lected. Long time follow up was conducted after removal of the last dorsal
duct stent, and then to observe children’s recovery, as well as their weight,
growth and intelligence.
Results:A total of 227 pediatric ERCPs were performed for 117 pediatric patients
during this period. Of which 24 were PD cases. The endoscopic detection rate of
PD was 20.5%. Of the 24 patients, 12 were PD associated with RAP, among
which 10 were complete PD and 2 were incomplete PD. A total of 21 therapeutic
ERCPs were performed for these cases. All procedures were successful with
100% (21/21) of cannulation rate of the minor papilla. The mean interval of
changing pancreatic dorsal duct stent is 3 months (from 2 to 6 months).
ERCP-related complications were mild with a rate of 9.5% (2/21). One was
acute mild pancreatitis and the other was hyperamylasemia, both of which
were managed conservatively. During follow up from 15 to 74 months (mean
33.9 months), all patients had pain relief with a relief rate of 100%, of which 10
were asymptomatic with no longer onset of acute pancreatitis. During follow-up,
MRCP or CT scan showed no more dilation of dorsal ducts in all children and all
presented normal in weight, growth and intelligence.
Conclusion: The techniques of ESCS and Bi-ESCS under ERCP are safe and
effective methods to manage PD associated with RAP in pediatric patients. It
seems very vital for such children to undergo endoscopic interventions as early as
possible in order to avoid developing CP.
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Introduction: Endoscopic biliary stenting is the treatment of choice in presence of
malignant biliary obstruction (MBO), especially if palliative treatment. The role
of endoscopic biliary sphincterotomy (EBS) before stent insertion is not clearly
defined. The primary outcome of our meta-analysis was to assess the technical
success of biliary (plastic or metal) stent insertion. Secondary outcomes included
early complications within 30 days from ERCP and late complications which
(from 30 days since ERCP).
Aims & Methods: We performed a literature search by using PubMed, SCOPUS,
Google Scholar and the Cochrane Central Register of Clinical Trials (up to
February 2017) to identify full-text studies evaluating the efficacy and safety of
stent positioning, with and without EBS, in patients with MBO not suitable to
surgery.
Results: 14 papers were assessed via full text for eligibility. 8 articles were
excluded leaving 6 prospective studies (total of 711 patients). Technical success:
The overall rate of biliary stent insertion was not significantly different: 384/392
patients (98%) in the no-EBS group versus 331/339 (97.6%) in the EBS arm (OR:
1.05; 95%CI, 0.42–2.63). Early complications: The overall early AEs developed in
43/392 (11%) of patients whithout EBS versus 68/339 (20.1%) of patients who
received EBS, with a significantly difference (OR: 0.55; 95%CI: 0.33–0.92). Post-
ERCP pancreatitis (PEP) was no significantly different in the two groups: 24/392
(6.1%) in no-EBS group versus 17/339 (5%) in EBS group (OR: 1.33; 95%CI:
0.68–2.59). The bleeding was significantly different in patients without EBS: 0/
351 of patients in no-EBS group versus 15/298 (5%) in the EBS group (OR: 0.12;
95% CI, 0.03–0.45). The rate of duodenal perforation was not significantly dif-
ferent: 1/320 (0.3%) in no-EBS versus 4/260 (1.5%) in EBS (OR: 0.52; 95%CI:
0.09–2.88). Early cholangitis was significantly lower in patients who didn’t
receive EBS: 13/392 (3.3%) patients in no-EBS group vs 25/339 (7.4%) subjects
in the EBS group (OR: 0.38; 95%CI: 0.17–0.83). Early mortality rate was 0% in
both groups. Late complications: No significantly difference occurred in the over-
all late adverse events in the two groups: 50/251 patients (19.9%) in no-EBS
group vs 38/201 subjects (18.9%) in the EBS group (OR: 0.93; 95%CI: 0.56–
1.53). No significantly differences in stent occlusion (11.6% patients in no-EBS vs
11.4%in EBS - OR: 0.90; 95%CI: 0.4–2.0). No significantly differences in stent
migration (4% in no-EBS group vs 5.5% - OR: 0.81; 95%CI: 0.29–2.25). No
significantly differences in late cholangitis (2.6% in no EBS vs 0% in EBS group -
OR: 1.83; 95%CI: 0.17–19.85). Long-term mortality was not significantly differ-
ent (2.5% in no-EBS group and 2.9% in the EBS arm - OR: 1.18; 95%CI: 0.22–
6.29).
Conclusion: Our meta-analysis showed no significantly differences in technical
success and in PEP. In consideration of the significantly increase of the overall
AEs in the EBS group, and in particularly of the bleeding and cholangitis, the
EBS seems not be recommended in patients not suitable to surgery undergone
biliary stenting.
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Introduction: Acute recurrent pancreatitis (ARP) refers to a clinical entity char-
acterized by episodes of acute pancreatitis which occurs on more than one occa-
sion. Biliary microlithiasis plays an important role in the etiology of ARP. Bile
sludge may induce acute pancreatitis as a consequence of transient papillary
edema that can obstruct the pancreatic juice flow. The established treatments
of microlithiasis with ARP include endoscopic sphincteropapillotomy (EST) and
empirical cholecystectomy. However, EST may increase the morbidity of biliary
reflux or cholelithiasis recurrence. We hypothesized that endoscopic pancreatic
sphincterotomy (EPS) can save the function of biliary sphincter and prevent the
recurrence of ARP.
Aims & Methods: The aim of the study is to evaluate the effectiveness of EPS
combined pancreatic duct stent for preventing ARP caused by biliary microlithia-
sis. 67 patients with ARP from 2005 to 2016 were diagnosed as biliary micro-
lithiasis by endoscopic retrograde cholangiopancreatography (ERCP), bile
microscopy or intraductal ultrasonography (IDUS). The whole was divided
into two groups according to endoscopic therapy by EST or EPS with pancreatic
stent. Rate of pancreatitis recurrence, early complication of post ERCP pancrea-
titis (PEP), and late complications (3 months after treatment) which included
cholangitis, cholecystitis or cholelithiasis were compared between the two groups.
Results: (1) 38 and 29 patients were included in EST and EPS group, respectively.
The mean age and follow-up duration of EST and EPS were 48.4 15.1yrs,
45.7 36.5months and 45.6 15.2yrs, 24.1 26.3months, respectively. (vary
from 2months to 115months). (2) The mean episodes of ARP in EST and EPS
group before endoscopic therapy were 3.9 3.3 times and 7.9 11.8 times. (3)
Four patients in EST group and 6 patients in EPS group suffered PEP after the
endoscopic therapy (P¼ 0.418). (4) 15 patients in EST group and 3 in EPS group
suffered recurrent pancreatitis. The efficiency in EST group and EPS group is
68.4% and 89.6% respectively (P¼ 0.039). (5) The incidence of late complica-
tions is 18.4% in EST group and 10.3% in EPS group (P¼ 0.567).
Conclusion: EPS combined with pancreatic stent is a promising strategy to pre-
vent recurrence of ARP due to biliary microlithiasis.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Periampullary diverticulum (PAD) is frequently asymptomatic,
usually encountered in patients undergoing endoscopic retrograde
cholangiopancreatography(ERCP).
Aims & Methods: The aim of this study was to investigate the association of PAD
with bile duct stones, biliary cannulation success and
different types of PAD.
A total of 1164 ERCP procedures were performed in 833 patients in a single
center by single operator from January 2012 to October 2016 after excluding
post liver transplant, emergency procedures. Out of 1164 ERCP procedure 49
patients were encountered with PAD, they were compared with 635 controls
without PAD in terms of age, sex, CBD cannulation success and complications
of ERCP.
BASELINE CHARACTERISTICS AND COMPARISON OF FINDINGS
PAD GROUP
(n¼ 49)
NON-PAD
GROUP
P-VALUE
(n¼ 635) P-VALUE
Age(mean SD) 59.10 15.16 52.74 17.94 50.05
Sex (male/female) 21/28 315/320 NOT
SIGNIFICANT
Patients with bile duct stones
(n¼ number of patients) %
35 (71.4%) 210 (33.1%) 50.05
CBD cannulation (easy/difficult)
n¼ numbar of patients %
35/14 (75.5%) 263/72 (82.3%) 50.05
Complications(bleedi
ng/pancreatitis/perfor ation)%
2%/2%/2% 0.1%/0.1%/0.1% 50.05
Results: PAD identified in 49 (4.2%) cases, PAD type 1 (inside the diverticulum)
was found in 7 pts (14.3%), Type ll (at edge/brim) in 34 pts (69.4%), Type lll
(adjacent/near diverticulum) in 8 pts (16.3%). Patients with PAD had mean age
59.10 years (range 18 to 84 years) 17 were550 yrs while 32450yrs, compared to
controls mean age 52.74 yrs (range 12 to 95 yreas) 230 were 550 yrs while
remaining more than 50yrs. P-value (50.5). PAD predominantly occurred in
females 28/49 cases.
Patients with PAD had increased prevalence of gallstone/biliary stone disease
compared with controls, 71.4%vs 33.1 (p5 0.01) compared with controls. Easy
cannulation of CBD without difficulty (PRECUT/Pacreatic cannulation/stent-
ing) was more frequent in patients controls (82.3%) compared to PAD group
(75.5%) p5 0.05. However, CBD clearance was same in both groups490% (p
value not significant) Incidence of complications in PAD group bleeding (2%),
Pancreatitis (2%) and one small retroduodenal perforation (2%) all managed
conservatively. In without PAD group bleeding 0.6%, pancreatitis 0.7% and no
perforation.
Conclusion: PAD is seen with advanced age, predominantly in female and fre-
quently associated with bile duct stones. In this case control study PAD did not
appear to be a barrier for successful ERCP with acceptable complication rates.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Since the emergence of the fiberoptic single-operator cholangio-
scopy, the sensitivity for detecting bile duct lesions has been increased and the
management of difficult stones is facilitated, establishing its superiority over
standard endoscopic retrograde cholangio-pancreatography and often altering
the clinical management. Digital cholangioscopes provide higher-resolution ima-
ging of the pancreatobiliary tract compared with the fiberoptic instruments.
Aims & Methods: The aim of the present study was to assess the frequency of
digital cholangioscopy (DC) to alter the diagnosis and clinical management of
bile duct disease compared with fiberoptic cholangioscopy (FC). A retrospective
review of 68 cases needing cholangioscopy, and which were performed in our
department, was conducted. Patients enrolled exhibited stenosis of the biliary
tract (67.6%), stones (20.6%), primary sclerosing cholangitis (PSC 4.4%) or
other rare cause for cholangioscopy (e.g. stent migration, guidewire passage).
All patients underwent endoscopic retrograde cholangiography (ERC) before
cholangioscopy. Aim of cholangioscopy was to confirm ERC diagnosis, obtain
adequate biopsy specimens for histological evaluation and remove biliary stones.
From 5/2009 to 8/2015 all cholangioscopies were performed with the fiberoptic
scope. From 9/2015 to 3/2017 all cholangioscopies were performed with the
digital scope.
Results: 30 women and 38 men with a mean age of 61years underwent cholangio-
scopy. Fiberoptic cholangioscope was used in 39 cases and digital cholangioscope
was performed in 29 cases respectively. Cholangioscopy-guided biopsies for
malignancy were obtained in 11 and 15 cases respectively. In only one case of
FC (9.1%) biopsy confirmed the endoscopic diagnosis, in contrast with 10 cases
of DC-guided biopsies (66.7%) confirming the diagnosis. In 13 patients who
underwent DC (44.8%) the initial diagnosis and clinical management was altered
after cholangioscopy (e.g. cancer diagnosis, successful EHL lithotripsy), in con-
trast with 11 cases of FC (28.2%). Moreover it was unanimously felt by our staff
that DC was an easier procedure compared to FC.
Conclusion: Our data suggest that DC has overcome the impediment of fiberoptic
technology, providing increased sensitivity and specificity for visual impression
diagnosis of malignancy and successful therapy of biliary stones. Moreover DC
has the ability to alter more often the initial ERC diagnosis or management
compared to FC and provides a new sophisticated and easy to use equipment.
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Introduction: Tokyo Guidelines 2013 (TG13) have been used worldwide to assess
the diagnostic criteria and severity grading of acute cholangitis. Acute cholangitis
is a life-threatening disease, and the emergency biliary drainage procedure is
necessary for moderate or severe cases, according to TG13. In recent years,
with an aging society, necessity to perform endoscopic retrograde cholangiopan-
creatography (ERCP) in elderly patients are increasing. However, few studies
have examined the efficacy and safety of emergency ERCP in super-elderly
patients with severe cases.
Aims & Methods: In this study, we examined the efficacy and safety of emergency
ERCP in super-elderly patients with moderate to severe acute cholangitis,
according to TG13. We performed 178 emergency ERCP procedures in 132
patients during 3 years (June 2014–December 2016). We determined patients
90 years as ‘‘super-elderly’’ and those 590 years as ‘‘non-super-elderly’’.
Evaluation criteria included comorbidities, oral administration of anticoagu-
lants, cause of cholangitis, ERCP procedure (examination time, endoscopic bili-
ary sphincterectomy (EST)/pre-cut papillotomy, treatment success rate, presence
or absence of peripapillary diverticula and papilla after EST, sedation dosage),
ERCP-related complications (bleeding, perforation, post-ERCP pancreatitis,
post-ERCP pneumonia, death within 30 days after ERCP procedure), and
anesthesia-related complications (blood pressure decrease, pulse reduction,
respiratory depression).
Results: We examined 69 males (52.3%) and 63 females (47.7%). Women
accounted for a larger proportion in the super-elderly group (71% vs 40%).
The average age was 92.5 years (range, 90–97) in the super-elderly group and
77.9 years (range, 50–89) in the non-super-elderly group. The super-elderly group
comprised 54 ERCP procedures (moderate, 32; severe, 22) against 124 ERCP
procedures (moderate, 104; severe, 20) in non-super-elderly group, and severe
cases observed in the super-elderly group were statistically significant
(p5 0.001). Regarding comorbidities, chronic heart and renal failure were sta-
tistically dominant in the super-elderly group. However, no difference was seen in
the presence of other diseases and receiving anticoagulant medication between
the two groups. The causes of acute cholangitis were common in both groups
with common bile duct stone (46% vs 46%), followed by malignant obstruction
(9% vs 12%) and benign stenosis (0% vs 5%), but no difference was found.
Regarding the ERCP procedure, the examination time was longer in the super-
elderly group (37.5 28.1min vs 29.2 24.0min, p¼ 0.044), but there was no
difference in the procedure success rate (93% vs 97%, p¼ 0.249) and the presence
of peripapillary diverticula. The patients were sedated using midazolam (MDZ)
plus pentazocine (PTZ). The amount of anesthetic used was less in the super-
elderly group (MDZ: 2.2 vs 3.3mg, p5 0.001, PTZ: 3.1 vs 5.4mg, p¼ 0.005).
Regarding (i) ERCP-related and (ii) anesthesia-related complications, these were
higher in the super-elderly group [(i) 15% vs 9%, p¼ 0.293, (ii) 17% vs 7%,
p¼ 0.0504)]. Every patient with complication improved with conservative treat-
ment, and no intravascular or surgical treatment was required.
Conclusion: Acute cholangitis in super-elderly patients was more likely to become
severe and the complications were higher than that in non-super-elderly patients.
When performing an emergency ERCP procedure in super-elderly patients, we
should particularly pay attention to developing complications in patients with
moderate or higher acute cholangitis, according to TG13.
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Introduction: Dysplasia may persist at the termination of the common bile duct
(CBD) after endoscopic ampullectomy. Radiofrequency ablation (RFA) could be
an interesting alternative to surgery to reduce the risk of invasive cancer with less
morbi-mortality.
Aims & Methods: The aim of the study was to evaluate the efficacy and morbidity
of endo-biliary RF for the treatment of residual endo-biliary dysplastic lesions
after endoscopic ampullectomy. A prospective open-label multicenter study
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included 20 patients with low-grade dysplasia (DBG) or high grade (DHG)
lesions in the CBD, confirmed by a double anatomopathological lecture, in
relation to a residual adenomatous bud after endoscopic ampullectomy for
ampullary adenoma. The lesions should extend to a maximum length of 20mm
in the CBD. Endoscopic retrograde cholangio-pancreatectomy (ERCP) was per-
formed under general anesthesia with the Habib TM EndoHPB probe (EMcision,
UK) (effect 8, power 10Watts, 30 s). Biliarypancreatic stent were placed at the
end of the procedure. The primary endpoint was the rate of residual neoplasia
(eg, DBG, DHG or invasive carcinoma) at 1 year after treatment. Secondary
endpoints were: 1) residual neoplasia at 6 months after treatment; 2) rate of
surgery at 12 months; 3) adverse events.
Results: The mean age (SD) was 67 years (11), with 12 men and 8 women.
RFA was performed on average (SD) 1.9 years (3.5) after ampullectomy. The
mean resected ampullary adenoma size (SD) was 24.9mm (10.2), and 7
patients had adjacent duodenal mucosectomy at the time of ampullectomy.
The histology of the resected ampullary adenoma was DBG for 7 patients,
DHG for 12 patients, and in situ carcinoma for 1 patient. Lateral margins
were healthy for 13 patients. CBD recurrence was diagnosed predominantly on
ERCP and/or endoscopic ultrasonography surveillance procedures with an esti-
mated mean infiltration height (SD) of 11.2mm (4.5). The passage of the
RFA probe was judged to be easy in 100% of cases with visibility of the radio-
paque markers judged satisfactory to very satisfactory in 80% of the cases. All
patients included had RFA without any technical problems. All patients had
biliary stent (4 SEMS 10mm, 16 plastic stents 10 French) implanted following
RFA and 5 (25%) had a pancreatic stent. The residual rate of DBG, DHG,
invasive carcinoma at 6 months and at 12 months after treatment were 25%
(5/20, DBG, carcinoma) and 45% (9/20, DBG, carcinoma) respectively. The
adverse events were as follows: 4 benign pancreatitis all medically treated, 2
patients had angiocholitis requiring biliary stent replacement, 1 patient had an
episode of unexplained spontaneously resolved abdominal pain (normal CT scan,
colonoscopy and biological tests). At M12, one patient presented with a biliary
scar stricture resolved by dilation and a calibration biliary stent.
Conclusion: Endobiliary RFA performed on residual endo-biliary dysplastic buds
after ampullectomy is an alternative to surgery, with a rate 55% dysplasia era-
dication at 12 months after a single RFA session. Regular monitoring of these
patients is still necessary considering recurrence rate. Multiple RFA sessions may
be proposed in case of incomplete results.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0242 EXPERT VALIDATION OF A NOVEL MECHANICAL
CUTTING PAPILLA
S. E. Van Der Wiel1, A.D. Koch2, M.J. Bruno1
1Gastroenterology And Hepatology, Erasmus University Medical Center,
Rotterdam/Netherlands
2Erasmus MC Rotterdam Gastroenterology and Hepatology, Rotterdam/
Netherlands
Contact E-mail Address: s.e.vanderwiel@erasmusmc.nl
Introduction: Simulation-based training has become an important pillar in com-
petence-based learning in medicine, especially in training novice endoscopists.
Several simulators have been validated and implemented in training curricula
pertaining gastrointestinal endoscopy. Surprisingly, limited data are available
on simulators in ERCP training, despite the fact that ERCP seems to be an
ideal platform for simulator-based training due to its technical complexity. The
available simulators are difficult to implement in training settings due to the lack
of realism or use of live animals or ex-vivo components. Recently, the Boškoski-
Costamagna ERCP Trainer was validated as a very realistic training model by
our study group. A novel mechanical papilla has been designed allowing to train
(precut) sphincterotomy. The mechanical papilla is inserted into the simulator. A
specific alloy allows for electrical conduction and cutting of the material using
standard sphincterotomes and needle knives.
Aims & Methods: The aim of our study was to determine the expert validity of
this cutting papilla and its didactic value for training sphincterotomy, as judged
by experts. Expert participants with more than 2500 ERCPs lifetime were invited
to perform a sphincterotomy and fill out a questionnaire on the realism of the
sphincterotomy procedure and it’s didactic value.
Results: A total of 40 ERCP experts were included. All experts were men, origi-
nating from 16 different countries with a mean age of 49.6 years (range 37–65).
Thirty-seven participants were gastroenterologists (92.5%), 3 participants were
surgeons (7.5%). The mean number of years of endoscopic experience was 20.9
(range 10–40). Experts’ opinion on realism of performing a sphincterotomy was
rated 6.98 on a ten-point Likert scale, resemblance of the performed maneuvers
7.60 and tactile feedback 6.78. When asked if the cutting was perceived as
expected, experts rated 6.35 and the cutting result was rated 7.30 on a ten-
point scale. The potential as a training tool of the cutting papilla in training
novices was rated 3.93 on a four-point scale, and there was a high agreement
among the experts to include the papilla in the training of novices (3.93 on a four-
point scale).
Conclusion: This is the first mechanical papilla available for training sphincter-
otomy on the Boškoski-Costamagna ERCP Trainer and demonstrates good
expert validity. ERCP experts highly agree on the didactic value and added
value of this papilla in the training curriculum of novice endoscopists.
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Introduction: Complications in endoscopy can lead to adverse clinical events. The
likelihood of developing a complication depends on the degree of risk associated
with a certain procedure. It is generally noted that riskier the procedure larger is
the chance for a complication and higher the likelihood for medico legal issues.
This is relevant as in the event of the risk materialising, patients make seek legal
redress. The aim of this study was to investigate the degree of success of medico
legal claims based on the nature of the endoscopic procedure and the outcome of
the claims.
Aims & Methods: The National Health Service Litigation Authority (NHSLA)
database in U.K. was searched using a Freedom of Information request (F/2405)
to investigate endoscopic claims notified to the NHSLA between 2010/11 and
2014/15. The terms "Gastroscopy", "Sigmoidoscopy", "Colonoscopy", "PEG"
and "ERCP" were used to search the database. They were then analysed for
procedure type, characteristics and outcomes. StatsDirect statistical software
was used for statistical analysis.
OUTCOME OF ENDOSCOPY CLAIMS
PROCEDURE OPEN SUCCESSFUL UNSUCCESSFUL
Gastroscopy 6 10 7
PEG 12 19 12
Sigmoidoscopy 17 13 5
ERCP 22 26 24
Colonoscopy 50 40 28
Results: A total of 291 claims were notified to the NHSLA during this period.
107 (36.7%) of claims still remain ‘open’. Analysing outcomes by procedures
reveals a success rate of 44%, 44%, 37%, 36% and 34% (rounded up to the
nearest whole figure) for Gastroscopy, PEG, Sigmoidoscopy, ERCP and
Colonoscopy claims respectively. There is no statistical difference between the
proportions comparing Gastroscopy and Colonoscopy (StatsDirect software
used)
Conclusion: A significant number of claims remain open leading to concern and
worry among endoscopists. The impact on practitioners after a successful claim is
unknown and merits further investigation. Procedures considered as dangerous
like ERCP and Colonoscopy have the least successful claims. It is imperative that
clinicians remain vigilant. Performing Gastroscopy is dangerous and so is under-
taking a Percutaneous Endoscopic Gastrostomy. Endoscopists should tighten
their approach to all procedures.
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Introduction: Choledochocele has been rarely recognized. We focus on intra-
ampullary choledochocele (IAC). We had experienced some cases with IAC as
refractory access to bile duct (BD). IAC has small cyst within ampulla regulated
by Oddi’s sphincter, so the BD axis has changed via IAC. The cases with IAC
would require a high technical skill for axis alignment or alternative strategy such
as infundibulotomy or precut. We propose advantage of conventional ERCP
(cERCP) with contrast medium, which provides images of IAC and leads to
evaluate the difficulties in cannulation.
Aims & Methods: This study aims to recognize the morphology of intra-ampul-
lary bifurcation of bile duct (BD) and pancreatic duct (PD). Its variation allows
the elucidation of the reason for difficulties in cannulation. The current study is a
retrospective consecutive case study that is conducted in a single facility, with a
study period of 8 years. Our strategy for ERCP was carried out with the contrast
medium injected via a catheter, but without guide wire (GW) seeking. Intra-
ampullary bifurcation was particularly visualized with the contrast medium,
and X-ray images were magnified sequentially 5–10 times each. The eligibility
criteria were: it must be naive papilla and both of BD and PD must be visualized.
The following factors were evaluated: ampulla shape, number of orifices, angle of
intra-ampullary bifurcation and presence of IAC. The Location, size and shape
of IAC were observed. The requirement of GW placement on PD to access BD
were evaluated. The shapes of the ampulla were divided into three groups: long
nose (L/N), meaning a long protrusion, Dome (D), meaning a hemisphere and
flat (F). The IAC location were classified into BD (Ab), PD (Ap) and common
channel (Ac). The choledochocele shapes were divided into three groups: spindle
(Sp), sphere (Sh) and oval (Ov). IAC was also recognized on magnetic resonance
cholangiopancreatography (MRCP). We analyzed our results of image database
with descriptive epidemiology.
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Results: There were cases of 1223 naive papilla out of 2226 cases in total. The
success rate to access BD with naive papillae was 97.7% (1195/1223) and overall
post-ERCP pancreatitis (PEP) was 1.3% (29/2226). The eligible patients were 908
(505 male and 403 female), among whom IAC was identified in 6.0% (54/908).
The prevalence of IAC in the L/N, D and F types were 8.9% (48/542), 1.2% (4/
339) and 7.4% (2/27), respectively. IAC was significantly higher in the L/N
(p5 0.01) and F (p5 0.05) types than in the D type. The choledochocele
shapes of Sp, Sh and Ov were 59.3%, 13.0%, 27.8%, respectively. The average
size was 8.1mm (3.7–18.3) in diameter. The location of IAC in Ac and Ab were
63.0% and 37.0%. The IAC in Ab was found with L/N shape only. Patients of
53.7%(29/54) required GW placement on PD to access BD. IAC was alterna-
tively seen on MRCP in 10%(3/30).
Conclusion: Choledochocele is rarely seen on even cERCP, in addition the visua-
lization of IAC has been rarely reported. IAC could be actually visualized with
prudent contrast medium injection. Our results showed miscellaneous variations
in the intra-ampullary images. IAC would require refractory pursuit of the axis
alignment due to its unexpected pathway within ampulla to access BD. Moreover
6.0% prevalence of IAC should not be ignored. IAC can be one of the factor of
refractory cannulation. cERCP with focus on ampulla could the difficulty in
cannulation. On the other hand, WGC would not do. The previous randomized
control trials showed no difference to access to BD between WGC and cERCP.
However, both procedures still remained cases with refractory cannulation. It has
been reported that refractory cannulation might cause PEP1). Therefore careful
attention should be paid while passing through IAC to avoid PEP. According to
ampulla shapes, especially of L/N and F, cERCP would be recommended to
identify the presence of IAC. It will be a warrant strategy to choose.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Scienza di Torino, Molinette Hospital, University of Turin, Turin/Italy
15Digestive Endoscopy Unit, Department of Gastroenterology, Papa Giovanni
XXIII Hospital, Bergamo/Italy
16Emergency Endoscopy Unit, Borgo Trento Hospital, Verona/Italy
17Department of General Surgery and Transplantation, Niguarda Ca’ Granda
Hospital, Milan/Italy
18Liver Surgery, Transplantation and Gastroenterology, University of Milan and
Istituto Nazionale Tumori Fondazione IRCCS, Milan/Italy
19Gastroenterology and Hepatology Unit, Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan/Italy
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Introduction: Most appropriate endotherapy of biliary anastomotic strictures
(AS) remains to be defined.
Aims & Methods: Aim is to retrospectively report the endotherapy for duct-to-
duct AS in 2013, procedure related complications and medium-term outcome
results in Italy. A questionnaire was sent to the Endoscopy Units working with
Italian Liver Transplantation Centers (BASALT study group).
Results: At present sixteen of the 19 Units (84%) returned the questionnaire.
Complete endotherapy data and follow-up are available for 182 pts. One-hun-
dred and two patients have been treated with plastic multistenting (PM), 27 with
fully covered SEMS and 53 with single stenting (SS). Radiological success was
achieved in 144 pts (79%), i.e. 86% of PM, 89% of fully covered SEMS and 60%
of SS (p5 0.01 vs PM). Recurrence occurred in 31 pts, i.e. 21% of pts in whom
radiological success was achieved: 11% of PM (p5 0.0001 vs SEMS and
p5 0.05 vs SS), 41% of fully covered SEMS and 17% of SS. After failure of
first-line endotherapy (36) or recurrence (31), patients were re-treated with
endotherapy (75%), surgery (21%) or percutaneous balloon dilation (3%); one
patient dropped out because of death unrelated to endotherapy. Second-line
endotherapy was PM for 26%, fully covered SEMS for 52% and SS for 22%
of pts and radiological success was achieved in 82% of them (in 86%, 89%, and
60% with PM, SEMS and SS respectively). Procedure-related complications
occurred in 7.8% (51/656), i.e. 2.6% pancreatitis (1 severe leading to death),
4.1% cholangitis and 0.9% bleeding. Overall clinical success was achieved in
83% after a median f-up of 25 mos and no need of surgery in 92% of patients.
Conclusion: Endotherapy is confirmed as the preferred first-line and rescue
option for AS. Progressive plastic multi-stenting is most frequently used. Single
stenting has suboptimal results and should be abandoned. Use of SEMS is effec-
tive, but recurrences seem to be frequent, although a larger patients’ sample
needs to be evaluated.
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4Hôpital Saint Joseph, Marseille/France
5Digestive Diseases Institute, University of Nantes Institute of Digestive Disease -
Digestive Diseases Institute, University of Na, Nantes/France
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Introduction: EUS-guided Cysto-Enterostomy (EUCE), technique indicated for
drainage of symptomatic pancreatic pseudocysts and other peri-enteric fluid col-
lections, requires specific skills for which dedicated models are needed. Based on
a compact EASIE model (Erlangen Active Simulator for Interventional
Endoscopy) we developed two ex-vivo porcine models of retrogastric cysts and
evaluated learning performance within the frame of a structured training
program.
Aims & Methods: The first model was made of porcine colon (i.e. ‘‘natural cyst’’),
and second one was made with an ostomy bag (i.e. ‘‘artificial cyst’’). All proce-
dures were achieved with EUS scope under fluoroscopy. Both models were eval-
uated prospectively over a 2-days session involving 14 students and 5 experts.
Results: ‘‘Natural cyst’’ and ‘‘artificial cyst’’ were prepared respectively within 10
and 16.5 minutes (p¼ 0.78). More than 10 EUCE procedures were done in each
model. Model grading (analogic scale) showed no significant difference for pri-
mary endpoint of global satisfaction (p¼ 0.06). Regarding secondary endpoints,
difference was not significant for overall impression of realism (p¼ 0.75) whereas
it was significant favoring ‘‘artificial cyst’’ in terms of ability to teach procedural
steps (p¼ 0.01) and ease of puncture (p¼ 0.03) because of less elasticity.
Moreover, experts considered ability to improve students’ proficiency superior
with ‘‘artificial cyst’’ (p¼ 0.008)
Conclusion: Both ‘‘artificial and natural cysts’’ are efficient for EUCE training in
terms of global satisfaction. However, the ‘‘artificial cyst’’ model appears to
make procedure easier and better to teach procedural steps improving students’
proficiency. Larger applications of this model are needed to validate as a stan-
dard of training.
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Introduction: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)
is an established procedure for obtaining a pathological specimen. However,
detailed techniques of EUS-FNA vary substantially across medical centers.
There is a need to establish more efficient method for better diagnostic accuracy
and adequate sample. In the present study, we investigated the suction method
for collecting specimens by EUS-FNA.
Aims & Methods: The aim of our study was to compare conventional suction
using a 20mL syringe and capillary suction during EUS-FNA. Patients who
referred to EUS-FNA for solid mass lesion were prospectively enrolled. We
performed EUS-FNA with two needle passes and applied each pass of different
techniques which were randomly allocated. The diagnostic accuracy, the quantity
of samples (0–5.5 represents sufficient material for adequate for histological
interpretation and a high-quality sample), the degree of contamination, and
the amount of blood (0–2.2 represents significant amount of blood) were com-
pared between conventional suction and capillary suction. Further analysis was
carried out in the patients with pancreatic cancer. For patients with negative
EUS-FNA, surgical specimen evaluation, results of other diagnostic investiga-
tions and/or long term clinical follow-up (6 months) were used to establish the
definitive diagnosis.
Results:During the study period, 96 patients underwent EUS-FNA were enrolled
and 7 patients were excluded due to loss of follow-up. Finally 89 patients (aver-
aged 68.5 y/o, M;F¼ 47;42) were analyzed. There were 60 pancreatic lesions (42
pancreatic cancer, 6 neuroendocrine tumor, etc.), 17 lymph adenopathy, 6 sub-
mucosal lesions, 6 other lesions biopsied, with a mean diameter of 28 3mm.
Although there was no significant difference in the diagnostic accuracy (86.5%
vs. 79.8%, p¼ 0.32), the quantity of samples (3.64 vs.3.43, p¼ 0.21) and the
degree of contamination, the samples obtained by conventional suction con-
tained more blood compared to those obtained by capillary suction (0.17 vs.
0.02, p5 0.05)). Moreover, conventional suction showed favorable diagnostic
accuracy (83.3% vs. 69.0%, p¼ 0.20) and significantly higher quality of samples
(3.38 vs. 2.74, p5 0.05) than capillary suction, in the patients with pancreatic
cancer.
Conclusion: Capillary suction was effective in the EUS-FNA sampling and asso-
ciated with less contamination with blood, but conventional suction is recom-
mended in case of fibrotic pancreatic cancer for obtaining high-quality sample.
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Introduction: The effectiveness of endoscopic ultrasound (EUS) guided tissue
acquisition using a 25G-gauge core biopsy needle without and with a stylet has
never been compared.
Aims & Methods: The aims of this study were to evaluate the feasibility, safety,
and diagnostic yield for malignancy of the 25-gauge core biopsy needle without
(S-) a stylet and to compare its performance with that of the 25-gauge core biopsy
needle with (Sþ) a stylet. This study was a single-center randomized clinical trial.
From March 2013 to January 2016, a total of 114 patients (57 in a S- group and
57 in a Sþ group) with solid lesions were included. S- or Sþ EUS guided tissue
acquisition was performed using a 25-gauge core biopsy needle without an on-site
cytopathologist.
Results: There were no significant differences in technical success (100% vs.
100%, P¼ 1.000), the mean number of needle passes (6.8 vs. 7.0, P¼ 0.556), or
complication (0% vs. 3.5%, P¼ 0.496) between the S- group and the Sþ group.
The S- and Sþ groups exhibited comparable outcomes with respect to cytologic
diagnostic yield (91.2% vs. 93.0%, P¼ 1.000), histologic diagnostic yield (87.7%
vs. 86.0%, P¼ 1.000), and needle malfunction (7% vs. 0%, P¼ 0.118). The pro-
cedure time was significantly shorter in the S- group than in the Sþ group (32.4
vs. 39.7min, P5 0.001).
Conclusion: EUS guided tissue acquisition using a 25G-gauge core biopsy needle
without a stylet did not decrease the diagnostic yield for malignancy and is
associated with shorter procedure time.
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Introduction: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)
has been shown to be efficient for diagnosis of pancreatic masses. Only with
the smear method, however, its diagnostic efficacy may vary greatly depending
on the level of proficiency of the cytopathologists. On the other hand, the cell
block (CB) method allows cytological and/or histological evaluation with hema-
toxylin and eosin (HE) staining and with immunostaining for serial sections if
necessary.
Aims & Methods: The aim of this study was to evaluate the diagnostic efficacy of
EUS-FNA for a pancreatic masse using the CB method without rapid on-site
cytology retrospectively. A total of 206 patients with pancreatic masses (head: 87,
body: 86, tail: 33) who underwent EUS-FNA using a GF-UL240P or GF-
UCT260 (Olympus Medical Systems, LTd., Tokyo, Japan) between June 2005
and November 2016 were included in this study. The needles used were 22/25G
needles. At least two passes were made during the procedure (mean 3.0 0.9
passes). Adequate specimens were regarded to be those in which whitish flag-
ments were macroscopically achieved. The samples were immediately fixed in
10% formalin and processed by the cell block method using sodium alginate.
Rapid on-site cytology was not performed. All samples were stained by hema-
toxyline and eosin, periodic acid Schiff and Alcian-blue, and immunohistochem-
ical stainings if necessary. Class IIIb, IV, and V were defined as malignant. The
final diagnosis was based on histological findings of surgicaly resectioned speci-
men, image diagnosis and clinical course for more than six months.
Results: The final diagnosis was malignancy in 184 patients (pancreatic
ductal cancer (PDC), 171; neuroendocrine tumor (NET), 9; malignant lym-
phoma, 2; metastasis of malignant melanoma, 1; solid pseudopapillary neoplasm,
1), and benignancy in 23 patients (autoimmune pancreatitis (AIP), 11; chronic
pancreatitis, 7; organizing pancreatic pseudocyst, 4; IPMN, 1). Adequate tissue
sampling was successfully achieved in 97% (199/206). Of 199 patients with suc-
cessful tissue sampling, sensitivity, specificity and accuracy for malignancy were
98% (175/179), 95% (19/20) and 97% (194/199). The diagnostic accuracy of
PDC only by HE and PAS-AB staining was 76% (129/170) (Class V 91; IV
36; IIIb 2), but by adding immunochemical staining, the accuracy of PDC was
98% (167/170) (Class V 112; IV 50; IIIb 5). In the cases of highly suspicious
NET, all samples were stained by chromogranin A or synaptophysin and the
diagnostic accuracy of NET was 100% (6/6). No procedure-related complica-
tions occurred.
Conclusion: EUS-FNA of a pancreatic mass with the CB method without rapid
on-site cytology showed high accuracy for definitive diagnosis.
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Introduction: Patients with malignant biliary obstruction conventionally undergo
percutaneous transhepatic biliary drainage (PTBD) after failed endoscopic retro-
grade cholangiopancreatography (ERCP) (1). While PTBD is effective, it is asso-
ciated with significant morbidity, such as bile leakage, bleeding, and
pneumothorax, and involves uncomfortable external drainage (2). Endoscopic
ultrasound-guided biliary drainage (EUS-BD) is a minimally invasive endoscopic
option increasingly offered as an alternative to PTBD for malignant biliary
obstruction after failed ERCP (3). Although a recent meta-analysis reported
better clinical efficacy and superior safety of EUS-BD when compared to
PTBD, data from mainland China is sporadic (4).
Aims & Methods: We aimed to compare efficacy and safety of EUS-BD to PTBD
in patients with malignant biliary obstruction after failed ERCP at a single
tertiary referral center from mainland China. From November 2011 through
December 2015, consecutive patients undergoing EUS-BD or PTBD for malig-
nant biliary obstruction after failed ERCP were included. Demographical, bio-
chemical, and outcome data were registered for each group. The primary
outcomes included technical success rate and incidence of complications, the
second outcomes were clinical success rates and re-intervention rate.
Results: A total of 93 patients (mean age 68 13.5 years, 49 males) were included,
33 in the EUS-BD group and 60 in the PTBD group. Both groups were similar in
terms of age, gender, baseline bilirubin and functional status. Technical success
was achieved in 32 (97%) of 33 patients in the EUS-BD group and in 57 (95%) of
60 patients (p4 0.05) in the PTBD group. The clinical success (jaundice relief:
reduction in serum bilirubin by 50% within the first month) was achieved in all
patients with technical success (32/32, 100% EUS-BD vs. 57/57, 100% PTBD).
Procedure-related complication rates were higher in the PTBD group (18/57,
31.6%: 5 bleeding, 5 catheter site infection, 4 bile leaks, 2 cholangitis, and 2
tube malposition) than in the EUS-BD group (3/32, 9.4%: 2 bleeding and 1
cholangitis) (p¼ 0.018). Rate of re-intervention appeared to be lower in the
EUS-BD group (2/32, 6.3%: 2 stent occlusion) than in the PTBD group (17/
57, 29.8%: 6 stent occlusion, 5 catheter site infection, 4 bile leaks, and 2 tube
malposition) (p¼ 0.009).
Conclusion: Despite similar high technical and clinical success rates compared
with PTBD, EUS-BD was associated with reduced rate of complications and
required fewer re-interventions. EUS-BD seems a better alternative than PTBD
for malignant biliary obstruction after failed ERCP.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Distal CBD masses have always been a diagnostic dilemma. They
are difficult to diagnose with any modality used. Brush cytology under ERCP
guidance was used uptill now and also intraductal biopsies were used. The yield
was hardly around 60% using all together. We started doind EUS localization of
these difficult to identify distal CBD masses and took FNA from them. We
devised a protocol to see the results of EUS FNA and brush cytology in the
diagnosis of these masses.
Aims & Methods: We aimed to study the efficacy of EUS guided FNA for
attaining tissue from distal CBD masses and comparing it to ERCP guided
brush cytology from the same masses. 56 cases with distal bile duct mass with
obstructive jaundice in the last 3 years were taken for the study. The protocol we
followed First - EUS was done using a linear echoendoscope, mass identified and
FNA performed with a 25 G needle making 2 to 5 passes and material sent for
cytology. Same patients subjected to ERCP. A wide papillotomy was performed
and over the wire cytology brush was used and brush cytology was obtained.
Two passes were made and material taken on a slide and sent for cytology after
wet fixation.
Results: Total number of cases 56 Age (range) 57.2 13.6 Male to Female 40: 16
Total Serum Bilirubin 90mg/dl) 5.9 6.4 Mean size of the mass 12mm (7mm to
30mm). Mean Number of passes with FNA needle 2.5 (2 to 5 passes). Mean
number of passes with cytology brush 2 (2to 5). Positive diagnosis obtained with
FNA 47 (83.9%). Positive Diagnosis obtained by brush 34 (60.7%)
Diagnosis in Positive Cases
FNA (47) Brush Cytology (34)
Malignancy 38 (80.8%) 23 (67.6%)
Suspicious Of Malignancy 5 (10.6%) 7 (20.5%)
Benign 4 (8.5%) 4 (8.5%)
With EUS the tumors were sometimes difficult to locate and identify. But giving
some time and instilling water in duodenum were useful techniques to identify the
masses. Only a 25 G needle was used as the FNA had to be taken almost always
from the duodenum and with difficult angles. But we succeeded in taking FNA
from all cases.
Conclusion: EUS FNA is a very effective method for diagnosis of distal bile duct
masses with a certain diagnosis in almost 81% and a suspicious diagnosis in
around 11% cases. Its efficacy is better than ERCP guided brush cytology.
Even small masses are amenable to FNA using EUS guidance. Male over 57
years with jaundice and distal bile duct obstruction has a very likelihood of have
a distal CBD cholangio carcinoma.
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Introduction: Although lumen-apposing metal stents (LAMS) are being increas-
ingly used for drainage of walled-off necrosis (WON), their advantage over
plastic stents is unclear.
Aims & Methods: We aimed to compare the efficacy of LAMS and plastic stents
for drainage of WON.
Symptomatic patients with WON (420% necrosis) were randomized to undergo
transmural drainage using LAMS (Hot AXIOS, 15mm	 10mm) or two double
pigtail plastic stents (7Fr	 4 cm). Reintervention in persistently symptomatic
patients included additional stent placement, percutaneous drainage and/or
endoscopic necrosectomy. Treatment success was defined as symptom relief in
conjunction with resolution of WON on CT at 6-week follow-up. Main outcome
measure was to compare the no. of reinterventions. Secondary outcome measures
were to compare treatment success, procedural duration, resolution of systemic
inflammatory response syndrome (SIRS), clinical and stent-related adverse
events, readmissions and length of hospital stay. Sample size to detect a differ-
ence of 1 in the no. of reinterventions performed at 90% power was calculated at
58 patients.
Results: 60 patients were randomized to LAMS (n¼ 31) or plastic stent (n¼ 29)
placement. While there was no significant difference in the no. of reinterventions
(median 1 [IQR 1–2] for both stent types, p¼ 0.78), the procedural duration was
significantly shorter (15 vs. 42.5 mins, p5 0.001) and stent-related adverse event
rate was significantly higher with LAMS placement (32.3 vs. 6.9%, p¼ 0.02). At
an interim audit, significant adverse events (delayed bleeding [n¼ 3], buried stent
[n¼ 2], biliary stricture [n¼ 3]) were observed in the LAMS cohort after 3 weeks
post-intervention. This necessitated an amendment to the study protocol
whereby a CT scan was obtained at 3 weeks followed by LAMS removal if the
WON had resolved. After protocol amendment, no difference in stent-related
adverse events was observed between the cohorts (LAMS 6.5 vs. plastic 6.9%,
p¼ 0.99). Also, there was no significant difference in treatment success, SIRS
resolution, clinical adverse events, readmissions or length of hospital stay
between the cohorts (Table).
Metal
(n¼ 31)
Plastic
(n¼ 29) p-value
Procedure duration (mins): Median [IQR] 15 (8–25) 42.5 (21–55) 50.001
Resolution of
pre-intervention SIRS (%):
44.4 69.2 0.38
Length of hospital stay (days): Median [IQR] 3 (0–5) 3.5 (2–11) 0.16
Treatment success (%): 96.3 88.0 0.34
Adverse events (%): Overall 41.9 20.7 0.10
Stent-related 32.3 6.9 0.02
Other 9.7 13.8 0.70
No. of reinterventions (n): Median [IQR] 1 (1–2) 1 (1–2) 0.78
Readmissions (%): 29.0 34.5 0.78
Conclusion: Except for shorter procedural duration, there was no significant
difference in treatment outcomes between patients treated with LAMS or plastic
stents. Given the faster resolution of WON, to minimize adverse events, patients
undergoing LAMS placement should undergo post-intervention imaging at 3
weeks followed by stent removal if the WON has resolved.
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Introduction: Obtaining a tissue diagnosis from a lung tumour or a mediastinal
lymph node located lateral to the aorta (para-aortal) is a diagnostic challenge
because of the interposition of the aorta. Invasive surgical procedures like med-
iastinotomy, thoracotomy, or video-assisted thoracic surgery is required for the
diagnosis of these lesions. Lymph node stations immediately anterior to the
aortic arch and lateral to the descending aorta are difficult to access. Lymph
nodes on the ‘‘far-side’’ of major blood vessels can be visualized by endoscopic
ultrasound(EUS), however Fine needle aspiration(FNA) is avoided due to con-
cern for bleeding complications. Tumours and mediastinal lymph nodes located
in the para-aortic region can easily be visualized by esophageal EUS, because the
aorta provides an excellent medium to transfer ultrasound waves.
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Aims & Methods: We aimed to evaluate the feasibility, yield, and safety of EUS-
guided transaortic FNA of lung tumours and para-aortic lymph nodes
We undertook a retrospective case series of 12 consecutive patients with sus-
pected lung cancer or tuberculosis who underwent transaortic FNA during a
study period of 7 years. In all cases, the para-aortal lesion was the only site
suspicious for malignancy/tuberculosis (other lesion/lymph node if present
were negative). Based on CT/PET imaging, a transesophageal FNA performed
through the aorta was considered as the only option to diagnose or stage these
patients by means of a minimally invasive procedure. Seven patients had left-
sided lung mass (mean size 30mm). Four were located in left lower lobe and three
in left upper lobe. Four patients has enlarged para-aortic lymph node (mean size
18mm, range 8–22mm), suspicious for IASLC stations 5(n¼ 1) and 6(n¼ 3).
One patient had anterior mediastinum mass. EUS was performed with a linear
echoendoscope. All aspirates were obtained under real-time US guided FNA by
using a 22/25-gauge needle. A single real-time FNA of the lung mass or lymph
node was performed. The para-aortal area was observed on EUS for 5 minutes to
assess for immediate procedure-related complications.
Results: The final diagnosis was known in 11 patients (5 non-small-cell lung
carcinoma [NSCLC], 2 small-cell lung carcinoma [SCLC], 3 tuberculosis and
one thymolipoma). EUS-FNA established diagnosis in 9 of 12 patients (75%)
(4 NSCLC, 1 SCLC, 3 tuberculosis and 1 thymolipoma). One aspirate revealed
reactive nodal tissue, and one demonstrated nonrepresentative material. One
procedure was abandoned due to complication. Three patients in whom diagno-
sis was not established by transaortic FNA underwent subsequent surgical sta-
ging (1 thoracotomy, 1 mediastinotomy, and 1 VATS), and malignancy was
found in 2 of the 3 patients. Trans aortic FNA was found to be safe. In one
patient, EUS images after FNA were suspicious for a small para-aortic hema-
toma. This patient recovered without any adverse event.
Conclusion: This case series demonstrates the feasibility and probable safety of
single EUS guided transaortic aspiration in para-aortic lesions. The diagnostic
yield is 75 percent. Clearly, further study and very careful selection by expert
EUS operators is needed before this procedure can be routinely recommended.
Advantages of this procedure includes day care procedure, less invasive than
surgical procedures, low cost, good diagnostic yield and can be performed in
poor surgical candidate. Limitations includes single centre study, require EUS
expertise, more data is required. At present, Transaortic FNA should only be
performed in the absence of alternative minimally invasive diagnostic procedures.
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Introduction: Ultrasound-guided endoscopic transgastric drainage (EUSTD) of
pancreatic fluid collections (PFCs) by using double-pigtail plastic stents (DPPS)
requires placement of multiple stents and can be restricted by inadequate drai-
nage and leakage risk. Recently, the use of fully covered self-expanding metal
stents (FCSEMSs) has been reported as an effective alternative.
Aims & Methods: We aimed to evaluate the successful placement of stents, the
complete resolution of PFCs at 6-months, adverse events, and recurrence of
EUSTD of PFCs using DPPS and FCSEMSs.
This was a single-centre retrospective study (2012–2016) on 67 patients with
symptomatic/infected PFCs, who underwent EUSTD. PFCs were drained
using DPPS and FCSEMSs (Hanarostent BCF and Hot AXIOS system).
Results: We included 42 cases of pancreatic pseudocysts (PP), and 25 walled-off
necrosis (WON), drained using FCSEMSs in 51% of cases. The remaining cases
(49%) were drained using DPPS exclusevely. Eighteen (27%) patients had a prior
failed drainage attempt. Median follow-up time was 88 weeks (IQR: 42–140); 19
patients were lost to follow-up (6 deaths during follow-up). The median size of
lesions was 92mm (IQR: 74–120). The overall technical success rate was 78%
(74% for PP and 84% for WON; p4 0.05). Six patients required additional
drainage with a different modality (surgery/percutaneous drainage) and 8 cases
required another EUSTD attempt. Complete resolution of PFCs with DPPS was
lower compared with those that underwent drainage with FCSEMSs (58% vs.
84%; p5 0.05). Complete resolution of PP was lower than in the cases of WON
(65% vs. 79%; p4 0.05). Procedure-related adverse events were noted in 18% of
cases of the DPPS group and 21% in the FCSEMS group (p4 0.05); overall 1
procedure-related death was registred (massive bleeding after a FCSMES place-
ment). Recurrence occurred in 27% cases of PP and in none of WON (p4 0.05);
the recurrence was higher in the DPPS group than in the FCSMES group (43%
vs. 13%; p4 0.05).
Conclusion: EUSTD of PFCs using FCSEMSs improves clinical outcomes with
similar adverse event rates compared with the cases drained with DPPS.
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Introduction: Histological examinations and immunohistochemical stains (IHC)
are necessary for the differential diagnosis of gastrointestinal subepithelial lesions
(SELs). Endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) is the
primary modality in the diagnosis of SELs, but still has limited accuracy. A
new 20 gauge (G) biopsy needle with a core-trap technology (EchoTip
ProCore, Cook Medical) has been developed with a large core size and
enhanced flexibility.
Aims & Methods: The aim of this multicenter study was to determine the feasi-
bility, efficacy and safety of EUS-FNB with the new 20G needle in diagnosing
SELs. Data retrieved from a prospectively collected database at five medical
centers were analyzed and all consecutive patients with SELs undergoing EUS-
FNB with the 20G needle were included in the present study. The reference
standards for the final diagnosis were histology on surgical specimen or clinical
follow-up.
Results: A total of 50 SELs in 50 patients (22 males, mean age 61.5 14.8 years)
were included. The mean lesion size was 43.1 17.5mm. The lesion locations
were esophagus (n¼ 1), stomach (n¼ 37), distal duodenum (n¼ 5), rectum
(n¼ 6), and colon (n¼ 1). The procedure was technically feasible in all patients.
Mean number of passes required to reach a diagnosis was 2.2 (range 1–4).
Definitive diagnosis with full histological assessment including IHC was obtained
in 88% (44/50) of the patients. Diagnosis of EUS-FNB showed 36 (72%) malig-
nant SELs (32 GISTs, 1 metastasis from breast cancer, 1 leiomyosarcoma, 1
carcinoid, 1 SEL-like adenocarcinoma), 8 (16%) benign SELs (3 leiomyomas,
4 schwannomas, and 1 lipoma), and 6 (12%) indeterminate SELs. Considering
malignant vs. benign lesions, the sensitivity, specificity, PPV, and NPV were 85%
(95%CI 70.2–94.3), 100% (95%CI 58.7–100%), 100% (95%CI 85.1–100%), and
62.5 (95%CI 27.7–84.8), respectively. No major complications requiring addi-
tional care have been observed.
Conclusion: In this multicenter study, we found that EUS-FNB with the new 20G
core needle is an effective and safe method for the diagnosis of SELs with a high
rate of producing adequate histological material and high diagnostic accuracy
even from difficult-to-approach anatomical locations. Comparative studies with
different needle sizes are awaited.
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Introduction: Endoscopic ultrasonography(EUS)-guided ethanol ablation for
pancreatic cystic lesions (PCLs) is a recently introduced treatment option for
PCLs. The aim of this study was to compare the clinical outcomes of EUS-
guided ethanol ablation with those of the natural course of PCLs.
Aims & Methods: We performed retrospective study of patients with PCLs
divided in two groups: EUS-guided ethanol ablation group (n¼ 118, performed
between June 2006 to August 2015) and natural course group (n¼ 458, diagnosed
between January 1993 to August 2015). The propensity score-matching analysis
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between the two groups was applied in order to minimize the effect of selection
bias. The primary outcome was the rate of significant reduction in size (520% of
initial size). The secondary outcomes were the rate of significant growth in size
(410mm), complete remission rate, and surgical resection rate.
Results: In a propensity matched analysis of 88 pairs, the mean initial cystic size
of EUS-guided ethanol ablation group and natural course group was
23.72 10.99, 23.16 13.15mm and the mean follow-up duration was
75.45 38.12, 82.12 59.06 months respectively. Significant reduction in size
was detected in 53 (60.2%) of the EUS-guided ethanol ablation group and 17
(19.3%) of the natural course group (p5 0.001). Significant growth in size was
detected in 6 (8.9%) of ablation group and 11 (12.5%) of natural course group.
(p¼ 0.202). Seven patients (7.95%) underwent surgical resection in the EUS-
guided ethanol ablation group and 17 patients (19.3%) in the natural course
group (p¼ 0.028) during follow-up. Overall 28.8% patients (34 of 118) who
underwent EUS-guided ethanol ablation had achieved the complete remission.
Conclusion: PCLs that underwent EUS-guided ethanol ablation can be seen the
likelihood of getting clinical benefits such as reduction of the cystic size, the
chance for surgical resection in comparison to the natural course of them. It is
also expected to achieve a certain level of complete remission for PCLs.
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Introduction: Histological tissue comprising tumor and desmoplastic stroma is
required for molecular profile-based personalized chemotherapy in pancreatic
cancer. Recently, a three-plane symmetric needle with Franseen geometry and
a Fork-tip biopsy needle have been developed for histological tissue
procurement.
Aims & Methods: We aimed to compare tissue acquisition between the 22G
Franseen and 22G Fork-tip needles in patients undergoing EUS-guided sampling
of pancreatic masses.
Patients with pancreatic masses were randomized to undergo EUS-guided sam-
pling using the 22G Franseen and 22G Fork-tip needles. Two dedicated passes
were first performed using both needles in individual patients for cell block.
Subsequent passes were then performed for rapid onsite evaluation (ROSE)
using both needles alternately until a diagnosis was established. The main out-
come measures were to compare total tissue volume and presence of desmoplastic
stroma in pancreatic cancer. Secondary outcome measures were to compare rates
of diagnostic cell block and diagnostic adequacy at ROSE.
Results: In 50 patients randomized to undergo EUS-guided sampling, the diag-
nosis was pancreatic cancer in 43, neuroendocrine tumor in 2, lymphoma in 1 and
chronic pancreatitis in 4 patients. There was no significant difference in total
tissue area (median 6.1mm2 [IQR 3.5–10.5] vs. 8.2mm2 [IQR 4.0–13.0], p¼ 0.53),
presence of desmoplastic stroma in tumor (100 vs. 83.3%, p¼ 0.23), rates of
diagnostic cell block (96.0 vs. 92.0%, p¼ 0.68) and diagnostic adequacy at
ROSE (94.0 vs. 98.0%, p¼ 0.62) between the Franseen and Fork-tip needles,
respectively.
Conclusion: Both the Franseen and Fork-tip needles appear equally effective in
yielding histological tissue. By virtue of their ability to yield a diagnostic cell
block in greater than 90% of patients, the new generation FNB needles may
obviate the need for ROSE during EUS-guided tissue sampling.
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Introduction: To evaluate the success rate of double-balloon endoscopic retro-
grade cholangiography (DBERC) to reach the anastomosis in patients with sur-
gically altered gastrointestinal anatomy.
Aims & Methods: We review 346 patients with surgically altered anatomy who
underwent DBERC from April, 2002 to December, 2016 (47 patients with biliary
atresia(BA) after living donor liver transplantation (LDLT), 33 with LDLT with-
out BA, 45 with biliary resection and choledochojejunostomy, 111 with gastric
resection and Roux-en-Y bypass, 48 with gastric resection and Billroth-
IIremnant, 18 with pylorus-preserving pancreatoduodenectomy, and 42 others).
We evaluate the success rate according to the type of gastrointestinal anastomo-
sis, age, and age at surgery.
Results: The success rate for reaching the biliary anastomosis (or papilla of Vater)
in all 346 patients (66y.o (3–91)) was 83%. The rate in 47 patients with BA after
LDLT (12y.o (3–39)) was 57%. In the remaining 299 patients the rate was 87%.
The success rate of reaching the biliary anastomosis in patients with BA after
LDLT was significantly lower than other patients (p5 0.01). There was no sig-
nificant difference between the success rate in the patients over or under 13 years
at the time of ERCP (50% vs 56%, p¼ 0.70). The success rate was lower in
patients who underwent initial surgery as an infant (Kasai hepatoportoenterost-
omy) than in those past infancy (54% vs 88%, p5 0.01). When reaching the
biliary anastomosis is successful, the success rate of cannulation in the patients
after LDLT is high (92%).
Conclusion: The success rate for reaching the biliary anastomosis in patients with
BA after LDLT is significantly lower than other patients. The age at the time of
ERCP did not affect the success rate of reaching the biliary anastomosis, but the
success rate was lower in patients who underwent their initial surgery as infants.
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Introduction: Liver tumors such as hepatocellular carcinoma and liver metastases
sometimes occur in positions in which treatment using percutaneous radiofre-
quency ablation (RFA) is difficult, such as the caudate lobe and surface of the
left lobe. EUS-guided RFA (EUS-RFA) can offer an alternative treatment by
accessing these tumors through the stomach or duodenum. To the best of our
knowledge, only one report has described EUS-RFA of the liver in an animal
model, using a 19-gauge EUS-FNA needle with an umbrella-shaped array at the
needle.
Aims & Methods: We examined whether a novel 19-gauge RFA needle can be
introduced to ablate the liver in a porcine model under EUS guidance. Two pigs
were used in this study. All procedures were carried out under general anesthesia.
EUSRATM 19-gauge needles and a VIVA comboTM generator (TaeWoong
Medical, Gimpo city, Korea) were used for the procedures. Three kinds of
RFA needles (10-, 15-mm, and 20-mm exposed tips) were used. After the echoen-
doscope was advanced to the stomach, the RFA needle was inserted into the
surface of the left lobe. EUS-RFA was performed at 5–40 W for 2–6min in
general mode. In each pig, three RFA needles with 10-, 15-, or 20-mm exposed
tips were serially used for insertion and ablation. Subsequently, the RFA needle
with the 10-mm exposed tip was used in the quadrate lobe of the gallbladder
through the bulb of the duodenum.
Results: All procedures were technically successful. After the procedure, the liver
of the pig was removed, and visible RFA effect were evaluated macroscopically.
Histology with hematoxylin and eosin (HE) staining showed coagulative necrosis
in the ablated area, corresponding with the macroscopic ablated area.
Conclusion: In this experimental study, EUS-RFA could be performed techni-
cally not only in the surface of the left lobe, but also in the adjacent to the
gallbladder of the porcine liver. Further studies are required to confirm the
efficacy and safety.
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Introduction: Small bowel varices (SBV) occur as a consequence of portal hyper-
tension and may result in life-threatening mid-gut bleeding. First line manage-
ment usually involves radiological intervention (RI) (e.g. TIPSS, stenting of
occluded mesenteric veins þ/ embolisation of culprit varices). In cases where
RI is impossible, management options become very limited.
Aims & Methods: This case series evaluated the usefulness of DBE facilitated
cyanoacrylate injection of SBV. Retrospective review of DBE facilitated cyanoa-
crylate injection of SBV at our institution (December 2015 to August 2016).
Demographic, clinical, endoscopic and radiological findings, interventions and
follow-up data were analysed.
Results: Seven DBEs were performed in 5 patients (3 women, median age: 73-
years). Four patients had previous surgery (hemi-hepatectomy (n¼ 2); SB resec-
tion (n¼ 2)); one patient had a history of intra-abdominal sepsis in childhood
causing portal vein thrombosis. No radiological or surgical options were deemed
feasible in any case. SBV were diagnosed at capsule endoscopy and triple phase
CT mesenteric angiography. At DBE, a total of 10 nests of SBV were identified
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and injected with cyanoacrylate glue. There were no haemorrhagic or embolic
complications but 1 patient developed an infection of a congenital urachal cyst,
which was treated successfully with antibiotics. All patients underwent DBEs via
the anterograde route and 1 patient required bi-directional DBE for treatment of
both proximal and distal SBV and another patient required a 2nd anterograde
DBE for treatment of further patent proximal SBV. At 30-day follow-up post-
therapy, only 1 patient had experienced a mild recurrence of mid-gut bleeding.
Conclusion: Cyanoacrylate injection therapy of SBV at DBE appears to be a safe
and effective management strategy for this condition when other first-line
options are not feasible.
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Introduction: The development of balloon endoscopy and capsule endoscopy has
made observation of the small intestine possible in clinical practice. The useful-
ness of magnifying endoscopy has already been reported in observing the phar-
ynx, esophagus, stomach and colon. A single-balloon enteroscopy (SBE) with
80x magnification has been recently developed.
Aims & Methods: The aim of this pilot study was to assess the efficacy of narrow-
band imaging (NBI) magnifying findings for evaluating the severity of inflam-
mation in small intestinal crohn’s disease (CD). The study was conducted in
Showa University Northern Yokohama Hospital. We included CD patients
who underwent enteroscopy with magnification from September 2013 to
February 2015. NBI images and a biopsy specimen were obtained from small
intestinal mucosa for CD patients with use of SBE (Y-0007, Olympus, Tokyo).
Magnifying NBI was performed, and the images were evaluated by assessing
visibility, increased vascularization, and the increased caliber of capillaries into
three grades as follows: Normal, Visible and Irregular. Normal was indicative of
inactive disease, while Visible and Irregular were indicative of acute inflamma-
tion in our study. The outcome measures included the diagnostic ability of mag-
nifying NBI findings to distinguish active CD from inactive CD on the basis of
histological activity.
Results: Twenty-four patients were enrolled. There was a correlation between
magnifying NBI findings and the histological assessment (Spearman’s
jrj ¼ 0.549). The sensitivity, specificity, positive predictive value, negative predic-
tive value, and accuracy of magnifying NBI findings for diagnosing acute inflam-
mation were 88.2%, 71.4%, 88.2%, 71.4%, and 83.3%, respectively.
Conclusion: The NBI magnifying findings in the small intestinal mucosa had a
correlation with histological inflammation and could help in distinguishing
between active and inactive CD.
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Introduction:Double balloon enteroscopy (DBE) has revolutionised the diagnosis
and treatment of small intestinal conditions. However, even in expert hands, deep
small bowel (SB) insertion can be challenging, especially in patients with a history
of abdominopelvic surgery. Moreover, if the findings at DBE are not amenable
to endoscopic therapy, a further surgical procedure is usually required to provide
definite treatment. Laparoscopic-assisted DBE (LA-DBE) using a standard
multi-port technique has previously only been reported in a small series of 3
patients with Peutz -Jeghers Syndrome (PJS) 1.
Aims & Methods: This case series reports the development of LA-DBE using
single-incision laparoscopic surgery (SILS) applied to a wide range of clinical
indications. Retrospective review of LA-DBE procedures performed in a single
tertiary centre over a 6 year period. Demographics, indication, findings, diagno-
sis and therapeutic interventions were recorded. Completion, complication rates
and hospital length of stay were also captured.
Results: 17 procedures were performed over 6 years in 17 patients who had failed
standard DBE. Mean (range) age was 40 (17–73) and 41% of patients were male.
The enteroscopic approach was oral in 13/17 patients and rectal in 4/17.
Laparoscopic approach was standard (multiport) in the first 4 cases, SILS was
then used in all subsequent patients (13/17). The mean (range) procedure time
was 147 (84–210) mins. Indications were PJS (n¼ 10), suspected submucosal/
polypoid lesion at small bowel imaging (n¼ 5) and obscure gastrointestinal
bleed (OGIB) with vascular abnormalities seen at capsule endoscopy (n¼ 2).
In 15/17 procedures the target pathology was reached using laparoscopic assis-
tance only and 1/17 was converted to intraoperative enteroscopy (IOE). In 1/17
the suggested pathology at mangnetic resonance enterography (MRE) was not
identified. Therapy was applied in 15/17 (88%) cases. 7 underwent endoscopic
therapy of which 6 polypectomy and 1 ablation with argon plasma coagulation
(APC). 4 required limited SB resection and 4 underwent both endoscopic poly-
pectomy and small bowel resection for a second polyp that could not be removed
endoscopically. A total number of 57 polyps were removed with the largest
measuring 40mm. The range of length of surgically resected SB was 4–17 cm.
Diagnoses were PJS polyps (n¼ 9), neuroendocrine tumour (NET) (n¼ 2), PJS
polyps and NET (n¼ 1), transmural arteriovenous malformation (n¼ 1),
angioectesia (n¼ 1), inflammatory polyp (n¼ 1), leiomyoma (n¼ 1), Meckel’s
diverticulum (n¼ 1). Median length of stay post procedure was 2 (1–19) days.
8/17 patients were discharged at 24 hours. 3/17 patients developed complications:
1 post procedure ileus, 1 pelvic collection that was managed with antibiotics and
1 patient that was readmitted 8 days post procedure with subacute SB obstruc-
tion which resolved with conservative management.
Conclusion: LA-DBE appears to be a safe, effective and minimally invasive pro-
cedure that can be applied for the management of a wide range of small bowel
pathology. A SILS approach allows all therapeutic modalities to be available as
needed during the procedure, including conversion to IOE, laparoscopic small
bowel resection and laparotomy.
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Introduction: The complex relationship between inflammatory bowel disease
(IBD) and motility disorders of the digestive tract is a complex area of study,
so far incompletely elucidated. The association between Crohn’s disease and
gastric emptying time modification has been relatively less studied. However,
there is no single standardized method to study gastric emptying, one particular
investigation that could bring direct information in this field being the small
bowel capsule endoscopy (SBCE).
Aims & Methods: We aimed to study gastric emptying by small bowel capsule
endoscopy in patients with suspected and confirmed Crohn’s disease. We eval-
uated gastric passage time showed by SBCE in patients with small bowel Crohn’s
disease, compared to patients without IBD, investigated by SBCE (PillCam),
following recognized indications, in the Institute of Gastroenterology and
Hepatology of Iasi, tertiary center in North-East of Romania.
Results: 144 SBCE studies were included, 24 were cases of suspected and con-
firmed Crohn’s disease. The mean time of gastric passage in patients with
Crohn’s disease was 51 21.9 minutes, longer than in patients without inflam-
matory bowel disease, in which the mean gastric passage time was 24 16.6
minutes.
Conclusion: Gastric passage time, evaluated by SBCE, is prolonged in patients
with Crohn’s disease compared to patients without IBD, suggesting a relation-
ship between chronic inflammation and gastric motor disorders. Globally, the
values correlated with those considered as physiological by other exploration
methods. SBCE studies may provide additional data on gastric motility (and in
general gut motor disorders), with special usefulness in some individual cases, as:
particular symptoms or variations in the bioavailability of small bowel- released
drugs.
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Introduction: The value of purgative preparation (PBP) before small bowel video
capsule endoscopy (VCE) remains controversial and it has been recently
challenged.
Aims & Methods: The aim of this meta-analysis was to examine the effect of PBP
on small bowel VCE outcomes. We performed literature searches in MEDLINE
and Cochrane Library to identify randomized-controlled trials (RCTs) evaluat-
ing the effect of small bowel preparation –purgative (PEG, sodium phosphate,
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others) vs. clear liquids diet- on VCE outcomes. Examination’s diagnostic yield
(DY) was meta-analysis primary end point; small bowel visualization quality
(VQ), VCE completion rate (CR), gastric (GTT) and small bowel (SBTT) transit
times comprised the secondary endpoints. Study outcomes effect sizes were cal-
culated using RevMan 5.3 software fixed or random effect model, as appropriate,
and they are presented as OR[95%CI] or mean difference[95%CI], respectively.
Heterogeneity was measured using the I2 statistics. Publication bias was assessed
by Funnel plots inspection and the quality of the meta-analyzed studies was
assessed using the Jadad criteria.
Results: We identified 9 eligible RCTs with 12 sets of data, including 1029 sub-
jects. They were low risk of bias trials and no publication bias was detected. As
compared to clear liquids diet, PBP significantly increased small bowel VCE DY
(1.44 [1.14–1.83], I2¼ 39%). However, a sensitivity analysis that excluded studies
with sodium phosphate preparation (abandoned nowadays) and PBPs different
(not widely used) than PEG showed no benefit of PEG preparation over clear
liquids (1.31 [0.79–2.17], I2¼ 54%). VQ significantly improved after PBP (2.05
[1.49–2.82), I2¼ 45%), without any significant effect on VCE CR (0.98 [0.73–
1.33], I2¼ 0%) and GTT (-1.21 [-7.21–4.79] min, I2¼ 94%). On the contrary,
VCE SBTT was statistically lower by 15.06 [25.52–6.61] min (I2¼ 90%)
after PBP.
Conclusion: In comparison to clear liquids diet, PBP increases small bowel VCE
DY and improves VQ without affecting exam’s CR. However, the positive effect
of PBP on VCE DY is mainly derived from two relative small, old (2004 and
2009) RCTs and disappears if only PEG preparation studies are meta-analyzed.
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Introduction: The diagnostic yield of capsule endoscopy (CE) depends on the
adequate visualization of the mucosa. As with colonoscopy, cleaning scales
should be described in the report in order to better interpret results. In 2009,
Brotz et al proposed and validated 3 different cleansing scales in 40 patients.
Aims & Methods: A hundred CE videos (Mirocam) were reviewed by 2 authors
at a fixed frame rate of 100 frames per second in quadruple view (Miroview
Client). The CE were evaluated according to Brotz scales: (1) Overall adequacy
assessment (adequate/inadequate) (2) Qualitative scale (excellent, good, fair,
poor) and (3) Quantitative scale (0–10 score, graded from 0–2 visualization of
the mucosa, fluids, bubbles, bile and luminosity). The aim of this study was to
evaluate the inter-observer variability of this cleaning scales. The kappa coeffi-
cient was used to calculate the inter-observer agreement in overall adequacy
assessment and the intra-class correlation coefficient was used to evaluate the
concordance of the qualitative and quantitative scales.
Results: In overall adequacy assessment, the quality of bowel preparation was
classified as adequate by observer 1 in 67% and by observer 2 in 73%, with an
inter-observer kappa index of 0.76 (p5 0.001) suggesting strong agreement. In
the qualitative scale, most of the bowel preparations were considered reasonable
(40% observer 1 vs 36% observer 2), with an intra-class coefficient of 0.89
(p5 0.001). In the quantitative scale, the mean score of the two observers was
6.5 and 6.7, resulting in an intra-class agreement of 0.78 (p5 0.001).
Conclusion: The optimization of quality of bowel preparation and the diagnostic
yield of the CE requires, first, a well-validated cleaning scale. Brotz’s rating scales
have strong inter-observer agreement. The qualitative scale is easier to apply and
has better inter-observer agreement, so the authors propose that it should be used
routinely in the CE report.
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LESION VISUALISATION IN SMALL BOWEL CAPSULE
ENDOSCOPY
D. E. Yung1, X. Dray2, E. Toth3, E. Rondonotti4, R. Sidhu5, U. Kopylov6,
M. Mcalindon5, M. Pennazio7, J. N. Plevris1, A. Koulaouzidis1
1The Royal Infirmary of Edinburgh, Edinburgh/United Kingdom
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Introduction: Capsule endoscopy (CE) is the prime mode of investigation for
small bowel (SB) pathology. However, as an entirely visual medium it depends
heavily on image quality. The definition of optimal image quality remains
unstandardised between studies and poses significant limitations to the quality
of study reporting. As yet, there is no widely-accepted or integrated method for
scoring SB cleanliness during CE reporting. This pilot study aims to quantify the
image properties contributing to adequate visualisation quality in CE images.
Aims & Methods: Five clear images of SB pathology were obtained using
MiroCam (Intromedic, South Korea), image resolution 320	320 pixels(px):
P1 and P2 angioectasias, ulcer, aphtha and polyp. Each image was processed
using GIMP2 image editing software (www.gimp.org) for 3 parameters: (1) opa-
city (opacity filter matched in colour to commonly-seen SB contents, 10–90% in
10% increments), (2) blur (Gaussian blur, radius 1–10px), (3) contrast (-50% to
50% in 10% increments). Gaussian blur was used to simulate the effects of rapid
capsule movement as well as to affect image definition. A set of 5 original and
190 edited images was obtained. A web-based survey was created using Google
Forms and 9 expert CE readers were asked to indicate whether each image was
adequate or not for diagnosis. The order of images was randomised for each
reader. For each type of pathology, we determined the threshold of image quality
which was deemed adequate for diagnosis.
Results: For image opacity, both angioectasias and the polypoid lesion were
adequately visualised below 40% opacity whereas the threshold was lower for
both the ulcer and aphtha (10% opacity). Increasing blur radius significantly
impacted the acceptability of images for reaching a diagnosis with confidence;
for most images, blur radius 3px was the threshold for adequate visualisation but
even 1px of blur radius decreased the visualisation quality of the aphtha image.
The aphtha image was also affected the most by decreased contrast; conversely
the ulcer was deemed more inadequately visualised with higher contrast. The
other images were generally adequately visualised at 10% contrast. Results
are detailed in the table below.
Percentages of respondents finding each image adequate
Image parameter
P2
Angioectasia
P1
Angioectasia Ulcer Aphtha
Polypoid
lesion
Original image 100% 100% 100% 88.9% 100%
Opacity
10% opacity 100% 100% 100% 77.8% 100%
20% opacity 100% 100% 88.9% 77.8% 100%
30% opacity 100% 100% 88.9% 33.3% 100%
40% opacity 100% 100% 77.8% 33.3% 100%
50% opacity 100% 88.9% 77.8% 22.2% 100%
60% opacity 77.8% 75% 66.7% 11.1% 77.8%
70% opacity 66.7% 44.4% 22.2% 0% 44.4%
80% opacity 33.3% 22.2% 22.2% 0% 22.2%
90% opacity 0% 0% 0% 0% 0%
Blur radius
1px 100% 100% 100% 88.9% 100%
2px 100% 100% 100% 77.8% 100%
3px 100% 100% 100% 77.8% 100%
4px 77.8% 100% 100% 77.8% 77.8%
5px 33.3% 66.7% 100% 22.2% 44.4%
6px 33.3% 55.6% 88.9% 33.3% 11.1%
7px 22.2% 22.2% 55.6% 25% 0%
8px 11.1% 22.2% 33.3% 0% 0%
9px 22.2% 0% 33.3% 11.1% 0%
10px 0% 0% 33.3% 0% 0%
Contrast
50% 66.7% 77.8% 66.7% 0% 88.9%
40% 100% 85.7% 55.6% 11.1% 100%
30% 100% 100% 88.9% 11.1% 100%
20% 100% 100% 88.9% 22.2% 100%
10% 100% 100% 100% 44.4% 100%
þ10% 88.9% 100% 100% 88.9% 100%
þ20% 100% 100% 75% 100% 77.8%
þ30% 100% 100% 62.5% 88.9% 66.7%
þ40% 100% 100% 66.7% 88.9% 66.7%
þ50% 66.7% 55.6% 11.1% 88.9% 66.7%
Conclusion: This pilot study shows that image quality is a defining factor in
accurate diagnosis in CE. Image quality is commonly affected by the opacity
of luminal fluid/residue, and the quality of imaging delivered by the CE system.
More subtle mucosal lesions such as aphthae are affected more by decreased
contrast. Interestingly, a relatively high level of image opacity can be tolerated
by CE readers whereas blurriness seems to have a greater effect on visualisation
quality and reviewer confidence in the diagnosis. The effects of these aspects in
combination merit further investigation.
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Introduction: Inflammatory bowel diseases (IBDs) are chronic inflammatory dis-
eases that may affect the whole gastrointestinal (GI) tract, mainly the small bowel
and colon. Endoscopic evaluation of these parts is essential to assess disease
extent and severity. The small bowel colon capsule endoscopy (SBC-CE)
system is a new system composed of a two-headed capsule with a panoramic
field of view and adaptive frame rate, customized for complete coverage of IBD
lesions in the entire bowel, data recorder and new disease specific software,
allowing assessment and follow-up over time of disease severity and extent.
Aims & Methods: The aim was to evaluate SBC-CE system functionality in
suspected or established IBD (Crohn’s disease [CD] and Ulcerative Colitis
[UC]) patients. This was a prospective 5 center feasibility study assessing the
performance of the new capsule and software. Subjects enrolled into the study
ingested the new capsule after standard bowel preparation plus boosts.
Contraindications for its use included obstruction, dysphagia or swallowing dis-
orders, pacemakers etc. GI patency was assured using the patency capsule. The
primary endpoint was successful procedure in terms of video creation and report
generation in accordance to the video reading methodology. Secondary end-
points were subjective coverage of SBC, subjective duration of total and segmen-
tal reading time, over all video quality and occurrence/severity of adverse events.
Results: 68 patients were screened, of which 54 were enrolled and 49 ingested the
capsule (14 patency failure, 5 withdrew consent). Mean age was 40.1 years, 51%
were males. 69% of patients had established CD, 10% UC and 21% suspected
CD. The disease was active in 62% of known IBD patients. One patient who
underwent extensive colon resection was excluded from all colon analyses.
Overall cleansing was regarded good or excellent in 96% of patients. All 49
videos met the primary endpoint, i.e. video was created and report generated
with all included information and in accordance to the video reading methodol-
ogy. All capsules reached the rectum/toilet with no retention, most while photo-
graphing. Gastroenterologists were satisfied with small bowel coverage 6.6 0.6
(mean standard deviation) and colon coverage of 6.0 1.2 in a scale of 1–7
(unconfident to confident), image quality 6.1 0.8 (1–7, poor to excellent), and
subjective video reading time 3.9 1.4 (1–7, very short to very long). There were
4 patients with small interferences related to video continuity (gaps).
Conclusion: The new SBC capsule is a friendly, minimally invasive capsule allow-
ing complete evaluation of the entire gut of IBD patients. The system may be
used to assess disease severity and extent and for follow up of IBD patients.
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Introduction: Transpapillary dilation for severe main pancreatic duct (MPD)
stricture is sometime difficult and diathermic dilation is now getting attention
as a salvage technique for severe stricture; however its efficacy and safety remains
unclear.
Aims & Methods: To evaluate the efficacy and safety of a novel transpapillary
dilation technique with a diathermic catheter for severe MPD stricture due to
chronic pancreatitis. Between April 2011 and March 2017, 143 patients with
chronic pancreatitis underwent endoscopic transpapillary stent placement for
MPD. MPD dilatation was indicated in 18 patients, and diathermic dilation
was required in nine patients. We evaluated (1) the patients’ characteristics, (2)
procedure characteristics, (3) clinical outcomes, (4) adverse events.
Results: (1) Six patients were men and three were women (mean age, 50.1 years).
Alcohol 8, unknown 1. The strictures were in the head of pancreas: 8, body: 1.
The mean length of stricture was 20.2mm (range, 10–30.8). The mean MPD
diameter on the distal side of stricture was 6.2mm (range, 3–12.7). Five patients
(55.6%) among them had no former procedure for MPD including stenting. (2) A
wire-guided 6Fr diathermic catheter with 30W power was used for all cases. All
cases underwent diathermic dilation as salvage procedure subsequent to conven-
tional dilation. One to 7 diathermy procedures (mean 2.9) were required to pass
through each stricture. (3) Passage of the diathermic catheter and stent placement
was successful in all patients (100%). After diathermy and stent placement, 8
(88.9%) showed improvement of clinical symptoms (abdominal pain).
Recurrence of stricture was observed in 2 patients (22.2%). One of them
needed diathermic dilatation again. (4) Two adverse events (22.2%) were
observed and both of them were mild pancreatitis. Multiple diathermy proce-
dures (6 times and 4 times, respectively) and relatively long duration of total
diathermy (39 sec. and 25 sec. respectively) were observed in cases with
pancreatitis.
Conclusion: Transpapillary diathermic dilation is a relatively safe and effective
salvage procedure for severe MPD stricture due to chronic pancreatitis.
However, care should be taken in cases that require multiple times and long
duration diathermy procedures because of a risk of pancreatitis.
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NEOADJUVANT CHEMOTHERAPY/CHEMORADIOTHERAPY IN
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Introduction: It is controversial whether preoperative biliary drainage is necessary
or not in patients with pancreatic head cancer. Meanwhile, some reports indi-
cated the necessity of biliary drainage in the case of severe jaundice and neoad-
juvant chemotherapy/chemoradiotherapy (NAC/NACRT).(1, 2)
Aims & Methods: We aimed to clarify clinical outcomes of biliary drainage with
metal stent (MS) or plastic stent (PS) during neoadjuvant chemotherapy/chemor-
adiotherapy in patients with pancreatic cancer who underwent subsequent pan-
creatoduodenectomy Patients and methods: From Oct. 2013 to Apr. 2016, 96
patients with pancreatic cancer were registered to NAC (S-1 [80 mg/m2, twice
daily], 2 cycles) or NACRT (a total dose of 50.4Gy in 28 fractions and S-1 [80
mg/m2, twice daily on radiation day alone] for 1 month and subsequent che-
motherapy with gemcitabine for 3 cycles) studies conducted by by Hokkaido
Pancreatic Cancer Study Group (HOPS) (UMIN000013031/UMIN000012293).
Of them 29 patients who underwent biliary drainage with a MS or PS before
NAC/NACRT and subsequent pancreatoduodenectomy were analyzed.
Examination items were 1) patient characteristics, 2) preoperative recurrent bili-
ary obstruction (RBO: stent obstruction, migration, tumor ingrowth/over-
growth) occurrence rate, 3) NAC/NACRT delay or discontinuation rate, 4)
surgical time, volume of hemorrhage, and postsurgical adverse event rate.
Results: 1) The median of age was 67 years (50–83); M/F ratio was 13/16. The
distribution of pathological stages (based on the General Rules for the Study of
Pancreatic Cancer by the Japan Pancreas Society, 6th edition) included 2 patients
with stage I, 1 with II, 13 with III and 13 with IV disease. NAC and NACRT
were performed for 14 and 15 patients, respectively. MS and PS were used in 17
and 12 patients, respectively. The distribution of used MS and PS diameters
included 17 patients with 10mm, 9 with 7F, 2 with 8.5F and 1 with 10F. 2)
RBO occurred in 5.9% of patients in the MS group and 83.3% in the PS
group with a significant difference (p5 0.0001). The RBO included the following
conditions: stent obstruction, 1 patient in the MS group and 8 in the PS group;
stent migration, 0 in the MS group and 2 in the PS group. 3) NAC/NACRT delay
was observed in 35% of patients in the MS group and 50% in the PS group.
NAC/NACRT discontinuation was observed in 12% of patients in the MS group
and 17% in the PS group. There were no significant differences between both
groups in rates of delay and discontinuation of the neoadjuvant therapies. 4) The
operative time of the MS group was significantly longer than that of the PS group
(610min vs 495min, p¼ 0.036), while blood losses (870ml, the MS group vs.
658ml, the PS group) and postoperative morbidity rates (35%, the MS group vs.
33%, the PS group) of both groups were not significantly different.
Conclusion: MS is better than PS from the viewpoint of the prevention of RBO.
Meanwhile, MS was similar to PS in the postoperative outcome. For standardi-
zation of biliary stenting during NAC/NACRT, further large-scale and prospec-
tive studies are needed.
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Introduction: Endoscopic biliary decompression is widely used for advanced hilar
cholangiocarcinoma. Bilateral stenting has become more feasible with more
experienced endoscopists and the development of new devices. However, stent
dysfunction develops in 3% to 45% because of tumor ingrowth, overgrowth, or
debris as disease progresses. Endoscopic reintervention is difficult and complex
with worsening bile duct strictures. The present study aimed to evaluate a sui-
table reintervention procedure for stent malfunction after stent-in-stent (SIS)
deployment for malignant hilar obstruction.
Aims & Methods: From September 2009 to June 2016, a total of 52 patients who
underwent endoscopic bilateral stenting at Pusan National University Yangsan
Hospital were enrolled in this study. Among them, 20 patients who underwent
reintervention due to stent malfunction were analyzed. Reintervention was per-
formed endoscopically or percutaneously. Technical and functional success rates
were evaluated retrospectively.
Results: Technical and functional success rates of endoscopic reintervention were
83% (10/12) and 80% (8/10), respectively. Endoscopic bilateral and unilateral
reintervention success rates were 75% (6/8) and 100% (4/4), respectively.
Functional success was observed in 8 out of 10 patients (80%) who achieved
technical success. For bilateral reintervention, either plastic or plastic and metal
stents were used. PTBD was performed in 8 patients because of duodenal stenosis
(2 patients) and poor conditions.
Conclusion: Endoscopic reintervention could be considered in the case of stent
malfunction and fair patient conditions after SIS placement for malignant hilar
obstruction. Decisions regarding bilateral or unilateral drainage and types of
stents should depend on the conditions of the disease and the patient.
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Introduction: Endoscopic ultrasound-guided biliary drainage (EUS-BD) has been
regarded as an effective alternative in cases of endoscopic retrograde cholangio-
pancreatography (ERCP) failure or inaccessible papilla. However, EUS-BD for
right intrahepatic duct obstruction (EUS-BDR) remains challenging, although
recent studies showed promising result. The aim of current study was to evaluate
the feasibility and long-term outcomes of EUS-BD with transmural coved metal
stents for right intrahepatic duct obstruction.
Aims Methods: In this single-center, retrospective study, a total of 24 consecutive
patients who underwent EUS-BDR after failed ERCP were enrolled. The
patients were consisted of 12 cases of benign strictures and 12 cases of malignant
strictures. The biliary stents used in this study was covered metal stent with
antimigration properties (fully covered metal with anchoring flaps or partially
covered metal stent with anchoring flaps). The technical success rate, clinical
success rate and adverse events were evaluated.
Results: The target bile duct was right anterior in 6 patients and right posterior
segmental duct in 18 patients. Among them, percutaneous transhepatic biliary
drainage assisted EUS-BDR was performed in three patients. The technical and
clinical success rate was 95.8% (23/24) and 95.6% (22/23). Mean diameter of
right intrahepatic duct was 6.5 (4–30) mm. A fully covered metal stent was used
in 22 patients and partial covered stent in 2 patients. Early adverse events devel-
oped after EUS-BDR in 2 patients (1 case of cholangitis and 1 case of liver
abscess in patients with malignant biliary stricture). Late adverse event that
stent occlusion was observed in 5 patients. Neither proximal peritoneal stent
migration nor spontaneous distal stent migration was observed during follow-
up periods. The stent patency duration was 275.2 (147.8–402.7) days. During
follow-up period, stent revision via fistula tract was successful and additional
percutaneous biliary drainage for right intrahepatic duct obstruction was not
required in all patients who achieved clinical success.
Conclusion: EUS-BD using transmural covered metal stent with antimigration
properties for right intrahepatic duct obstruction may be technically feasible,
effective and relatively safe for both benign and malignant biliary strictures by
expert hands. Furthermore, the route of hepaticoduodenostomy created by cov-
ered metal stent was durable and endoscopically easily managed.
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Introduction: Recently, EUS-guided biliary drainage (EUS-BD) techniques such
as EUS-guided choledochoduodenostomy (CDS), hepaticogastrostomy (HGS)
antegrade stenting (AGS) and rendezvous stenting (RVS) are useful for biliary
drainage methods after unsuccessful ERCP. Among these procedures, CDS and
RVS require the echoendoscope reaching duodenum. Therefore, HGS or AGS
are indicated in cases with inaccessible duodenum. However, HGS is associated
with a higher risk of adverse events, compared with the other methods. When the
stent dysfunction occurs, re-intervention is more difficult after AGS alone than
after HGS or CDS. Thus, we started to add AGS during HGS in a single session
from Sep. 2011.
Aims & Methods: The aim of this study to assess the efficacy and safety of HGS
combined with AGS for malignant biliary stricture-induced obstructive jaundice.
Between Jan. 2006 and Dec. 2014, ERCP was attempted in patients with obstruc-
tive jaundice, which was successful in 641 patients and impossible in 154 patients
(101cases due to post-surgical altered anatomy or duodenal stenosis, 53 cases due
to difficult cannulation). A total of 145 patients received EUS-BD; HGS and
HGS with AGS were attempted in 42 (Group A; from Jan 2006 to Aug 2011) and
37 patients (Group B; from Sep 2011 to Dec. 2014), respectively. The assessed
outcomes were the technical and functional success rates, adverse events rate, re-
intervention rate, procedure time, overall patient survival time, and time to stent
dysfunction or patient death. In Group A, technical success of HGS was defined
as successful stent deployment between the left hepatic bile duct and the stomach.
In Group B, technical success of HGS with AGS was defined as successful stent
deployment at bile duct stricture (AGS) in addition to success of HGS.
Functional success for obstructive jaundice was defined as a decrease in bilirubin
levels to 540% of the pretreatment value within 2 weeks. The incidence rate of
adverse events such as peritonitis, bile leakage, bleeding, stent migration, and
stent occlusion was assessed. The re-intervention was defined as any endoscopic,
surgical, or percutaneous procedure that was required to improve symptoms
after placement of the stent. Time to stent dysfunction or patient death was
defined as the time from stent deployment to biliary re-intervention due to
stent dysfunction or the time from stent deployment to patient death. Groups
A and B were compared in terms of the technical success, clinical success, and
adverse events outcomes, the procedure time, the overall patient survival and
time to stent dysfunction or patient death. For subgroup analysis in patients who
underwent chemotherapy the Groups A and B were compared in the overall
patient survival, time to stent dysfunction or patient death and adverse events
rate.
Results: Technical success rate of Group A was significantly higher than Group B
(97.6 vs 83.8%, p¼ 0.03). The two groups were comparable for the functional
success rate (90.2% vs 90.3%), although the rate of adverse events tended to be
higher in Group A than in Group B (26.1% vs 13.5%, p¼ 0.10). The re-inter-
vention rate tended to be higher in Group A than in Group B (16.7% vs 8.1%,
P¼ 0.25). Groups A and B did not differ significantly in terms of median overall
patient survival (75 days vs. 61 days, P¼ 0.70), and median time to stent dysfunc-
tion or patient death (68 vs 63 days, P¼ 0.08) In patients who underwent che-
motherapy, there were no difference in the overall patient survival time (121 vs
157 days, p¼ 0.08) between the two groups although the time to stent dysfunc-
tion or patient death was significantly shorter in Group A than in Group B (71 vs
95 days, p¼ 0.02).
Conclusion: Technical success rate of HGS with AGS was lower than HGS,
although HGS with AGS is superior to HGS in terms of stent patency in patients
receiving chemotherapy.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0273 EUS-GUIDED GALLBLADDER DRAINAGE REDUCES LATE
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Introduction: Endoscopic ultrasound guided transmural gall-bladder drainage
(EUS-GBD) with covered metal stent has become increasingly used to treat
patients with acute cholecystitis who are not a candidate for surgical treatment.
However, there are limited data comparing long-term outcomes of EUS-GBD
with covered metal stent and conventional percutaneous cholecystostomy.
Aims & Methods: This is a single-center, retrospective study comparing long-term
outcomes of EUS-GBD and percutaneous cholecystostomy in patients who are
not suitable for cholecystectomy. Data about the patient who underwent EUS-
GBD for acute cholecystitis is obtained from prospective collected EUS database
of our institute. In percutaneous cholecystostomy group, electrical medical
record of patients who underwent percutaneous cholecystostomy was reviewed
and analyzed. Demographics and procedure related outcomes including early,
late adverse events and need for re-intervention in each group was compared.
Results: A total of 181 patients (74 in EUS-GBD group and 107 in percutaneous
cholecystostomy group) were enrolled in this study. The cause of cholecystitis
and ASA class were similar in both groups. The technical/clinical success rate was
100%/98.6% in EUS-GBD group and 99.1%/97.2% in percutaneous cholecys-
tostomy group (P¼ 0.591 and 0.646) respectively. Early adverse event rate was
also similar between two groups (6.8% in EUS-GBD group vs. 15.0% in percu-
taneous cholecystostomy group, P¼ 0.103). However, late adverse events includ-
ing migration of stent or dislodgement of drainage tube, stent or tube occlusion,
tract inflammation around percutaneous tube, bile leakage and recurrence of
cholecystitis was more frequently observed in percutaneous cholecystostomy
group (5/74 in EUS-GBD group and 21/107 in percutaneous cholecyststomy
group, P¼ 0.017). Percutaneous cholecystostomy tube was indwelled for
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median 20 days (14.0–45.2) after the procedure. A total of 7 patients in EUS-
GBD group received re-intervention for adverse events and all of them were
conducted successfully. The patients who underwent percutaneous cholecytost-
omy more frequently received re-intervention for adverse event or recurrence of
cholecystitis after removal of cholecystostomy. (7/74 vs. 23/106, P¼ 0.041).
Conclusion: EUS-GBD and percutaneous cholecystostomy were both effective
interventions to urgent drainage for acute cholecystitis. However, EUS-GBD
might be beneficial than percutaneous cholecystostomy in long term management
for the patients with acute cholecystitis who are not suitable for cholecystectomy.
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Introduction: The ‘‘fully covered self-expandable metallic stents’’(fcSEMSs) were
found to be non-inferior to multiple plastic stents (MPSs) for the treatment of
anastomotic biliary strictures after orthotopic liver transplantation (OLT).
However, there is scarce data about their efficacy in the treatment of anatomotic
biliary strictures after living donor liver transplantation (LDLT). We aimed to
compare the efficacy of fcSEMS and MPSs for the treatment of anastomotic
biliary strictures after LDLT.
Aims & Methods: We retrospectively analyzed the data of LDLT patients with
duct-to-duct anastomotic biliary strictures who underwent endoscopic treatment
at our center within the last 3 years. FcSEMSs were inserted in 23 patients (13
men, mean age: 53 10 years) (Group-1). Thirty-two patients (23 men, mean
age:51 9 years) were managed with MPSs insertion (Group-2). In Group-1,
secondary branch ducts were prophylactically drained with insertion of plastic
stent(s) in order to prevent the development of cholangitis due to their occlusion.
FcSEMS and plastic stent(s) were left in place for 2 months. In Group-2, max-
imum number of plastic stents were inserted and replaced every 3 months.
Patients with a follow-up duration of at least 3 months after stenting were
included to the study. Primary end-points were the number of endoscopic pro-
cedures and the time required for stricture resolution. The secondary end-point
was the recurrence rate of the stricture.
Results: FcSEMSs were successfully deployed in all cases. The diameter of the
Fc-SEMSs were 10mm in 22 patients and 8mm in 1 patient. The length of the
Fc-SEMSs were 8 cm in 13 patients, 10 cm in 8, and 6 cm in 2 patients. Secondary
branch ducts were prophylactically drained with a single plastic stent in 12
patients, 2 plastic stents in 8 patients, and 3 plastic stents in 3 patients. The
median number of endoscopic procedures was 2 (2–4) in Group-1 and 4 (2–9)
in Group-2 (p5 0.001). The time required for stricture resolution was shorter in
Group-1 (65.7 18.2 days) than in Group-2 (240.1 183.4 days) (p5 0.001).
The recurrence rates were similar in Group-1 (17.4%) and Group-2 (15.6%)
(p¼ 0.57) after a follow-up period of 515 290 and 378 86 days, respectively.
Conclusion: FcSEMS insertion is an effective method for the treatment of ana-
stomotic biliary strictures after LDLT, with a less number of endoscopic sessions
and a shorter stenting duration required for the resolution compared to MPS.
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Introduction: Colorectal stenting is a minimally invasive, reliable and effective
intervention in patients with malignant colonic obstruction, associated with a low
complication rate and mortality compared with traditional surgical treatment.
One of the actual problems associated with colorectal stenting is the recurrence of
symptoms of obstruction. The most common cause is migration of covered stents
and ingrown of uncovered stents1, 2, 3. The aim of our study was to compare the
results of the use of stents of a new design, the development of which was aimed
at preventing these complications.
Aims & Methods: We aimed to evaluate the results of the use of stents of the new
design (double uncoated and dual coated colorectal stents). Between December
2012 and April 2017, 77 patients with colonic malignant obstruction were
implanted 78 stents (39 bare, 39 covered EGIS Colorectal stent, S&G Biotech
Inc., South Korea). A double uncovered stent has a two-layer structure created
by crossing two stents, resulting in a smaller cell size. Such a design theoretically
can prevent migration and reduce tumor ingrowth. The covered stent is coated
with a silicone membrane between two layers of a metal mesh with distal,
uncoated ends of 5mm each. The role of the membrane is to prevent the
ingrowth of the tumor, localization and uncoated edges prevent the migration
of the stent. All interventions are performed by one operator using endoscopic
and radiological control. Groups of patients using coated and uncovered stents
were comparable in terms of sex, age, duration of symptoms of obstruction, and
stenosis localization. The reasons for the obstruction were primary tumors of the
colon 97.4%. The localization of the tumor is most common in the sigmoid colon
- 54% patients. Palliative care was provided to 43(55.8%) patients, «bridge to
surgery» – 34 (44.7%) patients.
Results: Clinical success was achieved in 74 (96.1%) patients. In two cases, when
using covered stents, the symptoms of obstruction could not be regressed, the
patients were operated. In one case, 18 hours after stenting with an uncovered
stent, was diagnosed perforation due to obstructive colitis. The average stay in
hospital after the intervention was 3 days; the difference between the groups was
statistically insignificant. H0 day mortality was 5.2%, the difference was statisti-
cally insignificant. Complications were detected in 3 patients in the group of bare
stents and in 1 patient in the group of covered stents, the difference was statis-
tically insignificant. One patient with the carcinoma of a sigmoid colon with
invasion in anterior abdominal wall noted the appearance of subcutaneous
emphysema without pneumoperitoneum, in 3 (3.8%) patients the occlusion of
the stents. The reasons for obstruction of the stents were occlusion by the
obstruction from stool (fibers) on the 83rd day (the endoscopic recanalization
was performed) and tumor overgrowth by 165 days (endoscopic «stent-in-stent»
placement). In one patient, the cause of occlusion is unknown, operated in
another hospital 34 days after stenting - a transversostomy was performed,
died on the 4th day after the operation.
Conclusion:Double bare and double covered colorectal stents were feasibility and
efficacy for relieving malignant colorectal obstruction. Reobstruction was rare
complication and not different in both groups stent groups. Necessary to con-
tinue to research for the accumulation of material from other centers.
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Introduction: Endoscopic therapy has been emerged as alternative treatment to
bariatric surgery for reducing weight. We developed a new endoscopic gastro-
intestinal (GI) bypass stent and designed a preclinical study to assess the safety in
a porcine model.
Aims & Methods: The aim of this study is to investigate the feasibility of our GI
bypass device in animal. Before animal study, we performed an experimental
study for durability test under simulated intestinal fluid flow. And next, we
performed an animal study with 10 Yorkshire pigs. The stents were placed on
pylorus with fixation by clippings or on duodenal bulb without fixation. Follow
up endoscopy was done per one week after implantation. After they were sacri-
ficed, gastric, duodenal, and jejunal tissues were harvested and examined for
histologic assessment of any device or procedure-related effects.
Results: Our new GI bypass stent showed a good durability in simulated solution
flow. No breakage or migration of stent occurred under continuous water flow in
simulation system setting. In animal study, the mean starting weight was
30.1 1.5 kg. Delivery of the implant took an average of 19.8min (range, 11–
32min) in pylorus stent group and 11.2min (range, 6–18min) in duodenal bulb
stent group. It required an average clipping time of 10.8min (range, 8–14min).
Followed for stent migration after implantation, the mean patency duration was
1.5 0.7 weeks. One pig was died due to small bowel perforation and peritonitis
after stenting. In histologic finding, there were moderate degree of mucosal ero-
sions, but no definite ulceration on pylorus and duodenum.
Conclusion: New GI bypass stent has a good physicochemical properties in simu-
lated intestinal system. In animal, all stents were successfully deployed but migra-
tion at short term follow-up were shown in this study. Proper fixation method
such as endoscopic suture machine and modification of stent would be required.
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Introduction:Dysphagia may occur due to benign pharingo-esophageal strictures,
often requiring repeated dilations. The aim of the study was to access long-term
efficacy of pharingo-esophageal dilations due to anastomotic or post-radiation
strictures.
Aims & Methods: Retrospective study of patients suffering of dysphagia due to
radiation (Group I) or anastomotic (Group II) induced pharingo-esophageal
benign strictures submitted to endoscopic dilation between January 2013 and
December 2015. The long-term efficacy (after a minimum follow-up of 12
months) was prospectively assessed by telephone interview by: a) dysphagia
improvement or b) resolution (grade 0 or 1 of Mellow-Pinkas scale), c) absence
of further dilations and d) absence of PEG. Additional therapy (PEG or proth-
esis placement, electroincision or surgery) was considered inefficiency criteria and
these patients were excluded from the interview. Post-procedure complications
were registered. Efficacy predictive factors were assessed.
Results: Forty-eight patients (296 dilations) were evaluated (median of 4 dila-
tions/patient): 85% were male, mean age of 62 years-old, 60% belonging in
Group I. The median interval between dilations was of 5 weeks. Pre-dilation
dysphagia Mellow-Pinkas score and luminal calibre were 3 1 and 7 2,
8mm, respectively. Twenty-eight patients (out of 30 live patients non-submitted
to additional therapies) answered to the interview: a) 96% had improved, b) 60%
had resolved dysphagia, c) 75% didńt need further dilations, d) 89% without
PEG, with a combined efficacy of 58, 3%. Nine patients required additional
therapy (6 PEGs, 2 prothesis, 1 eletroincision). Overall, 17 (out 21 with previous
PEG) were able to resume feeding per os. Fifteen and 29% presented Kochman
criteria for refractory and recurrent strictures, respectively. There were two post-
procedure complications (51%): one deep laceration and one pharingo-esopha-
geal fistula. Overall mortality was of 20% (10 patients died of non related pro-
cedure causes). Mean follow-up was 29, 2 11, 2 months. Number of dilations
and initial lumen calibre were significant predictors of combined efficacy in the
univariated analysis; radic strictures predicted a greater final dysphagia in the
uni- and multivariate analysis; recurrent/refractory stenosis didn’t significantly
predict global efficacy.
Conclusion: Our dilation programme presents relevant benefit to these patients
and a low rate of complications. Patients with post-radiation strictures presented
a worse prognosis. Even though retrospective we present the longest follow-up
and focusing not only in objective measures but also in patient perception of
relief.
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Introduction: Current guidelines favour the use of bleeding stents over balloon
tamponade for refractory esophageal variceal bleeding (EVB). However, data on
the efficacy of and outcomes after the placement of an SX-ELLA ‘‘Danis-Stent’’
are limited.
Aims & Methods: Retrospective multicenter study including cirrhotic patients
receiving Danis-Stents for massive/refractory EVB at 4 tertiary care centers in
Vienna (Medical University of Vienna, Krankenanstalt Rudolfstiftung,
Wilhelminenspital and Krankenhaus Hietzing). Rates of bleeding control (5
days), bleeding-related mortality (6 weeks) and overall mortality were assessed.
Results: Among 35 patients, 13 patients had an unsuccessful endoscopic band
ligation (EBL) prior to Danis-Stent placement. Danis-Stent controlled EVB in
80% (28/35) of patients. In the remaining uncontrolled bleeders (n¼ 7), 3
patients had subsequent EBL, while in 3 patients the stent had to be replaced
and 1 patient received a Linton-tube. Among these patients with initial Danis-
Stent failure, 4 died of uncontrollable EVB, 2 experienced early bleeding-related
mortality, and only 1 patient achieved a successful long-term bleeding control. In
total, early-rebleeding within 6 weeks occurred in 14.3% (including n¼ 1 while
Danis-Stent was still in place and n¼ 5 after Danis-Stent was removed): 3 under-
went EBL, 1 received a subsequent Danis-Stent, and 1 patient was treated with a
Sengstaken tube. Moreover, among n¼ 14 patients without early rebleeding
within 6 weeks, only n¼ 3 (21.4%) showed rebleeding later during follow-up:
n¼ 2 patients were treated with a Sengstaken-Tube (both experienced bleeding-
related death) and n¼ 1 had another Danis-Stent placed (successful bleeding
control). Only n¼ 11 (31.4%) patients did not experience any rebleeding after
Danis-Stent removal, while n¼ 8 patients died with the Danis-Stent in situ.
Notably, no ‘‘early-TIPS’’ was performed in this study, but 4 (11.4%) received
an elective TIPS during follow-up. N¼ 6 patients (17.1%) died due to uncon-
trolled bleeding (5days) and n¼ 10 died within 6 weeks (bleeding-related mor-
tality: 28.6%). Overall, n¼ 22/35 (62.9%) patients died. The median survival was
10.5 (IQR82) days after Danis-Stent placement. Median Danis-Stents dwell time
was 5 (range: 0–13) days. The most common adverse events were stent disloca-
tions (n¼ 13; 37.1%), while ulcers/necrosis of the esophageal mucosa were seen
in only 4 (11.4%) patients.
Conclusion: Danis-Stent controlled refractory/massive EVB in 80% of patients
but bleeding-related mortality was as high as 45%. While stent dislocations are
frequent, ulcers/necrosis of the esophagus were rare with a dwell time of 5 days.
The implementation of an early-TIPS strategy might improve the overall out-
come after Danis-Stent placement.
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Introduction: Benign anastomotic strictures are common adverse events of gas-
trointestinal tract surgery. And, they are difficult to be managed conservatively.
The first choices of treatment of anastomotic stricures are balloon dilatation and
bougination. But, they are requiring repeated sessions. Self-expandable metalic
stent (SEMS) placement has continous expanding effect for a long period. But, It
has problem of frequent stent migration, because of slow stent expanding, 2–3
days. Therefore the new mehod to inhibit stent migration is needed for more
successful management of anastomotic stenosis.
Aims & Methods: The aim of this study was to evaluate the clinical feasibility of
new method to inhibit stent migration in postoperative anastomotic stricture.
From May 2013 until February 2015, patients with benign anastomotic stricture
after subtotal gastrectomy were enrolled at a single tertiary referral hospital,
prospectively. The Niti-S ComVi pyloric stents (Taewoong Medical, Korea),
double-layered covered, were inserted. We made two nylon thread loops at the
proximal bared section of the stents. After stent placement, stent fastening with
loop and clip method was performed. Patients’ symptoms and oral intake were
assessed once or twice a week with a clinical check-up or telephone interview.
After two weeks, the loop and stent removals were done.
Results: In all patients, stents were successfully inserted and patency were con-
firmed (technical success rate, 100%). The obstructive symptoms were subsided
in 12 of 13 patients (clinical success rate, 92.3%). Stent migration was found in a
follow-up endoscopy on 14 days (1 of 13, 7.7%). Anastomotic restenosis
occurred in two patients 14 and 20 days after stent removal. However, obstruc-
tive symptoms were relieved by stent reinsertion.
Conclusion: The new method with fastening the stent with loop and clip can
reduce the risk of stent migration.
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Our fastening method can be feasible and useful technique for postoperative
anastomotic stricture after subtotal gastrectomy.
A large-scale prospective research is needed to validate the clinical effectiveness
of our method and to determine the appropriateness.
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Introduction: The optimum management of refractory or recurrent oesophageal
strictures (RBES) despite repeated attempts at dilatation is controversial1. An
accepted method includes temporary stent placement. Most commonly tempor-
ary fully covered self-expanding metal stents (FC-SEMS) are used but these
require removal some 8–12 weeks later. Oesophageal biodegradable stents
(EBS) have the advantage that they do not require removal. However, there is
a lack of good-quality evidence in support of their use2, 3. We aimed to review the
safety and efficacy of a large series of single and multiple EBS insertions for
benign RBES in a single tertiary referral centre.
Aims & Methods: A retrospective review of insertion of EBS (SX-ELLA) between
April 2008 and October 2016 was conducted. Patients with one or more EBS
insertion for benign RBES were included and clinical data extracted from the
hospital database. 30 day safety and efficacy for all stent insertions and 12 month
efficacy and median time to further intervention (MTFI) for first stents were
analysed using the Stata package.
Results: 20 patients (13m, 7f;age 44–93; Charlson index range 2–8, median 4)
with 37stents were included. Stricture aetiologies included peptic (55%), radio-
therapy (20%), post-surgical (20%) and post EMR (5%). Dysphagia score
ranged from 2–4(median 3). The total median number of dilatations prior
to first EBS was 6 (range 0–17). 15(75%) patients had previously had a
FC-SEMS placed with subsequent recurrence of symptoms. 30-day technical
success and symptom improvement was 100%. 30 day adverse events included
4(11%) stent migrations and 12(32%) with significant pain, 3 patients requir-
ing in-patient pain control (53 days). There were no significant bleeds or
perforations. 12 months following first EBS insertion 18(90%) required further
endoscopic intervention due to recurrent symptoms; 5(25%) had further dila-
tation, 9(45%) had either a FC-SEMS (2 patients) or a further EBS (7
patients), 3(15%) had NG tube insertion and 1(5%) patient died of unrelated
illness. 2(10%) were symptom free after one stent at 12m. MTFI was 139
days (range 75–517) and was not dependent on aetiology (peptic vs. non-
peptic; 135 vs. 127 days, p¼ 0.54). There was a significant reduction in
median number of interventions in the 12m following EBS insertion compared
to the preceding 12m (2 vs. 7 respectively, p¼ 0.0003). 7(35%) patients
received multiple EBS (range of stent insertions 2–9). 3 of these (43%) have
subsequently required no further intervention, 3(43%) continue to receive
intermittent EBS, inserted on a symptomatic basis, 1(14%) patient continues
to receive treatment for RBES, but has declined further EBS after 2 EBS
resulted in discomfort.
Conclusion: Use of EBS for RBES in our centre was safe and well tolerated but
there was short-lived pain in a significant number. In this highly selected cohort
of difficult strictures, EBS led to short-term benefit in all patients but sustained
benefit in only 10%. However, there was a significant reduction in intervention
frequency 12m after stent insertion and repeated EBS insertion appears a reason-
able strategy for the most resistant strictures. The role of EBS earlier in the
treatment pathway for RBES needs exploring in future studies.
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Introduction: Fully covered self-expanding metallic stents (SEMS) have an estab-
lished role in the palliation of oesophageal strictures, particularly in those with
malignancy. SEMS are advantageous as they reduce the rate of tumour ingrowth,
in doing so reduce the need for repeated endoscopic interventions in a cohort of
patients with severe comorbidity. A drawback to SEMS include their ability to
migrate distally, with some studies estimating the rate at around 20%(1–3). We
report a single-centre, retrospective cohort study on the use if SEMS, and aimed
to establish risk factors for stent migration.
Aims & Methods: Case note review was undertaken retrospectively on all
patients who had fully covered SEMS inserted at a high-volume tertiary oeso-
phageal cancer centre between Jul 13 to Feb 17. All SEMS were placed under
fluoroscopic guidance by experienced endoscopists. Stent migration was con-
firmed endoscopically or radiologically and was defined as displacement of the
stent into the stomach or distal to the baseline stenosis with subsequent loss
of the recannalised lumen. Shapiro-Wilks testing showed non-normal distribu-
tion of data. Non-parametric testing by logistic regression was therefore
performed.
Results: 188 stents were inserted to palliate malignant strictures, 75% in males.
We observed a migration rate of 20% (39) in our cohort. We observed a
significant association between predilation (within 7 days of the stent proce-
dure) and subsequent stent migration (31% in dilated vs 13% in undilated
[OR 2.89 CI: 1.33–6.30, (p¼ 0.005)]. This also met Bonferroni-corrected sig-
nificance. We demonstrate a trend towards shorter strictures being associated
with an increased risk of migration [OR 1.14 CI:1.122–1.164
(p¼ 0.052)]. There were no significant associations between migration and
whether patients received previous chemo-radiotherapy, or whether the stent
crossed the GOJ.
Conclusion: Endoscopic placement of SEMS is a safe and effective procedure in
the management of malignant dysphagia with a low risk of complications.
Predilation of lesions within 7 days of SEMS insertion carries a risk of subse-
quent stent slippage – suggesting that a cautious approach to dilation may be
prudent. Further, larger studies may demonstrate an association with shorter
strictures and migration. The migration rate at our centre is consistent with
those found in other studies.
Disclosure of Interest: All authors have declared no conflicts of interest.
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P0282 QOMBINED RESECTION IN ESOPHAGEAL CANCER: MYTH
OR REALITY
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Introduction: Esophagus cancer is one of the 10 most common malignant diseases
of the digestive tract and ranks 7th in the structure of mortality. The indicators of
5-year survival, at the present stage, rarely overcome the threshold of 15-20% in
the I-III stage of the disease. Most patients are considered inoperable by the time
of admission to hospital due to the spread of the tumor process. Local-regional
spread of the tumor is the reason for refusing to perform radical surgical inter-
vention. Taking into account the data for the last 10 years, only 1.6% of patients
had different types of combined and surgical treatment. According to various
authors, chemoradiotherapy is offered as an alternative to surgical intervention
in locally advanced forms of esophageal cancer. In addition, there is no consen-
sus between ‘‘western’’ and ‘‘eastern’’ authors about the issues of lymphodissec-
tion in esophageal cancer. Thus, for the optimal primary staging of esophageal
carcinoma and planning of surgical treatment, the surgeon needs a preoperative,
spatial picture of the prevalence of the tumor process in patients suffering from
esophageal cancer.
Aims & Methods: To analyze the probation of tumor using computer 3D-model
of mediastinum and long-term results of treatment. Describes the experience of
treatment of 190 patients with esophageal cancer from 2010 to 2015. Of them to
52 (27.3%) performed CT, to 37 (19.5%) EUS. Besides, CT to 101 (53.1%) and
MRI 7 (0.1%) with subsequent 3D-modeling. I group- 123 (64.7%) patients,
performed surgical treatment based on resection of thoracic part of esophagus,
fundamental part of stomach and two-field lymphodissection. To 15 (7.9%)
performed combined operations. The data obtained were compared with intrao-
perative findings and pathological examination. II group- 67 patients (35.3%),
used palliative treatments: 31 (16.3%)- esophageal stenting, 26 (13.7%)-argon-
tumor recanalization, 10 (5.3%)- argon-tumor recanalization with esophageal
stenting.
Results: On data of all 59 (100%) 3D-models, were estimated, localization and
length of esophageal tumor, it’s relationship with the structures of the mediasti-
num, severity of intraabdominal and intrathoracic lymphadenopathy. In most
cases, according to the data 3D- model, as well as intraoperative, met defeat of
middle and lower esophagus. Severity of involvement of mediastinal structures
rated at 48 patients (81.4%). At 35 (59.3%) and 37 (62.7%) cases amared fiber
mediastinum, at 5 (8.5%) patients - invasion to the main bronchi, At 13 (22.0%)
and 11 (18.6%) combination of anatomical structures of mediastinum defeat.
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Severity of intrathoracic and intraabdominal lymphadenopathy: mediastinal
lymphadenopathy marked at 19 (32.2%) and 20 (33.9%) patients, combined of
38 (64.4%) and 35 (59.3%). At pre-operated staging mostly met advanced form
of cancer: T4N1 at 16 (27.1%), T4N2 at 23 (38.9%). Sensitivity in staging of
tumor 89.8%. Long-term results: 1-year survival at I group 96.1%, 3-year is
42.3%, 5-year 19.6%; at II group 1-year survival 6.45%.
Conclusion: The use of 3D-modeling performed using MRI, spiral CT and EUS,
allows to planning the optimal surgery and lymph node for locally common form
of esophageal cancer, and improve the results of survival.
The scope of surgical intervention is advisable to plan taking into account the
constructed 3D-models, which helps to solve the problem of the possibility of
surgical intervention in esophageal cancer.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Endoscopic submucosal dissection (ESD) was a promising method
for the resection of superficial gastric neoplasms. The patient with antithrombo-
tic agents has increased for first or secondary prevention of cardiovascular or
cerebral disease. Continuous administration of low-dose aspirin (LDA) during
ESD was recommended in American, British and Japanese guidelines. However,
the influence of this drug for the hemostasis condition during ESD procedure is
still unclear. Therefore, we performed this study for addressing intraoperative
bleeding risk without cessation of LDA.
Aims & Methods: In this retrospective study, we assessed the hemostasis condi-
tion during ESD that were treated for superficial gastric lesions between January
2014 and March 2017. Patients with antithrombotic therapy by LDA (n¼ 42)
and those with no antithrombotic therapy (n¼ 187; Control) were compared
using propensity score matching. Primary outcome was frequency of intraopera-
tive major bleeding. Secondary outcomes included procedure time, Hb reduction
rate, En bloc resection rate, and adverse events rate.
Results: The propensity score analysis yielded 39 matched pairs. Adjusted com-
parison between the two groups showed similar with regards to major bleeding,
median [range] (times): 1.0 [0.0–4.0] vs. 1.0 [0.0–4.0], p¼ 0.621. Procedure time
was prolonged in Aspirin group by 16.7% without significant differences. Other
aspects were the same in both groups with low incidence of adverse events;
perforation (0%), thromboembolism (0%).
Conclusion: This study indicated the feasibility of gastric ESD with continuous
administration of LDA including little intraoperative bleeding and adverse
events.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Later weekday of surgery seems to reduce the prognosis in oeso-
phageal cancer, while any such influence on other cancer sites is unknown. This
study aimed to test whether weekday of surgery influences prognosis following
commonly performed cancer operations.
Aims & Methods: This nationwide Swedish population-based cohort study from
1997–2014 analysed weekday of elective surgery for 10 major cancer groups in
relation to disease-specific and all-cause mortality. Cox regression provided
hazard ratios with 95% confidence intervals (CI) adjusted for the covariates
age, sex, comorbidity, hospital volume, calendar year, and tumour stage.
Results: Included were 228,927 patients. Later weekday of surgery (Thursdays
and even more so Fridays) was associated with increased mortality rates for
gastrointestinal cancers. The adjusted hazard ratios for disease-specific mortality
comparing surgery on Friday with Monday were 1.57 (95% CI 1.31–1.88) for
oesophago-gastric cancer, 1.49 (95% CI 1.17–1.88) for liver-pancreatic-biliary
cancer, and 1.53 (95% CI 1.44–1.63) for colorectal cancer. Excluding mortality
during the initial 90 days of surgery made little change to these findings, and the
all-cause mortality was similar to the disease-specific mortality. The associations
were similar in analyses stratified for covariates. No consistent associations were
found between weekday of surgery and prognosis for cancer of the head-and-
neck, lung, thyroid, breast, kidney-bladder, prostate, or ovary-uterus.
Conclusion: Later weekday of surgery (Thursday-Friday) seems to negatively
influence the prognosis for cancer of the gastrointestinal tract, indicating a
need for re-scheduling of these operations.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0285 IMPACT OF POSTOPERATIVE COMPLICATIONS AND
PERIOPERATIVE ONCOLOGICAL TREATMENTS FOR GASTRIC
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Introduction: Recently, multidisciplinary treatments such as perioperative chemo/
radio treatments have been introduced to improve their prognosis in gastric
cancer surgery. Besides that, the postoperative severe complications are thought
to be the poor prognostic factor. Present study assessed the prognostic impacts of
severe postoperative complications and perioperative oncological treatments in
gastric cancer patients.
Aims & Methods: Consequent gastric cancer patients who underwent curative
gastrectomy in Karolinska University Hospital between 2006 and 2016 were
enrolled. Patients’ characteristics, surgical data, postoperative courses and prog-
nosis were examined retrospectively. Complications were evaluated according to
Clavien-Dindo classification. The significance of postoperative severe complica-
tions and perioperative oncological treatment for overall survival (OS) was eval-
uated by the Cox proportional hazard model.
Results:Hundred-sixty-nine patients were examined in this study. 89 (52.7%) and
66 (39.1%) patients had neoadjuvant and adjuvant treatment, 85 (50.3%) and 84
(49.7%) underwent distal and total gastrectomy, respectively. 24 (14.2%), 16
(9.5%) and 5 (3.0%) were diagnosed as grade III, IV, V complications. The
prognosis of the patients with grade III or higher complication was significantly
worse (3-year OS: 66.6% vs 47.3%, P¼ 0.001). Subgroup analysis by pathologi-
cal stage showed that the prognosis of pStage III/IV patients with postoperative
grade III or higher complication was significantly poorer than the patients with-
out grade III or higher complications (3-year OS: 45.3% vs 7.5%, P5 0.001).
For the patients who had either neoadjuvant or adjuvant treatment, however, no
obvious prognostic worsening were seen by the existence of complications (3-year
OS: 66.5% vs 52.9%, P¼ 0.13). Multivariate analysis identified that severe com-
plication was independent risk factor for OS (hazard ratio 1.82; 95% confidence
interval 1.08–3.05), especially in pStage III/IV gastric cancer (hazard ratio 3.00;
95% confidence interval 1.53–5.86).
Conclusion: Postoperative severe complications had considerable impact on the
OS, especially for pStage III/IV gastric cancer patients. Perioperative oncological
treatment may be able to prevent the prognosis from deteriorating due to post-
operative complications.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Duodenal papillary tumor as rare gastrointestinal neoplasm is
essential for curative therapy due to its malignant potential. Endoscopic papil-
lectomy to the treatment of duodenal papillary tumor has developed and is
accepted as an alternative approach to surgery in select cases. Endoscopic papil-
lectomy as a relatively difficult endoscopic technique mainly performed by
experienced endoscopists. Moreover, the indications and standard endoscopic
procedures for endoscopic papillectomy have not been established.
Aims & Methods: We aimed to investigate the clinical value of endoscopic
papillectomy for duodenal papillary tumor based on the endoscopic and clin-
ical characteristics. Between 2006 and 2017, seventy-five patients with duode-
nal papillary tumor under endoscopic papillectomy in the gastrointestinal
endoscopic center of Chinese PLA General Hospital were included. These
patients were diagnosed of duodenal papillary tumor by the clinical manifes-
tation, laboratory tests, CT, MRCP, endoscope, EUS, ERCP along with
biopsies and histopathologic tests. During the detailed clinical assessment
combined with patients’ wishes, endoscopic papillectomy and followed
ERCP procedures were performed successfully, and the clinical data of these
patients were retrospectively summarized.
Results: 75 patients (50 males and 25 females) with a median age of 58.6 yrs
(range 27 to 82 yrs) were evaluated. The main clinical symptoms were predomi-
nated by abdominal pain followed by cholestasis and cholangitis, but nine cases
with no abdominal symptoms. Endoscopic papillectomy was technically feasible
in all these patients, and was mainly performed by four experienced endoscopists.
The majority of excised tumors were exogenous (90.7%, 68/75), and the tumor
size ranged between 8 and 55mm. The final histopathological diagnosis included
adenoma (37.3%, 28/75), adenoma with high-grade intraepithelial neoplasia
(18.7%, 14/75), adenoma with low-grade intraepithelial neoplasia (26.7%, 20/
75), adenoma combined with local carcinoma (16%, 12/75), and neuroendocrine
tumor (1.3%, 1/75). En bloc resection was achieved in 53 cases (70.7%) and the
piecemeal resection was performed in 22 cases (29.3%). After endoscopic papil-
lectomy, the ERCP procedures were performed in 70 cases (93.3%). The pro-
phylactic pancreatic duct stent was placed in 30 cases (40%) for preventing
pancreatitis, the biliary plastic stent or nasobiliary drainage tube in 16% (12/
75), the combined of both in 17.3% (13/75), and no stent placement in 26.7%
(20/75). Moreover, intraoperative hemostasis was performed in 47 cases (62.7%),
including pure endoscopic clip placement, followed by injection therapy, thermal
therapy or in combination. Regarding to the postoperative adverse events,
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hemorrhage was identified in 11 patients (14.6%) but mainly cured by endoscopic
hemostasis, followed by pancreatitis (9.3%, 7/75) but cured with medical
treatment.
Conclusion: Endoscopic papillectomy can be considered as a feasible and reason-
able treatment option for suitable patients with tumors of duodenal papilla.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Prophylactic surgery of familial adenomatous polyposis (FAP)
ranges from total colectomy with ileorectal anastomosis (IRA) to proctocolect-
omy with ileoanal anastomosis and J pouch (IAA). Rectal preservation is based
on studies that did not include systematic endoscopic treatment that we perform.
The objective was to compare IRA to IAA in terms of oncological safety and
quality-of-life.
Aims & Methods: Between January 1965 and November 2015, all consecutive
patients who underwent prophylactic surgery for FAP with aggressive endo-
scopic follow up in our unit: systematic endoscopic treatment of adenomas
(argon, mucosectomie), were prospectively included. MYH-related polyposes
and patients who underwent abominoperineal resection were excluded from
analysis.
Results: 296 patients were included: 92 proctocolectomy with IAA (31.1%), 197
total colectomies with IRA (66.5%), and 7 abdominoperineal resections (2.4%).
Mean (SD) number of preoperative rectal adenomas was 24.7 (33.9) in the IRA
group vs. 52.8 (27.8) in the IAA group (p¼ 0.0001). Rectal cancer prevalence was
3.1% (n¼ 9). Mean (SD) follow-up was 16.6 (11.9) years, during which the mean
(SD) number of lower endoscopies was 3.4 (2.5) in the IRA group vs. 3.4 (2.5) in
the IAA group (p¼ 0.91); mean (SD) number of treated adenomas was 17.8
(20.8) and 12.9 (18.8), respectively (p¼ 0.06); secondary cancer incidence was
6.1% vs. 1.1% (p¼ 0.06). The 15-year recurrence-free and overall survival (IR
vs. IAA) were respectively 99.5% vs. 100% (p¼ 0.09) and 98.9% vs. 98.8%
(p¼ 0.82).
Conclusion: Combination of aggressive endoscopic treatment and extended rectal
preservation appears to be a safe alternative to ileoanal anastomosis and J pouch.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Many pregnant women have anal symptoms during pregnancy and
postpartum. The most common proctological problems reported are haemor-
rhoids, anal fissures and anal incontinence. Literature about this problem is
scarce.
Aims & Methods: The aim of this study is to determine the prevalence of anal
problems and constipation during the second and third trimester of pregnancy, in
the immediate postpartum and up to three months after childbirth. We also want
to identify the risk factors for the development of anal symptoms. This is a
prospective cohort study. Women between their 19th and 25th week of pregnancy
are included. High-risk pregnancy and non-Dutch speaking are exclusion criteria.
Ninety-four women were followed with a symptom questionnaire in the second
and third trimester, in the immediate postpartum (within 3 days) and three
months postpartum. Descriptive data were obtained from the patient files. A
specific proctological diagnosis was presumed on the basis of combined symp-
toms (rectal bleeding, anal pain and swelling). Constipation was defined by the
Rome III criteria. Statistical analysis was performed with SPSS and risk factors
were identified using multivariate analysis with binary logistic regression.
Results: Sixty-eight percent of the women developed anal symptoms during the
whole study period. Anal symptoms occurred in 50% of the women during
pregnancy, in 56.2% in the immediate postpartum and in 62.9% during the
three months postpartum. The most prevalent symptom was anal pain.
Constipation was reported by 60.7% during the whole study period. Most pre-
valent diagnoses were: hemorrhoidal thrombosis (immediate postpartum),
hemorrhoidal prolapse (3rd trimester and immediate postpartum) and anal fis-
sure (not episode-related). Anal incontinence was only reported in 2% during the
postpartum. Multivariate analysis identified constipation and a history of anal
problems as significant risk factors for the development of anal complaints pre-
partum and postpartum.
Conclusion: Two-thirds of pregnant women deal with anal symptoms during
pregnancy or postpartum, especially hemorrhoidal complications and anal fis-
sure. This high prevalence emphasises the clinical importance of this problem.
The most important risk factor is constipation. Therefore, prevention of consti-
pation in pregnant women is recommended.
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Introduction: Diverticulitis is a common gastrointestinal disease in developed
countries, especially among elders. It is classified into five stages according to
the severity of the inflammation with stage 5 involving peritonitis as a conse-
quence of perforation and organ dysfunction with 30-day-mortality reaching
32%. This indicates that acute diverticulitis is an emergency case requiring
rapid management. However, the surgical interventions of diverticulitis vary
according to its grade and severity, there is a controversy about the preferable
and suitable of these different surgical procedures for each grade or complication.
Aims & Methods: We aimed to systematically review and meta-analyze rando-
mized controlled trials (RCTs) comparing outcomes and complications between
different surgical approaches for acute diverticulitis and its complications. Nine
electronic databases, including PubMed, Scopus, Google Scholar, ISI Web of
science, WHO Global health library (GHL), POPLINE, Virtual health library
(VHL), NYAM (New York Academy of Medicine), and SIGLE (System for
information on grey literature in Europe), were searched for RCTs comparing
different surgical procedures for different grades of diverticulitis. Out of 1738
articles, we included 14 studies with 1076 patients. the primarily assessed out-
comes were post-surgical mortality rate besides short- and long-term post-surgi-
cal major and minor complications. The risk of bias was assessed using the
Cochrane Collaboration tool. The pooled risk ratio (RR) and 95% confidence
interval (CI) were calculated in the meta-analysis using the RevMan platform.
The protocol was registered in PROSPERO (CRD42015032290).
Results: Outcome data were analyzed from five RCTs comparing laparoscopic
sigmoid resection (LSR) (n¼ 247) versus open sigmoid resection (OSR) (n¼ 237)
for treatment of acute complicated diverticulitis with minimal heterogeneity. For
short-term outcomes, there was no significant difference in postoperative overall
morbidity (RR¼ 0.89, 95% CI [0.61–1.31]; P¼ 0.56), all major postoperative
morbidity (RR¼ 0.79, 95% CI [0.12–5.07]; P¼ 0.80), and all minor postoperative
complications (RR¼ 0.98; 95% CI [0.62–1.57]; P¼ 0.94). Similarly, there was no
difference between the two procedures regarding the long-term postoperative
overall morbidity (RR¼ 0.83, 95% CI [0.57–1.21]; P¼ 0.34), all major morbidity
(RR¼ 0.78, 95% CI [0.46–1.31], P¼ 0.34), and mortality (RR¼ 0.95, 95% CI
[0.04–24.59]; P¼ 0.98). In other four RCTs compared laparoscopic lavage with
resection (sigmoidectomy) for treatment of perforated diverticulitis with perito-
nitis, the postoperative mortality rate was non-significant in both short-term
(RR¼ 1.55, 95% CI [0.79–3.04]; P¼ 0.21) and long-term (RR¼ 0.67, 95% CI
[0.29–1.58]; P¼ 0.36) follow up. Interestingly, the short-term reoperation rate
and long-term precense of intra-abdominal abscesses were significantly higher
in LL group (RR¼ 1.74, 95% CI [1.01–3.02], P¼ 0.05) and (RR¼ 2.47, 95% CI
[1.03–5.92]; P¼ 0.04) respectively. The remaining five RCTs compared between
different procedures, like primary anastomosis versus non-restorative resection,
RP-LASR versus NRP-LASR, and primary versus secondary resection, for dif-
ferent situations and reviewed qualitatively.
Conclusion: The superiority of LSR over OSR was non-significant in the treat-
ment of acute symptomatic diverticulitis regarding postoperative complications,
operational time, and cost. However, the cosmetic aspect still gives LSR more
advantage. Regarding perforated diverticulitis with purulent peritonitis, our
results showed that LL is as safe as resection (either Hartmann’s operation or
sigmoidectomy with primary anastomosis) regarding short- and long-term post-
operative outcomes especially in long-term, hospital stay, and operational dura-
tion. Hence, LL is feasible and can act as definitive treatment. Further RCTs are
still needed to make a decision regarding these and other procedures.
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Introduction: There has been enormous progress in diagnosing and treatment of
colorectal cancer (CRC), however a great number of patients is nevertheless
diagnosed in advanced disease stages. It is of great importance to develop non-
invasive, inexpensive, prognostic, diagnostic, and treatment predicting biomar-
kers in early diagnostics of CRC considering its incidence worldwide. There are
studies suggesting that the systemic inflammation play an important role in CRC
tumor stage development, which can be reflected by the levels of neutrophil to
lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR).
Aims & Methods: This study was designed to investigate the efficiency of pre-
operative NLR, PLR as a tool for the assessment of synchronous lymph nodes
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and liver metastases in newly diagnosed patients with CRC. Three hundred
patients with I-IV stage CRC undergoing surgical resection were included in
this cross sectional study. Complete blood counts with automated differential
counts were performed preoperatively. The NLR was calculated by dividing the
absolute neutrophil count by the absolute lymphocyte count; also PLR was
calculated by dividing the absolute platelet count by the absolute lymphocyte
count. The diagnostic performance of NLR and was estimated by ROC curve.
Results: Our results suggest that there was high statistically significant difference
between NLR (p¼ 0.003), PLR (p¼ 0.002) and tumor stages (I to IV). ROC
curve analysis showed high diagnostic efficacy of NLR (AUC 0.774,
95%CI¼ 0.683–0.790) and PLR (AUC 0.698, 95%CI¼ 0.663–0.742) for syn-
chronous lymph node and liver metastases. Also combination of NLR and
PLR improved diagnostic efficacy (AUC 0.841, 95%CI¼ 0.811–0.863) for syn-
chronous liver and lymph node metastases.
Conclusion: Our results suggest that NRL and PLR could be useful diagnostic
CRC biomarkers, and could have potential use in early recognition of different
stages of CRC.
Disclosure of Interest: All authors have declared no conflicts of interest.
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APPENDICITIS IN SUSPECTED APPENDICITIS PATIENTS
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Introduction: Diagnosis of appendicitis is still clinically challenge where resource
is limited. The purpose of this study is to develop and externally validate
Ramathibodi Appendicitis Score (RAMA-AS) in aiding diagnosis appendicitis.
Aims & Methods: Two-phase cross-sectional study (i.e., derive and validation)
was conducted at Ramathibodi Hospital (for derive), Thammasat University
Hospital and Chaiyaphum Hospital (for validation). Patients with abdominal
pain and suspected of having appendicitis were enrolled. Multiple logistic regres-
sion was applied to develop parsimonious model. Calibration and discrimination
performances were assessed. In addition, our RAMA-AS was compared with
Alvarado’s score performances using ROC curve analysis. The study was con-
ducted and reported according to Transparent Reporting of a Multivariable
Prediction Model for Individual Prognosis Or Diagnosis (TRIPOD) statement.
Results: The RAMA-AS consisted of 3 domains 7 predictors including symptoms
(i.e. progression of pain, aggravation of pain, and migration of pain), signs (i.e.
fever and rebound tenderness), and laboratory (i.e. white blood cell count (WBC)
and neutrophil). The model fitted well with data and it performed better discri-
minate than the Alvarado score with C-statistic of 0.842 (95% CI: 0.804, 0.881)
versus 0.760 (0.710, 0.810). Internal validation by bootstrap yielded Sommer’s D
of 0.686 (0.608, 0.763) and C-statistics of 0.848 (0.846, 0.849). The C-statistics of
two external validations were 0.853 (0.791, 0.915) and 0.813 (0.736, 0.892) with
fair calibrations.
Risk group Sensitivity Specificity LRþ LR-
Post-positive
test odds
Very low 100 0 1 0 61.8
Low 89.75
(85.25–93.26)
54.97
(46.67–63.06)
1.98
(1.65–2.37)
0.19
(0.13–0.28)
76.00
(73.00–79.00)
Moderate 64.08
(57.73–70.09)
88.08
(81.82–92.78)
5.25
(3.39–8.13)
0.41
(0.34–0.49)
89.00
(85.00–93.00)
High 37.96
(31.86–44.36)
95.36
(90.68–98.12)
8.36
(3.96–18.00)
0.65
(0.59–0.72)
93.00
(86.00–97.00)
Conclusion: RAMA-AS is a useful tool for diagnosis of appendicitis. It has good
discrimination performance and good calibration performance after revision.
Practitioners should be encouraged to use the score in clinical practice in order
to conforming diagnosis and choosing the patient who should undergo imaging
or surgical management.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction:Haemorrhoidectomy in ulcerative colitis (UC) have been considered
to be potentially dangerous, but the evidence is poor.
Aims & Methods: A study was conducted to ascertain the safety of haemorrhoi-
dectomy in patients with UC. Retrospective review of 44 UC patients from 2004
to 2014. Patient demographics and clinical characteristics (anorectal symptoms,
prior non operative haemorrhoidal therapy, whether proven UC preoperatively
(BD) and unproven preoperatively (AD), whether to use azathioprine, presence
of other perianal disease, and activity, anatomic location of UC) were recorded.
Postoperative complications, and differences between BD and AD were analysed.
Results: The patients were 29 males (65.9%), median age 44 (range, 19–72) years.
Predominant symptoms were bleeding and prolapse (n¼ 24; 54.5%), prolapse
only (n¼ 6; 13.6%), bleeding only (n¼ 14; 31.8%). 17 patients (BD, 38.6%)
were diagnosed with UC prior to surgery. 4 patients (9.1%) had azathioprine
therapy before surgery. There was no other perianal disease. Disease was limited
to the rectum (n¼ 33; 75%), left-sided (n¼ 9; 20.5%), and extended to right-
sided (n¼ 2; 4.5%). During follow-up, there were no complications such as
sepsis, anal stenosis, abscess and fistula formation, and recurrence. There was
no difference in complications and other clinical characteristics between BD and
AD. There was no difference in complications according to disease extent
(p¼ 0.158).
Conclusion: Our data suggest that haemorrhoidectomy may be performed safely
in UC patients.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Temporary loop ileostomies are commonly performed to protect a
distal anastomosis in colorectal surgeries. Although they have been shown to
reduce the number of leaks requiring surgery, they remain a source of complica-
tions and have an adverse effect on the quality of life. A few non-randomized
studies have shown the feasibility of early stoma closure.
Aims & Methods: To compare the outcomes of early and delayed closure of
temporary loop ileostomy in terms of operative parameters, morbidity, mortality,
and quality of life. The study was conducted from May 2014 to September 2015.
Following creation of loop ileostomy after colorectal surgeries, distal loop con-
trast study was done on POD 7. Patients who had no leak were randomized to
either early closure (8–13 days) or delayed closure (after 6 weeks) group. Patient
demographics, operative parameters, morbidity, mortality and quality of life data
were recorded in both groups.
Results: There were 24 patients in each group. Both groups were comparable in
terms of demographic data except for age, which was significantly higher
(p¼ 0.012) in the early closure group. Incidence of stoma related complications
(p¼ 0.01) and Pittman ostomy complication severity index (p5 0.01) were sig-
nificantly higher in the delayed group. Operative time (p¼ 0.033) and Surgeons
assessment score (p¼ 0.0012) for the stoma closure surgery were significantly
lower for the early closure group. There was no significant difference in the
duration of hospital stay and the incidence of postoperative complications in
the two groups. Quality of life as calculated by the Ostomy Adjustment Index
score (OAI 23) was better in the early closure group (p¼ 0.014).
Conclusion: Early closure of a temporary loop ileostomy is feasible with the
advantages of decreased stoma related morbidity, operative difficulties without
increased morbidity and mortality when compared with conventional delayed
ileostomy closure.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Ger reported the Erst laparoscopic hernia repair in 1982 by approx-
imating the internal ring with stainless steel clips. The laparoscopic trans-abdom-
inal preperitoneal (TAPP) repair was a revolutionary concept in hernia surgery
and was introduced by Arregui and Dion in the early 1990s. Institutions perform-
ing radical laparoscopic surgery for inguinal hernia have been rapidly increasing
since the NHI point was amended in Japan. However, in the 12th JAPAN
SOCIETY FOR ENDOSCOPIC SURGERY questionnaire survey, the recur-
rence rate after surgery employing the TAPP method was reported to be 4%,
posing a problem regarding the thoughtless introduction of the TAPP method.
Our hospital performed surgery employing the TAPP method only occasionally
until April 2015, but treatment of inguinal hernia was integrated, the indication
was established in May 2015, and laparoscopic surgery employing the TAPP
method has been performed for the indicated cases. In this study, we investigated
the current state of inguinal hernia treatment at our hospital. Surgical indication
of inguinal hernia in our department is as follows. Symptomatic inguinal hernia
is treated using the TAPP method when there is only one POSSUM score-based
risk factor. When 2 or more risk factors are present or the patient has undergone
surgery of the prostate, the anterior approach is employed (the UHS and Mesh
Plug methods for internal and external inguinal hernia, respectively). Treatment
under local anesthesia is prioritized for patients aged 90 years or older and
patients with PS2 or higher. Arrangement in operating room is that the operator
and assistant stand on the left and right sides of the patient, respectively, an
anesthesiologist stands at the patient’s head, and a nurse stands caudal to the
assistant.
Aims & Methods: In this study, we investigated the current state of inguinal
hernia treatment at our hospital. The subjects were 120 patients who underwent
radical surgery for inguinal hernia before and after the full-scale introduction of
the TAPP method (early period: October 2014-April 2015 (7 months), late
period: May 2015-November 2015 (7 months), 47 and 73 patients were treated
in the early and late periods, respectively). Changes in the surgical procedure,
complications, and duration of hospital stay were investigated in 120 patients.
Results: The median age was 70 years old (19–91years old). There were 114 male
and 6 female patients, with a total of 132 lesions (unilateral in 108 (right: 60, left:
48) and bilateral in 12). The hernia classification (Japanese Hernia Society) was 1,
2, 3, 4, rec in 91, 37, 0, 3, and 1 lesions. Surgery was performed under local
anesthesia in 43, lumbar anesthesia in 1, and general anesthesia in 76. A laparo-
scope was used in 70 and not used in 50. TAPP, mesh plug, and UHS and others
were used in 58, 54, 17, 3 lesions. There was no change for both the Early period
and the Late Period about the median operative time (Early period: 93 minutes,
Late period: 102 miniutes). Early Period was 4 days (4–24), Late Period was 3
days (3–9) for median duration of hospital stay. In Early period, complications
which required treatment (Clavien Dindo Grade3 or higher) were intestinal
obstruction and recurrence in one each. In Late period, the recurrence and com-
plications of Clavien Dindo Grade3 or higher did not occur.
Conclusion: No severe complication or recurrence has occurred since
integrating treatment for inguinal hernia and introduction of the TAPP
method. Application after carefully deciding the indication may be important
for laparoscopic surgery for inguinal hernia. A randomized prospective explora-
tory study on analgesic methods for laparoscopic radical surgery for inguinal
hernia aiming at introducing day surgery (approved by the Ethics Committee) is
being performed.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: To evaluate the effectiveness of laparoscopic left colectomy with
primary anastomosis and loop ileostomy in the treatment of complicated acute
diverticulitis with diffuse purulent peritonitis (Hinchey 3), also considering the
lack of evidence about this topic due to the difficulty of carrying out comparative
trials with the laparoscopic washing/drainage technique.
Aims & Methods: A consecutive unselected series of 44 patients undergone emer-
gency surgery for acute complicated Hinchey 3 diverticulitis from January 2012
to December 2016 was retrospectively evaluate. All patients were treated by pure
laparoscopic left colectomy with primary colorectal anastomosis and temporary
loop ileostomy. All the procedures were performed by the same surgeons (IS,
ADL, FR). Perioperative care plan, operative steps and surgical instrumentations
were standardized. We collected patients-, surgery- and hospital stay–related
data, as well as short-term outcomes. Complications were classified using the
Clavien–Dindo classification system (CDCS).
Results: There were 31 men (70.4%) and 13 women (29.6%) with a mean age of
57.8 11.9 years. The mean body mass index was 28.3 3.1 kg/m2. No conver-
sion to open surgery was registered. The mean operative time and estimated
blood loss were 184.3 32.7 minutes and 81.2 72.7ml respectively. All the
specimens showed diverticulitis with peridiverticulitis. Length of hospital stay
was 7.8 2.8 days and we have not recorded any readmissions in patients dis-
charged within 60 days after surgery. The rates of postoperative complications
were 6.8% and 2.3% for grades 3 and 5 according to the CDCS respectively.
Conclusion: Laparoscopic left colectomy with primary anastomosis and loop
ileostomy seems to be a good technique that resulted in encouraging short-
term outcomes. In expert hands it represents an effective technique for the treat-
ment of acute diverticulitis complicated by diffuse purulent peritonitis.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Total mesorectal excision (TME) with lateral pelvic lymph node
dissection (LLND) is a standard procedure for low rectal cancer in Japan.
However, ME alone is the international standard surgical procedure for rectal
cancer. Complete LLND is difficult because of the narrow visual field in the
pelvic cavity and the complicated anatomical structure and invasive procedure
which needs longer operative time and greater blood loss. Herein we introduce
laparoscopic LLND as our new procedure securing equivalent range of lymph
node dissection and report the clinical outcomes.
Aims & Methods: After laparoscopic ME, first, the external iliac artery was
exposed and the external iliac nodes were completely removed from inguinal
ligament. Obturator nodes were completely dissected while preserving the
obturator nerve, resecting the obturator artery and vein, and confirming lateral
pelvic wall, bladder wall and sciatic nerve. Subsequently, proximal internal iliac
nodes were removed and superior vesical artery was separated. Distal internal
iliac nodes from the coccygeal muscle (Alcock’s canal) were completely dissected
while preserving the superior vesical artery and the pelvic plexus, and transecting
several inferior vesical arteries. Finally, bilateral hypogastric nerves were sepa-
rated to be preserved. Common iliac nodes were dissected; aortic bifurcation
nodes and presacral nodes were also dissected by exposing the aortic bifurcation
and the pelvic surface of the sacrum.
Results: Between 2015 and 2016, we performed laparoscopic ME with LLND for
10 patients with cT2 or deeper low rectal cancer. The median operative time was
502min (420–679min), and the median blood loss was 90ml (5–500ml).
Postoperative complications developed in 4 (40%) patients, and the most fre-
quent one was temporary urination disorder in 2 (20%) patients. The median
number of harvested lateral lymph node was 20 (14–23). So far there are no
recurrent cases.
Conclusion: Our laparoscopic LLND provides good visual field and reduces an
amount of operative bleeding and results in favorable clinical outcomes.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0297 TRANSGASTRIC-NOTES SIGMOID RESECTION IN AN
ANIMAL SURVIVAL MODEL USING THE ANUBIS-SYSTEM
J. Bernhardt
1, H. Steffen2, P. Koehler3, S. Schneider-Koriath2, K. Ludwig2
1Dept. Of Endoscopy, Klinikum Suedstadt Rostock, Rostock/Germany
2Dept. Of Surgery, Klinikum Suedstadt Rostock, Rostock/Germany
3Friedrich Loeffler Institute, Neustadt/Germany
Contact E-mail Address: joern.bernhardt@kliniksued-rostock.de
Introduction: Natural orifice translumenal endoscopic surgery (NOTES) pro-
posed advantages should be established by comparison with standard proce-
dures. Using a single side transluminal access, the feasibility of performing
advanced surgical procedures is still limited, especially for a single endoscope.
We used the ANUBIS-system for sigmoid resection with a transgastric access to
the abdominal cavity assisted by colonoscopy and one trocar.
Aims & Methods: The experimental study was conducted in a porcine model in
general anesthesia. After operation in an acute model, we started the study with 5
pigs in a survival model. Using Anubisscope, a transgastric access was reached by
needle-knife incision and balloon dilatation. CO2 peritoneum was achieved by
insufflation via a working channel. By steering the colonoscope, the colon was
maneuvered endoluminally and the colic mesentery was exposed. Bowel-close
mesocolic preparation was performed with a coagulating hook-knife with simul-
taneously assistance by a grasper via the Anubiscope. Both instruments have the
possibility of two-directional movements. The access angle for preparation and
visualisation could be altered during the procedure by manoeuvring the colono-
scope and the movements of the flexible endoscopic instruments. To prepare
anastomosis, circular stapler anvil was introduced transluminally and penetration
of the colon wall was carried out. Subsequently, proximal resection of the sigmoid
colon was performed using a linear stapler inserted through a trocar at the left
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lower abdomen. The bowel extraction was performed by invagination transrec-
tally. After extracorporeal distal linear stapling of the sigmoid, the colorectal
anastomosis was completed by applying a circular stapling device transrectally,
assisted by a transcutaneous inserted grasper. Function testing was performed by
the colonoscope. Gastric access closure was performed by OTSC clip.
Results: The procedure was successful in all animals with operation time ranging
from 4.5 to 6 hours. After weight gain in all cases, the animals were sacrificed
after postoperative day 42 and the workup showed competent anastomotic heal-
ing with a stenosis and consecutive prestenotic dilatation in one case. These
animal had a small peritoneal abscess beside the anastomosis. Gastric closure
was healed and the OTSC clip still in situ in all animals. In one case we used two
OTSC clips for gastric closure, there were severe adhesions with two perigastric
abscesses.
Conclusion: The use of an operating platform like the Anubisscope has the
advantage of flexible preparation in opposite position of the instruments. The
disadvantages are the only two degrees of freedom of the flexible instruments and
the rotation-like movements. Flexible colonoscopy provided a fixed reference
frame that enabled preparation and dissection. For resection and anastomosis
an additional transcutaneous access was necessary.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Peritoneal tuberculosis (TB) and advanced ovarian cancer, two
conditions with different management and prognosis, have many similarities:
ascites, complex adnexal mass, peritoneal deposits, and raised CA-125 level.
Symptoms such as weight loss, reduced appetite, and dull abdominal pain are
also common to these two entities.
Aims & Methods: The aim of this study was to analyze patients’ characteristics,
laboratory investigations, radiological and surgical findings in post-menopausal
women with pelvic TB who were diagnosed after laparotomy or laparoscopy for
suspected ovarian cancer. We report twenty-one cases of pelvic-peritoneal TB in
post-menopausal women who presented with features mimicking ovarian malig-
nancy from 2004 to 2014 in a Tunisian center.
Results: The mean age was 59.8 (46–87 years). Three patients have personal or
family history of TB. All women presented with abdominal pain and distension
of varying duration of 1 month to 6 months. Eleven patients had reduced appe-
tite and weight loss, and four women gave a history of low-grade fever. A CT
scan showed the presence of solid-cystic adnexal masses ranging rom 3 cm to
12 cm in 100% and ascites in 90.4%. Ascitic fluid analysis was done in 19 patients
which showed a lymphocytic predominant pattern, and absence of malignant
cells. Ascitic fluid cultures was negative in all. CA-125 was elevated in all and
ranged between 185 and 1300 IU/ml. CA-125 4600 IU/L was found in three
women. Quantiferon-TB Gold (QFT-G) performed in 3 patients was positive
in two. A laparoscopic evaluation with biopsies was performed in 16 patients
and an exploratory laparotomy in 4 women for suspected ovarian cancer.
Intraoperative findings of tubercles on the pelvic organs and peritoneal surfaces
suggested TB in 18 patients. In two, TB was not suspected intraoperatively. The
diagnosis of TB was confirmed by histopathology in 95.2%. Response to ther-
apeutic trial of anti-tubercular drugs was the basis of diagnosis in one case
because of a high anesthetic risk.
Conclusion: It is a diagnostic challenge to differentiate pelvic-peritoneal TB from
ovarian cancer which has entirely different management and prognosis. Ascitic
fluid showing lymphocytic predominance and no malignant cells and
positive(QFT-G) are pointers to obtain a histopathological diagnosis by laparo-
scopic biopsy or frozen section at laparotomy.
Disclosure of Interest: All authors have declared no conflicts of interest.
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INFLAMMATORY RESPONSE IN THE COLONIC MUCOSA IN
ULCERATIVE COLITIS
V. Pavlenko, F. Urusova, G. Eseneeva, A. Pavlenko, N. Korablina
Stavropol State Medical University, Stavropol/Russian Federation
Contact E-mail Address: pavlenkovv@yandex.ru
Introduction: Peptide growth factors including the IGF family are expressed in
the intestine and modulate proliferative activity of the intestinal epithelium in
ulcerative colitis (UC) and Crohn’s disease (CD). At the same time, IL-8 is one of
the main triggers behind the immunoinflammatory process in the colonic mucosa
(CM) in UC, and its level may be of prognostic value in determining the illness
course.
Aims &Methods: The aim of the study was to identify the role that IGF-I plays in
colonic inflammation in 35 patients with different clinical (Rahmilevich index)
and endoscopic (Mayo index) activity of UC. The treatment was administered in
view of the severity of UC. 20 healthy volunteers were the control group. IGF-I
levels in peripheral blood were determined by ELISA (Mediagnost, Germany).
The results were expressed as nmol/l. The spontaneous and E. Coli LPS-induced
synthesis of IL-8 in rectal bioptic samples were studied via ELISA. The results
were expressed as picograms per 1mg of wet tissue (pg/mg). The severity of the
inflammation in the CM was studied by the method of Avtandilov G.G. counting
with inflammatory infiltrate (in %) in the lamina propria. The study implied
investigating the cellular composition of the inflammatory infiltrate in the
lamina propria. Depending on the density of the inflammatory infiltrate, the
patients were divided into two groups: Group 1 revealed a weak inflammatory
response (20.2 0.8%), while Group 2 demonstrated prominent infiltration
intensity (39.0 2.09%, P5 0.05 to Group 1). Statistical processing was per-
formed using the SPSS 13.0 software.
Results: It has been shown that in acute UC stages the amount of IGF-I in the
blood plasma decreased (15.16 1.35 nmol/l (p5 0.05 to control)), while spon-
taneous production of IL-8 chemokine in rectal bioptic samples went up
(300.0 6.0 pg/ml, P5 0.05). In case of the LPS stimulation the production of
IL-8 in the CM went up more than 2 times (750.0 7.0 pg/mg, P5 0.05). There
was significant inverse correlation (rs) detected between the IGF-I levels in the
blood plasma, on one hand, and indicators of the UC clinical, endoscopic activity
and the intensity of the inflammatory infiltrate in the CM, on the other. Direct
relationship was found between the levels of spontaneous and stimulated produc-
tion of the IL-8 chemokine and the density of the inflammatory infiltrate in the
CM of patients with active UC. Through the period of the clinical remission
development (an average of 8 weeks) the IGF-I levels increased up to
94.125 28.18 nmol/l (P5 0.05), yet have not reached the control value
(P5 0.05 to control). Induction of the clinical remission was associated with a
decrease to the level of the control values for spontaneous and LPS-induced IL-8
production, regardless of UC activity.
Conclusion: The intensity of the inflammatory process in the CM depends on the
level of IL-8 produced by respective cells. Evidently, IL-8 has a capacity of
inhibiting the production of IGF-I at the peak of inflammation (acute UC).
Increased synthesis of IGF-I and reduced IL-8 in remission facilitates regenera-
tion of the damaged mucosa.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Epidemiological studies have showed that there was an inverse
association between Helicobacter pylori (H.pylori) infection and the incidence
of inflammatory bowel disease (IBD). Our previous research indicated that the
regulatory immune responses induced by H.pylori infection were not limited to
gastric mucosa, IL-10-producing Breg cells and Foxp3þTreg cells expanded in
spleen and mesenteric lymph nodes (MLN), the balance of intestinal mucosal
immunity was influenced to a skewed regulatory immune response.
Aims & Methods: A murine model with H.pylori infection and acute and chronic
colitis induced by dextran sulphate sodium (DSS) was established to explore the
function of the Breg cells in the effect of H.pylori infection on acute and chronic
colitis induced by DSS.A C57BL/6 mice model of acute and chronic colitis was
induced by 3% DSS with or without H.pylori infection in advance, the colitis
performances were assessed by disease acitive index (DAI) Kcolon length and
colonic histological inflammatory scores. The CD19þIL-10þBreg cells and
CD4þCD25þFoxp3þTreg cells in blood Kspleen KMLN KPP and gastrointestinal
mucosa were measured by flow cytometry, immunohistochemistry and immuno-
fluorescence. The anti- and pro-inflammatory cytokines were also detected at
mRNA level by real-time PCR.
Results: Compared with the DSS treated acute colitis group, H.pylori/DSS co-
treated acute colitis group: (1) DAI and colonic histological scores reduced
(9.25 4.42 vs 16.00 2.00, P¼ 0.025) and colon length shortened less
(6.56 0.63 vs 5.40 0.54, P5 0.001). (2) The percentages of CD19þIL-
10þBreg cells detected by flow cytometry expanded in different tissues: blood:
5.05 0.68 vs 2.89 0.55, P¼ 0.001; spleen: 4.32 0.56 vs 3.17 0.20, P¼ 0.05;
MLN:5.89 0.54 vs 4.94 0.65, P¼ 0.047; PP: 6.95 1.67 vs 5.39 0.88,
P¼ 0.005; respectively. (3) The percentages of CD4þCD25þFoxp3þTreg cells
expanded in different tissues: spleen: 13.50 1.37 vs 10.73 1.13, P¼ 0.008;
MLN: 17.50 0.82 vs 14.87 1.53, P¼ 0.001; PP: 12.70 3.24 vs 8.58 1.71,
P¼ 0.028. The numbers of Foxp3þ cells per HPF in colonic mucosa:
3.44 0.40 vs 2.58 0.34, P¼ 0.004. (4) mRNA expression in colonic mucosa:
IL-10 (P¼ 0.001) mRNA relative expression upregulated and IFN- (P¼ 0.048)
mRNA relative expression downregulated significantly. Compared with DSS
treated chronic colitis group, H.pylori/DSS co-treated chronic colitis group:
(1) DAI and colonic histological scores reduced (9.00 1.73 vs 14.67 1.53,
P¼ 0.001), and colon length shortened less (6.82 0.41 vs 5.98 0.15,
P¼ 0.001). (2) The percentages of CD19þIL-10þBreg cells expanded which
were consisted with the acute colitis groups: spleen: 7.05 0.28 vs 5.39 0.72,
P¼ 0.024; MLN: 4.78 0.73 vs 3.02 0.83, P¼ 0.047; PP: 7.14 1.04 vs
4.34 1.03, P¼ 0.005; respectively. (3) The percentages of
CD4þCD25þFoxp3þTreg cells decreased dramatically in different tissues:blood:
4.66 0.22 vs 7.37 0.87, P5 0.001; spleen: 9.07 2.88 vs 13.10 1.19,
P¼ 0.018; PP: 7.33 1.07 vs 12.80 0.96, P5 0.001; The numbers of Foxp3þ
cells per HPF in colonic mucosa: 3.66 0.99 vs 4.08 0.56, P¼ 0.392. (4) mRNA
expression in colonic mucosa: IL-10 (P¼ 0.023) KFoxp3 (P¼ 0.000) mRNA rela-
tive expression upregulated significantly, and IFN-(P¼ 0.001) KTNF-
(P¼ 0.005) KIL-17A(P¼ 0.019) and IL-23 (P¼ 0.000) mRNA relative expression
downregulated significantly.
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Conclusion: (1) H.pylori infection can alleviate the acute and chronic colitis
induced by DSS. (2) CD19þIL-10þBreg cells and CD4þCD25þFoxp3þTreg
cells expanded significantly in H.pylori/DSS co-treated acute colitis mice. (3)
CD19þIL-10þBreg cells expanded while CD4þCD25þFoxp3þTreg cells reduced
significantly inH.pylori/DSS co-treated chronic colitis mice. The potential pro-
tective effect of H.pylori infection on acute and chronic colitis induced by DSS
may through the expansion and function of CD19þIL-10þBreg cells.
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Introduction: The microbial dysbiosis plays a pivotal role in the pathogenesis of
inflammatory bowel disease (IBD), however, the role of fungal microbiota in
IBD was unclear. The aim of our study was to clarify the gut fungal composition
in IBD patients with different treatment strategies.
Aims & Methods: 73 IBD patients were divided into three groups, Untreatment
(n¼ 21), Antiinflammation (n¼ 43) and Immunosuppression (n¼ 9).
Antiinflammation was defined as treatment with 5-aminosalicylic acid (5-
ASA)/salazosulfapyridine (SASP) and Immunosuppression as treatment with
Glucocorticoid (GC), azathioprine (AZA), biologics and thalidomine.
Noninflamed and inflamed mucosae were acquired for 16S and ITS sequencing
to investigate the bacterial and fungal composition. Inflamed mucosa was used
for RNA extraction and real-time PCR to detect the expression of IBD-asso-
ciated biomarkers, such as TNF-alpha, IL-17A, MCP-1, etc. Analysis of
Spearman’s correlation was performed to estimate the fungi-bacteria and micro-
biota-biomarkers correlation.
Results: Compared with noninflamed mucosa, lower diversity and evenness were
observed in inflamed mucosa in all IBD patients, but no significance in nonin-
flamed (or inflamed) mucosa of different treatment strategies. Beta diversity
showed a treatment-dependent clustering in inflamed mucosa. Fungal microbiota
was constituted by fungi from Ascomycota, Basidomycota and Zygomycota
phyla. There was a higher proportion of Zygomycota in inflamed mucosa than
noninflamed mucosa in untreated IBD patients, and Antiinflammation and
Immunosuppression didn’t significantly alter its abundance. Mortierella from
Zygomycota was the richest fungi in both inflamed and noninflamed mucosae
of all patients. To analyze the effects of treatment strategies on fungal microbiota
in IBD patients, we found Immunosuppression decreased abundance of
Ascomycota in both noninflamed and inflamed mucosae, while antiinflammation
increased Ascomycota in noninflamed mucosa but decreased it in inflamed
mucosa. Both Antiinflammation and Immunosuppression increased
Zygomycota in inflamed mucosa, but not in noninflamed mucosa. Fungi-bac-
teria correalation analysis showed a weak correlation in noninflamed mucosa of
untreated IBD patients, and Antiinflammation and Immunosuppression didn’t
significantly alter fungi-bacteria correlation patterns in noninflamed mucosa.
However, after Immunosuppression, fungi including Candida, Chaetomium,
Cladosporium and Cryptococcus were positively correlated to bacteria such as
Coprococcus and Lachnospira. Futhermore, Mortierella was negatively correlated
with Blautia and Lachnospira in inflamed mucosa of immunosuppression. In
analysis of bacteria-biomarkers correlation, we found bacteria such as
Clostridiales, Lachnospiraceae, Parabacteroides, Blautia, Coprococcus,
Roseburia, Faecalibacterium, Ruminococcus and Megamonas were significantly
correlated to several biomarkers (such as IFN-gamma, IL-10, IL-17A, IL-22,
TNF-alpha, etc). Notably, there were different correlation patterns in different
treatment strategies, especially, IL-17A was extensively correlated to bacteria
such as Enterococcus, Corprococcus, Faecalibacterium and Klebsiella in
inflammed mucosa of Immunosuppression, but only correlated to
Faecalibacterium in inflammed mucosa of Antiinflammation. Additionally, we
found a weak fungi-biomarkers correlation in IBD patients, but fungi such as
Asterotremella and Verticillium were correlated to biomarkers such as IL-17A,
IL-22, IL-8 and MCP-1, and treatment altered microbiota-biomarkers correla-
tion patterns.
Conclusion: Treatment strategies affect fungal composition. To some extent,
immunosuppression may aggravate gut fungal dysbiosis in IBD patients, but
antiinflammation partially ameliorate it. The bacteria-fungi and microbiota-bio-
markers correlation displayed a treatment-specific feature, and treatments
change these correlation patterns. Additionally, IL-17A tended to be the main
mediator for bacteria to induce inflammation in IBD.
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Introduction: MMP9 is involved in the degradation of the extracellular matrix
and its expression is elevated in the inflamed tissue of patients with ulcerative
colitis (UC) [1–3]. Pre-clinical models of colitis demonstrate a therapeutic benefit
of anti-MMP9 in preventing and ameliorating colitis [4]. Andecaliximab (pre-
viously GS-5745) is a high-affinity IgG4 monoclonal antibody against human
Matrix Metallopeptidase 9 (MMP9). In a 36-day Phase 1b study in UC, ande-
caliximab demonstrated clinical efficacy relative to placebo treatment [5]. Here
we describe bacterial microbiota analysis of stool samples collected during the
Phase 1b study of andecaliximab in UC.
Aims & Methods: The objective of this study is to examine changes to the bacter-
ial microbiota pre- and post-andecaliximab treatment and relative to therapeutic
response. Stool was collected prior to treatment (Baseline) and at the end of the
study (Day 36). Clinical response was defined as a Mayo score reduction 3
point and 30% reduction from baseline score; accompanying decrease in
rectal bleeding sub-score of 1 or an absolute rectal bleeding sub-score of 0 or
1. DNA was extracted from fecal samples using a modified CTAB method and
16S rRNA amplicon sequencing was performed on 59 samples (27 paired and 5
unpaired samples). Alpha diversity, beta diversity (calculated in QIIME), and
taxonomic differences were examined between placebo and andecaliximab-trea-
ted patients and between responders and non-responders.
Results: Compared to placebo-treated patients, those who received andecalixi-
mab trended towards decreased alpha diversity (p¼ 0.06) at 36 days post-treat-
ment. These changes in alpha diversity were not dose related. At Day 36, a trend
towards a significant difference in community beta-diversity was observed
between the andecaliximab-treated group relative to placebo (p¼ 0.07).
Andecaliximab treatment was also associated with differences in bacterial tax-
onomy relative to placebo (p¼ 0.07). Specifically, the genera Clostridia and
Akkermansia represented some of the top organisms enriched post andecaliximab
treatment relative to placebo. Andecaliximab treatment exhibited a non-signifi-
cant expansion of Akkermansia from Baseline to Day 36 (p¼ 0.15). Amongst
andecaliximab-treated patients, responders exhibited a trend of increased relative
abundance of Akkermansia muciniphilia (p¼ 0.08).
Conclusion: Akkermansia muciniphilia is the most consistently enriched organism
for subjects treated with andecaliximab who respond to treatment. The presence
of Akkermansia muciniphilia at Baseline and/or an increase in Akkermansia rela-
tive abundance may be associated with response to andecaliximab. Analysis of a
larger study population would be required to verify these observations. Recent
Phase 2 studies of andecaliximab in UC and Crohn’s disease failed to demon-
strate clinical efficacy. Therefore these microbiome results are unlikely to be
pursued in relation to andecaliximab treatment effects, but may be beneficial
as a reference for future trials in inflammatory bowel disease.
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Introduction: Crohn’s Disease (CD) and Ulcerative Colitis (UC) are
Inflammatory Bowel Diseases (IBD) with a complex etiology, including an
immune response against microbial and autologous antigens and an imbalance
between pro-inflammatory and anti-inflammatory mediators. Different
approaches have been used to study the pattern of cytokines in IBD and few
data are available on cytokines production in different intestinal compartments.
Laser Capture Microdissection (LCM) is a powerful tool for the isolation of
specific tissue compartments (1).
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Aims & Methods: This work was designed to investigate the pattern of cytokines
that regulate the mucosal immune response occuring in different intestinal com-
partments of IBD patients, using LCM technology (1). Frozen sections of colonic
biopsies were obtained from 5 patients with active CD, 5 patients with active UC
and 5 controls. None of the patients with CD or UC had been ever undergone
medical therapy. Epithelium (EP) and lamina propria (LP) were isolated by
LCM, RNAs from EP and LP samples were extracted and, after a reverse tran-
scription, RNA levels of TNF-, IFN-, IL-17, IL-10 and TGF-b were deter-
mined by quantitative PCR, using glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as reference gene.
Results:We observed a significant increase in gene expression level of IL-17 in the
lamina propria of UC patients respect to CD and controls (p5 0.05). TNF-,
IFN-, IL-10 and TGF-b levels were significantly higher in the LP of CD as
compared to UC and controls (p5 0.05). All the cytokines investigated were not
significantly up-regulated in the surface EP of both CD and UC patients, when
compared to controls
Conclusion: Our data show that the LP compartment play a key role in the
mucosal immune response in IBD patients. In particular, CD seems to be pro-
minently an innate immune response-mediated disease, which is characterized by
an increased production of IFN- and TNF-a. On the opposite, UC seems to be
prominently a CD4 lymphocyte-mediated disease, which is characterized by an
increased production of IL-17. Concomitantly with the pro-inflammatory
response, high amounts of the anti-inflammatory cytokines IL-10 and TGF-b
are also produced in CD compared to UC patients, suggesting that in UC
patients the immune-regulatory mechanisms could be impaired. This work
underlines the importance of LCM as a valuable tool to determine potential
inflammatory components involved in IBD pathogenesis.
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Introduction: The gut microbiota play important roles in the development of the
ulcerative colitis (UC). Enough evidence has proven the role of intestinal bacter-
ial microbiota in UC pathogenesis. However, the role of intestinal fungal micro-
biota in UC pathogenesis has not been fully demonstrated.
Aims & Methods: Fungal microbiota from the descending colon mucosal samples
of 14 active UC patients and 15 healthy subjects (HS) were analyzed by high-
throughput sequencing method. The expressions of pro-inflammatory
cytokines(IL-Ib, TNF-, INF-, IL-6, IL-17A, and IF-23) in intestinal mucosal
tissues were examined. The Baron and Mayo scores of UC patients were eval-
uated, and the correlations between intestinal fungal composition and intestinal
inflammatory status were analyzed.
Results: The number of fungi decreased significantly in inflamed mucosal tissue
compared to HS counterpart while the shannon diversity did not show significant
differences. Fifteen major genera were examined, among which
Wickerhamomyces, unidentified genus of Saccharomycetales, Aspergillus,
Sterigmatomyces, and Candida showed increasing trends, whereas Exophiala,
Alternaria, Emericella, Epicoccum, Acremonium, Trametes, and Penicillium
showed decreasing trends in UC patients compared to HS. The pro-inflamma-
tory cytokines (IL-Ib, TNF-, INF-, IL-6, IL-17A, and IF-23) were up-regu-
lated in the UC patients. The genera Wickerhamomyces, Sterigmatomyces, and
Penicilium were positively correlated with the expression of several pro-inflam-
matory cytokines in the colonic mucosa, whereas Nigrospora was negatively
correlated. Nigrospora and Sterigmatomyces were positively correlated with the
Baron and/or Mayo score.
Conclusion: The fungal microbiota in the colonic mucosa of UC patients was
different from that of the HS. Alterations in gut fungal composition might be
associated with mucosal inflammation and pathogenesis of UC. Further studies
are needed to define the fungal composition in detail and identify the role of
different fungi in the gut, and determine the mechanism of the host-fungal inter-
action underlying the development of UC.
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Introduction: STAT6 plays a crucial role in M2a macrophage polarization in vitro
and these cells mediate mucosal healing in an acute model of TNBS-colitis
through the expression of Wnt ligands (Mucosal Immunology, 2016). We have
recently reported that STAT6 deficiency favours fibrosis in a murine model of
TNBS colitis (P031, ECCO 2016).
Aims & Methods: We aim to characterize here the functional relevance of the
macrophage phenotype in fibrosis development. WT or STAT6 (-/-) mice were
given TNBs (0.5, 0.5, 0.75, 0.75, 1, and 1mg, intrarectally) or saline weekly and
they were sacrificed 3, 5 or 7 weeks after the first TNBs administration. The
percentage of CD206, CD16, and CD86 positive cells was analyzed by flow
cytometry in F4/80þ macrophages isolated from the intestinal mucosa. The
mRNA expression of Wnt ligands was evaluated in F4/80þ CD16þ macro-
phages isolated from the mucosa, 7 weeks after the first TNBs administration
and results are expressed as fold induction vs vehicle-treated mice. The mRNA
expression of CD16 and fibrosis markers were evaluated in the colonic mucosa.
Data are expressed as MeanSEM with n 8 in all groups. In all cases results
were expressed as fold induction vs vehicle (*p5 0.05 vs TNBS WT) and corre-
lations between data were analyzed using Pearson’s correlation coefficient
(*p5 0.05).
Results: TNBs increased the percentage of CD206 positive macrophages in the
mucosa of TNBS-WT animals while it failed to do that in TNBS-STAT6 (-/-)
mice. The percentage of CD16 positive macrophages increased in a time-depen-
dent manner only in the mucosa of STAT6 (-/-)-TNBS-treated mice. The percen-
tage of CD86þ cells was similar between TNBS-WT and TNBS-STAT6 (-/-)
mice. In CD16þ macrophages isolated from TNBS-STAT6 (-/-) mice the
mRNA expression of canonical and non-canonical Wnt ligands was significantly
increased compared with cells isolated from TNBS-WT mice (Table). A positive
and significant correlation between CD16 and Vimentin (p¼ 0.0088*, r¼ 0.51),
-SMA (p¼ 0.0044*, r¼ 0.55) and MMP2 (p¼ 0.0002*, r¼ 0.67) was detected in
TNBS-STAT6 (-/-) mice but not in WT animals.
Table
2B 5A 6 7B 10A
WT 1, 6 0, 2 2, 1 0, 5 1, 2 0, 1 2, 7 0, 6 3, 3 0, 8
STAT6 (/) 1, 9 0, 4 6, 4 0, 6* 2, 7 0, 4* 15, 3 2, 2* 2, 9 1, 0
Conclusion: The expression of Wnt ligands from CD16 positive cells, which are
accumulated in the mucosa, may be involved in murine intestinal fibrosis
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Introduction: Although the etiology of ulcerative colitis (UC) has yet to be char-
acterized, it is increasingly accepted that the cause of UC might well be related to
commensal enteric bacteria in a genetically susceptible patient. Anti-inflamma-
tory drugs and immune system suppressors are usually prescribed for UC treat-
ment, and we previously demonstrated that triple antibiotic combination therapy
with oral amoxicillin (1500mg/day), tetracycline (1500mg/day) or fosfomycin
(3000mg/day), and metronidazole (750mg/day) (ATM/AFM), for two weeks,
induces remission in more than 27% of patients with active UC including
those with steroid-refractory or dependent disease, suggesting ATM/AFM to
possibly be effective for achieving UC remission.
Aims & Methods: Thirty-two patients with UC given ATM/AFM therapy for
two weeks on average were enrolled in this study. The clinical conditions of
these UC patients were evaluated by Mayo score. Fecal samples were
obtained prior to, after therapy and at three months after treatment comple-
tion. Gut microbiota were compared employing metagenomic analysis of fecal
samples.
Results: Of the 32 patients, 17 and eight, respectively, experienced complete and
partial remission over three months in response to ATM/AFM therapy, whereas
ATM/AFM showed no efficacy in seven patients. The metagenomic analysis
revealed abundant human DNA to correlate positively with the disease activity
indicated by the Mayo score. Furthermore, dramatic gut microbiota changes
were observed at an early stage, i.e. just two weeks after starting ATM/AFM
therapy. Comparison of the metagenomic data suggested that the dysbiosis
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before treatment in the active stage to possibly be associated with increased
populations of Bacteroides, Parabacteroides, Rickenella, Clostridium,
Flavonifractor, Pelagibacter, Bordetella, Massilia and Piscrickettsia species. In
responders after treatment, populations of Bifidobacterium and Lactobacillus
species were significantly increased. In this study, there was an especially
strong negative correlation between Bacteroides and Bifidobacterium both
before and after treatment.
Conclusion: These results suggested metagenomic analysis results to be associated
with a remarkable change in gut microbiota after antibiotic combination treat-
ment. In responders, remission is associated with increases in Bifidobacterium and
Lactobacillus species and a decrease in Bacteroides.
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Introduction: Classically, enteroendocrine cells (EEC) are renowned for regulat-
ing gastrointestinal motility, secretion, and insulin levels by release of peptide
hormones. Yet, via receptors and transporters, EEC are capable of sensing the
lamina propria and luminal environment, including the microbiota, and also
mediate immune-related signals. In particular, the L-cell-derived incretin hor-
mone glucagon-like peptide 1 (GLP-1) is increasingly recognized to exert direct
effects on immune cells and to orchestrate a metabolic-inflammatory response. In
inflammatory bowel disease (IBD), a role for EEC in disease pathogenesis is
indicated by a risk-associated SNP and autoantibodies affecting EEC function
as well as general disease symptoms like insulin resistance and altered intestinal
motility. However, the total number of studies investigating EEC number and
function in IBD and mouse models of intestinal inflammation is limited and
results are conflicting.
Aims & Methods: To characterize alterations in GLP-1-expressing EEC numbers
under intestinal inflammatory conditions, immunostainings for GLP-1 and
ChgA as well as mRNA expression analysis was performed in intestinal tissue
samples. Mouse models of intestinal inflammation used include genetic models,
Il-10/ mice (colitis), an adoptive transfer model, Rag2/ mice reconstituted
with CD4þ T cells (colitis), chemically (DSS)-induced colitis and an infection
model (Citrobacter rodentium).
Results: Numbers of GLP-1þ and ChgAþ cells were consistently reduced in all
mouse models of intestinal inflammation. These changes were confined to the site
of active inflammation. Neither absence of mature B and T cells in Rag2/ mice
alone was associated with reduced numbers of EEC, nor adoptive transfer of
CD4þ T cells per se, since transfer of non-colitogenic CD4þ CD25þ T cells did
not lead to changes in ChgAþ cell numbers in the colon. The reduction of GLP-
1þ and ChgAþ cells observed by immunohistochemistry was reflected by dimin-
ished levels of Gcg and Chga mRNA expression, whereby mRNA levels of the L-
cell derived-hormone Pyy remained unaltered.
Conclusion: To our knowledge, this work provides the first comprehensive study
of GLP-1þ and ChgAþ cell numbers in different mouse models of intestinal
inflammation. A reduction of GLP-1-expressing EEC seems to be a general
feature of small as well as large intestinal inflammation. Further research will
clarify if these alterations represent a consequence or causatively contribute to
intestinal inflammation and elucidate the functional consequences on immune
responses.
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Introduction: Neutrophil extracellular traps (NETs) are fibrous structures
released by activated neutrophils upon stimulation. NETs consist of chromatin
and cytoplasmic proteins, which are released extracellularly during a process
called NETosis. Tissue factor (TF) is the main in-vivo initiator of coagulation
and is expressed on NETs in a plethora of neutrophil-mediated thromboinflam-
matory conditions [1–3]. Ulcerative colitis (UC) is characterized by infiltration of
neutrophils into the affected mucosa and increased risk of thromboembolic
events; however the mechanism behind the thrombophilic state of UC has not
been clearly elucidated yet [4, 5].
Aims & Methods: We aimed to investigate for the first time the role of neutro-
phils/NETs through TF expression in the pathophysiology of UC. Neutrophils,
sera and colon biopsies were obtained from 10 naı̈ve patients with active UC (6
male and 4 female, mean age 34.6 19.1 years, mean Mayo score 8.5 1.4) and
from 10 naı̈ve patients suffered from active Crohn disease (CD) (7 male, 3 female,
mean age 34.2 18.5, CDAI4 220). Additionally, 10 sex- and age-matched
healthy subjects, were served as control subjects (5 male, 5 female, mean age
38.5 12.5). Ex-vivo findings regarding peripheral blood neutrophils and colonic
tissue specimens were verified using appropriate in-vitro stimulations of control
neutrophils with corresponding sera and intestinal tissue-conditioned media,
respectively. Identification and quantification of NETs were performed with
immunofluorescence confocal microscopy (ICM), flow cytometry and MPO/
DNA complex ELISA. The expression of TF on neutrophils/NETs was deter-
mined using ICM, qRT-PCR and western blot analysis. The bioactivity of TF on
NETs was assessed by measuring thrombin-antithrombin complex levels with
ELISA.
Results: Neutrophils from patients with active UC are characterized by increased
NET formation in both the peripheral blood and affected colonic mucosa, com-
pared to CD. Furthermore, NETs in UC are decorated with functionally active
TF and the amount of TF-bearing NETs was reduced from the inflamed to
normal colon. In-vitro stimulations of controls neutrophils with sera or intestinal
tissue-conditioned media corroborated the findings obtained ex-vivo.
Conclusion: NETs expressing bioactive TF may be involved in the induction of
intestinal inflammation and systemic thrombosis in UC probably constituting a
novel candidate diagnostic and/or therapeutic target.
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Introduction: The intestinal epithelium is a multicellular interface that is comple-
tely renewed every 3–5 days. Pluripotent stem cells reside at the crypt bottom
giving rise to transient amplifying cells and subsequently differentiated intestinal
epithelial cells (IEC) of all subtypes. Phases of cellular and functional transi-
tions are characterized by distinct metabolic identities, reflected by changes in
mitochondrial activity. Alterations in mitochondrial function and mitochon-
drial unfolded protein response (MT-UPR) activation are associated with
various chronic pathologies including inflammatory bowel diseases (IBD)
and cancer. We have previously shown that MT-UPR and mitochondrial
function itself is involved in the regulation of cell cycle progression and
intestinal stemness. Here, we present evidence that impaired mitochondrial
proteostasis is sufficient to drive differentiation of Lgr5þ stem cells (ISC)
into Paneth cells.
Aims & Methods: To depict the impact of imbalances in mitochondrial proteos-
tasis on ISC, we used mice with a tamoxifen-inducible ISC or IEC-specific con-
ditional knockout allele for the mitochondrial chaperone Hsp60 and the
mitochondrial protease ClpP. Molecular consequences of the gene deletions in
the different models were further characterized ex vivo using intestinal organoid
culture. In situ hybridization, IHC and combinations of both as well as IF were
performed to illustrate alterations of IEC subtypes. Readouts were complemen-
ted by mRNA expression analysis and biochemical approaches.
Results: ClpP-knockout as well as chemical inhibition of the respiratory chain in
intestinal organoids led to diminished Lgr5 expression confirming our results
from IEC and ISC specific Hsp60-deletion. In vivo, the ISC-specific loss of
HSP60 resulted in a transient drop in Lgr5þ cells with Lgr5 expression being
reduced from day 2 after end of tamoxifen treatment and signals reappearing
from day 4. Cells positive for the stem cell markers Olfm4 and Hopx expanded at
day 2, indicating reserve stem cell populations compensating for the Lgr5þ ISC
loss. Minimal numbers of Lgr5þ stem cells at day 2 were further paralleled by
increased numbers of Lgr5þ, Lyzþ Paneth cells and no signs of enhanced cell
death, indicating differentiation of ISC into Paneth cells. Lgr5þ, Lyzþ Paneth
cells displayed a premature phenotype with diffuse Lyz staining in the cytoplasm.
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Concomitantly, these cells were positive for the WNT ligand WNT10A and
autophagy/mitophagy- associated LC3, suggesting autoregulatory mechanisms
for the maintenance of the stem cell niche and mitochondria-associated func-
tional alterations, respectively.
Conclusion: Our results indicate that mitochondrial function not only reflects
IEC phenotypic changes but seems to be the driving force in differentiation
processes. Mitochondrial function might therefore represent a key player at the
edge of intestinal tissue homeostasis and repair/healing processes in the context
of diseases.
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Introduction: Previous studies have shown differences in disease phenotype of
ulcerative colitis (UC) in South Asian (SA) migrants compared to Caucasians
with pan-colonic phenotype predominant.1 The gut microbiota differs in
Caucasian and SA patients with UC2 however, there is limited evidence on
how this translates to the metabolome.
Aims & Methods: We aimed to examine the metabolic profile in a newly diag-
nosed cohort of UC patients recruited from St. Marks Hospital, London, UK.
Patients were stratified by ethnicity (SA, Caucasian, Other), treatment (None, 5-
ASA, Azathioprine and Steroids) and disease duration. Healthy controls (HC)
were recruited locally among the staff at St. Marks Hospital. Biofluids (urine,
faeces and serum) were collected at diagnosis (time point 1; months 0–3) and 2
further time points over one year (time point 2: months 4–8, time point 3: months
9–12) Metabonomics approach was applied using two different UPLC-MS pro-
filing methods; for small metabolites (hydrophilic liquid chromatography,
HILIC) and for bile acids (BA) platforms. Univariate (UV) and multivariate
(MV) data analysis was implemented to build models using principle component
analysis (PCA) and orthogonal partial least squares -discriminant analysis
(OPLS-DA) to find metabolites that were expressed in significantly different
amounts between the two populations, time points (1 vs 3) and treatment groups.
Results: Fifty patients with UC of SA and Caucasian backgrounds were
recruited. A total of 309 samples were collected. Sample collection was completed
for all time points for 18 SA (11 UC and 7 HC) and 21 Caucasians (9 UC and 12
HC). There was no significant difference between SA and Caucasian at time
points 1, 2 and 3 and treatment groups Significant differences were observed
between HC vs. disease, SA HC vs. Caucasian HC and SA UC vs Caucasian
UC. For the UC cohort, robust models were obtained by OPLS-DA between SAs
and Caucasians; Faecal HILIC (R2Y 0.869, Q2Y 0.451, p5 0.0003) and urine
HILIC (R2Y 0.783, Q2Y 0.526, p5 0.0001) and serum BA (R2Y 0.702, Q2Y
0.517, p5 0.0001) and faecal BA (R2Y 0.832, Q2Y 0.395, p5 0.0001).
Combined analysis revealed 1611 significant features (faecal HILIC 60, urine
HILIC 189, serum BA 489 and faecal BA 873). The assigned features are
shown in Table 1. Faecal HILIC showed significantly higher essential amino
acids (Adenine, L-phenylalanine, L-tryptophan) levels on UV and higher 1-leu-
cylproline and creatinine levels on MV analysis for SAs. Urine HILIC showed
lower creatine, L-phenylalanine and hippuric acid levels. Serum primary (Cholic
and chenodeoxycholic acid) and secondary bile acids (BA modified by the gut)
were significantly reduced in SAs. Table 1: Significant metabolites in OPLS-DA
model between South Asian (SA) and Caucasians with UC. *compound is
increased or decreased in SA compared with Caucasians respectively
Conclusion: This study highlights the promise of UPLC-MS profiling to differ-
entiate between SA and Caucasian groups. There are several possible reasons but
two important factors are differing microbial metabolism and diet between the
two groups. We are conducting further studies incorporating dietary data and
16S microbial analysis in this cohort. In combination with matching disease
extent (left-sided vs colonic disease) may help to identify possible explanations
for the different disease phenotype in this group.
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P0311 BASELINE CLINICAL AND ENDOSCOPIC FEATURES OF
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Introduction: Patients with active inflammatory bowel disease have elevated mye-
loid lineage leucocytes1 including the CD14þCD16þDRþþ phenotype known
as proinflammatory monocytes, and a major source of tumour necrosis factor-.2
Accordingly selective depletion of myeloid leucocytes by granulocyte/monocyte
apheresis (GMA) is expected to promote remission or enhance drug efficacy.
However, studies in ulcerative colitis (UC) patients have reported contrasting
efficacy outcomes, ranging from an 85%3 to statistically insignificant level.4
Patients’ baseline demographic features may guide to selecting responder
patients.
Abstract No:P0310
HILIC
Mass/RT
(mins) Biofluid
Univariate (UV)
or Multivariate (MV) Change* p-value Compound Pathway
136.061/2.13 Faecal UV Increased 0.0049 Adenine Protein digestion and absorption small bowel
166.084/3.65 Faecal UV Increased 0.0218 L-phenylalanine Release of gut hormones from endocrine system
205.1/3.61 Faecal UV Increased 0.0058 L-tryptophan Protein digestion and absorption small bowel
229.153/5.78 Faecal MV Increased 0.0075 1-Leucylproline Related to leucine pathway
114.065/2.53 Faecal MV Increased 0.0049 Creatinine Arginine and proline metabolism
132.099/4.89 Urine UV Decreased 0.0215 Creatine Facilitate recycling of ATP
166.119/3.62 Urine UV Decreased 0.0066 L-phenylalanine Release of gut hormones from endocrine system
180.063/0.99 Urine UV Decreased 0.0021 Hippuric acid Product of microbial metabolism of dietary aromatic compounds
268.103/1.72 Urine UV Increased 0.0011 Adenosine Purine biosynthesis
148.032/4.57 Urine MV Increased 0.0014 Glutamic acid Tyrosine metabolism
247.142/3.88 Urine MV Unassigned
249.149/3.87 Urine MV Unassigned
BILE ACIDS
375.28/10.79 Faecal UV Decreased 0.0046 Lithocholic acid Secondary bile acid from bacterial metabolism of chenodeoxycholic acid
375.28/10.81 Serum UV Decreased 0.0041 Lithocholic acid
391.28/10.35 Serum UV Decreased 0.0072 Deoxycholic acid Secondary bile acid from metabolism of cholic acid
407.28/8.33 Serum UV Decreased 0.0045 Cholic acid Primary bile acid
432.314/9.91 Serum UV Decreased 0.0230 Glycolithocholic acid Sulphur ester of lithocholic acid
373.272/10.17 Serum MV Decreased 0.0007 5-Cholenic Acid-3B-ol
391.283/10.34 Serum MV Decreased 0.0018 Deoxycholic acid
A266 United European Gastroenterology Journal 5(5S)
Aims & Methods: In a retrospective and single-centre setting we aimed to under-
stand if patients’ baseline clinical and endoscopic features were relevant guide for
identifying likely responders and non-responders to adsorptive GMA. The sub-
jects were 145 consecutive UC patients who had undergone GMA with the
Adacolumn as remission induction therapy between 2012 and 2016. Seventy-
three patients were steroid naive, 70 were steroid dependent, and 2 patients
were steroid refractory. Patients had received up to an 11 GMA sessions over
10 weeks. At entry and week 12, patients were clinically and endoscopically
evaluated, allowing each patient to serve as her or his own control. Clinical
activity index (CAI) 4 was defined as remission. Biopsies from endoscopically
detectable inflamed large intestinal mucosa were processed to see the impact of
GMA on leucocytes within the mucosal tissue.
Results: At entry, the average CAI was 12.8, range 10–17. Ninety-three patients
(64.1%) had responded to GMA, 52 of 73 steroid naı̈ve (71.2%), 40 of 70 steroid
dependent (57.1%), and 1 of the 2 steroid refractory cases. On average remission
was sustained for 8.6 months in steroid naı̈ve patients and for 10.4 months in
steroid dependent subgroup. Observations on mucosal tissue biopsies showed
that infiltrating leucocytes were mostly neutrophils and monocytes. There was
a marked reduction of infiltrating leucocytes in responder patients. Patients with
extensive deep UC lesions together with loss of the mucosal tissue at the lesions
were non-responders. Patients with the first UC episode were identified as the
best responders (100%), followed by steroid naive patients. Additionally, a short
duration of active UC prior to GMA marked a patient as a likely responder.
Further, all patients who achieved remission were steroid free at week 12.
Conclusion: First-episode and steroid-naı̈ve cases who responded well to GMA
attained a favourable long-term clinical course. Additionally, GMA was more
effective if applied immediately after a relapse than after a lag time. In general,
GMA is favoured by patients for its safety profile and for being a non-drug
remission induction therapy. Patients with extensive deep ulcers, with long dura-
tion of UC refractory to multiple pharmacologicals are unlikely to benefit from
GMA. In therapeutic settings, knowing baseline clinical and endoscopic features,
which may identify GMA responder patients should guide to stop futile use of
medical resources.
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Introduction: Much research has demonstrated that tolerogenic dendritic cell
(DC) with the capacity to induce regulatory T cells (Treg) play an important
role in maintaining immune tolerance and has been proposed for treatment of
inflammatory bowel disease (IBD). In this study, we report on the use of glial-
derived neurotrophic factor (GDNF) produced by Enteric glial cells (EGCs) as a
new approach to induce tolerogenic DCs with capacity to generate Treg, to
restore immune tolerance in vivo, and to ameliorated experimental colitis.
Aims & Methods: DCs were generated from rat bone marrow (BMDC) in the
absence (DCControl) or presence of GDNF (DCGDNF) and additionally stimu-
lated with LPS to induce maturation (mDC). The expression of major histocom-
patibility complex II (MHC-II), CD40, CD80, and CD86 was determined by flow
cytometry. Levels of IFN-, interleukin-4 (IL-4), and IL-10 in the culture super-
natants were determined by ELISA. The location of GDNF receptor-1 (GFR-
1) in DCs was detected by immuno-fluorescence staining. The expression of
GFR-1 and ERK1/ERK2 in DCs was tested by Western Blot. SD rats were
fed with 5% Dextran Sulphate Sodium (DSS) to induce experimental colitis, the
therapeutic action of DCGDNF were examined. Diverse clinical signs of the dis-
ease including weight loss, diarrhea, colitis, histopathology were evaluated, and
the mechanisms involved in the potential therapeutic effect of DCGDNF, such as
inflammatory cytokines and chemokines (IL-4, IFN-, TNF-, IL-1b, IL-17), the
generation of IL-10 –secreting Treg (Treg1), and the level of Treg1/Th2 KTreg1/
Th17 were investigated.
Results: GFR-1 was expressed in BMDC, and the expression of ERK1/ERK2
were significantly up-regulated after treatment with GDNF. DCGDNF did not up-
regulate MHC-II, CD40, CD80, CD86, and produced very low levels of proin-
flammatory cytokines (IFN-, IL-4) but secreted significant levels of the anti-
inflammatory cytokine IL-10 after LPS stimulation, as compared with DCControl.
CD4 T cells primed with DCGDNF resulted in weak proliferation and exhibited a
Tr1-like phenotype, which characterized by IL-10, whereas DCControl induced a
strong proliferation, exhibited a phenotype characterized by IFN-, IL-4.
DCGDNF injection significantly ameliorated body weight loss, diarrhea, and colo-
nic histopathologic injury in rat, and DCGDNF injection strikingly reduced the
production of inflammatory factors such as IL-4, IFN-, TNF-, IL-1b, and IL-
17, generated Treg1 with suppressive capacity on autoreactive T cells, and
demonstrated a higher level of Treg1/Th2 KTreg1/Th17.
Conclusion: GDNF could induce tolerogenic DCs through ERK1/ERK2 signal
pathway, and DCGDNF could alleviate the severity of DSS induced colitis in rats.
The mechanism may be related to down-regulation of inflammatory and immune
response, generating Treg1 and restoring immune tolerance.
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Introduction: Alterations in short chain fatty acid (SCFA) metabolism have been
reported in inflammatory bowel disease (IBD). Among SCFA, butyrate has been
described as a potent communicator to the immune system eliciting an anti-
inflammatory response and other positive effects to human health1. A reduction
of faecal butyrate levels has been reported in IBD but results have been conflict-
ing or discrepant because of small study numbers and failure to distinguish
disease type, activity or other variables such as diet. Microbiota is receiving
increasing attention as a key environmental factor influencing IBD2, and
butyryl-CoA:acetate CoA-transferase (BCoAT) is considered the main enzyme
involved in butyrate synthesis by gut microbiota3.
Aims & Methods: We performed a comparative assessment of the capacity of the
microbiota for butyrate synthesis by quantifying BCoAT gene content in stool
from patients with Crohn’s disease (CD; n¼ 71), ulcerative colitis (UC; n¼ 58)
and controls (n¼ 75), and determined whether it was related to disease activity,
inflammation, microbial diversity and composition and/or dietary habits.
BCoAT gene content was quantified by qPCR4. Disease activity was assessed
clinically and faecal calprotectin concentration measured as biomarker of inflam-
mation in the gut. Microbial composition was determined by sequencing 16S
rRNA gene. Dietary data were collected using an established food frequency
questionnaire.
Results: Reduced butyrate-synthetic capacity was found in patients with active
and inactive CD (p5 0.001 and p5 0.01, respectively), but only in active UC
(p5 0.05). In patients with CD, low BCoAT gene content (below 9.5 log10
copies BCoAT/g) was associated with active disease, increased inflammation,
lower microbial diversity, greater microbiota compositional change and
decreased butyrogenic taxa, while no major changes were observed between
patients with UC grouped according to BCoAT gene levels. Reduced BCoAT
gene content in patients with CD was, in part, linked with lower intake of certain
foods containing fibre (vegetables, fruits, high-fibre cereals, brown/wholemeal
bread and nuts).
Conclusion: Reduced butyrate-synthetic capacity by the microbiota is more evi-
dent in CD than UC and may relate to reduced fibre intake. The results suggest
that simple replacement of butyrate per se may be therapeutically inadequate,
whereas manipulation of microbial synthesis perhaps by dietary means may be
more appropriate and profitable for patients with CD.
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Introduction: Antibiotics sometimes have an influence on colitis negatively.
Although it is well known that dysbiosis is one of the major disturbances to
the gut environment, the molecular mechanisms underling the pathogenesis
remains unclear.
Aims & Methods: We aimed to clarify how antibiotics affect the gut microbiota
and the pathology of colitis. Mice were gavaged with ampicillin (ABPC), vanco-
mycin (VCM), metronidazole, neomycin, or a combination of ABPC and VCM
(A-V) for three consecutive days. Colitis was assessed by fecal occult blood test
(FOBT) and mRNA level of cytokines. Metabolites and short chain fatty acid
(SCFA) in the feces were measured by a chromatography-tandem mass spectro-
metry. Fecal microbiota was characterized by 16rRNA sequencing. In the gluta-
mine (Gln) treatment exam, the mice were given 30mg/mL of Gln in drinking
water ad lib for six days, and additionally gavaged A-V for the last three days.
In vitro experiments, mouse colon carcinoma cell line CMT93 and macrophage
cell line RAW267.4 were stimulated by butyric acid.
Results: ABPC and VCM, but not other antibiotics, resulted in FOBT-positive in
some cases. All A-V treated mice were FOBT-positve and IL-6, IL-12p40 and
MIP-1a were significantly increased. The caecums were enlarged and dun-colored
in the A-V mice. Moreover, Gln metabolites and SCFA including butyric acid
were decreased and family S24-7 and order Clostridiales were less abundant in
the feces of A-V mice. Interestingly, Gln treatment improved the antibiotics-
induced colitis. Butyric acid reduced mRNA expression of pro-inflammatory
cytokines in RAW267.4 and induced expression of antimicrobial peptides (secre-
tory leukocyte protease inhibitor and lactoferrin) in CMT93.
Conclusion: A-V treatment induced mild colitis with reduced abundance of family
S24-7 and order Clostridiales, which might disturb Gln and SCFA metabolisms.
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Introduction: Inflammatory bowel disease (IBD) is a group of gastrointestinal
tract diseases consisting mainly of Crohn’s Disease (CD) and Ulcerative Colitis
(UC). Various etiological factors contribute to the pathogenesis of IBD, includ-
ing modulation of microbiota, epithelial barrier disruption, genetics and envir-
onmental factors. Currently, the treatment of IBD comprises several groups of
drugs the choice of which is made based on disease activity and extent. The
treatment options include: analogs of 5-aminosalicylic acids, glucocorticoids
and other immunosuppressive drugs such as azathioprine. Biological therapy
with anti-tumor necrosis factor alpha (TNF) are considered when conventional
therapy fails. In portion of patients surgical approach is necessary. Therefore
novel pharmacological targets are sought in order to improve the remission rate
and avoid the disabling procedures. G protein-coupled receptor 18 (GPR18)
belongs to the endogenous cannabinoid system which already earned its place
in the pathogenesis of IBD. GPR18 was found to be implicated in protection
against bacterial infection and organ injury. Reports indicate that it may also be
connected to the obesity/diabetes-related inflammation. As we lack data regard-
ing its association with intestinal inflammation we attempted to shed some light
on this phenomenon.
Aims & Methods: The aim of the study was to assess the anti-inflammatory and
anti-nociceptive actions of GPR18 in the intestinal inflammation. The anti-
inflammatory activity of GPR18 agonist PSB-KK-1415 and antagonist PSB-
CB5 (1–5mg/kg, i.c., once daily) was characterized in two mouse models of
colitis, induced by 2, 4, 6-trinitrobenzenesulfonic acid (TNBS) and dextran sul-
fate sodium (DSS). The extent of inflammation was evaluated based on the
macroscopic score, microscopic score, quantification of myeloperoxidase
(MPO) activity and alpha (TNF) in colonic tissue. The expression of GPR18
gene in colonic samples from patients with IBD was quantified using real-time
RT PCR and Western blot analysis. GPR 18 was localized in human colonic
samples using immunohistochemistry methods.
Results: The results of our study with lower doses of GPR18 ligands in the semi-
chronic TNBS model of colitis showed a non-significant decrease in macroscopic
score, ulcer score and a significant decrease in MPO activity (p5 0.05) in mice
injected with PSB-KK-1415 compared with TNBS-treated mice. PSB-CB5
increased inflammation indices. Study in the mouse model of TNBS-induced
colitis with higher dose of PSB-KK-1415 presented a pronounced reduction in
the indices after treatment with the agonist. We also showed that GPR18 is
expressed in the colon of patients with IBD.
Conclusion: We demonstrated potential ability of the GPR18 agonist PSB-KK-
1415 to alleviate inflammation in the mouse models of colitis and showed that
GPR18 is expressed in the human colon. We conclude that GPR18 is another
receptor of the endogenous cannabinoid system family which may be implicated
in the pathogenesis of IBD and intestinal inflammation overall.
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Introduction: Our previous study showed that activation of D3 dopamine recep-
tors (D3R) had the beneficial effect in experimental colitis treatment while the
mechanism of this effect is unclear [1]. The disruption of surface colon mucosa
layer with subsequent activation of local immune response by the bacterial infil-
tration into the inner layer of the mucosa are the key pathogenic mechanisms of
ulcerative colitis progression and perpetuation. We found the localization of
D3R on the Goblet cells in colonic mucosa [2].
Aims & Methods: In present study we tested the hypothesis that activation of
D3R improves colonic mucus secretion during experimental colitis. Study was
done on male Wistar rats (180–230). Experimental colitis was induced by 6%
iodoacetamide (IA) (0, 1ml, enema). Selective D3R agonist 7-OH-DPAT
(0.02mg/100 g, s.c.) was injected 0, 5 h prior to IA enema. Rats were euthanized
0, 5 and 2 h after IA enema. During the autopsy 7 cm colon from the anus has
been removed. Surface mucus layer was separated from epithelial cells with N-
acetyl-L-cysteine and glycoproteins were measured by periodic acid/Schiff (PAS)
staining or by the reaction with Folin reagent. The content of hexose, fucose and
hexosamine were determined by standard biochemical assays. Morphometric
analysis was performed to evaluate the histological changes of colonic epithelial
and Goblet cells. Oxidative metabolism and arginase activity (analyzed by col-
orimetric method) in peritoneal macrophages were investigated.
Results: Pre-treatment with 7-OH-DPAT did not affect the glycoprotein levels in
normal mucosa, but significantly increased total levels of glycoprotein (1, 6-fold,
o5 0.05) and hexose (1, 1-fold, o5 0.05) during IA-colitis. Furthermore, 7-OH-
DPAT significantly increased functional reserve of peritoneal macrophages in 0,
5 h (1, 6-fold, p5 0.05) and in 2 h (1, 3-fold, p5 0.05) after IA enema. Pre-
treatment with 7-OH-DPAT decreased the mucosal layer thickness 1, 1-fold
(p5 0.05), crypt depth 1, 1-fold (p5 0.05) and Goblet cell intersection area 1,
2-fold (p5 0.05) after IA enema.
Conclusion: Pre-treatment with D3R-agonist increased levels of mucus secretion
and activated natural immune response by macrophage activation during experi-
mental colitis, which could indicate about the protective role of D3R.
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Introduction: Guidelines advise limited resection for Crohn’s terminal ileitis, as
previous literature did not demonstrate clinical benefit from more extensive
resections. Recently, some cohort studies identified positive resection margin as
an independent risk factor for postoperative Crohn’s recurrence. But it is difficult
to draw clinical conclusions, as non-uniform pathological definitions have been
used. The aim of this study was to assess the incidence of non-radical resections
by a validated pathological score, and correlate pathological findings to clinical
outcome.
Aims & Methods: H&E stained slides from proximal (ileum) and distal (colon)
resection sites were scored according to the modified Geboes score from all
consecutive patients undergoing primary ileocaecal resection between January
2002 and September 2009. Endpoints were clinical recurrence (defined as recur-
rent disease activity demonstrated by endoscopy or MRI) requiring upscaling
medical treatment or surgical recurrence.
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Results: Of 104 ileocaecal resections, 30 (29%) and 15 (14%) had inflammation at
the proximal and distal resection margins, respectively. After a median follow-up
of 8.6 years, clinical recurrence was seen in 57%, and surgical recurrence in 26%.
A significantly increased recurrence rate was seen in patients with active inflam-
mation at the distal resection margin whereas recurrence rates were comparable
for inflammation at the proximal site and radical resections (87%, 61%, and
50% resp., p5 0.001). Active inflammation at the distal resection margin (HR:
3.189 (1.635–6.220); p¼ 0.001) and smoking (HR: 2.502 (1.331–4.703); p¼ 0.004)
were the only independent predictors for clinical recurrence. The incidence of
surgical recurrence was too small to perform statistics.
Conclusion: Inflammation at the distal (colon) resection margin, and not the
proximal ileum, after ileocecal resection was associated with significantly
increased risk of clinical recurrence. This unexpected finding suggests that radi-
cality does not play a role in correctly diagnosed terminal ileitis (L1 disease),
while it is of crucial importance to exclude colonic activity (L3 disease). As this
different phenotype is unlikely to benefit from more extensive surgery, patholo-
gical finding of positive distal resection margin should be regarded as a risk
factor, warranting prophylactic drugs or close monitoring.
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Introduction: The genetic basis that constitutes an adherent-invasive Escherichia
coli (AIEC), a pathotype associated with Crohn’s disease, still needs to be dec-
iphered. Obtaining new molecular tools for AIEC identification would be of
great significance, as current techniques based on phenotypic screening of cul-
tured bacteria are time consuming (1).
Aims & Methods: Our aims were: (i) to search for genetic elements putatively
involved in the AIEC phenotype in order to find specific signature sequences and
(ii) to determine the distribution of these elements to assess their usefulness in
AIEC identification. AIEC-specific sequences were identified through compara-
tive genomics of three E. coli strain pairs (from different phylogroups) displaying
different AIEC phenotype but identical pulsotype. Paired-end libraries of
Illumina HiSeq and PacBio of the six strains’ genomes were combined de novo
and assembled by SPAdes. Differences in gene content between pairs were
accomplished with OrthoVenn. Harvest was performed to compare strain pairs
against an AIEC reference genome (UM146). Only non-synonymous single
nucleotide polymorphisms (SNPs) in coding regions were selected. We performed
Sanger sequencing to confirm the presence of SNPs and to evaluate the distribu-
tion of the SNPs in a collection of 22 AIEC and 29 non-AIEC isolates.
Nucleotides for each SNP were analysed taking into account AIEC phenotype,
adhesion and invasion indices by 2 test or Kruskal-Wallis test, as required.
Binary logistic regression was applied to assess the usefulness of particular var-
iants for AIEC screening. Isogenic mutants were generated with a PCR product
using the method previously described(2, 3) to assess the effect of the novel
candidate genes in AIEC phenotype. In this collection, point mutations or pre-
valence of previously AIEC-associated genes has also been examined.
Results: A total yield of 5209 gene clusters was obtained, 3327 of which were
common for the six strains and none was found to be common in the three AIEC
strains, not even exclusively in two of them. Comparative genomics identified 18
SNPs between the strains of the D-phylogroup pair, 17 in the B2-pair and 30 in
the B1-pair that met the selection criteria. Of those, 24 SNPs (found in 13 genes)
were confirmed and further analysed in the strain collection. Three of the SNPs-
encompassing genes were related with adhesion/invasion and two with stress
tolerance. Three SNPs resulted in differential nucleotide distribution between
AIEC and non-AIEC strains (p5 0.016). These SNPs also presented association
with adhesion and invasion strain capacities (p5 0.006). Interestingly, one of
these polymorphisms can predict the AIEC phenotype with a 71% of specificity
(p¼ 0.008). No differences according to pathotype were reported in the preva-
lence of previously AIEC-related genes, nor in point mutations frequency.
Conclusion: Our study corroborates the absence of AIEC-specific genetic markers
widely distributed across all AIEC strains. Nonetheless, three SNPs putatively
involved with the AIEC phenotype have been described and one of them could be
applied in AIEC screening.
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Introduction: Crohn’s Disease (CD), one of the two main types of inflammatory
bowel disease (IBD), constitutes a significant healthcare burden, especially in the
developed societies. Current methods of treatment are only partially effective
and/or associated with major adverse effects. New therapeutic solutions are
required to ameliorate the effects of medical therapy, reducing complications
and improving patients’ quality of life.
Aims & Methods: The objective of the study was to assess the effectiveness of
delivery of anti-inflammatory drugs encapsulated in the liposomal formulation.
Liposomes were prepared using thin-lipid hydration method. 0.9% sodium chlor-
ide was used as a solvent. The hydration solutions contained an aminosalicylate
mesalazine (5-ASA), two recently validated plant-derived anti-inflammatories
with low bioavailability, chlorogenic acid (CGA) and berberine, and pure solvent
as negative control. Colitis was induced in male BALB/c mice by a single intra-
colonic (i.c.) administration of 2, 4, 6-trinitrobenzene sulphonic acid (TNBS) on
Day 0. Liposomal suspensions containing 5-ASA (5mg/kg), CGA (20mg/kg),
berberine (5mg/kg) and the solvent were administered i.c. twice daily from Day 3
to Day 6. Mice were sacrificed on Day 7 and colonic damage was evaluated.
Results: The macroscopic scoring system included the evaluation of the colon
length and bowel thickness as well as the presence of ulcers, haemorrhage, faecal
blood and diarrhea. Additionally, tissue myeloperoxidase (MPO) activity was
determined and body weight was measured. The obtained results indicate that
the best anti-inflammatory effect was obtained when liposomal suspension with
berberine was used, while the treatment with 5-ASA was less effective.
Surprisingly, CGA administration caused a detrimental effect as demonstrated
by higher macroscopic score and increased MPO activity.
Conclusion: Drug-loaded liposomes may enhance the penetration of active com-
pounds through the gut wall and therefore allow for increased bioavailability and
effectiveness of the treatment at lower doses. We also showed that plant-derived
compounds with low bioavailability, such as berberine and CGA, provide a new
direction in the search of anti-inflammatory substances. However, increased
bioavailability of anti-inflammatories due to liposomal formulation may result
in adverse effects.
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Introduction: Diarrhoea is a common indication for colonoscopy. International
guidelines recommend colonic biopsies should be routinely taken at lower GI
endoscopy in patients with diarrhoea [1, 2] to look for microscopic colitis. The
epidemiology of contemporary microscopic colitis is largely unknown with pub-
lished data based on an earlier time period pre-2001 and in small retrospective
case series. We have systematically collected a large and contemporary cohort of
patients with incident microscopic colitis to help further our understanding of
this disease.
Aims & Methods: Colonic biopsies demonstrating microscopic colitis between
2005–2016 were identified from electronic pathology records. GI endoscopy pro-
cedures taking place during this time period were identified from an electronic
database. Incidence rates were calculated using the total population for
Nottinghamshire derived from UK mid-year population estimates [3]. Poisson
regression models were used to determine rate ratios.
Results: 843 people were diagnosed with microscopic colitis of which 60.7% were
female (n¼ 512). The mean age at diagnosis was 65.0 (95%CI 64.0, 65.9) years.
57.5% (n¼ 485) had collagenous colitis and 42.5% had lymphocytic colitis. The
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incidence rate of microscopic colitis appeared to increase with time (Table). The
incidence rate of microscopic colitis in 2016 was twice of that observed in 2009
(incidence rate ratio 1.86; 95%CI 1.41, 2.46). There was a strong, independent
graded association between the incidence of microscopic colitis and the number
of lower GI endoscopy procedures undertaken (p¼ 0.03).
Year
N
microscopic
colitis
Incidence per
100, 000
Incidence rate
ratio [95%CI]
N lower
GI endoscopy
2005 3 0.39
2006 4 0.52
2007 5 0.65
2008 23 2.96
2009 76 9.74 1.0
2010 74 9.44 0.97 [0.71, 1.34]
2011 94 11.95 1.22 [0.91, 1.66]
2012 104 13.16 1.35 [1.01, 1.82] 10124
2013 89 11.18 1.15 [0.84, 1.56] 10100
2014 118 14.72 1.51 [1.13, 2.01] 11026
2015 104 12.91 1.32 [1.01, 1.78] 13225
2016 147 18.15 1.86 [1.41, 2.46] 13031
Conclusion:Microscopic colitis diagnosis is becoming more common. It is unclear
whether microscopic colitis itself is increasing or greater numbers of lower GI
endoscopy are being undertaken causing an ascertainment bias. Further work is
required to explore environmental exposures such as drugs associated with
microscopic colitis and to observe its natural history.
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Introduction: Data on extra-intestinal manifestations (EIM) and their impact on
disease course of ulcerative colitis (UC) in population-based cohorts are scarce,
particularly in paediatric- and elderly-onset UC patients.
Aims & Methods: The aims of this population-based study were to assess 1) the
occurrence of EIM in paediatric- and elderly-onset UC; and 2) their impact on
long-term disease outcome. Paediatric-onset (517 years at diagnosis) and
elderly-onset UC patients (460 years) from a French prospective population-
based Registry (EPIMAD) were included. Data on EIM and other clinical fac-
tors at diagnosis and at maximal follow-up were collected.
Results: 158 paediatric- and 470 elderly-onset patients were included (median age
at diagnosis 14.5 and 68.8 years; median follow-up 11.2 and 6.2 years, respec-
tively). EIM occurred in 8.9% of childhood- and 3% of elderly-onset patients at
diagnosis and in 16.7% and 2.2% of individuals during follow-up (p5 0.01). The
most frequent EIM was joint involvement (15.8% of paediatric-onset and 2.6%
of elderly-onset). Presence of EIM at diagnosis was associated with more severe
disease course (need for immunosuppressive or biologic therapy or colectomy) in
both paediatric- and elderly-onset UC (HR¼ 2.0, 95%CI: 1.0–4.2 and HR¼ 2.8,
0.9–7.9). Extensive colitis was another independent risk factor in both age
groups.
Conclusion: Elderly-onset UC patients had lower risk of EIM either at diagnosis
or during follow-up than paediatric-onset individuals. EIM at diagnosis pre-
dicted more severe disease outcome including need for immunosuppressive or
biologic therapy or surgery in both paediatric- and elderly-onset UC.
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Introduction: Data on long-term natural history of microscopic colitis (MC),
including collagenous (CC) and lymphocytic colitis (LC) are lacking.
Aims & Methods: All new cases of MC diagnosed in the Somme area, France
between January 1st, 2005 and December 31th, 2007 were prospectively included.
Colonic biopsies from all patients were reviewed by a group of 4 expert gastro-
intestinal pathologists to assess the diagnosis of CC or LC. Demographic and
clinical data were retrospectively collected from diagnosis to February 31th,
2017.
Results: One hundred and thirty cases of MC, 87 CC and 43 LC, were included
(median age at diagnosis 70 and 48 years, respectively). The median follow-up
was 9.6 years (Q1¼ 7.6; Q3¼ 10.6). By the end of follow-up, 37 patients (28%)
relapsed after a median time of 3.9 years (1.2; 5) since diagnosis, without sig-
nificant difference between CC and CL (30% vs 26%, p¼ 0.47). Twenty patients
(15%) were hospitalized for a disease flare and 32 (25%) presented with another
autoimmune disease. Budesonide was the most widely used treatment (n¼ 74,
59%), followed by 5-aminoslaycilic acid (n¼ 31, 25%). Median duration of
budenoside treatment was 92 days (70; 168) and no adverse event to budesonide
were reported. Sixteen patients (22%) developed steroid-dependency and 4 (5%)
were corticoresistant. Only one patient was treated by immunosuppressants
(azathioprine). No colorectal cancer was reported during follow-up. Any of the
death (n¼ 25) observed during follow-up were linked to MC. In multivariate
analysis, age at diagnosis (HR 1.03; 95%CI, 1.00–1.06; p¼ 0.02) and budesonide
exposure (HR 0.40; 95%CI, 0.18–0.90; p¼ 0.03) were significantly associated
with relapse.
Conclusion: This population-based study showed that after diagnosis, two third
of patients with MC observed long term clinical remission. Age at diagnosis and
budesonide exposure were associated with a risk of relapse.
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Introduction: It has been demonstrated in many chronic conditions, including
inflammatory bowel disease (IBD), that better patients’ knowledge about pathol-
ogy and treatment improves the course and management of disease. The aim of
this study was to develop an updated self-questionnaire to assess patients’ level of
knowledge of IBD.
Aims & Methods: The IBD-INFO included 3 parts: an original part (Q1), and 2
parts from the translation of the pre-existing questionnaires Crohn’s and Colitis
Knowledge score (CCKNOW) (Q2) and Crohn’s and Colitis Pregnancy
Knowledge score (CCPKNOW) (Q3). The reliability and discriminatory ability
of the questionnaire were validated with 3 groups of non-IBD volunteers with
various theoretical knowledge levels. The final questionnaire (64 validated ques-
tions) was then tested on 364 in- and out- IBD patients from 4 French university
hospitals. The score for each part of the questionnaire was calculated and factors
associated with low scores were identified by uni- and multivariate logistic regres-
sion analyses.
Results: The scores obtained by the 3 non-IBD volunteer groups differed signifi-
cantly (p5 0.0001) and the IBD-INFO questionnaire showed excellent internal
reliability and consistency (¼ 0.98). The median total score obtained by the IBD
patients was 27/64 [0–59], and scores for Q1, Q2 and Q3 were, respectively, 10/23
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[0–21], 11/24 [0–23] and 4/17 [0–16]. In multivariate analysis, lack of a university
degree, not being a member of a patient association, not receiving anti-TNF
treatment, duration of IBD 3 years, male sex and age 438 years and were
independent risk factors of poor IBD-INFO knowledge score. The areas of
knowledge least mastered were vaccination, IBD-related cancers, treatments
and pregnancy.
Conclusion: Using the IBD-INFO, an updated self-administered questionnaire
built to assess IBD patients’ knowledge, several risk factors have been high-
lighted that allow better targeting of patients and areas requiring an improve-
ment in the level of information.
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Introduction: Inflammatory bowel diseases (IBDs), comprising Crohn’s disease
(CD) and Ulcerative colitis (UC), are characterized by chronic remittent
intestinal inflammation and carry the risk for extraintestinal manifestations
including primary sclerosing cholangitis (PSC). Available data on the impact
of PSC on the disease course in IBD patients is conflicting. Therefore, we
assessed the impact of coincidental PSC on the disease course in a large IBD
patient cohort.
Aims & Methods: In total 1814 patients with histologically confirmed IBD were
evaluated. Medical records from 705 UC and 1022 CD patients as well as from 77
UC-PSC and 10 CD-PSC patients were assessed. Data were evaluated using
standard statistical methods. In matched-pair analyses, IBD patients with and
without PSC were matched at the ratio of 3:1 by sex, disease entity, age at
diagnosis, time from diagnosis to first presentation, and duration of follow-up.
Time to event analysis was performed using survival analytic methods including
Kaplan-Meier method and Log-rank test.
Results: PSC was diagnosed in 77 and 10 patients out of 781 UC (9.8%) and
1033 CD patients (1.0%), respectively. Age at UC onset was significantly
lower in UC-PSC patients than in patients without PSC (23.3 vs. 29.3
years; p5 0.001). Extensive disease manifestation was observed in 46% of
UC patients, whereas pancolitis was more frequently diagnosed in UC-PSC
patients (75%, p5 0.001). Concerning CD, all patients with coincident
PSC showed colonic involvement, while only 69% of the CD patients without
PSC had colonic manifestation (p¼ 0.044). Interestingly, IBD patients without
PSC presented more frequently with active disease, as compared to IBD-PSC
patients (1.1/year vs. 0.7/year; p¼ 0.055). Conveniently, average disease activ-
ity assessed by complete Mayo score, was significantly higher in UC patients
with acute flare as compared to UC-PSC patients (7.3 vs. 6.2; p5 0.001).
Investigation of the average disease activity in 5-year-intervals in UC patients
revealed a stronger disease activity in UC patients without PSC especially
within the first 10 years after UC onset. Furthermore, biological therapy
including vedolizumab and anti-TNF antibodies was initiated more frequently
(35% vs. 22%, p¼ 0.043) and earlier (20.4 vs. 28.6 years after onset, p¼ 0.087)
in UC without PSC than in those with coincident PSC. Colorectal high grade
intraepithelial neoplasia (HGIEN) and CRC were detected in 25 IBD patients
without PSC and in 7 IBD-PSC (4 UC and 3 CD) patients (1.45% vs.
8.05%). Of note, in IBD-PSC patients, HGIEN/CRC occurred significantly
earlier than in IBD patients without PSC (20-year-risk: 9.6% vs. 5.6%;
p¼ 0.003).
Conclusion: In our large cohort study, IBD patients with coincident PSC showed
a distinct disease course with less relapse, lower disease activity, but earlier dis-
ease onset and higher risk for extensive disease manifestation as well as increased
risk for colorectal dysplasia development.
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F. Magro25, N. Arebi26, P.L. Lakatos9, P. Munkholm1
1Department Of Gastroenterology, North Zealand University Hospital,
Frederikssund/Denmark
2Herlev University Hospital, Herlev/Denmark
3Dept. Of Gastroenterology, County Hospital Timisoara Gastroenterology,
Timisoara/Romania
4Department Of Surgery, Oncology And Gastroenterology, Azienda Ospedaliera di
Padova, Padova/Italy
5Lithuanian University of Health Sciences Inst. for Digestive Research, Kaunas/
Lithuania
6Instituto de Investigación Biomédica, Xerencia de Gestión Integrada de Vigo,
Vigo/Spain
7Department Of Gastroenterology And Digestive Endoscopy, Morgagni Hospital,
Forli/Italy
8IBD Clinical And Research Center, ISCARE I.V.F. a.s., Prague/Czech Republic
91st Department Of Medicine, Semmelweis University Faculty of Medicine 1st
Dept. of Medicine - 1st Department of Medicine, Semmel, Budapest/Hungary
10Department Of Medicine, Herning Central Hospital, Herning/Denmark
11American Gastroenterology Center, Nicosia/Cyprus
12Department Of Hepatology And Gastroenterology, Aarhus University Hospital,
Aarhus/Denmark
13Department Of Gastroenterology, Tartu University Hospital, Tartu/Estonia
14Dept. Of Gastroenterology, Faculty Of Medicine And Health, Örebro University,
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Introduction: The EpiCom-cohort is a European prospective population-based
cohort of unselected, uniformly diagnosed patients with inflammatory bowel
disease (IBD) diagnosed in 2010 in centres from Western and Eastern
European countries. The cohort aims at describing differences in occurrence,
treatment strategies, disease course and prognosis within Europe.
Aims & Methods: Patients were followed each 3rd month for the first year after
diagnosis and then according to the treating physician for the 2–5th year of
follow-up. Clinical data on surgery, hospitalizations and medical treatment
incl. biological therapy were captured prospectively throughout the follow-up
period and entered in a validated web-based database. The aim of the study
was to investigate differences in disease outcome and the use of biologicals
between Eastern and Western Europe, from diagnosis and during the first 5
years of follow-up. Associations between outcomes and multiple covariates
were analysed by Cox regression analyses.
Results: A total of 1289 patients aged 15 years or older from 29 centres in 13
Western and 8 Eastern European countries were followed prospectively of whom
717 (56%) had ulcerative colitis (UC), 488 (38%) had Crohn’s disease (CD), and
84 (6%) had IBD unclassified (IBDU). Crude annual rates for CD and UC
patients regarding surgery, biological treatment and hospitalization are shown
in Table 1. Significantly more CD patients in Western Europe received biological
therapy (p5 0.05), while surgery and hospitalization rates did not differ between
the regions (p4 0.05). In UC, surgery rates did not differ between the regions,
while hospitalization rates were higher in Western Europe (p5 0.05). Cox regres-
sion analysis showed that in CD stricturing (B2) or penetrating disease (B3) and
progressing from luminal disease to B2/B3 increased while early (56 months
from diagnosis) treatment with immunosuppressives reduced the risk of surgery
and hospitalization. In UC, progressing to extensive colitis increased the risk of
colectomy while females, extensive disease, need for prednisolone at diagnosis,
and progressing to extensive colitis carried the highest risk for hospitalization.
The cumulative probability of CD patients receiving treatment with 5-ASA was
90% in Eastern Europe and 56% in Western Europe, 69% and 75% for pre-
dnisolone, 54% and 66% for immunomodulators, respectively. For UC patients
the cumulative probability of receiving treatment with 5-ASA within the first
year of disease was 100% in Eastern Europe and 91% in Western Europe,
44% and 52% for prednisolone, 27% and 30% for immunomodulators,
respectively.
Conclusion: In an era of early and aggressive immunological therapy, surgery and
hospitalization rates for CD and surgery rates for UC patients were similar in
Eastern and Western Europe. Overall, surgery and hospitalization rates were
comparable to population-based cohorts from the past decade and pre-biological
era. This similar disease course was in spite of more early and aggressive treat-
ment with biologics and immunomodulators, with significantly more CD and UC
patients in Western Europe receiving biologics.
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Introduction: Chronic abdominal pain is a common symptom in inflammatory
bowel disease (IBD). Pain management is complicated by clinically important
gastrointestinal side effects of many of the available analgesics, particularly opi-
ates. Opiate prescribing for cancer and non-cancer pain has increased dramati-
cally in recent years but there is a paucity of data on prescription trends for
individuals with IBD. The only population-based study is from Canada where
5% of subjects with IBD became heavy opiate users after 10 years of diagnosis
and there was a strong association between heavy opiate use and mortality (OR
2.91, 95% CI 1.58–5.02). In this study we explore trends in the prescription of
opiate medications and assess the association between opiate prescription and
mortality in English primary care cohort of patients with IBD.
Aims & Methods: We used the English primary care database ResearchOne for
this study which holds records from approximately 6 million individuals (410%
of the total population). We extracted relevant clinical codes and prescription
data on all patients with IBD, and separated out those with ulcerative colitis
(UC) and Crohn’s disease (CD). We created 4 categories of opiate medication
use, namely; any opiate medication, codeine only, tramadol, and strong opiates.
We defined 3 groups of prescription density as none/infrequent users, moderate
and heavy users as 51, 1–3 and 43 prescriptions per calendar year respectively.
We examined the trend in opiate prescriptions for all IBD patients in 4 year
blocks from 1990–2014 using chi2 for trend as a significance. Separate trends
were produced for each of our opiate classes. We calculated a propensity score
estimating the conditional probability of being prescribed an opiate medication
based on pre-defined characteristics which may influence the prescription of
opiates. All-cause mortality in opiate users and non-users was compared in a
propensity score matched, Cox proportional hazards regression analysis to pro-
duced hazard ratios (HR) and 95% confidence intervals (CI). All analyses were
performed for each opiate medication class in CD and UC patients.
Results: We included 3517 patients with CD and 5349 with UC. Opiate prescrip-
tions increased from 10% in 1990 to 30% in 2014 (chi2 for trend p5 0.005).
There was a similar, significant increase for codeine (chi2 for trend, p¼ 0.008),
tramadol (p5 0.005) and strong opiates (p5 0.005) when analyzed separately.
Table 1 shows the association between opiate use and all-cause mortality in
patients with IBD. Any opiate use in patients with UC was associated was
associated with increased mortality ((HR 1.67, 95% CI 1.25–2.23). The strongest
associations were for heavy users of strong opiates in patients with CD (HR 2.18,
95% CI 1.20–3.95) and UC (HR 3.30, 95% CI 1.77–6.18). There was no associa-
tions for prescriptions of tramadol at any prescription density in CD or UC.
Table 1: – The association between opiate prescriptions and all-cause mortality
in patients with inflammatory bowel disease in the English primary care database
Research One. Propensity score matched, Cox proportional hazards regression
analysis.
Crohn’s disease Ulcerative colitis
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
Any opiate medication
None/infrequent use (51 prescription per year) 1 1
Moderate use (1–3 prescriptions per year) 0.94 (0.64–1.39) 0.83 (0.56–1.21)
Heavy use (43 prescriptions per calendar year) 1.15 (0.85–1.55) 1.67 (1.25–2.23)
Codeine only
(continued)
Table 1 Continued
Crohn’s disease Ulcerative colitis
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
None/infrequent use (51 prescription per year) 1 1
Moderate use (1–3 prescriptions per year) 1.66 (0.89–3.09) 0.72 (0.35–1.47)
Heavy use (43 prescriptions per calendar year) 0.70 (0.35–1.39) 1.83 (1.10–3.05)
Tramadol alone or in combination with codeine
None/infrequent use (51 prescription per year) 1 1
Moderate use (1–3 prescriptions per year) 0.69 (0.27–1.72) 0.50 (0.19–1.36)
Heavy use (43 prescriptions per calendar year) 0.79 (0.35–1.81) 1.39 (0.66–2.94)
Strong opiates
None/infrequent use (51 prescription per year) 1 1
Moderate use (1–3 prescriptions per year) 1.34 (0.67–2.70) 2.44 (1.16–5.15)
Heavy use (43 prescriptions per calendar year) 2.18 (1.20–3.95) 3.30 (1.77–6.18)
Strong opiates versus weak opiates
None/infrequent use (51 prescription per year) 1 1
Moderate use (1–3 prescriptions per year) 1.36 (0.69–2.69) 1.81 (0.91–3.62)
Heavy use (43 prescriptions per calendar year) 2.04 (1.14–3.65) 2.47 (1.41–4.33)
Conclusion: Our study is the largest population based study of opiate use in
patients with IBD. We have shown a significant increase in the prescription of
opiates since 1990, with 30% being prescribed an opiate medication between 2010
and 2014. Prescriptions of codeine in UC and strong opiates in both CD and UC
were associated with increased all-cause mortality. There appears to be a dose
association as heavy users of strong opiates had the largest association with
mortality. Observational studies are not proof of causality and there may be
residual confounding. A dose reponse is a strong indicator that opiates could
be responsible for the associations seen, which is consistent with other studies
investigating opiates used for non-cancer pain in chronic disease. Randomised
controlled trials would be unethical and not faesible to investigate this potential
effect so population-based observational studies may provide the best estimate.
Opiate prescriptions are increasing worldwide for chronic non-cancer pain, and
individuals with IBD can now be included. Clinicians managing pain in indivi-
duals with IBD should consider the potential implications of prescribing, or
continuing with opiate prescriptions as they are a marker for increased mortality.
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Introduction: We aimed to: (1) evaluate the prevalence of periodontitis in patients
with inflammatory bowel disease (IBD), (2) assess the impact of IBD activity and
IBD therapy on parodontal outcomes.
Abstract No: P0325
Table 1: Crude rates for surgery, biological therapy and hospitalization after 1 and 5 years follow-up in the EpiCom-cohort
Biological therapy Surgery Hospitalization
1 year 3 years 5 years 1 year 3 years 5 years 1 year 3 years 5 years
Crohn’s disease Eastern Europe 4 (5%) 6 (7%) 12 (14%) 12 (14%) 16 (19%) 18 (21%) 22 (26%) 26 (31%) 26 (33%)
Western Europe 80 (20%) 110 (27%) 132 (33%) 50 (12%) 70 (17%) 89 (22%) 91 (23%) 122 (30%) 147 (36%)
Ulcerative colitis Eastern Europe 1 (1%) 6 (5%) 10 (8%) 2 (2%) 2 (2%) 3 (2%) 8 (6%) 16 (13%) 21 (17%)
Western Europe 28 (5%) 53 (9%) 70 (12%) 21 (4%) 33 (6%) 40 (7%) 85 (14%) 124 (21%) 142 (24%)
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Aims & Methods: In a prospective 6-months study, dental examination was per-
formed in 54 patients with IBD and in 19 healthy controls. IBD related variables
were prospectively collected, as well as markers for periodontitis including gin-
gival bleeding (BOP index, marker of periodontal inflammation), gingival reces-
sion (REC index, marker of cumulative periodontal destructions) and probing
depth (PPD as a marker of the severity of the disease). Additional dental exam-
ination was proposed 3 months after to all patients diagnosed with periodontitis.
Results: Among the 54 included patients, 44 had Crohn disease (81%) and 31
were women (55%). At the time of dental examination, median age was 33 years
(Q1¼ 26; Q3¼ 41), 20 (36%) were smokers and the median IBD duration was 8.4
years (3.4–16.3). Eleven (20%) were treated by corticosteroids, 27 (49%) by anti-
TNF, 6 (10%) by other biologics and 8 had no IBD treatment. IBD was sig-
nificantly associated with periodontitis (81% vs 27%; Odds Ratio 2.9,
95%CI1.3–6.2). Mild, moderate and severe periodontitis were respectively
observed in 34 (63%), 8 (15%) and 3 (5%) IBD patients. As compared to healthy
controls, IBD patients had significant increase of BOP index (p¼ 0.008), probing
death (p¼ 0.03), and REC index (p¼ 0.01). Patients with active IBD (Harvey
Bradshaw 44 or Mayo Score 41) had a significant increase of BOP index
(p¼ 0.007) as compared to patients with inactive disease. A significant correla-
tion between BOP and Harvey-Bradshaw index was observed (r¼ 0.44,
p¼ 0.0018). Anti-TNF therapy was significantly associated with lower BOP
index (p¼ 0.02). All patients with diagnosis of periodontitis were treated by
periodontal debridement and subgingival irrigation with povidone-iodine which
led to a significant decrease of BOP index three months after diagnosis.
Conclusion: Inflammatory bowel diseases were associated with an increase risk of
periondotitis. Gingival inflammation was correlated to disease activity and anti-
TNF therapy was associated with a lower risk of active parodontal disease.
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Introduction: Crohn’s disease is a chronic, immune mediated inflammatory con-
dition which affects the gastrointestinal tract. NOD2/Card15 mutations have
been linked to an increased risk of Crohn’s disease and to some of its phenotypes.
This study aimed to determine the presence of the above mutations in Arab
patients suffering from Crohn’s disease in Kuwait.
Aims & Methods: Blood samples were obtained from 103 Arab patients with
Crohn’s disease and 100 Arab control subjects. The genomic DNA was isolated
from the samples using Qiagen DNA Blood mini kit. The isolated DNA were
used in Polymerase Chain Reaction (PCR) using four sets of primers specific for
each mutation in the NOD2/Card15 (rs2066842, SNP5, Exon 802C4T;
rs2066844, SNP8, Exon4 2104C4T; rs2066845, SNP12, Exon 8 2722G4C;
and, rs2066847, SNP13, Exon11 3020insC). The PCR-amplified DNA were
sequenced using ABI 3130xl Genetic analyzer, and specific mutations were
detected by using the sequence analysis software.
Results: Table 1 shows the results of all homozygous and heterozygous mutations
found in the patients and control subjects. The mutation in rs2066842 (SNP5,
Exon4 802C4T) was detected in the NOD2/Card15 sequence of 17 (16.5%)
Arab patients with Crohn’s disease compared to 32 (32.0%) normal controls
(p5 0.05). This difference was statistically significant if the mutation was hetero-
zygous (p5 0.05) but not in homozygous. The mutation in rs2066845 (SNP12,
Exon 8 2722G4C) was found in 24 (23.3%) patients and 10 (10.0%) controls
(p5 0.05). This difference was statistically significant if the mutation was homo-
zygous (p5 0.05) but not in heterozygous. The mutation in rs2066844 (SNP8,
Exon4 2104C4T) was found only in one patient and no controls and rs2066847
(SNP13, Exon11 3020insC) was not detected in any of the patients or controls.
Table 1. Mutations in SNP5, SNP8, SNP12 and SNP13 of the NOD2/Card15
gene in Arab patients with Crohn’s disease and control subjects.
Conclusion: This study suggests that mutation in rs2066845 (SNP12, Exon 8
2722G4C) occurs more frequently in Arab patients with Crohn’s disease com-
pared to controls, but the disease is associated only with the homozygous muta-
tion. Mutation in rs2066842 (SNP5, Exon4 802C4T) occurs more frequently in
controls compared to patients and the heterozygous mutation appears to have a
protective effect against Crohn’s disease in the Arab population. Mutations in
rs2066844 (SNP8, Exon4 2104C4T) and rs2066847 (SNP13, Exon11 3020insC)
are not seen in this population.
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Introduction: There is limited data on genetics of inflammatory bowel disease
(IBD) in populations where the condition is emerging, especially from South
Asia.
Aims & Methods: A case [histologically confirmed ulcerative colitis (UC) and
Crohn disease (CD) of 1 year duration] control [unrelated, healthy, gender
matched] study was conducted at four major gastroenterology centres in Sri
Lanka. Phenotypic data (type, location, severity, treatment types, response to
treatment and complications) of cases were obtained. Cases and controls were
genotyped for 16 selected variants with known IBD disease associations in
Western and East Asian populations [IL12B:rs1045431, IL23R:rs11805303,
ARPC2:rs12612347, IRGM:rs13361189, IL26/IL22:rs1558744,
CDH1:rs1728785, IL10:rs3024505, FCGR2A:rs3737240, PTGER4:rs4613763,
IL17REL/PIM3:rs5771069, HNF4a:rs6017342, STAT3:rs744166,
SMURF1:rs7809799, LAMB1:rs886774, HLA DRB5, DQA1, DRB1,
DRA:rs9268853, MST1, UBA7, APEH:rs9822268]. Genotypes of all variants
were in Hardy-Weinberg Equilibrium. (P4 103). To account for multiple
hypothesis testing associations that had a p-value of 50.003 were considered
significant.
Results: There were 411 (males¼ 49.6%) cases [UC-258 (62.8%), males-47.7%),
CD-153 (37.2%), males-50.3%] and 465 (males-50.5%) controls. The following
variants were associated with corresponding phenotypes: IL23R:rs11805303 with
IBD (all cases) (p¼ 0.001); IL12B:rs1045431 with upper gastrointestinal (UGI)
CD (p¼ 0.001); IL17REL/PIM3:rs5771069 with relapsing IBD (p¼ 0.003);
MST1, UBA7, APEH:rs9822268 with maintained remission (p5 0.001);
IL17REL/PIM3:rs5771069 with disease complications in all cases (p¼ 0.001);
HLA-DRB5, DQA1, DRB1:rs9268853 with immunomodulator use in all cases
(p¼ 0.001). Two variants showed a non-significant trend toward s association-
PTGER4:rs4613763 with ileal CD (p¼ 0.005); IL17REL/PIM3:rs5771069 with
treatment-refractory IBD (all cases) (p¼ 0.005).
Conclusion: This first study, confirms the association of genetic variants of IBD
previously reported in other populations, with clinical, prognostic and treatment
phenotypes of IBD in a Sri Lankan (South Asian) population.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Mutation Any mutation Homogyzous mutation Heterogyzous mutation
Patients (n 103) Controls (n 100) P-value Patients (n 103) Controls (n 100) P-value Patients (n 103) Controls (n 100) P-value
SNP5 17 32 50.05 6 10 NS 11 22 50.05
SNP8 1 0 NS 0 0 NS 1 0 NS
SNP12 24 10 50.05 10 0 50.05 14 10 NS
SNP13 0 0 NS 0 0 NS 0 0 NS
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Introduction: Among the numerous genetic factors associated with ulcerative
colitis (UC), an increasing attention has been paid to the polymorphisms of
the vitamin D receptor gene (VDR) associated with disorders of innate and
adaptive immunity, as well as the barrier function of the intestinal epithelium.
However, the results of studies on the prevalence, clinical, diagnostic and prog-
nostic significance of polymorphisms of the VDR gene in different populations
are ambiguous and contradictory. In particular, associations of Bsm I poly-
morphism of the VDR gene with UC in the Chinese population and in the
Jewish Ashkenazi has been found, while in the Irish population, with a sufficient
prevalence of Bsm I polymorphism, this association is absent [1–3]. In the
Russian Federation, there is no data on the prevalence, clinical, diagnostic and
prognostic significance of Bsm I polymorphism of the VDR gene with UC. These
circumstances determined the purpose and objectives of this study.
Aims & Methods: The purpose is to assess the clinical, diagnostic and prognostic
significance of the Bsm I polymorphism of the VDR gene (rs1544410) at UC
among the residents of the Kemerovo region of the Russian Federation. The
study included 76 patients with UC and 85 controls. Genotyping was performed
by PCR method (‘‘SNP-express’’ reagents, Lytech Co. Ltd., Russia) with elec-
trophoretic detection of amplification products. Statistical analysis was per-
formed using the V2 and Mann-Whitney tests. In the presence of statistically
significant differences (p5 0.05), odds ratios (OR) with 95% confidence interval
(CI) were calculated.
Results: It was found that the frequency of the allele B polymorphism of the VDR
Bsm I gene was higher among patients with UC than in the control group (44%
vs. 26%, p¼ 0.02), which increases the risk of this pathology by 2.2% (95% CI:
1.2–4.1). In the case of carriers of the B/B genotype, the risk of developing UC
increased up to 3.5 times in comparison with the control group (21% vs. 7%,
p¼ 0.02, 95% CI: 1.4–8.6), whereas in b/b genotype the risk of UC decreased
(33% and 54%, respectively, p¼ 0.02, OR¼ 0.4, 95% CI: 0.2–0.7). Significant
differences between carriage of the B allele Bsm I polymorphism and the features
of the clinical course of the UC have not been established. However, it has been
shown that in carriers of allele B, the clinical implementation of UC develops
significantly later than in patients with the b/b genotype (43 and 28.5 years,
respectively, p¼ 0.04).
Conclusion: For the carriers of the B allele Bsm I polymorphism of the VDR gene
is a predictor of a high risk of ulcerative colitis with an increase in the age of
diagnosis. Genotype b/b Bsm I polymorphism of the VDR gene has a protective
effect in the development of ulcerative colitis among the residents of the
Kemerovo region of the Russian Federation.
Disclosure of Interest: All authors have declared no conflicts of interest.
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S. Cucchiara1, M. Aloi1
1Pediatric Gastroenterology And Liver Unit, Sapienza University of Rome, Rome/
Italy
2Institute For Maternal And Child Health, Irccs ‘‘burlo Garofalo, ’’, Pediatric
Department, Gastroenterology and Nutrition Unit, Trieste/Italy
3Pediatric Gastroenterology And Endoscopy, Pediatric Department, Pediatric
Department, Messina/Italy
4Department Of Translational Medical Science, University of Naples ‘‘Federico
II’’, Naples/Italy
5Pediatric Gastroenterology And Endoscopy, Pediatric Department, G. Martino
Hospital, Messina/Italy
6Pediatric Department, Gastroenterology Unit, University of Messina, Messina/
Italy
7Department Of Women, Child And General And Specialist Surgery, SUN, Napoli/
Italy
Contact E-mail Address: giuliadarcangelo87@gmail.com
Introduction:Having a family history for inflammatory bowel disease (IBD) is the
only known risk factor for disease development. Indeed, up to 30% of IBD
patients report at least 1 first-degree relative with IBD, and siblings carry the
highest risk. Recent data have shown that genetic and serological markers may
predict IBD development. However, there are only few studies evaluating a
genetically well-characterized population and at high risk for disease, such as
siblings and twins. Therefore, aim of this study was to evaluate genetic and
serological findings as markers of disease susceptibility in healthy siblings and
twins of children with IBD.
Aims & Methods: This is the first phase of a prospective, longitudinal, multi-
center, case-control study. Serum was collected from 80 siblings and twins of
children with IBD and 77 healthy controls with no family history for IBD.
Genotyping (TaqmanMGB) for variants of ATG16L1 (SNP rs2241880),
STAT3 (SNP rs744166), ECM1 (SNP rs3737240), NKX2-3 (SNP rs10883365),
was performed. Serological titers of anti-Saccharomyces cerevisiae (ASCA IgG
and ASCA IgA), perinuclear anti-neutrophil cytoplasmic antibodies (pANCA),
anti-outer membrane porin C antibody (anti-OmpC), and antibacterial flagellin
antibody (anti-CBir1), were determined by specific enzyme-linked immunosor-
bent assay (ELISA).
Results: Fifty-nine out of 80 cases (74%) and 50/77 controls (65%) were positive
for at least 1 of the serum autoantibodies (p¼ 0.29); a combination of any 4 of
them was found in 3 cases (4%) and no controls (p¼ 0.28). No significant dif-
ference was shown for any of the studied autoantibodies between cases and
controls. Homozigosity for any susceptibility gene variant was found in 60 out
of 80 cases (75%) and in 52/77 controls (67.5%) (p¼ 0.37), with no significant
association between family history and genotype status. No combination of gene
variants significantly differed between cases and controls.
Conclusion: Our preliminary results argue against a role of commonly recognized
genetic polymorphisms and microbial antibodies as markers of disease suscept-
ibility in siblings of children with IBD. However, data from larger and prospec-
tive studies, possibly including microbial characterization, are warranted before
drawing definite conclusions.
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Introduction: DNA methylation is an important epigenetic modification mechan-
ism of gene expression. Several studies have shown an association of impaired
methylation with inflammatory bowel diseases (IBD) pathogenesis. DNMT3A
and DNMT3B are two of the three members of the family of de novo DNA
methyltransferases. Variants in these proteins are responsible for the establish-
ment of de novo genomic DNA methylation patterns and are involved in the
normal development as well as in many diseases. However, it is unknown if
DNMT3A may play a role during the mechanism involved in this abnormal
methylation pattern and consequently the development of diseases.
Aims & Methods: To assess the function of DNMT3A in intestinal epithelial cells
(IECs), human Caco-2 colonic carcinoma cells were transfected with siRNA
targeting DNMT3A, DNMT3B and DNMT3L. Gene expression analysis and
DNA methylation analysis using qRT-PCR, RNA sequencing and 850k methy-
lation chip assay were performed. For long-term experiments, we used a
CRISPR/Cas9 genome editing to delete DNMT3A gene in Caco-2 cells.
DNMT3A knockout Caco-2 cells were grown in a 3D-Matrigel culture system
and after 2 weeks, spheroids cells were stained for actin/nuclei and subjected to
confocal microscopy analysis.
Results: From the RNA sequencing data, approximately 1000 genes were found
to be differentially expressed between cells lacking DNMT3A and controls. The
KEGG pathway analysis identifies differentially regulated genes associated with
several functional categories comprising extracellular matrix receptor interaction,
focal adhesion and MAPK signalling pathway. In contrast, we observed no
difference in DNA methylation between the groups. Furthermore, loss of
DNMT3A induces abnormal spheroids formation by reducing spheroids dia-
meter and defect in actin organization and lumen formation. Thus, the observed
morphological phenotype may be linked to the differentially regulated genes
involved in the previous analysed pathways.
Conclusion: Rapidly inactivation of DNMT3A in IECs promotes changes in gene
expression, but does not change global DNA methylation. The absence of
DNMT3A induces abnormal/defective spheroids formation in 3D culture
system. Hence, our data provide a preliminary overview of DNMT3A in intest-
inal epithelial cells and its potential role in maintaining intestinal homeostasis.
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Introduction: The endoplasmic reticulum (ER) plays a crucial role in maintaining
cellular homeostasis by coordinating the processing and folding of secretory and
membrane proteins. The accumulation of unfolded or misfolded proteins induces
ER stress. The unfolded protein response (UPR) aims at restoring ER function
and is comprised of three signaling branches via inositol-requiring enzyme 1
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(IRE1), double-stranded RNA-dependent protein kinase (PKR)-like ER kinase
(PERK) and activating transcription factor 6 (ATF6). Defects in the ER stress
response have been shown to predispose to chronic inflammatory bowel disease
(IBD). Genome-wide association studies identified disease susceptibility loci in or
adjacent to several UPR related genes including XBP1 and ORMDL3.
Aims & Methods: The objective of this study was to determine the function of
ORMDL3 in UPR signaling to gain insights into the molecular mechanisms
promoting chronic intestinal inflammation. Using molecular cell biology
approaches, we studied the effect of ORMDL3 on ATF6, PERK and IRE
signaling. The role of ORMDL3 in intestinal inflammation was determined
in vivo in both an acute and chronic DSS-colitis model using Ormdl3-deficient
mice.
Results: Our in vitro studies demonstrate that ORMDL3 facilitates ER stress-
induced ATF6 activation. Overexpression of ORMDL3 resulted in increased
cleavage of ATF6 and augmented ERSE promoter activity. Mechanistically, we
show that ORMDL3 colocalizes and directly interacts with ATF6.
Furthermore, ORMDL3 overexpression induced the PERK pathway by elevat-
ing p-eIF2 and CHOP protein levels. In contrast, we observed an inhibition of
IRE1 signaling exerted by ORMDL proteins as shown by reduced XBP1 splicing
and decreased UPRE promoter activity. Ormdl3-deficient mice showed an
increased susceptibility to acute DSS-induced colitis compared to their wild-
type littermates, as indicated by a more severe body weight loss and higher
disease activity indices (DAI). In contrast, Ormdl3-deficiency was observed to
be beneficial in the course of chronic colitis: compared to their wild-type litter-
mates, Ormdl3/ mice showed less body weight loss and an improved survival
rate.
Conclusion: This study demonstrates for the first time the modulatory functions
of ORMDL proteins as regulators of all three UPR signaling pathways.
Additionally, our in vivo studies suggest that ORMDL proteins constitute a
precise fine-tuning mechanism of the UPR determining cell fate decisions in
response to ER stress.
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Introduction: Several studies have assessed Crohn’s disease (CD) according to
disease activity using clinical, laboratory & radiological activity indexes; but
few have analyzed the damage the disease bring about on the GI tract.
Lémann score was designed to develop a comprehensive assessment of the struc-
tural bowel damage, including stricturing lesions, penetrating lesions (fistulas and
abscesses), and surgical resection. (1)
Aims & Methods: To calculate Lémann score in a cohort of Egyptian patients to
determine its ability to assess the structural damage caused by CD in Egyptian
population. Lémann score was calculated using specific computer software based
on the original paper by Pariente. B et al (1) in a cohort of Egyptian patients with
CDf ollowed from April 2013 - August 2015. The temporal relation between
Lémann score and disease duration was also assessed.
Results: A total of 100 Egyptian patients with CD were enrolled, 69% males and
31% females. Median age was 32 years, 36% were smokers. The clinical presen-
tation varied between abdominal pain occurring in 90% followed by 69% with
chronic diarrhea, 52% with weight loss. Few patients (26%) presented with
extraintestinal manifestations. According to ECCO classification of disease
severity 73% of our patients had mild disease, 17% had moderate disease,
10% had severe disease. According to Montreal classification, 25% of patients
were A1, 55% A2, 20% A3, 79% L1, 9% L2 & 12% L3, 63% B1, 7% B2, 26%
B3, & only 4% had perianal disease. According to CDAI, 83% were in clinical
remission, 11% mild ‘‘CDAI 150–220’’, 4% moderate ‘‘220–450’’, 2% severe
‘‘CDAI4 450’’ disease activity. When assessing structural damage of upper
GIT, 4% had stricturing lesions, 2% grade 1 & 2% grade 2 lesions. The small
bowel showed stricturing lesions in 65%: 39% grade 1, 23% grade 2, 3% grade 3
lesions. 25% of patients had grade 3 penetrating lesions, 5% had surgery which
was resection in all the cases. As regards the assessment of stricturing lesion in the
colon/rectum, the cecum showed stricturing lesions in 3%, 2% grade 2 and 1%
grade 3 lesions; ascending colon showed stricturing lesions in 20%, with 7%
grade 1 lesions, 11% grade 2 & 2% grade 3 lesions; transverse colon showed
stricturing lesions in 1%; sigmoid colon showed stricturing lesions in 2%; rectum
showed stricturing lesions in 1; while in only 1% whole colon showed grade 1
stricturing lesions affecting the 6 segments. In addition, 12% had grade 3 pene-
trating lesions while 9% had history of surgery mainly intestinal resection. In the
anal canal, only 3% of patients had grade 3 penetrating lesions. The mean
Lémann score was 4.02 4.19 & the median was 2. Increased median Lémann
score was statistically positively correlated with disease duration of 2 years &
42 - 510 years and 10 years respectively. (rs¼ 0.343 & p5 0.001)
(KW¼ 9.235(0.010)). The current study showed that affection of the GI tract
was (5%, 92%, 41%, and 3% with upper tract, small bowel, colon/rectum, &
anus CD location, respectively). There is an increase in median Lémann score
with increase in disease duration (global test p5 0.001): 0.60, 2.50, 6.40 for
disease duration of 2 years & 42 - 510 years and 10 years respectively.
These results are in concordance with what was published by Pariente B et al. (1)
Conclusion: Crohn’s disease affection pattern in our Egyptian Cohort is mainly in
the small bowel (92%) followed by the colon (41%) with the upper GI and the
anal canal representing only 5% and 3% respectively. Lémann score designed by
and derived from the linear mixed model showed a good fit with the investigator
organ damage evaluations in Egyptian population with CD. Lémann score could
strongly assess the damage to the digestive tract caused by CD in a cohort of
Egyptian patients. Despite calculating Lémann score in Egyptian cohort reflects
the same positive trend with western cohort but with relatively smaller figures
could reflect that Egypt is a young population for CD.
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Development of the Lémann index to assess digestive tract damage in
patients with Crohn’s disease. Gastroenterology. 2015 Jan;148(1):52–63.
P0335 FINAL RESULTS ON IMMUNOGENICITY PROFILE AND
PREDICTORS OF ADA DEVELOPMENT OF BIOSIMILAR
INFLIXIMAB DURING THE FIRST 12 MONTHS OF THE THERAPY:
RESULTS FROM A PROSPECTIVE NATIONWIDE COHORT
P.A. Golovics
1, B.D. Lovasz1, Z. Kurti1, M. Rutka2, Z. Vegh1, K.B. Gecse1,
K. Farkas2, J. Banai3, L. Bene4, L. Gonczi1, B. Gasztonyi5, T. Kristof6,
L. Lakatos7, P. Miheller8, K. Palatka9, A. Patai10, M. Papp11, A. Salamon11,
T. Szamosi3, Z. Szepes2, G.T. Toth12, A. Vincze13, E. Biro14, T. Molnar2,
P.L. Lakatos1
11st Department Of Medicine, Semmelweis University Faculty of Medicine 1st
Dept. of Medicine - 1st Department of Medicine, Semmel, Budapest/Hungary
2First Department Of Internal Medicine, University of Szeged, Szeged/Hungary
3Military Hospital – State Health Centre, Budapest/Hungary
41st Department Of Medicine, Peterfy Hospital, Budapest/Hungary
52nd Department Of Medicine, Zala County Hospital, Zalaegerszeg/Hungary
62nd Department Of Medicine, B-A-Z County and University Teaching Hospital,
Miskolc/Hungary
7Department Of Internal Medicine, Csolnoky Ferenc Regional Hospital, Veszprem/
Hungary
8Second Department Of Internal Medicine, Semmelweis University, Budapest/
Hungary
9Department Of Gastroenterology, University of Debrecen, Debrecen/Hungary
10Department Of Medicine And Gastroenterology, Markusovszky Hospital,
Szombathely/Hungary
11Department Of Gastroenterology, Tolna County Teaching Hospital, Szekszard/
Hungary
12Department Of Gastroenterology, Janos Hospital, Budapest/Hungary
131st Department Of Medicine, University of Pecs, Pecs/Hungary
14Department Of Laboratory Medicine, Semmelweis University, Budapest/
Hungary
Contact E-mail Address: golovics.petra@gmail.com
Introduction: Biosimilar infliximab CT-P13 received EMA approval in June 2013
for all indications of the originator product and its use is mandatory in all anti-
TNF naı̈ve IBD patients in Hungary since May 2014.
Aims & Methods: In the present study we aimed to prospectively evaluate the
immunogenicity profile of the biosimilar infliximab and predictors of TDM in
IBD during the first year of therapy in a nationwide, multicentre cohort.
Demographic data were collected and a harmonized monitoring strategy was
applied. Clinical and biochemical activity were evaluated at weeks 14, 30 and
54. Routine therapeutic drug monitoring (TDM) was applied. Trough level (TL)
and anti-drug antibody (ADA) concentration were measured by ELISA (LT-005,
Theradiag, France) at baseline and at 2, 6, 14, 30 and 54 weeks right before anti-
TNF administration during the induction treatment.
Results: 353 consecutive IBD patients (209 CD patients and 144 UC patients)
were included in the present cohort. 23.4% of CD patients and 19.4% of UC
patients had received previous anti-TNF therapy. None of the patients had
received infliximab within 12 months prior to initiation of the biosimilar inflix-
imab. 60/51% of CD/UC patients received concomitant immunosuppressives at
baseline. Mean TLs were 18.9, 17.3, 7.4, 4.3 and 5.3 mg/ml at weeks 2, 6, 14, 30
and 54 in CD and 19.1, 11.8, 5.0, 3.9 and 4.5 mg/ml UC. Previous anti-TNF
therapy was associated with lower early TL-s in both CD (week 2, 14, and 30,
p5 0.05) and UC (week 2 and 6, p¼ 0.03). ADA positivity rates were 4.3%,
12.0%, 20.9% and 28.6% in naı̈ve patients at weeks 0, 14, 30 and 54
(ntotal¼ 266, 312, 290 and 210). ADA positivity at week 14 was associated
with lower TLs in all CD (week 2, 14 and 30, p5 0.007 for all) and UC (week
6, 14 and 30, p5 0.001 for all) patients. Concomitant IS use prevented ADA
formation in anti-TNF-naı̈ve patients (week 14, 30 and 54, p¼ 0.01, 0.02 and
0.004) in CD but not in UC and did not affect clinical remission or response
rates. 32 (8.9%) patients had infusion reactions during induction or maintenance
treatment, of which 16 patients had received previous infliximab treatment.
Conclusion: Drug TLs and ADAs in IBD patients until week 54 were in line with
results reported for the originator in previous studies. Patients with previous
exposure to anti-TNFs had lower early TL coupled with ADA positivity and
were more likely to develop infusion reactions. Concomitant IS use prevented
ADA development in anti-TNF naı̈ve patients.
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Introduction: The most relevant scope of serologic antibodies in Crohn’s disease
[CD] is to stratify the risk of complicated disease course. Significance of distinct
antibody classes and their characterisation was rarely considered. We aimed to
address these concerns.
Aims & Methods: Sera of 266 well-characterized CD patients (m/f:112/154,
median age: 25 yrs, B1:80.1%, P1:18.0%) and 155 controls were assayed for
traditional anti-microbial antibodies (ASCA IgA/IgG, anti-OMP IgA).
Endotoxin core IgA (EndoCAb) and a panel of non-specific immunoglobulin
A (IgA) antibodies (IgA1, IgA2 and secretory [s] IgA) were also assessed by
ELISA. An observational follow-up study [median, 143 months] was conducted
to assess possible associations between serologic antibodies and the development
of various complications and subsequent surgical interventions. A novel flow
cytometry test system was established for characterisation of IgA type ASCA
to reveal possible origin of the antibody.
Results: A total of 65.7% and 46.2% of the CD patients were positive for
ASCA IgA/IgG and anti-OMP antibodies. Both ASCA types occurred
equally. EndoCAb IgA positivity was more frequent (15.4% vs. 5.4%,
p5 0.01) and sIgA levels were increased [median, 51 vs. 29mg/ml,
p5 0.001] in CD compared to controls. They were also associated with pre-
sence of IgA type anti-microbial antibodies. Contrary, ratio of IgA2/A1 in CD
corresponded with the value of the controls. In Kaplan-Meier analysis, devel-
opment of internal penetrating and/or stenosing (IP/S) complications and
resective surgery (SR) was significantly associated with IgA type
(pLogRank5 0.001 and pLogRank¼ 0.025 respectively), while development of
perianal penetration (PP) with IgG type ASCA (pLogRank¼ 0.008).
Performance OMP IgA was equal to ASCA IgA, however sIgA not. Anti-
microbial antibodies remained independent predictors in multivariate Cox-
regression analysis comprising relevant clinical factors.
Summary of multivariate Cox regression analysis for the association of serologic antibodies
with complicated disease course
HR [95% CI]; p IP/S in B1 pts SR in B1 pts PP in P0 pts
ASCA IgA 2.92 [1.85–4.62]; 50.001 1.77 [1.09–2.87]; 0.021
ASCA IgG 2.77 [0.36–5.63]; 0.005
ASCA IgA/IgG 1.76 [1.09–2.87]; 0.022 1.45 [0.86–2.45]; 0.163 2.07 [0.98–4.39]; 0.057
Omp IgA 1.66 [1.09–2.54]; 0.019 2.08 [1.28–3.38]; 0.003 1.13 [0.63–2.01]; 0.692
sIgA 1.54 [0.97–2.44]; 0.066 1.37 [0.82–2.28]; 0.23 1.25 [0.67–2.34]; 0.475
Endocab IgA 2.60 [1.62–4.17]; 50.001 1.66 [0.96–2.87]; 0.071 0.74 [0.33–1.68]; 0.475
Without uncoupling of Ig antibody classes yielded clearly inferior performance.
ASCA IgA subtyping assays revealed marked increase in the proportion of IgA2
subtype (29%) and presence of the secretory component (89% of total ASCA
IgA) concurrently.
Conclusion: Consideration of antibody classes is an important novel parameter in
serology-based prediction in CD. Involvement of gut mucosal immune system is
in center of IgA type antibody formation reflecting sustained exposure and dys-
regulated immunresponse to bacterial constituents.
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Introduction: Achievement of endoscopic healing is a key treatment goal in
patients with Crohn’s disease (CD). We previously reported that magnetic reso-
nance enterography (MRE) could exactly assess small bowel (SB) active lesions
such as ulcers using balloon assisted enteroscopy (BAE) reference [1, 2].
Aims & Methods: We aimed to evaluate whether MRE could predict patient
prognosis in prospective observational study. From July 2012 to December
2015, 139 CD patients in clinical and serological remission were followed up
after BAE and MRE procedure. Two endoscopists performed BAE and assessed
the endoscopic findings, while two radiologists assessed the MRE findings. Both
the endoscopists and radiologists were blinded to the patient’s clinical presenta-
tion and results of other studies. We used Simple Endoscopic Score for CD (SES-
CD) for endoscopic evaluation and Magnetic Resonance Index of Activity
(MaRIA) for MR evaluation. Endoscopic healing was defined as the absence
of ulcerative disease (SES-CDa5 5). Primary endpoints were clinical relapse and
serological relapse. The relationship between endoscopic SB lesions and end-
points was evaluated. Moreover, whether MRE findings could predict patient
outcomes was assessed.
Results: The median duration of follow-up was 27 months (range, 12–48).
Clinical and serological relapse occurred in 30 (21.6%) and 62 (44.6%)
patients, respectively. SB endoscopic healing (SES-CDa5 5) was achieved in
76 (54.7%) patients. Multiple regression analysis of BAE findings showed that
the absence of SB endoscopic healing (ulcerative disease; SES-CDa 5) was
an independent risk factor for clinical relapse (Hazard ratio [HR]¼ 4.78; 95%
CI: 1.94–11.80; P¼ 0.001) and serological relapse (HR¼ 2.84; 95% CI: 1.63–
4.95; P5 0.001), respectively. On Kaplan–Meier analysis, patients who did not
achieve endoscopic healing were at a significant risk of worse outcomes (clin-
ical relapse, P5 0.001; serological relapse, P5 0.001). MR ulcer healing
(MaRIA score 511) showed a high sensitivity (82.5%; 95% confidence inter-
vals [CIs]: 74.9%–88.2%) and specificity (85.5%; 95% CIs: 79.2%–90.2%) for
endoscopic healing. On Cox’s proportional hazards analysis, MRE findings of
ulcer healing were associated with a low risk of clinical relapse (Hazard
Ration [HR]: 0.24; 95% CIs: 0.111%–0.54%; P¼ 0.001) and serological
relapse (HR: 0.47; 95% CIs: 0.29%–0.78%; P¼ 0.003).
Conclusion: The absence of endoscopic healing (ulcerative disease) were seen in a
considerable number of CD patients who were in clinical-serological remission,
and these lesions were at risk factor for worse prognosis. MRE could evaluate SB
endoscopic healing with a high diagnostic accuracy and could predict patient
outcomes.
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Introduction: In Crohn’s disease (CD), accurate evaluation of location and small
bowel involvement are necessary at the time of diagnosis for prognostic concern
and planning of treatment strategy. Since Double Balloon Endoscopy (DBE)
enables us to examine deep small bowel either oral or anal it could be of great
utility in the management of Crohn’s disease patients.
Aims & Methods: We aimed to evaluate the diagnostic yield and therapeutic
impact of DBE on small bowel CD. The medical records of 180 CD patients,
from October 2009 to April 2015, were retrospectively analysed. Patients were
included if they had known CD based on clinical, colonoscopic and histological
findings and had been subjected to DBE. If one patient underwent more than one
DBE examination only the first evaluation was considered. The primary end
point of our study was to evaluate small bowel involvement that is beyond the
reach of conventional colonoscopy. The secondary endpoints were to determine
the impact of DBE findings on management strategy of CD. The diagnostic yield
of DBE in small bowel CD was determined. In addition, the changes in medical
treatment, endoscopic intervention and surgical procedures, within three months
after DBE, were analysed.
Results: Among 180 patients with CD, 90 patients underwent 168 DBE exam-
inations and were included. The mean age of included patients was 40 13.6
years. They were 63 males and 27 females. Eighty-two (91%) patients with
established CD underwent DBE for evaluation of small bowel involvement
and 8 (9%) patients underwent DBE because of suspicion of CD and had
been newly diagnosed. The overall diagnostic yield of DBE was 69%.DBE
revealed small bowel involvement proximal to the terminal ileum in 40
(64.5%) patients; of them 17 (42.5%) patients had isolated small bowel CD.
Within 3 months after DBE examination the management strategy of CD
changed in 47 (52.2%) patients, based on DBE findings. The medical treat-
ment escalated in 20 (32%) patients, and decreased in 7 (11%). Fourteen
(24%) patients underwent DBE-assisted balloon dilatation, and 6 (9.6%)
patients underwent CD-related surgery.
Conclusion: DBE is able to detect small bowel involvement in a significant pro-
portion of CD patients. The DBE findings modified the management strategy in
at least one half of CD patients.
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Introduction: Therapeutic adherence is crucial in the management of patients with
inflammatory bowel disease (IBD). Poor adherence may lead to suboptimal
control of the disease, decreased quality of life and increased health care costs.
Aims & Methods: 1) To evaluate the prevalence of non-adherence to treatment in
Spanish patients with IBD and 2) To identify factors associated with low,
medium and high adherence. We performed a cross-sectional study that included
consecutive patients with IBD attending our adult IBD clinic in a three-month
period. Consenting patients completed a survey performed by two researches not
involved in the care in our patients. Activity was assessed with Harvey-Bradhsaw
index in Crohn’s disease (CD) and Partial Mayo Score in Ulcerative colitis (UC).
Anxiety and depression were estimated by the Goldberg Anxiety and Depression
Scale and modified Morisky Medication Adherence Scale (MMAS-8) was used to
assess adherence (56, 6–7 and 8 points indicate low, medium and high adher-
ence, respectively). In statistical analyses, Chi-square and Student’s t-test were
used for side by side comparisons and logistic regression for multivariant
analysis.
Results: A total of 181 patients were evaluated. The median age was 47 16
years; 98 (54.1%) were males and 32 (17.7%) were active smokers. 82 (45.3%)
patients had CD and 99 (54.7%) had UC. The mean disease duration was
10.21 8.59 years. Most patients were in remission (87.8%). In relation to the
treatment, 35.9% were taking mesalazine, 2.8% steroids, 29.3% immunomodu-
lators and 30.4% biologics. The oral route was the most frequent (52.5%), fol-
lowing by rectal route (17.1%) and subcutaneous or intravenous (30.4%). Based
on MMAS-8, almost half of our patients 84 (46.4%) had high adherence to IBD
treatment, 56 (30.9%) had medium and 41(22.7%) had low adherence. In rela-
tion to factors associated with adherence, univariate analyses showed that
patients with high adherence were older (52.0 16.1 years vs. 42.5 14.4;
p5 0.001) and their disease had longer duration (12.2 9.7 years vs 8.5 7.1;
p¼ 0.004) than patients with medium/low adherence. However, smokers had a
low adherence (p¼ 0.007). Multivariate analysis confirmed that age was asso-
ciated with high adherence (OR:1.04, CI95% 1.01–1.06, p¼ 0.002) and being
smoker with low adherence (OR:3.47, CI95% 1.36–8.90, p5 0.01). Also, multi-
variate analysis showed that CD was associated with low adherence (OR:2.54,
CI95% 1.11–5.79, p5 0.05). Other factors as sex, anxiety, depression, quality of
life, disease activity, type of drugs or administration route were no significantly
associated with adherence.
Conclusion: Only active smoking and age were predictors of insufficient adher-
ence to drugs in IBD. Efforts for reinforce adherence should be especially direc-
ted to young patients. Quitting tobacco could improve adherence.
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Introduction: Magnetic resonance enterography is now recognized by the
European Crohn’s and Colitis Organization (ECCO) as a reference procedure
to assess the intestinal involvement of Crohn’s disease (CD), including extra-
mural complications, as well as to monitor patients under treatment. A new
MRI index of severity was developed in 2015 by the GETAID consortium,
specifically to evaluate lesions located in the small intestine. This score, labeled
CDMRIS (Crohn’s disease magnetic resonance index of inflammation severity),
considers, for each 20-cm small bowel segment, the intensity of relative contrast
enhancement (mild–moderate or severe), deep ulceration without fistula, ‘‘comb
sign’’, any fistula, and abscess. Although well standardized, this index has not yet
been validated, either for the initial assessment of CD at diagnosis, or for mon-
itoring patients under treatment. Its feasibility in routine practice has never been
tested.
Aims & Methods: The aims of this study were to evaluate the feasibility of
applying the CDMRIS score in clinical practice, to evaluate its variability after
the initiation or optimization of an anti-TNF treatment, and to measure its
correlation with an evaluation of clinical activity. Patients with known small
bowel CD who underwent two MRI examinations at a maximal interval of 30
months were included between 2010 and 2015. Each exam was interpreted twice
and the CDMRIS score was calculated on both exams in addition to classical
criteria. All patients had a clinical evaluation over time, separating them in two
groups: ‘‘active’’ and ‘‘inactive’’ disease.
Results: Seventy-two patients were included, with a mean CDMRIS of 3.4 at
baseline, decreasing to 2.6 (p¼ 0.052) independently of clinical disease activity.
The mean interval between the two MRIs was 15.4 months, and there was a
significant, larger decrease in the CDMRIS score when the interval was above 12
months. Two other radiological parameters decreased significantly: the rate of
patients with a mural T2-hyperintensity (36.1% to 20.8% p¼ 0.042), with a good
clinicoradiological correlation, and mean wall thickness (5.5 to 4.4mm,
p¼ 0.047).
Conclusion: This study demonstrated the feasibility of applying the CDMRIS in
clinical practice, but sensitivity was too low to detect early changes. Accuracy for
a long-term monitoring needs to be evaluated. Wall thickness and mural T2-
hyperintensity emerged as two sensitive radiological factors, significantly asso-
ciated with the disease activity, allowing monitoring of the short-term efficacy of
biotherapies.
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Introduction: Crohn’s Disease Activity Index (CDAI) has been shown to correlate
poorly with endoscopic measures of mucosal inflammation/ulceration.1, 2 There
is a movement towards using components of the CDAI, namely stool frequency
(SF) and abdominal pain (AP), rather than the total score, to evaluate a patient’s
disease activity in registration trials. This post hoc analysis assessed the associa-
tion between individual components of the CDAI with the Simple Endoscopic
Score for Crohn’s Disease (SES-CD) from EXTEND.
Aims & Methods: All patients randomized in the EXTEND study3 with both
CDAI and SES-CD values at the time point evaluated (week 12 and week 52)
were analyzed. Correlations between SES-CD and CDAI, SES-CD and indivi-
dual components of CDAI, and mean changes from baseline in both SES-CD
and CDAI were assessed at weeks 12 and 52 using Pearson correlation coeffi-
cient. Endoscopies were scored by a central reader. Data are reported as
observed.
Results: A total of 121 patients at week 12 and 80 patients at week 52 had both
CDAI and SES-CD values. Mean (SD) CDAI and SES-CD values at week 12
were at 193.8 (116.4) and 8.0 (7.4), respectively, and 132.5 (97.6) and 5.9 (6.6),
respectively, at week 52. A significant, but weak correlation was observed
between CDAI and SES-CD at week 12 (r¼ 0.31 [P5 0.001]) and at week 52
(r¼ 0.31 [P¼ 0.005]). Similar results were observed for correlations between
mean changes from baseline in CDAI and SES-CD at weeks 12 (r¼ 0.35
[P5 0.001]) and 52 (r¼ 0.31 [P¼ 0.005]). Correlations between individual com-
ponents of CDAI and SES-CD at weeks 12 and 52 are shown in the table. SF,
AP, extra-intestinal manifestations, and SFþAP were significantly correlated
with SES-CD at week 12; the strongest correlation was for SF (r¼ 0.46) and
the addition of AP to SF did not increase the correlation (Table). At week 52, SF,
hematocrit, and SFþAP were significantly correlated with SES-CD. At week 12,
the correlation of SES-CD with SF was similar regardless of whether the patient
had disease of the ileum (r¼ 0.44 [P5 0.001] with ileal disease; r¼ 0.48
[P5 0.001] without ileal disease), while SES-CD correlated more strongly with
AP in those with ileal disease (r¼ 0.27 [P¼ 0.036]) than those without ileal dis-
ease (r¼ 0.16 [P¼ 0.233]).
Table: Correlation of components of the CDAI with SES-CD
Variable
Week 12 n¼ 121 Week 52 n¼ 80
Mean (SD) r P-value Mean (SD) r P-value
Stool frequency* 47.1 (35.2) 0.46 50.001 33.7 (32.1) 0.35 0.002
Abdominal pain 41.0 (29.6) 0.21 0.020 21.8 (25.6) 0.06 0.597
General well-being 63.3 (50.2) 0.16 0.073 42.2 (46.7) 0.17 0.123
Extra-intestinal manifestations 14.0 (16.3) 0.22 0.017 11.5 (13.8) 0.11 0.317
Diarrhea/pain medications 3.2 (9.3) 0.01 0.927 1.9 (7.3) 0.08 0.465
Abdominal mass 0.8 (4.0) 0.50 0.588 0.0 (0.0) NA NA
HCT 21.1 (21.3) 0.09 0.355 17.7 (20.6) 0.40 50.001
Weight (kg) 3.2 (6.1) 0.03 0.770 3.8 (7.0) 0.07 0.568
Stool frequencyþAbdominal pain 88.1 (56.6) 0.40 50.001 55.5 (48.1) 0.26 0.018
*the number of liquid or very soft stools per day. SES-CD, Simple Endoscopic
Score for Crohn’s Disease. HCT, hematocrit. NA, not applicable.
Conclusion: Data from patients with moderate to severe CD and evidence of
mucosal ulceration in EXTEND supported previous findings that the CDAI
was only weakly correlated with SES-CD, as assessed at 12 and 52 weeks.
Only SF was significantly correlated with SES-CD at both time points. At 12
weeks, the correlation of SES-CD with SF was not affected by the presence of
ileal disease, while correlation with AP was stronger with ileal disease than with-
out it.
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Introduction: Crohn’s disease (CD) with complications such as penetrating, struc-
turing, and perianal disease are called complicated CD. However, no validated,
inexpensive, or sensitive models for prediction of risk are available in compli-
cated CD. We have found that a novel immunological balance, the CD8þCD28þ/
CD8þCD28, consisting of CD8þCD28þ and CD8þCD28 T cells, can predict
the prognosis for patients with inflammatory bowel disease (IBD). Thus, we
hypothesize that the CD8þCD28þ/CD8þCD28 balance (ratio) can predict the
poor outcome for patients with complicated CD.
Aims & Methods: To test the efficiency of CD8þCD28þ/CD8þCD28 balance to
predict a subsequent active stage, and to explore the correlation between the
balance and the risk factors, for the newly diagnosed complicated CD.
Seventeen patients with complicated CD were enrolled as the observation
group, while the other 48 CD patients with no complications were enrolled as
the control group. Peripheral blood samples were drawn from all the 65 newly
diagnosed CD patients for CD8þ T cells testing through flow cytometry (FCM)
when enrolling. The potential risk factors, including demographic, pathophysio-
logical, and therapeutic factors were compared between the two groups. A 30-
week follow-up was performed and the CD8þ T cells testing were repeated. The
sensitivity and specificity of the CD8þ T cells’ level and balance in predicting
were analyzed through receiver operator characteristic (ROC) curves. The cumu-
lative remission lasting rates (CRLRs) under the different risk factors were ana-
lyzed using the Kaplan–Meier method.
Results: I. Risk factors: compared with the control CD group, patients with
complicated CD had a larger proportion in male (P¼ 0.001), younger in age
(P¼ 0.019), lower body mass index (BMI) (P5 0.0001), higher Crohn’s disease
activity index (CDAI) (P5 0.0001), higher prescription rates in immunosuppres-
sants (P¼ 0.029) and steroids (P¼ 0.015), as well as a significant higher surgical
rate (P5 0.0001). Pearson and Spearman correlation analysis showed that
CD8þCD28þ/CD8þCD28 balance was associated with BMI, CDAI, steroids,
and surgery (all P5 0.005). II. Follow-up and dynamic changes of the balance:
the ratios of CD8þCD28þ/CD8þCD28 reached the bottom at the 30th week and
were significantly lower at the 0, 6th, 22nd, and 30th week during follow-up, in the
complicated CD patients when compared to the control ones (all P5 0.05). A
shorter lasting time of remission (LTR) was found in complicated CD patients
(P¼ 0.044). ROC curve showed that CD8þCD28þ/CD8þCD28 ratio could
accurately predict the active stage for the complicated CD patients [with area
under curve (AUC) of 0.890, and 95% CI of 0.822 to 0.958], and the best
sensitivity of 89.2% and specificity of 85.3% were found when the ratio was
1.03. III. Kaplan–Meier analysis: Undergoing of steroids and surgery was closely
related to worse outcome for the complicated CD patients, and patients who
underwent steroids and surgery had the significantly lower CD8þCD28þ/
CD8þCD28 ratio and lower CRLRs (all P50.05).
Conclusion: Depending on steroids and surgery stands for a more severe disease
activity and thus disequilibrate the immunological balance, which could be the
main reason for lower CD8þCD28þ/CD8þCD28 ratio, and this ratio can pre-
dict the active stage sensitively for patients with complicated CD. More strategies
should be taken when the ratio is to be lower than 1.03.
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Introduction: Successful colonoscopy requires effective bowel cleansing.
NER1006 is the first 1L polyethylene glycol (PEG)-based bowel preparation, a
patented combination optimised for effective bowel cleansing. The MORA study
was a multicentre randomised Phase 3 clinical trial using blinded central readers
to assess the cleansing efficacy of the overall colon and high-quality cleansing of
the ascending colon by NER1006 vs standard 2L PEG with ascorbate (2L
PEGþAsc) [1]. This post hoc analysis shows the cleansing assessment by site
colonoscopists, who typically guide clinical decision-making; hence this analysis
may be more relevant for clinical practice than previous analyses.
Aims & Methods: In the MORA study 849 patients (males and females, aged 18–
85) were randomly assigned in a 1:1:1 ratio to receive i) NER1006 in an evening/
morning split-dose (N2D), or ii) NER1006 in a morning-only dose (N1D) or iii)
2L PEGþAsc in an evening/morning split-dose. The 796 subjects who under-
went a colonoscopy and were assessed by a treatment-blinded site colonoscopist
were included in this analysis. Cleansing was assessed according to the Harefield
Cleansing Scale [2]; following segmental scoring, cleansing of the overall colon
was graded from A to D; grades A and B were judged as successful cleansing.
Cleansing of the ascending colon and caecum was scored from 0 to 4; scores of 3
and 4 were judged as high-quality cleansing.
Results: The bowel preparation quality of NER1006 showed a statistically sig-
nificant improvement over 2L PEGþAsc for the overall colon when both treat-
ments were administered as an evening/morning split-dose (P¼ 0.003; 95% CI:
2.0–10.1%) (Table 1). NER1006 administered either as an overnight split-dose or
morning-only dose produced high-quality cleansing of the ascending colon in a
statistically significantly higher proportion of patients compared to 2L
PEGþAsc (P5 0.001; 95% CI: 7.2–23.1% and P5 0.001; 95% CI: 7.2–
23.0% respectively). The morning-only dose showed no difference compared to
2L PEGþAsc as an evening/morning split-dose for overall colon cleansing qual-
ity (P¼ 0.924; 95% CI: 5.1–4.6%). Table 1. A comparison of bowel cleansing
efficacy as assessed by site colonoscopists between NER1006 (administered in a
N1D or N2D regimen) or 2L PEGþAsc.
Conclusion: Colonoscopists assessed both dosing regimens of NER1006 as having
a significantly increased rate of high-quality cleansing of the ascending colon
when compared with 2L PEGþAsc; this cleansing is important in ensuring
the detection of lesions in the ascending colon. When comparing similar over-
night split-dose treatment regimens, NER1006 showed a significantly increased
rate of overall bowel cleansing compared to 2L PEGþAsc.
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Introduction: The success of colonoscopy is dependent on efficient bowel
cleansing. Inadequate bowel cleansing may decrease diagnostic sensitivity,
necessitate repeat procedures and potentially delay appropriate treatment.
The increasing frequency of the incidence of colorectal cancer arising in the
ascending colon necessitates effective cleansing of this area; additionally these
cancers are often associated with poorer prognoses. Data suggest that detec-
tion in the ascending colon is more dependent on higher grades of cleansing,
perhaps due to the nature of polyps present, which may be more likely to be
sessile or serrated. NER1006 is the first 1L polyethylene glycol (PEG)-based
bowel preparation, a patented combination optimised for effective bowel
cleansing. The NOCT study (a multicentre randomised Phase 3 clinical trial
investigating bowel cleansing efficacy of NER1006 vs trisulfate solution)
reported bowel preparation quality assessed by central readers.1 This post
hoc analysis shows the cleansing assessment by site colonoscopists, who typi-
cally guide clinical decision making; hence this study may be more relevant for
clinical practice than previous studies.
Aims & Methods: In the NOCT study 621 patients (males and females, aged 18–
85) were randomly assigned in a 1:1 ratio to receive either NER1006 or trisulfate
solution, each administered as an overnight split-dose. Data from the 523
patients who underwent a colonoscopy and had a site colonoscopist assessment
were used in this analysis. Colonoscopists were blinded to the preparation admi-
nistered. Cleansing was assessed according to the Harefield Cleansing Scale;2
following segmental scoring, cleansing of the overall colon was graded from A
to D; grades A and B were judged as successful cleansing. Cleansing of the
ascending colon was graded from 0 to 4; grades 3 and 4 were judged as high-
quality cleansing.
Results: As Table 1 shows, the bowel preparation quality of NER1006 when
assessed by site colonoscopists did not show a statistically significant difference
to trisulfate for the overall colon (93% vs 94%, P¼ 0.681; 95% CI: - 5.1–3.3%)
or ascending colon (80 vs 74%, P¼ 0.079; 95% CI: 0.7–13.6%). There was,
however, a numerical advantage in favour of NER1006 on the proportion of
patients achieving high-quality cleansing success in the right colon.
Table 1: Successful colon cleansing rates when treated with NER1006 or tri-
sulfate solution.
Bowel
preparation N
Patients with
successful
cleansing n (%) Difference (%) P-value 95% CI (%)
Overall colon
NER1006 259 241 (93) 1 0.681 5.1–3.3
Trisulfate 264 248 (94)
Ascending colon
NER1006 259 208 (80) 6 0.079 0.7–13.6
Trisulfate 264 195 (74)
N.B. successful cleansing defined here as a Harefield Cleansing Scale grade of A
or B (overall colon) or 3 or 4 (ascending colon, high quality)
Conclusion: For both preparations, site colonoscopist findings demonstrated
similar very high rates of cleansing success for the overall colon (493%) and
high rates of high-quality cleansing of the ascending colon (473%), however,
statistical significance was not met in either comparison. The rates of cleansing
success in the ascending colon reported by the site colonoscopists are notably
higher than those previously reported by central readers.
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Introduction: The efficacy of colonoscopy is dependent on the quality of bowel
cleansing. NER1006 is the first 1L polyethylene glycol (PEG)-based bowel
cleansing solution and is a patented combination optimised for effective bowel
cleansing. The DAYB study was a European multicentre, randomised trial that
tested the hypothesis that NER1006 would be non-inferior to sodium picosulfate
and magnesium citrate (NaPicþMgCit) in terms of overall bowel cleansing and
high-quality cleansing of the ascending colon plus caecum [1]. Bowel cleansing
was assessed using the Harefield Cleansing Scale (HCS) [2]. The primary end-
points of the study were assessed by video review by a central reader. Bowel
cleansing on the HCS was also assessed by the site colonoscopist and this post
hoc analysis assessed the cleansing grades as determined by the site
colonoscopists.
Aims & Methods: In the DAYB study, 515 patients (aged 18–85, median age: 55.0
years) underwent screening, surveillance, or diagnostic colonoscopy and were
randomly assigned in a 1:1 ratio to receive either NER1006 or NaPicþMgCit,
each on the day before colonoscopy. In this analysis, data from 479 patients who
underwent a colonoscopy and had a completed assessment by the site colonos-
copist were included. Colonoscopists were blinded to the preparation adminis-
tered. Cleansing was assessed according to the HCS; cleansing of each segment of
the colon was scored from 0 to 4. Scores 3 and 4 of the ascending colon were
judged as high-quality cleansing. Cleansing of the overall colon was graded from
A to D; grades A (all segments scored 3 or 4) and B (1 segments scored 2, no
sections scored 1 or 0) were judged as successful cleansing.
Results: As indicated in Table 1, in the overall colon, successful cleansing was
achieved in 12% more patients who received NER1006 than who received
NaPicþMgCit (73% vs 61%, P¼ 0.003, 95% CI: 4.0–20.7). In the ascending
colon, high-quality cleansing was achieved in 20% more patients who received
Abstract No: P0343
NER1006 N2D 2L PEGþAsc NER1006 N1D 2L PEGþAsc
Overall colon
N 263 263 270 263
Patients with successful cleansing N (%) 255 (97) 239 (91) 246 (91) 239 (91)
Difference (%) 6 0
P-value 0. 003 0. 924
95% CI (%) 2.0–10.1 5.1–4.6
Ascending colon and caecum
N 263 263 270 263
Patients with successful (high quality) cleansing N (%) 196 (74) 156 (59) 201 (75) 156 (59)
Difference (%) 15 16
P-value 50.001 50.001
95% CI (%) 7.2–23.1 7.2–23.0
N.B. successful cleansing defined here as a Harefield Cleansing Scale grade of A or B (overall colon) or score of 3 or 4 (ascending colon, high quality)
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NER1006 than who received NaPicþMgCit (34% vs 14%, P5 0.001, 95% CI:
12.7–27.8).
Table 1: A comparison of bowel cleansing efficacy as assessed by site colonos-
copists between NER1006 and NaPicþMgCit
Bowel
preparation N
Patients with
successful
cleansing n (%) Difference (%) P-value 95% CI
Overall colon
NER1006 236 173 (73) 12 0.003 4.0–20.7
NaPicþMgCit 243 148 (61)
Ascending colon
NER1006 236 82 (34) 20 50.001 12.7–27.8
NaPicþMgCit 243 35 (14)
N.B. successful cleansing defined here as a Harefield Cleansing Scale grade of A or
B (overall colon) or score of 3 or 4 (ascending colon, high quality)
Conclusion: NER1006 was shown to provide significantly better cleansing of the
overall colon and high-quality cleansing of the ascending colon compared to
NaPicþMgCit, when both treatments were administered the day before colono-
scopy. The cleansing efficacy rate of the comparator was within its previously
reported cleansing rates for day before administration, suggesting the improve-
ment seen with NER1006 is of clinical relevance.
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Introduction: Several studies in recent decades have revealed new roles for vita-
min D. For example, vitamin D plays a role in regulating skeletal muscle, as well
as in cardiovascular and renal physiology, producing anticancer effects, suppres-
sing fibrosis, and as a regulator of the immune system. In light of these new
roles—especially as a regulator of the immune system and suppressor of fibro-
sis—vitamin D deficiency is considered to be related to disease activity and
intestinal fibrosis, including that seen in Crohn’s disease (CD). Several reports
have demonstrated a relationship between vitamin D deficiency and CD activity
according to clinical parameters such as Crohn’s disease activity index (CDAI)
and quality of life (QoL). However, no reports have demonstrated this relation-
ship by using endoscopic parameters such as endoscopic activity, mucosal inflam-
mation, and intestinal fibrostenosis.
Aims & Methods: The aim of this study was to clarify the relationship between
vitamin D deficiency and CD by using endoscopic parameters, as well as clinical
parameters. Of the CD patients visiting Nagoya University Hospital from May
2011 to February 2016, 82 patients were enrolled in this study. Serum 25-hydro-
xyvitamin D (25[OH]D) levels, disease activity, and clinical factors of the subjects
were investigated prospectively. Endoscopic findings of 52 of the 82 total patients
enrolled were investigated retrospectively from endoscopic records. This study
design was approved by the ethics committee of Nagoya University Hospital.
Clinical remission was defined as CDAI 150. Mucosal healing was defined as a
simple endoscopic score for Crohn’s disease (SES-CD) 1. Moreover, to evaluate
endoscopic activity from two aspects (mucosal inflammation and fibrotic steno-
sis), we divided SES-CD score into endoscopic ‘‘mucosal inflammation score’’
and ‘‘narrowing score’’. No mucosal inflammation was defined as mucosal
inflammation score 1, fibrostenosis was defined as narrowing score 0. The
primary endpoint of this study was the relationship between 25(OH)D and clin-
ical activity. Secondary endpoint was the relationship between 25(OH)D and
endoscopic findings, including mucosal healing, mucosal inflammation, and
intestinal fibrostenosis.
Results: Mean age of the subjects was 41.1l, and the male/female proportion was
64/18. The mean serum 25(OH)D level of subjects was 17.1 ng/mL, and 61 cases
(74.4%) were classified as severe deficiency or deficiency. Mean serum 25(OH)D
levels of the clinical remission and clinically active groups were 18.7 8.1 ng/mL
and 12.4 3.6 ng/mL, respectively (P5 0.001). In a multivariate analysis, low
levels of serum 25(OH)D and serum albumin and positive C-reactive protein
(CRP) results were correlated with clinical activity. Mean serum 25(OH)D
levels of the mucosal healing and no mucosal healing groups were
24.0 9.8 ng/mL and 15.1 6.6 ng/mL, respectively, (P5 0.001). Mean serum
25(OH)D levels for the no mucosal inflammation and mucosal inflammation
groups were 21.6 9.6 ng/mL and 14.3 5.5 ng/mL, respectively, (P5 0.001);
and those of the no fibrostenosis and fibrostenosis groups were 20.2 8.9 ng/
mL and 14.2 6.7 ng/mL, respectively, (P5 0.001; Mann-Whitney U test). In a
multivariate analysis, low serum 25(OH)D levels were related with mucosal
inflammation and intestinal fibrotic stenosis of CD (P5 0.05;logistic regression
analysis).
Conclusion: This study demonstrated the relationship between vitamin D level
and disease activity in CD patients. The disease pathology of CD consists of
repetitive intestinal inflammation and intestinal fibrostenosis formed during heal-
ing of the inflammation. We consider it important to demonstrate this relation-
ship not only using clinical parameters, but also using endoscopic parameters
such as mucosal inflammation and intestinal fibrostenosis.
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Introduction: Inflammatory Bowel Disease (IBD), mainly represented by Crohn’s
Disease (CD) and Ulcerative Colitis (UC), is a chronic, relapsing and remitting
disease impairing patients’ quality of life (QOL). To maintain a high QOL and to
decrease the inflammation burden, it is important to tightly monitor the disease
and promptly treat relapses when they occur. The quality of care perceived by
IBD patients play an important role in the management of IBD. An eHealth web
application consisting of a validated Fecal Calprotectin (FC) home testing kit
(Calpro SmartTM), questionnaires regarding disease activity and QOL has been
developed to improve disease monitoring, patient empowerment and patient-
caregiver communication.
Aims & Methods: The aim of this study was to evaluate patient satisfaction with
an eHealth home monitoring solution during the participation in a one year trial.
The trial includes 120 adult IBD patients which have been randomized into two
groups; one performing a disease activity screening procedure every 3 months
(3M) and one screening only at the patient’s discretion, on demand (OD). Both
groups used the web-program where they were requested to fill out a disease
activity questionnaire, Harvey-Bradshaw Index (HBI) for CD or Simple Clinical
Colitis Activity Index (SCCAI) for UC, and perform a home testing of FC. The
results from disease activity questionnaire and FC score are combined in the web-
program rendering a Total Inflammation Burden Scoring (TIBS) which is visua-
lized to the patient in a traffic light manner for instant recommendation of
individualized treatment strategies. At baseline and upon completion of the
trial the patients were requested to fill out a QOL questionnaire (Short-
Inflammatory Bowel Disease Questionnaire (s-IBDQ)) as well as a questionnaire
regarding their overall satisfaction with the trial and the home monitoring
solution.
Results: To date, 83 patients have been included, 15 patients have dropped out (7
in OD-group and 8 in 3M-group) and 68 (3M-group: n¼ 32, 47%; OD-group:
n¼ 36, 53%) patients have fulfilled the first year of follow-up and were included
in the analysis. The trial lived up to the expectations in n¼ 63, 93% (3M-group:
n¼ 29, 91%; OD-group: n¼ 34, 94%) of the patients and the support given to
the patients was estimated to be sufficient by n¼ 67, 99% (3M-group: n¼ 31,
97%; OD-group: n¼ 36, 100%). Only n¼ 14, 21% (3M-group: n¼ 6, 19%; OD-
group: n¼ 8, 22%) of the patients experienced difficulties with the application or
the home testing kit and n¼ 64, 94% (3M-group: n¼ 29, 91%; OD-group:
n¼ 35, 97%) wanted to continue to be monitored in an eHealth setting in the
future. The mean s-IBDQ scores at baseline were 58 (95% CL: 55–61) in the 3M-
group and 54 (95% CL: 50–58) in the OD-group as well as 58 (95% CL: 54–62) in
the 3M group and 61 (95% CL: 58–64) in the OD group at one year follow up.
No difference in s-IBDQ measured QOL was found between the two groups.
However, patients in the OD group had a significant increase in mean S-IBDQ
score at follow up (p¼ 0.04).
Conclusion: Patients in both groups were generally satisfied by the home mon-
itoring set up. Patients in the on-demand group also presented a significant
increase in quality of life over time.
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Introduction: Inflammatory bowel diseases (IBD), such as ulcerative colitis (UC)
and Crohn’s disease (CD), are chronic gastrointestinal diseases that are asso-
ciated with protein-energy malnutrition (PEM). Although the frequency of
altered body composition, such as reduced fat-free mass or skeletal muscle
volume, has been shown to be high in patients with IBD, the relationships
between skeletal muscle volume and the prognosis are yet to be elucidated.
Aims & Methods: We have conducted a retrospective study on 61 IBD patients
who have admitted due to exacerbation of the disease. We have enrolled IBD
patients who had abdominal computed tomography and assessed the nutritional
indices, such as the Onodera’s prognostic nutritional index (O-PNI) and control-
ling nutritional status (CONUT). O-PNI was calculated based on the serum
albumin and total lymphocyte count, using the following equation: O-
PNI¼ 10	 [serum albumin (g/dl)þ 0.005	 total lymphocyte count (/ml)]. The
L3 skeletal muscle index (SMI) which is the cross-sectional area of the skeletal
muscle at the level of the third lumbar (L3) vertebra normalized by the height
squared is used to identify sarcopenia.
Results: Sarcopenia defined as low SMI were observed in 44% of all IBD patients
(29% in CD, 54% in UC). In UC patients, the O-PNI, CONUT, height and
albumin were significantly lower than the CD patients. Spearman’s rank correla-
tion revealed that the SMI has a strong correlation to body weight and O-PNI in
IBD patients. Multivariate analysis using Cox regression model demonstrated the
presence of sarcopenia (P¼ 0.022), disease type (CD or UC) (P¼ 0.034), and C-
reactive protein (P¼ 0.047) were the significant factors predicting intestinal resec-
tion. The cumulative operation-free survival rate was significantly lower among
sarcopenic patients in all IBD patients (P¼ 0.039) and stratified analysis in CD
patients (P¼ 0.032) using Kaplan-Meier method and log-rank test.
Conclusion: The L3 skeletal muscle area can be a prognostic factor of intestinal
resection in IBD, especially in CD. The results may originate from the fact that
CD presents the gastrointestinal diseases which accumulate intestinal deformity.
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Introduction: Crohn’s Disease (CD) spans a wide range of severity, from mild to
severe. To avoid under- as well as overtreatment is challenging. While factors
determining bad prognosis are studied in detail, factors predicting a mild course
with the chance of simple treatments are less known. Here we show first results of
a prospective evaluation of a retrospectively created score (JCC 2013;7:e263) for
prediction of mild CD which consists of age at diagnosis, CRP, an endoscopy
score, presence of perianal lesions and complications.
Aims & Methods: This is a prospective, ongoing study performed in 12 IBD-
specialized private gastroenterology practices (outpatients only) in Germany. All
consecutive newly diagnosed CD patients (diagnosis 6 weeks) are included. At
screening ileocolonoscopy with histology, investigation of the perianal area,
laboratory tests including CRP are performed and CD complications (stenosis,
fistula, extraintestinal manifestations or fever 438C) evaluated to complete of
the above quoted score. Patients are treated at the discretion of the physician. In
case of a score indicating a good prognosis (2) or of mild clinical appearance
mesalamine is started. In all other cases patients are treated according to guide-
lines. 5 year follow up is planned for all patients. If initial therapy fails, treatment
is escalated. Source data verification is performed by external monitors. Primary
aim of the study is to confirm the previously identified score and to test its power
to predict a mild disease course as indicated by the need of not more than
mesalamine therapy. Additional analyses include the percentage of patients
with a score indicating a severe disease and their characteristics at diagnosis.
This interim analysis presents preliminary data.
Results: Currently, 78 patients (33 male, 45 female; age 16–72, mean 35 years)
with newly diagnosed CD are enrolled. 56 CD-patients with follow up 8 weeks
(mean 8.5 months), mean age 35 years, 35 female, 21 male, mean CRP 12.2mg/l
were included into the interim analysis. In 28 patients with a score from 0–2 step-
up treatment occurred in 7%, whereas in 28 patients with a score 42, step-up
rate was 43% (p¼ 0.0043). Differences between patients with a score 0–2 and42
were age (41 vs. 28 years, p¼ 0.0011), CRP 52mg/l (17/28 patients vs. 0/28,
p5 0.0001), endoscopic score 1.4 vs. 2.7, p5 0.0001), perianal lesions 0/28 vs. 4/
28, stenosis 1/28 vs. 6/28. There were no differences in terms of sex, fistula,
extraintestinal manifestations and fever.
Conclusion: In this early analysis of a prospective study planned with a 5-year
follow-up a significant proportion of patients with mild CD and simple mesala-
mine therapy can be identified. These initial results encourage to continue and
expand this prospective long-term study on the predictability of a mild CD
course.
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Sangrador2, G. Rascarachi1, L. Julian Gómez1, C. Bailador1, E. Martı́n1,
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Introduction: The Spanish Working Group on Crohn’s Disease and Ulcerative
Colitis (GETECCU) and other international guidelines recommend testing of
latent tuberculosis infection (LTI) before anti TNF therapy by screening with
tuberculin skin test (TST) and, in a potential state of anergy, double screening by
TST and interferon-gamma release assays (IGRAs) or two-time tuberculin test
(TST/booster). Routine repetition is not recommended.
Aims & Methods: We aimed to assess the correlation between (TST/booster) and
IGRAs using QuantiFERON-TB (QFT) and the usefulness of repeating periodic
(annual or biannual) screening in a population of IBD patients of Zamora
(Spain). In a single cohort of IBD patients attended in the department of gastro-
enterology of Zamora Hospital, we implemented a questionnaire and collected
TST/booster performed previously to February 2015. Afterwards, prospectively,
between February 2015 to February 2017, TST and QFT were performed at the
same day, and the TST/booster 7 days after. Finally we compared the results of
the LTI screening performed prospectively with the screening of the retrospective
cohort.
Results: A total of 404 patients were included with a mean age of 51.5 (SD 16.6),
225 (55.7%) male and 179 (44.3%) female. 227 patients (56.2%) were ulcerative
colitis, 167 (41.3%) were Crohn disease and 10 (2.5%) were diagnosed of inde-
terminate colitis. 160 patients live in rural areas (40.6%). 60/355 (16.9%) were
smokers. The prevalence of LTI and the correlation between TST/booster and
QFT is shown in table 1.
Table 1: Prevalence of LTI and correlation between TST/booster and QFT.
Prevalence of LTI
Prevalence of LTI
in patients on
immunomodulator
treatment
Prevalence of
LTI in patients
on anti-TNF
therapy
TST/booster or QFT (þ) 130/399 (32.6%)
(95% CI [27.8–37.3%])
47/239 (28.5%) 9/49 (18.4%)
TST/booster positives 116/371 (31.3%) 40/163 (24.5%)
TST ()/booster (þ) 28/272 (10.3%) 12/135 (8.9%) 3/42 (7.1%)
QFT positives 40/264 (15.5%) 6/105 (5.7%) 0/12
TST/booster()/QFT (þ) 12/264 (4.5%) 3/89 (0.8%) 0/11
TST/booster(þ)/QFT() 24/370 (6.4%) 4/162 (2.4%) 3/49 (6.1%)
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Prevalence of LTI in retrospective testing was of 54/246 (22.0%). Prospective
testings were positive in 72/261 (27.6%). During the follow up, 30/191 (15.7%)
patients who were negative for screening before 2015 were converted in positive
for LTI (95% CI [10.2–21.1]).
Conclusion: The prevalence of LTI in our area is high (32.6%). The simultaneous
performance of the TST/booster and QFT increases the detection of LTI. The
TST/booster increases the detection of LTI even when is performed in patients
without immunosuppressive treatments, in whom is not routinely recommended.
The QFT is more useful in patients without immunosuppressive therapy. The
repeated screening (annual or every two years) is useful in this population with
high prevalence of LTI, since it may detect LTI in patients with previous nega-
tives test (15.7%). The TST/booster is essential due to the possible false negatives
of QFT when screening patients on anti-TNF therapy.
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Introduction: Magnetic resonance enterography (MRE) and capsule endoscopy
(CE) are prime modalities for evaluation of small bowel in patients with Crohn’s
disease (CD). However, detection of proximal (jejunum and proximal ileum)
small bowel inflammation by MRE is challenging. Current quantitative scores
such as Magnetic Resonance Index of Activity (MaRIA) do not incorporate
proximal small bowel data and were validated against ileocolonoscopy.
Magnetic resonance enterography global score (MEGS) was designed for quan-
titative evaluation of the entire digestive tract; however, it was only validated
against ileocolonoscopy and its accuracy in the proximal small bowel was not
assessed. CE allows for accurate assessment of the entire small bowel and is the
modality of choice for evaluation of the proximal small bowel.
Aims & Methods: We aimed to compare the quantitative evaluation of the small
bowel inflammation by MEGS score and the Lewis capsule endoscopy score.
Patients with known quiescent small bowel (CD) for at least 3 months
(CDAI5 150) were prospectively recruited and underwent magnetic resonance
enterography (MRE) and capsule endoscopies (CE). MEGS score was calculated
for each bowel segment and the entire small bowel. MEGS is based on the
involved segment length, wall thickness, mural enhancement, mural and peri-
mural edema and extra-intestinal findings. In addition, MARIA score was cal-
culated for the terminal ileum. Small bowel inflammation on CE was quantified
using the Lewis score (LS) (LS5 135- mucosal healing; LS 790 – moderate to
severe inflammation). Proximal small bowel was defined as jejunum and duode-
num on MRE and as 1st and 2nd tertiles LS on CE. Distal small bowel was
defined as terminal ileum on MRE and 3rd tertile LS on CE. Fecal calprotectin
(FCP) levels were measured and correlated with all scores.
Results: Fifty-two patients were included in the study. There was a strong corre-
lation between MEGS and LS (Pearson correlation -r¼ 0.61. p¼ 0.001) for the
entire small bowel. In the proximal small bowel, the correlation was moderate
(for duodenum vs LS 1st tertile and proximal ileum vs 2nd tertile LS - both
r¼ 0.54, p¼ 0.001). In the terminal ileum, there was a strong correlation between
MEGS and MaRIA score (r¼ 0.74, p¼ 0.001) while both MRE based scores
were moderately correlated with 3rd tertile LS (r¼ 0.5, p¼ 0.001 for both). The
correlation with FC was stronger for MEGS (r¼ 0.68 p¼ 0.001) than for MaRIA
(p¼ 0.40 p¼ 0.01) or for LS (r¼ 0.38, p¼ 0.02).
Conclusion: MEGS score provides accurate evaluation of the small bowel in CD
and is strongly correlated with FC levels; the main advantage of MEGS is the
accurate quantification of proximal small bowel inflammation that is unavailable
for other quantitative MRE scores.
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Introduction: Small-bowel capsule endoscopy (CE) is a prime modality for eva-
luation of the small bowel. The Lewis score (LS) and the Capsule Endoscopy
Crohn’s Disease Activity Index (CECDAI) are validated endoscopic indices for
quantification of small bowel inflammation on CE. It is unclear whether these
indexes are interchangeable for evaluation of mucosal inflammation in estab-
lished Crohn’s disease (CD).
Aims & Methods:We aimed to prospectively compare the quantitative evaluation
of the small bowel inflammation by both scores. Patients with known quiescent
small bowel (CD) for at least 3 months (CDAI5 150) were prospectively
recruited and underwent CE. LS was calculated using the capsule reading soft-
ware (RAPID 8) and CECDAI was calculated manually, by 2 independent
experienced gastroenterologists (one for each score) unaware of each other’s
results. Mucosal healing was defined as LS5 135; LS 790 signified moderate
to severe inflammation. Fecal calprotectin (FCP) and C-reactive protein (CRP)
levels were measured and correlated with the scores.
Results: Fifty patients were included in the study. There was a strong correlation
between LS and CECDAI (Pearson’s r¼ 0.67, p¼ 0.001). CECDAI5 7.2 corre-
sponded to mucosal healing (LS5 135), while CECDAI4 11.1 corresponded to
moderate to severe inflammation (LS 790) by linear regression. There was a
moderate correlation between both scores and FCP levels that was somewhat
stronger for CECDAI (r¼ 0.39, p¼ 0.002 vs r¼ 0.53, p¼ 0.001 for both). There
was a weak correlation between LS and CRP levels (r¼ 0.27, p¼ 0.04) and none
for CECDAI and CRP (r¼ 0.21, p¼ 0.1).
Conclusion: In our prospective study, CECDAI and LS strongly correlated and
performed similarly for quantitative assessment of mucosal inflammation in
established CD.
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Introduction: Screening for latent tuberculosis infection (LTBI) is mandatory
prior to initiating anti-tumor necrosis factor (anti-TNF) medications. New guide-
lines recommend interferon-gamma release assays as first line screening method
for the general population. Studies have provided conflicting evidence on the
performance of interferon-gamma release assays (IGRAs), compared to tubercu-
lin skin test (TST) in inflammatory bowel disease (IBD) patients. We assessed the
concordance of these two tests in IBD patients and the effect of immunosuppres-
sion on their performance.
Aims & Methods: We performed a systematic search of MEDLINE, EMBASE
and Cochrane Library databases, from 2011 to 2016, for relevant studies testing
both TST and IGRA in IBD patients. The primary outcome was concordance
between TST and IGRA. Secondary outcomes were effects of immunosuppres-
sive therapy on both TST and IGRA. Immunosuppression was defined as either
steroids more than 5mg for at least two weeks, thiopurine, methotrexate or
cyclosporine. We used the Mantel-Haenszel method for a pooled random effects
model, given heterogeneity of studies included. We also compared the fixed
effects model to exclude any effect of smaller studies. Heterogeneity between
studies was analysed using the statistical I2, Q and Tau 2 tests. The quality of
included studies was evaluated using a modified QUADAS-2 method.
Results: Sixteen studies, including 2488 patients with IBD, were included for the
analysis. The pooled concordance between the TST and IGRA was 85% (95%
confidence interval [CI] 81%-88%, p¼ 0.01). Effects of immunosuppression on
both tests were reported in eight studies including 814 patients with IBD. The
odds ratio of testing positive by IGRA decreased to 0.57 if immunosuppressed
(95% confidence interval [CI] 0.31–1.03, p¼ 0.06). The odds ratio of testing
positive by TST if immunosuppressed was 1.14 (95% confidence interval [CI]
0.61–2.12, p¼ 0.69). Using the fixed effect model yielded similar results, however
the negative effect of immunosuppression on IGRA reached statistical signifi-
cance (p¼ 0.06 to 0.01).
Conclusion: While concordance was 85% between TST and IGRA, the perfor-
mance of IGRA seems to be negatively affected by immunosuppression. Given
the importance of detecting latent TB prior to anti-TNF initiation, using only
IGRA should be avoided in immunosuppressed IBD patients.
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P0354 THIOPURINE MAINTENANCE THERAPY FOR IBD: WHICH
IS THE BEST METHOD TO MEASURE MEDICATION ADHERENCE?
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Introduction: For the majority of patients with IBD long-term therapy is required
to maintain remission, yet 30–45% of patients do not adhere to their IBD med-
ication. Medication adherence can be assessed with prescription refill rates, bio-
logical measures (metabolites, trough levels, etc) and patient self-report tools.
There is currently no accepted gold standard and the feasibility and utility of
different adherence assessment tools in the routine outpatient clinic setting have
not been fully examined. The aim of this service improvement project was to test
the acceptability of self-report tools assessing thiopurine adherence in the IBD
clinic and to correlate the results with thioguanine-nucleotide (TGN) levels.
Aims &Methods: Consecutive outpatients on thiopurine maintenance therapy for
IBD for 43 months were recruited from clinic. Patients selfreported adherence
using a visual analogue scale (VAS), the validated Morisky adherence tool
(MOR) and the validated Medication Adherence Report Scale (MARS). TGN
levels were classed as complete non-adherence (5100 and MMP low), partial
adherence (TGN 100–235 and MMP low) or full adherence (4235 or MMP
high). Correlation analysis was performed using Pearson tests.
Results: Of 100 approached patients none refused participation and TGN levels
were available for 69. These included 38 women. Diagnoses were Crohn’s disease
in 27, ulcerative colitis in 41 and IBD-U in 1 cases. Concomitant therapy
included 5-ASA (25 cases), anti-TNF (13 cases) and Vedolizumab (2 cases).
The proportion of adherent patients was according to the relevant report tool
71% (TGN), 87% (VAS), 87% (Morisky) and 77% (MARS). VAS (Pearson
0.315; p¼ 0.005) and Morisky (Pearson 0.363; p¼ 0.001) correlated moderately
with TGN, but MARS (Pearson 0.09; p¼ 0.39) did not. The 7 patients, who were
non-adherent by TGN were detected by VAS in 3, Morisky in 6 and MARS in 3
cases. However, patients showing non-adherence according to self-report tools
had normal TGN levels in 6 of 10 cases for VAS, 10 of 26 for Morisky and 4 of 15
for MARS.
Conclusion: Self-report tools provided a patient-friendly and inexpensive way of
assessing adherence, but the correlation with TGN levels was only moderate.
While providing a more objective assessment TGN levels are problematic for
routine use in all patients. TGN require a more invasive and expensive approach.
Furthermore, TGN cannot detect ‘‘white coat adherence’’ (patients take medica-
tion only around appointments), which is the most likely explanation for normal
TGN levels in patients reporting to be poorly adherent. Neither TGN levels nor
self-report tools can be seen as the gold standard at present.
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Introduction: Anti-TNFa therapies have improved outcomes in patients with
inflammatory bowel disease. Their use has been associated with improved clinical
endpoints, reduced hospitalisation and rates of surgery. However secondary loss
of response (LOR) to both infliximab (IFX) and adalimumab (ADA) is a sig-
nificant problem, leading to further flares of disease, disease progression and
poorer outcomes. Therapeutic drug monitoring (TDM), which involves measure-
ment of an individual’s anti-TNFa trough and antibody levels, offers the oppor-
tunity of exploring an immune basis behind LOR, and potentially adjusting doses
or switching therapies to help regain clinical response.
Aims & Methods: The aim of this study was to evaluate whether TDM can help
predict secondary LOR to infliximab and adalimumab and whether dose
adjustments based on this information can help patients regain clinical response.
This was a prospective, single-centre study, performed from September 2015 to
April 2016, at our institution. Patients with Ulcerative colitis (UC) and Crohn’s
disease (CD) were enrolled, if they were clinically (based on Harvey-Bradshaw
(HBI) or partial Mayo scores) felt to be experiencing a secondary LOR to either
infliximab or adalimumab maintenance therapy. Patients had serum biochemical
markers measured, including CRP and albumin. In addition assessment of
inflammation took place, with measurement of SES-CD and Mayo scores, for
CD and UC respectively. Anti-TNFa trough and antibody levels were performed
using standard ELISA techniques. Patients were followed for a one-year period,
from their initial assessment for secondary LOR to assess outcomes.
Results: 46 patients were recruited, 40 CD with Harvey-Bradshaw Index (HBI)
44 points and 6 patients with UC with Partial Mayo Score (PMS) 42 points.
Mean age for the cohort was 40.9 years, 26 (56.5%) were female, mean duration
of disease was 9.8 years, 3 (8.3%) were smokers, 7 (15.2%) on immunomodula-
tors, and 11 (23.9%) had prior anti-TNFa exposure. 17 (48.6%) were on an
adalimumab maintenance dose of 40mg every other week. Overall HBI for the
group was 11.9, partial Mayo 6.5. In terms of markers of inflammation, mean
SES-CD was 8.5, Mayo endoscopy score 2.7. Mean adalimumab trough level was
4.5 ug/ml, and 15/36 (42.9%) had a sub-therapeutic trough level less than 1 ug/
ml. 9 patients (25.7%) had antibodies to adalimumab. Mean infliximab trough
level was 8.1 ug/ml and 2/10 (20%) had sub-therapeutic trough levels, none with
antibodies. Higher baseline adalimumab trough levels, were noted in patients
who were well or who had functional symptoms at one-year follow-up compared
to patients, who were unwell, and required change in therapy, mean trough 6.4
ug/ml (IQR 2.1–10.3) compared to 2.9 ug/ml (IQR 0.3–6.3) (p value¼ 0.0265
95% C.I. 0.4 to 6.5). The area under the curve [AUC] for association of ADA
level at secondary LOR with a good outcome was 0.766, p¼ 0.037. In addition a
trough level of 3.5 ug/ml predicted clinical response at one year, following sec-
ondary LOR to adalimumab, with a sensitivity of 85.7% and a specificity of
81.8%. Similarly for infliximab higher baseline trough levels, were noted in
patients who were well at one-year follow-up compared to those who required
change in treatment, 16.0 ug/ml (IQR 15–16.8) versus 4.6 ug/ml (IQR 1.1–6.1), p
value¼ 0.005 95% CI 4.5 to 18.3. The therapeutic strategy chosen for each group
was: 23.9% no change in treatment, 26.1% increase anti-TNFa dose or decrease
infusion interval, 19.6% switch to another anti-TNFa drug, 15.2% switch to non
anti-TNFa (ustekinumab). For patients who had doses adjusted, clinical
response (decrease of HBI 3 points for CD) was reached in 77.8% of patients
and remission (HBI 4 for CD) in 55.6% at the end of follow-up.
Conclusion: Secondary LOR to anti-TNFa therapy has a significant impact on
patient outcomes. Therapeutic drug monitoring is helpful for predicting second-
ary LOR and for facilitating dose adjustment or switch in therapy in a clinically
guided fashion.
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Introduction: Bowel Ultrasound (US) and Magnetic Resonance Enterography
(MRE) are accurate in assessing disease activity and complications in Crohn’s
disease (CD) patients. The comparative accuracy of US versus
MREþColonoscopy (CS) in assessing disease activity and complications and
influencing the decision-making process in CD is unknown.
Aims & Methods: Ileo-colonic CD consecutive patients seen in a tertiary referral
Center (Humanitas Research Hospital, Milan, Italy) were prospectively assessed
by MRE, CS and US, within 1 week. Sensitivity, specificity, accuracy, positive
and negative predictive values (PPV and NPV) of US in assessing localization
and extension (bowel wall thickening 43mm), bowel wall enhancement (increase
of vascularization at power Doppler), strictures (narrowing of the lumen), fistu-
las and abscesses, and active disease (presence of ulcers at colonoscopy) were
calculated using CS in combination with MRE findings as a reference standard.
Two independent blinded IBD specialists reviewed separately MRE and US
findings, and were asked to decide the therapeutic strategy (continue therapy
vs. optimize/change therapy). Kappa agreement between MRI and US was
also investigated.
Results: Forty-one consecutive CD patients, irrespectively of disease activity and
current therapy, were enrolled. Twenty-three patients had active disease as
assessed by MRE and CS (56%), 20/41 (49%) had CD-related complications.
Sensitivity, specificity, accuracy, PPV and NPV of US are showed in Table 1.
Based on US findings alone, compared to MREþCS, management of IBD
patients (continuing or changing/optimizing therapy) was judged accurate in
85% of patients, compared to 75% managed by MRI only (p5 0.001).
Agreement between MRE and US was 80%.
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Parameter Sensitivity % Specificity % Accuracy % PPV % NPV %
Localizationþ extension 80 (0.50–0.93)94 (0.70–0.99)85 (0.70–0.94)95 (0.76–0.99) 75 (0.50–0.91)
Bowel wall enhancement80 (0.58–0.94)88 (0.65–0.98)84 (0.69–0.94)89 (0.66–0.98) 80 (0.56–0.94)
Strictures 76 (0.50–0.93)79 (0.57–0.93)78 (0.62–0.89)72 (0.46–0.90) 82 (0.61–0.95)
Fistulas 100 (0.16–1) 97 (0.86–0.99)97 (0.87–0.99)66 (0.09–0-99)100 (0.90–1)
Abscesses 100 (0.02–1) 95 (0.83–0.99)95 (0.83–0.99)33 (0.01–0.90) 100 (0.90–1)
Active disease 83 (0.58–0.96)100 (0.85–1) 93 (0.80–0.98)100 (0.78–1) 88 (0.69–0.97)
Conclusion: US was as accurate as the combination CSþMRI in assessing dis-
ease activity and complications in CD patients. Therapeutic decisions based on
US findings alone were appropriate in the vast majority of CD patients. US is a
non-invasive, easy-to-use tool to manage CD patients in clinical practice.
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Introduction: Diagnostic delay seems to be common in inflammatory bowel dis-
ease (IBD), especially in Crohn’s disease (CD). We sought to investigate the
diagnostic delay in Austrian IBD patients and to identify associated risk factors
as well as the impact of delayed diagnosis on the risk of intestinal surgery in CD.
Aims & Methods: In a multicentre cohort study adult patients with IBD (CD,
ulcerative colitis UC, inflammatory bowel disease unclassified IBDU) attending
18 Austrian outpatient clinics were recruited between May 2014 and July 2015 to
complete a multi-item questionnaire, which recorded medical and socioeconomic
characteristics. Study outcome was the diagnostic delay defined as the time
period from first symptom onset to diagnosis of IBD. A multivariable propor-
tional hazard regressions model based on interval censored latency times was
calculated.
Results: 1217 patients (CD 779, UC 400, IBD 21, missing 17; females 615) with a
median age of 40 years (interquartile range (IQR) 31–52 years) and a median
disease duration of 10 years (IQR 4–18 years) were analysed. The median diag-
nostic delay was 0.53 years (IQR 0.20–1.92 years) in CD and 0.28 years (IQR
0.11–0.86 years) in UC, respectively (p5 0.001). In the multivariable regression
analysis patients with CD had a significantly longer diagnostic delay than
patients with UC (HR 1.56; 95% CI 1.34–1.82; p5 0.0001) and a quadratic
effect of age leading to higher risk of delayed diagnosis in older patients
(p5 0.0001) was found. Diagnostic delay did not differ significantly between
patients with intestinal CD-related surgery (53% of all CD patients) and those
without surgery. However, in the Kaplan-Meier curve for the probability of
being diagnosed after symptom onset a trend of a difference between both
groups was seen after 10 months (p¼ 0.13).
Conclusion: The median diagnostic delay was longer in CD (6 months) than in
UC patients (3 months) and was associated with older age at diagnosis.
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Introduction: Enterobacteria, especially adherent and invasive E. coli (AIEC), are
suspected to play a key role in Crohn’s disease (CD). These bacteria are able to
highly adhere to the ileal mucosa of CD patients through the CEACAM6 recep-
tor (Carcinoembryonic antigen-related cell adhesion molecule 6). It has been
shown that therapies targeting enterobacteria and/or AIEC could be more effec-
tive in mice overexpressing CEACAM6. In this line, the overexpression of
CEACAM6 in the ileum as well as the presence of AIEC in the ileum could be
potential biomarkers to select the patients who could benefit from drugs target-
ing the host-pathogen interaction. Unfortunately, the identification of these bio-
markers is time-consuming and invasive highlighting the need for more
convenient alternative.
Aims & Methods: We aimed to assess the correlation between the level of
CEACAM6 in the saliva and the level of CEACAM6 in the ileum in CD patients
and to define the best threshold of CEACAM6 in the saliva to detect overexpres-
sion of ileal CEACAM6. In addition, we attempted to identify non-invasive
biomarkers of AIEC infection. In this prospective multicentre study (8 centers),
all the patients requiring ileocoloscopy, regardless the indication, were consecu-
tively included between September 2015 and September 2016. Clinical and endo-
scopic data were collected on the day of colonoscopy. Blood samples, stool
samples (before bowel cleansing), saliva and ileal biopsies from healthy and
ulcerated areas were also collected. CEACAM6 from ileal biopsies and saliva
were measured (duplicates) using ELISA assays. AIEC were identified using
phenotypical assays.
Results: Overall, 102 patients were enrolled in the study (Table 1).
Table 1: Baseline characteristics of the 102 CD patients included in the study.
Female gender n, % 56 (56.6%)
Active smokers n, % 34 (34.3%)
Montreal classification
Disease location
L1 27 (28.4%)
L2 12 (12.6%)
L3 58 (61.1%)
L4 7 (7.4%)
Disease behaviour
B1 51 (54.3%)
B2 26 (27.7%)
Table 1: Baseline characteristics of the 102 CD patients included in the study.
B3 18 (19.1%)
Perianal lesions 20 (21.3%)
Prior intestinal resection 43 (43.4%)
Current therapies
(continued)
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5-ASA 7 (7.1%)
Corticsteroids 12 (12.4%)
Immunosuppressive therapies 33 (33.9%)
Anti-TNF agents 33 (33.9%)
Other biologics 3 (3.0%)
CDAI, mean standard deviation 131 109
CRP, g/L mean standard deviation 8, 1 13, 8
Fecal calprotectin, mg/g mean standard deviation 244 358
Ileal CEACAM6 level did not depend on disease severity or the site of
biopsies as the median level of ileal CEACAM6 was 854.9 pg/mg [570.2;
1646] and there was no difference in healthy or ulcerated zone (756 pg/mg
[487; 1617] vs 947 pg/mg [604; 1820], p¼ 0.86). The median level of
CEACAM6 from saliva was 3837 pg/mg [1889; 7338]. There was a positive
correlation between the levels of CEACAM6 in saliva and CEACAM6 in the
ileum (¼ 0.47; p5 0.0001) in both macroscopically healthy areas (¼ 0.53,
p5 0.0001) and ulcerated zone (¼ 0.39, p¼ 0.0082). Using a ROC curve, we
determined the best threshold of CEACAM6 in saliva for detecting ileal
CEACAM6 overexpression. Using a ROC curve (area under the curve
(AUROC)¼ 0.73), the cut-off value of 3800 pg/mg demonstrated the best
performances to detect ileal CEACAM6 overexpression with substantial spe-
cificity (76.0% [54.9–90.6]) and positive predictive value (87.5% [74.8–95.3]).
The number of enterobacteria was increased in CD patients with prior intest-
inal resection (562 [20;1674] vs. 116 [0;752] pg/mg, p¼ 0.03). Interestingly, the
number of enterobacteria was also increased in AIEC positive-patients (640
[184;2392] vs. 60 [0;1028] pg/mg, p¼ 0.004). Using a ROC curve, we deter-
mined the best threshold of enterobacteria in the ileum to detect the presence
of ileal AIEC bacteria. We found an area under the curve (AUROC) of 0.70
[0.61; 0.77]. The cut-off value of 60 cfu/biopsy demonstrated the best perfor-
mances to detect the presence of ileal AIEC bacteria. The number of enter-
obacteria associated to ileal mucosa (cut-off value 460 cfu/biopsy) strongly
predicted the presence of AIEC and then is a reliable test for AIEC screening
with very high negative predictive value (94.1% [80.3–99.3]) and high sensi-
tivity (91.7% [73.0–99.0]).
Conclusion: CEACAM6 measurement in the saliva is feasible, non time-con-
suming and non-invasive. It could be a reliable test to detect the overexpres-
sion of CEACAM6 in the ileum from CD patients and could then be
proposed as a non-invasive biomarker to select patients who might benefit
from anti-adhesive therapies. In addition, we identify that the number of
enterobacteria associated to the ileum is a convenient and reliable test to
screen CD patients for AIEC bacteria.
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Introduction: Fibroblast growth factor 19 (FGF19) is the ileal hormone providing
feedback inhibition of bile acid (BA) synthesis in the liver. BAs are actively
reabsorbed in the terminal ileum by the apical sodium-dependent BA transporter
(ASBT). FGF19 is produced by the ileal enterocytes in response to absorbed BAs
binding and activating the nuclear BA receptor, also known as farnesoid X
receptor (FXR) [1]. The FXR activation may enhance expression of anti-inflam-
matory genes and down-regulate pro-inflammatory genes [2]. The glucocorticoid
budesonide has been shown to increase the expression of ASBT and BA absorp-
tion inducing FGF19 release [3]. Disturbances in BA enterohepatic circulation
may be associated with colonic inflammation, but little is known about the
mechanisms of BA dysregulation in ulcerative colitis (UC).
Aims & Methods: The aim of the study was to evaluate serum FGF19 level in
patients with active and inactive phase of UC. Fasting serum FGF19 level was
measured using ELISA test in 14 patients with active UC (7 F, 7 M; mean age
44), 16 UC patients in remission (10 F, 6 M; mean age 39), and 7 healthy controls
(4 F, 3 M; mean age 35). Disease activity was assessed based on the clinical
evaluation and fecal calprotectin level. Non-parametric statistics were used and
results are expressed as median with interquartile ranges. The Mann-Whitney U
test was used for the comparison of differences between the groups. Spearman’s
rank correlation coefficient was also calculated.
Results: Median fecal calprotectin level in UC patients with active and inactive
phase of the disease amounted to 1675.1 vs 142.8 mg/g, respectively (p¼ 0.004).
Median serum FGF19 level was significantly higher in UC patients in remission
(median 192.6 pg/ml, range 155.1–351.2) than in UC patients with active disease
(median 82.6 pg/ml, range 64.0–151.8), p¼ 0.004. Median FGF19 level in healthy
controls (median 151.6 pg/ml, range 121.6–216.1) was lower than in UC patients
in remission and higher than that in patients with active UC, but the differences
did not reach statistical significance. A negative correlation between serum
FGF19 and fecal calprotectin levels was observed, but it was not statistically
significant (R¼ -0.328, p¼ 0.077).
Conclusion: The increased FGF19 level in UC patients in remission, compared to
the patients with active UC, may be influenced by the treatment, in particular
corticosteroids used to induce remission. Steroid-induced increase in FGF19
synthesis may be associated with anti-inflammatory effect. The stimulation of
FGF19 release during UC remission may also have beneficial effect by the inhi-
bition of BA synthesis and reduction of excess colonic BAs.
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Introduction: Crohn’s disease (CD) has a progressive course and often causes
mucosal injury throughout the gastrointestinal tract. Mucosal healing (MH)
has been proposed as a treatment goal for patients with CD. Endoscopy, com-
puted tomography, magnetic resonance imaging, and other examinations are
used to evaluate MH. However, repeated examinations require considerable
effort and are highly invasive. Recently, fecal calprotectin (FC) has attracted
attention as a new biomarker. The correlation between FC levels and CD activity
is well established in ileocolonic or colonic CD, but few reports have described
this correlation in ileal CD alone.
Aims & Methods: This study evaluated the correlation between FC levels and
endoscopic activity in ileal CD. Fifteen patients with ileal CD who underwent
double-balloon endoscopy (DBE) between May 2016 and February 2017 at our
hospital were included in this study. The entire small intestine was examined with
DBE and radiological enteroclysis. We evaluated the correlations of FC levels, C-
reactive protein (CRP) levels, erythrocyte sedimentation rates (ESRs), and CD
activity index (CDAI) scores with the endoscopic activity. To evaluate the endo-
scopic activity of the small intestine, we used Double-Balloon Endoscopic Score
for CD (DES-CD), which is a modified version of the Simple Endoscopic Score
for CD (SES-CD). To determine the DES-CD, the small intestine was divided
into four segments (upper jejunum, lower jejunum, upper ileum, and lower
ileum), and four variables were evaluated in each segment (ulcer size, extent of
ulcerated surface, extent of affected surface, and stenosis) in accordance with the
SES-CD. For the evaluation of mucosal injury, the partial DES-CD (pDES-CD)
was calculated by excluding ‘‘stenosis’’ from the DES-CD. The DES-CD and
DES-CD ranges were 0–46 and 0–24, respectively.
Results: Fifteen patients (11 males and four females) with a median age of 42
(range, 27–71) were assessed. No colitic lesions were observed in any of the
patients. The DES-CD correlated with FC ( ¼ 0.688, P¼ 0.005) and CRP
(¼ 0.765, P¼ 0.001) levels. In addition, the pDES-CD correlated with FC
levels (¼ 0.803, P¼ 0.001), CRP levels ( ¼ 0.673, P¼ 0.006), and ESRs
(¼ 0.704, P¼ 0.003). The CDAI scores did not correlate with either of the
endoscopic scores
Conclusion: In this study, the endoscopic activity in ileal CD correlated with FC
levels. In addition, pDES-CD scores exhibited a stronger correlation with FC
levels than did DES-CD scores. This might be because FC levels reflect mucosal
injury and not stenosis. Our findings suggest that FC can be used for monitoring
mucosal injuries in the small intestine and as a biomarker for evaluating MH.
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Introduction: Increasingly, immunosuppressive medications such as azathioprine
and biologics are being used in order to promote clinical remission in inflamma-
tory bowel disease (IBD) patients. It has been reported that such treatments
increase the risk of developing all types of skin cancer. Education of these
patients is key in order to promote their awareness of their increased risk and
it is vital for gastroenterologists to counsel patients on sun protection strategies
on initiating therapy. We recently performed a pilot study in this group which
highlighted gaps in their knowledge of the increased risk and prevention strate-
gies. We speculate clinician’s lack of knowledge was partly to blame.
Aims & Methods: Our aim was to determine Irish IBD clinicians’ knowledge of
the skin cancer risk and advised photoprotective behaviours in this cohort.
Cross-sectional descriptive study. We invited IBD clinicians via email to fill in
an anonymous online survey designed to assess knowledge of skin cancer risk and
prevention methods as recommended by the ‘‘Sunsmart’’ guidelines, as currently
gastroenterology based guidelines are lacking. In addition their grade of training
and clinical experience was noted.
Results: To date, 45 Irish Gastroenterology clinicians completed the online ques-
tionnaire. Of these, fifteen (33%) were consultants, fourteen (31%) gastroenter-
ology trainees, four (9%) general medical trainees and twelve (27%) IBD nurse
specialists. Overall, clinician’s knowledge of general factors associated with
increased risk of skin cancer was reassuring; with all 45 (100%) knowing sun
beds increased skin cancer risk and almost 100% (44, 98%) knew working out-
doors incurred increased risk. 42 (93%) knew a personal history of skin cancer
and previous blistering sunburn were risks; however, only 34 (79.1%) recognised
family history as a risk. Regarding gender associated risk; only 67.4% (n¼ 29)
knew men were greater risk than women of non-melanoma skin cancer (NMSC).
Their knowledge of specific immunosuppressant risk was suboptimal; while
many (37, 82%) recognized azathioprine was a risk factor for developing
NMSC, only 53% (n¼ 24) knew anti-TNF medications were strongly associated
with an increased risk of malignant melanoma. Regards prevention strategies; the
majority knew what changes to look for in a suspicious mole; 100% (n¼ 45)
knew to be suspicious of changing color and 84% (n¼ 38) of an irregular border,
but shockingly only five (11%) perform yearly skin checks on their patients on
immunosuppressants. Their knowledge of preventative measures was also lack-
ing; 37 (86%) knew patients should wear SpF 50 but almost half (47% n¼ 20)
thought it should be applied twice daily rather than two hourly (51% n¼ 23) and
only 47% (n¼ 20) knew patients should stay in the shade from 11am-3 pm.
Regards their own practice; 39 (87%) report they do emphasise the importance
of sun protection in their patients; however, worryingly only 24 (55.8%) had
heard of our national skin cancer prevention guidelines ‘‘Sunsmart’’. Of interest;
while physicians had a greater understanding of patient risk factors (p5 0.03),
nurse specialists were more likely to emphasise the need for sunprotection in
clinic (p5 0.0003), and of physicians, trainees had a more complete knowledge
of all advised preventative measures (p5 0.03).
Conclusion: Our study highlights IBD clinicians’ suboptimal knowledge of immu-
nosuppression risk and their lack of emphasis on preventative measures and skin
examination in clinics. A targeted educational and awareness programme may
address this.
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Introduction: Due to the chronic and progressive nature of inflammatory bowel
disease (IBD) it is of significant importance to detect and treat a relapse as soon
as possible in order to decrease the total inflammation burden and avoid pro-
gression of intestinal damage, and possibly improve the disease course. A vali-
dated Fecal Calprotectin (FC) home testing kit and smart phone application
CalproSmartTM have been added to an existing eHealth web-application,
enabling patients to monitor their disease activity using clinical scores and FC
from home with results shown on their smart phone. eHealth allows for tight
monitoring of disease activity, however, the frequency of an optimal screening
procedure for adult IBD patients has not yet been determined.
Aims & Methods: The aim of this one-year randomized controlled trial of 120
adult IBD patients, was to determine if an eHealth screening procedure for
disease activity should be implemented in clinical practice ‘every 3 months,
3M’ or according to patients own gut feeling, ‘on demand, OD’. Both groups
used the ehealth-program to tightly monitor their disease activity either OD or
every 3M. Patients randomized to screen every 3M were also allowed to monitor
themselves OD if they were feeling a flare was coming. The web-algorithm con-
sists of a short disease questionnaire either Harvey-Bradshaw Index (HBI) for
Crohn’s disease (CD) or Simple Clinical Colitis Activity Index (SCCAI) for
Ulcerative Colitis plus home monitoring of FC, which together gives a total
inflammation burden scoring (TIBS). Based on longitudinal FC and disease
activity scores area under the curve (AUC) were calculated by an algorithm
taking the inclusion date and the first observation 357 days after inclusion into
the calculation.
Results: To date, 83 patients have been included, 15 patients have dropped out (7
in OD-group and 8 in 3M-group) and 68 (3M-group: n¼ 32, 47%; OD-group:
n¼ 36, 53%) patients have fulfilled the first year of follow-up and were included
in the analysis. There were no statistical difference between the two groups OD
vs. 3M on the following indices: Active disease (FC4 600mg/kg) at inclusion
n¼ 17, 25% (3M-group: n¼ 6, 19%; OD-group: n¼ 10, 29%, p¼ 0.26), active
disease at least once throughout the whole year: 41 patients (61%) (3M-group:
n¼ 21, 66%; OD-group: n¼ 20, 57%, OD, p¼ 0.32). Patients screened them-
selves with regards to FC 233 times in the OD-group and 232 times in the 3M-
group. The mean no of FC home measurements pr. patient was similar in the two
groups: OD 6.7 (95% CL: 5.2–8.2) vs. 3M 7.3 (95% CL:5.9–8.5), p¼ 0.54.
Median (range) AUC for FC and disease active scores were not significantly
different in the groups (OD, 3M): 62016 (3782–541338) vs 89730 (10286–
353881) p¼ 0.71, 549 (0–3726) vs 610 (0–2.884) p¼ 0.61.
Conclusion: In this preliminary analysis, no difference between the two screening
procedures was found in regards to disease course and resource utilization. A
slightly but non-significant reduction in no of FC measurements pr. patient used
in OD-group relative to 3M-group could argue for an economical benefit of
choosing the OD screening procedure. Long-term results are awaited.
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Introduction:Ulcerative colitis (UC) and Crohn’s disease (CD) represent a serious
medical and socio-economic problem worldwide. The family of S100 proteins
represents a total of at least 25 relatively small calcium binding proteins. S100
proteins have a broad range of functions: they play a role in the regulation of cell
proliferation, differentiation, apoptosis, energy metabolism, cellular signalling,
and calcium homeostasis. S100A4 (metastatin-1, calvasculin) strongly contri-
butes to a process of metastasizing. Still, the role of S100A4 seems to be more
complex as its profibrotic effect has been confirmed in the myocardium, liver
parenchyme and in the intestine. Fibroblasts represent the key cell type in the
pathogenesis of fibrostenosing/stricturing CD.
Aims & Methods: The aim of this prospective study was to assess serum concen-
tration of S100A4 protein in UC and CD. Study included 118 subjects: 93
patients with CD (44 men, 49 women, aged 22–79, mean 44 14), 16 patients
with UC (8 men, 8 women, aged 20–74, mean 39 15) and 9 controls (average
risk population with normal findings on colonoscopy and with negative history
of colorectal neoplasia and/or inflammatory bowel disease; 2 men, 7 women,
aged 23–74, mean 52 17). CD group was divided according to the Montreal
classification: 20/93 (22%) patients had B1 phenotype, 19/93 (20%) B2, 20/93
(21%) B3 and 34/93 (37%) B2þB3. Perianal involvement was present in 27/93
(29%). L1 involvement was present in 15/93 (16%), L2 in 14/93 (15%) and L3 in
64/93 (69%). Serum concentration of S100A4 protein was investigated by means
of Human Protein S100-A4 ELISA kit, the quantitative sandwich enzyme immu-
noassay technique (purchased from My Biosource, San Diego, California, USA).
Results: Serum concentration of S100A4 protein was significantly higher in UC
(mean 158.6 56.2 mg/L) compared to controls (mean 104.8 40.5mg/L),
p¼ 0.019 and in CD (mean 154.4 52.1 mg/L) compared to controls, p¼ 0.007.
No difference in S100A4 was revealed between UC and CD, p40.05. In CD
group, serum concentration of S100A4 in each subgroup (divided according to
behaviour of CD) was significantly higher compared to controls, p50.05. No
differences in S100A4 were documented between each CD phenotypes. Serum
concentration of S100A4 was significantly higher in L2 (mean 144.6 44.2 mg/L)
compared to controls, p¼ 0.041 and in L3 (mean 163.0 52.8mg/L) compared to
controls, p¼ 0.002. Serum concentration of S100A4 was significantly higher in
L3 (mean 163.0 52.8mg/L) compared to L1 (mean 126.9 47.6mg/L),
p¼ 0.017. No difference in S100A4 was observed between patients with and
without perianal involvement, p40.05.
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Conclusion: Association of serum S100A4 protein with UC and CD was con-
firmed. In CD, disease behaviour did not have impact on serum concentration of
S100A4 protein. In CD, higher levels of serum S100A4 were observed in patients
with ileo-colonic and colonic involvement compared to those with isolated small
bowel involvement.
Acknowledgement: The study was supported by the Research Project PROGRES
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Introduction: Hypovitaminosis D is common in Inflammatory Bowel Disease
(IBD) patients. Some studies suggest that the finding may be related to severity
of the disease.1, 2
Aims & Methods: The aim of the study was to determine the Vitamin D (VitD)
status in an Italian IBD cohort in relation to disease activity. Serum 25-hydro-
xyvitamin D was measured in 260 IBD outpatients, not supplemented with VitD
(110 Crohn’s Disease (CD) and 150 Ulcerative Colitis (UC); 145 males and 115
females; mean age 50.7 15 years), and compared to those of 205 healthy blood
donors, matched by sex, age (þ/2 years) and month in which the blood sample
was collected. VitD levels were correlated to C-reactive protein (CRP), erythro-
cyte sedimentation rate (ESR), Harvey Bradshaw Index (HBI) and Crohn’s
Disease Activity Index (CDAI) for CD and Mayo partial score for UC. Chi
square, T test and linear correlation were used when appropriate.
Results: IBD patients were at higher risk of VitD deficiency (defined as 520 ng/
ml) than controls (OR 4.5, 95%CI 2.9–6.9, p5 0.0001). Of 260 IBD patients, 156
(60%) had VitD deficiency, more often in CD than in UC (72.7% vs 48%
respectively, p5 0.0001). Age 540 and 60 years, winter/spring season, CRP
0.5mg/dl, ESR 20mm/h, previous intestinal surgery and HBI 5 were sig-
nificant risk factors for VitD deficiency. No differences were observed in relation
to sex, smoking status, BMI, age at diagnosis, localization and behavior of dis-
ease, and need of steroids. There was a weak negative correlation between CRP
values, HBI scores and VitD levels (R¼ -0.13, p¼ 0.037 and R¼ -0.26, p¼ 0.006
respectively).
Conclusion: VitD deficiency is significantly more common in IBD patients than in
controls, more so in CD. Patients with active disease are more likely to have VitD
severe deficiency than those in remission. The correlation with activity indexes
should be confirmed in larger series.
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Introduction: Small bowel (SB) Crohn’s disease (CD) strictures can comprise of
both inflammatory and fibrotic elements. An accurate tool to discriminate fibro-
sis and inflammation would be clinically useful to guide therapy and predict
response. While the magnetic resonance index of activity (MaRIA) is a validated
means to assess activity, to date, no specific tool has been developed to identify
fibrotic from inflammatory disease. Lesions with a dense fibrotic matrix exhibit
delayed gadolinium enhancement on MRI. The role of delayed enhancement in
assessment of SB CD strictures is unclear. Recent evidence suggests relative
contrast enhancement (REC) of 424% on delayed MRI sequences may accu-
rately detect fibrosis.
Aims & Methods: To determine the feasibility of MRE SB stricture assessment
with early (70s) and late (7mins) phase post gadolinium imaging comparing
MaRIA, RCE and biochemical activity in patients with ileal CD. We performed
a retrospective review of 208 consecutive MREs with known and suspected
SBCD. MRE was performed as standard with additional coronal T1 sequences
7 minutes post gadolinium administration. Demographics, MRE findings and
biochemical markers were recorded. Patients with stricturing disease were further
assessed. Two independent blinded Radiologists calculated RCE and MaRIA’s
at 70 sec and 7min.
Results: Median age 40.5 years; male n¼ 83(39.9%). 117, 72 and 19 patients had
known CD, suspected CD and indeterminate IBD, respectively. In total,
119(57.2%) MREs were normal. Ileitis, strictures and fistulas were found in
40(19.2%), 49(23.6%) and 1(0.5%) patients, respectively. While there was no
difference in Hb between patient groups (Normal, Inflammatory and
Stricturing CD); Albumin and CRP were statistically different between normal
subjects and those with disease; albumin 42 g/L v 38.9 g/L in normal v stricturing
disease (p5 0.0181 95%CI 0.23–0.02). CRP 8.8mg/L v 18.3mg/L (p5 0.003
95%CI 0.46–0.10) and v 29mg/L (p5 0.002 95% CI 0.43–0.11) amongst
normal v inflammation and strictures respectively. Neither parameter could dif-
ferentiate between inflammatory and stricturing disease. 26 MREs performed
with ileal CD have been further assessed; median age¼ 41yrs, male¼ 10(38%).
RCE4 24% and high T2 signal intensity (SI); 6/26 (23%) and 11/26 (42.3%).
REC4 24% occurred in only 1/10 with a visible stenosis. Average MaRIAs: 2/
26(7.7%)5 7 mild; 3/26 (11.5%) 7–11 moderate; 21/26 (80.7%) 411 severe.
MaRIAs did not change significantly between 70 sec and 7min. As expected
T2 SI increased with MaRIAs 411, 26 v 13 (p5 0.001, 95% CI 7.73–17.27).
RCE did not correlate with MaRIA group, suggesting MaRIA is not a predictive
factor for fibrosis. Consistent with MRE findings, CRP was higher in patients
with MaRAI4 11(13.3 v 5.2) and lower in patients with RCE4 24% (3.9 v 14),
p5 0.04 95% CI 0.37–15.71 and p5 0.01 95% CI2.5–19.05 respectively.
Conclusion: Unlike biochemical markers, MRE may be a useful means to differ-
entiate between inflammatory and structuring disease. Further study is required
to assess the long-term predictive value. RCE may be a useful adjunct to current
MRE and help detect fibrosis in small bowel lesions and warrants further
investigation.
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Introduction: The need for upper endoscopy in patients with Crohn’s disease
(CD) without symptoms is controversial. The aim of this study was to establish
the prevalence of gastroduodenal involvement, regardless of symptoms, and its
prognostic implications.
Aims & Methods: Patients from a single centre with established CD (n¼ 347)
were retrospectively evaluated – inclusion criteria: upper endoscopy without
treatment. Gastroduodenal involvement was defined by considering macroscopic
(erosions, ulcers or stenosis) and microscopic criteria (focal gastritis, cryptic
irregularity, erosion/ulceration and granuloma in the absence of Helicobacter
pylori (HP) infection).
Results: We included 140 patients - phenotype: 50% inflammatory, 31% strictur-
ing and 19% penetrating; Location: 42% ileal, 45% ileocolic and 13% colic.
Upper endoscopy was performed in 19% for symptoms and in 81% for staging.
Gastric macroscopic findings were detected in 49% (69/140); the most common
were erosions (21%) and erythematous mucosa (18%). Biopsies were performed
in 56% of patients: chronic gastritis 66%, normal 23%, granuloma 5%, focal
gastritis 2% and cryptic microabcess in 2%. HP was positive in 25% of patients.
In the duodenum, endoscopic lesions were observed in 33% of the patients (46/
140); the most common were erosions (16%) and ulcers (9%). Biopsies were
performed in 32% and the most prevalent findings were chronic non-specific
inflammation 62%, ulcers 17%, granuloma 3% and erosion 3%. Applying
macro/microscopic criteria, gastroduodenal involvement by CD was considered
in 18% of the patients and was not correlated with the presence of symptoms,
phenotype or localization of the disease. The presence of gastroduodenal invol-
vement was a significant predictor of hospitalization (p¼ 0.009).
Conclusion: The prevalence of gastroduodenal involvement by CD in this sample
was 18%, and a larger percentage have macro/microscopic findings that are not
disease specific. The presence of symptoms does not predict gastroduodenal
involvement due to CD that is associated with a worse prognosis.
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Introduction: CT enterography is one of the most accurate imaging methods for
evaluating Crohn’s disease (CD) extent and intestinal involvement.
Aims & Methods: The aim of this study was to determine the frequency and
clinical impact of the incidental findings in CD patients who underwent CT
enterography.
This was a retrospective study that evaluated patients with CD who underwent
CT enterography between January 2012 and December 2016. Incidental findings
were defined as previously unknown extraintestinal lesions. The orientation of
the patients after their detection was evaluated.
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Results: A total of 520 patients who underwent CT enterography were identified,
with incidental findings being reported in 276 (53%). The median age was 43 (32–
53) years and 53% were women. The main indication for CT enterography was
CD staging (81%). A total of 531 incidental findings were detected (median of 2
[1–3] per patient). The main findings identified were hepatic nodules (n¼ 59),
hepatic cysts (n¼ 55) and sacroiliitis (n¼ 46). The findings implicated orientation
to another medical specialty in 80 patients (29%), the main ones being Urology
(n¼ 14) and Gynecology (n¼ 11). The findings implied additional exams in 59
patients (21%). Five (2%) underwent subsequent surgical intervention. Clinically
relevant findings were found in 38 patients (14%), including 2 renal tumors, 2
ovarian teratomas and 3 cases of primary sclerosing cholangitis. The detection of
incidental findings implied a change in CD therapy in 9 patients (3%): one
suspended biologic therapy, 2 suspended immunomodulator therapy and 6
initiated biologic therapy.
Conclusion: Incidental findings are relatively common in patients with CD who
undergo CT enterography. A significant proportion is clinically relevant and may
involve change CD therapy. A risk stratification may be important to avoid
morbidity associated with unnecessary examinations to assess benign situations.
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Introduction: Clinical significance of asymptomatic Clostridium difficile (C. dif-
ficile) carriage in patients on immunomodulator for inflammatory bowel disease
(IBD) is largely unknown. [1, 2]
Aims & Methods: The aim of this study was to investigate the clinical implication
of asymptomatic carriage of C diff in IBD patients.
Consecutive IBD patients on immunomodulators in clinical remission for the
past six months were prospectively recruited from the IBD clinic since 2013.
Those cases were excluded if they had past history of total colectomy, the dosage
of their immunodulators were titrated according to their disease activity in the
past six months or the types of their immunomodulators were other than
azathioprine, mercaptopurine or methotrexate.
Stool specimen for C. difficile cytotoxin real-time polymerase chain reaction
(RT-PCR) assay was obtained to all eligible patients at the time of enrollment
and every follow-up during the study period. Patients were monitored for any
IBD flare-up in which if happened, an additional stool specimen for C. difficile
cytotoxin RT-PCR assay was obtained.
The primary outcomes were the disease activity which was graded by Crohn
Disease Activity Index (CDAI) in Crohn disease (CD) (graded as follows:
5150: remission; 150-5220: mild-moderate; 220-5450: moderate-severe;
4450: severe/fulminant) and Ulcerative colitis Disease Activity Index (UC-
DAI) in ulcerative colitis (UC) (graded as follows: the total index score ranges
from 0–12; 0–2: remission; 3–6: mild; 7–10: moderate; 410: severe UC). The
secondary outcome was proportion with C. difficile diarrhea which was defined
in the patients with active lower gastrointestinal symptoms accompanying with
positive RT-PCR assay of C. difficile at that instant.
Statistical inference of the variables was examined by Mann–Whitney U and 2
test for numerical and categorical parameters respectively
Results: Of 197 IBD patients (CD: 98 (49.75%); male: 132(67.01%); age (yrs):
median 43, minimum 17, maximum 79), 9(4.57%; CD: 6 patients) patients were
found to be asymptomatic carriage of C. difficile during the study period. The
demographic features, including age, gender ratio, smoking history and the dura-
tion of IBD, of the patient group with and without asymptomatic carriage of C.
difficile were comparable each other. Four UC patients in the non-carriage group
had prior history of anti-TNF exposure in which three were treated as mainte-
nance therapy for the active disease activity, associated axial spondyloar-
throapthy and rectovaginal fistula while the other two patients (one from each
group) had received three doses of anti-TNF as rescue therapy for severe disease
flare-up.
Incidence rates of the disease flare-up were comparable (11.17 vs. 22.22%, p
0.313) between the non-carriage and carriage groups in which all these flares
were under-controlled by course of high-dose prednisolone.
The asymptomatic carriage group had a significant higher rate (33.33 vs. 7.45%,
p 0.007) and earlier onset (18.78 vs. 34.42 months, log rank p 0.009; Mann–
Whitney U, p 0.037) in evolving into clinical C. difficile infection as compared
with the non-carriage group.
No other serious complications, such as toxic megacolon, colonic perforation,
sepsis, and death, were reported in the both groups during the study period.
Clinical characteristics of the IBD patients with and without asymptomatic car-
riage of C. difficile
Non C.
difficile
carrier
(n¼ 188)
C. difficile
carrier
(n¼ 9) P value
Age (Yr) 43(26) 44(33) 0.788
Sex (m:f) 128:60 4:5 0.159
Smoker (n, %) 24(12.77) 1(11.11) 0.881
Year of Diagnosis (Yr) 7(9) 7(13) 0.940
Crohn disease (n, %) 92(48.94) 6(66.67) 0.298
Prior exposure of Anti-TNF (n, %) 4*(2.13) 1**(11.11) 0.095
Flare up (n, %) 21(11.17) 2(22.22) 0.313
mild/moderate/severe 16/5/0 2/0/0 0.165/0.617/ns
C. difficile infection (n, %) 14(7.45) 3(33.33) 0.007
Data were expressed as median(interquartile range)
*: all are UC cases and 3 for maintenance therapy with indications as follows:
refractory control, spondyloarthropathy, rectovaginal fistula
**: case of UC received 3 doses of anti-TNF for severe flare
Abbreviation: IBD, inflammatory bowel disease; C. difficile, Clostridium difficile;
ulcerative colitis, UC; ns, non-significant
Conclusion: The incidence of asymptomatic carriage of C. difficile in the IBD
patients on imunomodulators was not common. It did not associate with the
disease flare-up but a significant portion of them could evolve subsequently into
clinical infection.
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Introduction: Due to the relapsing and highly variable nature of ulcerative colitis
(UC), it would be desirable to have reliable tools for measuring parameters of
disease activity in order to monitor response to therapy and to detect relapse. In
Crohn’s disease it has already been shown that ultrasound (US) is a useful to
monitor the disease activity.1 The hypothesis of the TRUST&UC
(TRansabdominal UltraSonography of the bowel To monitor disease activity
in subjects with Ulcerative Colitis) study is that transabdominal US is an easy
to use, easily repeatable, and accurate diagnostic tool in the assessment of UC
activity, in monitoring the disease course, and response to therapy.
Aims & Methods: TRUST&UC is a German ongoing prospective, observational
multi-center study in patients with active UC. The primary objective of this study
is the prospective evaluation of bowel wall US in response to therapy in order to
assess its value in monitoring UC patients in routine medical practice. Clinical
parameters (e.g. CRP, fecal calprotectin) and the Simple Colitis Clinical Activity
Index (SCCAI) were used for routine assessment of disease activity.
Results: 176 patients with active UC have been enrolled in 37 German IBD study
group (GISG) centres until February 2017. 47.2% of the patients were female,
median age was 38.9 years (range 19–77) with median disease duration of 152.2
days (range -8–1017). Of all the patients with a clinical flare defined by SCCAI
90.3% showed a bowel wall thickening (BWT), and only 9.7% showed no US
signals. At US examination, a BWT in the colon sigmoideum was present in
87.5% of the patients, in the colon descendens in 83.7%, in the colon transver-
sum in 42.3% and in the colon ascendens in 18.3%. Loss of bowel wall
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stratification was the case in 20.6% of the patients, mesenteric fibro-fatty pro-
liferation in 40.0% and more than 50% had an increased signal in the color
Doppler US. At baseline systemic steroids were used in 62.1%, azathioprine in
36.2%, and TNF antagonists in 40.0% of patients (N¼ 174).
All follow-up patients (N¼ 104) displayed acute inflammatory symptoms at
baseline, with at least moderate disease activity which required an introduction
or escalation of treatment. After 12 weeks, the US examination showed signifi-
cant improvements of the following parameters: BWT in colon sigmoideum
(87.5% vs 33.7%, p¼ 0.034) and colon transversum (42.3% vs 15.4%,
p¼ 0.012), loss of haustration (54.8% vs 33.7%, p5 0.001), ascites (9.7% vs
2.9%, p5 0.001), mesenteric lymphadenopathy (31.6% vs 14.3%, p¼ 0.005),
mesenteric fibro-fatty proliferation (40.0% vs 10.0%, p¼ 0.041) and increased
signal in color Doppler US (56.7% vs 23.1%, p¼ 0.039). A decrease of BWT was
significantly accompanied by a decrease in SCCAI (8.0 to 1.5 points, p5 0.001).
Conclusion: In this real-life cohort almost 90% of the patients showed a BWT, a
pivotal IBD symptom and within 12 weeks selected bowel US parameters
improved significantly from treatment intensification. Therefore, US examination
is a useful tool to monitor disease activity and response to therapy in UC patients.
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Introduction: Blocking TNF is an important treatment option for inflammatory
bowel disease (IBD). The etiology of the disorder comprises a permanent activa-
tion of immune cascades and imbalanced cytokine networks. Evidence has been
put forward that alteration of the human gut microbiome may play a critical role
in the pathogenesis of IBD. However, the impact of targeted cytokine blockade
on dysbiosis of intestinal microbial communities is poorly understood. Here, we
investigate the effect of anti-TNF treatment on gut microbial community struc-
tures in a prospective, longitudinal study for 30 weeks. The study compares IBD
as a disorder, which primarily affects the gut, with seropositive and –negative
rheumatoid arthritis and ankylosing spondylitis as a rheumatic disorder (RD) as
an inflammatory disease complex, which usually does not affect the intestine.
Aims & Methods: anti-TNF naive patients suffering from IBD (n¼ 12) or RD
(n¼ 17), subject to first-time anti-TNF therapy were recruited for longitudinal
stool sampling at baseline and 2, 6 and 30 weeks after therapy induction.
Intestinal microbiota communities were studied by 16S rRNA gene (V4) sequen-
cing. Changes in microbiota before and after therapeutic interventions were
assessed in terms of alpha and beta diversity, indicator species and prediction
of metabolic cooperative interactions. Samples from healthy controls (n¼ 19)
were included as a benchmark of healthy microbial profiles.
Results: Intestinal microbial diversity and cooperativity are decreased in both
disease entities, IBD and RA. In IBD, anti-TNF therapy is able to restore
microbial diversity and cooperativity. More over cooperative metabolic interac-
tion is significantly increased only in anti-TNF responders. In RA, anti-TNF
therapy did not significantly restore microbial community structures.
Conclusion:We show that anti-TNF treatment increases the gut microbial diver-
sity and coupling of cross feeding metabolic interactions towards the state of
healthy individuals. Assessment of metabolic interactions of intestinal microbiota
may serve as a marker for clinical response in IBD patients.
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Introduction: Faecal calprotectin (FC) is a most reliable noninvasive means to
distinguish remission from active inflammation in inflammatory bowel disease
(IBD). Commercially available FC tests are time-consuming, and consequently
new rapid tests have been validated. As the incidence of IBD is increasing, self-
monitoring and eHealth technologies have been evaluated in managing patients
with this life-long disease.
Aims & Methods: The aim of this prospective study was to evaluate the feasibility
and cost-effectiveness of a semi-quantitative rapid FC home test and a validated
symptom questionnaire, in patients with colonic IBD. The influence of the self-
monitoring to the course of the disease will also be evaluated. Between April 2015
and December 2016, 180 patients with colonic IBD (126 with UC, 47 with CD,
and 7 with IBD unclassified) were included in the study and randomized in a
study group and control group. Patients in the study group were instructed to
perform the FC home test and fill in a symptom questionnaire every other month
and with increasing of the symptoms, and sent the results to the study/IBD nurse
by e-mail. The control group patients filled in the symptom questionnaire at
baseline and at 12 months and with the appointment to the outpatient clinic
according to normal practice. The patients were not reminded of performing
the stool tests or filling in the questionnaires. The study period was 12 months,
and it is still ongoing.
Results: By the end of February 2017, 134 of the 180 included patients had
completed the 12 months’ follow-up. In the study group, 20/91 (22%) patients
had performed the stool tests and filled in the symptom scores according to the
study protocol for 6 months, and 14/91(15%) patients for 12 months. In the
control group, 14/89 (16%) patients had filled in the symptom score at baseline
and at 12kk. There was no significant difference of the adherence between
patients stratified for IBD-diagnosis, age, or sex. The satisfaction of the patients
with the program as well as the reasons for the discontinuation of the study and
influence of self-monitoring in the number of relapses, phone calls, e-mails, and
appointments to the outpatient clinic in both groups will be evaluated.
Conclusion: The self-monitoring of IBD activity with a rapid FC home test
provides an option for individualized treatment for increasing amount of IBD
patients. However, in this study the adherence to the self-monitoring program
was low. The patients need to be reminded of performing the stool tests and
filling in the questionnaires in time. Also, the selection and education of the
patients, as well as the easy accessibility of the monitoring program are crucial
and need further consideration.
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Introduction: Although the incidence of ulcerative colitis (UC)-related colorectal
cancer (CAC) is increased in cases with long duration of disease, it should also be
recognized that sporadic tumors (ST) develop as older. Various studies have been
conducted on CAC, but there are few clinical studies on ST merged with UC. In
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this study, the clinical and endoscopic features of CAC and ST, treatment
method, and prognosis are compared.
Aims & Methods: Among 261 UC patients who underwent colonoscopy (CS) and
had neoplastic lesions, the clinical features, treatment and prognosis were com-
pared between 71 patients (88 lesions) with CAC (including HGD; CAC group)
and 47 patients (63 lesions) who underwent local excision (surgical or endoscopic
resection) within the presence of the past/present inflammation of UC (ST
group). Definition of CAC and ST was performed by conventional pathological
and immunohistochemical findings.
Results: The age of UC onset (29.8 vs. 39.0) and tumor detection (45.5 vs. 57.3) in
the CAC group were significantly higher than those in ST group (p5 0.01). The
CAC group (47.1%) has a higher percentage of chronic persistent type than the
ST group (2.3%), and the Mayo endoscopic score is also significantly higher
(p5 0.01) in the CAC group (1.43) than ST group (0.38). The percentage of
advanced cancer (35.2% vs. 7.9%) was higher in CAC group than ST group.
In patients with intraepitherial neoplasia (IEN) or submucosal lesions, flat lesion
was found in 15 lesions of CAC group and whereas no flat lesion was observed in
ST group. Only one lesion in ST group could not distinguish the lesions from the
surrounding mucosa without magnifying colonoscopy. In ST group who received
resections, 4 patients after resections observed ectopic CAC or low-grade dyspla-
sia during follow-up. In CAC group, 50, 5, 4 patients received total colectomy,
local colectomy, ESD, respectively, whereas in ST group, 1, 7, 40, 15 patients
received total colectomy, local colectomy, EMR and polypectomy, ESD, respec-
tively. Although mortality from cancer was 11.4% (8/70 cases) in CAC group,
group, no death due to cancer observed in patients whose lesions were found as
IEN. On the other hand mortality from cancer was 2.1% (1/47 cases) in ST
group.
Conclusion: Most sporadic lesions were endoscopically distinct and local resec-
tion was safe if inflammation was controlled. After the sporadic lesions were
resected in remitting UC patients, regular surveillance colonoscopy is necessary
because 8.5% (4/47) of patients was found CAC/dysplasia. Even in CAC group,
prognosis is well in patients with IEN.
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Introduction: Acute severe colitis (ASC) is a dangerous clinical condition that
requires intensive intravenous (iv) corticoisteroids treatment. Nevertheless, about
30–40% of patients fail to response. Intravenous cyclosporine is an effective
rescue therapy in steroid-refractory patients.
Aims & Methods: The aim of our study was to identify the clinical and biological
predictive factors of lack of response to cyclosporine as second-line therapy in
patients with ASC recfractory to IV corticosteroids.
Results: Our study included 52 females and 38 males, with a mean age of 35 years
[14–70 years]. There were 34 patients with Crohn’s disease and 56 diagnosed with
ulcerative colitis. Among the 90 patients enrolled, 68 patients (75.5%) had a good
reponse to cyclosporine. Eleven petients were non responders and underwent
colectomy. In univariate analysis, more than 6 bloody stools per day before
initiation of cyclosporine therapy, a C-Reactive Protein (CRP) greater than
45mg/l prior to treatment, and at day 3 and 7 of treatment by ciclosporine
(p¼ 0.007; 0.002 and 0.001 respectively), ESR greater than 30mm at day 3 of
treatment (p¼ 0.05), thrombocytosis at day 3 of treatment (p¼ 0.05), a Lichtiger
colitis activity index scoring greater than 10 at day 3 of treatment (p¼ 0.001) and
the need for blood transfusion (p5 0.0001) were significantly correlated with the
lack of response to cyclosporine therapy. In a multiple linear regression analysis,
only a CRP greater than 45mg/l on day 7 of treatment, and the necessity of
transfusion were predictive factors of no-response to cyclosporine (p¼ 0.008).
Conclusion: Cyclosporine therapy is rapidly effective in preventing surgery in
patients with ASC with a response rate of 75.5%. A high CRP on day 7 of
treatment with cyclosporine and the need for transfusion, predispose to poor
reponse to intravenous cyclosporine.
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Introduction: Accelerated treatment strategy, including tight disease control and
early aggressive therapy with immunomodulators (IM) and biological agents
have become increasingly common in IBD.
Aims & Methods: The aim of the present study was to estimate the early treat-
ment strategy and outcomes in newly diagnosed patients with Crohn’s disease
(CD) diagnosed between 2004–2015 in Hungary based on the administrative
database of the National Health Insurance Fund (OEP). We used the adminis-
trative database of the National Health Insurance Fund (OEP), the only nation-
wide state-owned health insurance provider in Hungary. Newly diagnosed CD
patients were identified through previously reported algorithms using the ICD-10
codes for Crohn’s disease in the out-, inpatient (medical, surgical) non-primary
care records and drug prescription databases between 2004–2015. Patients were
stratified according to the year of diagnosis and maximum treatment step during
the first 3-years after the diagnosis.
Results: A total of 6173 (male/female: 46.12%/53.87%) newly diagnosed CD
patients were identified during the observational period. Maximum treatment
steps did not differ in patients diagnosed before and after 2009 (5-ASA: 11.7%
vs, 13.5%, steroid 31% vs. 30.5%, IM 40.4% vs. 40.2%, biologicals 16.5% vs.
15.6%). Probability of hospitalizations during the first 3-years from diagnosis
was lower according to the maximal treatment step in patients diagnosed after
2009 (at 36	 30-day period: overall 55.7% vs. 47.4% (p¼ 0.000), anti-TNF: 73%
vs. 66.7% (p¼ 0.103), IS: 64.6% vs. 56.1% (p¼ 0.000), steroid: 44.2% vs. 36.8%
(p5 0.007), 5-ASA: 32.6% vs. 26.7% p¼ 0.157)), respectively. In contrast, sur-
gery rates were not different according to the maximum treatment step (at
36	 30-day period: overall 16.0% vs. 15.3% (p¼ 0.672) anti-TNF 26.7% vs.
27.2% (p¼ 0.993), IS: 24.1% vs 22.2% (p¼ 0.565), steroid 8.1% vs. 7.9%
(p¼ 0.896), 5-ASA 10% vs. 11% (p¼ 0.816)).
Conclusion: Distribution of maximal treatment steps and surgery rates was not
different in patients diagnosed before and after 2009, although immunosuppres-
sive and was commenced earlier. Of note, steroid and 5-ASA remained high after
2009. Maximal treatment steps were associated to hospitalization and surgery
rates, suggesting that maximal treatment steps can be used as proxy marker of
severity in CD. Hospitalization rates during the first 3-years after the diagnosis
decreased in all treatment groups, suggesting a change in the patient
management.
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Introduction: Numerous studies have shown that mesenchymal stromal cells
(MSCs) have a high potential for differentiation and immunosuppressive proper-
ties. Currently under phase I-III clinical trials evaluating the efficacy and safety
of MSCs in the treatment of patients with inflammatory bowel disease - ulcera-
tive colitis and Crohn’s disease.
Aims &Methods:We aimed to compare the frequency of relapses and duration of
remission for 5 years of follow up in patients with luminal Crohn’s disease (CD)
and the total defeat of ulcerative colitis (UC) receiving therapy with mesenchy-
mal stromal cells (MSCs), bone marrow. We compared the frequency of relapses
in patients with luminal form CD (colitis and ileokolit), with a group of patients
with UC (total lesion) receiving MSCs. A group of patients (CD) aged 22 to 56
years (Me-28) (n¼ 24) received MSC culture scheme (0-1-2 weeks, then every 26
weeks). The second group of patients with UC (n¼ 26) aged 20 to 62 years (Me-
28) received the culture of MSCs in a similar way. Evaluation of the effectiveness
of therapy for relapse frequency was carried out at 12, 24, 36, 48 and 60 months
after initiation of therapy.
Results: Among the patients in 1st group relapse in the 12 months of observation
occurred in 2/24 patients (8.3%) in 2nd group, relapse occurred in 3/26 (11.5%)
(OR-0.72; 95% CI 0, 13–3, 96, p¼ 0.92). After 24 months in the group of patients
(group 1) receiving MSC, relapse occurred in 5/24 (20.8%) in group 2 patients
with recurrent disease in 7/26 (26.9%) (OR 0.77; 95% CI 0.13–3.96, p¼ 0.92).
After 36 months in group 1 patients with a relapse of the disease in 8/24 (33.3%)
in group 2 relapsed in 14/26 (53.8%) (OR-0.62; 95% CI 0.32–1.21; p¼ 0.24).
After 48 months in group 1 receiving MSC, relapsed in 11/24 (45.8%) in
group 2 relapsed in 18/26 (69.2%) (OR-0.6; 95% CI 0.37–0.97, p¼ 0.048).
After 60 months in 1st relapse in 16/24 (66.6%) in group 2 relapsed in 22/26
(84.6%) (OR0.63; 95% CI 0.44–0 90, p¼ 0.013).
Conclusion: MSCs transplantation longer contributes to clinical remission in
patients with Crohn’s disease luminal shape compared to a group of patients
suffering from ulcerative colitis.
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Introduction: Perianal fistulas are the most widespread and common types of
fistulas in Crohn’s disease (CD). They are difficult to treat, worsen the quality
of life of the patient and increase the risk of bowel resection. Despite the sig-
nificant effect of anti-cytokine therapy fistulous forms of CD, treatment of these
patients remains a difficult task with high risk of relapse of CD. Mesenchymal
stromal cells have immunomodulatory properties and a large regenerative poten-
tial, at present also used for treatment of fistulous CD and perianal fistulas of
different etiologies.
Aims & Methods: We aimed compare the efficacy of combined therapy (local and
systemic) mesenchymal stromal cells (MSCs) of bone marrow, infliximab (IFX)
and antibiotics/immunosupression (IS) on the rate of healing of simple perianal
fistulas in Crohn’s disease. 36 patients with Crohn’s disease with perianal lesions
were divided into three groups depending on the method of therapy. The first
group of patients aged from 19 to 58 years (Me-29) (n¼ 12) received culture of
MSCS systemically via the scheme and locally: on the perimeter of the fistulous
introduced 40 million MSCs - 4 point of inject and 1ml of saline containing 10
million MSCs. Then after 4 and 8 weeks re-injected 40 million MSCs in the area
of the fistula. The second group of patients with CD (n¼ 10) aged 20 to 68 years
(Me-36) were receiving anti-cytokine therapy of IFX. The 3-rd group of patients
with CD (n¼ 14) aged 20 to 62 years (Me-28) received antibiotics and is. In the
dynamics evaluated the closure of the external opening of the fistula. Ano- and
rectosigmoscopy carried out after 3, 6, 12 and 36 months from start of therapy.
Results: After 12 weeks among patients of the 1st group simple healing of fistulas
was observed in 10/12 patients (83.3%), in the 2nd group healing simple fistulas
have a 8/10 (80.0%) (OR-0.83; 95% CI 0.14–4.9; p¼ 0.72). In the 3rd group – in
5/14 patients (35.7%) (OR 0.26; 95% CI 0.07–0.97; p¼ 0.04 in comparison with
the 1st group). After 6 months in the 1st group of patients receiving MSCs,
healing of simple fistulas persisted in 8/12 (66.6%) with the 2nd group - 7/10
(70.0%) (OR - 1.11; 95% CI 0.32–3.84; p¼ 0.76). In the 3rd group – patients 4/14
(28.6%) (OR - 0.47; 95% CI 0.2–1.11; p¼ 0.12 in comparison with the 1-st
group). After 12 months in the 1st group receiving MSCs, healing of simple
fistulas persisted in 7/12 (58.3%), in the 2nd group - in 6/10 (60.0%) (OR -
1.25, 95% CI 0.48–3.22; p¼ 0.69). In the 3rd group – in 2/14 patients (14.3%)
(NR-0.49; 95% CI 0.24 to about 0.98; p¼ 0.03 in comparison with the 1st group).
After 36 months among the patients of the 1st group, the closure of the fistula
was preserved in 5/12 patients (41.6%), in the 2nd group - 5/10 (50.0%) (OR
1.17; 95% CI 0.53–2.55; p¼ 0.96). In the 3rd group – in 0/14 patients (0.0%) of
(OR - 0.58; 95% CI 0.36–0.94; p¼ 0.01 in comparison with the 1st group).
Conclusion: Combined stem cell and anti-cytokine therapy of CD with perianal
lesions significantly contributes to more frequent and prolonged closure of simple
fistula, compared with antibiotics/immunosuppressant.
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Introduction: Mesenchymal stromal cells (MSC) are used for the treatment of
chronic inflammatory and autoimmune diseases in recent years, including rheu-
matoid arthritis (RA) and inflammatory bowel disease (IBD). In most cases,
together with the MSC, patients receiving concomitant immunosuppressive ther-
apy. It is found that immunomodulatory drugs (azathioprine (AZA), methotrex-
ate, 6-mercaptopurine, infliximab (IPF)), regardless of the concentration, do not
affect the viability, differentiation, phenotype, and ability to inhibit proliferation
of MSCs peripheral blood mononuclear cells [1]. However, studies conducted by
Huang HR et al. demonstrate that IPF rendered minimal impact on the MSC
proliferation, apoptosis and cell cycle, while, azathioprine inhibited cell prolif-
eration and induced apoptosis of MSCs in vitro [2].
Aims & Methods:We aimed to evaluate the effectiveness of therapy mesenchymal
stromal cells (MSCs) from the bone marrow of patients with Crohn’s disease
(CD) receiving azathioprine. 34 patients with inflammatory (luminal) form CD
were divided into two groups. The first group of patients aged 19 to 58 years old
(Me-29) (n¼ 15) was treated with anti-inflammatory therapy with MSCs culture
in combination with AZA. The second group of patients with CD (n¼ 19) aged
23 to 60 years old (Me-31) received MSCs according to the recommended scheme
without AZA. To assess the effectiveness of anti-inflammatory therapy was
determined by the dynamics of the level of pro-inflammatory interleukins (IL)
- TNF-, IFN- and IL-1b at 2, 6 and 12 months from the start of MSC therapy.
Initial level of IFN- in the 1st group was 110.4 12.5 pg/ml, in the 2nd -
450.8 22.4 pg/ml (p5 0.05), TNF - in 1st group - 13.9 1.9 pg/ml, in the
2nd - 66.7 14.2 pg/ml (p5 0.05), IL-1b in 1st group – 5.7 0.28 pg/ml, in the
2nd - 9.2 0.2 pg/ml (p5 0.05).
Results: After 2 months of therapy MSCs level of IFN- in 1st group was sig-
nificantly decreased from baseline and was 86.5 9.1 pg/ml, the 2nd was
96.9 12.1 pg/ml (between groups p¼ 0.5), TNF- in 1st group decreased to
39.6 8.4 pg/ml, in the 2nd - 56.5 10.7 pg/ml (between groups p¼ 0.2), IL-1b
in 1st group -50.7 9.3 pg/ml, in the 2nd - 56.2 10.2 pg/ml (between groups
p¼ 0.7). After 6 months of therapy MSCs level of IFN- in 1st group decreased
and amounted to 79.4 8.5 pg/ml, in the 2nd - 80.8 7.3 pg/ml (between groups
p¼ 0.9), TNF - in 1st group decreased to 44.9 6.3 pg/ml, in the 2nd -
49.7 10.4 pg/ml (between groups p¼ 0.7). IL-1b in 1st group - 45.6 7.3 pg/
ml, in the 2nd - 54.2 9.2 pg/ml (between groups p¼ 0.45). After 12 months of
initiation of therapy MSCs level of IFN- in 1st group decreased and amounted
to 90.8 6.5 pg/ml, in the 2nd - 128.8 12.3 pg/ml (between groups p¼ 0.02),
TNF- in the 1st group - 78.9 10.5 pg/ml, in the 2nd - 116.9 13.2 pg/ml
(between groups p¼ 0.04), IL-1b in 1st group - 68.7 8.9 pg/ml, in the 2nd -
96.9 9.6 pg/ml (between groups p¼ 0.03)
Conclusion: After one year of observation concomitant treatment with AZA
when administered MSCs significantly reduces the level of pro-inflammatory
cytokines, which could have a more pronounced anti-inflammatory therapeutic
effect.
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Introduction: Ulcerative colitis (UC) is characterized by diffuse and continuous
inflammation of the colon. Currently, the etiology and pathogenesis remain
unclear. According to a previous epidemiological study, approximately 75% of
newly diagnosed UC patients have active distal UC. Topical 5-aminosalicylic
acid (5-ASA) and corticosteroids are used frequently in the treatment of active
distal UC.
Aims & Methods: Our study aimed to determine the efficacy and safety of dif-
ferent topical drugs used to treat active distal UC. A random-effects model
within a Bayesian framework was utilized to compare treatment effects and
safety as odds ratios (ORs) with corresponding 95% credible intervals (CrI).
The surface under the cumulative ranking area (SUCRA) and median rank
(MR) with corresponding 95% CrI were calculated to rank the treatment
outcomes.
Results: In the induction of clinical and endoscopic remission, most regimens
showed significant advantages over placebo except topical budesonide 0.5mg/d
and hydrocortisone 100mg/d. According to SUCRA and MR values, rectal 5-
ASA 1.5 to 2.0 g/d þ Beclomethasone dipropionate (BDP) 3mg/d rendered the
highest probability of being the best regimen to achieve clinical and endoscopic
remission, followed by the separate use of 5-ASA 4 g/d and BDP 3mg/d. The
occurrence of adverse events was not significantly different between each treat-
ments and placebo.
Conclusion: In conclusion, the combined use of topical 5-ASA and BDP proved
to be the best choice for active distal UC and further well-designed researchers
are warranted to assess its efficacy and safety.
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Hospital Dept. of Gas, London/United Kingdom
Contact E-mail Address: suhail.nurbhai@vhsquared.com
Introduction: The oral delivery of therapeutic concentrations of anti-TNF to
affected mucosa of patients with inflammatory bowel disease (IBD) has remained
challenging despite advances in protein engineering, the attractions of oral dosing
for chronic therapies, and the acknowledged benefit of anti-TNF monoclonal
antibodies in the management of IBD. As the ileum is commonly involved in
Crohn’s disease (CD), it is important to deliver drug there if treatment is to be
effective. This is the first report of a domain antibody to TNF, V565, engineered
to be resistant to intestinal proteases, delivering high concentrations of active
compound in the ileal fluid following oral administration to human volunteers.
The oral domain antibodies (Vorabodies) are delivered via enteric coated mini-
tablets (MTs) designed to release active drug at pH 6.5.
Aims & Methods: Following prior placebo-controlled demonstration of the safety
and tolerability of high single and multiple doses of V565, this open label assess-
ment was performed to confirm the delivery of active domain antibody to the
terminal ileum of human subjects. Four subjects with a terminal ileostomy were
given a single oral dose of V565 and ileostomy bags were collected hourly for the
first 12 hours post dose with further collections 16, 20 and 24 h post dose.
Contents were analysed for V565 concentrations by competitive ELISA. In addi-
tion serial blood samples were taken for determination of V565 serum concen-
trations over 24 h.
Results: Four subjects with an ileostomy (3 with UC; 1 with a prior history of
colonic obstruction) were given a single 1665mg dose of V565. The dose was
selected based on the prior demonstration of safety and tolerability of this dose
and the likely maximum daily dose for initial clinical efficacy assessment. High
concentrations of active V565 were demonstrated in the ileal fluid of all four
subjects as shown in Table 1 below.
Subject
Micromolar concentration of V565 in ileal fluid
Hours post-dose
1 2 3 4 5 6 7–16 17–24
31001 – 406 306 0.8 0 0 0 0
31002 – 33 1130 792 82 13 5(ave) 0
31003 – – 1060 496 7 0 38(ave) 0
31004 – 126 0.2 11 4 7 0 0
In addition to the V565 concentrations in ileal fluid, partially dissolved MTs were
recovered from the ileostomy bags of all subjects. Each 1665mg dose contained a
total of 135 MTs. 50 MTs were recovered 2 h post dose from Subject 31001; these
were not analysed for V565 as this was a post hoc analysis and the MTs were not
stored in a way to enable reliable analysis. 64MTs (containing 135mg V565) were
recovered 3 h post dose from subject 31002; 78MTs (458mg) 3 h post dose from
subject 31003; and 125MTs (1260mg) 2 h post dose from subject 31004. Overall,
66–82% of an administered dose was recovered from ileostomy bags when MT
quantities were added to ileal fluid concentrations. V565 was not detected in any
serum sample (LLoQ 62.5 ng/ml).
Conclusion: V565, an oral domain antibody (Vorabody) to TNF engineered to be
resistant to intestinal proteases, resulted in high concentrations of active drug in
ileal fluid and was not detected in serum following oral administration. In
patients with no ileostomy the partially dissolved MTs seen in this study are
expected to provide active V565 to lesions distal to the ileum. This profile may
be beneficial for IBD and merits further investigation as a potential oral
treatment.
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PARTICULAR QUALITIES OF CLINICAL MANIFESTATIONS AND
MEDICAL THERAPY
E. Dobrolyubova
1, I. Ruchkina2, A. Parfenov3, O. Knyazev3
1Department Of Health Of Moscow, Moscow Clinical Scientific - Practical Center,
Central Scientific - Research Institute of Gastroente, Moscow/Russian Federation
2State Scientific Center of Gastroenterology, Moscow/Russian Federation
3Ibd, Moscow Clinical Research Center, Moscow/Russian Federation
Contact E-mail Address: dobroljubova.ekaterina@rambler.ru
Introduction: In recent years publications of different countries paid great atten-
tion to the symptoms, that specific for the functional bowel disease in patients
with UC in remission. Our aim was to determine the incidence of IBS – like
disorders in UC, especially their clinical manifestations and medical therapy.
Aims & Methods: The study included 162 patients with UC a year after the last
attack of the disease, that were on maintenance therapy with 5-ASA dosage of 2
gram per day for the last 12 months. Study group was dominated by women - 94
patients (58%), average the age of the subjects was 38 3 years. Localization of
the UC in 83% of cases revealed left-sided and 17% - subtotal lesion of the colon.
All patients underwent a standard examination of the definition of the level of C -
reactive protein (CRP), and faecal calprotectin (FCP), and exclude the acute
intestinal clostridial infection, faecal microbiota was determined. The clinical
activity of the general condition of the patient and endoscopic subscale were
evaluated using the Mayo score. Quality of life of patients was calculated on a
Gastrointestinal Simptom Rating Scale (GSRS), where the minimum score was
15 and the maximum 105. Evaluation of the severity of IBS symptoms was
calculated using a visual - analogue scale (VAS), where 0 was the absence of
clinical manifestations IBS, and 10 - the maximum clinical manifestations.
Results: Of the 162 explored patients in 122 cases (77.8%) clinical and endoscopic
remission in UC was determined: a total Mayo score 2, physician’ s global
assessment¼ 0, rectal bleeding¼ 0, endoscopic subscale¼ 0, the normal structure
of the colon mucosa by histological study of biopsies, CRP5 5, FCP 50mg/g,
the amount of points on the scale GSRS¼ 15, VAS¼ 0. In 36 (22.2%) patients
intestinal symptoms were determined: mushy stools 2–4 times per day at daytime,
bloating and rumbling in the abdomen. In the clinical picture of 5 patients of
these group (3.1%) there dominated loose stools 3–4 times a day, sometimes
streaked with blood. The examination revealed the exacerbation of UC, left-
sided lesion, moderate activity (a total Mayo score¼ 5, physiciań s global
assessment¼ 1, rectal bleeding¼ 1, endoscopic subscale¼ 2, intense lymphoplas-
macytic infiltration on histological studies of colon mucosa biopsies,
CRP¼ 11 0.9mg/l, FCP¼ 250 40mg/g, quality of life GSRS lowered to
35 5 points. For these patients the dose of mesalazine was increased to 3 g
per day and rectal forms of mesalazine were added. In 31 (19.1%) patients in
the clinical picture pain syndrome was dominated (daily abdominal pain, worse
before stool, severity of pain according to VAS¼ 7 1 points), abdominal dis-
tension (VAS¼ 6 1 points), rumbling, frequency stool reached 2–4 times per
day, sometimes with mucus, but without blood. The examination confirmed the
remission of UC (total Mayo score 2, physiciań s global assessment¼ 0, rectal
bleeding¼ 0, endoscopic subscale¼ 0, the minimum colitis histological study
biopsies of colon mucosa, CRP¼ 2.5 2.5mg/l, FCP¼ 125.0 25.0mg/g, the
level of quality of life was reduced by GSRS to 75 5 points. In this group of
patients showed changes in faecal microbiota: reducing the number of bifidoba-
cilles 5107 CFU (colony-forming unit) and lactobacilles 5105 CFU per 1 g. of
feces, the growth performance of opportunistic microbiota: Klebsiella 4104
CFU per 1 g. of feces, Proteus 4104 CFU per 1 g. of feces, Citrobacter 4104
CFU per 1 g. of feces, Coccious microflora, Escherichia coli hemolitica 40 CFU
per 1 g. of feces. Attempt to increase the dosage of 5-ASA and accession to
treatment the rectal forms of mesalazine in this group of patients have not led
to the disappearance of the existing symptoms. This group of patients was
appointed by pathogenetic therapy of functional bowel disease: myotropic anti-
spasmodics (mebeverin 405mg/day), a course of rifaximin (1650mg/day) and
combination probiotics on the background maintenance therapy mesalazine
2 g/day. As a result of therapy regression of IBS - like symptoms was reached:
severity of pain according to VAS¼ 0, bloating VAS¼ 0, stool frequency was 1
time per day without mucus, improved quality of life by GSRS to 15 points.
Conclusion: In 19.1% of the studied patients with UC in remission IBS-like
disorders was found. In the clinical picture pain sindrome, bloating, rumbling,
moderate diarrhea syndrome with mucus, a sharp decline in quality of life level
GSRS were determined. The development of clinical manifestations of IBS in the
target group of patients with UC is associated with persistent changes in faecal
microbiota. Remission of UC with IBS-like disorders reached by the appoint-
ment of pathogenetic therapy of functional bowel disease on the background of
mesalazine maintenance therapy.
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Introduction: Fatigue is a common symptom in inflammatory bowel disease
(IBD) and persists despite clinical remission. Acupuncture has been shown to
be effective for treating fatigue in many chronic diseases. Fatigue can be
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objectively evaluated by the IBD validated Functional Assessment of Chronic
Illness Therapy-Fatigue Scale (FACIT-F).
Aims & Methods: The main objective was to assess the efficacy of electroacu-
puncture (EAc) vs. sham EAc and no treatment for treating fatigue in patients
with quiescent IBD in a single-blind randomized trial. Secondary objectives were
to assess changes in quality of life, depression, anxiety and sleepiness after treat-
ment with EAc.
Methods: Fifty-two patients with quiescent IBD and severe fatigue (FACIT-
F540) (65.3% female, mean age 42 years) were randomized to EAc vs sham
acupuncture vs control group. Patients in EAC and sham EAC groups performed
a total of 9 acupuncture sessions during eight weeks (2 sessions/first week and
one session per week during 7 weeks). Fatigue was evaluated with IBD validated
Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F).
Patients also completed validated questionnaires to assess quality of life in
IBD, depression, anxiety and sleepiness during and after the treatment periods.
Results: Both EAc and Sham group improved the FACIT-F score post-treatment
(EAP 9.53 points, 95% CI (–12.3 to 6.75, Basal Vs 9th session p5 0.001);
Sham 5.46 points, 95%CI (9.7 to 2.7, Basal Vs 9th session p¼ 0.003). No
significant changes were observed in control group (p¼ 0.339). We found a trend
for better response in the EAP than in the sham group although the difference in
FACIT-F score was not significant (p¼ 0.09). EAc also improved quality of life
(-5.17 points, 95% CI (8.2 to 2.06, Basal Vs 9th session p¼ 0.003); depression
(8.9 points, 95% CI (4 to 13.8, Basal Vs 9th session p¼ 0.002), anxiety (10.6
points, 95% CI (3.6 to 17.6, Basal Vs 9th session p¼ 0.006) and sleepiness
scores (1.46 points, 95% CI (0.096 to 2.83, Basal Vs 9th session p¼ 0.038).
However, the differences in between EAc and sham and control groups were
not significant (p4 0.05).
Conclusion: Both targeted and sham electroacupuncture are effective in managing
fatigue in patients with quiescent IBD. NCT02733276.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Anti-TNF, such as adalimumab (ADA) and infliximab (IFX), have
improved the therapeutic care of Crohn’s disease (CD). However their use may
be associated with loss of efficacy, adverse events and sometimes primary failure.
After the first anti-TNF discontinuation, it is possible to switch to another anti-
TNF. In France, three anti TNF are available in ulcerative colitis (IFX, ADA
and golimumab), but only the first two are approved in CD, because golimumab
has not been studied in this indication. The aim of this study was to report
golimumab efficacy and safety in CD.
Aims & Methods: This national multicenter retrospective study included patients
with CD from 12 French tertiary centers who received golimumab and analyzed:
clinical response, duration of treatment, tolerance, reasons for discontinuation of
treatment, disease phenotype, and treatments preceding and associated with
golimumab. The main endpoint was the efficacy of golimumab defined by the
duration of treatment before failure (need for therapeutic optimization or cessa-
tion). Predictive factors of therapeutic response were determined (log rank and
Cox model), and the tolerance was evaluated.
Results: One hundred and fifteen patients with a median duration of the disease
of 13.5 years received on average golimumab in 3, 6 th line of biotherapy. The
overall clinical response assessed by the physician was 55.8% at the time of the
re-evaluation (on average, at 3.8 months [0.6–24] after initiation of therapy). The
mean duration of treatment was 12.3 months (0.55–44). Sixty-seven percent of
patients received treatment for more than 6 months and 48.7% of patients were
still treated with golimumab at the end of the follow-up. At 12 months, 34.9% of
patients still received golimumab without optimization. At 24 months, this figure
was 19.3%. In univariate analysis, the factors associated with a longer golimu-
mab treatment duration without stopping or optimizing were the active smoking
status (p¼ 0.043), the absence of anoperineal lesions (p¼ 0.012), the presence of
extra-intestinal symptoms (p¼ 0.035), the presence of a co-immunosuppression
of more than 6 months (p5 0.001) and discontinuation of the first anti-TNF
for intolerance (p¼ 0.022).) In multivariate analysis, discontinuation of the first
anti-TNF for intolerance and the presence of co-immunosuppression with thio-
purine derivatives or methotrexate over 6 months were independently associated
with golimumab efficacy (OR 2.16, 95% CI [1.25–3.86], p¼ 0.005 and OR
3.98.95% CI [2.3–7.1], p5 0.001, respectively). Side effects led to discontinuation
of treatment in 6% of patients. These were paradoxical psoriasis in three patients,
paresthesia (n¼ 1), lower extremity edema (n¼ 1), injection site reaction (n¼ 1)
and not reported reason for one patient.
Conclusion: After failure of the other anti-TNF agents, golimumab is well toler-
ated and results in sustained clinical response in one in two patients with Crohn’s
disease, particularly when associated with a co-immunosuppression, and if the
reason for discontinuation of the first anti -TNF was an intolerance.
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Aims & Methods: The purpose of this survey was to determine physicians’ famil-
iarity and comfort level with prescribing biosimilars to patients. The survey was
sent to physicians residing in the European Union and specializing in the follow-
ing clinical fields: dermatology, endocrinology, gastroenterology, neurology,
oncology, and rheumatology.
Introduction: Biologic medicines and their biosimilar counterparts are effective
therapies for many conditions, including inflammatory bowel disease, Crohn’s
disease, and ulcerative colitis. The European Medicines Agency (EMA) has
approved twenty-two biosimilar medicines, which are derivatives of eight original
biologics, and four more biosimilar are scheduled to be reviewed this year. As the
number of approved biosimilars rises, regulatory agencies must closely monitor
their safety and efficacy.
Results: The majority of survey respondents specialized in endocrinology (19%)
and gastroenterology (19%). Respondents were recruited almost equally from
the five countries, with France being the most represented country (22%) and the
UK being the least represented (18%). The majority of respondents (55%) indi-
cated that safety and efficacy is the most important factor in determining whether
a patient should be switched from a prescribed biologic therapy to its approved
biosimilar. Thirty percent of respondents indicated that clinical trials related to
the disease or condition being treated is the most important factor to switching.
Only 12% of respondents indicated that cost to the government or insurance
companies is a primary concern, and only 3% were primarily concerned with
immunogenicity.
Conclusion: This survey suggests that the safety and efficacy of biosimilar med-
icines is of paramount importance to physicians and that physicians highly value
clinical trial data for biosimilars. Given that biosimilars are structurally distinct
from their original innovator biologic counterparts, the EMA should consider
requiring more stringent clinical trials data for biosimilars seeking approval.
Specifically, the EMA should require clinical trials for each proposed indication
and should provide physicians with this data so that physicians can make
informed prescribing choices for the safety of their patients.
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Introduction: Oral steroids are effective in inducing remission of moderate flares
of patients with either ulcerative colitis (UC) or Crohn’s disease (CD). However,
we know little about their efficacy in immunosuppressed patients or their possible
role in reducing biologics and/or surgical needs in these patients
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Aims & Methods: We aimed to determine the efficacy of systemic or low bioa-
vailability oral steroid treatment for moderate flares of patients with at least 6
months of immunosuppressive treatment, and describe long-term follow-up
Inflammatory bowel disease (IBD) immunosuppressed patients (thiopurines or
methotrexate) from our population-data registry were analyzed. For statistical
analysis, Chi-square test, U Mann-Whitney test and Kaplan Meier survival ana-
lysis were used.
Results: 392 IBD patients with a median of 82 (6–271) months of immunosup-
pressive (IMM) treatment were identified (table 1). 89 patients (23%) (33% UC
and 67% CD) needed at least one steroid treatment during follow-up (63%
systemic steroid and 37% low bioavailability oral steroid) with a median time
of steroid treatment of 4 (1–168) months. Average time from IMM to steroid
treatment was 26 (6–207) months. In IBD patients there were no differences
regarding sex, age, disease, location, perianal disease, extra intestinal manifesta-
tions, appendectomy, smoke habit, need for steroids at diagnosis and previous
abdominal surgery between patients with no need of steroids and patients with
steroid treatment during follow-up. In CD patients, biological treatment for
perianal disease before IMM (p¼ 0.0039) and fibrostenotic (B2) or fistulizating
(B3) behavior (p¼ 0.005; OR 2.284) were risk factors for using steroids after
IMM treatment. In UC patients, no statistically significant variables were iden-
tified. 49 of these 89 steroid treatment patients (55%) needed biological treatment
or surgery after a median of 13 months (0–178); 19 (21%) needed more than one
steroid treatment (2–5) and just 31 patients (35%) did not need any other treat-
ment. CD patients had higher risk (p¼ 0.007; OR: 3.529) to receive biological
treatment or surgery versus UC patients. Otherwise, the more months using
steroids in UC patients, the greater risk for biological or surgery treatment
(p¼ 0.009). During follow-up, though it’s not statistically significant
(p¼ 0.078), we observe that 75% probability of rescue treatment for UC patients
is 62 months versus 36 months for CD patients.
Conclusion: 23% of IBD immunosuppressive patients needed at least one steroid
treatment after 6 months of IMM. Previous biological treatment and B2-B3
behavior predicted steroid treatment in CD patients, who had 3.5 times more
risk to receive biological treatment or surgery after steroid treatment using it
earlier than UC patients. Just 1/3 of patients who needed steroid treatment after
IMM did not need any other rescue treatment
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Introduction: PYRAMID was an international multi-center non-interventional
postmarketing registry assessing long-term safety and effectiveness of adalimu-
mab (Humira [ADA]) as used in routine clinical practice. Patients with and
without prior ADA experience were allowed to enroll. The final long-term
effectiveness of ADA is reported in adult ADA-naı̈ve patients (those who had
not received ADA before registry enrollment) with moderate to severe Crohn’s
disease (CD) who were treated according to the local product label.
Aims & Methods: All patients entering the registry were followed for up to 6
years. Effectiveness of ADA was measured using Physician’s Global Assessment
(PGA; [a composite of Harvey Bradshaw Index and rectal bleeding score]), Short
Inflammatory Bowel Disease Questionnaire (SIBDQ), and 4 components of the
Work Productivity and Activity Impairment (WPAI) questionnaire, including
absenteeism, presenteeism, overall work impairment, and activity impairment.
Effectiveness measures, captured in all patients who received at least 1 dose of
ADA in the registry and had at least 1 post-enrollment measurement, were
summarized descriptively by the number of observations that were not missing
at each registry visit; data were reported as observed. Values at enrollment are
considered as baseline values.
Results: Among 5025 patients evaluated in the registry, 2057 (40.9%) were ADA-
naı̈ve. Of these, 1199 patients (58.3%) were female; mean age 37.1 years at
enrollment. MeanSD ADA exposure for the ADA-naı̈ve subgroup during
the registry was 1118.5 842.3 days. A total of 1082 patients (52.6%) had
prior exposure to at least 1 anti-TNF/biologic; 853 (41.5%) and 831 patients
(40.4%) used immunomodulators and corticosteroids, respectively, at enroll-
ment. Mean change from baseline in effectiveness measures for patients with
CD is shown in the table. Mean PGA score and SIBDQ as well as WPAI
domains improved in ADA-naı̈ve patients from enrollment to 1 year and were
sustained for up to 6 years (table). No new safety signals were identified in the
registry.
Conclusion: At 1 year after entering the international postmarketing registry of
ADA use in routine clinical practice, clinically meaningful improvements in dis-
ease activity, work productivity, and activity impairment were achieved in ADA-
naı̈ve patients with moderately to severely active CD. These improvements were
maintained for up to 6 years of the registry among the patients who remained in
the study.
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Abstract No: P0384
IMM4 6 MONTHS CD 260 (65%) UC 138 (35%) TOTAL 392 (100%)
Gender (male) 136 (52%) 71 (54%) 207 (53%)
Location 46%L1/18%L2/36%L3 17%L4 52%E3/45%E2/3%E1
Behaviour 57%B1/43%B2–3 25%Perianal disease
Appendectomy 91 (77%) 6 (5%) 97 (25%)
Extraintestinal manifestations 49 (19%) 23 (18%) 72 (19%)
Smoke habit Smoker 84 (32%)
Ex-smoker 50 (19%)
Non smoker 126 (48%)
Smoker 17 (13%)
Ex-smoker 12 (9%)
Non smoker 103 (78%)
Smoker 101 (26%)
Ex-smoker 62 (16%)
Non smoker 229 (58%)
Steroids at diagnosis 200 (77%) 104 (79%) 304 (78%)
Biological before IMM 4 (2%) 0 (0%) 4 (2%)
Surgery before IMM 62 (24%) 2 (16%) 64 (16%)
Steroids post-IMM Classical 38 (63%)
Low biodisp 22 (37%)
Classical 18 (62%)
Low biodisp 11 (38%)
Classical 56 (63%) Low biodisp 33 (37%)
Surgery at follow-up 13 (5) 1 (0.8%) 14 (3.5%)
Biologic at follow-up 27 (10%) 9 (7%) 35 (9%)
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Introduction: Adalimumab (ADA) has been shown to improve clinical outcomes
and health-related quality of life (HRQoL) significantly in patients (pts) with
ulcerative colitis (UC) in a clinical practice setting.1 Evidence is limited about
benefits of ADA among UC pts with different characteristics.
Aims &Methods: The aim was to examine clinical and HRQoL effects of ADA in
pts with UC based on disease severity and prior use of tumour necrosis factor
inhibitor (TNFI). InspirADA details have been presented.1 Pts received ADA
160/80mg at week (wk) 0/2 followed by ADA 40mg eow at wks 4 through 26. Pts
who did not respond to ADA by wk 8 were to discontinue. Pts who lost response
at or after wk 8 could escalate to ADA 40mg weekly. UC pts were categorized
into subgroups based on physician global assessment (PGA) of disease severity
(moderate [baseline PGA¼ 2] vs severe [baseline PGA¼ 3]) and previous TNFI
use (naı̈ve vs experienced). Proportions of pts with Simple Clinical Colitis
Activity Index (SCCAI) response (defined as a decrease of 2 points vs baseline)
and remission (defined as an SCCAI 2) were calculated for each cohort at wks
2, 8 and 26. Change from baseline in HRQoL outcomes was calculated, including
Short Inflammatory Bowel Disease Questionnaire (SIBDQ), European Quality
of Life-5 Dimensions-5 Level (EQ-5D-5L), Treatment Satisfaction Questionnaire
for Medication (TSQM) and Work Productivity and Activity Impairment
(WPAI). Missing data were imputed using nonresponder imputation for
response/remission and last observation carried forward for all other outcomes.
Comparisons of remission rate (using logistic regression) and HRQoL outcomes
(using linear regression) were conducted in moderate vs severe UC and in TNFI
naı̈ve vs experienced cohorts.
Results: Among pts with moderate UC (n¼ 386) and severe UC (n¼ 74), SCCAI
response rates were 74.6% vs 74.3%, 80.1% vs 71.6%, and 67.1% vs 64.9% at
wk 2, 8, 26, respectively. Although remission rates were similar between moderate
and severe pts at wk 26 (49.5% vs 40.5%, p¼ 0.16), ADA provided greater
disease control for moderate pts at wk 2 (29.8% vs 9.5%, odds ratio [OR]
4.1.95% confidence interval [CI] 1.8–9.1; p5 0.001) and wk 8 (52.3% vs
31.1%, OR 2.4, 95% CI 1.4–4.4; p¼ 0.01) compared to severe pts (table). The
rate of dose escalation (ADA 40mg weekly) was 28.0% in moderate and 28.4%
in severe UC pts. HRQoL outcomes were similar between the moderate and
severe cohorts. Among pts who were naı̈ve (n¼ 389) and those experienced to
TNFIs (n¼ 72), response rates were 74.0% vs 76.4%, 79.2% vs 75.0%, and
66.3% vs 68.1% at wk 2, 8, 26, respectively. No significant difference was
observed in remission rates for naı̈ve vs experienced pts at wk 2 (28.0% vs
19.4%, p¼ 0.43) and wk 26 (49.4% vs 41.7%, p¼ 0.39), but naı̈ve pts showed
a significantly higher remission rate than those experienced to TNFIs at wk 8
(52.2% vs 31.9%, OR 2.1, 95% CI: 1.2–3.7; p5 0.001). The rate of dose escala-
tion was 26.5% in naı̈ve pts vs 36.1% in experienced pts (p¼ 0.09). In general,
HRQoL outcomes were similar between naı̈ve and experienced TNFI pts.
Table: Remission rate by disease severity and previous use of TNFIs
Remission rate,
n (%)
Moderate UC
(n¼ 386)
Severe UC
(n¼ 74)
Odds ratio
(95%CI)* P value
Wk 2 115 (29.8%) 7 (9.5%) 4.06 (1.81–9.12) 50.001
Wk 8 202 (52.3%) 23 (31.1%) 2.43 (1.43–4.40) 0.001
Wk 26 191 (49.5%) 30 (40.5%) 1.44 (0.87–2.38) 0.16
(continued)
Table Continued
Remission rate,
n (%)
Moderate UC
(n¼ 386)
Severe UC
(n¼ 74)
Odds ratio
(95%CI)* P value
Remission rate,
n (%)
Naı̈ve to TNFIs
(n¼ 389)
Experienced to
TNFIs (n¼ 72)
Adjusted
odds ratio
(95%CI)*
P value
Wk 2 109 (28.0%) 14 (19.4%) 1.30 (0.68–2.51) 0.43
Wk 8 203 (52.2%) 23 (31.9%) 2.09 (1.19–3.65) 0.01
Wk 26 192 (49.4%) 30 (41.7%) 1.26 (0.75–2.11) 0.38
*Comparison between naı̈ve and experienced groups was adjusted for baseline
SCCAI. Because baseline SCCAI is highly correlated with PGA, adjustment for
baseline SCCAI in moderate and severe UC pts defined by PGA was not
performed.
Conclusion: ADA treatment achieved clinically relevant rates of SCCAI response
and remission even in pts who had severe UC and those who were more treat-
ment-refractory (experienced to TNFIs), in clinical practice. In addition, ADA
was associated with greater disease control in the induction period for pts with
moderate than severe UC and for naı̈ve pts than those experienced to TNFIs.
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Table: Change from enrollment (baseline) in effectiveness measure scores in ADA-naı̈ve patients with CD (N¼ 2057)
Effectiveness measure Enrollment, mean (SD)
Change from enrollment, mean (SD)
Month 12 Month 24 Month 36 Month 48 Month 60 Month 72
PGA 8.0 (5.6) n¼ 1969 3.6 (5.4) n¼ 1305 3.7 (5.5) n¼ 1109 4.2 (5.3) n¼ 1036 4.2 (5.2) n¼ 962 4.2 (5.5) n¼ 858 4.1 (6.1) n¼ 809
SIBDQ* 40.7 (12.7) n¼ 1422 11.0 (12.4) n¼ 689 10.2 (14.1) n¼ 505 11.3 (13.4) n¼ 430 11.5 (13.1) n¼ 388 11.4 (13.1) n¼ 337 11.1 (12.9) n¼ 309
WPAI Absenteeism** 21.9 (33.5) n¼ 802 12.2 (33.8) n¼ 314 10.3 (32.8) n¼ 217 15.5 (35.3) n¼ 186 11.6 (39.3) N¼ 165 10.2 (34.3) n¼ 146 10.7 (31.6) n¼ 119
WPAI Presenteeism** 41.1 (30.0) n¼ 833 18.9 (32.4) n¼ 338 19.3 (35.7) n¼ 248 22.0 (33.2) n¼ 207 18.7 (37.8) n¼ 181 18.4 (31.3) n¼ 160 19.6 (30.4) n¼ 134
WPAI Overall Work Impairment** 49.8 (33.4) n¼ 800 23.4 (34.8) n¼ 310 22.7 (39.2) n¼ 214 27.5 (36.2) n¼ 181 22.7 (39.1) n¼ 164 20.2 (35.2) n¼ 145 23.0 (35.7) n¼ 117
WPAI Activity Impairment** 50.3 (30.1) n¼ 1386 21.9 (31.7) n¼ 664 22.5 (34.4) n¼ 491 23.4 (32.9) n¼ 411 22.2 (34.1) n¼ 371 22.2 (30.9) n¼ 320 21.3 (29.6) n¼ 292
*Total SIBDQ ranges from 1 (poor health-related quality of life) to 70 (optimum health-related quality of life). A 9-point change in total SIBDQ correlates with a 100-
point change in Crohn’s Disease Activity Index (Irvine EJ, Zhou Q, Thompson AK Am J Gastroenterol 91:1571–8, 1996). ** A 7-percentage point change in WPAI
represents the minimum clinically important difference. (Reilly MC, et al. Gut 2007. 56Suppl3 A159).
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P0387 SUBCUTANEOUS ADMINISTRATION OF A NOVEL
FORMULATION OF CT-P13 (INFLIXIMAB BIOSIMILAR) IS SAFE
AND ACHIEVES PROJECTED THERAPEUTIC DRUG LEVELS: A
PHASE I STUDY IN HEALTHY SUBJECTS
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Introduction: Treatment with intravenous (IV) CT-P13, a biosimilar infliximab
(INX) licensed for use in 80 countries, is highly effective and well tolerated. To
increase treatment modalities with CT-P13 for patients, a new subcutaneous (SC)
formulation was developed.
Aims & Methods: This phase I and open label study, conducted at a single site in
Korea, was designed to evaluate safety and pharmacokinetics (PK) of SC admin-
istration of CT-P13 in healthy subjects. In a single dose escalation study, 38
subjects received either SC injection or IV infusion of CT-P13 on Day 0 and
were followed for 12 weeks (20 subjects in 3 different dosages of SC; 18 subjects
in 2 different dosages of IV). After reviewing safety data observed for 48 hours,
the next cohort was conducted subsequently from low dose to high dose. The PK
profile of SC and IV formulation was evaluated by measuring the AUC0-last,
Cmax, Tmax and T1/2.
Results: A total of 38 male subjects with median age of 23 years (range 19, 30
years) had no treatment-emergent serious adverse events or systemic hypersensi-
tivity reaction. In SC cohort, two subjects experienced mild injection site reac-
tions, and both have resolved without any treatment. Mean AUC0-last and
Cmaxranged from 5016.4 to 14253.6 h*ug/mL and 10.0 to 23.1 ug/mL, respec-
tively, after a single SC injection of CT-P13. SC CT-P13 formulation was
absorbed slower into the systemic circulation (median Tmax ranging from 7.0
to 7.1 days) in comparison with IV formulation (median Tmax ranging from
2.2 to 3.2 hours) but the drug elimination measured by half-life (T1/2) was similar
(mean range 11.3 to 13.7 days vs. 11.7 to 12.2 days) between SC and IV formula-
tions, respectively. Bioavailability of CT-P13 SC was approximately 60.6%,
when comparing across all CT-P13 SC cohorts to CT-P13 IV cohorts.
Conclusion: PK profiles after a single SC injection were linear by dose levels. SC
administration of CT-P13 is feasible in terms of bioavailability and safety
profiles.
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P0388 REAL-WORLD HEALTHCARE UTILISATION IN PATIENTS
WITH INFLAMMATORY BOWEL DISEASE NEWLY TREATED
WITH VEDOLIZUMAB AND ANTI-TUMOUR NECROSIS FACTOR
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Introduction: Biological therapy has been highly effective for inflammatory bowel
disease (IBD). In addition to anti-tumour necrosis factor (anti-TNF) drugs, a
gut-selective anti-integrin biologic, vedolizumab (VDZ), has been approved since
2014. However, the real-world comparative effectiveness of VDZ and anti-TNF
has not been fully investigated.
Aims & Methods: This study aimed to evaluate all-cause and IBD-related health-
care utilisation in IBD patients (pts) newly treated with VDZ and anti-TNFs.
Crohn’s disease (CD) and ulcerative colitis (UC) pts 18 years old with 2
claims for VDZ or 2 claims for anti-TNF from 20/5/2014 to 31/12/2016 were
identified from a large, de-identified administrative claims database in the US
(Truven MarketScan Commercial and Medicare Supplemental Databases). The
date of the first VDZ/anti-TNF claim was defined as index date. New VDZ/anti-
TNF treatment was defined as no claims for these agents in the 1 year before
index date. All pts had 12-month continuous enrolment prior to and 6-month
following index date. All-cause and IBD-related healthcare utilisation including
hospitalisation, emergency department (ED) visits and outpatient visits during 6
months post-index were examined for the IBD cohort overall, as well as in CD
and UC cohorts. Multivariable logistic regression was employed to estimate the
odds ratio (OR) for hospitalisation and ED visits, while Poisson regression was
used to examine the rate ratio (RR) for outpatient visits with VDZ compared to
anti-TNF use, controlling for demographic characteristics, index year, baseline
Charlson comorbidity index (CCI) and baseline hospitalisation and ED visits 1
year prior to index date. In sensitivity analyses, outpatient visits related to infu-
sion administration for VDZ or anti-TNF were excluded to examine the RR
associated with outpatient visits that were not related to the visits for infusion
procedure.
Results: A total of 652 and 6974 IBD pts newly treated with VDZ and anti-TNF
were identified, respectively (mean age [year]: 45 VDZ vs 42 anti-TNF; male:
47% vs 48%). VDZ pts had a higher CCI than anti-TNF pts (0.7 vs 0.5). During
the 6 month follow-up, compared to anti-TNF, use of VDZ had significantly
higher rates of all-cause hospitalisation (16.3% vs 13.1%, OR 1.30, 95% con-
fidence interval [CI] 1.03–1.64), all-cause outpatient visits (mean visits 45.1 vs
31.0, RR 1.39, 95%CI 1.32–1.37) and IBD-related outpatient visits (mean visits
28.1 vs 17.5, RR 1.60, 95%CI 1.51–1.69). A sensitivity analysis excluding out-
patient visits related to infusion administration showed similar results for IBD-
related outpatient visits (RR 1.53, 95%CI 1.44–1.62). In pts with CD, the mag-
nitude of risk of IBD-related hospitalisation was even higher (OR 1.67, 95%CI
1.17–2.38), but no significant difference in IBD-related hospitalisation (OR 0.57,
95%CI 0.30–1.06) was observed in pts with UC. The difference in IBD-related
ED visits between VDZ and anti-TNF pts was not significant in CD (OR 1.32,
95%CI 0.96–1.82) or UC (OR 0.72, 95%CI 0.40–1.29). However, the rates of
outpatient visits were consistently higher in VDZ vs anti-TNF across CD (RR
1.82, 95%CI 1.69–1.96) and UC cohorts (RR 1.29, 95%CI 1.18–1.42). The
results were similar in the sensitivity analyses when infusion-related visits were
excluded.
Conclusion: In this real-world setting, VDZ treatment was shown to be associated
with higher all-cause hospitalisations and outpatient services compared to anti-
TNF for pts with IBD. A higher risk of IBD-related hospitalisation associated
with VDZ use was observed in CD but not UC pts. Outpatient visit rates were
consistently higher for VDZ users, regardless of taking into account the infusion-
related visits for biologics. These results should be interpreted with caution as
disease activity was not fully accounted for in this claims data analysis.
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P0389 SAFETY OF ANTI-TNF TREATMENT IN ELDERLY
PATIENTS WITH INFLAMMATORY BOWEL DISEASE
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Introduction: Due to population ageing and improved survival, the percentage of
elderly patients with inflammatory bowel disease (IBD) is increasing. The safety
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of tumour necrosis factor antagonists (anti-TNF) treatment in this populations is
ill-studied.
Aims & Methods: To assess the main adverse events (AE) of this therapy in the
elderly population in comparison with the younger patients, we performed a
retrospective cohort study of patients with IBD that initiated treatment with
anti-TNF between 2003 and 2014, with follow-up until December 2016.
Demographic, clinical and medication data were collected. AE (infectious includ-
ing opportunistic, malignancy, dermatologic, neurologic, cardiac and vascular,
hepatic, infusion reactions and others) occurring during anti-TNF treatment in
elderly and younger patients were analysed and both groups were compared. The
severe AE definitions from Food and Drug Administration (FDA) and European
Medicines Agency (EMA) were used.
Results: Of the 219 patients (55.3% women; average disease duration 13.60 þ/
7.74 years), 25 were more than 65 years-old (elderly group, mean age 70.0 years
vs. younger group, mean age 41.77 years). Infliximab was used in 174 patients (on
average 1585 days) and adalimumab in 93 (on average 1379 days), with a total
1106 years of anti-TNF exposure. In the elderly, azathioprine was used less
frequently (68.0 vs. 95.4%, p¼ 0.000). There were 46 severe AE overall, including
18 cancers and 16 opportunistic infections (5 tuberculosis). Malignancy (20.0%
vs. 6.7%, p¼ 0.039) and cardiovascular events (16.0 vs. 4.1%, p¼ 0.036)
occurred more frequently in the elderly, whereas dermatologic AE were more
common in the younger group (4.0 vs. 19.1%, p¼ 0.044). The total number of
severe AE (24.0 vs. 20.1%, p¼ 0.794) including death (4.0 vs. 2.6%, p¼ 0.521)
was not significantly different between groups.
Conclusion:Despite being at higher risk of malignancy and cardiovascular events,
the total number of severe adverse events was not significantly increased in
elderly patients. Particular attention to malignancy surveillance and treatment
of cardiovascular comorbidities is advised in this population.
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Introduction: Over the past twenty years, the introduction of biological agents
into clinical practice has radically improved outcomes in patients with inflam-
matory bowel disease (IBD), Crohn’s disease (CD) and ulcerative colitis (UC).
Tumor necrosis factor (TNF) antagonists, such as infliximab, act by preventing
TNF from binding to its receptor, neutralizing its activity and alleviating muco-
sal inflammation. However, biological agents are much more expensive than
traditional treatments, and the high cost of these drugs in the treatment of
IBD imposes a considerable burden on the national healthcare system. As a
result, interest in biosimilars has grown as biosimilar agents are highly similar
in terms of quality, efficacy, and safety to already licensed biologics but are
associated with lower development costs. CT-P13 (Remsima and Inflectra)
is a biosimilar of infliximab (Remicade), which is its reference product (RP).
Both CT-P13 and infliximab RP are chimeric IgG1 monoclonal antibodies pro-
duced in cell lines derived from the same cell type of murine hybridoma. CT-P13
was authorized by the EMA in 2013 for several indications, including IBD, based
on two pivotal clinical trials in patients with rheumatoid arthritis (RA) and
ankylosing spondylitis (AS). However, a number of observational studies of
CT-P13 in clinical practice in both anti-TNF-naı̈ve patients and those who
have been switched from infliximab RP have been published with good results.
Aims & Methods: We aimed to assess the effectiveness and safety of switching to
CT-P13 from infliximab reference product (RP) in patients with inflammatory
bowel disease. This was a prospective single-center observational study in
patients with moderate to severe Crohn’s disease (CD) and ulcerative colitis
(UC). All patients were switched from infliximab RP (Remicade) to CT-P13
treatment and followed for up to 12 months. The efficacy endpoint was the
change in clinical response assessed at 3-monthly intervals, according to the
Harvey-Bradshaw (HB) score and partial Mayo score for patients with CD
and UC, respectively. C-reactive protein (CRP) was also measured. The
Cochrane’s Q and Friedman tests were used to analyze the change in clinical
scores and CRP. Adverse events were monitored and recorded throughout the
study.
Results: A total of 98 patients with inflammatory bowel disease (67 CD/31 UC)
were included. 83.6% (56/67) of patients with CD were in remission at the time of
the switch and 62.7% were in remission at 12 months. The HB score showed a
significant change at 12 months (P¼ 0.007) but no significant change was
observed in median CRP at this timepoint (P¼ 0.364). 80.6% (25/31) of patients
with UC were in remission at the time of the switch and 65.3% (18/28) were in
remission at 12 months. No significant changes in the median partial Mayo score
(P¼ 0.058) or CRP (P¼ 0.329) were observed at 12 months. Serious adverse
events related to medication were reported in 11 (11.2%) patients. In this
group, six patients discontinued treatment because of these AEs.
Conclusion: Switching from infliximab RP to CT-P13 is efficacious and well
tolerated in patients with CD or UC for up to 12 months.
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Introduction: The role of biologics in medical management of inflammatory
bowel disease (IBD) has been established since anti-TNF agents invaded the
market several years ago. Vedolizumab, an anti-integrin gut-selective molecule,
is a more recent biologic treatment which has been approved for the management
of both Crohn’s disease and ulcerative colitis. Its efficacy in inducing and main-
taining remission was shown in GEMINI studies, although a good percentage of
the trial participants had previously failed anti-TNFs. We conducted this study in
order to describe outcomes in a real-life cohort of IBD patients who were treated
with Vedolizumab, consisting both of previously anti-TNF exposed but also anti-
TNF naive patients. Multivariate analysis searched for factors associated with
response to treatment.
Aims & Methods: All patients with IBD who received at least three doses of
Vedolizumab in UCLH since the drug was offically licensed in the UK were
included in the study. Demographics, clinical and endoscopic response rates
were recorded and analysis was conducted in the whole cohort and in the sub-
groups of Crohn’s and UC patients separately. Univariate analysis and logistic
regression were conducted in order to identify important associations with clin-
ical response.
Results: 59 patients with IBD were treated with vedolizumab from May 2015 to
October 2016. 28 (47%) had Crohn’s disease and the majority (n¼ 43, 73%) had
mainly colonic inflammation (12 colonic Crohn’s, 29 UC, 2 IBDU). Median time
from diagnosis to Vedolizumab initiation was 8 years. 17 (29%) were anti-TNF
naı̈ve (all UC) and 28 (67%) had previously failed both Infliximab and
Adalimumab. 36 (61%) were on a concomitant immunomodulator (IM), either
a thiopurine or methotrexate. 41 (70%) patients had a clinical response to
Vedolizumab based on a reduction of Harvey-Bradshaw index (HBI) from base-
line 3 points for Crohn’s patients or a reduction of partial Mayo score 2
points for UC patients. The rates of response were similar in Crohn’s and UC
patients while there was no difference in response according to gender, previous
anti-TNF exposure, disease duration or location of inflammation. Patients on no
concomitant IM were less likely to respond to Vedolizumab (Odds ratio 0.26,
95%CI 0.07–0.91, p¼ 0.036). 11(18.6%) patients experienced adverse events
while treated with Vedolizumab, five of which were related to active IBD.
There were two minor allergic reactions and two mild infections.
Conclusion: Clinical response to Vedolizumab was observed in two-thirds of our
IBD patients, similarly in Crohn’s disease and ulcerative colitis. Concomitant IM
were the only factor which was importantly associated with a higher response
rate. Overall there were no serious adverse events.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Anti-TNFa therapies have helped improved response rates, reduced
complication rates, and quality of life for patients with inflammatory bowel
disease (IBD). However primary loss of response (LOR) is still a big concern.
Therapeutic drug monitoring (TDM) potentially offers the opportunity of adjust-
ing doses of anti-TNFa in a treat to target fashion. The end of anti-TNFa
induction therapy is a key time point in the management of IBD. TDM is a
useful method to help explore an immune basis behind LOR. In addition anti-
TNFa trough and antibody levels, are a significiant predictor of future liklihood
of clinical response and mucosal healing.
Aims & Methods: The aim of this study was to explore the relationship between
infliximab (IFX) and adalimumab (ADA) trough and antibody levels with clin-
ical response rates, at the end of anti-TNFa induction therapy. This was a pro-
spective, single-centre study. Patients were recruited from the gastroenterology
department at our centre, from July 2015 to August 2016. Inclusion criteria were
all patients older than 17 years old with IBD who started treatment with anti-
TNFa drugs, either infliximab or adalimumab, during the study period. Patient
demographics, medication and clinical history were collected from the electronic
hospital information system. Baseline clinical disease activity indexes were per-
formed (Harvey-Bradshaw Index for Crohn’s disease (CD), and partial Mayo
scores for Ulcerative colitis (UC)). Clinical response was defined as reduction in
HBI 3 or reduction in partial Mayo score 4 and 530% from baseline. Anti-
TNFa trough and antibody levels were measured using standard ELISA techni-
ques. Blood was taken just prior to their first maintenance infusion. Only patients
who completed induction therapy were included. Standard induction were
regimes used, 5mg/kg week 0, 2 and 6 and 160mg, 80, mg and 40mg every
other week.
Results: 35 patients were recruited; 23 CD, 12 UC. 18 patients were treated with
ADA, 17 with IFX. Mean age was 40.3 years, 22 (62.9%) were female, 12
(34.3%) were on thiopurines and 9 (25.7%) had prior anti-TNFa exposure.
Overall response rate was 51.4%(n¼ 18), 33.3%(n¼ 6) for ADA, and
70.6%(n¼ 12) for IFX. Overall trough levels were 12.5 ug/ml for IFX, and
4.4ug/ml for ADA, 71.4% had therapeutic trough levels4 1 ug/ml. There was
a clear link between higher anti-TNFa trough levels at the end of induction with
clinical response rates. For infliximab, mean trough levels in responders was 16.4
ug/ml (IQR 8.4–22.7) versus 5.3 ug/ml (0.5–8.8) for non-responders (p value
0.026 95% CI: 1.50–20.7). The area under the curve [AUC] for association of
IFX level at end of induction with clinical response was 0.864, p¼ 0.0001. In
addition a trough level of 4.8 ug/ml predicted clinical response at end of induc-
tion, with a sensitivity of 90.91% and a specificity of 67%. Similarly there was a
link between higher ADA levels with clinical response, though not statistically
significant (Responders mean trough 6.6 ug/ml (IQR 4.9–8.7) versus non-respon-
ders 3.0 ug/ml (IQR 0.1–2.7) p value 0.135 95% CI 1.24–8.43). Antibody forma-
tion occurred in 6 patients (17.1%). Of the patients who had primary non-
response, 18/35 (51.4%) had doses of anti-TNFa escalated, 7/17 (41.1%) for
infliximab, and 11/18 (61.1%) for adalimumab. 4 patients required surgical inter-
vention, including 1 colectomy.
Conclusion: Higher trough levels at the end of anti-TNFa induction are asso-
ciated with improved response rates. Ongoing work will define optimal targets at
this key timeframe.
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Introduction: Lymphocytic colitis (LC) is a common cause of chronic, non-
bloody diarrhea. Budesonide appears to be effective based on small studies.
Mesalazine has been proposed as a treatment option but no placebo-controlled
trials have been reported. Thus, we performed a placebo-controlled, multicenter
study to evaluate budesonide and mesalazine as induction treatments for lym-
phocytic colitis.
Aims &Methods: Patients with active lymphocytic colitis were randomly assigned
to either budesonide 9mg once daily or mesalazine 3 g once daily, or placebo for
8 weeks in a double-blind, double-dummy design. The primary endpoint was
clinical remission defined by the Hjortswang-Criteria (1). Secondary endpoints
included histopathology and safety.
Results: Based on an interim analysis the trial was stopped in accordance with the
pre-specified adaptive design. The final analysis included 57 patients (19 per
group). Most patients were of female gender (72%) and mean age was 59
years. The proportion of patients in clinical remission at week 8 was significantly
higher in the budesonide group than in the placebo group (intention-to-treat
(ITT) 79% vs 42%; p¼ 0.01). The difference in clinical remission at week 8
between mesalazine (63%) and placebo failed statistical significance (p¼ 0.09).
The proportion of patients with histological remission at week 8 was higher with
budesonide (68%) than with mesalazine (26%; p¼ 0.02) and placebo (21%;
p¼ 0.008). The rate of adverse events did not differ among groups.
Conclusion: Oral budesonide 9mg once daily is highly effective and safe for
induction of clinical and histological remission in lymphocytic colitis, while
oral mesalazine 3 g once daily was only numerically, but not statistically signifi-
cant better than placebo.
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Introduction: A pregnant woman with ulcerative colitis (UC), compared with age-
matched controls, is at higher risk of adverse outcomes including spontaneous
abortion, preterm birth and low birth weight.1, 2 Tofacitinib is an oral, small
molecule Janus kinase inhibitor that is being investigated for UC. Tofacitinib has
been shown to be foeticidal and teratogenic in both rats and rabbits at exposures
146 times and 13 times, respectively, the human dose of 5mg twice daily (BID).
There are no adequate and well-controlled studies of tofacitinib in pregnant
women.
Aims & Methods: We report the pregnancy outcomes from three randomised,
placebo-controlled studies (OCTAVE Induction 1, NCT01465763; OCTAVE
Induction 2, NCT01458951; OCTAVE Sustain, NCT01458574) and one ongoing
open-label extension study (OCTAVE long-term study, NCT01470612) of tofa-
citinib monotherapy in patients (pts) with moderate to severe UC.3, 4 Pregnancy
outcomes following maternal or paternal exposure to tofacitinib 5 or 10mg BID
were identified from Pfizer’s internal safety database up to 23 March, 2017, and
categorised as: healthy newborn, medical termination, foetal death, congenital
malformation, spontaneous abortion or pending/lost to follow-up. Trial proto-
cols required use of highly effective contraception for females of childbearing
potential, and study drug to be discontinued in any female pts who became
pregnant.
Results: A total of 1139 unique pts (incl. placebo) enrolled in the UC OCTAVE
trials, of whom 296 were females of childbearing age. There were a total of 25
pregnancies reported with exposure to tofacitinib. Of these, 11 were cases of
maternal exposure, all during the 1st trimester, including: 2 (18.2%) spontaneous
abortions (5mg BID, n¼ 1; 10mg BID, n¼ 1), 2 (18.2%) medical terminations
(both 10mg BID), 4 (36.4%) healthy newborns (all on 10mg BID) and 3 (27.3%)
cases lost to follow up (all on 10mg BID). Out of the 14 cases of paternal
exposure, 11 (78.6%) were healthy newborns (5mg BID, n¼ 2; 10mg BID,
n¼ 9) and 3 (21.4%) were pending/lost to follow-up (5mg BID, n¼ 1; 10mg
BID, n¼ 2). Overall, there were no cases of foetal death or congenital
malformation.
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Table: Summary of pregnancy outcomes in the OCTAVE programme
Foetal
death
Congenital
malformation
Spontaneous
abortion
Healthy
newborn
Medical
termination
Pending/lost
to follow-up
Maternal exposure (n¼ 11)
Tofacitinib 5mg BID 0 0 1 0 0 0
Tofacitinib 10mg BID 0 0 1 4 2y 3
Paternal exposure (n¼ 14)
Tofacitinib 5mg BID 0 0 0 2 0 1
Tofacitinib 10mg BID 0 0 0 9 0 2
yCase 1: the subject decided to terminate pregnancy based on potential risks of
tofacitinib; Case 2: reason unknown;
BID, twice daily.
Conclusion: Based on the limited data and follow up available, pregnancy and
newborn outcomes among pts with UC with prenatal (maternal/paternal) expo-
sure to tofacitinib appear to be similar to those reported for the UC population,
as well as those previously reported in pts with RA and PsO.5 Larger, long-term
follow-up studies are needed to examine safety of tofacitinib during pregnancy.
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M.C. Dubinsky: Consultant for, Pfizer, AbbVie, Takeda, Janssen, UCB,
Celgene, BMS, Gilead
N. Lawendy: Employee and shareholder of Pfizer Inc
G. Friedman: Employee and shareholder of Pfizer Inc
G.G. Konijeti: Previously received honoraria from Pfizer (advisory board),
Abbvie (advisory board), Janssen (advisory board), and Takeda (speaker), but
is not funded by them for any research.
T.V. Jones: Employee and shareholder of Pfizer Inc
A. Marren: Employee and shareholder of Pfizer Inc
A.J. Thorpe: Employee and shareholder of Pfizer Inc
C. Nduaka: Employee and shareholder of Pfizer Inc
C. Su: Employee and shareholder of Pfizer Inc
All other authors have declared no conflicts of interest.
References
1. Cornish J et al. Gut 2007;56:830–7
2. de Lima-Karagiannis A et al. Am J Gastroenterol 2016;111:1305–12
3. Sandborn WJ et al. J Crohns Colitis 2016;10(S1):S15, Abstract OP019
4. Sandborn WJ et al. J Crohns Colitis 2017:11(S1):S19–20, Abstract OP032
5. Clowse ME et al. Drug Saf 2016;39:755–62
P0395 SAFETY AND EFFICACY OF GRANULOCYTE AND
MONOCYTE ADSORPTIVE APHERESIS IN 363 PATIENTS WITH
INFLAMMATORY BOWEL DISEASE WHO HAVE SPECIAL
SITUATIONS: AN INTERIM ANALYSIS OF A POST-MARKETING
SURVEILLANCE STUDY
S. Motoya
1, H. Tanaka2, T. Shibuya3, T. Osada3, H. Hongo4, T. Kimura4,
D. Saito5, A. Sakuraba5, C. Mizuno6, A. Ito7, T. Kobayashi8, D. Abukawa9,
S. Kokuma10, E. Hosoi10
1Sapporo Kosei Hospital, Sapporo/Japan
2IBD Center, Sapporo Kosei General Hospital, Sapporo/Japan
3Department Of Gastroenterology, Juntendo University Faculty of Medicine,
Tokyo/Japan
4Fujita Gastroenterological Hospital, Takatsuki/Japan
5The Third Department Of Internal Medicine, Kyorin University School of
Medicine, Mitaka/Japan
6Department Of Gastroenterology, Saiseikai Suita Hospital, Suita/Japan
7Department Of Gastroenterology, Tokyo Women’s Medical University, Tokyo/
Japan
8Department Of Gastroenterology, Hakodate Goryoukaku Hospital, Hakodate/
Japan
9Department Of General Pediatrics, Miyagi Children’s Hospital, Sendai/Japan
10JIMRO Co., Ltd., Tokyo/Japan
Contact E-mail Address: sa-motoya@nifty.com
Introduction: Granulocyte and monocyte adsorptive apheresis (GMA) has been
shown to be effective and safe in patients with inflammatory bowel disease (IBD).
We report an interim analysis of a post-marketing surveillance study of granu-
locyte and monocyte adsorptive apheresis using Adacolumn for patients with
inflammatory bowel disease who have special situations (PARTICULAR).
Aims & Methods: The aim of the PARTICULAR study was to assess the safety
and efficacy of GMA treatment in patients with IBD who have special situations.
This study was an interim analysis of the multi-centre observational study con-
ducted at 80 institutions in Japan. Data were collected from patients with ulcera-
tive colitis (UC) or Crohn’s disease (CD) who received GMA between November
2013 and September 2016. Patients who had at least one special situation were
included in the study. GMA was performed using Adacolumn (JIMRO,
Takasaki, Japan). Each patient received up to a maximum of 11 GMA sessions.
Safety assessments were performed on all patients in this study. All adverse
events (AEs) during the study period were recorded. AEs for which the causality
of GMA could not be ruled out were defined as side effects (SEs). Feasibility
problems (FPs) included blood withdrawal difficulty, venous pressure elevation,
coagulation in the apheresis system and venous access difficulty. The safety of
GMA was investigated in the following six special situation subgroups: the
elderly (65 years), concomitant treatment with multiple immunosuppressants,
retreatment with GMA, anaemia (haemoglobin 510 g/dl), paediatric (18 years)
and other groups. We also compared AEs, SEs and FPs between the subgroups
with/without each special situation by univariate analysis. The efficacy of GMA
was also assessed in patients with UC. Patients with a partial UC disease activity
index score (pUC-DAI) of 53, those with missing pUC-DAI scores and those
receiving concomitant treatment with infliximab, adalimumab, tacrolimus or
cyclosporine were excluded from efficacy assessment. pUC-DAI scores were
calculated at baseline and then after the final GMA session or when GMA
therapy had to be discontinued because of AEs or FPs. Remission was defined
as a pUC-DAI score of 2 with no individual sub-score exceeding 1 point.
Patients who received additional treatment by the final GMA session, including
steroids, infliximab, adalimumab, tacrolimus and cyclosporine, were considered
non-responders to GMA.
Results: This study included 363 patients (304 UC, 59 CD). Among these
patients, SEs, AEs and FPs were observed in 3.0%, 10.7% and 16.3% of the
patients, respectively. There were 105, 112, 103, 89, 43 and 39 patients in the
elderly, concomitant treatment with multiple immunosuppressants, retreatment
with GMA, anaemia, paediatric and other groups, respectively. The incidence of
AEs was significantly higher in patients on multiple concomitant immunosup-
pressants compared with those not receiving them. Likewise, the incidence of
AEs was significantly higher in patients of the anaemia group compared with
patients with haemoglobin of 10 g/dl. The incidence of FPs was significantly
lower in patients of the retreatment with GMA group than in those who received
GMA for initial treatment (Table 1). The efficacy of GMA was assessed in 209
UC patients. The numbers of patients administered prednisolone, infliximab,
adalimumab, tacrolimus and cyclosporine were 24, 6, 3, 6 and 1, respectively,
and these patients were considered to be non-responders to GMA. The mean
pUC-DAI score significantly decreased from 6.2 at baseline to 3.4 after the final
GMA session (P5 0.001) and the remission rate at the final GMA session was
43.5%.
Conclusion: This multi-centre observational study showed that GMA has an
acceptable safety profile in IBD patients and sufficient effectiveness in UC
patients who have special situations. However, care should be taken when
GMA is used in patients with anaemia or those who have received concomitant
treatment with multiple immunosuppressants.
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Introduction: People with Inflammatory Bowel Disease (IBD) commonly experi-
ence mental health issues (MHIs) such as anxiety and depression. MHIs reduce
quality of life and are associated with poor medication adherence and worse
disease course. However, psychological support is not routinely provided to
people with IBD. There are scant prospective, systematically gathered data on
MHIs in IBD, despite solid evidence of the value of psychological input for
people with other chronic diseases.
Aims &Methods: The current study is investigating: the prevalence of MHIs in an
IBD cohort; the acceptability and uptake of psychological screening; the accept-
ability and uptake of psychological support and treatment; whether MHIs cor-
relate with higher healthcare utilisation; and potential benefits of integrated
psychological care to patients’ mental health, physical health, and/or healthcare
utilisation. Potential participants were prospectively recruited from the IBD ser-
vice of a large tertiary hospital in South Australia via post and in-person at
scheduled/routine outpatient appointments. Data were collected at two time-
points – at baseline screening and at 12 month follow-up. Mental health, medica-
tion adherence, and quality of life were measured by questionnaires: the Hospital
Anxiety and Depression Scale (HADS), the Kessler 6 Scale of General
Psychological Distress (K6), the Morisky Medication Adherence Scale
(MMAS-8), and the Assessment of Quality of Life measure (AQoL-8D).
Demographic and healthcare utilisation data were collected by electronic,
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state-wide hospital records. Psychological support was offered where scores on
HADS and/or K6 indicated likely need.
Results: 500 patients were approached during the 12-month screening phase;
50.6% were male, 70.8% had Crohn’s disease, mean age of 40 years, mean
disease duration of 11 years, 43% in clinical remission, and 9.8% current smo-
kers (Australia’s average 13.3%). Of these 500, 67% participated in psychological
screening, 38% scored within the clinical range, and 17% accepted psychological
support. Gender was a significant predictor of participation in psychological
screening: women were 62% more likely to participate than men. Analgesics
and/or mental health medication increased the likelihood of scoring within the
clinical range nearly fivefold (analgesic use OR¼ 5.32, p¼ 030; psych OR¼ 6.04,
p¼ .001). Significant predictors of accepting psychological treatment included
older age (OR¼ 1.03, p¼ .041), anxiety (OR¼ 1.09, p¼ .045), general distress
(OR¼ 1.11, p¼ .003) and lower quality of life (OR¼ .93, p¼ .042). At baseline,
anxiety and depression were both negatively correlated with medication adher-
ence (anxiety r¼ -.323, p¼ .000, depression r¼ -.200, p¼ .000) and overall qual-
ity of life (anxiety r¼ -.708, p¼ .000; depression r¼ -.787, p¼ .000). Depression
and general distress were related to overall healthcare utilisation (depression
r¼ .131, p¼ .018, general distress r¼ .124, p¼ .026). Anxiety was not related to
overall healthcare utilisation, but was positively correlated with numbers of
emergency department presentations (r¼ .124, p¼ .024), outpatient appoint-
ments (r¼ .119, p¼ .030), and appointment cancellations (r¼ .155, p¼ .005).
Currently, approximately half of the twelve month follow-up data has been
collected. Preliminary analysis shows improvements for patients’ mental health,
quality of life and medication adherence (see table below).
Table1: Outcomes of psychological support
Variable
Screening
(Mean) SD
Follow-Up
(Mean) SD t value p value Eta2
Anxiety 12 3.6 9 4.1 4.87 .000*** 0.36
Depression 8.8 3.9 6.4 5.0 4.34 .000*** 0.30
Distress 18.2 4.8 13.9 5.1 7.47 .000*** 0.56
Mental QoL 51.1 15.9 60.6 18.5 4.91 .000*** 0.39
Physical QoL 72.5 14.9 75.0 17.7 1.50 .142 0.06
Total QoL 57.6 14.6 65.1 17.4 4.39 .000*** 0.34
Medication adherence 5.1 2.0 5.7 2.2 2.03 .049* 0.09
*p5 .05, **p5 .01, ***p5 .001
Conclusion: Psychological issues are prevalent in patients with IBD and asso-
ciated with lower quality of life and reduced medication adherence. Women
are more likely to participate in psychological screening, and in general the
screening approach was widely accepted. In addition, high proportions of
patients reported clinical levels of distress (irrespective of their IBD activity)
and went on to accept psychological intervention. All of which demonstrates a
widespread need for support in this cohort. Furthermore, preliminary data of
treatment outcomes are promising. At study completion we will be better able to
clarify the extent to which patients with IBD benefit from this new integrated
approach.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0397 LONG-TERM EFFICACY, SAFETY, AND IMMUNOGENICITY
DATA FROM A PHASE III CONFIRMATORY STUDY COMPARING
GP2017, A PROPOSED BIOSIMILAR, WITH REFERENCE
ADALIMUMAB
A. Blauvelt1, J. Lacour2, J. F. Fowler3, E. Schuck4, J. Jauch-Lembach4,
A. Balfour4, C. L. Leonardi5
1Oregon Medical Research Center, Portland/United States of America
2University of Nice Sophia Antipolis, Nice/France
3Dermatology Specialists, Louisville/United States of America
4Hexal AG, Holzkirchen/Germany
5Central Dermatology, St Louis/United States of America
Contact E-mail Address: julia.jauch-lembach@sandoz.com
Introduction: Demonstration of biosimilarity is based on the evaluation of phy-
sicochemical, biological, preclinical, and clinical data. Based on this totality of
evidence, a biosimilar may be approved for use in the same indications for which
the reference medicine is approved without conducting a clinical trial in each
indication. A prerequisite for this extrapolation is clinical confirmation of
biosimilarity in a patient population sensitive enough to detect potential differ-
ences in efficacy, safety, or immunogenicity between the proposed biosimilar and
the reference medicine. GP2017, a proposed biosimilar to adalimumab, was
investigated in patients with chronic plaque psoriasis.
Aims & Methods: To evaluate long-term efficacy, safety, and immunogenicity in
patients continuously treated with either GP2017 or reference adalimumab from
initial randomization to Week 51. Eligible patients with moderate-to-severe
chronic plaque psoriasis were randomized to receive an initial dose of 80mg
subcutaneous GP 2017 or reference adalimumab, followed by 40mg every
other week, starting one week after the initial dose, up to Week 17. At Week
17, patients with 50% improvement in Psoriasis Area and Severity Index (PASI
50) at Week 16 were re-randomized in a 2:1 ratio to either remain on their initial
study treatment or undergo a sequence of three treatment switches between GP
2017 and reference adalimumab until Week 35. Thereafter, patients were
returned to their originally randomized treatment up to Week 51.
Results: From randomization to Week 51, 168 and 171 patients received contin-
uous treatment with GP 2017 or reference adalimumab, respectively. In the per-
protocol analysis set, PASI 75 response rates for continual GP2017/reference
adalimumab at Weeks 17 and 51 were 75.2%/67.8% and 84.5%/79.6% respec-
tively. Investigator’s global assessment (IGA) response rates (IGA score of 0
[clear] or 1 [almost clear] and 2 point improvement from baseline) were also
similar between the continual GP2017/reference adalimumab groups, increasing
over time and remaining stable from Week 17 (60.0%/53.9%) to Week 51
(59.8%/55.1%). There were no clinically relevant differences between the con-
tinual GP2017/reference adalimumab groups in the frequency of adverse events
(AEs) (61.3%/64.9%), treatment-related AEs (17.9%/18.7%), serious AEs
(3.0%/8.8%), or AEs leading to discontinuation of study drug (4.8%/7.0%).
Infections/infestations were the most commonly reported AEs, with nasophar-
yngitis most frequently reported by 8.9%/10.5% of patients treated with contin-
ual GP2017/reference adalimumab. Between Weeks 1 and 51, binding antidrug
antibodies were detected in 38.8%/45.3% of patients treated with continual
GP2017/reference adalimumab, 88.7%/84.7% of which were neutralizing.
Conclusion: Efficacy was similar and sustained in patients with psoriasis continu-
ously treated with GP 2017 or reference adalimumab for up to 51 weeks. Safety
profiles and immunogenicity were generally similar in both groups. Clinical data
add to the totality of evidence suggesting GP 2017 could be used as a biosimilar
for the treatment of the same indications for which reference adalimumab is
approved, including inflammatory bowel disease.
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Introduction: Granulocyte-monocyte apheresis (GMA) can be employed for the
treatment of inflammatory bowel disease (IBD), especially for ulcerative colitis
(UC). The usual treatment schedule is a weekly session for 5 weeks processing
1800ml in 60 minutes. It has been described that different factors of the disease
and the technique can improve the response to this treatment.
Table1: Safety profile of GMA in each group
AEs (No. of patients) P value SEs (No. of patients) P value FPs (No. of patients) P value
All subjects (n¼ 363) 10.7 % (n¼ 39) 3.0 % (n¼ 11) 16.3 % (n¼ 59)
Elderly (n¼ 105) 9.5 % (n¼ 10) p¼ 0.6284* 0% (n¼ 0) p¼ 0.0690** 17.1% (n¼ 18) p¼ 0.7650*
Multiple immunosuppressants (n¼ 112) 17.0% (n¼ 19) p¼ 0.0134* 5.4 % (n¼ 6) p¼ 0.1011** 19.6 % (n¼ 22) p¼ 0.2685*
Retreatment (n¼ 103) 9.7 % (n¼ 10) p¼ 0.6859* 2.9 % (n¼ 3) p¼ 1.0000** 8.7 % (n¼ 9) p¼ 0.0172**
Anaemia (n¼ 89) 18.0 % (n¼ 16) p¼ 0.0158* 4.5% (n¼ 4) p¼ 0.4743* 21.4% (n¼ 19) p¼ 0.1548*
Paediatric (n¼ 43) 18.6 % (n¼ 8) p¼ 0.1096** 7.0 % (n¼ 3) p¼ 0.1027** 23.3 % (n¼ 10) p¼ 0.2136*
Others (n¼ 39) 2.6%(n¼ 1) p¼ 0.1001** 0%(n¼ 0) p¼ 0.6159** 15.4%(n¼ 6) p¼ 1.0000**
GMA; Granulocyte monocyte adsorptive apheresis *Chi-squared test **Fisher’s exact tests AEs; Adverse events SEs; Side effects FPs; Feasibility problems
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Aims & Methods: We performed a retrospective study of all patients treated with
GMA (Adacolumn) in 3 IBD Units in Spain. The clinical and analytical data
were assessed before and 1 month after the end of the GMA. The Ethics
Committee of Euskadi approved the study protocol. The aim of our study was
to evaluate the presence of clinical, analytical of technique–related factors asso-
ciated to a better response to GMA.
Results: A total of 105 patients were included [51 female (49%), age 35.7 (SD
16.5)]. Ninety-three had UC (50% extensive, 45% left-sided), 10 Crohn’s disease
(90% ileocolonic) and 2 IBD-U. Mayo score at baseline was 3.5 (SD 4.6) and
Harvey – Bradshaw was 10.1 (SD 3.8). The Mayo endoscopic subscore was 1
(16%), 2 (56%) or 3 (27%). Almost all patients (97%) have been previously
treated with steroids and 42% were exposed to biologics. At baseline, 85%
were on steroids, 38% thiopurines and 18% biologics. None of the previous or
concomitant treatments were associated with a better response to GMA. Fifty-six
subjects received weekly sessions for 5 weeks processing 1800ml/session in 60
minutes. Forty patients received an intensive GMA regimen: biweekly sessions
with a mean of 8 sessions (SD 2.6), processing 3886ml/session (SD 1729) and
lasting 91 minutes (SD 24). The intensive group showed a slightly higher response
rate to GMA as compared with those in the standard regimen (response rate 67%
vs 55%, p¼ 0.28). Those subjects treated with 45 sessions showed higher remis-
sion (24% vs 13%) and response rates (47% vs 24%) as compared to55 sessions
(p¼ 0.004). A mean duration of 460min/session also showed better results in
terms of remission (22% vs 16%) and response (45% vs 27%) when compared to
560min/session (p¼ 0.04). There was also a trend towards higher remission
rates in those with higher processed blood volume. Thirty-nine percent were
able to wean off steroids completely one month after GMA. We observed a
decrease in the mean platelet volume and the platelet to lymphocyte ratio after
GMA in those cases who did not respond.
Conclusion: GMA showed its clinical efficacy in this clinical practice study.
Increasing the number of sessions or its length were associated with a better
response to GMA. The mean platelet volume and the platelet to lymphocyte
ratio could help to predict the response.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Circulating and mucosal concentrations of matrix-metalloprotei-
nase-9 (MMP-9) are upregulated in patients with ulcerative colitis (UC) and
correlate with disease activity. Selective inhibition or deletion of MMP-9 reduced
disease severity in murine models of colitis. Accordingly, MMP-9 has been pro-
posed as a biomarker for disease activity and/or as a treatment target in UC.
Andecaliximab (GS-5745) is a monoclonal antibody that selectively binds and
inhibits MMP-9. A Phase 1 dose-ranging study of andecaliximab was conducted
in UC patients, demonstrating clinical response and remission. We conducted a
phase 2 study to further evaluate the safety and efficacy of andecaliximab in
subjects with UC.
Aims & Methods: This was a double-blind, randomized, placebo-controlled 8-
week induction study in adult subjects with UC with moderate to severe disease
activity; defined as an endoscopy score 2, rectal bleeding score 1, stool fre-
quency score 1 and physician global assessment of 2 or 3 (using the Mayo
score). Subjects were required to have an inadequate response to, or loss of
response or intolerance to at least 1 of the following treatments in the last 5
years: corticosteroids, immunomodulators, TNF-alpha antagonist or vedolizu-
mab. Subjects were randomized 1:1:1 to receive subcutaneous (SC) injections of:
placebo, 150mg andecaliximab every 2 weeks (Q2W) or 150mg andecaliximab
weekly (QW). Centrally-read sigmoidoscopies/colonoscopies were performed at
baseline and week 8. The primary outcome was EBS clinical remission, defined as
an Endoscopic subscore of 1, rectal Bleeding subscore of 0, and 1 point
decrease in Stool frequency from baseline to achieve a subscore of 0 or 1.
Results: A total of 165 subjects from 23 countries were enrolled. The percentage
(confidence intervals) of subjects achieving EBS clinical remission was similar
between subjects treated with andecaliximab Q2W, andecaliximab QW and pla-
cebo: 7.4% (2.1–17.9%), 1.8% (0–9.6%) and 7.3% (2.0–17.6%), respectively.
Confidence intervals overlap for all groups and no single EBS component sub-
score appears to have driven the results. No concerning imbalances occurred
between the treatments groups (Table 1).
150 mg Q2W
N¼ 54
150mg QW
N¼ 56
Placebo
N¼ 55
Mayo Clinical Score, mean (SD) 9 (1.3) 9 (1.3) 9 (1.3)
TNF-alpha experienced 53.7% 55.4% 54.5%
Corticosteroid use at baseline 37% 39.3% 30.9%
The frequency of adverse events (AEs) was similar in the andecaliximab Q2W,
andecaliximab QW and placebo groups: 53.7%, 58.9% and 60%, respectively.
Common AEs included anemia, abdominal pain and nausea. Three AEs led to
discontinuation in the andecaliximab QW group compared to one each in the
andecaliximab Q2W and placebo groups. Two serious AEs occurred in the ande-
caliximab QW group (anemia and angina pectoris) compared to one in placebo.
Frequency of arthralgia and musculoskeletal pain was similar between andeca-
liximab and placebo groups.
Conclusion: SC 150mg andecaliximab was well tolerated; however, neither dosing
regimen demonstrated a treatment effect in subjects with UC.
Disclosure of Interest: W.J. Sandborn: Consulted for Gilead Sciences.
Z. Younes: Consulted for Gilead Sciences
H. Chai: Employee of Gilead Sciences.
M. McKevitt: Employee of Gilead Sciences
S. Zhao: Employee of Gilead Sciences.
B. Kanwar: Employee of Gilead Sciences.
J. Sundy: Employee of Gilead Sciences.
S. Keshav: Consulted with Gilead Sciences
S. Danese: Consulted for Gilead Sciences.
All other authors have declared no conflicts of interest.
P0400 ANDECALIXIMAB (ANTI-MMP9) INDUCTION THERAPY
FOR CROHN’S DISEASE: A DOUBLE-BLIND, RANDOMIZED,
PLACEBO-CONTROLLED, PHASE 2 STUDY
S. Schreiber
1, C. Siegel2, K. Friedenberg3, U. Seidler4, B. R. Bhandari5,
Z. Younes6, K. Wang7, M. Mckevitt7, S. Zhao7, B. Kanwar7, J. Sundy7, S.
D. Lee8, E. V. Loftus Jr9
1Christian-Albrechts-University Kiel, Kiel/Germany
2Dartmouth-Hitchcock Medical Center, Lebanon/United States of America/NH
3Great Lakes Gastroenterology, Mentor/United States of America/OH
4Hannover Medical School, Hannover/Germany
5Delta Research Partners, Monroe/United States of America/LA
6GastroOne, Germantown/United States of America/TN
7Gilead Sciences, Foster City/United States of America
8University of Washington, Seattle/United States of America/WA
9Mayo Clinic College of Medicine, Rochester/United States of America
Contact E-mail Address: s.schreiber@mucosa.de
Introduction: Elevated levels of matrix-metalloproteinase-9 (MMP-9) and its
degradation products are detected in patients with active Crohn’s disease
(CD). Selective inhibition of MMP-9 reduced fibrosis in a murine model of
intestinal fibrosis, suggesting that MMP-9 may contribute to intestinal complica-
tions in CD. Accordingly, MMP-9 has been proposed as a therapeutic target for
CD. Andecaliximab (GS-5745) is a monoclonal antibody that selectively binds
and inhibits MMP-9. It was found to be safe in a phase 1 dose-ranging study in
UC subjects, where it showed clinical response and remission compared to pla-
cebo. The aim of this phase 2 study was to evaluate the safety and efficacy of
andecaliximab in subjects with moderately to severely active CD.
Aims & Methods: This was a double-blind, randomized, placebo-controlled 8
week induction study in adult CD subjects with moderate to severe disease activ-
ity (defined as: CDAI total score 220–450, weighted PRO2 score 11 [standard
CDAI weightings: abdominal pain 0–3 x7 plus mean number of daily stools x2]
and SES-CD total score 6 [or 4 score if disease limited to ileum and/or right
colon or ulcer presence and size score 2]). Subjects were required to have an
inadequate response, or loss of response or intolerance to at least 1 of the follow-
ing treatments in the last 5 years: corticosteroids, immunomodulators, TNF-
alpha antagonist or vedolizumab. Subjects were randomized 1:2:2:2 to receive
subcutaneous (SC) injections of: placebo, 150mg andecaliximab every 2 weeks
(Q2W), 150mg andecaliximab weekly (QW) or 300mg andecaliximab QW.
Centrally-read colonoscopies were performed at baseline and week 8. Co-primary
outcomes were clinical response (PRO2 score of 8 at week 8) and endoscopic
response (SES-CD decrease of 50% from baseline at week 8).
Results: A total of 187 subjects were enrolled from 13 countries. No concerning
baseline imbalances occurred between the treatment groups, overall: 17.6% of
subjects had evidence of fistula at screening, mean (SD) disease duration was 12
(9.5) years, 84.5% of subjects had previous exposure to TNF-alpha antagonist
and 44.4% of subjects were taking oral corticosteroids at baseline. The
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percentage of subjects achieving clinical response/remission and endoscopic
response was similar between treatment groups (Table 1).
Conclusion: SC andecaliximab was well tolerated; however, none of the treatment
regimens demonstrated a treatment effect in subjects with CD.
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Aims &Methods: Few data exist regarding the kinetics of this test during therapy.
Therefore, our study investigated the conversion rate of PPD-TST in IBD
patients under anti-TNFalpha treatment. Anti-TNFalpha-treated IBD patients
followed up in our centre with a baseline PPD-TST underwent a second one
during therapy. Those with a positive PPD-TST either at baseline or during
therapy (d4 10mm in naı̈ve and d4 5mm in those exposed to immunomodu-
lators [IMS]) received 300mg isoniazid orally for 9 months.
Introduction: Anti-TNFalpha therapy increases the risk of tuberculosis (TB) (re)-
activation in inflammatory bowel disease (IBD) patients. Purified protein deri-
vative tuberculin skin test (PPD-TST) is considered a pre-requisite at baseline.
Results: Sixty-eight IBD patients have currently been enrolled (males: 51.47%,
Crohn’s disease: 82.35%). Median age at IBD diagnosis was 33.1 years [IQR:
20.3, range: 16.7–66.7]. Median duration of IBD was 7.7 months [IQR: 9.8,
range: 1.4–32.7]. Nine patients (13.23%) had a positive PPD-TST at baseline.
48 patients have undergone a 2nd PPD-TST (median time between the 1st and 2nd
PPD-TST: 44.26 months [IQR: 42.8, range: 6.3–190.1]). Twenty patients were
under combination therapy with an IMS at the 2nd PPD-TST. Six patients with a
positive baseline PPD-TST remained positive (in 5 patients the diameter was
decreased & in one increased 7mm). Out of the remaining 42 patients with a
negative baseline PPD-TST, eight (19%) exhibited a positive 2nd PPD TST; three
of them were receiving infliximab for less than 3 years and five of them adali-
mumab (2 for less and 3 for more than 3 years). Only 2/8 were under combination
therapy. There was no case of active tuberculosis during the study. All patients
with a PPD-TST conversion received anti-tuberculous treatment.
Conclusion: A positive PPD-TST followed by anti-TB treatment before the initia-
tion of anti-TNFalpha in IBD patients was not associated with an increased rate
of TB infection during therapy. One-fifth of the patients with a negative baseline
PPD-TST demonstrated a conversion but without any undesirable consequence
if so treated. Therefore, the kinetic of PPD-TST in IBD patients under anti-
TNFalpha treatment should be monitored.
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Introduction: Adalimumab and anti-adalimumab-antibodies (AAA) levels have
been associated with clinical outcome of Crohn’s disease (CD). Nevertheless,
because adalimumab is usually self-injected at home, prospective serial-sampling
studies are scarce. Thus, data on the temporal evolution of adalimumab immu-
nogenicity is still limited, and the validity of comparisons of adalimumab versus
infliximab immunogenicity remains questionable.
Aims & Methods: Our aim was to assess trends in adalimumab and AAA levels
over time and their clinical implications. CD patients starting adalimumab ther-
apy were followed prospectively in three participating medical centers in Israel,
by establishing a program for home-visits by physicians at induction and every 3
months, or in case of relapse. At each home visit, patients’ clinical activity scores
were determined and blood tests obtained for CRP, drug and AAA trough levels.
AAA levels were determined by a drug-tolerant assay. A comparison with tem-
poral evolution of infliximab immunogenicity in a previously reported cohort
using the same assay and methodology was additionally performed.
Results: 102 CD patients starting adalimumab were prospectively followed.
Fourteen (14%) experienced primary non-response and 20 (20%) lost response
to adalimumab therapy during maintenance. Thirty-three (32%) developed
AAA, which were more common among those previously exposed to adalimu-
mab (p¼ 0.002) but were not affected by co-treatment with immunomodulators
or not (p¼ 0.28). AAA developed as early as week 2 in 18/33 (55%) of AAA
positive patients (7/18 with history of interrupted therapy), and in 26/33 (79%)
within week 14. Patients with week 2 AAA had 34% of primary non-response
compared to 9% in patients without early AAA (OR¼ 4.8, p¼ 0.009). In 92.6%
of cases, AAA preceded loss-of-response or occurred simultaneously (median
interval - 4 weeks). As compared to antibodies-to-infliximab (ATI), AAA for-
mation rate over time was significantly lower (p¼ 0.01, log rank test), and some
patients developed AAA even after one year of therapy. Transient AAA were
much less common than transient ATI (7% vs 32%, p5 0.0001), and 85% of
AAA events were associated with loss of response compared with 58% rate for
ATI (p¼ 0.01).
Conclusion: AAA formation often occurs earlier than appreciated, and associates
with primary non-response to adalimumab induction. Overall rate of immuno-
genicity is lower for adalimumab compared to infliximab. However, once they
occur, AAA are more specific than ATI.
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Introduction: Golimumab (GLB) has been the last anti-TNF agent authorized for
the treatment of Ulcerative Colitis (UC). Results from registratory trial
(PURSUIT) documented a clinical response in 51% of patients after 6 weeks
Abstract No: P0400
Number (%) of Subjects
Achieving [confident intervals] 150mg Q2W N¼ 53 150mg QW N¼ 53 300mg QW N¼ 53 placebo N¼ 28
PRO2 score of 8 9 (17.0%) [8.1–29.8] 7 (13.2%) [5.5–25.3] 6 (11.3%) [4.3–23.0] 4 (14.3%) [4.0–32.7]
50% decrease in SES-CD 6 (11.3%) [4.3–23.0] 7 (13.2%) [5.5–25.3] 4 (7.5%) [2.1–18.2] 3 (10.7%) [2.3–28.2]
CDAI 150 11 (20.8%) [10.8–34.1] 9 (17.0%) [8.1–29.8] 6 (11.3%) [4.3–23.0] 6 (21.4%) [8.3–41.0]
The frequency of adverse events (AEs) was similar between the treatment groups: placebo (67.9%), 150mg Q2W (60.4%), 150mg QW (62.3%), 300mg QW (69.8%).
Common AEs included abdominal pain, nausea, fatigue, anemia and pyrexia. One AE led to study discontinuation in the placebo group (3.6%) compared to 2 in the
150mg QW group (3.8%) and 4 in the 300mg QW group (7.5%). Three serious AEs occurred in the placebo group (10.7%) compared to 1 in the 150mg Q2W group
(1.9%), 6 in the 150mg QW group (11.3%) and 8 in the 300mg QW group (15.1%). Frequency of arthralgia and musculoskeletal pain was similar or lower in
andecaliximab groups compared to placebo.
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of GLB with 47–49% of patients maintaining the effect after one year. Due to its
relatively recent use there are still few real-life data on clinical outcomes of
patients receiving golimumab in the routinely activities. In our region GLB
became available starting July 2015.
Aims & Methods: Aim of this study has been to prospectively evaluate the effi-
cacy and safety of golimumab for the treatment of UC in the real-life setting of
our referral centre. 13 patients (7 male, 4 female) with moderate-to-severe UC
were enrolled in the study from June 2015 to December 2016. Patients received an
induction dose of GLB 200mg s.c. at baseline, 100mg at week 2 and then a
monthly dose of 50mg or 100mg for a body weight 5 or 480 kg, respectively,
with no optimization allowed. Partial Mayo score was computed at baseline and
every 2 weeks for the first 6 weeks of therapy, then every 4 weeks throughout the
maintenance period. Follow-up is still ongoing. Primary end point has been the
clinical response at the end of the induction phase (intended as the reduction of
Partial Mayo score 430% and 43 points vs baseline) and in the maintenance
period, the secondary end point being the steroid-free clinical remission (Partial
Mayo score 52 with all subscores 51) at the end of the induction phase and
throughout the maintenance phase. Complete follow-up is available for all
patients at week 30, with 4 patients reaching the week 54 of monitoring.
Results: At the time of GLB starting, localization of the disease according to
Montreal classification was left-sides colitis (E2) in 70%, pancolitis (E3) in 23%
and proctitis (E1) in 7% of patients. Ten patients (77%) were anti-TNF naı̈ve, 3
patients (23%) had already received one anti-TNF in the past. Clinical response
was obtained in 6/13 (46%) at week 6 and in 2 further patients at week 10, for a
total of 8/13 (62%). Three patients resulted in complete clinical steroid-free
remission after 6 weeks. At week 30, 5 patients still showed a clinical response
(38%), one of them (7%) resulted in complete steroid-free remission. Among the
4 patients reaching week 54, 2 experienced a flare of disease whereas 2 were still in
remission (16%); the last patient is in remission at week 42, potentially account-
ing for a total of 3/13 patients in remission after one year (23%). No differences
were found between naı̈ve and non-naı̈ve patients. No significant adverse events
were reported in the study period.
Conclusion: Our real-life data seem to suggest that Golimumab, as compared to
registratory trials, is able to induce a better initial clinical response but shows a
higher secondary loss of response in the long term. Whether this really reflects a
lower efficacy of GLB or could depend on the unavailability of dose optimiza-
tion, not allowed in the Italian prescription rules for GLB, needs to be evaluated.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0404 FIVE-YEAR SAFETY DATA FROM THE OBSERVATIONAL
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WITH ORIGINATOR INFLIXIMAB OR STANDARD THERAPY
J. Panés
1, J. Lindsay2, N. Teich3, S. Lindgren4, J. Colombel5, F. Cornillie6,
H.A. Flynn7, S. Huyck7, P. Stryszak7, R. Yao7, G. Philip7, W. Reinisch8
1Dept. Of Gastroenterology, Hospital Clı́nic Barcelona Dept. of Gastroenterology -
Dept. of Gastroenterology, Hospital Clı́nic Bar, Barcelona/Spain
2Dept. Of Digestive Diseases, Digestive Disorders Clinical Academic Unit, Barts &
The London School of Medicine, London/United Kingdom
3Internistische Gemeinschaftspraxis, Leipzig/Germany
4Lund University, Malmo/Sweden
5Icahn School of Medicine at Mount Sinai, New York/United States of America
6MSD Switzerland, Lucerne/Switzerland
7Merck & Co., Inc., Kenilworth/United States of America
8Dep.of Internal Medicine IV, Division Of Gastroenterology And Hepatology,
Medizin. Universität Wien Abt. für Innere Medizin III - Dep.of Internal Medicine
IV, Division of Gas, Wien/Austria
Contact E-mail Address: jpanes@clinic.ub.es
Introduction: The Observational Postmarketing Ulcerative colitis Study (OPUS)
registry was conducted to collect long-term (5 years) real-world clinical practice
safety data in patients with moderate to severe ulcerative colitis (UC) treated with
originator infliximab and to compare this safety profile to that of UC patients
treated with standard therapies.
Aims & Methods: The OPUS registry was a prospective, non-randomized, obser-
vational study that followed patients with UC (in routine practice in 14 European
countries) who were enrolled to receive treatment with either originator inflix-
imab or standard therapy (defined as initiation or dose-increase of corticoster-
oids and/or immunosuppressants), as determined by their treating physician.
Adverse events (AEs) were recorded during the 5-year follow-up period; at any
time during the 5 years of observation, the patient’s therapy could be changed to
any other UC therapy, based on the physician’s clinical judgment. Frequency of
events was evaluated in nine pre-specified categories (serious infection, infusion-
related reaction, fatality, worsening or new case of congestive heart failure
(CHF), central and peripheral demyelinating neurological disorder, hematologic
condition, malignancy/lymphoproliferative disorder, autoimmune disorder, or
hepatobiliary event). Multivariable Cox proportional hazards (PH) models
assessed time-to-first AE for the originator infliximab and standard therapy
groups, using an intent-to-treat approach, in eight of the pre-specified categories
(infusion-related reactions were not compared between originator infliximab and
standard [i.e., generally oral] therapies); p-values were not adjusted for multiple
comparisons. Safety data were collected every 6 months.
Results: Data for 2239 patients were available: 1180 patients enrolled to standard
therapy (including 296 patients who switched to originator infliximab during
follow-up) and 1059 patients enrolled to originator infliximab. Patients who
received originator infliximab, standard therapy, or who were switched to origi-
nator infliximab during follow-up on standard therapy, were followed for med-
ians of 59.4, 50.6, and 49.8 months, respectively. However, median exposure to
infliximab was 19.8 and 15.9 months in the originator infliximab and switched-
to-originator infliximab groups, respectively. Patients enrolled in the originator
infliximab group, compared with the standard therapy group, had more severe
disease at baseline, based on partial Mayo score (PMS): 46.0% of patients in the
originator infliximab group had severe disease (PMS of 7–9 [out of 9]), compared
with 30.5% in the standard therapy group. In time-to-event analyses adjusting
for risk factors/confounders, enrollment into the originator infliximab group was
associated with a higher risk of serious infection (hazard ratio¼ 2.08, 95% con-
fidence interval [CI] 1.42, 3.06; p5 0.001]) compared with enrollment into the
standard therapy group (Table). No notable risk differences between groups were
identified for hematologic condition, autoimmune disorder, malignancy/lympho-
proliferative disorder, hepatobiliary event, and fatality (Table). Because of very
low incidence of AEs in the categories of CHF and demyelinating disorder
(£0.3% in each group), meaningful multivariable time-to-event analyses could
not be performed for these categories.
Conclusion: Data from 5-year safety follow-up of patients with moderate to
severe UC in this non-randomized registry population demonstrate that, com-
pared with the standard therapy group, the patients enrolled to receive originator
infliximab had an increased risk of serious infection. This finding is consistent
with the previously established safety profile for originator infliximab in the
treatment of UC. In this large registry, the originator infliximab group, com-
pared with the standard therapy group, did not have a significantly increased risk
of a hematologic condition, autoimmune disorder, malignancy/lymphoprolifera-
tive disorder, hepatobiliary event, CHF, demyelinating disorder, or fatality. No
new safety concerns were observed with originator infliximab in the OPUS
registry.
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Introduction: Several oral mesalazine utilise pH-dependent release coating to
optimise mucosal delivery of active drug. Little data currently exist on concurrent
intestinal pH and transit times in patients with UC to predict likely efficacy-
based delivery profiles. No studies have accounted for acute variations in dietary
fibre intake, which might affect regional transit and pH profiles.
Aims & Methods: This study aimed to (1) to examine regional luminal pH and
transit after acute changes in fibre intake in quiescent UC patients; and (2)
deduce delivery of topically-acting drugs using published pharmacokinetic
(PK) data. In this randomised, double-blind study, patients with UC in clinical
remission (partial Mayo Score 1 þ faecal calprotectin 5150 mg/g) without
recent antibiotic (including sulfasalazine), probiotic or fibre use were recruited.
After a 7-day run-in, subjects were supplied with study meals containing high
(13 g oligosaccharides and resistant starch) (HF) or low (51 g) fermentable fibre
(LF) over a 12-h period prior to the ingestion of a pH-motility capsule (Smart
Pill). Telemetric recordings were made for 5 days or until the capsule had been
excreted. After a 3-day washout period, they crossed-over to the other dietary
arm and pH-motility test. Small and large intestinal pH profiles were defined as
the length in time (h) of different intraluminal pH ranges – pH56, 6 to57 and
7 and compared between diets. Using published PK of pH-dependent coated
mesalazine preparations, the patterns of dissolution in UC patients were
estimated.
Results: In 15 patients (aged 24–72 y; 9 males – 5 extensive, 5 distal and 5
proctitis), acute HF intake significantly increased median (IQR) time for colonic
pH5 6 [HF: 4.5 (2.4–10.2) vs LF: 0.9 (0.2–3.1) h; p¼ 0.004, Wilcoxon], tended to
increase colonic pH 6 to 57 [HF 7.5 (6.3–13.5) vs LF: 7.1(3.4–15.2) h] and had
no impact on colonic pH 7 [HF: 4.8(2.1–8.1) vs LF: 1.2(1.0–11.4)]. Table 1
summarises hypothetical dissolution profiles for pH-coated mesalazine in
patients with UC. Considerable variations across release mechanisms were evi-
dent, but, despite alterations in pH and transit, the patterns were not affected by
diet for Eudragit L alone or with slow release mechanisms. Only minor differ-
ences were found for Eudragit S and MMX.
Conclusion: Current delivery mechanisms for mesalazine lead to a proportion of
quiescent UC patients having incomplete release and suboptimal regional
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delivery. An acute high fermentable fibre intake delays drug dissolution in the
colon, but had little influence over total release. These findings have implications
for optimising drug selection in maintenance of remission in UC.
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Introduction: Golimumab (GLM) is a subcutaneously administered anti-tumor
necrosis factor (anti-TNF) antibody that is approved for the treatment of mod-
erate to severe ulcerative colitis (UC). We investigated the association between
systemic exposure (area under the curve (AUC)) of GLM during induction ther-
apy and endoscopic response in moderate-severe UC.
Aims & Methods: In this prospective observational trial, patients with moderate to
severe UC (Mayo endoscopy score 2) received induction treatment with GLM
200mg SQ (at week 0) and 100mg (at week 2) followed by 50 or 100mg at week 6, in
patients with a bodyweight of less or more than 80kg, respectively. Serum GLM
concentrations were measured at day 0, 4, 7, 14, 18, 28, 42 and 56, as well as anti-
GLMantibody levels, C-reactive protein (CRP) and albumin serum concentrations.
Serum GLM concentrations were measured with an enzyme-linked immunoassay
and anti-GLM antibody levels were measured with a drug-sensitive antigen binding
test, both developed by Sanquin laboratories. Endoscopic response was defined as
1 point reduction in endoscopic Mayo score at week 8–10 compared to baseline.
AUCs were calculated using nonlinear mixed effect modelling (NONMEM) and
were compared using the non-parametric Mann-Whitney U test. Correlation ana-
lysis was performed using Pearson’s correlation coefficient. A receiver-operating
characteristic (ROC) curve reported the predictive performance of GLM serum
trough levels at week 2 and 6 for endoscopic response.
Results: A total of 20 patients were enrolled of which 19 patients underwent an
endoscopy at baseline and 8–10 weeks after start of treatment. Median age
([interquartile range]) was 46 years [36–57], median baseline CRP serum concen-
tration was 4.5mg/L [1.1–13.7] and median baseline albumin serum concentra-
tion was 44 g/L [40–45]. None of the patients developed antibodies against GLM
during induction treatment. After the induction phase, 12 out of 19 patients
(63%) achieved an endoscopic response. Median AUC at week 2 and 6 was
higher in endoscopic responders compared to non-responders. Median GLM
trough concentrations at week 2 and 6 were higher in endoscopic responders
compared to non-responders (Table 1). Correlations between GLM trough con-
centrations and AUCs at week 2 (Pearson correlation coefficient: 0.86,
P5 .0001) and week 6 (Pearson correlation coefficient: 0.81, P5 .0001) were
statistically significant. Despite a low area under the ROC-curve (AUROC), a
GLM serum trough concentration 6.6mg/L at week 2 (AUROC: 0.68, 95% CI:
0.43–0.927, sensitivity: 75%, specificity: 57%) was associated with endoscopic
response after the induction phase. At week 6, a GLM serum trough
concentration 3.3mg/L (AUROC: 0.75, 95% CI: 0.526–0.974, sensitivity:
67%, specificity: 71%) was associated with endoscopic response after the induc-
tion phase.
Table 1: Median golimumab trough concentrations and AUCs at week 2 and 6
Endoscopic
responders
median [IQR]
Endoscopic
non-responders
median [IQR] P-value
AUC (mg/L/day), week 2 134 [102–170] 94 [80–169] .48
AUC (mg/L/day), week 6 333 [250–476] 212 [206–417] .21
Serum trough concentration (mg/L), week 2 9.1 [6.1–10] 6.1 [5.2–9.0] .20
Serum trough concentration (mg/L), week 6 3.8 [2.6–6.0] 2.4 [1.1–3.8] .08
Conclusion: Serum trough concentrations of GLM and AUCs at week 2 and 6
were higher in endoscopic responders compared to patients without an endo-
scopic response. A significant correlation was found between GLM trough con-
centrations and AUC. A GLM trough level 3.3mg/L at week 6 is associated
with improved endoscopic outcomes.
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Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibitor being
investigated for moderately to severely active ulcerative colitis (UC). We per-
formed a systematic literature review (SLR) and network meta-analysis
(NMA) to compare the efficacy and safety of tofacitinib to available tumour
necrosis factor inhibitors (TNFi) and integrin receptor antagonists for induction
therapy of adults with moderately to severely active UC.
Aims & Methods: Using indexing and free-text terms, searches were conducted in
the EMBASE, MEDLINE, CENTRAL, DARE and CINAHL databases to
identify RCTs published as of January 2015. Proceedings of relevant conferences
from 2012–2014 were also reviewed. Comparators of interest were infliximab,
golimumab, adalimumab and vedolizumab. Two reviewers independently
assessed studies for inclusion, and extracted and validated the study/patient
data. Fixed- and random-effects Bayesian NMAs were conducted to compare
efficacy outcomes and rates of adverse events (AEs) at 6–12 weeks in the overall
population (TNFi-naı̈ve or exposed) and by prior TNFi exposure.
Pre-specified Category of Adverse Event
Serious Infection
Hematologic
Condition
Autoimmune
Disorder Malignancy/Lympho-proliferative Disorder Hepatobiliary Event Fatality
Number of patients and incidence (%)
Originator infliximab (N¼ 1059) 97 (9.2%) 44 (4.2%) 23 (2.2%) 39 (3.7%) 47 (4.4%) 8 (0.8%)
Standard therapy (N¼ 1180) 40 (3.4%) 28 (2.4%) 13 (1.1%) 34 (2.9%) 43 (3.6%) 15 (1.3%)
Hazard Ratio (95% CI) and
p-value for time to event analysis
(multivariable Cox PH modeling)
Originator infliximab versus standard therapy 2.08(1.42, 3.06) p5 0.001 1.51(0.94, 2.42)
p¼ 0.089
1.42(0.70, 2.88)
p¼ 0.326
1.25(0.78, 1.99)
p¼ 0.359
1.04(0.69, 1.58)
p¼ 0.850
0.63(0.26, 1.56)
p¼ 0.321
Risk factors reaching significance (P5 0.05)
in the time-to-event analysis for each AE category
age, disease severity at baseline
(partial Mayo score),
history of previous dysplasia
(none) disease duration at
baseline
age, disease duration at baseline,
history of previous dysplasia
(none) age
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Results: Twelve induction trials were identified from the SLR (ACT 1 & 2,
EUCALYPTUS, GEMINI-I, PURSUIT SC, TOFACITINIB PHASE 2, Feagan
2005, 1 Probert 2003, 2 UC-SUCCESS, ULTRA 1, ULTRA 2, Suzuki 20143) and
included in the NMA. Unpublished data from tofacitinib Phase 3 induction trials
(OCTAVE 1 & 2) were also used in the analysis. Fixed-effects NMA showed that
tofacitinib 10mg twice daily (BID) is associated with a higher rate of mucosal
healing vs adalimumab 160/80/40mg in the overall population (odds ratio [OR]
1.82 [95% credible interval (CrI) 1.06, 3.14]), and vs vedolizumab 300mg (OR
3.71 [95% CrI 1.37, 10.64]) and etrolizumab 300mg (OR 12.09 [95% CrI 1.68,
122.73]) in TNFi-exposed patients. A higher rate of clinical remission was seen
with tofacitinib 10mg BID vs adalimumab in TNFi-exposed patients (OR 11.93
[95% CrI 1.84, 154.78]). AE rates were similar between tofacitinib 10mg BID and
comparators in the overall and TNFi-naı̈ve populations when analysed individually,
but tofacitinib 10mg BID was found to be associated with a higher rate of disag-
gregated AEs (‘‘any AE’’) than etrolizumab 300mg in the overall population (OR
2.78 [95% CrI 1.08, 7.41]). There were no statistically conclusive differences in the
rates of specific AEs between tofacitinib 10mg BID and comparators.
Conclusion: This NMA suggests that tofacitinib may be more effective as induc-
tion therapy in moderately to severely active UC than adalimumab and vedoli-
zumab in TNFi-exposed patients, and is associated with a higher rate of mucosal
healing than adalimumab in the overall population. Rates of specific safety
events were similar between tofacitinib and other treatments.
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Introduction: Patients with inflammatory bowel disease (IBD) experience higher
rates of C. difficile infection (CDI) than the overall population, often lack typical
risk factors, and frequently experience severe and recurrent episodes. MODIFY
I/II were global trials of the efficacy and safety of bezlotoxumab (bezlo: a human
monoclonal antibody against C. difficile toxin B), in which bezlo was superior to
placebo at preventing CDI recurrence (rCDI) in participants with primary or
recurrent CDI given antibacterial drug treatment for CDI. Participants with IBD
could be enrolled if, in the opinion of the investigator, symptoms were more
likely due to CDI than IBD.
Aims & Methods: The objective of this post-hoc subgroup analysis was to sum-
marize CDI-related outcomes, including initial clinical cure and rCDI, through
12 weeks in participants with IBD enrolled in the MODIFY trials. CDI-related
outcomes through 12 weeks in the subset of IBD participants enrolled in the
MODIFY trials included: initial clinical cure (no diarrhea during the 2 consecu-
tive days following completion of 14 days of an antibacterial drug treatment for
CDI); and rCDI (new episode of diarrhea associated with a positive stool test for
toxigenic C. difficile in participants who had achieved initial clinical cure). For
this post-hoc analysis, participants randomized to bezlo or actoxumabþbezlo
were pooled and are referred to as the ‘‘bezlo’’ group and participants rando-
mized to placebo or actoxumab were pooled and are referred to as the ‘‘no bezlo’’
group.
Results: Overall, 2559 participants were included in the mITT population; 1554
participants were randomized to a bezlo group and 1005 were randomized to a
no bezlo group. There were 44 participants with IBD: 23 (52.3%) had ulcerative
colitis; 18 (40.9%) had Crohn’s disease; and 3 (6.8%) had non-characterized
IBD. Compared with participants without IBD, participants with IBD tended
to be younger, were more often treated as outpatients, were more often immu-
nocompromised, and a smaller percentage had severe CDI. Among IBD parti-
cipants, a higher proportion had initial clinical cure in the no bezlo group
compared with the bezlo group and there was a higher proportion of participants
with rCDI in the no bezlo group compared with the bezlo group. In IBD parti-
cipants who did not receive bezlo, most of the recurrences (5 of 7) occurred
within 4 weeks after study infusion, while most of the recurrences among parti-
cipants who received bezlo occurred after week 4 (3 of 4).
Conclusion: Participants with IBD and CDI enrolled in the MODIFY trials were
younger, more likely to be diagnosed with CDI as an outpatient, to be immuno-
compromised, and to develop rCDI compared with non-IBD participants. Bezlo
yielded a 27.2% absolute reduction (50% relative reduction) in the incidence of
rCDI in participants with IBD. The efficacy of bezlo in preventing rCDI may
extend to patients with IBD, but additional data are needed due to the limited
cohort size.
IBD n-44 No IBD n¼ 2515
Female, n (%) 25 (56.8) 1419 (56.4)
Mean age, yrs (SD) 50.3 (18.9) 63.5 (17.5)
Severe CDI 4 (9.1) 416 (16.5)
Inpatient 20 (45.5) 1711 (68.0)
Immunocompromised 18 (40.9) 531 (21.1)
Bezlo No Bezlo
Initial Clinical Cure, n/m (%) 15/28 (53.6) 13/16 (81.3
rCDI, n/m (5) 4/15 (26.7) 7/13 (53.8)
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Abstract No: P0405
Table 1: Hypothetical dissolution profiles UC patients (n¼ 15)
Dissolution characteristics Eudragit L Eudragit L with slow release Eudragit S Multi-matrix (MMX)
Hypothetical complete dissolution pH 6 for 1 h pH 6 for 4–5 h pH 7 for 2–4 h pH 7 for 6 h
Complete in small intestine 67% 100% HF 25%; LF 19% HF 0%; LF 13%
Complete dissolution 100% HF 97; LF 100% HF 80; LF 87% HF 53; LF 67%
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COMPARED TO INFLIXIMAB-BIOLOGICAL IN PATIENTS WITH
INFLAMMATORY BOWEL DISEASE IN REMISSION - A
RANDOMIZED, CONTROLLED, DOUBLE BLIND, PHASE 4
NONINFERIORITY TRIAL
A. G. Volkers
1, J.M. Jansen2
1Gastroenterology And Hepatology, OLVG, Amsterdam/Netherlands
2Departement Of Gastroenterology And Hepatology, Onze Lieve Vrouwe Gasthuis,
Amsterdam/Netherlands
Contact E-mail Address: a.g.volkers@amc.uva.nl
Introduction: Crohn’s disease (CD) and ulcerative colitis (UC) are the main enti-
ties of inflammatory bowel disease (IBD). For most patients, medical treatment is
sufficient to keep the disease in remission. In both diseases tumor necrosis factor-
alpha (TNF-) inhibitors, such as Infliximab (IFX), are a major component in
inducing and maintaining remission in more refractory patients. Recently IFX-
biosimilars have been introduced for the treatment of IBD, these are less expen-
sive than IFX-biologicals. Efficacy of IFX-biosimilar and IFX-biological have
been compared for ankylosing spondylitis and rheumatoid arthritis showing no
difference between efficacy and safety. So far, no double blind randomized clin-
ical trial has been published that compared IBD patients who used IFX-biolo-
gical or IFX-biosimilar. Cohort studies in IBD patients showed switching from
IFX-biologicals to IFX-biosimilar had no impact on short-term clinical out-
comes. The aim of this study was to examine non-inferiority in safety and efficacy
of IFX-biosimilar compared with IFX-biologicals and to evaluate adverse effects
and pharmacokinetics.
Aims & Methods: We randomized patients with CD or UC in clinical and bio-
chemical remission to either switch to IFX-biosimilar or to continue using IFX-
biological. Randomization was performed in a 2:1 ratio (65% to IFX-biosimilar).
Patients in both arms received 4 to 6 doses of 5mg/kg to 10mg/kg during the 30-
week study period. Patients eligible for inclusion had to be in clinical remission
(HBI5 5 and MAYO5 2) and have a fecal calprotectin 5250mg/g. The pri-
mary endpoint was number of patients in remission at week 30. We measured C-
reactive protein [CRP], fecal calprotectin [FCP], infliximab trough level [TL] and
anti-drug antibodies [ADAs]. Patients were asked to fill in SIBDQ and Mayo or
HBI questionnaires three times during the study period. Adverse events (AE) and
serious adverse events (SAE) that patients experienced were documented.
Results: So far, we included 47 patients from 6 secondary Dutch Teaching hos-
pitals. 35 patients had CD and 12 had UC. 27 patients were female, 20 were male.
Mean age at inclusion was 42 years. 21 patients have finished the 30-week follow-
up. 15 received IFX-biosimilar, 6 IFX-biological. One patient experienced
relapse of IBD, this patient received IFX-biosimilar. 2 patients experienced a
SAE, none were related to the study drug.
Conclusion: This is the first double blind randomized clinical trial that compares
treatment of IBD with IFX-biological or IFX-biosimilar. The preliminary results
show that switching from IFX-biological to IFX-biosimilar is feasible and safe.
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Introduction: We analyzed the success of fecal microbiota transfer (FMT) via
encapsulated or endoscopic jejunal application to 14 patients with chronic, anti-
biotic refractory pouchitis.
Aims & Methods: FMT was performed either via encapsulated cryopreserved
microbiota or via endoscopic jejunal application to 14 patients. Stool samples
for FMT preparation derived from three unrelated healthy donors. Patients were
treated by FMT every 4 weeks according to the individual therapeutic outcome.
Stool samples before FMT and during follow-up were subjected to microbial
community structure analysis through high throughput sequencing of the V1-2
regions of the 16S rRNA (1), clinical response and mucosal inflammation was
assessed by fecal calprotectin (FCP) levels.
Results: Clinical response occurred in 7 of 14 patients after two to four FMTs. 4
patients showed clinical worsening and 3 patients showed no improvement. FCP
dropped in responders from 536mg/kg stool (med.; min-max: 116–3000) to
150mg/kg (191–1409), whereas in patients with flare FCP values increased
from 1005mg/kg (529–1579) to 1450mg/kg (1221–1778). Microbiota analysis
of 10 patients and two donors revealed a significantly lower diversity in pouchitis
patients compared to healthy donors as assessed by the total phylotype number,
the Shannon diversity and Pieloús evenness. In patients showing response, typi-
cally a significant increase in diversity was observed. This increase in diversity
was due to the successful establishment of the donor microbiota as assessed by
the analysis of sample-similarity matrices constructed using the Bray-Curtis algo-
rithm and a detailed analysis of the taxonomic composition. The encapsulated
fecal microbiota was as effective as the endoscopic jejunal application in its
competence to restructure the patients microbiota. However, an increase in the
diversity and an overall restructuring of the microbiota into a composition
resembling the donor not necessarily correlated with clinical outcome and clinical
worsening was observed during three FMTs where the established microbiome
structure resembled that of the healthy donor in diversity and composition.
Interestingly, a high abundance of Ruminococcaceae was associated with remis-
sion in a recent study on ulcerative coltis (2). However, two patients showed
worsening here despite a high increase in the relative abundance of
Ruminococcaceae after FMT.
Conclusion: Fecal microbiome transfer in patients with chronic pouchitis is a
promising therapeutic option and donor microbiomes could successfully be
transferred via capsules or via jejunoscopy delivering fresh stool filtrate.
However, a simple increase in microbial diversity and successful establishment
of members of the butyrate producing Lachnospiraceae and Ruminococcaceae
families is not sufficient for a successful outcome of FMT.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
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Introduction: Mucosal healing (MH) has been established as co-primary treat-
ment target in Crohn’s disease, predominantly defined by the absence of ulcera-
tion. However, even in patients with MH, inflammation may persist on histologic
examination1. Filgotinib (FIL), a selective inhibitor of JAK1 that blocks cytokine
signaling through inhibition of STAT phosphorylation, has recently shown effi-
cacy in a double-blind, placebo (PBO)-controlled Phase 2 study in CD
(FITZROY2). Effects of filgotinib versus placebo have been demonstrated on
centrally read endoscopy and histopathology assessments after a 10-week induc-
tion treatment.
Aims & Methods: In this post hoc analysis, we explored the correlation between
histologic and endoscopic disease activity at baseline (BL) and following FIL
induction therapy by comparison of total ileal Global Histology Activity Score
(IGHAS)/colonic GHAS (CGHAS) score or IGHAS/CGHAS activity subscores
(a; activity items: presence of epithelial damage, polymorphonuclear leukocytes
in lamina propria, neutrophils in epithelium, erosion or ulceration, granuloma3,
4) versus total ileal Simplified Endoscopic Score for CD (ISES-CD)/colonic SES-
CD (CSES-CD) score or ISES-CD/CSES-CD ulcer subscores (u; sum of size and
% affected surface). CD patients were randomized 3:1 to receive 200mg FIL or
PBO QD for 10 weeks2. Intestinal biopsies were collected at BL and Week 10
(W10) from the most affected areas of each predefined bowel segment (ileum,
ascending, transverse, descending, sigmoid colon and rectum). Biopsies were
formalin fixed and paraffin embedded. The mean changes from baseline for
each treatment group were compared to zero using a one-sample t-test.
Results: Baseline values were comparable across treatment groups, although
CGHAS and CSES-CD were numerically higher in the PBO group (Table 1).
Following 10 weeks of treatment with FIL 200mg, histologic measures of colonic
mucosal inflammation (CGHAS and aCGHAS) were significantly improved and
were coupled with macroscopic changes in both CSES-CD and uCSES-CD.
Changes in histology score for ileal segments were numerically greater after
FIL treatment versus placebo. Histology total and subscores were significantly
associated with total and endoscopic ulcer subscores at both time points, and
more pronounced when looking into the colonic segments versus the ileal seg-
ments (IGHAS v ISES-CD: Corr¼ .0.62, p5 0.001; Corr¼ .0.65, p5 0.001;BL
and W10 respectively)(aIGHAS v uISES-CD: Corr¼ 0.53, p5 0.001;
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Corr¼ 0.43, p5 0.001;BL and W10 respectively) (CGHAS v CSES-CD:
Corr¼ .0.80, p5 0.001; Corr¼ .0.77, p5 0.001;BL and W10 respectively)
(aCGHAS v uCSES-CD: Corr¼ 0.77, p5 0.001; Corr¼ 0.70, p5 0.001;BL
and W10 respectively).
Conclusion: Improvements in endoscopic severity induced by filgotinib are par-
alleled by reductions of histologic scores. In line with previous findings from anti-
TNF therapies4, 5 colonic mucosa is more prone to improve than ileal disease.
Spontaneous reductions of histologic activity under placebo were not observed.
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Introduction: Ustekinumab (UST) has been shown to induce and maintain clin-
ical response and remission in moderate to severe Crohn’s disease (CD) in 2
induction [(UNITI-1 (anti-TNF failures) and UNITI-2 (anti-TNF non-failures)
and 1 maintenance (IM-UNITI)] randomized, placebo controlled Phase 3 trials.
We evaluated the efficacy (response and remission) for all patients who received
an intravenous (IV) induction dose of approximately 6mg/kg, including respon-
ders (CDAI decrease 100) and non-responders, 8 weeks after the first UST
maintenance dose of 90mg subcutaneous (SC), i.e. 16 weeks from the IV induc-
tion dose.
Aims & Methods: Patients achieving clinical response 8 wks after a single IV
induction dose were randomized to SC placebo (PBO), UST 90mg every 12
weeks (q12w) or every 8 weeks (q8w). UST patients not in clinical response 8
weeks after the IV induction dose were given UST 90mg SC and if in clinical
response 8 weeks later were continued on 90mg SC q8w dosing. A total of 458
patients were exposed to an IV induction dose of 6mg/kg (UNITI-1, N¼ 249 and
in UNITI-2, N¼ 209) with a response rate at week 8 of 37.8% and 57.9% vs.
PBO response rate of 20.2% and 32.1% respectively. The remission rate at week
8 in UNITI-1 and UNITI-2 was 20.9% and 40.7 vs. PBO of 7.3% and 19.6%
respectively. For this evaluation, the response and remission status of the entire
population exposed to an IV induction dose of 6mg/kg of UST was evaluated 8
weeks after the first subcutaneous maintenance dose of UST. All patients who
received 6mg/kg IV UST induction were included, including responders rando-
mized to SC PBO (who did not receive SC UST at week 8).
Results: Of the 219 patients not in clinical response in UNITI 1&2, 37.6% and
60.5% respectively were in clinical response 8 weeks after the first maintenance
UST dose (90mg SC). Evaluating all patients exposed to 6mg/kg IV UST induc-
tion, response rates 8 weeks after the first subcutaneous injection (16 weeks after
the IV induction dose) for UNITI1&2 are 47.4% and 73.7% respectively (see
table for response and remission rate). Similar assessments were calculated in the
sub-population who were anti-TNF naı̈ve upon enrolment into UNITI-2.
Response rates and Remission rates for all patients 16 weeks after induction of
6mg/kg IV UST
Study IV UST (n)
% Clinical
Response
%Clinical
Remission
UNITI-1 249 47.4 24.1
UNITI-2 209 73.7 55.5
UNITI-2 TNF Naive 144 72.9 60.4
Conclusion: These numbers at week 16 are expected to reflect real-world experi-
ence in patients who receive the induction dose and one additional maintenance
dose 8 weeks later. The resulting rates of response and remission are higher than
previously reported in the induction studies across all populations (anti-TNF
non-failures and anti-TNF failures). About 73% of anti-TNF non-failures
attain clinical response and over half are in remission. The data support the
clinical rationale for providing at least one SC maintenance dose of ustekinumab
irrespective of clinical response 8 weeks after IV induction.
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Mean (SD)
IGHAS CGHAS ISES-CD CSES-CD
PBO FIL PBO FIL PBO FIL PBO FIL
Total Score Baseline 4.10 (3.94) 3.94 (3.74) 21.10 (19.26) 14.69 (12.25) 4.13 (3.32) 4.41 (3.53) 11.91 (8.31) 9.63 (8.04)
W10 0.24 (3.66) 0.37 (3.69) 0.81 (14.72) 4.83(11.07) 0.30 (1.72) 0.18 (2.27) 2.09 (6.62) 2.68 (4.90)
N 21 52 21 52 23 76 23 76
Subscore* Baseline 2.57 (2.56) 2.27 (2.67) 13.76 (13.05) 9.33 (8.47) 2.39 (1.90) 2.55 (2.07) 7.22 (5.23) 6.09 (5.34)
W10 0.10 (2.84) 0.23 (2.95) 0.86 (10.79) 3.48 (8.28) 0.00 (0.95) 0.21 (1.51) 1.70 (4.37) 1.76 (3.64)
N 21 52 21 52 23 76 23 76
Only subjects with non-missing data for all segments at BL and W10 were included in the calculation;*Subscore for GHAS data is activity subscore and for SES-CD
data is ulcer subscore; bolded texts indicate p-value 50.05 from t-test
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Introduction: Biologics such as infliximab (IFX) (an anti-TNF) and vedolizumab
(VDZ) (anti-integrin) are treatment options for patients with moderate-to-
severely active inflammatory bowel disease (IBD), who have failed conventional
therapy.
Aims & Methods: Our aim was to compare time to treatment discontinuation,
flares, and hospitalisations among patients with IBD initiating VDZ versus IFX
who were biologic-naı̈ve. All patients with IBD (ulcerative colitis or Crohn’s
disease [CD]) who initiated biologic treatment with VDZ or IFX between 01/
05/2014 and 22/02/2016 were identified in the US Explorys Universe database;
the first infusion was deemed the index date. Analyses focused on patients who:
(1) successfully completed induction therapy (3 infusions within 98 days of
index date); (2) were 18 years of age at index; (3) had 365 days of medical
history prior to index (‘‘baseline’’); and (4) had 365 days of follow-up after the
index date. VDZ initiators were matched to IFX initiators (1:3) using propensity
scores. Kaplan-Meier Method was used to compare median time to discontinua-
tion of VDZ and IFX during follow-up, defined as the first of either: no receipt of
biologic 90 days of previous infusion, or switch to another biologic. Similar
method was also used to compare median time to IBD-related hospitalisations,
surgeries, and flares (defined as use of intravenous steroids), respectively.
Interquartile range (IQR) was also calculated.
Results: 105 VDZ initiators were matched to 315 IFX initiators. Baseline char-
acteristics of both cohorts are described in Table 1. CD accounted for 60% of
patients in each cohort. In the baseline period, 70% of patients in both cohorts
had received corticosteroids; 20% of VDZ vs. 38% of IFX initiators received an
immunosuppressive therapy. Median time since diagnosis was 2.4 years for VDZ
initiators and 1.9 years for IFX initiators. Median time to treatment discontinua-
tion was 244 (IQR for VDZ: 194–307 and IFX: 190–300) days in both cohorts.
Median time to first IBD-related hospitalisation was 153 (IQR: 78–209) days for
VDZ initiators vs. 98 (IQR: 45–168) days for IFX initiators. For IBD-related
flares, median time was 111 (IQR: 40–226) days for VDZ initiators vs. 93 (IQR:
35–182) days for IFX initiators.
Table 1. Baseline characteristics of propensity-score matched IBD patients initi-
ating therapy with vedolizumab or infliximab
Vedolizumab
(N¼ 105)
Infliximab
(N¼ 315) p-value
Mean (SD) age, years 46 (16.0) 44 (16.8) 0.297
Female, % 52.4 52.7 40.999
Caucasian, % 89.5 84.1 0.180
Insurance type, % 0.202
Medicaid 6.7 11.1
Medicare 23.8 14.3
Private 63.8 65.7
Other 5.7 8.9
Patients with Crohn’s Disease, % 60.0 60.9
Mean (SD) time from diagnosis, years 3.6 (3.5) 3.1 (3.6) 0.667
Comorbidities, %
Congestive heart failure 3.8 2.9 0.745
Rheumatic disease 5.7 2.9 0.221
Mild liver disease 11.4 10.2 0.715
Malignancies 6.7 4.1 0.295
IBD-related measures (during the baseline period), %
Surgery 5.7 7.3 0.663
Hospitalisations 37.1 32.7 0.407
Corticosteroids 70.5 71.1 0.902
Immunosuppressives 20.02121 37.8 0.001
Conclusion: Among biologic-naı̈ve IBD patients, there was a trend toward pro-
longed median times to first IBD-related hospitalization or first flare with VDZ
compared to IFX. The median time to discontinuation was comparable between
the therapies. Future studies should examine comparative effectiveness outcomes
in a larger cohort over a longer follow-up period.
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Introduction: Cancer development has been linked to oxidative stress by increas-
ing DNA mutations or inducing DNA damage, genome instability and cell pro-
liferation. Interestingly, reactive oxygen species (ROS) seem to modulate antigen
presentation, a crucial event in the immune surveillance mechanisms1. We
recently showed that expression of the co-stimulatory molecule CD80 on epithe-
lial cells has a critical role during the immune surveillance process occurring in
colon carcinogenesis2. Remarkably, ROS have been involved in the transcrip-
tional regulation of CD80 gene expression3; in addition, oxidative DNA damage
was directly correlated to CD80 expression in colon mucosa dysplasia4.
Aims & Methods: Therefore, the aim of this work was to examine the role of ROS
on CD80 expression in colonic epithelial cells using an in vitro and an in vivo
model of colonic carcinogenesis. A mouse colorectal cancer cell line, CT26, was
used to quantify the expression of CD80 in response to pro-oxidant (such as
Antimycin A and H2O2) and antioxidant (N-acetyl cysteine) stimuli in presence
or absence of pharmacological inhibitors of p38MAPK (SB203580 and BIRB
796) and NF-kB (JSH-23). C57BL/6 mice (wild type, WT) received azoxy-
methane (AOM) i.p. at a dose of 10mg/kg body weight weekly for 6 weeks to
induce colorectal cancer (CRC) and then sacrificed four months after the first
AOM injection to perform flow cytometry analysis on colonocytes and mucosal
lymphocytes. Mice were also randomized to received 5mM N-acetyl cysteine
(NAC) in drinking water (pH 7) ad libitum after AOM treatment.
Results: In CT26 cells ROS-generating agents (Antimycin A and H2O2) caused a
significant CD80 up-regulation at mRNA (p¼ 0.01) and protein level
(p5 0.001). H2O2-induced CD80 up-regulation in colonic epithelial cells was
significantly inhibited by N-acetyl cysteine (p5 0.001) and by p38MAPK
(p¼ 0.001) but not by NF-kB pharmacological inhibition. In vivo administration
of N-acetylcysteine significantly reduced AOM-induced CD80, MHC-I and
MHC- II up-regulation in colonic epithelial cells (p5 0.001, p5 0.001 and
p5 0.001, respectively). Moreover, CD8þCD28þ, CD8þCD69þ,
CD4þCD25þ T cells rate in colonic mucosa was significantly lower in AOM-
NAC mice than AOM mice (p¼ 0.08, p¼ 0.03 and p¼ 0.01, respectively).
Conclusion: All in all, our data support the hypothesis that oxidative stress pro-
mote the antigen presenting function of colonic epithelial cells by inducing CD80
in the early stages of colonic carcinogenesis. ROS-mediated CD80 up-regulation
in colonic epithelial cells relies on the p38MAPK pathway in vitro.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
1. Maemura K, Zheng Qizhi, Wada T, Ozaki M, Takao S, Aikou T, Bulkley G,
Klein A, Sun Z. Reactive oxygen species are essential mediators in antigen
presentation by Kupffer cells. 2005 Aug;83(4):336–43.
2. Scarpa M, Brun P, Scarpa M, Morgan S, Porzionato A, Kotsafti A,
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Introduction: Altered immune activity and gut microbiota alterations are pro-
posed to be important factors in the pathophysiology of irritable bowel syndrome
(IBS), but the relevance for symptoms is unclear.
Aims & Methods:We aimed to determine if colonic antimicrobial gene expression
profiles differ between IBS and healthy subjects and if potential alterations are
linked to immune activity or gut microbiota composition. The expression of 84
key antimicrobial genes in sigmoid colon biopsies from patients with IBS, defined
as being either immuno-active or immuno-norm based on systemic and mucosal
cytokine profiles (Bennet et. al Am J Gastro, 2016), and healthy subjects was
assessed by Human Antibacterial Response RT2 Profiler PCR Array. Targeted
16S rRNA pyrosequencing was performed on faecal microbiota. To identify
discrimination profiles based on multiple variables between IBS patients and
healthy subjects, orthogonal partial least squares discriminant analysis (OPLS-
DA) with a cut off for Variable Importance for the Projection 40.7 was
performed.
Results:
Table 1: Differences in mucosal antimicrobial mRNA expression between IBS
(Immuno-active and Immuno-norm) and healthy subjects.
Gene
(2 Ct)
IBS (n¼ 31)
v Healthy
(n¼ 16)
Immuno-active
(n¼ 16) v
Healthy
Immuno-norm
(n¼ 15) v
Healthy
Immuno-active
v Immuno-norm
AKT1 0.01 0.01 – –
IRF7 0.0002 0.0008 0.004 –
MAP2K4 0.002 0.006 0.01 –
TICAM1 0.002 0.01 0.007 –
TNFRSF1A 0.003 0.005 0.03 –
SUGT1 0.004 0.05 0.002 0.01
LYZ 0.004 0.01 0.02 –
LTF 0.008 0.009 – –
CHUK 0.01 0.002 – –
IRAK1 0.02 0.02 – –
MAP2K1 0.02 – 0.02 –
ZBP1 0.04 0.05 – –
TLR4 0.04 – – –
IL1B 0.05 – 0.04 –
RIPK1 0.05 – 0.03 –
XIAP – – – 0.03
TIRAP – – – 0.04
NFKB1 – – 0.01 0.05
CARD9 – – – –
IL–18 – 0.05 – –
IRF5 – 0.01 – –
CXCL1 – – 0.03 –
TOLLIP – – 0.04 –
Data pressented as p-values (Mann-Whitney t-test) ’-’ ¼ non significant. We
included 31 IBS patients (16 females, median age 32 (25–44) years) and 16 healthy
subjects (8 females, median age 27(24–30) years). An OPLS-DA model demon-
strated that the antimicrobial profiles differed between IBS and healthy subjects
(R2¼ 0.54, Q2¼ 0.16). The mucosal mRNA expression of 14 antimicrobial genes
was downregulated, while one gene was upregulated in IBS patients compared to
healthy subjects (Table 1). Antimicrobial profiles did not differ between IBS
patients subtyped according to their predominant bowel habit (R2¼ 0.16,
Q2¼0.02). An OPLS-DA model showed discrimination between immuno-
active (n¼ 16) and immuno-norm (n¼ 15) IBS patients based on their mucosal
antimicrobial profiles (R2¼ 0.91, Q2¼ 0.61). This finding was corroborated by
four antimicrobial genes being altered between the two IBS groups (Table 1).
Adding healthy subjects to the model revealed three differing antimicrobial pro-
files for each respective group (R2¼ 0.44, Q2¼ 0.30). Compared to healthy sub-
jects, 19 genes in the immuno-active and immuno-norm IBS groups were
differently expressed (p5 0.05, Table 1). Only one of the antimicrobial genes
differently expressed between IBS patients and healthy subjects was associated
with faecal microbiota in immuno-norm IBS patients (Conserved Helix-Loop-
Helix Ubiquitous Kinase (CHUK) with Anaerovorax r¼0.76, p5 0.01). In the
immuno-active IBS group 11 associations were identified, including TNF
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Receptor Superfamily Member 1A (TNFRSF1A) with Bifidobacterium
(r¼0.80, p5 0.01).
Conclusion: The intestinal antimicrobial gene profiles differ between subsets of
IBS patients and healthy subjects. An altered ability to recognise microbiota
associated with immune activity and the relative abundance of gut bacteria
may play a role in the complex pathophysiology of IBS.
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Introduction: Recently, accumulating evidence suggested that the dysbiosis of the
intestinal microbiota was associated with increased risk of colorectal cancer and
might play a significant role in the colorectal carcinogenesis [1–2]. Many envir-
onmental factors (e.g. diet and lifestyle) that altered the gut microbiota had been
reported in the development of colorectal cancer[3]. Antibiotics are able to shift
the gut microbiota by altering bacterial composition and functions. The overuse
of antibiotics has been associated with several adverse effects, such as severe
infections, obesity, inflammatory bowel disease. Similarly, it is plausible to
hypotheses that overuse of antibiotic might be linked to CRC by altering the
colonic microbiota. However, the relationship between antibiotic and CRC was
unclear and studies regarding this topic were limited [4–7].
Aims & Methods: To evaluate the association between use of antibiotic and
the risk of developing colorectal cancer, a systematic literature search was con-
ducted using PubMed, EMBASE, Web of science and Cochrane library to
identify related studies published before October 2016. Two independent inves-
tigators screened and extracted data from included articles. A random-effects
model was adopted to calculate overall odds ratio (OR) and 95% confidence
interval (CI).
Results: From initial search, we identified four case-control studies and finally
included in the meta-analysis. Compared with no/low use of antibiotics, high
prescriptions of antibiotics were significantly associated with an excess cancer
risk (OR¼ 1.11, 95%CI 1.01–1.21). There was a significant heterogeneity across
studies (I2¼ 62.1%, P¼ 0.048). Longer duration of antibiotics was also signifi-
cantly linked to increased risk of CRC (OR¼ 1.14, 95%CI 1.03–1.25) with no
significant heterogeneity (I2¼ 39.6%, P¼ 0.191). There was no evidence of sig-
nificant publication bias among this meta-analysis.
Conclusion: Higher prescriptions and longer duration exposure of antibiotics
were associated with increased risk of developing colorectal cancer. Further
studies are needed to verify our results and explore underlying mechanisms.
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Introduction: Internal biliary drainage has been confirmed better than external
biliary drainage in alleviating the damage of intestinal mucosa barrier caused by
obstructive jaundice, but the relevant mechanism is still unclear.
Aims & Methods: We aimed to investigate the effect of internal and external
drainage of obstructive jaundice rats on intestinal mucosal barrier function
with special reference of intestinal immune-related index expression. Sixty male
Sprague-Dawley rats were randomly assigned to four groups: OJ, sham opera-
tion (SH), internal biliary drainage (ID) and external biliary drainage (ED). All
animals underwent surgical ligation of the bile duct, except SH was produced by
separating common bile duct locally but not dividing on day 1. Then ED and ID
were reoperated on day 8 for biliary drainage procedure. Blood from inferior
vena cava were collected for the test of DAO and slgA activities by the method of
ELASA. The terminal ileum specimens of each groups were collected for obser-
vation of the morphological changes with haematoxylin-eosin (HE) staining. The
expression of IgA mRNA, pIgR mRNA, GP-BAR1mRNA, RD-5mRNA were
measured by reverse transcription polymerase chain reaction (RT-PCR). GP-
BAR1 of the ileum mucosa was analyzed by Western blot.
Results: After bile duct ligation, the injures of the intestinal mucosa were obvious
in OJ group with thinner mucosa, sparser villi, destruction of the epithelial
integrity and accompanied by inflammatory cell infiltration. The mucosal lesions
evaluated by Chiu’s method was 2.158 0.579, while the impaired intestinal
mucosa have different degrees of recovery and ID group was more similar to
SH group in intestinal mucosal morphology. The levels of the DAO in OJ group
were increased more dramatically than that in SH, ID and ED groups while slgA
were decreased (p5 0.01), and the activities of the DAO, slgA in ID group were
similar to the level of SH group (p4 0.05), different to the level of ED group
(p5 0.01). The changes of the plasma DAO and slgA activities were significantly
correlated with the conditions of intestinal mucosa (P5 0.01). The expression of
RD-5 mRNA in OJ group were decreased significantly than that in SH, ID and
ED groups while GP-BAR1 mRNA, IgA mRNA, pIgR mRNA were increased
(p5 0.01). Interestingly enough, after external bile drainage, there is no improve-
ment in IgA mRNA and plgR mRNA (P4 0.05). But in ID, the relative expres-
sion of IgA mRNA and pIgR mRNA reduced markedly (P5 0.01). while the
mRNA expression of GP-BAR1 and RD-5 mRNA in ED group was changed
less than that in ID which were more similar to SH group. The protein expression
of GP-BAR1 was increased significantly in the intestinal mucosal of OJ group,
which was higher than that of in SH group (P5 0.01). After internal and external
biliary drainage to alleviate OJ respectively, the GP-BAR1 expression was
decreased significantly in ID group, similar with SH group (ID vs OJ,
P5 0.01; ID vs SH, P4 0.05), and lower than that of in ED group (P4 0.05).
Conclusion: The differential expression of IgA mRNA, pIgR mRNA, GP-BAR1
mRNA, RD-5 mRNA and activities of DAO and slgA in OJ, ID, ED and SH
reflect internal biliary drainage better than external biliary drainage. There may
be a regulatory mechanism between GP-BAR1 and intestinal immune-related
index, which thus appears to be a key factor in maintaining function of intestinal
mucosa barrier.
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Introduction: Xyloglucan (XG) is a film-forming agent exhibiting protective
effects against diarrhea linked to infectious gastroenteritis in humans; further
in animal models, xyloglucan efficacy against cholera-toxin-induced diarrhea
was timely prolonged when this mucoprotectant agent is associated with gelatin
from animal origin. The use of compounds from animal source in galenic for-
mulations is nowadays questionable.
Aims & Methods: Thus, in this study, we aimed at comparing the efficacy of XG
associated with gelatin vs XG associated with gelose a moiety from algae origin
on LPS-induced enteritis in rats. Since LPS-induced enteritis is characterized by
increased intestinal epithelial permeability and mucosal inflammation, the effi-
cacy of xyloglucan associations was evaluated by measurement of these two
parameters. Male Wistar rats (200–225 g) were orally treated with either XG
(10mg/kg)þ gelatin (25mg/kg) or XG (10mg/kg)þ gelose (25mg/kg) or XG
(10mg/kg)þ gelose (50mg/kg) or vehicle (NaCl 0.9%) 3 h before intraperitoneal
(IP) administration of LPS from E. coli (1mg/kg). Six hours later after LPS
administration, the animals were sacrificed and strips of jejunum were collected
in order to evaluate (i) intestinal epithelial paracellular permeability to FITC-
dextran 4Kd in Ussing chambers and (ii) mucosal inflammatory response by
myeloperoxidase (MPO) activity measurement.
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Results: Compared with control, LPS administration induced a significant
increase (p5 0.05) of intestinal paracellular permeability (53.0 4.9 vs
181.6 21.1 pmol/cm2, respectively) associated with jejunal mucosal inflamma-
tion (302.1 9.5 vs 655.6 108.9 U MPO/g protein, respectively). XG (10mg/
kg)þ gelose at the lowest dose (25mg/kg) failed to reverse the intestinal hyper-
permeability and mucosal inflammation induced by LPS. In contrast, XG
(10mg/kg)þ gelatin (25mg/kg) and XG (10mg/kg)þ gelose at 50mg/kg signifi-
cantly (p5 0.01) and equally prevented LPS-induced hyperpermeability
(34.8 2.8, 38.7 3.9 vs 181.6V21.1 pmol/cm2 respectively) and jejunal inflam-
mation (277.0 32.2; 286.2 28.8 vs 655.6 108.9 U MPO/g protein
respectively).
Conclusion: This study shows that oral treatment with xyloglucan associated with
gelose at 50mg/kg has similar protective effects on LPS-induced enteritis in rats
than xyloglucan associated with gelatin. These data demonstrate that algae is an
effective and safe substitute for replacing compounds from animal origin in
xyloglucan mucoprotectant formulations.
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Introduction: The old age is one of the most important risk factors for recurrent
C. difficile Infection (CDI). However, risk factors among the elderly patients are
largely unknown.
Aims & Methods: The purpose of this study was to investigate risk factors asso-
ciated with recurrent CDI in the elderly. Patients 65 years of age or older with
positive CDI toxin test between January 2005 and December 2016, who received
either oral metronidazole or oral vancomycin therapy were included. Recurrent
CDI was defined as another positive laboratory result for C. difficile toxin
between 15 days and 90 days after initial positive diagnostic test. Clinical
charts of relevant factors in 633 patients with positive CDI toxin tests were
reviewed. Continuous variables were tested via Student’s t-test, and categorical
data was analyzed via Chi-Square test. All variables with P5 0.1 in the univari-
ate analysis were included in the multivariable logistic regression analysis.
Results: The overall mean age was 77.0 7.0 years. In 96 (15.2%) of 633 patients,
C. difficile toxin was detected again after the initial test. The length of hospital
stay was longer in recurrent CDI group than in non-recurrent group
(80.54 89.44 vs. 43.81 65.42, P5 .001). Patients with eGFR5 60 ml/min/
1.73 m2 were at higher risk for the development of recurrent CDI than those
with normal renal function (OR 1.844; 95% CI, 1.139–2.985, P¼ .013). There
were no significant differences on mean age (77.21 6.65 in recurrent CDI group
vs. 77.01 7.04 in non-recurrent CDI group, P¼ .799) and proton pump inhi-
bitor therapy (OR 1.277; 95% CI, 0.825 to 1.977, P¼ .272) between both groups.
Renal function and length of hospital stay were significantly associated with
recurrence of CDI.
Conclusion: In this study, impaired renal function and prolonged hospitalization
were related to the increased risk of recurrent CDI.
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Introduction: Cytomegalovirus (CMV) colitis in adults is mostly described in
immunocompromised patients (solid organ or hematopoietic stem cell transplant
recipients, patients with human immunodeficiency virus (HIV) infection, use of
immunosuppressive drugs, including steroid or chemotherapeutic agents), and
often has poorer outcome than in children. Besides, it was also frequently pre-
sented in patients with known or subsequent new diagnosis inflammatory bowel
disease [1, 2]. However, there are only case reports and few case series with
limited patients (below 15 cases) among immunocompetent individuals without
steroid use or inflammatory bowel disease [3–5]. The largest meta-analysis study
of cytomegalovirus colitis in immunocompetent hosts included 44 patients and
noted advanced age, male gender, presence of immune-modulating comorbidities
and need of surgical intervention negatively influencing survival in 2005 [6]. The
case number of CMV colitis in immunocompetent patients seemed increasing in
our hospital these years. There was no single study showing comprehensive
clinical characteristics, identifying the independent factors of in-hospital mortal-
ity and comparing the differences between immunocompetent and compromised
patients with CMV colitis. Therefore, we tried to clarify the issue in this study.
Aims & Methods: We enrolled 42 immunocompetent patients and 27 immuno-
compromised patients with CMV colitis diagnosed by immunohistochemistry
stain between April 2002 and December 2016 in Linkou Chang Gung
Memorial Hospital, a 3383-bed tertiary medical center and referral center in
Taiwan. We analyzed the risk factors of in-hospital mortality and overall survi-
val. Furthermore, we compared the clinical differences between immunocompe-
tent and immunocompromised patients with CMV colitis.
Results: Early diagnosis (before 9 days) was independent predictor of in-hospital
mortality in CMV colitis patients. ICU admission (P¼ 0.010), requisite days of
diagnosis=9 days after admission (P¼ 0.018), shock (P¼ 0.001), respiratory fail-
ure (P¼ 0.033), hemoglobin5 10 g/dL (P¼ 0.002), Creatinine=1.37mg/dL
(P¼ 0.004) and CRP=59mg/dL (P¼ 0.011) negatively impacted on overall sur-
vival. There were older and more comorbidities in immunocompetent group.
However, the in-hospital mortality rate and overall survival rate was similar to
immunocompromised group. Besides, Clostridium difficile infection or steroid use
didn’t affect in-hospital mortality rate and overall survival rate nether. Melena
was first and most common symptom in immunocompetent group, but diarrhea
in the other.
Analysis of the clinical factors associated with in-hospital mortality in all patients
Characteristic Odd ratio 95%CI P-value
Univariate analysis
Age=65y 2.071 0.691 6.209 0.194
Gender (male/female) 0.545 0.184 1.619 0.275
Immunocompromised status 0.986 0.328 2.969 0.981
Intensive care unit admission 6.871 2.068 22.833 0.002*
Requisite time of diagnosis
(day after admission)
1.034 1.002 1.066 0.034*
General condition
Sepsis 1.039*109 0.00041012 0.998
Shock 5.714 1.793 18.210 0.003*
Respiratory failure 4.062 1.309 12.610 0.015*
Operation before diagnosis 3.200 0.583 17.553 0.180
Underlying diseases
Inflammatory bowel disease 0.000 0.000 0.999
Systemic lupus erythematosus 4.900 0.747 32.123 0.098
Solid organ transplantation 2.941 0.174 49.636 0.454
Solid organ malignancy 0.941 0.092 9.671 0.959
Hematological malignancy 2.941 0.174 49.636 0.454
Liver cirrhosis 0.941 0.092 9.671 0.959
Chronic kidney disease 2.067 0.576 7.421 0.265
End stage renal disease 3.357 0.742 15.181 0.116
Diabetes mellitus 1.682 0.543 5.205 0.367
HIV infection 0.000 0.00041012 0.999
Immunosuppressive medication
Immunosuppressant 3.200 0.583 17.553 0.180
Chemotherapy 4.846*109 0.00041012 1.000
Steroid 1.124 0.336 3.764 0.849
Steroid over 1 month 2.350 0.472 11.708 0.297
Laboratory data
Total WBC count (/mcL) 1.000 1.000 1.000 0.419
ANC (/mcL) 1.000 1.000 1.000 0.254
ALC (/mcL) 0.999 0.998 1.000 0.018*
Hemoglobin level (g/dL) 0.668 0.485 0.918 0.013*
Platelet count (1000/mm3) 0.995 0.990 1.001 0.100
Creatinine (mg/dL) 1.448 1.059 1.978 0.020*
ALT (IU/L) 0.995 0.958 1.033 0.787
Bilirubin (mg/dL) 1.370 0.965 1.944 0.078
Albumin (g/dL) 0.625 0.231 1.687 0.354
C-reactive protein (mg/dL) 1.009 1.000 1.018 0.047*
Viral markers
(continued)
A312 United European Gastroenterology Journal 5(5S)
Continued
Analysis of the clinical factors associated with in-hospital mortality in all patients
Characteristic Odd ratio 95%CI P-value
CMV pp65 antigenemia 0.656 0.140 3.079 0.593
CMV IgG positive 0.286 0.016 5.095 0.394
CMV IgM positive 3.125 0.547 17.841 0.200
Clostridium difficile infection 0.889 0.077 10.300 0.925
Ganciclovir or valganciclovir treatment 2.286 0.579 9.026 0.238
Treatment duration 0.989 0.953 1.026 0.563
Surgical treatment 1.840 0.392 8.630 0.439
Perforation 1.441 0.123 16.920 0.771
Multivariate analysis
Intensive care unit admission 4.726 0.374 59.747 0.230
Requisite time of diagnosis
(day after admission)
1.075 1.005 1.149 0.035*
Shock 4.905 0.596 40.362 0.139
Respiratory failure 0.661 0.053 8.269 0.748
ALC (/mcL) 0.998 0.996 1.001 0.157
Hemoglobin level (g/dL) 0.787 0.459 1.349 0.383
Creatinine (mg/dL) 0.618 0.306 1.246 0.179
C-reactive protein (mg/dL) 1.009 0.998 1.021 0.106
Conclusion: Immunocompromised patients or steroid users did not have higher
in-hospital mortality rate. Early diagnosis was only independent factor for lower
in-hospital mortality in patients with CMV colitis.
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Introduction: Clostridium difficile infection (CDI) is one of the most common
hospital-acquired infections. Faecal microbiota transplantation (FMT) is used
for complicated recurrent CDI treatment; however, to date no data on the effi-
cacy of this method in Eastern Europe have been published.
Aims & Methods: The aim of this study was to assess effectiveness of FMT for
recurrent CDI therapy in the hospital of Lithuanian University of Health
Sciences (LUHS KK, Kaunas, Lithuania). Clinical data of patients who were
treated for recurrent (42 times) CDI using FMT in the Department of
Gastroenterology of LUHS KK during 2015–2016, were analyzed. All patients
were monitored for disease relapse for six months. Clinical data, the use of
antibiotics and immunosuppressive drugs were included in analysis. Statistical
analysis was performed using statistical software package SPSS version 17.
Results: FMT was used for 18 patients with recurrent CDI. The mean age of
patient was 60.4 8.4 years. The patients were treated with antibiotics 14.8 days
on average before manifestation of CDI. FMT procedure was performed using
naso-enteral tube. After the first procedure, the positive clinical effect was
observed in 15 patients with a cure rate of 83.3%. FMT procedure was repeated
for two out of the three patients without positive effect (one patient refused
repetitive FMT). Normal stool habits were restored in both patients leading to
the increase of cure rate to 94.4% (17 out of 18 patients). Seventeen patients that
were successfully treated with one or two FMT procedures in the short term also
remained asymptomatic (100 %) at 6 months of follow up. All patients without
positive effect of first FMT procedure were on immunosuppressive drugs (3/3;
100%), as compared to only one patient in the group with positive effect (1/15;
7.1%), p¼ 0.028.
Conclusion: FMT is an effective therapy for recurrent CDI infection both in short
and long term follow-up. Effectiveness of primary FMT treatment could be
associated with the use of immunosuppressive drugs.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0423 A RANDOMISED CONTROLLED TRIAL OF RIFAXIMIN TO
PREVENT RELAPSE OF CLOSTRIDIUM DIFFICILE ASSOCIATED
DIARRHOEA AFTER RESOLUTION WITH STANDARD THERAPY
G. Major1, L. Bradshaw2, N. Boota3, K. Sprange2, A. Jawhari4, M. Diggle4,
A. Montgomery2, R. Spiller1
1NIHR Nottingham Digestive Diseases Biomedical Research Centre, University of
Nottinghan, Nottingham/United Kingdom
2Nottingham Clinical Trials Unit, University of Nottingham, Nottingham/United
Kingdom
3Warwick Clinical Trials Unit, University of Warwick, Coventry/United Kingdom
4Nottingham University Hospitals NHS Trust, Nottingham/United Kingdom
Contact E-mail Address: Giles.Major@nottingham.ac.uk
Introduction: Clostridium difficile associated diarrhoea (CDAD) is a common
nosocomial infection. The most commonly prescribed treatments, metronidazole
and vancomycine, have a primary cure rat of 90% but 1 in 4 cases suffer a relapse
in the following months. A disrupted microbiota is thought to increase the risk of
relapse. Rifaximin is a non-absorbable antibiotic that suppresses C.difficile pro-
liferation. In a trial of 68 patients Garey et al. found that a course of rifaximin
after standard therapy reduced relapse rate though not significantly1.
Aims & Methods: We aimed to further investigate the efficacy of rifaximin to
prevent CDAD relapse in a parallel group, randomised, placebo controlled trial
in 23 hospitals in England. Population: age 18 with resolution of CDAD after
treatment with metronidazole or vancomycin, defined as cessation of diarrhoea
for 2 days. CDAD diagnosis required evidence of toxin production or pseudo-
membranes at endoscopy. Exclusion criteria were pregnancy or breast feeding;
life expectancy 54 weeks; unable to take intervention (hypersensitivity or swal-
lowing disorder); 45 days elapsed since treatment. Randomisation was stratified
by hospital using a remote, internet-based system. Participants, clinicians and
researchers were blind to allocation. Intervention: Rifaximin 1200mg daily for
two weeks then 600mg daily for two weeks, in three divided doses. Comparator:
identical placebo. Primary Outcome: relapse 12 weeks after treatment initiation,
defined as diarrhoea (3 type 6 or 7 stools per day) for 2 days with evidence of
toxin production. Sample size: The planned sample size was 180 to detect a
difference in relapse of 20% (30% placebo, 10% rifaximin) with 80%
power, allowing for loss to follow-up of 20%. EudraCT 2012-003205-10;
www.clinicaltrials.gov NCT01670149; ISRCTN 65163992
Results: Recruitment occurred December 2012–March 2016. Of 2157 patients
screened, 151 were eligible, willing and randomised before funding limits were
reached (74 placebo, 77 rifaximin). Primary outcome data were available on 130.
Mean age was 71.9 (SD 15.3).
36% were in-patients at start of intervention. 13% had a prior recorded episode
of CDAD. 26% were using proton pump inhibitors pror to CDAD diagnosis,
with a higher rate of use in the rifaximin group (32% vs. 20%). 18/61 (29.5%) on
placebo relapsed within 12 weeks compared to 11/69 (15.9%) on rifaximin, a
difference between groups of 13.7% (95% CI 28.1% to 0.7%, p¼ 0.06). The
risk ratio was 0.54 (95% CI 0.28 to 1.05, p¼ 0.07). During 6-month safety follow
up 9 participants died in each group (12%). Adverse event rates were similar
between groups.
Conclusion: CDAD relapse rate was 13.7% lower than on placebo. The confi-
dence interval means that lack of effect remains possible but the estimated effect
size is similar to Garey’s trial1 with meta-analysis of the trials showing a statis-
tically significant effect. The effect size is similar to that reported for fidaxomicin
at 40 days2, or for bezlotoxumab at 3 months3. Age and mortality rate were
higher in our trial which may reflect greater similarity to the population at
risk. Comparative trials of the effectiveness and cost effectiveness of alternative
treatment strategies should follow.
Disclosure of Interest: R. Spiller: Trial funded through National Institute for
Health Research RfPB grant PB-PG-0110-21041. Norgine Pharmaceuticals Ltd
supplied product and comparator free of cost.
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Introduction: The traditional fear that every acute appendicitis will eventually
perforate leads to prompt surgery, but this fear may be outdated. In-hospital
delay of surgery for acute appendicitis has been subject of a large number of
studies. However, consensus about the consequences of delaying appendectomy
is lacking, which is reflected in variety or absence of recommendations in
guidelines.
Aims & Methods: The aim of this study was to assess in-hospital delay of surgery
as potential risk factor for complicated appendicitis and complications in patients
with acute appendicitis. PubMed and EMBASE were searched from 1990 to July
2016. Outcome measures of interest were complicated appendicitis, surgical site
infections and postoperative morbidity. All studies reporting surgically treated
patients with one of these outcome measures in two or more predefined time
intervals were included. Adjusted odds ratios were pooled using forest plots if
possible. All unadjusted data was pooled using generalized linear mixed models.
Results: Forty-five studies with 152, 314 patients were included. Pooled adjusted
odds ratios revealed no significantly higher risk for complicated appendicitis
when delaying appendectomy for 6 to 12 hours or 13 to 24 hours; odds ratio
1.07 (95% CI 0.98–1.17) and 1.09 (95% CI 0.95–1.24), respectively. For a delay
of more than 24 hours, insufficient adjusted data was available for meta-analysis.
Pooled unadjusted data showed a decreased risk for complicated appendicitis
when appendectomy was delayed for 24 to 48 hours, however statistical uncer-
tainty in this interval increased considerably compared to the first 24 hours.
Conclusion: Delaying appendectomy for up to 24 hours after admission did not
result in higher rates of complicated appendicitis, surgical site infections or mor-
bidity. When prompt surgery is hampered by logistic or personal reasons, delay-
ing appendectomy up to 24 hours is an acceptable alternative for patients with no
preoperative signs of complicated appendicitis.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Fecal microbiota transplantation (FMT) is effective for the treat-
ment of recurrent Clostridium difficile infection (CDI) but its role as an initial
therapy for patients with CDI has not been studied.
Aims & Methods: We assessed the efficacy of FMT in patients with an initial
episode of CDI compared with standard vancomycin regimen. In a single center,
open-label, randomised study, we assigned 30 patients with an initial episode of
CDI to receive either: oral vancomycin (500mg four times daily) followed by
FMT consisting of a single infusion of donor feces through a nasoduodenal tube;
or a standard oral vancomycin regimen (500mg four times daily for 10 days). The
primary end point was resolution of diarrhea associated with CDI without
relapse within 10 weeks after initiation of therapy. Secondary outcomes included
30-day and 6-month mortality, 30-day colectomy rates, length of hospital stay,
adverse effects and alteration of fecal microbiota after FMT using metagenomic
sequencing.
Results: Baseline characteristics including age, gender and co-morbidities were
comparable between the vancomycin and FMT arm. 60% and 47% of subjects in
the vancomycin and FMT arm, respectively, had severe CDI. Resolution of C.
difficile infection occurred in 10 of 15 patients (66.7%) receiving vancomycin and
11 of 15 patients (73.3%) receiving FMT (p¼ 1.00). Two deaths occurred in the
vancomycin group and none in the FMT group within 30 days. Nine (60%) and
three deaths (20%) occurred in the vancomycin and FMT arms, respectively,
within 6 months. None of the patients had a colectomy. Median length of hos-
pital did not differ between both arms (13 vs 15 days; p¼ 0.95). No serious
adverse events attributed to FMT were observed. A restoration of healthy con-
trol enriched bacteria in recipients was observed after FMT, with a decrease in
abundance of CDI-enriched bacteria. FMT, but not vancomycin treatment,
resulted in marked virome alterations.
Conclusion: In this pilot randomised controlled trial, FMT was not superior to
vancomycin in patients with an initial episode of CDI. 30-day and 6-month
mortality was higher in the vancomycin arm. A restoration of healthy control
enriched bacteria in recipients was observed after FMT, with a decrease in abun-
dance of CDI-enriched bacteria (Clinical Trial registry, NCT02570477; Funded
by the Hong Kong Society of Gastroenterology Society).
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Introduction: Tuberculosis (TB) carries significant morbidity globally and in
Europe: it is most commonly pulmonary but it can also affect the gastrointestinal
(GI) tract (6% of total cases in UK). Abdominal tuberculosis (A-TB) is a rare
disease which can also present an unique diagnostic challenge, mimicking various
GI diseases leading to late diagnosis and treatment. There is limited clinical data
on its presentation and clinical features in Europe - in the UK it is registered via
regional Public Health registries.
Aims & Methods: We reviewed a 10-year cumulative regional TB database in an
university teaching hospital covering an urban multi-ethnic population to report
clinical details of A-TB and results on this unusual condition. A clinical review of
patients diagnosed for A-TB between 2006 to 2016 in a single tertiary centre in
South Birmingham covering a multi-ethnic urban population of 750,000 was
conducted. A central suveillance database managed by Respiratory Physicians
and Public Health England were used to identify patients with A-TB. We
reviewed clinical data from electronic records including radiology, chemical
pathology, histopathology, endoscopy databases, surgical notes and letters.
Results: Of 41 patients [M¼ 22(54%); mean age 42y (SD 17y)] identified with
A-TB, 41% (17) were Pakistani, 15% (6) were other Asian, 19% (8) were Afro-
Caribbean. Thirty-three (80%) were residents of economically deprived areas
which were among the 10% of most deprived constituencies in the UK. The
most frequently reported symptoms were abdominal pain (n¼ 23; 56%),
weight loss (n¼ 17; 41%), fever (n¼ 10; 24%) & vomiting (n¼ 9; 22%).
Twelve (29%) patients were first seen in a surgical clinic and 9 (22%) in a medical
gastroenterology clinic. A-TB was confirmed on tissue biopsy in 22 (54%), of
which two were diagnosed post-bowel resection. Seventeen (41%) patients had
positive cultures with full drug sensitivity and 5 (12%) patients had polymerase
chain reaction (PCR) tests. Eight patients (20%) had concurrent pulmonary TB.
Thirty seven patients (90%) received full, successful treatment for A-TB.
Conclusion: Asian ethnicity and low socioeconomic status appear to be risk
factors for A-TB in a single UK tertiary centre. Histological diagnosis at endo-
scopic or surgical biopsy is a reliable diagnostic tool for confirming TB. Both
gastroenterologists and surgeons need to consider A-TB in their differentials, as
once diagnosed, most are successfully treated.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Clostridium difficile infection represents a major burden in Europe
and North America. However, data on its disease epidemiology remain sparse in
Asia. This study aims to investigate the burden, risk factors and clinical outcomes
of C. difficile infection in Hong Kong, using a large territory-wide population
database.
Aims & Methods: This is a population-based study conducted from 1 January
2006 to 31 December 2014, and included all in-patient C. difficile infections in
public hospitals in Hong Kong. Cases were identified from a territory-wide
electronic database, and were defined as the isolation of C. difficile, or positive
test for either toxin or molecular assay from the fecal specimens. The disease
incidence, mortality, risk factors and clinical outcomes were analyzed.
Results: A total of 15,753 cases were identified, including 14,402 (91.4%) health-
care-associated and 817 (5.1%) community-associated infections. The crude inci-
dence increased from 16.21 in 2006 to 49.36 in 2014 per 100,000 population
(Ptrend5 0.001), representing an over 30% increase annually. This rise was
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notably contributed by elderly patients, of which the incidence has increased by
three-fold over the period. Recurrence at 60 days increased from 5.7% in 2006 to
9.1% in 2014 (Ptrend5 0.001). The increased use of proton-pump inhibitors
accounted for 58.8% of the surge.
Conclusion: The incidence of C. difficile infection has increased more than three-
fold, and was associated with an increased disease recurrence and use of proton-
pump inhibitors. Our results suggest need for further surveillance in Asia which
habors over half of the world’s population.
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Introduction: Post-polypectomy bleeding (PPB) is the most common complica-
tion following polypectomy, especially in cases with large pedunculated polyps.
Although the clip application before snare polypectomy may decrease PPB, there
were few prospective randomized studies to confirm the efficacy of prophylactic
clip. This present study was conducted to investigate whether prophylactic clip
application for large pedunculated colorectal polyps could decrease PPB and to
evaluate associated risk factors of PPB.
Aims & Methods: We enrolled 137 pedunculated polyps (1 cm in size) in 116
patients. The polyps were randomized into the two groups with or without
prophylactic clips application. Immediate PPB was defined as bleeding that con-
tinued for over 30 seconds from the polypectomy site and graded from grade 1 to
4, and delayed bleeding was defined as a history of hematochezia from the day of
procedure to the day of first visit of outpatient clinic.
Results: Sixty-seven polyps were included in the clip group and 70 polyps in the
control group respectively. Immediate PPB occurred in 6 cases (9.0%) of the clip
group and 22 cases (31.4%) of the control group (P¼ 0.001). The occurrence of
immediate PPB of grade 3–4 which needed endoscopic treatment was lower in the
clip group than in the control group (4.5% vs. 20.0%, P¼ 0.008). However, that
of grade 1–2 was not different in both groups (4.5% vs. 11.4%, P¼ 0.208).
Delayed bleeding occurred in five polyps in both groups (P¼ 0.943). The pro-
phylactic clip application was a significant factor for lowering immediate PPB in
the univariate (OR 0.215, 95% CI 0.081–0.571, P¼ 0.002) and multivariate ana-
lysis (OR 0.210, 95% CI 0.074–0.591, P¼ 0.003). In addition, polyp size 20mm
and stalk diameter 4mm were significant risk factors of immediate PPB com-
pared with polyp size 10–19mm and stalk diameter 1–3mm.
Conclusion: The prophylactic clip application in large pedunculated polyps 1 cm
is effective in reducing immediate PPB. Polyp size and stalk diameter are asso-
ciated with PPB.
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Introduction: Heparin replacement (HR) during periprocedural periods is
described in various guidelines as the recommended method while discontinuing
warfarin. However, the rate of post-colonic polypectomy bleeding in patients
undergoing HR has been reported to be as high as 20%. As an alternative
method to HR, colonic polypectomy without discontinuation of warfarin may
be feasible, however there is still insufficient evidence. The aim of this study was
to assess the safety of colonic polypectomy/endoscopic mucosal resection (EMR)
without discontinuation of warfarin during periprocedural periods.
Aims & Methods: This is a prospective multicenter single-arm exploratory study
in Japan. Patients who received warfarin for the purpose of prevention of throm-
bosis were prospectively enrolled and underwent colonic polypectomy or EMR
without discontinuation of warfarin. Conventional clip closure of the resection
site was performed in all cases and oral diet was resumed 2 days after the pro-
cedure. The primary outcome was post-polypectomy/EMR bleeding that was
confirmed by emergency endoscopy or a decrease in the hemoglobin level of
42 g/dl with hematochezia even if the bleeding site was not identified.
Results: Between January 2015 and November 2016, a total of 30 consecutive
patients (M/F: 26/4, 69.9 8.0 years) were enrolled in this study after written
informed consent was obtained. A total of 81 lesions (tumor diameter:
5.4 2.9mm, adenoma 70, others 10, lost lesion 1, number of prophylactic clip-
pings 4.9 2.2) were treated by polypectomy/EMR. Four patients experienced
post-polypectomy/EMR bleeding (4/30: 13.3%) in 3–11 days after the procedure
although no cases required blood transfusion. In 3 of these bleeding cases, a
single responsible site was identified by emergency endoscopy. Therefore, the
confirmed rate of post-polypectomy/EMR bleeding based on the number of
resected lesions was 3.9% (3/76), but may range to 9.9% (8/81). There were no
other adverse events.
Conclusion: The rate of post-colonic polypectomy/EMR bleeding in patients
without discontinuation of warfarin single therapy was comparable to that in
patients undergoing HR. Colonic polypectomy/EMR without discontinuation of
warfarin is feasible and may reduce the hospitalization associated with HR.
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Introduction: Warfarin and direct oral anticoagulants (DOACs) rivaroxaban,
apixaban, dabigatran and edoxaban are approved for stroke prevention in
patients with atrial fibrillation (AF). The Japan Gastrointestinal Endoscopy
Society guidelines recommend that anticoagulants should be discontinued at a
low thromboembolic risk, or replaced by heparin bridging therapy at a high
thromboembolic risk, for colonoscopic polypectomy. However, safety and effi-
cacy of heparin bridging therapy for colonoscopic polypectomy remains scare.
Aims & Methods: The aim of the present study was to evaluate the risk of post-
polypectomy bleeding (PPC) in patients who take anticoagulants. We retrospec-
tively collected data of patients who underwent colonoscopic polypectomy
between January 2014 and February 2017 at Nagoya City University Hospital.
Polyp characteristics (number of polyps removed per patient, size, morphology)
and patient characteristics (age, sex, comorbidities, medication) was analyzed.
Results: A total of 1007 patients underwent colonoscopic polypectomy. 67
patients were in the anticoagulants group and 808 patients were in the normal
group (taking no antiplatelet agents and anticoagulants). The incidence of PPC
was significantly higher in the anticoagulants group than in the normal group
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(2.98% vs 1.49%, respectively). No patients experienced recurrent bleeding and a
blood transfusion. The mean age (71.3 8.2 years) and male (82.1%) in the
anticoagulants group were higher than those in the normal group (67.7 11.2
years and 64.1%). There was no difference between the groups in size of polyp
and morphology. In the anticoagulants group, 34 patients received heparin brid-
ging therapwarfarin 30, warfarin þ antiplatelet 3, rivaroxaban 1)and 33 patients
discontinued anticoagulants (warfarin 8, warfarinþ antiplatelet 1, rivaroxaban
10, apixaban 8, dabigatran 4, edoxaban 2). The incidence of PPC was no differ-
ence between two groups (1, 1 patient, respectively). There was no difference
between the groups in age, sex, size of polyp and morphology). Recurrent bleed-
ing didn’t occur. In the discontinued group, 1 patient developed acute myocardial
infarction in next day after colonoscopic polypectomy.
Conclusion: Patients taking anticoagulants have an increased risk of PPB com-
pared with the control, even if the anticoagulants are discontinued. Heparin-
bridge therapy might be responsible for increased PPB in patients taking
anticoagulants.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0431 ARTERIOSCLEROSIS IS A SIGNIFICANT CONTRIBUTOR
TO COLON DIVERTICULUM RECURRENT BLEEDING
T. Aoyama
1, S. Nagata1, T. Sakamoto2, Y. Shimohara1, H. Tamari1, Y. Ogawa1,
K. Shigita1, N. Asayama1, A. Fukumoto1, S. Mukai1
1Gastroenteorolgy, Hiroshima City Asa Citizens Hospital, Hiroshima City/Japan
2Radiology, Hiroshima City Asa Citizens Hospital, Hiroshima City/Japan
Contact E-mail Address: t-aoyama@asa-hosp.city.hiroshima.jp
Introduction: Intermittent bleeding from colon diverticulum has a significant
clinical impact with some cases experiencing recurrent bleeding episodes for
several years. No report has directly evaluated the association between arterio-
sclerosis and diverticulum bleeding recurrence.
Aims & Methods: We sought to assess the degree of arteriosclerosis in cases with
diverticulum bleeding as well as the patients’ clinical characteristics. We con-
ducted a retrospective cohort study in a group of 79 consecutive patients with
colon diverticulum bleeding (51 men) who underwent both colonoscopy and
computed tomography (CT) between August 2007 and March 2014. The mean
age of the patient population was 69.5 years (range 29–91 years) and mean
(standard deviation) follow-up time was 6.2 (2.0) years (range 3.1–9.7
years). Patients were divided into two groups: the recurrent bleeding episode
group and the single bleeding episode group. Recurrent bleeding episodes were
defined as bleeding intervals of 41 month. Cases that underwent successful
therapy during the initial bleeding episode were excluded. We compared
Agatston scores (total calcium score) between the two groups of patients to
assess the degree of arteriosclerosis. A calcified lesion was defined as an area
of at least 2 connected pixels with 4120 Hounsfield units (HU) on the unen-
hanced CT scan. Aortic mural calcified area cofactor (1:120–199HU, 2:200–
299HU, 3:300–399HU, 4:4400HU) was determined. The sums of the scores for
every calcified speck were calculated across all lesions in a slice from the level of
the diaphragm to the aortoiliac bifurcation to obtain the total calcium score.
Moreover, the relationship between recurrent bleeding episodes and the patients’
clinical characteristics, including age, sex, smoking habit, comorbidities (hyper-
tension, cerebro-cardiovascular disease, diabetes mellitus, hyperlipidaemia,
chronic liver disease, chronic kidney disease, and chronic obstructive pulmonary
disease), internal medicine (antithrombotic drug, non-steroidal anti-inflamma-
tory drug, and proton pump inhibitor), shock vital on hospitalization, and trans-
fusion need, was determined.
Results: Overall, 39 (49%) cases had recurrent bleeding episode and 40 (51%)
had single bleeding episode. The cumulative recurrent bleeding rate in the recur-
rent bleeding episode group was 33% and 59% at 1 and 3 years, respectively.
Agatston scores in the recurrent bleeding episode group were significantly higher
than those in the single bleeding episode group (5902 7187 vs 2912 4687,
P¼ 0.031). Clinical characteristics associated with recurrent bleeding episodes
were cerebro-cardiovascular disease (P¼ 0.0044), chronic kidney disease
(P¼ 0.031), and antithrombotic drug (P¼ 0.048) in univariate analysis.
Subsequent multivariate analysis determined that cerebro-cardiovascular disease
was an independent contributor to recurrent bleeding episode (OR: 5.48; 95%CI:
1.11–40.7).
Conclusion: Arteriosclerosis along with cerebro-cardiovascular disease may be a
significant contributing factor for colon diverticulum recurrent bleeding.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The incidence of acute lower gastro-intestinal bleeding (LGIB) is
estimated at 21 adults per 100,000 person years and is increasing with the ageing
of the population [1]. Diagnostic management of LGIB has been extensively
debated in recent literature, especially whether colonoscopy within 24 hours of
presentation is feasible and safe [2–4].
Aims & Methods: The aim of our study was to examine differences in length of
hospital stay in patients with LGIB receiving either early colonoscopy (within 24
hours of presentation) or standard colonoscopy (within 1–3 days).
We performed a single-centre, non-blinded randomized controlled trial, including
patients presenting at the emergency department with acute hematochezia and
excluding patients with an upper bleeding source. Primary outcome was the
length of hospital stay. Secondary outcomes included yield of colonoscopy,
blood transfusion requirements, recurrent bleedings, complications, diagnostic
and therapeutic interventions related to complications and 30-day mortality.
The follow-up period was one month.
Results: In total, 132 patients were randomized: 63 for early colonoscopy and 69
for standard colonoscopy. Baseline characteristics of both groups were compar-
able. In the intention-to-treat (ITT) analysis, the length of hospital stay was
significantly lower in patients that underwent an early colonoscopy, compared
to the standard colonoscopy group: median 2.0 days [IQR 2.0–4.0] vs. median 3.0
days [IQR 2.0–4.0] (p¼ 0.009). Recurrent bleedings and hospital re-admissions
were significantly more frequent in the early colonoscopy group: 13% vs. 3%
(p¼ 0.04) and 11% vs. 2% (p¼ 0.02) respectively. The reason for more recurrent
bleedings could not be established, although use of anti-thrombotic therapy
might be a factor. No difference was observed regarding the number of patients
diagnosed with either a confirmed active bleeding or presumptive bleeding
source. In both groups, blood transfusion rate was similar and thirty-day mor-
tality was zero.
Conclusion: In patients with LGIB, early colonoscopy reduces the length of
hospital stay compared to standard colonoscopy. However, more recurrent
bleedings are observed and no improvement of diagnostic yield could be
established.
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Introduction: Direct oral anticoagulants (DOAC) are now popularly used as
anticoagulation for atrial fibrillation and deep vein thrombosis, as well as
Warfarin. But, direct comparison of DOAC and warfarin in the patients with
gastrointestinal bleeding was little reported.
Aims & Methods: We retrospectively analyzed 18 on DOAC and 60 cases on
Warfarin of the patients with gastrointestinal bleeding from January 2011 to
March 2017 on the basis of single-center experience in Japan. We analyzed con-
centrated red cell (CRC) and fresh frozen plasma (FFP) transfusion rate, re-
bleeding rate during hospitalization, the duration from bleeding to endoscopy,
from endoscopy to discharge and from bleeding to discharge in both group. In
DOAC group, each 6 patients took Dabigatran, Rivaroxaban and Apixaban.
DOAC
(N¼ 18)
Warfarin
(N¼ 60) p value
Male sex, n (%) 15 (83.3%) 41 (68.3%) 0.20
Age, years 74.0 2.2 74.4 1.2 0.87
Anti-platelet therapy, n (%) 8 (47.1%) 22 (36.7%) 0.44
Lower gastrointestinal bleeding, n (%) 12 (66.7%) 29 (48.3%) 0.17
Bleeding after endoscopic procedure, n (%) 11 (61.1%) 22 (36.7%) 0.07
Hemoglobin, g/dl 11.1 0.7 9.6 0.4 0.06
PT-INR 1.51 0.36 2.50 0.19 0.02
Fresh frozen plasma transfusion, n (%) 3 (16.7%) 20 (33.3%) 0.16
Concentrated red cell transfusion, n (%) 9 (50.0%) 32 (53.3%) 0.80
Re-bleeding during hospitalization, n (%) 1 (5.6%) 12 (20.0%) 0.11
(continued)
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DOAC
(N¼ 18)
Warfarin
(N¼ 60) p value
The duration from bleeding to endoscopy, days 0.8 0.5 1.2 0.2 0.52
The duration from endoscopy to discharge, days 9.0 5.5 23.0 3.0 0.03
The duration from bleeding to discharge, days 9.8 5.4 24.2 3.0 0.02
Thrombotic embolism during hospitalization, n (%) 0 (0.0%) 1 (1.7%) 0.47
Results: Patient characteristics such as sex, age, anti-platelet therapy, location of
bleeding and bleeding after endoscopic procedure had no significant difference in
both groups. Upper gastrointestinal bleeding occurred 6 (33.3%) of DOAC
group and 31 (51.7%) of Warfarin group. Hemoglobin tended to be lower
(11.1 0.7 g/dl vs 9.6 0.4 g/dl, p¼ 0.06) and international normalized ratio of
prothrombin time (PT-INR) was significantly prolonged in Warfarin group
(1.51 0.36 vs 2.50 0.20, p¼ 0.02). CRC transfusion rate had no significant
difference in both group, but FFP tended to be transfused at high rate in
Warfarin group (16.7% vs 33.3%, p¼ 0.16). Re-bleeding rate during hospitaliza-
tion had no significant difference in both group, but tended to be higher in
Warfarin group (5.6% vs 20.0%, p¼ 0.11). The duration from bleeding to endo-
scopy had no significant difference in both group (0.8 0.5 days vs 1.2 0.2
days, p¼ 0.52), but the duration from endoscopy to discharge was significantly
longer in Warfarin group (9.0 5.5 days vs 23.0 3.0 days, p¼ 0.03). Also, the
duration from bleeding to discharge was significantly longer in Warfarin group
(9.8 5.4 days vs 24.2 3.0 days, p¼ 0.02). Thrombotic embolism during hospi-
talization occurred only 1 (1.7%) of Warfarin group.
Conclusion: The duration of hospitalization was significantly shorter in DOAC
group of the patients with gastrointestinal bleeding, and the rate of FFP transfu-
sion and re-bleeding tended to be lower in DOAC group. This study showed that
DOAC may be more superior to Warfarin as anticoagulation for atrial fibrilla-
tion and deep vein thrombosis at the quality of life (QOL) in the patients with
gastrointestinal bleeding.
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Introduction: In Korea, colorectal cancer is the most common cancer among old
aged women over 65 years old. The incidence of colorectal cancer, in particular,
is dramatically increasing due to environmental factors such as the westernized
eating habits. Furthermore, due to advances in medicine, the survival rate of
those with advanced colon cancer is increasing. An increased risk of malignant
tumors associated with colorectal cancer has been suggested recently, but ade-
quate studies have not been conducted. The purpose of the study is to determine
whether ovarian cancer is more common in the patients diagnosed with colorectal
cancer than in the general population. If a woman diagnosed with colorectal
cancer indeed has a high incidence of ovarian cancer, a screening test can be
performed on high-risk patients.
Aims & Methods: This is a retrospective cohort study using data registered in the
National Health Insurance Corporation as a cancer diagnostic code since 2007.
In Korea, once cancer is diagnosed, this information is recorded by the National
Health Insurance Corporation with a relevant code, and this system provides
every patient’s data for medical research purposes. The colorectal cancer group
includes patients newly enrolled with the corresponding diagnostic code (ICD-10
code C18, C19, and C20). The 56,682 colorectal cancer patients and 288,119 sex-
and age- matched general population was collected. Propensity score methods
were used to facilitate the creation of comparison group that is similar. Each
cancer patient was matched to five individuals in the unexposed cohort. All data
was followed up by a new diagnostic code of ovarian cancer (ICD-10 code C56)
was given. After adjusting for sex, age, smoking, drinking, exercise and comor-
bidities (diabetes mellitus, hypertension, and hyperlipidemia), further analysis
was performed. The hazard ratios and 95% confidence intervals were calculated
via Cox proportional hazards regression models. Statistical analysis will be per-
formed with SPSS version 24.0. When P5 0.05, the result was defined as statis-
tically significant.
Results: Patients with colorectal cancer were followed up for an average of 4.4
years until the occurrence of ovarian cancer. During the follow-up period, 338
out of 56,682 (0.60%) colorectal cancer patients and 258 out of 288,119 (0.09%)
people in the general population were diagnosed with ovarian cancer. Ovarian
cancer was more common in the colorectal cancer group than the general popu-
lation [Hazard ratio (HR) 7.13, 95% Confidence interval (CI)¼ 5.06–10.05]. The
additional analysis was conducted only for those who had medical checkup data
within one year (14, 190 patients in colorectal cancer group, 71,933 people in the
control group). Even though the subjects in this group were adjusted for several
factors (age, sex, smoking, drinking, exercise, diabetes, hypertension, and hyper-
lipidemia), the incidence of ovarian cancer was also higher in colorectal cancer
group [HR 7.12, 95% CI¼ 5.05–10.04]. Colorectal cancer patients had a higher
risk of ovarian cancer across all age groups including patients under the age of 55
years [HR 10.69, 95% CI¼ 6.26–18.26] and patients older than 55 years [HR
5.17, 95% CI¼ 3.26–8.19].
Conclusion: In conclusion, data from the National Health Insurance Corporation
revealed that the incidence of ovarian cancer in colorectal cancer patients was
higher than that of the general population. In woman diagnosed with colorectal
cancer, the screening test should be done to monitoring the occurrence of ovarian
cancer. Further research is necessary to determine the interactive association
between the development of ovarian cancer and colorectal cancer, and large
prospective studies are needed.
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Introduction: Colonoscopy is an imperfect tool. Several publications confirm
colorectal cancer may manifest after a negative colonoscopy(1–3). The term
‘‘interval cancer’’ has often been used for cancers appearing after a negative
colonoscopy. However, this is primarily a screening term(1). Post-colonoscopy
colorectal cancer (PCCRC) is a broader term for cancers detected after a negative
colonoscopy in any setting, including screening(2). Although there is overlap
between these two terms, they are not synonymous. PCCRC can be thought of
as the overarching term. PCCRCs can be subcategorised into interval cancers
(identified prior to the next recommended screening or surveillance procedure)
and non-interval cancers (identified at or after a recommended screening or
surveillance interval, or where no subsequent screening or surveillance interval
was recommended, up to 10 years following the colonoscopy).
Aims & Methods: The goal of this consensus process was to provide a framework
for the terminology, identification, analysis and reporting of cancers appearing
after a negative colonoscopy or computed tomographic colonography (post-
colonoscopy/post-imaging colorectal cancers- PCCRC/PICRC respectively).
We based our methodology on The Appraisal of Guidelines for Research and
Evaluation (AGREE II) tool(4). An international multidisciplinary team (gastro-
enterologists, pathologists, epidemiologists, a radiologist and a patient represen-
tative) were summoned by the World Endoscopy Organisation (WEO); the final
panel consisted of 20 voting members. The following topics were addressed by
2 working groups (WGs):
1. Aetiology WG
a. Terminology of aetiology categories
b. Risk factors/potential explanations of PCCRC
c. How to ascribe potential explanations
d. Minimal colonoscopy, histology and radiology datasets to examine PCCRC
e. Molecular tests to be performed to examine PCCRC
f. Prevention of PCCRC in high-risk groups
2. Performance WG
a. PCCRC calculation & reporting
b. PCCRC monitoring
c. PCCRC papers peer-review
d. Post-imaging CRC A literature search was performed in MEDLINE and
Cochrane using terms ‘‘colorectal cancer AND interval cancer’’, ‘‘healthcare
quality assurance AND colorectal cancer’’ and ‘‘healthcare quality assurance
AND colorectal cancer AND interval cancer’’. The final output consisted of
391 articles. Proposed statements were subjected to anonymous voting via e-
correspondence. Each statement was scored on an scale of 1 (strongly agree) to
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5 (strongly disagree). A modified Delphi process was followed; consensus
required at least 80% agreement. In areas of continuing disagreement, a recom-
mendation for or against a particular statement required both 450% of parti-
cipants in favour and 520% preferring the comparator. Failure to meet this
resulted in no recommendation. The GRADE system for rating evidence and
strength of recommendations was applied to final statements.
Results: The final output consists of 21 statements providing guidance on key
aspects of PCCRC/PICRC, namely definitions, terminology, qualitative review/
aetiology attribution and quantitative assessment of cases. A Root-Cause
Analysis checklist as well as a PCCRC/PICRC manuscript peer-review checklist
were also developed.
Conclusion: This is the first consensus aiming to standardise terminology around
PCCRC. Each previous study defined PCCRC differently, making its use for
benchmarking purposes impossible. This consensus presents a methodology for
analysis of causation of PCCRC/PICRC and defines its potential role as a key
quality indicator, providing recommendations for future investigators, policy
makers, services and patients.
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Introduction: Colorectal cancer (CRC) is still the third most common malignan-
cies in the US according to Colorectal Cancer Statistics, 2017[1]. During past
decades, the incidence and mortality of CRC among individuals aged over 50
years are declining significantly, while the rate of CRC in the young is sharply on
the rise curiously [2–3]. Escalating rate of young-onset CRC, coupled with
increased survival relate, would definitely lead to accumulation of young survi-
vors considerably. There is a growing study reporting the risk of second primary
cancers (SPCs) in certain cancer survivors, including CRC. Several population-
based studies revealed that patients with a history of CRC were at high risk of
SPCs than the general population [4–6]. However, to the best of our knowledge,
very little is known regarding the risk and sites of SPCs following prior diagnosis
of CRC in the young (aged 50).
Aims & Methods: To address this important gap, we aimed to quantify
the relative risk of SPCs after a diagnosis of CRC in the young CRC
survivors. We conducted this retrospective study by utilizing the Surveillance,
Epidemiology, and End Results (SEER) database and identified primary CRC
patients with subsequent cancers between 1973 and 2013. We excluded cases with
less than 6-months latency restriction. Standardized incidence ratios (SIR) and
absolute excess risk (AER) were calculated to assess the relative risk for SPCs.
SIRs for subgroup analysis were further stratified by gender, race, calendar year,
latency period, SEER stage, cancer subsite, radiotherapy. All statistical tests were
performed by SEER*Stat version 8.3 and a P value 50.05 was considered sta-
tistically significant. Our study was approved by the review board of Zhejiang
Institute of Gastroenterology, Sir Run Run Shaw Hospital, China.
Results: Among 340,992 CRC patients, there were 44,472 survivors who devel-
oped 51,084 SPCs during the follow-up, including 3283 young (young aged 50)
and 41,189 (old4 50) old survivors. The SIR of all sites significantly decreased
with increased age. Compared with the general population, SIRs of all solid
tumors and hematological disease were significantly increased in the young.
There was significant 43% risk of SPCs in young survivors (SIR¼ 1.43,
95CI%¼ 1.39–1.48, AER¼ 33.85) and slight increases in old survivors
(SIR¼ 1.02, 95CI%¼ 1.01–1.03, AER¼ 4.20). For young survivors, small
intestine (SIR¼ 8.36), colon (SIR¼ 3.77), rectum (SIR¼ 3.56), bile ducts
(SIR¼ 3.70) were the most common sites. This trend was persisted regardless
of other factors, such as gender, race, calendar year, stage, subsites, radiation,
latency. For young patients with second cancers, 36.4% died of their initial
cancer, but 44.6% died of their second primary malignancy.
Conclusion: Excess risk of developing a second malignancy existed in young-onset
CRC survivors and this trend was consistent among different subgroups. About
44.6% young patients died of their SPCs. We hope our results may provide some
implication for future surveillance and prevention strategies for young CRC
survivors.
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Introduction: Worldwide, many organized colorectal cancer (CRC) screening
programs use non-invasive fecal occult blood tests (FOBTs). Although the inter-
val colorectal cancer (iCRC) rate is an important performance indicator of a
screening program, data on iCRC after negative FOBTs are limited.
Aims & Methods: In this systematic review and meta-analysis we compared the
incidence of iCRCs following a negative fecal immunochemical test (FIT) or
guaiac fecal occult blood test (gFOBT). Second, we assessed if screening-related
or patient-related factors are associated with FOBT iCRCs. Ovid Medline,
Embase, The Cochrane Library, the Science Citation Index, PubMed publisher
and Google scholar were searched up to May, 2016. All studies reporting on the
incidence of FIT or gFOBT iCRCs in average CRC screening populations were
included, without language restrictions. Main outcome was pooled incidence rate
of iCRCs per 100, 000 person-years (p-y). FOBT iCRC was according to inter-
national standards defined as cancer that developed after a negative FOBT and
before the next FOBT was due. Pooled incidence rates were obtained by fitting
random effect poisson regression models. The between-study heterogeneity of
effect-size was quantified using the I2.
Results: We identified 5,873 records, of which 413 full-text articles were assessed
for eligibility and 30 studies were included in both qualitative and quantitative
syntheses. Meta-analyses comprised data of 5,252,563 screening participants, in
which 14,030 screen-detected CRCs and 5398 FOBT iCRCs were documented.
Pooled incidence rates of iCRC following FIT and gFOBT were 20 (95%CI 14–
28; I2¼ 94%) and 40 (95%CI 26–61; I2¼ 93%) per 100,000 p-y, respectively. The
pooled incidence rate ratio of FIT iCRC compared to gFOBT iCRC was 0.50
(95%CI 0.30–0.84, n¼ 30 studies). For every FIT iCRC, three CRCs were found
with FIT, while for gFOBT the ratio between iCRC and screen-detected CRC
was 1:1.3, Table 1. No significant differences were found between the relative risk
of FOBT iCRC in the second and third screening round compared to the first,
with 1.03 (95%CI 0.94–1.13) and 1.08 (95%CI 0.93–1.22), respectively. Incidence
rate ratio of FOBT iCRC was 1.2 (95%CI 0.8–1.7) for males relative to females
and 5.0 (95%CI 1.2–21) for screenees aged 60 relative to 560 years.
Table 1: Baseline data of 30 studies included in quantitative meta-analyses dis-
played per test type
Screening
participants
n¼ 5, 252, 563
Screen-detected
CRCs n¼ 14, 030
FOBT iCRCs
n¼ 5, 398
Ratio
screen-detected
CRC to FOBT iCRCs
FIT n, (%) 4,774,516 (91) 12,172 (87) 4003 (80) 3.0
gFOBT n, (%) 478,047 (9) 1858 (13) 1395 (20) 1.3
Conclusion: This is the first study to report on the pooled incidence of FIT and
gFOBT iCRC in screening setting. The incidence rate of iCRC after a negative
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FOBT is two-fold higher in gFOBT than in FIT, which supports the use of FIT
over gFOBT as screening stool test. However, for every three FIT-detected
CRCs, still one CRC is missed, which highlights the importance to adequately
inform screenees about the risk of developing a colorectal carcinoma after a
negative FIT.
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Introduction: Age and family history of colorectal cancer (CRC) are the strongest
risk factors for CRC. Obesity, commonly assessed based on body mass index
(BMI), is associated with an increased risk for CRC in men but the association is
weaker in women and differs between studies. We investigated which of the
following body composition measures: BMI, waist circumference (WC), waist-
hip ratio (WHR), weight-height-ratio (WHtR), weight-hip-height ratio
(WHHR), A Body Shape Index (ABSI) and percent body fat that best predict
the development of CRC in men and women.
Aims & Methods: We used data from Malmö Diet and Cancer cohort in Sweden,
including 16,840 women and 10,903 men (mean age, 58.1 years at baseline),
followed for a median of 19.8 years. We identified cases with CRC until the
end of 2014 using national Swedish registers. Hazard ratios (HR) for CRC,
colonic cancer (CC) and rectal cancer (RC) per one standard deviation increase
in each body composition measure respectively were calculated using Cox regres-
sion models, stratified by sex and adjusted for age, alcohol consumption, smok-
ing, education and physical activity. Likelihood ratio tests and C-statistics were
calculated to identify the anthropometric measure that improves the null model
the most.
Results: Incident CRC occurred in 880 individuals (477 women) during follow-
up. All body composition measures apart from WHHR significantly predicted
CRC in men and waist circumference (WC) was the best predictor based on
C-statistics and LR-test (HR per standard deviation [SD] increment, 1.19; 95%
CI, 1.08–1.31, LR-test p5 .001, C-statistics 0.6278). The association between
WC and CRC was only found in men with a BMI above 25. All body composi-
tion measures apart from WHHR and percent body fat significantly predicted
CC in men, again WC was the best predictor (HR 1.25; 95% CI, 1.11–1.42,
LR-test p5 .001, C-statistics 0.6444). ABSI was the only measure significantly
associated with risk for RC in men (HR, 1.24; 95% CI, 1.05–1.47). In women
neither of the measures was significantly associated with an increased risk for
CRC, CC nor RC.
Conclusion: In this Swedish population-based cohort study on well-characterized
participants, body composition measures predicted CRC in men but not in
women after adjusting for age, education and health behaviors. WC was the
best predictor of CRC and CC in men and the association was only significant
in overweight/obese men in stratified analyses. Gender difference in the interplay
between sex and metabolic hormones in the adipose tissue may explain the lack
of associations in women.
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Introduction: T helper 17 (Th17) cells participate in the progression of various
cancers. Both tumor-promoting and tumor-suppressing effect have been
reported. The role of Th17 cells in colorectal cancer (CRC) remains controversial
and the specific mechanism of how Th17 cells affect the development of CRC
remains to be explored.
Aims & Methods: The study aimed to clarify the role of Th17 cells in CRC and
identify the underlying molecular mechanisms. The percentage of Th17 cells and
IL-17 expression were evaluated via flow cytometry, enzyme-linked immunosor-
bent assay, and immunohistochemistry in tissue samples and peripheral blood.
Effects and underlying molecular mechanisms of IL-17 cells on epithelial-
mesenchymal transition (EMT) process were explored in vitro using IL-17 trans-
fection and in nude mice by implanting IL-17 overexpressed CRC cells. To detect
the direct role of Th17 cells on EMT process, SW480 cells were co-cultured with
Th17 cells via transwell system. Cancer signaling phospho antibody microarray
was used to explore the potential signaling pathway. The clinical significance of
Th17 cells was investigated in tissue microarrays containing CRC tissues from 90
patients following surgery using immunohistochemistry.
Results: A higher percentage of Th17 cells and serum IL-17 level were found in
CRC patients than healthy controls, and Th17 cells presented a gradual upward
trend in normal epithelium-adenoma-carcinoma sequence. The overexpression of
IL-17 significantly promoted tumor proliferation and invasion, and inhibited
apoptosis in vitro and in vivo. IL-17 overexpression reduced the expression of
E-cadherin and induced the expression of Snail, b-catenin, and Vimentin in both
SW480 cells and tumor xenografts, suggesting that IL-17 could induce the EMT
process in CRC. When co-cultured SW480 cells with Th17 cells, we found Th17
cells could directly promote the EMT process of tumor cells. Furthermore, using
cancer signaling phospho antibody microarray, we found that PI3K/AKT/Snail
signaling pathway played a key role in the regulation of EMT. EMT process
could be reversed by LY294002 and IL-17 mAb intervention, suggesting that IL-
17/PI3K/AKT/Snail pathway played a vital role in Th17 cells-induced EMT in
CRC. Supporting these findings, in human CRC tissues, immunostaining indi-
cated that the percentage of Th17 cells was significantly associated with E-cad-
herin expression and AKT phosphorylation. The clinical significance of Th17
cells was authenticated by revealing that the combination of intratumoral Th17
cells and E-cadherin served as a better prognosticator for postoperative tumor
recurrence than either marker alone.
Conclusion: Th17 cells promote EMT process and facilitate tumor progression
via activating IL-17/PI3K/AKT/Snail signaling pathway in CRC.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0441 MICRORNA EXPRESSION PROFILE IN RECTAL CANCER
J. Král1, V. Rusnakova2, L. Langerova2, V. Korenkova2, P. Vodicka3, J. Spicak1,
J. Slyskova3
1Dept. Of Hepatogastroenterology, Institute for Clinical and Experimental
Medicine, Prague/Czech Republic
2Institute of Biotechnology AS CR, v.v.i., Prague/Czech Republic
3Department Of The Molecular Biology Of Cancer, Institute of Experimental
Medicine AS CR, v.v.i., Prague/Czech Republic
Contact E-mail Address: jan.kral@centrum.cz
Introduction: Colorectal cancer (CRC) remains the second most common cancer
in women and third in men worldwide, with more than 1.3 million patients
diagnosed every year (1–3). Still more than 50% of patients are diagnosed with
advanced disease (stage III and IV), which has worse prognosis and survival.
There is a need for new biomarkers for early diagnostics, predicting patient’s
treatment response and follow-up. Recent data suggest that microRNAs
(miRNAs) might be utilized as these biomarkers (4, 5).
Aims & Methods: We focused on specifying differences in expression profile
between rectal tumor and adjacent healthy mucosa. Individual miRNA levels
were analyzed in relation to patient’s treatment response and post-treatment
survival, in order to identify miRNAs with possible role of predictive and prog-
nostic markers in rectal cancer. At first, we screened 20 pairs of rectal tumors and
healthy surrounding mucosae for the expression levels of 2555 microRNAs using
3D-Gene TORAY microarray system. We have identified 71 candidate miRNAs
with different expression profile in tumor and healthy tissue. These 71 miRNAs
were further explored and verified in larger cohort of 101 rectal tumors and 105
colon tumors compared to matched healthy tissues by qPCR (Fluidigm
BioMark). Results were analyzed in relation to different clinico-pathological
characteristics of tumors, to individual patient’s treatment response and overall
or disease-free survival.
Results: We confirmed 18 miRNAs to be differently expressed in rectal tumors as
compared to healthy mucosa. This expression profile was observed in tumors
resected prior to neoadjuvant therapy, but not in those that were neoadjuvantly
treated. Only 2 miRNAs were dysregulated irrespectively on neoadjuvant ther-
apy. We have further investigated whether this signature is specific for rectal
cancer, or is observed also in colon cancer. We have found that 14 out of 18
miRNAs were indeed commonly dysregulated in whole CRC, and 4 miRNAs
were dysregulated in rectal tumor only. In order to identify miRNAs with any
association to treatment, we have analyzed miRNA expression profile of rectal
tumors in relation to patient’s treatment response and their long-term survival.
Thirteen miRNAs were differently expressed between tumors that responded to
therapy and those that relapsed.
Conclusion: We have identified miRNA expression patters specific for rectal
cancer and identified miRNA candidates that might be used as a predictive
and prognostic marker in patient’s follow-up.
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Introduction: Studies with the colon cancer cell lines which express muscarinic-3
(M3) receptors showed that taurine conjugates of lithocholic acid, but not other
bile acids, bind to M3 receptors, and stimulate an increase in cell proliferation.
On the other hand, many microRNAs (miRNAs) are involved in colon carcino-
genesis. However, the interaction of bile acid-M3 receptors and miRNAs and
their potential effects in colon carcinogenesis remains to be elucidated.
Aims & Methods: For the first time in the literature, we examined the possible
role of M3 receptor-targeted miRNAs on two human colon cancer cell lines:
H508, which expresses M3 receptors, and SNU-C4, which does not. Cell prolif-
eration for 6 days after sodium taurolithocholat (ST) and atropin (A) treatment
was analysed by WST-1 method. Expression of M3 receptor gene at mRNA level
was analysed by qPCR, and at protein level by Western Blot method. Apoptotic
experiments were analysed by Annexin V assay. MiRNAs which possibly tar-
geted M3 receptors were identified by in silico analyses. The methods were
repeated three times, and the average values were calculated.
Results: When compared to SNU-C4 cells, M3 receptor gene expression was
found to be increased 70-fold on H508 cells. After a 6-day incubation, maximum
H508 cell proliferation (300%) was achieved on 5th day with a dose of 300 mM
ST, inhibited by a dose of 1 mM A. In contrast, the SNU-C4 cells showed no
significant change in cellular proliferation. Treatment of H508 cells with ST
caused a decrease (2.53-fold) of M3 receptor gene expression, however, no
change of M3 receptor at protein level was seen. No changes in apoptosis on
both colon cancer cell lines were observed. Of 25 M3 receptor-targeted miRNAs,
expression levels altered in 9; 6 of them were up-regulated (hsa-miR-129-5p, hsa-
miR-30c-5p, hsa-miR-224-5p, hsa-miR-30b-5p, hsa-miR-522-3p, hsa-miR-1246)
and 3 of them (hsa-miR-30e-5p, hsa-miR-147b, hsa-miR-885-3p) were down-
regulated on H508 cells (p5 0.05).
Conclusion: ST interact with M3 receptors which modulate colon cancer cell
proliferation on H508 cells. M3 receptor-targeted miRNAs are involved in ST
induced proliferation. Whether the use of ursodeoxycholic acid, selective anti-
miRNAs, anti-cholinergic agents or other approaches to blocking potential inter-
actions of bile acids/salts with neoplastic colonic epithelium may be a useful
adjunct to colon cancer prevention or treatment remains to be determined.
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Introduction: Dyslipidaemia and statin use have been associated to colorectal
cancer (CRC), but prospective studies have shown controversial results.
Dyslipidaemia has been thought to have an important role in inflammatory
pathways, oxidative stress and insulin resistance, which could contribute to the
pathogenesis of cancer. However, findings from prospective studies that have
examined the association between serum dyslipidaemia (low density lipoprotein
cholesterol (LDL), HDL or TG) and colorectal neoplasia have been inconsistent.
[1–4] It is unknown whether lipids and lipoproteins cause cancer or are inter-
mediate or correlated factors within carcinogenic pathways. Epidemiological
studies could be confounded by 3-Hydroxy-3-methylglutaryl-coenzyme A reduc-
tase inhibitors (statins) use, which might also have a protective effect to CRC. It
is unclear whether it is statin use or dyslipidaemia that prompted statin use,
which may be associated with CRC. Indeed, a large number of epidemiological
studies have examined the effect of statins on colorectal cancer risk, with often
inconsistent results.[5–6] A Mendelian randomization approach could help to
establish a causal relationship between dyslipidaemia and CRC.
Aims & Methods: We aimed at determining whether dyslipidaemia is causally
linked to CRC risk and to explore association of statins with CRC. A case-
control study was performed including 1336 CRC cases and 2744 controls
(MCC-Spain) between 2008 and 2013. Subjects were administered an epidemio-
logical questionnaire that included lifetime regular use of prescription drugs.
Also, subjects were genotyped with an exome array supplemented with 5000
custom SNPs. We applied the Mendelian randomization approach. The array
included 136 SNPs previously shown to be associated with blood lipids levels in
GWAS, that were used to build three genetic lipid scores, as the count of risk
alleles. The scores were specific for low density lipoprotein cholesterol (LDL),
high density lipoprotein cholesterol (HDL) or triglycerides (TG). We tested the
association on regular statin use and the genetic lipid scores with logistic regres-
sion models, adjusted for potential confounders.
Results: The LDL genetic risk score was significantly associated with statin con-
sumption (OR¼ 1.07, 95%CI 1.05–1.10, p¼ 4.4e-11). The dyslipidaemia genetic
risk score was not significantly associated with CRC for either of the target lipids
studied. Cases had the same average alleles as controls in all the lipids traits.
Statin use was a borderline significant protective factor for CRC (multivariate
adjusted OR¼ 0.83; 95%CI 0.69–1.00, p¼ 0.049).
Conclusion: Using the Mendelian randomization approach, our study does not
support the hypothesis that lipid levels are associated with the risk of CRC. This
study does not rule out, however, a possible protective effect of statins in CRC by
a mechanism unrelated to lipid levels.
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Introduction: Long non-coding RNAs (lncRNAs) contribute to different cancers
including colorectal cancer (CRC) through influencing cancer-related processes
such as cell proliferation, apoptosis, and invasion. Previous studies have shown
altered LINC00152 expression in CRC, but the detailed mechanism of its effects
during colorectal carcinogenesis and cancer progression is not well studied.
Aims & Methods: We aimed to study the effects of LINC00152 to the cell cycle
regulation and promoter DNA methylation of several CRC-associated tumor
suppressor genes in colon cancer cells. We also analyzed the expression and
promoter DNA methylation of LINC00152 and of its regulated molecules in
human colonic tissue samples. LINC00152 were silenced in SW480 colon carci-
noma cells using Stealth siRNAs. Cells were harvested 48 or 72 hours after
transfection. Flow cytometric cell cycle analysis was performed using propi-
dium-iodide DNA staining. Cyclin D1 protein expression was detected using
flow cytometry after labeling with anti-cyclin D1 antibody. The effect of
LINC00152 silencing to DNA methylation levels of SFRP1, SFRP2, SDC2
and PRIMA1 tumor suppressor gene promoters was studied using MethyLight
technology. Promoter methylation and expression of the above molecules were
also studied on human colonic tissue samples.
Results: LINC00152 expression was successfully silenced in SW480 cells with 93–
98% efficiency. Silencing of LINC00152 suppressed cell growth, induced apop-
tosis and decreased cyclin D1 protein expression. LINC00152 knockdown did
not affect the promoter methylation status of SFRP1, SDC2 and PRIMA1 genes,
while reduced the DNA methylation level of SFRP2 promoter. Remarkable
hypomethylation of LINC00152 promoter was detected in CRC compared to
normal samples (p5 0.01), which correlated with increased expression
(R¼ 0.90). SFRP2 promoter hypermethylation and decreased expression were
measured in CRC and adenoma tissues compared to normal samples (p5 0.05).
Conclusion: Our results support that LINC00152 lncRNA can contribute to CRC
development by facilitating cell proliferation through upregulation of cyclin D1
cell cycle progression gene and by affecting promoter methylation of SFRP2
tumor suppressor gene. On human tissue level, similar signaling pathway altera-
tions were detected in CRC.
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Introduction: Colonoscopy surveillance of polyps is based on their size, number
and pathological features. The role of their genetic profile to predict advanced
metachronous lesions (AML) remains unknown.
Aims & Methods: To study the relation between genetic profile of polyps and
both risk of AMLs and time to develop them in surveillance. 308 patients with
colonic polyps were consecutively enrolled between 2007 and 2009 for this cohort
study, and followed up to 2014. Variables as age, sex, smoking, weight, number
of colonoscopies and number and characteristics of polyps were collected. 995
polyps were analyzed for somatic mutations on BRAF and KRAS genes using
allelic discrimination by real-time PCR and direct DNA sequenciation, respec-
tively. High level of methylation on CpG islands (CIMP-H) was also tested using
MS-MLPA. AML was defined by a size higher than 9mm, high-grade dysplasia
or villous component in adenomatous lesions. Regarding serrated lesions, AML
was defined by a size higher than 9mm, any grade of dysplasia and proximal
location. Risk of developing AML for individual genetic markers was studied
using Chi-square tests and logistic regression for univariate and multivariate
analysis, respectively. Log-rank test with Kaplan Meier survival curves for uni-
variate analysis and Cox-regression model for multivariate analysis were also
performed. As logistic as Cox regression were adjusted by sex, age, familial
colorectal cancer, smoking and features of AML in first colonoscopy. P value
of 0.05 was considered significant.
Results: Patients were followed up for a median of 26 months (range 63). 21% of
polyps in first colonoscopy were CIMP-H. KRAS and BRAF mutations
accounted for 25% and 17% of polyps, respectively. In univariate analysis,
KRAS-mutated polyps were related to higher risk of AML in surveillance
(52% KRAS-mutated polyps vs 31% non-mutated; RR¼ 1.8, 95% CI 1.2–2.9;
p¼ 0.01). Similar results were obtained regarding CIMP-H (77% CIMP-H
polyps vs 38% non-CIMP; RR¼ 3.7, 95% CI 1.3–10.3; p¼ 0.005) but no asso-
ciation was found with BRAF-mutated ones. Logistic regression showed CIMP-
H as the unique genetic marker of risk for AML (OR 11.41, 95% CI 2.04–63.70;
p¼ 0.006). Regarding time to develop AML, shorter intervals were found related
to CIMP-H (median of 31 vs 48 months in non-CIMP-H; p¼ 0.002) and KRAS-
mutations (median of 36 vs 49 months in non-mutated; p¼ 0.029) in univariate
analysis. There were no significant results concerning BRAF status. Multivariate
analysis highlighted CIMP-H as the unique independent marker associated to
shorter time to develop AML (HR 4.01, 95% CI 1.36–10.46; p¼ 0.01).
Conclusion: Presence of CIMP-H in polyps associates higher risk of subsequent
AML and shorter interval to their development. Genetic profile of polyps
emerges as useful tool for colonoscopy surveillance.
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Introduction: Colorectal cancer (CRC) frequently harbours concomitant muta-
tions in KRAS and APC that promote carcinogenesis. Epigenetic dysregulation
plays essential roles in the tumorigenicity of KRAS mutant CRC. Our prelimin-
ary data demonstrated that simultaneous KRAS gain-of-function mutations in
APC-null CRC cells induced the hypermethylation of DNA and histones, an
effect driven by metabolic rewiring of glutamine metabolism. We recently
unveiled that glutamine metabolism in KRAS-mutant CRC could be rewired
by the mitochondrial glutamate transporter, SLC25A22, a synthetic lethal gene
in KRAS-mutant CRC in vitro and in vivo. In this study, we investigate the
potential role of SLC25A22-mediated glutaminolysis in regulating DNA and
histone methylation in CRC, its underlying mechanisms, and the association of
SLC25A22 with epigenetic dysregulation in human CRC cohorts.
Aims & Methods: We aim to 1) evaluate the impact of mutant KRAS on DNA
and histone methylation in CRC; 2) examine the role of SLC25A22 in DNA
and histone methylation in KRAS-mutant CRC; 3) elucidate the underlying
mechanisms that underlies SLC25A22-mediated epigenetic dysregulation;
and 4) investigate the clinical association between SLC25A22 and epigenetic
dysregulation in CRC patients. DNA methylation was determined by the
Illumina 860K methylation array and Methyl Light qMSP assays. Histone
methylation was determined by Histone H3 Modification Multiplex Assay
Kit and Western blot. U-13C5-Glutamine metabolic labelling and analysis
of glutamine metabolism via the TCA cycle was determined by liquid chro-
matography-mass spectrometry analysis. In clinical samples, SLC25A22
mRNA and protein expression was determined and their correlation with
CpG Island Methylator Phenotype (CIMP) status and histone methylation
mark (H3K36me2) was evaluated.
Results: Using three pairs of isogenic cell lines harbouring wild-type and mutant
KRAS (DKS8(WT) vs DLD1(mutant); HKE3(WT) vs HCT116(mutant);
ICT(WT) vs ICT-KRAS(mutant)), we demonstrated that significant DNA and
histone H3 hypermethylation in cell lines expressing mutant KRAS. DNA hyper-
methylation was associated with the up-regulation of 5-hmC, indicating sup-
pressed DNA demethylation in KRAS mutant CRC cell lines. Metabolomic
analysis revealed that KRAS mutation modified glutaminolysis via TCA cycle
leading to high succinate and fumarate to -ketoglutarate (KG) ratio, which
was to pivotal in suppressing the enzymatic activity of dioxygenases such as
DNA and histone demethylases, thereby leading to aberrant methylation.
Interestingly, simultaneous APC-loss and KRAS activating mutations synergis-
tically up-regulated the expression of SLC25A22, a key regulator of glutamine
metabolism via the TCA cycle. CRISPR-Cas9 mediated knockout of SLC25A22
suppressed glutaminolysis in KRAS-mutant CRC cell lines, which in turn,
reduced the ratio of succinate and fumarate to -ketoglutarate. The impact of
SLC25A22 knockout on glutamine metabolism had a profound effect on epige-
netic regulation, as DNA methylation profiling revealed that SLC25A22 knock-
out increased 5-hmC levels and decreased DNA hypermethylation in KRAS-
mutant CRC cell lines. Moreover, histone H3 methylation was reduced at multi-
ple histone marks after the knockout of SLC25A22. These data implied that
SLC25A22 inhibited DNA and histone demethylases by promoting the produc-
tion of succinate and fumarate. Indeed, succinate supplementation reversed the
effect of SLC25A22 knockout on DNA and histone methylation in KRAS-
mutant CRC cell lines. In addition, succinate restored cell growth in
SLC25A22 knockout cell lines, suggesting that epigenetic dysregulation was clo-
sely associated with tumorigenicity. In human CRC, SLC25A22 expression was
positively associated with CIMP (P5 0.0001) and histone H3K36me2 methyla-
tion status (P5 0.0001).
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Conclusion: SLC25A22 promotes the tumorigenicity of KRAS mutant CRC by
driving aberrant DNA and histone hypermethylation, an effect mediated by
increased production of TCA cycle intermediates succinate and fumarate,
which inhibits DNA and histone demethylases. SLC25A22 is correlated with
CIMP and histone hypermethylation in CRC patients.
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Introduction: Follistatin-like protein 1 (FSTL1) is a secreted glycoprotein, widely
expressed in human tissues, which plays key functions in the regulation of cell
survival, proliferation, differentiation and migration. Moreover, deregulated
expression of FSTL1 has been described in malignancies but its contribution
to carcinogenesis remains controversial.
Aims & Methods: We here investigated the expression and role of FSTL1 in
sporadic colorectal cancer (CRC). FSTL1 was evaluated in human CRC samples
and cell lines by immunohistochemistry, Western blotting and real-time PCR.
Cell proliferation and survival and cell cycle were evaluated in human CRC cell
lines (i.e., HCT-116, DLD-1) treated with a specific FSTL1 antisense (AS) or
control oligonucleotide by flow-cytometry. By Western blotting, we assessed
expression of proteins involved in cell cycle progression, poly ADP-ribose poly-
merase (PARP), caspase-9 and active caspase-3. Moreover, the effect of FSTL1
knockdown on cell death was evaluated in cells cultured in the presence or
absence of the pan-caspase inhibitor Q-VD-OPh by flow-cytometry.
Results: FSTL1 was significantly increased in both epithelial and lamina propria
compartments of human CRC specimens as compared to controls. In CRC cell
lines, FSTL1 knockdown caused accumulation of cells in G1 phase of the cell
cycle and reduced CRC cell proliferation. FSTL1-deficient CRC cells had
reduced levels of proteins involved in late G1 cell cycle phase, such as phosphory-
lated retinoblastoma protein (pRb), E2F-1, cyclin E and cyclin-dependent
kinase-2 (Cdk2), with no modification of early G1 phase proteins (i.e. cyclin
D). Treatment of CRC cells with FSTL1 AS increased the percentages of apop-
totic cells and this effect was associated with activation of PARP, caspase-9 and
caspase-3. Pre-incubation of HCT-116 and DLD-1 cells with Q-VD-OPh abol-
ished the FSTL1 AS-induced cell death and reduced PARP and caspase activa-
tion, thus indicating that FSTL1 silencing induces CRC cell death through a
caspase-dependent mechanism.
Conclusion: Our data indicate that FSTL1 is over-expressed in CRC cells and
suggest a role for this protein in promoting intestinal tumorigenesis.
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Introduction: In sporadic colon cancer, TP53 mutation is well known to occur in
the late phase of colon carcinogenesis as adenoma-carcinoma sequence.
Although numerous reports about clinical information of the patients with
colon cancer have suggested that TP53 mutation might be related to various
malignant potentials, direct effect of TP53 mutation on malignant potential in
colon cancer is still unknown. Notably, there is no report about a relationship
between TP53 mutation and cancer stemness. We therefore aimed to assess the
function of TP53 mutation in colon cancer cells, by using recently established
lentiviral CRISPR Cas9 system.
Aims & Methods: Two types of TP53 mutation were generated in LS174T cells,
which are derived from human colon adenocarcinoma with wild-type TP53 (WT-
TP53), by using lentiviral CRISPR Cas9 system. The guide RNAs were designed
to bind exon3 or exon 10 of TP53, respectively. TP53 mutation in LS174T was
confirmed by direct sequencing. The expression of TP53 protein was assessed by
immunohistochemistry. Loss of function of TP53 was assessed by Nutlin-resis-
tance and the expression of TP53 target genes. Malignant potentials of TP53-
mutated cells were assessed by MTS Assay, 3D sphere formation assay and cell
migration assay for cell proliferation, cancer stemness and cell migration, respec-
tively. Chemo-resistance was also assessed by the treatment with 5-FU and L-
OHP.
Results: We first selected LS174T cells with WT-TP53 because TP53 gene has
already been mutated in almost colon cancer cell lines. We then successfully
established 2 types of TP53 mutation in LS174T cells due to high effectiveness
of gene-mutating by lentiviral system. Mutation in exon3 (TP53Ex3) and exon10
(TP53Ex10) of TP53 created the shorter form of TP53 (TP53Ex3; 55a.a. and
TP53Ex10; 377a.a., respectively) compared to WT-TP53 (393a.a.). Mutant
TP53 (TP53Ex10) is strongly expressed in nuclei as often shown in colon
cancer region, whereas both WT-TP53 and mutant TP53 (TP53Ex3) are not
expressed in LS174T cells. In contrast, both TP53 mutants (TP53Ex3 and
TP53Ex10) showed Nutlin-resistance and the down-regulation of TP53 target
genes, suggesting that both mutants induced loss of function of TP53. We then
assessed the effect of both TP53 mutants on various malignant potentials, result-
ing equally in accelerated cell growth, enhanced invasiveness and the resistance
against 5-FU treatment compared to WT-TP53. Moreover, both mutants showed
more frequent formation of 3D sphere and more expression of Lgr5 than WT-
TP53, suggesting the promotion of cancer stemness by TP53 mutation even after
being adenocarcinoma.
Conclusion: We for the first time showed the direct effect of TP53 mutation on
malignant potential in colon cancer cells. Loss of function of TP53 induced by
not only TP53Ex10 but also TP53Ex3 mutation, might promote malignant
potentials including cancer stemness at the late phase of carcinogenesis. In gen-
eral, nuclear accumulation of TP53 protein in cancer region is represented as
TP53 mutation. However, negative staining of TP53 might also be careful for
TP53 mutation to estimate malignant potential in colon cancer, since N-terminal
mutation of TP53 in colon cancer has already been reported.
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Introduction: Endogenous opioid system is involved in the maintenance of the
intestinal homeostasis. Recently, we proved that stimulation of opioid receptors
using P-317 – a novel cyclic morphiceptin analog with mu- and kappa- opioid
receptor affinity, resulted in alleviation of acute phase of experimental colitis
(induced by dextran sodium sulfate [DSS]) in mice. Chronic inflammation is
associated with increased risk of colitis-associated colorectal cancer.
Stimulation of opioid receptors produces different effects on cancer progression
depending on the cancer type and stage of disease.
Aims & Methods: The aim of our studies was to characterize the role of the
endogenous opioid system in pathogenesis and treatment of colitis-associated
colorectal cancer using P-317. Colitis-associated colorectal cancer was induced
by a single intraperitoneal injection of azoxymethane [AOM] (10mg/kg) and
subsequent addition of DSS (1.5% w/v) into drinking water (week 2, 6, 9).
From week 3, P-317 was injected intraperitoneally at the dose of 0.1mg/kg
twice per week and the body weight and clinical score (rectal bleeding, stool
consistency) were assessed. After 14 weeks, the macroscopic colon damage
score was assessed and the samples were collected and used for biochemical,
molecular and histological studies.
Results: A significant difference in colorectal tumor development was observed
between vehicle- and P-317-treated mice. P-317 significantly decreased total
number of colonic tumors as well as colon thickness and width after 14 weeks
of disease induction. Myeloperoxidase activity, a marker of neutrophil infiltra-
tion, was inhibited by P-317 injections. Hematoxylin and eosin staining con-
firmed anti-tumor activity of P-317 as indicated by histological score
connecting the following features: muscle thickness, damage of the intestinal
wall, immune cell infiltration, invasion depth, crypt hyperplasia and disruption.
The expression of IL-1b and TNF- at mRNA level was decreased in P-317-
treated mice as compared to vehicle-treated group.
Conclusion: P-317 may become an important pharmacological tool to study the
factors that determine the development of inflammatory bowel disease and to
define the role of the endogenous opioid system in chronic colitis and colorectal
cancer.
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Introduction: Colorectal cancer (CRC) is the third most common type of cancer
in the world, and it’s incidence continues to rise[1, 2]. The probability of recur-
rence and subsequent death due to colorectal cancer is associated with its stage [1,
2]. Because of its insidious onset, the diagnosis of CRC is usually delayed.
However, serological markers can be a relatively easier and cheaper alternative
to colonoscopy for screening an average risk population [1]. Several recent studies
have shown that high-motility group box 1 (HMGB1) plays a critical role in
tumorigenesis, disease progression and metastasis by activation of cancer cells,
promotion of tumor angiogenesis, suggesting that HMGB1 may be useful as a
new biomarker of cancer [1, 2, 3, 4]. Studies have shown that HMGB1 is over-
expressed in various types of cancers, include CRC, and those cases with higher
expression of HMGB1 are associated with lymphatic metastasis, distant metas-
tasis and poor prognosis [5]. Several reports have demonstrated that HMGB1 is
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secreted by cancer cells may be involved in occurrence of tumor metastasis [6, 7].
In a study by Luo et al, the authors found that HMGB1 secreted by the primary
tumors had an apoptotic effect on the Kupffer cells which promoted develop-
ment of liver [6, 7]. Furthermore, some researchers showed that increased levels of
c-IAP2 and pERK, the downstream effector molecules of HMGB1 are found in
tumors [8]. The current studies suggest that HMGB1 may be useful for diagnosis
and treatment of CRC. However, whether HMGB1 has any role in the develop-
ment of CRC metastasis is not clear. In this study, we investigated the effects of
HMGB1 on CRC, and the possible underlying mechanisms were examined.
Aims & Methods: To investigate the relationship between high-mobility group B1
(HMGB1) and colorectal cancer (CRC) and the probable underlying pathogenic
mechanism. In this prospective study, patients with CRC undergoing primary
surgery and healthy subjects (control group) were included from July 2013 to
December 2014. Serum HMGB1 concentration was determined using ELISA and
HMGB1 mRNA expression was detected by RT-PCR method.
Immunohistochemical analysis was performed to determine HMGB1, pERK
and c-IAP2 protein expressions in the cancer tissues.
Results: 144 patients with CRC and 50 healthy subjects underwent serum
HMGB1 testing. Resected specimens of 50 patients were used for HMGB1
mRNA and protein expression analysis. Serum HMGB1 levels in CRC patients
were higher than that of the control group (8.42 vs. 1.79 mg/L, p5 0.05).
Preoperative serum HMGB1 concentrations were significantly higher than the
postoperative values (8.42 5.67 vs 1.64 1.89 mg/L, p5 0.05). Serum HMGB1
levels in CRC patients with distant metastasis were significantly higher
(13.32 6.12 vs 7.37 5.17mg/L, p5 0.05). HMGB1 mRNA and protein expres-
sion in CRC tissues was significantly higher than in the adjacent normal mucosa.
HMGB1 protein expression positively correlated with the lymph node metastasis.
There was positive correlation between HMGB1 and c-IAP2 (r¼ 0.457,
P5 0.05), HMGB1 and pERK (r¼ 0.461, P5 0.05) as well as pERK and c-
IAP2 (r¼ 0.399, P5 0.05).
Conclusion: HMGB1 expression in CRC correlates with distant and lymph nodal
metastasis. It may inhibit apoptosis by inducing activation of pERK and cIAP2.
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Introduction: Colorectal cancer (CRC) is often diagnosed at an intermediate or
late stage with poor prognosis. Hence, there is an urgent need for new biomarkers
for the early detection of colorectal cancer. The aim of the work was to investi-
gate the lipidomic profile of serum, red blood cells (RBCs), the serum metabo-
lomic profile from patients with CRC to identify the stage of the disease and the
presence of metastasis of various localizations.
Aims & Methods: Sera, RBCs from 64 patients (52 7 years old) with colorectal
adenocarcinoma were analyzed by 1H NMR spectroscopy, gas chromatography.
The metabolomics, lipidomic profiles generated from each platform were com-
pared between the following groups: locoregional CRC (N¼ 28 –with T2 n¼ 12,
with T3 n¼ 16); liver-only metastases (N¼ 19); and extrahepatic metastases
(N¼ 17). The control group consisted of 26 healthy people.
Results: Complex of serum metabolites as myristic acid, palmitic amide, olea-
mide, hexadecanedioic, octadecanoic, eicosatrienoic acids, LPC(18:2),
LPC(20:4), LPC(22:6), LPC(16:0) contributed to the differentiation of the early
CRC patients from healthy controls (AUC of 0.97), while lysophosphatidylcho-
line (18:0, 16:0), lysophosphatidic acid (18:0, 16:0), phosphatidylcholine (34:1)
were significantly increased with the CRC progression, which allowed us to
distinguish early stages from late ones (AUC of 0.82). The erythrocyte increased
levels of stearic (p¼ 0, 03), oleic acid (p¼ 0, 02) and decreased total phospholipid
fraction (p5 0, 05), arachidonic, eicosapentaenoic, docosahexaenoic acids
(p5 0, 01), polyunsaturated:saturated fatty acid ratio (p5 0, 001) occurred in
cancer patients. The linoleic acid proportion in the RBCs phospholipid fraction
was lower in patients with CRC (p¼ 0, 02), but no changes were found in the
serum phospholipid fraction. Changes in fatty acid composition may affect dif-
ferent aspects of cell structure and function, including proliferation. By 1H NMR
spectroscopy 55 metabolites were detected, with 25 found to be differentially
abundant in the initial data filtering process (p5 0.30). The serum metabolomic
profile associated with locoregional CRC was distinct from that associated with
liver-only metastases, based on 1H NMR spectroscopy (p¼ 4.43 10–7).
Similarly, the serum metabolomic profile differed significantly between patients
with liver-only metastases and with extrahepatic metastases (p¼ 0.04). So, we
revealed that isoleucine and 2-oxoglutarate were more abundant in sera from
patients with extrahepatic metastases, while methionine and fumarate were more
abundant in liver-only metastases.
Conclusion: Investigation of blood serum and erythrocyte metabolites should be
considered as promising for verification of colorectal cancer, the detection of
metastases of various localizations.
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Introduction: Accumulating data indicate that some microRNAs (miRNAs or
miRs) function as tumor suppressors or oncogenes in cancer development. We
previously reported that certain miRNAs (miR-143, -145, -7, and -34a) were
differently expressed in samples of tumors and paired non-tumorous samples
taken from the same patients with colorectal tumors, and there was a relation
close to adenoma-carcinoma sequence for these miRNAs expression.
Aims & Methods: In this study, we focus on the miRNA expression profiles of
multiple colorectal adenomas comparing between sporadic colorectal adenoma
and familial adenomatous polyposis (FAP). We examined the miRNA expression
profiles (miRs-143, -145, -7, and -34a) and morphological appearance of 102
sporadic colorectal adenomas (SA), 27 tumors of multiple colorectal
adenoma (over 10 adenomas/one patient, MA), 21 tumors of FAP and 114
sporadic cancer (SC).
Results: The expression levels of miRs-143 and -145 were reduced in all tumors
compared with the paired non-tumorous samples in the same patient. Especially,
these miRNAs were significantly reduced in MA (P¼ 0.042 and P¼ 0.004) and
FAP (P¼ 0.027 and P¼ 0.022) compared with SA. The expression levels of miR-
7 were significantly up-regulated in cancers compared with adenomas
(P5 0.001). The expression levels of miR-34a were significantly down-regulated
in CA (P5 0.001), MA (P5 0.001), and FAP (P¼ 0.006) compared with SA.
Conclusion: These findings suggest that the malignant potential of MA and FAP
was higher than SA, therefore MA needs strict follow-up like FAP.
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Introduction: Colorectal carcinoma (CRC) is an important cause of mortality and
morbidity and mostly encountered in anemic and non-anemic elderly sympto-
matic patients, irrespective of the iron status. There is a close association between
increased mean platelet volume (MPV) and the presence of many solid tumors
such as hepatocellular carcinoma, pancreatic carcinoma, lung cancer, endome-
trial cancer and gastric cancer. Neutrophil/lymphocyte ratio (NLR) and platelet/
lymphocyte ratio (PLR) are markers of systemic inflammatory response and their
elevation is closely some studies to be associated with progression of colorectal
carcinoma. Although colonoscopic examination is the standart way of colorectal
cancer screening, screening for patients between 75 and 85 years of age should be
tailored on the basis of the presence of coexisting conditions because the risk of
serious complications from colonoscopy also increase with age.
Aims & Methods: The aim of this study was to investigate whether MPV, plate-
letcrit, PLR and NLR may have a role in the discrimination of CRC and colonic
polyps in older patients. 418 patients aged 465 years with colorectal carcinoma
(n¼93) (Group I) and colonic polyps (n¼ 325) (Group II) were included into the
study. Also 601 (Group III) patients aged 465 years with normal colonoscopic
findings served as a control group. All study subjects were investigated by using
MPV, plateletcrit, PLR and NLR in order to establish sensitivity and specificity
for predicting colorectal carcinoma and colonic polyps for each parameter
studied.
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Results: MPV, PCT, NLR and PLR were significantly higher in Group III com-
pared to Groups II&III. However, only MPV was significantly higher in Group
II compared to group I (8.6 1.1 vs 8.2 1, p5 0.001). The cut-off value of
MPV in predicting CRC from patients with normal colonoscopic findings was
9.15 fL with a sensitivity and specifity of 80% and 91% respectively (r¼ 0.892).
MPV and PCT were also significantly higher in patients with neoplastic polyps
compared to patients with non-neoplastic polyps (MPV: 8.7 1.1 vs 8 1,
p5 0.001 ande PCT: 0.23 0.07 vs 0.19 0.05, p¼ 0.003).
Conclusion: MPV and PCT may have a role as useful and simple markers in the
distinguisment of patients with colorectal cancer from patients with normal
colonoscopic findings. In the clinical settings, these simple markers may be
useful in selecting older patients for colonoscopic examination.
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Introduction: Rectal cancer patients with clinical evidence of a complete response
after chemoradiotherapy may be selected for watchful waiting instead of surgical
resection (although currently mainly within the scope of clinical trials). The
clinical selection of potential candidates for watchful waiting to date is mainly
done using a combination of imaging (MRI) and endoscopy. However, it is
known that with this strategy up to 29% of complete responders may still be
missed1. Failure to identify complete responders will deny these patients the
option of watchful waiting as a result of which they will receive potentially
unnecessary surgery. Investigating the reasons why some complete responders
are missed with current selection tools can help to further optimize our selection
strategy and help improve the identification of potential candidates for watchful
waiting in the future.
Aims & Methods: Aim of this study was to assess what can be learned from
operated (’missed’) pathologic complete responders by re-evaluating their post-
CRT appearance on imaging and endoscopy.
Patients with a pathologic complete response (pCR) after CRT and surgery were
retrospectively selected from our hospital’s database (2005–2015). The MRIs
(including diffusion weighted images) þ endoscopic images performed post-
CRT were re-evaluated by a team consisting of an expert radiologist and
expert surgeon. The MRI morphology (signal abnormalities, diffusion restric-
tion, volume, shape, aspect of lymph nodes) was assessed on T2-weighted MRI
and diffusion-weighted MRI (DWI). On endoscopy the aspect of the scar
(normal/teleangiectatic, ulcer, polypoid) was assessed. Additionally, the likeli-
hood for a complete response was re-scored by the expert team according to
updated selection criteria and classified as (1) residual tumour or (2) (near) CR.
Results: 41 patients with ypT0 after surgery were identified: 9/41 (22%) had
ypT0Nþ disease, 32 (78%) were true complete responders (ypT0N0). Upon re-
assessment by the expert team, 20/32 ypT0N0 patients (63%) were still deemed to
have residual tumour (non-cCR group), the remaining 12 (37%) were deemed to
be possible clinical complete responders (cCR-group). In the non-cCR group (vs.
the non-CR group) patients more often showed heterogeneous signal on T2W-
MRI (75%vs.25%, p¼ 0.01), massive/spicular fibrosis (90%vs.58%, p¼ 0.07)
and residual high signal on DWI (58%vs.27%, p¼ 0.11). On endoscopy the
majority of patients still had mucosal abnormalities (see Table 1). Eight ypN0
patients were still overstaged as being yNþ at re-assessment, mainly based on
irregular nodal morphology.
Table 1: Endoscopic features of patients with ’missed’ complete response (pCR
after surgery)
Feature Present in (%) of patients
Gross residual tumour 33%
Polypoid tissue 38%
Ulcer with irregular border 29%
Flat ulcer 25%
White scar (with teleangiectasia) 33%
Conclusion: Main reasons for missing a complete response after CRT are hetero-
geneous T2W-MRI signal, massive/spicular fibrosis, residual diffusion-signal,
ycNþ disease and residual mucosal abnormalities at endoscopy. Knowledge
about these features may serve as a teaching reference to help improve the selec-
tion of patients for watchful waiting in the future.
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Introduction: In patients with locally advanced rectal cancer (LARC) that show a
very good response to neoadjuvant treatment, organ-preserving treatments such
as watchfull waiting may be a good alternative to surgical resection and can
improve functional outcome and quality of life. If we can predict upfront (i.e.
before onset of CRT) how patients will respond to treatment this may create
opportuinities to further personalize and optimize the neoadjuvant treatment to
enhance the chance of a good response, thereby ultimately offering more patients
the chance of organ preservation. A promising new tool in this regard is
’Radiomics’. Radiomics refers to a collection of analytical methods to convert
images into high dimensional data via a set of quantitative descriptors called
‘‘features’’. These features have the potential to uncover disease characteristics
that cannot be detected by means of conventional (visual) imaging evaluation.
Aims & Methods: We aimed to assess the Radiomics signature1 of patients with
LARC and evaluate its potential value for pre-treatment prediction of the
response to neoadjuvant chemoradiotherapy.
We retrospectively assessed the primary staging MRIs (1.5T) of 124 LARC
patients treated with CRT. The standard MRI protocol included T2-weighted
(T2W) and diffusion-weighted imaging (DWI) sequences, as well as quantitative
apparent diffusion coefficient (ADC) maps derived from the DWI scans. For
each patient, the whole volume of the rectal tumour was delineated on pre-
treatment MRI: [1] by 2 expert pelvic radiologists, [2] using a semi-automatic
(region growing) software algorithm, and [3] by manual adjustment of the semi-
automatic delineations by two non-expert readers, adding up to 5 delineations
per tumor/patient in total. Radiomics signatures were extracted from the images
for each of the five delineations (3802 features in total). Features showing both
sufficient stability (ICC 0.75) as well as reproducible performance (Wilcoxon
test, False Detection Rate (FDR) 10%) across different readers/delineations were
selected to test their performance in predicting response to CRT by means of
receiver operator characteristics (ROC) curve analysis. The main outcome was
complete tumour regression (yT0) versus residual tumour (yT1-4) using histology
and/or long-term FU as the standard of reference.
Results: Out of 3802 initially identified Radiomics features, 1853 proved stable
across different readers/delineations. For the four manual delineations 300/
3802 features per reader remained significantly performant after FDR correction.
However, these features did not sustain after FDR correction for the fully auto-
mated segmentation. A final subset of 266 features remained stable and perfor-
mant across all five readers/delineations. These features resulted in a mean AUC
of 0.67 (range 0.64–0.73) to predict a complete response and a mean ICC of 0.81
(range 0.75–0.95). Best results were obtained for textural features measuring the
heterogeneity of the tumor on DWI (all top 20 features). In contrast, more
’common’ radiological features such as volume showed inferior performance
(highest rating 56) Results derived from delineations performed by the two
expert radiologists and non-expert readers resulted in comparable diagnostic
performance.
Conclusion: 1) Various Radiomics features extracted from pre-treatment MRI
correlate to neoadjuvant treatment response and may be used as imaging bio-
markers to predict the response to chemoradiotherapy in rectal cancer.
2) Best results are obtained for textural features (representing tumour heteroge-
neity) derived from diffusion-weighted MR sequences
3) Features extracted from semi-automated (software generated) delineations
show inferior performance compared to features extracted from manual delinea-
tions, emphasizing the need for adequate tumour delineation. Interestingly, how-
ever, delineations from expert and non-expert readers rendered similar good
results, suggesting that the selected features are robust and do not necessarily
require highly expert input.
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Introduction: An analysis of the efficient implementation of the guidelines for
screening colorectal cancer (CRC) in patients with first diagnosed CRC
(according to the archival case histories of the two medical institutions in
Novosibirsk) was performed in 2013–2016, and leading reasons of late CRC
diagnostics were identified.
Aims & Methods: We aimed to investigate the correlation of the electrical and
viscoelastic parameters of erythrocytes with the fatty acid composition of their
membranes and blood serum in patients with colorectal cancer (CRC) of differ-
ent stages. 46 patients (median age of 53þ 9 years old) with CRC of various
localizations and stages and 16 conditionally healthy patients were examined.
Electrical and viscoelastic parameters of erythrocytes have been studied by die-
lectrophoresis. Fatty acid composition of erythrocyte membranes and serum has
been studied using GC/MS system triple quad Agilent 7000B (USA).
Results: Erythrocytes of patients with CRC were characterized by increasing the
proportion of deformed cells with reduced strain amplitude and surface charge
(low levels of cell velocity to electrodes and dipole moment) (p5 0.001–0.05).
Metastasis was associated with an increase in the cell electrical conductivity, a
sharp decrease of polarizability, and an increase in the tendency to hemolysis
(p5 0.0001–0.03). Saturated fatty acids prevailed in composition of erythrocyte
membranes in patients with CRC; omega 6/omega 3 fatty acid index was
decreased, while the level of linoleic acid was significantly increased as related
to oleinic acid in serum of the patients with CRC compared to the healthy people
(p5 0.01–0.04). The observed shifts correlated with a disease stage (r¼ 0.64;
p¼ 0.04). The erythrocyte strain amplitude was associated with the level of unsa-
turated fatty acids in erythrocyte membranes (r¼ 0.58; p5 0.05), as well as with
summarized viscosity (r¼0.47; p¼ 0.03) and rigidity (r¼0.41; p5 0.05).
While the level of hemolysis of erythrocytes and their tendency to aggregate
correlated with the level of lysofractions of fatty acids (r¼ 0.54, p¼ 0.04;
r¼ 0.42, p5 0.05). The surface charge of erythrocytes more closely correlated
to the level (C16:2 and C18:1) in the blood serum (r¼0.42; p¼ 0.04). There was
a shift of the crossover frequency to the high-frequency range (p¼ 0.03), a
decrease of the cell capacity (p5 0.01), and a decrease of polarizability at high
frequencies (106, 0.5 106Hz) (p¼ 0.02–0.05), as well as a decrease of C18:3,
C20:2, C20:3, C20:5 and C22:6 levels in erythrocyte membranes (but not in blood
serum) (p5 0.01) at the initial stages of CRC.
Conclusion: Revealing changes in the parameters of erythrocytes and fatty acid
composition in blood serum associated with a stage of the disease can be promis-
ing for diagnostics and the case follow-up of patients with CRC.
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Introduction: Laterally spreading tumors (LSTs) of the colorectum are classified
into the following four subtypes according to their morphology; granular homo-
geneous type (LST-GH), granular nodular mixed type (LST-GM), non-granular
flat-elevated type (LST-NGF), and non-granular pseudo-depressed type (LST-
NGPD). Clinical features of each subtype of LSTs have not been fully evaluated.
Aims & Methods: The aim of this study was to clarify the clinicopathological
features of colorectal LSTs focusing on their subtypes. We reviewed clinical
charts and surgical pathology files of 5352 endoscopically resected specimens
during January 2007 and December 2016 at our institution. A total of 422
LSTs were detected. We examined the clinical features (mean age, male to
female ratio, size, location, Incidence of concomitant carcinoma) according to
their subtypes.
Results: Of these 422 lesions, a total of 151 (35.8%) were LST-GH, 34 (8.1%)
LST-GM, 209 (49.5%) LST-NGF, and 28 (6.6%) LST-NGPD. Mean age of
patients with each subtype was 68.3 years old for LST-GH, 67.1 for LST-GM,
67.9 for LST-NGF, and 67.2 for LST-NGPD. Male to female ratio (M/F) was
1.21 for LST-GH, 2.05 for LST-GM, 1.95 for LST-NGF, and 1.65 for LST-
NGPD. Mean size of LST-GH (21.2mm) and LST-GM (25.8mm) were signifi-
cantly larger than that of LST-NGF (17.0mm) and LST-NGPD (15.1mm). All
subtypes were located predominantly in the proximal colon. Incidences of con-
comitant carcinomas in LST-GH, LST-GM, LST-NGF, and LST-NGPD were
19.2% (29 out of 151), 55.9% (19 out of 34), 16.3% (34 out of 209), and 57.1%
(16 out of 28), respectively. Incidences of concomitant submucosal carcinomas in
LST-GH, LST-GM, LST-NGF, and LST-NGPD were 0% (0 out of 151), 14.7%
(5 out of 34), 1.0% (2 out of 209), and 25.0% (7 out of 28), respectively.
Conclusion: Each subtype of LSTs has distinct clinical features. LST-GM and
LST-NGPD have higher malignant potentials than other subtypes. Especially
LST-NGPD has the highest risk of invasive carcinoma regardless of its size.
Therefore we should carefully detect these lesions and choose appropriate treat-
ment according to the subtypes.
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Introduction: Post-colonoscopy colorectal cancer (PC-CRC) rates are proposed
as a quality indicator of a colonoscopy service. Extrapolating the data is challen-
ging but important to assess local practise and to compare with recent published
National Data. We aimed to calculate the PC-CRC and the post CT
(Colonoscopyþ abdomen) CRC rate at Poole Hospital using the number of
colonoscopies or CT scans done within 3 years of a CRC diagnosis as the
denominator for post-investigation PI -CRC calculations as outlined in a pre-
vious study1.
Aims & Methods: Retrospective audit of all patients diagnosed with CRC during
a two year period 1st March 2015–28th February 2017 inclusive identified via the
Somerset Cancer registry database for Poole Hospital using Crystal software.
Previous colonoscopy and CT Colonoscopy (CTC) or CT abdomen results in
the 3 years preceding the diagnostic investigations were reviewed across two
neighbouring hospitals sharing the same electronic patient records. If patients
had multiple surveillance colonoscopies the latest was counted as false negative as
in previous studies1
Results: 416 patients were identified, 67 were excluded (39 non adenocarcinoma,
3 out of area, 12 patients where earlier decision was best supportive care, 6
patients diagnosed at laparotomy, 2 patients with abnormal PET scans and 6
with incomplete datasets). 348 patients were included for analysis. Colorectal
cancer was diagnosed by colonoscopy in 200 patients and by CTC or CT abdo-
men in 148 cases. In the colonoscopy diagnosed group, 55 were via Bowel Cancer
Screening Programme (BCSP), 138 via the symptomatic service and 7 from the
surveillance programme. In the BCSP group 1 patient had a preceding colono-
scopy within the previous 3 years (6–36 months)1. In the symptomatic service
groups there were 7 preceding colonoscopies and in the surveillance group there
were 5 preceding (‘‘false negative’) colonoscopies within the previous 3 years. The
overall PC-CRC rate was 6.5 (þ3.6, 2.2) % (90% confidence interval). In the
CT diagnosed group, 1 patient from the BCSP group, 10 patients from the
symptomatic service and 4 from the surveillance group underwent CT scans
within the preceding 6–36 months. All bar one of these 15 patients had under-
gone preceding CT abdomen scans with one elderly patient from the sympto-
matic group having undergone a prior CT colonoscopy. The post CT-CRC rate
was 10.2 (þ5.0, 3.2) % and the overall combined post investigation colorectal
cancer (PI-CRC) rates during this two year period was 8.0 (þ2.8, 2.0) %.
Conclusion: Our findings offer the opportunity for further review of individual
cases at local governance level and within the limitations of data collection (NHS
hospital records reviewed) our estimated PC-CRC rate of 6.5% compares favour-
ably to the published National PC-CRC rate of 8.6% between 2001–20071.
However, we question the validity of a post CT-CRC rate as a true quality
indicator as a CT abdomen scan is a non-colon dedicated study. In addition,
the method of calculating PI- CRC rates needs ratification as well as more robust
IT systems to capture and analyse the data if it is indeed a measure that is to
become part of endoscopic quality assurance. Finally our numbers are small and
methods suitable for retrospective observational population based studies may
not transfer to assessing quality indicators at a local level.
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Introduction: The fecal immunochemical test (FIT) has a high diagnostic accu-
racy for the detection of colorectal cancer (CRC) in symptomatic patients.
However, we do not know the risk of other gastrointestinal neoplasms associated
with a false positive test.
Aims & Methods: To calculate the risk of detection of gastrointestinal tract
tumors (GITT) and death in symptomatic patients with a positive FIT determi-
nation and without a CRC in a complete colonoscopy with an adequate bowel
preparation. We designed a prospective cohort study with follow-up. Patients
from the COLONPREDICT study with complete colonoscopy without CRC
were included. Two cohorts were defined: FIT positive and negative according
to the 20mg hemoglobin/g of feces threshold. We performed a descriptive ana-
lysis of the GITT detected during follow-up and mortality. We estimated the
differences in the risk of GITT detection and mortality between the two cohorts
by logistic regression and proportional hazards after adjusting for age, sex, and
significant colonic lesions (CSL) detection at baseline colonoscopy.
Results: We included 1061 patients without CRC and a complete baseline
colonoscopy; 320 (30.2%) with a positive FIT and 741 with a negative FIT.
The median follow-up was of 36.0 8.9 months with no difference between
both groups (p¼ 0.2). There were significant differences regarding age
(67.5 12.7 years vs 64.8 13.5 years, p¼ 0.04) and sex (45.9% vs 52.0%
females, p¼ 0.04) between both cohorts. We detected a GITT in 14 (4.4%)
patients with a positive FIT: 5 CRC, 6 gastric, one esophageal, 1 small intestinal
lymphoma and one patient with a CRC and a small intestine adenocarcinoma;
and in 12 (1.6%) with a negative FIT: 4 CCR, 4 gastric, 2 small intestine ade-
nocarcinoma, one esophageal, and one patient with a gastric and a CRC. Patients
with a positive FIT had a non-significant increase in the risk of GITT detection
(OR 2.1, 95% CI 0.9–4.8) after adjusting for age, sex and SCL. The overall
risk of death in both groups was 8.8% and 6.7%, respectively, with no
significant differences between both groups in the survival analysis (HR 1.3,
95% CI 0.8–2.1). However, the risk of death due to a GITT was 3.1% (10
deaths) in the positive FIT group and 0.8% (6 deaths) in the negative FIT
group., with a significant difference after adjusting for age, sex and SCL (HR
3.2 95% CI 1.2–8.9).
Conclusion: Symptomatic patients with a positive FIT and complete colonoscopy
without CRC are at increased risk of death due to GITT regardless of age, sex or
the presence of SCL.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0460 LONG-TERM OUTCOMES OF TRANSANAL COLORECTAL
TUBE PLACEMENT FOR DISTAL STAGE II/III COLORECTAL
CANCER WITH ACUTE COLORECTAL OBSTRUCTION
T. Yamada
1, Y. Okuda2, R. Yamaguchi2, E. Sakamoto1, Y. Hirata2, T. Shimura3
1Gastroenterology, Japanese Red Cross Nagoya Daini Hospital, Nagoya/Japan
2Kasugai Municipal Hospital, Kasugai/Japan
3Nagoya City University Graduate School of Medical Sciences, Nagoya/Japan
Contact E-mail Address: yamadatomonori@mac.com
Introduction: Emergency surgery is a standard treatment for colorectal cancer
(CRC) with acute colorectal obstruction (ACO). Transanal colorectal tube
(TCT) placement is an alternative endoscopic treatment for ACO; however,
the oncological outcomes of TCT placement for the curative treatment of
CRC remain unknown.
Aims & Methods: Data were retrospectively reviewed from patients with distal
stage II/III CRC who underwent surgery between January 2007 and December
2011 at two Japanese affiliate hospitals with an interexchange of endoscopists
and surgeons. One hospital conducted emergency surgery and the other per-
formed TCT placement as the standard treatment for CRC with ACO. To ana-
lyze the efficacy of TCT placement, we compared long-term outcomes for stage
II/III CRC with ACO among patients in the two institutions.
Results: In total, 764 patients with distal stage II/III CRC were identified for this
study. Among the 764 patients, 690 did not have ACO (non-ACO group), and 74
had ACO (ACO group). In the non-ACO group, we confirmed that the surgical
quality was equivalent between the two institutions, with no significant differ-
ences in overall survival (OS) (P¼ 0.271) or disease-free survival (DFS)
(P¼ 0.184). Among the 74 patients with ACO, 27 underwent emergency surgery
(surgery group) and 47 underwent TCT placement (TCT group). The rate of
primary resection/anastomosis was higher in the TCT group than in the surgery
group (91.5% vs. 22.2%; P5 0.001). No significant differences were noted
between the two groups in OS (surgery vs. TCT: 5-year OS, 65.9% vs. 58.1%;
P¼ 0.452) or DFS (surgery vs. TCT: 5-year DFS, 47.6% vs. 43.1%; P¼ 0.755).
Subset analysis also showed no significant differences in OS and DFS between
patients with stage II and stage III CRC.
Conclusion: TCT placement can achieve similar long-term outcomes to those of
emergency surgery, with a high rate of primary resection and anastomosis for
distal stage II/III CRC with ACO.
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Introduction: Self-expandable metallic stent placement for malignant colorectal
obstruction has been widely used; however, factors affecting the technical diffi-
culty of stenting remain unclear.
Aims & Methods: The aim of this study was to clarify the factors associated with
the technical difficulty of stenting for malignant colorectal obstruction.
We established the Colonic Stent Procedure Research Group to provide instruc-
tions on how to safety perform stent placement, and then, we conducted this
prospective, single-arm, observational, multicenter clinical trial between October
2013 and May 2014 in Japan. Thirty-two facilities participated in this study. A
double-wire woven uncovered stent was placed by using a standard through-the-
scope colonoscopic placement technique in each patient. Stent deployment time
was defined as the time from reaching a lesion with a colonoscope to finish
stenting. Technically difficult cases of stenting were defined as those that had a
longer than 75% deployment time. We examined the clinical data and extracted
factors associated with the technical difficulty of stenting by using univariate and
multivariate analyses.
Results: A total of 205 consecutive patients were enrolled in this study. Nine
patients including 3 patients with technical failure of stenting, 5 patients with
non-stenting and 1 patient with stenting for benign lesion were excluded. The
remaining all 196 patients were succeeded in stenting. Of these, 100 were men
(51%), and the median age was 72 years old (interquartile range (IQR), 62–82
years old). One hundred eleven patients (57%) underwent stenting as a bridge to
surgery, and 85 (43%) underwent stenting for palliation. The technical and clin-
ical success rates were 98.5% and 97.0%, respectively. None of the patients
experienced colorectal perforation. The median total procedure time in the
cohort with technical success was 30 minutes (IQR, 18–42 minutes). The
median deployment time was 21 minutes (IQR, 11–31 minutes). Forty-nine
patients with a deployment time longer than 31 minutes were regarded as tech-
nically difficult cases of stenting. The following were identified as independent
factors of the technical difficulty in stent placement: presence of ascites (odds
ratio, 2.483; 95% confidence interval [95%CI], 1.17–5.29; p¼ 0.02), placement of
41 stent (odds ratio, 4.80; 95%CI, 1.10–21.1; p¼ 0.04).
Conclusion: This study demonstrated the high technical and clinical success rate
of double-wire woven uncovered stent placement for malignant colorectal
obstruction. Clinicians should perform this procedure carefully in patients with
presence of ascites.
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Introduction: Colorectal cancer is the third most common cancer in the world and
the fourth leading cause of cancer death1. Treatment strategy for colorectal
cancer is selected considering clinical stages. T1 colorectal cancer (T1CRC) can
be treated with endoscopic resection. If patients have pathological risk factors
such as deep submucosal invasion, budding, por/muc pathological features and
lymphovascular invasion, they considered to be at high risk of lymph node
metastasis based on the indication of Japanese Society for Cancer of the Colon
and Rectum guideline2. In such cases, the selection of subsequent option is
important and has been frequently decided by clinicians’ customs and prefer-
ences. However, it is not clear whether these risk factors adequately predict
patients’ prognosis in the clinical practice.
Aims & Methods: This research aims at revealing the prognosis and clinicopatho-
logical features of pathologically high-risk T1CRC patients (the high-risk group)
with and without additional surgery; followed up by computed tomography,
ultrasound, endoscopy, and tumor marker (CEA: carcinoembryonic antigen).
1. To evaluate the difference of overall survival (OS), cancer specific survival
(CSS) and recurrent-free survival (RFS) between the patient performed addi-
tional colectomy with lymph node dissection (AS) and the patient followed up
without additional surgery (FU). 2. To reveal what clinicopathological factors
are considered in the selection of subsequent option, whether AS or FU, in the
high-risk group. We retrieved the clinical data of 162 patients who had diagnosed
and treated as T1 colorectal cancer at Kyoto University Hospital (Kyoto, Japan)
between February 2005 and February 2015. Treatment strategy after diagnosed
as ‘‘high-risk’’ and clinicopathological features, presence or absence of recurrence
and the final state as of Fubruary 2017. We used the Kaplan-Meier product limit
method and the Log-rank test to compare OS, CSS, and RFS between AS and
FU groups. In clinical setting, based on the guideline indication, the clinician
offered subsequent options and described their risks and benefits, and the patient
expresses his or her preferences and values. Factors considered through selecting
treatment strategy were extracted from informed consent and provider’s note of
electronic medical records.
Results: Among 162 T1CRC patients, 78 cases were treated with endoscopic
resection for the first time. Of them, 46 patients had at least one pathological
risk factor (high-risk patients). Among 46 high-risk patients, 22 patients were
carefully followed up (FU), 20 patients were performed additional surgery with
lymph node dissection (AS). Four patients treated with additional radiation
therapy were excluded. Median survival time was 39 (FU) and 62 (AS), respec-
tively. No difference was detected in OS (p value¼ 0.99), CSS (p value¼ 0.44)
and RFS (p value¼ 0.81) between FU and AS groups. From provider’s notes in
electric medical records, factors considered in selection of FU were extracted as
follows: Patient’s values and preferences 8, sole presence of ‘‘depth’’ risk factor 7,
possible intensive surgery due to T1CRC located in the lower rectum 3, other
advanced malignancy 1, and perioperative risks; advanced age 5, past history of
abdominal surgery or radiation 2 and severe comorbidities 12 (chronic heart
failure 4, chronic kidney disease 2, connective tissue disease 2, lung disease 1
etc). Together with absence of significant difference of prognosis in this study and
the burden of surgery, the subsequent option should be selected through shared
decision making between the clinician and the patient3.
Conclusion: Among high-risk group after endoscopic resection of T1CRC, no
significant difference in OS, CSS nor RFS are detected between FU and AS
groups. Factors considered in selecting FU were patient values and preferences,
sole presence of ‘‘depth’’ risk factor and severe comorbidity including periopera-
tive risk. Shared decision making should be achieved subsequent option in the
high-risk group.
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Introduction: Laterally spreading tumors (LSTs) are defined as colorectal tumors
defined by their characteristic laterally spreading growth pattern larger than
10mm in size. LSTs are divided into 4 four subtypes based on different surface
morphologies morphology [LST-granular (G)/homogeneous: LST-G-H and nod-
ular mixed: LST-G-M, LST-nongranular (NG)/flat elevated: LST-NG-F and
pseudodepressed: LST-NG-PD]. The aim of this study was to analyze the
long-term outcomes, including recurrence, 5-year disease-free survival (DFS),
5-year disease-specific survival (DSS), and 5-year overall survival rates (OS)
after treatment of T1 LSTs carcinoma.
Aims & Methods: We examined 169 patients with T1 LSTs carcinoma of LSTs
treated between January 1992 and December 2008 at the Hiroshima GI
Endoscopy Research Group (Hiroshima University Hospital and 9 nine affiliated
hospitals) with a mean follow-up period of 5 years. 62 Sixty-two patients who
were diagnosed with curable T1 LST carcinoma of LSTs after en bloc endoscopic
resection (ER), according to the Japanese Society for Cancer of the Colon and
Rectum (JSCCR) criteria, were defined as e-curable patients. One hundred seven
patients who did not meet the criteria were defined as non-e-curable patients.
According to the clinical and pathological diagnosis of LSTs, patients’ back-
grounds, and lesion location, the treatments were selected from among the fol-
lowing: ER alone (excluded histological incomplete resection), ER and an
additional surgical resection with lymph node (LN) dissection, and surgical resec-
tion with LN dissection alone.
Results: Tumor size in Group A was significantly larger (A: 36.6 22.6mm vs B:
21.6 7.2mm vs C: 24.6 7.6mm, p5 0.01) than in the other two groups. The
adenomatous component was more frequent in Group A than in the other two
groups. The rates of LN metastasis in Groups A, B, and C were 10% (5/49), 20%
(3/15), and 5% (1/21), respectively. There were no recurrences among the 62 e-
curable patients. On the other hand, five recurrences (5%) were found in non-e-
curable patients, and they were all in Group A. They consisted of local recurrence
(one patient who also had lung metastasis), LN metastasis (two patients), lung
metastasis (three patients), and liver metastasis (one patient who also had LN
metastasis). There were no significant differences in DSS between Group A and
Group BþC (LST-NG). However, OS was 93% in Group A, which was signifi-
cantly lower than that (96%) in Group BþC (p5 0.05). DFS in Group A was
90%, which was significantly lower than that (100%) in Group BþC (p5 0.05).
The prognosis of patients with non-e-curable disease after ER alone showed no
significant differences in OS, DFS, and DSS between Group A and Group BþC.
The prognosis of patients with non-e-curable disease after surgical resection
showed no significant differences in DFS or DSS. However, OS in Group A was
94%, which was significantly lower than that (97%) in Group BþC (p5 0.05).
Conclusion: Long-term outcomes supported the JSCCR criteria for e-curable
patients after ER for T1 LSTs. All recurrences occurred in patients with T1
LST-G-M carcinoma. OS and DFS in the LST-G-M group were significantly
shorter than in the LST-NG group.
The non-e-curable patients were divided into 3 groups: Group A (61 patients
were non-e-curable patients diagnosed with LST-G-M), Group B (23 patients
were non-e-curable patients diagnosed with LST-NG-F), and Group C (23
patients were non-e-curable patients diagnosed with LST-NG-PD). There were
no patients diagnosed with T1 LST-G-Hcarcinoma of LST-G-H.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0464 ASSESSMENT OF THE EFFECTS OF A PACLITAXEL-
ELUTING SELF-EXPANDING METAL STENT ON NAÏVE PORCINE
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Introduction: Cholangiocarcinoma and pancreatic adenocarcinoma account for
over 190,000 new clinical cases of pancreatobiliary malignancy worldwide
annually. For palliation of obstructive jaundice in these patients, plastic or
self-expanding metal stent (SEMS) are placed. However, re-occlusion rates for
currently available stents range as high as 36% for uncovered metal stents, 25%
for covered metal stents and 52% for plastic stents. Tissue ingrowth accounts for
up to 76% of occlusions of bare metal stents.1, 2, 3, 4 Stent occlusion can result in
recurrent obstruction and typically requires endoscopic re-intervention.
Therefore there is a real clinical need to reduce tissue ingrowth and improve
biliary stent patency rates.
Aims & Methods: In this study we developed and tested a controlled-release
paclitaxel-eluting SEMS designed to prevent tissue hyperplasia and stent occlu-
sion. A 4 cm length uncovered, laser-cut nitinol stent was coated with a polymer
matrix allowing slow release of paclitaxel. Naı̈ve Yucatan swine were assigned to
one of three stent groups: bare control (n¼ 3, no polymer), standard dose pacli-
taxel (n¼ 6, 149.4 mg paclitaxel) and challenge dose (n¼ 3, 538.0 mg paclitaxel.
Two stents were endoscopically implanted in each swine from its assigned group,
one in the intrahepatic/hilar region and a second in the common bile duct placed
proximal to the papilla. Stents were assessed for migration via digital radiographs
for the first 2 weeks and then monthly via endoscopy using SpyGlassTM DS
cholangioscopy and cholangiography with a targeted 6 month study endpoint.
Results: At 30 days post-implant, no significant tissue reaction to any stent was
observed. However, all animals displayed mild biofilm formation and increased
intraductal mucus production. Substantial dilation of the common bile duct was
observed in 5/11 animals with no apparent relationship between drug coating and
duct dilation. At 60 days post-implant, moderate mucus and biofilm formation
was observed within the stent, however in only 3 animals biliary ductal dilation
persisted and the majority of stents were fully apposed to the duct wall. Although
some animals displayed minimal tissue hyperplasia at the proximal end of the
stents, no tissue overgrowth or stent embedding was observed in any animal. Up
to 60 days post-implant, no persistent clinical symptoms were observed in any
animal. Stents in one standard dose animal migrated out of the bile duct between
days 15 and 30, this animal is not included in patency results reported. At both 30
and 60 day timepoints, no apparent differences in outcome were observed among
the three study groups.
Conclusion: At this mid-study follow-up, paclitaxel-eluting stents appear to be
safe for use in naı̈ve tissue and do not negatively impact function of the biliary
system, even at challenge condition doses. Although the cause of bile duct dila-
tion observed in all stent groups has not been conclusively identified, we hypothe-
size the cause may be distal stent impaction and intermittent (clinically
insignificant) obstruction of the papilla and/or stent, resulting in retained
mucus and bile. Bile duct dilation, in turn, has reduced the opportunity for
tissue overgrowth in all stent groups, which was expected to occur in the bare
stent control group by 60 days post-implant5. Given the observed 60% reduction
in number of dilated ducts between days 30 and 60, we expect increased rate of
apposition. Ongoing efforts include continued follow-up for an additional 120
days, and in a second cohort, determination of in vivo drug release rates in the
bile duct over a 30 day period. Future cholangioscopic and histopathological
assessment of these swine will further clarify the safety and effectiveness of
paclitaxel stent coatings to mediate bile duct tissue ingrowth.
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Introduction: Meta-analyses and guidelines recommend that deep submucosal
invasion (41mm) in malignant colonic polyps is an important risk factor for
residual malignant disease. However, the existing data are based on small retro-
spective studies with marked heterogeneity.
Aims & Methods: The aim of this study is to test the correlation between the
submucosal invasion depth and the rate of residual malignant disease in complete
endoscopic mucosal resection (EMR) of malignant colonic sessile polyps. The
secondary outcomes include risk factors such as: lymphovascular invasion, tumor
differentiation, resection margin status and the presence of tumor budding. A
retrospective review of the endoscopy charts for the period 2000–2016 was con-
ducted. All patients enrolled exhibited a malignant colonic sessile polyp which
was endoscopically completely resected. Histological findings of the polyps were
also recorded. Thorough computed or magnetic scanning was performed in all
patients before deciding on further management. All patients were advised for
the option of surgical treatment or endoscopic follow-up.
Results: 51 patients with confirmed adenocarcinoma in sessile colonic polyps
undergoing endoscopic mucosal resection (EMR) were retrospectively included
in this study. A total of 33 (64.7%) patients underwent subsequent surgery after
EMR, and 18 (35.3%) chose endoscopic follow up. The histological character-
istics are shown in Table 1. In 44 (86.3%) patients the submucosal invasion was
41mm. Residual malignant disease was identified in the surgical pathological
specimen of only one patient. With a median follow-up of 25.12 months (IQR:
31.5; range 1.84–144.92), no local recurrences or lymph node metastasis were
identified. 49 were alive without evidence of disease and 2 died of other causes
(without evidence of disease at last follow-up). The data regarding the other risk
factors are presented in Table 1.
Table 1: Histological characteristics of the patients
Factors
Total (N¼ 51),
n (%)
EMR only,
(n¼ 18),
n (%)
EMRþSurgery,
(n¼ 33),
n (%)
Submucosal invasion
1mm 41mm
7 (13.7)
44 (86.3)
2 (11.1)
16 (88.9)
5 (15.2)
28 (84.8)
Resection margin status
(mm) median (IQR;
range)
1 (2; 0–7) 1 (1; 0–4) 0, 8 (1.55; 0–7)
Lymphovascular invasion 7 (13.7) 0 7 (21.2)
Tumor differentiation:
well-differentiated;
moderate-differentiated;
poor-differentiated
14 (27.5)
28 (54.9)
9 (17.6)
6 (33.3)
9 (50)
3 (16.7)
8 (24.2)
19 (57.6)
6 (18.2)
Tumor budding 9 (17.6) 4 (26.7) 5 (15.2)
Conclusion: Our data suggest that even in cases with submucosal invasion 41m
and the presence of other high-risk features (lymphovascular invasion, tumour
budding), complete EMR in malignant colonic sessile polyps supported by the
histological findings predicts for a good clinical outcome.
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Introduction: The leucovorin (FOL) and fluorouracil (5-FU) plus oxaliplatin (l-
OHP; FOLFOX) or FOL and 5-FU plus irinotecan (SN-38; FOLFIRI) are
widely used as first-line chemotherapy in the treatment of advanced CRC.
However, second-line chemotherapy must be abandoned in certain cases due to
disease progression, adverse effects or high medical cost in clinical setting. First-
line chemotherapy is usually administered over a long period of time. In addition,
the response rate of the first-line chemotherapy is typically higher than the
second-lines. Therefore, the most effective regimen should be selected as first-
line chemotherapy. We have reported that individualization of first-line treat-
ment (FOLFOX/FOLFIRI/Dual/Poor responder) was possible using CD-DST
and individualized first-line therapy with the CD-DST may improve the prog-
nosis of patients with unresectable CRC (UEGW: 2014; P1538, 2015; P1681,
2016; P0929).
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Aims & Methods: In this prospective study, we evaluated the overall survival (OS)
of appropriate first-line chemotherapy group and inappropriate first-line che-
motherapy group based on CD-DST. Moreover, we evaluated additional effects
of EGFR (Cetuximab; Cmab, Panitumumab; Pmab) to FOLFOX/FOLFIRI
using CD-DST. Between Mar. 2008 and Aug. 2016, we obtained tumor speci-
mens from 131 CRC patients without preoperative chemotherapy. Informed
consent for measurement of individual chemosensitivity was obtained from all
patients in writing. Approval for the present study was obtained from the Tobu
Chiiki Hospital Institutional Review Board (No: 02.03.29. #1). The growth inhi-
bition rate (IR%) was determined by CD-DST. The regimens were as follow:
FOLFOX, FOLFIRI, Cmab, Pmab, and FOLFOX/FOLFIRIþCmab. The
incubation conditions were as follow: FOLFOX; 5-FU and l-OHP (6.0 and
3.0 mg/ml, respectively) for 24 h. FOLFIRI; 5-FU and SN-38 (6.0 and 0.2 mg/
ml, respectively) for 24 h. Cmab; Cmab 250mg/ml for 144 h. Pmab; Pmab
200mg/ml for 144 h. FOLFOXþCmab; Cmab 250mg/ml for 120 h after
FOLFOX/FOLFIRI incubation process. The cumulative distribution of IR
values under each condition was evaluated on the basis that the clinical response
to FOLFOX and FOLFIRI is equivalent (approximately 50%). The OS between
the group treated with appropriate first-line chemotherapy and the group treated
with inappropriate first-line chemotherapy were evaluated Kaplan-Meier
method. Additional effects of Cmab to FOLFOX/FOLFIRI were also evaluated.
Results: There was strongly relationship between the IR% of the FOLFOX and
FOLFIRI regimen (R2¼ 0.7415). The median of the IR% with the FOLFOX
and FOLFIRI regimen were 58.6 and 69.1, respectively. FOLFOX responder,
FOLFIRI responder, dual responder, and poor responder were 8, 10, 53, and 60,
respectively. There were 42 unresectable CRC patients with chemotherapy. The
median survival time of appropriate first-line chemotherapy group (n: 28) and
inappropriate first-line chemotherapy group (n: 14) were 1128 and 506 days,
respectively (P¼ 0.01). There was positive relationship between the IR% of
Cmab and that of Pmab (R2¼ 0.468). Additional rates (%) of Cmab to
FOLFOX between poor responder and other responder were 19.81 and 5.46,
respectively (P¼ 0.020). Additional rates of Cmab to FOLFIRI between poor
responder and other responder were 16.50 and 1.29, respectively (P¼ 0.005).
There was significantly more additional effect of Cmab to FOLFOX/FOLFIRI
in poor responder than in other responders.
Conclusion: Administration of the recommended first-line regimen using CD-
DST for unresectable CRC patient is important for improvement in the further
prognosis. Moreover, especially in poor responder, Cmab should be admini-
strated to FOLFOX/FOLFIRI regimen.
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Introduction: The standard treatment for locally advanced low rectal adenocar-
cinoma (ADC) is to conduct surgical resection after neoadjuvant chemora-
diotherapy (CRT). In the wait-and-see (W&S) strategy, those who achieve
clinical complete response (cCR) after CRT undergo regular clinical, radiologic
and endoscopic surveillance, with surgery being reserved for tumor ‘‘regrowth’’.
Aims & Methods: To evaluate the impact of a W&S strategy for low rectal ADC,
regarding overall and disease-free survival. Single-center prospective observa-
tional study. All patients with low rectal (up to 6 cm from the anal verge)
ADC, stage I to III, discussed in a multidisciplinary colorectal cancer clinic
since the implementation of the W&S strategy (11/2014–11/2016) were evaluated.
Demographic data, post-CRT evaluation and decision, recurrence rates,
‘‘regrowth’’ and mortality were analyzed.
Results: 56 patients were evaluated [(54% males; mean age at diagnosis 64, 4
years (34–90)], of which 53 had already completed CRT. Stage III prevailed
(79%) in the initial evaluation. From the 53 patients who completed CRT,
77% were clinically reevaluated and submitted to pelvic MRI and sigmoido-
scopy, after a mean of 6.7 weeks. 17% (7/41) displayed cCR and entered W&S
surveillance program. In this subgroup, with a maximum follow-up of 25
months, there was only one (14%) ‘‘regrowth’’, which was clinically detected
and then confirmed by the other surveillance methods. This patient underwent
a R0 low anterior resection and there were no complications. There were no
distant recurrences or deaths. In the subgroup of patients with no cCR: patho-
logic complete response was observed in 20%; there was one lymphatic recur-
rence; the overall survival was 95.2%.
Conclusion: Preliminary results of our series confirm that the W&S strategy is
associated with overall and disease-free survival not inferior to those of the
traditional approach, favoring its implementation.
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Introduction: Patients after surgical resection of colorectal invasive cancer and
those after endoscopic resections of colorectal adenoma and intramucosal cancer,
both of them have the risk of metachronous advanced neoplasia during follow-
up. The present study aimed to compare the risk of metachronous neoplasia
during a long-term follow-up between patients with colorectal invasive cancer
resected by surgery and those having colorectal adenoma and intramucosal
cancer resected at initial colonoscopy.
Aims & Methods: A total of 1078 patients were colonoscopically followed-up
during a long-term period in our hospital. They were divided into group A, B,
and C as follows; 445 in group A (mean age 64.7 yr, M:F¼ 2.37:1) with low-
grade adenoma colonoscopically resected at baseline, 245 in group B (66.1 yr,
2.31:1) with high-grade adenoma or intramucosal cancer colonoscopically
resected at baseline, 388 in group C (65.1 yr, 1.54:1) with invasive cancer resected
by surgery at baseline. During follow-up colonoscopies detected metachronous
neoplasms were resected and pathologically evaluated into non-index lesion (low-
grade adenoma) or index lesion (high-grade adenoma or cancer). The cumulative
incidences of metachronous colorectal neoplasms were compared with each other
group by Logrank test.
Results: Median follow-up periods and frequencies of colonoscopy were 64.3
months and 3.7 times in group A, 52.0 months and 3.5 times in group B, and
74.6 months and 3.9 times in group C, respectively. The cumulative incidences of
metachronous non-index lesion were 24.5% (109 patients with 289 low-grade
adenomas) in group A, 26.1% (64 with 184) in group B, and 19.3% (75 with
229) in group C, respectively. The prevalence of metachronous non-index lesion
was lower in group C compared to that in group A (p¼ 0.07), and group B
(p5 0.05). The cumulative incidences of metachronous index lesion were 7.0%
(31 patients with 34 high-grade adenmas or cancers) in group A, 6.9% (17 with
17) in group B, and 12.3% (48 with 55) in group C, respectively. The prevalence
of metachronous index lesion was higher in group C compared to that in group A
(p5 0.05) and group B (p5 0.05). The cumulative incidences of metachronous
invasive cancer were 0.9% (4 patients with 4 invasive cancers) in group A, 1.2%
(3 with 3) in group B, and 3.6% (14 with 14) in group C, disclosing highest
prevalence in group C (p5 0.05). Logrank test revealed that the cumulative
incidence of non-index lesion was lowest in group C, and statistical significances
were observed between group A and C (p5 0.01), and between group B and C
(p5 0.001). Logrank test also revealed that the cumulative incidence of index
lesion was highest in group C, but no significant differences were observed com-
pared to those in group A and B.
Conclusion: Significant higher prevalence of metachronous index lesion including
invasive cancer and, in contrast, significant lower prevalence of metachronous
non-index lesion were observed in patients after resections of colorectal invasive
cancer compared to those after endoscopic resections of colorectal adenoma and
intramucosal cancer.
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PATIENTS WITH UNRESECTED DIMINUTIVE POLYPS AND
THOSE WITH COLORECTAL ADENOMAS 4 5MM IN SIZE
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Introduction: A long-term risk of colorectal advanced neoplasia among patients
having diminutive polyps at initial colonoscopy has been unknown. The present
study aimed to compare the risk of metachronous advanced neoplasia during
follow-up between patients with untreated diminutive colorectal polyps and those
with small or large adenoma resected at baseline colonoscopy.
Aims & Methods: A total of 1595 patients were colonoscopically followed-up
during a long-term period in our hospital. They were divided into group A, B,
and C as follows; 581 in group A (mean age 65.0þ8.9 yr, M:F¼ 411:170) with
colorectal adenoma more than 5mm in size resected at baseline, 495 in group B
(65.2þ9.6 yr, 328:167) with diminutive polyps left untreated at baseline, and
519 in group C (62.5þ10.7 yr, 255:264) with no polyps at baseline. During
follow-up colonoscopies detected metachronous neoplasms more than 5mm in
diameter were resected and pathologically evaluated into non-index lesion (low-
grade adenoma) or index lesion (high-grade adenoma or cancer). The cumulative
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incidences of metachronous colorectal neoplasms were compared with each other
group by Logrank test.
Results: Median follow-up periods and frequencies of colonoscopy were 61.9
months and 3.6 times in group A, 61.6 months and 3.4 times in group B, and
72.3 months and 2.7 times in group C, respectively. The cumulative incidences of
metachronous non-index lesion were 24.1% (140 patients with 375 low-grade
adenomas) in group A, 14.7% (73 with 168) in group B, and 6.6% (34 with
56) in group C, respectively. The prevalence of metachronous non-index lesion
was highest in group A followed by those in group B and C, with significant
differences between group A and B (p5 0.0005), and B and C (p5 0.0001). The
cumulative incidences of metachronous index lesion were 7.2% (42 patients with
45 high-grade adenmas or cancers) in group A, 5.1% (25 with 27) in group B, and
2.3% (12 with 13) in group C, respectively. The prevalence of metachronous
index lesion was highest in group A followed by those in group B and C, and
significant difference was observed between group A and C (p5 0.001), and B
and C (p5 0.05). The cumulative incidences of metachronous invasive cancer
were 1.0% (6 patients with 6 invasive cancers) in group A, 1.4% (7 with 7) in
group B, and 0.2% (1 with 1) in group C with no significant difference. Logrank
test revealed that the cumulative incidence of non-index lesion was highest in
group A, and statistical significances were observed between group A and B
(p5 0.0001), and between group B and C (p5 0.0001). Logrank test also
revealed that the cumulative incidence of index lesion was highest in group A,
and statistical significances were observed between group A and B (p5 0.05),
and between group B and C (p5 0.005).
Conclusion: The results of a long-term colonoscopic follow-up disclosed a sig-
nificantly higher prevalence of metachronous advanced neoplasms in patients
with adenoma 45mm in size resected at baseline compared to those with
diminutive polyps left untreated at baseline. Persons with no polyps at baseline
colonoscopy were at very low risk of advanced neoplasia within five years during
follow-up.
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POPULATION AND COMPARISON WITH THE MODIFIED ASIA-
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Introduction: Colorectal cancer (CRC) is still a major cause of death even in
countries with a CRC screening program, indicating the need for improved
screening methods. Risk-stratification of populations is one strategy that might
satisfy this requirement. Currently, in the Asia-Pacific region, the use of the
modified Asia-Pacific Colorectal Screening (APCS) score [age 50–59: 1 point,
age 60: 2, male sex: 1, presence of a first-degree relative (FDR) with CRC: 1,
current or past smoker: 1, body mass index (BMI) 23 kg/m2: 1] has been pro-
posed for risk-stratification.1–4 However, further validation studies are required
to appraise its usefulness, and considering the reported limited discriminatory
capability of the score for advanced colorectal neoplasia (ACN), 4 the develop-
ment of a more useful scoring model is expected.
Aims & Methods: The aim of this study was primarily to develop and validate a
new scoring model for predicting ACN in asymptomatic screening populations
that is more useful than the APCS score. We externally validated the APCS score
in a Japanese screening population and compared its discriminatory capability
with that of our new scoring model. Data were reviewed from 5218 consecutive
asymptomatic screened individuals who underwent colonoscopy for their first
time at the Cancer Screening Center, National Cancer Center Hospital, Tokyo
between February 2004 and March 2013. Multivariate logistic regression was
used to investigate the associations between clinical variables and the presence
of ACN in the subjects, and then a new scoring model was developed based on
these associations. Scores were weighted according to the beta coefficient
obtained from the logistic regression model. Thereafter, the discriminatory cap-
ability of the new model was assessed using the c-statistics in the development set.
Performance of the new model was internally validated using bootstrapping with
1000 replicates. The discriminatory capability of the modified APCS score in the
5218 subjects was also assessed using the c-statistics. The value obtained was
compared with that of the new scoring model using the DeLong test, and this
comparison was also performed in the 1000 bootstrapped replicates.
Results: A total of 225 individuals (4.3% of 5218 subjects) had ACN (n¼ 257),
including 116 proximal lesions (45.1%) and 76 lesions with flat-type morphology
(29.6%). An 8-point scoring model to predict ACN was developed by using five
identified independent risk factors for ACN as scoring items. These included sex
(male: 1 point, female: 0), age (40–49 years: 0, 50–59: 2, 60–69: 3,470: 3.5), CRC
family history (presence of 2 FDRs with CRC: 2, others: 0), BMI (22.5: 0,
422.5: 0.5) and smoking (18.5 pack-years: 0, 418.5: 1). Presence of one FDR
with CRC was not detected as an independent risk factor for ACN and was not
assigned any score. Using the scoring model, the proportion of subjects with
ACN increased with the order of scores. The proportions were 1.6% (34/2172),
5.3% (127/2419) and 10.2% (64/627) in the groups with scores of 53, 3 and
55, and 5, respectively. The c-statistic of the score in the development set was
0.70 (95% CI, 0.67–0.73) and this was the same in the internal validation set. The
value of the modified APCS score was 0.68 (95% CI, 0.65–0.71). The c-statistics
of the new score were significantly higher than those of the modified APCS score,
both in the 5, 218 subjects (P¼ 0.03) and in 1, 000 bootstrapped replicates
(P¼ 0.03).
Conclusion: An 8-point scoring model to predict ACN in asymptomatic screening
population that might have a higher discriminatory capability than the modified
APCS score was developed and internally validated in this study. Our simple
scoring model could stratify the screened population into low-, moderate-, and
high-risk groups. Of the detected ACN, a substantial number were proximal or
flat; therefore, primary screening with total colonoscopy may be advisable for
high-risk individuals.
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Introduction: Previous studies have shown that increase of threshold for first
rectal sensation can be a predictor of fecal incontinence. However, significance
of percentage range of rectoanal inhibitory reflex (%RAIR) in development of
this disease remains unknown.
Aims & Methods: To determine association between %RAIR and threshold for
first rectal sensation in healthy adults and its significance in development of fecal
incontinence. 26 asymptomatic healthy volunteers (18 women, 8 men) median
age was 35.03 years (19–59) were studied. We performed them a high-resolution
anorectal manometry (HRAM) using a 20 channels silicone water-perfused
catheter (Solar GI, MMS, Netherlands). The following HRAM parameters
were analyzed: threshold for RAIR and %RAIR (automatically calculated as
the ratio of the amplitude of the relaxation of the anal sphincter (AS) to the basal
pressure AS *100%), threshold for first rectal sensation (RS) and for desire to
defecate. The statistical analyses were performed using Statistica for Windows
6.0 (StatSoft Inc.).
Results: Threshold for RAIR and %RAIR were 22.3ml (10.0; 30.0), 74.4% (38;
99.5) respectively. Threshold for first RS was 30, 07ml (11.1; 58.3) and desire to
defecate – 65.12ml (33.5; 182.0). Threshold for RAIR was not associated with
threshold for first RS (r¼0.07) and for desire to defecate (r¼ 0.02). %RAIR
was weak positively correlated with threshold for first RS (r¼ 0.26) and was not
associated with threshold for desire to defecate (r¼0.03).
Conclusion: Threshold for RAIR and %RAIR are not associated with first
rectal sensation. So, these parameters of RAIR cannot be predictors of fecal
incontinence.
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Introduction: Trait neuroticism has been consistently found to be associated with
more severe functional gastrointestinal (GI) symptoms (1). One explanation for
this is that high neuroticism predisposes individuals towards avoidant coping by
leading them to view negatively-valenced situations as catastrophic (2) and,
therefore, unsolvable (3). Avoidant coping, in turn, increases the risk of devel-
oping GI discomfort because over-reliance on ‘‘flight’’ strategies in stressful
situations overstimulates the sympathetic nervous system at the expense of para-
sympathetic activity necessary for digestion (4). Evidence for this proposed chain
of associations comes largely from studies that have observed relationships
between each pair of the chain’s components: neuroticism and avoidant coping
(e.g., 3), and avoidant coping and higher GI symptom burden (e.g., 1). Across
two studies, this paper integrates these findings, while also exploring the role of
somatisation. Somatisation is consistently observed in people suffering from
functional GI Conditions (e.g., 1) and refers to a subtype of avoidant coping -
the expression of psychological stress through complaints about bodily symp-
toms (6). Should evidence emerge that somatisation is an intermediary between
avoidant coping and GI symptom burden in the relationship between neuroti-
cism, coping styles and GI symptom burden, the dominant explanation for how
avoidant coping and GI symptoms are connected would need to be expanded to
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predict that somatisation has deleterious consequences for GI conditions - pos-
sibly because it encourages reduced physical activity (7).
Aims & Methods: In Study 1, 147 undergraduate students completed measures of
neuroticism, 14 coping styles (including avoidant styles such as denial and disen-
gagement), somatisation and GI symptom burden. In Study 2, where participants
were undergraduates and hospital outpatients (pooled N¼ 250), the variables
investigated in Study 1 were measured alongside hypochondriasis, which was
included to measure the aspect of somatisation that involves worry independently
of any actual physical symptoms. Statistical analysis was based on path modeling.
It involved fitting a model to test a priori hypothesised indirect relationships
between neuroticism and GI symptom severity via the selected coping styles and
somatisation. Direct effects were also estimated, meaning that the path analysis
provided information regarding the significance of any indirect effects once a
range of direct effects were accounted for. Only six coping styles found to correlate
with both neuroticism and GI symptom severity were included (see Results table).
Coping styles were assumed to covary, and the model in Study 2 assumed a
covariance relationship between somatisation and hypochondriasis.
Study 1 direct
effects on row
variables
Study 1
indirect effects
on symptom
burden via
row variables
Study 2 direct
effects on
row variables
Study 2
indirect effects
on symptom
burden via
row variables
Self-distraction .33(.07)*** n.s. .22(.07)*** n.s.
Denial .24(.07)*** n.s. .28(.05)*** n.s.
Venting .36(.07)*** n.s. .32(.06)*** n.s.
Substance-use .40(.07)*** n.s. .19(.06)** n.s.
Disengagement .52(.06)*** n.s. .55(.06)*** n.s.
Self-blame .53(.06)*** n.s. .62(.04)*** n.s.
Somatisation .42(.09)*** .16(.05)** .40(.07)*** .17(.04)***
Hypochondriasis Not applicable Not applicable .30(.08)*** .08(.03)**
Symptom burden n.s. Not applicable n.s. Not applicable
Substance-use and
somatisation
Not applicable .03(.02)* Not applicable n.s.
Disengagement and
somatisation
Not applicable .04(.02)* Not applicable n.s.
Self-blame and
somatisation
Not applicable -.05(.02)* Not applicable n.s.
Denial and somatisation Not applicable n.s. Not applicable .02(.01)*
Denial and
hypochondriasis
Not applicable Not applicable Not applicable .02(.01)*
Results: Significant standardised path model coefficients involving neuroticism
across the two studies. In Study 1, neuroticism exerted indirect effects on symp-
tom burden through substance-use-based coping and somatisation, as well as
through disengagement-based coping and somatisation. In Study 2, neuroticism
affected GI symptom burden through denial-based coping and somatisation, as
well as through denial-based coping and hypochondriasis. An indirect effect of
neuroticism through self-blame and somatisation, with the two intermediary
variables relating negatively to each other, was observed in Study 1. (Note:
***p5 .001, **p5 .01, *p5 .05. n.s. denotes non-significant coefficients).
Conclusion: Somatisation and hypochondriasis were found to be intermediaries in
the relationship between neuroticism, avoidant coping (through substance-use,
disengagement and denial) and GI symptom burden. Two interpretations of the
findings are: (1) avoidant coping can stimulate somatisation, leading to reduced
physical activity, which can interfere with digestion; and (2) GI symptoms are
among the wide range of functional somatic symptoms that can arise from avoi-
dant coping. These findings open new avenues for multidisciplinary treatment of
FGIDs.
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P0473 POTENTIAL REGULATORY EFFECTS OF
CORTICOTROPIN-RELEASING FACTOR ON TIGHT JUNCTION-
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Introduction: This study aimed to investigate the regulatory effects of corticotro-
pin-releasing factor (CRF) on the permeability of human intestinal epithelial cells
through CK8-mediated tight junction.
Aims & Methods: The expression of CRFR1 and CRFR2 on HT29 cell surfaces
were detected by immunofluorescence, RT-PCR, and Western blotting. After
treatment with 100 nM CRF for 72 h, the transmission of FITC-labeled
Dextran was measured by using a transwell chamber; the structural changes of
tight junctions were observed under transmission electron microscopy; the
expression of CK8, F-actin and tight junction proteins ZO-1, claudin-1, and
occludin were detected by immunoblotting and immunofluorescence. The activity
of RhoA was detected by immunoprecipitation. Furthermore, effects of CRF on
intestinal epithelial permeability were examined in CK8-silenced HT29 cells,
which were constructed by shRNA interference.
Results: CRF treatment increased FITC-labeled Dextran permeability, caused
opening of tight junctions, induced increased fluorescence intensity of CK8
and decreased intensity of ZO-1, claudin-1, and occluding, together with struc-
tural disruption. The expression of F-actin, occludin, claudin-1, and ZO-1 were
downregulated. RhoA activity peaked at 30min after CRF treatment. The
increased permeability and the downregulation of claudin-1 and occludin
induced by CRF treatment were not blocked by CK8 silencing. Nevertheless,
CK8 silencing blocked the effects of CRF with regard to decrease in the expres-
sion of F-action and ZO-1 and increase in RhoA activity.
Conclusion: CRF may increase intestinal epithelial permeability by upregulating
CK8 expression, activating the RhoA signaling pathway, promoting intestinal
epithelial actin remodeling, and decreasing the expression of the tight junction
protein ZO-1. Other CK8-independent pathways may lead to decreased expres-
sion of claudin-1 and occludin, which also contributes to increased intestinal
epithelial permeability.
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Introduction: Diarrhea-predominant irritable bowel syndrome (D-IBS) is a
chronic functional gastrointestinal disease. Its clinical manifestations are char-
acterized by diarrhea and abdominal pain or discomfort in the absence of a
demonstrable pathology. The diagnosis of D-IBS is based on symptom assess-
ment and the Rome III Diagnostic Criteria. According to an epidemiological
study, D-IBS mainly affects young adults of 20–40 years old, and the quality
of their lives is seriously affected. The pathogenesis of D-IBS has not been fully
clarified. Consequently, the usual treatment of the disease in Western medicine
involves symptomatic therapy, which is unsatisfactory for patients while simul-
taneously increasing the use of health-care resources. Because traditional Chinese
medicine (TCM) can significantly improve patients’ symptoms and quality of life,
increasing numbers of patients have begun to seek treatment with TCM.A series
of randomized, double-blind, placebocontrolled trials had shown that TongXie-
YaoFang(TXYF) formula can significantly improve the clinical symptoms, such
as diarrhea and abdominal pain or discomfort, of patients with D-IBS and
improve the quality of their lives. However, the specific mechanism of it has
not been completely elaborated. The purpose of this paper is to observe the
regulating effects of TXYF-formula on colonic epithelial secretion via relevant
ion channels.
Aims & Methods: We aimed to investigate the pharmacological effect of
TongXie-YaoFang (TXYF) formula, a Chinese herbal formula, on Diarrhea-
predominant irritable bowel syndrome (D-IBS) rats. In a neonatal maternal
separation plus restraint stress(NMSþRS) model of D-IBS, male Sprague
Dawley rats were randomly divided into two groups (NMSþRS group and
TXYF-formula group) with no handlings were used as controls (NH group).
Starting from postnatal day 60, rats in TXYF-formula group were administered
TXYF-formula (4.92 g/100 g bodyweight) orally twice a day for 14 consecutive
days while NH group and NMSþRS group were given distilled water. Using
short-circuit current technology, we observed 5-HT-induced changes of current
across ion channels, such as cystic fibrosis transmembrane conductance
regulator (CFTR) Cl– channel, epithelial Naþ channel (ENaC), Ca2þ-dependent
Cl– channel (CACC), Naþ-Kþ-2Cl– co-transporter (NKCC), and Naþ-HCO3
–
co-transporter (NBC), in the colonic epithelium of three groups after exposure
to drugs and specific blockers with a Power Lab System (AD Instruments
International).
Results: Under basal conditions, the changes of short-circuit current (DIsc, mA/
cm2) induced by 5-HT were similar in NH group and TXYF-formula group, and
both higher than NMSþRS group (70.86 12.32mA/cm2, 67.67 11.68mA/cm2
VS 38.8 7.25mA/cm2, P5 0.01, respectively). When CACC was blocked by
DIDS, 5-HT-induced DIsc was smaller in NMSþRS group than in NH group
and TXYF-formula group, respectively (48.41 13.15mA/cm2 VS
74.62 10.73mA/cm2, 69.22 11.7mA/cm2, P5 0.05, respectively). The similar
result could be obtained when ENaC was blocked by Amiloride
(44.69 12.58mA/cm2 VS 62.05 11.26mA/cm2, 62.11 12.01mA/cm2,
P5 0.05, respectively). However, when CFTR Cl– channel was blocked by
DPC, 5-HT-induced DIsc did not significantly differ in three groups
(42.28 10.61mA/cm2 VS 51.48 6.56mA/cm2 VS 47.75 7.99mA/cm2,
P4 0.05, respectively). The similar results could also be obtained in three
groups when NBC and NKCC were respectively blocked by their blockers.
Conclusion: TXYF-formula can regulate the Cl– and HCO3
– secretion of colonic
mucosa via CFTR Cl– channel, Cl–/HCO3
– exchanger, NBC and NKCC co-
transporters.
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Introduction: Stressful life events may trigger the symptoms of irritable bowel
syndrome (IBS). Preclinical chronic stress models have been developed in animals
to mimic changes in visceral sensitivity in response to gut wall distension seen in
IBS patients. In the rat, chronic passive water avoidance stress (WAS) is asso-
ciated with hypersensitivity to colorectal distension. Diosmectite, a purified sili-
cate clay, is an adsorbent widely used for the treatment of several gastrointestinal
diseases, mainly diarrhoea but also the functional abdominal pain experienced in
chronic IBS. However, the effect of diosmectite treatment on IBS visceral hyper-
sensitivity has never been investigated.
Aims & Methods: The aims of the present study were to evaluate the effect of
diosmectite on gut transit time and visceral hypersensitivity induced by WAS in
rats. Wistar rats (175–200 g) (n¼ 9–10) were randomized to one of four groups:
diosmectite (500mg/kg), diosmectite (500mg/kg, WAS procedure), water (0.5ml/
rat) or water (0.5ml/rat, WAS procedure). Treatment was for 5 days, with the
WAS procedure conducted once daily. The test apparatus consisted of a Plexiglas
tank with a block affixed to the center of the floor. The tank was filled with fresh
room temperature water to within 1 cm of the top of the block. Rats were placed
on the block for a period of 1 h every day. For both conditions (basal and after
WAS), intestinal transit was evaluated by fecal output measurement Visceral
sensitivity in response to colorectal distension (CRD) was assessed both in
basal conditions and 30min after the last WAS session.
Results: Under basal conditions, chronic oral treatment with diosmectite did not
modify visceral sensitivity in response to CRD (20 2 vs. 23 1 cramps/5min for
vehicle at 0.8mL; 20 4 vs. 24 2 for vehicle at 1.2mL; p¼ 0.97 and p¼ 0.75
respectively) or intestinal transit in comparison with control group (p¼ 0.33).
WAS treatment significantly increased the number of abdominal contractions at
both 0.8 and 1.2ml of CRD vs vehicle values (30.1 2.5 vs. 19.78 2.8 at 0.8mL
[p5 0.05]; 34.4 2.4 vs. 23.2 1.1 at 1.2mL [p5 0.05]). One hour after the
beginning of the last WAS session a significant increase of the fecal output in
comparison with vehicle non-stressed rat (6.3 1.1 vs. 0.3 0.3; p5 0.05) was
observed. Chronic administration of diosmectite significantly (p5 0.05) reduced
the number of abdominal contractions (a visceral sensitivity index) induced by
WAS: the number of abdominal contractions at 0.8 and 1.2ml of CRD in com-
parison with vehicle was (30 3 vs. 24 2 contractions at 0.8mL; 34 2 vs.
27 2 contractions at 1.2mL). Diosmectite also tended to improve stress-induced
intestinal transit acceleration (6.3 1.1 vs 4.9 1.2 number of feces for 1 h;
p¼ 0.38).
Conclusion: For the first time, these data illustrate in wistar rat, that diosmectite
treatment is able to suppress WAS-induced visceral hypersensitivity to colorectal
distension. This study adds relevant evidence to the use of diosmectite treatment
in the management of IBS.
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Introduction: We have recently shown that postprandial sensations correlate with
changes in circulating metabolites after a meal ingestion; however this phenom-
enon was demonstrated with a meal load up to the level of tolerance which
involved an unpleasant fullness sensation.
Aims & Methods: In the present study we aimed to evaluate the relation between
the hedonic and the metabolomic responses to a palatable meal. Healthy men
(n¼ 32; 18–44 yrs range) were evaluated after a 5 h fast. Perception measure-
ments and blood samples were taken before and 20 minutes after ingestion of a
palatable probe meal (juice and warm ham and cheese sandwich, total 300ml,
440 kcal). Homeostatic (satiety, desire of eating a food of choice and abdominal
fullness) and hedonic sensations (digestive well-being and mood) were measured
by 10 cm analogical scales. NMR spectroscopy was performed to determine
plasmatic Low Molecular Weight Metabolites (LMWM) and to characterize
lipoprotein profiles (number of particles, lipid content and size of the main
three lipoprotein classes (VLDL, LDL and HDL)).
Results: Meal ingestion induced a pleasant sensation involving mild fullness
(2.7 0.4 score increment; p5 0.001 vs baseline) and an increase in digestive
well-being and mood (3.1 0.3 and 2.0 0.3 score increment respectively;
p5 0.001 vs baseline). Distinctive changes in the spectrum of circulating meta-
bolites induced by meal ingestion were detected. A non-supervised PCA model of
the metabolomic response correctly discriminated between the pre and postpran-
dial state. The main variables determining the differences were glucose, triglycer-
ides, number of VLDL, HDL and LDL particles, alanine, isoleucine, acetate,
formate, creatine and lactate. The increase in the sensation of fullness correlated
with the levels of glucose, alanine and lactate (R¼ 0.44; p¼ 0.011 and R¼ 0.37;
p¼ 0.036 and R¼ 0.44; p¼ 0.008 respectively). Desire of eating a food of choice
decreased after meal ingestion and correlated with the increase in HDL-trigly-
cerides (R¼ 0.35; p¼ 0.047). The increase in the concentration of VLDL- trigly-
cerides correlated with the increase in sensation of digestive wellbeing (R¼ 0.36;
p¼ 0.044).
Conclusion: Homeostatic and hedonic sensations in response to a pleasant meal
correlate with changes in circulating metabolites. Metabolomic changes in the
response to a meal could serve as objective biomarkers of the postprandial
experience.
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Introduction: Bifidobacterium with appropriate doses has been suggested to
reduce the visceral hypersensitivity in IBS. But different treatment effects have
been reported. The negative effect of Bifidobacterium has been rarely studied and
reported.
Aims & Methods: We aimed to study the effects of gavage administration with
Bifidobacterium bifidus for two weeks on the visceral hypersensitivity of rats.
Colonic visceral hypersensitivity (CVH) was induced by colonic injection of
0.5% acetic acid (AA) in 10-day old rats while control (NS) induced with
0.9% normal saline. The abdominal withdrawal reflexes (AWR), induced by
colorectal distention (CRD), was used to quantify the level of colonic sensitivity
in adult rats. The CVH rats in 42-day old were treated by gavage administration
with Bifidobacterium bifidus (1*109 CFU/day) for two weeks (CVH-Bifi). Other
CVH rats were treated with 0.9% NaCL (CVH-NS). A group of control with
normal sensitivity was treated with sham gavage (Con-sham). In day 56th,
another AWR was assessed, and the hippocampus and prefrontal cortex (PFC)
were separated and used to analyze the c-fos, NMDAR 2A, NMDAR2B with
western-blot.
Results: After two-week gavage, the CVH-Bifi presented lower volume than that
of CVH-NS in CRD, though without statistical difference (2.35 0.28
vs.2.40 0.64, p¼ 0.11). No significant difference was found between CVH-
Bifi and Con-sham as well. In hippocampus, c-fos of CVH-Bifi was higher
than that of Con-sham (0.77 0.23 vs.0.31 0.08, p¼ 0.032) and CVH-NS
(0.77 0.23 vs.0.48 010, p¼ 0.171). The NMDAR2A of CVH-Bifi was higher
than that of Con-sham (1.04 0.22 vs. 0.51 0.16, p¼ 0.055). In PFC, the
NMDAR2A in CVH-Bifi was significantly higher than that of CVH-NS
(0.63 0.14 vs. 0.21 0.05, p¼ 0.004) and Con-sham (0.63 0.14 vs.0.20
0.07, p¼ 0.011).
Conclusion: We reported the negative effects of Bifidobacterium bifidus gavage,
which induced higher activation of c-fos and higher expression of NMDAR 2A
in hippocampus and PFC. The roles of Bifidobacterium bifidus and its metabo-
lites on visceral sensitivity needs further study to clarify.
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Introduction: DA-9701, a newly developed prokinetic agent formulated with
Pharbitis Semen and Corydalis Tuber, has been shown to effectively treat func-
tional dyspepsia. Recently, it has also been suspected to improve gastrointestinal
motor function.
Aims & Methods: The aims of this study were to assess the effect of DA-9701 on
colonic transit time (CTT) and symptoms of functional constipation. We pro-
spectively enrolled 33 patients with functional constipation based on the Rome
III criteria. The patients received 30mg DA-9701 three times a day for 24 days.
CTT was estimated initially and at the end of treatment. We also analyzed
symptoms such as spontaneous bowel movements (SBMs), straining, stool
form, feeling of incomplete emptying and anorectal blockage, abdominal discom-
fort and pain, overall defecation satisfaction, and incidence of adverse events.
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Results: Twenty-seven patients completed the study. DA-9701 was associated
with a significantly reduced CTT from 34.9 17.6 to 23.7 19.1 hours
(P¼ 0.001). Segmental CTT also significantly decreased after treatment (right
CTT: from 14.0 8.2 to 7.5 7.4 hours, P5 0.001; rectosigmoid transit time:
from 14.2 11.9 to 9.5 10.9 hours, P¼ 0.021). In addition, all constipation-
related subjective symptoms, including SBM frequency, significantly improved
compared to those before treatment. Serious adverse events did not occur.
Conclusion: DA-9701 accelerates colonic transit and safely improves symptoms in
patients with functional constipation. Therefore, we suggest that this novel agent
could help to treat patients with this condition.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Previous symptom-based criteria to diagnose irritable bowel syn-
drome (IBS) performed only modestly. The Rome IV criteria are the current
gold-standard, and dispensed with the symptom of abdominal discomfort, as
well as making slight modifications to the symptom frequency threshold and
associated symptoms required for a diagnosis of IBS. Epidemiological surveys
suggest that these modifications reduce the overall prevalence of IBS in the
community, but the effect on their performance in referral populations is uncer-
tain, as independent validation studies are lacking.
Aims & Methods: We collected complete symptom data from consecutive, unse-
lected patients referred to secondary care with lower GI symptoms, and seen in a
specialist IBS clinic. All participants completed the validated Rome IV question-
naire for IBS, and underwent investigation to the level deemed appropriate by
two clinicians with considerable experience in diagnosing and managing IBS. The
final clinical diagnosis, after a limited panel of investigations, was recorded.
Coeliac disease was excluded in all individuals, via serological testing. The refer-
ence standard used to define the presence of true IBS was a physician’s clinical
diagnosis of IBS, after appropriate limited investigation to exclude relevant
organic disease. Sensitivity, specificity, and positive and negative likelihood
ratios (LRs) were calculated for the Rome IV criteria.
Results: We recruited 104 adults referred with lower GI symptoms (81 (77.9%)
female, mean age 35.8 years (range 16 to 77 years)). Among 91 individuals with
IBS according to the reference standard, 72 met the Rome IV criteria
(sensitivity¼ 79.1%), and 19 did not. There were 13 individuals who did not
have IBS according to the reference standard, of whom 11 did not meet Rome
IV criteria (specificity¼ 84.6%). The other two individuals who met Rome IV
criteria, but who did not have IBS after appropriate investigation to exclude
relevant organic disease, both had bile acid diarrhoea. Positive and negative
LRs for the Rome IV criteria were 5.14 and 0.25 respectively. Among the 19
patients who had IBS according to the reference standard, but who did not meet
the Rome IV criteria for IBS, seven (36.8%) did not meet the minimum symptom
duration of 6 months, six (31.6%) did not meet the minimum pain frequency
threshold of once per week, and six (31.6%) did not report two or more of pain in
relation to defaecation, pain in association with a change in stool frequency, or
pain in association with a change in stool form.
Conclusion: The Rome IV criteria performed modestly in a specialist IBS clinic.
One-in-five patients felt to have IBS according to an experienced clinician, and
after limited investigation to exclude relevant organic disease, did not meet the
Rome IV criteria, suggesting they may be too restrictive for use in clinical
practice.
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Introduction: No studies have investigated how commonly individuals meeting
the new Rome IV IBS criteria seek medical care for their bowel symptoms, or
what factors determine medical consultation.
Aims & Methods: We aimed to characterize health care-seeking behaviour in
Rome IV IBS subjects in a large multi-national population sample. Data was
retrieved from a large Internet survey. The survey was completed by 6300 indi-
viduals distributed equally between United States, United Kingdom and Canada.
Equal sex, age and education distribution across the countries was ensured by use
of quota-based sampling. The survey included questions on demographics, the
Rome IV diagnostic questionnaire, the Patient Health Questionnaire (PHQ-12),
the 8-item Short Form (SF-8) quality of life (QOL) questionnaire, health care
utilization and past gastrointestinal (GI) disease diagnoses by doctors.
Respondents with an organic GI disease were excluded from the IBS population.
IBS consulters were defined as individuals meeting Rome IV IBS criteria who had
visited a doctor for GI symptoms.
Results: 6300 individuals completed the survey, 369 were excluded due to incon-
sistent responses, leaving 5931 (49.2% female; mean age 47.4 17.1 years) to be
included for analysis (1949 US, 1994 UK, 1988 Canada). After excluding 36
individuals due to lower GI organic disease, 305 subjects (5.1%; 66% female;
mean-age 44.7 14.5 years) fulfilled diagnostic criteria for IBS. From these, 195
(64%) had consulted a doctor for GI problems. IBS consulters had equal sex
distribution (63.6% vs. 69% female (p¼ 0.4) and somatization scores (p¼ 0.8)
compared to non-consulters, but were older (mean age 47.1 14.8 vs. 40.5 13.1
years), more concerned about their bowel function (p5 0.001), more frequently
bloated (p¼ 0.01), and experienced greater impact on social activities (p¼ 0.008).
The distribution of the most bothersome symptom was similar (p¼ 0.38), and
abdominal pain was the predominant symptom in both groups. See table for
details. The frequency of doctor visits for non-GI health issues did not differ
(p¼ 0.15), but IBS consulters had undergone more abdominal surgery (p¼ 0.04).
IBS consulters also reported higher consumption of GI related (p5 0.001), pre-
scribed pain (p5 0.001), and anti-depressive medications (p¼ 0.03), but had
similar consumption of anxiety (p¼ 0.11) and over the counter pain medications
(p¼ 0.34) as non-consulters. See table for details.
IBS consulters IBS non-consulters p-value
GI symptoms
Most bothersome symptom
Abdominal pain Loose
stools/high frequency
Hard stools/low fre-
quency Bloating None
of the above Frequency
Abdominal pain 43
times/week Bloating 43
times/month Concern of
bowel function Not at all
Somewhat Very
75 (38.5)
48 (24.6)
40 (20.5)
24 (12.3)
8 (4.1)
72 (36.9)
158 (81.0)
12 (6.2)
106 (54.4)
77 (39.5)
48 (43.6)
22 (20.0)
16 (14.5)
20 (18.2)
4 (3.6)
31 (28.2)
74 (67.3)
25 (22.7)
70 (63.3)
15 (13.6)
Somitization
PHQ-12 score 7 or above 147 (65.4) 85 (77.3) 0.82
Quality of life
Overall estimation of health
past 4 weeks (SF-8).
Very poor/poor Fair/
good Very good/
excellent
59 (30.3)
118 (60.5)
18 (9.2)
31 (28.2)
64 (58.2)
15 (13.6)
0, 5
Bodily pain past 4 weeks
(SF-8). None/very mild
Mild/moderate Severe/
very severe
22 (11.3)
110 (56.4)
63 (32.3)
19 (17.3)
58 (52.7)
33 (30.0)
0.35
Limitation in social activities
due to physical health or
emotional problems past
4 weeks (SF-8). Not at
all Very little/somewhat
24 (12.3)
98 (50.3)
73 (37.4)
29 (26.4)
46 (41.8)
35 (31.8)
0.008
(continued)
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Continued
IBS consulters IBS non-consulters p-value
Quite a lot/could do no
social activity
Frequency of doctor visits
At least one visit/year 159 (81.5) 82 (74.5) 0.19
Medication use
For GI related issues For
pain, over the counter
For pain, prescribed by
doctor For depression
For anxiety
146 (74.9)
69 (35.4)
92 (47.2)
77 (39.5)
65 (33.3)
48 (56.4)
45 (40.0)
30 (27.3)
30 (27.3)
27 (24.5)
50.001
0.34
50.001
0.03
0.11
Surgery
Cholecystectomy
Appendectomy
Hysterectomy Other
abdominal surgery
38 (19.5)
30 (15.4)
26 (13.3)
41 (21.0)
14 (12.7)
8 (7.3)
5 (4.5)
12 (10.9)
0.13
0.06
0.03
0.04
Conclusion: Among individuals who meet Rome IV criteria for IBS in the general
population, those who are older, have more frequent bloating, have greater
concern about their bowel function, and who are more socially affected by
their bowel symptoms, are more likely to consult doctors about their bowel
symptoms. In contrast, IBS consulters and non-consulters do not differ in their
abdominal pain severity or extra intestinal symptom burden. [Support: The
Rome Foundation].
Disclosure of Interest: All authors have declared no conflicts of interest.
P0485 PERFORMANCE OF A DIAGNOSTIC ALGORITHM FOR
FUNCTIONAL GASTROINTESTINAL DISORDERS
E. C. Linedale1, A. Mikocka-Walus2, P.R. Gibson3, J. M. Andrews4
1Department Of Medicine, The University of Adelaide, Adelaide/Australia/SA
2School Of Psychology, Deakin University, Melbourne/Australia
3Gastroenterology, Monash University, Melbourne/Australia/VIC
4Department Of Gastroenterology & Hepatology, Royal Adelaide Hospital - SA
Health, Adelaide/Australia
Contact E-mail Address: ecushla.linedale@adelaide.edu.au
Introduction: Non-urgent referrals to specialist gastroenterology exceed capacity,
resulting in long waiting lists and poor patient outcomes. New models of care are
needed to translate specialist knowledge of functional gastrointestinal disorders
(FGID) into primary care practice.
Aims & Methods: This study aimed to evaluate the safety and performance of an
algorithm-based approach to the diagnosis and management of FGID.
Consecutive patients triaged to the ‘routine waitlist’ of an Australian public
hospital Gastroenterology Department over 2 years, with non-specific GI symp-
toms (no alarms) were randomised to waitlist control or intervention (2:1).
Intervention patients were screened for alarms and abnormal blood/stool tests
without an in-person consultation, to exclude organic disease (full blood count,
C-reactive protein, biochemistry, thyroid function tests, iron studies, coeliac ser-
ology, þ/ H. pylori serology, þ/ faecal calprotectin and elastase) and classi-
fied according to the Rome III criteria. Information from patients with clinical
alarms was reviewed by a gastroenterologist (GE) and, where judged appropri-
ate, a prompt GE appointment offered. Elsewise patients received a letter stating
FGID diagnosis and management options. Referrals were analysed for quality
according to current triage practices.
Results: 89 intervention patients (61% female, mean 42, [SD 14] y) and 21 control
(75% female, mean 42, [SD 16] y) patients completed intake. 35 intervention
patients warranted prompt GE review after active screening. Organic disease
was diagnosed in 10 (diagnosed: 19 FGID, 2 IBD, 1 neoplasm, 1 pancreatic
insufficiency, 1 reflux oesophagitis, iron deficiency 1, 7 did not attend), and 4
had additional clinically significant findings (polyps, iron deficiency). 45 were
diagnosed with a FGID (9 had another non-urgent diagnosis). At follow up
(mean 2.7 yrs [SD 0.5yrs] post-referral), none of the 45 patients diagnosed with
FGID had received a gastroenterology consult based on the original referral (six
received a specialist appointment via duplicate referrals within the system).
Confirmation of diagnoses at follow-up was received by patients and/or referring
doctors in 42/45 cases (three no longer contactable). The majority of patients (37/
42, 88%) had received no alternate diagnosis to account for their gastrointestinal
symptoms since the study. Whilst two had additional diagnoses (FGID plus
diverticulitis, FGID plus prostatitis), and two – incidental yet clinically signifi-
cant findings (FGID plus polyps).
Conclusion: The quality of referrals of patients with clinically suspected FGIDs
was insufficient to allow the safe triage of patients according to urgency, with a
third warranting more urgent review. Organic disease was diagnosed in a signifi-
cant proportion of patients who would otherwise were unlikely to have been seen
in tertiary care. Use of this specialist-independent diagnostic algorithm in pri-
mary or tertiary care may facilitate more timely and accurate diagnosis of organic
gastrointestinal disease, and improve patient care.
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Introduction: IBS is common worldwide. In UK it exceeds the 20% of the popu-
lation1. Burden of Irritable Bowel Syndrome (IBS) on UK healthcare has been
estimated around 1800£per patient per year2. NICE guideline3 IBS provides a
systematic approach to symptoms and therapies available to GPs and general
gastroenterologists. This creates a good asset to minimize referrals to tertiary
centres and address costs.
Aims & Methods: We retrospectively reviewed, via electronic records, all the
patients seen at the Scottish Gut Motility Disorder Clinic between January
and December 2016 included, focusing on original referral, diagnosis and treat-
ment to evaluate the need for specialist input.
Results: In 2016, 378 patients attended the Motility Clinic; total of 459 visits; 333
females. Mean age was 51.4 (age range: 16 to 95 years). 60% of referrals origi-
nated via secondary care (40% GI, 50% Surgery, 10% other disciplines). The
commonest reason for referral was IBS (40%); IBS-Constipation (58%), IBS-
Diarrhoea (21%) or IBS-MixType (21%). 16% were referred with faecal incon-
tinence and 37% with chronic constipation. 35% of patient didn’t receive any
therapy at time of referral. 44% were prescribed treatment but not followed up
for assessment of successful response to therapy prior to referral to the specialist
clinic. In 28% of patients the diagnosis changed following Motility clinic assess-
ment. Diagnosis at clinic is based on ROMEIII questionnaire, depression and
anxiety score, thorough history taking and physical examination (including per
rectum exam), ad hoc psychiatry input and referral to specialist investigation. In
30% of patients referred with chronic constipation the diagnosis was changed to
IBS-Constipation, 8% changed from IBS-D to IBS-M, 8% referred with faecal
incontinence had Obstructive Defecation Syndrome, 6% referred as IBS-M were
diagnosed with IBS-C, 5% referred as IBS-D were diagnosed as IBS-M, 3%
referred with IBS-D had bile acid malabsorption. 56% of patients underwent
specialist investigations including anorectal physiology (70%).33% of patients
attending the Specialist clinic received 1st -line therapy and life style advice, albeit
57% of them, who received 2nd -line treatment, having failed 1st-line
management.
Conclusion: The above data indicate the need for education and expansion of
resources available in primary care to optimise patients’ management.
Furthermore, it highlights the necessity for the introduction of a formal
Neurogastroenterology curriculum in the general Gastroenterology training.
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Introduction: Irritable bowel syndrome (IBS) affects 5–15% of adults in the gen-
eral population, and is characterized by chronic recurrent abdominal pain and
discomfort and associated with altered bowel habits. The pathophysiology of IBS
is complex and not fully understood. Hence, treatment is often based on symp-
tomatology rather than underlying physiological aberrancies.
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Aims & Methods: The aim of this study was to compare the expression of mem-
brane transporters in mucosal biopsies of healthy subjects, IBS patients and post-
infectious (PI)-IBS patients. Mucosal biopsies were obtained from the unpre-
pared sigmoid colon in 18 IBS patients, 9 PI-IBS patients and 10 healthy subjects.
Total RNA was isolated and prepared for gene expression analyses using quan-
titative reverse-transcription polymerase chain reaction (qRT-PCR). We com-
pared the expression of genes encoding membrane-spanning transporters, using
GAPDH as a reference gene, and by using the comparative 2Ct method.
Results: Colonic expression of SLC7A5 and SLC3A2 (together comprising the
amino acid transporter LAT1þ 4F2hc) was significantly lower in IBS patients,
but not in PI-IBS patients, compared to healthy controls (P5 0.001). The expres-
sion of SLC7A8 (LAT2) tended to be lower in IBS patients compared to controls
(P¼ 0.06). Mucosal gene expression of the short chain fatty acid transporter
SMCT1 (SLC5A8) was lower in both IBS-patients and PI-IBS patients compared
to healthy subjects (P5 0.01).
Conclusion: The amino acid transporters LAT1 and LAT2 appeared to be
affected in IBS patients, but not in PI-IBS patients, compared to healthy subjects,
suggesting a possible alteration in amino acids transport in this patient group.
Furthermore, our results suggest a lower uptake of short chain fatty acids in both
IBS- and PI-IBS patients. Altered expression of these transporters may be
involved in the pathophysiology of IBS as well as being a potential biomarker
of this aberration, and therefore deserves further study in IBS.
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Introduction: Most colonic diverticulitis can be conservatively treated, but some
need surgical intervention due to intestinal complications. Risk factors associated
with complications of diverticulitis have been reported mainly from Western
countries, but few from Asian countries including Japan.
Aims & Methods: In this study, we aimed to determine risk factors for complica-
tions of colonic diverticulitis in Japan. Two hundreds and eighty-two patients with
acute diverticulitis who were hospitalized from November 2011 to November 2016
in our hospital were studied. Diagnosis of diverticulitis was based on symptoms,
physical examination, blood tests, and results of computed tomography. We retro-
spectively collected data of medical history, examinations, and therapy. Risk fac-
tors associated with complications were analyzed by using logistic regression.
Results: Of the 282 patients, 183 (64.9%) patients had right-sided diverticulitis,
and 70 (24%) had complications; perforation (n¼ 53), fistula (n¼ 8), abscess
(n¼ 5) and stenosis (n¼ 4). The rate of complication was highest in sigmoid
colon (88.6%) when compared with other locations; ascending colon (10%),
transverse colon (1.4%), and descending colon (0%). Multivariate analysis iden-
tified the location of sigmoid colon (odds ratio 62.2, 95% confidence interval
21.8–178.0) as a significant independent factor for complications of diverticulitis.
Among 70 patients with complicated diverticulitis, 55 (78.6%) patients under-
went emergent surgery; most of them (54 patients, 98.2%) were with diverticulitis
in the sigmoid colon.
Table. Risk factors associated with complications of colonic diverticulitis (uni-
variate and multivariate analysis)
Factor
Univariate Multivariate
Odds ratio
(95%CI) p-value
Odds ratio
(95%CI) p-value
Age Per 10-year
increment
NA 1.37 (0.99–1.89) 0.055
Sex Male 1.72
(0.95–3.19)
0.07
Female 1
Body mass index =25 2.13
(1.1–4.09)
0.019 1.79
(0.57–5.61)
0.32
525 1
Time from symptom
onset to diagnosis
=3 2.13
(1.13–4.02)
0.017 2.60
(0.97–6.91)
0.056
53 1
Fever =38 1.36
(0.71–2.55)
0.349
538 1
Current smoking Yes 0.82
(0.38–1.67)
0.616
No 1
Current drinking Yes 0.99
(0.51–1.91)
1
No 1
High blood pressure Yes 4.97
(2.66–9.39)
50.001 0.48
(0.14–1.62)
0.24
No 1
(continued)
Continued
Factor
Univariate Multivariate
Odds ratio
(95%CI) p-value
Odds ratio
(95%CI) p-value
Hyperlipidemia Yes 2.39
(1.07–5.21)
0.023 1.22
(0.31–4.73)
0.77
No 1
Diabetes Yes 1.27
(0.34–4.07)
0.77
No 1
Non-steroidal anti-
inflammatory drugs
Yes 0.6
(0.06–2.89)
0.736
No 1
Steroid/
Immunosuppressive
drugs
Yes 4.84
(1.11–24.1)
0.017 1.81
(0.26–12.4)
0.55
No 1
Antiplatelet/
Anticoagulant drugs
Yes 4.95
(1.0–12.7)
50.001 2.68
(0.59–12.2)
0.2
No 1
Location of
diverticulitis
Sigmoid colon 85.8
(34.3–243)
50.001 62.2
(21.8–178)
50.001
The other locations 1
Conclusion: The sigmoid colon was a significant risk factor for complication of
colonic diverticulitis in Japanese patients. Acute colonic diverticulitis in the sig-
moid colon should carefully be treated with surgical interventions in mind.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Colonic diverticulosis is one of the most common gastroenterolo-
gical disorders. Though diverticulosis is typically benign, many individuals
develop diverticular disease (DD). DD is thought to stem from a complex inter-
action of environmental, dietary and genetic factors; however, the exact patho-
genesis remains unknown.
Aims & Methods: The aim of our present study was to determine the role of
genetic variation within genes encoding for collagens of the connective tissue in
the development of diverticulosis. Genetic polymorphisms COL3A1 (rs3134646,
rs1800255) and COL1A1 (rs1800012) were genotyped in 422 patients with diver-
ticulosis and 285 controls of Caucasian descent using TaqMan assays.
Results: All genotype distributions did not deviate from the Hardy-Weinberg
equilibrium. Overall, rs3134646, rs1800255 and rs1800012 were associated with
diverticulosis. After multivariate logistic regression analysis, they were not linked
with the risk of developing colonic diverticulosis in general; when selectively
analyzing genders, the minor allele (AA) in rs3134646 remained significantly
associated with diverticulosis in men (p¼ 0.037).
Conclusion: Our study shows that a variant of COL3A1 rs3134646 is associated
with risk of developing colonic diverticulosis in Caucasian men, while COL3A1
rs1800255 and COL1A1 rs1800012 were not associated with this condition in our
cohort of patients after adjusting for confounding factors.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Although symptoms occurs in only 20% of patients harbouring
diverticula, Diverticular Disease (DD) of the colon DD represents the 8th disease
as burden in USA. Several treatment are currently advised in managing those
patients, but their impact on the burden of the disease is unknown. The recent
DICA endoscopic classification has been developed and validated for the classi-
fication of DD, founding that treatment of DICA 1 and DICA 3 patients did not
impact significantly in terms of acute diverticulitis occurrence/recurrence and
surgery occurrence. Our aim was to assess the impact of using DICA classifica-
tion on the burden of DD in Italy.
Aims & Methods: We assessed retrospectively the overall and the cost/year of
treatments (mesalazine and/or rifaximin, or any other treatment, including pro-
biotics, fibers, systemic antibiotics and spasmolithics) in DICA 1, DICA 2 and
DICA 3 population. Analysis of diverticulosis prevalence was estimated accord-
ing to data population provided by Italian Institute of Statistics (ISTAT). Cost of
treatments were calculated according to data on drugs’ consumption collected
during the DICA study.
Results: According to 2015 ISTAT population data, we estimated that 48 mil-
lion of Italian people 460 years may have diverticulosis. According to our
enrolled population, we estimated that about 75% of diverticular population
are on DICA 1, about 30% on DICA 2, and about 13% on DICA 3.
According to the drugs’ consumption recorded during our study, we estimated
that overall about 679 million of euros could be spent in Italy in treating those
patients. In particular, 4387 million of euros are spent in DICA 1 population,
4203 million of euros in DICA 2 population, and488 million of euros in DICA
3 population. Considering that medical treatments did not show any significant
advantage when treating DICA 1 and DICA 3 people in terms of prevention of
acute diverticulitis occurrence/recurrence and surgery occurrence, we can esti-
mated that 4475 million of euros could be spent in Italy without any significant
benefit for DD population.
Conclusion: DD has a significant burden for National Health System in Italy.
DICA endoscopic classification may have a significant impact of this burden,
helping to select DD people who effectively need treatments in terms of preven-
tion of acute diverticulitis occurrence/recurrence and surgery occurrence.
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Introduction: Symptomatic Uncomplicated Diverticular Disease (SUDD) affects
about 20% of patients having diverticulosis. However, SUDD natural history is
not completely understood yet. Our aim was to assess the outcome of a cohort of
SUDD patients during a 13-year follow-up.
Aims & Methods: 185 patients suffering from SUDD were enrolled during 2000–
2002, and followed-up until 2015. Symptoms assessed were abdominal pain,
meteorism, bowel movement/day, and each of them was scored from 0 (min)
to 3 (max), with a sum ranging from 0 (min) to 12 (max). Also Visual Analogic
Scale (VAS) was provided in order to assess patients’ quality of life. Patients were
treated according to physician convenience (rifaximin, mesalazine, probiotics,
spasmolithics) only when symptoms occurred during the follow-up. Follow-up
visit was performed every 6 months or whenever patients consider it necessary.
Results: During the observational period, 47 patients were lost to follow-up.
Among them, 9 deceased for causes not related to diverticular disease. Acute
diverticulitis occurred in 14 patients (7.56% of the overall population): 6 patients
(3.24% of the overall population) underwent to surgery, and 2 patients (1.08% of
the overall population) deceased for peritonitis. The mean symptoms’ score was
7.5 at baseline, ranged between 6.6 and 9 during the follow-up, and was 8.4 at the
end of the observation. VAS score was 4 at baseline, ranged between 4 and 9
during the follow-up, and was 4.5 at the end of observation.
Conclusion: SUDD is a clinical entity that, although benign, significantly affects
quality of life of patients. Acute diverticulitis may occur in those patients, some-
times needs of surgical treatment, and may cause mortal complications, although
not frequent.
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Introduction: Fecal microbiota and metabolome may be altered in patients with
Symptomatic Uncomplicated Diverticular Disease (SUDD). In particular, we
found that Akkermansia muciniphila species were significantly increased in
SUDD patients when compared with asymptomatic diverticulosis and healthy
people, as well as PLS-DA analysis of NMR-based fecal metabolomics showed
significant discrimination between HC and AD patient. Our aim was to assess the
effect of current treatments for SUDD on fecal microbiota and fecal metabolic
profiling in those patients.
Aims & Methods: Thirteen consecutive female patients, living in the same district
and suffering from SUDD, were studied. Patients were treated with a 2-week
course of 30 g/day fiber supplementation (3 patients), 1.6 grams/day of mesala-
zine (3 patients), 900 billion/day of probiotic mixture VSL#3 (currently available
in Europe as VivoMixx, 3 patients), and 800mg/day of rifaximin (4 patients).
Stool samples were collected at entry (T0), at the end of the 2-week course of
treatment (T1), and after 30 (T2) and therefore after 60 days at the end of the
therapeutic course (T3). Real-time PCR was used to quantify targeted microor-
ganisms. High-resolution proton nuclear magnetic resonance (NMR) spectro-
scopy associated to Multivariate Analysis with partial least square discriminant
analysis (PLS-DA) were applied on the metabolite data set.
Results: The overall bacterial quantity did not differ before and after treatment
(p¼ 0.449). The overall amount of Akkermansia muciniphila species was signifi-
cantly reduced at T1 (p¼ 0.017) and T2 (p¼ 0.026), while at T3 it became similar
to that of T0 (p¼ 0.09). The amount of Lactobacilli group was increased in all
groups but not significantly at T1 and T2, while at T3 it became similar to that of
T0. All treatments showed the same results except for probiotic group, who had
higher and persistent amount of Lactobacilli up to T3. PLS-DA analysis of
NMR-based fecal metabolomics showed significant changes at T1 and T2,
while at T3 it became similar to that of T0. All treatment were showed the
same behaviour in influencing fecal metabolome except for rifaximin group, in
which we did not find any metabolic change neither at the end of treatment nor
during the washout period.
Conclusion: This preliminary study confirms that Akkermansia muciniphila may
play a pathogenetic role in the occurrence of SUDD. We found also that current
treatments for SUDD patients are able to influence metabolic activity in those
patients except for rifaximin.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0493 5-YEARS ITALIAN REGISTER OF DIVERTICULOSIS AND
DIVERTICULAR DISEASE (REMAD): A LOW PROGRESSION RATE
OF DISEASE DURING THE FIRST YEAR OF FOLLOW-UP
M. Carabotti
1, R. Cuomo2, G. Barbara3, F. Pace4, P. Andreozzi5, R. Benini6,
B. Annibale7
1University Sapienza, Rome/Italy
2University of Naples ´́Federico II, Naples/Italy
3Department Of Medical And Surgical Sciences, University of Bologna, Bologna/
Italy
4Gastroenterology, Bolognini Hospital, Seriate (BG)/Italy
5Clinical Medicine And Surgery, University Of Naples " Federico Ii", Naples/Italy
6CD Pharma, Milano/Italy
7Department Of Medical-surgical Sciences And Translational Medicine,
Sant’Andrea Hospital, University Sapienza, Rome/Italy
Contact E-mail Address: mcarabotti@yahoo.it
Introduction: Natural history of colonic diverticulosis and diverticular disease
(DD) is poorly known, and available data derived mostly from retrospective
cohort studies.
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Aims & Methods: Aim of this study was to assess, in a cohort of patients with
colonic diverticula, the incidence of new cases of symptomatic uncomplicated
diverticular disease (SUDD) and diverticulitis, and recurrence of diverticulitis
after 1-year of follow-up. GRIMAD (Italian Diverticular Disease Group) pro-
moted the creation of REMAD (Register of Diverticular Disease) a prospective,
5-years, no-profit, cohort study involving 47 Italian centers. Each center enrolled
at least 20 consecutive patients during a period of two months. Inclusion criteria
were: informed consent; age 18years and endoscopic/radiological-confirmed
colonic diverticula. Outpatient/telephone visits were scheduled every 6 months.
The clinical data (patients’ characteristics and habits, characteristics of DD,
comorbidities and therapies) collected by participating centers were reported
on an electronic Case Report Form managed by CD Pharma, Milan. At entry,
patients were categorized according to the following criteria: i) diverticulosis
(presence of diverticula in the absence of abdominal symptoms); ii) SUDD
(recurrent abdominal symptoms as abdominal pain and/or changes in bowel
habit, in the absence of overt inflammation); iii) PD (patients who experienced
at least one episode of acute diverticulitis in the past). Patients were allowed to
continue their therapy for DD, if any. Logistic regression was performed to
identify patients’ features associated with new occurrence of SUDD and
diverticulitis.
Results: Overall, at baseline 1217 [556 (45.7%) female, median years 67 (28–95),
BMI 25.6Kg/m2 (16.2–43.4)] patients were enrolled: 707 (58.1%), 300 (24.7%),
and 210 (17.3%) with diverticulosis, SUDD, and PD, respectively. At 12 months,
922 patients (53.1%, 29.8%, and 17.1% with diverticulosis, SUDD, and PD)
were followed, and 27.4% of patients were lost at follow-up. In the 12 months
follow-up, 33 (6%) and 4 (0.7%) of diverticulosis patients developed SUDD and
acute diverticulitis, respectively; 4 (1.6%) of SUDD patients developed acute
diverticulitis, and in 14 (9.4%) of PD patients a new episode of acute diverticulitis
occurred. Overall, only 3 patients developed a complication, without need of
surgery. One year of follow-up logistic regression, showed that only female
gender was associated with subjects who changed subgroup from diverticulosis
to SUDD (OR 2.26, 95%CI 0.97–5.22). No specific features associated with
recurrence of diverticulitis could be identified.
Conclusion: These preliminary data suggested that, during an observation period
of one year, progression from diverticulosis to SUDD occurred in less than a
tenth of patients, and was associated with female gender. Overall incidence of
diverticulitis was very low (2.3%), whereas recurrent diverticulitis was not
uncommon. This observational study suggested, that although the vast majority
of patients did not show progression of disease, in those who progressed one in
ten tended to relapse during follow-up.
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Introduction: In the vast majority of patients colonic diverticula remain asympto-
matic (diverticulosis), while about 20% develop recurrent abdominal symptoms
(symptomatic uncomplicated diverticular disease, SUDD) or complications
(diverticulitis), with subsequent impact on quality of life (QoL). To date, clinical
features associated with each subgroup are not fully understood.
Aims & Methods: Aim of this study was to assess, in a cohort of patients with
colonic diverticula, the clinical features and QoL scores associated with each
subgroup of patients. GRIMAD (Italian Diverticular Disease Group) promoted
the creation of REMAD [(Register of Diverticular Disease (DD)] a 5-years pro-
spective, no-profit, cohort study involving 47 Italian centres. Each centre enrolled
at least 20 consecutive patients during a period of 2 months. Inclusion criteria
were: informed consent; age 18years; endoscopic/radiological-confirmed colo-
nic diverticula. The clinical data [patients’ characteristics and habits, character-
istics of DD, treatment, and QoL (SF-12 questionnaire with evaluation of
physical and mental component summary scores (RPCS12 and RMCS12)] col-
lected by participating centres were reported on an electronic Case Report Form
managed by CD Pharma, Milan. At entry, patients were categorized into sub-
groups according to the following criteria: i) diverticulosis (presence of diverti-
cula in the absence of abdominal symptoms); ii) SUDD (recurrent abdominal
symptoms as abdominal pain and/or changes in bowel habit, in the absence of
overt inflammation); iii) PD (patients who experienced at least one episode of
acute diverticulitis in the past). Patients were allowed to continue their therapy
for DD, if any. T test was used to compare QoL scores. Logistic regression was
performed to identify patients’ features associated with the presence of subtypes
of DD. A p value 50.05 was considered statistically significant.
Results: 1217 patients were enrolled. Characteristics of each subgroup of patients
are reported in the table.
N(%)
Diverticulosis
n¼ 707
(58.1)
SUDD
n¼ 300
(24.7)
PD
n¼ 210
(17.3)
OR
(95% CI)
Female 276
(39)
174
(58)
106
(50.5)
*2.18
(1.60–2.95) #2.06
(1.43–2.98)
Age years median
(range)
67
(34–93)
67
(37–90)
65
(28–95)
#2.33
(1.53–3.57)
BMI Kg/m2 median
(range)
25.6
(16.2–40.8)
26
(18–41)
25.3
(16.6–43.4)
ns
Family history for DD 129
(18.2)
65
(21.7)
60
(28.6)
#1.73
(1.15–2.60)
Gastrointestinal
(GI) comorbidities
224
(31.7)
134
(44.6)
69
(32.8)
*1.65
(1.21–2.25)
Charlson Index 43 108(15.3) 41(13.6) 26(12.3) ns
p value
RPCS12 (mean) 48.5 46.1 47.0 *0.0002;
# 0.0302
RMCS12 (mean) 48.2 45.0 45.9 *50.0001;
#0.0048
*diverticulosis vs SUDD; #diverticulosis vs PD; ns: not significant
Conclusion: These data showed that, with respect to diverticulosis, female gender
and presence of GI comorbidities are associated with SUDD, whereas younger
age, family history for DD and female gender are associated with PD.
Furthermore, patients with diverticulosis have higher physical and mental
scores compared both to patients with SUDD and PD, suggesting that SUDD
and PD reduced QoL of the affected patients.
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Introduction: Patients with symptomatic uncomplicated diverticular disease
(SUDD) and those with diverticulits share similar clinical patterns characterized
by abdominal pain or changes of bowel habits. In clinical practice, differential
diagnosis between the two conditions may be useful in the diagnostic approach
and therapeutic management.
Aims & Methods: Our aim was to assess the features of abdominal pain in
patients with SUDD and previous diverticulitis (PD). GRIMAD (Italian
Diverticular Disease Group) promoted the creation of REMAD (Registry of
Diverticular Disease), a prospective, 5-years, no-profit, cohort study involving
47 Italian centers. All patients were enrolled during a 2 months-period. At entry,
patients were categorized according to the following criteria: i) diverticulosis
(presence of diverticula in the absence of abdominal symptoms); ii) SUDD
(recurrent abdominal symptoms in the absence of overt inflammation); iii) PD
(patients who experienced at least one episode of acute diverticulitis). Patients
who fulfilled criteria for diagnosis of SUDD and PD were asked to fill in two
questionnaires assessing features of short pain (524 h) and long-acting pain
(424 h) in the last 6 months. Both questionnaires assessed patterns of pain,
including severity (evaluated by means of a 10-cm VAS), localization, association
with clinical parameters (fever, confinement to bed, medical consultation, anti-
biotic therapy and hospital admission). Data were expressed as percentages and
means standard deviations. P5 0.05 was considered significant.
Results: 1217 [556 (45.7%) female, age 66.1 9.9y] consecutive patients were
enrolled in the study. 300 (24.7%) and 210 (17.3%) fulfilled criteria for SUDD
and PD, respectively. Among them, 223 patients with SUDD (74.3%) and 154
patients with PD (73.3%) accepted to fill in short-lasting pain questionnaire,
whereas 156 patients with SUDD (52.0%) and 140 patients with PD (66.6%)
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filled in long-lasting pain questionnaire. Abdominal pain lasting 524 h was
reported by 192/223 patients with SUDD (86.1%) and 119/154 with PD
(77.3%)(p¼ 0.026). Symptom severity score was higher in PD group than in
SUDD group, but this difference was not statistically significant (5.5 2.4 vs
5.1 2.2 cm; p¼ 0.130). Patients with PD had short-lived pain located more
frequently in left lower abdomen (50.6% vs 39.9%;p¼ 0.002), whereas abdom-
inal diffuse pain was more prevalent in patients with SUDD (29.6% vs
20.8%;p¼ 0.058). Pain lasting 424 h was more prevalent in PD group compared
to SUDD group (62.1% vs 52.6%;p¼ 0.029). Pain severity was higher in patients
with PD, but this difference was not significant (6.4 2.6 vs 5.9 2.4;p¼ 0.069).
Long-lasting pain was more frequently located in left lower abdomen in patients
with PD (53.6% vs 23.7%;p5 0.01), whereas more frequently was diffuse in
SUDD patients (17.3% vs 7.1%;p5 0.001). Moreover, in patients with PD,
pain lasting 424 h was more often associated to fever (28.6% vs 6.4%;
p5 0.001), confinement to bed (35.7% vs. 18.6%; p¼ 0.002), medical consulta-
tion (38.6% vs 23.7%;p¼ 0.013), need for therapy (42.9% vs 19.2%;p5 0.001),
and hospitalization (28.6% vs 8.3%;p5 0.001).
Conclusion: SUDD and PD patients show some peculiar clinical features of
abdominal pain. SUDD patients frequently complained abdominal diffuse and
short lasting pain. In contrast patients with PD frequently complained pain
located in the left lower abdomen lasting for more than 24 h. Our results suggest
that these features are useful indicators to distinguish patients with SUDD and
PD and should be carefully assessed in clinical work-up of diverticular disease.
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Introduction: Colonic diverticulosis, as well as diverticular disease, is a multi-
factorial disorder characterized by neuro-muscular alterations consisting in
impaired contraction, inflammation and fibrosis. Mesenchymal smooth muscle
cells (SMC) are able to switch from a contractile phenotype to a less mature
synthetic phenotype, characterized by a loss of differentiation with decreased
expression of contractile markers as well as synthesis and release of several
pro-inflammatory cytokines. Different organ specific pathways have been
demonstrated to induce this mesenchymal transition. Renal fibrosis is driven
by transforming growth factor-b (TGF-b) through inverse regulation of
Smad2/3 while vascular fibrosis by PDGF-b, ending in downregulation of
marker gene Trb3 expression.
Aims & Methods: Aim of this study was to determine, both in human uninvolved
and involved tracts of asymptomatic diverticulosis (AD, ADþ) and in stenotic
segments of complicated diverticular disease (CDD), the alterations intrinsic to
smooth muscle. Circular and longitudinal smooth muscle strips and cells (SMC)
were isolated separately from surgical colon specimen of 18 patients
(585 age5 80years) affected either by sigmoid AD (6) or CDD (6) and patients
(615 age5 80years) submitted to surgery for cancer (6) (CTR). Contraction was
tested in response to carbachol and relaxation in response to VIP. qPCR analysis,
expressed as Relative Quantification, was performed for transcription of mRNA
encoding for TNF-, inflammasome components (NLRP3, ASC, CASP1, IL-1b)
and for SMC phenotypic switch molecules (Collagen I, -SMA, TGF-b, PDGF-
b, Trb3, Smad2/3). Data were normalized to b-actin mRNA and expressed as
meanSE. In addition, the activation of inflammasome complex was indirectly
tested trough quantification of IL-1b secretion by commercial ELISA kit.
Results: In both muscle layers, AD and ADþ SMC, compared to CTR, showed
an overall increase in inflammatory gene expression, with a trend of decrease
from AD to ADþ, the lowest expression been observed in CCD. This inflam-
matory state was associated with an increase in IL-1b secretion in SMC culture
medium compared to CTR and a progressive inhibition of contraction to carba-
chol, already in AD in circular strips and SMC. In contrast relaxation in
response to VIP resulted significantly decreased only in ADþ both on strips
and SMC with no alteration in AD and CDD. Peculiarity of circular SMC
was a progressive increase in Coll1 expression from AD to CDD compared to
CTR (3 hundred fold increase) paralleled to about 50% decrease in the contrac-
tile protein -SMA. Differently, longitudinal SMC, both in AD and CDD, pre-
sented a homogenous increased Coll1 expression, decrease in -SMA and
reduction of contraction. VIP-induced relaxation was significantly decreased in
CCD. Phenotypic switch was only observed in CDD, driven in circular layer, by
a TGF-b-dependent pathway (increased expression for TGF-b: 2.88 0.6 and
Smad3: 1.67 0.12 and reduced Smad2: 0.39 0.11) while in longitudinal driven
by PDGF-b-dependent pathway (increase of PDGF-b: 2.27 0.44 and parallel
decrease of Trb3: 0.58 0.13).
Conclusion: Intrinsic myogenic alterations are present in colonic asymptomatic
diverticulosis and complicated diverticular disease, both in the circular and
longitudinal layers characterized by a myogenic pro-inflammatory state and an
impaired contractile activity that, in complicated diverticular disease, ended in a
muscular synthetic pro-fibrotic switch.
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Introduction: Aberrant Notch activation has been implicated in multiple malig-
nancies, including gastric cancer (GC). However, the clinical significance of
Notch receptors and their functional role in gastric carcinogenesis remain
unclear.
Aims & Methods: We aim to delineate the dysregulated Notch signaling in GC
and comprehensively reveal its activation by silenced microRNAs (miRNAs) in
gastric carcinogenesis. The expression clinical relevance of NOTCH1-4 in GC
were achieved from online available dataset. The mRNA and protein expression
of NOTCH3 were examined by qRT-PCR and Western blot. The biological
function of NOTCH3 in GC was demonstrated by MTT proliferation, mono-
layer colony formation, cell invasion and migration assays through siRNA-
mediated knockdown. The prediction of miRNAs which potentially target
NOTCH3 was performed by www.microRNA.org and TargetScan. The regula-
tion of NOTCH3 by putative miRNAs was confirmed by qRT-PCR, Western
blot and dual luciferase activity assays through ectopic overexpression of miR-
491-5p and miR-875-5p. The functional downstream targets of NOTCH3 were
identified by gene expression microarray.
Results: NOTCH3, but not NOTCH1, 2, 4, is uniformly up-regulated and sig-
nificantly correlated with poor survival in multiple GC datasets. Knockdown of
NOTCH3 in AGS and MKN28 cells exhibited significant anti-oncogenic effect
in vitro. NOTCH3 downregulation suppressed cell proliferation, reduced mono-
layer colony formation, and inhibited cell invasion ability. Moreover, NOTCH3
knockdown significantly promoted cleaved caspase-3 and cleaved-PARP expres-
sion to induce apoptosis, which was further revealed by the gene set enrichment
analysis (NCBI/GEO/GSE57303 and NCBI/GEO/GSE57303 database).
NOTCH3 was further confirmed to be a direct target of tumor-suppressive
miRNAs, miR-491-5p and miR-875-5p. Enforced overexpression of miR-491-
5p and miR-875-5p in GC cells also exerted tumor-suppressive function by inhi-
biting cell proliferation and inducing apoptosis. More importantly, the expres-
sion of miR-491-5p showed negative correlation with NOTCH3 mRNA
expression in primary GC samples and re-overexpression of NOTCH3 rescued
the inhibitory effect of miR-491-5p and miR-875-5p. Pleckstrin Homology Like
Domain Family B Member 2 (PHLDB2) is identified as the functional down-
stream of NOTCH3 in GC. Concordantly, PHLDB2 knockdown significantly
inhibited cell proliferation and promoted apoptosis, which phenocopied
NOTCH3 knockdown or miR-491-5p/miR-875-5p overexpression. In primary
GC samples, the expression of PHLDB2 and NOTCH3 showed positive correla-
tion in The Cancer Genome Atlas (TCGA) cohort. Thus, the miR-491-5p/miR-
875-5p-NOTCH3-PHLDB2 oncogenic cascade was constructed.
Conclusion: NOTCH3 is over-expressed and plays an oncogenic role in gastric
carcinogenesis through its direct downstream PHLDB2. The activation of
NOTCH3 in GC is partly due to the silence of tumor-suppressive miRNAs,
miR-491-5p and miR-875-5p. These findings comprehensively revealed the acti-
vation of Notch signaling pathway and provided clinical translational potential
for GC.
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Introduction: We found that tumor suppressor gene FOXF2 was silenced in
gastric cancer (GC) through promoter hypermethylation. Restoration of
FOXF2 suppressed GC tumorigenicity through inhibition of canonical Wnt
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signaling pathway. However, the molecular mechanism of FOXF2 in GC is still
unknown.
Aims & Methods: We hypothesize that FOXF2 transcriptional upregulates a
novel E3 ligase that targets b-catenin for degradation. We aim to investigate
the molecular mechanism of FOXF2 in GC and identify such E3 ligase by
PCR array, Chromatin Immunoprecipitation (ChIP) assay and luciferase assay.
Results: FOXF2 significantly decreased both nuclear and cytosolic levels of b-
catenin in a GSK-3b independent manner and promoted b-catenin degradation
via ubiquitin-proteasome pathway in gastric cells. Using Human Ubiquitin
Ligases RT2 Profiler PCR Array and western blot, we identified that
IRF2BPL was upregulated upon FOXF2 overexpression and was a promising
E3 ligase for b-catenin. Overexpression of IRF2BPL suppressed the TOP-flash
luciferase reporter and reduced Wnt target gene c-myc expression in GC cells.
Overexpression of IRF2BPL significantly increased b-catenin ubiquitination and
reduced b-catenin protein without alteration of its mRNA level. Conversely,
knockdown of IRF2BPL significantly decreased endogenous b-catenin ubiquiti-
nation. Immunoprecipitation assay suggested that IRF2BPL interacted with b-
catenin. These results reveal that IRF2BPL is a potential E3 ligase that targets b-
catenin for degradation. To investigate whether FOXF2 directly regulates
IRF2BPL transcription, we performed ChIP assay and found that FOXF2
bound on to the IRF2BPL promoter region. We cloned the IRF2BPL promoter
region (-2700 bp to TSS) into pGL3-basic plasmid and performed a luciferase
activity assay. Wild-type FOXF2 but not the mutant FOXF2 significantly
activated the luciferase reporter in AGS and 293 ft cells, suggesting that
FOXF2 directly activated IRF2BPL transcription. Moreover, FOXF2 signifi-
cantly increased the level of H3K27Ac (a marker to distinguish active from
inactive enhancer element) on the 5’-flanking region of IRF2BPL gene, suggest-
ing that FOXF2 positively regulated IRF2BPL gene transcription. In addition,
IRF2BPL was significantly downregulated in human GC tissues compared to the
adjacent normal tissues (N¼ 30, P5 0.01) by real-time PCR analysis. IRF2BPL
mRNA showed a positive correlation with FOXF2 in gastric cancer in a Chinese
cohort (N¼ 30, Spearman’s rho¼ 0.42, P5 0.05) and in the TCGA cohort
(N¼ 421, Spearman’s rho¼ 0.38, P5 0.001).
Conclusion: We reported a novel FOXF2-IRF2BPL-b-catenin signaling axis in
gastric cells. FOXF2 is a critical tumor suppressor in gastric carcinogenesis
through promoting b-catenin degradation by transcriptionally upregulating E3
ligase IRF2BPL.
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Introduction: Gastric adenocarcinoma with enteroblastic differentiation (GAED)
is a rare variant of gastric carcinoma. It is well known that GAED is associated
with poor prognosis [1, 2]. However, the clinicopathological and molecular bio-
logical features have not been elucidated enough. We performed comprehensive
analysis by next generation sequencing (NGS) to clarify the clinicopathological
features of GAED and to find new therapeutic targets.
Aims & Methods: Among 1003 patients with primary gastric cancer who under-
went surgery or endoscopic resection in our hospital between April 2008 and
February 2017, we enrolled 52 cases (early:17, advanced:35) of GAED defined as
having tubular to papillary or solid structure with clear cytoplasm and immuno-
histochemical positivity for at least one of the following antibodies; AFP,
Glypican-3 and SALL4. NGS was performed for 24 cases of formalin-fixed
paraffin-embedded samples (early: 2, advanced: 22) using Ion PGM
TM
system
with cancer hotspot panel v2 targeting 50 genes (Thermo Fisher Scientific).
Immunohistochemical staining (IHC) was carried out to validate genetic altera-
tions. We also analyzed the association among these genetic alterations, clinico-
pathological factors and prognosis.
Results: As a previous study has shown, lymphatic and venous invasion, lymph
nodes metastasis and liver metastasis were frequently observed in this tumor
(67.3, 67.3%, 69.2% and 32.7%, respectively). Immunohistochemically, even
though AFP positive rate was low (32.7%), most cases were diagnosed by posi-
tivity of either of other two markers; glypican-3 (80.8%), SALL4 (80.8%). There
were significant association between lymphatic invasion, liver metastasis and
prognosis. NGS revealed that most cases harbored TP53 mutation (19/24,
79.2%), and other mutations such as CTNNB1 (2/24, 8.3%), APC (1/24,
4.2%), ATM (1/24, 4.2%), FBXW7 (1/24, 4.2%) were also detected.
Compared with the public data of conventional gastric carcinoma (CGA) [3],
TP53 mutation rate was significantly higher in GAED (79.2% vs. 47.8%,
p5 0.01). However, there was no association between TP53 mutation and clin-
icopathological factors including patients’ prognosis. With regard to the correla-
tion between TP53 mutation and p53-IHC, all cases with TP53 missence
mutation (n¼ 12) showed p53 overexpression. We found p53 overexpression
by IHC in 29 out of 52 GAED cases (55.8%), however, this did not affect
patients’ prognosis. We also detected ERBB2 amplification in 9 out of 24 cases
(37.5%) by analyzing copy number variation, and this rate was significantly
higher than that reported in CGA (13.0%) (p5 0.01) [3]. Most of GAED with
ERBB2 amplification showed HER2 overexpression by IHC.
Conclusion: GAED shows generally aggressive behavior characterized by fre-
quent lymphatic invasion and liver metastasis. TP53 mutation rate and ERBB2
amplification rate in GAED is significantly higher than those of CGA. HER2
overexpression associated with ERBB2 amplification could be a new therapeutic
target in GAED.
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Introduction: Ten percent of all gastric cancers show familial aggregation and
may account for at least three syndromes1, 2: hereditary diffuse gastric cancer
(HDGC), gastric adenocarcinoma and proximal polyposis of the stomach
(GAPPS)3, and familial intestinal gastric cancer (FIGC)4. Whilst germline defects
at the CDH15, 6and APC7 genes have been found for HDGC and GAPPS
families, respectively, FIGC remains genetically unexplained.
Aims & Methods: We hypothesised that the rare FIGC syndrome is caused by
germline co-occurrence of moderate-risk alleles and represents a polygenic,
rather than a classical monogenic disease. Therefore, this study aimed at dissect-
ing the germline and somatic landscapes of the largest FIGC cohort ever studied.
Constitutional and tumour DNA from probands of 53 families, fulfilling clinical
criteria of FIGC, were screened for 55 candidate gastrointestinal cancer-asso-
ciated genes with Illumina’s MiSeq-platform, and classified according to the
American College of Medical Genetics and Genomics (ACMG) guidelines.
Somatic second hits, such as second mutation, loss of heterozygosity and pro-
moter methylation, were searched for in FIGC tumours at potentially causative
genes by PCR-Sequencing.
Results: Twenty-five out of 53 (47%) FIGC families harboured germline variants,
and co-occurrence of germline moderate-risk alleles was found in ten families.
From these ten families, seven harboured one pathogenic or likely pathogenic
variant combined with one or more unclassified novel variants. The remaining
three families carried solely clusters of novel unclassified variants. Moderate-risk
alleles of BRCA2, MAP3K6, MSH6, MSR1, SDHB and SDHD were the most
frequently found in this cohort. In addition, tumours arising in these 10 families
were enriched in somatic variants within DNA repair genes and often display
microsatellite instability phenotype.
Conclusion: The clinical homogeneity and relatively high number of FIGC
families herein studied allowed supporting the hypothesis that FIGC may be a
polygenic syndrome caused by moderate-risk alleles in gastrointestinal cancer-
associated genes.
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Introduction: Endoscopic submucosal dissection (ESD) is widely accepted to treat
large superficial esophageal neoplasms. However, esophageal stenosis after ESD
has become a key complication. To prevent such stenosis, we developed new
regenerative therapies that suppresses contracture and stenosis. About two weeks
prior to the esophageal ESD, autologous oral mucosal epithelial cell sheets were
fabricated from the patient’s own oral mucosal tissue. The cell sheets were then
endoscopically transplanted onto the ulcer surface immediately after ESD. To date,
this cell sheet treatment, which resembles cultured epidermal cell sheet transplanta-
tion in severe burn cases, has been clinically applied, and successful outcomes have
been obtained at several institutions in Japan and Sweden. In addition to prevent-
ing stenosis by the simple dressing of the ulcer’s surface area, anti-inflammatory
and wound-heal promoting functions of the cell sheets were expected.
Aims & Methods: For understanding the therapeutic effects of the cell sheet
transplantation, we investigated the morphological and histological features of
the human oral mucosal epithelial cell sheets, in addition to the cellular gene and
protein expressions. From a small biopsy of human volunteer donors’ oral muco-
sal tissue, we isolated and cultured epithelial cells, which were then fabricated
into transplantable cell sheets using a previously described procedure. The cell
sheets were examined by immunohistochemistry (IHC) and electron microscopy
as well as the gene and protein expression analysis by RT-PCR, with a DNA
array. Furthermore, the culture supernatant obtained immediately before the
transplantation, were analyzed with a cytokine array.
Results: Histological and morphological analyses revealed that tissue-engineered
stratified epithelial cell sheets have an apical-basal polarity, and that the junc-
tions between the basal cells of the sheets were significantly loose, due to dis-
sociating desmosomes, which were also fewer in numbers. IHC showed that the
expression levels of E-cadherin and desmosomal cadherins were downregulated
in the basal cells of the epithelial cell sheets, but mesenchymal markers (N-cad-
herin, vimentin, and fibronectin) were upregulated. Taken together, these find-
ings implied that epithelial mesenchymal transition (EMT) was induced in the
basal cells. The results of the cytokine array showed that the cell sheets secreted
EMT-related proteins, growth factors (progranulin and epiregulin), and antimi-
crobial proteins (b-defensin).
Conclusion: The EMT of the basal cell layer of epithelial cell sheets may con-
tribute to the improved engraftment after cell sheet transplantation. The secre-
tion of antibacterial peptides and various growth factors from the cell sheets
would exhibit anti-inflammatory effects, and promote wound-healing compared
to reinforcement of esophagus with absorbable synthetic materials such as poly-
mer membrane of polyglycolic acid and polylactic acid.
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Introduction: Obestatin, a 23-amino acid peptide derived from the ghrelin peptide
precursor, was originally isolated from stomach and characterized to bind selec-
tively to the G protein-coupled receptor GPR39 (1). We have recently described
the expression of obestatin/GPR39 system in healthy human stomach as well as
in human gastric adenocarcinoma. In healthy human stomachs, obestatin expres-
sion was observed in the neuroendocrine cells and GPR39 expression was loca-
lized mainly in the chief cells of the oxyntic glands. In human gastric
adenocarcinomas, the reported data strongly suggest the involvement of the
obestatin/GPR39 system in the pathogenesis and/or clinical outcome, and high-
light the potential usefulness of GPR39 as a prognostic marker in gastric cancer
(2). However, the physiological role of the obestatin/GPR39 system in healthy
stomach remains unknown.
Aims & Methods: To investigate the implication of the obestatin/GPR39 system
in the regulation of pepsinogen secretion. GPR39, obestatin and pepsinogen I
(PGI) expression was determined in the AGS cell line by immunocytochemistry;
and in endoscopic biopsies of human healthy stomachs by immunohistochemis-
try and immunofluorescence. PGI secretion was measured after exogenous
administration of obestatin (hemoglobin method, immunoblot) in AGS cells
and in an in vitro explant culture of human stomach tissues obtained from
surgical specimens after bariatric surgery. The influence of the acute GPR39
deficiency on PGI secretion was determined using siRNA GPR39.
Results: AGS cells expressed obestatin, GPR39 and PGI. In these cells, exogen-
ous administration of obestatin (200 nM, 40min) stimulated PGI secretion (60%
over control). This effect was exerted via the GPR39 receptor. In the human
healthy stomach, GPR39 expression was detected mainly in the chief cells of the
oxyntic glands but also in a few cells of the neck section (pre-chief cells). This
expression co-localized with PGI expression in both cell types. The mucous neck
cells were positive for PGI and negative for GPR39. Obestatin also exerted a
dose-dependent stimulatory effect on PGI secretion in the in vitro explant culture
of human stomach, being significant for 100 and 200 nM compared to the control
sample at 20min (39% and 66% over control, respectively), for 200 nM at 40min
(51% over control) and 100 nM at 60min (64% over control).
Conclusion: The obestatin/GPR39 system is physiologically involved in the sti-
mulation of pepsinogen secretion in the healthy human stomach.
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Introduction: Novel biomarkers for the diagnosis of esophageal adenocarcinoma
(EAC) are urgently required. Currently, there is increasing evidence suggesting
that serum exosomal miRNAs may be potential noninvasive biomarkers for
certain diseases. The objective of the present study was to find and investigate
whether exosomal miRNAs could be effective biomarkers for EAC.
Aims & Methods: In the present study, exosomes were isolated from the serum of
both EAC patients and normal controls. Total RNA was extracted from exo-
somes and miRNA levels were compared between EAC and control patients in
serum exosomes. We also sought to investigate the relevance of exosomal
miRNA expression to clinicopathological factors in EAC.
Results: We measaured levels of several exosomal miRNAs, including miR-21,
miR-16, miR-25, miR-155, miR-192, miR-92a, in 9 EAC patents and 9 controls.
Theses miRNAs were chosen because they have been shown to function as onco-
miRs in previous studies. Levels of miR-21, miR-16, miR-25 and miR-155 were
significantly higher in EAC patients than in controls (fold- change 35.36, 30.87,
9.24 and 2.26, respectively). The level of miR-192 was significantly lower in EAC
patients than in controls (Fold-change: 0.35). We did not observe a significant
fold-change in miR-92a expression levels between EAC and controls. P-values
did not achieve statistical significance, possible due to large standard deviations
and relatively small sample sizes. We also visualized exosomes isolated from both
cell culture medium and sera of EAC patients and control subjects, with diameter
ranging from 30 to 100 nm using transmission electron microscopy.
Conclusion: Serum exosomal miRNAs can be isolated, measured, and may serve
as potential biomarkers in EAC patients. miRNA microarray or next-gen
sequencing analyses and larger sample sizes are needed to validate these early
results.
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Introduction: Endoscopic variceal band ligation (EVL) is an effective procedure
to control and prevent variceal bleeding in patients with liver cirrhosis. Although
EVL has some complications, yet these complications are related to post-EVL
ulcers. Few data exist regarding therapy of post-ligation ulcer and treatment been
mostly empirical with drugs used for peptic ulcer diseases.
Aims & Methods: We aimed to compare between the efficacy of rebamipide,
sucralfate and pantoprazole in treatment of post banding variceal ulcers.
Seventy-five patients with oesophageal varices eligible for elective band ligation
represented the population of the study. The patients were allocated into three
groups; rebamipide group, they received rebamipide 100mg 3 times daily; pan-
toprazole group, they received pantoprazole 40mg/day orally at morning; sucral-
fate group, they received sucralfate 1 gm every 6 hours, for 14 days beginning at
the next day of band ligation. Subjects underwent EGD 14 days after banding.
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Primary outcomes included the size and number of ulcers and the subjects’
reports of bleeding, dysphagia, chest pain and vomiting.
Results: At follow-up endoscopy, the number of patients with post-band ulcers
and size of ulcers were similar in the three groups. However, the number of ulcers
for each patient is statistically significant less in rebamipide group when com-
pared to pantoprazole and sucralfate (P5 .001). Chest pain, dysphagia and
vomiting scores were not significantly different. Dysphagia was by far the most
common symptom with no case of bleeding was reported in all patients of the
studied groups.
Conclusion: Rebamipide is effective in decreasing the post banding complication
and reducing size of ulcer as well as the number of ulcers with no significant effect
on post banding ulcer formation. Rebamipide can be used routinely in settings of
post-EVL as a good alternative to pantoprazole and sucralfate.
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Introduction: The over-the-scope-clip (OTSC) overcomes limitations of standard
clips and achieves a more efficient and reliable haemostasis in non-variceal upper
gastrointestinal bleeding (NVUGIB). The study aims to evaluate mortality,
rebleeding and mortality after rebleeding of patients in whom the OTSC was
used as first-line endoscopic treatment (FLET) of NVUGIB. Data on OTSC use
for NVUGIB in high-risk patients is currently limited.
Aims & Methods: In total, 118 patients (FLET cohort) with a median age of 73.5
years (range 29–93 years; mean (SD) 71.39 12.39 years) were included. The
distribution of patients with respect to risk category revealed a median Rockall
score (RS) of 7 (range 3–10; mean (SD) 7.25 1.51). For hypothesis testing, the
FLET cohort was categorized into 3 risk groups taking into account the Rockall
score: low risk (Rockall risk category (RRC) 3), moderate risk (RRC 4–7), and
high-risk (RRC 8). Event rates (mortality, re-bleeding and mortality after
rebleeding) observed per risk group were compared to predicted event rates
(Rockall cohort) using Fisher’s Exact Test.
Results: Primary successful haemostasis (PSH) was achieved in 92.4% either by
FLET alone or in combination with an additional haemostasis technique in 1.7%
(SCS¼ secondary clinical success). In 7.5 % of the FLET cohort PSH couldn’t be
achieved. Mortality in the FLET cohort was in the high-risk group (RRC 8)
lower compared to RRC prediction, but no significant difference. However mor-
tality after re-bleeding was significantly reduced from 27.9 % to 10.9 % in the
high-risk group (RRC 8) treated with FLET (p5 0.011). Furthermore, occur-
rence of re-bleeding or continued bleeding was significantly lower in the moder-
ate risk group (RRC 4–7) with 4.9 % as well as in the high-risk group (RRC 8)
with 21.4 % compared to RCC 24.0 % and 53.2 %, respectively, as predicted by
the Rockall scoring system (p5 0.001).
Conclusion: Our study shows that OTSC is superior to standard clipping techni-
ques and FLET of OTSC reduces significantly re-bleeding and re-bleeding asso-
ciated mortality in NVUGIB and it is for this reason we recommend FLET for
NVUGIB in high-risk patients.
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Introduction: Upper gastrointestinal bleeding can have various severities, with
some cases needing for intensive care while, others allow for patient to go
home. Thus, it is important to detect the patients who need endoscopic treat-
ment. The Glasgow Blatchford score (GBS) is currently regarded as the best
score for predicting endoscopic treatment (area under the receiver operating
characteristic curve (AUROC) 0.75)[1]. Contrast-enhanced CT is also useful
for patients with gastrointestinal bleeding [2]. However, it is a complicated pro-
cedure and it cannot be used for patients with renal failure.
Aims & Methods: The aim is to analyze the accuracy of the GBS and non-
enhanced CT in predicting the necessity of endoscopic treatment for patients
with upper gastrointestinal bleeding. This study was designed as a hospital-
based observation study. Patients who were hospitalized for upper gastrointest-
inal bleeding and had an endoscopy performed within 24 hours from April 2013
to March 2014 at Yodogawa Christian Hospital were studied. The clinical utility
of the GBS and CT were assessed separately and in combination
Results: A total of 113 patients were included in the study. The median GBS was
10 (interquartile range (IQR) 7–12). The score did not discriminate well with
AUROC of 0.63. The median CT number was 48HU (IQR 26.7–60.7). The
CT number also did not discriminate well with AUROC of 0.65. We set the
cut off for GBS at 4, and a CT number at 50HU. The endoscopic treatment
percentage of the group of GBS=4 and CT number=50HU was 63.5%, GBS=4
and CT number550HU was 30.6%, GBS54 and CT number=50HU was
33.3%, GBS54 and CT number 550HU was 11.1%. We counted that
GBS=4 was 1 point, CT number=50HU was 1 point. The points were added
up to a total score that predicts the necessity for endoscopic treatment. Those
scoring 2 points was about 60 percentage for the necessity for endoscopic treat-
ment, 1 points was about 30 percentage, 0 point was about 10 percentage.
AUROC of this model was 0.69.
Conclusion: Using both the GBS and CT in combination performed better for
predicting the necessity of endoscopic treatment for patients presenting with
upper gastrointestinal bleeding.
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Introduction: Fibrin glue can prevent bleeding after endoscopic submucosal
dissection.
Aims & Methods: We aimed to explore the utility of fibrin glue in prevention of
bleeding after endoscopic submucosal dissection and to investigate the risk fac-
tors for bleeding after endoscopic submucosal dissection. 330 patients who
underwent ESD between July 2015 and June 2016 in Jiangsu Province
Hospital were enrolled in this study, the patients were randomly divided into
two groups, fibrin glue was sprayed during the operation in 161 patients of
Group A, while 169 patients in group B were treated with routine hemostasis
method.postoperative bleeding was defined as hematemesis or melena or Hb
42 g/dL decrease after the end of ESD within 30 days. Delayed postoperative
bleeding was defined as bleeding 7 to 30 days after operation. Then bleeding rate
after ESD, average length of stay and average hospitalization expenses were
compared between the two groups to explore the clinical effect of fibrin glue.
37 patients experienced bleeding after ESD were grouped into bleeding group,
the remaining 293 patients were divided into non-bleeding group, several factors
were compared between the two groups to analyse the risk factors of bleeding
after ESD.
Results: There are no differences in age, gender, lesion location, underlying dis-
ease, taking anticoagulant drugs or not, invasive depth, pathological type and
procedure time between Group A and Group B. Bleeding rate after ESD was
lower in group A. (P5 0.05). And Intraoperative hemostasis rate was higher in
group A. (P5 0.05). 2 patients in group B experienced delayed postoperative
bleeding, while none in group A experienced delayed postoperative bleeding.
Patients in group B spent more time staying in hospital than group A, while
the average hospitalization expense was higher in Group B.37 patients experi-
enced bleeding after ESD, among whom 22 occurred within 24 hours after ESD,
13 within 1 week and 2 after 1 week. Univariate analysis revealed that resection
size and procedure time over 120 minutes are risk factors for bleeding after ESD.
The use of fibrin glue can reduce the bleeding rate after ESD. Multivariate
analysis revealed that resection size greater than or equal to 3cm and the absence
of fibrin glue are independent risk factor for bleeding after ESD.
Conclusion: The use of fibrin glue is safe, effective and economical in the proce-
dure of ESD. Resection size and procedure time over 120 minutes are risk factors
for bleeding after ESD. The use of fibrin glue can reduce the bleeding rate after
ESD. Resection size greater than or equal to 3cm and the absence of fibrin glue
are independent risk factor for bleeding after ESD. So adequate preparation and
close monitoring are needed during the procedure of ESD.
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Introduction: Proton pomp inhibitors (PPIs) have been widely used for the treat-
ment of endoscopic submucosal dissection-induced gastric ulcers. However, post-
operative bleeding is still one of the most important adverse side effects.1, 2
Vonoprazan (VPZ), a potaissium-competitive acid blocker, is a new class of
acid-suppressing agents, and it is expected to reduce bleeding after gastric endo-
scopic submucosal dissection (ESD) by strongly inhibiting gastric acid secretion
compared with PPIs.3
Aims & Methods: We compared the incidence of bleeding after gastric ESD
between subjects treated with VPZ and those treated with esomeprazole (EPZ).
Data for 101 patients who underwent gastric ESD from December 1, 2014 to
December 31, 2016 in Osaka City General Hospital and started to take VPZ
(n¼ 22) or EPZ (n¼ 79) by the day before ESD was reviewed. Twelve of them (3
in the VPZ group, 9 in the EPZ group) were excluded for simultaneous resection
of two or more sites. A case in which active bleeding or exposed vessels were
observed on the bottom of ulcers with hematemesis, melena or a drop of not less
than 2 g/dl of Hemoglobin within 4 weeks after ESD was defined as ‘‘post-ESD
bleeding’’. In addition, we perform second-look endoscopy on the day after ESD.
A case in which hemostasis was needed with hemorrhage of Forrest IIa or more
when we underwent second-look endoscopy was defined as ‘‘next-day hemostasis
case’’. We investigated retrospectively post-ESD bleeding rate and next-day
hemostasis rate in the VPZ group and the EPZ group.
Results: Gender, age, resected specimen diameter, oral antithrombotic drug
administration, and dialysis were not significantly different in both groups.
Two of the 19 patients in the VPZ group (10.5%) and 6 of the 70 patients in
the EPZ group (8.6%) had Post-ESD bleeding (Table). In addition, 6 patients in
the VPZ group (31.6%) and 37 patients in the EPZ group (52.9%) had next-day
hemostasis. There was no significant difference in both groups regarding post-
ESD bleeding (p¼ 0.678) and next-day hemostasis (p¼ 0.197). However, next-
day hemostasis rate was somewhat higher in the EPZ group than that in the VPZ
group. That is possibly because EPZ or VPZ was first administered mostly from
the day before ESD in both groups in our hospital, moreover, VPZ rapidly
inhibited gastric acid secretion after administration compared with PPIs.3
Table: Incidence of post-ESD bleeding and next-day hemostasis
Vonoprazan
group, n (%)
Esomeprazole
group, n (%) P-Value
Total 19 70
Post-ESD bleeding 2 (10.5) 6 (8.6) 0.678
Next-day hemostasis 6 (31.6) 37 (52.9) 0.197
Conclusion: VPZ didn’t significantly reduce post-endoscopic submucosal dissec-
tion bleeding compared with EPZ.
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Introduction: Acute gastrointestinal bleeding (AGIB) can carry poor outcomes
unless prompt endoscopic haemostasis is achieved. Hemospray is a novel pro-
prietary mineral blend that forms a mechanical barrier over the bleeding site
when applied endoscopically.
Aims & Methods: The primary aim of this international multicentre registry is to
collect data on the successful cessation of GI bleeding following application with
Hemospray. Secondary outcomes of recurrent bleeding (within 72 hours), 30 day
mortality, disease and procedure specific outcomes were also collected.
Method: Data was collected prospectively (January 2016 – April 2017) on the use
of Hemospray in acute upper and lower GI bleeding, from 3 initial centres in the
international registry. The use of Hemospray in GI bleeding was at the endosco-
pist’s discretion at the time of endoscopy. Hemospray use was either as mono-
therapy, as dual-therapy with standard endoscopic techniques or as rescue ther-
apy once standard methods had failed.
Results: To date 56 cases have been recruited (39 male and 17 female). The
Forrest Classification of the bleeding lesions were in 5 (9%) cases Forrest Ia
bleed, 41 (73%) Ib, 3 (5%) IIa, 4 (7%) IIb and 3 (5%) Forrest III bleed.
Sources of GI bleed included Peptic ulcer disease 24 (43%), post endoscopic
therapy 9 (16%), malignancy 11 (20%), inflammation 3 (5%), Mallory Weiss
tear 2 (4%), angiodysplasia 1 (2%), bleeding polyp 2 (4%), duodenal diverticular
bleed 1 (2%), oesophageal variceal bleed 1 (2%), post radiation 1 (2%), and
bleed post NGT insertion 1 (2%). A total of 48 patients (86%) achieved immedi-
ate haemostasis after Hemospray endoscopic therapy. 8 patients did not achieve
haemostasis. 2 managed conservatively, 1 treated by radiological intervention
and 5 died. Hemospray was used in 25 patients (45%) as monotherapy [haemos-
tasis achieved in 22/25 (88%)], in 22 patients (39%) in combination with other
modalities [haemostasis achieved in 17/22 (77%)] and in 9 patients (16%) used
as rescue therapy where other modalities failed [haemostasis achieved in
9/9 (100%)]. 9 patients (16%) were anticoagulated at the time of emergency
endoscopy. Haemostasis was achieved in all anticoagulated patients. There
were 6 cases of delayed re-bleeding of which 1 occurred in less than 24 hours
post initial endoscopy, 2 at 24–72 hours, 1 at 4–7 days, 1 at 7–14 days and 1 more
than 14 days after the initial endoscopy. There was no prior use of anticoagula-
tion in any of these patients. There were no reported immediate or delayed
complications from the treatment.
Conclusion: Early data from our registry show a high rate of immediate haemos-
tasis (86%) with Hemospray and an excellent safety profile. The imminet expan-
sion of this registry to other centres in Europe will provide invaluable data on the
efficacy of Hemospray in various disease and patient types over the coming years.
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Introduction: Current guidelines suggest dual antiplatelet therapy (DAPT), clo-
pidogrel or ticagrelor with aspirin, for patients with acute coronary syndrome.
Other indications of DAPT include recurrent ischemic stroke and peripheral
vascular disease. Gastrointestinal bleeding (GIB) is one of the most common
adverse effects of DAPT, potentially causing hospital admission and death.
Scanty information regarding safety of DAPT in Thailand is available.
Aims & Methods: The objectives were to determine cumulative incidence and risk
factors of GIB in patients received DAPT, clopidogrel with aspirin and ticagrelor
with aspirin among Thai patients.
A retrospective cohort study was conducted. We reviewed the medical records
of patients received clopigogrel with aspirin or ticagrelor with aspirin
between January 2013 and June 2015 at Ramathibodi hospital. In patients
with GIB, the endoscopic finding with stigmata of recent hemorrhage was also
recorded.
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Results: A total of 201 patients received clopidogrel with aspirin and 199 patients
received ticagrelor with aspirin were recruited. Mean standard deviation age
was 66.2 11.3 years and 63.3% of patients were male. The most common
indication of DAPT was acute coronary syndrome (85.4% in clopidogrel
group vs.100% in ticagrelor group). Duration of treatment with clopidogrel
and ticagrelor were 121.5 days vs. 231 days, respectively (p¼ 0.216). There
were 20 (10.1%) GIB events in clopidogrel group and 11 (5.5%) in ticagrelor
group. The most endoscopic findings of GIB was gastric erosion (44 % in clo-
pidogrel group vs. 66.7 % in ticagrelor group). Risk ratio (RR) of GIB event of
clopidogrel compared to ticagrelor was 1.84 [95% confidence interval (CI) 0.9–
3.7, p¼ 0.093]. By multivariate logistic regression analysis, duration of DAPT
5180 days (RR 3.28; 95% CI 1.89–5.69, p5 0.001) and history of previous GIB
were associated with GIB events (RR 10.35; 95% CI 6.04–17.71, p5 0.001).
Conclusion: Risk of GIB is almost two times higher among patients received
clopidogrel with aspirin compared to those received ticagrelor with aspirin.
Closed monitoring patients who had duration of DAPT 5180 days and previous
GIB might be minimized the risk of GIB event after receiving DAPT.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
1. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and second-
ary prevention of vascular disease: collaborative meta-analysis of individual
participant data from randomized trials. Lancet 2009; 373: 1849–1860.
2. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA Focused
Update of the Guidelines for the Management of Patients With Unstable
Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007
Guideline). J Am Coll Cardiol 2011; 57(19): 1920–59.
3. Serebruan VL, DiNicolantonio JJ, Can MM, et al. Gastrointestinal Adverse
Events after Dual Antiplatelet Therapy: Clopidogrel Is Safer than
Ticagrelor, but Prasugrel Data Are Lacking or Inconclusive. Cardiology
2013; 126: 35–40.
4. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first
reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with
acute coronary syndromes: rationale, design, and baseline characteristics of
the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J
2009; 157: 599–605.
P0512 REAL-LIFE ANALYSIS OF FREQUENCY, LOCATIONS AND
BLEEDING SOURCES IN UNSELECTED EMERGENCY PATIENTS
DURING NON-VITAMIN K ANTICOAGULANT (NOAC) THERAPY
AND COMPARISON TO CONTROLLED APPROVAL STUDIES
M. Raithel
1, H. Albrecht2, L. S. Maass2, S. Peter1, A.K. Kluger1, M.F. Neurath3,
A. F. Hagel2
1St. Marien Waldkrankenhaus, Erlangen/Germany
2University Clinical Center Erlangen, Erlangen/Germany
3Department Of Internal Medicine 1, University Clinical Center Erlangen,
Erlangen/Germany
Contact E-mail Address: martin.raithel@waldkrankenhaus.de
Introduction: Non-vitamin K direct oral anticoagulants (NOAC) are increasingly
used in thromboembolic disorders due to an efficacy at least equally as vitamin K
antagonists (VKA) and/or significantly higher saftey for intracerebal bleeding or
major bleedings of any source. In the approval studies, there was no generally
increased bleeding rate for all types of bleeding, but different gastrointestinal
bleeding (GIB) rates for apixaban, dabigatran, edoxaban and rivaroxaban.
Aims & Methods: The patient cohort included consecutive unselected patients
manifesting with a GI bleeding under anticoagulation in 2014. All patients who
were diagnosed with a GI bleeding under NOAC or VKA therapy in the emer-
gency department of the University Hospital Erlangen were analyzed. Their data
were entered in a registry and evaluated in terms of bleeding type, localization,
use of proton pump inhibitor and frequencies. These real-life results were then
compared with the published data from important approval studies, reporting
each on the above mentioned NOACs.
Results: In 213 patients with GI bleeding, 31 patients received VKA (14.5%) and
23 patients (10.8%, n.s.) had NOAC with major bleeding rates of 68% and 61%,
resp.. In patients with VKA 87% had an upper GIB, 12% a lower GIB, and none
had a rectal bleeding (0%). During NOAC therapy, a similar distribution was
found with 71% and 17%, but the proportion of rectal bleeding was higher with
10%.
This frequency of GIB rates in unselected emergency patients is significantly
higher than reported in the controlled NOAC approval studies that included
selected patients (1.8–3.6% GIB!). In these NOAC studies a lower rate of
upper GIB (55%, 0–71%), a higher rate for lower GIB (32%, 17–84%) and
rectal bleeding (15%, 10–47%) was found. Although NOACs are associated
with a lower rate for GIB than VKA in the setting of emergency patients,
NOACs show a shift of the type of bleeding to lower GIB or rectal bleeding
sources in our analysis from emergency patients and in the NOAC approval
studies. Only 50% of patients with NOAC were on proton pump inhibitor
therapy.
Conclusion: The frequency of GIB in everyday life is approximately 10% higher
than reported from the controlled NOAC studies, irrespective of the type of
anticoagulation used. NOACs were associated with a non-significantly lower
bleeding rate compared with VKA, but major GIB rates were similar. VKA
with a bioavailability of 100% after oral ingestion showed a tendency of
higher rates of upper GIB, while NOACs with a reduced GI absorption rate of
7–68% were found to occur more frequently at lower GIB sites. Thus, prior to
any anticoagulation, a pre-therapeutic risk analysis for the occurrence of GIB is
still required. Certain patient groups (anemia, aortic valve stenosis, renal insuffi-
ciency, NSAIDs, etc.) can benefit from proton pump inhibitor therapy, early
endoscopy with intervention, or NOAC differential therapy.
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Introduction: Small intestinal bacteria overgrowth (SIBO) is common in patients
with irritable bowel syndrome (IBS), and symptoms of IBS improve after treat-
ment of SIBO with antibiotics. Although the pathogenesis of SIBO specifically in
IBS patients is not well defined, intestinal dysmotility and immune activation are
likely involved.
Aims & Methods: We aimed to investigate the role of interstitial cells of Cajal
(ICC) and intestinal inflammation in the development of SIBO using a post-
infectious IBS (PI-IBS) mouse model. Sixty NIH mice were randomly assigned
in a 2:1 fashion into T.spiralis infected PI-IBS vs. healthy control group. Visceral
sensitivity was evaluated by measuring abdominal withdrawal reflex (AWR) in
response to colorectal distension (CRD) before infection and at 8-weeks post-
infectious (PI). Fecal consistency and the number of stool pellets were evaluated
by visual inspection. Intestinal bacteria counts from jejunum and ileum were
measured by quantitative real-time PCR to evaluate the presence of SIBO.
ICC density in ileum was evaluated by immunohistochemistry and expressed
as number of DMP-ICC per villus. Intraepithelial lymphocytes (IELs) in sections
of bowel was counted in hematoxylin and eosin (H&E) staining slice and
expressed as number of lymphocytes per 100 epithelial cells. Intestinal cytokine
levels (IL1-b, IL-6, Toll-like receptor-4 (TLR-4), IL-10) in the ileum were also
examined.
Results: PI-IBS mice demonstrated increased mean AWR scores, decreased pain
and volume thresholds compared with the control group suggested that infected
group as a good model of PI-IBS with visceral hyperalgesia. One-third of the PI-
IBS mice developed SIBO (SIBOþ/PI-IBS) and was more likely to have altered
stool form compared with SIBO negative PI-IBS (SIBO-/PI-IBS) mice but with-
out difference in mean number of fecal pellets and visceral sensitivity. There was
reduced number of ICC in SIBOþ/PI-IBS compared with SIBO-/PI-IBS mice
(0.47 0.35 vs. 1.58 0.89, P¼ 0.01) and control mice (1.44 0.77, P¼ 0.02).
IELs counts were higher in SIBOþ/PI-IBS mice compared with SIBO-/PI-IBS
mice in ileum (24.2 6.5 vs. 15.0 4.4, P¼ 0.01) and rectum (12.7 3.2 vs.
8.2 1.8, P¼ 0.01). In duodenum, jejunum, ileum, left colon and rectum, IELs
counts were significantly increased in PI-IBS group compared with control
group. No difference in inflammatory cytokine expression levels were detected
between the groups except for increased TLR-4 among PI-IBS mice compared
with the control group.
Conclusion: The development of SIBO in PI-IBS mice was associated with
reduced ICC density and increased IELs counts in the ileum. Our findings sup-
port the role of intestinal dysmotility and inflammation in the pathogenesis of
SIBO in IBS and may provide potential therapeutic targets.
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Introduction: Augmented chemosensitivity to capsaicin has been demonstrated in
approximately half of functional dyspepsia patients, as can be determined by the
oral capsaicin capsule test (Hammer et al, NGM 2008). Sensations induced by
gastric capsaicin are distinct from sensations induced by stimulation of mechan-
oreceptors (Hammer & Vogelsang, NGM 2007).
Aims & Methods: The aim of the study was to determine clinical characteristics of
FD patients with and without chemical hypersensitivity at baseline and after
capsaicin ingestion for 4 weeks. N¼ 49 outpatients with confirmed FD received
an oral sensitivity test with 0.75mg capsaicin at two occasions, before and after
ingesting 0.25mg capsaicin tid for four weeks. Symptomatic response to capsai-
cin at the initial test allowed stratification to a capsaicin positive (chemosensitive)
and a capsaicin negative (not chemosensitive) patient group. Symptom diaries for
upper and lower gastrointestinal symptoms (visual analogue scales) were com-
pleted in the week before and during capsaicin ingestion and weekly aggregate
symptom scores were calculated. Results are given as median; 25%/75%,
p5 0.05 was considered significant.
Results: 53% FD had a positive capsaicin test. Basic clinical characteristics (age,
gender, FD subtype, medication, psychological profile) were comparable in cap-
saicin positive and negative FD, but median daily aggregate upper gastrointest-
inal symptoms scores were significantly higher in capsaicin positive (median: 9.4;
5.4/11.7) than in capsaicin negative patients (6.6; 4.1/8.1) (p5 0.05). Median
scores for epigastric pain, nausea and epigastric distension were similar in cap-
saicin positive and negative patients (p4 0.05). On the contrary, capsaicin nega-
tive patients had significantly lower scores for satiety (p5 0.001) and epigastric
bloating (p5 0.01) than capsaicin positive patients. Lower abdominal symptoms
were comparable in capsaicin positive and negative patients at baseline (NS).
After capsaicin ingestion, aggregate upper gastrointestinal symptoms scores
were reduced by 3.3 (4.9/1.9; p5 0.001) in capsaicin positive and 2.6
(3.8/0.3; p5 0.05) in capsaicin negative patients. Lower abdominal symp-
toms scores after capsaicin ingestion were reduced by 1.0 (1.8/0.1;
p5 0.05) in capsaicin positive but not significantly altered (0.6; 1.7/þ0.9;
NS) in capsaicin negative patients. After long-term capsaicin ingestion, the cap-
saicin test turned negative in 53% of chemosensitive patients (p5 0.01).
Conclusion: Differences in upper GI symptoms distinguished capsaicin positive
and negative patients at baseline. Symptom improvement after long-term capsai-
cin ingestion was indirect proportional to the result during the initial capsaicin
test. Sensitivity to orally ingested capsaicin decreases after long-term capsaicin
ingestion.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
Hammer J, Führer M, et al. Neurogastroenterol Motil 2008; 20:125
Führer M, Vogelsang H, Hammer J. Neurogastroenterol Motil 2011;23:918
Hammer J, Vogelsang H. Neurogastroenterol Motil 2007;19:279
P0515 NUCLEAR LORICRIN AND A DYSREGULATION OF
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Introduction: Gastro-oesophageal reflux disease (GORD) is one of the most
common disorders encountered in clinical gastroenterology. GORD patients
can be categorised as having erosive oesophagitis or non-erosive reflux disease
(NERD), with the latter being more frequently encountered in clinical practice.
In NERD, even though the endoscopic presentation of the oesophageal mucosa
appears visibly normal, histological changes within the oesophageal epithelium
such as dilated intercellular spaces and basal cell hyperplasia are present, which
are indicative of an altered epithelial barrier (Tobey et al 1996).
Aims & Methods: Here, via immunohistochemical staining and subsequent
immunoflourescent (IF) microscopic analysis, we investigate differences in the
expression intensity, localisation and activity of key barrier function proteins
present within the stratified squamous epithelium of proximal and distal biopsies
derived from 13 patients with typical GORD symptoms. We compared this to
biopsies taken from 5 healthy controls. Endoscopic oesophageal mucosal biop-
sies were taken from 5 cm above the LOS (distal) and at 20 cm from the incisors
(proximal). Where no erosions were seen, NERD was confirmed by wireless pH
capsule.
Results: IF analysis of loricrin (LOR), exhibits upregulated expression levels in 11
out of 13 GORD biopsies when compared to controls. This is also accompanied
by an increased level of specific nuclear localisation, away from its more fre-
quently observed membranous or cytoplasmic site. In addition, IF analysis of
involucrin (INV), revealed sporadic regions of cytoplasmic localisation in multi-
ple GORD biopsies, different from the specific membranous localisation
observed in all control samples analysed. The transglutaminase-1 (TGM-1)
enzyme functions to reinforce barrier function through its ability to crosslink
LOR and INV during terminal differentiation in epithelial tissues at the cellular
membrane. Analysis of TGM-1 enzymatic activity was performed in all GORD
and control biopsies using a targeted assay combined with subsequent IF analy-
sis. When compared to controls, we observed a dysregulation in TGM-1 activity
levels throughout our GORD biopsies. This result also correlates with an
observed reduction in the expression of ADAM17, a regulator of TGM-1
activity.
Conclusion: The observed increase in nuclear LOR combined with the sporadic
cytoplasmic INV localisation, dysregulation of TGM-1 activity and reduced A17
expression levels in our GORD epithelial samples are all indicative of an altered
epithelial barrier present within these individuals. For the first time, we highlight
the importance of these barrier proteins in GORD pathogenesis. Further inves-
tigation into these barrier proteins and their associated signalling pathways could
provide possibilities for the development of novel therapies designed to specifi-
cally target patients suffering from GORD.
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Introduction: Ineffective esophageal motility (IEM) is frequently found in
patients with gastroesophageal reflux disease (GERD). Secondary peristalsis
functions to maintain an empty esophagus by clearing refluxed gastric contents.
Prucalopride, a high-affinity 5-hydroxytrypatamine 4receptors agonist, is useful
in the treatment of chronic constipation by improving colon motility.
Prucalopride also promotes secondary peristalsis in healthy adults (Clin Transl
Gastroenterol. 2016).
Aims & Methods: We aimed to determine whether prucalopride would augment
secondary peristalsis in reflux patients with IEM. After a baseline recording of
primary peristalsis, secondary peristalsis was stimulated by slow and rapid mid-
esophageal injections of air in 15 patients. Two separate sessions with 4mg oral
prucalopride or placebo were randomly performed.
Results: Prucalopride significantly increased primary peristaltic wave amplitude
(68.1 10.0 vs. 55.5 8.8mmHg, p¼ 0.02). The threshold volume for triggering
secondary peristalsis was significantly decreased by prucalopride during slow
(9.3 0.8 vs. 12.0 0.8mL; p¼ 0.04) and rapid air injection (4.9 0.3 vs.
7.1 0.1mL; p¼ 0.01). Secondary peristalsis was triggered more frequently
after application of prucalopride (55% [4370%]) than placebo (45%
[3350%]) (p¼ 0.008). Prucalopride didn’t change pressure wave amplitudes
during slow air injection (84.6 8.1 vs. 57.4 13.8mmHg; p¼ 0.19) or pressure
wave amplitudes during rapid air injection (84.2 8.6 vs. 69.5 12.9mmHg;
p¼ 0.09).
Conclusion: Prucalopride enhances mechanosensitivity of secondary peristalsis
and promotes motor properties of primary peristalsis in IEM patients. Our
study suggests that prucalopride could be a therapeutic option in the manage-
ment of GERD patients with significant esophageal hypomotility.
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Introduction: Symptoms compatible with diabetic gastroparesis (DG) affect up to
1 in 5 patients with type I diabetes mellitus. Those affected suffer postprandial
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nausea, vomiting, abdominal pain and impaired glycaemic control. Repeated
hospital admissions are common. Endoscopy is normal in most patients.
Impaired gastric function is thought to cause the condition. DG does not respond
reliably to intensive insulin regimes or prokinetic medications. Jejunal nutrition
(JN) is an option in patients that cannot maintain their weight. The benefits are
thought to follow improved nutrition and glycaemia; however, we have observed
that some DG patients eat normally during and after JN (i.e. a quasi-pharma-
cological effect). One explanation could be that DG represents a failure of oral
nutrition to ‘‘switch’’ the stomach from the fasted to the fed state. According to
this hypothesis, nutrition delivered direct to the small bowel triggers the release of
peptide hormones that induce normal gastric function.
Aims & Methods: The study tests the hypothesis that JN prior to a test meal
improves postprandial symptoms (primary outcome) and gastric function.
Diabetic patients with severe symptoms (gastroparesis cardinal symptom index
(GCSI) 427), diabetic controls (GCSI 514) and healthy controls entered a
randomized, double blind, controlled trial. An insulin/glucose infusion controlled
glycaemia. A JN feeding tube was placed at endoscopy with biopsies taken from
the stomach and duodenum. Either liquid nutrient (2 kcal/min) or water was
infused for 60min. Afterwards the Nottingham Test Meal was ingested (NTM
liquid: 400mL, 300 kcal; solid: 12 non-nutrient agar beads) 1. Symptoms were
documented by VAS, gastric function by MRI and the GI-peptide response was
monitored over 120min using published methodology. Bayesian methods pro-
vided 95% posterior ("credible") intervals and mixed model analysis compared
response to intervention and between groups.
Results: 9 DG patients, 9 diabetic and 12 healthy controls were recruited. There
was no difference in sex distribution, age, weight, medical history (e.g. duration
of disease) or endoscopic findings (including histology) between groups. DG
patients had more psychiatric co-morbidity and reported higher satiety, bloating
and pain after ingestion of the NTM than diabetic and healthy controls
(p5 0.05). Sensations were not affected by JN in the controls; however, fullness,
bloating and pain were reduced by JN in DG patients (p5 0.05). Compared to
water, JN induced a greater GI-peptide response (e.g. PP, GLP-1) and initial
liquid GE was slower (gastric content volume after meal: GCV0 31 13mL
higher, p¼ 0.019). Subsequent liquid GE was similar in both study conditions
(T50þ 3 8min, p¼ 0.727). Antral contraction wave (ACW) frequency was 2.7
(2.6–2.9)/min in health and was highest in diabetic controls (3.1 (2.7 to 3.3)/min).
Solid GE was more rapid after JN than water (2 (1 to 3) beads emptied @60min)
and, again, was highest in diabetic controls (3 (1 to 7) beads emptied @60min).
Numerically the GI-peptide response was less pronounced in both diabetic
groups than healthy controls; however, the difference was not significant and a
correlation with postprandial symptoms or gastric function was not identified.
J4G study results from mixed model analysis
Measurement
DG
Patient
JN
DG
Patient
Water
DM
control
JN
DM
control
Water
HV
control JN
HV
control
Water
median GCSI
(range)
30
(27–39)
4
(1–12)
7
(1–9)
Liquid GE
(T50) SE
68 7 72 11 55 7* 59 11* 75 7 79 11
Solid GE
(beads/hr)CI
3
(1–6)
2
(1–3)
3
(1–5)*
4
(2–8)*
3
(1–5)
2
(1–3)
ACW frequencyCI 2.9
(2.7–3.1)
2.9
(2.7–3.1)
3.1
(2.8–3.3)*
3.1
(2.8–3.3)*
2.7
(2.6–2.9)
2.7
(2.6–2.9)
Fullness
(VAS) SE
16 7x 27 11* 15 11 23 11 20 11 20 7
Nausea
(VAS) SE
4 9xx 8 9* 2 9 4 9 2 6 2 6
Bloating
(VAS) SE
16 12x 27 11* 4 6 5 7 5 7 5 7
Pain
(VAS) SE
2 6xx 12 6* 0 6 0 6 0 6 0 6
VAS - visual analogue score over course of study * p5 0.05 ** p5 0.01 vs. HV; x
p5 0.05 xx p5 0.01 JN vs. water infusion
Conclusion: This clinical study demonstrates beneficial effects of prior JN on
fullness, bloating and pain after a 400mL test meal in diabetic patients with
moderate-severe symptoms compatible with gastroparesis (GCSI4 27).
Additionally, solid GE was accelerated after JN; however, this effect was not
limited to DG patients and, thus, the treatment effect that improved symptoms
could not be identified. Few patients in the DG group had objective evidence of
abnormal gastric motor function and the benefit of "prior JN" on symptoms was
not limited to patients with slow GE. However, it was observed that diabetic
controls had relatively rapid ACW and solid GE. Future studies will identify
patients likely to benefit from this novel approach to treatment.
(ClinicalTrials.gov Identifier: NCT01919021, NCT00944593)
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IN OVER 500 PATIENTS
Z. Nabi, M. Ramchandani, R. Chavan, S. Darisetty, R. Kalapala, D.N. Reddy
Gastroenterology, Asian Institute of Gastroenterology, Hyderabad/India
Contact E-mail Address: zaheernabi1978@gmail.com
Introduction: Per-oral endoscopic myotomy (POEM) has emerged as an effica-
cious treatment modality for achalasia cardia (AC). Prior treatment (PT) may
affect the outcomes of subsequent. The impact of prior treatment on technical
and clinical success of POEM is not well known. Small studies with short follow-
up indicate that POEM is safe and feasible in PT failure cases. However, there is
paucity of large studies with long-term follow-up.
Aims & Methods: In this study we aim to compare the safety and efficacy of
POEM in treatment naı̈ve (TN) cases versus prior treatment (PT) failure cases.
The data of consecutive patients with AC who underwent POEM at a single
tertiary care center from (January 2013 to November 2016) was analysed retro-
spectively. A comparative analysis was performed between TN and PT failure
cases. Technical and clinical success, adverse events (AE), operative time (OT) for
POEM were compared between TN versus PT failure cases.
Results: Overall, 502 patients with AC underwent POEM during the study
period. 260 patients (51.8%) were TN and 242 (48.2%) patients had PT. Type
II AC was the most common subtype in both the groups (TN -63.5% vs PT –
57.8%) followed by type I and type III. There was no significant difference with
regards to AC subtypes between the two groups. The distribution of patients
according to prior treatment history is as follows – PBD (205), LHM (23), LHM
and PBD both (7), botulinum toxin injection (4) and POEM (3). Significantly
more patients in the PT group had sigmoid oesophagus (47 vs 18). Mean OT was
significantly more in the PT group when compared to the TN group (PT vs TN -
74.9 30.6 vs 67.0 27.1min; P¼ 0.002). On multivariate analysis- type of AC,
dilated esophagus (46 cm) and type of knife used were significant predictors of
OT. Technical (98.1% vs 97.1%, P4 0.05) and clinical success (94.9% vs 91.9%)
of POEM procedure was similar in TN and PT cases. Gas related events and
mucosotomies were equal in both groups (TN-35.7% vs PT-33.1%; p-0.57).
Objective evidence of gastroesophageal reflux was found in 17/53 patients
(32.1%) in PT group as compared to 11/44 (25%) in TN group (p-0.50).
Predictors of operative time on multivariate analysis
Factor OR p value 95% CI
1. Type of AC (III/I-II) 16.24 0.002 2.66 99.1
2. Esophageal diameter (46/56 cm) 2.76 0.012 1.24 6.13
3. Knife(TT/TTJ) 14.41 0.001 5.68 36.5
4. Adverse events 0.98 0.941 0.59 1.62
5. Prior treatment 1.16 0.480 0.75 1.81
6. Pediatric Achalasia 0.71 0.544 0.23 2.13
Conclusion: POEM is equally efficacious and safe in treatment naı̈ve and prior
treated cases. POEM should be considered in treatment failure cases.
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Introduction: Both EGJ and esophageal body motor abnormalities are found on
esophageal HRM in reflux disease, and contribute to reflux burden assessed
using acid exposure time (AET) on ambulatory reflux monitoring. Mean noctur-
nal baseline impedance (MNBI) represents a new paradigm that may assess long-
itudinal esophageal reflux burden, but its precise role in clinical esophagology,
particularly in relationship to AET, remains unclear.
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Aims & Methods: Our aim was to evaluate the complex interrelationships
between EGJ and esophageal motor abnormalities, and esophageal reflux
burden in this ongoing multicenter collaboration. Esophageal function studies
from patients with persisting reflux symptoms were reviewed from four centers (2
each in Europe and US) for this preliminary report. EGJ morphology was cate-
gorized using HRM into hypotensive (EGJ-CI5 46mmHg.cm), hiatus hernia
(HH, manometric separation between lower esophageal sphincter and crural
diaphragm) and intact EGJ (normotensive EGJ-CI, no HH). Esophageal body
metrics were characterized using Chicago Classification v 3.0 into intact, ineffec-
tive esophageal motility (IEM) and absent contractility. Total and supine AET
were extracted from ambulatory pH-impedance studies. Baseline impedance was
calculated at the 5 cm impedance channel (to correspond to AET) at three stable
10-min time periods (1, 2, and 3 AM) during the ambulatory pH-impedance
study, and averaged to yield MNBI (normal42292 ohms). Univariate and multi-
variate analyses were performed to assess EGJ and esophageal body predictors of
esophageal reflux burden, and to discern the value of MNBI in comparison to
AET.
Results: 1244 patients (53.4 0.4 yr, 59.6%F) undergoing esophageal motor
testing using HRM (Medtronic, Duluth, GA) and ambulatory pH or pH-impe-
dance monitoring studies performed off antisecretory therapy were included. A
hypotensive EGJ was noted in 70.9%, HH in 34.0%, IEM in 26.3% and absent
contractility in 3.5%. A disrupted EGJ and absent contractility had the highest
proportions with AET4 6%; combinations thereof raised the proportions even
higher (Table, p5 0.001 for each comparison to intact EGJ and/or esophageal
body). Compared to an intact EGJ, the odds ratio (OR) of total AET4 6% with
HH was 2.0 (95% CI 1.1–3.9, p¼ 0.04). Supine AET4 2% was even more
impacted (HH: OR 2.4, 95% CI 1.3–4.5, p¼ 0.007; HHþ hypotensive EGJ:
OR 3.3, 95% CI 2.1–5.2, p5 0.001). A hypotensive EGJ was not discriminative
of AET or MNBI values. Concordance between AET and MNBI thresholds was
noted in 401 of 596 studies (67.2%; both abnormal in 24.8%, both normal in
42.4%). When concordant and abnormal, proportions with EGJ and esophageal
body abnormalities were highest (p 0.005) compared to concordant and normal
AET/MNBI, and discordant studies. On multivariate regression with categorical
and linear EGJ and esophageal body motor findings as dependent variables,
presence of HH (p5 0.0001), IEM (p¼ 0.032), and absent contractility
(p¼ 0.0012) were independent categorical predictors of AET4 6%; HH size
(p5 0.0001), lower EGJ-CI (p¼ 0.002), and increasing numbers of ineffective
swallows (p¼ 0.043) were independent linear predictors. Only the presence of
HH was an independent categorical predictor of abnormal MNBI
(p5 0.0001), increasing HH size (p5 0.0001) and proportions of ineffective
swallows (p5 0.0001) were independent linear predictors.
Proportions with abnormal reflux burden in relationship to EGJ and esophageal
body motor findings on high resolution manometry
AET4 6%
n¼ 431
AET5 4%
n¼ 642
MNBI5 2292
ohms n¼ 596
EGJ findings
Intact EGJ (n¼ 280) 25.7% 60.7%** 58.3% (63/108)
Hypotensive EGJ (n¼ 862) 36.5%* 49.2%** 56.3% (259/460)
Hiatus hernia (n¼ 422) 49.0%* 36.5%** 69.8%* (138/199)
Both (n¼ 342) 49.4%* 34.8%** 70.9%* (124/175)
Esophageal body motor findings
Intact esophageal body (n¼ 686) 31.0% 56.9%** 46.5% (158/340)
IEM (n¼ 326) 41.4%* 44.8% 69.6%* (94/135)
Absent contractility (n¼ 43) 53.5%* 39.5% 88.2%* (15/17)
Combined EGJ & esophageal
body motor findings
Intact EGJ and body (n¼ 170) 25.3% 61.2%** 49.3% (36/73)
Hypotensive EGJ, HH, IEM (n¼ 105)56.2%* 24.8%** 83.0%* (44/53)
Hypotensive EGJ, HH,
absent contractility (n¼ 7)
71.4%* 14.3% 100%* (5/5)
*p5 0.05 compared to intact EGJ and/or esophageal body function **p5 0.05
compared to AET4 6% EGJ: esophagogastric junction; AET: acid exposure
time; MNBI: mean nocturnal baseline impedance; IEM: ineffective esophageal
motility, HH: hiatus hernia
Conclusion: A disrupted EGJ and IEM on esophageal HRM are independent
predictors of elevated esophageal reflux burden. Hierarchical HRM evaluation of
EGJ and esophageal body metrics adds confidence to categorization of esopha-
geal reflux burden.
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Introduction: Electrical stimulation therapy is a new way to treat digestive dis-
orders such as constipation, colonic inertia. It is necessary to understand the
physiology of smooth muscle contraction in developing novel medical devices
related with electrical stimulation therapy. The aims of this study were to mea-
sure the active characteristics of smooth muscle with acetylcholine in porcine
intestine segment.
Aims & Methods: We used five female pigs and obtained ten centimeters of each
porcine small intestine. To measure passive characteristics of small intestine, a
universal testing machine with a tensile rate of 30mm/min. To estimate the active
characteristic parameters of smooth muscle and isometric and isotonic intestinal
motility of smooth muscle, muscle contraction was induced by applying the
stimulation solution (HTK solution containing 1mM of acetylcholine chloride).
Then, we obtained the maximum muscle contractile force of the specimens to
measure the isometric and isotonic intestinal motility.
Results: In tensile test, the maximum repulsive force, that indicate passive muscle
force of smooth muscle 0.702 N, was measured. In the isometric and isotonic
contractions in the porcine small intestine, the maximum myotility, 12.35mN,
was obtained in isometric experiments, and the maximum velocity of muscular
contraction, 0.4476mm/min, was obtained in isotonic experiments. We demon-
strated that in equal lengths, the muscle contraction velocity of the smooth
muscle is 10–100 times slower than that of the skeletal muscle indicating force-
velocity relationship of smooth muscle. And we obtained that the maximum
contraction force from each individual percentage of active force (25%, 50%,
and 100%) was achieved at L/Lopt¼ 1.
Conclusion: We straighten out the active and passive property of porcine intest-
inal smooth muscle. Our study may be helpful for developing novel medical
devices and understanding the physiology of smooth muscle in the porcine
small intestine.
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Introduction: Partial recovery of esophageal peristalsis has been reported in up to
47% of achalasia patients treated by myotomy (either per-oral endoscopic myot-
omy (POEM) or laparoscopic Helleŕs myotomy) in several rather small studies.
The aim of our study was to assess motility patterns focusing on possible
‘‘recovery’’ of esophageal peristalsis in a large cohort of patients after POEM.
Aims & Methods: We performed a retrospective analysis of prospectively col-
lected data of patients undergoing POEM at our tertiary referral center. All
patients in whom high-resolution manometry (HRM) studies were performed
prior to and 3 months after POEM and who completed at least 6-month
follow-up were included. All HRM studies were reviewed and the Chicago
Classification (CC) v3.0 of motility disorders was applied to characterize both
pre- and post-POEM motility patterns.
Results: From 192 patients who underwent POEM since 2012, 127 patients met
the inclusion criteria. The initial CC diagnoses before POEM were as follows:
type I achalasia – 20 pts (16%), type II achalasia – 100 pts (79%), type III
achalasia – 5 pts (4%), other (esophago-gastric junction outflow obstruction
(EGJOO) and Jackhammer) – 2 pts (1%). Only 6 patients (5%; type III achala-
sia, Jackhammer, EGJOO) had had some signs of esophageal contractility before
POEM. After POEM, peristaltic fragments were present in 28/127 patients (22%)
- 9x ineffective esophageal motility, 5x fragmented peristalsis, 2x distal esopha-
geal spasm, 5x EGJOO, 7x type III achalasia. Thus, the partial ‘‘recovery’’ of
esophageal peristalsis was observed in 22/121 patients (18%) and it only occurred
in patients with type II achalasia; contractile activity was not detected in any
patient with type I achalasia after POEM (22/100 vs. 0/20, p¼ 0.023).
Panesophageal pressurization completely resolved in 88 patients (88%) with
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achalasia type II. The mean integrated-relaxation pressure (IRP) decreased from
27 (13) mmHg to 13 (5) mmHg (p5 0.0001). The presence of partial peri-
staltic recovery was neither associated with normalization of IRP (IRP normal-
ized in 17/28 (61%) patients with peristaltic recovery and in 72/99 (73%) patients
without, p¼ 0.25), nor with overall treatment success of POEM (Eckardt score
53).
Conclusion: In this so far largest case-series investigating the rate of peristaltic
recovery after POEM this was present in 18% of patients, therefore, the rate may
be lower than previously reported. Peristaltic recovery seems to have no clinical
impact on post-POEM symptomatology. Esophageal contractility after POEM
was not observed in any patient with achalasia type I.
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Introduction: Medical treatments, endoscopic balloon dilatation, Botox and
Heller myotomy are treatment modalities for managing achalasia. Recently
per-oral endoscopic myotomy (POEM) has became a new option for achalasia
patients and since 2010 it has became widespread. Earlier, anterior myotomy was
used in this technique but in the last few years there are studies reporting that
posterior myotomy is more effective. However, there are limited numbers of
publications comparing anterior and posterior myotomy. This study aimed to
investigate the effect of myotomy site on POEM, to our knowledge it is the first
time in Europe and our country.
Aims & Methods: Between May 2014 and January 2017, POEM was performed
to 225 achalasia patients at the gastroenterology clinics under general anesthesia
by an endoscopist experienced at endoscopic submucosal dissection and trained
for POEM. Demographic data, previous history for balloon dilatation and
results of the procedure were recorded prospectively. Patients with anterior myot-
omy were grouped as "group A" and those with posterior myotomy as "group P",
and the results were compared.
Demographic features and results of POEM procedures
Group Anterior
N¼ 114
Group Posterior
N¼ 111 p
Sex (Male/Female), n 56/58 58/53 0.639
Age mean (SD)
(median; range) year
41.05 14.89
(41.5;12–73)
42.24 13.52
(41; 18–75)
0.905
Prior achalasia treat-
ment, n (yes or No)
48/66 36/75 0.087
Achalasia sub-type;
Unknown I/II/III, n
3/6/94/11 0/17/86/8 0.029
Tunnel length, mean
(SD) (median;
range) cm
17.07 2.63
(17;12–27)
17.32 2.49
(17;12–25)
0.278
Myotomy length, mean
(SD) (median;
range)cm
13.79 2.46
(14;10–25)
14.04 2.44
(14;8–21)
0.235
Procedure Time, mean
(SD) (median;
range) min
58.63 21.47
(53; 27–153)
46.58 13.49
(44; 26–107)
50.001
Tunnel time, mean (SD)
(median; range) min
34.60 14.67
(30; 12–82)
27.02 9.74
(25; 10–68)
50.001
Myotomy time, mean
(SD) (median;
range) min
12.11 6.67
(10; 4–40)
10.08 4.89
(9; 3–30)
0.012
Dysphagia Score preo-
perative/postopera-
tive (median; range)
(3;3–4)/(0;0–2) (3;3–4)/(0;0–1)
Eckardt Score, preo-
perative/postopera-
tive (median; range)
(8;6–12)/(0;0–2) (8;5–12)/(0;0–2)
38 3 33 0 0.176
(continued)
Continued
Demographic features and results of POEM procedures
Group Anterior
N¼ 114
Group Posterior
N¼ 111 p
Adverse events, n -
Capnoperitoneum -
Mucosal injury
Results: There were 114 patients in group A, 111 patients in group P. There was
no statistical difference between the groups in regards of tunnel length, myotomy
length, tunnel entrance time and frequency of homeostatic forceps use (p4 0.05).
However duration of opening the tunnel, myotomy, closure of the tunnel and
total procedure time were significantly shorter in group P (p5 0, 05). Eckardt
and dysphagia scores before the procedure were similar in both groups. After the
procedure Eckardt scores were significantly low in all patients (p5 0.005).
Demographic features and data of the procedures are shown in the table
below. Mucosal damage during the procedure occurred in 3 patients and capno-
peritoneum developed in 71 patients. All complications were treated endoscopi-
cally. Control endoscopy was performed to 151 patients at 3rd month; that
revealed esophagitis grade A in 24, grade B in 6 and grade C in 3 patients.
Conclusion: According to our results posterior approach can shorten the proce-
dure time in POEM compared to anterior myotomy. This may be due to a better
angle of approach with endoscopic equipments for posterior myotomy. We
believe that long-term results will also show the effects of myotomy site on
clinical outcome of patients.
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Introduction: Peroral endoscopic myotomy (POEM) has gained trust by proven
safety and short-term efficacy and at present, it is considered to be a standard
method for treatment of esophageal achalasia. However, long-term data concern-
ing the efficacy and safety especially with regard to post-POEM reflux are still
awaited.
Aims & Methods: The aim of this prospective single-center case series was to
assess the long-term clinical outcome of POEM with emphasis on post-POEM
reflux evaluated by pH monitoring, endoscopy findings, reflux symptoms and use
of proton pump inhibitors (PPIs). Since 2012, a total of 192 patients with acha-
lasia underwent 202 POEM procedures. Follow-up visits at 3, 12, 24 and 36
months were completed in 160, 116, 70 and 27 patients. Upper GI endoscopy,
high-resolution manometry (HRM) and 24-hour pH monitoring were performed
3 months after POEM; endoscopy was then repeated between 24–36 months.
Main outcomes were treatment success defined as Eckardt score 53, recurrence
rate and post-POEM reflux.
Results: At 3, 12, 24 and 36 months, treatment success was achieved in 97% (95%
CI: 94–100), 95% (CI 91–99), 88% (CI 82–95) and 81% (CI 69–93) of patients. A
total of 14 patients experienced treatment failure (n¼ 5) or recurrence (n¼ 9).
The recurrences occurred most often in patients with HRM type I achalasia (4
out of 26, 15.4%) followed by type II (3 out of 113, 2.6%) vs. none in type III
achalasia (0 out of 10, 0%); p¼ 0.022. At 3 months, reflux esophagitis was
diagnosed in 63/160 patients (39.4%; severe esophagitis LA C or D in 8 patients).
Abnormal acid exposure on pH-metry studies was detected in 58/146 (39.7%). At
24–36 months, endoscopy was performed in 41 patients and reflux esophagitis
was present in 9 patients (21.9%; none of the patients has been treated with
PPIs). At 3 and 24M, a proton pump inhibitor was administered to 33.5%
and 31.4% of patients.
Conclusion: POEM is effective treatment modality for achalasia with treatment
success around 90% at 2 years, slightly dropping down to 81% at 3 years.
Generally mild reflux esophagitis and abnormal esophageal acid exposure are
diagnosed in about 40% of patients 3 months after POEM but are successfully
manageable with proton pump inhibitors. Occurrence of reflux esophagitis tends
to decrease with time.
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Introduction: Beer has been related to gastroesophageal reflux (GER) and dys-
pepsia (1, 2), based on its alcohol and gas content. Main objective was to evaluate
if moderate regular and non-alcohol beer consumption is related to postprandial
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dyspeptic symptoms after a controlled meal. Secondary objectives were to eval-
uate its relation with postprandial GER and gastric acommodation and to eval-
uate its relation with daily digestive symptoms under real conditions.
Aims & Methods: Healthy people over 18 years old, free of frequent digestive
symptoms (5once a week) and GER disease (GERD), were included. Basal
symptoms were assessed through PAGI-SYM(3) and QOLRAD (4) question-
naires, both validated to Spanish. Study was divided in two substudies based
on the study intervention: 33 cl of regular beer (substudy 1) and the same
ammount of non-alcohol beer (substudy 2). Mineral water (33 cl) was the control
intervention in both substudies. Each participant was its own control. The study
lasted two weeks (control study week and intervention study week). Each week
started with a visit to the laboratory at 7:30 h am, when a pHimpedance catheter
was placed and taken off 24 hours later. Gastric acommodation was assessed
through the maximum tolerated volume during a nutrient drink test (ENSURE
HN, 500ml) in a rithm of 15ml/minuts, after the ingestion of beer (intervention)
or water (control). It was defined as the volume after which the test finished or
the participant reported the maximum puntuation for any dyspeptic symptoms
(early satiety, bloating, epigastric pain and nausea), which were asked every 5
minutes (1 meant no symptom and 5 meant the highest perception). GER was
evaluated in the postprandial period and during 24 hours through pHimpedance
register. Weekly symptoms evaluation was made though a diary adapted from
PAGYSYM questionnaire and sum of symptoms was used for analysis. Data
were collected daily through email. Variables were compared between both visits
and weeks in both substudies using a non parametric test for matching data.
Participants should drink 33 cl of beer before lunch and dinner during the inter-
vention week. Other alcohol drinks were prohibited during the study.
Results: Ten participants were enrolled in substudy 1, mean aged 24 years old
(SD 4, 1 (18–32)); 80% were men. Twenty participants were enrolled in substudy
2, mean aged 23.4 years (SD 5.5 (20–38)); 65% were men. No significant differ-
ences were detected in the increase of symptoms during the nutrient drink test
between control and intervention visits in both substudies (table 1). Maximum
tolerated volume did not show any difference between visits in both substudies.
Reflux episodes after nutrient drink test and reflux episodes registered in 24
hours did not show significant differences between control and study visits.
The sum of weekly symptoms did not show any difference between control
and intervention weeks in both substudies.
Conclusion: Moderate beer consumption (regular and non-alcohol beer) does not
cause an increasement of dyspeptic symptoms and reflux in healthy people. It has
been shown in a controlled situation (nutrient drink test and pH impedance
register) as well as real life (diary weekly symptoms). Gastric acommodation
and reflux episodes have either shown to be affected by moderate beer
consumption.
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Introduction:Rumination syndrome is a functional gastrointestinal disorder char-
acterized by effortless, post-prandial regurgitation of food. In addition to regur-
gitation, a large proportion of patients report functional dyspepsia (FD)
symptoms including post-prandial discomfort, early satiety and nausea1, 2.
Recently, duodenal eosinophilia has been described both in adult and pediatric
patients with FD3–5. Because of the significant symptomatic overlap between FD
and rumination syndrome we hypothesized that histological changes similar to
those described in FD might exist among patients with rumination syndrome.
Aims & Methods: We therefore aimed to assess histology of duodenal biopsies
from patients with rumination syndrome and compared these to healthy controls.
Rumination syndrome was diagnosed with post-prandial esophageal high resolu-
tion impedance manometry (HRIM) and/or fulfilled ROME II/III criteria. This
study was approved by the Institutional Review Board. We included persons
aged 18 and above with a diagnosis of rumination syndrome in whom we had
also obtained 4–6 duodenal biopsies from diagnostic upper endoscopy. Normal
controls were aged 18 and above without any gastrointestinal symptoms in whom
4–6 duodenal biopsies were obtained for research purposes. Cases and controls
with a personal history of an eosinophilic disorder, gastric or esophageal surgery,
recent (within 30 days) intake of NSAIDS and pregnant and/or lactating females
were excluded. Duodenal biopsies obtained were routinely processed to formalin-
fixed paraffin-embedded tissue blocks which were cut at 3 mm, stained with H&E
and scanned to digital images (Aperio). The pathologist, blinded to the case–
control status, analyzed de-identified digital images of the biopsy specimens and
assessed for eosinophil counts/mm2 in sections. Individual sections were also
assessed for the presence of Brunner’s glands (BG) and intraepithelial lympho-
cyte counts (IEL)/100 enterocytes. This was done in order to distinguish the first
part of the duodenum with BG, D1 and the second part, generally without BG,
(D2) and intraepithelial lymphocyte counts (IEL)/100 enterocytes.
Results: Patients with rumination syndrome (22) had a mean age of 39.2 years
(range 19–71) and 77% were female. Controls (10) had a mean age of 34.3 (range
19–69) and 80% were female. The mean eosinophil counts/biopsy fragment þ/
Brunners glands (BG), showed no difference in counts in the sections þ/ BG
(D1 vs D2), p¼ 0.8. No overt pathology was noted, but IEL counts were sig-
nificantly higher in rumination patients (mean 15, range 8–29, and 2 cases had
lymphocytic duodenosis) vs controls (mean 11, range 11–18), p¼ 0.02. Compared
to controls, there was a significant increase in the mean eosinophil count among
the patients with rumination syndrome rumination, 26 per mm2 (range 16–42), vs
18 mm2 (range 10–28), p¼ 0.006.
Conclusion: These findings demonstrate that patients with rumination syndrome
have duodenal eosinophilia and increased IEL counts compared to healthy con-
trols. To our knowledge, histopathological changes among patients with rumina-
tion syndrome compared to controls have not previously been described.
Therefore, a potential role of duodenal immune mechanisms in the pathophy-
siology of rumination syndrome warrants further enquiry.
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Table 1
BEER CONSUMPTION
AND DYSPEPTIC
SYMPTOMS
SUBSTUDY 1 (Regular beer) SUBSTUDY 2 (Non alcohol beer)
Mean increasement of dys-
peptic symptoms compared
to Minute (Min) 0 Control visit (Mean) Intervention visit (Mean) p value Control visit (Mean) Intervention visit (Mean) p value
Min 5- Min 0 0, 1 (0, 73 (2–1)) 0 0, 655 0 0, 1 (0, 3 (0–1)) 0, 157
Min 10- Min 0 0, 1 (0, 73 (2–1)) 0, 2 (0, 42 (0–1)) 0, 18 0, 3 (0, 47 (0–1)) 0, 55 (0, 6 (0–2)) 0, 132
Min 15- Min 0 0, 2 (0, 63 (0–2)) 0, 4 (0, 51 (0–1)) 0, 317 0, 65 (0, 67 (0–2)) 0, 8 (0, 76 (0–2)) 0, 454
Min 20- Min 0 0, 5 (0, 97 (0–3)) 0, 8(0, 63 (0–2)) 0, 18 1, 15 (0, 93 (0–3)) 1, 35 (0, 98 (0–4)) 0, 521
Min 25- Min 0 1, 1 (1, 19 (0–3)) 1, 2 (0, 78 (0–2)) 0, 655 1, 75 (1, 12 (0–4)) 1, 85 (1, 26 (0–4)) 0, 685
Min 30- Min 0 1, 3 (1, 41 (0–4)) 1, 3 (0, 82 (0–2)) 1 2, 15 (1, 06 (0–4)) 2, 3 (1, 45 (0–5)) 0, 38
Min 33- Min 0 1, 2 (1, 31 (0–4)) 1, 5 (1, 08 (0–3)) 0, 18 2, 57 (1, 21 (0–5)) 2, 8 (1, 24 (0–5)) 0, 131
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Introduction: The role of afferent sensory pathways in the pathophysiology of
post-stroke oropharyngeal dysphagia (OD) is not known [1]. We hypothesized
that chronic post-stroke patients with OD (PSD) would show impaired sensory
cortical activation in the afected hemisphere.
Aims & Methods: We studied 28 chronic unilateral post-stroke patients (17 PSD
and 11 nondysphagic [PSnD]) and 11 age-matched healthy volunteers (HV).
Electroencephalography was used to assess event-related sensory evoked poten-
tials to pharyngeal stimulation (pSEP) and sensory thresholds with a naso-phar-
yngeal catheter with two electrodes passed through the nostrils 14–15 cm until the
pharynx (Gaeltec Ltd, Dunvegan, Scotland) [2]. We analyzed pSEP peak-latency
and amplitude (N1, P1, N2, P2) and neurotopographic stroke characteristics
from brain MRI.
Results: HV presented a highly symmetric bi-hemispheric cortical pattern of
brain activation at centro-parietal areas (N1-P1, N2-P2) to pharyngeal stimuli.
In contrast, an asymmetric pattern of reduced ipsilesional activation was found
in PSD (N2-P2; p¼ 0.026) but not in PSnD. PSD presented impaired safety of
swallow (Penetration- Aspiration score: 4.3 1.6) and delayed laryngeal vestibule
closure (360.0 70.0ms), and higher NIHSS (7.0 6.2 vs. 1.9 1.4, p¼ 0.001)
and Fazekas scores (3.0 1.4 vs. 2.0 1.1; p5 0.05) than PSnD. pSEP showed a
unilateral delay at stroke site exclusively for PSD (peak-latency inter-hemispheric
difference vs. PSnD: N1, 6.5 6.7 vs. 1.1 1.0ms; N2, 32.0 15.8 vs.
4.5 4.9ms; p5 0.05).
Conclusion: Chronic post-stroke OD is associated with stroke severity and degree
of leukoaraoisis. Impaired conduction and cortical integration of pharyngeal
sensory inputs at stroke site is a key feature of chronic PSD. These findings
highlight the role of sensory pathways in the pathophysiology of post-stroke
OD and offer a potential target for future treatments.
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Introduction: Gastroparesis is characterized by abnormal gastric motor function
with delayed gastric emptying in the absence of mechanical obstruction. In our
tertiary referral centre, patients are treated with a stepwise approach, starting
with dietary and lifestyle advice and prokinetics followed by pyloric botulinum
toxin. When these initial measures fail, in the presence of malnutrition, one of the
following interventions are considered: three months nasoduodenal tube feeding
with ‘gastric rest’ and placement of a percutaneous endoscopic gastrostomy with
jejunal extension (PEG-J). Our primary aim was to evaluate the effect of nutri-
tional treatment entities in patients with gastroparesis who fail previous treat-
ments, on weight and symptoms.
Aims & Methods: Prospectively collected data of all referred gastroparesis
patients between 2008 and 2016 were reviewed.
Results: A total of 101 gastroparesis patients (71% female, 20–86yrs, mean 55yrs)
were analyzed. Etiologies were idiopathic (37%), diabetes mellitus (30%), post-
surgical (27%) and other (7%). Of the 101 patients, 51 patients had adequate
responses to dietary advice and prokinetics, not requiring further therapeutic
interventions. For the remaining 60 patients, various treatments were used.
With respect to nutritional interventions, 36 patients were treated with three
months of gastric rest via complete nasoduodenal tube feeding. Enteral tube
feeding was well accepted, occlusion occurred in 8% of patients. Mean weight
gain in symptom responders was 3.5% (2.4 kg, p¼ 0.02), in non-responders 3.7%
(2.4 kg, p¼ 0.01). These 19 patients with insufficient symptomatic response after
3 months gastric rest continued treatment with enteral feeding through PEG-J. A
significant weight gain of 8.2% was seen (mean 5.0 kg, range 6% to þ29%),
p¼ 0.003) within 3–6 months after PEG-J placement. Thereafter only 3 patients
(16%) have been able to resume complete oral intake, the PEG-J was removed
after a mean treatment time of 11 months. In 84% of patients the PEG-J is still in
use, with a mean treatment time of 894 days. Over 75% of patients report
adequate effect on symptoms. Most frequent complication was luxation of the
jejunal extension to the stomach (32% of patients). Other complications were
peristomal infection (11% within 30 days, 16% after 30 days) and buried bumper
(16%).
Conclusion: This study describes the sequelae of a large group of tertiary referral
gastroparesis patients treated with PEG-J treatment. In gastroparesis patients
who failed all previous treatment, PEG-J is an excellent option to regain and
maintain adequate nutritional status with marked symptom control.
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Introduction: Reduced sleep quality has been linked to gastroesophageal reflux
disease (GERD) and functional gastrointestinal disorders. It is unknown whether
GERD, functional dyspepsia (FD) and irritable bowel syndrome (IBS) are more
prevalent in subjects with significant sleep disturbance (SD) than those without
SD.
Aims & Methods: The aim of the study was to investigate gastrointestinal symp-
toms, clinical characteristics, and psychological factors in subjects with and with-
out SD in a general population undergoing health checkups. We enrolled 2752
consecutive subjects who received upper gastrointestinal endoscopy and colono-
scopy during their health checkups. All participants underwent an evaluation
with questionnaires including Reflux Disease Questionnaire score, Pittsburgh
Sleep Quality Index (PSQI), Taiwanese Depression Questionnaire, and State-
Trait Anxiety Inventory before receiving endoscopic exam. Demographic char-
acteristics and biochemical data were also recorded. FD and IBS were based on
Rome III diagnostic criteria, and metabolic syndrome was defined by the
National Cholesterol Education Program Adult Treatment Panel III definition.
Sleep disturbance was confirmed when PSQI score was greater than 5. We com-
pared the clinical and psychological factors between subjects with and without
sleep disturbance.
Results: Among the study population (n¼ 2674), 956 (36%) individuals had SD.
SD subjects had more female gender, older age, lower level of education, higher
systolic blood pressure, higher serum high-density lipoprotein levels, and higher
prevalence of FD and IBS than those without SD. In addition, SD patients also
had more depression, more anxiety, more severe GERD symptoms, and higher
prevalence of non-erosive reflux disease (NERD) (p5 0.001). Multivariate ana-
lysis revealed that female sex (OR¼ 1.75, p5 0.001), older age (OR¼ 1.03,
p5 0.001), more severe GERD symptoms (OR¼ 1.03, p5 0.033), NERD
(OR¼ 1.63, p¼ 0.023), IBS (OR¼ 1.48, p¼ 0.05), and depression (OR¼ 1.16,
p5 0.001) were positive predictive factors for SD, whereas higher level of educa-
tion (OR¼ 0.57, p5 0.001) was negative predictive factor for SD.
Conclusion: Our study demonstrates that SD is associated with female sex, older
age, lower education level, greater GERD symptom burden, greater depression,
and higher prevalence of NERD and IBS. Future studies will be needed to clarify
the relationship between functional gastrointestinal diseases and sleep disorders.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The prevalence and frequency of esophageal symptoms suggestive
of a functional esophageal disorder according to the Rome IV criteria are
unknown. This study aimed to describe the general population prevalence and
risk factors for esophageal symptoms compatible with functional esophageal
disorders.
Aims & Methods: Data from an online survey of 6300 individuals age 18 years
in the United States, United Kingdom and Canada (2100 in each country) includ-
ing the Rome IV diagnostic questionnaire for adults and demographic questions
was used. Quota-based sampling ensured equal proportions of sex, age groups,
and education distributions across countries. Prevalence and frequency of eso-
phageal symptoms in the past 3 months and putative functional esophageal
disorders were retrieved from the Rome IV questionnaire. Symptoms were con-
sidered present if they occurred at least weekly for dysphagia, chest pain, and
globus, and at least twice weekly for heart burn. Variables with a p 0.1 in
univariate analyses were entered into a multivariate analysis (logistic regression)
to identify factors independently related to esophageal symptoms. As endoscopy
and pH measurement are parts of the clinical diagnosis of esophageal disorders in
the Rome IV criteria, we only describe esophageal symptoms compatible with
functional esophageal disorders. Somatization was assessed with the Patient
Health Questionnaire (PHQ)-12.
Results:Data from 5177 participants (47.8% female; mean age 46.7 (range 18–92)
years; 1645 US, 1734 UK, 1798 Canada) were retained for analysis after 369
inconsistent responders and 754 previously diagnosed with gastroesophageal
reflux disease (GERD) were excluded. Esophageal symptom prevalence was:
feeling of a lump or something stuck in the throat (globus) 8.1% (n¼ 420),
heartburn 6.5% (n¼ 334), dysphagia 4.5% (n¼ 233) and chest pain 5.2%
(n¼ 269). Independent predictors for increased risk of esophageal symptoms
included younger age, symptoms consistent with other FGIDs, using medications
for gastrointestinal symptoms, somatization, cannabis use, and certain foods (see
table 1). When individuals with GERD were included in re-analyses, GERD was
a significant predictor for chest pain and heartburn (OR 1.939 and 1.525), but
not globus and dysphagia. The prevalence of symptom constellations consistent
with Rome IV esophageal diagnoses was 1% for globus, 3.2% for functional
dysphagia, 0.7% for reflux hypersensitivity, 0.8% for functional chest pain, and
1.1% for functional heartburn. There was a significant difference in symptoms
consistent with any functional esophageal disorder between USA 7.0%, UK
4.3% and Canada 5.9% (p¼ 0.003).
Table 1: Factors independently associated with presence of esophageal symp-
toms compatible with a functional esophageal disorder
Symptom Factor
Odds
ratio
95 % Confidence
interval R2 value
Globus PHQ12 1.138 1.105–1.172 0.189
Medication for constipation 1.718 1.146–2.577
Diet rich in pasta 1.068 1.000–1.139
Gastroduodenal disorder 2.616 2.006–3.412
Bowel disorder 1.318 1.032–1.684
Anorectal disorder 1.699 1.243–2.321
Chest pain Cannabis consumption 1.949 1.215–3.128 0.301
Previously diagnosed with
functional dyspepsia
6.492 1.342–31.417
Medication for acid/
heartburn
1.488 1.039–2.130
PHQ12 1.214 1.171–1.259
Gastroduodenal disorder 2.820 2.051–3.877
Bowel disorder 1.791 1.311–2.446
Anorectal disorder 1.536 1.058–2.230
Diet rich in tofu 1.192 1.058–1.343
Home with electricity as a
child
2.509 1.256–5.011
Heartburn PHQ12 1.074 1.035–1.114 0.315
(continued)
Table 1 Continued
Symptom Factor
Odds
ratio
95 % Confidence
interval R2 value
Medication for acid/
heartburn
11.427 8.602–15.179
Gastroduodenal disorder 2.789 2.049–3.798
Bowel disorder 2.165 1.632–2.872
Diet rich in pasta 1.113 1.026–1.206
Dysphagia Age 0.990 0.980–1.000 0.242
Medication for diarrhea 1.882 1.100–3.221
Medication for acid/
heartburn
1.456 1.007–2.106
Medication for gas/bloating 1.913 1.178–3.106
Gastroduodenal disorder 4.368 3.146–6.065
Anorectal disorder 1.585 1.072–2.343
Diet rich in rice 1.097 1.006–1.196
PHQ12 1.110 1.069–1.154
Variables with a p-value of 0.1 or less in univariate analysis were entered into a
multivariate analysis (logistic regression) in order to identify factors indepen-
dently associated with esophageal symptoms (up to 33 variables).
Conclusion: Esophageal symptoms compatible with a functional esophageal dis-
order are common in the Western population. Age and presence of other GI and
non-GI symptoms are associated with reporting esophageal symptoms.
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Introduction: Eosinophilic esophagitis (EoE) affects children and young adults
and has rapidly grown over the past decade, especially in developed countries.
Presently, it represents the second leading cause of chronic esophagitis after
gastroesophageal reflux disease (GERD) and the main cause of dysphagia in
children and young adults. EoE affects health-related quality of life (HRQoL).
Data on determinant factors and the influence of dietary interventions are scarce.
Aims & Methods: In this study we aimed (1) to determine for the first time the
health-related QoL in a representative sample of Spanish adults with EoE, and
(2) to identity determinants of impaired HRQoL, including the effect of dietary
restrictions. Multicentre observational, cross-sectional study in eight Spanish
centers attending adult EoE patients throughout several Spanish Regions. A
validated Spanish version of the self-administered Adult Eosinophilic
Esophagitis Quality of Life (EoE-QoL-A) questionnaire was used, as well as a
survey of demographic and clinical data. Multiple linear regression was used to
identify and quantify determinant factors of HRQoL.
Results: Responses provided by 170 patients were assessed (73.5% male; mean
age 33.5 11.4y). Overall mean score for the EoE-QoL-A index was 1.4 0.8,
with no differences between patients on dietary or pharmacological therapy
(1.82 0.8 vs. 1.62 0.8; p¼ 0.132). Disease anxiety showed the highest. The
mean score (2.13 0.9 points), followed by choking anxiety 1.97 1.1; social
impact, 1.77 1.1, and diet/eating impact 1.68 0.9 points. Emotional impact
had the lowest rating (1.15 0.9), and the only with a significantly worse score in
patients under dietary restrictions. Recurrent food impaction, a higher educa-
tional level, dietary interventions and symptom duration were all independent
determinant factors significantly impairing HRQoL. Female gender and empiric
elimination diets negatively influenced on diet/eating impact.
Conclusion: HRQoL is impaired in adult EoE patients, especially disease and
chocking anxiety. Recurrent food impaction, dietary interventions and symptom
duration are the most important factors influencing the perception of HRQoL in
EoE.
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Introduction: Eosinophilic oesophagitis (EoE) is a chronic, immune-mediated,
inflammatory disorder, defined symptomatically by esophageal dysfunction
and histologically by eosinophil-predominant inflammation of the esophagus.
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Several studies have provided information on the prevalence of different atopic
conditions in paediatric and adult EoE patients and compared them with several
groups of control subjects. The findings indicate that, overall, EoE patients show
a higher frequency of asthma, rhinoconjunctivitis, eczema, and food allergies
than control groups; however, definitions for the associated atopic conditions
have not always been provided and the selection process for the controls has not
been such that they can be considered universally representative of the general
population without EoE. These two limitations have hampered researchers in
their efforts to clearly assess the magnitude of the association between atopy and
EoE. Weaim to conduct a systematic review of the literature and to perform a
meta-analysis in order to evaluate the presence of atopic diatheses in patients
with EoE as well as to summarize the prevalence of atopic conditions in both
paediatric and adult EoE patients in comparison with the non-EoE control
population.
Aims & Methods: A highly sensitive search strategy was designed to identify and
retrieve all documents dealing with the relationship between atopy and EoE in
children and adults. This systematic literature search was performed indepen-
dently by two researchers (AA and AJL) on April 6th, 2016 in three major
bibliographic databases (PubMed, EMBASE, and Scopus) for the period up to
March 2016. The search was not restricted with regard to the language of pub-
lication. A predetermined protocol was used in accordance with the quality
standards for reporting meta-analyses of observational studies in epidemiology.
Four reviewers (JG-C, AA, MM-CM, and AJL) independently extracted relevant
information from each eligible study using a standardized data extraction sheet
and then proceeded to cross-check the results. Estimates for the prevalence of
each atopic manifestation in EoE patients and controls were summarized with
the aid of a fixed- or random-effects meta-analysis, depending on intra-study
heterogeneity, weighted for inverse variance following the method elaborated
by DerSimonian and Laird. Summary estimates, including 95% confidence inter-
vals (CI), were calculated for each season and month, whenever possible.
Results: Of the 2954 references identified, data was collected from 21 studies
including a total of 53,542 EoE patients and 54,759 controls. The criteria for
defining a diagnosis of atopy in either EoE patients or controls was not structu-
rally considered in most of the studies. The frequency or prevalence of the dif-
ferent atopic manifestations among EoE patients was compared with that
observed in several types of control populations, including series of patients
with gastroesophageal reflux disease (GORD), other patients, and healthy volun-
teers, all of whom were endoscopically assessed with a diagnosis of EoE specifi-
cally ruled out. In all cases, EoE was considered as independent from GORD and
other upper GI tract diseases. Some studies included database-registered subjects
as control groups. The criteria for defining a diagnosis of atopy among EoE
patients and control subjects varied widely across the different studies, from
self-reported/parent-reported atopic background to strict allergist/immunolo-
gist-provided diagnoses. Overall, allergic rhinitis was significantly more
common among EoE patients compared to control subjects (OR 5.58; 95% CI,
3.27, 9.53; I2¼ 86%) as were bronchial asthma (OR 3.06 (95% CI, 2.01, 4.66;
I2¼ 83.4%) and eczema (OR 2.86; 95% CI, 1.88, 4.36; I2¼ 57.2%). Food aller-
gies and other atopic conditions were also assessed. No significant publication
bias was found for studies dealing with allergic rhinitis and eczema in EoE.
Finally, our search uncovered two papers that reported on the frequency of
drug allergy in EoE patients compared to controls, showing no significant differ-
ences between these two populations (OR¼ 0.981; 95%CI, 0.07, 14.72).
Conclusion: The present study shows that an accurate diagnosis of atopy is lack-
ing in most of the research evaluating the prevalence of asthma, rhinitis, and
eczema among EoE patients. Still, the prevalence of these three conditions seems
to be significantly higher in children and adults with EoE as compared to control
subjects representative of the general population. Further research should clearly
document and use standard definitions of allergic rhinitis, asthma (including its
severity and level of control), skin allergy, and food allergy (rather than mere
sensitization) when assessing and documenting concurrent allergic diseases in
patients with EoE.
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Introduction: APT-1011 is an orally disintegrating tablet (ODT) formulation of
fluticasone propionate (FP) that provides a novel approach for the treatment of
eosinophilic esophagitis (EoE).
Aims & Methods: A randomised, single-dose, three-way, crossover study was
conducted in healthy volunteers to compare the pharmacokinetics (PK), safety,
and tolerability of APT-1011 when administered under morning (AM) fed or
fasted conditions or before bedtime (HS). Participants were administered 6mg
APT-1011 following these three different administration schedules, with a 7-day
washout separating the three periods. Serial plasma samples for FP PK were
collected predose and up to 72 hours following each dose. Noncompartmental
and statistical analyses were performed for PK parameters.
Results: A total of 24 participants enrolled and 22 (92%) completed the study. A
summary of the PK parameters by test group is presented in Table 1. AM dosing
was associated with a higher rate of absorption under fed compared to fasted
conditions. Following a high fat meal, there was a higher peak concentration
{Cmax: ratio [90% CI (confidence interval)]¼ 120.65% [99.84%145.79%]} and
a faster time to peak concentration compared to the fasted state (Tmax:
fed¼ 5.00 h, fast¼ 10.00 h). However, lower total exposure in the fed compared
to the fasted state {AUC [area under the curve]last: ratio (90% CI)¼ 76.97%
[67.64%87.59%]} was observed. HS dosing was found to slow the rate of
absorption compared to AM dosing conditions. Specifically, the time to peak
concentration with HS dosing (Tmax¼ 14 h) was longer than with AM dosing
(Tmax: fast¼ 10 h, fed¼ 5 h). HS dosing was associated with higher overall expo-
sure (AUCinf: ratio [90% CI]¼ 122.36% [107.02%139.88%]) and lower Cmax
(Cmax: ratio [90% CI]¼ 67.79% [56.29%81.64%]) versus the fed dosing regi-
men. Compared to the fasted regimen, HS dosing yielded lower overall exposure
(AUCinf: ratio [90% CI]¼ 87.00% [75.24%100.59%]) and lower Cmax (Cmax:
ratio [90% CI]¼ 81.78% [67.93%98.47%]). Across all dosing regimens, the
Cmax of FP with APT-1011 ranged from 5.97–200 pg/mL. Seven subjects (29%)
reported 12 treatment-emergent adverse events over the course of the study; all
were mild in severity. No serious adverse events or deaths were reported.
Conclusion: Oral APT-1011 was safe and well-tolerated when administered under
AM fasted, AM fed, or HS conditions to healthy subjects. While there was faster
absorption of APT-1011 under fed conditions and slower absorption at bedtime,
overall absorption of FP with this ODT formulation is low (5200 pg/mL).
Slower absorption with HS dosing suggests a potential for longer dwell times
in the esophagus; the relationship of HS dosing with histological efficacy in both
the proximal and distal portions of the esophagus will be explored in future
studies of APT-1011 in EoE.
Table 1: Plasma FP PK Parameters
Parameter
AM Fast Geometric
Mean (CV%)
AM Fed Geometric
Mean (CV%)
HS Geometric
Mean (CV%)
Cmax (pg/mL) 31.1 (103.6) 34.2 (102.3) 23.8 (111.9)
Tmax (h)* 10.00 (2.00–30.00) 5.00 (1.00–10.00) 14.00 (2.00–20.00)
AUC0–24 (pgh/mL) 366.607 (115.8) 361.277 (105.5) 359.541 (100.5)
AUCinf (pgh/mL) 1044.308 (90.1) 587.890 (107.2) 726.451 (100.2)
CV%¼percentage coefficient of variation. *Median and range are presented.
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Introduction: Eosinophilic esophagitis (EE) is a chronic condition of the esopha-
gus with pathognomonic clinical, endoscopic and histologic features. We aimed
to prognosticate which cohort of patients respond best to proton pump inhibitor
monotherapy or topical steroids based on index endoscopy and histology in
conjunction with symptoms at presentation and on follow-up.
Aims & Methods: All patients referred with dysphagia or with an incidental
histology finding of 415 eosinophils/high power field (eos/hpf) between Feb
2013 and Dec 2015 were analyzed by retrospective case note review and patient
communication. Univariate analysis and binary logistic regression was used to
identify associations between patient characteristics, presentation, endoscopic
findings, degree of eosinophilia and subsequent response to treatment.
Associations were assessed by Fishers exact test, t-test and Mann-Whitney for
nominal, continuous parametric and non-parametric variables respectively.
Results: 1653 patients fulfilled the entry criteria. 544 with previous cancer, acha-
lasia, post-operative strictures or Barrett’s endotherapy were excluded. 95
patients had histological eosinophilia in keeping with EE; 85 with dysphagia
and 10 with reflux as their presenting complaint (67 male, mean age
42 17years). 31(32%) of these had at least one presentation with food bolus
obstruction (FBO). There was a trend towards a higher eos/hpf in patients who
presented with FBO (47 21) compared to dysphagia (38 17) and reflux
(38 17) (p¼ 0.073). Endoscopic evidence of chronic stricturing disease was
associated with a higher eos/hpf than those with no strictures (mean 50.3 vs
38.6; p¼ 0.04). 31 patients had endoscopic biopsies taken at least 3 months
post therapy. Those with index features of chronic disease were more likely to
be associated with failure of the eosinophilia to normalize regardless of medical
treatment compared to those with acute changes (furrows, exudates) (33% vs.
75%; p¼ 0.02). Furthermore, patients with dysphagia or FBO demonstrated a
reduced normalisation of eos/hpf following either steroid or PPI therapy com-
pared to those not presenting with these symptoms at a minimum of 3 months
(46% vs. 100%; p¼ 0.03). Overall, there were no significant associations between
concentration of eos/hpf and response to steroids or PPI. On the other hand,
regardless of endoscopic findings, patients presenting with dysphagia and/or
FBO demonstrated a higher response to steroids than those with reflux symp-
toms (50% vs 9% p¼ 0.018) who responded best to PPI (91%). 78 patients were
contactable a minimum of 3 months following initiation of treatment. Patients
with chronic EE findings at initial endoscopy were less likely to respond symp-
tomatically to PPI monotherapy compared to those with normal or acute endo-
scopic findings (32% vs. 68%; p¼ 0.003) while they were more likely to respond
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to steroids (64% vs 36%; p¼ 0.002. Specifically, the presence of strictures indi-
cated a more likely clinical response to steroids compared to PPI alone.
(p¼ 0.007).
Conclusion: A higher eos/hpf was found in patients with chronic EE features at
index endoscopy than those with normal or acute endoscopic signs. In those with
normal or acute EE changes and without dysphagia as a presenting complaint, a
clinical response was noted with PPI therapy alone. In those with chronic EE
changes or with dysphagia/FBO, steroids appear to be the preferred therapeutic
option, although at 3 months follow up a clinical response might precede a
histological one.
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Introduction: Proton Pump Inhibitor-response esophageal eosinophilia (PPI-
REE) is an emerging condition characterized by a constellation of clinical, endo-
scopic, and histopathologic features in the setting of eosinophilic inflammation
on esophageal biopsies responding to a course of proton pump inhibitor (PPI)
therapy. A recent meta-analysis explored the role of different PPIs in inducing
clinical and histological remission in patients with esophageal eosinophilia with-
out observing significant differences among them due to several limitations (i.e.
limited number of studies using each PPI drug, small sample size, and hetero-
geneity among the various studies).
Aims & Methods: We aimed to prospectively compare the effect of different PPIs
in inducing endoscopic and histologic remission in patients with PPI-REE.
Consecutive patients with symptoms suggestive of EoE underwent upper endo-
scopy to assess the presence of at least 15 eos/hpf on oesophageal biopsies at mid/
proximal esophagus and, then, were treated with twice-daily PPI for at least 8
weeks. Patients were assigned to receive esomeprazole 20mg bid, rabeprazole
20mg bid or pantoprazole 40mg bid in a 1:1:1 ratio. Thereafter, patients
repeated upper endoscopy and PPI-REE was identified in case of less than 15
eos/hpf and a 50% decrease from baseline. Endoscopic, according to Endoscopic
Reference Score (EREFS), and histologic features were blindly reviewed for each
patient and treatment
Results: Twenty-eight patients [23M/5F; mean age 35] reporting dysphagia
(93%), bolus impaction (68%) and chestpain (25%) were diagnosed with PPI-
REE. According to treatment allocation, 8 (29%) patients received esomepra-
zole, 9 (32%) rabeprazole and 11 (39%) pantoprazole. At baseline, demographic
and clinical data, including age, sex, BMI, H. pylori infection, concomitant
allergy conditions and latency from diagnosis were similar (p¼ns). Moreover,
no differences were found in terms of frequency of symptoms reported (p¼ns).
Endoscopic and histologic features at baseline and after PPI therapy are shown in
the Table. Esomeprazole, rabeprazole and pantoprazole reached the same degree
of efficacy in inducing endoscopic and histologic changes in PPI-REE patients
(p¼ ns).
Table: Endoscopic and histologic features at baseline and after PPI therapy in
PPI-REE
Esomeprazole
Group (n¼ 8)
Rabeprazole
Group (n¼ 9)
Pantoprazole
Group (n¼ 11)
Baseline
After-
Therapy Baseline
After-
Therapy Baseline
After-
Therapy
Endoscopic Features, %
Rings 75% 26% 67% 22% 63% 18%
Linear furrows 62% 13% 55% 11% 54% 9%
Whitish exudates 50% 13% 44% 11% 54% 18%
Edema 26% 13% 33% 11% 27% 9%
Crepe paper 13% 0% 0% 0% 9% 0%
Strictures 13% 13% 22% 11% 18% 9%
Mean EREFS Score 7.3 1.2 8.1 1.6 8.4 1.7
(continued)
Table Continued
Esomeprazole
Group (n¼ 8)
Rabeprazole
Group (n¼ 9)
Pantoprazole
Group (n¼ 11)
Baseline
After-
Therapy Baseline
After-
Therapy Baseline
After-
Therapy
Histologic Features, n or
%
Median maximum eos
count*
75 6 87 5 95 6
Median eos count (of 5
HPFs)*
55 4 68 3 62 5
Degranulation present 88% 13% 100% 11% 90% 18%
Microabscess present 63% 13% 55% 11% 48% 9%
Basal layer present 100% 26% 100% 22% 100% 18%
Spongiosis present 88% 26% 88% 11% 90% 18%
Subepithelial tissue
present
75% 13% 55% 11% 81% 9%
Lamina propria fibrosis
present
0% 0% 0% 0% 9% 0%
Eos¼ esosinophils *Calculated for an HPF area¼ 0.24 mm2
Conclusion: Esomeprazole, rabeprazole and pantoprazole administered at double
daily dose were equally effective in determining endoscopic and histologic remis-
sion in patients with PPI-REE. These data, although obtained in a small sample
of patients, suggest that the pharmacokinetic and pharmacodynamic differences
among these drugs do not affect their effect on PPI-REE patients.
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DEVICE»: A NEW ENDOSCOPIC MEDICAL DEVICE TO DIAGNOSE,
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Introduction: The « GARD» (Gastroesophageal Anti-Reflux Device) is an anti-
reflux tubular valve placed in the lower esophagus under endoscopic control
allowing normal ingestion of food and beverages but blocking all gastro-esopha-
geal refluxate mechanically (fluid, solids and gas)
Aims & Methods: The « GARD» has an upper ring sized to the diameter of the
patient’s esophagus with an accessory called the « calibration device » placed
through the 2.8mm working channel of a standard gastroscope. The GARD is
held in place by pressure. The upper ring holds an anti-reflux thin-walled tubular
valve moulded in one piece under the ring. After placement of a standard guide-
wire, the « GARD» is placed through the patient’s mouth and is released in the
lower esophagus. The procedure is performed under sedation on an ambulatory
basis in about 15minutes when experienced. The « GARD» was placed in the
esophagus of 8 pigs during 7 days to evaluate placement, feeding, weight gain,
absence of migration as well as removal. Deployment of the « GARD » was easy,
there was no migration in the stomach and removal of the GARD with the
developed accessories was easily achieved. However, pigs have a strong lower
esophageal sphincter and have no reflux so gastro-esophageal reflux could not be
evaluated. In a human volunteer with very severe gastro-esophageal reflux who
had previously failed anti-reflux surgery and had an unsatisfactory response to
clinical and pH metric measurement under 80mg of esomeprazole, the « GARD»
was placed preoperatively. Hereafter are this patient’s pH metric results without
PPIs (table 1); with the patient taking 80mg/day PPIs (table 2) and after GARD
placement and PPIs stopped for 10 days, table 3.
Results: Fig 1. First pH metric study (no PPIs for 10 days): The patient has very
severe reflux with 63% of the time with a pH under 4 (normal less than 4% of the
time at a pH under 4) after PPIs were stopped for 10 days. Fig 2. Patient is taking
80mg of esomeprazole a day. pH metric measurement remains highly patholo-
gical at 23% of the time under pH 4 once PPIs have been resumed at 80mg of
PPIs daily. Fig 3. After placement of the GARD and PPIs have been stopped for
10 days, there is no longer any reflux measured. The pH tracing does not drop
under the red line at pH 4.
Conclusion: a new medical device blocking GERD is presented. A first clinical
trial is scheduled to start in 2018 to help diagnose and manage Refractory
GERD. Further clinical indications are at the planning stage including treatment
of Refractory GERD and LPR.
Disclosure of Interest: All authors have declared no conflicts of interest.
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P0538 SYMPTOM PATTERNS AND TYPES OF
GASTROESOPHAGEAL REFLUXES SIGNIFICANTLY DIFFER IN
GROUPS OF EROSIVE ESOPHAGITIS AND NON-EROSIVE FORM
OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) PATIENTS
M. Konovalova, S. Morozov, V. Isakov
Gastroenterology And Hepatology, Federal Research Center of Nutrition and
Biotechnology, Moscow/Russian Federation
Contact E-mail Address: sunnysister@mail.ru
Introduction: Patients with gastroesophageal reflux disease (GERD) demonstrate
a range of different symptoms (esophageal and extraesophageal) however the
relationship between symptoms and types of reflux was not evaluated.
Aims & Methods: The aim of the study was to assess the relationship between
GERD patients’ symptoms with characteristics of refluxes obtained by 24-h
esophageal pH-impedance. One hundred fifty eight GERD patients (68 men,
89 women, age (Mm) 42 4.8 yrs) and 49 controls (22 men, 27 women, age
(Mm) 46 6.7 yrs) were examined using 24-hours esophageal pH-impedance
recordings (Ohmega, MMS, the Netherlands; 2pH-6 impedance channels cathe-
ters, UnisensorAG, USA) and validated GERD-Q questionnaire. According to
baseline endoscopy 91 patients were classified as non-erosive reflux disease
(NERD) and 67 as erosive reflux disease (ERD) patients. Patients’ symptoms
were classified according to Montreal classification.
Results: Extraesophageal symptoms as well as weak acid gastroesophageal
refluxes were found significantly more often in patients with NERD compared
to ERD group (table 1). However higher number of acid refluxes, higher GERD-
Q score and DeMeester score were present in ERD. The total number of gastro-
esophageal refluxes didn’t differ between ERD and NERD groups of patients.
Table 1: Results of the study
Controls
(n¼ 49)
NERD
(n¼ 91)
ERD
(n¼ 67) o
Number of refluxes/
day, n
17 1.3 55 3.07* 55 4.7* *o¼ 0.729
Number of acid
refluxes/day, n
6 1.0 27 2.2* 33 3.7* *o¼ 0.040
Number of weak acid
refluxes/day, n
7 0.93 22 2.1* 15 2.3* *o¼ 0.038
Number of high gastro-
esophageal refluxes/
day, n
2 0.47 15 1.4* 12 2.2* *o¼ 0.347
DeMeester score 3.16 1.75 13.3 2.0* 26.92 6.2* *o¼ 0.0001
GERD-Q score 5 0.31y 10 0.24* 13.1 0.22*y *yo¼ 0.0001
Extraesophageal symp-
toms (cough, laryn-
gitis, etc.) (presence,
% in group)
0 61.5* 31.3* *o¼ 0.0001
Conclusion: ERD and NERD groups of patients are charachterized by different
symptom patterns and types of gastroesophageal refluxes registered with 24-
hours esophageal pH-impedance monitoring. These findings could reflect differ-
ences in pathogenesis and clinical manifestations of mentioned forms of GERD.
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Introduction: Several clinical-based studies from Western countries have investi-
gated the prevalence of extra-esophageal symptoms in various degrees of reflux
erosive esophagitis. However, the independent factors related to the development
extra-esophageal manifestations remain unclear.
Aims & Methods: Our aim was to assess the prevalence of extra-esophageal
symptoms (laryngeal disorders and chronic cough) in adults with (cases) and
those without (controls) erosive esophagitis in Albania, a developing Southeast
European country. A case-control study was conducted at the Regional Hospital
of Durres, the second main district in Albania, a transitional country in South
Eastern Europe, including 248 patients with erosive esophagitis (aged 46.5 16.3
years) and 273 controls (aged 46.4 16.0 years; response rate: 70%) enrolled
during the period January 2013 – June 2014. Both cases and controls underwent
upper endoscopy. Information on socio-demographic characteristics and lifestyle
factors was also collected. Binary logistic regression was used to assess the asso-
ciation of erosive esophagitis and extra-esophageal symptoms.
Results: Patients with erosive esophagitis had a higher prevalence of excessive
alcohol consumption, smoking, sedentarity and obesity compared to their con-
trol counterparts (9% vs. 5%, 70% vs. 49%, 31% vs. 17% and 22% vs. 9%,
respectively). The prevalence of hiatal hernia was higher in cases than in controls
(21% vs. 8%, respectively), whereas the prevalence of gastric-duodenal ulcer was
similar in both groups (13% vs. 14%, respectively). Upon adjustment for all
socio-demographic characteristics and lifestyle/behavioral factors, there was evi-
dence of a strong association of erosive esophagitis with chronic cough
(OR¼ 3.1, 95%CI¼ 1.7–5.7), and even more so with laryngeal disorders
(OR¼ 4.4, 95%CI¼ 2.6–7.4). In all models, the association of erosive esophagitis
with any extra-esophageal symptoms was strong and mainly consistent with each
of the symptoms separately (fully-adjusted model: OR¼ 4.6, 95%CI¼ 2.9–7.3).
Conclusion: Our findings indicate that the prevalence of extra-esophageal symp-
toms is higher among patients with erosive esophagitis in a transitional country
characterized conventionally by the employment of a Mediterranean diet.
Therefore, the upper endoscopy should be part of the evaluation in patients
with suspected reflux-related chronic cough and laryngeal disorders.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Gastroesophageal reflux disease (GERD) is a disease caused by
backflow of gastric contents into the esophagus due to the failure of physiological
antireflux mechanisms and can lead to esophageal and extraesophageal sympto-
matology. Extraesophageal reflux (EER) is a condition where refluxate penetrate
above the upper esophageal sphincter (UES) in to the oral cavity, pharynx, upper
and lower respiratory tract and leads to pathological changes like e.g. chronic
cough, globus pharyngis, laryngitis, pharyngitis, rhinosinusitis, otitis media,
bronchial asthma, COPD, sleep apnea and noncardiac chest pain. Currently
there is no suitable, non-invasive diagnostic method applicable for GERD in
clinical practice. Exhaled breath condensate (EBC) and saliva are two easily
obtained samples that could be used in monitoring of patients suffering from
extraesophageal symptoms of GERD. The aim of this study was to compare the
pH and total ionic profile of EBC with 24-hour multichannel intraluminal impe-
dance and pH monitoring (MII-pH) and salivary Peptest in a group of patients
with acid reflux (pH5 4), weakly acid reflux (pH 4–7) and healthy controls.
Aims & Methods: A portable EBC sampler was used for collection of EBC. 10mL
sample aliquots of EBC were analyzed. For pH measurement, the CO2 from EBC
was removed with N2 gas for 5min. The pH of EBC was measured with a pH-
microelectrode and total ionic profile (anions, cations, organic acids - NH4
þ, Kþ,
Ca2þ, Naþ, Mg2þ, Cl, NO2
, NO3
, SO4
2, acetate, lactate, propionate, buty-
rate) was analyzed by capillary electrophoresis in each sample. Saliva was col-
lected using the commercial Peptest sampling containers, applied to the Peptest
lateral flow devices and analyzed using the device reader. The data from EBC
were compared with MII-pH and Peptest. In total the study comprised of 39
participants. The patients were divided by dominant findings from MII-pH in to
groups with acid reflux (n¼ 17), weakly acid reflux (n¼ 8) and without reflux
(n¼ 14).
Results: The values of pH (after CO2 removal with N2) were significantly higher
in the group with acid reflux (p5 0.01), (mean pH 7.13, interquartile ranges
6.83–7.47) and in the group with weakly acid reflux (p5 0.01) (7.37, (7.18–
7.57)) vs. healthy controls (6.8, (6.65–6.99)). Butyric acid (BA) was the second
most significant parameter that was significantly elevated (p5 0.01) in both
patient groups (acid reflux- mean BA 2.29mM, weakly acid reflux- mean BA
3.33mM) compared to healthy subjects (mean BA 0.69 mM).
Further statistically significant differences were found in chloride (Cl), nitrate
(NO3
) and sodium (Naþ) ions concentration. Cl was elevated (p5 0.01) in
group with acidic reflux vs. healthy controls and NO3
 and Naþ were elevated
(p5 0.01) in group with weakly acidic reflux vs. healthy controls. Peptest for
saliva sampling and pepsin analysis showed no statistically significant differences
within the groups. In the groups of patients with acid reflux, the incidence of high
pepsin concentration (above 75 ng/ml) was found only in 50% of the patients.
Conclusion: We found statistically significant difference in pH and selected ions
from EBC between different groups of patients and healthy controls. The ana-
lysis of selected parameters in EBC could provide a fast and non-invasive diag-
nostic method for GERD patients with EER symptoms in the future. This can
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potentially reduce the diagnostic cost and avoid unnecessary invasive MII-pH
testing in future. Unlike the EBC, pepsin analysis using Peptest did not provide
any diagnostic value.
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Introduction: Impedance-pH testing is actually considered the gold standard diag-
nostic tool for reflux assessment. In fact, it allows to characterize any type of
gastro-esophageal reflux (GER), namely acid and non-acid, and therefore per-
mits – in presence of typical reflux symptoms – to diagnose functional heartburn
(FH) based on the lack of abnormal acidic or non-acidic refluxate (i.e. normal
number of reflux episodes and negative reflux-symptom association). Gastrin-17
(G17) has been proposed as a non-invasive marker of GERD, due to the negative
feedback between acidic output and this hormone. Indeed, preliminary data
showed that intermediate values of G17, between very low to normal levels,
may identify GERD subjects with abnormal non-acid reflux.
Aims & Methods: We aimed to correlate various patterns of refluxate (i.e. pre-
dominant acidic refluxate, predominant non-acidic refluxate and no reflux at all),
as assessed by impedance-pH, with different levels of G17 in endoscopy-negative
subjects with heartburn. Thirty-five consecutive patients (19F/16M, mean age 47
years, range 31–56 years), all reporting heartburn since 6 months with at least 3
episodes/week, entered the study. All patients underwent upper endoscopy off-
medication and in case of no lesions were classified as endoscopy-negative. In all
subjects, impedance-pH was performed off-therapy and blood determination of
G17 (Biohit Oji, Finland; normal values: 1–9 pmol/l) was evaluated on the same
day of reflux monitoring. Impedance-pH tracings were blindly and manually
analyzed to detect the distal acid exposure time (AET abnormal if 3.2% over
24 hours) and the number as well as the characteristics of reflux episodes (acidic/
weakly acidic refluxate). Patients were then divided in three groups according to
the results of impedance-pH: a) Group A: subjects with increased number of acid
refluxes or abnormal AET; b) Group B: subjects with increased episodes of non-
acid reflux and normal AET; c) Group C: subjects without increased of any kind
of reflux and normal AET.
Results: According to impedance-pH results, 14 out of 35 patients had increased
acid reflux episodes or abnormal AET (Group A), 14 patients showed increased
non-acid reflux episodes (Group B) and 7 patients had no increased number of
any kind of GER (Group C). In the Group A, the mean value of G17 was
0.9 pmol/l, in the Group B was 2.6 pmol/l, and, in the Group C was 5.1 pmol/l
(p5 0.01). Very low G17 levels were significantly associated with increased acid
reflux episodes or abnormal AET, confirming the background of the negative
feedback between acidic output and G17 levels. Interestingly, when impedance-
pH showed a feature of non-acid reflux pattern (Group B), levels of G17 were
always low, but higher than in case of acid reflux pattern (Group A) (p5 0.05).
Finally, when impedance-pH did not show any kind of abnormal reflux, suggest-
ing a diagnosis of FH, G17 levels were always normal.
Conclusion: In this preliminary study, G17 levels well correlated with the three
different categories of patients suffering of heartburn and included in the NERD
umbrella (i.e. NERD patients with increased acid reflux episodes or abnormal
AET, endoscopy-negative patients with increased non-acidic reflux and subjects
with FH), suggesting its use as surrogate marker of NERD or non-acid reflux
disease, without the need of performing invasive tests.
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Introduction: As a treatment for gastro esophageal reflux disease (GERD),
proton pump inhibitors (PPIs) are the mainstay of medical therapy.
Laparoscopic fundoplication is generally advised when symptoms are poorly
controlled with PPIs and is regarded as a gold standard of treatment, with
excellent control in the short- and midterm. Long-term results, however,
remain equivocal. Following on from the principles of surgical fundoplication,
a variety of endoscopic procedures for GERD have been proposed to achieve
non-surgical control. Linx procedure, Stretta have been proposed as less invasive
options.
Aims & Methods: We recruited all patients who had GERD refractory to stan-
dard medical therapy to see whether anti reflux mucosectomy prevents acid
reflux into the esophagus. We screened all GERD patients who were refractory
to proton pump inhibitors, hydrogen 2 receptor blockers and alginates and had
an endoscopy suggestive of a lax cardia with mucosal flap valve grading of 1 to 3.
We performed a baseline screening endoscopy to rule out a hiatus hernia and to
exclude helicobacter infection. A GERDQ questionnaire was filled by all the
patients indicative of severity of reflux All patients had a high resolution mano-
metry (Sandhill scientific) to exclude significant dysmotility and 24 hour pH
measurements using Zephyr pH probe (Sandhill scientific) on therapy to demon-
strate significant acid reflux. Only patients with mucosal flap valve grading 1, 2
or 3 were selected for anti reflux mucosectomy.
Results: Technique: Crescentic ARMS of the esophagogastric junctional (EGJ)
mucosa was conducted with the standardized technique of endoscopic mucosal
resection (EMR) of at least 3 cm length in the stomach, with the length of muco-
sal resection at the cardia measured in retroflexion from the gastric side. ARMS
was conducted along the lesser curve of the stomach, thus preserving a sharp
mucosal valve at gastric cardia. All the patients who underwent ARMS had a
significant reduction in the DeMeester score, with predominant decrease in the
recumbent acid exposure. 7/12 patients were able to discontinue all the medical
therapy. PPI dose reduction was possible in the other patients with a mean
reduction of 50%, alginates were stopped in all patients and H2RA were also
discontinued.
Conclusion: Results suggest a potential anti-reflux effect of ARMS. The mechan-
ism is presumed to be due to scar formation after healing of the mucosal defect.
On the gastric side, this induces narrowing of the gastric cardia opening, while
preserving and/or re-creating a robust his angle. After ARMS, the lesser curve of
the gastric cardia takes on an almost ‘‘mechanically-stitched’’ appearance. The
mucosal flap is rebuilt and looks well-defined. Furthermore, the lesser curve side
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of the EGJ is shortened with scar formation, and greater curve of EGJ (his angle
side) is kept non-scarred and therefore retains its flexibility as a mucosal flap
valve. The quantity of mucosa to be resected to induce appropriate (‘‘not too
tight and not too loose’’) scar formation is a key issue in this procedure. Total
circumferential resection causes stricturing as demonstrated in previous studies,
while subtotal dissection, which we have termed crescentic, produces better
results in this regard, while still resulting in symptom control. Mucosal flap
valve grading is not only a good predictor of reflux in these patients but also
is a prognostic marker of effectiveness of ARMS, i.e. higher the grade worse the
outcome. Perhaps tailoring the extent and type of mucosal resection (EMR vs.
ESD) according to the mucosal flap valve grading may be a better predictor of
outcome than a box standard procedure. This technique has a potential role in
people with oesophageal dysmotility wherein Nissen’s fundoplication is relatively
contraindicated.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Observational and epidemiologic data have suggested an associa-
tion between proton pump inhibitor (PPI) use and osteoporotic fractures. To
evaluate potential mechanisms for this association, we measured bone turnover,
bone mineral density (BMD), true fractional calcium absorption (TFCA), and
serum and urine mineral levels in healthy postmenopausal women taking PPIs or
placebo for 26 weeks.
Aims & Methods: Postmenopausal women aged 45–75 were randomised to daily
oral 60-mg dexlansoprazole (DEX), 40-mg esomeprazole (ESO), or PBO for 26
wks with follow-up at wk 52. Primary endpoints were 26-wk % change vs pla-
cebo in procollagen type 1 N-terminal propeptide (P1NP) and C-terminal telo-
peptide of type 1 collagen (CTX). Additional endpoints included changes in
BMD (26 and 52 wks) and serum and urine mineral levels (26 wks). Fractures
between baseline and wk 26 were recorded as adverse events. TFCA (0 and 26
wks) was measured in a subset (n¼ 34) of patients.
Results: Excluding 1 disqualified site, 115 women were randomised and 93 com-
pleted the study. There were no substantial differences in age, BMI, baseline
serum calcium, or vitamin D levels between groups. The bone turnover markers
P1NP and CTX remained within normal range during 26 wks of PPI therapy.
Within each group, there was no statistically significant 26-wk change in bone
turnover, except a small increase in CTX levels with DEX (0.12 ng/mL, 95% CI
0.03–0.23). The 26-wk median % increases in P1NP from baseline vs PBO (dif-
ference in median % change [95% CI] were 19% (7%30%) for DEX and 18%
(7%30%) for ESO. CTX levels increased vs PBO by 27% (13%43%) for
DEX and 22% (8%36%) for ESO. PPI effects on BMD, serum and urine
mineral levels, and parathyroid hormone were not statistically different vs
PBO. Median % change from baseline in TFCA vs PBO was not statistically
significant for DEX, but was significant for ESO (6%, 95% CI 2%11%). No
spontaneous fractures occurred during treatment; 1 traumatic foot fracture
(DEX) and 1 humerus fracture (circumstance unknown; ESO) occurred during
follow-up.
Conclusion: 26 wks of DEX or ESO therapy increased bone turnover markers,
but did not reduce BMD, TFCA, or serum or urine mineral levels. ESO increased
TFCA by 51%. Although bone turnover markers increased with PPI therapy,
levels remained within the normal ranges. No clear explanation for an association
between PPI therapy and fracture risk was found in this study.
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Introduction: Raft-forming alginates may inhibit gastroesophageal reflux; how-
ever, remains unexplored effect of alginates on postprandial processes in the
stomach.
Aims & Methods: 25 patients (14 F, age 23–69) with typical GERD symptoms,
participated in this study. All patients underwent a 3-hour combined gastro-
esophageal pH-impedance monitoring with standardized breakfast (muffin and
coffee). To determine the effect of alginates on postprandial reflux and pH in the
esophagus and stomach, all patients underwent a repeat of similar monitoring the
next day but in this case, they took alginate after breakfast. The difference in pH
in the esophagus, in two parts of the stomach and the different types of gastro-
esophageal reflux (acid, low acid, alkaline, liquid, gas & mixed) was estimated.
To evaluate the effects of raft-forming alginate on the severity of postprandial
reflux in patients with GERD and for the postprandial stomach content.
Results: Monitoring with alginate showed significantly (P5 0.05) less number of
acid [average values 5.42 0.69 (Mm) vs. 3.33 0.43 during 1st postprandial
hour and 3.96 0.8 vs. 1.82 0.57 during 2nd postprandial hour] and gas
[0.26 0.06 vs. 0.08 0.05 during 1st postprandial hour and 0.47 0.35 vs. 0
during 2nd postprandial hour] gastroesophageal reflux, but increased of
number low acid reflux [2.52 0.46 vs. 3.91 0.82 during 1st postprandial
hour and 1.00 0.42 vs. 2.16 0.45 during 2nd postprandial hour; P4 0.05].
Also noted is a significant (P5 0.05) increase in the pH in the esophagus for
120 minutes after ingestion [average pH values 6.04 0.27 vs. 4.86 0.23 during
0–60min., and 5.93 0.25 vs. 4.15 0.26 during 60–120min.]. pH in the gastric
cardia (a typical place of formation of postprandial acid pocket) showed signifi-
cant (P5 0.05) higher values for the first 60 minutes after intake of alginate [pH
4.3 0.37 vs. 3.04 0.25], during 60–90min. pH values wasn’t significantly
(P4 0.05) different [2.75 0.45 vs. 2.43 0.20]. In the stomach body no signifi-
cant effect of the drug on pH was recorded [average pH values for stomach
2.56 0.46 vs. 2.1 0.18 during 1st postprandial hour and 2.29 0.49 vs.
2.09 0.18 during 2nd postprandial hour; P4 0.05].
Conclusion: Our findings demonstrate that raft-forming alginate is an effective
means for the prevention of postprandial acid and gas reflux and to reduce the
injurious effect of acid in the esophagus. At the same time alginate showed no
effect on stomach content in the postprandial period, it means that the main
mechanism of action is through the movement of postprandial acid contents of
the stomach from the lower esophageal sphincter, but not the neutralization of
stomach acid, unlike nonraft-forming antacids and PPIs.
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Introduction: S-isomer (S) pantoprazole is more bioavailable and less dependent
on cytochrome 2C19 than is racemic pantoprazole.
Aims & Methods: We aimed to evaluate the efficacy and safety of 10mg S-panto-
prazole for treatment of non–erosive reflux esophagitis (NERD). This study was
designed as a multicenter, randomized, double-blind, placebo controlled
trial.NERD was defined as reflux symptoms and normal endoscopy findings.
Patients were allocated to take either 10mg S-pantoprazole or placebo once daily
for 4 weeks, after which reflux symptoms were reassessed. Recurrence of symptoms
was assessed at 4 weeks after cessation of medication. The efficacy endpoints were
complete relief of symptoms, improvement of reflux symptoms, and safety.
Results: Eighty-eight patients were randomly assigned to the S-pantoprazole
group (25 males, 43.7 years old) and 86 to the placebo group (32 males, 43
years old), and 163 patients were subjected to a per protocol analysis. A higher
proportion of patients in the S-pantoprazole group had complete symptom relief
(34% vs. 14%, P5 0.001). In both groups, symptoms of heartburn, acid regur-
gitation and epigastric discomfort significantly improved after treatment com-
pared with baseline; however, improvement of all symptoms was greater in the s-
pantoprazole group compared to placebo group. Therapeutic gains in controls of
heartburn, acid regurgitation and epigastric discomfort were 0.66, 1.82, and 0.57.
The factors associated with poor symptom responsiveness to PPI were older age,
female sex, greater body mass index and symptom severity in both groups.
Conclusion: S-pantoprazole (10mg) was more efficacious than placebo in provid-
ing reflux symptom relief in patients with NERD, especially acid regurgitation
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Refractory non erosive reflux disease (NERD) is defined by absence
of clinical response to a 12-week course of proton pump inhibitors (PPI) at full
dose in absence of esophagitis. It accounts for about 20% of all NERD cases. 24-
hour multichannel intraluminal impedance pH (MII-pH) monitoring should give
useful patho-physiological information about refractory NERD. Therefore, our
aim was to assess whether this technique could be useful to guide a ‘‘tailored’’
therapy to refractory NERD patients.
Aims & Methods:We retrospectively recruited patients undergoing MII-pH mon-
itoring for refractory NERD. All patients had undergone upper endoscopy, and
cases of esophagitis were excluded. No patient received PPI during MII-pH
monitoring. Subjects were subgrouped into 3 categories according to Zerbib’s
classification: i) Acid reflux (exposure to pH5 4 for at least 1.1% of record
time), ii) Non acid reflux (symptom association probability to pH4 4 reflux
episodes 495%) and iii) Functional heartburn (no pathologic reflux, with symp-
tom association probability 550%). MII-pH guided therapy was performed as
follows: patients with acid reflux received PPI at double dose, patients with non
acid reflux PPI at full dose plus alginates and patients with functional heartburn
levosulpiride 75mg/day for 4 weeks. A visual analogue scale (VAS) ranging 0–
100 was administered before and after such tailored therapy to evaluate overall
symptoms. Responders were defined by VAS improvement of at least 10%.
Comparisons between continuous variables were performed by ANOVA or
paired/unpaired t-test where required, and Fisher’s exact test was applied to
categorical variables. Variables with statistical significance p5 0.10 at univariate
analysis were analyzed by binomial multivariate regression analysis, aimed to
investigate factors predictive of response to tailored therapy.
Results: Thirty-four patients with refractory NERD were selected (female:male
ratio 20:14, mean age 47.4 12.8). Twelve had acid reflux, 7 non acid reflux and
15 functional heartburn. Overall effectiveness of tailored therapy was 82.3% (28
out of 34), and it did not differ between subgroups (91.7% acid reflux, 71.4%
non acid reflux, 80.0% functional heartburn, p¼ 0.51). At univariate analysis,
therapy failure directly correlated with dysphagia (OR¼ 0.15, p¼ 0.10) and
inversely with sensation of slow digestion (OR¼ 7.70, p¼ 0.05). However, at
multivariate analysis, these parameters were not statistically significant. We
found a mean VAS reduction of 30.2 24.9, which was similar between acid
reflux (36.7 22.7), non acid reflux (30.0 27.7) and functional heartburn
(25.0 25.7), p¼ 0.49.
Conclusion: A tailored approach to refractory NERD, guided by MII-pH mon-
itoring, demonstrated to be effective, independently from disease subtype.
Therefore it should be advised to patients who complain of symptom persistence
despite PPI therapy.
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Introduction: STW5, a herbal combination preparation of nine different plant
extracts (Iberis amara (L.), Menthae piperitae (L.) Chamomilla recutita (L.),
Glycyrhiza glabra (L.), Angelica archangelica (L.), Carum Carvi (L.), Silybium
marianum (L.) Gaertn. Melissa officinalis (L.) und Chelidonium majus (L.)) has
been extensively studied for the treatment of gastrointestinal disorders resulting
in an recommendation in the German therapy guidelines for both upper and
lower functional gastrointestinal disorders (1). We investigated the mode of
action of STW5 in a rat model of reflux-esophagitis (RE) (2). RE is the most
common condition treated by gastroenterologists with possible long-term impli-
cations such as Barrett’s esophagus and esophageal adenocarcinoma.
Aims &Methods:We were especially interested in the tight junction proteins (TJ),
which are multi-protein complexes in epithelial and endothelial cells known to
contribute to the barrier-function, but recently discovered to play an important
role in tumorigenesis (3). TJ proteins like ZO-1 and 2 participate in cell-cycle
regulation, occludin (OCCL) regulates the mitotic entry via centrosome separa-
tion and correlates with decreased cell proliferation, claudins (CLDNs) are made
responsible for increased proliferation of the crypt cells (3). CLDN 1, 3, 4, 5, 7, 10
and 16 have been found altered in various types of cancer and OCCL is regarded
an anti -transformation protein (3).
Results: In our model, RE was induced by surgical methods and rats (n¼ 6 per
group) were treated with STW5 (0.5 or 2ml/kg) or the proton pump inhibitor
(PPI) omeprazole (O) (30mg/kg) as described earlier (2). RNA was isolated from
defined tissue areas of the esophagi. In the inflamed tissue we found a simulta-
neous transcript down regulation of claudin 3 (p5 0.0001), confirmed by RT-
PCR. Also claudin 4, claudin 23, OCCL, MARVELD2 and ZO1 were signifi-
cantly downregulated (p5 0.001). The down regulation of ZO1 was seen by
Western Blot, too. Transcripts of MarvelD1 and JAM 2 were increased. The
treatment of rats with STW5 (2ml/kg) or O (partially) normalized the esophageal
tissue transcripts of ZO1, CLDN3, CLDN23, OCCL, MARVELD1, 2 and JAM.
Conclusion: Data demonstrate a reversal of inflammatory changes in the TJ-
proteins by STW5 and O. They also suggest that inflammatory changes in TJ
are consistent with TJ-protein modulations in tumorigenesis. Subsequent studies
are necessary to better define the complex role of TJ in inflammatory processes
and in tumorigenesis and the potential benefit arising from a treatment with
STW5 or O.
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Introduction: Chronic reflux, a risk factor for the development of Barrett’s eso-
phagus (BE), causes damage to the normal squamous epithelium of the esopha-
gus, which eventually is replaced by a columnar type of epithelium. It has been
shown that bile acids (BAs) play a role in the development of BE. The effect of
different BAs in the refluxate has been poorly studied with respect to the patho-
genesis of BE. Insights in the effects of the bile components in reflux can help
provide more efficacious targets for preventing the development of metaplasia
and the progression from BE to EAC. Before being released into the duodenum,
BAs produced by the liver are conjugated with either taurine or glycine. BAs not
only have detergent properties, but can also act as signaling molecules by acti-
vating the farnesoid X receptor (FXR) and G-protein coupled bile acid receptor
(TGR5). Both receptors are upregulated in BE and EAC compared to normal
squamous mucosa, suggesting a possible role in the progression of BE (De
Gottardi 2006; Hong 2010).
Aims & Methods: The aim of the study was to analyze refluxates of BE patients
and evaluate the effect of the different bile components on metaplastic gland
development and bile receptor activation.
Results: Determination of the bile composition in refluxate of BE patients by
HLPC showed the presence of both glyco-conjugated (67.6 8.8%) and tauro-
conjugated BAs (31.5 9.1%). Only a low percentage of unconjugated BAs was
found in the patient refluxates (0.5 0.4%). Although unconjugated BAs were
absent in our refluxates, others have shown their presence in GERD patients
(Nehra 1999). Deoxycholic acid (DCA), a secondary bile, is formed through
deconjugation by microbial enzymes present in the colon, but the increase in
pH due to PPI use can cause gastric bacterial overgrowth, resulting in the pre-
sence of DCA in reflux (Theisen 2000). Each of the six conjugated bile compo-
nents [glycocholic-, glycodeoxycholic-, glycochenodeoxycholic-, taurocholic-,
taurodeoxycholic- and taurochenodeoxychoic acid] and DCA were tested indivi-
dually in vivo for 16 weeks at 10mM. All mice developed multi-layered glands at
the SCJ (36/36). Overall, mice treated with glyco-conjugated BAs developed
more glands compared to DCA treated or tauro-conjugated BAs. Also alcian
blue expression, representing mucin production, was higher compared to DCA
treated or tauro-conjugated BAs treated group. To investigate which bile com-
ponents are able to activate bile receptors we transfected primary mouse esopha-
geal keratinocytes with either TGR5 or FXR and treated the cells with different
BAs. Activation of the receptors result in conformational changes, which can be
detected by measuring fluorescence resonance energy transfer (FRET). Both
DCA and all conjugated BAs were able to activate the membrane bound
TGR5 receptor, as shown by a change in signal. DCA was able to activate
FXR, while the addition of all conjugated BAs did not result in a signal change.
Conclusion: The possibility of DCA to activate the FXR may result in the onset
of different genes, which might result in the progression from BE to EAC.
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Introduction: Barrett’s esophagus (BE) is a metaplastic abnormality in patients
with Gastro-esophageal reflux disease in which the normal stratified squamous
epithelium in the esophagus is replaced by columnar epithelium. BE predisposes
for esophageal adenocarcinoma. One underlying mechanism of BE is that colum-
nar stem cells residing in the esophageal mucosa (e.g., in submucosal glands) or
multipotent stem cells give rise to the columnar lining. Bone Morphogenetic
Proteins (BMPs) are a family of growth factors that control tissue architecture,
homeostasis and stem cell differentiation. In BE, BMP4 is upregulated in colum-
nar cells.
Aims & Methods: Organoid cultures are widely used because they mimic in vivo
differentiation of self-organizing stem cells and represent the perfect model to
study stem cell interaction in basic and translational research. We developed an
in vivo organoid model of human BE to investigate the potential to modulate the
metaplastic process using an innovative anti-BMP2/4 llama-derived Dwarfbody
(DB). Endoscopic BE biopsies were implanted into immunocompromised mice
intramuscularly and grown for a period of three months with DB or control.
These structures were assessed histologically and immunohistochemically (IHC)
using panels of squamous, intestinal and stem cell markers.
Results: BE organoids were lined by a columnar epithelial layer containing goblet
cells and recapitulated the crypt and villous regions seen within BE glands. IHC
validation confirmed that the xenograft structures were of human origin and
expressed markers of intestinal differentiation (CK8, CDX2 and villin). In con-
trast, treatment with the BMP inhibitor lead to the formation of multi-layered
squamous epithelium expressing both the stem cell marker p63 and the squamous
marker CK5.
Conclusion: Preliminary results demonstrate that inhibition of BMP2/4 in this
model enhanced the amount of squamous epithelium. These pre-clinical results
may be translated to the clinical setting in order improve treatment of BE and as
such prevent the development of esophageal adenocarcinoma.
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Introduction: Metaplastic phenomena in the upper gastrointestinal tract are still
poorly understood. A prominent theory is that Barrett’s esophagus originates
from gastric glandular epithelium. However, in absence of evidence that the
gastric stem cell has broad differentiation potential, this theory remains contro-
versial. The gastroesophageal junction is a high prevalence area for metaplasia
and subsequent cancer. Characteristic of this area are the gastric cardia glands
which cover only the most proximal part of the anatomic gastric cardia. Recent
evidence from human and mouse studies has shown Barrett’s esophagus can
originate from these gastic cardia glands.1, 2 If it can be shown that gastric
cardia glands contain elements associated with positional misspecification, this
theory could be substantially bolstered. HOX genes are a family of transcription
factors that convey positional information. The 3’ to 5’ sequence of HOX genes
corresponds to the sequence in which they act along the anterior to posterior axes
of the gut. This property is termed collinearity and links clustering to function. In
gastrointestinal physiology, HOXA13, a 5’ member of the HOXA cluster, has an
expression pattern restricted to the colonic epithelium. However, pathological
metaplastic lesions of the esophagus and stomach are also characterized by
HOXA13 expression. This in parallel with the similarities of these lesions with
physiological colonic morphology. Hence, investigating HOXA13 expression in
gastric cardia glands appears a rational strategy in assessing the potential of this
gastric cardia epithelium to serve as the origin of Barrett’s esophagus.
Aims & Methods: We aimed to determine HOXA13 expression in physiological
gastric cardia glands. Firstly, strips of tissue from surgical specimens containing
squamous esophageal epithelium, gastric cardia glands, and oxyntic stomach
glands, were collected. These were continuous strips, from proximal to distal,
to preserve morphological information. Material from three patients was
selected, they suffered from either a neuroendocrine tumor, or decompensated
achalasia, or an adenocarcinoma. Antibodies against HOXA13 were found not
to be specific. Therefore, RNA in situ hybridization by RNA-scope was per-
formed to visualize HOXA13 RNA. Secondly, a Hoxa13GFP x C57BL/6 J het-
erozygous mutant mouse model was used. In these animals, the cardiac glands
were analyzed directly for GFP expression using a fluorescence confocal
microscope.
Results: All three patients showed HOXA13 expression of a portion of gastric
cardia epithelial cells. The squamous epithelium, the oxyntic epithelium, and the
stroma did not show any signal. The signal is located relatively close to the base
of the crypts of the cardiac glands. The Hoxa13GFP x C57BL/6 J heterozygous
mice showed GFP expression localized to the nucleus of some of the epithelial
cells of the cardiac gland. No nuclear signal was detected in the squamous or
oxyntic epithelium, nor in the stroma. The colonic epithelium of the mouse
showed nuclear GFP signal. Rectal squamous epithelium was negative as well
as ileal epithelium, in accordance with HOXA13 collinearity in mouse and
human. A littermate negative for Hoxa13GFP was analyzed and showed no
nuclear GFP signal in either gastric cardia gland cells or in colon epithelial cells.
Conclusion: Gastric cardia gland epithelial cells in both human and mouse exhibit
HOXA13 expression. All other physiological upper gastrointestinal tract tissues
are HOXA13 negative in line with HOX gene collinearity in the gut. This dichot-
omy proves positional information in these glands is discordant with their actual
location. These findings suggest that gastric cardia glands have a broad differ-
ential potential. This is consistent with an origin of Barrett’s metaplasia in the
gastric cardia and might be indicative of Barrett’s not being a true
transdifferentiation.
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Introduction:We have previously demonstrated that transcriptionally active high-
risk HPV (hr-HPV) is strongly incriminated in Barrett’s dysplasia (BD) and
oesophageal adenocarcinoma (OAC) using mainly fresh frozen tissue.1–4 This
study aimed to identify biomarkers of active HPV infection in Barrett’s metapla-
sia, (BM)/BD/OAC by immunohistochemical staining (IHC) of formalin-fixed
paraffin embedded (FFPE) tissue for aberrations of p53 and the retinoblastoma
(pRb) pathway which are targets for the viral oncoproteins, E6/E7 respectively.
Aims & Methods: Prospectively, BM(n¼ 81)/BD(n¼ 72)/OAC(n¼ 65) FFPE
specimens were subjected to IHC staining for pRb, p16INK4A, cyclin D1, p53
and RNA in-situ hybridization (ISH) for E6/E7 transcripts. HPV DNA was
determined via PCR in fresh frozen specimens. Viral load measurement (real-
time PCR) and Next Generation Sequencing of TP53 was also performed.
Results: Of 218 patients, 56 were HPV DNA positive [HPV16 (n¼ 42), 18
(n¼ 13), 6 (n¼ 1)]. Viral load was low. Transcriptionally active HPV (DNAþ/
RNAþ) was only found in the dysplastic and adenocarcinoma group (n¼ 21).
The majority of HPV DNAþ/RNAþ BD/OAC were characterized by
p16INK4Ahigh (14/21, 66.7%), pRblow (15/21, 71.4%) and p53low (20/21,
95%) and was significantly different to controls [combination of HPV DNA-/
RNA- (n¼ 94) and HPV DNAþ/RNA- cohorts (n¼ 22)] p53low had the stron-
gest association with DNAþ/RNAþ oesophageal lesions (OR¼ 23.5, 95%
CI¼ 2.94–187.8, p¼ 0.0029). Seventeen HPV DNAþ/RNAþ BD/OAC identi-
fied as p53low, were sequenced and all but one exhibited wild-type status.
pRblow/p53low provided the best balance of strength of association (OR¼ 8.0,
95% CI¼ 2.6–25.0, p¼ 0.0003) and sensitivity (71.4%)/specificity (71.6%) for
DNAþ/RNAþ BD/OAC. Transforming infections i.e viral positive BD/OAC
lesions exhibiting p16high/pRblow was found in 47.6% of the RNA
þ patients
and 31.8% of RNA subjects.
Conclusion: Active HPV involvement in BD/OAC is characterized by wild-type
p53 and aberrations of the retinoblastoma protein pathway. Transforming infec-
tions which are a feature of HPV driven lesions was identified in a significant
proportion of virally positive BD/OAC.
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Introduction: Barrett’s oesophagus is defined as the replacement of the normal
stratified oesophageal squamous epithelium with a metaplastic columnar intest-
inal-like epithelium. Dipeptidyl peptidase-4 (DPP4) is an integral membrane
glycoprotein that is highly expressed on the small intestinal brush border.
DPP4 is part of a larger enzyme family that also includes DPP8, DPP9 and
fibroblast activation protein (FAP).
Aims & Methods: We aimed to characterise DPP4 enzyme activity in a panel of
oesophageal metaplasia, dysplasia and cancer cell lines, and in Barrett’s oeso-
phagus patient biopsies. FLO-1, OE33 and JH-EsoAd1 (oesophageal adenocar-
cinoma), OE21 and TE7 (oesophageal squamous cell carcinoma), GihTERT,
GohTERT, ChTERT (dysplastic Barrett’s) and QhTERT (non-dysplastic
Barretts) were grown to confluence in T75 flasks using standard cell culture
techniques. Oesophageal squamous tissue biopsies were collected from non-
Barrett’s patients participating in the Barrett’s screening endoscopy program at
Flinders Medical Centre (n¼ 6). Duodenal and gastric tissue biopsies were also
collected as positive and negative control tissue respectively. Membrane and
soluble enzyme activity was determined in cell and tissue extracts by colorimetric
enzyme assay using the DPP selective substrate H-Gly-Pro-pNA. Sitagliptin (a
DPP4 selective inhibitor) and 1G244 (DPP8/9 selective inhibitor) were used to
define specific enzyme activity. Final enzyme activity was expressed as nm pNA
released/min/mg protein. Data is expressed as mean standard error of the
mean.
Results: Relatively high DPP activity was detected on the membrane of OE33
(13.92 nm pNA/min/mg protein), GihTERT (6.93 nm pNA/min/mg protein),
GohTERT (2.65 nm pNA/min/mg protein) and QhTERT (1.80 nm pNA/min/
mg protein) compared to all other cell lines, where activity was 51 nm pNA/
min/mg protein). Addition of 1mM sitagliptin completely inhibited enzyme
activity in OE33 cells, indicating that membrane enzyme activity was specific
to DPP4. Cytoplasmic DPP activity was highest in FLO-1 (3.77 nM pNA/min/
mg protein) and ChTERT (2.39 nM pNA/min/mg protein). Addition of 1mM
sitagliptin did not reduce cytoplasmic DPP activity in FLO-1 cells, suggesting the
presence of other peptidases. High DPP4 activity was detected in the membrane
fraction of duodenal biopsies (45.90 8.55 nm pNA/min/mg protein) compared
to gastric (3.35 1.59 nm pNA/min/mg protein) and oesophageal biopsies
(0.65 0.71 nm pNA/min/mg protein). In contrast, differential DPP activity
was detected in the soluble fraction of all duodenal, gastric and oesophageal
tissue biopsies. Using 1uM sitagliptin, this was found to be specific to DPP4 in
oesophageal samples, but likely derived from other peptidases in gastric and
duodenal samples.
Conclusion: Our preliminary in vitro findings suggest a differential pattern of
DPP activity in Barrett’s metaplasia and dysplasia, which could have potential
significance as a biomarker target for the continuum of Barrett’s oesophagus.
Human tissue sample collection is ongoing to define specific DPP enzyme activity
and expression in tissue specimens from Barrett’s metaplasia and dysplasia sub-
groups compared to normal, non-Barrett’s tissue.
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Introduction: Barrett’s Oesophagus (BE) is an acquired condition resulting from
oesophageal reflux that causes intestinal metaplasia. These mucosal alterations
can progress to dysplastic lesions, which ultimately lead to oesophageal adeno-
carcinoma (EAC). The incidence of EACs is rising in the Western world and
5-year survival rates are below 20%. Hence, new diagnostic and prognostic
markers are needed. Since elevated levels of interleukin (IL-) 22 and IL-17A
producing cells are associated with a poor prognosis in colorectal cancer we
wanted to investigate their influence in EACs.
Aims & Methods: None of the patients enrolled in this study received chemo-
radiation therapy prior to surgery and all patients had pathologically confirmed
BE. mRNA expression levels of interleukins in tumour tissue and non-malignant
peritumoral samples of 39 patients were measured. Immunohistochemical ana-
lysis was conducted to investigate interleukins during the progression from BE to
EAC. Interleukins were investigated by flow cytometry in freshly resected eso-
phageal cancer specimens and in its non-malignant peritumoral tissue (n¼ 11).
During routine endoscopy samples from healthy volunteers were obtained and
analysed by flow cytometry as controls (n¼ 5).
Results: During progression from BE to EAC an increase of CD4þ cells was
observed. The number of IL-22þ cells and IL-17Aþ cells as well as the number
of FOXP3þ cells/mg tissue increased in oesophageal cancer and in its peritu-
moral tissue as compared to healthy controls. The relative amounts of IL-22þ
and IL-17Aþ cells decreased while an increase of FOXP3þ cells was observed.
Also more IL-10þ cells/mg tissue were observed in the tumours. In accordance to
the latter finding high IL-10 mRNA expression levels were associated with poor
survival in EAC patients. Interestingly, high mRNA expression levels of IL-10 in
the non-malignant peritumoral tissue also correlated with poor survival.
Conclusion: During progression from BE to EAC the infiltration of CD4þ
immune cells increases. While the relative amount of pro-inflammatory cells
decreases an accumulation of immunosuppressive cells was observed. Our data
suggest that especially regulatory T cells influence overall patient survival in
EAC. Notably, high levels of IL-10 in the non-malignant peritumoral tissue
also demonstrated to be unfavourable for patient survival. Thus, a pro-tumori-
genic field effect in yet unaltered oesophageal mucosa might contribute to local
recurrences despite radical endoscopic or surgical resection.
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Introduction: A range of complex glandular phenotypes exist in Barrett’s esopha-
gus (BE), but how these phenotypes are related and evolve is unknown. Genetic
diversity is an established risk factor for cancer development in BE, yet as phe-
notype not genotype is selected for and as the gland is the unit of selection, we
suggest that phenotypic diversity may confer a increased risk of cancer progres-
sion. Exploiting mutations in the itochondrial genome (MtDNA) as a marker of
clonality we have demonstrated that the glandular phenotypes seen in Barrett’s
represent an evolutionary pathway and that phenotypic diversity also leads to an
increased cancer risk.
Aims & Methods: Biopsies from patients with a new diagnosis or surveillance for
BE were obtained at endoscopy and frozen. Immunohistochemistry was per-
formed on frozen sections for proteins including MUC5AC, MUC2, MUC6
and HþKþ ATPase to distinguish intestinal from gastric cell lineages.
Individual glands were laser capture microdissected and DNA was extracted
using the ARCTURUS PicoPure DNA Extraction Kit. Sanger sequencing
of the entire mitochondrial genome was performed to determine the clonal rela-
tionships between different Barrett’s gland phenotypes.
Gland phenotypes and phenotypic diversity was counted in archived FFPE cases
of BE who had progressed to dysplasia versus those who had not (n¼ 10 in each
group – counts performed in a blinded fashion). Using the Shannon index as a
measure of diversity, 5 distinct BO gland phenotypes were counted to determine
if there was a significant increase in gland phenotype diversity in those biopsies
taken adjacent to dysplastic glands compared to biopsies from patients who did
not have dysplasia.
Results: In 2 separate cases specialised mature intestinal type glands were shown
to be present expressing both MUC2 and MUC5AC. Furthermore, in the same
section MUC5ACþ MUC2- cardia-like Barrett’s glands and MUC5AC-
MUC2þ mature intestinal-like Barrett’s glands were also present. LCM sequen-
cing of DNA extracted from each of these glands yielded an m.7148C4T muta-
tion and m.10492T4C mutation respectively in each gland that was not present
in the stroma. This is the first time that different gland phenotypes have been
demonstrated to be clonal and suggests that Barrett’s displays phenotypic as well
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as genotypic evolution. Patients with dysplasia also show a significant increase in
gland phenotype diversity (Shannon) per biopsy in adjacent to dysplasia glands
compared with patients who do not have dysplasia.
Conclusion: BE is phenotypically diverse with a range of glandular phenotypes
that are clonally related. An increase in phenotypic diversity may be a potential
biomarker for predicting which patients are at risk of progressing from BE to
cancer with implications for diagnostic and surveillance policy.
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Introduction: The importance of skilled endoscopic assessment of Barrett’s oeso-
phagus (BO) has been clearly established and forms part of the British Society of
Gastroenterology guidelines1. Use of Prague classification when reporting on
areas of BO improves standardisation, and adherence to the Seattle biopsy pro-
tocol (quadrantic biopsies every 2 cm) when sampling Barrett’s mucosa is
thought to improve dysplasia detection2. In East Kent Hospitals NHS
Foundation Trust we have created a dedicated nurse-led BO surveillance endo-
scopy list with the aim of improving compliance with guidelines and the quality
of biopsies taken. Here we present a retrospective observational study of patients
who underwent upper GI endoscopy on a general endoscopy (GE) list compared
with the dedicated BO endoscopy (DBO) list.
Aims & Methods: We searched our endoscopy software for patients who had had
an indication for gastroscopy documented as BO and who had an endoscopy on
a GE list from 2012–2013. The same search was performed for patients who were
scoped on the DBO list from 2014–2016. Endoscopy reports were reviewed to
assess the use of Prague classification and determine numbers of biopsies taken.
Biopsy results were reviewed on our electronic pathology database.
Results: One hundred procedures for BO surveillance on GE lists were audited,
comprising 65% male patients with median age 68 years; 60% were performed by
a consultant gastroenterologist and the remainder were performed by other
operators including surgical consultants and gastroenterology registrars. Of the
105 procedures on the DBO lists, 63% of patients were male, median age 70
years. Prague classification was used in 94% of endoscopy reports on the DBO
lists compared with 5% on the GE lists. The Seattle biopsy protocol was
observed in 70/94 (74%) cases on the DBO lists as opposed to 30/100 (30%)
on the GE lists. Dysplasia detection rate (low grade, high grade or indefinite) was
similar in both groups: 8/105 (7.6%) on the DBO list and 6/100 (6%) in the GE
group. All (100%) of the dysplasia detected on the GE lists occurred in proce-
dures performed by consultant gastroenterologists.
Conclusion: Our comparison shows that observance of Prague classification is
significantly higher on the DBO lists when compared with GE lists (94% vs 5%),
and compliance with the Seattle biopsy protocol is similarly higher (74% vs
30%). These are indicators of higher quality endoscopic surveillance on DBO
lists. However, this did not translate to a different dysplasia detection rate which
appeared to be more influenced by the endoscopy operator since all of the dys-
plasia detected on GE lists was identified by consultant gastroenterologists. We
believe that this reflects the additional familiarity of guidelines and possible
greater experience of endoscopists regularly taking BO biopsies. We therefore
recommend that all Barrett’s oesophagus patients have their surveillance endos-
copies performed on dedicated BO endoscopy lists.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
1 Fitzgerald RC et al. British Society of Gastroenterology guidelines on the
diagnosis and management of Barrett’s oesophagus. Gut 2014;63:7–42.
2 Levine DS et al. Safety of a systematic endoscopic biopsy protocol in patients
with Barrett’s esophagus. Am J Gastroenterol 2000;95:1152–7
P0556 ADHERENCE TO QUALITY INDICATORS AND
SURVEILLANCE GUIDELINES IN THE MANAGEMENT OF
BARRETT’S ESOPHAGUS: A RETROSPECTIVE ANALYSIS
D. Westerveld1, V. Khullar2, M. B. Riverso2, Y. Perbtani2, M. Agarwal1, J.
J. Forde1, J. Chakraborty1, T. S. Brar1, F. Ayoub1, A. Gupte2, C. E. Forsmark2,
P. V. Draganov2, D. Yang2
1Medicine, University of Florida, Gainesville/United States of America/FL
2Gastroenterology, University of Florida, Gainesville/United States of America
Contact E-mail Address: dennis.yang@medicine.ufl.edu
Introduction: Adherence to quality indicators and surveillance guidelines in the
management of Barrett’s esophagus (BE) promotes high-quality cost-effective
care.
Aims & Methods: The aims of this study were to evaluate (1) adherence to
standardized classification (Prague Criteria) and a systematic four-quadrant
biopsy protocol, (2) identify predictors of practice patterns, and (3) to assess
adherence to surveillance guidelines for non-dysplastic BE (NDBE).
This was a Single-center retrospective study of endoscopies (EGDs) performed for
BE between June 2008 to December 2015. Data on patient demographics,
procedure characteristics and histology results were obtained from a prospectively
collected endoscopy database and chart review. Adherence to the use of Prague
Criteria and systematic biopsy protocol were assessed based on operative report
documentation. Guideline adherent surveillance EGD was defined as those per-
formed within 6 months of the recommended 3–5 year interval. Uni- and multi-
variate analysis were performed to identify predictors of practice patterns.
Results: A total of 397 patients (66.5% male; mean age 60.1 12.5 years) had an
index EGD during the study period. Adherence to the use of Prague Criteria and
systematic biopsies were 27.4% and 24.1%, respectively. Endoscopists who per-
form therapeutic interventions for BE were more likely to use the Prague Criteria
(OR: 3.16; 95%CI: 1.47–6.82) than those who do not. Longer time in practice (in
years) was positively associated with adherence to Prague Criteria (OR 1.07; 95%
CI: 1.02–1.12; p5 0.01) but with a lower likelihood of performing systematic
biopsies (OR 0.91; 95%CI: 0.85–0.97; p5 0.01). Nearly 41% of patients with
NDBE (11/27) underwent surveillance EGD sooner (range 1–24 months) than
the recommended interval.
Conclusion: Adherence to quality indicators and surveillance guidelines in BE is
low. Operator characteristics, including experience with endoscopic therapy for
BE and time in practice predicted adherence to the use of Prague Criteria and
systematic biopsies. Future efforts are needed to reduce variability in practice and
promote high-value care.
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Introduction: Adenocarcinoma near the esophagogastric junction is one of the
most lethal GI malignancies known. Surgical treatment of these cancers stay
determinative factors of patient survival. Older persons often differ from the
younger adult population in terms of biological and functional perspectives; as
such, they may have particular needs which require an interdisciplinary approach
and intervention, especially when faced with a cancer diagnosis.
Aims & Methods: The aim of this study was to detected expression of TGF-ß and
CD-44 in age specific subgroup. The expressions of TGF-ß and CD-44 were
evaluated immunohistochemically in 23 patients with adenocarcinoma of gastric
cardia who underwent curative surgery (R0) without any neo/adjuvant therapy.
Additionally we analyzed control group of patients with non-cancer lesion or
normal tissue of upper digestive tract (13 patients). We divided the patients into
two groups. Group A consisted of 13 cancer patients and 7 control patients 65
years of age or older, while Group B consisted of 10 cancer and 6 control patients
younger than 65 years of age. The two groups were comparable - there were no
differences between the two groups regarding tumor stage.
Results: Elderly patients have statistically significant better survival (median 20.2
month) compared with younger patients (median 15.4 month) (p¼ 0.045). The
median survival rate of patients without TGF-ß and/or CD-44 expression was
significantly lower (7m) than that of patients with positive expression (415m)
(p¼ 0.003). Regardless of patients age, CD-44 was significantly higher in the
cancer tissue of elderly patients than in younger (p5 0, 035). But no significant
difference was observed in the TGF-ß expression between group A and group B
cancers tissue (p¼ 0.005).
Conclusion: The biology of tumors may be different in elderly patients, leading to
a lower rate of tumor-related mortality.
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Introduction: Barrett’s oesophagus (BO) is considered a premalignant condition
for oesophageal adenocarcinoma (OAC). Once diagnosed, interval endoscopic
surveillance is recommended to promote early detection of dysplasia and cancer.
Occurrence and incidence of dysplasia and cancer among BO vary across popu-
lations. Recent studies show BO patients mortality is mainly related to non-
oesophageal cancer and cardiovascular morbidity.
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Aims & Methods: In this cross-sectional study, our aims were to describe the local
BO clinical, endoscopic and histologic profile in our tertiary referral centre, and
discover whether the Prague classification reporting requirements are filled. We
identified and included all consecutive patients with oesophageal intestinal meta-
plasia (identified by the presence of goblet cells) from March 2009 to May 2015.
All endoscopies and biopsy reports were reviewed: BO segment length, use of the
Prague classification, endoscopic abnormalities, treatment modalities, and histo-
logic findings of dysplasia. Participants were sent a clinical questionnaire, via
which pertinent clinical data including personal and familial cancer history, were
collected.
Results: Clinical profile- Our cohort consists of 406 patients, with a mean age of
60.9 13.3 years, 69% were male. Endoscopic profile- Mean maximal BO length
(Prague classification M) was 2.8 1.9 cm (reported in 49.6% of endoscopies)
Mean circumferential BO (Prague classification C) was 4.9 3.1 cm (reported in
18.1% of endoscopies). Histologic profile- Low-grade dysplasia(LGD) was seen
in 4.4% of patients, high-grade dysplasia (HGD) in 3%, intramucosal carcinoma
(IMC) in 0.7%, and OAC in 2%. A subgroup of 250 patients underwent more
than one endoscopy, allowing for prospective incidence analysis. They had 914
years of follow-up, with a mean number of endoscopies of 4.7 3. The incidence
rates of LGD, HGD, IMC, OAC per 1000 patient years were 20.8, 15.3, 2.2, and
7.6 respectively.
One hundred and fifty-five patients returned the questionnaire. In this subgroup
analysis, we learned BO was diagnosed at 57.8 12.5 years of age, with a mean
duration of 4.9 5.7 years. A personal history of non-oesophageal malignancy
was reported in 15.4%. A family history of BO, OAC and non-oesophageal
cancer were reported in 5.2%, 4.5%, and 35.4%, respectively.
Conclusion: Compared to the information gathered by Katz et.al (1), we demon-
strated a lower rate of LGD, but comparable rates of HGD and OAC. The
personal and familial history of non-oesophageal malignancy was higher than
the oesophageal malignancy rates. Our findings may support the importance of
age appropriate non-oesophageal malignancy screening in BO patients. Physician
compliance in reporting BO according to the Prague classification is lacking.
Factors associated with our local BO profile as well as the implication of family
history requires further prospective studies
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Introduction: Endoscopic mucosal resection (EMR) is an established diagnostic
and treatment tool in the management of Barrett’s oesophagus (BO) with early
neoplasia. Our objectives were to demonstrate EMR’s efficacy in removing early
neoplasia within BO and its usefulness in obtaining comprehensive histological
specimens to accurately stage the early neoplasia and effectively deliver therapy.
Aims &Methods:We have conducted a retrospective analysis using our electronic
database for endoscopic procedures for patients with BO, who underwent EMR
from October 2010 to December 2016. We analysed the resection margins for
both en bloc and piecemeal EMRs. We compared the original histology from the
referral endoscopy to the histology obtained from the EMR, to analyse any
deviation and to demonstrate the importance of histological staging of the
early neoplasia in BO. We also investigated the three-year survival in patients,
who have had their EMR longer than 3 years ago, along with causes of death.
Results: A total of 99 patients underwent 134 EMR procedures and 259 EMRs,
84% were male, the mean age at first EMR was 71 years (SD¼ 8.2). 24 patients
underwent 2 EMR procedures, 2 patients underwent 3 EMR procedures and 2
patients underwent 4 EMR procedures. The median length of the circumferential
and maximum extent of the BO segments were 3 and 4 cm respectively (inter-
quartile range (IQR) 2–4). 44 patients underwent 60 en bloc resections. After
histologic assessment of these EMR specimens, 34 (56.7%) had clear deep and
radial resection margins, 14 (23.3%) showed at least low-grade dysplasia at the
radial margin, 2 (3.3%) at the deep margin and 8 (13.4%) at both margins. 2
(3.3%) were clear at the deep margin, but due to thermal damage the radial
margins were indeterminate. Following the 60 EMRs there was no visible resi-
dual early neoplasia on the follow up endoscopy in 37 cases (61.7%). 55 patients
underwent 74 piecemeal EMRs, of which 52 (70.3%) had clear deep margins on
histologic assessment and 38 (51.4%) had no visible residual neoplasia on the
follow up endoscopy. Pre EMR histology was available in 82 patients and it
showed high-grade dysplasia (HGD) in 49 (59.8%), mucosal adenocarcinoma
in 24 (29.2%) and low-grade dysplasia in 9 patients (11%). However the EMR
histology resulted in altered grading in 59 (72%) patients, with 47 (57%)
upgraded and 12 (14%) downgraded from the pre EMR histology and
unchanged only in 23 patients (28%). The EMR histologies in the 82 patients
showed HGD in 16 (19.5%) patients, intramucosal adenocarcinoma in 33
(40.2%), adenocarcinoma with submucosal invasion in 20 (24.4%) and LGD
in 13 (15.9%). The remaining 52 EMRs were performed for visible lesions
within BO without pre EMR histology result, predominately for patients in the
radiofrequency ablation program. The 3 year survival rate for 42 patients was
81%, 8 patients died, 5 due to cardiac failure, 1 due to a PE and 2 due to
advanced oesophageal adenocarcinoma.
Conclusion: In this moderately sized retrospective study EMR has been proven to
be an effective tool in managing early neoplasia within BO. It not only allows the
potential complete resection of the visible early neoplasia (61.7% for en bloc and
51.4% for piecemeal EMR), but also gives a histological specimen with a more
accurate grading of the neoplasia (upgraded in 57%, downgraded in 14% and
unchanged in only in 23% of all EMRs), both aspects culminating in more
effective and precise patient treatment. In all patients managed and assessed by
EMR we have seen 19% mortality of which only 4.8% was cancer related.
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Table: Factors associated with the adherence to the use of Prague Criteria and systematic four-quadrant biopsies for BE evaluation
Clinical Variable
Prague Criteria Systematic Biopsies
Univariate Multivariable Univariate Multivariate
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Age 1.02 (0.99–1.04) 0.06 1.00 (0.98–1.04) 0.53 1.02 (0.99–1.05) 0.06 1.01 (0.97–1.05) 0.42
BMI 1.00 (0.95–1.04) 0.84 0.98 (0.93–1.04) 0.60 0.96 (0.90–1.03) 0.23 0.96 (0.89–1.05) 0.40
Sex (male) 2.34 (1.38–3.94) 0.001 2.07 (0.99–4.31) 0.05 1.32 (0.73–2.40) 0.35 1.18 (0.46–3.01) 0.73
GERD 1.31 (0.71–2.43) 0.40 0.64 (0.17–2.40) 0.51 1.74 (0.78–3.89) 0.18 1.75 (0.34–8.96) 0.50
PPI use 1.48 (0.90–2.47) 0.13 1.29 (0.49–3.39) 0.61 1.25 (0.68–2.28) 0.72 0.45 (0.15–1.33) 0.15
Smoking history
Current smoker
Previous smoker
1.53 (0.77–3.00)
0.97(0.57–1.70)
0.22
0.91
2.16 (0.81–5.80)
0.82 (0.37–1.81)
0.17
0.62
1.98 (0.86–4.60)
1.91 (0.97–3.8)
0.11
0.06
1.59 (0.45–5.65)
1.29 (0.46–3.63)
0.47
0.63
Short segment BE 1.28 (1.09–2.84) 0.02 0.22 (0.18–0.82) 0.01
Long segment BE 0.78 (0.44–1.37) 0.40 0.61 (0.27–1.34) 0.22 4.54 (2.37–8.7) 0.001 2.36 (0.96–5.88) 0.06
1 experience year% 1.06 (1.02–1.11) 0.001 1.07 (1.02–1.12) 50.01 0.91 (0.87–0.94) 0.001 0.91 (0.85–0.97) 0.001
BE therapeutics* 3.82 (2.31–6.33) 50.001 3.16 (1.47–6.82) 50.01 1.40 (0.78–2.50) 0.26 1.11 (0.43–2.88) 0.83
Attending only z 0.70 (0.43–1.14) 0.157 0.77 (0.36–1.64) 0.50 1.40 (0.77–2.56) 0.27 1.41 (0.54–3.63) 0.48
Total years& 5.0–9.9
10.0–14.9 15–24.9
0.94 (0.47–1.88)
2.16 (1.09–4.26)
2.54 (1.22–5.31)
0.866
0.03
0.01
0.93 (0.44–1.95)
3.25 (1.52–6.96)
2.84 (1.27–6.36)
0.85
0.002
0.01
0.93 (0.47–1.84)
0.32 (0.13–0.77)
0.28 (0.10–0.80)
0.84
0.01
0.02
0.74 (0.33–1.66)
0.35 (0.13–0.95)
0.29 (0.10–0.91)
0.47
0.04
0.03
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Introduction: Barrett esophagus (BE) is a premalignant condition for esophageal
adenocarcinoma (EAC) where recommended. Guidelines aim to reduce treat-
ment variation and improve quality of care. Data on the extent to which level
BE surveillance guidelines are followed are scarce.
Aims & Methods: The objectives of this systematic review and meta-analysis were
to (1) quantify adherence to guidelines in BE surveillance and (2) identify factors
that are associated with adherence. A systematic literature research was per-
formed using EMBASE, MEDLINE, PubMed and Web of Science up to
September 2016. Studies reporting adherence in at least one of the following
four domains were selected: surveillance interval, biopsy protocol, landmark
identification and histopathological information. Relevant publications were
assessed using the STROBE statement for observational studies (http://strobe-
statement.org/). Adherence was considered a prevalence ratio and reported as a
percentage. Pooled data for the associated factors were reported as odds ratios
with analysis of heterogeneity (I2 statistic).
Results: From a total of 373 studies, 49 were eligible for this meta-analysis. For
BE surveillance in non-dysplastic BE patients a prevalence ratio for adherence of
54% (95% confidence interval (CI) 45%;63%) was found and 41% (95% CI
37%;45%) in patients with low-grade dysplasia, but with large heterogeneity
(I2¼ 98% and I2¼ 100%). Adherence to the Seattle protocol was 47% (95%
CI 33%;61%, I2¼ 100%), length of BE was reported according to the Prague
classification in 34% (95% CI 23%;44%, I2¼ 98%) and in 51% (95% CI
27%;75%, I2¼ 99%) of patients with a dysplastic BE the histology samples
were reviewed by a second pathologist. Shorter BE length, an academic practice
setting, younger age and the involvement of the clinical set-up incorporating a
multifaceted intervention program were associated with better adherence.
Endoscopists following the Seattle protocol detected more dysplasia.
Conclusion: Adherence to guidelines for the surveillance of BE is far from optimal
and highly heterogeneous. A clinical set-up of a dedicated BE surveillance pro-
gram is needed, for example follow-up within a research program, involvement of
a dedicated nurse managing the program or guideline promotion by using posters
stating recommendations. Besides initiating more and better studies to facilitate
the creation of evidence based guidelines, more effort should be directed to
stimulate and monitor the implementation of guidelines in clinical practice.
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Introduction: Since squamous cell carcinoma in the esophagus confined to the
muscularis mucosae (MM) or submucosa up to 200 mm (SM1) has a risk of
lymph node metastasis, it is defined as relative indication for endoscopic sub-
mucosal dissection (ESD) by the Japan esophageal society guideline. Although
additional surgical treatment after ESD is recommended, long-term outcomes of
ESD compared with surgery has not been clarified.
Aims & Methods: This study aimed to evaluate the long-term outcomes of ESD
and surgery for cN0M0 relative indication lesions of ESCC. Between 2006 and
2016, patients with relative indication lesions of ESCC treated endoscopically or
surgically in Okayama University Hospital were retrospectively analyzed. We
evaluated risk factors for mortality using cox regression analysis, adjusted
hazard ratios for ESD compared with surgery, the survival curves stratified
with risk factor, and perioperative comlication rate.
Results: 54 lesions in the ESD group and 51 lesions in the surgery group met the
pathological criteria of relative indication for endoscopic resection. 10 patients
underwent additional chemoradiation in the ESD group. 8 patients underwent
additional chemotherapy and 1 patient underwent additional chemoradiation in
the surgery group. Lymphovascular invasion, submucosal invation, and ASA-PS
was significantly associated with mortality using Cox analysis. Adjusted for
lymphovascular invation, submucosal invation, and ASA-PS, multivariate Cox
proportional hazard ratio of mortality for ESD compared with surgery was not
significantly dfferent (hazard ratio [HR], 0.76; 95% confidence interval [CI],
0.26–2.2; P¼ 0.61). The survival curves for ESD and surgery stratified with
each risk factor were not significantly different. Perioperative comlication rate
were significantly low in ESD compared to surgey (29.6% vs 49.1%; P¼ 0.047).
Conclusion: ESD dose not compromise the long-term outocome compared to
surgery. Further large number randomized controlled trials are necessary to
confirm these resluts.
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Introduction: Patients with Fanconi anemia (FA) have an increased risk of devel-
oping esophageal squamous cell carcinoma. Data regarding endoscopic findings
in patients with FA are lacking. Furthermore, there are no clear guidelines for
endoscopic surveillance of patients with FA.
Aims & Methods: We aimed to describe the endoscopic findings among subjects
with FA undergoing endoscopic surveillance and to determine the interval to
development of esophageal cancer.
Results: Eight FA subjects with a median age of 22.2 years at first endoscopy
(range16–41) were identified. The median upper endoscopies number per patient
was 5.5 (range 2–14) with a median time of follow-up of 4.5 years (range 1–9
years). All subjects (100%) had an endoscopic evidence of reflux esophagitis: 3
(37.5%) had mild and 5 (62.5%) had moderate-severe reflux esophagitis. Three
subjects (37.5%) had complicated esophageal reflux disease (two subjects devel-
oped Barrett’s esophagus and one subject had an esophageal stricture). Two
subjects (25%) developed esophageal squamous cell carcinoma during follow-
up, with interval time of 8 and 18 months from previous upper endoscopy. Both
had tumor expression of p16 protein suggesting human papilloma virus (HPV)
infection. The calculated standardized incidence ratio (SIR) for the development
of esophageal squamous cell carcinoma is 5107.
Conclusion: FA patients are at an increased risk for developing esophageal cancer
and reflux esophageal disease with associated complications. Larger, prospective
studies are needed to determine the optimal interval for endoscopic screening in
these patients.
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Introduction: Multiple development of squamous cell carcinoma (SCC) in the
upper aero-digestive tract is known as the ‘‘field cancerization phenomenon, ’’
and alcohol is a definite carcinogen. Multiple dysplastic lesions in the esophagus
are a useful predictor of the risk for the field cancerization. However, what causes
the development of dysplastic squamous epithelium in the esophagus is still
unclear.
Aims & Methods: The aim of this prospective cohort study was to identify asso-
ciations between patients’ lifestyle, including alcohol consumption, the genetic
trait of aldehyde dehydrogenase-2 (ALDH2), and the development of dysplastic
squamous epithelium in the esophagus. This is a post hoc analysis of the Japan
Esophgeal Cohort (JEC) study (UMIN1676). Patients with superficial SCC
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treated by endoscopic resection were prospectively recruited from 16 hospitals
throughout Japan. This cohort study was approved by the institutional review
board at each hospital, and we obtained written informed consent from all
patients. Using Lugol chromoendoscopy, we evaluated the dysplastic squamous
epithelium in the esophagus. Lugol voiding lesion (LVL) was graded into 3
categories (A¼ no lesion; B¼ 1 to 9 lesions; C¼410 lesions per endoscopic
view). Endoscopic images obtained from eligible patients at study entry were
centrally reviewed in a blinded fashion by three endoscopists to determine the
grade of LVL. ALDH2 status was determined by questionnaire facial flushing
after alcohol drinking (present and past flushing¼ inactive ALDH2, never flush-
ing¼ active ALDH2). Lifestyle surveys were conducted using a self-assessment
questionnaire. Data collected between July 2000 and Dec 2001 from a different
cross-sectional cohort (n¼ 1042; M/F¼ 610/432) were used as an historical
control.
Results: Between Sep 2005 and May 2010, 330 patients (M/F¼ 278/52) were
registered. The proportions of the different grades of LVL were A¼ 50
(15.2%), B¼ 174 (52.7%), and C¼ 106 (32.1%). After adjusting for sex and
age, controls and the LVL grade was associated with progressively higher pro-
portions of heavy drinkers (8.4%, 24.8%, 26.2%, and 52.5%, respectively,
p5 0.0001), frequently strong alcoholic beverages (2.3%, 7.2%, 11.8%, and
11.6%, respectively, p5 0.0001), heavy smokers (34.6%, 38.7%, 65.7%, and
70.8%, respectively, p5 0.0001), liking high-temperature food (4.6%, 19.6%,
20.8%, and 20.7%, respectively, p5 0.0001), not eating green-yellow vegetables
almost every day (55.0%, 48.9%, 54.9%, and 71.1%, respectively, p5 0.0001),
and not eating fruit almost every day (51.6%, 74.3%, 68.0%, and 75.3%, respec-
tively, p5 0.0001). The risk of LVL grade B and C was strongly associated with
the amount of alcohol consumption especially in inactive ALDH2. Odds ratio
(OR) of LVL grade B associated with heavy drinking was significantly stronger
in inactive ALDH2 (OR¼ 47.5) than active ALDH2 (OR¼ 12.8) (p5 0.05). OR
of LVL grade C associated with heavy drinking was significantly stronger in
inactive ALDH2 (OR¼ 358) than active ALDH2 (OR¼ 138) (p5 0.05).
Alcohol drinking
Controls
(n¼ 1042)
Grade A
(n¼ 50)
Grade B
(n¼ 174)
Grade C
(n¼ 106) P
Never/rare 38.2% 25.1% 7.9% 4.7%
Light 30.5% 15.0% 21.4% 8.9%
Moderate 21.4% 30.1% 30.9% 25.7%
Heavy 8.4% 24.8% 26.2% 52.5%
Ex-drinker 1.4% 5.1% 13.6% 8.3% 5.0001
P, vs. controls – 0.002 5.0001 5.0001
Units/week (Mean SE) 5.9 0.4 9.2 1.5 13.9 0.8 20.1 1.0 5.0001
P, vs. controls – 0.037 5.0001 5.0001
Conclusion: The development of dysplastic squamous epithelium in the esopha-
gus was associated with the amount of alcohol consumption and genetic trait of
inactive ALDH2.
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Introduction: Metachronous multiple squamous cell carcinoma (SCC) of the
oesophagus and the head and neck often occurs in patients who previously
underwent endoscopic resection (ER) for SCC of the oesophagus. This has
become a problem regarding the curability of ER. Katada et al reported that
alcohol abstinence significantly decreased the risk of developing a secondary SCC
of the oesophagus, based on a prospective study of 330 patients from 16 hospi-
tals1. However, there are few studies that have investigated the risk of developing
a secondary SCC of the oesophagus and the head and neck based on the genetic
polymorphisms of alcohol dehydrogense-1B (ADH1B) and aldehyde dehydro-
genase-2 (ALDH2) which are closely associated with developing oesophageal
SCC. No studies have evaluated the risk of developing a third (or more) SCC
after ER for SCC of the oesophagus.
Aims & Methods: The study group included patients who underwent ER for SCC
of the oesophagus at Hokkaido University Hospital. All patients were followed
up by using endoscopic examination for 2 years. Overall, 126 patients were
included in the study. The drinking and smoking histories before and after ER
were carefully documented. To examine two single nucleotide polymorphisms
(SNPs) on ADH1B and ALDH2 genotyping, we obtained approximately 1ml
of saliva with a pipette or cotton swab before the endoscopic examination. The
subjects were classified as rare drinkers who consumed 51 units/week, current
drinkers who consumed 1 to 8.9 units/week (light drinkers), 9 to 17.9 units/week
(moderate drinkers), or = 18 units/week (heavy drinkers); alcohol consumption
(1 unit¼ 22 g, the ethanol content of one serving of sake). The physicians recom-
mended all subjects to temperate in drinking and smoking. We retrospectively
evaluated the risk of metachronous SCC of the oesophagus and the head and
neck after ER for SCC of the oesophagus, based on the genetic polymorphisms
for ADH1B and ALDH2 and the drinking and smoking histories.
Results: During a median follow-up period of 80 months (range, 24–228 months),
a secondary SCC of the oesophagus and the head and neck was detected in
46 patients (36.5%). The high incidence groups had inactive heterozygous
ALDH2 (rs671 GA, 36/83; p5 0.05), moderate and heavy drinkers (42/93;
p5 0.01), continuous moderate and heavy drinkers after ER (21/35; p5 0.01).
Multivariate analysis revealed that the inactive heterozygous ALDH2 (OR¼ 2.24;
p5 0.05), moderate and heavy drinkers (OR¼ 3.54; p5 0.05) and continuous
moderate and heavy drinkers after ER (OR¼ 2.73; p5 0.05) were independently
associated with the risk of developing a secondary SCC after ER. A third SCCwas
detected in 19 patients (15.1%), and the high incidence groups had inactive het-
erozygous ALDH2 (17/83; p5 0.05), moderate and heavy drinkers (19/93;
p5 0.01) and continuous heavy drinkers after ER (10/16; p5 0.01). A fourth
SCC was detected in seven patients (5.6%), who were all cases of continuous
moderate and heavy drinkers after ER. Six of the seven patients had an inactive
heterozygous ALDH2. We analysed the 63 patients with inactive heterozygous
ALDH2 and moderate and heavy drinkers before ER based on their temperance
history and found 38 patients in the temperance group (5light drinkers after ER)
and 25 patients in the non-temperance group. The 3-year cumulative incidence
rate of secondary SCC in the temperance and non- temperance groups revealed an
incidence of 16.2% vs 49.8%, respectively (p5 0.05). The 5-year cumulative inci-
dence rate of a third SCC revealed an incidence of 0% vs 28.3%, respectively
(p5 0.01). The 7-year cumulative incidence rate of a fourth SCC revealed an
incidence of 0% vs 16.9%, respectively (p5 0.05).
Conclusion: Among the patients who underwent ER for oesophageal SCC, an
inactive heterozygous ALDH2 with a continue drinking habit were the signifi-
cant risk factors of developing metachronous multiple SCC. These are the greater
risk factors for developing a third (or more) SCC. Patients with an inactive
heterozygous ALDH2 and a drinking habit should receive strict instruction for
temperance.
Disclosure of Interest: All authors have declared no conflicts of interest.
Reference
1. Katada C, Yokoyama T, Yano T, et al. Alcohol Consumption and Multiple
Dysplastic Lesions Increase Risk of Squamous Cell Carcinoma in the
Esophagus, Head, and Neck. Gastroenterology 2016.
P0565 IS IT FEASIBLE TO TREAT ESOPHAGEAL SQUAMOUS
CELL CARCINOMA WITH CLINICAL DEPTH OF MM/SM1 BY
ENDOSCOPIC RESECTION?
K. Namikawa, T. Yoshio, A. Ishiyama, T. Tsuchida, J. Fujisaki
Gastroenterology, Cancer Institute Hospital Ariake, Tokyo/Japan
Contact E-mail Address: ken.namikawa@jfcr.or.jp
Introduction: According to the Japanese guidelines for the treatment of esopha-
geal cancer, T1a-EP or T1a-LPM squamous cell carcinoma (SCC) is definitive
indication for endoscopic resection (ER) which is the first line treatment for
them. T1a-MM or T1b-SM1 is a relative indication of ER, because 10–20% of
the cases has metastasis in the previous analysis of operation cases. Recent
advances in ER such as endoscopic submucosal dissection (ESD) and steroid
injection for the prevention of stricture, provide us increasing opportunity to
treat clinical MM/SM1 which means preoperative predicted invasion depth of
MM/SM1. Recently we start to treat them because MM without lymphovascular
invasion were reported to have very low risk of metastasis and occupy majority
part of MM/SM1. There is no report about long term outcome of ER for clinical
MM/SM1.
Aims & Methods: This study aimed to evaluate the clinical outcomes in patients
having esophageal SCC with a predicted invasion depth of MM/SM1. We retro-
spectively reviewed 45 patients having esophageal SCC with a predicted invasion
depth of MM/SM1. We predicted the invasion depth using conventional endo-
scopy, magnifying endoscopic classification of Japan esophageal society, and
endoscopic ultrasound (EUS). The patients were diagnosed and treated at our
hospital from 2010 to 2013. If pathological diagnosis after ER reveals T1b-SM2
or lymphovascular invasion, we recommended CRT or esophagectomy as addi-
tional therapy.
Results: The median age was 67 years (range, 3981 years), including 37 males
and 8 females. The median diameter of the tumor was 27mm (range, 4–70mm).
The tumors were located in the cervical esophagus (n¼ 2), upper esophagus
(n¼ 9), mid-esophagus (n¼ 30), and lower esophagus (n¼ 4). The number of
tumors subclassified as types 0-I, 0-IIa, 0-IIb, and 0-IIc was 0, 7, 1, and 37,
respectively. Forty cases were diagnosed as MM/SM1 using the Japanese
Esophageal Society classification for magnifying endoscopy, and its accuracy
was 62.5% (25/40). EUS was performed for 21 patients, and its accuracy was
68.8% (16/21). The patients underwent endoscopic mucosal resection (n¼ 5) or
ESD (n¼ 40). In pathological diagnosis, LPM invasion was found in 14 patients,
MM/SM1 invasion in 28 patients, and SM2 invasion in 3 patients. The overall
accuracy rate of diagnosing MM/SM1 invasion was 62% (28/45). Among
patients with MM/SM1 invasion, 20 had no lymphovascular invasion, and
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they were not recommended additional therapy. The remaining eight patients
had lymphovascular invasion, and they were recommended additional therapy.
In total 33 cases were treated only by ER without additional therapy. Besides
97% (32/33) of those cases had no recurrence except for one case with a lymph
node recurrence, which was successfully treated by additional CRT. The other 12
cases including cases with lymphovascular invasion or SM2 were recommended
additional therapy. They underwent CRT (n¼ 4), radiotherapy (n¼ 3), or eso-
phagectomy (n¼ 3). No recurrence was observed after the abovementioned treat-
ments. At the end of the follow-up, the 3-year overall and disease-specific
survival rates were 91.1% and 100%, respectively. Considering ER for clinical
MM/SM1, 76% of all cases were completed their treatment only with ER, and
24% of high risk case for metastasis were treated appropriately with additional
therapy.
Conclusion: Conclusions: Our study suggests that ER is a valid treatment for
esophageal SCC with a preoperative predicted invasion depth of MM/SM1.
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Introduction: Triamcinolone injection is an effective and widely used method for
preventing postoperative stricture after wide-spreading esophageal endoscopic
submucosal dissection (ESD), but even with this method there is a stricture
risk of 10–62%, and there is a need for an even more effective method. The
objective of our study was to evaluate the efficacy of combining this method
with the shielding method with polyglycolic acid (PGA) sheets and fibrin glue,
another novel and effective method for the prevention of postoperative stricture.
Aims & Methods: 2 consecutive single-arm pilot studies were performed, and
retrospectively compared with the results of a historical control group. After
approval by the Institutional Review Board and trial registry, we enrolled
patients with a diagnosis of superficial esophageal squamous cell carcinoma
covering over half the circumference of the esophagus. In study group A
(UMIN000014642), performed October 2014 to July 2015, immediately after
the enrolled patients underwent esophageal ESD, a total of 40mg of triamcino-
lone acetonide was injected into the submucosal layer of the ESD defect, fol-
lowed by adhesion of a PGA sheet to the post-ESD defect with fibrin glue. In
study group B (UMIN000011058), performed July 2013 to September 2014,
immediately after the enrolled patients underwent esophageal ESD, only adhe-
sion of a PGA sheet to the post-ESD defect with fibrin glue was performed. As
historical control group C, all patients at our institute who had undergone ESD
for superficial esophageal squamous cell carcinoma covering over half the cir-
cumference of the esophagus during 2002 to June 2013 were extracted. After
exclusion of patients who did not undergo followed-up for at least 3 months,
and patients who underwent salvage surgery after non-curative ESD, statistical
analysis of the incidence of postoperative stricture and required endoscopic bal-
loon dilation (EBD) sessions in each of these 3 groups was performed.
Results:During the study period, 15 patients were enrolled in study A, 13 patients
in study B, and 37 patients were extracted as group C. After exclusion, 11 cases in
group A (2 circumferential, 9 semi-circumferential), 11 cases in group B (11 semi-
circumferential), and 30 cases in group C (3 circumferential, 27 semi-circumfer-
ential) were analyzed. Although postoperative stricture occurred in all circumfer-
ential cases in group C, it was successfully prevented in 1 case of circumferential
ESD in group A. A sub-analysis comparing the semi-circumferential ESD cases
was performed. There were no significant differences in tumor size (A: 34.9 8.1,
B: 31.5 7.0, C: 34.8 13.8mm) and operation times (A: 95.4 23.8, B:
108.2 33.1, C: 112.1 50.3min) in the 3 groups. Group A demonstrated the
most effective results in both the incidence of postoperative stricture (A: 11.1%,
B: 36.4%, C: 55.6%), and the number of EBD sessions required (median A: 0, B:
0, C: 3).
Conclusion: The combination of triamcinolone injection and the shielding
method with PGA sheets and fibrin glue is a promising method for preventing
stricture after esophageal ESD. Prospective studies for confirmation of efficacy
and safety are required.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0567 MULTICENTRIC ASSESSMENT OF THE ENDOSCOPIC
MANAGEMENT OF SUPERFICIAL ESOPHAGEAL SQUAMOUS-
CELL CARCINOMA IN WESTERN POPULATION
A. Berger
1, G. Rahmi2, G. Perrod3, M. Pioche4, J. Canard5, E. Cesbron
Métivier1, J. Boursier6, E. Samaha7, A. Vienne2, V. Lepilliez8, C. Cellier9
1CHU Angers, Angers/France
2Gastroenterology And Digestive Endoscopy, Georges-Pompidou European
Hospital, Paris/France
3Gastroenterology, Hopital Européen Georges Pompidou, Paris/France
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Introduction: Endoscopic mucosal resection (EMR) and endosopic submucosal
dissection (ESD) are the first line treatment for superficial esophageal squamous-
cell carcinoma (SCC). Comparatively to surgery, endoscopic resection is mini
invasive and associated with a lower morbidity and mortality.
Aims & Methods: Evaluation of the endoscopic resection efficiency for superficial
esophageal SCC and long-term outcome. Primary outcome was recurrence rate
after endoscopic resection defined as local recurrence or metastatic evolution. We
conducted a retrospective multicenter study in 5 french tertiary care hospitals. All
patients treated by EMR or ESD for histologically proven SCC were consecu-
tively included. Esophageal SCC were defined as superficial after macroscopic
evaluation including Lugol staining and endoscopic ultrasonography (EUS).
Curative resection was defined as pT1a with free resection margins, without
lympho-vascular embols.
Results: Between 1998 to 2016, 132 patients were enrolled and 148 tumors were
resected (EMR¼ 80, ESD¼ 68). The mean age was 63.9 [35.7–86.0] years-old and
108 (73%) patients were male. Mean tumor size was 15.0mm in the EMR group
and 35.0mm in the ESD group (p5 0.001). The complete resection rate in the
EMR and ESD groups were respectively 30% (24/80) and 100% (68/68)
(p5 0.0001). The mean follow-up period was 22 months. The recurrence rate
was 14.2% (19/80 in the EMR group and 2/68 in the ESD group, p¼ 0.001). At
12 months, recurrence-free survival rate was 84.4% and 74.6% at 24 months.
Factors associated with recurrence in univariate analysis were: tumors size
(p¼ 0.013), resection by EMR (p¼ 0.001), piecemeal resection (p¼ 0.016), and
microscopic positive margins (p¼ 0.044). In multivariate analysis, risks factors for
recurrence were: resection by EMR (OR¼ 7.315; IC [1.685–31.762]; p¼ 0.008)
and tumor deep infiltration m3 (OR¼ 2.635; IC [1.065–6.519]; p¼ 0, 036). At
24 months, recurrence-free survival rate were 95.2% in ESD group, versus 59.8%
in EMR group (p¼ 0.001). For infiltrating tumors m3, metastasis free survival
rate at 24 motnhs were 100.0% after complementary treatment by radio-
chemotherapy, and 62.2% without complementary treatment (p¼ 0.042).
Conclusion: Endoscopic resection of superficial esophageal SCC is safe and effi-
cient. According to our results, ESD should be preferred to EMR because it is
associated with a higher curative rate and an increased recurrence free survival
rate.
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Introduction: Oesophageal squamous cell carcinoma (ESCC) with invasion into
the muscularis mucosae (MM) or submucosae up to 200-mm (SM1) has approxi-
mately 10% lymph node metastasis and is a relative indication for endoscopic
resection (ER) as per the Japanese Esophageal Society (JES) guidelines. The
consideration criteria for additional treatment of MM/SM1 ESCC are as follows:
(1) lymphovascular invasion, (2) SM1, (3) positive vertical margin, and (4) diffuse
pattern of infiltration (INFc). However, the clinical validity of the JES guidelines
has not been established. We evaluated the curative conditions after ER for MM/
SM1 ESCC based on long-term outcomes.
Aims & Methods: We recruited 98 patients with MM/SM1 ESCC who underwent
ER between August 1992 and October 2013 and were followed up for more than
3 years at Hiroshima University Hospital. As per the JES guidelines, the e-cur-
able group was characterised by en bloc resection lesions with pathological MM,
tumor infiltration pattern (INF) a/b, VM0, ly0 and v0. We evaluated the clin-
icopathological characteristics of patients and lesions and the rates of overall
survival, disease-specific survival, recurrence-free survival, lymph node recur-
rence and local recurrence in the e-curable and non-e-curable groups.
Results: We enrolled 98 consecutive MM/SM1 ESCC patients (88 males; mean
age, 67 9 years; e-curable group, 39 patients; non-e-curable group, 59 patients;
mean follow-up period, 75 44 months). There were no significant differences in
the clinicopathological characteristics of the patients and lesions between the 2
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groups. The proportion of patients with additional treatment after ER was sig-
nificantly higher in the non-e-curable group (66%, 39/59) than in the e-curable
group (23%, 9/39) (p5 0.05). Operation, radiotherapy, and chemoradiotherapy
were administered to 3 (8%), 4 (10%), and 12 (5%) patients, respectively in the e-
curable group and to 7 (12%), 22 (37%), and 10 (17%) patients, respectively in
the non-e-curable group. The 5-year overall survival rates in the e-curable and
non-e-curable groups were 97% and 75% (p5 0.05), respectively. The overall
survival rate was significantly higher in the e-curable group. Three deaths (10%)
occurred due to primary cancer. The other reasons were as follows: other organ
cancer, 10 cases; heart failure, 4 cases; pneumonia, 3 cases; and others, 11 cases.
The 5-year disease-specific survival rates in the e-curable and non-e-curable
groups were 100% and 98%, respectively. The lymph node recurrence rates in
the e-curable and non-e-curable groups were 3% (1/39) and 7% (4/59), respec-
tively. The local recurrence rates in the e-curable and non-e-curable groups were
0% (0/39) and 7% (4/59), respectively. The 5-year recurrence-free survival rates
in the e-curable and non-e-curable groups were 97% and 98%, respectively. The
5-year recurrence-free survival rates in the group with INFa and no lymphovas-
cular invasion and in the group with INFb, INFc, or lymphovascular invasion
were 100% and 87%, respectively. The recurrence-free survival rate was signifi-
cantly higher in the group with INFa and no lymphovascular invasion than in the
group with INFb, INFc or lymphovascular invasion.
Conclusion: Our outcome data support the clinical validity of the e-curative
conditions after ER for MM/SM1 ESCC of the JES guidelines. However,
MM/SM1 ESCC with INFa and no lymphovascular invasion may have more
possible curative conditions after ER without additional treatment.
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Introduction: The development of endoscopic submucosal dissection (ESD)
allows en-bloc resection of early gastric cancer (EGC) with wide resection mar-
gins [1, 2]. En-bloc resection resulted in adequate resection margins and reduced
local recurrence. When compared to gastrectomy, endoscopic resection should
theoretically result in better perioperative outcomes and quality of life [3]. There
is currently no study in the literature which directly compares laparoscopic
assisted gastrectomy against ESD for treatment of intramucosal EGC. The objec-
tive of the study is to compare clinical, oncological and immunological outcomes
of endoscopic submucosal dissection (ESD) against laparoscopic assisted gas-
trectomy (LAG) for treatment of early gastric cancer.
Aims & Methods: All patients with endoscopic diagnosis of early gastric cancer
(EGC) and biopsy confirmed to be high grade dysplasia or adenocarcinoma were
recruited. They received staging investigations including image enhanced endo-
scopy, EUS and CT and those predicted to be T1a (intramucosal) neoplasia were
randomly assigned to receive ESD or LAG. ESD were performed according to
the previously reported procedure, while LAG were performed with D1þß lym-
phadenectomy. The baseline demographics, clinical perioperative outcomes,
immunological and oncological outcomes were compared between the two
groups. Primary outcome was rate of complication after operation.
Results: From 2011 to 2016, 36 patients with early gastric cancers were randomly
assigned to receive ESD (n¼ 18) or LAG (n¼ 18). There was no difference
between the two groups in terms of age, gender, ASA grade and baseline demo-
graphics (Table 1). ESD was associated with significantly shorter operative time
(109.4 55.4 vs 266.2 47.8 mins, p5 0.001), hospital stay (4 (3–6) vs 8 (4–14)
days; p5 0.001) and lower complication rate (1 (5.6%) vs 7 (38.9%); p¼ 0.041).
There was no mortality at 30 days for the two groups, while those in ESD group
tolerated full diet earlier (2 (1–5) vs 5 (3–12) days; p5 0.001). Patients who
received ESD had significantly lower level of CRP as well as VAS pain scores
on postoperative days 1, 2, 3 and 7 when compared to LAG. The median follow-
up was 41.5 months for ESD group and 36 months for LAG group, and there
was no difference in the cancer recurrence and overall survival. 27.8% of patients
required re-intervention after ESD.
Table 1: - Outcomes of ESD vs Lap Gastrectomy
Parameters Lap Gastrectomy ESD p value
Male (%) 7 (38.9) 11 (61.1.) 0.317
Age (mean þ/ SD) 62.5þ/10.4 61.7þ/11.2 0.899
ASA (I/II/III) 5/8/5 5/8/5 1.0
Comorbidities (Median) 2 (0–5) 1 (0–4) 0.505
Smoker (No/Ex/Current) 10/3/3 11/3/4 0.534
(continued)
Table 1 Continued
Parameters Lap Gastrectomy ESD p value
Drinker (No/Social/Heavy) 12/1/3 14/2/2 0.480
Operation time (mins)
(Median(range))
263.5 (165–365) 97.5 (30–195) 50.001y
Hospital stay (days)
(Median(range))
8 (4–14) 4 (3–6) 50.001y
Days to resume full diet 5 (3–12) 2 (1–5) 50.001y
Complications (%) 7 (38.9) 1 (5.6) 0.041y
30 days mortality 0 0 –
Reintervention
(Gastrectomy/ESD/
Reoperation)(%)
0(0) 5 (27.8) 50.001y
Postop Day 1 VAS pain 49 (8–80) 23 (0–57) 0.013y
Postop Day 3 VAS pain 39.5 (6–65) 5 (0–37) 50.001y
Postop Day 7 VAS pain 21 (0–53) 0 (0–10) 0.003y
Postop CRP Day 1 81.1 (54–249) 11.7 (2–46) 50.001y
Postop CRP Day 3 110.3 (39.1–229.4) 22.8 (1.4–60.0) 50.001y
Pathology T1a 12 14
Pathology T1b 3 3
Pathology T2 0 1
Pathology T3 3 0
Conclusion: Our prospective randomized study showed that patients treated by
ESD had significantly lower complication rate and better perioperative outcomes
when compared laparoscopic gastrectomy. ESD should be the first line treatment
for intramucosal early gastric cancers.
Disclosure of Interest: P.W.Y. Chiu: I serve as chairman of Asia Novel Bio-
Imaging & Intervention Group which received sponsorship from Olympus Co
Ltd
All other authors have declared no conflicts of interest.
References
1. Chiu PW, Chan KF, Lee YT, Sung JJ, Lau JY, Ng EK. Endoscopic sub-
mucosal dissection used for treating early neoplasia of the foregut using a
combination of knives. Surg Endosc. 2008 Mar;22(3):777–83.
2. Chiu PW. Novel endoscopic therapeutics for early gastric cancer. Clin
Gastroenterol Hepatol. 2014 Jan;12(1):120–5.
3. Chiu PW, Teoh AY, To KF, Wong SK, Liu SY, Lam CC, Yung MY, Chan
FK, Lau JY, Ng EK. Endoscopic submucosal dissection (ESD) compared
with gastrectomy for treatment of early gastric neoplasia: a retrospective
cohort study. Surg Endosc. 2012 Dec;26(12):3584–91.
P0570 PREVALENCE OF PRE-MALIGNANT LESIONS IN BIOPSIES
TAKEN FROM GASTRIC MUCOSA ENDOSCOPICALLY NORMAL
OR WITH GASTRITIS
V. Yep-Gamarra
1, P. Rojas-Perez1, A. Aldave1, C. Rodriguez-Ulloa2, C. Dı́az-
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Introduction: Pre-malignant conditions and lesions of the stomach (PCLS): atro-
phy, intestinal metaplasia and dysplasia are risk factors for the development of
stomach cancer; therefore, its diagnosis is very important to identify patients with
greater probability of this malignant neoplasm. The Clinical Guidelines recom-
mend that during endoscopy procedure, to avoid an under diagnosis, biopsies of
different areas of the stomach should be taken even when no lesion is evident in
order to identify PCLS that are generally multi-focal. The initial identification of
patients with this type of lesions and their subsequent stratification with the
OLGA and OLGUIM systems allows defining the subgroup of patients that
merit follow-up because they have a higher risk of developing gastric cancer.
However, there is a discrepancy between endoscopists, because it is now preferred
to take biopsies directed at the lesions and not to do them systematically at fixed
sites, so that no lesion is observed.
Aims & Methods: We aimed to evaluate and compare the prevalence of PCLS in
biopsies taken from gastric mucosa with or without lesion during the endoscopic
examination. A retrospective, cross-sectional study was performed on 356 dys-
peptic patients. We reviewed the reports of esophagogastroduodenoscopies at the
Trujillo Regional Teaching Hospital-Perú from October 2016 to March 2017.
This study included reports which were consigned diagnosis with biopsies of
different areas from the stomach. These biopsies were sent in different vials.
Permission was obtained from the Hospital’s research committee. Those reports
that had a diagnosis of stomach cancer, gastrectomy, and those with not biopsy
A364 United European Gastroenterology Journal 5(5S)
or those in which the biopsies were still taken from the different anatomical areas
were sent in a single vial were excluded.
Results: Only 148 patients were admitted to the study. The mean age was 49.7þ/
3 years, 60% were female (CI: 52–67, 95%). 264 vials were sent with biopsies of
the different areas of the stomach distributed as follows: 148 of antrum, 54 of
angle and 62 of body. Only 48 (32.4%) patients had biopsies of antrum, angle
and body. From 148 patients, 116 (78.4%) had an endoscopic diagnosis of
normal gastritis or mucosa and 32 (21.6%) had endoscopic diagnosis of PCLS.
From 116 patients with endoscopic diagnosis of gastritis or normal mucosa,
LCPM was identified in 46 patients (39.6%) (p5 0.001) and 1 of them were
low-grade dysplasia. From 32 of patients with suspected endoscopic PCLS, the
diagnosis was confirmed with histology in 26 patients (81.2%). A total of 72
patients had PCLS vs. 32 who were initially suspected (p5 0.01), with a total
prevalence of 48% (CI 40.7–56.6, 95%).
Conclusion: Pre-malignant conditions and lesions of the stomach (PCLS) can
show as normal mucosa or gastritis during endoscopic procedure. 39.9% of
patients who underwent endoscopic procedure with presumptive gastritis had
PCLS. PCLS may be under-diagnosed if random biopsies are not taken.
Therefore, taking biopsies from areas without suspected PCLS causes a change
in the clinical management of patients, both for the initial diagnosis and for the
staging according to OLGA and OLGUIM systems.
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Introduction: Prognosis of GC has a noticeable relation with its clinical stage.
Atrophic gastritis (AG), intestinal metaplasia (IM) and dysplasia are well-recog-
nized risk factors for intestinal type GC (GC). A large cohort study demonstrated
that the annual incidence of GC were approximately 0.1% for patients with AG,
0.25% for IM and 6% for high-grade dysplasia, which were much higher than
those with normal mucosal. In addition, long-term follow-up studies have con-
firmed that the extent/topography of mucosal atrophy parallels the risk of GC
and it is on this ground that a system for staging gastritis, known as the
Operative Link for Gastritis Assessment (OLGA) was created. It is widely
accepted that serum PG level reflects the functional and morphologic status of
gastric mucosal. While the gold standard for atrophy assessment is histology, the
combination of serum pepsinogen and Helicobacter pylori (Hp) antibody, known
as the ABC method, has been suggested as a predictive marker for patients
with GC.
Aims & Methods: We aimed to discuss the correlation between the combination
of Helicobacter pylori antibody and pepsinogen and OLGA/OLGIM staging
system in gastric precancerous lesions risk assessment. A total of 331 patients
were enrolled after the examination of endoscopy at Endoscopy Center, the First
Affiliated Hospital of Zhejiang Chinese Medical University from October 2014 to
December 2015. According to the result of gastroscope, gastric secretion and
serum Helicobacter pylori antibody test, patients were divided into four
groups: Group A: Hp (-)PG (-), Group B: Hp (þ)PG (-), Group C: Hp (þ)PG
(þ) and Group D: Hp (-)PG (þ). PG positive was defined as PGI70mg/L and
PGR7.0. According to the range and degree of atrophy/intestinal metaplasia,
patients were divided into five groups on the basis of OLGA/OLGIM staging
system. The levels of Hp infection rate, PG I, PG II and PGR were compared
between different groups, and the correlation between ABC method and OLGA/
OLGIM staging system were evaluated. Statistical analysis was accomplished by
chi-square test and logistic regression modeling analysis.
Results: A total of 331 patients were enrolled. 214 patients were classified into
group A, 106 patients into group B, 4 patients into group C and 7 patients into
group D, respectively. According to the pathological results, 177 cases were non-
atrophic gastritis and 154 cases atrophic gastritis. For OLGA staging system, 177
patients were divided into stage-0 group, 82 patients into stage-I group, 49
patients into stage-II group, 16 patients into stage-III group and 7 patients
into stage-IV groups. The Hp infection rate was significant higher in patients
with higher OLGA stages (2¼ 13.42, P¼0.006). PGI and PGR level correlated
inversely with the rising OLGA stages (F¼ 2.127, P¼0.041, F¼ 4.350, P¼0.002).
For OLGIM staging system, 172 patients were divided into stage-0 group, 81
patients into stage-I group, 47 patients into stage-II group, 19 patients into stage-
III group and 12 patients into stage-IV group. The Hp infection rate was sig-
nificant higher in patients with higher OLGIM stage (2¼ 16.09, P¼0.003)and
the PGR level correlated inversely with the rising OLGIM stages (F¼ 3.207,
P¼0.013). Logistic regression modeling showed significant correlations between
ABC methods and OLGA/OLGIM staging system (P50.001).
Conclusion: Serological ABC method and histological OLGA/OLGIM staging
system are closely linked in gastric precancerous lesions risk assessment. Serum
pepsinogen test could be applied for high risk population identifying and provide
a recommendation for further endoscopy examination.
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Introduction: Endoscopic treatment of sporadic duodenal adenoma is mainly
performed in tertiary centers because it is technically challenging and associated
with major complications (perforation 1–5% and delayed bleeding 10–15%). The
aim of this study was to evaluate the safety and efficacy of the endoscopic
treatment for non ampullary sporadic duodenal adenomas (SDA) in two tertiary
centers in a large series and to try to determine the predictive factors of outcomes
with a long follow-up.
Aims & Methods: This retrospective study was conducted in two tertiary centers
between 12/2003 to 03/2016. All the patients who underwent at least one endo-
scopic treatment by EMR for SDA histologically proven were included. Patients
with PAF and ampullary adenoma were excluded. All the following outcomes
were systematically recorded in both centers: complete endoscopic resection,
resection with negative lateral and vertical margins, recurrence, success of the
endoscopic treatment and adverse events (Perforation, intra-procedural bleeding,
delayed bleeding, others). There were analysed with multivariate analysis.
Results: 134 procedures were performed. The mean patient age was 65 years (33–
85), 50.7% were women. The mean SDA size was of 20.7mm (5–50mm), mostly
located in the second duodenum (61.2%). 64.9% of the adenomas had a villous
component, 34.3% with high grade dysplasia and 7.5% with in situ or intramu-
cosal. Discrepancy between biopsies and the final histology was demonstrated,
32% of the lesions being upgraded and 10.6% being downgraded. An EMR was
performed in 98.5% of the cases with a complete endoscopic resection rate of
96.2% which was associated in multivariate analysis with the lesion size and
depressed relief. The en-bloc resection’s rate was of 44%. Vertical margins
were negative in 91.8% of the cases. Negative lateral and vertical margins was
associated in multivariate analysis with the lesion size and its en-bloc resection.
Intraprocedural bleeding occurred in 5.9% of the case and was associated in
multivariate analysis. Delayed bleeding occurred in 13.4% of the cases and
was associated with a larger lesion size and the presence of high-grade dysplasia
or adenocarcinoma. usual use of antiplatelet or anticoagulant did not increase
the risk of bleeding after pre operative management. A prophylactic hemostasis
was realized for 61.9% of the procedure, by clips alone or associated in 72.3% of
the cases. Prophylactic clipping reduced significantly the risk of delayed bleeding
Perforation occurred in 3.7% of case. Median follow-up was of 31.2 months with
at least one follow-up endoscopy (78.3%). Final success of endoscopic treatment
occurred in 83.8% of the case. 30 patients had a recurrence (28.6%). 13 among
them being successfully retreated with endoscopy, 12 still receiving endoscopic
treatment with multiple sessions, and 5 were referred to surgery. In multivariate
analysis, the main risk factor for recurrence was the lesion size.
Conclusion: Endoscopic treatment of SDA appears to be effective and relatively
safe in tertiary centers. All the bleeding complications were endoscopically con-
trolled and their occurrence could be reduced with clipping prophylactic hemos-
tasis. Perforation is rare. Recurrence rate is frequent and associated with piece-
meal resection but can be endoscopically managed.
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Introduction: Additional surgery should be recommended in patients with non-
curative endoscopic resection for early gastric cancer (EGC). However, this deci-
sion has been often hesitated according to patient’ condition such as advanced-
age or comorbidities. After the recognition of recurrence, the salvage surgery has
been considered difficult. However, little has been reported on it.
Aims & Methods: The aim of this study was to clarify the results of salvage
surgery for recurrence after non-curative ESD for EGC using data from multi-
center retrospective study (EAST study*). Of 15,785 patients who underwent
ESD for EGC at 19 participating institutions from January 2000 to August
2011, 1969 patients who failed to meet the current curative criteria for ESD
were retrospectively reviewed. Among 1969 patients enrolled into EAST study,
1064 patients underwent additional surgery, and 905 patients were observed
without any additional treatment. We evaluated first site of recurrence, clinical
course after salvage surgery, and long-term survival on non-treatment group.
Recurrence was classified regional LNM, and distant metastasis.
Results: Over a median follow-up period of 64 months, recurrence was detected
in 27 patients. Among them, 2 patients were excluded from this study due to
missing data. First sites of recurrence were only local site (intra-gastric relapse 3,
regional LNM 7), and distant metastasis 15 (60%). The first treatments for
recurrence were endoscopic treatment 1, salvage surgery 7 (28%), chemotherapy
6, and best supportive care 11. Only one patient was alive without any recurrence
for 31 months after salvage surgery. And one patient died of acute myocardial
infarction just one month after salvage surgery. In the remaining 5 patients,
recurrence was detected at 0, 2, 3, 5, 30 months after salvage surgery, and all
of them died of gastric cancer. Median survival time of all 25 patients with
recurrence was 5 months from recurrence. And median survival time of 7 patients
who underwent salvage surgery was only 7 months from salvage surgery.
Conclusion: More than half of recurrence after non-curative ESD without addi-
tional surgery were distant metastasis, and the survival rate after salvage surgery
was quite low.
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Introduction: Due to the increase of elderly patients who are often receiving
antithrombotic therapy for cardio- and cerebrovascular diseases, postprocedure
bleeding after endoscopic treatments for early gastric lesions has become one of
the major concerns of therapeutic endoscopists. The Japan Gastroenterological
Endoscopy Society (JGES) and other related associations published the
Guidelines for Gastroenterological Endoscopy in Patients Undergoing
Antithrombotic Treatment in 20121. According to the guideline it is not necessary
to suspend an antiplatelet agent before endoscopic treatments including endo-
scopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) if
the agent is not combined with other antithrombotic drugs (monotherapy). On
the other hand it is recommended that anticoagulants should be substituted with
heparin before EMR/ESD. The aim of this study is to clarify the efficacy of the
recommendations of the guideline.
Aims & Methods: In this study 888 early gastric lesions in 783 patients who
underwent EMR/ESD at our hospital between January 2012 and March 2017
were retrospectively analysed. Postprocedure bleeding was defined as: (1) hema-
temesis or melena for which an emergency endoscopy was required and (2)
bleeding which were confirmed with a repeat endoscopy after a drop 2 g/dL
of haemoglobin level.
Results: The total number of patients undergoing antithrombotic therapy was 78,
out of which 38 patients were taking antiplatelet agents only, 29 were taking
anticoagulants only, and 11 were taking the both. The antithrombotics were
suspended in 22 cases (Group A), substituted with heparin in 18 (Group B),
and kept continued in 38 (Group C). Postprocedure bleeding was encountered
in 31 out of 783 cases (4.0%), 21 of which occurred in patients on antithrombotic
therapy (21/78: 27%) whereas 10 of which occurred in those without (10/752:
1.3%). A univariate analysis between the patients with postprocedure bleeding
and those without concerning such variables age, gender, the diameter and
number of the resected lesions, use of antithrombotics, and the expertise of the
operating endoscopist revealed that only the use of antithrombotics was signifi-
cant risk factor for the postprocedure bleeding (odds ratio¼ 15.926, 95% con-
fidence interval: 7.415–34.208, p5 0.01). However, the rate of postprocedure
bleeding was not significantly different among Group A, B and C. Among the
21 bleeding patients with antithrombotics, the agent had been suspended or
substituted with heparin before EMR/ESD in 10 and had been continued without
suspension in 11. There was no significant difference of bleeding rate between the
two groups.
Conclusion: The use of antithrombotics was a significant risk factor for the
postprocedure bleeding after EMR/ESD for early gastric lesions. The rate of
bleeding was not significantly different regardless if the antithrombotics were
suspended, substituted with heparin, or continued without suspension.
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Introduction: Since population-based screening for gastric cancer in Korea was
implemented in 2002, endoscopic treatment of early gastric cancer (EGC) has
been popularized. Most patients with early neoplasm have no alarming symp-
toms/signs. In addition, the strategy for detecting factors predicting curative
endoscopic resection of EGC is becoming important, because the general popu-
lation is aging and considering the quality of life after treatment.
Aims & Methods: This study investigates factors affecting curative endoscopic
resection of EGC in the era of population-based screening for gastric cancer. The
subjects consisted of patients newly diagnosed with stomach cancer at Seoul St.
Mary’s Hospital between May 2011 and May 2016. All patients completed ques-
tionnaires about symptoms, social history, family history, knowledge of national
cancer screening program, the reason for screening and the interval between
endoscopy screening examinations for gastric cancer.
Results: Of a total of 469 patients, 147 (31.3%) had a curative endoscopic resec-
tion, 260 (55.4%) had a curative surgical resection and 62 (13.3%) were in non-
curative surgical resection or an inoperable state. The patients with curative
endoscopic resection had minimal abdominal symptoms and fewer alarm symp-
toms/signs (a family history of gastric cancer, anemia, and clinically important
weight loss), whereas alarm symptoms were more common in patients with
advanced cancer. In multivariate analysis, regular surveillance endoscopy was
only the factor predicting the curative endoscopic resection [Odd ratio (95%
CI) 6.099 (2.532 14.933), p¼ 0.000]. In addition, the proportion of curative
endoscopic resection was significantly higher in the 1-year [(Odds ratio (95%
CI) 10.381 (4.081 26.405), p¼ 0.000)], 2-year endoscopy interval groups
[(Odds ratio (95% CI) 3.161 (1.106 9.035), p¼ 0.032)] than patients who had
no endoscopy within 2 years.
Conclusion: Most patients with the curative endoscopic resection have minimal
abdominal symptoms and no alarming symptoms/signs. Regular surveillance
endoscopy was the only factor predicting the curative endoscopic resection of
gastric cancer. In addition, more frequent endoscopic surveillance could help to
early detect gastric cancers with curative endoscopic resection.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Atrophic gastritis and intestinal metaplasia are the cancerization
field in which gastric cancer (GC) develops in case of intestinal type. The OLGA
and OLGIM staging systems have been suggested to provide risk estimation for
GC.
Aims & Methods: The aim of this study is to evaluate the usefulness of OLGA
and OLGIM staging according to Laurens’s histological classification of GC in
considering with other risk factors of gastric cancer. From January 2006 to
December 2015, 607 GC patients and 677 control subjects were enrolled who
underwent esophagogastroduodenoscopy. Biopsies were taken from the greater
and lesser curvatures of the antrum and mid-body, respectively. The OLGA and
OLGIM stage (0–IV) was recorded by combining antral with body atrophy
scores using the Updated Sydney System. Stage III and IV OLGA or OLGIM
was classified as high-risk stage group and Stage 0-II as low-risk group. H. pylori
infection was assessed by modified Giemsa stain, rapid urease test and culture
and was defined by a positive result on any of these tests. Multivariate logistic
analysis was performed for the age, sex, smoking, alcohol and family history of
GC.
Results: GC patients had more high-risk OLGA stages (25.9%) than controls
(6.8%, P5 0.001) and high-risk OLGIM stages (18.3%) than controls (4.9%,
P5 0.001). In the multivariate logistic analysis, Old age [odds ratios (ORs),
1.932; P¼ 0.004 and 2.584; P5 0.001 for ages in the 40 59 and 460, respec-
tively], family history of GC (OR, 2.119; P5 0.001), and H. pylori infection (OR,
1.963; P5 0.001) were independent risk factors for GC in the diffuse type as well
as intestinal type (Table). High-risk OLGA stages were significantly associated
with increased risk of GC in comparison to low-risk (OR, 3.778; P5 0.001):
intestinal-type (OR, 4.318; P5 0.001) and diffuse-type (OR, 2.920; P5 0.001)
(Table). High-risk OLGIM stages were also significantly associated with
increased risk of GC in comparison to low-risk (OR, 3.306; P5 0.001): intest-
inal-type GC (OR, 3.051; P5 0.001) and diffuse-type GC (OR, 3.981;
P5 0.001).
Conclusion: High-risk OLGA and OLGIM stages were useful for intestinal type
as well as diffuse type. This usefulness will be increased when combined with H.
pylori status and family history of GC in regions with high prevalence of GC.
Analysis regarding specific interaction among these three factors is undergoing.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The association between body mass index (BMI) and digestive
cancer mortality is not conclusive in East Asians.
Aims & Methods: We evaluated the relationship between BMI and digestive
cancer mortality, using prospective cohort data by the National Health
Insurance Service in Korea, which consisted of more than one million subjects.
A total of 510, 148 Korean adults were followed-up until 2010. The adjusted
hazard ratios (HRs) of cancer mortality were calculated using a Cox model.
Results: During follow-up, 7774 total deaths occurred from digestive cancer. HR
for digestive cancer mortality across seven BMI categories. Below 25 kg/m2, the
HRs of death for each 5 kg/m2 increase in BMI were 0.43 (95% confidence
interval [CI]¼ 0.32–0.58) for esophagus cancer, 0.70 (0.62–0.79) for stomach
cancer, and 0.77(0.65–0.90) for colorectal cancer. Over 25 kg/m2, the HRs of
death for each 5 kg/m2 increase in BMI were 1.30 (95% CI¼ 1.04–1.64) for
colorectal cancer, 1.28 (1.07–1.53) for liver cancer, and 1.28 (0.96–1.71) for gall-
bladder cancer and biliary tract cancer. BMI were not associated mortality from
small intestine cancer and pancreatic cancer.
Conclusion: Low BMI were predictors of mortality from esophageal cancer and
stomach cancer. High BMI were predictors of mortality from liver cancer and
gallbladder cancer and biliary tract cancer. Both low and high BMI were pre-
dictors of mortality from colorectal cancer. Further research is needed to evalu-
ate whether interventions involving weight change (loss or gain) reduce the risk of
cancer or improve the survival.
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Abstract No: P0576
Gastric cancer patients (n¼ 607) Intestinal-type (n¼ 354) Diffuse-type (n¼ 233)
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Sex
Female 1 1 1
Male 1.193 0.847–1.679 0.312 2.833 1.833–4.381 50.001 0.474 0.295–0.761 0.002
Age(year, meansd)
540 1 1 1
4059 1.932 1.229–3.036 0.004 7.266 2.570–20.544 50.001 1.238 0.748–2.047 0.406
60 2.584 1.647–4.056 50.001 14.706 5.244–41.243 50.001 0.908 0.538–1.535 0.720
Smoking status
Never-smoker 1 1 1
Ever-smoker 1.467 0.974–1.918 0.050 1.012 0.589–1.351 0.289 2.194 1.355–3.553 0.001
Alcohol consumption
Never-drinker 1 1 1
Ever-drinker 1.322 1.010–1.731 0.042 1.183 0.852–1.643 0.317 1.402 0.970–2.026 0.072
Family history of gastric cancer
Negative 1 1 1
Positive 2.119 1.521–2.953 50.001 1.995 1.344–2.960 0.001 2.436 1.600–3.709 50.001
H. pylori status
Negative 1 1 1
Positive 1.963 1.540–2.503 50.001 1.604 1.193–2.157 0.002 2.800 1.991–3.937 50.001
OLGA
low risk 1 1 1
high risk 3.778 2.612–5.465 50.001 4.318 2.899–6.431 50.001 2.920 1.779–4.793 50.001
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Introduction: Endoscopic submucosal dissection (ESD) is not currently accepted
as an alternative treatment to surgery in ulcerative type EGC due to relatively
higher probability of lymph node metastasis (LNM). This present retrospective
analysis examined the correlation of various histologic factors with the presence
of lymph node metastasis in ulcerative type EGC.
Aims & Methods: A retrospective analysis on 200 patients with ulcerative type
EGC who underwent radical gastrectomy with D2 lymph node dissection.
Several clinicopathologic factors were investigated to identify predictive factors
for LNM: tumor size, histopathologic type of tumor, lymphovascular invasion
and depth of invasion. Multivariate logistic regression analysis was performed to
evaluate the risk factors for LNM.
Results: The total rate of LNM was 15.5% (31/200). The rate of LNM was 2.1 %
(2/95) in the lesions confined to the mucosa and 27.6 % (27/105) in those that had
infiltrated the submucosa On univariate analysis, depth of invasion (p¼ 0.047)
and lymphovascular invasion (p5 0.001) were significant associated with LNM.
However, there was no significant association between tumor size, histopatholo-
gic type of tumor and LNM. On multivariate analysis, only lymphovascular
invasion (p5 0.001) was significantly associated with LNM. There was no sig-
nificant association between tumor size and lymph node metastasis in ulcerative
type EGC.
Conclusion: Ulcerative EGC confined to the mucosa could be considered for
candidate for curative ESD due to the low risk of LNM. This finding should
be confirmed by more data from other centers, which focus on LNM after ESD
in ulcerative type intramucosal EGC.
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Introduction: Gastrointestinal cancers are one of the most common malignancy
worldwide. Especially endoscopic submucosal dissection (ESD) for early
gastrointestinal cancers have been considered as the current standard cancer
treatment. However, lack of counter traction during ESD procedure is one of
major difficulty. To overcome this problem, we developed new endoscopic tech-
nique using robotic manipulator and conducted study about efficacy and safety
in vitro animal study.
Aims & Methods: A novel robotic suture manipulator is composed of control
panel and a working arm, which grasp and move objects at the end of scope. A
total of 10 porcine stomachs were used for the test. Porcine stomachs were
assigned randomly to 2 groups and ESD was performed on mucosa of stomach
using conventional technique and new endoscopic technique with robotic manip-
ulator. Endoscopic experts and novice endoscopists performed ESD in 2 parts
(antrum & body) of stomach. During procedure, robotic manipulator lifts up
dissected tissue of stomach to make better visibility. Procedure time, complete
resection rate, and complication such as perforation was recorded.
Results: The average procedure time for the robotic manipulator and conven-
tional ESD was 42 minutes and 45.9 minutes. In novice endoscopists, the average
procedure time using robotic manipulator is faster than conventional ESD group
(47.5min vs 55.3min, p5 0.05). Both endoscopic expert and novice endoscopist
completed the ESD procedure for en bloc resection of target lesions using
KUMC robotic manipulator. There was no difference in complete resection
rates between two groups. No complication such as perforation was occurred
in both groups during the procedures. There was no difference depending on
resected location in stomach.
Conclusion: The robotic manipulator, which can perform ESD more easily
showed feasible result comparing with conventional ESD. ESD using robotic
manipulator could be helpful, especially in novice endoscopists. This research
proposes a novel approach for safe and feasible method during ESD.
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Introduction: Irreversible electroporation (IRE) is a promising novel technique
for the ablation of tumors. An advantage of IRE is its mechanism to remove
undesired cells by affecting the cell membrane without thermally destructing
blood vessels, nerves and the surrounding tissues. Several clinical trials for apply-
ing IRE to human organs such as liver, pancreas, and kidney are conducted and
studies about IRE ablation for gastrointestinal tumors also have been conducted
recently. Here, we developed new endoscopic IRE device, and studied about its
effectiveness and feasibility in animal model.
Aims & Methods: Newly developed endoscopic IRE ablative catheter works with
single channel of endoscope. A pair of dipolar electrodes consist of pre-shaped f
0.63mm nitinol wire and the distance between each electrode is 10mm. The
electrodes are loaded within braided tube for stent delivery system then deployed
when IRE catheter put in stomach through the endoscope. We performed endo-
scopy and IRE ablation was done on pig’s stomach mucosa by using endoscopy
with newly developed IRE catheter. We divided pig’s stomach into 2 parts
(antrum & body), and IRE ablation was applied on each part of the stomach.
Pigs were sacrificed after 24 hours, and we collected their stomachs with surgical
technique. Following fixation, tissues were stained with H&E.
Results: Ten male Yorkshire pigs and in vitro stomachs were used in this study.
The tissue with H&E stain showed diffuse cell death 24 hr after IRE ablation.
Abstract No: P0577
Digestive cancer mortality associated with baseline BMI according to BMI ranges
All participants (12–47 kg/m2) 12–24.9 kg/m2 25–47 kg/m2
per 5 kg/m2 increase inBMI per 5 kg/m2 decrease inBMI per 5 kg/m2 increase in BMI
Digestive cancer Deaths P-value HRa (95% CI) Deaths P-value HRa (95% CI) Deaths P-value HRa (95% CI)
Esophagus 310 50.001 0.53 (0.43–0.65) 252 50.001 0.43 (0.32–0.58) 58 0.491 1.28 (0.64–2.57)
Stomach 2, 032 50.001 0.77 (0.72–0.83) 1488 50.001 0.70 (0.62–0.79) 544 0.244 1.14 (0.91–1.43)
Colon and rectum 1328 0.845 1.01 (0.92–1.11) 866 0.002 0.77 (0.65–0.90) 462 0.024 1.30 (1.04–1.64)
Colon 835 0.347 1.06 (0.94–1.19) 536 0.070 0.82 (0.66–1.02) 299 0.089 1.28 (0.96–1.71)
Rectum 493 0.366 0.93 (0.80–1.08) 330 0.006 0.69 (0.53–0.90) 163 0.136 1.34 (0.91–1.97)
Small intestine 61 0.049 0.64 (0.41–1.00) 49 0.863 0.94 (0.46–1.92) 12 0.231 0.26 (0.03–2.36)
Liver 2365 0.601 1.02 (0.95–1.09) 1577 0.323 0.94 (0.82–1.07) 788 0.007 1.28 (1.07–1.53)
Pancreas 929 0.937 1.00 (0.90–1.12) 603 0.626 0.95 (0.77–1.17) 326 0.504 0.90 (0.67–1.22)
GB and Biliary tract 749 0.012 1.16 (1.03–1.31) 471 0.644 1.06 (0.84–1.34) 278 0.221 1.28 (0.96–1.71)
BMI, body mass index; CI, confidence interval; GB, gallbladder; HR, hazard ratio. a Hazard ratios were calculated using Cox proportional hazards models after
adjustment for age at baseline (continuous variable), smoking status (current smoker, former smoker, never-smoker, and missing smoking status), alcohol consump-
tion (frequency; five or more times/week, one to four times/week, less than one times/week, past drinker [no alcohol for a year], never-drinker, or missing information),
monthly household income (Korean won [KRW], 1 United States dollar¼ 1170 KRW as of August 1, 2004; 5500, 000, 500, 000–990, 000, 1, 000, 000–1, 490, 000, 1,
500, 000, missing information), and physical activity (yes, no). HRs were not presented for causes with less than 10 deaths.
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Consistent with the mechanism of action of IRE on the cell membrane only, there
was complete cell death within the IRE lesions without intervening live cells. But
there was no difference in histology depending on gastric part in which ablation
was applied. During the study, no complication was observed in pigs in 24 hours
after ablation.
Conclusion: The new endoscopic IRE device, which can perform IRE ablation on
gastrointestinal tract using endoscopy showed safe and feasible result.
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Introduction: It is difficult to delineate gastric cancer that is detected after suc-
cessful eradication of Helicobacter pylori. One reason is reportedly the difficulty
in identifying the demarcation line between the cancerous lesion and non-cancer-
ous gastric mucosa due to a mixture of non-neoplastic epithelial-lined structure
inside the neoplasm. However, almost all previous studies have only used mag-
nification endoscopy (ME) at low power magnification which could evaluate
microsurface pattern (MSP) but could not evaluate microvascular pattern
(MVP)1). The highest power magnification was necessary to evaluate MVP accu-
rately2), and the diagnostic efficacy of ME in delineating the gastric cancers
might not have been accurately assessed in these studies.
Aims & Methods: The aim of this study was investigating diagnostic efficacy of
ME with narrow band imaging (NBI) in delineating the gastric cancers after
eradication HP, using ME at highest power magnification, and classifying ME
features of the marginal area according to the vessel plus surface classification
system (VSCS) to realize which was more important ME findings MSP or MVP
to detect demarcation line. Endoscopic examination was performed using a mag-
nification endoscope (GIF-H260Z; Olympus Medical Systems Co, Tokyo, Japan)
and NBI system (EVIS LUCERA Spectrum system; Olympus Medical Systems
Co, Tokyo, Japan). Endoscopic imaging procedures were performed at low-
power magnification followed by highest power magnification. On the day of
ESD, the resection line was marked 3–5mm outside of the margin of the lesion. A
lesion meeting all of the following criteria was defined as a lesion with successful
delineation: (1) the demarcation line of the lesion is endoscopically identified with
a high level of confidence; (2) According to histopathological findings, the lesion
is confined within the resection line. The diagnostic accuracy of ME-NBI in
delineating the lesions was evaluated. On the other hand the ME findings of
the marginal area in each lesion were classified in terms of microsurface pattern
(MSP) and microvascular pattern (MVP) according to the VSCS to identify the
findings that were useful in delineating the lesions in patients with differentiated-
type early gastric cancers. The classification according to the VSCS was made in
the marginal area with the least irregular findings.
Results: Of 178 consecutive lesions of differentiated-type early gastric cancer
treated with endoscopic submucosal dissection (ESD) between August 2013
and March 2017, the study included 59 lesions that were detected after successful
H. pylori eradication. The result of ME-MBI findings are summarized in the
table. Gastric cancer was successfully delineated in 98.3%(58/59) of the lesions
with irregular MSP and/or irregular MVP with a demarcation line. Among the
ME findings of the demarcation line, irregular MSP and irregular MVP were
present in 67.7%(40/59) and 93.2%(55/59), respectively, according to the VSCS,
with a higher percentage of lesions with irregular MVP than those with irregular
MSP. In addition, there was no finding which was irregular MSP and regular
MVP, but 27.1%(16/59) was regular MSP and irregular MVP, which indicated
that the ME findings of MVP was more important than MSP. One lesion showed
regular MSP or regular MVP without a demarcation line in a portion of the
marginal area, resulting in unsuccessful delineation.
Regular MVP Irregular MVP Absent MVP
Regular MSP 1(1.6%) 16(27.1%) 0(0%)
Irregular MSP 0(0%) 37(62.7%) 3(5%)
Absent MSP 0(0%) 2(3.3%) 0(0%)
Conclusion: The accuracy of ME with NBI in delineating gastric cancer detected
after H. Pylori eradication was 98.3%, which was higher than the values reported
previously. In addition, the MVP as visualized by ME appeared to be a more
reliable marker than MSP. These results indicate a meticulous observation of the
MVP under maximal magnification to be crucial for the delineation of gastric
cancer detected after eradication of H. pylori.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
1. Kobayashi M, Hashimoto S, Nishikura K, et al. Magnifying narrow-band
imaging of surface maturation in early differentiated-type gastric cancers
after Helicobacter pylori eradication. J Gastroenterol 48:1332–1342, 2013
2. Uchita K, Yao K, Uedo N, et al. Highest power magnification with narrow-
band imaging is useful for improving diagnostic performance for endoscopic
delineation of early gastric cancers. BMC Gastrorntrology 15:155, 2015
P0582 ENDOSCOPIC SMALL CAPACITY FORCEPS INCREASE
THE PATHOLOGICAL DIAGNOSIS OF GASTRIC INDEFINITE
NEOPLASIA
Y. Matsuo
1, H. Yasuda2, M. Kato2, H. Kiyokawa2, M. Ozawa2, Y. Sato2,
Y. Ikeda2, M. Yamashita2, T. Fujino3, H. Yamamoto2, M. Takagi3, F. Itoh2
1St. Marianna University School of Medicine, Kawasaki/Japan
2Gastroenterology And Hepatology, St. Marianna Medical University, Kawasaki/
Japan
3Pathology, St. Marianna Medical University, Kawasaki/Japan
Contact E-mail Address: yasumasa_matsuo@marianna-u.ac.jp
Introduction: Endoscopic forceps biopsy (EFB) is the gold standard for gastric
epithelial tumor diagnosis. However, definitive diagnosis is often difficult, and
some cases are diagnosed as gastric indefinite neoplasia (GIN), which corre-
sponds to category 2 in the revised Vienna classification. GIN lesions require
short periods of follow-up.1 The most appropriate forceps size for gastric biopsy
has yet to be determined. In the Japanese Classification of Gastric Cancer, diag-
noses of GIN are attributed, at least partly, to the small size of biopsy speci-
mens.2 Since specimens yielded by small biopsy forceps are small, the use of small
biopsy forceps is expected to increase the rate of GIN diagnoses.
Aims & Methods: The relationship between forceps size and the frequency of
GIN was investigated. The patients in this cohort were divided into two historical
groups. The first group comprised patients evaluated during the period when
standard biopsy forceps (StF) were used (April 2010–March 2011), and the
second comprised patients evaluated during the period when small biopsy forceps
(SmF) were used (April 2011–March 2013). Standard caliber endoscopy was used
for all esophagogastroduodenoscopy(EGD). We count the number of GIN and
gastric carcinoma lesions. Patient characteristics, lesion characteristics (e.g., site,
macroscopic appearance, and color tone), endoscopist experience level, biopsy
sample size were investigated in both groups diagnosed as GIN. The clinical
courses of GIN cases were followed for 3 years, and the timing of EGD after
the GIN diagnosis and the final pathological result were investigated.
Results: Among the 8420 patients who underwent EGD in the first period, 2, 584
(30.7%) underwent gastric biopsy with StF. Among the 15,968 patients who
underwent EGD in the second period, 4204 (26.3%) underwent gastric biopsy
with SmF. Gastric carcinoma was diagnosed in 7.93%(205/2584) and 7.54%(317/
4204) of the StF and SmF groups, respectively (P¼ 0.556). GIN was diagnosed in
0.73%(19/2583) and 1.25%(52/4204) of the StF and SmF groups, and the differ-
ence was significant (P¼ 0.048). The two groups diagnosed as GIN did not differ
significantly in terms of the patient characteristics, the lesion characteristics,
endoscopist experience level and biopsy related hemorrhage. The mean minor-
axis lengths of the biopsy samples were 1.50 0.50mm and 1.38 0.40mm in the
StF and SmF groups, respectively. The SmF group samples tended to be shorter
(P¼ 0.088). In both groups, 40% of the final diagnoses were epithelial neopla-
sias; no significant differences were observed.
Conclusion: SmF use may increase the rate of GIN. Thus, SmF use should be
avoided with a standard caliber endoscopy.
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Introduction: Stomach cancer is a leading cause of cancer-related deaths in the
world. It well knows that stress play an important role in the cancer. However,
for the role of stress in cancer initiation is contradicted and debatable. Other
natural factors such as nitrites, which are widely presented in daily food, are
actively discussed as carcinogenic to humans. But, there is no clinical and epide-
miological evidences that nitrosamines itself can induce the stomach cancer.
Aims & Methods: For the better understanding of carcinogenic effects of daily
stress and nitrites in development of stomach cancer, here we studied the role of
these factors in adenocarcinoma in stomach of rats. The experiments were carried
out with male adult rats (n¼ 200). To examine the role of stress and nitrosamines
in gastric mucosal injuries we used: 1) the model of chronic social stress (over-
population during 9 months); 2) the daily using of toluidine (2 g/kg) in food and
water with nitrites (2 g/l); 3) the combined effects of stressþnitrosamines. The
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upper endoscopy was performed using our in-house custom-made multichannel
endoscopy system. Histological assay performed to analyze the changes in the
gastric tissues.
Results: Using upper gastroscopy, we studies the stomach tissues during 9
months of lining of rats in chronic stress. There were no changes in the gastric
mucosa during the first two months. In the third month 35% (7 of 20) of animals
demonstrated multiple small peptic ulcer (n¼ 11). These changes progressed
during other time of observation. 9 months of experiment. So, this time all
rats showed peptic ulcers both types with significant increase in the number of
ulcers (small, n¼ 21 and large, n¼ 9). Thus, this series of experiments clearly
showed that chronic stress plays provoking role in the peptic ulcer formation in
the stomach of rats. The deleterious effects of nitrosamines on the gastric mucosa
observed 4 months after the beginning of daily using of toluidine and nitrites in
75% of rats (15 of 20). These rats showed symptoms of atrophic gastritis. Other
25% (5 of 20) of animals did not demonstrate any changes in gastric mucosa.
Thus, this series of experiments markedly showed that effect of long-term eating
low-dose nitrosamines induced of atrophic gastritis in the stomach of majority of
rats. Using similar protocol of the first and second parts of experiments, we
observed the changes in the stomach tissues during 9 months. The same scenarios
of typical gastric injuries induced by stress and nitrosamines were observed in
rats, i.e. they showed development of peptic ulcers and atrophic gastritis. But, 7
months after the start of experiment, these pathological changes of gastric tissues
were associated with intestinal metaplasia of goblet cells, which is the pre-cancer
symptom. In 9 months of study, symptoms of gastric adenocarcinoma were
observed in 82% of rats (131 of 160). Tumor lesions was accompanied by the
migration of metastatic tumor cells through the bloodstream in the liver. The
number of metastatic nodes varied from 1 to 5.
Conclusion: Thus, in our research we clearly show that only combination of two
pro-cancer factors such as stress and nitrosamines cause development of gastric
cancer with metastasis in the liver while the presence of these factors alone
contribute mucosal injuries without oncological changes in the stomach.
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food intake and gastric and oesophageal cancer risk: a systematic review
of the epidemiological evidence.’’ World journal of gastroenterology 12.27
(2006): 4296
5. Semyachkina-Glushkovskaya, O. V., et al. ‘‘Adrenergic mechanism respon-
sible for pathological alteration in gastric mucosal blood flow in rats with
ulcer bleeding.’’ Twelfth International Conference on Photonics and Imaging
in Biology and Medicine (PIBM 2014). International Society for Optics and
Photonics, 2014
P0585 RELEVANCE OF PTGS1 AND PTGS2 GENE
POLYMORPHISMS TO GASTRIC CANCER RISK AND PHENOTYPE
IN CAUCASIANS
M.A. Garcı́a-González
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E. Piazuelo8, C. Thomson9, Á. Pérez-Aı́sa10, M. Badı́a11, D. Nicolás-Pérez3,
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Introduction: Cyclooxigenases 1 (COX-1) and 2 (COX-2) are key enzymes in
mediating the conversion of arachidonic acid into prostaglandins which are
important regulators of the immune inflammatory response in the gastrointest-
inal mucosa1, 2. COX-1 is constitutively expressed in most cell types and involved
in maintaining gastric mucosal homeostasis, whereas COX-2 is induced by proin-
flammatory and mitogenic stimuli and involved in several relevant mechanisms
of gastric cancer (GC) development.
Aims & Methods: Since variants in the PTGS1 and PTGS2 genes may modify the
expression or function of their encoded enzymes COX-1 and COX-2, the aim of
our study was to assess the relevance of environmental factors and several func-
tional PTGS1 and PTGS2 gene polymorphisms on GC risk and phenotype in a
Caucasian population in Spain. Methods: DNA from 603 unrelated Spanish
patients with primary GC and 603 sex- and aged- ( 5 years) matched cancer-
free healthy controls was typed for 10 single nucleotide polymorphisms (SNPs) in
the PTGS1 (þ50C/T, and þ644C/A) and PTGS2 (1195A/G, 765G/C, 297C/
G, þ3050G/C, þ8473T/C, þ9850A/G, þ10335G/A, and Val511Ala) genes by
PCR, RFLP and TaqMan assays. H. pylori infection and CagA/VacA antibody
status were also determined by western blot in patients and controls.
Results: H. pylori infection with CagA strains (OR: 1.99; 95% CI: 1.55–2.54),
smoking habit (OR: 1.77; 95% CI: 1.22–2.57) and positive family history of GC
(OR: 3.02; 95% CI: 1.99–4.60) were identified as independent risk factors for GC.
Concerning gene polymorphisms, no differences in carriage, genotype, and allele
frequencies of the PTGS1 and PTGS2 gene polymorphisms were found between
GC patients and controls. However, when GC patients were stratified according
to the localization of the tumor, we found that carriers of the PTGS2 -1195
(rs689466) G allele were significantly more frequent in the group of cardia-GC
patients than in controls (46.8% vs. 32.8%; OR: 1.77; 95% CI: 1.06–2.95).
Moreover, carriers of the PTGS2 GGGTAG haplotype that contains the
PTGS2-1195G allele, were also more frequent in the group of cardia-CG patients
than in controls (41.3% vs. 32.1%; OR: 1.73; 95% CI: 0.86–3.49). Finally, no
differences in carriage, genotype, and allele frequencies of the PTGS1 and PTGS2
gene polymorphisms were found when GC patients were categorized according to
gender, age, smoking habit, H. pylori infection, CagA/VacA antibody status,
family history of GC, and histological subtype of the tumor.
Conclusion: Our data show that the PTGS2-1195A/G (rs689466) gene poly-
morphism is involved in defining the genetic basis of the susceptibility to
cardia-gastric cancer in a South-European population.
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Introduction: Gastric cancer (GC) contributes a heavy burden to the global
health, especially in Asian countries. Early diagnosis is crucial to improve
patients’ outcome, but reliable biomarkers are desperately needed. In our pre-
vious studies, we established several endogenous fluorescence spectra of gastric
juice for GC diagnosis and screening [1, 2], isolated and identified three fluores-
cence candidates (aromatic amino acids, AAAs), which can be used to distinguish
GC from non-neoplastic gastric diseases (NGD) regardless of the stage [3, 4].
However, the characteristic biosignature for the whole metabolic spectra of gas-
tric juice free amino acids (GJFAAs) in GC patients remain unclear. Although
many investigators had reported on the changes of amino acids’ concentrations
in the peripheral blood, urine and tissues of GC patients [5, 6].
Aims & Methods: In order to determine the metabolic patterns of GJFAA in GC
and NGD patients, gastric juice samples were collected from GC patients (n¼ 47)
and age-matched NGD patients (n¼ 83) from December 2015 to May 2016, and
then measured by an automatic amino acid analyzer. Orthogonal partial least
squares discriminant analysis (OPLS-DA) and Mann-Whitney U test are used for
data analysis. The diagnostic value of GJFAAs was evaluated by ROC curve.
Furthermore, significantly altered metabolic pathways were identified by path-
way analysis using public databases such as KEGG and MetaboAnalyst 3.0.
Results: GJFAA profiles significantly differed between the GC and NGD
patients. A total of 14 kinds of GJFAAs, whose first principal component of
variable importance in the projection (VIP) value exceeding 1 and P-value less
than 0.05, were screened as differential GJFAAs. Compared with the NGD
patients, GC patients had higher levels of threonine, serine, alanine, valine,
methionine, isoleucine, leucine, tyrosine, phenylalanine, lysine and arginine,
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together with lower levels of phosphoserine, ethanolamine phosphate and urea
(Table 1). The 14 GJFAAs revealed diagnostic values with AUC from 0.666 to
0.868, and the combined AUC of them reached to 0.902 (95% CI, 0.846–0.959)
for the diagnosis of GC. Importantly, their AUCs were from 0.649 to 0.857, and
the combined AUC reached to 0.880 (95% CI, 0.792–0.969) for the diagnosis of
early GC. Particularly, leucine, threonine and serine are the most altered three
GJFAAs between the two groups, whose fold change more than 2 and AUC
value greater than 0.8. Moreover, the combined AUC of the 3 non-AAAs was
0.869 (95% CI, 0.805–0.934) for the diagnosis of GC. It was slightly higher than
that combined with 3 AAAs 0.841 (95% CI, 0.773–0.908). Additionally, the
pathway of aminoacyl-tRNA biosynthesis metabolism was excessively activated,
which significantly responsible for the above metabolic alternations in GC.
Table 1: Differential GJFAAs between GC and NGD patients and their dis-
criminating performance
Number Abbreviation
Median
GC
Median
NGD P-value VIP FC AUC 95% CI
AA01 PSer 0.028 0.037 0.002 1.054 0.768 0.666 0.561–0.771
AA03 PEtN 0.007 0.018 50.001 1.028 0.606 0.718 0.615–0.820
AA04 Urea 0.178 0.604 50.001 1.058 0.486 0.804 0.729–0.880
AA06 Thr 0.022 0.007 50.001 1.489 2.431 0.835 0.764–0.907
AA07 Ser 0.016 0.005 50.001 1.420 2.671 0.831 0.759–0.903
AA12 Ala 0.033 0.016 50.001 1.238 1.973 0.783 0.702–0.865
AA15 Val 0.025 0.013 50.001 1.025 1.763 0.717 0.621–0.814
AA17 Met 0.017 0.007 50.001 1.178 2.148 0.797 0.718–0.877
AA18 Ile 0.026 0.007 50.001 1.343 2.674 0.812 0.736–0.887
AA19 Leu 0.075 0.020 50.001 1.626 2.697 0.868 0.803–0.933
AA20 Tyr 0.066 0.026 50.001 1.580 1.926 0.833 0.765–0.902
AA21 Phe 0.069 0.032 50.001 1.415 1.754 0.802 0.720–0.883
AA31 Lys 0.044 0.015 50.001 1.091 2.321 0.804 0.725–0.883
AA32 Arg 0.036 0.008 50.001 1.332 2.722 0.772 0.686–0.859
P-value, Statistically significant difference using Mann-Whitney U test; VIP,
variable importance in the projection; FC, Fold Change; AUC, area under the
ROC curve; 95%CI, 95% confidence interval.
Conclusion: GJFAA profiles may be helpful for improving GC diagnosing even
in the early stage and for providing more information about its metabolism.
Leucine, threonine and serine, three non-AAAs, warrant further validation as
alternative metabolic biomarkers for GC.
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Introduction: It is reported that aromatic amino acids (AAAs) in gastric juice
could be used as potential diagnostic biomarkers to screen gastric cancer (GC)
[1–3]. However, the underlying mechanism remain elusive [4]. Our group had
conducted a series of explorations on the reasons to cause such phenomenon
before. The candidate molecules: 1) L- type amino-acid transporer 1 (LAT1),
which is involved in the enhancement transport of amino acids and the accumu-
lation of AAAs near cancer foci; 2) intracellular amino-acid-metabolizing
enzymes, such as indoleamine 2, 3-dioxygenase (IDO) and monoamine oxidase
(MAO); 3) proteins involved in intracellular protein degradation or autophagy,
(e.g., SQSTM1/p62) had been examined [5]. However, because of the difference
in the expression of the above proteins in different pathological classifications of
GC tissues, it is impossible to explain the phenomenon that the elevation of
AAAs’ levels in gastric juice in almost all types of GC patients.
Aims & Methods: To investigate the role of proteolytic enzymes matrix metallo-
proteinase -2/9 (MMP-2/9) in the abnormal elevation of AAAs’ concentrations in
gastric juice of GC patients, gastric mucosal specimens and gastric juice samples
were simultaneously collected from 29 GC patients and 91 age- and gender-
matched non-neoplastic gastric disease (NGD) patients. The expression levels
of MMP-2/9 and type IV collagen (Col IV) in gastric mucosal tissues were
examined by immunohistochemical staining while the levels of AAAs in gastric
juice were measured by liquid chromatography-tandem mass spectrometry (LC-
MS/MS). Furthermore, the association between them was evaluated by
Spearman correlation analysis.
Results: On the one hand, the expression intensity of MMP-2/9 in GC group were
significantly higher than those in NGD group, while Col IV was markedly lower
than that in NGD group (P5 0.001 for all). Moreover, there was a positive
correlation between the expression level of MMP-2 and MMP-9 (rho¼ 0.439,
P5 0.01), but they were both negatively correlated with Col IV (rho¼0.454,
P5 0.01; rho¼0.392, P5 0.01). On the other hand, significantly higher levels
of AAAs in gastric juice were observed in GC patients than those in NGD
individuals (P5 0.001 for all). Ultimately, the expression levels of MMP-2/9 in
gastric mucosal tissues were both positively correlated with the concentrations of
AAAs in gastric juice (MMP-2 rho¼ 0.262, 0.295, and 0.293, respectively,
P5 0.01 for all; MMP-9 rho¼ 0.457, 0.455, and 0.417, respectively, P5 0.001
for all), but Col IV was negatively correlated with them (rho¼0.283, 0.280,
and 0.273, respectively, P5 0.01 for all) (Table 1).
Table 1: Relationship between the expression levels of MMP-2/9 and Col IV in
gastric tissues and the levels of AAAs in gastric juice
Variable MMP-2 MMP-9 Col IV
Tyrosine 0.262** 0.457*** 0.283**
Phenylalanine 0.295** 0.455*** 0.280**
Tryptophan 0.293** 0.417*** 0.273**
**represents significant correlation using Spearman correlation analysis when the
confidence level was 0.01;*** represents significant correlation using Spearman
correlation analysis when the confidence level was 0.001.
Conclusion: The overexpression of MMP-2/9 resulting in the degradation of Col
IV in basement membrane and extracellular matrix may lead to the variation of
AAAs’ levels in gastric juice of GC patients.
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Introduction: Gastric cancer (GC) is the fourth most common type of cancer and
the second leading cause of cancer related death. The gold standard for diagnosis
is the esophagogastroduodenoscopyy (EGD) with targeted biopsies.
Aims & Methods: Retrospective, observational and descriptive study in patients
diagnosed of gastric cancer from January 2013 to December 2016 in the area of
Ciudad Real (Spain). Missing rate of gastric cancer was defined as the percentage
patients who had a negative EGD three years before the diagnosis of CG. A
survival analysis was performed with Kapplan Meier curves, mainly focussing on
the influence of missing rate for gastric cancer. We studied the features related to
EGD that could lead this issue.
Results: 162 patients were included, 65% male with a mean age at diagnosis of 72
years. Intestinal type was the most common histology (76%). A rate of 6.8%
missing of gastric cancer was detected with an average of 20 months in delay of
diagnosis. However, the survival rate was similar between patients with and
without a previous EGD (7.08 vs 5.05 months p¼ 0.60). Among the patients
who passed away, a longer delay period was observed comparing to patients
who were still alive (6 months vs. 25 months; p¼ 0.006). In the aforementioned
subgroup, biopsias were taken in 72% with gastric atrophy in all these cases.
Helicobacter pylori infection was detected in 50% of them. 55.6% of the EGDs
were carried out without sedation. At no point chromoendoscopy was per-
formed, pictures were taken and withdrawal times were not reflected.
Conclusion: Despite the fact that EGD is by far the most effective method to
diagnose gastric cancer, 1 out of 10 cancers or premalignant lesions are not
figured out. Therefore, it is of utmost importance to put in place quality proto-
cols in EGD that may help to increase the diagnosis of early gastric cancer, and
by this way, improve the survival rate of these patients.
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Introduction: Several studies have demonstrated serum PGII level as a marker of
the functional gastric mucosa, and a marker of some tumor including the gastric
cancer. However, the modulation of the protein and its role in cancer is not fully
understood. The aim of this study was to analyse the polymorphisms in the
TATA BOX region, which provides a binding site for the transcription factor
for the PG2 gene, in association with the PG2 circulating level and clinical
parameters in population at risk for GC and in GC patients.
Aims & Methods: Gastric function of 180 patients (67 GC, 71 first-degree rela-
tives of GC patients (FDR-GC) and 42 autoimmune chronic AG (ACAG)) was
assessed by gastropanel test. We investigated the PG2 TATA BOX polymorph-
ism frequencies in relation to serum PG2 (sPG2) expression level, HP-positivity
and risk for GC. TATA BOX DNA fragments were amplified by PCR and
analyzed by the capillary-electrophoresis (GeneMapper software). Association
among clinical data and PG2 polymorphisms were estimated by Receiver oper-
ating characteristic (ROC) curve and linear regression analyses.
Results: After ROC curve analysis, the sensitivity to discriminate GC at 15 ng/mL
PG2 cut-off was 70.15% and 79, 65% sensibility and sensitivity, respectively
(AUC: 758, p5 0.0001). We obtained 26 different PG2 TATA box fragments
(from 308 bp to 479 bp). These fragments were grouped into 4 sized categories
(1¼ 308–400 bp; 2¼ 401–436 bp; 3¼ 437–438 bp; 4¼ 439–479 bp). A positive cor-
relation among the increase of PG2 sized fragments and the sPG2 level was found
in the GC group (linear regression y¼ 16, 4381þ 2, 6846 x, p¼ 0.02).
Conclusion: Accordantly to the literature, we confirm sPG2 level as a marker
discriminating between GC and individuals at risk for GC (i.e ACAG and FDR)
in our series. In addition we reported a correlation between the shortest PG2
TATA BOX fragments and the lower PG2 level. Since highest PG2 level was
related to the GC condition, our data suggest that carriers having longer TATA
BOX region may produce higher sPG2 level than patients with shorter region.
The clinical significance of the differences in PG2 level associated with the TATA
BOX fragments, by interfering with the transcriptional factor and then with the
expression of the corresponding gene, are under investigation. This study will be
important to deeper understand the physiopathological PG2 role in GC.
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Introduction: Previous studies suggested a link between Helicobacter pylori (H.
pylori) infection and nonalcoholic fatty liver disease (NAFLD), yet large-scale
longitudinal studies are lacking to elucidate this association.
Aims & Methods: A cohort study of 17,028 adults without NAFLD at baseline,
who participated in a repeated health screening examination including an
H. pylori-specific immunoglobulin G antibody test, was conducted to evaluate
the association between H. pylori and NAFLD development. Fatty liver was
diagnosed by ultrasonography.
Results: During the 83,130 person-years follow-up, participants with H. pylori
infection had a higher rate of incident NAFLD than those who were uninfected.
In a multivariable model adjusted for age, sex, body mass index, smoking status,
alcohol intake, regular exercise, year of screening exam, and education level, the
hazard ratio (HR) for NAFLD development in participants with H. pylori-infec-
tion compared to those without infection was 1.21 (95% confidence interval [CI],
1.10–1.34). The association persisted after further adjustment for metabolic vari-
ables, inflammatory marker, and liver enzymes. The association between H.
pyloriand NAFLD was still evident in an analysis using fatty liver index as a
surrogate marker of NAFLD. In addition, the association between H. pylori
infection and incident NAFLD did not differ across clinically relevant subgroups
evaluated.
Table 1: Development of nonalcoholic fatty liver disease (NAFLD) by H. pylori
status
Person-
years
Number of
Incident
cases
Incidence
density
(per 1, 000
person-years)
Age- and
sex-
adjusted HR
(95% CI)
Multivariable-
adjusted
HRa (95% CI)
H. pylori (–) 34,960.7 1301 37.2 1.00 (reference) 1.00 (reference)
H. pylori (þ) 48,169.3 2080 43.2 1.14 (1.06–1.22) 1.21 (1.10–1.34)
aEstimated from Cox proportional hazard models adjusted for age, sex, body
mass index, year of screening exam, smoking status, alcohol intake, regular
exercise, and education level. H. pylori, helicobacter pylori; HR, hazards ratio;
CI, confidence intervals.
Conclusion: H. pylori infection was significantly associated with the development
of NAFLD, independent of metabolic and inflammatory risk factors. H. pylori
infection may play a pathophysiologic role in NAFLD development, indicating
that H. pylori eradication might play a role in reducing risk of NAFLD.
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Introduction: Helicobacter pylori infects the gastric mucosa and causes chronic
gastritis via the immunoreaction of the host. By contrast, the human immuno-
deficiency virus (HIV) infects CD4-positive T lymphocytes and destroys the
immune system of the host. Some studies pointed out that the H. pylori infection
rate is lower in HIV-positive patients. This is because in these patients, H. pylori
is incidentally eradicated by the course of antibiotic therapy for HIV infection
and because the supply of nutrients to H. pylori is prevented by the decrease in
the number of CD4 lymphocytes.
Aims & Methods: We enrolled 290 HIV-positive patients who underwent esopha-
gogastroduodenoscopy in our Hospital between January 2013 and September
2016. As end points of H. pylori infection examination, we retrospectively exam-
ined for the presence of gastric mucosa atrophy, H. pylori infection, H. pylori
eradication and comorbidity. As end points of HIV infection examination, we
quantified the number of CD4 lymphocytes and the titer of HIV and investigated
the presence of acquired immunodeficiency syndrome (AIDS). Based on these
data, we examined the relationship between H. pylori and HIV infections.
Results: Of the 290 patients, 281 were men and 9 were women, whose median age
was 46 years (range, 22–82 years). Ninety patients had atrophic gastritis or
stomach or duodenal ulcer, of whom 40 underwent examination for H. pylori
infection. The median number of CD4 lymphocytes in the 21 H. pylori-positive
cases was 505/mL (range, 108–952/mL). The titer of HIV ranged from non-detec-
tion to 90, 900 copies/mL, and one patient had AIDS. Meanwhile, the median
number of CD4 lymphocytes in the 19 H. pylori-negative cases was 331/mL
(range, 15–998/mL), the titer of HIV ranged from non-detection to 1, 590, 000
copies/mL, and three patients had AIDS. H. pylori eradication therapy was
applied in 18 of 21 H. pylori-positive cases. The success rate of primary
H. pylori eradication was 37.5% (6/16 patients) and that of secondary eradication
was 70% (7/10 patients). In addition, 2 (7.7%) of the 26 patients with stomach or
duodenal ulcer needed urgent hemostasis. Five (6.7%) of the 74 cases of atrophic
gastritis had gastric cancer, of which two were undifferentiated stomach cancers.
Conclusion: In our study, the number of CD4 lymphocytes was higher in the
HIV-positive patients with H. pylori infection, implying that the high CD4
count was suggested to be associated with persistent H. pylori infection. In addi-
tion, the success rate of H. pylori eradication was shown to be insufficient in
HIV-positive patients.
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Introduction: In Western European and Northern American populations a
decreasing prevalence of H. pylori infection has been observed, along with an
increasing prevalence of Barrett’s oesophagus and an increasing incidence and
prevalence of the adenocarcinoma of the oesophagus and gastro-oesophageal
junction. In previous meta-analyses, H pylori infection has been proven a pro-
tective factor against Barrett’s oesophagus, but some individual studies suggested
the opposite.
Aims & Methods: Our aim was to scrutinise all data available on the relationship
between H pylori infection and Barrett’s oesophagus prevalence, to see, if H
pylori has a protective role for Barrett’s oesophagus and if it is dependent
from the geographical location. A meta-analysis was performed using the pre-
ferred reporting items for systematic review and meta-analysis protocols
(PRISMA-P). We conducted a systematic search in PUBMED, EMBASE and
COCHRANE databases from inception to December 2016, for the keywords of
Barrett’s, Barrett’s metaplasia, Barrett metaplasia, Barrett’s oesophagus,
Barrett’s oesophagus, Barrett oesophagus, Barrett oesophagus, Helicobacter
pylori, H pylori, H. pylori and Helicobacter. We also used information from
the references of relevant publications to find further eligible studies. We have
conducted a meta-analysis of the data from all studies included. We used the
random effect modell by DerSimonian and Laird.
Results: We have found 568 articles in PUBMED, 741 in EMBASE and 15 in
COCHRANE databases. After exclusion of the articles without sufficient data
on the prevalence of H pylori and Barrett’s oeosphagus, we have identified 83
articles with detailed data, suitable for statistical analysis. This meta-analysis
involved 98 665 patients with Barrett’s oesophagus and 720 800 patients without
Barrett’s oesophagus. The statistical analysis from all 83 studies from five con-
tinents and 27 countries showed a protective effect of H pylori for Barrett’s
oesophagus on four continents, but not in Africa, overall Odds Ratio¼ 0.63
(95% CI:0.55, 0.71). The OR and 95% CI values were 0.34 (0.17, 0.67) for
Asia, 0.71 (0.55, 0.91) for Europe, 3.05 (0.59, 15.73) for Africa, 0.60 (0.51,
0.71) for North-America, 0.95 (0.56, 1.64) for South- America and 0.56 (0.39,
0.80) for Australia. The OR and 95% CI values were 0.84 (0.43, 1.64) for Eastern
Europe; 0.68 (0.52, 0.90) for Western Europe and 0.71 (0.55, 0.91) for all of
Europe, suggesting that the protective role of H pylori infection is not different
across Europe.
Conclusion: This large meta-analysis has given further evidence, thatHelicobacter
pylori infection has a protective role for Barrett’s oesophagus and this protective
role is independent from the geographical location, apart from Africa. In view of
the decreasing prevalence of H pylori in developed countries and the epidemio-
logical rise of Barrett’s oesophagus and adenocarcinoma, it would be important
to conduct further large, prospective, multinational studies on the effect of
H. pylori infection on Barrett’s oesophagus.
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Introduction: Helicobacter Pylori (H. Pylori) has been implicated in worsening
outcomes in patients with hepatic encephalopathy. This is believed to be the
result of its urease enzyme that increases the production of ammonia. Small
studies so far have yielded contradictory results on whether the presence of H.
pylori worsens treatment outcomes in hepatic encephalopathy. Therefore, the aim
of this study was to assess the impact of H. pylori on mortality, morbidity and
resource utilization among patients with hepatic encephalopathy using a national
database.
Aims & Methods: This was a case-control study using the National Inpatient
Sample 2013, the largest publically available inpatient database in the United
States. All patients with an ICD-9 CM code for a principal diagnosis of hepatic
encephalopathy were included. There were no exclusion criteria. Patients positive
for H. pylori were identified using the appropriate ICD-9CM codes. The primary
outcome was all cause mortality. The secondary outcome was resource utilization
as measure by use of abdominal imaging (CT scan and ultrasound of the abdo-
men), length of hospital stay (LOS), total hospitalization charges and costs.
Multivariate regression analyses were used to adjust for the following confoun-
ders: Age, sex, race, income in patients’ zip code, Charlson Comorbidity Index,
hospital region, location, size and teaching status.
Results: A total of 55,360 patients with hepatic encephalopathy were included in
the study, of which 20 had H. pylori infection. The mean patient age was 60 years
and 42% were female. After adjusting for confounders using multivariate analy-
sis, patients with and without H. pylori had similar adjusted odds of mortality
(adjusted Odds Ratio (aOR): 1.71, 95% CI: 0.62–4.74, p¼ 0.30). As far as
resource utilization, patients with and without H. pylori had similar adjusted
odds of abdominal imaging (aOR: 3.02, 95% CI: 0.88–10.40, p¼ 0.08), LOS
(adjusted mean difference: 1.7 days, 95% CI: 0.02–3.42, p¼ 0.52), and total
hospitalization charges (adjusted mean difference: $16588, 95% CI: -$4499 -
$37675, p¼ 0.12). However, patients with H. pylori had higher adjusted total
hospitalization costs compared with patients without H. pylori (adjusted mean
difference: $6128, 95% CI: $1141 - $11115, p¼ 0.01
Conclusion: Presence of Helicobacter Pylori has no impact on inpatient mortality
among patients with liver cirrhosis and hepatic encephalopathy. In addition, the
presence of Helicobacter Pylori is not associated with any increase in resource
utilization among this patient population, with the exception of total hospitaliza-
tion costs. It is surprising to note that, although total hospitalization costs dif-
fered between the two groups, they received the same total hospitalization
charges from admitting hospitals.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0594 ERADICATION THERAPY FOR HELICOBACTER PYLORI –
AN IMPORTANT TOOL TO IMPROVE THE HEART FUNCTION IN
PATIENTS WITH CORONARY HEART DISEASE
A. Suceveanu1, A. P. Suceveanu2, I. R. Parepa3, F. F. Voinea4, D. Catrinoiu5,
L. Mazilu6
1Gastroenterology, Ovidius University, Constanta/Romania
2Gastroenterology, Ovidius University, c/Romania
3Cardiology, Ovidius University, Constanta/Romania
4Gastroenterology, Ovidius University, constanta/Romania
5Internal Medicine, Ovidius University, constanta/Romania
6Internal Medicine, Ovidius University, Constanta/Romania
Contact E-mail Address: andrasuceveanu@yahoo.com
Introduction: Literature data involves Helicobacter Pylori (HP) as a pro-inflam-
matory and pro-coagulant risk factor for ischemic coronary heart disease1, 2, but
the benefit of the curative treatment against HP infection and its repercussions on
heart function were not explored sufficiently.
Aims & Methods: We aimed to investigate the role of HP eradication therapy in
patients with different stages of heart insufficiency (HI) and coronary heart
disease (CHD). 290 patients with CHD admitted in Cardiology and
Gastroenterology Departments of St. Andrew Apostle Constanta were explored
for HP infection status and found positive. The infection was determined by HP-
Ag in faces, urea breath test or endoscopic biopsy. The CHD was assessed by
electrocardiography (ECG) and HI was staged according to NYHA classifica-
tion. According to the implementation of eradication therapy for HP, we divided
the patients in two equal groups, matched by age, gender and severity of HI: one
group of 145 patients with treatment and the other group of 145 patients without
eradication therapy. We compared the heart function improvement after treat-
ment for HP in both groups. We also compared the evolution of PCR, fibrino-
gen, IL-6 and other inflammatory cytokine.
Results: The eradication therapy for HP with one PPI and two antibiotics asso-
ciated with cardiac treatment, improved the clinical status based on NYHA
criteria in 118 patients with at least 1 stage decrease in NYHA staging compared
with only 52 patients from the group with cardiac treatment but without eradica-
tion therapy (p¼ 0.03). The laboratory finding also revealed a favorable course
of pro-inflammatory tests in treated patients compared with untreated patients,
regarding protein C-reactive, leucocytes, Il-6 and fibrinogen (p¼ 0.019,
p¼ 0.037, p¼ 0.08, respectively p¼ 0.005, ss).
Conclusion: HP should be one of the treatment targets when managing infected
patients with CHD, the eradication therapy being along with cardiac treatment
important steps to improve the cardiac function.
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Introduction:Helicobacter pylori infection has become more and more resistant to
conventional first-line treatment regimens. So, there is a considerable interest in
evaluating new antibiotic combinations and regimens. Nitazoxanide is an anti-
infective drug with demonstrated activity against protozoa and anaerobic bac-
teria including Helicobacter pylori.
Aims & Methods: This work is designed to evaluate the efficacy and safety of a
unique triple Nitazoxanide containing regimen as a treatment regimen in
Egyptian patients with Helicobacter pylori infection.
Methods: Two hundred and twenty four patients with upper Gastro-intestinal
tract (GIT) dyspeptic symptoms in whom Helicobacter pylori induced GIT dis-
ease was confirmed were included in the study. They have been randomized to
receive either Nitazoxanide 500mg bid, Clarithromycin 500mg bid and
Omeprazole 40mg twice daily for 14 days or Metronidazole 500mg bid,
Clarithromycin 500mg bid and Omeprazole 40mg twice daily for 14 days.
Laboratory evaluation for Helicobacter pylori antigen within the stool was
done 6 weeks after cessation of Helicobacter pylori treatment regimens to
assess the response.
Results: The response to treatment was significantly higher in group 1 of
Nitazoxanide treatment regimen than group 2 of traditional treatment regimen.
One hundred and six cases (94.6%) of 112 patients who completed the study in
group 1 showed complete cure while only 63 cases (60.6%) of 104 patients who
completed the study in group 2 showed the same response according to per-
protocol (PP) analysis (p5 0.001). The regimen was well tolerated by all the
patients enrolled in the study.
Conclusion: Nitazoxanide-containing triple therapy is a promising therapy for the
first-line eradication of Helicobacter pylori. (ClinicalTrials.gov Identifier:
NCT02422706)
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Introduction: There is some evidence that prior use of macrolides is a useful
predictor of the likelihood of standard triple therapy failure in H. pylori eradica-
tion (Lim SG, et al. Dig Liver Dis 2016). The goal of this study is to evaluate
whether previous intake of various macrolide antibiotics can predict failure to
eradicate H. pylori using first-line clarithromycin-containing regimens.
Aims & Methods: Between February 2014 and June 2016 a total of 250 patients
with H. pylori infection were prospectively included in a study whose goal was to
assess the eradication rates obtained with first-line clarithromycin-containing
regimens in our health area. Patients were randomly assigned to one of two
regimens: A/Triple therapy (PPI, amoxicillin, clarithromycin, optimized with a
double dose of PPI) for 10 days; and B/Concomitant therapy (PPI, amoxicillin,
clarithromycin, and metronidazole administered concurrently) for 10 days. The
eradication was evaluated by the Stool antigen test or with the Urease test in
those patients with a gastroscopy performed after the treatment. A total of 113
patients in the group A (58 women; Median age: 54 years; Range: 21–79) and 106
patients in the group B (56 women; Median age: 49 years; Range: 18–81) com-
pleted the study protocol. The electronic medical records of the patients, which
contain information regarding all the medication prescribed to the patient during
the previous 12 years, were reviewed and the intake of macrolides (clarithromy-
cine, azithromycine and erythromycine) was registered.
Results: 89/219 patients (40, 6%) had received at least one treatment with macro-
lides during the previous 12 years. H. pylori eradication rates with the two
treatment regimens are shown in Table 1.
Table 1: H. pylori eradication rates in patients with and without previous intake
of macrolides.
Previous use
of Macrolides
No previous use
of Macrolides p
A: Triple therapy (n¼ 113) 24/45 (53, 3%) 65/68 (95, 5%) 50, 0001
B: Concomitant (n¼ 106) 37/44 (84, 1%) 61/62 (98, 4%) 0, 0085
Total (n¼ 219) 61/89 (68, 5%) 126/130 (96, 9%) 50, 0001
Conclusion: Previous use of macrolide antibiotics predicts a low response to triple
and to concomitant clarithromycin-containing regimens. In addition, our study
shows that in patients without previous use of macrolides triple therapy achieves
per-protocol eradication rates over 90%.
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Introduction: Due to increasing prevalences of clarithromycin resistance in H
pylori infection, current guidelines recommend quadruple therapies as first-line
therapy1, 2. Bismuth quadruple therapy (BQT) has been proven superior to stan-
dard triple therapy in clinical trials3, however little is known about the efficacy of
BQT in clinical routine practice.
Aims & Methods: In a prospective single center cohort study we analyzed con-
secutive patients in whom three-in-one capsule BQT (Pyleraþomeprazole) has
been prescribed between 1/2013 and 12/2016. All patients were instructed in a
standardized fashion and a prospective follow-up was planned. In a subgroup of
patients, genotypic susceptibility testing for clarithromycin and levofloxacin by
PCR was carried out on gastric biospies before treatment. Treatment outcome
was assessed by 13C urea breath test or by histology not earlier than 4 weeks
after end of treatment.
Results: Three-in-one capsule BQT has been prescribed in 322 patients (mean age
41 years (18–80), 65% female, 26% active smoker). 71% of patients had a migra-
tional background including Southern-/Eastern Europe, Eurasia/Central Asia,
Southeast-Asia, Africa, and Central/South America. PCR results were available
in 163 patients (50.6%) and identified resistance to clarithromycin and levoflox-
acin in 29 (17, 8%) and 20 (12, 3%) of cases, respectively. BQT was administered
as firstline, secondline and rescue treatment in 74%, 17% and 9% of cases,
respectively. 5 patients discontinued treatment prematurely due to side effects
(1, 8%) and 43 patients were lost to follow-up (13, 4%). By modified intention-
to-treat and per-protocol analysis the H. pylori eradication rates were 94, 9%
(95% CI: 92.1–97.5%) and 96.7% (95% CI: 94.4–98.8%), respectively. The low
number of treatment failures (n¼ 9) did not allow to identify risk factors for
failure.
Conclusion: Three-in-one capsule bismuth quadruple therapy is highly effective
and safe for treatment of H. pylori infection in clinical routine practice, irrespec-
tive of the patient’s migrational background or the number of previous treatment
failures.
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Introduction: Background: Eradication ofHelicobacter pylori (H. pylori) infection
represents a clinical challenge. The current requirements demand eradication
rates above the 90%, which has made that the use of triple treatment including
clarithromycin or metronidazole had been gave up on those countries, such as
Spain, with high resistance rates. Quadruple therapy with a proton pump inhi-
bitor (PPI) plus a single three-in-one capsule containing bismuth subcitrate
potassium, metronidazole, and tetracycline (BMT) have shown high eradication
rates in clinical trials.
Aims & Methods: We aimed to evaluate the efficacy and safety of a PPI-bismuth
based quadruple therapy in patients diagnosed of H pylori infection in a clinical
setting of a Private Hospital, located at the North of Madrid (Spain). A pro-
spective and real-life study was conducted, between March 2016 to February
2017, on consecutive patients with confirmed H pylori infection eradication indi-
cation. Patients were treated for ten days with a galenic preparation containing
bismuth subcitrate potassium 140mg, metronidazole 125mg, and tetracycline
125mg, three capsules four times daily, and esomeprazole 40mg twice daily
and probiotic during 30 days. The primary endpoint was H. pylori eradication
rate, defined as one negative urea breath test performed, at least 28 days, after the
end of treatment. Intent-to-treat (ITT) efficacy analyses included all patients who
received study medication and took at least one dose of study medication;
patients without an observed outcome were considered as treatment failures.
Per protocol (PP) analyses, which excluded patients who did not complete the
study or who had major protocol violations, were also conducted to confirm the
ITT results.
Results: A total of 100 patients, 60 (60.0%) women and 40(40.0%) men, who
fulfilled the respective demands of the inclusion and exclusion criteria, were
enrolled consecutively. Five of these were lost to follow-up. Mean (standard
deviation) [95% confidence interval] age was 47.1 (15.4) [44.0 to 50.2] years.
Twenty-five (25.0%) patients had a prior history of using medications to treat
H. pylorimost often clarithromycin, amoxicillin, and PPI. In the ITT population,
the eradication rates were the 90.7 % (68/75) and the 80.0% (20/25) depending
on whether the PPI-BMT treatment was administered as first-line or as rescue
therapy, respectively. In the PP population, the eradication rates were the 98.6%
(68/69) and the 95.2% (20/21) in those patients treated with PPI-BMT as first-
line or as rescue therapy, respectively. Eighteen (18.0%) patients reported at least
one adverse event.
Conclusion: In patients with confirmed H pylori infection, 10 days of treatment
with a quadruple regimen of bismuth, metronidazole and tetracycline plus esome-
prazole provides high eradication rates not only as first-line but also as rescue
therapy, with an acceptable safety profile.
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Introduction: Most Helicobacter pylori (Hp) infections are asymptomatic but
15% of those infected with Hp will eventually experience dyspepsia symptoms
or peptic ulcer.
Aims & Methods: We aimed to evaluate the cost effectiveness of population
screening and eradication for Helicobacter pylori (Hp). This was a cost effective-
ness analysis and cost utility analysis alongside randomized controlled trial with
13-years follow-up, with a random sample of the general population from the
county of Funen, Denmark. 20,011 individuals aged 4065 were randomized and
invited in 199899; 12,530 were enrolled and of these 8658 individuals have been
successfully followed up at 1, 5, and 13 years after intervention. Questionnaires
included Gastrointestinal Symptom Rating Scale and the quality of life instru-
ment SF-36. From SF-36 responses an SF-6D score was derived and used for
calculation of quality adjusted life years (QALY). EQ-5D-5L was incorporated in
the last follow-up. The intervention was an invitation to Hp screening by in-office
blood test; positive tests were validated by 13C-Urea Breath test. Those with a
positive 13C-Urea Breath test received eradication therapy. The Hp prevalence
was 17.5%. Main outcome measure was incremental cost per quality adjusted life
year (QALY) and Life-years gained. The evaluation has a National Health Sector
perspective.
Results: There was no significant difference in index scores and in mean QALY
between groups. Hp population screening and eradication with 13-years follow-
up was not effective in regards to quality of life and the cost of screening was
higher than not screening (14,327DKK (95%CI: 415524,499)). The probability
of being cost-effective was 80% with a willingness to pay of 400,000 DKK per
life-year gained. When including only peptic ulcer disease related costs the prob-
ability was 85% a willingness to pay of 100,000DKK per life-year gained.
Conclusion: Hp population screening and eradication with 13-years follow-up
was not effective in regards to quality of life and the cost of screening was
higher than not screening.
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P0600 A SEVEN-DAY TRIPLE THERAPY CONTAINING A
POTASSIUM-COMPETITIVE ACID BLOCKER COMPARED WITH
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Introduction: This study was evaluated the effectiveness and safety of
Vonoprazan, a potassium-competitive acid blocker (P-CAB) compared with
proton pump inhibitors (PPIs) for a first-line Helicobacter Pylori (H. pylori)
eradication.
Aims & Methods: We retrospectively analyzed data from first-line H. pylori
eradication treatment (vonoprazan or PPIs with 400mg clarithromycin and
750mg amoxicillin twice daily for 7-day) (n¼ 1393) between April 2008 and
February 2017 at Sadamoto GI clinic, Japan. Patients who received 7-day P-
CAB therapy (vonoprazan 20mg twice daily; n¼ 498) were compared with those
who received 7-day PPI therapy (lansoprazole 30mg;n¼ 216, rabeprazole
10mg;n¼ 331, esomeprazole 20mg; n¼ 348 twice daily). Eradication rates were
calculated by intention-to-treat (ITT) and by per-protocol (PP). Compliance and
adverse events were also assessed for each study group.
Results: ITT and PP analysis of the first-lineH. pylori eradication for vonoprazan,
lansoprazole, rabeprazole, and esomeprazole were 75.5%/86.8%, 63.9%/76.2%,
68.0%/79.5%, and 63.2/70.8%, respectively. The vonoprazan eradication rates
were significantly higher than those of these PPIs (P5 0.05), respectively. There
was no significant difference in the adverse events between the two therapies.
Conclusion: 7-day P-CAB based triple therapy is more effective than 7-day PPI
based triple therapy as a first-line H. pylori eradication without differences in
tolerability.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Vonoprazan (VPZ) is a novel, orally bioavailable, potassium-com-
petitive acid blocker for the treatment and prevention of acid-related gastroin-
testinal diseases. A phase III study revealed that VPZ is superior to lansoprazole
as part of first-line therapy for Helicobacter pylori (HP) infection when combined
with 400 or 800mg/day clarithromycin (CAM).
Aims & Methods: The aim of the current study was to evaluate the efficacy and
safety of VPZ, CAM (400mg/day), and amoxicillin (ABPC; 1500mg/day) triple
therapy in post-marketing use in Japan. A randomized, open-label, single-center
study was conducted to verify the superiority of VPZ to esomeprazole (EPZ) as
part of first-line triple therapy in patients with HP infection. Three hundred and
forty-nine Japanese patients with HP infection diagnosed using a rapid urease
test were enrolled between June 2015 and October 2016. The patients were ran-
domly allocated to VPZ group (VPZ 40mg/day, ABPC 1500mg/day, CAM
400mg/day) or EPZ group (EPZ 40mg/day, ABPC 1500mg/day, CAM
400mg/day) with stratification according to endoscopic findings of gastric/duo-
denal ulcer/scar and CAM resistance determined via a microbial sensitivity test.
The eradication rates were evaluated using the urea breath test 8 to 12 weeks after
cessation of therapy.
Results: Three hundred and forty-five patients (177 men, 168 women; mean age
64.7 years [range 27–89 years]; VPZ group, 169; EPZ group, 176) completed the
study. One patient in the VPZ group and three patients in the EPZ group dis-
continued the treatment because of adverse events. One patient in the VPZ group
and three patients in the EPZ group were lost to follow-up. There was no sig-
nificant difference in the overall first-line eradication rate between the two groups
(81.7% [138/169] in the VPZ group vs. 74.4% [131/176] in the EPZ group
[P¼ 0.10]). Furthermore, there was no significant difference in the first-line era-
dication rate in patients with CAM-sensitive HP (87.2% [82/94] versus 84.6%
[77/91] in the VPZ and EPZ groups, respectively, [P¼ 0.60]), although the era-
dication rate was significantly higher among patients with CAM-resistant HP in
the VPZ group than that in the EPZ group (73.6% [39/53] vs. 55.6% [35/63],
[P¼ 0.044]). The first-line eradication rate in the patient with high estimated
glomerular filtration rate (eGFR; 100ml/min/1.73m2) was significantly lower
than that in the patients with low eGFR (560ml/min/1.73m2; 86.4% [32/37] in
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the patients with low eGFR, 65.3% [34/53] in the patients with high eGFR [P ¼
0.034]), and it was significantly higher in the VPZ group than that in the EPZ
group (79.3% [23/29] versus 50% [11/13], respectively, [P¼ 0.025]). The first-line
eradication rate in continuous smokers was significantly lower than that in non-
smokers (81.0% [187/231] in non-smokers vs. 64.3% [27/42] in continuous smo-
kers [P¼ 0.016]). However, there were no significant differences between the VPZ
and EPZ groups in non-smokers (84.2% [96/114] versus 77.8% [91/117], respec-
tively, [P¼ 0.21]) and in continuous smokers (84.2% [12/16] versus 57.7% [15/
26], respectively, [P¼ 0.33]). Furthermore, the first-line eradication rates in both
groups were not influenced by age, sex, body mass index, drinking habit, and the
endoscopic findings of gastric/duodenal ulcers/scars. There were no significant
differences with regard to adverse effects between the two groups.
Conclusion: In contrast to the previous reports, the first-line eradication rate of
VPZ-based triple therapy with 400mg/day CAM and 1500mg/day ABPC was
similar to that of EPZ-based triple therapy in all groups except in patients with
CAM-resistant HP and high eGFR. It is necessary to determine the most appro-
priate conditions that will maximize the therapeutic effect of VPZ-based triple
therapy.
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Introduction: The impact of amoxicillin resistance on the efficacy of regimens
containing amoxicillin for Helicobacter pylori (H. pylori) eradication remains
inconclusive. Therefore, we aimed to investigate whether the efficacy of amox-
icillin containing regimen is affected by amoxicillin resistance and to identify the
optimal breakpoint of amoxicillin resistance.
Aims & Methods: This was a post-hoc analysis of five randomized trials con-
ducted in Taiwan from 2007 to 2016. Patients who received amoxicillin-contain-
ing regimens were recruited. The minimum inhibitory concentrations (MICs)
were determined by agar dilution test. Meta-analysis was performed to assess
the risk ratio of eradication failure in amoxicillin resistant strains compared to
susceptible strains of seven different regimens. We further performed pooled
analysis and logistic regression in patients treated with clarithromycin triple
therapy to identify the optimal breakpoint of amoxicillin resistance.
Results: A total of 2339 patients with available data of amoxicillin MICs were
enrolled. Meta-analysis showed that the presence of amoxicillin resistance was
consistently associated with increased risk of treatment failure of amoxicillin-
containing regimens at different breakpoints (RR [Risk ratio]: 1.41, 95% CI
[confidence interval]: 1.12–1.78, P¼ 0.004 when cut at 0.5mg/ml). The hetero-
geneity was low (I2¼ 0%, p¼ 0.615). Pooled analysis also showed that amox-
icillin resistance was an independent risk factor of treatment failure of
clarithromycin triple therapy at different breakpoints. The best correlation was
observed when the breakpoint of amoxicillin resistance was 30.125mg/ml (Kappa
coefficient 0.298), at which the resistance rate was 11.1% (110/990).
Conclusion: The efficacies of amoxicillin containing regimens are affected by
amoxicillin resistance and the optimal breakpoint of MIC is 30.125mg/ml.
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Introduction: Previous genome-wide association studies showed that genetic poly-
morphisms in toll-like receptor (TLR) 1 and protein kinase AMP-activated alpha
1 catalytic subunit (PRKAA1) were associated with gastric cancer (GC) or
increased Helicobacter pylori (H. pylori) infection susceptibility.
Aims & Methods: The aim of this study was to evaluate associations between
TLR1 and PRKAA1 genes polymorphisms and H. pylori infection, atrophic
gastritis (AG) or GC in European population. Single-nucleotide polymorphisms
(SNPs) were analyzed in 1178 subjects (511 controls, 340 AG patients and 327
GC patients) from 3 gastroenterology centers in Germany, Lithuania and Latvia.
Patients with AG and controls were from the out-patient departments, who
underwent upper endoscopy because of dyspeptic symptoms and had no history
of malignancy. GC patients had histopathological verification of gastric adeno-
carcinoma and were recruited from out-patient and stationary departments.
Genomic DNA was extracted from peripheral blood mononuclear cells. TLR1
C4T (rs4833095) and PRKAA1 C4T (rs13361707) were genotyped by the
real-time polymerase chain reaction. H. pylori status was determined by testing
for anti-H. pylori IgG antibodies in sera. Associations between SNPs and pre-
sence of H. pylori infection were evaluated using logistic regression analysis. The
same analysis with adjustment for sex, age andH. pylori infection status was used
for evaluation of associations between gene polymorphisms and AG or GC. The
Bonferroni-corrected alpha level was set at 0.025 (0.05/2 SNPs).
Results:We observed similar distribution of TLR1 and PRKAA1 genotypes in H.
pylori positive and negative cases. Moreover, no significant differences in the
frequencies of all polymorphisms between AG patients and controls were
found. TC genotype of TLR1 gene was more prevalent in GC patients compared
to control group (22.3% and 29.7% respectively, P¼ 0.018). Logistic regression
analysis revealed that polymorphism in TLR1 gene was associated with increased
risk of GC. Carriers of TC genotype had higher odds of GC when compared to
TT genotype (OR – 1.89, 95% PI 1.26–2.83, P¼ 0.002). Similar association was
observed in a dominant model for TLR1 gene, where comparison of CCþTC vs
TT genotypes showed an increased risk of GC (OR – 1.86, 95% PI 1.26–2.75,
P¼ 0.002). No association between genetic polymorphism in PRKAA1 gene and
GC was observed.
Conclusion: TLR1 rs4833095 SNP is associated with increased risk of GC in
population of European descent, while polymorphism in PRKAA1 gene is not
linked with the presence of GC. Both genetic polymorphisms showed no associa-
tions with H. pylori infection susceptibility and risk of AG.
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Introduction: Gastric adenocarcinoma of the fundic gland type (GAFG) is gastric
adenocarcinoma with low-grade atypia occurring in the mucosa of the fundic
gland without atrophy, and is recognized that it is not related to H.pylori (Hp)
infection. However, GAFG is also found in Hp-infected and past Hp-infected
patients, as well as in Hp-uninfected patients. It can not deny the relationship
between the progress of GAFG and Hp infection.
Aims & Methods: Ten lesions of GAFG resected endoscopically or surgically in
our hospital from December 2010 to October 2016 were classified as Hp-unin-
fected (n¼ 3)/past Hp-infected (n¼ 5)/Hp-infected (n¼ 2), and each endoscopic
and clinicopathological features were examined.
Results: Median age of Hp-infected/past Hp-infected/Hp-uninfected were 65/71/
54.5 years old, respectively, male ratio were 100/80/0%, occupied site U area
were 33/80/50%. There was no difference between the 3 groups in these para-
meters. However, a significant difference in the rate of submucosal invasion is
recognized between the Hp-uninfected and past Hp-infected group and the Hp-
uninfected group (submucosal invasion was found at 0/80/100%, p¼ 0.035).
According to endoscopic features, background mucosa of gastric fundus gland
mucosa without atrophic change was found in 100/100/100%, whitish color in
67/60/50%, submucosal tumor shape in 67/60/0%, dilated vessels with branching
architecture in 100/100/50%. The association with Hp infection was not clear. In
immunohistochemical staining, MUC6 positive, Pepsinogen-I positive, MUC2
negative, CD 10 negative in all cases, whereas the rate of MUC5AC positive
was significantly higher in the Hp-infected group as 0/20/100% (P¼ 0.045). We
reported that black pigmentation is recognized in GAFG (stomach and intestine
50: 1521–1531, 2015), but no association between Hp infection and black pig-
mentation was observed. On the other hand, the rate of PPI administration
divided pigmentation (n¼ 6)/no pigmentation (n¼ 4) are 50/0%, and it is sug-
gested that the pigmentation in GAFG may relate with PPI (p¼ 0.091).
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Conclusion: Hp infection is suggested to be related to the invasion depth of
GAFG and the MUC5AC prevalence, which is also an important profile in
GAFG cases. Pigmentation in GAFG is found frequently, but it may be related
to taking PPI.
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P0605 MUCIN EXPRESSION IN THE SMALL BOWEL OF CELIAC
DISEASE – A SYSTEMATIC REVIEW AND META-ANALYSIS
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Introduction: Mucins, heavily glycosylated glycoproteins, synthesized by mucosal
surfaces and have an important role in healthy and malignant states. Changes in
mucin synthesis, expression and secretion may be a primary event or may be
secondary to inflammation and carcinogenesis.
Aims & Methods: Since untreated celiac disease (CD) is associated with intestinal
malignancy, we aimed to assess the current knowledge about mucin expression in
the small bowel of CD patients, and to look for a possible association between
mucin profile and gluten-free diet. English Medical literature searches were con-
ducted for ‘‘mucin’’ and ‘‘celiac’’. Observational studies were included. Meta-
analysis was performed by using Comprehensive meta-anaslysis software. Pooled
odds ratios and 95% confidence intervals were calculated.
Results: Out of 18 titles initially generated by the literature searches, 3 observa-
tional studies that fulfilled the inclusion criteria remained eligible for meta-ana-
lysis. They included 58 patients and 68 controls from 3 countries (Finland, Japan,
USA). Mucin expression was significantly increased in small bowel mucosa of
CD patients than in normal small bowel mucosa [OR 10.789, 95%CI
(1.062–109.634), p¼ 0.044] (random-effect model). Heterogeneity was significant:
Q¼ 9.470, df (Q)¼ 3, P¼ 0.024, I2¼ 68.323%. ORs for MUC2 and MUC5AC
expression in the small bowel mucosa of untreated CD patients were 1.143,
95%CI 0.060–21.870, P¼ 0.929 and 21.429, 95%CI 3.883–118.255, P5 0.0001,
respectively.
Conclusion: We found that expression of certain mucin genes in the small bowel
mucosa of CD patients may serve as a diagnostic tool, and assist in surveillance
programs.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0606 HEPATIC ABNORMALITIES ASSOCIATED WITH CELIAC
DISEASE
D. Tagzout1, A. Tebaibia2, N. Oumnia3, N. Benfenatki3
1Medicine, University Hospital Center, Tizi Ouzou/Algeria
2Medicine, University Hospital Center, Algiers/Algeria
3Medicine, Hospital University center, Algiers/Algeria
Contact E-mail Address: tagzout.d@gmail.com
Introduction: Celiac disease (CD) is a gluten-sensitive enteropathy that resolves
with gluten-free diet (GFD). It’s now considered as multisystem disorder. A
number of studies have shown the occurrence of liver diseases at a higher fre-
quency in patients with CD compared with that in the general population.
Cryptogenetic hypertransaminasemia is observed in about half of celiac patients
not following GFD with reversibility in the majority of cases after 6 to 12 months
of GFD (1). Other liver abnormalities such as autoimmune hepatitis, cholestatic
liver diseases, cirrhosis can be observed.
Aims & Methods: The aims of our study are to report the prevalence of liver
diseases during CD and to describe the characteristics, etiologies and response to
GFD of these liver disorders. Prospective multicentric study including 154 celiac
patients (42 H; 112 F); middle age: 36, 1 ans 13, 6, recruited over a period of 18
months from 01-01-2013 to 30-06-2014 and followed at least over a period of 12
months. Hepatic abnormalities were investigated with an etiologic assessment.
The evolution of liver disorers after GFD was assessed.
Results: The prevalence of hepatic disorders in celiac patients is estimated at
18.1% (n¼ 28). A cryptogenetic hypertransaminase is found in 12.3% of cases
(n¼ 19). This diagnosis was retained after a negative etiological assessment of
hepatic cytolysis in patients at a diagnosis of CD. Severe hepatic pathologies are
associated with CD in 5.8% (n¼ 9) of cases, and in almost all cases in the hepatic
cirrhosis stage. Cirrhosis is cryptogenetic in 55.5% (5/9) of cases and secondary
to an autoimmune origin in 44.5% (4/9). Chronic hepatopathy revealed CD in
1.9% of the celiac population (3/154), two cases of autoimmune cirrhosis, one
associated with pituitary insufficiency, and one case of cryptogenetic cirrhosis.
The diagnosis of cirrhosis preceded the diagnosis of CD in 55.6% (5/9) of cases,
and was contemporary and revealing the CD in 33.3% (3/9). In a single case
(11.1%, 1/9), the diagnosis of cryptogenetic cirrhosis was made in a celiac patient
diagnosed in childhood without the concept of GFD followed, 7 years after the
diagnosis of CD. It’s noted that hepatic cirrhosis occurred in the celiac popula-
tion at a young age, on average 31.1 years. Cirrhosis is most often complicated
(77.8%), with bleeding esophageal varices in 22.2% (n¼ 2) of the cases and
ascitic decompensation in slightly more than half of cases 55.6% (n¼ 5).
Hepatocellular insufficiency was noted in 66.7% of cases. Specific management
of hepatic cirrhosis has been established with ligation of esophageal varices in 2
patients after bleeding esophageal varices until eradication of varices. A treat-
ment with b blockers was prescribed in primary prophylaxis of digestive bleeding
by rupture of oesophageal varices in 4 patients. Diuretic therapy and aspiration
of the ascites fluid are performed in cirrhotic patients with ascites. A GFD is
established in addition to the specific management of liver cirrhosis. Liver tests
were standardized in 100% of patients with cryptogenetic transaminasemia
followed GFD. The chronic liver disease was often decompensated and the
hepatic signs for cirrhosis were in the foreground masking the response to GFD.
Conclusion: It is recommended to look for hepatic abnormalities during CD and
even to think of the diagnosis of CD in front of liver cytolysis syndrome without
obvious etiology and in the presence of a chronic cryptogenetic or dysmimunes
liver diseases.
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Introduction: Celiac disease (CD) is a life-long autoimmune disease affecting
multiple organs of genetically susceptible individuals. One of the extra intestinal
manifestations of the disease is thromboembolic events like strokes and veins’
thrombosis.
Aims & Methods: The aim of this work is to determine the prevalence and clinical
characteristics of the thrombosis observed during CD. Prospective multicenter
work involving 154 adult celiac patients (42H, 112F), with an average age of 36.1
years 13.6, recruited between 01-01-2013 and 30-06-2014 with a minimum
follow-up of 12 months. The diagnosis of CD was in all cases based on clinical,
serological and histological arguments. Thrombotic complications were noted as
well as their modalities of occurrence.
Results: Vascular thrombosis was noted in 13 patients (8.4%), and occurred
almost exclusively in women (84.6%) (11 F - 2 H). There are 6 cases of portal
cavernoma, one associated with lower limb thrombosis, 4 cases of stroke and 3
cases of thrombosis of the lower limbs. The diagnosis of thrombosis revealed the
diagnosis of MC in 8 patients (61.5%) with an average delay of 11.6 months and
extreme delays of 1 to 43 months. These include 4 cases of a portal cavernoma,
one associated with deep limb thrombosis, 3 cases of stroke, and one case of deep
thrombosis of the lower limbs. The diagnosis of CD was made on average 72
months after that of thrombosis in 4 patients (30.8%). In one case, thrombosis
was complicated 39 years after diagnosis of CD diagnosed in childhood at the age
of 5 years without gluten-free diet. The thrombophilia assessment was carried out
in all patients and. The thrombophilia assessment was was negative in 11 cases
(84.6%). A S protein deficiency associated with the CD in one case and an
antithrombin III deficiency in another case were detected. The use of oral contra-
ceptives and in all cases a micro-dosed oestro-progestin was found in 7 women
(63.6% of the women involved in thrombosis).
Conclusion: The diagnosis of CD must be evoked when there is a thrombotic
disease without obvious cause, factors of thrombophilia may be present during
the CD. Early CD diagnosis with respect to the gluten-free diet may prevent the
development of this complication.
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Introduction: Celiac disease (CD) is an organ-specific autoimmune disease, and
both adaptive and innate immunity are involved in its development. Recent
studies suggest the dysregulation Toll-like receptors (TLRs) in innate immunity
can confer risk to autoimmune diseases such as CD.
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Aims & Methods: In this study we investigated the TLRs 2, 4, 7, 9 genes expres-
sion in the Iranian patients with celiac disease comapred with healthy control.
Blood samples from 120 CD patients diagnosed according to the Iranian Society
for Gastroenterology were collected and 120 healthy individuals were served as a
control group during 2016. Also, among them, 20 duodenal biopsy specimens
were collected randomly. Total RNA for both boold samples and biopsy speci-
mens was isolated using a standard commercial kit. The mRNA expression of
TLRs were quantified by relative qPCR with B2M as a reference gene.
Results: Significantly higher expression of TLR4 and TLR9 mRNA was observed
in blood samples of CD patients compared to the healthy controls (P5 0.05); but
there were no significant differences between expression of TLR2 and TLR7
mRNA compared to the controls. Furthermore, TLR4 and TLR2 expression
level was increased in CD biopsy specimens compared to controls, whereas
expression of TLR9 mRNA was decreased in CD patients. No significant differ-
ences in expression of TLR7 was observed in biopsy specimens.
Conclusion: The result of this study show that the alteration of TLR4 and TLR9
genes expression in intestinal mucosa of CD can be detected in PBMs in periph-
eral blood. Further, this data supports the potential implication of innate
immune system in the pathomechanism of celiac disease.
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Introduction: Low bone mineral density (BMD) is common in celiac disease (CD).
Aims & Methods: The goals of the study were to identify the predictive factors of
low BMD and of bone density variations. The medical files of 607 patients with
CD at Europeen Georges Pompidou Hospital were reviewed (2000–2015). Four
hundred and four had an osteodensitometry and 133 had one before or until six
months after beginning a gluten free diet (GFD). An univariate and multivariate
analysis were performed for the different factors. The speed of variation of T and
Z-score was calculated by the ratio between T and Z-score variation and the
duration between these two measures.
Results: 46% of patients had osteopenia and 17.5% had osteoporosis. The pre-
dictive factors of low BMD in celiac patients were, in lumbar spine and forearm
tests, male gender (p5 0.001), in lumbar spine and femoral neck tests, low body
mass index (BMI) (p5 0.001) and in the three sites, old age at the diagnosis
(p5 0.001). In the femoral neck, secondary hyperparathyroidism was a predic-
tive factor of low BMD at celiac disease diagnosis (p¼ 0.016). The factors with
an impact on gain of bone density were, in the forearm, female gender (p¼ 0.034)
and in the femoral neck, the HLA-DQ2/DQ2 status (p¼ 0.008).
Conclusion: 64% of celiac patients had low BMD. The predictive factors were
male gender, old age at diagnosis, low BMI and secondary hyperparathyroidism.
The gain of bone density was better in woman and in HLA-DQ2/DQ2 patients
whereas GFD had no impact.
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Introduction: The mucus layer, covering the gastrointestinal mucosa, is consid-
ered the first line of defence against mechanical, chemical, or microbiological
aggressions arising from the luminal contents1. Among all different cell types of
the intestinal epithelium, the goblet cells are specialised in the secretion of mucus
constituent2. As an example of failing barrier function, patients with coeliac
disease (CD) have been reported to have altered intestinal barrier3. Human
colonic mucus-secreting cells HT-29-16E are valuable tools to explore the
effect of a specific treatment on permeability and mucus production by the
human intestinal epithelium.
Aims & Methods:We investigated the new and innovative gluten detoxified bread
(GFB; patent PCT/IB2013/0007974) effects on mucus production by means of
Alcian blue staining in comparison to the control bread (CB). In addition,
MUC2 and MUC3 were quantified by ELISA and the permeability of the intest-
inal epithelium monolayer was evaluated by trans-epithelial electrical resistance
(TEER) measurement. The statistical analysis was conducted by one-way
ANOVA followed by a Bonferroni post-hoc t-test.
Results: Mucin production by Alcian blue staining was expressed as % black
pixels obtained from Image Tool software. GFB increased the secretion of mucin
after 24 hours by Alcian blue staining (10.28 1.82; P 0.01), whereas CB did
not (9.94 0.67; P¼ 0.05). Higher MUC2 concentrations expressed as ng/ml
were found on cells treated with GFB (10.82 1.35; P¼ 0.01) compared to con-
trol, which was not found for CB (9.54 0.18; P¼ 0.05). Additionally, greater
TEER values, expressed as a percentage of initial TEER, were observed after 24
hours of incubation with GFB in comparison to the control (163.2 33.8,
P¼ 0.01) which was not observed or CB (139.4 28.8, P¼ 0.05).
Conclusion: It could be concluded that GFB has a potential of inducing MUC2
secretion by intestinal epithelial cells and improving intestinal epithelium perme-
ability in vitro. Such observed potential may effectively contribute to consequent
benefits such as higher gut barrier defence, decreased susceptibility to infections
and better absorption regulation, thus ameliorating such alterations in coeliac
patients.
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Introduction: Non celiac gluten sensitivity (NCGS) is a gluten-related enteropa-
thy with distinct features compared to celiac disease. Patients with NCGS experi-
ence symptoms, such as diarrhea or abdominal pain, shortly after gluten
exposure. Differently from celiac disease, serology is negative, and histological
picture is characterized by no lesion or a mild enteropathy (Marsh 1 stage). Few
studies have investigated possible histopathological characteristics of NCGS. An
immune response against gluten elicited exclusively by innate immunity has been
hypothesized. On these bases, we attempted to depict an immunohistochemical
trait of NCGS by exploring markers of lymphocyte and innate immunity
activation.
Aims & Methods: Duodenal biopsy samples of patients diagnosed of NCGS
according to Salerno criteria were retrieved. Duodenal biopsy samples of positive
controls (overt seropositive celiac disease at Marsh 1 stage) and negative controls
(functional dyspepsia and normal microscopic picture) were selected.
Immunohistochemistry for CD3 (intraepithelial lymphocytes), CD4 (T-helper
lymphocytes), CD8 (T-cytotoxic lymphocytes) and CD1a (Langerhans cells)
was performed. Cell count was carried out both in the epithelial layer (expressed
as positive cells/100 enterocytes) and in the lamina propria (positive cells/mm2).
Comparison of means was performed by ANOVA test with Bonferroni’s post-
hoc analysis.
Results: Twenty NCGS, 12 celiac patients (positive controls) and 16 negative
controls were selected. CD3 positive intraepithelial lymphocytes in NCGS were
expressed at intermediate levels (18.5 6.4) between negative controls
(11.9 2.8) and celiac disease (40.8 8.1, p5 0.0001). CD4 T-helper lympho-
cytes were present only in lamina propria and NCGS had a lower level
(31.0 22.1) than controls (72.5 29.5) and celiac disease (103.7 15.7,
p5 0.0001). Intraepithelial CD8þ cells were similar between NCGS and nega-
tive controls (14.0 7.4 versus 17.8 4.2), but lower than celiac disease
(34.0 7.1, p5 0.0001). CD1aþ Langerhans cells were over-expressed in the
lamina propria of NCGS (1.9 1.1) in comparison to celiac disease and negative
controls (respectively 0.3 0.8 and 0.4 0.5, p5 0.0001).
Conclusion: NCGS is characterized by a mild immunologic reaction, as shown by
the slight increase in CD3 intraepithelial lymphocytes. The over-expression in the
A378 United European Gastroenterology Journal 5(5S)
lamina propria of Langerhans cells, which are antigen presenting cells mainly
involved in innate immunity, seems to confirm previous hypotheses on the patho-
genesis of NCGS. Additionally, this finding could represent an useful patholo-
gical feature of NCGS.
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Introduction: Coeliac disease (CD) is estimated to affect up to 1 in 100
Australians (1). Although CD has a wide range of clinical manifestations,
patients frequently present with gastrointestinal (GI) symptoms which overlap
with functional GI disorders, particularly irritable bowel syndrome (IBS) and
functional dyspepsia (FD); the prevalence of biopsy proven CD is higher in IBS
(2) and in dyspepsia (3). Patients with CD have been shown to experience per-
sistent GI symptoms despite long term treatment with a gluten-free diet (4).
Aims & Methods: The aim of this study was to define GI symptoms reported in
an Australian cohort with a doctor diagnosis of CD and compare with those not
reporting CD. A total of 3825 people (mean age 58.4 years, age range 18–100
years and 47.5% males) randomly selected from the Australian population
returned a mail survey (Digestive Health & Wellbeing Survey, response rate-
¼ 45%) which contained questions on whether the participant had ever been
told by a physician that they had CD, and questions regarding GI symptoms
to establish whether they had co-existent functional GI disorders. Adherence to a
gluten-free diet was not assessed. Prevalence of CD, FD and IBS are reported
with 95% exact confidence intervals. The difference between symptoms in those
with CD compared with the unaffected population was tested for significance by
the Pearson chi-square test.
Results: The prevalence of doctor-diagnosed CD was 1.2% (95% CI 0.84–1.59) in
this cohort. Subjects with CD reported significantly higher levels of GI symptoms
than unaffected individuals, including abdominal pain associated with abnormal
bowel habit, diarrhoea, bloating, distention, epigastric burning and early satiety
(see Table). There was no significant difference observed in symptoms of post-
prandial fullness, nausea, constipation, abnormal stool consistency, or straining
with defecation. The prevalence of FD as defined by Rome III criteria in the CD
cohort was 37.5% (95% CI 22.7–54.2) compared to 13.9% (95% CI 12.8–15.1) in
the non-affected population (OR 3.7, 95% CI 1.9–7.1, p5 0.001). There was no
significant difference in the prevalence of IBS in the affected compared with the
non- affected cohort (30.8% versus 22.2%, p¼ 0.2).
Table: Gastrointestinal symptoms reported by patients with and without self
reported coeliac disease (CD). Items reported as greater than one day per week
(*) or greater than or equal to ‘‘often’’ (**)
Symptoms
self report
CD - Yes
self report
CD - No p value
Abdominal pain associated with
loose bowel motions **
16/37 43.2% 600/3234 18.6% P5 0.001
More bowel motions
associated with pain **
13/38 34.2% 504/3248 15.5% P¼ 0.002
Bloating * 13/40 32.5% 436/3381 12.9% P5 0.001
Distention * 12/40 30% 395/3371 11.7% P5 0.001
Abdominal pain * 9/39 23.1% 362/3378 10.7% P¼ 0.014
43 bowel motions per day ** 7/40 17.5% 7/40 17.5% P¼ 0.046
Epigastric burning * 8/40 20% 165/3380 4.9% P5 0.001
Early satiety * 8/40 20% 230/3378 6.8% P¼ 0.001
Conclusion: The prevalence of gastrointestinal symptoms and in particular func-
tional dyspepsia are significantly higher in patients with a doctor diagnosis of CD
than in the unaffected population. Studies show that biopsy proven coeliac dis-
ease in IBS is higher in IBS cohorts than healthy controls (2) and the value of
screening with duodenal biopsy testing for CD in FD is concluded to be useful
(3), this study supports these views
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Introduction: Osteoporosis is a systemic skeletal disorder characterized by low
bone mass and micro-architectural deterioration with increase of bone fragility
and consequent fracture risk. About 50–75% of patients (pts) with untreated
coeliac disease (CD) suffer from bone mass loss (osteopenia or osteoporosis).
Despite this strong correlation, guidelines do not express with certainty on the
need to undergo a dual-energy X-ray absorptiometry (DEXA) scan in every
patient with new diagnosis of CD. Recently, the DEXA screening was suggested
for CD peri-post menopausal females, males over 55 years, pts with overt malab-
sorption or with a history of fragility fractures. Studies on bone mineral density
(BMD) in CD pts led to discrepant results, probably due to heterogeneous
designs.
Aims & Methods: The aim of this study was to evaluate, in a cohort of consecu-
tive newly diagnosed CD adults, the prevalence of BMD alterations at diagnosis
time and to evaluate associated clinical features. From January 2004 to
December 2016, 258 consecutive pts (F¼ 72.4%) were diagnosed with CD. All
pts were adults (median age 38, range 18–72 years), had atrophic disease and
were invited to undergo a DEXA within 3 months from diagnosis to screen for
osteoporosis (T-score52.5) or osteopenia (T-score 51and 2.5). A total
of 214 (82.9%) pts underwent the DEXA scan and were included in the study
(F¼ 71.5%, median age 38, range 18–72 years). On the basis of DEXA results
(codified according to WHO classification) pts were divided into 3 groups: pts
with normal BMD, with osteopenia, and with osteoporosis. For each patient,
reported risk factors for low BMD (underweight, alcohol intake, drugs, meno-
pause, smoke) and serological PTH values were assessed. The signs/symptoms
leading to CD and their duration before diagnosis, autoimmune/not-autoim-
mune comorbidities, familiarity for CD, previous fractures and serological
assays (specific antibodies for CD, ferritin, cholesterol, triglycerides, and albu-
min) were also assessed. All the variables described were analyzed and compared
between the 3 groups. Logistic regression was performed including into the model
those independent variables which showed a significant difference at univariate
analysis.
Results: At the DEXA scan, 85 (39.7%) and 129 (60.3%) pts had normal or low
BMD, respectively. Among pts with low BMD, 91 (42.5%) had osteopenia and
38 (17.8%) osteoporosis. At logistic regression, clinical features significantly
associated with osteoporosis were male gender (OR 4.7; 95%CI 1.3 to 17.4),
underweight (OR 8.1; 95%CI 1.8 to 35.3) and increased PTH values (OR 5.1;
95% CI 1.4 to18.8), while age 40 years and gastrointestinal symptoms at diag-
nosis time, menopause, alcohol intake and previous fractures were not asso-
ciated. Clinical features significantly associated with osteopenia were
underweight (OR 4.0, 95% CI 1.4 to11.2) and increased PTH values (OR 2.6,
95%CI 1.1 to 6.4).
Conclusion: In newly diagnosed coeliac pts, the overall prevalence of BMD
alterations was more than 60%, with osteoporosis in nearly 1/5. Osteoporosis
was significantly associated with male gender, underweight and increased PTH.
This study suggests that at CD diagnosis, DEXA scan might be of benefit, in
particular in male underweight pts.
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Introduction: Coeliac disease (CD) affects 0.6–1% of the population worldwide
(1). Wheat avoidance in the absence of CD is common, and studies report a
population prevalence of self-reported wheat or gluten sensitivity (SRWS) of
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up to 13% (2, 3). SRWS is defined as gastrointestinal (GI) or extra intestinal
symptoms on ingestion of wheat or gluten-containing food (2, 3).
Aims &Methods: The aim of this study was to determine the prevalence of SRWS
in an Australian population, define associated GI symptoms, and relate the
diagnosis to demographic, lifestyle and medical factors. A total of 3825 people
(mean age 58.4 years, age range 18–100 years and 47.5% males) randomly
selected from the Australian population returned a mail survey (Digestive
Health & Wellbeing Survey, response rate¼ 45%) which contained questions
on wheat avoidance, GI symptoms, demographic, medical and lifestyle factors.
We defined SRWS as people who reported gastrointestinal symptoms on inges-
tion of wheat based foods, but did not suffer from doctor diagnosed coeliac
disease, inflammatory bowel disease or bowel cancer. Prevalence of SRWS is
reported with 95% exact confidence intervals. The association between SRWS
prevalence and potential risk factors was reported using unconditional logistic
regression. The degree of differentiation of SRWS from health was evaluated
through the area under the receiver-operator-characteristic curve.
Results: The prevalence of SRWS in this cohort was 13.5% (455/3331, 95% CI
12.5–14.9%). Only 11% (50/455) of these subjects had received a doctor diag-
nosis of wheat or gluten intolerance. The most commonly reported GI symptoms
(reported as more than weekly or often) associated with SRWS included abdom-
inal pain relieved by bowel movements (54.5%), bloating (37.6%) and abdominal
distention (30.8%). In a multivariate analysis, a diagnosis or SRWS was signifi-
cantly associated with irritable bowel syndrome (IBS) and functional dyspepsia
(FD) (Rome III criteria), female gender, and food allergy (see Table). Older age
was negatively associated with SRWS. In this multivariate model, factors with no
observed association included body mass index, depression, anxiety, sleep pro-
blems, proton pump inhibitor use, gastrointestinal infection, rheumatoid arthri-
tis, scleroderma, migraine, Parkinson’s disease, asthma, pollen allergy, animal
allergy or psoriasis, diabetes and recent antibiotic use. The model provided useful
although imperfect differentiation of SRWS from health (AUC¼ 0.76).
Table: Medical and demographic factors associated with a diagnosis of self-
reported wheat sensitivity (SRWS).
SRWS -YES SRWS -NO
Odds
ratio 95% CI, p value
Age: mean (SD) 51.9
(14.9)
59.3
(16.5)
0.98 0.98–0.99, p5 0.001
Female gender
(total¼ 52.5%)
336/450
(74.7%)
1392/2854
(48.8%)
1.86 1.51–2.30, p5 0.001
Functional dyspepsia 128/466
(27.5%)
327/2865
(11.4%)
1.74 1.38–2.20, p5 0.001
Irritable bowel
syndrome
248/453
(54.8%)
571/2866
(19.9%)
3.96 3.23–4.86, p5 0.001
Food allergy 56/455
(12.3%)
151/2878
(5.3%)
2.05 1.50–2.80, p5 0.001
Conclusion: SRWS has a prevalence of 13.5% in this Australian cohort. Those
with SRWS are likely to report abdominal symptoms, including abdominal pain
associated with abnormal bowel habits, bloating, or abdominal distention.
SRWS is significantly associated with IBS and FD, younger age, female
gender, and food allergy.
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Introduction: Pathogenesis of functional bowel disease is usually associated with
disorders of visceral sensitivity and intestinal motility, which result from a dys-
function of the central nervous system, intestinal microflora and immune system
Aims & Methods: We aimed to highlight importance of intestinal enzymes (glu-
coamylase, maltase, sucrase and lactase) in the etiology and pathogenesis of
functional bowel disease. 74 patients with functional bowel diseases in age
from 18 to 50 years (36 men and 38 women) were examined. According to
Rome IV criteria (2016), 21 had irritable bowel syndrome (IBS) with predomi-
nance of diarrhea, 33 - functional diarrhea, 6 – IBS with predominant constipa-
tion, 4 - functional constipation and 10 - mixed type of IBS. Activity of the
mucosa enzymes of the small intestine was determined by Dahlquist-Trinder
method in duodenal biopsies obtained during esophagogastroduodenoscopy.
Results: Lactase deficiency was identified in 87.8% of patients, maltase deficiency
– in 48.6%, sucrase deficiency – in 51.3%, the glucoamylase deficiency – in
85.1%. The activity of all investigated enzymes was reduced in 23 (31.1%)
patients with functional bowel diseases, failure of 1 to 3 enzymes detected in
47 (63.5%). Normal activity of enzymes was observed in 4 (5.4%) patients.
Conclusion: In 70 of 74 (94.5%) patients with functional bowel disease and a
disorder of the stool, abdominal pain and flatulence, there was a decrease in the
activity of intestinal enzymes, which may be a cause of intestinal symptoms.
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Introduction: Epidemiological studies estimate a worldwide prevalence of CD of
approximately 1:100 individuals, with a considerable proportion of patients
remaining undiagnosed and untreated.
According to a study performed by the National Health and Nutrition
Examination Survey in the United States, the prevalence of self-prescribed
GFD in an unselected population of subjects aged 6 years or older was 0.5%.
Epidemiological studies report a prevalence of WA in American population of
around 0.4% untill 0.6%.
The diagnosis of WA is classically based on skin prick tests (SPT), in vitro
specific Immunoglobulin E (sIgE) assays and functional assays. SPTs and sIgE
in vitro assays are the first-level diagnostics for WA. However, they are affected
by a low predictive value. In particular, their low sensitivity can be explained by
the fact that the commercial test reagents are mixtures of water/salt-soluble
wheat proteins that lack allergens from the insoluble gluten fraction. The asso-
ciation between food allergy and celiac disease (CD) is still to be clarified.
Gluten-related disorders are an epidemiologically relevant phenomenon whit a
global prevalence that is estimated around 5%, drawing the attention of the
scientific community.
Aims & Methods: We visited in our unit of celiac disease and gluten-related
conditions during 2016 423 (F/M:312/111) new patients with clinical suspicion
of CD. Of these 113 they were not celiac but were investigated for suspected non-
celiac gluten sensitivity. After in vitro tests for the exclusion of celiac disease, to
verify the real prevalence of food allergy particularly to wheat protein, in non
celiac patient referred our unit for symptoms after gluten ingestion, all these
patients underwent allergologic workup consists on: skin prick tests for foods
including wheat (Alk-abello), LTP (lipid transfer protein) (peach Alk abello),
alpha amylase, wheat flour, barley, corn, rice, grass pollen and histamine. Also
they all performed patch tests for suspected allergy to nickel, if they reported
reactions after a few hours of ingestion of gluten. Molecular-based allergy (MA)
diagnostics could overcome some limitations of sIgE in vitro assay using wheat
flour extracts. We have used omega-5 gliding (TRI a 19) and nsLTP (TRIa 14),
gli admin, wheat, gluten that are available in the immunoCap assay, whereas the
Alfa -amylase/trypsin inhibitor (TRI a A/TI) is available only in the microarray
ISAC assay. The sIgE to omega-5 gliadin assay is highly reliable and now widely
used to identify the patient with WDEIA.
Results: In our overall population, 113 (26.7%) non celiac patients had a history
of immediate or not immediate reaction after ingesting gluten: the Allergologiic
tests found wheat protein sensitization in 14 patients of these (12.4%, 9 F). In
addition we also found 5 (4.5%, 4F) patients with real allergy to wheat or wheat
protein.
Conclusion: In our population 19/113 (16.8%) non celiac patient had real reac-
tion after ingesting gluten: 14 (12.3%) had wheat protein sensitization and 5
(4.5%) had WA. These percentages are different and very high than that reported
in the literature.
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Introduction: Excessive amounts of bile acids entering the colon cause chronic
diarrhoea (bile acid diarrhoea (BAD)). Diagnosis of BAD is possible by measur-
ing the retention level of orally ingested 75Selenium homotaurocholic acid
(SeHCAT). Standard treatment of BAD is bile acid sequestrants (BAS), such
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as colestyramine. Short-term outcome of having BAD is well-described, but long-
term effects remain unclear. The aim of the present study was to describe long-
term symptoms, adherence to treatment and quality of life in a well-defined
group of patients with BAD.
Aims & Methods: Between 2003 and 2016, 559 patients referred to our hospital
for diarrhoea had abnormally low seHCAT retention levels (515% at day 7).
Questionnaires about medical history, bowel function, use of medication, and
quality of life were sent to all patients.
Results: Among 559 patients, 381 (68.2%) responded ((242 women (63.5%),
median age: 53 years (range 22 to 89), median age at diagnosis 47 years (range
16 to 85)). In 123 respondents (32.3%) BAD was due to ileal dysfunction (type 1),
199 (52.2%) had idiopathic BAD (type 2), and 59 (15.5%) had BAD due to
cholecystectomy (type 3). At follow-up, 272 patients (73.9%) still reported both-
ersome diarrhoea and 244 (65.1%) regularly used antidiarrheal medication.
Treatment included BAS in 45.1% while 32.3% of patients used other treatment.
184 patients (49.9%) reported that treatment had improved their symptoms,
while 116 (31.4%) reported that they were the same, and 69 (18.7%) felt
worse. Quality of life was still affected by diarrhoea in 242 patients (63.5%).
Conclusion: BAD must be considered as a chronic disease and despite correct
diagnosis and treatment, most patients continue to have significant diarrhoea
and reduced quality of life. This supports the need for further research in patho-
physiology and new therapy principles.
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Introduction: Chronic intestinal pseudo-obstruction (CIPO) is an intractable rare
digestive disease manifesting persistent small bowel distension without any
mechanical cause. Intestinal decompression is a key treatment, but conventional
method including a trans-nasal small intestinal tube is invasive and painful.
Therefore, a less invasive and tolerable new decompression method is urgently
desired. We conducted a pilot study and assessed the efficacy and safety of
percutaneous endoscopic gastro-jejunostomy (PEG-J) decompression therapy
in CIPO patients.
Aims & Methods: Eight definitive CIPO patients (2 males and 6 females) were
enrolled. All patients received PEG-J decompression therapy. The number of
days with any abdominal symptoms in a month (NODASIM), body mass
index (BMI), serum albumin level (Alb), and small intestinal volume before
and after PEG-J were compared in all patients.
Results: PEG-J was well tolerated and oral intake improved in all patients.
NODASIM has significantly decreased (24.3 vs 9.3 days/months) and BMI/
Alb have significantly increased (14.9 vs 17.2 kg/m2 and 2.6 vs 3.8 g/dl, respec-
tively), whereas total volume of the small intestine has not significantly reduced
(4.05 vs 2.59 L, p¼ 0.18). Reflux esophagitis and chemical dermatitis were
observed in one case but was successfully treated conservatively.
Conclusion: PEG-J decompression therapy can contribute greatly to improve-
ment of abdominal symptoms and nutritional status in CIPO patients.
Although sufficient attention should be paid to acid reflux symptoms, PEG-J
has the potential to be a noninvasive novel decompression therapy for CIPO
available at home. However, accumulation of more CIPO patients and long-
term observation are needed.
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Introduction: In genetically susceptible subjects, gluten exposure determines celiac
disease, but it has also been shown that gluten ingestion could alter intestinal
absorption even in patients with non-intestinal diseases (Doherty, Lancet 1981)
and in healthy subjects (Levine, NEJM 1966). However, whether gluten causes
intestinal alterations in healthy volunteers (HV) is still a matter of debate: in HV
we recently demonstrated that gallbladder motility and gastric emptying were not
affected by the ingestion of gluten, whereas a slight increase of intestinal fermen-
tation was evident (Di Stefano, DLD 2015). A cytotoxic effect of gluten on
intestinal cell lines was also previously shown (Rivabene, BBA 1999). We recently
demonstrated that in dyspeptic patients the ingestion of a standard meal induces
both an inflammatory and an antioxidant response, correlated with symptom
occurrence (Di Stefano, UEGW 2016). It is therefore possible that food-related
alterations of the intestine could be responsible for post-prandial activation of
inflammation and anti-oxidant systems.
Aims & Methods: We therefore studied whether gluten intake induces alterations
of post-prandial activation of inflammation and anti-oxidant systems. Twenty
consecutive, non-smoking, normal-weight HV (8 females, mean age 27.9 3.6
yrs) were enrolled. The presence of acute or chronic disorders was excluded in all
of them. After an overnight fast and at the same time in the morning, all the
subjects underwent evaluation of post-prandial modifications of serum levels of
pro-inflammatory cytokines (IL-1b, IL-6, TNF), endogenous antioxidant
system (uric acid), glucose, insulin and serum lipopolysaccharide (LPS), mea-
sured as putative factors responsible for inflammatory response. Serum samples
were collected at fasting and every 30 minutes for a 4-hour period after an oral
gluten load of 2 gr (in 10 HV) or 20 gr (in the other 10 HV). The presence and
severity of symptoms such as epigastric pain, epigastric burning, fullness, early
satiety, abdominal pain, abdominal distention, bloating, flatulence, nausea,
vomiting, belching, heartburn, regurgitation, diarrhea, and headache, were eval-
uated by visuo-analog score at fasting and every 30 minutes in the post-prandial
period.
Results: In comparison with mean fasting values, none of the measured para-
meters showed a significant increase in the post-prandial period after the inges-
tion of 2 gr of gluten. On the contrary, after the ingestion of 20 gr of gluten mean
post-prandial values of TNF and IL-b showed a significant increase
(2.45 1.75 pg/mL and 0.65 0.31 pg/mL) as compared to mean fasting values
(1.17 1.49 pg/mL and 0.29 0.15 pg/mL; p5 0.05). Mean post-prandial values
of uric acid were also significantly higher (74.98 33.02 nmol/mL) than fasting
values (45.34 10.08 nmol/mL; p5 0.05). No significant differences were
detected in IL-6, glucose, insulin and LPS d after the ingestion of the 20 gr
gluten oral load. Symptoms were absent after both oral loads.
Conclusion: The ingestion of a high, but not a low, oral load of gluten induces a
significant post-prandial inflammatory response causing the activation of the
main endogenous anti-oxidant system. In HV, these activations are not accom-
panied by a symptomatic response. Further studies are needed to investigate the
inflammatory and anti-oxidant post-prandial response in patients with gluten-
related disorders.
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Introduction: Ketogenic Enteral Nutrition (KENTM) is a modification of
Blackburn’s protein-sparing modified fast, using a hypocaloric, ketogenic
liquid diet. The study is about Ketogenic enteral nutrition (KEN) in overweight
and obese patients receiving short treatment of the nutritional solution as 24-
hour infusion. It is a retrospective analysis that examines safety, weight loss and
body composition changes after three sequential 10-days cycles of KEN therapy.
Aims & Methods: Anthropometric and bio-impedance data from 629 patients
who underwent KEN were collected before and after completing a ten-day
cycle. The study focuses on the change in outcomes from the first cycle to the
second cycle and from the first cycle to the third cycle. The following outcomes
were explored: weight, waist circumference, BMI, fat mass, lean mass, dry lean
mass, phase angle, wellness marker, water mass as a percentage of total body
weight. The cycle 1, 2 and 3 outcomes were analyzed using descriptive statistics
(mean, standard deviation, n) summarizing the outcome at each cycle. Statistical
tests were used to test for significant differences between paired cycle 1 and cycle
2 outcomes and also between paired cycle 1 and cycle 3 outcomes. For normally
distributed outcomes, the paired t-test was used. Whereas for skewed outcomes,
the Wilcoxon signed-ranks test was used. Scatter plots were used to plot percen-
tage of excess weight loss against phase angle. The Pearson’s correlation coeffi-
cient was calculated. Regression analysis for the outcome percent change in
weight from cycle 1 to cycle 2 for phase angle and basal metabolic rate
(BMR)/Weight ratio as predictors was carried out.
Results: The results suggested significant changes for all analyzed parameters.
There were significant decreases in weight, waist circumference, BMI, fat mass,
lean mass, dry lean mass and phase angle. Quantitative changes in lean mass and
dry lean mass were negligible with respect to changes in fat mass. There was also
a statistically significant increase in water mass as a % of total body weight and
wellness marker from cycle 1 to cycle 3. The Pearson’s correlation coefficients
r¼ 0.18, p¼ 0.004 and r¼ 22, p¼ 0.04 indicated changes in cycle 1 and cycle 3 in
percentage of weight excess to be significantly, positively correlated to phase
angle. The multivariate linear regression model showed that for a 1 unit increase
in BMR/weight there was a 3.3 percent decrease in percent change in weight.
KEN treatment was overall well tolerated. 92% of patients on oral hypoglycae-
mics and 80% of patients on anti-hypertensive medication were able to discon-
tinue their medication safely during KEN therapy.
Conclusion: KEN treatment is safe, well tolerated and results in rapid fat loss
without detriment to dry lean mass.
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Introduction: Obesity is a global disease and its management includes pharmaco-
logical therapy, nonabsorptive surgery and, Intragastric Balloon (IGB). Any
form of therapy, including surgery, is flawed by weight regain in the long-
term. IGB has gained popularity recently; however, there is a lack of studies
addressing the use of IGB and its effect on weight control in the long-term.
This is the first study that aimed to assess the weight regain in a large cohort
of patients treated with IGB, with a time span from two to five years after the
removal of the device.
Aims & Methods: All obese patients treated with IGB in a specialized obesity
center, and that underwent balloon removal from June 2009 to June 2013 were
invited to participate in the study. Exclusion criteria: pregnancy or bariatric
surgery after balloon removal, impossibility to contact, and refusal to participate.
Patients that agreed to participate were interviewed by a trained investigator in
person and answered a questionnaire survey and had their body weight mea-
sured. Interviews started on July 2015 and ended on July 2016. Medical records
of recruited patients were reviewed and the body weight at the moment of IGB
introduction and removal registered. Patients were stratified by segment time-
frame from balloon removal and interview date (2, 3, 4 and 5 years) and all
intervening factors related to weight control, as well as behavior habits were
analyzed and compared with logistic multivariate analysis.
Results: A total of 224 patients entered the study. Of these, 81.3% (182) were
women. During the use of IGB, patients lost an average of 15% of their body
weight; representing a mean loss of 66% of excessive weight. Between 2 and 5
years after removal of IGB, 67% (150) of the subjects had regained weight; the
mean weight regain was 4 kg during this period. Most patients (62%) regained
10% to 19% of weight lost during treatment. The mean weight regain increased
during follow-up, but without significant difference among groups: 2 years
[n¼ 10]: 4.66 4.91 kg; 3 years [n¼ 83]: 8.66 6.96 kg; 4 years [n¼ 54]:
9.99 8.44 kg and 5 years [n¼ 3]: 19, 96 12, 24; (p¼ 0, 51). The lower the
BMI at the beginning of treatment, the greater the weight regain after the IGB
withdrawal. This correlation was inverse (r¼0.20) and significant (p5 0.01).
The correlation was stronger and more significant with patients who had with-
drawn the balloon at two years (r¼ -.59, p5 0.01) followed by those in which
balloon withdrawal was undertaken four years before(r.¼0.23, p¼ 0.03).
Weight regain group contained more individuals who did not perform psycho-
logical and nutritional follow-up and who were also sedentary, during and after
treatment. Each year, after removal of IGB, the chance of regaining weight
increased 1.5 times. No follow-up with a nutritionist after the procedure
increased chance of weight regain in 1.8 times. Lack of follow-up with a psychol-
ogist during treatment had a weight regain 1.9 times increased. Multivariate
logistic analysis determined risk factors for weight regain according to time
span after IGB removal. After 2 years of balloon removal, the significant risk
factor was lack of follow-up with a psychologist during treatment; increasing the
chance of weight regain 1.13 times compared with those subjects that received
psychological follow-up. An independent and significant risk factor for weight
regain after 3 years of IGB removal was the lack of follow-up with a nutritionist
after the use of IGB. Chance of weight regain was 3.36 times higher in this group
than in individuals who did the nutritional follow-up. After 4 years of IGB
removal, sedentary behavior was an independent and significant risk factor,
increasing the chance of weight regain 3.86 times compared with physically
active behavior.
% of weight regained * 2 years 3 years 4 years 5 years
510% 20% (2) 15.6% (13) 18.5% (10) 33.3% (1)
Between 10 and 19% 70% (7) 62.7% (52) 59.3% (32) 66.7% (2)
Between 20 and 29% 10% (1) 14.5% (12) 14.8% (8) 0
Between 30 and 39% 0 2.4% (2) 1.9% (1) 0
Between 40 and 49% 0 1.2% (1) 5.6% (3) 0
Between 50 and 59% 0 2.4% (2) 0 0
Between 90 and 99% 0 1.2% (1) 0 0
Conclusion: IGB has a suboptimal long-term effect on body weight control after 2
to 5 years of balloon removal, with weight regain observed in up to two thirds of
patients (66%). The following variables adversely affect long-term body weight
control after IGB removal: lack of psychological support and nutrition counsel-
ing and sedentary lifestyle. A multidisciplinary team approach is of paramount
importance to assist obese patients treated with IGB in order to effectively main-
tain long-term body weight control.
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Introduction: The Duodenal-Jeujenal Bypass Linear (DJBL) is an endoscopic
device which prevents ingested nutrients absorption in the duodenum and first
part of jejunum. The resultant effects are weight reduction and improvement in
glycemic control in patients with type 2 diabetes mellitus (T2DM).
Aims & Methods: The aim of the current study is to assess weight and glycemic
control changes resulted from the device implantation and a year after the device
removal. Between February 2013 and September 2016, 51 diabetic patients were
treated with DJBL in our center. This prospective observational study included
36 patients who completed at least 9 months of active treatment. However,
adverse events and early removals were analyzed for the whole cohort. Blood
tests, body weight and medications data were collected during scheduled visits
and phone interviews. The primary end points were body weight and glycemic
control changes a year after implantation. Secondary end points were the same
parameters after device removal. The protocol was approved by the local ethic
committee.
Results: Thirty six patients (52.8% male) were treated for at least 9 months with
the device, 10 of which completed a whole year follow-up after device removal.
At the end of 12 months post implantation, the average body weight and BMI
dropped from 109.5 19.1 kg and 37.4 5.0Kg/m2 to 93.7 20.4Kg and
31.3 3.4 Kg/m2, respectively (P 0.001). Although parameters increased up
to 97.4 14.6 kg and 33.3 5.0 Kg/m2 at the end of a year follow-up, both
parameters remained significantly lower than the baseline (P5 0.05). HbA1c
was reduced during the treatment from 7.6 1.6% to 6.6 1.2% (P¼ 0.02)
and increased to 6.8 1.0% after 12 month follow-up (P¼NS). Among 15 insu-
lin-dependent patients (42%), insulin average dose was reduced by 65%
(p¼ 0.05), but the dose was doubled after a year follow-up. Interestingly, the
glycemic control in this insulin-dependent population was difficult to maintain as
evidenced by the increased HbA1c a year after the device removal (6.9 1.1 % to
7.3 1.1% p¼ 0.585). In contrast, among non-insulin dependent patients, there
was a non-significant decrease in HbA1C during the year post the device removal
(6.5 1.3 to 6.4 0.8, P¼ 0.812). Ten patients (19.6%) of the initial 51 treated
suffered from adverse events, 4(7.8%) of which were categorized as severe ones
(two major bleedings and 2 hepatic abscesses).
Conclusion: DJBL is an effective tool for weight reduction glycemic control
among insulin and non-insulin dependent diabetic patients. Moreover, substan-
tial metabolic achievements are preserved at least a year after device removal.
Since DJBL bears a considerable amount of side effects, strategies to mitigate
them are warranted.
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Introduction: NAFLD is the most important cause of chronic liver disease and is
considered the hepatic manifestation of the metabolic syndrome associated with
type 2 diabetes. The prevalence of NAFLD in the general population reaches 15–
20% and it goes up to 76 to 90% in the obese population. The search of new non-
toxic drugs for preventing the development of obesity is the most important
challenge of modern science. The question about impact of probiotics and pre-
biotics on fat metabolism and obesity is being actively debated in the scientific
literature. So the aim of the study was to investigate the effect of synbiotic (S) on
development of experimental obesity in rats with NAFLD.
Aims & Methods: The study was carried out on 60 white rats, that were divided
into 6 groups (I-III – males, IV-VI – females). I and IV groups were intact control
(4-month old). Newborn rats of groups II and III s.c. in volume 8 ml/g were
administered a saline or monosodium glutamate (MSG) (4mg/g) at 2–10 days
of life. Since the age of 1 month, rats of III and V group had been injected with
water, rats III and VI groups - S (Inulin, Lactobacillus, Bifidobacterium and
Saccharomyces boulardii) (‘‘Opefera’’ World Medicine) in a dose of 1, 94 109
JNFþ 2, 9mg/inulin. Introduction had been performed with 2-week course for 3
months courses alternated with two-week breaks) for 3 months. In 4-month rats
anthropometrical parameters and visceral adipose (VAT) tissue mass were esti-
mated, and adiponectin in serum and leptin in VAT were measured by ELISA.
Results: In 4-month rats we diagnosed the changes of the anthropometrical para-
meters and significant increase of VAT mass that confirmed development of
visceral obesity. ln male rats, there were more pronounced changes. It was estab-
lished that under condition of obesity caused by the introduction of MSG, the
level of adiponectin in serum decreased but leptin in VAT was increased. S
significantly improvement lipid profiles and histological state of liver: decrease
of dystrophy, inflammation and necrosis and reduction of the NASH incidence.
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Also consumption of S led to reduction of pro-inflammatory cytokines and leptin
and increased anti-inflammatory cytokines and adiponectin.
Conclusion: Thus, the introduction of S reduced the obesity, that shows the
effectiveness of therapy for the prevention of obesity.
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Introduction: Endoscopic bariatric approaches are gaining traction as possible
treatment modalities for obesity. Especially, intragastric balloon was demon-
strated to be associated with a significant weight loss in obese patients. Despite
many advances in the design and material of intragastric balloon devices, there
still remains a need for improved devices which is safer, faster, and less expensive
than before. In the present study, we evaluated feasibility of newly developed
intragastric balloon.
Aims & Methods: We used a newly developed intragstric balloon with improved
employment for this study. The intragastric balloon was supplied as delicately
rolled up inside a thin silicon sheath and mounted by surrounding the endoscope.
Endoscopic intragastric balloon placement and positioning was simply per-
formed with direct vision. 10 pigs were submitted to the novel intragastric bal-
loon placement. We evaluated feasibility of the intragastric balloon and
compared procedure time between the novel intragatric balloon and End-ball
(Endalis, Brignais, France) intragastric balloon.
Results: In all cases, the novel intragastric balloons were successfully placed
under usual sedation of diagnostic endoscopy. The procedures were simple and
fast; the mean insertion time was 41.314.3 and 153.8 134.8 sec in novel intragas-
tric balloon group and end ball group, respectively. The mean inflation time was
412.46 and 512.83 sec in novel intragastric balloon group and end ball group,
respectively.
Conclusion: This preliminary data suggest that the procedure with the new intra-
gastric balloon attain technical improvements in the placement without severe
adverse events. The new intragastric balloon could offer constantly effective
procedure regardless of the ability of the endoscope practitioner.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The endoscopically implanted DJBL is a 60 cm long, impermeable
fluoropolymer device which prevents food from making contact with the prox-
imal intestine, thus inducing considerable weight loss and improvement of type 2
diabetes mellitus (T2DM). Both weight and HbA1c levels have been reported to
increase post explantation. The question remains as to whether it is possible to re-
implant the DJBL, and what the results would be in terms of BMI (Body Mass
Index) change and T2DM control.
Aims & Methods: The aim of this study was to investigate the safety, feasibility
and effectiveness of DJBL re-implantation in patients who show a relapse in
glucose levels after DJBL explantation. This prospective, observational study
was conducted at the Department of Gastroenterology of DGD Clinics
Sachsenhausen, Frankfurt (Germany) between 2014 and 2016. Five obese
patients with T2DM and with a body mass index (BMI) ranging from 35–
59 kg/m2, who completed follow-up after their first implant and underwent
removal of the DJBL after 12 months, were selected for re-implantation after
an additional 4 months of follow-up. Weight loss, BMI, and HbA1c were ana-
lysed before reimplantation and twelve months thereafter.
Results: In all 5 patients, the DJBL was initially implanted and explanted without
complications. Re-implantation and re-explantation were also performed with-
out complications. Changes in body weight, BMI and glycated haemoglobin
(HbA1c) are shown in Table 1.
Table 1: Body weight, BMI and HbA1c changes at different timepoints
Timepoint
(months)
Mean weight
in kg (SD, range)
Mean BMI
(SD, range)
Mean HbA1c
in % (SD, range)
0 115.8 (45.4; 88–196) 40.9 (10.3; 35.3–59.2) 9.1 (1.3; 8–10.7)
6 97.4 (39.8; 72–164) 29.9 (2.2; 26.4–51.2) 7.6 (0.8; 6.6–8.3)
12 95.0 (38.8; 72–164) 33.5 (9.0; 29.549.5) 6.7 (0.9; 5.9–7.8)
16 (0) 97.1 (37.8; 75–164) 34.3 (8.6; 29.3–49.5) 7.7 (1.6; 6.2–9.9)
22 (6) 93.2 (40.6; 63–164) 32.8 (9.7; 24.6–49.5) 7.0 (1.0; 5.7–7.7)
28 (12) 92.5 (43.6; 61–160) 31.5 (9.1; 23.8–48.6) 7.0 (0.7; 6.3–7.7)
Conclusion: The results of this observational study show that re-implantation of
the DJBL is viable and safe even only 4 months after explantation. After re-
implantation, weight and HbA1c levels decreased once more.
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Introduction: Obesity in the young population is becoming increasingly prevalent.
It is associated with short- and long-term consequences. Early and effective
interventions are paramount. Current treatment options include: lifestyle mod-
ifications, pharmacological therapies, endoscopic treatments and bariatric sur-
gery. However, the relative effectiveness of these treatments in this cohort
remains unclear.
Aims & Methods: To systematically identify and meta-analyse studies evaluating
treatments that reduce body mass index (BMI) in overweight and obese young
people. A systematic literature review of EMBASE and MEDLINE databases
was conducted. Studies were included/excluded based on pre-specified eligibility
criteria. Included patients were 21 years or younger. Lifestyle modification and
pharmacological therapy searches were restricted to randomised control trials.
Results: 16,372 studies were identified with 80 studies complete with sufficient
data for meta-analysis. Bariatric surgery caused the most weight loss in the short-
and medium-term [pooled estimate of mean BMI loss: 13.77 kg/m2]. Lifestyle
modifications and pharmacological therapy had a more modest impact on
weight [pooled estimate of mean BMI loss: 0.99 kg/m2 and 0.94 kg/m2 respec-
tively]. Individual studies demonstrated that endoscopic treatment results in
short-term BMI reduction, however insufficient data prevented meta-analysis.
Conclusion: This is the first systematic review and meta-analysis to comprehen-
sively summarise and quantify the comparative efficacy of BMI reducing treat-
ment options in the obese, young population. Currently, bariatric surgery is
rarely considered in this young cohort. However, due to its high efficacy, physi-
cians and patients should have a lower threshold for considering bariatric surgery
when lifestyle and pharmacological interventions have failed. The non-surgical
interventions provide smaller but statistically significant impacts on BMI reduc-
tion. There should be effective communication discussing the relative efficacy of
all treatment options and their associated complications between those involved.
This knowledge will assist clinicians in determining a holistic, patient-centred
treatment programme for obese, young patients.
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Introduction: Tumor development is a multistep process, which involves genetic
and environmental factors. Diet is among the most important contributing fac-
tors and processed and red meat has been classified as carcinogenic for colorectal
cancer. MicroRNAs (miRNAs) are functional, ubiquitously present molecules
with great impact on tumor initiation and progression. Exogenous microRNA or
xenomiRs have been identified in sera from different species suggesting an active
cross-kingdom trespassing through biological barriers during digestive process.
Aims &Methods: In the present work, we evaluated whether miRNAs are present
in various foods, and if miRNAs may be degraded through cooking and other
forms of food processing. Furthermore, we tested if short-term vegetarian or
meat-rich diet may influence human or plant-derived miRNA in feces and
blood. For this purpose, six healthy subjects were asked to adhere to vegetarian
or meat rich diet for 5 to 7 days and fecal and blood specimens were obtained at
different time points. Plant-miRNAs were further investigated in gastric and
colon mucosa. To evaluate the presence of miRNA in food, we selected several
common foods prior and after cooking/processing. Quantitative real-time PCR
was performed using TaqMan Assay.
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Results: All analyzed microRNAs were present in all studied foods with highest
expression for miR-21 followed by miR-16 and miR-155. Especially, hash, beef
and salmon showed the highest miRNA expression, while lowest expression was
found in cheese and milk. Food procession led to only marginal changes (max.
1.5-fold) in miRNA expression and thus demonstrating its stability against
degradation. Short-term changes in diet (from usual to vegetarian and to meat-
rich diet) in healthy subjects was not associated with variation in miR-21, miR-
155 and miR-16 expression. Interestingly, in comparison to several previous
reports, we repeatedly failed to detect any plant miR-168 in sera. However,
vegetarian-diet was associated with a significant increase in miR-168 level in
feces (up to 8-fold), while meat-rich diet was associated with slight decrease if
compared to the starting time point (meanSD 0.0031 0.002 for no diet vs
0.025 0.042 for vegetarian vs. 0.0016 0.00096 for meat-rich; p¼ 0.03 Kruskal-
Wallis test, with p4 0.05 for Dunńs multiple comparison test for vegetarian vs.
meat-rich).
Conclusion: The results of this study show that various foods provide a great
source of miRNAs, which remains stable despite processing. We further demon-
strate that minor short-term changes in diet do not impact on the miRNA
expression pattern in feces and blood supporting its value as biomarkers. A
functional role of diet-induced increase in plant-derived miRNA expression
needs further evaluation.
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Introduction: The gut and brain peptide neuromedin U (NMU) is reported to
decrease food intake and body weight, and to improve oral glucose tolerance
suggesting that NMU could exert an incretin effect. NMU is thus considered as a
promising candidate for the treatment of obesity and diabetes. However, and in
contradiction with previous observations, NMU was recently presented as a
‘‘decretin’’ hormone able to decrease insulin secretion. The pathways through
which NMU controls glycemia are thus uncertain and we sought to clarify some
of NMU mechanisms of action on glucose homeostasis.
Aims & Methods: Oral (OGTT) and intraperitoneal (IPGTT) glucose tolerance
tests were performed after an intraperitoneal injection of NMU or PBS in C57Bl6
mice that underwent a laparotomy or a troncular subdiaphragmatic vagotomy.
During OGTT, blood was sampled to measure insulin secretion. [14]-C-glucose
uptake was assessed in isolated intestinal loops in presence or absence of NMU.
Gastric retention of a phenol red gavage and total intestinal transit time were
evaluated after an intraperitoneal injection of NMU or PBS. Activation of vagus
nerve neurons by intraperitoneal injection of NMU was assessed by cFos immu-
nostaining on brainstem slides going through the nucleus of the solitary tract
(NTS) and the dorsal nucleus of the vagus (DMV). Direct impact of NMU on
pyloric contraction was assessed ex vivo in isometric chambers.
Results: A single intraperitoneal injection of NMU in C57Bl6 mice prevented the
rise of glycemia following an oral but not an intraperitoneal load of glucose
(OGTT versus IPGTT). Unexpectedly, during the OGTT, NMU injection pre-
vented insulin secretion and only slightly improved peripheral insulin sensitivity.
Furthermore intestinal [14]-C-glucose uptake in isolated intestinal loops was
barely reduced by NMU addition (17% P5 0.05 vs PBS). Actually NMU
injection blocked gastric emptying (gastric retention of a phenol red gavage at
30min:þ 285% P5 0.0001 vs PBS). This effect was partly prevented in vagoto-
mized mice. In addition, injection of NMU induced c-fos expression in the
nucleus of the solitary tract (NTS) of control but not vagotomized mice. In
isotonic chambers, NMU directly induced pyloric contraction in a dose depen-
dent manner (basal contraction þ21, 7% at 10–6 M).
Conclusion: These data demonstrate that a single intraperitoneal injection of
NMU blocks gastric emptying directly by inducing pylorus contraction and
indirectly via afferent vagal fiber activation. Through the blockade of gastric
emptying, NMU reduces intestinal nutrient absorption and thus improves oral
glucose tolerance. The gastric emptying blockade induced by NmU could also
contribute to its anorexigenic effect.
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Introduction: Dietary restriction of fermentable carbohydrates (low FODMAP
diet, LFD) is effective at managing symptoms in 50–80 percent of patients with
irritable bowel syndrome (IBS). Prebiotic B-galacto-oligosaccharide (B-GOS;
HOST-G904) also reduce symptoms in IBS however the combination of the
two therapies has not previously been investigated. What differentiates those
who respond to the LFD from those who do not is unclear.
Aims & Methods: This randomised controlled trial aimed to investigate whether:
1) addition of prebiotic B-GOS could improve symptoms of IBS alongside the
LFD; and 2) if urinary metabolites, faecal short-chain fatty acids (SCFA) or
volatile organic compounds (VOC) could identify factors at baseline that predict
response. Sixty-nine adults fulfilling Rome criteria for IBS were recruited to a 3-
arm RCT: control (sham diet/placebo), LFD (LFD/placebo) or LFD plus B-
GOS (LFD/B-GOS) for four weeks. Validated questionnaires (Global symptom
question and gastrointestinal symptom rating scale) assessed GI symptoms
(response) and urine and stool samples were collected for analysis at baseline
and week 4. To examine the relationship between responders and non-respon-
ders, urine metabolomics (700 MHz 1H-NMR), stool SCFA (gas liquid chroma-
tography (GLC)) and stool VOC (GC-mass spectrometry) were analysed on
samples at baseline and 4-weeks. Urine metabolomics spectra and VOC profiles
were analysed using unsupervised principal component analysis (PCA) and
supervised pattern recognition methods (orthogonal partial least square discri-
minant analysis (OPLS-DA)) or PLS-DA respectively. Stool SCFA were com-
pared using t-tests, models of prediction were tested using receiver operator
characteristic (ROC) curves.
Results: There was a significant difference in response rates (adequate relief)
between control (30%), LFD (50%) and LFD/B-GOS (67%) (p¼ .046), with
post-hoc differences specifically between control and LFD/B-GOS (p¼ 0.015).
Individual IBS symptoms were more markedly improved in the LFD/B-GOS
group compared to control. In the LFD group only, there was a significant
difference in the urine metabolome between responders and non-responders at
both baseline (Q2¼ 0.296 vs randomised 0.175) and at 4-weeks (Q2¼ 0.485 vs
randomised 0.203). At baseline, there were significant greater stool isobutyrate
between responders (51.4mg/100g) and non-responders (31.9mg/100g, p¼ 0.04),
with ROC curves supporting this as a predictor of response (AUC¼ 0.747,
p¼ 0.063). Finally, there was a significant difference in VOC profiles between
responders and non-responders to the LFD at baseline (p¼ 0.04). VOC profiles,
modelled by PLS-DA, reveal significant separation of VOC profiles across the
three treatment groups at 4-weeks (p¼ 0.02).
Conclusion: Addition of B-GOS to the LFD improves symptoms in IBS. Urine
metabolomics, stool SCFA and VOC profiling are relatively low-cost and non-
invasive techniques that may predict response to the LFD as well as helping to
further understand the underlying mechanisms. Prospective clinical trials to test
these algorithms are warranted and may lead to personalised therapy for patients
with IBS.
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Introduction: Small intestinal bacterial overgrowth (SIBO) is common in patients
with gastrointestinal diseases. SIBO symptoms are improved with antimicrobial
treatment, but recurrence rate is high (approximately 40% for 9 months). Dietary
modification is essential for prevention of recurrence of SIBO however there are
no detailed studies of nutrition in SIBO patients. Protein consumption is con-
sidered important for SIBO, as the proteins from animal source are essential for
growth of CH4/H2-producing microorganisms.
Aims & Methods: The aim of the study was to assess the protein consumption
patterns in patients with different types of SIBO. Three-day food diary was
collected from 574 patients, undergoing CH4/H2 lactulose breath test. The
photographs used to estimate the size of the portions eaten. According to food
composition and portion all dishes in food diary were converted into constituent
products by food groups. Each food group were compared with the normal levels
of a healthy diet pyramid based on daily calories (normal value¼ 1.0). According
to the breath test results the patients were divided into 4 subgroups of different
SIBO types (H2, CH4, H2 and CH4) and a subgroup with no signs of SIBO
(Table 1).
Results: All types SIBO patients consumed less meat than control (no signs of
SIBO), however patients with hyperproduction of CH4 only demonstrated high-
est consumption of fish, and it was a trend in patients with isolated H2-hyper-
production to consume more poultry than other groups. There were no
differences between groups in consumption of processed meat foods or eggs.
Conclusion: There are specific animal protein consumption patterns related to the
type of the SIBO, which can be used for the planning of dietetic interventions in
patients for prevention of SIBO recurrence
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Patients suffering from chronic radiation-induced small bowel dis-
ease (RISBD) after cancer treatment have similar symptoms as patients with IBS
(irritable bowel syndrome), despite dissimilar pathological origin. RISBD is a
common late effect after pelvic radiation therapy for gastrointestinal (GI), gyne-
cological and urological cancer. The delayed development of ischemia, fibrosis,
dysmotility and malabsorbtion in GI tissue, leads to IBS-like symptoms like
abdominal pain, diarrhea, constipation and bloating. The low FODMAP (fer-
mentable oligo-, di-, monosaccharides and polyols) diet (LFD) is a widespread
management strategy for IBS. The aim of the conducted study was to investigate
the effects of LFD on symptoms and health related quality of life (HRQOL) for
patients with chronic RISBD.
Aims & Methods: In an open pilot study, 11 patients (mean age 46 years) with
RISBD related IBS symptoms were instructed to follow LFD throughout a 4-
week intervention period. IBS Severity Scoring System (IBS-SSS) and IBS
Symptom Questionnaire (IBS-SQ) were used to assess symptoms. An Ad hoc
questionnaire measured grade of tissue damage and typical RISBD complaints
(fecal incontinence, rectal mucus and rectal bleeding). Short Form Nepean
Dyspepsia Index (SF-NDI) and 12-item Short Form Health Survey (SF-12)
were used to evaluate HRQOL. A 3-day food record was used to estimate base-
line intake of FODMAPs, to reveal dietary changes and to assess adherence to
the diet. All schemes were completed at baseline and at 4 weeks. The study
included no control group.
Results: FODMAP intake was successfully reduced, and main additional changes
in the diet were reduced intake of energy, carbohydrates and fiber. The adherence
to the diet was high (mean 94.8%). IBS symptoms improved significantly based
on mean total score of IBS-SSS and IBS-SQ, which changed from 310.2 60.7 to
171.4 107.2 (p¼ 0.001) and 27.4 4.1 to 15.7 10.1 (p¼ 0.002), respectively.
The severity of abdominal pain, abdominal distension, belching/flatulence, con-
stipation, diarrhea, early satiety, dissatisfaction with bowel habits and interfer-
ence with life in general, improved significantly. Tendencies of improvement were
also measured in comorbidity complaints (nausea, headache, backache, fatigue
and muscle pain) and typical RISBD complaints. HRQOL improved based on
SF-NDI total score, which changed from 30.5 9.4 to 18.3 8.2 (p¼ 0.001) and
based on mental (p¼ 0.047) and physical (p¼ 0.134) component summary score
of SF-12.
Conclusion: The low FODMAP diet seems effective in alleviating IBS symptoms,
and improving HRQOL in patients with RISBD. High compliance to LFD is
possible with adequate diet counseling and continuous guidance. Further con-
trolled studies with larger sample size should be conducted to verify our results
and hopefully enable the implementation of LFD as a future management strat-
egy for chronic RISBD.
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Introduction: Dietary interventions are gaining popularity in terms of alleviating
symptoms experienced by patients with functional GI disorders (FGID), espe-
cially with irritable bowel syndrome (IBS). Available strategies rely on low intake
of foods high in short-chained carbohydrates, dairy products, wheat, spices etc.
Although some studies indicate increased rectal sensitivity after duodenal lipid
administration in patients with IBS and suggest delayed transit after high fat
intake, the effects of dietary supplementation with different types of fatty acids in
IBS have not been explored so far.
Aims & Methods: The aim of the study was to evaluate the differences in GI
motor function and visceral sensitivity in rats exposed to diet supplemented with
either medium-chain- (MCFA) or long-chain fatty acids (LCFA). Male Wistar
rats were fed with control diet (A), and diet supplemented with 3.5 % coconut oil
(B) (abundant with MCFA) or 3.5 % evening primrose oil (C) (abundant with
LCFAs) for 4 weeks. The effects of each diet on GI motility were measured
radiographically after contrast administration (p.o; X rays were taken 0–8 h
before and after feeding, on day 0 and day 28, respectively), and by performing
the colon bead expulsion test. Temporal changes in the size of the stomach and
caecum of each rat were analyzed based on digitalized X-rays, using an image
processor. Visceral sensitivity was assessed with abdominal withdrawal reflex to
colorectal distension. Body weight gain and food/water ingestion were measured
throughout the experiment.
Results: Diet supplementation in neither group B nor group C affected the GI
motor function in comparison to control group (A). The number of contractions
and the mean time of each contraction in response to colorectal distension mea-
sured during each 5min for 40min were higher in the control group (A), when
compared to either B or C groups but the differences were not statistically sig-
nificant. No changes in morphometric measurements of stomach and caecum, the
body weight gain or food/water consumption were found.
Conclusion: Diets differing in MCFAs or LCFAs contents did not induce marked
effects on GI motility and visceral pain in rats. Available data and the results
obtained herein suggest that the amount of FAs intake, rather than the types of
FAs may provoke IBS symptoms.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Glucagon and insulin are pancreatic peptides essential for the con-
trol of glucose homeostasis. Pancreatectomy in human leads to a loss of plasma
insulin while glucagon is still detectable, suggesting the existence of an extra-
pancreatic source of glucagon. More specifically, in pancreatectomized patients,
glucagon secretion is increased when glucose is administered orally, a release that
Abstract No: P0630
Table 1: Consumption of protein products in SIBO patients.
Food
No SIBO
n¼ 65
M2 SIBO (420ook)
n¼ 312
CH4 SIBO (412 ppm)
n¼ 77
H2/CH4 SIBO
n¼ 123 Significance
Meat 0.58 0.71 0.37 0.58 0.42 0.67 0.31 0.45 p¼ 0.015 no SIBO vs M2 SIBO;
p¼ 0.017 no SIBO vs M2/
QM4 SIBO; p¼ 0.059 no
SIBO vs QM4 SIBO
Poultry 0.38 0.49 0.52 0.63 0.41 0.50 0.39 0.48 p¼ 0.074 M2 SIBO vs M2/QM4
SIBO
Eggs 0.11 0.19 0.14 0.22 0.13 0.21 0.10 0.17 NS
Fish 0.27 0.37 0.22 0.43 0.56 0.75 0.33 0.77 p¼ 0.001 QM4 SIBO vs M2
SIBO; p¼ 0.004 QM4 SIBO
vs M2/QM4 SIBO p¼ 0.024
QM4 SIBO vs No SIBO
Processed meat pro-
ducts (sausages, etc)
0.08 0.11 0.12 0.14 0.07 0.11 0.08 0.12 NS
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is similar to the oral glucose-stimulated secretion of glucagon-like peptide 1
(GLP-1). GLP-1 is an incretin hormone secreted by enteroendocrine L cells
(EEC) from the distal gut. GLP-1 and glucagon, both originate from the same
proglucagon precursor, differentially processed by prohormone convertase 2
(PC2) into glucagon in pancreatic  cells and by prohormone convertase 1/3
(PC1/3) into GLP-1 in EEC.
Aims & Methods: We hypothesized that, after pancreatectomy, proglucagon can
also be processed into glucagon in EEC. We developed a 75% subtotal pancrea-
tectomy model in C57Bl6 mice. Control (Ct) mice underwent a laparotomy. Post-
surgery, blood glucose levels were measured daily and oral glucose tolerance tests
(OGTT) were performed after 1 week. Insulinemia and glucagonemia were also
measured in fed and fasted mice and during OGTT. After 2 weeks, animals were
sacrificed and the remnant pancreas was sampled for glucagon and insulin immu-
nostaining and for alpha- versus beta-cell mass quantification. Proximal and
distal intestinal segments were sampled for morphometric analyses as well as
measurement of proconvertase and proglucagon mRNA levels. Colonic segments
were incubated in a glucose-enriched medium for one hour and glucose-induced
secretions of glucagon and GLP-1 were measured in the supernatant.
Results: As soon as one day post-surgery, pancreatectomized (Px) mice developed
a hyperglycemia that maintained for over a week (351mg/dl in Px mice vs
140mg/dl in Ct mice, P5 0.05, 5 days post-surgery). This hyperglycemic state
was accompanied by an oral glucose intolerance (area under the curve þ278% in
Px mice, P5 0.01 vs Ct mice, 1 week post-surgery). During, OGTT, intestinal
glucose absorption increased (slope between 0 and 15minþ 69.9% in Px mice
P5 0.01 vs Ct mice, 1 week post-surgery). Glucagonemia increased in fasted
pancreatectomized mice (þ146.6% in Px mice P5 0.01 vs Ct mice 1 week
post-surgery). After sacrifice, alpha cell mass was decreased in the remaining
pancreas (79.25% in Px mice P5 0.05 vs Ct mice, 2 weeks post-surgery).
However an increased ability of the proximal colon to secrete glucagon ex vivo
was observed (þ290.6% in Px mice P5 0.05 vs Ct mice, 2 weeks post-surgery). In
pancreatectomized mice, an hypertrophy of the duodenum was associated with
an increase in crypt depth (þ77.7%, in Px mice P5 0.05 vs control mice, 2 weeks
post-surgery) and villus height (þ53.8% in Px mice P5 0.05 vs control mice, 2
weeks post-surgery).
Conclusion: These data establish an ability of the whole gut to adapt in response
to pancreatectomy. The upper intestine (duodenum) become hyperplasic and
may contribute to the increased intestinal capacity to absorb glucose. The
distal intestine (colon) is able to produce glucagon and may participate to the
development of the reported hyperglucagonemia.
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Introduction: A probiotic formula to be functional and reliable should: i) contain
viable cells, ii) have a reproducible composition, iii) to be taxonomically defined.
Here we detail the consistency of the multispecies probiotic product VSL#3,
which has been produced for the last 20 years and is marketed globally for
threating Inflammatory Bowel Disease, Pouchitis and other intestinal diseases
(Mimura et al 2004; Reiff et al., 2009).
Aims & Methods: To show consistency in the quality, viability and composition
of the multispecies probiotic product VSL#3 various batches of the multispecies
probiotic VSL#3 were analyzed in detail and derived from productions in the
USA and Italy. The product batches have been tested using a series of micro-
biological, phylogenetic and genomic methods. The microbiological analysis
included plating on selective media, cell counting and viability analysis by
Flow Cytometry (FCM) using fluorescent dyes that allowed high throughput
separation and quantification of live, dead and damaged cells (ISO 19344 IDF
232, 2015). A metagenetic approach, based on 16S rRNA gene profiling, was
used to define the bacterial community structure of different productions
batches. In addition, Lactobacillus helveticus and L. acidophilus S-layer proteins,
which are known to exert anti-inflammatory effects by reducing the activation of
NF-B on the intestinal epithelial Caco-2 cell line, have been extracted and
visualized on SDS-PAGE (Konstantinov et al., 2009; Taverniti et al., 2013).
Moreover, urease activity of Streptococcus thermophilus, known to exert positive
effect human health by competing with the undesired urease-positive bacteria of
the human microbiota (Mora and Arioli, 2014), was quantified using a spectro-
photometric-, and flow cytometry-based assay.
Results: The different test batches were all found to contain a common bacterial
community structure based on the presence of the following species Streptococcus
thermophilus, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus
plantarum, Lactobacillus helveticus, Bifidobacterium breve and B. animalissubsp.
lactis. The stability of the batches was confirmed by FCM and viable cells were
always above the value of 2 1010 event/g. The Lactobacillu helveticus and L.
acidophilus S-layer protein SlpA was detected in each VSL#3 batches tested thus
highlighting that this relevant immunomodulatory factor was not subjected to
degradation during the shelf-life of the product. Likewise, urease activity of S.
thermophilus was stable in all VSL#3 batches along the shelf-life.
Conclusion: In conclusion, stability, molecular and taxonomic comparative ana-
lysis shows that VSL#3 is reliably and reproducibly produced in different parts of
the world.
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Introduction: Soybean oil intravenous lipid emulsion (IVLE) is also known as
conventional lipid is rich in linoleic acid (!-6 PUFA). !-6 PUFA may exaggerate
inflammatory response and indirectly detrimental in the critically ill patients1, 2.
To overcome this, the use of alternative IVLEs such as medium chain triglycer-
ides (MCT), fish oil and olive oil alone or in combination with soybean oil IVLE
have been used to lower the content of !-6 PUFA. Most studies on alternative
IVLEs have been conducted in the critically ill patients, elective surgical patients
and cancer patients. No previous studies have evaluated the clinical outcomes of
several different IVLEs in non-critically ill patients in acute hospital setting.
Aims & Methods: The purpose of this study is to determine whether there is a
difference in clinical outcome amongst patient who received conventional soy-
bean oil IVLE versus alternative IVLEs in non-critically ill patients in acute
hospital setting. All patients on parenteral nutrition (PN) were identified in a
prospective compilation database from July 2007 to September 2010 and were
analysed retrospectively. Patients were analysed based on the IVLE received,
namely soybean oil based (Lipofundin-N 20%, type 1), MCT oil based
(Lipofundin MCT/LCT 20%, type 2), olive oil based (ClinOleic, type 3) and
fish oil containing (Lipidem, type 4). Patients must receive PN for at least 5
days in general ward or high dependency unit not requiring invasive/non-invasive
ventilator support or inotropes support. Exclusion criteria included patients who
received less than 5 days of PN, intensive care unit (ICU) patients, PN started in
ICU and continue in general ward or HDU, PN restarted in less than 3 days after
receiving PN in ICU, patient on invasive/non-invasive ventilator support or
inotropes support and home PN patients.
Results: 537 patients were started on PN and 388 patients were included in the
study. 90 patients were on type 1 (soybean based) IVLE, 60 patients were on type
2 (MCT based) IVLE, 141 patients were on type 3 (olive oil based) IVLE and 97
patients were on type 4 (contain fish oil) IVLE. Baseline characteristic were
similar in four groups of IVLEs. Majority of PN were initiated in patients
admitted under surgical team. There were no difference in terms of mortality,
readmission and infection rate between conventional and alternative IVLE as a
group, odd ratio (OR) was 0.66 (CI 0.36–1.24; p¼ 0.16), 1.71 (CI 0.84–3.73;
p¼ 0.15) and 0.90 (CI 0.55–1.49; p¼ 0.73) respectively (as shown in table 1).
The length of stay in log-scale was significantly lower in alternative IVFE as a
group (p¼ 0.03). There were no difference in terms of mortality, readmission and
infection rate between conventional IVLE versus each of the alternative IVLE.
Length of stay was only statistically significantly lower for olive oil based IVLE
(Type 3) when compared to conventional IVLE (p¼ 0.05).
Table 1: Clinical outcomes with conventional IVLE versus alternative IVLE as a
group
Conventional
Alternative
(As a group) OR (95% CI) P Value
Mortality Yes (N) No (N) 21 70 49 248 0.66 (0.36–1.24) 0.16
Readmission Yes (N) No (N) 12 58 65 183 1.71 (0.84–3.73) 0.15
Infection Yes (N) No (N) 41 50 126 171 0.90 (0.55–1.49) 0.72
Length of stay (Mean (SD)
in log-scale)
3.58 (0.59) 3.43 (0.57) 0.03
Conclusion: Length of stay was significantly lower in alternative IVLE compared
with conventional IVLE. However, there were no clinical difference in terms of
mortality, readmission and infection between conventional and alternative IVLE
in non critically ill patients.
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Introduction: Percutaneous endoscopic gastrostomy (PEG) is currently the
method of choice for medium- and long-term enteral feeding and is nowadays
one of the most common endoscopic procedures performed worldwide. To date,
data on complications and mortality rates are generally retrospective and only
few prospective studies have been published on small number of patients.
Aims & Methods: We aimed to prospectively evaluate the complication rates and
the mortality of patients after PEG insertion or PEG replacement. This is a
multicenter prospective cohort study. Between 15th September 2015 and 15th
September 2016, all patients that underwent PEG insertion or replacement, were
included. Details about patient’s characteristics, ongoing therapies, comorbid-
ities, indication for PEG placement/replacement, informed consent form signa-
ture were collected. Early and late (30 days) complications and mortality were
assessed.
Results: 912 patients (426 [46.7%] male) were enrolled in 34 centers. Patients
mean age was 72y (SD16.01, range 18–99). ASA status was 1 in 4.0%, 2 in
23.4%, 3 in 58.4%, 4 in 14.1%. PEG 1st placement was performed in 582
(64%) patients. Indications were: dysphagia for cerebrovascular diseases in
33.3%, degenerative neurological illness in 21.3%, dementia in 14.6%, head
and neck cancer in 14.4%, management of patient after the discharge in 8.9%,
nutritional support in oncological patients in 3.4%, medication administration in
1.5%, gastric decompression in 0.2%. The informed consent form was signed by
a relative (without legal guardianship) in 49.6%, patient in 28, 2%, legal guar-
dian in 16%, medical director in 6, 2% of patients. The majority of patients
(63.2%) had antiplatelet and/or anticoagulant concomitant therapy.
Anesthetist was present in 47.7% of procedures and sedoanalgesia was the
more common modality for sedation (69.8%). The complication and mortality
rate were 4.6% and 7.8%, respectively. The most frequent complication was
infection (2.4%), followed by bleeding (1.4%), tube dislodgment (0.4%),
buried bumper syndrome (0.2%). PEG replacement was carried out in 330
(36%) patients. The indications for PEG replacement were obstruction/mal-
function/deterioration of the tube in 52.9%, tube dislodgment in 26.4%.
Endoscopic procedure was necessary in 9.7% of cases. The informed consent
was signed by relative (without legal guardianship) in 66.3%, patient in
10.5%, legal guardian in 16.25%, medical director in 7% of patients.
Thirty-days mortality was 2.4%.
Conclusion: Our data confirm that PEG placement is a safe procedure with a
mortality rate at 30 days of 8%. To our knowledge this is the largest prospective
study on the use of PEG. Surprisingly in more than 50% of patients the consent
form was not properly signed, leading to possible medico-legal consequences.
Moreover, in 9% of the cases PEG was placed for an early discharge (more
than for real clinical indication).
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Introduction:Nasogastric tube (NG) feeding is an essential part of in-patient care.
Tubes can be placed at the bedside with no need for specific equipment or
sedation. However placement of NG tubes is not without risk and avoiding
the introduction of substances into the respiratory tract through a misplaced
NG tube was highlighted as a UK National Patient Safety Agency alert in
2005. In 2011 the NPSA made this a ‘never event’. The only acceptable methods
of checking the position of an NG tube are: pH5 5.5 on aspirate or confirmation
on chest x-ray (CXR) by competent medical staff. Reporting a CXR for NG tube
position is a frequent request particularly for junior doctors out of hours.
Practise vaires across the UK - some trusts require NG checking to be done
only by senior clinicians (medical registrars or consultants) and some only
allow reporting by a consultant radiologist. We assessed documentation of NG
position on CXR by medical registrars from the region to find out if documenta-
tion was adequate, as would be expected of senior clinicians. NPSA guidance
suggests four points should be documented in the medical notes to confirm NG
position: 1. Does the tube follow the contours of the oesophagus and avoid those
of the bronchi? 2. Does the tube clearly bisect the carina or the bronchi? 3. Does
it cross the diaphragm in the midline? 4. Is the tip clearly visible below the left
hemi-diaphragm? All four criteria were met in only 17.6% of repsonses and
answers were considered incorrect in 20.5%. An aide-memoir sticker with an
abbreviated version of the above four points, time, date, doctor signature and
whether tube is safe to use or not with Yes/No answers, is used on some wards in
Southampton and we assessed whether its use would improve quality of reporting
both a correctly placed and misplaced NG tube.
Aims & Methods: Medical registrars from first to final year of specialist training
and from various specialties were presented with a CXR showing a correctly sited
NG tube and were asked to complete a sticker answering yes or no, to check
position and whether it was safe to use. Following this they were presented with a
CXR showing an incorrectly sited NG tube and asked to use the sticker to assess
position. The CXR was projected and anonymous responses collected after suffi-
cient time for the group to complete both stickers.
Results: 31 complete responses were obtained for the correctly sited tube with
58% stating that it should be used and 42% that they would not use the tube
without further review. 10 incomplete responses were obtained and therefore
86% of responses met NPSA guidance for reporting CXR for NG position. 28
complete responses were obtained for the incorrectly sited tube and 100% stated
that the tube should not be used.
Conclusion: Use of the sticker increased compliance with NPSA guidance for
CXR reporting for NG tube position from 17.6% to 86%. The misplaced tube
was correctly reported and not used in 100% of responses. The correctly sited
tube was reported as safe to use in 58%. The CXR used was of an anonymous
real patient and was slightly rotated to reflect a real-life scenario which meant the
tube was slightly off the midline. In this real-life scenario some trainees would be
happy to make a judgement considering these factors and others may be cautious
and follow the sticker statements exactly prompting further review by radiology
or removal of the tube. Overall this increases patient safety and avoids use of a
misplaced tube in accordance with UK guidance. We intend to roll out use of the
sticker on all wards which use NG tubes to rapidly improve documentation and
patient safety. The other option we may consider is developing a pathway for
radiology consultants to report all these CXRs before the NG tube is used;
however, this is likely to take considerable time and is unlikely to be available
out of hours.
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Introduction: Intestinal failure patients by definition have reduced ability to
absorb fluid and macronutrients through the gastrointestinal tract. Type two
intestinal failure patients require months of intravenous nutrition (parenteral
nutrition) for weeks or months either in hospital or at home. Type three intestinal
failure patients generally require long-term parenteral nutrition (PN), which is
given at home (HPN) and may be life-long. In addition to a reduction in the
ability to absorb macronutrients, patients on long-term PN have a reduction in
absorption of micronutrients (copper, zinc, selenium and manganese) and vita-
mins (A, B12, D and E) which are required for metabolism and enzymatic reac-
tions at a cellular level. PN is routinely supplemented with micronutrients and
should be sufficient. Toxicity can occur at high levels and deficiency can cause a
variety of symptoms. ESPEN guidelines recommend that serum vitamin and
trace element levels be checked at baseline and at least once per year. NICE
guidelines specify more frequent monitoring for in-patients and that selenium;
manganese and vitamin D should be checked three to six monthly in HPN
patients. Some trace elements (copper and zinc in particular) are affected by
acute illness. Current local practise is to avoid checking levels until there is
evidence that inflammation or infection has resolved.
Aims & Methods: Our aim was to audit the frequency of micronutrient screening
in our cohort of HPN patients. All type two and three intestinal failure out-
patients were included. Current in-patients were excluded due to the effect of
acute illness on micronutrient levels. Patients on parenteral fluid rather than
nutrition were excluded as current guidelines give recommendations for HPN
patients and do not specify recommendations if fluid alone is required. A
search of the blood results system was performed for all micronutrient results
from one full year to the date of the search. Results were recorded in spreadsheet
format and analysed. Many patients live out of the region; however, many local
trusts do not have the laboratory facilities to check micronutrient levels so they
tend to be done in Southampton. If no results were avaiable on the Southampton
system then the local hospital was contacted for local results if available.
Results: 57 home parenteral nutrition patients were identified. 51 (89.5%) of
these patients had micronutrients checked at some point during their care. 44
of 49 (89.7%) had micronutrients checked within one year (two of the 51 had
only recently so did not have results within a year). 32 (61.5%) of those who had
micronutrients checked had them done within the last six months. 6 patients had
never had micronutrients checked. One had them requested just prior to the time
of audit but results were not yet available. Two were out of area and had not
been to clinic within the past year. One of these commenced PN in 2015 and
found it difficult to attend clinic. The other had not been seen in clinic due to an
administrative error and has now been seen with micronutrients requested. Two
further patients had never had micronutrients checked due to a persistently raised
CRP.
Conclusion: Despite a lack of clarity between guidelines about the frequency of
monitoring of micronutrients, it is recommended that HPN patients receiving
long-term intravenous nutrition should have regular monitoring to reduce risk of
deficiency or toxicity. The majority of our cohort of HPN patients had micro-
nutrients checked annually and over half were checked six monthly. This is
compliant with ESPEN guidelines; however, we need to aim for 100%. We
have introduced a template to use in clinic to trigger review of results and request
micronutrients when required. Alongside this we have introduced a virtual ward
round to remotely review all out-patients regularly and plan ahead to request
blood tests when required. Following the introduction of these measures we will
repeat the audit to find out if the situation has improved.
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Introduction: Early recognition and delivery of nutritional care by physicians has
been shown to improve outcomes in malnourished hospitalized patients.
However, physicians encounter multiple barriers in providing appropriate nutri-
tional care. While comprehensive international guidelines and nutritional train-
ing in medical education have been introduced to overcome these barriers, there
appears to be a discrepancy in practice amongst physicians despite the availabil-
ity of these resources.
Aims & Methods: We aim to assess the knowledge and attitudes of physicians
towards clinical nutrition in a large tertiary teaching hospital in Singapore. An
anonymous questionnaire comprising 15 multiple-choice questions from stan-
dard nutrition textbooks was administered. The questionnaire was designed to
assess (a) recognition of nutritional needs of hospitalized patients, (b) knowledge
on principles of clinical nutrition, and (c) application of nutritional intervention
in common clinical practice. We included consultants, fellows and residents
working in units where nutritional problems were common. Finally, we con-
ducted a separate 5-question opinion survey to assess each participant’s nutri-
tional training and exposure, based on a 5- point Likert scale ranging from
‘‘strongly agree’’ to strongly disagree’’.
Results: A total of 305 physicians volunteered to participate in this study. Forty
(13%) did not reveal their specialty or staff grade and were excluded from ana-
lysis. The remaining 265 responders comprised 77 (29%) consultants, 58 (22%)
fellows, and 130 (49%) residents. Amongst them, 232 (87%) were from medical
disciplines and 33 (13%) from surgical disciplines. The median aggregate score
(out of a maximum score of 15) obtained by consultants, fellows and residents
was 6.0 2.2 (range 2–12), 7.0 1.8 (range 3–11), and 7.0 1.8 (range 1–10)
respectively. All 3 grades of physicians achieved less than 50% of the maximum
possible score. No significant difference in median aggregate score was observed
between physicians from medical disciplines (6.5 1.9) and those from surgical
disciplines (7.0 1.8). However, gastroenterologists performed significantly
better than non-gastroenterologists (median aggregate score 9.0 2.2 vs
6.0 1.8, p5 0.001). In the opinion survey, a majority of physicians (63%)
believed that nutrition-related teaching was inadequate during residency training
and 44% felt that clinical nutrition was accorded insufficient attention during
ward rounds. Only 33% of responders reported that they performed nutritional
screening on admission, and a mere 10% were confident in providing nutrition
counselling to malnourished patients. Interestingly, their overall performance
was not different from that of other participants (see Table 1).
Table 1: Median aggregate scores by grade, specialty and response in opinion
survey
Median
aggregate
score SD Range P value
Physician Grade
Consultants (n¼ 77) 6.0 2.2 2.0–12.0 0.617
Fellows (n¼ 58) 7.0 1.8 3.0–11.0
Residents (n¼ 130) 7.0 1.8 1.0–11.0
Specialty
Medical disciplines (n¼ 232) 6.5 1.9 1.0–12.0 0.193
Surgical disciplines (n¼ 33) 7.0 1.8 2.0–10.0
Gastroenterologists (n¼ 25) 9.0 2.2 3.0–12.0 50.001
Non-gastroenterologists (n¼ 240) 6.0 1.8 1.0–11.0
Performed nutrition screening on admission
Agreed (n¼ 81) 7.0 2.0 1.0–12.0 0.321
Disagreed (n¼ 99) 7.0 2.2 2.0–11.0
Confident in providing nutrition counselling
Agreed (n¼ 23) 7.0 2.0 3.0–10.0 0.467
Disagreed (n¼ 137) 7.0 2.0 2.0–11.0
Conclusion: Our study highlights that knowledge on nutrition and its clinical
application to hospitalized patients remains inadequate across all physician
grades, especially amongst non-gastroenterologists. The current state of clinical
nutrition-related teaching during residency training falls short of achieving its
goals, and may need re-examination.
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Introduction: Per-oral endoscopic myotomy (POEM) is a novel treatment mod-
ality for achalasia cardia (AC). The studies are limited in paediatric population.
Aims & Methods: In this study our aim was to analyse the feasibility, safety and
efficacy of per-oral endoscopic myotomy in children We retrospectively evalu-
ated the data of all children (18 years) who underwent POEM at our institution
from September 2013 to February 2017. All POEM procedures were performed
under general anaesthesia in an endoscopy suit. Technical feasibility, safety and
efficacy were analysed. Clinical success was defined as Eckardt score  3.
Objective parameters including-timed barium swallow and high resolution mano-
metry were assessed and compared before and after POEM.
Results: Thirty children (15-boys, 15-girls) with mean age of 14.1 3.32 (4–18)
years, underwent POEM during the specified period. The sub-types of AC were-
type I (8), type II (19) and type III (1). Eight children had prior treatment with
pneumatic balloon dilatation. POEM was successfully performed in all children.
Anterior myotomy was performed in majority of children 23 (76.7%). Mean total
length of myotomy was 10.9 2.25 cm, with 7.9 2.09 cm on esophageal and
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3.03 0.67 cm on gastric side. Mean operating time was 76.7 45.5 (30–240)
minutes. Mild gas related adverse events requiring temporary discontinuation
of procedure and or drainage procedure were encountered in eight (26.7%) chil-
dren (capno-peritoneum-4 and retro-peritoneal carbon dioxide -4). There was
significant reduction in mean LES pressure after POEM (36.25 16.5 vs
11.47 5.06, p¼ 0.0001). Significant improvement of esophageal emptying on
timed barium esophagogram (450%) was documented in 94.4% children. At
median follow up of 504 days (30–1290) clinical success was noticed in 29 chil-
dren (96.7%). Mean Eckardt score before and after POEM were 6.8 1.63 and
0.86 0.77, respectively (p¼ 0.0001). Gastroscopy revealed erosive gastroeso-
phageal reflux in five children at 1 year (27.8%).
Conclusion: Conclusion-POEM is safe and effective for children with achalasia
cardia. POEM can be safely performed in an endoscopy suit in paediatric
patients.
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Introduction: Because of high prevalence of gastric malignancies in the adult
population, high Helicobacter pylori (Hp) prevalence in Armenia is suspected.
Rising antibiotic resistance of Hp both in children and adults lead to decrease of
effectiveness of standard eradication therapy [1, 2]. The aim of this study is to
determine frequency of Hp antibiotic resistance in Armenian children.
Aims & Methods: 47 children with suspected gastroduodenal disease (GDD),
hospitalized in Arabkir MC, were selected from April to December 2016 (23
boys and 24 girls, average age 8.98 4.10). Hp-associated GDD were diagnosed
according to clinical, endoscopic and histological criteria. Antral biopsy was
cultured on 5% sheep blood Columbia agar and selective Hp media. Antibiotic
susceptibility test was done by disk diffusion method.
Results: Hp-associated GDD was diagnosed in 40 patients out of 47: 37 (92.5%)
had gastritis and/or duodenitis, 3 (7.5%) had peptic ulcer disease (PUD). Seven
out of 47 children were excluded from the study due to both histology and culture
negative for Hp. Thirty-four (85%) were treatment-naı̈ve patients and 6 (15%)
had received eradication therapy previously. Main clinical symptoms were recur-
rent epigastric pain 34 (85%), nausea 28 (70%) and vomiting 13 (32.5%). By
endoscopy erosive gastritis and/or duodenitis was seen in 18 (45%), non-erosive
gastritis in 16 (40%), PUD in 3 (7.5%), normal mucosa in 3 (7.5%). Rapid urease
test was positive in all antral biopsies (100%). Histology showed chronic gastritis
and/or duodenitis in 28 (70%), atrophic gastritis in 5 (12.5%), gastric glandular
dysplasia in 2 (5%), gastric metaplasia of duodenal mucosa in 3 (7.5%), normal
mucosa in 2 (5%). Hp was positive in 38 (95%) and negative in 2 (5%). Cultures
were positive for Hp in 14 of 40 patients (35%). Susceptibility test was possible in
12 Hp strains from available14: all but to 2 were resistant to metronidazole
(83.3%), 4 to clarithromycin (33.3%), 3 double resistant to both metronidazole
and clarithromycin (25%), and 66.6% to doxycycline. All strains were susceptible
to amoxicillin and levofloxacine (100%), 6 strains were tested and found suscep-
tible to nifuratel.
Conclusion: These data indicate a high rate of resistance to conventional triple
therapy antibiotics: metronidazole (83.3%) and clarithromycin (33%). High
resistance to doxycycline also was seen, despite limited use of this antibiotic in
Armenian paediatric practice. High susceptibility to nifuratel might be useful for
further development of specific eradication schemes for Armenia. High frequency
of both erosive and non-erosive gastritis as well as high rate of gastric atrophy
and dysplasia in these patients were noticed.
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Introduction: Children’s gastric microbiota in the presence or absence ofH. pylori
(HP) has not been studied well.
Aims & Methods: We aimed to study the composition of the microbiota in the
biopsy material of the antral part of the stomach, according to the 16S-rRNA
sequencing, of children with chronic gastritis, in the presence or absence of HP,
and also to compare it with the histological data. Biopsy materials of mucous
tunic from antral part of the stomach were taken from 16 children aged 10–17
with chronic gastritis and after the preliminary extraction the biopsy materials
were examined using the method of sequencing with a pair of oligonucleotide
primers, which are specific for the conservative regions of the 16S-rRNA gene, on
the Life Technologies Ion Torrent sequencer using the 318v2 chip. Bioinformatic
processing was conducted using the QIIME package. The results were compared
with the data from the histological examination of the biopsy materials from the
same part of the stomach as well as with the results of diagnosis using rapid
urease test AMA RUT Expert with digital Reader.
Results: 8 out of 16 patients were identified as HP(þ) positive, 2 of them had HP
in small amounts, 6 of them – in significant amounts. The dominant types of
bacteria in the stomach of all children were Proteobacteria, Bacteroidetes,
Firmicutes; in a lesser extent - Actinobacteria, Cyanobacteria, Fusobacteria.
64.1% of HP(þ) patients’ microbiome was constituted of HP, among
Proteobacteria it reached 75–99%, the amount of other bacteria herewith shor-
tened, and the species diversity decreased. Non-helicobacter microbiota of chil-
dren with small amount of HP was almost identical in composition as HP(-)
patients’, the amount of other microbes was more numerous and diverse, also
within Proteobacteria. The signs of inflammation in mucous coat of the stomach
in case of HP presence were more pronounced than in HP absence, they corre-
lated with the amount of HP.
Conclusion: Microbiome of the children’s stomach is diverse, it is similar to
adults’. The infection from HP inhibits another microbiota and it is accompanied
with the signs of mucous coat inflammation, which correlates with the amount of
HP.
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Introduction: It is known that co-infection of the gastric mucosa with highly
pathogenic Hp strains and the Epstein-Barr virus is a risk factor for the devel-
opment of severe gastritis and gastric adenocarcinoma. However, the character-
istics of such co-infection in children are not sufficiently studied
Aims & Methods: The aim of this study is to estimate the role co-infection of
highly pathogenic strains of Helicobacter pylori andEpstein-Barr virus in pedia-
tric patients with chronic gastritis Patients and methods. 190 children aged 8–16
with chronic Hp-associated gastritis were studied. All the patients underwent
clinical and laboratory examinations and endoscopy. Gastric biopsies were
taken and inflammation graded according to the Sydney system. Polymerase
chain reaction (PCR) was used to detect the presence of Epstein-Barr virus
(EBV), Helicobacter pylori (Hp) and its highly pathogenic strains in the gastric
mucosa of the patients.
Results: Persistent EBV infection was found in 83 children (43.7%) with chronic
gastritis of the antral and (or) gastric body areas. Helicobacter pylori strains that
possess the virulence factors (cytotoxin-associated gen A (CagA), vacuolating
cytotoxin gen A (VacA), induced by contact with epithelium (IceA), and blood
group antigen-binding adhesion (BabA) were detected in 49 patients (25.8%). In
most cases, the association of two or more virulence factors in one patient was
observed. It was found that 39 pediatric patients had co-infection of the highly
pathogenic strains of Hp and EBV. The study revealed no significant effect of the
variant of the gastric mucosa infection on the clinical manifestations of gastritis -
the nature of intoxication, abdominal and dyspeptic syndromes. At the same
time, the endoscopic and morphological data analysis has revealed a severe
gastritis with the development of pangastritis and signs of gastric mucosa atrophy
observed mainly in the antral region, in patients with co-infection (highly patho-
genic strains of HpþVEB). In addition, by correlation analysis, we found that
the increase and development of the inflammatory process in the gastric mucosa
was mostly influenced by the presence of CagA-positive strains of H. pylori in
combination with EBV. We found that children infected by EBV without highly
pathogenic Hp strains had mild mononuclear and polymorphonuclear cell infil-
tration without atrophy.
Conclusion: Co-infection with highly pathogenic Hp strains and the Epstein-Barr
virus in pediatric patients is significantly associated with severe gastritis.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Helicobacter pylori is one of the most widespread bacterial infec-
tions worldwide, therefore nowadays its prevalence was decreasing, mostly in
developed countries. There are some studies which support that H pylori could
favor the development of food allergy.
Aims & Methods: To assess the relationship between H pylori infection and
specific immunoglobulin E (Ig E) antibodies to food allergens in symptomatic
children. We conducted a prospective study of 394 symptomatic children (249
girls, age range 6 months-18 years), mostly with uninvestigated dyspepsia requir-
ing an endoscopic evaluation in our unit, from January 2015 to December 2016.
All patients were evaluated for H pylori infection by at least two standard inva-
sive tests and for specific immunoglobulin E antibodies to major food allergens
(R-biopharm, Germany). The nutritional status of patients was assessed in all
cases by the new World Health Organization (WHO, 2007) growth charts. EPI-
INFO version 7 was used for statistical analysis. A two sided p-value less than
0.05 was considered statistically significant.
Results: Active H pylori infection was documented in 246 (62.3%) cases. The
allergic sensitization to at least one of the food allergens was identified in 134 of
394 patients (34%). The majority of Ig E positive children (109 of 134 cases;
81.3%) were positive for cow’s milk followed by egg (17.9%), wheat (7.46%),
peanut (4.5%), soybean (3.73%). The allergic sensitization to food allergens was
associated with abnormal levels of specific Ig E antibodies to common inhalatory
allergens in 55 of 134 cases (41.04%). Regarding the association of H pylori
infection with an elevated serum Ig E level to at least one of the food allergens
tested, there was no significant correlation (p¼ 0.14). 77 of 134 (31.30%) patients
positive for food specific Ig E antibodies were H pylori infected and 57 of them
(38.55%) were H pylori negative (Fisher exact test¼ 0.08). The assessment of the
patients nutritional profile in relationship with H pylori infection and food
allergy not revealed a statistically significant effect on the two ends of the poor
nutritional status (undernutrition and overnutrition).
Conclusion: The recent decline of H pylori infection is not evident in our study.
There was no association between H pylori infection and Ig E mediated food
allergy. Undernutrition and overnutrition were not associated with the H pylori
infection and food allergy in our patients.
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Introduction: Current evidence suggests the decline of the eradication rates of H
pylori in children treated with standard first line therapy, partly determined by its
antibiotic resistance.
Aims & Methods: To evaluate the effectiveness of current first and second-line
therapy recommendations for H pylori eradication in children. We conducted a
prospective open-label study of 158 symptomatic children (age range 6 months-
18 years; 106 girls) who required a first upper digestive endoscopy over the past
year. Active H pylori infection was documented in 122 of the 158 investigated
children (77.2%). Infected children were randomly assigned to receive either a 7–
14 days standard empiric triple therapy consisting of esomeprazole (ESO) plus
amoxicillin (AMO) and clarithromycin (CLA) or metronidazole (MET), either a
sequential therapy for 10–14 days. Bismuth salts are not easily available in our
country. Eradication efficacy was assessed by follow-up endoscopy 4–8 weeks
after the end of anti-H pylori therapy by at least two different invasive tests. In
patients failing to be cured through the first treatment a second alternative was
applied (a triple therapy based on quinolones or metronidazole either sequential
therapy) associated with antibiotic susceptibility testing. The primary and sec-
ondary outcomes were the rate of H pylori eradication after the first and second
line therapy, by intention to treat (ITT) and per-protocol (PP) analysis. Statistical
analysis was performed with EPI INFO 7. The differences between eradication
rates were analysed by x2 test and the Odds Ratio (p5 0.005 was considered
statistically significant).
Results: Patients with H pylori infection were treated with an initial empiric first
line standard therapy (n¼ 52) or a sequential therapy (n¼ 70). Of the 122 chil-
dren, 9 patients were lost to follow-up (7.38%). Overall H pylori was eradicated
in 87/122 children (71.32% for ITT analysis versus 76.99% for PP analysis). The
first eradication rates were significantly higher using the sequential therapy (55/
70 cases; 78.57% for ITT analysis and 55/64 cases; 85.93% for PP analysis)
compared with standard first line triple therapy (32/52 cases; 61.53% for ITT
analysis and 32/49 cases; 65.30% for PP analysis). The ITT and the PP eradica-
tion rates were significantly higher with sequential treatment (OR¼ 0.43; 95%
CI: 0.19–0.97; p¼ 0.04; x2¼ 3.43; p¼ 0.06 for ITT analysis and OR¼ 0.30; 95%
CI: 0.12–0.77; p¼ 0.013; x2¼ 5.55; p¼ 0.01 for PP analysis). A second-line ther-
apy was recommended in 26 of cases with an overall eradication rate of 80.76%
(21/26 cases) for ITT analysis and respectively 87.5% (21/24 cases) for PP ana-
lysis. The choice of second line therapy was tailored by antimicrobial
susceptibility only in some cases (15/26 cases; 57.7%). The eradication rates
for PP analysis were: 90% (9/10 cases) for triple therapy based on MET; 80%
(8/9 cases) for triple therapy based on quinolones and 80% (4/5 cases) for sequen-
tial therapy.
Conclusion: This endoscopic series reveals a high rate of H pylori infection
(77.2%). The sequential therapy achieved a significantly higher rate of eradica-
tion than the standard empiric triple regimens regardless of using ITT (78.57%
versus 61.53%) or PP (85.93% versus 65.30%) analysis. The eradication rates for
the second-line therapy was significantly higher (87.5% for PP analysis) com-
pared with the first-line empiric standard therapy (76.99% for PP analysis).
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Introduction: Imbalanced gut microbiota is suggested to be involved in the patho-
genesis of coeliac disease (CD). In many CD patients, despite a long-term treat-
ment with a gluten-free diet (GFD), the intestinal dysbiosis is not completely
restored. Prebiotics, substances of the unique ability to shape intestinal micro-
biota are promising, low-risk GFD supplement to remedy the intestinal dysbiosis
in CD patients.
Aims & Methods: The aim of the present study was to assess the effect of pre-
biotic oligofructose-enriched inulin (OEI) administration on the quantitative gut
microbiota characteristics of CD children following a strict GFD for 1 year. A
randomized, placebo-controlled 12-weeks dietary intervention was conducted on
34 CD children (62 % female, mean age 10 years) on GFD who were randomly
assigned to prebiotic (OEI; 10 g/day) or placebo group (maltodextrin; 7 g/day).
Before (baseline) and after the intervention, the anthropometric (weight, height)
and biochemical blood parameters (C-reactive protein, creatinine, aspartate ami-
notransferase, alanine aminotransferase), quantitative gut microbiota character-
istics (by real-time PCR) and concentration of short-chain fatty acids (by gas
chromatography with a flame ionization detector) were assessed.
Results: Thirty CD patients completed the study. After 12-weeks intervention,
the biochemical blood parameters reminded normative in all CD patients, and
the gut microbiota counts within eachexperimental group did not differ from
their counts at baseline. However, in comparison with placebo group,
Bifidobacterium counts was significantly (p5 0.01) higher in CD children con-
suming OEI-supplemented GFD. Moreover, the counts of Clostridium leptum
group in children of prebiotic group did not show the decreasing tendency
along with the time of GFD as it was observed in placebo group. These changes
were reflected intotal bacteria number after the intervention that was constant in
prebiotic group but tended to fall in placebo group. Microbiota counts corre-
sponded well with microbial metabolic activity. In comparison with placebo
group, the concentration of short-chain fatty acids increased significantly in
prebiotic group (50.27 vs. 69.95 mmol/g, p5 0.05), mainly due to a significantly
higher acetate formation (28.82 vs. 44.06 mmol/g, p5 0.05).
Conclusion: A long-term administration of OEI in GFD prevents from a gut
dysbiosis observed along with the duration of the GFD, and maintains a con-
stant quantity of beneficial bifidobacteria. Moreover, the administered of OEI in
GFD stimulates activityof gut microbiota observed asthe increased SCFA
formation.
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A. Cebolla4, C. Sousa2, The Deliac Group2
1Gastroenterology And Nutrition, Instituto Hispalense Pediatria, Seville/Spain
2Departamento de Microbiologı́a y Parasitologı́a, Facultad de Farmacia,
Universidad de Sevilla, Sevilla/Spain
3Servicio De Análisis Clı́nicos., Hospital Universitario INGESA de Ceuta, Ceuta/
Spain
4Biomedal, Sevilla/Spain
Contact E-mail Address: alfonsorodriguez@ihppediatria.com
Introduction: Treatment for celiac disease (CD) is a lifelong strict gluten-free diet
(GFD). Patients should be followed-up with dietary interviews and serology as
CD markers to ensure adherence to the diet. However, none of these methods
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offer an accurate measure of dietary compliance. Presence of gluten related sub-
stances in faeces proves that transit through gastrointestinal tract happened and
confirms gluten ingestion.
Aims & Methods: Detection of gluten immunogenic peptides (GIP) in stools as a
marker of GFD adherence in CD paediatric patients was evaluated and com-
pared against traditional methods of GFD monitoring.
A prospective, non-randomized, multi-centre follow-up study, 2 years long,
including 64 CD patients started on GFD when diagnosed was conducted (age
range 0–18 years).
Fecal GIP was quantified by enzyme-linked immunosorbent assay (ELISA).
Anti-tissue transglutaminase (anti-tTG) IgA and anti-deamidated gliadin peptide
(anti-DGP) IgA antibodies were measured simultaneously, during basal and
follow-up visits at 0, 6, 12 and 24 months. Correlations between fecal GIP and
serum antibodies were stablished by Cochran’s and Friedman tests.
Results: 62 patients (97%) had detectable GIP levels in stools, during basal visit,
before initiation of the GFD, whereas 20.3% of the patients were found to have
positive GIP after treated with a GFD. Dietary transgressions were more fre-
quent in children over 8 years of age.46.1% of them showed more than one
detected transgression. Anti-tTG IgA remained in high concentrations in 48,
34 and 20% of the patients at 6, 12 and 24 months of follow-up. Anti-DGP
was positive in 13, 4.5 and 0% of cases when tested at 6, 12 and 24 months
follow-up. Both serological methods did not correlate with GIP in stools
(p5 0.05).
Conclusion: The GIP ELISA enabled direct and quantitative assessment of gluten
exposure early after ingestion. Detection of GIP in stools revealed lack of accu-
racy of traditional serological methods to verify GFD compliance in CD paedia-
tric patients. The antibodies can take several months or even years to decrease
after initiation of the GFD and reduction (but incomplete suppression) of gluten
intake appeared to be sufficient to decrease antibodies in sera. Faecal GIP could
be a useful tool: 1) on the diagnosis of CD, to ensure that a sufficient amount of
gluten has been ingested to allow a correct CD diagnosis. 2) on treatment, for
monitoring of short-term and long-term GFD compliance. 3) on the differential
diagnosis of unresponsive CD versus dietary non-compliance.
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Introduction: There are sporadic reports of occurrence of intussusception in celiac
disease but no systematic study yet. The prevalence and natural history of intus-
susception in children with celiac disease is not known.
Aims & Methods: We prospectively studied the prevalence and natural history of
intussusception in newly diagnosed celiac disease in children. From January 2010
to October 2013, 150 children, diagnosed to have celiac disease on the basis of
positive celiac serology (IgA tissue transglutaminase/anti-endomysial antibody)
and duodenal biopsy showing villous atrophy, were prospectively recruited in this
study. Abdominal ultrasonography was done before starting gluten-free diet and
repeated in those who had intussusception, on day three and then weekly till the
resolution of intussusception.
Results: A total 167 children were diagnosed to have new onset celiac disease
during the study perios. Out of them 150 were recruited in the study and 17 were
excluded; 15 did not get an ultrasonography before starting gluten-free diet and
two children were consuming gluten-free diet prior to presentation to our hospi-
tal. The median age of 150 children with celiac disease was 72 (range, 16–204)
months and 79 (53%) were boys. Their median duration of symptoms was 18
months (range, 1–136 months). Diarrhea was presenting symptoms in 119 (79%)
of cases. A total 45 intussusceptions were detected in 37 (24.7%) children.
Majority (86.5%) had single intussusception and the most common site was
ileo-ileal (46.7%), followed by jejuno-jejunal intussusception (40%). Out of 45
intussusceptions, 43(95%) involved small bowel. All but one had asymptomatic
intussusception. On gluten-free diet, intussusception resolved spontaneously
within 7 days in 24 (65%), within 14 days in 31 (84 %) and within 28 days in
34 (92%) cases, and none required surgical or hydrostatic reduction. On
univariate analysis, younger age, low weight z score, presentation with diarrhea,
abdominal distension, rickets, lower serum albumin, more severe villous atrophy
and refeeding syndrome were found to be significantly more common in children
with intussusception as compared to children without intussusception. On multi-
variate analysis abdominal distension (Odds ratio: 3.9, 95% Confidence Interval:
1.3–11.9) and hypoalbuminemia (Odds ratio: 1.8, 95% Confidence Interval: 1.2–
2.7) were found to be significantly associated with intussusception.
Conclusion: Intussusception is frequently (25%) seen in children with newly diag-
nosed celiac disease, generally asymptomatic and resolves spontaneously on
gluten-free diet. It is often associated with more severe disease. As spontaneous
resolution is the rule for intussusception in the setting of pediatric celiac disease,
attempt for reduction (either surgical or hydrostatic) should be deferred unless
indicated otherwise.
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Introduction: PPIs have become one of the most commonly prescribed classes of
medications.1 Although PPIs are generally well tolerated, accumulating evidence
suggests that PPIs have long-term risks.2 One potential risk of PPI use is devel-
opment of small intestinal bacterial overgrowth (SIBO), which is defined as
4105 bacteria colony-forming units (CFU) per mL upon culturing upper gut
aspirates. However, this is controversial due to conflicting results from prior
studies.3–8
Aims & Methods: The aim of this meta-analysis was to evaluate the association
between use of PPIs and the risk of SIBO. We systematically searched the online
PubMed, Embase, Cochrane Library databases and Web of Science for relevant
articles before November 2016. Two researchers identified and extracted data
independently. The pooled analysis was performed using generic inverse-variance
random-effects model. Subgroup and sensitivity analysis were conducted to
assess the stability and heterogeneity of the pooled results. The risk of publica-
tion bias was evaluated by examining funnel plot asymmetry, Egger’s test and
Begg’s test. All statistical analyses were performed using Stata software version
13.0.
Results: A total of nineteen articles met the eligibility criteria for the meta-ana-
lysis. The pooled odds ratio (OR) showed a statistically significant association
between increased risk of SIBO and PPI use (OR¼ 1.71 95% CI:1.20–2.43). No
statistically significant publication bias was found based on the Egger’s test
(p¼ 0.149) or Begg’s test (p¼ 0.115). Furthermore, subgroup analyses demon-
strated an association between SIBO and PPI use in studies that employed small
bowel aspirates culture and glucose hydrogen breath tests (GHBT) as diagnostic
tests for SIBO. However, when the pooled analysis was limited to studies recruit-
ing irritable bowel syndrome (IBS) patients as study population, no statistically
significant association between PPI use and SIBO was observed, which suggests
that PPI use does not affect the risk of SIBO among IBS patients.
Conclusion: Our meta-analysis suggests that the use of PPI moderately increases
the risk of SIBO, which highlights the need for appropriate prescription of PPIs.
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Introduction: Nowadays food allergy continue to increase, especially in wester-
nized countries and is now recognized as a worldwide problem. Transforming
growth factor-b1 (TGF-b1) is a profibrotic cytokine, which plays an important
role in promoting the structural changes in food allergy. Also for patients with
food protein - induced enterocolitis syndrome TNF- appears to have an impor-
tant role.
Aims & Methods: The aim was to determine the significance of the Transforming
Growth Factor - b1(TGF – b) and Tumor Necrosis Factor –  (TNF – ) in
children with food protein induced enterocolitis syndrome. It was examined 38
patients with FPIES at the age from 4 months to 3 years, the average age was
19 4 months. The control group consisted of 11 healthy children of the same
age. The determination of TGF-b1 and TNF - in serum was performed by an
enzyme-linked immunosorbent assay kits from Bender Medsystem (Austria).
Results: The level of TGF-b1 in patients with FPIES exceeded the norm and was
respectively 33.5þ 1.6 ng/ml, at norm 20.2þ 2.1 ng/ml, p5 0.001. The indices of
TNF - were also increased and amounted to 8.8þ 1.3 ng/ml in comparison with
the norm 4.2þ 0.67 ng/ml p5 0.001. For our patients it was characterized by an
increase in specific antibodies IgE to cow’s milk in 18 (47.3%) children. In these
cases disease was more severely with vivid clinical manifestations (indomitable
vomiting, stool with blood, expressed weight deficit). Also among of patients in
this group TGF-b1 level was significantly higher than in the control group,
amounting to 42, 01 7.5 ng/ml. TNF -  indicators were also increased:
11 1.2 ng/ml.
Conclusion: It is believed that TGF – b1 inhibits allergic inflammation, but in our
observations, an increase in its values was established, especially in the group of
children with high specific IgE levels to cow’s milk. It is likely that an increase in
TGF – b1 stimulates the release of TNF - , which supports chronic inflamma-
tion in allergic diseases.
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Introduction: Newborns’ birth weight is influenced by maternal factors (mother’s
weight at the onset of pregnancy, gestational weight gain - GWG), genetic,
obstetrical and environmental factors, but also socio-economical ones.
Excessive GWG, mother’s increased BMI and the adipose tissue mass determine
a bigger birth weight and increase the risk of newborns’ obesity. Glutathione S-
transferases (GSTs) is an oxidative stress-related gene which is associated with
and ist complications.
Aims & Methods: The aim of the study was to investigate the role of mother-child
GTS1 and GTM1 polymorphisms as independent risk factors for newborn’s
weight, but also to establish correlations between these polymorphisms and
anthropometrical parameters, and bioimpedance (BIA) ones, respectively. We
assessed the anthropometrical parameters in both mothers and their newborns
(BMI- body mass index, MUAC – medium upper arm circumference, TST –
tricipital skin thickness, weight - W), BIA parameters in mothers, but we also
determined the clinical, paraclinical and genetic parameters in both mothers and
newborns.
Methods: We performed a cross-sectional study on 202 mothers and their new-
borns in a Clinic of neonatology & Gynecology and Obstetrics from Romania.
Results: We noticed that in newborns with W4 3000 gr there was a significant
statistical correlation between weight and mother’s GST1 polymorphism
(p¼ 0.046), birth at term (p5 0.001), with mother’s percentage of fat mass
assessed by BIA (p5 0.001), and multi parity, respectively (p5 0.001). We
obtained a tendency towards correlations between W4 3000 gr and basal meta-
bolism rate (p¼ 0.063), and GWG seemed to be a protective factor for this W
(p¼ 0.072). We also found that GSM1 in newborns was a risk factor with ten-
dency towards statistical significance in newborns with increased birth weight.
We did not find any interaction effect between newborns’ and mothers’ GST1
and GSM1 polymorphisms and anthropometrical parameters (p¼ 0.545 for
MUAC, and 0.664 for TST), or paraclinical parameters.
Conclusion: Mother’s GSTM1 is an independent risk factor for newborns’
W4 3000 gr, while mother’s GWG seems to be a protective factor for
W4 3000 gr. Further studies are needed in order to determine the clear role of
this polymorphisms in newborns’ obesity risk. This research was supported by
the Research Grants of the University of Medicine and Pharmacy Tı̂rgu Mureş ,
Romania - ‘‘The role of genetic determinism of the mother in child’s obesity corre-
lated with measurements of bioimpedance and anthropometry" no.275/4/
11.01.2017.
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Introduction: Deficits in lean mass and muscle measures are well described in
children with chronic disease e.g. childhood inflammatory bowel disease[1].
Sarcopenia is a poor prognostic biomarker in adults with advanced cancer,
liver transplantation and in children with acute lymphoblastic leukaemia [2–4].
Psoas muscle cross sectional area (PCA) has been shown to correlate with whole
body muscle mass and can be measured from axial imaging [5]. Little is known
about sarcopenia in children with intestinal transplantation (IT). Sarcopenia is a
poor prognostic biomarker in adults with advanced cancer, liver transplantation
and in children with acute lymphoblastic leukaemia. Psoas muscle cross sectional
area (PCA) has been shown to correlate with whole body muscle mass and can be
measured from axial imaging [5]. Little is known about sarcopenia in children
with intestinal transplantation (IT).
Aims & Methods: The primary objective was to determine whether children who
had IT show differences in total PCA when compared to healthy controls. The
secondary objective was to investigate association of PCA and survival after IT.
A retrospective, case note review of children who had IT at a single centre since
inception in 2009 to May 2016. Controls were identified from abdominal trauma
series. Total PCA (mm2) was measured using direct techniques of magnetic reso-
nance imaging or computed tomography at the level of the anterior superior iliac
spine. To correct for body size, PCA index was derived for all subjects: PCA
divided by height. PCA index was then described according to outcome.
Statistical analysis was carried out using Social Sciences (SPSS) version 23.
Results: 16 patients (9 male) underwent IT at our centre. Post-transplant axial
imaging was available for 12(6 males), median age 6.2[3.6 to 12.91] years patients
in whom the diagnoses (n): Chronic intestinal pseudo-obstruction(3), gastroschi-
sis(3), intestinal ischaemia(1), intestinal lymphangiectasia (1), volvulus (1), pro-
gressive familial intrahepatic cholestasis (1), Hirschsprung’s disease (1) and
intestinal failure of indeterminate aetiology(1). One patient was excluded from
analysis as she was a bilateral amputee. Children who had IT had a significantly
lower PCA and PCA index than controls; median PCA index (x103 mm2) [IQR]
in IT vs controls; 4.71[3.68 to 6.10] vs 9.55 [8.44 to 11.33], p5 0.05. There was a
trend toward higher PCA index in those who survived (n¼ 9) compared to those
who did not (2).
Conclusion: Children who underwent IT had sarcopenia of the psoas muscle in
comparison to healthy controls. In IT patients who died there was a trend toward
psoas muscle sarcopenia. This study adds to the evidence that body core muscle is
consistently deficient in children with chronic disease and is the first to comment
on children with IT. This small study provides the basis to develop PCA as a
prognostic marker in children with transplantation.
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Introduction: Primary lactose intolerance (PLI) is a frequent condition caused by
a genetically programmed and progressive loss of lactase expression. It is con-
sidered that PLI is the ancestral variant, while lactase persistence is caused by 2
polymorphisms: the dominant C/T13910 and G/A22018. Homozygotes (CC or
GG) have undetectable lactase levels. In clinical practice only half of people with
PLI have symptoms. However, some studies showed that PLI subjects have lower
dairy intake.
Aims & Methods: To investigate whether genetic predisposition to PLI influences
the quality of life and dairy intake in a group of Romanian children. We con-
ducted a prospective study, recruiting consecutive children evaluated in our unit
in May-August 2016. Our study population included 87 children aged 6–17 years
(mean age 10.64 3.51 years), 45 (51.72%) girls. We used strip genotyping to
identify genetic predisposition to IPL. Subjects were asked to complete a vali-
dated quality of life questionnaire and a dairy intake questionnaire. We used
Spearman’s test to evaluate the correlation between IPL and quality of life and
dairy intake.
Results: (51.7%) subjects had a CC genotype. 30 (34.5%) subjects had a GG
genotype. Our results were consistent with Hardy-Weinberg equilibrium. We
found no correlation between homozygosity for PLI and dairy intake (CC:
r¼0.06, p¼ 0.54; GG: r¼0.01, p¼ 0.86). We found no correlation between
either CC, or GG homozygosity and quality of life (r¼0.11, p¼ 0.3 and
r¼0.1, p¼ 0.34).
Conclusion: In our group genetic predisposition to IPL followed European
trends. It did not influence quality of life and dairy intake.
Disclosure of Interest: C. Pienar: This work was supported by an internal grant of
‘‘Victor Babes’’ University of Medicine and Pharmacy, PII-C4-TC-2016-08
All other authors have declared no conflicts of interest.
TUESDAY, OCTOBER 31, 2017 09:00-17:00
LIVER & BILIARY II - HALL 7____________________
P0656 HYPOXIA CAUSES HEPATIC STELLATE CELLS
ACTIVATION IN THE ABSENCE OF CUX1
E. Becker1, P. Di Fazio1, J. Hänze2, T.M. Gress3, D. Bartsch1, T.
T. Wissniowski3
1Department Of Visceral Thoracic And Vascular Surgery, Philipps University
Marburg, Marburg/Germany
2Department Of Urology And Pediatric Urology, Philipps University Marburg,
Marburg/Germany
3Klinik Für Gastroenterologie, Endokrinologie, Stoffwechel Und Infektiologie,
Philipps Universität Marburg, Marburg/Germany
Contact E-mail Address: eva-mareike.becker@t-online.de
Introduction: CUX1 (CUTL1) is a transcription factor belonging to homeobox
proteins. It is responsible of driving the transcription of genes deputed to many
cellular functions like proliferation, differentiation and cell death. It has been
shown that its role can change and drive tumorigenesis. Up to now, its role is
unknown in hepatic stellate cells. W
Aims & Methods: We focused on CUX1 activity in hepatic stellate cells under-
going hypoxic stress. LX-2 cells were treated with 100 ng/ml CoCl2 or kept at 37
C at low oxygen (50.5%). Expression of hypoxia markers and activation mar-
kers was performed by RT-qPCR. Western blotting was performed to analyze
the protein level of CUX1 and HIF-1alpha. Transfection with plasmid contain-
ing a promoter sequence for HIF1alpha was performed simultaneously with
CUX1 knock-down.
Results: LX-2 cells treated for 6 hours with CoCl2 or low oxygen showed an over-
expression or a restoration of COL1A1 and ACTA2 after knock down of CUX1.
Additionally, CDKN1A, CDKN1B, VEGFA and HIF1alpha were up-regulated
in LX.2 cells previously transfected with siCUX1. Protein level of CUX1 was
significantly down-regulated, whereas HIF1alpha protein was strongly up-regu-
lated by hypoxia condition. Transcriptional activity of HIF1alpha is not corre-
lated with CUX1 expression.
Conclusion: CUX1 controls the activation of hepatic stellate cells. Its knock down
promotes the hypoxia response. CUX1 could represent a key factor for
controlling liver fibrogenesis. Its role in a liver fibrosis scenario needs to be
further investigated.
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Introduction: Fibroblast growth factor-21 (FGF21) and omentin-1 have been
recognized as potent antidiabetic agents, with potential hepatoprotective activity.
Aims & Methods: The aim of this study was to evaluate hepatic FGF21 and
omentin-1 mRNA expression, and their serum levels as predictive markers of
liver injury and insulin resistance in morbidly obese women with NAFLD. The
study included 56 severely obese women who underwent intraoperative wedge
liver biopsy during the bariatric surgery. Hepatic FGF21 and omentin-1 mRNA
was assessed by quantitative real-time PCR, while their serum concentration with
commercially available enzyme-linked immunosorbent assays.
Results: FGF21 serum level was significantly higher in patients with more extent
steatosis (grade 2 and 3) compared to those without or with mild steatosis (grade
0 and 1) (p¼ 0.049). However, ROC analysis showed poor discriminant power
for FGF21 serum level in differentiation between more and less extensive stea-
tosis with AUC¼ 0.666. There was evident tendency to higher levels of hepatic
FGF21 mRNA in patients with lobular inflammation and fibrosis, and to lower
levels in the case of ballooning degeneration and steatosis. There was positive
mutual correlation between hepatic FGF21 and omentin-1 mRNA levels
(r¼ 0.73; p5 0.001). Fibrosis stage was associated with serum glucose and
HOMA-IR (p¼ 0.03 and p¼ 0.02, respectively). Serum omentin was not asso-
ciated with histopathological features. Hepatic omentin-1 mRNA levels exerted
the tendency to be lower in patients with advanced steatosis and hepatocyte
ballooning.
Conclusion: In conclusion our study, which focused on hepatic FGF21 and omen-
tin-1 mRNA expression, confirmed a marked expression of both molecules in the
liver of morbidly obese patients with NAFLD. mRNA levels were affected by
histopathological abnormalities. More extent steatosis was associated with evi-
dent change in serum FGF21 concentration in morbidly obese women with
NAFLD. The vast amount of fat, both visceral and subcutaneous in severely
obese patients may affect FGF21 and omentin-1 serum levels.
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Introduction: Liver fibrosis is the result of repeated healing repair and interstitial
reconstruction after chronic liver injury. Activation of hepatic stellate cells repre-
sents a critical event in fibrosis because these cells become the primary source of
extracellular matrix in liver upon injury. Inhibiting HSCs’ activation, prolifera-
tion, extracellular matrix production and promoting HSCs’ apoptosis are the
important therapeutic approaches of liver fibrosis.
Aims & Methods: We aimed to investigate the anti-liver fibrosis ability of lour-
eirin B and the molecular mechanisms involved it. After hepatic stellate cells
United European Gastroenterology Journal 5(5S) A393
(HSCs), which were separated from Sprague-Dawley rat, were treated with dif-
ferent concentrations of loureirin B, MTT assay was employed to determine
HSCs proliferation, western blot were used to test the expressions of Frizzled-4
receptor protein and -SMA. In addition, enzyme-linked immunosorbent assay
(ELISA) was performed to measure the content of -SMA, TGF-b1 and VEGF
in the cultured HSCs’ supernatant, and reverse-transcription PCR (RT-PCR)
were utilized to detect the expressions of Frizzled-4 and -SMA genes.
Results: MTT test showed that the proliferation of HSCs was inhibited signifi-
cantly with a time and dose dependent relationship by the treatment of loureirin
B with the half maximal inhibitory concentrations of 0.180mg/mL
(IC50¼ 0.180mg/mL). Western blot analysis showed that the expressions of Wnt
receptor Frizzled-4 protein and -SMA were obviously lower in the group of
loureirin B treatment than that in the control group. Moreover, the Loureirin B
also inhibited -SMA (p5 0.01), TGFb1 (p5 0.01) and VEGF (p5 0.05) secre-
tion in the cultured HSCs’ supernatant in different degree by the ELISA assay,
and RT-PCR results revealed that Loureirin B down-regulated the expressions of
Frizzled-4 and -SMA genes in the level of mRNA.
Conclusion: CONCLUSIONS: The Loureirin B mediated anti-hepatic fibrosis by
inhibiting the proliferation of HSCs through restraining the Wnt signaling
pathway.
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Introduction: Macrophages play a pivotal role in the pathogenesis of non-alco-
holic steatohepatitis (NASH) and are a major component of inflammatory cells
infiltrated in NASH. However, the precise mechanism of how macrophages
contribute to the pathogenesis of NASH remains unexplored.
Aims & Methods: We aimed to characterize the role and molecular regulators of
macrophages in NASH and the therapeutic effects of macrophage depletion on
NASH. C57BL/6 wildtype (WT) mice and transgenic LysM-Cre/DTR mice were
fed with methionine-and-choline-deficient (MCD) diet for 5 weeks to induce
steatohepatitis. Hepatic macrophages were depleted in WT mice by injecting
liposomal clodronate (i.p. 50mg/kg/week) and in LysM-Cre/DTR mice by inject-
ing diphtheria-toxin (DTox) (i.p. 100 ng/mice). Primary macrophages were iso-
lated from bone marrow of WT mice. For the in vitro study, mouse immortalized
hepatocytes AML-12 were cultured with primary macrophage conditioned
medium and mouse primary macrophages were cultured with AML-12 hepato-
cytes conditioned medium to evaluate the interaction between macrophages and
hepatocytes in steatohepatitis. A series of assays including cytokine profiling
assay, DNA binding activity, flow cytometry and Western blot were performed.
Results:Hepatic macrophage marker CD68 expression was significantly higher in
human NASH patients compared with normal controls (P5 0.001).
Steatohepatitis was established in WT mice and LysM-Cre/DTR mice fed
MCD diet, concomitant with significantly enhanced hepatic macrophage infiltra-
tion as indicated by F4/80 staining. Macrophage depletion by liposomal clodro-
nate or DTox attenuated steatohepatitis in both animal models. This was also
associated with reduced hepatic necroinflammation, oxidative stress, hepatic tri-
glyceride accumulation, and secretion of pro-inflammatory cytokines in both
liposomal clodronate-treated WT mice and DTox-treated lysM-Cre/DTR mice
as compared to the corresponding control mice. Macrophage depletion was also
accompanied by the reduction of neutrophils, which together can reduce inflam-
mation. Upregulated macrophages were associated with the increased expression
of hepatic pro-inflammatory cytokines including interleukin (IL)-1a, IL-1b, IL-
12, IL-17, Granulocyte-macrophage colony-stimulating factor, Monocyte che-
moattractant protein-1 (MCP-1) and macrophage inflammatory protein 1a
(MIP-1a), and the activation of NF-B and JNK signaling pathways in the
liver. Macrophage-induced steatosis was mediated by increased hepatic lipogen-
esis through inducing liver X receptors (LXR and LXRb), sterol regulatory
element binding protein-1c and carbohydrate-responsive element-binding protein
Moreover, autophagy deficiency and endoplasmic reticulum (ER) stress were
involved in macrophage-induced steatohepatitis as indicated by p62/SQSTM1
accumulation and increased GRP78 and p-IRE1a expression. For the in vitro
study, macrophage conditioned medium significantly promoted lipid accumula-
tion in AML-12 hepatocytes. On the other hand, MCD-cultured hepatocytes
medium promoted primary macrophage polarization to M1 phenotype as well
as the production of pro-inflammatory cytokines (TNF-a and MCP-1).
Conclusion: We demonstrated that macrophages contribute to the progression of
NASH through promoting inflammation, lipogenesis, autophagy impairment,
ER stress and also through a crosstalk with hepatocytes. Similarly, macrophage
depletion has mitigation effects on NASH and may provide a potential treatment
approach of steatohepatitis.
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Introduction: Non-alcoholic fatty liver disease (NAFLD) is considered the hepa-
tic manifestation of metabolic syndrome, with simple liver steatosis being capable
of gradually progressing to inflammation, fibrosis, cirrhosis and even hepatocel-
lular carcinoma. Still, disease pathogenesis is complex and no targeted therapies
have yet been approved for NAFLD. Bile acids (BAs) constitute a wide class of
steroid molecules with pleiotropic functions, contributing to the homeostasis of
lipids and glucose. In the liver, they specifically modulate nuclear receptors from
the NR1 subfamily, such as Farnesoid X Receptor (FXR) and Liver X Receptor
(LXR), thus tightly regulating bile acid synthesis and oxidation and storage of
triglycerides.
Aims & Methods: Our aim was to screen BA derivatives for their potential to
selectively activate FXR, thus protecting liver cells against free fatty acid (FFA)-
induced lipid accumulation and lipotoxicity. Nineteen novel BA derivatives were
analyzed by in silico molecular docking studies for FXR binding affinity, further
evaluated in human cells using a FXR reporter assay. Assessment of FXR-depen-
dent gene and protein expression was analyzed upon incubation of primary
mouse hepatocytes and HepG2 cells with selected BA derivatives. In parallel,
BA derivatives were co-incubated with oleic and palmitic acids (2:1) for assess-
ment of cellular cytotoxicity and intracellular lipid accumulation.
Results: From the compound library, five BA derivatives showed stronger activa-
tion of FXR, comparing with their natural precursors. Incubation of HepG2 cells
with FFAs led to a 25% reduction in cell viability and 35% increase in cell
death, with a dose-dependent accumulation of lipid droplets. Pre-incubation of
cells with selected derivatives efficiently prevented FFA-induced cell death and
lipid accumulation. Finally, incubation of both HepG2 cells and primary mouse
hepatocytes with BA derivatives strongly induced FXR, RXR, SHP, BSEP,
FGF19 and VLDLR mRNA levels, and repressed PARP1, LXR, SREBP1-c
and CYP7a1 mRNA expression. Molecular docking studies and FXR reporter
assays confirmed ligand affinity to FXR. Furthermore, chenodeoxycholic acid
(CDCA)-based derivatives were potent activators of FXR at lower concentra-
tions comparing with the parent molecule.
Conclusion: In conclusion, we identified novel BA derivatives that directly mod-
ulate liver nuclear receptors, such as FXR and LXR, thus protecting liver cells
against lipotoxicity and preventing FFA accumulation. These new molecules may
be used as scaffolds for the development of targeted therapies for NAFLD.
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Introduction: NAFLD is currently classified in non-alcoholic fatty liver (NAFL)
and non-alcoholic steatohepatitis (NASH). It is a liver disease related to meta-
bolic syndrome with rising socio-economic impact worldwide. NAFLD is defined
by significant lipid deposition in hepatocytes that is unrelated to alcohol con-
sumption. This high prevalence of liver disease occurs after a protracted inflam-
matory status caused by insulin resistance derived from high consumption of
fructose-rich goods as shown by the multi-parallel hit theory. Autophagy is a
self-digesting mechanism that helps the cells to overcome stress conditions
derived by nutrient deprivation and massive storage, e.g. lipid and proteins.
Autophagy dysfunction has been implicated in lipid accumulation related dis-
eases. Up to now, it in yet fully understood the role exerted by autophagy in liver
diseases not related to alcohol.
Aims & Methods: Here, autophagy has been analyzed in a mouse model of
NAFL/NASH and in human in vitro model. Liver specimens were collected
from 24 weeks old FLS and FLS-ob/ob mice. Liver tissue was snap frozen and
kept at 80C. RNA and proteins were isolated. RT-qPCR and western blotting
was performed. HepG2 cells were incubated for 24 h with 2mM oleic acid (OA)
A394 United European Gastroenterology Journal 5(5S)
alone and in combination with 100 pM Bafilomycin and 2mM Caffeine. RT-
qPCR and western blotting was performed also. Real time fluorescence monitor-
ing of HepG2 cells stably expressing ectopic MAP1LC3B-GFP-RFP-tag was
performed with Incucyte.
Results: FLS-ob/ob mice, representing a NASH mouse model, showed an over-
expression of the autophagy markers BECN1, MAP1LC3B, SQSTM, UVRAG,
TFEB, PRKAA 1_1 and PRKAA 2_1 in comparison with FLS mice that repre-
sent the NAFL model. Furthermore, the protein level of BECN1 and
MAP1LC3B was down-regulated in FLS-ob/ob mice, whereas SQSTM and
UVRAG resulted over-expressed. Interestingly, the phosphorylated form of
AMPK was found up-regulated in FLS-ob/ob mice, while FLS mice did not
show a quantifiable expression of P-AMPK. AMPK was found stably
expressed in both FLS-ob/ob and FLS mice. HepG2 cells treated with oleic
acid showed a down-regulation of BECN1, MAP1LC3B, UVRAG and
SQSTM proteins. AMPK and its phosphorylated form resulted unvaried.
Interestingly, Caffeine treatment caused a stronger reduction of autophagy mar-
kers, including the reduction of P-AMPK also. The combination of Caffeine
and OA had an additive effect compared to single compounds by causing a
stronger reduction of autophagy markers protein level. Bafilomycin caused a
reduction of MAP1LC3B and UVRAG only. Its combination with OA caused
a stronger reduction of protein level. HepG2 MAP1LC3B-GFP-RFP showed an
increase of red fluorescence after 48 h of treatment with 2mM OA.
Conclusion: Autophagy mechanism is significantly activated in FLS-ob/ob mice,
that lack of Leptin expression, and in HepG2 treated with OA, supporting that
autophagy is strongly implicated in NASH. Targeting autophagy could represent
a valid future therapeutic strategy for patients affected by NASH. Further studies
are needed to better understand the role exerted by Leptin during autophagy in
NASH.
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Introduction: Non-alcoholic fatty liver disease (NAFLD) pathogenesis associates
with intracellular lipid accumulation in the liver. In addition, recent evidence
supports a functional role for both mitochondrial dysfunction and microRNAs
(miRNA/miRs) in NAFLD pathogenesis. In particular, deregulation of mito-
chondrial dynamics proteins, like mitofusin-2 (Mfn2) is frequently observed in
obese and diabetic patients.
Aims & Methods: Our aims were to profile global liver miRNA expression
changes during NAFLD progression and correlate them with the development
of mitochondrial dysfunction in both experimental and human NAFLD.
C57BL6 mice were fed either a standard or a fast food (FF) diet for 25 weeks;
or a methionine- and choline-deficient (MCD) diet for 2 and 8 weeks. miRNA
profiling was performed using liver RNA from 8 weeks MCD-fed mice, in
TaqMan MicroRNA arrays. qPCR array data was analyzed using the
HTqPCR package in Bioconductor. Liver biopsies were obtained from patients
with simple steatosis or NASH. mRNA and protein expressions were analyzed by
qRT-PCR and immunoblotting, respectively. miRNA targeting was evaluated by
dual-luciferase reporter assays.
Results: Both FF- and MCD-fed mice developed NASH-like features, including
liver steatosis, inflammation and insulin resistance; as well as progressive steato-
hepatitis, severe liver damage and fibrosis. Strikingly, liver Mfn2 protein levels
significantly decreased in both models (p5 0.05). Inversely, expression of Drp1,
a mitochondrial fission protein, was found increased (p5 0.05). Other mitochon-
drial proteins, such as the voltage-dependent anion channel (VDAC), presented
no expression changes. In human patients, Mfn2 protein levels decreased from
steatosis to NASH (p5 0.05). Microarray profiling indicated that liver miRNAs
are significantly modulated during NAFLD progression. Specifically, 25
miRNAs were found significantly increased in the liver of MCD-fed mice,
while, inversely, 27 miRNAs were decreased. Curiously, in silico analysis revealed
that several of the up-regulated miRNAs could target Mfn2 in, at least, one Mfn2
3́UTR binding site. Binding of miRNAs to Mfn-2, including miR-34a, was vali-
dated in HepG2 cells using a dual-luciferase reporter vector containing the Mfn2
3́UTR. Finally, overexpression of miR-34a in C2C12 muscle cells lead to Mfn2
inhibition and insulin resistance (p5 0.05).
Conclusion: In conclusion, mitochondrial dysfunction, particularly downregula-
tion of Mfn2, plays a key role in human and experimental NAFLD and is
targeted by miRNAs, like miR-34a. A better understanding of the network of
miRNAs targeting mitochondrial proteins during NAFLD may help in the devel-
opment of novel targeted therapies for metabolic diseases associated with mito-
chondrial dynamics dysfunction. (Supported by PTDC/BIM-MEC/0895/2014,
SFRH/BD/104160/2014, FCT, PT and Gilead Sciences International Research
Scholars Program 2015).
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Introduction: Alcoholic Hepatitis, Decompensated Chronic Liver Disease and
Acute-on-Chronic Liver Failure form a bulk of in-patients in Nepal. Mortality
is quite high in these presentations despite all the medications currently available
in our country. Prednisolone and Pentoxifylline are not up to the mark in terms
of both short and long-term outcomes1. The only option that remains is liver
transplant, which is not readily available in our country, and even if available in
the near future, needs at least some months for planning and preparation and is
costly. G-CSF (Granulocyte Colony Stimulating Factor) has shown both mor-
bidity and mortality benefit in some studies in these groups of patients2, 3, 4. By
comparing the outcomes in those receiving and not receiving G-CSF, we can
suggest G-CSF therapy to reduce mortality and morbidity in these patients.
Although most of the studies done in the role of G-CSF in ACLF (Acute-on-
Chronic Liver failure) and decompensated CLD (Chronic Liver Disease) have
used 5mg/Kg/dose of G-CSF subcutaneously for 10 doses2, our study has used
fixed dosage of 300mg of G-CSF subcutaneously twice a day for a total of 3 days
(6 doses).
Aims & Methods: We aimed to study the role of G-CSF in the treatment of
alcoholic hepatitis, Decompensated CLD and ACLF. From January 2016 to
December 26, a total 49 patients with alcoholic hepatitis, decompensated chronic
liver disease and acute-on-chronic liver failure admitted in TUTH (Tribhuvan
University Teaching Hospital) were studied. Patients were randomized (in a 1:1
ratio) to either the ‘GCSFþ SMT’ (Standard Medical Therapy) group (cases) or
the ‘SMT-alone’ (control) group according to computer-generated random num-
bers. Patients in G-CSF group received G-CSF 300mg twice daily for 3 days (total
6 doses). Mortality rates at 1 month and CTP (Child Turcotte Pugh) and MELD
(Model for End stage Liver Disease) scores at enrollment and at Day 30 were
compared in the two groups.
Results: A total of 49 patients [median age: 49 (range: 27–73) years, 70% males)
were included in the study. 24 of them received G-CSF along with SMT and 25
received SMT alone. Baseline characteristics were similar in both the groups. The
3-day GCSF therapy did not lead to any significant adverse effects. At one
month, in GCSFþSMT group, 4 had died whereas in SMT alone group 15
had died. 83% survived in GCSF group whereas only 40% survived in control
group (P¼ .002). Also significant improvement in CTP and MELD scores was
seen in the group treated with GCSF at one month after therapy. Also, there
were fewer complications of sepsis, hepatic encephalopathy and renal impairment
in the GCSF group compared to the SMT alone group.
Conclusion: GCSF therapy improves survival and clinical outcome in patients
with alcoholic hepatitis, decompensated chronic liver disease and acute-on-
chronic liver failure. It may be useful in patients who do not have access to
transplant services and also to the patients awaiting transplantation to prevent
worsening during the waiting period. Further studies are needed to explore
whether lower doses (total 6 doses) of GCSF are as effective as higher doses
(total 10 doses).
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Introduction: Cirrhosis and its complications are common causes of death among
patients with end-stage liver disease. Liver transplantation as a definitive treat-
ment is limited by shortage of donors and high cost. Autologous bone marrow
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mononuclear layer containing stem cells is a novel approach for regeneration of
liver cell which can be a therapeutic option for those patients.
Aims & Methods: To determine the outcome after intrasplenic or intrahepatic
injection of autologous bone marrow stem cells (ABMSC) transplantation in
patients with liver cell failure secondary to chronic hepatitis C infection. Sixty
chronic hepatitis C patients with liver cell failure were prospectively enrolled.
They were classified into 3 groups; group I: 20 patients underwent (ABMSC)
injected intrasplenic. Group Ia: 10 patients underwent (ABMSC) injected intras-
plenic after trans differentiation into hepatocytes with regular amount of growth
factor. Group Ib: 10 patients underwent (ABMSC) injected intrasplenic after
trans differentiation into hepatocytes with the double amount of growth
factor. Group II: consisted of 20 patients underwent (ABMSC) injected intra
hepatic (right portal branch). Group IIa: 10 patients underwent (ABMSC)
injected intrahepatic after trans differentiation into hepatocytes using regular
amount of growth factor. Group IIb: 10 patients underwent (ABMSC) injected
intrahepatic; after trans differentiation into hepatocytes with the double amount
of growth factor. Group III: (Control Group): consisted of 20 patients received
traditional supportive treatment for chronic liver cell failure and symptomatic
treatment of ascites and bleeding abnormalities. All groups of patients were
followed regularly for nine months clinically, biochemically and ultrasonogra-
phically. Fatigue was assessed by the modified fatigue impact scale questionnaire
before, during and at end of the study.
Results: Our study included 60 patients (78.33% males) with mean ageSD
(49.9 6 years). Patients who had ABMSC injection showed improvement in
clinical parameters as bleeding tendency, ascites, lower limb edema and hepatic
encephalopathy. There was statistically significant improvement in serum albu-
min level and prothrombin time in group I and group II in comparison group III.
There was also statistically significant improvement in Child-Turcotte-Pugh in
group I and group II in comparison group III at the third month and this was
maintained till the end of the study. Fatigue improved in all patients who had
ABMSC. There was improvement in serum albumin, ascites, lower limb edema,
bleeding tendency and physical activity. Also there was improvement in MELD
score and performance status.
Conclusion: Stem cell transplantation has a beneficial effect on synthetic func-
tions of the liver and possibly improves survival and quality of life of patients
with end stage liver disease. Autologous bone marrow transplantation is safe and
beneficial technique in treatment of in patients with liver cell failure secondary to
chronic hepatitis C infection.
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Introduction: It is well known that severe liver disease requires a liver transplan-
tation to be treated. But liver transplantation is not available in many countries.
An alternative treatment can be a transplantation of autologous bone marrow
derived cells which can stimulate liver regeneration. Proliferating cell nuclear
antigen (PCNA) shows nuclei of dividing cells and may be useful for calculating
proliferation index.
Aims & Methods: The aim of this study was to evaluate changes of proliferation
intensity of liver cells in patients with alcoholip liver cirrhosis after autologous
peripheral blood mononuclear cell (PBMC) transplantation. This uncontrolled
open-labeled clinical trial was approved by Ethical committee of Ministry of
Health of the Republic of Tatarstan, Russia. Eleven patients took part in the
study, they received granulocyte colony-stimulating factor injections for 5 days
for PBMC mobilization. On the 6th day PBMCs were collected and injected into
the celiac trunk. Liver biopsies were obtained three times from each person on
next time-points: before transplantation of PBMCs into the celiac trunk (initial),
three and twelve months after the procedure. Liver biopsy specimens were
embedded in paraffin and stained immunohistochemically with antibodies
against PCNA. The PCNA labeling index was calculated as the number of
PCNA-labeled nuclei for 1000 hepatocyte nuclei in each specimen and the results
were expressed as percentage ratios. Statistical analysis was done by Wilcoxon
signed-rank test using Statistica v.12 software. p value 50.05 was considered
significant.
Results:. Before the transplantation of PBMCs 28.3 18.3% of all the hepato-
cytes expressed PCNA without any topographic prevalence. Three months after
the transplantation the proportion of proliferating hepatocytes increased up to
36.7 24.8%. Twelve months after transplantation of PBMCs we found hepa-
tocytes proliferation to be 2 times higher than before the procedure. Proportion
of proliferating hepatocytes reached 50.2 17.0% (p¼ 0.04). Great increase in
hepatocytes proliferation intensity coincided with biochemical improvements of
serum bilirubin, ALT and alkaline phosphatase.
Conclusion: Our study showed that proposed treatment was safe and effective.
We can conclude that after transplantation of autologous PBMC s proliferation
of hepatocytes greatly contributes to the liver regeneration and improvement of
blood biochemical data in patients with alcoholic liver cirrhosis. However, effect
of our treatment is not constant and requires repeated PBMC transplantation.
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Introduction: The prevalence of non-alcoholic fatty liver disease (NAFLD) has
increased and several studies have shown that there is an association between
NAFLD and metabolic syndrome (MetS). The aim of this study was to deter-
mine how much impact the risk factors of metabolic syndrome has on ultrasono-
graphic fatty liver, especially NAFLD.
Aims & Methods: A total of 41,258 adults who underwent routine comprehensive
health evaluations, including abdominal ultrasonography, were selected. We cal-
culated the adjusted prevalence ratios (PRs) for components of MetS (high blood
pressure (BP), impaired fasting glucose, low high-density lipoprotein cholesterol
(HDL-C), and high triglycerides (TG) according to NAFLD.
Results: NAFLD was found in 13.8% of non-obese subjects and 52.3% of obese
subjects. NAFLD was associated with most components of MetS in both obese
and non-obese subjects. However, non-obese NAFLD patients had significantly
higher PRs for certain components of MetS than did obese patients, especially
among women. Body mass index, waist circumference, fasting blood glucose,
triglyceride, HDL-C and aspartate aminotransferase, alanine aminotransferase,
-glutamyl transpeptidase levels all affected NAFLD independently. The preva-
lence of metabolic syndrome was increased in mild (40.8%) and moderate
(57.8%) NAFLD groups. When odd ratio (95% CI) for NAFLD group was
compared to the contrast group, there was an increased risk of metabolic syn-
drome with odd ratio of 12.8 (95% CI, 9.1 17.0).
Conclusion: NAFLD and its severity has a close connection with MetS and also
with each risk factors of MetS. Therefore, assessment for concurrent MetS
among NAFLD patients is considered to be necessary.
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Introduction: Obesity is a global problem. Data from the South Asian region is
limited.
Aims & Methods: In a cohort follow-up study we investigated obesity among
urban, adult, Sri Lankans [selected by age-stratified random sampling from
Ragama-MOH area, Gampaha District; initial screening 2007 (aged 35–64
years); re-evaluation 2014 (aged 42–71 years)]. On both occasions structured
interview, anthropometry, liver ultrasound, biochemical and serological tests
were performed. Total body fat (TBF) and visceral fat percentage (VFP) were
assessed by impedance in 2014. General-obesity (GO) was BMI4 25 kg/m2.
Central-obesity (CO) was waist circumference (WC)4 90 cm males and
WC4 80 cm females. Non-alcoholic fatty liver disease (NAFLD) was diagnosed
on ultrasound criteria, safe alcohol consumption and absence of hepatitis B/C
markers. Multinomial logistic regression was fitted to assess associations.
Results: In 2007 (n¼ 2967), 614(20.7%) were overweight [51.9%-women],
1161(39.1%) had GO [65.9%-women] and 1584(53.4%) had CO [71%-women].
Females (p5 0.001), raised-TG (p5 0.001), low-HDL (p5 0.001), diabetes
(p5 0.001), hypertension (p5 0.001), NAFLD (p5 0.001), and low household
income (p5 0.001) were significantly associated with prevalent GO and CO
respectively. Additionally, increased-age (p¼ 0.05), low-educational level
(p5 0.001) and unhealthy eating (p5 0.001) were associated with prevalent
CO. Inadequate physical activity was not associated with either. 2137(72%)
attended follow-up in 2014. Of those who were initially non-obese who attended
follow-up, 189/1270(14.9%) [64% women] had developed GO (annual-incidence
2.13%) and 206/947(21.9%) [56.3% women] had developed CO (annual inci-
dence 3.12%) after 7 years. TBF and VFP significantly correlated with incident
GO and CO (p5 0.001). Females gender (OR-1.78, p5 0.001; 2.81, p5 0.001)
and NAFLD (OR-2.93, p5 0.001; OR-2.27, p5 0.001) independently predicted
incident GO and CO respectively.
Conclusion: The prevalence and incidence of GO and CO were high in this
cohort. Both incident GO and CO were associated with female gender and
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lean-NAFLD with lean-NAFLD being the strongest predictor of future devel-
opment of GO.
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Introduction:Worldwide, the prevalence of fatty liver disease (FLD) is increasing,
particularly in countries with rising obesity rates, such as Ireland. Studies suggest
that up to 25% of those with FLD can progress to non alcoholic steatohepatitis
(NASH) and be at risk of its sequelae, including cirrhosis and hepatocellular
carcinoma. Indeed, NASH is now the second most common indication for
liver transplantation in the US. Despite this alarming data, there is no prevalence
data for Ireland in relation to FLD.
Aims & Methods: We aimed to use a simple screening tool, the Fatty Liver Index
(FLI) to identify those at risk of having fatty liver disease (FLD) amongst all
comers presenting to an Acute Medical Unit (AMU) and to use this data as an
indicator of prevalence of FLD in Ireland.
Methods: In this prospective cohort study, all patients attending the Acute
Medical Unit (AMU) were invited to take part. Their height, weight and waist
circumference were measured, and triglycerides (TG) were added to their ‘routine
AMU blood panel’, which also included measurement of gamma glutamyl trans-
ferase (GGT). Exclusion criteria were as follows: known liver disease, excess
alcohol intake (417 units per week for males, 411 units per week for females),
age 518 years, pregnancy, active malignancy. The Fatty Liver Index (FLI), an
algorithm based on Body Mass Index (BMI), waist circumference, TG and GGT
was used to stratify patients into groups based on risk of having FLD. A FLI
score of 460 is highly suggestive of having FLD, a score of 30–60 is indetermi-
nate and a score of530 is considered low risk for FLD. Ethical approval for this
research was granted by the ethics committee of UHG.
Results: Data was completed on 316 participants; 58 were excluded, the majority
due to either a history of alcohol excess or known liver disease. A total of 258
participants were therefore evaluated; 50% were male. One hundred and sixteen
(45%) participants scored 460 on the FLI; 57.3% of which were male. Only
16% of males had a FLI 530, compared with 44% of females. Males had a
significantly higher FLI than females; 60.9 vs. 43.12 (p5 0.0001). Those with
FLI4 60 had a mean weight¼ 93.5 kg and BMI¼ 31.5, vs. 64.9 kg and 22.4
respectively for those with FLI5 30 (P4 0.0001). There was a statistically sig-
nificant difference in all parameters measured between all 3 groups (p5 0.0001),
apart from height, although there was a trend toward lower height in the
FLI5 30 group, most likely due to the fact that it was 73% female. When
only males were looked at, there was no height difference between the 3
groups. Those with a FLI4 60 were older than those with FLI5 30, 54.6 vs.
48 (p¼ 0.01).
Conclusion: In this study looking at prevalence of fatty liver in Ireland, 45% of
participants were found to be at high risk, and 70% were at high or indeterminate
risk. Worryingly, only 16% of males fell into the low-risk group. Apart from
weight, GGT, TG and BMI this study also showed age and male sex to be
significant risk factors for developing fatty liver. This group clearly needs
follow up to further evaluate and manage their fatty liver.
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Introduction: Bisphenol A (BPA) is an endocrine disrupting chemical, a hetero-
genic group of chemicals usually found in food packaging or insecticide residues
on vegetable crops, associated with type 2 diabetes mellitus (T2DM), cardiovas-
cular disease and liver enzyme abnormalities, and in general with the whole blood
glucose homeostasis.
Aims & Methods: We have evaluated BPA plasma and urine levels in non-alco-
holic fatty liver disease (NAFLD) patients compared to healthy subjects and we
evaluated the possibility to eliminate this environmental factor after a BPA-free
diet regimen. Furthermore, we evaluated, in human HepG2 cells, the effects of
exposure to different BPA concentrations on both oxidative stress induction and
cell proliferation. We enrolled sixty patients with histologic diagnosis of NAFLD
with or without T2DM, before a BPA-free diet, and healthy subjects, by subject-
ing them to evaluation of body composition using bioimpedance analysis.
In vitro, the proliferation of BPA-exposed HepG2 cells at two different concen-
trations (0.025 and 0.05mM) was evaluated, both at high (H-HepG2), in order to
simulate human hyperglycemia, and at low (L-HepG2) glucose concentrations,
for 48 h. Lipoperoxidation was also assessed by TBARS assay.
Results: BPA levels were significantly higher in 60 NAFLD subjects, both in
urine and in plasma (p5 0.0001) if compared to controls and, among this
group, it appeared to be higher in 30 non-alcoholic steatohepatitis (NASH)
patients compared to 30 simple steatosis (NAFL) ones (p5 0.05), independently
from the presence of T2DM. After following a BPA-free diet for one month,
NAFLD patients showed a significant reduction of BPA circulating levels
(p5 0.05) without a significant reduction of urine levels, which represents the
only way to eliminate BPA amount released into circulation by the adipose BPA
reservoir. In fact subjects with a higher fat percentage in body composition
showed higher BPA levels in plasma and urine. In our population study,
NASH patients showed a higher fat percentage in body composition in compar-
ison to NAFL ones. Only H-HepG2 cells treated with BPA (0.05mM) increased
proliferation compared to controls at 48 h (p5 0.0001). Moreover, BPA
increased TBARS levels at 48 h in H-HepG2 cells versus controls.
Conclusion: Our study reveals a possible role of BPA as an environmental factor
involved in the progression of NAFLD, particularly in obese and/or T2DM
patients.
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Introduction: The clinical implications of non-alcoholic fatty pancreas disease
(NAFPD) are still the topic of debate in human studies. It has been shown
that fatty infiltration in pancreas correlates with metabolic risk factors and
may represent significant manifestation of metabolic syndrome (MeS) in associa-
tion with nonalcoholic fatty liver disease (NAFLD). The aim of our study was to
determine the association of fatty pancreas (FP) in NAFLD patients with fea-
tures of MeSand to determine a simple new noninvasive scoring system for FP
prediction in NAFLD patients.
Aims & Methods: We conducted across-sectonal study that included 143 subjects-
with NAFLD classified into two groups according to the severity grade of FP as
follows: patients with non fatty pancreas and grade I light FP (n¼ 59) and
patients with grade II severly and grade III highly FP (n¼ 84). Patients were
analyzed for diagnostic criteria of MeS, underwent sonographic examination
with adiposity measurments and liver biopsy. Liver fibrosis was evaluated semi-
quantitative according to the METAVIR scoring system and using non-invasive
markers of hepatic fibrosis (NAFLD fibrosis score (NFS), BARD score,
Fibrosis-4 score (FIB-4), AST to Platelet Ratio Index (APRI)).
Results: Of these 143 patients with NAFLD, 84 had criteria for metabolic syn-
drom (MeS), while there was no significant difference in frequency among FP
groups. Out of all clinical and laboratory characteristics, no statistical differences
were registred in demographic data, lifestyle factors, body mass index (BMI),
systolic and distolic blood preasure, presence of hypertension and dyslipidemia,
values of insulin, high density lipoprotein (HDL) and triglycerides. Waist cir-
cumference (WC) showed significant difference among groups, indicating WC as
a posible marker for higher risk of FP in NAFLD patients (P¼ 0.018). Diabetes
mellitus (DM) was more frequent in patients with severly FP (P¼ 0.02), with
greater portion of patients with HOMA-IR4 3. Higher values of fasting plasma
glucose, total cholesterol, serum amylase and lipase were associated with pre-
sence of highly fatty pancreas (P¼ 0.052, P¼ 0.007, P¼ 0.014; P¼ 0.024, retro-
spectively). Values of hemoglobin A1c (HbA1c)4 6% were significantly
associated with NAFLD patients with severly FP, highlighting its impaired func-
tion in MeS (P¼ 0.008). While no significant difference was found in the use of
statins and hypertensives, higher number of patients with severly FP did not use
antidiabetic agents and asociation was registred among NAFLD patients with
use of metformin and glimeprid and the first FP group (P¼ 0.035). Out of all
visceral fat amounts, only measures of mesenteric fat were associated with severly
FP (P¼ 0.013). Results of our study determined highly significant association of
NAFLD and NAFPD. Neither NAFLD non-invasive markers nor hystological
reports of liver fibrosisshowed significant associationwith presence of fatty pan-
creas. In multivariate analysis of FP predictors in our study cohort, logistic
regression approach was used. Model of predicting occurence of FP was designed
from multivariate logistic regression analysis. The probability was estimated with
the equation: 0.627þ 0.640 * 0.593 * glucose (fasting glucose level) – cholesterol
level (total cholesterol)þ 0.058þ 1.585 * serum lipase * ultrasonography level of
liver steatosis. According to the score values for different cut off levels, best
ability in the prediction of severly FP has shown the score value above 6.5.
Conclusion: Our study demonstrated that pancreatic fat infiltration due to its
impaired function presents an additional factor that contributes to aggravation
of MeS manifestations, affects glucose metabolism and severity of NAFLD.
Interestingly, significant association was registred among NAFLD patients
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with use of antidiabetic agents and the absence of highly fatty pancreas, indicat-
ing its potential protective role. Simple new noninvasive scoring system was
designed frommultivariate logistic regression analysis to estimate the occurence
of severly FP in NAFLD with best ability in the prediction in score values above
6.5.
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Introduction: Non- alcoholic fatty liver disease (NAFLD) is a rapidly growing
disease worldwide. The pathogenesis of NAFLD is not well recognized. Thyroid
is totally involved in regulation of lipid and carbohydrate metabolism, body
weight, and energy homeostasis. Therefore, the role of thyroid hormones in
pathogenesis of hepatic steatosis is anticipated.
Aims & Methods: This study aimed to investigate thyroid hormone abnormalities
in euthyroid subjects with hepatic steatosis. A cross sectional study was con-
ducted between September 2012 and September 2015 at Namazi hospital,
Shiraz, Iran. Study subjects were healthy individuals who had undergone liver
biopsy for evaluation of liver histology as a routine pre-transplant checkup
before living related liver transplantation. Liver function tests, age, gender,
weight, height, fasting plasma glucose, thyroid hormones, and lipid profile
were recorded. Liver biopsy specimens were reviewed by an expert pathologist
for hepatic steatosis and steatohepatitis. Individuals with a history of chronic
liver disease, hepatitis B or C infection, hepato-billiary cancers, those with 420
grams/day alcohol consumption, and individuals receiving medications causing
hepatic steatosis were excluded from the study.
Results: A total of 210 individuals (130 women and 80 men) were included.
Seventy six individuals (36.19 %) had hepatic steatosis and 19 individuals had
steatohepatitis (9.04 %) in liver histology. Mean age of individuals with and
without hepatic steatosis were 32.9 6.69 and 31.8 6.72 years respectively
(P¼ 0.26). In univariate analysis higher weight, triglyceride, total cholesterol,
alanine aminotransferase (ALT), alkaline phosphatase, fasting blood sugar
(FBS) and thyroid stimulating hormone (TSH) were associated with hepatic
steatosis (P5 0.05). Serum T4 and T3 were not associated with hepatic steatosis
(P4 0.05). In regression analysis, higher FBS, higher alkaline phosphatase,
higher ALT and higher TSH (OR¼ 1.36; 95 % CI: 1.02–1.80, P¼ 0.03) were
independent predictors of hepatic steatosis. In regression analysis, higher
serum TSH was independently associated with steatohepatitis compared to
those without steatohepatitis (6.83 6.04 mIU/L and 2.10 1.27 mIU/L)
(OR¼ 2.11; 95% CI: 1.45–3.07, p5 0.001). A cutoff value of 3.75 mIU/L for
TSH was predictor of presence of steatohepatitis in liver biopsies
(sensitivity¼ 75%; specificity¼ 89 %; AUC¼ 0.754; P¼ 0.004).
Odds Ratio (OR) 95 % Confidence Interval (CI) P-Value
Weight 1.05 0.96–1.16 0.245
Triglyceride 1 0.98–1.01 0.989
ALT 1.007 0.93–1.08 0.867
TSH 2.11 1.45–3.07 50.001
Conclusion: Higher serum TSH is associated with hepatic steatosis and steatohe-
patitis in euthyroid subjects. Thyroid hormones may have crucial role in hepatic
steatosis and may be targeted for treatment of NAFLD patients.
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Introduction: Glucosidase II is part of the functional pathway of co-translational
protein translocation and maturation in the endoplasmic reticulum. It is impli-
cated in autosomal dominant polycystic liver disease (ADPLD) and autosomal
dominant polycystic kidney disease (ADPKD). The b-subunit of glucosidase II,
encoded by PRKCSH, has been identified as one of the causative genes of
ADPLD. Recent data suggest that the -subunit of glucosidase II (GII),
encoded by GANAB, is associated with ADPKD and ADPLD. We aimed to
identify GANAB mutations in an independent cohort of patients with the pri-
mary phenotype of polycystic liver disease (PLD) and to predict the influence of
these mutations on glucosidase II function.
Aims & Methods: We identified genetic mutations in GANAB using molecular
inversion probe (MIP) analysis in a cohort of PLD patients. Both patients with
ADPKD and ADPLD were included for analysis. Mutations identified with MIP
analysis were validated using Sanger sequencing. Bioinformatics prediction tools
(PolyPhen-2, Align GVGD, SIFT, MutationTaster) were used to predict the
functional significance of the mutations. YASARA&WHAT IF were used for
analysis of the structural effects of the mutations. Primary cholangiocytes
obtained from a patient with GANAB mutation (c.2515C4T) were used to
study loss of heterozygosity.
Results: We identified and validated 6 new bona fide GANAB mutations in 7
unrelated families. These are 2 frameshift (c.687delT and c.11_16delTAGCGG),
1 splicing (c.2691-28C4G), 2 nonsense (c.2509C4T and c.2656C4T) and 1
missense (c.1835G4C) mutation. In silico analysis showed c.687delT and
c.11_16delTAGCGG are located in N-terminal domain of the protein. These
mutations probably lead to a total defective protein. c.1835G4C is located in
the active site of the protein. It is predicted to disrupt the composition of the
active site and reduce enzymatic activity. The remaining mutations (c.2691-
28C4G, c.2509C4T and c.2656C4T) are located in the distal C-terminal
domain, which interacts with PRKCSH. The mutations could result in early
termination of this domain. It is speculated this disrupts the ability of the two
subunits to interact. Western Blot showed no differences in GII expression in an
ADPLD patient with GANAB mutation c.2515C4T compared to primary cho-
langiocytes obtained from a patient without PLD. This indicates in this patient
no loss of heterozygosity occurs in cholangiocytes lining the hepatic cysts.
Conclusion: We describe six novel GANAB mutations that can cause PLD in a
mixed population of ADPKD and ADPLD patients. These mutations are found
in functionally important domains of -subunit of glucosidase II, which may lead
to impaired enzymatic activity of the complex. In contrast to other PLD related
genes no loss of heterozygosity was found for GANAB in cyst epithelium.
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Introduction: In patients with morbid obesity, dietary treatment and physical
activity are the first line of treatment, but if not responding, bariatric surgery
is the only validated alternative. The main surgical procedures are sleeve gas-
trectomy (SG) and gastric bypass (GBP), and they are chooses in function of
BMI, age and comorbidity. Both techniques have proven effective in weight loss.
It is known that liver fibrosis evaluation with Point Shear Wave Elastography
(pSWE) is difficult in these patients.
Aims & Methods: To study the difference between SG and GB and their impact
on main clinical and laboratory hepatic metabolic indicators and scores 6 and 12
months after the intervention and pSWE at 12 months. We studied 68 obese
subject candidate to bariatric surgery (45 female, 23 male). 28 underwent GBP
and 40 SG. Blood tests, physical examination were assessed before surgery, after
6 months (68 patients) and after 12 months (51 patients) and pSWE after 12
months.
Results: In the comparison between GBP vs SG there was a statistically signifi-
cant difference in the reduction in Fatty Liver Index (61% vs 37%, p¼ 0.015),
waist circumference (26% vs 18%, p¼ 0.045), BMI (34% vs 28%, p¼ 0, 016),
total cholesterol (23% vs 0, 05%, p¼ 0, 001), ALT (increased by 15% in GBP,
decreased by 27% in SG, p¼ 0, 023) while no differences were observed in the
other indicators considered. Ferritin level increased (52%) in SG and decreased
(25%) in GBP (p¼ 0.02). No difference was observed for pSWE.
Conclusion: This study showed some significant differences in clinical and labora-
tory terms between the two types of intervention, in fact GBP seems to have a
more powerful effect on weight loss and all related markers: all steatosis scores
(FLI, HSI, LAP), BMI, waist circumference. This can be explained by better
malabsorbitive effect of this intervention and by a lower BMI starting point
for reasons related to the intervention technique.
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Introduction: Polycystic liver disease (PLD) occurs in the setting of 2 different
genetic disorders: autosomal polycystic liver disease (ADPLD) and autosomal
polycystic kidney disease (ADPKD). These patients may develop hepatomegaly
as a result of multiple fluid-filled cysts. It is unclear whether PLD severity differs
between ADPLD and ADPKD. Height adjusted liver volume (htTLV) reflects
with symptomatic disease and diminished quality of life. We assessed hepatome-
galy with htTLV, as an objective parameter, in a large cohort of ADPKD and
ADPLD patients
Aims & Methods: PLD patients, defined by 410 liver cysts on radiological
imaging, were included in the international PLD registry. The cases were identi-
fied from clinical records at the University Leuven (Belgium), Seoul National
University Hospital (South-Korea) and Radboud University Hospital Nijmegen
(the Netherlands). For this cross-sectional analysis, we selected patients when
height adjusted total liver volume was measured prior to liver reducing therapy.
We performed univariate and multivariate analyses to explore risk factors asso-
ciated with severity of disease.
Results: Out of a total 1674 patients in the PLD registry, 1222 patients (1110
ADPKD, 112 ADPLD) could be selected. In the ADPKDþPLD group height
adjusted liver volume is significantly lower compared with ADPLD patients
(1050ml/m vs 1922ml/m; p¼ .000). Females have higher htTLV than men in
both ADPLD and ADPKD. Severe disease (htTLV4 3.200mL/m) is more pre-
valent in ADPLD. Diagnosis, gender and age are independent predictors for
severity of disease.
Conclusion: In this cohort more ADPLD patients had moderate to severe PLD
compared to those with ADPKD. Longitudinal studies are needed to further
explore the differences in national course of PLD phenotype between ADPLD
and ADPKD patients and to identify new risk factors.
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Introduction: Non-alcoholic fatty liver disease (NAFLD) affects about 1 billion
people worldwide. Those with non-alcoholic steatohepatitis (NASH) among
NAFLD patients have increased mortality rates compared to the general popula-
tion, with cardiovascular diseases beeing the leading cause of death. Identifying
patients at risk of developing cardiovascular events is of major importance, both
in terms of prognosis, as in the terms of therapeutic attitude.
Aims & Methods: Our aim was to cuantify the risk of developing atherosclerosis
as a main cardiovascular risk factor, in NAFLD patients and to identify a screen-
ing strategy for those patients. We included patients with NAFLD and metabolic
syndrome (MS) into 2 arms: with NAFLD and MS, and with NAFLD without
MS. NAFLD diagnosis was based on clinical, biological and ultrasound deter-
minations. We used Fibromax for evaluating the hepatic modifications (presence
of NASH, the degree of steatosis and the stage of fibrosis; F3-F4 counted as
advanced fibrosis). We performed ultrasound measurement of the carotid intima-
media thickness (in the common carotid artery, 1 cm before the bifurcation).
Values above 0.07 cm were consider pathologic and values above 0.12 cm were
considered as atherosclerotic (ats) plaques. Routine antropometric and labora-
tory determinations were performed.
Results: We included 95 patients with NAFLD, from which 53 were with MS and
43 were without MS. In all patients with NAFLD, with and without MS, there
was a correlation between the value of intima-media thickness and the presence
of NASH (p¼ 0.025), the degree of steatosis (p¼ 0.027) and the severity of
fibrosis (p5 0.001). Patients with NAFLD and MS had higher values pf the
intima-media thickness than those with NAFLD, but without MS (p¼ 0.002).
In all patients with NAFLD, there was a correlation between the presence of ats
plaque and advanced fibrosis (p5 0.001). The sex of the patients (p¼ 0.638) and
the level of total cholesterol (p¼ 0.438), LDL cholesterol (p¼ 0.505), HDL-cho-
lesterol (p¼ 0.458), and triglycerides (p¼ 0.911) were not correlated with the
presence of ats plaque, nor on the entire group of patients or on each arm. In
the logistic model for the prediction of the risk of developing ats plaque, we
included presence of NASH, the grade of steatosis, the stage of fibrosis, body
mass index, abdominal circumference and creatinine clearence level. In this
model, the stage of fibrosis has been shown to be a predictor with a positive
effect on the presence of ats plaque (p¼ 0.004, adjusted OR¼ 7.19,
CI[1.86;27.72]). This model correctly classified 90.9% of patients with ats
plaque and 91.7% of patients without ats plaque.
Conclusion: NAFLD patients were found to be atypical for the development of
cardiovascular risk. Staging of fibrosis has proved to be an important prognostic
factor. On the other hand, identifying NAFLD patients with ats plaques might
select the patients in which liver biopsy might be indicated for better character-
ization of the liver disease. Screening and agressive treatment of cardiovascular
risk factors should be done in every NAFLD patient.
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Introduction: Liver biopsy is the reference standard for diagnosing and staging
non-alcoholic fatty liver disease (NAFLD). Steatosis grade and fibrosis stage are
typically reported using semi-quantitative scores. Inter-and intra-observer varia-
bility in the current scoring systems may impact upon histological staging, and
consequently upon the interpretation of responses to interventions in clinical
trials.
Aims & Methods: We developed an automated method for steatosis and fibrosis
quantitation using biopsies of NAFLD patients. We further validated Liver
Stiffness Measurements (LSM) and controlled attenuation parameter (CAP) in
this group, using quantitative assessment as reference. 246 consecutive patients
with biopsy-confirmed NAFLD and transient elastography within 3 months of
the biopsy were evaluated. Biopsies were independently scored by two histo-
pathologists and digitalised at 2x magnification. Areas of steatosis and fibrosis
were annotated manually using the NDP.view2 to facilitate machine learning.
Each image was then analysed by the automated software: fat percentage (fat%)
and Collagen ProportionateArea (CPA) computed by the software were com-
pared with the manual annotation. They were also correlated with LSM and
CAP.
Results: There was an excellent concordance between manual and automatic
measurements, with inter-class correlation coefficient, ICC¼ 0.98,
(95%CI¼ 0.96–0.99, p¼ 0.0001). There was good correlation between fat%
and steatosis grade, but with significant overlap between groups. Results were
similar between CPA and fibrosis stage.LSM was significantly associated with
CPA (Rho¼ 0.8, p¼ 0.001).CAP score correlated significantly with fat%
(Rho¼ 0.45, p¼ 0.002) and effectively diagnosed steatosis4 5% (AUROC
0.82, 95%sensitivity, 60% specificity), but could not distinguish between grades.
Conclusion: We have developed an automated software, using low-resolution
images to provide a rapid, easily performed, objective assessment of steatosis
and fibrosis in NAFLD, with excellent correlation with experts’ annotation.
Objective measures would be helpful in the assessment of therapeutic response
in clinical practice and in clinical trials for patients with non-alcoholic fatty liver
disease.
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Introduction: Today, nonalcoholic fatty liver disease (NAFLD) is the most pre-
valent form of liver disease and it is an increasingly frequent cause of cirrhosis.
Although several factors have been associated with the disease, the biological
basis of the histological diversity of severity of NAFLD remains unknown.
Several relatively noninvasive parameters have been identified as predictive for
advanced fibrosis stage in patients with NAFLD, but none of them has sufficient
sensitivity or specificity to replace liver biopsy.
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Aims & Methods: Aim of our study was to compare two non-invasive methods:
fibrosis scores based on serum markers and transient elastography Fibroscan
(TE). We included 152 patients with NAFLD, 40 males (26.31%) and 112
females with age from 23 to 79 years.35 patients (23.02%) were overweight, 9
patients had normal weight and 24 (15.79%) had severe obesity. In all patients we
calculated BMI and fibrosis scores: BARD, FIB-4 and NAFLD fibrosis score
(NAFLD-FS). Blood samples were collected to determinate aminotransferases,
glucose, albumin level, platelet count. The abdominal ultrasonography was per-
formed by the same physician and steatosis was graded using a semi-quantitative
scale of 1 (mild) to 3 (severe).TE was, also, performed by a single physician using
conventional M probe or XL probe, with 10 valid acquisitions. We considered
significant fibrosis (F2) when estimated cutoff of F2 was 7.1 kPa, severe fibrosis
(F3) when cutoff value was 9.5 kPa, and cirrhosis (F4) with cutoff value
12.5 kPa.
Results: 86.84% patients had metabolic syndrome and 51.31% had diabetes
mellitus.40 patients had mild steatosis, 59 had moderate and 53 had severe stea-
tosis. After we performed TE 69.07% of patients had no significant fibrosis,
14.47% had F2, 9.86% had F3 and 7.23% had F4. The area under the recei-
ver-operating characteristic curve (AUROC) of TE was 0.823 (95%,
0.2520.394) (p5 0.0001). Sensibility and specificity for cutoff 7.1 kPa was
0.74 respectively 0.79 to exclude significant fibrosis. NAFLD-FS correlated sta-
tistic significant with TE (p5 0.0001). BARD score did not correlate with TE
and NAFLD-FS for significant fibrosis.FIB-4 correlated with TE for high degree
fibrosis (p¼ 0.004).
Conclusion: NAFLD-FS, FIB-4 and TE can be used together to evaluate the
progression of fibrosis in NAFLD and to select the patients for liver biopsy.
In our study BARD score was not useful in detection of high degree fibrosis.
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Introduction: Dyslipidemia has an important role in NAFLD and inflammation
progress and insulin resistance development. The studies suggested the role of
UDCA in lipid profile correction. UDCA replaced bile acid balance and
improved triglyceride and cholesterol levels in NAFLD patients, has immuno-
modulatory action.
Aims & Methods: The aim of study was estimation of the efficacy of different
dosage of ursodeoxycholic acid (UDCA) with statin combination treatment in
patients with NASH and NAFLD. There are 180 patients with NAFLD. It was
divided into two subgroups: fatty liver (90 subjects) – patients with normal level
of ALT, and nonalcoholic steatohepatitis (NASH, 90 subjects) – patients with
elevated level of ALT (the median is 78.5 U/l). All patients was divided in 3
groups. The blood test, liver enzymes, lipid profile, HOMA-IR, Fibroscan and
stool test was checked every 2 weeks of treatment. First group was taken UDCA
10mg/kg/dayþStatin. The patients of first group continue treatment for 3
months. Second group was taken UDCA 15mg/kg/dayþ Statin. Third group
were fed the low-lipid and low-glycemic index diet only (900 kcal/day). After 3
months of treatment patients of third group (diet only) add UDCA 15mg/kg/day
to treatment for extra 3 months.
Results: The subgroups did not show any difference in terms of initial total
cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides
(TG). Analysis of the lipid spectrum showed a more intense dynamics in the
group of patients taken UDCA combined with statin. After 3 months of
follow-up there was a significant reduction in TC to 4.2mmol/l, LDL-C to
1.8mmol/l and TG to 1.2mmol/l in the fatty liver subgroup, and TC to
4.1mmol/l, LDL-C to 1.8mmol/l and TG to 1.2mmol/l in the NASH subgroup.
Changes were similar in the subgroups. The level of total cholesterol, triglyceride
and liver enzymes were decreased faster in group taken UDCA and statin inde-
pendent from UDCA dosage. There are no side effects or liver enzyme elevation
in group treated with UDCA and statins. In the NASH subgroup there was a
significant decrease in ALT to 35 U/l. At the end of the first month of statin
therapy combined with UDCA in the NASH subgroup a significant positive
dynamics of ALT was found in patients with NASH (initially 78.5 U/l; after
treatment decrease to 38.5 U/l). Stage of liver fibrosis was significant in patients
taken UDCA and statin, as evidenced by the decrease in the index of fibrosis.
Conclusion: 3-month statin therapy in combination with UDCA showed signifi-
cant lipid-lowering effects in patients with NAFDL, as well as normalization of
ALT in the NASH subgroup. Among the patients who previously had not taken
statins in the NASH subgroup, higher levels of TC and TG were observed. The
same subgroup showed more evident lipid-lowering effects than the fatty liver
subgroup during the first month of the treatment. There are no differences
between the dosages of UDCA.
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P0679 EFFECT OF GRANULOCYTE COLONY-STIMULATING
FACTOR (G-CSF) ON MORTALITY AND COMPLICATIONS VIZ.
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GASTROINTESTINAL BLEED IN SEVERE ALCOHOLIC HEPATITIS-
A RANDOMIZED CONTROLLED STUDY
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Introduction: Severe alcoholic hepatitis has very high short-term mortality.
Compared to standard medical therapy (SMT), GCSF improves clinical and
biochemical profiles, morbidity and mortality in these patients. We evaluated
efficacy of GCSF in modulating the disease course of severe alcoholic hepatitis
over a period of 3 months in terms of mortality, morbidity by Discriminant
function (mDF), Child–Turcotte–Pugh (CTP) and Model for End-Stage Liver
Disease (MELD) scores and various complications viz. sepsis, GI bleed, ence-
phalopathy, hepatorenal syndrome (HRS) in comparison to SMT. We also stu-
died the mobilising effect of GCSF on bone marrow stem cells measured by
counting CD34þ cells from peripheral blood.
Aims & Methods: The present study was performed to evaluate the safety and
efficacy of GCSF on mortality and complications viz. sepsis, encephalopathy,
hepatorenal syndrome (HRS) and gastrointestinal bleed (GI Bleed) and also to
investigate whether G-CSF therapy could improve the indices of severity of liver
disease, such as Discriminant function (mDF), Child–Turcotte–Pugh (CTP),
Model for End-Stage Liver Disease (MELD) score in patients with severe alco-
holic hepatitis. 50 patients with severe alcoholic hepatitis were randomly assigned
to groups A and B (25 in each). Both groups were given SMT, while in addition,
patients in group A were given 5m/kg GCSF subcutaneous (10 doses for 5 days).
We assessed survival, changes in CTP, MELD and mDF scores and the devel-
opment of complications till 90 days.
Results: The baseline parameters in both groups were comparable. On day 6
group A had higher mean leukocyte and CD34 counts than group B
(P5 .001). On 90 days follow up 17 patients in group A (68%) and 9 in group
B (36%) survived (p¼ .04). Mean changes for different scores were greater in
group A then group B i.e. CTP (41.97% vs 8.84%), MELD (50.89% vs
10.09%) and mDF (74% vs 18%) (p5 .001). The percentages of patients who
developed HRS, HE, or sepsis were lower in group A than in group B (28% vs
64%, 32% vs 64%, and 28% vs 68%, respectively) (p5 .001). There was no
significant difference in GI bleed in both groups.
Conclusion: In severe alcoholic hepatitis, GCSF therapy significantly improves
the survival. It also significantly reduces CTP, MELD, and mDF scores and
prevents the development of complications.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
1. Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y,
Yokoyama Y, Uchida K, Yamasaki T, Fujii Y, OkitaK, Sakaida I.
Improved liver function in patients with liver cirrhosis after autologous
bone marrow cell infusion therapy. Stem Cells 2006; 24: 2292–2298
2. Tseleva T, Brenner DA. The phenotypic fate and functional role for bone
marrow-derived stem cells in liver fibrosis. J Hepatol 2012; 56: 965–972
3. Spahr L, Lambert JF, Brandt LR et al. Granulocyte-colony stimulating
factor induces proliferation of hepatic progenitors in alcoholic steatohepati-
tis: a randomized trial. Hepatology 2008; 48: 221–9.
4. Virendra Singh et al Granulocyte Colony-Stimulating Factor in Severe
Alcoholic Hepatitis: A Randomized Pilot Stud Am J Gastroenterol 2014;
109:1417–1423.
5. Theocharis SE, Papadimitriou LJ, Retsou ZP, et al. Granulocytecolony sti-
mulating factor administration ameliorates liver regeneration in animal
model of fulminant hepatic failure and encephalopathy. Dig Dis Sci
2003;48:1797–1803.
6. Gaia S, Smedile A, Omede P, et al. Feasibility and safety of G-CSF admin-
istration to induce bone marrow derived cells mobilization in patients with
end stage liver disease. J Hepatol 2006;45:13–19.
7. Garg V, Garg H, Khan A et al. Granulocyte-colony stimulating factor mobi-
lizes CD34þ cells and improves survival of patients with acute on chronic
liver failure. Gastroenterology 2012; 142: 505–12
P0680 ALCOHOLIC LIVER DISEASE/NON ALCOHOLIC FATTY
LIVER DISEASE INDEX (ANI): HOW TO DISTINGUISH
ALCOHOLIC FROM NON ALCOHOLIC LIVER DISEASE WITHOUT
HISTOLOGY
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Introduction: Steatosis/steatohepatitis is one of the most common liver diseases
with increasing prevalence and results from excessive alcohol consumption (alco-
holic liver disease) or as nonalcoholic fatty liver disease (NAFLD). The differ-
ential diagnosis is of paramount importance as they have different management
and therapeutic approaches, being liver biopsy the gold standard for establishing
the diagnosis. The distinction between these two entities without biopsy is
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difficult due to the unreliable history of alcohol consumption and lack of sensi-
bility and specificity of a single marker. In order to overcome these difficulties,
ANI (alcoholic liver disease/nonalcoholic fatty liver disease index) was created
for a non-invasive determination of fatty liver diagnosis.
Aims & Methods: The aim of this study was to evaluate the reliability of ANI as a
noninvasive method to distinguish NAFLD from ALD. A retrospective study
between 2010 and 2015 in patients with definite diagnosis of NAFLD and ALD
based on clinical, biochemical and histological criteria was performed. ANI scor-
ing system in the differentiation of ALD and NAFLD was evaluated through the
area under receiver-operating curve (AUROC). ANI score was calculated
through Mayo Clinic formula.
Results: This study was carried out in 22 patients with ALD and 120 with
NAFLD, 87 men (61.3%) with a median age of 51 13 years. NAFLD patients
presented a body mass index (BMI) of 28.9 5.9 vs 23.9 6 in ALD. ANI
showed a sensitivity of 81% and specificity of 79% for the diagnosis of ALD
with a cut-off value of 1.96 [AUROC 0.806 (0.715–0.898), p5 0.001]. ANI
greater than - 1.96 indicates a diagnosis of ALD whereas ANI less than 1.96
indicates a greater probability of NAFLD.
Conclusion: ANI scoring system is a non invasive diagnostic and reliable tool that
may be used to distinguish NAFLD from ALD, decreasing the need for live
biopsy. ANI greater than 1.96 suggests the diagnosis of ALD and ANI lesser
than 1.96 suggest NAFLD.
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Introduction: Alcohol consumption is an accepted phenomenon in Western
society, although harmful effects of excessive alcohol intake on health have
been widely shown. Alcohol has a direct toxic effect on the liver, potentially
leading to steatohepatitis and eventually liver fibrosis and cirrhosis. Excessive
use is furthermore associated with obesity, hypertension, hypercholesterolemia
and diabetes. Cessation of alcohol may reverse these effects to some degree. The
biological effects of short-term abstinence from moderate alcohol consumption
are not known.
Aims & Methods: A prospective interventional study in 16 healthy moderate
drinkers (3 units alcohol/day or 21 units/week) who discontinued alcohol use
for one month. Nine complete abstainers served as a control group. In both
groups an extensive health evaluation was performed at three time points: at
baseline (T0), at end of cessation (T4) and after one month of resuming alcohol
intake (T8). Outcomes consisted of morphometrics (blood pressure, body mass
index and body impedance analysis), transient and shear wave elastography to
assess liver stiffness and computer assisted ultrasonography to assess liver fat. A
blood panel consisted of liver enzymes, cholesterol, glucose and iron metabolism
and inflammatory parameters. Several quality of life components were assessed
with VAS scales.
Results: The intervention and control group were comparable on baseline in
terms of age, gender and morphometrics. Prior to intervention the participants
consumed on average 10.4 4.5 units alcohol/week and when they resumed
alcohol use, an average of 12.4 5.1 units/week. During the intervention
period, complete cessation was ascertained by blood parameters. Liver stiffness
and liver fat percentage did not differ between both groups nor change within
participants at any time point. Compared to baseline, GGT decreased at T4 (28
to 22 IU/L, p¼ .001) and increased at T8 to 26 IU/L (p¼ .010). AST showed a
similar trend (T4: p¼ .071 resp.T8: 0.021). Cessation of alcohol also led to a
significant drop in total cholesterol and LDL. Interestingly, subcutaneous fat
decreased significantly at T4 (19.5mm to 18.1mm, p¼ .008). Ferritin was
higher at baseline in drinkers compared to controls (median 107 mg/L (IQR
52–280) vs. 55 mg/L (IQR 21–100), p¼ .027) and decreased at T4 to 86 mg/L
(p¼ .053). All parameters remained unaltered in the control group during all
time points. Physical fitness improved significantly within drinkers after cessation
of alcohol, other parameters of quality of life remained stable and were similar
between groups.
Conclusion: Metabolic and biochemical changes within the liver, amelioration of
lipid profile and improvement of physical fitness can be observed after one
month of alcohol cessation in moderate drinkers. These pilot results should be
further assessed in larger cohorts but already endorse the public message to
subdue and possibly even altogether cease alcohol use.
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P0682 PROBIOTICS REDUCE ETHANOL-INDUCED HEPATIC
INJURY BY MODULATING GUT MICROBIOTA AND INTESTINAL
BARRIER INTEGRITY IN MICE
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Introduction: Gut-liver axis plays an important role in the pathogenesis of ALD.
The metabolic products of intestine enter the blood through the damaged intest-
inal mucosal barrier and cause liver damage. Nowadays, probiotics have been
used in the prevention and treatment of a variety of diseases, including ALD. It
has become a hot spot for the study of regulating intestinal micro ecological
balance and enhancing intestinal barrier function, to prevent alcoholic liver
injury. In this study, ALD mice were given probiotics to observe the protective
effects on ALD and explore the possible mechanism.
Aims & Methods: Gut-liver axis plays an important role in the pathogenesis of
ALD. The metabolic products of intestine enter the blood through the damaged
intestinal mucosal barrier and cause liver damage. Nowadays, probiotics have
been used in the prevention and treatment of a variety of diseases, including
ALD. It has become a hot spot for the study of regulating intestinal micro
ecological balance and enhancing intestinal barrier function, to prevent alcoholic
liver injury. In this study, ALD mice were given probiotics to observe the pro-
tective effects on ALD and explore the possible mechanism.
Results: HE and oil red O staining of liver tissues in alcohol group showed
significant steatosis and inflammatory response, and probiotics treatment can
reduce liver injury. Compared with the control group, the LPS of alcohol
group was significantly higher than that of the control group (62.36 3.05 vs
12.23 1.19 pg/ml, p5 0.05) and TNF- (779.4 10.01 vs 272.4 6.78 pg/ml,
p550.05) was significantly increased. Probiotics can effectively ease endotox-
emia (35.63 1.84 vs 6 2.36 3.05 pg/ml, p5 0.05) and inflammatory factors
TNF- (526.6 25.04 vs 779.4 10.01 pg/ml, p5 0.05) induced by alcohol.
RT-PCR results showed that probiotics increased the expression of Reg3b and
Reg3g (P5 0.05). Compared with the alcohol group, the mRNA levels of intest-
inal tight junction protein Occludin and Claudin-1 were increased with probiotics
treatment (P5 0.05). However, compared with the alcohol group, the mRNA
level of ZO-1 showed no significant difference (P4 0.05). WB results showed
that the expression of Occludin and Claudin-1 increased in probiotic treatment
group (P5 0.05).
In addition, Bacteroides (p5 0.05) and Bacteroides (p5 0.05) were significantly
increased in the intestine of the alcohol group. While the Clostridium (p5 0.05),
Lactobacillus (p5 0.05) and Coccidia (p5 0.05) were decreased. With the treat-
ment of probiotics, the levels of Enterococcus (p5 0.05) and Enterobacteriaceae
(p5 0.05) decreased, and the levels of Lactobacillus (p5 0.05) and
Bifidobacterium (p5 0.05) increased.
Conclusion: Probiotics showed protective effects on ALD by reducing alcohol-
induced endotoxemia and liver inflammatory injury as well as improving the
intestinal mucosal barrier and restoring the intestinal micro ecological imbalance.
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Introduction: Chemotherapy drugs have a direct hepatotoxic effect, which leads
to multiple increase in the risk of liver injury in patients with acute leukemias
(AL). The development of hepatotoxicity limits the chemotherapy (CT) provid-
ing in full doses.
Aims & Methods: We aimed to assess the overweight role in an increase of risk
level of hepatotoxic reactions in AL chemotherapy dynamics. The study involved
84 patients with newly diagnosed AL (64 – acute myeloid leukemia (AML), 20 –
acute lymphoblastic leukemia (ALL)), ECOG I-II, aged 24–67 years, 41(48.8%)
women, 43(51.2%) – men. The body mass index (BMI) was determined, the liver
function was assessed by the activity of alanine aminotransferase (ALT), aspar-
tate (AST) aminotransferase, alkaline phosphatase (ALP), gamma-glutamyltran-
speptidase (GGT), total bilirubin, total protein in the blood serum three times: at
baseline and on the 28th and 56th day after starting induction of remission
therapy, according to the ALL (prednisolone, doxorubicin, vincristin, asparagi-
nase, cyclophosphamide, cytarabine, mercaptopurine) and AML (cytarabine,
doxorubicin) treatment protocols. To assess the severity of hepatotoxic reactions
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the CTCAE scale was used. Overweight was detected in 40 patients: BMI¼ 25–
29.9 – in 29 (34.5%), BMI4 30 – in 11 (13.1%) patients. Depending on the
overweight presence the patients were divided into 2 groups: I (n¼ 44) – patients
with AL with normal body weight, II (n¼ 40) – patients with AL and overweight.
Results: In AL patients of group I before the start of chemotherapy functional
liver state was not significantly different from healthy people. In group II there
was an increase of ALT activity in 1.5 times, AST – in 1.2 times, ALP and GGT
in 1.4 times compared to the norm (p5 0.05) and reached grade I level, and no
change in bilirubin and total protein levels. On the 28th day of treatment in 3
(6.8%) patients of group I the violation of the functional liver state was revealed,
which was characterized by the increased activity of ALT in 1.5 times, AST – in
1.2 times, ALP – in 1.3 times, GGT – in 1.5 times compared to normal levels, that
consistent with grade I level, the bilirubin and total protein levels remained in the
normal range. In group II hepatotoxicity was detected in 19 (47.5%), which was
characterized by the increased activity of ALT and AST in 2.3 and in 2.2 times
respectively, GGT and ALP in 1.9 and 2.4 times respectively, the level of total
bilirubin increased in 2.1 times (p5 0.05), of which in 17 (42.5%) patients hepa-
totoxic reactions were of grade I and in 2 (5%) – of grade II level, with no
statistically significant changes in protein synthesis liver function. On the 56th
day of treatment in 7 (15.9%) patients of group I the violation of the functional
liver state was revealed, which was characterized by the increased activity of ALT
in 1.8 times, AST – in 1.3 times, ALP – in 1.6 times, GGT – in 1.9 times
compared to normal levels, the bilirubin and total protein levels remained in
the normal range, that consistent with grade I. In group II hepatotoxicity was
detected in 26 (65%), which was characterized by the increased activity of ALT
and AST in 2.6 and in 2.3 times respectively, GGT and ALP in 2.6 and 3.7 times
respectively, the level of total bilirubin increased in 3.6 times (p5 0.05), of which
in 10 (25%) patients hepatotoxic reactions were of grade I and in 16 (40%) – of
grade I† level.
Conclusion: The presence of the overweight results in a significant increase in the
frequency and degree of hepatotoxic reactions in patients with AL during
chemotherapy.
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Introduction: Alcohol abuse and alcohol dependence have become the world’s
growing public health problems. With the improvement of living standards in
China, alcohol consumption is growing and the incidence of alcoholic liver injury
also increased year by year. However, the mechanism of alcohol-induced liver
injury is not clear yet, and its pathogenesis is mainly related to oxidative stress,
lipid peroxi-dation, cytokines and mitochondrial dysfunction. Ferroptosis is an
iron-dependent cell death and its inhibitors can improve cell biochemical and
morphological changes[1]. The presence of Ferroptosis in liver injury induced by
alcohol has not yet been reported.
Aims & Methods: We aim to investigate the presence of Ferroptosis and the
expression of glutathione peroxidase 4 (GPX4)[2] in alcoholic liver injury by
establishing a cytological model of acute alcoholic liver injury and animal
model of alcoholic liver injury, and further elucidating the pathogenesis of
liver injury caused by ethanol. 1. By recovering human primary hepatic cell
lines to establish a model of acute alcoholic liver injury, Fer-1 and erastin were
used to intervention, DMSO control. 2. The biochemical indexes ALT, Fe, GSH
and MDA were detected by the kit. The expression of GPX4 in liver cells was
detected by qRT-PCR and Western Blot. 3. To establish an animal model of
alcoholic liver injury, Fer-1 and erastin were used to intervention, DMSO con-
trol. HE staining and electron microscopy were used to observe the changes of
liver tissue morphology.
Results: 1, Acute alcoholic liver injury cytology model showed that in the
untreated group, the Fe content is 0.809 0.140 nmol/mg, GSH
14.978 0.398 nmol/mg, MDA 3.402 0.546 nmol/mg; The content of Fe in
the alcoholic model group was 1.059 0.005 nmol/mg, GSH
6.826 0.013 nmol/mg and MDA 8.598 0.669 nmol/mg, which was statistically
significant compared with the untreated group (P5 0.05). The content of Fe in
Ferroptosis inhibitor Fer-1 group was 0.889 0.007 nmol/mg, GSH
11.11 0.413 nmol/mg, MDA 5.465 0.317 nmol/mg, compared significantly
with alcoholic liver model group (P5 0.05). The expression of GPX4 mRNA
in the untreated group, alcohol model group and Ferroptosis inhibitor group was
2.041 0.236, 1.420 0.219, 1.693 0.294 respectively. The protein level of
GPX4 respectively were 9.65 1.453, 1.36 0.770 and 4.04 0.709. The results
of the above analysis showed that there was significant difference bitween alco-
holic model group and Ferroptosis inhibitor group at both mRNA and protein
level of GPX4 (P5 0.05). 2, Liver microelectiography showed that the size of
mitochondria in liver cells of untreated group was normal. The mitochondrial
atrophy and membrane density were increased in the liver alcoholic model group,
suggesting that Ferroptosis occurred in the liver injury induced by alcohol. The
size of the mitochondria was normal and the mitochondrial ridge was seen in the
liver of the Ferroptosis inhibitor group.
Conclusion: 1, Ferroptosis exists in alcohol-induced liver injury. 2, The acute
alcohol liver injury cell model showed GSH content decreased, Fe and MDA
content increased and the expression of GPX4 decreased in both protein and
mRNA levels. Ferroptosis inhibitor Fer-1 could improve the above biochemical
changes and the expression of GPX4. 3, In the animal model of alcoholic liver
injury, electron microscopy showed that there was Ferroptosis in mouse liver
cells, which showed that the mitochondria of the liver cells were smaller and
the mitochondrial membrane density was increased. The Ferroptosis inhibitor
Fer-1 could improve the above mitochondrial morphological changes.
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Introduction: Ingestion of amatoxin-containing mushrooms is a rare medical
emergency. Amatoxin can cause massive hepatocyte necrosis and acute liver
failure. Liver transplantion can be life saving but liver transplantation criteria
are complex and not consensual. Mushrooms poisoning is associated with a high
mortality rate.
Aims & Methods:We conducted a retrospective analysis of demographic, clinical,
therapeutic and prognostic data of all patients with Amanita phalloides poisoning
admitted to a Gastroenterology Intensive Care Unit (GICU) of a tertiary hospi-
tal between 1997 and 2017.
Results: A total of 27 patients were included: 55.6% were male and the mean age
was 53 15 years old (range, 16–75). The most frequent initial symptoms were
vomiting (100%), diarrhea (88.9%) and abdominal pain (74.1%). The mean time
between ingestion and onset of symptoms was 10.1 hours and GICU admission
was 50.9 hours. At admission 33.3% presented hepatic encephalopathy (25.9%
grade 1; 3.7% grade 3 and 3.7% grade 4). Laboratory characterization at admis-
sion: mean INR was 4, total bilirubin 3.5mg/dL, creatinine 1.9mg/dL and factor
V 25.8%. The different criteria for emergent liver transplantation were assessed:
37% (n¼ 10) met Clichy’s criteria, 59.3% (n¼ 16) met King’s College criteria,
33.3% (n¼ 9) met Ganzert criteria and 40.7% (n¼ 11) met Escudié criteria.
Overall, 59.3% fulfilled criteria for liver transplantation: 25.9% on admission
and 33.3% during hospitalization. Regarding specific medical treatment: 92.6%
received silibinine, 59.3% acetylcysteine and 48.1% penicillin. In the group of
patients with emergent liver transplantation criteria, 63% were effectively trans-
planted. In the sub-group of patients who met criteria but were not transplanted
(n¼ 6): in 66.7% (n¼ 4) the reason was absence of donor, in 16.7% (n¼ 1) there
was liver function recovery and in 16.7% (n¼ 1) a contraindication was found
(irreversible intestinal ischemia diagnosed intraoperatively). The mortality in this
sub-group was 83.3%. The mortality rate in transplanted patients was 60%. All
patients without emergent liver transplantation criteria survived.
Conclusion: Amanita phalloides poisoning has a severe and rapidly progressive
presentation, often with indication for liver transplant. Patients are admitted late
in GICU. Mortality rate remains high even in transplanted patients.
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1Catholic University of Rome, Rome/Italy
2Digestive And Liver Diseases Unit, Sapienza Università di Roma at Sant’Andrea
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Introduction: Binge drinking is a common pattern of alcohol consumption among
young population. At present few data are available on the possible relationship
between binge drinking and alcohol use disorder (AUD) in adolescent. The aim
of this study was to assess drinking habits, patterns of alcohol consumption,
smoking habits, use of illicit drugs, the prevalence of binge drinking and AUD
among young students. The correlation between binge drinking and AUD was
also investigated.
Aims & Methods: This study was performed on 2704 subjects attending high
school. Questionnaires regarding socio-demographic data, anthropometric char-
acteristics, pattern and amount of alcohol intake, smoking habits, use of illicit
drugs, and physical activity were administered to students. Moreover Italian
versions of AUDIT, STAI-Y1, STAY-Y2 and ZUNG scale were administered.
Results: Alcohol intake was reported by 2126 students (79%); among them 1278
(60%) reported at least one episode of binge drinking in the last year and 715
(34%) in the last month. According to AUDIT questionnaires, a diagnosis of
AUD was made in 165 (6%) subjects. The prevalence of AUD was higher in
subjects that reported binge drinking behavior than in those that did not report
binge drinking (p5 0.0001).
Conclusion: Alcohol consumption and abuse among young students is alarming.
Binge drinking behavior among young students seems to be very common and it
seems a risk factor for the development of AUD.
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Introduction: Severe alcoholic hepatitis (SAH) remains a condition which bears
high mortality and morbidity rates, as well as high healthcare costs. This is why
adequate selection of patients who would benefit the most from corticotherapy is
of utmost importance. Although serum biomarkers are available (Maddrey
Discriminant Function - MDF), the diagnostic of SAH relies on liver biopsy.
Previous metabolomic studies have shown a core metabolic phenotype
represented by decreased serum lysophosphatidylcholines (LPC) and increased
serum bile acids that occurs relatively early in liver diseases regardless of etiology,
and remains stable in their evolution, including liver cirrhosis and hepato/cho-
langiocarcinoma (1). Our previous work also showed that decreased LPC levels
are associated with alcoholic liver disease (ALD).
Aims & Methods: The aim of the study was to assess the metabolic profile of
patients with ALD and to identify potential new biomarkers associated with
severity. Between December 2015 and September 2016, 64 patients with biopsy
proven AH were included (38 with SAH - MDF 32 and 24 with non-severe AH
- MDF5 32). Fasting serum was stored at 80 degrees after centrifugation at
5000 rpm for 10 minutes. Specific purification protocol metabolomic analysis was
performed using Thermo Scientific UHPLC UltiMate 3000 system, equipped
with a Dionex quaternary pump delivery system and a Bruker Daltonics
MaXis Impact MS detection equipment (version 2012). Biostatistical analysis
The chromatograms obtained were processed using CompassDataAnalysis_4.2
software (Bruker, Germany) and about 3000–4000 molecular masses were iden-
tified. Those data were further processed using ProfileAnalysis (Bruker,
Daltonics): time alignment, normalization by sum of bucket values in analysis,
80% bucket filter, internal recalibration, etc. The matrix obtained was further
processed by MetaboAnalysis, to analyze samples through univariate and multi-
variate statistical analysis.
Results: Univariate and multivariate statistical analysis by MetaboAnalysis iden-
tified 10 potential biomarkers. Among them, LPC (18:0) showed good discrimi-
nation for SAH (AUC¼ 0.804) with significantly lower values as compared with
non-severe AH (0.38 fold change, p¼ 6 1011).
Conclusion: SAH appears to have a different metabolic profile, mainly due to
changes in lysophosphatidylcholine metabolism. Targeted metabolomic studies
are required in order to confirm the results and to evaluate the possible applica-
tions in current clinical practice.
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Gender Age
Hours from
ingestion to
GICU admission
Clichy’s
criteria
(Yes/No)
King’s
College
criteria
(Yes/No)
Ganzert
criteria
(Yes/No)
Escudié
criteria
(Yes/No)
Listed
to ELT
(Yes/No)
ELT
(Yes/No) Outcome
Patient 1 Male 48 72 No Yes No Yes Yes Yes Died from acute myo-
cardial infarction
after ELT
Patient 2 Female 29 72 Yes Yes No Yes Yes Yes Alive
Patient 3 Female 52 48 Yes Yes Yes Yes Yes No Died, absence of donor
Patient 4 Male 67 24 Yes Yes Yes Yes Yes Yes Alive
Patient 5 Female 55 72 No Yes No No Yes No Alive, hepatic function
recovery
Patient 6 Male 40 48 Yes Yes Yes Yes Yes Yes Died from cardiopul-
monary arrest after
ELT
Patient 7 Male 16 48 No Yes No Yes Yes Yes Alive
Patient 8 Female 66 48 Yes Yes Yes Yes Yes Yes Died from cardiopul-
monary arrest after
ELT
Patient 9 Male 43 96 Yes Yes Yes Yes Yes No Died, absence of donor
Patient 10 Male 55 72 Yes Yes Yes Yes Yes No Died, absence of donor
Patient 11 Male 48 16 Yes Yes Yes Yes Yes Yes Alive
Patient 12 Female 64 24 Yes Yes Yes Yes Yes No Died, absence of donor
Patient 13 Male 63 56 No Yes No No Yes Yes Died, peritonitis after
ELT
Patient 14 Male 68 37 No Yes No No Yes Yes Died
Patient 15 Female 63 56 No Yes Yes No Yes Yes Died from acute myo-
cardial infarction
after ELT
Patient 16 Male 70 57 Yes Yes No No Yes No Died, irreversible
intestinal ischemia
ELT - emergency liver transplantation
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Introduction: Acute kidney injury (AKI) is a common complication in patients
with decompensated liver cirrhosis. Recently, the International Club of Ascites
(ICA) defined new diagnostic criteria: the ICA-AKI criteria.
Aims & Methods: This study aims to identify patients hospitalized for acute
decompensation of cirrhosis with AKI, according to the ICA-AKI criteria, and
to determine if its application leads to greater prognostic accuracy.
Methods: Retrospective analysis of hospitalized patients in a gastroenterology
department for acute decompensation of cirrhosis, without acute-on-chronic
liver failure, between January 2014 and December 2015. Identification of AKI
patients according to ICA-AKI criteria. Compared the hospital length of stay,
severity of liver disease and in-hospital and short-term mortality among patients
with and without AKI. Compared the accuracy of the conventional criteria vs.
ICA-AKI criteria in the prediction of mortality.
Results: 161 patients included, 85.7% male, mean age of 65 10.8 years. Average
length of stay of 11.6 9.5 days. 39.8% of patients had AKI on admission or
during hospitalization according to the ICA-AKI criteria (60.9% in stage 1,
20.3% in stage 2 and 18.8% in stage 3). Patients with AKI according to ICA-
AKI had longer hospitalizations (14.55 vs. 9.78 days, p5 0.05), higher severity of
hepatic disease quantified by the MELD and MELD-Na scores (17.62 vs. 12.83
511, p5 0.05 and 17.61 vs. 12.83 P5 0.05) and higher in-hospital, 28 and 90-day
mortality when compared to patients without AKI (23.4 vs. 6.2%, p5 0.05, 31.3
vs. 9.3%, p5 0.05, 42.9 vs. 23.7%, p5 0.05). There was a statistically significant
association between the presence of infection and the development of AKI
(p5 0.05). The ICA-AKI area under the curve (AUC) to predict in-hospital,
28 and 90-day mortality was significantly higher than the AUC of conventional
criteria (0.682vs 0.533; 0.678 vs. 0.588; 0.618 vs. 0.509, p5 0.05).
Conclusion: The ICA-AKI criteria allow the identification of decompensated
cirrhotic patients in whom a worse prognosis is predicted. Thus, they constitute
a useful tool in daily clinical practice.
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Introduction: The pathophysiology of hepatic encephalopathy is not fully under-
stood. A nationwide nested case-control study was conducted to investigate risk
factors in the development of hepatic encephalopathy (HE) among patients with
liver cirrhosis (LC) in Taiwan.
Aims & Methods: A total of 913 patients with incident HE and 3499 patients
without HE (control) were identified from a cohort of liver cirrhosis (n¼ 14, 428)
using the population-based, Longitudinal Health Insurance Database 2000 in
1997–2012. Controls were matched to case patients on age at LC diagnosis (þ/
2 years), sex, Charlson Comorbid index score, year of LC and follow-up time at
1:1 ratio. A multivariate logistic regression model for HE was developed to
explore the relative contribution of various risk factors, including patient
demographics, infections, cirrhosis-related complications (hepatocellular carci-
noma, decompensated cirrhosis), H. pylori therapy, and peptic ulcer bleeding.
A Cox regression model for all-cause mortality was performed.
Results: 714 cases of HE and matched to 714 controls were enrolled in the
analysis. Infections (adj. OR, 3.41, 95% CI, 2.7–4.31, p5 .0001) and frequency
of infections yearly (3:adj.OR 11.26, 95%CI, 5.7–22.22; 1–3: adj.OR 2.82,
95%CI, 2.26–3.53) were significantly associated with increased risk of HE. H.
pylori infection (13.31% vs. 8.68%, p¼ 0.0052) and sites of infections such as
pneumonia (14.99% vs. 10.50%, p¼ 0.0111), peritonitis (14.29% vs 2.52%,
p¼50.0001), sepsis (25.63% vs. 9.52%, p¼50.0001), urinary tract infection
(18.77% vs. 11.20%, p5 0.0001), biliary tract infection (7.14% vs. 3.22%,
p¼ 0.0008) and cellulitis (11.62% vs. 3.98%, p¼ 0.0207) increased risk for HE.
HE (adj HR, 0.90, 95% CI, 0.76–1.06, p¼ 0.02) and infections (adj. HR, 1.13,
95% CI 0.93–1.38, p¼ 0.23) increased hazards of death but did not reach statis-
tical significance.
Conclusion: This is the first reported case-control study of HE in Taiwan. The
study provides further evidence that infections are strongly associated with HE
development among patients with liver cirrhosis; risks for HE vary by relative
frequencies and sites of infections. These data provides important information
relevant to the prevention and management of cirrhotic patients at risk for HE.
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Introduction: Patients with cirrhosis have a high risk of sepsis, which confers a
poor prognosis. Systemic inflammatory response syndrome (SIRS) criteria have
several limitations in cirrhosis. Recently, new criteria for sepsis (Sepsis-3) have
been suggested in the general population (increase of Sequential Organ Failure
Assessment [SOFA] 2 points from baseline). Outside the ICU, the qSOFA (at
least 2 among: alteration in mental status, systolic blood pressure 100mmHg,
or respiratory rate 22/min) was suggested to screen sepsis. These criteria have
never been evaluated in cirrhotic patients.
Aims & Methods: The aim of our study was to assess the ability of Sepsis-3
criteria in predicting in hospital mortality in patients with cirrhosis and bacterial
infections. Consecutive patients with cirrhosis and bacterial/fungal infections
were prospectively included. Demographic, laboratory and microbiological
data were collected at diagnosis of infection. Preadmission SOFA was assessed
using preadmission data as provided for acute kidney injury criteria. Patients
were followed-up until death, liver transplantation or discharge.
Results: 259 patients were included (Age¼ 61 12 years, MELD-score¼ 20 7).
The most common infections were urinary tract infection (33%), spontaneous
bacterial peritonitis (23%) and pneumonia (14%). SIRS, qSOFA and Sepsis-3
criteria were found in 34, 23 and 64% of patients, respectively. During the
hospitalization 19% of patients died. Sepsis-3 and qSOFA had significantly
greater discrimination for in-hospital mortality (AUROC¼ 0.784 and 0.732,
respectively) than SIRS (AUROC¼ 0.606; p5 0.01 for both). In multivariate
analysis, Sepsis-3 (OR¼ 5.71; p¼ 0.007), qSOFA (OR¼ 3.11;p¼ 0.004), CLIF-
C-AD score (OR¼ 1.05;p¼ 0.007), C-reactive protein (OR¼ 1.62;p¼ 0.014) and
nosocomial infections (OR¼ 2.15;p¼ 0.058), were found to be independent
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predictors of in-hospital mortality. Patients with Sepsis-3 had higher incidence of
acute-on-chronic liver failure (36 vs 11%; p5 0.001), septic shock (15 vs 0%;
p5 0.001) and transfer to the ICU (16 vs 2%; p¼ 0.001) than those without
Sepsis-3. Similar findings were found for qSOFA.
Conclusion: Sepsis-3 criteria are more accurate than SIRS criteria in predicting
the severity of infections in patients with cirrhosis. qSOFA is a useful bedside
tool to assess risk for worse outcomes in these patients. Patients with Sepsis-3 and
positive qSOFA deserve more intensive management and strict surveillance.
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Introduction: Portopulmonary hypertension (POPH) is characterized by pulmon-
ary vasoconstriction, while hepatopulmonary syndrome (HPS) is characterized
by vasodilatation. Given that HPS could be resolved after orthotopic liver trans-
plantation (OLT) even when hypoxemia were severe (PaO25 50mmHg), impli-
cations for OLT is accepted not only for deceased donor LT (DDLT), but also to
living donor related LT (LDLT). However, the post-OLT course of POPH com-
plicated patients are often unsatisfactory and severe (mPAP4 45 to 50mmHg)
patients are considered as an absolute contraindication for OLT. The
International Liver Transplant Society Practice Guidelines indicate that, unlike
HPS, there are no data to support the concept that POPH (treated or untreated)
should be an indication for OLT. Furthermore, the Practice Guidelines recom-
mend that patients with mPAP5 35mmHg be indicated for OLT, and PA-tar-
geted therapy should be initiated in patients with mPAP 35mmHg. However,
almost all of the patients in these articles had received DDLT, and no such
analyses have been for LDLT patients. Given that left or right lobe LDLT
grafts are smaller than DDLT grafts, PH-induced hepatic venous pressure
might result in a strong congestive impact on the LDLT grafted liver.
Although patients with confirmed POPH and HPS are rare, relatively pulmonary
hypertensive patients and mild HPS patients may be more common.
Aims & Methods: The present objective is to investigate the clinical impact of
subclinical PH on the inevitably small survival in grafted living donor OLT
(LDLT). We recruited 84 OLT candidates for liver cirrhosis in a retrospective
cohort study. Patients exhibiting a tricuspid regurgitation pressure gradient
(TRPG) 25mmHg (median) on echocardiography were categorized as poten-
tially having PH (subclinical PH; n¼ 34). The mean pulmonary artery pressure
(mPAP) measured after general anesthesia with FIO20.6 (mPAP-FIO20.6) was
also also included as advisory data. Patients exhibiting pO25 80mmHg and an
alveolar-arterial oxygen gradient (AaDO2) 15mmHg were categorized as
potentially having HPS (subclinical HPS; n¼ 29). The clinical course after
LDLT was investigated according to subclinical PH or HPS.
Results: Subclinical PH was correlated with a worse 1-year survival (p¼ 0.003).
Subclinical PH (p¼ 0.012) and older donor age (p¼ 0.008) were correlated with a
poor 40-month survival. Although a higher mPAP-FIO20.6 was expected to
correlate with a worse survival, a high mPAP-FIO20.6 was not a significant
risk factor for the post-LDLT survival. When the post-LDLT survival was inves-
tigated according to the TRPG and mPAP-FIO20.6 status, it was worst in
patients who had a high TRPG and low mPAP-FIO20.6. The patients with a
high mPAP-FIO20.6 and low TRPG showed a good survival, probably because
co-existing HPS released the regurgitation pressure.
Conclusion: In cirrhosis patients, mPAP-FIO20.6 may not accurately reflect the
congestive pressure to the liver, as the pressure might escape via a pulmonary
shunt. Subclinical high TRPG is an important marker for predicting congestive
pressure to a grafted small liver, resulting in a worse survival after LDLT.
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Introduction: Portal vein thrombosis (PVT) is reconized as an independent factor
of variceal bleeding. Beta blockers are the mainstay treatment to prevent variceal
bleeding in cirrhotic patients. Carvedilol has been shown to be equal to propra-
nolol in preventing first bleeding in cirrhotic patients, however, the efficacy of
this policy in patients with PVT is unknown.
Aims & Methods: The aim of this study was to evaluate the efficacy of carvedilol
versus propranolol in primary prophylaxis of variceal bleeding in cirrhotic
patients with occlusive portal vein thrombosis. Between January 2014 and
December 2015, cirrhotic patients with occlusive non-malignant PVT were
enrolled in a tertiary center. PVT was susspected by Doppler ultrasound and
confirmed by computeted tomography. Cirrhotic patients with esophageal
varices and no previous variceal bleeding were randomized to carvedilol
6.125mg daily or Propranolol 40mg daily. End points were esophageal variceal
bleeding or death.
Results:During the study periode forty eight patients were evaluated. Twenty one
and twenty seven patients were randomized in carvedilol and propranolol arms
respectively. Mean age was 49 12.2 years; 33 (68.7%) were males; 60.4% had
viral cirrhosis; mean Child-Pugh score was 7.2 2.6 and mean follow up was
12.3 9.1 months (range 1–29 months). All the patients had occlusive non-malig-
nant PVT, most of them involving only the trunk, and grade 2 or 3 esophageal
varices. Both carvedilol and propranolol groups had comparable variceal bleed-
ing rates (14.2% vs. 14.8%, P¼ 0.002), bleed related mortality (9.5% vs. 11.1%,
P¼ 0.027) and overall mortality (23.8% vs. 22.2%, P¼ 0.004) respectively.
Adverse events in carvedilol group were hypotension (n¼ 2), requiring cessation
of therapy, while and dyspnea (n¼ 3) resolved spontaneously. In the propranolol
group there was 1 advers event that required discontinuation of treatment (grade
2 atrio-ventricular block).
Conclusion: Our study suggests that carvedilol is probably not superior to pro-
pranolol in preventing first variceal bleeding in cirrhotic patients with occlusive
PVT, and they both can be used as primary prophylaxis.
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Introduction: The ALBI score was recently developed to assess the severity of
liver dysfunction, taking into account albumin and bilirubin levels. We aimed to
assess its prognostic performance in patients with liver cirrhosis complicated with
upper gastrointestinal bleeding (UGIB) while comparing it with Child-Pugh (CP)
and MELD scores.
Aims & Methods: Retrospective unicentric study, including consecutive adult
patients with cirrhosis admitted for UGIB between January 2011 and
November 2015. Clinical, analytical and endoscopic variables were assessed
and ALBI, CP and MELD scores at admission were calculated. Statistical ana-
lysis was performed using SPSS v21.0 and MedCalc v.16.4.3, and a two-tailed p
value5 0.05 was defined as indicating statistical significance.
Results: Included 111 patients with a mean age of 57 12 years, 76.6% were
males. Liver cirrhosis was most frequently alcoholic (89.2%) and the most
common etiology for UGIB was variceal hemorrhage, in 75.5% of patients.
During the first 30 days of follow-up 12 patients (10.8%) died, and during the
1st year of follow-up another 10 patients died (1st year mortality of 19.8%).
When comparing the three scores, regarding in-stay and 30 days mortality,
only ALBI score showed statistical significant results, with an area under the
curve (AUC) of 0.82 (p5 0.01) for both outcomes. Regarding 1st year mortality,
AUC for ALBI, CP and MELD scores, were 0.71 (p5 0.01), 0.64 (p5 0.05) and
0.66 (p¼ 0.02), respectively, while for global mortality AUC were 0.75
(p5 0.01), 0.72 (p5 0.01) and 0.72 (p5 0.01), respectively. When comparing
the AUC of the three scores, no significant differences were found regarding
1st year mortality and global mortality.
Conclusion: In our series, ALBI score accurately predicted both in-stay and 30
days mortality (0.82 (p5 0.01)), while CP and MELD scores weren’t able to
predict these outcomes. All scores showed a fair prognostic prediction perfor-
mance regarding 1st year and global mortality. These results suggest that ALBI
score is particularly helpful in the assessment of short term outcomes, with a
better performance than the most commonly used scores, and may assist the
clinician in the stratification of care at admission and maybe even in the referral
to liver transplant.
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Introduction: Despite the progress in the treatment of cirrhosis, infections remain
a common problem, being responsible for the great majority of morbidity and
mortality in these patients.
Aims & Methods: The aim of this study was to identify predictive factors for
infection in the first hospitalization for decompensated cirrhosis (DC).
Retrospective analysis of patients with the first hospitalization for DC between
January of 2009 and March of 2016. Demographic, clinical and biochemical data
was compared between patients with and without proven infection in the first
hospitalization for DC.
Results: From the 179 patients with a first hospitalization for DC, 6% had ascites
on admission, 45.8% had upper gastrointestinal bleeding, 38.5% had jaundice,
and 28.5% had hepatic encephalopathy. Regarding medication, 29.6% of the
patients were taking proton pump inhibitors (PPI), 22.3% had beta-blockers
prescribed, and 1.7% were on prophylactic antibiotic. In those 53 patients with
proven infection, spontaneous bacterial peritonitis was the most common infec-
tion (34%), followed by urinary tract infection (30.2%) and pneumonia (13.2%).
Infected patients presented with jaundice (p¼ 0.03), severe ascites (p¼ 0.009), use
of PPI (p¼ 0.003) and acute-on-chronic liver failure (p¼ 0.006) more frequently
than those without infection. Additionally, infected patients presented with sig-
nificantly increased values of C-reactive protein (p5 0.001), INR (p¼ 0.04),
creatinine (p¼ 0.013) and MELD scores (p¼ 0.001). Mortality rates were
higher in infected patients at 30-day (4.0% vs. 9.4%), 3 months (7.9% vs.
18.9%), 6 months (12.7% vs. 24.5%) and 1 year (22.2% vs. 26.5%). In the
multivariate analysis, the use of PPI was independently associated with an
increased risk of infections (OR¼ 2.3; 95% CI 1.052–5.173).
Conclusion: Almost a third of patients will develop infections right at the first
hospital admission for decompensated cirrhosis, which are associated with higher
short and long-term mortality rates. As PPI more than double the risk of infec-
tion, the indication for the use of these drugs should be strictly reviewed and their
interruption considered in cirrhotic patients.
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Introduction: Critical flicker frequency (CFF) values 39Hz identify cirrhotic
patients with minimal hepatic encephalopathy (mHE) and predict their risk of
developing overt hepatic encephalopathy (oHE). However, these results have
been obtained in cirrhotics with advanced liver disease suffering a previous epi-
sode of liver decompensation (74% of patients) or oHE (14% of patients).
Aims & Methods: Herein, we evaluated the effectiveness of CFF in predicting the
first episode of oHE in compensated outpatients undergoing a long-term follow
up. A total of 134 selected patients and 150 healthy subjects were evaluated using
CFF. A CFF value was considered normal when 439Hz and pathological when
39Hz. At baseline, we evaluated demographic characteristics, laboratory tests,
model for end-stage liver disease (MELD) score, and Child-Pugh class in all
patients. Then, they were followed up for 31.5 18.9 months and received clin-
ical examinations and laboratory tests every six months.
Results: At baseline, all controls had a CFF 439Hz with a mean value signifi-
cantly higher than that observed in 93 patients with CFF 439Hz (p5 0.001),
while the remaining 41 patients showed a CFF 39Hz. Our analysis demon-
strated a significant inverse correlation between CFF and MELD (r: 0.33,
p¼ 0.0003), while the prevalence of CFF values 39Hz significantly increased
with the progression of the Child-Pugh class (p¼ 0.003). Interestingly, the CFF
value at baseline was predictive of the first episode of overt HE both by log-rank
test (p5 0.001) and Cox regression analysis (HR¼ 5.623; 95%CI¼ 2.433–
12.991; p5 0.001).
Conclusion: We demonstrated, for the first time, that CFF predicts the first
episode of oHE in a population of compensated cirrhotics that never experienced
oHE. Cirrhotic patients should be routinely screened by CFF to identify patients
at risk of oHE.
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Introduction: The Fontan circulation causes some degree of hepatic congestion by
its nature of anatomical reconstruction. This may lead to liver fibrosis or even
cirrhosis, but to what extend is unknown. A profound hepatic evaluation, incor-
porating several non-invasive and invasive modalities, in an asymptomatic
Fontan patient cohort may further elucidate this.
Aims & Methods: Consecutive patients with a Fontan circulation are prospec-
tively included for screening of liver fibrosis. This screening consists of a blood
panel including biomarkers, liver ultrasonography, transient elastography
(Fibroscan), contrast-enhanced liver MRI or CT-scan and liver biopsy. Liver
biopsies were systematically scored with the Fontan specific fibrosis score.
Mild fibrosis was defined as a maximum score of 2 on sinusoidal and portal
fibrosis component, severe fibrosis as score 3 or 4 on at least one component.
Non-invasive markers for portal hypertension (PHT) such as presence of collat-
erals and splenomegaly on imaging, platelet count (N/mLmm3)/spleen diameter
(mm) ratio (PSR) and von Willebrand factor (VWF) were measured.
Results: From November 2015 until March 2017, 52 Fontan patients were
included (mean age 27 7.5 years, 60% male). The majority of patients had
one or more elevated liver enzymes (elevated GGT in 68%, median 67mmol/l
IQR 51–107). Median platelets were 174 10e9/l (IQR 147–213) and mean VWF
104 23%. Mean liver stiffness was 21.8 9.3 kPa. The majority (77%) of ultra-
sonographies showed no sign of cirrhosis or splenomegaly (mean spleen size
11.9 1.8 cm). However, 54% of advanced imaging (MRI or CT-scan) showed
cirrhosis, 23% congestion and in 21% signs of PHT were observed. Of 33
patients with histology, none were without fibrosis or sinusoidal dilatation and
cirrhosis was present in 21%. Of these only 57% also showed signs of cirrhosis on
imaging. Of all patients with signs of PHT on imaging only one (13%) patient
had histologically confirmed cirrhosis whereas five (63%) had mild fibrosis. Liver
stiffness was equal in patients with mild (22.3 9.2) compared to severe fibrosis
(25.3 12.1) (p¼ .458). Median PSR in patients with mild fibrosis was 1557 (IQR
1139–1910) and 1233 (IQR 1045–1451) in severe fibrosis (p¼ .114). VWF was
comparable between groups (99 12 vs. 105 20%, p¼ .241). Patients with
severe fibrosis were not older (resp 28 7 vs. 26 6 years, p¼ .555) nor had a
longer duration of the Fontan circulation (22 5 vs. 21 4 years, p¼ .644).
Conclusion: All Fontan patients are at risk of developing severe liver fibrosis,
irrespective of age, duration of Fontan circulation and even when asymptomatic.
Portal hypertension may occur in the absence of severe fibrosis. Assessment by
solely non-invasive modalities may both under- and overestimate the incidence of
fibrosis. For generalizability of the current findings, Fontan patients should be
prospectively assessed with multimodality assessment in larger cohorts.
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Introduction: Probiotics has been recently used to treat cirrhotic patients with any
grade of acute or chronic hepatic encephalopathy (HE). Herein, we evaluated the
efficacy of Lactobacillus Rhamnosus GG (LRGG) on the treatment of minimal
HE (mHE) in compensated cirrhotics.
Aims & Methods: 134 patients were screened by critical flicker frequency (CFF)
to diagnose mHE. Among them, 41 patients were CFFþ (39Hz) and were
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randomized to placebo or LRGG treatment, for 2 months. In all intention to
treat and per protocol patients, demographic characteristics, laboratory test,
model for end-stage liver disease (MELD) score, and Child-Pugh class were
evaluated.
Results: CFF value increased in both LRGG and placebo groups at the end of
treatment. However, in the former group CFF value significantly increased as
compared to placebo (46.5 5.7 vs. 41.1 4.6Hz, p¼ 0.015), thus indicating a
better therapeutic outcome on mHE. Moreover, mHE reversal was achieved in
75.0% vs. 35.7% of the patients from LRGG and placebo groups, respectively
(p¼ 0.047).
Conclusion: For the first time, we demonstrate that LRGG improves mHE
(expressed by a significant CFF increase).
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Introduction: Hepatitis C virus infection is a pressing national problem in Egypt.
HCV carries a variable clinical course in different patients. The human Toll like
receptors (TLRs) family consists of ten receptors that are critically important for
innate immunity. TLRs recognize and respond to diverse microbial molecules
and enable the innate immune system to discriminate among groups of pathogens
and to induce an appropriate cascade of effector responses. Toll-like receptors 3
and 7 are recognition receptors that allow the innate immune system binding to
RNA materials. The genetic polymorphism of these receptors has a direct role on
the outcome of many diseases.
Aims & Methods: The aim of this study was to assess the association between
genetic polymorphism of TLR 3 and Sex- linked TLR 7 alleles with HCV infec-
tion outcome in Egyptian families using high resolution techniques. A total of
135 Egyptian families (622 individuals) were recruited in this study from upper
and lower Egypt (East and West delta). We compared the risk of allele carriage of
selected markers in different groups. These groups included spontaneous virus
clearance (SVC) (108 subject), chronic HCV (CHC) patients (216), and negative
control (298) individuals. The rs3775291 (C/T) was genotyped for TLR3. While
the rs3853839 (C/G) was genotyped for TLR7 by real time PCR using
TaqManallelic discrimination kit (Applied Biosystems) according to the manufac-
turer’s protocol. The distribution of the TLR7 rs3853839 (C/G) polymorphism
was assessed separately in female and male subpopulations of the study due to
the X-linked nature of the TLR7 gene.
Results: As regard TLR3 the frequency of the C allele was 88.5%, 83.4% and
71.06% for the SVC, control and CHC groups respectively. While the allele
frequency of the T allele was found to be 11.5%, 16.5%, 38.9% in SVC, control,
and CHC groups respectively. When these alleles were compared between the 3
studied groups, The T allele of TLR 3 rs3775291 was found to be significantly
higher in chronic HCV group when compared to both spontaneous clearance
(SVC) and control groups [OR 15.285 (95% CI 2.04 to 114.08, corrected P (Pc)
50.02) and OR 5.17 (95% CI 2.30 to 11.64, Pc5 0.0003)] respectively. As regard
the sex- linked TLR-7 it was found that the frequency of the C allele was 69.5%,
69.1% and 46.3% for the SVC, control and CHC groups respectively. While the
frequency of the G allele was found to be 30.95%, 30.9%, 53.7% in SVC, control
and CHC groups respectively. When the association of these alleles with HCV
infection outcome was studied in the female and male subpopulations it showed
that: The C allele of TLR 7 rs3853839 in the female subpopulation was signifi-
cantly higher in both HCV spontaneous clearance (SVC) and control groups
when compared to chronic HCV group [OR 0.42 (95% CI 0.21 to 0.82,
Pc5 0.0372) and OR 0.40 (95% CI 0.23 to 0.71, Pc5 0.0054)] respectively.
The same results was also reported in the male subpopulation as the same
allele was found to be significantly higher in both HCV spontaneous clearance
(SVC) and control groups when compared to chronic HCV group [OR 0.289
(95% CI 0.14 to 0.59, Pc5 0.0021) and OR 0.17 (95% CI 0.1009 to 0.28,
Pc5 0.0001)] respectively.
Table(1): Association of the allele T of TLR3 rs3775291 polymorphism among
the studied groups.
control Vs
spontanous
CHC vs
Spontaenous CHC vs control
Odds ratio (OR) 2.9517 15.2857 5.1786
95% CI 0.3648 to 23.8807 2.0481 to 114.0824 2.3038 to 11.6406
z statistic 1.015 2.659 3.979
P 0.3102 0.0078 0.0001
Pc 0.9306 0.0234 0.0003
Conclusion: The risk of development of chronic HCV infection was associated
with T allele carriage of TLR3rs3775291 SNP. While the carriage of C allele of
TLR7 rs3853839C allele was associated with spontaneous HCV clearance in both
male and female subpopulations in Egyptian families.
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Sá, K.S.G.d., et al., Toll-like receptor 3 gene polymorphisms are not associated
with the risk of hepatitis B and hepatitis C virus infection. Revista da Sociedade
Brasileira de Medicina Tropical, 2015. 48(2): p. 136–142.
P0701 ACTIVATED HEPATIC STELLATE CELLS CAN DIRECTLY
INDUCE PATHOGENIC TH17 CELLS IN CHRONIC HEPATITIS B
VIRUS INFECTION
Y. Liu
1, W. Jiang2
1Zhongshan Hospital, Fudan University, Shanghai/China
2Gastroenterology & Hepatology, Zhongshan Hospital, Fudan University,
Shanghai/China
Contact E-mail Address: liuyun2008294@126.com
Introduction: Th17 cells are involved in liver fibrosis by activating hepatic stellate
cells (HSCs). We aimed to investigate whether HSCs could regulate the function
of Th17 cells and the relevant mechanism.
Aims & Methods: Sixty-five patients diagnosed with chronic hepatitis B (CHB)
were enrolled in this study. To unravel the effect of HSCs on T cells, naı̈ve
CD4þT cells and Th17 cells were sorted from CHB patients and cultured with
or without activated-HSCs, and cytokines expression and genes transcription
were analyzed. In addition, the regulatory mechanism of HSCs was also
investigated.
Results: ELISA and qRT-PCR showed that Th17 cells from CHB patients were
more pathogenic via the expression of IL-17A, IL-23R, RORC, CCL20 and
CCR6, and meanwhile, they could activate the primary HSCs. The co-culture
experiment indicated that activated HSCs dramatically promoted the prolifera-
tion of CD4þT cells in a time- and dose-dependent manner. In addition, they
could also induce the naı̈ve CD4þT cells into Th17 cells which had a more
pathogenic phenotype. Moreover, activated-HSCs-mediated induction of Th17
cells might depend on IL-1b and IL-6 release as well as COX-PGE2 pathway.
Conclusion: Th17 cells cooperated with HSCs in a proinflammatory feedback
loop provide us a more understanding of the pathogenic role of Th17 cells in
the chronicity of HBV infection.
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Introduction: Living donor liver transplantation (LDLT) has become the only
life-saving treatment option for patients with end stage liver disease secondary to
HCV infection in Egypt, unfortunately recurrence of infection is nearly universal,
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resulting in cirrhosis and graft failure within 5 years after transplant. Different
studies have been published studying efficacy and safety of direct acting antiviral
(DAA) drugs in treatment of HCV infection post-liver transplantation. We
aimed to evaluate the efficacy and safety of treatment with DAA drugs early
post-transplant period in LDLT recipients with HCV genotype 4
Aims & Methods: The study was descriptive retrospective analysis on twenty-six
LDLT patients with HCV genotype 4 treated with DAA drugs (fifteen patients
received Sofosbuvir 400mg and weight based Ribavirin dose for 24 weeks, eight
patients received Sofosbuvir 400mg and Daclatasvir 60mg for 24 weeks and
three patients received Sofosbuvir 400mg and Simeprevir 150mg for 12 weeks)
in the early post-transplant period who were transplanted during the period from
January 2014 till December 2015 at Egyptian tertiary center for organ
transplantation
Results: Twenty-six patients completed the treatment course. sustained virologi-
cal response (SVR) at week 12 was achieved in 80.8% (21/26) of recipients, 100%
(11/11) for Sofosbuvir- Daclatasvir and Sofosbuvir- Simeprevir group versus
66.7% (10/15) for Sofosbuvir-Ribavirin group (p5 0.05). No major side effects
had been reported, anemia developed in patients received ribavirin respond to
treatment with erythropoietin and reduction of the ribavirin dose.
Conclusion: Use of Daclatasvir/Sofosbuvir or Simeprevir/Sofosbuvir in early
treatment of HCV genotype 4 post living donor liver transplant recipient
achieved higher rates SVR than Sofosbuvir/Ribavirin.
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Introduction: Direct antiviral agents (DAAs) have led to high sustained virologi-
cal responses (SVR) in HCV patients. However, genotype 3 patients respond to
treatment in a suboptimal way.
Aims & Methods: This study aims to identify which of the several treatment
schedules recommended for genotype 3 would constitute the best option.
Twenty-four Italian centers were involved in this real-life study where HCV
genotype 3 patients treated with DAAs. To expand the number of cases, we
conducted a systematic review of literature on the outcome of genotype 3 patients
treated with DAAs.
Results: A total of 233 patients with HCV genotype 3 were enrolled. Cirrhotic
patients accounted for 83.7%. Overall, the SVR12 rate was achieved by 205
subjects (88.0%); the SVR rates were 78.8% after sofosbuvir/ribavirin, 92.5%
after sofosbuvir/daclatasvir ribavirin, and 100% after sofosbuvir/ledipasvir
(7patients). No difference of rate of SVR was observed in cirrhotic and non
cirrhotic patients (92.2vs94.4) using a combination regimens of NS5A and
NS5B inhibitors. The systematic review of literature provided data of 3311
patients: the mean weighted SVR12 rate was 84.4% (CI:80.4–87.8); the rates
varied from 79.0%(CI:70.9–85.3) with sofosbuvir/ribavirin, to 83.7% (CI:66.2–
93.1) with sofosbuvir/ledispavir, and to 88.2% (CI:83.3–91.7) with sofosbuvir/
daclatasvir.
Conclusion: Our results reinforce the concept that HCV genotype 3 should no
more considered difficult to treat individuals. The optimal therapeutic regimen
for these patients appears to be the combination sofosbuvir/daclatasvir, adminis-
tered for 12 weeks without the use of RBV in non cirrhotic patients. In cirrhotics
the meta-analytic approach suggests to extend therapy at 24 weeks.
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Introduction: An improvement in liver stiffness (LS) measured by transient elas-
tography (TE) has been observed in patients with chronic hepatitis C treated with
direct action antivirals (DAA). (1, 2). The Baveno VI guidelines (3) propose that
patients with compensated advanced chronic liver disease (cACLD), LS measure-
ment 520 kPa and a platelet count 4150000/mL can avoid screening endoscopy
as their combination is highly specific for excluding clinically significant oeso-
phageal varices (EV). These criteria have been validated recently. (4, 5, 6)
Aims & Methods: The aim of this study was to quantify LS regression both
quantitatively (measured in Kilopascals) and qualitatively (Stages of F0-F4 fibro-
sis) in a stationary phase after the sustained virological response (SVR) in
patients with cACLD (F4). The secondary objective was to assess whether this
improvement in LF measurements has a clinical correlation with changes in
platelet numbers and the presence of varices according to Baveno VI criteria.
Results: 84 patients (49 men and 35 women) with cACLD were included in the
study. Median TE on baseline (BL) prior to DAA treatment was [mean (range),
23.86 (12.5–75) kPa] and decreased to [mean (range, 15.6 (4.8–75) kPa] at SVR 24
and [mean Range), 16.19 (3–62.7) kPa] at SVR4 54. Both were statistically
significant, showing a decrease in LS about 30% between BL and SVR24 and
about 33% between BL and SVR4 54. We did not find statistically significant
differences between SVR 24 and SVR4 54. Regarding the probability of quali-
tative improvement of the LS (improve from F4 to F3 or less) the AUC was 0.8
with 17.9 kPa as the cut-off point which has a Sensitivity of 0.76 and Specificity
of 0.81. NPV¼ 78.12, PPV¼ 78.57. 32 patients with highly suggestive cACLD
(LS4 15 kPa) underwent upper endoscopy (UE): 10 (32%) had varices (5 small
EV and 5 big EV).17 (53%) fulfilled the Baveno VI criteria (3 with small EV and
4 with small) EV. There were only 3 cases of EV misdiagnosed by Baveno VI
Criteria. We did not find any significant differences in platelet levels or in the
regression of varices.
Characteristics
Main Cohort
n¼ 84
Age mean (st) 60 (9.8)
Male-sex (%) 49 (58.3%)
Aetiology of liver disease (%) HCV 100%
Platelet count 103/mm3 Baseline mean (st) 149.21 (59.62)
Platelet count 103/mm3 SVR 54 mean (st) 168.15 (60.33)
Fibrosis Stage F0–1 in SVR 54n (%) 8 (12.7%)
Fibrosis Stage F2 in SVR 54 n (%) 12 (19.5%)
Fibrosis Stage F3 in SVR 54 n (%) 13 (20.63%)
Fibrosis Stage F4 in SVR 54 n (%) 30 (47.62%)
Liver Stiffness (kPa) Baseline [n¼ 84]mean (st) 23.86 (12.63)
Liver Stiffness (kPa) SVR 24 [n¼ 59] mean (st) 15.6 (12.14)
Liver Stiffness (kPa) SVR 54 [n¼ 63]mean (st) 16.18 (10.99)
Patients who underwent Upper Endoscopy n (%) 32 (38.01%)
Patients with varices (VE) (any size) [n¼ 32] n (%) 10 (31.25%)
Patients fulfilling Baveno criteria [n¼ 32]n (%) 17 (53.15%)
Patients with high-risk VE [n¼ 32] n (%) 5 (15.6%)
Patients fulfilling Baveno criteria with
hight-risk VE [n¼ 32] n (%)
4 (12.5%)
Conclusion: There is a significant improvement in LS data after treatment with
DAA both at SVR24 and SVR4 54. This improvement seems to be more likely
to happen in patients with lower TE values (in our study 17.9 kPa). We did not
have enough available data in our study to support that this improvement in LS
measured by TE has a relevant impact on the clinical management of the patient.
The Baveno VI criteria are a useful tool in daily practice to avoid unnecessary
UE. Further investigation with larger samples is needed.
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1. Bachofner JA, Valli PV, Kröger A, Bergamin I, Künzler P, Baserga A, et al.
Direct antiviral agent treatment of chronic hepatitis C results in rapid regres-
sion of transient elastography and fibrosis markers fibrosis-4 score and aspar-
tate aminotransferase-platelet ratio index. Liver Int. Mar 2017;37(3):369–76.
2. Knop V, Hoppe D, Welzel T, Vermehren J, Herrmann E, Vermehren A, et al.
Regression of fibrosis and portal hypertension in HCV-associated cirrhosis
and sustained virologic response after interferon-free antiviral therapy. J
Viral Hepat. Dec 2016;23(12):994–1002.
3. de Franchis R, Baveno VI Faculty. Expanding consensus in portal hyperten-
sion: Report of the Baveno VI Consensus Workshop: Stratifying risk and
A408 United European Gastroenterology Journal 5(5S)
individualizing care for portal hypertension. J Hepatol. Sept 2015;63(3):743–
52.
4. Llop E, Lopez M, de la Revilla J, Fernandez N, Trapero M, Hernandez M,
et al. Validation of non invasive methods to predict the presence of gastro-
esophageal varices in a cohort of patients with compensated advanced chronic
liver disease. J Gastroenterol Hepatol. Mar 2017 on press.
5. Jangouk P, Turco L, De Oliveira A, Schepis F, Villa E, Garcia-Tsao G.
Validating, deconstructing and refining Baveno criteria for ruling out high-
risk varices in patients with compensated cirrhosis. Liver Int. Feb 2017; 00:1-7.
6. Maurice JB, Brodkin E, Arnold F, Navaratnam A, Paine H, Khawar S, et al.
Validation of the Baveno VI criteria to identify low risk cirrhotic patients
not requiring endoscopic surveillance for varices. J Hepatol. Nov
2016;65(5):899–905.
P0705 8 VERSUS 12 WEEKS OF LEDIPASVIR/SOFOSBUVIR
REGIMEN IN PATIENTS WITH CHRONIC HEPATITIS C
GENOTYPE 1 INFECTION
J.R. Carvalho, P. Alexandrino, F. Serejo, R.T. Marinho, F. Ramalho,
B. Rodrigues, P. Ferreira, M. S. Dias, H. Cortez-Pinto, C. Baldaia, A. J. Pedro,
L. X. De Brito, L. Carrilho Ribeiro, N. Fatela, J. Velosa
Department Of Gastroenterology And Hepatology, North Lisbon Hospital Center,
University of Lisbon, Portugal, Lisbon/Portugal
Contact E-mail Address: joana.rita.carvalho@gmail.com
Introduction: The therapeutic regimens for chronic hepatitis C are now tending to
be shorter and ribavirin free, more cost-effective and with fewer adverse effects.
Aims & Methods: We aimed at comparing the 8 weeks versus the 12 weeks regi-
men of ledipasvir plus sofosbuvir in patients with hepatitis C virus (HCV) geno-
type 1 infection without cirrhosis, treatment naı̈ve, HCV RNA 56000000 UI/
mL. We included 281 patients (pts) with genotype 1 and RNA 56000000 UI/mL
treated with ledipasvir plus sofosbuvir in the recommended dose: 120 pts - 8
weeks (group 1) and 161 pts - 12 weeks (group 2). The fibrosis stage was eval-
uated by transient elastography (Fibroscan, Echosens, Paris) considering
F44 12.5 kPa. Patients with undetectable RNA after 12 weeks of treatment
were considered cured – sustained virologic response (SVR).
Results: No significant demographic and clinical differences were found between
the two groups with the exception of the fibrosis stage (table). Two hundred and
forty-four patients concluded the treatment; the SVR was 99% in group 1 and
100% in group 2, without differences between the two groups (p¼ 0.275). Thirty
three patients are still in follow up: group 1–15 pts and group 2–18pts. The
reported adverse effects were mild in both groups (fatigue, insomnia, headache
and pruritus) but more frequent in group 2 (p¼ 0.046).
Patients characteristics 8 weeks n¼ 120 12 weeks n¼ 161 p
Average age (years) 50.4 (20–81) 53.6 (19–86) 0.473
Male sex, n (%) 62 (51.7%) 89 (55.3%) 0.548
Genotype (n)
1a 74 94 0.579
1b 44 66 0.462
1 and 1a/1b 1þ 1 1þ 0
Average RNA SD (UI/mL) 903275 1093067 1826591 1611806 0.348
Initial transient elastography (n)
F0/F1 111 105 50.001
F2/F3 8 56 50.001
F4 1 0 0.246
Previous treatment with INFRibavirin
Yes 8 0 0.001
No 112 161 50.001
HIV co-infection 1 14 0.004
RNA – week 4, n (%)
Undetectable 86 (71.7%) 124 (77.0%) 0.307
515 UI/mL 13 (10.8%) 13 (8.1%) 0.430
Virologic response
SVR, n (%) 103 (99.0%) 141 (100.0%) 0.275
No response (no compliance) * 1 0 *
Awaiting response (in follow up) 15 18 0.734
Lost for follow up 1 2 0.742
Mild adverse effects, n (%) 7 (6%) 21 (13%) 0.046
* Patient retreated with ledipasvirþ sofosbuvirþ ribavirine during 12 weeks with
SVR
Conclusion: In patients with chronic HCV genotype 1 infection and RNA
56000000 UI/mL, the 8 weeks regimen of ledipasvir plus sofosbuvir without
ribavirin has similar high cure rates with less adverse effects.
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Introduction: Although the conventional IFN-based therapy has made a signifi-
cant achievement in treating patients with hepatitis C virus (HCV), including the
preventive effect of hepatocarcinogenesis after achieving sustained virological
response (SVR), patients intolerant of IFN, such as those with advanced age
or liver cirrhosis (LC), could not savor its privilege. The appearance of direct-
acting antivirals (DAAs) provided almost every patient with the chance to receive
the treatment for HCV infection without any serious adverse effects (AEs). In
addition, SVR could be highly expected in more than 95% of patients treated
with DAAs. However, the preventive effect of DAAs for the future hepatocarci-
nogenesis following eradication of HCV remains unknown. In our facility, the
administration of DAAs to patients with HCV infection led to 97% (153/157) of
SVR, among which 5.9% (9/153) of patients developed hepatocellular carcinoma
(HCC) within 2 years after achieving SVR.
Aims & Methods: We evaluated the clinical features of patients developing HCC
after confirming SVR with DAAs against HCV. One hundred and fifty-three
patients achieving SVR defined as negative HCV-RNA 12 weeks after cessation
of DAA (oral combination therapy with Daclatasvir/Asunaprevir, Ombitasvir/
Paritaprevir/Ritonavir, Sofosbuvir/Ledipasvir, or Sofosbuvir/Ribavirin) were
enrolled in this study (Age 69.2 0.8, male/female 71/82, genotype1/2 122/31,
chronic hepatitis/LC 124/29, PLT 15.3 0.5 104/mL, ALT 44.9 3.5 IU/L, FIB-4
index 3.9 0.2, APRI 1.3 0.1, Wisteria floribunda agglutinin positive Mac-2-
binding protein (WFA(þ)-M2BP) 3.3 0.5 COI, AFP 12.1 2.4 ng/mL,
PIVKA-II 29.8 4.5 mAU/mL). All patients were divided into 2 groups (A: 9
patients with HCC developing after SVR achievement, B: 144 without HCC after
SVR achievement). Serum parameters (PLT, WFA(þ)-M2BP, FIB-4 index,
APRI, ALT, Alb, AFP, PIVKAII) and age were evaluated between 2 groups.
Results: In group B, significant declining (pre-DAA treatment/the time of achiev-
ing SVR) was observed in ALT(44.8 3.6/19.5 1.1 IU/L), AFP(11.9 3.1/
4.1 0.3 ng/mL), WFA(þ)-M2BP(3.2 0.5/1.9 0.3 COI), FIB-4
index(3.7 0.2/3.0 0.2) and APRI(1.2 0.1/0.7 0.05), and significant increase
in Alb(4.1 0.04/4.3 0.04 g/dL) and PLT(15.4 0.5/16.1 0.5 104/mL). In
group A, significant declining was observed only in ALT (45.1 10.9/
16.7 2.2 IU/L). This result indicates that DAA treatment significantly amelio-
rates parameters related with hepatic fibrosis as well as hepatic inflammation in
group B, however, it led to the significant amelioration only in those related with
hepatic inflammatin in group A. Next, focusing on parameters after achieving
SVR, WFA(þ)-M2BP (A:3.4 0.6/B:1.7 0.2 COI) and FIB-4 index (5.7 1.6/
3.0 0.2) were significantly higher and Alb (3.8 0.2/4.3 0.04 g/dL) was sig-
nificantly lower in group A comparing with group B. When dividing group A
into 2 groups (C: new occurrence/D: recurrence), AFP(3.0 1.3/6.2 1.8 ng/
mL), WFA(þ)-M2BP (2.0 0.8/3.8 0.7 COI), FIB-4 index (3.6 2.4/
6.3 2.0) and APRI (0.6 0.4/1.1 0.3) were higher and Alb(4.3 0.1/
3.6 0.3 g/dL) and PLT (20.9 13.2/13.4 3.4 104/mL) were lower in group D
than group C, although no significant difference was seen between 2 groups. This
result suggests that there might be more patients with progressive hepatic fibrosis
in group D comparing with group C. Finally, while univariate analysis showed
WFA(þ)-M2BP, FIB-4 index and Alb were significantly associated with the
development of HCC after achieving SVR with DAA against HCV, multivariate
analysis revealed only Alb was the significantly independent factor contributing
to HCC development after SVR achievement.
Conclusion: Low level of serum albumin as well as the progression of hepatic
fibrosis could be associated with the development of HCC after confirming SVR
with DAA to HCV.
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Introduction: Direct-acting antivirals (DAAs) are novel antiviral drugs for hepa-
titis C virus (HCV) and have enabled the achievement of a high rate of sustained
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virological response (SVR) [1]. However, the impact of DAAs on the occurrence
of hepatocellular carcinoma (HCC) and HCC recurrence after curative hepatic
resection of HCC has been recently discussed [2, 3], but remain unclear.
Aims & Methods: The clinical data of 97 patients who underwent curative hepatic
resection for primary HCC with HCV at our department between January 2012
and March 2017 were reviewed to clarify the impact of DAAs on HCC occur-
rence and recurrence. SVR was defined as no detection of HCV RNA in the
serum at 24 weeks after the cessation of antiviral therapy.
Results: SVR was achieved in 21 patients treated with interferon (IFN)-based
regimens and in 9 with DAAs at hepatectomy. Between the two groups, there
were no significant differences in the clinical characteristics, including the age,
prevalence of diabetes mellitus, drinking history, preoperative liver function,
operative procedures, tumor size and presence of liver cirrhosis, but the
median duration from the date of SVR to the date of HCC incidence was sig-
nificantly shorter in patients treated with DAAs (14 days, range: 123 to 235
days) than in those treated with IFN-based regimens (324 days, range: 35 to 4190
days). In particular, HCC was detected within 24 weeks after the cessation of
antiviral therapy in 3 patients treated with DAAs. After hepatectomy, SVR was
achieved in 21 (DAAs: 16 patients, IFN-based regimens: 5 patients) of the 67
patients without SVR when hepatectomy was performed, and the 1- and 3-year
disease-free survival (DFS) rates were 93.3% and 83.0% in patients after SVR
treated with DAAs (n¼ 25), 90.9% and 71.8% in patients with IFN-based regi-
mens (n¼ 26) and 57.8% and 19.7% in patients without SVR (n¼ 46), respec-
tively, regardless of the timing of hepatectomy, respectively. The DFS rate was
significantly higher in patients with SVR than in those without SVR (p5 0.01),
but was not markedly different according to the antiviral treatments (p¼ 0.504).
Conclusion: While DAAs were able to reduce the DFS rate, the early occurrence
of HCC in patients after SVR treated with DAAs is more frequent than that
among patients treated with IFN-based regimens. Therefore, careful follow-up
with imaging series is needed even for patients with SVR treated with DAAs.
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Introduction: Hepatitis C virus infection is a leading cause of chronic liver disease
affecting more than 170 million people worldwide. HCV infection in the setting
of renal impairment is not uncommon. Despite the major developments in the
treatment of HCV, treatment of this sub group of patient with impaired renal
function is still a challenge.
Aims & Methods: The aim of this study is determine the efficacy and safety of
sofosbuvir and ribavirin in HCV positive patients with renal impairment. All
consecutive patients of with HCV related liver disease with creatinine clearance
less than 50ml/min were included in the study. Data was collected for tolerabil-
ity, efficacy and on treatment adverse events. All the patients received Sofosbuvir
and dose adjusted Ribavirin according of CrCl. Virological response was checked
at 1 month (RVR), 3 months (EVR) and at the end of treatment.
Results: A total of 31 patients were included in the study were 31 out of which
17(54.8%) were male. Mean age was 52.23  17.6 years while the mean BMI was
25.0 4.50 kg/m2. 10 (32.25%) patient were on regular hemodialysis. 26 (83.9%)
patients had CTP-A while 5 (16.1%) had CTP-B disease. Majority of the patients
22 (71 %) were genotype 3 while 7 (22.6 %) were genotype 1. 24 (77.4 %) patients
were treatment naı̈ve, while those who were treatment experienced, 3 patients
received each Interferon and Peg interferon therapy. Treatment was stopped in 2
(6.5%) patients because of disease decompensation while 3 (9.7%) were lost to
follow up. ETR was achieved in 25 (96.1%) out of 26 patients who completed
treatment. Similarly 12 (80 %) out of 15 patients have achieved SVR-12 so far.
During the therapy 10 (32.3%) patients had adverse events, 6 (19.4 %) suffered
from depression while 4 (12.9 %) developed grade II anemia.
Conclusion: In resource constraint population where newer DAAs are not avail-
able, combination of sofosbovir and low-dose ribavirin in patients with renal
impairment seems to be better tolerated and efficacious in terms of achieving
the virological response.
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Introduction: Chronic hepatitis C infection is a systemic disease, one of the lead-
ing causes towards cirrhosis and hepatocellular cancer and it is to be considered
nowadays a major health-related quality of life (HRQoL) burden.
Aims & Methods: The aim of this study was to assess HRQoL impairment of
hepatitis C virus (HCV) infection among a broad sample of compensated HCV
cirrhotic patients. We conducted a prospective study between January 1st 2016 to
January 31, 2017, in a tertiary center, in which we included 110 patients with
compensated HCV cirrhosis, aged between 50 and 75, with no history of neu-
ropsychiatric illness but associated comorbidities (diabetes type 2, hypertension,
dyslipidemia). The patients were completely evaluated according to the national
protocol. Health status and fatigue of our patients were evaluated using the
FACIT- F (version 4) and SF-36 survey. Respondents with HCV compensated
cirrhosis were compared with a control group matched for age and sex with no
prior history of HCV infection on the Mental (MCS) and Physical (PCS)
Component Summary scores.
Results: Unadjusted comparisons between subjects infected with HCV (n¼ 110)
and controls (n¼ 60) revealed that HCV patients had lower FACIT- F utility
scores (43.2 0.8 vs 49.5 0.5, P5 0.05). Severe fatigue was present in 30% (33
patients) of the HCV group compared to 11.6 %(7 patients) in controls.
Subgroup analyses of respondents age 60 years and older revealed lower MCS
score in HCV patients compared to controls (41.95 vs. 49.72, p5 0.05). Control
group registered higher PCS score (53.30 vs 45.2, P5 0.05) compared to the
study group.
Conclusion: Although the results were obtained on a small group we observed
that in untreated patients with chronic HCV infection, HRQoL is significantly
impaired due to fatigue severity and age. Our result underline the need for
effective antiviral treatment to decrease the burden of fatigue in this segment
of population.
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Introduction: Hepatitis C virus (HCV) is the most common cause of cirrhosis in
this part of the world. Advent of Directly acting antivirals (DAAs) like
Sofosbuvir (SOF) has dramatized the treatment and is the corner stone in treat-
ment of (HCV). Most trials have been conducted in HCV genotype 1 and data
for Interferon free regimen in genotype 3 (GT-3) is limited especially in cirrhotics.
Aims & Methods: We aimed to evaluate the safety and efficacy of SOF plus
Ribavirin (RIB) in patients with compensated and decompensated cirrhosis.
This is a prospective real-world cohort study of HCV with compensated or
decompensated cirrhosis. Efficacy was assessed by Sustained Viral Response
after 06 months of completion of treatment. Adverse events were recorded on
designed proforma on serial follow-up visits.
Results: The cohort consisted of 9 1consecutive patients out of which 41 were
compensated cirrhotics and 50 had decompensated cirrhosis. The mean age was
53.4 11years. Males were 47 (51.6%) and females were 44 (48.4%). Mean CTP
and MELD score were 7.71 and 9.21 respectively. In compensated cirrhosis, SVR
was achieved in 25 (84%) treatment naı̈ve patients compared to treatment experi-
enced patients where 5 (80%) achieved SVR. In decompensated cirrhosis SVR
was achieved in 22 (77.3%) treatment naı̈ve patients, whereas 13 (76.9%) patients
achieved SVR in treatment experienced group. In 72% patients with cirrhosis,
there were no side effects whereas most common adverse event was fatigue and
drop of Hemoglobin by 1.0 gm/dl. Furthermore, CTP and MELD scores
decreased to 6.9 and 8.7 respectively after treatment.
Conclusion: Sofosbuvir in combination with Ribavirin in GT-3 HCV patients
achieved good SVR in compensated cirrhosis than decompensated cirrhosis
wheras fatigue and drop of Hb were the most common adverse effects.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: New direct-acting antivirals (DAA) have changed the management
of HCV infection by being effective in more than 90% of cases [1, 2].
Unfortunately, it has been reported an unexpected high rate of HCC early recur-
rence following DAA treatment, but more data are needed [3–5].
Aims & Methods: From a national prospective cohort, enrolling 3717 Romanian
patients with hepatitis C virus compensated liver cirrhosis who received reim-
bursed DAA with Paritaprevir/Ombitasvir/ritonavir, Dasabuvir and Ribavirin
(OBV/PTV/rþDSVþRBV) for 12 weeks, from December 2015 to August 2016,
we analyzed 21 patients with previous HCC. Most of them were treated through
surgical resection (9/21), followed by radiofrequency ablation (RFA) 6/21, trans-
arterial chemoembolisation (TACE) 5/21 and only one percutaneous ethanol
injection (PEIT). The patients received DAA treatment only if they had no
cancer relapse 6 months after their last therapy session for HCC. All these
patients were evaluated through CT scan or MRI 3 to 6 months after having
finished their DAA therapy. The median follow-up is 6 months (3	12). Data
were obtained from the Romanian National Health Agency.
Results: Two female patients decompensated and died because of acute liver
failure (9.5%), the first one after having finished the 12 weeks therapy, and the
other one in week 7 of DAA therapy. This cohort was 52% females, median age
64 years (51 - 77), 76% IFN pre-treated, 50% associated NASH, 67% with severe
necroinflammatory activity (severity score 3 - Fibromax), 30% with co-morbid-
ities, 24% with Child Pugh A6. The median MELD score was 9 (6 	 11). SVR
was reported in 19/21 as per protocol analysis (90.5%). Recurrence rate of HCC
was 29%, higher in males (40%) than females (18%), higher in patients treated
with TACE (40%) than in those with hepatic resection (33%), and the lowest risk
of recurrence was encountered in RFA (17%). These differences were not statis-
tically significant because of the small sample size. The pattern of recurrence was:
intrahepatic growth (1 patient), new intrahepatic lesion (1 nodule in 2 patients,
up to 3 nodules less or equal to 3 cm in 1 case) and infiltrative ill-defined
hepatocellular carcinoma in 2 patients. We found no correlation between the
HCC-free interval of time and recurrence rate (p¼ 0.62).
Conclusion: Early recurrence rate of HCC in treated patients with compensated
liver cirrhosis that received DAA with OBV/PTV/rþDSVþRBV was 29%,
significantly increased compared to the natural recurrence rate. This rate is
higher in males (40%) and in patients treated with TACE (40%).
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Introduction: Shear wave elastography (SWE) has been used in clinical practice as
a noninvasive method to diagnose liver fibrosis by measuring tissue stiffness.
Aims & Methods: The usefulness of SWE in the diagnosis of esophagogastric
varices (EGVs) associated with portal hypertension was evaluated. 550 patients
who underwent measurements of liver stiffness (LS), spleen stiffness (SS) and
EGV evaluation between January 2011 and July 2016 were included (no varices,
n¼ 340; esophagus only, n¼ 107; stomach only, n¼ 14; esophagus and stomach,
n¼ 89). Virtual Touch Quantification (VTQ) was used for measurements of LS
and SS, and the spleen index (SI) was calculated. EGVs were evaluated according
to forms and red colour sign (RC sign) based on the General Rules for Study of
Hypertension in Japan.
Results: LS, SS and SI showed significant increase in accordance with the severity
of forms (p5 0.01). The area under the receiver operating characteristic curve
(AUROC) of LS, SS and SI for detecting EGVs were 0.8526, 0.9048, 0.8199, with
the cut off values 1.67m/s, 2.81m/s, 18.5cm2, respectively, and SS showed use-
fulness in detecting EGVs. When LS, SS and SI were compared for their ability to
detect EGVs which were 5F2 or with RC sign positive, LS, SS and SI were
significantly higher for EGVs which require treatment (p5 0.001). The AUROC
of LS, SS and SI for detecting EGVs which require treatment were 0.8131,
0.8693, 0.8270, respectively. All modality showed good detecting ability, and
SS particularly showed better performance. When each modality was compared
in detection of gastric varices, LS and SS were significantly higher with the
presence of gastric varices, but SI did not show a significant difference. The
AUROC of LS, SS and SI for detecting gastric varices were 0.7359, 0.8611,
0.6470, respectively, and SS showed a superior detecting ability while LS and
SI showed decreased abilities.
Conclusion: LS, SS and SI were all useful in detecting EGVs and predicting the
presence of EGVs which require treatments. SS particularly showed the highest
diagnostic ability.
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Introduction:Nonalcoholic fatty liver disease (NAFLD) is the most common liver
disorder in developed countries with a global prevalence of approximately 25%.
NAFLD represents a spectrum of disorders and starts with benign steatosis
(NAFL, 5% hepatic steatosis but may lead to nonalcoholic steatohepatitis
(NASH), inflammation with hepatocyte injury with or without fibrosis, which
may lead to cirrhosis. Liver biopsy still is the gold standard for staging steatosis.
The BRUNT score stages steatosis in 4 categories (5%, 5–33%, 34–66%,
66%), which provides a limited sensitivity to detect changes in steatosis content.
For evaluation of treatment and disease activity a quantitative and preferably
non-invasive tool is needed urgently. Therefore we developed and tested a com-
puter aided ultrasound (CAUS) protocol for the non-invasive assessment of
hepatic steatosis using ultrasound (US) B-mode images, which showed high pre-
dictive values (area under the curve (AUC) up to 0.95) in cows and similar
correlations in a human pilot study. The current study was conducted in order
to assess the predictive values of CAUS in staging hepatic steatosis in-vivo.
Aims & Methods: Consecutive patients indicated for a liver biopsy received a
simultaneous transabdominal US examination (Siemens Acuson X150; Siemens
Healthcare GmbH, Erlangen, Germany, with CH5-2 transducer). Currently 205
patients with liver biopsies and QUS images are included. Biopsies were qualita-
tively scored using the Brunt-score for steatosis grading. Metavir, Ishak and/or
Roenigk scores were used for disease specific fibrosis staging. All US images were
further post-processed using the CAUS method. In CAUS corrections are
applied for the: look up table (linearization); beam-profile; attenuation caused
by the superficial tissue layers. Furthermore segmentation of large blood vessels
and bile ducts is performed automatically. Finally echo-level and texture para-
meters are estimated on average and as a function of depth by estimation of slope
and intercept of a linear fit.
Results: Best correlating CAUS parameter with BRUNT steatosis stage was
found to be the residual attenuation coefficient (RAC, R¼ 0.79, p5 0.01).
Parameters used in the multiple linear regression analysis using the leave one
out method were: Residual attenuation coefficient (RAC¼ slope of the mean
echo level (MU)); MU; slope of the Signal to noise ratio; and the lateral speckle
size. AUC for HS was found to be 0.95 (n¼ 71) with a sensitivity and specificity
of 86% and 85% respectively, which are in line with previously performed stu-
dies. 87% of the included patients were found to have NASH with fibrosis.
However, no significant correlations of the CAUS parameters to a pure fibro-
sis-group (N¼ 106) was found.
Conclusion: CAUS is able to classify steatosis accurately and does not suffer from
the presence of fibrosis, making CAUS a feasible tool for screening and evalua-
tion of hepatic steatosis.
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Introduction: Recently, fusion imaging technology has been reported as useful for
radiofrequency ablation (RFA) and various models of ultrasound equipment
have been developed to include fusion imaging systems. The 3D Sim-
Navigator (HITACHI) is a navigation system that can be used in real-time
virtual sonography (RVS) by simulating and navigating the 3D positions of
electrodes. As an addition, the 3D Sim-Navigator is now equipped with a new
system that shows the predicted ablative area. This function indicates the electric
field that occurs around the electrodes as the predicted ablative area on MPR
images. The E-field Simulator (E-field) can manage various electrodes, such as
monopolar and bipolar RF systems. E-field can be used to predict the ablative
areas from not only a single electrode but also multiple electrodes, which was
difficult to do in the past. We therefore examined the accuracy of E-field on 3D
Sim-Navigator.
Aims & Methods: We evaluated 10 nodules treated using a bipolar RF system
(CelonPOWER; Olympus Medical Systems) with multiple electrodes and 72
nodules treated using a monopolar RF system (VIVARF system; STARmed)
between April 2016 and March 2017 prospectively. We compared the major
and minor axes of maximum axial ablative area for 72 nodules ablated by the
monopolar RF system on both E-field and post-RFA contrast-enhanced com-
puted tomography (CT). We then compared ablative volumes of 10 nodules
ablated by the bipolar RF system on E-field and on post-RFA contrast-enhanced
CT. Finally, we compared treatment efficacy using a grading system (J
Gastroenterol 2013 Aug;48(8):951–65.) on E-field and on post-RFA contrast-
enhanced CT.
Results: On the evaluation of maximum axial ablative area by monopolar elec-
trodes, major and minor axes were smaller on E-field than on CT, but these
differences were not significant. On the evaluation of ablative volume by bipolar
electrodes, the correlation coefficient for ablative volumes on E-field and CT was
greater than 0.96. On comparing treatment efficacy using the grading system, the
degree of agreement between E-field and CT was 0.691 and the weighted kappa
coefficient was 0.929.
Conclusion: Ablative volume on E-field correlated well with that on post-RFA
contrast-enhanced CT. Furthermore, good agreement was observed between the
treatment efficacy based on E-field and post-RFA contrast-enhanced CT. E-field
can be used to predict the ablative area from not only a single electrode, but also
multiple electrodes, which was difficult to do in the past. The present results
suggest that contrast-enhanced CT may become unnecessary for confirming ther-
apeutic effects in the future.
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Introduction: The presence of fat droplets in the hepatocytes (micro- or macro-
vesicular hepatic steatosis) under condition of chronic diffuse liver disease
(CDLD) increases the attenuation of ultrasound (US). A group of Ukrainian
scientists proposed an original algorithm for real-time US attenuation measure-
ment (attenuation coefficient measurement – ACM – patent UA „2014 111234).
Aims & Methods: From total of 3274 patients who underwent to comprehensive
abdominal US (2015–2016) in our clinic, 949 have been diagnosed with fatty liver
according to Hamaguchi criteria. All these patient we provide ACM (dB/cm)
measurement on SoneusP7 device (Ultrasign, Ukraine), with a 1–6MHz convex
transducer in the right and left lobes. For diagnostic accuracy assessment (used
CT as standard) and comparison with CAP measured by Fibroscan (Echosens,
France) we included 142 patients for subanalysis. Evaluation of diagnostic accu-
racy of ACM performed using ROC-analysis.
Results: Depending on the stage of steatosis according to B-mode median, 25 and
75 quartiles for ACM were as follows: control group 1.57 (1, 32–1, 85); S1–1, 86
(1, 78–2, 11); S2–2, 26 (2, 20–2, 49) and respectively for S3–2, 7 (2, 40–2, 82) dB/
cm. ACM value increase parallel the hepatic steatosis progression (p5 0.001),
which was also accompanied with presence of very strong correlation between
these parameters (r¼ 0.814, p5 0.001). In patient with NAFLD the association
between maximum value of ACM and duration of T2DM and triglycerides
(model 1, multiple correlation coefficient¼ 0.55; R2¼ 0.26; p¼ 0.004) and ALT
(model 2, multiple correlation coefficient¼ 0.55; R2¼ 0.25; p¼ 0.005) were
observed. After adjustment by the duration of T2DM the level of triglycerides
(r¼ 0.44, p¼ 0.012) and activity of ALT (r¼ 0.44, p¼ 0.012) significantly corre-
lated with ACM. The AUROC of ACM for steatosis diagnosis was 0.925 (95%
CI 0.877–0.973). The optimal cutoff point was 42.27 dB/cm, with sensitivity,
specificity, PPV and NPV respectively 91.5, 77.3, 84.6 and 83.8%. ACM value
also significantly correlated with CAP (r¼ 0.630, p5 0.001).
Conclusion: The ACM as novel real-time ultrasound approach can be used for
noninvasive hepatic steatosis diagnosis, allows clinicians to monitor disease pro-
gression and response to treatment.
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Introduction: The aim of this paper is to evaluate the performance of CEUS as a
first step in the evaluation of focal liver lesions (FLLs) in cirrhotic and non-
cirrhotic patients.
Aims & Methods: A retrospective study was performed on a cohort of 2904 FLLs
evaluated by CEUS between September 2009-December 2016, according to
EFSUMB guide lines (2) in a tertiary center. 979 (33.7%) FLLs did not com-
pletely fulfill the EFSUMB-CEUS criteria thus needing to be confirmed by other
imaging technique (contrast-enhanced CT, contrast-enhanced MRI) or histology.
Lesions that were previously diagnosed have been excluded. Using CT, MRI and
histology for the final diagnosis we calculated the specificity, sensibility and
accuracy of CEUS for the difficult FLLs that challenged the examiner, in cir-
rhotic and non-cirrhotic patients.
Results: CEUS managed an overall correct diagnosis in 76.8% (752/979) of the
lesions. From the 979 FLLs, 335 (34.3%), (67.7% HCC, 4.7% Hemangioma,
3.8% Metastasis, 18.2% Other benign lesions and 5.3% Other malignant
lesions), were detected in liver cirrhosis (LC) and 644 (65.7%), (36.1%
Metastasis, 19.5% Hemangioma, 6.8% HCC, 31.3% Other bening lesions and
6% Other malignant lesions) were in non-cirrhotic liver (NC). In LC CEUS
performance for benign lesions was: 87.7% Se, 93.6% Sp and 90.4% Ac. For
malignant lesions in LC, CEUS performed: 76.1% Se, 92.4% Sp and 83.8% Ac.
In the NC group, CEUS performance for benign lesions was: 82% Se, 95.8% Sp
and 88.4% Ac. and for malignant lesions was: 90.16% Se, 90.13% Sp and 89.4%
Ac. CEUS performance on the most frequent lesions: Hepatocellular carcinoma
(HCC) in LC: 65.2% Se, 86% Sp, 68.5% Ac. HCC in NC: 65.9% Se, 94.7Sp, 92.1
Ac. Metastasis in LC: 30.7 Se, 97.3Sp, 92.9% Ac. Metastasis in NC: 78.5% Se,
91.2% Sp, 85.5% Ac. Hemangioma in LC: 68.7% Se, 95.6 Sp, 93.4% Ac.
Hemangioma in NC: 77.2% Se, 96.1% Sp and 91.3 Ac.
Conclusion: CEUS is an accurate and reliable method as a first step in the eva-
luation of FLLs. Liver cirrhosis does not influence significantly CEUS
performance.
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Introduction: CUX1 (CUTL1) is a transcription factor able to promote the
expression of several genes implicated in cellular proliferation, differentiation
and demise. In normal adult cells, it preferentially favors the expression of proa-
poptotic genes. Its aberrant expression in tumor turns its role as foe. It favors the
expression of oncogenes and survival factors, especially in stress condition, thus
supporting tumorigenesis.
Aims & Methods: Here, we show CUX1 activity during hypoxia in liver cancer
cells. CUX1was knocked down and its targets were analysed by RT-qPCR in
HepG2 and Hep3B cells under hypoxic and/or normal culture condition. The
hypoxia condition was established by 24h treatment with 150 mM CoCl2 or with
0.5% O2 atmosphere. Hypoxia markers and CUX1 were analysed by RT-qPCR.
Transfection qith plasmid expressing a reporter sequence for HIF1alpha was
performed in combination with CUX1 knock-down.
Results: Hypoxia determined the up-regulation of HIF1-alpha (Hypoxia induci-
ble factor1-alpha) and a stable or up-regulated expression of its inhibitor FIH-1
(SLC2A1) up to 24 h prolonged hypoxia. VEGFA was significantly
A412 United European Gastroenterology Journal 5(5S)
overexpressed. Knock-down of CUX1 determined a significant down-regulation
of HIF-1alpha, FIH-1 and VEGFA. Interestingly, the expression of CDKN1A
was only attenuated after CUX1 knock down and hypoxic stress. HIF1alpha
transcriptional activity is dependent by CUX1 expression.
Conclusion: CUX1 exerts an oncogenic role in liver cancer by sustaining the
survival mechanism beyond hypoxia. CUX1 silencing results in suppression of
the hypoxia inducible factor and its target VEGFA causing a block of cell cycle
in liver cancer cells modulated by the stable expression of CDKN1A.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0718 S-ADENOSYLMETHIONINE AFFECTS CELL CYCLE
PATHWAYS AND SUPRESSES PROLIFERATION IN LIVER CELLS
L. Yan, G. Zhang, Y. Chen
Department Of Gastroenterology, Xiangya Hospital, Central South University,
Changsha/China
Contact E-mail Address: yanlu_152@163.com
Introduction: S-Adenosylmethionine (SAMe) is a kind of common liver-protect-
ing medicine. Recent studies have shown that SAMe has the inhibitory effects on
hepatocellular carcinoma(HCC). But the specific mechanism has not been
elucidated.
Aims & Methods: Here, we examine the effects and relevant mechanism of SAMe
on human hepatocellular carcinoma cell HepG2 and mouse hepatocyte AML12.
RNA sequencing (RNA-Seq) was used to identify the differentially expressed
genes between HepG2 cells which were treated with SAMe or not. And we
used western blot and QRT-PCR to confirm some of these genes. MTS and
flow cytometry-based assays were carried out in response to SAMe treatment.
Results: A total of 472 SAMe-related genes were identified by RNA-Seq. We
found that differentially expressed genes were enriched in cell cycle related sig-
naling pathway significantly by the KEGG and GO Pathway enrichment analy-
sis. Through the construction of protein-protein interaction network, we
observed the module associated with cell cycle is in the middle of the whole
network. All these results implied that cell cycle pathway may play a very impor-
tant role in the regulation of SAMe effected on HepG2 cells. Then the RNA-Seq-
characterized genes involved in cell cycle (MCM3, MCM4, and E2F1) were
confirmed by Western blot and QRT-PCR in HepG2 and AML12 cells. MTS
analysis showed that SAMe could diminish cell proliferation. And flow cytome-
try-based assays indicated that treatment with SAMe altered cell cycle kinetic S
phase cell cycle arrest.
Conclusion: Altogether, our data enforce the evidence of SAMe possessing of
antiproliferative action in liver cells, capable of up-regulating MCM3, MCM4
and E2F1 expression leading to cell cycle inhibition, and provide an important
theoretical basis for the clinical chemoprevention and treatment in HCC of
SAMe.
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Introduction: The chromatin remodeler complex SWI/SNF plays an important
role in physiological and pathological processes. The role of BRG1, a catalytic
subunit of the SWI/SNF complex, that is known to be mutated in hepatocellular
carcinoma (HCC) remains unclear. The aim of this work is to investigate the role
of BRG1 on cell growth, cell invasion and its effect on the expression of target
genes.
Aims & Methods: We examined the expression of BRG1 in human tissue samples
and HCC cell lines by qRT-PCR and Western Blot. We used siRNA to down-
regulate BRG1 in human HCC cell lines. Cell growth and cell invasion of
siRNA-treated cells was analysed by growth curves, colony formation assay
and invasion assay. The expression of target genes after BRG1 downregulation
was investigated by qRT-PCR.
Results: BRG1 was found to be significantly increased in HCC samples com-
pared to non-HCC samples. After BRG1 downregulation by siRNA, cell growth
and cell invasion decreased in HuH7 and HepG2 cell lines. A positive modulating
effect by BRG1 was shown for the expression of CyclinB, D, E and MMP7 in
either HepG2 or HuH7 cell lines.
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Conclusion: Our results support the hypothesis that overexpression of BRG1
increases cell growth and cell invasion in HCC. Furthermore, the data highlight
genes promoting proliferation and invasion that are being regulated by BRG1
during hepatocarcinogenesis. In particular, CyclinB, D, E and MMP7 appear to
play a major role in this context and might be an important link between BRG1
expression and HCC development.
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Introduction: Inflammation may play an important role in progession, and a high
neutrophil-to-lymphocyte ratio (NLR) has been reported as a poor prognostic
indicator in several malignancies.
Aims & Methods: This study was aimed to investigate the prognostic value of
NLR in patients with HCC. We performed a retrospective study including
patients with hepatocellular carcinoma admitted in the hepato-gastroenterology
department of Sousse between January 2010 and December 2015.
Results: A total of 76 patients were included in this study. Mean age was 59.8
(33–87 years). The sex ratio was 3.22 (M/F¼ 58/18). Hepatocellular carcinoma
occurred on a liver of cirrhosis in the majority of cases (90.7%). The main causes
of cirrhosis were hepatitis B virus infection (43 patients-62.3%), hepatitis C virus
infection (11 patients-16%), non alcoholic steatohepatitis (6 patients-8.6%) and
alcohol consumption (5 patients-7.2%). Our results showed that high NLR was
associated with poor overall survival (OS) in HCC regardless of therapeutic
choice (P5 0.05). Otherwise, high NLR was significantly correlated with the
presence of vascular invasion (P¼ 0.002), lymph node mestasis (P¼ 0.04),
tumor multifocality (P¼ 0.01) and higher incidence of AFP 200 ng/ml
(P¼ 0.04).
Conclusion: Elevated NLR indicates a poor prognosis for patients with HCC.
The NLR is a readily available and inexpensive biomarker, and its addition to
established prognostic scores for clinical decision making warrants further
investigation.
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Introduction: The Wnt/b-catenin plays essential roles in the growth of hepatocel-
lular carcinoma (HCC). The Dickkopf (Dkk) protein family (Dkk1-4) is known
as Wnt signal antagonists, and reduced expression in immortalized cells (REIC)/
Dkk-3 over-methylation is associated with poor prognosis of HCC patients. But
the roles of REIC/Dkk-3 in inhibiting Wnt signaling remains still unclear.
Aims & Methods: In our previous study, REIC/Dkk-3 protein induced significant
production of interferon gamma from lymphocytes incubated with pancreatic
cancer cells, indicating that REIC/Dkk-3 protein might activate cancer immunity
in the tumor-bearing patients.1 We hypothesized that REIC/Dkk-3 expression
was correlated with cancer immunity in HCC patients. Thus, we investigated the
correlation between serum REIC/Dkk-3 protein level and the prognosis in HCC
patient. We retrospectively studied 58 HCC patients who underwent primary
liver resection for HCC admitted to out unit from 2008 to 2017. Patient serum
was gathered before resection. Serum REIC/Dkk-3 protein level was measured
by an enzyme-linked immunosorbent assay.
Results: 58 HCC patients were divided into two groups, 41 REIC/Dkk-3 high
concentration group (protein level 4800) and 17 Dkk-3 low concentration group
(protein level 5800), according to the presence of REIC/Dkk-3 proteins in the
blood, as detected by ELISA spectrometry. There was no significant difference in
age, sex, Child-Pugh score and HCC stage in the patient groups. REIC/Dkk-3
Protein tended to be declining in liver cancer patients with poor prognosis.
(p¼ 0.186)
Conclusion: Our results demonstrated that the serum Dkk-3 protein levels might
be a prognosis marker in HCC patients. Further study is necessary with more
number of HCC patients.
Disclosure of Interest: All authors have declared no conflicts of interest.
Reference
1. Uchida, D., H. Shiraha, H. Kato, et al., Synergistic anti-pancreatic cancer
immunological effects by treatment with reduced expression in immortalized
cells/dickkopf-3 protein and peripheral blood mononuclear cells. J
Gastroenterol Hepatol, 2016. 31(6): p. 1154–9
P0722 SURGICAL OUTCOME OF PATIENTS WITH
FIBROLAMELLAR HEPATOCELLULAR CARCINOMA. DOES IT
DIFFERS FROM COMMON HEPATOCELLULAR CARCINOMA?
E. El-Hanafy
Facultu Of Medicin, Mansoura University, Gastroenterology Surgical Center,
Cairo/Egypt
Contact E-mail Address: dr_ehab_elhanafy@yahoo.com
Introduction: Fibrolamellar hepatocellular carcinoma (FL-HCC) has convention-
ally been considered to be a histologic variant of hepatocellular carcinoma
(HCC), with distinct clinicopathologic features. It is a rare primary hepatic
malignancy that was first described as a pathological variant of HCC by
Edmondson in 1956 [1]. The etiology of FL-HCC remains unclear. It typically
occurs in normal livers without underlying liver fibrosis or cirrhosis [2]. In con-
trast to HCC which usually found in the presence of cirrhosis or chronic hepatitis
[3]. FL-HCC has been reported to occur in association with focal nodular hyper-
plasia (FNH) a type of benign liver lesion. Many series have mentioned that FL-
HCC is less aggressive than conventional HCC [4]. However, other studies have
failed to confirm the observation of a better outcome in FL-HCC [5]. Other
studies reported that the survival was similar between common HCC and FL-
HCC, and that may be related to the higher resectability rate which improve the
survival of patients with FL-HCC [6].
Aims & Methods: The aim of this study was to evaluate the clinicopathological
features and the surgical outcomes of patients with FL-HCC who were referred
to our tertiary referral center over a 15-year period. This is a retrospective study
including 22 patients with a pathologic diagnosis of FL-HCC who underwent
hepatectomy over a 15-year period. Tumor characteristics, survival and recur-
rence were evaluated.
Results: There were 11 male and 11 female with a median age of 29 years (range
from 21 to 58 years). Two (9%) patients had hepatitis C viral infection and only 2
(9%) patients had alpha-fetoprotein level 4200 ng/mL. The median size of the
tumors was 12 cm (range from 5–20 cm). Vascular invasion was detected in 5
(23%) patients. Four (18%) patients had lymph node metastases. The median
follow up period was 42mo and the 5-year survival was 65%. Five (23%)
patients had a recurrent disease, 4 of them had a second surgery with 36mo
median time interval. Vascular invasion is the only significant negative prognos-
tic factor.
FL-HCC (n¼ 22)
Number
Single 19 (86%)
Multiple 3 (14%)
Size (cm) Median 12 cm (range, 5–20)
Location 9 right, 10 left, 3 bilateral
Hepatic resection
Hepatectomy 16 (73%)
Extended hepatectomy 4 (18%)
Localized resection 2 (9%)
Stage
I 10 (45%)
II 5 (23%)
III 7 (32%)
IV 0
Nodal metastases 4 (18%)
Vascular invasion 5 (23%)
Positive safety margin 2 (9%)
Repeated hepatectomy 4 (18%)
Factor No. (%)
Overall
survival
(month) p. value
Age (year)
540 16(73%) 86
40 6(27%) 72 0.4
Gender
Female 11 (50%) 84
Male 11(50%) 79 0.6
Tumor size (cm)
510 8(36%) 82
10 14(64%) 76 0.3
Number
1 19(86%) 89
41 3(14%) 77 0.2
Hepatic resection
Hepatectomy 16 (73%) 86
(continued)
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Factor No. (%)
Overall
survival
(month) p. value
Extended hepatectomy 4 (18%) 77
Localized resection 2 (9%) 79 0.62
Nodal metastases
Negative 18(82%) 88
Positive 4 (18%) 78 0.09
Vascular invasion
Absent 17(77%) 92
Present 5(23%) 58 0.03
Safety margin
Negative 20(91%) 87
Positive 2 (9%) 72 0.08
Conclusion: FL-HCC has a favorable prognosis than common HCC and should
be suspected in young patients with non cirrhotic liver. Aggressive surgical resec-
tion should be done for all patients. Repeated hepatectomy or excision of recur-
rent disease should be considered for these patients as it has a relatively indolent
course.
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Introduction: Hepatocellular adenoma (HCA) is a rare benign tumor of the liver
that typically presents in women within their reproductive years. The recent
increase in the HCA prevalence is noticeably associated with the rising prevalence
of obesity and the metabolic syndrome. Because of high risk of complications
such as hemorrhage, rupture and malignant transformation, appropriate treat-
ment strategy should be considered. Given the success of image-guided ablation
in treating malignant hepatic tumors, there is increased interest in treating benign
masses with percutaneous ablation.
Aims & Methods: To investigate the efficacy and safety of Microwave versus
Radiofrequency Ablation in management of HCA. Out of 320 Patients presented
with hepatic focal lesions over 1 year, data of 15 patients diagnosed to have HCA
were collected retrospectively. The diagnosis of HCA in those patients was based
on radiological findings using triphasic pelvi-abdominal CT, dynamic MRI or
cytopathological examination of FNAC for those whose radiological findings
were not conclusive. The size of the all tumors was ranged between 2.5 to
3.4 cm. Tumors were selected for treatment by percutaneous ablation after
review at a multidisciplinary that included radiologists, hepatologists, hepatobili-
ary surgeons. Decisions to pursue percuteneous ablation therapy were based on a
multidisciplinary discussion of multiple factors, including patient preference,
number and location of tumors impacting the extent of a possible liver resection
and hepatic reserve and the decreased morbidity compared with surgery. The
patients were divided into 2 groups: Group(A):included 7 patients (5 females, 2
males) underwent Radiofrequency Ablation. Group(B):included 8 patients (5
females, 3 males)underwent Microwave Ablation. Follow up was perfomed
every 3 months over a period of 1 year.
Results: Microwave and Radiofrequency thermal Ablation had the same safety
and efficacy in management of HCA with no evidence of residual tumour, tumor
recurrence nor complications but Microwave thermal ablation was superior in
large size tumors and needed only single skin puncture while Radiofrequency
ablation needed more than single puncture in the same session.
Conclusion: Percutaneous ablation of HCA using Microwave or Radiofrequency
thermal Ablation is safe, feasible and able to eradicate the targeted hepatic focal
lesion and prevent known complications of HCA. Of note Microwave ablation is
much more efficient in treating larger lesions through single puncture in contrast
to Radiofrequency which needs more than one puncture.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
Agrawal S, Agarwal S, Arnason T, Saini S, Belghiti J. Management of hepato-
cellular adenoma: recent advances. Clin Gastroenterol Hepatol 2015; 13:1221–
1230.
Atwell TD, Brandhagen DJ, Charboneau JW, Nagorney DM, Callstrom MR,
Farrell MA. Successful treatment of hepatocellular adenoma with percutaneous
radiofrequency ablation. AJR Am J Roentgenol 2005; 184: 828–831.
Brace CL. Microwave tissue ablation: biophysics, technology, and applications.
Crit Rev Biomed Eng 2010; 38:65–78.
Dokmak S, Paradis V, Vilgrain V, et al. A single-center surgical experience of 122
patients with single and multiple hepatocellular adenomas. Gastroenterology
2009; 137:1698–1705.
P0725 METABOLIC DISORDERS ACROSS HEPATOCELLULAR
CARCINOMA IN ITALY
F. Morisco1, M. Guarino1, M.R. Valvano2, V. Cossiga1, F. Farinati3,
E.G. Giannini4, F. Ciccarese5, F. Piscaglia6, G.L. Rapaccini7, M. Di Marco8,
E. Caturelli9, M. Zoli10, F. Borzio11, R. Sacco12, C. Cammà13, M. Felder14,
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Introduction: Metabolic disorders, such as obesity and diabetes, are well known
risk factors for hepatocellular carcinoma (HCC). Conversely, their impact on the
natural history of HCC patients is not established.
Aims & Methods: This study aimed at evaluating the impact of metabolic dis-
orders on clinical features, treatment and survival of HCC patients regardless of
its etiology. We analyzed the Italian Liver Cancer (ITA.LI.CA) database regard-
ing 839 HCC patients prospectively collected from 2009 to 2014. The following
metabolic features were analyzed: BMI, diabetes, arterial hypertension, hyperch-
olesterolemia and hypertriglyceridemia. According to these features, patients
were divided into 3 groups: 0–1 metabolic features, 2 metabolic features, 3–5
metabolic features.
Results: As compared with patients with 0–1 metabolic features, patients with 3–5
features showed lower percentage of HCC diagnosis on surveillance (p 0.021),
larger tumors (p 0.038), better liver function (higher percentage of patients with
Child-Pugh A [p 0.007] and MELD5 10 [p 0.003]), higher percentage of metas-
tases (p 0.024), and lower percentage of portal vein thrombosis (p 0.010). The
BCLC stage and treatment options were similar among the 3 groups, with the
exception of a less frequent access to locoregional therapies for BCLC stage B
patients with 3–5 features (p 0.012). Overall survival and survival according to
BCLC stage and/or treatment did not significantly differ among the 3 groups.
Diabetic patients showed a lower survival (p 0.046). MELD score, HCC
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morphology, nodule size, BCLC stage, portal vein thrombosis and metastasis
were independent predictors of lead-time adjusted survival.
Conclusion: Our ‘‘real-world’’ study suggests that metabolic disorders shape the
clinical presentation of HCC but do not seem to play a major role in setting the
patient survival, except for diabetes.
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Introduction: Chronic hepatitis C virus (HCV) infection pose risk for develop-
ment of hepatocellular carcinoma (HCC), even after viral eradication with effec-
tive antiviral therapy. Therefore, risk prediction is clinically important for
effective surveillance of chronic hepatitis C (CHC) patients, but studies are
insufficient compared to chronic hepatitis B. The liver volume has been reported
to correlate with the severity of liver cirrhosis, but it is not known whether
decreased liver volume predicts the HCC risk in CHC.
Aims & Methods: The aim of this study was to assess the significance of liver
volume in the prediction of HCC risk in CHC patients. A retrospective cohort of
101 CHC patients who received 4-phase dynamic CT imaging studies during
surveillance was analyzed for liver volume and outcome of surveillance. Liver
volumes were measured on portal venous phase of CT image and corrected for
body weight and height: liver volume index (LVI)¼ ratio of the expected stan-
dard volume to the measured liver volume. Kaplan–Meier analysis with the log-
rank test used to compare HCC. Cox proportional hazard analysis was used to
identify the independent predictors of HCC risk.
Results: The cumulative incidence of HCC was 2.1%, 16.2% and 46.1% at 1, 4
and 8 years, respectively. The risk of HCC was significantly higher in patients
with LVI4 1 (P5 0.001). Presence of liver cirrhosis was also associated with
higher risk for HCC. (P5 0.001), whereas age, sex, alpha-fetoprotein and HCV
RNA level were not significant predictors of HCC. Multivariate analysis show
that LVI4 1 and presence of LC were independent predictors of HCC (HR:
63.53, CI: 3.24–1244.28, P5 0.001/HR: 3.10, CI: 1.28–7.51, P¼ 0.12,
respectively).
Conclusion: Decreased liver volume is an independent predictor of HCC in
chronic hepatitis C. Liver volume index is useful in predicting risk of HCC in
CHC.
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Introduction: Sorafenib is a multi-thyrosine kinase inhibitor classified as a neo-
vascularization inhibitor. A previous study indicated that the administration of a
thyrosine kinase inhibitor, cetuximab, significantly prolonged the survival of
patients with dermal disorder1. However, few studies have reported the efficacy
of sorafenib administration in patients with hand and foot syndrome (HFS).
Aims & Methods: In this study, we investigated the prognosis of sorafenib-treated
patients with HFS. HFS grading was conducted according to the Common
Terminology Criteria for Adverse Events (CTCAE) v.4.0. Patients with grade 1
or higher dermal disorder were regarded as having HFS, and grade 0 patients as
not having HFS. For HFS evaluation, a double-check system was adopted:
primary evaluation based on a specific evaluation sheet at the Pharmacists’
Outpatient Clinic and final evaluation by physicians at the outpatient clinic.
We examined the influence of HFS on the effects of treatment after the introduc-
tion of sorafenib in 42 patients with a history of multidisciplinary treatment, such
as transcatheter arterial chemoembolization (TACE), between May 2009 and
March 2017.
Results: Grade 1 or higher HFS was observed in 22 patients (53%), and it was
absent in 20 (47%). Overall, the median sorafenib administration period was 2.1
months. In the HFS-free and HFS groups, it was 0.9 and 2.7 months, respectively
(p5 0.001). Survival analysis was performed using the Kaplan-Meier method.
Overall, the median survival was 5.2 months. In the HFS-free and HFS groups, it
was 3.0 and 7.8 months, respectively (p5 0.001). Multivariate analysis showed
that the presence of HFS (hazard ratio, 0.41; 95% CI, 0.19 to 0.88; p¼ 0.023) and
administration period (hazard ratio, 0.45; 95% CI, 0.20 to 0.98; p¼ 0.045) were
significant predictive factors. The following were not significant predictive fac-
tors: age, BCLC staging, dosage, and tumor markers.
Conclusion: The prognosis of hepatocellular carcinoma patients receiving sorafe-
nib treatment was closely related to the presence of HFS and administration
period. HFS was a predictor of outcome in patients with hepatocellular carci-
noma treated with sorafenib. This study indicated that a multi-thyrosine kinase
inhibitor, sorafenib, prolonged survival in patients with HFS, as demonstrated
for cetuximab. HFS reduces the quality of life (QOL), and is a sorafenib admin-
istration-inhibiting factor. In our hospital, a system for patients to initially con-
sult the Pharmacists’ Outpatient Clinic, followed by the feed-back of grade-based
HFS control strategies to physicians at the outpatient clinic, was established.
Skin control for sorafenib-treated patients with HFS may have prolonged the
administration period, improving the prognosis.
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Introduction: Hepatocellular carcinoma is the most common primary tumor of
the liver and is estimated to cause more than a quarter of a million deaths each
year throughout the world. Extrahepatic metastasis of HCC occurs in about 30–
50% of patients, and it depends on HCC stages.1 The most frequent site is lung,
followed by lymph node, bone, and adrenal gland.2 Extrahepatic metastases to
unusually sites from HCC have been reported in a few case reports. We report
cases of patients with unusual extrahepatic metastatic sites from HCC.
Aims & Methods: We carried out a retrospective study of 16 patients with unu-
sual extrahepatic metastasis of hepatocellular carcinoma out of 1047 cases of
HCC treated at the hepatogastroenterology department "Medicine C" of the
IBN SINA University Hospital during the past 22 years. The diagnosis was
suspected based on clinical signs and imaging data, and confirmed by histology
when the biopsy of the metastasis was possible, were excluded from this study,
patients with lung metastasis, lymph node and portal thrombosis.
Results: Our study included 16 patients, 10 men and 6 women with a mean age of
58.5 years ranging from 37 years to 75 years. 13 patients had cirrhosis due to
hepatitis C virus, 1 patient had a cirrhosis due to viral B infection and 2 patients
had HCC within anoncirrhotic liver. All patients had one or more HCC, ranging
in size from 2 to 10 cm. The AFP was normal in 11 cases and elevated in 4 cases
(4200 ng/ml). We collected 4 cases of adrenal metastases, 3 costovertebral
metastases, 2 gastric metastases, 2 brain metastases, 1 cranial metastasis, 1 cla-
vicular metastasis, 1 ovarian metastasis, 1 nasopharyngeal metastasis, and a case
of metastasis in the path of percutaneous biopsy of HCC. In 4 cases the diagnosis
of HCC and metastasis was synchronous while in 12 cases median time from
diagnosis of hepatocellular carcinoma andextrahepatic HCC was 15.5 months.
Therapeutic abstention was decided in 14 patients for the advanced stage of the
disease. cutaneous metastasis was resected surgically and HCC occurring in
healthy liver was treated by lumpectomy and upper pole gastrectomy in gastric
metastasis. The average survival was estimated at 14 months with a decline of
17.3 months, 6 cases were lost to follow and 6 deaths occurred in our series.
Conclusion: The incidence of unusual and extrahepatic metastasis of HCC diag-
nosed during clinical course was not frequent. The diagnostic procedures for
extrahepatic metastasis have not been standardized, however considering the
substantial advances in treatment of HCC, the detection of extrahepatic HCC
is crucial for patients to receive appropriate therapy, which ultimately determines
patient survival.
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Introduction: Hepatocholangiocarcinoma is a rare primary hepatic tumor com-
bining features of both, cholangiocarcinoma and hepatocellular carcinoma
(cHCC-ICC). Few data concerning the epidemiology of cHCC-ICC have been
reported, mainly from surgical series in Asian and American populations.
Aims & Methods: The main objective of this retrospective multicenter study was
to evaluate epidemiological features and overall survival of histologically proven
advanced CHCC patients in a French population. Data from patients treated for
histologically proven cHCC-ICC in six French university hospitals between 2008
and February 2017, were retrospectively collected. The main clinical, biological,
therapeutic features and OS were reported. Statistical analysis was performed
using Graph Pad Prism 6.
Results: Thirty patients were included (76.6% of men, median age 64 years
[extreme 37–88]. Cirrhosis was associated in 33.3% of cases (Child-Pugh score
A: 70%). Positive serology for hepatitis B virus and C was found in respectively,
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5 (16.6%) and 2 (6.6%) patients; and 1 co-infection was observed. Chronic
alcoholism was noted in 33.3%, diabetes and obesity (body mass index
30 kg/m2) were both present in 26.6% of cases. Alpha-fetoprotein,
Carbohydrate Antigen 19–9 and carcinoembyonnic antigen serum levels were
above normal in respectively 39% (median¼ 5.3 mg/L [2–21 479]), 50%
(median¼ 21.8 IU/mL [4.5–20 000]) and 14% (median¼ 2.4 mg/L [2–88]) of
cases. Six patients (20%) were initially treated by surgical resection. At the
diagnosis of advanced non resectable disease, 66.6% of patients presented a
multifocal hepatic lesions, 50% presented distant metastases (bones metastases
(23.3%), lung metastases (20%) and peritoneal metastases (13.3%). Twenty-
seven patients (90%) received first line of systemic treatment. Twenty-four
patients were treated by chemotherapy: Gemcitabine (Gem) alone (n¼ 1),
Gemþoxaliplatine (n¼ 12), Gemþ oxaliplatineþbevacizumab (n¼ 9),
Gemþ cisplatine (n¼ 2). Two patients were treated by chemoembolization and
1 patient received sorafenib. Twenty-one (70%) and 4 (13.3%) patients received a
second and third line of treatment, respectively. Median overall survival was 14.5
months.
Conclusion: Advanced cHCC-ICC appear to be aggressive tumors with a poor
prognosis. Cirrhosis was associated in one third of patients. Systemic treatments
are not standardized and must be evaluated in a dedicated study.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Barcelona Clinic Liver Cancer (BCLC) C stage is defined as patients
with preserved hepatic function and one of those adverse predictors including
performance status (PS) 1–2, vascular invasion (VI), or extrahepatic spread
(EHS). Therefore, BCLC C demonstrates extreme heterogeneity because patients
with PS 1–2 are categorized to BCLC C regardless of tumor burden, VI or EHS.
This study aimed to modify BCLC system based on PS to derive more relevant
staging system.
Aims & Methods: A total of 7501 subjects, who were registered in Korean Liver
Cancer Study Group during the period 2008–2013, were analyzed. Kaplan-Meier
analysis was used to compare overall survival (OS). The relative goodness-of-fit
between staging system was compared by Akaike information criterion (AIC)
and integrated area under the curve (iAUC).
Results: Two modified BCLC (mBCLC) systems (#1 and #2) were derived by
reducing role of PS in BCLC system. The patients with PS 1 or 2 without VI or
EHS were reassigned to stage 0, A, or B according to their tumor burden.
Prognostic accuracy was compared between mBCLC systems and original
BCLC by AIC and IAUC. As a result, mBCLC#2 system identified as most
explanatory and desirable model for HCC staging by showing smallest AIC
value (AIC¼ 70088.01) and largest IAUC (IAUC¼ 0.722), while original
BCLC showed the biggest AIC value (AIC¼ 70697.17) and smallest IAUC
(IAUC¼ 0.705). The mBCLC#2 stage C was further sub-classified into C1,
C2, C3 and C4 according to the variables which selected by statistical and clinical
importance. The C1-C4 sub-groups showed significant different OS distribution
between groups (P5 0.001).
Conclusion: Modification of BCLC system based on PS derived accurate and
relevant modified BCLC system for HCC patients.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Primary tumors of the liver, beyond hepatocellular carcinoma, are
difficult to characterize and are associated with poor prognosis. Hepatic involve-
ment in the lymphomatous process is uncommon and primary hepatic lympho-
mas are rare. The etiology is not yet known but it is thought that hepatitis B and
C may be risk factors. The therapeutic approach is not yet fully defined.
Aims & Methods: The aim of this study was to evaluate the clinical manifesta-
tions, risk factors and prognosis in lymphomas with hepatic involvement. We
conducted a retrospective study of patients diagnosed with hepatic lymphoma at
our center between 2005 and 2016.
Results: During the 12 years, 36 hepatic lymphomas were identified, 27 primary
hepatic lymphomas and 9 with secondary hepatic involvement. The mean age at
diagnosis was 53.5 14.6 years and 50% were males. Only one patient had
hepatitis B and none had hepatitis C. The majority (94.4%) had symptoms at
the time of diagnosis, with fatigue (83.3%), night sweats (61.1%) and loss of
weight (61.1%) being the most common. The imaging presentation was of a
single mass in 47.2% of cases, multiple masses in 30.6% and infiltrative mass
in 22.2%. The most common lymphoma subtypes were diffuse large B-cell lym-
phoma (52.8%), MALT lymphoma (11.1%) and Hodgkin’s lymphoma (11.1%).
Survival at the end of one year was 63.8% and 27.8% at 3 years. Age4 60 years
(p¼ 0.004) was the only factor that was significantly associated with higher
mortality.
Conclusion: Hepatic lymphomas are rare entities that may occur in different
ways, with diffuse large B-cell lymphoma being the most common subtype.
They presented a 3-year survival of only 27.8% and the age over 60 years was
the only factor significantly associated with mortality.
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Introduction: Microbiotas, as part of our bodies, actually affect the body’s meta-
bolism, defense and digestion. Gut microbiotas are the typical examples and they
are mainly regulated by bile acids. Each bile acid has different properties, 1 and
the inhibition or promotion effects of microbiotas are very diverse.2 Each indi-
viduals have a characteristic microbial distribution and composition within the
intestinal tract, presumably related to the composition of their respective char-
acteristic bile acids.3 The bile acids, released into the intestinal tract, are mostly
reabsorbed (about 95%) through the enterohepatic circulation and recycled. If a
certain bile acid is continuously orally-supplied, the ratio of supplied bile acid to
the total bile acid is gradually increased due to the continuous enterohepatic
circulation. It has been reported that changes in the composition of intestinal
bile acids cause dysbiosis, 4 and it is presumed that an artificial change in the
composition of bile acid can be an effective method of controlling the prolifera-
tion of target microbiotas.
Aims & Methods: First, we wanted to identify the effects of certain bile acids on
each microbiotas. We observed the effect of bile acids in human body (cholic
acid, deoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid) on micro-
organisms by the disk diffusion method, used for antibiotic susceptibility test.
Second, we intended to observe actual intestinal microbial changes through the
supply of specific bile acids in animal models. Specific bile acid (UDCA), which is
commercialized, was fed to rats, and real time polymerase chain reaction (RT-
PCR) was used to observe the changes of the colon microbiotas. Fermicutes and
bacteroidetes, which consist more than 90% of total intestinal microbiotas, were
analyzed.5 Next, to minimize the role of endogenous bile acid, we used bile duct
ligation rat model. Next generation sequencing (NGS) method was used to ana-
lyze the changes of microorganisms according to the supplied amount of UDCA.
Examinations were divided into three groups for 3weeks, considering the capa-
city of commercial UDCA product: control group; 10mg/kg/day group; and
15mg/kg/day group. Fecal contents were collected from cecum of sacrificed rats.
Results: Each bile acid formed various inhibitory or promoting regions in target
strains. Saccharomyces boulardii and Lactobacillus casei, which are commercially
available as probiotics, were mainly inhibited by hydrophobic bile acids.
Enterococcus faecalis and Klebsiella pneumoniae, which are frequently observed
in bile during biliary infections, did not form a large inhibitory zone of bile acids.
Escherichia coli, which is occasionally found in the lower intestinal tract, prolif-
erated more around bile acid. Other microorganisms, which cause opportunistic
infections in various organs in the body, showed various patterns. As a result of
relative quantitative analysis(RT-PCR) based on the control group, the ratio of
Fermicutes to Bacteroidetes was decreased in the group treated with UDCA for 3
weeks. In the cholestatic model, NGS showed changes in the proportion of
intestinal microbiota and an increase in diversity after 3 weeks of UDCA supply.
Conclusion: The effects of various kinds of bile acids on microbiotas are very
diverse, and the oral administration of certain bile acids may cause changes in
microbial environment in the intestinal tract. Finally, oral feeding of certain bile
acids can be used as a therapeutic treatment for dysbiosis by controlling the
microbial environment in the intestinal tract.
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Introduction: Inhibition of microRNA-21 (miR-21) prevents necroptosis in the
mouse pancreas. In turn, we recently showed that necroptosis contribute to
hepatic necro-inflammation in the common bile duct ligation (BDL) murine
model.
Aims & Methods: We aimed to evaluate the role of miR-21 in mediating deleter-
ious processes associated with cholestasis. The functional crosstalk between miR-
21 and necroptosis was investigated in vitro. miR-21 expression was evaluated in
the liver of primary biliary cholangitis (PBC) patients. C57BL/6 wild-type (WT)
or miR-21-deficient (miR-21/) mice were subjected to BDL or sham surgeries,
with biochemical, molecular and histological analysis of hepatic damage, fibrosis,
necroptosis and bile acid metabolism, after either acute (3 days) or chronic (14
days) injury.
Results: Studies in miR-21/ primary mouse hepatocytes established a func-
tional link between miR-21 and necroptosis through cyclin dependent kinase 2
associated protein 1 (CDK2AP1). miR-21 expression increased in the liver of
PBC patients and BDL WT mice at both 3 and 14 days. Notably, under BDL,
miR-21/mice displayed decreased serum levels of liver injury markers com-
pared with WT mice, accompanied by reduced hepatocellular degeneration, oxi-
dative stress and pro-fibrotic gene expression. Hallmarks of necroptosis were
decreased in the liver of BDL miR-21/ mice, via relieved repression of
CDK2AP1. Further, miR-21/ mice displayed improved adaptive response in
the expression of bile acid homeostasis-associated genes.
Conclusion: miR-21 ablation ameliorates liver damage and necroptosis in BDL
mice; as such, inhibition of miR-21 should arise as a promising approach to treat
cholestatic liver diseases. Supported by FCT, Portugal through grants PTDC/
BIM-MEC/0895/2014 and UID/DTP/04138/2013, and fellowships SFRH/BD/
91119/2012 (MBA), SFRH/BD/88212/2012 (PMR), and SFRH/BD/104160/201
(ALS).
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Introduction: Endoscopic sphincterotomy, endoscopic papillary balloon dilation,
and endoscopic papillary large balloon dilation are widely recognized as safe and
effective treatments of choledocholithiasis. However, endoscopic stone removal
does have some complications. Although the life expectancy of elderly patients
has increased dramatically worldwide, little information is available on the neces-
sity of complete endoscopic stone removal in extremely elderly patients.
Aims & Methods: The aim of this study was to evaluate the safety and efficacy of
complete endoscopic stone removal in extremely elderly patients. We retrospec-
tively evaluated all extremely elderly patients (older than 90 years) who had
undergone endoscopic stone removal for choledocholithiasis at Ise Red Cross
Hospital between January 2012 and December 2016. Included patients were
divided into complete stone removal and incomplete stone removal (failure to
achieve complete stone removal and insertion of a plastic stent) groups. We
compared the complication rate, overall survival (OS), and disease-specific sur-
vival (DSS) rate between the two groups.
Results: In total, 67 patients were included this study; 36 (54%) had complete
stone removal and 31 (46%) had incomplete stone removal. The median age of
the patients was 92 years (range 90–100 years), median follow-up period was 462
days (range 6–1449 days) and the male-to-female ratio was 15:52. Baseline char-
acteristics (age, body mass index, performance status, and comorbidities), rate of
complications (perforation, bleeding, hypoxemia, or decreased blood pressure
during the endoscopic procedure), and total number of endoscopic procedures
did not significantly differ between the two groups. The median number of stones
was one (range 0–5) and two (range 1–5) (P¼ 0.013), while the median diameter
of the largest stones was 9mm (range 0–27) and 14mm (range 5–32) (P¼ 0.001)
in the complete and incomplete stone removal groups, respectively. During the
follow-up period, OS was 33.3% and 41.9% and DSS was 5.56% and 3.23% in
the complete and incomplete stone removal groups, respectively. Kaplan-Meier
analysis found no significant difference in OS and DSS between the two groups
(P¼ 0.187 and P¼ 0.581, respectively).
Conclusion: Patients in the incomplete stone removal group tended to have more
numerous and larger stones. This single-centre retrospective study revealed no
significant difference in OS and DSS between the two groups. Complete stone
removal might not be always necessary in extremely elderly patients aged 90 years
and older.
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Introduction: The number of indications for endoscopic transpapillary gallblad-
der drainage (ETGBD) to acute cholecystitis patients has been increasing with
the aging of the population and prescribing antithrombotic agents. ETGBD is
one of the challenging procedure because it is difficult to identify the cystic duct
(CD) orifice. From November 2015, we performed with ETGBD using intraduc-
tal ultrasonography (IDUS) complementarily. The CD orifice can be identified
using IDUS, resulting in cannulation in to the CD. We investigated the success
rate and clinical outcomes of ETGBD in combination with using IDUS.
Aims & Methods: ERCP was performed in 1000 patients (1400 times) at New
Tokyo Hospital between July 2012 and December 2016. Among them, a total of
97 patients underwent ETGBD; 58 patients with IDUS and 39 without IDUS. In
this study, we investigated the success rate of ETGBD retrospectively. The suc-
cess of ETGBD was defined as cannulation into the gallbladder within two trials.
Results: The mean age and male proportion of patients in the group with IDUS
was similar to that in the group without IDUS (74.5 11.4 vs 73.3 11.3;
P¼ 0.600 and 18/40 and 13/26; P¼ 0.828). The procedure success rate was
78.4% (76/97) in total; 86.2% (50/58) in the group with IDUS and 66.7% (26/
39) in the group without IDUS (P¼ 0.026). Using IDUS under fluoroscopic
image allowed all patients in the group with IDUS to identify the CD orifice.
ETGBD procedures in eight patients were unsuccessful because of a highly flex-
ion of the CD in seven patients and an obstruction of the CD orifice caused by
tumor invasion in one patient. Although both groups developed mild pancreatitis
(one patient in the group with IDUS, and two patients in the group without
IDUS), no significant difference was observed in the two groups (P¼ 0.563). All
patients were successfully managed with conservative treatment. There were no
any other complications in the two groups.
Conclusion: The success rate of ETGBD in the group with IDUS was significantly
higher than that in the group without IDUS. IDUS is may be useful as a com-
plementary option of endoscopic gallbladder drainage.
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Introduction: Bile Duct Injury (BDI) following laparoscopic cholecystectomy is a
persisting problem. The rendezvous procedure (RV) provides a combined endo-
scopic and percutaneous approach in order to re-establish bile duct continuity in
complex BDI.
Aims & Methods: The aim of this study is to assess short-term and long-term
outcomes of the RV. All consecutive patients with BDI referred to our tertiary
referral center between 1995 and 2016 were analyzed retrospectivally. RV pro-
cedure was performed when endoscopic stenting or PTC failed and when deemed
feasible by a dedicated multidisciplinary team including a hepato-pancreato-bili-
ary surgeon, gastroenterologist and interventional radiologist. Classification of
BDI, technical success of RV, procedure-related complications and outcomes
were assessed.
Results: Among a total of 812 patients, RV was performed in 47 (5.8%) patients,
of which 31 (66%) were diagnosed with complete transection of the bile duct
(type D/Strasberg type E injury). Primary success rate of RV was 94% (44/47
patients). Reasons for failure (N¼ 3) were inability to pass a stricture and inabil-
ity to make contact between the two wires. In 26/47 patients (55%) RV was the
final successful treatment. In 17/47 patients (36%) RV acted as a bridge to
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surgery; although the RV was initially successful, late complications (stenosis,
stent dysfunction) required elective hepaticojejunostomy (HJ). Procedure-related
adverse events occurred in 10 patients (18%) with cholangitis being the most
frequent complication (N¼ 4.7%). No life-threatening adverse events and no
30-day mortality occurred.
Conclusion: In experienced hands, RV is safe with a final non-surgical success
rate of 55%. When endoscopic stenting fails in patients with complex BDI, RV
can be considered as a viable treatment option before surgical repair.
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Introduction: The time interval between endoscopic retrograde cholangiopancrea-
tography (ERCP) and laparoscopic cholecystectomy (LC) is a matter of debate.
This study was planned to compare early LC versus late LC.
Aims & Methods: This is a prospective randomized study on patients who are
presented with concomitant gallbladder and common bile duct stone. The study
population was divided into two groups; group (A) managed by early LC within
three days after ERCP; and group (B) managed by late LC one month after
ERCP.
Results: No significant difference between both groups as regards the conversion
rate, the degree of adhesion, cystic duct diameter, and intraoperative common
bile duct injury or bleeding. Recurrent biliary symptoms were significantly more
in delayed LC group in 7 (12.71%) patient versus 1 patient in early LC (P¼ 0.03).
Conclusion: No significant difference between both groups as regards the con-
version rate. Recurrent biliary symptoms were significantly more in delayed LC
while waiting LC. Morbidity was significantly more in delayed LC.
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Introduction: Transcolonic and transrectal NOTES in human cases was greatly
restricted by the fact of fecal contamination. We developed a detachable intra-
colonic balloon to help keep the colon sterile by blocking the colonic lumen.
Although cholecystectomy is widely used for treating gallbladder polyps and
gallstones, there is still a controversy about whether or not the gallbladder
should be preserved. However, postcholecystectomy syndromes, such as bile
duct injury and the correlation with colon cancer, remind us of the importance
of gallbladder preservation.
Aims & Methods: Approved by the Independed Ethics Committee, we’ve com-
pleted 8 transrectal gallbladder preserving cholecyctolithotomy (TRGPC) and 3
transrectal gallbladder preserving polypectomy (TRGPP) and 2 combined cases
by pure NOTES. Moreover, 1 case of TRGPC was done by hybrid NOTES. As
the figures show, the balloon was placed in the transverse colon to block the
colonic lumen, and the distal colon cavity was disinfected with povidone-iodine
solution. An incision was made on the anterior rectal wall 12–17 cm from the
anus. The endoscope was advanced into the peritoneal cavity with liver and
gallbladder identified. The bile was aspirated before an incision on the gallblad-
der wall was made. Stones and/or polyps were found inside of the gallbladder.
Stone extractor and biopsy forceps were used to take out the stones. The polyps
were coagulated and removed by electric biopsy forceps. The muscular layer and
the adventitial layer were successively closed with endoclips. Peritoneal cavity
lavage was performed with sterile saline. The rectal incision was closed with
endoclips and endoloops tightly. At the end of the procedure, the balloon was
pulled out after being deflated.
Results: The mean operation time (from incision making till the last clipping) was
180.5min. (89–467min.). 6 hours after anesthesia, the patients could drink water,
and liquid diet was resumed 24 hours later. Postoperatively, 4 of the 14 patients
felt mild abdominal distention which disappeared within 12 hours when they
were able to get off the bed. For 1 patient with acute cholecystitis, a hybrid
NOTES with laparoscopy was performed. Moreover, gallbladder drainage and
peritoneal lavage were used, and the abdominal pain relieved soon. All the
patients were discharged without any adverse events and all felt good during
the follow-ups.
Conclusion: The usage of the detachable balloon can prevent the operative field
from fecal contamination effectively. TRGPC and TRGPP by pure NOTES are
suitable for both males and females. Transrectal route provides a novel alterna-
tive approach for the treatment of gallbladder polyps and gallstones. To our
knowledge, this is the first human case series of transrectal gallbladder preserving
cholecyslithotomy and polypectomy by pure NOTES. However, multicentered,
prospective, controlled researches with more cases are needed in the future.
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Introduction: Sodium metaarsenite (NaAs2O3: code name KML001) is an orally
bioavailable arsenic compound with potential anti-cancer activity. However, the
effect of KML001 has not been evaluated in patient with biliary tract cancers. We
investigated the potential of KML001 as palliative chemotherapy in patients with
advanced biliary tract cancers who non-respond to gemcitabine-based
chemotherapy.
Aims & Methods: The study was designed to evaluate safety, tolerability and
effectiveness of KML001 as palliative chemotherapy in advanced biliary tract
cancer. Inclusion criteria were 1) inoperable or metastatic cholangiocarcinoma
and gallbladder cancer, and 2) previous history of failure to gemcitabine-based
chemotherapy. Exclusion criteria were 1) naı̈ve patient to chemotherapy, 2)
ECOG PS 43, and 3) history of decompensated congestive heart failure, uncon-
trolled arrythmia, and QT prolongation (QTc4 480ms). KML001 (Kominox,
Komipharm International Co., Ltd.) was administrated as 7.5mg daily to eligible
subjects. Every two months, patient took response evaluation by biliary CT scan.
Results: A total of 44 patients (21 females and 23 males) were enrolled prospec-
tively between November 2011 and October 2014. Mean age of the patients was
United European Gastroenterology Journal 5(5S) A419
61.5 years old. There were 17 patients (38.6%) with intrahepatic cholangiocarci-
noma, 9 patients (20.5%) with perihilar cholangiocarcinoma, 7 patients (15.9%)
with extrahepatic cholangiocarcinoma and 11 patients (25.0%) with gallbladder
cancer. All patients had stage IV disease and median number of prior anticancer
treatments of patients was 2 (range 1–5). After an average of 1.5 months of
treatment (range 0.5–10.0 months), three patients (6.8%) presented stable disease
as best overall response, 23 patients (52.3%) presented progression and 18
patients (40.9%) could not survive until response evaluation. Median progression
free survival was 1.7 months (interquartile range (IQR) 0.8–2.3 months) and
median overall survival from study-enroll was 2.5 months (IQR 1.4–4.9
months). During treatment, 25 patients (55.6%) could maintain tolerable general
condition without increasing ECOG PS, and 35 patients (79.6%) could maintain
or decrease the requirement for morphine as pain killer. During treatment, there
were 12 cases (12/44, 27.3%) of severity grade 3 adverse events (AE) and no cases
of grade 4 AE. Most common AE was ALT/AST elevation (11/44, 25%) fol-
lowed by anemia (10/44, 22.7%). The major causes of the drop outs from study
were due to disease progression or patient’s death (30 cases, 66.7%), and there
were only 5 cases (11.1%) who dropped out due to adverse drug reactions or
severe AE.
Table 1: Treatment outcomes
Study period, mean, mo (range) 1.5 (0.5–10.0)
Progression free survival, mo (IQR) 1.7 (0.8–2.3)
Survival from study-enroll, mo (IQR) 2.5 (1.4–4.9)
Best response, n (%) SD 3 (6.8%)
PD 23 (52.3%)
Not evaluated 18 (40.9%)
ECOG, n (%) Increased 19 (43.2%)
Maintain 25 (56.8%)
Morphin requirement, n (%) increased 8 (18.6%)
maintain 31 (72.1%)
decreased 4 (9.3%)
Adverse event, n (%) Grade 1 16 (36.4%)
Grade 2 29 (65.9%)
Grade 3 12 (27.3%)
Grade 4 0 (0%)
Drop out cause, n (%) - drug reaction 1 (2.3%)
Adverse event 4 (9.1%)
Patient’s death 7 (15.9%)
Disease progression 22 (50.0%)
Withdrawal consent 5 (11.4%)
Loss of follow-up 2 (4.5%)
Poor general condition 3 (6.8%)
Conclusion: KML001 was safe and well tolerated in respects of adverse events.
KML001 was also shown promising result in disease control and pain control.
KML001 can be another palliative treatment option for patients with advanced
biliary tract cancers who non-respond to gemcitabine based chemotherapy.
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Introduction: ESGE stated in 2012 that more than 50% of the liver had to be
drained in case of unresectable hilary liver stenosis, however it remains unclear if
unilateral or bilateral palliative drainage has to be perform for this kind of
stenosis. Our policy is to try to drain the most possible segments of the liver in
case of hilar stenosis. The aim of our study was to evaluate the efficiency of hilary
drainage in function of the number of segments drained.
Aims & Methods: The study is a retrospective analysis of a prospective registry of
drainage of malignant stenosis of the hilum. Drainage were performed by 5
operators performing ERCP, EUS-drainage, and per-cutaneous drainage. The
choice of the technique was left to the appreciation of the operators. All techni-
ques could be associated. A Ct-scan or MRI was performed before and after
drainage to decide the plan of the drainage and to evaluate efficiency and quality
of the drainage. All drainages were performed under general anesthesia in a
intubated patient. The quality of the drainage was evaluated by calculation of
the percentage of drained segments. This percentage was calculated by dividing
the number of liver segment drained with the number of liver segment. The
number of liver segment was obtained by removing from the 8 classical liver
segments with the segments resected in case of surgery, and/or the segments
with invasion of more than 50% by tumor. The aim of the study was to evaluate
the effect of the quality of the drainage on the patients survival. Quality of the
drainage was defined by the percentage of liver segments drained.
Results: 60 (38 men) patients were included from from 01/2015 to 07/2016. Mean
age¼ 69.84 years old. The classification of the stenosis was type II for 17 (29%)
patients, type III for 20 patients (34%), type IV for 22 (37%). Histology corre-
sponded to CCK from 26 patients (43%), metastatic disease from colorectal
cancer for 15 patients (25%) and others cancers for 19 (32%). Median follow-
up was 8.5 months (5.5–16.5). The median of survival was 5 months (2.3–12.3). In
unvaried and multi varied analysis there was a significant correlation between the
percentage of segments drained4 80% (p5 0.05) and the survival. The other
factor with impact on the survival was an invasion of the liver4 50% by tumor.
There was no impact on the survival according to the different techniques used to
drain the bile ducts. To confirm the efficiency of the quality of the drainage, a
ROC curve was performed establishing a correlation between patients receiving
chemotherapy and percentage of liver drained (area curve¼ 0.77 (0.65–0.88).
Conclusion: The survival of patient with a malignant stenosis of the biliary con-
fluence is highly correlate with the rate of the liver segment drained.
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Introduction: Approximately 0.6% to 4% of cholecystectomies are for gallblad-
der polyps. The decision to perform cholecystectomy is based on presence of
gallbladder polyp on transabdominal ultrasound (TAUS) or endoscopic ultra-
sound (EUS), or both. This decision is also influenced by whether the polyp is a
true or pseudo polyp. Pseudo polyps are non-neoplastic and do not need surgery.
True polyps are neoplastic, either benign (adenoma) or (pre)malignant (dys-
plastic polyp/carcinoma). True polyps usually need surgery, as they are thought
to have malignant potential through the adenoma-carcinoma sequence.
(Pre)malignant lesions should be operated sooner than benign lesions. There
has been no systematic review and meta-analysis on the accuracy of TAUS
and EUS in the diagnosis of gallbladder polyps, true gallbladder polyps and
(pre)malignant polyps.
Aims & Methods: The aim was to determine and compare the accuracy of TAUS
and EUS for diagnosis of gallbladder polyps, differentiating between true and
pseudo polyps and differentiating between (pre)malignant and benign polyps.
MEDLINE, EMBASE, Science Citation Index Expanded and the Cochrane
library were searched. The search was not restricted based on language, publica-
tion status, or prospective or retrospective nature of the studies. Only studies
with data on true positives, false positives, false negatives and true negatives for
TAUS or EUS were included. Histopathology after cholecystectomy was the
only accepted reference standard, except for studies on diagnosis of gallbladder
polyp, for which follow-up by TAUS or EUS was also accepted as reference
standard. Two authors independently screened abstracts, selected studies for
inclusion and collected the data from each study. The quality of the studies
was evaluated using the QUADAS-2 tool. If possible the bivariate model was
used to obtain pooled estimates of sensitivity and specificity. Otherwise the prin-
ciples of Takwiongi et al. for meta-analysis of sparse data were used.1
Hierarchical summary receiver operating characteristics curve (HSROC) were
used to test whether TAUS or EUS was superior. Post-test probabilities were
calculated using the median prevalence (as pre-test probabilities) and summary
positive and negative likelihood ratios.
Results: A total of 17 studies were included in this review. For diagnosis of
gallbladder polyps six studies on TAUS were included. The sensitivities and
specificity of the studies ranged from 0.45 to 1.00, and 0.91 to 0.98 respectively.
There were no studies on EUS for this topic. For differentiating between true and
pseudo polyps, seven studies were included. All seven studies retported on
TAUS, four studies also reported on EUS. The sensitivities and specificities of
the studies ranged from 0.47 to 1.00 and 0.51 to 0.98 for TAUS, and from 0.63 to
1.00 and 0.84 to 0.96 for EUS. For differentiating between (pre)malignant and
benign polyps, five studies were included. Four studies reported on TAUS and
three studies on EUS. The sensitivities and specificities of the studies ranged from
0.09 to1.00, and 0.46 and 1.00 for TAUS and from 0.69 and 0.92, and 0.87 to 0.95
for EUS.
No studies were of high methodological quality. The results of the pooled sensi-
tivities, specificities and post-test probabilities are shown in Table 1. HRSOC
analysis showed no significant difference between the diagnostic accuracy of
TAUS and EUS for differentiating between true and pseudo polyps and for
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differentiating between (pre)malignant and benign polyps (p¼ 0.174 and
p¼ 0.589 respectively).
Conclusion: Diagnostic accuracy of TAUS for diagnosis gallbladder polyps is
moderate and decreases further when differentiating between polyp types.
TAUS would regularly provide false positive results, leading to unnecessary
surgery. There was no evidence that diagnostic test accuracy of EUS was
better than TAUS. Further studies of high methodological quality are needed
to determine diagnostic accuracy of EUS and TAUS for differentiating between
polyp types.
This abstract is based on a pre-peer review draft of a Cochrane Review.
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Introduction: In its early stages, gallbladder cancer is an asymptomatic disease,
and is associated with a poor prognosis if found in an inoperable condition.
Several investigators have reported the utility of contrast-enhanced ultrasono-
graphy (CEUS) in low mechanical index (MI) contrast mode using a microbub-
ble contrast agent for gallbladder lesions. However, CEUS images with low MI
setting are influenced by the echogenicity of background B-mode and cannot
depict precise vessel images, in contrast with high MI contrast mode.
Aims & Methods: The aim of this study was to assess the diagnostic value of
CEUS in high MI contrast mode for characterizing polypoid lesions of the
gallbladder (PLG). Thirty-six patients with PLG, including 17 with gallbladder
cancer and 19 with benign polyps, who underwent CEUS were enrolled. The
institutional review board approved this study and informed consent was
obtained. Perflubutane-based contrast agent and high MI contrast mode was
used for CEUS. Two blinded readers retrospectively evaluated images obtained
in B-mode and CEUS. Kappa values, which reflect inter-observer agreement.
Subsequently, patients were stratified according to lesion size at the largest dia-
meter, and the diagnostic accuracy for gallbladder cancer in B-mode and CEUS
were assessed.
Results: Two patients with malignant PLG could not be evaluated in B-mode due
to sludge. Kappa values for CEUS were graded as good or excellent, and were
better than in B-mode. Age and size of malignant PLGs were significantly larger
than benign lesions. In B-mode, 80% (12/15) of malignant PLGs exhibited het-
erogeneity (p5 0.01). On CEUS, malignant PLGs exhibited sessile-shape (76%
[13/17]), dilated vessels (71% [12/17]), irregular vessels (82% [14/17]), and hetero-
geneous enhancement (59% [10/17]) (p5 0.01). Except for heterogeneous
enhancement, all features remained significantly different after stratification
according to size of PLG between 11mm and 20mm on CEUS. The sensitivity,
specificity, and accuracy for diagnosis of gallbladder cancer was 80% (12/15),
79% (13/19), and 73% (25/34) in B-mode, 94% (16/17), 89% (17/19), and 92%
(33/36) on CEUS, and 88% (7/8), 91% (10/11), and 89% (17/19) on CEUS after
stratification according to size, respectively.
Conclusion: CEUS in high mechanical index contrast mode was a useful modality
for differentiating gallbladder cancer and benign PLGs.
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Introduction: Multiple recent studies have indicated that some of adipose tissue-
derived hormones may significantly influence the growth and proliferation of GI
tumors including liver cancer (1, 2). However, the role of adipokines such as
adiponectin and leptin in biliary tract cancer have not been well studied
before. The aim of the study was to analyze plasma concentrations of adiponectin
and leptin in cholangiocarcinoma (CC) patients and to compare these concentra-
tions to clinicopathological parameters.
Aims & Methods: Baseline levels of adiponectin and leptin were determined in 38
consecutive patients with newly diagnosed cholangiocarcinoma and 38 healthy
control subjects. The association between adiponectin and leptin and tumor stage
was evaluated using nonparametric Spearman’s correlation test. Control subjects
were matched to case patients by age, sex and BMI. Survival analysis used the
Kaplan-Meier curve and the Cox proportional hazards model.
Results: Overall median adiponectin concentrations were lower in CC patients
versus control subjects (5.1 vs 9.3mg/mL, P¼ 0.001). In CC patients with T stage
2–4 (n¼ 22) median adiponectin concentrations were significantly lower than in
CC patients with T stage 1 (n¼ 16) (3.8 vs 6.6mg/mL, P¼ 0.001). The mean
leptin levels were not significantly decreased in CC patients (P¼ 0.45).
Adiponectin concentrations were inversely correlated with tumor T stage
(r¼0.811, P¼ 0.01) of CC patients. Higher adiponectin levels at baseline
were associated with increased overall survival in T stage 2–4 patients (Cox F
test¼ 2.139, P5 0.05).
Conclusion: This study identified an association between adiponectin levels and
tumor stage suggesting a potential role for adiponectin in progression of cholan-
giocarcinoma. Furthermore these results suggest, for the first time, that serum
adiponectin levels might represent a prognostic indicator in patients with CC.
Our results support the hypothesis linking adipose-tissue derived hormons levels
to growth of obesity-associated cancers (3). Adipokines appear to play an impor-
tant role in risk prediction and management of cholangiocarcinoma patients.
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Table 1: Results of meta-analysis and post-test probabilities
Index Test Target condition
Number of
studies (patients)
Summary
sensitivity
(95% CI)
Summary
specificity
(95% CI)
Mininum, median
and maximum
prevalence of target
condition¼pre-test
probability
Positive post-test
probability (95% CI)
Negative post-test
probability (95% CI)
TAUS Gallbladder polyp 6 studies (16260
patients)
0.80 (0.55–0.98) 0.97 (0.95–0.98) Minimum: 0.4%
Median: 6.4%
Maximum: 53.3%
0.10 (0.07–0.11)
0.65 (0.55–0.69)
0.97 (0.95–0.97)
0.00 (0.00–0.00)
0.01 (0.01–0.04)
0.19 (0.08–0.38)
TAUS True gallbladder polyp 7 studies (1272
patients)
0.77 (0.48–0.92) 0.78 (0.59–0.90) Minimum: 9.1%
Median: 20.2%
Maximum: 60.0%
0.26 (0.16–0.39)
0.47 (0.32–0.62)
0.84 (0.74–0.91)
0.03 (0.01–0.07)
0.07 (0.03–0.16)
0.31 (0.15–0.53)
EUS True gallbladder polyp 4 studies (267
patients)
0.84 (0.54–0.96) 0.84 (0.70–0.92) Minimum: 9.1%
Median: 20.2%
Maximum: 60.0%
0.35 (0.20–0.53)
0.57 (0.39–0.74)
0.88 (0.79–0.95)
0.02 (0.01–0.07)
0.05 (0.01–0.15)
0.22 (0.07–0.51)
TAUS Dysplastic polyp/
carcinoma
4 studies (1637
patients)
0.60 (0.22–0.89) 0.89 (0.76–0.96) Minimum: 4.1%
Median: 20.1%
Maximum: 95.6%
0.19 (0.07–0.46)
0.59 (0.30–0.83)
0.99 (0.97–1.00)
0.02 (0.01–0.05)
0.10 (0.04–0.24)
0.91 (0.78–0.96)
EUS Dysplastic polyp/
carcinoma
3 studies (350
patients)
0.85 (0.56–0.96) 0.91 (0.75–0.97) Minimum: 4.1%
Median: 20.1%
Maximum: 95.6%
0.28 (0.12–0.54)
0.70 (0.44–0.87)
0.99 (0.99–1.00)
0.01 (0.00–0.02)
0.04 (0.01–0.13)
0.78 (0.51–0.92)
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Introduction: Recently many studies have been conducted to investigate the asso-
ciation between obesity and survival in cancer patients. Cancer has a significant
influence on the nutrient status of patients and obesity can affect on the phar-
macokinetics of anti-cancer drugs. The impact of obesity on survival is known to
vary in different cancers. Biliary tract cancer was less frequently analyzed and
most of the studies were on the relationship between obesity and cancer
incidence.
Aims & Methods: We performed this study to investigate the association between
BMI and overall survival in advanced biliary tract cancer patients with che-
motherapy. Between January 2005 and December 2015, two hundred and
eighty-four patients who underwent chemotherapy for biliary tract cancer were
retrospectively reviewed. The relationship between BMI (kg/m2) and overall sur-
vival (OS) was assessed. Based on World Health Organization BMI category and
2014 Clinical Practice Guidelines for Overweight and Obesity in Korea, BMI was
classified as follows; underweight, 518.5 kg/m2; normal, 18.5–22.9 kg/m2; over-
weight, 23–24.9 kg/m2; obese, =25 kg/m2.
Results: Median OS was 12.1 months for underweight patients, 10.5 months for
normal patients, 16.1 months for overweight group, 13.6 months for obese
patients, respectively. (p¼ 0.047) Univariate analysis showed that BMI, local
status of disease, operation, radiotherapy and ECOG performance were signifi-
cantly associated with better survival. Compared with normal patients, over-
weight patients (BMI 23–24.9 kg/m2) had a reduced risk of mortality in
multivariate analysis (HR 0.491, CI 0.334–0.721; 95% p¼ 0.036). In the addi-
tional analysis for the effect of change in body weight and BMI to the overall
survival, larger amount of change in body weight was associated with further
decrease in overall survival.
Conclusion: Slightly overweight status and the maintenance of body weight
during the initial period of chemotherapy is independent predictor of better
overall survival in advanced biliary tract cancer patients with good performance
status.
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Introduction: To perform curative operation of biliary carcinoma, the pre-opera-
tive identification of exact proximal and distal margins is important. A biopsy
forceps is conventionally inserted to common bile duct via duodenum ampulla
guided with an antecedent guide wire. Cannulation of the bile duct with the
biopsy forceps may sometimes be difficult in cases where no sphincterotomy is
performed, placing the patient at risk of post-ERCP pancreatitis after multiple
attempts to advance the forceps into the duct. Pancreatobiliary endoscopists have
reported the biopsy methods.
Aims & Methods: The aim of this study was to assess the feasibility and safety of
the biopsy methods. This was a retrospective review of bile duct biopsies with this
new method conducted in Sendai Kousei hospital from February 2015 to
October 2016. All patients who had biliary stenosis were included. Patients’
demographic data, technical success, adverse events and the diagnostic accuracy
were evaluated.
Results: A total of 95 biopsy procedures were performed in 40 patients. The
technical success rate was 95% (90/95). Post-ERCP pancreatitis occurred in 1
of 40 patients (2.5%, 1 grade 1 patient). There were no other adverse events like
perforation or bleeding. The diagnostic yield of mapping biopsy procedures was
100% (7 of 7 patients).
Conclusion: The new biopsy methods to biliary stricture were feasible and safe. It
opens up exciting possibilities for endoscopic preoperative diagnosis of the biliary
carcinoma.
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Introduction:Up to half of all patients with resectable PHC on imaging are found
unresectable during exploratory surgery. Moreover, mortality is high in patients
who do undergo resection for PHC.
Aims & Methods: The aim of this study was to identify patients at high risk for
adverse outcomes of exploratory surgery and developing a preoperative risk score
model to predict adverse outcomes in perihilar cholangiocarcinoma (PHC)
patients undergoing exploratory surgery. Consecutive PHC patients who under-
went exploratory laparotomy in two tertiary referral centers between 2002 and
2014 were identified. Baseline patient and tumor characteristics were collected
frommedical records. Adverse postoperative outcome was defined as unresectable
disease at exploratory laparotomy, 90-day surgical mortality, or an R1 resection.
A multivariable Cox proportional hazards analysis was performed to identify
preoperatively available poor prognostic factors for an adverse outcome.
Results: In total, 331 patients underwent exploratory laparotomy with a median
OS (95% confidence interval) of 20.7 (17.8–23.6) months. Adverse outcomes
were found in 229 patients (69.2%): 145 patients (43.8%) had preoperative
adverse outcomes of the exploratory surgery, 53 (16%) patients had postopera-
tive adverse outcomes and 31 (9.4%) patients experienced both peri- and post-
operative adverse outcomes. Median OS for patients with an adverse outcome
was 13.1 months (11.3–15.0) compared to 50.9 months (39.6–62.2) in patients
without adverse outcomes (p5 0.001). Cholangitis at or before first presentation
(hazard ratio (HR) 2.38, 95% CI 1.16–4.99, p¼ 0.0422), CA 19-9 above 1000 U/
mL (HR 3.26, 95% CI 1.14–11.8, p¼ 0.0195), and tumor involvement of the
hepatic artery on imaging (HR 2.07, 95% CI 1.01–4.33, p¼ 0.0492) were inde-
pendent prognostic factors for an adverse outcome at exploratory laparotomy. A
risk score based on these three factors identified patients with a substantial
(49%), high (66%), and very high (87%) risk of adverse outcome.
Table 1: Calculation of prognostic score
Characteristic Score
CA 19.9 (U/mL) 1000 U/mL 1
Cholangitis before or at presentation in referral center# 1
Hepatic artery involvement * 1
Risk group Substantial
High Very high
Total score
0 1 2–3
Number of
patients 41 74 69
Absolute risk
48.8% 66.2%
87.0%
Conclusion: PHC patients undergoing exploratory laparotomy have a high risk of
an adverse outcome. A preoperative risk score for adverse outcome may help
clinicians to inform patients.
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Introduction: Patients with perihilar cholangiocarcinoma (PHC) have few treat-
ment options and a poor prognosis. Most staging models for patients with PHC
have been developed for the minority of patients with potentially resectable
disease and are not applicable to the vast majority of patients.
Aims & Methods: The aim of this study was to develop a prognostic score for all
PHC patients using variables available at presentation. All consecutive patients
with PHC (regardless of tumor stage and treatment) in two tertiary referral
centers between 2002 and 2014 were identified and included. Baseline patient
and tumor characteristics were collected from medical records. Cox proportional
hazards regression was used for multivariable analysis. Age, BMI, bilirubin, CA
19-9, and tumor size were modeled as continuous covariates.
Results: A total of 674 patients were included of whom 342 (50.8%) had unre-
sectable disease at presentation and 176 (26.2%) underwent exploratory lapar-
otomy. Multivariable analysis identified age (HR 1.41 (95% CI 1.23–1.63)), BMI
(HR 1.11 (95% CI 1.05–1.17), serum bilirubin level (HR 1.45 (95% CI 1.21–
1.71), CA 19.9 serum level (HR 1.22 (95% CI 1.07–1.38), tumor size (HR 1.33
(95% CI 1.14–1.56), WHO performance status 3–4 (HR 1.48 (95% CI 1.10–1.95),
suspected distant metastases on imaging (HR 1.69 (95% CI 1.29–2.20), unilateral
HA involvement: HR 1.28 (95% CI 1.05–1.57), and main/bilateral HA involve-
ment: (HR 1.61 (95% CI 1.21–2.14)) as independent prognostic parameters.
Based on these factors, a prognostic score was created to predict survival for
patients with PHC from the time of presentation. Discrimination using Kaplan-
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Meier curves, and calibration curves revealed good predictive abilities. The risk
scored identified patients with a 1-year survival probability ranging from 15–
73%.
Conclusion: We developed a prognostic score to predict overall survival for PHC
patients using eight independent poor prognostic factors available at presenta-
tion. This score may help to inform patients and guide individualized treatment
decision making.
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Introduction: Malignant biliary obstruction has a poor prognosis unless second-
ary to a resectable primary cancer. Recent data on PTC for the relief of malig-
nant obstruction in a palliative setting demonstrated a high early mortality. We
have therefore examined outcomes of ERCP in inoperable malignant
obstruction.
Aims & Methods: The Hospital Episode Statistics (HES) database contains diag-
nostic and procedural data for all hospital attendances in England. HES is linked
to the Office for National Statistics (ONS) to provide mortality data. All subjects
from April 2001 to April 2015 in England with an ICD10 code for cancer 2 years
prior to ERCP or in the following 6 months were examined. Subjects undergoing
a curative surgical procedure were excluded. Associations between demographics,
co-morbidities, unit ERCP volume and mortality were examined by logistic
regression.
Results: 49055 subjects were included in the study of whom 48.7% were male,
median age 74.5 years (range 19–104). Pancreatic cancer was the most common
aetiology (63.5%) followed by liver and intrahepatic bile duct malignancy
(19.4%). Mortality was 4.16%, 10.9% and 19.6% for 7 day, in hospital and 30
day respectively. In multivariate analysis male gender (OR 1.14, (95% CI 1.08–
1.20) p5 0.001); increasing by age quintile 64–71 (1.34, (1.23–1.47) p5 0.001),
72–77 (1.57, (1.44–1.72) p5 0.001), 78–83 (1.83, (1.68–2.00) p5 0.001), 483
(2.78, (2.55–3.03), p5 0.001); most deprived quintile (1.22, (1.12–1.33),
p5 0.001); increasing co-morbidity score 1 to 5 (1.09, (1.02–1.16), p¼ 0.012), 6
to 10 (1.23, (1.12–1.35), p5 0.001) 11 to 15 (1.49, (1.33–1.66), p5 0.001), 16 to
20 (1.97, (1.70–2.28), p5 0.001), 420 (2.79 (2.39–3.25), p5 0.001); advancing
year of ERCP 2013/14 (0.78, (0.68–0.90), p¼ 0.001), 2014/15 (0.85, (0.74–0.98)
p¼ 0.028); and previous renal failure (1.92, (1.77–2.09), p5 0.001) were asso-
ciated with increasing 30 day mortality. Asian ethnicity (0.82, (0.67–0.99),
p¼ 0.036), Cancer of extrahepatic and unspecified parts of biliary tree (0.60,
(0.55–0.65), p5 0.001) and upper tertile of unit ERCP activity (4230) per
annum (0.86, (0.80–0.93), p5 0.001) were negatively associated with 30 day
mortality.
Conclusion: Short-term mortality in subjects with malignant biliary obstruction
following ERCP was high. A better prognosis was observed in; high-volume
ERCP units, Asian ethnicity and extrahepatic primary cancers. Male gender,
advancing age, increasing co-morbidity score, greater deprivation and previous
renal failure predicted death at 30 days.
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Introduction: Non-alcoholic fatty liver disease (NAFLD) is a common chronic
liver disease and in particular a health threat in obese children. Single nucleotide
polymorphisms in genes encoding PNPLA3 (rs738409) and TM6SF2
(rs58542926) contribute to the development of NAFLD. It is however unknown
whether liver pathology and cardiometabolic disturbances coincide in carriers
and non-carriers of these risk alleles in an at-risk obese pediatric population.
Therefore, we assessed cardiometabolic derangements, genetic predisposition
for NAFLD and liver transaminase levels in children with overweight and
obesity.
Aims & Methods: One hundred and seventy-four children (49% boys) from the
Centre for Overweight Adolescent and Children’s Healthcare (COACH) at the
Maastricht University Medical Centre were genotyped for PNPLA3 I148M and
TM6SF2 E167K. Anthropometric, cardiometabolic risk and liver-related para-
meters were determined.
Results: Anthropometric parameters did not differ significantly between carriers
and non-carriers of the risk alleles. ALT and AST were significantly higher in
PNPLA3 G allele carriers as compared to the C allele carriers (ALT; CC 21, 00
(17, 00;28, 00); CG 26, 50 (18, 00;34, 50); GG 29, 00 (23, 00;51, 00)(p¼ 0.004) and
AST; CC 24, 00 (19, 00;30, 00); CG 27, 50 (21, 00;40, 00); GG 30, 00 (26, 00;36,
00)(p¼ 0.004)). The odds ratio for having ALT levels above the cut-off values
increased for every PNPLA3 G allele, with an OR of 2, 51 (1, 22;5, 18; p¼ 0, 013)
for the PNPLA3 CG genotype and 5, 54 (1, 53;20, 02; p¼ 0, 009) for the GG
genotype, compared to the CC genotype. Carriers of the PNPLA3 risk allele did
not show a deteriorated metabolic profile compared to non-carriers.
The TM6SF2 T allele carriers also showed a tendency towards increased transa-
minase levels, but a significantly healthier cardiometabolic profile, i.e. lower total
cholesterol (p¼ 0.024), LDL cholesterol (p¼ 0.015) and triglyceride concentra-
tions (p¼ 0.003) and a higher central retinal artery equivalent (p¼ 0.020) com-
pared to the major allele carriers. Carrying the TM6SF2 T allele in addition to
carrying the PNPLA3 ‘risk’ allele, did not significantly increase the odds ratios
for increased ALT concentrations. The prevalence of the metabolic syndrome did
not differ between the different PNPLA3 genotype carriers nor between the
TM6SF2 genotype carriers.
Conclusion: Despite significantly higher liver transaminase levels and a positive
correlation between ALT levels and triglyceride and fasting insulin concentra-
tions in PNPLA3 G allele carriers, these children did not have a more deterio-
rated cardiometabolic profile compared to non-carriers. The metabolic syndrome
was not more prevalent in risk allele carriers. These results suggest that hepatic
aberrations and metabolic disturbances apparently do not develop concordantly
in this specific population. Furthermore, these children with a high liver health
risk may not be identified by measuring cardiometabolic parameters.
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Introduction: Pediatric chronic liver diseases are becoming a public health issue.
Ultrasound based elastographic techniques have emerged as non-invasive meth-
ods of pediatric liver fibrosis assessment. The most recent are two dimensional
shear-wave elastographic (2D SWE) techniques. While they are proved to be
highly reproducible in children, there is still no consensus regarding the
number of measurements to be performed for a high-quality evaluation.
Aims & Methods: We aimed to investigate the number of liver stiffness measure-
ments (LSM) needed for a high-quality evaluation using a 2D SWE technique.
We conducted a prospective study which included 73 children (age range: 3–17
years, mean age 11.73 3.55 years, 37% girls, mean body mass index (BMI)
25.12 7.38 kg/m2). We used the 2D-SWE.GE (Logiq E9, GE Healthcare,
Chalfont St Giles- UK), with a C1-6-D probe. One examiner performed 10
LSM for each child. We randomly extracted 1 LSM, 2 LSM, 3 LSM and 5
LSM from all 10 and calculated their respective medians. We employed the
Friedman test to compare the medians of 1, 2, 3, 5 and 10 LSMs. We used the
interclass correlation coefficient (ICC) to assess the agreement between the med-
ians of 1, 2, 3, 5 and 10 LSMs.
Results: Medians calculated from 1, 2, 3, 5 and 10 LSMs were similar
(4.21 1.05 kPa vs 4.22 0.91 kPa, 4.25 1.03 vs 4.2 0.99 kPa vs
4.19 0.99 kPa, p¼ 0.94). Furthermore, the agreement between medians calcu-
lated from 1, 2, 3, 5 and 10 LSMs was excellent (ICC¼ 0.960, 95% confidence
interval: 0.944–0.974).
Conclusion: We suggest obtaining 5 LSM for a high-quality evaluation using this
2D SWE technique.
Disclosure of Interest: S.A. Popescu: I hereby confirm that I have received finan-
cial support (congress travel grants, speaker fee) from: Philips, General Electric,
Abbvie, AstraZeneca, Zentiva
All other authors have declared no conflicts of interest.
I. Sporea: I hereby confirm that I have received financial support (congress travel
grant or speaker fee) from Philips, Siemens, General Electric, Abbvie, Zentiva,
Bristol Meyers Squibb
TUESDAY, OCTOBER 31, 2017 09:00-17:00
PANCREAS II - HALL 7____________________
P0752 PERCUTANEOUS EMBOLIZATION OF VISCERAL ARTERY
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Introduction: Visceral artery pseudo-aneurysms are rare, but potentially fatal if
rupture. Pseudoaneurysm usually occurs most frequently after pancreatitis.
Angioembolization with conventional trans-catheter approach is the standard
treatment. Direct percutaneous embolization has been commonly used for treat-
ment of peripheral artery pseudoaneurysm when trans-catheter approach is not
feasible. However, very limited data is available regarding its safety and efficacy
in visceral artery pseudoaneurysm.
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Aims & Methods: We aimed to assess the technical feasibility, safety and effec-
tiveness of direct percutaneous embolization as an alternative treatment option
for visceral pseudo aneurysms. We retrospectively evaluated the data of
patients who underwent percutaneous embolization at our institution from Feb
2007 to March 2017. All procedures were performed under ultrasound (US)
guidance under local anaesthesia. Technical feasibility, safety and efficacy of
percutaneous embolization were analysed. At 30 days follow up US with color
Doppler/dual phase computed tomography was done to see for recurrence of
pseudoaneurysm.
Results: 23 patients(18-male) with mean age of 34.47 21.28 (7–72) years, under-
went direct percutaneous embolization for visceral pseudoaneurysm. Most
common aetiology for pseudoaneurysm was pancreatitis (16) followed by
trauma (3), paracentesis (3) and surgery (1). The site of pseudoaneurysm was-
splenic artery (13), left gastric artery (3), hepatic artery (3), inferior epigastric
artery (3) and gastroduodenal artery (1). Mean size of pseudoaneurysm was
1.8 0.6 (1–3.5) cm. Reasons for choosing percutaneous approach over trans-
catheter embolization included- technical difficulties in 11 patients, excess collat-
erals obstructing view of feeding artery in 5 patients, and recurrence after pre-
vious embolization in 6 patients. Agents used for embolization- glue with lipiodol
(21), coil (1) and coil with glue (1). Mean procedural time was 11.3 2.11 (8–16)
minutes and fluoroscopy exposure time was 2.4 1.34 (1–6) minutes.
Percutaneous embolization was successfully performed in all patients (technical
success-100%). Mild adverse events included - local site pain in 19 (80%)
patients. Moderate adverse event included - splenic infarct in 5 patients, all of
which responded to conservative management. There were no major adverse
events and no occurrence of distant embolization. At median follow up of 910
days (30–3186) there was no recurrence of pseudoaneurysm (clinical success-
100%).
Conclusion: Percutaneous embolization is safe and effective for treatment of
visceral artery pseudoaneurysm. Percutaneous technique may be considered as
an alternative to trans-catheter embolization in cases of challenging anatomy,
multiple collaterals and recurrence after previous embolization precluding trans-
catheter advancement.
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Introduction: Chronic (CP) and autoimmune pancreatitis (AIP) are characterized
by different inflammatory processes. Whether CP is a prerequisite for autoim-
munity is still unclear. AIP is considered mostly a T-cell mediated disease; how-
ever, in induction of chronic pancreatitis macrophages play a pivotal role. Cyclin
dependent kinase (cdk) inhibitors are critical regulators in inflammatory disease
as they can influence proliferation, activation and differentiation of inflamma-
tory cells, and apoptosis. In particular, p21 has been described as a mediator of
inflammation and various autoimmune diseases by regulating T-cell activation
and promoting macrophage development. We therefore examined the role of
p21-mediated inflammation in AIP.
Aims & Methods: Human pancreas samples from CP and AIP patients were
evaluated for p21 expression. To investigate the effects of p21 in pancreatitis,
we intercrossed lymphotoxin overexpressing mice (Tg(Ela1-LTa, b)) - a model to
study CP and AIP – with p21 deficient (p21-/-) mice. Infiltrating cells were
visualized by immunohistochemistry, supported by gene expression analysis in
an early and a progressive phase. Circulating autoantibodies and the presence of
tertiary lymphoid organs (TLOs) were analysed to assess autoimmunity.
Results: p21 was upregulated in human CP patients but remained unchanged in
AIP patients. p21 deficiency in LT mice (LTp21-/-) prevented early pancreatic
injury. LTp21-/- mice had normal serum amylase, reduced inflammatory gene
expression and cell influx. In acinar cells diminished proliferation and abrogated
activation of non-canonical NF-kB pathway was observed. In contrast, 12
months old LT mice with and without p21 had similar inflammatory gene expres-
sion and T & B cell infiltration. Interestingly, LT and LTp21-/- mice had com-
parable tertiary lymphoid organs (TLOs), autoantibodies and elevated IgG
levels. However, acinar cell proliferation, acinar-to-ductal metaplasia and
acinar non-canonical NF-kB pathway activation remained impaired in
LTp21-/- pancreata.
Conclusion: Our findings indicate that p21 is crucial for pancreatitis in LT-driven
pancreatic injury. p21 is involved in early acinar secretion of inflammatory med-
iators that attract innate immune cells. However, p21 is not essential for humoral
immune response, accountable for autoimmunity and lack of p21 does not rescue
AIP development. Remarkably, p21 interferes with acinar NF-B signaling and
renders acinar cells less susceptible to proliferation and transdifferentiation. We
therefore suggest that chronic and autoimmune pancreatitis follow different
inflammatory processes.
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2Medizin 3, Universitätskliniken Erlangen, Erlangen/Germany
3Institut Für Molekulare Medizin, Universitätsmedizin Mainz, Mainz/Germany
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Introduction: Various forms of pancreatitis (e.g. severe acute pancreatitis, auto-
immune pancreatitis type 2) are characterized by an infiltration of neutrophil
granulocytes. Yet, despite sharing the feature of granulocytic infiltration, these
diseases take opposing natural courses of disease. A novel function of granulo-
cytes, the formation of aggregated neutrophil extracellular traps (aggNETs), has
been described and called for a reevaluation of the specific role of neutrophils in
pancreatitis. We were interested in the specific function of granulocytes in various
models of pancreatic inflammation.
Aims & Methods: Experimental models of pancreatic inflammation were
employed including caerulein-induced pancreatitis and a novel model of IL-
17A-induced pancreatitis. The outcome of disease was characterized by immu-
nohistochemistry, RNA expression and flow cytometric analyses.
Results: Transgenic systemic delivery of IL-17A alone can induce granulocytosis
and neutrophil infiltration to the pancreas. Interestingly, neutrophils do not
remain in the interstitium, yet enter the pancreatic ducts and form aggregates
in the ductal lumen. Our experimental models further indicate that peptidyl
arginine deiminase 4 (PAD4) is critical for intraductal aggregate formation and
that PAD4-deficiency abrogates disease progression. Mechanistically, we identify
the pancreatic juice as a strong instigator of neutrophil chromatin extrusion.
Characteristic single components of pancreatic juice, such as bicarbonate ions
and calcium carbonate crystals, induce aggregated NET formation.
Conclusion: Granulocytes aim to contain an inflammatory focus and enter pan-
creatic ducts with potentially detrimental consequences to dependent areas of the
organ.
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Z. Rakonczay4, P. Hegyi5
1First Department Of Medicine, University of Szeged, Szeged/Hungary
2Department Of Pathology, University of Szeged, Szeged/Hungary
3Department Of Medical Biochemistry, Semmelweis University, Budapest/
Hungary
4Department Of Pathophysiology, University of Szeged, Szeged/Hungary
5Institute For Translational Medicine/1st Department Of Medicine, University of
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Introduction: Mitochondrial dysfunction is a hallmark of several disease patho-
genesis including acute pancreatitis (AP). Our results suggest that mitochondrial
damage is crucial in bile acid induced inhibition of pancreatic ductal HCO3

secretion, however the details of mitochondrial function and dysfunction in pan-
creatic ductal epithelial cells (PDEC) is not known yet.
Aims & Methods: The aim of our study was to characterize the mitochondrial
distribution and function in PDECs under physiological and pathophysiological
conditions. Guinea pig and Cyclophilin D WT and knock out (KO) mouse
pancreatic ducts were used. Mitochondrial distribution was studied by electron
microscopy (EM). Mitochondrial membrane potential ( m) was measured by
confocal microscopy and pancreatic ductal HCO3
 secretion by
microfluorometry.
Results: EM measurements revealed that the mitochondrial density is signifi-
cantly higher on the apical side of the guinea pig PDEC compared to the
middle or the basal segment in HEPES solution. The apical mitochondrial den-
sity increased further in CO2/HCO3
 buffered solution, or during the adminis-
tration of 5 mM forskolin. That was also confirmed by the  m measurements as
we detected increased TMRM fluorescence on the apical side of the PDEC
during stimulation. The genetic KO of cyclophilin D significantly reduced the
loss of  m and protected pancreatic ductal HCO3
 secretion during the admin-
istration of 500 mM chenodeoxycholic acid.
Conclusion: Our results revealed that mitochondrial function has a central role in
the function of PDEC presumably by providing ATP for fluid and ion secretion.
On the other hand the opening of MPTP seems to be crucial in the bile acid
induced toxicity offering a potential therapeutic target in AP.
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Introduction: Infectious complications are main causes of mortality in severe
acute pancreatitis (AP) (1). Most infections in AP are intestinal origin (2). The
Nucleotide oligomerization domain 2 (NOD2) is a NOD-like receptor family
member that senses and responds to bacterial wall peptides (3). Guenther et al.
reported that p.R702W mutation was found to be associated with multipl organ
failure and mortality in patients with AP (4). We aimed to investigate whether
there is a correlation between NOD2 variants and AP severity in this study.
Aims & Methods: Group 1 (n¼ 27) was healthy. Group 2 (n¼ 36) and Group 3
(n¼ 32) were composed of mild and severe pancreatitis patients according to the
Atlanta 2012 classification (5). Four NOD2 variants and serum interleukin-6 (IL-
6), Tumor Necrosis Factor- (TNF-) and lipopolysaccharide-binding protein
(LBP) levels were studied.
Results: We detected p.R702W variant in 3 patients (3/32, 9.4%) in severe pan-
creatitis group, but this variant was not seen in the other two groups. 1007fs
variant was found in 3, 3 and 1 patient in mild (3/36, 8.3%) and severe pancrea-
titis (3/32, 9.4%) groups, and in healthy group (1/27, 3.7%), respectively. There
was no significant difference the frequencies of NOD2 variants between groups.
Serum IL-6, TNF- and LBP levels were significantly higher in the severe pan-
creatitis group than in the healthy group and mild pancreatitis group (all
p5 0.001). However, there was no significant difference between these cytokine
levels and NOD2 variants.
Conclusion: Our results suggest that there may be a relationship between the
presence of p.R702W variant and severe pancreatitis.
Disclosure of Interest: All authors have declared no conflicts of interest.
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2Gastroenterology, Complejo Universitario de Navarra, Pamplona/Spain
3Gastroenterology, Hospital son Llater, Palma de Mallorca/Spain
4Gastroenterology, Hospital Universitario Araba, Vitoria-Gasteiz/Spain
5Gastroenterology, Hospital Gregorio Maranon, Madrid/Spain
6Gastroenterology, Hospital Universitari i Politecnic la Fe, Valencia/Spain
7University Clinic Hospital Aragon Health Research Institute, Zaragoza/Spain
8Gastroenterology, Hospital Costa del Sol, Marbella/Spain
9Gastroenterology, Hospital Arnau de Vilanova, Valencia/Spain
10Surgery, Consorci Sanitari de Terrassa, Barcelona/Spain
11Gastroenterology, Hospital Universitario Miguel Servet, Zaragoza/Spain
12Gastroenterology, Hospital Clinico Universitario, Valencia/Spain
13Gastroenterology, Complexo Hospitalario Universitario de Vigo, Vigo/Spain
14Gastroenterology, Hospital Universitario Virgen Macarena, Seville/Spain
15Hospital Universitario Doctor Peset, Valencia/Spain
16Hospital Clinico Universitario, Valladolid/Spain
17Gastroenterology, Hospital Puerta del Mar, Cadiz/Spain
18(isabial-fundación Fisabio), Instituto de Investigación Sanitaria y Biomédica de
Alicante, Alicante/Spain
19Gastroenterology, Hospital General Universitario de Alicante - Gastroenterology,
Hospital General Universitario de Ali, Alicante/Spain
Contact E-mail Address: hannasternby@gmail.com
Introduction: Acute pancreatitis (AP) has a wide clinical spectrum, ranging from
mild cases to patients with high morbidity and a 3–5% mortality. Severity clas-
sifications used local and systemic complications to define different subgroups of
patients, but it is important to ascertain which of them are independent determi-
nants for the clinical course of the disease.
Aims & Methods: The aim of this study was to analyze which complications were
independently associated to worse outcomes (time to oral refeeding, invasive
treatment, ICU admission, hospital stay and mortality). Patients with AP were
prospectively enrolled at 23 centers, 60% had biliary etiology, 17% necrotizing
AP and 14% organ failure. Associations between possible determinants and out-
come variables were assessed through binary logistic regression analysis (with
adjustment for sex, etiology, Charlson comorbidity score (including age) and
recurrent AP in the model).
Results: In total 1665 patients were included. Independent determinants of
increased morbidity and mortality (vs category with lower risk) were: persistent
organ failure (POF) vs transient organ failure (TOF), all local complications
(especially combined peripancreatic and pancreatic necrosis) vs no local compli-
cations, infected necrosis vs sterile necrosis and multiple-organ POF vs single-
organ POF. We found no independent effect for late (47th day) vs early POF
nor POF associated to infected necrosis vs sterile POF.
Conclusion: Results of this study demonstrate that major determinants of severity
to be included in a future classification of severity of AP are 1) local complica-
tions, where necrosis should be further categorized into infected vs sterile and 2)
POF/TOF, with POF further categorized into multiple vs single POF.
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Introduction: Pancreatic pseudocyst (PC) and walled-off necrosis (WON) are
frequent complications of acute pancreatitis. Drainage procedure is required
when symptoms and complications such as pain, biliary obstruction, or infection
occur. With technological advances, endoscopic ultrasound (EUS)-guided drai-
nage replaced surgical treatment and has become the standard treatment. We
developed a novel fully-covered lumen apposing metal stent (LAMS) with anti-
reflux valve for the purpose of preventing complications such as stent migration
or reflux of bowel contents while improving the stent patency. The aim of this
study is to investigate the efficacy and the rate of complications of EUS guided
drainage using novel LAMS with anti-reflux valve for PC and WON.
Aims & Methods: We compared the treatment outcomes and the rate of compli-
cations of EUS-guided drainage using LAMS with EUS-guided drainage using
plastic stents. Ten patients underwent EUS-guided drainage using the novel
LAMS (LAMS group) and eighteen patients using conventional plastic stents
(plastic stent group) from December 2013 to October 2016. A novel LAMS used
in this study was designed to have bilateral flare ends, 4 anti-migration flaps (at
each side) and a pair of 2 anti-reflux valves (inside the lumen). Technical success
is defined as a successful placement of the stent without immediate complication
and clinical success is defined as a resolution of the PC/WON and disappearance
of the symptoms.
Results: Among 10 patients treated with LAMS, 4 patients had complicated PC
and 6 patients had WON. In plastic stent group, 15 patients had complicated PC
and 3 patients had WON. The median size of fluid collection before treatment
was 69.5mm (range, 48–214mm) in LAMS group and 92.0mm (56–253mm) in
plastic stent group. Median duration of stent placement was 47 days (1–355 days)
in LAMS group and 55 days (1–216 days) in plastic stent group. Treatment
outcomes of the LAMS group were not inferior despite the significantly higher
proportion of WON patients in the LAMS group compared to the plastic stent
group. There were no statistically significant differences in the technical success
rate (90% versus 94.4%; p¼ 0.595), clinical success rate (70% vs. 77.8%;
p¼ 0.491), resolution rate (76.8% vs. 80.7%; p¼ 0.705), complication rate
(40% vs. 50%; p¼ 0.456). In LAMS group, 3 patients experienced mild fever
and 1 patient showed peritonitis due to immediate stent migration. In plastic
stent group, mild fever was developed in 4 patients, small amount of pneumo-
peritoneum was in 1 patients, self-migration of stent (after resolution of fluid
collection) was in 2 patients. 3 patients showed serious adverse events - 1 patient
in each group experienced peritonitis due to immediate stent migration and 1
patient in plastic stent group had active bleeding. Procedure time (30.7 minutes
vs. 41.2 minutes; p¼ 0.106) and fasting period after treatment (3.1 days vs. 2.1
days; p¼ 0.344 were also not different between two groups.
Conclusion: For EUS-guided drainage, LAMS showed acceptable treatment out-
comes and the rate of complications even in relatively more severe cases of
pancreatic fluid collection. And no additional fasting period was required in
the LAMS group compared to the plastic stent group. Further well-designed
prospective studies are needed to validate these findings.
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Introduction: Endoscopic ultrasound-guided transmural drainage (EUS-TD) has
been shown to be a safe and effective minimally invasive treatment for walled-off
necrosis (WON). However, in some cases, simple drainage is not sufficient to
manage the symptoms of WON and step up approach such as direct endoscopic
necrosectomy (DEN) and surgical necrosectomy may be required. The factors
associated with the outcome of endoscopic treatment for WON remain unclear.
Aims & Methods: This study aimed to retrospectively correlate the clinical char-
acteristics of WON with the outcome of endoscopic transmural drainage. 49
patients (38 males; mean age 60.79 13.44) with symptomatic WON treated by
an attempted EUS-TD initially were enrolled in this study. The relationship
between the outcome of treatment and the clinical characteristics including mor-
phological feature and expansion of WON was evaluated.
Results: The mean size of WON was 126.63 46.79mm. EUS-TD was techni-
cally successful in 48/49 (97.9%) patients and 26 (54.2%) improved with EUS-
TD alone while step up approach was needed in 19 patients. DEN, percutaneous
drainage and surgery were done in 14, 2 and 3 patients, respectively. All patients
with step up approach had successful outcomes. Three patients died before step
up approach was performed, but death was not related with the procedure itself.
The patients who needed step up approach had multi-locular (p5 0.05) and large
size WON (p¼ 0.02) as compared to patients treated with EUS-TD alone. The
extent of WON correlated significantly (p¼ 0.001) with the type of treatment.
Gas bubbles sign within necrotic tissue on the abdominal CT imaging early after
EUS-TD indicated the necessity of necrosectomy during the treatment
(p5 0.01). Bleeding as adverse events was observed in 3 patients (6.2%). Two
patients improved with conservative therapy and 1 patient underwent transcath-
eter arterial embolization.
Conclusion: The step up approach is safe and effective for the treatment of WON.
Multi-locular, large size and extensive WON were important predictors for per-
forming a step up approach. Gas bubbles sign within necrotic tissue after EUS-
TD may help to perform necrocectomy.
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Introduction: Patients with a first episode of acute pancreatitis can develop recur-
rent or chronic pancreatitis (CP). However, little is known about the incidence or
risk factors for these events.
Aims & Methods: We performed a retrospective study of 489 patients with a first
episode of acute pancreatitis from September 2012 - September 2015. We col-
lected relevant information of disease course and follow up until June 2016. We
classified these patients according to etiology, explore the relevant characteristics
of recurrence episode and performed univariate and multivariate regression of
possible risk factors.
Results: During a median follow-up of 30.4 months, 411 cases were followed up
completely. The total recurrence rate was 27.5% (113/411), with a median recur-
rence interval of 6.5 (IQR 2.61–10.33) months. The recurrence rate and median
recurrence interval of biliary group, hyperlipidemic group and other etiology
group were 21.5% (57/265), 5.78 (IQR 2.52–9.92); 49.2% (30/61), 8.28 (IQR
5.35–16.30); 30.6% (26/85), 6.18 (IQR 2.60–9.07). To biliary AP, the recurrence
rate of patients who underwent cholecystectomy less than two weeks after AP
attack is lower than patients without cholecystectomy, and the difference was
statistically significant. Logistic regression suggested that hyperlipidemic pan-
creatitis (OR¼ 2.133; 95% CI, 1.117–4.075; P5 0.001), pancreatic necrosis
(OR¼ 2.52; 95% CI, 1.251–5.078; P¼ 0.01), smoking (OR¼ 2.918; 95% CI,
1.728–4.928; P¼ 0.01), complicated with diabetes (OR¼ 2.190; 95% CI, 1.282–
3.741; P¼ 0.04) were independent risk factors for recurrence.
Conclusion: Quitting smoking, properly treating diabetes, hypertriglyceridemia
and biliary disease, making close follow-up of patients complicated with pan-
creatic necrosis may reduce ARP attack.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Clinical data has indicated that severe acute pancreatitis is a serious
inflammatory disease with a systemic inflammatory response and multiple organ
dysfunction Acute renal injury caused by acute pancreatitis is a common com-
plication that is associated with a high rate of mortality. Although the pathogen-
esis of acute necrotizing is not completely clear, the activation of inflammatory
cytokines and coagulation are keys in the etiology.
Aims & Methods: We examined 155 patients with acute necrotizing pancreatitis.
According to the international classification in 98 patients we diagnosed the
moderate severe AP, and in 57 patients the severe AP. Disorders of kidney
function were in 48 patients. We determined the creatinine level, indicators of
hemostasis and inflammation
Results: Analysis of the relationship of inflammation and hemostasis in patients
with acute pancreatitis and renal dysfunction is accompanied by decreased of
activated partial thrombin time (F¼ 25.227, o5 0.00001), increased of thrombin
time (F¼ 19.428, o¼ 0.00004), fibrinogen concentration (F¼ 4.6046,
o¼ 0.03568), D-dimers level (F¼ 28.456, o5 0.00001), and level of soluble
fibrin-monomer complexes (F¼ 34.015, o5 0.00001), lack of activity of antith-
rombin III (F¼ 42.123, o5 0.00001), increased synthesis of C-reactive protein
(F¼ 15.591, p¼ 0.00020), excessive production of proinflammatory cytokines
IL-2 (F¼ 29.997, p5 0.00001), IL-6 (F¼ 21.076, p¼ 0.00002), and TNF-
(F¼ 25.643, p5 0.00001). In acute pancreatitis patients with renal dysfunction
was shown a direct correlation between severity of renal failure (SOFA score)
and concentrations of IL-6 (R¼ 0.416484, p¼ 0.000504), CRP (R¼ 0.510742,
p¼ 0.000012), D-dimers (R¼ 0.321619, p¼ 0.008456), soluble fibrin-monomer
complexes (R¼ 0.290750, p¼ 0.017868), and duration of thrombin time
(R¼ 0.296007, o¼ 0.015814).
Conclusion: The mechanism of the acute renal injury following acute necrotizing
pancreatitis is complicated. The inflammatory cascades and hypercoagulative
state are initiated this pathological process.
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Introduction: Acute Pancreatitis (AP) may be severe in up to 20% of patients with
substantial morbidity and mortality, which is related to a generalized inflamma-
tory response. In some individuals, this severe inflammatory response is down-
regulated; in others it escapes control. Our group has previously described a TH1
profile associated with poor prognosis in AP, and a TH2 profile associated with a
mild or moderate condition.
Aims & Methods: Our aim was the development of an index for an early assess-
ment of prognosis in AP. We analyzed 12 cytokines in 117 patients, upon
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admission to hospital. A receiver operating characteristic (ROC) analysis was
built at day 0 for the prediction of severity. Later, a multiple discriminant ana-
lysis was performed, using the Wilks lambda test, to identify the variables that
differ most between patients with mild AP and moderate/severe AP. A ratio
calculated using the most discriminant cytokines was studied in relation to sever-
ity and mortality.
Results: ROC curves showed that TH1 cytokines IL6, IFN- and TNF- can be
measured for the prediction of severe AP, while TH2 cytokines IL4, L13, GM-
CSF, for the prediction of a mild or moderate condition. A stepwise analysis
showed that IL13 and IFN- were the biomarkers which contributed most to the
discrimination between mild and moderate/severe AP (Wilks’ lambda¼ 0.855,
p5 0.0001; Wilks’ lambda¼ 0.747, p5 0.0001, respectively). We calculated the
IL13/IFN index. This ratio was significantly higher in patients with mild AP
when we compared between groups (p¼ 7.36 10–8). This difference was also
observed between severe AP and the rest of patients (p¼ 0.007). The ROC curve
was also modified, increasing the area under the curve (AUC), the sensibility and
the specificity, in relation to AP severity.
Conclusion: We describe an IL13/IFN ratio that could be of great interest in the
assessment of prognosis in AP. A high value of the IL13/IFN ratio at hospital
admission is associated with a good prognosis of AP.
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Introduction: According to the diagnostic criteria by Cotton et al.1), post-ERCP
acute pancreatitis is defined as the persistence of serum amylase levels three times
or higher than the upper limit of the standard for 18 6 h after ERCP with
persistent upper abdominal pain for 4 h or longer. However, the criterion of
three times or higher than the upper limit was mostly based on retrospective
studies, and has not been necessarily supported by imaging diagnosis. In this
study, using CT findings as the gold standard of ERCP-induced pancreatitis, we
investigated the cutoff serum amylase level that suggested ERCP-induced pan-
creatitis in a prospective multicenter study.
Aims & Methods: At five high-volume centers, 2078 patients examined by ERCP
between April 2015 and May 2016 were prospectively followed. CT was per-
formed in patients whose serum amylase level exceeded the institutional upper
limit on the day after ERCP (after 12–20 h) to investigate the presence or absence
of pancreatitis findings. Two expert radiological diagnosticians assessed the
images blinded and judged the presence or absence of pancreatitis based on
the Balthazar grade. Patients with a preexisting high amylase level, clinically
diagnosed pancreatitis, and had a difficult imaging evaluation due to the presence
of cancer before ERCP were excluded from analysis. Correlations of the serum
amylase level after 2 h, that on the following day, abdominal pain under 4 h, and
that persisting longer than 4 h with the presence or absence of pancreatitis were
investigated using ROC analysis and the chi-square test.
Results: Amylase levels increased on the following day in 402 (21.5%) of the 1868
patients included, and 340 patients examined by CT were included in the analysis.
ERCP-induced pancreatitis was diagnosed based on imaging in 204 patients
(10.9%). The cutoff amylase level for judging the presence or absence of pan-
creatitis on the following day was 2.75 times higher than the institutional upper
limit (sensitivity: 73.3%, specificity: 79.0%, positive likelihood ratio: 3.48, nega-
tive likelihood ratio: 0.34) with an AUC of 0.80. The cutoff level after 2 h was
2.73 times higher than the institutional upper limit (sensitivity: 45.6%, specificity:
79.7%, positive likelihood ratio: 2.24, negative likelihood ratio: 0.68) with an
AUC of 0.63. Abdominal pain under 4 h was noted in 36 of the 204 patients in
the pancreatitis group, and 12 of 136 patients in the non-pancreatitis group with
a sensitivity of 17.7%; specificity, 91.1%; positive likelihood ratio, 1.99; and
negative likelihood ratio, 0.90. Abdominal pain that persisted longer than 4 h
occurred in 75 patients in the pancreatitis group and 12 in the non-pancreatitis
group with a sensitivity of 36.7%; specificity, 91.1%; positive likelihood ratio,
4.12; and negative likelihood ratio, 0.69.
Conclusion: The appropriate cutoff serum amylase level for judging ERCP-
induced pancreatitis on the day following ERCP is 2.75 times higher than the
institutional upper limit. The diagnostic value of serum amylase levels 2 h after
ERCP may be low. Regarding abdominal pain persisting for longer than 4 h, the
specificity was high but the sensitivity was low. Therefore, setting a cutoff serum
amylase level on the day after ERCP is very useful to diagnose ERCP-induced
pancreatitis.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Recently, lumen apposing metal stent (LAMS) has been developed
and employed in abscess drainage. However, its use is limited by its cost [1] and
its safety rises concerns as apparently associated with more adverse events.[2] The
aim of this study was to investigate the efficacy and safety of LAMS in endo-
scopic ultrasound (EUS) -guided pancreatic wall-off necrosis (WON) drainage.
Aims & Methods: Patients All consecutive patients with necrotizing pancreatitis
with WON who underwent EUS-guided drainage using LAMS during the period
of 1st Jan 2012 and 30th Jun 2016 were retrospectively retrieved from the institu-
tion database. Necrotizing pancreatitis and WON were defined as according to
the revised 2012 Atlanta classification. Those encapsulated fluid collection out-
side the pancreas were excluded from this study. The following data were col-
lected: patient demographics, EUS and microbiologic features of the necrosis,
procedural characteristics and their outcomes. Procedures All procedures were
performed by 2 endosonographers. Once the WON was identified, a 19-gauge
needle was inserted with 0.035-inch guidewire to allow for insertion of the
AXIOS device, which was then advanced to create the fistula tract by using
the electrocautery tip. Once the delivery catheter was inside the WON, the
distal and proximal flange of the stent were deployed subsequently under EUS
and endoscopic guidance respectively. Outcome measures Primary outcome mea-
sures were: 1.technical success defined as stent deployment without any difficulty
nor reposition; 2.clinical success defined as symptom resolution with the abscess
size 2 cm on computed tomography (CT); Secondary measures are: 1. Stemt
revision due to its migration/dislodgment in case of unresolved abscess; 2.adverse
events; 3.WON recurrence Data analysis Continuous variables were expressed as
median and IQR. Categorical data were expressed as absolute numbers and
percentages.
Results: The clinical characteristics of the patients and their WONs are shown in
Table 1. In the cohort, the deployment of LAMS (AXIOS: 15 10mm, n¼ 38;
10 10mm, n¼ 8) was technically success in 45 (97.8%, 3 cases required 2nd
attempt for proper deployment) cases while one case required to switch over to
a fully-covered metal stent due to the lengthy insertion tract. 28(60.9%) cases
were manageed with necrosectomy (median 1, IQR 2) in which 15(32.6%) of
them had concurrent nasocystic drainage prior to each procedure. 43(93.5%)
patients were treated successfully while two refractory cases required superim-
posed insertion of a fully-covered tubular metal stent coaxially and one case
required to switch over to percutaneously drainage. 20(43.5%) cases reported
to have adverse events. Six patients experienced immediate bleeding during inser-
tion of LAMS in which two related to process of necrosectomy; among them, one
case required the superimposed insertion of a tubular fully covered metal stent
coaxially to control the bleeding while the other five had bleeding stopped spon-
taneously. Delayed bleeding was reported in 4 cases:three were managed by local
administration of adrenalin, one managed by arterial embolisation to the bleed-
ing site and one with uncontrolled bleeding due to disseminated intravascular
coagulopathy and then died of multiple organ failure. Ten cases were reported to
have stent migration during management in which two cases were dislodged
during necrosectomy while the others were found during follow-up.
Table 1: Clinical Characteristics of the cohort and its management outcome
measures
LAMS (n¼ 46)
Age, year 70(26)
Male sex 32(69.6)
Comorbidities
Diabetic mellitus1 6(13.0)
Cardiovascular disease2 19(43.2)
Chronic obstructive airway disease 3(6.5)
Malignancy on chemotherapy 3 8(19.6)
Cause of pancreatitis
Gallstones 40(87.0)
Miscellaneous4 2(4.5)
APACHE II score 10(7)
White cell count (x1.000/mL) 13(7.20)
C-reactive protein (mg/L) 150(129)
Total bilirubin (mg/dL) 0.7(0.57)
ALT (U/L) 45(41.5)
Wall-off necrosis (WON)
(continued)
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Table 1 Continued
LAMS (n¼ 46)
Diameter (cm) 9(4.5)
Location
Head 13(28.3)
Body/tail 31(67.4)
Whole 2(4.3)
Features
Poorly-defined wall 4(8.7)
Loculation 11(23.9)
Lumpy/mass content 18(39.1)
Organism
Gram positive 7(15.2)5
Gram negative 4(8.7)
Mixed 15(32.6)
Unknown 20(43.5)
Site of cyst enterostomy6
Stomach 36(78.3)
Duodenal bulb 10(21.7)
Necrosectomy
Patient (n, %) 28(60.9)
Number of Necrosectomy (n, IQR) 1(2)
Nasocystic drainage (n, %) 15(32.6)
Technical success 45(97.8)7
Stent revision 12(26.1)
Spontaneously migration 8
Dislodged during necrosectomy 2
Ineffective drainage 28
Adverse events 20(43.5)
Bleeding 9 10
Migration 10
Outcomes
Duration of hospital stay (days) 64(33)
Duration of stent insertion (week) 10(4.5)
Clinical success 43(93.5)10
Recurrence 3(6.5)
Data are either median (IQR) or no. (%) of patients, unless otherwise indicated.
1: coexisting dyslipidemia 2: coexisting congestive heart failure 3: myeloprolifera-
tive disease (n¼ 4)), colon (n¼ 4), lung (n¼ 1) 4:alcoholism, hyperclcemia, post
ERCP (n¼ 1); idiopathic (n¼ 3) 5: Enterococcus spp (n¼ 5), Methicillin-sensitive
Staphylococcus aureus(n¼ 2) 6: AXIOS 10 10mm: n¼ 6(transgastric);
n¼ 2(transduodenal) 7: mal-deployed stent: n¼ 4, all successfully placed in 2nd
attempt (among them, one changed into Wallflex stent 60 10mm) 8: diverted to
a tubular metal stent (n¼ 1); percutaneous drainage (n¼ 1) 9: immediate bleed-
ing: n¼ 6, among them, one case managed by a fully-covered tubular metal stent
placed co-axially within lumen of LAMS; early bleeding: within 48 hr, n¼ 1,
embolisation required;delayed bleeding: all spontaneously subsided 10: refractory
cases: managed by percutaneous drainage (n¼ 1), superimposed fully-covered
tubular metal stent co-axially (n¼ 2) NB: LAMS, lumen-apposing metal stent
Conclusion: Pancreatic WON can be effectively treated by EUS- guided LAMS
assisted drainage with high technical and clinical success rate. Bleeding and stent
migration are the two major adverse events during the management that can be
managed accordingly.
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Introduction: Post-endoscopic retrograde cholangiopancreatography (ERCP)
pancreatitis (PEP) is a common and serious adverse event following ERCP,
with a reported incidence of 9.7% in unselected patients [1]. Given huge eco-
nomic and clinical burden, effective approaches for post-ERCP pancreatitis pro-
phylaxis remains a major priority for research. Nonsteroidal anti-inflammatory
drugs (NSAIDs) have also been shown the potential efficacy in prophylaxis PEP
across high-risk patients, especially for diclofenac or indomethacin [3–5].
Recently, a prospective, double-blind, controlled trial conducted by Levenick
[6] and colleagues in the USA showed that the reduction in PEP using indo-
methacin was not as significant as previously reported. In fact, even more
cases of pancreatitis occurred in indomethacin group compared with placebo
group. Subsequently, a high-quality meta-analysis also concluded that there is
no prophylaxis for the prevention of PEP among average-risk patients[7]. These
findings raised the question that whether administration of rectal indomethacin
should be recommended in average-risk patients.
Aims & Methods: We aimed to determine the beneficial effect of rectal indo-
methacin in the prevention of post-ERCP pancreatitis in average-risk of patients.
We systematically searched PubMed, EMBASE, Web of science and Cochrane
library before October 2016. Studies that evaluated rectal administration of
indomethacin in the prevention of post-ERCP pancreatitis were included in the
analysis. We adopted a random-effects model to calculate overall relative risk
(RR) and 95% confidence interval (CI).
Results:We identified ten randomized clinical trials from initial search and finally
included in the meta-analysis. Administration of rectal indomethacin signifi-
cantly reduced the incidence of PEP in combined population (RR, 0.63; 95%
CI, 0.50–0.77). There was no significant heterogeneity across included studies
(I2¼ 14.2%, P¼ 0.31). In subgroup analysis, rectal indomethacin was effective
in both high-risk (RR, 0.49; 95%CI, 0.35–0.71) and average-risk (RR, 0.69;
95%CI, 0.55–0.86) patients and reduced the risk of mild and moderate to
severe pancreatitis. The overall results remained unchanged and robust in sensi-
tivity analyses. There was no evidence of significant publication bias among this
meta-analysis.
Conclusion: Rectal administration of indomethacin is an effective approach to
prevent the incidence of post-ERCP pancreatitis both in high-risk and average-
risk population undergoing ERCP. However, more high-quality randomized
controlled trials are needed to further investigate the optimal timing for admin-
istration of indomethacin.
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Introduction: Acute pancreatitis (AP) is one of the most common gastrointestinal
diseases requiring hospitalization with an annual incidence of 13–50 cases per
100,000 persons. It is a potentially fatal disease with an overall mortality ranging
from 2 to 8%. Both epidemiology and outcomes are variable according to the
different countries. Furthermore, few studies have considered the impact of hos-
pital units on AP outcomes.
Aims & Methods: To evaluate both the trend and outcomes of acute pancreatitis
according to the admitting hospital units: Surgery, Internal/General Medicine,
Gastrointestinal (GI) Unit, Intensive Care Unit (ICU). This is a retrospective
A428 United European Gastroenterology Journal 5(5S)
cohort study based on the anonymous computerized database of hospital dis-
charges in the Veneto Region (North-East of Italy). The principal diagnosis of
AP according to the International Classification of Diseases 9th revision, Clinical
Modification (ICD 9-CM, code 577.0) of the hospital discharges was selected.
The period from January 2001 to December 2015 was analysed. Veneto popula-
tion was considered as the reference population (in the period, it varied from
4,529,823 to 4,927,527 inhabitants, with 51% females). Hospitalization, Length
of stay (LOS), in-hospital mortality, need for surgery (according to the DRG
191–194, 199–201 which identified bilio-pancreatic surgery) were reported
according to the admitting hospital Units. Statistics: Chi squared for trend and
Odds Ratio (OR) were applied.
Results: During the analysed period, 23,389 overall hospitalizations for AP,
annual hospitalizations of 32 patients/100,000 inhabitants and in-hospital mor-
tality of 3.2% were observed. Characteristics of the patients were: mean age: 62.2
þ/19.3ys, 54% Males (M); Female (F) mean age: 65ys þ/19.3ys, male mean
age: 59.4þ/19.3ys (p5 0.05). Hospitalizations was higher in males (M: 35.4, F:
28.4, OR 1.24 (95% CI: 1.20–1.27, p5 0.05) and it increased in a stepwise
progression from youngest to oldest patients (from 4.4 to 151.2 p5 0.05); a
similar trend was observed when considering in-hospital mortality (from 0.5 to
10.3%, p5 0.05). From 2001 to 2015, hospitalization (32.4 to 29.5, p¼ 0.04), in-
hospital mortality (1.41 to 0.79, p5 0.05) and need for surgery (NFS: 5.6% to
3.0%, p5 0.05) trends decreased. Conversely, admission trends increased during
the analysed period both in General Medicine (from 34 to 63, p5 0.05) and
Gastrointestinal (GI) units (from 14 to 29, p5 0.05). The Overall in-hospital
mortality was the lowest in GI Units with a NFS of 3.6% (see Table). In com-
parison to General Medicine Units, GI units were associated with a low in-
hospital mortality (OR: 0.37, CI 95%: 0.28–0.49, p5 0.05) and an high NFS
(OR: 2.88, CI 95%: 2.18–3.81, p5 0.05).
Admitting Hospital Unit
(2001–2015)
Number of
cases (%)
Lengths of
stay (days)
In-Hosp.
Mortality NFS (%)
General Medicine (Non GI) 6, 960 (30%) 13.5 10.7 4.3% 88 (1.3%)
Gastrointestinal (GI) Units 3, 797 (16%) 12 11.2 1.7% 135 (3.6%)
Surgical Units 12, 112(52%) 13þ /13.6 2.7% 443 (3.7%)
Intensive Care Unit 520 (2%) 17.2 21.8 12.9% 42 (8.1%)
Conclusion: During the last 15 years in the Veneto Region, hospitalization rate,
in-hospital mortality rate and need for surgery of acute pancreatitis significantly
decreased. Conversely, admissions in both General Medicine and GI units
increased. Management of AP in GI units seems to be related with a best out-
come: lower in-hospital mortality and probably, more eligible patients for surgi-
cal treatment.
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Introduction: Recurrent acute pancreatitis (RAP) and acute on chronic pancrea-
titis (ACP) are likely to have less severe disease and local complications in com-
parison to acute pancreatitis (AP) possibly due to underlying chronic changes or
fibrosis. However there is lack of literature regarding comparative studies
between the natural course of disease and outcome of patients of AP vis-à-vis
that of RAP and ACP.
Aims & Methods: This study was conducted to compare the clinical course and
outcomes of patients with AP, RAP and ACP. 248 consecutive patients with
diagnosis of AP, RAP or ACP were included during study period. Outcome
measures studied were severity, organ failure (OF), persistent organ failure
(POF), need for ICU stay, ventilator and dialysis, hospital stay, need for percu-
taneous catheter drain (PCD), surgery and mortality.
Results: Out of 248,158 (64%) patients had AP, 45 (18%) patients had RAP and
45 (18%) patients had ACP. 86 (54%) of AP, 4 (9%) of ACP and none of
patients in RAP group had severe AP according to revised Atlanta classification
(p5 0.001). On comparison of OF, 101 (63%; of whom 54% had POF) of AP, 6
(13%; of whom 9% had POF) of ACP and none of RAP patients developed OF
(p5 0.001). PCD and surgery requirement were seen in 89 (56%) & 9 (6%) of
AP, 5 (11%) &4 (9%) of ACP and none of RAP patients respectively (p5 0.001
& p¼ 0.44). Length of hospital stay (days) was significantly higher in AP and
ACP as compared to RAP (18.80 14.5.8.82 11.2.3.36 4.4, P5 0.001)
whereas ICU requirement was seen in significantly more patients in AP group
(59; 37%) than in ACP (5; 11%) and RAP (0; 0%) (p5 0.001). 41 (26%) of AP, 2
(4.4%) of ACP, but none of patient with RAP needed ventilatory support
(p5 0.001), while 13 (8%) of AP patients, 1 (2.2%) of ACP and none with
RAP required dialysis (p5 0.05). Mortality in AP, ACP and RAP was 29
(18%), 2 (4.4%), 0 (0%) respectively (p5 0.05).
Conclusion: Patients with first attack of AP had more severe disease course as
compared to those with ACP, while those with RAP had the least severe course.
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Introduction: In literature the frequency of acute pancreatitis (AP) in patients
with IPMNs varies between 12 and 65%, but most of studies are from surgical
series and often pancreatitis occurred after surgery was included. Furthermore,
most of the studies includes in the diction of "symptomatic IPMNs" the presence
of less severe disorders, such dyspeptic symptoms, making series unclear.
Aims & Methods: The aim of this study was to investigate the correlation between
the presence of IPMN and acute pancreatitis to determine the frequency, evaluate
the different characteristics from asymptomatic IPMNs patients, evaluate the
possible differences between type and localization of IPMNs in occurrence of
acute pancreatitis and his disease severity. A retrospective analysis was per-
formed on all observed patients with IPMN-MD, IPMN-BD and mixed type
at Gastroenterology Unit in the period between January 2009 and March 2016.
In the study patients with an instrumental or histological diagnosis of IPMNs
were included.
Results:We studied 346 patients (164 males and 182 females, mean age at the first
report 61.6 12.2 years). At the time of radiological diagnosis, 45% were asymp-
tomatic, 51% had had symptoms, while 4% of the data were missing: the fre-
quency of AP (excluding biliary etiology) of all 346 patients with IPMN was
26%. AP was edematous in 85% of patients and necrotic in 15%. We found
increased frequency in patients with PA with IPMN of the main pancreatic duct
(MD and mixed), and unifocal type. The localization to the body seems to be
more correlated with the presence of AP. The number of cysts (for IPMN-BD
and mixed type) was significantly lower in patients who have had AP.
Conclusion: Our medical extraction series confirms that the PA is an event
that occurs in 26% of patients with IPMNs, with a prevalence of the male
sex, it is associated with a IPMN central and mixed type, predominantly
localized to the body. The pancreatitis is not associated with malignancy in
resected patients
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Severe acute pancreatitis (SAP) has a considerable mortality and
morbidity rate. Although many indices have been developed to classify the sever-
ity of acute pancreatitis (AP), there is no ideal method for predicting SAP. The
ratio of apolipoprotein B to A-I (apoB/A-I) is associated with metabolic syn-
drome and inflammatory status.
Aims &Methods: This study aimed to investigate the association between severity
of AP and serum apoB/A-I ratio. Patients with AP were prospectively enrolled at
Yonsei University Wonju College of Medicine from March 2015 to August 2016.
The severity of acute pancreatitis was assessed according to the revised Atlanta
classification criteria (Atlanta 2012).
Results: Of 191 patients with AP, 134 (70.2%) were classified as mild AP, 42
(22%) as moderately severe AP, and 15 (7.9%) as SAP. The apoB/A-I ratio was
highest in patients with SAP compared with those with mild and moderately
severe AP (P¼ 0.001). The apoB/A-I ratio positively correlated with Atlanta
classification, computed tomography severity index, and Bedside index for sever-
ity of AP. The apoB/A-I ratio showed the highest ability to predict SAP in
patients with AP compared with apolipoprotein B or apolipoprotein A-I alone.
Conclusion: Serum apoB/A-I ratio appears to have value in predicting SAP in
patients with AP.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The Scandinavian-Baltic-Pancreatic-Club database collects data
from patients with chronic pancreatitis (CP) in Nordic countries. Grading of
structural changes is important in the description of a CP cohort.
Aims & Methods: We aimed to characterise structural changes of the pancreas in
patients with CP. Subjects with definitive or probable CP according to the M-
ANNHEIM diagnostic-criteria were included. Structural changes were graded
according to the M-ANNHEIM-classification. A subgroup was also scored by
the modified Cambridge score. Clinical data on disease-duration, nutrition, exo-
crine function, pain, alcohol/smoking habits and frequencies of malnutrition and
diabetes were collected. A grouping of the M-ANNHEIM score (A: Normal¼ 0,
B: Minimal change¼ 1þ 2 and C: Moderate/marked¼ 3þ 4) was performed for
correaltion to the clinical data.
Results: The database contains 932 patients (623 men). The M-ANNHEIM-score
was present from 446 subjects and both imaging scores from 93 subjects.
According to M-ANNHEIM subjects were graded as 0: Normal (8.1%), 1:
Equivocal (22.9%), 2: Mild (12.1%), 3: Moderate (17.9%) and 4: Marked
(39.0%). Correlation of the imaging scores: The imaging-scores demonstrated
acceptable correlation (¼ 0.75, p5 0.001) and good agreement (ICC¼ 0.71
(0.59, 0.8), p5 0.001). Agreement was best for groups with marked changes.
The clinical parameters divided by M-ANNHEIM groups are presented in the
table:
Clinical parameter A: Normal
B: Minimal
change C: Marked
Disease duration (Years) 3.6(5.2) 4.6(5.8) 5.0(6.4)
Pain (VAS 0–100) 38.3 (39.2) 39.4 (36.5) 35.5 (35.3)
Nutrition (BMI kg/m2) 24.2(5.0) 24.7(5.5) 23.7(4.7)
Malnutrition (%) 4 10 11
Faecal Elastase (mg/g) 35[17–168] 69[15–304] 45[15–142]
Diabetes (%) 37 43 39
Smoke (Pack years) 0[0–20] 0[0–25] 17[0–37]*
Alcohol (Lifetime
years4 5units/day)
0[0–2.5] 0[0–18] 0[0–18]
*p5 0.05 (Kruskal-Wallis). No other differences reached significance. Values:
mean (SD) or median [IQ-range]. Malnutrition: BMI5 18.5.
Conclusion: Subjects with marked structural changes had the highest lifetime
smoke-doses. There was poor correlation of structural changes to the clinical
features. The two imaging scores demonstrated acceptable correlation and agree-
ment. Poor agreement in normal/minimal-change groups may reduce the value of
the scores where they are most needed. The results are presented on behalf of the
SBPC study group
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Introduction: In patients with chronic pancreatitis (CP) malabsorption of vita-
mins D and K, alcoholism, smoking and inflammatory status contribute to low
bone mineral density (BMD). A recent meta-analysis estimated the prevalence of
osteoporosis (25%) and osteopenia (40%) in CP and highlighted limitations of
the reviewed studies.
Aims & Methods: To evaluate the prevalence of osteoporosis and osteopenia in
patients with CP and to investigate the correlation between BMD and CP fea-
tures, and vitamin D and PEI. This is a multicentre cross-sectional study (P-
BONE, a Pancreas 2000 project) on prevalent CP patients. The Diagnosis and
severity of the disease was defined according to the M-ANNHEIM classification.
Clinical information and biochemical variables were recorded; PEI was assessed
by fecal elastase. Standardized Osteodensitometry was performed by dual energy
x-ray absorptiometry (DEXA). Categorical variables were analysed by means of
Fisher’s exact test, and continuous variables by t-test. A logistic regression ana-
lysis was performed to identify risk factors for osteoporosis or osteopenia. The
relationship between continuous variables was assessed with Pearson correlation
coefficient.
Results: 211 consecutive CP patients were enrolled at 6 Centres (67% M; mean
age 60 13 years). Osteopenia was diagnosed in 42% and osteoporosis in 22% of
cases. Aetiology was alcoholic in 43%, and 18% had severe CP. 56% of patients
had PEI. The mean value of vitamin D was 20 ng/ml and 56% of cases had
vitamin D insufficiency. There was no correlation between vitamin D levels, or
elastase levels and t-score at either spine or femur. Alcoholic aetiology was
associated with higher risk of having low levels of fecal elastase (p 0.02) and
with lower level of vitamin D (p 0.001) but not with osteopenia or osteoporosis.
Female sex and older age seems to be associated with a higher risk of developing
osteoporosis (OR 4.5 95%CI 2–9.8 p 0.001; OR 1.09 95% CI 1–1.3 p 0.01) while
a higher BMI is associated with a reduced risk of its occurrence (OR 0.8 95% CI
0.77–0.94 p 0.001).
Conclusion: The present data confirm a high rate of osteopathy in CP patients.
However, there was apparently no correlation between BMD, pancreatic exo-
crine function, severity of the disease or vitamin D levels. Other factors, such as
vitamin K might deserve investigation for their possible relationship with bone
mineral density in CP patients.
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Introduction: SPINK1 is a gene coding for the inhibitor of the cationic trypsino-
gen. Heterozygous mutations prevalence is estimated at 2%. They are recognized
as a risk factor for chronic pancreatitis. However few data are available regarding
the natural history and the risk of complications in these patients.
Aims & Methods: A prospective monocentric study was carried out from 2000 to
2016 to describe the natural history of SPINK1 mutation related pancreatitis All
patients referred for idiopathic acute and/or chronic pancreatitis with a SPINK1
mutation, were included and followed annually. Epidemiological, genetic, clinical
and morphological data were collected.
Results: We included 158 patients. Mutations of SPINK1 were: heterozygous
(65%), homozygous (8%) N34S, others (27%). Median age at first symptoms
and diagnosis was 20 [2–73] and 29 years [3–76]. During follow-up (median
length:7.45 years), clinical manifestations were pancreatic pain (73%), pseudo-
cyst (15%), acute pancreatitis (77%), cholestasis (6%), exocrine pancreatic insuf-
ficiency (EPI) (33%), diabetes (15%) and pancreatic adenocarcinoma (n¼ 6.4%).
Calcifications and ductal abnormalities were found in 56% and 62%. Endoscopic
treatment and surgery were performed for 16% and 14% of the patients. Four
patients died including 3 due to pancreatic cancer). The risk of pancreatic cancer
at 55, 60, 70 and 75 years was 9.4%, 14.7%, 28.9% and 46.7%. Risk factors of
cancer were calcifications (p¼ 0.03) and EPI (p¼ 0, 04).
Conclusion: SPINK1 mutations should be searched for in young patients with
idiopathic pancreatitis. Risk of pancreatic cancer is probably underestimated.
A430 United European Gastroenterology Journal 5(5S)
Cancer screening should be discussed especially in case of pancreatitis with
calcifications.
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Introduction: The Scandinavian-Baltic-Pancreatic-club database collects patients
with chronic pancreatitis (CP) from Nordic countries. Description of exocrine
pancreatic insufficiency (EPI) and consequences is important in characterization
of CP cohorts.
Aims & Methods: Characterise EPI from CP in a Northern European cohort.
Patients with definitive or probable CP (M-ANNHEIM diagnostic criteria) were
included from nine centres. Demographic data, body-mass index (BMI), faecal
elastase (FE), enzyme-doses and lab-parameters were collected. Values: Mean
(SD) unless otherwise stated. EPI-classification grouped patients as follows: A:
Normal, B-Mild: EPI not requiring enzymes, C-Proven: EPI requiring enzymes.
Results: Included patients: 932 (623 men: 309 women). Missing EPI-classifica-
tion: 46 patients. Included patients: 932 (623 men: 309 women). Missing EPI-
classification: 46 patients.
Clinical
parameter
(A)
Normal
(B) Mild
insufficiency
(C) Proven
insufficiency
Exocrine pancreatic function
(%)
33 16 51
Faecal Elastase (mg/g) (mean
(SD)) p5 0.001
368 (161) 128 (144) 51 (69)
Nutrition: BMI (kg/m2) (mean
(SD)) p5 0.005
24.6(4.9) 23.7(4.3) 22.6(4.3)
Frequency BMI5 18.5 (%)
p5 0.005
5 16
Vitamin D: Frequency
525nmol/L (%) (I vs II)
p5 0.005
7.4 23.7 17.6
Enzyme Treatment (lipase-
units/day) (median [IQ
range])*
0[0–75000] 120000
[75000–150000]
Hemoglobin: (median [IQ
range] p5 0.05
11.8(2.7–3.0) 10.7(2.8)
Faecal Elastase and disease
duration (years)**
510: 143(175) 410: 91(118)
*p5 0.001. 9% received 550000 lipase-units/day. 14 subjects having FE4 200
received enzymes, 48 subjects with FE5 100 received no enzymes.
**no age/sex differences in EPF
Conclusion: In our material frequency of EPI is higher than reported in the
NAPS2 study (31%). Consequences of EPI were lower BMI, more frequent
underweight, higher enzyme-doses and lower haemoglobin. Need for vitamin
D supplements was highest in the group with mild EPI not receiving enzymes.
Exocrine function was correlated with disease duration, but neither with age nor
gender.
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Introduction: Smoking represents an independent risk factor for the development
of chronic pancreatitis (CP). It is well documented that secretion of pancreatic
ductal alkaline fluid (which is regulated mostly by the anion exchanger and
CFTR) is diminished in CP.
Aims & Methods: In this study we would like to understand whether smoking has
any effects on pancreatic ductal fluid and HCO3
 secretion. Guinea pigs were
exposed to cigarette smoke four times a day for 30min for 6 weeks. The CFTR
expression was analysed by immunohistochemistry. Pancreatic ducts were iso-
lated from guinea pig pancreas. Cigarette smoke extract (CSE) was prepared by
smoking of 15 cigarettes into 10ml distilled water by a smoking machine.
Intracellular Ca2þ concentration and pH were evaluated by microfluorometry.
Fluid secretion was measured by video microscopy. CFTR currents were detected
by whole cell configuration of patch clamp technique.
Results: Cigarette smoking significantly diminished the expression of CFTR and
the fluid and HCO3
 secretion in guinea pig pancreas. CSE dose dependently
decreased fluid and HCO3
 secretion in guinea pig pancreatic ducts via inhibition
of anion exchanger, Naþ/Hþ exchanger and Naþ/HCO3
 cotransporter and also
forskolin-stimulated Cl current of CFTR Cl channel. CSE incubation altered
the pattern of carbachol–induced Ca2þ signal in pancreatic ducts suggesting that
some of the inhibitory effects may be regulated by calcium signalling.
Conclusion: Cigarette smoking and CSE inhibits pancreatic ductal fluid and
HCO3
 secretion and the activity of the CFTR which may play role in the
smoke-induced pancreatic damage. This study was supported by OTKA,
MTA, SZTA and ÚNKP.
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Introduction: Rapid on-site cytologic evaluation (ROSE) for determining the
suitability of a specimen often provides high efficacy of endoscopic ultrasound-
guided fine needle aspiration (EUS-FNA). In our center, we propose an addi-
tional role of ROSE in histological diagnosis aimed at improving diagnostic
accuracy.
Aims & Methods: From January 2009 and December 2015, 215 patients were
evaluated who underwent both EUS-FNA for pancreatic solid lesions and sur-
gery. We retrospectively compared the diagnostic performance of ROSE during
EUS-FNA with the final diagnosis confirmed by surgically resected specimens.
Diagnosis by ROSE using Diff-QuikTM was carried out by both a cytopatholo-
gist and an endoscopist.
Results: The median of needle passes required for ROSE was 1 (range, 1–5). Final
diagnoses for the 215 lesions were pancreatic ductal adenocarcinoma (PDAC;
n¼ 162), pancreatic ductal adenosquamous carcinoma (PDASC; n¼ 9), pancrea-
tic neuroendocrine tumor (pNET; n¼ 30), solid pseudopapillary neoplasm (SPN;
n¼ 9), metastatic tumors (n¼ 4), and acinar cell carcinoma (ACC; n¼ 1).
Primary lesions for metastatic tumors in the pancreas were renal cell cancer
(RCC; n¼ 2), small cell lung cancer (SCLC; n¼ 1), and colon cancer (n¼ 1).
ROSE could not diagnose14 cases. When adenocarcinoma (including suspicious)
was suspected by ROSE, ROSE diagnosed 94.6% (159/168) of adenocarcinomas.
When special type tumor (pNET, SPN, RCC, SCLC) was suspected by ROSE,
ROSE diagnosed 96.4% (27/28) of special type tumor.
Conclusion: All adenocarcinomas suspected by ROSE were malignant tumors.
When special type tumor (pNET, SPN, RCC, SCLC) was suspected by ROSE,
Diagnostic accuracy of ROSE was 96.4%. Diagnostic accuracy using ROSE is
high agreement in final histological diagnosis. It is suggested that ROSE may also
be useful for diagnosis of special type tumor.
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Introduction: Pancreatic ductal adenocarcinoma (PDAC) has one of the most
dismal prognoses of all cancer types. Diagnostic techniques for early malignant
lesions are limited, which shows an evident need to understand the pathomechan-
ism leading to PDAC and find a suitable marker for early detection. Initial
processes in PDAC development involve acinar to ductal metaplasia (ADM)
with further neoplastic progression into four pancreatic intraepithelial neoplastic
(PanINs) stages. After accumulation of mutations, these lesions will further
evolve into PDAC. Gastrokine 1 & 2 (GKN1 & GKN2) are secreted proteins
found almost exclusively in the stomach, where they are involved in gastric
epithelial homeostasis. While current research focuses on the exploration of
tumor-suppressive properties of GKN1 in gastric tumors, nothing is known
about GKN function in other organs. A whole genome microarray of
KrasG12D Ptf1aCre (KC) mice, a mouse model with predisposition to pancreatic
cancer, revealed strikingly high gastrokine expression. We will further analyze the
involvment of GKNs in the development and progression of PDAC and explore
the possibility to use them as biomarkers.
Aims & Methods: GKN1 & GKN2 expression was confirmed by qPCR in human
and mouse pancreas samples. The presence of GKN1 was verified by western
blot and immunohistochemistry (IHC) in mouse pancreas. Mouse pancreatic
juice and serum were analyzed by proteomic analysis. To investigate the role
of GKNs in pancreatic carcinogenesis in vivo, we established mouse models by
intercrossing KC mice with Gkn1/ and Gkn2/ mice respectively. The capa-
city of acinar cells lacking Gkn1 and Gkn2 to transdifferentiatie into ductal
lesions in vitro was tested.
Results: GKNs were upregulated during early stages of pancreatic carcinogenesis
in mouse and peri-tumoral human pancreas. GKNs were absent in healthy pan-
creas and tumor tissue. IHC showed specific GKN1 expression in premalignant
PanIN lesions, while GKN2 positive cells were also localized in the stroma.
ELISA and proteomic analysis in mice confirmed the secretion of GKNs into
pancreatic juice. Preliminary results from the first timepoint of analysis showed
accelerated tumor development in GKN1/ KC mice. Wild type acinar cells
transdifferentiated in vitro only in the presence of TGFa. On the contrary,
Gkn1/ acinar cells transdifferentiated spontaneously, and resulted in a
higher number of ADMs.
Conclusion: We identified for the first time specific gastrokine expression in pre-
neoplastic lesions in human and mouse pancreatic tissue. The secretion into
pancreatic juice during carcinogenesis could make gastrokine a potential biomar-
ker for the detection of early pancreatic premalignant lesions. With our mouse
models we will provide in vivo evidence on the role of GKNs as potential tumor
supressors in the pancreas.
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Introduction: Pancreatic cancer is one of the deadliest malignancies and there are
no effective therapies for it. According to a search of The Cancer Genome Atlas
(TCGA), alterations in Kirsten rat sarcoma (KRAS), Tumour protein (TP)53,
Cyclin-dependent kinase inhibitor (CDKN)2A and Cyclin-dependent kinase
inhibitor (CDKN)2B are the most frequent genetic aberrations in human pan-
creatic cancer(91%, 63%, 53% and 34% of cases, respectively). Macroautophagy
(hereafter referred to as autophagy) has been implicated in some of human dis-
eases, and it plays a complex role in pancreatic cancer.
Aims & Methods: We aimed to investigate autophagy response in a new huma-
nized genetically-modified adult mouse model of pancreatic cancer. To induce
pancreatic cancer, lentiviruses expressing oncogenic KRASG12D and shRNA tar-
geting tumour suppressors Tp53, Cdkn2a and Cdkn2b (lentiviruses-KTCC) were
injected into pancreas of 9-week old adult mouse. Autophagy was detected by
immunofluorescence staining for autophagic protein light chain-3 (LC-3) and
Lysosomal-associated membrane protein 1(LAMP-1). Additionally, the expres-
sion of autophagic protein LC3, autophagy related protein 7 (ATG7), LAMP-1
and P62 were determined by western blot. In vitro, pancreatic duct epithelial cells
of normal mice were primary isolated, LC3 was determined by immunofluores-
cence staining in the lentiviruses-KTCC infected primary cells.
Results: Mice developed pancreatic cancer ten weeks after lentiviruses-KTCC
injection, both in macrography and histopathology analysed. The mRNA
levels of autophagic genes Atg7 and Atg12 were up regulated. In addition, the
LC3 and LAMP-1 positive areas were significantly increased. And co-localiza-
tion of LC3 and LAMP-1 was found in pancreatic tumour sections. Moreover,
the increased protein levels of ATG7, LC3, LAMP-1 and decreased P62 protein
was observed in the pancreatic tumour tissues. In vitro, the protein level of LC3
in the lentiviruses-KTCC infected primary cells was increased by 6 times when
compared with that in the control primary cells (P¼ 0.0104).
Conclusion: An adult mouse model of pancreatic cancer can be generated by
altering Kras, Tp53, Cdkn2a and Cdkn2b genes. Besides, increased autophagy
was observed during the development of pancreatic cancer in our mouse model.
These findings provide considerable insight into the role of autophagy in pan-
creatic cancer and autophagy inhibition might be a potential target in treating
pancreatic cancer.
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Introduction:Hyperthermia as a positive additive to chemotherapy is described in
multiple studies. Despite controversial results hyperthermal intraperitoneal che-
motherapy (HIPEC) is a standard treatment option for some types of gastro-
intestinal cancer that invades peritoneum. However, the results of clinical data
and basic research are uneven. Moreover, there is a lack of fundamental knowl-
edge on additive cytotoxic effect of hyperthermia on cancer cells of different
origin.
Aims & Methods: Our aim was to analyse gastrointestinal cancer cell response to
various hyperthermia levels, accompanied by chemotherapy, in a manner of cell
cytotoxity, apoptosis and intracellular cisplatin concentration. Cancer cell lines
of gastric (AGS), pancreatic (T3M4) and colorectal (CACO-2) origin were
exposed to cisplatin and different temperature regimens (37C to 45C) either
in isolated manner, or in combination. Cells were treated for one hour, mimick-
ing HIPEC timing in clinical setting. The intracellular concentration of cisplatin
was measured immediately after experiment by mass spectrometry. 48 hours later
changes of cell viability and apoptosis rates depending on temperature in addi-
tion to cisplatin treatment were evaluated by MTT and Annexin/7 AAD flow
cytometry respectively.
Results: Response of AGS to hyperthermia was as implied. Viability of the cells
was gradually decreasing by raising the temperature. CACO-2 cells had no sig-
nificant response to temperature rise up to 42C, but at 43C viability dropped by
14% constantly remaining at higher temperatures. T3M4 cells acted in unpre-
dictable manner, whereas decreasing viability by 30% in the interval between
37C to 42C and 20% increase at 43C was observed. Following simultaneous
exposure to hyperthermia and cisplatin we observed no additive temperature
affect in interval between 37C to 41C. However, at particular temperature
regimens, we observed temporary proliferation increase: AGS – at 42C
(33%); T3M4 – at 43C (32%). Higher temperatures dramatically inhibited
AGS – by 70%, T3M4 – by 76%. There was the linear pattern of slight decrease
(up to 26% at 45C) of viability in CACO-2 cells. Isobologram analysis of
combined hyperthermia and cisplatin treatment revealed strong antagonism of
hyperthermia and chemotherapy in all analyzed cell lines. Nevertheless,
hyperthermia of 43C in addition to cisplatin promoted apoptosis of AGS cells
by 33%, CACO-2 by 26%, T3M4 by 19%. Moreover, application of hyperther-
mia (43C) could contribute to increase of intracellular cisplatin concentration by
30%, 20% and 18% AGS, CACO-2 and T3M4 cells respectively.
Conclusion: Our results indicate that there is no linear contribution of hyperther-
mia to chemotherapy in all analyzed cell lines. Therefore, in clinical setting it
should be applied individually, regarding cancer type. Moreover, particular tem-
peratures can worsen the treatment and increase cancer cell growth.
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Introduction: Cachexia is a multifactorial syndrome, characterized by the loss of
skeletal muscle mass which is not fully reversible by nutritional support. Activin
play a dominant role in the development and progression of cachexia and also in
tumor cell growth in pancreatic adenocarcinoma via non-SMAD (MAPK, PI3K/
Akt) pathways. Cachexia might be a keypoint in pancreatic ductal adenocarci-
nomas (PDAC) poor outcome.
Aims & Methods: Our goal was to assess the significance of activin protein
expression in PDAC related to the clinical stage and survival. There were
included patients with histological proven of adenocarcinoma (n¼ 115) and a
matched control group (n¼ 124). The plasma levels of activin was analyzed using
western blot. The t test was used to determine the difference between the two
groups, Kaplan-Meier curve and log-rank tests were used to determine the dif-
ferences in survival curves of studied patients.
Results: The activin was overexpressed more frequently in PDAC compared to
controls (p¼ 0.001). and has been closely related to advanced clinical stage (stage
III-IV), tumor size, location and with the presence of metastasis (p5 0.05).
Activin expression was higher in patients with type 2 diabetes (p¼ 0.04). No
relationship between activin level and the patients age, sex or tumor size, was
noted. Patients with activin high expression had a shorter survival time than
PDAC patients with activin low expression (Log-rank¼ 4.35, p¼ 0.03).
Conclusion: Activin pathway is related to cachexia and the local spread of PDAC,
metastasis, the presence of diabetes and survival.
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Introduction: Intracellular cytoskeleton in pancreatic ductal adenocarcinoma
(PDAC) might be a key point in its poor outcome. Reliable biomarkers estimat-
ing the cytoskeleton involvement are lacking and their relationship with the
cachexia is not known. Ezrin is involved in intracellular signaling and adhesion,
by linking in the PI3K/Akt pathways.
Aims &Methods: The goal is to assess the significance of ezrin protein expression
in PDAC related to the clinical stage and survival. There were included patients
with histological proven of adenocarcinoma (n¼ 51) and a matched control
group (n¼ 51). The plasma levels of ezrin were analyzed using western blot.
The t test was used to determine the difference between the two groups,
Kaplan-Meier curve and log-rank tests were used to determine the differences
in survival curves of studied patients.
Results: The ezrin was overexpressed more frequently in PDAC compared to
controls (p¼ 0.009 and p¼ 0.05). Ezrin expression has been closely related to
advanced clinical stage (p¼ 0.03), but not with the presence of metastasis No
relationship between ezrin levels and the patients age, sex or tumor size and
location of tumor was found. The survival of patients with high or low levels
of ezrin expression was similar.
Conclusion: Ezrin pathway as a intracellular cytoskeleton biomarker is related to
the local spread of PDAC, but not in metastasis or survival.
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References
1. Capello M, Cappello P, Linty FC et al (2013) Autoantibodies to Ezrin are an
early sign of pancreatic cancer in humans and in genetically engineered
mouse models. J Hematol Oncol 6:67
2. Meng Y, Lu Z, Yu S, Zhang Q, Ma Y, Chen J: Ezrin promotes invasion and
metastasis of pancreatic cancer cells. J Transl Med 2010, 8:61
3. Yeh TS, Tseng JH, Liu NJ et al. Significance of Cellular Distribution of
Ezrin in Pancreatic Cystic Neoplasms and Ductal Adenocarcinoma, Arch
Surg. 2005;140:1184–1190
4. Piao J, Liu S, Xu Y, et al. Ezrin protein overexpression predicts the poor
prognosis of pancreatic ductal adenocarcinomas. Experimental and
Molecular Pathology 98 (2015) 1–6.
5. Li J, Wei K, Yu H, Jin D, Wang G, Yu B (2015) Prognostic value of Ezrin in
various cancers: a systematic review and updated meta-analysis. Sci Rep
5:17903
P0782 QUALITY OF LIFE DURING CHEMOTHERAPY IN
JAPANESE PATIENTS WITH UNRESECTABLE ADVANCED
PANCREATIC CANCER
K. Shibayama
1, F. Koga2, S. Nakashita2, N. Oza2, T. Otsuka3, N. Ureshino3,
Y. Kawaguchi2
1Department Of Nursing, Saga-Ken Medical Centre Koseikan, Saga/Japan
2Department Of Hepatobiliary And Pancreatology, Saga-Ken Medical Centre
Koseikan, Saga/Japan
3Department Of Oncology, Saga-Ken Medical Centre Koseikan, Saga/Japan
Contact E-mail Address: kaoru_1238@yahoo.co.jp
Introduction: FOLFIRINOX (FFX) or nab-paclitaxel plus gemcitabine (GnP)
are standard regimens in patients with advanced pancreatic cancer. However,
chemotherapy can impair quality of life (QoL) due to adverse events. Because
the life expectancy of this population is typically short, QoL is as important as
the actual length of life.
Aims & Methods: The aim of this study was to assess QoL during chemotherapy
in patients with advanced pancreatic cancer. Twenty-one Japanese patients with
unresectable advanced pancreatic cancer and performance status 0–1 were
included in this study. All patients were treated with FFX or GnP as first-line
chemotherapy. QoL was assessed using the European Organization for Research
and Treatment for Cancer Quality of Life Core Questionnaire (EORTC QLQ-
C30), and anxiety and depression were measured using the Hospital Anxiety and
Depression Scale (HADS) at baseline and 2 weeks and every month after initia-
tion of chemotherapy. Changes between score at baseline and median score after
chemotherapy were compared using Wilcoxon signed-rank test. Continuous vari-
ables are presented as median (range).
Results: Thirteen male and 8 female patients were included, with a median age of
65 (50–75) years and BMI of 21.2 (16.0–26.2) kg/m2. The chemotherapy regimens
were FFX in 5 men and 2 women, modified-FFX in 4 men and 4 women, and
GnP in 4 men and 2 women. Eight patients took opioids for pain, and 4 received
celiac plexus neurolysis. Regarding global health status (GHS) and functional
scales in QLQ-C30, baseline scores were: GHS, 50 (17–92)%; physical, 87 (53–
100)%; role, 83 (33–100)%; emotional, 67 (33–100)%; cognitive, 83 (33–100)%;
and social, 67 (11–100)%. After chemotherapy, role function scale was decreased
significantly (p¼ 0.04), and nausea (p¼ 0.02) and diarrhea (p¼ 0.049) were more
frequently observed, while pain was relieved (p¼ 0.002). In analysis according to
patients’ background, a lot of evaluation in patients with BMI521 kg/m2 tended
to be worse than in those with BMI 21 kg/m2 after chemotherapy. Regarding
HADS at baseline, 5 patients reported depression, 7 borderline depression, 5
anxiety requiring intervention, and 5 anxiety requiring follow-up. There were
no significant changes in HADS after chemotherapy.
Conclusion: In patients with advanced pancreatic cancer, GHS and mental status
had already deteriorated at baseline. Although pain scale might be improved due
to analgesic treatment, role function scale, nausea and diarrhea became worse
during chemotherapy. In particular, QoL tended to deteriorate in lean patients.
These results indicate that pain as well as QoL factors should always be consid-
ered to manage chemotherapy properly in patients with advanced pancreatic
cancer.
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Introduction: Pain devastates the quality of life and is often difficult to control in
unresectable PC. Opioid analgesics are used to alleviate the pain. However,
pharmacologic intervention sometimes fails and the side effects could become
major problems. Recently, EUS-CPN has been shown to have a therapeutic
effect against PC pain in the short term.
Aims & Methods: The objective of the study was to evaluate the efficacy and
safety over the long term and to identify predictors of pain relief in patients
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treated by EUS-CPN. Clinical information was obtained retrospectively from the
medical charts and endoscopy reporting system. The follow-up period was until
the patient died or was lost to follow-up. Between November 2014 and March
2017, 70 patients with PC pain were enrolled. We performed EUS-CPN by
injection of 5ml of bupivacaine mixed with 15ml of pure ethanol on the celiac
plexus and superior mesenteric plexus using a 22G endoscopic ultrasound-guided
fine needle aspiration needle. Treatment response was assessed by self-reported
pain relief and change in the daily dose requirement of morphine. Treatment
response was defined as to decrease or stay of the same amount of morphine
consumption after EUS-CPN, or achieve morphine dosage level within 4 weeks
after EUS-CPN if morphine consumption temporarily elevated because of the
delayed response of EUS-CPN. Pain evaluation was conducted at 1 week, 4
weeks, 12 weeks after EUS-CPN and tumor disease progression.
Results: The overall response rate was 81.4% (57/70). The median duration of
pain relief was 4.0 months. 10 patients required a second EUS-CPN due to pain
relapse, and 90% (9/10) showed response to the repeat procedure. Of the 44
patients who showed response to the initial EUS-CPN during chemotherapy,
the pain relief persisted after the diagnosis of tumor progression in 16 patients
(16/44: 36.3%). Between the response group and no-response groups, there were
significant differences in the prevalences of liver metastasis (47 vs. 92%,
P¼ 0.003), lung metastasis (12 vs. 38%, P¼ 0.02) and lymph node metastasis
(56 vs. 92%, P¼ 0.015), and in the serum levels of CEA (median: 6.7 vs. 17.1 ng/
ml, P¼ 0.017), CA19-9 (median: 617.2 vs. 3519 U/ml, P¼ 0.009), CRP (median:
0.61 vs. 1.91mg/dl, P¼ 0.029) and albumin (median: 3.4 vs. 3.8 g/dl, P¼ 0.029).
Univariate analysis revealed a significantly smaller percentage of patients with
CRP level elevation over 3.0mg/dl from baseline within 4 weeks after EUS-CPN
(11 vs. 38%, P¼ 0.01). The overall survival after EUS-CPN was also significantly
longer in the response group as compared to the no-response group (median: 5.8
vs. 3.1 months, P¼ 0.01).
Conclusion: Our study demonstrated that EUS-CPN had therapeutic effect on
intractable pain in unresectable PC in the long follow-up. Repeat EUS-CPN was
also effective in patients who showed a treatment response to the first EUS-CPN.
Patients who did not benefit from EUS-CPN had strong cancer inflammation
and aggressiveness, indicative of higher CRP, CA19-9 and lower albumin levels,
and the higher frequencies of liver metastasis.
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Introduction: Pancreatic ductal adenocarcinoma (PDAC) 5-year survival rate is
only 6% as only 20% of patients are eligible for surgery at diagnosis, due to
delayed diagnosis as symptoms are often unrecognized. Data on the association
between presentation symptoms, diagnostic delay, disease stage and survival are
however limited, with heterogeneous results. Furthermore, the association
between risk factors for developing PDAC, such as smoking, obesity, alcohol
intake, diabetes and PDAC family history and diagnostic delay has not been
explored specifically.
Aims & Methods: We aimed to investigate the association between presentation
symptoms, diagnostic delay, risk factors for PDAC, stage at diagnosis and sur-
vival. This was a retrospective analysis of a single-centre cohort of prospectively
evaluated PDAC patients with the above mentioned data recorded in a dedicated
database. Fisher test for comparison of proportions for categorical variables and
Student’s t-test for continuous variables were employed. Multiple logistic regres-
sion analysis was employed to investigate factors associated with metastatic stage
at diagnosis or death. Survival probability was calculated with the Kaplan-Meier
curve and Cox analysis was employed to calculate hazard ratios (HR). Tests of
statistical significance and confidence intervals were two-sided; a p5 0.05 was
considered to be statistically significant.
Results: In 434 PDAC patients the mean diagnostic delay was 4 months (95% CI
3.6–4.4). Jaundice was the leading presentation symptom in 74 (17%), weight loss
in 164 (37.7%), pain in 105 (24%), new-onset diabetes in 43 (9.9%). Diagnosis
was incidental in 24 cases (5.5%) or related with undetermined complaints in
other 24 (5.5%). The diagnostic delay was significantly shorter for patients with
jaundice (mean 1.1 months) compared to those with pain (3.6), new-onset dia-
betes (5.46) and weight loss (5.96). PDAC family history, smoking and previous
diabetes were not associated with presentation symptoms or delay, but obese
patients (4.3 vs 3.4 months; p¼ 0.03) and those drinking alcohol (4.5 vs 3.6
months; p¼ 0.03) had a longer delay. The mean diagnostic delay was of 4.5
months in patients with distant metastases, 4.1 in locally advanced and 3.4 in
resectable disease (p¼ 0.02). Patients presenting with jaundice had distant metas-
tases at diagnosis in only 18% of cases compared to 45% of other presentations
(p¼ 0.00001). The mean survival was 11.8 months in the 395 patients with avail-
able follow-up. At Kaplan-Meier and Cox-proportional regression analysis age
at diagnosis (HR¼ 1.02 per year) and metastatic stage at diagnosis (HR 2.5), but
not the different presentation symptoms, or the diagnostic delay were associated
with worse survival.
Conclusion:Different presentation symptoms, the presence of obesity and alcohol
intake are associated with the diagnostic delay, which is in turn related with
disease stage at diagnosis. However, symptoms and delay do not seem to affect
prognosis. These results suggest that diagnosis at the preclinical stage is necessary
to change disease prognosis.
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Introduction: Cell-free DNA (cfDNA) shed from tumors into the general circula-
tion offers opportunities to trace the genomic evolution of cancer. The level of
cfDNA is generally higher in cancer patients than healthy individuals; however,
detecting the rare fraction of circulating tumor-derived DNA (ctDNA) in patient
plasma remains a technical challenge. Initial efforts have been made to quantify
the ctDNA using conventional PCR, but the low sensitivity of this approach has
limited its feasibility as a routine clinical test. New technologies for quantifying
ctDNA are now sensitive enough for reliable application in the clinic (ref 1).
Pancreatic ductal adenocarcinoma (PDA) is among the most lethal human malig-
nancies. Intraductal papillary mucinous cystic neoplasias (IPMNs) are precursors
of PDA and provide models of neoplastic progression from a benign intraductal
tumor through increasing grades of dysplasia to PDA, and mutations in KRAS
and/or GNAS mediate key signaling during early development of the tumors (ref
2). Better prediction of histological grades using non-invasive tools is urgently
needed for IPMN patients to make appropriate management decisions.
Aims &Methods: In the current study, we sought to determine if quantification of
major driver mutations such as KRAS and GNAS in the plasma cfDNA could
serve as biomarkers for diagnosis of localized PDAs and risk stratification of
IPMNs. We first established protocols for absolute quantification of very low
concentrations of the target mutant alleles using a Bio-Rad QX200 droplet digital
PCR platform (ddPCR). Using this novel protocol, feasibility of the assay was
tested. At present, 92 PDA and 145 IPMN patients with either benign or malig-
nant disease have been recruited (UMIN000012810).
Results: Although ddPCR-based assays have rather high precision and sensitivity
(0.01%), limited plasma cfDNA yields in patients with resectable PDAs (Stage 0-
II) resulted in significant intrinsic errors due to ‘‘subsampling’’. The issue asso-
ciated with missing targets at very low abundance during compartmentalization
could be effectively overcome by pre-amplification, and the sensitivity of mutant
KRAS detection was greatly improved (80.3%) relative to a standard protocol
(37.5%). Given the highly accurate assay, risk assessment of the IPMN cases was
performed during follow-up. Although the concentration of plasma cfDNA in
patient with IPMNs was not robustly higher than healthy subjects (15.1 þ/
5.8 ng/mL plasma vs 11.3 þ/3.2 ng/mL plasma), mutant KRAS/GNAS alleles
from patients, particularly in high-grade IPMNs, can be successfully quantified
albeit at low levels. In the subset of patients who had no evidence of ‘‘high-risk
stigmata’’ as well as ‘‘worrisome features’’ by imaging modalities (ref 3) and
normal tumor markers (CA19-9 and CEA), oncogenic KRAS could be detected
in plasma cfDNA earlier than the detection of invasive PDAs by imaging.
Conclusion: By setting an appropriate protocol for ddPCR-based cfDNA assay,
serial blood sampling allows physicians to conduct real-time detection and mon-
itoring of tumor genomic alterations (ref 4). Although larger validation studies
are required before introduction into the clinic, early results of the study indicate
that our approach allows the detection of localized early-stage disease and offers
an alternative tool to monitor IPMN progression non-invasively.
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Introduction: Pancreatic cancer is a lethal disease and the fifth most common
cause of cancer-related death in Korea. Pancreatic cancer patients show dismal
prognosis with a 5-year survival rate less than 10%, because the majority of
patients are diagnosed in advanced stage. Since the late 1990s, gemcitabine-
based chemotherapy has been used as a mainstay of metastatic pancreatic
cancer (mPC) treatment and various combination therapies (such as combination
with capecitabine or erlotinib) had been attempted to improve the patients’
survival, so far. Recently, MPACT trial, a randomized phase III trial showed
that combination of gemcitabine and nab-paclitaxel had statistically significant
survival benefit compared with gemcitabine monotherapy. Based on the results
of this trial, gemcitabine with nab-paclitaxel combination therapy is currently
being used as a standard therapy for pancreatic cancer patients. However, only
2% of the MPACT trial study population was Asian, and other researches on
Asian population group are also lacking. Therefore, we investigated treatment
efficacy and safety of gemcitabine plus nab-paclitaxel combination therapy for
mPC treatment in Korean population.
Aims & Methods: Total 66 metastatic pancreatic cancer patients treated with
gemcitabine (1000mg/m2) and nab-paclitaxel (125mg/m2) regimen (on day 1, 8,
15 of a 28-day cycle) as the first line chemotherapy from February 2016 were
identified using the Severance Hospital Pancreatic Cancer Cohort Registry.
Treatment efficacy (overall survival (OS), progression-free survival (PFS), objec-
tive response rate) and treatment-related adverse events (AE) of patients (occur-
rence rate, severity grade and dose-intensity) were analyzed.
Results: The median follow-up period was 7.4 months (range 1.5–14.9 months);
during this period, 21 (31.8%) patients died. Median cumulative dose of gemci-
tabine and nab-paclitaxel were 13,000mg/m2 and 1487.5mg/m2. The median OS,
PFS and objective response rate were 12.0 months (95% confidence interval [CI]
9.515–14.485), 7.8 months (95% CI 5.021–10.579) and 48.5%, respectively. The
incidence of neurotoxicity was 54.5% and 12 (18.2%) patients experienced
grade 3 neurotoxicity. 30 (45.5%) patients showed grade 3 neutropenia and
10 (15.2%) patients had febrile neutropenia. Grade 3 gastrointestinal AE was
occurred in 11 (16.7%) patients and 28 (42.4%) patients experienced dermatolo-
gic AE such as alopecia and skin eruption. About 59% of patients experienced
treatment delays due to adverse events. Dose reduction was performed in 39
(59.1%) patients and 14 patients experienced treatment cessation due to severe
AE.
Table 1: Treatment efficacy and treatment-related adverse events of gemcitabine
with nab-paclitaxel
Variables
Duration of chemotherapy
Cycles (28-day schedule) 5 (2–12)
Duration, days 141 (32–435)
Efficacy of Chemotherapy
Overall survival - months (95%CI) 12.0 (9.515–14.485)
Progression-free survival - months (95%CI) 7.8 (5.021–10.579)
Adverse events
Peripheral neuropathy 36 (54.5%)
Grade 3 neuropathy 12 (18.2%)
Grade 3 Neutropenia 30 (45.5%)
Febrile neutropenia 10 (15.2%)
Administration of G-CSF 14 (21.2%)
Grade 3 adverse event 11 (16.7%)
General weakness 32 (48.5%)
Dermatologic adverse event 28 (42.4%)
Dose reduction due to AE
Gemcitabine 21 (31.8%)
nab-paclitaxel 39 (59.1%)
Delay of administration due to AE
n (%) 39 (59.1%)
Cessation of administration due to AE
n (%) 14 (21.2%)
Conclusion: These results suggest that gemcitabine and nab-paclitaxel combina-
tion therapy is effective for metastatic pancreatic cancer treatment in east-Asian
population group. Similar to previous studies, this combination therapy showed
remarkable neurotoxicity and myelosuppression. Careful monitoring and proper
management during chemotherapy is required.
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Introduction: Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is
a useful and safe method for tissue confirmation of malignancy. This method has
the risk of tumor cell dissemination along the needle track or within the perito-
neum by preoperative EUS-FNA.
Aims & Methods: The aim of our study was to estimate the risk of peritoneal
recurrence and the impact on long-term outcomes by preoperative EUS-FNA in
resected pancreatic cancer. The records of patients diagnosed with pancreatic
cancer who underwent curative resection between 2009 and 2013 were reviewed
retrospectively. A total of 394 patients were included: 78 patients with preopera-
tive EUS-FNA (EUS-FNA group) and 316 without preoperative EUS-FNA
(Non-EUS-FNA group). Peritoneal recurrence was diagnosed based on image
findings.
Results: Median length of follow-up was 23 months (range 1 94 months). A
total of 82 patients had peritoneal recurrence; 34.6% (27/78) in EUS-FNA group
vs. 28.2% (89/316) in Non-EUS-FNA group (P¼ 0.26). Cancer-free survival and
overall survival were not different between the groups: median cancer-free survi-
val in EUS-FNA group was 10.8 months compared with 10.6 months in Non-
EUS-FNA group (P¼ 0.83), and median overall survival in EUS-FNA group
was 56.4 months compared with or 56.7 months in Non-EUS-FNA group
(P¼ 0.93).
Conclusion: Preoperative EUS-FNA for pancreatic cancer was not associated
with an increased rate of peritoneal recurrence and mortality. Our study suggests
that EUS-FNA is a safe method for obtaining tissues of pancreatic masses.
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Introduction: Gemcitabine (Gem) therapy had been the standard treatment for
advanced pancreatic ductal adenocarcinoma (PDAC) for long time. Even though
FOLFIRINOX, a combination of fluorouracil, oxaliplatin and irinotecan, and
gemcitabine/nab-paclitaxel (GnP) therapy are currently recommended as first-
line drugs, Gem is still one of the important options. Efficient permeation of Gem
into cells requires specialized integral membrane transporter proteins to cross
plasma membranes. Among these transporters, the major mediators of Gem
uptake into human cells are the human equilibrative nucleoside transporter 1
(hENT1). In the previous study started since 2005, we found hENT1 expression
in endoscopic ultrasonography-guided fine-needle aspiration biopsy (EUS-
FNAB) samples to be a useful prognostic marker of Gem-based chemoradiother-
apy (Gem-CRT) for pancreatic ductal adenocarcinoma (PDAC) (Pancreas 2016).
Since November 2011, our institution has replaced Gemþ tegafur/gimeracil/oter-
acil (S-1) (GS)-CRT with Gem-CRT in an attempt to improve clinical response
and prognosis. Aggregate median survival time (MST: months) of GS-CRT was
compared with previous Gem-CRT result, and the superior efficacy of GS-CRT
was observed (MST: 16 versus 20, respectively), particularly in hENT1-negative
patients (MST: 9 versus 14, respectively). However, there were no differences in
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hENT1-positive patients (MST: 25 versus 25, respectively). We suspect that
genetic factors might play a role in this observed variability.
Aims & Methods: In the present study, we evaluated hENT1 and dihydropyrimi-
dine dehydrogenase (DPD: enzyme involved in the degradation of tegafur)
expression in EUS-FNAB samples for evaluating and predicting the clinical
efficacy of GS-CRT. EUS-FNAB samples were obtained prior to GS-CRT
administration. In total, 95 formalin-embedded PDAC specimens were obtained.
In the samples determined to have sufficient material remaining following cyto-
logical/histological diagnosis (n¼ 76), hENT1 expression was evaluated via
immunohistochemical (IHC) examination. Following IHC analysis of hENT1,
a further assessment of DPD expression was carried out in those samples deter-
mined to have sufficient material remaining (n¼ 58).
Results: By reusing the EUS-FNAB specimens after diagnosis of PDAC, hENT1
and DPD expression could be successfully assessed in 79.2% (76/95) and 61.1%
(58/95) of these cases, respectively. In those sufficient for hENT1 testing, 67.1%
(51/76) were found to be positive. And in those sufficient for DPD testing, 27.6%
(16/58) were found to be positive. MST was significantly longer in hENT1-posi-
tive patients (25 versus 14 negative; P¼ 0.015). As for DPD, MST was signifi-
cantly longer in DPD-negative patients (33 versus 14 positive; P5 0.001). In the
multivariate model including pretreatment clinical factors (age, sex, tumor loca-
tion, tumor size, UICC-T classification, hENT1 expression, and DPD expres-
sion) and the clinical response after GS-CRT (response of GS-CRT, reduction
rate in serum CA19–9 level, and distant metastasis after GS-CRT), only hENT1
expression (HR¼ 3.511; 1.545–7.981, P¼ 0.003) and DPD expression
(HR¼ 0.232; 0.108–0.496, p5 0.001) were found to be significant independent
prognosis factors.
Conclusion: hENT1 and DPD expression observed in EUS-FNAB samples can
be useful clinical predictors in PDAC cases treated with GS-CRT.
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Introduction: Intraductal Papillary Mucinous Neoplasms (IPMN) require a close
follow-up to early detect worrisome features, which imply a pejorative evolution
towards dysplasia and surgery. However, some patients are symptomatic includ-
ing post-prandial pancreas related abdominal pain (PPAP) or recurrent acute
pancreatitis (RAP). We currently do not know if those symptoms are risk
factor of cancer in IPMN, and there are no data about the efficacy of endoscopic
sphincterotomy (ES) to manage them.
Aims &Methods: This was a retrospective multi-centered observational study in 4
tertiary expert centers. The files of 27 patients that underwent ES for sympto-
matic IPMN without worrisome features nor surgical indication were considered.
Six were excluded (4¼ lack of data; 1¼pseudocyst; 1¼ adenocarcinoma), thus
21 were analyzed. Age, sex, medical history, time of follow-up, characteristics of
IPMN and ERCP procedures, clinical success, evolution and need for surgery
were recorded. The primary endpoint was to assess the efficacy of ES for improv-
ing the symptoms of pain related to IPMN. The efficacy was defined as the
resolution or the decreasing 450% of the symptoms’ frequency. The secondary
endpoints were to document, the need for a second ES, the occurrence of WF
during follow-up, the need for surgery and its indications.
Results: There were 10 men and 11 women involved, with a mean age of 66 years
old [45–87] and a mean total follow-up of 105 months [17–276]. Their symptoms
were PPAP in 6 patients and RAP in the 15 others (5 being severe AP), with a
mean of 3.6 episode/year [1–12]. The delay between diagnosis and ES was 41
months [1–192] and the patients were followed by MRI (81%), EUS (95%)
CTscan (36%) or by alternating (MRI and EUS) for 45%. The IPMN were
involving the accessory branch duct in 71%, or mixed type in 29%, with a
wirsung duct always 57mm. The mean number of cysts was 3.5 [1–10], the
larger measuring 12.7mm [5–25] mean. They were located for 59% in the
head, 17% in the body or tail, and they were diffuse in 24%. None patient
had worrisome features. Endoscopy: ERCP with pancreatic ES was performed
in 100% of the cases (5 with pancreas divisum, 2 pre-cut required), associated
with a biliary ES in 33% of the cases. A prophylaxis with NSAIDS was carried
out in 38% of the cases and a plastic stent placement in 33%. There were 4 post-
ERC benign pancreatitis, and the mean follow-up after ES was 54 months [13–
167]. The clinical efficacy rate as defined after one session was 81% (17/21).
Among them, one had a late recurrence (41 months) and underwent a second
ES session with final success, whereas 4 have been operated (2 for initial pain, 2
for WF). Among the patients whom failed (4/21), one had a second ES with final
success and 3 finally had surgery. The two groups were comparable in terms of
age, sex, mean follow-up time, and characteristics of IPMN. The final efficacy of
ES was 86% (19/21). In total seven patients were operated after a mean of 19
months of follow-up, 24% if success of ERCP and in 75% if failure. The indica-
tions were WF (n¼ 4) or pain (n¼ 3). The histopathology showed four low-grade
dysplasia, one high-grade dysplasia, and two no dysplasia (¼surgery for pain).
No patients evolved towards adenocarcinoma in the follow-up.
Conclusion: ES for symptomatic IPMN without WF is effective in 81% of the
cases. A symptomatic IPMN (pain) does not seem to be a valuable indication for
surgery, since no patients developed with cancer after a follow-up greater than 5
years.
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Introduction: Statins are widely prescribed both for primary and secondary pre-
vention of coronary artery disease and for the treatment of dyslipidemia. Several
studies evaluated the association between statin use and the onset of pancreatic
cancer (PDAC) in order to evaluate a possible chemopreventive effect, with
heterogeneous results. Previous meta-analyses evaluating researches published
up to 2012 did not find any association to the risk, but in the latest years new
studies with interesting results have been published.
Aims & Methods: The aim of our study was to conduct a new systematic review
and meta-analysis to clarify this association. A comprehensive literature search of
PUBMED for articles published up to November 2016 and abstracts presented
between 2012–2016 at the DDW and ASCO conventions was carried out. Eligible
studies were case-control studies (CC), cohort studies (C) and randomized con-
trolled trials (RCTs) assessing the effect of statin use on the risk of PDAC,
compared with placebo or no treatment. Studies had to report Odds Ratio
(OR), Relative Risk (RR), or Hazard Ratio (HR), estimates with 95% confi-
dence interval (CI), or provide sufficient data for their calculation. Pooled
adjusted ORs with corresponding 95% CIs were calculated using random effects
model. Publication bias was assessed through Begg and Mazumdar test.
Heterogeneity was assessed by means of the I2 value.
Results: A total of 21 studies (12 CC, 6 C, 3 RCTs) contributed to the analysis. A
total of 11383 PDAC patients and 2991004 controls were included. The pooled
incidence of PDAC was 0.27% (3161/1167130) among statin users and 0.44%
(8144/1835153) among the non-users. The overall pooled result for all studies
demonstrated a reduced risk of PDAC among statin users (OR 0.82; 95% CI
0.69–0.96; p¼ 0.019), compared to non–statin users. In a subgroup analysis the
protective effect was limited to case-control studies (OR 0.72; 95% CI 0.56–0.93)
and not to cohort (OR 0.93; 95% CI 0.73–1.19) nor RCTs (OR 1.04; 95% CI
0.56–1.94). No publication bias was found.
Conclusion: This is the first meta-analysis showing that statins exert a protective
effect on the incidence of PDAC. Further studies taking into account statin dose,
duration and subgroups of patients are needed in order to clarify the association.
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Introduction:Genetic alterations responsible for the initiation of cancer may serve
as immediate biomarkers for early diagnosis. Plasma levels of circulating cell-free
DNA (cfDNA) in cancer patients are higher than those in healthy individuals;
however, the major technical challenge for the widespread implementation of
cfDNA genotyping as a diagnostic tool is the insufficient sensitivity and specifi-
city of detecting early-stage tumors that shed low amounts of cfDNA. Droplet
Digital PCR (ddPCR) has rather high precision and sensitivity for absolute
quantification (0.01%). However, due to very low target concentrations of
cfDNA in plasma, there may be an intrinsic error due to ‘‘subsampling’’ (Ref.
1). This is caused by limited cfDNA yield and missing targets at very low abun-
dance during compartmentalization in ddPCR-based liquid biopsy assays. Such
issues potentially result in large variations or errors in quantification, even when
using highly accurate platform. Using ddPCR technology for early cancer diag-
nosis and risk stratification is still challenging.
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Aims & Methods: In this study, we aimed to overcome the subsampling issue and
to establish a more reliable framework for digital quantification of rare tumor
cell-derived mutant alleles for non-invasive diagnosis of gastrointestinal cancer.
To establish more reliable dd-PCR protocol for quantification of low-frequency
alleles within a limited cfDNA pool, two-step multiplex ddPCR targeting eight
clinically relevant mutant KRAS variants was examined using a Bio-Rad QX200
droplet digital PCR platform. Plasma samples from patients with colorectal
(n¼ 10) and pancreatic cancer (n¼ 9) were evaluated, and cfDNA from healthy
volunteers (n¼ 50) was utilized to calculate reference intervals.
Results: Limited cfDNA yields in patients with resectable colorectal and pancrea-
tic cancers did not meet the requirement for efficient capture and quantification
of rate mutant alleles by ddPCR. To overcome the the subsampling issues and
achieve better assay specificity, we attempted pre-amplification of plasma cfDNA
using primers flanking KRAS exon 2 as the first-step PCR. Eight pre-amplifica-
tion cycles followed by a second-run ddPCR were sufficient to obtain approxi-
mately 5000–10,000 target alleles/ng cfDNA, resolving the subsampling issue;
furthermore, the signal-to-noise ratio for rare mutant alleles against the massive
background presented by the wild-type allele was significantly enhanced. The
cut-off limit of reference intervals for mutant KRAS was determined to be
0.09% based on samples from healthy individuals.
Conclusion: The modification introduced in the ddPCR protocol facilitated the
quantification of low-copy alleles carrying driver mutations, such as oncogenic
KRAS, in localized and early-stage cancers using small blood volumes, thus
offering a minimally invasive modality for timely diagnosis.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Benefit of second line chemotherapy (SL) after failed first-line che-
motherapy (FL) in advanced pancreatic cancer has not yet been established. We
intend to identify prognostic factors and ultimately devise a model of clinical
parameters for decision of SL versus basic supportive care (BSC) after failure of
FL chemotherapy.
Aims & Methods: 408 patients who received gemcitabine based-first-line che-
motherapy for advanced pancreatic adenocarcinoma at Yonsei University
Hospital between January 2010 and December 2014 were retrospectively
reviewed. Significant clinical parameters regarding second line related survival
were reviewed for analyzing predictive factors.
Results: 161 of 408 (39.5%) received SL therapy. Median overall survival from
the beginning of SL (OS2) was 20.0 weeks (14.0 34.0). Significantly more SL
patients presented higher body mass index (BMI) (p¼ 0.001) and ECOG 0–1
(p¼ 0.003) at diagnosis, lower rate of lung metastasis (p5 0.001) and longer
duration of FL (p5 0.001). More SL patients had received gemcitabine-based
concurrent chemo-radiation therapy (CCRT) (p¼ 0.029) compared to FL only
patients. Prognostic factors significant to OS2 were BMI at diagnosis (p¼ 0.019
HR¼ 0.870), duration of FL therapy (median duration 16weeks (8.00–28.00)
p¼ 0.004, HR¼ 0.986), presence of peritoneal metastasis (p¼ 0.002, HR1.732)
at diagnosis, malignant thrombotic event during firstgline chemotherapy
(p¼ 0.001, HR¼ 0.428). Experience of CCRT was also a significant prognostic
factor (p¼ 0.001, HR¼ 2.245); initial staging of the CCRT group was TNM
stage3, which might be the ultimate factor impacting OS2.
Conclusion: Study suggests that SL chemotherapy may be beneficial for patients
with longer duration of FL chemotherapy, higher BMI at diagnosis, patients
without peritoneal metastasis at diagnosis, no malignant thrombosis event
during chemotherapy and patient initially TNM stage3, who received
Gemcitabine based CCRT.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Rapid on site evaluation for endoscopic ultrasound-guided fine-
needle aspiration (EUS-FNA) of the pancreas provides immediate information
regarding cellular adequacy, avoiding repeated procedures.
Aims & Methods: The aim of this study was to evaluate the impact of ROSE in
EUS-FNA of solid pancreatic lesions. Retrospective study of consecutive EUS-
FNA of solid pancreatic lesions, in a tertiary center, between 2012 and 2016.
Results: A total of 259 EUS-FNA in 197 patients were included, 63.6% male,
with mean age of 63.4 (þ/12.8) years. The anatomical distribution of the lesions
was: 56.4% in the head, 17% in the body, 10% in the uncinate process and 5.8%
in the tail. The mean number of passes were 3.3 (þ/1.4) and the needle size was
25G in 60.8% and 22G in 23.8%. ROSE was performed in 34.7% of the punc-
tures (23.6% along with the initial EUS-FNA), with a mean number of passes 3.4
(þ/1.9). The diagnostic yield of initial EUS-FNA without ROSE was 44.8% vs
83.6% when ROSE was performed (p5 0.001). When not conclusive, there was
no significant differences in the diagnostic yield of the repeated EUS-FNA (with
and without ROSE). Beyond ROSE in the first puncture, higher levels of Ca 19.9
(199 vs 10 ng/mL, p¼ 0.001), size of the lesion (36.1 vs. 29.8mm, p5 0.001),
invasion of adjacent structures (64.6% vs 47.9%, p¼ 0.009) and malignancy
(73.2%vs 25.4%, p5 0.001) were associated with EUS-FNA diagnostic accu-
racy. In multivariate analysis, ROSE (p¼ 0.001) and the size of the lesion
(p¼ 0.023) were independent predictors of adequate diagnostic samples. In this
series, the definitive diagnosis was of malignancy in 64.9% (ductal adenocarci-
noma 54.7%), benign in 25.8% and indeterminate in 9.3%.
Conclusion: In agreement with the reported evidence, ROSE along EUS-FNA
improved the diagnostic yield in solid pancreatic lesions and should be consid-
ered whenever possible in the first procedure, until an overall adequate diagnostic
yield (480%) is achieved.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Postoperative digestive fistula remain a challenging condition asso-
ciated with a high morbi-mortality, unsatisfactory healing rates and high refrac-
toriness. The limitation of current approaches highlights the need for a better
therapeutic strategy in terms of both long-lasting efficacy and safety.
Mesenchymal stem cell (MSCs) are strongly involved in tissue injury repair.
MSCs feature an immune-privileged status while displaying pro-angiogenic,
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and antifibrotic properties. Increasing evidences point out MSC action via sub-
cellular entities known as extracellular vesicles (EVs). MSC EVs recapitulate the
therapeutic properties of their cellular counterparts while offering remarkable
advantages in terms of safety (no proliferation, no differentiation, no vascular
occlusion following administration) and shelf life stability. Herein, we evaluated,
in a porcine fistula model, the healing potential of allogenic MSC-EVs delivered
through a thermoresponsive gel (Pluronic F127) allowing the administration in a
sol state through a catheter and gelation in situ at body temperature to retain EVs
at fistula site.
Aims &Methods: Seventeen esophageal fistulas were surgically created by placing
two plastic stents during 30 days into the neck of 9 pigs and randomized into
control group (n¼ 6) and treated groups (gel alone n¼ 6 and gel-EVs n¼ 5). In
the gel-EVs group, Pluronic F127 gel contained allogenic EVs collected from the
swine adipose stem cell conditioned medium. Clinical, endoscopic and radiolo-
gical evaluation of fistula healing was performed at day 30 and day 45, before
histological assessment.
Results: All fistulas were successfully induced at day 30. At day 45, the control
group featured open internal and external fistula orifices in all pigs. For this
group, radiological evaluation showed open fistula tracts, which were confirmed
by histology. In the gel group and gel-EVs groups, radiological examination
showed a complete fistula closure in 67% (4/6) and 100% (5/5) of the animals,
respectively. In the gel group, histological analysis confirmed a complete fistula
for 3 from 6 cases while a partial closure was observed for 1 case from 6. In the
gel-EVs group, histological complete fistula closure was reported for 4 from 5
cases while a partial closure was evidenced in 1 from 5 cases. In comparison with
control group, treated fistulas showed a reduced inflammatory infiltrate and
fibrosis and an enhanced angiogenesis, especially in the gel-EVs group.
Conclusion: This study provides the first evidence in the literature that MSC-EVs
may provide a therapeutic effect in a pre-clinical fistula model. EVs were success-
fully administered via a thermoresponsive Pluronic F127 hydrogel, gelling in situ
to enable EV retention in the fistula tract. Besides, the gel further provided a pro-
angiogenic and an anti-inflammatory effect. The combined action of MSC EVs
and the gel enhanced fistula healing associated with an anti-fibrotic effect in this
esophageal fistula model. This investigation paves the way towards a future sub-
cellular localized fistula therapy merging safety and efficacy.
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Introduction: Compared with histopathology, real-time histology or virtual
biopsy is important for clinical diagnosis, especially for endoscopic examination.
Based on two photon fluorescence (TPEF), multiphoton microscopy (MPM)
imaging could demonstrate cell autofluorescence and second-harmonic genera-
tion (SHG) signal from collagen, which implied real-time information on tissue
architecture and cellular morphology. More importantly, no contrast agent is
needed for this live diagnosis. The aim of this study is to evaluate the feasibility of
MPM to histologically diagnose gastric diseases, compared with other chromoen-
doscopy and H&E histopathology.
Aims & Methods: A pilot study was performed between March 2016 and August
2016. 30 gastric tissue slides (normal, low-grade dysplasia (LGD), high-grade
dysplasia (HGD), and cancer) were examined under MPM. MPM and H&E
images were compared by the experienced pathologist. Cellular-to-nuclei ratio
was analyzed to compare morphological features, while the major/minor axis
ratio was calculated to reveal cellular asymmetry.
Results: Near-infrared light(800 nm) was optimized and applied for multiphoton
autofluorescence imaging in gastric tissue. Under MPM, gastric dysplasia tissue
demonstrated enlarged, while cancer cells were characterized by irregular size and
shape, enlarged nuclei, and increased nuclear-to-cytoplasmic ratio. All these were
confirmed by H&E images. (Figure 1) The mean cellular/nuclei ratio for normal
mucosa was 20.55 4.84, LGD 34.60 3.90, HGD 46.85 3.22, and cancer
56.80 3.37 (P50.05). The mean major/minor axis ratio for normal mucosa
was 1.31 0.09, LGD 2.02 0.16, HGD 1.70 0.18, and cancer 1.43 0.18
(P50.05).
Conclusion: MPM-based optical biopsy was feasible and efficient to clinically
diagnose gastric cancer. With miniaturization and integration of endoscopy,
MPM will be applied to provide real-time histological diagnosis without invasive
biopsy for gastric cancer in the future.
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Introduction: Type 2 diabetes (T2D) and fatty liver disease are highly prevalent,
often overlapping metabolic disorders where upstream insulin resistance is
thought to be a common pathogenic driver. Simultaneous treatment of both
conditions has been reported with insulin sensitizing interventions including
weight loss, pharmacotherapy (GLP1 receptor agonists, TZDs), and bariatric
surgery. Duodenal Mucosal Resurfacing (DMR) is a minimally invasive endo-
scopic procedure that has demonstrated glycemic efficacy in patients with T2D
seemingly via an insulin sensitizing mechanism.1 We report data supporting 12-
mo durability of improved metabolic indices in patients with T2D after a single
DMR procedure in a single-arm, open-label, multicenter study.
Aims & Methods: In this endoscopic DMR procedure, the duodenal mucosa was
treated with hydrothermal ablation using a patented balloon catheter. Efficacy
was analyzed in a modified intent-to-treat cohort (mITT, patients who received
1 ablation) stratified into baseline alanine aminotransferase (ALT) level tertiles
– lowest (ALT5 28 U/L), middle (28ALT5 37 U/L), and upper (ALT 37
U/L). Change from baseline in ALT, aspartate aminotransferase (AST), body
weight, homeostasis model assessment index (HOMA-IR) and HbA1c were ana-
lyzed using repeated measures ANOVA. Data are reported as mean(SD).
Results: Baseline ALT and HbA1c in the mITT cohort (n¼ 27; age, 55(9) y;
diabetes duration, 6(2.5) y; BMI, 32.5(4.2) kg/m2) were 37.0(20.6) U/L, and
8.7(1.0)%, respectively.12-mo reductions in HbA1c, ALT, AST and weight
were 1.0(1.2)% (P¼ 0.005), 8(14) U/L (P¼ 0.18), 6(7) U/L (P¼ 0.005),
2.0(4.2) kg (P¼ 0.83) and 3.6 (P¼ 0.037). In the upper tertile, ALT reductions
from baseline (59 (23) U/L) at 3 and 12-mo were 22(15) (P¼ 0.024), and
16(20) U/L (P¼ 0.72); respective body weight changes were 3.8(2.9)
(P¼ 0.24), and 1.9(5.9) kg (P¼ 0.99). 12-mo reductions in AST, HbA1c and
HOMA-IR were: 9(7) U/L (P¼ 0.13), 1.1(0.5)% (P¼ 0.002); and 4.7(5.2)
(P¼ 0.94). In the middle and lowest tertiles, 12-mo ALT reductions were 4(11)
and 2(3) U/L.
Conclusion: A single DMR procedure in patients with T2D produced significant
reductions in HbA1c up to 12 months in the total cohort. In the highest baseline
ALT subgroup, ALT was significantly lower at 3 months and remained lower
than baseline at 12 months accompanied by significant lowering of hyperglyce-
mia up to 12 months. Further studies are planned to quantify the efficacy, safety
and durability of the hepatic and glycemic effects associated with DMR.
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Introduction: Limited data are available with regard to the prevalence of upper
gastrointestinal endoscopic findings in asymptomatic healthy individuals as an
endoscopy is an invasive and costly procedure.
Aims & Methods: Individuals were recruited from general population in Latvia as
part of the GISTAR pilot study. The study group has been referred for an upper
endoscopy and was tested for serum pepsinogens and pepsinogen I/II ratio 53
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(Biohit, Plc., Helsinki, Finland) was considered decreased. Data were obtained
from 1034 individuals (74% response rate). Upper gastrointestinal endoscopy
procedures were performed between February 2014 and June 2016. The study
was approved by local ethics committees and the Ethics Committee of the
International Agency for Research on Cancer.
Results: Altogether 1034 (45% male) participants (average age 52; min-max 39–
64) were enrolled and upper endoscopies performed in the study. Main endo-
scopic findings were not present only in 21% 219/1034 of asymptomatic indi-
viduals. The majority of the participants (n¼ 815, 79%) showed abnormal
endoscopic findings including the following: reflux esophagitis A- 18%, reflux
esophagitis B- 6%, reflux esophagitis C-1, 3% and histologically confirmed
Barrett’s esophagus-1.3%. The most common main endoscopic finding was
noted gastric erosions 232/1034 (22.4%). The prevalence of gastric peptic ulcer
was 2.9% (30/1034) and gastric scar 0.9% (9/1034), but duodenal ulcer 2.3% (24/
1034) and duodenal scar 5.9% (62/1034). In addition, three gastric adenocarci-
noma cases (0.29%) have been identified during the upper endoscopy. The study
showed statistically significant difference between the groups of individuals with
normal and decreased pepsinogen tests with gastric polyps 3.6% vs 9.2%,
p¼ 0.02, gastric erosions 23.6% vs 11.2%, p¼ 0.04, duodenal ulcer (scar) 6.5%
vs 1%, p¼ 0.02, duodenal lymphangiectasia 1.9% vs 6.1%, p¼ 0.02 and reflux
esophagitis A 18.7% vs 9.2%, p¼ 0.01.
Conclusion: In this group of asymptomatic healthy individuals, only 20% showed
normal endoscopic findings while the majority had clnically significant findings,
some of which were related to the decreased pepsinogens levels. Futher studies
are needed to confirm our observations.
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Introduction: Peroral administration of rebamipide in additional to proton pump
inhibitor (PPI) was reported to be effective to promote ulcer healing after endo-
scopic submucosal dissection (ESD). In this pilot study, we assessed the efficacy
and safety of a novel rebamipide solution as a submucosal injection agent for
ESD using in vivo porcine models.
Aims & Methods: The protocol was approved by the ethics review board of our
animal experimental laboratory in advance (13055 -(0)). ESDs of about 30mm in
diameter were performed at four sites in the stomachs of three pigs. An endos-
copist blinded to the test agents performed the ESDs with a 2% rebamipide
solution at two sites (rebamipide group) and with base solution alone at the
other two sites (control group). The safety and the treatment results of rebami-
pide group were assessed. The gastric ulcer stages were evaluated by endoscopy
once weekly up to week 4 after the ESD to determine a healing score based on
ulcer staging using the classification of Sakita and Miwa. A1 stage was defined as
score 1. A2, H1, H2, S1, S2 were defined as healing score 2, 3, 4, 5, 6, respectively.
The average scores of each week were compared in the rebamipide group and the
control group. One pig was sacrificed at 1 week after the ESD and the other two
were sacrificed at 4 weeks, for pathological evaluation of ESD-induced ulceration
and ulcer scarring by HE. The number of neutrophils and width of the fibrosis
were also compared between the rebamipide group and control group at 1 week
and 4 weeks. Neutrophils were counted in five fields around the ESD-induced
ulcer in HE stained sections under 400 magnification and the average counts of
the five fields. The width of the fibrosis was defined as the maximum diameter of
SMA-positive area in the depth direction from the submucosa to the muscle
layer at a site of ESD-induced ulceration or ulcer scarring.
Results: There were no adverse events related with the use of the rebamipide
solution. The average healing score was significantly higher in the rebamipide
group than in the control group at 2 weeks (p¼ 0.027). The folds into the centers
of the ulcer scars were more regular in the rebamipide group than in the control
group at 4 weeks after ESD. In the histopathological assessment of the ulcers at 4
weeks, mucosal healing was remarkably better in the rebamipide group than in
the control group, with a thicker and more homogeneous mucosal layer. Fibrosis
was significantly less extensive in the rebamipide group than in the control group
at 4 weeks (p¼ 0.02). In the evaluation of inflammation, the average number of
neutrophils was lower in the rebamipide group than in the control group at both
1 week and 4 weeks, but not to a significant extent.
Conclusion: The rebamipide solution appeared to be safe and effective as an
injection material for promoting the healing of ESD-induced ulcers. It also
seemed to smoothen the folds of the ulcer circumference after ESD by suppres-
sing fibrosis.
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Introduction: The optimal treatment regimen or duration of endoscopic submu-
cosal dissection (ESD)-induced gastric ulcer has not been established. The aim of
this study was to assess the efficacy of novel PPI, ilaprazole for the treatment of
ESD-induced gastric ulcer.
Aims & Methods: This was a prospective, open-label, randomized multicenter
study. Between June 2015 and April 2017, a total of 88 patients who underwent
ESD for gastric neoplasm were randomly allocated with ilaprazole 20mg or
rabeprazole 20mg daily for 8 weeks. The primary outcome was ulcer healing
rate at 4 and 8 weeks.
Results: In the intention-to-treat analysis, the ulcer healing rate of each treatment
group was not significantly different at 4 or 8 weeks (ilaprazole vs. pantoprazole;
96.7% vs. 96.4%, P¼ 0.80 at 4 weeks, 99.7% vs. 99.0%, P¼ 0.19 at 8 weeks).
There was no independent predictive factors for a high ulcer healing rate in the
multivariate analysis.
Conclusion: According to this interim analysis of trial, ilaprazole and rabeprazole
showed no significant difference in the healing of artificial gastric ulcer. Most of
the ulcers achieved complete healing within 4 to 8 weeks.
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Introduction: ESD is the standard treatment for early gastric cancer and less
invasive procedure compared with gastrectomy. Proton pump inhibitors (PPIs)
have been widely used for the treatment of ESD-induced gastric ulcers. Many
studies have reported that it is critical issues for ESD procedure to prevent post-
operative bleeding. Vonoprazan, a potassium-competitive acid blocker (P-CAB),
has a strong and continuous inhibition of gastric acid secretion, and is expected
to improve effectively ESD-induced gastric ulcerations compared to the treat-
ment with PPIs.
Aims & Methods: To determine whether vonoprazan can ameliorate more effec-
tively ESD-induced gastric ulcerations and can reduce the incidence of post-
operative bleeding than PPIs, we compared healing rate of ulcerations and
bleeding incidence in the patients treated with vonoprazan with those treated
with PPI. 139 patients who underwent gastric ESD between January 2015 and
December 2016 were enrolled in Nippon Medical School Hospital. 11 patients
who were injected triamcinolone into mucosa preventing stricture of the prepy-
lorus were excluded. 59 patients were treated with P-CAB for 4 weeks (P-CAB
group) and 69 patients were treated with PPI (4 omeprazole, 22 esomerazole, 11
lansoprazole or 32 rabeprazole) for 4 weeks (PPI group), and subsequently
underwent endoscopy for evaluation of ulcer size and intra gastric pH using
gastric juice. The area of ulcerations was approximated by multiplying the
length (mm) by the width (mm).
Results: The shrinking rate of ESD-induced ulcer at 4 weeks after ESD were not
significantly (95.4 8.1% and 94.5 6.4%, p¼ 0.4852) different between P-CAB
and PPI groups. The post-ESD bleeding incidence (6.8%) in the P-CAB group
were not significantly (p¼ 0.8189) different from that (5.8%) in the PPI group.
The intra gastric pH at 4weeks after ESD in the P-CAB group was significantly
higher than that in the PPI group (6.9 1.0 vs 6.1 1.9, respectively, p¼ 0.0028).
Conclusion: Vonoprazan is superior to PPI in acid suppression, but there were no
significant differences in ulcer healing and bleeding incidence between the two
groups.
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Introduction: Endoscopic submucosal dissection (ESD) for superficial gastric
neoplasms is gaining an acceptance as one of curative treatment options.
However, delayed bleeding still exists as a major complication of ESD. On the
other hands, the number of patients taking antithrombotic agents are increasing
because the evidence of antithrombotic therapy for prevention of thrombotic
events has been established and population aging advances, which is thought
to be a serious problem related to increasing delayed bleeding after ESD.
Aims & Methods: To assess the influence of antithrombotic therapy on delayed
bleeding after ESD, we retrospectively investigated the delayed bleeding rate after
ESD among the continuation of antithrombotic agents, the cessation of antith-
rombotic agents and heparin bridge therapy. 735 lesions in 665 patients were
treated with ESD from January 2006 to December 2016. We compared the
delayed bleeding rate in 153 patients receiving antithrombotic therapy with 512
patients without that. Furthermore, we compared the delayed bleeding rate in the
patients continuing antithrombotic therapy with that in the patients with the
cessation of antithrombotic therapy or with heparin bridge therapy. The patients
who were taking two or more antithrombotic agents were treated with continua-
tion aspirin or cilostazol. The cessation period of antithrombotic therapy before
ESD followed the guidelines for therapeutic endoscopy in antithrombotic agents-
users from Japan Gastrointestinal Endoscopy Society. We defined delayed bleed-
ing as a hematemesis, a melena, or a decrease of Hb 42 g/dl.
Results: The delayed bleeding rate in the patients receiving antithrombotic ther-
apy was 14.4% (22/153), which was significantly higher than that in the patients
without antithrombotic therapy (5.7%: 29/512) (p¼ 0.0007). The median timing
of delayed bleeding in patients receiving antithrombotic therapy and that in
patients without antithrombotic therapy were 5.7 4.6 days and 7.0 6.8 days,
respectively, without significant difference (p¼ 0.48). Of 153 patients taking
antithrombotic therapy, 38 continued a single antithrombotic agent (all of
them were antiplatelet drugs) during ESD (continuation group), 38 discontinued
antithrombotic therapy and resumed it after ESD (cessation group), and 30
switched to heparin therapy before ESD (heparin bridge group). One patient
was excluded because of uncertain about the period of cessation. The delayed
bleeding rate of continuation group, cessation group and heparin bridge group
were 13.2% (5/38), 13.1% (11/84) and 20.0% (6/30), respectively, without sig-
nificant difference (p¼ 0.63). The delayed bleeding rate of continuation group
was equal to that of cessation group (p¼ 0.60). The delayed bleeding rate of
heparin bridge group seemed to be high (20.0%), but there was no significant
diffrence compared to that of total number of continuation and cessation group
(13.1% (16/122), p¼ 0.24). Deep vein thrombosis was observed in one patient in
the cessation group.
Conclusion: Antithrombotic therapy increased the delayed bleeding rate.
However, the delayed bleeding rate in the patients continuing antithrombotic
therapy during ESD was similar to that in the patients discontinuing antithrom-
botic therapy before ESD. Therefore, it is appropriate that the patients with high
risk of thrombosis continue antithrombotic therapy on gastric ESD, but the
heparin bridge therapy requires a further examination.
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Introduction: Endoscopic submucosal dissection (ESD) permits en bloc resection
for larger lesions. The number of the patients taking anti-thrombotic agents
including low-dose aspirin (LDA) has increased. The Japanese guidelines recom-
mended endoscopic procedures without interruption of LDA therapy in patients
at high risk of thrombotic events who use LDA alone. And, bile acid reflux is
known to cause gastric mucosal damage though the exact mechanisms are still
unclear.
Aims & Methods: In this study, we aimed to clarify whether LDA treatment and
gastric bile acid contents synergistically affect on postoperative bleeding and
healing of ulceration after gastric ESD procedure. A total 224 patients with
gastric neoplasms were treated with ESD at Nippon Medical Hospital, between
January 2013 and June 2016. To investigate whether anti-thrombotic agents
affect the ESD procedure-induced ulceration and ESD postoperative bleeding
rate, we compared ulceration reduction rate (one month after ESD), postopera-
tive bleeding rate and gastric bile acid contents among the patients treated with
low dose aspirin, other anti-thrombotic agents and non-antithrombotic agents.
On the day of ESD and one day after ESD, gastric juice was taken in endoscopy
and total bile acids were measured spectrophotometrically after the enzyme
reaction.
Results: Ulcer reduction rate in the patients treated with LDA was significantly
(p¼ 0.0036) higher compared to that in the patients with non-anti-thrombotic
agents. ESD postoperative bleeding rate in the patients with LDA was signifi-
cantly higher (p¼ 0.028 and p5 0.0001, respectively) compared to those in the
patients with other anti-thrombotic agents and the patients with non anti-throm-
botic agents. The difference of gastric bile acid contents between pre- and post-
ESD procedure in the patients with low dose aspirin was significantly
(p¼ 0.0426) higher compared to that in the patients with non anti-thromobotic
agents.
Conclusion: LDA increased gastric bile acid contents, which delayed the ulcer
healing and increased the bleeding after ESD.
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Introduction: Advanced endoscopic imaging has become an essential part of the
diagnostic algorithm for characterization of gastric lesions. NBI endoscopy with
magnification allows enhancing visualization of gastric mucosa and provides
accurate pathology prediction. European Society of Gastrointestinal
Endoscopy (ESGE) recommends the application of validated classification sys-
tems to support the use of optical diagnosis [1]. The improvement of current
classifications and development of validated criteria or scales for diagnosis by
advanced endoscopic imaging are a key areas of research for the endoscopic
community.
Aims &Methods: The aim of this study was to evaluate the diagnostic accuracy of
NBI features described in ESGE proposed NBI classification for gastric precan-
cerous and neoplastic lesions [2]. 180 gastric lesions in 97 patients (mean age 59.7
years, SD¼ 13.7, 48% male, 52% female) were observed with NBI endoscopy
and dual focus magnification (GIF- HQ190, Exera III, Olympus, Japan).
Mucosal and vascular patterns were classified into type A (regular circular muco-
sal pattern with regular vesels), type B (regular tubulo-villous mucosal pattern
with regular vesels) and type C (irregular mucosal and vascular pattern), presence
of ‘‘light blue crests" - LBC (blue-whitish areas) and demarcation line were
assessed. Forceps biopsy or endoscopic mucosal resection/endoscopic submuco-
sal dissection were performed for a histological evaluation of lesions.
Results: From 180 gastric lesions (62 lesions with chronic gastritis, 67 – intestinal
metaplasia (IM), 20 – hyperplastic polyp, 5 – low-grade dysplasia, 10 – high-
grade dysplasia, 16 – adenocarcinoma) 70 lesions had pattern A, 62 lesions –
pattern B (36 lesions were LBC positive and 26 lesions were LBC negative) and
28 lesions – C pattern (table 1). 20 lesions of hyperplastic polyps had specific
"coarse" pattern and were not classified due to the absence of appropriate cate-
gory. Demarcation line was identified in 2%, 66% and 100% of lesions with
pattern A, B, and C, respectively.
Conclusion: ESGE proposed NBI classification for gastric precancerous and
neoplastic lesions demonstrated high diagnostic accuracy in detection intestinal
metaplasia and neoplasia. Combination of pattern B, LBC and demarcation line
was found to be the most accurate criterion for intestinal metaplasia. Benign
hyperplastic polyps were characterized by specific pattern that need to be vali-
dated in further studies.
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Introduction: Esophageal endoscopic submucosal dissection (ESD) to remove
superficial esophageal neoplasms is gradually becoming the standard treatment
for superficial oesophageal cancer, but is associated with esophageal stenosis,
particularly when ESD involves the entire circumference of the luminal. Many
methods to prevent post-ESD stricture, such as repeated Endoscopic balloon
dilatation (EBD), temporary stent insertion, and oral steroid and intralesional
steroid injection, have been used in different institutions. In recent years, new
technologies such as autologous oral mucosal sheets or extracellular matrix scaf-
fold material have also been suggested to manage esophageal strictures. There are
no standard guidelines to prevent stricture in a patient with circumferential
mucosal defect after ESD. In this study, we aimed to assess the effectiveness
and safety of endoscopic transplantation of autologous esophagus mucosa in
preventing formation of strictures after ESD.
Aims & Methods: We performed a single-arm, single-institute study. Nine
patients who underwent wholly circumferential ESD for superficially extended
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esophageal squamous cell carcinoma at the endoscopic center of Xinqiao
Hospital, Third Military Medical University (Chongqing, China) from January
2015 to February 2017, were enrolled in this study. We collected specimens of
autologous esophageal mucosal tissue from these patients. After undergone ESD,
these mucosal patches were Erst attached to the ‘‘ulcer surface’’ by hemoclips and
then Exed by means of a covered metal mesh stent. The stent was removed on
post-procedure day 7. All patients were monitored by endoscopy.
Results: En bloc ESD was safely achieved in all cases. The overall longitudinal
diameter of resected specimens was 117.8mm (range, 70 to 150mm). Autologous
esophagus mucosa were successfully transplanted to ‘‘ulcer surface’’ using an
endoscope. The number of mucosal patchs ranged from 8 to 28. Complete re-
epithelialization occurred within a median time of 8.6 days with a graft survival
rate at 93.06%. Postprocedural stricture accompanied by dysphagia occurred in
seven patients on post-procedure day 24.7 (range, 18–34 days). The median ses-
sions of EBD and intralesional steroid injection was 3.3 (range 1–6). No other
serious complications occurred in these patients, such as immediate bleeding and
perforation. Eight patients were still alive during the mean follow-up period of
11.6 months (range, 2.5 to 21 months). One patient developed lung metastasis
and died of the disease 15 months after ESD.
Conclusion: Transplantation of autologous esophagus mucosa appears to be a
safe means of relieving the severity of esophageal stenoses following
Circumferential ESD.
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Introduction: Gastrointestinal perforations and post-surgical fistulas are feared
complications with high morbidity and mortality. The over-the-scope-clip
(OTSC) has been successfully used for its resolution.
Aims & Methods: We aimed to evaluate the therapeutic efficacy of OTSC in the
management of upper digestive tract post-surgical fistulas or perforations.
This was a retrospective review of consecutive patients at a single center from
January 2011 to January 2017 who underwent upper endoscopy with attempt
OTSC placement for the closure of post-surgical fistulas or perforations.
Statistical analysis: IBM SPSS 23.0.
Results: A total of 18 patients (72% women), with a mean age of 48.9 18.1
years were treated with an OTSC for the closure of post-surgical fistulas or
perforations. Mean fistulas size was 5.8 3.5mm. Median follow-up time was
20.5 (5–84) months.
Etiology of fistulas: post-surgical (n¼ 16), perforation by foreign body (n¼ 1)
and after endoscopic procedure (n¼ 1). Location of the fistulas: cardia (33%),
esophagus (28%), gastric body (16%), antrum (11%), esophagus-jejunal anasto-
mosis (6%) and duodenal bulb (6%).
Overall clinical success rate was achieved in 72.2% (n¼ 13). Fistulas were sucess-
fully closed in both non-surgical cases.
Regarding post-surgical fistulas (n¼ 16), 50% (n¼ 8) were after bariatric sur-
gery. There was a clinical success rate of 68.8% (n¼ 11). The median time
between surgery and the endoscopic intervention was 20.5 (2–550) days. There
was no association between clinical success and the time between surgery and the
endoscopic intervention (p¼ 0, 624) or the location of the fistula (p¼ 0, 334). In 1
case, endoscopic re-intervention with placement of OTSC was required due to
persistence of fistula. In 5 (31%) cases the OTSC was not effective, requiring
endoscopic re-intervention with stent placement (n¼ 2) or surgical intervention
(n¼ 3). The overall recurrence rate was 11% (n¼ 2).
Conclusion: OTSCs can be safely and effectively used in patients presenting with
post-surgical fistulas or perforations and, when feasible, may be more
advantageous and less costly than surgery. Further research is required to char-
acterize the determinants of long-term success and risk factors for failure.
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Introduction: Early neoplastic lesions in Barrett’s Esophagus (BE) can be effec-
tively and safely removed by endoscopic resection (ER) using multi-band muco-
sectomy (MBM). Recently a new MBM device became available, designed for
improved visualization, easier passage of accessories, and better suction power
compared to other marketed MBM devices.
Aims & Methods: This study aims to document performance of the new MBM
device for ER of early neoplastic lesions in BE.
This is a company sponsored, international, multicenter, single-arm, prospective
registry study enrolling 300 subjects with early neoplasia in BE. Primary endpoint
is successful ER defined as complete resection of the delineated target area in one
procedure. Secondary outcomes: adverse events, procedure time.
Results: To date 259 subjects have been enrolled at 14 centers (Europe 10, US 3,
Canada 1). Mean age was 67 9 years, with 87% males. In these 259 subjects, a
total of 301 lesions were removed using the new MBM device, with a mean of
2.5 1.92 resections per procedure. Indication for ER was high-grade dysplasia
(HGD) in 65%, early adenocarcinoma in 20%, visible lesion with low-grade
dysplasia in 10%, and a visible lesion suspicious for neoplasia without pre-treat-
ment histology in 5%. The primary endpoint of successful ER of a target lesion
Abstract No: P0803
Table 1: Results of the study
Pattern or endoscopic feature Pattern A Pattern B LBC
Pattern BþLBCþ
demarcation line Pattern C
Expected outcome Absence of intestinal
metaplasia and neoplasia
Intestinal
metaplasia
Intestinal
metaplasia
Intestinal
metaplasia
Neoplasia
Sensitivity (CI 95%) 0.94 (0.87–0.996) 0.84 (0.75–0.92) 0.54 (0.42–0.66) 0.97 (0.92–1.02) 0.87(0.75–0.99)
Specificity (CI 95%) 0.88 (0.81–0.94) 0.94 (0.89–0.99) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 0.99(0.98–1)
Accuracy (CI 95%) 0.9 (0.85–0.95) 0.89 (0.85–0.94) 0.8 (0.75–0.87) 0.99 (0.98–1.0) 0.97 (0.94–1.00)
Positive predictive value (CI 95%) 0.83 (0.74–0.92) 0.9 (0.83–0.98) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 0.96(0.94–1.00)
Negative predictive value (CI 95%) 0.96(0.91–0.998) 0.89(0.83–0.95) 0.75(0.67–0.83) 0.99 (0.98–1.00) 0.97(0.94–1.00)
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was reached in 290/301 (96%) procedures. A perforation occurred in 3/301 ER
procedures (1%, 95% CI 0.21%2.88%). Two perforations were closed with
clips, all three patients received intra-venous antibiotics and were admitted to
hospital for 2, 3 and 9 days. Bleeding requiring intraprocedural hemostasis
occurred during 15% of procedures. Significant post-procedural bleeding requir-
ing an intervention occurred in 5 cases (2%). Dysphagia requiring endoscopic
dilatation occurred in 7 patients (3%), after ER with a mean number of 4 2.9
resected pieces. Mean total procedure time for ER using the new MBM device
was 33 17.1 minutes.
Conclusion: The new MBM device used in this study proved to be effective for
resection of early neoplastic lesions in BE: successful ER was achieved in 96% of
procedures. Perforations were seen in 1% and significant post-procedural bleed-
ing in 2%, complications were effectively managed endoscopically.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Endoscopy has greatly influenced gastroenterological diagnosis.
However, most lesions can be suspected but not certainly diagnosed only on
the basis of endoscopic findings and therefore histology is needed. On the
other hand the reliability of detecting lesions histologically depends on the site,
number, and size of biopsy (Bx) specimens with a 20–30% probability of sam-
pling mistakes. Probe based Confocal Laser Endomicroscopy (p-CLE) allows
endoscopic in-vivo mucosal cellular evaluation of the gastrointestinal (GI)
tract with a high (90%) diagnostic accuracy. It allows to perform target Bx.
Moreover, the NPV is 498%. There is no information in the literature regarding
the economic impact of performing digital biopsies (DBx) by p-CLE.
Aims & Methods: The aim of this study is to perform a cost–effectiveness analysis
comparing the diagnosis of upper GI tract pathologies using only standard Bx
following the literature recommendations (LR) vs. the diagnosis with DBx using
p-CLE. This was a retrospective study with prospective collection data of
patients included from Jan 2014 to Nov 2016. The pathologies included for p-
CLE evaluation are summarized in Table 1. The diagnosis costs using standard
Bx was calculated following the literature recommendations (Table 2). The stan-
dard Bx costs included the histological process and physician honoraria per Bx
(USD 50.oo), and one biopsy forceps per patient (USD 38.oo). The DBx costs by
p-CLE included the probe, the processor and the physician honoraria (USD
500.oo). Baseline characteristics, p-CLE indications, the diagnostic accuracy of
p-CLE and costs were described.
Results: 78 patients were included, 51.2% were female. The mean age was 50.18
years old. p-CLE indications distribution was: esophagus 29 (37.2%), stomach 46
(59%) and duodenum 3 (3.8%) subgroups. Biopsies were performed in 71/78
cases (91.0). Table 1 shows the procedure cost reached with the different pathol-
ogies, by following the Bx LR for initial diagnosis and follow-up. The efficacy of
p-CLE in our study was 91.7% sensitivity, 89.8% specificity, 64.7% PPV, 98.2%
NPV and 90.1% accuracy for the diagnosis of the malignant upper GI tract
pathology, by Digital Biopsy with p-CLE. Finally, the cost-effective analysis
showed that when applying p-CLE a diminishing cost in $ 188 USD and $138
USD is detected if more than 10 biopsies are attempted by procedure.
Table 1: Cost analysis following the Literature Recommendations (LR) for
initial diagnosis and follow-up
Pathology
No. of
Bx by LR
No. of
Bx by
Updated
Sydney
System
No. of
total Bx
Total
cost of
Bxc(USD)
Esophageal Tumor a 8 – 8 438.00
Barrett’s Esophagus 1 to 3.9 cm a, b 4 – 4 238.00
Barrett’s Esophagus 4 cm a, b 8 – 8 438.00
Gastric Tumor a 8 5 13 688.00
Gastric Atrophy and/or
Metaplasia a, b
12 – 12 638.00
Gastric Ulcer a 8 5 13 688.00
Bx: biopsies; LR: Literature Recommendations. a. For initial diagnosis. b. For
follow-up. c. Cost includes histological process and physician honoraria per
biopsy (USD 50.oo), and the Bx forceps per patient (USD 38.oo).
Conclusion: In our population, the digital biopsy by p-CLE proved to be more
cost-effective, when 10 biopsies were indicated, like in cases of a Barrett’s
Esophagus 4 cm, a Gastric Tumor, or in the context of two or more suspected
pathologies (e.g.: esophageal and gastric disease).
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Introduction: Gastroparesis is a syndrome characterized by a delayed gastric
emptying in absence of a mechanic obstruction. Reduction in QOL scores have
been observed. Etiologies include: idiopathic, diabetic, post-surgical. Diagnosis is
based on the combination of symptoms and a delayed gastric emptying
scintigraphy(GES) of 410% after 240min. Multiple treatments have been
used with temporary results or high morbidity, so new treatment options have
been explored. G-POEM is a new endoscopic treatment which is based in the
POEM treatment for achalasic patients and consist in a creation of a submucosal
tunnel in order to perform an endoscopic pyloromyotomy. Initial results have
been promising.
Aims & Methods: The aim of this study was to evaluate the safety and efficacy of
G-POEM in a group of Mexican patients with refractory gastroparesis. This
prospective study was carried out in a tertiary care center in Mexico city, between
December 2016 and April 2017. We included patients with refractory gastropar-
esis defined as presence of symptoms such as: nausea, vomiting, early satiety with
inability to finish a normal meal, bloating and upper gastrointestinal pain. These
patients were on medical treatment and didńt respond and have a positive gas-
troparesis cardinal symptom index (GCSI) score combined with a 410% of
retention at 240min in the GES study. Exclusion criteria were malignancy,
peptic ulcer disease, normal GES and coagulation disorders. Procedure steps
were based in POEM procedure, beginning 5cms before the pyloric arch with
an longitudinal incision, then submucosal tunnel creation, myotomy of the pilo-
ric arch up to the serosa and 2cms before this point and finally closure with clips.
Follow-up included GCSI, endoscopy and GES at 3 months after procedure.
Characteristics of procedure, and patients were documented. Student paired t-
test was used for comparisons between groups and p5 0.05 was considered as
statistically significant.
Results: There were 9 patients included in this initial study, the mean age was
42.4 8.5years. 6 patients were female and 3 male. The most common etiology
was postsurgical 4/9 (44.4%), followed by diabetic 3/9(33.3%) and idiopathic 2/
9(22.2%). The mean G-POEM time was 61.4 7.8min, and complications were
self-limited and presented in only 4 patients. the GCSI score decreased 68%
between the pre-procedure levels as well as the GES which decresed 67% com-
pared with levels at 3 months after G-POEM (34.3 5.8 vs 13.1 3.2 p¼ 0.003/
20.74 5.3 vs 6.83 1.78 p¼ 0.001 respectively). 7/9 (77.7%) normalized the
GES(510% at 240min). Endoscopy at 3 months after procedure didńt show
any complication (Table 1).
Conclusion: G-POEM is a safe and effective procedure in Mexican patients with
refractory gastroparesis with a normalization of the GES in up to 77% of these
patients.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Foreign body (FB) ingestion including food bolus impaction is
frequently encountered in clinical practice. Few studies with large sample size
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towards endoscopic management of FBs had been reported. No direct evidence
has demonstrated the relationship between duration of FB impaction and out-
comes of endoscopic management. Moreover, it remained unclear whether endo-
scopic management of FBs under general anaesthesia could improve endoscopic
outcomes when compared with topical pharyngeal anaesthesia.
Aims & Methods: The aim of the present retrospective study is to analyze our
endoscopic outcome and explores the best timing and anaesthesia methods of
endoscopic intervention in population with FB ingestion. All consecutive patients
suspected of FB ingestion were enrolled. The demographic, clinical and endo-
scopic data were collected and analyzed.
Results: Totally, 1294 cases were recruited in this retrospective research. The ages
ranged from 7 months to 94 years, with a median age of 47.0 (31–63) years. The
majority of patients (1191/1294 cases, 92.0%) presented with some symptoms
after FB ingestion, in order of frequency odynophagia (415 cases, 32.1%), for-
eign body sensation (340 cases, 26.3%) and sore throat (267 cases, 20.1%). The
duration of FB impaction ranged from 4 hours to more than 2 years with a
median time of 1 (0.63–3) days. Bony FBs, jujube pit, food bolus and dental
prosthesis were the most frequent FBs in population. Anatomically, FBs were
mostly impacted in the oesophagus (n¼ 1025, 86.9%), especially in the upper
oesophagus (n¼ 832, 70.5%), followed by stomach (n¼ 95, 8.1%), duodenum
(n¼ 36, 3.0%) and pharynx (n¼ 24, 2.0%). Nearly half of the patients (49.9%)
developed FB-related complications, mainly including mucosal injures (356 cases,
27.5%) and ulcers (210 cases, 16.2%). The most common underlying pathologies
were oesophageal stricture (35 cases, 39.3%) and oesophageal cancer (11 cases,
15.5%). As the duration of FB impaction increased, positive finding and success-
ful removal of FB by endoscopy significantly decreased (p5 0.001).
Furthermore, complication rate significantly increased with time (p5 0.001).
Age (OR¼ 1.15, 95%CI: 1.20–1.91, p5 0.001), type and location of FBs
(OR¼ 4.51, 95%CI: 2.95–6.90, p5 0.001; OR¼ 2.26, 95%CI: 1.48–3.46,
p5 0.001), anaesthesia methods (OR¼ 1.35, 95%CI: 1.05–1.75, p¼ 0.02) and
duration of FB impaction (OR¼ 1.74, 95%CI: 1.50–2.00, p5 0.001) were ver-
ified as risk factors for development of FB-related complication by logistic
regression analysis. General anaesthesia could not improve positive FB detection
(p¼ 0.818) or success rate of endoscopic management of FBs (p¼ 0.135), as well
as decrease the complication rate when compared with topical pharyngeal anaes-
thesia (52.3% VS 47.5%, p¼ 0.033).
Conclusion: FB-related complication rate increased with time, endoscopic man-
agement under general anaesthesia could not improve therapeutic effects when
compared with topical pharyngeal anaesthesia. Overall, Patients suspected of FB
ingestion should receive endoscopic management as soon as possible.
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P0810 CLINICAL OUTCOMES AFTER ENDOSCOPIC RESECTION
FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA COMPARING
THE CASES WITH MM AND SM1 INVASION
S. Yoshimizu1, T. Yoshio2, K. Namikawa2, A. Ishiyama2, T. Tsuchida1,
J. Fujisaki2
1Cancer Institute Hospital, Tokyo/Japan
2Gatroenterology, Cancer Institute Hospital, Tokyo/Japan
Contact E-mail Address: toshiyuki.yoshio@jfcr.or.jp
Introduction: Recent advances in endoscopic resection (ER) provide us increasing
chances for resecting esophageal squamous cell carcinoma (ESCC) with muscu-
laris mucosae (MM) and SM1 invasion. As MM/SM1 invasive cancer is reported
to have 8–20% of metastatic risks and is defined as relative indication for ER in
guideline by Japan Esophageal Society. For them, we perform additional therapy
such as chemo radiotherapy (CRT) or operation considering the risk of metas-
tasis and patients’ condition.
Aims & Methods: To know the difference of metastatic risk and long time out-
comes, we retrospectively studied 121 cases of ESCC with pathological MM/SM1
invasion (MM/SM1:97/24) resected by ER from 2003 to 2013 in Cancer Institute
Hospital. After pathological diagnosis of resected lesions, we performed addi-
tional therapy such as CRT, radiation therapy (RT) or operation, to the cases
with lymphovascular invasion (LVI) or droplet infiltration (DI). Median obser-
vation period was 48 months.
Results: Enrolled cases included 112 males and 9 females and their median age
was 66 (39–86). We resected ESCC by ESD in 71 cases and by EMR-C in 50 cases
and their median size was 27mm. Local recurrence was observed in 6 cases which
were all after EMR (12%). As for local recurrence 5 cases were treated by re-
EMR and 1 case by APC, resulted in no re-recurrence. Of 97 cases of MM, 15
cases (15.5%) had LVI, 10 cases (10.3%) had DI. We recommended additional
therapy in 21 cases (21.6%). Additional therapy was performed in 15 cases
(15.5%) (ope/CRT/RT:9/5/1). No case died of ESCC and 22 cases (22.7%)
died of other diseases. Of 24 cases of SM1, 9 cases (37.5%) had LVI, 5 cases
(20.8%) had DI. We recommended additional therapy in 12 cases (50.0%).
Additional therapy was performed in 9 cases (37.5%) (ope/CRT/RT/chemother-
apy: 3/4/1/1). Three cases died of ESCC and 5 cases (20.8%) died of other
diseases. Comparing both groups, tumor size and local recurrence rate were
not different each other. The frequency of LVI was significantly higher in SM1
than in MM (p5 0.05) and the frequency of DI was higher in SM1, although not
significant (p¼ 0.161). The metastatic recurrence was observed significantly fre-
quent in SM1 than MM (16.7% vs 2.1%; p5 0.01). The 5-year overall survival
(OS)/disease specific survival (DSS)/relapse free survival (RFS) were 81.7%/
100%/94.1% for MM and 62.9%/87.9%/91.7% for SM1. OS and RFS were
not different each other, however, CSS was superior in MM than in SM1
(p5 0.01).
Conclusion: ESCC with MM invasion was superior in metastatic recurrence and
CSS than ESCC with SM1 invasion, although we treat MM/SM1 in the same
way. Additional therapy should be considered more positively in cases of SM1
than in cases of MM, considering metastatic risk and patients’ conditions.
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Introduction: ESD in generally is still under evaluation. The one-piece resection of
lesions larger then 2 cm has many advantages against piece meal resection. One
problem in ESD is to lift and prepare the specimen simultaneously. We used the
ANUBIS-system for intragastric ESD.
Aims & Methods: The experimental study was conducted in a porcine model in
general anesthesia. We started the study with 7 pigs in a survival model using the
Anubisscope (Karl Storz, Germany). After insertion of the scope insufflations of
the stomach was done using CO2. After the opening of the valves at the tip of the
scope, an area of 5 cm in diameter was selected for resection. Injection was done
through the working channel with a hyperosmolaric solution added with blue
colour. After circle incision, preparation was done with the two arms of the scope
using a grasper and a hook-knife. Also the grasper could use for coagulation. The
specimen was removed with the scope after closing its valves.
Results: The procedure was successful in all animals with operation time ranging
from 102 to 189 minutes with a learning curve. After weight gain in all cases, the
animals were sacrificed after postoperative day 42 and the workup showed com-
petent healing with a star-like scar.
Conclusion: The use of an operating platform like the Anubisscope has the
advantage of flexible preparation in opposite position of the instruments in
ESD. The disadvantages are the only two degrees of freedom of the flexible
instruments and the rotation-like movements. Also, it is not possible to reach
all regions of the stomach.
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MAGNIFYING ENDOSCOPY AS A SCREENING TEST FOR GASTRIC
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Abstract No: P0808
Table 1: Characteristics of procedure and patients before and 3 months after G-POEM
Patient
Age/
Gender
GCSI pre
(score)
GES pre
(%)
G-POEM
time (min)
Adverse
events
GCSI at
3m (score)
GES
at 3m (%)
1 25/F 37 25.4 61 Mild Abdominal pain 16 8.5
2 57/F 41 25.4 65 None 25 9
3 45/F 31 22.4 60 None 15 5
4 73/F 36 16.7 97 Mild abdominal pain 12 3
5 42/M 25 20.9 55 None 10 5
6 45/M 35 22.4 45 None 14 11
7 28/M 29 26.4 55 None 5 12
8 37/F 35 12.5 60 Mild abdominal pain 10 4
9 30/F 40 15.5 55 Mild Abdominal pain 11 4
Total 42.4 8.5 6F 3M 34.3 5.8 20.74 5.3 61.4 7.8 5 None 4 Mild abdominal pain 13.1 3.2 6.83 1.78
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Introduction: Narrow band imaging with magnifying endoscopy (NBI-ME) is
useful for diagnosis of gastric cancer; however, whether NBI-ME is useful as a
screening test for gastric cancers has not yet been determined. Additionally, it is
important to consider the impact on the atrophy of the background gastric
mucosa in gastric cancer screening because the incidence of gastric cancer
depends largely on the degree of atrophy noted in the background gastric
mucosa.
Aims & Methods: We aimed to determine the usefulness of NBI-ME as a screen-
ing tool for gastric cancer. We retrospectively studied 3515 patients who had
undergone screening upper gastrointestinal endoscopy between April 2013 and
March 2014. We excluded patients with advanced gastric cancer and those who
had undergone gastrectomy. Thus, we studied 1080 patients who received NBI-
ME and 2435 patients who had undergone conventional endoscopy. We classi-
fied the degree of atrophy of the background gastric mucosa using the Kimura-
Takemoto classification. Severe atrophy was noted in 1620 patients (Group S),
and mild atrophy in 1895 patients (Group M). We evaluated the biopsy rate, the
detection rate of gastric neoplasms, and the accuracy of biopsy using NBI-ME
compared to conventional endoscopy.
Results: The biopsy rate of NBI-ME and conventional endoscopy in Group M
was 5.4 and 7.7%, respectively, while in Group S it was 14.9 and 14.8%, respec-
tively. The biopsy rate did not differ significantly between those who received
NBI-ME and those who had undergone conventional endoscopy. The detection
rate of gastric neoplasms using NBI-ME and conventional endoscopy in Group
M was 0 and 0.2%, respectively, while in Group S it was noted to be 4.2 and
1.8%, respectively. Thus, the detection rate of NBI-ME was significantly higher
than that of conventional endoscopy in Group S (p5 0.01). The accuracy of
biopsy with NBI-ME and conventional endoscopy in Group M was 0 and 3.2%,
respectively, but in Group S was noted to be 36.4 and 14.1%, respectively. Thus,
the accuracy of biopsy using NBI-ME is significantly superior to conventional
endoscopy in Group S (p5 0.01).
Conclusion: NBI-ME as a screening test for gastric cancer is useful for patients
with severe atrophy of the background gastric mucosa because this technique has
shown a higher detection rate of gastric neoplasms and better accuracy of biopsy.
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Introduction: ME-NBI is an important modality to diagnose early gastric cancer.
A unified diagnostic system, the magnifying endoscopy simple diagnostic algo-
rithm for early gastric cancer (MESDA-G), was proposed in 2016 by Muto et al.
[1] and was thought to become a future mainstream system. Although the useful-
ness of ME-NBI has been often reported [2, 3], some cases are difficult to diagnose
with ME-NBI.
Aims & Methods: We aimed to clarify endoscopic and histological features of
difficult-to-diagnose cases using MESDA-G. We retrospectively analyzed 362
cases of early gastric cancer that underwent endoscopic resection at our hospital
from January 2013 to December 2016. Lesions for which ME-NBI images were
not taken at maximum magnification or difficult to evaluate because of mucus or
erosions were excluded. After exclusion, a total of 350 lesions were enrolled in
this study. Two expert endoscopists reviewed ME-NBI images of all lesions.
Lesions diagnosed as non-cancer by both experts were defined as ME-NBI incor-
rect diagnosis lesions (ME-NBI-IDL). ME-NBI and histopathological findings of
ME-NBI-IDL were analyzed. ME-NBI findings were defined according to the
presence (þ) or absence (-) of a demarcation line (DL) and regular (R), irregular
(I) or absent (A) of micro vascular (MV) and micro surface (MS) patterns.
Results: Of 350 lesions, 32 (9.1%) were ME-NBI-IDL. Macroscopic types were I/
IIa/IIaþ IIc/IIb/IIc¼ 3/13/2/7/7, respectively. Twenty-seven of ME-NBI-IDL
showed DL (-). Five of ME-NBI-IDL showed R or A of MS/MV patterns,
despite of DL (þ). The details were as follows; In the DL (-) group, MV/MS
were R/R:25, I/R:1, and R/A:1. In the DL (þ) group, MV/MS were R/R:4 and
A/R:1. Histological types of ME-NBI-IDL were gastric adenocarcinoma of
fundic gland type (GAFG)/well-differentiated carcinoma (well)/well-to-moder-
ately differentiated carcinoma (well to mod)/papillary carcinoma (pap)/signet
ring cell carcinoma (sig)¼ 20/4/1/1/6, respectively. Diagnostic difficulties were
caused by two histological findings: 1) low-grade atypia type; surface structure
of cancerous lesion was similar to surrounding mucosa due to very low-grade
atypia (well/well to mod/pap¼ 4/1/1, respectively.), 2) covered type; cancer was
unexposed to the superficial mucosal layer (GAFG/sig¼ 20/6, respectively).
Conclusion: Diagnostic limitations of ME-NBI (MESDA-G) were dependent on
distinct histological characteristics. However, we suggest that the low-grade
atypia type might be able to diagnose correctly by improving diagnostic accuracy
of ME-NBI.
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Introduction: Levodopa is the gold standard in pharmacological treatment of the
advanced Parkinson’s disease (APD) and its oral administration in advanced
disease is associated with development of symptoms and motor and non-motor
complications. Due to its short plasma half-life, Levodopa requires repeated
dosing (1, 2). Impaired gastric emptying is common in APD and reduces the
absorption of Levodopa, requiring progressively higher doses and more frequent
administrations. Continuous duodenal administration of modulated Levodopa/
Carbidopa gel by Jejunal Extension Tube Placement through Percutaneous
Endoscopic Gastrostomy (PEG-J), is a new therapeutic protocol in advanced
APD (3).
Aims & Methods: Aim of this work is to verify efficacy and safety of intestinal gel
(LCIG) delivered continuously through an Intrajejunal percutaneous tube (PEG-
J).24 adult (14 M, 10 F, median age 71 years) with APD and preserved sensitivity
to L-Dopa were enrolled. 7 days before PEG-J placement, to evaluate the pos-
sible presence of mucosal or anatomical gastric anomalies, each patient under-
went a diagnostic esophagogastroduodenoscopy (EGD). Treatment with LCIG
consists in a water-based suspension containing micronized levodopa (20mg/mL)
and carbidopa (5mg/mL) in methylcellulose, administered by continuous jejunal
infusion for 12 h/day using a portable pump by PEG-J. Clinical evalutations were
performed at baseline(T0), before LCIG initiation, and after 3 (T3) and 6 (T6)
months of therapy. To evaluate efficacy and safety outcomes it has been used
Unified Parkinson’s Disease Rating Scale (UPDRS) parts II, III and IV. For the
analysis of the differences between the clinical variables and to exclude biases due
to the small number of the sample in question, the non-parametric Kruskal-
Wallis H test was used for the comparison of three samples. A statistically sig-
nificant value of p was less than 0.05. The analyzes were carried out using SPSS
version 13 (SPSS Inc., Chicago, IL, USA).
Results: 1) Success rate for PEG-J placement was 100%; 2) Eight/24 patients
(33%) dropped-out LCIG at T3; 3) Sixteen/16 patients (100%) showed statisti-
cally significant (p 0.05) higher performances in daily common activities and
statistically significant (p 0.05) lower incidence and severity of motor fluctua-
tions, as assessed by UPDRS part IV, compared to their best oral therapy;
4)During observational period, 6 patients experienced adverse events.
Conclusion: 1) This study demonstrates that continuous intrajejunal LCIG’s infu-
sion treatment is highly effective in decreasing motor fluctuations in advanced
PD patients compared to oral administration of levodopa-carbidopa; 2) This
therapeutic approach should be proposed in well selected APD patients with
preserved sensitivity to L-dopa.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
1. Lee A, Gilbert RM. Epidemiology of Parkinson Disease, Neurol Clin 2016
Nov; 34(4):955–65
2. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a
review. JAMA 2014; 311(16):1670–83
3. Zulli C, Sica M, De MiccoR, Del Prete A, Amato MR, Tessitore A, Ferraro
F, Esposito P. Continuous intra jejunal infusion of levodopa-carbidopa
intestinal gel by jejunal extension tube placement through percutaneous
endoscopic gastrostomy for patients with advanced Parkinson’s disease: a
preliminary study. Eur Med Pharmacol Sci 2016; 20(11):2413–17
P0815 PREDICTIVE RISK MODEL FOR POST-ENDOSCOPIC
SUBMUCOSAL DISSECTION ULCER BLEEDING OF STOMACH
Y.H. Choe1, S.K. Shin2, E.H. Kim1, Y.C. Lee1, S.K. Lee1, J. Park3
1Gastroenterology, Severance Hospital, Yonsei University College of Medicine,
Seoul/Korea, Republic of
2Dept. Of Gastroenterology, Yonsei University College of Medicine Dept. of
Internal Medicine, Seoul/Korea, Republic of
3Dept. Of Internal Medicine, Yonsei University, Seoul/Korea, Republic of
Contact E-mail Address: last_message@yuhs.ac
Introduction: Post-endoscopic submucosal dissection (ESD) bleeding is the most
common complication of ESD. In previous studies, the post-ESD bleeding
occurred from 1.8% to 15.6% of total procedures [1–4]. Recently, many patients
who underwent ESD, have been prescribed antiplatelets or anticoagulants,
because of various underlying diseases such as cerebrovascular accidents or
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cardiovascular diseases [5]. Thus, the verified risk prediction model of post-ESD
bleeding may enable to determine preventive therapeutic options and restarting
date of antiplatelet agents.
Aims & Methods: The aim of this study is to develop the predictive risk model of
post-ESD bleeding. A total of 5374 patients, who were taken ESD from January
2007 to November 2016, in a Korean tertiary hospital, were included in this
retrospective study. To avoid overfitting of the prediction model, we divided
the patients randomly into two groups, either a derivation group or a validation
group. Preoperative and procedural-related variables were selected via univariate
and multivariate analysis. A risk score was calculated to assess the bleeding
prediction model of a patient in the derivation group and was discriminated in
the validation group.
Results: Post-ESD bleeding occurred in 248 patients (4.84%). In the derivation
group, multivariate logistic regression revealed renal diseases (odds ratio [OR],
3.90; 95% confidence interval [CI], 1.48–9.09; P¼ 0.0029), anti-platelet agent
(OR, 3.07; 95% CI, 1.44–6.05; P¼ 0.002), and en-bloc resection (OR, 3.83;
95% CI, 1.34–9.34; P¼ 0.0059) as significant risk factors (C-statistic¼ 0.607;
95% CI, 0.552–0.661). In the validation set, the model also showed good dis-
crimination power (C-statistic¼ 0.580; 95% CI, 0.533–0.627). Based on the scor-
ing system of odds ratio, bleeding risk was 4.1% in the low risk set (score 4),
7.0% in the high risk set (score4 4, P¼ 0.003) (validation set).
Conclusion: Our study investigated a prediction scoring system of estimating the
bleeding risk, including the patient, endoscopist factors. A risk score can be
calculated before the procedure and the endoscopists can predict bleeding
potency before the gastric ESD. Based on the scoring system, endoscopists
may alter therapeutic plans such as prolongation of admission dates or medica-
tion schedules.
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Introduction: Endoscopic submucosal dissection (ESD) remains difficult proce-
dure due to bleeding and perforation. One of the reasons that these complications
are occurred is unclear visibility of submucosal layer. Dual red imaging (DRI) is
a novel endoscopic image enhanced technology that is focus on slightly deeper
layer by using narrow long wavelength light than white light imaging(WLI).
Therefore, DRI improves the visibility of vessels and demarcation line between
the submucosal and muscle layers for colorectal ESD1. The aim of this study is to
estimate efficacy of DRI for esophageal and gastric ESD.
Aims & Methods: A retrospective analysis was performed on patients who under-
went ESD for esophageal or gastric cancer in our institution. ESD was performed
by circumferential incision using WLI at first. Submucosal dissection was per-
formed using DRI in principle, and Ulcer bed was observed with DRI after
resection. Total resection time (from precut to complete resection), perforation
rate, and hemostasis rate after procedure were recorded. These parameters were
compared with our matched previous procedures using propensity score (1: 2).
We recorded paired endoscopic images using DRI and WLI at the same point
during the dissection, then estimated the visibility of vessels and submucosa by
those images using visual analog scale (0–100) by 5 endoscopists. We compared
the visibility of DRI with WLI followed by the estimation.
Results: Twenty lesions (esophagus: 3, stomach: 17) of 18 patients were enrolled
for this study. Total resection time was 67.0 27.9min, and was shorter than
matched data (141.7 113.5min) significantly (p¼ 0.0054)). Hemostasis rate
after resection and perforation rate were not different significantly. The score
of vessels visibility using DRI and WLI were 68.6 17.5 and 62.3 19.6, respec-
tively. The score of submucosal visibility using DRI and WLI were 70.0 18.0
and 64.9 19.0, respectively. DRI was superior to WLI in both scores signifi-
cantly (p5 0.0001).
Conclusion: Though our study is preliminary, DRI improves total resection time,
visibility of vessels and demarcation line between the submucosal and muscle
layers significantly as previous study showed on colorectal ESD. DRI uses
narrow long wavelength light. The light reaches slightly deeper layer than
WLI. Therefore, we can see not only clear vessels but intact submucosa with
DRI, through submucosal surface is dirty and unclear by blood, fat, and fibrosis.
We named this effect "noise cancelling effect" by DRI. This effect gets better the
visibility better, therefore the esophageal and gastric ESD makes easier and safer.
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Introduction: Endoscopic diagnosis of early gastric cancer (EGC) is essential for
ESD, which is a standard treatment for EGC. Magnifying endoscopy with blue
laser imaging was useful for diagnosis of EGC prior to ESD [1]. A novel endo-
scopic system powered by unique four kinds of LED light sources sets a white-
light imaging, blue light imaging and linked color imaging.
Aims & Methods: We prospectively evaluated whether blue light imaging with
magnifying endoscopy (LED-BLI-ME) could be as efficient for diagnosis of
EGC as blue laser imaging with magnifying endoscopy (BLI-ME). 43 patients
with 45 tumorous lesions including 28 well-differentiated adenocarcinomas, two
moderately differentiated adenocarcinoma, six poorly differentiated, and five
adenomas that were diagnosed by biopsy specimens were enrolled in this study
between Deccember 2016 and May 2017. The patients with EGC underwent
LED-BLI-ME observation, following BLI-ME observation in the same day.
At first, an endoscopist evaluated a demarcation line and micromorphology in
the part of EGC using LED-BLI-ME according to vessel and surface classifica-
tion system. Then, the same endoscopist evaluated adenmarcation line in the
same part of EGC using BLI-ME. All of the EGCs were immidiately resected
by ESD after the observation of two modalities. All of the EGCs could be
evaluated one-to-one correspondence between the endoscopic image and patho-
logical finding in detail. Primary end point was to analyze the diagnostic accu-
racy of LED-BLI-ME for EGC. Secondary end point was to compared the
diagnostic accuracy and between LED-BLI-ME and BLI-ME. Our study was
approved by the Ethical Review Committee of Kyoto Prefectural University of
Medicine, and performed in accordance with the World Medical Association’s
Declaration of Helsinki. In addition, this study has been registered in the
University Hospital Medical Information Network Clinical Trials Registry
(UMIN-CTR; http://www.umin.ac.jp/ctr/) as trial UMIN 000025275.
Results: The clinicopathological features in the patients were as follows; mean age
was 71.9 8.74, gender (male:female) was 31:14, location(U:M:L) was 9:15:21,
macroscopic type (elevated: flat: depressed) was 18:1:26, median tumor size was
18.1 0.298mm, and final pathological diagnosis (well-differentiated adenocar-
cinoma: moderately differentiated adenocarcinoma: poorly adenocarcinoma)
was 37:1:7, respectively. Diagnostic accuracy of demarcation line of EGC
using LED-BLI-ME and BLI-ME were 91.1% (41/45) and 91.1% (41/45),
respectively. The rate of high confidence for diagnosis of a demarcation line of
EGC using LED-BLI-ME and BLI-ME were 84.4% (38/45) and 91.1% (41/45),
respectively. There was no significant difference of diagnostic accuracy between
two modalities. The consistency rate in the demarcation line, microvascular pat-
tern, and microsurface pattern of EGC between LED-BLI-ME and BLI-ME was
80.0% (41/45), 97.8% (44/45), and 97.8% (44/45), respectively.
Conclusion: LED-BLI-ME were demonstrated the high diagnositc performance
for diagnosis of EGC demarcation, similar to BLI-ME.
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Introduction: Foreign bodies (FBs) ingestion is a common medical emergency
accounting for 4% of all emergency endoscopies, secondary only to the GI
bleeding.[1] 70 75% of FBs are located in the esophagus[2]. The need of endo-
scopic management reached up to 63 76%[3–5] with 3% 20% of incidence of
complications[6]. According to the latest guidelines from ESGE, emergent endo-
scopy is recommended for the impaction of sharp-pointed objects within 24
hours[5]. However, there were still different opinions on the endoscopic methods
with different FBs.
Aims & Methods: The study was performed from October 2015 to August 2016
among 595 patients with clinical suspicion of foreign body ingestion from 18
general hospitals in China. The patient data including age, gender, clinical fea-
tures, and data about endoscopic management including types and locations of
foreign bodies, retrieval devices, outcomes and complications were collected and
analyzed.
Results: 1) The most common types of foreign bodies were fish bones (34.0%),
chicken bones (22.1%), fruit nucleus (17.1%) and food bolus (14.6%). The
majority of them were short objects (52.5 cm, 74.0%), subsequently followed
by middle objects (2.5 6.0 cm, 24.5%) and long objects (46 cm, 1.5%). Most
objects were lodged in the proximal esophagus (75.9%), followed by the middle
segment (15.2%) and the distal segment (8.9%) of esophagus. 2) 96.3% of all
cases had obvious clinical symptoms. Clinical symptoms occurred more often in
the proximal segment of the esophagus (98.1%) than any other segments of the
upper gastrointestinal tract (92.6%) (P5 0.001). 3) The successful removal rate
through endoscopy was 94.5%. It was even higher with general anesthesia
(99.3%) than without it (92.7%) (P5 0.01). 4) Complication rate was as high
as 34.0%, which was increased with long retention time and sharp objects
(P5 0.001). The rate was increased by 2.2- and 6.1- folds after impacted for
over 24 hours or 48 hours as compared to 12 hours. Logistic regression
analysis indicated that sharp objects had obviously more complications than
non-sharp ones (OR 3.36, 95% CI: 1.97–5.74). In particular, the incidence of
perforation was 5.6%, which was strongly related with long retention time and
sharp objects (P5 0.01), but not with locations or lengths of the objects
(P4 0.05).
Conclusion: General anesthesia could largely improve the retrieval rate through
endoscopy. Foreign bodies, especially sharp ones, should be removed as soon as
possible within 24 hours, to further decrease severe complications.
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Introduction: GA and IM are detectable precursor lesions of most gastric carci-
nomas. Early endoscopy examination may potentially result in early detection
and treatment of advanced precursor lesions and cancer. The annual incidence of
GC is quite low in central Europe, for GAwas 0.1% and for IM was 0.25% [1–2].
The histological assessment and biopsy sampling protocol has been standardized
in the updated Sydney system and the recommended five gastric biopsies were
widely applied in the staging system for gastric cancer risk stratification [3]. Some
believe that the GA risk screening requires consideration of the cost , suffering of
patients as well as rational utilization of medical resources, so adopt five biopsy
may be presumably less appropriate in large-scare population gastric cancer risk
screening. In this study, we evaluated the OLGA and OLGIM staging in a
standardized five biopsy protocol through screening patients underwent endo-
scopy with abdominal pain and discomfort. In order to identify a more optimal
biopsy strategy with quite high consistence with the standardized five biopsy
protocol in OLGA and OLGIM staging and less number of biopsies during
cancer risk assessment, we re-evaluated OLGA and OLGIM staging adopting
different biopsy combinations (evaluated the appropriate biopsy locations and
number of biopsies).
Aims & Methods: Gastric atrophy (GA) and intestinal metaplastic (IM) are pre-
cursor lesions of gastric cancer (GC), the extent and severity of which was inti-
mate correlated with the occurrence of GC. Operative Linkon Gastritis
Assessment (OLGA) and Operative Linkon Gastric Intestinal Metaplasia
Assessment (OLGIM) with five biopsy samples are superordinate stages system
during Gastric risk stratification. We analysis the degree of GA and IM in these
five locations and screen out an more representative, simple and convenient
biopsy samples composition for gastric risk screening.
Methods: 368 patients with abdominal pain and other discomfort undergoing
endoscopy were enrolled in the study. Five biopsy pieces (two from antrum,
namely lesser and larger curvature, two from corpus, larger and lesser curvature
and one from incisura angularis) were acquired and graded by senior gastroin-
testinal pathologists according to the updated Sydney system. Gastric risk stra-
tification was calculated by adopting OLGA and OLGIM staging system.
Results: GA and IM are more frequently acquired in the incisura angularis
mucosa than the both lesser and larger curve of antrum and corpus respectively
(P50.05), especially the moderate and severe degree. More GA and IM alterna-
tions happened in the lesser curve of the antrum and corpus than in the corpus
(P50.05). The composition three biopsy pieces (lesser curvature of the antrum
and corpus, angulus biopsy) with quite accurate consistence with five biopsy
pieces protocol using OLGA and OLGIM staging (94.0% and 92.9%), together
with a rather low omission diagnostic rate of OLGA and OLGIM IIIþ IV (3.8%
and 7.2%)
Conclusion: The incisura angularis with more moderate and severe GA and IM
should be recommended as conventional biopsy site during endoscopy. The three
biopsy pieces (lesser curvature of the antrum and corpus, angulus biopsy) with
quite high consistence, more convenience and less cost comparing with five
biopsy pieces protocol using OLGA and OLGIM staging system, and thus
could be recommend in the further gastric risk screening applying OLGA and
OLGIM staging.
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Introduction: LCI is a novel color enhancement feature available for LASEREO
endoscopy systems (FUJIFILM CO., Tokyo, Japan), which can enhance the
slight color difference on gastrointestinal mucosa. Recently we reported that
color enhancement of the diffuse redness by LCI was useful for the diagnosis
of H. pylori infection. Therefore, we expected that LCI facilitate the endoscopic
recognition of early gastric cancer and gastric adenoma by enhancing its color
difference between normal and atypical mucosa.
Aims & Methods: The aim of this study was to evaluate the usefulness of LCI for
recognition of early gastric cancer and gastric adenoma compared to conven-
tional white light imaging (WLI), WLI with Indigo Carmine contrast staining
(IC) and Blue Laser Imaging-bright (BLI-brt) imaging. We retrospectively ana-
lyzed 39 lesions in 33 patients who had endoscopic submucosal dissection (ESD)
at Murakami Memorial Hospital from June 2014 to May 2016. All lesions were
scanned with four imaging mode, WLI, IC, BLI-brt and LCI (LASEREO with
EG-L590ZW scope), and assigned a recognition score from 3 (excellent visibility)
to 0 (poor visibility) by three endoscopists.
Results: The overall mean recognition score of LCI was significantly higher than
that of WLI/IC/BLI-brt (2.18 0.073 vs. 1.56 0.080/1.86 0.099/1.91 0.073).
For type 0-IIa lesions (18 lesions), the mean recognition score of LCI was sig-
nificantly higher than WLI and BLI-brt (2.26 0.12 vs. 1.83 0.12/2.14 0.097),
whereas no significant difference was seen between LCI and IC (2.26 0.12 vs.
2.35 0.12). For type 0-IIb or 0-IIc lesions (21 lesions), the mean recognition
score of LCI was significantly higher than WLI/IC/BLI-brt (2.11 0.11 vs.
1.33 0.10/1.44 0.13/1.73 0.10). And the mean recognition score of BLI-brt
was also significantly higher than WLI/IC, but no significant difference was seen
between WLI and IC. Regarding WLI, IC, and BLI-brt, the mean recognition
score of type 0-IIa lesions in each mode was significantly higher than that of type
0-IIb or 0-IIc lesions. However, regarding LCI, there was no significant differ-
ence in the mean recognition score between type 0-IIa lesions and type 0-IIb or 0-
IIc lesions. These results indicated that the detection of type 0-IIb or 0-IIc lesion
was difficult compared to 0-IIa in WLI, IC and BLI-brt mode. However, LCI
mode enable us to detect these type 0-IIb or 0-IIc lesion as easily as type 0-IIa.
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Conclusion: LCI mode was useful for recognition of early gastric cancer and
gastric adenoma, especially for type 0-IIc and 0-IIb lesions that are frequently
found in post- H. pylori eradication gastric mucosa.
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Introduction: In gastrointestinal stromal tumors (GISTs) without a risk of metas-
tasis to other organs, local resection is acceptable. In small GISTs, however, it is
controversial whether surgical resection is necessary because a risk of recurrence/
metastasis in these tumors are considered to be quite low. Laparoscopic endo-
scopic cooperative surgery (LECS) is a promising surgical technique as one of
minimally-invasive, function-preserving surgeries. By using this technique, we are
aggressively resecting gastric SMTs including relatively small ones.
Aims & Methods: To investigate necessity of surgical resection for small GISTs,
we retrospectively assessed a malignant potential of these tumors which were
resected nonexposed endoscopic wall-inversion surgery (NEWS) (nonexposure
LECS technique) as well as feasibility and safety of this technique. Between
August 2013 and October 2016, NEWS was conducted in 33 consecutive
SMTs which met all of following conditions: possible GIST which was preopera-
tively diagnosed by histology or imaging modalities, less than 3 cm in size and
intraluminally-/intramurally-growing type. In the NEWS procedure, a lesion was
resected in a following manner: endoscopic mucosal markings, laparoscopic ser-
osal markings just behind the mucosal markings, endoscopic submucosal injec-
tion, laparoscopic sero-muscular incision and suturing with the lesion inverted
toward the inside of the stomach, endoscopic muco-submucosal incision and
peroral retrieval. Short-term outcomes of NEWS and a potential risk of recur-
rence/metastasis in each tumor according the Fletcher’s classification were
assessed.
Results: Mean age and size of the lesion were 59.9 13.7 years-old and
23.3 8.4mm, respectively. The procedure was successfully completed in all
cases in a mean procedure duration of 206 43min. The patients were dis-
charged without severe adverse events 7.3 1.5 days after the procedure. The
first endoscopy after the procedure was performed 5.8 months after discharge in
22 cases, which showed no residual food in the remnant stomach in all cases.
Neither apparent impairment of food intake nor disease-related death occurred
and a body weight loss was 0.9 2.3 kg during the mean observational period of
16 months. GIST was histologically diagnosed in 20 cases. A risk of recurrence/
metastasis in these GISTs was classified into high (2), intermediate (1), low (12)
and very-low (5), respectively. In a comparison of two groups (high/intermediate
and low/very-low), a mean tumor size and existence of delle formation were
31.7mm and 21.6mm (p¼ 0.036), and 67% and 12% (p¼ 0.028), respectively.
Conclusion: Some small GISTs which could be retrieved transorally had a high
malignant potential. NEWS was feasible, safe and therefore recommended for
these tumors including ulcerated GISTs as a minimally-invasive surgical option
to avoid an additional surgical scar for the retrieval of the specimen and a risk of
iatrogenic tumor cell seeding into the peritoneum during the procedure.
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Introduction: Achalasia is a rare esophageal motor disorder characterized by
esophageal aperistalsis and incomplete relaxation of lower esophageal sphincter
(LES). The Elderly patients have longer courses of disease, less perception of
symptoms and similar manometric findings compared with younger patients.
Peroral endoscopic myotomy (POEM) is a novel endoscopic therapy which
recently has been described as an incisionless and less invasive scarless myotomy
alternative for treating achalasia. However, very few studies concentrated on the
long-term outcomes of POEM for achalasia patients, especially for elderly
patients.
Aims & Methods: Peroral endoscopic myotomy (POEM) is a minimally invasive
endoscopic myotomy for achalasia. But the long-term outcomes of POEM for
achalasia in elderly patients are unclear. We therefore aim to evaluate the efficacy
and safety of POEM for achalasia in patients older than 70 years. A total of 33
consecutive patients aged 70 years were enrolled in this study, who had under-
gone POEM for achalasia from May 2011 to March 2016 in the Endoscopy
Center of Zhongshan Hospital. We retrospectively assessed the short and long
term outcomes of these patients including Eckardt score, lower esophageal
sphincter pressure, adverse events and recurrence.
Results: All patients underwent POEM successfully. Mean procedure time was
50.7 22.0min and postoperative hospital stay was 2.8 1.5 days. No severe
complications related to POEM were encountered. During a mean follow-up
period of 40.5 19.1 months (range from 12.2 to 70.9 months), the therapeutic
success rate was 90.9% (30/33). Mean Eckardt score was 7.6 2.0 and 1.4 1.3
before and after POEM, respectively (P5 0.001). Mean LES pressure decreased
from a mean of 20.3 5.8mmHg to 3.9 2.9mmHg after POEM (P5 0.001).
Clinical gastroesophageal reflux occurred in 11 cases (33.3%) after the procedure
which was successfully resolved by proton pump inhibitors.
Conclusion: POEM can be a safe and effective treatment option for achalasia in
elderly patients older than 70 years with significant improvement in symptoms.
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Introduction: POEM has become a standard treatment of achalasia based on its
excellent efficacy and safety. However, unlike in laparoscopic myotomy, POEM
is not accompanied by an antireflux procedure and thus the rates of both clini-
cally relevant post-POEM reflux (measured by symptoms and/or 24 h pH mon-
itoring) and post-POEM esophagitis are key questions of long-term POEM
safety. Several studies have reported the rates of post-POEM reflux and post-
POEM esophagitis being as high as 30–40%. The aim of this retrospective ana-
lysis was to analyze whether esophageal erosions, detected endoscopically early
after POEM, represent real reflux esophagitis or rather signs of still ongoing
healing process after POEM.
Aims & Methods: A single-center retrospective analysis of 192 patients who
underwent POEM in our institution. Three months after POEM, 162 patients
underwent both pH monitoring and endoscopy and treatment with PPIs was
assessed. At 24–36 months, a control endoscopy was performed in 41 patients
to screen for esophagitis. We reviewed all available video recordings of POEM
procedures and subsequent control endoscopies to analyze whether the localiza-
tion of erosions was limited to the site of submucosal tunneling (e.g. between 2–4
óclock in patients after anterior POEM) or also outside this area (real reflux
esophagitis). We also analyzed evolution of esophagitis in time and correlated it
with pH monitoring and intake of PPIs.
Results: At 3 months, esophagitis was present in 64 out of 162 patients (39.6%).
Of those, 21 (33%) were on PPIs by the time of endoscopy and 43 (67%) were
not. Among 43 patients with esophagitis and available video recording, 29
(67.4%) had erosion(s) only on the site of submucosal tunnel and 14 (32.6%)
had erosions also elsewhere. Among patients with erosion(s) only on site of the
tunnel, 13 (44.8%) had normal acid exposure time (assessed by pH monitoring
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performed off PPIs). At 24–36 months, esophagitis was present in 9 out of 41
examined patients (21.9%), p¼ 0.04 vs. 3 months. In 6 out of 10 patients with
esophagitis present at 3 months, who underwent control endoscopy at 24–36
months, esophagitis resolved completely even though only 2 patients had been
treated by a PPI.
Conclusion: After POEM, the majority of patients with esophagitis had erosions
on site of submucosal tunnel and early esophagitis often occurred in patients
without an abnormal acid exposure. These findings suggest that an ongoing
healing process after POEM might interfere in findings of presumed post-
POEM reflux esophagitis. Thus, the rate of real post-POEM reflux esophagitis
may be lower than previously thought.
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Introduction: Endoscopic submucosal dissection (ESD) has been widely used for
resection of gastrointestinal neoplastic lesions, but there are still technical chal-
lenges in treating large ones especially located in lesser gastric curvature. In the
tunnel technique, incisions at the lower and upper lesion edges are joined by a
submucosal tunnel and then lateral incisions are made. The mucosa is thereby
easily separated from the muscular layer. We report our experience of endoscopic
submucosal tunnel dissection (ESTD) in lesser gastric curvature.
Aims & Methods: To estimate the safety and efficiency of endoscopic submucosal
tunnel dissection (ESTD) for lesser curvature superficial neoplasms.47 patients
with lesser curvature superficial neoplasms undergoing endoscopic resection were
analyzed retrospectively. 26 patients underwent ESTD and 21 received endo-
scopic submucosal dissection (ESD). Operation time, security, En bloc resection
rate and complications were compared between the two groups. The major dif-
ference between ESTD and ESD is that, instead of pre-cutting circumferential
mucosal, a submucosal tunnel was created by submucosal dissection from the
oral incision to the anal incision. Bilateral resection was then performed to
remove the lesion completely.
Results: The differences between the two groups in the age of the patients and the
diameter of the lesions had no statistically significant (P4 0.05). En bloc resec-
tion rate was 100% in the study group and 90.5% in the control group (19/21),
and the difference was statistically significant (P5 0.05). The average operation
time was 46 minutes (36 59 minutes), the control group was 67 minutes
(48 110 minutes), the difference was statistically significant (P5 0.05). The
intraoperative bleeding rate of the study group was 57.7% (15/26), the control
group was 100%, the difference was statistically significant (P5 0.05). The inci-
dence of perforation was 0% in the study group and 9.5% in the control group
(2/21), and the difference was statistically significant (P5 0.05). There was 1 case
of delayed bleeding after operation in the two groups, there were no postopera-
tive perforation, and the difference was not statistically significant (P4 0.05).
There were no recurrence and metastasis in the two groups after the operation.
Conclusion: ESTD for lesser curvature superficial neoplasms can obviously
shorten the operation time and have a higher security, compared with the tradi-
tional ESD operation.
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Introduction: Propofol is recommended for sedation in gastrointestinal endo-
scopy (GE) [1], but preliminary data suggests addictive potentials in animal
models [2, 3] and healthy volunteers [4]. There is an increasing number of reports
of propofol addiction in physicians and nurses associated with high mortality up
to 30% within the first year of abuse [5–7]. Some patients and medical laymen
developed propofol addiction and feigned an indication for endoscopy to receive
propofol [8, 9]. Survivors after propofol abuse reported that the abiding memory
of the intense relaxation many years ago was a major reason to abuse propofol
years thereafter [10]. However, it is unknown how many patients develop a
euphoric drug reaction after endoscopy.
Aims & Methods: The primary objectives were to define the frequency of a
euphoric reaction pattern under propofol sedation, to evaluate the reminiscence
one week later and to investigate the superposition of negative feelings by that
respective propofol-induced euphoria. Eighty-two patients undergoing elective
GE under propofol-sedation in an ambulatory setting were enrolled in a pro-
spective observational study. The grade of anxiety, expectation or relief about the
examination’s result and affective state in terms of cheerfulness, relaxation, acti-
vation, sedation and anxiety were surveyed using a numeric rating scale (1 to 10)
immediately before (t1), after GE (t2) and seven days (t3) later. Statistics: hier-
archical cluster analysis, heat map, 2 test and paired t-test.
Results: Mean propofol dosage was 264 120mg. The average indices of cheer-
fulness, relaxation and activation increased significantly (t1 to t2 to t3), whereas
sedation and anxiety decreased. Two clusters of mood changes emerged (t1 vs.
t2). One (n¼ 46.56.1%) was characterized by an unease reaction pattern with
equal values regarding cheerfulness, relaxation and anxiety, while relaxation
decreased; the other cluster showed a euphoric reaction pattern (n¼ 36,
43.9%) with markedly increased cheerfulness, relaxation and decreased anxiety.
These effects intensified at recall (t3). Despite similar endoscopy results, euphoric
cluster patients rated these more positively. No association between cluster and
personal traits, prior use of psychotropic drugs, alcohol consumption or smoking
habits were found.
Conclusion: Propofol induces euphoria in nearly half the patients undergoing
elective GE with persisting, even enhanced reminiscence. Consequently, endos-
copists should be aware of a potential risk of addiction in vulnerable subjects.
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Introduction: Submucosal tumours (SMT) in the upper gastrointestinal tract
(UGI) impose diagnostic and therapeutic challenges. They may have malignant
potential and endoscopic ultrasound (EUS) guided diagnosis is often inaccurate.
A substantial proportion may not involve the muscularis propria (MP) and thus
may be amenable to endoscopic excision. Snare-based techniques are usually
unable to completely excise such lesions, though without complete excision
ongoing endoscopic surveillance may be necessary. Endoscopic submucosal dis-
section (ESD) offers the possibility of complete resection and definitive
A448 United European Gastroenterology Journal 5(5S)
histological diagnosis to guide management decisions. Western data on ESD for
SMT is absent. Our aim was to analyse the data from our referral centre.
Aims & Methods: A prospectively collected ESD database was analysed to iden-
tify patients with SMT of the UGI. All lesions underwent EUS assessment with
the aim to exclude MP involvement prior to resection, and in the case of neu-
roendocrine tumours (NET) blood tests and Octreotate PET scan were
performed.
Results: Over 42 months, 30 ESDs for SMT lesions were performed. The mean
age was 62 years with 19 male patients (63%). Mean lesion size was 18mm.
Twenty five patients (83.3%) had completely resected tumours. Four patients
(13%) had involvement of the MP which was identified during the resection, and
one patient (3%) had MP injury which precluded complete resection. Three of
five lesions of the incompletely ESD procedures were in the proximal body of the
stomach, however only two lesions of the completely resected lesions were in the
proximal body (P-0.004). Otherwise, there were no significant differences
between the patients and lesions characteristics. The histology of the SMT lesions
were 9 NET, 6 leiomyoma, 5 Granular cell tumours, 4 inflammatory fibroid
polyp, 2 GIST, 2 dysplastic Lipoma, one myofibroblastic tumour and one
Warthin’s like tumour. Nineteen patients had completed surveillance endoscopy
(SE) without an endoscopic and histological recurrence (Median follow up 18
months). Six patients are pending SE. The four patients with deep MP involve-
ment were referred for surgery.
Conclusion: ESD for selected UGI SMT is an effective treatment. Long-term
endoscopic follow-up confirmed the absence of recurrence endoscopically and
histologically. MP involvement cannot be reliably excluded by prior EUS. This
technique should be considered for UGI SMT lesions without MP involvement in
experienced centres.
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Introduction: The incidence of oesophageal cancer has increased significantly over
the past two decades. The majority of these cancers are incurable at diagnosis.
Therefore, the management is aimed at maintaining quality of life by ensuring
adequate nutrition and palliation of symptoms, mainly dysphagia. Self-expand-
ing metallic stents (SEMS) have a well-recognised role in the palliative manage-
ment of patients with oesophageal cancer. These stents are inserted
endoscopically, under direct vision (EC) or with fluoroscopic assistance to endo-
scopy (FAE). There is little evidence to compare outcomes between these
approaches.
Aims & Methods: The objective of this study was to compare the outcomes, using
various performance indicators, in patients who underwent SEMS for palliation
in oesophageal cancer via different approaches (EC or FAE) at the Royal
Infirmary of Edinburgh (RIE). A retrospective observational study was con-
ducted between May 2014 to April 2016; a total of 62 SEMS. The approach to
stent insertion was subject to operator choice and availability of fluoroscopic
assistance, and as such can be akin to randomized study. We compared early and
late complications associated with two techniques. Early complications included
pain, vomiting, bleeding, perforation and tachyarrhythmia. Late complications
included tumour overgrowth, oesophagitis, stricture and stent migration. We also
compared morbidity, the need for repeat procedures and the number of addi-
tional stents required following each approach.
Results: Forty-seven stents where inserted by EC and fifteen by FAE. The
median age among the two groups were comparable at 75 and 69 years respec-
tively. There was male predominance in both the groups (70% and 67%).
Adenocarcinoma was the most common malignancy (56%), followed by squa-
mous cell carcinoma (35%) among the study subjects. We observed a higher
frequency of technical difficulties with EC placement (13%) to FAE (0%), how-
ever no malposition was observed in the EC group. Early complications were
comparable in both groups, however chest pain (21%) was more frequently
associated with the EC group. Late complications such as tumour overgrowth,
oesophagitis, oesophageal stricture and stent migration were comparable in both
groups. Food bolus obstruction and dysphagia was more common in EC place-
ment (28%) to FAE (0%) necessitating a higher number of endoscopies.
However, a relatively higher number of re-stent procedures where performed in
the FAE group. Median survival was comparable in both of the groups.
Variable EC (47) FAE (15)
Male (%) 33 (70) 10 (67)
Location of tumour Upper
Limit (IQR) Lower
Limit (IQR)
32 (9)
37 (5.1)
40 (6)
38 (7)
Sedation and analgesia use-
median dose (IQR)
Midazolam dose (mg)
2 (1.8)
50 (50) 100 (0)
3 (2.5)
75 (50)
100 (0)
(continued)
Continued
Variable EC (47) FAE (15)
Fentanyl (mcg) Local
Throat Spray (mg)
Commonest Stent 7/10 ultraflex (38) 7/10 ultraflex (33)
Placement difficulties 6 (13) 0 (0)
Previous failed attempts 1 (2) 0 (0)
Early complications:
Vomiting
Tachyarrhythmia
Apiration pneumonia
Chest pain
3 (5) 2 (4) 3 (6) 10 (21) 1 (7) 0 (0) 1 (7) 1 (7)
Late complications Tumour
overgrowth
Oesophagitis Stricture
Stent migration: Mean
days
9 (19) 2 (4)
1 (2) 9 (20) 32
5 (33) 0 (0)
1 (7) 3 (15) 29
Malposition 0 (0) 1 (7)
Food bolus obstruction 10 (21) 0 (0)
Second stent: Mean days 8 (17) 96.1days 5 (33) 171days
Third stent: Mean days 2 (4) 188.5days 2 (7) 286.5days
Fourth Stent: Mean days 0 (0) 2 (7) 377.5days
Median Survival days
(IQR)
102 (73) 126 (161)
Conclusion: Our results are comparable to findings of other authors (1, 2), in that
neither approach is superior. Both FAE and EC techniques have similar early
and late complications and comparable median survival. EC offers the advantage
of stent placement with direct visualization, however a learning curve must be
acknowledged. FAE insertion is a time-consuming procedure and exposes both
patients and endoscopy staff to radiation. In conclusion, the approach used
should be based on individual characteristics including operator experience,
tumour characteristics and previous endoscopic interventions.
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Introduction: Ingestion of caustic substances is relatively frequent and can cause
serious lesions in the upper gastrointestinal tract, carrying important morbidity
and even mortality.
Aims & Methods: We aimed to characterize the population assisted for caustic
ingestion, the therapeutic approach, complications and risk factors for severe
oesophageal lesions.
Retrospective cohort of adults presenting due to caustic ingestion between 2000
and 2015. Demographic and clinical data were collected. The endoscopic Zargar
classification was applied. We analysed risk factors for severe oesophageal
lesions, defined as Zargar 2b-3. Statistical tests: Mann-Whitney; Spearman (sig-
nificance level 5%).
Results: Overall 72 patients were included, with a mean age 53 17 years, 65.3%
female. Ingestion was voluntary in 49.3% of the cases, 33.3% had previous
suicide attempts. Alkaline substance in 90.4%. Most common symptoms at
admission: 60.3% odynophagia, 41.1% epigastric pain, 32.9% vomiting.
Oropharyngeal lesions in 41.1%. In 79.5% endoscopy was performed in the
first 12 hours. Oesophageal lesions were present in 46.6% of patients (Zargar
classification: I-2.7%, IIa-23.3%, IIb-5.5%, IIIa-6.8%, IIIb-8.2%); gastric
lesions in 58.9% and duodenal lesions in 13.7%. 53.4% were hospitalized,
51.3% in intensive/intermediate care units. The mean length of hospital stay
was 14.9 days. Medical treatment prescribed: 76.7% proton pump inhibitors,
15.1% corticoids, 15.1% prophylactic antibiotics. Parenteral feeding was
initiated in 28.8% of patients. Eight patients required invasive ventilation and
two were tracheotomised. Early complications: infections in 12 patients (16.4%),
perforations in 2 (2.7%); late complications: stenosis in 7 (9.6%): dilation in 6,
surgery in 3. One patient died from gastric perforation after voluntary ingestion
of acid. Severe oesophageal lesions were associated with increased inflammatory
parameters, tachycardia and/or hypotension at admission and motivated longer
hospital stays, requirement of intensive care and further complications
(p 0.002). The ingestion of acidic substances (100% of voluntary intake) was
associated with severe oesophageal damage in 3/7 (42.9%) patients, severe gastric
lesion in 5/7 (71.4%), acidemia in 5/7 (71.4%), complications in 5/7 (71.4%) and
100% hospitalization.
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Conclusion: Early changes in blood tests were seen in severe oesophageal lesions.
Severe oesophageal lesions were associated with longer hospitalization and com-
plications (infection/stenosis/perforation). Ingestion of acidic substances was a
risk factor for severe digestive lesions.
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Introduction: A value of the combination of magnifying endoscopy of and image
enhancement endoscopy (IEE) technology (e.g. NBI, BLI) is reported in a diag-
nosis for the early gastric neoplasm. That method is useful, but in order to master
it it is necessary to learn and familiarize complex classifications. Therefore, this
diagnostic method is still more difficult for general endoscopists. Linked Color
Imaging (LCI) was recently developed using a laser endoscopic system (Fujifilm
Co., Tokyo, Japan). LCI acquires images by simultaneously using narrow-band
short wavelength light and white light in an appropriate balance. This combina-
tion of light provides more information about the vasculature and architecture
on the mucosal surface than that obtained with typical white-light imaging.
When we use acetic acid indigocarmine mixture (AIM) with LCI mode, we
reported that the magnifying images of early gastric cancer are very clear,
three-dimensional and near to real histology. So, we examined the examined
the utility of this method.
Aims & Methods: This was a prospective observational study performed at a
single tertiary referral center. The subjects are 120 lesions of 115 patients with
gastric neoplasm. We are indicated of the endoscopic submucosal dissection
(ESD), and were given preoperative endoscopy in our hospital from September
2014 to February 2017. Firstly we observed the lesions by magnifying endoscopy
with the BLI mode and diagnosed using VS classification system. Secondly we
observed the lesions by magnifying endoscopy with LCIþAIM method and
diagnosed using VS classification system. Furthermore, we classified tumor dif-
ferentiation into high differentiation, moderately differentiated, and poorly dif-
ferentiated by its surface pattern. Finally, we classified the visualization ability of
the surface fine structure in Clear, Visible, and Invisible and evaluated it. We
carried out ESD and compared the image with the histopathology.
Results: By the pathology results, 92 lesions were gastric cancer and 28 lesions
were gastric adenoma. The differentiation ability of a cancer and the non-cancer
(adenoma) did not have the significant difference between the BLI mode and the
LCIþAIM methods. Diagnosis of differentiation of gastric cancer was correct in
87 of 92 cases (94.6%). In the classification of visualization ability, 32 lesions
were Clear, 44 lesions were Visible, 44 lesions were Invisible by BLI mode, On the
other hand, 45 lesions were Clear, 64 lesions were Visible, 11 lesions were
Invisible by LCIþAIM method. In the visualization ability of the surface fine
structure, LCIþAIM method is significantly clearer than BLI mode (p5 0.001).
Conclusion:When we use AIM, indigocarmine accumulates in pit of the duct, and
duct structures become clear by the acetic acid, By LCI mode, we can observe the
vascular pattern of the lesion clearly. So by the combination of AIM and LCI, we
can observe the endoscopic images closer to actual histological images. By this
method, we can compare histopathology with an endoscopic image intuitively, so
we believe that a magnifying endoscopy diagnosis of the gastric cancer is enabled
even if we do not use various confusing classifications.
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Introduction: Endoscopic submucosal dissection (ESD) is one of the most useful
methods for treating early gastric neoplasms. The advantages of ESD include the
ability to control the size and shape of the resection, permitting en bloc resection
of large and ulcerated lesions. The frequency of gastric ESD for patients aged 85
years or older has increased along with increases in the average population age.
However, few studies have reported the short-term and long-term outcomes of
gastric ESD in elderly patients.
Aims & Methods: The aims of our study were to evaluate and compare the
efficacy, safety, and clinical outcomes of gastric ESD in patients aged 85 years
or older and in younger patients. The subjects were 705 patients who collectively
presented with 876 gastric tumors (288 adenomas and 588 early gastric cancers).
All patients underwent ESD at our hospital between June 2007 and December
2016. The patients were divided into two groups: elderly (Group A: aged 85
years, consisting of 59 patients with a collective 71 lesions) and non-elderly
(Group B: aged 585 years, consisting of 646 patients with a collective 805
lesions). We evaluated the clinical and pathological findings, resection rates,
complications, and long-term outcomes, including the survival rate. The local
and distant recurrence rates were analyzed in the cohort with curative resection
and observationally managed with non-curative resection. The 3- and 5-year
overall survival and tumor-specific survival rates were analyzed in the entire
study cohort.
Results: The patients’ mean ages were 87 (Group A) and 71 years (Group B), and
the male-to-female ratios were 30/29 (Group A) and 646/805 (Group B). No
significant differences were found in the mean tumor size for Group A
(15mm) and Group B (20mm). Regarding histopathological findings, the pre-
valence rates of tubular adenoma were 28.3% (21/71; Group A) and 33.8% (267/
805; Group B); intramucosal carcinomas, 52.1% (37/71; Group A) and 53.8%
(433/805; Group B); shallow submucosal invasive carcinomas (5500 mm), 7.0%
(5/71; Group A) and 6.5% (52/805; Group B); and deep submucosal invasive
carcinomas (4500 mm), 11.3% (8/71; Group A) and 6.6% (53/805; Group B).
Once again, the groups showed no significant differences. The en bloc resection
rates were 100% (71/71 lesions; Group A) and 97.1% (782/805 lesions; Group B),
histological complete resection rates were 94.4% (67/71; Group A) and 92.9%
(748/805; Group B), and the curative resection rates were 78.8% (56/71; Group
A) and 86.3% (695/805; Group B). Among the non-curative cases, 13 (86.6%) of
the 15 patients in Group A and 41 (46.3%) of the 110 patients in Group B
received no additional treatment. These results were significantly higher for
Group A than for Group B. Concerning complications, the postoperative hemor-
rhage rates were 2.8% (2/71 patients; Group A) and 2.6% (12/479 patients;
Group B), and the perforation rates were 0% (0/71; Group A) and 0.5% (4/
805; Group B). Regarding long-term outcomes, analysis of recurrence revealed
the local and distant recurrence rates to be 0% for Group A and 0.9% (7/746;
local) and 0.1% (1/746; distant) for Group B. Regarding survival analysis, the
mean follow-up period in Group A and Group B was 839 and 1156 days, respec-
tively. The 3- and 5-year overall survival rates were 95.5% (3 year) and 74.7% (5
year) for Group A and 92.8% (3 year) and 87.7% (5 year) for Group B. The 3-
and 5-year tumor-specific survival rates were 100% for Group A and 99.2% (3
year) and 98.3% (5 year) for Group B (using the Kaplan–Meier method and
long-rank test). There were no significant differences observed in the survival
rates. 6 (10.0%) of 59 patients in Group A and 54 (9.3%) of 646 patients in
Group B died, and disease-specific mortality rates in Groups A and B were 0%
(0/59) and 0.8% (5/646), respectively.
Conclusion: Gastric ESD in patients aged 85 years or older can be effectively and
safely performed. According to the long-term outcomes, gastric ESD performed
as a local resection (total biopsy) in elderly patients may be acceptable, even in
non-curative cases.
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Introduction:Data from the UK Bowel Cancer Screening Programme (BCSP) has
established that the assessment and management of large non pedunculated
colorectal polyps (LNPCPs) varies markedly, leading to variable and often sub-
optimal outcomes, especially for the most complex lesions1. A multicentre com-
plex polyp multidisciplinary team meeting was created within the North East of
England BCSP with the aim of ensuring more robust decision making and man-
agement of complex LNPCPs.
Aims & Methods: A virtual multicentre MDM was conducted via audiotelecon-
ferencing within the North East of England between 2014–6 to discuss complex
LNPCPs (LNPCPs with increased risk of malignancy or complexity associated
with endotherapy, as defined in BSG/ACPGBI guidelines2). Non-complex
LNPCPs were not discussed. Patient data was distributed securely via
NHSmail. Outcomes were assessed prospectively using key performance indica-
tors (KPIs) from the BSG/ACPGBI guidelines.2
Results: 61 complex LNPCP cases were managed via the MDM with 8 excluded
from analysis (7: managed prior to MDM referral, 1: MDM advice not fol-
lowed), 27 lesions were managed with primary endotherapy, 23 with primary
surgery and 3 cases conservatively. Of the endoscopic cases, 2 required surgery
due to failed endotherapy and 2 due to a finding of malignancy. 12-month
recurrence was 8.7% with no reported complications. The rate of surgical man-
agement using the BSG/ACPGBI KPI (including only surgically managed benign
lesions or lesions subject to failed endotherapy) was 39.5%. The en-bloc resection
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rate of complex LNPCPs with features suggestive of increased malignancy risk
was 71.4%. Breakdown of Outcomes (n¼ 53) *Primary endoscopic therapy
(n¼ 27) -23 excised with curative intent -21 cases with no recurrence at 1y -2
cases with recurrence (8.7%) both 51 cm and managed endoscopically -4
required secondary surgery -2 failed endotherapy -2 proved to be malignant
*Primary Surgical Management (n¼ 23) -10/23 malignant lesions (43.5%) -9/23
subject to transanal surgery (39.1%) *Conservative management (n¼ 3)
Breakdown via High risk features of malignancy/SMSA4/SMSA3 (n¼ 53)
*High risk features of malignancy (any SMSA score) (n¼ 21) -7 endoscopically
managed -5 pEMR, 2 ESD -2/7 (28.6%) cases (both managed with pEMR)
malignant -13 managed surgically (4/13 (30.8%): transanal surgery) -9/13 malig-
nant (69.2%) -1 managed conservatively *SMSA 4 (n¼ 25) -12 managed endosco-
pically -12 managed surgically (due to technical considerations) -3/12 malignant
(25%) -1 managed conservatively *SMSA3 (n¼ 7) -4 managed endoscopically -2
management surgically (both lesions originating from within appendix) -1 managed
conservatively.
Conclusion: 61 complex LNPCP cases were managed via the MDM with 8
excluded from analysis (7: managed prior to MDM referral, 1: MDM advice
not followed), 27 lesions were managed with primary endotherapy, 23 with pri-
mary surgery and 3 cases conservatively. Of the endoscopic cases, 2 required
surgery due to failed endotherapy and 2 due to a finding of malignancy. 12
month recurrence was 8.7% with no reported complications. The rate of surgical
management using the BSG/ACPGBI KPI (including only surgically managed
benign lesions or lesions subject to failed endotherapy) was 39.5%. The en-bloc
resection rate of complex LNPCPs with features suggestive of increased malig-
nancy risk was 71.4%.
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Introduction: Patients of endoscopists with high (20%) adenoma detection rate
(ADR) have less risk for interval cancer than of those with an low ADR
(520%). Lesion-related-factors, such as size, shape and histology influence
these quality measure, as physicians with high ADR tend to detect more flat
and serrated adenomas than those with low ADR.
Aims &Methods: Our study aim is to investigate the differences of size, shape and
serrated histology of adenomas between low- and high-ADR group in our screen-
ing cohort. We analyzed 221.534 screening colonoscopies performed by 261
endoscopists between 2007 and March 2017 within the austrian certificate of
screening colonoscopy. T-Test was used to assess differences.
Results: 39.1% of endoscopists were categorized in the ADR low- and 60.9% in
the high-ADR group. Overall, mean ADR was 23.06% (SD 0.55) with a mini-
mum of 0.39% and a maximum of 48.72%. In the low-ADR-group mean ADR
was 14.56 (SD 0.42) and 28.51 (SD 0.50) in the high-ADR group. Relating to
size, there was a significant difference (p¼ 0.029) in detection of adenomas of 1–
2 cm with a mean of 8.44% (SD 6.02) in low- vs. 10.22% (SD 6.64) of all
adenomas in high-ADR group but no differences between adenomas 50.5 cm,
0.5–1 cm and those bigger than 2 cm. Regarding shape, proportion of peduncu-
lated adenomas in low-group-ADR differ significantly higher (p¼ 0.002), with a
mean of 19.36% (SD 14.69) vs. 14.70% (SD 9.55) but there were no differences
between flat and sessile adenomas. With a mean proportion of 4.43% (SD 5.61)
vs. 6.64% (SD 5.97), the proportion of sessile serrated adenomas (SSA) differ
significantly between low-ADR vs. high-ADR-group (p5 0.01). There was no
significant difference regarding traditional serrated adenomas (p¼ 0.800).
size ADR-Group Mean SD p-value
50.5 cm 520% 53.49 20.58 p¼ 0.384
20% 51.31 19.14
0.5–1 cm 520% 34.04 18.23 p¼ 0.980
(continued)
Continued
size ADR-Group Mean SD p-value
20% 34.09 15.46
1–2 cm 520% 8.44 6.02 p¼ 0.029
20% 10.22 6.64
42 cm 520% 4.04 3.69 p¼ 0.470
20% 4.39 3.81
shape
flat 520% 20% 26.64 27.11 25.11 24.23 p¼ 0.883
pedunculated 520% 20% 19.36 14.70 14.69 9.55 p5 0.01
sessile 520% 20% 53.99 58.19 27.23 26.36 p¼ 0.216
SSA & TSA
SSA 520% 20% 4.43 6.64 5.61 5.97 p5 0.01
TSA 520% 20% 0.88 0.94 2.10 1.44 p¼ 0.800
Conclusion: Endoscopists with higher ADR tend to detect significant more SSA
and adenomas with 1–2 cm in size, but have lower proportions of pedunculated
adenomas than those with a low ADR. In our study cohort no significant differ-
ences in flat shape or diminutive size was measurable.
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Introduction: ESD is a complex procedure, mainly in non-Asian countries where
the learning process is not well established. Results may be improved in Western
countries with a careful selection of lesions for ESD and avoiding those with a
greater chance of technical difficulty. Factors predicting technically difficult ESD
when it is performed by non-Asian endoscopists should be clarified.
Aims & Methods: We aimed to identify the potential risk factors that are asso-
ciated with a higher technical difficulty during ESD in a Western European
setting where there are no available Asian experts. We prospectively recorded
consecutive ESD cases performed by members of the ESDWorking Group of the
Spanish Society of Digestive Endoscopy. Demographic and clinical characteris-
tics of the patients, location and morphology of the lesions, and technical factors
were collected. We defined difficult ESD as those aborted procedures, time-con-
suming (duration4180min.) or when changing the technique to piecemeal resec-
tion was needed to remove the tumor. Analyses were carried out using IBM SPSS
software for Windows (IBM Corp., Armonk, NY, USA). Parametric continuous
variables are reported as the mean standard deviation (SD). A Kolmogorov-
Smirnov test was used to evaluate normal distribution. Categorical variables are
reported as either frequencies or percentages. Statistical differences between the
groups were analyzed using a chi-squared method for categorical data. The
meaningful variables with a p value 50.1 in the univariate analysis were included
in the logistic regression model. Multivariate analysis was performed using
binary logistic regression methods. Odds ratios (ORs) and 95% confidence inter-
vals (CIs) were calculated to assess the strength of the influence of each individual
variable.
Results: We included 265 lesions in 265 patients [mean ageSD: 69 10 y; 150
males (56.6%)]. They were recruited in 15 Spanish University Hospitals between
January 2016 and March 2017. Location of the lesions were: esophagus (n¼ 7;
2.6%), cardia (n¼ 5; 1.8%); stomach (n¼ 48; 18.1%); duodenal bulb (n¼ 1;
0.3%); colon (n¼ 144; 54.3%) and rectum (n¼ 60; 22.6%). Mean lesion size
was 38.6 18.5mm. Median duration of the procedure was 105min. (8–375).
In 73 cases (27.5%) criteria for difficult ESD were fulfilled. Endoscopic resection
was aborted in 7 cases (2.6%). When endoscopic resection was achieved (n¼ 258;
97.3%) both situations, duration 43 h and a piecemeal resection, were noted in
21 (8.1%) patients. Duration 43 h in 25 cases (9.7%) and unsuccessful en bloc
United European Gastroenterology Journal 5(5S) A451
resection in 20 (7.7%) were observed in isolation, respectively. Table 1 shows the
univariate and multivariate analysis of factors regarding technically difficult
ESD.
Table 1: Univariate and multivariate analysis of possible factors related to
technically difficult ESD.
UNIVARIATE
ANALYSIS
MULTIVARIATE
ANALYSIS
Variables OR (C.I. 95%) p OR (C.I. 95%) p
Procedure
Case load 10 0.8 (0.4–1.6) 0.5
2 endoscopists (vs. 1 operator) 20.6(5.9–72.6) 50.0001 9.7 (0.9–94.9) 0.06
Location
Colorectal 2.6 (1.2–5.7) 0.01 2.2 (0.6–8.3) 0.2
Stomach 0.5 (0.2–1.0) 0.06
Lesion
Size 430mm 2.4 (1.3–4.4) 0.004 5.0 (1.7–14.4) 0.003
Recurrent tumor 3.2 (1.3–8.1) 0.008 8.1 (1.4–45.9) 0.02
Protruded morphology 0.9 (0.5–1.9) 0.9
Depressed component 0.6 (0.2–1.7) 0.4
Poor manoeuvrability 3.5 (1.7–7.5) 0.001 3.5 (1.4–8.7) 0.006
Previous biopsy 1.0 (0.6–1.8) 0.9
Submucosal invasion 1.3 (0.5–3.7) 0.6
Severe submucosal
fibrosis (F2 vs. F0/F1)
3.3 (1.7–6.4) 0.0002 1.3 (0.4–4.4) 0.6
Complications
Intraprocedural bleeding 4.1 (1.9–8.7) 0.0003 5.1 (1.3–19.9) 0.02
Conclusion: The factors independently associated with technically difficult ESD
(aborted procedures, time-consuming or finished with a piecemeal resection)
were: lesion size 430mm, poor manoeuvrability, recurrent lesions and intrapro-
cedural bleeding. Except for the last one, the remaining factors can be identified
during the first diagnostic endoscopy. Endoscopists who will start performing
ESD should try to avoid these difficult procedures in the early part of their
learning curves.
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Introduction: We established the Laparoscopy Endoscopy Cooperative Surgery
(LECS) procedure to overcome the limitation of colorectal endoscopic submu-
cosal dissection (ESD). This procedure is a local full-thickness resection of the
combined procedure of laparoscopy assited colectomy (LAC) and ESD proce-
dure. Also, it is the method that is epoch-making for minimal invasive treatment
that kept an intestinal function.
Aims & Methods: The aim of this study was to investigate the feasibility and
safety of LECS procedure applied with endoscopic submucosal dissection (ESD)
technique obtained adequate surgical margin. We performed ESD on 1376 color-
ectal tumors in 1341 patients (male: female¼ 777:564; mean age, 66.1years).
Among these cases, six cases had perforation (0.4%), and three of six cases
required emergent surgery. We examined the cause of perforation and the limit
of ESD from the view point of safety. We performed one-piece resection for 11
cases (male: female¼ 7:4; mean age, 63.5years) of colorectaltumors using LECS
procedure. In the first, the indication of LECS is at high risk of the perforation
by the treatment of ESD and EMR and is the lesion that safety cannot secure. In
addition, the indication is the lesion which is curable by the local excision without
lymph node dissection. Therefore, submucosal invasive (T1) cancer with the risk
of lymph node metastases does not become the indication for this full-thickness
resection technique. From the above-mentioned basic concept, indications of the
LECS procedure for colorectal tumors were thought to be as follows: 1) Intra-
mucosal carcinoma (Tis) and adenoma with high-grade atypia (Vienna
Classification;Category 3, 4) accompanied by wide and severe degree fibrosis
in the submucosal layer (tumor recurrence after endoscopic and surgical resec-
tion); 2) submucosal tumors; 3) Intra-mucosal carcinoma (Tis) and adenoma
with high-grade atypia involved appendix or diverticle. We examined the clin-
icopathological outcomes of the above-mentioned 11 cases.
Results: Four of six cases that caused perforation in ESD were cases with fibrosis
in the submucosal layer. Three cases of those were moderate to severe degree
fibrosis cases, and a limit of ESD seemed to exist in these lesions from the
viewpoint of safety and curability. We accomplished full-thickness resection suc-
cessfully for 11 cases using LECS procedure as follows: 5 cases of Tis cancer, 4
cases of adenoma, 1 case of schwannoma, and 1 case of GIST. The reasons that
we judged as the indication of LECS procedure were as follows: three cases
accompanied by severe degree fibrosis, 2 cases involved diverticle, 3 cases
involved appendix, 2 cases of submucoal tumor, and 1 case of poor endoscopic
operability. These cases were considered a limitation of ESD due to the high risk
of perforation. An operative time was an average of 195.8 minutes (127 to 332),
and the perioperative bleeding was an average of 8.9 g/dl (3 to 20). We experi-
enced no complications, and average post-operative hospital stay was 7.7(6 to 12)
days. Histological examination of the resected specimens revealed negative lateral
and deep margins. The postoperative follow-up was carried out first a half year
later, and it was every one year subsequently. In the above-mentioned follow-up
schedule, blood examination, colonoscopy, CT scan were performed for clinical
evaluation. The residual/local recurrence case was absent for 31.6 months (range
10–60 months) for the mean follow-up period. Also, without complications such
as postoperative anastomotic stricture or adhesive ileus, we followed favorable
course.
Conclusion: We developed a LECS procedure to overcome the limit of ESD, and
completed full-thickness one-piece resection of the tumors considered as high risk
of perforation in the endoscopic treatment.
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Introduction: Endoscopic mucosal resection (EMR) and submucosal dissection
(ESD) are effective procedures for reducing the need for colorectal surgery.
Many studies have focused on major adverse events related to EMR and ESD
such as bleeding and perforation. However, data on structured assessment of
minor post-procedural adverse events remain scarce. We therefore evaluated
the incidence of major and minor adverse events within 30 days of EMR or ESD.
Aims & Methods: We prospectively performed a single-center study on consecu-
tive patients who underwent colonoscopic EMR or ESD between April 2014 and
April 2016. We asked for permission to interview the patients 1 day, 14 days, and
28 days after their procedure. Four gastroenterologists performed all procedures.
The assigned nurse prospectively recorded the data and interviewed the patients
in person on 1 day and 14 2 days, and via phone on 28 2 days after their
respective EMR/ESD procedure. A standardized interview form was developed
to assess the occurrence of (i) major adverse events (hospital visit required), (ii)
minor adverse events, and (iii) working days lost due to adverse events. The
primary outcome was the occurrence of all adverse events, which were classified
as either ‘‘major’’ or ‘‘minor’’.
Results: We enrolled 630 patients who underwent EMR or ESD. 615 (97.6%)
patients (499 EMR, 116 ESD) were contacted. Male comprised 68.5% (n¼ 415),
and the mean age was 57.9 years (11.3). Major adverse events occurred in 31
(5%), 16 (2.5%), and 1 (0.2%) patients on days 1, 14, and 28, respectively. Minor
adverse events occurred in 284 (46.1%), 344 (55.9%), and 25 (4.1%) patients on
days 1, 14, and 28, respectively. Bleeding was the most common major event on
days 1 and 14; abdominal bloating and bowel habit change were the most
common minor events on days 1 and day 14, respectively. 11 (1.8%) and
2(0.3%) patients took leaves of absence due to adverse events on day 14 and
28, respectively. The detailed events are listed in Table 1.
Conclusion: Although the number of major adverse events was small, nearly half
of the patients reported minor adverse events on 14 days following colon EMR/
ESD. Most minor adverse events subsided by the day 28.
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Introduction: Patient experience is increasingly recognised as a key measure of
quality of care. Ensuring positive experience is important to patients and funda-
mental in maximising participation in screening programmes and re-attendance
for surveillance procedures. Current measures of patient experience of gastroin-
testinal (GI) endoscopy are clinician derived.(1) Patient Reported Experience
Measures (PREMs) should be patient derived and incorporate pre-and post-
procedure experience. We aimed to identify themes considered as important to
patients undergoing GI procedures as a basis for developing PREMs.
Aims & Methods: We aimed to identify themes important to patients undergoing
GI investigations, to enable questionnaire development. Patients who had under-
gone upper or lower GI investigations (gastroscopy, colonoscopy and CT pneu-
mocolon) were invited to attend for a semi-structured interview. 32 interviewees
were purposefully sampled to ensure diversity. Interviews were conducted by a
research fellow trained in qualitative methods and were audio recorded and
transcribed verbatim. Recruitment continued until saturation was achieved.
Analysis used qualitative thematic methods focusing on anticipated and emergent
themes, using constant comparison to ensure that all perspectives were included
in the explanation of the data.
Results: 168 patients were approached. 32 interviews were completed (12 gastro-
scopy, 10 colonoscopy and 10 CT pneumocolon), with a male:female ratio of
18:14. The time interval from examination to procedure ranged from 5 to 44
days. Mean age was 63.1 years (SD 11.5)
The interviews provided an in-depth understanding of patient experience of GI
procedures. 6 over-arching and inter-linking themes emerged across all proce-
dures; anxiety, expectations, choice/control, communication/information, com-
fort and embarrassment/dignity. Relation of themes was seen e.g. if the
procedure appointment was sooner than expected, patients were anxious about
the potential outcome. Choice was important in terms of appointment, endosco-
pist and choice of pre-medication, however it was highly individualised.
Communication prepared patients and managed expectations, with one patient
describing poor endoscopist communication affecting the whole experience.
Patients described embarrassment related to changing and waiting areas; sensi-
tive nature of the test; exposure and physical reaction. Discomfort during the
procedure was attributed to instrument and air insertion.
Conclusion: Despite heterogeneity between procedures consistent themes related
to patient experience emerged. This work will be used to develop PREMs for
Gastrointestinal Endoscopy.
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Introduction: Adequate bowel preparation is important to perform colonoscopy
for accurate mucosa examination, lesion detection and treatment. Walking exer-
cise is known to be effective for colon cleansing. However, it is difficult for
patients with uncomfortable walking to improve the status of bowel cleansing.
Aims & Methods: Therefore, we prospectively evaluated the clinical feasibility
and clinical validity of the abdominal vibration stimulation for bowel
Abstract No: P0836
Table 1: Number of Patients with Adverse events on Day 1, 14, and 28.
Day 1 N¼ 315(51.2%) DAY 14 2 days N¼ 360(58.5%) DAY 28 2 days N¼ 26(4.2%)
Major 31(5.0%) Major 16(2.5%) Major 1(0.2%)
EMR ESD EMR ESD EMR ESD
19(3.8%) 12(10.3%) 11(2.2%) 5(4.3%) 1(0.2%)
Hematochezia 15 8 9 4
Chest pain 2 1
Microperforation 1 2
Severe abdominal pain 1 2 1
Perforation 2
Minor 284(46.1%) Minor 344(55.9%) Minor 25(4.1%)
EMR ESD EMR ESD EMR ESD
217(43.5%) 67(57.8%) 267(53.5%) 77(66.4%) 19(3.8%) 6(5.2%)
Bowel habit change 156 41
Abdominal bloating 112 28 30 14 5
Minor bleeding 36 25 45 22 2
Mild abdominalpain 42 16 54 24 2
Dizziness 33 13 25 10 2
Headache 26 7 19 6
Back pain 17 3 16 3 1
Easy fatigability 10 1 65 21 4 2
General Myalgia 4 2 26 8
Nausea/vomiting 3 3 8 2
Tenesmus 3 3 18 9 2 1
Febrile sesnse 2 1 7
Voiding difficulty 1 1 5
Dry mouth 1 1
Epigastric pain 2 3
Leg pain 1 1
Urticaria 1 2 1 1
Indigestion 1 23 5 3 1
Drowsiness 1
Herpes zoster 2
Flank pain/proctalgia 1 3
Sleep disturbance 1
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preparation. In this randomized, prospective, investigator-blind study and single
center study, 141 inpatients for elective colonoscopy were randomized to two
groups. PEG solution was used for bowel cleaning in all patients. The one is
walking over 3000 steps and the other is having abdominal vibrator more than 30
minutes before colonoscopy. After examination we recorded procedure results,
sedation information, patient’s satisfaction and adequacy of bowel preparation
by using the Boston Bowel Preparations Scale (BBPS).
Results: There were no significant differences between vibrator group (n¼ 75)
and walking group (n¼ 66) in bowel preparation quality (Total BBPS 7.40 vs
7.23, p¼ 0.519), withdrawal time (30.40 vs 30.05 mins, p¼ 0.829), number of
polyps (4.09 vs 3.17, p¼ 0.085), patient satisfaction (4.39 vs 4.12, p¼ 0.249)
and number of diarrhea after taking PEG (11.49 vs 11.42, p¼ 0.503). Vibrator
group was superior than walking group in time of first defecation after taking
PEG (112. 89 vs 123.42 mins, p¼ 0.005) and cecal intubation time (6.23 vs 8.52
mins, p¼ 0.011).
Conclusion: Bowel preparation accompanied with abdominal vibration stimula-
tion showed almost similar results to a walking group which was conventional
methods for adequate bowel preparation. The patients with the conditions which
cause uncomfortable gait such as old age, CVA, Parkinsons, or joint disease,
bowel preparation with abdominal vibrator is expected to help in proper bowel
cleansing for therapeutic colonoscopy.
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Introduction: Electrical and rhelogical properties of the submucosal cushing solu-
tions are crucial to avoid complications secondary to endoscopic resections.
Electrical resistance (R) of a substance is a measure of the difficulty to pass an
electric current through that solution. The higher the R, the resection will be
quicker, easier and safer, with less temperature increase. Our group has devel-
oped a new solution to perform submucosal injection (TriBio).
Aims & Methods: To analize the electrical (R) and rheological (temperature,
viscosity, height and lasting of the cushing) properties of different submucosal
solutions in an ex vivo model of porcine stomach. Tested solutions were: Saline
(S), Gliceol (GC), Hyaluronic acid (HA), Distilled water (DW), Platelet-rich
plasma (PRP), Glucosated serum 10% (GS), Gelaspan (GP), TriBio (TB) and
PRPþTB. Measurements were done at time 0 and 30 minutes.
Results: The solutions that showed the best basal R were: PL, HA, GS, TB and
TBþPRP. At 60 minutes, the best R were: PRP, TB, PRPþTB, HA and GS.
The best durability at 60 minutes was for TB, PRP, TBþPRP and PL that
maintained the height at around 80% of its original in comparison to the
other substances with were at around 60%. During the resection the solutions
that underwent a lower temperature increase were: TBþPRP, PL, and TB.
Viscosity
(pa)
% diminution
cushion (60min)
Trans-epithelial
R (MV)
Increase in
Ta during
endoscopic
resection (C)
Basal n.a. n.a. 10 83.5
Saline 0.0043 39.6 9 49.1
Gelaspan 0.009 45.5 9 116.6
Glyceol 0.009 26.3 10 44.9
(continued)
Continued
Viscosity
(pa)
% diminution
cushion (60min)
Trans-epithelial
R (MV)
Increase in
Ta during
endoscopic
resection (C)
Glucosated saline 10% 0.008 29 12 29.9
Pluronic 20% 0.9* 0.52 14 12
Hyaluronic acid 5% 0.04 24.4 13 12.5
TriBio (TB) 0.9* 2.8 15 36.5
Platelet-rich Plasma (PRP) 0.01** 17 13 20.8
TBþPRP 0.45* 11.5 15 5.6
n.a: not applicable * gelification at 37C ** viscoelastic solid when activated
Conclusion: Based on electrical and rheological properties, the best submucosal
solutions to perform safer endoscopic resections are: TBþPRP, TB, PL and
PRP.
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Introduction: Patients with chronic diseases, such as inflammatory bowel disease,
experience a lower degree of being involved in health care than others. Compared
with other countries Swedish patients report lower possibility to be involved in
their care and receive less information about care (1).
Aims & Methods: To investigate the perception of written and oral information
given before and after a colonoscopy, the perceived knowledge of planned
follow-up and preference to be more involved in decisions/participate in their
care in different patient groups. Outpatients (418 y) undergoing colonoscopy
(all indications) were consecutively included (n¼ 862). Before the procedure
patients completed questionnaires regarding sociodemographic data and the
written information about bowel preparation and examination. After the proce-
dure patients reported their perceptions about the information provided regard-
ing the colonoscopy and the follow-up.
Results: Data from 862 patients were analyzed (447 females) (mean age 52; 18–90
y) A large number of patients (n¼ 740, 87%) rated the written information sent
home before the colonoscopy as distinct, while a subset (n¼ 110, 13%) rated it as
indistinct/very indistinct. When questions of importance were asked to the med-
ical staff during the colonoscopy most patients were content with the answers
from the physician or nurse. A small proportion of patients (n¼ 57, 7%) stated
that they received too little information or that they did not understand the
information about the colonoscopy results; these patients were mainly younger
(550 y) (p5 0.001). The majority of the patients (n¼ 602, 74%) reported thor-
ough knowledge about the follow-up, while 26% (n¼ 207) lacked this knowl-
edge. More than 1/3 (n¼ 275) of the patients wished to be more involved in
decisions regarding their care and treatment. Desire for a higher degree of invol-
vement were more pronounced in patients 540 y (p5 0.05) and in patients with
IBD (p5 0.05) compared to patients with other indications for colonoscopy.
Patients referred from outpatient clinics in the hospital desires a higher degree
of involvement than patients referred from primary care (p5 0.01).
Conclusion: The majority of the patients undergoing colonoscopy reported that
they received satisfactory information about the procedure and preparation.
However, there is room for improvement regarding follow-up information and
patients’ involvement in their care and treatment. Specifically, improvements
seem warranted for younger patients and patients with chronic diseases, such
as IBD.
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Introduction: A ‘‘skirt’’ is a slightly elevated flat lesion with wide pits occasionally
observed at the margin of laterally spreading tumors (LSTs), and rectal LSTs had
significantly more skirt lesion in comparison to colonic LSTs. Although the
clinicopathological, endoscopic, and molecular characteristics of LSTs with a
skirt have been reported [1], there are no reports concerning the incidence of
synchronous neoplastic lesions of rectal LSTs with a skirt.
Aims & Methods: The aim of this retrospective study was to clarify the incidence
of synchronous advanced neoplasia (AN) of rectal LSTs with a skirt. A total of
13,116 cases underwent colonoscopy in our hospital between January 2012 and
June 2016. Of these, 101 consecutive rectal LSTs were examined to assess the
incidence of synchronous AN detection rate and the number of AN according to
the location of AN lesion; divided into the right colon, left colon and rectum. A
skirt was defined on the basis of the following endoscopic findings: spreading
across the margins of the LST, consisting of a slightly elevated flat lesion, and
containing wide pits. AN was defined as the presence of any of the following
features: adenomas larger than 10mm, adenomas with villous histology or high-
grade dysplasia including intra-mucosal carcinoma and invasive cancer.
Synchronous advanced neoplasias of rectal LSTs with and without skirts
Rectal LSTs
with skirts
(n¼ 25)
Rectal LSTs
without skirts
(n¼ 76) p value
Patients with advanced neoplasia
Total 5 (20.0%) 36 (47.4%) 0.02
Right colon 2 (8.0%) 23 (30.3%) 0.03
Left colon 1 (4.0%) 21 (27.6%) 0.01
Rectum 3 (6.0%) 5 (6.6%) 0.41
Number of advanced neoplasia
Total 7 74 0.02
Right colon 2 35 0.03
Left colon 2 34 0.04
Rectum 3 5 0.44
Results: A skirt was observed in 25 of 101 rectal LSTs (24.8%). Rectal LSTs with
a skirt (median age 69 years, 52% female, mean size 51.7 27.1mm) had 22 high-
grade dysplasia and 3 submucosal carcinomas, and rectal LSTs without a skirt
(median age 72 years, 34% female, mean size 24.7 16.0mm) had 8 low-grade
dysplasia, 45 high-grade dysplasia, and 23 submucosal carcinomas, respectively.
The overall AN detection rate in rectal LSTs with a skirt (20.0%) was signifi-
cantly lower compared with rectal LSTs without a skirt (46.8%, p¼ 0.02). As for
the analysis of AN detection rate according to the location, there were significant
differences in the right colon (8.0% vs 29.9%, p¼ 0.03) and the left colon (4.0%
vs 27.3%, p¼ 0.01) between LSTs with and without a skirt. In contrast, there was
no significant difference with respect to the rectum (6.0% vs 6.5%, p¼ 0.41). The
total number of AN in rectal LSTs with a skirt (n¼ 7; right colon: 2, left colon: 2
and rectum: 3) was significantly lower than in rectal LSTs without a skirt (n¼ 74;
right colon: 35, left colon: 34 and rectum: 5). There were significant differences in
the right colon (p¼ 0.03) and the left colon (p¼ 0.04), while, there was no sig-
nificant difference between these groups with respect to the rectum.
Conclusion: The rectal LSTs with a skirt had significantly lower synchronous
advanced neoplasia than rectal LSTs without a skirt, especially in the right
and left colon. Our results may suggest that rectal LSTs with a skirt have differ-
ent characteristics compared with rectal LSTs without a skirt in terms of the
incidence of synchronous neoplastic lesion.
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Introduction: Endoscopic resection of large lesions leads to extensive mucosal
defects and submucosal exposure, with a substantial risk of adverse events.
The prevention of these complications is inefficient with current methods.
Endoscopic shielding, as a simple and safe technique, has been proposed to
improve mucosal restoration, and therefore, the incidence of these events.
Previous reports have confirmed the efficacy of the placement of hydrogels
based on platelet-rich plasma (PRP) (1) or hialuronic acid with other substances
(TriBio) (2), but never the combination of both hydrogels, in the prevention of
delayed complications after mucosal damage.
Aims & Methods: To assess the efficacy of endoscopic shielding with the combi-
nation of PRP and TriBio in a rat model of thermal injury. Thermal injury was
obtained according to our rat model (3). Lesions were performed in male
Sprague-Dawley rats (400–450 g) under general anesthesia. Animals were rando-
mized to receive one of the following shields onto the lesions: PRPþTriBio, PRP
and TriBio. Rats underwent endoscopic follow-up at 7 days and 2 weeks.
Afterwards, animals were sacrificed and ulcers sites were macroscopically and
histopathologically evaluated.
Results: Animals treated with PRPþTriBio obtained the best results in compar-
ison with other hydrogels (PRP and TriBio). Mucosal healing rate (percentage of
mucosal restoration) at 14 days was significantly higher with PRPþTriBio
(100% vs 82% and 90%; p5 0.05). Histological study confirmed these data,
showing total restoration of mucosal layer with PRPþTriBio
Conclusion: The use of a combination of two covering agents (TriBio and PRP) is
the best approach to obtain mucosal healing in a rodent model of endoscopic
thermal injury in colon
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Introduction: Colonoscopic procedures have become massive in the last years
since colorectal cancer (CRC) is becoming a prevalent disorder. The next frontier
of this technique will be to provide an active substance in a precise site of the
colon (targeted therapy). This has many advantages (targeted therapy, dose
adjustment, limiting side effects, assessment of mucosal healing, etc.); however,
this selective and direct administration of drugs is not possible nowadays, but it is
a true challenge. Following these evidences we have developed drug eluting plat-
form to locally treat CRC lesions
Aims & Methods: To evaluate the efficacy of intratumoral injection of our drug-
eluting platform with different combinations of these antitumoral drugs (afliber-
cept 2mg/mL, cetuximab 16mg/mL, panitumumab 6mg/mL, irinotecan 3.5mg/
mL and bevacizumab 5mg/mL) in a rat model of azoxymethane-induced color-
ectal cancer. Rats underwent endoscopic follow-up at 1 and 2 weeks after endo-
scopic therapy. Afterwards, animals were sacrificed and tumors were excised and
macroscopically and histopatologically evaluated.
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Results: Intratumoral injection was feasible in all animals with no adverse events.
Basal mean size of tumors ranged from 6 to 8mm. Anti-VEGF in comparison
with Anti-EGF obtained the best results (significantly reduction in size and cell
necrosis). However, only aflibercept showed total acute tumoral necrosis.
Conclusion: Intratumoral injection of anti-VEGF in a drug-eluting platform is
able to produce tumoral necrosis in an experimental model of CRC. This tech-
nique could open a new way to manage CRC.
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Introduction: Three-dimensional (3D) imaging techniques have been developed in
the medical field. Previous research reports that simulated 3D colonoscopy
improves the detection of colonic lesions [1]. A novel 3D imaging system has
been recently developed, which can create 3D virtual video images from conven-
tional two-dimensional (2D) endoscopic images [2]. However, actual cases have
not been studied.
Aims & Methods: This study aimed to investigate whether the 3D system can
improve the visibility of colorectal neoplasms compared with conventional 2D
endoscopy. We studied two non-polypoid colorectal neoplasms and recorded
their videos using conventional 2D endoscopy and the 3D system. The movies
were evaluated by 8 endoscopists (4 experts and 4 non-experts) and 4 medical
students. Each neoplasm was assigned a visibility score between 4 (excellent
visibility) and 1 (poor visibility).
Results: The mean visibility scores were 3.35 0.58 for 2D endoscopy and
3.75 0.44 for the 3D system. The score was significantly higher for the 3D
system than for 2D endoscopy (p5 0.01). When comparing the evaluations by
the experts, non-experts, and medical students, the differences in the scores by the
non-experts and medical students were noted to be higher (p5 0.05). In contrast,
the scores by the experts were also higher for the 3D system, but no statistical
difference was observed (3.50 0.53 for 2D endoscopy and 3.87 0.35 for the 3D
system, p¼ 0.08). As a result, 10 out of 12 observers noted that the 3D system
had better visibility than conventional 2D colonoscopy, and none of the obser-
vers noted deterioration in visibility with the 3D system.
Conclusion: The present findings suggest that the 3D imaging system improves
the visibility of non-polypoid colorectal neoplasms, and this is more effective for
non-experts. Our findings would contribute to improvement in the detection of
these neoplasms.
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Introduction: Pain is a subjective perception, which contributes to difficulties to
provide adequate pain relief according to every patient’s needs. Colonoscopy is
by many patients considered as a painful and strenuous procedure.
Aims & Methods: To investigate congruence and differences between patients’
and caregivers’ report of pain during colonoscopy. Patients (18 years) under-
going an outpatient colonoscopy (all indications) have consecutively been
included (n¼ 862). Before the procedure the patients completed questionnaires
regarding sociodemographic information and anxiety. After the colonoscopy the
patients registered their pain experience on a six-grade scale, ranging from ‘‘no
pain’’ to ‘‘extremely severe pain’’. Caregivers (physicians and endoscopy nurses)
estimated patient’s pain using the same scale.
Results: Data from 785 patients has been collected, mean age 52 (18–90) years;
413 women. Approximately half of the patient’s reported no or mild pain, 21%
moderate pain and a subgroup of 14% were not adequately relieved. These
subgroup reported severe, very severe or extremely severe pain. 90% of the
patients were given analgesics and sedation during the investigation. For patients
who reported, ‘‘severe, very severe or extremely severe pain’’ (n¼ 111), pain was
underestimated by physicians and nurses in 58% of all assessments. This was
most commonly seen among the youngest patients, 18–29 years (n¼ 99), where
pain was underestimated in 25.5% among the group. There was also a difference
according to gender; physicians underestimated pain in 60% of men who
reported ‘‘moderate pain’’ (n¼ 66) while the nurses underestimated pain in
27% among the same group of men. Women’s pain was overestimated by care-
givers in 26% (n¼ 188) of all cases with mild pain. Patients undergoing colono-
scopy for the first time (n¼ 331), and reporting ‘‘moderate pain’’, were
underestimated by physicians in 58% and by nurses in 25%. 58% of the patient
reports that they were anxious before the procedure. This group reported more
pain than the group without anxiety (p5 0.001). Presence of anxiety and a high
level of pain among the group enhanced the agreement between the caregiver’s
and the patient’s pain report. The agreement between pain reports from patients
and caregivers were poor to fair, with slight differences between nurses
(Kappa¼ 0.37; p5 0.000) and physicians (Kappa¼ 0.29; p5 0.000) In total,
congruent pain reports between patients and caregivers were seen in 36% of all
assessments.
Conclusion: Agreement between caregivers’ and patients’ pain reports is far from
perfect, and the agreement is influenced by several factors such as the profession
of the caregiver, as well as patient factors including pain severity, anxiety, age,
gender and previous experience of colonoscopy. The goal for the future should be
to individualize the use of analgesics based on every patient’s needs, which seems
to be of special importance in specific groups of patients.
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Introduction: The SCENIC consensus proposed recommendations for optimal
detection and management of dysplasia during colonoscopic surveillance for
IBD1. Characterization of colonic lesions in IBD remains challenging even by
using advanced endoscopic imaging modalities (high definition [HD], virtual
chromoendoscopy [VCE] dye chromoendoscopy [DCE].
Aims & Methods: We aimed to develop a unified endoscopic classification of
advanced imaging to predict histology of colonic lesions, and to validated by
international experts (Frankfurt Advanced Chromoendoscopic Ibd LEsions-
FACILE Group). We developed an endoscopic classification of IBD lesions,
based on morphology, colour, demarcation, surface pattern, vessel pattern,
signs of inflammation (table). A library of 60 colonic lesions, including dysplasia,
sessile serrated adenomas/polyps, invasive cancer and pseudopolyps collected at
surveillance colonoscopy by using HD, DCE and VCE with i-scan or NBI were
assessed. The diagnostic performance of the score was tested based on the final
histopathology and the inter-observer variability of the eight examiners. The
examiners have had to perform a pre-test (45 minutes) before analyzing the
colonic lesions. Multivariate analysis with bootstrapping, of characteristics of
the classification was performed to determine the strength of endoscopic predic-
tors of dysplasia.
Results: Of the 60 IBD lesions, 33 (55%) were dysplasia, 6 (10%) cancer, 9 (15%)
SSA/Ps and 12 (20%) pseudopolyps. Across the experienced academic raters
sensitivity, specificity, PPV, NPV and accuracy in predicting histology, were
72%, 72%, 91%, 40%, 72%. Individual rater accuracy ranged from 66% to
77%. Sensitivity, specificity, PPV, NPV, accuracy, for predictions made with
high confidence were 72%, 90%, 97%, 46%, 76%, which were significantly
more accurate compared with a low confidence of diagnosis (76% vs 65%;
P5 0.001). Univariate analysis showed that the non polypoid lesions, irregular
and vessel architecture and signs of inflammation within the lesion were predic-
tive of dysplasia. Subsequent multivariate analysis confirmed that of these endo-
scopic findings non polypoid lesion OR 11.6 (95% CI:6.71–20.2), surface pattern
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OR 0.31 (95% CI:0.17–0.54), vessel architecture OR 5.1 (95% CI: 2.7–10.2), sign
of inflammation within the lesion OR 0.39 (95% CI: 0.18–0.85) were independent
predictors of dysplasia, with vessel architecture and morphology being the best
predictors. The sensitivity, specificity, PPV, NPV and accuracy at the multivari-
ate analysis stage were 94% (95% CI: 90–96%), 51%(95% CI: 43–58%), 88%
(95% CI: 82–92%), 69% (95% CI:62–75%), 85% (95% CI: 7990%). Inter-
observer agreement of the raters improved from the pre-test (Kappa¼ 0.27.95%
CI: 0.19–0.38) to post test (Kappa¼ 0.34.95% CI: 0.23–0.45;P¼ 0.02) but was
moderate.
Conclusion: We developed and validated the first endoscopic classification using
all imaging modalities (HD, VCE, DCE) to characterize and differentiate dys-
plastic from non-dysplastic lesions in IBD. Non polypoid lesions, irregular sur-
face and vascular pattern as well as inflammation within the lesions were
predictive of dysplasia. The inter-observer variability of the score was moderate.
The classification will be further refined based on the multivariate analysis and a
prospective study is ongoing.
Table 1: Advanced endoscopic classification of IBD lesion
Morphology (mm):
Polypoid/non polypoid
Paris Classification (Ip, Is, IIa, IIb, IIc, III)
Endoscopic inflammatory activity (within the lesion)
No ulcerations
Ulceration
Endoscopic inflammatory activity (surrounding area)
No ulcerations
Ulcerations
Demarcation
Yes
No
Colour of the lesion (relative to the background)
Paler
Same intensity
Darker
Surface architecture (tissue)
Roundish
Villous –regular
Villous – irregular
Irregular/non-structural
Vessel architecture
Non visible
Regular
Irregular
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Introduction: Participants’ experience with a screening test can influence adher-
ence, and therefore the efficacy of a screening programme. We compared the
satisfaction with decision and willingness to repeat colorectal cancer screening
with flexible sigmoidoscopy(FS) and faecal immunochemical test (FIT).
Aims & Methods: In a prospective, randomised trial 3257 individuals (50–74
years) were invited to either FS or FIT(1:1) of whom 1650 (52.6%) attended.
In total, 1497 screening participants completed at least one questionnaire mea-
suring willingness to repeat screening, recommend screening and satisfaction with
decision to attend, either before screening, and/or three times in the following
year. There were 769 and 728 responders in the FS and FIT group respectively.
Of these FS participants, 581 participants also completed a pain-questionnaire.
Results: One year after screening, 10% of the FS participants were not willing to
repeat screening, compared to 5% of FIT participants, adjusted OR 0.47 (95%
CI: 0.31–0.72). In the FS group, there was a higher percentage of women who
would not repeat screening, compared to men, adjusted OR 2.52 (95%CI: 1.48–
4.28). Notably, 22% of women reported pain during the FS, compared to 5% of
the men. Both men and women who self-reported pain were statistically signifi-
cantly less willing to attend FS screening again compared to participants who
reported no pain. When we added pain to the model, pain was significantly
associated with the unwillingness to repeat FS OR 3.15 (95%CI: 1.68–5.87),
while gender was no longer OR 1.53 (95%CI: 0.82–2.88).
Conclusion: Acceptance for FS and FIT were high among Norwegian screening
participants, though FIT participants were more willing to repeat screening.
Women were less willing to repeat screening with FS compared to men. This
gender difference seemed partly due to pain, and therefore preventable.
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Introduction: Detection, characterization and therapeutic management of flat
dysplastic lesions during surveillance colonoscopy in inflammatory bowel disease
(IBD) can be a challenge. The recent SCENIC consensus has introduced a new
terminology and concept ‘‘endoscopically resectable’’ when the distinct margins
of a detected lesion could be identified. New endoscopic techniques and skills are
required to recognize the margins reliably and assess the surrounding mucosa to
plan endoscopic removal successfully and organ sparing. We report our experi-
ence of the use of probe confocal endomicroscopy (pCLE) combined with selec-
tive electronic virtual (VCE) and dye chromoendoscopy (DCE) for management
of challenging dysplastic lesions during surveillance in IBD.
Aims & Methods: IBD patients underwent surveillance colonoscopy using high-
definition (HD)-iSCAN (Pentax EC-3940Fi; Japan) VCE and DCE in combina-
tion with pCLE (Cellvizio, Paris, France). pCLE was applied following IV injec-
tion of fluorescein 5% 10ml to assess the histological features of the lesion, the
margins and the mucosa surrounding the visible colonic lesion. Biopsies even-
tually proved dysplasia or SSA of the colonic lesions. The study was approved by
the Calgary Conjoint Health Services Research Ethics Board of the University of
Calgary. All patients gave informed consent.
Results: Seven patients with IBD and disease duration of 8 years and in clinical
remission {Eaden, 2001 #2} (mean age 55 years; 6 male, UC¼ 4 CD¼ 3) were
prospectively included. They underwent surveillance colonoscopy using HD–
iSCAN (Pentax EC-3940Fi; Japan). When a colonic lesion was detected, selective
iSCAN -VCE was performed with or without DCE (five out of seven had DCE)
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UC/CD
Endoscopic Findings
Endomicroscopy Findings Histology OutcomeKudo Paris Border
Left sided UC IIO/IV IIb Size4 2.5 cm distinct Villiform appearance of the
crypts with stellar open-
ing. The colonic mucosa
surrounding the lesion
was normal.
SSA En-block EMR
Crohn’s colitis IIIS/IIIL IIb Size4 2.5 cm indistinct Villiform elongated appear-
ance of the crypts with
dark epithelium,
decreased number of the
LGD Surgical resection
(continued)
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with methylene blue 1% to characterize the surface, vascular pit pattern and the
margins of the lesion. Each of the 7 patients had non polypoid colonic lesions, 4
were sessile (Paris Is) and 3 flat (IIa/IIb). Four of them were amenable to endo-
scopic therapy and were successfully removed using endoscopic mucosal resec-
tion (EMR) en-block or piecemeal technique. Interestingly, one patient with
multiple scattered ‘pseudopolyps’ had a 8mm sessile pseudopolypoid lesion
with a suspicious areas of SSA in the midst that was confirmed by real pCLE.
The endoscopic, endomicroscopic and histological findings of all the lesions were
described in Table 1.
Conclusion: This case series highlights the first successful use of pCLE in combi-
nation with VCE and DCE to predict, characterise and treat colonic neoplasia in
IBD. pCLE may be an additional tool to aid the endoscopist in therapeutic
management by deciding endoscopic resectability versus colectomy.
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UC/CD
Endoscopic Findings
Endomicroscopy Findings Histology OutcomeKudo Paris Border
goblet cells with leakage
of fluorescein and dis-
tortion of the crypts
around the lesion.
Ulcerative
pancolitis
IIIL/IV Is Size4 2.5 cm distinct Villiform appearance of the
crypts with stellar open-
ing of the lumen of the
crypts. Areas of dark
epithelium with
decreased number of
goblet cells.
Surrounding mucosa
was normal.
SSA with focal LGD En-block EMR
Colonic Crohn’s II0/IV Is Size4 2.5 cm distinct Villiform -elongated
appearance of the crypts
with stellar opening of
the lumen. The mucosa
surrounding the lesion
was normal.
SSA En-block EMR
Colonic Crohn’s IIIL/IV IIb Size4 2.5 cm indistinct Villiform- elongated
appearance of the crypts
with dark epithelium
and decreased number
of goblet cells. The sur-
rounding mucosa
showed irregular archi-
tecture of the crypts and
leakage of fluorescein.
LGD Surgical resection
Ulcerative
Pancolitis
IIO IS Size4 5mm distinct In the midst of psudopolyp
villiform appearance of
the crypts with stellar
opening of the lumen
SSA En-block EMR
Ulcerative
Pancolitis
IIIL/IV IIb Size4 2.5 cm indistinct Villiform appearance of the
crypts with dark epithe-
lium and absence of
goblet cells. The mucosa
surrounding the lesions
had irregular architec-
ture of the crypts
HGD Surgical resection
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Introduction: Endoscopic submucosal dissection (ESD) is one of the most useful
methods for treating early colorectal neoplasms and conventionally utilizes an
IT, hook, or needle knife. However, because these devices are used without
fixation to target, it confers a potential risk of complications due to unexpected
incision. To reduce the risk of complications from ESD performed using a con-
ventional knife, we used a scissors-type knife (SB Knife Jr: Akita Sumitomo
Bakelite, Japan) that allows keeping an adequate dissection layer and preventing
unexpected muscular layer injury. In the previous study, we reported that ESD
performed using SB Knife Jr is a technically efficient and safe method for treating
early colorectal neoplasms. However, the efficacy and safety of colorectal ESD
using SB Knife Jr in elderly patients remain unclear.
Aims & Methods: The aims of our study were to evaluate the efficacy, safety, and
clinical outcomes of colorectal ESD using SB Knife Jr in patients aged 75 years
in comparison with those in younger patients. We evaluated 291 colorectal
lesions in 271 patients (male-to-female ratio, 148:123; median age, 70 years)
treated with ESD using SB Knife Jr between October 2010 to March 2017 at
Kure Medical Center and Chugoku Cancer Center. The patients were divided
into two groups, an elderly group (group A: age, 75 years; 95 patients, 97
lesions) and a non-elderly group (group B: age, 575 years; 176 patients, 194
lesions). We evaluated the en bloc resection rate, complete resection rate, curative
resection rate, resected tumor size, procedural time, complications, and long-term
outcomes, including survival rate. The 3-year overall survival and tumor-specific
survival rates were analyzed in the entire study cohort, and the local and distant
recurrence rates were analyzed in the cohort with curative resection and obser-
vationally managed with non-curative resection.
Results: The mean age was 80.0 years in group A and 64.3 years in group B. The
male-to-female ratios were 45:50 and 103:73 in groups A and B, respectively.
Regarding histopathological findings, the prevalence rates of tubular adenoma
were 37.1% (36/97) and 36.1% (70/194); Tis, 39.2% (38/97) and 44.8% (87/194);
T1a, 10.3% (10/97) and 10.3% (20/194); and T1b, 13.4% (13/97) and 8.8% (17/
194) in groups A and B, respectively, showing no significant difference. The mean
resected tumor size was 33.9 16.6mm in group A and 34.7 15.2mm in group
B, and the median procedure time was 75.6min (range, 10–420min) in group A
and 75min (range, 10–533min) in group B, showing no significant difference.
The en bloc resection rates were 96.9% (94/97) and 99.0% (192/194); the com-
plete resection rates, 94.8% (92/97) and 94.8% (184/194); and the curative resec-
tion rates, 83.5% (81/97) and 88.1% (171/194) in groups A and B, respectively,
showing no significant difference. Regarding complications, no perforation
during the procedure occurred in any of the cases. The delayed bleeding rate
was 1.0% (1/97) in group A and 2.6% (5/194) in group B. Delayed perforation
and rectal stricture occurred in one patient each in group A and were treated
conservatively. Regarding long-term outcomes, the local recurrence rate was
1.0% (1/97) in group A and 0.5% (1/194) in group B, and no distant recurrence
was observed in the recurrence analysis cohort. Regarding survival analysis (mean
follow-up period: group A, 523 469 days; group B, 628 582 days), the 3-year
overall and disease-specific survival rates were respectively 98.8% and 100% in
group A, and 93.3% and 98.3% in group B. One patient (0.5%, 1/194) died of
colorectal cancer and 5 patients (2.6%, 5/194) died of other diseases in group B,
while one patient (1.1%, 1/95) died of other diseases in group A.
Conclusion: ESD performed with SB Knife Jr. is a technically efficient and safe
method associated with favorable long-term outcomes in cases of early colorectal
neoplasms both in elderly and non-elderly patients.
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Introduction: Poor quality and incomplete colonoscopy is associated with missed
diagnosis and failure to prevent interval cancers.1 Caecal intubation rate is the
most frequently used Quality Indicator of colonoscopy. British Society of
Gastroenterology guidelines recommend obtaining ‘‘clear images of caecal
landmarks or terminal ileum’’ while the European and American guidelines sug-
gest ‘‘auditable photo documentation of completion preferably a panoramic view
of the ileocecal valve and caecum’’. In this retrospective study we aimed to assess
colonoscopists’ practice in photo documentation of colonoscopy completion.
Aims & Methods: Colonoscopy reports for colonoscopies performed at an endo-
scopy site in a University Hospital over a period of three months from 01/01/
2014 to 31/03/2014 were retrieved from the Trust’s Endoscopy database. Photo
documentation from the reports were then analysed for caecal landmarks and
terminal ileum images.
Results: A total of 292 colonoscopies were performed by 21 endoscopists {5
Colorectal Surgeons (24%), 3 Nurse Endoscopists (14%), 3 Specialist Registrar
Gastroenterology (14%) and 10 Consultant Gastroenterologist (48%)}. Caecal
intubation was achieved in 248 cases (85%). In 8(3%) cases the anastomosis was
reached. The ileo-caecal valve was photographed in 172(70%) cases, the appen-
dix in 102(41%) cases, the caecum in 83(33%) cases and a panoramic view was
achieved only in 43(17%) patients. Terminal Ileum was intubated in 53 cases
(21%) and images were recorded in 25 cases (40%). In the case of anastomosis, 7
images (88%) of the anastomosis were obtained. In some of the reports images
were labelled and in a number of reports no photos were recorded at all.
Conclusion: This study shows that photo documentation is poor and needs to be
improved in order to adhere to national and international guidelines. Evidence of
caecal intubation is imperative as it can protect against medicolegal implica-
tions2. Obtaining clear images of caecal landmarks will ensure definite caecal
intubation and efforts towards recording them will prompt the endoscopist to
attain adequate mucosal views. In order to achieve excellence we suggest colo-
noscopists obtain images of all caecal landmarks including the ileum (when
intubated), label photographs and where possible record video clips of caecal
intubation.
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Introduction: Sessile Serrated polyps (SSA/Ps) are pre-malignant lesions that may
lead to colorectal cancer in accelerated manner. These lesions are easily missed by
endoscopists as these are difficult to detect in IBD patients. We aimed to assess
the prevalence, detection rate and endoscopic findings of SSA/Ps in long standing
IBD patients prospectively undergoing surveillance colonoscopy using dye
(DCE) or virtual electronic chromoendoscopy (VCE) or high definition white
light (HD-WLE) colonoscopy alone.
Aims & Methods: A total of 270 randomized patients (55% men; age range 20–77
years, median age 49 years) with long–standing IBD (median duration of the
disease 14 years) undergoing surveillance colonoscopy were assessed by HD-
WLE (n¼ 90), VCE (n¼ 90) or DCE (n¼ 90). Surveillance colonoscopy with
High Definition (HD) alone, or with iSCAN VCE or DCE was performed.
Endoscopic features were recorded in each group with regard to location, mor-
phology (polypoid/non polypoid), size and mucosal pit pattern, and these were
characterised using the Kudo modified classification and Paris classification. The
histology was reported by modified Vienna classification.
Results: Thirty -three SSA/Ps were detected in 20 (11UC; 9 CD; 11 female, age
range 34–72 y, median age 61 years) patients out of the 270 patients with IBD
enrolled (12.2%). The endoscopic features of SSA/P lesions were: non-polypoid
appearance (51.5%), predominant localization in the proximal colon (vs distal)
(87%), 5mm in size (48.4%), Kudo pit pattern modified type IIO (79%). Kudo
pit pattern modified type IIO had a sensitivity of 79% and specificity of 82% for
diagnosing SSA/Ps at surveillance colonoscopy in IBD patients. There was no
difference in detection rates of SSA/P using HD-WLE, DCE or VCE.
Conclusion: SSA/Ps are not an infrequent finding at surveillance colonoscopy in
IBD. There are prevalent in the right colon location and these generally have
Kudo pit pattern of IIO. SSA/Ps can be recognized endoscopically by Kudo pit
Abstract: P0851
F Age mean UC/CD
Localization&Size Paris classification Kudo pit pattern
Right Left 55mm 5mm Is/p IIb/IIa I/II IIO III-IV
Serrated adenoma n¼ 33 11 61 11/9 29 4 16 17 16 17 1 26 6
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pattern even in IBD patients. Further studies are needed to evaluate the natural
history and outcome of the SSA/Ps pathway lesions in IBD patients.
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Introduction: The histological characterization of colorectal polyps using FICE
(Fujinon Intelligent Color Enhancement) technology presents high diagnostic
acuity. However, the excellent results in histological prediction are a reflection
of the clinical practice by trained endoscopists, and their application remains to
be confirmed outside this context.
Aims & Methods: To evaluate the in vivo histological prediction acuity of color-
ectal polyps 510mm (hyperplastic polyps vs adenomas) in WLE (White light
endoscopy) and using FICE technology, comparing both modalities. Prospective
evaluation, using WLE and FICE, of colorectal polyps 510mm in patients
submitted to colonoscopy between 12/2016 and 02/2017 by four inexperienced
endoscopists in FICE, except for a previous 20-minutes interactive session.
Polyps were evaluated using the FICE classification [tubular or oval crypts (ade-
noma), round crypts or featureless appearance (hyperplastic polyps), indicating
their confidence level (low 590% vs high4 90%). Statistics: SPSS v23
Results: 25 polyps were included, with a mean size of 4.5mm, 14 adenomas, 10
hyperplastic and 1 serrated adenoma. From the global assessment of all polyps
and observations, the use of the FICE classification for prediction of adenoma-
tous histology obtained values of sensitivity, specificity, positive and negative
predictive value identical to WLE (100%, 62.5%, 60% and 100%, respectively).
Overall, diagnostic acuity in histological prediction was identical in both mod-
alities (76%). The individual acuity of the endoscopists ranged from 66% to
100%. Higher confidence scores were not associated with a higher probability
of correct classification, both in WLE (77% vs. 75%) and FICE (75% vs. 80%),
p4 0.05).
Conclusion: The use of FICE technology by inexperienced endoscopists in the
histological prediction of colorectal polyps has no advantage over WLE, having
both suboptimal acuities. The lack of recourse to magnification may have con-
tributed to these results.
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Introduction: Colonoscopies are performed under general anaesthesia (GA) for
various reasons, but mainly due to previous procedures being poorly tolerated
with normal sedation. During the procedure, the endoscopist must be aware of
the patient’s comfort levels and reactions to endoscopic manoeuvres. Polyp
detection rate is a recognised indicator of quality of colonoscopy. It has been
demonstrated that use of sedation increases the quality of colonoscopy[1]. We
hypothesised that complete removal of the patient factor may increase the detec-
tion rate of polyps further.
Aims & Methods: The study was undertaken retrospectively at a district general
hospital. Results were analysed for all colonoscopies performed under GA
between February 2016 and February 2017 to identify whether polyps had
been detected, the number of polyps detected, and the site of polyp detection.
Studies performed for surveillance of previously diagnosed Inflammatory Bowel
Diseases (IBD) were excluded. The age and gender of each group was also
analysed to identify possible confounding factors.
Results: 40 colonoscopies were performed under propofol sedation within the
defined criteria; 40 colonoscopies performed using conventional sedation were
randomly selected to use for comparison. A significant increase in rate of polyp
detection was found in GA studies (45% vs non-GA studies 30%, p¼ 0.0384).
GA studies identified a mean of 1.275 polyps per study, compared to a mean of
0.325 polyps where conventional sedation was used (p5 0.0001). There was an
insignificant (p¼ 0.175) difference in age between the GA (59.7 18.2) and non-
GA (64.7 14.2). There was a significant (p¼ 0.0005) difference in gender
between groups; there was an even distribution of gender in the conventional
pool, while the GA pool of patients was 77% (31:9) female.
Conclusion: Use of propofol sedation during colonoscopy provides a statistically
significant increase to both the rate of detection of polyps, and the number of
polyps identified when compared to procedures performed for similar indications
using conventional sedation. This may be due to elimination of the patient factor.
The implications of this are unclear and thus further larger comparison studies
are needed. It is not practical for all colonoscopies to be performed under GA
due to capacity issues, anaesthetic requirements and time allocated to lists.
However, it may be a clinically effective tool for high-risk patients, such as
those being screened for hereditary colonic malignancies or IBD patients.
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Introduction: Adenoma and polyp detection rates are correlated to the risk of
interval colorectal cancer and is consequently considered as a quality benchmark
for colonoscopy. We prospectively evaluated this variable in our daily practice,
involving all the endoscopists of our endoscopy unit.
Aims & Methods: 6027 colonoscopies were performed between 01/01/2016 and
31/12/2016 by 30 physicians. Regarding patients, the following data were pro-
spectively collected: age, gender, indication for colonoscopy, preparation proce-
dure and quality of the preparation (assessed by the Boston Scale), number and
size of polyps and polyp histopathology. Regarding physicians, age, gender,
number of colonoscopies and mean withdrawal time (calculated from the
normal colonoscopies) were studied. Neoplasia was defined as grade 4 or 5 of
the Vienna classification (4: non-invasive high grade neoplasia (high grade ade-
noma/dysplasia, non-invasive carcinoma and suspicion of invasive carcinoma; 5:
invasive neoplasia (intramucosal carcinoma, submucosal carcinoma or beyond).
Links between these data and polyp detection rate (PDR) were assessed by uni-
and multivariate analysis (stepwise logistic regression).
Results: We enrolled 2719 Male patients (45.1%) and 3308 Female patients
(54.9%), 73.6% of them of 50 year-old or more. A sub-optimal preparation
(defined by Boston scale score 56 or at least one sub-sore 52) was observed
in 6.1 % of the patients. Caecal intubation rate was 99%. 21 endoscopists were
Male and 10 were under 50 year-old. The median number of colonoscopy per
physician was 140 (range: 10–720). 2054 colonoscopies detected 3914 lesions or
polyps: 2914 tubular/villous adenomas, 496 serrated adenomas, 242 hyperplastic
polyps (hyperplastic polyps located in the rectum and sigmoid colon were not
considered as at risk for cancer and were excluded), 212 other histology leading
to a Mean Number of Polyps (MNP) of 0.65 and a Polyp Detection Rate (PDR)
of 34.1%. 1935 coloscopies detected at least one adenoma (adenoma detection
rate, 32.1%). Large Polyp Detection Rate was 7.9% with detection of 538 polyps
41 (13.7% of polyps), in 477 patients. Neoplasia Detection Rate was 3.6% (300
neoplasias in 220 patients). Among the endoscopists, the median PDR was
32.5% (range 14–62%). Among them, 4 had a PDR5 20%, 17 had a PDR
between 20 and 39% and 9 had a PDR4 40%. Mean withdrawal time was
490 seconds (range 228–831). 10 physicians had a mean withdrawal time 5420
seconds with a mean ADR of 31% compared to 34.5% for physicians with a
withdrawal time of more than 420 seconds (p4 0.05). In the univariate analysis,
a high PDR was significantly associated with patient-dependant factors: age,
Male gender, a familial history of polyp/cancer, screening or positive faecal
immunochemical test (FITþ) and quality of preparation. Regarding physician-
dependant factors, a high PDR was significantly associated with Male gender,
high volume (4140 colonoscopy per year) and withdrawal time. In the multi-
variate analysis, the only factors associated with a high PDR were: familial
history of polyp/cancer, FITþ and patient age.
Conclusion: In this large series of routine colonoscopies, we found medically-
relevant polyps in more than one third of the patients, irrespectively of age
and indications. In multivariate analysis, a high PDR was significantly associated
with familial history of polyp/cancer, FITþ and age of the patient. This may
suggest that the Male gender is no longer a risk factor for polyps. In addition,
even if there are still discrepancies regarding PDR among physicians, we found
no physician-dependant factor associated with a high PDR in the multivariate
analysis.
Aknowledgment to all the endoscopists and nurses of the Clinique de Bercy.
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Introduction: Fecal immunochemical test (FIT) has progressively replaced the
guaiac test for colorectal screening in average risk population in France since
May 2015. With a high sensitivity and a good specificity, it is supposed to
increase colonic cancer detection. However, its efficiency has not been described
in routine colonoscopy.
Aims & Methods: Among 6027 colonoscopies performed between 01/01/2016 and
31/12/2016 in our endoscopy unit, 391 were performed for a positive FIT (FIT
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þ). The following variables were prospectively collected: patient age and gender,
quality of preparation (Boston scale), number, size and histopathology of polyps.
Neoplasia was defined as categories 4 and 5 of the Vienna classification (high-
grade dysplasia, in-situ carcinoma, intra-mucosal carcinoma, submucosal carci-
noma or beyond). Comparison was made with the whole population of 3876
patients aged of 50 to 75, referred for other reasons. Statistical analysis was
performed in uni- and multivariate analysis using a stepwise logistic regression
study.
Results: 391 patients with FIT þ were included (6.4% of the patients). 201 were
Males and 190 were Female with a median age of 58 (range: 50–75). The pre-
paration was considered as sub-optimal in 6.4% of cases (Boston scale score 56
or at least one sub-score 52). 498 lesions were detected in 230 patients. These
lesions corresponded to 423 adenomas and adenocarcinomas, 41 serrated adeno-
mas, 14 hyperplastic polyps (hyperplastic polyps located in the rectum and the
sigmoid colon were not considered as lesions at risk and were therefore excluded
from the analysis), 20 other pathology, leading to a mean number of polyps
(MNP) of 1.27. Polyp detection rate (PDR) and adenoma detection rate
(ADR) were 58.8% and 58%, respectively. By comparison, PDR and ADR in
the whole population were 39.1% and 37.0%, respectively. From the 498
detected lesions, 122 (24.5%) were 1 cm in 109 patients, resulting in a large
polyp detection rate (LPDR) of 27.9% as compared to 9.4% in the whole popu-
lation; 66 neoplastic lesions (13.2% of the polyps) were detected in 57 patients,
resulting in a neoplasia detection rate (NDR) of 14.6% as compared to 4.9% in
the whole population. In Males, MNP, ADR and NDR were 1.52, 67% and
18.9% respectively compared to 1, 49.5% and 10% respectively in female
patients. The multivariate analysis showed that FIT þ was significantly asso-
ciated with a high PDR (OR 2.8; 95%CI 2.2–3.6), a high LPDR (OR 8.1; 95%CI
5.4–12.3) and a high NDR (OR 12.8; 95%CI 6.2–26.4).
Conclusion: In case of positive FIT, colonoscopy detects medically-relevant
polyps in 59% of patients. Furthermore, the detection rates of large polyps
and neoplastic lesions were very high, especially in Male patients, confirming
the high predictive positive value of FIT compared to guaı̈ac test. Our results
are in agreement with the highest quality benchmarks recently proposed in case
of positive FIT (et al., Am J Gastroenterol, 2016 Oct 11). Aknowledgment to all
the endoscopists and nurses of the Clinique de Bercy.
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Introduction: Adequate bowel preparation is one of the most important quality
factors of colonoscopy. Several formulations of bowel preparation have been
evaluated for their ability to have a clean colon and be well tolerated by patients.
Currently, PEG 4L solution is the preferred method of bowel preparation to
colonoscopy. This preparation has the disadvantage of being poorly tolerated
by patients. Furthermore, recent studies have shown that a low -volume PEG
solution (2L) associated with Bisacodyl for bowel cleansing is as effective and
better tolerated as a large volume PEG (4L).
Aims & Methods: This study aims to assess the efficacy and tolerance of the new
regimen (2L of PEGþBisacodyl) compared to the classical regimen (4L of PEG).
Materials and methods: A prospective comparative randomized study comparing
the tolerance, acceptability and efficacy of a protocol A based on 4L of PEG and
a protocol B corresponding to 2L of PEGþ 15mg of Bisacodyl. Using the
Boston Bowel Préparation Scale (BBPS) by endoscopists, who did not know
bowel preparation type, to evaluate the quality of preparation.
Results: Sixty-six patients were included (35 in group A and 31 in group B), with
a sex ratio¼ 1. The average age of patients was 52 þ/15 years [17–86 years] with
a median of 51.5 years. Eight patients in the first group found the preparation
difficult or moderately difficult vs 3 in group B (p¼NS) with mild to severe side
effects 54% of group A and 29% of group B (p¼ 0.03) and A mean side effect per
patient was 2.26 vs. 1.89 (p¼NS). Nausea and vomiting were respectively (34%
and 26% vs 19% and 13%) (p¼NS). However, 5 patients in group A had sleep
disorders vs only one case in group B. Four patients who received 4 L of PEG
had expressed their refusal to resume the same preparation if necessary while 2
patients in group B had refused. A score greater than or equal to 7 was recorded
60% versus 84% respectively (p¼ 0.03). On average; the overall score obtained
was 6.49 versus 7.32, respectively. This score (BBPS) tended to be better in
protocol B than in protocol A in the right segment (2.55 vs 2.17), transverse
colon (2.58 vs 2.43) and left colon (2.19 vs 1.94). This same trend was recorded
in relation to the number of patients with a maximal score of (9/9), with 4
patients in group B and no patient in group A. Seven patients refused to
repeat the test even if indicated. This refusal was secondary to the preparation
in 4 cases (2 cases of each group). Abdominal pain and post-endoscopic disten-
sion in both groups A and B were respectively (62.8% and 65.7% vs 32% and
22.5%) (p¼ 0.016 and p5 0.001).
Conclusion: Preliminary results from our study suggest that the low-volume 2 L
PEG with bisacodyl does improve patient tolerability with a tendency to be better
for good Bowel preparation as compared to the traditional 4 L PEG. We
continue our study to have a more significant number of patients view these
encouraging results.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Contact E-mail Address: irina.mocanu.24@gmail.com
Introduction: Colonoscopy is a cumbersome technique to train, with high varia-
bility of time spent to reach the cecum, depending on endoscopist experience,
patient characteristics and type of colonoscope used. Recently, the ROLCOL
study demonstrated an advantage in time and patient comfort during progression
in right lateral position(RLP) when compared with traditional left lateral posi-
tion (LLP).
Aims & Methods: To compare time to reach cecum, patient and endoscopist
comfort (using a visual analogue scale (VAS) in colonoscopies with progression
on RLP and LLP. Prospective study, between January and April 2017, of colo-
noscopies under conscious sedation, randomly assigned to RLP and LLP.
Olympus 190 series and Fuji EC-530 WI3 colonoscopes were used. Inclusion
criteria: routine colonoscopies, patients 418 years of age, abdominal surgeries
other than colonic, examinations done by residents in second and fifth year of
training and specialists. Exclusion criteria: incomplete colonoscopies or prior
history of colonic surgery.
Results: One hundred and eighty-eight colonoscopies (94 on each side) were
included. There was no statistical difference in mean age (RLP:LLP¼ 61 Vs.
64 years; p4 0.05), gender (49 Vs. 52 males; p4 0.05), body mass index (27.4
Vs. 26.4; p4 0.05), previous history of abdominal surgery (44 Vs. 34; p4 0.05),
endoscopist́s experience (residents: 53 Vs. 41, specialists: 41 Vs. 53; p4 0.05),
sedation dosage (midazolam 1.04 Vs. 1.09mg, petidine 25 Vs. 25mg; p4 0.05) or
colonic preparation (BBPS 6 Vs. 6, 01; p4 0.05). Globally, there was no differ-
ence in ‘‘time to cecum’’ between the two positions (612 Vs. 633 seconds;
p4 0.05), nor the patient́s comfort (VAS 3.92 Vs. 3.94; p4 0.05). This did not
change after exclusion of less experienced endoscopistś colonoscopies (581 Vs.
579 seconds, VAS 3, 71 Vs. 3.76; p4 0.05). Surgical and overweight patients did
not benefit from any of the positions (time to cecum: 650 Vs. 702 and 570 vs 657;
p4 0.05, comfort: 4.2 Vs. 4.12 and 3.83 Vs. 3.96; p4 0.05, respectively).
However, endoscopist́s comfort was higher in LLP (4.62 Vs. 3.78; p5 0.05).
Both groups required position change during progression or loop palpation by
the nurse in equal percentage (54% Vs. 46%; p4 0.05 and 49.5% Vs. 50.5%;
p4 0.05). Additionally, there was no difference in time do cecum, patient́s or
endoscopist́s comfort between the colonoscopies performed with Fuji or
Olympus colonoscopes.
Conclusion: In our experience, progression in right lateral position did not show
additional advantage over standard LLP in time to reach the cecum or patient́s
comfort. We did not find any difference in time to progression or comfort
between Olympus and Fuji colonoscopes.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The surface morphology of laterally spreading colonic lesions
20mm (LSL) can be described as granular (G) or non-granular (NG). NG
lesions are more difficult to detect, harder to resect endoscopically and harbour
a higher risk of submucosal invasive cancer (SMIC) than G lesions.
Aims & Methods: We aimed to characterise the population of LSL in patients
presenting for endoscopic mucosal resection (EMR). From 9/2008 until 03/2017
LSL were identified within a prospective observational cohort of patients under-
going endoscopic mucosal resection at a single academic tertiary centre. LSL
were interrogated using high-definition white light (HDWL) at the time of
EMR and the morphology of LSL were described along with patient, lesion
and procedural factors. All LSL detected during the study period were eligible.
LSL with mixed or indeterminate morphology were excluded. Serrated LSL were
excluded. Lesions not attempted for EMR were excluded. Patients with multiple
LSL were categorised according to the largest (dominant).
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Results: 1382 LSL in 1243 patients were analysed. 1155/1243 (92.9%) patients
had a solitary LSL. The majority of patients with multiple LSL had two (77.3%)
or three (15.9%) lesions. 889/1382 (64.3%) of LSL were G. G LSL were more
likely to be solitary (87.0%) than NG LSL (77.5%, p5 .001). G LSL were more
commonly large (40mm in size) (49.3%) than NG LSL (26.0%, p5 .001) and
were more commonly found in the right colon (proximal to transverse colon)
(54.2% versus 48.3%, p¼ .034). In 88 patients with multiple LSL the dominant
LSL was G (49/88 [55.7%]). A dominant G LSL was associated with fewer other
LSL than a dominant NG LSL, p¼ .029.
Table 1; The morphology of the dominant (largest) laterally spreading lesion
(LSL) predicts the presence and number of synchronous LSL. Morphology of
the dominant lesion did not predict the others would be of the same morphology
(p¼ .697). The dominant LSL was large in 43.2% of cases. Size of the dominant
LSL predicted size of the other LSL (p5 .001). 58.0% of dominant LSL were
located in the right colon. In 65.9% patients all LSL were in the same colonic
segment; this was not predicted either by the location of the dominant LSL
(p¼ .860) or its morphology (p¼ .228).
Dominant LSL Morphology Solitary (n¼ 1155) Multiple (n¼ 227) P
Granular (n¼ 889) 773 (87.0) 116 (13.0) 5.001
Non-granular (n¼ 493) 382 (77.5) 111 (22.5)
Dominant LSL Morphology Number of synchronous LSL
2 3 4 5 P
Granular (n¼ 49) 41 (83.7) 4 (8.2) 3 (6.1) 1 (2.0) .029
Non-granular (n¼ 29) 27 (69.2) 10 (25.6) 0 2 (5.1)
Conclusion: 7% of patients will have more than one LSL. In these patients the
dominant lesion morphology predicts the presence and number of additional
LSL (the Colonic Mucosal Phenotype). More than 20% of NG LSL are asso-
ciated with an additional LSL whereas G LSL are predominantly large and
solitary. Practitioners of endoscopic resection should be aware that NG LSL
may be multiple and ensure full examination of the colonic mucosal surface,
particularly since they are higher risk for SMIC than G LSL.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Large series suggest endoscopic mucosal resection is safe and effec-
tive for the removal of large sessile serrated polyps 10mm (large SSP) but it
exposes the patient to the risks of electrocautery, principally delayed bleeding.
Aims & Methods: We aimed to examine the feasibility and safety of piecemeal
cold snare polypectomy (pCSP) for the resection of large SSP. Over 12 months
sequential large SSP without endoscopic evidence of dysplasia referred to a
tertiary endoscopy centre were considered for pCSP. The technique for pCSP
was standardised. The lesion and its margins were assessed using high definition
endoscopic imaging. Snare resection commenced at one margin including a 2–
3mm rim of normal tissue. A thin-wire snare was used in all cases. Firm down-
ward pressure and suction of luminal gas aided tissue capture. Subsequently the
assistant closed the snare until resistance was felt, and then completely once the
endoscopist was satisfied with the amount of captured tissue. If transection did
not occur within five seconds gentle traction was exerted on the snare catheter
against the tip of the colonoscope. If transection still did not occur, the snare
placement was revised. The mucosal defect was then expanded with a flushing
pump containing 0.9% saline. Further resections were then performed aligning
the snare with the cut edge of the expanding mucosal defect. Once the resection
was completed the mucosal defect was inspected for residual serrated tissue. If
residual was detected further generous snare resection was performed. Oozing of
blood from the resection site was common and was not actively treated.
Submucosal injection was not performed. High-definition imaging of the defect
margin was used to ensure the absence of residual serrated tissue. Adverse events
were assessed at 2 weeks and surveillance was planned between 6 and 12 months.
Results: 41 SSP were completely removed by pCSP in 34 patients. 7 patients had
two lesions removed. The median size of SSP was 15mm (IQR 14.5–20), range
10–35mm. The median duration of procedures was 4.5 minutes (IQR 1.4–6.3).
There was no evidence of perforation or significant intra-procedural bleeding.
There were no significant adverse events at 2 week follow up including delayed
bleeding and post polypectomy syndrome. 8/41 lesions underwent first follow-up
at median 6 months with no evidence of recurrence.
Table 1: Baseline characteristics and outcomes of the 34 patients and 41 SSP
that underwent piecemeal cold snare polypectomy (pCSP). IQR – interquartile
range, SC1 - first surveillance colonoscopy.
pCSP (n¼ 41)
Patient
Age, mean (standard deviation) 68.58 (10.12)
Sex, female (%) 27 (79.4)
Lesion
Size, median (IQR) 15 (14.5–20)
Location, proximal to transverse colon (%) 26 (63.4)
Paris classification (%)
0-IIa 40 (97.6)
0-IIb 1 (2.4)
Endoscopic evidence of dysplasia (%) 0 (0)
Kudo, highest (%)
II-O 41 (100)
Procedure
Duration, median minutes (IQR) 4.5 (1.4 to 6.3)
Pieces, median (IQR) 3.0 (3–5)
Protrusion within defect (%) 9 (22.0)
Intra-procedural bleeding requiring intervention (%) 0 (0)
Histopathology, serrated adenoma (%) 41 (100)
Low grade cytological dysplasia (%) 3 (7.3)
Outcomes pCSP (n¼ 41)
Adverse events
Clinically significant post endoscopic bleeding (%) 0 (0)
Delayed perforation (%) 0 (0)
Post procedural pain (%) 0 (0)
Admission to hospital for related complication within 2 weeks 0 (0)
Follow up
Months to SC1, IQR 6 (5–7)
Recurrence at SC1, (%), n¼ 8 0 (0)
Histologic recurrence at SC1, (%), n¼ 5 0 (0)
Conclusion: There is potential for pCSP to become the standard of care for non-
dysplastic large SSP. This may reduce the burden on patients and healthcare
systems of removing SSP, particularly by avoidance of delayed bleeding.
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Introduction: Polypectomy of adenomas reduces death due to colorectal cancer;
therefore colonoscopy is the gold standard to detect and treat adenomatous
lesions. Most adenomatous lesions are less than 20mm in size. Therefore, these
are not indication for endoscopic submucosal dissection (ESD). Recently, there
are some reports about cold snare polypectomy (CSP). CSP is effective and easy
to remove lesions of less than 5–10mm in size. On the other hand, in over 10mm
lesions, many endoscopists would remove it by endoscopic mucosal resection
(EMR) with monopolar snare. It is expected that the bipolar snare would
decrease the incidence of perforation because of electric current flow peculiar
to bipolar snare that does not flow through the wall of colon. So, by using
bipolar snare, hot snare polypectomy (HSP) that can be easily resected in a
short time may be safely performed for over 10mm colorectal lesions.
However, there is no report about them.
Aims & Methods: We aimed to clarify removal method, procedure time and
complications for over 10mm colorectal lesions endoscopically resected using
bipolar snare. Consecutive patients with over 10mm colorectal lesions endosco-
pically resected using bipolar snare in National Cancer Center Hospital East
between September 2016 and March 2017 were enrolled in this study, prospec-
tively. The removal method rate of these lesions, each procedure time, complete
resection rate, bleeding rate and perforation rate, and pathological finding were
assessed.
Results: A total 92 lesions in 67 patients were analyzed. 47 patients (70%) were
male, and the median age was 67 years (range: 44–88). The median lesion size was
13mm (range: 10–30). The macroscopic type was 33 (36%) polypoid lesions and
59 (64%) flat lesions. The location was 55 (60%) lesions in right colon, 31 (34%)
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in left colon and 6 (6%) in rectum. Pathological diagnosis was 22 (24%) hyper-
plastic polyp or SSA/P, 42 (46%) low grade dysplasia (LGD), 23 (26%) high
grade dysplasia (HGD), and 1(1%) submucosal invasive cancer. In the removal
methods, HSP was 71 (77%) lesions and EMR was 21 (23%). The median
procedure time of HSP and EMR was 37 seconds (range: 7–430) and 167
(range: 60–450) (p5 0.001). The median lesion size of was HSP and EMR was
12mm (range: 10–30) and 20 (range: 10–28) (p5 0.001). The immediate bleeding
of HSP and EMR occurred in 7 (10%) lesions and 6 (33%) (p¼ 0.009). The
delayed bleeding of HSP and EMR occurred in 2 (3%) lesions and 0
(p¼ 0.437). Perforation was not occurred. No tumors were horizontal and ver-
tical margin positive. In the pathological diagnosis, 86% of hyperplastic polyp or
SSA/P, 86% of LGD, and 57% of HGD was resected by HSP, and submucosal
invasive cancer was resected by EMR.
Conclusion: Of over 10mm colorectal lesions was resected by using bipolar snare,
77% were resected by HSP. The procedure time of HSP was significant shorter
than EMR.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The ‘SMSA’ polyp scoring system is a method of risk stratifying the
difficulty of polypectomy based on expert consensus opinion. The score is simple,
intuitive and has previously not been evaluated in a large multicentre setting.
Aims & Methods: We aimed to determine the ability of the SMSA polyp score to
predict robust endpoints after endoscopic mucosal resection (EMR) of colonic
laterally spreading lesions (LSL). The SMSA polyp score was applied to a pro-
spectively collected multicentre database of LSL resected by EMR over eight
years. This score describes the complexity of polypectomy with respect to four
major domains (table 2) and is subsequently divided into four levels. Standard
inject and resect EMR procedures were performed with detailed patient, proce-
dural and outcome data recorded prospectively over the study period including
all features of the SMSA. In patients who had multiple lesions resected the largest
lesion was retained for analysis. The primary endpoints were correlation of
SMSA score with completion rate, adverse event rate and adenoma recurrence.
Results: 2305 lesions in 2305 patients (47.4% M, 45, 2% right colon) underwent
EMR. The majority of lesions were SMSA 4 (50.2%) with a median lesion size of
30mm (range 20–160mm). Failed single session EMR occurred in 97 (4.2%) and
this was predicted by increasing SMSA (p5 .001). Intra-procedural bleeding was
significantly more common with increasing SMSA (SMSA 2, 19/229 (8.3%)
versus SMSA 4 291/1158 (25.1%), p5 .001). Clinically significant post EMR
bleeding (CSPEB) was more common as SMSA increased with 4 (1.7%) in the
SMSA 2 group and 90 (7.8%) in the SMSA 4 group, p¼ 0.001. Intra-procedural
perforation and delayed perforation were no different between the groups. After
EMR surgery at two weeks was more common in the SMSA 4 group (p5 .001).
Of those patients that underwent their first surveillance colonoscopy (SC1),
endoscopic recurrence (EDR) was more common in the SMSA 4 group than
the SMSA 2 group, 206 (23.7) as compared to 9 (5.4%), p5 .001. This was
also the case for histologic recurrence (p5 .001). The difference in EDR persisted
to the second surveillance colonoscopy (SC2) with no recurrences in the SMSA 2
group versus 9.1% in the SMSA 4 group.
Table 1: Outcomes after endoscopic mucosal resection at the initial procedure, 2
weeks and subsequent surveillance procedures.
SMSA 2 SMSA 3 SMSA 4 p value
Total 229 (9.9) 918 (39.8) 1158 (50.2)
Successful EMR (%) 226 (98.7) 894 (97.4) 1088 (94.0) 5.001
Duration - min (median IQR) 10 (5–15) 15 (10–20) 30 (20–45) 5.001
IPB (%) 19 (8.3) 115 (12.5) 291 (25.1) 5.001
Deep injury * (%) 11 (4.8) 33 (3.6) 54 (4.7) .448
CSPEB (%) 4 (1.7) 46 (5.0) 90 (7.8) .001
Delayed Perforation (%) 0 (0) 2 (0.2) 5 (0.4) .640
Surgery at 2w (%) 20 (8.7) 50 (5.4) 117 (10.1) .001
Underwent SC1 (n) 166 685 871
EDR SC1 (%) 9 (5.4) 71 (10.4) 206 (23.7) 5.001
HDR SC1 (%) 3 (6.4) 36 (13.4) 120 (28.7) 5.001
Surgery SC1 (%) 1 (0.6) 7 (1.0) 12 (1.4) .747
Underwent SC2 (n) 88 326 462
EDR SC2 (%) 0 (0) 21 (6.4) 42 (9.1) .008
Surgery SC2 (%) 0 (0) 1 (0.3) 3 (0.6) .766
EMR – endoscopic mucosal resection, IPB – intra-procedural bleeding, IPP –
intraprocedural perforation, CSPEB – clinically significant post endoscopic
bleeding (bleeding after EMR requiring admission to hospital or re-intervention),
2w – two weeks, SC1/2 - surveillance colonoscopy 1/2. * target sign or actual hole
corresponding to DMI type III/IV - Sydney Classification (1)
SMSA score (2)
Size Points Morphology Points Access Points Site Points
51 cm 1 Pedunculated 1 Easy 1 Left 1
1–1.9 cm 3 Sessile 2 Difficult 3 Right 2
2–2.9 cm 5 Flat 3
3–3.9 cm 7
44 cm 9
SMSA Level Points
1 4–5
2 6–9
3 9–12
4 412
Conclusion: SMSA is a simple readily applicable clinical score that identifies a
subgroup of patients who are at increased risk of EMR related complications
including CSPEB and recurrence. This information is useful for planning EMR
lists with respect to time and resource allocation. Moreover SMSA could have a
major impact on training, both in identifying appropriate training cases and
providing an objective benchmark against which to assess the progress of trainees
in EMR.
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Introduction: Sessile serrated adenoma/polyp (SSA/P) has been accumulated
increasing attention since its risk for developing to cancer had been clarified.
These polyps are difficult not only to detect but also to determine their precise
margin after detection especially in right side colon. Such a difficulty leads high
recurrence rate after endoscopic resection. Magnifying function and narrow band
imaging (NBI) is reported to be useful for evaluation of SSA/P but it needs
special equipment, extra time, and expertise. Easier, uncomplicated, and non
time consuming method is desired. The use of acetic acid or acetic acid-indigo
carmine mixture have been introduced into endoscopic diagnosis in Barrett’s
esophagus, early gastric cancer, and colorectal early cancer. However, there
have been no reports on using this agent as aid for the optimal diagnosis of
the margin of SSA/P. If this rather cheap agent were helpful for realizing the
precise margin of SSA/P, it could decrease insufficient removal of the polyp and
recurrence after that.
Aims & Methods: The aim of this pilot study is to assess whether the acetic acid
could facilitate the recognition of the margin of SSA/P. We used acetic acid as a
mixture with indigo carmine and compared it to conventional evaluating meth-
ods; narrow band imaging (NBI) and indigo carmine. From December 2016 to
February 2017, patients in whom SSA/P more than 10mm were found in right
side colon in daily practical colonoscopy by single endoscopist in our institute
were included. We used the standard scope without magnifying function. First we
observed lesions with conventional white light and NBI. Second, we recorded
pictures with indigo carmine (IC) spray alone on it. Finally, we sprayed the
mixture of acetic acid and indigo carmine mixture (AIC) directly through the
endoscopic working channel without using catheter onto lesion. Using recorded
pictures during these procedures, ability for recognizing the margin of polyps
were compared between IC and AIC, or NBI and AIC by 3 endoscopists, and the
concordance rate of diagnosis among these three were assessed as Kappa
statistics.
Results: 9 SSA/P lesions in 7 patients were investigated. In all cases, AIC was
helpful to recognize the margin of polyps without causing any obstructive effect.
We also observed disappearance of mucous on the surface, dilated crypts caused
by acid contact, and aceto-whitish reaction on the surficial glands in all lesions.
In comparing the ability for recognizing the margin of the lesions, 6.3 in 9 lesions
(mean among 3 practitioners) were thought to be as AIC better than IC, and
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similarly 7.3 in 9 were better than NBI. Kappa value among participants was 4.8;
moderate agreement (p¼ 0.0016). All polyps were removed endoscopically after
evaluation. All lesions were histologically diagnosed as SSA/P without dysplasia.
Conclusion: Acetic acid was useful and promising to facilitate the endoscopic
recognition of the precise margin of SSA/P in right side colon. Strength of this
method is that it is very simple and needs no special equipment nor skill.
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Introduction: Preoperative localization or tattooing is essential for minimally
invasive surgery. Although preoperative endoscopic tattooing using India ink
or indocyanine green is widely used, clinical evidence and safety profile support-
ing the use of these agents is lacking.
Aims & Methods: We assessed the efficacy and safety of preoperative endoscopic
tattooing using autologous blood. A total of 80 patients who underwent endo-
scopic tattooing using either India ink or autologous blood were included in this
study. From February 2016, all patients who required localization of a target
lesion before colorectal surgery underwent endoscopic tattooing using autolo-
gous blood at a single tertiary medical center, and the outcomes were collected
prospectively. As a comparison, we retrospectively reviewed the medical records
of a further 40 consecutive patients who underwent endoscopic tattooing using
India ink before February 2016. The primary outcomes were the visibility of the
tattooing in the peritoneal cavity and related adverse events.
Results: Endoscopic tattoos produced using India ink were visible in 38 (95%)
patients, and tattoos created using autologous blood were visible in 36 (90%)
patients. In the autologous blood group, the tattoo could not be identified in four
patients due to excessive peritoneal fat, bleeding tendency, congenital anomaly,
and tattooing to an inadequate depth. Eight (20%) patients in the India ink
group and four patients (10%) in the autologous blood group experienced endo-
scopic tattooing-related adverse events.
Conclusion: Preoperative endoscopic tattooing using autologous blood is a fea-
sible and safe modality for the preoperative localization of colorectal lesions.
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Introduction: Laterally spreading tumors (LSTs) are defined as lesions 410mm
with a low vertical axis and lateral extension. They are separated in 2 groups with
2 subclasses for each of them: granular LST (LST-G) with, or without large
nodule; and non-granular LST (LST-NG), separated into flat lesions (IIa) and
depressed lesions (IIaþ IIc). Every subclass have been associated with a proper
risk of cancer and submucosal invasion (T1sm)1, 2. Knowing this aspect could
help for the decision of the resection technique (endoscopic mucosectomy EMR,
endoscopic submucosal dissection ESD, or surgery). The aim of our study was to
determine the rate of cancer (submucosal and mucosal adenocarcinoma) in a
western series of LST treated by endoscopic resection, and to evaluate the ability
of the endoscopist to predict the depth of cancer invasion.
Aims & Methods: The entire patients with a LST 20mm treated between
January 2012 and December 2016 in our single center were included.
Endoscopic data were collected (size, location, LST classification, analysis of
pit pattern, endoscopic suspicion of cancer). We also reported the resection
technique, histological results, and the follow-up at 1 year.
Results: 377 LST were included in our study. The average age was 67.7 years old.
The mean size of lesion was 40.6mm. LST were located in the right colon, the
rectum, the left colon and the transverse colon in 44.5%, 32.6%, 14.0% and
8.8%, respectively. The resection technique used was a monobloc EMR in
15.4%, piecemeal EMR (pEMR) in 42.9%, ESD in 27.3% and assisted ESD
in 14.5%. ESD was associated with a significant lower risk of recurrence after
1 year (4.9% against 18.1%). Considering the LST classification, there were
27.0% LST-G without large nodule, 28.4% LST-G with large nodule, 35.5%
flat LST-NG IIa, and 9.0% LST-NG with depression IIaþ IIc. The overall rate
of adenocarcinoma was 19.7%, and 9.0% with submucosal invasion. The rates of
adenocarcinoma and the rates of submucosal invasion in every subtype of LST
are reported in table 1. They were higher for LST-G with large nodule (34.5%
and 15.9% respectively) and for LST-NG with depression (35.3% and 20.6%).
Regarding the prediction of submucosal cancer by the endoscopist, we report a
low sensitivity, and positive predictive value (respectively 64.7% and 32.8%).
However, we had a good specificity and negative predictive value (86.0% and
96.0%). Endoscopic predictors of submucosal cancer were invasive pit pattern
(HR 33.0; p¼ 5.78e-07) and depression (HR¼ 11.86; p¼ 0.049).
Rate of adenocarcinoma and submucosal invasion for each type of LST
LST G
LST-G with
large nodule
LST-NG
type IIa
LST-NG
IIaþ IIc
Number (n/%) 102/27, 0 107/28, 4 134/35, 5 34/9, 0
Cancer (n/%) 12/11, 8 37/34, 5 11/8, 2 12/35, 3
T1sm (n/%) 5/4, 9 17/15, 9 4/3, 0 8/20, 6
Conclusion: Our western series confirm similar rates of submucosal adenocarci-
noma according to the type of LST as compared to Asian series. LST-G with
large nodule, and LST-NG with depression were associated with a higher risk of
submucosal invasion and invasive pit pattern was the stronger predictor of malig-
nancy. Endoscopic submucosal dissection should be systematically performed in
these cases.
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Introduction: Evidence on an international variation of pathological types and
anatomical distribution of colonic polyps is beneficial for early detection and
management but limited.
Aims & Methods: To characterize differences in colonoscopy findings by ethni-
city, a random sample of patients aged at least 50 years without colonic symp-
toms or history of colonic diseases who underwent colonoscopy were reviewed.
Of 26,508 subjects, 2651 were randomly selected. Of 1300 subjects who met the
inclusion criteria, abnormal findings were identified in 878 cases (67.54%), of
which 452 cases had 940 polyps and 7 cancer lesions were found in 6 cases. Of 452
patients with polyps, half had only one polyp (53.76%) and were Asian (54.65%),
followed by Caucasian (26.99%), Middle Eastern (15.71%), and other ethnic
origins (2.65%) (Figure). Ethnicity-specific polyp prevalence were 36.26%,
38.05%, 27.24%, and 34.15%, respectively. Polyps of Caucasian subjects
tended to be smaller (4.52mm) and locate on the left side of the colon
(65.63%) than that of other ethnicities (44.44%–60.53%). The majority of the
polyps (84.04%) were small (5¼ 5mm) whereas 8.19% were large (4¼ 10mm);
hyperplastic polyp, tubular adenoma (TA), and tubulovillous (TVA) adenoma
were identified in 43.19%, 53.83%, and 2.34%, respectively. Premalignant
(TAþTVA) polyps were found in 56.08%, 50.19%, and 64.23% of the polyps
of Asian, Caucasian, and Middle Eastern patients, respectively. Premalignant
lesions were found in 52.91% of small polyps.
Conclusion: The findings suggested that number, size, distribution, and patholo-
gical type of colonic polyps vary across ethnic groups. As more than half of small
polyps were a tubular adenoma, we propose that polyps of all sizes should be
removed when feasible.
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Introduction: Endoscopic submucosal dissection represents the standard of care
for large superficial colo-rectal neoplasms in Japan. In Europe, only few studies
reported promising results, essentially in the rectal location. Colonic ESD is more
technically challenging because of the colonic loops, intestinal motility, the
folded anatomy, problems caused by inconstant gravity, and submucosal fibro-
sis. Colonic ESD is although more risky because perforations are most often non
clinically significant in the rectal location (under peritoneal reflection) contrary
to the colonic location. Here we reported our results of two years of colonic ESD
performed by two French expert teams that began colonic ESD after a strong
animal training and a strong experience in rectal and upper-digestive tract ESD.
Aims & Methods: Retrospective bicentre study of all cases of colonic ESD per-
formed between 01/2016 and 03/2017 for superficial pre-cancerous or cancerous
neoplasms. Primary Endpoint was to evaluate the En bloc, R0, curative resection
rate and extended curative resection rate (Curative resectionþnon-curative due
to positive horizontal margins and without recurrent disease on endoscopic con-
trol). Secondary endpoints were to compare these results with results of rectal
ESDs performed during the same period.
Results: 87 colonic ESD were performed in two French centers between 01/2015
and 03/2017 for superficial pre-cancerous or cancerous neoplasms. During the
same period 93 rectal ESDs were performed for superficial pre-cancerous or
cancerous neoplasms. Descriptive results: male 54 (61%), mean size of the speci-
men: 49mm, mean duration of procedure 125.1min, mean speed of ESD: 18.9
mm2/min, perforation rate: 9 (10.3%), post procedural bleeding rate: 2.3%, sec-
ondary surgery 13 (15.3%) (3 (23%) for a perforation; 10 (77%) for a failure or
pathological risk factor or lymph node metastasis) Colonic location: 26 (30%)
sigmoid, 8 (9.2%) left colon, 6 (6.9%) splenic flexure, 9 (10.3%)transverse colon,
10 (11.5%)hepatic flexure, 14 (16.1%) right colon, 14 (16.1%) caecum
Pathological analysis: low grade dysplasia in 24.7%, high grade dysplasia in
35.8%, intra-mucosal carcinoma in 19.8%, superficial submucosal carcinoma
in 7.5%, deep submucosal carcinoma in 8.6% and T2 adenocarcinoma in
3.7%. Only 2 patients (3.1%) had a recurrent disease during endoscopic follow
up. Primary Endpoint: En bloc resection: 87.4%, R0 resection: 73.5%, curative
resection: 63.8%, extended curative resection: 85.7% Secondary Endpoint: No
statistically significant parameters have been found between rectal and colonic
ESD (Table 1).
RECTUM n¼ 87 COLON n¼ 93 p
Age (Y) 66.9 66.9 0.99
Duration (min) 124 125 0.93
Large diameter (mm) 54.6 49 0.03
Small diameter (mm) 41.6 38 0.17
Surface (mm2) 1948 1937.5 0.95
Speed (mm2/min) 20.1 18.9 0.6
Exclusive ESD 96% 92% 0.09
Monobloc resection 94.40% 87.40% 0.09
R0 resection 74.10% 73.50% 0.73
Curative resection 68.50% 63.90% 0.87
Extended curative resection 91.40% 85.80% 0.3
Perforation 7.70% 10.30% 0.6
Post ESD bleeding 6.60% 2.30% 0.28
Pathological analysis 0.76
DBG 24.80% 24.70%
DHG 33.70% 35.80%
Intramucosal ADK 27% 19.80%
sm5 1000 ADK 3.40% 7.50%
sm4 1000 ADK 9% 8.60%
T2 ADK 2.20% 3.70%
secondary surgery 8 (8.8%) 13 (15.3%) 0.16
Perforation 0 (0%) 3 (23%)
failure 2 (25%) 6 (46.1%)
Pathological reason 6 (75%) 4 (30.8%)
Recurrence 0 (0%) 2 (3.1%) 0.7
Conclusion: Colonic ESD could be perfomed with similar results than rectal ESD
in French expert teams with prior strong experience in animal ESDs and rectal
ESDs. It allows en bloc resection of large superficial colorectal neoplasms with a
very low risk of recurrence. RCTs comparing colonic ESD to piece-meal EMR
are needed to determinate the appropriate place of each technique in Europe.
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Introduction: It is well known that acromegalics have been at an increased risk of
colorectal neoplasm. However, there has been few reports of them in Japanese
patients with acromegaly. In this study, we attempted to elucidate the risk of
colorectal neoplasm in Japanese patients with acromegaly comparing with
healthy controlled patients.
Aims & Methods: Between April 2008 and September 2016, a total of 745 patients
were underwent Hardy operation in our institute. Among them, a total of 178
patients were performed colonoscopy in our hospital during perioperative period
and were enrolled in the case group. In contrast, a total of 356 patients were
selected randomly from those who were performed colonoscopy in our medical
check-up in the same period by means of being matched to cases of the age and
gender. The incidence, size, location and histology of colorectal neoplasm were
investigated.
Results: As background, 84 patients (47.2%) were men and 94 patients were
women, and the median age was 47.5 years old (18 to 75) in the case group.
The median height/weight was 165.5 cm/65.1 kg in the case group and it was
significantly larger than the control group (163.4 cm/60.1 kg) (p¼ 0.038,
p5 0.001 respectively). The median Body Mass Index (BMI) were 23.4 in the
case group and 22.5 in the control group. There was a significant difference
between two groups (p5 0.001). The frequency of colorectal neoplasm was
66.8% (119/178 patients) in the case group and was significantly higher than
control group of 24.2% (86/356 patients) (p5 0.001). The average number and
size of neoplasm were 2.44 and 4.74mm in the case group and 1.77 and 3.89mm
in the control group. There was a significant difference between two groups
(p¼ 0.001). The distribution of neoplasm in the case group vs in the control
group was shown 12.6% vs 12.8% in cecum, 30.3% vs 36% in ascending
colon, 23.5% vs 30.2% in transverse colon, 15.1% vs 10.5% in descending
colon, 66.4% vs 40.7% in sigmoid solon, and 31.9% vs 19.8% in rectum. The
incidence of neoplasm in sigmorectal region had a significant difference in two
groups (the case group 80.7% vs the control group 53.5%) (p5 0.001). In terms
of neoplasm larger than 5mm, the frequency was 34.3% (61/178 patients) in the
case group and 7.6% (27/356 patients) in the control group (p5 0.001). In addi-
tion, as for neoplasm larger than 10mm, that was 15.2% (27/178 patients) and
2.2% (8/356 patients) respectively (p5 0.001). The number of neoplasm resected
by endoscopy was 71 lesions (24.5% of all) in the case group and 25 lesions
(16.4%) in the control group. The pathological examination in the case and
control group showed eight and one had hyperplastic polyps, 2 and zero had
sessile serrated adenoma/polyp, 3 and zero had inflammatory polyp, 48 and 19
had low to moderate grade adenomas, 4 and 3 had High grade adenomas, one
and zero had carcinoid, and 5 and 2 had carcinoma respectively. There were no
significant differences between two groups in the limited cases of high grade
adenoma and carcinoma.
Conclusion: This study showed the acromegalic patients had an increased risk of
colorectal neoplasm especially, in the sigmorectal region. It is important to be
performed colonoscopy at the diagnosis of acromegaly.
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Introduction: Colonoscopy in ulcerative colitis (UC) is performed as first diag-
nosis and during screening for dysplasia and disease flares. It is an invasive
procedure with a burden of discomfort and possible complications. To overcome
discomfort and complications due to colonoscopy an Italian high-tech start-up
(Endotics, Peccioli, Italy) developed a soft, self-propelled, disposable robotic
colonoscope (R), approved with CE mark.
Aims & Methods:We wanted to compare diagnostic performance and tolerability
of R with those of standard white light colonscope (S) in patients with ulcerative
colitis. Consecutive patients referred for colonoscopy to our endoscopy depart-
ments with clinically mild to moderate ulcerative colitis that signed the informed
consent for both procedures were studied first with R and then with S (Olympus
CF-145), by two different operators, blinded to previous observations. R had the
following technical specifications: 17mm outer diameter, rest position length
probe 30 cm; maximum length of probe 54 cm; working length 210 cm; NTSC
CMOS analog camera. Conscious sedation with midazolam was administered as
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needed. We recorded endoscopic activity according to Baron criteria, time to
reach the caecum, sedation, patient’s pain/discomfort and operator’s difficulty.
Results: We studied 12 patients (7M/5F), mean age 41 yrs and disease duration
5.33 yrs. 53 colonic segments out of the 54 evaluated had the same assessment of
disease activity (absent¼ 0 points, mild¼ 1 pt, moderate¼ 2 pts and severe¼ 3
pts) with R and S. Mean activity score with R was 0.35 pts (SD 0.60) and 0.33 pts
(SD 0.60) with S, without significant difference. The caecum was reached in 11/12
cases by S in an average of 29.42min (SD 28.94), and in 10/12 cases by R, in an
average of 46.67min (SD 24.98min), with a mean difference of 17, 25min., not
statistically significant. Incomplete colon explorations with R clustered in Milan,
probably because of smaller experience. An average of 1.45 (SD 0.79) mg of
midazolam were used during S while 0.41 (SD 0.38) mg during R. Mean pain/
discomfort on a 0–10 scale was 2.08 (SD 1.67) for R and 4.17 (SD 1.74) for S,
with a statistically significant difference (p¼ 0.066) favouring R. Mean perceived
operator’s difficulty on a 0–10 scale was 4.44 (SD 1.78) for R, and 4.08 (SD 1.44)
for S, with a mean difference of 0.42 pts favouring S, not statistically significant.
Conclusion: R appears to be a promising method for disease staging in patients
with ulcerative colitis, because of comparable accuracy and reduction in pain and
discomfort. A tool channel to obtain biopsies and perform therapeutic endo-
scopy, together with images of higher definition (CMOS digital Camera HD
ready) and virtual chromo-endoscopy, useful for follow-up and screening for
dysplasia in patients with long duration of disease are now available in the
latest version of R. The ‘‘column’’ connected to the latest version of the robot
is the size of a portable suitcase, and suitable for remote operation. Further
studies with newer versions of R are needed to assess the role of this technology
from an economic point of view and in special settings like failed screening
colonoscopies, dysplastic lesions in UC, bed-side colonoscopy, colonoscopy in
rural areas.
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Introduction: The LST classification and Paris classification systems are interna-
tionally used to describe polyp morphology. Differences between Japanese and
Western endoscopists in the use of classification systems, have been observed. We
aimed to evaluate the inter-observer agreement of LST classification amongst
Western & Japanese experts.
Aims & Methods: A total of 40 endoscopic video clips depicting LSTs (10%
malignant) were by 6 expert endoscopists; 3 from Japan and 3 from the West.
Assessments included LST classification (LST-G homogeneous, LST-G mixed,
LST-NG flat, LST-NG pseudodepressed), Paris classification, invasiveness,
treatment suggestion and mean size of lesion. We calculated the interobserver
agreement with weighted kappa and Chi square.
Results: Japanese endoscopists diagnosed more lesions as LST-G than Western
(62.7 vs. 45.4%), Western diagnosed more LST-NG than Japanese (54.6 vs.
37.3%; p¼ 0.007). The interobserver agreement of the LST classification
among the six experts was good with a weighted Kappa of 0.61 (IC 95% 0.43–
0.78) for Japanese, and moderate at 0.45 (IC95% 0.27–0.64) for Western.
Difference in concordance between the two cohorts was not statistically signifi-
cant (p¼ 0.22). When only two categories were considered (LST-G vs NG),
agreement was very good for Japanese (weighted Kappa of 0. 81; 95% CI
0.65–0.97) and good for Western endoscopists (0.65; 95% CI 0.46–0.85).
Again, difference in concordance was not statistically significant (p¼ 0.22).
Piecemeal Endoscopic Resection was suggested in 34, 7% cases by Western,
but never by Japanese endoscopists, whereas Endoscopic Submucosal
Dissection was recommended in 50.4% and 16.1% cases by Japanese and
Western experts respectively (p5 0.0001).
Conclusion: This study is the first to validate the LST classification system com-
paring East and West. There were significant differences in the types of LST
diagnosed, and concordance was good in the Japanese cohort and moderate in
the Western, but not significantly different. The recommendations for treatment
were also different. We suggest a modification of the classification system to
enable a more unanimous diagnosis and therapeutic strategy.
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Introduction: A scoring system based on size, morphology, site and access (SMSA
score) was established for determining the complexity of polypectomy or endo-
scopic mucosal resection (EMR) and it could predict outcomes.
Aims & Methods: The aim of this study was to assess the usefulness of the SMSA
scoring system relating the difficulty level with outcomes and complications of
EMR and to compare it with a subjective classification of difficulty. We con-
ducted a prospective multi-center study with 1997 consecutive patients with large
(20mm) non-pedunculated colorectal lesions (LNPCL) treated by EMR
(n¼ 2198) at 23 hospitals belonging to the Spanish Endoscopy Society
Endoscopic Resection Group, from January 2013 to October 2016. We
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calculated the SMSA score of difficulty and assessed the ability of SMSA to
identify 5 outcomes: 3-months recurrence, 1-year recurrence, global recurrence
(endoscopy not effective after 2 or more treatments), delayed bleeding and per-
foration. We compared results with those obtained using a subjective classifica-
tion of difficulty: easy or medium vs difficult. Comparisons were conducted using
chi-squared tests and complemented with logistic regression models.
Results: The SMSA scoring system classified 690 polyps (39%) as level 4 and
1098 (61%) as level 3, whereas the subjective classification system classified 399
(22%) as difficult and 1389 (78%) as easy or medium. The agreement between
measures of difficulty was weak (k¼ 0.33). 255 patients (19.9%) had recurrence 3
months after EMR, 84 (11.6%) had recurrence at 1 year, 78 (3.5%) suffered
delayed bleeding and 35 (1.8%) perforation. The level 4 polyps had significantly
higher rates of recurrence at 3 months and 1 year (p5 0.001 in both cases) and
delayed bleeding (p¼ 0.012). We did not found differences for global recurrence
and perforation. Using the subjective indicator of difficulty, recurrence was also
more frequent in the higher difficulty category at 3-months, 1-year and the global
recurrence (p5 0.001 in all three cases) and for delayed bleeding too (p¼ 0.006),
but not for perforation.
Conclusion: The SMSA grading tool is a predictor of outcomes or recurrences
and bleeding following resection of LNPCL. However, in our multi-center
sample, it does not appear to overcome the ability of a subjective indicator of
difficulty made by the endoscopist during the EMR. It seems that this score can
be used to facilitate planning, training or competency assessment, but efforts
should be focused on validating the scoring system in a real situation, adjusting
the score of variables or including new ones.
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Introduction: Accurate diagnosis of gastrointestinal tuberculosis (GITB) is chal-
lenging due to pauci-bacillary nature of disease and poor sensitivity of histo-
pathology. Role of tissue acquisition using narrow band imaging magnification
(NBI-M) to improve yield of histopathology over high-definition white light
endoscopy (HD-WLE) has not been assessed.
Aims & Methods: To compare the utility of narrow band imaging with magnifi-
cation versus high-definition white light imaging guided endoscopic biopsy for
diagnosis of gastrointestinal tuberculosis. In this prospective study from July
2015 to November 2016, adult cases of clinically suspected GITB were recruited.
All patients underwent mantoux test, contrast enhanced computed tomography
of abdomen, esophagogastroduodenoscopy and/or colonoscopy using both HD-
WLE and NBI-M and guided biopsies using both were taken. Histopathological
examination was done by two independent pathologists. A final diagnosis of
GITB was made if acid-fast bacilli were seen in tissue or grown in culture,
histopathology showed caseous necrosis with granulomatous inflammation or
clinical/radiological and endoscopic features were suggestive of tuberculosis
and a good clinical response to antitubercular therapy.
Results: A total of 55 cases of clinically suspected GITB were recruited. A final
diagnosis of tuberculosis was made in 32 cases (duodenal n¼ 4, ileocolic n¼ 28).
Concomitant evidence of active or healed pulmonary tuberculosis was seen 21%
of cases. The mean age, haemoglobin and erythrocyte sedimentation rate of
patients with tuberculosis were 36.41þ 14.6 years, 10.2þ 2.4 g/dl,
37.8þ 15.3mm/hour respectively. The mean duration of symptoms was 10.9
months. The most common symptoms were pain abdomen (78%), weight loss
(62.5%), and loss of appetite (40.6%), fever (37.5%), vomiting (34%) and diar-
rhoea (22%). Mantoux test was positive in 40.6% cases. The most common
endoscopic findings were ulcerations (75%), nodularity (46.8), distorted ileocecal
valve (28%) and strictures (21.8%) (Table 1). The most common radiological
findings were mural wall thickening (65.6%), mesenteric lymphadenopathy
(56%) and strictures (40%) (Table 1). NBI-M guided biopsy confirmed the diag-
nosis of GITB in 46.88%, while HD WLE guided biopsy confirmed diagnosis of
GITB in 28.12% (P, 0.04). The two sets of biopsies together confirmed diagnosis
of GITB in 53.1%. The area under curve for NBI-M plus HDWLE, NBI-M
alone and HDWLE alone were 0.77(0.63–0.87) 0.73 (0.60–0.85) and 0.64 (0.50–
0.77) respectively. Patients were started on anti-tubercular therapy for nine
months. Four patients underwent surgery for intestinal obstruction while on
antitubercular therapy. Twenty eight completed full therapy and improved.
Conclusion: NBI-M guided biopsy improved the yield of histology for diagnosis
of GITB.
Endoscopic findings Radiological findings
Parameter N (%) Parameter N (%)
Ulcerations 24 (75) Mesenteric lymphadenopathy 18 (56)
Nodularity 15 (46.8) Mural thickening 21 (65.6)
Stricture 7 (21.8) Stricture 13 (40)
Distorted Ileocecal valve 9 (28.1) Ascites 5 (15.6)
Hyperemia 3 (9.3) Peritoneal thickening 1 (3.1)
Pseudopolypii 2 (6.2) Omental nodularity 1 (3.1)
Intussception 1 (3.1) Psoas abscess 1 (3.1)
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Introduction: Colorectal cancer is a leading cause for cancer related mortality.
Adenomatous polyp, the precursor, can usually be endoscopically resected to
prevent cancer. Currently, there are no criteria for surgical vs. endoscopic resec-
tion and decision is individually made by the treating physician.
Aims & Methods: We aimed to evaluate factors associated with short-term effi-
cacy and safety of endoscopic resection of large (20mm) and giant (40mm)
adenomas. Consecutive cases that underwent endoscopic resection of adenomas
larger than 20mm were included. Endoscopic, clinical and histological details of
polyps and of the endoscopic procedure were recorded as well as the need for
surgical resection.
Results: Total of 351 resections were included. Average diameter was
30.34 10.66mm. Surgery was indicated in 21 (5.98%) cases. In a multivariate
analysis for efficacy, two variables were independent risk factors for surgery:
adenoma size (OR 95%CI 1.08 (1.04–1.12)) and cecal location (OR 95%CI
5.97 (1.60–22.33)). Post-polypectomy complications were documented in 85
cases (24.2%): bleeding - 69 (19.7%, 54/69 managed during procedure), perfora-
tions - 8 (2.3%) and significant discomfort up to early termination of procedure -
15 (4.3%). Only 21 (6.0%) developed serious complications requiring further
hospitalization. In multivariate analysis for safety, independent risk factors for
post-polypectomy complications were: adenoma size (OR 95%CI 1.04 (1.01–
1.06), polyp morphology (sessile OR 95%CI 2.55 (1.45–4.51), flat OR 95%CI
2.40 (1.04–5.52)) and submucosal adrenaline injection (OR 95%CI 1.87 (1.11–
3.20)). Every increment of 1mm in adenoma diameter above 20mm, increased
the need for surgery by 8% and the risk for complications by 4%.
Conclusion: Resection of large or giant adenomas is generally a safe procedure
when performed by an experienced endoscopist. Although adenoma size is the
most significantly related to efficacy and safety, each case of giant adenoma
should be evaluated in a referral center for feasibility of endoscopic resection.
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Abstract: P0871. Outcome by SMSA grade. Odds ratios and 95% CI ROC Curves by SMSA using the score in the continuous format.
SMSA score Subjective difficulty score ROC Curves by SMSA
Level 3 Level 4 p-value Not difficult Difficult p-value ROC curve OR(95%CI) p-value
3-months recurrence 73(12.2%) 125(27.6%) 50.001 125(15.2%) 72(30%) 50.001 0.64(0.60, 0.69) 1.28(1.18, 1.38) 50.001
1-year recurrence 29(7.7%) 46(17.2%) 50.001 46(9.0%) 28(20.9%) 50.001 0.66(0.59, 0.72) 1.33(1.18, 1.50) 50.001
Global recurrence 25(5.8%) 27(8.9%) 0.106 27(4.7%) 24(14.7%) 50.001 0.54(0.46, 0.63) 1.08(0.94, 1.24) 0.318
Delayed bleeding 29(3.1%) 35(5.6%) 0.012 41(3.4%) 24(6.6%) 0.006 0.61(0.53, 0.68) 1.23(1.09, 1.39) 0.001
Perforation 18(1.9%) 10(1.6%) 0.631 18(1.5%) 10(2.8%) 0.105 0.55(0.46, 0.64) 1.06(0.88, 1.27) 0.521
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Introduction: Clinically meaningful delayed bleeding is the most frequent adverse
event following endoscopic colorectal mucosal resection. Observational and
interventional studies on the efficacy of prophylactic closure (PC) following
endoscopic mucosal resection (EMR) showed conflicting results.
Aims & Methods: The primary objective of this review is to evaluate the effec-
tiveness in preventing bleeding and post-polypectomy syndrome (PPS) or per-
foration of PC of colonic mucosal defects following endoscopic resection. We
performed a systematic review and meta-analysis of randomized controlled trials
(RCTs) from MEDLINE. We included studies with humans submitted to colo-
noscopy and in whom mucosal flat or sessile (Paris classification 0-II or Is)
lesions with an estimated size 10mm were found and removed.
Results: 269 articles were initially screened: 5 were RCTs, 4 of them were pooled
in the quantitative analysis. A total of 555 patients and 557 resected lesions
(proximal colon: 220; distal: 337) were included. Endoscopic procedures: 459
loop polypectomies and 98 submucosal dissections. A total of 298 lesions were
randomized to PC versus 259 to non-closure (NC). Number of events on PC
group: delayed bleeding (n¼ 3), PPS and perforation (n¼ 6). Number of events
on NC group: delayed bleeding (n¼ 13), PPS and perforation (n¼ 14).
Prophylactic mucosal defect closure was effective in reducing delayed bleeding
risk (OR 0.206, 95%CI 0.054–0.779; p¼ 0.020; I2¼ 0, 0%; 2 RCT and 452 lesions
included). There was a non-significant trend for PPS/perforation risk reduction
after PC (OR 0.349, 95%CI 0.114–1.070, p¼ 0.066; I2¼ 0, 0%; 2 RCT and 374
lesions included).
Conclusion: Prophylactic closure of mucosal defects after EMR of flat or sessile
colorectal lesions 10mm reduces de risk of delayed bleeding. Further studies
are needed to evaluate the effect on PPS/perforation prevention.
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Introduction: Endoscopic Submucosal Dissection has become the standard of
care for large superficial rectal precancerous and cancerous lesions. It allows
an en-bloc resection of large superficial lesions that increase the quality of patho-
logical analysis and considerably decrease the risk of recurrence. Risk of having
large superficial lesions increase with age and no study have focused specifically
on ESD in very old people (480 years). Indeed in this population alternative
surgery had a high morbidity and is often refused or contraindicated for these
patients
Aims & Methods: Retrospective bicentre study of all cases of rectal ESDs per-
formed between 06/2010 and 12/2016 for superficial pre-cancerous or cancerous
neoplasms in patients older than 80 years four French teams that performed
more than 150 ESDs in the last 5 years. Primary Endpoint was to evaluate the
En bloc, R0, curative resection rate and complications in patients older than 80
years. Secondary endpoints were to compare these results with results of rectal
ESDs performed during the same period for patients younger than 80 years.
Results: 58 rectal ESDs were performed in four French centers between 06/2010
and 12/2016 for superficial pre-cancerous or cancerous neoplasms in patients
older than 80 years. Descriptive results: male 28 (48%), mean size of the speci-
men: 56.4mm, mean duration of procedure 143.7min, mean speed of ESD: 19.8
mm2/min, perforation rate: 3 (5.2%), post procedural bleeding: 7 (12%), second-
ary surgery 2 (3.4%) (All for pathological reason) Pathological analysis: low-
grade dysplasia in 19%, high-grade dysplasia in 28%, intra-mucosal carcinoma
in 5%, superficial submucosal carcinoma in 5%, deep submucosal carcinoma in
5%, T2 adenocarcinoma in 3.4% and anal SCC in 6.9%. Only 1 patients (1.7%)
had a recurrent disease during endoscopic follow up. Primary Endpoint: En bloc
resection: 86.2%, R0 resection: 62.5%, curative resection: 62.5%, Secondary
Endpoint: Duration of procedure was longer in older people. Speed of ESD
was lower. En bloc and R0 resection were lower in very old patients. Cancer
was more frequent in very old patients. All comparative data between very old
patients (480 years) and younger patients (580 years) are resumed in table 1.
480 (n¼ 58) 580 (n¼ 275) p
Duration 143.69 113.78 0.053
Large diameter (mm) 56.43 56.36 0.98
(continued)
: Continued
480 (n¼ 58) 580 (n¼ 275) p
small diameter (mm) 43.31 41.42 0.54
Surface (mm2) 2289.67 2154.64 0.68
Speed (mm2/min) 19.76 24.72 0.01
Perforation 5.20% 6.30% 1
post ESD bleeding 12% 5.50% 0.07
Exclusive ESD 86.20% 95.50% 0.007
En bloc 86.20% 95.50% 0.007
R0 62.50% 74.20% 0.08
Curative 62.50% 69.30% 0.31
Pathological analysis 0.009
LGD 19% 23.6%
HGD 28% 34%
im ADK 31% 29%
sm5 1000 ADK 5% 6.9%
sm4 1000 ADK 5% 3.6%
T2 ADK 3.4% 2.1%
anal SCC 6.9% 0.3%
Secondary surgery 3.40% 7.30% 0.39
Recurrence 1.70% 1.40% 0.84
Conclusion: ESD is feasible and efficient in very old patients. However, En bloc
resection and R0 resection are less frequent than in younger patients probably
due to more challenging lesions (more frequent cancer on the pathological ana-
lysis). ESD should be the treatment of choice for large rectal superficial neo-
plasms of the rectum in very old patients in view of its oncological efficiency and
its safety in comparison to the surgical alternative.
Disclosure of Interest: All authors have declared no conflicts of interest.
Reference
Dong J, Wang W, Yu K, Gao Y, Cheng X, Liu P, et al. Outcomes of laparo-
scopic surgery for rectal cancer in elderly patients. J BUON. 2016 Jan;21(1):80–6.
P0876 COLONOSCOPY SPLIT-DOSE PROTOCOL
IMPLEMENTATION: A SINGLE-CENTRE EXPERIENCE
C. Palmela, C. Gomes, M.P. Costa Santos, M. Rocha, S. Pereira, D. Tavares,
R. Ribeiro, A. O. Ferreira, E. Barjas, M. Cravo
Gastroenterology Department, Hospital Beatriz Ângelo, Loures/Portugal
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Introduction: Split-dose bowel preparation (SD) is more effective in bowel cleans-
ing than previous day preparation (PD).
Aims & Methods: The main objective of the study was to explore the impact of a
SD protocol in bowel cleansing quality in patients from a district hospital. This
was an exploratory observational study of patients who underwent total colono-
scopy between jun/2016-mar/2017 with polyethylenoglycol bowel preparation
before and after SD protocol implementation. Bowel cleansing quality was
assessed prospectively (using Boston Bowel Preparation Score) and compared
between SD and PD groups. Tolerance was assessed using a patient
questionnaire.
Results: A total of 344 patients were included, 53% were male, mean age of
61.8 13.6 years. Bowel preparation: 66% SD and 34% PD. Overall, 72% of
colonoscopies occurred in morning shifts. Mean interval between finishing bowel
preparation and colonoscopy was 4h50 (SD) and 8h09 (PD). Adequate bowel
cleansing was found in 81% of patients (SD 83% vs. PD 79%; p¼ 0.34). There
was an association between adequate bowel cleansing and a shorter interval
between finishing preparation and colonoscopy (5h40 vs. 7h15; p¼ 0.010).
Split-dose preparation was associated with a better cleansing in the right colon
(2.17 0.69 vs. 2.03 0.65; p¼ 0.047) and a trend for better overall cleansing
(6.70 1.87 vs. 6.32 1.90; p¼ 0.067). On morning shifts, there was a significant
association between SD prep and better overall cleansing (p¼ 0.030) and also
right colon cleansing (p¼ 0.034). After adjusting for morning shifts, we found an
association between SD preparation and better bowel cleansing (risk difference
0.406; 95%CI 0.023–0.834; p¼ 0.063). There was no difference between groups
on bowel urgency (SD 2.6% vs. PD 1.7%; p¼ 0.718). SD preparation was asso-
ciated with worse sleep quality (SD 25% vs. DA 7%; p¼ 0.004).
Conclusion: The implementation of a split-dose bowel preparation protocol in
our hospital was associated with better bowel cleansing, especially on the right
colon. Split-dose preparation was not associated with higher bowel urgency,
although there was a worse sleep quality.
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Introduction: Spinal cord injury (SCI) is a devastating event that occurs with a
discharge incidence of 109 per million, which results in an estimated prevalence of
up to 2525 per one million [1]. Cancer is a major cause of death in patients with
spinal cord injury (SCI) [2]. Preventive strategies claim increasing attention, but
must deal with special problems. Most SCI patients suffer from neurogenic bowel
alterations, characterized by loss of bowel control, diarrhea, reduced bowel moti-
lity, constipation or evacuation difficulties. Therefore, bowel preparation
requires modified and intensified regimens and more intensive care to prevent
pressure ulcers and optimum skin management [3, 4, 5]. Colonoscopy itself might
be associated with reduced efficacy in SCI patients, since a poorer quality of
bowel cleansing or failure to reach the caecum could diminish adenoma detection
rates (ADR) [6, 7], while complication rates could increase due to severe
morbidity.
Aims & Methods: The primary objective was to determine the adenoma detection
rate (ADR) in general, right and left hemicolon. Secondary objectives were
polyp, advanced adenoma and carcinoma detection rates, size of adenomas
and polyps in either localization, intensity and effect of bowel preparation,
rate of complete colonoscopies, need for re-endoscopy, duration of colonoscopic
procedures, deepest point of insertion and complication rates. We reviewed retro-
spectively consecutive SCI patients who underwent colonoscopy from 2003 to
2014 and assigned an age-, gender- and year of performance-matched control
group.
Results: In 236 SCI, compared to 414 control patients, bowel preparation lasted
longer (3.57 1.5 vs. 1.15 0.6 days, p¼ 0.001), achieved insufficient cleansing
results more often (23.7 vs. 3.6%) and caused more adverse events. Colonoscopy
needed longer time (36.9 vs. 25.0min, p¼ 0.001), remained incomplete more
often (24.6 vs. 4.6%), resulting in more re-colonoscopies (14.8 vs. 4.3%).
Endoscopy- and sedation-related adverse events were equal. However, neither
overall nor size-dependent polyp (30.9 vs. 34.8%), adenoma (21.2 vs. 21.0%),
advanced adenoma (6.8% vs. 7.2%) or cancer (1.7 vs. 2.0%) detection rate
differed.
Conclusion: Despite intensified protocols, bowel preparation shows inferior
results in SCI patients and colonoscopy needs more efforts to succeed, but
achieves a comparable quality.
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Introduction: There are limited data concerning risk factors and consequences of
colorectal endoscopic submucosal dissection (ESD) conversion to mucosal resec-
tion (EMR) in western centers.
Aims & Methods: Hospital-based frequency-matched case-control retrospective
study. All patients were identified from a database of 225 consecutive dissections
between 2013 and 2017. The cases were those with ESD conversion to EMR for a
420mm colonic lateral spreading tumor (LST). The controls were randomly
selected by frequency 1:2 matching for tumor size (50mm) and location
(rectum/non-rectum). The presences of different factors were evaluated to deter-
mine whether they predicted ESD conversion.
Results: One-hundred and seventeen patients (39 cases, 78 controls) were
included (mean age: 68 10.9 years, 52.1% male). Mean tumor size was
38.5 14.4mm and the most common location was the right colon/transverse
(n¼ 71, 60.7%). By multivariable analysis using backward stepwise method, non-
lifting [OR: 0.324 (CI95%: 0.117–0.896), p¼ 0.03], duration4 120min [OR:
3.127 (CI95%: 1.305–7.493, p¼ 0.011) and LST-G type [OR: 2.881 (CI95%:
1.074–7.727), p¼ 0.036] were independent factors associated to ESD conversion.
Duration was also significant when adjusted by fibrosis (ORa: 21.212, p¼ 0.028)
and related to en-bloc resection (62.8% vs. 91.9%, p5 0.001). Fibrosis
(p¼ 0.032) and non-retroview (p¼ 0.025) were significant factors only in univari-
ate analysis. Previous biopsy/polypectomy, referral status, presence of a fellow,
circumferential (475%) tumor, intra-procedure complications (14.5%) and start
time were not associated to ESD conversion. R0 was achieved in 64.7% (n¼ 11/
17) cases with en-bloc EMR resection and in 91% controls (p5 0.001). There
were two recurrences (13.3%) at 3-months within the 15 cases with piecemeal
resection, treated endoscopically. No recurrences were noted in en-bloc (ESD or
EMR) resection patients (p¼ 0.044). Three (7.7%) and one (1.3%) patients had
an indication for surgery in case-control groups (p¼ 0.107).
Conclusion: The presence of certain factors should be assessed during the proce-
dure to identify patients who are high-risk for ESD conversion regardless of size
or location, particularly the duration of the dissection.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0879 CONTRIBUTION OF COLONOSCOPY IN ELDERLY
PATIENTS OLDER THAN 70 YEARS
A. El Mekkaoui1, A. Taiymi1, A. Zazour1, W. Khannoussi2, G. Kharrasse3,
Z. Ismaili4
1Hepato Gastro Enterology, University hospital Mohammed VI, Oujda/Morocco
2Hepato Gastroenterology, Farabi Hospital, Oujda/Morocco
3Avicenne, Faculty of medicine Oujda, Oujda/Morocco
4Medical School, Casablanca/Morocco
Contact E-mail Address: mekamine@hotmail.com
Introduction: The elderly patients are considered as a particular population.
Colonoscopy has an important place at this population because of the limited
number of normal paraclinic examinations and the high incidence of tumor
disease, specially the colo rectal cancer.
Aims & Methods: The aim of this study was to determine the indications and
results of colonoscopy in people older than 70 years We performed a retrospec-
tive descriptive study over a period of 2 years from the beginning of the endo-
scopic unit until February 2017, conducted in the department of hepato-
gastroenterology of our university hospital. All patients over the age of 70
years who have underwent colonoscopy have been included.
Results: A total of 1059 colonoscopies were performed, 10.3% were indicated for
people older than 70 years. The mean age was 74.15 years with a median age of
75 years and a maximum age of 91 years. The prevalence of males was 51%.
10.5% of cases (n¼ 10) were diabetic, 12.6% (n¼ 12) hypertensive, 12.6%
(n¼ 12) with ischemic heart disease. 8.4% (n¼ 8) had cirrhosis and 9% (n¼ 9)
had a digestive neoplasia. Colonoscopy was indicated for hematocheziain 40%
(n¼ 38), transit disorders in 33.6% (n¼ 32), abdominal pain in 14.7% (n¼ 14),
IBD in 3.1% (N¼ 3), radiographic abnormalities in 13.6% (n¼ 13), iron defi-
ciency anemia in 4.2%, and for patients with a family history of colorectal cancer
in 1% of cases. Colonoscopy was abnormal in 83% (n¼ 93), with polyps in
48.3% (n¼ 45), suspected lesions of malignancy in 16.1% (n¼ 15), Diarrhea in
19.3% (n¼ 18), IBD in 3.2% (n¼ 3), arteriovenous malformations in 12%
(n¼ 11) and rectal erosions in 2.1% (n¼ 2). The rate of malignant lesions diag-
nosed by colonoscopy was 53.3% of females (n¼ 8) versus 46.7% of males
(n¼ 7) (p¼ 0.26), 13.3% (N¼ 2) with hematochezia versus 86.7% (n¼ 13) with-
out hematochezia (p¼ 0.07), and 26.7% with altered general status (n¼ 4) versus
73.3% with conservated general status (n¼ 11) (p¼ 0.07). The evolution of
46.6% of patientsdiagnosed with malignant tumor pathology showed that
33.3% of patients underwent surgery and 13.3% of patients had died.
Conclusion: In our study, suspected lesions of malignancy were diagnosed in
16.1% of cases. Colonoscopy in this age group is intended not only to detect
possible polyps which could degenerate in the future but rather to diagnose the
cancer already installed, especially with the presence of clinical signs.
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Introduction: Acute iatrogenic perforations are one of the recognized complica-
tions of both diagnostic and therapeutic gastrointestinal endoscopy. For decades,
surgical treatment has been the standard of care, but endoscopic closure has
become a more popular approach, due to feasibility and the reduction of the
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burden of surgery, combined with the availability of various endoscopic closure
devices.
Aims & Methods: To assess the technical and clinical success and safety of endo-
scopic closure, in total, and for each endoscopic device used. Also, to identify
factors predicting surgery as a first line treatment, and failure of endoscopic
treatment. Medical literature (Cochrane library, EMBASE, MEDLINE) from
1966 till September 2016 was searched. A systematic review and meta-analysis
were performed on studies reporting technical and clinical success of endoscopic
closure of acute iatrogenic perforations, according to PRISMA (Preferred
Reporting Items for Systematic Reviews and Metaanalyses) guidelines.
Results: 764 studies were identified. 28 studies, in human, met our inclusion
criteria and were analysed. A total of 474 endoscopic closures were attempted
in these studies. The overall technical success rate was 93.1% (n¼ 451/474, 95%
CI: 89.8%96.4%), clinical success was 89.7% (n¼ 431/474, 95% CI:
85.5%93.9%), and complication rate was 1.3% (n¼ 7/474, 95% CI:
0.3%2.3%). Technical success for endoclip closure was 96.6% (95% CI:
94.2%98.2%), and clinical success was 93% (95% CI: 87.1%97.2%), and
complication rate was 1.5% (95% CI: 93.75%96.25%). For OTSC (Over the
scope clip device), technical success was 83.8% (95% CI: 63.9%96.6%), clinical
success was 77.9% (95% CI: 56.8%93.3%), and complication rate was 4.1%
(95% CI: 90.3%99.1%). The technical success rate for Self-expanding metal
stent (SEMS) is 100% (95% CI: 71.5%100%), clinical success is 91% (95% CI:
74.1%108%), and complication rate of 9.1% (95% CI: 78%112%). Only one
study for endosuturing met our criteria, with technical and clinical success rate of
100%, and without any complication. Factors predicting failure of endoscopic
treatment and need for early surgical intervention included large perforation size,
leucocytosis, fever, severe abdominal pain, large amount of peritoneal free air,
necrotic or soft inflammatory margins, unfavourable anatomical site, stool con-
tamination, diffuse peritonitis and failure of endoscopic closure.
Conclusion: Our study suggests that endoscopic closure is a suitable treatment
option for acute iatrogenic gastrointestinal perforations. Several factors have
been suggested as predictors of need for surgery as a first line treatment. The
study is limited by the low methodological quality of most studies included,
indicating the need for further research.
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Introduction: Narrow-band imaging (NBI) allows, after training, "in-vivo" clas-
sification of colorectal polyps. Recent guidelines propose a ‘‘do not resect’’ strat-
egy for rectosigmoid hyperplastic polyps 5mm, characterized with a high
degree of confidence, with 90% negative predictive value (NPV) for adenoma-
tous histology.
Aims & Methods: We aimed to evaluate the impact of training for the simulta-
neous application of NICE (International Colorectal Endoscopic Classification)
and WASP (Workgroup Serrated Polyps and Polyposis) classifications.
Prospective, single-center study of patients undergoing elective colonoscopy
(colonoscopy-CF-H190, Olympus), in two periods: P1: January-February/
2016 and P2: January-February/2017. Endoscopists had no prior experience in
NBI in P1, except for an interactive session of 20 minutes, and after P1 applied
the technique during 2016 at their discretion. Polyps were assessed for its loca-
tion, size and morphology (Paris classification); NICE/WASP: 1p (hyperplastic),
1s (sessile serrated), 2 (adenoma), 3 (deep submucosal invasive cancer); confi-
dence level (low: 590% vs high: 490%) of the predictions. NICE/WASP clas-
sifications were compared with histology. Learning impact evaluated by P1 and
P2 comparison. Statistics: Software-R (version 3.1.2I).
Results: 290 polyps of 135 patients were analysed (P1: n¼ 192; P2: n¼ 98),
average size 6.4mm (2–35mm), 60% located in the left colon, 71.0% 0-Is. No
difference in size, location, morphology and histology between P1 and P2 groups.
An improvement of global acuity in the application of NICE/WASP classifica-
tion in P2 was observed: 74.5% (95% CI: 67.7%80.5%) vs 81.6% (95% CI:
72.5%88.7 (p¼ 0, 222), statistically signficant for high confidence level predic-
tions (P1: 77.6%, P2: 75.5% of the predictions): 78.5% (95% CI: 71.1%84,
8%) vs 90.5% (95% CI: 81.5%96.1%) (p¼ 0.044). In the P2 data subanalysis,
NICE/WASP classification for adenoma showed sensitivity, specificity, positive
predictive value and NPV of 82% (70–99%), 94% (80–99%), 96% (87–100%)
and 72% (56–85%), respectively; for rectosigmoid polyps 5mm, with high
confidence level (n¼ 35), NPV for adenoma was 80% (59–93%).
Conclusion: The overall performance of endoscopists significantly improved with
one year of training, but did not meet the standards for the implementation of the
"do not resect" strategy. However, the results may have been affected by the
addition of an additional category (1s) to the NICE classification.
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Introduction: In recent years, post-colonoscopy colorectal cancer (PCCRC) has
become a focus of attention as likely representing ‘‘missed’’ or ‘‘rapidly-growing’’
lesions in colonoscopic screening for colorectal cancer (CRC). Currently, lesions
thought responsible for PCCRC include sessile serrated adenomas/polyps or flat
and depressed-type lesions occurring on the right side of the colon, and there is
an increasing need for endoscopic modalities to prevent overlooking these
lesions. Colorectal screening using narrow-band imaging (NBI) during colono-
scope withdrawal from the cecum, which was started at our clinic since
November 2008, suggested that NBI colonoscopy was superior to white-light
imaging (WLI) colonoscopy in detecting flat and depressed-type lesions (1).
With NBI, the depressed area of a lesion is recognized as ‘‘whitish’’ and the
surrounding ring-like mucosa as ‘‘brownish’’, which constitutes the ‘‘O-ring
sign’’.
Aims & Methods: We aimed to evaluate the incidence and characteristics of the
‘‘O-ring sign’’ in depressed-type colorectal lesions. A total of 227 endoscopically
resected and histologically confirmed depressed lesions (IIaþ IIc, 156; IIc, 71)
were included for analysis. The colonoscopic images of these lesions were retro-
spectively examined for ‘‘O-ring sign’’ positivity and intensity (grade 0, negative;
grade 1, mildly to moderately positive; and grade 2, highly positive). Of these, 16
were excluded as unevaluable and a total of 211 evaluable lesions were analyzed.
Results: Of the 211 lesions (IIaþ IIc, 141; IIc, 70) analyzed, 84 (IIaþ IIc, 60; IIc;
24), 105 (IIaþ IIc, 69; IIc, 36), and 22 (IIaþ IIc, 12; IIc, 10) were found to be in
grades 0, 1, and 2, respectively, with 60.2% of these shown to be ‘‘O-ring sign’’-
positive (127/211), with IIaþ IIc and IIc accounting for 57.4% (81/141) and
65.7% (46/70), respectively, of these lesions. While an examination by tumor
size and location revealed no clear tendency in ‘‘O-ring sign’’ positivity, an exam-
ination by grade revealed a higher ‘‘O-ring sign’’ positivity rate among those with
high-grade dysplasia (84.6%; 11/13) than those with low-grade dysplasia (59.2%;
116/196).
Conclusion:NBI colonoscopy screening for the ‘‘O-ring sign’’ as an index appears
to improve the detection of depressed-type colorectal lesions.
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Introduction: Endoscopic submucosal dissection (ESD) has been acceptable as a
minimally invasive therapy and providing en-bloc resection for early malignant
and pre-malignant lesions of gastrointestinal cancer. Colorectal ESD has some
difficulties such as a risk of perforation and its severity compare to gastric ESD.
Hence, Colorectal ESD is more challenging than gastric ESD in endoscopic
technique. In Japan, where has high incidence of gastric cancer, endoscopists
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could have many experiences of gastric ESD that may be beneficial for the
introduction of colorectal ESD. However there is little knowledge about the
learning curves of the young endoscopists who perform the colorectal ESD first.
Aims &Methods:We conducted multi-center retrospective observational study to
elucidate the safety and learning curve of the trainee who perform the colorectal
ESD first. The study subjects were consecutive 261 cases of colorectal ESD
performed by three endoscopists in Nippon Medical School Hospital and
Machida Icho Hospital from 2010 to August 2016. The ESD devices were
Flush knife BT (Fujifilm), Dual knife (Olympus), Hook knife (Olympus) or a
combination of these selected by operators demand. The endoscopist A and B,
who had over 10000 examinations of colonoscopy and experiences of gastric ESD
(as expert group), and endoscopist C had about 1000 colonoscopy and stared
colorectal ESD first (as trainee group). The completion rate of operation, which
is defined as en-block resection rate without changing operator, operation time,
speed (time/mm2) and complications were analyzed in each endoscopist.
Furthermore, we divided these procedures in three periods equally such as
early, middle and late.
Results: The median age was 70 (range 26–91) years old, and genders were 158
males and 103 females. Tumor locations were proximal colon, distal colon and
rectum in 143(54.8%), 59(22.6%), and 59(22.6%), respectively. The histological
types were well and moderately differentiated tubular adenocarcinoma, ade-
noma, hyperplastic polyp, SSA/P, and neuroendocrine tumor in 139(60.4%),
68(29.6%), 5(2.1%), 10(4.3%) and 8(3.8%), respectively. There is no statistical
significance in age, gender, tumor location, tumor size and histological type. The
average operation time was 68.0 minutes, the median 80.1 (range 13–353) min-
utes. The completion rates of endoscopist A and B reached 100% in all three time
periods and endoscopist C showed an increase: 41%, 67%, and 100% in the
initial, middle, late period, respectively. In the operation time, there was a sig-
nificant difference between endoscopist A (73.1 38.9, median 67.5) and C
(100 60.8, median 85), B (62.9 45.1, median 55.5) and C (P5 0.001). In addi-
tion, there was difference in the operation speed of endoscopist C among each
periods. The complications were perforation and delayed bleeding in 8 cases
(3.1%) and 2 cases (0.8%). All cases recovered with medical and/or endoscopic
treatment alone.
Conclusion: Trainee endoscopist may have a good learning curve in completion
rate and increasing experience reflects in a remarkable success in colorectal ESD.
We concluded that the training of colorectal ESD first was acceptable by the
trainee endoscopist who had no experience of gastric ESD.
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Introduction: Removal of large common bile duct (CBD) stones is one of the
challenges during ERCP and it seems more difficult in cirrhotic patients due to
suspected higher rates of adverse events especially bleeding diathesis. Patients
with liver cirrhosis can tolerate ERCP to treat their biliary tract or pancreatic
diseases. Patients with liver cirrhosis are three times more susceptible to chole-
lithiasis, than the non-cirrhotic population plus the biliary and pancreatic cancer
and other diseases and that is why ERCP is increasingly performed for patients
with cirrhosis. Endoscopic sphincterotomy (EST) has become a standard step in
mangement of CBD stones and introduction of both mechanical lithotripsy (ML)
and large balloon dilation (LBD) facilitated extraction of the large stones.
Despite the increasing use of both techniques, a head-to-head comparison
between EST followed by LBD and EST followed by ML is lacking in the
literature, and to the best of our knowledge none were done on cirrhotic patients
Aims & Methods: This study aimed at comparing the therapeutic benefits and
complications between mechanical lithotripsy and large balloon dilation after
sphincterotomy in patients with liver cirrhosis. Ninety eight cirrhotic patients
with calcular obstructive jaundice were included and randomly divided into 2
groups: Group A; 49 patients treated by large balloon dilation (LBD), Group B;
49 patients treated by mechanical lithotripsy. All patients underwent sphincter-
otomy initially. Inclusion criteria for this study included: Age of 18–60 years, any
sex, liver cirrhosis patients Child A or B with clinical and laboratory proved
obstructive jaundice, presence of large bile duct stones and deep selective cannu-
lation of the bile duct. Exclusion criteria included: Known allergy to the used
contrast material, Child C cirrhosis, the Need for needle knife precutting in order
to achieve bile duct cannulation, Selective bile duct cannulation achieved after
more than five accidental pancreatograms and severe Coagulopathy All patients
were subjected to thorough history taking, complete clinical examination.
Pancreatic enzymes concentrations were measured 4 hours before and 24 hours
after the procedure, complete blood cell count and liver function tests were
performed before and the morning after the procedure. Before and during
ERCP, stone size and number were verified. Diagnosis of common bile duct
stones was confirmed either by pre-ERCP investigations including abdominal
ultrasonography (US), CT, MRCP or at the time of ERCP Large CBD stone:
Is defined before ERCP by a bile duct stone12 mm or more (transverse diameter
of the largest stone) by US, CT or MRCP and during cholangiography showed
large filling defect more than 12mm that could not be extracted using a standard
balloon catheter
Results: There were no dropouts and all subjects remained in the study till the
end. The demographic and biochemical data of both groups at base line were
comparable. At base line, there was no significant difference between both groups
regarding CBD diameter (18.96 2.5 vs 18.8 1.5, p value 0.8), stones size
(17.1 2.2 vs 17.2 1.53, p value 0.71) and stone number (1.49 0.65 vs
1.41 0.49, p value 0.61) The overall success rate for stone extraction in this
study is 95.6% (94/98). The success rate of ERCP was also comparable between
the two groups. The success rate for CBD clearance was 98% and 93.8% for
large balloon dilation and mechanical lithotripsy respectively. Although, patients
in balloon dilation group showed more success in stone retrieval rate, the differ-
ence was not statistically significant (P value 0.61). The rate of adverse events in
this study was 10.2% (10/98) and bleeding was the commonest reported compli-
cation 50% (5/10); group B that was treated by ML developed more (16.3%)
adverse events than group A treated by LBD (4.1%) and the difference was
satstically significant (P value 0.04)
The reported complications in both groups
Complications Group A Group B P value
No 47 (95.9%) 41 (83.7%) 0.04
Bleeding 1 (2%) 4 (8%)
Pancreatitis 1 (2%) 2 (4%)
Cholangitis 0 (0%) 2 (4%)
Conclusion: In conclusion endoscopic sphincterotomy plus LBD is a safe and
effective treatment for endoscopic removal of large common bile duct stones in
cirrhotic patients when compared with endoscopic sphincterotomy plus ML.
Bleeding is the most common adverse event reported in cirrhotic patients under-
going these procedures
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Introduction: Endoscopist-directed balanced Propofol sedation (BPS), defined as
a fixed dose of an opioid and benzodiazepine combined with incremental doses of
Propofol, has been shown to be a safe and effective moderate sedation regimen
for gastroscopy and colonoscopy. However, there are very limited data on the
safety and efficacy of endoscopist-directed BPS in ERCP.
Aims & Methods: We aimed to evaluate the safety and efficacy of endoscopist-
directed BPS, as well as to compare patient outcomes with anesthesiologist-
administered BPS, for both in-patients and out-patients undergoing ERCP. We
performed a retrospective cohort study using prospectively collected endoscopy
data from a tertiary care, university-affiliated medical center where endoscopist-
directed BPS during ERCP is routine practice amongst the ERCPists, all of
whom have up-to-date advanced cardiac life support (ACLS) certification.
ERCP nurses also maintain up-to-date certification in ACLS and cardiopulmon-
ary resuscitation equipment and medications are available within the advanced
endoscopy suite. During ERCP, the endoscopist and the endoscopy nurse as a
team were responsible for monitoring patient vital signs (e.g., pulse, blood pres-
sure, oxygen saturation levels). Each endoscopist was responsible for directing
the provision and dosing of the BPS. Patient-level demographics and pre/post
procedure vital signs were collected along with BPS drug dosages, American
Society of Anesthesiologists score (ASA) and measured "hard endpoint" patient
outcomes, including: need for bag-mask ventilation or endotracheal intubation,
aborted ERCP due to sedation effects, need for hospital admission post-ERCP
(out-patients only) or need for change in level of hospital care (in-patients only),
and mortality within 24 hours of ERCP.
Results: Over the course of 17 months (October 2015 – March 2017), 501 patients
underwent ERCP and received endoscopist–directed BPS (Cohort 1: 380 (76%)
inpatient, mean age 64.1 years, 46% males, 24% ASA I, 65% ASA II, 11% ASA
III). During this same time period, 24 patients received anesthesiologist–admi-
nistered BPS (Cohort 2: 19 (79%) inpatient, mean age 65.0 years, 67% males,
12% ASA I, 25% ASA II, 38% ASA III, 25% ASA IV). In Cohort 1, the
indications for ERCP were: 231 (46%) suspected choledocholithiasis, 68 (13%)
stent replacement, 62 (12%) evaluation of know/suspected malignancy, 48 (10%)
jaundice, 40 (8%) post-hepatobiliary intervention complications, 8 (2%) abdom-
inal pain, and 44 (9%) other/unspecified. BPS dosages (mean SD: range) were:
Fentanyl 0.06mg 0.02mg: 0.05–0.10mg; Midazolam 1.7mg 0.7mg: 1.0–
2.5mg; and Propofol 178mg 103mg: 10–640mg. Propofol dose inversely cor-
related with patient age (r¼0.42, p5 0.001), ASA score (r¼0.19, p5 0.001)
and Mallampati score (r¼0.24, p5 0.001). No clinically meaningful differ-
ences were found in patient vital signs pre and post ERCP. Moreover, no patient
required bag-mask ventilation, endotracheal intubation nor hospital admission/
change in level of in-hospital care following ERCP. One patient in Cohort 2 who
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received anesthesiologist-directed BPS, required bag-mask ventilation and the
ERCP was aborted due to sedation effects. There was no mortality from any
cause within 24 hours of ERCP. All patients were discharged from the advanced
endoscopy suite without adverse events.
Conclusion: Endoscopist-directed BPS appears feasible, safe and efficacious for
ASA I-III patients undergoing inpatient or outpatient ERCP.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Endoscopic insertion of plastic or metal stents is a well-established
treatment for malignant or part of benign biliary obstruction. The major limita-
tion of this technique is stent occlusion. Duodenobiliary reflux has been consid-
ered as a key contributor to stent occlusion. No appropriate method can so far
prevent duodenobiliary reflux. Different strategies to prolong the patency of
plastic stents included changing stent size, stent design, but stent sluge due to
duodenal biliary reflux remains an unsolved problem. We have been using a
novel suspended overlength biliary stents (reformed with nasobiliary tube) as
substitution for ordinary biliary plastic stent to prevent the reflux from
January 1, 2016 to December 31, 2016.
Aims & Methods: The aim of the study is to evaluate the efficacy and patency of
the suspended overlength biliary stents. The suspended overlength biliary stents
(SOBS) were placed in introhepatic bile duct in 61 patients with extrahepatic bile
ducts stricture who were followed up at least three months from January 1, 2016
to December 31, 2016. Nasobiliary tube of 7.5Fr or 8.5Fr with multiple side holes
were cut 30 cm with operation knife from the top on sterile operating table. The
purpose of the set of 30 cm length is to ensure the tail reaches the duodenal
horizontal part. The SOBS were placed in the introhepatic biliary duct by
using conveyer under the fluoroscopic guidance at the end of ERCP.
Radiography of the Meglumine Diatrizoate was performed in each patient of
SOBS group to evaluate the existence of duodenal biliary reflux. 74 patients who
were performed at least two or more ERCP with extrahepatic bile ducts stricture
treated with ordinary plastic stents (OBS group) from last ten years were com-
pared with SOBS group.
Results: (1) The mean age of SOBS and OBS were 68.8 15.8yrs and
60.4 14.7yrs (P¼ 0.002), respectively. (2) 35 (57.4%) and 34 (45.9%) patients
were malignant biliary obstruction in SOBS and OBS group, respectively
(P¼ 0.227). Malignant obstruction included bile duct cancer and biliary duct
invasion of pancreatic cancer. Benign obstruction included autoimmune pancrea-
tits, chronic pancreatits, post operation stenosis, inflammatory stenosis due to
cholelithiasis. (3) The mean first and second patency was 4.5 months and 5.6
months in OBS groups. All the patients in OBS group experienced at least three
ERCP to exchange plastic stents. The mean first and second patency were 3.9
months and 4.4months in OBS patients with malignant biliary obstruction. Yet
the mean patency was 5.1 and 6.5months in OBS patients with benign biliary
obstruction. (4) The occlusion rates of SOBS and OBS group after 3, 4, 5, 6
months of first ERCP were 13.1% and 36.5%, 27.1% and 55.4%, 42.4% and
67.6%, 55.9% and 77.0%, respectively (P¼ 0.003, 0.001, 0.005, 0.015). Multiple
factors with logistic regression analysis showed that gender, age, location of
biliary stricture were not related with the patency except the character of stric-
ture. (5) SOBS were occluded in only 11 patients (11/61, 18%) with the patency
from 80 days to 12 months (mean patency was 5.2 months). The mean follow-up
period of the other 50 patients in SOBS groups was 6.5 months. (range from
3 months to 15 months). No evidence of duodenal biliary reflux were detected in
SOBS group.
Conclusion: Suspended overlength biliary stents can prolong the patency and
reduce the occlusion rate effectively due to duodenobiliary reflux in both malig-
nant and benign biliary stricuture.
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Introduction: Recent studies describe multiple outbreaks of multi-drug resistant
organisms caused by contaminated duodenoscopes, used for endoscopic retro-
grade cholangiopancreatography (ERCP) procedures. Contamination of duode-
noscopes is attributed to their complex design, which includes a side viewing tip,
forceps elevator and elevator wire channel. Linear echoendoscopes (LEs), used
for endoscopic ultrasound (EUS) procedures, have a similar design with an
additional balloon channel. Previously, we found that contamination of duode-
noscopes was widespread in the Netherlands. It is unclear if the increased aware-
ness of contamination and associated outbreaks has improved reprocessing
outcomes of duodenoscopes and linear echoendoscopes (DLEs).
Aims & Methods: This cross-sectional study was conducted to determine the
prevalence of bacterial contamination of all reprocessed DLEs in The
Netherlands. All 75 Dutch ERCP/EUS centres were invited to sample all
DLEs using centrally distributed kits, according to uniform sampling methods
explained by video instructions. Local staff sampled four to six sites per DLE
depending on endoscope type, including swabs (protection cap, forceps elevator),
flushes (biopsy, suction, air/water and forceps elevator channel) and brushes
(biopsy, air/water and balloon channel). Samples were centrally cultured.
Sampling procedure, culture processing and culture interpretation were consis-
tent with Dutch guidelines. Contamination was defined as AM20: any microor-
ganism with 20 colony forming units (CFU)/20mL, and MGO: presence of
microorganisms with gastrointestinal or oral origin, independent of CFU count.
Results: Between October 2016 and April 2017, 62 (85%) Dutch ERCP/EUS
centres responded with 1130 samples of 215 DLEs (158 duodenoscopes and 57
LEs). Fifteen different DLE types from three distinct manufacturers were
sampled. In total 29/62 (47%) centres had at least one AM20 or MGO contami-
nated DLE, similar to the prevalence (31/66 centres; 47%) in our previous study
(p¼ 0.98). Twenty-eight (13%) DLEs from 19 (31%) centres were AM20 con-
taminated. Thirty-two (15%) DLEs from 23 (37%) centres were contaminated
with MGO, including Enterobacteriaceae, Pseudomonas aeruginosa and Candida
spp. AM20 contamination was identified in eight different DLE types, MGO
contamination in all nine duodenoscope types and three LE types. For both
definitions, contamination was not duodenoscope or LE dependent (P-
values4 0.72), nor type (P-values 40.14) or microbial surveillance dependent
(P-values 40.45).
Conclusion: Similar to our previous findings, in 47% of all Dutch ERCP/EUS
centres at least one patient-ready DLE was AM20 or MGO contaminated. Of all
DLEs, 15% was contaminated with digestive tract bacteria, indicating inade-
quate reprocessing. These results suggest that any additional awareness of con-
tamination has had no lasting effect or that the current reprocessing technique is
not suitable for current DLE designs. This highlights the need for new preventive
measures to minimize the risk of interpatient microbial transmission by DLE.
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Introduction: Although a newly digital cholangio/pancreato-scopy (SpyDS) has
been reported to be useful for therapeutic purpose in patients with biliary dis-
eases, clinical application for diagnostic purpose of pancreatobiliary neoplasm
remains unclarified.
Aims & Methods: To evaluate the usefulness and safety of cholangio/pancreato-
scopy using a SpyDS for preoperative evaluation of pancreatobiliary neoplasm.
Patients and methods: Between Oct/2015 and Feb/2017, consecutive 26 patients
(19, cholangiocarcinoma; 7, IPMN) who underwent cholangio/pancreasto-scopy
using a SpyDS for preoperative evaluation were included in this study.
Diagnostic accuracy of malignancy and tumor extent evaluation by cholangio/
pancreato-scopic guided biopsy/cytology and adverse event after the procedure
were retrospectively investigated.
Results: Of 19 patients with cholangiocarcinoma, success rate of SpyDS guided
mapping biopsy was 83% (103/124 sites). Diagnostic accuracy of longitude
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tumor extent using SpyDS plus mapping biopsy was 92%. One patient developed
mild cholangitis after the procedure. As for IPMN, pancreatoscopy using a
SpyDS could visualize intraductal papillary tumors in all patients, and SpyDS
guided biopsy/cytology was successfully performed. Diagnostic accuracy of
malignancy was 100% without any adverse event after the procedure.
Conclusion: Preoperative evaluation using a SpyDS plus histological evaluation
for pancreatobiliary neoplasm was found to be useful and safety. Further study is
needed to establish evidence about the usefulness of this techdnique.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) is one of
the most technically complex procedures performed by gastroenterologists. After
a significant increase in the indications for implementing ERCP, gastroenterol-
ogists began to pay greater attention to complications identification and preven-
tion. Despite the widespread improvement of endoscopic techniques and
increased experience of endoscopists, the rate of complications has not declined
significantly.
Aims & Methods: To analyze the frequency of probable causes of asymptomatic
hyperamylasaemy and acute pancreatitis after ERCP and their prevention. Two
groups of patients were covered: a retrospective (340) and prospective (154)
group. Patients had evidence of bile ducts impaired passability of varying etiol-
ogy. In these cases ERCP is the final stage in the diagnostic and therapeutic
algorithm. All ERCPs were carried out by one expert endoscopist. Patients
from the prospective group were administered intramuscularly with Diclofenac
(75mg) before and after the manipulation. The methods used in the study were:
demographic data; history and physical examination; laboratory data; imaging
methods; ERCP; clinical course and statistical methods for processing data
received.
Results: The most common indication for ERCP in all patients was cholestasis
constellation (88.1%). In a minority of patients ERCP was purely diagnostic
(6.1%), while at 93.9% it was also therapeutic. Of all patients at 47 of cases
(9.5%) hyperamylasaemy was observed, and at 12 or 2.4% - acute pancreatitis
was observed. Patients who developed acute pancreatitis often have acute calcu-
lous cholecystitis. Due to the small number of patients with acute pancreatitis,
however, these results should be carefully commented. Patients who developed
acute pancreatitis were found to have a lower level of alkaline phosphatase and
ESR and higher values of leukocytes on the 72nd hour. The univariant logistic
regression analysis identified the following risk factors for developing hyperamy-
lasaemy: cholelithiasis; sclerosing papilooditis of ERCP; normal values of serum
total bilirubin and elevated CRP levels in receiving. In order to establish a
predictive model a multiple logistic regression analysis was performed. The
model includes: average total bilirubin at entry and cannulation of the pancreatic
duct more than 3 times. The estimated true percentage for predicting lack of
hyperamylasaemy with this predictive model is very good - 97%. Univariant
logistic regression analysis identified the following risk factors for the develop-
ment of acute pancreatitis: cannulation of the pancreatic duct and the presence of
calculous cholecystitis when entering.
Conclusion: We detected a low incidence of asymptomatic hyperamylasaemy
(9.5%) and acute pancreatitis (2.4%) in the group of patients which were sub-
jected to ERCP. Clinical and laboratory parameters characterizing the patients
who developed these complications, and risk factors for acute pancreatitis and
asymptomatic hyperamylasaemy were determined. The effect of intramuscular
Diclofenac administered before and after ERCP has no effect.
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Introduction: Advanced endoscopy trainees (AETs) achieve ERCP competency
at variable rates and specific case volumes do not ensure competence. However,
training and credentialing guidelines continue to utilize an absolute procedure
volume to determine competence. There are limited data on whether current
training composition and volumes ensure ERCP competence in the US.
Aims & Methods: (i) To define ERCP learning curves, utilizing a centralized
database, with a focus on cannulation rates using a large national sample of
AET programs (AETPs). (ii) To critically examine the composition of current
ERCP training in AETPs. ASGE-recognized AETPs were invited to participate
and AETs were graded on every ERCP after completion of 25 hands-on ERCP
exams. Grading was performed using our previously developed and validated
tool [The EUS and ERCP Skills Assessment Tool (TEESAT)] which assesses
technical and cognitive competence in a continuous fashion. Grading for each
skill was done using a 4-point scoring system: 1-no assistance, 2-minimal verbal
cues, 3-multiple verbal cues or hands-on assistance and 4-unable to complete. A
comprehensive data collection and reporting system was built using REDCap, a
web-based data collection software, and SAS to create learning curves using
cumulative sum (CUSUM) analysis for overall and individual technical and
cognitive components of ERCP. Individual results and comparison to peers
were sent to AETs and trainers quarterly. Acceptable and unacceptable failure
rates were set a priori. AETs with 520 evaluations were excluded and success
was defined as a skill score of 1 or 2. Individual and combined graphs to assess
change in cannulation success rates were constructed and the Cochran-Armitage
trend test was used to assess improvement in success rates.
Abstract: P0890. Table 1: Learning curves and competence in ERCP
Study Endpoint
No. of AETs meeting
inclusion criteria*
No. of
evaluations
No. of AETs achieving
competence (%)
No. of AETs achieving
competence (%)
Primary Analysis* Sensitivity Analysis**
Basic Technique
- Intubation 20 2239 20 (100) 19 (95)
- Achieving short position 20 2226 19 (95) 15 (75)
- Identifying the papilla 20 2223 19 (95) 18 (90)
Technical Aspects
- Overall cannulation 19 2075 13 (68.4) 6 (31.5)
- Cannulation: native papilla 17 1041 3 (17.6) 0 (0)
- Stent removal 14 737 13 (92.8) 9 (64.2)
- Wire placement in biliary duct 18 1815 16 (88.8) 8 (44.4)
- Sphincterotomy 15 731 10 (66.6) 0 (0)
- Balloon sweep 19 1602 18 (94.7) 10 (52.6)
- Stone clearance 14 697 12 (85.7) 6 (42.8)
- Stricture dilation 10 432 9 (90) 3 (30)
- Stent insertion 17 1029 14 (82.3) 3 (17.6)
Cognitive Aspects
- Demonstrated clear understanding of indiciation 20 2264 20 (100) 14 (70)
- Appropriate use of fluoroscopy 20 2169 18 (90) 7 (35)
- Proficient use of real time 20 2219 19 (95) 9 (45)
- Logical plan based on cholangiogram 20 2220 19 (95) 10 (50)
- Demonstrated understanding of use of indomethacin 19 1630 19 (100) 16 (84.2)
Overall Technical Success
Overall Cognitive Success 20 2268 12 (60) 5 (25)
* Primary analysis: success defined as score of 1 or 2 (no assistance/minimal verbal cues), Acceptable failure rate -p0¼ 0.1 and unacceptable failure rate - p1¼ 0.3 **
Sensitivity analysis: success defined as score of 1 (stringent definition of success)
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Results: Of the 62 programs invited, 20 AETPs participated and 20 AETs were
included in the final analysis. At the end of training, median number of ERCPs
performed/AET was 350 (15–500). Overall, 2649 ERCP exams were graded; the
majority were ASGE biliary grade 1 (77%) and only 14% for pancreatic indica-
tion. Among biliary ERCP cases, AETs attempted native papilla cannulation and
sphincterotomy in 1199 (53%) and 901 (40%) cases, respectively. The mean time
allowed for cannulation was: overall - 4.0min (SD 4.3), native papilla - 5.7min
(SD 4.8), and AET failed cannulation cases - 6.2min (SD 5). There was no
change in the time allowed for native papilla cannulation during the 1-year
period (p¼ 0.28). AETs were involved in a small proportion of cases requiring
advanced cannulation techniques such as double-wire technique, placement of
pancreatic duct stent and precut sphincterotomy (6%). Learning curves for indi-
vidual endpoints, overall technical and cognitive aspects noted substantial varia-
bility. Majority of AETs achieved overall technical (60%) and cognitive (100%)
competence at the end of training. While there was a statistically significant
improvement in overall and native papilla cannulation rates (both p5 0.001),
only 18% of AETs achieved competence for native papilla cannulation (Table 1).
Conclusion: The results of this study confirm the substantial variability in learn-
ing curves and competence among AETs in ERCP validating the shift away from
threshold numbers to determine competence. We report the feasibility of estab-
lishing a centralized national database to report individualized ERCP learning
curves using a novel web-based comprehensive data collection and reporting
system. Using strict definitions, a minority of AETs achieved competency in
native papilla cannulation which may, in part, be due to limited cannulation
time provided to AETs. Selective native papilla deep cannulation needs to be
an important benchmark for assessing competence. Methods to improve native
papilla cannulation rates and strategies to increase AET exposure to advanced
ERCP techniques are required.
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Introduction: A recent randomised study by Buxbaum et al1 demonstrated a
significantly lower rate of post-endoscopic retrograde cholangiopancreatography
(ERCP) pancreatitis (PERCPP) in endoscopist- versus assistant-controlled bile
duct cannulation. We set out to audit the rates of PERCPP at our centre based
on this finding.
Aims & Methods: All ERCPs performed by two endoscopists between April 2015
and March 2016 were audited retrospectively. The two endoscopists practiced
endoscopist- (E1) and assistant-controlled (A1) wire-guided cannulation exclu-
sively. Both E1 & A1 had access to the same medications, sphincterotomes,
equipment, and teams. Data was obtained and anonymised from electronic
patient records and endoscopy reporting software. PERCPP was defined as
abdominal pain with hyperamylasaemia at least three times the upper limit of
normal (ULN) 24–48 hours after ERCP with or without corresponding imaging
findings within 7 days; or abdominal pain with a further rise in pre-existing
hyperamylasaemia to at least three times ULN 24–48 hours after ERCP with
or without corresponding imaging findings within 7 days. Additional data was
collected for CT evidence of post-ERCP complications, hyperamylasaemia with-
out pancreatitis, bleeding, and post-ERCP cholangitis. Patient and procedural
characteristics predisposing to pancreatitis were also recorded.
Results: A total of 250 procedures were audited. E1 performed 132 procedures
(54% female; median age 63.5) and A1 performed 118 procedures (67% female;
median age 63). The rates of PERCPP in E1 and A1 were 2.3% (3 patients) and
1.7% (2 patients) respectively. One 84-year-old patient of E1 with a presumed
malignant common bile duct (CBD) stricture had PERCPP and died 17 days
after ERCP, having opted for palliation. The remaining 4 patients had uneventful
conservative management of PERCPP. E1 had one patient with immediate bleed-
ing post-sphincterotomy controlled with a CBD stent whilst A1 had 2 patients
requiring adrenaline injection for haemostasis. In addition, E1 had one patient
with retroduodenal perforation managed conservatively and A1 had one patient
with CT evidence of intramural duodenal haematoma which was uneventful.
Both E1 and A1 had one case each of uncomplicated hyperamylasaemia. A
summary of complications, with patient and procedural characteristics, is listed
in Table 1.
Conclusion: In our observational study, which was not intended or powered for
statistical analysis, there was no overt difference in the rates of PERCPP when
comparing between endoscopist- or assistant-controlled wire-guided CBD can-
nulation. The overall complication rate was similar and although there were some
differences in procedural characteristics between the two endoscopists, there were
no characteristics predisposing to PERCPP overtly skewed towards either endos-
copist’s case load. Further randomised trials, or a crossover study; provided the
endoscopists and assistants are equally competent in both methods of wire can-
nulation, are needed to clarify the safety profile of either technique.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Most endoscopic retrograde cholangiopancreatography (ERCP) -
related procedures are performed under ‘‘conscious sedation’’, a drug-induced
depression of consciousness during which patients are comfortable and able to
maintain purposeful responses to verbal or tactile stimulation, and cardiorespira-
tory function generally remains intact 1). Meanwhile, we sometimes observe
adverse events related to conscious sedation after ERCP such as aspiration
pneumonia 2). So far, it is unknown whether immediate recovery from conscious
sedation with antagonists is necessary or not.
Aims & Methods: We aimed to reveal the efficacy of flumazenil, an antagonist to
benzodiazepines, on the prevention of adverse events, especially, aspiration pneu-
monia related to conscious sedation which is most frequent after ERCP. One
hundred ninety patients who underwent ERCP between January to December
Abstract: P0891. Table 1.
E1 Notes A1 Notes
Procedure numbers 132 118
Complications
Pancreatitis (PERCPP) 3; 2.3% One death within 30 days 2; 1.7%
Perforation 1; 0.8% Retroduodenal 0
Hyperamylasaemia 1; 0.8% Metal stent for cholangiocarcinoma 1; 0.8% Plastic stent for bile leak
Immediate bleeding 1; 0.8% Controlled with metal stent 2; 1.7% Haemostasis with adrenaline injection
Delayed bleeding 0 0
Intramural duodenal haematoma 0 1; 0.8% On CT
Post-ERCP cholangitis 0 0
Patient & procedural characteristics
Female 71; 53.8% 79; 66.9%
Median age 63.5 63
History of Sphicter of Oddi dysfunction 0 0
History of PERCPP 0 0
History of chronic pancreatitis 1; 0.8% 1; 0.8%
Trainee involvement 0 0
Normal LFTs 21; 16.5% No data for 5 patients 11; 10% No data for 8 patients
Non-dilated bile ducts 39; 29.5% 18; 15.3%
Pancreatic duct wire/contrast 19; 15% Excludes 5 unsuccessful cannulations 30; 25.9% Excludes 2 unsuccessful cannulations
Precut sphincterotomy 4; 3% 9; 7.6%
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2014 in a general hospital in Japan were included. The patients were divided to
two groups: the group with flumazenil (F group) and the group without fluma-
zenil (non-F group) just after ERCP and they were compared and analyzed.
Examination items were 1) patient characteristics, 2) procedure characteristics,
and 3) occurrence rates of post-ERCP aspiration pneumonia. Pearson’s Chi-
squared test and Fisher’s exact test were used for statistical analysis of categorical
data.
Results: 1) One hundred fifteen patients (60.5%) were administered flumazenil
just after ERCP (F group) and 75 patients (39.5%) were not (non-F group).The
median age, 76 (47–94) in the F group and 78 (46–94) in the non-F group; male/
female ratio, 57/58 in the F group and 34/41 in the non-F group. The distribu-
tions of the basic disease (CBD stone/malignant biliary disease/malignant pan-
creatic disease/others) were 64/8/17/26 in the F group and 30/11/16/18 in the
non-F group. The distributions of used benzodiazepines (midazolam/diazepam/
none) and the patient number who got aspiration pneumonia were 102/13/0 and
1 in the F group and 59/13/2 and 1 in the non-F group, respectively (Fisher’s test:
p-value¼ 0.074). There were no significant differences of patient characteristics
between both groups. 2) The mean procedure times were 36.7 minutes in the F
group and 30.3 minutes in the non-F group, respectively. The details of proce-
dures for the major papilla (endoscopic sphincterotomy/endoscopic papillary
balloon dilation/others/none) were 40/13/5/56 in the F group and 25/5/3/41 in
the non-F group. The distributions of endoscopic biliary drainage or stenting/
none were 94/21 in the F group and 59/16 in the non-F group. (Fisher’s test: p-
value¼ 0.85) There were no significant differences of procedure characteristics
between both groups. 3) Two patients (1.05%) developed aspiration pneumonia
after ERCP. One (94 years old, male) was in the F group and the other (81 years
old, female) was in the non-F group (Pearson’s Chi-squared test p-value¼ 1).
Both of them were over 80-year old. The patients who were given oxygen during
ERCP were 86 (45.2%). Of them, one patient developed pneumonia (Pearson’s
Chi-squared test p-value¼ 1).
Conclusion: Flumazenil did not have no preventive effect on the occurrence of
aspiration pneumonia related to conscious sedation after ERCP.
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Introduction: Pancreatitis is the leading complication of endoscopic
retrograde cholangiopancreatography (ERCP). Some studies have shown
that aggressive intravenous hydration may reduce the incidence of this
serious adverse event, the post-endoscopic retrograde cholangiopancreatogra-
phy pancreatitis (PEP). In our department we implemented an aggressive
hydration protocol (AHP) for patients undergoing ERCP in order to prevent
PEP.
Aims & Methods: The aim of this study was to evaluate the impact of this
protocol on the incidence and severity of PEP. Patients and methods
Retrospective analysis of all patients submitted to ERCP in one center
during 16 months, including patients hospitalized in the gastroenterology
department who were managed according to the AHP and patients hospita-
lized in other departments who underwent standard hydration (SH). Patients
who underwent AHP received intravenous sodium lactate solution (RL) at
200mL/hour starting 1 hour before, during the procedure and the anesthetic
recovery; in those who remained asymptomatic after the ERCP, the RL was
maintained at 100mL/hour for 8 hours and after it was changed to a balanced
salt solution with glucose (PG) at 80mL/hour; in those patients who had
abdominal pain or amylase 43 times normal limit after ERCP, the RL was
maintained at 200mL/hour during 8 hours and after it was changed to PG at
120mL/h. We evaluated the incidence and severity of PEP, the established
patient and procedure-related risk factors for PEP (except the difficulty of
cannulation) and the occurrence of complications. Data were analyzed with
SPSS statistical software.
Results: We analyzed 192 patients, 290 ERCP (AHP n¼ 168, SH n¼ 122). The
incidence of PEP was 3.8% (11/290), slightly lower in the SH group (4/11
versus 7/11; p¼ 0.766). In the SH subset, only 1 PEP was moderate and the
remaining 3 were mild. In the AHP group, 3 PEP were moderate and 4 were
mild. There were no complications related to AHP. We didn’t find any patient
or procedure-related variable significantly associated with the development of
PEP.
Conclusion: Our AHP didn’t reduce the incidence of PEP or its severity. Indeed,
the AHP group presented more PEPs than the SH group, although the difference
between both PEP incidences was not significant. Despite our study didńt show
any advantage related to the use of an AHP, intravenous aggressive hydration
may have a role in PEP prophylaxis. Further studies are needed to establish its
true value.
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Introduction: Extra-hepatic biliary tree strictures are caused by a variety of malig-
nant and benign diseases. The brushing of such stenosis during ERCP is safe and
easy to perform, however, it has a low sensibility, ranging from 30 to 60%.
Efforts to improve citology yield include dilation of the stricture prior to brush-
ing and multiple brush passages, both without significant success. In 2011, US
Endoscopy introduced the Infinity cytology brush - a 14Fr (4, 75mm) device
that combines soft and stiff bristles in order to improve acquisition of cytology
samples.
Aims & Methods: We aimed to determine if a new-design brush can improve the
diagnostic yield of biliary cytology. From February 2015 until December 2016,
the new Infinity brush was used in all cases of ERCP cytology. These were
compared with historical controls, where a classical 8Fr biliary cytology brush
was used. In both groups, at least two passages were made, with transfer to a thin
prep solution, as per prior protocol. Follow-up data, namely clinical course,
radiological data or other histological results were collected for a definitive
diagnosis.
Results: Thirty-five new brush cases were compared with 52 historical controls.
There was no significant difference between gender (57% Vs. 52% male;
p4 0.05), age (mean 70.5 Vs. 74 years; p4 0.05), location of stricture
(common bile duct 77% Vs. 84%; p4 0.05), length of stricture (between 1–
3 cm in 80% Vs. 84%; p4 0.05) or dilation prior to sampling (71% Vs.
57.7%; p4 0.05) between the two groups. Physicians’ impression of malignant
stricture during ERCP was more frequent in new brush cases, with near statistical
significance (91% Vs. 75%; p¼ 0.052). Sufficient sample size for cytological
analysis was more frequently obtained in cases when compared to controls
(86% vs. 100%, p5 0.05). Definitive diagnosis were as follows (cases Vs. con-
trols): pancreatic neoplasia 57% Vs. 48%, cholangiocarcinoma 25.7% Vs. 23%,
ampuloma 0 Vs. 1.9%, benign conditions 17.3% Vs. 21%, no definitive diagnosis
0 Vs. 6.1%. In malignant cases, there was no difference between sensibilities of
the cases (31%) and controls (27%), either for pancreatic cancer (20% Vs. 24%;
p4 0.05) nor cholangiocarcinoma (55.6% Vs. 50%; p4 0.05). Specificity, posi-
tive predictive value and negative predictive value of Infinity brush and classi-
cal 8Fr brush were as follows: 100% Vs. 100%; 100% Vs. 100%, 23% vs. 35.7%.
Of the 16 strictures with benign features on ERCP (3 cases Vs. 13 controls), 14
had negative cytology and 2 were inconclusive (both controls).
Conclusion: There were significantly more samples with adequate cellularity for
cytological analysis with the new Infinity brush, however, the global sensibility
of the new brush was not superior to the standard devices. With both brushes, the
yield is twice as better for cholangiocarcinoma than for pancreatic cancer. One
disadvantage we noted with the Infinity brush is the increased difficulty in pas-
sing very tight, fibrotic strictures, even after dilation, due to its width and rigidity.
Further ways to improve results would be the routine production of a smear
sample, cell block analysis or intra-ductal biopsies. The future era of cholangio-
scopy could dramatically increase our ability to sample biliary strictures.
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Introduction: In biliary access, repeated biliary cannulation attempts are a risk
factor for post ERCP pancreatitis (PEP). Early precut is an effective technique
for successful biliary cannulation and can significantly reduce the incidence of
PEP. The aim of this study was prospectively to evaluate clinical efficacy the
performance of utmost early precut with pancreatic stent in the patients in whom
pancreatic duct cannulation was performed initially.
Aims & Methods: When guidewire was placed in the pancreatic duct initially by
chance, the patients were randomized into early precut (Group A) or utmost
early precut sphincterotomy with pancreatic stent (Group B). In Group A, pan-
creatic duct cannulation within 5 times and attempted precut papillotomy with-
out pancreatic stent. In Group B, from the first, pancreatic stent was inserted and
then precut with an incision over a pancreatic stent was done. Main outcome
measurements were frequency of successful CBD cannulation and post-proce-
dure related complications.
Results: From January 2015 to August 2016, the two groups were similar with
regard to patient demographics. A total of 50 patients were enrolled. 26 patients
were assigned to the Group A and 24 to the Group B. Successful CBD cannula-
tion was achieved in 23 of 26 (88.5%) patients in the Group A and 23 of 24
(95.8%) patients in the Group B. The mean cannulation time was 16.9 minutes in
the Group A and 14.8 minutes in the Group B. Post-procedure hyperamylasemia
was significantly higher in Group A. The overall incidence of post-procedure
pancreatitis was 11.5% (3/26) in the Group A and 4.2% (1/24) in the Group B
(P5 0.001).
Conclusion: In patients with pancreatic duct cannulation initially by chance,
compare to early precut group, utmost early precut with pancreatic stent over
the guidewire group not only facilitate biliary cannulation and the success rates
but also promise low incidence of post-ERCP pancreatitis. In experienced hands,
utmost early precut technique can dramatically reduce the trauma of ampulla
and risk of PEP compared with conventionally persistent cannulation attempts.
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Introduction: Antithrombotic therapy with antiplatelet agents (APA) has been
increasingly utilized during the last few decades. This study aimed to determine
the risk of post-ERCP bleeding among those patients who are taking APAs,
especially in the era of multiple agents.
Aims & Methods: From July 2012 to May 2016, the patients who underwent 1st
therapeutic ERCP were identified from the ERCP database of 3 institutions in
USA and Korea. The primary outcomes were the frequency, type, and severity of
ERCP-related bleeding according to the use of APA.
Results: The frequencies of post-ERCP bleeding among the four different groups
were 16 of 2083 (0.8%) in No drug group, 12 of 256 (4.7%) in Aspirin group, 3 of
48 (6.3%) in Single APA group, and 4 of 48 (8.3%) in Multiple APA group
(p5 0.001). Most cases of post-ERCP bleeding were mild (29/35, 88%). In the
univariate analysis, post-ERCP bleeding was associated with age, pull-type
sphincterotomy, and APA, and inversely associated with balloon dilation of
the biliary orifice. In the multivariate analysis, pull-type sphincterotomy (odds
ratio [OR] 7.829, 95% confidence interval [CI] 1.411–43.453, p¼ 0.019) and
country (Korea; OR 0.124, 95% CI 0.042–0.361, p5 0.001) were associated
with post-ERCP bleeding.
Conclusion: The frequency of post-ERCP bleeding was statistically higher in
patients on any APAs within 6 days prior to ERCP. However, in the multivariate
analysis, APA use was not associated with post-ERCP bleeding. Until a large
study adequately powered to detect differences in bleeding rates, caution is
recommended when considering invasive procedures during ERCP in patients
on APAs.
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Introduction: In a recent, a digital version of single-operator cholangioscope
(SpyGlass DS) and direct POC (DPOC) using a mulibending ultraslim endoscope
were introduced as improved forms of each POC, especially in image quality and
technical difficulty, respectively.
Aims & Methods: In this study, we prospectively compared the procedure success
rate of SpyGlass DS and DPOC for diagnosis and treatment of BD lesions. A
total of 15 patients with BD lesions (diameter of CBD 8mm) requiring evalua-
tion or treatment using POC were enrolled prospectively. All patients received
POCs using SpyGlass DS and mulibending ultraslim endoscope for DPOC.
According to the presence of obstructive lesion, all patients were classified as
obstructive type or non-obstructive type, respectively. Procedural success defined
as an ability to advance the cholangioscope to the desired target and get adequate
cholangioscopic visualization for the targeted lesion.
Results: The overall technical success rates of SpyGlass DS and DPOC were
100% and 93.3%, respectively (P¼ 0.5). In DPOC, 1 patient was failed to
insert the endoscope into the CBD. In SpyGlass DS, 2 patients were failed to
visualize the targeted lesion. The procedural success rates of SpyGlass DS and
DPOC according to the type of lesion were not different in 9 obstructive type
(100% vs. 88.9%, P¼ 0.5) and 6 non-obstructive type (66.7% vs. 100%,
P¼ 0.227). The successful diagnostic and therapeutic procedures by DPOC
and SpyGlass DS were observed in 8 of 8 patients (100%) and 7 of 9 patients
(77.8%) (P¼ 0.265), respectively.
Conclusion: Both advanced image quality of SpyGlass DS and improved techni-
cal difficulty of DPOC by a mulibending ultraslim endoscope showed compar-
able and high procedure success rates in patients with dilated BD. Future
prospective studies focused on overall cost savings and long-term clinical out-
comes are seems to be required for deciding adequate indications of each POC
systems.
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Introduction: Management of common bile duct stones (CBDS) in patients with
borderline CBD presents a surgical challenge. The aim of this study was to
compare conservative treatment with endoscopic stone extraction for the treat-
ment of borderline CBD with stones.
Aims & Methods: This prospective randomized controlled trial includes patients
with CBDS in borderline CBD (CBD 510mm) associated with gallbladder
stones who were treated with conservative treatment or endoscopic stone extrac-
tion followed by laparoscopic cholecystectomy (LC) and intraoperative cholan-
giogram (IOC). The primary outcome was successful CBD clearance. The
secondary outcomes were the overall complications, cost, and hospital stay.
Results: LC and IOC revealed complete clearance of CBDS in 48 (96%) cases in
the endoscopic retrograde cholangiopancreatography (ERCP) group (52% of
patients by ERCP, and 44% of patient passed the stone spontaneously), and
in the remaining two patients, the CBDS was removed by transcystic exploration.
In the conservative group, LC and IOC revealed complete clearance of CBDS in
90% of cases, and in the remaining 10% of patients, the CBDS was removed by
transcystic exploration. Post-ERCP pancreatitis (PEP) is noticed significantly in
the ERCP group (2 [4%] versus 8 [16%]; P¼ .04). The average net cost was
significantly higher in the ERCP group. Recurrent biliary symptoms developed
significantly in the ERCP group after 1 year (10% versus 0%; P¼ .02) in the
form of recurrent cholangititis and recurrent CBDS.
Conclusion: Management of CBDS in patients with borderline CBD represents a
surgical challenge. Borderline CBD increases the technical difficulty of ERCP
and increases the risk of PEP. Conservative management of CBDS in borderline
CBD not only avoids the risks inherent in ERCP and unnecessary preoperative
ERCP, but it is also effective in clearing CBDS. The hepatobiliary surgeon
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should consider a conservative line of treatment in CBDS in borderline CBD in
order to decrease the cost and avoid unnecessary ERCP.
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Introduction: The cannulation of a virgin papilla is the most difficult and high-
risk step in ERCP and it requires significant experience to maximize the success
and to minimize poor outcomes. Cannulation rate is one of the accepted quality
indicators of ERCP. It is mandatory to regularly assess quality indicators of
endoscopic procedures to maintain and improve endoscopic service.
Aims & Methods:We prospectively collected data about cannulation details of all
patients with virgine papillas and post-ERCP complications from April 2016 to
April 2017.
Results: During this 12-months period we have performed 1102 ERCPs, in 458 of
them we had virgin papilla. All ERCPs had therapeutic intentions and all of the
patients were followed up. In 13 patients papillas were not accessible due to
duodenal stenosis (10/13) or postoperative situations (3/10). In two of them
the indication was ceased (because the biliary obstruction resolved sponta-
neously), 11 patients got percutaneous transhepatic drainage (PTD). The primary
cannulation success rate of accessible papillas was 88.5% (394/445) while the
overall cannulation success was 96.6% (430/445). 56.1% of primary successful
cannulations were achieved by conventional method, in 14.2% we used pancrea-
tic guidewire assisted technique, in 20.1% we used early precut sphincterotomy,
and in the rest cases we used combined techniques. In 51 primary unsuccessful
cases we repeated ERCP attempt in 4 days on average and successfully cannu-
lated 70.5% (36/51) of them at the second or third attempts. 27 of them were
achieved by conventional method, 7 of them after extending the precut, one case
was cannulated using pancreatic guidewire technique, and we used profilactic
pancreatic stent in one patient, as well. Out of the 15 patients with finally unsuc-
cessful cannulation, we performed precut without deep cannulation in 10 cases. 7
of them resolved after precut, 2 of the 10 patients got PTD and one patient
refused further investigation. In 4 patients out of the 15 unsuccessful cannula-
tions the obstruction resolved without any further intervention and one patient
got PTD. We had in sum 3.4% (15/445) post-ERCP pancreatitis, 7 of them were
mild, and 8 moderate, we had no severe one. We observed endoscopic signs of
bleeding during ERCP in 34 cases that needed some endoscopic interventions
(infiltration/coagulation/stenting), 7 of them (1.6%) required blood transfusion.
Three patients suffered perforation during ERCP. One of them got biliary stent
and was discharged uneventfully on the 8th day. We had 2 sphincterotomy
related perforations, 1 had early surgery – he died on the 14th day, another
patient had delayed surgery, he recovered.
Conclusion: Quality assessment of ERCP performance is essential. Our overall
cannulation rate was acceptable. We used pancreatic guidewire technique just
after first guidewire passage of pancreatic duct and switched on to precut at early
phase of process to avoid long lasting traumatisation of the papilla. Our com-
plication rate of post-ERCP pancreatitis was good while the post-sphincterotomy
bleeding rate should be considered higher than in the literature, therefore we
changed the settings of electrosurgical current.
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Introduction: The procedures related to endoscopic retrograde cholangiopancrea-
tography (ERCP) play a major role in the diagnosis and treatment of pancrea-
tobiliary disease. However, post-ERCP pancreatitis (PEP) remains the most
common and severe complication of ERCP. The incidence rates of and risk
factors for PEP have mainly been reported from retrospective studies.
Aims & Methods: This study aimed to identify the incidence rate of and risk
factors for PEP in a prospective large cohort study. This is a prospective
cohort study of all patients who underwent ERCP-related procedures at 5
high-volume centers between February 2015 and May 2016. Patients who pre-
sented with acute pancreatitis, post biliary reconstruction, and failure to reach
the papilla were excluded. The incidence rates of PEP and its severity were
examined. Multivariate analysis was used to identify the risk factors for the
disease. Patients who presented with at least two of the following three manifes-
tations were diagnosed with PEP: 1) elevated levels of serum amylase, 2) abdom-
inal pain lasting more than 24 hours, and 3) abnormal findings of acute
pancreatitis on computed tomography. An increase in serum amylase level of
at least three times greater than the normal upper limit at approximately 18 h
after the procedure (the next morning) was regarded as significant. The severity
of PEP was graded according to the severity assessment of the Japanese Ministry
of Health, Labour, and Welfare.
Results: A total of 1932 patients were finally analyzed. PEP occurred in 142
patients (7.3%); it was mild in 117 patients (6.0%) and severe in 25 patients
(1.3%). Univariate analysis showed that female gender, naive papilla, surgically
altered gastrointestinal anatomy, no coexistence of acute cholangitis, diagnostic
ERCP, elective ERCP, procedure time after reaching the papilla, number of
cannulation attempts, precut sphincterotomy, intraductal ultrasonography, pan-
creatic duct injection, insertion of guidewire into the pancreatic duct, and place-
ment of prophylactic pancreatic stent were significant risk factors. In the
multivariate analysis, female gender (OR 2.273; 95%CI 1.570–3.291), naı̈ve
papilla (OR 3.024; 95%CI 1.805–5.066), surgically altered gastrointestinal anat-
omy (OR 2.607; 95%CI 1.378–4.931), procedure time after reaching the papilla
(OR 1.009; 95%CI 1.001–1.017), pancreatic duct injection (OR 2.297; 95%CI
1.493–3.534), and intraductal ultrasonography (OR 1.620; 95%CI 1.015–2.585)
were independent risk factors.
Conclusion: The incidence of PEP was similar to those reported in previous
studies. These risk factors are important as predictors of PEP. A shorter proce-
dure time and avoidance of unnecessary pancreatic duct injection are important
for prevention of PEP.
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Introduction: The severity of post-ERCP pancreatitis (PEP) is a major problem
because of occasional lethality. However, no predictor of the severity has been
identified. In the present multicenter prospective study, SOSUI, we investigated
the potential predictors of severity.
Aims &Methods: Of 2078 subjects who underwent ERCP between February 2015
and May 2016 at five high-volume centers, 1932, excluding those who had been
complicated by pancreatitis, undergone biliary tract reconstruction, or had
papilla not reached, were included. Of the 1932 patients, 163 who developed
PEP were compared between the mild and severe cases to examine potential
predictors of severity. PEP was diagnosed based on two or more of the following
three conditions: (1) serum amylase elevation (above the upper limits of each
center) on the following day, (2) abdominal pain lasting for longer than 24 hours,
and (3) pancreatitis on CT. Severity was assessed based on the severity criteria of
the Ministry of Health, Labour and Welfare. For continuous variables, the
Mann-Whitney U test was employed. For binomial comparison, univariate ana-
lysis was conducted using a chi-square test.
Results: Twenty-five severe (1.3%) and 138 mild (7.1%) PEP patients were
included. Patient and procedural factors were examined, demonstrating that
the AMY values at 2 hours after ERCP were significantly higher in the severe
cases than in the mild ones (P¼ 0.005). ROC analysis was conducted on the
AMY values at 2 hours as a predictor of severe PEP, demonstrating that the
cutoff value was 3.7 times higher than the upper limits of each center (sensitivity:
64%; specificity: 70%; and AUC: 0.65). In multivariate analysis using logistic
regression by dividing the AMY values at 2 hours after ERCP into higher or
lower than 3.7 times the reference values of each center, abdominal pain imme-
diately after ERCP and AMY values at 2 hours after ECRP were identified as
independent factors.
Conclusion: Severe PEP should be diagnosed as early as possible for intervention.
However, it may take a long time to assess clinical courses or examine images
after examination. In the present study, abdominal pain immediately after ERCP
and AMY values at 2 hours were identified as predictors of severity, being useful
for facilitating early therapeutic intervention.
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Introduction: Laparoscopic cholecystectomy (LC) has become the ‘gold standard’
for the treatment of symptomatic gallstones. However, before clinical implemen-
tation, instruments still need modification, and a more convenient treatment is
still needed.
Aims & Methods: The aim of this study was to evaluate the transduodenal
tractcholecystoscopy technique in the treatment of gallbladder disease without
cholecystectomy. The patient with cholesterol gallstones and high surgical risks
were enrolled between January 2015 and March 2017. Endoscopic ultrasound
(EUS)-guided cholecystoduodenostomy by deploying a double-flanged fully cov-
ered metal stent with hot stent delivery was performed and endoscopic sphinc-
terotomy (EST) was also performed during this procedure for those patients with
accompanying common bile duct stones. One or two weeks later an forward-
viewing endoscope was advanced into the gallbladder via the stent, and chole-
cystolithotomy or polypectomy was performed. After the stents were removed, a
pigtail-type naso-cholecystic drainage catheter was inserted into the gallbladder
over the guide wire and removed 2 days later. Four weeks later gallbladder was
assessed by abdominal ultrasound.
Results: EUS-guided cholecystoduodenostomy with double flanged mental stent
deployment was successfully performed in all of 26 patients (Male/Female, 11/15;
mean age, 61 16.19yrs). After the procedure, fistulas had formed in each of
thepatients and the stones of 7 patients expelled themselves completely.
Endoscopic cholecystolithotomy (19) and polyps resection (2) were successfully
performed through the stents, and then the stents were removed. Common bile
duct stones were also successfully removed in 6 patients. EGD showed all the
fistula closed completely after 3 days. The ultrasound examination of the gall-
bladder 4 weeks later showed no stones remaining and also showed satisfactory
functioning of the gallbladder. The mean follow-up period was 11 months (range:
1–27months). Cholesterol gallstones recurrence were not detected in any patient
during follow-up.
Conclusion: The EUS-guided placement of a novel metal stent with hot stent
delivery is a safe and simple approach for performing an endoscopic cholecysto-
duodenostomy, which can subsequently allow procedures tobe performed for
treating biliary disease, including cholecystolithotomy.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
1. Strain M, Chisevescu D, Blaj S, et al. The first NOTE (Natural Orifice
Translumenal Endoscopic) cholecystectomy in Romania: An experimental
model in pig. Chirurgia (Bucur) 2009;104:173–9.
2. Cuadrado-Garcia A, Noguera JF, Olea-Martinez JM, et al. Hybrid natural
orifice transluminal endoscopic cholecystectomy: Prospective human series.
Surg Endosc 2011;25:19–22.
3. Cho YB, Park CM, Chun HK, et al. Transvaginal endoscopic cholecystect-
omy using a simple magnetic traction system. Minim Invasive Ther Allied
Technol 2011;20:174–8.
4. Ogredici O, Linke GR, Lamm S, et al. Routine cholangiography during
rigid-hybrid transvaginal natural orifice transluminal endoscopic cholecys-
tectomy. Surg Endosc 2014;28:910–7.
5. Hall RC. Is natural orifi ce transluminal endoscopic cholecystectomy as safe
as laparoscopic cholecystectomy? Arch Surg 2008;143:604.
6. Parra V, Kedia P, Zerbo S, et al. Drainage of infected pancreatic necrosis by
using 2 lumen-apposing metal stents, a nasocystic drain, and hydrogen per-
oxide. Gastrointest Endosc 2015;81:1261.
P0904 QUANTITATIVE ENDOSCOPIC ULTRASOUND
ELASTOGRAPHY IN THE DIFFERENTIAL DIAGNOSIS OF
PANCREATIC SOLID TUMORS
H. Ribeiro
1, C. Leitão1, J. Pinto2, R. Azevedo1, F. Pereira1, R. Sousa1,
A.I.L. Pires Caldeira1, E. Pereira1, A. Banhudo1
1Gastroenterology, Amato Lusitano Hospital, Castelo Branco/Portugal
2Gastrenterologia, Unidade Local de Saúde de Castelo Branco, Castelo Branco/
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Introduction: Quantitative second generation endoscopic ultrasound (EUS) elas-
tography allows the quantitative analysis of tissue stiffness and can be a useful
auxiliary tool in the differential diagnosis of pancreatic solid tumors (1)(2).
Aims & Methods: The aim of this study was to evaluate the accuracy of the
quantitative EUS elastography in the differential diagnosis of pancreatic solid
masses, discriminating malignant from benign masses, using strain ratio (SR)
analysis. A prospective study was performed for 15 months and included 29
consecutive patients who underwent EUS for the evaluation of solid pancreatic
masses. EUS elastography was performed by 2 operators, using a linear echoen-
doscope. The mean of 3 measures was considered as the SR final result for each
lesion. EUS–fine-needle aspiration of the lesions was performed after SR assess-
ment and the final diagnosis was based on the cytology or histology results.
Accuracy of the elastography was obtained by the analysis of ROC curves.
Results: Included 29 patients in a total of 30 lesions with conclusive histological/
cytologic diagnosis (8 inflammatory masses, 19 adenocarcinomas, 2 neuroendo-
crine tumors and 1 undifferentiated carcinoma). The mean SR value was signifi-
cantly higher in the malignant tumors comparing with the benign tumors (55.56
vs 23.93, p¼ 0.001). The sensitivity and specificity of SR for detection of pan-
creatic malignancy for a cut of 15.89 were, respectively, 95.45% and 87.5% (area
under the curve of 0.89, 95% CI). The overall accuracy of the EUS elastography
using the SR for the detection of pancreatic malignancy was 93%.
Conclusion: Quantitative EUS elastography presents good accuracy in the differ-
entiation between malignant and benign pancreatic masses. It is a promising EUS
technique in the diagnostic approach of solid pancreatic lesions, which may
complement the study and characterization of the tumors, aiding in the diagnos-
tic and follow-up of this patients.
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Introduction: Esophageal squamous cell carcinoma (ESCC) ranked the seventh
most frequent cancers, and is the fifth leading cause of cancer death in Taiwan.
The overall 5-year survival rate of ESCC is 12–15%. It is import to diagnose
ESCC in early stage and receive curative treatment. Endoscopic submucosal
dissection (ESD) is a well-developed skill to complete resect gastrointestinal
(GI) tract early cancer. The limitation of ESD is cancer invasion to submucosal
layer and increasing the risk of lymph node metastasis (10–45%) of
ESCC.Endoscopic ultrasonography (EUS) is an examination for detecting the
invasion depth (T stage) of GI tract cancer, the reported accuracy of T1 stage is
around 85% of ESCC, however, the result of detail discrimination of EUS
among each subdivision of mucosa (T1a or m) or submucosa (T1b or sm) is
unsatisfied.
Aims & Methods: The aim of this study is to evaluate the accuracy of T1 stage
subdivision of ESCC by higher frequency EUS probe prior to ESD treatment.
From 2013 to 2016, there are 825 patients diagnosed with ESCC, further stage
with EUS, computered tomography and PET-CT. The EUS examination is per-
formed with miniprobe (UM-2R, 12MHz, UM-3R, 20MHz; Olympus Optical
Co. Ltd., Tokyo, Japan) and water immersion method.
The enrolled criteria of this study: 1. ESCC was proved by biopsy result. 2. T1a
or T1b stage diagnosed by EUS. 3. No lymph nodes or distant metastasis. 4.
Treatment with ESD. All EUS-T stage results were correlated with final patho-
logical T stage, including T1a/T1b.
Results: Total 90 patients enrolled in this study and there were 83 patients with
T1a and 7 were T1b stage of ESCC by EUS. After ESD treatment, all specimens
were confirmed as T1 on pathology, EUS stage of T1a in 83 patients and 66
(80%) were confirmed as T1a, 17 (20%) were T1b on pathology; of 7 T1b
(patients refuse surgery) on EUS, 2 (29%) were confirmed as T1a and 5 (71%)
were T1b on pathology, further subdivision of pathological T1a: 68 (m1: 33, m2:
15, m3: 20), and T1b: 22 (5sm1: 6, 4sm2: 16). The sensitivity, specificity,
positive predictive value and negative predictive value of EUS T1a is 97%,
23%, 80% and 71%, respectively. All the patients with pathological T1b stage
received further esophagectomy or concurrent chemoradiotherapy if surgery
unfit.
Conclusion: EUS demonstrates excellent accuracy for T1a diagnosis, but low
accuracy of distinguishing between stages T1a and T1b of ESCC. Even with
high-frequency miniprobe (20 MHz), the main cause of understage of T1b is
difficult to detect the cancer micro-infiltration into submucosal layers, and peri-
tumoral inflammation or submucosal fibrosis causes some difficulties in differ-
entiating mucosal from submucosal lesions is the reason of overstage of T1a. To
improve the diagnostic accuracy, developing advanced EUS device and more
experience endoscopist are needed. Comparing with other locoregional staging
method, EUS remains a valuable tool of detecting ESCC T1a stage when ESD
treatment is considered.
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Introduction: Determining the cause of suspected biliary strictures is always chal-
lenging in clinical practice. Although EUS-guided tissue sampling (EUS-TS)
revealed a better diagnostic yield in suspected malignant biliary obstructive
lesions comparing to ERCP-guided tissue sampling (ERCP-TS), there was few
studies for which techniques are better dependent on primary tumor.
Aims & Methods: The aim of our study is to compare the diagnostic yields
between EUS-TS and ERCP-TS in patients with suspected malignant biliary
obstructive lesion according to primary tumor sites. By reviewing medical
records, we enrolled patients who underwent same-session examination of EUS
and ERCP for the evaluation of suspected pancreatobiliary obstructive lesion.
For cytopathologic diagnosis, endoscopic ultrasound-guided fine needle aspira-
tion (EUS-FNA) or biopsy (EUS-FNB) and ERCP-TS using brush cytology
and/or forceps biopsy were performed. The diagnostic performances were com-
pared between two techniques according to primary tumor sites.
Results: From January 2011 to September 2016, we enrolled 125 patients and 32
patients were excluded due to the following reasons: loss of follow up in 8,
ERCP-TS from pancreatic duct in 23, and ERCP-TS from periampullary
biopsy in 4. Among the enrolled patients (93 patients; 62 males, mean age 65.8
years), 86 (92.5%) had malignant tumor such as cholangiocarcinoma in 39,
pancreatic cancer in 37, and other malignant tumors in 10 patients. And 7
(7.5%) patients had benign lesions. EUS-TS revealed higher rate of overall diag-
nostic accuracy comparing to ERCP-TS (82.8% vs. 60.2%, p¼ 0.001).
Depending on primary lesions, the diagnostic accuracy for pancreatic lesions
was statistically higher in EUS-TS than ERCP-TS (84.4% vs. 51.1%, p¼ 0.003).
Conclusion: EUS-TS is superior to ERCP-TS for the evaluation of suspected
malignant pancreatobiliary obstructive lesions. Especially, if the biliary obstruc-
tion was caused by pancreatic lesions, EUS-TS would need to be a priority for
cytopathologic diagnosis
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Introduction: Significant heterogeneity in geographic distribution in the preva-
lence and features of mediastinal lymphadenopathies have been documented in
CT studies. Awareness of the geographic prevalence and characteristics of lym-
phadenopathies will be relevant when performing endoscopic ultrasonography
(EUS) for nodal staging of malignant neoplasia.
Aims & Methods: 1. To document the prevalence and characteristics of mediast-
inal lymphadenopathies in patients submitted to EUS for non-malignant extra-
thoracic disease. 2. To identify predictive factors for the presence of mediastinal
lymphadenopathies. A prospective, unicentric study was performed between July
and December 2016. Mediastinal stations 9, 8, 7, 6, 5, 4L and 2 were system-
atically evaluated using a linear echoendoscope in all patients undergoing EUS
due to benign extra-thoracic pathology, without history of oncologic disease.
Demographic, clinical and EUS features were analysed, including location,
number, shape, dimensions and echogenicity of the lymphadenopathies.
Results:We analysed 75 patients: M/F, 32/43; Mean age, 63 years. The majority
(72%) of the patients presented lymphadenopathies in at least one mediastinal
station and 88% of these were found in stations 7 or 4L. Only 6% of these had
short axis diameter 410mm, most were oval (59%) or triangular (37%) and
40% had a hyperechogenic center. The prevalence of lymphadenopathies was
higher in smoker patients (83% vs 64%, p¼ 0.024), with a higher average
number of lymphadenopathies per patient in this group (2.1 vs 1.6;
p¼ 0.017). Similar findings were documented in patients with relevant occupa-
tional or environmental respiratory exposure (prevalence 83% vs 71%; average
number 3 vs 1.7). By logistic regression analysis, none of the variables
analysed was independently associated with the presence of mediastinal
lymphadenopathies.
Conclusion: This prospective Portuguese study documented a higher prevalence
of mediastinal lymphadenopathies than previously reported in northern Europe1,
in patients with no evidence of oncologic disease. This higher prevalence, mostly
in smokers or patients with relevant occupational exposure, may negatively influ-
ence the specificity and positive predictive value for malignancy of mediastinal
lymph node (N) staging by EUS, with particular relevance in esophageal and
pulmonary cancer staging.
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Introduction: Recent studies demonstrated the positive impact of neoadjuvant
treatment for gastric adenocarcinoma T 2 and/or Nþ.
Aims & Methods: We aimed to assess the accuracy of endoscopic ultrasound in
the selection of patient with gastric adenocarcinoma for neoadjuvant therapy. A
unicentric retrospective analysis of patients with the anatomopathological diag-
nosis of gastric adenocarcinoma between 2011 and 2016, who performed endo-
scopic ultrasound for staging and underwent surgery without prior neoadjuvant
treatment. The concordance (kappa) and accuracy [sensitivity (S) and specificity
(E)] of the endoscopic ultrasound for T 2 and/or N þ (criteria for neoadjuvant
treatment) were assessed using the anatomopathological staging of the resected
surgical specimen.
Results: The final sample included 144 patients (64.6% male) with a median age
of 68.5 12.2 years. In most cases (80.6%), the neoplasia was distal (antrum,
incisura angularis and body). The neoplasia was of the intestinal type, diffuse and
mixed in 65.3%, 18.8% and 16% of the cases, respectively. After examination of
the resected surgical specimen, 53.5% of patients had criteria for neoadjuvant
treatment (T 2 and/or N þ). The overall kappa, sensitivity and specificity of the
endoscopic ultrasound for T 2 and/or N þ were 0.720 (p5 0.001), 85.2% (95%
CI: 75.6–92.1%) and 87.3% (95% CI: 76.5–94.4%), respectively. The overall
kappa, sensitivity and specificity of the endoscopic ultrasound for T 2 and/or
N þ were higher in proximal lesions (cardia and JEG) (k¼ 0.924, S-94.4% and
E-100%) compared with distal lesions (k¼ 0.671, S-82.5% and E-84.9%) and in
intestinal type lesions (k¼ 0.765, S-84.9% and E-92.7%) compared with diffuse
type lesions (k¼ 0.682, S-88.4% and E-80%) or mixed (k¼ 0.566, S-81.8% and
E-75%).
Conclusion: In one of the largest series of patients, we showed that endoscopic
ultrasound has an overall high agreement and accuracy in the selection of gastric
adenocarcinoma patients for neoadjuvant therapy, although they higher for
proximal and intestinal lesions.
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Introduction: Pancreatic cystic neoplasms (PCNs) require initial imaging charac-
terization and frequently follow-up. Endoscopic ultrasound with fine-needle
aspiration (EUS-FNA) for CEA measurement and cytology of cystic fluid is
the most accurate diagnostic method in these lesions. The role of repeated
EUS-FNA with cystic fluid analysis in follow-up of PCNs is not clear.
Aims & Methods: To determine if patients with pancreatic cysts with a second
repeated EUS-FNA for cystic fluid analysis for CEA and cytology had a change
in cyst classification or on clinical decision. Retrospective analysis of a EUS
database, with 284 patients who had EUS-FNA for pancreatic cyst evaluation
from 2007–16, of which 35 had 2 EUS procedures, and of these, 22 had 2 con-
secutive EUS-FNA procedures.
United European Gastroenterology Journal 5(5S) A479
Results: In our series: 16/22 females (73%), mean age¼ 58 13 years old (29–77).
Mean follow-up time¼ 60 34months (6–116). Cyst location: head/body/tail:11/
8/3. Mean size in 1st EUS-FNA: 3 1, 5 cm (1, 2–7 cm) vs 2nd EUS-FNA: 3,
1 1, 9 cm (1, 2–10 cm); with both EUS-FNAs with 36% cysts 43 cm. Mass/
mural nodule present:7/22 vs 4/22 on 2nd EUS-FNA. Repetition of EUS-FNA
due to: nodule, imagiologic change or increasing size. Mean interval between the
two subsequent EUS-FNAs: 35 months (3–117). Cysts with CEA level 4192 g/
mL (7 vs 10 patients) and acellular cystic fluid samples (62% vs 59%), between
the 1st and the 2nd EUS-FNA, not statistical significant. There were 4 patients
operated that had previously a repeated EUS-FNA (2nd EUS-FNA 3, 4, 7 and 10
months after the 1st EUS-FNA). Surgical pathology (respectively): Intraductal
papillary mucinous neoplasm, mucinous cystic neoplasm, solid pseudopapillary
neoplasm and a neuroendocrine tumour. Comparing the group of patients who
had pancreatic cyst surgery with patients on imagiological follow up, there was a
statistical difference in cystic size43 cm and the presence of a mural nodule or
mass in the surgery group, but no significant differences in age, CEA value or a
diagnostic cytology between the two groups. The mean time between the two
EUS-FNA procedures was significantly shorter in the surgical patients group.
Conclusion: Clinical follow-up of pancreatic cysts with successive EUS-FNAs can
be useful in larger cysts and if worrisome features (mural nodule or mass) are
present, and should be performed early on follow-up. If these features are absent,
most cysts have an identical CEA (increase to 4192mg/mL in only 14% of
patients, without statistical significance) ant the EUS-FNA doesn’t change clin-
ical decision making.
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Introduction: Despite advances in imaging techniques, differential diagnosis of
pancreatic cysts still remains challenging. There has been an increasing interest in
new pancreatic cyst biomarkers as a way to differentiate different cyst subtypes
and avoid unnecessary surgery. Recently intracystic fluid glucose has been pro-
posed as a promising marker. The aim of this prospective study was to verify this
early finding.
Aims & Methods: We enrolled in the study all the patients who underwent
Endoscopic Ultrasound (EUS) guided Fine Needle Aspiration of a pancreatic
cyst at our Institution from October 2015 to February 2017. The cyst fluid was
sent for cytology, mucin staining and determination of amylase, Carbohydrate
Antigen 19-9 (CA 19-9), Carcinoembryonic Antigen (CEA) and glucose. When
deemed necessary by the endoscopist, needle-based confocal laser endomicro-
scopy (nCLE) of the cyst wall and/or contrast-enhanced EUS was performed.
A definitive diagnosis of the nature of the cyst was reached relying on surgery,
citology or mucin staining, a typical pattern of nCLE or by consensus (on EUS
and radiological features) by three expert endosonographers, blinded to cyst
markers concentrations.
Results: Twenty-nine patients (13 males, median age 72 years, range: 30–83)
entered the study. Nineteen (66%) pancreatic cysts were unilocular while 10
(34%) were multilocular, the median largest diameter was 45mm (range: 20–
70mm). Sixteen (55%) cysts were located in the pancreatic head, 10 (35%) in
the body and 3 (10%) in the tail. CE-EUS was performed in 14 (48.3%) patients,
nCLE in 12 (42.8%) subjects. Eighteen (62.1%) cysts were finally classified as
mucinous (6 mucinous cystadenomas; 12 intraductal papillary mucinous neo-
plasm) and 11 (37.9%) as non-mucinous (6 serous cystadenomas; 5 pseudocysts).
The final diagnosis was reached relying on surgery in 9 patients (31%), on
citology in 4 (13.8%), on nCLE in 8 (27.6%) and on consensus in 8 (27.6%).
Mean glucose concentrations in mucinous cyst were significantly lower than in
non-mucinous cysts (7.7mg/dl vs 95.7mg/dl, p5 0.0001). In the diagnosis of
mucinous cysts, sensitivity of CA 19-9 (cutoff more than 5000 U/ml), CEA
(cutoff more than 192mg/ml) and glucose (cutoff less than 50mg/dl) was respec-
tively 22.2%, 66.7% and 94.4%. Specificity was respectively 72.7%, 100% and
100%. Accuracy was respectively 41.4%, 79.3% and 96.6%. Only two subjects in
this cohort were affected by diabetes, this condition did not impact on intracystic
glucose concentration.
Conclusion: Although limited by the small sample size, this study confirms the
utility of intracystic glucose levels in differentiating mucinous from non-muci-
nous pancreatic cysts. This cheap, new marker outperformed CA 19-9 and CEA
in sensitivity, specificity and accuracy.
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Introduction: Liquid-based cytology (LBC) preparation method is one of the
preparation methods of cytology samples, which is being increasingly used in
gynecological and non-gynecological cytology samples, due to its ability to
decrease screening time, insufficient sample rate, and air-drying artifacts com-
pared to a conventional smear method. Additionally, immunocytochemistry
(ICC) can be performed after LBC.
Aims & Methods: The aim of this study is to show the actual method of LBC and
to evaluate the utility of LBC in EUS-FNA samples of the pancreatic lesions. 292
specimens obtained by EUS-FNA from patients with pancreatic disease were
enrolled in this study. Clinical diagnosis was pancreatic cancer (PC) in 210
cases, acinar cell carcinoma in three cases, adenosquamous cell carcinoma in
one case, invasive ductal carcinoma derived from IPMN in three cases, metastatic
pancreatic tumor in eight cases, pancreatic neuroendocrine tumor (PNET) in 20
cases, solid pseudopapillary neoplasm in one case, serous cystic neoplasm (SCN)
in five cases, mass-forming pancreatitis in four cases, and autoimmune pancrea-
titis (AIP) in 40 cases. Just after EUS-FNA, tissue sample in the FNA needle was
flushed out into petri dish with saline. The specimen was carefully examined to
divide visual tissue core from liquid specimen. Divided visual tissue core was
formalin-fixed and processed for pathological evaluation. All residual liquid
specimen in whole was immediately immersed in liquid-based fixation medium
(CytoRichTMRed) at the bedside. The liquid was centrifugalized and processed
for cytological evaluation in the laboratory. Sufficient material rate of cytology
was retrospectively evaluated in all cases, and diagnostic yield between cytology
and histology in patients with malignant diseases was compared. In addition,
availability of immunohistochemistry (IHC) and ICC was assessed
retrospectively.
Results: Sufficient material rate in cytological evaluation was 96.6% in all
enrolled specimens (282/292). 10 insufficient materials were obtained from PC
in two, SCN in four, PNET in one, and AIP in three. In seven of the 10 cases with
insufficient materials, sampling error occurred because sufficient material was
not confirmed using rapid onsite evaluation. Accuracy of cytology, histology,
and combination of cytology and histology were 84.4%, 72.9%, and 90.0%,
respectively. In the study of 255 specimens with malignant diseases, sufficient
material rate of cytology and histology are 99.1%(223/225) and 89.3%(201/255).
Positive predictive values of cytology and histology are 81.7%(184/225) and
67.6%(152/225). 65.8% (48/73) of pathologically non-diagnosed cases could be
diagnosed as malignancy owing to cytology. In 26 specimens where immuno-
chemistry was needed, IHC was available in 23 of the 26 specimens (88.5%) and
ICC was available in all specimens. In the three specimens, IHC was not available
owing to pathological insufficiency.
Conclusion: LBC in pancreatic cell samples obtained by EUS-FNA may be useful
for reducing insufficient material rate and conducting ICC as well as in samples
in other medical fields.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Echoendoscopy with fine needle aspiration (EUS-FNA) is a useful
tool for the characterization of pancreatic cystic lesions (PCL) due to its ability to
provide samples for biochemical and cytological examination. This is a safe
procedure, with low complications rate (02, 5%). Nevertheless, peri-procedural
and even several days after EUS-FNA antibiotic prophylaxis has been the stan-
dard practice due to the possible risk of pancreatic infection.
Aims & Methods: We aimed to compare adverse outcomes after EUS FNA of
PCL with two protocols: group 1: Ciprofloxacin 200mg iv, one-dose, immedi-
ately before FNA, and group 2: Ciprofloxacin 200mg iv, one-dose, immediately
before FNA plus three days of oral Ciprofloxacin, 500mg, bid. Retrospective
study of single-operator EUS-FNA of CLP in two centers with different anti-
biotic prophylaxis protocols, between January 2014 and December 2016. A tele-
phonic questionnaire regarding post-procedural complications was applied to all
patients that agreed to enter the study.
Results: Two hundred and four EUS-FNA were analyzed: 51.5%(n¼ 105) in
group 2.60% (n¼ 123) women, mean age 63.4þ12.8 years. We were able to
contact 86.9% (n¼ 86) patients in group 1 and 94.3% (n¼ 99) in group 2
(p4 0.05). The mean time between EUS-FNA and questionnaire application
was 14, 7 months for group 1 and 17 months for group 2 (p4 0.05). There
was no statistical difference between the two protocol groups regarding the mor-
phological features of the PCLs (size, morphology, location) or procedure (needle
size, location of puncture, number of passages or percentage of cysts with com-
plete collapse after aspiration). Five patients had intra-cystic limited bleeding
after puncture (two in group 1 and three in group 2). In group 1, 6.2% (n¼ 6)
reported complications: 1 major (mild acute pancreatitis) and 5 minor (epigastric
pain, vomiting). In group 2, 9.1% (n¼ 9) reported 1 major (mild acute pancrea-
titis) and 8 minor (epigastric pain, transient fever, nausea) complications, with no
difference between the two groups (p4 0.05). The patients with intra-cystic
bleeding did not have a worse outcome. Additionally, five patients (1.9%)
reported any type of adverse reaction related to antibiotic use (75% in group 2).
Conclusion: EUS-FNA is a safe procedure, with 1% rate for major complications
in our series and none of them with evidence of infection. We did not find any
additional benefit from extension of antibiotic prophylaxis beyond the one-time
administration during EUS-FNA. It has even been questioned whether antibiotic
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prophylaxis is mandatory during EUS-FNA of PCLs, since it does not seem to
have a protective effect. Moreover, the raise in antibiotic resistance and possible
adverse effects related to their use should be balanced against the very low
infectious complication rate of EUS-FNA. One limitation of our study is its
retrospective nature, with a significant delay between the EUS-FNA and the
time to inquiry, which could have biased the patientś answers.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The endoscopic ultrasound (EUS) has proven useful in the study
and evaluation of the adrenal gland (AG) by endoscopic ultrasound-guided fine-
needle aspiration (EUS-FNA), in both the left and right glands.
Aims & Methods: To analyze the diagnostic performance, safety, impact on
clinical management, predictors of malignancy and cyto-pathological correlation
of the EUS-FNA with adrenal gland.
National multicenter retrospective study. Mailing-SEED (Spanish Society of
Digestive Endoscopy) partners. Participation: 17 Spanish centers. Inclusion
period: April/2003 to April/2016. Inclusion criteria: All adrenal gland (Left/
Right) punctured by endoscopic ultrasound. Variables reviewed: demographic
characteristics, clinical, extension studies, EUS and pathological data.
Comparison between variables; and estimation of multivariate logistic model
for cytology, mortality and therapeutic change.
Results: A review of 205 EUS-FNA of adrenal gland in 200 patients (154 males).
Average age: 65.3 (DE 9.6). Primary tumor: lung 69%, unknown 10%, another
20%. Adrenal gland left (191); adrenal gland right (14). Main features: CT scan-
pathological (71.2%), PET scan-high uptake (82%), hypoechoic (88%) and sus-
pected by endoscopist (69%). Puncture technique most commonly used: cytolo-
gical needle (75%), 22-G (64%), suction-syringe (66.3%), passes 2.17 (DE 1.38).
92% of samples allowed a cytological diagnosis, 60% malignant. Variables asso-
ciated with malignancy: CT scan pathological morphology (OR: 2.99 IC 95%
1.41–6.44), heterogeneous pattern EUS (OR: 2.11 CI 95% 1.13–3.97), morphol-
ogy EUS ’Variegated’ (OR: 2.46 CI 95% 1.00–6.24) and suspected by endosco-
pist (OR 17.46 CI 95% 6.2 to 58.5). A size 530mm was associated with lower
mortality (OR: 2.27 CI 95% 1.17 to 4.48). Pathological suspicion of the endos-
copist was associated with a greater therapeutic change (OR: 4.48 CI 95% 2.38 to
8.62). No description of adverse events.
Conclusion: Adrenal gland by endoscopic ultrasound-guided fine-needle aspira-
tion is a safe and high diagnostic yield method. The variables most associated
with malignancy are the suspicious echo endoscopic images objectified by expert
endoscopists, a heterogeneous pattern and variegated morphology. The results
suggest the possibility of developing a predictive malignancy model pre-
procedure.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The current classifications of non-metastatic GIST are based on
post-operative pathologic criteria and are usefully employed to estimate the
potential risk of postoperative recurrence and determine the value of adjuvant
Imatinib. The proposed pre-treatment classification currently recognized risk
factors as tumor diameter, mitotic rate and site (gastric vs non-gastric). EUS-
guided tissue samples remains mainstay for pathological diagnosis of GIST, but
previous studies showed that EUS-FNA with standard 19 or 22 gauge needles
does not reliably reflect GIST’s proliferation and size.
Aims & Methods: We aimed to investigate the EUS-FNB diagnostic yield for
GIST and to evaluate whether EUS-FNB samples reflect prognostic criteria
obtained from resected GISTs.
A prospectively maintained database was retrospectively reviewed to identify
consecutive patients with surgically resected subepithelial lesions who received
a diagnosis of GIST at a previous EUS-FNB with a 19 or 22 gauge core-needle
(EchoTipProCoreTM, Cook Medical). Size from EUS examinaton and mitotic/
proliferative indexes obtained from EUS-FNB samples were compared with sur-
gical specimens.
Results: Between November 2012 and December 2016 18 patients were studied
(11 males; mean age 71.6 years, range 44–88 yo). The tumour site was the sto-
mach in 15 out of 18 patients and the duodenum in 3 out of 18 patients.
Agreement between EUS-FNB and surgical pathology was 100% with respect
to the diagnosis of GIST (18/18). Proliferative indexes (Ki67/MIB1) were deter-
minable in 14/18 (77.7%) of biopsies versus all cases (as expected) in resected
specimens. In our series Ki67/MIB1 were generally underestimated. We found
only 2 patients with the required number of 50 HPFs for mitotic count examina-
tion. They showed a mitotic index 55/50 HPFs comparable to surgical speci-
mens. No mitotic figures were seen in core biopsy specimen from any of the
remaining 16 patients. In these patients the number of HPFs for mitotic count
examination ranged from 1 to 22. In their corresponding surgical specimen we
found mitoses in 16/16 patients, ranging from 1 to 5 per 50 consecutive HPFs.
Tumour size of the surgical specimen exceeded (45mm) tumor EUS-size in 12
out of the 18 investigated cases (66.6%) and was equal (5 mm) in 6 cases
(33.3%).
Conclusion: In our experience, EUS-guided tissue core biopsy have an extremely
high diagnostic accuracy for GIST diagnosis, but underestimates the prolifera-
tion indexes and rarely allows for a reliable mitotic count. The main reason
responsible for these results is the uneven distribution of the mitotic figures
throughout the lesion, which can cause the biopsy to miss the most mitotically
active areas. Furthermore, EUS examination generally underestimates the size of
the lesions; this limit is fundamentally linked to the ‘‘bidimensional’’ evaluation
of lesions obtained by ultrasound. In addition, the underestimation of the size is
greater for large lesions because of the low depth of field evaluated by high
frequencies used in EUS. Our data obtained with EUS-FNB are similar to pre-
vious studies with FNA and constitute a major limitation for developing a pos-
sible pre-treatment and biopsy-based risk classification of GIST. Alternative
parameters (genotype profiling) must be validated on pre-surgical biopsy samples
from GISTs for prognostication purposes.
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Introduction: Pancreatic cancer (PC) remains a disease with overall poor prog-
nosis, despite significant advances over the past decade. Stereotactic body radia-
tion therapy (SBRT) is able to deliver higher biological effective dose to the
tumor over a shorter period of time with reduced local toxicity compared to
conventional external beam radiation therapy. EUS-guided fiducial placement
has been shown to improve the accuracy and localization during SBRT.
United European Gastroenterology Journal 5(5S) A481
Conventional EUS-guided fiducial placement requires back-loading each fiducial
through the tip of the FNA needle. Thus, delivery of multiple fiducials can be
cumbersome and time-consuming.
Aims & Methods: We aimed to evaluate the feasibility, safety, and performance
characteristics of fiducial deployment in PC patients using a novel exchange-
able FNA system with pre-loaded 22-gauge EUS fiducial needles. This was a
single-center pilot study of 10 consecutive PC patients undergoing EUS-guided
fiducial placement for SBRT. The fiducial delivery system contains a 22-gauge
EUS needle pre-loaded with 2 gold markers with knurled design. After the 2
markers were deployed, the EUS fiducial needle insert was exchanged out for
a second pre-loaded EUS fiducial needle insert through the exchangeable
FNA system for total deployment of 4 markers in each patient. All patients
underwent CT after fiducial placement as part of SBRT to evaluate successful
deployment and complications. The primary endpoint was procedure success,
defined as deployment of at least 3 fiducials into the desired target area.
Secondary endpoints were total procedure time, fiducial delivery time, and
safety.
Results: Fiducial placement was attempted in 10 consecutive patients with PC
(mean age 61.7 years, males 60%). The tumor was located in the head (n¼ 6),
neck (n¼ 2), and the body (n¼ 2) of the pancreas. Mean size of the tumor was
2.7 cm (range 1.6–5.3). Procedure success was achieved in all 10 (100%) patients.
All 10 patients successfully received 4 fiducials. Mean total procedure time was
12.2 minutes (range 5–18). By comparison, using historic controls of the first 10
patients who underwent conventional EUS-guided fiducial placement, the mean
total procedure time was 26 minutes (range 16–44, p¼ 0.002). Mean fiducial
delivery time was 4.2 minutes (range 1–8). There were no immediate or delayed
(7 days) complications.
Conclusion: EUS-guided fiducial placement with a novel exchangeable FNA
system with pre-loaded 22-gauge EUS fiducial needle is quick, technically
feasible and safe. This system may theoretically decrease the risk to the
clinical staff by eliminating the need for back-loading fiducials through
exposed needle tip and handling of potentially dirty needles. Given the poten-
tial safety and time advantages, further prospective studies are warranted for
validation.
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Introduction: Bubbles can impair the visualization of the small bowel (SB)
mucosa during capsule endoscopy (CE).
Aims & Methods: Our aim was to develop and to validate a computed algorithm,
which would evaluate theabundance of bubbles in SB-CE. Two sets of 200 SB-
CE normal still frames were extracted from 45 complete third-generation SB-CE
videos. Two experienced SB-CE readers analyzed both sets of images twice, in a
random order. Each still frame was categorized as "scarce in" or "abundant in’’
bubbles (510% or 10% of bubbles covering the frame, respectively).
Reproducibility ( coefficient), sensitivity (Se), specificity (Sp), Receiver
Operating Characteristic [ROC] curve, and calculation times were measured
for different algorithms (Grey-level of co-occurrence matrix [GLCM], fractal
dimension, Hough transform, and Speeded-Up Robust Features [SURF])
using the experts’ reading as reference. Algorithms with highest reproducibility,
Se and Sp were then selected for a validation step on the second set of frames.
Criteria for validation were ¼ 1, Se 90%, Sp 85%, and a low calculation
time.
Results: Both SURF and GLCM algorithms had high operating points (Se and
Sp over 90%) and a perfect reproducibility (¼ 1). At the validation step, the
GLCM detector strategy had the best diagnostic capabilities, with Se¼ 95.79%,
Sp¼ 95.19%, and a mean calculation time of 0.037s per frame. Table 1:
Sensitivity (Se), specificity (Sp), negative predictive value (NPV), positive pre-
dictive value (PPV) and area under receiver operating characteristic curve
(AUROCC) of four algorithms for evaluation of bubble abundance in small
bowel capsule endoscopy still frames (development step).
Conclusion: A GLCM detector strategy has high diagnostic performances to
categorize "scarce in" or "abundant in bubbles" SB-CE frames. This algorithm
is of interest for clinical use (i.e. quality in CE reporting) and for research (pro-
viding an objective comparison tool of different preparations, including anti-
bubble agents).
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Introduction: Capsule endoscopy has been demonstrated to be a first-line tool for
small bowel visualization. However, it has some limitations such as incomplete
examinations - i.e: the capsule does not reach the cecum - leading to missing
lesions.
Aims & Methods: To evaluate those factors that can predict incomplete examina-
tions, to identify those patients at risk for incomplete procedures and to define
those approachs that may improve the efficiency of the examination reducing the
time of the diagnostic process as well as the need to repeat procedures. A total of
1918 patients who underwent capsule enteroscopy at our center between 2008
and 2015 were retrospectively analyzed. We evaluated variables such as age, sex,
anthropometric parameters, comorbidity, drugs, outpatient care, analytical para-
meters, indication of the test and transit times. Initiallly, a univariate analysis and
then, a multivariate analysis using a logistic regression model were carried out.
Results: In the univariate analysis, the following variables showed a statistically
significant association with the rate of incomplete examinations: age, gender,
indication of procedure, outpatient care, history of abdominal surgery, heart
disease, capsule ingestion posture, hemoglobin levels, renal failure and both
gastric and small bowel transit times. These variables were included in the multi-
variate analysis were age4 65 years (OR¼ 1.99, 95% CI: 1.34–2.95), gastric
transit time 441 minutes (OR¼ 2.60, 95% CI, : 1.72–3.93) and small bowel
transit time 4 than 286 minutes (OR¼ 3.52 95% CI: 2.26–5.48) showed a sta-
tistically significant association with the risk of incomplete examination.
Conclusion: Incomplete capsule endoscopy is predictable. Patients older than 65
years and/or a gastric emptying time greater than 42 minutes are independent
predictive factors for incomplete procedures. In these clinical scenarios, pharma-
cological preventive measures or endoscopic introduction should be taken into
account to avoid incomplete examinations.
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Abstract: P0917
Sensitivity (%) Specificity (%)
Negative predictive
value (%)
Positive predictive
value (%)
Area under
Receiver operating
characteristic curve
Calculation time (s)
by frame (meanSD)
Development step
Algorithm 1: GLCM 94.38 93.58 95.32 92.31 0.9852 0.040 0.003
Algorithm 2: Fractal dimension 84.27 82.57 86.54 79.78 0.9269 10.1 0.7
Algorithm 3: Hough transform 85.39 81.65 87.25 79.17 0.9252 1.45 1.2
Algorithm 4: SURF 94.38 97.24 95.45 96.55 0.9897 11.47 7.11
Validation step
Algorithm1: GLMC 95.79 95.19 96.12 94.79 0.037 0.005
Algorithm 4: SURF 94.74 94.23 95.15 93.75 1.45 1.78
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Introduction: A many variety of pharmaceuticals for the treatment of colon dis-
ease can be more effective and have less side effects if targeted for precise delivery
in the colon. Over the years, many types of delivery vehicles have been developed
with the aim of targeting the colon, such as Ph based delivery technologies, time
dependent drug release mechanisms, pressure based mechanisms, flora sensitive
mechanisms and others. These technologies have performed with variable degrees
of success due to the wide distribution of motility and other physiological varia-
bility between patients. We describe a novel capsule technology which incorpo-
rates a diffused gas sensor that allows for an accurate sensing of colon entrance;
as well as a 3D real time positioning system that allows for an accurate, pro-
grammable, localized, and in colon drug delivery system.
Aims & Methods: Data was collected from 14 patients that swallowed capsules in
a multi-center clinical trial using an x-ray imaging capsule (GUT 2016). The
patients were sent home to continue their normal life routine while the capsule
naturally traveled in the gastrointestinal tract until excretion. (Subjects signed
informed consent forms and the study was performed after local IRB approval).
The capsules contained electronics and software that allowed for live commu-
nication between the capsule and a recording device that is placed directly on the
patient’s back. This device tracks the position of the capsule and communicates
with it, receiving diffused gas pressure from the capsule sensor and fusing this
information with 3D position information from the capsule. The capsule system
exhibited position accuracy of 1 cm and the ability to detect movements in real
time, as well as potential of 1ml of payload for drug containment.
Results: The average total transit time of the capsule was 43 hours (range: 15–68
hours). The average transit time to cecum was 13.8 hours, and the average time
across the colon was 12.8 hours (range 6–25). The position tracking and the RF
communication between the capsule and the recorder showed 490% coverage in
all cases, even in obese patients. No adverse events were reported. Figure 1
illustrates the recorder placement on the patient back. Figure 2 is a typical
averaged capsule position trace in the colon.
Conclusion: A capsule with accurate position tracking, 2-way communication,
and on line algorithms can determine colonic entrance and identify exact loca-
tions in the colon. A wide variety of drugs can accurately be delivered to their
exact target in the colon. It enables for a more effective (high dose) and less toxic
(no systemic delivery) therapy for IBD and cancer.
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Introduction: Colon Capsule Endoscopy (CCE) procedure requires a preparation
regimen, which provides a clean colon, clear capsule images and promotes cap-
sule propulsion through the entire colon. A four-point cleansing grading scale
system (poor, fair, good and excellent) has been used to describe the quality of
colon preparation. ‘‘Poor’’ and ‘‘fair’’ are considered inadequate cleansing, while
‘‘good’’ and ‘‘excellent’’ – adequate for polyp detection. Adequate cleansing has
been associated with significantly higher diagnostic accuracy, when compared
with inadequate cleansing (72% vs. 28% respectively).[1]
Aims & Methods: Evaluate the relation between CCE procedure cleansing and
accuracy – with an emphasis on inadequate cleansing. This is an additional post
study analysis[2], including 767 screening population participants, from 17 sites
in the United States and Israel, who underwent CCE procedure followed by a
blinded colonoscopy. Capsule preparation included 12mg Senna, 4 liters split
dose of sulfate-free polyethehylene glycol (PEG), with 6 and 3 oz of oral sulfate
solution - for capsule propulsion. The CCE video was reviewed by 1 of 5 highly
experienced CCE gastroenterologists. These physicians assessed colon cleansing
on a ‘‘poor’’ to ‘‘excellent’’ scale. Incomplete studies were included in the analy-
sis. Polyps were considered a match, if the size measured by the capsule (50%)
range overlapped the size measured by the colonoscopy (50%) range, and polyp
location estimates by the 2 methods were in the same or adjacent segments[2].
Results: The mean age of the analyzed cohort was 57.1 (SD 5.8) with 342 males
(44.6%).
Conclusion: This analysis indicates, that when utilizing 4 liter PEG and oral
sulfate solutions for CCE procedure preparation, current cleansing assessment
scale and methodology may need to be re-evaluated - to better correlate with
polyp detection. Currently, ‘‘fair’’ cleansing may not indicate inadequate cleans-
ing for polyp detection.
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Introduction: Colonoscopy miss rate is an area of intense focus, as it directly
correlates with colorectal cancer incidence rate. Previous studies reported a
colonoscopy miss rate of 2%22%, depending on polyp size and histology [1].
Colon Capsule Endoscopy (CCE) is a visualization diagnostic modality of the
colon mucosa, which has demonstrated high sensitivity for polyps and adeno-
mas [2]. Determining the nature of polyps detected by CCE but missed by the
imperfect gold standard (colonoscopy), may facilitate both optimization of
CCE application (potential CCE additive value) and increase colonoscopy
polyp detection.
Aims & Methods: Characterize polyps detected by CCE, which were missed by
colonoscopy. 695 screening population participants, from 17 sites in the
United States and Israel, underwent CCE procedure followed by a blinded
colonoscopy. The overall colonoscopy adenoma detection rate in this study
was very high – 39% [2]. Following the blinded colonoscopy, the patient’s
CCE report was assessed. Based on the findings in this report, the colono-
scopy performing physician decided whether or not to immediately follow up
with a second colonoscopy. 70 of the CCE findings were detected by the
second colonoscopy. These 70 polyps were compared with 683 polyps
detected by blinded colonoscopy, using logistic regression model. Adjusted
Odds Ratios (Adj.OR) and corresponding Confidence Intervals (CI) were
estimated.
Results: Of the 70 polyps missed by first colonoscopy and detected by second
colonoscopy, 20 (29%) were 6mm or larger (based on colonoscopy size estima-
tion), 19 (27%) were either adenomatous or sessile serrated lesions and 16 (23%)
were described as either flat or sessile-flat by colonoscopy performing physician.
Stratification of polyps based on location:
Detected by
blinded colonoscopy
(n¼ 683)
Detected after
CCE and
unblinding (n¼ 70)
Cecum 64 (84%) 12 (16%)
Ascending 181 (94%) 11 (6%)
Transverse 98 (96%) 4 (4%)
Descending-Sigma 243 (90%) 26 (10%)
Rectum 97 (85%) 17 (15%)
Abstract: P0920
Colon cleansing Sensitivity (6mm); n¼ 272 Specificity (6mm); n¼ 495
Adequate cleansing 153/195¼ 78.5% (72.2%83.7%) 308/350¼ 88.0% (84.2%91.0%)
Inadequate cleansing 54/77¼ 70.1% (59.1%79.2%) 130/145¼ 89.7% (83.5%93.7%)
P-value 0.147 0.600
Poor cleansing 3/9¼ 33.3% (11.7%64.9%) 15/16¼ 93.8% (69.7%100%)
Fair, good and excellent cleansing 204/263¼ 77.6% (72.1%82.2%) 423/479¼ 88.3% (85.1%90.9%)
P-value 0.007 1
Poor cases had significantly lower CCE sensitivity compared with fair, good and excellent cases, for 6mm polyps (P-value¼ 0.007). When stratifying cases based on the
current adequacy cutoff, sensitivity for 6mm polyps is similar in inadequate (‘‘poor’’þ ’’fair’’) cases compared to adequate (‘‘good’’þ ’’excellent’’) cases (70.1%, 78.5%
respectively; P-value¼ 0.147).
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Multivariate logistic regression revealed that after adjusting to polyp’s size, cecal
and rectal segments were associated with increased chance of CCE additive value
to colonoscopy (cecum vs. ascending or transverse colon: Adj.OR¼ 3.2 [95%CI:
1.3–7.6] and Adj.OR¼ 4.5 [95%CI: 1.4–14.6] respectively; rectum vs. ascending
or transverse colon: Adj.OR¼ 2.6 [1.1–5.8] and Adj.OR¼ 3.6 [95%CI: 1.2–11.4]
respectively). There were 59 patients (8.49% of study population), with at least
one CCE additive value to colonoscopy event.
Conclusion: CCE has the ability to detect polyps missed by traditional colono-
scopy, especially lesions in the cecum and rectum.
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Introduction: Only small series (510 patients) have described endoscopic man-
agement of postoperative pancreatic fistulas (POPF). The purpose of this retro-
spective study was to describe the indications, technique and results of
endoscopic treatment of POPF.
Aims & Methods: From a prospective database of an endoscopic unit of a tertiary
center, patients with POPF who underwent pancreatic endoscopic treatment
during a retrograde endoscopic cholangiopancreatography (ERCP) were identi-
fied between January 2010 and June 2016. POPF was classified according to the
definition of the International Study Group of Pancreatic Fistula Working
Group. The indications, the techniques and results of endoscopic drainage and
the patients’ outcomes were registered.
Results: Among 6473 ERCPs performed during the inclusion period, 31 patients
had POPF treated endoscopically (14 men, 7 women, mean age standard devia-
tion [SD]: 63 years [15]). Surgeries at the origin of the fistula were: distal
pancreatectomy with spleen resection (n¼ 19); spleen preserving distal pancrea-
tectomy (n¼ 3); central pancreatectomy (n¼ 2); enucleation (n¼ 4); partial pan-
createctomy (n¼ 1); left nephrectomy (n¼ 2), for the following indications:
IPMN (n¼ 7), pancreatic adenocarcinoma (n¼ 5), neuroendocrine tumors
(n¼ 4), insulinoma (n¼ 3), adrenocortical carcinoma (n¼ 6), metastasis (n¼ 2),
pheochromocytoma (n¼ 1), cystadenomas (n¼ 2), spleen artery aneurysm
(n¼ 1). The mean time between surgery and first ERCP (SD, [range]) was 70
days (145, [6–806]). POPF was grade B in 19 patients and grade C in 12
patients. All patients had somatostatin analogs and 13 (41.9%) had an external
radiological drainage prior to endoscopic drainage. In 9 patients (29%) a pan-
creatic cystogastrostomy was performed during follow-up (FU) in addition to the
transpapillary drainage. The pancreatic cannulation rate was 96.8% at the first
ERCP and 100% after 2 ERCPs: 90.3% by the major papilla, 9.7% by the minor
papilla. All patients had a pancreatic sphincterotomy and the placement of a
pancreatic plastic stent. 3 early complications (572 h) occurred: 2 post-sphinc-
terotomy bleeding and 1 perforation, all medically treated. The mean FU (SD,
[range]) was 378 days (497 [2–2227]) after the first ERCP. During FU, there
were 3 stent migrations and 2 stent obstructions requiring a subsequent ERCP
for stent replacement. Eight patients (25.8%) died after surgery complications.
Among the 23 remaining patients, the closure rate of POPF was 100% within an
average (SD [range]) of 153 days (81 [16–326]) after the first ERCP, after a
mean number of ERCP performed per patient (SD) 2.5 (1.0). No late reopen-
ing fistula occurred after removal of the pancreatic stent.
Conclusion: This retrospective study, the most important one reported to date,
shows that the endoscopic treatment of POPF resistant to medical therapy is an
effective option.
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Introduction: Difficult biliary cannulation is defined by the presence of one or
more of the following: more than 5 contacts with the papilla while attempting to
cannulate; more than 5 minutes spent attempting to cannulate following visua-
lization of the papilla; more than one unintended, pancreatic duct cannulation or
opacification. In these situations, pancreatic stent insertion might prove to be
very useful for prophylactic and tactical purposes.
Aims & Methods: We are proposing in this paper to present the experience of
Clinical Emergency Hospital Bucharest regarding difficult biliary cannulation
and how pancreatic stent insertion proves to be efficient in these situations.
This paper is a retrospective study of the patients who presented difficult cannu-
lation and to whom pancreatic stents were inserted for prophylactic and tactical
purpose. The study included patients with ERCP (Endoscopic Retrograde
Cholangiopancreatography) performed in Clinical Emergency Hospital
Bucharest between December 2014 and December 2016. The patients were eval-
uated in terms of pancreatic stents efficiency regarding successful cannulation
and post ERCP pancreatitis rate. The stents used were 5 Fr, 3 cm and 5 cm.
Results: We introduced in the study 158 patients with ERCP and difficult biliary
cannulation, who required pancreatic stent insertion for prophylactic and tactical
purpose. Patients’ mean age was 60 years, while the sex ratio was 2:1 in favor of
the female gender. Pancreatic stents proved their efficiency in 98% cases, in only
3 patients deep cannulation being unsuccessful. On average, patients required 1,
15 ERCP procedures in order to obtain biliary access. ERCP indication for
benign pathology was predominant (60%). The stents used were 5 Fr, 5 cm
(102 patients) and 5 Fr, 3 cm (56 patients). Precut sphincterotomy was performed
in 82 cases (37 before stent insertion and 45 after stent insertion). From all
patients included, only 19 patients (12%) presented post procedure elevation of
serum amylase 3 times higher than normal value associated with abdominal pain.
Conclusion: Pancreatic stents proved to be efficient in obtaining biliary cannula-
tion in difficult situations. Regardless of their length, 5 Fr (3 cm, 5 cm) stents
ensure the same success rate for cannulation and offers protection against post
ERCP pancreatitis, as long as they are correctly inserted.
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Introduction: Endoscopic ultrasonography (EUS)- guided biliary drainage (EUS-
BD) is increasingly used in the treatment of malignant biliary obstruction after
failed ERCP. However, Multi-step process for EUS-BD is closely related to
adverse events.
Aims & Methods: The present study was designed to determine feasibility and
safety of stent placement using a thin delivery-system stent without dilation step
during EUS-BD. Three types of the new designed partially covered laser-cut
metal stents (6-mm-wide and 60-mm-long) with 7Fr delivery catheter with hard
tip (7Fr hard tip), 7.5Fr delivery catheter with hard tip (7.5Fr hard tip) and 7Fr
delivery catheter with soft tip (7Fr soft tip) were prepared respectively. A phan-
tom model with a silicon plate was created. The plate was punctured with s 19-G
needle and a guidewire was passed the plate. The delivery system was advanced
over the guidewire to pass the plate and the resistance force was measured. A
biliary obstruction model was created by clipping the papilla in 10pigs, EUS-BD
(choledochoduoduodenostomy) using the thin delivery system stents was
attempted following 19-G needle puncture without the use of dilation devices.
The technical success and adverse events within 2 weeks after EUS-BD were
analyzed for three types of stents.
Results: Among the three types of stents, 7Fr soft tip had the least resistance in
the phantom model. In the animal model, the median common bile duct diameter
before puncture measured on EUS and the median procedure time was 7.66mm
(4.05–9.5) and 29.3 minutes (16–47) respectively. In all pigs, EUS-BD using the
three types of stents were technically successful. Dilation was unnecessary in 25%
(1/4), 0% (0/2) and 100% (4/4) for the 7Fr hard tip, 7.5Fr hard tip and 7Fr soft
tip, respectively. Even in the cases requiring dilation, stent placement was suc-
cessful, immediately after dilation only with a thin catheter (5.5Fr). Neither
cautery dilation nor balloon dilation was needed. There were no procedure-
related complications occurring during and 2 week after EUS-BD. All stents
remained in place without migration. At necropsy, fistulas were created between
the bile duct and duodenum in all pigs and the growth of fibrous tissue was
observed in the microscopic findings.
A484 United European Gastroenterology Journal 5(5S)
Conclusion: Among the three types of stents, the 7Fr soft tip was suitable for
EUS-BD without dilation in the phantom and animal models. The thin delivery-
system stent may be technically feasible and safety for EUS-BD and possibly
reduce adverse events.
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Introduction: Post-endoscopic sphincterotomy bleeding is treated endoscopically
with pharmacologic injection, electrosurgical cohagulation, balloon tamponade
or clipping, but severe cases may require angiographic or surgical approach. An
alternative long-acting tamponade treatment with fully-covered metal stents
(FCMS) has been advocated.
Aims & Methods: We report here on the use of FCMS in post-sphincterotomy
early and late bleeding. Patients referred for in- and out-patient ERCP were
informed of the potential off-label treatment with FCMS of post-sphincterotomy
bleeding, and of treatment approval by the local ethical committee. We treated
post-spincterotomy bleeding first with adrenaline and/or sclerosing agent injec-
tion. When this first line hemostasis failed, we placed short FCMS in the distal
choledochus. Endoscopy was rescheduled after 1 month to remove the FCMS.
During the early post-procedural period the patients were treated with blood
transfusions if needed, and antiplatelet drugs as well as oral anticohagulants
were avoided.
Results: 17 Patients (10M/7F), aged on an everage 70 years (range 38–90)
received 18 FCMS (10mm 40mm, Boston Scientific) for failed hemostasis
since 2015. Technical success was 100%. Hemostasis was obtained in 16 patients,
with an everage loss of 1 g/dl of Hb and 9 packed red cells units transfused. In our
cases we had 1 outlayer, a patient that had received needle-knife sphincterotomy
without early bleeding but developed delayed bleeding with hypovolemic shock
He received a second ERCP and a FCMS after 3 days. After further 3 days the
patient was in the intensive care unit because of persistent bleeding and we
performed a third ERCP. The FCMS was in place, but we removed it, retreated
the bleeding by injective therapy and placed a second FCMS, obtaining a stable
hemostasis. This single patient received 8/9 of the packed red cells unit used in the
study. The FCMS spontaneously migrated in 4/18 cases, one had been removed
for incomplete bleeding control and substituted after 3 days, and 13 were easily
removed as per protocol. In two cases FCMS were removed and a plastic double
pig-tail stent was put in place, for persistent choledochal distal stenosis.
Conclusion: These cases represent a large collection of evidence showing that
treating post-sphincterotomy early bleeding with FCMS is feasible, safe and
effective. Late bleeding associated with needle-knife pre-cut was much harder
to control and required endoscopic revision, intensive care unit support and re-
stenting. Our results are consistent with and support previous research in the
field.
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Introduction: Anastomotic bile duct stricture (ABS) remains as one of the most
common complications after orthotopic liver transplantation (OLT). Current
standard of practice of endoscopic retrograde cholangiopancreatography
(ERCP) with insertion of multiple plastic stents (PS) often requires multiple
procedures before achieving satisfactory stricture resolution. In recent years,
studies utilizing covered self-expandable metallic stent (cSEMS) in refractory
ABS management reported varying degree of success.
Aims & Methods: The aim of this study was to analyze efficacy of SEMS in
resolution of anastomotic stricture in patients with orthotopic liver transplanta-
tion. In addition, we sought to identify factor(s) influencing the likelihood of
stricture resolution, the rate of adverse outcome(s) A retrospective cohort study
was conducted using a registry of consecutive patients who underwent ERCP
with biliary SEMS placement from January of 2010 to November of 2016 for the
management of refractory ABS. Demographic variables including age, gender,
and clinical variables including body max index (BMI), number or prior ERCP
with PS insertion, stent brand and dimensions and duration of SEMS insertion
period were collected. The rates of stricture resolution, adverse outcomes
including post ERCP pancreatitis, cholangitis and stent dysfunctions (occlusion,
and) migration) were calculated. This study was approved by the Institutional
Review Board of the Cleveland Clinic.
Results: There were 47 OLT patients who underwent ERCP-cSEMS insertion for
refractory ABS during the study period. Of 47 patients, 37 patients (78.8%)
achieved stricture resolution after single SEMS treatment. Longer duration of
SEMS insertion was the only variable associated with increasing probability of
stricture resolution as there was 20% increase in odds of stricture resolution for
every additional week SEMS was in place. Among those who achieved initial
stricture resolution, 27 patients (73%) maintained bile duct patency throughout
the follow up period. The most common adverse outcome was internal migration
of cSEMS which occurred in 11 patients (23.4%). Post-ERCP pancreatitis was
observed in 3 (6.4%) patients
Conclusion: The efficacy rate observed in resolving refractory ABS with cSEMS
placement appears to be comparable to that of multiple ERCPs with PS place-
ment method. Furthermore, durability of ABS resolution with cSEMS use
further supports its potential long-term efficacy. Hence, cSEMS should be con-
sidered as a viable alternative treatment of refractory ABS. Longer stent insertion
period is associated with higher likelihood of ABS resolution. The high rate of
internal migration observed with SEMS warrants further endeavor in stent
design improvements.
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Introduction: Disconnected pancreatic duct (DPD) can occur in patients after
drainage of pancreatic fluid collections (PFC). Concerns have been raised
about clinical relevance of DPDS.
Aims & Methods: To assess the frequency of DPD and its clinical significance
after EUS guided drainage of PFC. Patients of acute or chronic pancreatitis with
symptomatic PFC, who underwent Endoscopic Ultrasound (EUS) guided drai-
nage between January 2011 to December 2016 were included, after an informed
consent. Stents used for drainage procedure were either bi-flanged metal stent
(BFMS) or double pigtail plastic stent. All these patients underwent MRCP
between 4 to 8 weeks after drainage to evaluate pancreatic duct (PD) anatomy
and confirm resolution of PFC. Subsequently, they had Endoscopic Retrograde
Pancreatography (ERP) and, if required, stent removal. BFMS was removed in
all patients. Plastic stents were retained indefinitely, if DPD was confirmed. All
patients were systematically followed at 3–6 monthly intervals for any recurrence
of PFC or new onset clinical event.
Results: A total of 407 patients (346 males, mean age 33.5 years, range 5–69
years) were followed up after EUS guided drainage for PFC. Of these 260 under-
went BFMS and 147 underwent plastic stents placement. 319 patients had pan-
creatogram (ERP and MRCP) after resolution of PFC. The pancreatic duct
abnormalities observed were as follows: DPD in 197 (61.7%), PD leak in 36
(11.3%), PD stricture in 20 (6.3%) patients. Normal PD was seen in 43
(13.5%) patients. Calcific pancreatitis was noted in 23 (7.2%). Among the
patients with DPD, the location of PD ‘‘cut off’ was in head (32, 16.2%), genu
(59, 29.9%), body (90, 45.6%) and tail (16, 8.1%). Overall, the follow-up after
stent removal ranged from 3–72 months, with a median follow up of 12months.
Pseudocyst recurred in 29 patients (8.5%) at a mean follow up of 3.5 months
(range 1–30 months), which included DPDS 27, PD stricture 1, and CCP 1. 20/29
had pain (symptomatic) and rest 9 were asymptomatic. 15/20 underwent inter-
vention (EUS drainage with plastic stent in 12, surgery in 3) and 5 resolved
spontaneously.
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Conclusion: Disconnected Pancreatic Duct is observed in 60% patients following
EUS guided drainage of PFC. However; only a small proportion (510%) of
DPD had symptomatic recurrent fluid collection.
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Introduction: ERCP-related perforation is rare (0.39%), but it is associated with
an overall mortality of 7.8%. Duodenal retroperitoneal perforation (Type II) is
the most frequent, among the ERCP-related perforations. The management of
this complication has not been standardized yet: traditionally surgery was con-
sidered the only rescue therapy, but in the last years the majority of cases has
been managed conservatively. The endoscopic treatment included biliary stent
and/or nasobiliary drainage. In our institution, from 2010 we has been using fully
covered self-expandable metallic stent (FCSEMS) with nasobiliary drainage
always after resolution of the initial indication for ERCP. These stents have
the advantage of covering the laceration and allowing free flow of bile into the
duodenum instead of into the retroperitoneal space. The aim of this study was to
evaluate in our cohort of patients, the benefits of FCSEMS in type II
perforations
Aims & Methods: We experienced six type II perforations associated with ERCP.
We retrospectively evaluated the clinical findings, the length of hospital stay, the
need for surgery and death.
Results: Of the 3250 ERCP procedures performed from March 2010 to
November 2016, only six (0.18%) resulted in perforations (male/female, 2/4;
median age: 69 years; age range: 54–80 years). ERCP procedures were performed
with carbon dioxide insufflation. Five patients underwent ERCP for biliary
stones. In all cases standard sphynterotomy was performed and perforation
was immediately detected. Successful closure of persistent sphincterotomy-
related duodenal perforation using FCSEMS was obtained in all patients. One
patient developed ERCP-related pacreatitis, successfully treated with medical
therapy. Three FCSEMS were successfully removed after a median of 18 days,
the remaining three fell out spontaneously. The median length of hospital stay
was 8.5 days (range 4–20 days). There were no deaths or need for surgery.
Conclusion: The placement of FCSEMS is easy, safe and quick. In our cohort of
patients, FCSEMS is the effective endoscopic approach for management of type
II perforations recognized during ERCP.
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Introduction: Duodenal obstruction is often seen in patients with advanced pan-
creatic cancer (APC). Endoscopic duodenal stenting (DS) has become increas-
ingly popular due to its less invasiveness compared with surgical
gastrojejunostomy.With recent new advances in chemotherapy and radiation
therapy, conversion surgery after neoadjuvant therapy are performed in some
cases with APC.
Aims & Methods: To evaluate the efficacy and safety of DS as palliative treatr-
nent and bridge to sugery in patients with APC. We retrospectively analyzed
patients who received DS placement between March 2012 and March 2017.
Twenty-three patients (11 men/12 women median age, 65.9; 46–82 years) with
APC. GOO scoring system (GOOSS) was used as an index of clinical success.
Results: A total of 23 Patients consisting of 6 patients treated with chemotherapy
and 11 patients treated with neoadjuvant chemoradiotherapy were included in
this study. Obstructed parts of the duodenum were D1 in 2, D2 in 5, D3 in 12,
and D4 in 4. Technically success of DS was achieved in 100% of patients. The
mean GOOSS before DS and after DS were 0.5 and 2.6 respectively (p5 0.001).
The median time to restart soft solid meal after DS was 2.9 days. Biliary obstruc-
tion was seen in 13 patients and managed with endoscopic biliary stenting.
Adverse events occurred in 6 patients, including 1 with cholangitis, 1 with bleed-
ing and 3 with stent occlusion. The reintervention technical and clinical success
rates were 100% (5/5) and 80% (4/5), respectively. The median survival time after
DS was 159 days. In neoadjuvant chemoradiotherapy patients, 4 patients were
performed surgery for APC.
Conclusion: DS in patients with APC was effective and safe. The findings of this
study suggest that DS is worth considering as the bridge to surgery in patients
receiving neoadjuvant therapy.
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Introduction: Endoscopic stenting with self-expandable metallic stents (SEMS)
has become widely accepted for an alternative to emergency surgery in the man-
agement of malignant large bowel obstruction (LBO) after the initial introduc-
tion of SEMS in 1991. Recent years, advance in procedural equipment and
accumulation of experience have improved technical success rate in colonic stent-
ing for malignant LBO. However, there is still a divergence in the success rate of
technical and clinical.
Aims &Methods: The aim of this study is to clarify the factors that reduce clinical
success rate of stent placement. This study was conducted by a retrospective chart
review at a single center. The endoscopy database and clinical records from the
University of Tokyo Hospital, Tokyo, Japan, were reviewed retrospectively
between May 2007 and February 2017. Patient’s symptoms, characteristics, clin-
ical data were obtained from electric medical record. The obstructions were
diagnosed clinically and radiologically and were evaluated by the Colorectal
Obstruction Scoring System (CROSS). Technical success was defined as deploy-
ment of a stent across the entire length of the stricture on the first attempt.
Clinical success was defined as resolution of symptoms and radiological relief
of the obstruction within 24 hours, as confirmed by radiographic observations.
Results: A total of 172 patients (91 males, 81 females; mean age 66.9 years)
underwent colonic stenting for malignant LBO. This procedure was performed
to 80 colorectal cancer (CRC) patients (48%) and to 92 patients (52%) with
cancer of other etiology. Stenting was performed as a bridge to surgery (BTS)
therapy in 33 patients (19.2%), whereas stenting was planned palliative proce-
dure in 139 patients (80.8%). Sixty-seven patients (39%) had a tumor causing
obstruction in the proximal colon, and 105 patients (61.0%) in the distal colon or
rectum. The mean length of obstruction was 6 cm, and obstruction of 60 patients
(34.9%) longer than 6 cm. The technical and clinical success rate was 98.8% and
89.5%, respectively. Clinical success rate dropped from 98.9% (91/92) to 78.8%
(63/80) when the obstruction caused by extra-colonic malignancy (ECM)
(p5 0.05). There was also reduction of clinical success rate from 99.1% (111/
112) to 71.7% (43/60) in all patients (p5 0.05) when attempting to stent lesions
of longer than 6 cm. Clinical success rate was 85.7% (90/105) and 95.5% (64/67)
(p5 0.05) when the patient had obstruction of distal colon or rectum vs in
proximal colon. In multivariate analysis, placement in distal colon or rectum,
obstruction by ECM, and obstruction longer than 6 cm were independent risk
factors associated with lower clinical success rate (odds ratio [OR] 3.19; 95%CI
0.96–10.6, [OR] 24.5; 95%CI 3.19–189.3, [OR] 31.7; 95%CI 4.32–232.7).
Conclusion: The placement of SEMS for malignant LBO is safe and effective, but
clinical success rate drops in the cases with obstructions of distal colon or rectum,
longer than 6 cm, or caused by ECM. Considering the indication of colonic
stenting for malignant LBO, these factors should be evaluated before procedure.
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Introduction: Refractory Esophageal Stenosis (RES) definition differs among
studies. Unresolved benign esophageal stenosis even after 5 or more sessions of
endoscopic dilation therapy in most studies. Until now, there have been no
treatment showing the satisfactory results. Mitomycin C (MMC) inhibits DNA
synthesis/reduces Ebroblastic collagen formation. Tried in RES in several studies.
The meta-analysis about treatment of refractory gastrointestinal stenosis with
MMC in total 24 studies. The most commonly reported site esophagus (79%).
Only 9 recruited adult patients (n¼ 38). Of these, 23 patients were RES.
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Complete/partial response of MMC for RES patients: 59.5%/40.5%,
respectively.
Aims & Methods: The aim of this study was to evaluate the clinical efficacy of
MMC injection therapy in patients who had refractory benign esophageal ste-
nosis. Between October 2013 and February 2016 Enrollment criteria: Patients
with refractory benign esophageal stenosis who did not respond even after five or
more endoscopic dilation therapy. The patients should be more than eighteen
year old. Exclusion criteria: Malignant esophageal stenosis, Pregnant or breast
feeding women, Deteriorated patients who could not tolerate endoscopic proce-
dures. The method of MMC application –Via 23 gauge injection needle (Optimos
injector, Taewoong Medical, Korea) 4mL of saline-diluted MMC was pre-
pared, with concentration of 0.5mg/mL –Injection of 0.5ml MMC at eight
points of the stenotic site immediately after bougination. Follow-up –Interview
After 1 week and every four weeks after MMC injection upto 52 weeks.
Endoscopy Four weeks after MMC injection and when the obstructive symptoms
appeared. Primary end-point –The rate of clinical success. Secondary end-points
–The mean score of GOOSS before and after MMC injection therapy,
Complication rates. Definition –Clinical success: Improvement of GOOSS
score more than one point after MMC injection therapy, compared before
MMC injection
Results: Ten patients with refractory benign esophageal stenosis were initially
enrolled. Two patients were excluded due to death from hypovolemic shock
due to persistent bleeding and esophagectomy as patient’s wish. Finally, Eight
patients were analyzed. The rate of clinical success of MMC injection therapy in
patients with refractory benign esophagea stenosis was 87.5%. Mean scores of
GOOSS were significantly reduced after MMC injection therapy, from 2.5 to
0.29. In all patients, MMC injection therapy below two sessions was needed to
improve the symptoms of enrolled patients. Major complications did not occur in
any patients.
Table 1: Outcomes of MMC injection therapy
Variables values
Number of Bougie dilation before MMC injection 5/6/7/8/9 5/1/0/1/1
The number of session of MMC injection 1/2 3/5
Mean GOO score before MMC injection 2.5
Mean score of GOOSS after final MMC injection 0.29
Mean diameter of stenosis before MMC injection, mm 5.2
Mean diameter of stenosis 3 month after final
MMC injection, mm
8.9
Clinical success rate (%) 87.5
Complications (N,%) perforation bleeding requiring
transfusion of other interventions others
0(0) 0(0) 0(0)
Conclusion: In our study, the mitomycin injection therapy was effective in
patients who had retractable benign esophageal stenosis. The mitomycin injec-
tion therapy could be considered as an alternative for retractable benign esopha-
geal stenosis. A large-scale prospective studies are required in future.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Anastomotic stenosis or dehiscence are serious complications of
colorectal surgery. Colostomy or ileostomy and later redo anastomosis or
Hartmann’s procedure are the mainstay of therapy, but edema and inflammation
due to abdominal sepsis or later adherences can prevent the use of standard
management, and therefore alternative salvage repair methods may be required.
Reabsorbable polydioxanone stents are a proposed method but with still deba-
table results in terms of correct placement, clinical success, early and late stenosis,
stent migration, perforation, bleeding, fecal incontinence and local pain.
Aims & Methods: We report here on the use of reabsorbable polydioxanone
stents (RPS) in colorectal anastomotic stenosis or dehiscence. We treated with
RPS placement, endoscopic dilation and daily mesalazine enemas and/or suppo-
sitories 5 complex cases since 2015. Endoscopy was repeated 1 month after and
then every two months or earlier if needed. Endoscopic dilation and progressive
apposition of partially overlapping stents were repeated until a stable lumen was
observed. During follow-up the patients were treated with local mesalazine.
Results: 5 Patients (3 M/2F), age (49 years mean; range 23–70) were informed of
the off-label use of stents and treatment approval by the local ethical committee.
See table 1. Technical initial success was 100%. We did not dilate patients with
dehiscence prior to stent placement. After the first RPS we could deploy a 2nd
(100%, average 3.5 – range 1.5–6 months) and a 3rd stent (40%, average 11,
range 7.5–14.5 months). Later, after 2.5–15.5 months, lumen was stable and
restored. Granulation tissue in-between stent fibers produced early stenosis, trea-
ted by re-stenting. 1 stent prolapsed partially from the anus and was shortened
with scissors. Bleeding was not present. Pelvic pain in all the patients needed
NSAIDs and reduced over time.
Conclusion: These cases show that stenting with RPS of anastomotic dehiscences
is feasible, safe and effective. Due to restenosis associated with dehiescence multi-
ple stents were needed. Distal migration was easily managed. Distal anastomoses
might explain the presence of pelvic pain. 3 patients have been subjected to
recanalization without complaints.
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Introduction: The prevalence of post-ESD esophageal strictures is non-negligible,
with a critical impact on the patients’ quality of life. Balloon-dilation may be the
first-line therapy. However, factors associated to a successful dilation in post-
ESD strictures remain unclear.
Aims & Methods: This is an observational and analytical retrospective study.
Sixty-eight consecutive patients (mean age: 65 11y, 76.5% men) who underwent
endoscopic dilation because of post-ESD symptomatic esophageal strictures
between 2006 and 2016 were included. They had Barrett’s esophagus (n¼ 46,
67.6%), epidermoid carcinoma (n¼ 21, 30.9%) and other (n¼ 1). Patients with
previous endoscopic dilations or resections, esophageal surgery, radiotherapy or
motor disorders were excluded. Clinical, morphological and technical features
were collected and analysed to determine the factors associated with a positive
outcome, defined as the absence of dysphagia during at least twelve months
following last dilation. The need of surgery, gastrostomy or prosthesis was con-
sidered as negative.
Results: Resected lesions (95.6% en-bloc) presented a median size of 52.5mm
(range: 22–110) and achieved 75% of the circumference in 50% of cases
(p¼ 0.435). They were mostly located in inferior esophagus (70.6%, p¼ 0.231)
and required two endoscopic sessions in 8 patients (11.8%). Oral and injected
corticoids were used in 11 (16.2%) and 12 (17.6%) cases, with no effect in out-
come (p¼ 0.181/0.282). No specific factor could be associated to a better out-
come (median follow-up: 23 months): early dilation (15days after ESD),
number of dilations (p¼ 0.345), short (2 cm) stenosis (p¼ 0.319), balloon dia-
meter (p¼ 0.475) and Barrett’s vs. squamous cell carcinoma (p¼ 0.458). The
overall positive outcome rate was 92.6% after a median of 3 (range:1–27) dilations
and 5 months of treatment (1 dilation/6.7weeks). A prosthesis was placed in 4
patients with clinical improvement in two of them. There were 3 complications
(4.4%, all perforations).
Conclusion: Most of patients presenting with post-ESD strictures and dysphagia
improve at long-term buy they need a median of 3 sessions. No specific factor
was associated to a better outcome.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Refractory or recurrent esophageal begnign strictures (REBS) are
frequent, and defined as the impossibility to reach or maintain a diameter of
14mm after 5 sessions of endoscopic dilation (ED). Because of a lack of guide-
lines, their management remains challenging, sometimes leading to radical surgi-
cal procedure.
Aims & Methods: The aim of this study was to define the efficacy of long-term
and repeated ED in the management of REBS. This was a monocentric retro-
spective study involving patients managed in our tertiary center between January
2002 and April 2017 for REBS. All the endoscopic dilations were performed
using Savary bougies or hydraulic balloons, depending on the operator’s
choice. Demographical and clinical data were recorded for each patient. The
endoscopic management was detailed with the number of procedures, the endo-
scopic device used, the diameter of dilation, and potential concomitant treatment
(as self-expanding metal stent, steroid injection or incisional therapy). The pri-
mary endpoint was the efficacy of sustained and recurrent ED, defined as the
absence of further dilation within 3 months of the last procedure or an interval
between the 2 last ED greater than 3 months. A failure was considered in case of
death, need for surgery, permanent enteral feeding tube or an interval between
the last 2 procedures lower than 3 months. The secondary endpoints were to
document the characteristics of dilation procedures and concomitant treatments,
the decreasing of the number of dilations per trimester, and to elucidate potential
predictive factors for success of ED.
Results: A total of 39 patients (23 men) with a mean age of 47.5 20.7 years were
included. The etiologies of strictures were anastomotic (46.1%), caustic (28.2%),
peptic (10.3%) or other etiologies (radiation injuries, esophageal diverticulect-
omy, severe viral esophagitis, 15.4%). A clinical success of repeated ED was
acheived in 27 patients (69.2%). Twelve patients (30.8%) experienced failure,
among them seven (17.9%) required frequent dilatations, two (5.1%) underwent
surgery, two (5.1%) maintained an enteral feeding tube, and one patient (2.6%)
died consecutively to inhalation pneumonia. A mean of 9.8 4 ED sessions were
performed per patient, with a mean treatment duration of 22.6 20.1 months.
Regarding concomitant treatments, 16 patients (41%) had at least one fully-
covered metallic stent placement, incisional therapy was performed in 11 patients
(28.2%), and 3 patients (7.7%) received corticosteroid injections. The number of
dilations per trimester gradually decreased over time. No significant predictive
factor of success was found, such as etiology of stricture or the use of concomi-
tant treatment, particularly. Nevertheless, an greater number of dilations during
the first trimester could promote the success of the management (3.2 2.2 dila-
tions in the success group vs 2.2 0.8 in failure group, p¼ 0.056).
Conclusion: Repeated and maintained endoscopic dilations are effective (70%) in
the management of REBS, regardless of the etiology of stricture. A prolonged
management up to 2 years, and the initial rhythm of endoscopic procedures may
favor the final success. A systematic schedule for ED would improve the efficacy
of this management.
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Introduction: Endoscopic stenting with self-expandable metallic stents (SEMSs) is
a widely accepted procedure for treating malignant colonic obstruction. This
procedure was covered by the National Health Insurance of Japan in January
2012, and the WallFlex colonic stent and Niti-S colonic stent can currently be
used in Japan. In the previous study, we reported that the WallFlex colonic stent
has more expanded force than the Niti-S colonic stent. On the other hand, the
risk of stent-related perforation was lower when using the Niti-S stent due to its
structure. Currently, we newly developed an SEMS (Niti-S structure, with 18-mm
diameter with increased expanded force compared with the conventional type),
which comprised the benefits of both WallFlex and Niti-S. In this study, we
compared the efficacy and safety of the newly developed colonic stent with the
conventional colonic stents.
Aims & Methods: This study aimed to compare the efficacy and safety of the
newly developed colonic stent with the conventional colonic stents (the WallFlex
colonic stent and the Niti-S colonic stent). Overall, 91 patients (96 lesions, male/
female: 48/43, average age: 73.2 years) underwent endoscopic SEMS placement
between November 2011 and March 2017 at Kure Medical Center and Chugoku
Cancer Center. The WallFlex colonic stent was used in 36 patients (38 lesions:
Group W), the Niti-S colonic stent in 51 patients (53 lesions: Group N), and the
newly developed colonic stent in 5 patients (5 lesions: Group D). Stratified ana-
lysis of the clinical background, technical success rate, procedure time, clinical
success rate, and complications was performed to compare Group W, Group N,
and Group D.
Results: Endoscopic SEMS placement was attempted in 96 lesions as a bridge to
surgery (BTS) in 52 lesions (54%) and as palliative therapy (PAL) in 44 lesions
(46%). In Group W, SEMS was placed in 19 lesions (50%) as BTS and in 19
lesions (50%) as PAL; in Group N, SEMS was placed in 32 lesions (60%) as BTS
and in 21 lesions (40%) as PAL; and in Group D, SEMS was placed in 1 lesion
(20%) as BTS and in 4 lesions (80%) as PAL. The technical success rate was
100% in all groups. The overall clinical success rate was 93.7% (90/96): 89.5%
(34/38) in Group W, 96.2% (51/53) in Group N, and 100% (5/5) in Group D.
Complications within 7 days included abdominal pain (3/38, 8%), poor
Abstract: P0932
Patient Age (Y) M/F Primary disease Primary treatment Complication
Secondary treat-
ment and result
N. Stents N
dilations
Follow-Up
(months)
CD 70 F sigmoid adeno K Sigmoid resection
and colorectal
anastomosis
with colostomy
and
radiotherapy
anastomotic
stenosis
Endoscopic dilation
Sub-total
dehiscence
3 4 8.5
RS 52 M rectal adeno K Knight–Griffen rec-
tosigmoid
resection
Perianal fistulas an
anastomotic
dehiescence
Ileostomy þ3 re-do
low colorectal
anastomosis þ1
FC-SEMS pla-
cement and
removal Sub-
total
dehiescence
3 4þ 1 FC-SEMS
placement and
removal
15.5
AI 23 M Occlusion due to
Hirsch prung’s
disease
Ileostomy, left emi-
colectomy,
coloanal anasto-
mosis, closure of
ileostomy
Abscess and
dehiescence
Re-do ileostomy
and anastomo-
sis, 1 FC-SEMS
placement and
removal Abscess
and total
dehiescence
2 3 2.3
UN 53 M sigmoid adeno K Sigmoid resection
and colorectal
anastomosis
anastomotic steno-
sis and
dehiescence
Endoscopic dilation
and 1 FC-SEMS
placement and
removal Sub-
total dehiscence
2 3 15
DN 54 F sigmoid adeno K Sigmoid resection
and colorectal
anastomosis
anastomotic steno-
sis and
dehiescence
Endoscopic dilation
and 1 FC-SEMS
placement and
removal Sub-
total dehiscence
2 3 10
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expansion (1/38, 3%), and fever (1/38, 3%) in Group W and perforation due to
obstructive colitis (2/53, 4%) in Group N. Complications after 8 days included
stent-related perforations (4/38, 11%) and stent occlusion (1/38, 3%) in Group
W and stent occlusion (2/53, 4%) in Group N. All 4 patients with stent-related
perforations had undergone palliative stenting with the WallFlex colonic stent,
and the stent-related perforation rate in Group W was significantly higher than
that in Group N (P5 0.05). In Group D, there were no complications and no
stent occlusion.
Conclusion: The technical and clinical success rates were extremely high in all
groups. The risk of stent-related perforation was higher when using the WallFlex
stent, while there was also perforation due to obstructive colitis when using the
Niti-S stent. On the other hand, there were no complications when using the
newly developed endoscopic colonic stent with an increased expanded force.
Although these results were obtained for a limited sample size, this new stent
is expected to exhibit more efficacy and safety than conventional colonic stents.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Heller-Dor operation is a radical treatment for cases of esophageal
achalasia. However, postoperative recurrence of symptoms is observed in some
cases. Conventionally, repeat surgery or endoscopic balloon dilatation is addi-
tionally performed on such cases. Repeat surgery is associated with issues related
to adheision, whereas endoscopic balloon dilatation is associated with issues
related to effect reliability and constancy. Peroral endoscopic myotomy
(POEM) is a new endoscopic treatment that was first reported by Inoue et al.
in 2008. POEM can be accomplished normally without being affected by the
previous Heller Dor operation, if POEM is performed at the contralateral site
of the previous myotomy. Moreover, POEM enables making a long myotomy
that cannot be made in laparotomy. At our hospital, we have performed POEM
on 12 cases that previously underwent the Heller-Dor operation. Herein, we
report on the treatment outcomes.
Aims & Methods: We performed POEM on 210 cases between September 2011
and April 2017. Of those cases, 12 cases (5.7%) had previously undergone Heller-
Dor operation. The treatment outcomes were retrospectively investigated. The
reasons for the relapse of the symptoms were investigated based on the results of
medical interview, endoscopy, esophagography, esophageal manometry, and 24-
hour PH monitoring test.
Results: The POEM cases that previously underwent Heller-Dor operation
included 8 men and 4 women with the mean age of 54.8 15.4 years. As regards
the cause for the recurrence of symptoms, the lower esophageal sphincter was the
responsible lesion in 10 patients, the esophageal body in 1 patient, and another
reason in 1 patient. POEM was performed by incising the posterior wall in all
cases, and the treatment was not prematurely discontinued for any cases. The
mean length of the muscular layer incision was 14.3 6.1 cm on the esophageal
side and 2.8 1.0 cm on the gastric side. The mean surgical duration was
136.5 35.6 minutes. No accidental symptom associated with POEM was
observed. The integrated relaxation pressure was preoperatively
22.1 8.6mmHg and 13.6 5.4mmHg. The Eckardt score was 4.1 2.5 preo-
peratively, 0.67 1.1 at 3 months after the surgery, and 1.0 1.2 at 12 months
after the surgery (P5 0.05). The symptoms improved in all cases.
Conclusion: The treatment outcomes of the POEM performed on cases that pre-
viously underwent Heller-Dor operation were favorable. POEM differs from
repeat surgery by laparotomy as it can be used to perform a long muscular
layer incision without adhesion if an appropriate route is used. The major advan-
tages of POEM are the reliability and constancy of the effectiveness compared to
endoscopic balloon dilatation. POEM is a very effective treatment method for
cases for which Heller-Dor operation has not been sufficiently effective.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Postoperative immunosuppression in transthoracic esophagectomy
for patients with esophageal cancer is a common finding [1]. In fact, both trans-
hiatal and transthoracic esophagectomy induce severely depressed monocyte and
T-lymphocyte cytokine production [2]. Remarkably, lymphopenia is an indepen-
dent predictive factor for long-term survival in patients with esophageal cancer
[3].
Aims & Methods: The aim of this study was to assess the predictors of post-
operative immune suppression in esophageal or esophago-gastric junction
cancer. One hundred ninety three consecutive patients with esophageal or eso-
phago-gastric junction cancer were enrolled in this retrospective study. White
blood cells count, polymorph nucleate cells and lymphocytes counts were
observed at preoperative time, post-operative day (POD) 1, 3 and 7. Post-opera-
tive outcome details were also retrieved. Multiple regression models were fitted to
the data to test the association between potential predictors and preoperative
lymphopaenia and lymphopenia on POD1 as parameters of immune suppression.
Results: The preoperative lymphocyte count was 1, 240/ml (IQR: 0.895–1.700)
while the lymphocyte count on POD1 was 0.670/ml (IQR: 0.500–0.982),
p5 0.001; on POD3, it was 0.800/ml (IQR: 0.580–1.070), p5 0.001; and on
POD7, it was 0.825/ml (IQR: 0.550–1.180), p5 0.001. In a modeltha also
included the interval between the end of neoadjuvant therapyand the esophagect-
omy and the preoperative whiteblood cells count, only the final dose of radio-
therapy resulted to be an independent predictor of preoperative lymphocyte
count. Similarly, in a model that also included the intervalbetween the end of
the neoadjuvant therapy and the esophagectomy, the number of surgical accesses
(laparotomy, thoracotomy and cervicotomy) and the number of nodal metasta-
sis, only the final dose of radiotherapy resulted to be an independent predictor of
lymphocytes count on POD1.
Conclusion: Patients with esophageal and esophago-gastric junction cancer pre-
sent a significant post operative immunosuppression that lasts at least for the first
postoperative week. The total amount of radiation received by the mediastinum
is the only predictor of the preoperative and postoperative lymphocyte count.
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Introduction: Surgery and endoscopic stapling have been the mainstay of treat-
ment modalities for Zenker’s diverticulum. The need for general anesthesia (GA)
is however a limiting factor in high-risk patients, as patients with ZD are often
elderly with cardiorespiratory co-morbidities. In recent years, flexible endoscopic
septum division (FESD) has gained popularity as a less invasive treatment mod-
ality for ZD, that can be performed under deep sedation, and has the potential to
be performed safely in patients otherwise deemed unfit for full GA.
Aims & Methods: The aim of this pilot study was to assess the efficacy and safety
of FESD for patients deemed unfit for GA. Patients had been referred to our
tertiary centre for FESD. Data on 14 consecutive day case patients (median age
81, range 67–95, 7 females) with an ASA score of 3 that underwent FESD
between August 2015 and November 2016 were collected retrospectively. All
patients underwent FESD under deep sedation with propofol and remifentanyl,
and did not require ventilatory support. The amount of propofol used was
recorded. Demographic data as well as information of the nature of symptoms
and recurrences was retrieved. The severity of dysphagia was measured with the
Dakkak scale. Data on procedural and 30-day post-procedural complications,
including sedation-related side effects, were collected
Results: All patients complained of dysphagia (median Dakkak score 2, range 1–
3) and regurgitation before the procedure. There were no procedure-related nor
sedation related adverse events in any of the patients. There were no 30-day post-
procedural adverse events. All patients but one experienced complete symptom
relief after one treatment session. Median propofol used was 173mg (range 59–
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330mg). One patient required an additional treatment session due to persisting
dysphagia (score 1) to achieve symptom remission. This was carried out without
complications.
Conclusion: Our results suggest that FESD is a safe, feasible and effective treat-
ment in high risk patient who are otherwise not suitable for GA, and can be
performed as a day case in an endoscopy unit. It is less invasive hence should be
considered as a preferred option over endoscopic stapling. Close interaction and
team working with anesthesiologist is important to ensure a safe outcome
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Introduction: To improve the quality of esophageal cancer surgery in the
Netherlands, the number of retrieved lymph nodes (LNs) is evaluated in one
of the quality indicators in the Dutch Upper gastrointestinal Cancer Audit
(DUCA).(1) All hospitals in the Netherlands can use the outcomes of the
DUCA indicators it to monitor their own results in relation to the national
average. The aim of this study was to analyze the outcomes of the quality indi-
cator: ‘a minimal number of 15 retrieved LNs’ in the past years and to determine
factors associated with this outcome.
Aims & Methods: Patients with an esophageal carcinoma who underwent an
esophagectomy with curative intention and who were registered in the Dutch
Upper gastrointestinal Cancer Audit between 2011–2016 were included in this
retrospective national cohort study. The primary outcome: ‘percentage of
patients with 15 LNs’ was analyzed by year and hospital. Factors tested with
univariable and multivariable analysis for the association with 15 LNs were:
age, Charlson score, weight loss, BMI, cT-, cN-, cM-stage, tumor location, neo-
adjuvant therapy, type of procedure, intraoperative complications, hospital
volume and year of resection. The postoperative outcomes: radicality, intrao-
perative complications, morbidity, and mortality were tested on association
with 15 LNs.
Results: The overall percentage of patients in the Netherlands with 15 LNs
increased between 2011 and 2016 from 51% to 81%. The variation between
hospitals decreased. Multivariable analysis showed an independent association
with 15 LNs for the factors: cN2-stage (OR [95% confidence interval]:
1.37[1.05–1.79]), resection in a hospital with 26–50 or 450 resections/year (refer-
ence: 0–25 resections, 2.03[1.57–2.63] and 3, 21[2.43–4.23]) and resection between
2012–2016 (reference: 2011, ORs: 1.55, 1.81, 2.43, 2.20, 2.64). Factors indepen-
dent associated with515 LNs are: neo-adjuvant chemo-radiation-therapy (refer-
ence: no neoadjuvant therapy, 0.66[0.47–0.93]), intraoperative complications
(0.55[0.39–0.80]) and open and minimally invasive transhiatal resections (refer-
ence: open transthoracic, 0.24[0.18–0.32]) and 0.38[0.26–0.55]). Postoperative
morbidity and mortality were not associated with 15 LNs.
Conclusion: The outcomes of the quality indicator ‘a minimal number of 15
retrieved LNs’ is increased between 2011 and 2016. The variation between hos-
pitals is decreased. The cN-stage, neoadjuvant therapy, type of procedure, intrao-
perative complications, year of resection and hospital volume seem to be
associated with the outcomes.
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Introduction: Colonic interposition was first described as a method to create a
neo-oesophagus in 1911 by Kelling and Vuillet, and in contemporary practice is
usually only considered if the stomach is not a viable neo-conduit because of the
associated high morbidity and mortality. There is no consensus on the optimum
choice of colonic conduit (right vs. left) or the route of placement (posterior
mediastinal, retrosternal or subcutaneous).
Aims & Methods: The aim of this review was to determine the optimum choice
and route of conduit following colonic interposition after oesophagectomy in
adults. PubMed, MEDLINE and the Cochrane Library (January 1985 to
January 2017) were systematically searched for studies which reported outcomes
of colonic interposition after oesophagectomy in adults. The primary outcome
measure was overall morbidity and secondary outcome measure was operative
mortality.
Results: Twenty-seven studies, involving 1849 patients (median age 60 years, 1177
males, 697 malignant disease) who underwent colonic interposition were ana-
lysed. The overall pooled morbidity rate of left vs. right colonic conduit was
9.6% [95% CI (6.24–12.87), p5 0.00001] vs.16.5% [95% CI (11.07–22.02),
p5 0.00001] respectively. The overall pooled mortality rate of left vs. right colo-
nic conduit was 5.6% [95% CI (3.50–7.60), p5 0.0001] vs. 10.3% [95% CI (7.23–
13.27), p5 0.0001] respectively. Retrosternal route placement was associated
with the lowest overall pooled morbidity of 9.2% [95% CI (6.48–11.99),
p5 0.00001], and lowest overall pooled mortality of 4.8% [95% CI (3.74–
5.89), p5 0.0001].
Conclusion: Left colon is the conduit of choice for colonic interposition after
oesophagectomy in adults and the retrosternal route should be favoured.
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Introduction: The combination of chemotherapy and molecular targeted therapy
has improved the outcome of patients with colorectal liver metastasis (CRLM);
however, treatment outcomes of liver resection after preceding chemotherapy for
CRLM, especially synchronous CRLM (sCRLM), remain unclear. For patients
with technically resectable and oncologically suitable sCRLM, we conduct hepa-
tic resection for the metastases at an interval of 3 months after colorectal resec-
tion, whereas for those with technically unresectable or oncologically unsuitable
sCRLM, we perform preceding chemotherapy. The aim of this study was to
retrospectively evaluate treatment outcomes of our strategy for sCRLM and
explore prognostic factors for determining the indication for liver resection,
particularly in patients receiving chemotherapy for sCRLM.
Aims & Methods: Between April 2006 and March 2016, 157 consecutive patients
underwent primary tumor resection for sCRLM at our department; of them, 35
patients (S group) underwent subsequent staged liver resection, 109 patients
received preceding chemotherapy, and remaining 13 patients received other treat-
ments. Among those who received preceding chemotherapy, 25 patients (CS
group) underwent liver resection after chemotherapy, but 84 patients (C group)
could not undergo liver resection and continued ongoing chemotherapy. In the
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CS group, 16 patients had unresectable disease (due to lack of remnant liver
volume, invasion to hepatic hilar area, or invasion to three hepatic veins) and
9 initially had unsuitable disease (progressive primary disease or suspicion of
other distant metastasis); therefore, upfront chemotherapy was selected.
Results: The frequency of adverse prognostic factors tended to be higher in the
CS group than in the S group, e.g., tumor number (mean SD: 6.0 3.5 vs
2.7 1.7) and number of metastatic lymph nodes (4.2 6.3 vs 2.7 2.3).
Nevertheless, overall survival (OS) in the CS and S groups since primary
tumor resection was equivalent (3-year survival rate: 86.9% vs 93.4%, Log-
rank P¼ 0.34) and much better than that in the C group (3-year survival rate:
40.2%). Although liver-limited relapse-free survival (RFS) since hepatectomy
tended to be worse in the CS group than in the S group (3-year survival rate:
45.0% vs 62.7%, Log-rank P¼ 0.14), RFS after hepatectomy was equivalent in
the CS and S groups (3-year survival rate: 33.3% vs 21.6%, Log-rank P¼ 0.97).
Early tumor shrinkage (ETS) was found to be a stronger poor prognostic factor
for liver resection after chemotherapy than existing prognostic factors in univari-
ate and multivariate analyses, and RFS was much better in patients with ETS
than in those with non-ETS (3-year survival rate: 62.5% vs 7.7%, Log-rank
P¼ 0.05).
Conclusion: OS and RFS in the CS group compared favorably with those in the S
group despite the high frequency of poor prognostic factors; patients with ETS
had a better prognosis after liver resection. Liver resection after chemotherapy
revealed comparatively favorable prognosis in well-selected patients with
sCRLM, and early responsiveness to chemotherapy was useful in determining
the indication for liver resection in patients receiving chemotherapy for sCRLM.
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Introduction: Hepatopancreatoduodenectomy associated with hemihepatectomy
or more extended liver resection (HPD) is occasionally indicated in patients with
advanced gallbladder or bile duct cancers, and is still a highly invasive surgical
procedure. Feasibility of this invasive procedure for biliary cancers has not fully
invastigated.
Aims & Methods: The aim of this study is to review surgical outcome of HPD in
terms of case series of a single surgeon at three Japanese tertiary referral centers.
Consecutive one hundred one hepatobiliary resections with caudate lobectomy
were carried out by a single surgeon (TS) at National Cancer Center, Tokyo,
Aichi Cancer Center, Nagoya, and Aichi Medical University, Nagakute since
2002 and 2016. Of these 14 included 13 patients with bile duct cancer and one
with gallbladder cancer underwent HPD were analyzed. Essentially, liver trans-
ection was performed in terms of Pean clamp crushing method under intermittent
inflow occlusion and pancreatojujunostomy was carried out in terms of duct to
mucosa anastomosis.
Results: There were 9 men and 5 women. The median age was 66 years old (34–
81). All patients underwent preoperative biliary drainage and 12 patients under-
went preoperative portal vein embolization. As to the extent of liver resection,
left hemihepatectomy was performed in 2, right hemihepatectomy in 11, and
right trisectionectomy in 1 patient, respectively. Combined portal vein resection
and reconstruction was carried out in 6 (42.9%), and hepatic arterial resection
and reconstruction in one patients (7.1%). The median operation time was 822
minutes (518–992), and the median intraoperative blood loss was 1716ml (730–
2930), respectively. Although one patient underwent left trisectionectomy with
segmental portal vein resection and reconstruction of 101 hepatobiliary resec-
tions resulted in the postoperative mortality (mortality rate 1.0%), HPD was
accomplished with zero mortality in this studied period. Histologically, the prox-
imal bile duct margins were confirmed positive for cancer cells in two patients
with bile duct cancer (R1 resection). Four patients with bile duct cancer survived
more than 5 years without evidence of tumor recurrence, on the other hand one
patient with gallbladder cancer died from recurrence 7 months after the surgery.
Conclusion: HPD may become a safe and potentially feasible surgical procedure
for bile duct cancer, the indication of HPD for gallbladder cancer should be
elucidated for further investigations in terms of large case series.
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Introduction: Pancreatoduodenectomy (PD) is one of the operations associated
with high rate of surgical site infection (SSI). The one of the reasons is said that
SSI is associated with the preoperative biliary infection caused by preoperative
examinations or drainage of biliary tract. In our clinical trial [1], SSI after pan-
creatobiliary surgery could be decreased by using the perioperative selective
antibiotics based on preoperative bile culture. The bacteria cultured from SSI
were Enterobacteriaceae such as Enterococcus and Enterobacter species with high
frequency.
Recently, however, most of the patients who had planned to undergo PD
received internal biliary drainage preoperatively. It means preoperative collection
of the bile juice is hard for the patient with internal biliary drainage. In order to
solve this problem, we compared the conventional perioperative prophylactic
antibiotics (Cefmetazole: CMZ) and the broad-spectrum antibiotics covering
the Enterobacteriaceae (Piperacillin/Tazobactam þVancomycin: PIPC/
TAZþVCM), retrospectively. The aim of this study is to assess the impact of
two types of perioperative antibiotics usage in patients undergoing PD.
Aims & Methods: Sixty-nine patients underwent PD at Hokkaido University
Hospital (Japan) between April 2015 and March 2016, when prospective surgical
site infection surveillance was performed. Thirty-eight patients were administered
CMZ as perioperative prophylactic antibiotics from April 2015 to March 2016,
and 31 were PIPC/TAZþVCM from April 2016 to March 2017. CMZ was
injected intravenously every three hours from the start of operation, and once
after the operation. PIPC/TAZ was injected intravenously every three hours from
the start of operation and three times on the next day of the operation, whereas
VCM was injected intravenously in the morning of operation (20mg/kg) and just
after the operation (15mg/kg).
Comparison between CMZ group and PIPC/TAZþVCM group was performed
to variables from clinical features (gender, age, body mass index, performance of
neoadjuvant chemotherapy and preoperative biliary stent), operative outcomes
(operation time and blood loss) and postoperative course (the incidence of SSI,
the duration of postoperative antibiotics and postoperative stay). The side effects
of VCM or PIPC/TAZ, and the occurrence of multidrug resistant bacteria were
investigated, as well.
Results: There were no significant differences in clinical features and operative
outcomes between the two groups. The patients with PIPC/TAZþVCM received
significantly shorter duration of postoperative antibiotics administration than the
patients with CMZ (5.9 8.5 vs. 13.0 18.2 days; p¼ 0.048). Significantly lower
incidence of SSI was revealed in patients with PIPC/TAZþVCM (9/31(29.0%))
than in those with CMZ (20/38(52.6%)) (p¼ 0.048). Especially, significantly
lower incidence of incisional SSI was revealed in patients with PIPC/
TAZþVCM (2/31(6.5%)) than in those with CMZ (14/38(36.8%)) (p¼ 0.004).
The redneck syndrome as one of the side effects of VCM was observed in 5/31
patients (16.1%). No multidrug resistant bacteria were identified.
Conclusion: The broad-spectrum perioperative antibiotics covering
Enterobacteriaceae such as Enterococcus and Enterobacter species could decrease
the incidence of SSI and duration of postoperative antibiotics administration
compared to CMZ. More strict indication to select the patients who should be
administered VCM, because the occurrence of side effects of VCM was relatively
high.
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Introduction: Gallbladder cancer is the fifth most common gastrointestinal malig-
nancy and the most common of all biliary tract cancers. Overall, it is associated
with a poor prognosis. Consensus guidelines suggest that patients with T1a
cancers can be observed with cholecystectomy alone while patients with T1b or
greater lesions should undergo lymphadenectomy in the hepatoduodenal liga-
ment. Extent of surgery is especially important for those patients given efficient
systemic therapy is lacking.
Aims & Methods: The aim of this study was to critically explore whether those
suggestions hold true on a population-based level given that current evidence is
mainly based on small patient series. Especially we assessed the rate of T-stage
specific lymph node positivity and the impact of lymphadenectomy on long-term
outcomes. The National Cancer Data Base of the United States was reviewed
from 2004 to 2012 to identify non-metastatic gallbladder cancer patients with
T1a, T1b, or T2 stage primary tumors. Patients were grouped by whether a
dedicated lymphadenectomy was performed or not while those with missing
information were excluded. Groups were compared for baseline characteristics.
Predictors of dedicated lymphadenectomy were assessed by univariate and multi-
variable adjusted logistic regression with adjustment for important patient- and
tumor characteristics. Overall survival was assessed using Cox proportional
hazard regression analyses before and after full bipartite pairwise propensity
score matching.
Results: Of the 3879 patients included, 287 (7.4%) had T1a, 661 (17.0%) T1b,
and 2931 (75.6%) T2 gallbladder cancer. Most patients were female (n¼ 2751,
70.9%), median age was 72 years (range 21–90). Among patients with T1a, T1b,
and T2 disease, 102 (35.5%), 278 (42.1%), and 1526, (52.1%) underwent a dedi-
cated lymphadenectomy, respectively. Over the study period, the rate of lymph
node excision increased from 43% to 58% (p for trend¼ 0.005). The rates of
positive lymph nodes were 11.8%, 16.2%, and 42.5% for T1a, T1b, and T2-stage,
respectively. 5-year overall survival rate was 31.6% for patients without and
44.6% for patients with a dedicated lymphadenectomy and 58.6%, 43.9%, and
34.5% for T1a, T1b, and T2-stage, respectively. After multivariable adjustment,
the odds of undergoing a lymphadenectomy increased with tumor stage com-
pared to T1a disease (vs. T1b: OR: 1.37; CI: 1.01–1.86, vs. T2: OR: 1.95; CI:
1.48–2.57). Compared to their counterparts, patients who underwent lymphade-
nectomy for gallbladder cancer were more likely to have had an R0 resection
status, underwent chemo- or radiation therapy, were diagnosed in later years,
were younger, had a lower Charlson-Deyo-comorbidity score, were operated in
high volume centers and traveled a longer distance to the treatment facility. In
univariate analysis, no survival benefit of lymphadenectomy was found for T1a
disease (HR 1.04, 95%CI 0.70–1.54) while lymphadenectomy improved overall
survival in T1b (HR 0.72, 95%CI 0.58–0.90) and T2 stage (HR 0.59, 95%CI
0.53–0.65). Given significant bias of undergoing lymphadenectomy, full bipartite,
pairwise propensity-score matching was performed. A trend towards overall sur-
vival improvement was then also found for T1a disease (HR 0.65, 95%CI 0.39–
1.09). Overall survival benefit remained for T1b (HR 0.68, 95%CI 0.51–0.91) and
T2-stage (HR 0.63, 95%CI 0.55–0.71).
Conclusion: Our results support current consensus guidelines that T1b and T2
gallbladder cancer patients should undergo LA. However, based on the high rate
of nodal positivity among patients with T1a disease and the trend towards overall
survival improvement among T1a patients who underwent lymphadenectomy, we
suggest to rethink this dogma and advocate to perform lymphadenectomy also in
surgically fit patients with T1a disease.
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P0945 RECTAL SWAB CULTURE CAN DIRECT ANTIMICROBIAL
PROPHYLAXIS AND PREDICT THE RISK OF INFECTIOUS
COMPLICATIONS AFTER PANCREATICODUODENECTOMY
M. De Pastena1, S. Paiella1, D. Ciprani1, G. Marchegiani1, A.M. Azzini2,
E. Concia2, R. Salvia1, C. Bassi1
1General And Pancreatic Surgery Department, Pancreas Institute, University of
Verona, Verona/Italy
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Introduction: Despite improvements in the perioperative care, the morbidity rate
after Pancreaticoduodenectomy (PD) is still higher than 50%. In particular,
infectious complications (ICs) occur in about one-third of cases. This study
aims to examine the correlation between preoperative rectal swab (RS) and
intraoperative bile cultures, and its impact on postoperative course of patients
submitted to PD.
Aims & Methods: The institutional electronic database was queried for all con-
secutive PD performed from January 2015 to July 2016. Data were retrospec-
tively analyzed. Based on the positivity/negativity of preoperative surveillance
RS for multi-antibiotic resistant Gram-negative and Gram-positive enteric rods,
the population was divided into two groups consequently compared (RSþ vs.
RS-).
Results: Three hundred thirty-eight patients were considered for the analysis.
Overall 50 patients (14.8%) showed a RSþ. Preoperative biliary drain (PBD)
was the only independent risk factor associated to RSþ (p¼ 0.021, OR 2.6). The
groups statistically differed in the overall morbidity, ICs, sepsis, pulmonary
complications, reoperation and mortality (p5 0.05). At multivariate analysis,
ICs and mortality remained independently associated to RSþ (p¼ 0.013 OR
2.9, p¼ 0.009 OR 3.4, respectively). Bile-culture showed a perfect correlation
(species and antibiotic susceptibility) with RS culture in 157 patients (86.7%).
The most common microorganisms found were E. Coli ESBL (6.6%) and
Klebsiella pneumoniae carbapenemase-resistant (2.2%).
Conclusion: Preoperative RS-culture’s positivity strictly correlates to biliary colo-
nization with enteric rods that occurs after PBD. Infectious complications and
mortality after PD are independently associated with a positive RS culture. Our
study suggests that preoperative RS can direct antibiotic prophylaxis in order to
reduce the burden of ICs and deadly events after PD.
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P0946 EFFECT OF TRICLOSAN-COATED SUTURE USE ON THE
INCIDENCE OF SUPERFICIAL INCISIONAL SURGICAL SITE
INFECTIONS AFTER GASTROENTEROLOGIC SURGERY: A
PROPENSITY SCORE MATCHING RETROSPECTIVE STUDY
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Introduction: Surgical site infections (SSIs) after gastroenterological surgery cause
significant morbidity, prolong hospitalisation and increase health care costs.
Thus, SSI prevention is critical. To prevent bacterial colonisation in suture mate-
rial, which disables local mechanisms of wound decontamination, triclosan-
coated sutures were developed. We retrospectively analysed the efficacy of tri-
closan-coated polydioxanone sutures in abdominal fascia and skin closure using
a propensity score matching analysis.We further analysed the surgery types for
which these sutures are best suited.
Aims & Methods: The study protocol followed the principles of the Declaration
of Helsinki and received ethical approval from the Ethics Committee of the
Fukuoka University (approval no. 12-7-06). At our department, we used con-
ventional abdominal closure methods during gastroenterological surgery before
August 2012. Thus, we retrospectively collected surveillance data over a 1.5-year
period for the control group. From September 2012, we began using triclosan-
coated sutures for closure. Hence, we collected data for the study group from
September 2012 to September 2013. In total, we included 1768 patients (control
group, n¼ 640; study group, n¼ 1128) who underwent gastroenterological sur-
gery. Baseline differences and selection bias were adjusted using propensity score
matching.
Results: Before matching, the SSI incidence differed significantly between the
control and study groups for all gastroenterological surgeries [12.4% (140/
1128) vs. 5.5% (35/640); p5 0.001]. The SSI incidence according to the surgery
type was as follows in the control and study groups: 12.7% (26/204) vs. 10.5%
(12/114) (p¼ 0.347) for upper gastrointestinal (GI) surgery, 14.6% (43/294) vs.
5.3% (10/190) (p¼ 0.001) for lower GI surgery, 8.8% (24/274) vs. 4.1% (7/169)
(p¼ 0.045) for hepato-biliary-pancreatic surgery, 18.2% (40/220) vs. 7.8% (5/64)
(p¼ 0.030) for emergency surgery and 5.1% (7/136) vs. 1.0% (1/103) (p¼ 0.074)
for others. Of 1768 cases, 483 pairs were matched using propensity score match-
ing. No parameter used for the propensity score differed between the groups.
After matching, we found a significant difference in the SSI incidence between
the control and study groups for all gastroenterological surgeries [9.7% (47/436)
vs. 5.7% (28/455); p5 0.001]. We found a significant difference in the SSI inci-
dence between the control and study groups for lower GI [17.0% (16/78) vs.
4.3% (4/90); p¼ 0.008] and hepato-biliary-pancreatic [16.4% (11/56) vs. 4.3%
(4/63); p¼ 0.049] surgeries. No significant difference was found between the
groups for upper GI surgery, emergency surgery and others. Multivariable logis-
tic regression analysis showed that triclosan-coated suture use for lower GI
surgery was the independent factor affecting the SSI incidence (p¼ 0.017). The
sutures demonstrated a significant efficacy in lower GI surgery.
Conclusion: Few studies have focussed on the types of surgery best suited for
triclosan-coated sutures. Our findings suggest that abdominal fascia and skin
closure using these sutures reduces the SSI risk, particularly after lower GI
surgery.
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P0947 COMPARISON OF POSTOPERATIVE CONDITIONS
BETWEEN ESOPHAGOGASTROSTOMY WITH THE DOUBLE-FLAP
TECHNIQUE AND THAT WITH A CIRCULAR STAPLER IN
LAPAROSCOPIC PROXIMAL GASTRECTOMY
M. Hayashi, H. Kawakubo, S. Mayanagi, K. Fukuda, R. Nakamura, K. Suda,
N. Wada, Y. Kitagawa
Department Of Surgery, Keio University School of Medicine, Tokyo/Japan
Contact E-mail Address: sas.jtf@gmail.com
Introduction: In recent years, laparoscopic proximal gastrectomy (LPG) has been
actively performed in our institution to reduce invasiveness. However, proximal
gastrectomy is sometimes followed by reflux. Until February 2015, we performed
esophagogastrostomy with a circular stapler (CS) accompanied by fundoplica-
tion in LPG. Since March 2015, to avoid the postoperative complication, we have
been using esophagogastrostomy with the double-flap technique (DFT) in LPG
for gastric cancer.
Aims & Methods: We conducted this study to examine whether DFT can reduce
the incidence of reflux and influence postoperative conditions. From January
2012 to February 2017, 47 LPGs were performed at Keio University Hospital.
First, surgical time, bleeding, incidence of postoperative complication, post-
operative hospital stay, and incidence of anastomotic stenosis were examined
as surgical factors and compared between the DFT and CS groups. Second,
gastroesophageal reflux finding on endoscopy, condition of the remnant stomach
according to residue, gastritis, bile (RGB) classification at postoperative 6
months and 1 year, and proton pump inhibitor (PPI) intake were examined as
postoperative factors. Finally, albumin and hemoglobin levels at postoperative 6
months and 1 year were examined as nutrient factors. Gastroesophageal reflux
was assessed with scores of 0–5 in accordance with the Los Angeles (LA)
classification.
Results: Twenty-three LPGs with DFT and 24 LPGs with CS were performed
during the period. Compared with the CS group, the DFT group had a signifi-
cantly longer surgical time (272.3 35.5 vs 241.1 26.7min, p5 0.01). Other
surgical factors showed no statistically significant differences between the two
groups. As for postoperative factors, although no significant differences in PPI
intake, LA classification, and RGB classification were found, the DFT group
showed a significantly lower score than the CS group (p5 0.01). Postoperative
nutrient factors did not show any significant difference between the groups.
Conclusion: Although LPG with DFT required a longer surgical time than LPG
with CS, DFT is thought to be a safe reconstruction method in LPG. In addition
to its safety, DFT can reduce postoperative reflux in patients who undergo LPG.
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P0948 NOVEL ENDOSCOPIC REPAIR TECHNIQUE FOR
GASTROINTESTINAL LEAKS AND PERFORATIONS USING
NEGATIVE PRESSURE THERAPY WITH OPEN-PORE
POLYURETHANE-FOAM AND FILM DRAINAGE
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Introduction: Gastrointestinal (GI) leaks and perforations are difficult to manage
and often mandate laparotomy and extensive surgical interventions for their
repair. Endoscopic Negative Pressure Therapy (ENPT) has been developed to
treat GI defects such as leaks, fistulae and perforations. However, ENPT has
only been utilized in the management of rectal and esophageal leakages. By
modifying the delivery catheter we were able to adapt ENPT to treat duodenal
defects, that otherwise would have required surgery or more invasive methods to
be repaired.
Aims & Methods: Herein, we report ENPT using open-pore Polyurethane-foam
and Film Drainage in a series of 10 patients with duodenal leakages.This is an
open-label, retrospective, single-center study. Open-pore polyurethane-foam
drainage (OPD) devices were constructed out of a piece (1.5 cm 1.5 cm 3 cm)
of open-pore polyurethane-foam which was fixed surrounding the tip of a naso-
gastric drainage tube. Small bore open-pore film drainage (OFD) device was
constructed with a strip of a very thin fragment open-pore double layered film
(2 210 cm) which was wrapped surround the tip of a nasogastric drainage tube.
The open- film consists out of two permeable membranes with a small interspace.
Fluids are drained along the interspace and through the membranes. Diameter of
small-bore OFD is 46mm, depending on the diameter of the drainage tube.
OPD is inserted transorally. The foam is grasped with endoscopic forceps and
guided to the duodenal lumen. After correct placement into the duodenal lumen
for intraluminal ENPT, the tube is transferred out nasally, to become a naso-
duodenal tube. Due to its smaller outer diameter OFD insertion is similar to
placing a naso-gastric or naso-intestinal feeding tube (i.e. through the nose).
After nasal insertion into the esophagus OFD is grasped with a forceps and
advanced into the stomach, and guided into the duodenal lumen for intraluminal
ENPT. In case of a duodeno- cutanous fistula the pull-through technique has
been used for duodenal placement. In one case rendezvous technique was used in
combination with operative procedure. OPD and OFD are connected to an
electronic vacuum device and negative pressure is applied. We use standard
negative pressure of 125mmHg, continuous suction, and high intensity, which
results in collapse of the duodenal lumen around the open-pore foam or film with
subsequent closure of the defect zone. Furthermore, duodenal secretions are
actively removed through the tubes.
Results: We treated 10 patients with ENPT because of a duodenal leakage.
Reason of duodenal defects were: rupture of operative suture (n¼ 8), iatrogenic
perforation during ERCP (n¼ 1), perforation due to an operative drain (n¼ 1).
Nine patients were treated with intraluminal and one patient with intracavitary
variant of ENPT. In 7 patients we used the OPD device, in one patient OFD, and
in two patients OPD and OFD. All leakages (100%) were successfully closed
after a treatment period of 11 days in median (range 7–19 days).
Conclusion: ENPT using small diameter tube with open-pore film was effective to
treat duodenal leakages. Advantage of OFD is the small diameter which allows
easy endoscopic placement through small openings and nasally insertion. OPD
and OFD devices can be positioned accurately at the site of duodenal leaks and
perforations using common endoscopic techniques and thus represent a potential
addition to the armamentarium to treat these difficult lesions.
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P0949 INFLUENCE OF THE HYBRID METHOD OF
DETOXICATION ON BLOOD CLARIFICATION EFFECTIVENESS AT
PATIENTS WITH THE MULTIORGAN FAILURE
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Introduction: The main releaser for development of multiorgan failure syndrome
(MOFS) in most cases are aggressive mediators of inflammation which are very
often occur after surgical complications and more than in 70% of cases leads to
lethal outcomes. Increase of an endotoxemia leads to development of the
expressed pathological processes and to a fast decompensation of bodies of
natural detoxication with the subsequent development of a multiorgan failure.
Increase in detoxication ability of sorbents can happen due to change of chemical
composition, or due to collimating of padding properties to them by their mod-
ification by various agents by means of an immobilization on their surface of
organic and inorganic compounds. In this plan especially important role is got by
the researches directed to development of sorbents with oxidizing activity.
Aims & Methods: Aim of study is to estimate effectiveness of the modified hae-
mosorbent application for patients about the MOFS. The experimental part of
work was conducted on 14 not purebred dogs with the acute liver failure mod-
elled by bandaging of distal department of the CBD. After development of
pathological process animals were divided into 2 groups. To the first group of
animals the procedure of a haemosorbtion was carried out by a reference tech-
nique with use of a haemosorbent of SKN-2K. To the second group of animals
the haemosorbtion was carried out by the developed technique with the same
sorbent, but the solution of a neutral anolyte subjected to oxidizing modification.
For this purpose, in the flowing mode carried out a half-hour incubation of a
sorbent from 2 l of solution of a neutral anolyte.
Results: Results showed that at animals of the 2nd group in comparison with
group of comparison improvement of a condition of an organism was expressed
in much larger degree. After performing detoxication therapy by the developed
technique a normalization of all studied parameters is registered. The same ten-
dency is revealed also concerning nontoxical components. It is necessary to pay
special attention to dynamics of a ratio of the common protein and an index
average molecules/the common protein, pointing to synthesis process activation.
The carried-out all-clinical blood test revealed the considerable improvement of
indexes of white blood. In group of comparison it was not succeeded to achieve
the complete normalization of the studied indexes. On the basis of what the
conclusion was drawn on high effectiveness of the developed technique, and
expediency of its introduction in clinical practice. Under our observation there
were 45 patients needing carrying out getter detoxicating in the postoperative
period. The control group (25) was created by a random sample of case histories
from set of the patients with a similar syndrome who were earlier on treatment in
our clinic and receiving a course of haemo perfused therapy by a reference
technique. The analysis of results of treatment of patients of a basic group
showed that the positive dynamics of clinical indexes expressed in decrease of
manifestations of an intoxication syndrome, improvement of health and labora-
tory indexes is noted in earlier terms, and degree of expressiveness of positive
changes at them was much higher. Dynamics of decrease in endogenic intoxica-
tion is reflected by data of laboratory researches.
Conclusion: Thus, the received results showed that it is possible to increase qual-
ity of detoxicating by a pretreatment of a haemo sorbent solution of a neutral
anolyte. As a result of it the sorbent gains padding, oxidizing properties. At such
modification there is an inclusion of oxygen-containing and acid groups in struc-
ture of a haemo sorbent. Besides, on a surface of a sorbent protogenic groups of
carboxylic and phenolic types thanks to which the oxidized coals gain the
expressed cation-exchange ability are formed. Therefore, besides actually
getter, such sorbent follow-up gains oxidizing properties. Modification of a sor-
bent solution of a neutral anolyte incidentally allows to solve also other problem
connected about need of use of anticoagulants for prevention of a thrombogen-
esis in a column. Use it in this quality provides decrease in risk of postoperative
violations from system of a hemostasis.
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P0950 CARDIAC SEPTAL DEFFECT OCCLUDER DEVICE FOR
ENDOSCOPIC TREATMENT OF GASTRO-CUTANEOUS AND
GASTRO-PULMONARY LEAKS AFTER BARIATRIC SURGERY
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Introduction: Gastric leaks are severe complications of Bariatric Surgery (BS).
Surgical re-intervention may be indicated but is associated with high morbidity
and mortality. The use of self-expanding esophageal metallic stents (SEMS) has
become an effective alternative. Over the scope clips (OTSC) have also been used.
Nevertheless some patients develop a refractory fistulae after stent removal or
other failed endoscopic treatments. Cardiac Septal Defect Closure Devices
(CSDCD), used in interventional cardiology have been described to treat post-
surgical digestive fistulae in non-bariatric cases.
Aims & Methods: We aim to present the experience using CSDCD for gastric
leaks secondary to BS. In this retrospective study, patients with leaks secondary
to gastric bypass (GBP) or sleeve gastrectomy (SG) from 4 centers were included.
Data collected from november 2012 to january 2016 included sex, age, type of
surgery, previous treatment, tract path, size of the leak opening and defect clo-
sure. Leaks were grouped according to the International Sleeve Gastrectomy
Expert Panel Consensus in acute (post-operative days 1–7), early (1–6 weeks),
late (after 6 weeks) and chronic (412 weeks). Biliary catheters were adapted to
introduce the CSDCD through the gastroscopes working channels. Clinical suc-
cess was defined as complete and permanent resolution of abdominal or thoracic
drainage with imaging documentation of closure (CT with contrast or upper GI
contrast study) after 2 months.
Results: 42 patients with leaks were included (31 SG, 11 GBP). Three acute leaks,
5 early, 22 late and 12 chronic. Prior failed therapies included: SEMS and enteral
tube feeding (ETF), SEMS alone, SEMS and gastrostomy of excluded stomach,
OTSC, ETF alone, jejunostomy and none (3 acute leaks had CSDCD as the
primary treatment). Tract path was grouped as gastric-cutaneous (37), gastric-
pleural (3) and gastric-bronchial (2). Median follow-up was 34, 8 weeks. All 3
patients with acute leak failed to close the defect. The CSDCD were removed
within 7 days and SEMS were placed instead leading to defect closure. The 5
patients with early leaks had initial good response but within 30 days drainage
recurred. The CSDCD were removed and replaced for a larger diameter device
leading to permanent defect closure. Clinical success was achieved on 38 patients
(90, 5%). In one patient with late leak the tract path was connected to an
undrained cavity. Evolution was unsatisfactory and total gastrectomy
accomplished.
Conclusion: CSDCD are effective to treat post bariatric surgery late and chronic
leaks despite of the failed previous endoscopic treatment. Although early leaks
finally healed it seems advisable to maintain conservative treatment and wait for
the leak to become late or chronic before CSDCD placement. Acute leaks must
be managed with a combination of SEMS, ETF, OTSC as first step.
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SINGLE-PORT (SILS) CHOLECYSTECTOMY AND LAPAROSCOPIC
FOUR-PORT CHOLECYSTECTOMY
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Introduction: Laparoscopic cholecystectomy is the gold-standard for the treat-
ment of gallbladder stone disease. Single-incision laparoscopic (SILS) cholecys-
tectomy was introduced with the aim of reducing the invasiveness of classic
laparoscopic surgery. Despite satisfactory cosmetic results of SILS cholecystect-
omy and its repute of a painless procedure, there are few published studies
comparing early and long-term postoperative period of laparoscopic SILS cho-
lecystectomy versus laparoscopic four-port cholecystectomy.
Aims & Methods: The aim of this study is the comparative evaluation of SILS
cholecystectomy and laparoscopic four-port cholecystectomy. Early and long-
term postoperative period has been analyzed in 240 patients who underwent
laparoscopic cholecystectomy including 120 cases of single-port technique and
120 cases of four-port technique. Both groups were compared in surgical time,
pain syndrome severity (visual analog scale), need for analgesics, postoperative
complications, hospital-stay, daily activity recovery and return to physical work,
patients’ satisfaction of surgical results and their aesthetic effect.
Results: It was revealed that SILS cholecystectomy is associated with lower
severity of postoperative pain, quick recovery of daily activity and return to
physical work, high satisfaction of surgical results and their aesthetic effect com-
pared with four-port cholecystectomy. Disadvantages of SILS cholecystectomy
include longer duration of surgery, high incidence of postoperative umbilical
hernia. However, hernia was predominantly observed during the period of sur-
gical technique development.
Conclusion: Further studies to standardize, evaluate the safety and benefits of
SILS cholecystectomy are necessary.
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P0952 LAPAROSCOPIC SURGERY’S 100 MOST INFLUENTIAL
MANUSCRIPTS: A BIBLIOMETRIC ANALYSIS
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Introduction: Bibliometric analysis highlights key topics and publications, which
have shaped the development of laparoscopic surgery (LS). Here the 100 most
cited manuscripts in the field of LS are analyzed.
Aims & Methods: The Thomson Reuters Web of Science database was used to
identify all English language full manuscripts for the study with the search term
’laparoscop*’and ‘surg*’. The 100 most cited papers were further analyzed by
topic, journal, author, year and institution.
Results: 71,524 eligible papers were returned and the median (range) citation
number was 585.76 (range 1635 to 368). The two most cited papers received
1635 citations each. The first (Nelson1) compared laparoscopic and open colect-
omy for malignancy, and the second (Clavien2) described the classification of
post-operative morbidity. Annals of Surgery published the highest number of
papers (n¼ 22) and received most citations (n¼ 12,356). The country with the
highest number of publications was the USA (n¼ 55), and the year with the
greatest number of publications was 2004 (n¼ 13). The most ubiquitous topic
was the treatment of cancer (n¼ 35), followed by surgical technique (n¼ 24), and
comparison of laparoscopic with open surgery (n¼ 22).
Conclusion: The most cited manuscripts highlighted laparoscopic surgical tech-
nique and compared laparoscopic with open surgery, and this review provides the
most influential references in this arena, serving as a guide as to a citable paper.
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Introduction: Laparoscopic technique is the first choice for multiple surgical
procedures today. Laparoscopic surgery differs from traditional open surgery
in several aspects, for example two-dimensional view of a three-dimensional
interior, higher demands on eye-hand coordination and lack of tactile feedback.
Laparoscopic surgical skills can be substantially improved by simulator training.
Learning via simulators are under constant development and it is important to
understand the value of baseline characteristics and abilities to further optimize
simulators and training curricula within surgical education. In this study, focus,
will be on the impact of PC-gaming experience and visuospatial skill.
Aims & Methods: The aim of the study is to further analyse different factors to
laparoscopic simulator training. 48 medical students completed three tasks in a
laparoscopic virtual reality simulator, a validated Minimally Invasive Surgical
Trainer (MIST, Mentice, Gothenburg, Sweden). Prior to the task, they per-
formed a visuospatial test and answered questions regarding baseline character-
istics (e.g. PC-gaming experience, age, gender, previous simulator experience).
The data where analysed regarding different parts of the simulation (time, econ-
omy of movement, error and total score).
Results: The group with high PC-gaming experience performed significantly
better in total time (Mean differerence¼ 85.49, p¼ 0.021) and economy of move-
ment (M¼ 25.30, p¼ 0.018) in task 1 and 2. There were no differences between
either of the groups in task number 3. A high visuospatial score correlated with a
better result in time to completion (M¼ 68.89, p¼ 0.026) and total score
(M¼ 80.16, p¼ 0.036). The group with both low PC-gaming experience and
low visuospatial score performed worst in the simulator exercises.
Conclusion: Both PC-gaming experience and visuospatial abilities have an impact
on laparoscopic simulator performance. No remaining significant differences by
the third simulation exercise indicates a learning effect that could be more impor-
tant than baseline skills. It could be valuable to identify individuals with both low
PC-gaming experience and low visuospatial score to offer them additional simu-
lator training.
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Introduction: Tuberculosis is a major cause of morbidity and mortality world-
wide. Its incidence is continually increasing. Peritoneal localization is a particular
entity, even less well known, because of its atypical and confusing symptomatol-
ogy, which in most cases imposes a malignant condition.
Aims & Methods: We collected all patients hospitalized for peritoneal tubercu-
losis between 2005 and 2015. The aim of this retrospective study was to study the
epidemiological, clinical, paraclinical, diagnostic, therapeutic and evolutionary
specificities of peritoneal tuberculosis in its various presentations.
Results: The total number of patients was 65. It was 15 men (23.1%) and 50
women (76.9%).The sex ratio was 0.3. The mean age at diagnosis was 40 years
(15–79 years). No personal history of tuberculosis has been found in our series. A
personal history of tuberculosis was found in 3 patients (4.6%). The general signs
of tuberculin impregnation were frequently found (91%). The digestive func-
tional signs that brought the patients to consult are: abdominal pain (87.7%),
abdominal distension (87.5%), diarrhea (16.9%) and sub occlusive syndromes
(4.6%). An abdominal mass was observed in only 4 patients (6.1%).
Hepatomegaly and splenomegaly were noted in 2 cases for each. The intradermal
reaction was positive in only 24% of patients. The research of BK in the ascites
fluid was systematically performed in all patients but returned negative in all
cases. The quantiferon-TB Gold was performed in 3 patients only and returned
positive. The mean level of CA 125 was 250.3 IU/ml. Confirmation of diagnosis
was obtained on the histological analysis of peritoneal biopsies or adnectomy
pieces. The main operative findings (in patients with coelioscopy or exploratory
laparotomy) were: Whitish granulations (98%), adhesions (43.1%) and aggluti-
nated loops (1.5%). The presence of tuberculous granuloma was observed in 52
patients (81%). The course of treatment was as follows: cure in 50 patients
(80.6%), recurrence in 6 patients (9.6%), relapse in 2 patients and 3 patients
were lost to follow-up. The mortality in our series was 0%.
Conclusion: Peritoneal tuberculosis raises diagnostic problems in the first place,
because of its polymorphic and non-evocative clinical expression; Hence the
value of carrying out radiological, endoscopic and histo-bacteriological investi-
gations to confirm the diagnosis before the evolution towards serious or even
fatal forms.
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Introduction: Tuberculosis is still a problem of public health in Tunisia, which is a
country of endemicity. The epidemiological situation of the disease is marked by
the rise of the extrapulmonaires forms especially abdominal tuberculosis.
Aims &Methods: The aim of this study was to analyze the epidemiologic, clinical,
diagnostic, therapeutic and evolutive features of abdominal tuberculosis in a
series of 150 patients. This was a retrospective and descriptive monocentric
study of 150 cases of abdominal tuberculosis conducted from 2004 to 2014 in
a tunisian center. Diagnosis of tuberculosis was based on histological evidence or
otherwise on a beam of arguments.
Results: There were 150 patients enrolled. The mean age was 37.2 (17–72 years).
Ninety seven (64.6%) were females. Symptoms were ascites 107 (71.3%), abdom-
inal pain 28 (18.6%), weight loss and reduced appetite 80 (53.3%). Un tableau
pseudochirurgical a révélé la maladie dans 9.3% des cas (14 cas). Sub-acute and
acute intestinal obstruction was seen in 10 (6.6%) and 4 (2.6%) respectively. 105
patients (70%) had peritoneal tuberculosis, 34 (22.6%) had intestinal tuberculo-
sis. The association of the two forms was found in one case. 10 patients (6.6%)
had a Lymph node involvement. Basis of diagnosis of abdominal tuberculosis
were histo-pathology (tissue obtained during surgery, colonoscopy, CT or ultra-
sound guided biopsy, laparoscopy and upper gastro intestinal endoscopy) in 122
(81.3%) patients. Response to medical treatment was found in 141 (94%)
patients.
Conclusion: Abdominal tuberculosis is one of the most common site of extra-
pulmonary tuberculosis. No single test is adequate for diagnosis of abdominal
tuberculosis in all patients. Abdominal TB remains an ongoing diagnostic
dilemma requiring a high index of clinical suspicion.
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Introduction: Inability to maintain a stable and beneficial microbiota is associated
with chronic gut inflammation, which classically manifests as colitis but may
more commonly exist as low-grade inflammation that promotes metabolic syn-
drome. Alterations in microbiota and associated inflammation can originate
from dysfunction in host proteins that manage microbiota, such as the flagellin
receptor TLR5, and/or be promoted by exogenous factors that disturb host-
microbiota interactions, such as the detergent-like dietary emulsifiers carboxy-
methylcellulose (CMC) and polysorbate 80 [1, 2, 3]. That the complete absence of
a microbiota (i.e. germ-free conditions) eliminates all evidence of inflammation in
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TLR5-deficient and emulsifier-treated mice demonstrates that these models of
gut inflammation are microbiota dependent. We hypothesize that such micro-
biota dependency of inflammation reflects an inability to manage pathobiont
bacteria, such as Adherent-Invasive E. coli (AIEC).
Aims & Methods: Our goal was to examine extent to which microbiota misman-
agement and associated inflammation in TLR5-deficient and emulsifier-treated
mice would manifest in a limited pathobiont-free microbiota. WT and TLR5-
deficient mice were maintained in gnotobiotic isolators containing altered
Schaedler flora (ASF), a community of eight bacterial species. Mice were treated
with either CMC or P80, or inoculated with AIEC reference strain LF82 [4].
Feces were assayed for bacterial loads, microbiota composition, and inflamma-
tory marker lipocalin-2. Fecal LPS and flagellin bioactivity were measured via a
cell-based reporter assay, and morphologic and metabolic parameters were
determined.
Results: Neither CMC nor P80 induced evidence of intestinal inflammation nor
metabolic syndrome in WT ASF animals. Analogously, relative to similarly
maintained WT mice, loss of TLR5 did not result in low-grade intestinal inflam-
mation nor metabolic syndrome under ASF conditions. Concomitantly, the ASF
microbial community was not disturbed by CMC nor P80 and, moreover, was
similar between WT and T5KO animals. Inoculation with AIEC strain LF82
resulted in profound alteration of the ASF community in T5KO mice compared
to WT control animals. AIEC LF82 inoculation in ASF T5KO mice correlated
with microbiota exhibiting elevated levels of bioactive LPS and flagellin, and was
associated with modest level of low-grade inflammation and increased adiposity.
Conclusion: In a limited-complexity pathobiont-free microbiota, loss of the fla-
gellin receptor TLR5 or emulsifier consumption does not impact microbiota
composition nor its ability to promote inflammation. Addition of AIEC to this
ecosystem perturbs microbiota composition, increases levels of lipopolysacchar-
ide and flagellin, but only modestly promotes gut inflammation and adiposity,
suggesting that the phenotypes previously observed require disruption of com-
plex microbiota.
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Introduction: Lamina propria represents a thin layer of connective tissue rich in
lymphoid cells and macrophages, underlying the epithelium of mucous mem-
branes. Lamina propria mononuclear cells (LPMCs) are immune system’s first
line of defense in the intestine characterized by the ability of differentiating
invading pathogens from beneficial intestinal flora and swiftly removing them.
Disrupted regulation of LPMCs is implicated in pathology of a group of disor-
ders causing chronic intestinal inflammation, termed Inflammatory bowel disease
(IBD). Two major types of IBD are ulcerative colitis, limited to the colon and
Chron’s disease affecting any segment of the gastrointestinal tract. Chron’s dis-
ease and ulcerative colitis were shown to be mediated by Th1-polarized helper
(CD4þ) T-cells and Th2-polarized CD4þ and NKT cells, respectively, while
Th17-polarized cells are involved in pathogenesis of both diseases1. Therefore,
research into biology and regulation of LPMCs is of essential importance for
development of treatments for IBD symptoms.
Aims & Methods: The aim of this study was development of a robust method for
isolation and characterization of LPMCs from human colonic mucosa, compa-
tible with further ex vivo cell culturing and research. Mucosal tissue samples
contained the tissue not affected by tumor, removed during tumor surgery of
patients that consented to donation of tumor and the surrounding resected tissue.
The tissue may be considered as healthy in terms of IBD. We have employed an
isolation method consisting of disruption of epithelial cells by incubation of
mucosa in a DTT and EDTA containing solution, followed by enzymatic and
mechanical digestion of tissue and purification of mononuclear cells by density
gradient centrifugation. Isolated cells were characterized by flow cytometry
(FACS) detection of cell-type specific surface antigens and cytological analysis.
To examine the plasticity of isolated cells in terms of polarization towards IBD-
associated phenotypes, the cells were seeded at conditions mediating Th1, Th2
and Th17 differentiation of CD4þ T-cells and analyzed for activation of differ-
entiation-specific gene expression and cytokine production by qPCR and ELISA
assays. Aliquots of cells were cryopreserved and further analyzed for the effect of
cryopreservation on distribution of surface antigens and CD4þ T-cell responses.
Results: Approximately 95% cell viability and 90% leukocyte (CD45þ) cell
purity was determined by FACS analysis of isolated LPMCs. According to cyto-
logical analysis, CD45-negative cells may represent CD45-negative population of
plasma cells; no contamination with epithelial cells was detected. Within CD45þ
cell population, 26–47% T-lymphocytes, 17–24% B-lymphocytes, 8–17% macro-
phages and 21–46% monocytes were detected by FACS and cytological analyses
(N¼ 3). Cryopreservation did not significantly affect cell viability and surface-
antigen distribution. Isolated cells were successfully polarized towards Th1, Th2
and Th17 CD4þ T-cell phenotypes, as confirmed by IFNY gene expression and
cytokine production for Th1, IL13 gene expression and IL5 cytokine production
for Th2 and IL17 cytokine production for Th17 differentiated cells.
Differentiation was confirmed also in cryopreserved cells, with lower level of
phenotype-specific cytokine production.
Conclusion: Method for LPMC isolation from human colonic mucosa tissue
samples was successfully established with approximately 95% viability of isolated
cells, 90% purity of CD45þ cells and no detectable epithelial cell contamination.
Within CD45þ cells, 26–47% of T-lymphocytes, 17–24% B-lymphocytes, 8–17%
macrophages and 21–46% of monocytes were detected. Isolated cells were suc-
cessfully polarized towards IBD-associated Th1, Th2 and Th17 CD4þ T-cell
phenotypes, as confirmed by activation of phenotype-specific gene expression
and cytokine production. Cryopreservation of isolated LPMCs did not signifi-
cantly affect cell viability, distribution of cell-type specific surface antigens or
polarization towards Th1, Th2 and Th17 CD4þ T-cell phenotypes.
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Introduction: The Inflammatory Bowel Disease-Disability Index (IBD-DI) has
recently been validated to measure disability in IBD.
Aims & Methods: We aimed to assess disability in IBD outpatients using IBD-DI
and to determine the sociodemographic, clinical and psychological factors that
are associated with greater disability. Between August and October of 2016,
patients with an established diagnosis of Crohn’s Disease (CD) or Ulcerative
Colitis (UC) for at least 3 months and followed up at our outpatient clinic
were invited to participate. Socio-demographic and clinical data were collected
from electronic health record and interview. Optimism and disability were eval-
uated by applying, personally or by phone, the validated Portuguese versions of
the Revised Life Orientation Test (LOT-R) and IBD-DI, respectively. The asso-
ciation between sociodemographic, clinical and psychological variables (opti-
mism) and IBD-DI (scale 0–100, proportional to the reported disability) was
determined by univariate and multivariate analysis.
Results: A total of 143 patients (70 DC and 73 UC; 50.3% females) with a mean
age of 38 13 years were included. Most (85.3%) was in clinical remission. The
median IBD-DI-PT score was 17.9 10.7, with no significant difference between
DC and CU (p¼ 0.944). In univariate analysis, female gender, high level educa-
tion, number of days off from work, articular manifestations, number of comor-
bidities, use of psychotropic drugs and pessimism (low LOT-R score) were
significantly associated with higher disability (IBD-DI-PT score). In multivariate
analysis, only female gender (ß¼ 0.150), number of comorbidities (ß¼ 0.186) and
pessimism (ß¼ 0.370) were significantly associated with higher disability. Clinical
activity was associated with higher disability only for CD patients (ß¼ 0.321).
Conclusion: IBD outpatients reported low levels disability associated with their
disease, which can be explained by the high percentage of patients in clinical
remission. Comorbidities and psychological factors (optimism) emerged as the
main predictive factors of greater disability, reinforcing the importance of multi-
disciplinary approach to these patients. Clinical activity seems more important to
CD than UC patients in terms of disability.
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Introduction: Imbalance of immune bowel environment is associated with devel-
opment of many diseases, such as Crohn’s disease (CD). Although the pathogen-
esis of CD remains unclear, a key feature of CD is dysregulation of immune
system (Zhang and Li, 2014). Human immune cells are the front line of inflam-
matory responses and include, in addition to other cells, CD4þ and CD8þ T
cells, which comprises adaptive phase and require proper inflammatory cues for
their effector function. After activation, CD4þ and CD8þ T cells express several
markers that give them powerful functional abilities (Abbas et al., 1996). CD38
and HLA-DR besides being classically markers of cellular activation, are also
known as markers of diseases progression (Lovelace et al., 2017). Some studies
shows that CD4þ T cells play a key role in the immune inflammatory response
leading to CD but this cells are poorly characterized in the blood of the patients.
Aims & Methods: This study aimed to characterized CD4þ and CD8þ T cells in
the blood of patients with CD.The study was performed in individuals with CD
(n¼ 46) and healthy controls (n¼ 38). Blood of healthy donors and patients with
CD was collected in clinical laboratory from Hospital Albert Einstein. CD4þ
and CD8þ T cells was quantified by multiparametric flow cytometry. Dosage of
calprotectin and ASCA was performed by commercial Elisa kit. The groups were
compared for numerical measures using Student’s t-tests, ANOVA, Mann-
Whitney or Kruskal-Wallis, depending on the suitability of the data and the
number of groups to be compared. The computational package used for the
analyzes was R 3.0.3 and GraphPad Prisma 6.
Results: The highest prevalence in both group was female, aged between 19 and
66 years with a median of 37.5 years. Among clinical exams, 61% of cases present
a value greater than 200 in the dosage of Calprotectin, whereas in the control
group the rate was only 18.4% (p5 0.001). ASCA IgG (p¼ 0.001) and IgA
(p5 0.001) measures were also higher in group of cases when compared to con-
trol group. The population of CD3þ cells in peripheral blood of healthy controls
and patients with CD was evaluated both in biological and corticoid treatment. A
significant increase in this population was observed in patients receiving corti-
costeroids (p¼ 0.02) compared to healthy controls. In the population of CD4þ a
significant increase was observed in patients undergoing treatment with corticos-
teroids in relation to patients undergoing biological treatment (p¼ 0.0027). In
CD8þ population, no statistical difference was observed between the groups.
The markers CD38, CD62L and HLADR were also evaluated. In relation to
CD38 (p¼ 0.0022) and CD62L (p¼ 0.015) in subpopulation of CD4þ T cells, a
significant increase in the expressions was observed in the group of patients
receiving corticosteroids in relation to the group receiving biological therapy.
Regarding HLADR, statistical difference (p¼ 0.01) was observed between the
group undergoing biological treatment and the group of healthy controls. In the
subpopulation of CD8þT cells, a significant increase (p¼ 0.02) was observed in
the CD38 marker when compared patients on corticoid treatment with patients
undergoing biological treatment. Regarding the CD62L marker, only a statistical
difference (p¼ 0.04) was observed when compared patients on corticosteroid
treatment with healthy controls. Finally, a statistical difference (p¼ 0.02) was
also observed in relation to the HLADR marker when comparing the group of
patients receiving corticoid with the group of patients in use of biological
therapy.
Conclusion: We conclude that the use of biological therapy suppresses activated
state of CD4þ and CD8þT cells by regulation of CD38, CD62L and HLADR
in relation to the use of corticosteroids.
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Introduction: Advancing of sequencing technologies in the first decade of the XXI
century gives the opportunity to realization of large scale projects such as the
1000 human genomes project. This project provides enormous amount of the
data forH.sapiens population genetics studies and different GWAS studies aimed
to investigate connection of the human genetics variations with different diseases.
It is especially interested to study the connection between the human genetics, the
microbiome metagenomics of mucosa and different pathological conditions.
Previously revealed, the size of the summary gut microbiome metagenome is
on order more than the size of a human genome. The most of works devoted
to the study of the connection of metagenome changes with different pathological
conditions based on the investigation of fecal samples. On our opinion, in the
case of ulcerative colitis it is more effective to study the mucosal microbiome of
the affected regions.
Aims & Methods: The aim of our work was to study the composition of mucosal
microbiomes in the colon mucosa biopsies from patients with ulcerative colitis by
using the target high throughput sequencing of bacterial 16S rRNA genes.
Biopsies from four caucasoid race patients with left-sided ulcerative colitis in
the abating relapse phase (Meyo endoscopical index - 3, Rachmelevich clinical
index - 4) and two patients from control group with irritable bowel syndrome
were collected. The DNA was extracted from mucosal biopsies and 16S rRNA
genes from it’s were target sequenced by using Illumina Miseq sequencer.
Sequencing reads were quality checked by the FastQC software and trimmed
by using the trimmomatic software. To characterize the composition of the
microbiota, trimmed reads were analyzed by the QIIME software. The obtained
results were compared with the earlier published data: SRA Project - ERP001780
(96 samples from patients of control group, 44 samples from patients with ulcera-
tive colitis)[1] and SRA Project - SRP056002 (703 samples from patients with
ulcerative colitis).
Results: More than 124 bacterial genuses were founded in biopsies of four
patients with ulcerative colitis. The analyzed samples of patients with ulcerative
colitis were split in two groups by using the PCoA analysis. The first group was
characterized by decreasing the concentration of the Firmicutes type bacteria (p-
value5 0.005) and increasing the concentration of Bacteroidetes type bacterias
(p-value 50.05). For the second group, It was founded decreasing of the con-
centration of the Actinobacteria type bacterias (p-value 50.05), 70-fold excess of
Bacteroides vulgatus species bacterias concentration was revealed for one sample
of the first group (normalized number of reads in control samples was less than
0.003 and reached 0.21 in samples of patients with ulcerative colitis).
Additionally, the concentration of Escherichia coli species bacterias was increased
in the 40 times for that sample (normalized number of reads in control samples
was less than 0.0008 and reached 0.03 in samples of patients with ulcerative
colitis). Although, the predominance of Proteobacteria genus bacteria was not
founded. The concentration of Faecalibacterium prausnitzii species bacteria was
decreased by three orders of the magnitude for samples from the first group
(normalized number of reads in control samples reached 0, 2 and was less than
0, 06 in samples of patients with ulcerative colitis).
Conclusion: The concentration increase of the conditional-pathogenic mucosal
microflora (a mostly Bacteroidetes type bacteria) was discovered, which playing
the important role in the development of ulcerative colitis and lead to a mucosa
damage. Also, the deficiency of Faecalibacterium prausnitzii species bacteria was
discovered, which decrease resistance of mucosa to the conditional-pathogenic
microflora.
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Introduction: The role of incretin hormone, GLP-1, in inflammatory bowel dis-
eases (IBD) development and exacerbations is still poorly understood. GLP-1
decreases blood glucose level and is co-secreted by intestinal L cells with GLP-2,
which may be responsible for intestinal growth and enhancement of intestinal
function. The prevalence of type 2 diabetes among IBD patients is low, even
though IBD sufferers may be at a greater risk of development of T2D due to
overproduction of pro-inflammatory cytokines and excessive administration of
diabetogenic drugs. We hypothesize that the possible mechanism underlying this
phenomenon is related to changes in the levels of incretin hormones.
Aims & Methods: The primary aim of this study was to investigate, in the mouse
model, whether coexisting colitis postpones development of experimental dia-
betes. The secondary goal was to investigate the potential involvement of incretin
hormones as an underlying factor. Experimental diabetes was induced by admin-
istration of streptozotocin for 5 consecutive days (50mg/kg, i.p.). Mice with
blood glucose levels above 200mg/dL were considered as diabetic. To develop
a chronic and relapsing colonic inflammation, mouse model of colitis induced by
intracolonic administration of TNBS (first dose: 150mg/kg at day 1, booster
dose: 75mg/kg at days 12, 23, 34, 45, 56) was used. On day 60 mice were
sacrificed and macroscopic score, ulcer score, colon length and bowel thickness
were recorded. In all experiments the levels of inflammation markers: myeloper-
oxidase (MPO) activity, TNF- and IL-1b expression were determined. The
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effect of colitis on T2D development was studied by assessing fasting glucose
levels, as well as the incretin hormone levels, GLP-1 and GLP-2 in the blood.
Results: The development of hyperglycemia in mice treated with TNBS was
delayed compared to a non-inflamed group, what was associated with signifi-
cantly higher level of GLP-1 in blood. Surprisingly, the levels of GLP-2 were
significantly reduced in diabetic mice with colitis, suggesting that two distinct
mechanisms are involved in the regulation of the incretin hormones in response
to intestinal inflammation. There were no significant differences in macroscopic
score, colon length, and bowel thickness in diabetic mice with or without colitis.
Notably, ulcer score was significantly increased in diabetic mice with colitis
compared to diabetic mice with no inflammation. No changes in MPO, TNF-
, IL-1b were observed between these groups.
Conclusion:We propose that GLP-1 production may be stimulated in response to
colonic inflammation and thus postpone development of diabetes. This observa-
tion is the first to reveal possible connections between T2D and IBD and may
lead to better understanding of the pathophysiology of these two diseases.
Furthermore, our data suggest that the incretin hormones may become a poten-
tial new therapeutic option in treatment of IBD.
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Introduction: Pathogenesis of inflammatory bowel disease (IBD) is multifactorial
and establishing diagnosis requires a performance of series of variable tests. The
alternative, non-invasive, markers of IBD are intensively searched for.
Eosinophils are acidophilic multifunctional granulocytes that remain outside
the mainstream research on IBD. However, they are a rich source of cytotoxic
proteins, pro- and anti-inflammatory cytokines, chemokines and growth factors
and are likely to contribute to both inflammatory and regenerative phases of the
disease. Accordingly, peripheral eosinophils of IBD patients are primed and pre-
activated. They display increased responsiveness, adhesiveness, migration, and
degranulation and are characterized by up-regulated secretion of their
mediators.Locally, increased number and activation of eosinophils have been
repeatedly observed in areas of active inflammation. Despite the acknowledged
contribution of eosinophils to the disease pathogenesis, available data on cyto-
kines closely related to the development and activity of peripheral eosinophils in
IBD patients are either scattered or non-existent.
Aims & Methods: Aim of the study was assessment of the circulating eosinophil-
associated cytokines and growth factors as differential markers and indicators of
mucosal healing in inflammatory bowel disease.
Study population consisted of 277 individuals: 101 patients with Crohn’s disease
(CD), 77 with ulcerative colitis, 16 with irritable bowel syndrome (IBS) and 83
healthy controls. The disease severity was assessed using the Crohn’s Disease
Activity Index (CDAI) for CD and the Mayo Disease activity index (MDAI)
for UC. Additionally, Mayo endoscopic score was applied to evaluate the sever-
ity of bowel inflammation in UC patients. The concentrations of eosinophil-
associated cytokines and growth factors: eotaxin, GM-CSF, IFN, IL4, IL5,
IL8, IL12(p70), IL13, RANTES and TNF were measured simultaneously in
patient’s sera using Luminex xMAP technology and referred to IBD activity
and the levels of hsCRP. The suitability of eosinophil-associated cytokines and
growth factors as differential markers and potential indicators of mucosal heal-
ing, individually and in multi-marker panels, was evaluated using ROC analysis.
Results: As compared to IBS patients or healthy controls, patients with CD had
significantly higher levels of IL5, IL8, IL12(p70), GM-CSF, and TNF and
patients with UC the levels of eotaxin, IL4, IL5, IL8, IL12(p70), IL13, GM-
CSF, and TNF. As compared to CD patients, patients with UC had signifi-
cantly higher levels of eotaxin, IL4, IL5, IL8, and IL1. In turn, the concentra-
tions of hsCRP were significantly higher in CD than UC. Except for IL13, all
cytokines and hsCRP positively correlated with CDAI but solely IL12(p70) and
hsCRP were significantly higher in patients with active than inactive CD. In UC,
a positive correlation with MDAI was observed for hsCRP, GM-CSF,
IL12(p70), and IFN and a negative one for IL8. The concentrations of
hsCRP, GM-CSF, IFN, IL12(p70) and RANTES were higher in UC patients
with active than inactive disease whereas those of IL8 and TNF were signifi-
cantly lower. As differential individual markers, eotaxin displayed superior accu-
racy as an indicator of active UC (71%), followed by hsCRP as an indicator of
active CD (66%). The combined assessment of eotaxin, hsCRP and IFN had
slightly higher accuracy (78%) and allowed for a correct classification of 72%
patients. The concentrations of hsCRP, GM-CSF, IFNg, and IL12(p70) were
significantly and positively correlated with the degree of bowel inflammation,
expressed as Mayo endoscopic subscore. Of these, a drop in GM-CSF had super-
ior accuracy as an indicator of mucosal healing (91%), allowing for a correct
classification of 87% of patients. IL5, IL8, IL12(p70), TNF, and GM-CSF were
significantly higher in both CD and UC than in IBS. Of these, IL8 had superior
accuracy in differentiating IBS and IBD (91%), allowing for a correct classifica-
tion of 93% of patients.
Conclusion: Eosinophil-associated cytokines are elevated in IBD, more pro-
nouncedly in UC, and may support the differential diagnosis of IBD and aid
in monitoring of mucosal healing.
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Introduction: Interleukin(IL)10 is an important anti-inflammatory cytokine for
the maintainance of gut homeostasis. Defects in the IL10 signalling pathway in
macrophages leads to disregulation of regulatory (M2) type macrophages and
subsequent inflammatory bowel disease (IBD). IBD patients are frequently suc-
cesfully treated with anti-TNF antibody therapy, although not all patients are
responsive.
Aims & Methods: We determined the effect of anti-TNF therapy in both IL10
knock-out (KO) mice and in the CD4þCD45Rb high T-cell transfer model of
colitis. Macrophage populations were quantified using qPCR analysis for CD206
and iNOS and flow cytometry for CD206. IL10 mRNA and protein levels were
analysed with qPCR and ELISA.
Results: Colitis in the IL10 KO mice was completely resistant to anti-TNF
therapy, in sharp contrast to the colitis in SCID or Rag1 KO mice upon transfer
of CD4þCD45Rb high T-cells, which was significantly reduced by anti-TNF
therapy. Succesfull anti-TNF therapy was accompanied by an increase of IL10
levels and an increase of regulatory (M2) type macrophages in the intestine.
Blocking IL10 signaling, with an IL10 Receptor blocking antibody, diminshed
the therapeutic efficacy of anti-TNF therapy. Anti-TNF therapy was also
effective in RAG1 KO mice that received a transfer with IL10 Receptor KO
CD4þCD45Rb high T-cells, indicating that IL10 signaling in T-cells was not
important for the therapeutic efficacy of anti-TNF. In contrast, LysMCre
IL10Ra flox/flox Rag1 KO, mice defective in macrophage IL10 signaling, were
unresponsive to anti-TNF therapy upon receiving CD4þCD45Rb high T-cells.
In these mice there was also no increase of intestinal M2 macrophages.
Conclusion: IL10 signaling in macrophages is pivotal for the therapeutic efficacy
of anti-TNF therapy in animal models for IBD. Defects in the IL10 pathway
may also play a role in anti-TNF non-responders which is subject of further
investigation.
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Introduction: Epidemiological studies revealed that antibiotics exposure increases
the risk of inflammatory bowel diseases (IBD) development (Hviid, 2011, Shaw,
2011, Kronman, 2012). However, mechanisms of this association are not fully
understood. Recent studies revealed sustained alterations in gut microbiota after
antibiotic treatment (Rashid, 2015, Dethlefsen, 2011), the full consequences of
which remain unknown.
Aims & Methods: Here we investigated long-term effects of antibiotic treatment
on gut microbiota, short-chain fatty acids (SCFAs) production, transport &
sensing, colon mucosa functional state, surface mucus layer and epithelial barrier
integrity. Male Wistar rats (n¼ 178, 140–160 g) were treated for 14 days with
broad-spectrum antibiotic ceftriaxone (Cf) (300mg/kg, i.m.) or vehicle; eutha-
nized in 1, 14 or 56 days after Cf withdrawal. The fecal microbiota was analyzed
by bacteriological culture methods; fecal SCFAs– by gas chromatography; colo-
nic localization and levels of FFA2 & FFA3 receptors and MCT1, MCT4 &
SMCT1 transporters of SCFAs – by immunohistochemistry; levels of FFA2,
FFA3, ERK1/2, p38, HIF1 proteins in colon mucosa – by Western blot ana-
lysis; superoxide dismutase (SOD) and matrix metalloproteinases (MMP) activity
– by zymography method; catalase activity, level of thiobarbituric acid (TBA)
reactive substances, mucus glycoproteins and its carbohydrate composition –
colorimetrically; epithelial permeability was evaluated by Evans blue permeation
and bacterial translocation.
Results: Cf injection leads to compositional changes of fecal microbiota which
progress over time. In 56 days, we found increased level of Clostridium spp, E.
coli, conditionally pathogenic and hemolytic bacteria. Levels of Bifidobacterium
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& Lactobacillus were unchanged during the study. Moreover, the concentrations
of acetic, propionic, butyric acids and total SCFAs were decreased 2.9-, 13.8-,
8.5-, 4.8-fold (P5 0.05), respectively, the first day after Cf withdrawal. These
changes were accompanied by decreased immunoreactivity for the FFA2, FFA3
receptors, SMCT1 and increase MCT1 & MCT4 transporters of SCFAs in colon
mucosa. In 56 days, concentration of SCFAs and level of FFA3 was still below
control values. These changes evoked a significant shift in colonic mucosal home-
ostasis. We revealed increased level of TBA-active substances, decreased the
activity of SOD and catalase antioxidant enzymes with increased HIF1, activa-
tion ERK1/2 and decreased p38 MAP kinases activity after Cf injection. Hypoxia
and oxidative stress development were associated with increased permeability of
colon epithelium and bacterial translocation to blood in 56 days after Cf with-
drawal. Moreover, the levels of mucus glycoproteins, hexoses and fucose
decreased while sialation of mucus glycoproteins increased which is typical for
IBD development. These changes were accompanied by increased activity of
MMP-9 and decrease – MMP-2 in rats colon mucosa.
Conclusion: We showed for the first time that antibiotic treatment induced long-
term changes in SCFAs composition, levels of their receptors and transporters in
colonic mucosa. It was associated with alterations in mucus composition,
increased epithelial permeability that might increase susceptibility to IBD
development.
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Introduction: According to our previous report, the imbalance of Treg/Th17 cells
in the DSS induced UC mice is related with the reduction of CD45RAFoxP3high
activated Treg(FrII) cells, which has the real function of immunosuppression,
and with the elevation of CD45RAFoxP3low Treg(FrIII) cells, which provide
FoxP3þIL17aþ trait but lack of immunosuppressive capacity.Activation of Toll-
like receptor 2(TLR2) leads to elevation of FrIII, which show FoxP3þIL17aþ
trait by secrecting IL-17a.
Aims & Methods: To investigate the influence of TLR2 on imbalanced Treg/Th17
in DSS induced ulcerative mice .18 mice were divided into three groups, including
healthy control mice (group A), ulcerative colitis mice (group B) and TLR2mAb
intervened-UC mice (group C).Weight and DAI (disease activity index) of every
mice were recorded once a day. After being sacrificed, pathological examination
of the rectum of all the mice were carried out. Treg cells with their subsets, Th17
cells and CD3þCD8CD25þFoxP3þIL-17aþ cells from the lamina propria of
colon (LPC) and other tissues of mice were evaluated by flow cytometry.
Results: (1) Declined vitality, anorexia, weight lost and bloody purulent stool
were the major symptoms of UC mice. The symptoms of TLR2mAb intervened-
UC mice were alleviated, and the DAIs of these mice showed difference from UC
mice(P50.05). The inflammation of colonic mucosa in TLR2mAb intervened-
UC mice were also attenuated compared with UC mice. (2) Compared with
group A, the Treg cells of group B were increased in PBMC, MLN and LPC
(1.275 0.063 vs 1.168 0.028, 6.067 0.152 vs 3.652 0.639, 5.657 0.211 vs
1.173 0.150, P50.05 respectively). The level of Treg cells in PBMC of group C
was declined compared with group B (1.153 0.028 vs 1.275 0.063, P50.05).
(3) The levels of Th17 cells were elevated in PBMC and LPC of group B com-
pared with group A (0.488 0.015 vs 0.328 0.023, 4.300 0.137 vs
1.333 0.126, P50.05), but Th17 cells were decreased in PBMC of group C
compared with group B (0.273 0.061 vs 0.488 0.015, P50.05). (4)
Descended FrII cells were detected in PBMC, MLN and LPC of group B com-
pared with group A(0.016 0.005 vs 0.030 0.009, 0.123 0.012 vs
0.465 0.024, 0.233 0.022 vs 0.367 0.018, P50.05 respectively). Otherwise,
increased FrII cells were in spleen, PBMC, MLN and LPC of group C compared
with group B (0.577 0.016 vs 0.220 0.309, 0.030 0.009 vs 0.016 0.005,
0.467 0.016 vs 0.123 0.012, 0.365 0.019 vs 0.233 0.022, P50.05 respec-
tively). FrIII cells were elevated in PBMC, MLN and LPC of group B compared
with group A(4.215 0.490 vs 3.128 0.171, 14.463 0.463 vs 8.740 1.140,
9.487 0.604 vs 3.760 0.104, P50.05 respectively). Moreover, declined FrIII
cells were observed in spleen and PBMC of group C compared with group B
(8.967 0.354 vs 14.122 0.438, 3.070 0.763 vs 4.215 0.490, P50.05). (5)
Compared with group A, CD3þCD8CD25þFoxP3þIL17aþ cells were increased
in PBMC, MLN and LPC in group B(3.915 0.264 vs 2.533 0.076,
1.672 0.158 vs 0.898 0.044, 5.967 0.100 vs 2.308 0.252, P50.05 respec-
tively). But the level of CD3þCD8CD25þFoxP3þIL17aþ cells were decreased
in spleen, PBMC, MLN and LPC compared with group B(0.538 0.021 vs
1.238 0.017, 2.523 0.066 vs 3.915 0.264, 0.897 0.040 vs 1.672 0.158,
2.443 0.052 vs 5.967 0.100, P50.05 respectively).
Conclusion: By blocking TLR2, TLR2mAb could improve the level of FrII cells
in PBMC, MLN and LPC, but reduce the levels of FrIII and FoxP3þIL17aþ cells
in DSS induced UC mice. Furthermore, TLR2mAb could alleviate the DAI
index as well as the inflammation of colitis in DSS induced UC mice.
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Introduction: Previous studies have shown that the gut microbiota plays an
important role in IBD, however there is not a consensus on which bacteria are
responsible for the disease. 16S gene profiling studies generate large amounts of
information, however they can be confounded by genetic and environmental
factors. Twin studies are instrumental in controlling for some of these variabil-
ities, and in this study we investigated the microbiota of twin pairs discordant for
Crohn’s disease (CD) and Ulcerative colitis (UC) using 16S rRNA gene sequen-
cing, with the aim of identifying taxa associated with disease.
Aims & Methods: Participants were recruited via the UK IBD Twin Registry.
Stool samples were collected and frozen using standard methods. Participants
who had received antibiotics within 3 months were excluded. Harvey Bradshaw
Index and Simple Clinical Colitis Activity Index were recorded. Full medical
history was available from the UK IBD Twin Registry. Samples underwent
16S rRNA sequencing using the Illumina MiSeq platform and analysed using
our data analysis pipeline. PERMANOVA was used to evaluate associations
with clinical metadata, which included matching of twin pairs for analysis, and
STAMP was used to identify taxonomic differences between groups.
Results: 20 twin pairs discordant for CD (5MZ:15DZ mean age 52 years) and 17
discordant for UC (6MZ:11DZ mean age 59.7 years) were recruited. 7 subjects
with CD had active disease as did 4 with UC.
Gut microbiota from active CD patients had lower bacterial diversity compared
to remission CD patients and healthy twins (Shannon diversity index, p5 0.001
healthy vs active CD, active vs remission CD, 1-way ANOVA post-hoc¼Tukey).
Active UC patients also had lower bacterial diversity compared to remission UC
patients and heathy twins (Shannon diversity index, p5 0.01 healthy vs active
UC, p5 0.05 active vs remission).
We found that active CD patients had a higher proportion of Clostridium hyle-
monae and Lactobacillus delbrueckii compared to healthy twins, and a lower
proportion of Bacteroides uniformis, Bacteroides vulgatus, and Faecalibacterium
prausnitzii (p5 0.05). We found that active UC patients had a lower proportion
of Alistipes spp. compared to their healthy twins and UC patients in remission
(p5 0.05).
Conclusion: This study confirms previous findings showing decreased diversity in
IBD patients and changes in some bacterial taxa, however our study is the first to
show decreases in Alistipes spp. in active UC.
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Introduction: Chronic and acute inflammation is often associated with an upre-
gulation of extracellular UTP and ATP nucleotides, which are able to interact
with various cell types via purinergic G protein-coupled P2 receptors.
Interestingly, former studies already described an increased expression of the
ATP/UTP receptor subtype P2Y2 (P2Y2R) in the colonic tissue of IBD patients
[1]. However, it remained unknown in how far immune cells of IBD patients are
also characterized by an altered P2Y2R expression and whether this might
impact on their pro-inflammatory capacity.
Aims & Methods: P2Y2R mRNA and protein expression on primary CD4þ T
cells from the blood of IBD patients or healthy donors was analyzed via qPCR or
western blot, respectively. Furthermore, primary human CD4þ T cells were sti-
mulated in the presence of UTP or the selective P2Y2R agonist 2-thio-UTP and
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subsequently analyzed for STAT3 signaling (western blot), NFkB signaling
(NFkB Transcription Factor Assay, western blot) and cytokine secretion
(ELISA).
Results: Peripheral blood CD4þ T cells from IBD patients could be characterized
by a significantly increased P2Y2R expression compared to healthy controls,
while expression levels of the P2Y4 receptor subtype turned out to be comparable
between both groups. Further subdividing the group of included IBD patients
into Crohn’s disease and ulcerative colitis patients, we could not observe a sig-
nificant difference in the P2Y2R levels between both disease entities.
Interestingly, the increased P2Y2R expression in the lymphocyte compartment
of IBD patients seemed to be limited to CD4þ T cells, as CD8þ T cells of those
patients even showed decreased P2Y2R levels. Regarding potential regulators of
P2Y2R expression in the context of IBD, our data identified IL-6 and TGF-beta
as potent inducers of P2Y2R expression in human CD4þ T cells. Interestingly
high extracellular UTP levels resulted in a decreased expression of the TGF-beta1
receptor on CD4þ T cells, implicating a potential negative feedback loop in
which P2Y2R signaling might inhibit TGF-beta induced P2Y2R expression
over time. Regarding the impact of P2Y2R signaling on the pro-inflammatory
capacity of human lymphocytes, our data indicate that the selective P2Y2R
agonist 2-Thio-UTP is able mediate NFkB as well as STAT3 activation and to
induce secretion of the pro-inflammatory cytokines IL-6 and IL-17 in stimulated
human CD4þ T cells.
Conclusion: The observed increased expression of P2Y2R in CD4þ T cells of IBD
patients together with the demonstrated pro-inflammatory effects of P2Y2R
signaling in human T cells markedly strengthen the role of P2Y2R as a promising
molecular target in IBD.
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Introduction: Environmental hypoxia has been increasingly recognized as an
important environmental factor associated with Inflammatory Bowel Disease
(IBD). Hypoxia allows the stabilization of hypoxia inducible factor (HIF) com-
plexes and has been linked to the activation of autophagy. HIF1 is induced in
the inflamed mucosa from IBD patients and mouse models of colitis, but its role
in intestinal inflammation is still controversial since both, positive and negative
effects have been reported.
Aims & Methods: We aim to elucidate the effects of HIF1 stabilization in
autophagy and the development of intestinal inflammation in a murine model
of colitis. Female C57BL/6 J mice between 8–10 weeks of age were exposed to 2%
DSS in drinking water for 7 days, and received 8mg of the hydroxylase inhibitor
dimethyloxaloylglycine (DMOG) intraperitoneally every second day. Mice were
killed at day 9, mucosal damage was assessed by colonoscopy and murine endo-
scopic score of colitis severity (MEICS) was calculated. H&E staining was per-
formed to analyze the histological damage. Expression of TNF, IL-6, IL-1b and
Nlrp3 was analyzed by qPCR and protein expression of p-NFB, NFB, p-
mTOR, mTOR, Nlrp3, p62, LC3 was assessed by Western Blot. HT-29 cells
were subjected to normoxia (21% O2) or hypoxia (0.2% O2) for 24 h in the
presence or absence of 40 mM chloroquine. Cells were stained with DAPI and
LysoTracker Yellow-HCK-123 to monitor lysosomal accumulation. Chromatin
immunoprecipitation (ChIP) analysis was performed using an antibody against
HIF1 and PCR was performed using the promoter-specific primers for the p62
promoter binding sites of HIF1.
Results: DMOG administration induced a significant lower reduction of body
weight in DSS-treated mice compared to DSS-treated mice administered with
vehicle. Furthermore, mice administered with DMOG presented less reduction in
the colon length, a significant reduction in the MEICS and histological scores
showing intact crypts in large areas without extensive infiltration or thickening of
the mucosa. The mRNA expression of the pro-inflammatory factors TNF, IL-6,
IL-1b and Nlrp3 was significantly reduced in mice treated with DMOG com-
pared to vehicle-treated mice. At a protein level, DMOG administration reduced
p-NFB and NLRP3 expression. DMOG-treated mice also showed activation of
autophagy, as evidenced by a decrease in p-mTOR and p62 expression and
increase of LC3II. In vitro, hypoxia induced a significant accumulation of lyso-
somes in HT-29 cells and a reduction of p-NFB. The late-stage autophagy
inhibitor chloroquine reverted this effect indicating that was autophagy-
mediated. Finally, ChIP analysis revealed that hypoxia induced the binding of
HIF1 to the promoter of p62.
Conclusion: Our results indicate that DMOG-mediated HIF1 stabilization ame-
liorates DSS-induced colitis, activates autophagy and significantly reduces
inflammatory gene expression and signaling. In cultured intestinal epithelial
cells hypoxia triggers lysosomal formation and HIF1 binds to the promoter
of p62, thereby promoting autophagy.
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Introduction: There are several medical treatment options for inflammatory
bowel disease (IBD), but all have drawback due to their significant adverse
effects. Many new drugs are being developed for more safe and effective treat-
ment. Apocynin is a chemical 4-hydroxy-3-methoxyacetophenone which is an
inhibitor of NADPH oxidase and has showed promising effect in various chronic
inflammatory diseases such as asthma and atherosclerosis. Due to its anti-inflam-
matory effect and safety profile, apocynin can be new candidate for the treatment
of IBD.
Aims & Methods: In this study, we aimed to investigate effect of apocynin on
colonic inflammation and the action mechanism using chemically-induced colitis
mouse model. We used dextran sulfate sodium (DSS)-induced colitis model. 8
weeks old male BALB/c mice were divided into four groups (each group, n¼ 6):
control, DSS only, DSS with apocynin, and DSS with sulfasalazine. Water (con-
trol and DSS group), apocynin (400mg/kg) and sulfasalazine (150mg/kg) were
administrated by oral route using sonde during 7 days. For western blot anaylsis,
mouse colon was lysed and protein was extracted. The following antibodies were
used; iNOS (BD Biosciences), COX-2, Nrf2 (Santa Cruz Biotechnology Inc),
MCP-1, TNF-, p-Nrf2, HO-1 (Abcam), and b-actin (Sigma).
Results: Protective effect of apocynin was evident by weight change and colon
length. Histologic analysis also showed improved erosion and decreased neutro-
philic infiltration in apocynin group compared to DSS group. In colon tissue,
several pro-inflammatory enzymes and cytokines are decreased by apocynin.
Apocynin also activated anti-inflammatory pathway by inducing activation of
Nrf2 and production of heme oxygenase-1 (HO-1).
Conclusion: Apocynin, a NADPH-oxidase inhibitor, showed significant anti-
inflammatory effect in DSS induced colitis model. Considering its good safety
profile, this molecule can be a new candidate for the treatment of IBD.
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Introduction: Faecal metabolic profiling has been shown to distinguish
Inflammatory Bowel Disease (IBD) from healthy controls (HC), specifically
with depletion of gut-associated short chained fatty acids (SCFA) as the predo-
minant feature separating these groups (1). Previous and current studies have
used proton nuclear magnetic resonance (1H NMR) spectroscopy or mass spec-
troscopy (MS) to measure faecal metabolites to examine the metabolic, micro-
biomic and clinical response of IBD patients to different treatments. Both
techniques require a significant amount of sample pre-processing.
Rapid Evaporative Ionization Mass Spectrometry (REIMS) is a relatively new
technology which applies a laser to a biological sample, and the resulting vapour,
containing gas phase ions of metabolites and structural lipids, is analysed by a
mass spectrometer (2). Unprocessed faecal samples can be rapidly assessed using
this technique to obtain lipidomic spectral profiles (2). To our knowledge this is
the first study that has used REIMS to investigate whether IBD patients can be
distinguished from healthy controls using faecal samples.
Aims & Methods: Unprocessed faecal samples from 109 IBD patients and 46
healthy controls were analysed using Rapid Evaporative Ionization Mass
Spectrometry. Clinical and dietary data were collected, and patients with signifi-
cant other co-morbidities were excluded. Partial least squares discriminative
analysis (PLSDA) was performed to examine whether there was differences in
the metabolic data between patients with Inflammatory Bowel Disease and
healthy controls. Further subgroup analysis was then carried out including exam-
ining whether ulcerative colitis could be distinguished from Crohn’s disease.
A500 United European Gastroenterology Journal 5(5S)
Participant characteristics
IBD Healthy Control
Number (%) 109 46
Age (mean) 48 55
Male 51 (47%) 19 (41%)
Caucasian 63 (58%) 21 (46%)
Crohn’s disease 62 (57%) –
High IBD (430 kg/m2) 14 (13%) 10 (21%)
Results: Supervised multivariate analysis (PLSDA) was able to separate faecal
samples of IBD patients from healthy controls, and sub-analysis showed a stron-
ger separation of Crohn’s disease patients from healthy controls (Q2 quality
assurance of 0.2) compared to UC from healthy controls. A model comparing
Crohn’s disease from UC was able to separate the two groups.
Conclusion: This early preliminary analysis shows that there is a degree of separa-
tion between samples of IBD patients compared to healthy control. This suggests
that REIMS analysis has good potential as a research tool in IBD metabonomic
studies, and importantly in the current ongoing longitudinal IBD research.
Further analysis will include identifying the principal metabolites that separate
these groups.
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Introduction: The abnormal differentiation of intestinal innate lymphoid cells
ILC3 and ILC1 exist in autoimmune disease. ILC3 decreased and ILC1 increased
in Crohn’s disease (CD) patients, suggesting that CD patients have abnormal
intestinal ILC3/ILC1 alteration.
Aims & Methods: The present study investigated the aberrant colonic mucosal
ILC3/ILC1 in active CD patients and 2, 4, 6-trinitrobenzene sulphonic acid
(TNBS)-induced colitis mice. The expressions of aryl hydrocarbon receptor
(AhR) in colon of active and quiescent CD patients were detected by western
blot and immunofluorescence. The ILC3/ILC1 were investigated in CD patients
and 2, 4, 6-trinitrobenzene sulphonic acid (TNBS)-induced colitis mice (AhR/,
AhRþ/þ).
Results: Compared to quiescent CD patients, the expression of aryl hydrocarbon
receptor (AhR) in the intestinal tissue in active CD patients was decreased.
Meanwhile, the number of ILC3 in active CD patients and AhR knockout
mice was decreased while ILC1 increased. The intestinal inflammation in AhR
knockout mice given TNBS was more severe than wild-type mice.
Conclusion: These findings suggest that AhR may mediate abnormal differentia-
tion of ILC3/ILC1, and the production of inflammatory cytokines, finally, pro-
motes the pathogenesis of CD.
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Introduction: Long polar fimbriae (LpfA), FimH adhesin and ChiA chitinase
have been related with adherent-invasive E. coli (AIEC) pathogenesis.
Controversial results have been found regarding the prevalence of LpfA in
AIEC vs non-AIEC (1, 2). Some FimH amino acid variants were reported to
be specific for AIEC (3) whereas other variants were associated with phylogroup
and disease origin of the strains (4). Differences in the ChiA sequence were
reported between LF82 and K-12 strains but this gene has not been studied in
other AIEC yet (5).
Aims & Methods: The prevalence of lpfA and the distribution of fimH and chiA
variants in a collection of AIEC and non-AIEC from different disease origins -
Crohn’s disease (CD), ulcerative colitis (UC) and colorectal cancer (CRC)- were
studied with the purpose to determine if these genes could be used as molecular
markers for AIEC identification and disease diagnostics. In a collection of 37
AIEC and 29 non-AIEC isolated from CD, UC, CRC patients and controls, lpfA
gene was PCR-amplified to assess its presence and fimH and chiA genes were
sequenced to identify point mutations. For comparison of FimH and ChiA
protein sequences, UPGMA phylogenetic tree and allele identification was per-
formed using MEGA5. The genetic differences were annotated using as reference
the K-12 strain. Then, they were analysed statistically according to AIEC patho-
type, phylogroup, and disease origin by the 2 test and non-parametric tests were
used to evaluate amino acid variability regarding the adhesion and invasion
indices.
Results: Low gene frequency for lpfA141 and lpfA154 was reported (11.7% and
16.7% respectively). LpfA154 was only found in strains from A (22%) and B1
phylogroup (86%) and no relation with AIEC phenotype or disease was
observed. Two main clusters of FimH were obtained by phylogenetic analysis,
classifying the strains according to the presence of S78N mutation. N70S and
S78N variants were characteristic from strains of B2 and D phylogroups as none
of the A or B1 strains presented it. Despite statistical significance was not
reached, the strains with N70S, S78N, V163A, R166H mutations showed the
highest adhesiveness. Regarding ChiA, two main clusters defined by the presence
or absence of an insertion in 312–314 residues were obtained. None of the five
previously mutations found in LF82 strain were associated with AIEC strains,
whereas the V415A variant was found specifically in AIEC (20%) (p¼ 0.049). Of
note, among the strains harbouring the 312–314 insertion, a subcluster that
shared identical amino acid sequence included the LF82 strain and the 44% of
AIEC strains but only the 10% of the non-AIEC (p¼ 0.019). No differences
between FimH/ChiA variants and origin of isolation was observed.
Conclusion: In contrast with other studies, no relation of lpfA presence nor in
FimH mutations with AIEC pathotype or disease was observed. Nonetheless, a
variant in ChiA sequence more frequently found in AIEC isolates was reported,
being an interesting signature sequence for the detection of at least a subgroup of
AIEC strains. Further confirmation in a wider strain collection would be
required.
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Introduction: Primary sclerosing cholangitis (PSC) is a progressive disorder of
biliary tree which can lead to end-stage liver disease, liver transplantation or even
death 1, 2. Colitis accompanying PSC is considered to be a phenotype of IBD
(inflammatory bowel disease) distinct from ulcerative colitis (UC) and is often
referred to as "PSC-IBD" 3.
Aims & Methods: Our aim was to compare the gut bacterial microbiota of
patients with PSC and UC. Stool samples were prospectively collected and rele-
vant clinical data obtained from 106 study participants, 43 PSC patients with
(n¼ 32) or without (n¼ 11) concomitant IBD, 32 UC patients, and 31 healthy
controls (HC). Sequencing of the 16S rRNA gene including the V3 and V4
regions was performed on Illumina MiSeq platform to cover low taxonomic
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levels. Data were further processed in QIIME employing MaAsLin and LEfSe
tools for analysis of the output data.
Results: Microbial profiles in both PSC and UC were characterized by low bac-
terial diversity and significant change in global microbial composition. Rothia,
Enterococcus, Streptococcus, Veillonella, and three other genera were markedly
overrepresented in PSC regardless of concomitant IBD. Rothia, Veillonella and
Streptococcus were tracked to the species level to identify Rothia mucilaginosa,
Streptococcus infantus, S. alactolyticus, and S. equi along with Veillonella parvula
and V. dispar. PSC was further characterized by decreased abundance of
Adlercreutzia equolifaciens and Prevotella copri. Decrease in genus
Phascolarctobacterium was linked to presence of colonic inflammation regardless
of IBD phenotype. Akkermansia muciniphila, Butyricicoccus pullicaecorum and
Clostridium colinum were decreased in UC along with genus Roseburia.
Unclassified Actinomyces species were markedly increased in overlap syndrome
of autoimmune hepatitis (AIH) and PSC. Low levels of serum albumin were
significantly correlated with enrichment of order Actinomycetales.
Conclusion: PSC was characterized by microbial features independent of conco-
mitant IBD. Several bacterial taxa clearly distinguished IBD phenotypes (PSC–
IBD and UC) as well as PSC from PSC/AIH.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
1. Gow PJ, Chapman RW. Liver transplantation for primary sclerosing cho-
langitis. Liver 2000; 20(2): 97–103
2. Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer
PJ, Sherlock S. Primary sclerosing cholangitis: a review of its clinical fea-
tures, cholangiography, and hepatic histology. Gut 1980; 21(10): 870–877
3. Loftus EV, Jr., Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS,
Zinsmeister AR, Jewell DA, Sandborn WJ. PSC-IBD: a unique form of
inflammatory bowel disease associated with primary sclerosing cholangitis.
Gut 2005; 54(1): 91–96
P0976 HYPOXIA INDUCIBLE FACTOR (HIF)-1 ACCELERATES
EPITHELIAL WOUND HEALING THROUGH INTEGRIN
REGULATION
B. J. Goggins1, K. Minahan2, D. Knight2, J. Horvat2, M. M. Walker3, S. Keely2
1School Of Biomedical Sciences And Pharmacy, University of Newcastle,
Callaghan/Australia/NSW
2University of Newcastle School of Biomedical Science and Pharmacy, Callaghan/
Australia
3School Of Medicine And Public Health, The University of Newcastle Australia,
Callaghan/Australia/NSW
Contact E-mail Address: simon.keely@newcastle.edu.au
Introduction: The characteristic inflammation associated with IBD contributes to
repeated cycles of epithelial wounding and repair in the intestine. The epithelium
functions as a selective barrier, critical for mucosal protection. During intestinal
inflammation, damage to the vasculature leads to reduced oxygen availability
(hypoxia) at the mucosa. Epithelial wound healing processes occur in this
hypoxic environment and are critical to restore barrier integrity and gut home-
ostasis. A key factor in the co-ordination of mucosal wound healing is the tran-
scription factor Hypoxia inducible factor (HIF)-1. HIF-1 mediates an array of
protective mechanisms for cell survival and repair. Previous work has shown that
pharmacological stabilisation of HIF-1 by prolyl hydroxylase inhibitors (PHDi)
is protective in murine models of colitis. Importantly, our work has identified
HIF-1-mediated induction of integrin-b1 at the mucosa as critical to this process.
Aims & Methods:We aimed to examine the functional role and post-translational
activity of epithelial -integrin subunits dimerizing with integrin-b1 to promote
HIF-1-mediated wound healing by PHDi. Cell migration and inhibition scratch
assays were performed on T84 monolayers (1% O2 and/or PHDi (AKB-4924),
wound closure was monitored over 24 hours. Monolayers were stained by immu-
nofluorescence for -integrin subunits at 12 hours post-wound. Novel biopsy-
wound models were used to extend the study of PHDi-mediated wound healing
in vivo.
Results: PHDi treatment significantly accelerated wound closure in T84 mono-
layers, which was inhibited by antibodies functionally targeting integrin-3.
Immunofluorescent imaging of cell monolayers showed both hypoxia and
PHDi treatments increased expression of integrin-3, localized at the leading
edge of the wound. PHDi treatment also significantly accelerated mucosal
wound closure in the colons of mice following biopsy wounds with elevated
expression of integrin-3 associated with the wound epithelium.
Conclusion: These data suggest that PHDi-mediated HIF-1 stabilisation pro-
motes mucosal healing through regulation of epithelial integrins, in particular
3b1. Integrin-3b1 is a key regulator of epithelial cytoskeletal organization
therefore PHDi compounds may enhance wound closure through integrin-
3b1-mediated re-organisation of the cytoskeleton.
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Introduction: Metabolic profiling (metabonomics) has been proposed as a novel
clinical tool in IBD to predict development of complex disease, or for longitu-
dinal non-invasive monitoring of activity and/or response to drug treatment.
Urinary metabonomics can distinguish IBD from healthy controls(1) but no
studies to date have assessed the stability of these discriminatory profiles over
time. Studies in healthy adults show metabolic signatures are largely unchanged
over periods of upto 3 years(2), but signals are influenced by multiple external
factors including medication and surgery, so how these change in IBD is
unknown. The aim of this study was to compare baseline urinary metabolic
profiles of IBD patients with a repeated sample several years later to assess
similarity, and also to test if any clinical outcomes could be retrospectively pre-
dicted from the baseline sample.
Aims & Methods: Two urine samples from 39 IBD patients (22 Crohn’s disease
(CD) and 17 ulcerative colitis (UC)) were collected - one at baseline and one
several years later (range 7–9 yrs). These were analysed by 1H NMR spectro-
scopy. Disease progression was defined as initiation of immunosuppression or
biologics, progression of disease location or phenotype, or surgery. Principal
components analysis was used to visualise the variance between the two time-
points within the cohort. Orthogonal partial least squares discriminant analysis
(OPLSDA) was used to establish if the metabolic signatures could be used to
predict adverse clinical outcomes in the patients studied.
Results: 57% of CD patients and 17% of UC patients had clinical progression at
follow-up sampling. PCA showed clustering of sample pairs from the baseline
and several years later in most individuals, suggesting intra-individual similarity
across time. OPLSDA showed no statistical models could be built to predict
combined poor outcome based on the initial urinary metabolic profile
(p¼ 0.26). However, the small subgroup who went on to require surgical inter-
vention could be separated from the cohort in a model (Q2¼ 0.015; p¼ 0.03)
constructed on their baseline profiles.
Conclusion: The metabolic profile of IBD in an individual appears relatively
stable over a significant time period despite a variety of clinical outcomes and
interventions. Variations in longitudinal measurements appear to be subtle, and
therefore application of this technique for disease monitoring and risk stratifica-
tion could prove difficult. These results may suggest that metabolic profiling
could be exploited to predict a higher risk of requiring future surgery.
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Introduction: Mucosal healing is considered to be the hallmark of successful
therapy in Ulcerative Colitis, and has become increaingly used as a target of
therapeutci interventions. Loss of mucosal integrity and associated translocation
of bacterial components across the mucosal epithelial barrier occurs in Ulcerative
Colitis and persistance of a structural mucosal defecit is a characteristic of
chronic inflammatory bowel disease. Mucosal healing can be defined by clinical,
endoscopic and histological means but no clear definition of the required extent
of mucosal healing exists, nor is there agreeent on how functional mucosal heal-
ing is defined.
Aims & Methods: To define the extent and associations of mucosal healing in
patients with Ulcerative Colitis and the relationship with bacterial translocation
and clinical remission. Patients with established diagnosis of Ulcerative Colitis
undergoing endoscopic evaluation were recruited to the study (Ethics: South
West London REC2 10/H0706/26). Clinical history and long-term follow-up
data were recorded. Blood and mucosal samples were prepared as mononuclear
cells. Healthy controls recruited from cohort undergoing routine lower gastro-
intestinal investigations without positive findings. Flow cytometry characterisa-
tion of cells by cell surface CD45RO, CD27, CD3, CD14, CD8 and CD161 and
cytokine expression after staphylococcal enterotoxin B stimulation by IL-2, IL-
17a, IL-22, TNF, IL-17f and IFN. Immunohistochemistry to define tight junc-
tion apical epithelial expression (Claudin 1, Claudin 4 and Occludin) and lipo-
polysaccharide within the lamina propria. Peripheral blood markers of bacterial
translocation: bacterial DNA (16srDNA), lipopolysaccharide Binding protein
(LBP), soluble CD14 and plasma lipopolysaccharide. Statistical analysis by
Mann Whitney or Kruskall Wallis analysis with Dunn’s post test correction,
or by Spearman rho correlation.
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Results: 28 patients with Ulcerative Colitis, duration of disease 4 months to 31
years (median 6.3 years) and 22 Healthy Controls were recruited to the study.
Half of the patinets had active disease as assessed by Ulcerative Colitis Severity
Score. Disease severity positively correlated with frequency of mucosal Th17
(CD4þIL-17aþ) and IL-17f. Breaches in tight junction protein expresion were
greater in UC than controls: Claudin 1 (p5 0.0001), Claudin 4 (p¼ 0.0016) and
occludin (p¼ 0.03). The serum marker of bacterial translocation, lipopolysac-
charide binding protein (LBP) was elevated in UC compared to controls
(p¼ 0.0078) and was positively correlated with breaches of Claudin 1 and
Occludin (p¼ 0.018 and p¼ 0.012 respectively) Staining colon biopsies for the
presence of lipopolysaccharide in the lamina propria demonstrated positive find-
ings in healthy controls, supported by data from 16s rDNA analysis of blood
from healhty controls. In the Ulcerative Colitis cohort in clinical remission the
abscence of lipopolysaccharide in the lamina propria was associated with ele-
vated levels of LBP and increased breaches of Occludin (p¼ 0.0022).
Conclusion: Breaches of tight junction proteins in the colon of patients with stable
clinical remission can be detected and are assocaited with perturbations of muco-
sal immunological function and markers of bacterial translocation.
Lipopolysaccaride presence in the lamina propria of patients in remission
appears to be assocated with less tight junction breaches and reduced local and
systemic evidence of bacterial translocation. These findings require further study,
specifically to examine the role of mucosal immune tolerance to lipopolysacchar-
ide and other bacterial cell products that may be present in the healed mucosa of
ulcerative colitis.
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Introduction: Diet may influence intestinal inflammation via various pathways
but the evidence regarding the role of fiber or fat intake in patients with inflam-
matory bowel disease (IBD) is controversial.
Aims &Methods: The aim of this study was to investigate the association between
dietary fiber or total fat intake and disease activity or quality of life in Greek IBD
patients. We prospectively collected food frequency questionnaires (FFQ) from
consecutive IBD patients at outpatient visits. The European Prospective
Investigation into Cancer and Nutrition (EPIC) Study FFQ for Greek popula-
tion with the MAFF photographic food atlas were used in order to collect
information for dietary habits of IBD patients. Moreover, disease activity
using the simple colitis activity index (SCCAI) (for ulcerative colitis (UC)) and
Harvey-Bradshaw index (HBI) for Crohn’s disease (CD)) as well as quality of life
using the short inflammatory bowel disease questionnaire (SIBDQ) were evalu-
ated. Patients’ demographic, clinical characteristics, nutritional status, laboratory
data [C reactive protein (CRP), haemoglobin, erythrocyte sedimentation rate
(ESR), platelets and albumin] and treatment data were recorded and analysed
for all participants.
Results: A total of 141 consecutive IBD patients (53 UC, 88 CD, mean age
47.2 16.1 years, 84 males 57 females, mean BMI 26.7 5.3) were included.
Patients’ mean daily fiber intake was 21.8 gr (IQR 13.8–34.6) and mean daily
total fat was 161.4 gr (121.2–237) with 43.5% percent energy from fat. Regarding
disease activity 34 (24.1%) patients had active disease with HBI or SCCAI score
5 whereas 45 (31.9%) patients had poor quality of life with SIBDQ score 50.
There was no difference in daily fiber or fat consumption between patients with
UC and CD [median daily fiber intake 23.5 (IQR 10.8–36.5) gr vs 21.7 (14.6–
34.2) gr (p¼ 0.86), median fat intake 148.7 (112.4–242.8) gr vs 169.4 (127.1–
236.7) gr (p¼ 0.30)]. There was a significant negative correlation between fiber
intake and disease activity in both UC (r¼0.37 p¼ 0.007) and CD (r¼0.32,
p¼ 0.002) while there was not significant correlation between fat intake and
disease activity (in both diseases p4 0.05). No association of fiber or fat con-
sumption with abnormal CRP, increased ESR, presence of anemia, thrombocy-
tosis or low albumin was found (all with p4 0.05). SIBDQ score had a
significant correlation only with fiber intake (r¼ 0.31 p¼ 0.0002) but not with
fat intake (r¼ 0.07 p¼ 0.40).
Conclusion: Higher dietary fiber intake is associated with lower disease activity
and better quality of life in patients with IBD. Fat consumption does not seem to
influence the disease activity and patients’ quality of life. Based on these results it
could be suggested that the amount of fiber consumption by IBD patients may
play an important role in the disease course.
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Introduction: Crohn’s disease (CD) is a progressive disease that over time can lead
to the development of complications such as strictures or internal penetrating
disease that will ultimately lead to surgery. Only few population-based studies
from the biological era and widespread use of immunodulators have investigated
the change in disease behaviour and subsequent risk of surgery in CD.
Aims & Methods: The EpiCom-cohort is a population-based cohort of unselected
patients with inflammatory bowel disease diagnosed in 2010 in Eastern and
Western European centres. Patients were followed prospectively for five years
and clinical data were captured throughout the follow-up period. Disease beha-
viour was defined according the Montreal classification as B1: non-stricturing,
non-penetrating, B2: stricturing; B3: penetrating based on endoscopy, cross-sec-
tional imaging or surgery. The risk of progressing from B1 to B2/B3 as well as the
risk of surgical resection was analysed by Cox regression analyses using the
proportional hazard assumption including multiple covariates (age, gender, dis-
ease location, diagnostic delay, smoking status, change in behaviour, geographic
region and treatment with biologics within 6 months from diagnosis).
Results: A total of 488 incident CD patients were included in the study, of which
347 (71%) had B1. A total of 141 (29%) patients had complicated CD at diag-
nosis. After 5 years’ follow-up, this number increased to 190 (39%) (Table 1). Of
patients diagnosed with B1, 35 (10%) progressed to B2 while 14 (4%) progressed
to B3 after a median of 21 months (range: 0–62). The proportion of B1 patients
changing behaviour was highest during the 1st year of disease (5%) but stable
during the remaining follow-up period (approx. 2%/year). Colonic location (L2
vs L4 HR: 0.3 CI95%: 0.1–0.8), extra-intestinal manifestations at diagnosis (HR:
0.2 CI95%: 0.1–0.8), and the need for early biologics (HR: 2.5 CI95%: 1.2–5.1)
were associated with progression in behaviour. During follow-up, a total of 107
(22%) patients had a resection. Of patients with B1 as initial behaviour a total of
37 (11%) patients had a resection. A change in behaviour from B1 to B2/B3 (HR
6.8 CI95%: 3.0–15.6) and early biologics (HR 0.5 CI95%: 0.2–0.5) was
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associated with the risk for resection. No difference in the results was found
between Eastern and Western European patients.
Table 1: Disease behaviour in Crohn’s disease at diagnosis and follow-up
At diagnosis
At follow-up
B1 B2 B3
Total
(diagnosis)
B1, non-stricturing,
non-penetrating
298 (61%) 35 (7%) 14 (3%) 347 (71%)
B2, strictuing – 89 (18%) 11 (3%) 100 (21%)
B3, penetrating – – 41 (8%) 41 (8%)
Total (follow-up) 298 (61%) 124 (25%) 66 (14%) 488 (100%)
Conclusion: In this European population-based inception cohort of unselected
CD patients 14% of patients with B1 progressed to B2 or B3 after five years of
follow-up. The risk of surgery was increased in patients with B1 who progressed
to B2/B3. No clinical predictors for progression in behaviour including smoking
and treatment with biological therapy could be identified.
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Introduction: Introduction: Faecal microbiota are believed to play an important
role in the pathogenesis of Crohn’s disease (CD). It is not known for certain
whether gut microbiota composition (GMC) changes in response to inflamma-
tion or whether inflammation in the gut wall is a response to changes in GMC.
Dynamic changes in bowel wall inflammation and short term changes in GMC
have not previously been studied, but would give a clue as to the aetiological
importance of GMC.
Aims & Methods: We aimed to assess the correlation between short changes in
GMC and a faecal marker of gut inflammation faecal calprotectin (FC) and CRP
a marker of systemic inflammation.
We conducted a blinded sham controlled cross-over study of 32 subjects assigned
to IgG4 guided exclusion diets. Each subject was randomised to one month of
true or sham diet followed by a one month washout period followed by a further
cross-over trial diet. Stool and blood specimens were obtained at time 0, 1 month
(completion of first trial diet), 2 months (completion of washout) and 3 months
(end of cross-over trial diet). Taxonomic profiling was performed using 16s RNA
next generation sequencing. Copy counts were made for firmicutes and bacter-
oidetes as a phylum; Roseburia and Bifidobacterium as a genus and
Faecalibacterium prausnitzii as a species. Shannon diversity was calculated.
Results: 26 people fully completed the study. For each participant this provided
six timepoints for comparison: timepoint 1–2, 2–3, 3–4, 1–3, 1–4 and 2–4. The
relative abundance of bacteria groups were calculated. Kendall Tau correlation
coefficient was used to assess correlation between change in FC and CRP to
change in relative abundance of various bacteria. We found significant negative
correlation with change in FC and CRP with Bifidobacterium genus and change
in CRP with Roseburia genus. There were poor correlation and inconsistent
changes in other species and firmicutes and bacteroidetes and Shannon diversity.
Conclusion: Bifidobacterium relative abundance correlate closely with short term
changes in FC suggesting a possible causal association. Other genera and species
had poor and inconsistent correlations with short term changes in FC suggesting
that they may not be causally related to short term changes in gut inflammatory
activity.
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Introduction: Risk factors for colorectal cancer (CRC) in Inflammatory Bowel
Disease (IBD) are still debated (1).
Aims & Methods: In a prospective multicenter, nested case-control IG-IBD study
at 4 years, we aimed to assess the frequency and risk factors for incident CRC in
IBD. The role of IBD phenotype vs thiopurines (IS) and/or anti-TNFs use as risk
factors for CRC was also evaluated. From Jan. 2012 to March 2017, all incident
cases of CRC in IBD pts referring to 16 IG-IBD Units were recorded. Each IBD
pt with CRC (IBD-CRC) was matched with 2 IBD pts with no cancer (IBD-C)
for: IBD type (Crohn’s Disease, CD vs Ulcerative Colitis, UC), gender, age (5
yrs). Cases of CRC derive from a larger cohort of IBD pts referring to the same
Units, with incidence of any cancer separately reported at 4 years (follow up at 3
yrs reported for cancer overall)(2). Statistical analysis: data expressed as median
(range), Wilcoxon test, Chi-squared test, Fisher exact test; multivariate logistic
regression analysis.
Results: Incident cases of CRC occurred in 66 IBD pts: 41 UC (UC-CRC), 25 CD
(CD-CRC). IBD group therefore included 198 pts (66 IBD-CRC, 132 IBD-C),
UC group included 123 pts (41 UC-CRC, 82 UC-C) and CD group included 75
CD pts (25 CD-CRC, 50 CD-C). The frequency of incident CRC was higher in
the tested UC versus CD population (62.1% vs 37.9%;p¼ 0.009). Gender was
equally distributed in IBD groups (UC: 14 F [34%]; CD:12 F [48%];p¼ 1). The
median age was comparable between IBD-CRC and IBD-C (UC-CRC vs UC-C
62 [37–86] vs 59 [35–86]; CD-CRC vs CD-C:51 [23–76] vs 55 [22–76];p¼ 1). UC
duration was longer in pts with vs without CRC (20 [0–37] vs 10 [0–35];510 yrs:
6 [15%] vs 35 [43%]; 10 yrs:35 [85%] vs 47 [57%];p¼ 0.001). Conversely, CD
duration was comparable between pts with vs without CRC (20 [1–47] vs 13 [0–
35];510 yrs:6 [24%] vs 15 [30%];10 yrs:19 [76%] vs 35 [70%]; p¼ 0.58). IBD
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Firmicutes Bacteroidetes Roseburia Bifidobacterium Faecalibacterium prausnitzii Shannon Diversity
Timepoint
Kendal
Tau p value
Kendal
Tau p value
Kendal
Tau p value
Kendal
Tau p value
Kendal
Tau p value
Kendal
Tau p value
FCP 1–2 0.352 0.015 0.211 0.147 0.056 0.731 0.265 0.068 0.179 0.233 0.131 0.374
FCP 2–3 0.073 0.624 0.173 0.234 0.043 0.785 0.320 0.027 0.239 0.107 0.220 0.129
FCP 3–4 0.067 0.657 0.227 0.117 0.027 0.870 0.147 0.315 0.190 0.214 0.114 0.441
FCP 1–3 0.048 0.739 0.123 0.381 0.031 0.835 0.009 0.967 0.014 0.934 0.048 0.739
FCP 1–4 0.048 0.739 0.031 0.835 0.054 0.707 0.453 0.001 0.043 0.770 0.060 0.677
FCP 2–4 0.062 0.675 0.006 0.982 0.203 0.152 0.431 0.002 0.080 0.582 0.043 0.774
CRP 1–2 0.117 0.427 0.040 0.797 0.130 0.398 0.183 0.207 0.083 0.585 0.143 0.327
CRP 2–3 0.114 0.440 0.207 0.154 0.004 1 0.124 0.400 0.040 0.804 0.134 0.362
CRP 3–4 0.201 0.168 0.020 0.907 0.490 0.001 0.262 0.072 0.028 0.874 0.111 0.454
CRP 1–3 0.242 0.080 0.054 0.707 0.003 1.000 0.185 0.182 0.151 0.278 0.017 0.917
CRP 1–4 0.111 0.428 0.091 0.518 0.009 0.967 0.060 0.677 0.060 0.677 0.031 0.835
CRP 2–4 0.103 0.465 0.126 0.369 0.158 0.260 0.080 0.573 0.089 0.531 0.215 0.122
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pts with CRC were younger at diagnosis of IBD than their IBD-C (UC-CRC vs
UC-C: median yrs:39 [15–76] vs 46 [20–81];540 yrs, n¼ : 21 [51%] vs 27
[33%];40 yrs: 20 [49%] vs 55 [67%]; p¼ 0.04;CD-CRC vs CD-C: median yrs
27 [6–67] vs 37 [10–67];540 yrs, n¼ 19 [76%] vs 26 [52%]; 40 yrs: 6 [24%] vs 24
[48%]; p¼ 0.04). The median age at diagnosis of CRC was comparable in UC vs
CD (60 [35–83] vs 51 [20–76];p¼ 0.19). The frequency of CRC was comparable
between UC pts using or not IS and/or anti-TNFs (CRC-UC vs CRC-UC: IS
monotherapy 6 [15%] vs 17 [21%]; Anti-TNFs monotherapy: no CRC;
Combotherapy: 5 [12%] vs 6 [7%]; no IS/no anti-TNFs: 11 [27%] vs 23 [28%];
p¼ 0.88). No differences were also observed between CD pts treated or not with
IS and/or anti-TNFs (CRC-CD vs CRC-C: IS monotherapy: 4 [16%] vs 9 [18%];
Anti-TNFs monotherapy:2 [8%] vs 3 [6%]; Combotherapy:10 [40%] vs 23 [46%];
no IS/no anti-TNFs: 16 [64%] vs 35 [70%]; p¼ 0.59). CD pts with CRC showed a
higher frequency of pattern B1 (B1 vs B2 vs B3 (n [%]): 14 [56%] vs 3 [12%] vs 8
[32%];p¼ 0.019). Risk factors for CRC considered In multivariate analysis
included: age (540 vs 40 yrs), IBD duration (510 vs 10 yrs), smoking
habits (Yes/No;Y/N), ISS-anti-TNFs (Y/N), IBD-related surgery, UC extent
(extensive vs distal; subtotal vs distal), CD pattern (B3 vs B1, B2 vs B1), perianal
CD. In UC, the only significant risk factor was UC duration (OR [95% CI]: OR
3.33 [1.44–9.1I], as the other risk factors were not significant: OR 0.94 [0.36–
2.98];1.28 [0.48–3.04];0.96 [0.36–3.08];1.78 [0.60–4.66];1.36 [0.66–2.89];0.38 [0.08–
1.23], respectively). In CD, perianal disease was the only significant risk factor
for CRC (OR 3.11 [1.16–8.33I, as no other significant risk factors were identified
(OR 2.21 [0.70–9.87]; 1.66 [0.62–4.96]; 0.56 [0.19–1.41]; 0.99 [0.41–2.52], 0.54
[0.2–1.43], 0.83 [0.26–2.55], 0.23 [0.04–0.83], respectively).
Conclusion: In a prospective, multicenter, nested-case control IG-IBD study,
incident cases of CRC were more frequent in UC than in CD. In our cohort,
UC duration and perianal CD, but not immunomodulators use, were identified
as risk factors for incident cases of CRC in IBD.
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Valencia/Spain
12Gastroenterology, Hospital Universitario Central de Asturias, Gijón/Spain
13Gastroenterology, Hospital Universitario de Valdecilla, Santander/Spain
14Gastroenterology, Hospital San Pedro de Alcantara, Cáceres/Spain
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Aims & Methods: Aims: Primary: to evaluate the incidence of inflammatory
bowel disease (IBD) in Spain. Secondary: to describe the characteristics of
patients at diagnosis; to evaluate the need for immunomodulators (IMM), bio-
logics, surgery and hospital admissions in the first year of diagnosis and to assess
the time from the onset of symptoms to the diagnosis of the disease.
Methods: Prospective and population-based nationwide study. Adult patients
diagnosed with IBD gCrohn’s disease (CD), ulcerative colitis (UC) or indeter-
minate colitis (IC)g during 2017 in the 17 Spanish regions are being included.
Each case is also being followed-up for 12 months after diagnosis to describe
changes in phenotype or location, to evaluate the requirement of IMM and
biologics and to determine the need for hospitalization or surgery during the
first year from the diagnosis. Data was captured in a web-based database
(AEG-REDCap).
Results: An updated interim analysis of the incidence of IBD is planned 6 months
after the beginning of the study (June 2017). Up to April 1st 2017, 557 patients
from 156 centres have been included: 53% males, mean age 40 years, 27%
smokers. 51% had UC, 44% CD, and 5% IC. 13% of patients had a family
history of IBD. The mean time to IBD diagnosis from symptoms onset was 3
months (range 0–198). At the time of diagnosis, 10% of the patients had extra-
intestinal manifestations (the most frequent being rheumatologic manifestations,
in 6% of the cases). In CD patients, 53% had ileal location, 20% colonic, 26%
ileocolonic, 2.4% upper gastrointestinal tract involvement, and 13% perianal
disease; 8% of patients had stenosing and 7% fistulising behaviour at the time
of diagnosis. In UC patients, 30% had extensive colitis and 36% left-sided colitis
at diagnosis. The therapeutic requirements were: 28% oral steroids, 13% intra-
venous steroids, 9% thiopurines, 0.9% methotrexate, 0.4% cyclosporin, and
3.2% anti-TNFs. Twelve patients (2.2%) were operated (5 abdominal and 7
perianal surgery), and 133 patients (24%) required hospital admission within
the first 3 months following diagnosis.
Conclusion: In this large nationwide epidemiologic study we describe how the
treatment requirement and the consumption of health resources was already high
from the time of diagnosis as, indeed, a relevant proportion of IBD patients
required surgery or hospital admission within the first 3 months after the
diagnosis.
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Introduction: Anorectal complaints occur in a considerable group of patients with
IBD. There is a dearth of evidence relating to the impact of these complaints on
IBD patients’ lives. We aimed to survey the effect of anorectal complaints on
quality of life in a large cohort of patients who engaged in the Dutch Crohn’s and
Colitis organisation (CCUVN).
Aims & Methods: In October 2016, the CCUVN had a membership database of
10,047 patients. A comprehensive study questionnaire was sent out online by the
CCUVN in January 2015 and October 2016 to a voluntary panel, which con-
sisted of 1710 CCUVN patients. The panel is represented by patients who volun-
tary participate in online surveys with regard to disease related subjects. Inclusion
criteria were age over 18 years old and a self-reported diagnosis of Crohn’s
disease (CD), ulcerative colitis (UC) or IBD-unclassified (IBD-U). The survey
included the St. Marks incontinence score, perianal disease activity index, faecal
incontinence quality of life (FI-QOL) questionnaire and the SF-36 questionnaire.
Multiple imputation was used for covariates with missing data. Multivariate
regression analysis was performed.
Results: A total of 1094 patients (64%) responded the online survey. Mean age
was 47 years (range 18–87), CD diagnosis was predominant (621 CD patients
(57%), 431 UC patients (39%) and 42 IBD-U patients (4%)) and diagnosis was
established for a mean period of 13 years (interquartile range 3–19 years). Active
perianal disease was present in 243 CD patients (39%) and perianal surgery
(abscess- or fistula-related) was previously performed in 153 (25%). Faecal
incontinence (1 episode per month) was reported in 305 CD (58%), 230 UC
(56%) and 20 IBD-U (51%) patients. Weekly episodes occurred in 41 CD (8%),
22 UC (5%) and 3 IBD-U (8%) patients (mean St. Marks incontinence score 14).
FI-QOL scores were not different between the different diagnoses. Multivariate
regression analysis (adjusted for gender, diagnosis and previously performed
abdominal operations) showed a reduced total SF-36 score in patients with
faecal incontinence (b 8.57 [11.33; 5.81]; p5 0.0001) and active perianal
disease (b 4.13 [7.35; 0.91]; p¼ 0.01). A better score was reported in UC
patients compared to CD patients (b 3.53 [0.48–6.58]; p¼ 0.02). Previously per-
formed perianal surgery was not associated with SF-36 score in the multivariate
analysis.
Conclusion: Anorectal complaints have a substantial impact on the quality of life
in patients with IBD, with a (usually unmet and) clear need to treat. More
awareness for this highly distressing and most commonly cumbersome treatable
disease manifestation is needed.
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Introduction: The human gut microbiome is made up predominately of four
major bacterial phyla, Firmicutes, Bacteroidetes, Proteobacteria and
Actinobacteria. Changes or imbalance of these phyla is termed dysbiosis.
Specifically, in inflammatory bowel disease (IBD), key changes have been iden-
tified such as a reduction in beneficial bacterial species including
Faecalibacterium prausnitzii and increases in more pathogenic species including
members of the Enterobacteriacae. Currently it is not understood if dysbiosis is
the cause of, or the effect of, intestinal inflammation. It is difficult to chronolo-
gically assess the microbiota changes prior to developing IBD as currently we are
unable to predict those individuals who will develop the disease. The pouch is a
potential model to study pathogenesis of inflammation as 40% of those that
develop pouchitis do so within 12 months. The relative short time from pouch
formation to inflammation allows the longitudinal study of the microbiota which
gives insight into potential microbiota patterns occurring both in disease and
non-diseased states. Interestingly, inflammation within the pouch is rarely seen
in patients who have this operation for Familial Adenomatous Polyposis (FAP),
thus raising the possibility that pouchitis shares a similar pathogenesis to the
inflammation that is seen in ulcerative colitis.
Aims & Methods: 1. To understand changes in pouch microbota over time. 2. To
understand pouch microbiota that is associated with pouch inflammation A
computer assisted search of the on-line bibliographic databases MEDLINE
and EMBASE was carried between 1966 and February 2016. Randomised con-
trolled trials, cohort studies and observational studies were included. Inclusion
criteria: Studies which reported microbiota analysis on either faecal samples or
tissue from the ileo-pouch anal anastomosis. Studies that provided information
on specific bacterial taxa. Exclusion criteria: Studies which did not report on
patterns of individual bacterial taxa differences in the pouch. Studies on the
microbiota of Crohn’s disease or UC in isolation without any data on pouch
patients. Studies with less than ten patients.
Results: The search strategy found 844. There were a total of 27 papers included
in the analysis. Microbiota in pouchitis: Bacteroidetes, Enterococcaceae,
Lachnospiraceae, Faecalibacterium, Ruminococcaceae, Streptococci
Alcaligenaceae and Bifidobacterium were reduced in patients with pouchitis.
Whereas Enterobacteriaceae, including E. coli Fusobacterium and Clostridia
were increased in patients with pouchitis. One study highlighted bacteria that
were exclusively found in pouchitis which included Leptospira,
Pseudoalteromonas, Desulfosporosinus, Microcystis, Methylobacter. Chronic pou-
chitis was associated with a significant increase in Staphylocococus aureus and it
has been suggested that this may be a responsible pathogen for chronic pouchitis.
Furthermore, Enterococcus, F. prausnitzii, Lachnospiraceae and Insertae Sedis
XIV and have been shown to be significantly reduced in chronic pouchitis
patients. These differences were largely due to a decrease in sequences from
members of the genera Ruminococcus, Dorea, Clostridium, and Eubacterium.
Conclusion: The microbiota undoubtedly plays an important role in both the
inflamed and the healthy pouch. However, a direct causal relationship has not
yet been established between individual microbiota changes and inflammation.
There are many studies that highlight changes in bacterial composition, but
studies are limited by heterogeneity of and in particular, analysis techniques
and sampling strategies. Studies used a variety of methods to define microbial
diversity which can be broadly split into culture vs culture-independent
approaches. Culture-based studies are likely to have a bias towards culturing
more aerobically friendly microbes than exist in a true pouch environment,
thus over-representing aerobic bacteria whilst possibly under-representing anae-
robic bacteria. The use of 16 S rRNA analysis methods will negate this effect and
represents the future in accurately determining the microbiota.
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Abstract: P0985. Table 1: Evolution of pouch microbiota over-time
Study Year Analysis method UC or FAP Comparator Key findings in UC
Two-three months
Almeida 2008 Mucus- culture UC Two vs eight months after
ileostomy closure
Enterobacter Klebsiella
Kohyama 2009 Faeces–PCR Terminal restriction
fragment length polymorphism
amplification
UC Uc vs healthy controls C. coccides
Hinata 2012 Faeces-16S RNA UC UC vs healthy C. coccides group C. leptumsubgroup
B. fragilis group Atopobium
Six-eight months
Almeida 2008 Mucus- culture UC Two vs eight months post ileostomy Most prevalent: E coliVeillonella
Enterobacter, Klebsiella Peptococcus
Bednarz 2015 Swab-culture UC UC longitudinal Enterobacteriaceae most common
1 year
Luukkonen 1988 Faeces-culture UC Kock ileostomy and ileostomy Transformation to a ‘‘colonic’’ microbiota
Hinata 2012 Faeces-PCR UC Healthy volunteers Enterococcus Lactobacillus
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Introduction: Anti TNF cross placenta during pregnancy and are detectable in the
newborn in the first 6 months at least. Along this, European consensus recom-
mends to avoid live vaccines within 6 months of live in newborn exposed in utero
to anti TNF treatments. Moreover, anti-TNF treatments are of low risk for
breastfed infants but data are scarce. The aim of our study was to evaluate the
rate and tolerance 1) of live-vaccines before and after 6 months of life in newborn
exposed in utero to anti TNF and 2) of breastfeeding under anti TNF.
Aims & Methods: We performed an observational and retrospective study in 22
French departments of gastroenterology from February 2016 to April 2017.
Included patients were inflammatory bowel disease (IBD) women, pregnant
under anti TNF, giving birth to alive newborn and agree to answer a question-
naire concerning 1) live-vaccines (BCG, rotavirus, MMR) in their child during
first year, 2) breastfeeding and complication and 3) information given during
pregnancy.
Results: 124 pregnant women treated with antiTNF were included. The mean age
of women was 31 year (IQR 5). 96 (77%) women received anti TNF for Crohn’s
disease and 28 (23%) for ulcerative colitis or undetermined colitis. AntiTNF used
were Infliximab in 76 (61%) patients, Adalimumab in 46 (37%) patients,
Golimumab in one patient (1%) and Certolizumab in one (1%) patient.
Thiopurine was associated in 29 (23%) patients. 31 (25%) patients experienced
flare of IBD during pregnancy, 18 (15%) women were treated with steroids.
AntiTNF was discontinued before 26 gestational weeks in 66 (53%) women
and resumed after delivery in 112 (90%) patients. 55 women (45%) breastfed
their infant and no complication was noted. Among 69 women who did not
perform lactation, 42 (63%) did not for personal choice and and 25 (37%)
because not recommended by the gastroenterologist. Concerning vaccination
questionnaires, 96 responses were obtained. BCG was performed in 29 children
(30%) and was administered before 6 months in 15 children (14%). One local
abscess was reported with favorable evolution. Rotavirus vaccination was per-
formed in 7 children (7%) and before 6 months in 5 (%) cases. One case of fever
was reported. MMR vaccination (Measles, Mumps and Rubella) was performed
in 62 children (65%); before 6 months in 5 cases. Information concerning fetal
exposure to antiTNF and vaccination recommendation was given to 111 (91%)
IBD women during pregnancy, by at least the gastroenterologist in 89% of cases,
the obstetrician in 25% of cases and the pediatrician in 16% of cases.
Information was at least oral in 105 (86%) cases and written in 39 (32%) cases.
Conclusion: Half of women breastfed their child with no reported complication.
BCG was administered in 30% of the newborn and performed before 6 months in
50% of cases, with only one case of local abscess. Rotavirus vaccination is rare
but often performed before 6 months. Information to pregnant IBD women is
only given by gastroenterologist in the majority of cases. Information in mater-
nity by obstetrician and pediatrician should be improved.
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Introduction: For a long time, dysplasic lesions in ulcerative colitis were only
treated by surgery. Recent guidelines recommend the complete endoscopic resec-
tion of dysplasic lesions in ulcerative colitis.
Aims & Methods: The aim of this study was to determine the outcome of dys-
plasic lesions resected endoscopic ally in ulcerative colitis. In this prospective
study between January 2008 and January 2015, dysplasic lesions detected in
patients with longstanding ulcerative colitis were assessed for their resecability,
then when it was possible were resected. The patients were followed, and an
endoscopic control was done at 6 month than every one year.
Results: 36 dysplasic lesions were identified in 25 patients; 5 lesions were judged
not resectable and reffered to surgery. 31 lesions were resected in 21 patients: 22
low-grade dysplasia, 7 lesions indefinite for dysplasia, and 2 high-grade dyspla-
sia. 18 patients (85.7%) had endoscopic control: mean 2.8 (maximum: 5 mini-
mum: 1). 2 patients refused next colonoscopy, one patient was not controlled
because of a bad bowel preparation for 4 times. In 13 patients (72.2%) no
dysplasia was detected after a mean follow up of 30.16 months (range: 7.56–
62.5). Neoplasic lesions were found in 5 patients (27.7%): one adenocarcinoma
of the sigmoid detected in a women that have had a high-grade dysplasia resected
in the sigmoid; in 3 patients new dysplasic lesions localized in other segments of
the colon than those initially resected. In one patient a serrated rectal adenoma
was found in the same place where was resected a serrated adenoma, reflecting an
incomplete resection.
Conclusion: Our results confirm that a complete endoscopic resection may be
sufficient in dysplasic lesions occurred in ulcerative colitis. Nevertheless a
closer follow-up is necessary because these patients may develop newer neoplasic
lesions.
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Introduction: Cytomegalovirus (CMV) infection has been associated to resistance
to several immunomodulatory therapies in Ulcerative Colitis (UC) patients. The
impact of CMV infection in UC patients treated with Vedolizumab is unknown.
The aim of this study was to analyze the outcome of UC patients treated with
Vedolizumab and to analyze the risk factors for CMV disease associated to
Vedolizumab therapy.
Aims & Methods: We performed a retrospective case-control study of all patients
with UC treated with Vedolizumab from June 2014 through November 2016 at
our IBD center. All eligible patients had presented latent CMV infection with
presence of IgG against CMV and undetectable CMV DNA load determined by
real time PCR (qPCR) in colonic biopsies before treatment. During the follow-
up, a colonoscopy or rectoscopy with sampling of 2 biopsies in inflamed tissue
was performed for each patient in case of loss of clinical response under
Vedolizumab. Patients with primary non response to Vedolizumab were
excluded. All patients with high mucosal CMV DNA load (4250 copies/mg of
tissue) were treated with valganciclovir. Patients with undetectable CMV DNA
load disease were considered as control group.
Results: Thirty two patients were eligible (sex ratio M/F: 3/1, mean age: 43.6
years, mean disease duration: 7.5 years, E3 phenotype according to the Montreal
classification: 90%). Six patients (19%) exhibited high colonic CMV DNA load
(median load: 734 copies/mg of tissue) during the first year of the follow-up and
were treated with valganciclovir for 6 weeks in association with continued
Vedolizumab treatment; the 26 others patients with a undetectable CMV DNA
load were included in the control group. After antiviral treatment, the CMV
DNA load was found undetectable for all 6 patients. Treatment change was
more frequent in the CMV disease group (HR¼ 3.15 [1.02–9.7], p¼ 0.03507)
with only 16.7% patients who continued Vedolizumab treatment versus 65.4%
in the control group (p¼ 0.052). Colectomy was also more frequent in the CMV
group (33.3% versus 7.7% p¼ 0.064). By multivariate analysis, the only factor
associated with the occurrence of CMV disease was a fecal calprotectin less than
600mcg/g stools at the beginning of the vedolizumab treatment. A previous
CMV colic infection also was more frequent but not statistically significant.
There was no association between CMV infection and Vedolizumab levels in
the sera.
Conclusion: The occurrence of CMV disease, documented with high CMV DNA
load on colonic biopsy samples, in UC treated with Vedolizumab is responsible
for a negative impact on the natural evolution of UC, with more therapeutic
failure and surgical treatment, even after an efficient antiviral treatment.
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Introduction: Gastrointestinal disorders may exhibit overlapping symptoms
making diagnosis difficult in the primary and specialty care settings.
Inflammatory bowel disease (IBD), with a prevalence of 50.5% in the general
population[1], is characterized by chronic inflammation of the gastrointestinal
tract, non-specific elevation of conventional inflammatory markers such as ESR
and CRP and may present with extra-intestinal manifestations. Irritable bowel
syndrome (IBS), in contrast, is a functional disorder without gastrointestinal
inflammation and with an estimated prevalence of 10–20% [2]. Endoscopy is
the gold standard for detecting and quantifying IBD vs. IBS, but due to the
low prevalence of IBD, is negative in the majority of cases. Furthermore, it is
invasive, expensive, and uncomfortable for the patient and not without risks.
Moreover, inadequate bowel preparation prior to colonoscopy is known to
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increase the burden of disease from both the clinical and the economic perspec-
tive: shorter intervals between repeated procedures, higher missed rates, patient
inconvenience, and increased risk of complications are reported in the scientific
literature. F-Calprotectin (FC) is a fecal marker of intestinal inflammation; IBD
patients exhibit FC levels significantly higher than the general population; IBS
patients have FC levels higher than healthy controls, but significantly lower than
IBD patients [3]. Therefore, FC can be used as a pre-endoscopic test to differ-
entiate between IBD and IBS. The present study aims at evaluating the cost-
effectiveness of FC compared to the combined usage of CRP and ESR, and the
gold standard to distinguish IBD from IBS in Spain.
Aims & Methods: An 18-week Markov model was developed for each diagnostic
strategy, simulating 1000 patients presenting to a primary care physician with
non-specific gastrointestinal symptoms. In the model, 1.6% of the colonoscopies
brought about complications [4], which may result in Emergency Room visits
and surgery. Inadequate colon preparation (23%)[5] and consequent repeated
colonoscopies (30.3%)[6] were also included in the calculations. Outcomes
include cost savings, cost per corrected IBD diagnosed, and colonoscopy reduc-
tion. Uncertainty was addressed with sensitivity analysis.
Results: FC is cost-effective when compared to CRPþESR, and to colonoscopy
(Table 1): It results in more correctly IBD diagnoses at a lower price; It reduces
the number of unnecessary endoscopies, increasing the number of correctly diag-
nosed IBD (N¼ 63) and IBS (N¼ 26) patients.
Clinical and health economics results
F-Calprotectin CRPþESR Colonoscopy
N correctly diagnosed IBS 683 657 900
N correctly diagnosed IBD 98 35 100
Total costs (EUR) 290 527 477 787 582 106
Average cost/patient (EUR) 290.5 477.8 582.1
Colonoscopy complication
costs (EUR)
1 978 2 269 6 313
N colonoscopies avoided 706.3 640.6 0
Savings ascribable to the
avoided colonoscopies
336 338 305 051 0
Conclusion: Results show that the usage of FC as pre-endoscopic diagnostic tool
is associated with fewer colonoscopies and correctly identifies more disease while
decreasing costs compared to the alternatives. Consequently, FC demonstrates
superior value both from patient and payer perspective, while simultaneously
increasing diagnostic efficacy.
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Introduction: The increased use of immunomodulators and biological agents for
the treatment of patients with inflammatory bowel disease (IBD) is associated
with a key safety concern considering potential serious infection. Healthcare
workers were thought to be at substantial risk for acquiring such infection due
to daily and close interactions with infected patients and asymptomatic carriers
of pathogens.
Aims & Methods: We performed a retrospective observational study, collecting
data from the Groupe d’Etude Thérapeutique des Affections Inflammatoires du
tube Digestif (GETAID) from January 2015 to June 2016, on all 482 consecutive
patients with IBD (68.5% with rohn’s disease, 28.4% with ulcerative colitis and
3.1% with IBD undetermined) who work as healthcare workers (27.2% of phy-
sicians, 33.0% of nurses; 13.1% of nurses’ aides and 26.7% of other healthcare
personnel working in interaction with in-hospital patients), in 17 tertiary centers
in France and Belgium. We selected a control group of patients with IBD who do
not work as healthcare personnel from the monocentric MICISTA database.
Controls were matched on age (2.5 years), sex, IBD type and date of IBD
diagnosis (2.5 years). Serious infection was defined as (1) Clostridium difficile
infection (2) community-acquired pneumonia (3) Mycobacterium tuberculosis
infection (4) any community-acquired infection that required hospitalization.
Serious infection-free survival was studied with Kaplan-Meier method, log-
rank test and Cox regression model. In each patient, the duration of IBD was
divided into semesters which were independently analyzed regarding the occur-
rence of serious infection too take into account the influence of various
treatments.
Results: 482 patients (126 male; median age: 24.0 [IQR 19.9–32.1] years) were
included in the present study. The median follow-up period was 9.3 [4.6–16.2]
years. A total of 74 serious infection was recorded in healthcare workers includ-
ing 14 Clostridium difficile infection, 19 EBV or CMV-related serious viral infec-
tion, 8 tuberculosis infection including 4 tuberculosis and 4 tuberculous primo-
infection, 8 community-acquired pneumonia and 25 miscellaneous serious infec-
tion. The probabilities of serious infection-free survival were 1.0%, 6.1%, 10.8%
and 14.1% at 1, 5, 10 and 15 years. No difference was found between healthcare
workers and control patients regarding the occurrence of serious infection in
time-dependent analysis and in independent semester analysis. However, a
increased risk of tuberculosis infection was found in healthcare workers (0.07
infections for 100 patient-years vs. 0.009, p¼ 0.02). In multivariate analysis,
serious infection was decreased in patients with Crohn’s disease (OR¼ 0.63,
IC95%[0.43–0.91], p¼ 0.01) and increased in patients treated with corticoster-
oids (OR¼ 3.05, IC95%[2.06–4.52], p5 0.001), immunosuppressant (OR¼ 1.98,
IC95%[1.38–2.84], p5 0.001) and anti-TNF agents (OR¼ 2.93, IC95%[2.02–
4.27], p5 0.001).
Conclusion: Although there is an higher exposure to potential pathogens in
healthcare worrkers, this is not associated with an higher risk of serious infection
as compared with controls with the exception of tuberculosis infection.
Prospective studies are needed to confirm that the level of occupational exposure
to potential pathogens should not be taken into account when discussing the
introduction of immunomodulator or biological agents with the exception of
the risk of tuberculosis infection.
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Introduction: Several endoscopic scores have been used to assess the severity of
inflammatory activity in Ulcerative Colitis (UC), however, few consider the
extension of the disease. Scores such as the Dublin Score (DS) and the
Modified Mayo Endoscopic Score (MMES) combine the severity of inflamma-
tion with the extent of the disease.
Aims & Methods: We aimed to calculate the correlation between the endoscopic
scores -Mayo Endoscopic Score (MES), DUBLIN, MMES and the biomarkers
of inflammation - erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP) and Calprotectin - and to compare the ability of these scores to predict
Calprotectin 4100 mg/g. This was a retrospective study, including patients with
diagnosis of left or extensive UC who underwent colonoscopy between 2015 and
2016. The biomarkers were obtained with a maximum interval of one week in
relation to colonoscopy and without introduction of new therapy. The Spearman
test calculated the correlation between scores and biomarkers. ROC curves
(AUC) were obtained for each score to predict Calprotectin4100 mg/g.
Results: 60 patients were included, 46.7% female patients with mean age
45.3 12.8 years with mean values of ESR 4.4 12.8mm, CRP 5.12 6.00mg/
l and Calprotectin 354 430 mg/g. The correlation between Calprotectin and
MES was rs¼ 0.623 p5 0.001, for DS rs¼ 0.548 p5 0.001 and for MMES
rs¼ 0.588 p5 0.001. Regarding CRP, a correlation with the MES was
rs¼ 0.415 p¼ 0.001 and with the MMES was rs¼ 0.404 p¼ 0.001, but no corre-
lation was found with the DS. There was no significant correlation between ESR
and endoscopic scores. To predict values of Calprotectin4100 mg/g the AUC for
the MES was 0.848, for the DS 0.801 and for the MMES 0.815, and there was no
statistically difference between the curves.
Conclusion: Although there is a good correlation between endoscopic scores and
Calprotectin, the correlation between scores that take into account the extension
were not superior to Mayo Endoscopic Score.
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Introduction: Although is not yet established, recent studies suggest an increase
prevalence of hepatic steatosis (HS) in patients with inflammatory bowel disease
(IBD). Factors such as chronic inflammation, previous surgeries, drug-induced
hepatotoxicity, malnutrition and intestinal dysbiosis seem to be involved in the
pathogenesis of this disease.
Aims & Methods: We aimed to assess the frequency of HS in IBD patients
quantified by CAP (controlled attenuation parameter) and by clinical-analytical
methods: Hepatic Steatosis Index (HSI) and Fatty Liver Index (FLI). A second-
ary aim is to investigate risk factors associated with HS in IBD patients. This was
a cross-sectional study that included consecutive outpatients that were observed
in our department between January and March 2017. Patients with known liver
disease or alcohol habits were excluded. HS was defined as HSI  36 or FLI 60
or CAP4 248.
Results: 149 patients included with mean age 40.7 13 years, 83 female (55.7%),
59.7% with Crohn’s disease (CD). 62 patients (41.7%) had CAP4 248.20
(13.4%) FLI4 60 and 40 (26.8%) HSI4 36. There were no differences in the
mean CAP value (244 54.2), HSI (33.3 5.18), and FLI (31.5 25.3) among
patients with CD and Ulcerative Colitis. We found that patients with CAP4 248
were more frequently obese (27.4% vs 0% p5 0.001), males (54.8% vs. 36.8%
p¼ 0.029) and presented more frequently metabolic syndrome (25% vs 4.6%
p5 0.001). Regarding the IBD factors, patients with HS had a higher frequency
of previous surgeries (30.6% vs16.1% p¼ 0.035). There were no differences
between hospitalization, duration of the disease, use of corticosteroids or other
IBD treatments.
Conclusion: In our cohort the frequency of HS varied between 13.4% and 41.7%
defined by non-invasive methods. We found that the presence of metabolic syn-
drome and obesity were more frequent in patients with HS. Regarding factors
related to IBD, patients with previous history of surgery were more frequently
diagnosed with HS.
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Introduction: Osteoporosis and fractures are common in Crohn’s disease (CD).
Recently, several inflammatory cytokines, including tumor necrosis factor
(TNF)-alpha have been linked to increased bone resorption. Therefore, it is
hypothesized that anti-TNF therapy may influence osteoporosis and fracture
risk. However, few studies have evaluated osteoporosis and fracture risk in the
CD population.
Aims & Methods: The aim of this study is to gain a better understanding of the
epidemiologic risk factors for osteoporosis and vitamin D deficiency in the era of
TNF-alpha inhibitors. We conducted a retrospective review of 714 consecutive
patients with CD in our GI clinic between 2008 and 2015 to identify 464 patients
who met the inclusion criteria for the study comprising of all adults older than 18
years with confirmed CD based on labs and endoscopic findings. Data extracted
for analysis included demographics data, disease phenotype, duration of disease,
measures of disease activity, imaging and endoscopic data. Statistical analysis
was performed using student t-test and chi-square test.
Results: We reviewed the charts of 290 patients with CD treated with TNF-alpha
inhibitors (TNF) and 174 patients who are anti-TNF naı̈ve (NB). There were 207
(45%) males and 257(55%) females in this cohort. TNF patients tended to be
younger (average age of 43þ/15 and 54 þ/18 years in TNF and NB groups
respectively). Mean duration of disease was 14.9 þ/10.2 for TNF and 18.6 þ/
19.2 for NB group. Approximately half of the patients had a smoking history.
Average BMI was 27.6 þ/6.6. Rates of vitamin D deficiency, insufficiency and
normal vitamin D-25-OH levels were not significantly different between TNF
and NB groups. Vitamin D level was not associated with age, duration of disease,
or inflammatory markers (ESR). However, there was a weak positive correlation
between nutritional status (lowest albumin) and vitamin D level (Pearson’s
R¼ 0.19). DXA scans were available for 168 patients which included 100 patients
in the TNF group and 68 patients in the NB group. There was similar rate of
osteoporosis (16% vs 18%), osteopenia (53% vs 57%) and normal bone density
(31% vs 25%) between the TNF and NB groups respectively. Furthermore, there
was no statistically significant difference in T-scores at the hip (1.2 vs 1.3), the
spine (1.0 vs 0.95), or the lowest T-scores (1.5 vs 1.4) between TNF and
NB patients. However, Z-scores at the spine (0.47 vs 0.05), the hip (0.55 vs
0.40) and the lowest Z-scores (0.91 vs 0.67) were lower in the TNF group,
but only reached significance at the spine (P¼ 0.03). Interestingly, a significantly
higher proportion of TNF patients under 60 years of age met the criteria for
osteoporosis (T-score5 2.5 below the mean) as compared to NB patients (15%
vs 3.6%). Additionally, rates of osteoporosis in the NB group were very different
before and after age 60 (3.6% vs 30%) [table 1]. There was no correlation with
bone density and vitamin D level, nutritional status (based on lowest albumin
level), or degree of inflammation (highest ESR or CRP levels). However, there
was a moderate positive correlation with BMI and bone density (Pearson
R¼ 0.39) and a negative correlation with age (R¼0.25).
Table 1): Osteoporosis rates in patients on anti-TNF therapy (TNF) and those
naı̈ve to biologic medications (NB) before and after age 60.
Group Age5 60 Age4 60
TNF 15.4% 18.2%
NB 3.6% 30.0%
Conclusion: Rates of vitamin D deficiency, and osteoporosis were similar among
patients on anti-TNF medications to those on no biologics. TNF group patients
were diagnosed with osteoporosis at an earlier age compared to NB group.
Patients on anti-TNFs also had statistically lower Z-scores at the spine.
Prospective studies are necessary to further determine the role of anti-TNF med-
ications in osteoporosis.
Disclosure of Interest: All authors have declared no conflicts of interest.
P0994 THE AVAILABILITY OF INFLIXIMAB TROUGH LEVELS IN
IBD PATIENTS ON MAINTENANCE THERAPY DEEPLY IMPACTS
THERAPEUTIC DECISION-MAKING
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Introduction: Infliximab (IFX) trough levels (ITLs) have emerged as a promising
tool for the management of inflammatory bowel disease (IBD) patients and they
correlate with clinical response and endoscopic remission. However, its use in
clinical practice is still under debate, particularly in clinically stable patients.
Aims & Methods: 1) to describe real-life ITLs in clinically stable IBD patients; 2)
to identify factors associated with infratherapeutic ITLs; and 3) to evaluate the
impact of ITLs availability by comparing the CCD with TLGD. The decisions
between experts were also compared. Both comparisons were calculated by the
linear Cohen’s Kappa () index. IBD patients on maintenance IFX therapy were
prospectively included from June 2015 to June 2016. Demographic, clinical and
biological data including C-reactive protein (CRP) levels from the same infusion
day were collected. At each IFX infusion, patients were visited by their physician;
a ‘‘current clinical decision’’ (CCD) was taken regarding clinical data and CRP.
ITLs were measured just before the IFX infusion and were considered as infra-
therapeutic if 52 mg/ml. Once ITLs were known, 3 experts took a hypothetical
decision on treatment based on the same clinical and biological data plus ITLs
(ITL-guided decision –TLGD-).
Results: A total of 224 IFX infusions from 74 patients (76% Crohn’s disease)
were analyzed. Median (IQR) disease and IFX therapy duration was 10 years (5–
18) and 23 months (7–61), respectively; 87% received concomitant immunosup-
pressant therapy; 70% were on standard dosing, whereas 10% were scheduled
every 4–6 weeks and 20% every 10–12 weeks. 60% of the patients were in clinical
and biological remission. Median (IQR) CRP levels were 3.1mg/mL (1.5–6.1).
Median (IQR) ITLs were 1.79mg/ml (0.35–3.74), with 52% of patients having
infratherapeutic ITLs. In the multivariate analysis, the only risk factor for infra-
therapeutic ITLs was the presence of biological activity. Concordance between
CCD and TLGD was poor (¼ 0.10 [95%CI:0.01–0.20]/¼ 0.11 [95%CI:0.01–
0.21]/¼ 0.10 [95%CI:0–0.21]) for experts A/B/C, respectively. This ‘‘dis-
agreement’’ was mainly due to a higher proportion of dose-escalations according
to the TLGD as compared to the CCD. Among the 203 infusions in which no
action was taken according to the CCD, 93 (40%), 48 (20%) and 65 (30%) would
have been dose-escalated according to the TLGD for experts A, B and C, respec-
tively. Moreover, concordance between experts was moderate (¼ 0.55
[95%CI:0.41–0.71]/¼ 0.40 [95%CI:0.26–0.55]/¼ 0.30 [95%CI:0.21–0.40]) for
experts A-B/B-C/A-C respectively.
Conclusion: Our results highlight the impact of the inflammatory burden on ITLs
and the need of re-defining their therapeutic range in patients clinically stable.
Both the clinical and economical impact of ITL-assisted decision-making in IBD
patients should be evaluated in prospective cohorts.
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Introduction: Recent studies recommend the histological mucosal healing of the
intestinal tissue as a treatment goal in ulcerative colitis (UC). The intestinal
activity in UC is usually evaluated based on conventional endoscopic findings
by white-light imaging (WLI). However, these findings are not always correlated
with the histological findings, and often tend to underestimate the inflammatory
activity in comparison to the histological findings. Linked-color imaging (LCI) is
a new endoscopy system that enhances the color differences of the gastrointest-
inal mucosa. We investigated the efficiency of LCI in the evaluation of the
intestinal activity, including the histological activity, in patients with UC.
Aims & Methods: Thirty-one UC patients underwent colonoscopy from August
to December 2016. Twenty-one UC patients, who were evaluated using an EC-
L600ZP endoscope with the LASEREO system (FUJIFILM Co., Tokyo, Japan),
were enrolled. All of the target lesions were observed by WLI and LCI, and
biopsy specimens were obtained from the lesions with the reddest tones in each
view. A total of 96 lesions were biopsied. We quantified the color tones on LCI
based on the L*a*b* color values (LCI-L, LCI-a, LCI-b), where L* a* and b*
represent lightness, red color, and yellow color, respectively. We also quantified
the color tones on WLI and LCI (WLI-L, WLI-a, WLI-b) based on the L*a*b*
color values. The endoscopic images were classified according to the Mayo endo-
scopic score (MES), and biopsied specimens were classified according to the
Geboes score. The endpoint of this study was to measure the correlation between
the L*a*b* color values and the (1) MES, (2) Geboes score, (3) mucosal healing,
and (4) histological healing. Furthermore, we defined MES 0 as inactive endo-
scopic disease, mucosal healing, and a Geboes score of 2 as inactive histological
disease, histological healing.
Results: (1) A moderate correlation was observed between the LCI-a and MES
values (r¼ 0.56, p5 0.001). (2) The Geboes score was moderately correlated with
the LCI-a value (r¼ 0.45, p5 0.001) and weakly correlated with WLI-a (r¼ 0.24,
p5 0.001), and WLI-b values (r¼ 0.28, p¼ 0.006). (3) The LCI-a and WLI-a
values were significantly higher in patients with active endoscopic disease than
they were in those with mucosal healing (p5 0.001). The area under the curve
(AUC) of the receiver operating characteristic (ROC) curve of LCI-a for mucosal
healing was 0.82, while the ROC-AUC of WLI-a was 0.71. (4) The LCI-a values
of was patients with active histological disease were significantly higher, in com-
parison to those with histological healing (p¼ 0.001). The ROC-AUC of LCI-a
for histological healing was 0.69. Moreover, WLI was not correlated with histo-
logical activity.
Conclusion: LCI was superior to WLI for predicting mucosal healing and histo-
logical healing. The findings suggest the utility of LCI in evaluating mucosal
inflammation in patients with UC.
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Introduction: Inflammatory Bowel Disease (IBD) patients live situations that may
trigger negative feelings and psychological malaise. ENMENTE Project aims
globally to improve identification and early management of psychological
impact in IBD patients followed in Spanish hospital gastroenterology clinics.
The aim of the study was to describe possible differences among perceptions
from physicians and patients about the clinical situations triggering anxiety in
patients with IBD.
Aims & Methods: During April 2016 two surveys were available on-line, one for
IBD patients, in the ACCU Spain website (Confederation of IBD Spanish
Patients’ Associations) and another one for physicians members of GETECCU
(Spanish Group for IBD treatment). Both invited their members to participate by
email and the patients’ survey was announced in social networks. The scientific
committee (3 gastroenterologists, 2 psychologists, 1 nurse and 1 patient) decided
which potentially stressful clinical situations were considered. Physicians and
patients rated these situations on a scale from 1 to 10 as potential triggers of
anxiety for the patient. A Mann-Whitney test was used to compare perceptions
from patients and physicians taking 151 valid questionnaires from physicians and
a randomized sample of 155 patients’ questionnaires.
Results: The survey was completed by 912 patients (mean age 39 (10) years,
67% women) and 170 physicians (mean age 44 (10) years, 58% women).
Having an ostomy, fecal incontinence in public or surgery are important triggers
of anxiety agreed between physicians and patients (table). Patients, however
experience anxiety from a possible new flare or from being fatigued, whereas
physicians are more concerned about anxiety due to telling about a new IBD
diagnosis and about pregnancy in IBD patients (table).
Mean scores from physicians and patients about clinical situations triggers
anxiety or depression
To what extent these clinical situations
may trigger anxiety or depression?
Physicians
(n¼ 151)
Patients
(n¼ 155) p-value
The lack of diagnosis 6.3 6.0 ns
The diagnosis of IBD 6.2 5.6 p5 0.05
The performance of an endoscopy 5.6 5.7 ns
The explanation of an ostomy 6.6 5.9 ns
A new oral treatment 4.8 4.8 ns
A new auto-injectable treatment 5.6 5.3 ns
A new intra-venous treatment 5.9 5.3 ns
A surgery 6.7 6.5 ns
Having an ostomy 6.9 6.6 p5 0.05
A pregnancy 5.9 4.0 p5 0.05
The pain 6.3 6.1 ns
An episode of public incontinence 6.8 6.6 ns
A new flare 6.2 6.5 p5 0.05
Changes in the body image 6.3 5.9 ns
Tiredness, fatigue, reduction in performance 6.0 6.3 p5 0.05
Conclusion: The main anxiety triggers in patients were having an ostomy, fecal
incontinence in public, a surgery, a new flare and the feeling of fatigue. These last
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two situations were scored higher by patients than by physicians. Teaching the
patient to identify and early manage a new flare and the treatment of fatigue are
aspects that would help to reduce the anxiety feeling and should be taken into
account in clinical practice Acknowledgements. Funded by Merck Sharp &
Dohme of Spain and endorsed by ACCU España and by GETECCU
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Introduction: Flixabi, an infliximab biosimilar referencing Remicade, was devel-
oped by Samsung Bioepis, the joint venture between Samsung BioLogics and
Biogen. SB2 received approval in EU for all approved indications of the reference
infliximab. Many decision algorithms based on the measure of Infliximab (IFX)
trough levels and antibodies to infliximab (ATI) have been increasingly used to
optimize infliximab in Crohn’s disease and ulcerative colitis. The aim of our
study was to appreciate if the biosimilar SB2 could be efficiently monitored
using the Lisa-Tracker infliximab and anti-infliximab immunoassays developed
by Theradiag (France).
Aims & Methods: During this evaluation, standard curves of Infliximab and two
different batches of SB2 were compared and then accuracy of the Lisa-Tracker
IFX kit in detecting the spiked concentration of SB2 was measured using the
Lisa-tracker assay. Levels of infliximab (from 5 spiked samples with known
amount of SB2 and 10 clinical samples from patients treated with infliximab)
were calculated according to each of the 3 standard curves (infliximab, SB2
batch1 and SB2 batch2). All samples and standards were tested in duplicate.
R2 must be 40.95 and the slope must be comprised between 0.9 and 1.1.
Intra-run and inter-run precision were also measured with spiked samples
of different known SB2 (from 2 to 12 mg/ml) amounts. Capacity of polyclonal
antibodies directed against infliximab to block the detection of SB2 using the
Lisa-Tracker infliximab assay and the capacity of SB2 to block the detection of
anti-infliximab antibodies using the Lisa-Tracker anti-infliximab assay were
tested.
Results: We demonstrated the perfect equivalence of infliximab standard curve to
the SB2 standard curve and that the Lisa-Tracker assay is suitable for the quan-
tification of SB2 in human serum samples (R2¼ 0.99; the levels of infliximab of
the 20 samples were calculated according to the 3 standard curves infliximab, SB2
batch 1 and SB2 batch 2 with CV ranged from 2.1 to 12.6%). Quantification of
SB2 is not affected by serum matrix and the % of recovery were comprised
between 82% and 113%. High intra-run and inter-run precision were obtained
with the Lisa-Tracker infliximab assay for the quantification of SB2 (CV ranged
from 3.3 to 17.9%). Finally, the capacity of polyclonal antibodies to infliximab to
block the detection of SB2 in 5 spiked samples was demonstrated with percen-
tages of inhibition comprised between 80% and 97%. The capacity of SB2 to
block the detection of anti-infliximab antibodies in 5 positive clinical samples was
also confirmed with high percentages of inhibition between 84% and 95%.
Conclusion: In conclusion, Lisa-Tracker Infliximab and anti-Infliximab assays
are suitable for the monitoring of patients treated with SB2.
Acknowledgements: Biogen provided the SB2 drug for this study. Biogen
reviewed the abstract and provided feedback to the authors.
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Introduction: If the association between trough levels of infliximab (TLI) and
clinical remission or mucosal healing is demonstrated, we don’t really know
the cause and effect between TLI and target value to obtain this association.
So, the aim of our study was to evaluate the causality or the association between
TLI and clinical remission.
Aims & Methods: We prospectively included all IBD patients treated in our IBD
unit and in clinical remission (CDAI5 150 for Crohn’s Disease (CD) or partial
mayo score5 3 for ulcerative colitis (UC) with biomarker normalization (fecal
calprotectin 5250 mg/g stools) or in deep remission (clinical remission with fecal
calprotectin 550mg/g stools). We analyzed median of TLI and fecal calprotectin
at the inclusion (M0) and 6 months before eligibility (M-6). We excluded patients
with deep remission at M-6.
Results: 111 patients were included (60 CD, sex ratio M/F: 0.8, 51 patients in
deep remission at M0). All these 111 patients were in clinical remission at M-6.
Median fecal calprotectin at M-6 were similar in the two groups of patients
(210 mg/g in the group of patients who achieved deep remission at M0 vs
220 mg/g in the group of patients who achieved only biomarker remission respec-
tively; p¼ 0.40). Conversely, median TLI at M-6 was significantly lower in
patients who did not achieved deep remission at M0 (2.8 vs 4.1 mg/L respectively;
p¼ 0.01). A ROC curve analysis was not able to isolate a cut-off value associated
to deep remission achievement. (AUROC¼ 0.61). Next, we analyzed separately
median of TLI and fecal calprotectin levels 6 months before eligibility (M-6) of
patients in deep remission at M0 (51 patients). The median TLI was significantly
lower at M-6 than at M0 (4.1 mg/mL vs 5.9mg/mL respectively; p¼ 0.03).
Conversely, median fecal calprotectin was significantly higher at M-6 in compar-
ison to M0 (190 vs 35 mg/g stool; p¼ 0.01). A negative and weak significant
correlation between fecal calprotectin and TLI wad observed (Spearman’s rank
correlation coefficient (q)¼ -0.25; p¼ 0.045).
Conclusion: Although TLIs may increase with decreased drug clearance due to
deep remission, we show for the first time that the residual rate is the causal
element for achieving clinical remission.
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Introduction: Fecal volatile organic compounds (VOCs) are gaseous carbon-
bound metabolic products considered to reflect intestinal microbiota composi-
tion. There is increasing evidence that VOCs may serve as non-invasive biomar-
kers for a broad range of gastrointestinal diseases. As smoking leads to a
substantial shift in intestinal microbial composition in healthy and diseased per-
sons, the aim of this study was to assess the effect of smoking status on fecal VOC
pattern.
Aims & Methods: In this cross-sectional pilot-study adult smokers, non-smokers
and former smokers scheduled for colonoscopy at the VU University medical
center were instructed to collect a fecal sample prior to bowel cleansing. Patients
were included if no abnormalities were found during colonoscopy. Exclusion
criterium was use of antibiotics three months prior to participation. All partici-
pants completed a questionnaire on standard demographics, BMI, diet and
smoking habits. Fecal VOC profiles were measured using an electronic nose
device (Cyranose 320).
Results: Fecal samples from 56 subjects (11 smokers, 21 non-smokers, 24 former
smokers) were analyzed. Median age was 62 years (27–82 years). Furthermore,
there were no significant differences between groups for the variables age, sex,
BMI, diet, sample weight, chronic diseases and medication and supplement use.
Fecal VOC profiles differed between smokers and non-smokers (PC1: p-
value¼ 0.003). Smokers could be distinguished from non-smokers based on
fecal VOC profiles was possible with an overall accuracy of 75% and correspond-
ing sensitivity and specificity values of 72.7% and 76.2%. No significant differ-
ences between the fecal VOC profiles from smokers and former smokers (PC1: p-
value¼ 0.083) and between profiles from non-smokers and former smokers (PC1:
p-value¼ 0.081) were observed.
Conclusion: This study showed that smoking status has a significant influence on
fecal VOC profiles. This implicates that the smoking status should be taken in
account when performing (fecal) VOC analysis. The finding that VOC profiles
did not differ between smokers and former-smokers could be due to the wide
divergence (6 month – 43 years) in smoke-free time in former smokers group.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The prevalence of Clostridium difficile infection (CDI) in patients
suffering from inflammatory bowel disease (IBD) has increased rapidly over the
past several decades. However, the exact global epidemiology remains unclear
because of insufficient data from developing countries.
Aims & Methods: The goal of our study is to examine the incidence of CDI in
patients with IBD. A retrospective, observational study evaluating IBD patients
in a referral center was performed to evaluate the incidence of Clostridium diffi-
cile. Diagnosis was confirmed with stool toxin analysis. Demographic informa-
tion, diagnosis, anatomic location, IBD therapy, antibiotic exposure,
hospitalizations, and surgeries were recorded. For a period of 3 years 202 IBD
patients were studied, 105 of which have UC and 97 - Chron’s disease (CD). We
used the Clostridium difficile Glutamat DehydrogenaseþToxin AþB based on
the principle of quantitative immunochromatographic assay for the determina-
tion of Clostridium difficile Glutamat Dehydrogenase, Toxin A and Toxin B in
stool samples.
Results: The results show that all patients with a positive CDI test have a clinical
picture, which resembles a relapse of the disease (o5 0.05). There’s a tendency
towards growth in the incidence of IBD patients who are CDI positive. Their
number in 2016 is significantly higher than that in 2014. In 2014 it was 5.90%
with CD and 12.50% with UC, whereas in 2016- 12.20% with CD and 27.80%
with UC (o5 0.05). The results show that the incidence of CDI patients with UC
is significantly higher than in patients with CD, respectively 18.1% to 9.30%
(o5 0.05). There is a stong correlation between CDI incidence in patients with
IBD and the severity of their disease. Patients positive for CDI have a much more
severe course of the disease, UC (46.40%) and CD (24.20%) (o5 0, 05).
Conclusion: There is an increase in incidence of CDI, and patients with UC are
more affected by it. The results of our study are confirmed by other authors as
well. A significant part of patients with CDI have a severe disease that needs
extra prospective researches to determine the incidence and influence of the
infection amongst patients with IBD, who receive different therapy regimes
and also to understand how the CDI affects the evolution of the disease.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: There is no blood test predictive of sustained clinical remission in
patients with Crohn’s Disease (CD) or Ulcerative colitis (UC) under Infliximab
(IFX) - azathioprine (AZA) combotherapy.
Aims & Methods: All patients with CD or UC, consecutively treated by the
combination of IFX-AZA between August 2015 and March 2017, were included
in this monocentric study. Clinical, biological (blood cells count, liver function
enzymes, C-reactive protein (PCR)) were retrospectively collected at baseline, at
week 14 (W14) and at 6 months (W24) from the start of combination therapy.
Trough level of IFX (TLI) at W14 was also recorded. Sustained clinical remission
was defined as clinical remission for 6 months under combotherapy with no need
of AZA dose modification, nor therapeutic switch or need for surgery. A pre-
dictive score before combotherapy was developed basing on receiver operating
characteristic (ROC) curves and logistic regression analyses.
Results: Of 71 patients enrolled (median age: 36.3 yrs; women: 52.5%; CD:
61.3%; current tobacco: 28.7%), 58 (81.7%) experienced sustained clinical remis-
sion. The clinical biological score was calculated at baseline by adding attributed
points for these variables as follows: alkaline phosphatase 58UI/L (11 pts),
lymphocytes 1.2 109/L (6 pts), red blood cell count5 4.4 1012/L (5 pts),
mean corpuscular volume 487 fl (4 pts), white blood cell count 59.3 109/
L(4.5 pts), neutrophils55.0 109/L (4 pts), body mass index4 22 kg/m2 (3
pts), platelets count5 330 109/L (3 pts), PCR4 3.7mg/L (3 pts) and
Gamma-glutamyl transpeptidase 530UI/L (3 points). A total score 17 was
predictive of sustained clinical remission with good performance (Area under
the curve (AUC): 90.1% [95%CI: 81.8%98.5%]; sensitivity (Se): 81.3%, speci-
ficity (Sp): 90.9%; Positive predictive value (PPV): 97.7%; Negative predictive
value (NPV): 50%); especially in UC patients (AUC: 98.2% [95%CI:
93.9%100%], Se: 90.5%, Sp and PPV: 100%; NPV: 66.7%). Corresponding
outcomes for CD were also satisfying (AUC: 83.9% [95%CI: 70%97.8%], Se:
75%, Sp: 85.7%, PPV: 96%; NPV: 42.9%). In contrast, performance of TLI at
W14 (42.87mg/mL) for the prediction of sustained clinical remission were mod-
erately interesting (AUC: 60.9% [95%CI: 38.7%83.1%]; Se: 79.3%, Sp: 61.3%;
PPV: 90.2%; NPV: 40%). These results were not significantly different between
patients who had received an AZA monotherapy before combotherapy com-
pared to those who did not.
Conclusion: This new score is a promising tool for the prediction at baseline of
sustained clinical remission in inflammatory bowel disease patients who start
combotherapy. It may help to identify easily patients who should benefit opti-
mization of IFX rather than early switch treatment in this setting. However, a
prospective validation is needed before recommending its use in clinical practice.
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Introduction: Young patients commonly present with lower gastrointestinal
symptoms to gastroenterology clinics nationwide. Most colonoscopies in such
patients are normal, but risk potentially serious complications. There is an over
reliance on endoscopy in clinical practice leading to increasing demand on limited
resources. As a result, some patients with potentially life-threatening conditions
(e.g. colon cancer) may have a significant delay in diagnosis that may result in a
worsened prognosis. Many endoscopic procedures are absolutely necessary, but
many might be avoided if other, non-invasive forms of investigations were avail-
able which could reliably exclude significant pathology. This in turn could lead to
reduced waiting times and improved access for those who really need them.
Aims & Methods: We aimed to assess colonoscopies, relevant faecal and blood
tests in young patients with lower gastrointestinal symptoms. Colonoscopies
performed over a 1-year period were retrospectively identified from the
Endoscopy Reporting System. Patient charts, faecal calprotectin (FC), C
Reactive Protein (CRP), and Coeliac serology were reviewed. A raised
CRP4 5mg/L or FC of 50 ug/g was considered abnormal. A Colonoscopy
with mucosal inflammation confirmed on histology was considered abnormal.
Inclusion and exclusion criteria are in table 1.
Table 1: Study criteria
Inclusion criteria Exclusion criteria
Age 45 years Known Iron deficiency anaemia
Presenting complaint: diarrhoea,
constipation and abdominal
pain/bloating
Overt or obscure GI bleeding
Known Inflammatory
Bowel Disease
Results: 2155 medical GI outpatient colonoscopies performed over 12 months
were identified. 242 met inclusion criteria for the study. Median age of the patient
cohort was 34 years (range 16–45), with 141 (58%) females. The cohort was
stratified according to indications; Group A; 132 (55%) patients with diarrhoea
predominant symptoms, and Group B; 110 (45%) patients with constipation,
abdominal pain and bloating. Colonoscopy was normal in 104 (79%) of
Group A and 102 (93%) of Group B (p¼ 0.002). 36 (15%) Colonoscopies
were abnormal; 7 patients had active ileitis, 22 had colonic inflammation (12
IBD, 2 lymphocytic colitis, 8 non-specific inflammation), and 7 had ileocolonic
inflammation (all diagnosed with IBD). 28 of 36 (78%) patients with mucosal
inflammation confirmed on histology had diarrhoea (p¼ 0.0001). FC was avail-
able in 36 patients, and CRP in 171 patients. In group A the negative predictive
value, positive predictive value and specificity of CRP/FC were 88%, 43% and
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86% respectively. In group B these figures were 95%, 38% and 95% respectively.
21 patients had incidental early adenomatous polyps. 180 (74%) patients were
investigated for Coeliac Disease. 4 had positive findings: 3 in Group A and 1 in
Group B. One patient in Group A had both coeliac disease and lymphocytic
colitis.
Conclusion: Colonoscopy has low yield in young symptomatic patients, especially
those with non–diarrhoeal symptoms. Non-invasive tests should be used system-
atically to better identify patients requiring colonoscopy. We are conducting a
prospective study to explore non-invasive diagnostic paradigms. Implementation
of these strategies will help reduce colonoscopy waiting times.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: As surgical resection is not curative in Crohn’s disease (CD), post-
operative recurrence (POR) remains a crucial issue. The POCER trial (1) has
recently confirmed that the therapeutic management has to be adapted according
to endoscopic findings within the first year following surgery to prevent POR.
However, as colonoscopy is a burdensome procedure, alternative tools have been
developed such as faecal biomarkers and magnetic resonance imaging (MRI).
Aims & Methods: We aimed to assess the performances of MRI and faecal
calprotectin to detect endoscopic POR in CD patients. Adult CD patients
from two tertiary centers who underwent ileal or ileocolonic resection were con-
secutively included in this prospective study. All the patients underwent magnetic
resonance enterography including diffusion-weighted sequences with apparent
diffusion coefficient (ADC) calculation (mm2/s) and evaluation of Clermont
score (2), MaRIA (3) and MR score (4) within the first year after surgery or
restoration of intestinal continuity (median¼ 6 months IQR[5.0–9.3]).
Colonoscopy and MRI were performed within a median time of 14 days IQR
[6.5–31] and stools were collected for faecal calprotectin measurement the day
before the colonoscopy.
Results: Overall, 30 CD patients were enrolled in the study. Among them, 15
(50.0%) were female and 7 (23.3%) were active smokers. Disease location was
ileal, colonic or ileocolonic in 15 (50.0%), 1 (3.3%) and 14 patients (46.7%),
respectively. The patients included in this study were treated with no medication
(20.0%), 5-ASA (6.7%), thiopurines (56.7%) or anti-TNF agents (20.0%) in
preventing endoscopic POR. Within the first year after surgery, endoscopic find-
ings according to Rutgeerts index were i0 for 8 patients (26.7%), i1 for 5
patients(16.7%), i2a for 4 patients (13.3%), i2b for 6 patients (20.0%), i3 for 5
patients (16.7%) and i4 for 2 patients (6.7%). In defining endoscopic POR as
Rutgeerts index i2, ADC value (2.22 vs 2.12; p¼ 0.35), related contrast
enhancement (RCE) (77% vs 119%, 0.056), Clermont score (9.3 vs 7.9;
p¼ 0.11), MRI score (p¼ 0.57) and MaRIA (5.3 vs 6.4; p¼ 0.21) were not sig-
nificantly different in patients with endoscopic POR. Using Rutgeerts index i2b
as cut-off value to define endoscopic POR, ADC mean value was lower in
patients with endoscopic POR (i2b) (2.03 vs 2.27, p¼ 0.032). Clermont score
(7.4 vs 10.4, p¼ 0.038) and related contrast enhancement (RCE) (75% vs 132%,
0.01) were higher in patients with endoscopic POR (i2b). In contrast, MaRIA
(5.0 vs 7.3; p¼ 0.15) and MRI scores (p¼ 0.17) were not significantly higher in
patients with endoscopic POR (i2b). In case of severe endoscopic POR (i3),
RCE (87% vs 135%; p¼ 0.046) was increased while none of the following MRI
parameters was significantly different: ADC (2.05 vs 2.20; p¼ 0.18), Clermont
score (8.0 vs 11.0; p¼ 0.14), MaRIA (5.3 vs 7.8; p¼ 0.25) and MRI score
(p¼ 0.11). Faecal calprotectin values were significantly higher in patients with
endoscopic POR defined as i2 (87.8 vs 314.9 mg/g; p¼ 0.0064), i2b (92.6 vs
366.1 mg/g; p¼ 0.0075) or in patients presented with severe endoscopic POR i3
(98.8 vs 544.4 mg/g; p¼ 0.0003). CRP value was not significantly higher in
patients with endoscopic POR defined as i2 (2.5 vs 5.9; p¼ 0.10) and i2b
(3.2 vs 6.2; p¼ 0.43), but was increased in patients with severe endoscopic
POR (3.0 vs 9.8; p¼ 0.02). Using ROC curves, we determined the best thresholds
and their performances to detect endoscopic POR (Table 1).
Table 1: Performances of MRI parameters and faecal calprotectin to detect
endoscopic postoperative recurrence in Crohn’s disease
AUC Se Spe NPV PPV
Detection of Rutgeerts i2
Clermont score4 8.4 0.70 36% 77% 47.6% 66.7%
MaRIA4 7 0.67 29% 77% 45.5% 62.5%
Faecal calprotectin 4100 mg/g 0.84 60% 100% 64.7% 100%
Detetection of Rutgeerts i2b
Clermont score 48.4 0.73 47% 82.4% 66.7% 66.7%
MaRIA 47 0.70 38.5% 82.4% 62.5% 63.6%
Faecal calprotectin 4100 mg/g 0.79 66.7% 92.9% 76.5% 88.9%
Detection of Rutgeerts i3
Clermont score 48.4 0.67 42.9% 73.9% 81% 33.3%
MaRIA 47 0.63 42.9% 78.3% 81.8% 37.5%
Faecal calprotectin 4100 mg/g 0.96 100% 89.5% 100% 77.8%
Conclusion: Faecal calprotectin and MRI are reliable tools to detect endoscopic
POR in CD patients and could be used as non-invasive alternative options to
colonoscopy.
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Introduction: PEG preparations reduce the acceptability of endoscopic explora-
tions but remains recommended before performing a small bowel videocapsule
(SBVC). No study has evaluated its impact on the small bowel cleanness com-
pared to other modalities in patients with Crohn’s disease (CD). The objective of
this study was to compare three methods of preparation, one using polyethylene-
glycol and two simplified methods in adult patients with CD.
Aims & Methods: Three methods of preparation i.e. low-residue diet the evening
before more 1 L PEG before the capsule (PEG), liquid diet the evening before the
capsule (LD) and 1.5 L of water at the time of the capsule (Water) were com-
pared. All patients were prospectively included and had an SB3 (Medtronic)
capsule after the ingestion of a Patency Agile TM capsule. The small bowel was
identified between the 1st duodenal and the 1st cecal images or the last recorded
image and was separated into 3 equal segments. A standardized quantitative
cleanliness score was calculated rating the luminosity, the presence of bubbles,
turbid liquids, food residues and the percentage of visible mucosal surface in the
entire small bowel and in each tertiles. The quantitative score ranged from 0
(worse) to 10 (best) and a qualitative score was obtained rating the cleanness
in excellent, good, fair and poor. After anonymization of the films, the recordings
were randomized and re-read by 4 investigators blinded to the mode of prepara-
tion. The demographic and clinical characteristics of the patients were collected
at the time of the capsule. The cleanness scores were compared on the whole
small bowel and on each segment.
Results: Between January 2015 and August 2016, 97 patients (38 men, mean age
40.8yrs) were included and performed 105 capsules with 35 capsules in each
group of preparations. The groups were comparable concerning the clinical
and demographic characteristics (sex ratio, disease duration, history of intestinal
resection, phenotype, treatment, indication of the capsule). The mean duration of
the small bowel transit time was comparable between the three groups (198min
(PEG), 245min (LD), 226min (Water) (P¼ 0.102). The endoscopic activity of the
disease was comparable between the 3 groups (P¼ 0.358). The cecal intubation
rate was significantly lower in the PEG group 66% versus 91% (LD) and 94%
(Water) (P¼ 0.04). No capsule impaction was observed. The mean quantitative
cleanliness score for the whole small bowel was not significantly better for the
PEG group (5.7) compared to the other modalities LD (6.3) and Water (6.5)
(P¼ 0.262). In the first tertile, the quantitative score was significantly better in
the LD (7.9) and Water (7.6) groups compared to the PEG group (6.8)
(P¼ 0.043). The preparation by water was considered qualitatively better com-
pared to the two other modalities (P¼ 0.04).
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Conclusion: This is the first study evaluating the relevance of PEG preparation in
a large population of adult patients with CD. Our study has demonstrated that
there is no benefit in using PEG for the preparation of the small bowel before the
capsule in patients with CD. Quantitatively, the two simplified preparation meth-
ods were more efficient than the preparation with PEG and qualitatively, the
preparation using water was considered as the most efficient.
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4Gastroenterology, Instituto Maimónides de Investigación Biomédica, Córdoba/
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Introduction: Bile acid malabsorption (BAM) is a well-known disorder associated
to inflammatory bowel disease patients, however, it is underdiagnosed in clinical
practice. 75SeHCAT test is the current clinical gold standard for diagnosing bile
acid diarrhoea widely used in Europe.
Aims & Methods: We aimed to analyze the incidence of BAM in Crohn’s disease
(CD) patients with chronic diarrhoea through 75SeHCAT and to assess whether
there is a relationship between the malabsorption degree and the presence of ileal
resection. We analyzed, retrospectively, 30 patients with CD and chronic diar-
rhoea with and without ileal resection during the period between August 2015-
April 2016. In all patients, an inflammatory activity was previously discarded
through biomarkers and endoscopy/MRI. No patients had received treatment
with bile acid sequestrants (Cholestyramine) before the study. We perform the
test after the ingestion of a 75SeHCAT capsule (0, 37 MBq) prior fasting the night
before. Seven-day measurements were compared with 3 hours activity to calcu-
late the abdominal retention percentage. The interpretation of the retention
results was made considering 10% BA is consistent with a normal result.
Mild BAM is considered 7–10%, moderate 4–7% and severe 54% retention
at seventh day measurements. Epidemiological and clinical data were collected
from the local database ENEIDA.
Results: We studied 15 women and 15 men with mean age of 46.5 years old (26–
58). The median duration of the disease was 13 years (2–27). At diagnosis, ileal
location was present in 50% of the patients, ileocolonic 40% and colonic in 10%.
According to the behavior of the disease, 50% presented non-stricturing no-
penetrating, 23% stricturing and 27% penetrating pattern, and 43% patients
had perianal disease. In relation with smoking status, 34% were active smokers.
Regarding actual treatment, 40% of the patients are controlled with only immu-
nosuppressive drugs, 10% with biologics, while 20% used combotherapy. 83.3%
of the patients had undergone ileal resection. Median length of intestinal resec-
tion was 24 cm (2–80). Six of them needed more than one intestinal resection
during the evolution of the disease. Median time from CD diagnosis to surgery
was 24 months (0–192 months). In the total number of patients, the median of
depositions was 6 per day (2–10). After performing 75SeHCAT scan, 96.8% of
patients demonstrated abnormal values defined as510% abdominal retention of
75SeHCAT after seven days. All patients with ileal resection had BAM but also
the majority of patients without resection (86%). 92% of patients with ileal
resection had severe malabsorption and 8% moderate malabsorption. 72% of
patients without resection had severe malabsorption, 14% moderate malabsorp-
tion and 14% had normal retention. There was no statistical association
(p¼ 0.253) between 75SeHCAT retention and intestinal resection.
Conclusion:
75SeHCAT is an useful procedure for diagnosing BAM in patients
with CD and chronic diarrhea. High incidence of BAM is present in CD patients
and there was no significant association between 75SeHCAT retention and per-
forming surgery.
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Introduction: Linked Color Imaging (LCI) is a novel image-enhanced endoscopy
technique which increases distinctiveness of the mucosal color of endoscopic
images. The aim of this study is to investigate the usefulness of LCI to evaluate
the activity of mucosal inflammation in ulcerative colitis (UC) patients
Aims & Methods: Totally, 10 consecutive patients with inactive or mildly active
UC were enrolled, and fifty-three areas were assessed by LCI. All examinations
were conducted with a LASEREO endoscopic system (FUJIFILM CO., Tokyo,
Japan). During the colonoscopy, each region of interest (ROI) of terminal ileum,
cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and
rectum was observed by both white light imaging (WLI), and LCI. The
Commission international de l’éclairage (CIE) LAB color differences (C)1)
were calculated among WLI and LCI in each ROI. After ROI was observed
by colonoscopy, the biopsy specimen was taken in each ROI. Inflammatory
cell infiltration, erosion, crypt abscesses, and goblet cell depletion were assessed
as the histologic findings of acute inflammation. For evaluation of chronic
inflammation, crypt atrophy, crypt distortion, and basal plasmacytosis were
assessed. The correlation between C and Mayo endoscopic sub-score was
assessed, indicating that the higher C mean easier color difference for
recognition.
Results: The mean age of patients who were enrolled in the present study was
41.6 17.7 years. The sex ratio (men/women) was 4: 6. The type of extent of UC
(ulcerative proctitis/left-sided UC/extensive UC) was 0:3:7. 1.Correlation
between CIELAB color differences and histology. The mean C of ROI without
inflammatory cell infiltration was significantly higher than that of ROI with
inflammatory cell infiltration (15.9 4.9 vs. 12.5 6.7, p¼ 0.046). The mean
C was not affected by histological findings of erosions, crypt abscesses,
goblet cell depletion, crypt atrophy, crypt distortion, and basal plasmacytosis.
LCI distinguished colon mucosal white color compared to WLI with use of three-
dimensional color space, indicating the remission-colon mucosa of UC with no
inflammatory cell infiltration in ROI was easily detected by LCI. 2.Correlation
between CIELAB color differences and Mayo endoscopic subscore. Low Mayo
endoscopic sub-scores tended to be inversely proportional to high C (C:
15.5 4.9, 11.8 5.1, 13.0 , 9.1 5.3), but not significant in the present evalua-
tion. The colon mucosa with the low Mayo endoscopic sub-scores were relatively
easily detected by LCI compared to WLI.
Conclusion: The present pilot trial indicated that the inactive UC mucosa could
be easily detected as the white area by the LCI mode compared to WLI, suggest-
ing that LCI might be one of novel approaches for evaluation of disease activity
of UC.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: There is an ever growing body of evidence that indicates that Health
Related Quality of Life (HRQoL) is significantly impaired in IBD. While clinical
variables and disease activity status influence HRQoL, a host of psychosocial
and personality variables also play an important role. This contention is sup-
ported by evidence of impaired HRQoL and disability in IBD patients in the
absence of demonstrable disease activity. Moreover, individual differences may
play a key role in the psychological adaptation to living with IBD and coping
with the psychological distress associated with the disorder. Sense of coherence
(SOC) is an emerging theoretical and dynamic construct that seeks to explain
why some individuals in the face of adversity experience illness while others do
not. Antonovsky’s theory of SOC suggests that individuals with strong SOC
exhibit effective and flexible coping strtaegies when faced with stressors (e.g.
chronic medical condition) whereas those with weak SOC are less likely to
adapt to health stressors and have less motivation when confonted with chal-
lenges to their health. While a number of studies have shown that SOC appears
to have an impact on HRQoL, data regarding this association in IBD are limited.
Aims & Methods: The goal of the current study was to examine the associations
between an individual’s sense of coherence, and their overall health-related qual-
ity of life. The first part of this analysis looked at whether sense of coherence
accounted for more of the variance in disability level, and an individual’s illness
perception, as compared to other reported psychosocial factors. The second part
of this study evaluated whether sense of coherence, as well as illness perception,
were associated with an individual’s self-reported quality of life, and if this inter-
action was moderated by the individual’s level of anxiety. Additionally, the
correlations between sense of coherence, and self-efficacy, as well as self-reported
emotional intelligence were also were further evaluated. This is a cross-sectional
observational cohort of IBD patients attending MUHC (McGill University
Health Center) IBD outpatient clinics. The patient population (N¼ 95) demo-
graphics are as follows: mean age (42.4 12.44), gender (40.6% male), disease
type (58.4% CD, 33.7% UC), disease activity (27.7% active, 65.3% inactive).
Patients completed multiple validated questionnaires pertaining to a variety of
psychosocial parameters. Data was analyzed by multiple linear regression using
statistics software (SPSS version 17.0).
Results: Preliminary analyses of this patient population reveal that 40.2% of the
variance in level of disability is explained by sense of coherence. This model
suggests a significant negative correlation between sense of coherence and level
of disability (ß¼0.64, p5 0.05). A smaller, albeit significant contribution of
sense of coherence with illness perception was additionally found (14.1% of the
variance, and ß¼0.39, p5 0.05). Furthermore, 32.3% of the variance in self-
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reported quality of life was explained by sense of coherence (ß¼ 0.43, p5 0.05)
and illness perception (ß¼0.28, p5 0.05). However, the individual’s report of
anxiety did not moderate this relationship. Significant positive correlations
between sense of coherence and self-efficacy were also seen in this patient popu-
lation (r¼ 0.61, p5 0.01), as well as with self-reported emotional intelligence
(r¼ 0.52, p5 0.01).
Conclusion: These data indicate that Sense of Coherence is an important psycho-
logical construct that is associated with HRQoL and disability in IBD. Screening
for these factors, in addition to the physiological markers, should be considered
in order to provide the most holistic treatment strategies.
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Introduction: Inflammatory bowel disease (IBD) is primarily assessed by endo-
scopy, which is a costly and invasive procedure with serious risk of complication,
underlining the need for novel non-invasive diagnostic biomarkers. In previous
studies, plasma amino acid analysis has revealed significant differences between
IBD subjects and controls. This ‘aminogram’ has not yet been studied in faecal
samples of IBD patients. The aim of this explorative study was to compare faecal
amino acid composition between paediatric de novo IBD patients and healthy
controls, and between the phenotypes ulcerative colitis (UC) and Crohn’s disease
(CD).
Aims & Methods: In this cross-sectional case-control study, paediatric treatment
naı̈ve IBD patients from a tertiary centre were included, before bowel cleansing
and colonoscopy. Control patients were recruited from schools in the province
North Holland, the Netherlands. All participants collected a faecal sample on
which amino acid analysis was performed by means of high performance liquid
chromatography (HPLC, Biochrom 30). To correct for the influence of faecal
consistency, the samples were freeze dried for 24 hours before the analysis was
performed. To prevent bias by peak overlap of different amino acids, outcomes
of 5 nmol/mg or lower were excluded from further analysis.
Results: Faecal samples from 15 subjects (5 healthy, 5 UC, 5 CD) were analysed.
Median age was 14 (8–17) years. Subjects and controls were matched on age and
sex. A total of 42 different amino acids were analysed, of which 30 were excluded
due to quantities of 5 nmol/mg. In particular, alanine, glycine, phenylalanine,
leucine, isoleucine, valine and lysine differed between IBD patients and healthy
controls with ratios up to 5:1 (table 1). In addition, UC and CD patients differed
remarkably based on levels of glycine, phenylalanine and serine with ratios up to
4:1 (table 1).
Table 1: Levels of amino acids in patients with Crohn’s disease, ulcerative colitis
and healthy controls
Amino acid
healthy
controls
median
ulcerative
colitis
median
Crohn’s
disease
median
Alanine 2.07 (1.88–4.39) 5.28 (3.31–10.38) 8.21 (4.59–13.05)
Phenylalanine 0.48 (0.48–1.46) 1.37 (1.07–3.09) 2.62 (1.74–3.91)
Glycine 1.06 (0.91–2.65) 1.91 (1.10–3.58) 5.28 (2.17–5.97)
Leucine 1.00 (0.86–2.88) 3.04 (2.34–5.32) 4.13 (3.80–7.45)
Isoleucine 0.76 (0.09–2.15) 1.69 (0.88–2.01) 3.07 (1.68–4.56)
Valine 0.96 (0.76–2.61) 2.43 (2.35–5.19) 4.41 (3.29–6.64)
Lysine 1.72 (1.21–4.03) 2.63 (1.27–5.64) 4.62 (2.27–8.04)
Serine 0.81 (0.52–1.69) 1.08 (0.97–1.96) 2.57 (1.48–4.57)
all levels are displayed in nmol/mg
Conclusion: This was the first pilot study to assess the potential of the faecal
aminogram as non-invasive biomarker for disease activity of paediatric IBD. We
observed remarkable differences in faecal amino acid composition between IBD
patients and healthy controls, and between the IBD phenotypes. Whether these
differences reflect decreased absorption or increased loss by inflamed intestines
needs to be elucidated. Currently, we are awaiting the results of a larger proof-of-
concept study on these faecal amino acid profiles.
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Introduction: Measurement of infliximab trough levels (IFX-TLs) and antibodies
to infliximab (ATIs) has been suggested as an important parameter for the opti-
mization of IFX treatment of patients with inflammatory bowel disease (IBD).
Aims & Methods: We aimed to cross-sectionally investigate the correlation
between IFX-TLs or ATIs and clinical, biochemical as well as endoscopic activity
in Greek IBD patients. Consecutive IBD patients on maintenance treatment with
IFX, were included. IFX-TLs and ATIs were measured using ELISA (Eagle
BioSciences, Nashua, NH, USA) on serum samples drawn before infusion. At
the same time quality of life using short IBD questionnaire (SIBDQ) and clinical
disease activity using Harvey-Bradshaw Index (HBI) for Crohn’s disease (CD) or
simple colitis activity index (SCAI) for ulcerative colitis (UC) were assessed.
Moreover, biomarkers (hemoglobin, ESR, CRP, platelets, albumin) were mea-
sured and latest colonoscopies (within 6 months) were reviewed and evaluated for
presence or not of mucosal healing.
Results: A total of 74 patients receiving IFX maintenance therapy [55 CD, 19
UC, 49 males, mean age 42.3 years, 45 on combination therapy with immuno-
modulators (IMMs), 10 under intensified dose (either 10mg/kg/8w or 5mg/kg/4–
6w)] were studied. Median time since IFX initiation was 26 (13–71) months and
median value of serum IFX-TL was 4.83mg/ml (0.03–30.7). Seven out 74 (9.5%)
were positive for ATIs (410tAU/ml). Patients on combination treatment had
significantly higher IFX-TLs (6.98 mg/ml, 0.34–30.7) compared to those on IFX
monotherapy (1.85mg/ml, 0.09–25.8) (p¼ 0.01). Patients with positive ATIs had
median IFX-TLs 0.99mg/ml (0.09–1.40) statistically lower compared to those
with negative ATIs (6.01mg/ml, 0.03–30.69) (p¼ 0.0005). The correlations of
IFX-TLs and ATIs with clinical, biochemical and endoscopic indices of disease
activity in IBD patients are presented in Table 1. No other significant correla-
tions of IFX-TL or ATIs with other disease characteristics were observed. In the
logistic regression analysis only IFX-TLs (OR 0.86, 95% CI 0.76–0.97 p¼ 0.017)
and duration of IFX treatment (OR 0.97, 95% CI 0.95–0.99 p¼ 0.04) were
independently correlated with the presence of mucosa healing.
Table 1: Correlations of infliximab trough levels and antibodies to infliximab
with clinical, biochemical and endoscopic indices of disease activity in patients
with inflammatory bowel disease
N¼ 74
Infliximab trough
levels (IFX-TLs)
Antibodies to
Infliximab (ATIs)
r p r p
HBI (CD) 0.11 0.41 0.31 0.02
SCAI (UC) 0.18 0.48 0.17 0.47
SIBDQ 0.09 0.44 0.06 0.63
CRP (mg/dl) 0.27 0.02 0.24 0.04
Hgb (mg/dl) 0.08 0.48 0.19 0.10
ESR 1st hour (mm) 0.09 0.42 0.05 0.65
PLT (x109/mL) 0.19 0.09 0.17 0.88
Alb (mg/dl) 0.003 0.77 0.009 0.94
ATIs 0.34 0.01 – –
Combined with IMMs 0.25 0.03 0.26 0.02
Mucosal healing (N¼ 53) 0.38 0.006 0.34 0.01
Conclusion: Therapeutic drug monitoring is valuable in IBD-patients on main-
tenance IFX-treatment. Combination treatment with IFX and IMMs is asso-
ciated with higher IFX-TLs compared to IFX monotherapy. Higher IFX-TLs
are independently associated with the presence of mucosal healing.
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Introduction: In recent years, the gut microbiota has been recognized as a relevant
fingerprint to predict the development of inflammatory bowel disease (IBD) like
ulcerative colitis (UC). Accordingly, inter-individual variation in the gut micro-
bial community may reflect inter-individual variation in the risk of developing
IBD or other diseases. Further recently, the Next-Generation Sequencing (NGS)
has been validated for determining bacterial species in faecal samples. Essentially,
NGS is a molecular biology sequencing technique for the precise identification
and assessment of bacterial species.
Aims & Methods: With the major focus of our study being to establish a relevant
biomarker of disease activity in UC patients based on the intestinal microbiota,
82 UC patients together with 61 healthy relatives as controls were included for
investigations of gut microbiota in faecal samples. Twenty-five patients had
active UC (group I) and 57 had quiescent UC; 29 with mild inflammation in
the large intestine (group II), and 28 without inflammation (group III). The
patients’ relatives were consanguineous (group IV, n¼ 33), and non-consangui-
neous (group V, n¼ 28). The subjects’ age ranged from 15 to 69 years. Faecal
bacteria between groups I to V were compared by the t-test. The Discriminant
analysis in all five groups was done for each Phylum, Class, Order, Family,
Genus and Species. The Canonical Discriminant Function Coefficient (Df) for
each bacterial community was calculated. The quantity of each bacteria was
multiplied by the Df value, and the sum was termed the Discriminant Score
(Ds). Next, we tried to analyze the quantity and the diversity of the bacteria
which had significant difference.
Results: We obtained 1011 varieties of bacteria as Phyla, Class, Order, Family,
Genera and Species. Any individual bacterial quantity with 0 value 95% of
group I and group V, the mean of the individual quantity of bacteria 0.05%
cases (648) were excluded. The t-statics was done on 363 bacteria between groups
I to V. Significant difference was calculated in 18 Species, 10 Genera, and 4
Families. The Discriminant analysis was done on these 18 Species from all
groups. The Ds value showed an increasing tendency in this order: group
I5 group II5 group III5 group IV5 group V. Significant difference was cal-
culated for group I vs group II, vs group III, vs group IV, and vs group V
(P5 0.05). Likewise, group V vs group I, vs group II, vs group III (P5 0.05),
indicating a relevant association between gut microbial species and the develop-
ment of UC. In bacteria having significant difference, especially Bacteroidaceae
Family and Bacteroides Genus were numerous clearly, and both were higher in
group I, active UC. It’s odd that the diversity of Bacteroides Genus was higher in
Group V, non-consanguineous relatives, but the quantity of Bacteroides Genus
was higher in group I. And Bacteroides fragilis was increased in group I, and the
others of Bacteroides were increased in group V, it depends on the amount of
Bacteroides fragilis. In active UC, the amount of Bacteroides fragilis was
increased, but the diversity of Bacteroides Genus was decreased. It’s very inter-
esting, and the balance can be key point between Bacteroides fragilis and the
diversity of Bacteroides in UC activity. And about Genus Anaerococcus,
Finegoldia and Peptoniphilus, about Species Anaerococcus vaginalis, Finegoldia
magna and Peptoniphilus gorbachii were increased in group I significantly. All
these bacteria belong to Peptoniphilaceae Family.
Conclusion: In this study, we compared 363 bacteria between active UC patient to
control, significant difference was calculated in 18 Species, 10 Genera, and 4
Families. To our knowledge, this is the first report on so many bacteria being
related to UC activity. Additionally, the Ds related to UC, or otherwise absence
of UC in the five groups. Potentially, Ds might be a clinically relevant biomarker
of disease activity in UC. This is the first application of the Ds to the study of
microbiota in UC patients, consanguineous and non-consanguineous relatives by
using NGS. Moreover we could obtain a lot of interesting results about the
quantity and the diversity of the bacteria, especially Bacteroides and
Peptoniphilaceae. Clinical trial No: UMIN000017103
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Introduction: Endoscopy is the gold standard diagnostic tool in ulcerative colitis
(UC). However noninvasive methods like cross-sectional imaging and fecal bio-
markers are needed for interval clinical assessments and assessing response to
medical treatment. The combination of positron emission tomography (PET)
with 18F-fluorodeoxyglucose (18F-FDG) with magnetic resonance imaging
(MRI) as integrated PET/MRI in one examination is a new cutting-edge tech-
nology for the non-invasive assessment of the inflammatory activity in UC. In
addition a panel of noninvasive biomarkers like Lactoferrin and Calprotectin are
increasingly popular and used in all-day patient care.
Aims & Methods: To compare the performance of non-invasive biomarkers to
PET/MRI and colonoscopy in patient with UC. In every patient a PET/MRI
including the maximum standardized uptake value ratio gut/liver (SUVQuot)
and a colonoscopy including an endoscopy index (EI) was performed within 48
hours and the Disease Activity Index Mayo score (DAI) was calculated. Fecal
Lactoferrin (LF), CalprotectinIMUN (CalI), CalprotectinCALPREST (CalP),
PMN-elastasis (PMN-E), S100A12, Eosinophil-derived Neurotoxin (EDN) as
well as CRP were correlated to the SUVQuot, the DAI and the EI using correla-
tion analyses. Sensitivity, specificity and diagnostic accuracy were calculated
using optimized cut-offs. All analyses were performed using SPSS (IBM SPSS
Statistics for Windows, release 22.0).
Results: 32 patients (21 female), mean age 44.4 10.63 years (range 23–67) with
diagnosed UC were included in the study. Mean time since diagnosis was 11.41
years (SD¼ 6.42). EI and SUVQuot (r (32)¼ .45; p¼ .009), EI and DAI (r
(32)¼ .87; p¼ .000) as well as DAI and SUVQuot correlated significantly (r
(32)¼ .40; p¼ .022). SUVQuot was correlated significantly with LF (r
(32)¼ .36; p¼ .046), EDN (r (32)¼ .49; p¼ .005), and CRP (r (32)¼ .36;
p¼ .043), but not with PMN-e, CalP, S100A12, and CalI (all p4 .05). DAI
was correlated significantly with PMN-e (r (32)¼ .55; p¼ .001, LF (r (32)¼ .55;
p¼ .001), EDN (r (32)¼ .70; p¼ .000), CalP (r (32)¼ .46; p¼ .008), and CRP (r
(32)¼ .56; p¼ .001), but not with S100A12 and CalI (all p4 .05). EI was
correlated significantly with LF (r (32)¼ .61; p¼ .000), EDN (r (32)¼ .68;
p¼ .000), PMN-e (r (32)¼ .51; p¼ .003), S100A12 (r (32)¼ .41; p¼ .021),
CalP (r (32)¼ .52; p¼ .002), CRP (r (32)¼ .44; p¼ .012), but not with CalI
(p4 .05). The median levels (inactive/active) were: LF: 1.75/20.13 mg/g, CalI:
60.25/105.60mg/g; CalP: 167.25/370.65 mg/g; PMN-E: 0.07/0.19 mg/g, S100A12:
18.82/88.96; EDN: 0.39/2.35 mg/g; CRP: 0.15/0.75mg/dl.Sensitivity, specificity,
diagnostic accuracy (confidence interval) and optimized cut-off for LF was
87.5%/87.5%/87.5% (CI 72.1%100%); 4, 27 mg/g; CALP: 62.5%/62.5%%/
62.5% (CI 38.9%97.5%); 361 mg/g; CALI: 62.5%/62, 5%/62.5% (CI
36.7%86.2%), 68, 43mg/g; PMN-e: 83.3%/75.0%/81.25% (CI
60.5%99.9%); 0.085 mg/g; S100A12: 75.0%/75.0%/75% (CI 56.9%94.1%);
60.40; EDN: 75.5%/75.0%/75% (CI 80.5%100%); 1, 30mg/g; CRP: 70.8%/
75.0%/71.9% (CI 53.5%94.9%); 0, 35mg/dl.
Conclusion: Using EI as gold standard reference we found that fecal biomar-
kers LF, EDN, PMN-E and S100A12 can reliably distinguish between active
and inactive UC. However, Calprotectin did not perform well. LF, EDN and
CRP were significantly correlated to the SUVQuot which was significantly
correlated with EI and DAI. In conclusion, Lactoferrin and Eosinophil-
derived Neurotoxin performed best using endoscopy and PET/MRI as
reference.
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Introduction: At present, drug response to infliximab is monitored by trough
levels (TL) and anti-drug antibody levels (ATI). Recently, another pathway of
drug degradation has been hypothesized since MMP3 and MMP9 were found to
be able to cleave IgG, like infliximab, in both animal and human experimental
studies (1).
Aims &Methods:We collected serum samples in 102 patients (27 Crohn’s Disease
and 75 Ulcerative Colitis) treated with stable doses of infliximab for at least 6
months (t0) and 6 months thereafter (t1). In each patient TL, ATI values and
MMP3 levels were assessed at t0 and t1 by ELISA. In addition, MMP3 levels
were also determined in 28 healthy subjects as controls. Clinical (HBI or Mayo
score) and biochemical (CRP, fecal calprotectin) markers were assessed to define
disease remission/activity. TL were considered therapeutic if43.8mcg/ml, ATI
were considered positive if 410mcg/ml. Data are presented as meanStandard
Error Mean (SEM). Comparison among groups was performed by non-para-
metric tests.
Results: MMP3 levels were similar at t0 and t1 in patients which maintained
therapeutic TL (14.5 1.7 pg/ml and 15.0 1.6 pg/ml, respectively) and in
healthy controls (13.1 0.8 pg/ml). Patients with low TL but ATI negative had
significantly higher MMP3 levels compared to the group with low TL and ATI
positive (33.2 3.0 and 20.0 2.7 respectively, p¼ 0.0003), showing another
pathway of drug degradation. 21 patients lost response between t0 and t1: 15
out of 21 patients demonstrated high levels of MMP3 (22.0 2.1 pg/ml) already
at t0; in addition, 17 of these 21 patients were in clinical remission at t0, while at
t1 all patients had disease activity.
Conclusion: Serum MMP3 levels are useful in predicting loss of response to anti
TNFa in patients with low TL but without ATI. High MMP3 levels predict with
90.5% accuracy loss of response over the next 6 months.
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Introduction: More than one third of inflammatory bowel disease patients (IBD)
present extraintestinal manifestations, with articular manifestations being the
more common, clearly the more incapacitating and which more alter the quality
of life of IBD patients. These patients could benefit from a multidisciplinary
approach for quicker diagnosis and for optimizing treatments.
Aims & Methods: The aim of the study was to evaluate the impact of a multi-
disciplinary approach carried out by both a rheumatologist and a gastroenterol-
ogist in the management of these patients. Therapeutic changes after the
combined assessment were also evaluated. Methods From April 2015 to April
2017, all IBD patients reporting articular pain to the IBD-dedicated gastroenter-
ologist were referred to an experienced rheumatologist. The day of the consulta-
tion a multidisciplinary committee with a rheumatologist and a
gastroenterologist evaluated and discussed in all patients their possible diagnosis
and potential changes in their treatment. Assessment was made according to
current guidelines and data recorded in a common database regarding the rea-
sons why patients were remitted from IBD, their rheumatologic diagnosis and all
changes implemented in their treatments. Results are shown in percentages.
Results: 112 consecutive IBD patients were remitted from the IBD Unit and
analyzed by the committee. Mean age 38 years (ranging from 18 to 73). Most
patients were women (67%), 19% were smokers and 23% former smokers. 51%
of patients analyzed had Crohn’s disease and 49% ulcerative colitis. The main
causes for derivation from IBD were a suspicion of inflammatory arthropathies
in 43% and of arthromyalgias in 40%. The more frequent diagnosis after the
rheumatology consultation and the committee meeting were inflammatory
arthropathies associated with IBD in 41% (51.5% presented axial arthropathies
and 48.5% presented peripheral arthropathies) and fibromyalgia in 15%.
Regarding treatment changes, after the multidisciplinary committee with a rheu-
matologist and a gastroenterologist, changes were made in 28% of patients. Of
those, in 35% of patients methotrexate was added in patients with biologic
treatment (in some of them patients were in monotherapy, but in others the
drug was introduced for replacing thiopurines). In 24% of patients sulfasalazine
was introduced instead of mesalamine. In the other patients either other biologics
like ustekinumab were introduced or the doses of anti-TNF were optimized in
accordance with rheumatologic schedules.
Conclusion: A multidisciplinary consultation combining inflammatory bowel dis-
ease and rheumatology allows both an earlier detection of inflammatory arthro-
pathies associated with IBD and earlier changes in treatment, thereby helping to
optimize the hospitality resources. Fibromyalgia is common among IBD
patients, though it is important that it is detected it should not be confused
with inflammatory arthropathies.
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Introduction: Adalimumab is a human monoclonal antibody used for the treat-
ment of inflammatory diseases like Crohn‘s Disease (CD) and Ulcerative Colitis
(UC). For efficient treatment trough levels of adalimumab need to be adjusted
within a therapeutic window between 5 to 10 mg/mL1. A rapid test allows a much
faster analysis of trough levels, providing a great advantage over test formats that
need samples to be sent to a central laboratory. Here, we present the analytical
performance characteristics as part of the validation of the Quantum Blue
Adalimumab test from BÜHLMANN.
Aims & Methods: The sandwich lateral flow immunoassay uses a tumor necrosis
factor alpha coated label and a highly specific monoclonal antibody to detect
adalimumab in a diluted human serum sample. Evaluation was performed
according to CLSI guidelines. The linearity study included multiple concentra-
tion levels covering and exceeding the expected measuring interval, obtained by
blending two sample pools, low and high. The within laboratory precision was
performed with five (5) samples within the measuring range (20 days - two runs
per day in two replicates). Method comparison was performed with a commercial
available ELISA (RIDASCREEN ADM Monitoring, Art. No. G09043, R-
Biopharm, Darmstadt, Germany) and is based on 106 serum samples. For recov-
ery analysis six clinical samples over the measuring interval of the test were
spiked with 6 mg/mL adalimumab in negative serum and compared with the
expected values. The high dose hook effect was evaluated with spiked pooled
human serum in two runs, the second run with an additional dilution of the
samples into the measuring interval of the test.
Results: The BÜHLMANN Quantum Blue Adalimumab test exhibits a linear
range from 0.93 to 34.61 mg/mL. The recovery of clinical samples ranged from
80% to 89%. No high dose hook effect was observed up to 1002 mg/mL of
adalimumab. The applied additional dilution into the measuring interval yielded
a linear relationship. The mean total within-laboratory precision of the device
was 23.9% (20.7 to 28.9%) with a repeatability of 21.2% (16.4 to 27.8%). The
method comparison revealed a slope of 1.18 and a regression coefficient (r) of
0.92 (Passing Bablok) suggesting that the new Quantum Blue Adalimumab test
showed an excellent correlation compared to the ELISA method.
Conclusion: The BÜHLMANN Quantum Blue Adalimumab lateral flow test
enables the quantitative determination of adalimumab trough level in serum with
time to result of only 15 minutes. The developed test allows to measure adali-
mumab over a wide range, well beyond the therapeutic window. Hence, it repre-
sents a valuable tool for the clinician to assess the adalimumab trough level.
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Introduction: Adalimumab (ADA) is an anti-TNF drug approved for patients
with refractory luminal Crohn’s disease (CD). Recently, mucosal healing (MH)
emerged as a major therapeutic goal in inflammatory bowel disease. Few data are
available on ADA trough levels (TL), anti-ADA antibodies (AAA) during long
term follow-up of CD patients, and their potential association with MH and
disease outcome.
Aims & Methods: The aim of our prospective study was to evaluate a possible
association between achievement of MH, ADA TL, and AAA in CD patients.
Moreover, we assessed the presence of a possible association between clinical
outcome and MH. We prospectively enrolled moderate to severe CD patients
who were primary responders to ADA treatment. Blood samples were withdrawn
at standardized time points during treatment (0-, 2-, 6-week and every 8 weeks
thereafter), before ADA administration. ADA TL were measured using an
homogenous mobility shift assay (HMSA; Prometheus Lab, San Diego, United
States). Disease activity was assessed by means of Harvey-Bradshaw Index (HBI,
remission defined by HBI5 5). As to endoscopic activity, we defined MH in case
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of a value of Crohn’s Disease Endoscopic Index of Severity below 8, so far we
included patients with complete MH and those with a minimal residual endo-
scopic activity. Endoscopic evaluation was performed within two weeks of blood
sampling, and at least after 6 months of ADA treatment.
Results: In our prospective study we enrolled 22 CD patients primary responders
to ADA therapy (13 males, median age¼ 43 years, range 23–67 years) who had a
median treatment duration of 52 weeks (range 24–121 weeks). ADA TL were
significantly higher (P¼ 0.0002) in patients who achieved MH (12.1mcg/mL,
range 6.8–17.2mcg/mL) as compared to patients without MH (4.50mcg/mL,
range 0.0–9.9mcg/mL). Receiver Operating Characteristic curve identified an
ADA TL cut-off of 6.43mcg/mL as the threshold with the highest accuracy
for identification of patients who achieve MH (AUROC 0.934, sensitivity
100%, specificity 81.8%, PPV 84.6, PNV 100). Moreover, achievement of MH
was associated with absence of AAA (P¼ 0.012). Lastly, HBI was significantly
lower (P¼ 0.0002) in patients with MH (4, range 3–8) than in patients without
(11, range 4–17).
Conclusion: In our cohort of CD patients, we observed a clear association
between ADA TL, AAA development, and MH. In particular, an ADA TL of
6.43mcg/mL has been identified as the best cut-off to obtain endoscopic remis-
sion or at least a minimal residual endoscopic activity. Moreover, we observed
that CD patients on ADA therapy who achieved MH had a lower disease clinical
activity. Thus, our data support the use of therapeutic ADA monitoring for the
management of CD patients in order to obtain clinical and endoscopic remission
of the disease
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Introduction: Crohn’s disease (CD) management targets mucosal healing on ileo-
colonoscopy as a treatment goal.
Aims & Methods: We hypothesized that ultrasonographic response to anti-TNFs
is also associated with better long-term outcomes. Patients with CD treated with
anti-TNFs who had serial small intestine contrast ultrasonography (SICUS)
between January 2011 and April 2017 were identified. Disease site (based on
bowel wall thickness), extent of lesions, and presence of complications (stenosis,
prestenotic dilation, abscess, or fistulas) were evaluated using SICUS. Inclusion
required pre-therapy SICUS with follow-up SICUS after 12 months, or 2
SICUS 12 months apart while on maintenance therapy. At second SICUS,
complete responders had improved lesions, non-responders had worsening or
new lesions, and partial responders had other scenarios. CD-related outcomes
of corticosteroid need, hospitalization, and surgery were assessed at one year
from the second SICUS.
Results: Seventy-nine CD patients treated with anti-TNFs (37% with Infliximab,
63% with Adalimumab) were identified. Most patients had ileal disease (67%)
and stricturing phenotype (52%). Based on SICUS, thirty-six patients (46%)
were complete sonographic responders, 30 partial (38%), and 13 non-responders
(16%). Complete and partial responders at SICUS had a reduced risk for surgery
in comparison with non responders [p¼ 0.003 (OR:34.6, CI:1.7–700), p¼ 0.003
(OR 12, CI:0.6–2.40)]. Complete responders at SICUS had a reduced number of
hospitalizations in comparison with non responders [p¼ 0.04 (OR 4.2, CI:1–
17.3)]. Complete and partial responders at SICUS had a reduced risk for need
for rescue corticosteroids in comparison with non responders [p¼ 0.005 (OR:7.8,
CI:1.9–32.4), p¼ 0.002 (OR 5.2, CI:1.7–15.3)].
Conclusion: Ultrasonographic response to medical therapy is associated with
significant reductions in long-term risk of surgery, hospitalizations and steroid
usage among CD patients. These findings suggest the significance of response
assessed by ultrasonography as a treatment target.
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Introduction: Inflammatory bowel disease (IBD) is characterized by recurrent
flares of disease activity, which may lead to hospitalisations, surgery, and even-
tually disease progression. The exact role of psychosocial factors as triggers
remains controversial and current literature focuses on the global presence of
psychosocial symptoms preceding a flare instead of distinguishing pre-existing
from novel symptoms. In this prospective study, we aim to explore the impact of
newly developed symptoms of anxiety, depression, fatigue, psychological stress,
and life events on IBD flares.
Aims & Methods: IBD patients were recruited from the MyIBDCoach study
cohort (de Jong et al., Lancet 2017, in Press). MyIBDCoach is a telemedicine
tool to monitor IBD patients at home. During the 12-month study period, parti-
cipants reported on disease activity and psychosocial parameters (including psy-
chological stress, anxiety, depression, fatigue, and life events) through
MyIBDCoach every 1–3 months. Flares were defined as clinical disease activity
in combination with one of the following: faecal calprotectin 4250 mg/g, disease
activity on endoscopy or other imaging techniques, or dose escalation or initia-
tion of a new drug to induce remission. For all psychosocial parameters, a binary
variable was created to indicate whether symptoms were newly developed or pre-
existing with reference to the previous measurement, thereby correcting for
invariability. A generalized estimating equation model was used to separately
determine which psychosocial parameters were associated with flares in the
three preceding months, correcting for immortal time bias after a flare and
adjusting for gender, disease phenotype, smoking status and disease duration.
Results: In total, 2748 measurements from 381 IBD patients were included. Fifty-
one patients (13%) flared after clinical remission was achieved. Newly developed
psychological stress was associated with a flare in the following three months
(odds ratio [OR]¼ 3.01; 95% CI¼ 1.48, 6.12). Newly reported symptoms of
depression (OR¼ 1.29; 95% CI¼ 0.53, 3.14), anxiety (OR¼ 1.06; 95%
CI¼ 0.46, 2.43), fatigue (OR¼ 1.59; 95% CI¼ 0.79, 3.22), or the occurrence of
a life event (OR¼ 2.07; 95% CI¼ 0.94, 4.55) were not significantly associated,
although the latter did occur more frequently before flares.
Conclusion: Newly developed psychological stress is associated with disease flares
in IBD patients. Therefore continuous monitoring of patients’ stress levels and
interventions such as mindfulness and coaching might be interesting to prevent
flares and eventually improve disease course.
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Introduction: Strain elastography has become a new emerging technique in ultra-
sonic diagnostics of gastrointestinal pathology. Currently there is few published
data on the use of elastography for making the diagnosis and following the
course of inflammatory bowel diseases.
Aims & Methods: Objective. To assess the accuracy of strain elastography con-
cerning stricture detection in Crohn’s disease (CD).
Materials and Methods. 24 patients aged from 18 to 43y were included into the
study, 1 of them having a colonic stricture, 1 patient having a stricture of ileo-
transverse anastomosis and 22 patients having a stricture in the small intestine.
Surgical treatment was carried out in 22 patients, in each case histopathological
evaluation of surgery specimens was conducted. We performed transcutaneus
ultrasonic examination of the bowel using 7.5MHz linear and 3.5MHz convex
probes with power Doppler mode and colonoscopy in all 24 patients. Strain
elastography was used during each US-examination to differentiate inflamma-
tory and fibrotic strictures.
Results: Ultrasonic examination invariably showed local narrowing of the intest-
inal lumen in stricture sites. Inflammatory stricture length was 29mm (21.1–
55.5), (median (2.5th - 97.5th percentile)) with intestinal wall thickening of
6mm (4.23–9.00) and the presence of ulcers. The lesion length in fibrotic stric-
tures was 30mm (20–60), wall thickness 6mm (4.16–8.27), ulcers were visua-
lized either. In 22.7% of cases we observed the signs of partial bowel obstruction.
Strain ratio (SR) values for inflammatory strictures were 1.53 (0.43–3.17), for
fibrotic strictures – 4.19 (1.57–6.42), the difference being statistically significant
(Mann-Whitney test, p5 0.05). According to morphologic studies inflammatory
strictures were characterized by transmural inflammatory infiltration. In fibrotic
strictures we found fibrosis in submucosal layer with loci of muscularis propria
involvement. No significant differencies were found between ultrasonic and mor-
phologic data, p4 0.05.
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Conclusion: The proposed ultrasonic and elastographic signs of stricturizing CD
facilitate preoperative detection and differential diagnosis of fibrotic and inflam-
matory strictures, helping to choose appropriate surgical treatment.
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Introduction: IBDs are disabling conditions that negatively affect physical, psy-
chological, familial and social dimensions of life. The concept of quantifying
disability has become established for the evaluation of many other chronic dis-
eases. Thus, specific tools have been used to assess the impact of disease and its
treatment options on relevant end-points such as health-related quality of life
(HRQL), measured by the IBD-Questionnaire (IBD-Q). Recently, the IBD-
Disability Index (IBD-DI) has been developed to evaluate the entire spectrum
of limitations in functioning in patients with IBD. This index is inspired to the
International Classification of Functioning, Disability and Health (ICF). The
aim of the present study was to assess the relationship between the IBD-DI,
clinical characteristics and HRQoL in a cohort of Sicilian patents with ulcerative
colitis(UC) and Crohn’s disease (CD) followed up in a referral center.
Aims & Methods: IBD-Q and IBD-DI questionnaires were administered to con-
secutive UC and CD adults outpatients from July 2016 to April 2017. The IBD-
DI consists of 28 items that evaluate the 4 domains of body functions, activity
and participation, body structures and environmental factors. IBD-Q consists of
32 questions grouped into 4 dimensions: bowel, systemic, social, emotional.
Scores range from 1 (poorest QoL) to 7 (best QoL) with higher scores indicating
better QoL. Disease activity was assessed by partial Mayo score for UC and by
Harvey-Brandshaw Index for CD. The mean differences of DI score in relation to
dichotomic clinical variables were performed by Student’s t test. By linear regres-
sion analysis we assessed also the relationship between DI and IBD-Q.
Differences were reported as statistically significant if the p value was50.05.
Results: Data from UC and CD patients were analysed separately. 100 UC
patients (59% males, median age 49 years) were enrolled; 17% were smokers.
83% had inactive or mild disease, 17% moderate disease. None of the recruited
patients had severe disease. Concomitant medications at the time of the interview
were conventional therapy (5-aminosalicylic acid, oral steroids) in 72 patients
(72%) or immunosuppressive therapy (immunosuppressant or anti-TNF-a) in
28 patients (28%). The mean IBD-DI score was 23.15 17.492; 62% of patients
had low DI 25 (62/100) while 7% had high DI (450). No correlations were
found between IBD-DI and gender, disease duration, disease extension
(Montreal Classification) and immunosuppressive therapy. IBD-DI was related
to clinical disease activity (p5 0.001) and extraintestinal manifestations
(P¼ 0.005) By linear regression analysis, IBD-DI was significantly associated
with IBD-Q (R2 0, 573; p5 0.001). Interestingly, 5% (n¼ 5) of patients with
inactive or mild disease had severe disability (50) and 5% (n¼ 5) with active
disease had low disability (25). 54 CD patients (59% males, median age 41
years) were enrolled; 22% were smokers. 94% had mild disease, 17 (6%)
severe disease. Concomitant medications at the time of the interview were con-
ventional therapy (5-aminosalicylic acid, oral steroids) in 22 patients (40%) or
immunosuppressive therapy (immunosuppressant or anti-TNF-a) in 32 patients
(60%). The mean IBD-DI score was 20.17 16.24; 72% of patients had low
DI 25 (39/54) while only 2 patients had high DI (450). No correlations were
found between IBD-DI and disease characteristic (gender, disease duration, dis-
ease extension, extraintestinal manifestations. By linear regression analysis, IBD-
DI was significantly associated with IBD-Q (R2 0, 604; p5 0.001).
Conclusion: Our preliminary results show that the IBD-DI is significantly related
to HR-QoL both in UC and CD. In UC IBD-DI is also related to disease activity
and presence of extraintestinal manifestations. However, most of our patients
were in clinical remission. A larger sample with different grades of disease activity
could provide a more accurate evaluation of the reliability of this tool in measur-
ing functional status and disability in IBD. IBD-DI could become a major end-
point in RCTs targeting the course of IBD.
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Introduction: DPP-4 is a membrane-bound glycoprotein expressed on the cell
surface of enterocytes and lymphocytes. It is released in plasma, maintaining
its proteolytic activity and inactivating cytokines, chemokines and neuropeptides.
Aims & Methods: We aimed to investigate the diagnostic and prognostic value of
DPP-4 in patients with inflammatory bowel disease (IBD). A total of 203 adult
patients [n¼ 149 IBD patients; n¼ 42 healthy controls; n¼ 12 immune controls -
systemic lupus erythematosus (SLE) in remission] were prospectively recruited.
Plasma DPP-4 was analysed in all groups; faecal samples from IBD patients were
collected for DPP-4 and calprotectin analysis. Disease activity was assessed using
the Harvey-Bradshaw Index (HBI) for Crohn’s disease (CD), the partial Mayo
Score (pMS) for Ulcerative colitis (UC) and the Systemic Lupus Erythematosus
Disease Activity Index for SLE. A multi-biomarker model was derived using
logistic regression to evaluate predictors of disease activity and Cox regression
to evaluate predictors of treatment escalation (disease outcome). Treatment esca-
lation was defined as the need for escalation to immunomodulatory/biologic
therapies or intestinal resection surgery, as a consequence of a disease flare.
Results: Median plasma DPP-4 values were lower in active CD vs CD in remis-
sion [1043ng/mL, interquartile range (IQR): 824–1345 vs 1685 ng/mL, IQR:
1519–2237; P5 0.001]; as well as in active UC vs UC in remission (1323 ng/
mL, IQR: 1064–1766 vs 2149 ng/mL, IQR: 1616–2478; P5 0.001). IBD patients
in remission showed plasma DPP-4 values significantly lower than healthy sub-
jects; no differences were found between immune and healthy controls. Median
faecal DPP-4 values were much lower in active UC vs UC in remission [1213ng/
mL, IQR: 559–1682 vs 7814 ng/mL, IQR: 2555–7985; P5 0.001], but no differ-
ences were found between active CD and CD in remission. In CD, plasma DPP-4
correlated strongly with faecal calprotectin (FC) (r¼0.61, P5 0.001), C-reac-
tive protein (CRP) (r¼0.60, P5 0.001) and HBI (r¼0.56, P5 0.001), while
no statistically significant correlation was found with faecal DPP-4. In UC,
plasma DPP-4 correlated moderately with FC (r¼0.31, P5 0.05) and CRP
(r¼0.32, P5 0.05), strongly with pMS (r¼0.52, P5 0.001) and with faecal
DPP-4 (r¼ 0.52, P5 0.001). The multivariable logistic regression model showed
that plasma DPP-4 and CRP are independent predictors of CD activity [odds
ratio (OR): 26.95; 95% confidence interval (CI): 3.01–240.96; P¼ 0.003 and OR:
38.02; 95% CI: 4.25–340.48; P¼ 0.001, respectively]. In UC patients, plasma
DPP-4, FC and CRP showed to be independent predictors of disease activity
(OR: 62.10; 95% CI: 2.93–1315.62; P¼ 0.008 and OR: 65.90; 95% CI: 4.96–
875.53; P¼ 0.002 and OR: 48.19; 95% CI: 3.35–692.76; P¼ 0.004, respectively).
At follow-up (median 578 days; IQR: 426–688), plasma DPP-4 and CRP inde-
pendently predicted treatment escalation in CD [hazard ratio (HR) 9.09; 95% CI:
1.77–46.57; P¼ 0.008 and HR 5.90; 95% CI: 1.53–22.78; P¼ 0.010; respectively],
as well as in UC (HR 7.80; 95% CI: 1.60–38.04; P¼ 0.011 and HR 12.23; 95%
CI: 2.30–64.98; P¼ 0.003; respectively). At 1 year, the proportion of patients who
needed treatment escalation was 66% in CD and 41% in UC, if 2 biomarkers
criteria were met.
Conclusion: An activity assessment model and a prognostic model that combines
plasma DPP-4 and other biomarkers accurately predicts IBD activity and an
aggressive disease course. Faecal DPP-4 correlates well with plasma DPP-4 in
Ulcerative colitis, but not in Crohn’s disease.
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Introduction: Disease activity in ulcerative colitis (UC) is best assessed clinically
by Mayo score and endoscopy. Positron emission tomography -computerized
tomography (PET-CT) is a non-invasive imaging technique to assess disease
activity, extent, treatment response in UC, specially in pediatric population,
sick patients and those unwilling for endoscopy.
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Aims & Methods: We conducted a prospective observational study at our tertiary
care centre with the aim of assessing and correlating UC disease activity by
clinical criteria, endoscopy, histology, serum and fecal biomarkers and PET-
CT. 60 eligible patients of UC were enrolled into 3 groups (26 remission, 24
moderate and 10 severe activity) as per Mayo score and 18F FDG PET-CT
was performed within 72 hours of endoscopy. ESR, CRP and fecal calprotectin
levels were determined for all patients.
Results: Of 60 enrolled patients, 10% patients had proctitis, 43.3% had left-sided
colitis and 46.7% had extensive colitis. ESR, CRP, fecal calprotectin levels and
rectal PET activity were significantly higher in patients with moderate and severe
disease activity as compared to those in remission. Rectal PET activity showed a
significant correlation with the Mayo score (k¼ 0.465, p5 0.001), endoscopic
sub-score (k¼ 0.526, p5 0.001), histological score (k¼ 0.496, p5 0.001), and
fecal calprotectin levels (k¼ 0.279, p¼ 0.031). Extent evaluation by PET-CT
and colonoscopy also showed a significant correlation (k¼ 0.582, p5 0.001)
with each other. We found that CRP at a cut-off level of 512mg/L had a
sensitivity of 70.59% and specificity of 92.3%, and fecal calprotectin at a cut-
off of 5143ug/g had a sensitivity of 82.35% and specificity of 88.46% to predict
remission. Besides, PET-CT identified sacroilitis in 1, mesenteric lymphadeno-
pathy in 5, mesenteric stranding in 4, and adenocarcinoma in 1 patient.
Conclusion: PET-CT is a reliable non-invasive tool for assessing disease activity
in UC with good correlation with the Mayo score, endoscopic score, histology
and fecal calprotectin. It is an accurate measure to determine disease extent, and
a good predictor of remission. Thus, with a better patient compliance, it holds
promise in replacing colonoscopy where it is refused or difficult to perform.
Biomarkers and rectal PET activity of patients
Variables
Remission
(n¼ 26)
Moderate
activity
(n¼ 24)
Severe
activity
(n¼ 10)
Total
(n¼ 60)
P* value
between
groups
ESR (mm) (mean SD) 23.3 18.7 35.1 22.3 48.9 9.7 32.3 21.0 0.002
CRP mg/L (mean SE) 5.6 1.2 25.3 4.3 93.3 23.4 28.1 5.7 0.000
Fecal calprotectin (mg/g)
(mean SE)
72.27 13.65 276.29 30.43 426.6 64.95 212.93 24.23 0.001
Rectal PET-CT activity
(SUVmax) (Mean SD)
6.04 5.50 10.79 3.88 12.70 10.50 9.05 6.56 0.004
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Introduction: The importance of therapeutic drug monitoring (TDM)-based algo-
rithms to guide infliximab (IFX) adjustments in inflammatory bowel disease
(IBD) patients is unquestionable. Currently, most of the methods commercially
available for the quantification of IFX are ELISA-based delaying the target
dosage adjustment to the following infusion. A new rapid assay is now available
in the market.
Aims & Methods: This study aimed to explore a recently-launched IFX quanti-
fication rapid test from a clinical perspective. A prospective cohort involving 110
ulcerative colitis (UC) patients under IFX maintenance therapy was study. IFX
trough levels were quantified using a rapid quantification assay and a commonly
used reference kit.
Results: IFX values were statistically different when comparing patients with or
without endoscopic remission (Mayo endoscopic score¼ 0) and stratified by their
faecal calprotectin (FC) levels, regardless the methodology used. Though the two
methods correlated well with each other (Spearman correlation
coefficient¼ 0.843, p5 0.001; intraclass correlation coefficients¼ 0.857, 95%
CI: 0.791–0.903), values obtained with the reference kit were on average 2.62
units higher than those obtained with the rapid system. Nevertheless, 3 ug/ml was
shown to be an appropriate cut-off to assess endoscopic remission and inflam-
matory burden levels with both assays. In fact, eighty eight percent of patients
that had a positive outcome showed IFX values, with the rapid assay, above 3ug/
mL, Mayo endoscopic score 1 and for an FC concentration 5250 ug/g.
Conclusion: Our results show that the rapid IFX assessment system is a reliable
alternative to the time-consuming ELISAs in patients on the maintenance phase
of IFX operating a threshold of 3 ug/ml.
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Introduction: Patient education and awareness in those who have inflammatory
bowel disease (IBD) and is regarded by the United Kingdom (UK) IBD stan-
dards group as a key standard in the provision of care towards patients with
IBD.1 Our district general hospital implemented an IBD education clinic in 2015
which is run quarterly per annum by a multidisciplinary panel of doctors, spe-
cialist nurses, pharmacists and dietitians. Patients who have been newly diag-
nosed with IBD are invited to attend this clinic. Clinic attendees are given an
overview of their disease, treatment modalities, options of non-medical support
(e.g: psychology) and are made aware of our telephone helpline open access
service. To date, there has not been any published data on the impact of an
IBD education clinic on resource use or patient outcomes.
Aims & Methods: We aimed to evaluate the impact of the education clinic on
resource use in patients who attended the clinic compared to patients who did
not. A retrospective analysis was done of patients who were diagnosed with IBD
between January 2013 and May 2015. 40 patients were identified and divided
equally (20 patients each) into clinic attenders (CA) and non-attenders (NA).
Resource use was determined at 12 months from diagnosis in the NA group
and 12 months from attendance in the CA group. The median time from diag-
nosis to clinic attendance in the CA group was 7 months. Data was obtained
from our hospital’s electronic database system. Statistical analysis was carried
out with the student’s t-test.
Results: The median age was 37 in the CA group and 33 in the NA group. In the
CA group, 10 patients had ulcerative colitis (UC), 9 patients had Crohn’s Disease
(CD) and 1 patient had unclassified IBD. In the NA group, 13 patients had UC
and 7 patients had CD. The median of resource use and patient outcomes over a
12 month period (from diagnosis in the NA group and from clinic attendance in
the CA group) is detailed in the table below.
Resource use and patient outcomes NA CA p-value
Steroid courses 0.47 0.51 1
Unplanned hospital admissions 0.19 0.21 1
IBD telephone helpline consultations 0.24 2.58 0.001
Clinic appointments 3.71 2.84 0.08
Blood tests (excluding essential monitoring blood tests) 5.81 3.68 0.14
Endoscopies 0.33 0.26 0.77
Radiological imaging 0.24 0.16 0.5
Therapy escalation 1.4 1.15 0.62
Conclusion: In our cohort of patients, patients who attended the IBD education
clinic were more likely to utilise our open access IBD telephone helpline service.
There was a trend towards increased frequency of outpatient clinic appointments
and blood tests in patients who did not attend the IBD education clinic although
this was not statistically significant. There were no differences in the rates of
hospital admissions or steroid courses in either group. The limitations of our
data include the small sample size and short follow-up period.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Tumor necrosis factor (TNF) inhibitors (anti-TNF) are considered
to be effective in inducing mucosal healing in patients with moderate-to-severe
Ulcerative Colitis (UC). The role of IL-33 and its receptor, ST2, in intestinal
inflammation is incompletely understood, with both pro-inflammatory and reg-
ulatory properties described. Recent evidence has shown that anti-TNF is able to
modulate the IL-33/ST2 axis in inflammatory conditions.
Aims & Methods: The aim of our study was to explore the potential role of the
IL-33/ST2 axis in the mucosal healing process mediated by anti-TNF therapy in
UC. Endoscopic MAYO score was calculated before the first anti-TNF infusion
(T0) and after 6 weeks (T2). 24 UC patients (MAYO score at T0 2), grouped
into 12 responders with mucosal healing (MAYO score 1) and 12 non-respon-
ders to anti-TNF at T2 (MAYO score 2) were enrolled. 10 healthy controls
undergoing routine colonoscopy for tumor screening were also enrolled. At each
time point, serum samples were collected and ELISA performed to assess IL-33/
ST2 protein levels. Intestinal biopsies were also taken from the rectum and IHC
was done to evaluate mucosal IL-33/ST2 expression and localization.
Results: IL-33 protein levels were significantly increased in responders vs. non-
responders, both at T0 and T2. Among responders, IL-33 protein was slightly
reduced at T2 vs. T0, while unchanged in non-responders. Interestingly, signifi-
cantly higher levels of ST2 were found in responders vs. not responders at T0,
while no differences between groups were found at T2. Among responders, ST2
levels were dramatically reduced at T2 vs. T0. No significant differences were
found in non-responders at both time points. Healthy controls showed signifi-
cantly lower levels of both IL-33 and ST2 compared with other groups. IHC
confirmed these observations. In particular, IL-33 and ST2 staining was more
intense within the inflamed and ulcerated mucosa of responders compared to
non-responders at T0. After 6 weeks, ST2 staining was even more evident in
responders, notably localized to the healed mucosa and in close proximity to
areas of re-epithelialization. Little to no staining for both IL-33 and ST2 was
present in healthy controls.
Conclusion: Our results suggest a possible role for IL-33/ST2 in predicting gut
mucosal wound healing in patients with moderate-to-severe UC treated with
anti-TNF. Further studies are underway to determine mechanisms of action
that support these findings.
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Introduction: Higher infliximab (IFX) serum concentrations have been associated
with higher rates of clinical remission in inflammatory bowel disease patients1, 2.
However, the correlation between IFX trough levels (TL) during the induction
phase and in medium or long-term remission in Crohn’s disease (CD) patients is
less clear3.
Aims & Methods: We aimed to analyse whether the IFX-TL were able to predict
medium (22 weeks) and long-term (54 weeks) remission in CD patients.
Consecutive CD patients receiving IFX (5mg/kg at weeks 0, 2, 6 and every
eight weeks at least until 22 week) were included retrospectively. IFX-TL were
measured by capture ELISA and anti-Infliximab antibodies (ATI) by a bridging
ELISA before each infusion4. Clinical response and biological parameters were
also measured. The investigator defined remission based on clinical (Harvey-
Bradshaw score), biological and endoscopic or imaging technics; partial or no
response, as well as intensification decided by investigators were considered as
non-remission patients. U-Mann Whitney test was used to assess association
between IFX-TL and remission. ROC curves were included to obtain cut
points for clinical use.
Results: 32 CD patients were screened, but finally 29 analysed, because 3 patients
had IFX discontinued at week 14. Baseline characteristics included: 16 female:
55.2%, 31% smoker, 31% ex-smoker, 79.3% ileal or ileocolonic involvement,
44.8% inflammatory behavior, with 6.9% previous abdominal surgery and
86.2% on concomitant immunosuppressant, 34.5% non-naive to biological ther-
apy. On week 22, 44.8% patients were in remission; on week 54.40% were in
remission.
Week
REMISSION
Median (IQR)
IFX-TL(mg/mL)
NO REMISSION
Median (IQR)
IFX-TL(mg/mL) Z p
Week 6 22 24.6 (18.4–41.3) 12.7 (5.2–22.2) 2.982 0.002
54 28.2 (18.3–40) 15.1 (5.6–21.3) 2.441 0.014
Week 14 22 9.5 (6.8–14) 1.8 (0.9–9.2) 2.647 0.007
54 8.4(5.2–13.3) 3.8 (1.3–9.5) 1.580 0.123
On week 6, IFX-TL4 24mg/mL was associated with remission at week 22 (ROC
0.83; S: 61.5%, Sp: 81.3%) and at week 54 (ROC 0.79; S 60%, E 80%). On week
14, IFX-TL4 11 mg/mL was associated with remission at week 22 (ROC 0.80; S:
41.7%, Sp: 93.8%) and at week 54 (ROC 0.70; S: 44.4%, Sp: 86.7%).
Conclusion: IFX-TL during the induction period are associated with remission at
6 and 12 months. Optimal TL ranges associated to remission can be calculated to
guide clinical decisions. can be calculated to guide clinical decisions.
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Introduction: Several histological scores of activity have been developed in
Inflammatory Bowel Disease (IBD). However, their usefulness in clinical practice
and the correlation between clinical, endoscopic and histological scores is
undefined.
Aims & Methods: To assess, in a prospective study, the correlation between
clinical, endoscopic and histological activity scores in a cohort of IBD patients
(pts) undergoing colonoscopy. Secondary end-point was to assess the role of
histological scores in clinical practice. From Feb. to Dec. 2016, IBD pts under-
going colonoscopy according to clinical indication were enrolled. Inclusion cri-
teria: 1. Diagnosis of IBD; 2. Age4 18 and 580 yrs; 3. Regular follow up;
4. Indication for colonoscopy; 5. No severe comorbidities. During colonoscopy,
2 biopsies were taken from 1 macroscopically involved area and, possibly,
from 1 uninvolved area. Clinical activity was assessed by the Mayo score
(activity 3)(2) for Ulcerative Colitis (UC) and the CDAI (activity 150)(1)
for Crohn’s Disease (CD) pts. All colonoscopies were performed by one IBD-
dedicated gastroenterologist. Endoscopic activity was assessed in UC pts by the
Mayo score (activity 2)(2), and in CD by the Rutgeerts’ score
(recurrence 2)(3) or the SES-CD (activity 3)(4), according to previous sur-
gery. Histological activity was assessed by one pathologist using the Global
Histologic Activity Score (GHAS) for CD (5) or the Geboes simplified score
for UC (activity 3.1)(6). Each of the 3 investigators was blind regarding the
other activity scores. Statistical analysis. Data expressed as median [range], cor-
relations assessed by the Spearman correlation test.
Results: IBD group included 107 pts: 67 (62.6%) UC (M 36 [53.7%], age 50 [24–
80], UC duration 14 yrs [1–48]), 40 (37.4%) CD (M 24 [60%], age 46 [19–75], CD
duration 14 yrs [1–36]). UC extent included: pancolitis in 34 (51%), left sided in
17 (25%), proctitis in 16 (24%) pts.CD involved (n¼ [%]): the ileum (21 [52%]),
colon (6 [15%]), ileum-colon (12 [30%]), upper GI (1 [3%]), previous surgery in
18 (45%). CD behavior was fibrostricturing (n¼ 15;37%), penetrating
(n¼ 11;28%), non-stricturing non-penetrating (n¼ 14;35%), No complications
occurred. Clinical Activity: UC. The day of colonoscopy, UC was clinically
active in 14 (21%), in remission in 53 (79%) pts. Endoscopic activity: UC.
Endoscopic activity was observed in 31 (46%), remission in 36 (54%) pts.
(Mayo score: 0 [n¼ 14];1 [n¼ 22]; 2 [n¼ 13], 3 [n¼ 18]). Histologic activity:
UC. Microscopic activity was observed in 24/67 (36%) pts: 4/24 pts showed
endoscopic remission. Correlations: UC. In UC, a significant correlation was
observed between: clinical and endoscopic scores (r¼ 0.52;p5 0.0001); clinical
and histologic scores (r¼ 0.28;p¼ 0.02); endoscopic and histological scores
(r¼ 0.56; p5 0.0001). Clinical Activity: CD. At colonoscopy, CD was clinically
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active in 5 (12%), in remission in 35 (88%) pts. Endoscopic activity: CD.
Colonoscopy was incomplete in 2/40 pts. In the 24 pts with no previous surgery,
SES-CD was: 0 (n¼ 4), 3 (n¼ 1) 4 (n¼ 3), 6 (n¼ 2); 8 (n¼ 3); 9 (n¼ 2); 10 (n¼ 1);
11 (n¼ 1); 12 (n¼ 1); 13 (n¼ 1); 14 (n¼ 1); 17 (n¼ 1); 19 (n¼ 1) pts (median 4 [0–
19]; activity: 20/24 [80%], remission: 4/24 [20%]). In the 16 pts with previous
surgery, the Rutgeerts’ score was: 0 (n¼ 3);1 (n¼ 1), 2 (n¼ 6);3 (n¼ 2) 4
(n¼ 4)(recurrence:12/16 [75%]). Histologic activity: CD. The GHAS was:0
(n¼ 5);1 (n¼ 11);2 (n¼ 3);4 (n¼ 1);6 (n¼ 2);7 (n¼ 1);9 (n¼ 1) in pts without
previous surgery, and 0 (n¼ 3);1 (n¼ 9);3 (n¼ 1);10 (n¼ 1) in pts with previous
surgery.In CD, the histological score showed a slightly significant correlation
with SES-CD (r¼ 0.41;p¼ 0.046) and no correlation with the Rutgeerts’ score
(r¼ 0.31;p¼ 0.247).
Conclusion: In a prospective study, a significant correlation was observed
between clinical, endoscopic and histological activity in UC. Histological activity
may be observed in UC patients in endoscopic remission, thus suggesting that
this finding may represent a predictive marker of clinical relapse.
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Introduction: Assays to measure TNF inhibitors and anti-drug antibodies
(ADAb) in patient serum are being utilized to manage failure to respond and
loss of response. These monitoring assays may also be used to proactively titrate
doses and dosing intervals. Here, 36,477infliximab (IFX) and 21,284 adalimumab
patient results from the past 4 years were analyzed.
Aims & Methods: Measurements of drug and ADAb levels were performed by
lab-developed chemiluminescent immunoassays.[1] Lower limits of quantitation
are 0.4 ug/mL for IFX and 0.6 ug/mL for adalimumab. ADAb assays are drug
tolerant in the presence of up to 100 ug/mL of drug. Clinical histories and blood
collection timing are unknown.
Results: Of 36,477 measured IFX samples, 56% (20,353) were ADAb-free and
44% (16,224) had measureable ADAb ranging from 22 to 3.5 million ng/mL. In
the absence of ADAb, IFX concentrations were from 0.4 to 4100 ug/mL, with
the majority (460%) between 3.0 to 20 ug/mL. In the presence of ADAb, an
inverse relationship between IFX concentrations and anti-IFX antibodies is
clearly evident (Table 1). As a reference, an ADAb-free mean drug level was
determined from samples with IFX between 0.4–30 ug/mL. Decreasing mean
IFX concentrations (column 3) with increasing ADAb (column 1) are demon-
strated where low ADAb (5200 ng/mL) appears to have minimal impact on
mean drug levels while high ADAb (41000 ng/mL) is invariably associated
with severely diminished IFX (10% or less than the mean). A similar drug -
ADAb relationship was observed with adalimumab (Table 2). Interestingly,
even low titer anti-adalimumab antibodies are associated with a diminished
mean adalimumab (3.4–5.6 ug/mL) where the baseline mean adalimumab (6.1
ug/mL) was calculated from 10, 784 ADAb-free samples with adalimumab from
0.6–15 ug/mL. Anti-adalimumab antibody levels 4300 ng/mL are associated
with free adalimumab concentrations 530% of the mean. Of all adalimumab
patient samples, 60% (12, 873) were free of ADAb, and 40% (8411) were ADAb
positive, ranging from 25 to 2.8 million ng/mL. For adalimumab in Table 2, as
ADAb levels increase (column 1), their corresponding mean drug concentrations
diminish (column 3), similar to IFX results in Table 1.
Table 1: Anti-Infliximab Antibody Distribution and Corresponding Mean Free
Drug Levels
Anti-Infliximab
Antibody
Ranges (ng/mL) n
Mean Drug
Concentration
(ug/mL)
% with
Undetectable
Drug (50.4 ug/mL)
undetected 15692 10 0%
22–100 6785 9.5 11%
101–200 2684 8.6 19%
201–300 1344 6.3 27%
301–500 1427 5.2 38%
501–700 789 3.7 53%
(continued)
Table 1: Continued
Anti-Infliximab
Antibody
Ranges (ng/mL) n
Mean Drug
Concentration
(ug/mL)
% with
Undetectable
Drug (50.4 ug/mL)
701–1000 802 3.0 63%
1001–2000 1246 1.0 79%
2001–4000 575 50.4 86%
4001–3.5 million 572 50.4 100%
Table 2: Anti-Adalimumab Antibody Distribution and Corresponding Mean
Free Drug Levels
Anti-Adalimumab
Antibody
Ranges (ng/mL) n
Mean Drug
Concentration
(ug/mL)
% with
Undetectable
Drug (50.6 ug/mL)
undetected 10784 6.1 0%
25–100 3904 5.6 5%
101–200 1144 3.4 12%
201–300 570 2.4 24%
301–500 655 1.8 39%
501–700 330 1.1 57%
701–1000 303 0.7 75%
1001–2000 496 50.6 93%
2001–4000 394 50.6 97%
4001–2.8 million 610 50.6 99%
Conclusion: Upon analysis of 57,861 infliximab and adalimumab patient samples
from 2012–2016, 43% exhibited anti-drug antibodies. We found that low-titer
antibodies do not appear to impact drug levels. Our findings are consistent with
American Gastroenterological Association Critical Care Pathways for Crohn’s
Disease and Ulcerative Colitis where low and high antibody scenarios are man-
aged very differently (increase drug/consider immunomodulator vs. switch drug
within class). High resolution antibody assays may be helpful in dosing TNF
inhibitors and in other treatment and management decisions.
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Introduction: Immunosuppressives (IM) are often used as maintenance therapy to
reduce the risk of relapse among patients with inflammatory bowel disease
(IBD). Vedolizumab (VDZ), a humanized monoclonal antibody that targets
the 4b7 integrin, has been approved for the treatment of moderately-to-severely
active Crohn’s disease (CD) and ulcerative colitis (UC).
Aims & Methods: The aim was to assess the real-world use of IM therapy and
compare outcomes in IBD patients with, versus without a history of IM use, who
initiated treatment on VDZ in the United States. The Explorys Universe data-
base was used to identify all IBD patients 418 years of age who: (1) initiated
VDZ therapy between May 20, 2014, and February 22, 2016 (the date of VDZ
initiation was the assigned index date); and (2) had 365 days of available data
pre- and post- index date (follow-up). Patients were stratified based on the use of
IM at any point in their treatment history before the index date. Key outcomes in
the follow-up period included the use of IM; and the incidence of IBD-related
surgeries, hospitalizations, and flares (defined as the use of intravenous corticos-
teroids, IBD-related surgeries, or hospitalizations).
Results: A total of 567 patients were included, of which 68.4% had CD, and
31.6% had UC. Mean (standard deviation [SD]) age at index was 44 (15.0) years;
58.6% were female. Overall, 54.6% had a history of prior IM use, and 64.6%
received anti-TNFs before starting VDZ therapy. On average, patients initiated
VDZ 4.5 (3.6) years following their initial diagnosis. Of the 54.6% of patients
with a history of IM therapy, 61.0% did not use IM during maintenance treat-
ment with VDZ during follow-up. Of the 45.4% of patients without a history of
IM use, 87.0% did not initiate IM therapy during follow-up. Amongst VDZ
patients with a history of IM vs. without history of IM use, there was a trend
of increased flares (38.7% vs. 30.0%, p¼ 0.034), hospitalizations (21.9% vs.
19.8%, p¼ 0.605), and surgeries (10.6% vs. 6.6%, p¼ 0.103). Findings for UC
and CD patients are presented in Table 1.
Conclusion: The majority of patients with a history of IM use did not use IM
therapy after initiating VDZ in a real-world clinical practice. The use of IM after
initiating VDZ was also low amongst patients without a history of IM use. Lower
rates of healthcare resource utilization were observed among patients without a
history of IM use. Further research is needed to better understand the degree to
A522 United European Gastroenterology Journal 5(5S)
which IM therapy is used concomitantly with VDZ and potential impact on
outcomes in real-world clinical practice.
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Introduction: Biomarkers of inflammatory bowel disease activity have been
researched for decades but objective markers of disease severity that support
clinical decision-making are still needed. Well-established markers include
serum C-reactive protein and fecal calprotectin, but their use as a standalone
surrogate for disease activity has been controversial. We hypothesize that novel
objective markers of tissue inflammation are best identified at the site of disease
with a tissue-level assessment of disease activity.
Aims & Methods: Biopsy samples were obtained from participants in the UNITI
trials of ustekinumab in moderate-to-severe Crohn’s disease. The UNITI induc-
tion trials included two cohorts, patients who failed 1 TNF antagonists
(UNITI-1) or patients who failed conventional therapies (UNITI-2). Pairs of
adjacent biopsies were taken from the rectum, splenic flexure, and ileum. One
biopsy from each pair was assessed by Global Histology Disease Activity Score
(GHAS) while the other was submitted to microarray analysis. Partial least
squares regression and random forest were used to identify biomarkers asso-
ciated with histological severity in the UNITI-1 cohort. Robustness of the result-
ing models was assessed using cross-validation within the training set and
multiple external validation sets (defined within the UNITI-1 and UNITI-2
cohorts).
Results: In UNITI-1, a single multivariate model comprising 16 genes was iden-
tified that predicted histological activities in rectum or splenic flexure biopsies.
This model was characterized by R2¼ 0.78 for the training set, and R2¼ 0.59,
0.54, and 0.32 on external validation sets also from UNITI-1. A separate 14-gene
model capturing histological activity in ileal biopsies was characterized by
R2¼ 0.5 for the training set and R2¼ 0.45 in the external validation set. In gen-
eral, both models contained genes related to tissue degradation, barrier function,
and immune regulation, including CXCL11 (I-TAC). Both models retained per-
formance in external validation datasets from UNITI-2 but exhibited lower per-
formance. De novo models generated from UNITI-2 also exhibited lower
performance. Indeed, weighted gene co-expression network analysis indicated
weaker associations between gene expression and histology scores for UNITI-2
compared to UNITI-1 subjects.
Conclusion: Our analysis supports the ability of biopsy transcriptomics combined
with machine learning approaches to capture disease-relevant variability in
Crohn’s disease and, more importantly, supports the use of similar approaches
to identify additional surrogate markers. Interestingly, this approach was more
successful in the TNF antagonist failure cohort compared to the conventional
therapy failure cohort. We hypothesize that this is related to increased strength of
the transcriptional signal in the TNF antagonist failure cohort. We identified
specific genes that could be used together as surrogates for histologic measure-
ment, which may not be susceptible to the subjectivity inherent in GHAS scoring.
Finally, the specific genes identified by our analysis provide insight into the
molecular processes driving histological disease activity in Crohn’s disease.
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Introduction: Indirect evidence is needed to inform the clinical efficacy of usteki-
numab in Crohn’s disease (CD). Indirect treatment comparisons in CD are chal-
lenged by withdrawal trial designs limiting placebo arm transitivity. This
treatment sequence analysis builds on previous work1 proposing a solution to
challenges inherent to CD datato compare one year efficacy of biologics in CD
patients having failed anti-TNF therapy. Analyses accounted for delayed respon-
ders (induction non-responders attaining response after additional doses) to gen-
erate more comprehensive estimates of biologics’ relative efficacies.
Aims & Methods: A systematic literature review identified randomized controlled
trials in CD patients having failed anti-TNF therapy for induction and main-
tenance of ustekinumab (UST), adalimumab (ADA), or vedolizumab (VDZ).
Clinical response (CDAI-100 point reduction) and remission (CDAI 150)
were assessed. The probability of achieving response after induction was multi-
plied by the conditional probability of maintaining response/achieving remission
at one year. Separate calculations were conducted for early and delayed respon-
ders. Their respective treatment sequence rates were summed to obtain overall
response and remission rates. Placebo rates were imputed using data from
patients induced and maintained on placebo from the IM-UNITI study, adjusted
for responder and remitter induction rates. Bayesian analyses generated relative
Abstract: P1028. Table 1: Characteristics and outcomes among patients newly started on vedolizumab stratified by IBD type and history of immunosuppressive
therapy
CD (N¼ 388) UC (N¼ 179)
With history of
IM use (N¼ 225)
Without history of
IM use (N¼ 163) P-value
With history of
IM use (N¼ 85)
Without history of
IM use (N¼ 94) P-value
Mean (SD) age, years 43 (14.8) 47 (14.7) 0.009 41 (14) 44 (16) 0.193
Female, % 64.9% 59.5% 0.290 51.8% 47.9% 0.655
Mean (SD) time from
diagnosis to VDZ
initiation, years
6.0 (3.9) 4.2 (3.4) 50.001 3.6 (2.7) 2.6 (2.6) 50.001
Pre-index exposure to
anti-TNF therapy, %
78.2% 55.2% 50.001 68.2% 44.7% 0.002
IBD-related measures
in the 365 days pre-index
Hospitalisations 42.2% 28.8% 0.0076 28.2% 33.0% 0.520
Surgeries 18.7% 6.7% 0.0008 3.5% 2.1% 0.669
Flares 56.9% 43.6% 0.0103 37.6% 43.6% 0.449
IBD-related measures in the
365 day follow-up period
Hospitalisations 24.9% 20.2% 0.328 14.1% 19.1% 0.426
Surgeries 12.4% 7.4% 0.128 5.9% 5.3% 40.999
Flares 43.6% 32.5% 0.035 25.9% 25.5% 40.999
Note: IM therapy included use of azathioprine, 6-mercaptopurine, methotrexate, mycophenolate mofetil, cyclosporine, and Tacrolimus
United European Gastroenterology Journal 5(5S) A523
odds ratios (OR), credible intervals (CrI), and posterior distribution probabilities
for superiority of UST.
Results: Accounting for delayed responders, the absolute proportions of patients
having maintained response and being in remission at one year were 30% of
patients receiving UST every 8 weeks, 19% of those receiving VDZ every 4
weeks, and 23% of patients receiving ADA every other week or weekly. Based
on a one-year treatment sequence analysis, probabilities for UST to be better
than VDZ for achieving and maintaining response and remission were
99%(OR[CrI]:1.94[1.07;3.48]) and 98%(OR[CrI]:1.82[1.00;3.28]), respectively.
UST had higher likelihoods of remission than ADA given weekly(83%,
OR[CrI]:1.36[0.72;2.58) or every other week(85%, OR[CrI]:1.41[0.74;2.68]).
Conclusion: This approach deals with methodological issues inherent to CD trial
data. In CD patients having failed anti-TNF therapy, ustekinumab had higher
likelihoods of response or remission than adalimumab and vedolizumab over a
one-year treatment sequence. Additional induction doses and continued main-
tenance therapy with ustekinumab have demonstrated benefits in delayed respon-
ders compared to other biologics. Previous research, is limited to indirect
treatment comparisons in early responders only. Including delayed responders
provides a more accurate picture of CD patients’ response to biologics and better
informs clinical practice.
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Introduction: Indirect evidence is needed to inform the clinical efficacy of usteki-
numab in Crohn’s disease (CD). Indirect treatment comparisons in CD are chal-
lenged by withdrawal trial designs limiting placebo arm transitivity. This
treatment sequence analysis builds on previous work1 proposing a solution to
challenges inherent to CD data to compare one year efficacy of biologics in CD
patients having failed conventional therapy. Analyses accounted for delayed
responders (induction non-responders attaining response after additional
dosing) to generate more comprehensive estimates of biologics’ relative efficacies.
Aims & Methods: A systematic literature review identified randomized controlled
trials in CD patients having failed conventional therapy for induction and main-
tenance of ustekinumab (UST), adalimumab (ADA), or vedolizumab (VDZ).
Clinical response (CDAI-100 point reduction) and remission (CDAI 150)
were assessed. The probability of achieving response after induction was multi-
plied by the conditional probability of maintaining response/achieving remission
at one year. Separate calculations were conducted for early and delayed respon-
ders. Their respective treatment sequence rates were then summed to obtain
overall response and remission proportions. Placebo rates were imputed using
data from patients induced and maintained on placebo from the IM-UNITI
study and adjusted for responder and remitter induction rates. Bayesian analyses
generated relative odds ratios (OR), credible intervals (CrI), and posterior dis-
tribution probabilities for superiority of ustekinumab.
Results: When accounting for delayed responders, the absolute proportions of
patients having maintained response and being in remission at one year were of
50% in patients receiving UST, 39% in those receiving VDZ, and 33 or 36% in
patients receiving ADA every other week or weekly, respectively. Based on a one-
year treatment sequence analysis, probabilities for UST to be better than VDZ
for achieving and maintaining response and remission were
84%(OR[CrI]:1.39[0.73;2.62]) and 69%(OR[CrI]:1.19[0.59;2.38]), respectively.
UST had higher likelihoods of remission than ADA given weekly (75%,
OR[CrI]:1.33[0.58;3.02]) or every other week (82%, OR[CrI]:1.47[0.64;3.33]).
Conclusion: This approach deals with methodological issues inherent to CD trial
data. In CD patients having failed conventional therapy, higher likelihoods of
response or remission were observed for ustekinumab versus adalimumab and
vedolizumab over a one-year treatment sequence. Additional induction doses and
continued maintenance therapy with ustekinumab in delayed responders have
demonstrated benefits compared to other biologics. Previous research, is limited
to indirect treatment comparisons in early responders only. Including delayed
responders provides a more accurate picture of CD patients’ response to biolo-
gics and better informs clinical practice.
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Introduction: Anti-TNF therapies have revolutionised the management of IBD.
Recently, the infliximab (IFX) biosimilar (CT-P13) received market authorisa-
tion for IBD allowing cost benefits with switches to CT-P13 with annual savings
of £5400/patient (70 kg patient receiving 5mg/kg 8 weekly). We present our
experience of switching patients from the originator IFX to CT-P13 for new
and existing patients.
Aims & Methods: Recorded baseline characteristics included indication, age, sex,
disease duration, treatment duration, concomitant immunomodulators, baseline
CRP and HBI/Mayo scores. Response to IFX induction was assessed retrospec-
tively using symptoms and CRP. Treatment response and remission rates, pri-
mary and secondary loss of response rates, and adverse events in patients who
initiated IFX in the 12 months pre-Feb 2016 were compared with those who
initiated CT-P13 in the 12 months post-Feb 2016. Sustained response was com-
pared for existing IFX patients who switched to CT-P13 in Feb 2016 against
those who continued with the original IFX. Drug and antibody levels were
measured before switch and at 3, 6, and 12 months post.
Results: 53 patients commenced IFX in the 12 months pre-Feb 2016 (26 Crohn’s
Disease (CD), 13 fistulating CD, 13 Ulcerative Colitis (UC), 1 IBD-Unclassified
(IBD-U)) compared with 69 patients who commenced CT-P13 in the subsequent
12 months (22CD, 9 fistulating CD, 35UC, 3IBD-U). Baseline characteristics did
differ, with a greater proportion of UC patients in the CT-P13 cohort (51% v
24.5% (p¼ 0.003)). This group had a higher mean CRP (20.2 v10.6 (p¼ 0.008))
although a lower median Mayo score (5 v 11 (p¼ 0.007)). There was no difference
in response (12(23%) v 15 (21.74%) (p¼ 0.905)), remission (14(26%) v 29(42%)
(p¼ 0.074)), primary non-response (8(15%) v 4(5.8%) (p¼ 0.087)), secondary
loss of response (12(23%) v 15(21.74%) (p¼ 0.905)), or adverse events (6(11%)
v 6(8.7%) (p¼ 0.629)) in those who initiated originator IFX compared with CT-
P13. 191 patients switched to CT-P13 post-Feb 2016, while 19 patients continued
on originator IFX. There was no difference in the response (2(11%) v 24(12.6%)
(p¼ 0.797)), remission (9(47%) v 111(58.1%) (p¼ 0.367)), secondary loss of
response (8(42%) v 47(24.6%) (p¼ 0.098)), or adverse events (0% v 9(4.7%)
(p¼ 1)) between the originator IFX and CT-P13 respectively. Drug and antibody
levels were available pre-switch to CT-P13 for 134 patients. Therapeutic drug
levels with no significant antibodies were associated with clinical remission 12
months post-switch compared with low/undetectable drug levels and significant
antibodies (60(67%) v 0% (p¼ 0.0008)). Loss of response or discontinuation of
therapy at 12 months post-switch was significantly lower in those with therapeu-
tic drug levels and no significant drug antibodies compared with patients low/
undetectable drug levels and significant antibodies (18(20%) v 7(100%)
(p5 0.0001) and 6(7%) v 6 (86%) (p5 0.0001) respectively).
Conclusion: There was no significant difference in response and remission rates,
primary and secondary loss of response, or adverse events between originator
IFX and CT-P13 during the first 12 months after switching. The presence of low/
undetectable drug levels and significant antibodies pre-switch was associated with
loss of response and discontinuation of treatment. Switching to CT-P13 in 191
patients in our unit lead to 4£1million in savings.
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Introduction: Low prevalence of Helicobacter pylori (HP) infection has been
reported in patients with inflammatory bowel disease (IBD), however, it is
unclear whether the eradication therapy for HP can exacerbate disease activity
of IBD. We then aimed to clarify the safety and efficacy of HP eradication in
patients with IBD.
Aims & Methods: This was a multicenter, retrospective cohort study in 26 institu-
tions. Patients who eradicated HP by proton pump inhibitor and amoxicillin-
based triple therapy after the diagnosis of IBD (ulcerative colitis (UC) or Crohn’s
disease (CD)) from March 2005 to July 2015 were enrolled. Two IBD patients
without HP eradication whose gender, age, disease, location, severity, and obser-
vation period were matched with each HP-eradicated patient were enrolled in the
same institution. Disease activity of IBD at baseline, 2 and 6 months after
observation (eradication) was investigated. Exacerbation of IBD was defined
as increase/addition of IBD drug, IBD-associated hospitalization or surgery;
and physicians’ assessment was also analyzed. Factors associated with exacerba-
tion of IBD were assessed by univariate and multivariate logistic regression
analysis.
Results: A total of 429 IBD (378 UC and 51 CD) patients, including 144 patients
who eradicated HP (eradication group) and 285 control patients (non-eradication
group), were enrolled. IBD exacerbation rates in 2 and 6 months of observation
were 8.3% (12/144) and 11.8% (17/144) in eradication group, which showed no
significant differences compared with those of 4.9% (14/285) and 7.7% (22/285)
in non-eradication group. Physicians’ assessment showed similar results in terms
of disease exacerbation, but in 2 months of observation no patient was improved
in eradication group whereas 3.2% (9/285) of patients was improved in non-
eradication group (P¼ 0.019). Multivariate analysis revealed that the indepen-
dent factor of IBD exacerbation after HP eradication was active disease at base-
line (OR 5.3 (95%CI: 1.5–16.9), P¼ 0.011). HP was eradicated in 82.9% (102/
123) of patients using clarithromycin as first-line treatment and 90.4% (19/21)
using metronidozole as second-line, both of which were comparable with pre-
vious reports in non-IBD patients.
Conclusion: HP eradication therapy does not exacerbate disease activity of IBD
without affecting eradication rate, but may not improve disease activity, suggest-
ing that careful observation is neccesary after eradication, especially for patients
with active disease.
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Introduction: The use of immunosuppressors, including Azathioprine (AZT) in
inflammatory bowel disease (IBD) is considered reference treatment. They are
indicated especially in the case of corticodependence, corticoresistance and in
postoperative reccurence. Their efficacy is primarily judged on clinical evaluation
and relapses. Few data are available on long-term healing during Crohn’s disease
(CD). The aim of this study is to evaluate the long-term clinical effectiveness of
AZT in luminal Crohn’s disease and in prevention of postoperative recurrence
with endoscopic evaluation.
Aims & Methods: In this retrospective study, 133 consecutive patients followed
for intestinal MC with or without anoperineal involvement were included
between 1/1/2016 and 31/03/2016. All patients with Rutgeerts score greater
than or equal to 2 received AZT. All patients were under AZT for at least 12
months, maintaining remission for luminal involvement or preventing
postoperative recurrence. All our patients have received clinical (HBI), biological
(CRP) and endoscopic evaluation (and MR enterography in some cases). They
were checked at different times (during the first 2 years¼G1, between 2 and 5
years¼G2 and beyond 5 years¼G3). Endoscopic remission was defined by the
absence of ulceration. Statistical analysis used the Student Fisher and U tests of
Mann Whitney.
Results: AZT was prescribed in 46.6% (62/133) cases of luminal involvement and
53.4% of cases to prevent post-operative recurrence. In the luminal disease
group, the sex ratio M/F was 1, the age at diagnosis was 27 years 9; A delay
in diagnosis was estimated at 1.5 years 2.5 (0–13 years). Smoking was found in
26% of cases (16/61). It was ileocolonic or colonic in 16.4% and 49.2% of cases,
phenotype B1 or B2 in 32.8% and 44.6% respectively. 47.5% had more than 2
corticosteroid treatments (CTC), the average time to start AZT was 4 6 years.
The mean duration of treatment was 3.5 5.2 years. The persistence of endo-
scopic lesions was observed in 46%, 20% and 25% of cases in G1, G2 and G3
respectively. Loss of response was observed in patient with more than 2 cures of
CTC (48% versus 25%, p¼ 0.042), and the B2B3 phenotype of the disease
[47.2% versus 26% (B1), p¼ 0.037] There was no correlation between HBI
and endoscopic healing. For postoperative recurrence, sex ratio 2.3 F/1 M, age
at diagnosis was 32 years 11 (17–70); The duration of the disease before surgery
was 34 months 44 (0–156), the time between surgery and AZT was estimated at
3 years 6 (0–20). 26% of patients were smokers. 63/72 (87.5%) underwent
surgery for stenosis and 5.5% after severe flare. 61% had intestinal resection
and 20.8% a right hemi colectomy. 6/72 (8.3%) had more than 2 resections.
60/72 had a colonoscopy before and after AZT. The persistence of i2-i4 lesions
was observed in 44%, 21% and 19% in G1, G2 and G3 respectively.
Conclusion: In our work, the existence of endoscopic lesions and the absence of
symptoms is not uncommon. The prediction after one year of clinical relapse in
case of endoscopic lesions is uncertain. The aim of this study, which is still
ongoing, is to determine the rate and predictive factors of failure, as well as
the modalities of endoscopic control especially concerning timing.
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Introduction: Based on the totality of evidence with similar analytical, pharma-
cokinetic (PK) and clinical results, SB2 was approved by European Medicines
Agency and U.S. Food and Drug Administration as a biosimilar of the reference
infliximab (INF) for all indications for which INF has been approved. Here we
report the PK profiles of SB2 compared to that of INF in two animal models,
healthy subjects and patients with rheumatoid arthritis (RA).
Aims & Methods: The pre-clinical PK profiles were evaluated in single and
repeated dose studies (1, 3, and 10mg/kg of SB2, European Union sourced
INF [EU-INF] or United States sourced INF [US-INF]) in two animal models
(Sprague Dawley [SD] rat and transgenic Tg197 mouse). The clinical Phase I
pivotal study for PK was conducted in healthy subjects1. The subjects received a
single 5mg/kg intravenous infusion of study drugs (SB2, EU-INF or US-INF)
and were observed for 10 weeks. PK equivalence was to be concluded if the 90%
confidence interval (CI) for the ratio geometric least squares means (LSMeans) of
the primary PK endpoints (area under the concentrationtime curve [AUC] from
time zero to infinity [AUCinf], AUC from time zero to the last quantifiable
concentration [AUClast] and maximum concentration [Cmax]) were within the
standard equivalence margin of 0.8 to 1.25. The steady state PK profile was
assessed in a Phase III study in RA patients2. In this study, the patients received
3mg/kg of SB2 or EU-INF at weeks 0, 2, 6 and then every 8 weeks up to 46
weeks. PK analyses were performed up to week 30. Infliximab serum concentra-
tion was measured through two different enzyme-linked immunosorbent assays
for pre-clinical and clinical studies.
Results: In pre-clinical studies, available PK profiles from animal studies showed
no significant differences in Cmax and AUClast between SB2, EU-INF and US-
INF. In healthy subjects, the 90% CIs for the primary PK parameters were
within the pre-defined equivalence margin of 0.8 to 1.25 between SB2 and refer-
ence products (SB2 vs. EU-INF and SB2 vs. US-INF). In RA patients, the mean
trough level was comparable between SB2 (ranging from 1.915 to 17.965 to mg/
mL) and EU-INF (ranging from 2.224 to 16.954 to mg/mL) from week 2 to week
30. The PK profiles were also comparable between SB2 and INF when analysed
by the presence of ADA in both Phase I and Phase III clinical studies.
Conclusion: Similar PK profiles of SB2 and reference products were confirmed in
pre-clinical and clinical studies. Altogether, the previously demonstrated analy-
tical similarity and the data presented here indicate that similar PK are expected
in all indications approved for SB2.
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Introduction: According to infliximab (IFX) license in inflammatory bowel dis-
eases (IBD), infusion doses are based on patient weight. In daily practice, treat-
ment is prepared by pharmacist after clinical patient assessment, leading to an
increased duration of hospital stay and consequently costs. A pharmacokinetic
study (1) has shown that a weight-based dose (WBD) strategy does not reduce
interindividual variability of IFX trough levels when compared to fixed doses.
According to these findings, our hospital implemented dose banding (DB) of IFX
infusions, defined by doses rounded up or down according to one of eight pre-
determined standard doses with a maximum theoretical deviation of þ/5%,
that allowed to prepare infusions at the pharmacy before patient admission.
Aims & Methods: The aim of the study was to compare hospitalisation length of
stay in patients receiving IFX DB as compared to those treated with IFX WBD.
From February to March 2017, we conducted a prospective, case-control study
in our unit, including all IBD patients admitted for an IFX infusion. Patients
who should receive an IFX dose between 250 and 800mg were included in the
DB group (treatment pre-prepared at the pharmacy, sent to the hospital unit
before patient admission and administered just after the clinical validation).
Patients who should receive an IFX dose below 250mg or above 800mg were
included in the WBD group (treatment prepared after clinical validation includ-
ing weight, and then sent to the hospital unit). Patients were analysed only when
precise length of stay could be obtained and measured in minutes. Primary
objective was to compare the length of stay at hospital in both groups.
Secondary objective was to compare the proportion of IFX doses cancelled,
reattributed and wasted infusions and the saved or wasted price associated (reim-
bursement price of one 100mg IFX vial: 382.28 E).
Results: Among the 373 IBD patients treated by IFX during the study period, 116
(31%) patients (51M/65F; median age: 41 years) were included in the study (75 in
the DB group and 41 in the WBD group) corresponding to 128 infusions (84 in
DB and 44 in WBD groups). Mean length of hospitalisation stay were
238 21min in the DB group and 308 32min in the DBW group, respectively
(p5 0.001). DB was associated with a mean reduction of length of stay of 23%,
corresponding to 70 minutes per patient. DB reduced significantly the mean
duration of stay by decreasing the waiting time between clinical assessment
and start of the infusion: 16min vs. 84min with WBD (p5 0.001). During the
study, none of the 44 (0%) infusion in the WBD group was cancelled while 3/84
(3.5%) were cancelled in the DB group (p¼ 0.55). Two out these three infusions
could be reattributed to other patients, saving 2801E.
Conclusion: When used routinely in IBD, IFX DB is associated with a shortened
length of stay as compared to WBD, with a mean reduction of 70 minutes per
patient. As IFX DB seems having similar efficacy to weight-based doses, it may
improve functioning of daily hospitalisation units.
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Introduction:Rapidity of response to treatment in CD is now considered a field of
major interest, due to the importance of achieving the highest benefit in the
shortest possible time. There are no studies specifically designed to evaluate
the rapidity of response to ADA neither other antiTNF therapies. The aim of
this trial was to evaluate the rapidity of onset of clinical response to ADA
therapy.
Aims & Methods: Adult antiTNF naı̈ve patients with active luminal (Harvey-
Bradshaw Index (HBI) 8) moderate-to-severe CD (excluding penetrating and
stricturing disease), with no response to a full and adequate course of therapy
with corticosteroids and/or immunosuppressants, were enrolled in this
interventional, prospective, open label, single arm and multicenter clinical trial.
Patients received standardized ADA treatment (160mg – 80mg – 40mg eow).
The HBI was evaluated to determine the response at day 4 and week 1; and
clinical remission at weeks 2, 4 and 12. Response was defined as a decrease of,
at least, 3 points in the HBI global score and remission was defined as HBI global
score55. CRP (C Reactive Protein) and fecal calprotectin (FC) were analyzed at
baseline, day 4, week 1, 2, 4, 12. The modified intention to treat (mITT) popula-
tion was the primary population for efficacy analysis and consisted of those
patients enrolled in the study who had received at least one dose of ADA.
Treatment-emergent serious adverse events (AEs) were recorded to assess
safety throughout the study until 70 days after last treatment dose. All patients
who received at least one dose of ADA were included in the safety population.
Statistical analyses were performed by the t-test or the Wilcoxon signed rank test,
as applicable. Time to clinical response was analyzed using a Kaplan-Meier
survival analysis model.
Results: 86 antiTNF naı̈ve patients were analyzed. A response at day 4 and week
1, was experienced by 60.5% and 74.4% of patients, respectively. Remission was
achieved by 53.5% of patients at week 2, 61.6% at week 4 and 54.7% at week 12.
The median time to obtain response was 4.0 days (95% confidence interval (CI):
1.0, 4.0) and the median time to remission was 7.0 days (95%CI: 4.0, 14.0).
Median CRP
levels (mg/L)
Median FC
levels (mg/g)
p-value vs baseline
for CRP and FC
Baseline 4.87 795 p5 0.0001
Day 4 1.70 430 p5 0.0001
Week 1 1.50 438 p5 0.0001
Week 2 1.56 419 p5 0.0001
Week 4 1.98 296 p5 0.0001
Week 12 1.68 300 p5 0.0001
During the study, 42.5% of the patients suffered from any adverse event (AE).
Only 3 patients (3.5%) showed a serious AE.
Conclusion: ADA produces rapid clinical remission and response since day 4 in
patients with moderate-to-severe CD unresponsive to therapy with corticoster-
oids and/or immunosuppressants.
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Introduction: Patients with gastrointestinal diseases such as inflammatory bowel
disease (IBD) often suffer from iron deficiency anaemia (IDA) and have a high
annual iron need. Intravenous administration of high-dose iron is the most effi-
cient approach to replenish iron stores. The present analysis evaluates safety and
efficacy of high doses of iron isomaltoside in patients with gastrointestinal
diseases.
Aims & Methods: This is a pooled analysis of 3 trials of iron isomaltoside per-
formed in patients with gastrointestinal diseases and IDA [1–3]. Outcome mea-
sures were adverse drug reactions (ADRs) and haemoglobin (Hb) measurements.
Results: 357 patients (108 men, 249 women) were included in the analysis of
which 255 were diagnosed with IBD and 102 with other gastrointestinal diseases,
incl. bariatric surgery, gastrointestinal bleeding etc. A cumulative dose of
1000mg and 41000mg iron isomaltoside was administered in 199 and 158
patients, respectively. ADRs were observed in 13.6% (36 events in 27 patients)
and 12.0% (30 events in 19 patients) of the patients dosed with 1000mg and
41000mg iron isomaltoside, respectively (p¼ 0.8). Similar frequencies was
observed in the IBD subgroup (14.3% versus 12.1%, p¼ 0.8). 0.5% of the
patients experienced a serious ADR (2 events in 2 patients; grand mal convulsion
and syncope). ADRs with a patient frequency 41% are shown in the table
below:
Patients (%)
ADR
1000mg iron
isomaltoside N¼ 199
41000mg iron
isomaltoside N¼ 158
Flushing 3.0 0
Constipation 0 1.9
Increased hepatic enzyme 1.5 0.6
Diarrhoea 0.5 1.3
Dyspepsia 0 1.3
Headache 1.0 1.3
Hypersensitivity 1.0 1.3
Abdominal pain 1.0 0.6
Hypertension 1.0 0
Hypotension 1.0 0.6
Nausea 1.0 0
Urticaria 1.0 0.6
No ADRs of hypophosphatemia were reported. In patients dosed with 1000mg
iron isomaltoside, Hb increased with a mean of 1.72 (95% confidence interval
(CI): 0.12) g/dL from baseline to week 3, 2.00 (0.12) g/dL to week 4, and 2.32
(0.13) g/dL to week 8. In patients dosed with 41000mg iron isomaltoside, Hb
increased with a mean of 2.04 (0.10) g/dL from baseline to week 3, 2.51 (0.09) g/
dL to week 4, and 3.01 (0.12) g/dL to week 8. The observed increase in Hb was
statistically significantly higher in patients dosed with 41000mg iron isomalto-
side (p5 0.04). In the IBD subgroup, a similar dose-depended statistically
increase in Hb was observed at week 3 and onwards (p5 0.02).
Conclusion: No dose-response for ADRs was observed with administration of
high cumulative doses of iron isomaltoside whereas Hb increased more after 3
weeks with doses 41000mg. Thus, high doses (41000mg) of iron isomaltoside
can be administered without additional safety concerns including concerns of
hypophosphatemia and with efficacious increases in Hb in patients with gastro-
intestinal diseases.
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Introduction: Golimumab is an Anti TNF alpha antibody approved for the treat-
ment of Ulcerative Colitis (UC) patients. Its efficacy and safety were studied in
randomized, double blind trials1, 2, but its effectiveness and safety in daily clinical
practice are still little known3.
Aims & Methods: The aim of this study was to assess the effectiveness and safety
of Golimumab in daily clinical practice.
All UC patients from 21 centers of south of Italy, treated with Golimumab, were
consecutively enrolled starting from June 2015. Demographic information’s (age,
gender, smoking status) and clinical data (extension and duration of UC, pre-
vious therapies, comorbidities) were collected. Clinical, laboratory and endo-
scopic data during the treatment with Golimumab were collected every three
months.
Results: A total of 190 patients (120 males) were enrolled. The mean age at
diagnosis and mean duration of disease were respectively 38.8 14.6 years, and
9.1 7.0 years. Only 21 patients were active smokers (11%). About the extension,
111 were pancolitis (58%), 72 had a distal colitis (38%) and 7 a proctitis (4%). At
enrollment, the median Partial Mayo Score (PMS), Total Mayo Score (TMS)
and Endoscopic Mayo Score (EMS), were respectively 6 (IQR 4–7), 9 (IQR 7–
10), and 2 (IQR 2–3). The median values of ESR, C Reactive Protein and faecal
calprotectine were respectively 25mm/1st hour (IQR 15–38), 3mg/dl (IQR 1–9),
and 250mg/kg (IQR 174–500). One hundred twenty five patients (66%) were
naı̈ve to anti TNF alpha, while 65 have been treated with Infliximab (n¼ 42),
Adalimumab (n¼ 5) or both (n¼ 19). The indications for Golimumab were:
steroid-resistance in 37 patients (20%), steroid-dependence in 130 (68%), extra-
intestinal manifestations in 6 (3%), and Anti TNF alpha failure in 17 (9%).
Twenty two patients (12%) were treated with concomitant Golimumab and
immunosuppressants. A total of 142 patients have been completed at least 3
months of therapy. Of these patients, a significant reduction of mean PMS
(n¼ 142; p5 0.001), TMS (n¼ 45; p5 0.001), EMS (n¼ 45; p5 0.001), ESR
(n¼ 125; p5 0.001), and CRP (n¼ 134; p5 0.001) were observed after 3
months. The rate of responders (reduction of 42 points of PMS) was 60%,
while the rate of clinical remission (PMS5 2) was 39%, and the rate of mucosal
healing (EMS 1) was 53%. Among the 85 responder patients, 67 (79%) have
also completely discontinuated the steroids. At univariate analysis for predictive
factors of response (gender, duration of disease, smoking status, previous Anti
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TNF, combo therapy, PMS, EMS, TMS, ESR, CRP, calprotectin, and indication
to therapy), the naı̈ve status to anti TNF alpha (p¼ 0.0001), higher values of
CRP (p¼ 0.0001), PMS (p¼ 0.0001), TMS (p¼ 0.0001) and EMS (p¼ 0.006)
were associated with better response. About the indication, steroid-resistance
was associated to the best response (p¼ 0.002), while Anti TNF resistance with
the worse response (p¼ 0.002). At multivariate analysis only TMS (p5 0.001,
OR 1.5 - CI95% 1.2–1.8) and Naı̈ve to Anti TNF alpha (p¼ 0.015, OR 3.0 - CI
1.2–7.5) were confirmed associated to better response. To date, only 33 patients
have discontinuated Golimumab (17%). A total of 15 adverse events (3 serious)
were observed. Ten non-responder patients underwent to colectomy (7 of them
were refractory to other anti TNF alpha).
Conclusion: Golimumab was effective and safe in induction of response in UC
patients in daily clinical practice.
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Introduction: The formation of antibodies to infliximab (ATI) is associated with
increased drug clearance. Patients with undetectable infliximab (IFX) levels and
positive ATI may indicate a group who may no longer be benefitting from the
drug. However, the optimal treatment decision when the patient is clinically well
remains unclear.
Aims & Methods: The aim was to assess the course of disease of patients in
remission, with undetectable IFX levels and positive antibodies. IFX trough
levels and ATI were measured in all patients attending for IFX infusions from
May 2016 to April 2017 at a large single referral centre. Results were retrospec-
tively reviewed in March 2017 to identify patients with undetectable (50.8 mg/L)
IFX trough levels and positive ATI (410mg/L). A local guideline suggested that
in in well patients of this cohort, patients should be switched to an alternative
biologic if duration of IFX treatment was 512 months, or if the duration of
therapy was 12 months to consider withdrawal of IFX or to assess disease
activity - with withdrawal of IFX in inactive disease or a switch to an alternative
biologic for active disease. Trough levels for IFX and ATI were measured using
drug tolerant enzyme-linked immunosorbent assays (Biohit, UK). Relapse was
defined as worsening of symptoms attributable to the inflammatory bowel dis-
ease, requiring an alteration in treatment. Kaplan-Meier with Tarone-Ware test
was used to compare survival curves for relapse and Cox regression model used
to analyse the impact of the different treatment decision on the rate of relapse.
Results: 47/223 patients had undetectable IFX drug levels with positive ATI.
Follow-up data was available in 45 patients. 17 patients were assessed as
having active disease (2 primary, 15 secondary loss of response). Of the 28 in
remission (at time of most recent TDM, median Harvey Bradshaw Index (HBI)
3.5; median Simple Clinical Colitis Activity Index (SCCAI) 2.5). 79% had a HBI/
SSCAI 55 but all were deemed to be in remission at time of review. 6/28 patients
had received prior anti-tumour necrosis factor- antagonists and 14/28 were
receiving concomitant immunosuppression (thiopurines 12; methotrexate 2). Of
these patients in remission, 7 continued on IFX (1 dose escalated), 13 had IFX
withdrawn and 8 were switched to an alternative biologic (adalimumab 4; vedo-
lizumab 3; ustekinumab 1). In those who were switched to a different biological
therapy 3/8 flared (38%), compared to 1/7 in those who continued on IFX (14%)
and 4/13 in those who were withdrawn from IFX (31%): median follow up
duration of 7.5 months (range 2–10 months). There was no significant difference
in the survival curves regarding rate of relapse based on the different manage-
ment decisions taken (p¼ 0.81; Figure 1). Patients withdrawn from IFX were not
at an increased risk of relapse compared to those who continued on treatment
(hazard ratio 1.62, p¼ 0.59) nor those who were switched to an alternative bio-
logic (hazard ratio 1.42, p¼ 0.65). Figure 1. Kaplan Meier of the rate of relapse
during follow-up of patients in clinical response with undetectable IFX levels
with positive ATI who were continued on IFX (n¼ 7), switched to an alternative
biologic (n¼ 8) and withdrawn from IFX n¼ 13 (p¼ 0.81).
Conclusion: Initial early experience in our centre suggests that withdrawal of IFX
in selected patients with undetectable IFX levels and positive ATI is not asso-
ciated with an increased risk of flare. Although not statistically significant, the
rate of relapses in those who continued on infliximab was lower compared to
those who were switched or withdrawn from therapy, however further follow-up
and greater numbers are required in this group.
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Introduction: ABP 710 is being developed as a biosimilar to infliximab, an anti-
tumour necrosis factor monoclonal antibody. Analytical and functional compar-
isons between ABP 710 and infliximab have been completed. This report
describes the results of a Phase 1 pharmacokinetic (PK) equivalence study com-
paring ABP 710 with infliximab
Aims & Methods: This was a single-blind, single-dose, 3-arm, parallel-group
study in healthy adults, 18 to 45 years of age and with a body mass index of
18 to 30 kg/m2. Subjects were randomised to receive a 5mg/kg intravenous (IV)
infusion of ABP 710 or infliximab sourced from the EU and the US after pre-
treatment with an antihistamine and acetaminophen 30 minutes prior to start of
infusion. The primary objective was demonstration of PK similarity of ABP 710
with infliximab EU and with infliximab US based on area under the serum
concentration-time curve from time 0 to infinity (AUCinf) as the primary end-
point. The criteria to achieve PK equivalence were for geometric mean (GM)
ratio and its 90% confidence interval (CI) to be within the range of 0.80 to 1.25.
Secondary endpoints included maximum observed serum concentration (Cmax),
safety, and immunogenicity.
Results: A total of 148 subjects received study treatment (ABP 710: n¼ 49; inflix-
imab EU: n¼ 49; infliximab US: n¼ 50). After a single dose, the adjusted least
square (LS) GM of AUCinf and Cmax were as follows: ABP 710, 33559 mgh/mL
and 123 mg/mL; infliximab EU, 33706 mgh/mL and 121 mg/mL; infliximab US,
37523 mgh/mL and127 mg/mL. Ratios of adjusted LS GM (90% CIs) for AUCinf
and Cmax between ABP 710 and infliximab EU were 0.996 (0.9042, 1.0963) and
1.021 (0.9624, 1.0827) and that between ABP 710 and infliximab US were 0.894
(0.8122, 0.9848) and 0.972 (0.9167, 1.0301). The ratios of adjusted LS GM (90%
CIs) of AUCinf and Cmax between infliximab US and infliximab EU were 1.113
(1.0115, 1.2252) and 1.05 (0.9906, 1.1138). The 90% CIs of these ratios were fully
contained within the 0.80 to 1.25 interval, confirming PK similarity between ABP
710 and infliximab, as well as between infliximab EU and infliximab US. There
were no deaths, serious adverse events, or treatment-emergent adverse events
(TEAEs) leading to discontinuation from the study; 1 subject in the infliximab
EU group developed polyarthritis that resolved with treatment and the subject
completed the study. The incidence of TEAEs was similar in the 3 groups (ABP
710: 83.7%; infliximab EU: 83.7%; infliximab US: 86.0%); the majority was mild
or moderate. The most frequently reported TEAEs were somnolence, headache,
nasopharyngitis, upper respiratory tract infection, nausea, and lethargy. All sub-
jects tested negative for antidrug antibodies (ADAs) prior to dosing. At the end
of study (Day 57), 40% subjects on ABP 710, 27% on infliximab EU, and 32%
on infliximab US were positive for binding ADAs; 13% on ABP 710, 19% on
infliximab EU and 10% on infliximab US were positive for neutralising ADAs.
Conclusion: Results of this study demonstrate PK similarity between ABP 710
and infliximab sourced from the EU and the US, as well as between infliximab
EU and infliximab US following a single 5mg/kg IV infusion in healthy subjects.
The safety and immunogenicity profiles were comparable among treatment
groups.
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Introduction: Complex perianal fistulas (CPF) are common among Crohn’s dis-
ease (CD) patients and are associated with substantial morbidity. The burden
and management of CPF are poorly studied.
Aims & Methods: To systematically review the literature on epidemiology, global
disease burden, and treatment outcomes for CPF in CD patients. PubMed,
Embase, and Cochrane were searched for relevant articles published from 2000
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forward; congress abstracts were searched from 2011 forward. CPFs were defined
as fistulas with intersphincteric, transsphincteric, suprasphincteric, extrasphinc-
teric, or horseshoe tracts.
Results: 535 records were reviewed by 2 independent researchers, and 63 relevant
articles and abstracts were selected for inclusion (including 3 epidemiology and 3
burden; the rest were treatment guidelines/patterns or treatment outcome stu-
dies). The estimated cumulative incidence of CPF in CD, based mostly on studies
conducted in referral centres, ranges from 12%14% (2 studies). CPF can result
in significant morbidity and greatly diminished quality of life; up to 59% of
patients (1 study) are at risk of fecal incontinence. Treatment options include a
combination of medical and surgical interventions. However, across all options
identified, a high proportion of patients experience treatment failure (lack of or
inadequate response) and relapse (Table). Only 4 identified studies were con-
ducted specifically in patients refractory to anti–tumor necrosis factor (TNF)–
 agents—a population with high unmet needs (one study of perifistular injec-
tions of infliximab, and three studies of surgical interventions). Available data
suggest that anti-TNF- dose escalation or switching between different anti-
TNF- agents is of limited value (2 studies). Table – Rates of treatment failure
and relapse or reoccurrence among patients withcomplex perianal fistulain
Crohn’s Diseasea
Conclusion: CPFs in CD pose substantial clinical burden. There is a high unmet
need for effective treatment options for CPF in CD patients, especially those
refractory to anti-TNF- agents, as evidenced by high treatment failure and
relapse rates.
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Introduction: Vitamin D deficiency is common in patients with Crohn’s disease
(CD). It is believed that this deficiency is related to the CD activity. Vitamin D
supplementation have many effects, including imunomodulation. However, the
role of Vitamin D (VD) in severe CD patients using Anti-TNF is still unclear.
Aims & Methods: To evaluate the results of the VD replacement at different
doses; check possible immunomodulatory action of vitamin D in CD patients
with Anti- TNF. We conducted a double-blind, randomized, prospective study.
42 patients were selected with history of moderate to severe CD in use of anti-
TNF, of both sexes, between 18 to 60 years, with dosage of 25-hydroxyvitamin D
575 nmol/L (30 ng/ml) who signed the informed consent. Were excluded patients
with less than 18 or over 70 years, pregnant women, chronic kidney or liver
disease, sarcoidosis, tuberculosis, hyper- or hypoparathyroidism, neoplasias,
use of anticonvulsants; and patients who received calcium supplements or VD
in the last 6 months. 30 patients were randomized. Patients were submitted to a
questionnaire of sun exposure, quality of life (IBDQ), clinical examination, VD
dosage, C-reactive protein (CRP), fecal calprotectin (FC) and were divided into
three groups: 1 Group (G1): 10 patients receiving 2,000U /VD, VO/week for 8
weeks, 2 Group 2 (G2): 10 patients receiving 10,000U /VD, VO/week for 8
weeks; 3 Group (G3): 10 patients receiving 50,000U /VD, V.O/week for 8
weeks. At the end of 8 weeks the patients answered IBDQ and were submitted
to VD, FC and CRP dosage. All patients were followed for 52w and checked for
disease activity recurrence (CDAI4 150, FC4 300, CT scan), FC, CRP and VD
levels.
Results: IBDQ improvement was observed in all groups with statistically signifi-
cant results in G2 (p¼ 0.04) and G3 (p¼ 0.01). Increased VD were observed in all
groups (meanSDmean SD): G1 - (19.5 5.1 26 6.7) p¼ 0.07; G2 -
(19.1 4.1 26 5.8) p¼ 0.04; G3–19.5 6.4 46.4 12.7) p5 0.0001. CRP
dosage were reduced, although not statistically significant, at G2 and G3
(5.8 4 3 9 2.8) p¼ 0.18 (5.2 7.3 2.4 3.6) p¼ 0.2; and increased in G1
(8.1 10, 3 13, 4 19.9) p¼ 0.3. There was a significant decrease in FC in G3
(1014 850 483 564) p¼ 0.04, no significant decrease in G2
(767 751 823 535) p¼ 0.2, and increase in G1 (1101 744 1357 819)
p¼ 0.4. 52 w follow period showed that recurrent disease activity were predomi-
nant in patients with VD5 30 (p¼ 0.0004) and statically significant results were
observed in disease activity recurrence rate (p¼ 0.006), FC (p¼ 0.02) and CRP
(p¼ 0.01) when compared patients with VD4 30 and VD5 30.
Conclusion: 50,000U /week was the best dosage for VD replacement and is
related to immunomodulation. Most of patients with CD in Anti-TNF therapy
have recurrent disease when VD5 30 and a hight remission rate with VD4 30.
VD levels are related to the effects of Anti-TNF therapy in CD patients.
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Introduction: Golimumab is approved for the treatment of moderate to severe
ulcerative colitis, but not Crohn’s disease (CD). Therefore, its potential efficacy
in CD remains largely unknown. Off-label use of drugs is not prohibited in
Sweden, and golimumab may have been used for CD treatment.
Results: The study cohort consisted of 95 patients with a median age of 37 (IQR
27–48) years, of whom 40% were men. The majority of the patients (90.5%) had
previously experienced treatment failure for at least one anti-TNF agent. At the
start of golimumab, 41% were on a concomitant immunomodulator and 16% on
corticosteroids. After a median follow-up time of 21 (IQR 10–36) months, 60
(63%) patients had stopped treatment with golimumab. Reasons for discontinua-
tion were inadequate response; n¼ 45 (75%), intolerance; n¼ 11 (18%) and other
reasons; n¼ 4 (7%). Estimated drug continuation rates were 73% at 12 weeks
and 42% at 52 weeks. Concomitant treatment with corticosteroids at baseline
seemed to be associated with a higher risk of discontinuation of golimumab
(unadjusted HR: 1.97; 95% CI: 1.04–3.73; p¼ 0.04), although the assocation
did not remain significant after adjusting for potential confounding factors
(adjusted HR: 1.76; 95% CI: 0.84–3.67; p¼ 0.13).
Aims & Methods: We aimed to describe the CD population that is treated with
golimumab in Sweden and to assess the long-term effectiveness, defined as drug
continuation rate, as well as identify predictors of drug discontinuation. Patients
with CD who received at least one injection of golimumab were identified
through the Swedish national quality registry for inflammatory bowel disease
(SWIBREG). Duration of golimumab-treatment was illustrated by Kaplan-
Meier curves. Univariate and multivariate Cox proportional hazard regression
models were used to identify predictors of golimumab discontinuation. The vari-
ables sex, age, duration of disease, location, perianal disease, smoking status,
previous surgery, concomitant treatment with corticosteroids or immunomodu-
lators at baseline, prior anti-TNF therapy and CRP at baseline were included in
the models.
Abstract: P1042
Treatment
Treatment failureb Relapse/recurrence
Rates, %
Number of
studies
Number of patients
per study (range) Rates, %
Number
of studies
Number of patients
per study (range)
Anti-TNF- agents
(agent unspecified)
46–60 3 39–66 27 1 66
Infliximab 12–58 4 6–52 41 1 52
Adalimumab 22–73 4 9–38 0 1 9
Surgical interventions 0–69 10 5–40 13–20 3 5–10
Combined medical and
surgical management
0–80 15 9–212 0–41 7 9–71
Standard of carec 30–68 4 15–250 23–66 3 79–250
a44 studies reported treatment outcomes for CPF in CD patients. Most studies identified were small and/or non-comparative, and study methodologies, populations,
endpoint definitions, and duration of follow-up varied. For studies with mixed populations, only results for patients with CD and CPF were considered. bDefined as
lack of or inadequate response to therapy (i.e. lack of complete response). cDefined as standard of care used at each centre excluding anti-TNFs and surgery in 2 studies
and as standard medical care at each centre including anti-TNF and surgery in 2 studies.
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Conclusion: Golimumab-treated patients with CD are a treatment-refractory
group. Despite this, more than 40% of the patients seemed to have sustained
clinical benefit after one year, since they were receiving continued golimumab
treatment. Co-concomitant corticosteroid treatment at start of golimumab
appears to be associated with worse outcome.
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Introduction: Clinical response and patient’s quality of life improve as a result of
the direct benefit of Crohn’s disease (CD) effective treatment. Rapidity of
response to treatment in CD is a field of major interest, due to the importance
of achieving the highest benefit in the shortest possible time. There are no studies
specifically designed for early evaluation of the quality of life in patients with
active CD receiving adalimumab therapy. The aim of this study was to evaluate
the rapidity of improvement of quality of life in response to adalimumab therapy
in adult antiTNF naı̈ve patients with active luminal (Harvey-Bradshaw Index
8) moderate-to-severe CD, and with no response to a full and adequate course
of therapy with corticosteroids and/or immunosuppressants.
Aims & Methods: To this purpose we designed an interventional, prospective,
open label, single arm and multicenter clinical trial. Quality of life was evaluated
by using the validated questionnaires EuroQol-5D (EQ-5D) and the 36 items
version of the Inflammatory Bowel Disease Questionnaire (IBDQ-36).
Questionnaires were administered at baseline, day 4 and weeks 1, 2 4 and 12
with standardized adalimumab treatment (160mg – 80mg – 40mg eow). The
modified intention to treat (mITT) population was the primary population for
analysis and consisted of those patients enrolled in the study who had received at
least one dose of adalimumab. Statistical analyses were performed by the t-test or
the Wilcoxon signed rank test, as applicable.
Results: Eighty-six patients were included. At baseline, the median EQ-5D index
score was 0.68. EQ-5D scores improved significantly versus baseline, at day 4 and
weeks 1, 2, 4 and 12, with median changes of 0.05 (p¼ 0.0005), 0.05 (p5 0.0001),
0.11 (p5 0.0001), 0.10 (p5 0.0001) and 0.11 (p5 0.0001), respectively.
Similarly, EQ-5D VAS median scores also improved significantly, compared to
baseline (median score at baseline: 55.00), at day 4 and thereafter, with median
changes of 5.00, 5.50, 9.50, 10.00 and 12.00, respectively (p 0.0001 at all time-
points). The comparison, versus baseline, of the IBDQ-36 overall score (median
score at baseline: 142.50) at day 4 and weeks 1, 2, 4 and 12, also yielded statis-
tically significant differences, with median improvements of 14.0, 18.0, 29.0, 42.0
and 35.5 respectively (p5 0.0001 at all time-points). Restoration of normal
health (IBDQ-36 score 4209) was obtained in 9% of patients at day 4 and
increased to 35% at week 12.
Conclusion: Adalimumab produces rapid improvement of quality of life since day
4 in patients with moderate-to-severe Crohńs disease.
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Introduction: Anti-tumor necrosis factor- (anti-TNF) agents are commonly
used treatment options for moderate to severe Crohn’s Disease (CD) and
Ulcerative Colitis (UC). However, despite their clinical effectiveness, few data
regarding the role on quality of life (QoL) are available.
Aims & Methods: To prospectively evaluate disease activity and QoL in a single-
centre cohort of CD and UC patients, after introduction of anti-TNF agents
(infliximab or adalimumab). All consecutive adult CD and UC patients who
started Infliximab (IFX) or Adalimumab (ADA) from 2014 to 2015 at Padua
University Hospital were enrolled. Disease severity was evaluated through
laboratory tests (Haemoglobin, C-reactive protein (CRP) and Fecal calprotectin)
and commonly used scores (Harvey Bradshow Index (HBI) for CD and Modified
Truelove and Witts Severity Index (MTWSI) for UC) for each patient, at anti-
TNF introduction and 12 months thereafter; QoL was assessed through the
Short-Inflammatory Bowel Disease Questionnaire (S-IBDQ).
Results: A total of 115 patients were consecutively evaluated, 33 patients were
excluded due to non-compliance (11.3%) or drop-out for adverse events or pri-
mary non response (17.3%) within 12 months. Eighty-two (71.5%) were included
in the statistical analysis (M/F 53/29, median age 43 years, CD/UC 42/40). Forty
and 42 patients started IFX and ADA, respectively. QoL was significantly higher
in CD than UC at baseline (median S-IBDQ 49 vs 32, p¼ 0.004). In CD patients,
anti-TNF determined significant reduction of HBI (median 3 vs 1; p5 0.01),
CRP (median 5 vs 2.9mg/L; p¼ 0.004), fecal calprotectin (median 429 vs 119 mg/
g; p5 0.001) but not haemoglobin (median 13.6 vs 13.2 g/dL, p¼ 0.25). QoL
significantly improved (median S-IBDQ 49 vs 59; p5 0.001), both in IFX and
ADA groups (IFX: p5 0.001; ADA: p¼ 0.02). In UC patients, anti-TNF ther-
apy improved disease activity (median MTWSI 7 vs 4, p¼ 0.03), haemoglobin
levels (median 11.6 vs 13.2 g/dL; p¼ 0.006), fecal calprotectin (median 1600 vs
108 ug/g; p¼ 0.004), but not CRP (median 5 vs 2.9mg/L, p¼ 0.08). QoL
improved at 12 months (median S-IBDQ: 32 vs 56, p¼ 0.001) both in patients
treated with IFX (p¼ 0.003) and ADA (p¼ 0.005). No adverse events were
reported during the study period.
Conclusion: Anti-TNF therapy is safe and improves disease activity and quality
of life of UC and CD patients.
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Introduction: Anti-TNF agents are widely used in the treatment of inflammatory
bowel diseases (IBD). Despite the fact that the intestine is the main therapeutic
A530 United European Gastroenterology Journal 5(5S)
target, little or no information is available regarding the ratios of free and TNF-
bound infliximab in the intestinal tissue.
Aims & Methods: We aimed to assess the presence of free versus TNF-bound
infliximab in the intestinal tissue of IBD patients and its possible association with
clinical outcomes. Protein was extracted from frozen intestinal tissues of inflix-
imab-treated patients. Free infliximab and TNF-bound infliximab were detected
using ELISA and normalized to tissue protein concentration. Concurrent serum
drug levels (SDL), anti-drug antibodies (ADA), serum TNF-bound infliximab
levels, patient’s pharmacotherapy, clinical response based on physician global
assessment, endoscopic appearance (severity determined according to mayo scor-
ing in ulcerative colitis and endoscopist’s assessment of ulceration severity, extent
of disease and affected area in Crohn’s disease) and pathological results (severity
determined by observing pathologist graded as normal, mild, moderate and
severe disease) at the time of colonoscopy were determined. Correlation were
performed using Spearman’s rank correlation test.
Results: Twenty four biopsies from 13 patients (11 Crohn’s disease and 2 ulcera-
tive colitis patients) were tested. Non-inflamed tissue infliximab levels, but not
inflamed tissue levels, correlated with SDL (R¼ 0.8499, p¼ 0.0037,
FDR¼ 0.0185) and were negatively correlated with the endoscopic appearance
(R¼0.7214, p¼ 0.0185) and pathological severity (R¼0.7959, p¼ 0.0059).
TNF-bound infliximab was measured in both inflamed and non-inflamed speci-
mens and did not correlate with drug levels in the serum or tissue. ADA was only
detected in a single patient, precluding statistical analysis. Notably, no TNF-
bound infliximab was measured in the serum.
Conclusion: These findings show that pharmacokinetic-pharmacodynamics inter-
action, as measured by SDL, better reflects drug levels in healthy mucosa rather
than the inflamed one, and suggest a more complex drug/target interaction in
inflamed tissue, which cannot be explained by target binding only. Future studies
assessing SDL dynamic changes during the process of mucosal healing may allow
their use as surrogate markers for this purpose.
Disclosure of Interest: B. Ungar: Bella Ungar has received consultancy fees from
Abbvie and Jannsen.
S. Ben-Horin: SBH has received consultancy and/or advisory board fees from
Schering-Plough, AbbVie, Celltrion, Pfizer, Ferring, Janssen and Takeda; and
has received research support from Celltrion, AbbVie & Takeda
Y. Chowers: YC declare Abbvie grant support, lecture and advisory fees, Janssen
lecture and advisory fees, Takeda grant support lecture and advisory fees,
Medtronics advisory fees
All other authors have declared no conflicts of interest.
P1050 LONG-TERM OUTCOMES OF MAINTENANCE ANTIBIOTIC
THERAPY IN CHRONIC ANTIBIOTIC-DEPENDENT POUCHITIS
S. Poo
1, J. Segal2, S. Mclaughlin3, O. Faiz4, S. Clark2, A. Hart5
1Imperial NHS Trust, London/United Kingdom
2Surgery And Cancer, Imperial College London, London/United Kingdom
3Royal Bournemouth and Christchurch Hospitals, Bournemouth/United Kingdom
4St. Marks Hospital, Harrow/United Kingdom
5IBD Unit, St Mark’s Hospital, Harrow/United Kingdom
Contact E-mail Address: stephanie.pooxw@gmail.com
Introduction: Restorative proctocolectomy (RPC) is considered the treatment of
choice in patients with ulcerative colitis (UC) who have failed medical therapy
and in some patients with familial adenomatous polyposis (FAP). After RPC,
approximately 40% of UC patients develop acute pouchitis at 5 years, for which
the mainstay treatment is empirical antibiotics. 10–15% of these patients subse-
quently develop chronic antibiotic-dependent pouchitis (CADP), and are main-
tained on long-term antibiotics to maintain clinical remission. Clostridium
difficile and tendon rupture are recognised significant complications associated
with long-term ciprofloxacin. We aimed to evaluate the effectiveness and safety
of long-term antibiotic use in patients with chronic pouchitis.
Aims & Methods: A retrospective analysis of patients started on antibiotic ther-
apy between Jan 2007 - Jan 2009 for CADP was performed. 39 patients (30
males) who underwent RPC for UC (n¼ 37) and FAP (n¼ 2) with a diagnosis
of CADP (defined as the need for antibiotics for at least one month and with a
Pouch Disease Activity Index (PDAI) of greater than 7) were identified.
Antibiotic-associated complications and functional outcomes were evaluated.
Patients were followed-up at a tertiary referral centre until the last clinic appoint-
ment or the development of pouch failure, defined as the need for an ileostomy.
Results: The median follow-up was 102 months (range 9–125); 27 (69%) patients
with CADP remained on antibiotics at last follow-up. The most common anti-
biotics used were ciprofloxacin (30%), metronidazole (19%) or a combination of
both (11%). Median 24 h stool frequency was 10 (range 4–25) at last follow-up.
This was unchanged from baseline (p4 0.05). Reported complications included:
7 (18%) perianal fistula, 12 (31%) anastomotic strictures requiring dilatation, 6
(15%) perianal sepsis, 5 (13%) incontinence and 11 (28%) antibiotic-related side
effects. Of 39 patients, 7 (18%) achieved remission while 8 (21%) developed
pouch failure requiring an ileostomy or pouch revision, over a median duration
of 6 years (range 3–9). Antibiotic resistance was identified from at least one stool
sample in 28/36 (78%) patients, however Clostridium difficile toxin was not
detected in any stool samples. No patient developed tendon rupture. 36 pouch-
related hospital admissions occurred in 11/39 (28%) patients. Reasons for admis-
sion included: 23 obstructive symptoms, 1 incontinence, 1 bleeding from pouch,
11 elective examinations under anaesthetic.
Conclusion: The management of chronic pouchitis remains challenging despite
long term antibiotic therapy. This is the first study to report the long-term out-
comes of long term antibiotics on patients with CADP. 69% of patients remained
on antibiotics at last follow up. Although the use of antibiotics in chronic pou-
chitis is justified, the complication rates remain high and pouch failure is an
inevitable consequence and occurs in 21% of our patient cohort. Antibiotic
resistance was reported in 78% of patients. The utility of long term antibiotics
must therefore be weighed against potential complications associated with pou-
chitis and antibiotics.
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Introduction: Infliximab (IFX) is an important agent in the treatment of inflam-
matory bowel disease (IBD). However, its use may be limited by the development
of antibodies to infliximab (ATI). The aim of this study was to assess the timing
and significance of ATI development in clinical practice.
Aims & Methods: Since May 2016, all IBD patients receiving intravenous IFX for
maintenance treatment, at a large, single, referral centre, have undergone ther-
apeutic drug monitoring (TDM). Serum IFX trough levels and ATI were both
measured by drug-tolerant enzymelinked immunosorbent assays (Biohit, UK)
from 199 patients at a variable interval following the start of IFX treatment.
IFX trough levels were considered undetectable (50.8 mg/L), low (0.8–2.9mg/
L), therapeutic (3–7mg/L) and supratherapeutic (47mg/L). ATI were consid-
ered positive if 410mg/L. Clinical remission was defined as a Harvey Bradshaw
Index or Simple Colitis Activity Index 4. Risk factors for ATI development
were assessed by binary logistic regression model, using 522 sera taken from
patients on maintenance therapy. Time to develop ATI, undetectable IFX
levels and loss of response to treatment was assessed by Cox regression and
Kaplan-Meier analysis.
Results: Male sex (OR¼2.1; p5 0.001), week of treatment (OR for each extra
week of treatment¼ 0.999; p5 0.038) and use of concomitant immunosuppres-
sion (IS) (OR¼ 0.373; p5 0.001) were associated with ATI formation. During
the period of observation, those not taking IS were more likely to develop ATI at
any time throughout their IFX treatment (Hazard Ratio¼ 2.4; p¼ 0.03). 59/199
patients were ATI positive at their first TDM, of whom 2 were in their first 6
months of IFX treatment. 140/199 patients were ATI negative at their first TDM.
During follow-up, we observed 32 patients develop ATI (19 patients developed
antibodies within 6 months of starting IFX treatment, 5 between 6–12 months
treatment and 8 after 12 months). At any given time, patients with positive ATI
are 3.4 times as likely (p¼ 0.002) to develop undetectable levels than ATI nega-
tive patients. Transient ATI formation was seen in only 5/162 patients. Figure 1.
Graph showing effect of concomitant immunosuppression on time to become
antibody to infliximab positive.
Conclusion: Although IS therapy protects against ATI formation, the risk of
antibody development continues throughout treatment. If concomitant IS is
aimed at reducing ATI formation, then this also needs to be continued for the
duration of IFX therapy.
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CROHN’S DISEASE
G. Moors
1, B. Verstockt1, S. Bian2, S. Tops2, V. Ballet1, G. Van Assche1,
S. Vermeire1, A. Gils2, M. Ferrante1
1Department Of Gastroenterology And Hepatology, University Hospitals Leuven,
Leuven/Belgium
2Laboratory For Therapeutic And Diagnostic Antibodies, Department Of
Pharmaceutical And Pharmacological Sciences, KU Leuven, Leuven/Belgium
Contact E-mail Address: gitte.moors@uzleuven.be
Introduction: Antidrug antibodies (ADA) may develop in up to 35% of patients
with Crohn’s disease (CD) receiving adalimumab (ADM). Although ADA to
ADM are predominantly neutralizing, standard drug-sensitive assays do not
allow ADA measurement in patients with detectable trough levels (TL) and
drug-tolerant assays are suboptimal in case of high TL.
Aims &Methods:We aimed to identify ADA using a drug-resistant assay, instead
of the standard drug-sensitive assay, and to correlate their presence with clinical
outcome. Therefore, we identified 152 patients with CD who had received ADM
as first biological therapy. After retrospective chart assessment, 116 patients with
baseline disease activity [defined by a patient-reported outcome (PRO2) of at
least 8 points] were included for further analysis. Clinical remission was defined
as an average daily stool frequency 2.8 and an average abdominal pain score
1. Serum samples were available in 70/116 at week 12 after ADM initiation.
ADA presence was determined via both a monoclonal drug-sensitive assay in
case of undetectable TL, and via an in-house developed drug-resistant assay
regardless of TL [1].
Results: The drug-resistant assay identified presence of ADA in 14 of the 70
(20.0%) patients at week 12, whereas a drug-sensitive assay could detect ADA
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in just one of these 14 patients (1.4%) (p5 0.001). Median (IQR) TL were
significantly higher in the ADA negative group compared to the ADA positive
group [9.21 (7.00–12.99) vs. 3.45 (1.72–5.44) mg/mL, p5 0.001]. A significant
correlation between TL and ADA levels could be found (Spearman’ rho
0.562, p5 0.001). Although the presence of these ADA was not significantly
associated with lack of clinical remission at week 12, a clear tendency was
observed (p¼ 0.136). During median (IQR) follow-up of 1.46 (0.32–3.48)
years, 43 out of 116 patients (37.1%) needed ADM dose-escalation.
Importantly, escalation-free-survival significantly differed between ADA positive
and negative patients (p¼ 0.001). Univariate analyse could not identify any more
factors (weight, BMI, gender, disease behaviour, disease location, CRP, serum
albumin, PRO2, concomitant therapy, smoking) associated with ADA presence
at week 12. Interestingly, 50% of the ADA positive patients had TL above 4 mg/
mL and would not have been dose optimized proactively according to current
practice. Though, 3 out of these 7 patients needed dose-escalation afterwards
which could have been expected based on the ADA positivity.
Conclusion: A drug-resistant assay can identify ADA to ADM before all drug has
been neutralised and TL become undetectable. As these ADA at week 12 are
significantly associated with need for dose-escalation and can appear before TL
drops below the threshold of 4 mg/mL, they may be better to identify those
patients who could benefit from dose-escalation. Moreover, the differences in
TL between patients at week 12 can finally be explained by the presence of ADA
measured with a drug-resistant assay.
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Introduction: Compliance is a significant problem in the medication of patients
with chronic diseases, especially during periods where patients are completely
unaware of their disease and just take their drugs to prevent disease recurrence.
(1) During the last years Shared Medication Record (SMR) was introduced in
Denmark (2). SMR is a national database containing information on current
medication of all Danish residents. SMR include information on where, when,
and how much medicine the patients by at the pharmacies. Therefore with SMR
it becomes possible for doctors to see if patients retrieve the prescribed medicine
at the pharmacy. Patients with chronic inflammatory bowel diseases (IBD),
ulcerative colitis (UC) or Crohns Disease (CD), have periods of flares of the
disease but in many cases also long periods when the disease is in remission.
The majority of patients need medication to reduce the risk of recurrence of
disease activity. This means that they need to take medicine even if they have
no symptoms of disease. Previous American studies have shown that a number of
patients in this situation do not take their medication and thus are at increased
risk for relapse of the disease (1). There are no corresponding data for Danish
patients. We wanted to find out the proportion of Danish IBD patients in remis-
sion who buy the prophylactic treatment as prescribed, and whether this propor-
tion will change when the patients are informed about that the doctor can see if
they pick up the medicine at the pharmacy.
Aims & Methods: The purpose of this study was to investigate whether Danish
patients with IBD in remission buy the prophylactic treatment as prescribed, if
these patients buy a larger part of their medicine when they know that the doctor
can see which medicines they buy at the pharmacy. 100 consecutive patients with
UC or CD in remission for at least six months and treated with a fixed dose of
Mesalazine, azathioprine, or Mercaptupurine during the preceding six months
were enrolled from Randers Regional Hospital Adult Gastroenterological
Outpatient Clinic. Patients were randomized 1:1 either to receive information
that the doctor could follow their pharmacy refills, or not to get information
on this. The patients were not informed that they participated in a study. All
patients had a second visit six to 12 months later. Patients who had flares in
disease activity during the study period was excluded. Adherence to the treatment
was defined as pharmacy refills according to the prescribed dose for at least 80%
of the period of the preceeding six months. Fisher’s exact test was used as test of
indenpendence between groups
Results: 67% of the patients in the study were adherent to their medical treatment
during the first study period decreasing to 48% during the second study period
(P5 0.01). There was no difference in the decrease in adherence between patients
informed about SMR and those who were not informed. Younger patiens were
less prone to adherence compared to older patients at the first study visit (Age
groups: 19–39/40–59/60þ Years, adherence 48/71/81%) (P5 0.05). We found no
differences related to disease (UC/CD), sex, 5-ASA/antipurins, or administration
route (oral/rectal).
Conclusion: Adherence to treatment fell from the first visit when the disease had
been in remission for at least six months, to the second study visit when the
disease had been in remission for at least 12 months. This was indenpendent of
whether the patients were aware that the physician could follow their medication
refills or not. This might indicate that adherence to medical treatment of IBD
decreases over time when the disease is in remission.
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Introduction:Golimumab (GOL) is a fully human monoclonal antibody to TNF
approved for the treatment of patients with moderate to severe ulcerative colitis
(UC) with inadequate response or intolerance to steroids or immunosuppressive
therapies. The aim of this study is to evaluate the efficacy and safety of GOL in
both biologic naı̈ve (BN) and biologic experienced (BE) patients.
Aims & Methods:Data were prospectively collected from a cohort of UC patients
treated with GOL from March 2015 to March 2017 at two centers. Data were
analyzed from two patient cohorts, namely BN patients and patients who have
already undergone treatment with infliximab or adalimumab (BE). Patients
received GOL 200mg sc. at week 0, GOL 100mg sc. at week 2, then 50mg or
100mg sc. every 4 weeks depending on body weight. The primary outcomes were
clinical response rate and incidence of adverse events (AEs).
Total
Biologic
Naı̈ve (BN)
Biologic
Experienced
(BE) p value
PATIENT CHARACTERISTICS
Number of patients (n, %) 59 (100) 27 (46) 32 (54)
Sex (n, %) 0.9
Male 28 (47) 13 (48) 15 (47)
Female 31 (53) 14 (52) 17 (53)
Charlson Comorbidity index (n, %) 0.7
0 56 (95) 26 (96) 30 (94)
1 3 (6) 1 (4) 2 (6)
Charlson Global index (n, %) 0.4
0–1 55 (77) 18 (67) 27 (85)
41 14 (23) 9 (33) 5 (15)
Age at diagnosis (years) (median, IQR) 33 (23–45) 33 (25–45) 32 (23–45) 0.5
Disease duration (years) (median, IQR) 8 (4–14) 8 (4–15) 9 (3–14) 0.7
Disease extension
(Montreal classification) (n, %)
0.3
E1 2 (3) 0 (0) 2 (6)
E2 33 (56) 17 (63) 16 (50)
E3 24 (41) 10 (37) 14 (44)
Endoscopic disease activity
(Mayo score) (n, %)
0.3
1 2 (3) 2 (7) 0 (0)
2 12 (20) 5 (18) 7 (22)
3 45 (77) 20 (74) 25 (78)
Previous ICS use (n, %) 0.7
Steroid dependence 49 (83) 23 (85) 26 (81)
Steroid resistance 10 (17) 4 (15) 6 (19)
Previous IMS (n, %) 0.7
Yes 41 (69) 18 (67) 23 (72)
Concomitant combination therapy (n, %) 4 (7) 1 (4) 3 (9)
STUDY RESULTS
(continued)
A532 United European Gastroenterology Journal 5(5S)
: Continued
Total
Biologic
Naı̈ve (BN)
Biologic
Experienced
(BE) p value
Surgery required after treatment (n, %) 13 (22) 3 (11) 10 (31) 0.2
Adverse events (n, %) 0.8
Yes 10 (17) 4 (15) 6 (19)
Discontinuation due to adverse events (n, %) 5 (50) 3 (75) 2 (33)
Time to discontinuation due to adverse
events (months) (median, IQR or mead, SD)
4 (1–4) 4 (2–4) 2 (1–4)
Patients eligible for analysis (n, %) 54 (92) 24 (89) 30 (94)
Duration of therapy (months) (median, IQR) 7 (4–14) 7 (4–13) 7 (4–14) 0.8
Follow-up data at 3 months (n, %)
Clinical response 26 (48) 14 (58) 12 (40) 0.8
Treatment failure 28 (52) 10 (42) 18 (60) 0.8
Follow-up at March 2017 (n, %)
Clinical response 17 (31) 8 (33) 9 (30) 0.5
Treatment failure 37 (69) 16 (67) 21 (70) 0.5
Results: Overall, data from 59 patients were analyzed. Of these, 27 (46%) were
BN and 32 (54%) BE. Baseline patient’s characteristics and main study results
are shown in Table 1. BN and BE patients were comparable in terms of comor-
bidity profile, age at diagnosis, disease duration, pattern of previous and con-
comitant conventional therapies, as well as of disease extension and severity.
Overall, surgical intervention after GOL therapy was performed in 13 (22%)
cases: 3 (11%) belonging to the BN and 10 (31%) and BE group, respectively
(p¼ 0.2). In 10 (17%) patients AEs were recorded, most of which were genitour-
inary or herpes simplex infections. Of note, two cases of basal cell carcinoma
were registered. The rate of AEs did not significantly differ among the BN and
BE groups (p¼ 0.8). In 5 (50%) patients AEs were responsible for therapy dis-
continuation after a median (IQR) period of 4 (1–4) months. Of the 54 (92%)
patients who continued therapy, median (IQR) duration of GOL treatment was 7
(4–14) months. At 3 months follow-up, 26 (48%) patients showed clinical
response to GOL. Clinical response rate was similar in the BN and BE cohorts
(p¼ 0.8). 28 (52%) patients were non-responders, without a statistically signifi-
cant difference between the two groups (p¼ 0.8). At March 2017, 17 (31%)
patients maintained clinical response, whereas 37 (69%) failed the treatment.
No statistically significant differences were noticed between the BN and BE
cohorts concerning the clinical response or the treatment failure (p¼ 0.5).
Conclusion: In our cohort, clinical response at 3 months follow-up was obtained
in almost half of patients while at the last follow-up in one third. BN and BE
patients had similar results in terms of clinical response, even though there seems
to be a better early response in BN patients. Even if not statistically significant,
surgery was required most frequently in the BE group. Rate of AEs was accep-
table and similar in both BN and BE patients. Although our findings need to be
confirmed in larger series, GOL therapy appears to be safe and to achieve an
acceptable disease control in both the biologic naı̈ve and experienced setting.
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Introduction: Endoscopic recurrence precedes clinical recurrence after ileocolonic
resection for Crohn’s disease (CD). Guidelines recommend an ileocolonoscopy
within the first year after surgery where timely treatment decisions may be
affected. The aim of our study was to describe the endoscopic monitoring and
associated treatment decisions within the first year after surgery in a cohort of
CD patients operated on between 2007 and 2010.
Aims & Methods: PRACTICROHN was a study that included patients aged 18
years-old from 26 Spanish hospitals who underwent CD-related ileocolonic resec-
tion with ileocolonic or ileorectal anastomosis between January 2007 and
December 2010. Clinical data was retrospectively collected from clinical charts
during 5 years follow-up after surgery. Categorical variables were compared with
the 2 test or Fisher’s exact test.
Results: Three hundred and fourteen patients were analyzed (mean age 40 years
[SD 13], 48% men). Throughout the observational period, 262 patients (83.4%)
underwent colonoscopy and 52 patients (16.5%) lacked endoscopic follow-up.
First endoscopy was performed mainly within the first year after surgery (45.5%,
n¼ 143) and the leading reason was a planned monitoring (66.4%, n¼ 95). In
total, 30.3% of the patients underwent planned endoscopy within first year after
surgery. By year, it was found a positive trend in the number of both total and
‘‘planned’’ endoscopies carried out within this period (p¼ 0.017 and p¼ 0.027,
respectively) (table).
Table
Patients underwent surgery
2007
n¼ 75
2008
n¼ 83
2009
n¼ 77
2010
n¼ 79 p-value
Patients with endoscopy within
first year after surgery, n(%)
24 (33.80) 36 (43.90) 36 (46.75) 47 (59.49) 0.017
Patients with ‘‘planned’’ endoscopy
within first year after surgery, n(%)
15 (20.00) 25 (30.12) 21 (27.27) 34 (43.04) 0.027
Treatments received by patients at discharge were Immunomodulators (30.8%),
antibiotics (21.3%), corticoesteroids (19.1%), mesalazine (12.1%) and antiTNFa
(0.9%). A total of 235 patients (74.8%) had a medication change throughout the
follow-up period, mainly within the first year after surgery (47.1%, n¼ 148).
Median time to first medication change was 10 (IQR 4–22) months. More
often therapeutic decision was the introduction or dose escalation of thiopurines
or change to a more potent agent (68.1%, n¼ 160) followed by the introduction
of an antiTNFa drug or dose escalation (51.4%, n¼ 121). Ninety-two out of 95
patients with planned endoscopy within first year after surgery had Rutgeerst
scoring (RS) available, 37 (40.2%) and 55 (59.7%) showed RS i2 and 5i2
respectively. More patients with a RS i2 had a medication change as compared
to patients with a RS5 i2, but the differences didn’t reach statistical significance
(45.95% vs 36.36%). Reasons for medication change were ‘‘endoscopic without
clinical recurrence’’ (52.9% RS i2 vs 10.0% RS5 i2, p¼ 0.010), ‘‘clinical recur-
rence’’ (29.4% RS i2 vs 25.0% RS5 i2) and ‘‘others’’ (23.5% RS i2 vs 60.0%
RS5 i2, p¼ 0.045).
Conclusion: The number of planned endoscopies carried out within the first year
after surgery increased significantly from 2007 to 2010 showing a steadily imple-
mentation of guidelines recommendations. Changes in medication within this
period were more frequent in the setting of endoscopic recurrence.
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Introduction: Etrolizumab, an anti-b7 monoclonal antibody targeting 4b7 and
Eb7 integrins, showed efficacy and safety versus placebo (PBO) during 10 weeks
(wk) of induction in patients with moderate-to-severe ulcerative colitis in the
Phase 2 EUCALYPTUS trial (Vermeire S. Lancet. 2014;384:309–18). Since a
reduction in histologic inflammation has been linked with improved long-term
clinical outcome (Bryant RV. Gut. 2016;65:408–14), and the FDA recommends
using both histologic and endoscopic assessments for efficacy evaluation, the
effect of etrolizumab on histologic inflammation was evaluated in mucosal biop-
sies from EUCALYPTUS patients using the Robarts histopathology index
(RHI; Mosli MH. Gut. 2017;66:50–8) and Nancy histological index (NHI;
Marchal-Bressenot A. Gut. 2017;66:43–9).
Aims & Methods: 124 patients were randomly assigned (1:1:1) to receive subcu-
taneous etrolizumab (100mg at wk 0, 4, and 8, with PBO at wk 2, or 420mg
loading dose at wk 0, followed by 300mg at wk 2, 4, and 8) or matching PBO.
Biopsies were taken using flexible sigmoidoscopy/full colonoscopy from the most
inflamed colonic area within 10–40 cm from the anal verge at baseline (BL) and
at wk 10. 62 patients provided consent for long-term sample storage for research;
batched H&E-stained slides were scored by a single pathologist using the Geboes
scale (later converted to RHI) and NHI. At wk 10, mean changes in RHI and
NHI scores for pooled etrolizumab or PBO were calculated. Subanalyses
explored histologic response (reductions of  6 or 10 points or 50% improve-
ment from BL RHI and 1 or 2 points reduction from BL NHI), remission (no
neutrophils, RHI 4 and NHI¼ 0, 1 or 2) and correlation with endoscopic
improvement.
Results: Analysis included 56 patients with BL data and BL NHI4 1. At wk 10,
RHI and NHI scores decreased by a greater extent with etrolizumab compared
with PBO, regardless of anti-tumor necrosis factor  (aTNF) experience (RHI
8.4 vs 1.6; P¼ 0.032 and NHI 1.2 vs 0.2; P¼ 0.011 for all comers). A
greater proportion of etrolizumab-treated patients achieved categorical histologic
improvement and remission. Of patients with an endoscopic subscore (ES) 1 at
wk 10 (n¼ 6), 100% experienced histologic response as assessed by RHI (5/5 with
RHI non-missing at wk 10), and 83% (5/6) by NHI. Mean (SD) RHI changes
were 19.2 (10.0) in patients with an ES 1 at wk 10 versus 4.4 (10.1) in
patients with an ES4 1. Mean (SD) NHI changes were 2.5 (1.5) in patients
with an ES 1 at wk 10 versus 0.6 (1.3) in patients with an ES4 1. Spearman’s
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correlation coefficients between RHI and NHI were 0.82 at BL and 0.91 at wk
10, while both histologic scores were similarly correlated with ES (0.25–0.28 at
BL and 0.38–0.40 at wk 10).
Table 1: Percentage of Patients Achieving Histologic Response and Remission
at Week 10
aTNF-naive
(n¼ 16)
aTNF-experienced
(n¼ 34)
All comers
(n¼ 50)
Etrolizumab Placebo Etrolizumab Placebo Etrolizumab Placebo
RESPONSE (decrease from baseline)
RHI 6 55% 17% 46% 36% 49% 30%
10 55% 0% 33% 21% 40% 15%
50% 36% 0% 25% 7% 29% 5%
NHI 1 73% 17% 52% 14% 58% 14%
2 55% 0% 32% 14% 39% 10%
REMISSION (absolute score)
RHI 4 36% 0% 8% 7% 17% 5%
No neutrophils 36% 0% 8% 7% 17% 5%
NHI ¼0 36% 0% 4% 14% 14% 10%
1 45% 0% 20% 14% 28% 10%
2* 73% 33% 56% 21% 61% 25%
*Must have achieved 1 point improvement
NHI 0¼no histologically significant disease
NHI 1¼ chronic inflammatory infiltrate with no acute inflammatory infiltrate
NHI 2¼mildly active disease
Conclusion: Histologic activity assessment using RHI or NHI demonstrates
improvement after wk 10 with etrolizumab treatment and was greater in
aTNF-naive patients. Importantly, RHI or NHI reductions were associated
with improved ES at wk 10.
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Introduction: GO-COLITIS (NCT02092285; 2013-004583-56) is a phase 4, multi-
centre, open-label, single-arm trial in the UK assessing efficacy of golimumab
(GLM) in induction and maintenance of clinical response in patients with mod-
erate to severe ulcerative colitis (UC) resistant to conventional treatment. Results
of the maintenance phase are presented here.
Aims & Methods: Anti-TNF naive adults with UC 3 months who responded to
induction therapy with subcutaneous GLM at week 6, according to partial Mayo
score (PMS), continued to receive a maintenance dose of 50mg or 100mg GLM
(dependent on the patient’s weight) every 4 weeks as per the Summary of Product
Characteristics for a total of 54 weeks. Measurements were taken at week 6, week
30 and week 54. The primary endpoint was the proportion of patients meeting
PMS response criteria at week 54 (defined as decrease in PMS of 2 points and
30% from baseline, plus a decrease in rectal bleeding subscore of 1 point or
absolute rectal bleeding score 1). Secondary endpoints included proportion of
patients meeting PMS remission criteria at week 54 (defined as PMS 2 and no
individual Mayo subscore 41), change from baseline in IBDQ and EQ-5D at
each visit and normalization of CRP.
Results: Overall, 205 patients enrolled in GO-COLITIS and received at least one
dose of GLM. Of these, 140 patients responded in the induction phase and
received GLM in the maintenance phase. Clinical response was maintained
through week 54 in 52/140 patients (37.1%; 95% CI, 29.1% to 45.7%) and 42/
140 patients were in remission at week 54 (30.0%; 95% CI, 22.6% to 38.3%).
Improvements in PMS subscores from baseline to week 54 were noted in stool
frequency (mean change, 1.9; SD, 1.1 [n¼ 59]), rectal bleeding (mean change,
1.5; SD, 0.8 [n¼ 59]), and physician’s global assessment (mean change, 1.8;
SD, 0.8 [n¼ 57]). Normal CRP levels at week 54 were seen in 50/59 patients
(response rate, 84.7%; 95% CI, 73.0% to 92.8%). IBDQ and EQ-5D results
are summarised in the Table. Serious adverse events (SAEs) occurred in 49/205
patients (23.9%), with 3 SAEs considered treatment-related.
Table: Mean (SD) Change from baseline to week 54 in IBDQ and EQ-5D.
n Baseline n Week 54 n
Change From
Baseline
IBDQ total score 138 116.4 (32.7) 59 186.2 (27.1) 59 66.8 (36.7)
EQ-5D index score 136 0.7 (0.2) 60 0.9 (0.2) 58 0.2 (0.3)
Conclusion: In the maintenance treatment with GLM phase of GO-COLITIS,
37.1% and 30.0% of patients with moderate to severe UC in the UK demon-
strated clinical response and remission at week 54, respectively. Improvements in
patient-reported quality of life measures (IBDQ/EQ-5D) were seen; the degree of
improvement in IBDQ total score exceeded the IBDQ increase cutoff (i.e. 420)
for patient defined-remission previously identified as representative of a patient-
defined improvement in an assessment of UC clinical endpoints.1 Adverse events
were consistent with previous observations.
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Introduction: Only a third of patients (pts) with inflammatory bowel disease
(IBD) treated with current pharmacological options achieve clinical remission
at 1 year, and most experience drug-related adverse events (AEs). Herein we
characterise the clinical and economic burden of IBD treatment limitations in
terms of AEs of interest, medical resource utilisation (MRU) and associated
medical costs.
Aims &Methods:Using pts taking only aminosalicylates (ASA) as a reference, we
compared AE incidence, MRU and medical costs in pts with ulcerative colitis
(UC) or Crohn’s disease (Crohn’s) who initiated treatment with oral corticoster-
oids (OCS), immunosuppressants (IS), anti–tumor necrosis factor agents (aTNF)
or with combinations thereof. Eligible pts (aged 418 years) in the IMS
PharMetrics insurance claims database between 7/1/10 and 6/30/15 had 2 med-
ical claims (7 days apart) and a diagnosis of UC (ICD-9-CM: 556.x) or Crohn’s
(ICD-9-CM: 555.x), with 41 qualifying claim in the year preceding treatment.
Univariate comparisons included statistical tests of significance (2, F test, or
Kruskal Wallis). Multivariate analyses were based on Cox proportional hazards
regression, negative binomial regression, logistic regression or linear regression
A534 United European Gastroenterology Journal 5(5S)
analysis adjusted by significant socio-demographic, clinical and disease severity
covariates.
Results: This analysis included 30,676 (Crohn’s: N¼ 14,528; UC: N¼ 16,148).
OCS monotherapy was the strongest predictor of any AE occurring for pts with
Crohn’s or UC (Crohn’s: HR, 1.62 [1.51–1.73]; UC: HR, 1.57 [1.49–1.66]). A
similar pattern was observed for severe infection (Crohn’s: HR, 2.43 [2.07–2.85];
UC: HR, 2.37 [2.07–2.72]) and bone-related conditions (Crohn’s: HR, 1.88 [1.74–
2.03]; UC: HR, 1.77 [1.67–1.89]). The strongest predictors for serious hepatic
events were ISþOCS (Crohn’s: HR, 2.38 [1.72–3.31]; UC: HR, 2.36 [1.75–
3.18]) and OCS (Crohn’s: HR, 2.09 [1.65–2.66]; UC: HR, 1.92 [1.57–2.34]). Pts
with UC or Crohn’s receiving OCS or ISþOCS were more likely to have emer-
gency department visits; IBD-related hospitalisation, visits or procedures; and
gastrointestinal surgery compared with pts receiving other therapies. Annualised
total medical costs were greatest for aTNFþ IS or aTNF therapy in both
Crohn’s and UC. However, annualised medical service costs (that exclude IBD
drug costs) were highest for pts initiating OCS-containing therapies (Crohn’s:
OCS, $27,041 and OCSþ IS, $23,332; UC: OCS, $19,659) followed by other
index therapies (Crohn’s: ASA, $10,823 and aTNFþ IS, $19,151 [P5 0.001];
UC: ASA, $7,980 and aTNFþ IS, $18,771 [P5 0.001]).
Conclusion: Chronic OCS use was associated with increased risk of severe infec-
tion, bone conditions, and serious hepatic events compared with other therapies.
Consistent with an increased AE risk, OCS regimens were associated with higher
rates of MRU and medical service costs compared with other therapies.
Although limiting the use of OCS regimens may be more costly initially, treat-
ment decisions should consider downstream benefits of alternate options.
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Introduction: Infliximab has been shown to induce and maintain long-term clin-
ical remission in inflammatory bowel disease (IBD) patients. However, 10–30%
of patients show no clinical benefit by the end of induction (week 14) and are
considered primary non-responders. The mechanisms underlying primary non-
response have not yet been clearly defined.
Aims & Methods: In this study we aimed to evaluate to which extent pharmaco-
kinetics (early induction infliximab and anti-infliximab-antibody (ATI) levels)
are associated with primary non response. A retrospective observational case-
control study of patients with IBD attending the Gastroenterology Department
of Sheba medical center and treated with infliximab between 2009 and 2016 was
performed. Clinical scores were determined and sera were collected prospectively
before infusions. Infliximab and ATI levels were measured by our previously
described drug-tolerant ELISA assay.
Results: Thirty five primary non responders have been identified and matched at
1:3 ratio with 105 primary responders for a total of 140 patients. Both week 2 and
week 6 infliximab levels were significantly lower among primary non-responders
compared to responders (week 2: median level 7.2 mg/ml vs. 13.5mg/ml,
p¼ 0.0019, week 6: median level 2.2 mg/ml vs. 9.5 mg/ml, p5 0.0001, respec-
tively). ATI appeared more frequently (either week 2 or 6, OR¼ 4.6, CI 2–
10.8, p¼ 0.0004) and at higher levels in non-responders compared to responders
(week 2: median ATI 7.3 mg/ml-eq vs. 3.8 mg/ml-eq, p¼ 0.005, week 6: 10.8 mg/ml-
eq vs. 4.4 mg/ml-eq, p¼ 0.008, respectively). Moreover, week 2 ATI levels
44.3 mg/ml-eq (AUC¼ 0.78, p¼ 0.0004, sensitivity 77%, specificity 71%) and
infliximab levels 56.8 mg/ml (AUC¼ 0.68, p¼ 0.002, sensitivity 50%, specificity
86%) were predictive of primary non-response. In analyses of various demo-
graphic and clinical factors correlated with primary non-response the only inde-
pendent factors found significant on multivariable analyses were lower infliximab
and higher ATI levels at either week 2 or 6, infliximab monotherapy and previous
IBD-related surgeries. Sub-analyses according to IBD type demonstrated that in
addition to lower drug and higher ATI levels, older age and previous surgeries
increased the risk for primary non-response among Crohn’s disease patients.
Monotherapy was the only other factor significant among ulcerative colitis
patients, although multivariate analysis was not performed due to limited
sample size (n¼ 32).
Conclusion: Although direction of causality cannot be ascertained, infliximab
levels below 6.8 mg/ml and ATI levels above 4.33mg/ml-eq before the second
infusion (week 2) are predictive of primary non response, in addition to previous
CD-related surgeries and infliximab monotherapy. These findings suggest that
preemptive interventions in a subset of patients might minimize this
phenomenon.
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Introduction: Topical therapies for ulcerative colitis have shown evidence of good
efficacy and can induce better responses and earlier improvement in distal ulcera-
tive colitis (UC) when compared with oral therapies. Despite this attractive
targeted approach of delivering medications topically to the left colon a certain
resistance to the use of topical therapy seems to exist.
Aims & Methods: The goal of this market research was to assess the familiarity
with and perceptions of patients towards topical products. A qualitative market
research study was performed in the USA and 3 European countries (Germany,
UK and Italy). The primary patient recruitment sources were online web portals,
e-mail campaigns and social networking sites. Informal feedback gathered from
outspoken patient activists to identify the right sources was also used. In order to
select UC patients with more advanced disease and/or a longer disease history
current or past steroid medication was mandatory as a qualification for inclusion
in the market research. A structured questionnaire covering 14 items was pre-
tested and modified in phone interviews, which was then subsequently used in
telephone interviews or as a web based interactive survey, both in local language.
A total of 148 patient responses were obtained via 10 phone interviews and 138
web-survey, 60 patients came from the US, 27, 25 and 36 from Germany, UK
and Italy, respectively.
Results: In this survey cohort patients had been diagnosed with UC for 45 years
on average, 2/3 of patients had left-sided disease and less than a third had
extensive disease. The majority of patients experienced at least 1–2 flare-ups
each year and less than 18% of patients had them only rarely. ASA and steroids
were the most commonly used medications in all countries, biological treatments
were reported as highest in 35% (US) to the lowest 16% (UK) as stated by the
patients. The vast majority of patients stated that they had treatment experience
with rectal products at some point during their treatment journey with only a
slightly lower number in the US (83%) compared to the EU countries (Range 89–
92%). Rectal enemas were the most common formulation delivery for topical
ASA products in all markets (79%) followed by suppository (25%) and foam
(13%). A total of 53% of patients were not concerned about the rectal mode of
administration, while 47% reported some concerns. These mainly comprised the
need to hold the enema in place, a generally uncomfortable feeling with rectal
medications and painful administration.
Conclusion: Despite a certain resistance to use topical therapy almost all patients
stated to have used rectally administered products at some point during their
disease journey and even patients in the USA were very familiar with these
medications. Although physicians see patients as the primary driver for the resis-
tance to use topical products in UC, less than 50% of the patients were actually
concerned about the use of topical therapy in this study, thereby calling for better
physician–patient communication.
Disclosure of Interest: T. Bayrhoffer: Consultancy for Index Pharmaceuticals
A. Thompson: Consultancy for Index Pharmaceuticals
T. Knittel: Consultancy, CMO position and share holding of Index
Pharmaceuticals
P1061 SELF-MANAGEMENT IN INFLAMMATORY BOWEL
DISEASE: A PERSPECTIVE OF NURSES AND PHYSICIANS
S. P. Van Den Burg, N. M.s. Peek, A. E. Van Der Meulen - De Jong,
J.P.w. Maljaars
Gastroenterology And Hepatology, LUMC, Leiden/Netherlands
Contact E-mail Address: s.p.van_den_burg@lumc.nl
Introduction: Over the last years, self-management (SM) has been advocated as
an instrument to empower and enable patients, increase patient involvement and
reduce healthcare costs in chronic diseases. Although many SM programs have
been developed for inflammatory bowel disease (IBD) patients, little research has
been performed on needs and wishes of IBD physicians, nurses and patients.
Nurses and physicians play an important role in providing and stimulating
SM.1–3
Aims & Methods: This study aimed to gain insight in what caregivers consider
good SM-options, and which patient- or disease-related factors they consider of
influence on the degree of SM a patient is willing to apply. During a nurses IBD
day at our hospital, a survey regarding SM was distributed among 46 nurses.
Also, 50 IBD-interested gastroenterologists were invited to respond to the same
survey by email with a link to the survey. The survey contained questions regard-
ing the caregivers’ views on ways for patients to apply SM in an outpatient
setting (12 options were given). Caregivers were asked to state whether they
thought these options would be valuable to patients or not, and to name their
top three options. Also, caregivers were asked their views on factors that could
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influence the degree of SM a patient is willing to apply, such as: disease duration,
activity and perception, health literacy, self-efficacy, patients’ age, and level of
trust between patient’s and their IBD team. Caregivers were asked per item
whether they thought this factor would be of influence and to name the three
most important factors.
Results: 38 nurses (mean age 42 years) and 32 physicians (mean age 44 years)
responded to the survey. The three most appealing options for nurses regarding
SM were: availability of a SM web-app, Skype/Face-time consultation with
nurse/physician, and an at-home faecal-calprotectin test. Physicians preferred
the availability of a SM web-app, an at-home faecal-calprotectin test, and
making patients in charge of their patient records. When comparing the value
of each of the 12 possible choices in which patients could apply SM, only one
option was valued differently between nurses and physicians. 56% of physicians
favoured patients being in charge of patients records compared to 18% of nurses
(p¼ 0.001). Physicians thought that the 3 most important factors influencing SM
in patients were: level of trust between physician and patient, self-efficacy, and
disease perception. Also, 41% of the physicians found health literacy to be an
important factor. Nurses suggested that self-efficacy, disease perception and dis-
ease activity were most important. One factor was valued differently between
nurses and physicians: 78% of nurses thought that patients’ age was an impor-
tant factor in patient’s SM, compared to 34% of physicians (p¼ 0.000).
Conclusion: Overall, nurses and physicians agree on many aspects of SM in IBD-
care. However, more physicians are in favour of making patients in charge of
their patient records. Nurses and physicians agree that patient characteristics, in
contrast to disease characteristics, influence SM, with self-efficacy being the most
important. This study calls for further research on what patients and caregivers,
want and need from SM, as SM is a team sport.
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Introduction: The combination of myrrh, chamomile flowers, and coffee charcoal
has shown first evidence for potential efficacy in maintaining remission in ulcera-
tive colitis (UC). SCFA are end products of the microbial fermentation of dietary
fibers in the gut. They are involved in the regulation of the gut immune system,
promote mineral absorption, lipid metabolism, mucin production and expression
of antimicrobial peptides. UC patients often show reduced occurrence of SCFA
especially during flare. This might lead to unfavorable health impairments
including higher risk of inflammation and heightened cancer risk.
Aims & Methods: The purpose of the present study was to evaluate the influence
of mesalazine and of the herbal preparation on SCFA in ulcerative colitis.
Analyses was proceeded as sub-study of a randomized double-blind, double-
dummy, controlled clinical trial that has been published previously. Patients
were treated with the herbal preparation consisted of 100mg myrrh, 70mg cha-
momile extract and 50mg coffee charcoal (Myrrhinil-Intest; Repha GmbH,
Hannover, Germany) 4tblx3/d or the gold standard treatment with mesalamine
500mg 3xd. Clinical activity was monitored with the CAI (Rachmilewitz) with a
CAI 44 indicating a clinical flare. Fecal samples were collected, gas chromato-
graphy was performed and SCFA (butyrate, acetate, propionate, iso-valerate and
iso-butyrate) were measured at baseline, in the event of a clinical flare or at the
end of the 12-month time interval.
Results: A total of n¼ 89 patients were included in the study. N¼ 43 pts devel-
oped a clinical flare (descriptive statistics are shown in table 1). Patients who were
treated with mesalamine showed a significant decline of the SCFA (M
basline¼ 66.12; SD¼ 39.59; M flare¼ 29.83; SD¼ 15.05; 95% BCI [18.86–
58.60]) in the event of a flare. In contrast, patients who were treated with the
herbal preparation showed no significant decline of the SCFA (M
basline¼ 64.80; SD¼ 53.74; M flare¼ 48.09; SD¼ 35.90; 95% BCI [-.71–
42.28]) in the event of a flare. There was no significant decline in SCFA in the
patients in remission neither for the herbal preparation (n¼ 19; M base-
line¼ 65.77; SD¼ 43.38; M 12month¼ 48.63; SD¼ 23.23; 95% BCI [-7.02–
39.95]) nor for mesalamine (n¼ 27; M basline¼ 57.01; SD¼ 34.40; M 12 month-
¼ 42.01; SD¼ 19.84; 95% BCI [-.34–29.54]).
Conclusion: Findings show that the herbal preparation might induce different
effects on the SCFA of patients with UC compared to mesalamine and therefore
might exhibit different modes of action in treating UC. Since a decline of SCFA
might lead to unfavorable health impairments like higher cancer risk, treatment
options like the herbal preparation might yield additional beneficial effects in the
treatment of UC. A combination of the two treatment modalities might be useful
and should be investigated in further studies.
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Introduction: Selective GMA using Adacolumn  device is a non-pharmacologi-
cal therapeutic option for patients affected by IBD, but its precise role among the
various treatments available and its true effectiveness are still debated. In parti-
cular, steroid-dependent patients, refractory or intolerant to immunosuppressant
and biologics, represent a sub-group of patients with limited options of treat-
ment. Recently, a multicentric open-label trial [the ART trial *] showed, for the
first time, a clinical benefit of GMA in these problematic patients.
Aims & Methods: The aim of this study was to further evaluate, in our real-life
clinical experience, the efficacy and safety of GMA in these difficult-to-treat
patients. We retrospectively reviewed the clinical data of patients treated with
GMA-Adacolumn in our center between 1/1/2008 and 31/12/2016. Only ster-
oid-dependent and/or AZA/IFX/ADA-resistant or intolerant cases were consid-
ered. GMA was performed once a week for a minimum of five consecutive weeks.
Occasionally, one or two additional sessions were performed. A clinical response
was defined as a 3 points reduction of the clinical activity index (CAI) for
ulcerative colitis (UC) and a 100 points reduction of the Crohn disease activity
index (CDAI) for Crohn disease (CD) after 12 weeks from the beginning of the
treatment.
Results: The study population included a total of 30 patients (17 males, 13
females, mean age 49 years, range 21–73) affected by UC (20 patients) and CD
(10 patients). Eight patients (5 UC, 3 CD) were excluded from the final analysis
for incomplete data. In the remaining 22 pts a clinical response, at week 12, was
observed in 15 (68%). The response was better in UC (11/15¼ 73%) than in CD
(4/7¼ 57%). A steroid-sparing effect was observed in all responsive patients.
GMA was generally well tolerated, as only 4 patients (13%) reported mild
adverse events (headache in two, hypotension in one, vascular procedure com-
plication in one) and no patients discontinued the apheresis due to the adverse
events.
Conclusion: In our real-life single-center experience, focused to a selected group
of difficult-to-treat patients affected by IBD, GMA with Adacolumn seems to
be, in a short-time evaluation, a useful and safe option of treatment, supporting
the recent data from the ART trial. Prospective randomized trials in larger
sample of patients and with more extended follow-up are needed to confirm
these results.
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Introduction: The herbal medicinal product Myrrhinil-Intest, a combination of
myrrh (Commiphora molmol E.), chamomile flower (Matricaria chamomilla L.)
and coffee charcoal (Coffea Arabica L.) is used for the treatment of gastrointest-
inal complaints. Clinical data suggest its use for the maintenance therapy of
inflammatory bowel disease [1]. Despite existing clinical data, pharmacological
data supporting the observed efficacy remain insufficient.
Aims & Methods: The present study aims to investigate the influence of the single
and combined herbal extracts with regard to its antispasmodic and immune-
modulating activities. Thus, the effect of myrrh, chamomile flower, coffee char-
coal extract on intestinal motility was determined using isometric tension mea-
surement in isolated rat small intestinal preparations. Furthermore chemokine
(IL8; CXCL10; CXCL13) release from cytokine-(10 ng/mL TNF; 5 ng/mL
IL1b; 10 ng/mL IFN)-challenged intestinal epithelial cells (Caco2) and LPS-
challenged human macrophages (THP-1) was investigated respectively using an
ELISA test system. Budesonid served as positive control. To characterize the
combined effect, concentration-response relations of single components and the
herbal combination were compared and IC50 values derived. Interpretation of the
data was based on a dose reduction index (DRI;¼ IC50-single/IC50-comb.) which
estimates the extent to which the dose of one or more components in the combi-
nation can be reduced to achieve effect levels that are comparable with those
achieved with single component.
Results: Myrrh and chamomile flower extract exerted spasmolytic effects by
inhibiting acetylcholine-induced contractions in rat small intestinal preparations
(IC50: myrrh¼ 144 mg/mL; chamomile flower¼ 383 mg/mL). In combination,
chamomile flower and myrrh interacted additively (IC50: myrrh¼ 74 mg/mL; cha-
momile flower¼ 196 mg/mL) resulting in a DRI of 1.9. All three plant compo-
nents inhibited CXCL13 release from LPS-stimulated human macrophages (IC50:
myrrh¼ 19 mg/mL; chamomile flower¼ 82mg/mL; coffee charcoal¼ 106 mg/mL).
Synergistic effects exerted by the herbal combination in inhibiting CXCL13
release significantly reduced IC50 values (IC50: myrrh¼ 5 mg/mL; chamomile
flower¼ 22mg/mL; coffee charcoal¼ 29mg/mL) resulting in a DRI of 3.7.
Cytokine induced CXCL10 release from Caco2 cells was reduced by all herbal
components (IC50: myrrh¼ 41mg/mL; chamomile flower¼ 364 mg/mL; coffee
charcoal¼ 447 mg/mL) with comparably high IC50 values. However, application
of the herbal combination, significantly reduced the IC50 of the plant extracts
(myrrh-IC50¼ 25 mg/mL, DRI¼ 1.7; chamomile flower-IC50¼ 124 mg/mL,
DRI¼ 2.9; coffee charcoal-IC50¼ 124 mg/mL, DRI¼ 3.6). IL8 release from cyto-
kine-challenged Caco2 cells was inhibited after myrrh (IC50¼ 3 mg/mL; 28% max
inhib.) and coffee charcoal (IC50¼ 218 mg/mL; 75% max inhib.) but increased
after chamomile flower treatment (EC50¼ 39 mg/mL; 29% max stimul.).
Treatment with all three plant extracts resulted in a moderate IL8 inhibition
with an inverted U-shape concentration-response curve (IC50: myrrh¼ 56mg/
ml; coffee charcoal¼ 281 mg/ml; 77% max. inhib.).
Conclusion: The herbal components myrrh, chamomile flower and coffee char-
coal influenced chemokine signalling of stimulated intestinal epithelial cells and
activated macrophages. Myrrh and chamomile flower additionally exerted anti-
spasmodic effects. Synergistic and additive effects between the plant extracts
justify the combinatory composition of the traditional herbal medicinal product
(Myrrhinil-Intest) and its application for the treatment of inflammatory intest-
inal disorders.
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J. González-López1, M. Barreiro-De Acosta2, C. Llamas3, J.E. Dominguez-
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Introduction: Therapeutic drug monitoring of infliximab (IFX) and adalimumab
(ADA) in inflammatory bowel disease are commonly used if patients show loss of
response, but there are scarce data about the influence of trough levels on
prognosis.
Aims & Methods: The aim of the study was to evaluate the relationship between
drug concentration of anti-TNF and treatment failure and duration of treatment
in a real life environment. METHODS A prospective observational study was
performed in a cohort of patients with inflammatory bowel disease. Patients were
included consecutively through visits to the hospital to receive IFX or ADA.
Inclusion criteria were all age 418 year patients, being treated with one of the
study drugs at standard dose as maintenance therapy and giving consent to
participate in the study. In the first visit, blood samples were extracted for
drug concentration determination. Patients were followed-up for the next 2
years. Trough drug concentrations and drug antibodies were measured by an
ELISA technique (Promonitor). Patients with IFX levels 53mcg/mL and
ADA 55mcg/mL were considered under lower limit of therapeutic range
(LLTR). After the follow-up period, the number of patients that continued (suc-
cess) or discontinued (failures) the treatment were analyzed. Any change in
dosage (intensification) or in the type of drug was considered as discontinuation
of the treatment. Chi square test was used to analyze the dependence between the
categorical variables and t-student for continuous variables with normal
distribution.
Results: 134 patients were consecutively included, 53 male (40%), 92 (68%)
patients with Crohn’s disease (CD) and 42 (32%) with ulcerative colitis (UC),
82 (61%) received maintenance treatment with IFX and 52 (39%) with ADA.
Mean age was 43 [19–71] years. After finishing the follow-up, 107 (79%) patients
continued the same treatment regimen (success). A total of 59% of this group of
patients were with drug concentrations above LLTR. The remaining 27 patients
changed their treatment (failures). In the failure group, only 41% of the patients
were above LLTR, 18.2% less with respect to success treatment group. These
results did not reach statistical significance (p¼ 0.09), but are in agreement with
current evidence. When type of inflammatory disease was analyzed, a greater
percentage of patients below the LLTR were found in the UC group (41.3% vs
52.4%, CD and UC respectively), but the difference did not reach statistical
significance. Regarding the duration of the treatments, the duration was similar
in the group of patients with low concentrations compared to the group with high
drug concentrations (46.6 vs 42.6 months). However, when the duration of treat-
ment was analyzed in patients who discontinued, significant differences were
observed (43.8 vs 20.2 months in the 5LLTR and 4LLTR groups respectively).
Therefore, there are patients who relapse rapidly even with drug levels above
LLTR. We observed 14 patients with positive antibodies, all of them with drug
concentrations below the LLTR.
Conclusion: The percentage of patients who continue treatment was higher when
drug concentrations were above LLTR. However, these high levels did not pre-
vent the early relapse of some of them.
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Introduction: In Crohn’s disease there is clear benefit from combination therapy
with infliximab (IFX) and immunosuppressive drugs (IS), while the benefit seems
more limited for adalimumab (ADA). Although some studies suggest a benefit of
combination therapy with IFX in ulcerative colitis (UC) few data are available
[1].
Aims & Methods: Our aim was to compare real life efficacy of anti-TNF mono-
therapy (IFX and ADA) and anti-TNFþ IS for UC maintenance. This was a
retrospective study of patients with UC treated with IFX or ADA in 2 Belgian
academic and regional Hospitals. Treatment periods were divided into 6-month
semesters. A combination therapy semester was defined as anti-TNFþ IS for at
least 3 months, a failure semester as anti-TNF withdrawal for secondary loss of
response, intolerance or surgery, a treatment optimisation semester as anti-TNF
dose escalation or steroids start. Semesters with and without failure and with or
without optimisation were compared through univariate and multivariate analy-
sis. Patients receiving 6 months anti-TNFþ IS during the first semesters were
separately analysed.
Results: 478 semesters in 60 patients with IFX and 175 semesters in 33 patients
with ADA were included. The mean IFX and ADA treatment duration were
respectively 49 (33) months and 38 (19) months. Within patients treated with
IFX, 32/60 patients received IFXþ IS during the first semester. IFX was admini-
strated as monotherapy in 361/478 semesters (76%). Respectively 218/478 (46%)
and 78/478 semesters (16%) with IFX required dose escalation and corticoster-
oids course. IFXþ IS was associated with more semesters with failure (5% vs
3%, p¼ 0.02) and numerically more semesters with dose escalation (64% vs 28%,
p¼ 0.06). There was no difference in corticosteroids use (p¼ 0.63). IS during the
first semester was not associated with lower risk of IFX failure (p¼ 0.41) nor
with a longer survival without IFX withdrawal (p¼ 0.20). Continuing the IS
treatment beyond the first semester was not associated with fewer semesters
with failure (p¼ 0.18). Within patients treated with ADA, 19/33 patients received
IFXþ IS during the first semester. ADA was administrated as monotherapy in
93/175 semesters (53%). Respectively 84/175 (48%) and 42/175 (24%) semesters
with ADA required dose escalation and corticosteroids course. ADAþ IS was
not associated with less semesters with failure (7% vs 5%, p¼ 0.58), less seme-
sters with corticosteroids use (p¼ 0.63). More semesters with ADAþ IS required
ADA dose escalation (61% vs 30%, p¼ 0.01). IS during the first semester was
not associated with lower risk of ADA failure (p¼ 0.84) nor with a longer survi-
val without ADA withdrawal (p¼ 0.78). Continuing the IS treatment beyond the
first semester was not associated with fewer semesters with failure (p¼ 0.20).
Conclusion: In this real-life experience, combination therapy of IFX or ADA with
IS during the first semester or prolonged after the first semester was not asso-
ciated with less dose escalations, steroid courses or treatment failures.
United European Gastroenterology Journal 5(5S) A537
Disclosure of Interest: All authors have declared no conflicts of interest.
Reference
1. Panaccione R et al. Gastroenterology. 2014 Feb;146(2):392–400
P1067 EFFICACY AND SAFETY OF ADALIMUMAB AFTER
INFLIXIMAB FAILURE IN PEDIATRIC ULCERATIVE COLITIS: A
REAL-LIFE EXPERIENCE FROM THE SIGENP-IBD REGISTRY
M. Aloi
1, M. Bramuzzo2, S. Arrigo3, C. Romano4, D. Iacorte5, S. Gatti6,
M.T. Illiceto7, F. Zucconi1, D. Dilillo8, G. Zuin8, D. Knafelz9, A. Ravelli10,
G. D’Arcangelo1, P. Alvisi11
1Pediatric Gastroenterology And Liver Unit, Sapienza University of Rome Dept. of
Pediatric Gastroenterology SIGENP IBD Group, Rome/Italy
2Institute For Maternal And Child Health, Irccs ‘‘burlo Garofalo,’’, Pediatric
Department, Gastroenterology and Nutrition Unit, Trieste/Italy
3Pediatric Gastroenterology Unit, Institute ‘‘Giannina Gaslini’’, Genova/Italy
4Pediatric Gastroenterology And Endoscopy, Pediatric Department, Pediatric
Department, Messina/Italy
5Pediatric Gastroenterology Unit, Maggiore Hospital, Bologna/Italy
6Pediatric Gastroenterology Unit, Salesi Children Hospital, Ancona/Italy
7Pediatric Gastroenterology And Endoscopy Unit, Spirito Santo Hospital, Pescara/
Italy
8Pediatric Department, Gastroenterology Unit, Buzzi Children Hospital, Milan/
Italy
9Gastroenterology And Nutrition Unit, "Bambino Gesù" Children Hospital, Rome/
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Introduction: The objective of the present study was to evaluate the effectiveness
and safety of adalimumab (ADA) in children with ulcerative colitis (UC) who
experienced previous infliximab (IFX) failure or intolerance.
Aims & Methods: This retrospective study included all children with UC from a
national pediatric registry who received ADA therapy. The primary endpoint
was the rate of corticosteroid (CS) free remission (PUCAI5 10) at week 52.
Secondary outcomes were: the rate of continuous clinical response and remission,
primary non-response and loss of response at Weeks 12, 30, and 52 and rate of
mucosal healing (MH) at week 52.
Results: A total of 32 children with UC received ADA (median age 10 4years).
Median disease duration before ADA therapy was 27 months. All patients
received previous IFX therapy (43% intolerant, 50% not-responders, 7% posi-
tive anti-IFX antibodies). Fifty-two weeks after ADA initiation 13 patients
(41%) were in CS-free remission. MH occurred in 9 patients (28%) at 52
week. The cumulative probability of clinical relapse-free course was 69%, 59%
and 53% at 12, 30 and 52 weeks, respectively. Ten patients (31%) had a primary
failure and 5 (15%) loss of response to ADA. No significant differences in terms
of efficacy were reported between not-responders and intolerant to IFX (p¼ 1.0).
Overall, 19 patient (59%) maintained ADA therapy during 52-week follow-up.
Seven patients (22%) experienced a an adverse event. No serious side effects were
observed and none resulted in ADA discontinuation.
Conclusion: In this cohort of children with UC ADA had a favorable short- and
long-term efficacy, allowing to recover a significant percentage of patients intol-
erant or not-responding to IFX. The efficacy was not related to the cause of IFX
discontinuation (intolerance/failure). Overall, the safety profile was good.
Larger, prospective, controlled trial with longer follow-up should be suggested
to better clarify the role of ADA in pediatric UC.
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Introduction: Inflammatory Bowel Diseases (IBD), Crohn Disease (CD) and
Ulcerative Colitis (UC), are idiopathic autoimmune conditions whose pathogen-
esis is still unknown. It has been hypothesized that, in genetic predispose subjects,
a deregulated immune response associated to an increase of intestinal permeabil-
ity may lead to bowel damage and clinical manifestations. Thus, environmental
factors and, in particular, food intake may play a pivotal role in IBD
pathogenesis.
Aims & Methods: The aim of this prospective study was to evaluate the effects of
a 6-week low fermentable Oligosaccharides, disaccharides, monosaccharides and
polyols (FODMAP) diet on disease activity and quality of life in patients with
IBD. At first visit (T0), patients were clinically evaluated by a gastroenterologist
and a nutritionist, filled a questionnaire on quality of life (the IBD-Q) and under-
went blood tests as well as fecal calprotectin assessment. Disease activity was
defined using the Mayo score and the Harvey Bradshaw Index (HBI) for UC and
CD, respectively. After the baseline visit, patients were randomized into two
groups: A) patients underwent a low FODMAP diet; B) patients underwent a
diet with normal FODMAP amount. A food diary was used to assess patients’
adherence to the different diets. After six weeks (T1), patients had a second visit
to assess disease activity, complete the IBD-Q, and repeat blood tests as well as
fecal calprotectin assessment.
Results: In this prospective, interventional, cohort study, we enrolled 55 conse-
cutive IBD patients who agreed to participate from an initial cohort of 127 IBD
patients. Twenty-six patients were randomised to a low FODMAP diet (group
A), while 29 patients to a standard FODMAP diet (group B). Among CD
patients (n¼ 35, 63.6%), median HBI values significantly decreased during the
study, in the whole population and in group A, whereas no change was recorded
in group B (respectively P¼ 0.02; P¼ 0.02; P¼ 0.3). Among UC patients (n¼ 20,
36.4%), median Mayo scores did not significantly decrease during the study,
both considering the whole population and the two groups (P¼ 0.3, P¼ 0.3,
and P¼ 0.8, respectively). Moreover, despite no statistically significant difference
in quality of life in both groups at T0, in group A quality of life improved after
the diet compared to group B (respectively, P¼ 0.06, P¼ 0.05 and P¼ 1).
Conclusion:We demonstrated that a low FODMAP diet, for a limited period of 6
weeks, is able to improve both disease activity, at least for CD, and quality of life
in IBD patients. Further, larger multicentre studies are needed to confirm these
preliminary data.
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Introduction:Ustekinumab has shown a good safety profile and efficacy to induce
and maintain remission in adult patients with refractory Crohn’s Disease (CD).
Data are lacking in children.
Aims & Methods: All CD patients under 18 years who received ustekinumab were
included in this retrospective observational study performed in a single tertiary
pediatric centre.
Results: See table.
Conclusion: Subcutaneous ustekinumab is effective to induce and maintain remis-
sion in severe pediatric CD refractory to anti-TNF antibodies.
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References
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S,
Johanns J, Blank M, Rutgeerts P; Ustekinumab Crohn’s Disease Study Group.
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal
antibody, in patients with moderate-to-severe Crohn’s disease.
Gastroenterology. 2008 Oct;135(4):113041.
Sandborn WJ, Gasink C, Gao L-L, Blank MA, Johanns J, Guzzo C, Sands BE,
Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R,
Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group.
Ustekinumab induction and maintenance therapy in refractory Crohn’s disease.
N Engl J Med. 2012 Oct 18;367(16):1519–28.
Kopylov U, Afif W, Cohen A, Bitton A, Wild G, Bessissow T, Wyse J, Al-Taweel
T, Szilagyi A, Seidman E. Subcutaneous ustekinumab for the treatment of anti-
TNF resistant Crohn’s disease–the McGill experience. J Crohns Colitis. 2014
Nov;8(11):151622.
Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos
B, Grimaud JC, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-Biroulet L,
Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B;
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P1070 TROUGH LEVELS TO INFLIXIMAB AT W6 ARE
PREDICTIVE OF REMISSION AT W14, IN PEDIATRIC CROHN
DISEASE
C. Martinez-Vinson, O. Courbette, C. Aupiais, J. Viala, J. Hugot
Gastroentérologie Pédiatrique, Hôpital Robert Debré, Paris/France
Contact E-mail Address: christine.martinez-vinson@aphp.fr
Introduction: Loss of response to anti-tumor necrosis factor (TNF) agents is
a common clinical problem. 40% of patients lose response within 12 months
of therapy initiation. This retrospective study aimed to analyse factors
associated with remission after 14 weeks of induction treatment by IFX in chil-
dren with CD.
Aims & Methods: All patients aged from 2 to 18 years old with CD meeting
European Crohn’s and Colitis Organisation criteria and treated for the first
time by IFX between January 2002 and March 2014 at a single tertiary pediatric
center were considered for inclusion in this retrospective study. The following
baseline characteristics were anonymously recorded for each patient: gender, age
at CD onset, age at inclusion, duration of disease, CD classification according to
Paris classification, prior exposure to CD treatments, previous intestinal resec-
tions and reasons for anti-TNF initiation. At each infusion visit (week 0, 2, 6 and
14) disease activity was determined using Pediatric Crohn’s disease Activity Index
(PCDAI). Four blood samples were obtained for each patient (at W0, W2, W6
and W14). The following laboratory tests were recorded: ESR, CRP, hemoglo-
bin, hematocrit, albumin, blood levels of lymphocytes, Trough levels to IFX
(TRI) and antibodies to IFX (ATIs). Children were classified in three groups
according to response at week 14: (1) remission was defined by a Crohn’s Disease
Activity Index under or equal to 10; (2) partial response was defined by a PCDAI
decreased by more 12.5 points since inclusion without a remission as defined
above; (3) absence of partial response or remission.
Results: We analyzed 107 patients with CD, with a total of 428 visits until W14.
The principal reason to start infliximab was failure of immunosuppressive ther-
apy (60%). Infliximab proved to be an effective treatment in our cohort since
75.7% (n¼ 81) patients were responders to infliximab and 40% (n¼ 42) were in
clinical remission whereas 24.3% (n¼ 26) were non respondents at W14. At week
14, 107 patients were divided in three groups related to the clinical activity of
their disease: lack of clinical response, partial clinical response, clinical remission.
It concerns respectively 26, 39 and 42 patients. Major baseline characteristics
were not associated with clinical remission: sex, age at diagnosis, disease location,
time between diagnosis and induction, age at induction. Drugs associated with
infliximab at W0, W2, W6 or W14, whether it was immunosuppressive agents or
corticoids were not associated with remission. Patients with low albumin levels
had a worse response at induction Activity score at induction was also statisti-
cally associated with clinical remission: each decreasing of 10 points of activity
score at induction increase of 0.48 times the risk to obtain clinical remission.
Trough residual of infliximab 48.5 mg/ml at w6 increase of 11.3 times the risk to
obtain clinical remission at w14. Lack of growth retardation at induction
increased of 3.98 times the risk to obtain clinical remission at w14.
Conclusion: Infliximab measurement in combination with evaluation of clinical
severity (low body weight, growth retardation, hypoalbuminemia, severe disease)
appears to be a reasonable strategy for predicting both short- and long-term
treatment outcomes with IFX in the initial stage of treatment. Early detection
of response to IFX is critical for the management of CD, especially in acute
severe patients: it seems that the infliximab trough level at week 6 (more than
8.5) is predictive of a remission at week 14. Second, some patients, especially
patients with low body weight, growth retardation, hypoalbuminemia and severe
disease may require higher doses than standart doses.
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P1071 INFLIXIMAB INDUCED PSORIASIS IN A COHORT OF
CHILDREN WITH INFLAMMATORY BOWEL DISEASE: A 12 YEARS
FOLLOW-UP STUDY
C. Martinez-Vinson, O. Courbette, C. Aupiais, J. Viala, J. Hugot
Gastroentérologie Pédiatrique, Hôpital Robert Debré, Paris/France
Contact E-mail Address: christine.martinez-vinson@aphp.fr
Introduction: In adult Inflammatory bowel disease (IBD), skin adverse reactions
have an estimated prevalence of 1.6 to 22%. This side effect occurs more fre-
quently in patients treated with infliximab (IFX) for IBD. Datas in the pediatric
population are lacking so far.
Aims & Methods: All patients aged 2 to 18 years, with Crohn’s disease (CD) or
Ulcerative colitis (UC) and treated for the first time by IFX between January
2002 and March 2014, were considered for inclusion in this monocentric retro-
spective study.
Results: Basline Patients: 115 patients were treated with IFX for CD and 23 for
UC. IFX treatment was initiated at the age of 14, about 2 years after diagnosis.
The indication for treatment was in 61.6% (n¼ 85) resistance to conventional
therapy, in 26.8% (n¼ 37) a perianal fistulizing disease and in 11.6% (n¼ 16) a
severe colitis. At the first injection, the median PCDAI was 35 (25; 45) for CD
and the median PUCAI 35 (25; 45) for UC. The duration of treatment with IFX
ranged from 45 days to 8 years and median was 23.9 months (11.6; 36.5).
Psoriasis: 20 patients (14% of the cohort) had an IFX-induced psoriasis. 70%
of them (n¼ 14) of patients were in remission when the psoriasis was diagnosed.
Psoriasis was diagnosed at the 8th injection (6; 15), though 355 (239; 532) days
after the start of biotherapy. 20% of patients had a combo therapy: 50% of them
were treated by 6-mercaptopurine, 25% by azathioprine and 25% by methotrex-
ate. The median IFX trough levels (TRI) when psoriasis occured was 4.7mcg/mL
(1.8; 9.6) and 4.1mcg/mL (2.1, 8.8) at the previous visit. Median Antibodies to
IFX (ATI) rate was 0%. All were supported by local treatments. No patients
discontinued biotherapy following the psoriasis. Personal or family history of
psoriasis, and the smoking status have not been collected. We compared the
population of patients with psoriasis (n¼ 20) and without psoriasis (n¼ 127)
with an univariate model. All children in the psoriasis group were followed for
a CD. There was more perineal location of CD in psoriasis group with a sig-
nificant difference (p¼ 0.033).
Conclusion: 14% of our IBD patients treated with IFX developed psoriasis
during follow-up. All were CD, more frequently it occurred for CD with perineal
lesions, at the 8th injection in median, with no ATI.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
Kerbleski JF, Gottlieb AB. Dermatological complications and safety of anti-
TNF treatments. Gut 2009;58:1033–9.
Davet N, Ritchlin C. Paradoxical adverse events associated with anti-TNF alpha
agents. Seneschal J, Milpied B, Vergier B et al. Cytokine imbalance with
increased production of interferon-alpha in psoriasiform eruptions associated
with antitumour necrosis factor-alpha treatments. Br J Dermatol
2009;161:1081–8.
Collamer A N, Battafarano D F. Psoriatic skin lesions induced by tumor necrosis
factor antagonist therapy: clinical features and possible immunopathogenesis.
Semin Arthritis Rheum 2010;40:233–40.
De Gannes G C, Ghoreishi M, Pope J et al. Psoriasis and pustular dermatitis
triggered by TNF-alpha inhibitors in patients with rheumatologic conditions.
Arch Dermatol 2007;143:223–31.
Tillack C, E hmann L M, F riedrich M et al. Anti-TNF antibody-induced psor-
iasiform skin lesions in patients with infl ammatory bowel disease are charac-
terised by interferon- -expressing Th 1 cells and IL-17 A/IL-22-expressing Th 17
cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014; 63: 567–77.
Rahier J -F, Buche S, Peyrin-Biroulet L et al. Severe skin lesions cause patients
with inflammatory bowel disease to discontinue anti-tumor necrosis factor
therapy. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc
2010; 8: 1048–55.
Broge T, Nguyen N, Sacks A et al. Infl iximab-associated psoriasis in children
with Crohn’s disease may require withdrawal of anti-tumor necrosis factor ther-
apy. Infl amm Bowel Dis 2013; 19: 75–7.
Collamer A N, Guerrero K T, Henning J S et al. Psoriatic skin lesions induced by
tumor necrosis factor antagonist therapy: a literature review and potential
mechanisms of action. Arthritis Rheum 2 008; 5 9: 9 96– 1 001.
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P1072 PLATELET ABNORMALITIES AND ANEMIA IN
PAEDIATRIC IBD: ARE THEY LINKED?
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Introduction: Crohn’s Disease (CD) and Ulcerative Colitis (UC) are two mayor
forms of Inflammatory Bowel Disease (IBD). In children with IBD anemia is
common and is a combination of iron deficiency and anemia of chronic disease
(ACD). IBD are associated with several alterations of platelets, including
number, shape, and function1. In clinical practice, the most common platelet
alteration is thrombocytosis. In IBD, thrombocytosis is associated with iron
deficiency anemia and chronic inflammation2. The importance of platelet func-
tion is due to the substantially increased incidence of thromboembolic phenom-
ena in IBD 3.
Aims & Methods: The aim of the study is to demonstrate the link between
anemia, thrombocytosis and platelet aggregation in pediatric IBD patients.
This study includes 51 children and adolescents recruited from the Pediatric
Gastroenterology Unit of Policlinico Umberto I in Rome. Patients younger 6
years, with inherited platelet defects, hemoglobinopathies, and receiving thera-
pies that alter platelet function, are excluded. We collect disease activity scores
(Pediatric Crohn’s Disease Activity Index [PCDAI], Pediatric Ulcerative Colitis
Activity Index [PUCAI]). The laboratory investigations include: complete blood
count, mean corpuscular volume (MCV), mean platelet volume (MPV), mean
corpuscular haemoglobin concentration (MCHC), levels of hemoglobin (Hb) and
levels of serum ferritin (SF), transferrin and iron. Diagnostic criteria for anemia
are based on ECCO guidelines. Platelet aggregation is evaluated on platelet-rich
plasma in an AggRAM aggregometer with Born’s Method. The results were
reported as the maximal percentage of aggregation observed after 4min stimula-
tion in response to collagen (1 mg/mL) and adenosine diphosphate (ADP 0.8mM
and ADP 2 mM).
Results: The study include 51 children and adolescents, 24 with UC and 27 with
CD (median age is 15.3 years 3.5). Iron deficiency anemia combined to ACD is
the most common type (58.3% in UC and 50% in CD). Hemoglobin levels are
significantly lower in patients with UC compared to CD patients (p¼ 0.0320).
No significant differences are observed between mean values of red cells, MCV,
MCHC, RDW, iron, transferrin and serum ferritin both in CD and UC.
Thrombocytosis prevails in UC compared to CD patients, but no significant
correlation was found. No differences are oserved between mean values of
PDW and MPV in both groups.In patients with UC, a negative correlation
was found between mean values of hemoglobin and platelet count (p¼ 0.0134).
Moreover in patients with CD, disease activity was positively correlated with
platelet count (p¼ 0.0040). Platelet aggregation results higher in anemic patients.
In anemic children, mean baseline platelet aggregations - induced by
ADP 0.8 mM and collagen 1 mg/mL- are significantly higher in UC compared to
CD (p¼ 0.001 and p¼ 0.030 respectively). Another significant correlation is
observed between platelet aggregation - induced by ADP 0.8 mM and ADP
2 mM - in anemic UC patients compared to non-anemic UC patients (p¼ 0.002
and p¼ 0.040 respectively). Platelet aggregation–induced by ADP 0.8 mM–is sig-
nificantly higher in anemic UC patients with active disease (PUCAI4 20) com-
pared to same patients whose disease is in remission (p¼ 0.042) and compared to
patients with active CD (p¼ 0.054).
Conclusion: In our cohort, mixed anemia (iron deficiency anemia combined to
anemia of chronic disease) is the most common type of anemia. Thrombocytosis
is a condition more frequent in anemic IBD patients, specially in UC. In UC,
anemia and disease activity are significant correlated with platelet hyperaggrega-
tion. Therefore UC patients–specially with active disease and anemia–might pre-
sent major risk of thrombosis, independently from acquired or inherited
hemostasis defects.
A540 United European Gastroenterology Journal 5(5S)
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P1073 RELATIONSHIP BETWEEN CLINICAL COURSE OF
ULCERATIVE COLITIS (UC) DURING PREGNANCY AND
OUTCOMES OF PREGNANCY: A RETROSPECTIVE EVALUATION
STUDY
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Tokyo/Japan
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Introduction: Ulcerative colitis (UC) is a chronic, intractable disease with a long
clinical course. UC has a marked influence on the lifestyle of patients, and its
effects on pregnancy and childbirth can especially become a problem for women
in their child-bearing years. Various studies have suggested that it is desirable for
pregnant women with UC to give birth while remaining in a state of remission.
Aims & Methods: The present study evaluated pregnant women with UC attend-
ing our hospital who became pregnant during remission, in order to examine the
factors that contributed to recurrence of UC during pregnancy. We investigated
40 pregnant patients in remission (44 cases) attending our hospital between
January 2008 and July 2016 who had remained in remission for one year prior
to pregnancy. After becoming pregnant while in remission, patients who stayed
remission until delivery were classified into the ongoing remission group (35
cases) and patients with recurrence during pregnancy were classified into the
recurrence group (9 cases). Remission was defined as a Lichtiger clinical activity
index (CAI) of less than 4. Relapse was defined as a CAI 5 with the need for
initiation or dose escalation of steroids or administration of biological agents
during pregnancy. Items examined: Clinical characteristics (age at onset, disease
duration, age of becoming pregnant, disease type, and treatment), the CAI in the
first, second, and third trimesters, and whether or not patients continued treat-
ment during pregnancy were examined and compared between the two groups.
The reasons for discontinuation of treatment were also investigated.
Results: There were significant differences between the two groups with respect
to the age of becoming pregnant (32.9 4.6 years in the ongoing remission
group vs. 28.3 7.0 years in the recurrence group), the CAI in the second
trimester (2.9 4.6 vs. 3.5 1.6), the CAI in the third trimester (2.9 0.7 vs.
5.4 2.0), and whether oral treatment was continued (continuation of treat-
ment [yes:no]; 30:5 in the ongoing remission group vs. 5:4 in the recurrence
group). Regarding the discontinuation of oral treatment, two patients in the
ongoing remission group and one patient in the recurrence group discontinued
it on their own judgment, while two patients in the recurrence group discon-
tinued it due to hyperemesis. Discussion: The present study revealed that fac-
tors influencing the recurrence of UC during pregnancy were the age of
becoming pregnant and the continuation of oral treatment. Our results
showed that younger women were more susceptible to recurrence. As expected,
discontinuing oral treatment was a factor that contributed to recurrence.
However, the reasons for discontinuing treatment during pregnancy differed
from those for non-pregnant women. Some patients discontinued treatment
on their own judgment because they were concerned about adverse effects on
the fetus, while others had difficulty with continuing treatment due to hyper-
emesis. With regard to the effects of medications on the fetus, medical staff
should provide an explanation about the safety of treatment and should be
aware that patients may have various concerns about drug therapy. If patients
have difficulty continuing oral treatment due to severe hyperemesis, adminis-
tration of local therapy should be considered.
Conclusion: During pregnancy, it is important to continue treatment for UC so
that patients can give birth while remaining in remission. Accordingly, interven-
tion by medical staff is particularly necessary in order to provide pregnant
women with information and explanations regarding treatment.
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Introduction: Corticosteroids have been effectively used for decades for the rapid
induction of clinical remission in patients with Inflammatory Bowel Disease
(IBD). However their adverse event profile is well-known, particularly with
long-term use and in younger populations, and they have no role in maintenance
of remission. Steroid-sparing agents and more recently biological therapy have
reduced systemic steroid use but the true incidence of steroid prescriptions espe-
cially in the outpatient setting is not known.
Aims &Methods: The aim of this study was to capture real-life steroid use in both
adult and adolescent populations older than 13 years old who attend a dedicated
IBD clinic in a tertiary referral centre. We tried to identify risk factors associated
with appropriate or excessive steroid use in the whole cohort and in the two
subgroups separately. All consecutive IBD patients who were followed up for
at least one year in the adult and adolescent clinic in UCLH and attended their
IBD appointment during February and March 2017 were included in the study.
A steroid assessment questionnaire was completed by the clinician during the
visit for eligible patients. Use and type of steroids prescribed during the past year
was recorded, as well as appropriate bone protection and disease activity based
on Physician Global Assessment.
Results: 60 adolescents and 59 adults were included in the study. Two thirds of
adolescents had Crohn’s disease while in the adult population Crohn’s and
ulcerative colitis (UC) were equally distributed. 57 (95%) adolescents had been
exposed to thiopurines and 47 (78%) to anti-TNFs as opposed to 69%
(p¼ 0.002) and 39% (p5 0.001) of adults respectively. Vedolizumab exposure
was similar in adults and adolescents. The percentage of patients with moderate
to severe disease at last visit was comparable between two groups (18/60, 30%
adolescents vs 18/59, 31% adults, p¼NS). 27/119 (23%) of patients were offered
steroids during the past year and the incidence was the same in the adult and
adolescent populations. 4/27 (15%) received excessive steroids, ie 42 courses
within the preceding 12 months. Of the 27, 17 (62%) had Prednisolone and the
rest received Budesonide, while the choice of steroid was associated with a diag-
nosis of Crohn’s disease and was not different between the two groups. One third
of patients did not receive bone protection with the steroid prescription, however
this was mainly observed with Budesonide rather than Prednisolone (7/10 vs 2/
17, p¼0.003). Steroid use overall was not associated with the age group or initial
diagnosis but was expectedly associated with severity of disease (sever-
e4moderate4mild, p5 0.001). The use of thiopurines or anti-TNFs did not
affect steroid prescriptions, but interestingly the majority of Vedolizumab users
received steroids in contrast to Vedolizumab naı̈ve patients (7/9, 78% vs 20/109,
18%, p5 0.001). This association remained significant even after adjustment for
disease severity and other co-factors, suggesting possibly the higher need for
‘bridging’ steroids due to the slow-acting effect of Vedolizumab therapy
(binary logistic regression showed naı̈ve to Vedolizumab patients were protected
against steroid use, OR 0.043 CI 95% 0.005–0.382, p¼ 0.005).
Conclusion: The use of steroids in an outpatient population with IBD is still
common regardless of age group and use of anti-TNFs, as almost 1 in 4 patients
received some type of oral steroid during a period of one year. Newer biologics,
such as Vedolizumab, may predispose patients to higher steroid use, possibly due
to slow induction of remission.
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Introduction: In patients with active ulcerative colitis (UC), myeloid lineage leu-
cocytes are known to be elevated with activation behaviour,1 including the
CD14þCD16þDRþþ monocyte phenotype, which is a major source of
tumour necrosis factor-.2 Therefore, selective depletion of myeloid leucocytes
by adsorptive granulocyte/monocyte apheresis (GMA) with an Adacolumn is
expected to promote remission, or enhance drug efficacy. Potentially, GMA
should be a relevant treatment option in patients in whom drug therapy has
limitations.
Aims & Methods: Our major objective was to apply GMA as remission induction
therapy in paediatrics and adolescents UC setting when first-line 5-aminosalicy-
lates had failed. Thirty consecutive patients with active ulcerative colitis (UC),
age 11–19 years, body weight 33–55.5 kg were given mesalazine (n¼ 23) or sul-
phasalazine (n¼ 7) as the first-line medication. Twenty patients relapsed while
receiving the first-line medications or did not respond, and received GMA with
the Adacolumn, at 2 sessions in the first week, then weekly, up to 11 sessions.
Patients who achieved 5 decrease in the clinical activity index (CAI) after 5
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GMA sessions continued with GMA while non-responders received GMA in
combination with a low dose prednisolone, 0.5 to 1.0mg/kg bodyweight. At
entry and week 12, patients were clinically and endoscopically evaluated with
each patient serving as her or his own control.
Results: At entry, all 30 patients were corticosteroid naı̈ve and none had deep
colonic lesions or extensive loss of the mucosal tissue at the affected sites (GMA
non-responder features). Ten patients achieved stable remission with the first-line
medications and did not receive GMA. Six patients did not respond well to the
first 5 GMA sessions and received prednisolone together with GMA, while 12
patients responded well to GMA, and achieved stable remission, but 2 patients
withdrew to receive high dose prednisolone (up to 2mg/kg bodyweight). At
entry, the average CAI was 14 0.4. Prednisolone was tapered to 0mg within
3 months in those who received. Therefore, at week 12, all 30 patients were in
remission, majority with mucosal healing.
Conclusion: In this treatment design, GMA in young corticosteroid naı̈ve patients
with active UC refractory to the first-line 5-aminosalicylates was associated with
clinical remission and mucosal healing, while in non-responders to GMA mono-
therapy, addition of a low dose prednisolone enhanced the efficacy of GMA and
tapering of the prednisolone dose was not associated with relapse. Therefore, the
majority of young steroid naı̈ve UC patients who fail to respond to first-line 5-
aminosalicylates should respond well to GMA and avoid pharmacologicals.
Additionally, GMA has a good safety profile, which is a very favourable feature
in growing patients.
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Introduction: Autoimmune liver disease (AILD), in particular autoimmune scler-
osing cholangitis (ASC) is associated with inflammatory bowel disease (IBD).
Little is known about the effect of IBD on the outcome of AILD. Faecal cal-
protectin (FC), a stool biomarker, screens for bowel inflammation without the
need for invasive endoscopic evaluation and is easy to collect.
Aims & Methods: The aim of this study was to review the investigations and
outcomes of IBD and AILD in children with a primary diagnosis of AILD and to
identify possible risk factors for development of IBD in children with AILD.
Children with AILD were identified from electronic case notes between 2007 and
2010 and those with a diagnosis of IBD prior to AILD excluded. AILD was
diagnosed and treated as per centre protocol. Diagnostic endoscopy for IBD was
performed, based on GI symptoms and/or elevated FC (460U/g). Data were
documented at time of liver diagnosis; endoscopy and last liver follow up.
Patients were classified as AILD-IBD or AILD.Mann Whitney and Chi squared
test were used to analyse data where appropriate, significance p5 0.05.
Results: Out of 37 (12 male) children, diagnosed with AILD (ASC 11), 23 under-
went diagnostic endoscopy after a median time from diagnosis of 27.6 [20.1 to
53.9] weeks. 20/23 reported GI symptoms and FC was elevated in 13/18 tested.
At endoscopy 57% (13/23) a diagnosis of IBD (AILD-IBD group) (UC (n¼ 12),
IBD-U (n¼ 1)) was made, 10/23 were within normal limits (AILD group). There
was no difference in gender or diagnosis of ASC between the 2 groups. At
presentation of AILD, children in the AILD-IBD group were significantly
leaner in terms of weight and BMI, had lower haemoglobin, with a trend for
younger age at presentation (table 1). GI symptoms and FC4 60 U/g were
significantly more prevalent in the AILD-IBD group. At the time of endoscopy,
22 were on treatment for AILD with prednisolone and 13 with an additional
agent (azathioprine or mycophenolate mofetil). Biochemical remission for AILD
was achieved in 45% at endoscopy and in 74% at last liver follow-up (median 4.1
[3.5 to 5.0] years) with no difference for both groups. All patients are alive;
however, in the AILD-IBD group 1 underwent an isolated liver transplantation
(LT) and 1 required a subtotal colectomy. One girl underwent LT combined with
subtotal colectomy after decompensation of her liver disease.
Table 1: Diagnostic parameters of AILD at presentation median [IQR]/*p
value5 0.05
AILD-IBD AILD
n (male) 13(5) 10(3)
Age (years) 12.5 [10.3 to 14.6] 14.4[12.0 to 15.5]
ASC (n) 6 2
Weight (kg) 48.8 [38.8 to 55.9] 61.5 [52.9 to 75.4]*
Height (cm) 160.7 [152.3 to 168.0] 164.0 [154.4 to 168.8]
BMI (kg/m2) 19.2 [18.2 to 20.2] 22.5 [19.5 to 27.3]*
Haemoglobin (g/l) 113.0 [90.5 to 122.0] 127.5 [118.5 to 146.5]*
(continued)
Table 1: Continued
AILD-IBD AILD
AST(IU/l) 235.0 [113.5 to 470.5] 461.0 [241.0 to 1039.0]
IgG (g/l) 25.3 [16.2 to 37.8] 25.1 [19.2 to 30.1]
Faecal calprotectin (U/g) 298.5 [114.5 to 439.8] 42.5 [34.6 to 66.3]*
GI symptoms (n) 12 8
Faecal protectun 460 U/g (n/total) 11/12 2/6
Conclusion: In our cohort 35% of children presenting with AILD were subse-
quently diagnosed with IBD. Possible risk factors for development of IBD in
AILD are low haemoglobin, being leaner and younger at diagnosis. An elevated
FC and the presence of GI symptoms are useful to assess the need for diagnostic
endoscopy when considering diagnosis of IBD in the context of AILD. As con-
current immunosuppression may mask mild symptoms and signs of IBD a lower
threshold for endoscopy should be considered in these patients.
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Introduction: We aimed to identify early clinical and laboratory predictors of
sustained clinical and endoscopic remission in children with Crohn’s disease
(CD) under infliximab (IFX).
Aims & Methods: Prospective study conducted in children with moderate-to-
severe CD starting IFX treatment. All patients underwent endoscopy, weighted
pediatric CD activity index (wPCDAI) assessment, C-reactive protein (CRP) at
week 0 and 52. wPCDAI and CRP were also evaluated at 14 weeks. The primary
outcome was to determine the ability of 14-week wPCDAI and CRP to predict
steroid-free sustained remission and mucosal healing at 1 year. As a secondary
outcome we sought to evaluate the concordance between wPCDAI and Simple
Endoscopic Score for CD (SES-CD) at week 52.
Results: Forty-one children were enrolled (median age 13.5 2.7, females
41.5%). At 1 year, 21 (51%) and 16 (39%) were in clinical (wPCDAI 512.5)
and endoscopic (SES-CD5 3) remission, respectively. Fourteen-week wPCDAI
didn’t differ between patients who achieved both clinical and endoscopic remis-
sion at 1 year (p¼ 0.21 and p¼ 0.35, respectively). By using a multivariable
logistic regression model, neither week-14 wPCDAI nor CRP were predictors
of 1-year clinical (p¼ 0.83 and p¼ 0.30, respectively) and endoscopic remission
(p¼ 0.22 and p¼ 0.48). wPCDAI resulted significantly correlated with 1-year
SES-CD (r¼ 0.38, p¼ 0.01). The concordance between wPCDAI and SES-CD
was excellent and good for severe disease and remission (k cohen 0.87 and 0.76),
moderate and absent for mild and moderate disease, respectively.
Conclusion: Based on our results, 14-week post induction wPCDAI and CRP are
not predictors of 1-year sustained steroid-free clinical and endoscopic remission
in children with CD under biologic therapy. Continuous wPCDAI shows a good
correlation with SES-CD, particularly for patients in remission and with severe
disease.
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Introduction: Gastrointestinal angiodysplasia, either inherited or acquired, is an
important and challenging cause of acute gastrointestinal haemorrhage, particu-
larly in the elderly, sometimes refractory to treatment. Although multiple treat-
ment modalities, both medical and surgical, are being used, there is no
established medical treatment available for these patients. Thalidomide is a
potent inhibitor of angiogenesis in experimental models. As angiodysplasias
are a result of unregulated vessel growth, antiangiogenic treatment may inhibit
growth of angiodysplasias. But its benefits and risks nevertheless remain unclear.
Aims & Methods: This retrospective study evaluates the efficacy, safety, and side-
effect of thalidomide in the treatment of patients with refractory gastrointestinal
bleeding from angiodysplasias. Patients with recurrent gastrointestinal bleeding
of angiodysplasia who were from Hangzhou First people’s Hospital from
October 2012 to July 2015 were collected for this open and nonrandomized
study. Thalidomide was started with 50mg/day and then increased incrementally
by100 mg/day, if tolerated, and continued for 6 months. Adverse events, hemo-
globin, blood chemistry, the changes of coagulation and blood transfusion were
monitored during the treatment and for 6-months post-treatment.
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Results: Twenty-one patients with chronic refractory angiodysplasis bleeding
were recruited in this study, included 10 women, aged between 40–85;11 cases
of male, aged between 31–70. One patient with colic vascular malformation died
of massive hemorrhage due to self withdrawal. Among the remaining 20 patients
who were given thalidomide regularly for 6 months. (1). Eight patients come
across constipation, sleepiness and dry mouth. There were no skin rashes, per-
ipheral neuropathy and any other adverse reactions during the treatment. All
side-effects resolved when thalidomide was discontinued. (2). The red blood cell
after treatment (3.76 0.56)*10^9/L compared with before treatment
(3.38 0.60)*10^9/L; hemoglobin after treatment (94.7 13.15 g/L) compared
with before treatment (83.2 19.76 g/L); HCT after treatment (0.32 0.05) com-
pared with before treatment ( 0.29 0.06); the difference was statistically signifi-
cant (P5 0.05). (3). The ALT after treatment (32.9 18.5U/L) compared with
before treatment (30.6 12.8U/L); AST after treatment (28.1 8.56U/L) com-
pared with before (28.0 12.4U/L); -GT after treatment (34.4 8.4U/L) com-
pared with before (35.6 12.7 U/L ); AKP after treatment (85.5 19.8U/L)
compared with before (83.0 20.8U/L); ALB after treatment (36.2 3.1 g/L)
compared with before (36.3 4.3 g/L); there was no statistically significant dif-
ference (P4 0.05). (4). Prothrombin time (PT) after treatment (12.1 1.3s) com-
pared with before (11.8 1.4s); APTT after treatment (30.2 3.7 s), compared
with before (31.0 6.2s); the difference was not statistically significant
(P4 0.05). (5). 6 cases of colonic capillary malformation review colonoscope,
and the vascular malformation improved significantly after treatment.
Conclusion: Thalidomide, with its antiangiogenic mechanism of action, seems to
be a promising drug in bleeding angiodysplasias as a treatment option for
patients unable to benefit from other available modalities of treatment. the
study drug was well tolerated.
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Introduction: Colonic diverticular bleeding is the most common cause of lower
gastrointestinal bleeding. We have reported the preliminary safety results of
endoscopic detachable snare ligation (EDSL), a new method for diverticular
hemorrhage1). The bleeding diverticulum was ligated with a detachable snare.
Unlike the endoscopic band ligation, removal of the scope to attach a ligation
device and reinsertion for treatment are not needed in this method. We per-
formed a clinical trial to evaluate the effecy and safety of EDSL.
Aims & Methods: This multicenter single arm phase II study was conducted in 12
Japanese institutions. Patients suspected of diverticular bleeding were enrolled
from June 2015 to March 2017. Patients with serious heart, renal, or liver failure,
sepsis, disseminated intravascular coagulation, and high-dose steroid use (pre-
dnisolone dosage 410mg/day) were excluded. The primary endpoint was the
early (within 1 month) rebleeding rate in patients who were treated with EDSL.
The secondary endpoints were overall early rebleeding rate in patients who had
confirmed diverticular bleeding (intention to treat: ITT), success rate of EDSL,
total procedure time, EDSL procedure time, identification rate of bleeding diver-
ticula, and adverse events. This study was approved by the ethics committee of
each participating hospital and conformed to the Helsinki Declaration and the
Japanese Clinical Research Guidelines.
Results: Of 123 patients with diverticular hemorrhage, 101 were treated with
EDSL and the early rebleeding rate was 5% (5/101). The rebleeding rate in
ITT population was 9% (11/123). Success rate of EDSL was 78% (96/123).
The median total procedure time and EDSL procedure time were 40 (15–150)
and 4 (1–57) min, respectively. The identification rate of bleeding diverticula was
60% (123 in 205 enrolled patients). Two mild adverse events occurred; colonic
diverticulitis cured with antibiotics and temporary abdominal pain during EDSL.
Conclusion: EDSL is an effective, safe, and convenient treatment method for
colonic diverticular hemorrhage.
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Introduction: Incidence of colonic diverticular bleeding has increased in recent
years. Colonic diverticular bleeding is problematic because of the following rea-
sons: the low detection rate of the bleeding source by endoscopy and frequent re-
bleeding. At our hospital, we have a policy of performing emergency lower
gastrointestinal endoscopy for all patients with colonic diverticular bleeding
within 24 h of their admission. We have reported that the following factors can
contribute to the successful identification of the bleeding source: extravasation
revealed by abdominal contrast computed tomography (CT), and mounting of a
hood to the tip of an endoscope during lower gastrointestinal endoscopy.
However, risk factors for re-bleeding in patients with colonic diverticular bleed-
ing were still unknown.
Aims & Methods: In this study, we examined the risk factors for early and late re-
bleeding in patients with colonic diverticular bleeding. From January 2004 to
April 2016, we admitted 432 patients (285men and 147 women, mean age: 71 13
years) to our hospital for treatment following a diagnosis of colonic diverticular
bleeding based on abdominal CT and endoscopy findings. Early and late re-
bleeding was defined as macroscopically bloody stools as a result of colonic
diverticular bleeding during hospitalization and after discharge, respectively.
Risk factors for early and late re-bleeding were retrospectively examined using
univariate and multivariate analysis.
Results: Early re-bleeding occurred in 112 patients (26%; 86 men and 26 women,
mean age: 71 12 years). The mean duration until re-bleeding was 3.9 2.4 days,
and on average, early re-bleeding recurred 1.7 1.2 times. On average, lower
gastrointestinal endoscopy was performed 2.7 1.2 times and endoscopic hemo-
static treatment was performed 1.0 1.0 times. In the univariate analysis, sig-
nificant differences were seen in males (P¼ 0.005), in the use of oral antiplatelet
agents (P¼ 0.012), and in patients not undergoing endoscopic hemostasis
(P¼ 0.004). In the multivariate analysis, male gender (P¼ 0.006; odds ratio
2.06, 95%CI 1.23–3.44), the use of oral antiplatelet agents (P¼ 0.008; odds
ratio 1.85, 95%CI 1.17–2.93), and patients not undergoing endoscopic hemosta-
sis (P¼ 0.005; odds ratio 1.5, 95%CI 0.31–0.81) were independent risk factors for
early re-bleeding. Late re-bleeding was seen in 72 of 345 patients who were able
to follow up (21%; 46 men and 26 women, mean age: 73 12 years). The mean
duration until late re-bleeding was 41 40 months, and on average, late re-bleed-
ing recurred 1.5 1.2 times. Only the use of oral antiplatelet agents (P¼ 0.05;
odds ratio 1.72, 95%CI 0.98–2.98) was identified as an independent risk factor
for late re-bleeding in the univariate and multivariate analysis.
Conclusion: Not undergoing endoscopic hemostasis and male gender were iden-
tified as risk factors for early re-bleeding, indicating the importance of choosing
measures and hemostatic treatments to improve the detection rate of bleeding
sources during endoscopy. The use of oral antiplatelet agents was a risk factor for
both early and late re-bleeding, suggesting the need for patient management
through multi-departmental cooperation.
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Introduction: Acute lower gastrointestinal bleeding (ALGIB) constitutes an
important gastroenterological emergency. A new score (NOBLADS) that intends
to determine the risk of severe ALGIB was recently developed. We aimed to
assess the validity of this score in a cohort of patients with ALGIB.
Aims & Methods: Retrospective study. Emergency consecutive admissions for
ALGIB were reviewed. Severe ALGIB was defined as transfusion of 2 units
of packed red blood cells (PRBC) and/or hematocrit decrease of 20% within
the first 24 h and/or recurrent bleeding after 24 h of stability. NOBLADS score
was calculated and its discriminative capacity for severe ALGIB as well as for
other outcomes was assessed.
Results: Included 118 patients with a mean age of 73 14.4 years and 52.5%
males. Most frequent etiologies for ALGIB were diverticular bleeding (23.7%)
and post-polipectomy (21.2%). ALGIB was severe in 38.1% of patients.
NOBLADS score showed a weak discriminative capacity to determine severe
ALGIB (AUC¼ 0.68, p5 0.01). However, when comparing patients with
NOBLADS 54 and 4, patients with higher scores were significantly older
(69.2 15.7 years vs 78.6 10.0 years, p5 0.01), had lower hemoglobin levels
at admission (11.8 2.6 g/dL vs 10.2 2.5 g/dL, p5 0.01), were transfused with
more units of PRBCs during the first 24 hours and during hospital in-stay
(0.4 0.9 vs 1.1 1.3, p5 0.01 and 1.0 2.2 vs 3.0 3.3, p5 0.01, respectively)
and were more frequently admitted to intermediate care units (35.2% vs 59.6%,
p5 0.01). No differences were found between the two groups regarding in-stay
length, rebleeding rate, need for surgery or death.
Conclusion: NOBLADS score showed a weak discriminative capacity to deter-
mine severe ALGIB however, patients with NOBLADS 4 had greater PRBCs
transfusion need and were more frequently admitted to intermediate care units.
New or improved scores that can predict severe ALGIB are needed to determine
more precisely appropriate care and to allow for a standardized approach.
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Introduction: In Japan, CRC screening was launched as a national policy for all
people aged over 40 years in 1992. 2-day FIT has been widely accepted, and has
been recommended performing in every year.
Aims &Methods: The aim of this study is to verify the validity of an annual 2-day
FIT. This analysis was performed by the OC-SENSOR DIANA (EIKEN,
JAPAN) automated analyzer with cut-off value of 20mg Hb/g stool. Between
2011 and 2014, 957 CRCs and 12,290 polyps were detected. 957 CRCs were
analyzed by screening history about sizes and Dukes’ stage. The person who
had undergone 2-day FIT 1 year before was defined as repeated group. And
hadn’t undergone more than 5 years before was defined as first-time group.
Results: The number of FIT positive participants was 9,370 for the first time
group and 25,595 for the repeated group. With regard to CRCs and benign
polyps, 457 CRCs and 3,010 benign polyps were detected for the first time
group, and 500 CRCs and 9,280 benign polyps were detected for the repeated
screening group. The positive predictive value (PPV) for CRCs was higher by the
first time group than by the repeated group. The PPV for benign polyps was
higher by the repeated group than by the first time group. 393 cases in the first
time group and 438 cases in the repeated group were reported for sizes. In the
first time group, 231 cases were 1–24mm, 110cases were 25–49mm, and 52 cases
were over 50mm. In the repeated group, 288 cases were 1–24mm, 117 were 25–
49mm, and 33 cases were over 50mm. The size of detected cancers by the
repeated group was significantly smaller than by the first time group. In the
first time group, 187 cases were intra-mucosal Dukes A, 109 cases were Dukes
A, 65 cases were Dukes B, 61 cases were Dukes C, 21 cases were Dukes D. In the
repeated group, 258 cases were intra-mucosal Dukes A, 127 cases were Dukes A,
36 cases were Dukes B, 54 cases were Dukes C, and 7 cases were Dukes D. As a
result, Dukes’ stage was higher in the first group, and was lower in the repeated
group.
Table 1: Dukes
Intra-mucosal A A B C D Unknown
First-time
group
187
(40.9%)
109
(23.9%)
65
(14.2%)
61
(13.3%)
21
(4.6%)
14
(3.1%)
Repeated
group
258
(51.7%)
127
(25.5%)
36
(7.2%)
54
(10.8%)
7
(1.4%)
16
(1.5%)
P value 0.0008 0.5666 0.0004 0.2304 0.0035 0.6477
Conclusion: Repeated FIT screening might be more efficient to detect benign
polyps, smaller CRCs, and CRCs of intra-mucosal Dukes A. We’ll go on
researching CRCs locations about screening history.
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Introduction: In Japan, CRC screening has been launched as a national policy for
all people aged over 40 years since 1992. 2-day FIT has been widely accepted, and
has been recommended performing in every year. It is demanded that CRC
screening is performed effectively depending on the capacity of colonoscopies.
We will show so much data on fecal hemoglobin concentration (referred as
concentration) and progress of colorectal cancer among them.
Aims & Methods: The aim of this study is to analyze the concentration of FIT for
colorectal cancers (CRCs) from the screening. The cut off value is adapted 20 mg
Hb/g stool and the rate of further examination is around 75% for many years. In
Ibaraki prefecture, CRCs were detected 3,421 cases from the screening (2000–
2014) with 2-day FIT. The concentration of FIT was grouped in 20–80, 80–140,
140–200 and over 200 mg Hb/g stool. Screening have been performed with the
OC-SENSOR DIANA (EIKEN, JAPAN) automated analyzer. CRCs were ana-
lyzed with age group (40–49, 50–59, 60–69, over 70 year-old), size(1–24, 25–49,
over 50mm), location(proximal, distal), Dukes’ classification(Dukes A-m, A-
invasive, B, C, D) depending on the concentration. The chi-squared test was
used to compare of each group.
Results: There was no difference in gender and age group for concentration. The
concentration of CRCs in the distal colon was significantly higher in the prox-
imal colon [distal 39% (861/2,200) and proximal 32% (337/1,053) with over
200 mg Hb/g stool]. The concentration of CRCs with larger size was significantly
higher than smaller size [1–24mm 27% (533/1,961), 25–49mm 54% (439/818)
and over 50mm 64% (169/263) with over 200 mg Hb/g stool]. The concentration
of invasive CRCs was significantly higher than intra-mucosal CRCs [intra-muco-
sal 23% (370/1,617) and invasive 50% (888/1,793) with over 200 mg Hb/g stool].
The concentration of Dukes B, C and D were significantly higher than Dukes A
except for intra-mucosal. There was no difference between Dukes B and D
[Dukes A except for intra-mucosal 36% (325/910), B 68% (247/363), C 60%
(232/385) and D 69% (61/89) with over 200 mg Hb/g stool].
Table 1: Fecal Hb concentration and progress of colorectal cancer
Age Size(mm) Location Dukes
conc.
(mg/g)
40–49 50–59 60–69 70- 1–24 25–49 50- proximal distal A-m A B C D
20–80 48 190 588 605 993 224 53 495 871 885 375 61 82 15
80–140 14 51 185 199 268 107 16 146 286 230 140 32 38 6
140–200 17 33 117 100 167 48 25 75 182 132 70 23 33 7
200- 55 177 529 497 533 439 169 337 861 370 325 247 232 61
total 134 451 1,419 1,401 1,961 818 264 1,053 2,200 1,617 910 363 385 89
Conclusion: In 20–80 mg Hb/g stool, there were CRCs with smaller size, no inva-
sion, in the proximal colon, Dukes A except for intra mucosal CRCs and so on.
When the cut off value is raised over 80mg Hb/g stool, the detection of early stage
CRCs and proximal CRCs may be lost. There were many advanced CRCs with
concentration over 200 mg Hb/g stool. Therefore, when the participants, who are
positive with high concentration of FIT, need to take a further examination as
soon as possible. Why concentration of CRCs in the distal colon were higher
than in the proximal colon? It may be related to the fact that the number of
detectable CRCs in the distal colon are more than in the distal colon. We will go
on researching mechanism about this.
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Introduction: Hodgkin lymphoma (HL) survivors treated with abdominal radio-
therapy and/or alkylating chemotherapy have an increased risk of colorectal
cancer. This study evaluated the prevalence of colorectal neoplasia in HL
survivors.
Aims & Methods: The primary aim of this multicenter cohort study was to assess
the diagnostic yield of advanced colorectal neoplasia detected by a first surveil-
lance colonoscopy among HL survivors treated with abdominal radiotherapy
and/or procarbazine. Advanced colorectal neoplasia was defined as an advanced
adenoma (high-grade dysplasia, 25% villous component, or 10mm diameter),
an advanced serrated lesion (dysplasia or 10mm diameter), or CRC. Results
were compared with a Dutch general population cohort that underwent a pri-
mary screening colonoscopy (n¼ 1276 asymptomatic individuals between 50–75
years of age). This study demonstrates the results of a predefined interim
analysis.
Results: A colonoscopy was performed in 101 HL survivors, who were signifi-
cantly younger than general population controls (median 51 years (interquartile
range 45–57) vs. 60 years (interquartile range 55–65), p5 0.001). A mean of 3.5
neoplastic lesions was detected per HL survivor (standard deviation 4.9) vs. 1.1
per control (standard deviation 1.8, p5 0.001). Despite their young age, the
prevalence of advanced neoplasia was higher in HL survivors than in controls
(25% (95% confidence interval 16–33%) vs. 12% (10–14%), p5 0.001).
Advanced adenomas were detected in 14% (8–21%) of HL survivors and 9%
of controls (7–10%, p¼ 0.08). The prevalence of advanced serrated lesions was
higher in HL survivors than in controls (12% (6–18%) vs. 4% (3–5%,
p5 0.001). Serrated polyposis syndrome was present in 6% (2–11%) of HL
survivors and absent in controls (p5 0.001).
Conclusion: HL survivors treated with abdominal radiotherapy and/or procarba-
zine have a high prevalence of advanced colorectal neoplasia. Colonoscopy sur-
veillance should therefore be implemented as standard of care.
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Introduction: Colorectal cancer is one of the most common cancers diagnosed
worldwide, and prostate cancer is also the most common malignancy in men and
a major cause of cancer deaths. Both colorectal cancer and prostate cancer also
tend to occur more frequently in developed countries. There have been several
reports on the association between colorectal cancer and prostate cancer, but the
conclusions are inconsistent.
Aims & Methods: We aim to investigate the incidence of prostate cancer as a
second primary malignancy among patients with prior primary colorectal cancer
(CRC) using a nationwide population-based dataset. This study is a nationwide
population-based retrospective cohort study. We followed up with patients
registered in the Republic of Korea National Health Insurance Corporation
who were diagnosed with colon cancer between 2007 and 2014 and investigated
the incidence of prostate cancer (one year lag period). The incidence of prostate
cancer was also evaluated in age and gender-matched controls using a cohort of
patients diagnosed with colorectal cancer during the same period. The incidence
rate (IR) was defined as the number of newly diagnosed prostate cancer patients
per 1000 person-years. To assess the role of detection bias-related to the follow-
up of CRC, follow-up started at the date of CRC diagnosis and continued until
the earliest date of prostate cancer diagnosis, death, loss to follow-up, or the 2015
year-end. We used Cox proportional hazards models to identify prostate cancer
occurrences among CRC patients. We also performed the multivariable analysis.
Multivariable models included the variables of age, sex, body mass index, hyper-
tension, diabetes mellitus, dyslipidemia, and income.
Results: We analyzed a total of 85,462 Erst primary CRC survivors. During the
follow-up period of 494,222 person-years, 2005 (2.3%) developed prostate cancer
(incidence rate 4.06/1,000 person-years). The median duration of follow-up
was 5.78 years. Compared with the general population, CRC patients had a
significantly increased risk of secondary prostate cancer (HR¼ 2.30, 95%
CI¼ 2.182–2.426; P5 0.001). Multivariate analysis (including age, sex, body
mass index, hypertension, diabetes mellitus, dyslipidemia, and income) showed
that age5 55 years (HR¼ 20.85, 95% CI¼ 11.88–36.59; P5 0.001) is a signifi-
cant independent predictor of prostate cancer development.
Conclusion: Men who develop colorectal cancer are at an increased risk of pros-
tate cancer, with the greatest risk in men under the age of 55. This data suggests
that CRC patients under 55 years old require regular screening for prostate
cancer.
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Introduction: To reduce the burden of colorectal cancer (CRC) mortality, screen-
ing has been introduced. Screening can be beneficial if cancers are detected in an
earlier stage or in a pre-malignant stage, as survival rates of these patients will
improve.
Aims & Methods: In this study stage distribution of screen detected CRCs were
compared with clinically detected CRCs in the Netherlands. All CRCs detected
in men and women aged 55 to 75 years in the Netherlands in 2015 were included
in the analysis. Data were gathered from the Dutch Cancer Registry. The current
analysis is based on 70% of these cancers that had staging information
available at initial data retrieval. Data will be updated in May 2017.
Proportions of site and stage distribution of screen detected and clinically
detected CRCs were compared.
Results: A total of 6,517 CRCs in 2015 with staging information were available
for the preliminary analysis. Of those, 2,591 (39.8%) were diagnosed as a result
of CRC screening (screen detected), 3,463 (53.1%) presented with symptoms
(clinically detected), 118 (1.8%) were detected during surveillance colonoscopy,
202 (3.1%) as coincidental finding and of 143 (2.2%) the method of detection was
unknown. Screen detected cancers were more often diagnosed in an earlier stage
(stage I and II) compared with clinically detected cancers, 1,687 (66.5%) and
1,355 (39.6%) respectively (p5 0.001). Screen detected cancers were more often
diagnosed in the left side of the colon compared with clinically detected cancers,
46.2% vs 31.5% (p5 0.001). Comparison of stage distribution by location
showed that left sided cancers were most often diagnosed in an early disease
stage with 59.0% of the CRCs in stage I or II, followed by the right sided cancers
with 52.8% of the CRCs in stage I or II. The CRCs of the rectum were most
often diagnosed in a late disease stage, only 39.4% in stage I or II. Table 1 shows
the comparison of stage distribution by location and method of detection. With
screening, 68.8% of the right sided cancers, 71.0% of the left sided cancers, and
56.5% of the rectum CRCs were diagnosed in an early disease stage (stage I and
II) which was all higher than clinically detected cancers (p5 0.001).
Table 1: Stage distribution of screen detected and clinically detected colorectal
cancers by location and method of detection
Screen detected Clinically detected
Right sided Left sided Rectum Right sided Left sided Rectum
Stage n (%) n (%) n (%) n (%) n (%) n (%)
I 254 (38.3%) 637 (54.5%) 316 (45.7%) 147 (12.2%) 217 (20.2%) 188 (17.0%)
II 203 (30.6%) 193 (16.5%) 75 (10.8%) 381 (31.7%) 277 (25.7%) 130 (11.8%)
III 166 (25.0%) 262 (22.4%) 257 (37.1%) 344 (28.6%) 310 (28.8%) 543 (49.1%)
IV 41 (6.2%) 77 (6.6%) 44 (6.4%) 329 (27.4%) 272 (25.3%) 245 (22.2%)
Conclusion: Screen detected CRCs show a more favourable stage distribution
compared with clinically detected cancers, with two third of the cancers
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diagnosed in stage I or II. As those patients will have better survival rates, it is
expected that screening will decrease CRC mortality rates.
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Introduction: According to European and American series,1,2 up to 20% of color-
ectal cancers are characterised by instability at microsatellite sites and have
deleterious mutations in mismatch repair (MMR) genes (MLH1, MSH2,
MSH6 and PMS2) or hypermethylation of the MLH1 promotor gene. MMR
deficient colorectal cancers are predominantly found in the right colon. Although
an increasing rate of colorectal cancer has been observed in many low- and
middle-income countries including in West-Africa,3 data on epidemiology and
biology of colorectal cancer in native Africans from this region are scarce.
Aims & Methods: We aimed to study the incidence of MMR deficiency in Ivory
Coast and to compare the data with those from a tertiary center in Belgium.
Immunohistochemistry for MLH-1, MSH-2, MSH-6 and PMS-2 was performed
on paraffin-embedded tissue samples from 83 colorectal cancers (54% males)
operated in Abidjan and from 343 colorectal cancers (48% males) from the
Erasme University Hospital in Brussels. Immunohistochemical staining was
interpreted as normal or loss of expression.
Results: Colorectal cancer is occurring at a younger age in Ivory Coast compared
to Belgium (median age: 53 vs. 66). In both populations, MMR deficiency was
detected in 13% of cases (11 and 43 cases, respectively). Whereas MMR deficient
cancers in Brussels were mainly found in women (26/43 i.e. 61%), only 3/11
(27%) of the MMR deficient cancers from the Abidjan series occurred in
female patients. Moreover, the predominant location of MMR deficient tumours
was different between both series: in the Brussels patients group, MMR deficient
tumours were mainly located in the right colon (33/43 i.e. 77%) whereas in the
Abidjan group they were predominant (10/11 i.e. 91%) in the left colon. With
regard to the involved proteins, 6/11 (55%) of the MMR deficient cases from
Ivory Coast were characterised by loss of expression of MSH2 and MSH6
whereas this immunohistochemical staining pattern was observed in only 9/43
(20%) cases from Belgium.
Conclusion: Our pilot study reveals marked differences in presentation of MMR
deficient colorectal cancer between the two geographic regions. In contrast to
Europe, MMR deficient colorectal cancer in Ivory Coast is mainly found in male
patients and in the left colon. Moreover, there are differences with regard to the
involved mismatch repair proteins. Together with the younger age at presenta-
tion, these data suggest differences in epidemiology and biology of colorectal
cancer in native Africans from West Africa compared to the European
population.
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Introduction: Lynch syndrome (LS) is the most common hereditary cause of
colorectal cancer (CRC). Identifying LS carriers and their affected family mem-
bers is of great importance for prevention of CRC. Routine screening for LS by
immunohistochemical staining (IHC) in CRC patients 70 years of age is recom-
mended. LS screening in adenoma patients could yield more benefit, since CRC
can still be prevented in these patients. A small number of participants of the
national CRC screening program is expected to have LS. We aimed to assess the
diagnostic yield of IHC for LS in patients with advanced and multiple adenomas
or CRC within the Dutch national fecal immunochemical test (FIT)-based CRC
screening program.
Aims & Methods: We included participants of the national CRC screening pro-
gram, referred to our center after a positive FIT from December 2013 to
December 2016. IHC for MLH1, MSH2, MSH6 and PMS2 protein was per-
formed on advanced adenomas and CRCs found at colonoscopy. Adenomas
were considered advanced if they had a villous component, high-grade dysplasia
or were 10mm in size. Also, in cases with 4 non-advanced adenomas, IHC
was performed on the largest adenoma. MLH1 hypermethylation analysis was
used to distinguish sporadic MLH1 deficiency fromMLH1 deficiency suspect for
LS. Patients with IHC suspect for LS were offered germline mutation analysis. If
no pathogenic mutation was found, we performed somatic mutation analysis.
Results: A total of 1006 patients (54% male; mean age of 67 years (6 years))
with positive FIT were included in the study. At colonoscopy, 352 (35%) patients
(63% male; mean age of 67 years (6 years) had a CRC and/or adenoma eligible
for IHC. A total of 322 adenoma patients were analyzed. None had aberrant
IHC. Of the examined adenomas, 151 (47%) had a villous component and/or
high grade dysplasia (132 (41%) with villous component and 37 (11%) with high
grade dysplasia). Out of 48 CRC patients, 7 (15%) showed loss of protein expres-
sion. All seven cases had loss of MLH1 and PMS2 protein. Five cases had
MLH1promoter hypermethylation. The two patients without MLH1 promoter
hypermethylation were referred for genetic counselling. Both patients had no
family history suspect for LS. In both cases no germline MLH1 mutation was
found and somatic mutation analysis showed that both had a likely sporadic
tumor.
Conclusion: Our results indicate that routine LS screening by IHC and MLH1
hypermethylation in patients with advanced and multiple adenoma within a
national FIT-based screening CRC program is not an effective strategy. The
diagnostic yield of LS screening in younger adenoma patients should be assessed.
Also, our results imply that MLH1 promoter hypermethylation may be a late
event in oncogenesis, since none of the adenomas had aberrant IHC.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Colorectal cancer (CRC) is a leading cause of cancer mortality in
the Veneto Region (North-eastern part of Italy). Population screening of adults
between 50 and 75 for CRC was begun in 2002, and it became standard practice
in all 21 local health units (LHU) of the region in 2008, 14 LHU provided also
follow-up colonosopies and 7 LHU no. The current retrospective cohort study
was carried out to evaluate the impact of CRC screening on the rate of surgical
oncology procedures to treat colon and rectal cancer.
Aims & Methods: Data from hospital discharge records (HDR) regarding CRC
patients hospitalized between 2000 and 2015 were collected. All CRC patients
whose principal diagnosis was colon and/or rectal cancer were included in the
study. The number of patients studied rose approximately 18% reaching
1,547,097 for the last year (2015). The Standardized Hospitalization Ratio
(SHR) using five-year age groupings was calculated and expressed per 10,000
population.
Results:During the study period, 30,399 surgical procedures for colorectal cancer
were performed (colon 63%, rectum 36%, secondary malignant neoplasm 1%)
with a SHR of 139.1; the number was higher in males (1.69 vs. 1.02; OR: 1.66; CI
95%: 1.62–1.7; p5 0.05). An analysis of the annual SHR distribution uncovered
two distinct phases: during the first phase there was a rising tendency that
reached a maximum value in 2007 (166.9; X2 trend: 46.731; p5 0.05) and
during the second there was a falling tendency that reached its minimum value
in 2015 (102.3; X2 trend: 429.791; p5 0.05). When the cancer sites were ana-
lyzed, it was seen that despite the peak in 2007, the rate of surgical procedures of
the proximal colon during the last year was the same as the 2000 value (41.5);
there was, instead, a relevant decrease in the rate of procedures on the distal
colon and rectum which fell from 94.4 to 59.2 (37.3%). The study also shows
that there was no significant difference in the reduction in surgical procedures for
CCR in LHU in which the screening program included a follow-up colonoscopy
(SHR 2015: 139.8; 29%) with respect to those centers wehere it was not forseen
(SHR 2015: 138.5; 28%).
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Conclusion: Study findings confirmed that CRC screening was effective in redu-
cing the number of oncological surgical oncology procedures particularly with
regard to the distal colon and rectum. Data analysis showed that the screening
seemed to accelerate reaching the peak rate in surgical procedures that took place
in 2007. After that time point the number of operations began to fall as far as
the distal colon was concerned (it fell by 37.3%). Finally our data suggest that the
real benefit in reduction of oncological surgery procedures is due to the first
screening colonoscopy.
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Introduction: The NHS bowel scope screening programme was introduced in
2013 with all adults aged 55 invited for a ‘one-off’ flexible sigmoidoscopy fol-
lowed by a colonoscopy if significant adenomas are detected. University
Hospitals of Leicester Bowel Cancer Screening Centre serves an ethnically diverse
community with approximately 25% of the population eligible for sigmoido-
scopy screening being British Asian Indians and 45% being British Whites1.
Within the faecal occult blood based bowel cancer screening programme we
have previously reported a lower polyp detection rate (PDR) and adenoma
detection rate (ADR) in Asians undergoing colonoscopy compared to White
British2. This study aims to evaluate PDR, ADR and cancer detection (CDR)
in British Asian Indians taking part in the bowel scope screening programme.
Aims & Methods: Patients who underwent screening sigmoidoscopy between
February 1st, 2015 to 28th Feb 2017 were included. All individuals participating
in screening sigmoidoscopy routinely report their self-selected ethnic origin. This
database was cross referenced with the endoscopic and histology findings from
the ’Exeter’ online database. The findings in British Asian Indians were com-
pared with British Whites.
Results: A total of 4287 patients underwent screening sigmoidoscopy over the
2-year period. 1169 individuals had polyps (500 adenomas). Overall polyp detec-
tion rate (PDR) was 1169/4287 (27.3%), adenoma detection rate (ADR) was
500/4287 (11.7%), hyperplastic polyps were 642/4287 (15%), sessile serrated
lesions were 13/4287 (0.3%), and other polyps were 14/4287 (0.3%)
(Inflammatory polyps 13, Juvenile polyp 1). Cancer detection rate was 6/4287
(0.14%). During the period studied, 3509 British white individuals (82%) and 778
British Asian Indians screened. Six cancers were detected in British white
(CDR¼ 0.17%) but none in British Asian Indians.
British White British Asian Indians P value
PDR 30.8%
(95% CI 26.7–34.9%)
11.4%
(95% CI 10.1–12.4%)
50.001
ADR 12.0%
(95% CI 8.0–16.0%)
9.0%
(95% CI 6.7–11.2%)
50.01
Conversion
to colonoscopy
4.0%
(95% CI 2.8–5.2%)
1.8%
(95% CI 0.9–3.2%)
50.001
Conclusion: This study found no cancers and significantly lower PDR and ADR
in British Asian Indians compared to British White participants in the bowel
scope screening programme. Further long term evaluation of these differences is
needed and may shed light on factors contributing to the development of
bowel cancer.
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Introduction: We identified for the first time that DDX27 (DEAD box polypep-
tide 27) gene was amplified in colorectal cancer (CRC) by whole genome sequen-
cing. Amplification of DDX27 was detected in 47% (47/100) of primary CRC
tumors and positively correlated with its mRNA overexpression. DDX27 plays a
pivotal oncogenic role in colorectal carcinogenesis by promoting cell prolifera-
tion and inhibiting apoptosis. In this study, we investigate its function, mechan-
ism of action and clinical implication in CRC.
Aims & Methods: Downstream effectors and pathways of DDX27 were identified
by promoter luciferase reporter assay, RT2 Profiler PCR array and western blot.
The interacting partners of DDX27 were screened by BioID method and further
validated using immunoprecipitation assay and immunofluorescence staining
method. Clinical implication of DDX27 was assessed in two human CRC cohorts
by quantitative PCR method and immunohistochemical staining of tissue
microarrays.
Results: Promoter luciferase reporter assays revealed that DDX27 mainly acti-
vated nuclear factor kappa B (NF-B) pathway in CRC cell lines (HCT116 and
SW480). Ectopic expression of DDX27 promoted transcription of NF-B signal-
ing targets including BCL2A1, BIRC3, CCL20, CXCL3, NFKBIA, TNF and
TNFAIP3. Conversely, silencing of DDX27 showed an opposite effect on NF-B
signaling. Treatment of NF-B inhibitors CAPE and JSH-23 abrogated the pro-
moting effect of DDX27 on CRC cells growth. We reveled that DDX27
enhanced and prolonged NF-B signaling via reducing the accumulation of
nuclear IB, which negatively regulates transcriptional activities of NF-B
and transport NF-B proteins back to the cytoplasm. DDX27 overexpression
markedly increased the recruitment of NF-B p65 inside nuclear and promoted
NF-B activity in CRC cells under TNF- stimulation. NPM1 was identified as a
potential binding partner of DDX27 by BioID method to screen for protein-
protein interactions. The interaction of NPM1 and DDX27 inside nucleus was
further validated by endougenous immunoprecipitation assay and immunofluor-
escence staining. Knockdown of NPM1 abrogated DDX27-activating NF-B
signaling, as well as its tumor-promoting function. Kaplan–Meier curves
showed that higher DDX27 expression was significantly associated with shor-
tened survival in patients with CRC of two independent cohorts (N¼ 199 for
Beijing cohort using quantitative PCR method, and N¼ 275 for Shanghai cohort
using immunohistochemical staining of tissue microarrays; both P5 0.05).
Conclusion: DDX27 plays an important oncogenic role in promoting CRC
tumorigenicity via activation of NF-B pathway. Higher expression of DDX27
is correlated with poor prognosis in CRC patients.
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Introduction: Serrated lesions of the colorectum are the precursors of microsa-
tellite unstable carcinomas. However, their clinical and pathologic features are
still unclear and need further exploration.
Aims & Methods: The aims of this study was to clarify the clinicopathological
features of colorectal serrated lesions. We reviewed clinical charts and pathology
files of 5352 endoscopically resected specimens performed during January 2007
and December 2016 in our hospital. A total of 463 serrated lesions (8.7%)
resected were classified into three categories: HP (hyperplastic polyp), SSA/P
(sessile serrated adenomas/polyps), and TSA (traditional serrated adenoma),
according to the WHO criteria. We examined the features of these cases and
evaluate the morphologic characteristics by using immunochemical staining for
Ki-67 and the expression of MUCs (MUC2, MUC5AC and MUC6) in differ-
entiating serrated lesions.
Results: Of these 463 lesions, a total of 241 (52.1%) were HP, 102 (22.0%)
SSA/P, and 120 (25.9%) TSA. Male to female ratio (M/F) was 2.38 for HP,
0.98 for SSA/P, and 2.45 for TSA. Mean size of SSA/Ps (13.1mm) and TSAs
(10.4mm) were significantly larger than that of HP (8.1mm) (p50.005, respec-
tively). SSA/Ps were located predominantly in the proximal colon, whereas HP
and TSA were mainly located in the sigmoid colon and rectum. 84% of SSA/Ps
were flat in macroscopic appearance. SSA/Ps and HPs were whitish or almost the
same as adjacent mucosa in color, whereas TSAs had a tendency to be reddish.
Magnified colonoscopy showed Type II open pit pattern as characteristic of
SSA/Ps, whereas pinecone-shaped pit pattern as that of TSAs. Incidences of
concomitant carcinomas in HP, SSA/P, and TSA were 0% (0 out of 241),
2.9% (3 out of 102), and 4.2% (5 out of 120), respectively. Ki-67 positive cells
in HP showed regular, symmetric distribution, and those in SSA/P did irregular
asymmetrical pattern, whereas most of those cells in TSA distributed in the so-
called ectopic crypts. Expression levels of MUC2, MUC5AC and MUC6 were
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significantly different between serrated lesions, SSA/Ps and HPs were positive for
MUC5AC in comparison with TSAs.
Conclusion: Our studies showed the three types of serrated lesions have their own
distinct features and could be helpful to distinguish between them. SSA/P and
TSA are premalignant lesions of colorectum and we should detect these lesions
and completely remove endoscopically.
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Introduction: It is generally accepted that exosomes, small, membrane-bounded
vesicles are formed in multivesicular bodies (MVBs) which fuse with plasma
membrane resulting in the release of individual exosomes into the extracellular
space. Recently, sporadic in vitro observations of a novel, unconventional
mechanism have been reported in which the exosome-like vesicles remain in
one block during their secretion.
Aims & Methods: Our aim was to examine this phenomenon in migrating color-
ectal cancer (CRC) cells in situ. Immunohistochemistry (IHC) examination of
migrating, individual cancer cells was performed in surgically removed, meta-
static CRC samples (n¼ 38). We used epithelial specific cytoplasmic (cytoker-
atin/CK) and cell membrane (E-cadherin) markers for the identification of
migrating CRC cells as well as ALIX and CD63 proteins for the detection of
exosomal transport. Samples were analyzed with confocal and stimulated emis-
sion depletion (STED) microscopy-based 3D reconstructions.
Results: 3D reconstructions showed ALIX-positive and CD63-positive exosome
clusters (ECs) with 0.62 to 1.94mm diameter (meanSD: 1.17 0.34 mm) loca-
lized partially inside, and/or outside the cytoplasm in 85.96% (n¼ 98/114) of
migrating CRC cells. E-cadherin IHC showed that ECs were not only captured
during their exit from the cytoplasm and localized among plasma
membrane proteins, but they were also detected extracellularly, in the plasma
membrane-stroma interface. STED-microscopic images showed that released
ECs were composed of smaller, distinguishable ALIX-positive spheroids of 98
to 150 nm diameter (meanSD: 128.96 16.73 nm), which fall into the size
ranges of exosomes.
Conclusion: Our study demonstrates in situ for the first time that besides con-
ventional exosome release, migrating CRC cells also secrete large, extracellular
ECs. These structures might fundamentally contribute to the autocrine/paracrine
regulation of cancer development, which effect may differ from that mediated by
conventionally secreted exosomes.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1094 ALTERED ARGININE METABOLISM IN
HYPERPROLIFERATIVE INTESTINAL EPITHELIAL CELLS: A
POTENTIAL ROLE IN TUMORIGENESIS AND WOUND HEALING
J. H.m. Van Der Meer1, W. L. Smit1, B. J. Meijer1, C. N. Spaan1,
T. B.m. Hakvoort1, M.A. Boermeester2, G.R. Van Den Brink3, V. Muncan1
1Tytgat Institute For Liver And Intestinal Research, Academic Medical Center,
Amsterdam/Netherlands
2Dept. Of Surgery, Academic Medical Center Amsterdam, Amsterdam/
Netherlands
3Dept. Of Gastroenterology, Academisch Medisch Centrum, Amsterdam/
Netherlands
Contact E-mail Address: j.h.vandermeer@amc.nl
Introduction: The semi-essential amino acid arginine is important for intestinal
epithelial cell proliferation and is an essential dietary component delivered by
solid food. In homeostatic proliferating adult intestinal enterocytes arginine is
catabolized, by the enzyme arginase 2. During embryonic development, the
demand for arginine increases, due to rapid growth. Arginine is lacking from
milk and arginine therefore has to be synthesized de novo to sustain epithelial
expansion in the rapidly growing intestinal tube. Neonatal enterocytes are cap-
able of de novo synthesis of arginine from citrulline. The rate-limiting enzyme in
this process is argininosuccinate synthetase 1 (ASS1). Similarly to postnatal
development, hyperproliferative epithelium is a hallmark of tumorigenesis and
wound healing.
Aims & Methods: The aim of this study is, to investigate, whether de novo
arginine synthesis via ASS1 plays a role in intestinal carcinogenesis and repair.
We performed immunohistochemistry on intestines from APCfl/fl mice, and
C57BL/6 mice that either underwent colonic biopsies or irradiation of the intes-
tine. Intestinal organoids from APCfl/fl mice were transduced with a shRNA for
ASS1. RNA and protein levels of ASS1 were measured by qPCR and western
blot. Arginine concentrations were determined by HPLC. Protein synthesis was
measured by [35S]-methionine labelling.
Results: ASS1 expression is highly increased in adenomas and hyperpoliferative
crypts during epithelial repair after mechanical wounding and irradiation
wounds, compared to homeostasis. Variable expression of ASS1 is seen in dif-
ferent colorectal cancer cell lines, and expression correlates with resistance
against arginine deprivation. In APC/ organoids generated from the APCfl/fl
genotype, ASS1 RNA and protein are highly expressed, with concomitant
increase of intracellular arginine. Upon knockdown of ASS1 in APCfl/fl orga-
noids, protein sysnthesis is reduced and organoid growth is compromised.
Furthermore, knockdown of ASS1 decreases overall protein synthesis.
Conclusion: In a hyperproliferative state, intestinal epithelial cells synthesize argi-
nine via ASS1. Our data suggests this plays a functional role to support growth
and protein synthesis during intestinal carcinogenesis and repair.
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Introduction: Toll-like receptors have a pivotal role in natural immunity but their
role is indefinite and, sometimes controversial, in tumor development. TLR4
signalling through MyD88 has been linked to tumour growth and progression
in mice models, whereas in humans TLR4/MyD88 signalling seems to correlate
with colorectal cancer poor prognosis [1]. On the other hand, TLR4 signalling
seem to be correlated to adaptive immunosurveillance in inflammatory related
colonic carcinogenesis [2].
Aims & Methods: The aim of this study was to define the role of TLR4 in the
immune surveillance mechanisms in a non-inflammatory model of colonic carci-
nogenesis. The azoxymethane (AOM) induced colon carcinogenesis mouse model
was used. Colonic mucosal samples were collected from wild type (WT) C57bl/6
and TLR4 knock out (KO) mice before AOM administration (T0), at 4 and at 8
months after the first AOM injection. Colons were removed and examined for
occurrence of adenoma and inflammatory infiltrate. Macroscopic tumor load
was assessed counting the number of polyps. Flow cytometry on colonic
mucosa single cell suspensions for CD8þ lymphocytes expressing CD28, CD38
or CD69, for CD4þ lymphocytes expressing CD25 or CD25 and FoxP3 and for
epithelial cells expressing CD80 or MHC-I or MHC-II were performed. Non
parametric statistics was used.
Results: In TLR4KO mice sacrificed at 8 months, 1.4 polyps/mouse were
observed while none was observed at T0 or at 4 months (p¼ 0.006).
In TLR4KO mice at 8 months, the rates of epithelial cells expressing CD80,
CD86, MHC-I and MHC-II 8 months were significantly lower than in those at
T0 or at 4 months (p¼ 0.01, p¼ 0.003, p¼ 0.003, p¼ 0.001, respectively).
Moreover, at 8 months, 5/7 TLR4KO mice compared to 0/7 WT ones had at
least a colonic adenocarcinoma (p¼ 0.02). At this time point, CD4þCD25þ,
CD4þCd25þFoxP3þ, CD8þCD28þ, CD8þCD38þ cells rate was significantly
lower in TLR4KO mice than in WT ones (p5 0.001, p5 0.001, p¼ 0.01,
p¼ 0.002, respectively). Similarly, at 8 months the rate of epithelial cells expres-
sing MHC-I and MHC-II were significantly lower in TLR4KO than in WT mice
(p¼ 0.02, p5 0.001, respectively).
Conclusion: TLR4 deficiency significantly accelerate the progression of colonic
carcinogenesis through a progressive decline of antigen presentation and lack of
co-stimulation at later stages. These impairments are associated to a decline of T
cell response in all its form (Treg, T helper and cytotoxic). All these findings are
coherent with a pivotal role of TLR4 in the immune surveillance mechanism.
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Introduction: Less than a hundred polyps defines attenuated familial adenoma-
tous polyposis (AFAP). APC or MUTYH involvement has been described in
60% of the cases. The natural history of AFAP without identified genetic defects
is not enough evaluated. In our study we compare clinical and endoscopic fea-
tures of polyposis in patients carrying APC or MUTYH mutation and wild type
patients.
Aims & Methods: 102 cases (35 F, 67 M; mean age 51; range 28–79) of AFAPs
were registered at our Institution between 1996 and 2014. They had no cancer
family history and presented more than 10 adenomas at index colonoscopy.
Genetic testing for APC and MUTYH genes was performed. Patients were put
in a program, after having cleaned the colon, consisting in colonoscopy after one
year and then the colonoscopic interval was based on the number of polyps from
1 to 3 years. Odds Ratio test was used to compare APC or MUTYH mutated and
wild-type patients.
Results: Out of 102 patients with AFAP we identified a genetic defect in 36
patients (35.3%; 12 with APC and 24 MUTYH) and 66 (64.7%) were wild-
type. The mean endoscopic follow up was 10 years (2–31) in the mutated
group and 9.7 years (2–23) in the wild-type group. Table 1 describes endoscopic
and clinical features between the two groups. We observed some statistically
differences between groups: the mutated group was younger than 50 years of
age with a higher number of polyps, right colon was mainly involved and endo-
scopic follow-up was mostly every year. Patients of wild-type group never under-
went to colectomy during follow-up and they displayed few adenoma recurrences
in 24% of cases. On the other hand 14% of mutated patients underwent colect-
omy for dense polyposis and 28% had more polyps than at index colonoscopy
and 11% no polyps at all. These 11% displayed mutation in MUTYH.
Regarding extra-colonic manifestations we observed duodenal adenomas in 5
(13.8%) patients and desmoids tumor in one patient of mutated group. Two
gastric cancers and one melanoma were diagnosed in the wild type group.
Table 1: Comparison of clinical and endoscopical feature between APC or
MUTYH carriers versus wild type patients.
APC or MUTYH
mutation¼ 36
Wild
type¼ 66
Statistics
Number % Number %
Gender
male 19 52,78 48 72,73 OR 2.3860,
95% CI: 1.0203
to 5.5794
female 17 47,22 18 27,27 P¼ 0.0448
Age at onset
550 25 69,44 13 19,70 OR 9.2657 95%
CI: 3.6441
to 23.5597
50 11 30,56 53 80,30 P5 0.0001
Number of polyps
at index colonoscopy
520 17 47,22 47 71,21 OR 0.3617 95%
CI:0.1555
to 0.8411
420 19 52,78 19 28,79 P¼ 0.0182
Polyps site
right 29 80,56 18 27,27 OR 11.0476 95%
CI: 4.1162
to 29.6510
left 7 19,44 48 72,73 P5 0.0001
Synchron colorectal cancer
yes 10 27,78 21 31,82 OR 0.8242 95%
CI: 0.3369
to 2.0161
no 26 72,22 45 68,18 P¼ 0.6718
Treatment polyposis
colectomy 13 36,11 14 21,21 OR 2.0994 95%
CI: 0.8532
to 5.1660
endoscopic polypectomy 23 63,89 52 78,79 P¼ 0.1065
Colonoscopic interval
1 year 19 52,78 0 0,00 OR 455.0000 95%
CI: 23.3975
to 8848.1863
2–3 year 4 11,11 52 78,79 P¼ 0.0001
Burden polyps in follow up
(continued)
Table 1: Continued
APC or MUTYH
mutation¼ 36
Wild
type¼ 66
Statistics
Number % Number %
no 4 11,11 36 54,55
less than at index
colonoscopy
4 11,11 16 24,24 OR 0.0936 95%
CI: 0.0274
to 0.3197
more than at index
colonoscopy and
dense polyposis
15 41,67 0 P¼ 0.0002
Tot 36 100,00 66 100,00
Conclusion: We observed a different behavior between mutated and wild-type
patients. Patients with genetic involvement still developed adenomas during the
follow-up and some needed colectomy. Instead, wild-type patients had mostly no
recurrence. Constitutional genetic background could be suspected in wild-type
patients when a continuous development of new polyps has observed and further
genetic investigation should be offered by multi-gene testing.
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Introduction: Besides local hypermethylation on promoters of certain tumor sup-
pressor genes, global DNA hypomethylation is characteristic in various types of
cancers including colorectal cancer (CRC). The DNA methylation level of long
interspersed nuclear element-1 (LINE-1) repetitive retrotransposon sequences
constituting 17% of the human genome can be used to estimate global methyla-
tion level.
Aims & Methods: We aimed to analyze the alterations of the global DNA methy-
lation levels along the colorectal normal-adenoma-carcinoma sequence progres-
sion on the basis of LINE-1 methylation and to study the methyl-cytosine pattern
in tissue samples. Genomic DNA was isolated from 10 colorectal adenoma, 10
CRC and 30 normal colonic biopsy samples. Bisulfite conversion of DNA sam-
ples was performed using EZ DNA Methylation-Direct Kit (Zymo). For methy-
lation level quantification of the LINE-1 retrotransposable element, bisulfite-
specific PCR (BS- PCR) was applied, and 146 bp long PCR products were
sequenced on Pyromark Q24 system (Qiagen). Tissue localization of 5-methylcy-
tosine (5-mC) in normal, adenoma and CRC tissues was analyzed by immuno-
histochemistry using mouse monoclonal anti-5mC antibody (GeneTex).
Results: According to the LINE-1 bisulfite sequencing results, significant
(p5 0.01) global DNA hypomethylation was detected both in CRC
(63 8.7%) and adenoma samples (67 5.1%) compared to normal tissue
(72 1.4%). 5-mC labeling of both the epithelial and stromal components of
normal samples was strong (scoring values: þ2 and þ3) with diffuse and nuclear
staining. In adenomas, decreased nuclear 5-mC staining (scoring value: þ2) was
detectable in the epithelium and the stroma compared to normal epithelium. In
CRC samples significantly lower 5-mC levels could be observed than in normal
tissue samples (p5 0.05).
Conclusion: Global DNA hypomethylation could be shown in CRC compared to
healthy normal tissue samples both by LINE-1 bisulfite-sequencing and by 5-mC
immunohistochemistry. Genome-wide DNA methylation decrease occurs already
in adenoma stage of colorectal carcinogenesis.
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Introduction: MiRNAs have a critical relevance in regulation during tumorigen-
esis. The expression profiles of miRNAs alter along tumor progression moreover;
these miRNA may spread into tumor macro- and microenvironment.
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Extracellular miRNAs are stable and its expression is less characterized in
plasma. Altered and overlapped miRNA profiles between tissue and plasma
are less explored.
Aims & Methods: The present study was designed to characterize the tissue and
circulating miRNA profile through colorectal adenoma-carcinoma sequence in
human specimens and also in mice peripheral blood samples. Furthermore, the
purpose of our study was to determine the origin of detected miRNAs in tumor-
adherent C38/C57BL/6 and non-adherent CBAJ mice tumor models. To achieve
that goal, human peripheral blood and biopsy of normal (N), tubular (AT),
tubulovillous adenoma (ATV) and colorectal cancer (CRC) were selected and
plasma were also collected two times a week over 45 days from C57BL/6-C38,
CBAJ mice. MiRNAs were isolated and Affymetrix GeneChip miRNA array
analysis was performed for screening of the altered miRNA profile. RT-qPCR
method was used for validation.
Results: In the case of human samples out of 1733 detectable miRNAs, 306
miRNAs were expressed in normal, 334 in adenoma and 321 in CRC.
Characteristic miRNA expression alteration was observed in the comparison of
AD vs. CRC (miR-149*, miR-3196, miR-4687) in plasma. In the case of N vs.
CRC, overexpression of miR-612, miR-1296, miR-933, miR-937 and miR-1207
was validated by RT-PCR (p5 0.05). Partial co-expression of these miRNAs
was observed in tissue pairs as well. We identified high plasma levels of
94 miRNAs in healthy animals and 176 miRNAs in late tumor stages. Based
on CBAJ-C38 mice model experiment where the injected tumorous cells could
not adhere miR-676 found to be a host originated while miR-92a was a tumor-
derived miRNA. MiR-676 and miR-92a shown significant overexpression (388x
and 37x p5 0.05) in plasma samples based on real-time PCR and microarray
results.
Conclusion: Circulating miRNAs alteration could observe in animal models and
in the human circulatory system. Cancer-associated miRNAs in the circulation
may originate from the immunologic system or from other metastatic regions far
from the primer tumor location.
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Introduction: The mechanism of colorectal cancer (CRC) invasion and metastasis
is still unclear. Epithelial-mesenchymal transition (EMT) is one of the key mole-
cular steps in the process of distant metastasis. EMT is referred to conversion of
cells with an epithelial phenotype into cells with a mesenchymal phenotype,
which lead to loss of cell polarity, with acquisition of migratory and invasive
properties of cancer cells.1 MicroRNAs (miRNAs) are small non-coding RNAs
that negatively regulate gene expression at post-transcriptional phase.2
MicroRNA-126 (miR-126) originates from a common precursor structure
located within the egfl7 gene, which acts as a tumor suppressive miRNA in
various carcinomas.3 Our previous studies found that miR-126 was significantly
down-regulated in human CRC tissues and negatively related with patient’s
prognosis.4 MiR-126 was also low-expressed in high metastatic cell lines, and
inhibited proliferation, invasion and metastasis of CRC in vitro.5 However,
whether miR-126 can regulate the process of EMT in CRC is still unclear. Ras
homologue A (RhoA) is one of most characterized members of Rho GTPases
which belong to Ras superfamily. RhoA, as molecular switch, cycles between an
active GTP-bound state and inactive GDP-bound state. RhoA and its compo-
nents of signaling pathway are known to participate in a diverse array of cellular
events related to invasion and metastasis of cancer cells.6 Our previous study
found that miR-126 down-regulated RhoA and ROCK activity in CRC cells.5
Whether RhoA activity and RhoA signaling pathway play an important role in
miR-126 regulating EMT process, cell proliferation, migration and invasion of
CRC remains unclear.
Aims & Methods: To identify RhoA signaling pathway associated with the func-
tions of miR-126 in EMT, proliferation, migration and invasion of CRC cells.
Constructed CRC cell lines of miR-126 over-expression or knockdown.
Performed MTT, colony formation, wound-healing, migration, invasion assays
and RT PCR, western blot analysis to study the functions of miR-126 in EMT,
proliferation, migration, invasion and expression RhoA signaling pathway of
CRC cells. Constructed pDsRed2-V14RhoA (constitutively active RhoA,
V14RhoA) and pDsRed2-N19RhoA (domain-negative, N19RhoA) mutants,
then transfected them into the CRC cell lines of miR-126 over-expression or
knockdown to restore RhoA activity. Pulldown assay detected RhoA activity
after transfected. Then repeated the experiments above to investigate the biolo-
gical behavior changes of CRC cells.
Results: MiR-126 promoted the expression of E-cadherin and suppressed the
expression of SLUG, Snail, Vimentin, Fibronectin of CRC cells. MiR-126 also
inhibited proliferation, migration and invasion of CRC cells, and negatively
regulating RhoA signaling pathway. V14RhoA mutant effectively increased the
activity of RhoA and reversed the role of miR-126 by promoting EMT, prolif-
eration, migration and invasion in miR-126 overexpressing HCT116 cells.
Conversely, N19RhoA mutant effectively decreased the activity of RhoA and
suppressed EMT, proliferation, migration and invasion in miR-126-silenced
SW480 cells.
Conclusion: RhoA signaling pathway was the key signaling pathway of miR-126
in suppressing the EMT, proliferation, migration and invasion of CRC cells.
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Introduction: Colorectal cancer development is characterised by sporadic muta-
tions and epigenetic alterations. DNA mutations occur randomly and sporadi-
cally in growth-related genes, mostly on cytosine nucleotides. Active
demethylation of cytosines in relation to RNA expression alterations may lead
to genetic instability and DNA mutations. Whole genomic DNA methylation
and mutation analysis with RNA expression profiling could demonstrate the
primary and secondary order of the epigenetic and genetic changes and their
relation to the malignant phenotype development.
Aims & Methods: In this study we aimed the whole genome methylation analysis
and targeted mutation analysis of colorectal cancer (CRC)-related genes (12)
with upstream whole genomic mRNA expression evaluation. Special focus was
set on the p53 pathway and the involved genes. Methyl capture sequencing
(Illumina) was performed on normal (N: 6), adenomatous (Ad: 15) and colorectal
cancer (CRC: 9) biopsy specimens. Methylation results were confirmed by in
silico methylation studies’ results (TCGA) and by methylation array-PCR
(Qiagen Methylation array). Specimens were further evaluated for 32 mutations
of 12 CRC-related genes (APC, BRAF, CTNNB1, EGFR, FBXW7, KRAS,
NRAS, MSH6, PIK3CA, SMAD2, SMAD4, TP53) by new generation sequen-
cing (Roche 454 Junior). mRNA expression evaluation was performed by whole
genomic expression analysis (HGU 133, Affymetrix). Tageted pathway analysis
was performed for the p53 pathway. Bioinformatic analysis included overall
quantitative methylation analysis, selection of top hyper/hypomethylated
genes, methylation changes on the tumor mutation regions and related pathway
gene promoters were evaluated by targeted analysis.
Results: Overall hypomethylation was observed on the N-Ad-CRC sequence in
the gene body and non coding genomic regions. In Ad-N comparison e.g. p73,
NGFR, PDGFRA genes were hypermethylated for their promoters, FMN1,
SLC16A7 genes were hypomethylated, respectively. In CRC-N comparison
DKK2, SDC2, SOX1 genes showed hypermethylation, while ERBB4, CREB5,
CNTN1 genes were hypomethylated in the promoter regions. In silico analysis on
the TCGA database yielded confirmatory results. The common hyper- and hypo-
methylated genes were also in correlation with methylation array results yielded
by methylation specific PCR. A significant negative correlation of the top methy-
lated genes could be demonstrated to the RNA expressions. In the certain muta-
tion hot spot, genebody regions significant DNA methylation alterations (mainly
hypomethylation) were detected. APC, P53 and KRAS mutations were found in
30%, 15%, 21% of adenomas, and in 29%, 53%, 29% of CRCs, respectively.
RNA expressions profiling could not detect any significant quantitatve changes
related to these DNA sequence alterations. The p53 gene body was addressed by
hypermethylations in adenomas. mRNA expression changes were observed in
most of the p53 pathway genes showing promoter methylation alterations.
Conclusion: DNA methylation with consecutive phenotypic effect can be
observed in a high number of gene promoters and gene body regions through
CRC development. The mutation hot spot areas of the most relevant colorectal
cancer mutation genes (APC, p53,KRAS, NRAS) were involved in methylation
alterations without detectble quantitative RNA expression changes. p53 cance-
pathway genes are highly methylated in promoters and gene body with corre-
sponding expression changes. The tumor mutation hot spot areas in the p53 gene
are hypomethylated and thus genetically instabile and therefore mutated.
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Introduction: Colorectal carcinoma is one of the leading causes of cancer-related
mortality worldwide. Tumor associated macrophages (TAMs) are critical stro-
mal components intimately involved with the progression, invasion, and metas-
tasis of cancer cells. Recently, increasing studies have demonstrated that
microRNA-126 (miR-126) had an important role in colorectal cancer. The
expression of miR-126 decreased significantly in colorectal cancer, particularly
in highly metastatic cell lines, indicating that miR-126 may inhibit tumor devel-
opment and metastasis. However, the mechanism underlying miR126 inhibiting
cancer is uncertain, and its function in cross-talk between colorectal cancer cells
and TAMs are still in its infancy.
Aims & Methods: In this study, we investigate the cross-talk between cancer cells
and TAMs in colorectal cancer microenvironment, and find out what role the
miR-126-CXCL12-IL6 axis plays in it. Methods: (1)The effect of miR-126 on
CXCL12 expression was assessed in the CRC cell line Caco2 transferred with a
miR-126 mimic or inhibitor to increase or decrease miR-126 expression; (2) We
build a co-culture system of TAMs and transferred cancer cells, and use
AMD3100(100 ng/ml) to block CXCL12/CXCR4 axis, then detect the recruit-
ment and inflammation factors secretion of TAMs; (3) Furthermore, the TAMs
co-cultured before were taken away from the previous system and put into a new
co-culture system with untreated colorectal cancer cells, and IL6 neutralizing
antibodies were added in. We detect the expression of EMT associated factors
and STAT3 pathway activation by western blot, cell growth by CCK8, metastasis
by Transwell. The definition of statistical significance was defined as P5 0.05
(two-tailed).
Results: (1)miR-126 negatively regulate CXCL12 expression in post-transcript
level; (2)Inhibiting miR-126 of colorectal cancer cells could promote TAMs
recruitment and up-regulate inflammation factors IL1b and IL6 expression.
However, blocking CXCL12/CXCR4 axis by AMD3100 could reverse this
effect, vice versa;(3) Inhibiting miR-126 of colorectal cancer cells could recruiting
TAMs, therefore down-regulate E-cadherin protein, up-regulate slug protein,
and activate STAT3 pathway of untreated cancer cells. It could also promote
cancer cells growth and metastasis. In addition, IL6 neutralizing antibodies could
block this effect, vice versa.
Conclusion: Our results reveal a novel mechanism by that miR-126 repress
recruitment and inflammatory factor secretion of TAMs through controlling
secretion and paracrine signaling of CXCL12 to inhibit colorectal cancer
growth and metastasis.
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Introduction: Narrow Band Imaging (NBI) enable detection for vascular-rich
small, flat lesion and recognition of mucosal surface compared with normal
colonic mucosa and vascular pattern in colonoscopy. However, recent studies
reported no significant difference in overall adenoma detection rate with the use
of NBI compared with white light imaging (WLI). Blue Laser Imaging (BLI) is
next-generation of image enhanced endoscopy technique using LASER light
source that were realized with lighting and image processing suitable for visua-
lization of microvessels and structures in the superficial portion of the mucous
membrane.
Aims & Methods: Our aim was to determine whether the use of BLI enhances the
adenoma detection rate (ADR) and miss rate compared with WLI. A total of 130
patients who underwent screening or surveillance colonoscopy in Saga University
Hospital were included. Three patients were excluded because of poor bowel
preparation. One hundred and twenty-seven patients were randomized to
tandem colonoscopy with BLI followed by WLI (BLI-WLI group) or WLI fol-
lowed by WLI (WLI-WLI group). Polyp (adenoma) detection rates, miss rates
and the number of polyps (adenoma) detected per person (mean adenoma detec-
tion rate) were examined between the two groups.
Results: The BLI-WL group and WL-WL group comprised 64 and 63 patients,
respectively. The proportion of patients with polyps (adenoma) was 62.5% in
BLI-WL group compared with 63.5% in WL-WL group. There was no signifi-
cant difference between two groups regarding ADR (). The number of adenomas
detected per person (ADR) of BLI-WL group and WL-WL group were 2.84 and
1.90, respectively. However, the polyp miss rate of BLI-WL group was less than
that of WL-WL group (1.6% vs 10.0%: P¼ 0.0014).
Conclusion: There were no significant difference in the overall polyp (adenoma)
detection rate with BLI-WLI group or WL-WL group. However, miss rate was
higher in WL-WL group compared with BLI-WL group (10.0% vs 1.6%,
P¼ 0.0014). Further, BLI detected more polyps per patient compared with WL
group (2.84 vs 1.90). BLI may improve polyp miss rate and the number of polyps
per subject (mean adenoma detection rate) in the colonoscopy.
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Introduction: The National Health Service Bowel Cancer Screening Programme
(NHS BCSP) offers colonoscopy to people testing positive for Faecal Occult
Blood Test (FOBT) after the age of 60. In addition, the ’Bowel scope screening’
test offers once-only flexible sigmoidoscopy (FS) to people in the UK after the
age of 55. The Norwegian (NORCCAP) and Italian (SCORE) trials evaluated
the effectiveness of FS screening and reported a non-statistically significant
decrease in colorectal cancer (CRC) specific mortality at follow-up. It is unclear
if significant proximal neoplasia is being missed in people undergoing flexible
sigmoidoscopy alone.
Aims & Methods: We aim to investigate the distributions of pathology within the
BCSP at a busy district general hospital in London. In 2015, 22,539 FOBT kits
were returned out of the 43,884 (51.4%) sent out in the boroughs of Barking,
Havering and Redbridge (BHR). Of those returned, 398 (1.8%) tested positive.
We collected data for the 326 patients who attended for colonoscopy at BHR
University Hospitals (81.9%). Subgroup analyses included age, sex, histology,
location of polyps, number of polyps, polyp size and therapies.
Results:Mean age 67, Male 60.4%. Polyps were found in 199 patients (61%), 488
polyps found in total, mean number of polyps 2.5 (Range 1–14), mean size 7mm
(Range 1mm–60mm); 49 (15%) hyperplastic, 156 (47.9%) adenomas and 16
(4.9%) adenocarcinoma. Patients with adenoma/carcinoma were older (67.6 vs.
66.5, p¼ 0.02) but there was no difference in sex (Male 61.4% vs. 59.4%,
p¼ 0.49) when compared to those without adenoma/carcinoma. Of 172 patients
with adenoma/carcinoma, 111 (64.5%) were proximal to the splenic flexure (SF).
5 out of 16 (31.2%) adenocarcinomas were proximal to SF and 2 (40%) of these
patients had no polyps distal to the SF.
Adenoma/Carcinoma according to location in colon
Adenoma/
Carcinoma
SFþDistal
(n¼ 61)
Proximal to
SF (n¼ 111) *p value
Age 67.4 67.7 0.67
Male 41 (67.2%) 67 (60.4%) 0.32
Number of polyps 1.7 3 50.01
Size of polyps (mm) 8.6 6.0 50.01
Carcinoma 11 5 0.71
Conclusion: Patients with adenomas/carcinomas are older and those with prox-
imal adenomas/carcinomas have more polyps but are smaller in size. One in three
adenocarcinomas picked up during colonoscopy would be out of reach of a
flexible sigmoidoscopy. Furthermore, over one third of the proximal cancers
did not have distal polyps.
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Introduction: Colorectal cancers have two development theories. One of
the development theories is ‘‘adenoma-adenocarcinoma sequence’’ developing
from protruded-tyepes ‘‘polypes’’ we know generally. The other is considered
to emerge directly from nomal epithelium, not through the adenomatous stage.
Recently, it is revealed most of this type are depressed-type carcinomas. This
theory is called ‘‘de novo’’ pathway. We studied clinicopathological character-
istics and long-term prognosis mainly on depressed-type colorectal carcinomas.
Aims & Methods: The aim is to clarify the pathological characteristics of
depressed-type colorectal carcinomas compared with flat- and protruded-type.
A total of 29030 colorectal neoplasms excluding advanced carcinomas were
resected endoscopically or surgically in our Center from April 2001 to
December 2016. Of these, 1127 lesions were T1 carcinomas. According to the
morphological/development classification, 244 lesions (21.7%) were depressed-
type, 385 lesions (34.2%) were flat-type and 498 lesions (44.1%) were protruded-
type. We analyzed the pathological features of these lesions.
Results: The rate of distant metastasis or recurrence was 0.9% (10/1127). Among
these 10 cases, 5 cases were developed from depressed-type lesions and one
showed a para-aortic lymph node metastasis and four showed a lung metastases.
The rate of submucosal invasion in all the lesions was 72.4% in depressed-type,
3.2% in flat-type and 2.9% in protruded-type. Within less than 5mm in diameter,
that was 10.6%, 0% and 0% respectively. Among T1 carcinomas, the rate of
vessel invasion was 64.3% in depressed-type, 34.3% in flat-type and 38.4% in
protruded-type, that of poorly differentiated or mucinous adenocarcinoma was
17.2%, 10.4% and 13.5%, that of massively submucosal invasion was 94.7%,
71.7% and 69.7%, and that of tumor budding was 36.5%, 16.1% and 17.3%,
respectively. The rates of these pathological factors were significantly higher in
depressed-type lesions. On the other hand, the rate of adenomatous component
was 4.9%, 52.2% and 50.8% ,respectively.It was significantly lower in depressed-
type lesions, suggesting that they emerge directly from normal epithelium without
going through the adenoma stage. The rate of lymph node metastasis was 11.6%,
6.8% and 13.0%, respectively. And 2 depressed-type lesions had synchronous
liver metastasis.
Conclusion: Depressed-type colorectal carcinomas invade massively even when
they are small. They had higher risks of vascular invasion, poorly differentiated
or mucinous adenocarcinoma, massive invasion, and tumor budding than flat- or
protruded-types. For their rapid growth and malignant potential, whether the
lesion is depressed-type or not is very important in the diagnosis of colorectal
carcinomas.
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Introduction: Recent cancer genome analyses identified extensive genetic intratu-
moral heterogeneity (ITH), suggesting a Big Bang model in which tumors grow
as an expansion producing numerous subclones. As subclone mixing is indicative
of an early malignant potential, ITH may be a hallmark to identify precursor
lesions at high-risk of developing CRC.
Aims & Methods: We aim to clarify the association between ITH of driver muta-
tions and clinicopathological characteristic in colorectal tumors. A total of 711
specimens from 477 colorectal tumors were analyzed in this study.
Subcomponents of the tumors were endoscopically defined using the microsur-
face structures according to Kudo’s pit pattern classification, and biopsy speci-
mens were obtained from respective portions. BRAF, KRAS and TP53mutations
were analyzed by pyrosequencing and direct sequencing. Hot spot mutations of
50 cancer related genes were analyzed using the Ion PGM sequencer.
Results: ITH of KRAS and TP53mutations was frequently observed in colorectal
tumors with multiple subcomponents. Heterogeneity of KRAS or TP53 muta-
tions between early and advanced subcomponents (e.g., KRAS G12D in early
portion and KRAS G13D in advanced portion) progressively increased during
the steps of carcinogenesis: high grade adenomas (KRAS, 8%; TP53, 0%), non-
invasive cancers (KRAS, 14%; TP53, 12%) and submucosal cancers (KRAS,
25%; TP53, 38%). These results suggest that subcomponents defined by micro-
surface structure may represent genetically distinct subclones. By contrast, only 4
of 41 BRAF-mutant lesions exhibited ITH of BRAF mutation. Pathological
findings of the 4 lesion were low grade adenoma (n¼ 1), non-invasive CRCs
with adenoma (n¼ 2) and serrated lesions (n¼ 1), whereas majority of the
BRAF-mutant lesions without ITH (n¼ 37) were serrated lesions or CRC with
serrated lesions. Sequencing of 50 cancer-related genes in 8 tumors with KRAS/
TP53 ITH revealed that both subcomponents exhibited identical mutations in
genes including FBXW7, HRAS and SKT11, suggesting that these were founder
mutations.
Conclusion: Our results demonstrate that degree of ITH of KRAS/TP53 muta-
tions increases during the progression of colorectal tumorigenesis. Intratumoral
variations in the microsurface structure may represent molecular subclones in
early colorectal lesions and may be predictive of the malignant progression.
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Introduction: Hypoxia signalling has been found to enhance cancer cell survival,
chemoresistance, motility, tumour angiogenesis as well as self-renewal capacity
and proliferation of putative cancer stem cells. One of the key player in hypoxia is
carbonic anhydrase IX (CAIX) which is a hypoxia-inducible enzyme. CAIX is
overexpressed in a variety of cancers including colon cancer and plays a crucial
role in maintaining favourable intracellular pH in hypoxia. There is also evidence
that extracellular vesicle (EV) production is increased in response to hypoxia and
promotes adaptive response of cancer cells and we have previously demonstrated,
that CAIX positive EVs secretion is increased in response to hypoxia in color-
ectal cancer cell lines SW480 and SW620.
Aims &Methods:Within this study, we explored a possibility to use CAIX for the
isolation of hypoxic EVs from colorectal cancer (CRC) patients’ plasma. EVs
were isolated from plasma samples of 27 CRC patients and 25 healthy donors
(HD) by using sequential centrifugation, filtration and size-exclusion chromato-
graphy steps. EVs where quantified by Nanoparticle tracking analysis (NTA) and
CAIX positive EVs where determined by ApogeeA50.
Results: Statistically significant increase in the amount and size of EVs was
observed between CRC and HD cohorts based on NTA data. ApogeeA50 data
revealed that there is a tendency for the percentage of CAIX-positive EVs to
increase with the stage of CRC and is higher in stage III-IV CRC patients than in
HD. In addition, it is higher in patients with metastasis than without distant
metastases.
Conclusion: There is an increased total EV number, EV size and CAIX positive
EV amount in CRC patient plasma compared to HD plasma, that might have
diagnostic and prognostic value. (Financed by Latvian Council of Science
Collaboration project No: 625/2014).
Disclosure of Interest: All authors have declared no conflicts of interest.
P1107 THE GENESIS STUDY: GENETIC BIOPSY FOR PREDICTION
OF SURVEILLANCE INTERVALS AFTER ENDOSCOPIC
RESECTION OF COLONIC POLYPS
A. W. Berger1, K. Raedler2, C. Langner3, L. Ludwig4, N. Dikopoulos4,
K.F. Becker5, J. Slotta-Huspenina5, M. Quante6, D. Schwerdel1, L. Perkhofer1,
A. Kleger1, E. Zizer1, F. Oswald2, T. Seufferlein7, A. Meining1
1Department Of Internal Medicine I, Ulm University, Ulm/Germany
2Clinic For Internal Medicine I, Ulm University, Ulm/Germany
3Institute For Pathology, Medical University Graz, Graz/Austria
4Gastroenterologische Schwerpunktpraxis, Dornstadt/Germany
5Institute For General Pathology And Pathological Anatomy, Technical University
Munich, München/Germany
6II Department Of Internal Medicine, Technical University Munich, München/
Germany
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Introduction: Colorectal cancer (CRC) is an important contributor to cancer
mortality and morbidity worldwide. 80% of CRCs arise via the adenoma-carci-
noma sequence, 10–20% CRCs by sessile serrated adenomas (SSA). Hyperplastic
polyps are regarded harmless. Current surveillance strategies for CRC following
polypectomy are determined by endoscopic and histopathological factors. Such a
distinction has also been challenged.
Aims & Methods: The study was aimed for molecular characterization of colonic
polyps in patients who underwent screening colonoscopy. Correlation of the
genetic analysis with endoscopic, clinical and histopathological data was
attempted to potentially better define relevant risk marker or sub-groups at
risk for prediction of surveillance intervals. 100 Patients were enrolled in this
multicenter study (NCT02595645; Median age: 62.9 y, 50 males, 50 female). Up
to 6 representative polyp biopsies were collected and stored in a formalin-free
medium and finally embedded in paraffin-blocks, followed by histopathological
assessment. Targeted Next Generation Sequencing (tNGS) was performed from
identical tissue specimens (38 CRC-related genes; GeneRead DNAseq Targeted
Panels V2, Qiagen) on a MiSeq platform (Illumina). Genetic and histopatho-
logical analysis was done blinded to the endoscopic and clinical data.
Results: In 100 patients, 224 polyps were removed. 121 polyps (54.0%) are sized
510mm, 71 (31.7%) were 10mm. For 32 polyps (14.3%) no size was available.
90 polyps (40.2%) were located in the left, 126 polyps (56.3%) in the right colon,
for 8 polyps (3.6%) no location was noted. 112 polyps (50.0%) were adenoma-
tous and 110 polyps (49.1%) non-adenomatous lesions. No data were available
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for 2 polyps (0,9%). Clinical, endoscopic and histopathological data were corre-
lated to molecular characteristics. Significant associations of genetic alterations
with endoscopic or histopathological polyp characteristics were observed for
BRAF, KRAS, TCF7L2, FBXW7 and CTNNB1 mutations. Multivariate ana-
lysis revealed that polyps 10mm have a significant higher relative risk (RR) for
harboring oncogene mutations (RR 3.467 (1.742–6.933)). Adenomas and right-
sided polyps are independent risk factors for CTNNB1 mutations (RR 18.559
(2.371–145.245) and 12.987 (1.637–100.00)).
Conclusion: We were able to show that assessment of the mutational landscape of
resected polyps/poly biopsy can easily be integrated in the workflow of current
colonoscopy practice. There are distinct genetic patterns related to size and
location of polyps and the clinician can appreciate this additional information
to better estimate a patient’s individual risk.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Cell-free DNA (cfDNA) is circulating in human plasma and its
amount is different in certain physical conditions. It is well known, that in
healthy people the quantity of cfDNA is very low, but it rises in chronic disorders
such as cancer. At the same time, very high cfDNA level can be measured in
healthy people during physical exercise.
Aims & Methods: We aimed to analyze cfDNA changes (quantity, fragment
length, global DNA methylation level) in physiological conditions (during phy-
sical exercise) and its alterations in neoplastic and inflammatory colorectal dis-
eases. Plasma was separated from 64 patients (16 colorectal carcinomas (CRC),
13 colonic adenomas (AD), 19 inflammatory bowel disease (IBD), and 16 normal
(N) donors without evidence of disease). Plasma samples were also collected from
6 healthy athletes before, during and after physical training. DNA was isolated
with High Pure Viral Large Volume NA isolation Kit (Roche). cfDNA was
quantified with Qubit fluorometry (Invitrogen). CfDNA fragment length distri-
bution was assessed by Bioanalyzer 2100 using High Sensitivity DNA assay
(Agilent). Global DNA methylation was analysed by bisulfite pyrosequencing
of long interspersed nuclear element-1 (LINE-1) (Qiagen).
Results: High increase of cfDNA amounts was observed in plasma samples of
patients with colonic adenoma (20.61 10.70 ng/ml), colorectal cancer
(24.13 20.02 ng/ml) and IBD (22.27 14.60 ng/ml) compared to healthy sub-
jects (10.33 3.22 ng/ml). Highly elevated cfDNA amounts were found in plasma
samples of athletes during physical exercise (66.17 29.00 ng/ml), while the
cfDNA amount decreased after physical activity (51.87 39.80 ng/ml).
Characteristic cfDNA fragment length distribution pattern (with different peak
heights at 180 bp, 360 bp, 550 bp) was observed in each patient group. Global
DNA hypomethylation was shown in CRC plasma samples with advanced tumor
stage (N: 79% 0.80%, AD: 79% 1.70%, advanced CRC: 70% 0.03%).
Conclusion: Remarkable increase was found in plasma samples of colorectal AD,
CRC, IBD patients and also in healthy athletes during physical exercise. CfDNA
fragment length analysis showed differences between each group. Global DNA
hypomethylation could be observed only in CRC patients with advanced tumor
stage. Based on our results, the above DNA analysis methods might contribute to
non-invasive detection for colorectal diseases.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Epigenetic instability, primarily aberrant DNA methylation seems
to be a common phenomenon in colorectal cancer (CRC) influencing gene
expression and contributing to tumor formation. In recent years, blood-based
assays came into focus as potential screening tools for colorectal adenoma and
cancer cases, as the analysis of the methylation status of circulating cell-free
DNA (cfDNA) in plasma samples provides a good opportunity for cancer
detection.
Aims &Methods: Our aim was to analyse the methylation pattern of four selected
genes in biopsy and plasma samples of healthy, colorectal adenoma and CRC
patients. Moreover, we aimed to examine the effect of methylation alterations on
protein expression. MethyLight (ML) PCR was used after bisulfite-conversion to
study certain DNA sequences of the promoter regions of SFRP1, SFRP2, SDC2
and PRIMA1 in 32 biopsy-plasma pairs and in 121 additional plasma samples.
For validation, DNA methylation status (b-values) of the 4 markers was deter-
mined using methyl capture sequencing data from our research group.
Furthermore, the methylation status of the four candidates’ whole promoter
regions was examined in silico using Illumina Infinium HumanMethylation450
BeadChip methylation array data downloaded from The Cancer Genome Atlas
(TCGA) database and from NCBI Gene Expression Omnibus Database (GEO
accession number: GSE48684). In order to examine the effect of promoter methy-
lation on the protein expression, immunohistochemistry analysis was performed.
Results: Using ML assays, methylation of SFRP1, SFRP2, SDC2 and PRIMA1
was observed in 85.1%, 72.3%, 89.4% and 80.9% in the plasma fraction of
patients with CRC and 89.2%, 83.8%, 81.1% and 70.3% of adenoma patients,
respectively. In multiple logistic regression analysis, the four markers together
were able to distinguish CRC patients from healthy individuals with 91.5%
sensitivity and 97.3% specificity (AUC¼ 0.978) and could differentiate adenoma
samples from healthy controls with 89.2% sensitivity and 86.5% specificity
(AUC¼ 0.937). In silico analyses confirmed our results on the altered methyla-
tion pattern of the four markers in tissue samples. Immunohistochemistry ana-
lysis indicated decreasing protein levels of the four markers along the colorectal
adenoma-carcinoma sequence.
Conclusion: Our findings suggest that SFRP1, SFRP2, SDC2 and PRIMA1 can
be promising epigenetic biomarker candidates for colorectal adenoma and cancer
diagnosis with high sensitivity and specificity.
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Introduction: Metabolomics, a dynamic portrait of the metabolic status of living
systems, has demonstrated its great potential for use in the diagnosis of various
cancers by applying advanced analytic techniques and bioinformatics tools.
Recently, very few metabolic markers in CRC have been consistently discovered,
but metabolic profiles of patients with CRC including precancerous lesion in
colorectum remains poorly understood and warrants investigation due to its
non-invasive sampling method. In the last decade, several metabolomic
approaches have been applied toward identifying metabolic alterations in CRC
using variety of sample types including urine, tissue, serum, and feces. However
there are only few urinary metabolomic studies and especially nuclear magnetic
resonance (NMR) spectroscopy, which has several advantages including rela-
tively high degree of reproducibility, easy-to-identify metabolites, high through-
output, and non-destructive sample treatment, has not been applied to urine
samples.
Aims & Methods: In this study, we investigate the differences in urine metabolic
profiles of patients with colorectal neoplasia (CRN) including CRC and precan-
cerous lesion, and healthy volunteers using a NMR-based urine metabolomic
study. In addition, we evaluate applicability as diagnostic tool of urine metabo-
lomics for early detection of precancerous colorectal lesion with high sensitivity
and specificity. Urine metabolomic profiles from patients with colorectal neopla-
sia (CRN; 36 advanced adenomas and 56 various stages CRC) and healthy
controls (n¼ 156) were analyzed by NMR spectroscopy. Healthy and CRN
groups were statistically discriminated using orthogonal projections to latent
structure discriminant analysis (OPLS-DA). The class prediction model was vali-
dated by three-fold cross-validation. The advanced adenoma and stage 0 CRC
were grouped as pre-invasive CRN.
Results: After patients underwent endoscopic resection or surgical resection for
CRN, advanced adenoma has been diagnosed in 36 patients, stage O CRC in 24
patients, stage I CRC in 8 patients, stage II CRC in 7 patients, stage III CRC in
13 patients and stage IV CRC in 4 patients. CEA and CA 19-9 levels for patient
with stage I to IV CRC and healthy control were also assessed. Among patients
with stage I to IV CRC, CEA and CA 19-9 were increased only in two patients,
respectively. The sensitivity and specificity of CEA and CA 19-9 were 6.2% and
99.3% The OPLS-DA score plot showed statistically significant discrimination
between pre-invasive CRN as well as advanced CRC and normal with a Q2 value
of 0.746. In the prediction validation study, the sensitivity and specificity for
diagnosing pre-invasive CRN was 96.2% and 95%, respectively. The grades
predicted by the PLS-DA model showed that area under the curve was 0.823
for taurine, 0.783 for alanine and 0.842 for 3-aminoisobutyrate. In multiple
receiver operating characteristics curve analyses, taurine, alanine, and 3-aminoi-
sobutyrate were good discriminator for CRC patients.
Conclusion: NMR-based urine metabolomic profiles significantly and
accurately discriminate between patients with pre-invasive CRN as well as
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advanced CRC, and healthy control with high accuracy. It demonstrates an
applicability of urine-NMR metabolomics as screening tool for accurate diag-
nosis of pre-invasive CRN.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Symptoms alone are poor predictors of underlying colonic pathol-
ogy.1 Only 14% of patients referred for colonoscopy from primary care have
significant bowel disease (SBD), [colorectal cancer (CRC), high risk adenoma
(HRA, defined as 3 or any 1 cm) and inflammatory bowel disease (IBD)].2 We
have reported that undetectable faecal haemoglobin (f-Hb), measured by a faecal
immunochemical test (FIT) is a good rule-out test for SBD.2,3 Since December
2015, GPs in Tayside have been encouraged to use FIT test as an adjunct to
history, examination and mandatory blood tests in patients referred with bowel
symptoms. Referrals are vetted by a Consultant and triaged to test or clinic. We
have examined the impact of the introduction of the FIT test on referral rates and
colonoscopy yield.
Aims & Methods: Patients in primary care with new bowel symptoms were
encouraged to complete a FIT in addition to blood count and renal function
check. We prospectively recorded FIT tests received, referrals to secondary care
and colonoscopy findings over 1 year from December 2015 to December 2016.
FIT tests were analysed by HMJACKarc (Kyowa Medex Co. Ltd., Japan) with
an analytic range of 510 to 4400 mg Hb/g faeces. Referral rates with FIT were
examined along with clinical findings at colonoscopy.
Results: 5,655 FIT tests were received. 76.2% had undetectable fHb, and 152
(2.7%) were untestable. 4,108 patients were referred of whom 2,338 (57%)
returned a FIT. In 1,378 patients with a FIT result vetted to colonoscopy,
284 had SBD (20.6%); 86 CRC, 124 HRA and 74 IBD. 44% of patients
scoped had undetectable f-Hb in whom prevalence of SBD was 6.6%. Only
13% of SBD was in this cohort; 7/7 CRC patients had co-existing iron deficiency
anaemia, 14/25 HRA and 3/6 IBD had anaemia or diarrhoea. 32.2% of those
with f-Hb 410mg Hb/g faeces had SBD rising to 54.9% in those with f-Hb
4400 mg Hb/g faeces. 2,677 patients completed a FIT but were not referred, in
whom 94.1% had undetectable f-Hb. Referrals to secondary care were 14%
down on the previous year.
Conclusion: A FIT test is an essential adjunct to the history, examination and
blood tests in the assessment of bowel symptoms. Undetectable f-Hb is reassuring
Primary Care that SBD is unlikely and referrals to secondary care have reduced.
At colonoscopy, yield of SBD has increased and is high in those with detectable
f-Hb. Excluding patients with co-existing anaemia or diarrhoea, an undetectable
f-Hb is a good rule-out test and will miss only 5% of all SBD. Furthermore, f-Hb
concentration could aid triage irrespective of symptoms.
Disclosure of Interest: C.G. Fraser: Prof. Callum Fraser has undertaken consul-
tancy with Immunostics, Ocean, New Jersey, USA; Mode Diagnostics, Glasgow,
Scotland; and Kyowa-Medex Co., Tokyo, Japan: and has received travel support
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Introduction: The immunological screening test (FIT) for colorectal cancer
(CCR) was introduced in January 2015 in Ile de France (15 million habitants)
after Hemocult was abandoned due to its low sensitivity. The Hemocult (HC)
launched in 2007 had reached less than 30% participation rate.
Aims & Methods: We report one-year on FIT in CRC screening in Ile de France
and compare results to those with HC test for speculating on adjustment actions.
The raw data were extracted by request from the registry of the screening struc-
ture (in various areas 75, 77, 78, 91, 92, 94 and 95) covering a target population of
3026366 habitants. Rates of participation were calculated, and after one-year
experience period, profiles of individual with positive tests, rates of those with
normal colonoscopy, with polyps (all stages combined) and with cancerþhigh-
grade dysplasia (HGD) were described. Results were compared to those with HC
from the launch to the end of the last campaign (Dec 2014) normalized for mean
one-year output. The comparisons were made by an X2 test (qualitative variable)
or a student t (quantitative variable) and multivariate stepwise analysis was
performed for identifying predictive factors for cancer diagnosis.
Results: At the end of the HC-based screening campaigns 2014, 2.5 million
individuals were annually invited and the participation rates since 2009, ranged
from 28.5% to 24.6%, with females showing higher rates for participation (30.7
to 26.1%) than men (26 to 21.8%, p5 0.0001). During the first (2015) year FIT
experience, the O Sensor device was used by 450120 (34% estimated participation
rate) individuals (versus 294603 participants with HC in 2014 p5 0.00001; 24%
estimated participation rate), and the rate of positivity was 4.6% (versus 1.9%
with HC; p5 0.00001). Among all positive FIT individuals, 93% underwent
colonoscopies: 35% were normal (vs 41%; p5 0.01), 13.2% presenting with
cancer or HGD and 52% with polyps (vs. 37.7%; p¼ 0.00051). More women
(54.5%) than men (45.5%) responded to invitations while positivity rate in
women (3.7%) was lower than in men (5.5%; p5 0.00001). More advanced
polyps and cancer were found in men (14.5%) than in women (11.3%;
p5 0.00001) with normal colonoscopy rates lower in men (24.2%) than in
women (40.7%; p5 0.0001). The levels (mean ng/mL; SD) of FIT were signifi-
cantly higher (p5 0.001) in individuals with cancer þHGD (667; 9) or with
polyps (374; 4) than in those with normal colonoscopy (440; 4). In multivariate
analysis, risk factors for abnormal colonoscopies with cancerþHGD were male
gender, FIT4 340 ng/mL and age4 63.5 yrs. More men than women with posi-
tive FIT test did not yet undergo colonoscopy
Conclusion: FIT test has gained a better adhesion in Ile de France probably
because to its simplicity and a wider distribution. The lower rate of normal
colonoscopies and a higher positive predictive value for cancer leads to more
early lesions detected indicating its higher specificity. Men of 63.5 yrs old or more
with Hemoglobin levels higher than 340 ng/mL are of very high risk of cancer
and should be absolutely conducted to the colonoscopy in case positive FIT test.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Most T1 colorectal cancers (CRCs) undergo surgical colectomy in
accordance with established clinical guidelines despite the low incidence (approxi-
mately 10%) of lymph node metastasis (LNM). Therefore, many patients with-
out LNM undergo unnecessary surgeries.
Aims &Methods: To reduce unnecessary surgeries, we aimed to predict the risk of
LNM in T1 CRCs by using artificial intelligence (AI). Data on 690 consecutive
patients with T1 CRCs who had undergone colectomy between April 2001 and
March 2016 were retrospectively analyzed. Data of a randomly selected
590 patients were used for machine learning for the AI model, which analyzed
five clinicopathological factors: tumor location, lymphatic invasion, vascular
invasion, tumor budding and histological grade. The remaining 100 patients
served as a test set for validating the AI model and output the predicted LNM
as positive or negative. To validate the AI model, sensitivity, specificity and
A554 United European Gastroenterology Journal 5(5S)
accuracy were calculated and compared with American, European and Japanese
guidelines.(1–5)
Results: Sensitivity was 100% (95% CI, 56%–100%) in all models. Specificity
and accuracy of the AI model, American, European and Japanese guidelines were
68% (58%-78%) vs. 45% (35%-56%) vs. 12% (6%-21%) vs. 8% (3%-15%), and
71% (61%–80%) vs. 50% (40%-60%) vs. 20% (13%-29%) vs. 16% (9%-25%),
respectively. The rate of unnecessary surgeries of the AI model was calculated as
29% in comparison with American 50% (P¼ 0.004, odds ratio [OR] 2),
European 80% (P5 0.001, OR 10), and Japanese 84% (P5 0.001, OR 13).
Conclusion: AI can significantly reduce unnecessary surgeries compared with
current guidelines while providing high sensitivity. AI will help in making deci-
sions as to whether additional surgery is indicated after endoscopic resection of
T1 CRCs. Grant support: Grants-in-Aid for Scientific Research (Number
17K15972) from the Japan Society for the Promotion of Science.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
1. Network NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines) Rectal Cancer (Version 1.2017). 2017.
2. Network NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines) Colon Cancer (Version 1.2017). 2017.
3. Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol 2013;24 Suppl 6:vi64–72.
4. Glimelius B, Tiret E, Cervantes A, et al. Rectal cancer: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol
2013;24 Suppl 6:vi81–8.
5. Watanabe T, Muro K, Ajioka Y, et al. Japanese Society for Cancer of the
Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal
cancer. Int J Clin Oncol 2017.
P1114 RISK FACTORS OF ADVANCED METACHRONOUS
NEOPLASM IN COLONOSCOPIC SURVEILLANCE AFTER COLON
CANCER RESECTION
K. Nam
1, J.E. Shin1, K.B. Bang1, H.D. Shin1, H. Namgung2, D.G. Park2
1Gastroenterology, Dankook University Hospital, Cheonan/Korea, Republic of
2Surgery, Dankook University Hospital, Cheonan/Korea, Republic of
Contact E-mail Address: nambag1108@gmail.com
Introduction: Regular surveillance colonoscopy after colon cancer resection is
recommended to detect metachronous adenoma and cancer. However, risk fac-
tors of advanced metachronous neoplasm during postoperative surveillance have
not been fully evaluated yet.
Aims & Methods: This study aimed to assess the risk of advanced metachronous
neoplasm during surveillance colonoscopy in patients who underwent curative
colon cancer resection. The patients who underwent curative colonic resection for
non-metastatic colon cancer between January 2002 and December 2012 in a
single tertiary center were retrospectively reviewed.
Results: A total of 298 patients were enrolled in this study. Surveillance colono-
scopy was performed after perioperative clearing colonoscopy. Among the
patients, 182 (61.6%) were male, and the median age was 65 years. On perio-
perative clearing colonoscopy, accompaning high-risk adenomas (3, size
10mm, with high-grade dysplasia and villous histology) were detected in 95
patients (31.9%) and were significantly associated with old age (65 years), male
sex, alcohol use, smoking, and stage 3 colon cancer (P5 0.05). During the post-
operative follow-up periods (median, 5.35 years), advanced metachronous neo-
plasm was found in 45 patients (15.1%) during surveillance colonoscopy,
including colon cancer in 4 patients (1.3%). In the multivariate analysis, distal
colon cancer (distal to splenic flexure; odds ratio [OR]¼ 4.463; P¼ 0.002),
accompaning high-risk adenomas on perioperative clearing colonoscopy
(OR¼ 3.414; P¼ 0.001), and hypertension (OR¼ 2.344; P¼ 0.026) were signifi-
cant risk factors of advanced metachronous neoplasm during surveillance
colonoscopy.
Conclusion: Patients who had distal colon cancer, accompaning high-risk ade-
noma on perioperative clearing colonoscopy, and hypertension may need a
shorter colonoscopic surveillance interval. A more tailored surveillance strategy
is needed to improve overall outcome in patients who undergo curative colon
cancer resection.
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Introduction: Despite major advances in white light endoscopy detection of colon
polyps remains challenging with significant polyp miss rates. The novel second
generation full spectrum endoscopy (FUSE) is a new scope with two additional
cameras in the sides that provides a panoramic 330 field of view.
Aims & Methods: The aim of this study is to identify the role of the FUSE in
improving polyp detection. This was a single-center, prospective, randomized,
open label study in patients that presented for routine colonoscopy at an out-
patient unit during a six months period. Patients were randomized to either
FUSE (FUSE colonoscope CDVL slim c38) or standard frontal view (SFV)
colonoscopy (Olympus Evis Exera III 190). The primary outcomes were polyp
detection rates (PDR), diverticulum detection rate (DDR) and complete colono-
scopy. Secondary outcomes were procedure time, adverse event rates, size and
characteristics of the polyps and success of endoscopic treatment (R0 resection).
All procedures were performed by experienced endoscopists, who had carried out
45000 colonoscopies and had cecal intubation rates of 495%.
Results: A total of 197 patients (49.2% female, 50.8% male, median age 60 years,
range 16 years) were studied. No significant difference was seen between the
2 groups for the primary endpoints of polyps detection rate (PDR), diverticulum
detection rate (DDR) or complete colonoscopy (table 1). About secondary
endpoints: R0 endoscopic resection was achieved in 95% in both groups
(p¼ 0.68). The median procedure time in minutes was higher with SFV
(26.1 13min) than FUSE 21.5 þ/ 10.7min (4.6, IC95%: 8 a 1.2)
(p¼ 0.008). There were no significant differences regarding adverse events, deter-
mination of colon cleanliness, or others epidemiologic factors. 2 case were
excluded of the statistical analysis due to surveillance of polyposis syndrome,
to avoid skewing of results.
Conclusion: In expert hands, PDR and DDR exceed 50% with advanced
white light and FUSE systems. FUSE was not superior to advanced white
light endoscopy for the PDR and DDR. However, with FUSE we can reduce
procedure duration without any additional adverse events or increased discom-
fort. These data further demonstrate the safety and feasibility of the new FUSE
system.
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Introduction: Underwater Endoscopic Mucosal Resection (UEMR) has been
demonstrated as a safe and effective technique for removal of flat and sessile
colorectal lesions. Until now, only UEMR with cap has been described in litera-
ture. In addition there is no consensus about the electrosurgical settings.
Aims & Methods: This prospective study was conducted between January and
November 2016 in two university tertiary referral centers. UEMR was per-
formed using a standard colonoscope without the distal cap. The lesions were
marked with snare tip prior to resection. Insufflation was switched off. Then,
the colon lumen was entirely deflated. Water at room temperature was infused
using an irrigation pump until complete filling of the lumen was achieved. All
gas pockets in the operative field were evacuated. Two sizes of polypectomy
snare (13 and 25mm) were used according to the preference of the endosco-
pist. No submucosal injection was performed. One of these three different
electrosurgical settings (DRYCUT, AUTOCUT and ENDOCUT) was
selected. All resection wounds were carefully inspected after UEMR.
Endoclips were employed for the management of bleeding and suspected
perforation.
Results: Between January and November 2016, 45 patients (27 female, mean age
67 years, range 53–87) with 55 non-pedulated colorectal lesions (mean size
16mm, range 10–40mm) were included. Six lesions were located in cecum,
21 in the ascending colon, nine in transverse, eight in descending colon, five in
sigmoid, and six in rectum. In five patients, we selected DRYCUT mode; in
fifteen AUTOCUT; and in twenty-five the ENDOCUT mode. All lesions were
successfully and completely removed by UEMR. The procedure time was
recorded in 24 resections (mean 13 minutes, range 4–40). Thirty-three of them
were removed en bloc (60%). Histology revealed the following: 40% tubular
adenomas; 20% - tubulovillous adenomas; 25.45% - sessile serrated adenomas;
3.65% - traditional serrated polyps; 7.25% intramucosal adenocarcinomas and
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3.65% were superficial submucosal carcinomas (51000mm). During UEMR,
two cases (both using AUTOCUT mode) of spurting bleeding were observed
(4.45%). Hemostasis was easily achieved in both cases by clipping. No patient
requires blood transfusion. One patient had abdominal pain on the day after
resection without signs of pneumoperitoneum on CT scan. There was no perfora-
tion or delayed bleeding.
Conclusion: This study supports the existing data indicating acceptable rates of
technical success and low incidence of adverse events with UEMR. The results of
this study without cap were similar with the previous ones using cap. Further
comparative studies with and without cap, using different settings and especially
between UEMR and traditional EMR are needed.
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Introduction: Current guidelines recommend surveillance colonoscopy after
10 years or surveillance in 5–10 years in individuals with no or 1–2 non-advanced
adenomas.
Aims & Methods: We hypothesized that risk of metachronous advanced color-
ectal neoplasia (AN) differs based on clinical characteristics and colonoscopy
quality. We identified 7,171 participants with no or non-advanced adenomas at
first-time screening colonoscopy. The risk of metachronous AN at surveillance
colonoscopy 3–5 years later was investigated according to clinical characteristics
and endoscopist adenoma detection rate (ADR).
Results: In multivariate analyses, strong associations between increasing age,
male sex, current smoking, family history of colorectal cancer, follow-up interval,
increasing number of adenoma, and low ADR and risk of any metachronous
colorectal neoplasia were observed. For metachronous AN, increasing age, male
sex, increasing number of adenoma, and low ADR were independent risk factors.
Among patients with 1–2 small adenomas, women with age 60 years or men
comprised a hidden-risk group, which had 5.3% risk of metachronous AN at
surveillance. Women 560 years old with 1–2 low-risk adenomas had very low
risk (1.2%) of metachronous AN as individuals with no adenoma. Furthermore,
incidence of metachronous AN was significantly higher in individuals who were
colonoscopy screened by endoscopists with a lower ADR (532%) than in those
screened by endoscopists with a higher ADR (32%) (3.2% vs. 0.6%, respec-
tively; P¼ 0.001).
Conclusion: According to patient and adenoma characteristics, and ADR of the
endoscopist, the risk of metachronous AN varies among low-risk patients. In
recommending surveillance colonoscopy, these factors should be taken into
consideration.
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Introduction: The technique of endoscopic submucosal dissection has recently
been improved, and large and complexed lesions such as those invading ileocecal
valve and appendix orifice can be resected en bloc. However, lesions accompany-
ing severe fibrosis in the submucosal layer and exhibiting the muscle retraction
(MR) sign are often difficult to be resected completely1). We devised a new
method called ‘Per Anal Endoscopic Myectomy’ for rectal lesions involving
severe fibrosis, in which dissection is done between the inner circular and outer
longitudinal muscles instead of between submucosal layer and muscle layer2).
Aims & Methods: The aim of this study is to examine the usefulness and safety of
PAEM. The PAEM cases performed in our hospital and an affiliated hospital
were retrospectively reviewed. When fibrosis in the submucosal layer was sus-
pected, pocket creation method3) was applied and if severe fibrosis with MR sign
was found, PAEM was selected. In PAEM procedure, after dissecting circumfer-
entially around the fibrotic area with a double tunneling method, the inner
circular muscle is cut in a circular manner, which makes the outer longitudinal
muscle clearly visible. The space between the inner circular and outer longitudi-
nal muscles is sparse and suitable traction with the tunneling method makes it
easier to dissect this space. PAEM was performed only for rectal lesions, and no
clip closure was carried out after the procedure in most cases.
Results: Ten rectal lesions were treated with PAEM between July 2015 and
March 2017. Among them, 7 cases including 2 cases with mucosal cancer,
4 cases with deep submucosal invasion and 1 case with muscle invasion were
resected en bloc with negative margin. The other 3 cases showed tumor invasion
to the muscle layer and the vertical margin was positive. The clinical course after
PAEM was preferable in all cases. Three cases which achieved resection with
negative margin but found lymphovascular invasion of the tumor underwent
additional surgery or adjuvant chemoradiation. In surgical cases, they could
permit anus-preservation.
Conclusion: PAEM for lesions exhibiting MR sign with severe fibrosis will enable
complete en bloc resection and lead to accurate pathological diagnosis. No com-
plications were recorded in our experiences. Further investigation into the sig-
nificance of PAEM would be needed.
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P1119 LOCAL RECURRENCE AFTER ENDOSCOPIC MUCOSAL
RESECTION FOR HIGH-RISK LESIONS: MAY WE BETTER PLAN
THE ENDOSCOPIC FOLLOW-UP ACCORDING TO PROCEDURAL,
MORPHOLOGICAL AND HISTOLOGICAL CHARACTERISTICS?
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Introduction: Endoscopic mucosal resection (EMR) is an increasingly used tech-
nique for the removal of large sessile and flat-laterally-spreading colorectal
lesions. At present, surveillance colonoscopies are ever performed to ensure
detection and adequate treatment of residual or recurrent adenoma (RRA),
which, occurring in 10–40% of non-pedunculated lesions, currently represents
the main limitation of this technique. Fortunately, endoscopic detection of RRA
in the post EMR scar is currently highly accurate using HD-WL (high definition-
white light) and NBI (narrow band imaging). Anyway, indications for follow-up
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colonoscopies and optimal time intervals are currently unclear. An adequate
comprehension of the predicting factors of RRA would be very relevant to try
to prevent it, better plan surveillance intervals, establish role and timing of sur-
gery and reduce costs.
Aims & Methods: Our aims were to assess the frequency of local recurrence after
EMR for high-risk lesions, to identify risk factors for recurrence, and to provide
follow-up suggestions. We considered all consecutive patients undergone
EMR of flat or sessile adenomas 10mm containing high-grade dysplasia or
adenocarcinoma until pT1 from May 2015 to April 2016. EMR procedure was
performed by 2 endoscopists with extensive EMR ‘‘inject and cut’’ experience
and only lesions with a positive lifting sign were endoscopically treated.
An endoscopic follow-up was performed at a planned interval of 3, 6 and
12 months by using high-definition instruments white light (HD-WL) and
narrow-band imaging (NBI) allowing an appropriate scare assessment with the
execution of biopsies when needed. Data collection included: (a) lesion size,
morphology, Paris classification, pit pattern (kudo), technique of removal (en
bloc vs piecemeal) and histology for all primary lesions and RRA; (b)
Information about budding, grading, microinvasion, margins, submucosal exten-
sion for all pT1 removed ‘‘en bloc’’.
Results: 50 patients were included (mean age 63 12 years, 54% females).
The mean size of lesions was 21mm (range 10–50mm), 40% were sessile, 35%
granular LST and the reimaging 25% non-granular LST, the most frequent sites
of location were sigmoidal colon (40%), ascending colon (25%) and cecum
(12%). According to the morphological characteristics, 60% of lesions were
removed ‘‘en bloc’’ and 40% ‘‘piecemeal’’. Metallic clips were used as prophy-
laxis in 35% of patients and only in 1 for intraprocedural bleeding. No post-
procedural bleeding or perforation occurred. APC has never been used. During
the endoscopic follow-up a suspect early (3-months) RRA was documented and
immediately treated in 16% and histologically confirmed only in 8%. At 6-month
controls a RRA was again detected only in 2 of these patients. New cases of RRA
were not found both at 6 and 12 month controls. Only 1 case of RRA was
documented for lesions treated ‘‘en bloc’’ but this was the only one with histo-
logical characteristics strongly suggesting high risk of RRA (pT1, 42 cm, grad-
ing G2, free-disease margins51mm). As concerned lesions removed
‘‘piecemeal’’, RRA (70% high grade dysplasia and 30% low grade dysplasia)
was higher in pT1, lesions 42 cm, non-granular LST. No correlation was
found with other factors.
Conclusion: EMR results a technique safe and effective particularly for lesions
removable ‘‘en bloc’’; in this cases in fact the rate of RRA seems to be low and
easily histologically predictable. Although factors related to RRA in ‘‘piecemeal’’
EMR appear less clear more attention would be applied in relation to determined
morphological pattern and presence of in situ carcinoma. Moreover, RRA seems
to be ever early suggesting a close follow up only in the first period.
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Introduction: Local recurrences after endoscopic resection (ER) frequently
occur, especially after piecemeal resection. Recently, the efficacy of endoscopic
submucosal dissection (ESD) for local recurrences has been reported. However,
an appropriate treatment strategy for these lesions including ESD remains
unclear.
Aims & Methods: This study aimed to clarify the appropriate treatment strategy
for local recurrences after ER. A total of 81 patients (81 lesions) who received
treatment for local recurrences after ER for colorectal neoplasms between
January 2010 and December 2016 were enrolled. Patients with pathological diag-
nosis of hyperplastic polyp, sessile serrated adenoma/polyp, and submucosal
invasive cancer in their first ER were excluded. Seven patients who underwent
surgery because of submucosal invasion or technically difficult locations were
also excluded. Procedural outcomes, recurrence rate and disease control rate
(DCR) were evaluated according to preoperative endoscopic diagnosis of recur-
rent lesions (adenomatous or cancerous). The DCR was defined as proportion of
patients who were diagnosed with curative resection after ER or received addi-
tional surgery based on pathological diagnosis after ER.
Results: Seventy-four patients were included in the final analysis. Forty-nine
patients diagnosed with adenomatous recurrences were treated by cold polypect-
omy in 15, by endoscopic mucosal resection (EMR) in 26, and by ESD in 8
patients. Cold polypectomy was applied only to diminutive (55mm) lesions
and there was no local recurrence. The en bloc resection rates of EMR and
ESD were 53.8% and 100%, respectively (P¼ 0.030). Two cases (7.7%) in the
EMR group developed local recurrences, but additional ER achieved curative
resection. The DCR of three methods were all 100%. Meanwhile, 25 patients
diagnosed with cancerous recurrences were treated by EMR in 7 and by ESD in
18 patients. The en bloc resection rates of EMR and ESD were 28.6% and
83.3%, respectively (P¼ 0.017). Three cases (42.9%) in the EMR group devel-
oped local recurrences. One case required surgery because of invasive local
recurrence, the second case required chemotherapy because of distant metastasis,
and the third case was followed-up because of severe comorbidities. Therefore,
the DCR in the EMR group was significantly lower than that of in the ESD
group (28.6% vs. 83.3%, P¼ 0.017).
Conclusion: The selection of ER for local adenomatous recurrences could be
based on lesion size. On the other hand, ESD is desirable for local cancerous
recurrences to achieve complete disease control.
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Introduction: Endoscopic stent placement in acute large-bowel obstruction due to
colorectal cancer has been established as a palliative therapy or bridge to surgery
with good outcomes in Japan. While, efficacy of chemotherapy after endoscopic
colonic stenting has not been evaluated.
Aims & Methods: The aim of this study was to evaluate efficacy of chemotherapy
after endoscopic colonic stenting by comparing with that after surgery. Sixty five
patients with colorectal cancer of stage IV presenting obstructive symptom visit-
ing Aomori Prefectural Central Hospital from January 2012 to December 2016
were classified into SC group who have underwent chemotherapy after endo-
scopic colonic stenting (32 patients) and OC group who have underwent che-
motherapy after surgery (23 patients). The patient’s background, adverse effects
and prognosis were compared with two groups.
Results: There have not been any significant differences in patient age (65.5 9.3
in SC vs. 61.5 14.1 in OC, p¼ 0.21), male to female ratio (25:7 in SC vs. 14:9
p¼ 0.16) and performance status (0.6 0.7 in SC vs. 0.7 0.8 in OC, p¼ 0.66).
The averaged colorectal obstruction scoring system (0, Requiring continuous
decompressive procedure; 1, No oral intake; 2, Liquid or enteral nutrient; 3,
Soft solids, low-residue, and full diet with symptoms of stricture; 4, Soft solids,
low-residue, and full diet without symptoms of stricture) score was significantly
severe in OC (1.7 1.1) than in SC (0.7 0.9, p5 0.01). Adverse effects included
perforation (1), stent slippage (6), re-obstruction by tumor progression (3) in SC,
and ileus (1), abdominal abscess (1), renal insufficiency (1) in OC. The frequency
of combined use of molecular target drugs (Bevacizumab/Panitumumab/
Cetuximab) at first chemotherapy has significantly differed (p5 0.01) between
SC (0/11/9) and OC (12/4/0). The median survival day was not significantly
different between SC (595) and OC (459, p¼ 0.93). In SC, survival was found
significantly longer with additional surgery (913, n¼ 13) than without (325,
n¼ 19, p5 0.01). In OC, survival did not significantly differed between with
resection of the primary tumor (666, n¼ 16) and without (595, n¼ 7, p¼ 0.93).
Conclusion: This study has demonstrated that the survival of SC was identical
to that of OC, and additional surgery was found to significantly improve the
prognosis in SC. Chemotherapy after endoscopic colonic stenting has been con-
sidered tolerable as a palliative therapy or bridge to surgery for obstructive
colorectal cancer.
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Introduction: A self-expandable metallic stent (SEMS) placement is potentially a
colostomy-sparing option to manage a malignant colonic obstruction (MCO).
However, in patients with coexisting peritoneal dissemination (carcinomatous
adhesion), for example, insertion of a standard caliber colonoscope (SCC) is
challenging, whereas such an endoscope equipped with a large working channel
is suitable for through-the-scope (TTS) SEMS placement. Failure in stenting
necessitates continuous tube drainage, stoma formation, or other surgical proce-
dures and decreases quality of life (QOL).
Aims & Methods: We examined feasibility and efficacy of, ‘‘Over-the-Catheter’’
Colonoscope Replacement technique (OTC-CR) detailed below, in palliative (not
preoperative) SEMS placement for MCO. From Oct 2012 to Dec 2016, MCO
patients were consecutively considered for decompression by SEMS placement
unless stoma formation was preferred. When a conventional TTS procedure was
unsuccessful, specifically, when the MCO site was inaccessible with an SCC
(CF-H260AI, Olympus Medical Systems, Tokyo, Japan) with a 13.2mm tip
diameter and 3.7mm working channel, needed for a 22mm (not 18mm) SEMS
United European Gastroenterology Journal 5(5S) A557
delivery system passage (e.g. Niti-S Colonic Stent, Taewoong-Medical, Seoul,
South Korea) or when a guidewire was unable to be passed through the stricture
because of limited maneuverability of the endoscope, procedures below were
followed. (1) A thinner scope, PCF-PQ260I/L, with a 9.2mm tip and a 2.8mm
channel (Olympus Medical Systems, Tokyo, Japan) is inserted and advanced to
the stricture, facilitated by its ‘‘passive bending’’ feature. An ultrathin endoscope
(for transnasal use) or a gastroscope are alternatives. (2) A guidewire ((GW),
0.035 inch Jagwire) is traversed through the stricture by coordinating manipula-
tion of an ERCP-catheter (Article-No.0130211; MTW Endoskopie, Wesel,
Germany). (3) Fluorescent examination through the catheter to delineate the
lesion. (4) For colonoscope replacement, withdraw the scope and the catheter,
leaving only GW. (5) Before reinsertion of the SCC, insert the catheter from
the channel until it sticks out of the scope tip. (6) Pass GW backward into the
catheter tip. Then move the catheter over GW past the anus and further advance
it proximally until it reaches the stricture site. (7) Gently move the SCC ‘‘over the
catheter’’ into the rectum and advance it in the more straightened (less winding)
intestine. (8) After the colonoscope is advanced only as proximally as possible,
shift to a standard TTS maneuver (withdraw only the catheter, leaving GW and
insert the SEMS delivery along GW past the stricture where it is deployed).
Results: See table.
Conclusion: "Over-the-Catheter" colonoscope replacement (OTC-CR) technique
can be a salvage maneuver which facilitates a successful SEMS placement in
MRO cases with peritoneal disseminations that preclude a conventional TTS
procedure. Reachability of thin endoscopes and appropriate rigidity and force
transmissibility of an ERCP-catheter that enable advancement of an SCC with
maximum safety are thought to be linked to reduced chances of technical failures.
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Introduction: Colorectal cancer (CRC) is the most common cause of cancer in
western countries. In Balearic Islands 700 new cases per year are diagnosed.
The cost-effectiveness of CRC screening programmes are clearly demonstrated
in the studies and the important public health problem of CRC justifies the
development of control strategies. The aim of this study is to present the results
and impact during the first round of the program in Balearic Islands.
Aims & Methods: The first round includes the period from January 2015 through
December 2016. The program has been developed in the areas of Menorca, Ibiza,
Formentera and Tramuntana (Mallorca), including 30% of the Balearic Islands
population. The target population (people who reside in these areas aged between
50 and 69 years old) was 75,575 individuals. Exclusion criteria. Colonoscopy
performed in the previous 5 years, previous diagnosis of CRC, follow-up
colonoscopies because colon disease and severe illness-contraindication for the
participation. People received the invitation by letter. Quantitative immunochem-
ical fecal occult blood testing (i-FOBT/OC-Sensor) was the screening method.
The kit was delivered at pharmacies joined the program. The samples were
deposited in urns placed in health centres. Participants who tested positive
(100 ng/ml) were referred to pre-endoscopy evaluation and follow-up colono-
scopy. The colonoscopies were performed according to the quality criteria of
guidelines.
Results: Overall participation rate (number of people who provide their i-FOBT
sample) was 36.5% (n¼ 21,555). Positive rate of i-FOBT was 7% (1438) and
94.3% of those positive tests underwent a colonoscopy (5,7% of exclusions in
pre-endoscopy evaluation). 996 colonoscopies were performed. 47 adenomas
with high grade dysplasia, 24 carcinomas in situ and 60 adenocarcinomas were
found. Only 19% of these adenocarcinomas were T3 or T4 lesions while the rest
presented earlier stages. 26% of colonoscopies were classified as high risk (5
adenomas or at least one 20mm). They have been reported 2 cases of colon
perforations, both resolved by endoscopic treatment.
Conclusion: We obseved an acceptable participation rate in the first round of the
colorectal cancer screening programme of the Balearic Islands. The index of
positivity rate of i-FOBT and the results of the endoscopic explorations are
according with the observed in other colorectal cancer screening programmes.
We can conclude a successful development of the first round of the programme in
our area.
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Introduction: The prevalence, gender distribution, and clinical presentation of
irritable bowel syndrome (IBS) differ between Asian and Western countries.
The densities of enteroendocrine cells are abnormal in Western IBS patients.
This study aimed at studying large-intestine enteroendocrine, Musashi 1(Msi 1;
a marker for both intestinal stem cells and their early progeny), and neurogenin 3
(neurog 3; a marker for early intestinal endocrine cell progenitors) cells in Thai
and IBS patients.
Abstract No: P1122
List of 6 cases with malignant colonic obstruction in whom ‘‘Over-the-Catheter’’ colonoscope replacement technique was tried.
Case
No.
Age,
Sex
Primary
cancer site
Site of
stricture
Nature of
stricture
Alternative
scope
Distance from
Reinserted SCC
to stricture
Technical/Clinical
outcome
CROSS
score* change
1 71, F Peritoneum Splenic flexure Extrinsic PCF-PQ260L Away (SCJ) Success/Success 1 ! 4
2 66, F Sigmoid colon Sigmoid colon Intrinsic PCF-PQ260L Close Success/Success 2 ! 4
3 76, M Pancreas Splenic flexure Extrinsic PCF-PQ260L Away (SCJ) Success/Success 1 ! 4
4 41, F Transverse
colon (resected)
Sigmoid colon Extrinsic GIF-Q260J Close Success/Success 1 ! 4
5 55, F Ovary Sigmoid colon Extrinsic EG-580NW Away
(Sigmoid colon)
Success/Success 0 ! 3
6 49, F Stomach Transvers colon Extrinsic PCF-PQ260L Close Success/Success 0 ! 3
*CROSS, ColoRectal Obstruction Scoring System (Reference 1)
Among 63 palliative MCO cases, initial attempt to place a 22mm SEMS by TTS procedure was unsuccessful in 6 cases (Table), all of whom had peritoneal
dissemination. The reasons for technical failures were; impossible insertion of an SCC to the stricture due to carcinomatous adhesions or narrowing in 5 cases and
failure in passing GW through the stenosis due to a limited viewing angle to the stricture in one case. With OTC-CR, approach to the main stenosis with a thinner
(alternative) scope, GW traverse, "over-the-catheter" replacement to the SCC, and a 22mm SEMS placement were successful in all of the 6 cases with adequate clinical
improvements (CROSS score change). Notably, ultimate TTS procedures were possible from reinserted SCC distant from the stricture in 3 cases. No adverse events
occurred during the procedures.
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Aims & Methods: Thirty Thai IBS patients, and age and sex matched 20 Thai
controls were included. Four biopsy samples were taken from each of the sigmoid
colon and the rectum during a standard colonoscopy. Sections from these biopsy
samples were immunostained for serotonin, peptide YY, oxyntomodulin (enter-
oglucagon), pancreatic polypeptide, somatostatin, Msi 1, neurog 3. The densities
of immunoreactive cells were determined with computerized image analysis (1).
Results: In both the colon, and rectum the density of serotonin cells was lower in
IBS patients than controls. Whereas the density of PYY cells was increased in
both the colon and rectum of IBS-D, it was reduced in IBS-M and IBS-C.
The density of oxyntomodulin cells was reduced in both the colon and rectum
of all IBS subtypes. While the density of PP cells was unaffected in the colon, it
was reduced in the rectum. Somatostatin cell density was unaffected in both the
colon and rectum. The densities of Msi 1 and neuro 3 were unchanged in both the
colon and rectum.
Conclusion: The present findings of abnormal densities of the large-intestine
enteroendocrine cells in Thai patients combined with previously reported changes
in Western IBS patients (2) support the notion that intestinal enteroendocrine
cells are involved in the pathophysiology of IBS. However, the changes in the
enteroendocrine cells differed from those in Western patients. The present obser-
vations highlight that IBS differs in Asian and Western countries, and show that
the changes in large-intestine enteroendocrine cells in Asian and Western IBS
patients might be caused by different mechanisms.
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Introduction: Opioid-induced constipation (OIC) is a common side effect of
opioid therapy that significantly affects multiple aspects of a patient’s life.
Naldemedine (NAL) is a peripherally-acting mu-opioid receptor antagonist
developed for the treatment of OIC. In Phase 3 studies, NAL improved the
frequency of spontaneous bowel movements, straining, consistency of stools,
and patient assessment of constipation symptoms (PAC-SYM) and quality of
life (PAC-QOL), measures of patient’s quality of life, compared with placebo
(PBO). The aim of this analysis is to assess the impact of NAL on overall
satisfaction and to show if a simple score can assess the impact of treatment of
OIC with NAL 0.2mg once daily on patient’s satisfaction with constipation and
abdominal symptoms in patients with OIC associated with non-cancer pain.
Aims & Methods: In three Phase 3 randomized, double-blind, PBO-controlled
trials of NAL (2 of 12-week duration [COMPOSE 1 and COMPOSE 2] and 1 of
52-week duration [COMPOSE 3]), a 7-grade scale (1¼markedly, 2¼moderately,
or 3¼ slightly worsened; 4¼unchanged; 5¼ slightly, 6¼moderately, or
7¼markedly improved) was used to assess overall satisfaction with constipation
and abdominal symptoms at the last study visit. The number and proportion of
subjects in each grade were calculated and the overall difference between groups
was assessed by Wilcoxon rank sum test. The mean subject global satisfaction
score (SGSS) was also compared between groups. For SGSS, scores from 1 to 7
were replaced with scores from 3 to þ3, with 4 (unchanged) replaced with 0.
This proposed new approach provides a single score that may be easier to inter-
pret than the 7-grade scale.
Results: There were 547 subjects in COMPOSE 1, 550 in COMPOSE 2, and 1246
in COMPOSE 3 (all 18 years of age) randomized (1:1) to NAL 0.2mg once
daily or PBO. The baseline characteristics of the study population were consis-
tent between groups in each trial and between trials. Overall satisfaction assess-
ment was completed in 372 subjects in COMPOSE 1, 296 in COMPOSE 2, and
1101 in COMPOSE 3. There were greater improvements in satisfaction with
constipation and abdominal symptoms in the NAL group compared with the
PBO group in all three studies (all P 0.0005; Table). The mean SGSS were 1.5
and 0.9 with NAL and PBO, respectively, in the two 12-week studies pooled, and
1.7 and 1.0, respectively, in the 52-week study.
COMPOSE 1 COMPOSE 2 COMPOSE 3
NAL PBO NAL PBO NAL PBO
Total subjects assessed 185 187 204 192 497 504
Global satisfaction category, n (%)
Markedly worsened (1) 3
(1.6)
7
(3.7)
6
(2.9)
6
(3.1)
12
(2.4)
10
(2.0)
Moderately
worsened (2)
11
(5.9)
8
(4.3)
5
(2.5)
10
(5.2)
3
(1.1)
14
(2.8)
Slightly worsened (3) 4
(2.2)
7
(3.7)
3
(1.5)
12
(6.3)
5
(1.4)
11
(2.4)
Unchanged (4) 27
(14.6)
58
(31.0)
28
(13.7)
54
(28.1)
74
(14.9)
169
(33.5)
Slightly improved (5) 49
(26.5)
38
(20.3)
37
(18.1)
39
(20.3)
100
(20.1)
116
(23.0)
Moderately
improved (6)
39
(21.1)
41
(21.9)
53
(26.0)
39
(20.3)
129
(26.0)
89
(17.7)
Markedly
improved (7)
52
(28.1)
28
(15.0)
72
(35.3)
32
(16.7)
174
(35.0)
95
(18.8)
P-value between
groups*
0.0005 50.0001 50.0001
*Wilcoxon rank sum test
Conclusion: Treatment of OIC with NAL 0.2mg once daily for 12 or 52 weeks led
to greater satisfaction with constipation and abdominal symptoms compared
with PBO, consistent with previously-reported improvements of PAC-SYM
and PAC-QOL with NAL compared with PBO. The proposed SGSS appears
to be a simple way to assess the impact on quality of life of OIC treatment.
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Introduction: The herbal preparation STW 5 has been reported to increase intest-
inal chloride secretion. However, the ability of STW 5 to modulate paracellular
and transcellular permeability remains currently unknown. Therefore, we aimed
Abstract No: P1125
Table 1: Densities of enteroendocrine, Msi 1, and neurog 3 cells in the colon of Thai and Norwegian controls and IBS patients.
Cell type
Colon Rectum
Controls IBS-total IBS-D IBS-M IBS-C Controls IBS-total IBS-D IBS-M IBS-C
Serotonin 202 20 119 10*** 104 9** 93 8** 144 21 333 25 176 12*** 163 14*** 166 16** 191 23**
PYY 79 8 95 10 143 20** 68 7 67 7 177 19 184 23 315 27*** 102 9* 112 20*
Oxyntomodulin 70 7 40 4*** 42 7* 39 7** 39 6** 224 30 93 10*** 78 13** 72 10** 86 15**
PP 46 5 54 4 56 8 51 11 55 6 177 17 100 13* 117 21* 73 17* 61 8***
Somatostatin 91 12 77 7 86 13 60 9 78 9 106 12 102 8 118 15 116 16 83 11
Msi 1 5.0 0.4 5.0 0.3 5.0 0.6 5.0 0.8 5.0 0.5 7.0 0.5 8.0 0.5 8.0 1.0 7.0 1.0 8.0 0.8
Neurog 3 130 10 129 11 131 19 105 16 138 18 274 31 258 28 287 54 182 35 268 42
Data was expressed as mean SEM. *, P5 0.05; **, P5 0.001; ***, P5 0.0001
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to study the ability of STW 5 to modulate intestinal permeability under basal and
repeated acute stress conditions.
Aims & Methods: C57 bl6 mice were gavaged for 14 days with STW 5 (3mL/kg).
After 10 days of treatment, mice were subjected to water avoidance stress (WAS)
during 4 consecutive days. In vivo permeability to FITC –Sulfonic Acid (FSA,
400 Da) and Horse Radish Peroxydase (HRP, 44KDa), total transit time and
colonic transit (fecal pellet output - FPO) were assessed at Day 0 (D0), D10 and
D14 of IB treatment. Ex vivo permeability to FSA and HRP was assessed on
jejunum, ileum, proximal colon and distal colon at D14 using Ussing chambers.
Corticosterone blood level was measured at D11 and D14.
Results: In vivo permeability to FSA and HRP as well as total transit time were
not modified by STW 5 in basal and WAS conditions. However, STW5 pre-
vented the increase in permeability to FSA induced by WAS in the distal colon
ex vivo. Conversely, STW 5 prevented the increase in permeability to HRP
induced by WAS in the jejunum and proximal colon. Furthermore, while STW
5 tended to increase colonic transit as compared to control in basal conditions, it
prevented the increase in colonic transit induced by WAS. Finally, STW 5 did not
modify the changes in corticosterone induced by WAS.
Conclusion: Our study suggest that STW 5 can prevent WAS induced changes in
paracellular and transcellular permeability in specific regions of the gastrointest-
inal tract. Such effects could contribute to the therapeutic effects of STW 5 in
irritable bowel syndrome and support novel therapeutic indications for pathol-
ogies in which barrier functions are altered.
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Introduction: Large conductance Ca2þ- activated Kþ channel (BKCa channel)
was shown to play critical roles in regulating smooth muscle contractility by
modulating membrane potential, at the same time, age-associated changes
in BKCa expression may contribute to the development of motility disorders
of the gastrointestinal tract. Sphingosine-1-Phosphate (S1P), component of
Sphingolipids in the cell membranes, may affect BKCa expression. Thus, in
this study, we investigated whether altered S1P due to aging may affect the
motility of colon smooth muscle (CSM) in rats.
Aims & Methods: Thus, in this study, we investigated whether altered S1P due to
aging may affect the motility of colon smooth muscle (CSM)in rats. Forty
Sprague-Dawley rats at the same age were randomly divided into five groups.
After different times of administration, finally they were divided into different-
age-group: 10-week group, 20-week group, 40-week group, 60-week group and
80-week group. Colonic motility function and contractility of circular muscle
strips were measured. The expression of BKCa and phosphorylated myosin
light chain (P-MLC) level were tested in colonic tissues of rats with varying
ages by immunohistochemical, RT-PCR and western blot. S1P levels in colonic
tissues were tested by LC-MS/MS analysis. Primary cultured colonic smooth
muscle cells (SMCs) from normal adult rats were used in complementary
in vitro studies. In the absence and presence of S1P with different concentrations,
the expression of BKCa, P-MLC level, single-channel activity, intracellular Ca2þ
mobilization were tested. At the same time, in the presence and absence of S1P,
SMCs were transfected with anti-S1P antibody. BKCa siRNA transfection was
used to investigate whether P-MLC expression and intracellular Ca2þ mobiliza-
tion were affected by BKCa expression in SMCs. The expression and phosphor-
ylation of Akt, JNK, ERK, NF-B, and PKC were examind by western blot
analysis to investigate the effect between S1P and BKCa.
Results: Aged rats showed prolonged colonic transit time and weakness of cir-
cular muscle contraction compared with the young (10 weeks old) SD
rats.LC-MS/MS analysis exhibited that the levels of S1P were significantly
greater in the CSM from aged rats, demonstrating that S1P varies depending
on age. BKCa (-subunit and b-subunit) levels in CSM were shown to increase in
an age-dependent manner from 10- to 80-week-old rats by mRNA ,protein and
immunohistochemical, but P-MLC expression decreased. In colon SMCs ,by
BKCa siRNA transfection, we found P-MLC levels increased. Exogenously
added S1P upregulated BKCa in colon SMCs in a concentration-dependent
manner, impaired intracellular Ca2þ mobilization though inhibiting Ca2þ
influx and induced the decline of P-MLC.Our results also provedt that S1P
upregulated BKCa through the Akt/ERK/JNK pathways.The expression of
BKCa decreased by treatment with inhibitor of Akt/ERK/JNK pathways
or siRNA.
Conclusion: The results of our study show that altered S1P due to aging upregu-
lates BKCa via the Akt/ERK/JNK mediated pathway in CSM.BKCa upregula-
tion inhibits Ca2þ influx and MLC phosphorylation and thereby reduces the
contractility of CSM to evoke contractile dysfunction.These findings represent
the first evidence for the mechanism of the contractile dysfunction of CSM
observed in older individuals, which may be implicated in age-associated gastro-
intestinal motility disorders.
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Introduction: Growing amount of evidence has indicated that increase of the
hyperglycaemia-induced oxidative stress and decreased effectiveness of the endo-
genous antioxidant protection play the major role in the initiation of diabetes-
related neuronal damage1,2. Using a streptozotocin-induced diabetic rat model
we recently demonstrated that nitrergic myenteric neurons, which are key regu-
lators of peristalsis, display different susceptibilities to diabetic damage and also
to insulin treatment in the different gut segments3. Based on these results we
suggested the importance of the molecular differences in the neuronal microen-
vironment in the pathogenesis of diabetic nitrergic neuropathy.
Aims & Methods: Aim to reveal the quantitative differences in the expression of
the pro-inflammatory cytokines like tumor necrosis factor alpha (TNF) and
interleukin 6 (IL6) in the myenteric ganglia and its microenvironment of the
different intestinal segments, quantitative immunogold electron microscopy
was used. Ten weeks after the onset of diabetes, segments from the duodenum,
ileum and colon of streptozotocin-induced diabetic, insulin-treated diabetic, and
control rats were processed for post-embedding immunohistochemistry.
Results: The density of TNF- and IL6-labelling gold particles was strictly
region-dependent, with increasing to the distal part of the gastrointestinal tract
of controls. In diabetic rats, the number of TNF gold particles was significantly
increased in the duodenal, decreased in the colonic myenteric ganglia, while did
not show any significant differences in the ileal ganglia. The number of IL6 gold
particles was not affected by diabetes in the myenteric ganglia of different gut
regions. The diabetes-related alterations of TNF- and IL6 expression were not
protected by the immediate insulin replacement in any of the investigated intest-
inal segments. The differences in TNF- and IL6 density were not significant in
the capillary endothelium under different experimental conditions.
Conclusion: Based on these findings we presume that regionally alterations in the
TNF and IL6 expression are correlated with the diabetes-related region-specific
nitrergic myenteric neuropathy.
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Introduction: Critical developmental stages of the enteric nervous system (ENS)
occur during the postnatal period leading to the formation of a mature neuroglial
network characterized by the assembly of enteric neurons into ganglia and the
formation of a highly organized pattern of neuronal connectivity. However, the
mechanisms underlying these maturation processes are poorly understood.
Semaphorin 3A (SEMA3A) is a secreted protein playing key roles in the neuronal
circuitry formation of the central nervous system. Here, we studied the expres-
sion, the cellular distribution and the role of SEMA3A and its receptor neuro-
pilin 1 (NRP1) in the maturation of enteric neurons.
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Aims & Methods: Gene and protein expression of SEMA3A and its receptor
NRP1 were analyzed in rat distal colon from postnatal day 1 (PN1) to adulthood
by qRT-PCR and Western blot respectively. The cellular distribution of
SEMA3A and NRP1 was performed at PN7 and PN36 in whole mount distal
colon tissue by double immunofluorescence for SEMA3A or NRP1 with specific
markers of glia (S100b), neurons (Hu, Tuj-1), and muscle cells (a-SMA). The
impact of SEMA3A on neuronal outgrowth was assessed in cultures of enteric
neurons cocultured with SEMA3A-transfected COS-7 cells.
Results: A peak of mRNA expression for SEMA3A and NRP1 was observed in
distal colon at P7, corresponding to a stage of intense neural circuit remodeling.
At the protein level, NRP1 was also found to be predominantly expressed during
the early postnatal period. Immunohistofluorescence of colon tissue indicated
that SEMA3A immunoreactivity was not associated with any specific cellular
profile, but was distributed in small clusters disseminated throughout the tissue, a
pattern consistent for a secreted protein. NRP1 was found in neurons, mainly
associated with axonal processes, and was not detected in glial or muscle cells.
Enteric neurons cultured in the presence of SEMA3A-expressing COS cells
showed a strong reduction in axon length and complexity, while the ganglion
size was unaffected.
Conclusion: This study shows the expression of SEMA3A and its receptor NRP1
in the ENS during early postnatal period. By controlling axonal outgrowth,
SEMA3A might be an important factor to restrict the axonal trajectories in
the appropriate paths between ganglia.
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Introduction: Constipation is a chronic disorder with an estimated
prevalence of 17% in Europe. Epidemiological studies on bowel habits in the
Portuguese general population have not been done previously, as in many other
western countries. The aim of this population-based study was to describe bowel
habits and the prevalence of self-reported constipation in a Portuguese
community.
Aims & Methods: We aimed to describe bowel habits and the prevalence of self-
reported constipation in a Portuguese community. Methods: Cross-sectional
study with convenience sampling between November 2015 and November
2016. The physician applied a questionnaire, to adult patients at primary
health care consultation. The questionnaires were anonymous, and the only
personal information the participants were required to give was their age and
sex. The questionnaire contained objective questions on possible causes and
constipation-associated conditions and medications (according to the criteria
defined by the World Gastroenterology Organization), daily water and fiber
intake, physical activity, bowel habits and Bristol stool scale (BSS). Descriptive
statistics and uni and multivariate analysis were performed using IBM SPSS
Statistics 22 with p5 0.05 deemed to be statistically significant.
Results: A total of 814 questionnaires were performed to individuals from 35 dif-
ferent municipalities (54% women; mean age 46 18 years). Concerning possible
causes of constipation, 43% subjects had a history of constipation-associated
condition and 36% were taking constipation-associated drugs. Regarding
bowel habits, 35% subjects had 51 bowel movement per day and 2% had 51
bowel movement per week. Using BSS, 66% of the cases reported type III or type
IV stool consistency. Among women, 19% reported a change in bowel move-
ments according to the phase of the mentrual cycle. In total, 22% of subjects
considered to be constipated, and 78% of these, complied the Roma III criteria
for functional constipation. Noteworthy, 6% of subjects with daily bowel move-
ments and 38% of those with 51 weekly bowel movement considered to have
constipation. Complaints of excessive straining, tenesmus, feeling of incomplete
evacuation and abdominal pain were associated with the presence of constipation
(64 vs. 12%, 56 vs. 20%, 54 vs. 19% and 37 vs. 18%, respectively; p5 0.0001).
No associations were found between constipation and physical activity, daily
water or fiber intake.
Conclusion: This study represents the first assessment of bowel habits in the
Portuguese population, depicting the high prevalence and related risk factors
of a disorder that decreases the health-related quality of life and has major
economic consequences. The prevalence of constipation (22%) was higher than
that reported in other European countries.
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Introduction: Objective means of evaluation of the defecatory process include
high resolution ano-rectal manometry (HRM), balloon expulsion test (BET)
and imaging of the defecatory process (X-ray defecography, dynamic trans-
pelvic ultrasound (DT-PUS) or MR defecography). These tests have a place in
the evaluation of suspected evacuatory dysfunction (ED), fecal incontinence (FI)
and chronic pelvic pain (CPP). Test choice may influence subsequent patient
management; however, there is only limited information regarding the agreement
between HRM, DT-PUS and BET.
Aims &Methods: The aims of this study were to compare the diagnostic yield and
agreement between different tests of evacuation and to define the relation
between the diagnoses of evacuation dysfunction to objective evacuatory failure.
63 consecutive patients (60 females, mean age 51ys) were prospectively evaluated
with HRM, BET and PUS. Inter test agreement for the diagnosis of anismus was
assessed using the Kappa statistic. Correlation between anismus to evacuatory
failure (assessed by PUS) was also assessed.
Results: 36 patients were assessed for ED, 6 for CPP and 21 for FI. Anismus was
diagnosed in 26 patients by HRM and 45 patients by DT-PUS. All cases of
anismus diagnosed by HRM or DT-PUS had a positive BET. The Kappa agree-
ment for the diagnosis of anismus between HRM and DT-PUS was poor
(0.143 0.01). 9 patients had significant pelvic floor anatomic pathology
(4 rectal prolapse, 6 pathological pelvic descent, 4 enterocele and 3 rectocele
43.5 cm). There was a moderate correlation between diagnosis of anisums on
DT-PUS to failure to evacuate the rectum (r¼ 0.636). The correlation between
rectal evacuation on DT-PUS to the diagnosis of anismus on manometry was
weak (r¼ 0.296).
Conclusion: There is considerable disagreement between the results of various
evacuatory tests, and between the diagnoses of evacuatory dysregulation to fail-
ure of rectal evacuation. Therefore, more than one test should be applied in order
to evaluate the defecatory dysfunction.
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Introduction: Complex gastrointestinal (GI) motility disorders such as chronic
intestinal pseudo-obstruction (CIPO) or Hirschsprung’s disease (HD) are chal-
lenging to diagnose and treat appropriately. Thorough assessment of patient
history, radiographic exams, endoscopy and motility measurements aid in diag-
nostic workup, yet underlying histology is the cornerstone to enable a more
distinct diagnosis of neuromuscular GI disorders. Traditionally, surgical proce-
dures have been performed to obtain specimen suitable for accurate histologic
analysis.
Aims & Methods: We performed endoscopic full-thickness resection (eFTR)
using a full-thickness-resection device (FTRD) under moderate propofol seda-
tion in four patients with suspected severe neuromuscular gut disorders including
CIPO.
Results: Patient 1: A 21-year-old male patient with cerebral palsy suffering from
acute small bowel ileus with a history of laparotomy, detorquation and appen-
dectomy after cecal volvulus at the age of 15. Histologic analysis revealed irre-
gular configuration of the myenteric plexus, but primary neuro- or myopathic
disorder such as HD were ruled out. Thus, GI dysmotility due to cerebral palsy
syndrome was suspected. Patient 2: After a life-long history of recurrent obstipa-
tion, colonic dilatation, ileus symptoms and various colonic segment resections,
diagnostic eFTR was performed in a 55-year-old female patient. The diagnosis of
hypoganglionosis was established by LDH histochemical and by immunohisto-
chemical reactions with Calretinin and Map2-Kinase. Patient 3: A 19-year-old
male patient with a history of a sigmoid volvulus and massively dilated large
bowel segments. Enzyme histochemistry excluded HD upon histopathological
analysis. The inner muscle layer showed fibrosis, eosinophilic leiomyositis and
lymphocytic ganglionitis. Congenital CIPO was diagnosed due to degenerative
leiomyopathy. Patient 4: A 56-year-old male patient with acute ileus and a year-
long history of constipation and abdominal pain. Histopathological analysis
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revealed hypoganglionosis, severe fibrosis of the inner muscle layer and reduced
ICC networks (550%). HD was excluded and acquired CIPO was diagnosed due
to hypoganglionosis. Technical as well as histological success providing large full-
thickness specimen of excellent quality was achieved in all four patients (success
rate 100%). The mean procedure time was 12 minutes (range 5–20min).
The mean diameter of the resected specimen was 21mm (range 20–22mm). No
adverse events connected to the procedure itself occurred during the follow up.
Conclusion: In conclusion, diagnostic eFTR using the FTRD as a close-and-
resect device is a well feasible and effective technique to provide full-thickness gut
specimens of excellent quality and size, allowing detailed routine and sophisti-
cated histologic, histochemical and immunohistochemical analysis for the diag-
nosis of neuromuscular gut disorders.
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Introduction: There is emerging interest in non-pharmacological management of
gastrointestinal dysmotility via neuromodulatory techniques. A new method of
non-invasive neuromodulation - transabdominal interferential electrical stimula-
tion - has apparent efficacy in a paediatric population with difficult
constipation.1
Aims & Methods: We report our experience of its use in adult patients with
functional constipation who are refractory to conventional management.
This is a descriptive case series of consecutive adult patients presenting to a
tertiary referral functional gastrointestinal disorders clinic with refractory con-
stipation that were taught and used home-based interferential stimulation for
an hour a day over a three-month period by a functional gut nurse-
specialist between October 2015 and Feb 2017. The validated PAC-SYM and
PAC-QOL questionnaires were given at commencement of stimulation and after
three months of use. Overall symptom severity was assessed by 10 cm VAS.
An intention to treat analysis was conducted for any patients who commenced
stimulation.
Results: Seven patients with refractory constipation (3 with slow-transit and 4
with idiopathic constipation) responding inadequately to pharmacological and
non-pharmacological therapies underwent stimulation. Mean (range) age was 47
(26–73) y and 2 were male. All 7 patients completed the stimulation period. There
was a reduction in PAC-SYM in all patients (median IQR 24 [18–36] vs 14 [10–
21]) and VAS median IQR 8 [7–9] vs 4 [2–5] (p¼ 0.004). PAC-QOL was assessed
in 4 patients where this also fell from 75 [69–85] to 38 [19–52]. Four were able to
cease previously heavy daily laxative use and 2 were able to halve their use, one
currently weaning off prucalopride. One remained on daily laxative use despite
soft, formed stool. All reported satisfaction with stool type. Ongoing benefit
remains in 2 after 4 and 12 months since ceasing its use, where the rest tend to
use the stimulator intermittently.
Conclusion: Interferential electrical stimulation improved symptoms in patients
with functional constipation. Randomized placebo controlled trials are justified.
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Introduction: The 5-HT4 receptor is an attractive drug target that can stimulate
gastrointestinal motility. YH12852 is a novel, potent and highly selective 5-HT4
receptor agonist currently under clinical development for the treatment for gas-
trointestinal motility disorders (GIMDs).
Aims & Methods: The study aim was to evaluate the safety, tolerability, pharma-
cokinetic and pharmacodynamic profiles for YH12852 in healthy volunteers with
3 spontaneous bowel movements per week (SBMs/week) and patients with
functional constipation (FC). A randomized, double-blind, placebo- and
active-controlled phase 1/2a study was performed in healthy subjects and FC
patients, who were administered YH12852 (0.3, 0.5, 1, 2 or 3mg), prucalopride
2mg or placebo once daily after breakfast for 2 weeks. Subjects recorded bowel
habits throughout the study period. Intensive pharmacokinetic blood samples
were also collected (ClinicalTrials.gov identifier NCT02538367).
Results: Twenty-nine healthy subjects and 27 FC patients were enrolled.
Treatment-emergent adverse events (TEAEs) were mostly mild and no serious
adverse event was reported. The most frequently reported AE in the YH12852
and prucalopride group was headache. TEAEs in the YH12852 groups were
similar to those in the prucalopride group. The change from baseline in weekly
SBM frequencies averaged over the 2-week treatment period were 3.5, 3.8, 6.3,
4.6 and 3.9 for YH12852 0.3, 0.5, 1, 2 and 3mg, respectively, 4.0 prucalopride
and 2.6 placebo. The proportion of responders (defined as those with a 1
increase in SBM/week over 2 weeks from baseline) was higher in the YH12852
treatment groups (87.5%, 100.0%, 100.0%, and 100.0% in 0.3, 0.5, 1 and 2mg,
respectively), with the exception of the 3mg group (80.0%), compared with that
in the prucalopride (83.3%) and placebo groups (28.6%). The mean stool con-
sistencies assessed by the Bristol Stool Form Scale were comparable between the
YH12852 and prucalopride groups. The time to reach the peak concentration of
YH12852 was 4 hours. Steady state was achieved approximately 5 days after the
first administration of YH12852 with a half-life of 23–28 hours. YH12852
showed a linear pharmacokinetic profile over 0.3–3mg.
Conclusion: YH12852 was well tolerated and its safety profile was comparable to
that of prucalopride. YH12852 appeared to increase bowel movement greater
than prucalopride, particularly at 0.5–2mg. YH12852 may have a significant
potential for the treatment of lower GIMDs.
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Introduction: Constipation is a common side effect of opioid use. Available laxa-
tive therapies for opioid-induced constipation (OIC) leave the patient with sig-
nificant residual symptoms, which may lead them to adjust or stop their opioid
intake in order to have a bowel movement, unless effectively counselled.1
Aims & Methods: This subgroup analysis of an international survey investigated
counselling resources, information-seeking, and sources of support in subjects
with constipation caused by the use of strong opioids (e.g. buprenorphine, fen-
tanyl). This was a quantitative, questionnaire-based, online survey conducted in
France, Germany, Italy, Spain and the UK among respondents aged 40 years
with largely non-cancer-related chronic pain, treated long-term with strong
opioids and having constipation (N¼ 2016). The survey assessed past medical
history, opioid use, treatment and treatment-seeking behaviour, symptoms,
burden of disease, and effects on quality of life of constipation.
Results: In general, responders find it difficult to combine pain management relief
and constipation and dislike having to balance between them (36%).
Approximately one-fifth (22%) of respondents were very or somewhat dissatis-
fied with the effectiveness of their current constipation treatment and only 43%
strictly adhered to prescribed treatment regimens, with 32% researching other
treatment options. A significant number of responders (44%) admitted that their
constipation becomes so bothersome that they have to combine different meth-
ods to relieve it, and 40% often cut down their opioid medication or even skip it
entirely (9%) to relieve constipation. To manage their constipation, respondents
regularly used a variety of approaches, including dietary measures (48%), exer-
cise (23%) and single (32%) or multiple (15%) laxative treatments. Only 45% of
respondents reported that their healthcare professionals (HCPs) had warned
them about constipation as a potential side effect of opioid use. Almost two-
thirds of respondents (63%) reported that their HCP was the main information
source on opioid-induced constipation. Although 58% of respondents stated that
they would have liked their HCP to provide more information about OIC, 48%
preferred to deal with constipation on their own, rather than discuss it with their
HCP. Other common sources of information were online search engines (44%)
and online health forums (29%). Less than half of respondents (43%) strictly
adhered to prescribed treatment regimens, with 32% researching other
treatments.
Conclusion: A proportion of patients are not satisfied with their current constipa-
tion treatment and they sometimes find balancing the need for adequate pain
relief with constipation side effects challenging; consequently, many fail to adhere
to their prescribed treatment regimens, or resort to using suboptimal strategies,
such as reducing their opioid intake, to relieve constipation. Despite this dissa-
tisfaction, many HCPs are not counselling patients adequately about constipa-
tion as a common potential side effect of opioid use. While most patients would
like to have more support from their HCP, nearly half prefer to deal with con-
stipation on their own, perhaps due to embarrassment or resignation.
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Introduction: Three-dimensional high-resolution anorectal manometry
(3DHRAM) is the most precise tool to assess function of the anal canal and
may be useful in evaluation of children after surgery on lower gastrointestinal
tract that may present wide spectrum of symptoms from gastrointestinal tract.
Our aim was to evaluate children after surgery for anorectal disorders using
3DHRAM.
Aims & Methods: We performed a prospective study of 43 children (30 male,
mean age, 7 years) after surgery for anorectal disorders at the Departments of
Pediatric Gastroenterology and Nutrition, Medical University of Warsaw,
Poland. The group consisted of 24 children after surgery for Hirschsprung’s
disease (HD), 12 children after surgery for anal atresia (AA) and 7 children
after proctocolectomy for other reasons (PC). In all children conventional mano-
metric parammeters were obtained. Pressures of the anal canal was divided into 8
segments and the resting and squeeze pressures of puborectalis muscle (PRM)
were recorded in segments covering its anatomical localization. These data were
compared to raw data obtained in our laboratory from healthy children pub-
lished previously (HC group). To assess correlation between manometry and
symptoms, all children (after surgery and HC group) were divided into groups
with respect to symptoms, as follows: asymptomatic (A), nonretentive fecal
incontinent (NFRI), constipated (C) and retentive fecal incontinent (RFI).
Results: The lowest values of resting, squeeze and the pressure of PRM were
observed in AA (55.6mmHg, 121.7mmHg and 44.17mmHg, respectively). As
compared to asymptomatic children, the lowest mean and maximum resting
pressures were observed in NRFI (69.6mmHg and 61.3mmHg, respectively;
p5 0.000). Significantly lower maximum squeeze pressure were recorded in
both, NRFI and RFI (168.1mmHg and 103.8mmHg, respectively; p¼ 0.03).
ROC cut-off value for mean resting pressure between asymptomatic children
and patient with fecal incontinence was 68,5mmHg. Significantly lower PRM
resting pressure were observed in NRFI group and lower PRM squeeze pressure
in RFI (45.6mmHg and 63.6mmHg, respectively). Threshold of urge were sig-
nificantly higher in group C as compared to A group (87.5 cm3 and 30 cm3,
respectively; p¼ 0.003).
Conclusion: Our study demonstrated lower pressure parameters in children after
surgery with the lowest values in patients suffering from anal atresia, which was
correlated with incontinence. 3DHRAM may be useful tool for assessing the
function of the anorectum of children after surgery.
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Introduction: Linaclotide, a guanylate cyclase C agonist, has been shown in clin-
ical trials to relieve constipation and improve abdominal pain and discomfort in
patients with irritable bowel syndrome with constipation (IBS-C), but there are
limited UK-specific real-world data to support this.
Aims & Methods: A multi-centre, observational, prospective 52-week study was
conducted in eight specialist hospitals in England and Scotland. The primary
objective was to describe the change in IBS-Symptom Severity Scale (IBS-SSS)
score from baseline at 12 weeks after linaclotide initiation. Consenting patients
aged 18 years initiated on linaclotide (290mcg) for IBS-C were recruited. Data
on patient demographic and clinical characteristics, concomitant medications,
patient-reported outcomes, including IBS-SSS score, and adverse events were
collected. Results at 12 weeks (primary endpoint) have been presented previously;
here we report analysis of real-world clinical experience 52 weeks post-linaclotide
initiation.
Results: 202 patients were recruited; 185 (92%) were female. At baseline, median
age was 44.9 (range 18–77) years; 84 (42%) reported concomitant laxative use.
Mean baseline IBS-SSS score was 339 (standard deviation [SD] 92; n¼ 193);
129 (67%) patients had IBS-C classified as severe (score 300), 54 (28%) mod-
erate (175–300), nine (5%) mild (75–175) and one (0.5%) normal (575). At 52
weeks, mean IBS-SSS score was 256 (SD 116; n¼ 78); 31 (40%) patients had
severe IBS-C, 27 (35%) moderate, 14 (18%) mild and six (8%) normal. IBS-SSS
scores improved significantly between baseline and 52 weeks, with a mean
decrease of 71 (SD 106) points overall (t-test p5 0.001; n¼ 76 with paired
data) and 94 (SD 102) points in the patients remaining on linaclotide
(p5 0.001; n¼ 34). Of the 76 patients with paired data, 41 (54%) reported
responding to treatment (ie reduction in IBS-SSS score of 50 points, or score
fell below 150 [if baseline score 150]) [Table]. At 52 weeks, 41 (20%; n¼ 202)
patients remained on linaclotide, 87 (43%) had stopped (54 doses in past week),
most commonly due to side effects (n¼ 51) or lack of efficacy (n¼ 18), and 74
(37%) were lost to follow-up/not known. Overall, 174 adverse events possibly
related to linaclotide were reported in 77 (38%) patients, most commonly diar-
rhoea (25%; n¼ 51), abdominal pain (9%; n¼ 18) and abdominal distension
(6%; n¼ 13).
Table: Change in IBS-SSS score at 52 weeks from start of linaclotide
Change in IBS-SSS Patients, n Patients, %
3505300 1 1
3005250 5 7
2505200 5 7
2005150 4 5
1505100 11 14
100550 14 18
505 0 15 20
No change 1 1
405 50 10 13
505 100 7 9
1005 150 3 4
1505 200 0 0
2005 250 0 0
2505 300 0 0
3005 350 0 0
Total 76 100
Conclusion: Linaclotide was associated with a significant improvement in IBS-
SSS score at 52 weeks and was reasonably well tolerated. These results provide
valuable insights into the longer-term outcomes of linaclotide treatment in
patients with IBS-C in real-world clinical practice.
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Introduction: Irritable bowel syndrome (IBS) may be associated with disturbances
of gut microbiota composition and functions, such as altered bacterial
fermentation.
Aims & Methods: The aim was to study the effect of faecal microbiota transplan-
tation (FMT) on gut bacterial fermentation products: short-chain fatty acids
(SCFAs). Patients diagnosed with IBS according to Rome III criteria (n¼ 13)
were included. They received freshly donated faeces from relatives, instilled into
the descending part of the duodenum via gastroscope. Faecal samples were col-
lected from the donors and the patients before FMT and from the patients after
FMT at weeks 1, 3, 12 and 20/28. All the samples were stored at 80C until
analysis. Faecal concentrations of major SCFAs (acetic, propionic and n-butyric
acids) and minor SCFAs (iso-butyric, n-valeric, iso-valeric, n-caproic and iso-
caproic acids) were analysed by vacuum distillation followed by gas chromato-
graphy. The patients completed IBS symptom questionnaire (IBS-SQ) before and
after FMT at weeks 1, 3, 12, and 20/28, assessing the following domains: nausea,
bloating, abdominal pain, diarrhea, constipation and anorexia.
Results: Before FMT, concentrations of several SCFAs were significantly lower
in IBS patients compared to donors (Table 1). After FMT, concentrations of
SCFAs increased within the first 3 weeks, and the increment lasted up to 28
weeks (Table 1). Symptom scores as assessed by IBS-SQ improved from before
FMT until week 20/28 after FMT as follows: nausea (P¼ 0.0013), bloating
(P5 0.0001), abdominal pain (P¼ 0.0005), diarrhea (P5 0.0001), constipation
(P¼ 0.03), and anorexia (P¼ 0.09). Correlations were found between abdominal
pain and both acetic acid (r¼ 0.69, P¼ 0.04) and total SCFAs (r¼ 0.69,
P¼ 0.044) in IBS patients before FMT. Inverse correlations were found 3
weeks after FMT between nausea and iso-valeric acid (r¼ -0.65, P¼ 0.014),
and between constipation and propionic (r¼ -0.74, P5 0.0001), iso-butyric
(r¼ -0.79, P5 0.0001), n-valeric acids (r¼ -0.79, P5 0.0001) and iso-valeric
(r¼ -0.72, P5 0.0001).
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Conclusion: Our results reveal differences in faecal fermentation products
between patients with IBS and healthy donors, and suggest that FMT may act
to normalise such alterations of gut microbial functions.
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Introduction: Irritable bowel syndrome with diarrhoea (IBS-D) is a chronic gas-
trointestinal disorder associated with significantly increased healthcare resource
use (HCRU) and a substantial economic burden. In clinical practice, adequate
relief (AR) of symptoms is an important measure of treatment effectiveness.1,2
However, the difference in HCRU related to IBS-D between patients with AR
and those with inadequate relief (IR) has not yet been assessed.
Aims & Methods: This objective of this study was to quantify the HCRU in
patients with AR of IBS-D symptoms compared to patients with IR. An
online survey assessing HCRU was distributed to general practitioners (GPs)
recruited from market research panels in the UK in August 2016. GPs opted-
in to complete the survey via an email link and were screened before being invited
to complete the main survey. Screening criteria included having seen patients
with a chronic gastrointestinal condition in the past three months, having seen
patients with IBS-D in the past 3 months and having decided on what treatments
were prescribed for patients with IBS. The survey was a 15-minute web-based
survey, including 12 questions collecting information on the use of medical ser-
vices and procedures amongst patients with IBS-D for the first year following
diagnosis and for subsequent years. Respondents were required to answer the
survey considering patients who had AR of IBS-D symptoms and those who did
not (IR), based on the respondents’ own assessments. Statistical analyses
included t-tests for two independent samples comparing mean scores for those
with IR vs those with AR during the first year after diagnosis at a 5% risk level,
with p5 0.05 denoting significance.
Results: The online survey was completed by 50 GPs, with responses from 46 GPs
included in this analysis (four responses were excluded due to data quality reasons).
The reported total number of medical visits was significantly higher for patients
with IR vs patients with AR during the first year after diagnosis (mean 10.11 vs
5.20; p5 0.001), with similar results seen for subsequent years (mean 8.20 vs
4.38). Significantly higher numbers of GP office visits, outpatient visits and
emergency room visits were reported for patients with IR, with the greatest
difference seen for GP office visits (2.37 more visits/year on average; incremental
4-week increase of 0.182; p¼ 0.003) [Table]. Similarly, the total reported mean
number of procedures was significantly higher for patients with IR vs patients
with AR (8.11 vs 4.52; p¼ 0.046), with number of colonoscopies having the
greatest difference between the two groups (2.17 vs 0.91; 1.26 more proce-
dures/year on average; incremental 4-week increase of 0.097; p¼ 0.008).
Similar results were seen for the subsequent years after diagnosis, with patients
with IR having more medical procedures compared to patients with AR (4.08 vs
2.56).
Table
Mean resource use
(standard deviation)
Adequate
relief
(1styear
after
diagnosis)
Inadequate
relief
(1st year
after
diagnosis)
Difference
per year
Incremental
mean
quantity
per 4 weeks
Medical visits
Total 5.20 (4.87) 10.11 (5.30)* 4.91 0.378
GP office 3.33 (2.87) 5.70 (3.12)* 2.37 0.182
Outpatient 0.96 (1.53) 2.30 (1.68)* 1.35 0.104
Emergency room 0.52 (1.24) 1.17 (1.36)* 0.65 0.050
Hospitalisations 0.39 (1.00) 0.93 (1.10) 0.54 0.042
Procedures
Total 4.52 (6.96) 8.11 (7.58)* 3.59 0.276
Colonoscopy 0.91 (1.47) 2.17 (1.61)* 1.26 0.097
Sigmoidoscopy 0.70 (1.43) 1.37 (1.56) 0.67 0.052
Ultrasound 1.13 (2.06) 1.76 (2.26) 0.63 0.048
Endoscopy 0.67 (1.28) 1.22 (1.37) 0.54 0.042
Computerised
tomography scan
0.48 (1.01) 0.85 (1.10) 0.37 0.028
X-ray 0.63 (1.53) 0.74 (1.68) 0.11 0.008
*p5 0.05 compared to patients with adequate relief
Conclusion: GPs reported that patients with IBS-D considered as having IR of
symptoms had increased HCRU, including more GP office visits and more colo-
noscopies, compared to patients with AR. These results highlight that IR is
potentially an important driver of increased HCRU in patients with IBS-D,
emphasising that effective treatments that provide AR may reduce HCRU and
the associated economic burden.
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Table 1: Concentrations (mmol/kg) of short-chain fatty acids (SCFAs) in faecal samples collected from donors and patients with irritable bowel syndrome (IBS) before
and after faecal microbiota transplantation (FMT).
SCFAs
Donor,
(n¼ 13)
Patients
before FMT,
(n¼ 9)
Patients after FMT
*P **P ***P ****P *****P
Week 1,
(n¼ 12)
Week 3,
(n¼ 10)
Week 12,
(n¼ 13)
Week 20/28,
(n¼ 12)
Acetic acid /33.9 2.8 23.6 6 31.1 4.9 35.5 3.9 25.8 4.4 28.5 2.4 0.77 40.9 40.9 0.3 40.9
Propionic acid 9.5 1 6.2 1.6 7.9 1.5 8.2 1.5 7.3 1.9 8.1 1.2 0.18 40.9 40.9 0.2 40.9
n-butyric acid 10.4 1.6 4.7 1.2 7.7 1.8 8.4 1.5 5.8 1.4 5.96 1.11 0.049 0.78 40.9 0.095 0.25
Iso-butyric acid 1.27 0.17 0.67 0.11 0.77 0.12 0.92 0.13 0.7 0.12 0.98 0.2 0.03 0.089 40.9 0.025 0.96
n-valeric acid 1.4 0.18 0.68 0.008 1.05 0.2 1.06 0.15 0.77 0.13 0.93 0.093 0.013 0.67 40.9 0.042 0.47
Iso-valeric acid 1.6 0.2 0.8 0.2 0.9 0.15 1.16 0.2 0.8 0.14 1.27 0.2 0.014 0.046 40.9 0.011 40.9
n-caproic 0.8 0.02 0.3 0.1 0.5 0.2 0.5 0.1 0.2 0.08 0.3 0.09 0.2 40.9 40.9 0.059 0.17
Iso-caproic 0.01 0.005 0.02 0.02 0.008 0.006 0.013 0.01 0.01 0.005 0 0 40.9 40.9 40.9 40.9 0.6
Total SCFAs 58.8 5.4 37 8 49.9 8 55.7 6.2 41.4 7.1 46 4.7 0.17 40.9 40.9 0.15 0.6
Data are presented as meanSEM. Comparison: Kruskal-Wallis multiple comparisons test with Dunn’s post test. *Donors at the beginning of the study vs. patients
on FMT day before faecal installation, **Donors at the beginning of the study vs. patients 1 week after FMT, *** Donors at the beginning of the study vs. patients 3
weeks after FMT, ****Donors at the beginning of the study vs. patients 12 weeks after FMT, *****Donors at the beginning of the study vs. patients 20/28 weeks after
FMT. FMT: faecal microbiota transplantation. SCFAs: short-chain fatty acids
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Introduction: Selective Serotonin Reuptake Inhibitors (SSRI’s) have shown effi-
cacy in reducing symptoms but less so on pain in irritable bowel syndrome (IBS).
Comorbid anxiety frequently occurs in IBS. We hypothesized that SSRI’s will
particularly be effective in reducing abdominal pain in IBS patients with pro-
nounced comorbid anxiety. As methods for symptom evaluation were used 1)
gastrointestinal symptom rating scale (GSRS) as primary parameter and 2) a new
method called the Experience Sampling Method (ESM). With ESM digital
assessments are completed randomly and repeatedly during daily life, therewith
capturing fluctuating symptom patterns more accurately than retrospective ques-
tionnaire methods.
Aims & Methods: IBS patients with comorbid panic disorder were included in a
randomized controlled trial on escitalopram versus placebo. Measurements were
completed at baseline (t¼ 0) and after 3 (t¼ 3) and 6 months (t¼ 6). At each time
point, the gastrointestinal symptom rating scale (GSRS) and a 7-day ESM period
were completed. Subjects completed ESM assessments on a palmtop computer at
10 random moments each day during 7 consecutive days. ESM periods were
analysed when at least 1/3 (i.e. 23) of the assessments were completed. Mixed
linear modelling was used with the GSRS-abdominal pain domain (GSRS-AP) as
the dependent and treatment group as the independent variable, as well as with
ESM- abdominal pain scores as the dependent and treatment group and ESM-
anxiety scores as the independent variables.
Results: In total, 29 subjects (15 escitalopram and 14 placebo; 21 female;
37 14.8 years; equal abdominal pain and anxiety scores at baseline) were
included. Average GSRS-AP scores were not significantly different between esci-
talopram and placebo at t¼ 3 (B: 0.265, SE: 0.451, p¼ 0.557) or t¼ 6 (B: 0.229,
SE: 0.539, p¼ 0.670). For the ESM analyses, at t¼ 6, average abdominal pain
scores were significantly lower (B: 1.30, SE: 0.623, p¼ 0.037) (on a 1–7 scale) in
the escitalopram group compared to placebo. With increasing anxiety levels
(scores 2, 3 and 4) this difference further increased to 1.57, 1.84 and 2.11, respec-
tively. A sensitivity analysis on subjects that completed all 3 valid ESM periods
(i.e. at least 1/3 of total number of assessments at t¼ 0, t¼ 3 and t¼ 6) showed
similar results.
Conclusion: Using GSRS as primary outcome, no significant effect of escitalo-
pram over placebo on abdominal pain was found over a 6-month period.
However, using ESM, a significant improvement in abdominal pain was
observed, related to anxiety scores. These data 1) challenge the value of tradi-
tional retrospective methods with end-of-period symptom recording and 2) are in
favour of novel more accurate momentary symptom registrations such as the
Experience Sampling Method.
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Introduction: Linaclotide, a guanylate cylase-C agonist, stimulates intestinal fluid
secretion and decreases visceral hypersensitivity and is licensed for use in irritable
bowel syndrome with constipation (IBS-C). There is a relative paucity of data
concerning its effect on gastrointestinal (GI) motility.
Aims & Methods:We aimed to compare the effect of linaclotide on segmental and
pan-enteric motility in IBS-C. 14 patients with Rome III defined IBS-C (3 male,
mean age 37 years, range 20–64) underwent a wireless motility capsule (WMC)
using a standardized protocol. Segmental transit was derived from measures
around known anatomical landmarks as identified by compartmental pH
changes. Ileal and colonic motility measures are presented as area under the
curve (AUC) derived from contraction amplitude and frequency. Validated ques-
tionnaires assessing GI (verbal descriptor anchored visual analog scale (VDVAS)
assessing sensory intensity (VDVAS-I) and unpleasantness (VDVAS-U)) and
somatic symptoms (Personal Health Questionnaire (PHQ) as well as quality of
life (EQ-5D) were administered. The WMC and questionnaires were repeated
after 28 days of linaclotide 290mcg po od.
Results: Changes in GI motility are shown in Table 1. Linaclotide improved
VDVAS-I and VDVAS-U (130.7 20.8 vs. 106.5 33, p¼ 0.03 and 113 22
vs. 85.8 33, p¼ 0.01) and quality of life (58.4 21.2 vs. 68 17.6, p¼ 0.02).
Linaclotide reduced somatic symptoms (8.3 2.2 vs. 5.9 1.4, p¼ 0.007).
Change in pH across the ileocaecal junction correlated with improvement in
VDVAS-I and U (r¼ 0.6, p¼ 0.03 and r¼ 0.64, p¼ 0.02).
Table 1: Changes in GI physiology following linaclotide.
Baseline
(mean and
standard
deviation)
Post treatment
(mean and
standard
deviation)
P
Value
Gastric emptying time (minutes) 154 64 177 57 0.4
Small bowel transit time (minutes) 353 152 299 139 0.3
Colonic transit time (minutes) 3017 1305 1983 1216 0.04
Whole gut transit time (minutes) 3517 1375 2432 1180 0.04
Ileal contractility (AUC) 262 142.4 221 113.5 0.5
Colonic contractility (AUC) 90.9 78.3 134.6 93 0.006
Changein pH across
the lleocaecal junction
2.4 0.2 2.1 0.4 0.03
Linaclotide improved VDVAS-I and VDVAS-U (130.7 20.8 vs. 106.5 33,
p¼ 0.03 and 113 22 vs. 85.8 33, p¼ 0.01) and quality of life (58.4 21.2 vs.
68 17.6, p¼ 0.02). Linaclotide reduced somatic symptoms (8.3 2.2 vs.
5.9 1.4, p¼ 0.007). Change in pH across the ileocaecal junction correlated
with improvement in VDVAS-I and U (r¼ 0.6, p¼ 0.03 and r¼ 0.64, p¼ 0.02).
Conclusion: Linaclotide reduced colonic transit and enhances contractility. These
changes in GI motility are accompanied by improvements in symptoms and
quality of life and are associated with a reduction in extra-gastrointestinal symp-
toms. Change in pH across the ileocaecal junction has been proposed as a sur-
rogate marker of caecal fermentation. Thus the beneficial effect of linaclotide on
symptoms may therefore be related to a reduction in fermentation. This potential
biomarker warrants further exploration.
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Introduction: Bile acids (BAs) and gut microbiota have been involved in IBS
pathophysiology. BA diarrhea (BAD) is often found in patients with irritable
bowel syndrome with diarrhea (IBS-D) or functional diarrhea (FD)1.
Colestyramine and rifaximin have both been shown to improve symptoms in
these patients2,3. It is unknown whether a SeHCAT test may help to predict
response to rifaximin or whether rifaximin treatment affects SeHCAT test result.
Aims & Methods: a) To determine if a SeHCAT test may be used to predict
response to rifaximin in patients with IBS-D or FD. b) To assess if rifaximin
modifies SeHCAT result.
Consecutive patients diagnosed with IBS-D or FD were prospectively included in
the study. All patients received rifaximin (400mg TID for 2w). A SeHCAT test
was performed to evaluate presence of BAD before and 1 month after rifaximin
treatment. BAD was defined as SeHCAT retention 510%. Number of daily
stools, number of daily watery stools, Bristol stool scale, abdominal pain, dis-
tension and presence of urgency were recorded before and after treatment. IBS
severity score (IBS-SS) was also calculated.
Results: Forty-one patients were included. BAD was present in 23 patients
(56%). No clinical differences were found between BAD or non-BAD patients
at study entry. Rifaximin resulted in a significant improvement in the number of
daily stools ( 1.5; P5 0.01), daily watery stools ( 2.1; P5 0.01), Bristol
scale ( 1.1; P5 0.01), abdominal pain ( 0.5; P5 0.01), distension ( 0.3;
P5 0.01), urgency ( 0.7; P5 0.01) and in the IBS-SS ( 78; P5 0.01). No
differences were found between BAD and non-BAD patients in the improvement
of any item. Rifaximin treatment did not modify SeHCAT value (9.5% before
treatment and 10.7% after treatment; P¼ 0.4).
Conclusion: Half of the patients diagnosed with IBS-D or FD present BAD
according the SeHCAT test. Rifaximin treatment confers significant clinical
improvement irrespective of the presence of BAD. Rifaximin treatment does
not affect SeHCAT test.
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Introduction: In 10–15% of patients with irritable bowel syndrome (IBS), the
onset of symptoms follows an episode of gastrointestinal infection or use of
antibiotics. Both antibiotic-induced and post-infectious IBS may be caused by
alterations of the gut microbiota, which provides a rationale for treatment with
fecal microbiota transplantation (FMT).
Aims & Methods: We performed an open label pilot study in the VU University
medical center in Amsterdam from August 2016 through January 2017, to eval-
uate the effect of FMT in patients with post-infectious IBS (n¼ 5) and patients
with antibiotic-induced IBS (n¼ 5). Participants with clinical symptoms lasting
over six months, an IBS-symptom severity score (IBS-SSS) of at least 175 points,
and a negative screening for gastrointestinal pathology were eligible. Donor feces
(198ml) was provided by the Netherlands Donor Feces Bank (NDFB) and
administered via a duodenal tube. Participants did not receive pre-treatment or
bowel cleansing. Participants were followed for eight weeks via two validated
questionnaires: IBS-SSS (range 100–500), and IBS-Quality of Life score
(IBS-QOL; range 0–100%). Fecal samples were obtained before and after
FMT for microbiota analysis. Following the recommendation of the European
Agency Medicines, FMT was considered clinically effective if participants
reported an IBS-SSS improvement of at least 30% compared to baseline, eight
weeks after FMT.
Results: The mean IBS-SSS of all patients had improved significantly from
328 (74) points at baseline to 245 (117) at eight weeks after FMT
(p¼ 0.008); the median IBS-SSS improved with 40% from 340 (range 230–480)
to 205 (range 80–470). Also, a significant improvement was seen in abdominal
pain (p¼ 0.039), satisfaction about bowel habit (p¼ 0.018), and influence of IBS
symptoms on daily life (p¼ 0.011). There was no difference in bloating, or
number of days with abdominal pain. The mean IBS-QOL improved from
51% to 66% (p¼ 0.008). FMT was considered effective in three patients with
antibiotic-induced IBS, and one patient with post-infectious IBS (30%
improvement). In general, fecal microbiota analysis showed that the microbiota
composition of responders shifted to that of their corresponding donors. Non-
responders initially also did (which was associated with IBS-SSS improvement),
however, eight weeks after FMT, the microbiota composition had shifted back
towards baseline.
Conclusion: Treatment with FMT appears promising for antibiotic-induced and
post-infectious IBS. Based on these results, a randomized placebo controlled trial
is warranted.
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Introduction: Adequate relief (AR) of irritable bowel syndrome (IBS) symptoms
is a commonly used global outcome measure to assess treatment benefit in both
clinical trials and real-life clinical practice. Conversely, inadequate relief (IR) is
considered an important driver for patients to use healthcare resources such as
general practitioner or gastroenterologist consultations. Eluxadoline (ELX) is a
mixed m-opioid receptor (OR) and -OR agonist and -OR antagonist approved
for the treatment of IBS with diarrhoea (IBS-D) in the US and Europe.
Aims & Methods: To evaluate IR in patients treated with ELX in a post hoc
analysis from two randomised, double-blind, placebo (PBO)-controlled Phase 3
trials (IBS-3001, IBS-3002). Patients meeting Rome III criteria for IBS-D were
randomised 1:1:1 to twice-daily (BID) ELX (75 or 100mg) or PBO. Efficacy was
evaluated through Week 26. For evaluation of AR, patients were asked ‘‘In the
last 7 days, have you had adequate [or satisfactory] relief of your IBS symp-
toms?’’ (Yes/No) on a weekly basis, via an electronic diary. As previously
described, patients answering ‘‘Yes’’ for 50% of the total weeks during the
target time interval were considered AR responders.1,2 Patients answering
‘‘No’’ were considered to have IR. This analysis evaluated the number of con-
secutive weeks that patients reported IR over Weeks 1–12 and 13–24 of treat-
ment. Patients without AR analysis were ineligible for intention-to-treat (ITT)
analysis; missing data were not imputed.
Results: Overall, 2428 patients with IBS-D were enrolled across the two Phase 3
trials and 2423 were included in the ITT analysis. In the pooled dataset, a sig-
nificantly greater proportion of patients were AR responders2 with either ELX
100 or 75mg BID vs PBO at 12 weeks (56.1% [p5 0.001] and 56.3% [p¼ 0.001]
vs 46.4%, respectively) and at 26 weeks (51.5% [p5 0.001] and 49.0% [p¼ 0.004]
vs 41.8%, respectively).3 Over the first 12 weeks of treatment, a greater propor-
tion of patients reported no IR of IBS-D symptoms with ELX 100 or 75mg BID
vs PBO (Table). Greater proportions of patients reported only 1–55 consecutive
weeks of IR with ELX 100 or 75mg BID vs PBO. A significantly lower propor-
tion of patients reported IR for 48 consecutive weeks with ELX 100 or 75mg
BID vs PBO (13.2% [p5 0.0001] and 15.6% [p¼ 0.004] vs 22.6%, respectively).
In contrast, a greater proportion of patients reported IR for the full 12 conse-
cutive weeks with PBO vs ELX 100 or 75mg BID (Table). Similar results were
observed in Weeks 13–24 of treatment, with ELX-treated patients generally
having fewer consecutive weeks of IR compared to PBO-treated patients (Table).
Table: Consecutive weeks of inadequate relief
Weeks 1–12 Weeks 13–24
Inadequate
relief rate, %
PBO
(n¼ 809)
ELX
75mg
BID
(n¼ 808)
ELX
100mg
BID
(n¼ 806)
PBO
(n¼ 809)
ELX
75mg
BID
(n¼ 808)
ELX
100mg
BID
(n¼ 806)
Number of
consecutive
weeks with
inadequate relief
0 14.4 23.6 24.8 26.8 39.5 37.1
1–5 5 46.7 50.2 49.2 35.9 33.8 37.6
5– 8 16.3 10.7 12.7 13.1 8.6 8.5
48–5 12 5.3 3.8 2.9 4.7 3.9 3.7
12 17.3 11.8 10.3 19.4 14.1 13.1
Conclusion: In this post hoc analysis of the pooled ELX Phase 3 studies, ELX-
treated patients experienced fewer consecutive weeks of IR compared to those
receiving PBO, within both Weeks 1–12 and 13–24 of treatment. As IR is thought
to drive increased healthcare provider visits, these data suggest that ELX could
potentially reduce healthcare resource use and subsequent healthcare costs asso-
ciated with IBS. Further prospective study of the impact of ELX on AR and any
subsequent reduction in healthcare costs is required, including the relationship
between the number of consecutive weeks of IR and patients’ behaviour towards
healthcare resource use.
Disclosure of Interest: D. Collomb: David Collomb is an employee of
Allergan plc.
A. Marciniak: Anne Marciniak is an employee of Allergan plc and shareholder in
Pfizer, Amgen, and Allergan plc.
Y. Mo: Yifan Mo is an employee of Allergan plc.
D.A. Andrae: David A. Andrae is an employee of Allergan plc and shareholder
in Allergan plc.
G. Wiseman: Gwen Wiseman is an employee of Allergan plc.
References
1. Lembo AJ et al. N Engl J Med 2016; 374: 242–253
2. Chey WD et al. Aliment Pharmacol Ther 2017; doi: 10.1111/apt.14031 [Epub]
3. Covington PS. Poster 55 presented at ACCP Global Conference on Clinical
Pharmacy, USA, 2015
P1147 CLINICAL RESPONSE AND DISCONTINUATION OVER
TIME IN PHASE 3 TRIALS OF ELUXADOLINE FOR IRRITABLE
BOWEL SYNDROME WITH DIARRHOEA
A. Marciniak1, R. T. Carson2, J. L. Abel2, D. A. Andrae3, K. Fust4, D. Becker5
1Allergan plc, Marlow/United Kingdom
2Allergan plc, Jersey City/United States of America/NJ
3Allergan plc, Austin/United States of America/TX
4Optum, Plymouth/United States of America/MA
5Optum, Burlington/Canada/ON
Contact E-mail Address: Anne.Marciniak@Allergan.com
Introduction: Irritable bowel syndrome with diarrhoea (IBS-D) is a chronic gas-
trointestinal disorder characterised by recurrent abdominal pain associated with
diarrhoea. Eluxadoline, a mixed m- and -opioid receptor agonist and -opioid
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receptor antagonist, is approved for the treatment of IBS-D in adults, based on
two large Phase 3 clinical trials where eluxadoline met the primary composite
response endpoint of simultaneous improvement in abdominal pain and stool
consistency over 26 weeks.
Aims & Methods: These post hoc analyses of two double-blind, placebo-
controlled, Phase 3 clinical trials of eluxadoline (IBS-3001 and IBS-3002)
aimed to assess responder and non-responder rates over 4-week intervals for
eluxadoline vs placebo, and the proportion of responders/non-responders who
continued or discontinued treatment. Patients meeting Rome III criteria for IBS-
D were randomised to twice-daily treatment with eluxadoline (75 or 100mg) or
placebo. Patients rated IBS symptoms daily, including worst abdominal pain
(WAP; 0–10 scale, with 0¼no pain and 10¼worst imaginable pain), stool con-
sistency (Bristol Stool Form Scale [BSFS]), and Global Symptom Score (GSS;
0–4 scale, where 0¼no symptoms and 4¼ very severe symptoms). A responder
for a 4-week interval was defined as a patient with a simultaneous daily improve-
ment of 30% in WAP score vs baseline and BSFS score 55 with 50% of days
demonstrating a response and a minimum of 20 days of diary data. The inten-
tion-to-treat (ITT) analysis set included all patients randomised to a treatment
group. For these analyses, patients with baseline GSS 3 (severe or very severe
symptoms) and self-reported inadequate symptom control with loperamide were
classified as having severe IBS-D.
Results: Of the 2423 patients in the pooled Phase 3 ITT population, 249 were
classified as having severe IBS-D. Over Weeks 1–4, 26.8% and 30.3% of patients
with severe IBS-D were responders with eluxadoline 75 and 100mg, respectively,
vs 8.1% of patients on placebo (Table). Higher proportions of patients were
responders with eluxadoline vs placebo over each subsequent 4-week interval,
with response rates observed at Weeks 1–4 consistently maintained across all
subsequent 4-week time intervals. With both eluxadoline and placebo, propor-
tions of responders discontinuing were 52% across each 4-week interval, and
discontinuation rates in non-responders were higher than in responders (Table).
Similar findings were observed in the ITT analysis set: over Weeks 1–4, 22.7%
and 24.6% of patients were responders with eluxadoline 75 and 100mg, respec-
tively, vs 12.5% of patients on placebo. Over Weeks 21–24, 28.1% and 30.2% of
patients were responders with eluxadoline 75 and 100mg, respectively, vs 20.1%
on placebo. Discontinuation rates among responders with both eluxadoline and
placebo remained 51% across all 4-week time intervals.
Table
Placebo (n¼ 74)
Eluxadoline
75mg (n¼ 86)
Eluxadoline
100mg (n¼ 89)
Responder,
%
Non-
responder,
%
Responder,
%
Non-
responder,
%
Responder,
%
Non-
responder,
%
Weeks C DC C DC C DC C DC C DC C DC
1–4 8.1 0.0 89.2 2.7 25.6 1.2 68.6 4.7 29.2 1.1 58.4 11.2
5–8 18.9 1.4 73.0 6.8 30.2 0.0 55.8 14.0 31.5 1.1 49.4 18.0
9–12 18.9 0.0 63.5 17.6 31.4 0.0 52.3 16.3 30.3 1.1 47.2 21.3
13–16 16.2 1.4 63.5 18.9 30.2 0.0 52.3 17.4 27.0 0.0 48.3 24.7
17–20 24.3 0.0 50.0 25.7 33.7 0.0 40.7 25.6 37.1 0.0 37.1 25.8
21–24 14.9 1.4 54.1 29.7 30.2 1.2 39.5 29.1 29.2 1.1 38.2 31.5
C, patients continuing on treatment; DC, patients discontinuing from treatment
Conclusion: Proportions of responders with eluxadoline 75 and 100mg were
consistently higher vs placebo across all 4-week intervals in the treatment
period in patients defined as having severe IBS-D. Furthermore, discontinuation
rates among patients showing a treatment response remained consistently low
compared to non-responders. However, as these analyses were conducted in a
clinical trial setting, the relatively high continuation rates in non-responders may
not reflect the real-world situation. These findings suggest that eluxadoline has
sustained efficacy in treating the diarrhoea and abdominal pain associated with
IBS-D, including in patients with severe and inadequately managed symptoms.
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Introduction: Diets reducing the content of fermentable short chain carbohy-
drates (fermentable oligo-, di-, monosaccharides, and polyols (FODMAPs)) as
well as the National Institute of Health Care Excellence (NICE) diet have been
reported to be effective in the treatment of patients with irritable bowel syndrome
(IBS) (1,2). The mechanisms by which this efficacy is achieved are incompletely
understood but it has been proposed that such diets reduce fermentation,
mediated by changes in the microbiota (3). Change in pH around the ileocaecal
junction is considered to be a surrogate biomarker of caecal fermentation (4,5).
Aims & Methods: We aimed to compare the effect of a low FODMAP diet vs. the
NICE diet on change in ileocaecal pH. We performed a single centre, randomized
controlled trial of adult patients with Rome III defined IBS-mixed bowel habit
(IBS-M) comparing the two dietary interventions. At baseline, patients ingested a
wireless motility capsule (WMC) using a standardized protocol. Segmental tran-
sit times were derived from measures around known anatomical landmarks as
identified by compartmental pH changes. Ileal and colonic motility measures are
presented as area under the curve (AUC) derived from contraction amplitude
and frequency. Validated questionnaires evaluating GI (verbal descriptor
anchored visual analog scale (VDVAS) assessing sensory intensity (VDVAS-I)
and unpleasantness (VDVAS-U)) and somatic symptoms (Personal Health
Questionnaire (PHQ)) as well as quality of life (EQ-5D) were administered.
The WMC and questionnaires were repeated after 28 days of dietary interven-
tions. The primary endpoint was change in ileocaecal pH after the intervention.
Secondary outcomes included changes in transit times, contractility and symp-
tom scores.
Results: After screening, 32 patients (23 female, median age 37 years, range
18–65) were randomized. Baseline symptom severity and demographics were
similar between the two groups. Relative to baseline, there was a reduction in
the change in ileocaecal pH with the low FODMAP diet group compared to the
m-NICE group (3.37 0.3 vs 0.0003 0.4, p¼ 0.047) suggesting reduced fermen-
tation. Changes in GI motility are shown in Table 1.
Table 1: Changes in segmental/whole gut transit times and ileal/colonic motility,
relative to baseline between the low FODMAP and m-NICE diets. Both the low
FODMAP and NICE diets improved VDVAS-I and VDVAS-U (18 17 vs.
26 27, p¼ 0.4 and 13.6 26 vs. 29.7 29, p¼ 0.2, respectively). Similarly,
both diets reduced somatic symptoms (2 1.4 vs. 0.8 1.8, p¼ 0.07) and
improved quality of life (9.5 10.2 vs. 4.4 9.8, p¼ 0.23).
Low
FODMAP NICE P value
Change in Gastric emptying
time (minutes)
122 249 7 370 0.5
Change in Small bowel
transit time (minutes)
63 43 33.6 80 0.07
Change in Colonic transit
time (minutes)
512 1425 53 1728 0.53
Change in Whole Gut
Transit time (minutes)
710 1486 35 1588 0.3
Change in Ileal contractility
(AUC)
64 139 114 175 0.5
Change in Colonic contrac-
tility (AUC)
5 58 26 72 0.5
Conclusion: The low FODMAP diet reduces caecal fermentation in comparison
to the NICE diet as indexed by a reduction in the change in pH across the
ileocaecal junction. Both diets improved GI and extra-GI symptoms as well as
quality of life. Neither diet has a demonstrable differential effect on ileal/colonic
contractility or segmental/whole gut transit times. It is therefore plausible that
the efficacy of the low FODMAP diet in IBS-M is via mediated by alterations in
the microbiota.
Disclosure of Interest: A.D. Farmer: Speaker Bureau and Advisory Boards for
Allergan
All other authors have declared no conflicts of interest.
References
1. Bohn et al. Gastro 2015.
2. Eswaran et al. Am J Gastro 2016.
3. McIntosh et al. Gut 2016.
4. Farmer et al. World J Gastro 2014.
5. Ringel-Kulka et al. Am J Gastro 2015.
P1149 ORAL A-GALACTOSIDASE IMPROVES
GASTROINTESTINAL TOLERANCE TO A DIET HIGH IN GALACTO-
OLIGOSACCHARIDES: ADJUNCT THERAPY TO A LOW FODMAP
DIET IN IRRITABLE BOWEL SYNDROME
C. J. Tuck1, K. M. Taylor2, J. S. Barrett1, P.R. Gibson1, J. G. Muir1
1Dept Gastroenterology, Monash University, Melbourne/Australia/VIC
2Dept Gastroenterology, Monash University and Alfred Hospital, Melbourne/
Australia/VIC
Contact E-mail Address: caroline.tuck@monash.edu
Introduction: Galacto-oligosaccharides (GOS) are indigestible short-chain carbo-
hydrates (FODMAPs, fermentable, oligo-, di-, mono-saccharides and polyols)
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associated with triggering gastrointestinal symptoms in irritable bowel syndrome
(IBS).
Aims & Methods: This study aimed to assess whether oral -galactosidase co-
ingestion with foods high in GOS and low in other FODMAPs would reduce
symptoms and breath hydrogen production in a double-blind, placebo-con-
trolled, cross-over trial approved by Monash University Ethics Committee.
Patients meeting the Rome III criteria for IBS who produced410 ppm hydrogen
on two consecutive breath samples following 10 g fructan were recruited.
Participants were randomly assigned to full-dose enzyme (300 GALU -galacto-
sidase), half-dose (150 GALU -galactosidase) and placebo (glucose). Following
a 3-day low FODMAP run-in period, participants consumed provided diets high
in GOS for a further 3-days. Gastrointestinal symptoms were measured daily
using a 100mm visual-analogue-scale. Breath samples were taken hourly on the
second last day and analysed as area-under-the-curve, faecal samples were taken
on the final day.
Results: Thirty-one participants with IBS (20 IBS-D, 4 IBS-C, 7 IBS-M) com-
pleted the study. The addition of high GOS foods resulted in a significant
increase in overall symptoms (median 13.0 [IQR 1.5–22.0] to 35.5 [12.8–54.0]
mm; p¼ 0.000, Wilcoxon signed-rank test). No significant increase in overall
symptoms was seen with the full-dose enzyme (14.0 [3.5–24.0] vs 14.7 [2.3–32.7]
mm; p¼ 0.422). Twenty-one participants exhibited GOS-sensitivity (410mm
increase for overall symptoms). Of those, full-dose enzyme reduced overall symp-
toms (24.5 [17.5–35.8] mm vs 5.5 (1.5–15.0) mm; p¼ 0.006) and bloating (20.5
[9.5–42.0] vs 6.5 [2.0–15.8]; p¼ 0.017). Breath hydrogen production was minimal
with no differences seen between placebo (mean 5248 SD 3339 ppm.12h) and
full-dose (5585 3205; p¼ 0.597, paired samples t-test).
Conclusion: An oral -galactosidase supplement taken with high GOS foods
provides a clinically significant reduction in symptoms in GOS-sensitive indivi-
duals with IBS. The lack of change in breath hydrogen suggests the mechanism
may not be related to reduced gas and distention, rather suggesting a role of
alterations to the microbiota. Future analysis of the faecal microbiota may pro-
vide insight for the mechanism of action. This strategy can be easily translated
into practice to improve tolerance specifically to high GOS foods for patients
with IBS as an adjunct therapy to the low FODMAP diet.
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Introduction: Balloon expulsion testing (BET) is a recommended means of iden-
tifying dyssynergic defecation (DD) in patients with chronic constipation (CC)
but remains poorly standardized and underutilized outside of specialized centers.
We aimed to assess the clinical utility of BET as an initial test for DD and to
determine appropriate testing parameters.
Aims & Methods: We performed a literature search (PubMED, EMBASE,
conference abstracts from 1950–2016) to identify (1) case-control studies
of DD or unselected CC subjects and healthy controls and (2) cohort studies
of unselected subjects with CC. Eligible studies reported BET test parameters
and results as well as presence of DD defined by constipation symptoms and
a positive reference test (anorectal manometry[ARM], defecography, or
electromyography[EMG]). Study quality was assessed using QUADAS criteria.
We extracted age, sex, enrollment criteria, BET test parameters (subject position,
stool surrogate, volume instilled, allowed expulsion time), and DD diagnostic
criteria. Data were independently extracted by two authors. Meta-analysis was
performed using a bivariate mixed-effects regression model. Meta-regression
was performed to evaluate effects of individual test parameters. Between-study
heterogeneity of summary results was assessed using an I2 statistic. Publication
bias was assessed using Deeks’ funnel plot assymetry test.
Results: We identified 15 eligible studies comprising 2,090 individual assessments
of balloon expulsion, of which 14 studies of 1,760 subjects were eligible for cohort
analysis and 15 studies of 1,988 subjects were eligible for case-control analysis.
Among cohort studies, the AUC was 0.80 (95% CI 0.61–0.91) with 70% sensi-
tivity (95% CI 52%-83%) and 77% specificity (95% CI 70%-82%). Among
pooled cohort and case-control studies, the AUC was 0.84 (95% CI 0.68–0.93)
with 70% sensitivity (95% CI 53%-82%) and 81% specificity (95% CI 75%-
86%). Further test performance characteristics stratified by subject position are
reported in Table 1. Subject positioning (seated vs. left lateral decubitus) did not
significantly affect AUC in cohort (p¼ 0.82) or case-control (p¼ 0.43) analysis.
Pooled sensitivity (p¼ 0.50) and specificity (p¼ 0.66) were similar between seated
and left lateral BET in analysis of unselected CC cohort studies, though specifi-
city was higher with left lateral BET in pooled analysis of all studies (p¼ 0.03).
The allowable time for balloon expulsion did not significantly affect summary
sensitivity (p¼ 0.92) or specificity (p¼ 0.96) in meta-regression within the eval-
uated range of 1 and 5 minutes. While there were not enough studies to warrant
meta-analysis of balloon distension characteristics, 13 of 17 studies instilled 50–
60mL of water. When pooling cohort and case-control studies, both age
(p5 0.01) and gender (p5 0.01) appeared to influence test performance.
Choice of reference test did not significant affect test performance (ARM
[p¼ 0.35], defecography [p¼ 0.43], or EMG [p¼ 0.08]). Continent of origin
(p¼ 0.34) and year of study (p¼ 0.29) did not appear to significantly influence
test performance. There was no evidence of publication bias (p4 0.5).
Table 1: Sensitivity and specificity of balloon expulsion testing in diagnosing
dyssynergic defecation (stratified by subject positioning with 95% confidence
intervals)
Summary test
characteristic Seated position
Left lateral
position
Case-control and cohort studies (optimal estimates)
Sensitivity 69% (54% to 85%) 54% (7% to 100%)
Specificity 81% (76% to 86%) 90% (79% to 100%)
Only cohort studies evaluating unselected subjects with constipation
(real world estimates)
Sensitivity 69% (53% to 86%) 76% (70% to 83%)
Specificity 54% (6% to 100%) 76% (51% to 100%)
Conclusion: The performance characteristics of balloon expulsion could support
use as an office-based point-of-care test to screen for dyssynergic defecation in
chronically constipated subjects.
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Introduction: Anal squamous intraepithelial lesions are precancerous lesions of
anal squamous cell carcinoma and are largely related to human papillomavirus
infection. Immunosuppressed patients have a higher prevalence of these lesions.
There are some studies in renal transplant recipients, but no information exists
regarding prevalence in liver transplantation.
Aims & Methods: Our aim was to evaluate the prevalence of anal squamous
intraepithelial lesions in liver transplant recipients compared with healthy sub-
jects. This was a prospective case-control study involving liver transplant recipi-
ents that were compared with a healthy control group. All patients were
submitted to anal cytology. Those with abnormal cytological results, namely
high-grade squamous intraepithelial lesions (HSIL), atypical squamous cells
which cannot exclude high-grade squamous intraepithelial lesions (ASC-H),
low-grade squamous intraepithelial lesions (LSIL) and atypical squamous cells
of undetermined significance (ASC-US), were submitted to high-resolution ano-
scopy with biopsies of any suspicious lesion.
Results: A total of 59 liver transplant recipients and 57 controls underwent anal
cytology. In the liver transplant group, 37 (63%) were men, with a mean age of
54 10 years. The most common indication for transplantation was alcoholic
cirrhosis in 26 patients (44%), the majority of the patients were only on tacro-
limus (n¼ 23, 39%) and had been transplanted a mean of 8 5 years ago. In the
healthy control group, 36 (63%) were men, with a mean age 59 11 years.
Regarding anal cytology, 10 (17%) of liver transplant recipients had abnormal
results, 7 patients had ASC-US, 1 patient ASC-H and 2 patients HSIL. In the
control group only 1 patient (2%) had an ASC-US result (p¼ 0.005). Anal
squamous intraepithelial lesions were confirmed in 7/10 of liver transplant
patients and 0/1 in control group (p¼ 0.013) by high-resolution anoscopy with
biopsies. Smoking was the only risk factor for abnormal anal cytology (OR¼ 5.9,
95%CI¼ 1.224–28.121, p¼ 0.027).
Conclusion: Liver transplant patients have a higher risk of anal squamous intrae-
pithelial lesions and screening should be considered especially in smokers.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Gastrointestinally mediated food allergy (GMA) is a common dis-
ease, whose prevalence has risen in recent years. The scientific research on this
disease has increased, however its diagnosis still remains difficult to date.
Diamine oxidase (DAO) is an enzyme that deactivates histamine, the main med-
iator in allergic reactions, through oxidative deamination. It has been shown that
the enzymatic activity of DAO is diminished in the colonic mucosa of patients
with GMA. Up to now no studies concerning the expression of DAO in the upper
gastrointestinal tract (GIT) of patients with GMA have been published.
Therefore, the objective of this study was to analyse the immunohistochemical
staining of DAO and its localisation in the upper GIT of patients with or without
GMA.
Aims & Methods: The study was retrospective. The GMA group consisted of 21
patients with diagnosed food allergy. The control group (CG) included 17
patients with neither food allergy nor food intolerance. Tissue samples from
esophagus, cardia (subdivided in esophageal and gastric region), corpus,
antrum and duodenum already obtained during endoscopy were immunohisto-
chemically stained for DAO. The expression of DAO was semi-quantitatively
analysed with the following scale based on the staining intensity of DAO (SI-
DAO): 0¼none, 1¼ low, 2¼medium, 3¼high intensity. The localisation of
DAO was also examined vertically from the epithelium to the submucosa in all
tissues. The analysis was performed twice by the same examiner in two separate
points of time. Furthermore, the tissue samples were immunohistochemically
stained for MBP and CD117 in order to count the number of eosinophils and
mast cells respectively. Two measurements were performed inside an area of
100mm2 in the lamina propria (LP); one in the subepithelial superficial lamina
propria (SLP) and one in the deeper lamina propria (DLP). The average of these
two measurements constituted the number of these cells for each tissue.
Results: Immunohistochemical analysis found DAO in all segments of the upper
GIT, but the SI-DAO was overall low. Across the upper GIT the median SI-
DAO in the CG was 1.1 (range 0.9–1.3). The SI-DAO did not differ between the
examined tissues. The SI-DAO was also low in the GMA group (median 1.0;
range 0.8–1.3) and it was statistically significantly lower compared to the controls
(median: 0.8 vs. 1.1; p¼ 0.04) only in duodenum. In the GMA group the SI-DAO
in the esophageal region of the cardia and in corpus was significantly higher than
in duodenum (see Table 1). The strongest DAO-staining was detected in the
subepithelial lamina propria (SLP) of all tissues. A strong inverse correlation
of SI-DAO with the number of eosinophils across the upper GIT was observed
only in the GMA group (r¼ -0,89, p¼ 0,02). An inverse correlation of the SI-
DAO with the number of mast cells was also observed in both groups, but this
result was not statistical significant (GMA: r¼ -0.71, p¼ 0.11; CG: r¼ -0.6,
p¼ 0.14).
Table 1: SI-DAO in the upper GIT. P1-Value: comparison between GMA and
control group. P2-Value: comparison of the SI-DAO in duodenum with the other
segments of the upper GIT in the GMA-group. N¼ number of tissue samples
Group Parameter Esophagus
Cardia
-esophageal
region
gastric
Cardia Corpus Antrum Duodenum
GMA
Group
N 9 10 8 18 18 18
Median 1.3 1.1 1.1 1.2 1.1 0.8
25th Percentile 0.8 0.8 0.8 0.7 0.7 0.4
75th Percentile 1.5 1.3 1.1 1.5 1.4 1.3
Control
Group
N 8 9 8 15 14 11
Median 1.3 1.2 1.3 0.9 0.9 1.1
25th Percentile 1.1 1.0 0.9 0.8 0.7 1.0
75th Percentile 1.7 1.4 1.6 1.2 1.1 1.5
P1 - Value 0.33 0.41 0.46 0.29 0.28 0.04*
P2 - Value 0.07 0.01* 0.06 0.02* 0.16 x
Conclusion: The above findings indicate that DAO is present in low amounts in
all segments of the upper GIT. But only in the duodenum a significant difference
was found between GMA and CG, thus indicating that histamine-mediated
symptoms most likely arise in duodenum. Therefore, regarding the upper GIT,
the immunohistochemical staining for DAO only in duodenum could serve as an
additional diagnostic parameter for detecting patients with GMA and possibly
other histamine-mediated diseases. The above mentioned distribution pattern of
DAO strengthens the theory that DAO acts extracellularly and is responsible for
the elimination of the transepithelially absorbed exogenous histamine as well as
of the endogenous histamine, as its highest staining intensity is found at the SLP
throughout the upper GIT.
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Introduction: Chronic atrophic gastritis (CAG) is claimed to be a pre-cancerous
condition for gastric cancer, being serological markers like serum pepsinogens
and gastrin-17 (G17) proposed as non-invasive useful tools. OLGA histological
classification has been proposed as of prognostic value. Aim of the study was to
assess, by using serological markers, the prevalence of CAG in general popula-
tion and to correlate the results with OLGA classification.
Aims & Methods: One thousand and nine hundred consecutive patients (M¼ 915;
mean age¼ 53.5, range¼ 27–82) showing upper-gastrointestinal (GI) troubles
entered the study. Exclusion criteria were: previous history of upper-GI neo-
plasms, previous surgery, concomitant Proton Pumps Inhibitor (PPI) therapy.
All patients underwent a blood sample for GASTROPANEL (BioHit Oyj,
Finland) based on: pepsinogen I (PGI), pepsinogen II (PGII), gastrin-17
(G-17) and IgG against Helicobacter pylori. (Hp-IgG). The normal values are:
PGI: 30–120 mg/L, PGII: 2–15 mg/L, G-17: 1–9 pmol/L, Hp-IgG: 530 EIU,
respectively. Low levels of PGI (PGI5 30 mg/L) as well as high levels of G-17
(G-174 15 pmol/L) were considered diagnostic for CAG. Eighty-three patients
with serology suggestive for CAG underwent upper endoscopy and histology
according with OLGA staging. The relationship between PGI, G-17 and the
different OLGA stages was statistically analyzed.
Results: Eighty-three (M¼ 44, mean age¼ 61, range¼ 49–82) out of 1900 inves-
tigated patients showed CAG (4%). Out of the 83 CAG patients, 19.2% was
classified as OLGA 2, 56.6% as OLGA 3 and 24.2% as OLGA 4. The relation-
ship between PGI levels and OLGA stage shows a statistically significant differ-
ence between the stages OLGA 0, 1, 2 and the stages 3 and 4 (PGI mean values:
OLGA 0: 72.45 mg/L, OLGA 1: 85.95 mg/L, OLGA 2: 47.38 mg/L, OLGA 3:
16.00mg/L, OLGA 4: 10.10 mg/L; p5 0.001). The relationship between OLGA
stages and G-17 serum levels shows a statistically significant difference (G-17
mean values: OLGA 0: 4.6 pmol/L, OLGA 1: 5.2 pmol/L, OLGA 2: 26.5 pmol/L,
OLGA 3: 44.6 pmol/L, OLGA 4: 38.5 pmol/L; p5 0.01 by comparing OLGA
0–1 against OLGA 2–4) (p5 0.02).
Conclusion: The prevalence of CAG assessed by serological markers is low in the
studied population (4%). The majority of patients (56.6%) were classified in the
OLGA 2 stage. Both PG1 and G-17 showed a statistical significant relationship
with the more severe degrees of CAG.
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Introduction: Chronic atrophic gastritis (CAG) is considered to be a precancerous
condition of gastric cancer; it is either autoimmune in origin or caused by infec-
tion with Helicobacter pylori. The majority of CAG patients are asymptomatic or
experience aspecific manifestations like epigastric fullness, early satiation,
nausea, bloating. The drugs currently used for upper gastrointestinal (GI) dis-
eases, mainly proton pump inhibitors (PPIs), appear inappropriate in such
patients, mainly because acid production is virtually lacking. The use of
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L-cysteine has been proposed as adjuvant therapy in CAG; the amino acid binds
covalently to acetaldehyde (a Group I human carcinogen), removing it from the
stomach. The aim of present study was to use L-cysteine to improve the symp-
toms in patients with diagnosis of CAG.
Aims & Methods: One hundred fourteen consecutive patients (M¼ 43, mean
age¼ 52.5 yr, range¼ 31–69 years) (with histological diagnosis of CAG by
means of both gastric histology (moderate to severe chronic, atrophic, body
gastritis according to the OLGA staging system) and serology (pepsinogen 1
525 mg/l; gastrin-17 414 pmol/l - GastroPanel, Biohit Oyj, Finland) entered
the study. Forty-one patients (11 M, mean age 49.4 yr, range 27–71 years) were
treated with L-cysteine (100mg 3 times daily, with meals) for 24 months (Group
1). As a control group we enrolled 73 CAG patients (M¼ 32, mean age¼ 55.3 yr,
range¼ 32–77 yrs) followed up for 24 months without any related therapy
(Group 2). Symptoms (epigastric fullness, early satiation, nausea, bloating)
were recorded at baseline and after 3, 6, 12, 24 months, according to severity
score (0–3 for each symptom, min. 0¼no symptoms; max. 12¼ full
symptomatic).
Results: The global symptomatic score results as follows, lasting the 24 months
follow-up. Group 1: baseline 4.93; 3 months 3.36; 6 months 2.96; 24 months 2.64.
Group 2: baseline 5.9, 3 months 6.2, 6 months 5.6, 24 months 5.8 (p5 0.01).
Subdividing the CAG patients according to the etiology (autoimmune gastritis or
previous Helicobacter pylori infection) no differences were found in improving
symptoms. No relevant side effects were observed during the study.
Conclusion: The administration of L-cysteine to subjects affected by moderate–
severe chronic atrophic gastritis seems able to improve the symptoms in a two-
year follow-up.
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Introduction: Despite undergoing potentially curative resection a significant pro-
portion of patients develop cancer recurrence. Several cellular and humoral com-
ponents of systemic inflammatory response have been reported and associated
with poor outcome. To date, no study has comprehensively examined the rela-
tionship between readily available markers of inflammation and survival in gas-
tric cancer.
Aims & Methods: Patients undergoing surgery for stage I-III gastric cancer
between 2004–2016 at a regional unit were identified. Measurements of various
systemic inflammation markers were recorded pre-operatively. Pathological fac-
tors were recorded from reports issued at the time of resection. The modified
Glasgow Prognostic Score (based on CRP and Albumin), Neutrophil-
Lymphocyte Ratio, Platelet-Lymphocyte Ratio and Neutrophil-Platelet score
were calculated. Pathological variables including TNM stage, differentiation
and vascular invasion were also recorded. Survival endpoints of overall survival
(OS) and disease-free survival (DFS) were used.
Results: 331 patients were identified and 291 patients underwent potentially
curative resection for gastric cancer. On univariable DFS analysis, female
gender, proximal location, T-stage, N-stage, TNM, vascular invasion, poor dif-
ferentiation, lymph node ratio, R1 status, platelet count and mGPS were signifi-
cantly associated with poor survival. On multivariable DFS analysis, mGPS
(Hazard Ratio (HR) 2.51 95% Confidence Interval (CI) (1.35–4.65); p¼ 0.011)
was the only inflammatory marker to retain independent significance. This was
also observed in OS with mGPS (HR 2.75 (95%CI 1.65–4.59); p5 0.001). The
mGPS was associated with advanced T-stage (p¼ 0.001), TNM stage (p¼ 0.013)
and poor differentiation (p¼ 0.030).
Conclusion: The mGPS was the only inflammatory based marker to indepen-
dently predict poor DFS and OS and may represent the optimum method for
systemic inflammatory response quantification.
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Introduction:Upper gastrointestinal bleeding (UGIB) is one of the main causes of
hospital admission and urgent endoscopy in Gastroenterology departments.
In-hospital mortality from UGIB has decreased throughout the past 2 decades
with a corresponding increase in the performance of endoscopy and endoscopic
therapies. This may suggest that improvements in the therapeutic procedures for
patients with UGIB could be responsible of the mortality decline. Despite this,
UGIB represents a true emergency, associated with significant morbidity,
mortality and healthcare costs. Furthermore, rebleeding after initial endoscopic
therapy is observed in 10–20%, and it has been associated with a higher mortality
rate. Therefore, the definition of predictive factors for rebleeding is of outstand-
ing importance.
Aims & Methods: The aim of our study is to analyze risk factors and outcomes in
a population of patients who suffered rebleed. We present a retrospective study
on a prospectively built database of patients with GI bleeding admitted to the
Emergency Room of ‘‘Virgen de las Nieves’’ University Hospital over 42 months,
from January 2013 to July 2016. All patients underwent upper endoscopy, and
information regarding patients’ demographic data, comorbidities, current medi-
cations (including antiplatelet drugs, NSAIDS and oral anticoagulants), clinical
presentations, hemodynamics, admission laboratory test results, and endoscopic
findings was collected. Interventions were documented, including the need for
blood transfusion and the number of packed red cells units per patient, endo-
scopic therapy, interventional radiology procedures, and surgery. Clinical out-
comes documented were in-hospital and delayed 6-months mortality, rebleeding
and delayed 6-months bleeding and cardiovascular events.
Results: 507 patients were included (339 males; aged 64.21 16.4). The incidence
of rebleeding was 17.3% (n¼ 88). In the univariate analysis, factors related with
rebleeding were creatinine levels (1.52 vs. 1.15; p5 0.001), tachycardia (96.28 vs.
88.24; p5 0.001), low levels of albumin (2.80 vs. 3.238; p5 0.001) and low
systolic blood pressure (103 vs. 113; p5 0.001). In a logistic regression analysis
tachycardia and high creatinine were independent risk factors for rebleeding, and
albumin showed as an independent protective factor (Table 1). Rebleeding was
associated with in-hospital mortality (p5 0.0001); by contrast, it was not related
nor with delayed 6-months mortality, neither with delayed cardiovascular and
hemorrhagic events. The UGIB risk scores AIMS 65 and Rockall showed poor
predictive ability for acute mortality in the rebleeding patients’ group and was
similar for Blatchford score (based on AUROc).
Exp (B) IC 95% P
PULSE 1.021 1.007–1,034 0.003
ALBUMIN 0.406 0.267–0.618 0.000
CREATININ 1.403 1.079–1.824 0.012
Conclusion: Rebleeding in UGIB is associated with increased in-hospital mortal-
ity; nevertheless, it is not related with delayed 6-months mortality, hemorrhagic
and cardiovascular events. High creatitinine and low albumin levels were inde-
pendent risk factors for rebleeding, suggesting a potential predictive role of these
parameter. AIMS65, Rockall and Blatchford were predictors for in-hospital
mortality but worked poorly in the patients who suffered rebleeding.
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Introduction:Upper gastrointestinal (GI) adverse effects induced by NSAIDs and
anti-thrombotic drugs are increasing along with progressive aging of society.
Recently it is essential to perform pharmaco-epidemiological studies to identify
adverse effects in the real-world setting using a large-scale medical database. We
conducted a case-control study on the risk of upper GI mucosal injuries in
subjects prescribed NSAIDs and anti-thrombotic drugs using the large organized
database of claims in Japan.
Aims & Methods: The medical claims database developed by Japan Medical Data
Center (JMDC) Co., Ltd. was selected as data source in the present retrospective
observational study. The JMDC claims database comprised of integrated medical
and pharmacy claims, and includes both hospital and outpatient care from over
90 payers (approximately 3.7 million of population on an accumulated basis).
Eligible subjects were aged 20 to 74 and registered for at least 3 months in the
database from January 2009 to December 2014. The evaluated upper GI mucosal
injuries were peptic ulcers (143,271 cases), upper GI bleeding (10,545 cases) and
gastroesophageal reflux disease (GERD: 154,755 cases) with diagnosis by ICD-
10 codes and implementation of the upper GI endoscopy. For the each test-case,
ten controls who matched age, sex and diagnosis month were identified from the
database. Multivariate logistic regression analysis was used to calculate odds
ratios of occurrence of each upper GI mucosal injuries caused by NSAIDs,
COX-2 selective inhibitors, low-dose aspirin, antiplatelet drugs (except low-
dose aspirin) and anticoagulants.
Results: The odds ratios of peptic ulcers were 1.45, 1.31, 1.50, 1.53 and 1.62 for
NSAIDs, COX-2 selective inhibitors, low-dose aspirin, antiplatelet drugs, and
anticoagulants, respectively. All the medicines significantly affected the occur-
rence of peptic ulcers (p5 0.0001 in each). The odds ratios of upper GI bleeding
were 1.76, 1.62, 1.96, 1.82 and 2.38, and those of GERD were 1.54, 1.41, 1.89,
1.67 and 1.91, and these odds ratios were statistically significant in each medicine
with GI bleeding and GERD (p5 0.0001 in each). The odds ratios of all the
upper GI mucosal injuries were the highest in the patients with anticoagulants,
and the ratios were relatively low in those with NSAIDs and COX-2 selective
inhibitors. The odds ratios tended to increase with the number of prescribed
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medicines (1 agent52 agents53 agents, peptic ulcers: 1.385 2.495 4.52, upper
GI bleeding: 1.745 3.955 7.77, GERD: 1.615 2.965 5.88, respectively). The
upper GI mucosal injuries were exacerbated in complication of lifestyle-related
diseases, including hyperlipemia and diabetes mellitus.
Conclusion: Prescribing NSAIDs and anti-thrombotic medicines was associated
with increased risks of developing upper GI injury. The present case-control
study utilizing the large organized database of claims in Japan provided precise
clinical evidence for safety management of medical drugs in the clinical settings in
Japan.
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Introduction: Percutaneous left atrial appendage occlusion (LAAO) is increas-
ingly recognized as valid alternative therapy to reduce thrombo-embolic risk in
patients with non valvular atrial fibrillation (AF) and contraindications for long
term oral anticoagulation (OAC) therapy1,2. Patients at high thromboembolic
risk with previous gastrointestinal bleeding (GIB) might be at risk of bleeding
recurrence in case of resuming anticoagulation. They could be selected for alter-
native therapies like LAAO. Up to now, there is no scientific consensus for
patient selection for LAAO based on recurrent GIB risk.
Aims & Methods: We aimed to review the literature on gastrointestinal (GI)
bleeding recurrence and proposed to define the reversibility profile of each
lesion in an organ by organ and lesion by lesion approach to stratify the risk
of bleeding individually. We systematically collected data from both prospective
and retrospective studies from pubmed in order to extract rebleeding risk by
etiology. The reversibility profile was defined by type of treatment needed to
cure the lesion. Low reversibility (LR) profile was defined as a need for heavy
treatment (surgery, radiotherapy, embolisation) to cure the lesion or as diffuse
lesions.
Results: The most frequent reported causes of bleeding are peptic
gastroduodenal ulcer (60%) for upper GI, diverticulosis (40%), colitis (20%)
and anorectal diseases (20%) for lower GI and angiodysplasia (23%) for the
midgut, these latters being responsible for 5% of all GI bleeding causes. The
rate of reccurent GI bleeding under OAC therapy is 5–7% with vitamin K
antagonists (VKA), an incidence that might increase with direct OAC.
Recurrent bleeding rates for upper GIB, lower GIB and obscure GIB are respec-
tively 5–7%, 16%, and 40.3%.
In the upper GI tract, lesions at high risk of bleeding reccurence are Dieulafoy
lesions and angiodysplasia with reported rates up to 40% in some series. In the
lower GI tract, lesions at highest risk are diverticular disease, angiodysplasia,
colitis and radiation rectitis with bleeding recurrence rates reaching 60%, 20%,
40% and 20% respectively. For the midgut, angiodysplasia (20%) and bleeding
of unknown origin (20%) are associated to the highest risk of reccurent bleeding.
LR profile lesions with high rebleeding risk are present for diffuse angiodyspla-
sia, colonic diverticulosis and Dieulafoy lesions.
Conclusion: In conclusion, GI lesions at high risk of reccurent bleeding with low
reversibility profile are infrequent and include in particular: diffuse angiodyspla-
sia, colonic diverticulosis and Dieulafoy lesions. Patients with AF having those
lesions with GIB under anticoagulation might be the best candidates for alter-
native therapies like LAAO. Larger studies are needed to assess the long term
outcome of patients treated by LAAO for GIB under current oral anticoagulant
therapies.
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Introduction: Peptic ulcer disease (PUD) accounts for 25–56% of acute upper
gastrointestinal bleeding (AUGIB) and is associated with high mortality.
Aims & Methods: In line with international guidelines, we aimed to audit our
practice of bleeding PUD at a district general hospital within the West Midlands,
UK. We retrospectively identified all patients with AUGIB who had inpatient
endoscopic confirmation of PUD between November 2012–2014. We scrutinised
all endoscopy and case records to assess management related to PUD, in addition
to follow-up records with the general practitioner.
Results: We identified 91 patients (median age 78.4, 65.9% male), of whom
63.7% were admitted with AUGIB, whereas 36.3% developed bleeding during
their inpatient stay. The majority were duodenal (74.7%) vs. gastric (25.3%).
31.8% were related to aspirin/non-steroidal anti-inflammatory drug use.
48 (52.7%) had high risk (Forrest 1a-2b) lesions, of whom 38/48 (79.2%) received
dual endoscopic therapy and 6/48 (12.5%) received adrenaline monotherapy.
18.8% received the recommended adrenaline volume of 13ml. Of 90% prescribed
intravenous proton pump inhibitor infusion, 85% did not complete the full
72-hour duration. Rebleeding occurred in 12 patients (13.2%) after a median
of 3-days post endoscopy. 10 (83.3%) underwent repeat OGD, 2 (16.7%) under-
went CT embolisation, whilst 3 (25.0%) underwent surgery. Aspirin resumption
was observed in 4/20 (20.0%) after haemostasis for PUD, whilst rebleed planning
was documented on the endoscopy report in 33.0%. Regarding H. pylori, 51%
underwent assessment with serology/biopsy. 10 (36%) had positive results, of
whom 7 (70%) received eradication. 12/23 (52.2%) patients underwent follow-
up endoscopy following gastric ulcer. The median transfusion requirement per
patient was 2 units. Despite this, rates of anaemia at discharge and at 6 months
were high at 83.5% and 62.9% respectively, with iron therapy initiated in 12.1%.
Overall, our 30-day mortality rate was 12.1%.
Conclusion: In this single-centre study, the management of PUD could be
improved in multiple areas in line with international guidelines. Audits in
other centres are required to quality assure the management of PUD.
Interestingly, rates of anaemia at discharge and on follow-up are high. Such
patients may benefit from iron replacement at discharge.
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Introduction: In nonvariceal upper GI bleeding (NVUGIB) patients, it is impor-
tant to predict the risk early and to take appropriate medical treatment. Recently,
the AIMS65 score has been used to make simple predictions.
Aims & Methods: The aim of this study is to compare the risk stratification of
each predictor by comparing AIMS65 score with Glasgow-Blatchford score
(GBS), full Rockall score and pre-endoscopic Rockall score. We retrospectively
studied patients who visited the Sanggye Paik Hospital with NVUGIB between
2013 and 2016. Among these, AIMS65, GBS, and Rockall scores were measured.
The primary outcome was inpatient mortality, and secondary outcomes were
rebleeding, needs of endoscopic intervention, requirement of transfusion, inten-
sive care unit (ICU) admission. Each scoring system and prognostic factors were
compared using the ROC curve.
Results: In this study, 17 of the 512 selected patients died, and re-bleeding was
confirmed in 30 patients. AUROC between AIMS 65 and mortality was mea-
sured at 0.844 higher than 0.721 and 0.743/0.749 for GBS and pre-endoscopic/
full Rockall score. (p5 0.001) For AUROC for secondary outcomes, AIMS 65
was superior to other scores in predicting the ICU admission (0.728, p5 0.001).
There was no significant difference in the superiority of each scoring system by
pairwise comparison. GBS was superior to other scores for predicting blood
transfusion requirement. (p5 0.0001)
Conclusion: The AIMS65 score in NVUGIB patients was not inferior to other
scoring systems in predicting the prognosis, such as mortality and ICU admission
rate. At the emergent department, we recommend using AIMS65 which is easier
to access than other scoring systems.
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Introduction: There are several risk-scoring systems are available to assist the
management of upper gastrointestinal bleeding (UGIB). The aim of this study
is to compare the performance of pre-endoscopy (pre-RS), post-endoscopy
Rockall score (post-RS), GBS and AIMS65 scores in predicting the need for
interventions and outcomes in patients admitted to hospital for UGIB.
Aims & Methods: Data related to the three scoring systems were collected pro-
spectively and scores calculated in consecutive patients who were admitted with
acute UGIH to the Royal Adelaide Hospital over 24 months. The performance
of these scores, using operating characteristic (ROC) curves, in predicting the
following outcomes was assessed:the need for endotherapy, rebleeding risk,
transfusion requirement, surgical intervention and death. All patients received
high dose acid suppression therapy.
Results: Of the 777 patients (491M; 66.4 0.6yrs) who presented with UGIB, 622
(402M; 65.7 0.6yrs) underwent endoscopy with 123 (38%) required endoscopic
therapy, 42 (13%) repeated endo-therapy and 12 (3.7%) surgery for haemostasis.
155 (89M; 68.8 0.6yrs) patients were treated conservatively due to medically
unfit (n¼ 50), low suspicion (n¼ 25), known diagnosis (n¼ 17), and suspected
MWT (n¼ 28). Death occurred in 33 (8%) patients, of which 10 (2.4%) were
related to bleeding. Patients who required endoscopic or surgical intervention
had higher GBS, pre-ERS, post-ERS and AIMS65 scores (P5 0.001). On ROC
analyses, GBS and post-RS were superior to pre-RS and AIMS65 in predicting
the need for (1) endotherapy (AUC: 0.75 and 0.78 vs. 0.65 and 0.59, P5 0.01),
(2) repeated endoscopy due to re-bleed (AUC: 0.66 and 0.65 vs. 0.56 and 0.60,
P¼ 0.03), and (3) blood transfusion (AUC: 0.83 vs. 0.72 and 0.70, P5 0.01).
The scoring systems performed equally well in predicting the need for surgery
(GBS vs. Rockall vs. GBS AUC: 0.72 vs. 0.67 vs. 0.71) and death (AUC: 0.75 and
0.72 vs. 0.69).
Conclusion: Although GBS performs equally well for predicting need of surgery
and death, it is superior to both Rockall and AIMS65 scores in predicting the
need for endotherapy, repeated endoscopy, and blood transfusion in patients
with acute UGIH. These findings suggest that GBS is the best performed risk
scoring system in the evaluation of patients with UGIB.
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Introduction: Hemorrhagic gastroduodenal ulcer is commonly seen in routine
clinical practice, and there have been many studies investigating risk factors
for rebleeding. However, few studies have evaluated hemorrhagic gastric ulcers
(HGUs) and hemorrhagic duodenal ulcer (HDUs) separately. Furthermore, the
relation between steroid administration and rebleeding in hemorrhagic gastro-
duodenal ulcer remains unclear.
Aims & Methods: The aim of this study was to clarify the difference of rebleeding
between HGU and HDU, and associated factors for rebleeding of HGU and
HDU. Between March 2005 and September 2016, 176 consecutive patients with
hemorrhagic gastroduodenal ulcer (106 with HGU and 70 with HDU), who
underwent endoscopic hemostasis, were enrolled in this study. Regular dose
proton pump inhibitor was administrated to all patients after the diagnosis of
hemorrhagic gastroduodenal ulcers. Rebleeding was defined as hematemesis or
melena with ulcers confirmed by endoscopy or a decrease in the hemoglobin level
42 g/dl in the presence of endoscopically proven ulcers. First, we compared the
rebleeding rate between HGU and HDU. Subsequently, associated factors for
rebleeding of HGU and HDU were calculated by logistic regression analysis
individually. The estimated factors were age (565/65 years), gender, location
of ulcer (upper third/middle or lower third in HGU and 2nd portion/bulbs in
HDU), underlying comorbidities (ischemic heart disease, liver cirrhosis, hyper-
tension, diabetes mellitus, and hyperlipidemia), number of ulcers (multiple/
single), hemostasis method (pure ethanol injection therapy/other therapies), anti-
platelet therapy, anticoagulant therapy, NSAIDs administration, steroid admin-
istration, antacid administration in the initial ulcer bleeding, hypoalbuminemia
(serum albumin level 2.5 g/dl), and hemodialysis. We further investigated the
detailed association between steroid administration and rebleeding in HDU,
including dose-response relation.
Results: The rebleeding rate of HGU and HDU were 5.7% and 22.9%, respec-
tively, which was statistically significant (P¼ 0.001). There was no missing data
in the estimated factors. Although no factor was associated with rebleeding in
HGU, multivariate logistic regression analysis revealed that the independent risk
factors for rebleeding in HDU were multiple ulcers [odds ratio (95% confidence
interval)¼ 24.2 (2.76–213), P¼ 0.004], steroid administration [14.0 (1.73–113),
P¼ 0.013], and hemodialysis [9.53 (1.00–90.7), P¼ 0.049]. Regarding the detail
of steroid administration, multivariate analysis showed that middle or high ster-
oid administration (20mg in prednisolone) (52.7 [3.19–871], P¼ 0.006) was a
significant risk factor for rebleeding of HDU, with a dose-response relation (P
for trend¼ 0.015).
Conclusion: HDU developed significantly higher rebleeding after endoscopic
hemostasis, compared with HGU. In addition to multiple ulcers and hemodia-
lysis, we firstly demonstrated by multivariate analysis that steroid administration
is an independent risk factor for rebleeding of HDU after endoscopic hemostasis,
with a dose-response relation.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1163 EFFICACY AND SAFETY OF BIO-INSERT MINERAL
SMECTITE IN CONTROLLING GASTROINTESTINAL
HEMORRHAGE: AN ANIMAL PILOT STUDY
J. Wang1, L. Zhao2, M. Wang1, L. Liu2, Z. Fan2, X. Wang2
1The First Affiliated Hospital with Nanjing Medical Universtiy, Nanjing/China
2Digestive Endoscopy Center, the First Affiliated Hospital of Nanjing Medical
University, Nanjing/China
Contact E-mail Address: kit9178@sina.com
Introduction: Gastrointestinal bleeding is common in clinics, especially after
endoscopic operation. Besides from hemoclips, APC or electrocoagulation,
more novel hemostasis approaches should be developed to improve endoscopic
bleeding management. Granular smectite is bioinert mineral and efficient for
curing diarrhea. Inspired by its dehydration and tissue-covering effect, this
pilot study was to investigate its efficacy and safety for controlling hemorrhage
in rats.
Aims & Methods: 32 rats were divided into four equal groups. For hemorrhage
model, a horizontal 10-mm incision was made on the lower part of the left
hepatic lobe. Commercial hemostatic powder, smectite, starch and normal
saline were respectively applied. Bleeding duration and blood loss were recorded.
1 week later, rats were sacrificed and liver tissue was collected for histopathology.
Results: Smectite demonstrated the best hemostasis effect, and its mean coagula-
tion time was 1.45 0.026min. Commercial hemostatic chitosan styptic powder
need 2.5 0.04min for complete clotting, while Starch group was
4.275 0.056min and normal saline group was 4.925 0.108min (p5 0.05).
Similarly, smectite led to less loss of blood (0.6188 0.034 g), while rats lost
2.3288 0.123 g blood (p5 0.05) under normal saline treatment. For starch
and commercial chitosan, the blood loss was respectively 2.0862 0.061 g and
1.2325 0.028 g. Histopathologic results confirmed that smectite was biocompa-
tible to tissue.
Conclusion: The mineral smectite powder was the superior candidate for hemos-
tasis treatment in vivo. Compared with common polysaccharide agents, smectite
could induce faster coagulation and reduce blood loss. More importantly, bioi-
nert smectite was biocompatible and even promoted the wound healing. For
gastrointestinal application, smectite powder could be delivered through endo-
scopic spray tube, while its inspiring efficacy required more endoluminal hemos-
tasis tests.
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Introduction: Life-threatening bleeding could occur early after variceal sclerother-
apy in cirrhotic patients.
Aims & Methods: We aimed to determine simple predictive factors of this com-
plication in cirrhotic patients. Among 750 patients treated with variceal scler-
otherapy (esophageal varices (EV), n¼ 655, 87.3%) and (gastric varices (GV),
n¼ 95, 12.7%) Zagazig University hospital–endoscopy unit- Internal medicine
department, in the period from October 2014 till July 2016. 150 patients (20%,
mean age 46.2 9.4 years) (EV¼ 129, GV¼ 21) developed bleeding due to scler-
otherapy induced ulcers confirmed by endoscopy 6.4 2.1 days after the proce-
dure. Cirrhosis was post viral hepatitis C (89%), hepatitis B (10%) and
cryptogenic in (1%). A case-control study was performed comparing these
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patients with 150 patients who underwent endoscopic variceal sclerotherapy
without the development of bleeding due sclerosant ulceration.
Results: Bleeding occurred 6.4 2.1 days (2–10) following sclerotherapy. Twenty-
three patients died following the bleeding (15.3%). Using a multivariate analysis;
pre-procedural factors as serum albumin 2 g/dl [OR 1.3], total bilirubin
41.6mg/dl [OR 1.5], high platelet ratio index (APRI) 41 [OR 1.2], low pro-
thrombin concentration 550% [OR 1.5]. Intra-procedural factors as amount of
ethanolamine 415.5ml [OR 2.6], amacryate 43.5ml [OR 2.9]. Post- procedural
factors within 24 hours after endoscopy: leucocytosis412,000 cell/ul [OR 1.9],
drop of hemoglobin 410% of the pre-endoscopic value [OR 3.2], prolonged
INR4 1.55 [OR 1.2].
Conclusion: Bleeding related to sclerosant ulcers is not uncommon, but may be
life threatening. The proposed predictive factors should be watched and mini-
mized before and during variceal sclerotherapy
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Introduction: Few studies were reported on the association between sleep disor-
ders and Rome III-based functional dyspepsia (FD).
Aims & Methods: The aim of this study is to investigate the prevalence of sleep
disorders in FD patients and the risk factors associated with sleep disorders. This
multicenter, cross-sectional study had been conducted from August 2014 to
December 2016 at 6 hospitals in Korea. Inclusion criteria were FD patients
(18years) met the Rome III criteria among the patients visited the gastroenter-
ology department for dyspepsia. Exclusion criteria were prior surgery to the
upper gastrointestinal tract, history of ulcer disease, erosive GERD, history of
malignancy, and severe comorbidity. Healthy control group who had no clinical
history of gastroduodenal related disorder and no abnormal finding on endo-
scopy recruited from health examination center for screening. The Pittsburgh
Sleep Quality Index was used to assess sleep disturbance. Hospital anxiety and
depression scale was used to identify anxiety and depression.
Results: This study included 160 FD patients and 223 healthy control groups.
The total Pittsburgh Sleep Quality Index score was higher in FD patients than
health controls (7.8 4.3 vs 5.6 3.1, p¼ 0.000) The prevalence of sleep disorder
was significantly higher in FD patients than healthy control (41.2% vs 18.4%,
p¼ 0.000). In univariate analysis, FD was significant risk factor for sleep dis-
order (OR 3.12, p5 0.0001). The independent risk factors for sleep disorder in
multivariate analysis were FD (OR 1.80, p¼ 0.026), female (OR 1.78, p¼ 0.028)
and depression (OR 2.91, p5 0.001).
Conclusion: FD significantly impacted on sleep disorder. FD was independent
risk factor in sleep disorder.
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Introduction: Dyspepsia and gastro-oesophageal reflux are highly prevalent in the
general population, but the two conditions are felt to be separate entities.
However, There are numerous mechanisms implicated in the pathogenesis of
functional dyspepsia, some of which are common to gastro-oesophageal reflux
symptoms (GORD), including visceral hypersensitivity and delayed gastric emp-
tying. To inform future research on potential shared pathophysiological mechan-
isms, it is important to estimate the strength of association between the two
conditions, and whether this association remains stable depending on the criteria
used to define these conditions, as well as geographic location.
Aims & Methods: We conducted a systematic review and meta-analysis to esti-
mate the prevalence of dyspepsia in individuals with gastro-oesophageal reflux
symptoms, and to quantify the overlap between the two disorders. MEDLINE,
EMBASE, and EMBASE Classic were searched (up until September 2016) to
identify population-based studies reporting the prevalence of dyspepsia and
GORS in adults (15 years), defined using specific symptom-based criteria or
a questionnaire. The prevalence of dyspepsia and weekly GORS were extracted
for all studies. Pooled prevalence, according to study location and criteria used to
define weekly GORS or dyspepsia, as well as odds ratios (OR), with 95% con-
fidence intervals (CIs) were calculated. The degree of overlap between the two
was examined.
Results: Of 14,132 papers evaluated, 79 reported prevalence of weekly GORS.
Nineteen of these study populations, containing 111,459 participants, also
reported the proportion of individuals with dyspepsia. The prevalence of dyspep-
sia in those with weekly GORS was 43.9% (95% CI, 35.1–52.9%). The pooled
OR for dyspepsia in individuals with weekly GORS, compared with those with-
out, was 6.94 (95% CI 4.33 to 11.12). The OR for dyspepsia in weekly GORS
remained significantly higher in all geographical regions studied, and across all
diagnostic criteria used. The pooled degree of overlap between the two conditions
was 25.9% (95% CI, 19.9–32.4%), varying from 22% when the Bowel Disease
Questionnaire was used to define weekly GORS, to 42.6% with the Mayo Reflux
Questionnaire.
Conclusion: The OR of dyspepsia in individuals with weekly GORS was seven-
fold that of individuals without GORS, and that there is overlap between the two
conditions in up to one-quarter of individuals. Reasons for this remain specula-
tive, but may include shared pathophysiological mechanisms or residual
confounding.
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Introduction: Functional gastrointestinal (GI) disorders (FGIDs) have been the-
orized to be a disorder of the brain-gut axis with both somatic markers (e.g.,
abdominal pain) and psychological ones. Exactly how abdominal and psycholo-
gical disorders are related remains poorly understood. While there have been a
small number of methodologically rigorous longitudinal studies that examine this
question (1,2), even these have typically only studied a small number of psycho-
logical traits and only quite general GI symptoms. There remains a need for
further longitudinal studies of how psychological traits predict subsequent
FGID symptoms.
Aims &Methods: The present study is a longitudinal examination of the influence
of a broad range of psychosocial predictors on later bowel-related and epigastric
discomfort in a community sample. A sample of 188 individuals randomly
sampled from the Australian electoral roll were surveyed, and, of them, 123
met Rome criteria for irritable bowel syndrome (IBS) or functional dyspepsia
(FD) while 65 did not meet criteria for FGIDs. Subjects were of mean age 49
(SD¼ 15, range 20–87) and 73% were female. A broad range of psychological
constructs (24 in total) were measured at baseline. Among them were anxiety,
depression, somatization, childhood abuse, neuroticism, hypochondriasis,
somatic vs psychological symptom attribution, coping, and social support. GI
symptoms were measured 18 months later using two Likert-type scales: one
concerning epigastric pain and the other concerning bowel symptoms.
Exploratory factor analysis (EFA) was used as a data-reduction technique to
create a smaller number of composite predictors. Statistical analysis was based
on ordinal regression.
Results: Ten composite scores were derived via EFA to be examined as predic-
tors. In the full sample (N¼ 188) a number of psychological traits (including
worry, non-sexual childhood abuse, psychological symptom attribution and
childhood sexual abuse; see Table 1) were individually related to subsequent
bowel symptom severity 18 months later. All four of these were independently
associated with epigastric pain severity 18 months later (Table 1). There was
evidence of variation in psychological predictors of gastrointestinal symptoms
between individuals who met and did not meet criteria for IBS or FD. With
respect to bowel symptoms, no psychological trait reached statistical significance
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as a predictor among individuals with FGIDs (Table 1). Epigastric symptom
severity was predicted by worry and psychological attribution of symptoms
among FGID individuals but no psychological trait predicted symptom severity
among non-FGID individuals (Table 1).
Conclusion: A range of psychosocial factors predict later gastrointestinal symp-
tom burden. For bowel symptoms, associations between psychological traits and
symptom burden appear to be most clearly driven by the non-FGID subgroup,
among whom psychological attributions for symptoms and problem-focused
coping are positively related to later symbptom burden. For epigastric symptoms,
a range of psychological traits were relevant, with the predictive patterns being
most clearly driven by individuals who qualified for FGIDs. In light of these
results, studies of the brain-gut axis need to consider a greater array of psycho-
logical traits, particularly outside of anxiety and depression. Further, the com-
monly reported associations between psychological traits and gastrointestinal
symptoms may be moderated by symptom level but are relatively similar
across upper and lower gastrointestinal symptoms.
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Introduction: In the recent years, there has been an increasing recognition of
the presence of gastrointestinal (GI) dysfunction in patients with neurologic
diseases. There are no studies examining a relationship between achalasia and
neurodegenerative/demyelinating diseases of central nervous system, although
these diseases might have common features. For example, a number of genetic
variations have been shown to increase the risk of both conditions (e.g. HLA-
DQB1-insertion on chromosome 6 may be strongly associated with both acha-
lasia and multiple sclerosis suggesting that autoimmune processes are involved in
their etiopathogenesis). Several other findings (e.g. inflammatory infiltrates,
Lewy’s bodies, geospatial gradient etc.) are also present in both patients with
achalasia and with neurodegenerative/demyelinating diseases.
Aims & Methods: The aim of our prospective study is to examine a prevalence
of neurodegenerative/demyelinating diseases in a cohort of consecutive patients
with confirmed esophageal achalasia. Achalasia was diagnosed by high-
resolution manometry, endoscopy and esophagogram. A total of 140 consecutive
patients with esophageal achalasia have been questioned about the occurrence of
neurological diseases and symptoms in their personal and family history. Those
with a suspicion of a neurological disease were referred for a detailed clinical
neurological examination, MR imaging of the brain and electrophysiological
study. A total of 106 patients with a neurodegenerative/demyelinating disease
have been questioned by using a questionnaire about the occurrence of symptoms
typical for achalasia (dysphagia, regurgitation, chest pain).
Results: A total of 51 out of 140 patients (36.4%) exhibited some
neurological symptoms–most often visual disturbances in 17 patients (33.3%)
and limbs paresthesia in 12 patients (23.5%). Among patients with a presence
of neurological symptoms, 5 patients (3.6%) had definitely been diagnosed with a
neurodegeneration/demyelinating disease (multiple sclerosis - 2 patients, Lebeŕs
optic neuropathy - 1 patient, Parkinsońs disease - 1 patient and Allgrove syn-
drome - 1 patient). Furthermore, 7 patients with a positive questionnaire had
been diagnosed with other neurological diseases (tetany n¼ 2, carpal tunnel
syndrome n¼ 3, epilepsy n¼ 2). Fourteen patients (27.4%) among those with
neurological symptoms (vs. 0 out of 89 patients without neurological symptoms)
had a positive family history of a neurodegenerative or a demyelinating disease.
Among 106 patients with a neurodegenerative/demyelinating disease, 30 of them
(28%) described dysphagia in their personal history. These patients will be exam-
ined by esophageal manometry.
Conclusion: Our results imply an increased prevalence of neurodegenerative/
demyelinating diseases in patients with achalasia (3.6% vs. approx. 1.4% in
the Czech controls). Also, a high prevalence of dysphagia was found among
patients with a neurodegenerative/demyelinating disease. These results warrant
further confirmation in a large population-based study.
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Introduction: Visceral pain is a complex percept influenced by numerous factors.
Of these, differences in the autonomic nervous system (ANS)–in particular, para-
sympathetic cardiac vagal tone (CVT)–has been suggested to have a physiological
role in the regulation and modulation of painful sensory signalling, to the extent
of vagal nerve stimulation (to raise subject CVT) being tested as a possible anti-
nociceptive.
Aims & Methods: To date, no studies have explored the brain functional con-
nectivity or network properties of CVT in relation to a painful stimulus, and thus
this was our aim. In 21 healthy participants (10 male; mean age 30 years (range
21–53 years)), we quantified resting CVT using a Neuroscope. For all subjects,
functional MRI data were acquired using a 3T MRI scanner during painful
oesophageal balloon distention, as described elsewhere(1). The effect of resting
CVT on brain networks during acute oesophageal pain were determined by
means of network based statistics(2). Brain nodes were selected a priori of pre-
vious autonomic/visceral pain literature and included the following: bilateral
nucleus accumbens (NAc), amygdala, insula, pallidum, thalamus and single
hypothalamus (
PNodes
¼ 11) (3). Blood oxygen level dependant (BOLD) signal
during oesophageal balloon distention to pain tolerance threshold was extracted
from each of these regions and cross-correlated to produce nodal correlation
matrices of 55 r values. Participants were dichotomised by means of median
split based upon resting CVT value, and a two-tailed t-test of was undertaken.
A primary threshold was applied (t¼ 1.65; p5 0.05) and permutation tested
50,000 times to ensure statistical stringency applied.
Results:We identified a unique subcortical brain connectivity network in the high
resting CVT individuals when exposed to acute oesophageal pain. This complex
symmetrical network comprised all 11 nodes with a total of 18 edges (significant
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Table 1: Associations between individual psychological traits and symptom severity. Numeric entries are odds ratios (SEodds ratio), *** indicates p5 .001, ** indicates
p5 0.01, * indicates p5 0.05, and ^ indicates 0.05 p 0.1.
Bowel Symptom Severity Epigastric Symptom Severity
Predictor Non-FGID FGID Combined Non-FGID FGID Combined
Problem-focused coping 2.92 (1.23)* 0.93 (0.14) 1.16 (0.15) 1.00 (0.44) 1.03 (0.15) 1.12 (0.15)
Worry 1.44 (0.51) 1.35 (0.22)^ 1.60 (0.22)*** 1.60 (0.65) 1.55 (0.26)** 1.71 (0.24)***
Avoidant coping 0.41 (0.21)^ 0.89 (0.14) 0.91 (0.12) 0.97 (0.39) 0.93 (0.15) 0.99 (0.13)
Doctor relationship 2.96 (1.77)^ 1.09 (0.16) 1.06 (0.14) 1.00 (0.54) 1.03 (0.16) 0.97 (0.13)
Childhood non-sexual abuse 1.65 (0.68) 1.06 (0.15) 1.33 (0.17) 1.94 (0.88) 1.05 (0.15) 1.32 (0.17)*
Social support 0.53 (0.22) 0.85 (0.12) 0.88 (0.11) 0.68 (0.32) 0.82 (0.12) 0.87 (0.11)
Somatic rather than
psychological attribution
0.27 (0.11) *** 0.93 (0.15) 0.72 (0.10)* 0.83 (0.36) 0.64 (0.11)** 0.63 (0.09)***
Doctor reassurance 0.99 (0.31) 1.16 (0.26) 0.94 (0.14) 1.06 (0.34) 1.49 (0.33)^ 1.01 (0.16)
Somatisation 2.92 (1.23)* 0.93 (0.14) 1.16 (0.15) 0.30 (0.30) 1.27 (0.18)^ 1.54 (0.20)***
Childhood sexual abuse 1.44 (0.51) 1.35 (0.22)^ 1.60 (0.22)*** 2.16 (0.88)^ 1.11 (0.18) 1.16 (0.16)
When considered jointly with other predictors, psychological attribution of symptoms was significantly positively related to both bowel symptom severity (non-FGID:
OR¼ 0.31, SE¼ 0.13; Full: OR¼ 0.74, SE¼ 0.11) and epigastric symptom severity (FGID: OR¼ 0.63, SE¼ 0.09; Full: OR¼ 0.63, SE¼ 0.11). The same was the case
for worry (Bowel: Full: OR¼ 1.40, SE¼ 0.21; Epigastric: FGID: OR¼ 1.58, SE¼ 0.27; Full: OR¼ 1.54, SE¼ 0.23). For bowel symptoms, problem-focused coping
(OR¼ 2.30, SE¼ 0.98) was an additional independent positive (notably, not negative) predictor among participants without FGIDs.
A574 United European Gastroenterology Journal 5(5S)
functional connections). These interconnections included the following: thala-
mus-amygdala, thalamus-hypothalamus, hypothalamus-NAc, amygdala-puta-
men amygdala-NAc and insula-putamen. No significant network was identified
for the low CVT group.
Conclusion: During acute oesophageal pain, resting cardiac vagal tone yields a
unique functional brain network comprising numerous complex subcortical brain
regions, many of which have been previously associated with either visceral pain
or modulation of baseline autonomics either at the physiological or neuroana-
tomical level (3). Previous research has suggested that a high resting CVT may be
protective of nociceptive signalling, and furthermore studies investigating vagal
nerve stimulation have included and report that of anti-nociception (4). Given
the well-established role of these subcortical regions in pain processing, we sug-
gest that this network identified may be of significance as to the neurophysiolo-
gical process of parasympathetic modulation of painful sensory signalling.
Lastly, to date, no studies have undertaken real-time assessment of the ANS
(including CVT) during functional brain imaging and acute visceral pain.
Future studies should investigate for this.
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Introduction: Oesophago-gastric junction outflow obstruction (OGJOO) is of
unclear significance. It may be secondary to an incomplete form of achalasia,
a mechanical obstruction or be idiopathic. Rapid drink challenge (RDC) test is
easy to perform during oesophageal HRM.
Aims & Methods: We aimed to assess the yield of RDC in patients with OGJOO.
From a database of 3522 consecutive oesophageal HRM performed from 01/
2012 to 03/2017, we extracted patients with OGJOO according to the Chicago
Classification v3.0. HRM protocol consisted of 10 5-ml water swallows in supine
position and RDC test (200-ml free drinking) in sitting position. Distal contrac-
tile integral (DCI) integrated relaxation pressure (IRP), distal and pan-oesopha-
geal pressurization (POP; homogeneous oesophageal pressurization 430mmHg)
were reported for 5-ml swallows. POP and oesophageal shortening (OS) were
analysed during RDC. Symptom severity was assessed with Eckardt score.
Causes of OGJOO were determined by reviewing patients’ chart for previous
history, complementary work up and treatment. Quantitative data were
expressed as median (range) and qualitative data as percentage. They were com-
pared using non parametric and Chi square tests.
Results: 75 patients (2%) (29 males, mean age 62 years (25–92)) were included.
The dominant symptom was dysphagia (69%), regurgitation (9%), chest pain
(5%), other (13%), no symptom (3%). The causes of EGJOO were previous
oesophago-gastric surgery (43%), incomplete achalasia (7%), mediastinal neo-
plasia (7%), miscellaneous (19%) and unknown (25%). RDC test was success-
fully performed in 70 patients (93%) and associated with POP and OS in 41%
and 13% respectively. Dysphagia as dominant symptom was more frequent (79%
vs 59%, p¼ 0.057) and more severe (Eckardt score 5 (1–11) vs 3 (0–10), p¼ 0.01)
in patients with POP during RDC compared to those without. The same obser-
vation was achieved in patients with OS vs those without (dysphagia 100% vs 62,
p¼ 0.02 and Eckardt score 6 (2–10) vs 1 (0–11), p¼ 0.02). Manometric para-
meters are reported in the table. The causes of OGJOO were similar in patients
with and without POP during RDC (previous oesophago-gastric surgery 34%
and 51% respectively, achalasia 14% and 2%, mediastinal neoplasia 3% and
7%, miscellaneous 10% and 22%, unknown 38% and 17%). OS was not
observed in patients with unknown cause of EGJOO vs 20% of patients with
an identified cause (p¼ 0.09).
Manometry
parameters
for 5-ml swallows
POP during
RDC
n¼ 29
No POP
during RDC
n¼ 41 OS n¼ 9 No OS n¼ 61
Mean IRP (mmHg)
Maximal IRP
(mmHg)
Mean DCI
(mmHg.s.cm)
Maximal DCI
19(15–35)*
29(18–57)*
2700
(496–14492)*
4536
(639–42139)*
18(15–29)
24(16–78)
1384
(109–16108)
2146
24(16–35)
31(23–78)z
1503 (593–4095)
2264 (1036–10127)
20(0–70) 0(0–40)
18(15–29)
25(16–57)
1671 (109–16108)
3016 (156–42139)
0(0–100) 0(0–100)
(continued)
: Continued
Manometry
parameters
for 5-ml swallows
POP during
RDC
n¼ 29
No POP
during RDC
n¼ 41 OS n¼ 9 No OS n¼ 61
(mmHg.s.cm)
%distal
pressurization
%POP
20(0–100)*
0(0–100)
(156–38846)
0(0–100) 0(0–60)
*p5 0.05 vs patients without POP; zp5 0.05 vs patients without OS
Conclusion: While RDC test cannot be used to determine EGJOO cause, patients
with POP or OS during RDC had more severe dysphagia than those without. In
patients with POP, the highest DCI might be secondary to obstruction. Further
prospective studies should determine if RDC test could help to select patients
who might benefit from treatment.
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Introduction: High resolution manomety (HRM) is performed with solid-state
catheters (SS) in many centers. However according to Chicago classification,
very limited data from healthy volunteers are available for some catheters and
starting from IRP, numerical values are crucial for the diagnosis. Because of the
cost of the SS-HRM catheters many centers especially from developing countries
use water perfusion HRM (W-HRM) catheters up to 24 channels and normal
values are even more limited.
Aims & Methods: We evaluated a prototype 36 channels W-HRM reused catheter
allowing tomeasure 3-Dpressure vector volume analysis of lower esophageal sphinc-
ter in healthy volunteers and compared to 36 channels SS-HRM catheters (Laborie-
MMS Canada). We included 43 healthy volunteers without any upper gastrointest-
inal complaint. Upper gastrointestinal endoscopy and 24h impedance-pH monitor-
ing performed in all subjects. Four subjects were excluded because of silent
GERD. 39 subjects were analysed (25 males, W-HRM (n¼ 39), SS-HRM
(n¼ 33)). Thirty-three patients underwent two esophageal manometry studies
within two consecutive days with a random order. Procedures were performed in
supine positionwith receiving ten times 5ml water, five times solid food andmultiple
water swallow with 200ml of water. 36 channel water- perfused 3-D HRM catheter
and 36 channel solid state HRM catheter were used (Laborie-MMS Canada).
Results: There was significant differences between two catheters in terms of
Integrated Relaxation Pressure (IRP), Distal Contractile Integrale (DCI) and
DCI- expanded, LES resting pressure, % of ineffective peristalsis, and esopha-
geal length both with water and solid food swallows (Table). No difference has
been shown with distal latency (DL), LES length, breaks size (Table).
36 ch solid
statemean SD
36 ch water
perfusion
(mean SD)
Esophageal length
(inspirium) (cm)
23.1 2 22.5 2
5ml LES resting pressure (mmHg) 34.8 13 17.4 7
IRP (mmHg) 17.6 5 (7–25) 6.5 4 (0–18)
DCI (mmHg*s*cm) 1281 759 701 432
Mean % ineffective peristalsis 15% 28%
solid
food
LES resting pressure (mmHg) 33.5 11 17.6 7
IRP (mmHg) 17.6 5 6.4 4
DCI (mmHg*s*cm) 1969.1 1051 1159.9 836
DCI expanded (mmHg*s*cm) 2122.9 1117 1171.1 895
Mean % ineffective peristalsis 12% 23%
Conclusion: Water perfusion HRM catheter exhibits significantly lower values
especially for IRP, DCI, LES resting pressure. Centers which are working with
water perfusion catheters should not accept universal normal established with
solid state catheters and need to work on their normative values. The ineffective
peristalsis pattern is common with water perfusion catheters.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The Chicago Classification V3.0 (CCv3) defined ineffective esopha-
geal motility (IEM) by the presence of 50% or more of weak or failed peristaltic
waves during high resolution manometry (HRM). Both low-volume (10ml) mul-
tiple rapid swallow (MRS) and high-volume (200ml) rapid drinking test (RDT)
have been suggested as test to recognize the esophageal peristaltic reserve. Which
test might better represent the esophageal peristaltic reserve is still a matter of
discussion.
Aims & Methods: The aim of this study was to compare the diagnostic value of
MRS and RDT in patients with IEM. From a larger group of patients evaluated
for heartburn (twice/week with poor response to standard dose proton pump
inhibitors), we enrolled consecutive patients with IEM and with functional heart-
burn (FH). FH were enrolled as controls. IEM was defined according to the
CCv3, and FH were defined according to the Rome IV criteria and with
normal peristalsis. HRM was performed according to the Italian Guidelines.
All patients underwent 3 MRS (10ml of water in 5 swallows in less then 10s)
and 1 RDT (200ml of water freely drunk). All patients underwent 24-h impe-
dance and pH recording (MII-pH). Mean DCI of MRS and DCI of RDT were
compared with mean DCI of 10 single swallows (SS). The MRS/SS and RDT/SS
ratio were calculated.
Results: We evaluated 30 patients with IEM (18 males and 12 females; mean age
45.7 11.4 yrs) and 30 patients with FH (13 males and 17 females; mean age
41.2 13.6). The MII-pH showed higher acid exposure time (AET) and number
of reflux events in IEM than in FH (p5 0.05). Mean DCI of SS resulted lower in
patients with IEM compared to FH (p5 0.05). One-hundred and eighty MRS
and 60 RDT were evaluated. DCI of MRS was lower than 450mmHg-s-cm in
39% (35/90) of IEM patients, and in 7% (6/90) of FH (p5 0.05). DCI of RDT
was lower than 450mmHg-s-cm in 77% (23/30) of IEM patients, and in 50% (15/
30) of FH (p5 0.05). The MRS/RDT ratio resulted 41 in both groups. All
results are reported in Table 1.
Table 1: Results of SS, MRS and RDT in patients with IEM and FH
IEM group FH group p
Mean DCI (mmHg-s-cm) 508.7 318.6 1493.7 799.2 0.001
Mean DCI MRS 614.2 437.1 1982.6 974.4 0.001
Mean DCI RDT 506.9 311.5 1269.2 1027.6 0.001
MRS/SS ratio 1.2 0.4 1.6 0.7 0.008
RDT/SS ratio 0.9 0.3 1 0.5 0.351
MRS/RDT 1.3 0.4 1.4 0.7 0.499
Conclusion: MRS is a more reliable test to detect peristaltic esophageal reserve
when compared to RDT both in patients with IEM or those with normal eso-
phageal peristalsis.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The Chicago Classification (CC V3.0) defined the presence of eso-
phago-gastric outflow obstruction (EGJ-OO) when the value of integrated releas-
ing pressure (IRP) is higher than 15mmHg during high-resolution manometry
(HRM). Both low-volume (10ml) multiple rapid swallow (MRS) and high-
volume (200ml) rapid drinking test (RDT) were never evaluated to detect the
inhibition of esophageal body in patients with EGJ-OO.
Aims & Methods: The aim of this study was to compare the efficacy of MRS and
RDT in evaluating the esophageal body inhibition during repetitive swallow in
patients with EGJ-OO and in patients with functional heartburn (FH) considered
as control group. From a larger group of patients evaluated for dysphagia with
negative upper endoscopy, we enrolled consecutive patients with EGJ-OO, and as
control group, patients with functional heartburn (FH) defined according to the
Rome IV criteria. EGJ-OO was defined according to CC V3.0. HRM performed
according to Italian guidelines. All patients underwent 3 MRS (10ml of water in
5 swallow in less then 10s) and 1 RDT (200ml of water freely drunk). The mean
DCI of MRS and the DCI of RDT were compared with DCI of 10 single
swallows (SS) mean value. The MRS/SS and RDT/SS ratio were calculated.
The lack of esophageal body inhibition during multiple swallow tests were
defined if contraction was identified measuring 43 cm using the 30mmHg iso-
baric contour tool.
Results: We evaluated 30 patients with EGJ-OO (18 females; mean age
49.5 12.4 yrs) and 30 patients with FH (17 females; mean age 41.2 13.6).
Impedance and pH 24-h analysis was performed to select patients with FH
(normal AET and number of reflux and lack of reflux-symptom correlation).
During HRM the mean DCI resulted similar in patients with EGJ-OO compared
to FH (p5 0.839). One-hundred and eighty MRS and 60 RDT were evaluated.
The lack of body inhibition was found in 11% (20/180) during MRS and in 53%
(16/30) during RDT in EGJ-OO. No patients in FH showed lack of body inhibi-
tion during both MRS and RDT. All results are reported in Table 1.
Table 1: Results of SS, MRS and RDT in patients with EGJ-OO and FH
EGJ-OO group FH group p
Mean DCI MRS 1455 1436.1 1982.6 974.4 0.101
Mean DCI RDT 817.3 665.4 1269.2 1027.6 0.047
MRS weak/failed (90) 24/30 2/4 N/A
RDT weak/failed (30) 6/20 3/12 N/A
MRS/SS ratio 0.9 0.3 1.6 0.7 0.001
RDT/SS ratio 0.5 0.4 1 0.5 0.001
MRS complete
body inhibition (%)
89 100 0.001
RDT complete
body inhibition (%)
47 100
Conclusion: Patients with EGJ-OO showed less peristaltic reserve during MRS
and RDT. The RDT evidenced more frequently lack of body inhibition in
patients with EGJ-OO.
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Introduction: Esophageal motor dysfunction and abnormal bolus transit are often
encountered on high resolution impedance manometry (HRIM) performed prior
to anti-reflux surgery (ARS) in gastroesophageal reflux disease (GERD).
Esophageal motor dysfunction can be characterized using established software
tools embedded in HRIM software, while new paradigms of interrogation of
bolus presence and flow have been introduced with automated pressure flow
analysis (PFA). The prevalence, and clinical relevance of these motor and
bolus flow abnormalities to symptom presentation or symptom outcome from
ARS are incompletely understood.
Aims & Methods: Our aim was to evaluate the interrelationships between eso-
phageal motor function and bolus transit using varying bolus consistencies, in
health and in the context of symptomatic GERD prior to ARS. HRIM studies
(Medtronic, Duluth, GA) from 18 controls (28.4 1 yr, 50% F) and 86 GERD
patients (56.2 2 yr, 58% F) were reviewed, all of which were performed using
5mL water (10 swallows), 5mL viscous (5 swallows) and 1 cm3 bread boluses
(2 swallows). All controls were asymptomatic; all GERD patients completed
symptom questionnaires evaluating dominant and secondary symptoms using
5 point Likert scales for symptom frequency and severity (0¼none, 4¼ frequent
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or severe); the product of frequency and severity constituted the symptom score,
assessed at baseline and after ARS. Automated PFA was performed for each test
swallow by blinded investigators using purpose built software (Esophageal
AIMplot, copyright T Omari) programmed in MatLab (The MathWorks Inc,
Natick, MA, USA). The nadir impedance point (NI) indicating peak distension,
and the contractile deceleration point (CDP) were determined. Latency was mea-
sured from NI to the contraction front at the CDP (distension to contraction
latency, DCL). Intrabolus pressures (IBP) were measured during accommodation
(IBP-A), compartmentalized transport (IBP-CT) and esophageal emptying (IBP-
EE). Bolus clearance in the esophageal body was assessed using the impedance
ratio (IR) based on the relationship between NI and impedance at the contractile
peak. Bolus flow at the esophagogastric junction (EGJ) was assessed using bolus
flow time (BFT) in seconds when both pressure and impedance traces indicated a
flow permissive paradigm. Univariate and multivariate analyses were performed to
assess the relationships between bolus flow metrics and motor function, taking
baseline symptom scores and symptom change following ARS into consideration.
Results: Of 86 patients, 72.1% had typical symptoms. The mean baseline symp-
tom score was 158.8 15.8, with a mean decline of 139.9 15.8 following ARS.
Peak pressures in the proximal esophagus were lower in GERD patients com-
pared to controls with all bolus consistencies (p 0.007). Concurrently, metrics
assessing esophageal bolus presence (NI) and clearance (IR) were consistently
abnormal in GERD patients (Table, p¼ 0.001 for all bolus consistencies for each
comparison to controls). Trans-EGJ bolus flow metrics were similarly abnormal
in GERD (BFT, p 0.001 for all bolus consistencies compared to controls). IBP
metrics were highest with solid swallows, especially in GERD patients compared
to controls (Table). Within GERD, a gradient of increasing dysfunction in bolus
presence and bolus clearance was noted, with least abnormalities with water
swallows and the worst metrics with bread swallows (p 0.02 across groups
for each comparison). IBP-EE (p 0.05) and trans-EGJ BFT (p 0.004) were
higher during water and viscous swallows with atypical symptoms compared to
typical symptoms. NI was consistently lower in patients reporting 75% symp-
tom improvement following ARS with all bolus consistencies (p 0.046).
Pressure Flow Analysis Comparisons Using Water, Viscous and Bread Swallows Between
Controls and GERD Patients
water swallows viscous swallows bread swallows
controls GERD controls GERD controls GERD
Proximal peak
pressure (mmHg)
98.5 6 75.2 3* 105.5 5 84.7 2.5* 109.1 5 91.4 3*
Distal peak
pressure (mmHg)
72 9 63.9 3 75.0 8 59.4 3* 68.9 7 60.9 3
Nadir impedance
(ohms)
309 27 882 59* 300 13 633 45* 302 23 650 40*
Distension to
contraction
latency (s)
3.2 0.1 3.4 0.3 1.7 0.3 2.0 1.0 1.5 0.2 1.6 0.2
Impedance ratio 0.3 0 0.5 0* 0.3 0 0.4 0* 0.4 0 0.5 0*
Distal IBP (mmHg) 6.6 1.1 8 0.5 10.5 1.0 13.4 0.6* 11.4 1.0 15.3 0.9*
IBP-A (mmHg) 5.2 1.0 5.1 0.5 8.5 0.9 8.6 0.5 8.9 1.1 12 1.0*
IBP-CT (mmHg) 6.4 1.0 8.7 0.5* 8.5 0.8 9.5 0.5 9.1 0.9 11.6 0.6*
IBP-EE (mmHg) 10.3 0.8 11.7 0.5 12.5 0.8 16.1 0.6* 13.1 0.8 17.7 0.7*
Bolus flow time (s) 4.1 0.5 2.0 0.2* 3.8 0.5 2.1 0.1* 3.3 0.4 1.8 0.2*
*p 0.04 compared to controls. IBP: intrabolus pressure; IBP-A: IPB-accomoda-
tion; IBP-CT: IBP-compartmentalized transport; IBP-EE:IBP-esophageal
emptying
Conclusion: Automated pressure flow analysis of HRIM studies demonstrates
abnormalities of esophageal bolus transit and esophageal emptying in conjunc-
tion with lower proximal smooth muscle contractile function with all bolus con-
sistencies in GERD compared to controls. Metrics assessing esophageal bolus
presence may have prognostic value in GERD patients undergoing ARS.
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Introduction: Oesophageal diverticula are rare diverticula of the gastrointestinal
tract known to be associated with oesophageal motor disorders.
Aims & Methods: The aim was to study manometric abnormalities associated
with oesophageal diverticula, using both wet and solid swallows. Patients under-
went high resolution oesophageal manometry (HRM) in the upright position. 18
patients with oesophageal diverticula were found and were free of previous sur-
gery. Traction diverticulum was excluded in all patients. We also included 10
healthy controls. HRM was performed using wet (5mL of water) swallows in
both groups, followed by solid (meat) swallows in patients. Mean age of the
controls was 50 years old while it was 70 years old for patients.
Results: The main reported symptom was dysphagia (76%). HRM found 11
(61%) patients with an oesophageal motor disorder, including 2 oesophagogas-
tric junction outflow obstruction [OGJOO], 4 achalasia (subtype 2: n¼ 2; sub-
type 3: n¼ 2), 4 distal oesophageal spasms [DES] and 1 jackhammer oesophagus,
and was normal in 7 (39%) patients. In those patients with normal findings, solid
swallows identified 4 (57%) additional motor disorders, including 2 OGJOO,
1 jackhammer oesophagus and 1 DES. Provocative testing using solid swallows
increased the diagnostic yield by 22% in overall patients and by 57% in patients
with normal manometry using wet swallows only. Mean pressure slopes at mid-
oesophagus and distal oesophagus were greater in patients than healthy controls
(p5 0.05 for wet swallows), as previously reported1. Other metrics are summar-
ized in the table.
HRM metrics with comparisons between wet swallows in controls and patients, and between
wet and solid swallows among patients. * p5 0.05 ** p5 0.01 *** p5 0.001
Controls Patients Patients
(liquids) (liquids) (solids)
Number of swallows 9.30 9.94 9.41
EGJ resting pressure (mmHg) 29.30 28.76 34.66
Mean IRP 4s (mmHg) 11.50 14.32 18.25*
Mean DCI (mmHg.s.cm) 1315.10 2877.99 7343.07***
Distal latency (s) 6.70 6.05 7.11*
Intrabolus pressure (mmHg) 8.10 11.88* 15.19
Mean pressure slope
mid-oesophagus (mmHg/s)
0.65 2.27*** 2.59
Mean pressure slope distal
oesophagus (mmHg/s)
0.36 1.41** 0.46
Conclusion:While more than one-third of HRM using wet swallows were normal,
provocative testing using solid increased the diagnostic yield of the procedure by
more than 50% in these patients. Analysis of pressure slopes confirmed the
association of propagating peristalsis with the disease.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The management of achalasia targets relieving the obstruction at
the esophagogastric junction (EGJ) by pneumatic dilation (PD), laparoscopic
Heller myotomy (LHM) plus a fundoplication variant (Dor, Toupet and more
rarely Nissen/Nissen-Rossetti). However, effective ablation of the LES barrier
can induce gastroesophageal reflux disease (GERD). Recently, new metrics to
evaluate EGJ function with high resolution manometry (HRM) have been intro-
duced, such as EGJ contractile integral (EGJ-CI). Currently there are few data
investigating how achalasia treatments impact EGJ function based on these
metrics.
Aims & Methods: We aimed to assess the EGJ-CI metric in achalasia before and
after different treatments, to verify if post-operative changes in this metric cor-
relate to symptom relief and iatrogenic GERD following surgical treatments.
Methods Between 2014 and 2015, we enrolled consecutive achalasia patients.
All patients underwent clinical evaluation with Eckardt and GERDQ score, as
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well as upper endoscopy, barium esophagogram and HRM before and 6 months
after treatment. Achalasia was classified according to the Chicago Classification
V3.0. The EGJ-CI was calculated using the distal contractile integral tool-box
during three consecutive respiratory cycles. Patients underwent to pneumatic
dilatation (PD), or LHM plus a Dor (LHM-D), Toupet (LHM-T) or a Nissen-
Rossetti (LHM-NR) fundoplication. Ethical approval for the study was
obtained.
Results: We enrolled 35 achalasia patients (14 Type I, 16 Type II and 5 Type III).
Ten patients underwent PD, 11 LHMD, 8 LHM-T and 6 LHM-NR. At baseline,
no differences among treatment groups regarding age, sex, pre-operative mean
Eckardt score, GERDQ score, integral relaxation pressure (IRP) and EGJ-CI
were recorded. All Type III subjects underwent LHM-D (3) and LHM-T (2).
After all the procedures, in all the patients there was a significant decrease in
Eckardt score, IRP and EGJ-CI (p5 0.001,5 0.001 and5 0.05, respectively).
PD and LHM-NR showed higher EGJ-CI (20 9.3 and 25.3 11.1mmHg*cm,
respectively) and IRP (12.2 3.4 and 13 4.5, respectively) than LHM-D and
LHM-T (18.4 5.9, p5 0.05 and 9.3 4.1 p5 0.05mmHg*cm, respectively for
EGJ-CI; 5.2 2.5, p5 0.05 and 2.3 3.7 p5 0.001mmHg*cm, respectively for
IRP). Post-operative Eckardt score was lower in LHM-D and LHM-T (2.1 0.5
and 2.0 0.6, respectively) than PD and LHM-NR (4.2 1.0, p5 0.01 and
3.7 1.5, p5 0.05). Post-operative GERDQ score was significant higher in
LHM-T (3.0 1.7 vs. 8.2 3.9, p5 0.05). Low post-operative EGJ-CI values
correlated with an increased risk of higher post-operative GERDQ score
(p5 0.05, odds ratio 4.223, 95% CI 0.964–2.123).
Conclusion: All procedures performed to treat achalasia produced an adequate
relief of dysphagia. LHM-D and LHMT seem to result in a stronger alteration of
the EGJ, with LHM-T resulting in an increased risk of post-operative reflux.
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Introduction: Jackhammer esophagus is a rare esophageal motility disorder. Little
is known about its physiopathology; however, an excess of cholinergic drive has
been suggested as an important etiologic factor.1 Multiple rapid swallowing
(MRS) is an adjunctive test in order to evaluate integrity of inhibitory and
excitatory neural pathways. In healthy subjects body motor inhibition is
observed during MRS and a contraction stronger than single swallows (SS)
occurs after MRS, the so-called peristaltic reserve (MRS/SS DCI ratio 41). In
patients with nutcracker esophagus preservation of motor inhibition during
MRS has been described with traditional manometry2. No study has evaluated
peristaltic reserve and motor inhibition with high-resolution manometry (HRM)
in patients with jackhammer esophagus.
Aims & Methods: To evaluate MRS in a consecutive multicenter series of 42
Jackhammer esophagus patients (18 Male; 63 years; 55–71) according to
Chicago 3 classification. 18 healthy subjects (HS) (seven male; 28 years; 23–33)
from a published series were used as a control group.3 All patients underwent
solid state HRM with ten 5ml SS and one to three 10ml MRS (30 patients
performed at least two MRS). Standard HRM parameters during SS were eval-
uated. During MRS presence/absence of motor inhibition and 4 second inte-
grated relaxation pressure (4 sec IRP) were evaluated. After MRS distal
contractile integral (DCI) was evaluated and DCI ratio between MRS and SS
was measured. Mann Whitney, Wilcoxon and chi-squared tests were used when
appropriate; data are shown as median-IQ range.
Results: Descriptive data in jackhammer patients are shown in table 1. Twelve
patients did not have motor inhibition during at least one MRS (28% vs 5% in
HS, p5 0.05). There was a trend toward a lower 4s IRP during MRS compared
to SS (see table 1); however, values were higher than those of 4s IRP MRS in HS
(5.1mmHg; 2.2–11 vs 1.6mmHg; 0.3–2, p5 0.0001). MRS DCI was significantly
lower than SS DCI; interestingly 26 patients had a MRS/SS DCI ratio 51 (62%
vs 22% in HS, p5 0.005) and it was lower than the MRS/SS DCI ratio of HS
(0.8; 0.4–1.1 vs 1.9; 1.1–2, p5 0.0001) suggesting a reduction of the hypercon-
tractile activity in the esophageal body.
HRM parameters during single and multiple rapid swallows in jackhammer
patients. Median; interquartile range.
SS MRS p value
4 s IRP, mmHg 7.5; 4.9–13.1 5.1; 2.2–10.1 p¼ 0.06
DCI, mmHg.sec.cm 6506; 5605–8582 5537; 3568–8572 p5 0.05
CFV, cm/s 3.9; 2.9–5.5 4.4; 2.9–6.4 p¼ 0.10
DL, sec 6.8;6.2–7.6 6.8;5.5–7.4 p¼ 0.09
SS, single swallows; MRS, multiple rapid swallows; 4 sec IRP, 4 second inte-
grated relaxation pressure DCI, distal contractile integral; CFV, contractile
front velocity; DL, distal latency.
Conclusion: Contrary to what occurs in healthy subjects, MRS reduce DCI value
compared to SS in jackhammer esophagus patients, suggesting altered neural
control of peristalsis. Differently to what previously observed with traditional
manometry, motor inhibition during MRS is altered in a quarter of patients.
Studies are needed in order to evaluate if reduction of DCI during MRS can
improve dysphagia and chest pain in these patients.
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Introduction: Functional delayed gastric emptying is a difficult-to-treat disorder,
which is often expressed clinically as nausea/vomiting, fullness/early satiety,
bloating and weight loss. Gastric peroral endoscopic myotomy (G-POEM) has
been regarded as a novel and minimally-invasive therapy for functional delayed
gastric emptying refractory to medical therapy. We herein report our initial
experience of G-POEM in an Asian population with focus on technique in addi-
tion to safety and efficacy of this promising endoscopic therapy.
Aims &Methods: The data of consecutive patients who underwent G-POEM by a
single expert endoscopist from October 2015 to November 2016 was collected.
Procedures were performed, similar to POEM for achalasia, including initial
mucosal incision, creating a submucosal tunnel, full-thickness (pyloro)myotomy,
and closure of the mucosal entry. Patient demographics, etiology, Gastroparesis
Cardinal Symptoms Index (GCSI) and gastric emptying scintigraphy (GES) were
recorded before and after the procedure. Treatment outcomes and procedure
related adverse events were also evaluated.
Results: A total of fourteen patients with refractory functional delayed gastric
emptying, including eleven post-surgical (78.6%) and three diabetic (21.4%),
were enrolled. The median age was 60 (range, 26–82) years. All patients were
suffering from nausea, vomiting, bloating and weight loss. They all failed medical
therapy including proton pump inhibitor, metoclopramide, mosapride, or dom-
peridone. All fourteen patients underwent G-POEM successfully (100%) with the
mean procedure time of 43.71 13.08 mins. Gastric emptying scintigraphy
(GES) was performed in five patients with improvement of mean half empty
time (191.88 83.19mins vs. 91.44 32.92mins), and retention at 2 hours
(70.02 12.68% vs. 33.48 20.32%). The median hospital stay after procedure
was 6 days (range, 4–10). No procedure related adverse event (0%) was observed.
During a median follow-up of eight months (range, 3–17.5 months), one patient
(post-surgical) had symptom recurrence after 45 days after the procedure because
of stenosis related to scan formation. One of the two diabetic patients with severe
diabetes and diagnosis as diabetic peripheral neuropathy showed little response
to G-POEM, while the GCSI was 34 before and 28 after. The other showed initial
improvement with GCSI score 22 before and 10 after during the first follow-up.
However, his symptoms reoccurred seven months after G-POEM and the latest
GCSI score was 19. Overall GCSI after G-POEM (mean, 5.00 2.57) decreased
significantly comparing with the one before (mean, 22.55 3.42).
Conclusion: G-POEM is a promising new endoscopic treatment option for func-
tional delayed gastric emptying. Our initial data suggest it is safe and effective.
Large studies are needed to determine safety, efficacy, long-term outcomes and
determine which patient population benefits the most from this treatment option.
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Introduction: Although cap-assisted technique has been shown to be effective in
retrieving foreign bodies from the upper gastrointestinal tract, there is no data in
food bolus obstruction (FBO). This study aimed to assess the performance of
cap-assisted technique in the management of esophageal FBO, as compared to
conventional endoscopic methods.
Aims & Methods: Outcomes of all patients who presents with FBO requiring
emergency endoscopic management between 2011 and 2016 were prospectively
collected. The main measured outcomes were procedural success, procedural
time, complications and length of hospital stay.
Results: Of the 315 patients (214M:102F; 58.3 18.3 years) with FBO,
267 (84.7%) had evidence of food bolus in the esophagus on endoscopy and
48 (15.2%) patients had spontaneous passage of food bolus. Out of the
199 patients who had impacted FBO, 93 had cap-assisted technique and 106
had conventional approach, with no differences in the type and location of
FB. The success rate of cap-assisted technique (100%) was comparable to that
of conventional techniques (97.2%, P¼ 0.10). Patients who had failed extraction
by conventional techniques (n¼ 3) were successfully treated when switched to
cap-assisted approach. Cap-assisted approach was associated with a shorter total
procedural time (34 8 and 43 22min, P¼ 0.006), a shorter length of hospital
stay (0.95 0.56 and 1.58 1.36 days, P¼ 0.0017) and more en-bloc removal
(87.3% vs 22.8%, P5 0.001). There were more complications in the conventional
than the cap-assisted group (7/106 vs. 0/93; P¼ 0.01).
Conclusion: Cap-assisted technique is 100% effective in the management of
impacted FBO in the esophagus, with a significantly shorter procedural time
and no complication. Although the findings suggest that cap-assisted technique
should be the first line technique in the management esophageal FBO, further
evaluation with a randomized multicenter trial is warranted.
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Introduction: Functional dyspepsia (FD) is defined that there is no evidence of
organic disease which is likely to explain the symptoms. However, there was no
obvious definition about ‘‘organic disease’’. Therefore, during the endoscopic
examination, it happens that we can’t judge whether obvious mucosal change
like gastric erosion fulfill the exclusion criteria or not. Indeed, this issue was
pointed out that there is notable inconsistencies in the exclusion criteria of FD
(1). Recently, the Kyoto classification of gastritis has been published and used
widely for the management of gastritis in Japan (2). In this classification, endo-
scopic findings are defined precisely. However, it is not discussed whether we can
consider such findings as the ‘‘organic disease’’ or not. If these findings have no
relation to FD symptoms, we can diagnose patients group as FD even if they
have such endoscopic findings.
Aims & Methods: The aim of this study is to explore which endoscopic findings
defined in the Kyoto classification of gastritis bring FD symptoms. To assess the
symptoms of patients, we employed the modified-Frequency of Scale for the
Symptoms of GERD questionnaire (m-FSSG) (3), which was developed for
evaluation of dyspeptic symptoms in patients. It comprised 14 symptoms and
was rated on a scale of zero to four in each question. This questionnaire is useful
to distinguish between NERD and FD because the m-FSSG contains seven
question about reflux symptoms (question 1, 4, 6, 7, 9, 10 and 12) and seven
questions about dyspeptic symptoms (question 2, 3, 5, 8, 11, 13 and 14). We
investigated 19 endoscopic findings (atrophy, intestinal metaplasia, diffuse red-
ness, spotty redness, mucosal swelling, enlarger fold, nodularity, foveolar-hyper-
plastic polyp, xanthoma, depressive erosion, regular arrangement of collecting
venules: RAC, fundic gland polyp, red streak, raised erosion, hematin, erosion,
patchy redness, map-like redness, multiple white and flat elevated lesions) were
classified based on the definition in the Kyoto classification of gastritis. Data
were extracted from the records of subjects who underwent upper gastrointestinal
endoscopy at our department between April 2015 and March 2017. Of the 2,079
subjects analyzed, we focused on 255 subjects who answered m-FSSG at the time
of endoscopy after excluding subjects diagnosed with organic disease (GERD,
peptic ulcers and cancers) endoscopically. We also excluded subjects who
answered had symptoms related acid reflux (score 3 or 4) in m-FSSG. We divided
255 subjects into FD group and Control group. FD group was defined as the
subjects who had epigastralgia (score 2, 3 or 4), postprandial fullness (score 3 or
4) or early satiation (score 3 or 4) in m-FSSG. After that, we compared the rate of
FD group of patients with or without findings in each 19 finding.
Results: This study included 55 subjects in FD group and 200 subjects in Control
group. The ratio was statistically lower in men than women in FD group than in
Control group (43.6% vs. 61.0%, p¼ 0.02). Atrophy (16.6% vs. 30.4%,
p¼ 0.01), spotty redness (9.1% vs. 23.0%, p¼ 0.02), hyperplastic polyp (9.0%
vs. 0%, p¼ 0.016), were frequently seen in Control group than in FD group.
RAC (43.0% vs. 67.3%, p¼ 0.002) were frequently seen in Control group than in
FD group. Multivariate logistic regression (stepwise selection) showed that low
age (under 65 years old) (OR 2.427, 95%CI 0.209–0.812, p¼ 0.01) and RAC (OR
2.123, 95%CI 0.206–0.821, p¼ 0.012) were related to FD. None of the findings of
gastritis examined were related to FD.
Conclusion: It is revealed that endoscopic gastritis is NOT related to FD
symptoms.
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Introduction: There was not available data about the overlap between functional
dyspepsia (FD) and pancreatic diseases.
Aims & Methods: We aimed to determine whether epigastric pain syndrome
(EPS) accompanying with pancreatic enzyme abnormalities were associated
with early chronic pancreatitis proposed by Japan Pancreas Society (JPS) using
endosonography. We enrolled 99 consecutive patients presenting with typical
symptoms of FD, including patients with postprandial distress syndrome
(PDS) (n¼ 59), EPS with pancreatic enzyme abnormalities (n¼ 41) and EPS
without pancreatic enzyme abnormalities (n¼ 42) based on Rome III criteria.
Gastric motility was evaluated using the 13C-acetate breath test. Early chronic
pancreatitis was detected by endosonography and graded from 0 to 7.
Results: The ratio of female patients among EPS patients (34/41) with pancreatic
enzyme abnormalities was significantly (p¼ 0.0018) higher than the ratio of
female EPS patients (20/42) without it. Postprandial abdominal distention and
physical component summary (PCS) scores in EPS patients with pancreatic
enzyme abnormalities were significantly disturbed compared to those in EPS
patients without it. Interestingly, AUC5 and AUC15 values (24.85 1.31 and
56.11 2.51, respectively) in EPS patients with pancreatic enzyme abnormalities
were also significantly (p¼ 0.002 and p¼ 0.001, respectively) increased compared
to those (19.75 1.01 and 47.02 1.99, respectively) in EPS patients without it.
Overall, 64% of EPS patients with pancreatic enzyme abnormalities were diag-
nosed by endosonography as having concomitant early chronic pancreatitis pro-
posed by JPS.
Conclusion: Further studies are warranted to clarify how EPS patients with pan-
creatic enzyme abnormalities were associated with early chronic pancreatitis
proposed by JPS.
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Introduction: Caustic esophageal injury is corrosive burns of esophagus and
mostly caused by ingestion of chemical caustic substances such as strong acid
or alkali. The caustic esophageal stricture is refractory and patients suffered from
multiple dilation. Clinical ESD results revealed that benign stricture would be
usually caused by more 75% mucosa loss of circumferential esophagus. Cultured
skin tissue was effective for wound healing and preventing undesired fibrosis. We
hypothesized that autologous esophageal mucosa transplantation might inhibit
refractory fibroplasia and delay the recurrence of esophageal strictures.
Aims & Methods: A man presented with the caustic esophageal stricture (32–
40 cm from the incisors), which was caused by accidental exposure of anhydrous
acetic acid. Under X-ray, routine endoscopic dilation was firstly applied to a
diameter of 1.28 cm. Three days later, with the informed consent, ESD operation
was utilized to dissect 5*0.5 cm normal esophageal mucosa at the 18–23 cm loca-
tion from the incisors. Mucosal defect was cured by fibrin glue after Argon
plasma coagulation. Under endoscopic surveillance, the excised mucosa was
transplanted to the surface of the narrowed segment and fixed with 3 titanium
clips.
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Results: The endoscopic follow-up was planned every month. After 1 months,
18–23 cm esophageal region has healed to be normal. Within 6 months, the
stricture process was excitingly delayed as expected. The patient stated his symp-
tom was remarkably improved. Gastroscopy revealed the esophageal implanted
lesion was covered with an epithelium and the luminal surface was flat, without
ulceration.
Conclusion: Autologous esophageal mucosa transplantation might facilitate
tissue re-epithelialization, reduce pathological fibroplasia, and be helpful for
managing or preventing esophageal strictures. More clinical controlled trials
are required to provide evidenced-based recommendation and promote its clin-
ical application.
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Introduction: Functional dyspepsia (FD) is commonly associated with sleep dis-
turbance, which has been attributed to comorbid anxiety, depression and bother-
some gastrointestinal symptoms. However, it is unclear whether obstructive sleep
apnoea (OSA) is specifically associated with FD.
Aims & Methods: We aimed to compare the prevalence of FD in patients with
OSA and healthy volunteers. A total of 60 consecutive OSA patients (defined as
Epworth sleepiness scale4¼ 10, and apnea-hypopnea index4¼ 10/hour during
polysomnography; mean age: 47.6 years, male: 83.3%) and 60 healthy age-and-
sex-matched volunteers were recruited in a prospective case-control study.
Questionnaires were applied for the diagnosis of functional gastrointestinal dis-
orders (FGIDs) according to Rome III criteria. Anxiety and depression were
evaluated using the Hospital Anxiety and Depression Scale (HADS), sleep qual-
ity was evaluated by the Pittsburgh Sleep Quality Index, and fatigue was assessed
by the Multidimensional Fatigue Inventory (MFI-20) Chinese version.
Results: The prevalence of FD was 28.3% and 8.3% (17 vs 5, P¼ 0.005), and the
prevalence of symptomatic gastro-oesophageal reflux disease was 18.3% and 5%
(11 vs 3, P¼ 0.023) in the OSA group and healthy volunteer group, respectively.
OSA patients had higher anxiety and depression symptom scores, worse sleep
quality, and more fatigue compared with healthy volunteers. In the multivariate
logistic regression adjusting for age, sex and body mass index, OSA (odds ratio
4.93, 95% CI 1.01–24.1, P¼ 0.049) and depression (odds ratio 4.91, 95% CI
1.44–16.71, P¼ 0.011) were independently associated with FD.
Conclusion: To the best of our knowledge, this is the first study showing that
OSA is independently associated with functional dyspepsia. Sleep disturbances
previously attributed to psychological comorbidities in FGID may in fact arise
from undiagnosed OSA. We recommend screening for OSA as part of the man-
agement of FD.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1184 INDIVIDUAL ASSESSMENT OF GASTRIC ACID
PRODUCTION BY MEANS OF A NON-INVASIVE TEST:
RELATIONSHIP BETWEEN MAXIMAL ACID OUTPUT AND
PEPSINOGEN I LEVELS
F. Di Mario1, S. Scida2, C. Miraglia2, L. Franzoni2, M. Franceschi3, A. Bertelè4,
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Introduction: The assessment of acid secretion is important in order to prescribe
PPIs. The gold-standard to measure the maximal acid output (M.A.O.) is the
collection of gastric after an i.m. injection of pentagastrin. However, this method
is not currently used in clinical practice. Serum pepsinogen I (PGI) has been
proposed as a non-invasive surrogate. Aim of this study was to compare in a
group of patients with different acid related diseases serum levels of PGI and
M.A.O.
Aims & Methods: We enrolled 124 patients (M¼ 84, mean age¼ 45.3 þ/ 13.05
range¼ 17–80) affected by chronic atrophic gastritis (28, M¼ 17, mean age 51.2
þ/ 13.7 ys range 20–73) characterized by achlorhydria or low levels of acid
production (Group 1), or by duodenal ulcer (50, M¼ 42, mean age¼ 43.5 þ/
11.5 range¼ 17–65) in which an hypersecretory status is claimed (Group 2).
As control group, we studied 46 patients (M¼ 44 mean age¼ 44.0 þ/ 13.4
range¼ 25–80) with normal upper GI endoscopy and gastric histology, without
previous history of neoplasms or upper gastrointestinal surgery (Group 3). In all
patients we measured M.A.O. by means of two hours collection of gastric juice
(basal 30’, followed by an i.m. injection of pentagastrin at the dosage of 6 mg/kg)
(M.A.O. normal values: 5–25 mEq/h). All patients underwent blood sample for
determination of serum PGI (BioHit Ojy, Finland; normal values: 30–120 mg/l).
All determinations, both for M.A.O. and PGI were made off medication.
Results: The mean M.A.O. value in Group 1 was 2.15 mEq/h, in Group 2 52.49
mEq/h, in Group 3 17.48 mEq/h. A statistically significant difference was found
between the 3 groups (Group 1 vs. Group 2 p5 0.000001; Group 1 vs. Group 2
p5 0.0001; Group 2 vs. Group 3 p5 0.0001). The PGI mean values in Group 1
was 11.39 mg/l, in Group 2 107.72mg/l, in Group 3 84.28 mg/l (Group 1 vs Group
2: p5 0.000001; Group 1 vs Group 2: p5 0.00001; Group 2 vs Group 3
p5 0.05). The relationship between M.A.O. and PGI showed a Pearson
R¼ 0.683 (p¼ 0.0001). No statistically significant difference was found compar-
ing M.A.O. and PGI in the single groups (p¼ ns).
Conclusion: Serum PGI levels are fitting with M.A.O. both in hypo- and hyper-
acid secretory conditions like chronic atrophic gastritis and duodenal ulcer, as
well as in control subjects, suggesting that PGI could be adopted in clinical
practice to assess gastric acid production in individual subjects for a proper
management of acid related diseases.
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Introduction: Gastroesophageal reflux disease (GERD) is caused by reflux of
gastric acid into esophagus. It is reported that chronic inflammation caused by
GERD can lead to precancerous changes; Barrett’s esophagus. Thus, it could be
critical to assess the GERD. Diagnosis of GERD is based on the subjective
symptoms such as acid regurgitation. GERD is also diagnosed by endoscopy,
and the Los Angeles (LA) classification is commonly used to grade reflux eso-
phagitis endoscopically. It is well known that diabetes mellitus (DM) patients can
develop neuropathy and their ability to feel pain can decrease. However, it is not
known whether there is a discrepancy between the symptoms and endoscopic
GERD grade in DM patients.
Aims & Methods: From May 2015 to September 2016, patients who were taken
esophagogastroduodenoscopy by experienced endoscopists at our institution
were consecutively enrolled. All the patients completed the Gastrointestinal
Symptom Rating Scale (GSRS); an interview-based rating scale consisting of
15 items including the question on acid regurgitation (Dig Dis Sci 1988).
The GSRS has a seven-graded Likert type scale (score 1 represents absence of
symptom, and score 7 represents very bothersome symptom). Gastric atrophy,
reflux esophagitis, and esophageal hiatal hernia were diagnosed endoscopically.
The study patients were categorized according to the grade of LA classification of
GERD. The prevalence of patients with positive GSRS score (i.e. 2 or more) in
the DM group and non-DM group were compared using the Pearson’s chi-
square test.
Results: A total of 2438 patients (647 females and 1791 males, mean age 62.4
years) were examined. Of these, 1040 patients (42.7%) were DM, and 1398
patients (57.3%) were non-DM patients. The prevalence of gastric atrophy,
reflux esophagitis, and esophageal hiatal hernia were not different in DM
group and non-DM group. Mild GERD (LA-A) was found in 251 patients
(10.6%, 92 DM patients and 159 non-DM patients), and severe GERD (LA-B
and more severe) was found in 76 patients (3.12%, 40 DM patients and 36 non-
DM patients). Of the 36 non-DM patients with severe endoscopic GERD, 30
patients (83.3%) had positive GSRS score of acid regurgitation; however, of the
40 DM patients with severe endoscopic GERD, 19 patients (47.5%) had positive
GSRS score of acid regurgitation. The prevalence ratio of patients with positive
GSRS score in severe endoscopic GERD was statistically lower in DM patients
than in non-DM patients (p¼ 0.0016).
Conclusion: There is a discrepancy between the subjective symptoms and endo-
scopic GERD grade in DM patients. DM patients’ ability to feel acid regurgita-
tion could decrease.
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P1186 SARCOPENIA AS A LEADING RISK FACTOR FOR EROSIVE
ESOPHAGITIS: A LARGE-SCALE CROSS-SECTIONAL STUDY
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Introduction: Obesity is an established risk factor for reflux esophagitis. Yet, the
association of sarcopenia and obesity status with reflux esophagitis remains
unclear. We studied the association between obesity, sarcopenia, and sarcopenic
obesity and risk of reflux esophagitis in a large number of asymptomatic men and
women.
Aims & Methods: We conducted a cross-sectional study of 32,762 asymptomatic
adults who underwent routine health check-ups including screening endoscopy
from August 2006 to December 2011. Sarcopenia was defined as appendicular
skeletal muscle mass (ASM)/body weight (%) value beyond two standard devia-
tions below the mean for healthy young adults. Participants were categorized into
four groups according to obese and sarcopenic status: normal, obese, sarcopenic,
and sarcopenic obese.
Results: In a multivariate model adjusted for age, sex, smoking status, alcohol
intake, regular exercise, and metabolic variables, risk of reflux esophagitis was
higher in obese [adjusted odds ratio(aOR), 1.38; 95% confidence interval (CI),
1.26–1.52], sarcopenic (aOR, 2.20; 95% CI, 1.48–3.29), and sarcopenic obese
participants (aOR, 1.68; 95% CI, 1.39–2.03) than in normal participants. The
ORs comparing sarcopenic and sarcopenic obese participants to obese partici-
pants were 1.59 (95% CI, 1.06–2.38) and 1.22 (95% CI, 1.02–1.47), respectively.
In addition, the risk of reflux esophagitis according to sarcopenic and obese
status was observed similarly in all subgroups that were evaluated.
Conclusion: Our findings suggest that sarcopenia, regardless of obesity, is more
harmful condition for reflux esophagitis than obesity without sarcopenia.
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P1187 FOOD RATE (FREQUENCY AND TIME SPENT IN EATING)
IN PATIENTS WITH MORBID OBESITY. DIFFERENCES AND
SIMILARITIES BETWEEN MEN AND WOMEN
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Introduction: Obesity is considered one of the 21st century plagues in the Western
world. Although its etiology is multifactorial, eating habits represent an impor-
tant factor in its development. (1). The caloric load, the proportion of its com-
ponents and its patterns have been the object of multiple studies (1–5). One of the
most controversial aspects is the relationship between the frequency of meals and
body weight.
Aims & Methods: The aim of the study was to determine the food rhythm (fre-
quency and time spent in eating) in patients with morbid obesity (MO), based on
data from the diary of the 24-H esophageal pH-monitoring studies.
This was a retrospective study, including 100 patients (77 women), with MO in
whom bariatric surgery was indicated and 118 non-obese subjects from the con-
trol group of the Spanish Digestive Motility Group.
All were submitted to esophageal manometry and 24-H esophageal pH-monitor-
ing according to the usual technique. During pHmetry it was recommended that
the diet be similar as usual.
The relationship of demographic aspects with the number of meals and the time
invested in them, based on data from the pH meter was analyzed.
Statistical analysis was performed with the STATGRAPHICS Centurion pro-
gram. The limit of statistical significance was set at p5 0.05.
The study was approved by the ethics committee of our hospital. The informed
consent of the participants was obtained for the performance of the tests.
Results: The mean age of patients with MO was 43.1 years (range 19–68) with no
difference between men and women. The mean BMI was 41.55 (M 43.3; F 41,
P5 0.05).
In the 118 subjects of the control group (63 women), the mean age was 28.3 years
(range: 18–72 years), BMI 23.2, (M 24.2; F 22.3, P5 0.05). Age and BMI differ-
ences between controls and obese were statistically significant.
The number of meals is higher in the obese patients than in the controls. 76.3%
of the controls performed 4 meals. In obese patients this percentage was 56%.
The mean time spent at each meal showed statistically significant differences
between controls (20.5 7.7min) and obese (17.7 7.25min) and between con-
trols and obese women (17.8 7.2min).
In MO, the relationship between BMI and the number of meals shows a higher
BMI in those who do less number of meals, with significant differences between
those who perform 3 meals and those that perform 4. This difference is set at
the expense of men and not achieved statistical significance in women.
Conclusion: - MO patients eat more times a day than controls, this behavior is
more evident in women.
- MO patients eat faster than controls without differences between men and
women.
- Our results show an inverse relationship between the number of meals and body
mass index. This behavior is more evident in men.
Disclosure of Interest: All authors have declared no conflicts of interest.
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P1188 ONE DRINK CAN INCREASE A RISK FOR ESOPHAGEAL,
STOMACH AND COLORECTAL CANCER IN A COHORT OF
23,323,730 KOREAN ADULTS
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Introduction: Epidemiologic findings of low-volume alcohol consumption in rela-
tion to gastrointestinal cancers including gastric cancer are inconsistent.
Aims & Methods: The association between alcohol intake and esophageal, gastric
and colorectal cancer risk was examined in a population-based prospective
cohort of 23,323,730 adults in Korea who had undergone a biennial evaluation
provided by the National Health Insurance Corporation between the years 2009
and 2012.
Results: After median 5.4 years of follow-up, 9171 esophageal, 135,382 gastric
and 154,970 colorectal cancer cases were identified. Cox proportional hazards
regression models were used to estimate hazard ratios (HR) and corresponding
95% confidence intervals (95% CI). Light drinking as well as moderate to heavy
alcohol consumption significantly increased the risks of the three gastrointestinal
cancers (HR 1.51; 95% CI, 1.43–1.60; HR 1.08; 95% CI, 1.06–1.09; HR 1.12;
95% CI, 1.11–1.14) compared with non-drinkers after adjusting for age, sex,
smoking, exercise, income, body mass index, and diabetes. For esophageal
cancer, there was a dose-dependent linear relationship. However, no association
was observed between prediagnostic alcohol consumption and all cause-
mortality.
Conclusion: Light drinking including even one alcoholic drink a day is associated
with increased risks of esophageal, gastric and colorectal cancer.
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P1189 THE INFLUENCES OF VISCERAL FAT AREA ON THE SITES
OF ESOPHAGEAL MUCOSAL BREAKS AND SYMPTOM
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Introduction: Some studies have suggested the central obesity as a risk factor for
gastroesophageal reflux diseases (GERD). However, the associations between
visceral adipose tissue (VAT) and the sites of esophageal erosions or the symp-
tom severities of GERD have not been studied yet.
Aims & Methods: The aim of this study was to evaluate the influences of visceral
fat area on the locations of erosions and symptoms of GERD. The subjects who
underwent abdomen computerized tomography and esophagogastroduodeno-
scopy for routine checkup at the same day were collected from January 2007
to October 2016. 177 subjects who had erosive esophagitis (LA class A to D) were
enrolled. Questionnaires including gastrointestinal symptoms were written before
examinations. The abdominal obesity was evaluated by measuring visceral adi-
pose tissue (VAT), subcutaneous adipose tissue (SAT), ratio of VAT to SAT,
total adipose tissue (TAT), body mass index (BMI) and waist circumference
(WC).
Results: Lesser curvature (LC) side of esophagogastric junction (EGJ) was the
most frequent site of mucosal breaks (103 cases, 58.2%) followed by posterior
wall side (71 cases, 40.1%), anterior wall side (25 cases, 14.1%) and fundus side
(16 cases, 9.0%). Mucosal breaks in LC side were frequently observed in male
subjects (61.3% vs. 36.4%, p¼ 0.04). BMI (25.6 4.5 vs. 24.2 3.1, p¼ 0.019)
and WC (89.0 11.8 vs.85.0 9.1, p¼ 0.01) were significantly higher in LC
group. Moreover, VAT, ratio of VAT to SAT, and TAT were significantly
higher in LC group. In the multivariate analysis, a higher VAT area (odds
ratio (OR) 3.47, 95% confidence interval 1.38 to 8.73, 1st quartile vs. 4th quartile,
p5 0.01) and ratio of VAT to SAT (OR 2.99, 95% CI 1.15 to 6.70, 1st quartile
vs. 4th quartile, p¼ 0.02) were strongly associated with the mucosal breaks in LC
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side. However, TAT was not significant in the multivariate analysis. Lower
HDL-cholesterol levels (OR 0.28, 95% CI 0.11 to 0.67, p5 0.01) and much
coffee consumption (OR 2.50, 95% CI 1.06 to 5.86, p¼ 0.035) were associated
with the severities of GERD.
Conclusion: Mucosal breaks in LC side of EGJ were associated with visceral
obesity measured by VAT, ratio of VAT to SAT, BMI and WC. Life style
modification such as in left decubitus sleeping position might be emphasized in
the subjects with visceral obesity.
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P1190 A LESS COMPETENT OESOPHAGO-GASTRIC JUNCTION
IS ASSOCIATED WITH OESOPHAGEAL ACID HYPERSENSITIVITY
EVEN IN HEALTHY CONTROLS
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Introduction: In normal subjects, the oesophago-gastric junction (OGJ) sphincter
complex maintains a tight barrier between the oesophagus and stomach acid.
However, gastro-oesophageal reflux disease (GORD) caused by acidic reflux has
a prevalence of up to 26% [1]. One major factor determining whether gastro-
oesophageal reflux occurs and eventually generates symptoms is the competency
of the OGJ, which can be studied using distensibility testing. This way, we have
previously shown in patients with Barrett’s oesophagus and healthy controls that
an incompetent sphincter function was associated with more frequent reflux
symptoms [2]. In the same patient groups, we also found greater oesophageal
acid exposure and lower mucosal baseline impedance to be associated
with impaired sphincter function. The latter probably represents a proxy for
mucosal damage [3]. Other factors known to increase the perception of gastro-
oesophageal reflux episodes are greater acidity, larger volume, and more prox-
imal extent of the reflux content along with impaired mucosal integrity and
sensitisation (peripheral and central) [1]. All of this said no studies of our knowl-
edge have specifically addressed the possible association between sphincter func-
tion of the OGJ and oesophageal sensitivity.
Aims & Methods: We aimed to characterize oesophageal sensitivity in relation to
OGJ competence, hypothesizing that sensitivity increases with impaired sphincter
function. Twenty-three patients with Barrett’s oesophagus (mean age: 64.2 7.7
years) and 12 healthy controls (mean age: 54.9 10.8 years) were examined.
A standard upper endoscopy to locate the OGJ was followed by distensibility
testing of the OGJ using the EndoFLIP probe. At a later visit, experimental
oesophageal sensitivity was assessed using a multimodal stimulation probe.
After placement in the oesophagus just above the OGJ, the probe allows the
filling and emptying of an attached polyurethane bag with water, stimulation
with electrical current, and infusion of acid. Using this probe, mechanical dis-
tension of the bag, thermal stimulation at increasing temperature, electrical sti-
mulation, and acid perfusion with 0.1 M hydrochloric acid (a Bernstein test) were
performed. All stimulations were stopped when the subject felt moderate pain,
equal to seven on a 0–10 visual analogue scale validated for visceral pain. Data
were analysed using multi-level, mixed-effects regression analysis in Stata 12.
Results: Oesophageal acid sensitivity increased with a more incompetent sphinc-
ter function: A lower tolerated acid volume was associated with greater disten-
sibility index (P¼ 0.03) and with lower pressure (P¼ 0.03) in the OGJ in all
subjects analysed together and separately in healthy controls (P¼ 0.006 and
0.01 respectively). Performing separate analyses in patients with BO, these asso-
ciations were not present (all P4 0.7). Sphincter function was associated with
neither oesophageal sensitivity to mechanical, heat, nor electrical stimulation
(all P4 0.13).
Conclusion: Oesophageal acid sensitivity increased with a more incompetent
OGJ. Based on this and previous findings, we suggest that even in some healthy
controls, a modest degree of OGJ incompetence allows gastric acid to reflux. This
may again lead to low-grade oesophageal inflammation and mucosal damage,
thus evoking acid hypersensitivity. The latter mechanism probably constitutes a
reflex protective mechanism towards acid reflux.
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P1191 THE MUCOSAL INTEGRITY IN PHENOTYPES OF
GASTROESOPHAGEAL REFLUX DISEASE AND FUNCTIONAL
HEARTBURN
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Introduction: Three different phenotypes of gastroesophageal reflux disease
(GERD) such as erosive reflux (ERD), nonerosive reflux (NERD), esophageal
hypersensitivity (EH) and functional heartburn (FH) might have different patho-
physiological changes within the esophageal epithelium and the data is limited.
Aims & Methods: We aim to investigate the electrophysiological differences and
diffusion characteristics as a reflection of tissue integrity using Ussing chamber
system. Distal esophageal mucosal biopsies from 14 healthy controls (5 men,
40.6 11.2 years) and 62 patients with GERD (40 men, 42.9 12.3 years,
n¼ 26 LA grade A/B, n¼ 8 LA grade C/D, n¼ 22 NERD, n¼ 6 EH) and 11
patients with FH were studied from November 2015 until March 2017. GERD
and quality of life questionnaires, high-resolution esophageal manometry, 24 h
impedance-pH monitoring, upper gastrointestinal endoscopy with esophageal
biopsies were performed in all patients. Biopsies were put into the chambers to
measure the transepithelial resistance (TEER), potential difference (PD) and
tissue permeability via fluorescein diffusion within two hours as well as evalua-
tion of dilated intercellular spaces with light microscopy.
Results: Esophageal biopsies of healthy volunteers (163.6 41.1 ohms) had sig-
nificantly higher TEER when compared to total GERD patients (132.5 38.7
ohms). Although the TEER results of whole GERD subtypes were decreased
compared to healthy controls, only ERD groups were significantly lower
(123.3 29.8 ohms) (Table 1). There was also no significant difference in any
parameters between NERD, FH and EH groups. The mucosal permeability of
GERD subtypes was significantly higher than the healthy controls. The PPI-
unresponsive subjects (n¼ 10, 94.8 36.5 pmols) were much more permeable
to fluorescein compared to PPI-responsive subjects (n¼ 52, 56.0 32.4 pmols)
within all GERD patients (p¼ 0.009).
Table 1
GROUPS TEER (Ohms) PD (V)
PERMEABILITY
(pmols)
Healthy Controls 163.6 41.1 2.2 0,9 43.9 16.6
GERD (total) 132.5 38.7** 2.6 1.5 62.2 35.8*
Esophageal
Hypersensitivity
150.6 23.9 2.2 1.0 71.8 34,5
NERD 139.6 50.2 2.2 1.3 65.6 39,2*
ERD (total) 123.3 29.8* 3.0 1.6**Ø 58.3 34.7**
ERD grade A/B 130.5 27.8* 2.9 1.6 54.0 30.5
ERD grade C/D 105.8 32.7* 3.2 1.6 72.6 43.6
Functional Heartburn 145.3 42.7 1.9 0.9 67.0 35.2
Conclusion: The TEER and permeability results imply that ERD and NERD
groups showed a barrier disruption. However, epithelial permeability was not
different in EH and FH groups. The dilatation of intercellular spaces may con-
tribute to increased mucosal permeability in true-NERD and ERD patients. EH
and FH patients might have different pathophysiology than others.
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Introduction: The major noxious agents of gastroesophageal reflux disease
(GERD) on the esophageal epithelium are gastric acid and pepsin.
Nevertheless, there is no precise information about pepsin concentrations in
gastric juice.
Aims & Methods: We aim to address the pepsin values and pH results among
subtypes of GERD and functional heartburn. 46 patients with GERD (23 erosive
reflux disease LA grade A/B (ERD-A/B), 5 ERD-C/D, 14 nonerosive reflux
disease-NERD, 4 esophageal hypersensitivity-EH), 8 functional heartburn
(FH) and 17 healthy controls (HC) were included into the study. Upper gastro-
intestinal endoscopies were performed off PPI. Patients were instructed not to
aspirate the local anaesthetic solution and biopsy channel of the endoscope was
dried before the suction. The gastric juices from the subjects were aspirated
during endoscopy into a special beaker and their pH values were measured
immediately. The specimens were analysed using the Peptest lateral flow device
(RD Biomed Ltd UK), a colorimetric assay containing two unique human mono-
clonal antibodies that capture and detect pepsin protein.
Results: There were no significance between pepsin levels in any GERD pheno-
types, FH and healthy controls (Table 1). The pH results of patients with ERD
(1.8 0.6) were significantly lower versus HC (2.6 1.5). The pH levels of the
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esophageal hypersensitivity (1.5 0.2) were significantly decreased when com-
pared to HC (2.6 1.6) and also true NERD (4.0 2.0).
Table 1
Pepsin (ng/ml) pH
ERD (total) 514.7 282.1 1.8 0.6"
ERD-A/B 521.0 284.9 1.8 0.6
ERD-C/D 485.5 299.2 2.1 1.0
Total NERD 456.9 322.1 3.5 2.1
True NERD 428.1 293.0 4.0 2.0
EH 536.0 432.1 1.5 0.2*
GERD (total) 494.5 294.1 2.4 1.6
FH 654.2 300.4 2.1 1.1¥
HC 596.2 302.8 2.6 1.5
Conclusion: Pepsin may be considered a damaging factor in pathophysiology of
GERD, but we could not find any difference between GERD phenotypes and
unaffected controls. NERD group had less gastric acid versus other groups but
this finding needs more studies to confirm.
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Introduction: Gastropanel is a non invasive test suggested able to perform a
kind of ‘‘serological biopsy’’ of gastric mucosa. Aim of the study was to assess a
proper diagnosis of different upper gastrointestinal (GI) diseases in a population
suffering from upper GI disturbances in a primary care settings by means of
serology.
Aims & Methods: We enrolled 1900 consecutive patients (M¼ 769; mean
age¼ 56.4 ys, range¼ 29–78 ys) showing upper GI troubles. Exclusion criteria:
upper GI surgery, alarm symptoms. All patients underwent a blood sample for
Gastropanel (BioHit Oyj, Finland): pepsinogen I (PGI), pepsinogen II (PGII),
gastrin-17 (G-17) and IgG against Helicobacter Pylori (Hp-IgG). The normal
values: PGI: 30–120 mg/L, PGII: 2–15mg/L, G-17: 1–9 pmol/L, Hp-IgG: 530
U/L. The diagnosis of Hp-related non-atrophic gastritis was made by means of
the levels of PGII4 10 mg/L and Hp-IgG4 30 U/L; the diagnosis of gastroeso-
phageal reflux disease (GERD) was made when G-17 was low: 52 pmol/L; the
diagnosis of chronic atrophic gastritis (CAG) was made when PGI was 530mg/L
and G-174 14 pmol/L. Finally when all the four parameters were normal, the
subjects were classified as normal. All patients underwent upper GI endoscopy to
support the serological diagnosis, with appropriate gastric biopsy according with
OLGA classification.
Results: Four hundred and eighty eight patients were classified as affected by Hp-
related non-atrophic gastritis (26%); 782 patients were classified as GERD
patients (41%); 547 patients were classified as normal (29%). 83 patients were
classified as CAG (4%). In 96% out of the 488 patients with Hp-related non-
atrophic gastritis the features was confirmed by gastric histology (OLGA 0, 1, 2);
in 91% out of the 782 patients diagnosed as GERD subjects, the diagnosis was
confirmed by oesophagitis at endoscopy in 313 patients, positive Demeester score
in 170 out of 221 patients at 24 hours pH-metry or presence of typical symptoms
(heartburn and/or regurgitation) in 547 patients. The great majority of 83
patients in which the diagnosis was CAG showed a picture of OLGA 3
(56.6%) or OLGA 4 (24.2%).
Conclusion: Non-invasive diagnosis of upper-GI diseases when alarm symptoms
are absent seems to be promising to improve the appropriateness of endoscopy,
as well as to address subjects affected by Hp infection to the cure and GERD
patients to the therapy for reflux. The diagnosis of a precancerous condition like
CAG before performing endoscopy could address to a better bioptic sampling
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Introduction: Prevalence of obesity and the obesity-related diseases have been
increasing in recent years(1). In the studies conducted there are views claiming
that visceral fat-related central obesity causes digestion system diseases and
increase in the number of gastroesophageal reflux symptoms in particular (1–6).
Aims & Methods: In this study, in the cases of non-obese (Body mass index
(BMI)530), it is aimed to assess the effects of insulin resistance and the changes
observed in the anthropometric and bioelectrical impedance measurements upon
the reflux symptoms. Our study 120 BMI5 30 dyspeptic non-obese, gastroeso-
phageal reflux disease (GERD) diagnosed according to FSSG scale (Frequency
scale for the symptoms of gastroesophageal reflux disease) and 50
BMI5 30 non-dyspeptic, non-obese and not (GERD) diagnosed according to
FSSG cases have been included. The cases included in the study concerned have
been surveyed by means of the questionnaire including the demographic data and
the extra esophageal reflux symptom. Serum biochemistry analyses (fasting glu-
cose, insulin, lipid panel, uric acid, TSH, ALT) have been checked. Waist cir-
cumference has been measured. Body compositions and anthropometric
measurements have been assessed through the bioelectrical impedance method
(TANITA).
Results: _In this study a statistically significant difference (p5 0.05) has been
found when GERH-diagnosed group is compared with the healthy control
group in regard to waist circumference, BMI; LDL, Fat, Fat Mass, Total
Body Water(TBW), obesity level, reflux score, acid reflux score and total score
measurements. Fat free mass (FFM), muscle mass, bone mass, bone mineral
density (BMR) measurments in between the both groups have not been found
stattistically significant difference (p4 0.05) (Table 1). Considering the extra
esophageal reflux symptoms a significant difference (p5 0.05) between the
group suffering from sore throat, apnea, teeth grinding and GORH and the
healthy control group has been found. Within the patients group a positive
correlation between acid reflux score and BMI (r¼ 0.298) (p5 0.001), LDL
(r¼ 0.387) (p5 0.001), visceral fat (r¼ 0.180) (p5 0.049) has been determined.
A negative correlation between acid reflux score and TBW (r¼ -0.273)
(p5 0.003) has been determined.
Table 1: Metabolic parameters and bioelectrical impedans findings
Control Group Patient Group Total Number
P Value
(n¼ 50) (n¼ 120) (N¼ 170)
Median
(Min.-Max.)
Median
(Min.-Max.)
Median
(Min.-Max.)
Glucose 90.50 (77–165) 92 (53–165) 91.50 (53–165) 0.508
Insulin 8.05 (1.90–93) 8.35 (1.32–108) 8.20 (1.32–108) 0.553
HDL 51.50 (3.10–99) 47.50 (3.10–90) 48.50 (3.10–99) 0.066
LDL 74.50 (42–129) 87 (11–243) 80 (1–243) 0.035
Triglyceride 81 (33–350) 97 (28–404) 95 (28–404) 0.184
Total Cholesterol 146.50 (73–222) 161 (19–310) 159 (19–310) 0.216
Uric Acid 4.05 (1.20–41) 4.30 (1.20–59) 4.20 (1.20–59) 0.471
TSH 1.68 (0.07–7.56) 1.54 (0.02–10) 1.58 (0.02–10) 0.476
ALT 12.50 (5–39) 13 (5–65) 13 (5–65) 0.213
Fat 19.30 (3–41.80) 24.75 (3–95.20) 22.55 (3–95.20) 0.016
Fat Mass 12.80 (1.10–36.20) 15.15 (1.10–43.40) 14.20 (1.10–43.40) 0.012
FFM 45.95 (19–75.10) 46.05 (36.80–74.20) 45.95 (19–75.10) 0.613
Muscle Mass 43.95 (35–70.50) 43.90 (34.90–516) 43.90 (34.90–516) 0.520
TBW 32.70 (25.10–52.60) 32.50 (25.10–52.60) 32.55 (25.10–52.60) 0.341
TBW Yüzde 55.80 (41.60–80.90) 52.50 (41.60–80.90) 53.80 (41.60–80.90) 0.018
Bone Mass 2.40 (1.90–3.70) 2.40 (1.90–4) 2.40 (1.90–4) 0.442
BMR 5.858 (55.94–9.138) 5.851.50 (78.12–8.996) 5.858 (55.94–9.138) 0.586
Metabolic Age 16 (12–64) 27 (12–66) 22 (12–66) 0.002
Visceral Fat 1 (1–12) 3 (1–10) 3 (1–12) 50.001
Degree of Obesity 0.70 (29.90–35.90) 10.95 (29.90–35.90) 8.80 (29.90–35.90) 0.015
Homa-IR (mg/dl) 1.90 (0.42–19.06) 1.84 (0.27–22.93) 1.88 (0.27–22.93) 0.495
Acid Reflux Score 13.50 (5–23) 15 (8–23) 14 (5–23) 0.020
Reflux Score 7 (7–7) 19 (9–35) 15 (7–35) 50.001
BMI 22.43 3.43 23.79 3.60 23.39 3.59 50.022
Waist
Circumference
74.63 5.62 79.94 10.60 78.38 9.71 50.001
Total Score 20.50 (12–30) 33 (17–53) 29 (12–53) 50.001
Mann Whitney U Test(Monte Carlo) - Min.:Minimum - Max.:Maximum
Conclusion: The frequency and severity of gastroesophageal reflux symptoms in
the non-obese is closely related with body fat composition as those in the obese.
Increase in abdominal and visceral fat composition may cause high risk of gas-
troesophageal reflux disease in individuals irrespective of their obesity.
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Introduction: Esophageal baseline impedance (BI) levels have been recently pro-
posed as a marker of mucosal integrity. Indeed, patients with non-erosive reflux
disease (NERD) showed lower distal esophageal BI levels compared to healthy
controls (HCs) due to the presence of abnormal distal esophageal acid exposure
time (AET). On the other hand, no differences were found between NERD and
HCs at proximal esophagus due to the limited proximal migration of the reflux-
ate. Systemic sclerosis (SSc) is a systemic disease characterized by the deposition
of collagen and matrix proteins in the connective tissue of the skin and visceral
organs, such as the gastrointestinal tract. This event could potentially affect the
conductivity of the oesophageal wall and consequently reduce BI levels, also at
proximal level, but data in this regard are limited.
Aims & Methods: We aimed to prospectively compare BI levels between a group
of NERD patients and two groups of SSc patients, one with a clear manometric
picture of scleroderma esophagus (i.e. hypotensive esophago-gastric junction
pressure and absent peristalsis) and one without esophageal involvement.
Consecutive patients with heartburn and those with a definite diagnosis of SSc
underwent upper endoscopy in order to assess the presence of esophageal muco-
sal lesions. Further, a group of healthy subjects was used as controls (HCs).
Thereafter, all endoscopy-negative and SSc patients underwent esophageal
high-resolution manometry and impedance-pH testing off-therapy. Impedance-
pH tracings were blindly and manually reviewed, and we measured distal AET
and BI values at 3, 5, 7, 9, 15 and 17 cm above the lower esophageal sphincter,
during the overnight rest, for at least 30 minutes after excluding swallows and
reflux induced changes. NERD was diagnosed in case of reflux symptoms and
abnormal AET.
Results: Fifty patients [38F; mean age 51yrs] with NERD, 50 SSc patients [44F;
mean age 48yrs] with esophageal involvement, 30 SSc patients [28F; mean age
49yrs] without esophageal involvement and 50 HCs [37F; mean age 49yrs] were
enrolled. All 50/50 (100%) NERD patients [median 7.2] and 44/50 (88%) SSc
patients with esophageal involvement [8.3] showed an abnormal AET compared
to 8/30 (26%) SSc patients without esophageal involvement [3.1] and 0/50 (0%)
HCs [0.8] (p5 0.01). BI details are shown in the Table. Proximal median BI
levels (i.e. at 9, 15 and 17) were similar between NERD, SSc patients without
esophageal involvement and HCs (p¼ns), whereas they were much lower in SSc
patients with esophageal involvement (p5 0.05).
Median
BI Values NERD
SSc patients
with esophageal
involvement
SSc patients
without esophageal
involvement HCs
at 3 cm,  1180 961 1890 2965
at 5 cm,  1250 1114 2310 2688
at 7 cm,  1684 1230 2670 3110
at 9 cm,  2480 1640 2540 2890
at 15 cm,  2770 1520 2960 3320
at 17 cm,  2840 1980 3100 3250
Conclusion: Proximal esophageal BI levels are able to segregate between sclero-
derma patients with and without esophageal involvement. The advent of novel
and poorly invasive methods for the assessment of esophageal mucosal
impedance will allow us to perform this measurement without the need of pro-
longed probe insertion.
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Introduction: Gastroesophageal reflux disease (GERD), is characterized by fre-
quent relapses after withdrawal of therapy and no prognostic markers of relapse
are available to predict the outcome of the patients. Gastrin-17 (G-17) has been
proposed as a non-invasive marker of reflux disease as well as a good marker of
response to the therapy. Pepsinogen I (PG I) and Gastrin-17 (G-17) are claimed
to increase in a statistically significant manner after proton pump inhibitors
(PPIs) therapy. Aim of the study was to assess the prognostic value of G-17
serum levels in order to single out GERD patients more prone to develop an
early reflux relapse in a prospective open study.
Aims & Methods: We prospectively enrolled 221 consecutive GERD patients (F
113, mean age 52.5 years; range 28–74 years) with endoscopically proved diag-
nosis of esophagitis, according to the L.A. classification, all symptomatic (heart-
burn and/or regurgitation). All patients were treated with rabeprazole 20mg once
a day for 6–8 weeks, assessing at the end of the therapy the symptoms’ modifica-
tions by means of a questionnaire. In the group of asymptomatic patients, we
performed a one-year follow-up, recording the GERD relapse episodes; only on-
demand antacids were permitted. All patients underwent at baseline a blood
sample and after the acute course of PPI therapy.
Results: One hundred eighty five patients were asymptomatic after the 6–8 weeks
of PPI therapy and entered in the prospective evaluation for 12 months. 19
subjects were lost lasting the follow-up and finally 166 patients were available
for the study analysis. 72 patients experienced at least one GERD relapse episode
(first group) against 94 ones free of symptoms for one year (second group). The
mean values of both PG I and G-17 after the 6–8 weeks of PPI therapy in
comparison with the baseline levels, were higher in first group than in the
second one (first group: baseline PG I 96mg/L, G-17 2.6 pmol/L; after therapy:
PG I 164 mg/L, G-17 19 pmol/L; p5 0.0001; second group: baseline PG I 98 mg/
L, G-17 2.9 pmol/L; after therapy: PG I 116 mg/L, G-17 6.3 pmol/L; p: ns). The
good response to full dose of PPI, assessed by an increase of both PG I and G-17,
seems to be the pathophysiological background to explain the prognostic value of
such markers.
Conclusion: Gastrin-17 and pepsinogen I increase after full-dose of PPI in GERD
acute phase seems to be a simple non-invasive marker to predict early GERD
relapse in one-year follow-up.
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Introduction: Various biomarkers have been studied to evaluate the integrity of
esophageal epithelium in distinguishing phenotypes of gastroesophageal reflux
disease (GERD). Baseline impedance (BI) measurement is likely to be one of
these and can be measured during the 24-hour ambulatory intra-esophageal
impedance-pH study. Mucosal impedance (MI) measurement is a technique
introduced in recent years and is a practical method that can be applied during
endoscopy, but the validation studies are insufficient. BI & MI measured with the
same regular impedance catheter and data from 118 patients with different reflux
phenotypes and controls were evaluated.
Aims &Methods: Patients were divided into five groups: mild (ERD A-B, n¼ 31),
severe erosive esophagitis (ERD C-D, n¼ 11), non-erosive reflux disease
(NERD, n¼ 26), functional heartburn-esophageal hypersensitivity (FH-EH,
n¼ 17), healthy controls. High resolution manometry, 24-h MII-pH, upper gas-
trointestinal endoscopy were performed. BI values were taken at the sleeping
period at night where reflux and swallowing did not occur. MI measured
during endoscopy, a regular impedance-pH catheter passed through the biopsy
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channel of the scope. Distal two rings were contacted to the distal and proximal
parts of the esophagus approximately 20–30 seconds. MMS Omega ambulatory
recorder and Greenfield (6 imp, 1 pH) impedance catheter were used.
Results: MI can differentiate ERD from non-erosive groups but do not have a
diagnostic value to discriminate NERD from FH-EH or controls. However, BI
can segregate NERD from ERD addition to controls (Table 1).
Table 1
Groups
Baseline
impedance
Distal
mucosal
impedance
Mucosal
impedance
(proximal
esophagus)
Control (n¼ 15/n¼ 18) 2267 393# 2673 547# 3190 515
FH and EH (n¼ 17) 1906 716# 2654 721# 3350 880
NERD (n¼ 26) 1305 759*# 2423 852# 3407 1074
ERD A-B (n¼ 31) 868 481* 1538 646* 3096 928
ERD C-D (n¼ 11) 441 301* 1355 672* 3236 1653
Conclusion: As a new diagnostic tool, MI needs validation studies and our results
failed to show additional diagnostic value in non-erosive patients compared to
healthy controls. Since regular catheters are failed, new baloon-shaped catheters
should be validated. BI might be a better tool to discriminate NERD from
controls. This implicates that the esophageal epithelial resistance is impaired in
this particular group compared to controls.
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Introduction: Atrophic body gastritis (ABG) is characterized by loss of oxyntic
glands with consequent reduced acid secretion, hypergastrinaemia and, in a later
stage, pernicious anemia (PA). Up to 40% of ABG patients complain of dyspep-
sia. Despite hypochlorhydria, in 21% of autoimmune gastritis (AG) patients
gastro-esophageal reflux (GER) symptoms have been reported and in one third
of them (mostly non acidic) reflux has been documented at pH-monitoring. At
now, data regarding endoscopic and histopathologic GER-related esophageal
findings in this setting are lacking.
Aims & Methods: Aim of this study was to assess the occurrence of GER symp-
toms and endoscopic-histopathologic esophageal findings in ABG patients.
During 12-months, 35 consecutive ABG patients [80% female; median age
60 yrs (27–81); BMI 25.7 kg/m2(18.2–32.3); fasting gastrinaemia 329 pg/ml
(215–1476); pepsinogen I 10 ng/l (0–44); positive Ab against parietal cells
74.3%], undergoing scheduled gastroscopy for malignancy surveillance irrespec-
tive to gastrointestinal (GI) symptoms, were included. The presence of GER
typical symptoms (heartburn and regurgitation), atypical (cough, no cardiac
chest pain and dysphagia) and dyspepsia [postprandial distress syndrome
(PDS) and epigastric pain syndrome (EPS)] was assessed by a standardized ques-
tionnaire. Hiatal hernia and erosive esophagitis were evaluated. Biopsies from
distal esophageal (at least 2) and gastric mucosa (at least 5) were collected.
Histopathological evaluation, performed by experienced pathologist who was
unware of clinical data, assessed: i) dilatation of intercellular spaces (DIS); ii)
basal cell layer hyperplasia; iii) intraepithelial eosinophils; iv) neutrophils and iv)
mononuclear cells. Gastric biopsies were evaluated according to updated Sydney
System. Moderate-severe body gastric atrophy was confirmed in all patients.
No patient was in treatment with anti-secretory drugs.
Results: 74.3% (26/35) of ABG patients complained at least one GI symptom:
45.7% (16/35) reported GER symptoms [typical (2/14), atypical (9/14) and both
typical and atypical symptoms (5/14)], 48.6% (17/35) PDS and 11.4% (4/35) EPS
dyspepsia. One GER patient had erosive esophagitis (LA-C according to Los
Angeles classification) with concomitant hiatal hernia and another one presented
a short tongue of columnar lined mucosa at distal esophagus with an area of
intestinal metaplasia (Barrett’s esophagus, C2M2 according to Prague
Classification). Among ABG symptomatic patients, 34.6% (9/26) presented
GER-related microscopic esophagitis, whereas the remaining symptomatic
patients were free of microscopic esophagitis. Esophageal findings, both endo-
scopic and microscopic esophagitis, were exclusively present in symptomatic
ABG patients (Fisher-t: p¼ 0.00027). Evaluating only autoimmune gastritis
patients (n¼ 26), the occurrence of esophageal findings was not related to the
presence symptoms (Fisher-t: p¼ 0.1915).
Conclusion: A third of ABG symptomatic patients, investigated by specific ques-
tionnaire and esophageal biopsies, presented pathological findings of esophageal
mucosa ranging from GER-related microscopic esophagitis to Barrett’s esopha-
gus. These findings show that, even in hypochlorhydric patients, esophageal
mucosal damage may occur, suggesting the opportunity to accurately investigate
GI symptoms, including GER symptoms, in ABG patients.
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Introduction: Gastroesophageal reflux disease (GERD) is considered a multi-fac-
torial disease characterized by the presence of both typical and extra-oesophageal
symptoms, as well as related risks factors, such as smoking habits. In primary
care setting, dyspeptic symptoms could overlap GERD symptoms, being the
differential diagnosis sometimes difficult, almost because when we performed
in such patients upper-gastrointestinal (GI) endoscopy, a picture of esophagitis
is observed in no more than 30–40% of the subjects. Aim of the study was to
search in a primary care settings possible differences in clinical presentations in a
group of patients with GERD, in comparison with a group of dyspeptic patients.
Aims & Methods: One thousand and six hundred consecutive dyspeptic patients
(M¼ 766; mean age¼ 51.5 years; range¼ 27–79 yr) were enrolled in the study,
according with presence of upper-GI troubles like epigastric pain, fullness,
nausea, vomiting but not heartburn or regurgitation. All patients showed a
negative upper-GI endoscopy and were helicobacter Pylori (H.p.) negative
(Urea Breath Test and HpSA). Patients with history of peptic ulcer, neoplasms
or upper-GI surgery were excluded. Seven hundred and one patients showing
heartburn and/or regurgitation, a picture of esophagitis according with L.A.
classification or a positive DeMeester score (414) at 24 hours pH-metry were
enrolled in GERD group. By using a questionnaire, we collected data on both
alcohol and smoking habits.
Results: No differences were found for sex and age between the two groups
(GERD: M:F¼ 1:1.2, mean age: 56 years; dyspeptics: M:F¼ 0.9, mean age: 53
years; p¼ns); heavy smokers was 29% in GERD group, 26% in dyspeptics;
p¼ns. Heavy drinkers were 23% in GERD group, 22% in dyspeptics; p¼ns.
In GERD group, typical symptoms were detected in 547 out of 701 patients,
being heartburn the prevalent symptom in 479 subjects and regurgitation in
68 ones. Atypical symptoms, mainly chronic cough were present in 303 patients.
313 patients showed grade A esophagitis, 32 grade B, 4 grade C. One hundred
and seventy out of 221 patients showed a positive DeMeester score for
acid reflux.
Conclusion: Sex, age, smoking habits and alcohol consumption seem no differ in
the two studied population. In GERD cohort, the majority of patients experi-
enced Non Erosive reflux Disease (NERD). The majority of GERD patients
suffered by typical symptoms; chronic cough represented the most frequent man-
ifestation among the atypical and extra-oesophagial ones.
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Introduction: In China, 13.6% of gastrointestinal outpatients suffer from gastro-
esophageal reflux disease (GERD), among which only 36.9% undergo endoscopy
[1]. For patients with symptoms of GERD, empirical proton pump inhibitor
(PPI) treatment is recommended as a diagnostic test of GERD and as a thera-
peutic trial to control symptoms by Chinese GERD consensus guidelines [2].
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Currently, there are no real-world data assessing the efficacy of short-term
empirical treatment with PPIs in GERD patients in China.
Aims &Methods: This was a multicenter, prospective, observational study carried
out in a real-world setting. The primary objective was to determine the overall
responder rate in patients with typical GERD symptoms after 4 weeks of empiri-
cal treatment with PPIs. Responders were defined as having heartburn/regurgita-
tion on 1 day during the prior 7 days, assessed by the Gerd-Q questionnaire.
Outpatients aged between 18 and 65 years with a Gerd-Q score 8 were enrolled
if they were prescribed standard-dose PPIs as empirical treatment and were not
planned to have an endoscopy within 4 weeks of enrolment. The PPI regimen
prescribed was decided completely at the physicians’ discretion. Patient demo-
graphics, diagnosis, prescribed PPI regimens, Gerd-Q score and symptom fre-
quency were recorded. Data were collected at baseline, 2 weeks and 4 weeks after
initiating PPI treatment. Results from the full analysis set (FAS) are presented.
Results: A total of 1,000 patients from 10 centers were screened for this study, of
which 987 met the inclusion criteria and were included in the FAS. The mean age
was 45.2 11.6 years, the mean body mass index was 23.4 3.3 kg/m2, and
50.3% of the patients were male. The mean duration of GERD was 0.8 2.6
years, with a mean baseline Gerd-Q score for the week before screening of
10.5 1.9. During the 4 weeks’ treatment, the proportion of patients receiving
at least one dose of PPI was 99.5%. Esomeprazole was the most frequently
received PPI (57.1% of patients). Other PPIs (rabeprazole, lansoprazole, panto-
prazole and omeprazole) were received by 50.1% of patients and 7.2% of the
patients sequentially received 2 PPIs in the duration of the study. A total of
787 (79.7%) patients either completed the 4-week PPI treatment or withdrew
after response, of which the responder rate was 74.0% [95% CI, 70.7%–
77.0%] (Table 1). Among the 818 patients who completed 2 weeks’ treatment,
the responder rate was 57.0% [95% CI, 53.5%–60.4%]. The overall median time
to response was 13 days [95% CI, 12–15]. Over the study duration, patients’
Gerd-Q score demonstrated a decreasing trend. The proportion of patients
with a Gerd-Q score 8 reduced from 100% at baseline to 29.5% and 17.4%
at 2 and 4 weeks, respectively.
Table 1: Responder rate [1] and median time to response for different PPIs
Esomeprazole Other PPIs Total
4-week responder
rate, % [95% CI]
75.2 (342/455)
[70.9–79.1]
72.3 (240/332)
[67.1–77.0]
74.0 (582/787)
[70.7–77.0]
2-week responder
rate, % [95% CI]
57.1 (268/469)
[52.5–61.7]
56.7 (198/349)
[51.4–62.0]
57.0 (466/818)
[53.5–60.4]
Median time to response [2],
days [95% CI]
12 [11–14] 14 [12–17] 13 [12–15]
[1] Responder rate¼number of responders/number of patients who completed
the corresponding treatment or withdrew after response. [2] Response was defined
as heartburn/regurgitation frequency 1 days during the prior 7 days.
Conclusion: In Chinese clinical practice, short-term PPI empirical treatment effec-
tively improves symptom control in GERD patients and gains a satisfactory
overall responder rate.
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Introduction: Electrical stimulation of lower esophageal sphincter (LES) has been
approved to increase LES pressure (LESP) and commercially treat gastroesopha-
geal reflux disease (GERD). EndostimTM-like active appliance was efficient but
need reoperation for replacing the battery part. Therefore, one novel passive LES
stimulation system was invented and evaluated here in rabbits.
Aims & Methods: Different from EndostimTM, wireless power technology was
firstly applied in the implanted part. The LES stimulation could be easily self-
controlled and powered by external system. No reoperation or implantation
replacement need. In order to evaluating its efficacy and safety, GERD rabbit
model was created by balloon dilation and applied to optimizing stimulating
parameters. Body weight, food intake and LESP were recorded in the experi-
mental course.
Results: A total of 12 rabbits (male, 3 4 kg) were successfully applied for equip-
ment implantation. LES stimulation was delivered at 20Hz, 215ms, 3–8 mA in
multiple 30-minute sessions. The muscle contraction phenomenon was obviously
observed during the surgery in the stimulation group(6 rabbits). The mean LESP
was increased significantly in stimulation group than sham group (stimulation
group: 9.25 1.24mmHg vs 13.99 1.28mmHg, P5 0.05; sham control
group:9.00 1.22mmHg vs 9.23 1.27mmHg, P¼ 0.267). After operation, the
body weight initially decreased but recovered after one week. No serious
implantation or stimulation-related adverse effects were reported in the two-
month follow-up.
Conclusion: Electric stimulation represents a prospective approach for treating
GERD in clinics. This novel wireless LES stimulation system was also safe and
effective for treating GERD rabbits. After implantation, its passive medical
strategy will benefit patients and keep the long-term efficacy for clinical
GERD management.
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Introduction: Laparoscopic Anti-Reflux Surgery (LARS) is an established alter-
native treatment to pharmacological therapy for patients with Gastro
Oesophageal Reflux Disease (GORD), yet its safety and efficacy in obese patients
is controversial. A systematic review and meta-analysis was performed to com-
pare LARS related to obesity.
Aims & Methods: The primary outcome measure was the relative incidence
of recurrent reflux related to BMI. Secondary outcome measures were relative
incidence of perioperative complications, re-intervention rates in the form of
endoscopic dilatation or surgery, conversion to open surgery, and early return
to theatre. Embase, MEDLINE and the Cochrane Library (January 1970 to
November 2016) were searched for studies reporting clinical outcomes of
LARS in patient cohorts stratified by Body Mass Index (BMI). Data was
grouped according to BMI, 530 kg/m2 (non-obese) and 30 kg/m2 (obese).
Results were pooled in meta-analyses as Odds Ratios (OR).
Results: Eleven eligible observational studies comparing LARS in non-obese
(n¼ 6003) and obese (n¼ 1620) patients were identified. Recurrence of reflux
was significantly lower in the non-obese cohort (OR 0.34, 95% CI 0.19 to
0.60, p5 0.001), however no significant differences were observed in rates of
operative morbidity (OR 0.87, 0.65 to 1.18, p¼ 0.38), redo surgery (OR 1.08,
0.68 to 1.72, p¼ 0.73), endoscopic dilatation (OR 1.06, 0.49 to 2.33, p¼ 0.88),
conversion to open surgery (OR 1.17, 0.55 to 2.48, p¼ 0.68), or early return to
theatre (OR 0.77, 0.44 to 1.37, p¼ 0.38).
Conclusion: LARS can be performed safely in obese patients, but risks higher
GORD recurrence. Clinicians and patients should be aware that obesity may
adversely affect LARS outcome and careful consideration be given in the consent
process inherent within the optimal management of GORD.
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Introduction: The use of PPIs represents the main treatment in gastroesophageal
reflux disease (GERD), having demonstrated its effectiveness both in the control
of inflammation and symptomatology. However, between 10–20% of patients
present persistent symptoms or lesions despite the treatment.
Aims & Methods: The aim of the study was to assess the presence of acid reflux in
patients submitted to our department with the diagnosis of refractory GERD,
due to low or no response to PPIs. This was a retrospective study including 190
patients (55 men, 135 women) referred to our service with the diagnosis of GERD
from January 2008 to December 2015. Based on the diagnostic criteria, two
groups were made. Group 1: included 63 patients (33.2%) diagnosed of
GERD due to typical symptomatology and at least one positive complementary
test (radiology, pHmetry or endoscopy). All of them underwent a 24-H pHmetry
study with a dual channel, esophageal and gastric, on-PPI treatment. In 17
patients the pHmetry was completed with multichannel intraluminal impedance
(15 cases) or Bilitec (2 cases). Group 2: included 127 patients (66.8%) who had
been diagnosed of GERD only on the basis of typical symptoms; all of them
underwent esophageal double channel 24-H pH-metry off-PPI. All of the studies
(24-hour pHmonitoring or multichannel intraluminal impedance-pH studies)
(MARK III, Delta and Digitrapper pH-Z; Synectics, Gyven, Medtronic) were
performed according to standard technique.
Results: Pathological reflux was present in 91 patients (47.9%), 24 from group 1
and 67 from group 2. Pathological acid reflux was therefore ruled out as a cause
of symptoms in 52.1% of all cases studied: 60 patients (47.2%) from group 2, and
39 patients (61.9%) from group 1. In addition, out of the 24 patients with
pathological reflux in group 1 (true refractory patients), 9 had an incomplete
response, with a percentage of time with pH 54 less than 7.5% (mild reflux),
which probably was not the cause of the symptomatology.
Conclusion: Proton pump inhibitors (PPIs) are the drugs of choice in the treat-
ment of GERD. However, its efficacy may be compromised for a variety of
reasons including: non-compliance, bioavailability, episodes of nocturnal acid
break-through, poor gastric emptying, etc. In most of the patients referred for
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studying with the diagnosis of refractory reflux to PPIs, this diagnosis had only
been based on GERD-compatible symptoms. When the diagnosis is exclusively
clinical, about a half (47.2%) of the patients with persistent symptoms on double
doses of PPIs, considered as GERD patients refractory to PPIs, have an incorrect
diagnosis (patients do not have pathological reflux). More than half of the
patients (61.9%) who have a diagnosis of GERD confirmed by complementary
tests that do not respond to treatment with PPIs, acid reflux is not the cause of
their symptoms.
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Introduction: Recently, low-FODMAP diet has been proposed as potential treat-
ment in patients with irritable bowel syndrome (IBS) given its high efficacy in
symptoms relief. Recent data showed that IBS frequently overlap with functional
heartburn (FH) and functional dyspepsia.
Aims & Methods: The aim of this study was to evaluate the efficacy of low-
FODMAP diet in reducing heartburn in patients with FH and no pathophysio-
logical evidence of gastroesophageal reflux (GERD) compared to patients with
non-erosive reflux disease (NERD). As secondary aim we investigated the reduc-
tion of lower gastrointestinal symptoms in both groups. We enrolled patients
with heartburn and negative upper endoscopy who were scheduled for upper
pathophysiological tests (esophageal manometry and impedance and pH mon-
itoring, MII-pH) at Gastroenterology Unit in University of Pisa. We excluded
patients older than 75 and younger than 18, those with primary esophageal
motor disorders and with previous abdominal surgery. Medical history, volup-
tuary habits and response to proton pump inhibitor (PPI) treatment were
recorded. By means of MII-pH we splitted patients in two populations: NERD
group (abnormal esophageal acid exposure or number of refluxes) and FH group
(normal esophageal acid exposure and number of reflux, no symptom-reflux
correlation and no heartburn relief during PPI treatment). All enrolled patients
were evaluated with validated questionnaires (Likert and VAS) to evaluate heart-
burn occurrence pre- and post a nutritional approach with low-FODMAP diet
for 6 weeks.
Results: We included 31 patients (20 female; mean age 49.1 yrs; mean BMI 24.4)
into the study. NERD group was composed of 13 patients (6 female; mean age
48.7 yrs; mean BMI 25.7). FH group was composed by 18 patients (11 female;
mean age 50.9 yrs; mean BMI 23.9). All patients showed symptom improvement
regarding bloating, abdominal pain and stools composition (p5 0.001) after
low-FODMAP diet (see Table 1). Moreover, we observed a very important
improvement of heartburn in the FH group (from 8.4 2.5 to 2.3 1.1;
p5 0.001 on VAS scale) compared to the NERD group (7.2 2.2 a 6.9 1.9;
p¼ 0.624 on VAS).
Table 1: abdominal symptoms perception pre- and post- low-FODMAP diet in
NERD and FH groups
NERD group FH group
Pre-diet Post-diet P value Pre-diet Post-diet P value
Abdominal pain 3.6 1.8 2.7 0.9 0.041* 5.8 2.1 1.7 1.3 0.0001*
Bloathing 4.3 2.6 3.1 1.7 0.187 6.3 1.5 2.1 0.9 0.0001*
Wind 4.9 2.3 3.3 1.7 0.055 6.1 1.9 2.2 1.15 0.0001*
BSC
(type 3–5)
3/13 7/13 0.226 2/18 13/18 0.005*
Legend: BSC¼Bristol Stool Classification; *¼statistically significant (p5 0.05)
Conclusion: This pilot study showed that a low-FODMAP diet was able to reduce
heartburn perception in patients with FH and who did not obtain any symptom
relief after PPI treatment. Larger prospective randomized controlled trial is man-
datory to further explore these findings
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Introduction: Because of a higher prevalence of BE in males, recommendations in
current guidelines are mainly based on male BE patients and make no difference
in surveillance according to gender. Nevertheless, it is unknown whether female
BE patients have the same neoplastic progression and acceleration rate as male
patients.
Aims & Methods: The aims of this study were (1) to evaluate the difference
between males and females in probability of and (2) time to neoplastic progres-
sion, as well as (3) gender differences in stage distribution of neoplastic progres-
sion in surveilled BE patients. In this multicenter prospective cohort study we
included 729 patients with BE who met the inclusion criteria of a segment of
2 cm and confirmed intestinal metaplasia. Endoscopic surveillance was per-
formed according to the American College of Gastroenterology guidelines.
Cox regression modelling as well as accelerated failure time modelling were
used to estimate differences in probability of and time to neoplastic progression
to HGD, EAC and both HGD and EAC between sexes, respectively. All models
were adjusted for age, presence of esophagitis and length of BE. In case of a
limited number of events, descriptive statistics were used.
Results: 532 males (73%; median age 58 years, IQR 51–67) and 197 females
(median age 64 years, IQR 57–70) were included with a median follow-up of
8.2 years (IQR 5.3–10.3). High-grade dysplasia (HGD) was detected in 35 males
versus 4 females, EAC in 12 males versus 5 females. The total number of patients
with neoplastic progression was 56 (8%), which was twice as high among males
compared to females (HR 1.90, 95% CI 0.92–3.92). Especially the risk of HGD
was higher in males than in females (HR 3.34, 95% CI 1.17–9.50). The ratio
HGD/EAC in males was 2.92, in females 0.80. Apparently in females propor-
tionally more EAC was identified compared to males. Though these data might
suggest accelerated neoplastic progression rates in females, time to event was
significantly shorter for males in HGD (AR 0.45, 95% CI 0.22–0.94).
There was no difference for overall neoplastic progression (AR 0.59, 95% CI
0.32–1.09). Stage distribution is as shown in Table 1, females tend to have a
higher stage of neoplastic progression than males.
Conclusion: The risk of HGD and overall neoplastic progression and acceleration
rate of HGD development is higher in male BE patients compared to females. On
the other hand descriptive statistics show proportionally more EAC in females as
well as an advanced stage of EAC at diagnosis. Further research into the differ-
ential aspects of neoplastic progression in BE between men and women, may
have future consequences for gender specific guideline recommendations, includ-
ing the timing of follow-up.
Table 1: Stage distribution of neoplastic progression between males and females
Stage 0 Stage 1 Stage 2 Total
Male 40 85% 4 8.5% 3 6.4% 47
Female 5 56% 3 33% 1 11% 9
Total 45 80% 7 13% 4 7.1% 56
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Introduction: Given its proven safety and efficacy, RadioFrequency Ablation
(RFA) is the preferred ablation modality for dysplastic Barrett’s Esophagus
(BE). However, RFA is associated with significant drawbacks, such as the
need for large controller units, multiple deployment steps and capital investment.
The Focal CryoBalloon Ablation system (FCBA; C2 Therapeutics Inc. Redwood
City, CA, USA) is another ablation method -based on the application of extreme
cold- that has been recently developed to overcome these RFA drawbacks.
Additionally, FCBA might be better tolerated. FCBA comprises a handheld,
through-the-scope system with a conformable balloon that is simultaneously
inflated and cooled using nitrous oxide, resulting in ice patches of approximately
2cm2 on the targeted mucosa. Previous studies applying FCBA to limited areas of
BE (1 to 2 small BE islands per patient) have shown promising results. Data on
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efficacy and safety of FCBA in the treatment of larger BE segments, however, are
lacking. Therefore we aimed to assess the safety and efficacy of a single treatment
with FCBA for dysplastic BE.
Aims & Methods: Patients were seen between March and December 2016 at two
tertiary referral centers in the Netherlands. Patients with a BE 56 cm in length
and with a confirmed diagnosis of low-grade (LGD) or high-grade dysplasia
(HGD) or after endoscopic resection for visible lesions, were included.
Exclusion criteria included previous focal ablation therapy and strictures.
At baseline, all visible BE was treated with side by side ablations of 10 seconds,
including circumferential treatment of the gastroesophageal junction (GEJ). Pain
scores were assessed directly post-treatment and at days 2 and 7. Follow-up
endoscopy with biopsy and photo documentation was scheduled after 3
months. Primary outcomes included dysplasia regression rate and incidence of
esophageal stricture or other adverse events.
Results:We enrolled 20 patients with dysplastic BE (85% male, mean age 66 (8)
years), with a median BE length of C0M2 (IQR 0–0; 1–3) and with a baseline
diagnosis of LGD (10; 50%), HGD (1; 5%), or mucosal adenocarcinoma
(9; 45%). Ten (50%) had undergone endoscopic resection of a visible lesion
before cryoablation and 8 (40%) had undergone previous circumferential
RFA. During a median ablation time of 16 minutes (IQR 11–19), all BE, includ-
ing circumferential ablation of GEJ was successfully ablated in all patients.
No adverse events occurred, and median pain directly post-treatment was 4
out of 10 (IQR 0–5), whereas this was 1 (IQR 0–2) and 0 (IQR 0–1) at days 2
and 7. At the 3-month follow-up endoscopy, median endoscopic regression of
initial BE was found to be 95% (IQR 83–98), this included 3 patients (15%) with
a complete 100% regression. All biopsies confirmed squamous regeneration with-
out evidence for subsquamous BE. No significant esophageal strictures or other
complications were noted.
Conclusion: Our multicenter, prospective trial shows that a single treatment with
Focal CryoBalloon ablation therapy is safe, well-tolerated and effective for era-
dication of dysplastic BE.
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Introduction: Radiofrequency ablation (RFA) is safe and effective for eradication
of dysplastic Barrett’s Esophagus (BE), but may be associated with significant
post-procedural pain. As an alternative, cryoablation using the Focal
CryoBalloon Ablation system (FCBA) has recently been developed, which
ablates BE by freezing it using nitrous oxide. Early uncontrolled studies suggest
comparable safety and efficacy of FCBA and RFA in eradicating dysplastic BE.
Therefore, secondary endpoints like pain might play a determining role in select-
ing the best treatment modality. In contrast to heat-based ablation, FCBA pre-
serves the extracellular matrix which might be associated with less pain while
maintaining sufficient depth of ablation. In this study, we aimed to compare
post-procedural pain between focal RFA and FCBA.
Aims & Methods: Between January 2016 and March 2017 all patients undergoing
focal ablation therapy of BE, either with RFA or FCBA performed in two
tertiary referral centers in the Netherlands, were approached to complete a digital
diary. A short questionnaire was daily sent to patients for 14 days post- treat-
ment, to assess (1) odynophagia, (2) chest pain in rest (both were assessed using
VAS score ranging from 0 to 10), (3) dysphagia (assessed using a score ranging
from 0 to 4) and (4) use of analgesics. Primary outcome included maximum VAS
score (maximum score for either item 1 or 2), secondary outcomes included area
under the curves (AUCs) for all items assessed, maximum reported VAS score at
any time, time to VAS 0 and analgesics use. According to national guidelines, all
visible BE was ablated, including circumferential treatment of the gastro-esopha-
geal junction (GEJ). In a standardized way, all patients were advised to use
paracetamol (up to 4 times 500mg daily) as necessary with additional ibuprofen,
if needed.
Results: Fifty-five patients were included (35 with focal RFA; 20 with CBA) and
median BE length was similar for the two groups (FCBA: C0M2, RFA: C0M1,
p0.72). All other baseline characteristics were similarly comparable for both
groups (table 1A). Maximum VAS score was lower after FCBA compared
with RFA at all days, reaching statistical significance at 13/14 days (table 1B).
All AUC curves were significantly smaller after FCBA compared to RFA: for
maximum VAS score (12.3 vs 26.7, p5 0.01), for odynophagia (11.6 vs 26.7,
p5 0.01), for pain in rest (7.8 vs 20.5, p5 0.01), for use of analgesics (0.9 vs 3.1,
p5 0.01) and for dysphagia (2.6 vs 8.2, p5 0.01). The maximum median VAS
score reported on any of the 14 days was 2 (IQR 0–4) after FCBA and 4 (IQR 3–
7) after RFA (p5 0.01). After 4 (IQR 1–10) days, half of the FCBA patients
reported a pain score of 0, whereas this was 13 (IQR 10–15) days for RFA
(p5 0.01). FCBA patients used analgesics during median 1 (IQR 1–1) days,
compared to 4 (IQR 1–11) days for RFA patients (p5 0.01).
Table 1: Baseline characteristics and maximum pain scores
FCBA
(N¼ 20)
RFA
(N¼ 35) P-value
1A. Baseline characteristics
Male gender, n (%) 17 (85%) 29 (83%) 0.84
Age, mean (SD) years 65 (8) 66 (8) 0.66
Worst diagnosis
prior to FCBA
LGD, n 10 (50%) 19 (54%) 0.54
HGD, n 1 (5%) 6 (17%)
EAC, n 9 (45%) 10 (29%)
Prior treatment ER, n 10 (50%) 17 (52%) 0.92
Circumferential
RFA, n
10 (50%) 23 (66%) 0.33
BE length
prior to FCBA
Circumferential, cm 0 (0–0) 0 (0–0) 0.64
Maximum, cm 2 (1–2) 1 (1–3) 0.72
1B. Maximum pain scores on day 1 to 14 post treatment
Maximum VAS,
median (IQR)
Day 1 2 (0–4) 3 (1–7) 0.06
Day 2 1 (0–4) 3 (1–6) 0.02
Day 3 1 (0–3) 3 (1–4) 0.03
Day 4 1 (0–2) 2 (1–4) 0.05
Day 5 0 (0–2) 2 (1–5) 0.02
Day 6 0 (0–1) 2 (1–5) 50.01
Days 7 to 9 0 (0–1) 2 (0–4) 50.01
Days 10 to 14 0 (0–0) 1 (0–2/3) 50.01
Conclusion: In this multicenter, non-randomized, open prospective cohort study,
patients reported less post-procedural pain and dysphagia after FCBA as com-
pared with RFA and, moreover, FCBA patients used less analgesics. Although a
randomized trial should provide definitive evidence for differences in post-pro-
cedural tolerability, our results strongly suggest a significantly different post-
procedural course, thus favoring FCBA over RFA.
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Introduction: Radiofrequency ablation (RFA) with endoscopic mucosal resection
is recommended for Barrett’s Oesophagus (BO) related neoplasia. In this study,
we evaluated RFA treatment outcomes for BO stratified according to baseline
histology, i.e. low-grade dysplasia (LGD), high-grade dysplasia (HGD) and
intramucosal carcinoma (IMC).
Aims & Methods: The aim of this study was to compare RFA outcomes for BO
with low-grade dysplasia (LGD), high-grade dysplasia (HGD) and intramucosal
carcinoma (IMC). We retrospectively reviewed the treatment outcomes of
patients with dysplastic BO between January 2007–2017. Patients received 3-
monthly RFA until endoscopic and histologic remissions were achieved.
Outcomes measured were: 1) complete remission of dysplasia (CRD) and intest-
inal metaplasia (CRIM), 2) stricture rate, and 3) durability of CRD and CRIM.
Patients on active treatment protocol were excluded.
Results: We identified 113 patients who completed RFA treatment (21 LGD, 46
HGD and 46 IMC). There were no significant difference between the groups in
the age, gender, circumferential and maximum length of BO, and stricture rate.
CRD and CRIM were achieved in 94.7% and 78.8% of patients, respectively.
When stratified according to baseline histology, there was no significant differ-
ence in CRD rate among LGD (95.2%), HGD (95.7%) and IMC (93.5%)
(p¼ 0.89). Similarly, there was no significant difference in CRIM rate among
LGD (71.4%), HGD (76.1%) and IMC (84.8%) (p¼ 0.31). CRD durability at 12
and 36 months (n¼ 107) were 99.0% and 97.0%, respectively. CRIM durability
(n¼ 89) at 12 and 36 months were 98.5% and 92.7%, respectively. When strati-
fied according to baseline histology, CRD durability at 12 and 36 months for
LGD and IMC were 100% at both time points, and 97.7% and 93.6% for HGD,
respectively (log rank p¼ 0.31). CRIM durability at 12 and 36 months for LGD,
HGD and IMC were 100%, 96.4%, 100%, and 100%, 88.5%, 95.5%, respec-
tively (log rank p¼ 0.60).
Conclusion: The treatment outcomes for BO were similar in patients with differ-
ent baseline histology. Our results showed that once CRD and CRIM were
achieved, these were durable over time.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Endoscopic mucosal resection (EMR) is currently the first-line
treatment for high-grade dysplasia (HGD) in Barret’s esophagus (BE). Despite
improvements in the characterization of dysplasia, the management depend on
the pathological analysis of biopsies previously performed. However, the level of
concordance between cytologists in such situation remains discussed. The aim of
this study was to evaluate the discordance between biopsy sample (BS) and EMR
specimen in case of HGD, as well as cytologists’ inter and intra-observatory
variability.
Aims & Methods: This was a retrospective study including a prospective histolo-
gical relecture (BS and specimen) in two expert centers. The inclusion criteria
were: BE with HGD on pre-operative biopsies resected by EMR. The initial
biopsies from other centers were collected and re-exanimated by our cytologists.
The BS discordant with EMR specimens were recorded in a numeric file
(Teleslide) and a second lecture was carried out by 2 experts and 2 fellows
(1 of each per center). Five diagnoses were considered: no metaplasia
(no BE), metaplasia without dysplasia, LGD, HGD, Adenocarcinoma.
Concordance statistical tests were performed to assess the variability between
BS and EMR specimen, and among the cytologists.
Results: Between January 2005 and December 2015, 87 patients have undergone
EMR for HGD on biopsies, in both centers. Among them, 41 (47%) had a
discordant result between biopsies and resection specimen. The histological diag-
nosis was LGD in 23 cases (16.4%), metaplasia in 13 cases (14.9%), adenocarci-
noma in 4 cases (4.6%) and one patient had no metaplasia. Finally, 33 patients
could be analyzed, 29 men and 4 women, with a mean age of 63 years old. The
mean length of BE according to Prague classification was C3-M5, with relief
abnormalities in 18.2% of the cases. A mean number of 1.4 endoscopic session
was performed, with a mean of 2.7 resected pieces per EMR, which was macro-
scopically complete in 63.6% of the cases. The mean follow-up was 38 months.
After histological relecture, the Kappa coefficient for the diagnosis of HGD was
low on the initial BS, and ranged between 0 and 0.6 for the EMR specimen.
The inter-observatory concordance was 0.2 (for both BS and EMR specimen) for
the diagnosis of HGD. For other diagnoses, it was ranged between 0 and 0.5 for
biopsies and between 0 and 0.6 for EMR specimen. The kappa coefficient regard-
ing HGD between experts was 0.5 for biopsies and 0 for EMR, whereas it was 0.4
and 0.5 for the fellows, respectively. The intra-observatory (between BS and
EMR specimen) after relecture was ranged between 0 and 0.6.
Conclusion: The discordance rate between initial diagnosis of HGD on BS and
final results on EMR specimen is high, around 47%. The intra and inter obser-
vatory concordance is insufficient, even in expert tertiary centers. Thus, the
question about performing EMR based on random biopsies rather than endo-
scopic assessment has to be asked, and clearly evaluated in further studies.
This could have a direct impact on the management of BE.
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Introduction: Neoadjuvant chemoradiotherapy (CT-RT) before esophagectomy
is standard management for locally advanced squamous cell carcinoma (SCC) of
the esophagus and in several cases, it can lead to complete response (CR).
Aims & Methods: The aims of this study were to identify possible immunological
predictors of CR after neoadjuvant CT-RT and of cancer persistence/recurrence
in patients who had a clinical CR. Eighty-eight consecutive patients with SCC
of the thoracic oesophagus who underwent to neoadjuvant CT-RT were included
in this retrospective study. Patients were included in the study if they had
had neoadjuvant CTRT for locally advanced SCC and having had histologicla
samples taken at diagnosis available in our Pathology Unit archive.
Immunohistochemistry for PD1, PDL1, CD80, CD4 and CD8 was performed.
Outcome details were retrieved and clinical CR and recurrence/relapse rate was
compared. Non parametric comparison tests and non paramentric combination
test were used for small sample size comparison.
Results: After neoadjuvant CT-RT, 23 patients had CR, while 65 had partial
response, stable disease or progression. CD8þ and CD4þ lymphocyte rate and
PDL1 leukocyte expression were significantly higher in patients who had CR
compared to those who had not (p5 0.0014, p5 0.001 and p¼ 0.004 respec-
tively). The accuracy of leukocyte expression of PDL1 and CD8þ and CD4þ
lymphocyte rate was 0.76 (p¼ 0.001), 0.81 (p¼ 0.0001) and 0.75 (p¼ 0.0001),
respectively. Within the CR group, all patients with high infiltration of CD4þ
T cell recurred/relapsed while only the 38.9% of those with low CD4þ T cell
infiltration did the same (p¼ 0.058).
Conclusion: In our group of patients, CD4þ and CD8þ lymphocyte rate and
PDL-1 leukocyte expression were predictive of clinical complete response after
neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oeso-
phagus with adequate accuracy. Moreover, high infiltration level of CD4þ T cell
was associated to recurrence/relapse. These preliminary observations might be
used to plan further study aimed to identify reliable predictors of response to
chemoradiation in oesophageal SCC.
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Introduction: Esophageal adenocarcinoma (EAC) is a highly aggressive malig-
nancy with poor prognosis. Advances in therapy have achieved incremental
improvements in overall outcome in EAC, but over- and undertreatment of
undefined subgroups of patients might undermine these benefits (Courrech
Staal et al. 2010). The biological diversity of EAC complicates patient selection
and treatment stratification and impedes the development of new targeted agents.
Further insight into the heterogeneous molecular pathology of EAC and a pos-
sible relation to outcomes and response to current treatment strategies is urgent.
Aims & Methods: We included 75 patients with EAC and junctional adenocar-
cinomas between 2012 and 2017. Most patients received neoadjuvant
chemo-radiotherapy (nCRT) with carboplatin and paclitaxel. Pre-treatment
tissue samples of the tumor and healthy adjacent mucosa were collected during
upper gastrointestinal endoscopy. RNA was extracted from all tumor biopsies
and a subset of matched healthy biopsies. Samples were sequenced using Illumina
sequencing technology. Count files were obtained, which served as input into the
R language and environment for statistical computing for further analyses.
We performed unsupervised hierarchical clustering on the tumor RNA profiles to
identify distinct clusters associated with clinical outcome.
Results: We could identify three distinct subtypes with a metabolic, immune and
cell cycle regulating signature respectively. The subtype with the immune signa-
ture was associated with tendency to poorer response to therapy. We will develop
a subtype classifier to perform subtype prediction in an independent patient
cohort from the TCGA database (The Cancer Genome Atlas Research 2017).
Conclusion: Our studies support the existence of three distinct EAC/junctional
subtypes associated with different response to therapy. Based on these sub-
groups, we will develop an EAC subtype classifier that might improve stratifica-
tion of patients for (targeted) therapies and subsequently improve outcomes.
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Introduction: Esophageal squamous cell cancer (ESCC) is one of the most
common carcinomas worldwide. Long noncoding RNAs (lncRNAs) have been
reported to play an importance role in the progression of many diseases espe-
cially in cancers. Recent studies reveal that lncRNA TRPM2-AS is upregulated
in many cancers and may function in tumor development and metastasis. This
study aimed to explore the expression of TRPM2-AS and its clinical value in
ESCC.
Aims & Methods: To investigate the function of long noncoding RNA TRPM2-
AS in ESCC, RT-qPCR was used to monitor the expression level of long non-
coding RNA TRPM2-AS in 50 paired ESCC tissues and ESCC cell lines.
Moreover, the associations between long non-coding RNA TRPM2-AS expres-
sion level and clinical characteristics was analyzed. In addition, over-expression
and RNA interference (RNAi) approaches were used to study the biological
functions of TRPM2-AS in ESCC cells. Cell growth and proliferation was
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analyzed by cell counting kit-8 assay. Cell cycle and apoptosis were evaluated by
flow cytometric analysis. Protein levels of p53 were determined by western blot
analysis. Differences between groups were tested for significance using
Student’st-test (two-tailed).
Results: ESCC tissues examined in this study showed an obvious increment in
TRPM2-AS expression when compared to normal tissues. Meanwhile, TRPM2-
AS expression was positively related to lymph nodes metastasis, TNM stage and
clinical stage. And upregulated TRPM2-AS expression was turned to be remark-
ably correlated with the shorter survival of ESCC patients which could act as an
independent prognostic factor for both overall survival time and disease-free
survival. In addition, overexpression of TRPM2-AS could promote the prolif-
eration and inhibit the apoptosis of ESSC cells, while knockdown of TRPM2-AS
had a reverse function. Furthermore, downregulation of TRPM2-AS enhanced
the expression of p53 in ESCC cells.
Conclusion: This study suggested that long non-coding RNA TRPM2-AS could
be a potential oncogene of ESCC. TRPM2-AS expression might be served as
another potential therapeutic target and prognostic biomarker. In addition, our
study presents the first evidences that TRPM2-AS contributes a lot to inhibiting
apoptosis of ESCC by regulating the expressions of p53 in vitro, which may be a
potential oncogene and therapeutic target for ESCC.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1213 ROLE OF CD80 EXPRESSION IN INFLAMMATORY-
RELATED ESOPHAGEAL CARCINOGENESIS
M. Scarpa1, L. Dall’Olmo2, M. Fassan3, A. Porzionato4, A. Kotsafti1,
V. Macchi4, R. Alfieri1, S. Realdon5, M. Rugge6, I. Castagliuolo7, C. Castoro1,
M. Scarpa1
1Esophageal And Digestive Tract Surgical Unit, Regional Centre For Esophageal
Disease, Veneto Institute of Oncology (IOV-IRCCS), Padova/Italy
2Ospedale Civile di Venezia, Venezia/Italy
3University of Padova, Padova/Italy
4Dept. Of Molecular Medicine, University of Padova Dept. of Molecular Medicine,
Padova/Italy
5Istituto Oncologico Veneto Endoscopy Unit, Padova/Italy
6Pathology, Medical School of the Padova University, Padova/Italy
7Molecular Medicine, University of Padua, Padova/Italy
Contact E-mail Address: melania.scarpa@iov.veneto.it
Introduction: Esophageal adenocarcinoma (EAC) is an increasingly common
cancer with a poor prognosis. EAC is the final step of a pathway starting with
esophageal reflux disease, intestinal metaplasia, and dysplasia. The expression of
costimulatory molecules such as CD80 and CD86 in the esophageal cancer tissue
is significantly lower than in the normal mucosa of healthy patients. This may be
one of the mechanisms of immune escape of cancer cells in the esophageal cancer.
Aims & Methods: The aim of this study was to investigate the role of CD80 in
the inflammatory esophageal carcinogenesis and to characterize the immune
environment of EAC. Mucosa samples from cancer and from healthy esophagus
were obtained during esophagectomy from patients affected by EAC. Fresh
biopsies were obtained from patients who underwent endoscopy for screening
or follow-up. Immunohistochemistry for CD80 was performed. Fresh biopsies
were analyzed by flow cytometry to quantify the expression of CD80, its receptor
CD28 and the lymphocytes activation marker CD38 on esophageal epithelial
cells and CD8 infiltrating lymphocytes, respectively. A model of reflux induced
esophageal carcinogenesis was created with a esophago-gastro-jejunostomy:
C57bl/6 mice were randomized to receive or not intraperitoneal injections of
anti-CD80 antibody. The esophago-gastric specimens were collected 32 2
weeks after randomization and analyzed in a blinded fashion. Non parametric
statistics was used.
Results: Flow cytometric analysis of esophageal biopsies from healthy controls,
Barrett esophagus, dysplastic esophagus and esophageal adenocarcinoma reveals
that the expression of the costimulatory molecule CD80 by epithelial cells peaks
during metaplasia in the inflammatory esophageal carcinogenesis. In the mice
that received antiCD80 antibodies the rate of dysplasia in the fore stomach was
significantly higher (5/7) compared to that observed in vehicle treated wild type
mice (1/6).
Conclusion: The human and the in vivo data that we obtained suggest that in
inflammation-driven esophageal carcinogenesis there is evidence of an active
immune surveillance process mediated by the overexpression of CD80 costimu-
latory molecule on esophageal epithelial cells.
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Introduction: Esophageal adenocarcinoma (EAC) microenvironment is character-
ized by several oncogenes activation and oncosuppressor down regulation within
the tumor cells, by lack of cytokines with anti-cancer effect and by high expres-
sion of immuno-suppressive factors. The interplay between oncogenes’ disregula-
tion and immune microenvironment and its effect on patients’ prognosis is still
largely unknown.
Aims & Methods: The aim of this study was to evaluate the effect of the interplay
between dysregulation of oncogenes and oncosuppressor genes within the tumor
cells and immune microenvironment on EAC prognosis. Mucosa samples from
EAC tissue were obtained during esophagectomy from 169 consecutive patient-
soperated. Immunohistochemistry for MLH1, MSH2, MSH6, PMN2, cMyc,
p16, HER2 and nuclear p53 expression was performed. CD8 infiltration, CD8
and NK cells cytolytic activity (CD107) of tumor infiltrating lymphocytes and
antigen presenting cells activity within the tumor (CD80) were analysed with
immunohistochemistry. Mutational analysis for BRAF was performed. Cox pro-
portional hazard models were created to investigate the role of each marker
adjusted for cancer stage. The association between each marker and the presence
of nodal metastasis was assessd with Fisher exact test.
Results: In our EAC patients’ series, one patients had BRAF mutation (V600E)
and 5 of them had microsatellite instability. CD107 overexpression within the
cancer was associated to the presence of nodal metastasis (p¼ 0.029). In patients
with EAC, nuclear p53 overexpression revealed to be an independent predictor of
early recurrence with [HR¼ 2.995(95%CI¼ 1.1224–7.9896) p¼ 0.029] as well as
cancer stage [HR¼ 2.993 (95% CI¼ 1.6693 to 5.3666) p5 0.001]. On the other
hand, nuclear p53 overexpression also tended to be an independent predictor of
overall survival [HR¼ 2.9359 (95% CI¼ 0.9613 to 8.9663) p¼ 0.06] while cancer
stage confirmed to be the main survival predictor [HR¼ 1.8689 (95%
CI¼ 1.0810 to 3.2314) p¼ 0.025].
Conclusion: In EAC, CD8 and NK cytolyic activity within the tumor was asso-
ciated to nodal metastasis and CD107 expression might be used as a marker of it.
Moreover, nuclear p53 overexpression within the tumor might be used as a
marker of early recurrence after esophagectomy and then used to plan follow
up strategies. No apparent relation between prognosis and mismatch repair genes
expression or BRAF mutation was observed.
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1CIBER Enfermedades Hepáticas y Digestivas, Madrid/Spain
2Hospital Clinico Universitario Lozano Blesa, Zaragoza/Spain
3Instituto de Salud Carlos III, Madrid/Spain
4Universidad de Zaragoza, Zaragoza/Spain
5Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza/Spain
6Hospital Universitario Miguel Servet, Zaragoza/Spain
Contact E-mail Address: educhuec@gmail.com
Introduction: Altered glucose metabolism has become a recognised feature of
tumor cells, which is characterized by an increased glucose uptake and prefer-
ential dependence on glycolysis for energy production. As a consequence, cancer
cells produce large amounts of lactate, which is pumped out the cytosol by
monocarboxylate transporters (MCTs), mainly MCT 1 and 4. MCT inhibition
has previously been related to increase apoptosis in cancer cells, but this aspect
has not been investigated in esophageal adenocarcinoma (EAC) yet.
Aims & Methods: We aimed to analyze the expression of MCT1 and 4 in human
samples of EAC and to evaluate in vitro the effect of extracellular glucose con-
centration and pharmacological inhibition of MCT1 on lactate concentration,
intracellular pH (pHi), and cell apoptosis. MCT1 and MCT4 expression was
assessed by immunohistochemistry in 29 human samples of EAC. For the
in vitro study, two different EAC cell lines were used: OE33 (ECACC), estab-
lished from an EAC of the lower esophagus and OACM5.1C (ECACC), obtained
from a lymph node metastasis derived from an EAC. MCT1 and MCT4 expres-
sion and location were assessed by immunocytochemistry in both cell lines. The
MCT1 selective inhibitor AZD3965 (0, 10 and 100 nM) was added to the culture
medium under a normoxic and hypoxic atmosphere in standard(11mM) or
high(30mM) glucose content in the media. Apoptosis was determined by flow
cytometry (Annexin V-FITC and propidium iodide). Intracellular lactate con-
centration was evaluated in a colorimetric assay. pHi was evaluated by flow
cytometry with the probe SNARF-1 AM. Experiments were performed at least
in triplicate. Statistical analysis was performed by student-t test.
Results: MCT1 and MCT4 expression was found in all the EAC samples eval-
uated. MCT1 expression was confined to tumor cells, with 62% of the biopsies
showing moderate or intense staining, whereas MCT4 was expressed in both
tumor and stromal cells, with 40% of moderate/intense stained samples. Both
cell lines expressed MCT1 transporter, whereas MCT4 expression was present in
OE33 cells and only in a small population of the metastatic cell line. High
extracellular glucose concentration increased intracellular lactate levels in
OE33 cells but not in the metastatic line, and did not have any effect either in
pHi or in apoptosis under any of the conditions evaluated (normoxia and
hypoxia) in both cell lines. Treatment with AZD3965 (10 and 100 nM) increased
intracellular lactate concentration in OE33 and OACM5.1C cells, but this
increase was higher (600–700%) in the metastatic cell line than in OE33 cells
(50–70%). Under normoxic conditions AZD3965 significantly increased pHi of
both cell lines whereas under hypoxic atmosphere had no effect on metastatic
cells. The highest concentration (100 nM) of the MCT1 inhibitor significantly
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increased apoptosis of OACM5.1C cells whereas did not affect apoptosis of
OE33 cells.
Conclusion: Metastatic and non-metastatic esophageal adenocarcinoma cells
exhibit different glycolitic metabolism and response to pharmacological inhibi-
tion of MCT1, which increases apoptosis in metastatic cells. Further preclinical
studies are necessary in order to define the potential of blocking lactate trans-
porters on the treatment of metastatic EAC.
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Introduction: Although endoscopic submucosal dissection (ESD) is accepted as a
standard treatment for early stage esophageal neoplasia, esophageal perforation
is sometimes experienced as main adverse event. Esophageal perforation causes
mediastinal emphysema, mediastinitis, and pneumothorax, those sometimes
require emergency surgery.
Aims & Methods: We evaluated the predictive factors for esophageal perforation
in patients who received esophageal ESD. This was a retrospective observational
study in a single institution. Between May 2004 and March 2016, 549 consecutive
patients with 927 esophageal lesions were treated with ESD. Exclusion criteria
was cases with lacking data. The primary outcome was determination of the
predictive factors for esophageal perforation in patients who received esophageal
ESD. The secondary outcome was clinical outcomes. Perforation was defined as
a visual hole in the esophageal wall exposing the mediastinal cavity. Logistic
regression multivariate regression analysis with generalized estimating equations
were used to analyze repeated measures data.
Results: A total of 549 cases with 927 lesions were evaluated. Of those, perfora-
tion occurred in 15 cases (2.7%) with 15 lesions (1.6%). A lesion diameter
(Odds ratio; OR¼ 1.05, 95% confidence intervals; CI: 1.02–1.07, p50.001)
and the proximity of the tumor to a previous ESD scar (OR¼ 6.66, 95%
CI: 1.80–24.6, p¼ 0.004) were both associated with perforation using crude logis-
tic regression analysis. Multivariate logistic regression analysis also showed that a
lesion diameter (OR¼ 1.05, 95% CI: 1.03–1.07, p50.001) and the proximity of
the tumor to a previous ESD scar (OR¼ 13.0, 95% CI: 2.48–67.9, p¼ 0.002) were
independent predictive factors for perforation.
Conclusion: Larger lesion and the proximity of the tumor to a previous ESD scar
increased the likelihood of perforation in patients who received esophageal ESD.
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Introduction: According to the current Japanese guidelines for the diagnosis and
treatment of esophageal cancer, endoscopic resection is indicated for pathologi-
cal T1a (epithelium/lamina propria mucosae) and relatively indicated for
T1a(muscularis mucosae) and T1b(a tumor invading the submucosa to a depth
of 200mm or less). In accordance with the guidelines, we have actively performed
endoscopic resection for esophageal squamous-cell carcinoma(ESCC). Evidence
of submucosal or lymphovascular invasion on histopathological examination
of the resected specimens was considered to indicate non-curative resection,
chemoradiotherapy (CRT) was additionally administered, taking into account
the risk of lymph-node metastasis. In principle, CRT comprised 2 courses of
cisplatin plus 5-fluorouracil. Patients who were 76 years or older or who
had mild renal dysfunction received 2 courses of nedaplatin plus 5-fluorouracil.
The radiation dose was 50.4 Gy in patients who had a tumor-positive vertical
margin and 41.4 Gy in those who had a tumor-negative vertical margin. The field
of radiation was determined according to the recommendations of the
Japan Clinical Oncology Group Study JCOG0508(UMIN-CTR: identification
number UMIN000000553).
Aims & Methods: We retrospectively studied patients who underwent endoscopic
resection in our hospital to evaluate the clinical utility of additional CRT in
patients who had evidence of submucosal or lymphovascular invasion on histo-
pathological examination of the endoscopically resected specimens. Among
364 patients with ESCC (425 lesions) who underwent endoscopic resection
from January 2000 through July 2015, a total of 93 patients (93 lesions) had a
histopathological diagnosis with submucosal or lymphovascular invasion.
Among these 93 patients, 41 received additional CRT (CRT group), and
52 were followed without CRT(follow-up group). CRT comprised cisplatin
plus 5-fluorouracil and radiation in 37 patients, nedaplatin plus 5-fluorouracil
and radiation in 2, docetaxel plus cisplatin, 5-fluorouracil, and radiation in 1, and
radiation alone in 1.
Results: The median age was 68 years (53 to 79) in the CRT group and 72 (59 to
89) in the follow-up group (p¼ 0.01). The median tumor diameter was 22mm
(6 to 55) in the CRT group and 25 (3 to 47) in the follow-up group (p¼ 0.63).
The tumor invades the MM in 9 patients, the SM1 in 3, and the submucosa to a
depth more than 200mm (SM2) in 29 in the CRT group and the LPM in 3
patients, the MM in 16, the SM1 in 18, and the SM2 in 15 in the follow-up
group (p¼ 0.91). Lymphatic invasion was positive in 21 patients in the CRT
group and 12 in the follow-up group (p5 0.01). Vascular invasion was positive
in 27 patients in the CRT group and 29 in the follow-up group (p¼ 0.32).
Involvement of the submucosal vertical margin was found in 7 patients in the
CRT group and 9 in the follow-up group (p¼ 0.97). CRT-related grade 3 or 4
early adverse events were leukopenia 24.3% (10 patients), neutropenia 29.3%
(12), febrile neutropenia 4.9% (2), diarrhea 2.4% (1), anorexia 17.0% (7). In the
CRT group, 38 of 40 patients received chemotherapy as scheduled. Treatment
was discontinued in the second course in 2 patients, and 7 required dose reduc-
tion. Lymph-node metastasis were found in 2 patients in the CRT group and 7 in
the follow-up group (p¼ 0.15). In 2 patients with recurrence in the CRT group,
lymph-node metastases were seen in the irradiated field 46 and 49 months after
treatment, respectively. 1 patient in the CRT group and 3 in the follow-up group
died of esophageal cancer (p¼ 0.43). The overall survival (OS) rate at 2 years was
97.1% in the CRT group and 93.8% in the follow-up group (p¼ 0.02). The
relapse-free survival (RFS) rate at 2 years was 97.1% in the CRT group and
83.4% in the follow-up group (p¼ 0.02).
Conclusion: Additional CRT after endoscopic resection in patients with esopha-
geal squamous-cell carcinoma who have submucosal invasion, lymphovascular
involvement, or vertical-margin invasion can become an effective organ-preser-
vation strategy.
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Introduction: Endoscopic submucosal dissection (ESD) was developed in Japan
for en bloc resection of large gastrointestinal neoplasias and has progressively
been adopted in the West. Currently, early Barrett’s neoplasia is mainly treated
with endoscopic mucosal resection (EMR) and/or radiofrequency ablation, being
the role of ESD in this context not well-established yet. Our aim is to evaluate the
safety, efficacy and outcome of ESD for the treatment of early Barrett’s
neoplasia.
Aims & Methods: Fifty consecutive ESD cases of early Barrett neoplasia were
performed in 42 patients in our center between 2011 and 2016. All ESDs were
performed under full narcosis after multidisciplinary team conference discussion
and patient’s consent. The primary endpoint was the rate of en bloc resection.
Secondary endpoints included rate of R0 and curative resection, a comparison of
pre- and post- ESD histology, procedure time, procedure-related adverse events,
and rate of remission at follow-up. This study was approved by the Stockholm
Regional Ethical Committee.
Results:Mean age was 67 years-old (range 46–84), being 74% male and 72% long
segment BE. The mean specimen size was 52mm (range 16–150mm). ESD resec-
tions included 525%, 25–50%, 50–75% and 75–100% of the lumen circumfer-
ence in 4/31/12/3 of cases, respectively. En bloc, R0 and curative resection were
obtained in 96% (48/50), 80% (40/50) and 70% (35/50) of cases, respectively. The
pre-ESD histology corresponded to low-grade dysplasia (n¼ 5), high-grade dys-
plasia (n¼ 30) and adenocarcinoma (n¼ 15). One case of LGD was upstaged to
intramucosal AC, 10/30 cases of HGD were upstaged to adenocarcinoma. In 8/
15 cases of AC, there was submucosal invasion on the ESD specimen. In 14/50 of
resected specimens there was multifocal neoplasia. The mean procedure time was
120 minutes. There were 2 perforations (4%) treated endoscopically and 2 (4.0%)
postoperative bleedings treated conservatively. Six patients (12%) developed
esophageal strictures that were managed endoscopically. The 30 days mortality
was 0%. In the 15 non-curative cases, 10 went through esophagectomy, 2 patients
to further ESD, 1 received chemoradiotherapy and 2 patients are under surveil-
lance. In the 10 esophagectomy cases, 4 patients had AC in the remnant Barrett’s
esophagus and 2 patients had lymph node metastasis. Complete remission was
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found in 100% (35/35) of patients with curative resection at median follow-up of
21 months (4–60 months).
Conclusion: In the proper setting, ESD is safe and effective for the treatment of
early Barrett’s neoplasia with high en bloc and complete resection rates and good
curative rate. ESD enables full pathological assessment in lesions not suitable for
en bloc resection with EMR. There were no recurrences in the curative cases,
which increases the role of ESD for the management of early Barrett’s neoplasia.
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Introduction: Recently, it has been reported that proton beam therapy (PBT) is
the effective treatment for patients with esophageal squamous cell carcinoma
(ESCC). However, there are few reports regarding the endoscopic evaluation
of efficacy after PBT at the primary site.
Aims & Methods: The aim of this study is to clarify the adequate endoscopic
evaluation for primary lesion of ESCC after PBT, and the clinical results of
salvage endoscopic treatment for local recurrence. Patients with clinical T1
ESCC, and who had been treated with PBT between April 2013 and June 2016
at the National Cancer Center Hospital East were investigated. The total dose of
PBT was 60 Gray-Equivalent (GyE). The efficacy of PBT at the primary site was
evaluated with endoscopy, and the definition of complete response (CR) was
used according to the same criteria as that of conventional chemoradiotherapy
(CRT) as follows; disappearance of tumor lesion and ulcer, and absence of cancer
cells with biopsy was verified. The endoscopic evaluation was performed within
2 months after the completion of PBT, and we repeatedly evaluated every month
if the lesion did not achieve CR. The treatment for local recurrence after PBT was
chosen based on the depth of the tumor as follows; endoscopic resection (ER) for
cT1a, esophagectomy or photodynamic therapy (PDT) for cT1b or deeper
depending on patient’s condition.
Results: Among 44 patients who underwent PBT, the median age was 70 years
(range, 41–79). The number of patients with clinical stage I was 23 (52%), and
those with stage II, III, and IV were 16 (36%), 2 (5%), and 3 (7%), respectively.
All patients underwent concurrent systemic chemotherapy. 43 patients (98%)
could achieve a CR at the primary site and only one patient (2%) did not
show a CR (non-CR) at the primary site. The median time to CR from the
start of PBT at the primary site was 85 days (range, 70–554 days) and
6 months or longer period was required to confirm CR due to the remaining
PBT induced erosion or ulceration in 7 patients (15%). One patients whose
primary site did not reached to CR showed prolonged ulceration for 385 days.
Of the 43 patients, 6 patients (14%) developed local recurrence without regional
lymph node recurrence or distant metastasis, and the median time to local recur-
rence from CR was 257 days (range, 111–722 days). The endoscopic finding
of local recurrence was resembling submucosal tumors (SMT) in 3 and flat
lesion in other 3 tumors., All 6 patients with local recurrence were indicated
for endoscopic treatment (ER:4, PDT:2). No complications, such as major bleed-
ing or perforation, were observed. And, 6 patients (100%) were alive without any
recurrence at the median follow up period of 11 months (range, 1–32 months).
Conclusion: Longer period was required to confirm CR after PBT with
chemotherapy in some cases comparing with the historical reports of that of
conventional CRT. Careful closed endoscopic follow-up according to the way
of conventional CRT enabled early detection of local recurrence and preferable
local control with salvage endoscopic treatment.
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Introduction: Surveillance programs of gastrointestinal endoscopy for
detection of a second primary cancer in patients with head and neck squamous
cell carcinoma (HNSCC) are very important since it can detect synchronous or
metachronous esophageal squamous cell carcinoma (ESCC) in up to 15%–25%1.
The detection of ESCC in an early phase has paramount importance, since super-
ficial lesions are amenable to endoscopic submucosal dissection (ESD) 2.
Aims &Methods: The aim of this study was to investigate the clinical outcomes of
ESD in superficial esophageal neoplasm (SEN) of HNSCC patients in an oncol-
ogy tertiary center. From 2010 to 2016, 3280 endoscopies were performed in
patients with HNSCC and in 1887 chromoscopy with Lugol and NBI were
performed. A total of 26 SENs, submitted to ESD, in 25 patients were retro-
spectively analyzed.
Results: The median tumor size was 4,37 cm (1.83). The en bloc resection were
100% and free margin (R0) were 92.3%.The two patients with positive margins
had a depressed component in endoscopic evaluation. Recurrence occurred in
11,5% (3/26) and one of these patients was successfully treated with mucosect-
omy. The circumferential extension, number of patients e stenosis rate are show
in table 1.
Table 1: The circumferential extension, number of patients and stenosis rate
Circumferential
Extension
Number
of lesions
Stenosis
Rate
25–49% 1 (2.56%) 0 (0%)
50–74% 14 (53.84%) 5 (35.71%)
75–99% 6 (23.07%) 2 (33.33%)
100% 5 (19.23%) 5 (100%)
75–100% 11 (42.30%) 7 (63.63%)
The circumference of the resection 75% was significantly associated with post-
operative stricture (OR¼ 3.5; P5 0.05). The average number of endoscopic dila-
tations for resolution of stenosis was 9.16 (7.62). No procedure-related
mortality occurred. Follow-up data median was 11 months.
Conclusion: Endoscopic surveillance of HNSCC is very important for SENs
detecting. Esophageal ESD of these lesions are feasible and safe with acceptable
complication risks despite the high rates of stenosis in resections 475% of the
circumference.
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Introduction: Globally, 80% of all esophageal cancer cases are esophageal squa-
mous cell cancer (ESCC), arising from esophageal squamous cell neoplasia
(ESCN). Patients with ESCC have poor prognosis, but when diagnosed at the
stage of ESCN, curative endoscopic treatment can be performed. ESCN mainly
occurs in developing countries, often with limited endoscopic expertise and
resources, like Central and Eastern Asia and Eastern and Southern Africa.
Hence, an easy-to-use, low-cost treatment for ESCN would be of great value.
Focal Cryoballoon Ablation therapy (FCBA) (C2 Therapeutics Inc. Redwood
City, CA, USA) is a new endoscopic ablation therapy that comprises a
through-the-scope catheter with a conformable balloon that obviates the need
for sizing, a handle, and a small disposable cryogen cartridge. The balloon is
simultaneously inflated and cooled with nitrous oxide from the cartridge, result-
ing in ice patches of approximately 2cm2. FCBA is easy to use and requires no
capital equipment. Early studies for FCBA of Barrett’s esophagus have shown
promising results, however, limited data are available for FCBA of ESCN. In this
study we aimed to assess the safety, tolerability and efficacy of FCBA in the
eradication of ESCN.
Aims & Methods: In this ongoing multi-center prospective trial in China, patients
with one flat type (Paris 0-IIb) unstained lesion (USL) on Lugol’s chromoscopy,
56 cm in length and 550% of circumference, with a confirmed diagnosis of
Moderate or High Grade Intraepithelial Neoplasia (MGIN/HGIN) were
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enrolled. At baseline, side-by-side ablations of 10 seconds were performed on
USLs. Treatment was repeated every 3-months until eradication of ESCN was
confirmed. Outcomes: safety and tolerability (11-point visual analog scale (VAS)
for pain), complete response (CR) rates (absence of MGIN or worse in biopsies),
neoplastic progression and adverse events.
Results: We enrolled 80 patients (63 MGIN, 17 HGIN) with a median lesion of
2 (IQR 2–3) cm in length. Of these, 79 patients (99%) were successfully treated;
3 developed superficial, self-limited mucosal lacerations upon balloon inflation
and 2 of them were successfully re-ablated 3 months later. A median of 5
(IQR 4–7) side-by-side ablations were performed per patient, in a median abla-
tion time of 8 (IQR 5–10) minutes. As of April 2017, 77/79 (97%) patients
completed a 3-month follow up endoscopy and 69/77 patients (89%) exhibited
endoscopic and histologic CR. Eight patients had residual USL and were again
treated; 5 had a CR 3 months later and results for other 3 pts are pending.
To date, 4 patients have undergone a 12 month endoscopy and all continue to
exhibit endoscopic and histologic CR. No significant strictures have been noted
on follow-up. Three patients developed fever shortly after treatment which was
treated with aspirin. Post-procedure median VAS was 1 (IQR 0–2) at day 2, and 0
(IQR 0–0) at days 7 and 30.
Conclusion: Preliminary results of our multicenter open prospective cohort study
suggest that FCBA of ESCN is safe, well-tolerated, and highly effective in indu-
cing endoscopic and histologic remission. Longer term (12 month) follow-up
data is pending.
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Introduction: Endoscopic submucosal dissection (ESD) allows en bloc removal
of superficial esophageal squamous cell carcinoma (SCC). However, esophageal
stricture often occurs after ESD when the lesion involves more than three-fourth
of the circumference of the lumen. Frequent balloon dilatation via endoscopy is
required in such situation, thus causing health economic problem. In this study,
we investigated the clinical outcomes, and prevention of post-ESD stenosis.
Aims & Methods: A total of 667 cases in 516 consecutive patients were treated by
ESD in our department from April 2006 to December 2016. We investigated the
following 2 items. 1. Clinical outcomes and complications. 2. Usefulness of oral
steroids administration, the local steroids injection, endoscopic transplantation
of tissue-engineered autologous oral mucosal epithelial cell sheets, or steroid
oralþ local injection combination therapy for the prevention of post-ESD
stenosis.
Results: 1. Clinical outcomes: En bloc resection rate was 99.8% and en bloc
curative resection rate was 90.0%. The rate of perforation, post-ESD bleeding,
and post-ESD stenosis was 0.2%, 0.8% and 6.1%, respectively. 2. Prevention of
post-ESD stenosis: (1) Oral steroid vs Steroid injection vs Cell sheet transplanta-
tion: In oral steroid group, the stenosis rate was 14.9%, and the ulcer healing
period was 59.5 days. In steroid injection group, the stenosis rate was 12.9%, and
the ulcer healing period was 66.0 days. In cell sheet transplantation group, the
stenosis rate was 40.0% and the ulcer healing period was 36.0 days. There was no
significant difference between these 3 therapies, and these therapies prevent post-
ESD stenosis to significant extent. However, ulcer healing period of the cell sheet
transplantation was significantly shorter compared with the other 2 therapies. (2)
The usefulness of SH oralþ local injection combination therapy. We investigated
limitations of steroid administration, and cell sheet transplantation in order to
prevent post-ESD stenosis. The following 4 factors (more than 9/10 of circum-
ferential resection, more than 5 cm of longitudinal resection, cervical esophagus,
post history of chemo-radiation therapy or endoscopic resection) were the
stenosis prevention treatment-resistance factors. Therefore, we examined the
stenosis rate according to the number of these 4 factors. The stenosis rate of
the cases which have 0 or 1 factor, the case which has more than 2 factors in
semicircular cases, and the complete circular cases is 4.9%, 30.3%, and 44.8%,
respectively. The stenosis rate of the cases which have more than 2 factors and
complete circular cases are significantly higher, compared to the cases which have
0 or 1 factor. As a result, the cases which have more than 2 factors and complete
circular cases were regarded as the stenosis prevention treatment-resistant cases.
In contrast, in SH oralþ local injection combination therapy, the stenosis rate of
the cases which have more than 2 factors and the complete circular cases is 12.5%
and 14.3%, respectively. Taken together, the stenosis rate of SH oralþ local
injection combination therapy is significantly lower, compared to the other
3 therapies.
Conclusion: Esophageal ESD achieved high en bloc resection rate and curability
with low rates of complications. Oral steroid, steroid injection therapy and cell
sheet transplantation may be effective treatment strategy for reducing post-ESD
stenosis. However, the above-mentioned 4 factors are the stenosis prevention
treatment-resistant factors in these 3 therapy cases. Furthermore, the cases
which have more than 2 factors and complete circular cases were regarded as
the stenosis prevention treatment-resistant cases. SH oralþ local injection com-
bination therapy is very useful for prevention of post-ESD stenosis and has a
potential to overcome treatment-resistant stenosis.
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Introduction: Endoscopic ultrasonography (EUS) is the standard modality for
qualitative diagnosis of submucosal tumors (SMTs) and determining the depth
of invasion of esophageal cancer. Standard EUS, however, comprises a contin-
uous water-filling or water-filled balloon method, which creates some problems
(e.g., difficulty filling the water, aspirating water, poor image quality because of
balloon compression). Aspiration of water is especially problematic during the
diagnosis of lesions in the cervical or upper thoracic esophagus. To resolve such
disadvantages, we recently reported a method that includes probe EUS with a
jelly-filling technique (EUS-J) for evaluating superficial esophageal squamous
cell carcinoma (SCC). The procedure is characterized by filling the esophageal
lumen with a water-soluble lubricating jelly (K-Y lubricating jelly; Johnson &
Johnson, Tokyo, Japan) that is used for routine endoscopy and is harmless to
humans. In the current study, we retrospectively evaluated the usefulness of
EUS-J with water-soluble lubricating jelly for lesions located in the cervical
and upper thoracic esophagus.
Aims & Methods: Patients with an esophageal SCC or SMT in the cervical or
upper thoracic esophagus were included. EUS-J with water-soluble lubricating
jelly was performed using a high-resolution probe. Before examination, several
5-mL syringes containing the Water Soluble Lubricating Jelly were prepared.
With the patient under conscious sedation with midazolam, an endoscope
(GIF-2TQ260M; Olympus, Tokyo, Japan) was inserted into the targeted area
in the esophagus. A 30- or 20-MHz miniature probe was then inserted through
the left channel of the endoscope, and 40mL of jelly was instilled through the
right channel until the esophageal lumen was filled.
Results: From December 2010 to March 2017, we used EUS-J to evaluate
61 patients with esophageal SCCs and 10 with SMTs in the cervical or upper
thoracic esophagus. There were 10 lesions in the cervical esophagus and 61 in the
upper thoracic esophagus. Among the 61 SCCs, 13 were recurrences following
chemoradiotherapy. The other 48 SCCs did not undergo chemoradiotherapy. Of
these 61 patients with esophageal SCC, 60 lesions (98.3%) could be detected with
EUS-J. 44 lesions treated either by esophagectomy (n¼ 7) or endoscopic resec-
tion (n¼ 37). Histologic diagnosis was T1a in 27 lesions, T1b in 17 lesions. The
overall accuracy of diagnosing invasion depth was 70.5% (31/44 lesions) by EUS.
Among the 10 SMTs, we diagnosed seven leiomyomas derived from muscularis
mucosa and one lesion due to vertebral body compression. The remaining two
lesions were, respectively, a diminutive SMT (53mm) and a small lesion in the
cervical esophagus adjacent to the hypopharynx. Neither was detectable using
EUS-J because of their small size and difficulty with instrumental maneuvering.
There were no adverse events during EUS-J, including aspiration pneumonia.
Conclusion: EUS-J with water-soluble lubricating jelly is useful and safe for
diagnosing lesions in the cervical or upper thoracic esophagus. To our knowl-
edge, this is the first report of using EUS with lubricating jelly for lesions located
in this anatomic region.
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Introduction: The patients with early gastric cancer (EGC) who have undergone
non-curative endoscopic resection (ER) need additional surgery. Our previous
study reported short-term data about 29 days were optimal time when consider-
ing better surgical outcome. (Ann Surg Oncol. 2014 Jan;21(1):232–9.). This study
is long-term follow-up study to evaluate the impact of previously proposed opti-
mal time interval from ER to additive surgery by on the surgical and oncological
outcomes.
Aims & Methods: A total of 2850 patients who were diagnosed with EGC under-
went ER at the Severance and Gangnam Severance Hospitals, Seoul, Korea,
between January 2007 and December 2014. We analyzed totally 302 (10.6%)
patients who underwent additive gastrectomy after non-curative ER. The
patients were divided into 2 groups according to the time interval point, as the
earlier operation group (group A) and the later operation group (group B).
The time interval point, at which operative time and estimated intraoperative
blood loss (EBL) of the earlier operation group and the later operation group
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showed the greatest disparities, was evaluated. We retrospectively evaluated long-
term follow-up study for oncological outcomes about follow-up duration, locor-
egional recurrence, distant recurrence.
Results: The median follow-up duration is 40.36 20.74 months in all patients
Based on the previous our study, we divided patients two groups who underwent
operation before and after 29 days. Of the 302 patients, 133 were in Group A
(29days) and 169 in Group B (429days). There were more differences between
two groups about ASA score, ER Specimen size, intra-op. transfusion, POD#1
Hemovac discharge, Maximal postoperative CRP in the clinicopathological
characteristics. Like previous our study the operative time, EBL, tumor size
was significantly longer and more in group A compared with group B. There
were totally 7 patients locoregional and distance recurrence during follow-up
period. There were no differences in oncological outcomes between two groups.
Oncological recurrence for Each Group
Characteristics
Group A
(29days)
n¼ 133
Group B
(429days)
n¼ 169 p-value
F/u duration (months,
meanSD)
37.02 20.54 44.18 19.49 0.002
Locoregional
recurrence (n, %)
1 (0.8) 1 (0.6) 0.757
Distant recurrence (n, %) 3 (2.3) 2 (1.2)
Conclusion: Based on long-term follow-up data, surgery time after ER in EGC
does not affect oncological outcome. These long-term follow-up results suggest
that additive surgery at about 1 month after ER is optimal for better surgical
outcomes without affecting the oncological outcomes.
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Introduction: This study discusses two endoscopic findings which improve the
accuracy of the diagnosis of early gastric cancers (EGC). After successful
Helicobacter pylori eradication, we often observe multiple reddish depressed
lesions called ‘‘patchy redness’’ or ‘‘map-like redness’’ in the gastric mucosa.
Even though most are intestinal metaplasia (IM), EGC is found among these
lesions. A light blue crest (LBC) has been a highly accurate sign of the IM. There
are, now, additional two endoscopic findings that should improve the accuracy of
diagnosis of EGC. They are 1) ‘‘intraepithelial microinvation (IEMI)’’, and 2)
‘‘Over flow’’. Over flow is that the endoscopic finding that the structure of the
depressed lesion spreads to the outside of the depression.
Aims & Methods: The aim of this study is to clarify the usefulness of two endo-
scopic findings in order to detect the EGC in the group thought to be an IM. This
is a retrospective control study. There were 234 cases of EGC performed endo-
scopic submucosal dissection (ESD) between November 2011 and August 2016 in
Okayama Medical Center. We included 57 cases in this study. As EGC group, we
included 45 cases that were 0-IIc, 10mm or less, pT1a (M), a differentiation type
cancer. As IM group, we included 12 cases identified as IM by biopsy in the same
period. The EGC group is then divided into 2 groups; 1) eradication group (13
cases) who had a history of eradication and, 2) a small EGC group (32 cases)
without a history of eradication. We evaluated 1) the ratio of LBC, 2) the ratio of
irregular microsurface pattern 3) the ratio of irregular microvascular pattern, 4)
the ratio of IEMI and 5) the ratio of Over flow.
Results: The ratio of LBC was 75% in IM group, which was significantly higher
than eradication group (7.7%), and small EGC group (9.4%). The ratio of
irregular microsurface pattern was 33% in IM group, which was significantly
lower than eradication group (92%), and small EGC groups (84%). The ratio of
irregular microvascular pattern was 0% in IM group, which was significantly
lower than eradication group (92%), and small EGC group (81%). The ratios of
IEMI were 0% in IM group, 39% in eradication group and 41% in small EGC
group. The ratios of Over flow were 0% in IM group, 46% in eradication group
and 50% in small EGC group. Furthermore, the ratios to have either in two
endoscopic findings were 0% in IM, 77% in eradication group and 69% in small
EGC group.
Conclusion: IEMI and Over flow leads to the diagnosis of ECG in addition to
other endoscopic findings.
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Guimarães/Portugal
3Pt Government Associate Laboratory, 4 ICVS/3B’s, Braga/Guimarães/Portugal
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Introduction: Iron deficiency anemia (IDA) may be the only sign of gastrointest-
inal (GI) malignancy. The identification of predictive factors of GI malignancy in
patients with IDA could help the physician to establish patients’ priority to
endoscopic assessment, contributing to an earlier diagnosis.
Aims & Methods: Retrospective study of 344 patients submitted to endoscopic
assessment for IDA. Included adult patients with IDA and excluded patients
with GI or extra-GI bleeding, total gastrectomy, exclusively vegetarian diet or
insufficient medical records.
Results: Included 121 patients with mean age of 68.5 17.0 years and 54.5%
females. GI malignancy was identified in 14.9% of patients (gastric in 12, colonic
in 6 patients). A statistically significant association was found between the pre-
sence of GI malignancy and age (75.2 12.9 vs 67.2 17.4, p5 0.05), male
gender (72.2% vs 40.8%, p¼ 0.01), GI symptoms (61.1% vs 11.7%, p5 0.01),
weight loss (61.1% vs 5.8%, p5 0.01), need for hospitalization (88.9% vs 49.5%,
p5 0.01), iron seric levels and transferrin saturation (19.7 10.1mg/L vs
30.4 18.9mg/L, p5 0.01 and 6.1 4.1% vs 9.2 6.3%, p5 0.03, respectively).
At logistic regression analysis only weight loss (p5 0.01), GI symptoms
(p5 0.01), transferrin saturation (p5 0.01) and need for hospitalization
(p¼ 0.02) showed a significant relation with the diagnosis of GI malignancy.
Transferrin saturation showed a weak discriminative capacity (AUC¼ 0.67,
p¼ 0.01) however, values of transferrin saturation 11% had a sensibility of
94.4% and a negative predictive value of 97.1% for GI malignancy (CI 95%
85.1–99.9).
Conclusion: In patients with IDA the diagnosis of GI malignancy is established in
a significant percentage of patients and patients with GI symptoms, weight loss
or with need for hospitalization should be given priority in the performance of
endoscopic examinations. Transferrin saturation may help the physicians in
establishing the urgency of endoscopic assessment, since patients with values
over 11% have a very low probability to have GI malignancy.
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Introduction: Detection of gastric cancer in its early stage is pertinent in reducing
disease-specific mortality. However, this has not been achieved in many countries
where the incidence of gastric cancer is high. In order to overcome this problem,
we developed an e-learning system for international endoscopists to improve
endoscopic diagnosis of early gastric cancer. However, it has not been investi-
gated whether such learning system is useful in clinical practice.
Aims & Methods: The objective of this trial is to investigate whether the intensive
on-site TTT course is useful for increasing early detection rate of gastric cancer in
Chinese high-volume endoscopy center. Five Chinese doctors (the TTT group)
who were invited to the TTT course and the other five age and experiece-matched
Chinese doctors (the non-TTT group) in the same facility who did not attend the
TTT course were included in this trial. Endoscopists of the TTT group attended
2-day learning course 4 times from March 20, 2015 to March 25, 2016.
Endoscopists of the non-TTT group did not attend any learning program
during the same period. Lectures of the TTT course included the detection of
early gastric cancer by screening endoscopy using white-light endoscopy alone
and the feature of the detected subtle gastric mucosal lesion using white-light
endoscopy or magnifying endoscopy with narrow-band imaging. Contents used
in the lecture had been reported to be useful by an e-learning trial [1, 2]. All the
instructions were given by an experienced Japanese endoscopist (K. Yao) who
constructed the e-learning system [1, 2]. Endoscopists also received on-site hands-
on instructions in order to check whether they obtained enough knowledge and
technique. Furthermore, we held case conferences in order to share common
experiences. During the period, the number of both newly detected early gastric
cancers and screening gastrosocpy procedures was recorded. The primary end-
point was to compare the early detection rate between the TTT and the non-TTT
group. (Early detection rate¼ the number of newly detected early gastric cancers/
the number of screening endoscopy procedures)
Results: The data obtained from the 275 consecutive cases of screening gastro-
scopy procedures by the TTT group endoscopists and from the 323 consecutive
cases of screening endoscopy procedures by the non-TTT group endoscopists
were analyzed. In the TTT group, four cases with early gastric cancers were
detected and no early gastric cancer was detected. The early detection rates of
A594 United European Gastroenterology Journal 5(5S)
the TTT and the non-TTT group were 1.5% and 0%, respectively. There was a
significant difference in early detection rate between the TTT and the non-TTT
group (Fisher’s exact test, P¼ 0.046).
Conclusion: This clinical trial clearly showed that the systematic intensive TTT
course is useful for improving early detection rate of gastric cancer in clinical
practice at Chinese high-volume endoscopy center. (NCT02385578)
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Introduction: Endoscopic submucosal dissection (ESD) is believed to be a possi-
ble modality for early gastric cancer. But there is little report about long-term
outcomes of the ESD directly compare with the surgery. The purpose of this
study is the comparison between the two treatment modalities about the
outcomes.
Aims & Methods: We performed a retrospective analysis of 1243 patients with
stage I early gastric cancer without lymph node involvement. 551 patients were
treated with ESD, and 692 patients were treated with subtotal or total gastrect-
omy. Long-term overall and disease-specific survival rates, development of new
lesions, and complications were analyzed.
Results: The mean age was higher in the ESD group (64.9 9.5 vs. 58.5 11.7,
P¼ 0.001) and female distribution was higher in surgery group (30.5% vs. 38.9%,
P¼ 0.001). In ESD group, diabetes was more frequent (12.9% vs. 7.1%,
P5 0.001). The overall survival rate was similar (96.2% vs. 96.7%, P¼ 0.136),
but disease-specific survival rate was significantly higher in ESD group (99.8%
vs. 98.7%, P¼ 0.037, log-rank test). During 10 year follow up period, new lesions
were observed in 3.6% of ESD group and in 1.3% of surgery group (P5 0.001).
ESD group showed less complications (4.5% vs. 16.3%, P5 0.001) and shorter
hospital day than surgery group (5.27 days vs. 12.09 days, P5 0.001).
Conclusion: Although the development of new lesions were more frequent than
surgery, ESD has similar overall survival rate and even higher disease-specific
survival rate than surgery. Also, ESD has less complications and shorter hospital
day than surgery. Therefore, ESD is an effective therapeutic method in early
gastric cancer as well as surgery.
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Introduction: Gastric malignant lymphoma (ML) is most popular lymphoma of
the gastrointestinal tract. Especially we often see gastric MALT lymphoma in
cases of H. pylori (HP) infection positive, and we also sometimes find out HP
negative gastric MALT lymphoma. Since gastric carcinoma (GC) is more
common rather than gastric MALT lymphoma, typical endoscopic diagnostic
characteristics of GC are established on usual endoscopic examination for
most of gastroenterologists. On the other hand, endoscopic characteristics of
gastric MALT lymphoma on usual endoscopy have not been established for
most of gastroenterologists.
Aims & Methods: Our aim of this study is to estimate of the difficulty on endo-
scopic diagnosis of gastric MALT lymphoma for 24 gastroenterologists
(12 experts and 12 trainees of endoscopy) on usual endoscopic examination.
We investigated a total of 72 gastric MALT lymphoma cases in our hospital and
other 7 hospitals. We estimated total number of endoscopic examinations to
achieve diagnosis of gastric MALT lymphoma endoscopically and histologically.
In addition, we had analyzed the difference of abilities to diagnose of gastric
MALT lymphoma between experts and trainees on endoscopic examinations
using past endoscopic profiles (245 profiles).
Results: The average number of endoscopic examinations up-to diagnose gastric
MALT lymphoma was 3.4 times (from 1 to 7 times) on whole endoscopies after
first appearance of lymphoma. Though average total number of endoscopic
examinations of experts was only 1.2 times, on the other hand average total
number of endoscopic examinations of trainees was 5.4 times. There was a sig-
nificant difference between experts and trainees of endoscopy on average total
number of endoscopic examinations (p¼ 0.022). Major reason of misdiagnosis
was insufficient recognition of endoscopic appearances of ML on endoscopic
trainees. Typical representative appearances of gastric MALT lymphoma were
erosions, ulcers and surface irregularities. Since these lesions are also appeared as
typical appearances of GC and gastritis, most of non-expert of endoscopy cannot
distinguish the difference of GC, ML and gastritis due to those similarities.
For example, even if typical ML cases, non-expert could not diagnose repeatedly,
but expert could diagnose minimal lesions of ML at first endoscopy. Especially
HP positive gastric MALT lymphoma was similar to gastritis and GC on endo-
scopic findings, most of non-expert could not diagnose exactly.
Conclusion: There was significant difference of ability to diagnose gastric MALT
lymphoma between specialists and trainees. Therefore, hematologists should
order endoscopic examination to experts of endoscopy knowledgeable of ML
in case of endoscopic check-up of gastrointestinal malignant lymphoma.
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Introduction: Gastric cancer is the fifth most common cancer worldwide and the
third leading cause of cancer-related death globally [1]. With the widespread
eradication ofH. pylori and early detection, the incidence and mortality of gastric
cancer have been declined rapidly in the past few decades [2–3]. However, the
prognosis of patients with metastatic diseases was still dismal and most cases
survived less than one year [4]. Current primary and standard therapies for
metastatic gastric cancer mainly included chemotherapy, consisting of fluoropyr-
imidine/cisplatin-based combination regimens[5]. Although radical gastrectomy
was the first-line treatment for early gastric cancer[6], the value of gastrectomy in
stage IV was still a great controversy.
Aims & Methods: We aimed to investigate the impact of primary tumor resection
on survival outcomes among patients with metastatic cancer. We identified an
eligible cohort of the population with stage IV gastric cancer from the
Surveillance, Epidemiology and End Results (SEER) database between 2004 to
2012. The overall prognosis of advanced patients with or without gastrectomy
was assessed by Kaplan–Meier and log-rank analysis. Multivariate Cox propor-
tional hazards regression models was performed to analyze the effect of primary
tumor resection on overall and cancer-specific mortality. To further reduce
potential baseline bias in patient selection between two groups, we adopted 1:1
propensity score matching to re-examine the effect of resection.
Results: We finally identified 12984 eligible patients with metastatic GC between
2004 and 2012, including 1977 patients with gastrectomy and 11007 without
resection. The median survival time for patients with or without surgery were
9.0, 4.0 months respectively. Patients who received surgery had a significantly
better survival outcome compared with those without gastrectomy (P5 0.05). In
multivariate Cox analysis, gastrectomy was associated with decreased overall
mortality (HR,0.55, 95%CI 0.52–0.58, P5 0.001) and cancer-specific mortality
(HR, 0.55, 95%CI 0.52–0.58, P5 0.001). In the propensity score matched model
analysis, gastrectomy was associated with increased overall (HR,0.54, 95% CI,
0.51–0.58) and cancer-specific survival (HR,0.54, 95% CI, 0.50–0.55).
Conclusion: Based on population-based studies, we demonstrated that there was a
survival advantage of gastrectomy in patients with stage IV gastric cancer.
Further prospective studies are needed to verify our findings.
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Introduction: Endoscopic submucosal dissection (ESD) is technically difficult and
is associated with risks of perforation and bleeding. Although knife-type instru-
ments are primarily used to make incisions during ESD, it is necessary to be
proficient in endoscopic procedures and be able to perform them simultaneously
with electrification and incision. Scissors-type knives are fairly easy to manipu-
late in colorectal ESD. We have fabricated SB knife Jr type (SBJr), short scissors-
type knife with outer insulated layer, in collaboration with SUMITOMO
BAKELITE CO.
Aims & Methods: SBJr is short length (electrode length: 3.5mm) to be easy to
handle in narrow colorectal lumen. The surface of the rotatable monopolar
scissors is coated with insulating material in order to enhance the cutting
power and prevent electric effects in the surrounding tissue. The shearing struc-
ture make sharp cutting quality and very small round tips prevent to grasp the
muscular layer. SBJr was used in circumference incision, submucosal dissection
and hemostasis. After infected hyaluronic acid in submucosal layer, grasped the
tissue, confirming safety, make incision. SBJr was used not only used in incision
but also in hemostasis. At sites containing blood vessels or bleeding, they were
grasped and induceed coagulation using SBJr. It has been used on 180 colorectal
lesions from January 2008.
Results: The circumference incision and submucosal dissection were basically
performed with High-frequency cutting wave. There were 3 cases of perforation
during ESD and 1 case of post-operative bleeding. The procedure itself was fairly
easy and was particularly effective at fibrosis sites, sites difficult to stable the
endoscope and sites containing blood vessels, where conventional devices would
encounter difficulties. Due to the very small round tips of the instrument, detailed
operation become simply. For coagulation of blood vessels or bleeding, it is not
required to replace SBJr which is used cutting and coagulation.
Conclusion: This short insulated scissors-type knife (SBJr) made it easier to per-
form colorectal ESD, we conclude that it is an effective device and easy for a
beginner in colorectal ESD.
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Introduction: The gastrointestinal tract (GIT) is the most commonly extranodal
site affected in lymphomatous pathology. Infection with Helicobacter pylori,
human immunodeficiency virus and Epstein Barr and immunosuppression
have been studied as possible risk factors. The diagnosis is often late, presenting
at an advanced stage, with limited therapeutic options.
Aims & Methods: The objective of this study was to characterize the anatomical
distribution, clinical manifestations, risk factors and prognosis of GI lympho-
mas. Retrospective study of patients diagnosed with GI lymphomas between
1997 and 2016.
Results:During the 20 years, 127 GI lymphomas were identified. The mean age at
diagnosis was 58.2 16.5 years, 53% of males. The majority (92.9%) had symp-
toms at the time of diagnosis, with fatigue (54.3%) being the most common.
The most commonly affected organ was the stomach (65.3%) and the most
common subtypes were diffuse large B-cell (48.8%) and MALT (27.6%). Most
were diagnosed through upper endoscopy (68.5%) and 10.2% after exploratory
laparotomy. Sixty-five percent of patients underwent chemotherapy and 26%
underwent surgery. In the univariate analysis, lymphomas 44 cm (p¼ 0.037),
anorexia (p¼ 0.006), tobacco use (p¼ 0.038), alcohol consumption (p¼ 0.006),
lymphadenopathy (p¼ 0.014), high b2-microglobulin 50.01), ECOG4 2
(p5 0.001) and IPI index4 2 (p5 0.001) were associated with lower survival.
Conclusion: The stomach is the main organ affected by lymphomatous disease
but, unlike the literature in which MALT lymphoma predominates, the most
common subtype was diffuse large B-cell lymphoma. Upper endoscopy was the
main form of diagnosis. Alcohol and tobacco consumption, lymphadenopathy,
lymphoma4 4 cm, b2 high microglobulin, ECOG4 2 and IPI index4 2 are
poor prognostic factors.
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Introduction: Previous studies have shown that non-cardiac gastric cancer had no
associations with the obesity even if cardiac or gastroesophageal junctional
cancer was related with the obesity. These studies have included high portion
of advanced gastric cancer. Patients with most advanced cancer already experi-
enced weight loss.
Aims & Methods: We evaluated the effect of body mass index (BMI) on early
gastric cancer in patients undergoing endoscopic treatment for early gastric
cancer. A total of 748 patients with early gastric cancer undergoing endoscopic
treatment (endoscopic submucosal dissection) including age and sex matched
healthy controls consist of this case-control study. Body mass index was classified
into underweight (BMI5 18.5), normal (BMI 18.5–23), overweight (BMI 23–25),
and obese (BMI =25) by Asian-Pacific guideline. Adjusted analysis using odds
ratio (OR) and 95% confidence interval (CI) was performed to evaluate the effect
of BMI on early gastric cancer.
Results: The mean age was 57 years and male sex was 60% (n¼ 447). BMI was
higher in gastric cancer comparing to healthy control (24 vs 23, P5 0.001).
The OR of gastric cancer was increased according to the BMI increase; 1.57
(95% CI, 0.89–2.79, P¼ 0.12) in normal BMI, 1.88 (95% CI, 1.06–3.35,
P¼ 0.03) in overweight, and 2.28 (95% CI, 1.29–4.06, P¼ 0.005) in obese persons
comparing to underweight (P value for trend 50,001).
Conclusion: The early gastric cancer was strongly associated with the increased
BMI and its effect has dose-dependent pattern.
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Introduction: Gastrointestinal subepithelial tumors include potentially malignant
tumors. When considering the diagnostic yield for subepithelial tumors, it is
important to evaluate whether the samples obtained are adequate for histological
analysis, as immunohistological analysis is indispensable for a definitive diagno-
sis. However, it may be difficult to make a correct histological diagnosis with
only by the endoscopic ultrasonography-guided fine-needle aspiration (EUS-
FNA). Therefore, there has been an interest in exploring an alternative modality
for tissue sampling as mucosal-incision assisted biopsy (MIAB) based on the
endoscopic submucosal dissection.
Aims & Methods: The aim of this study was to compare the usefulness of EUS-
FNA and MIAB in the histological diagnosis of gastrointestinal subepithelial
tumors (SET). We performed the retrospective study comparing 37 patients
who underwent either EUS-FNA (n¼ 18) or MIAB (n¼ 19). Diagnostic yield
feasibility and safety of those EUS-FNA and MIAB were compared.
Results: The location of the SET was esophagus (n¼ 6), stomach (n¼ 29), and
duodenum (n¼ 2). The histological diagnosis were gastrointestinal stromal
tumors (n¼ 10), leiomyoma (n¼ 17), aberrant pancreas (n¼ 3), poorly differen-
tiated adenocarcinoma (n¼ 2), metastatic carcinoma (renal cell carcinoma,
n¼ 1), and no-diagnosis (n¼ 4). There were no significant differences in the
clinical characteristics-including sex and age-of the patients in the EUS-FNA
and MIAB. In EUS-FNAs/MIABs, the morphological findings of the SET
by EUS were as follows. The mean diameter of tumor was 29.16 15.6/
17.77 7.16mm(p¼ 0.0034). The rate of intraluminal growth was 55.6%/
94.7%(p¼ 0.0078). The mean procedure time was 40.89 10.79min in
EUS-FNA and 55.15 27.42min in MIAB(p¼ 0.0234). Histological diagnosis
was made in 72.2% of the EUS-FNAs and 94.7% of the MIABs(p¼ 0.0897).
No complications were found in either method.
Conclusion: The mean procedure time was significantly longer in MIAB than in
EUS-FNA. However, the mean diameter of the tumor was significantly smaller
in MIAB than in EUS-FNA the higher diagnostic yield in MIAB than in EUS-
FNA was borderline significant.
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Introduction: In 2012 the reported incidence of gastric cancer in both sexes was
12.3/100,000 but the mortality was still high (8.7/100,000), being early detection
strictly related to a better survival. Parma area is considered at medium-low
incidence of gastric cancer. For early diagnosis, the detection of a precancerous
condition like atrophic gastritis seems crucial, but the majority of such patient is
asymptomatic and the use of non invasive diagnosis like serology (Pepsinogens
and Gastrin 17) as suggested in the guidelines of Kyoto and Maastricht V is up to
now limited in clinical practice. Aim of the study, therefore was to establish the
burden of gastric cancer in the diagnosis of the last six years, focusing on the
detection of early gastric cancer.
Aims & Methods: Six years (from July 2010 to July 2016) were considered in
search for diagnosis of gastric cancer as reported in the archives of the Pathology
Department of Parma University. Overall, 816 cases of gastric cancer were found
but we decide to consider only the surgically removed cases, therefore the avail-
able sample is based on 584 cases. For every cases we classified the cancer in
early, following the Kodama classification, and advanced. The presence of
atrophic gastritis nearby the neoplasia was assessed according with OLGA clas-
sification. In both early and advanced cancer the node status was investigated.
Results: Overall, 584 cases of gastric cancer was detected in the six years con-
sidered interval (M¼ 318, F¼ 223, mean age 78ys, range 36–105ys) The diagno-
sis of early gastric cancer was made in 44/584 (7.53%) (M¼ 24, F¼ 20 mean age
75.68ys, range 47–92ys). A diagnosis of advanced gastric cancer was established
in 540 pts (M¼ 318, F¼ 222, mean age 78.20ys, range 36–105ys). The picture of
chronic atrophic gastritis was found in more than 95% of the cases, both in early
and advanced ones. The node status was also recorded. Early cancers showed a
25% of node metastasis compared with 84.65% in advanced ones. As regards the
number of involved nodes, in early presentation of neoplasia we found 98% of
pN1 staging whereas in advanced the pN1 cases were only 9.1%.
Conclusion: Early gastric cancer diagnosis is still confirmed as very infrequent
and this could account for the high mortality rate for the gastric neoplasia.
The search for precancerous condition like chronic atrophic gastritis is therefore
mandatory.
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Introduction:Gastric adenocarcinoma of fundic gland type (GAFG) is an uncom-
mon variant of gastric adenocarcinoma which has a distinct clinicopathological,
immunohistochemical, and endoscopic features 1–3). However, the molecular
biological features of GAFG have not been well elucidated.
Aims & Methods: We evaluated clinical and molecular characteristics of GAFG
in comparison with conventional gastric adenocarcinoma. Among 831 patients
with gastric adenocarcinoma who underwent surgery or endoscopic resection in
Juntendo hospital between January 2010 and December 2016, we enrolled
13 cases of GAFG, defined as an extremely well differentiated adenocarcinoma
with expression of pepsinogen-I and/or Hþ/Kþ-ATPase 1). To clarify concurrent
mutations of GAFG, next generation sequencing (NGS) was perfumed for all
cases of the tumor and normal tissue formalin-fixed paraffin-embedded samples,
using Ion PGMTM system with the Hotspot Cancer Panel v2 targeting 50 genes
(Thermo Fisher Scientific). We also carried out immunohistochemical staining
including MUC2, MUC5AC, MUC6, and CD10, and analyzed association
among genetic alterations and mucin phenotype.
Results: Clinicopathologically, all patients [62.9 y (range 43–80), 8 male, 5 female]
had submucosal invasive adenocarcinomas with no H. pylori infection; the mean
depth of the submucosal invasion was 288.4 (50–700) mm. Neither local recur-
rence nor metastases were detected at a median of 6.7 months (1–47) follow-up
after treatment. NGS analysis revealed that nine of 13 patients (69.2%) had
oncogenic driver mutations including GNAS (5/13, 38.5%), KRAS (2/13,
15.4%), STK11 (1/13, 7.7%), and TP53 (1/13, 7.7%), and these alterations
were mutually exclusive. Mutations of APC and CTNNB1, members of the
Wnt/b-catenin pathway, were absent in all cases examined. Compared with
public data sets of conventional gastric adenocarcinoma 4), the frequency of
GNAS mutation was significantly higher (38.5% vs. 6.2%, p5 0.01) in
GAFG. Furthermore, the frequency of TP53 mutation was significantly lower
(7.7% vs. 47.8%, p5 0.05) in GAFG. However, there were no significant differ-
ences in the frequencies of KRAS and STK11 mutations. In addition, all lesions
showed gastric phenotype (i.e. immunopositive for MUC5AC and/or MUC6),
and there were no significant differences between genetic alterations and mucin
phenotype.
Conclusion: The present clinical and comprehensive genetic analysis identified
that GAFG is a neoplasm with low-grade malignancy, and the frequent presence
of GNAS mutation is a characteristic genetic feature of GAFG.
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Introduction: Runt-related transcription factor 3 (Runx3) is a transcription factor
playing an inhibitory role in the malignant behavior of gastric cancer. Long non-
coding RNAs (LncRNAs) exert their functions mainly by binding with corre-
sponding proteins, among which, transcription factors are the most common
ones. However, the LncRNAs that could bind with and affect the expression
or activity of Runx3 are still unclear.
Aims & Methods: Potential Runx3-binding LncRNAs were screened by an online
prediction software RPISeq, and then validated by RNA Immunoprecipitation.
Specific HOTIAR binding site with Runx3 was confirmed further by RNA Pull
down. The E3 ubiquitin ligases being involved in the ubiquitin-proteasome
degradation of Runx3 were recognized through co-immunoprecipitation assay.
Besides, the expressions of HOTIAR and Runx3 were measured in human gastric
cancer tissues and correlated with each other.
Results: A total of 11 lncRNAs that might bind with Runx3 were selected by in
silico analysis, among which, HOTIAR, MALAT1, PVT1 and LET were signifi-
cantly amplified in RNAs precipitated by Flag antibody. Ectopic expression of
HOTIAR inhibits the protein expression of Runx3, while addition of exogenous
MG132 could partially recover this. RNA Pull down assay with a stepwise dele-
tion of Runx3 shows that HOT-D2 (1951–2100) is a major Runx3 binding site
along the sequence of HOTIAR. Mex3b was markedly enriched by Runx3 anti-
body, and siRNAs targeting either HOTIAR or Mex3b could enhance the sta-
bility of Runx3 by impairing its ubiquitination. in addition, HOTIAR was
negatively associated with the protein level of Runx3 in gastric cancer tissue.
Conclusion: HOTAIR induces the ubiquitin-proteasome degradation of Runx3
by enhancing its interaction with a E3 ubiquitin ligase Mex3b in gastric cancer.
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Introduction: Promoter hypermethylation plays a vital role in cancer development
through transcriptional silencing of tumour suppressive genes. Using Infinium
Human Methylation 450 BeadChip (450K) array, we first identified calcium
binding protein 39-like (CAB39L) to be preferentially methylated in gastric
cancer (GC) and it may function as a potential tumour suppressor gene.
Aims & Methods: In this study, we aim to investigate the biological function,
molecular mechanism and clinical implications of CAB39L in GC. Clinical rele-
vance was validated by bisulfite genomic sequencing (BGS), western blot and
immunohistochemistry (IHC). In vitro functional assays were carried out by cell
viability, colony formation, apoptosis, cell cycle, cell invasion and migration
assays in GC cell lines. In vivo tumorigenicity was evaluated in an orthotopic
mice model. Pathway analysis was performed using RNAseq and Phospho-
kinase Antibody Array. The interaction of CAB39L with its protein partners
was determined by co-immunoprecipitation.
Results: CAB39L mRNA was down-regulated in 13 out of 14 GC cell lines.
Silencing of CAB39L was associated with promoter hypermethylation, and
demethylation 50- treatment using Azadeoxycytidine (5-Aza) restored the expres-
sion of CAB39L. In human GC, CAB39L mRNA and protein level (p5 0.0001)
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were significantly decreased in GC tissues comparing to adjacent normal tissues
both in Chinese cohort (n¼ 48 pairs) and TCGA cohort (n¼ 450). CAB39L
hypermethylation was correlated with poor overall survival in Chinese cohort
(n¼ 87, p5 0.005) and validated in TCGA cohort (n¼ 354, p5 0.005), which
suggesting that CAB39L might function as a tumour suppressor. The functional
importance of CAB39L in GC was therefore examined. Ectopic expression of
CAB39L in three GC cell lines (AGS, BGC823, MKN45) suppressed cell pro-
liferation in MTT (p5 0.01) and colony formation assays (p5 0.0001). CAB39L
induced apoptosis and G1 cell cycle arrest in GC cells, concomitant with the
enhanced expression of cleaved caspase-8, caspase-3, p21 and decreased cyclin
D3 expression. Cell migration and invasion abilities were inhibited by CAB39L in
wound healing and gel invasion assays, respectively. Conversely, CAB39L
knockdown in MKN28 demonstrated opposite effects. Orthotopic mice model
also showed inhibited tumorigenicity with CAB39L-overexpressing BGC823
cells. Mechanistically, RNAseq and gene set enrichment analysis (GSEA)
revealed that AMPK and ERBB2/ERBB4 signaling were involved in the
tumour suppressive role of CAB39L in GC. Consistent with our RNAseq
data, Phospho-Kinase Antibody Array identified AMPK as the top activated
kinase; whilst ERK1/2 was the most strongly down-regulated in CAB39L over-
expressing GC cells, suggesting that CAB39L up-regulates AMPK concomitant
with down-regulation of ERBB2/4-ERK signalling. Moreover, co-immunopreci-
pitation identified a direct interaction between CAB39L and LKB1, a bona-fide
tumour suppressor that functions to activate AMPK to suppress tumorigenesis.
Western blot confirmed activation of LKB1-AMPK/b cascade in GC cells
expressing CAB39L, while an opposite effect was observed in CAB39L-silenced
MKN28 cells. Administration of an AMPK activator, AICAR, inhibited growth
of control cells but not CAB39L-expressing (thus AMPK activated) cells, sug-
gesting that AMPK activation by CAB39L contributes to tumour suppression.
Conclusion: CAB39L is a novel tumour suppressor silenced by promoter methy-
lation in GC. CAB39L inhibits gastric tumorigenesis via LKB1-mediated activa-
tion of AMPK/b. CAB39L methylation may serve as an independent prognostic
biomarker for GC patients.
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Introduction: Using 450K DNA methylation array, we identified PBX/Knotted 1
Homeobox 2 (PKNOX2) as a novel gene differentially methylated in gastric
cancer (GC). PKNOX2 belongs to the TALE (three-amino acid loop extension)
family of homedomain transcription factors, which play fundamental roles in cell
proliferation, differentiation and death. However, the role of PKNOX2 in GC
remains largely unknown.
Aims & Methods: We aimed to investigate the function, molecular mechanism
and clinical implication of PKNOX2 in GC. PKNOX2 promoter methylation
was evaluated by bisulfite sequencing. PKNOX2 expression was determined by
RT-PCR and qPCR. Biological functions of PKNOX2 were determined in GC
cells by MTT, colony formation, apoptosis, cell cycle, cell migration/invasion
assays, and in vivo using nude mice tumorigenicity assay. Pathways targeted by
PKNOX2 were identified by Cancer pathway PCR array and dual luciferase
reporter assay.
Results: PKNOX2 was silenced in 15 out of 18 GC cell lines through promoter
methylation, and 50-Azadeoxycytidine treatment restored PKNOX2 expression.
PKNOX2 mRNA expression was down-regulated in GC compared to adjacent
normal tissues (P5 0.001). Moreover, promoter methylation of PKNOX2 was
associated with poor survival in GC patients (P5 0.05), suggesting that
PKNOX2 may function as a tumor suppressor in GC. We therefore examined
its functional effect in GC. Ectopic expression of PKNOX2 in GC cell lines
suppressed cell proliferation, induced cell apoptosis and cell cycle arrest, conco-
mitant with increased expression of apoptosis markers cleaved caspase-9,-7,-3
and PARP and cell cycle inhibitors p53, p21 and p27. PKNOX2 also attenuated
cell migration and invasion by inhibiting epithelial-mesenchymal transition.
PKNOX2 knockdown in HGC27 cells resulted in opposite effects.
Tumorigenicity assay in nude mice showed that stable PKNOX2 expression sig-
nificantly suppressed tumor growth in vivo. To probe the mechanism of action of
PKNOX2 in GC, we performed Cancer pathway PCR array, which unveiled a
profound up-regulation (46-fold) of Insulin like Growth Factor Binding Protein
5 (IGFBP5) in PKNOX2-overexpressing GC cells. IGFBP5 knockdown abol-
ished the growth inhibitory effect of PKNOX2 in GC cells, indicating that
IGFBP5 mediated the tumor suppressive function of PKNOX2. Chromatin
immunoprecipitation (ChIP) assay showed that PKNOX2 bind directly to
IGFBP5 promoter to mediate transcription. Consistent with our data,
PKNOX2 expression was positively correlated with IGFBP5 expression in
the TCGA GC dataset. IGFBP5 mediated the tumor suppressive effect of
PKNOX2 via activating p53 signaling pathway, as determined by western blot
and luciferase reporter assays. Consequently, p53 transcription target genes were
coordinately up-regulated in PKNOX2 overexpressing cells, leading to tumor
suppression.
Conclusion: PKNOX2 functions as a novel tumor suppressor silenced in GC by
promoter methylation. Its tumor suppressive effect is mediated via IGFBP5 and
the activation of p53 signaling pathway. Promoter methylation of PKNOX2 may
be a useful biomarker for predicting patient prognosis.
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Introduction: Gastric cancer is one of the most common malignancies worldwide.
A multitude of factors contribute to the progression of gastric cancer, including
activation of oncogenes and inactivation of tumor suppressors. To find the key
molecules and their mutual relations in gastric carcinogenesis is of great signifi-
cance for the diagnosis and treatment of gastric cancer. The homeobox (Hox)
superfamily genes encode transcription factors and usually regulate the expres-
sion of target genes at transcription level. Dysregulation of Hox genes will cause
the abnormality in individual development and tissue formation, and may also
lead to malignant transformation. Our group have previously screened by gastric
cancer tissue microarray and found that the expression of HoxC10 was remark-
ably upregulated in gastric cancer. At the present time, the function and mole-
cular mechanisms of HoxC10 in gastric cancer remains poorly understood.
Aims & Methods: To investigate the expression of HoxC10 in gastric cancer,
tissue samples from two clinical cohorts were used. We analyzed HoxC10 expres-
sion in gastric cancer tissues and the corresponding adjacint non-tumor tissues,
as well as its correlation with clinical pathological parameters. In addition,
we also verified the results by utilizing bioinformatics analysis. We studied the
effects of HoxC10 on gastric cancer cell cycle control and proliferation through
combination of in vitro cell function tests and in vivo nude mice model. Then, we
screened HoxC10 potential downstream targets by using cDNA microarray and
verified the results by RT-qPCR. We studied the effects of HoxC10 on p21
expression and its downstream cell cycle-related proteins and validated the cor-
relation of HoxC10 and p21 expression in vitro and in vivo. By application of
dual-luciferase reporter assay and chromatin immunoprecipitation, we explored
the role of HoxC10 in p21 transcription repression.
Results: HoxC10 mRNA expression were significantly higher in fresh frozen
gastric cancer tissues than in matching adjacent non-tumor tissues (91.43%,
64/70, P5 0.01). The expression of HoxC10 was related to the depth of tumor
invasion, lymph node metastasis and tumor stage (P5 0.01). Using tissue micro-
array, HoxC10 protein expression was also found widely upregulated in gastric
cancer tissues (91.3%, 137/150, P5 0.01) and was closely correlated with patient
survival (HR¼ 2.8; 95% CI 2.0–7.2). Besides, in TCGA database of gastric
cancer, HoxC10 was upregulated by 122 times (n¼ 33, P5 0.01), and in
Kaplan-Meier Plotter database, high HoxC10 expression was associated with
poor prognosis of patients with gastric cancer (HR¼ 1.8; 95% CI 1.5–2.16).
HoxC10-overexpressing gastric cancer cells showed accelerated G1-S phase
transformation and proliferation, whereas HoxC10 knocking-down induced
cell cycle arrest in G1 phase and repressed cell proliferation. Moreover, over-
expression of HoxC10 accelerated gastric tumor growth in a mouse xenograft
model, while knocking-down of HoxC10 inhibited gastric tumor growth. cDNA
microarray showed that HoxC10 regulates multiple downstream genes including
p21, a potent cell cycle regulator. A significantly negative correlation between
HoxC10 and p21 were detected in gastric cancer cells and tissues. Knocking-
down of HoxC10 also altered the expression of some p21 downstream cell
cycle-related proteins, such as CDK2 and CDK4. Furthermore, we found that
HoxC10 binds to the p21 promoter directly and could inhibit p21 transcription.
Conclusion: Taken together, our results suggest that HoxC10 functions as a
tumor promoting gene in gastric cancer and may be an important regulator of
cell cycle control through p21 transcription regulation.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The relationship between Helicobacter pylori (H.p.) eradication and
atrophic changes is debated. Although some studies report a partial restoration
of serum pepsinogen I (PGI) levels after eradication, it is not clear whether this
finding reflects gastric mucosal healing. L-cysteine, reducing acetaldehyde pro-
duction after food intake, has been proposed for prevention of gastric carcino-
genesis in patients with chronic atrophic gastritis (CAG). To assess modifications
in gastric function after L-cysteine administration in CAG by means of PGI and
gastrin 17 (G17) serum levels
Aims & Methods: 62 patients (18 men, mean age 47.2 yrs), with histological
diagnosis of moderate to severe chronic, atrophic, body gastritis (according to
the O.L.G.A. staging system) and PGI serum levels 525mg/L, underwent upper
gastrointestinal endoscopy with gastric biopsy samplings and PGI and G-17
measurement by means of Gastropanel. 22 out of 62 patients had autoimmune
gastritis while 40 of them reported previous H.p. infection. All patients,
Helicobacter pylori negative at baseline, were treated with L-cysteine (100mg
three times daily), up to now 24 out of 62 reached 36 months-treatment.
Serum PGI and G-17 were measured at baseline and after 3, 6, 12, 24, 36
months after starting therapy.
Results: The PGI showed an increased serum level after the starting of L-cysteine
administration, as it follows: PGI mean value at baseline was 8.42mg/l, but after 3
months therapy was 10.58, after 6 months 11.65, after 12 months 12.19, after 24
months 13.88, and after 36 months was 14.21 (p: 0.0001). The G-17 serum level
resulted gradually decreased over the 36 months therapy, as it follows: G-17
mean value was 51.33 pmol/l at baseline, 43.13 after 3 months therapy, 38.66
after 6 months, 28. 34 after 24 months and 26.03 after 36 months (p: 0.0041).
Conclusion: After L-cysteine administration, patients with chronic, atrophic,
body gastritis showed long-lasting improvements of physiological gastric
function, reflected by a significant increase of PGI levels and a parallel decrease
of G-17 serum levels over a 36 months follow-up period.
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Introduction: Signaling pathway mediated by androgen receptor (AR) plays an
important role in the development of gender-related tumors, such as hepatocel-
lular carcinoma, prostate cancer. Gastric cancer (GC) is the third cause of cancer
related death all over the world, and its incidence in male is also much higher
than female. However, the molecular mechanisms of AR in gastric cancer are still
poorly characterized.
Aims & Methods: To investigate the role of AR in gastric cancer, we identify the
transcriptional downstream targets of AR by chromatin immunoprecipitation.
We detected mRNA and protein expression level of AR and its target in paired
GC samples and GC cell lines by RT-PCR and western blot. The biological
functions of AR signaling pathway in GC cell lines were determined by colony
formation and cell migration/invasion assay.
Results: CCRK was demonstrated as the direct target of AR by chromatin
immunoprecipitation assay. AR expression was elevated in most (6/7) GC cell
lines compared with the immortalized gastric cell line GES1. CCRK was upre-
gulated in all (7/7) tested GC cell lines. The correlation of AR and CCRK
expression was statistically significant. Higher mRNA level of both AR and
CCRK were detected in GC tissues compared with the adjacent normal tissues
(P5 0.01). Ectopic re-expression of AR or CCRK by stable transfection pro-
moted colony formation and invasiveness (P5 0.05). Consistently, the numbers
of colony formation, migrated cells and invasive cell were reduced by knockdown
of AR or CCRK in GC cell lines (P5 0.01).
Conclusion:Our results demonstrate that AR directly regulates CCRK expression
in GC. AR and CCRK gene may act as a potential oncogene in gastrocarcino-
genesis by playing an important role in promoting of cell proliferation, migration
and invasion, which may partially explain the higher prevalence of gastric cancer
among males.
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Introduction: Timely progress through diagnostic pathways is a leading quality
measure for NHS cancer services. A hypothesis of sooner diagnosis being achiev-
able with direct access to hospital tests from primary care is a core part of CRUK
ACE program (1), and in the context of UGI cancer pathway, there is known
wide variation of direct access (DA) OGD (2). This pilot evaluates the efficacy
and utility of DA OGD or clinic (DA OPD) for GP concerns a patient may have
OG cancer. Comparison was made with thestandard 2WW pathway, where allo-
cation to OGD v OPD first is performed by OG consultant.
Aims &Methods: Pilot and UGI standard 2WW referrals 01/01/16–01/08/16 were
identified from Cancer Centre records.
Results: 192 patients were in the pilot pathway, 430 via the standard 2WW. GPs
were more likely to allocate patients to DA OGD (52%) compared to 32%
having DTT OGD allocated by the hospital. Despite under-utilisation of pro-
tected slots for DA OGD, time to DA OGD compared to DTT did not differ
(11.0 days [95%CI 10.5,11.2] versus 12.4 days [95%CI 11.0,13.9]). The same was
seen for DA OPD. The total time on pathway was not improved in the pilot
group at 16.8 days [95%CI 4.9,28.6] compared to 17.9 days [95%CI 16.9, 18.9].
The subgroup of patients allocated in the pilot to DA OGD did have a quicker
exit from the pathway, at 12.4 days [95%CI 6.5,18.3] compared to 14.8 days
[95%CI 12.9,16.6] on the DTT OGD group. The pilot overall detected 8 cancers
(4.2%); the standard 2WW path detected 55 (12.8%). OG cancers were in 4 of the
DA OGD (4%) and 14 of the DTT OGD (10.2%). A further 10 non-OG cancers
were detected in the DTT group after clinicians requested further investigations
to determine the cause of their symptoms. Those patients allocated to OPD first
by either GP or hospital were as likely to have cancer as those having OGD, with
4.3% of those in the pilot having acancer detected this way, but none OG cancer,
and 10.3% found to have cancers in the standard 2WW group following inves-
tigation directed after clinic visit. Of these 65% were cancers other than OG
cancers and would not be detected on OGD alone.
Conclusion: OGD as a sole investigation for symptoms has its utility in excluding
or detecting OG cancer. A high proportion of cancers detected via 2WW criteria
on OG pathway are outside of OG tract and require other tests to diagnose them.
In this pilot no additional utility of opening direct access OGD for GP concerned
a patient may have an OG cancer was not demonstrated unless exclusion of OG
cancer is viewed as the major purpose of the pathway. Our data demonstrates
that such a view would be detrimental and lead to missed opportunity to detect
other cancers that cause symptoms overlapping with those often ascribed to OG
tumours.
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Introduction: Coeliac disease is a common cause of malabsorption in Western
countries. The gold standard method of diagnosing coeliac disease is by way of
duodenal biopsy. Weight loss is a symptom of malabsorption. Patients referred
for upper gastrointestinal endoscopy with symptoms of a weight loss commonly
undergo duodenal biopsy to assess for presence of coeliac disease. We hypothe-
sise that those patients with weight loss and who routinely have duodenal biop-
sies very rarely have coeliac disease unless there are other pointers towards
malabsorption.
Aims & Methods: A single-centre, retrospective analysis of consecutive patients
undergoing upper gastrointestinal endoscopy for the sole indication of weight
loss was undertaken within a large associate teaching hospital within North
London from 2005–2016. Of these patients, we reviewed those that had duodenal
(D2) biopsies and the results. If they proved abnormal, we looked back for
additional markers of malabsorption, clinically and biochemically.
Results: 142 consecutive patients, 65 were Male, 77 were female, underwent OGD
for weight loss. Out of this cohort, 62% (n¼ 88) had a duodenal biopsy. 89%
(n¼ 78) of these had a normal biopsy. 11% (n¼ 10) had an abnormal biopsy,
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and 6 of these patients had coeliac, whilst 4 had other pathology such as gran-
ulomas or duodenitis.
For all the patients who had abnormal D2 biopsies, they had other clinical
markers of malabsorption, such as abdominal pain and diarrhoea, or biochem-
ical indices such as anaemia or elevated TTG antibodies.
Conclusion: From this study we conclude that the yield of routine duodenal
biopsies in patients endoscoped for the sole indication of weight loss is poor.
In patients with weight loss in whom coeliac disease is identified on biopsy is
always associated with additional symptoms or abnormalities in blood indices.
We conclude that there is no need to take biopsies of the duodenum on a routine
basis for weight loss alone unless there are other signs of malabsorption. This will
save time (both from taking the biopsy and sampling in the lab), lower the cost
(forceps and pot) and improve the safety (potential perforation and bleeding risk)
of the procedure.
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Introduction: In 2015, the five most common digestive cancers (colorectal, pan-
creatic, liver, gastric, and esophageal) accounted for 16% of incident cancer cases
and 24% of all cancer deaths. It is unclear whether the amount and recent trends
in US federal funding for digestive cancer research corresponds to the burden of
disease.
Aims & Methods: We obtained the total annual funding for cancer (including the
five most common digestive cancers) from 2008 to 2015 using a public database
of research funded by US federal agencies. We calculated funding in 2015 con-
stant USD using the Consumer Price Index. Cases and deaths estimated by the
American Cancer Society were used to calculate funding per death or case for
each cancer. For comparison, we also extracted data for the three most common
cancers (breast, lung, prostate) and all cancers combined. As funding for research
in the United States was boosted by the American Recovery & Reinvestment Act
in 2009–2010 and declined thereafter, we analyzed trends in funding and disease
burden from 2010–2015 using the Spearman correlation.
Results: In 2015, 8 billion USD in federal funding was issued to all cancer
research and 658 million USD to the five common digestive cancers. The five
digestive cancers accounted for 23–24% of all cancer deaths from 2010–2015, but
only received 7% of cancer funding in 2010, and 8% of funding in 2015.
The ratio of the proportion of all cancer death to the proportion of all cancer
funding, a marker of funding disparity, was 2.9. In comparison, breast cancer
accounted for 7% of cancer deaths in all years, 11% of funding in both 2010 and
2015, and had lower proportional death than proportional funding (ratio¼ 0.6).
Prostate cancer likewise had lower proportional death than funding (ratio¼ 0.8).
Funding disparity, measured by proportional death and funding, was highest for
esophageal and gastric cancer among digestive cancers and for lung cancer over-
all. The estimated number of deaths and cases decreased for colorectal cancer but
increased for the other digestive cancers during the study period. Funding per
death among digestive cancers in 2015 was highest for liver cancer and lowest for
esophageal cancer. Funding per death for breast cancer was more than 3-fold
that of liver cancer and nearly 7-fold that of esophageal cancer. From 2010–2015,
funding per death for digestive cancers decreased by 20% for esophageal cancer,
24% for colorectal and gastric cancer, and 28% for liver cancer; funding per
death increased by 10% for pancreatic cancer. Statistically significant trends were
observed for colorectal and liver cancer (p5 .05 for both). Over the same period,
funding per incident case decreased by 15% for esophageal cancer, 21% for
colorectal cancer, 34% for gastric cancer, and 37% for liver cancer; funding
increased for pancreatic cancer by 6%. Statistically significant trends were
observed for liver (p5 .01), colorectal, and gastric (p5 .05) cancer. Despite
the larger relative funding decrease for liver cancer, it remained the best-
funded digestive cancer relative to both incident case and death. Liver cancer
received more than 2.5-fold funding per incident case than colorectal and gastric
cancer in 2015. Gastric cancer was the only digestive cancer to measure in the
bottom two for both funding per death and per incident case.
Conclusion: From 2010 to 2015 in the US, federal research funding relative to the
burden of disease has decreased for all digestive cancers except pancreatic cancer.
Although a similar trend was observed for all cancer research, there appears to be
a funding disparity for digestive cancers—especially gastric cancer—compared to
breast cancer and all cancers combined. Greater investment and more equitable
funding allocation may improve digestive cancer outcomes.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Helicobacter pylori infection induces aberrant DNA methylation in
gastric mucosa. We evaluated the long-term effect of H. pylori eradication on
promotor CpG island hypermethylation in gastric carcinogenesis.
Aims &Methods: H. pylori-positive patients with gastric adenoma or early gastric
cancer who underwent endoscopic resection were enrolled. According to H.
pylori eradication after endoscopic resection, the participants were randomly
assigned to H. Pylori eradication or non-eradication group. H. pylori-negative
gastric mucosa from normal participants provided the normal control. CpG
island hypermethylation of tumor-related genes (p16, CDH1, and RUNX-3)
was evaluated by quantitative MethyLight assay in non-tumorous gastric
mucosa. The gene methylation rate and median values of hypermethylation
were compared after one year by H. pylori status.
Results: In H. pylori-positive patients, hypermethylation of p16 was found in
80.6%, of CDH1 in 80.6%, and of RUNX-3 in 48.4%. This is significantly
higher than normal control (p16, 10%; CDH1, 44%; RUNX-3, 16%)
(p5 0.05). In the H. pylori eradication group, methylation rates of p16 and
CDH1 decreased in 58.1% and 61.3% of the patients, and the median values
of hypermethylation were significantly lower at one year compared with the non-
eradication group. However, RUNX-3 hypermethylation did not differ signifi-
cantly at one year after H. pylori eradication. The non-eradication group hyper-
methylation did not change after one year.
Conclusion: H. pylori infection was associated with promotor hypermethylation
of genes in gastric carcinogenesis, and H. pylori eradication might reverse p16
and CDH1 hypermethylation
Disclosure of Interest: All authors have declared no conflicts of interest.
P1247 CURCUMIN DOWNREGULATES INTERLEUKIN (IL)-17 BY
INCREASING THE EXPRESSION OF INDOLEAMINE 2,3-
DIOXYGENASE (IDO) IN HELICOBACTER PYLORI-INFECTED
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Introduction: IDO promotes the effector T-cells apoptosis by catalyzing the rate-
limiting first step in tryptophan (Trp) catabolism. We demonstrated that the high
expression of IDO in H. pylori-infected human gastric mucosa attenuates Th1
and Th17 immune responses. The anti-inflammatory and anti-microbial proper-
ties of the nutraceutical compound curcumin suggest its use as an anti-H. pylori
agent, but mechanisms that underlie its helpful activity are still not clear.
Aims & Methods: Five antral biopsies were taken from 22 patients (10 M, median
age 47.5 yrs, range 20–74) who underwent gastroscopy for dyspeptic symptoms: 1
for urease quick test (Eurospital, Trieste, Italy), 2 for histology (Giemsa staining
forH. pylori), and 2 for organ culture. 13A C-urea breath test was also performed
(at least two tests positive and all the three tests negative to be considered
H. pylori-infected or uninfected). Biopsy samples were immediately placed in
an organ culture chamber, treated with and without curcumin 200 mM (Sigma,
St. Louis, MO, USA) for 20 hours and evaluated for the expression of IDO and
IL-17 by Western blotting. Levels of IL-17 were also measured in culture super-
natant by ELISA. Further antral biopsies from a subgroup of 14 patients were
treated with curcumin in addition with the IDO inhibitor 1-methyl-L-Trp (1-MT,
Sigma, St. Louis, MO, USA) and the expression of IL-17 was assessed in total
protein extracts by Western blotting. The ratio of IDO and IL-17 with b-actin
was calculated by densitometry, while results from ELISA were normalized on
protein content. Values were given as meansSD arbitrary units (a.u.) and
pg/mL, respectively. Data were analysed using the Mann–Whitney U test.
Results: In gastric biopsies cultures fromH. pylori-infected patients (n¼ 13), IDO
significantly increased in curcumin-treated compared with untreated samples
(1.26 0.64 a.u. vs 0.87 0.61, p¼ 0.02). Levels of IL-17 were significantly
lower in curcumin-treated compared with untreated samples, both in gastric
biopsies (0.53 0.26 a.u. vs 0.85 0.31 a.u., p¼ 0.02) and culture supernatant
(22.91 13.72 pg/mL vs. 40.46 21.69 pg/mL, p¼ 0.04).). In the subgroup of
H. pylori-infected patients (n¼ 9), samples treated with curcumin in addition
to IDO inhibitor 1-MT, IL-17 expression was significantly higher compared
with untreated samples as well as with those treated with curcumin alone
(1.44 0.52 a.u. vs 0.91 0.34 a.u. and vs 0.78 0.21 a.u., p¼ 0.04 and
p¼ 0.01, respectively). Both IDO and IL-17 expression were very low in
untreated H. pylori-uninfected samples and did not significantly change when
treated with curcumin alone or in addition to IDO inhibitor 1-MT.
Conclusion: Curcumin is capable of down-regulating IL-17 production in
H. pylori-infected human gastric mucosa. This effect is, at least in part, mediated
by increasing IDO expression. This endorses the potential role of curcumin in
dampening H. pylori-induced immune-mediated inflammatory changes.
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Introduction: Alterations in salivary microbiota have been linked to elevated
inflammatory responses and has been reported in patients with inflammatory
bowel disease and pancreatic cancer. As yet, the potential association between
salivary microbiota and patients with gastric pathology has not be determined.
Aims & Methods: In this study, we characterized the salivary microbiota in
patients with H. pylori (HP)-associated gastritis and the potential changes of
salivary microbiota after receiving HP eradication. We enrolled subjects who
were scheduled for diagnostic upper GI endoscopy. We excluded patients with
peptic ulcer or cancer found on endoscopy, who have received prior HP eradica-
tion therapy, and who have recent exposure to antibiotics or acid suppressive
therapies. Unstimulated saliva samples were obtained from subjects during fast-
ing state prior to endoscopy. During endoscopy, gastric biopsies were obtained
for determination of HP statuses by rapid urease test and histology. Another
gastric biopsy was obtained for characterization of gastric microbiota. Serial
salivary samples were obtained from HP-infected subjects 8-week after complet-
ing HP eradication therapy. Bacterial DNA was extracted for 16s rRNA sequen-
cing by using the MiSeq Platform (Illumina). OTU clustering was performed and
taxonomy assigned to the Greengene and HOMD database. Alpha and beta
diversity were determined. Linear Discriminant Analysis Effect Size (LEfSe)
was used to identify differentially expressed bacterial DNA in different groups.
Results: We enrolled 16 subjects with confirmed HP-gastritis and 14 HP-negative
subjects. Baseline salivary samples of all subjects were found to have significantly
higher microbial diversity than corresponding gastric samples. The predominant
microbial family identified in the stomach is Helicobacteraceae (55.2%) whereas
Helicobacteracece constitutes only 0.1% of salivary microbiota. In contrast, the
predominant families in saliva microbiota are Prevotellaceae (23.9%) and
Neisseriaceae (20.3%). When compared to HP-negative subjects, salivary micro-
biota in HP-positive patients showed a significant increase in the Bacteroidetes
and Spirochaetaceae, and a decrease in Flavobacteriaeceae families. HP eradica-
tion therapy resulted in a significant reduction in the relative abundance of
families Bacteriodetes and Spirochaetaceae, and an increase in Flavobacteriaceae.
Conclusion: There was a significant difference in the microbial diversity and
compositions between gastric and salivary microbiota in HP-infected subjects,
with Helicobacteracece dominating the gastric microbiota. HP-infected subjects
have distinctive microbiota in the saliva which is reversed by HP eradication
therapy. The significance of these microbial alterations in the saliva of HP-
infected subjects and its correlation with gastric diseases deserves further
investigation.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Seroconversion of Helicobacter pylori occurs more often in serone-
gative adults living with a H. pylori-infected family member or in those with a
history of upper gastrointestinal endoscopy. Nonetheless, there are controversies
on alcohol drinking and seroconversion; a positive correlation was found in
Korea, but an inverse correlation was found in Japan.
Aims & Methods: In this study, we tried to elucidate the risk factors for serocon-
version including alcohol drinking. Korean adults who showed negative finding
on the serum anti-H. pylori IgG assay were analyzed. Subjects were included if
they underwent serum anti-H. pylori IgG assay, serum pepsinogen assay, and
upper gastrointestinal endoscopy annually at our center. Subjects were excluded
if they had a history of H. pylori eradication or gastrectomy.
Results: Of the 267 included subjects, 26 (9.7%) showed seropositive findings at
the mean follow-up of 39.0 19.1 months. Subjects with seroconversion showed
a higher body mass index (p¼ 0.033), heavier alcohol drinking (p¼ 0.001), more
intake of nonsteroidal anti-inflammatory drug (p¼ 0.015), and longer follow-up
period (p¼ 0.038). On multivariate analysis, heavy alcohol drinking [odds ratio
(OR)¼ 6.867, 95% confidence interval (CI)¼ 2.089–22.577, p¼ 0.002)] and
social drinking (OR¼ 5.026, 95% CI¼ 1.410–17.913, p¼ 0.013) were indepen-
dent risk factors for seroconversion.
Conclusion: In Korean adults, the amount of alcohol drinking positively corre-
lates with seroconversion in H. pylori-seronegative subjects. Although serocon-
version does not indicate an activeH. pylori infection, our study findings suggests
that drinking is a significant risk factor for new H. pylori infection in Korean
adults.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Autoimmune gastritis (AIG) results in hypo/achlorhydria due to
parietal cells destruction1. It is characterized by lower levels of serum pespinogen
(Pg) I and PgI/PgII ratio and increased levels of gastrin2. Some Authors support
an association between AIG and Helicobacter pylori (HP) infection3.
Aims &Methods: The aim of our study was to assess epidemiologic, serologic and
pathologic features of AIG patients with and without previous HP infection.
Two hundred and eleven consecutive patients with AIG, undergoing endoscopy
were included. Serum gastrin, PgI, PgII and Cromogranin A levels were deter-
mined in all patients. Multiple gastric biopsies were obtained for histology,
OLGA staging and HP detection. Previous or current HP infection (HPþ) was
confirmed in patients by anamnestic and/or pathologic and/or serologic data.
Statistics was performed using non parametric tests.
Results: Present or previous HP infection was confirmed in 50/211 patients while
161 were negative (HP-). When we compared HPþ vs HP- AIG, no differences
were found for age and gender distribution, antral and fundic/body atrophy,
OLGA staging, PgI, PgII, PgI/PgII ratio and Cromogranin A levels. Gastrin
levels and Gastrin/PgI ratio, a global marker of gastric damage we previously
identified, were higher in HP- vs HPþ (p5 0.02). Interestingly, 15% HP- pre-
sented antrum atrophy. Severity of ECL hyperplasia was higher in HP- (p¼ 0.02)
with a 3.5 RR of developing nodular or carcinoid lesions when compared with
HPþ. Serum PgI, PgII PgI/PgII and gastrin levels correlated with disease severity
in HP- (p5 0.01) but not in HPþ.
Conclusion: HPþ AIG have/have had a mild infection without differences in
OLGA staging when compared with HP-. HPþ are characterized by lower gas-
trin and gastrin/PGI levels that, considered the lack of differences in OLGA
staging, seem to suggest an impairment of gastrin release and could have a
selective G Cell damage leading to lower levels of gastrin and Gastrin/PgI
ratio. Consequently, they have lower degrees of ECL hyperplasia and a lower
risk of developing carcinoids when compared with HP-. The presence of antrum
atrophy in HP- could be explained with the supposed autoimmune antrum-
damage hypothesis in AIG4–5. In conclusion, HPþ and HP- AIG have some
differences in serological phenotype and HP infection may correlate in AIG
with lower ECL hyperplasia and lower risk of neuroendocrine tumor.
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Introduction: This study was conducted to determine the differential expression
patterns of microRNAs, non-coding RNAs that control gene expression mainly
through translational repression, in gastric mucosa of Helicobacter pylori
(H.pylori) positive patients. Several miRNA have been associated with promot-
ing the inflammatory response initiated by the H. pylori infection, increasing the
malignant progression of the gastric epithelium, and enhancing the invasiveness
and migratory capacity of cancer cells.Using serum specimens, expression pat-
terns of hsa-miR-155, hsa-miR-21, hsa-miR-146-a and hsa-mir-223 were deter-
mined by Real-Time Polymerase Chain Reaction (Real-Time PCR).
Aims & Methods: Patients who underwent upper gastrointestinal endoscopy, in
Mersin University Faculty of Medicine, Department of Gastroenterology and
diagnosed H.pylori positive and negative were recruited. H. pylori status was
assessed by the rapid urease test. Serum specimens of patients, were taken for
miRNA isolation. hsa-miR-155, hsa-miR-21, hsa-miR-146-a and hsa-mir-223
expression levels were determined using comparative 2CT analysis by using
Real-Time PCR Systems, SDS 2.0.3 software programme. Statistical analysis
of miRNAs between H.pylori positive and negative groups were compared
with the Mann–Whitney U test. p5 0.05 was considered statistically significant.
The relationship between categorical variables were tested using Pearson’s
chi-square test.
Table 1
H.pylori positive N¼ 46 H.pylori negative N¼ 49
Average Median Average Median p value
hsa_miR_155 0,990199 2,006536 0,393990 0,749915 1,276566 0,295334 0,48
hsa_miR_223 6,929772 19,222485 2,031475 7,064999 18,103347 2,108900 0,97
hsa_miR_146a 4,730933 8,343877 2,138397 9,332742 28,023032 1,447617 0,28
hsa_miR_21 4,412535 5,519648 2,030767 4,669136 8,019229 1,858662 0,85
Results: H.pylori positive (n¼ 46) and negative (n¼ 49) were included. H.pylori
was not able to effective the hsa-miR-155, hsa-miR-21, hsa-miR-146-a and hsa-
miR-223 expressions in serum specimens and nuclear factor–kB (NF-kB) and
Transforming growth factor, beta (TGFB) pathways. There was no statistically
difference between H. pylori positive and negative individuals in the analysis of
hsa-miR-155, hsa-miR-21, hsa-miR-146-a and hsa-miR-223 miRNA expressions
levels (Table 1). In surveys, there is no statistically difference between in each
groups, the level of education, intake of smoking-alcohol, hypertension, diabetes,
cardiovascular disease, family history of gastroduodenal disease, type of gastro-
duodenal disease.
Conclusion: This study may contribute to the literature in terms of preventing
pro-cancerous progression in the cases of cancer resulting from H. pylori infec-
tion before the onset of the cancer process.
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CAGA(þ) AND CAGA() STRAINS OF HELICOBACTER PYLORI
N.V. Baryshnikova
1, Y.P. Uspenskiy2, A. Suvorov1
1Science Research Institute, St-Petersburg/Russian Federation
2First Pavlov Saint-Petersburg State University, St-Petersburg/Russian Federation
Contact E-mail Address: baryshnikova_nv@mail.ru
Introduction: Qhange of interleukin level can be in patients with of chronic infec-
tions, in particular at Helicobacter pylori invasion. Change of interleukin level in
H. pylori-infected patients is intensively studied. For example, increase in level of
interleukin-8 according to a number of works is accompanied by infection with
virulent strains of a microorganism. CagA gene coding synthesis of the cytotoxin
(CagA) of the same name capable, in addition, to exert impact on development of
interleukin, in particular interleukin-8 is considered a marker of presence of
pathogenecity island of H. pylori.
Aims & Methods: The aim was to define features of change of level of interleukin-
1b and interleukin-8 (pro-inflammatory) and interleukin-4 (anti-inflammatory)
at patients with the chronic gastritis associated withH. pylori infection depending
on existence or lack of a gene of cagA in a microorganism genome. 40 patients
with the chronic gastritis associated with H. pylori have been examined.
Endoscopy was made for all patient for specification of a condition of stomach
mucosa and taking biopsy from stomach antrum (2 bioptates) for the purpose of
verification of H. pylori infection. Detection of a microorganism was made by
rapid urease test, a histologic method and molecular-genetic research–the poly-
merase chain reaction (PCR) with definition of genes of urease (ureC, ureI).
Besides, the PSR method presence of a cagA gene in a genome of H. pylori
was detected. All patients were divided on two groups: with cagA (þ) strains
and with cagA () strains. Levels of interleukins 1-b,-4,-8 decided by immunefer-
mental analysis (the Vektor-Best sets, Russia).
Results: cagA gene was detected in 30 patients (cagA(þ) group) and absence in 10
patients (cagA() group). In cagA(þ) patients mean level of interleukin-1-b was
395.6 pg/ml, but in cagA() patients–311.2 pg/ml (p5 0.05). Level of interleu-
kin-8 in cagA(þ) patients was 2.4 pg/ml but in cagA() patients–0.32 pg/ml
(p5 0.05).Level of interleukin-4 r cagA(þ) patients was 21.6 pg/ml, but in
cagA() patients–83.4 pg/ml (p5 0.05).
Conclusion: presence in a genome of H. pylori cagA gene is accompanied by
reliable increase in level of pro-inflammatory interleukins (1-b, 8) and decrease
in level anti-inflammatory interleukin-4 that can be an additional factor of devel-
opment of an inflammation during H. pylori invasion.
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Introduction: The incidence and mortality rate of gastric cancer are high in Japan.
The International Agency for Research of Cancer (IARC) reported that 80% of
gastric cancer is caused by Helicobacter pylori (H. pylori) infection and that the
incidence of gastric cancer can be reduced by 30%-40% through H. pylori era-
dication. H. pylori eradication therapy for chronic gastritis was approved for
national health insurance in February 2013 in Japan. However, the success
rate of H. pylori eradication by conventional primary triple therapy has been
decreased by resistance to clarithromycin. Vonoprazan, which is a potassium ion-
competitive acid blocker (P-CAB), became available in Japan in February 2015,
before its release on the world market. There have been some reports on the
usefulness of vonoprazan for H. pylori eradication.
Aims & Methods: The aim of this study was to investigate the transition of
H. pylori eradication therapy including therapy with vonoprazan in our
institution.This study was a retrospective single center study between January
2010 and December 2016. The subjects were patients who had received H. pylori
eradiation therapy. The subjects were divided into a conventional triple therapy
group (PPI: omeprazole lansoprazole, esomeprazole, and rabeprazole) and a
group who received triple therapy with vonoprazan instead of a PPI.
Regimens with amoxicillin, clarithromycin and a PPI or vonoprazan were
regarded as 1st line treatment, and a regimen with metronidazole instead of
clarithromycin was regarded as 2nd line treatment. Success rates of 1st line treat-
ment and 2nd line treatment with a PPI or vonoprazan were compared.
Results: There were 1278 patients who underwent H.pylori eradication therapy.
The mean age of the patients was 61.5 years (13–92), and the patients included
722 males and 556 females. The patients who received H.pylori eradication ther-
apy included 857 patients with chronic gastritis, 300 patients with stomach/
duodenal ulcers, 82 patients with gastric cancer, 27 patients with polyps, and
12 other patients. The number of patients with chronic gastritis undergoing
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eradication therapy of H. pylori increased remarkably from 48.4% in 2012 to
73.8% in 2016. The total success rate was 76.5%. The success rate of the con-
ventional PPI regimen was 75.8% (846/1116), and that of the vonoprazan regi-
men was 85.1% (74/87). The success rate of vonoprazan regimen was
significantly higher than that of the PPI regimen (Fisher’s exact test: p5 0.05).
The success rate of H.pylori eradication in 2nd line treatment was 84.7% (210/
248). The success rate of H.pylori eradication in patients who received the con-
ventional PPI regimen was 84.4% (35/224), and that in patients who received the
vonoprazan regimen was 87.5% (21/24).
Conclusion: Vonoprazan is considered to be useful for H.pylori eradication
instead of a PPI in first line treatment.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Clarithromycin (CLA)-containing quadruple therapy, i.e. concomi-
tant therapy (CT), and bismuth-containing quadruple therapy (BQT) have been
suggested as first line therapies for eradication of H. pylori infection. Both treat-
ments are reported to have an eradication rate higher than 90%. International
guidelines recommend that chosing one regimen vs the other should be based on
the regional prevalence of antimicrobial resistance, knowledge of patient’s pre-
vious antimicrobial exposure or allergy to amoxicillin, and patient’s wish.
However, this therapeutic approach has never been tested systematically.
Aims & Methods: The primary endpoint of this study was to evaluate the eradi-
cation rate in H. pylori-infected subjects naive to treatment in an area of high
(415%) CLA resistance using CT or BQT, based on knowledge of patient’s
previous antimicrobial exposure or allergy to amoxicillin, and patient’s wish.
Secondary endpoint was to assess any difference between CT and BQT in
terms of efficacy, safety and compliance. Because in Italy bismuth compounds
are not available, BQT was by using the new three-in-one pill (TiOP) (metroni-
dazole 125mgþ tetracycline 125mgþ bismuth 140mg). Patients and Methods: 1)
Observational study on 144 consecutive dyspeptic patients (57 M and 87 F,
median age 51 yrs); 2) Diagnosis of H pylori infection was through 13C Urea
Breath Test (UBT), or rapid urease test and histology in patients who performed
endoscopy; 3) Groups of treatment: a) 84 CT (36 M and 48 F, median age 52 yrs)
and 60 BQT(21 M and 39 F, median age 50 yrs) patients; 4) Regimens: a) CT:
esomeprazole 40mg bidþ amoxicillin 1 g bidþ clarithromycin 500mg
bidþ tinidazole 500mg bid; b) BQT: esomeprazole 40mg bidþTiOP 3 tablets
qid. Both for 10 days; 5) Evaluation of eradication was performed at least 45
days after the end of therapy by UBT; 6) Compliance to and side effects of both
regimens were assessed by a questionnaire at the end of therapy; 6) Statistics: ITT
and PP analyses; significance of differences by chi square test (p5 0.05).
Results: 1) Eleven/144 patients (7.6%, 95%CI 4.3–13.5) [6/84 (7.1%, 95%CI 3.3–
15.4) in the CT group and 5/60 (8.3%, 95%CI 3.6–19.3) in the BQT group]
discontinued therapy because of severe side effects (p: ns); 2) Overall eradication
rate was 122/133 (91.7%, 95%CI 87.2–96.5) in the PP analysis and 122/144
(84.7%, 95%CI 79–90.1) in the ITT analysis; 3) PP eradication rate was 69/78
(88.5%, 95%CI 81.6–95.8) in the CT group and 53/55 (96.4%, 95%CI 91.6–
101.4) in the BQT group (p¼ns); 3) ITT eradication rate was 69/84 (82.1%,
95%CI 74.3–90.8) in the CT group and 53/60 (88.3%, 95%CI 80.6–96.8) in
the BQT group (p¼ ns); 4) Among patients who completed therapy, no signifi-
cant differences between the two groups were found as to the incidence of side
effects (29.4% in the CT group and 35.8% in the BQT group) or compliance to
treatment.
Conclusion: 1) In an area of high CLA resistance, use of CT or BQT as first-line
therapy, based on patient’s previous antimicrobial exposure, allergy to amoxicil-
lin and wish, is a highly effective strategy with an eradication rate4 90%; 2)
BQT was more effective but with more side effects compared to CT, however
differences were not statistically significant.
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Introduction: Potent acid inhibition with acid inhibitory drugs is crucial to the
success of eradication for Helicobacter pylori infection. Vonoprazan competi-
tively inhibits the binding of potassium ion to Hþ/Kþ-ATPase in gastric parietal
cells and inhibits Hþ/Kþ-ATPase activity at 400-fold more potent than that of
lansoprazole, proton pump inhibitor (PPI). Therefore, the eradication regimen
contained vonoprazan has advantage for increasing the eradication rate com-
pared with a PPI-based therapy. Although vonoprazan is mainly metabolized by
CYP3A4/5, it is unclear whether its acid inhibitory effect and outcome of
H. pylori eradication differ among CYP3A4/5 genotypes. Our aim was to clarify
the influence of CYP3A4/5 genotypes on outcome of H. pylori eradication
including vonoprazan in Japanese.
Aims & Methods: We investigated the influence of CYP3A4/5 and CYP2C19
genotypes and susceptibility to antimicrobial agents for outcome of vonopra-
zan-contained eradication regimen for 7 days in 105 Japanese: (1) with amox-
icillin 750mg and clarithromycin 20mg twice daily (bid) as the first-line
treatment (n¼ 76); (2) with amoxicillin 750mg and metronidazole 250mg bid
as the second-line (n¼ 29). Eradication status was assessed at eight weeks via a
13C-urea breath test. CYP3A4*22, CYP3A5*3 and CYP2C19*2/*3 were geno-
typed for all patients.
Results: Eradication rate on intention-to-treat analysis was 82.9% (95% confi-
dence interval: 72.5%-90.6%, 63/76) in the first-line treatment and 93.1%
(77.2%-99.1%, 27/29) in the second-line. None with CYP3A4*22 was observed.
38.3% of patients (46/120) were CYP3A5 *1/*3 type and 55.0% were *3/*3 type.
In naive patients, the prevalence of clarithromycin-resistant strain was 42.4%
(14/33). Eradication rate in patients with CYP3A5 *1 carrier type (CYP3A5
*1/*1 and *1/*3 types) was 72.7% (54.5%-86.7%, 24/33), which was significantly
lower than that in the *3/*3-type (90.7%, 77.9%-97.4%, 39/43, p¼ 0.039) in the
first-line treatment. However, no significant differences of clinical outcome in the
second-line therapy were seen among CYP3A4/5 genotypes.
Conclusion: Eradication rates of vonoprazan-based eradication therapy can be
achieved high compared with PPI-based therapy. However, because CYP3A5*3
genotype may be one of determinate for outcome of eradication regimen includ-
ing vonoprazan, genotyping of CYP3A5*3 will be required to be paid attention
for clinical outcome before treatment.
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Introduction: Proton pump inhibitor (PPI) based therapy is one of most popular
H.pylori eradication in the world. On the other hand, eradication rates have been
decreasing because of resistance to the clarithromycin (CAM). It is known that
most antibiotics are not effective under strong acid secretion. So in order to
improve the eradication rate, gastric acid must be reduced more rapidly and
strongly. Vonoprazan(VPZ) is a new potassium competitive acid blocker and
the usefulness is expected in Japan.
Aims & Methods: Our aim was to investigate the efficacy of the VPZ-based
eradication therapy. The subjects were 999 patients who were diagnosed as
H.pylori infection in our institution from June 2014 to December 2016. The
patients were grouped into three: VPZ group and conventional PPI
(Lamsoprazole or Rabeprazole) group. We evaluated the first-, the second-line
eradication rate and statistical analysis. Each regimen of VPZ group was first-line
eradication (VPZ 20mg bidþ amoxicillin 750mg bidþ CAM 200mg bid for 7
days), second-line eradication (VPZ 20mg bidþ amoxicillin (AMPC) 750mg
bidþ Metronidazole 250mg bid for 7 days). Each regimen of PPI group was
first-line eradication (PPI bidþ AMPC 750mg bidþ CAM 200mg bid for 7
days), second-line eradication (PPI bidþ amoxicillin 750mg bidþ
Metronidazole 250mg bid for 7 days). One of the following PPI was used:
Lamsoprazole (LPZ) 30mg, Rabeprazole (RPZ) 20mg. After several months,
eradication status was examined by urea breath test, stool antigen testing and
blood antibody test.
Results: The number of first-line regimen of VPZ patients was 109, and the
eradication was achieved in 97 patients (87%). RPZ patients were 308, and the
eradication was achieved in 228 patients (74%), and LPZ patients were 377, and
the eradication was achieved in 300 patients (80%) respectively. The eradication
rate of VPZ was statistically higher than RPZ and LPZ (P¼ 0.0006, and¼ 0.019
respectively). The number of second-line regimen of VPZ patients was 24, and the
eradication was achieved in 19 patients (79%). RPZ patients were 68, and
the eradication was achieved in 60 patients (88.2%), and LPZ patients were
68, and the eradication was achieved in 60 patients (88.2%) respectively. There
were statically no significant differences in second-line regimens. Adverse events
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such as eruption and diarrhea were reported in 6.6%(9/136) of patients in VPZ,
in 15.5%(58/375) in RPZ and in 6.1%(28/456) in LPZ.
Conclusion: The first-line regimen with VPZ was superior to conventional PPI
regimen, and was a result not to be inferior in the safety either.
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Introduction: Eradication of H. pylori infection cures peptic ulcer disease (PUD);
however, current treatment strategies are far from ideal and many patients
require repeated courses of treatment. We, and others, have recently documented
that currently, within the UK, less than 30% of patients with with proven PUD,
are subsequently documented to have been cured by H. pylori eradication (1).
Currently there is no consensus regarding 2nd line treatments, but the British
National Formulary recommends a two regimen containing bismuth subcitrate,
omeprazole, tetracycline and metronidazole. However since 2016, bismuth sub-
citrate has not been available in the UK, but is thought to be an important in
treating persistent H. pylori infection(2).
Aims & Methods: The aim of this observational cohort study was to evaluate the
effectiveness of a 2 week bismuth based quadruple therapy in patients who had
persistent infection following previous failed eradication therapy. Patients were
identified from electronic hospital records using endoscopy data set, patient
administration records, and pathology data sets from Jan 2011 to Dec 2016.
Initial failed H.pylori eradication was defined by either by a positive 13C-Urea
Breat Test (13C-UBT) or positive HpStool Antigen test (HpSA) following H.
pylori treatment in either primary or secondary care. All patients were seen,
assessed and warned about the importance of compliance with treatment and
of possible side effects by the specialist (RL) or the dyspepsia nurse specialist
(LB). After treatment with omeprazole 20mg bd, tetracycline 500mg qds, metro-
nidazole 400mg qds and bismuth subcitrate qds for two weeks, eradication was
assessed at least 4 weeks after finishing treatment by 13C-UBT (or HpSA in those
patients unable to attend hospital appointment). Endoscopy was also performed
in those patients whom had failled mutliple previous treatments to ascertain the
clinical need for further treatment by assessing any underlying ulcer diathesis and
for H. pylori culture and sensitivity testing.
Results: Within the inclusion period, (and from 4560 patient records), 41
patients (22 female), mean age 44 yr, (range 17–84 yr) were identifed as having
persistent H.pylori infection by þve 13C-UBT (n¼ 25), HpSA (n¼ 10) or histol-
ogy/CLOtest (n¼ 6). All had failed at least one treatment, but 14/41 (34%) had
failed 2 or more. Most patients were non or light drinkers (90%) and non-
smokers (74%). OGD was performed in 19 patients to clarify indication for
further attempts at H. pylori eradication and showed evidence of ulcer disease
(ulcer, scarring or erosions) in 13/19 (68%). Culture and antibiotic sensitivity
testing was unsuccessful in 5/5 patients. At least 6 weeks after the end of treat-
ment a repeat 13C-UBT or HpSA was negative in 34/36 (94% (95%CI 82–98%).
5 patients failed to attend for assessment of eradication. During the follow up
period from 2011 onwards, 11 patients underwent repeat 13C-UBT or HpSA
testing, and all remained cured of infection.
Conclusion: Two week standard bismuth based quadruple therapy remains a
highly effective treatment for persistent H. pylori infection in those patients in
whom eradication of infection is mandated by the an underlying ulcer diathesis.
The high eradication rate is likely due to the use of bismuth/high doses of anti-
biotics, but also by specialists ensuring patients complied with their medication.
These data, together with the poor outcomes of H. pylori eradication when
undertaken by general physicians, also highlight the need for H. pylori eradica-
tion to be only undertaken by specialists who have access to alternative sources of
colloidal bismuth subcitrate.
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Introduction: Despite several evidences in literature have demonstrated a role for
probiotics as adjunctive treatment forHelicobacter pylori (H. pylori) eradication,
national and international guidelines as well as meta-analyses suggest that only
co-administration of probiotics may have a beneficial effect on the prevention of
side effects and eradication rates. Herein, we performed a systematic review with
pooled-data analysis aimed to clarify whether probiotics alone may eradicate the
bacterium.
Aims & Methods: Methods of analysis and inclusion criteria were based on
PRISMA recommendations. Relevant publications were identified by a research
in PubMed, MEDLINE, Science Direct and EMBASE. The end-point was to
estimate the mean eradication rate and variations of delta value at urea breath
test across all studies and, overall, with a pooled data analysis. The data have
been expressed ad proportions/percentages, and 95% confidence intervals (CI)
were calculated. For continuous variables, we calculated the weighted mean
difference. Odd ratios (OR) were calculated, where available, based on the
Mantel-Haenszel method. Data were entered into the RevMan 5.3 software.
Results: Ten studies (both randomized clinical trials and open label pilot studies)
were selected. In one study patients with peptic ulcers were selected, while in the
remaining 9 only dyspeptic patients were recruited. Probiotics eradicated H.
pylori in 50 out of 391 cases. The mean weighted eradication rate was 14%,
with a 95% CI of 2–25% (p¼ 0.02). Most of studies investigated a probiotic
formulation based on a single lactobacilli strain. Lactobacilli eradicated the bac-
terium in 30 out of 235 patients, with a mean weighted rate of 16% (95% CI 1–
31%). Multistrain combinations were effective in 14 out of 105 patients, with a
pooled eradication rate of 14% (95% CI 16–43%). In the comparison probio-
tics versus placebo, we found an OR¼ 9.65 in favor of probiotics, with a 95% CI
of 1.97–47.36 (p¼ 0.005). Finally, probiotics induced a mean reduction in delta
values of 8.61% (95% 5.88–11.34, p5 0.00001). No study provided data about
adverse events.
Conclusion: Probiotics alone show a minimal effect on the eradication of H.
pylori, thus suggesting a presumable direct effect. However, they cannot be
indicated as a therapeutic regimen for the low eradication rate.
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Introduction: The new bismuth-containing quadruple therapy is currently advised
due to emergence of H. pylori strains resistant to several antibiotics. Our aims
was to assess the real-life effectiveness and safety of this therapeutic regimen in a
large population of patients who were infected by H. pylori.
Aims & Methods: Consecutive dyspepticH. pylori-positive patients were enrolled,
both naı̈ve for treatment and already unsuccessfully treated. Patients were treated
with Pylera (3-in-1 capsules containing bismuth subcitrate potassium 140mg,
metronidazole 125mg and tetracycline 125mg) 3 capsules four times a day plus
omeprazole 20mg or esomeprazole 40mg two times a day for 10 days.
Eradication was confirmed using a urea-breath test (at least 30 days after the
end of treatment). Efficacy and safety were assessed.
Results: Three hundred and twenty patients were included in the study: 131
(40.9%) patients were naı̈ve, and 189 (59.1%) patients with previous failure
treatment. H. pylori eradication was achieved in 299 (93.4%, 95% confidence
intervals (CIs) 83.1 to 1.0) patients. No difference in eradication rate was found
either between naı̈ve and previously treated patients (95.4% vs 92.1%, P¼ 0.336).
Treatment-emergent adverse events occurred in 61 patients (19.1%, 95% CIs 14.6
to 24.549). They were mild in all cases except in ten, who discontinued the study
due to diarrhea (four patients) and diffuse urticarial rash (6 patients).
Conclusion: This bismuth-containing quadruple therapy achieved a remarkable
eradication rate in real life, irrespective as first treatment or as a salvage therapy,
despite the frequent occurrence of mild adverse events.
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Introduction: According to the Maastricht IV consensus report, Clarithromycin-
containing triple therapy can be considered as a suitable option for first-line
Helicobacter pylori (H. pylori) eradication in areas with less than 20% resistance
rates to Clarithromycin. On the other hand, resistance to Clarithromycin is
increasing in Iran, influencing the efficacy of standard triple therapy in this
country. Therefore, regimens containing other antibiotics have to be considered
in Iran.
Aims & Methods: One hundred and forty patients with peptic ulcer disease and
naı̈ve H. pylori infection were randomly divided into two groups to receive either
10-day standard triple therapy (Pantoprazole 40mg, Amoxicillin 1 gr and
Clarithromycin 500mg, all given twice daily) or 10-day Levofloxacin-containing
triple therapy (Pantoprazole 40mg BD, Amoxicillin 1000mg BD and
Levofloxacin 500mg/daily). Eight weeks after the treatment, H. pylori eradica-
tion was assessed by 14C- urea breath test.
Results: One hundred and thirty three patients completed the study. According to
intention to treat analysis, H. pylori eradication rates were 75.7% (95% confi-
dence interval (CI): 65.7%–85.7%) and 58.5% (95% CI¼ 47.1%–70%) in stan-
dard and Levofloxacin-containing therapies, respectively. Also, per-protocol
eradication rates were 83% (95% CI: 74%–92%) and 61% (95% CI¼ 49%
73%), respectively. The rates of severe adverse effects of therapy were 7.1%
and 2.9% in the mentioned groups, respectively.
Conclusion: Both Clarithromycin-containing triple therapy and Levofloxacin-
containing triple regimen do not seem to be suitable options for first-line H.
pylori eradication in Iran. We suggest using Clarithromycin in quadruple regi-
mens such as hybrid or concomitant therapies and reserve Levofloxacin to be
used in second-line eradication regimens, as it is recommended by Maastricht V
Consensus Report.
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Introduction: Rebamipide is an orally prostaglandin E2 and I2 synthesis inductor.
A latest clinical trial showed that the adhesion of H. pylori to stomach wall was
reduced by rebamipide. This could improve eradication rates by increasing the
availibility of Helicobacter to antimicrobial.
Aims & Methods: We aimed to determine eradication rate, the effectiveness and
advantage of rebamipide in triple eradication therapy of H. pylori infection.
Subjects comprised patients undergoing eradication therapy for H. pylori infec-
tion in our clinics. Patients with a history of eradication therapy, gastrectomy, or
allergy to medications in triple therapy were excluded. Written informed consent
was obtained for each patient. This trial was performed as a randomised open-
labelled clinical study with the permission of an institutional review board. All
patients was tested on H. pylory infection. The number of cases was 160 (80 cases
in each group). Each patient was randomly enrolled for rebamipide therapy
group (RBD) (esomeprazol 40mg, amoxicillin 1000mg, clarithromycin 500mg,
rebamipide 100mg twice a day for 14 days) or standart triple therapy group
(STD) (esomeprazol 40mg, amoxicillin 1000mg, clarithromycin 500mg, twice
a day for 14 days). Before starting therapy, we checked the background char-
acteristics of each patient (age; gender; weight; height; drinking habit; smoking
habit; use of probiotics, bismuth, PPI; and endoscopic findings). After the ther-
apy, we asked physicians and patients about medication compliance and side
effects. The primary endpoint was the eradication rate. The secondary endpoints
were the rates of side effects.
Results: For RBD therapy group and STD therapy group, the eradication rates
were 94.0% (95% confidence interval, 85%-100%) and 82% (95% confidence
interval, 74%-95%) respectively, and the rates of side effects were 8.5% (95%
confidence interval, 7.0%-26.5%) and 29% (95% confidence interval, 17.5%-
41.0%) respectively. For each group, statistically significant difference in eradi-
cation rate was seen. The RBD group revealed trends of high eradication rates
and low rates of side effects.
Conclusion: The findings suggest that rebamipide is effective in eradication of
H. pylori infection, significantly improve eradication rate in triple therapy. The
advantage of rebamipide has efficacy and good tolerability.
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Introduction: Intestinal graft-versus-host disease (GVHD) represents one of the
most serious complications of allogeneic stem cell transplantation (allo-SCT).
Almost 10%-40% of patients who undergo allo-SCT develop significant clinical
acute graft-versus-host disease (GVHD) [1]. Endoscopic and histological proofs
are required because of the number of differential diagnoses manifesting as diar-
rhoea. Previous studies reported that endoscopic features, such atrophied term-
inal ileum [2,3], are useful in diagnosing acute GVHD. However, these previous
studies did not address details of the random sequence, and were performed in a
single centre.
Aims & Methods: The present study investigated the incidence of the character-
istic finding, particularly microvilli atrophy of the terminal ileum, of colono-
scopy, and inter-observer agreement of the finding among experienced
endoscopists in multiple centres. Consecutive patients who underwent allo-
HSCT were referred to the Okayama University Graduate School of Medicine
between May 2008 and September 2015. Fifty-four patients underwent colono-
scopy after allo-SCT as intestinal acute GVHD was suspected. We recorded the
colonoscopic imaging. Subsequently, they were checked by three observers, from
different institutions, to determine whether microvilli atrophy in the terminal
ileum is present. Demographic information, disease, symptoms, and histological
finding were obtained from the patients’ medical records retrospectively. All
study participants provided informed consent. The local ethics review committee
granted ethical approval (approval 1610-013), and was registered in the
University Hospital Medical Network Clinical Trials Registry (UMIN-CTR)
as number UMIN 000025390.
Results: Definitive pathological and non-pathological GVHD were found in 22
patients and 32 patients, respectively. In the analysis of all 54 lesions, for three
observer (A, B, and C), sensitivity of the microvilli atrophy in the terminal ileum
was 86.4%, 77.3%, and 79.2%, whereas specificity of the appearance were
62.5%, 62.5%, and 86.2%. In addition, the positive predictive value of the
appearance was 61.3%, 58.6%, and 82.6%, and negative predictive value
(NPV) was 87.2%, 87.2%, and 83.9%, respectively. The kappa coefficient of
the inter-rater reliability was 0.85, 0.63, and 0.63 in observers AB, AC, and BC.
Conclusion: Conclusions: Microvilli atrophy in the terminal ileum is an effective
colonoscopy finding for real-time predictive histological diagnosis of acute intest-
inal GVHD. We achieved substantial inter-observer agreement for the analysis of
microvilli atrophy in the terminal ileum and excellent agreement for predictive
histological diagnosis.
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Introduction: Chemotherapy-induced mucositis is a common complication during
anticancer treatment. Epigallocatechin-3-gallate (EGCG), derived from green
tea, has been shown to have antioxidant effects and immunomodulatory activ-
ities. However, studies on EGCG for chemotherapy-induced mucositis have been
scarce.
Aims & Methods: In this study, we aimed to prove the protective effect of EGCG
in murine chemotherapy-induced mucositis model.Twenty-four 8-wk-old male
C57BL/6 mice were randomized to 4 groups: control, EGCG, 5-Flurouracil
(5-FU), EGCG plus 5-FU. Mucositis was induced by intraperitoneal injection
of 5-FU (400mg/kg). EGCG (50mg/kg) was administered orally for 5 days from
the day before administration of 5-FU. After 6 days of 5-FU injection, the mice
were sacrificed and intestinal tissue was obtained. WBC count was performed
with whole blood from Inferior vena cava of mice. The end points were villus
height, villus/crypt ratio, histologic characteristics, and mRNA expression of
tumor necrosis factor (TNF)-, and interleukin (IL)-6.
Results: In 5-FU group, neutropenia was confirmed by laboratory test (5-FU,
0.650 K/mL; Control, 5.317 K/mL), indicating sufficient 5-FU effect. Histologic
findings showed that crypt dilatation, villus stunting, and villus atrophy were
reduced in EGCG plus 5-FU group than in 5-FU group (Figure 1).
Quantitatively, mean villus height (EGCG plus 5-FU, 352 mm; 5-FU, 319 mm)
and villus/crypt ratio (EGCG plus 5-FU, 3.28; 5-FU, 2.31) in EGCG plus 5-FU
group, compared with 5-FU treated group, were significantly higher. mRNA
expression of TNF- was significantly lower in EGCG plus 5-FU group com-
pared with 5-FU group (P5 0.05)(Figure 2). Figure 1. Effects of EGCG admin-
istration on chemotherapy-induced mucositis in mice jejunum (A) control (B)
5-Fluorouracil (5-FU) group with significant villus atrophy and crypt dilatation
(c) EGCG group (d) EGCG plus 5-FU group with mild villi destruction and less
crypt dilatation Figure 2. mRNA expression of TNF-. 5-FU plus EGCG group
showed significantly lower 2^ddCT than 5-FU only group. (*,** P5 0.05)
Conclusion: EGCG derived from green tea reduced 5-FU induced intestinal
mucositis, suggesting a possibility for novel treatment of chemotherapy-induced
mucositis.
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Introduction: Proton pump inhibitors (PPIs) have become one of the most com-
monly prescribed medicine due to their strong effects of suppressing gastric acid
and high curative effects for acid related diseases. On the other hand, their side
effects have been attracting more attention. One of them is the increased inci-
dence of infectious intestinal diseases. Those are mostly reported by clinical
publications, and the exact mechanism has not been clarified. To investigate
whether PPIs can increase the susceptibility to peroral enteropathogenic bacterial
infection, we used Citrobacter rodentium (C. rodentium), a well-known attaching/
effacing-associated pathogen, which is used for the model of human enterohe-
morrhagic Escherichia coli (EHEC) and enteropathogenic Escherichia coli
(EPEC) infection: the major causes of food poisoning.
Aims & Methods: To investigate whether LAZ can influence the steady-state
intestinal environment, C57BL/6 J mice were divided into two groups, and
8mg/kg/day of lansoprazole (LAZ group) or saline (control group) were admini-
strated intraperitoneally for two weeks. The ileal contents and feces were col-
lected before and after LAZ administration. Genomic DNA of the gut microflora
was analyzed by 16S ribosomal RNA (16SrRNA) gene sequencing, and the
metabolites were analyzed by a CE-TOFMS platform. To examine the changes
of immune cell distribution by LAZ, hematopoietic cells in the lamina propria
were analyzed by flow cytometry. The changes of gene expressions of the ileum
were comprehensively analyzed by microarray. Finally, mice were orally inocu-
lated with C. rodentium after LAZ administration, and the establishment of
enteritis was evaluated by body weight loss, histology and inflammatory cytokine
expressions examined by real-time PCR.
Results: At steady-state, no prominent change of metabolites and gut microflora
were observed in the feces of LAZ group. On the other hand, the concentrations
of short chain fatty acids, such as butyrate and propionate, were decreased in the
ileum of LAZ group. The result of 16SrRNA analysis also showed that the
composition of ileal microflora were different between LAZ and control group.
However, it did not show the change of immune cell distribution in the intestine.
The gene expression levels in the ileum were not altered either. Interestingly, the
ileal microflora of LAZ group became similar to that of the feces. As mice have a
habit of coprophagia, it was assumed that perorally invaded bacteria could sur-
vive and pass through the stomach due to suppression of gastric acid by LAZ.
Accordingly, in the LAZ group, infectious inflammation was established by less
numbers of C. rodentium inoculation, indicating that PPIs could raise the sus-
ceptibility to peroral enteropathogenic bacterial infection.
Conclusion: Our data showed that administration of PPIs could alter the intest-
inal environment such as microflora and luminal metabolites. However, neither
the gene expressions nor distribution of immune cells in the intestinal tissue were
affected. It was assumed that the increased risk of peroral enteropathogenic
bacterial infection was not because of the immunological modification by PPIs,
but it was mainly because of the increased number of pathogenic bacteria passing
through the stomach.
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Introduction: Because recent studies have demonstrated that amino acid trans-
porters, which transport amino acids into cells, are correlated to various cancers
and are major transporters that supply essential amino acids to tumor cells, these
transporters are considered as novel biological tumor markers. On the other
hand, because anticancer agents are frequently used clinically, the number of
patients suffering from anticancer agent-induced intestinal mucosal injuries is
increasing; hence, it is important to take appropriate measures for reducing
these side effects. Because the L-type amino acid transporter (LAT) transports
a wide range of nonselective amino acids, including essential amino acids, it is
considered to be a gastrointestinal transporter that is important for nutrient
absorption. Furthermore, the involvement of other amino acid transporters in
inflammation has been reported in several studies.
Aims & Methods: We aimed to clarify the pathophysiological role of an amino
acid transporter in gastrointestinal tract inflammation caused by an antitumor
agent in this study. The antitumor agent fluorouracil (5-FU) was orally adminis-
tered to mice. The severity of mucositis was assessed based on the length, villus
height, mucus production, cell infiltration, and immune response of the intestinal
tract. We measured the mRNA expressions of LATs in the tissues of the small
intestines. In addition, we compared the protein expressions among the small
intestines using anti-LAT antibodies.
Results: After the administration of 5-FU, the body weight, food intake, water
consumption, and fecal volume decreased; thus, a systemic influence was
observed. The length and villus height of the intestinal tract decreased because
of the administration of 5-FU, and mucosal damage with histological change was
observed. The number of PAS-positive cells decreased in the small intestinal
mucosa, and it was assumed that the defensive function of the epithelial cells
had decreased. In addition, an increase in the mRNA expression of IL-1b, IL-6,
and TNF- in the Peyer’s patch along with an increase in the cell infiltration after
the administration of 5-FU significantly enhanced the immune response asso-
ciated with the inflammatory cytokine production. Furthermore, on investigating
the mRNA and protein expressions of LAT1 and LAT2 in the tissues of the small
intestines, we observed that LAT1 expression significantly increased and LAT2
expression decreased after the administration of 5-FU.
Conclusion: It was considered that the uptake capacity of amino acids, such as
Gly, Ala, Ser, Thr, Cys, Asn, and Gln, that transported through LAT may be
decreased in case of small intestinal mucosal injuries. On the other hand, LAT1
expression associated with the production of inflammatory cytokines suggested
that LAT1 is a gastrointestinal inflammatory marker.
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Introduction: Acetyl salicylic acid (ASA) has been used for the secondary preven-
tion of cardiovascular diseases. Especially, the enteric coatedASA is widely used
to prevent ASA-induced gastric mucosal injury. Recent technology such as video
capsule endoscopy and balloon endoscopy enabled us to look inside the small
intestine in more detail. Consequently, not a few cases of ASA-induced small
intestinal mucosal injury have been reported. However, the effective prophylaxis
and treatment is not clear yet. Previously, we reported direct detrimental effect of
ASA on small intestinal epithelial cells using an in vitromodel [1]. However, there
are the thick mucus layer between intestinal lumen and epithelial cells. The
mucous has been reported to prevent foreign objects such as bacteria, medicine
and food from epithelial cells.
Aims & Methods: This study was conducted to clarify the role of mucus on ASA-
induced small intestinal mucosal injury using a rat model. Male Sprague-Dawley
rats, 9 weeks old was used. These rats were divided into four groups; group 1:
sham (carboxy methyl cellulose: CMC alone), group2: polysorbate-80 (P80)
alone, group 3: ASA alone, and group 4: P80 plus ASA. CMC and/or
50–200mg/kg ASA was injected into the proximal duodenum of fed rats. P80,
an emulsifier, which has been reported to reduce mucous thickness [2], was
administered via drinking water for 2 weeks before ASA treatment. Indeed,
P80 also reduced the thickness of mucous layer in our analyses. One hour after
ASA treatment, 1% Evans blue was injected into a vein of rats to visualize small
intestinal lesions. Ninety minutes after ASA treatment, the entire small intestine
was removed for histological assessment. To further investigate the importance
of mucus, rebamipide (Reb, 300mg/kg) or saline were orally administered for one
week prior to P80 and ASA treatment. Reb is a gastric muco-protective drug
widely used for the treatment of gastric ulcer, and increases mucous secretion by
small intestinal goblet cell.
Results: Evans blue method suggested that high-dose ASA (200mg/kg) induced
severe jejunal mucosal lesions, which was further confirmed by the histological
examination. Although lower doses of ASA (50 and 100mg/kg) did not cause
mucosal damage, P80 significantly induced Evans blue exudate and severe muco-
sal lesions in jejunum at these concentrations, suggesting the pivotal role of
mucus in these phenomena. Moreover, orally administered Reb significantly
suppressed reducing small intestinal mucus and the exacerbation of ASA-induced
mucosal lesions by P80, indicating that mucus is inevitable in the protection of
ASA-induced small intestinal mucosal injury.
Conclusion: A mucous secretion increasing therapy might be a useful for the
prevention of ASA-induced small intestinal mucosal injury.
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Introduction: Food allergy is characterised by a T helper type-2 immune response
against a food antigen, manifesting as symptoms including nausea, diarrhoea,
vomiting or anaphylactic events. It is estimated that 10% of the Australian
population have a food allergy, and common allergens include cow’s milk, shell-
fish and peanuts. Epidemiological studies have identified antibiotics as a signifi-
cant risk factor for food allergy in infants.
Aims & Methods: We examined how the broad spectrum antibiotic amoxicillin
influenced mucosal immune responses to peanut proteins and the development of
peanut allergy in mice.Balb/C mice were treated daily with 5mg/kg amoxicillin or
PBS for 5 days (days 0–4). On days 5 and 6 animals received 0.2mg peanut
extract or PBS vehicle by oral gavage. Animals were rechallenged with peanut
or vehicle by oral gavage on days 11 and 13 and sacrificed on day 16 and immune
responses to peanut challenge in blood and intestinal tissues were assessed by
protein, mRNA and histological analysis.
Results: The proportion of circulating eosinophils was increased in the blood of
mice treated with both antibiotics and peanut. Histological examination revealed
an increase in small intestinal eosinophils, predominantly at the villous tips,
indicating recruitment to the mucosa. RNA and protein analysis revealed an
increase in IL-5 associated with increased Nod-Like Receptor Protein 3
(NLRP3) inflammasome activation.
Conclusion: These studies demonstrate that antibiotic treatment prior to food
antigen challenge can lead to altered mucosal immune homeostasis, facilitating
IL-5-mediated eosinophil recruitment, characteristic of allergic responses.
Importantly, we have demonstrated an adjuvant-free model of food sensitisation
and small intestinal eosinophilia. These findings contribute to a better under-
standing of how disruption of mucosal homeostasis by antibiotics contributes to
the development of allergic sensitisation and reaction.
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Introduction: Intestinal mucositis is a severe side-effect of chemotherapy with a
current deficiency in effective treatments.
Aims & Methods: This study investigated three prebiotics, galacto-oligosaccaride
(GOS), mannan-oligosaccharide (MOS) and fructo-oligosaccharide (FOS) for
their potential to reduce the severity of 5-Fluorouracil (5-FU)-induced intestinal
mucositis in rats. Female Dark Agouti rats (n¼ 8/group) were orally gavaged
with either 5% FOS, GOS, MOS or water (controls) for 16 days, and received an
intraperitoneal injection of 5-Fluorouracil (5-FU: 150mg/kg) or saline (controls),
on day 13. Rats were housed in metabolic cages for the duration of the study, and
metabolic data was recorded daily. Rats were killed on day 16 and visceral organ
weights and lengths were analyzed post mortem. Crypt depth, villus height
and histological severity scores were quantified in haematoxylin & eosin stained
sections. Sucrase and myeloperoxidase [MPO] activity were quantified by bio-
chemical assay. White and red blood cell types were quantified by whole blood
analysis. Fecal volatile fatty acids (VFAs), acetic, propionic, isobutyic, butyric,
isovaleric and valeric acid were also measured. Statistical analysis was by one-
way ANOVA or Kruskal Wallis and Mann Whitney U test, where p5 0.05 was
considered statistically significant. Data are expressed as mean standard error
of the mean
Results: %Bodyweight loss was significantly decreased in all treatment groups
following 5-FU injection. Total fecal output was increased in rats treated with
GOS or FOS, pre and post 5-FU compared to saline treated controls (p5 0.05).
Ileal villus height was significantly higher in GOS treated rats pre 5-FU
(284.16 11.95 mm) compared to respective water controls (240.40 8.83mm;
p5 0.05). Villus height and crypt depth was significantly decreased in all treat-
ment groups after 5-FU injection (p5 0.05) and prebiotic treatment did not
significantly modify this parameter. Similarly, jejunal and ileal sucrase activity
was decreased in all groups after 5-FU injection (p5 0.05), correlating with
histological measurements. Tissue MPO activity was significantly increased
post 5-FU injection, reflecting increased neutrophil activation, and was
unchanged by prebiotic treatment. Interestingly, MOS and GOS both lowered
%circulating neutrophils pre 5-FU compared to water controls (p5 0.05). Pre 5-
FU treatment with GOS significantly increased the fecal VFAs acetic acid
(16.76 1.22mM/L) and propionic acid (4.60 0.99mM/L) compared to saline
treated controls (7.73 0.92mM/L and 3.05 0.28mM/L respectively;
p5 0.05). MOS and GOS treatment also significantly increased fecal acetic
and propionic acid post 5-FU compared to water control (p5 0.05).
Conclusion: Our study has found that prebiotics, MOS, GOS and FOS modified
some parameters of intestinal health and immune regulation in healthy rats;
however, these prebiotics were not protective against 5-FU induced intestinal
damage. Furthermore, our findings have demonstrated that prebiotic treatment
significantly increases VFA production, suggesting functional changes to the
intestinal microbiome. Further studies are indicated to investigate prebiotics,
both alone and in combination, during the repair phase of intestinal mucositis,
and to determine their effect on gut microbial composition.
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Introduction: Crohn’s disease has been thought to be caused by abnormal
immune responses affecting many parts of digestive tract in which Th1 cells
are particularly dominant. The recruitment of Th1 cells is regulated by interac-
tion of their expression of chemokine receptor CXCR3 and its ligands. There
have been many IBD murine models showing the increase of CXCR3 expression
and its roles on the disease promotion. However, there are limited evidences in
the roles of CXCR3 in human IBD. In fact, a small study in large bowel in a
cohort of 10 Crohn’s disease patients showed lower expression of CXCR3 on T
lymphocytes, compared to colon cancer patients. In terms of inhibition of T-
lymphocyte migration into intestine in IBD patients, anti a4b7 (Vedolizumab)
therapy is currently shown to be effective.
Aims & Methods: Our study aimed to assess expression of CXCR3 by different
subsets of small intestinal lamina propria T-cells and its association with a4 and
b7 integrin in Crohn’s disease (CD) patients. Total of 56 duodenal biopsies were
obtained from CD (n¼ 15), functional dyspepsia (FD)/irritable bowel syndrome
(IBS) (n¼ 24) or iron deficiency patients (n¼ 17) with ethical approval. Lamina
propria (LP) cells were isolated from biopsies using EDTA, collagenase and
gradient density centrifugation with Ficoll. Expression of CXCR3, a4, and b7
on isolated T-lymphocytes was examined by flow cytometry. Statistical signifi-
cance was assessed using T-test or Spearman correlation.
Results: The expression of CXCR3 on CD4 lymphocytes was significantly lower
(35.6%) in CD patients, compared to 61.6% in control group (FD/IBS/iron
deficiency). Although the expression of CXCR3 on CD8 lymphocytes was
higher than CD4 lymphocytes, it was not different between CD and other
group (75.8% in CD patients vs 82.2% in controls). Similar observation was
obtained on the double positive CD4 and CD8 lymphocytes. Interestingly,
only expression of CXCR3 on CD4 lymphocytes positively correlated with
expression of the gut-homing integrins, a4 and b7.
Conclusion: These observations showed significant expression of CXCR3 across
different patients with GI-related disease, with consistently higher expression
seen in CD8þ lymphocytes compared to CD4 lymphocytes. An unexpected
reduction of CXCR3 expression was seen in small intestinal of CD patients,
which associated with gut-homing integrins. This result showed CXCR3 expres-
sion may play a role in migration of CD4 lymphocytes but not CD8 lymphocytes
into duodenum in relation with integrins, a4 and b7. However, CXCR3 expres-
sion on CD4 lymphocytes in CD patients’ small intestine may have protective
role. This propose further study to clarify.
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Introduction: Acute Gastroenteritis (AGE) is one of the diseases that most fre-
quently affects paediatric population. Successful treatment in AGE has been
mainly based on prevention and treatment of its complications; every day, we
find more publications on the use of adjuvants to decrease its duration.
Probiotics have gained greater importance because some of them report benefits.
We look for Clinical Practice Guidelines (CPG) that recommend their use in
AGE in children. The AGREE II instrument was developed to address the
issue of variability in guideline quality, so it is a tool that assesses the methodo-
logical rigour and transparency in which a guideline is developed.
Aims & Methods: To assess the methodological quality of clinical practice guide-
lines (CPG) on the use of probiotics in infant diarrhoea. The search was con-
ducted in December 2016, of CPG based on the evidence, the last 10 years and
unrestricted language, PubMed, ScienceDirect, and Lilacs. In PubMed, the
search terms were: probiotics AND infants; limit: ‘guideline’. In ScienceDirect:
Probiotics AND infants; limit: Medicine and Dentistry and LILACS: ‘probiotics’
AND ‘infants’ and ’probióticos’ AND ‘guı́a’.The CPG selected were evaluated
with the instrument AGREE II by two evaluators who were independent one
from the other and by a third evaluator, when there were discrepancies. The
concordance of the evaluations was measured with the index of kappa.
Results: Ten documents were recovered only in PubMed, and selected only 03
that fulfilled the criteria about probiotics.The other two were located in a direct
way. The 5 CPG were: 1. Diarrhea and vomiting caused by GE - NICE; 2. CPG
on the diagnosis and treatment of the AID in Pediatrics - Peru; 3. ESPGHAN-
ESPID evidence-based guidelines for the management of AGE in children in
Europe. Update (2014); 4. Clinical practice guideline ILA on the management
of GEA in children under 5 years and 5. Use of probiotics for management of
AGE. A position paper by the ESPGHAN Working Group for Probiotics and
Prebiotics. All of the CPG consider that the administration of Lactobacillus
rhamnosusGG and Saccharomyces boulardii should be considered in the manage-
ment of children with AGE as an adjunct to rehydration therapy with different
level of evidence. The concordance between evaluators was 40.9 and 51.0 for
all guidelines. Four CPG had one rating higher than 60% in 4 or more domains
and one in only one domain. Only a CPG was greater than 60% in all domains.
Four had an overall score greater than or equal to 5 and were ’recommended’,
and one with modifications, according to the instrument AGREE II. The CPG 5
is a Position Paper of a Working Group, not a Guideline, and it́s the reason for
the lower rates obtained.
Domain
CPG1
NICE
CPG2
Gonzales
et al
CPG3
Guarino
et al
CPG4
Polanco
et al.
CPG5
Swajeska
et al.
1.Scope and purpose 97.22% 100% 83.33% 88.89% 19.44%
2.Stakeholder
Involment
88.89% 80.56% 77.78% 69.44% 30.56%
3.Rigour and
Development
79.17% 75.00% 73.96% 67.71% 54.16%
4. Clarity of
Presentation
97.22% 100% 80.56% 69.44% 61.11%
5.Applicability 68.75% 58.33% 54.17% 41.67% 27.08%
6.Editorial
Independence
68.75% 75.00% 62.5% 62.50% 58.33%
Rate Overall 7 6 5 5 3
Recommendation Yes Yes Yes Yes Yes with
modifications
Conclusion: Conclusions: The selected CPG have good methodological quality,
but are not specific to probiotics. Despite, they should be spread for better
decision making.
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Introduction: The excessive use of pesticides, often found as residues in our diet
and as contaminants in drinking water, has become a public health problem.
Most of these substances are considered as endocrine disruptors and their daily
exposure is likely to have severe and irreversible consequences. Indeed, prelimin-
ary studies have shown that chronic exposure to low doses of chlorpyrifos (CPF)
causes intestinal imbalance (dysbiosis) in vitro.
Aims & Methods: The objective of this study is to evaluate the preventive poten-
tial of a prebiotic (inulin) in co-exposure with the CPF on the intestinal dysbiosis,
the bacterial translocation and the integrity of the intestinal mucosa. For this we
used an in vitro system: the SHIME (Simulator of the Human Microbial
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Intestinal Ecosystem). The SHIME consists of series of fermenters, mimicking
the human intestinal environment from the stomach to the colon.
The SHIME was exposed to a daily dose of 3.5mg of CPF, combined with 10 g
of inulin for 30 days. The samples were collected at day 0 (baseline, without CPF
or inulin), D15 and D30 to determine the profile and microbial metabolism.
Results: Contrary to the previous results with CPF alone showing dysbiosis,
prebiotic supplementation seems to reestablish CPF-induced imbalance, particu-
larly in the potentially pathogenic microflora (Staphylococcus), which an
increase in short term (D15: p5 0.001), and a recovery at D30. (difference vs
D0: NS). The same happened for the beneficial flora (Bifidobacteria).
Inulin also beneficially influences the fermentation profile, with higher produc-
tion of volatile fatty acids (VFA), especially propionic acid and butyric acid.
Conclusion: The CPF/inulin co-exposure therefore had a positive impact on bac-
terial profile and metabolism, suggesting that prebiotic supplementation could
reduce some intestinal damages caused by an exposure to CPF.
Perspective: In a second step, the Caco-2/TC7 cell line, which mimics a functional
human intestinal epithelium, will be exposed to samples from the colic fermenters
of the SHIME (D0, CPF inulin at D15 and D30) in porder to mesure the
impact on the epithelial barrier.
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Introduction: Lactulose methane and hydrogen breath test(LMHBT) is now
widely used in assessing small bowel bacterial overgrowth(SIBO) and irritable
bowel syndrome(IBS). SIBO and IBS have similar clinical symptoms such as
floating, diarrhea and abdominal pain. Although there is no clear relationship
between IBS and SIBO yet, they are both in relationship with dysbiosis. Diet is
associated with disease closely, especially for gastrointestinal diseases. Different
dietary structures have different effects on the structure, metabolism and func-
tion of intestinal microbiota. Reduce fermentable oligosaccharides, disacchar-
ides, monosaccharides and polyols (FODMAPs) diet can release parts of IBS
symptoms obviously. There were rare reports for the effects of diet on LMHBT,
especially for IBS-D with SIBO patients, nor sufficient researches of the effects of
diet on intestinal microbiota profiles in IBS-D or SIBO patients. High fat diet
may change the intestinal microbiota pofiles and SCFAs was reported in the past
researches, most of which were animal experiments, lacking of effects diet on the
clinical manifestations and intestinal microbiota profiles in patients with IBS-D,
especially for high-fat diet.
Aims & Methods: We aimed to analyze the characteristics of diet and lactulose
methane and hydrogen breath test (LMHBT) in patients of diarrhea predomi-
nant irritable bowel syndrome (IBS-D) with small intestinal bacterial
overgrowth (SIBO), and comparing with health controls. IBS-D patients (18–
65 years old), who met Rome III criteria were enrolled in Gastrointestinal out-
patient clinic of Peking University Third Hospital from. Health volunteers were
enrolled as controls (HC). All subjects underwent colonoscopy to excluded colo-
nic organic disorders. All subjects completed the case report form (CRF), IBS
symptom severity scale (IBS-SSS), the MOS item short form health survey (SF-
36). The patients were divided into IBS-D with SIBO (IBS-P) group and IBS-D
without SIBO (IBS-N) group according to the LMHBT.Diet information was
collected by food frequency questionnaire (FFQ) and three days recalls. The high
fat diet is defined as the daily total calories supplying from fat is more than 50%.
Statistical analysis were performed by SPSS 20.0 software, P50.05 was consid-
ered statistically significant.
Results: Eighty-eight IBS-D patients and 32 HC were enrolled. The positive rate
of LMHBT in IBS-D was significantly higher than that of HC [39.8% (35/88) vs.
12.5% (4/28), P¼ 0.005]. The 28 HC with negative LMHBT were enrolled in the
follow-up analysis. (1) There were no significant differences in age and gender
ratio among IBS-P, IBS-N and HC. The BMI of IBS-P was significantly lower
than IBS-N [(21.57 0.54) vs. (23.30 0.53)kg/m2, P¼ 0.032]. High fat diet
IBS-D patients and along with IBS-P had higher abdominal pain scores.
(2)The proportion of dietary protein and carbohydrate in IBS-D was significantly
higher than that of HC (14.39% vs.12.22%, P¼ 0.001; 53.94% vs. 46.25%,
P¼ 0.003, respectively), while the intake of fiber was a little lower than HC
[(16.85 1.54) vs. (21.29 3.07)g/d, P¼ 0.169]. The proportion of diet fat was
significantly higher in IBS-P than IBS-N [(47.19 2.62)% vs. (40.74 1.66)%,
P¼ 0.038]. IBS-P had more high fat diet individuals than IBS-N [37.1% (13/35)
vs. 20.8% (11/53), P¼ 0.088]. (3) The positive rate of LMHBT in IBS-D was
significantly higher than that of HC [39.8% vs. 12.5%, P¼ 0.005]. IBS-D patients
with high fat diet had higher LMHBT positive rate than that of non-high fat diet
patients [54.2% (13/24) vs. 17.2% (11/64), P¼ 0.001)]. The baseline of breath
methane in IBS-P was significantly higher than that of in IBS-N [(8.69 0.39) vs.
(6.39 0.47) ppm, P¼ 0.002]. Breath methane peak value was positively related
with the fat proportion of diet (r¼ 0.413, P¼ 0.022).
Conclusion: About 39.8% IBS-D patients existed SIBO. IBS-D patients with high
fat diet had higher morbidity of SIBO, and the proportion of diet fat was posi-
tively correlated with breath methane baseline of LMHBT. SIBO can worsen
nutritional status for IBS-D patients. High-fat diet might be one of the risk
factors for IBS-D with SIBO.
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Introduction: Alterations to the gut microbiota and bacterial translocation have
been implicated as relevant factors for the progression of chronic liver disease
(CLD). While the sequence of events leading to translocation remains unclear,
deficiencies in local host immune defences, increased permeability of the intest-
inal mucosal barrier and dysbiosis of the gut microbiota are suggested to play a
role. Small intestinal bacterial overgrowth (SIBO), in which an excessive and/or
abnormal type of bacteria is present in the small bowel has been implicated as a
potential factor in translocation. However, systematic assessments of the extent
of SIBO in CLD remain limited. We therefore aimed to compare the prevalence
of small intestinal bacterial overgrowth (SIBO) in patients with chronic liver
disease (CLD) and controls.
Aims & Methods: Using the search terms ‘small intestinal bacterial overgrowth
(SIBO)’ and ‘chronic liver disease (CLD)’ or ‘small intestinal bacterial over-
growth (SIBO)’ and ‘cirrhosis’, 19 case-control studies that met inclusion criteria
were identified. Data were extracted to calculate prevalence rates and 95% con-
fidence intervals (CI).
Results: The final dataset included 1,000 adult patients with CLD and 488 con-
trols. Nine studies employed glucose breath tests (GBT), four lactulose breath
tests (LBT), with one each of glycine-1-14C-labeled glycocholate and 14C-D
xylose breath test. Five studies utilised culture methods and one quantitative
PCR. Across all testing methods, the prevalence of SIBO in patients with CLD
was 38.9% (95% CI 36.9–42.0) versus 9.8% (95% CI 7.5–12.8) in controls.
Prevalence of SIBO in CLD was increased as compared to controls
(RR¼ 7.15, 95% CI 4.9–10.4). In patients with cirrhosis the prevalence of
SIBO was 40.1% (95% CI 36.6–43.8) compared to 7.3% (95% CI 4.9–10.8) in
the respective controls. When the method of detection was limited to breath tests,
the prevalence of SIBO in CLD was 35.8% (95% CI 32.6–39.1) compared to
8.0% (95 CI 5.7–11.0) in controls. In contrast, based upon culture techniques, the
prevalence of SIBO in CLD was 68.3% (95% CI 59.62–76.0) vs 7.94% (95% CI
3.44–12.73) in controls.
Conclusion: Regardless of the diagnostic modality, prevalence of SIBO is signifi-
cantly increased in patients with CLD when compared to controls. It is notable
that culture-based detection leads to a higher prevalence in CLD, suggesting
breath tests may underestimate overall prevalence. Given the levels of SIBO
detected, further studies need to explore the role of intestinal dysbiosis for the
progression of CLD.
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Introduction: In humans, enteric methane (CH4) production is highly variable
and related to the gastrointestinal microbiome and diet. Previous work suggests
that CH4 production is more common in patients with ‘constipating’ conditions
such as encopresis and diverticulosis. We aimed to explore the link between
gastrointestinal symptoms breath CH4 exhalation in patients with unexplained
GI symptoms.
Aims & Methods: Consecutive patients (n¼ 100) with unexplained GI symptoms
underwent a combined H2/CH4 breath test after ingestion of 75 g of glucose. H2
and CH4 were measured by Breathtreacker microlyser (Quintron, USA).
Gastrointestinal symptoms were assessed utilising the (Structured Assessment
of Gastrointestinal Symptoms Instrument (SAGIS). The association between
methane exhalation and symptoms during the 2 weeks prior the test were eval-
uated using non parametric test.
Results: 100 consecutive patients (55f), aged 52.2 15.7 yrs (meanSD) were
included. Of these, 14 with positive GBT and 19 without SAGIS data were
excluded, resulting in 67 data-sets available for analysis. Methane peak and
methane baseline values were highly correlated (r¼ 0.96, p5 0.001). Methane
peak (and baseline) were inversely correlated with the SAGIS diarrhoea score
(0.35, p5 0.01, Figure 1). Contrary to current opinion, CH4 exhalation
was not associated with constipation (r5 0.1, P4 0.4). In addition, excessive
belching and acid eructation were significantly associated with the baseline and
peak CH4 exhalation (r all 0.3, p all5 0.04).
Conclusion: There is an inverse association between CH4 exhalation and diar-
rhoea symptoms. At the same time, CH4 is associated with bloating and acid
eructation. These data suggest that CH4 or metabolic products from CH4 pro-
ducing microbes modulate human gut function.
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Introduction: The prevalence of osteoporosis is higher among patients suffering a
distal radius fracture than in healthy controls [1]. Celiac disease (CD) is asso-
ciated with low bone mineral density [2], and overall findings indicate an
increased risk of fracture in CD patients [3, 4]. This study is to our knowledge
the first case control study investigating whether there is a higher prevalence of
CD in adult patients suffering a peripheral fracture (distal radius or ankle) than
in healthy age- and sex matched controls.
Aims & Methods: Main objective was to investigate if patients with a recent
fracture of the distal radius or ankle have a higher risk of having CD than healthy
controls. 400 consecutive patients over the age of 40 with acute distal radius
fracture (n¼ 293) or ankle fracture (n¼ 107) were included in a case control
study by referral from the orthopedic department at Forde General Hospital,
Norway. The controls were 197 age- and sex- matched subjects from Sogn and
Fjordane County identified from the National Population Registry, with no
previous fracture history. BMD of the hips and spine was measured and history
of previous fracture, comorbidities, medication, life-style factors, body mass
index (BMI) and nutritional factors were registered. Serum analysis to detect
secondary osteoporosis including IgA tissue transglutaminase was performed.
Results: See table.
Ankle
fracture
Distal
radius
fracture
All
fractures Controls
N 107 293 400 197
Fracture cases % 26.8 73.3
Female gender % 69.1 80.2 77.3 82.7
T-score 52,5 % 23.4 44.7 39.0 22.3
T-score 1.0–2,5 % 36.4 33.8 34.5 34.0
Mean age 62.9 57.1 61.4 60.3
Mean BMI1 26.5 28.6 27.1 27.2
Known CD2 % 0 (n¼ 0) 1.4 (n¼ 4) 1.0 (n¼ 4) 1.5 (n¼ 3)
Positive TTG3 % 2.8 (n¼ 3) 2.4 (n¼ 7) 2.5 (n¼ 10) 1.3 (n¼ 2)
Known CD or
positive TTG
2.8 (N¼ 3) 3.8 (n¼ 11) 3.5 (n¼ 14) 2.8 (n¼ 5)
Vitamin D
deficiency4 %
6.6 2.4 3.6 5.6
1body mass index 2celiac disease 3IgA tissue transglutaminase 4Vit D5 37 nmol/l
Conclusion: The prevalence of celiac disease was in preliminary analyses not
significantly higher among persons suffering a distal fracture (3.5%) than
among healthy age- and sex- matched controls (2.8%). Osteoporosis and low
Vitamin D levels are significant risk factors for distal radius fracture, but this is
not the case with ankle fractures.
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Introduction: Celiac disease (CeD) is an immune disorder, triggered by
gluten intolerance in genetically susceptible patients. Clinical outcome includes
several extraintestinal manifestations, including neurologic complications in
about 10% of patients. Previous studies confirmed the subclinical changes of
autonomic nervous system (ANS) activity resulting to impaired gastric myoelec-
tric activity. In CeD disturbances of parasympathetic-sympathetic balance of the
ANS activity with sympathetic dominance is observed. Tight junctions impair-
ment is one of postulated pathomechanism in CeD and its complications.
Transmembrane proteins of tight junctions include claudin and occludin. There
is lack of publications referring to soluble claudin and occludin concentrations in
CeD. Interleukin-1 beta (IL-1beta) is an important mediator of the, and there are
no data concerning on its influence on gastric myoelectric activity and ANS
activity in CeD.
Aims & Methods: The study was aimed to evaluate occludin, claudin and IL-
1beta concentrations in serum in neurologically asymptomatic patients with CeD
and its correlation with selected parameters of ANS activity markers (heart rate
variability, electogastrography HRV) and gastric myoelectric activity (EGG).
Thirty four patients with CeD (70% females, mean age 34 years, 41.2 16.6)
without neurological symptoms were tested for occludin, claudin, IL-1beta con-
centrations in serum using ELISA, and HRV and EGG.
Results: Biochemical parameters. Patients with CeD presented with lower average
level of occludin (1.41(0–2.9) ng/ML) than healthy subjects (1.68(0.39–4.8) ng/
ML) (P¼ 0.07, the Mann-Whitney test). No significant impact of CeD on the
average results of IL-1 beta concentrations was observed (P¼ 0.44, the Mann-
Whitney test). The rest HRV. In the celiac group the assessment of HRV revealed
a negative statistically significant correlation of claudin concentration and very
low frequencies (VLF-RRI; Spearman’s rank correlation coefficient: r¼ -0.51,
P¼ 0.018) as well as positive correlation between IL-1beta and LF/HF was
demonstrated (r¼ 0.51, P¼ 0.032). Statistically significant, negative and strong
correlation of IL-1 beta concentration and DP (Dominant Power of EGG) (r¼ -
0.58, P¼ 0.038) was shown.
Conclusion: ANS activity measured by EGG and HRV seems to be correlated to
presence of IL-1beta. In celiac group the serum concentration of claudin and
occludin do not correlate to ANS activity. Due to former research on autonomic
imbalance in CeD with sympathetic overdrive, the hypothesis of influence of
IL-1beta on ANS activity should be considered.
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Introduction: Small bowel villous atrophy (VA) is mainly related to coeliac dis-
ease (CD) that develops in HLA DQ2/DQ8 positive patients and improves on a
gluten-free diet. Other forms of VA unrelated to CD are common variable
immune-deficiency, autoimmune enteropathy, small bowel malignancies, medi-
cation-related enteropathies, HIV, tropical sprue, and giardiasis [1–3]. However,
there are also forms of VA in which CD can be neither confirmed nor excluded
and there are forms of VA in which, although CD is excluded, a definitive
diagnosis cannot be made. Some years ago, we coined the terms undefined
sprue (US) and non-coeliac refractory sprue (NCRS) to define these two
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conditions [4]. Although other Authors described similar patients [2,3], it is still
unclear whether US and NCRS are two independent conditions or whether they
are two faces of the same coin. Alternatively, they could be umbrella terms
covering one or more atrophic enteropathies still awaiting to be identified, as
was the case of olmesartan-associated enteropathy until a few years ago.
Aims & Methods: Our aim was to clarify the nature of these forms of VA.
We retrospectively re-evaluated the clinical notes of patients referred to our
Clinic from January 1999 to October 2016 with a previous diagnosis of refractory
CD. Patients with VA in whom CD could not be confirmed and in whom other
causes of VA were ruled out were selected.
Results: 7 patients (2F, age at diagnosis of VA 46 26 years, all with severe
malabsorption) were identified. 3 were DQ2 positive and so were diagnosed as
US: case 1 (F, 32 years) died of ulcerative jejunitis 8 years later; case 2 (M, 38)
died of pulmonary embolism complicating systemic candidiasis 1 year later and
case 3 (M, 71) died of intestinal lymphoma after 4.5 years. The remaining
4 patients were HLA DQ2/DQ8 negative, so a diagnosis of NCRS was made.
3 were DQ7.5 positive: case 4, (F, 61) died of EATL type 2 after 4.5 years; case 5
(M, 25) is still alive 10 years after diagnosis of VA and in good clinical condi-
tions; case 6 (M, 69) is still alive but could be affected by a form of enteropathy
due to candesartan. He is in good clinical condition and has been refusing follow-
up. The last patient, case 7 (M, 29) is DQ7.3 positive. He is still alive 11 years
after the diagnosis of VA, although complains of diarrhoea.
Conclusion: We described 7 patients with VA unrelated to CD or other known
enteropathies. Although overall mortality among them is very high (57%) and
mainly due to lymphoproliferative disorders, 3 of the 4 DQ2/DQ8 negative
patients are alive many years after the diagnosis of VA with no evidence of
malignancy. This suggest that these 7 patients are not affected by the same
condition. We speculate that DQ2 positive patients who died of lymphoma
could be affected by a form of CD who escaped diagnosis and get complicated.
However, we feel that the 3 DQ2/8 negative patients with long survival are
affected by a still unidentified form of VA.
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Introduction: Strict gluten-free diet (GFD) in celiac disease is burdensome and
difficult to maintain, which might predispose to poor dietary adherence and
impaired quality of life. We aimed to evaluate adult patients’ experience of
living with celiac disease diagnosed in childhood, and identify factors associated
with possible everyday life restrictions caused by the disease.
Aims & Methods: 232 adults (women 69%, median age 27.0 yr) with a childhood
diagnosis of celiac disease fulfilled a questionnaire evaluating their experiences
about general health and lifestyle, possible co-morbidities, adherence and atti-
tudes towards GFD and long-term follow-up of celiac disease. In addition, they
completed validated Gastrointestinal Symptom Rating Scale (GSRS) and
Psychological General Well-Being (PGWB) surveys for gastrointestinal symp-
toms and quality of life. Patient records were used to confirm clinical and histo-
logical presentation at diagnosis and other relevant medical data.
Results: Altogether 108 (47%) out of the 232 responders felt that celiac disease
restricts their daily life. This was experienced especially when eating in a restau-
rant (72%), traveling abroad (38%) and visiting a friend (30%). Patients report-
ing restrictions had more often anemia (38% vs 22%, p¼ 0.013) and severe
symptoms (16% vs 6%, p¼ 0.047) at diagnosis, whereas the groups did not
differ in age, gender or other clinical and histological presentation. Current age
(median 26.3 vs 27.7 yr, p¼ 0.315) and time from the diagnosis (18.6 vs 17.9 yr,
p¼ 0.468) were also comparable, as well as were self-experienced general health
and concern about health, presence of co-morbidities and complications, smok-
ing, physical exercise, socioeconomic status, membership of celiac society and
presence of celiac disease in relatives. There was also no difference in specific
gastrointestinal symptoms as measured by GSRS scores, but patients considering
the disease restrictive reported more overall symptoms possibly related to celiac
disease than those without restrictions (32% vs 17%, p¼ 0.007). Furthermore,
despite similar dietary adherence (strict GFD 78% vs 82%, p¼ 0.770) they
experienced adhering to the diet more challenging (somewhat difficult 33% vs
7%, p5 0.001) and had significantly lower PGWB vitality scores (median 17 vs
18, p¼ 0.023).
Conclusion: Almost half of the patients diagnosed in childhood experienced celiac
disease to cause marked restrictions in adulthood. This was associated with
current symptoms, lower vitality scores and difficulties to maintain GFD.
Patients with severe symptoms and anemia at diagnosis might require special
attention and tailored follow-up in these circumstances.
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Introduction: The prevalence of diagnosed coeliac disease (CD) has rapidly
increased in developed countries over the last 30 years. The economic burden
of diagnosing, managing, and monitoring CD can be substantial but is poorly
understood. To assess the economic burden of CD, we systematically reviewed
current evidence quantifying economic costs and health resource utilization
(HRU) for CD in North America and Europe.
Aims & Methods: Searches of Medline, Embase, EconLit, the Cochrane Library,
and conference abstracts systematically identified literature published in English
during the last 10 years assessing direct and indirect costs, cost-effectiveness
analyses, and HRU for CD.
Results: Of 33 studies meeting criteria for inclusion, most (20) were from Europe,
and most (18) reported or modeled costs associated with screening and diagnosis.
Cost per positive CD diagnosis of screening patients already undergoing upper
gastrointestinal biopsy for other indications, such as anaemia or irritable bowel
syndrome, ranged from approximately $1,300 in Canada to more than E44,000
in the Netherlands (costing year not reported). In these populations, screening
was judged to be cost-effective with various strategies combining diagnostic
modalities, including serology then biopsy, compared to no screening.
Strategies using either endoscopy/biopsy or serology alone were not considered
cost-effective. Direct annual excess costs to a US payer per diagnosed CD patient
totaled $4,000 ($US 2007) to $6,000 ($US 2013) more than for a person without
CD, chiefly due to outpatient care, with higher costs among patients with poor
disease control. High use of outpatient care is also reflected in studies of HRU,
although hospitalization, emergency visits and medication use are also more
common in individuals with CD than in controls. After initiation of a gluten-
free (GF) diet, patients visit primary care providers less often, but use more
medications. Patients often pay out of pocket for gluten-free (GF) foods,
which cost 240–518% more than gluten-containing equivalents. Three studies
on absenteeism from Scandinavia found fewer days missed from school and
work following diagnosis and initiation of a GF diet.
Conclusion: Most economic studies of CD have focused on the cost of screening
and diagnosis, especially in Europe. Methods of screening generally are consid-
ered cost-effective when they combine diagnostic modalities, such as serology
then biopsy, in people being evaluated for symptoms. Much of the cost to a
payer of managing CD derives from outpatient care, especially for patients
with poorly controlled disease. Patients on a GF diet lose fewer days from
work and school but pay high costs for GF foods.
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Introduction: Metabolic syndrome (MS) and hepatic steatosis (HS) are frequent
in patients with celiac disease (CD) after commencing gluten-free diet (GFD), but
data about predictive factors for such a condition are still scarce.
Aims & Methods: We aimed to evaluate the role of PNPLA3 rs738409 in the
development of MS and HS in CD patients after starting GFD. From June 2014
to September 2016 we consecutively enrolled all patients referred to academic
gastroenterological centre, suffering from CD, with our without HS. All patients
underwent anthropometrics and serological investigations, ultrasonography (US)
evaluation to assess the degree and severity of HS and genotyping of PNPLA3
rs738409 polymorphism.
Results: Finally, 370 subjects were enrolled (136 with HS and 234 without HS).
At genotyping assays, CC genotype was found in 194 subjects (52.4%), CG
genotype in 138 subjects (37.3%), while 38 individuals (10.2%) showed the GG
genotype. At binary logistic regression, only G and GG alleles were predictive for
the development of HS (OR 1.97; p5 0.01 for G carriers and OR 6.9; p5 0.001
for GG carriers), while BMI (OR 3.8; p5 0.001) and waist circumference
(OR 2.8; p¼ 0.03) at CD diagnosis were the only independent factors for the
development of MS. The intergroup comparison among HS patients showed that
United European Gastroenterology Journal 5(5S) A611
the severe grade of HS was more frequently observed in GG than in CC carriers
(74% vs 11.3%, p5 0.001, OR 21.8).
Conclusion: PNPLA3 G and GG carriers with CD have higher susceptibility to
hepatic steatosis, but not to metabolic syndrome. Moreover, patients with GG
alleles display a more relevant disease in terms of severity of HS based on US
evaluation.
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Introduction: Recent research has shown that patients with celiac disease (CD)
are at-risk of developing metabolic syndrome (MS) and hepatic steatosis (HS)
after commencing gluten-free diet.
Aims & Methods: We aimed to evaluate the predictive factors for MS and HS in
CD after one year of GFD. All consecutive newly diagnosed CD patients were
enrolled. We prospectively collected data about: BMI; waist circumference; blood
pressure; cholesterol; triglycerides, glucose and insulin blood levels; insulin resis-
tance (through the homeostatic model assessment HOMA-IR); treatment with
proton pump inhibitors (PPI). Diagnosis of MS was made in accordance with
current guidelines and HS was diagnosed by ultrasonography. The prevalence of
MS and HS was re-assessed after 1 year of GFD. A logistic regression analysis
was performed to identify risk factors for MS and HS occurrence after 1 year of
GFD.
Results: Of 301 patients with newly diagnosed CD, 13 (4.3%) met criteria for
diagnosis of MS and 25.9% presented HS at the time of CD diagnosis; 99 sub-
jects (32.8%) had long-term exposure to PPI during the study period. After
1 year, 72 (23.9%) patients had developed MS (4.3% vs 23.9%; p5 0.001,
OR 6.9) and 112 (37.2%) had developed HS (25.9% vs 37.2%; p5 0.01,
OR 1.69). At multivariate analysis, high BMI at diagnosis (OR 10.8;
p5 0.001) and PPI exposure (OR 22.9; p5 0.001) were the only factors asso-
ciated with the occurrence of MS; HOMA-IR (OR 9.7; p5 0.001) and PPI
exposure (OR 9.2; p5 0.001) were the only factors associated with the occur-
rence of HS.
Conclusion: PPI exposure adds further risk of occurrence of MS and HS for
patients with CD on GFD. The use of PPI in patients with CD on GFD
should be limited to strict indications.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Patients with coeliac disease (CD) are usually stable clinically and
biochemically at their annual review. Due to pressures on out-patient services we
reviewed data to assess which patients actually require specialist gastrointestinal
(GI) input, and raise the question on who ought to see CD patients in clinics.
Aims & Methods: Barnet Hospital is a District Hospital serving a population of
500,000 just outside North West London. This was a single-centre, retrospective
study, of confirmed CD patients, under the care of three different gastroenter-
ologists. Data was obtained from each consultant from their database.
We reviewed the electronic records relating to each patient’s last three clinic
appointments, and assessed whether or not they were stable clinically and bio-
chemically. We excluded patients with other significant GI co-morbidities and
who were newly diagnosed within the last two years.
Results: There were 192 patients with CD of whom, 160 fulfilled the inclusion
criteria. Female¼ 107;67%. In each of the last 3 clinic reviews 83% (n¼ 133)
were stable. Only 17% (n¼ 27) required specialist GI input; including 18%
(n¼ 7) due to poor adherence to a gluten-free diet, 28% (n¼ 11) due to GI
symptoms, 18% (n¼ 7) due to weight loss, 18% (n¼ 7) due to anaemia, 8%
(n¼ 3) due to elevated TTG and 10% (n¼ 4) other. Annual reviews by a gastro-
enterologist occurred in 83% (n¼ 133). Dieticians saw patients less than once per
year in 62.5% (n¼ 100) of cases, and 37.5% (n¼ 60) were actually never referred
to a dietician.
Conclusion: BSG guidelines recommend that patients with CD are seen annually
by a dietician and/or clinician for a clinical review, biochemical checks and for
dietary adherence and advice1. NICE guidelines also state that patients should be
seen annually for clinical review, height and weights check, bloods and to assess
the need for nutritional advice2. We have demonstrated that in a hospital that
does not have a dietician-led coeliac service, gastroenterologists typically see
straight forward and stable patients annually 83% of the time. Assuming a
10 minute consultation, this equates to 22 hours per anum of specialist time,
equivalent to 6.3 clinics a year. Given the need to access our services for
urgent referrals or unwell patients with other conditions, this study forms the
basis for a business case to set up a dietician-led coeliac service, with access to
gastroenterologists where needed.
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Introduction: Patients with coeliac disease (CD) should be seen annually for a
clinical review, blood tests and a DEXA scan if needed 1,2. The indication for a
DEXA scan is unclear due to conflicting recommendations in current guide-
lines2,3. The aim of our study was to audit our practice, with a focus on requests
for DEXA scans.
Aims & Methods: This was a single-centre, retrospective study of CD patients
under the care of 3 consultants. We accessed the electronic records to identify if
haematological and biochemical profiles were being monitored annually. We also
identified when patients had their first DEXA scans and whether or not they were
indicated2,3.
Results: Data were collected on 160 patients (Female¼ 107[67%]). Annual
checks of FBC occurred in 94% of patients, vitamin B12 in 74%, folate in
77%, ferritin in 88%, calcium in 85% and vitamin D in 69%. DEXA scans
occurred in 74% of patients (n¼ 119), including 65% (n¼ 77) who were screened
around the time of diagnosis. However, only 24% (n¼ 28) actually warranted the
scan according to guidelines2,3, and 68% (n¼ 81) did not fulfil criteria for a
DEXA. In 8% of patients (n¼ 10), there was inadequate data. Of the 81 patients
who did not warrant a DEXA scan, 77 results were available: normal in 48%
(n¼ 37), osteopenia in 43% (n¼ 33) and osteoporosis in 9% (n¼ 7). Of the 7
patients that had osteoporosis, 4 patients were under 50 years old (57%). Of the
appropriate DEXA requests, 25% (n¼ 7) were normal, 39% (n¼ 11) had osteo-
penia and 36% (n¼ 10) had osteoporosis.
Conclusion: Most CD patients require very little clinical input at their routine
appointments. Annual blood checks and adherence to a gluten-free diet are
standard enquiries. However, there is a cohort of patients who are not getting
their regular blood tests: 33% for bone profile and 25% for haematinics.
Clinicians tend to order a DEXA in most CD patients because it is easier than
attempting to judge an individual’s risk in the setting of conflicting
guidance2,3.The pick-up rate of osteoporosis in 36% of appropriately screened
patients (vs 9% in inappropriate scan requests) suggests that targeted screening
allows for a more rational and cost-effective use of a limited resource. We hope
that the guidelines can now be updated with more clarity for the practitioners
who request DEXA scans in CD patients.
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Introduction: A life-long gluten-free diet (GFD) is the only available treatment
for patients with celiac disease (CD). Adherence to the GFD is associated with
symptoms remission, reversal of mucosal atrophy and, possibly, prevention of
CD-related complications. However, data on the long-term effects of a good or
poor adherence to the GFD are limited.
Aims & Methods: The aim of this study was to assess the rate and accuracy of
compliance to a strict GFD in patients with a CD history of more than 30 years
and to compare endpoints such as complications, symptoms and histology
between patients following a strict GFD and patients not compliant to the
diet. Between 2015 and 2016, data from all patients diagnosed with CD at the
Fondazione IRCCS Ca’ Granda before 1985 were retrieved. Patients not under-
going regular follow-up at the clinic were contacted in order to collect recent
clinical updates as regards symptoms, adherence to the GFD, laboratory data
and complications occurrence. All patients were asked to fill in a questionnaire
investigating their knowledge on gluten free products and behavioral rules; in
case of patients with CD diagnosis in childhood, the same questionnaire was
administered to their parents.
Results: Clinical data from 196 patients were collected and analyzed. Patients
were divided into 3 groups according to their adherence to GFD: 133 patients
reporting a lifelong strict GFD, 29 patients on GFD at the time of follow-up but
with a history of at least 5 years of gluten-containing diet (GCD), and 35 patients
who reported to be on a GCD. No significant differences were found between
groups regarding symptoms and histology at diagnosis, onset of associated auto-
immune disorders, family history of CD and compliance to follow up. The onset
of complications at follow-up did not significantly differ in the three groups as
well. Follow-up histology was available in 63 patients (32.1%). Persistence of
villous atrophy was as expected more frequent in patients on GCD as on GFD
(41% vs 7%, p¼ 0.008); however 20 patients showed normal histology during
long-term GCD. The questionnaire was returned by 90 patients and 66 parents: a
slightly better knowledge about the GFD and its behavioral rules was found
between patients on lifelong GFD and patients with ongoing or past GCD
(p¼ 0.03).
Conclusion: Poor adherence to the GFD is reported by almost one-third of
patients with a long-term history of CD, confirming the high rate of poor com-
pliance to such a strict diet among patients. Poor adherence to the GFD was
confirmed as a major predictor of persistence of villous atrophy, but this does not
necessarily imply the development of CD complications. Moreover, results from
follow up biopsies showed that a GCD does not imply recurrence of villous
atrophy in all patients, attesting the possibility that some CD patients may
maintain a gluten tolerance over time.
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Introduction: Parenteral support (PS) volume needs vary depending on disease
severity in patients with intestinal failure associated with short bowel syndrome
(SBS-IF). Patient classification has focused on the diagnosis that led to resection
and the remnant bowel anatomy.
Aims & Methods: Recently, the idea that grading severity of SBS-IF is based on
magnitude of PS volume needs led to this clinical trial data post hoc analysis of
patients with SBS-IF based on their baseline PS volume. STEPS (NCT00798967;
EudraCT2008-006193-15) was a 24-week, placebo-controlled study of teduglu-
tide (TED) 0.05mg/kg/day in patients with SBS-IF. Three baseline PS volume
groups were evaluated: Group I, 9 L/week; Group II, 49 to 18 L/week; and
Group III, 418 L/week.
Results: The predominant diagnosis leading to SBS-IF in Group I (12/28; 43%)
and Group II (15/41; 37%) was vascular gut complications; in Group III (8/16;
50%), Crohn’s disease. Baseline PS volume and TED-induced volume reduction
(% change) at Week 24 was highest in Group III (Table). Evaluation of indivi-
dual patient response showed a close, linear, and significant correlation between
absolute PS volume reduction at Week 24 in relation to TED treatment and daily
volume at baseline (y¼ -0.387xþ 90.03, R2¼ 0.61; P5 0.0001); no significant
correlation was observed in the placebo group (y¼ -0.06x-220.15, R2¼ 0.02;
P¼ 0.36). Adverse events were reported by 93% (Group I), 80% (Group II),
and 71% (Group III) of TED patients.
Table: Baseline PS Volume and Percent Change at Week 24
Baseline PS Volume
9 L/week 49–18 L/week 418 L/week
Mean (SD)
PS Volume,
Actual Based
TED
(n¼ 15)
PBO
(n¼ 13)
TED
(n¼ 20)
PBO
(n¼ 21)
TED
(n¼ 7)
PBO
(n¼ 9)
Baseline, mL/day 806.9
(328.11)
856.1
(310.24)
1791.8
(338.33)
1870.2
(408.27)
3826.1
(715.49)
3527.4
(749.04)
Change at
Week 24, %
28.5
(18.45)*
29.2
(35.49)y
33.5
(20.97)z
19.1
(20.40)z
36.7
(13.97)
14.9
(17.07)x
PBO¼placebo. *n¼ 13; yn¼ 12; zn¼ 19, xn¼ 8.
Conclusion: Higher baseline PS volume in patients with SBS-IF correlates with
greater absolute reduction in PS volume with TED treatment. This research was
funded by Shire International GmbH, Zug, Switzerland.
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Introduction: Plasma citrulline has been proposed as a biomarker for remnant
intestinal length, but it is unclear if plasma citrulline levels reflect intestinal
absorptive function.
Aims & Methods: This post hoc analysis investigated the relationship between
reductions in parenteral support (PS) volume and changes in plasma citrulline
levels with teduglutide (TED) in patients with intestinal failure associated with
short bowel syndrome (SBS-IF). STEPS (NCT00798967; EudraCT2008-
006193-15) was a 24-week, placebo-controlled study of TED 0.05mg/kg/day
in patients with SBS-IF. Plasma citrulline levels were assessed at baseline and
Week 24 in all patients randomised to TED and in patients stratified by bowel
anatomy.
Results: In the TED arm (n¼ 42), plasma citrulline levels at baseline were sig-
nificantly correlated with remnant small bowel length (R2¼ 0.14; P¼ 0.02;
n¼ 36) but not with baseline PS volume (R2¼ 0.03; P¼ 0.30; n¼ 39). The corre-
lation between baseline plasma citrulline and plasma citrulline change at Week 24
was significant (R2¼ 0.80; P¼5 0.0001; n¼ 39). No correlation was found
between change in plasma citrulline levels and change in PS volume at Week
24 with TED (R2¼ 0.05; P¼ 0.16; n¼ 39). When patients were analysed by bowel
anatomy subgroups, significant increases in plasma citrulline were seen with TED
but not placebo (Table).
Table: Mean (SD) Change From Baseline at Week 24 in PS Volume and Plasma
Citrulline Stratified by Bowel Anatomy
No Colon,
Stoma Present,
No Colon-in-
Continuity
50% Colon,
No Stoma,
Colon-in-
Continuity
Other
Bowel
Anatomies
Mean (SD)
Change at
Week 24
TED
(n¼ 17*)
PBO
(n¼ 16y)
TED
(n¼ 18)
PBO
(n¼ 20)
TED
(n¼ 7)
PBO
(n¼ 7z)
PS Volume
mL/day –919 (644)x –340 (436) –355 (306) –327 (349) –728 (532) –297 (498)
% –40 (18)jj –19 (29) –23 (16) –24 (22) –40 (19) –19 (31)
Citrulline
mM 30.1 (18.9)x 2.2 (6.9) 11.8 (9.9)x 0.8 (5.3) 24.0 (20.9)x –2.7 (7.6)
% 138 (50)x 8 (31) 87 (63)x 21 (71) 116 (85)x –1 (40)
PBO¼placebo.
*n¼ 14 with data; yn¼ 13 with data; zn¼ 6 with data; xP 0.01; jjP5 0.05.
Conclusion: Plasma citrulline may serve as a marker of remnant small bowel
length in patients with SBS-IF, but plasma citrulline does not predict PS
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volume reductions with TED. Plasma citrulline changes with TED may reflect
increased enterocyte mass. This research was funded by Shire International
GmbH, Zug, Switzerland.
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P1287 LACTULOSE, LACTOSE AND FRUCTOSE INGESTION
INDUCES SPECIFIC PATTERNS OF GASTROINTESTINAL
SYMPTOMS IN CHINESE SUBJECTS WITH FUNCTIONAL
DYSPEPSIA AND IRRITABLE BOWEL SYMPTOMS
V. Tan
1, N. H.S. Chu1, C. K. Yao1, P.R. Gibson2
1The University of Hong Kong, Hong Kong/Hong Kong PRC
2Dept. Of Gastroenterology, Alfred Hospital Dept. of Gastroenterology,
Melbourne/Australia
Contact E-mail Address: vpytan@hku.hk
Introduction: Prevalence rates of Functional Dyspepsia (FD) in East Asia are
three times higher than Irritable Bowel Syndrome (IBS) rates. Many researchers
have suggested that IBS subjects in the region experience their pain and discom-
fort in the upper abdomen, leading to misdiagnosis as FD.
Aims & Methods: We aimed to compare patterns of gastrointestinal (GI) symp-
tom genesis in the Chinese population with FD or IBS during provocative hydro-
gen breath testing (HBT) with lactulose, lactose and fructose. Subjects fulfilling
the ROME III classification of FD and IBS, and control subjects with no known
GI disorder/symptoms were recruited. All subjects underwent HBT þ/methane
assessment with lactulose (10ml), lactose (25 g) and fructose (25 g). Subsequent
breath tests were performed after a washout period of at least one week. Breath
tests were performed after an overnight fast, with the patient sedentary. Breath
samples taken every 15 minutes for 3 h. GI symptoms were recorded during these
3 h and at a telephone follow-up 24 hours later.
Results: A total of 353 subjects completed at least one breath test examination
and 313 subjects completed all three breath tests. 16%, 55% and 29% were
control, FD and IBS subjects. All study subjects were ethnic Chinese, the
mean age was 53 [Range; 18–76) y and 27% [95% CI; 23–32%] were male.
85% [95% CI; 82–89%] of subjects were hydrogen-producers and 100%
methane-producers. Symptoms were induced in a relatively low proportion of
healthy controls. Both FD and IBS subjects experienced similar proportions of
epigastric pain on consumption of lactulose, lactose and fructose. See Table 1.
Subjects with FD experience more belching than subjects with IBS when lactu-
lose [58 vs. 42%, p¼ 0.011] and lactose [62 vs. 46%, p¼ 0.014] were ingested,
respectively. Subjects with IBS experience significantly more ‘‘lower GI’’ symp-
toms of abdominal pain and development of loose stools when lactulose was
ingested when compared with subjects with FD. In general subjects with IBS
experienced both epigastric pain and abdominal pain when any of the three
carbohydrate solutions were ingested. Healthy controls experienced minimal
symptoms.
Conclusion: Chinese subjects commonly co-produced hydrogen and methane.
Ingestion of poorly absorbed sugars induces symptom patterns in patients with
FD in similar proportions. Chinese IBS subjects commonly experienced epigas-
tric and abdominal pain. Reducing poorly absorbed short-chain carbohydrates
(FODMAPs) might be efficacious in FD as it is in IBS.
Disclosure of Interest: All authors have declared no conflicts of interest.
Table 1: Induction of Gastrointestinal Symptoms with Lactulose, Lactose and
Fructose Hydrogen Breath Testing in Functional Dyspepsia and Irritable Bowel
Syndrome Subjects
Functional
Dyspepsia
Irritable Bowel
Syndrome P-value
Lactulose % [95% Confidence Interval]
Epigastric Pain 40% [33–47%] 29% [20–38%] 0.056
Belching 58% [51–65%] 42% [32–52%] 0.011
Abdominal Pain 4% [1–7%] 37% [28–47%] 50.0001
Flatulence 34% [27–40%] 27% [18–36%] 0.246
Loose Stools 19% [14–25%] 30% [21–39%] 0.045
Lactose % [95% Confidence Interval]
Epigastric Pain 44% [36–52%] 41% [31–52%] 0.692
Belching 62% [55–69%] 46% [36–56%] 0.014
Abdominal Pain 5% [2–8%] 35% [25–44%] 50.0001
Flatulence 50% [42–58%] 50% [40–60%] 1.00
Loose stools 28% [21–35%] 38% [27–48%] 0.109
Fructose % [95% Confidence Interval]
Epigastric Pain 37% [30–45%] 26% [16–35%] 0.060
Belching 52% [44–59%] 31% [35–56%] 0.331
Abdominal Pain 23% [1–7%] 77% [18–37%] 50.001
Flatulence 27% [20–34%] 23% [14–32%] 0.507
Loose Stools 19% [13–25%] 29% [20–39%] 0.082
P1288 PATIENTS WITH SHORT BOWEL SYNDROME STRATIFIED
BY DIAGNOSIS: POST HOC ANALYSIS OF TEDUGLUTIDE ON
FLUID COMPOSITE EFFECT
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Introduction: Inflammatory bowel disease (IBD) and mesenteric vascular (Vasc)
disease are underlying conditions for intestinal failure associated with short
bowel syndrome (SBS-IF). Fluid balance, urine production, and parenteral sup-
port (PS) volume are variable among patients with SBS-IF.
Aims & Methods: This is a post hoc analysis of the impact of teduglutide (TED)
on fluid composite effect (FCE¼ sum of urine volume output increase, oral fluid
intake reduction, and PS volume reduction) in patients stratified by diagnosis.
STEPS (NCT00798967; EudraCT2008-006193-15) was a 24-week, placebo-
controlled study of TED 0.05mg/kg/day in patients with SBSIF. Three
groups were evaluated: SBS-IBD, SBS-Vasc, and Other.
Results: The SBS-IBD group included more patients with stoma (95%; SBS-
Vasc, 19%; Other, 41%) and fewer with colon-in-continuity (11%; SBS-Vasc,
78%; Other, 62%). At Week 24 (Table), PS volume reductions were significantly
higher in SBS-IBD patients treated with TED vs placebo (P¼ 0.02) and vs TED
patients in the SBS-Vasc (P¼ 0.04) and Other (P¼ 0.02) groups. Change in FCE
was greater in SBS-IBD patients treated with TED vs placebo (P5 0.02) and vs
TED patients in the SBS-Vasc (P5 0.01) and Other (P¼ 0.05) groups.
Table: Components of Fluid Composite Effect at Baseline and Week 24 and
Fluid Composite Effect at Week 24 by Diagnosis
SBS–IBD SBS–Vasc Other
Mean (SD),
mL/day
TED
(n¼ 11)
PBO
(n¼ 8)
TED
(n¼ 15)
PBO
(n¼ 17)
TED
(n¼ 16)
PBO
(n¼ 18)
Baseline
PS volume 2268 (1480) 3088 (1156) 1827 (982) 1338 (731) 1399 (811) 1928 (855)
Oral fluid
intake
2456 (1176) 1521 (532) 1780 (761) 1634 (536) 1600 (575) 1692 (708)
Urine output 1160 (160) 1302 (243) 1385 (252) 1389 (327) 1448 (114) 1387 (226)
Change at Week 24
PS volume –1102 (654)* –357 (453)z –513 (539) –277 (428)x –450 (280)# –363 (345)
Oral fluid intake –220 (338)y 246 (608)z –24 (500) 188 (531)# 79 (611)# 254 (470)
Urine output 191 (180)y –138 (239)z 52 (286) 31 (243)# 222 (341)# 128 (466)
FCE –1437 (900)y 27 (818)z –588 (995) –147 (575)# –593 (444)# –237 (588)
PBO¼placebo. *n¼ 9; yn¼ 8; zn¼ 7; xn¼ 16; #n¼ 15.
Conclusion: TED had the largest absolute effect on FCE in the SBS-IBD
group; TED effect on FCE was not as major in SBS-Vasc or Other patients
at Week 24. This research was funded by Shire International GmbH, Zug,
Switzerland.
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P1289 RESULTS OF A POST HOC ANALYSIS OF BASELINE
CHARACTERISTICS AND CLINICAL RESPONSE TO
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Introduction: Intestinal resection resulting in short bowel syndrome (SBS) can
lead to intestinal failure (SBS-IF). SBS-IF arises from different aetiologies,
including vascular catastrophes and inflammatory bowel disease, resulting in a
heterogeneous population.
Aims & Methods: This post hoc analysis reports baseline characteristics and
clinical response to teduglutide (TED) in patients based on residual bowel anat-
omy. STEPS (NCT00798967; EudraCT2008-006193-15) was a 24-week, placebo-
controlled study of TED 0.05mg/kg/day in patients with SBSIF. Three groups
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were evaluated: Group 1 (no colon/stoma present/no colon-in-continuity),
Group 2 (50% colon/no stoma/colon-in-continuity), and Group 3 (other
bowel anatomies). Clinical response was defined as 20% reduction from base-
line in weekly parenteral support (PS) volume at Weeks 20–24. Data presented as
mean (SD).
Results: The predominant diagnosis in Group 1 was Crohn’s disease, whereas the
predominant diagnosis in Group 2 was vascular complications (Table). Group 1
patients required the highest baseline PS volumes compared with Group 2 or
Group 3. TED-induced PS volume reduction (change in L/week) took longer to
be realised in Group 2 (Week 12, 0.9 [1.2]; Week 24, 2.5 [2.1]) compared with
Group 1 (Week 12, 5.5 [3.8]; Week 24, 6.4 [4.5]) or Group 3 (Week 12, 2.7
[1.2]; Week 24, 5.1 [3.7]). Response rates were higher with TED versus placebo
in all groups, but the difference was significant only in Group 1 (76% vs 19%,
P¼ 0.001; Group 2, 56% vs 40%, P¼ 0.36; Group 3, 57% vs 29%, P¼ 0.33).
Adverse events were reported by 94%, 72%, and 86% of Group 1, Group 2, and
Group 3 patients receiving TED, respectively.
Table: Baseline Patient Characteristics
Group 1: No Colon,
Stoma Present,
No Colon-in-
Continuity
Group 2:
50% Colon,
No Stoma,
Colon-in-
Continuity
Group 3:
Other Bowel
Anatomies
Parameter
TED
(n¼ 17)
PBO
(n¼ 16)
TED
(n¼ 18)
PBO
(n¼ 20)
TED
(n¼ 7)
PBO
(n¼ 7)
Mean (SD)
age, year
52.1
(10.3)
50.7
(12.9)
51.3
(14.9)
50.3
(18.7)
49.6
(11.7)
46.0
(13.2)
Sex, n (%)
Men 8 (47) 7 (44) 9 (50) 10 (50) 3 (43) 2 (29)
Women 9 (53) 9 (56) 9 (50) 10 (50) 4 (57) 5 (71)
Mean (SD)
BMI, kg/m2
23.6
(3.6)
22.4
(3.2)
22.1
(2.9)
22.3
(3.0)
20.8
(2.1)
22.0
(3.6)
Cause of SBSIF, n
(%)
Crohn’s disease 9 (53) 7 (44) 0 0 1 (14) 1 (14)
Vascular
complications
2 (12) 2 (13) 9 (50) 13 (65) 2 (29) 1 (14)
Injury 1 (6) 3 (19) 3 (17) 1 (5) 0 0
Volvulus 0 0 2 (11) 4 (20) 1 (14) 2 (29)
Cancer 1 (6) 0 0 1 (5) 0 1 (14)
Other 4 (24) 4 (25) 4 (22) 1 (5) 3 (43) 2 (29)
Colon-in-
continuity, n (%)
0 (0) 0 (0) 18 (100) 20 (100) 7 (100) 7 (100)
Stoma present, n (%)
Jejunostomy 11 (65) 5 (31) 0 0 0 0
Ileostomy 6 (35) 9 (56) 0 0 0 0
Colostomy 0 0 0 0 4 (57) 1 (14)
Other 0 2 (13) 0 0 0 0
Ileocaecal valve
present, n (%)
0 0 3 (17) 8 (40) 0 1 (14)
Mean (SD)
estimated
remaining small
bowel length, cm
137.7
(70.9)*
113.7
(79.8)*
52.2
(27.4)
39.2
(30.4)y
59.3
(44.4)z
49.3
(30.0)z
Mean (SD) PS
duration, year
7.1 (6.7) 5.1 (3.1) 6.2 (6.5) 6.1 (6.4) 6.4 (5.6) 7.2 (8.2)
Mean (SD) PS
volume, L/week
14.5 (9.6) 18.8 (7.9) 10.6 (5.8) 10.5 (5.3) 12.4 (7.1) 9.1 (3.9)
BMI¼body mass index; PBO¼placebo; PS¼parenteral support;
TED¼ teduglutide. *n¼ 15; yn¼ 19; zn¼ 6.
Conclusion: Patients with SBSIF in Group 1 had the highest baseline PS volume
needs and responded most and fastest to TED with PS volume reductions, com-
pared with patients in Group 2 or Group 3. This research was funded by Shire
International GmbH, Zug, Switzerland.
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Introduction: Sporadic non-ampullary duodenal epithelial tumors (SNADETs)
are rare, accounting for less than 1% of gastrointestinal neoplasms, and thus
the mechanism behind the pathogenesis and carcinogenesis of these neoplasms is
still poorly understood. However, with the overall increase of small bowel cancer
in recent years, there is an increasing need to clarify the morphology of
SNADETs. This study was conducted with the objective of identifying genetic
markers and pathways specific to superficial SNADETs through gene-expression
analysis.
Aims & Methods: This was a prospective pilot study on patients with a diagnosis
of superficial SNADETs who were treated at the Department of
Gastroenterology, Graduate School of Medicine, The University of Tokyo
Hospital, Tokyo, Japan. Before enrollment, all patients had undergone endo-
scopic evaluation to preclude ampullary lesions, and had a preoperative histolo-
gic diagnosis of either adenoma or adenocarcinoma. Patients with familial
polyposis were excluded. Immediately before resection of the target lesions, a
single biopsy sample from the duodenal tumor and a paired sample from the
surrounding normal duodenal mucosa were endoscopically obtained from each
patient, followed by RNA extraction. Gene expression profiling with an oligo-
nucleotide microarray was performed in a training set of 4 matched tumor-
normal tissue superficial SNADET pairs. Genes and pathways with consistent
differences between pairs were identified, followed by a set-level gene enrichment
analysis with a pre-valuated curated gene set. Results were confirmed with rt-
PCR in all other independent SNADET pairs.
Results: From Nov 2014 to Jan 2016, a total of 12 consecutive patients were
enrolled in this study. One patient was excluded due to a post-treatment diag-
nosis of familial polyposis. In a training set of 4 tumor-mucosa pairs,
626 probes (168 up-regulated, 458 down-regulated) which consistently demon-
strated over a 2-fold expression difference between tumor and normal mucosa in
all matched pairs were identified. Rt-PCR of genes most highly differentially
expressed between the tumors and normal mucosa was performed in the 4
pairs in the training set as well as 7 independent pairs. Consistent gene
expression patterns concurrent with microarray results were demonstrated
in all pairs, confirming the results of this study. Gene set enrichment
analysis of the training set using a curated data set demonstrated a strong asso-
ciation between SNADETS with colorectal adenomas (p5 0.00001) and APC
down-regulation (p5 0.00001). No other significant associations were
demonstrated.
Conclusion: Superficial SNADETs demonstrate gene expression characteristics
with a strong resemblance to colorectal adenomas. Gene expression
characterization of these lesions has also demonstrated the significant role of
APC down-regulation in the pathogenesis of SNADETs, suggesting that an
adenoma-carcinoma sequence similar to colorectal adenomas may be seen in
SNADETs. Further analysis of genes which may play a key role in the carcino-
genesis of these neoplasms is required.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: We established a new imaging technique, 3D computed tomo-
graphic (CT) enteroclysis, to explore the small bowel (1). In our hospital, this
examination is performed routinely to detect gross lesions in the small intestine.
In our study, we analysed the clinical performance of 3D CT enteroclysis to
evaluate its safety, feasibility, and usefulness for small intestinal neoplasias.
Aims & Methods: Data on 3D CT enteroclysis performed in our hospital from
January 2010 to March 2017 were reviewed. In 3D CT enteroclysis, the small
bowel was inflated with air using a nasoduodenal tube, CT images were taken,
and then 3D overviews, virtual endoscopy views, and virtual dissection views
were generated using a virtual colonoscopy system. Total volume of injected
air, intraintestinal pressure, and length of the depicted small bowel were
recorded. The images of small intestinal neoplasias were collected and compared
to intraoperative findings.
Results: One-hundred thirty-nine 3D CT enteroclysis were performed for 93
males and 46 females. The mean age was 49.2 y (17–87). Examinations were
performed for definite/suspected Crohn’s disease in 55, intestinal obstruction in
54, small intestinal neoplasias in 25, and others in 5 patients. Vomiting/belching
and abdominal pain (requiring pain medication) were noted in 10 and 5 patients,
respectively, but no additional treatments were necessary. The volume of air and
intraintestinal pressure were recorded in 77 examinations for patients without
previous resection of the small bowel. The mean total volume of injected air was
1872 656ml, the mean maximum intraintestinal pressure was 2.7 0.8 kPa, the
mean length of the depicted small bowel was 517 102 cm, and whole small
bowel tracing was achieved in 71.4% of these 77 examinations. Twenty small
intestinal neoplasias were depicted in 4 cases of submucosal tumors, 3 cases of
gastrointestinal stromal tumors (GISTs), in 3 cases of neuroendocrine tumors, in
2 cases of cancers, in 2 cases of lipomas, 2 cases of malignant lymphomas, 1 case of
metastatic cancer, 1 case of Peutz-Jeghers syndrome, 1 case of Peutz-Jeghers type
polyp, and 1 case of pyogenic granuloma. Surgery was performed for 12 cases; the
total length of the small intestine and estimated location of the lesion by 3D CT
enteroclysis were comparable to intraoperative findings in 9 cases (no measurement
in 3 cases). In a case of multiple GISTs, some of the lesions of 6–8mm in size were
missed and no lesion smaller than 4mm was depicted.
Conclusion: 3D CT enteroclysis can be performed safely, and the whole small
bowel could be examined in most cases. 3D CT enteroclysis can depict stenosis
and lesions bigger than 1 cm, measure the length of the small intestine, measure
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the size and locate the position of the lesions, and present objective information
for surgery and follow-up of small intestinal neoplasias. Therefore, 3D CT enter-
oclysis is a powerful new tool for diagnosis, pre-surgical evaluation, and follow-
up for small intestinal neoplasias.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Balloon-assisted enteroscopy is a well-established tool in the diag-
nosis and therapy of small bowel diseases. Ink tattooing of the small bowel is
used in some centers to mark pathologic lesions or the depth of small bowel
insertion.
Aims & Methods: The purpose of this study was to determine the safety, the
detection rate within a surgical operation or video capsule endoscopy and the
clinical relevance of ink tattooing during balloon-assisted enteroscopy (BAE).
Between 01.01.2010 to 31.12.2015 229 BAE were performed in 156 patients (pts)
at the endoscopy unit of Klinikum Augsburg. We performed a retrospective
analysis of all 81 (52%) patients who received an ink tattooing during BAE.
Results: Main indications for BAE were known angiodysplasia (37 pts), sus-
pected bleeding of the small intestine (32 pts) and anemia (19 pts). Other indica-
tions were known or suspected tumor of the small intestine (17 pts) and Crohn’s
disease (3 pts). In 27 patients no pathologic findings were found. In 41 patients an
active bleeding, angiodysplasia or hemangioma were found and further thera-
peutic interventions were performed. Tumor/polyps (11 pts), inflammatory
lesions (7 pts) and ulcerative diverticula (1 pts) were other findings. In all 81
patients ink tattooing of the small intestine was performed with no complica-
tions. 46 (57%) of 81 patients received a follow-up mainly due to re-bleeding. 5
Patients underwent surgery directly after enteroscopy with ink-tattooing and
therefore received no follow-up. In total 26 (32%) patients received a capsule
endoscopy after BAE at our hospital. The ink tattooing could be detected via
capsule endoscopy in 19 of these 26 patients (73%). The ink tattooing of the
previous antegrade BAE could be detected via retrograde BAE only in 2 of 11
(18 %) patients. Nine patients received a second ink-tattooing of the small intes-
tine within these examinations without any complications. Ink tattooing had no
clinical relevance or therapeutic consequence in 62 of the 81 (72%) patients
within the observation period. 5 of these 62 Patients received no further diag-
nostic or therapeutic steps due to their clinical situation. In 9 patients ink tattoo-
ing influenced the choice of approach (antegrade versus retrograde) for re-
enteroscopy after a video capsule endoscopy. In 7 patients the ink tattooing
was used for intraoperative localization and in 3 patients for intraoperative
localization as well as for enteroscopy. The intraoperative detection rate of the
ink tattooing was 100%.
Conclusion: Ink tattooing of the small intestine is a minimally invasive and safe
endoscopic procedure to mark the depth of scope insertion or a pathologic lesion
during balloon-assisted enteroscopy. It is a useful tool to avoid unnecessary
examinations and aids the intraoperative localization of pathologic lesions. A
complete enteroscopy of the small intestine via BAE from retrograde and ante-
grade is achieved rarely in our setting.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Small bowel tumours (SBT) are very rare and generally grow insi-
diously, with alarm symptoms such as obstruction and overt GIB often occurring
at a later stage of disease. The introduction of small bowel capsule endoscopy
(SBCE) has enabled earlier detection of SBT and has been shown to affect the
therapeutic course. However, the reported frequency of small bowel malignancies
diagnosed by SBCE is highly variable.
Aims & Methods: We aimed to review the frequency of small bowel tumours
diagnosed by SBCE in a high-volume tertiary centre, and to assess the clinical
presentation and outcome of patients. A retrospective review of the database in
our institution was undertaken. All patients who had undergone SBCE from
2011–2016 were identified. All patients had undergone SBCE using the standard
protocol. The Given SB3 Pillcam was used for the majority of procedures from
2014 onwards and the SB2 was used prior to 2014. All videos were analysed by
experienced gastroenterologists and reported using the Rapid reader software
system (Given Imaging, Covidien, Medtronic, Yoqneam, Israel). SBCE reports
for all indications were reviewed and all patients with reports suggestive of a
small bowel tumour were included initially. A chart review was then performed
and information was obtained on patient demographics, clinical presentation/
indication for SBCE, laboratory markers, previous endoscopic or radiological
procedures, further endoscopic or surgical interventions carried out, and final
histological diagnosis. Only patients who went on to have a histological diagnosis
of a small bowel malignancy were included in the final analysis.
Results: A total of 1670 SBCEs were carried out.The overall indications for
SBCE were as follows: suspected small bowel Crohn’s disease 34% (n¼ 568),
iron deficiency anaemia/obscure occult GIB 41% (n¼ 685), obscure overt GI
bleeding 16% (n¼ 267), non-specific abdominal pain 6% (n¼ 100), known or
suspected polyposis syndrome 2% (n¼ 33) or Coeliac disease 1% (n¼ 17).
In total 1% (n¼ 19) of SBCE reports identified a possible small bowel tumour.
Of these, a final histological diagnosis of a small bowel malignancy was made in
14 patients. Of the 5 patients with a benign diagnosis, one patient was diagnosed
with myoepithelial hamartoma, two patients an adenomatous polyp, one a lym-
phangioma, and one ganglion cells only. Of the 14 patients diagnosed with a
small bowel malignancy, the majority, 71% (n¼ 10) were female and the mean
age was 58 years (18–90). The indication for referral in 12 (86%) patients was
obscure gastrointestinal bleeding, with occult bleeding in 57% (n¼ 8) and overt
bleeding in 29% (n¼ 4). Only one patient was referred for SBCE due to abnor-
mal imaging and the other patient had persistent diarrhoea. The mean length of
time from presentation to diagnosis of their small bowel tumour by SBCE was
18.8 months (16–24). Patient’s mean Haemoglobin at diagnosis was 10.6 g/dL
(7.4–12.4). Only 3 patients had a recognised risk factor,2 with coeliac disease and
1 patient had previous colorectal cance. In 79% (n¼ 11) of all patients, SBCE
was the first investigation suggestive of a small bowel tumour. In all, 7 (50%)
patients underwent cross sectional imaging prior to SBCE, of which 3 (42%) had
a reported no small bowel abnormalities. All patients had undergone at least one
negative upper and lower endoscopy prior to referral, and SBCE was the third
investigation in 50% (n¼ 7) of patients. After SBCE, 60% (n¼ 8) of patients
underwent a double balloon enteroscopy (DBE) for further evaluation of find-
ings and to obtain tissue samples. In terms of histological diagnoses, adenocar-
cinomas were found in 43% (n¼ 6), Neurendocrine tumours in 29% (n¼ 4),
Gastrointestinal stromal tumours (GISTs) in 14% (n¼ 2), and lymphoma in
14% (n¼ 2). All patients eventually underwent surgical resection of their small
bowel tumours and 80% (n¼ 11) patients remain well at present, after a mean
follow up time of 15.2 months (2–36).
Conclusion: SBT are rare but accounted for 1% of significant SBCE findings in
our cohort. The lack of concordance between SBCE and cross sectional imaging
suggests this modality should remain an early diagnostic test in OGIB.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The western diet (WD) high in fat and fructose is considered one of
the most relevant cause of metabolic disorders and cardiovascular diseases
(CVD). The aim of this study was to evaluate whether daily vitamin D3 supple-
mentation is able to modulate hepatic steatosis, or restore insulin resistance and
the metabolic alterations contributing to CVD and hearth failure (HF) caused by
a westernized diet, in a rat model without specific vitamin D deficiency.
Aims & Methods: Eighteen adult male Wistar rats were divided into 3 groups,
each of 6 rats, fed with: Group 1: Standard Diet, 3.3 kcal/g (SD); Group 2:
Western Diet, 5.6 kcal/g, (WD) containing 13 IU/day/rat of vitamin D3; Group
3: Western DietþVit D (WD Vit D) containing 23 IU/day/rat of vitamin D3.
The experiment was conducted for 6 months. Standardized tail-cuff blood pres-
sure (BP) measurements of conscious rats and transthoracic echocardiography
were performed in basal condition (Time 0), and after 3 and 6 months of diet.
Hepatic steatosis and collagen myocardial fibrosis were assessed using standard
methods. Serum insulin and 25(OH)D3 concentrations were determined using
rat-specific ELISA kits. Insulin resistance was determined according to the
Homeostasis Model of Assessment (HOMA-IR) method.
Results: In WD rats the percentage of hepatocytes with steatotic vacuoles was
61%, while in WDVitD group was only 27%. In WD group HOMA-IR
was significantly higher than in SD (41.9 8.9 vs 6.17 1.3, p5 0.01) and it
was reduced by vitamin D supplementation in WDVitD group (41.9 8.9 vs
19.4 5.2, p5 0.05). At baseline, no differences in systolic blood pressure
(SBP) were detected among the three groups showing normal systolic blood
pressure. SD did not increase SBP, significantly, during the study period. On
the contrary, WD, enhanced SBP by 27 12% p5 0.001 at 3 months, and by
47 11%, p5 0.001 at 6 months. At the end of the study, SBP resulted to be
higher in WD group (117 3mmHg) compared with both SD (84 3mmHg,
p5 0.001) and with WDVit.D (101 4mmHg, p5 0.01). During the study
period, WD group showed a significant increase of left ventricular mass
(LVM) (52 25% at 3 months p5 0.05, and 123 43% at 6 months
p5 0.001, vs basal conditions,). Supplementation of VitD abolished the WD-
induced increase of LVM (25 19% at 3 months, and 34 20% at 6 months,
p5 0.05 vs baseline respectively). At the end of the study LVM resulted to be
higher in the WD group in comparison to both SD and WDVitD groups, while
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no difference was detected between SD and WDVit.D. However, some collagen
staining resulted still present in WDVitD rats.
Conclusion: These results suggest that a daily supplementation of vitamin D3 is
able to improve insulin sensitivity, and to prevent diabetes. Vitamin D3 also
reduced hepatic steatosis and prevent cardiac alterations such as the increase
of systolic blood pressure and left ventricular hypertrophy in WD rats.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Gastric balloons (IGB) are an emerging option for overweight and
obese patients with a body mass index (BMI) greater than 31 kg/m2 and they
provide greater efficacy with lower risks than do conventional surgical proce-
dures. The balloon treatment is based on gastric space-occupying effects that
increase the feeling of satiety and may also effect gut neuroendocrine signaling.
However, widespread use of current generation IGBs has been limited by several
factors: placement and removal endoscopies require sedation, special training
and equipment; patients lost to follow-up are susceptible to IGB deflation and
unplanned passage into the gastrointestinal tract. The ElipseTM is the world’s
first procedureless gastric balloon that not require endoscopy or anesthesia.
Aims & Methods: We conducted a study to prospectively analyze the safety and
effectiveness of IGB ELIPSE in overweight adults. Six patients, 1 male and 5
female (average age 40, mean BMI¼ 40 kg/m2), were included in this study. Each
patient swallowed ElipseTM balloon intended to remain in the stomach for 16
weeks. Each balloon was filled with 560mL of filling fluid. Patients returned
every 2 weeks for abdominal ultrasound which documented the correct position-
ing of the device. All patients were followed up by a nutritionist with a specific
semiliquid diet.
Results: All 6/6 patients successfully swallowed the device. There were no major
adverse effects. All 6 patients had a significant weight loss (about 16 Kg). In all of
the patients, the balloon remained full throughout 16 weeks, self-emptied, and
were passed spontaneously without needing endoscopic removal.
Conclusion: This study demonstrates the efficiency, security and simplicity of
the ElipseTM system. Moreover, we highlighted the non necessity of deep seda-
tion and use of invasive endoscopic examinations for positioning and removal of
the IGB.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: There is evidence that the level of nutrition is a major determinant
for the outcome of hospitalized patients. The Malnutrition Universal Screening
Tool (MUST) is a five-step screening tool using the Body Mass Index (BMI),
unintentional weight loss before admission and the effect of acute disease on
subject’s nutritional status to identify adults who are malnourished, at risk of
malnutrition or obese. It also includes management guidelines which can be used
to develop a care plan. Although it is simple and quick, its use varies widely
among different health care settings.
Aims & Methods: We aimed to evaluate the need of nutritional support consulta-
tion, the rate of MUST tool use by the treating physicians and the rate of
nutritional support services utilization in a tertiary Greek hospital. This was a
prospective, cross-sectional, nutritional service-utilization, chart-review study
of hospitalized patients with follow-up until discharge, in a tertiary 500 beds
hospital in Athens, Greece. We reviewed data of patients admitted during
three consecutive hospital on-call days in March 2017 regarding the number of
patients at need for nutritional consultation during hospitalization and at
discharge. Intensive care, psychiatric, pediatric, obstetrics and day clinic admis-
sions were excluded. We used data from patient’s MUST tool (in case of absence
of these data, we calculated the MUST score using subject’s data) to identify
patients at high risk of malnutrition and we used BMI to identify overweight and
obese subjects. We measured the utilization of the nutrition department services
according to the actual consultations.
Results: We included data from 461 patients (50% males, aged 67 19 yrs).
MUST evaluation for malnutrition was not available in any of the reviewed
charts. We therefore calculated the MUST score using the available data in the
charts. There were 73 (15.8%) overweight-obese and 85 (18.4%) at high risk of
malnutrition patients admitted at the internal medicine (n¼ 127) and surgery
(n¼ 31) sections of the hospital. Nutritional consultation was requested in
4 (3.1%) and 1 (3.2%) internal medicine and surgery patients, respectively by
the treating physician during hospitalization. Among the 383 patients discharged
at the end of our observation, there were 72 (18.8%) overweight-obese and
46 (12%) at high risk of malnutrition patients. Nutritional consultation was
recommended in 24 (6 obese, 15 undernourished and 3 patients with low
MUST score) of them.
Conclusion: MUST -a simple screening tool for malnutrition- is not used by the
medical staff and nutritional support services are significantly underutilized in a
tertiary Greek hospital.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Bariatric surgery is an effective treatment for morbid obesity.
In Taiwan, the numbers of patient who received bariatric surgery increased
gradually. However, for long-term follow-up, nutritional deficiency may develop
in post-bariatric (metabolic) surgery patients, especially in patients who received
mal-absorptive or combination procedure. Deficiency of nutrition may cause
anemia, peripheral neuropathy, secondary parathyroidism and osteoporosis.
Follow-up of the nutritional status for patients after bariatric surgery is an
important issue.
Aims & Methods: The aim of our study is to evaluate the change of Vitamin D
and bone Mineral Density after bariatric surgery in Chinese population. This
prospective cohort study included 50 patients (ranged from 20 to 65 years old)
who received bariatric surgery at one teaching hospital in Taoyuan, Taiwan.
Patient with osteoporosis before surgery were excluded in this study. Baseline
(2012–2014) and one year after bariatric surgery (2013–2015), venous blood was
collected from each patients for assessment of the Calcium, Vitamin D and
parathyroid hormone (PTH) levels. BMD (g/cm2) was also measured at
lumbar spine (L2–L4) by dual energy x-ray absorptiometry (DEXA).
Results: Among 50 patients, 15 patients received laparoscopic sleeve gastrectomy,
24 patients received laparoscopic mini-gastric bypass (MGB), 5 patients
received laparoscopic Roux-en-Y gastric bypass (RYGB) and 6 patients received
laparoscopic duodeno–jejunal bypass with sleeve gastrectomy (DJB-SG).
The characteristic of the study population was shown as table 1. The differences
of mean for calcium, vitamin D, PTH and BMD after bariatric surgery
were 0.16mg/dl (P¼ 0.03), 4.2 ng/ml (P5 0.01), 8.6 pg/ml (P¼ 0.06) and
0.04 g/cm2 (P¼ 0.14) respectively.
Table 1: Characteristics of study population one year after bariatric surgery
LSG MGB RYGB DJBSG OVER ALL
N 15 24 5 6 50
Age, years 34.7 (7.4) 37.4(11.7) 41.4(14.1) 44(10) 37.8(10.5)
Sex(M:F) 7:8 5:19 2:3 3:4 17:33
BMI(kg/m2) 29.8(4.7) 27.6(4.4) 27.9(2.9) 24(2.4)
CA(mg/dl) 9.6(0.3) 9.1(0.3) 9.2(0.4) 9.3(0.4) 9.5(0.4)
PTH-I(pg/mL) 63.8(21.3) 70.4(25.9) 73.1(4.2) 50(14) 62(29.4)
VIT.D (ng/ml) 19.4(7.7) 14(6.9) 12.9(8.6) 16.9(5.3) 15.6(7.5)
VIT.D insufficiency
(510 ng/ml)
1(6.7%) 8(33.3%) 3(60%) 0 12(23.5)
VIT.D deficiency
(55.3 ng/ml)
0 0 1(20%) 0 1(2%)
BMD(g/cm2) 1.11(0.25) 1.15(0.23) 1.18(0.26) 1.11(0.19) 1.15(0.17)
Conclusion: One year after bariatric surgery, the prevalence of osteoporosis and
osteopenia was low. The serum Vitamin D level increased significantly but no
significant change of BMD was noted. Further longitudinal studies are war-
ranted to clarify the long-term effect of bariatric surgery on BMD in Chinese
population.
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Introduction: The intragastric balloon has been used for more than 20 years in
Brazil as an endoscopic method for assisting weight loss, and some intercurrences
were observed during more than 10,000 procedures performed. With the assis-
tance of a multidisciplinary team the results have been satisfactory.
Aims & Methods: To assess the efficacy and complications of the weight loss with
IGB in patients seen at the 07 private centers. A total of 10,255 patients with IGB
implanted from 1997 to 2017 were analyzed from a prospective fed databank. A
liquid filled IGB with a volume in-between 620 to 700ml was used. Initial BMI
started at 27 kg/m2 (as approved by Brazilian health authorities) and were fol-
lowed up by a multidisciplinary team during implant. IGB maximum period
implant was 09 months. Statistical analysis was performed according to sex
and degree of excess weight (overweight and grade I, II and III). Data were
analyzed using Student t-test, and and Tukey post-test. The level of significance
was set at p5 0.05.
Results: 492 patients (4,8%) were excluded from the final analysis associated with
weight loss: 226 (2,2%) due to early removal–These were analyzed in relation to
the previous consultation with psychologist and 94% of them did not make a
psychological evaluation before the procedure, 158 (1.54%) due fail on weight
loss or weight gain–These were analyzed in relation to follow-up with nutritionist
and 88% did not undergo nutritional monitoring during the use of IGB, 108
(1.05%) due to incomplete data. There were also spontaneous hyperinflation on
0.99% (n¼ 101) and balloon spontaneous deflation or leakage in 0.82% (n¼ 84).
Incidence of complications not leading to removal were 6.65% (n¼ 682).
Complications other happened as fungal contamination in in 7.9% (n¼ 810);
Wernick Korsakoff syndrome 0.01% (n¼ 2), pregnancy during implant period
was 1.2% (n¼ 123) and Dieulafoy lesion 0.009% (n¼ 1). The incidence of com-
plications with IGB removal was 0.05% (n¼ 6): gastric perforation. On the 9,763
remaining patients, 7.615 (78%) were women and 2.148 (22%) were men. Mean
age was 31.13 years. The patients showed a significant weight loss, with a sig-
nificantly lower final BMI (27.16 8.42 kg/m2; range: 15.71–34) than the initial
BMI (33.42 6.62 kg/m2; range: 27–79.35). The mean Weight Loss was
16.98 kg (þ/16.8 kg). Percent EW L was higher in the overweight group
(129.92%EWL), followed by obesities grades I (73.64%), II (57.85%) and III
(41.33%) sequentially. A total of 5.2% (66/1,268) of the patients followed up for
18 months after withdrawal of the IGB were submitted to bariatric surgery.
Conclusion: The intragastric balloon has been established as an valid endoscopic
therapeutic option for weight loss, especially in patients with overweight and
obesity grades I and II and multidisciplinary team follow-up is mandatory for
successful treatment.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The weight regained has been a described growing problem in
patients after bariatric surgery. This weight regained is multifactorial and asso-
ciated with dilation of Gastrojejunostomy (GJ). For the patients with significant
weight regain some revisional procedures had be attempted and more recently
endoscopic revisional procedures had being described.
Aims & Methods: To evaluate the safety and effectiveness of argon plasma coa-
gulation (APC) decreasing the diameter of the gastroenteric anastomosis in
patients who have undergone RYGB for morbid obesity and regained weight
associated to dilation of the GJ.From Jan-2014 to April-2017 554 RYGB subjects
with weight regain a dilated anastomosis (418mm) and at least 2 years from
procedure were submitted APC application. In relation to the anastomotic dia-
meter, the majority of studies use a diameter of more than 20mm to define
anastomosis dilation, although some studies use smaller diameters such as
12mm, similar to that created manually in the gastrojejunal anastomosis using
a 36 Fr Fouchet bougie. In the patients in the present study, the minimum cross-
section diameter was 18mm and the maximum measured in the first session
40mm. This anastomotic diameter was measured using a 33-mm long
Olympus articulated device. Interval between an APC session was 60 days
with a maximum of 03 applications. APC set was at 2–3L/m with 65–85W. GJ
diameter target was 8–12mm estimated with pre-measured grasper. At first APC
session, pre-op weight and BMI, post-op weight nadir, actual weight and BMI
and estimated diameter of GJ were the variables collected. Complications during
treatment were also collected. In the present study, psychological and nutritional
evaluations were performed before APC and during treatment and physical
activity was strongly recommended. Data were analyzed with descriptive statis-
tics, student’s t test and Spearman correlation.
Results: Of the 554 patients, 79.06% were women and 20.94% were men.
Average time between bariatric surgery and the first APC was 96.35 months
(42.17) and average weight regained in this interval was 22.08 kg (11.05).
The mean diameter of the anastomosis was 24.78mm (6.04) and the average
number of APC sessions were 1.78 times (0.61). The average reduction of
anastomotic diameter was 14.86mm (7.24) and the final average diameter
was 11.79mm (3.89). The average weight loss between the first and last APC
was 13.37 kg (7.82) and the average decrease of BMI was 4.59 kg/m2 (2.78).
122 patients (22.02%) did not achieve the target GJ diameter and 05 patient
(0.9%) did not lose weight even with the desired GJ diameter. From the 146
subjects (26.36%) followed up to 12 months, the weight regain was less than 20%
of the weight loss. Of the 554 patients APC, 51 (9.2%) required dilatation bal-
loon due to symptomatic stenosis at least once. No further complications were
reported.
Conclusion: Argon Plasma Coagulation (APC) has been shown to be an effective
and safe endoscopic technique for the reduction of gastro enteric anastomosis in
patients undergoing bariatric surgery who have regained weight with dilation of
the anastomosis. The reintroduction of the patient to the multisciplinary team is
mandatory in cases of weight regain and loss to postoperative follow-up.
A psychological and/or psychiatric evaluation is mandatory, as well as nutri-
tional therapy and encouragement of physical activity. The monitoring of food
intake and body weight, closer follow-up of the operated patients, appropriate
choice of technique according to the patient and the experience of the surgeon,
and a good learning curve are all factors that can reduce the failure rate of
bariatric surgery. The reintroduction of the patient to the multidisciplinary
team is mandatory if better results and sustainable weight loss and comorbidity
control are to be obtained.
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Introduction: With the aging of the population, the incidence of obesity has also
increased among the elderly. However, there is a higher incidence of severe
comorbidities in this population comparing to adults, which often makes baria-
tric surgery unfeasible. In this scenario, treatment with the intragastric balloon
(IGB) may be an interesting option.
Aims & Methods: We aimed to assess the efficacy and complications of obesity
treatment in the elderly using a non adjustable IGB. A total of 77 patients were
analyzed. The minimal initial body mass index (BMI) was 28 kg/m2. The level of
significance was set at p5 0.05.
Results: 58 patients were women (75.3%). Mean age was 64.26 (60–80) years. Ten
patients had no comorbidities, 52 had hypertension, 45 had dyslipidemia, 32 had
insulin resistance, 12 had tipe II diabetes, and 10 had isquemic heart desease.
There was no major complications. Results are shown on table 1. The treatment
success rates according to the following criteria: 10% total body weight loss
(TBWL) and 25% excess weight loss (EWL) were 96.11% (74 patients) and
A618 United European Gastroenterology Journal 5(5S)
98.7% (76 patients) respectively. 30 patients reached a normal body mass index
(BMI) (23–28 kg/m2) according to the Pan American Health Organization
(OPAS). Elderly shows a higher BMI reduction (p¼ 0.0002) and %TBWL
(p¼ 0.0003) than adults.
Table 1
n¼ 77
Body weight(kg)
Baseline 103.37 17.14
Final 81.66 15.71
Reduction 21.71 7.58
%TBWL 21.07 6.07
BMI(kg/m2)
Baseline 37.89 5.41
Final 29.86 4.76
Reduction 8.03 2.88
Excess weight(kg)
Baseline 35.53 16.98
Final 13.82 15.49
%EWL 69.27 30.01
*p5 0.0001 for all comparisons between values at baseline and at the end of the
study. IGB(intragastric balloon); TBWL(total body weight loss); EWL(excess
weight loss)
Conclusion: Endoscopic treatment of obesity with an IGB shows to be an excel-
lent therapeutic option for the elderly.
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Introduction: Non-coeliac gluten sensitivity (NCGS) is a new entity with
unknown prevalence and mechanisms, and there is a need for a standardized
procedure to confirm the diagnosis. The objective of this study was to character-
ize the response to a gluten challenge, when performed according to the updated
Salerno criteria.
Aims & Methods: Twenty patients (14F/6M, age range: 21–62 y) with suspected
NCGS, without coeliac disease and wheat allergy, were included while on a
gluten-free diet. All patients went through four periods of double-blinded pro-
vocation with gluten and placebo containing muffins. They were instructed to eat
two muffins a day (11 g gluten) for four days, followed by a three days’ wash-out.
Gastrointestinal symptoms were recorded with questionnaires at baseline and
after each provocation, while fatigue and quality of life were registered at base-
line and end of the trial.
Results: Four out of twenty patients (20%) correctly identified the two periods
when they received muffins containing gluten, hence were diagnosed with NCGS.
The diagnosed group tended to show higher symptom scores than the not-diag-
nosed group both at baseline, after gluten exposure and after placebo, but no
clear difference was seen in symptom change after provocation with gluten and
placebo. The not-diagnosed group showed more severe symptoms with placebo
than with gluten (p¼ 0.029). Symptom severity at baseline was significantly cor-
related with fatigue (r¼ 0.63, p¼ 0.003) and reduced quality of life (r¼ 0.76,
p¼ 0.0001).
Conclusion: This randomized, double-blind placebo-controlled challenge with
gluten diagnosed four patients with NCGS according to the Salerno criteria.
However, according to the symptom registrations there are no clear difference
between the diagnosed and the not-diagnosed group, or between symptoms after
gluten provocation and placebo, indicating no specific effect of gluten in a group
of patients with suspected NCGS.
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Introduction: By targeting specific receptors into the vascular system, bile acids
(BA) are cholesterol derivatives that are now considered as hormones. BA reg-
ulates the basal energy expenditure and gluco-lipidic metabolism. In animal
models of atheroma developement (ApoE -/- and Ldl -/- mouse model) a power-
ful anti-atherosclerotic effect of circulating BA has been evidenced: BA are
metabolites of the gut microbiota, suspected to play a role in the development
of atherosclerosis. This study examined whether variations in BA or in the gut
microbiota composition can be describe in the human Coronary Artery Disease
pathophysiology.
Aims & Methods: Consecutive patients undergoing coronary angiography
between February and May 2015 were enrolled. To avoid physiological or
induced variations in circulating BA or in the gut microbiota, highly restrictive
exclusion criteria were applied. Circulating and fecal BA were quantified by high
pressure liquid chromatography and tandem mass spectrometry. The fecal micro-
biota composition was assessed by 454 pyrosequencing of the total fecal bacterial
DNA.
Results: 80 patients were prospectively included of 406 screened, and divided in
two groups: with (n¼ 45) and a group without (n¼ 35) CAD. The mean serum
concentration of total BA was 1.02 0.16mmol/l in patients with, versus
2.16 0.38mmol/l in patients without CAD (P¼ 0.005). This decrease, (adjusted
for gender and age) was an independent predictor of CAD (odd ratio¼ 0.51;
95% confidence interval 0.31, 0.85; P¼ 0.01). The BA concentrations in feces
were similar in both groups. There was no group-specific pattern in the fecal
microbiota. In a subgroup of 17 patients, one month of statin therapy increased
the serum BA concentration from 0.68 0.08 to 1.37 0.213 mmol/l; P¼ 0.01).
Conclusion: There was no specific microbiota signature associated with CAD.
However, the decreased serum BA concentration was a strong predictor of CAD
in humans. With respect to the powerful anti-atherosclerotic effect of BA in
animal models, and their role in human lipid metabolism and diabetes, this
study unraveled the existence of a new metabolic disturbance associated with
CAD.
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Introduction: The low-FODMAP diet (LFD) is used to treat patients with irri-
table bowel syndrome (IBS) even if some nutritional concerns have been raised. It
starts with an elimination phase and is followed by a reintroduction phase to
clearly detect the ‘‘symptom trigger’’ foods in order to suggest a definitive and
less restrictive diet tailored to the patient.
Aims & Methods: The aims of this study were to evaluate: 1) the effects of
FODMAP reintroduction on a) body composition and nutritional status, using
Bioelectrical Impedance Vector Analyses (BIVA), b) abdominal symptoms, c)
quality of life, d) anxiety/depression, e) sleep quality. 2) if the patients’ perception
of the ‘‘trigger’’ foods was accurate.
66 IBS patients (54F, 12 M; 44.8 13.0 yrs.) started (T0) a LFD for 8 weeks (T1)
and followed a 9–14 week reintroduction period (T2). They underwent blood
tests at T0 and T1. BIVA, anthropometric data, IBS-Symptom Severity Score,
Bristol Stool Chart (BSC), SF36, Hospital Anxiety and Depression Scale and
Pittsburgh Sleep Quality Index were performed at T0, T1 and T2. The patients
were monitored by a nutritionist to verify their compliance.
Results: Neither change of blood tests at T1 nor variations of anthropometric
data and BIVA were reported at T1 and T2 in comparison with T0. A significant
improvement in abdominal symptoms (IBS-SSS), anxiety and quality of life, was
recorded at T1, this remaining unchanged also at T2 (p5 0.0001). Depression
improved at T2 (p5 0.01 vs. T0). Sleep quality improved at T1 (p5 0.05 vs. T0)
and at T2 (p5 0.001 vs.T0). Normal BSC feces were reported by 38 patients at
T0 to 60 patients both at T1 and T2. The degree of symptom relief with the diet
was 1.5 0.6 at T1 and 1.6 0.7 at T2 and the degree of satisfaction was high
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both at T1 (8.4 1.6) and T2 (8.2 1.7). When starting, LFD patients considered
as trigger foods lactose (67%), fructans (27%), fructose (17%), galacto-oligosac-
charides (GOS) (17%) and polyols (3%); the reintroduction phase (T2) enabled
us to detect lactose in 70%, fructans in 30%, fructose in 37%, GOS in 33% and
polyols in 27%, as real triggers. The agreement (Cohen’s kappa) was moderate
for lactose (k: 0.50), fair for fructans (k: 0.39) and fructose (k:0.32) and poor for
polyols (k: 0.16) and GOS (k: 0.01).
Conclusion: Not only did reintroduction not affect the improvements achieved
during the elimination phase, but it also precisely identified the foods responsible
for the clinical manifestations. This enabled us to suggest a personalized diet for
the patients. The real role played by FODMAPs in generating symptoms was
abundantly underestimated and misunderstood by our patients. This underlines
the fact that LFD has to be administered and carried out under the guide of an
expert nutritionist.
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Introduction: Fructose malabsorption (FM) is a frequent finding in patients with
abdominal symptoms due to high levels of fructose in Western diets. The role of
monosaccharide transporter dysfunction in the small intestine is incompletely
understood. The aim of this study was to investigate the histoanatomical distri-
bution of the main fructose transporter GLUT5
Aims & Methods: The study included 257 patients with FM diagnosed by hydro-
gen breath test and grouped according to the response to a fructose-free diet. 42
healthy individuals and 31 patients with coeliac disease (CD) served as control.
The fructose breath test was done with 50 g fructose. Fructose malabsorption was
defined as an increase of 20 ppm of endexpiratory hydrogen. Formalin-fixed and
paraffin-embedded duodenal biopsy specimens were obtained in all cases.
Histology was assessed using hematoxylin and eosin stained tissue sections.
Expression of GLUT5 was studied by immunohistochemistry. Expression pat-
terns of GLUT5 were correlated with clinico-pathological patient characteristics.
Results: The expression of GLUT5 did not differ significantly between patients
with FM complete diet responders (n¼ 183) and healthy controls (n¼ 42). Also
patients with FM responding to a fructose free diet did not differ in GLUT5
expression or in max. H2 increase and AUC measured in fructose breath testing
from patients not responding to the diet (n¼ 40). However, in patients with CD
(n¼ 29) significant differences in GLUT5 expression were found compared to
patients with FM and healthy controls (p¼ 0.009). The severity of CD assessed
by the Marsh score significantly correlated with the GLUT5 expression (rs¼ -
0.563, p¼ 0.001)
Conclusion: Changes in GLUT5 expression may not cause symptoms in adult
patients with FM. The symptoms induced by FM could be associated with
mechanisms known in the pathology of irritable bowel syndrome. However, in
secondary malabsorption decreased GLUT5 expression was detected. Further
investigation is needed to understand the essential factors in FM and the influ-
ence on functional gastrointestinal disorders.
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Introduction: Previous studies have shown a reduction of gastrointestinal symp-
toms in patients with disorders of gut-brain interaction (FGID) when following a
diet low in FODMAPs. Symptom relief due to a low FODMAP diet has espe-
cially been investigated in patients suffering from irritable bowel syndrome (IBS)
and has proven to reduce gastrointestinal symptoms in up to 86% of patients
with IBS. In addition, there is evidence for an association between gastrointest-
inal symptoms and joint hypermobility (JH). However, there is no clear data
regarding response rates to a diet low in FODMAPs in patients suffering from
JH. In this study we aimed to assess and compare the response to a diet low in
FODMAPs in JH positive and JH negative patients with FGIDs.
Aims & Methods: Data of patients presenting with FGID at the tertiary ambu-
latory functional bowel clinic between January 2015 and July 2016 were ana-
lyzed. FGIDs were diagnosed according to Rome III criteria. JH was assessed by
physicians using Beighton score and rated positive for scores 4/9 points.
Patients received professional nutritional counseling on a diet low in
FODMAPs. A global symptom response was assessed by a professional nutri-
tionist after 4 to 6 weeks following a low FODMAP diet.
Results: Of all 84 patients screened for JH, 62 (73.8%) were female and 22
(26.2%) were male. Median age was 35 [range 18–79] years. Females were
more likely to exhibit JH compared to males (38/62 [61.3%] vs. 6/22 [27.3%];
p¼ 0.006). Global symptom response rate to a diet low in FODMAPs was 64/84
(76.2%). Our data showed significantly better response to a low FODMAP diet
in JH negative patients than in JH positive patients (36/40 [90.0%] vs. 28/44
[63.6%], p¼ 0.005, ITT). Response of 7 patients was unknown because of
early therapy discontinuation before nutritional re-counseling. When excluding
7 patients with therapy discontinuation from our calculations, the difference in
diet response between JH negative and JH positive patients remained significant
(36/39 [92.3%] vs. 28/38 [73.7%]; p¼ 0.036).
Conclusion: Our data indicate an association between global symptom response
to a diet low in FODMAPs and joint hypermobility status in FGID patients. An
underlying structural pathology or different pathophysiological factors (motility,
intestinal permeability) causing gastrointestinal symptoms in JH positive patients
and limiting response to low FODMAP diet should be considered. Our findings
represent a further step towards pathophysiological features in FGIDs and might
help to select patients for individually appropriate therapies.
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Introduction: Gastrointestinal symptoms are often associated with dietary intol-
erances and are common in the developed world consuming a western diet low in
fiber.
Aims & Methods: To determine the effect of a high-sugar, low-fiber diet on GI
symptoms, small intestinal bacteria, and duodenal physiology. This is a prospec-
tive single-center study. Healthy adults with baseline fiber intake 14 g/1000
calories/day; 510% daily calories from added sugar; 5 servings of fruits and
vegetables/day; and 13% daily calories from saturated fat were recruited.
Exclusion criteria included known GI disease or symptoms, antibiotic/probiotic
use within 4 weeks of the study, pregnancy, and vulnerable adults. At baseline
visit, participants completed a symptom and demographic questionnaire
and underwent esophagogastroduodenoscopy (EGD) with duodenal biopsies
and aspirates. Symptoms assessed included: constipation, straining, incomplete
evacuation, hard stools, abdominal pain associated with bowel movements, diar-
rhea, bloating, nausea/vomiting, heartburn, fatigue, and appetite. All partici-
pants consumed a 7-day standardized diet with typical United States
macronutrient calorie distribution: 50% carbohydrates, 35% fat, 15% protein.
The diet was low in fiber (510 g/1000 calories/day) and high in simple sugar
(50% daily carbohydrates). After dietary intervention, participants filled out
follow up questionnaires and underwent repeat EGD with duodenal biopsies and
aspirates. Before and after the diet, quantitative aerobic and anaerobic cultures
were performed on duodenal aspirates. Duodenal biopsies were mounted in an
Ussing chamber. Intestinal permeability was evaluated using transepithelial elec-
trical resistance (TEER) and FITC flux (4KDa; a measure of paracellular trans-
port). Secretory responses were quantified in voltage clamp mode by measuring
baseline short circuit current (Isc) and change in Isc (Isc) in response to increas-
ing concentrations (0.003–300 mM) of serotonin (5-HT) on the submucosal side.
These measurements were repeated after the dietary intervention. Data are pre-
sented as mean SEM. Data were analyzed using paired-t test unless specified
and p5 0.05 was considered significant.
Results: A total of 10 participants (5 female; median age 26; 70% Caucasian)
were recruited. Average BMI was 23.1 kg/m2. At baseline, all participants were
asymptomatic. After dietary intervention, all patients endorsed at least one
new symptom and 9/10 participants endorsed multiple (2) new symptoms. At
baseline 4/10 participants had positive duodenal cultures (4 100,000 CFU/mL,
anaerobic) despite having no symptoms. Of the 6 who had no growth initially,
1 developed bacterial overgrowth following intervention. There was no signifi-
cant difference in TEER (26.45 1.98 vs 26.18 2.45 Ohms/cm2), FITC flux
(217 34.72 vs 217.6 42.57 ng/ml) or baseline Isc (48.27 6.39 vs 51.58
6.83mA/cm2) before and after dietary intervention. Interestingly there was a
significantly lower Isc response to increasing concentrations of 5-HT after diet-
ary intervention (P5 0.05, two-way ANOVA).
Conclusion: A low-fiber, high simple sugar diet led to gastrointestinal symptoms
in participants who normally consume a high-fiber diet. This was associated with
a significant decrease in 5-HT evoked secretory response in the duodenum, sug-
gesting a potential role for dietary modulation of host serotonergic pathway.
There was no correlation with quantitative bacterial cultures and there was no
overall significant change in intestinal permeability. Diet may mediate these
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effects via a qualitative change in gut bacteria but this still needs to be
determined.
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Introduction: Recently roles of gut hormons on appetite control have been
known. Among then, CCK is well known to suppress appetite and gastric motir-
ity. On the other hand, patients of functional dispepisia (FD) have hyper sensi-
tivity to CCK. And revels of CCK inbrad was shown to be high in FD patients.
In FD patients, stress have important roles of pathogenesis of the disease.
Aims & Methods:We undertook to clarify whether stress influences the actions of
cholecystokinin (CCK) on appetite and gastric emptying. As stress, we gave
restraint stress, corticotropin-releasing factor (CRF) or urocortin1 (UCN1) injec-
tion intraperitneally (IP). We also examined the effects of CCK and restraint
stress on c-Fos expression in the neurons of appetite center of the brain. In the
gastric emptying study, SD rats were fasted overnight. The amounts of the mix-
ture (food and glass beads) left in the stomach were measured at 2 hours after the
perorally injection of mixed food, and gastric emptying rate was calculated. In
the study on appetite, CCK was IP injected and the amounts of food was mea-
sured at 1 and 2 hours after the injection. In some experiments, CRF or UCN1
was IP injected and the interaction with CCK on food intake was examined. In
another study, restraint stress was given to rats and the interaction with CCK
was evaluated. To study the involvement of brain in the interaction between
CCK and stress, c-Fos expression in the neurons was examined and evaluated.
Results: CCKdose-dependently inhibited gastric emptying. CCK dose-depen-
dently inhibited food intake during 1 hr and 2 hr. CRF (10mg/kg rat) significantly
inhibited food intake. However, there was no interactive action between CCK
and CRF on food intake. UCN1 (3 nmol/kg rat) inhibited food intake at 1 and 2
hours. There was an synergistic action between CCK and UCN1 on food intake.
Restraint stress amplified suppressive effect of CCK on gastric emptying and
food intake. C-fos expression of the neurons in the nucleus of soritary tract
(NTS) and paraventricular nucleus of hypothalamus (PVN) by CCK was ampli-
fied by the addition of restraint stress.
Conclusion: The result suggests that stress might amplify anorexic effects of CCK
through the activation of satiety center of the brain that might be the possible
pathogenesis for postprandial distress syndromes of FD.
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Introduction: Cholecystokinin (CCK) and peptide tyrosine-tyrosine (PYY) have
been known to suppress appetite and gastric emptying. Both peptides raise in
blood by feeding, and maintain high levels simultaneously for 1–2 hours.
Therefore there might be possible to cause interactive actions between two pep-
tides, inducing satiation to finish food intake.
Aims & Methods: In this study, we undertook to elucidate whether CCK and
PYY have the interaction to decrease food intake. Study on gastric emptying.
Male SD rats were fasted overnight, and 1mL of mixture of food and glass beads
was given into the stomach and then PYY or CCK or CCK followed by PYY
was IP injected. The mixed food left in the stomach 1 hr after the injection was
measured and gastric emptying rate was calculated. Study on appetite. PYY or
CCK was IP injected to the rats just before setting food to eat. The amounts of
food were measured at 1 and 2 hrs after the injection. To clarify the involvement
of the brain in the interaction between CCK and PYY, c-Fos expression was
examined.
Results: CCK (0.5–10 nmol/kg) dose-dependently inhibited gastric emptying
(p5 0.001). CCK 10nmol/kg maximally inhibited food intake (p5 0.01).
PYY 25–2500 pmol/kg significantly inhibited gastric emptying for 1 or 2 hrs
after the injection (p5 0.01). PYY 250 pmol/kg significantly inhibited food
intake for 1 hr after the injection (p5 0.01). The combination of CCK
10 nmol/kg and PYY 250 pmol/kg inhibited gastric emptying more than CCK
alone (significant, p5 0.01) or PYY alone (not significant). PYY and
CCK additively inhibited food intake when PYY was injected 20 minutes later
from CCK injection. PYY significantly amplified c-Fos expression induced by
CCK in the nucleus of soritary tract (NTS) and paraventricular nucleus of
hypothalamus (PVN) in the brain.
Conclusion: The combination of PYY with CCK amplified the suppression of
gastric emptying and food intake. The result suggests that the sequencing secre-
tion of CCK and PYY might strengthen the inhibition of food intake through the
activation of satiety center in the brain, that is important for terminating food
intake and adjusting energy intake.
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Introduction: Transcriptions factors belonging to the p53 family (p53, p63, p73)
respond to cellular stress signals by inducing an accurately defined set of genes.
In a number of tumors, also in hepatocellular carcinoma (HCC), p53 proteins
can exert cancerogenic or tumorsuppressive functions. MicroRNAs are small,
non-coding RNA molecules which play an important role in gene regulation.
It is known that expression patterns of microRNAs can be controlled by the
p53 family. Depending on disease and cellular origin different sets of p53-induced
microRNAs have been identified.
Aims & Methods: Little is known about p53-dependent microRNA signatures in
HCC. The aim of the study was therefore to identify p53-family-regulated
microRNAs in HCC. Hep3B cells were transfected with rAd-p53 and -p73.
Microarray analyses were performed to identify p53- and p73-regulated
microRNAs. Verification of p53- and p73-dependent microRNA expression
was performed by qPCR. To evaluate the effect of HCC-relevant therapeutics
on p53-dependent regulation of microRNAs transfected Hep3B cells were incu-
bated with Doxorubicin, Sorafenib, Tivantinib, and Regorafenib in vitro.
Results: Overexpression of p53 and p73 induced a rash of microRNAs.
p53 induced miR-34a by 2.4-fold, miR-145 by 2.7-fold and led to a slight reduc-
tion of miR-149. In the presence of p73 miR-34a was induced by 5.4-fold, miR-
145 by 3.2-fold, and miR-149 by 55-fold. p53-dependent expression of miR-34a
was further increased in the presence of Doxorubicin (5.7-fold), Regorafenib
(2.5-fold) and Tivantinib (1.9-fold) compared to controls. Moreover, incubation
with Regorafenib resulted in an up to 5.4-fold increase of p53-dependent expres-
sion of miR-149 and miR-192.
Conclusion: p53 proteins affect the microRNA signature in HCC. Beside the
already known induction of miR-34a we demonstrate for the first time a regula-
tion of miR-145 and 149 by p53 und p73. We hypothesize that regulation of
tumorsuppressive microRNAs represents an effector mechanism by which p53
family members exert their role in tumor development and treatment response.
The observed synergistic effect of p53 and HCC-relevant therapeutics on
microRNA expression might provide new options for the development of ther-
apeutic and prognostic measures in HCC.
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Introduction: p53 transcription factors (p53, p63, p73) respond to cellular stress
by transcriptional regulation of specific sets of genes. In hepatocellular carci-
noma (HCC) and other tumors p53 family members exert cancerogenic or tumor-
suppressive effects. Depending on their splice variants–with transactivation
domain (TA)/dominant negative (DN)–and the characteristics of the particular
binding site (BS) p53 proteins activate or inhibit specific target genes. We pre-
viously identified the IGFBP2 gene (Insulin-Like Growth Factor Binding Protein
2) as one out of 7 putative target genes for p53 proteins with prognostic relevance
in HCC.
Aims & Methods: The aim of this study was to characterize the so far unknown
regulation of the IGFBP2 gene by p53 family members in HCC. Hep3B cells were
transfected with rAd-p53 and -TAp73 and transcriptional regulation of IFGBP2
was determined by qPCR. Intra- and extracellular IGFBP2 protein levels were
analyzed by Western Blot and ELISA. Transfac database analyses were per-
formed to identify potential BS for p53 and p73 in the IGFBP2 locus. These
sequences were cloned, mutated and analyzed for p53 family binding in luciferase
reporter assays. Binding of p53 and p73 to the identified BS was confirmed by
CHIP experiments.
Results: TAp73 transfection increased IGFBP2 expression by up to 60-fold and
resulted in elevated intra- and extracellular IGFBP2 protein levels, whereas
IGFBP2 protein was not detected in controls. p53 transfection induced
IGFBP2 expression by up to 7-fold. Two potential p53 and p73 BS are located
in the promoter region, another 5 potential p73 and one p53 BS were identified in
intron 1 of the IGFBP2 gene. Intron 1-dependent luciferase activity was
increased by up to 110-fold after TAp73 transfection and up to 20-fold after
p53 transfection. Mutation and deletion of the identified p53 BS in intron
1 resulted in a reduction of luciferase activity by up to 85%. Deletion of one
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potential p73 BS reduced luciferase activity by 85%. CHIP analyses verified
binding of p53 and TAp73 to the particular BS.
Conclusion: These results clearly identify IGFBP2 as novel target gene for TAp73
and p53 in HCC. We demonstrate for the first time an interaction of TAp73 with
IGFBP2 and therefore an important, so far unknown link between the p53 family
network and IGF pathways. p53 proteins exert predominantly tumor-inhibiting
effects, whereas the IGF axis is of critical importance for proliferative events.
The particular ratio of both important signaling seems to be decisive for tumor
characteristics and treatment response. Our results therefore not only expand our
knowledge of cancerogenic processes, but also indicate that finetuning of these
signalling pathways provides new therapeutic options in clinical management
of HCC.
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Introduction: Liver stiffness (LS) evaluation as a marker of fibrosis is usually
considered reliable when it fulfills some quality criteria. Classic criteria used
for Transient Elastography (TE) are: 10 valid measurements, 60% success
rate, and interquartile range/median ratio (IQR/M) 0.30 [1]. However, new
quality criteria were proposed using the IQR/M ratio, therefore the LS measure-
ments can be classified into three categories: very reliable (IQR/M5 0.10), reli-
able (0.105 IQR/M 0.30), poorly reliable (IQR/M4 0.30) [2].
Aims & Methods: The aim of this study was to assess the impact of using quality
criteria for liver stiffness (LS) evaluation by means of 2D Shear Wave
Elastography from General Electrics (2D-SWE.GE), while using Transient
Elastography (TE) as the reference. We included 226 subjects in our study,
with or without chronic liver disease, in whom LS was assessed using 2D-
SWE.GE (LOGIQ E9, GE Healthcare) and TE (FibroScan, EchoSens).
Reliable LS measurements were defined for TE as the median value of 10 mea-
surements with a success rate of 60% and an interquartile range (IQR)530%
of the median LS values. For 2D-SWE.GE 10 LS measurements were acquired in
a homogenous area and the IQR and the IQR/M were calculated in each case.
We divided our subjects into 3 groups according to the 2D-SWE.GE IQR/M:
IQR/M5 0.10: 41 (18.1%) cases; 0.105 IQR/M 0.30: 155 (68.6%) cases; IQR/
M4 0.30: 30 (13.3%) cases. We calculated the correlation coefficient between
TE and 2D-SWE.GE in each group.
Results: All 226 (100%) subjects included had 10 valid measurements by means of
2D-SWE.GE and reliable results by TE. A strong positive correlation was found
between LS values obtained by means of 2D-SWE.GE and TE in the IQR/
M5 0.10 group (r¼ 0.84, p5 0.0001). A strong positive correlation was found
between LS values obtained by means of 2D-SWE.GE and TE in the
0.105 IQR/M 0.30 group (r¼ 0.80, p5 0.0001). A weak positive correlation
was found between LS values obtained by means of 2D-SWE.GE and TE in the
IQR/M4 0.30 group (r¼ 0.41, p¼ 0.02). The correlations were significantly
stronger in the IQR/M5 0.10 and 0.105 IQR/M 0.30 groups as compared
to the IQR/M4 0.30 group (both p¼ 0.0013). No statistical differences were
found between the correlations in the IQR/M5 0.10 and 0.105 IQR/M 0.30
groups (p¼ 0.43).
Conclusion: Using the IQR/M5 0.30 as quality criteria significantly increase the
reliability of LS measurements by means of 2D-SWE.GE. Using IQR/M5 0.10
criteria does not significantly improve the reliability of 2D-SWE.GE LS measure-
ments as compared to 0.105 IQR/M 0.30 criteria.
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Introduction: 13C- methacetin breath test (13C-MBT) is used to specify the detox-
ification function of the liver by determination its metabolic capacity and degree
of hepatocytes recovery.
Aims & Methods: The study involved 113 patients with MS aged from 37 to 82
years, the average age was 55.8 3.5. There were 75 men and 88 women. The
criteria, which has been examined for the functional state of the liver was 13C-
MBT. The control group included 25 patients with a BMI of 25–30 kg/m2 with-
out severe concomitant diseases. Indicators of 13C-MBT were metabolic rate,
cumulative dose of 13C-methacetin on 40 and 120 minutes. Also evaluation was
carried by mathematical deduction which measured the liver dysfunction stage.
Results: The data showed normal detoxication liver function in patients without
MS (20.11% 0.55). The results were below normal in patients with BMI higher
than 25 kg/m2, which indicated that there were initial changes in the functional
state of liver. In patients with steatosis - cumulative dose on 120 minute was
15.12% 0.49, which corresponded to a moderate reduction of detoxification
function with the mass of function hepatocytes 50–100%. The data of 13C-MBT
in patients with steatohepatitis showed pronounced changes of the liver detox-
ification function (8.88 0.64%). All indicators at steatosis group have indicated
the moderate decline detoxification function with the level of function hepato-
cytes 50–100% (Mvmax40¼ 0.66, Cum.Dose 40¼ 0.7, Cum.Dose 120¼ 0.54).
The data of patients with steatohepatitis indicated the detoxification function
with declining of the mass of function hepatocytes to 20–50% (Mvmax40¼ 0.46,
Cum. Dose 40¼ 0.5, Cum. Dose 120¼ 0.32). The results of the control group
showed its compliance with norm, but one of the indicators (Cum. Dose 120) was
related to the moderate decline detoxification function. Despite it, most of the
criteria have been accorded to the norm. However, the results of data suggest the
opportunity of early violation of detoxification liver function in patients with a
BMI over 25 kg/m2.
Conclusion: In assessing to the data of 13C- MBT, main attention is paid to
mathematical calculation of CO2 labeled methacetin. It allows to identify the
early stages of the liver detoxification function violation.
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Introduction: Members of the p53-family, including p53, p63 and p73, are known
for their involvement in the regulation of cell cycle, cell senescence and apoptosis.
In their role as transcription factors and depending on their splice variants–with
transactivation domain (TA) or dominant negative (DN) - p53 and its siblings
are capable of activating or inhibiting the transcription of specific target genes.
We previously identified the gene for Insulin-like Growth Factor Protein 4
(IGFBP4) as potential p53-family target gene with prognostic relevance in hepa-
tocellular carcinoma (HCC). In contrast to p53, the IGF system takes part in
tissue growth and cell survival. IGFBP4 acts as inhibitor limiting IGF effects
suggesting a possible interaction with p53 affairs.
Aims & Methods: The aim of the study was to characterize the regulatory influ-
ence of p53 family members on the IGFBP4 gene. Hep3B cells were transfected
with rAd-p53, -TAp63, -TAp73, -DNp63, and –DNp73. Transcriptional regula-
tion of IGFBP4 was determined by real time qPCR. Intra- and extracellular
IGFBP4 protein levels were examined by Western Blotting and ELISA.
TRANSFAC database analysis was performed to identify potential p53-family
binding sites in the IGFBP4 locus. Identified sequences were cloned, deleted and
analyzed by luciferase reporter assays to evaluate binding of p53-family
members.
Results: IGFBP4 expression was increased by more than 30-fold in TAp73-
transfected Hep3B cells, by more than 15-fold in DNp63- and by 3-fold in
p53-transfected cells. Induction of intracellular IGFBP4 protein was detected
in all transfected Hep3B cells, whereas extracellular IGFBP4 levels were only
measurable after TAp73 and DNp63 transfection. Database analysis identified
2 putative p73 binding sites within intron 1 of the IGFBP4 gene. Intron 1-depen-
dent luciferase activity was increased by up to 20-fold in TAp73-transfected cells.
This induction was reduced by up to 70% when one of the putative binding sites
was deleted.
Conclusion: These results identify the IGF inhibitor IGFBP4 as novel target gene
for TAp73 in HCC. By demonstrating for the first time the interaction of TAp73
and IGFBP4 we enhance our knowledge in a so far unknown association of p53-
family network and IGF signaling. Since in an independent study we identified
IGFBP2 as a novel p53-family target gene, these results highlight the link
between p53-family-mediated tumor-inhibiting mechanisms and IGF-dependent
cell proliferation. We therefore suppose that the particular balance of these path-
ways decides on growth, cancerogenesis and treatment response.
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Introduction: It is known that to determine nonalcoholic fatty liver disease
(NAFLD), which develops in progress of body mass index (BMI) from 19% to
35%, using instrumental and laboratory methods, which include an ultrasound,
the determination of the transaminase levels, steatotest, 13C-methacetine test.
However, the above research methods do not allow to clearly differentiate stea-
tosis from the steatohepatitis, that reduces their credibility.
Aims & Methods: 163 patients (75 men, 88 women) with 2 type diabetes mellitus
and coronary heart disease with metabolic syndrome, were examined. The aver-
age age was 55.82 75. On the above criteria of ultrasound, 72 patients were
diagnosed as steatosis group, 66 - steatohepatitis group. In 25 patients liver
pathology was not found, which identified as a control group.
For verification of steatosis and steatohepatitis diagnosis the level of ALT, dia-
meter vena portae and data 13C-methacetin breath test were evaluated.
Results: The rate of liver metabolism based on 13C-methacetine test results in
patients without NAFLD was 22.07 0.66%, in patients with steatosis -
17.1 0.84%, steatohepatitis - 14.3 0.62%. Cumulative dose of methacetine
on 120 minute was 20.25 0.46% in patients without pathology of liver,
16.1 0.49% in patients with steatosis, 11.4 0.36 in patients with steatohepa-
titis. ALT level in control group was 0.4 0.05mmol/l, with steatosis
0.6 0.06mmol/l, steatohepatitis 0.9 0.1mmol/l. The diameter of vena portae
in control group was 11.2 0.26mm, in group of steatosis 11.9 0.21mm, in
patients with steatohepatitis 13.7 0.15mm. There were investigated, that the
rate of metabolism and its cumulative dose on 120 minute has decreased in
steatosis group in comparison of the control group, with simultaneous significant
increasing of ALT level and diameter of the portal vein. However, a significant
reduction of the metabolism rate of methacetin and the cumulative dose 13CO2 in
the background of the increase of a diameter of vena portae compared with a
group of steatosis, were examined in steatohepatitis group.The investigation
found that in ALT and the diameter of the portal vein negatively correlated
with cumulative dose of 13CO2 on 120 minute in patients with steatohepatitis.
Therefore, a decrease in the metabolic capacity from 15 to 10% accompanied
by an increase in ALT levels (more 0,68mmol/l) and diameter of the portal
vein (13mm).
Conclusion: The differentiation between steatosis and steatohepatitis should be
moderate with the speed of a metabolism, a cumulative dose of methacetine
on 120 minutes via 13C-MBT and vena portae diameter measurement. The
sensitivity of the method is based on the definition of the three proposed indi-
cators - ALT level, total concentration of 13C-methacetin on 120 minute and the
portal vein size, which is 75% for steatosis, and 76% for steatohepatitis.
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Introduction: Liver fibrosis (LF) is a progressive pathological process resulting in
accumulation of excess extracellular matrix proteins. A metalloprotease BMP1
cleaves various matrix proteins and procollagen type I. We have recently discov-
ered that BMP1–3 isoform circulates in the plasma and its neutralization
decreases the progression of chronic kidney disease. The role of BMP1 in liver
diseases associated with fibrosis has not been investigated. Bone Morphogenetic
Protein 1 (BMP1) and mammalian tolloid (mTLD) are alternatively spliced pro-
ducts of the Bmp1 gene that are essential for tissue pattering and ECM assembly
by biosynthetic processing of a wide range of ECM precursors specifically pro-
collagen type I undergoing enzymatic cleavage by BMP1 at the C-terminal end of
the procollagen finally leading to liver cirrhosis, portal hypertension and liver
failure.
Aims & Methods: We used the model of CCl4-inducedLF in rats. Animals were
treated with BMP1–3 antibody at two different concentrations (20 and 50 mg/kg)
for 3 and 8 weeks. Extent of LF was assessed by histology, morphometric ana-
lyses, shear wave elastography and hydroxyproline (HP) content measurement.
Gene expression analyses were performed by qRT-PCR, and protein localization
by immunohistochemistry. BMP7 protein (150 mg/kg) was used as a comparative
therapy.
Results: In our experiments the presence of BMP1-3 was immunohistochemically
demonstrated in both healthy and cirrhotic liver suggesting that at least a part of
circulating BMP1-3 is produced in the liver. Administration of BMP1-3 Ab
resulted in an effective inhibition of the fibrosis progression. Administration of
BMP1-3 Ab at a dose 20mg/kg and 50 mg/kg exerted antifibrotic activity compar-
able to that of BMP7. Apart from blocking the BMP1-3 activity, which is impor-
tant for collagen maturation, administration of BMP1-3Ab was accompanied by
the reduced expression of Tgf, Itg6 and -Sma gene expression whereas expres-
sion of Decorin mRNA was enhanced. Decorin has evident anti-fibrotic activity
in the liver after injury with CCl4 and silencing caused an increased activation of
HSCs both in vivo and in vitro. Rats treated with both BMP1-3 antibody con-
centrations had significantly lower amount of collagen type I when compared to
the CCl4-treated group. Direct proportionality was found between the degree of
fibrosis and liver stiffness. We showed for the first time a distinct correlation
between the HP level in liver, morphometric analysis and elastography of the
liver.
Conclusion: Our results suggest that neutralization of BMP1-3 is a promising
therapeutic aproach in preventing the liver fibrosis progression.
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Introduction: Recent studies have demonstrated an association between decreased
glucose tolerance, dyslipidemia and metabolic syndrome; and increased risk of
colorectal polyps. Patients with non-alcoholic fatty liver disease (NAFLD) often
have these risk factors. The association between NAFLD and colorectal polyps
has been poorly studied.
Aims & Methods: We aimed to evaluate the prevalence and risk factors of color-
ectal polyps in patients with NAFLD. This was a retrospective observational
cohort study of 237 patients with NAFLD submitted to transient elastography
by Fibroscan, between 01/2015–02/2017. Exclusion criteria: age518years,
absence of total colonoscopy with good preparation 53 years, inflammatory
bowel disease, hereditary polyposis syndromes and personal/family history of
colorectal polyps/neoplasia. Compared patients with colorectal polyps(cases)
and without colorectal polyps(controls). Demographic variables, cardiovascu-
lar/metabolic risk factors, comorbidities, laboratory parameters and
Fibroscan scores of steatosis(CAP4 300 dB/m) and fibrosis(F4:4 10KPa)
were evaluated.
Results: Of the 237 NAFLD patients who performed Fibroscan, 103 underwent
total colonoscopy. The prevalence of colorectal polyps was 28.2%(n¼ 29):
19.4%(20/103) hyperplastic, 16.5%(17/103) adenoma and 4.8%(5/103) advanced
adenoma/adenocarcinoma. The mean age was 58.32 51years
(vs57.09 10.53;p¼ 0.089), with men predominant (51.7%vs63.5%;p¼ 0.272),
mostly located in the left colon (55,2%vs44.8%;p¼ 0.314) and number and
mean size of 1.46 0.88 and 6.89 6.56mm, respectively. After multivariate
analysis, colorectal polyps were associated with F4 liver fibrosis (34.5%vs
14.9%;p¼ 0.026;OR¼ 3.01) and obesity (BMI4 30Kg/m2: 55.2%vs
29,7%;p¼ 0.016;OR¼ 2.91); hyperplastic polyps were associated with liver fibro-
sis for a cut-off value of 6.9Kpa (AUROC:0.689;p¼ 0.008; S¼ 85.7%;
Sp¼ 51.2%), mainly F4 (42.8%vs14.6%;p¼ 0.004;OR¼ 4.38), hyperuricemia/
gout (23.8%vs8.5%;p¼ 0.042;OR¼ 3.35) and peptic ulcer disease (9.5%vs
1.2%;p¼ 0.043;OR¼ 8.53); adenoma was associated with liver steatosis
(88.2%vs83.7%;p¼ 0.024;OR¼ 3.50), F4 liver fibrosis (41.2%vs16.2%;
p¼ 0.041;OR¼ 3.24) and obesity (58.8%vs32.6%;p¼ 0.040;OR¼ 2.96);
advanced adenoma/adenocarcinoma was associated with F4 fibrosis
(20.0%vs2.1%;p¼ 0.021;OR¼ 1.224), hyperuricemia/gout (40.0%vs10.3%;
p¼ 0.044;OR¼ 1.50) and dilated cardiomyopathy (20.0%vs1.0%;p¼ 0.003;
OR¼ 1.24).
Conclusion: More than 1/4 of the patients with NAFLD have colorectal polyps,
being 16.5% adenoma and 4.8% advanced adenoma/adenocarcinoma.
Obesity and liver steatosis are independent risk factors for colorectal adenoma.
Liver fibrosis, especially F4 is an independent risk factor for all types of color-
ectal polyps.
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Introduction: Non-alcoholic fatty liver disease (NAFLD) is a common clinico-
pathological condition which may progress from simple steatosis to NASH,
cirrhosis and hepatocellular carcinoma(HCC). Although obesity is accepted as
the main risk factor for NAFLD, non-obese individuals are often diagnosed with
NAFLD suggesting that high BMI may not be "a sine qua non" for the presence
of NAFLD. Recent studies suggested that there might be a correlation between
weight gain and metabolic diseases.
Aims &Methods: In our research; the relationship between NAFLD in non-obese
individuals and the amount of weight gain during adulthood was investigated
and a new index that is different from BMI was proposed. 362 individuals were
included in the survey. The subjects were selected among patients who had
abdominal ultrasonography(USG) in our clinic, during the last 6 months.
A 5% increase in echogenicity detected in the USG was defined as the diagnostic
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limit for hepatosteatosis. The beginning of adulthood was taken as 20 years old.
Exclusion criteria were; HBsAg or anti-HCV positivity, alcohol use, liver disease,
pregnancy, cancer treatment, renal insufficiency, being younger than 25 years
old. Patients were evaluated for the presence of diabetes, hypertension or cardi-
ovascular disease and ALT, AST, fasting plasma glucose and cholesterol values
were recorded. Statistical evaluations were done with IBM SPSS.
NAFLD evaluation with SAMI 3 cut-off value
NAFLD(þ) NAFLD()
SAMI4 3 144 38
SAMI5 3 25 77
Sensitivity 85,2%
Specificity 66,95%
PPV 79,12%
NPV 75,49%
Results: Among 362 participants 169(46.7%) were men with an average age of
44.81 10.73. 78 (21.6%) participants were obese, the average age of the group
being 46.78 9.12. Out of 78 obese individuals 73 (93.5%) were NAFLD(þ). The
average age of the 284(78.4%) non-obese subjects was 44 11.05. Among non-
obese people 169(59.5%) were NAFLD(þ) and average age was 48.07 10.13
while amongst NAFLD() people was 38.74 10.04. Non-obese NAFLD(þ)
patients reported they had gained significant amount of weight during their
adulthood. This information led us to create, a new index named ‘‘Subtracted
Adulthood Mass Index’’ (SAMI) to estimate the risk of NAFLD development in
non-obese individuals. SAMI is calculated by dividing the difference between the
subject’s current weight and his/her weight at the age of 20 years to his/her height
squared(kg/m2). SAMI values for non-obese attendants were calculated. When
the cut-off value was set as SAMI 4 kg/m2, sensitivity was 76.3%, specificity was
79.1, positive predictive value(PPV) was 84.3% and negative predictive
value(NPV) was 69.4%. At a cut-off of SAMI 3 kg/m2 sensitivity was 85.2%,
specificity was 66.9%, PPV was 79.1%, NPV was 75.4%.
Conclusion: In this pilot study, we found that weight gain in adulthood is an
important predictor of NAFLD development in non-obese individuals. The new
index named SAMI can correctly identify non-obese people under the risk of
developing NAFLD. Cut-off value of SAMI has been set as 3 kg/m2. We also
observed that NAFLD prevalence increases as SAMI value goes up. We propose
that SAMI is appropriate for clinical use to estimate the risk of NAFLD in on-
obese individuals.
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Introduction: Cisplatin-treated cancer patients often face therapy failure caused
by acquired cisplatin (cp) resistance. Development of resistance was previously
associated with modulation of transporters mediating cellular copper metabo-
lism. Overexpression of the Wilson disease protein ATP7B, a TGN copper trans-
porter, was proposed to increase cellular cp efflux.
Aims & Methods: The human hepatoma cell line HepG2 was compared with a
HepG2-variant lacking functional ATP7B expression (KO) in regard to cp sen-
sitivity. Hepatoma cell lines were generated that displayed cp resistance by step-
wise increasing cp concentrations. Cells were examined via growth, cell viability
assay (MTT) and analysed for apoptosis (Annexin V staining). Inductively
coupled plasma mass spectrometry was used to determine intracellular cp level.
Gene expression analysis (RT-qPCR) was carried out to determine the impact of
various transporters. Overexpression of individual transporter genes and siRNA
treatment were used for confirmation of the data.
Results: Treatment of HepG2 and KO cells with various cp concentrations
revealed no significant differences in cell viability and intracellular cp accumula-
tion. To examine how KO cells that lack ATP7B can adapt to high cp levels, a cp
resistant subline (CpR) was generated. Cp resistance was confirmed by viability
assays, cell growth, apoptosis and intracellular cp load. Gene expression analysis
of more than 16 transporters demonstrated an upregulation of metallothionein 1
(MT1: 8.91 4) and a downregulation of organic cation transporter 3 (OCT3:
5.17 2) compared to control cell lines. Weaning and regrowth of the CpR cell
line in the presence of cp revealed a stable phenotype of resistance in the cells.
Downregulation of OCT3 was identified to be permanent while MT1 upregula-
tion was transient and rapidly induced by cp. Overexpression of OCT3 in CpR
cells resulted in loss of cp resistance to a level of untreated cells indicating that
downregulation of OCT3 is responsible for acquired cp resistance.
Conclusion: We suggest that ATP7B does not seem to be involved in cp resis-
tance, at least in hepatic cells. OCT3 represents a novel marker of cp resistance.
OCT3 expression could be a valuable tool for improved prognosis of
cisplatin therapy.
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Introduction: Recent studies have shown that the single nucleotide polymorphism
(SNP) rs738409 in the PNPLA3 gene is strongly associated with severity of
nonalcoholic fatty liver disease (NAFLD).1,2 However, the traditional direct
sequencing (DS) method is time-consuming and labor-intensive. The i-
densyTM(ARKRAY, Inc.), which is based on the quenching probe (QP)
method, automatically detects target genes in blood samples by fluorescence
quenching within 90min.3
Aims & Methods: The current study compared the QP and DS methods for
detecting SNPs in the PNPLA3 gene, and established the impact of the genotype
on prognosis of NAFLD. We enrolled 107 patients with fatty liver irrespective of
etiology. We used the i-densy fully automated genotyping system with QP. The
requisite number of tips, reaction tubes, reagent packs and blood samples were
set in their designated places. The forward and reverse polymerase chain reaction
(PCR) primers and guanine QP were 5’-cttctctctcctttgctttcacag-3’, 5’-gtgtgagca-
cacttcagagg-3’ and 5’-ggcatgaagcaggaacatac-3’, respectively. PCR consisted of
initial denaturation for 1min at 95 C, and 60 cycles of denaturation at 95 C
for 1 s and annealing at 61 C for 30 s. After completion of the PCR, we analyzed
melting temperatures. The SNP genotypes were determined by monitoring the
change in fluorescence intensity with increasing temperature. The results
obtained with the QP method were compared with those obtained with the con-
ventional DS method. Then, we analyzed 73 patients with NAFLD according to
PNPLA3 genotype in terms of alanine aminotransferase (ALT), aspartate ami-
notransferase to platelet ratio index (APRI), Fibroscan value, and cumulative
hepatocellular carcinoma (HCC) development rate.
Results: The genotypes obtained with the QP method were identical to those
obtained with the conventional DS method. In 73 patients with NAFLD, the
frequency of the PNPLA3 genotypes CC, CG and GG was 21 (28.8%),
24 (32.9%) and 28 (38.4%), respectively. Serum ALT, APRI and Fibroscan
value according to PNPLA3 genotypes CC, CG and GG were 26 (14–59),
33 (11–113) and 46 (17–175) U/L, 0.3 (0.1–1.0), 0.5 (0.2–6.8) and 0.7 (0.2–3.1),
and 4.4 (2.7–25.1), 5.6 (2.5–26.5) and 6.6 (3.6–38.6) kPa, respectively (p¼ 0.001,
p¼ 0.001 and p¼ 0.033 by Jonckheere–Terpstra test). HCC developed in none of
the patients with CC genotype, one (4.2%) with CG and four (14.3%) with GG.
The cumulative HCC development rate in patients with GG genotype was sig-
nificantly higher than that in those with CCþCG genotype (p¼ 0.043 by log-
rank test).
Conclusion: The i-densy using the QP method can automatically, quickly and
easily identify PNPLA3 genotypes in real-world clinical settings. These findings
indicate the feasibility of personalized medicine for NAFLD.
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Introduction: Orlistat is an effective pharmacologic weight loss treatment by
inhibiting intestinal lipase to reduce dietary fat absorption. Previous studies
have suggested that it lowers liver fat by ultrasound or semi quantitative histo-
logical score in nonalcoholic fatty liver diseases (NAFLD).
Aims & Methods: We aimed to examine the efficacy of orlistat versus placebo in
reducing liver fat content by the magnetic resonance imaging (MRI) based on
chemical shift imaging. A total of 51 NAFLD patients diagnosed by MRI were
randomized and to receive trice-daily 120mg oral Orlistat or placebo for
6 months, among them 30 (14 in the Orlistat group and 16 in the placebo
group) were included in the interim analysis. Both groups received. Clinical
parameters, laboratory tests and liver fat content were measured at baseline
and 6 months including body mass index (BMI), waist hip ratio (WHR), liver
enzymes, haemoglobin A1c, total cholesterol (CHOL), serum triglycerides (TG),
fasting plasma insulin (FPI), homeostasis model assessment IR (HOMA-IR).
The primary outcome was a change in liver fat quantified by MRI which is
based on Dixon technique with two-point chemical shift-based fat-water separa-
tion method[1]. The chi-squared test and paired t test were used to compare mean
differences between fat fractions between two groups.
Results: At baseline, BMI was higher in Orlistat group (31.38 3.19) than that of
the placebo group (26.78 3.02, p5 0.001), while the other baseline character-
istics including liver fat fraction and the proportion of hypertension, hyperlipi-
daemia, diabetes mellitus type 2, and hyperlipidemia were similar. Compared to
baseline, end-of-treatment liver fat content was significantly lower in the Orlistat
arm (19.38% 9.52% to 11.56% 7.49%, change was 7.72 6.39%, P¼ 0.001)
but not in the placebo (16.05% 8.7% to 14.17% 9.58%, change was
1.43 9.84%, P¼ 0.640) arm. Change of BMI was the only independent factors
correlated with reduction of liver fat content(b¼ 0.522, p¼ 0.006).
Conclusion: Orlistat did significantly decreased liver fat in NAFLD patients via
its effect of lowering weight.
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Introduction: Copper transporter ATP7B is essential for hepatic Cu homeostasis
and loss of function results in the inherited autosomal recessive disorder Wilson
Disease (WD). Symptoms of WD are i.e. elevated Cu accumulation in liver and
brain. Understanding of molecular mechanisms involved in Cu homeostasis is
essential to improve therapeutic options. The molecular impact following long-
term elevated Cu in hepatic cells lacking functional ATP7B has not been
explored.
Aims & Methods: HepG2 cells lacking functional ATP7B (KO) were used for
generation of a copper resistant subline (CuR). Cell growth, cell viability (MTT)
and intracellular Cu load (atomic absorption spectroscopy) was assessed. RT-
qPCR was performed to quantify the expression of genes related to Cu home-
ostasis genes. Functional analysis of candidate genes was assessed via siRNA
transfection. Additional measurements of CTR1 expression was performed by
flow cytometry (FACS) and Western Blot.
Results: KO cells can survive for many months in the presence of high Cu and
gain resistance (CuR). Characterization of CuR cells revealed increased survival
up to 12-fold compared to control, whereas a high intracellular Cu accumulation
was noticed. Once Cu resistance was established, the termination of Cu exposure
did not result in the loss of resistance indicating a stable modification of the cells.
Two genes involved in Cu homeostasis displayed an altered expression pattern
(upregulation of MT1 and downregulation of CTR1 by 28.1 2.5 and 3.2 0.4
fold, respectively) which was however transient and dependent on Cu exposure.
The role of MDR1 which presented a stable modification was further investi-
gated by siRNA and drug activation (verapamil). Notably, cell viability and
intracellular Cu load was significantly affected by siRNA and verapamil indicat-
ing that MDR1 is involved in Cu homeostasis. In addition, hepatic cells derived
from a WD patient and from the rat animal model confirmed our observations.
Conclusion: Our analysis of long-term Cu exposure presents new insights in
copper metabolism and suggests a new role of MDR1 in the pathogenesis of
Wilson disease.
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Introduction: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic stea-
tohepatitis (NASH) are increasingly common cause of chronic liver
disease worldwide. Most patients with severe obesity who undergo bariatric
surgery have NAFLD, which is associated insulin resistance, type 2 diabetes
mellitus, hypertension, and obesity-related dyslipidemia. Identifying significant
fibrosis in patients is crucial to evaluating prognosis and possible therapeutic
intervention. Currently, liver biopsy is the gold standard for diagnosis of liver
fibrosis.
Aims & Methods: We aimed to evaluate the NAFLD fibrosis score for the assess-
ment of significant fibrosis in patients with morbid obesity before undergoing
Roux-en-Y gastric bypass. A total of 69 NAFLD patients (median BMI 47 kg/
m2) were prospectively enrolled from June 2015 to November 2016 at one
Brazilian university hospital. All patients were evaluated with routine laboratory
before bariatric surgery. Age, body mass index, hyperglycemia, platelet count,
albumin and AST/ALT ratio were applied to the score formula. Biopsies were
interpreted by a single experienced pathologist. NAFLD and fibrosis were clas-
sified according to the NASH Clinical Research Network NAFLD activity score.
These scores were compared to liver biopsy findings and the area under the
receiver operating characteristic curve (AUROC) was calculated for the diagnos-
tic test.
Results: On liver biopsy, 29 patients (42%) had some degree of fibrosis, with
13 patients (18.8%) having significant fibrosis (F2–4). With standard thresholds,
the specificity for the NAFLD fibrosis score for identification of significant
fibrosis was 58.9%. Using modified thresholds, the specificity could increase.
For predicting significant fibrosis, for a cut-off of 1.05, the score had 46.15%
sensitivity and 96.43% specificity with AUROC of 0.74.
Conclusion: The nonalcoholic fat liver disease fibrosis score has good accuracy to
identify and significant liver fibrosis in morbidly obese patients subjected to
bariatric surgery.
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Introduction: FLI was developed as a simple predictor of steatosis (Bedogni
et al.,2006) and a cut-off value 60 ruled in (positive likelihood ratio [LRþ]
4.3) steatosis in Italians diagnosed with ultrasound. FibroscanCAP is more
sensitive for the diagnosis of steatosis than ultrasound. Aim of this study is to
evaulate the use of Fibroscan in comparison with FLI to screen for fatty liver
disease in Austrian bank employees and to recalculate optimal FLI cut-off
values. Beside weight reduction and diet EASL guidelines recommend physical
activity 4150min. per week for prevention and treatment of steatosis.
Aims & Methods: More than 1000 Austrian bank employees will be screened for
liver diseases with Fibroscan. A kPa value 7.9 (M-probe) and 7.2 (XL-
probe) is categorized as fibrosis. Additionally FibroscanCAP with a cut-off
value 248 dB/m is defined as steatosis, 300 dB/m as high-grade steatosis.
Heavy drinkers are identified with AUDIT and SIAC questionnaires. Weekly
physical activity is classified into ‘‘none’’, ‘‘150min’’ and ‘‘4150min’’.
Results: To date 482 employees [age 45.9 8.7 (meanSD); m:207, f:275; BMI
25.4 4.4)] have been included in this analysis. 14/482 (2,9%) employees had
signs of liver fibrosis and received further investigations. FibroscanCAP
values 248 dB/m are shown in 156/482 (32,4%) employees (m:91 [58%], f:65
[42%]), 56/482 (11,6%) had CAP values 300 dB/m. Furthermore 15/156 (9,6%)
patients with steatosis are heavy drinkers. FLI significantly predicts
FibroscanCAP values (adj.R2¼ 0.551,t(424)¼ 22.9,p5 0.001), which indicates
a large effect size. For this study population, a FLI cut-off value 40
(CAP 248 dB/m) and 50 (CAP 300 dB/m) rules in fatty liver disease with
a LRþ of 4.7 (SN:84%; SP:75%) and 4.8 (SN:83%; SP:83%), respectively. An
additional consideration of physical activity level in the current cohort revealed
that inactivity increases the LRþ of FLI values to predict NAFLD (trendwise
significant, p¼ 0.051), indicating lower cut-off values.
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Conclusion: We conclude that Fibroscan represents an eligible tool to diagnose
liver diseases in Austrian bank employees. Compared to the previous work of
Bedogni et al FLI predicts fatty liver at a lower cut-off level, at least for the
examined population. This difference might be due to the fact that
FibroScanCAP is more sensitive than ultrasound.
Disclosure of Interest: All authors have declared no conflicts of interest.
Reference
Bedogni et al. (2006): The Fatty Liver Index: a simple and accurate predictor of
hepatic steatosis in the general population. BMC Gastroenterology, 6:33
P1326 METABOLOMICS IDENTIFIES PROGRESSIVE NAFLD
D. Crisan
1, M. Grigorescu1, A. Suciu2, H. Stefanescu2, F. Romanciuc3,
C. Socaciu4, L. Avram5, V. Donca1, C. Radu2
1University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca/Romania
2Hepatology, Cluj-Napoca University of Medicine and Pharmacy 3rd Medical
Clinic, Cluj-Napoca/Romania
3Faculty of Food Science and Technology, University of Agricultural Sciences and
Veterinary Medicine, Cluj-Napoca, cluj-napoca/Romania
4Research and Development Centre BIODIATECH for Applied Biotehnology in
Diagnostic and Molecular Therapy, Cluj-Napoca/Romania
5Clinical Municipal Hospital Cluj-Napoca, Cluj-Napoca/Romania
Contact E-mail Address: crisan.dc@gmail.com
Introduction: Nonalcoholic fatty liver disease (NAFLD) is an affection with
increasingly prevalence worldwide, having an important impact on morbidity
and mortality, especially when it associated severe fibrosis.
Aims & Methods: We aimed to assess the metabolites that are associated with
fibrosis stages in NAFLD, using metabolomic method. A total of 40 patients
were included in the study, 30 diagnosed with nonalcoholic fatty liver disease
(NAFLD) and 10 controls. Steatosis and fibrosis were assessed using Fibromax
elaborated by Biopredictive (R) (Paris, France). New metabolomic techniques
(high performance liquid chromatography coupled with mass spectrometry
(HPLC-MS) and principal component analysis (PCA) were used to identify
final products of various metabolic pathways correlated with liver fibrosis.
Results: Of the 30 patients with NAFLD included in the study, 6 patients (20%)
had severe fibrosis. The metabolomic profile identified four metabolites that are
associated with severe fibrosis: 1,25(OH)vitamin D, (p¼ 0.03), lisophosphatidy-
letanolamine LPE 0:0:22:6 (p¼ 0.05), Lysophosphatidylcholine LPC 18:2
(p¼ 0.003), and high levels of butenyl carnitine (p¼ 0.04). Of these, LPE was
the strongest predictor of severe fibrosis (AUROC-0.795, Sensitivity
(Se)¼ 88.33%, specificity (Sp)¼ 78.79%), but the others molecules were also
significantly associated with severe fibrosis: vitamin D (AUROC¼ 0.776), bute-
nyl carnitine (AUROC¼ 0.737), LPC 18:2 (AUROC¼ 0.768). As the metabolo-
mics permits the evaluation of all these molecules the same time, we can use them
combined in order to increase the diagnostic accuracy. In our case, the combined
use of the four metabolites determined an AUROC of 0.839, with Se of 100%
and Sp of 68.5%.
Conclusion: Using metabolomics, we can identify patients with fatty liver and
severe fibrosis who are significantly exposed to a progressive disease and a higher
mortality.
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Introduction: Chronic renal failure (CRF) is frequently associated bone metabo-
lism and osteoporosis with lowered levels of Vitamine D and/or hyperparathyr-
eodism particular in case of hemodialysis. Younger studies suggest an association
of low vitamin D levels with non-alcoholic fatty liver disease (NAFLD) and non-
alcoholic steatohepatitis (NASH), as well as metabolic syndrome, and diabetes
mellitus. Unfortunately, a causality could not yet be proven.
Aims & Methods: Our aim was to identify patients on higher risk to develop
NAFLD/NASH in a selected patient cohort being admitted for renal disorders.
176 patients, admitted to the department of nephrology of the University
Hospital Marburg for renal disorders whose plasma vitamin D concentration,
phosphate and parathormone levels and liver enzyme levels had been quantified
beforehand, were enrolled and a retrospective investigation of laboratory para-
meters (including electrolytes, hormones, and vitamins) and pre-existing medical
conditions (imcluding high blood pressure, diabetes, hyperlipoproteinaemia, and
more) followed. Appropriat statistical test were used to characterise the cohort
(ANOVA; MANN-Whitney-U; FISHER-EXACT) using SPSS TM. Other hepa-
topathies were excluded. Steatosis was assessed by ultrasonography.
Results: Patients were divided into 4 groups according to plasma vitamin D levels
(normal 425 ng/ml; low 525 ng/ml) and transaminase levels (AST/ALT/-GT
430 U/l; normal: AST/ALT/-GT 530 U/l). Low 1,25-hydroxyvitamin D levels
correlated signifactly with high kreatinine, urea, and LDL levels, while low
25-hydroxyvitamin D levels correlated with high cholesterol and trigylceride
levels, suggesting a relationship between low vitamin D levels and fat metabolism
disorders. Interestingly end stage renal failure (chronic hemodialysis) was signif-
icantly correlated with the development of NAFLD/NASH with significantly
higher levels of AST/ALT and gGT, hyperparathyreodism and hyperphosphate-
mia Transaminases were significantly lower if Vitamin D was supplemented
Conclusion: Vitamin D deficiency is often present in patients with kidney diseases
such as chronic renal failure. Vitamin D levels are correlated to age and sex of the
patient. Patients suffering from renal failure are on high risk developing
NAFLD/NASH if diminished vitamin D levels are present Supplement of
Vitamin D saves from NAFLD/NASH The correlation of hyperparathyreodism
and NAFLD/NASH has to be further investigated in larger patient groups
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Introduction: Usually for the determination of nonalcoholic fatty liver disease
(NAFLD) there are instrumental and laboratory techniques, including ultra-
sound diagnosis, determination of aminotransferases, steatotest, 13C-methacetin
breath test (13C-MBT). These methods in the diagnosis of NAFLD clinical
forms is not specific and do not allow make difference between steatosis and
steatohepatitis. The determination of NAFLD clinical forms is a priority in the
prediction of further disease and choice of treatment. Steatohepatitis is the active
form of NAFLD and progresses to fibrosis oftenly with subsequent liver par-
enchyma degeneration into cirrhosis. Simultaneously, steatosis could be possibly
treated in the early stages of disease.
Aims & Methods: The study involved 65 patients with type 2 diabetes and cor-
onary heart disease with metabolic syndrome, aged 37 to 82 years (mean age
55.82 3.46), 29 men, 36 women. According to the ultrasound, the stage of fatty
infiltration were differentiated by such criteria for steatosis as diffuse liver par-
enchyma echogenicity intensification against the background of a slight increase
in its size (liver echogenicity was significantly higher than normal kidney or
lumbar muscle echogenicity); for steatohepatitis - hyperechogenicity of liver par-
enchyma and expansion of portal vein (13mm or more in diameter).
Results: For steatosis and steatohepatitis determination the ALT monitoring was
used, where the level exceeding 0.68mmol/l signed to steatohepatitis, and below
0.68mmol/l - to steatosis. Portal vein diameter size above 13mm subscribed
steatohepatitis, and below 13 - steatosis. 13C-MBT data, which assesed the
liver antitoxic function was used, where the result 13CO2 on 120 minute from
10 till 15% was classificated as liver detoxification function violation like stea-
tohepatitis, and from 15 till 20 - steatosis. The present study found that indicators
of ALT and portal vein diameter negatively correlated with cumulative dose
13CO2 for 120 minute in case of steatohepatitis. Thus, reduction cumulative
dose 13QO2 on 120 minute from 15% to 10% was accompanied by ALT level
increasing (more than 0.68mmol/l) and portal vein diameter enlargement (over
13mm).
Conclusion: Differentiation between steatosis and steatohepatitis should be per-
form by the cumulative dose 13CO2 mn 120 minute evaluation and ALT levels
and portal vein diameter assessment.
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Introduction: Non-alcoholic fatty liver disease (NAFLD), the hepatic counterpart
of the metabolic syndrome in close relation to obesity and encompasses a disease
spectrum spanning simple steatosis through nonalcoholic steatohepatitis
(NASH) with/without cirrhosis, and hepatocellular carcinoma [1]. Clearly, not
all obese subjects develop NAFLD and NAFLD can also be found in non-obese
patients. Globally, the reported prevalence of non-obese NAFLD varies widely,
ranging from 3% to 30% [2]. Today remains unclear how patients without
obesity develop NAFLD, therefore it is important to understand the clinical
and pathological conditions of non-obese NAFLD.
Aims & Methods: In this study, we investigated the liver stiffness and liver fat
content in addition to other clinical and metabolic parameters in type 2 diabetes
patient with non-obese and obese NAFLD detected on ultrasonography (US).
In this cross-sectional study, 245 T2D patients with age of 40–80 years from the
Kyiv City Clinical Endocrinology Center were selected. Inclusion criteria were:
age over 18 years, presence of T2D in association with fatty liver disease. The
diagnosis of fatty liver was based on the results of abdominal ultrasonography,
which was done by trained technicians with Ultima PA (Radmir Co., Kharkiv,
Ukraine). Of 4 known criteria (hepatorenal echo contrast, liver brightness, deep
attenuation, and vascular blurring), the participants were required to have hepa-
torenal contrast and liver brightness to be given a diagnosis. According to body
mass index (BMI) value patients were assigned else to NAFLD group (n¼ 157,
BMI 30.0 kg/m2) or to non-obese NAFLD (n¼ 88, BMI5 30.0 kg/m2) group.
We performed 10 valid measurements of liver stiffness (LS) measured by Shear
Wave Elastography (SWE) in every patient, and a median value was calculated,
the result being measured in kPa. Also in all patient we calculated fatty liver
index (FLI). FLI a validated prediction score for hepatic steatosis severity
designed Bedogni et al [3]. Changes in transaminases activity, serum lipids and
cytokines (TNF-, IL-1b, IL-6, IL-8, INF-) levels were evaluated.
Results: Non-obese NAFLD patient had higher LS (7.52 0.2 vs 6.87 0.09,
p¼ 0.001) values measured by SWE, which were accompanied with increased
transaminase activity: for ALT–42.1 3.17 vs 35.8 1.28 (p¼ 0.028) and for
AST–40.81 2.68 vs 34.31 1.33 (p¼ 0.016) respectively. In contrast to non-
obese group patient in NAFLD group had significantly higher FLI
(86.59 1.09 vs 68.06 1.98, p5 0.001). Markers of chronic systemic inflamma-
tory state were also significantly higher in NAFLD obese as compared to non-
obese patient: IL-1b–44.64 2.0 vs 31.02 1.78 (p5 0.001); TNF-–54.11 2.20
vs 42.28 1.81 (p5 0.001); IL-8–29.18 1.27 vs 22.05 0.99 (p5 0.001) and
INF-–195.60 9.47 vs 132.47 7.54 (p¼ 0.016) respectively. Changes of IL-6
between groups were insignificant.
Conclusion: At present, the clinical-laboratory characteristics of non-obese
NAFLD are not fully understood. Therefore, we found that non-obese
NAFLD associated with higher liver stiffness values and transaminases activities.
On the other hand, patient with obese NAFLD are characterized with more
pronounced liver fat content and elevation of markers of chronic systemic
inflammatory state.
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Introduction: Non-alcoholic fatty liver disease (NAFLD) is usually considered as
the hepatic manifestation of metabolic syndrome and obesity. However, a sub-
group of NAFLD patients are lean. Some studies have reported severe liver
fibrosis in lean NAFLD and these patients are still at risk for development of
liver cirrhosis.
Aims & Methods: This study aimed to investigate the prevalence and risk factors
of lean NAFLD in a cluster of Iranian population. Study population was
recruited from Kavar cohort study which has been started from 2006 in Kavar
town, a small town near Shiraz. The study sampling was performed between
September 2011 and September 2015 among adult subjects (age4 18 years)
who underwent voluntary hepatobiliary ultrasound. NAFLD was diagnosed
using ultrasound and absence of chronic liver diseases such as autoimmune
hepatitis, hepatitis B or C viruses induced hepatitis, hepato-billiary cancers,
Wilson’s disease, 410 g/day alcohol consumption, and receiving some specific
medications known to cause hepatic steatosis (like amiodarone, valporic
acid, etc). Lean individuals were defined as those with body mass index (BMI)
525 kg/m2. Student’s t-test was used for comparisons of continuous variables
and Chi-square test was used for comparison of categorical variables. Receiver
operating characteristics (ROC) curve analysis using area under curve (AUC)
was used for analysis of optimal cutoff values for BMI and waist circumference in
association with lean NAFLD.
Results: 1343 individuals were included. 165 individuals (12.3%) was diagnosed
to have NAFLD. 129 individuals (9.6%) had mild NAFLD and 36 individuals
(2.7%) had moderate NAFLD. None of the participants had severe NAFLD.
In univariate analysis, history of diabetes mellitus (DM) (OR¼ 2.25; 95% CI:
1.15–4.40, P¼ 0.015) and metabolic syndrome (OR¼ 2.80; 95% CI: 1.74–4.48,
P5 0.001) were associated with NAFLD. Higher BMI and waist circumference,
higher systolic and diastolic blood pressure, higher serum triglyceride, total cho-
lesterol, fasting plasma glucose (FPG) and alanine aminotransferase (ALT) were
associated with NAFLD (P5 0.05). In multivariate regression analysis, higher
BMI and waist circumference, higher serum ALT, FPG and cholesterol were
independent predictors of NAFLD in our study population (Table). A cutoff
value of 22.3 kg/m2 for BMI was predictor of NAFLD (sensitivity¼ 72%;
specificity¼ 60%; AUC¼ 0.728, P5 0.001). A cutoff value of 79.5 cm for
waist circumference was predictor of NAFLD in our study population
(sensitivity¼ 80%; specificity¼ 68%; AUC¼ 0.753, P5 0.001). Table:
Multivariate regression analysis showing independent risk factors for lean
NAFLD.
Odds
Ratio (OR)
95% Confidence
Interval (CI) P-Value
BMI 1.27 1.106–1.459 0.001
Waist circumference 1.078 1.047–1.112 50.001
ALT 1.018 1.004–1.033 0.015
Cholesterol 1.008 1.003–1.013 0.003
FPG 1.010 1.003–1.017 0.004
Conclusion: Lean NAFLD was prevalent in our study population and was asso-
ciated with metabolic risk factors. BMI and waist circumference can be used for
prediction of NAFLD in lean individuals.
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Introduction: While some studies have evaluated the ability of new ‘‘real-time’’
elastography devices such as 2-D Shear Wave Elastography (SWE) and Virtual
Touch Quantification (ARFI) in predicting the presence of high-risk gastroeso-
phageal varices, no study has explored the potential role of another point-
SWE technique, ElastPQ, in the assessment of clinically significant portal
hypertension.
Aims & Methods: The aim of our study was to identify a liver stiffness cut-off
value measured by ElastPQ and/or laboratory parameters that could help iden-
tify those patients who can safely avoid screening endoscopy, similarly to the
recently proposed Baveno VI criteria which recommends a liver stiffness value
520 kPa measured by transient elastography in combination to a platelet count
4150,000/ml. Data were collected on 1385 patients who underwent ElastPQ
measurement from January 2013 to January 2016 in our Department.
Inclusion criteria were a liver stiffness value of 7 kPa and an upper gastroin-
testinal endoscopy within 12 months, with a diagnosis of compensated chronic
liver disease. We choose this specific liver stiffness cut-off value in order to
reasonably rule-in all patients with advanced fibrosis and cirrhosis, based on
the limited literature available on this specific elastographic technique.
Exclusion criteria were history of decompensated liver disease, evidence of
porto-spleno-mesenteric vein thrombosis and non-cirrhotic portal hypertension.
Varices were graded as low risk (grade 52) or high risk (grade 2).
Results: The study included 184 patients (114 [62%] hepatitis C, and 160 [87%]
Child-Pugh A). Varices were present in 36% cases, with 10% prevalence of high-
risk varices. According to ROC curve analysis liver stiffness measurement and
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platelet count were evaluated as predictors of high-risk varices. Overall 74/184
(40%) met the new ‘‘BAVElastPQ’’ criteria (that is, liver stiffness 512 kPa and
platelet count 4150,000/ml). Within this group 11/63 (17%) had any grade of
varices and only 1/73 (1%) had high-risk varices. The BAVElastPQ criteria gave
sensitivity of 0.95, specificity of 0.44, a positive predictive value of 0.16 and a
negative predictive value of 0.98. The AUROC for liver stiffness and platelet
count was 0.81 and 0.76, respectively.
Conclusion: The BAVElastPQ criteria correctly identified 99% of patients with-
out high-risk varices. By applying such criteria we could have potentially avoided
40% surveillance endoscopies in our cohort. To our knowledge this is the first
study that evaluated the potential role of a new p-SWE technique such as
ElastPQ in the non-invasive assessment of clinically significant portal hyperten-
sion, similarly to the recently proposed Baveno VI criteria though using ElastPQ
as an alternative to transient elastography.
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Introduction: Proton pump inhibitors (PPI) are commonly prescribed and predis-
pose to small bowel bacterial overgrowth. Hepatic encephalopathy is a frequent
complication of cirrhosis and is associated with intestinal dysbiosis.
Aims & Methods: This study aimed to identify a possible association between PPI
intake and hepatic encephalopathy development in cirrhotic patients.
Retrospective analysis of consecutive cirrhotic patients hospitalized in two
Gastroenterology Departments over 3.5 years. Collection of clinical data, PPI
intake, infection and hepatic encephalopathy at hospitalization. Statistical ana-
lysis was performed with SPSS 21, considering statistical significance p5 0.05.
Results: 386 patients, 321 males (83.2%), mean age 60.3 12.1 years. Main etiol-
ogies of cirrhosis were alcohol (67.4%), alcohol plus hepatitis C Virus (16.3%)
and hepatitis C virus (5.2%). Hepatic encephalopathy was present in 222 (57.5%)
of the patients and 26.9% had PPI intake. In univariate analysis hepatic ence-
phalopathy was associated with infection (p5 0.001), gastrointestinal bleeding
(p5 0.001) and Model for End-Stage Liver Disease (MELD) (p5 0.001).
There was no association between hepatic encephalopathy and PPI intake
(p¼ 0.057), gender (p¼ 0.228) or age (p¼ 0.352). In multivariate analysis, hepa-
tic encephalopathy maintained association with infection (p5 0.001), gastroin-
testinal bleeding (p5 0.001) and MELD score (p¼ 0.001).
Conclusion: In our series, PPI intake was not associated with hepatic encephalo-
pathy development in cirrhotic patients.
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Introduction: The incidence of bacterial infections in cirrhotic patients is signifi-
cantly higher than that observed in general population, being one of the most
important causes of decompensation. In theory, the final result of an infectious
disease depends of three major factors: the antibiotic resistance of the bacteria
and the prompt administration of treatment; the intrinsic virulence or pathogeni-
city of the bacteria; and finally the patient status in relation to risk factors such as
immune status, age, diet and stress. There are conflicting results regarding the
clinical outcome of multidrug-resistant (MDR) bacterial infections in cirrhotic
patients.
Aims & Methods: Our aims within this study were to 1) analyze the incidence of
MDR bacteria in patients with decompensated cirrhosis at admission (less than
24 hours after hospitalization), 2) to study its impact on 30 and 90-day mortality,
and 3) to identify independent risk factors for 30 and 90-day mortality.
We conducted a retrospective cohort study which evaluated all admissions due
to decompensated cirrhosis in one center between 2010 and 2015. MDR bacterial
infections, its acquisition site and the antibiotic resistance patterns were defined
according with the European Centre for Disease Prevention and Control
(ECDC) criteria.
Results: A total of 681 hospitalizations were evaluated and 41% had a bacterial
infection at admission. The 30 and 90-day mortality rate was 14.7% and 38.1%,
respectively. The most common infection was spontaneous bacterial peritonitis
(SBP; 40.5%), followed by urinary tract infection (UTI; 25%). About 55.6% of
the patients had a microbiological documented infection (MDI). MDR bacteria
were identified in 18.6% of all bacterial infections, matching 34.5% of the
nosocomial acquired infections and 8.3% of the community-acquired (CA) infec-
tions. In 40.6% of the UTI there was a MDI by a MDR bacteria. In patients with
documented infections, no difference was noticed between non-MDI, non-MDR
bacteria or MDR bacteria regarding the 30 (p¼ 0.801) and the 90-day (p¼ 0.525)
mortality rate. In the multivariate analysis, elevated BUN and bilirubin, presence
of bacterial infection and lower albumin, sodium and SpO2 were independently
associated with 30 and 90-day mortality. Higher INR and age were indepen-
dently associated with 90-day mortality.
Conclusion: The presence of bacterial infection, independently of the antibiotic
resistance profile, was associated with a worse prognosis in cirrhotic patients. We
identified a high incidence of MDR bacteria in patients with UTI. Given the
described risk factors for MDR bacteria development, we hypothesize that our
results are probably the consequence of a bad antibiotic politics in our district,
especially when managing CA UTIs.
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Introduction: Statins have been shown to decrease intrahepatic vascular resistance
and improve vasodilation of the liver vasculature via enhanced nitric oxide pro-
duction. This meta-analysis of randomized controlled trials (RCTs) was con-
ducted to determine if statin therapy reduces portal hypertension as measured
by the hepatic venous pressure gradient (HVPG) among adult patients with liver
cirrhosis.
Aims &Methods: The objective of this research was to perform a meta-analysis of
randomized control trials (RCTs) and determine if statin therapy reduces portal
hypertension as measured by the hepatic venous pressure gradient (HVPG)
among adult patients with liver cirrhosis. Specifically, this meta-analysis deter-
mined the pooled/standardized mean difference with 95% confidence interval
using the random effects models. A comprehensive literature search from the
PubMed- Medline, EMBASE, Cochrane Library, and Ovid databases was per-
formed using the following terms: cirrhosis, portal hypertension, HVPG, and
statin. Three studies were selected. The quality of the included studies was inde-
pendently appraised by four authors using the Jadad scale. All disagreements and
discrepancies of the reviewers were discussed. Trial results were combined under
a random-effects model. Continuous data were analyzed by calculating the stan-
dard mean difference with 95% confidence interval (CI) and a significant p value
of 0.05. Cochrane Review Manager Software version 5.0 statistical software was
used for all analyses.
Results: Three trials comprising of 98 patients met the inclusion criteria. In the
random-effect model, the weighted mean difference was 0.76mmHg, favoring
statin therapy over placebo. There was no evidence of significant heterogeneity
(P¼ 0.51; I2, 0%).
Conclusion: Statin therapy reduces portal hypertension as measured by the
HVPG among adult patients with liver cirrhosis. The findings of this study
reinforce the promising role of statins in decreasing portal hypertension.
Further RCTs with larger population and with longer duration of follow-up as
well as the use of different statin drugs to explore further on the class effect are
recommended.
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Introduction: The place of noninvasive techniques for the prediction of presence
of portal hypertension in patients with liver cirrhosis is one of the current
research topics.
Aims & Methods: The aim of this study was to evaluate the applicability of the
Baveno VI criteria in a cohort of known compensated HCV liver cirrhosis
patients, to see how often we misclassify the presence of esophageal varices
(EV). Material and method We did a prospective multicentre study, from
September 2015 to December 2016, which included all patients with perfectly
compensated HCV liver cirrhosis, diagnosed by means of elastography, ultra-
sound, endoscopic and biological criteria prior to interferon-free treatment. All
patients were evaluated by upper gastrointestinal endoscopy, transient elastogra-
phy (TE) and biological tests. By using Baveno VI criteria we classified the
patients in: probably without EV (liver stiffness - LS5 20 kPa and
thrombocites4 150.000/mm3), probably with EV (LS325 kPa) and the ‘‘gray
zone’’ in between these criteria.
Results: Out of 403 patients, 127 (30.7%) had LS5 20 kPa, 89 (22%) had LS
between 20–25 kPa, 190 (47.3%) had LS4 25 kPa, 120 (29.7%) had thrombo-
cytes 4150.000/mm3, while 283 (70.3%) had thrombocytes 5150.000/mm3. For
the subgroup probably with EV, the Baveno VI criteria had PPV¼ 84.6%
(Se¼ 40.7%, Sp¼ 74.6%, NPV¼ 26.8%) for predicting the presence of esopha-
geal varices, while for the subgroup probably without EV had NPV¼ 80.3%
(Se¼ 50.2%, Sp¼ 58.6%, PPV¼ 75.6). The subgroup that had LS 520 kPa
and thrombocytes 4150.000/mm3, was compound of 60 patients. Using these
criteria we correctly classified 80% patients, with a Se¼ 80%, Sp¼ 28.3%,
PPV¼ 50%, NPV¼ 61.2%, AUROC¼ 0.70, CI¼ (68.2–71.3). The best cut-off
value for TE for predicting the presence of EV of any grade in our group was
423 kPa, AUROC 0.79 (Se¼ 68.8%, Sp¼ 56.9%, PPV¼ 44.7%,
NPV¼ 78.4%).
Conclusion: By using the Baveno VI criteria in patients with liver cirrhosis for the
prediction of presence of esophageal varices, we can misclassify only 20% of
patients.
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Introduction: Non-invasive fibrosis scores (NIFs) are increasingly replacing liver
biopsy (LB) for estimation of liver fibrosis. Only limited studies have evaluated
the role of NIFs in predicting development of esophageal varices (EV) and
decompensation in cirrhotic patients. Similarrly there are limited studies evalu-
ating combination of radiologic and blood parameters in predicting fibrosis and
outcomes of cirrhosis.
Aims & Methods: We aimed to compare combined radiologic-blood parameters
(CRBP) and blood derived non-invasive fibrosis scores (NIF) for predicting pre
treatment cirrhosis, development of esophageal varices (EV) and liver decom-
pensation post antiviral treatment (AVT). 1605 patients (Jan 2002 to June 2015)
with CHC underwent liver biopsy (LB) and received AVT with pegylated inter-
feron and ribavirin. Three CRBPs (platelet count-bisplenic diameter index [PSI],
platelet count-bisplenicdiameterportal vein index [PSPVI], platelet count-bisple-
nic diameter-portal vein-caudate lobe length index [PSCLI]) and nineteen blood
derived NIFs were calculated from routine blood tests and abdominal ultrasound
done prior to starting AVT. AUROCs were calculated for each of these para-
meters for predicting cirrhosis on pre treatment LB and development of EV and
decompensation on follow-up after AVT.
Results: Mean age was 41.9 9.7 years (85% males), predominantly genotypes 4
(65%) and 1 (11%). Pretreatment LB (Scheuer criteria) showed stage-0 fibrosis in
1.9%, stage-1 in 32.9%, stage-2 in 39.5%, stage-3 in 19%, and stage-4 (cirrhosis)
in 6.6% of the patients. After AVT, there were 1,089 (67.8%) responders, 482
(30%) nonresponders and 34 (2.1%) relapsers. After median follow-up of 6580.5
patient-years post AVT; 39 (2.4%) developed EV (2 patients had both esophageal
and gastric varices and one had only gastric varices) and 52 (3.2%) had decom-
pensation (bleed-9, ascites-39, jaundice-22, hepatic encephalopathy-7, hepatore-
nal syndrome-4). CRBPs had higher accuracy for prediction of cirrhosis and EV,
while NIFs had higher accuracy for predicting decompensation (Table 1). The
highest AUROCs were seen with PSI for predicting cirrhosis (AUROC¼ 0.882)
and EV (AUROC¼ 0.885) and with FIB-4 score for decompensation
(AUROC¼ 0.854). At a cut of 1200 PSI had sensitivity of 87.2% and specificity
of 75% for predicting cirrhosis and at a cut off of 1100 PSI had sensitivity of
89.4% and specificity of 85.7 for predicting EV. At a cut off of 2.5, FIB-4 score
had a sensitivity of 82.5% and specificity of 80.1% in predicting decompensation.
Conclusion: CRBPs predict cirrhosis and development of esophageal varices with
high accuracy. Some of the blood derived NIFs have high accuracy in predicting
decompensation post antiviral treatment. Application of these simple scores may
help in non-invasive screening of patients at high risk for development of eso-
phageal varices and decompensation after antiviral treatment.
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Introduction: Minimal Hepatic Encephalopathy (MHE) is present in more than
30% of patients with chronic liver disease (CLD), and is associated with a poor
prognosis including a higher incidence of falls, RTAs and overall mortality.
Detection of MHE is often difficult due to time constraints associated with the
current gold standard, the psychometric hepatic encephalopathy score (PHES),
which includes five paper-based tests. A smartphone application (EncephalApp
Stroop Test) has been suggested as a viable alternative.
Aims & Methods: We aimed to validate the use of the EncephalApp Stroop Test
as a screening tool for MHE in an Irish population. CLD patients and healthy
controls were recruited from outpatients. CLD patients were identified based on
clinical and radiological evidence. Written consent was obtained. Exclusion cri-
teria: cognitive impairment from any other cause, colour-blindness or dyslexia.
Baseline demographics, level of education and medical history were obtained,
and a Child-Pugh score was calculated where relevant. Each patient performed
the PHES test and the Stroop test. Outcomes included the time taken to perform
each PHES test as well as the total PHES, the Stroop onþoff time and time
taken to complete 5 correct runs on the Stroop App. Results were analysed using
a Stroop cut-off defined by a previous publication: onþ off time 4190 seconds.
Both tests were compared and correlation coefficients calculated. Results were
compared amongst patient groups using a student t-test, where p5 0.05 was
considered significant. ROC analysis was used to establish a standard local
cut-off for a positive Stroop test.
Results: A total of 96 patients (51 males) were recruited. Overall, the mean age
was 51.7 16.6 years; mean years spent in education 13.8 4.2. In all there were
35 CLD and 61 healthy controls. While there was no difference in age or years
spent in education, there were more men in the CLD group compared to the
controls, 23/35 (66%) vs. 28/61 (46%), p¼ 0.06. Within the CLD cohort, 30
(86%) patients were Child-Pugh class A, 4 (11%) were class B and 1 (3%) was
class C. As expected, more CLD patients had a positive PHES, 4/35 (11%) vs. 3/
61 (7%). Overall, correlation between the two tests was poor. 7 (7%) participants
had a positive PHES, while 47 (49%) had a positive Stroop test (¼ 0.1516).
Among controls, 27 (44%) had a positive Stroop test, while 3 (5%) had a positive
PHES (¼ 0.1223). Similarly, 20 (57%) CLD patients had a positive Stroop test
and 4 (11%) had a positive PHES (¼ 0.1765). Regarding the Stroop test, the
mean time taken to complete 5 correct runs was significantly higher in CLD
patients, mean 117.9 s [58.3–217.8 s] vs. 101.2 s [55.3–218.6 s], p¼ 0.02.
However, mean Stroop onþoff times were similar, 198.4 s [102.6–307.7 s] in
the CLD cohort versus 187.9 s [101.2–420.9 s] in the control group. Of note,
CLD patients with a positive PHES had a significantly higher Stroop onþoff
time compared to those with a negative PHES, mean 260 s vs. 190 s, p¼ 0.02.
ROC analysis gave a Stroop onþ off time of 4187 s as a positive cut-off for our
cohort, sensitivity¼ 100%, specificity¼ 59%. In total, 39 patients had an onþ -
off time 4187 s, 18 (51%), 2 fewer false positives, in the CLD group, and a
slightly better correlation (¼ 0.2404). On average, PHES took 20 minutes to
complete, and the Stroop test 5 minutes. Older age and limited years of education
correlated with a poorer performance on the Stroop test (r¼ 0.62, p5 0.0001
and r¼ -0.322, p5 0.0001, respectively). However, neither age nor years of edu-
cation correlated with performance on the PHES (r¼ 0.087, r¼ 0.12,
respectively).
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Test PHESþ PHES - Stroopþ Stroop - Kappa
All patients 7 89 39 57 0.107
CLD 4 31 18 17 0.2404
Conclusion: This is the first study investigating the efficacy of the Stroop test in
Ireland. It was quicker and easier to perform compared to PHES test. Age and
years in education had a greater impact on the Stroop test, which may affect its
application and interpretation. While our ROC analysis suggests a similar cut off
to previously published values, there is significant variability and local validation
is likely to be required. Overall the comparison with the gold standard PHES was
poor. However, there were no false negative Stroop tests suggesting it may be a
convenient filter test for MHE.
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Introduction: Cirrhosis is accompanied by significant changes of the intestinal
microbiome including the overgrowth of the intestine with potential pathogens
that can translocate through a weakened gut barrier and cause severe infections.
We hypothesized that probiotic bacteria repress intestinal pathogen growth and
strengthen the gut barrier.
Aims & Methods: Therefore, we conducted a randomized, double-blind, placebo-
controlled study to test the effects of the multispecies probiotic Ecologic Barrier
(Winclove, Amsterdam, The Netherlands)/Omnibiotic Hetox (Allergosan, Graz,
Austria) on microbiome composition, predicted metagenome functions, and tight
junction function in cirrhosis patients. A once daily dose of the probiotic mixture
(1.5*1010 CFU) or placebo was administered to 58 patients with Child’s A cir-
rhosis. We analysed the stool microbiome prior, immediately after the interven-
tion and six months following end of treatment. Hypervariable region 1–2 of the
bacterial 16 S rDNA was sequenced and predictive communities were identified
using Ada Boost Classifier. Functional predictions were analysed by
Phylogenetic Investigations of Communities by Reconstruction of unobserved
States (PICRUSt). Zonulin and calprotectin were assessed in stool as markers
for gut permeability and intestinal inflammation, respectively.
Results: A community of 37 operational taxonomic units (OTUs) was sufficient
to pinpoint characteristic features of the microbiome before and after the inter-
vention. Within this predictive community, three OTUs were found to be differ-
entially abundant: Lactobacillus brevis and Lactococcus lactis increased
significantly and Enterococcus durans decreased significantly in the probiotic
group. Zonulin normalized in 20% of patients in the probiotic group.
Predicted metagenome functions (assessed by PICRUSt) and calprotectin did
not show any differences during intervention.
Conclusion: In conclusion, a six months intervention with a multispecies probiotic
enriched the microbiome of cirrhotic patients with probiotic bacteria.
Additionally, the abundance of Enterococcus durans was reduced and the gut
barrier was strengthened.
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Introduction: Diabetes mellitus (DM) is a growing disease worldwide. Some pre-
vious studies have reported negative impact of DM in patients with chronic liver
disease.
Aims & Methods: This study aimed to investigate the prevalence of DM in
patients with liver cirrhosis and its impact on post-liver transplant short-term
and long-term outcomes. In a cross-sectional study patients with liver cirrho-
sis on liver transplant waiting list who had undergone liver transplantation
between March 2012 and March 2015 at Shiraz Transplant Center, Shiraz,
Iran were included. Clinical and laboratory data of patients were recorded
and patients were followed during post-liver transplant period. DM was diag-
nosed if the patient had fasting plasma glucose (FPG) 126mg/dL or
random plasma glucose 200mg/dL in 2 different checkings or receiving
anti-diabetic medications. The impact of DM on post-transplant outcomes
was investigated using student t-test and chi-square test. Multivariate
logistic regression was used for analysis of independent risk factors of mor-
tality after liver transplantation. Kaplan-Meier method was used for analysis
of survival.
Results: 1014 patients were included in the study. 259 patients (25.5%) found to
have DM. Prevalence of DM was significantly higher among patients with cir-
rhosis due to non-alcoholic steatohepatitis (NASH) (P5 0.001). Portal vein
thrombosis (PVT) was significantly higher among cirrhotic patients with DM
(OR¼ 1.79; 95% CI: 1.18–2.70; P¼ 0.005). Mean model for end stage liver dis-
ease (MELD) score, body mass index (BMI) and duration of liver disease were
not different in patients with and without DM (P4 0.05). Mean blood urea
nitrogen (BUN) in 30 days post-transplant period was 16.17 17.4mg/dL in
patients without DM compared to 18.39 11.95mg/dL in patients with DM
(P5 0.001). Mean serum creatinine level was 1.46 0.95mg/dL in patients with-
out DM compared to 1.78 1.92mg/dL in patients with DM (P¼ 0.001).
Abstract: P1336. Table 1: Predictive Accuracy of Different Combined Radiological and Blood Parameters and Non-invasive Fibrosis Scores for Predicting Cirrhosis,
Development of Esophageal Varices and Decompensation
NIFs/CRBPs
Cirrhosis on liver biopsy
(pre treatment)*
Esophageal varices
(post antiviral treatment)*
Decompensation
(post antiviral treatment)*
AST-platelet ratio index (APRI) 0.842 (0.800–0.884), 0.021 0.769 (0.607–0.932), 0.083 0.538 (0.063–0.783), 0.120
Fibrosis-4 (FIB-4) 0.827 (0.781–0.874), 0.024 0.841 (0.716–0.886), 0.018 0.854(0.738–0.956),0.041
Lok score 0.800 (0.754–0.846), 0.024 0.820 (0.775–0.876), 0.023 0.803(.858–0.993),0.127
GUCI score 0.847 (0.805–0.889), 0.021 0.817 (0.667–0.967), 0.077 0.604(0.062–0.775),0.144
King score 0.851 (0.811–0.892), 0.021 0.816 (0.742–0.869), 0.032 0.641(0.016–0.898),0.150
Fibrosis index 0.820 (0.771–0.870), 0.021 0.819 (0.752–0.869), 0.032 0.767(0.529–0.873),0.079
Fibrosis cirrhosis index 0.794 (0.745–0.843), 0.025 0.801(0.658–0.945), 0.073 0.646(0.603–0.998),0.143
Cirrhosis discrimination score 0.793 (0.747–0.839), 0.023 0.766(0.883–0.849), 0.042 0.804 (0.610–0.988), 0.089
Age platelet index 0.819 (0.789–0.858) 0.020 0.757 (0.686–0.827), 0.036 0.816 (0.663–0.948), 0.078
Fibro-index 0.799 (0.753–0.845), 0.023 0.558 (0.308–0.809),0.128 0.678 (0.445–0.873), 0.114
Globulin platelet index 0.817 (0.793–0.881),0.021 0.500 (0.243–0.757),0.131 0.500 (0.297–0.800),0.146
Doha score 0.838 (0.797–0.880), 0.021 0.796 (0.733–0.858), 0.032 0.685 (0.586–0.842), 0.044
Fibro alpha 0.636 (0.568–0.704), 0.035 0.622 (0.371–0.874), 0.128 0.644 (0.362–0.999),0.146
AST-ALT ratio 0.605 (0.545–0.665), 0.031 0.565 (0.356–0.774), 0.107 0.671(0.405–0.999),0.137
Pohl score 0.586 (0.524–0.649), 0.032 0.588 (0.485–0.691), 0.052 0.619 (0.392–0.836),0.126
Globulin albumin ratio 0.762 (0.708–0.816), 0.027 0.507 (0.407–0.607), 0.051 0.452 (0.225–0.661), 0.110
Mean platelet volume 0.689 (0.563–0.816), 0.064 0.461 (0.289–0.633), 0.088 0.648 (0.478–0.756), 0.067
RDW to platelet count ratio 0.485 (0.426–0.545), 0.030 0.829 (0.816–0.943), 0.032 0.839 (0.742–0.959), 0.060
PSI^ 0.882 (0.700–0.963), 0.042 0.885 (0.794–0.977), 0.047 0.596 (0.319–0.874), 0.142
PSPV 0.872 (0.709–0.936), 0.033 0.845 (0.703–0.983), 0.071 0.551 (0.300–0.803), 0.128
PSPVCLI 0.850 (0.737–0.922), 0.047 0.852 (0.738–0.962), 0.057 0.495 (0.248–0.743), 0.126
*AUROC (95% Confidence interval), standard error
A630 United European Gastroenterology Journal 5(5S)
Rejection episodes (OR¼ 1.38; 95% CI: 0.47–1.1, P¼ 0.129) and acute kidney
injury (OR¼ 1.33: 95% CI: 0.96–1.84, P¼ 0.07) after liver transplantation were
not statistically different in patients with and without DM. Using Kaplan-Meier
method, mean post-liver transplant survival was 50.94 0.67 months in cirrhotic
patients without DM and 45.26 1.46 months in cirrhotic patients with DM
(P5 0.001). Post-liver transplant survivals at 6 months, 1 year and 4 years
were outlined in Table. In patients with DM, presence of hepatocellular carci-
noma (HCC) (OR¼ 4.01; 95% CI: 1.64–9.78, P¼ 0.002), acute kidney injury
within 30 days after transplant (OR¼ 2.05; 95% CI: 1.02–4.10, P¼ 0.042) and
pre-transplant PVT (OR¼ 2.51; 95% CI: 1.16–5.14, P¼ 0.019) were independent
predictors of mortality after liver transplantation.
Table: Post-liver transplant survival at 6 months, 1 year and 4 years in patients
with and without DM
6 month survival 1 year survival 4 year survival
With diabetes 81% 2.5% 79.1% 2.6% 75.9% 2.8%
Without diabetes 90.6% 1.1% 88.7% 1.2% 85.4% 1.3%
Conclusion: Diabetes mellitus is prevalent in patients with liver cirrhosis espe-
cially among those with NASH. Patients with DM may have lower post-trans-
plant survival and need more intense follow-up.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The Baveno VI guidelines propose that cirrhotic patients with a
liver stiffness measurement (LS) 520 kPa and a platelet count 4150000/mL
can avoid screening endoscopy as their combination is highly specific for exclud-
ing clinically significant varices.
Aims & Methods: The aim of the study was to validate the Baveno VI criteria. We
did a retrospentive study, from 2009–2014. We took all the patients with tran-
sient elastography data. Inclusion criteria were a LS 412 kPa and an upper
gastrointestinal endoscopy within 12 months, with a diagnosis of chronic liver
disease. Varices were graded as low risk (grade 52) or high risk (4grade 2).
Results: The study included 774 patients (hepatitis C virus 40.5%, hepatitis B
virus 16.1%, 31.6% etanolics, 11.8% other etiology, and 47.5% were Child Pugh
A). Varices were present in 561/774 (2.4%) cases, with 8% prevalence of high risk
varices. 306/774 (39.6%) were at low risk and 468/774 (60.4%) had high risk
varices. 59/774 (7.6%) met the Baveno VI criteria. The Baveno VI criteria gave a
Se¼ 62.2%, Sp¼ 80.6%, NPV¼ 44.6%, PPV¼ 89.5%, positive likelihood
ratio¼ 3.4, negative likelihood ratio¼ 0.47. If we combined the LS 520 kPa
and platelet count 4150,000, the AUROC was 0.73, CI (0.68–0.74), p5 0.0001.
Conclusion: The Baveno VI criteria has correctly appoint 85.3% of patients who
could safely avoid endoscopy.
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Introduction: Cirrhotic patients very often need to be hospitalized and it is known
that they have a higher mortality rate.
Aims & Methods: The aim of the study was to assess the factors associated with
mortality among cirrhotic patients and to create a new score for predicting
mortality. The study was retrospective, and we included all hospitalized patients
with the final diagnosis of liver cirrhosis on a period of 7 years. We divided them
in two cohorts, an initial group, which was analysed; and a control group, in
which we validated the score. We performed univariate and multivariate analysis
in order to determine a prediction model for mortality.
Results: A total of 1163 cirrhotic patients were included. In-hospital
mortality rate was 10%. The initial cohort included 899 patients. Regarding
cirrhosis etiology: 384/899 (42%) had hepatitis C, 158/899 (17.5%) had hepatitis
B, 293/899 (32.5%) were alcoholic, 6/899 (0.6%) were autoimmune, 7/899
(0.7%) were cardiac, 13/899 (1.4%) were primary biliary cirrhosis and in 5%
of cases the etiology was unknown. In univariate analysis, hyponatremia
(p5 0.0001), hyperpotasemia (p5 0.0001), hypoalbuminemia (p5 0.0001),
high values of bilirubin (p5 0.0001), high values of creatinine (p5 0.0001)
were strongly associate with in hospital mortality. In multivariate analysis,
the model including albumin, sodium, potassium, creatinine and bilirubin (all
p-values 50.05) had an AUROC¼ 0.78, CI (0.75–0.81), p5 0.0001. Using
this factors as predictors, by multiple regression analysis we obtained in the
initial group the following score: ABCPS
score¼ 0.04þ 0.03*Albuminþ 0.05þ 0.02*Creatinineþ 0.04þ 0.04*Bilirubinþ-
0.05þ 0.28* Potassiumþ 0.04*0.07*Sodium.
Conclusion: Prevention and prompt treatment of kidney injury, hyponatremia,
hyperpotassemia, can improve survival. ABCPS score can be an usefull score to
rule out patients with high mortality rate.
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Introduction: Bariatric surgery provides a durable method of weight loss but is
associated with serious adverse events. Some studies report an increase in drug-
induced acute liver injury following bariatric surgery.
Aims & Methods: We aimed to assess if bariatric procedures increase the risk of
acute liver failure in a large inpatient cohort. We retrospectively analyzed dis-
charge data on patients who developed acute liver injury (ALI) using the
Nationwide Inpatient Sample (NIS) database from 2010–2013. Discharges with
an ICD-9 code indicating ALI were included. The primary outcome was ALI in
patients with a history of bariatric surgery compared to all other patients with an
inpatient diagnosis of ALI. Secondary outcomes were mortality in the two
cohorts and independent socio-demographic and medical risk factors for mor-
tality in each cohort. Variables tested include age, gender, race, income, Charlson
criteria, hospital factors and medical comorbidities including Malnutrition,
HTN, Anemia, CKD, Diabetes, CHF, Coagulopathy, Alcoholism, HBV and
HCV. Univariate and multivariate logistic regression analyses were performed
to identify independent predictors.
Results: During the study period, a total of 437,390 patients were diagnosed with
acute liver injury and were included in the study, of which 3,799 had previously
undergone bariatric surgery. In the post-bariatric cohort, mean age was 58.7
years and 77% were women. The prevalence of acute liver injury in all inpatient
admissions for that time period was higher in patients with history of bariatric
surgery (0.85%) than in non-bariatric patients (0.75%), p5 0.01. Patients with
history of bariatric surgery displayed odds ratio of 1.52 of developing ALI when
compared to patients with no history of bariatric surgery (95%CI: 1.43–1.61,
p5 0.01). The rate of overall inpatient mortality was higher in non-bariatric
cohort (15.9% versus 9.3%). Post-bariatric patients admitted for ALI were
more likely to be younger, female, Caucasian and residing in more affluent
areas. Post-bariatric patients were also more likely to have higher rates of mal-
nutrition, anemia, alcoholism, and significantly lower prevalence of hepatitis B
and C, CHF, diabetes and kidney disease. In a multivariate regression model, the
presence of CHF and coagulopathy increased mortality risk, and diagnosis of
alcoholism was associated with lower mortality risk from ALI in patients with
prior history of bariatric surgery (Table).
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Comorbidity Adjusted Odds Ratio 95% CI p-value
Malnutrition 1.86 0.89–3.88 0.10
HTN 0.64 0.34–1.18 0.16
Anemia 0.63 0.36–1.11 0.12
CKD 1.66 0.79–3.54 0.18
Diabetes 1.04 0.55–1.94 0.91
CHF 3.92 1.77–8.71 50.01
Coagulopathy 1.75 1.03–2.96 0.04
Alcoholism 0.48 0.25–0.95 0.04
HCV 0.86 0.27–2.72 0.80
Conclusion: Bariatric surgery increases the risk of subsequent acute liver injury.
Post-bariatric surgery patients admitted for ALI are more likely to have anemia,
malnutrition, and alcoholism, supporting the hypothesis that baseline nutritional
status may predispose to drug-induced ALI. Addressing these potentially mod-
ifiable risk factors may decrease the significant morbidity and mortality of ALI.
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Introduction: Acoustic radiation force impulse (ARFI) imaging measures liver
stiffness (LS), which significantly correlates with the stage of liver fibrosis in
treatment-naive patients with chronic hepatitis B (CHB). So far, the use of
ARFI elastography to monitor change in liver fibrosis has not been properly
evaluated during antiviral therapy in CHB patients.
Aims & Methods: We aimed to prospectively assess the clinical usefulness of
ARFI during long-term antiviral therapy in CHB patients. Seventy-one CHB
patients were consecutively recruited and received antiviral therapy with enteca-
vir. Paired liver biopsies were performed in 27 patients at baseline and week 78 of
entecavir therapy. LS was assessed by ARFI at multiple follow-up sessions.
Results: LS significantly decreased with treatment and continued to decrease
after normalization of alanine aminotransaminase. Overall, 97.2% patients
achieved improvement of LS, whereas 19.7% patients had more than 30% reduc-
tion in LS values between baseline and week 104. Multivariate linear regression
analysis showed that the degree of LS reduction significantly correlated with the
baseline levels of LS value, platelet and cholinesterase. In the 27 patients who
received paired liver biopsies, LS significantly correlated with stage of fibrosis
and inflammatory grade at baseline. LS values decreased more significantly in
patients with fibrosis regression than those with static histological fibrosis.
Changes in LS value (change threshold¼ 15%) was significantly correlated
with the changes in histological fibrosis staging (r¼ 0.63, P5 0.001).
Conclusion: In CHB patients, LS assessed by ARFI was significantly reduced
during antiviral therapy. Longitudinal monitoring of LS might be a promising
noninvasive assessment of fibrosis regression during long-term antiviral therapy
in CHB. Further studies on large populations are warranted.
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1Life and Health Sciences Research Institute (ICVS), School of Medicine,
University of Minho, Braga/Portugal
2Gastroenterology Department, Hospital da Senhora da Oliveira, Guimarães,
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Introduction: In chronic infection with Hepatitis B virus (HBV) hepatic steatosis
is mainly attributable to metabolic risk factors, rather than virologic factors. We
aimed to assess the presence of hepatic steatosis in chronic HBV inactive carriers
using non-invasive methods, namely controlled attenuation parameter (CAP)
determined with fibroscan. We also aimed to identifiy risk factors associated to
hepatic steatosis and their impact in the values of fibrosis determined with
fibroscan.
Aims & Methods: Fibroscan was performed in chronic HBV inactive carriers,
with assessment of hepatic transient elastography and CAP, with simultaneous
assessment of anthropometric, clinical and analytical parameters. CAP values of
248,268 and 280 dB/m defined cut-offs of steatosis grade I, II and III,
respectively.
Results: Included 49 patients with a mean transient elastography of 5.1 1.5 Kpa
and a mean CAP of 248.9 49.3 dB/m. A significant association was found
between the value of CAP and the presence of steatosis in the last ultrasound
(234.4 46.0 dB/m vs 289.4 34.0 dB/m, p5 0.01), the presence of elevated tri-
glycerides (239.9 49.8 dB/m vs 284.1 28.1 dB/m, p¼ 0.01) and obesity
(244.0 46.7 dB/m vs 290.7 46.6 dB/m, p¼ 0.01). When comparing patients
with CAP4 and 268 dB/m, patients with higher CAP values more frequently
were overweight (BMI 25 kg/m2) (45.8% vs 84.0%, p5 0.01) and had meta-
bolic syndrome (MS) (12.5% vs 40%, p5 0.03), and also presented with higher
values of BMI (24.6 2.6 kg/m2 vs 29.2 6.4 kg/m2, p5 0.02), waist circumfer-
ence (85.0 9.0 cm vs 97.9 11.3 cm, p5 0.01) and triglycerides (95.6 31.4mg/
dL vs 136.1 62.9mg/dL, p¼ 0.01) and lower values of HDL cholesterol
(58.9 14.3mg/dL vs 50.4 14.4mg/dL, p5 0.01). A significant association
was also found between the value of elastography and female gender (females
4.6 1.3KPa vs males 5.8 1.5KPa, p5 0.01), elevated triglycerides
(4.9 1.5KPa vs 6.0 1.1KPa, p¼ 0.03) and obesity (4.9 1.4KPa vs
6.5 1.1KPa, p5 0.01).
Conclusion: Different components of MS seem to contribute both to fibrosis and
steatosis in chronic HBV inactive carriers. In this subset of patients, the inter-
pretation of fibrosis values assessed by fibroscan should be made with caution
since it may be influenced by metabolic parameters.
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Introduction: Chronic hepatitis B (CHB) is a serious health concern in terms of its
high prevalence, as well as restricted and costly health care resources in India.1
Unani herbal drugs such as root of Saussurea lappa and whole plant of Artemisia
absinthium have been used successfully in the treatment of hepatitis in Unani
Medicine for centuries. These drugs have exhibited potential anti-hepatitis B,
hepatoprotective, immuno-modulatory, anti-inflammatory and anti-oxidant
activities in various animal models.2 With this background, present prospective
clinical trial was tried to be designed according to the guidelines of American
association for the study of liver diseases (AASLD) and implemented after
Institutional ethical clearance.
Aims & Methods: Objective was to evaluate the antiviral effect of herbal drugs,
Saussurea lappa and Artemisia absinthium against hepatitis B virus (HBV) in the
management of CHB and to collect data to warrant further clinical trials. In an
open prospective single-arm study, we assigned 30 patients with HBeAg-negative
or HBeAg-positive CHB to receive decoction of root of Saussurea lappa, 15mL
(containing approx. 1 g of dried aquoues extract) in the morning and decoction of
Artemisia absinthium, 15mL (containing approx. 1 g of dried aquoues extract) in
the evening once daily empty stomach for 12 weeks. Physiochemical standardiza-
tion and TLC and HPTLC fingerprinting of decoctions were also done. Test drug
was evaluated for its efficacy in loss of HBsAg (miniVIDAS) and HBeAg
(CLIA tech.), a plasma HBV DNA level (RT PCR) of less than 200 IU/mL at
week 12 (after treatment). Normalization of alanine aminotransferase levels
[ALT (enzymatic essay)] without any significant adverse effects (clinical para-
meters, haemogram, kidney function test, and blood sugar fasting and post
prandial) at week 6 (mid-treatment) and 12 (after treatment) would be suggestive
of resolution of inflammation of liver.
Results: 1. HBsAg loss was observed in 5 (35.71%) patients in HBeAg-positive
group (n¼ 14) (p5 0.05) and 4 (25%) patients in HBeAg-negative group (n¼ 16)
at week 12 (after treatment) (p¼ 0.10). These 9 HBsAg negative patients were
further assessed on 26th week of treatment, all 9 maintained their negative
HBsAg status. 2. HBeAg loss was observed in 71.42% patients at week 12
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(p5 0.001). cVR was achieved in 57.14% patients in HBeAg-positive group
(p5 0.01) and 37.5% of patients in HBeAg-negative group at week 12
(p5 0.05). 3. Normalization of ALT was observed in 85.71% and 81.25%
patients in HBeAg-positive and HBeAg-negative group respectively at week 12
(p5 0.001) without any significant adverse effects in clinical and laboratory
parameters (p4 0.05) at mid and after treatment.
Conclusion: 1. Our study has substantiated that Saussurea lappa and Artemisia
absinthium have antiviral effect against HBV in chronic hepatitis B. 2. Test drug
effectively suppressed HBV DNA, HBeAg and HBsAg in study patients. 3.
Normalization of liver function test showed that the test drug can improve
functions of liver without any significant adverse effects for a treatment duration
of 12 weeks. 4. Limitation include small sample size, small duration and without
control. Unlike other studies on CHB evaluating effect of conventional antivirals,
we have enrolled only selected clinically stable CHB patients who were not
diabetic and hypertensive, without liver fibrosis, and not have other neurological,
kidney and heart disease, being a pilot study. 4. Future recommendation of
double blind randomized clinical trial with satndard control with large sample
size, longer duration and including cirrhotic patients.
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Introduction: Serum HBsAg loss is the recommended stopping rule in nucleo(t)-
side-analogues (NUC) responders, even if this event occurs rarely.
Aims & Methods: We aimed to investigate in patients with chronic HBeAbþ
hepatitis the kinetics of HBsAg levels during the NUC therapy to evaluate the
predictive parameters of HBsAg seroclearance. Patients with CHB, receiving
NUC antiviral therapy with stable viral suppression (HBV-DNA5 20 IU/ml),
were recruited at the Gastroenterology Unit of the University of Naples
‘‘Federico II’’. Sequential serum samples from these patients were tested for
HBsAg quantification with the ElecsysHBsAg II Quant immunoassay (Roche
Diagnostics, Indianapolis, USA). HBsAg levels were determined before starting
NUC treatment and on-treatment every 12 months.
Results: A total of 95 HBsAg-positive, HBeAg-negative patients (M/F: 73/22,
median age 50 yrs, 34% cirrhotic) with stable viral suppression by NUCs, were
enrolled. Precisely 56 patients underwent to Tenofovir, 22 Entecavir and 17
Lamivudine. The median treatment duration was 111 months, range 25–183
months. There was a significant decrease of the HBsAg levels during NUC
therapy from 3471 UI/ml at the baseline to 1758 IU/ml at the last determination
(p5 0.001). The statistically significant HBsAg decrease was also maintained
when the patients were clustered according to antiviral therapy, severity of
liver disease and previous interferon treatment. HBsAg seroclearance occurred
in 18/95 patients (19%). The multivariate analysis showed that the only predic-
tive parameter statistically significant of HBsAg seroclearance is the HBsAg level
at baseline. Moreover, HBsAg seroconversion to HBsAb occurred in 4/18
patients, in which undetectable HBsAg value was evidenced at least two years
before the seroconversion, and NUC therapy was successfully stopped, without
relapse after a mean follow-up period of 24 months.
Conclusion: The results of this study suggest a role of on-treatment HBsAg
quantiEcation in the management of NUC-treated patients. HBsAg measure-
ment would be a useful parameter to optimize antiviral treatment schedule.
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Introduction: Chronic hepatitis B (CHB) is a common liver disease worldwide,
and can be progressed to liver cirrhosis and hepatocellular carcinoma.
Unfortunately, only a minority of CHB patients could achieve the clearance or
seroconversion of hepatitis B virus e-antigen (HBeAg), the end point of
treatment, even after multiple years of antiviral therapy. Therefore, it is urgent
to develop new and effective strategy for treatment of CHB and examine the
mechanisms.
Aims & Methods: In this study, we performed 60 times of fecal microbiota trans-
plantation (FMT) by nasointestinal tube for 20 CHB patients who continued
with their previous antiviral treatment, and accordingly measured the HBeAg
level four weeks after each FMT. Fecal samples of CHB patients before
(Baseline) and after FMT as well as donors were collected for analyses of gut
microbiota by sequencing 16S V3-V4 regions on Illumina MiSeq using PE 250
reagents.
Results: Results showed that HBeAg of 13 patients (65%) was cleared or reduced
after one to seven times of FMT. Based on OTUs at cutoff of 3% disimilarity,
there were significant (PERMANOVA, P¼ 0.001) differences in overall gut bac-
terial communities among CHB-Baseline, CHB-FMT, and donors, forming three
major clusters in PCA ordination. Whereas, no significant differences (ANOVA,
P4 0.05) were detected in -diversity indexes among the three groups, including
observed OTU numbers, Shannon index, Simpson index, and Pielou evenness.
This implies that it is the taxonomic relative abundance, not taxon number, that
contributed to the bacterial community differences. Overall, gut bacteria were
mainly composed of Fimicutes (Lachnospiraceae, Ruminococcaceae,
Veilloneuaceae), Bacteroidetes (S24-7, bacteroidaceae, Prevotellaceae), and
Proteobacteria (Alcaligenaceae, Enterobacteriaceae). More specifically,
Actinomyces was significantly higher in CHB patients (CHB-Baseline) than
FMT-treated patients (CHB-FMT) and donors, and was identified as the bio-
marker of CHB using LEfSe analysis. Conversely, Prevotella and Epulopiscium
were significantly decreased in CHB-Baseline after FMT to almost equal to the
abundances in donors, and were also identified as biomarkers.
Conclusion: In summary, along with the clearance or remission of HBeAg, the gut
bacterial communities of chronic hepatitis B patients were remarkably alerted
after fecal microbiota transplantation, with some taxa abundances changed
accordingly, which suggested their potential application as targets for clinical
diagnosis and treatments in future.
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Introduction: Hepatitis B surface antigen (HBsAg) seroconversion is rarely
achieved in chronic hepatitis B (CHB) patients during nucleoside analogue
(NA) monotherapy. The efficacy of pegylated interferon alfa-2a (peg-IFN-2a)
add-on therapy in those CHB patients remains unclear.
Aims & Methods: We aimed to compare the efficacy of peg-IFN-2a add-on
therapy with NA monotherapy in treatment-experienced CHB patients. We
enrolled hepatitis B e antigen (HBeAg)-negative CHB patients aged older than
16 from the First Affiliated Hospital of Sun Yat-sen University in China. All had
received NA monotherapy for 3 years with sustained undetectable plasma HBV
DNA. The exclusion criteria included: cirrhosis or other chronic liver diseases,
previous immunological therapy, pregnancy and breastfeeding, contraindications
for peg-IFN-2a, or other serious diseases. The eligible patients were assigned to
receive peg-IFN-2a add-on therapy for 48/72 weeks or to continue to receive
NA monotherapy for 96 weeks. HBV DNA levels, HBV serologic indicators,
liver function, renal function, thyroid function, blood cells count and imaging
examination were assessed. The primary end point was HBsAg loss from baseline
to week 96.
Results: 71 patients were enrolled (22 to peg-IFN-2a add-on therapy group and
49 to NA monotherapy group), of whom 9 in peg-IFN-2a add-on therapy
group and 25 in NA monotherapy group completed more than 24 weeks of
follow-up, the remaining patients have not yet reached 24 weeks of follow-up.
There was no significant difference in age, gender, body mass index (BMI),
HBeAg levels, alanine aminotransferase (ALT), or aspartate aminotransferase
(AST) between the two groups at baseline. At week 24, HBsAg levels in peg-
IFN-2a add-on therapy group were significantly lower than the baseline
(2.96 0.14 vs 2.09 0.82 Log10IU/ml, p¼ 0.009), but there was no obvious
change in NA monotherapy group (3.43 0.46 vs 3.44 0.44 Log10IU/ml,
p¼ 0.843). The HBsAg loss in peg-IFN-2a add-on therapy group was signifi-
cantly higher than in NA monotherapy group at week 24 (0.87 0.76 vs
0.01 0.10 Log10IU/ml, p¼ 0.008). Among those patients who completed 96
weeks of follow-up, two patients in peg-IFN-2a add-on therapy group (22.22%)
achieved HBsAg seroconversion, but none in NA monotherapy group (0%).
Conclusion: The peg-IFN-2a add-on therapy increased loss of HBsAg in HBeAg
negative treatment-experienced CHB patients as compared to NA monotherapy.
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Introduction: As few reliable data on the burden of hepatitis C virus (HCV) are
available from the Middle East, we analyzed HCV burden in the Lebanese
population and the value of comprehensive screening and treatment at different
age groups and fibrosis stages.
Aims & Methods: A multi-cohort, health-state-transition model was developed to
project the number of HCV patients achieving a sustained virologic response 12
weeks after treatment (SVR12) or progressing to compensated cirrhosis (CC),
decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC), and liver-
related death (LrD) from 2016 to 2036. Epidemiology and mortality data were
extracted from the Ministry of Health bulletin while costs were collected from
insurance claims. The proportion of patients screened for HCV was projected to
increase to 60%/85%/99% (low/medium/high screening scenarios) in 2036, with
a new cohort of patients being diagnosed each year. SVR12 rates were extracted
from clinical trials. Separate models were used for 18–39 and 40–80 age groups to
account for difference prevalence and screening rates.
Results: Low, medium and high HCV screening scenarios showed that 3838, 5665
and 7669 individuals would be diagnosed with HCV infection from 2016 to 2036,
40% aged 18–39 and 60% aged 40–80. In the absence of treatment, the projected
number of patients reaching CC, DCC, HCC and LrD in 2036 was 899, 147, 131
and 147 respectively for the 18–39 age groups. In the 40–80 age groups, these
projections were substantially greater: 2828 CC, 736 DCC, 668 HCC and 958
LrD. The overall economic burden of these liver complications would reach 150
million E. However, introducing direct-acting antivirals (DAAs) for F0-F4
patients would increase by 43% and 62% the proportion of remaining life-
years (LYs) spent in SVR12 compared to DAAs given to F2-F4 or to F3-F4
only, respectively. Although DAAs for F0-F4 increase the cost of HCV treat-
ment, they also provide the greatest population health benefit and lowest cost per
LY gained in SVR12. Compared to no treatment and screening, adopting the high
screening variant and DAAs access to F0-F4 would cost an additional 1,957 E
for every LY gained in SVR12 for patients aged 18–39 and 168 E for the 40–80
age group
Conclusion: An enhanced screening policy coupled with broader access to DAAs
will diminish the future clinical and economic burden of HCV in the Lebanese
population and provide the greatest health benefits per amount invested, among
middle-aged and elder adults with a big difference in additional costs between the
2 groups
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Introduction: Hepatitis C virus (HCV) infection is a prevalent condition in
patients with end-stage renal disease (ESRD) and increases the risk of death.
Treatment of HCV in these patients reduces both morbidity and mortality rates
and improves the outcomes of one future kidney transplantation. Yet patients
with hepatitis C and chronic kidney disease have few treatment options. Direct-
acting antivirals (DAA) are a well-established, effective and safe treatment regi-
men of the HCV infection, but proofs on ESRD patients requiring hemodialysis
(HD) are scarce. Additional studies are still necessary in order to evaluate the real
impact of these agents in the daily clinical practice.
Aims & Methods: Our objective was to assess the efficacy and safety of DAA
treatment for HCV-infected patients with ESRD under HD, in the daily practice
of a tertiary care centre, describing the HCV infection, treatment type, the evolu-
tion of virological response and clinical outcomes (anemia and other adverse
effects). The HD and HCV-infected patients treated with DAA between April
2015 and February 2017 were analyzed.
Results: Our sample included 16 patients, 13 males (81%) and 3 females (19%),
with a mean age of 59 years (45–72 years). Fourteen Caucasians and 2 diabetics
patients. Four patients were treatment-experienced (25%). The mean viral load
was 5.5 Log10 (3.9–7.07 Log10). Genotype distribution was the following: geno-
type 1–81% (13/16) and genotype 4–19% (3/16). Distribution according to fibro-
sis stages was as follows: F 2–62% (10/16), F3–19% (3/16) and F4–19% (3/16).
All these patients underwent a treatment regimen with ombitasvir/paritaprevir/
ritonavir and dasabuvir (3D). Seven of these patients (44%) received concomi-
tant ribavirin at an average dose of 400mg per week (200–600mg per week). The
treatment duration was 12 weeks for 13 patients (81%) and 24 weeks for others 3
patients (19%). Regarding treatment response rates, 81% (13/16) of patients had
Rapid Virological Response (RVR) and 100% (16/16) of patients had End of
Treatment Response (ETR). The global sustained virologic response (SVR) rate
was 100%. Hemoglobin was monitored throughout the treatment, with 2 cases of
severe anemia, one led to a 3D suspension at week 21 and the other one to a
ribavirin suspension at week 4 of treatment. There were no other serious adverse
effects.
Conclusion: In our sample of ESRD under HD patients, 3D therapy allowed the
eradication of HCV with high efficacy, even in patients who did not meet the
expected duration of treatment or dose of ribavirin. The safety of DAA in this
group is demonstrated by the non-occurrence of severe adverse effects.
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Introduction: Hepatitis C virus (HCV) infection in renal transplant patients pre-
disposes to graft failure and progression of renal disease, increasing mortality.
Due to immunosuppression and oscillating glomerular filtration rate (eGFR) in
these patients, the treatment of HCV infection confers a greater challenge.
Direct-acting antivirals (DAA) are a well-established, effective and safe treatment
regimen of the HCV infection, however evidences on renal transplantation are
scarce. Additional studies are still necessary in order to evaluate the real impact
of these agents in the daily clinical practice.
Aims & Methods: Our objective was to assess the efficacy and safety of DAA
treatment for HCV-infected patients with renal transplantation, in the daily
practice of a tertiary care centre, describing the HCV infection, treatment type,
the evolution of virological response and clinical outcomes (kidney function,
anemia and other adverse effects). HCV-infected and renal transplanted patients
treated with DAA between April 2015 and February 2017 were analyzed.
Results: Including 19 patients, 10 males (53%) and 9 females (47%) with a mean
age of 57 years (40–70 years). The majority of these patients (89%) were treat-
ment-naı̈ve. Genotype distribution was the following: genotype 1–74% (14/19),
genotype 3–16% (3/19) and genotype 4–10% (2/19). Distribution according to
fibrosis stages was as follows: F 2–63% (12/19), F3–21% (4/19) and F4–16%
(3/19). Sixteen patients (85%) were treated with sofosbuvir/ledipasvir, 2 (10%)
with sofosbuvir/daclatasvir and 1 (5%) with sofosbuvir. Concomitant ribavirin
was given in 4 patients. The treatment duration was 12 weeks for 16 patients
(84%) and 24 weeks for others 2 (10%). One patient realized only 21 weeks of
treatment, needing to suspend it due to severe anemia. Regarding treatment
response rates, 74% (14/19) of patients had Rapid Virological Response
(RVR) and 100% (19/19) of patients had End of Treatment Response (ETR).
The global sustained virologic response (SVR) rate was 100%. Hemoglobin,
eGFR and immunosuppression levels were monitored during this period. The
eGFR (CKD EPI) did not change significantly, with pre and posttreatment mean
values of 66.4 and 65.4ml/min/1.73m2, respectively. There were 2 cases of severe
anemia, one that resulted in ADA suspension at week 21 and the other one
ribavirin suspension at week 7 of treatment. Immunosuppressive levels remained
stable. There were no other serious adverse reactions.
Conclusion: In our sample of HCV-infected with kidney transplant, DAA are
effective and well tolerated, even in the more advanced stages of fibrosis, main-
taining the integrity and viability of the graft, without interfering with the effi-
cacy of immunosuppressant.
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Introduction: Liver stiffness (LS) measurements by Transient Elastography (TE)
has been widely accepted as a tool for fibrosis assessment.
Aims & Methods: The aim of this study was to assess LS dynamics in a group of
patients with HCV liver cirrhosis after DAA treatment. This bicentric clinical
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trial included 276 patients with compensated HCV cirrhosis (all genotype 1b),
who received DAA for 12 weeks. All patients were evaluated by means of TE at
the beginning and at the end of treatment (EOT), and one subgroup (180
patients) also 12 weeks after EOT, all of them with sustained viral response
(SVR 12), and another subgroup (55 patients) also at 24 weeks after EOT
(SVR 24). Reliable LS measurements (LSM) were defined as median value of
10 valid LSM, with IQR5 30% and SR 60%. Both M and XL probes were
used. For diagnosing cirrhosis we used a cut-off value of 12 kPa as proposed by
the Tsochatzis meta-analysis. We considered a decrease or increase of more than
10% in LSM as being significant.
Results: Out of 276 subjects, reliable measurements were obtained in 92.7%, so
that the final analysis included 256 patients. The mean LS values decreased
significantly after DAA: 25 11.7 kPa vs. 22.5 12. kPa (p¼ 0.009). Most
patients, (59.7%–152/256) presented more than 10% decrease in LS values,
23% (59/256) had stable LS values, while in 17.3% (45/256) cases, the LS
values increased. In the subgroup of 180 patients where LSM were also per-
formed 12 weeks after EOT (SVR 12), the mean LS values were significantly
lower 12 weeks after EOT as compared to baseline: 20.3 10.8 kPa vs.
25.5 11.4 kPa (p5 0.0001) and also as compared to EOT: 20.3 10.8 kPa vs.
22.8 12.2 kPa, (p¼ 0.04). In the subgroup of 55 patients wher LSM were also
performed 24 weeks after EOT (SVR 24), the mean LS values were significantly
lower at SVR 12 and SVR 24 as compared to EOT (18.7 8.2 kPa vs.
21.6 7.7 kPa, p¼ 0.05 and 18.3 6.6 kPa vs. 21.6 7.7 kPa, p¼ 0.01).
Conclusion: In our group mean liver stiffness values evaluated by TE significantly
decreased after antiviral treatment at SVR 12 and SVR 24, as compared to EOT.
Overall, in our study almost 60% of patients had EOT liver stiffness values lower
than at baseline, at SVR 12 almost 75% of patients had liver stiffness values
lower than at baseline and at SVR 24 almost 77% of patients had liver stiffness
values lower than at baseline.
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Introduction: Baveno VI criteria suggest that cirrhotic patients with platelet count
(PLT) 4150,000/ml and liver stiffness measure values (LSM)520 kPa bare a low
risk of having high-risk esophageal varices (EV) and do not require endoscopic
screening. The direct-acting antiviral agents (DAA) determine a very high rate of
sustained virologic response (SVR) among patients with HCV induced chronic
hepatitis and cirrhosis, and therefore, might decrease the risk of decompensation,
including variceal bleeding.
Aims & Methods: Therefore, the aim of the study was to asses the influence of
DAA therapy on the accuracy of the Baveno VI criteria for in cirrhotic HCV
patients. All consecutive patients with compensated HCV liver cirrhosis
approved for DAA treatment in our center who gave their informed consent
were included. All patients were screened for EV before starting the therapy by
esogastroduodenoscopy. LSM (FibroScan) and usual biological parameters
were evaluated at baseline and when assessing SVR 12.
Results: 50 patients were included (59.5 (45–84) years, 54% women) between
December 2015 and July 2016. All patients achieved SVR (100%). At base
line, 17/50 patients had EV. After completing DAA therapy, liver enzymes
[GOT (p5 0.0001), GPT (p5 0.0001)], GGT (p5 0.003) and LSM
(p5 0.0001) significantly decreased, while albumin (p¼ 0.014) and PLT
(p¼ 0.39) increased. We found a moderate correlation between GOT and LSM
both at baseline (r¼ 0.31; p¼ 0.001) and at RVS12 (r¼ 0.45; p¼ 0.004), but the
amplitude of the decrease appears not to be correlated [r (GOT vs.
LSM)¼ 0.149; p¼ 0.3]. At baseline, acccording to Baveno VI criteria, 29
patients were classified at low risk of having EV (accuracy 68%, Se 69.7%, Sp
64.7%, PPV 79.31%, NPV 52.38%). At SVR12, 10 aditional patients entered this
class, but the accuracy (60%) decreased.
Conclusion: DAA therapy induces a significant decrease in liver inflammation
and liver stiffness and also a non-significant increase of platelets count. These
changes induce a decrease of the accuracy of classification of patients with low
risk of having EV (according to Baveno VI criteria), therefore is not advisable to
use Baveno VI criteria as surrogate for endoscopy screening for esophageal
varices in patients compensated HCV liver cirrhosis who obtained SVR.
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Introduction: Monocyte chemoattractant protein-1 (LCP-1) is a chemokine med-
iator in liver inflammation and fibrogenesis. It contributes to the severity of
nonalcoholic fatty liver disease and chronic hepatitis C (CHC) by recruiting
proinflammatory activated monocytes and macrophages. Signaling between the
mononuclear phagocyte system (MPS) and hepatic stellate cells is key for active
fibrogensis. The extent to which metabolic and immune factors are implicated in
fatty liver of patients with CHC is still not clear.
Aims & Methods: The aim of the study was to explore the associations between
serum MCP-1, liver fibrosis, fatty liver and metabolic factors in CHC patients
before, and after antiviral treatment. We included 21 patients in the study (11
men, 10 women, age 42 9.7) with chronic hepatitis C virus (HCV) infection–17
with genotype 1 and 4 with genotype 3. Liver biopsy was done in 19 and histol-
ogy showed fatty liver in 8 patients. Fatty liver was present in 17 of all patients on
ultrasound. Liver fibrosis was scored mild (F1) in 9, significant (F2) in 7 and
advanced bridging fibrosis (F3) in 2 cases (METAVIR). Compensated liver cir-
rhosis (F4) was diagnosed in 3 cases by liver biopsy or endoscopic screening for
varices. Weight was normal in 10, overweight in 5 and obese in 6 patients. MCP-1
was quantified by ELISA in serum. Laboratory panel included complete blood
count, liver tests, HOMA-IR and serum lipid levels. Seventeen patients received
treatment (standard of care peg-interferon alpha, ribavirin and/or direct-acting
antivirals). Sustained virologic response (SVR) was attained by 12 and non-
response/relapse (NVR) by 5 patients. Serum probes were obtained before treat-
ment and after response evaluation. Statistical analysis included Spearman’s rho,
Mann-Whitney U test, Wilcoxon’s test and Student’s paired t-test.
Results: MCP-1 in serum correlated with BMI (r¼ 0.522, p¼ 0.015). MCP-1
concentrations in overweight and obese patients were higher than in those with
normal weight (p¼ 0.020). Patients with F3-F4 had higher BMI (p¼ 0.010) and
HOMA-IR (p¼ 0.042). An increase in serum MCP-1 was found in patients after
SVR (p¼ 0.018), while no significant variation from baseline values was found in
NVR patients. The result remained significant in subgroup analysis of SVR
patients with F1-F2 (o¼ 0.028) and in those with fatty liver (o¼ 0.017). MCP-
1 in serum did not show any association with assessment of liver fibrosis, fatty
liver, insulin resistance and serum lipid levels.
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Conclusion: MCP-1 concentrations in serum depend on overweight in patients
with CHC. Overweight and insulin resistance are associated with progression of
CHC. Serum levels of MCP-1 increase after HCV clearance. Fluctuation of the
MCP-1 concentration in serum could reflect an antiinflammatory activation of
MPS and a gradient dependent dynamic replacement of the profibrotic cell sub-
sets in the liver with proresolution ones after SVR. Fatty liver plays a role for
inflammatory responses in CHC patients after SVR.
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Introduction: HCV interferes with the host lipid metabolism leads to insulin
resistance and hepatic steatosis. Although it is usually mild in genotype 4,
many data suggests that simple steatosis may have the potential to progress to
fibrosis, cirrhosis and subsequent hepatocellular carcinoma. Many heritable host
factors with observed inter-ethnic variation in the prevalence of steatosis are
decumented, and in many cases hepatic steatosis may be detected in absence of
all these risk factors; so a role for host genetic factors in development of hepatic
steatosis in chronic HCV patients may be suggested.
Aims & Methods: In this study, we aim to evaluate the association of HLA class
A-B alleles and presence of steatosis in chronic HCV genotype 4 infected
patients.This study included two hundred unrelated non diabetic non obese
chronic HCV patients with normal lipid profile, 98 of them had biopsy proven
steatosis. Serological testing of HLA class I antigens (HLA-A, and HLA-B
alleles) were performed with a standard complement-dependent micro-lympho-
cytotoxicity assay.
Results: The frequency of A02, A03, B15 and B17 alleles were significantly higher
in chronic HCV patients with steatosis (OR¼ 1.77, 2.64, 4.44, 5.68) and 95%
CI¼ 0.96–3.27; 1.02–7.04; 0.84–31.17; 1.12–38.65 with P¼ 0.034, 0.022, 0.044,
0.015 respectively. On the other hand, the frequency of A01 and B12 alleles
were significantly higher in patients without steatosis (OR¼ 0.56, 0.41) and
95% CI were 0.30–1.05; 0.20–0.83 and P¼ 0.015 and 0.005. On logistic regression
analysis, patients who carry HLA-A02, A03 and HjLA-B15 alleles may have 2.2,
3.9 and 11.18 fold risk to have hepatic steatosis (B coefficient: 0.79; 1.37; 2.41)
95% CI¼ 1.09–4.42, 1.04–11.05, 2.15–58.13; P¼ 0.027, 0.009, 0.004) while carry-
ing HLA-A01 alleles may be protected from having HCV associated hepatic
steatosis; (OR¼ 0.34,95% CI¼ 0.16–0.72; P¼ 0.005) with constant -9.47 and
overall accuracy of 69%. In addition, patients who have moderate activity
index in liver histopathlogy have 5.9 risk to have hepatic steatosis (OR¼ 5.92,
95% CI¼ 2.92–11.99, P50.001).
Conclusion: In chronic HCV genotype 4 patients, carring HLA-A02, HLA-A03
and HLA-B15 alleles may have a risk for presence of hepatic steatosis while
presence of HLA-A01 alleles may have a protective role.
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Introduction: Chronic liver diseases are quite frequently encountered in daily
practice and are due mainly to chronic viral infections (B or C viruses) and to
other conditions such as alcoholic steatohepatitis - (ASH) and to non-alcoholic
fatty liver disease (NAFLD). While liver biopsy remains the gold standard
method for fibrosis assessment, stage classification and also for necro-inflamma-
tory activity grading, in the last years, non-invasive assessment methods (biolo-
gical tests and elastographic methods) were developed and they are being used
more and more, to the detriment of liver biopsy.
Aims & Methods: The aim of this study was to evaluate the performance of the
2D-shear wave elastography technique from General Electrics (2D-SWE.GE),
for the evaluation of liver fibrosis in patients with HCV chronic hepatopathies,
using Transient Elastography (TE) as the reference method. The study included
145 consecutive subjects with HCV compensated chronic hepatopathies, in whom
liver stiffness was evaluated in the same session by means of 2 elastographic
measurements: TE (FibroScan, EchoSens) and 2D-SWE.GE (LOGIQ E9, GE
Healthcare). Reliable LS measurements were defined as follows: for TE–the
median value of 10 measurements with a success rate of 60% and an inter-
quartile range530% and for 2D-SWE.GE - the median value of 10 measure-
ments acquired in a homogenous area and an interquartile range (IQR) 530%.
To discriminate between various stages of fibrosis by TE we used the following
cut-offs: F 2: 7.1 kPa, F 3: 9.5 kPa, F¼ 4: 12.5 kPa [1].
Results: Reliable LS measurements were obtained in 138/145 (95.1%) subjects by
2D-SWE.GE and in 139/145 (95.8%) by TE (p¼ 0.9). The final analysis was
performed on 134 subjects with valid measurements by both methods. We
found a good positive correlation between the LS values obtained by the 2
methods: r¼ 0.79, p5 0.0001. Based on TE cut-off values [1] we divided our
cohort into 4 groups: F0-F1: 36/134 (26.8%), F2: 23/134 (17.2%), F3: 23/134
(17.2%) and F4: 52/134 (38.8%). The areas under the receiver operating char-
acteristic curve (AUROC) were 0.909 for significant fibrosis (F 2), 0.954 for
severe fibrosis (F 3) and 0.942 for cirrhosis (F¼ 4). The best cut-off values for
F 2 was 7 kPa (Sensitivity 85.7, Specificity 80.5), for F 3 it was 9.2 kPa
(Sensitivity 85.3, Specificity 91.5) and F¼ 4 it was 10.7 kPa (Sensitivity 84.6,
Specificity 91.4).
Conclusion: 2D-SWE.GE seems a reliable method for liver fibrosis staging in
patients with HCV compensated chronic hepatopathies. The best 2D-SWE.GE
cut-off values for F 2, F 3 and F¼ 4 in HCV chronic hepatopathies were 7,
9.2 and 10.7 kPa.
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Introduction: The risk of developing novo hepatocellular carcinoma (HCC) per-
sists after reaching sustained virological response (SVR) in patients infected with
hepatitis virus C. It has been suggested that risk is increased in patients treated
with the new direct antiviral agents (DAA). In this prospective study we present
our results of incidence and prevalence of novo HCC in cirrhotic patients treated
with DAA and SVR, and also, the risk factors involved in its development.
Aims & Methods: We included all cirrhotic patients due to HVC infection with-
out previous HCC who reached SVR after DAA treatment in our hospital from
February 2014 until December 2016 (n¼ 197, median of follow-up of 17
months). We evaluated with chi square test the following qualitative variables:
age, Child-Pugh stage, alcohol consumption pre-treatment, tobacco consumption
pre-treatment, diabetes mellitus (DM) pre-treatment, genotype, radiological and
endoscopic portal hypertension features pre-treatment. The quantitative vari-
ables were evaluated with student t test: age, no. of platelets pre-treatment,
fibroscan value pre-treatment.
Results: During follow-up 11 patients were diagnosed of HCC (5.6% prevalence,
3.9% annual incidence). Among all variables evaluated being in a Child- Pugh B
stage vs. an A stage (p¼ 0.007), pre-treatment DM (p¼ 0.002) and presence of
radiological portal hypertension (p¼ 0.001) were associated with developing
novo HCC. Among the quantitative variables, we evidenced statistically signifi-
cant differences in the mean value of platelets (p¼ 0.015).
Conclusion: In our group of patients, a worse hepatic function evaluated with the
Child-Pugh classification and indirect markers of portal hypertension (platelets
and radiological features) and also DM are associated statistically significant
with the development of novo HCC. The incidence (41.5%) of novo HCC
justifies the screening of HCC.
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Introduction: An acute insult to the liver in patients without pre-existing chronic
liver injury can cause acute liver failure (ALF). ALF is a life-threatening condi-
tion and requires specialized intensive care. Acute on chronic liver failure
(AOCLF) is a not yet clearly characterized situation, where the acute insult
occurs in addition to present chronic liver disease without cirrhosis. Though,
various definitions of AOCLF are found in the literature. Discrimination of
AOCLF from ALF might be trivial for pre-existing alcoholic or viral hepatitis.
However, non-alcoholic steatohepatitis (NASH) in obese or diabetic patients
might go unnoticed in the critical situation of an ALF/AOCLF. Thus, patients
admitted to liver transplantation centers with the diagnosis of ALF might be
suffering from AOCLF instead. It is also unclear if the ALF and AOCLF have
different impact on disease course, clinical management and transplant organ
allocation.
Aims & Methods: Aim of this study was to identify possible differences between
patients with ALF and AOCLF regarding routine parameters and clinical course.
In this retrospective single-center study all patients were recruited, who were
admitted to the University Hospital of Essen with the initial diagnosis of ALF
between 2008 and 2015. Patients included in this study were fulfilling the criteria
of the acute liver failure study group Germany. The diagnosis of AOCLF was
established upon retrospective examination of patient records. In total 163
patients were recruited (ALF: 131; AoCLF: 32). Clinical records, in particular
demographic data, serum parameters and outcome were analyzed for differences
between ALF and AOCLF.
Results: Patients with AOCLF were significantly older (50.3 15.1 vs.
39.8 16.2, p¼ 0.0008), had a higher BMI (27.5 5.1 vs. 24.5 6.2,
p¼ 0.0014) and were more often male (65% in AOCLF vs. 34% in ALF
p¼ 0.0008). In addition, the insults that caused the liver failure in AOCLF
were significantly different from those patients with ALF. Significant differences
were also found for liver enzymes, which were significantly lower in AOCLF
patients (AST p¼ 0.01; ALT p¼ 0.001). Cell death markers and the MELD
did not differ between ALF and AOCLF. Moreover, the outcome was not dif-
ferent between the two groups neither separated as survived or deceased nor as
spontaneous remission or non-spontaneous remission (combined transplantation
and deceased). Importantly, MELD and the modified MELD including the cell
death marker M65 were similarly effective in predicting outcome for both ALF
and AOCLF.
Conclusion: In the present study patients with ALF and AOCLF differed in age
and BMI, but did not exhibit differences regarding disease severity (according to
MELD) or clinical outcome. While the causes for an acute insult differed between
ALF and AOCLF, which might imply a different clinical management, clinical
outcome was predictable by common factors for ALF.
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Introduction: To explore the influence of preoperative transarterial chemoembo-
lization on short-term prognosis in patients with hepatocellular carcinoma after
liver transplantation.
Aims & Methods: A retrospective study was conducted among patients with
hepatocellular carcinoma who received liver transplantation from January 2009
to September 2015 in Ruijin Hospital. A total of 31 patients (Male: 29/Female: 2)
were included. Among them, 14 patients received preoperative hepatic arterial
chemoembolization was incorporated into observation group (n¼ 14), and the
other 17 patients were included in the control group (n¼ 17). The data including
TBL/ALT/AST levels in preoperative and 1, 3, 5, 7 postoperative days, operation
time, blood loss, postoperative complications happening (incision infection, vas-
cular complications, biliary complications, complications classification), perio-
perative mortality and hospitalized time was analyzed to compare the differences
between the two groups of patients.
Results:No statistical difference was found in the total operation time, blood loss
and length of hospital stay between two groups, and the occurrence rate of
vascular complications, biliary complications and postoperative infection also
showed no difference. Although more patients above Clavien IIIa were in the
observation group, there was no statistically significant difference in the perio-
perative mortality between two groups. Besides, preoperative TACE could effec-
tively reduce complications caused by immune reaction (P¼ 0.048). In terms of
postoperative indexs of liver function, TBIL, ALT, AST all had a transient rise
during the first 3 days after liver transplantation, but recovered gradually over
time. There’s no remarkable difference in the liver function recovery level
between two groups (P¼ 0.495; P¼ 0.141; P¼ 0.101).No statistical difference
was found in the total operation time, blood loss and length of hospital stay
between two groups, and the occurrence rate of vascular complications, biliary
complications and postoperative infection also showed no difference. Although
more patients above Clavien IIIa were in the observation group, there was no
statistically significant difference in the perioperative mortality between two
groups. Besides, preoperative TACE could effectively reduce complications
caused by immune reaction (P¼ 0.048). In terms of postoperative indexs of
liver function, TBIL, ALT, AST all had a transient rise during the first 3 days
after liver transplantation, but recovered gradually over time. There’s no remark-
able difference in the liver function recovery level between two groups (P¼ 0.495;
P¼ 0.141; P¼ 0.101).
Conclusion: Preoperative TACE won’t affect liver function recovery and perio-
perative safety after liver transplantation. For some patients, it could also educe
complications caused by immune reaction.
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Introduction: Romania has the highest incidence of tuberculosis (TB) in the
European Union, representing one quarter of the European TB burden.
According to clinical practice guidelines for liver transplantation (LT), the
second level of screening for infections consists of screening for Mycobacterium
tuberculosis, including history of TB, PPD, Interferon-gamma release assays.
Aims & Methods: The aim was to assess the importance of Quantiferon TB Gold
test for evaluating patients included on the wait list for LTin Romanian setting.
The study was a single–center retrospective cohort study (the single center for
LT)that included 264 patientsadmitted on the wait list for LT from January 1,
2014 to November 18, 2016. All patients underwent mandatory screening for
Mycobacterium tuberculosis, either using Quantiferon TB Gold test or skin test-
ing using purified protein derivative (PPD). The variables analyzed using Minitab
17 were: age, gender, etiology of liver disease, biochemical test, MELD score.
Results: From a total of 264 patients with liver diseases included on the wait list,
60.6% were males, the average age at diagnosiswas 47.78 9.92 years. The etiol-
ogy of liver cirrhosis was HCV infection in 31.43%, HBV and HBV-HDV co-
infection in 45.06%, and alcoholic liver cirrhosis in 18.93%; 24.62% of patients
have been diagnosed with superimposedhepatocellular carcinoma. Eighty three
patients (31.43%) had positive results for Quantiferon test, 150 patients (56.81%)
were negative and 17 patients (6.43%) had indeterminate results. Only 14 patients
(5.3%) were skin tested using PPD, 2 (0.75%) of them with positive results.
Comparing the subgroups, positive Quantiferon test was associated with HCV
etiology (p value¼ 0.049) and lower lymphocyte counts, but did not achieve
statistical significance (p¼ 0.187). Patients with indeterminate Quantiferon asso-
ciated hyperbilirubinemia (p¼ 0.044), hypoalbuminemia (p¼ 0.032) and had a
higher MELD score (p¼ 0.019). After assessment by a multidisciplinary team
that included a pneumologist, 38.63% of patients were diagnosed with latent TB.
Isoniazid chemoprophylaxis along with pyridoxine was postponed after LT, in
order to prevent further hepatic dysfunction. 48.5% of patients underwent LT,
followed by TB prophylaxis and no cases of TB reactivation have been reported
during a follow-up period of 14 months.
Conclusion: Patients transplanted for HCV-related liver cirrhosis should benefit
from a careful follow-up on the WL and prompt TB prophylaxis after LTin order
to prevent TB reactivation during early immunosuppression. Delaying TB pro-
phylaxis after LT in order to avoid liver toxicity of anti-bacillary drugs was not
associated with TB reactivation.
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Introduction: Primary sclerosing cholangitis (PSC) is associated with an increased
risk of cholangiocarcinoma, colorectal cancer (CRC) and gallbladder cancer.
Orthotopic liver transplantation (OLT) patients are at increased risk of develop-
ing de novo malignancies, however limited and conflicting data exists regarding
cancer risk post OLT for PSC.
Aims & Methods: To examine all recorded malignancies over 2 decades in OLT
PSC pts and compare to our non-transplanted PSC cohort. To analyse factors
associated with the development of malignancies post OLT. We retrospectively
studied PSC patients attending the Irish National Liver Unit (INLU) and the
Centre for Colorectal Disease (CCD) at St. Vincent’s University Hospital from 1/
1/94–30/9/16. We integrated this database with the National Cancer Registry in
Ireland. This enabled accurate determination of the no. of malignancies recorded
in the PSC cohort. Analyzed data included age of recipient at OLT, gender,
primary OLT indication, immunosuppressive regime, de novo malignancy post
OLT, time from OLT to diagnosis of malignancy or death. Statistical analysis
was primarily descriptive. Cox Proportional Hazard Model was used to analyse
factors associated with mortality in the PSC OLT cohort.
Results: 107 of 173 patients had undergone transplant for PSC. 27/107 pts were
transplanted for cholangiocarcinoma. 12 post-transplant de novo cancers and 12
BCC/SCC carcinomas were found in 107 patients during 737.8 person years of
follow-up. Median time to cancer diagnosis post OLT was 5 years (IQR 2.8–5.9).
Recurrence of PSC was observed in 21 patients (19.6%). Post-transplant lym-
phoproliferative disease (PTLD) remains a major complication after OLT. Prior
studies have reported rates of 1–3% in adult OLT pts. 5 pts were diagnosed with
lymphoma post OLT representing 4.7% of cohort. Median time to diagnosis was
5.3 yrs [IQR 2.8–10.2]. Regarding CRC, 2 patients developed CRC post OLT. 4
patients developed colonic dysplasia; 3/4 underwent colectomy. All those who
developed colonic dysplasia/CRC post OLT had co-existing IBD. All 5 colect-
omy specimens for dysplasia/CRC showed significant co-existing inflammation.
One patient post OLT underwent a completion proctectomy for rectal cancer. As
expected, cholangiocarcinoma as indication for OLT (p¼ 0.005, RR 2.573,
95%CI 1.3–4.95) and an older age at transplant (p¼ 0.05, RR 1.027, 95% CI
1–1.054) were associated with higher mortality.
Table 1
Cancer SIR 95% CI
Any cancer 3.239 1.885–5.186
Excluding skin cancer 1.97 0.848–3.882
Lymphoma 36.574 14.65–75.36
Colorectal cancer 1.779 0.023–9.898
Conclusion: These findings represent national cancer figures in our PSC OLT
cohort. The rate of cancer is more than three times higher in this population
than the general population. The rates of PTLD are 430 times higher than
those in the normal population, and slightly higher than previously reported
in unselected liver transplant groups. We could not find any association
between the development of PTLD and aggressive immunosuppressive regimes
for co-existing IBD post OLT. The study highlights that IBD/PSC patients
remain at significant risk of colonic neoplasia after OLT and require intensive
surveillance.
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Introduction: Primary sclerosing cholangitis (PSC) is a chronic liver disorder of
unknown etiology, characterized by inflammation, fibrosis and stenoses of both
extra- and intrahepatic bile ducts. For those who develop end–stage liver disease,
orthotopic liver transplantation (OLT) remains the only effective treatment cur-
rently available. PSC is accompanied with concomitant ulcerative coilitis (UC) in
a significant proportion of patients. Benefits of routine HLA typing in donor and
recipient prior to OLT were proved in the past.
Aims & Methods: The aim of this study was to assess the impact of HLA-DR
mismatch on acute cellular rejection (ACR), PSC recurrence (rPSC) and course
of UC after OLT. After applying inclusion/exclusion criteria we retrospectively
evaluated records of 57 patients transplanted at Institute for Clinical and
Experimental Medicine (Prague, Czech Republic) between July 1994 and
November 2011. Only patients with proper records 5years from OLT were
included. We evaluated likelihood for each variable (ACR, rPSC, course of
UC) in patients with either single, or double mismatch in HLA-DR. Input
data were analysed with 2 and Fisheŕs exact test using MedCalc statistical
software. A p - value 50.05 was considered as statistically significant.
Results: Out of 57 patients, 27 (47.4%) had single mismatch (‘‘M1’’ group) and
30 (53.6%) had double mismatch (‘‘M2’’ group) in HLA-DR. No patient had full
match. 33/57 (57.9%) patients had ACR: 15/27 (55.6%) of M1 and 18/30 (60%)
of M2 (p¼ 0.94). 4/27 (14.8%) of M1 and 2/30 (6.3%) of M2 had corticoresistant
ACR (p¼ 0.57). Multiple–episodes of ACR occurred in 11/57 (19.3%) patients:
6/27 (22.2%) of M1 and 5/25 (20%) of M2 (p¼ 0.74). 12/57 (21.1%) had de-novo
UC after OLT: 7/27 (25.9%) of M1 and 5/30 (16.7%) of M2 (p¼ 0.60). In 37
(68.5%) patients, UC was diagnosed prior to OLT. 9/16 (56.3%) patients with
M1 and 6/21 (28.6%) patients with M2 had more severe course of UC as com-
pared to course prior to OLT (p¼ 0.17). 38 patients were evaluated for rPSC,
which was diagnosed in 17 (44.7%) individuals. 6/19 patients with M1 and 11/19
with M2 had rPSC (p¼ 0.19).
Conclusion: Patients with single mismatch in HLA-DR have slight tendency
towards development of rPSC and worsening of UC after OLT as compared
to patients with double mismatch. Analysis of combined mismatch in HLA-
DR and HLA-DQ could demonstrate more substantial linkages in respective
clinical variables. Therefore, these data have to be considered as preliminary as
typing for HLA-DQ from frozen blood samples is currently underway. Supported
by Ministry of Health of the Czech Republic, grant nr. 15-28064A. All rights
reserved
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Introduction: Liver biopsy remains the gold standard in the diagnosis of graft
dysfunction in post-liver transplantation (GDPLT). Liver transient elastography
is a valid non-invasive method for liver fibrosis evaluation, with a good correla-
tion in chronic liver diseases. The progression of fibrosis represents a major
problem in the post-liver transplantation.
Aims & Methods: We aimed to evaluate the predictive role of liver transient
elastography in the evaluation of GDPLT and to determine the predictive factors
of liver transplantation fibrosis. This was a retrospective observational cohort
study of total of 49 patients with post-liver transplantation status who underwent
liver transient elastography by Fibroscan. Selected patients who underwent
percutaneous/transjugular liver biopsy. In case of more than one liver biopsy,
it was selected the biopsy closer to Fibroscan. The fibrosis and steatosis eval-
uated by Fibroscan were compared with those obtained by liver biopsy.
Significant fibrosis was considered if F2. Demographic, analytical and asso-
ciated liver transplantation variables were evaluated.
Results: A total of 32 patients underwent Fibroscan and liver biopsy. Mean age
of 48.53 11.20years and male gender in 68.8%(n¼ 22). The mean time between
Fibroscan and liver biopsy was 29.77 36.90months. The mean elastography
score was 13.45 8.31KPa with IQR/med of 17.11 8.66%. Mean CAP score
was 207.12 57.35 dB/m. Regarding liver biopsy, 34.4%(n¼ 11) had significant
fibrosis and 25.0% (n¼ 8) presented steatosis. Comparing two methods, there
was no concordance for steatosis (kappa¼ 0.273; p¼ 0.117) or inflammation
(Kappa¼ 0.063; p¼ 0.710). On the contrary, a moderate agreement for signifi-
cant fibrosis (kappa¼ 0.431; p¼ 0.003) was verified. The mean elastography
score showed an accuracy of 79.7% in predicting histological fibrosis
(AUROC¼ 0.797; p¼ 0.007) to a cut-off value of 11.6 KPa (S¼ 81.8%;
Sp¼ 76.2%). In relation to analytical parameters, only serum albumin was pre-
dictive of histological fibrosis (OR¼ 2.79; p¼ 0.043).
Conclusion: Liver transient elastography represents a non-invasive and valid
alternative procedure to liver biopsy in the evaluation of post-liver transplanta-
tion fibrosis but not steatosis or inflammation. Liver transient elastography
scoring 11.6KPa and low values of serum albumin are predictors of post-
liver transplantation fibrosis.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Orthotopic liver transplant has become the standard of care for
end-stage liver disease and hepatocellular cancer. Better immunosuppressant
paved way for improved survival rates post-transplant. But with this longevity
comes a higher prevalence of chronic diseases such as New Onset Diabetes After
Transplant (NODAT), Hypertension, metabolic syndrome etc. which have a
negative impact on graft function and patient survival.
Aims & Methods: Primary: To determine the incidence of New Onset Diabetes
After Transplant (NODAT), Impaired Fasting Glycaemia (IFG) and post-trans-
plant hyperglycemia in living-donor liver transplant recipients. Secondary: To
determine the risk factors associated with NODAT and IFG. To determine
impact of NODAT on survival and mortality. It was a retrospective cohort
study of 283 living donor liver transplant recipients from 29/4/2011 till 26/4/
2016. Data was collected from records. Simple means and standard deviation
was calculated for continuous variables while frequency statistics were calculated
for categorical ones. Risk factors were assessed using binary logistic regression
analysis.
Results: A total of 130 post liver transplant patients were analyzed after exclu-
sion. NODAT was present in 41/130 (31.5%) patients, while 19/130 (14.6%)
patients had impaired fasting glycaemia. Acute cellular rejection, Post-transplant
Hyperglycemia and Pre-transplant prediabetes showed increased odds of acquir-
ing NODAT post-transplant. NODAT had significant association with mortality
and decreased survival (p¼ 0.05).
Conclusion: This cohort showed that NODAT is an important post-transplant
entity with significant impact on mortality and survival. Early identification of
at-risk patients is suggested.
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Introduction: Serum vitamin B12 (vB12) levels are increased in myeloproliferative
diseases by increased production of the haptocorrin transporter and in liver
diseases by release of vB12 from hepatocytes death.
Aims & Methods: The aim of this study was to evaluate vB12 as a prognostic
marker in patients with cirrhosis and acute on chronic liver failure (ACLF)
induced by infection. Retrospective assessment of 58 patients admitted to an
intensive care unit with ACLF in the context of infection (group 1) and 53
patients with compensated hepatic cirrhosis followed as Hepatology outpatients
(group 2). Evaluation of vB12 as a predictor of 30 days’ mortality.
Results: 111 patients, 68% male, age 58 18 years. Group 1 had more advanced
liver disease (CPT 11.9 0.3 vs. 6.5 0.2 and MELD 27.0 1.0 vs. 10 0.5),
higher vB12 (1413 149 vs. 735 56 pg/mL) and lower survival (1.6 0.4 vs.
6.4 2.7 years). VB12 positively correlated with hepatic function scores (CPT:
R¼ 0.524; MELD: R¼ 0.566). MELD and vB12 were independent factors of
mortality at first month (OR 1.205 and 1.002 for increase of one unit of
MELD or vB12). In patients with ACLF, vB12 correlated with liver disease
severity (CPT: R¼ 0.411; MELD: R¼ 0.534) and multiorgan failure (number
of organ failures: R¼ 0.536, SOFA: R¼ 0.553). In group 1, survival was lower
in patients with high vB12 (8 3 vs. 37 11 months), and 1 month’ mortality was
associated with vB12, CPT, MELD, number of organ failure, urea, lactates and
fibrinogen, in univariate analysis (p5 0.001). In multivariate analysis only fibri-
nogen maintained statistical significance (p5 0.001).
Conclusion: There was a strong association between high levels of vB12 and
clinical decompensation of liver cirrhosis. VB12 correlated with scores of liver
function and multiorgan failure, as well as early mortality in patients with
ACLD.
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Introduction: Hepatocellular carcinoma (HCC) is the second leading cause of
cancer-related mortality worldwide. Patients with viral hepatitis and those with
non–alcoholic fatty liver disease (NAFLD) are especially susceptible to HCC.
Parallel to an increase in prevalence of NAFLD, the prevalence of HCC is
estimated to be increased in next years. Liver transplantation is now considered
as a modality of treatment for patients with HCC.
Aims & Methods: This study aimed to investigate outcomes of liver transplanta-
tion in patients with HCC compared to other causes of liver transplantation. In a
cross-sectional study patients who had undergone liver transplantation between
March 2012 and March 2015 at Shiraz Transplant Center, Shiraz, Iran were
included. Patients’ characteristics including age, gender, model for end stage
liver disease (MELD) score, rejection episodes, laboratory data and information
about mortality of patients were recorded. Characteristics of tumor including
size, number and vascular invasion were recorded. Based on these findings
HCC patients were divided to those within Milan criteria and those beyond
Milan criteria. The impact of HCC on post-transplant outcomes was investigated
using student t-test and chi-square tests. Multivariate logistic regression was used
for analysis of independent risk factors of mortality after liver transplantation.
Kaplan-Meier method was used for analysis of survival.
Results: Totally 1014 liver transplant patients were included. 94 patients with
HCC underwent liver transplantation. There was no statistically significant dif-
ference between those with and without HCC in terms of gender, portal vein
thrombosis (PVT), diabetes mellitus (DM), hepatic encephalopathy and hospita-
lization before liver transplantation (P4 0.05). HCC was significantly more pre-
valent in cirrhosis due to viral hepatitis (P5 0.001). Acute rejection episodes was
not different in patients with and without HCC in early post-transplant period
(OR¼ 0.563; 95% CI: 0.27–1.14, P¼ 0.108). In regression analysis, presence of
pre-transplant DM (OR¼ 3.89; 95% CI: 1.36–11.11, P¼ 0.011) and acute kidney
injury within 30 days after liver transplant (OR¼ 4.38; 95% CI: 1.44–1327,
P¼ 0.009) were independent predictors of post-transplant mortality. Mean
post-liver transplant survival in HCC patients within Milan criteria was
40.48 3.69 months compared to 36.80 6.28 months in those beyond Milan
criteria (P¼ 0.82). Mean post-transplant survival in patients with HCCþDM
was 32.75 4.7 months compared to 48.51 2.60 months in HCC patients with-
out DM (P¼ 0.009).
Conclusion: Liver transplantation can be used for patients with HCC, however,
post-transplant survival seems to be lower. Diabetes mellitus and acute kidney
injury were predictors of mortality among our patients with HCC after liver
transplantation.
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Introduction: Liver is one of the most common metastatic sites of colorectal
cancer, nearly 50% patients develop hepatic metastases during the course of
their disease. Metastatic spread influences survival rate of those patients. The
diffusion weighted imaging (DWI) is MRI sequence designed to detect random
movement of water protons in extracellular compartment. Biophysical parameter
expressing the flexibility of Brownian motion is the diffusion coefficient (ADC).
ADC values for b parameter lower than 300 s/mm2 are influenced by perfusion
whereas ADC values for b greater than 300 s/mm2 depend mainly on diffusion.
Aggressive malignant process often develops necrotic areas within neoplastic
lesion. Necrotic changes are characterized by high ADC values. We suppose
that low ADC values correlate with presence of necrosis in highly malignant
lesions effecting in lower survival rate.
Aims & Methods: This is a post hoc analysis of prospective study to assess the
predictive value of the ADC in survival outcomes of patients undergoing radio-
frequency ablation due to metastatic colorectal cancer lesions in the liver. We
analyzed the MRI studies of 52 patients (18 F, 34 M, aged 4383) performed on
1.5 T scanner one day before the percutaneous RFA treatment. The total number
of analyzed lesions was 110 (15 per patient), 83 of them were completely ablated,
27 incompletely, what was assessed in follow-up CT studies. The standard pro-
tocol of the liver MRI was applied including DWI sequence in b values of 0, 15
and 500 s/mm2. ADC maps were calculated for b values of 015 and 0500 s/mm2.
The mean ADC value was obtained by threefold marking ROI covering the
whole metastatic lesion. In cases of multiple foci only the lesion with the highest
ADC value was included into analysis. On basis of ROC analysis the cut-off
values of ADC were established: 2.49mm2/s for b value of 015 s/mm2 and
1.43mm2/s for b value of 0500 s/mm2. The survival outcomes were assessed by
mean of Kaplan-Meier estimator. The p value lower than 0.05 was considered
significant.
Results: The statistical analysis included KaplanMeier estimator for 52 patients
with 9 censored cases (17.3%). In ADC maps for b value of 0500 s/mm2, the
ADC value 1.43mm2/s correlated with longer survival time, whereas ADC
value 51.43mm2/s correlated with shorter survival time. Statistically significant
differences were identified by log rank test¼ 2.6998, p¼ 0.007. Such a correlation
was not observed for ADC values in ADC maps for b value of 015 s/mm2
(p¼ 0.058).
Conclusion: The study showed significant differences in survival rate depending
on diffusion influenced ADC values of metastatic lesions.
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Introduction: Type II diabetes and nonalcoholic fatty liver disease (NAFLD) are
frequently associated, NAFLD being considered the hepatic expression of the
metabolic syndrome.
Aims & Methods: The aim of the present study was to assess the severity of liver
fibrosis and steatosis in a cohort of type 2 diabetic patients, using non-invasive
methods:Transient Elastography (TE) and Controlled Attenuation Parameter
(CAP). The study included 354 type 2 diabetic patients, who were prospectively
randomized (every first 6 patients who were referred to the Metabolic Disease
Outpatient Clinic on a consultation day), evaluated in the same session by means
of TE and CAP (FibroScan EchoSens) to assess both liver fibrosis and steatosis.
Each patient was evaluated for the presence of viral hepatitis (B, C) and an
AUDIT-C score was performed to exclude alcohol abuse. Reliableliver stiffness
measurements (LSM) were defined as the median value of 10 LSM with an IQR/
median 530%. For TE and CAP, M and XL probes were used. A cut-off value
of 8.2 kPa [1] was used to define severe fibrosis (F 3). For differentiation
between stages of steatosis we used the following cut-off values [2]:
S2(moderate) - 255 db/m, S3(severe) - 290 db/m.
Results: Out of 354 diabetic screened we excluded those with associated viral
hepatitis, those with an AUDIT-C score 8 and those with unreliable LSM.
The final analysis included 239 subjects (59.4% women, 40.6% men, mean age
60.4 9.3; BMI¼ 31.8 6.1 kg/m2) with reliable LSM. Accordingly to BMI,
10.8% had normal weight, 26.4% were overweight and 62.8% were obese
(35.6% obesity grade I, 17.2% obesity grade II and 10% obesity grade III).
Moderate and severe steatosis by means of CAP was found in 18.4% and
69.5% cases respectively. Severe fibrosis was detected by means of TE
(LSM 8.2 kPa) in 29.3% (70/239) of subjects.
Conclusion: In our group, 87.9% of diabetic patients had moderate and severe
steatosis by CAP and 29.3% of them had severe fibrosis (TE 8.2 kPa), suggest-
ing the need for their systematical assessment.
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Introduction: Nowadays liver fibrosis can be assessed using non-invasive elasto-
graphic techniques. ElastPQ is a quite novel point share wave elastography inte-
grated into an ultrasound system.
Aims & Methods: The aim of our study was to evaluate the learning curve of
obtaining reliable liver stiffness measurements (LSM), using ElastPQ. LSM of
a trainee were compared to LSM of an elastography expert (with an experi-
ence of more than 500 examinations). Our study group included 50 subjects
(mean age- 52.7 years, 66.6% men, mean BMI¼ 25.6 kg/m2). Both the trainee
and the expert obtained LSM for each subject, using ElastPQ (EPIQ 7, Philips
Healthcare, Bothell, WA, USA). Reliable LSM were defined as the median
value of ten measurements acquired in a homogenous area avoiding large
vessels and with an IQR/median 530%. The learning curve was evaluated
using the Receiver Operating Curve analysis using the expert’s results as
reference.
Results: The trainee’s performance in obtaining reliable LSM was good (AUC:
0.735, 95% CI (0.557–0.913), p¼ 0.01). The trainee started to have similar results
with the elastography expert after the 30th subject. When looking at the IQRs,
they became significantly lower after the 30th subject (2.6 2.1 kPa vs
6.5 9.2 kPa, p¼ 0.03).
Conclusion: Obtaining reliable LSM using ElastPQ can be easily achieved after 30
LS examinations.
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Introduction: In patients with liver cirrhosis, hepatocellular carcinoma (HCC) can
be diagnosed by noninvasive imaging methods (contrast-enhanced ultrasound
CEUS, contrast CT/MRI).
Aims & Methods: The aim of this study was to evaluate which is the most
common enhancement pattern of HCC on CEUS in all three phases (arterial,
portal and late phase). We performed a retrospective study that included patients
with a final diagnosis of HCC established by an imaging method (contrast
enhanced CT or MRI) or biopsy. A total of 249 patients with HCC were exam-
ined (180 men, 69 women, mean age 64 10 years); 181 patients had liver cir-
rhosis and 68 patients chronic hepatopathy with severe fibrosis. All 249 HCCs
were evaluated by CEUS using low mechanical index ultrasound, following an
intravenous bolus of 2.4ml SonoVue. CEUS was considered conclusive for HCC
if a typical pattern was present following contrast examination (hyperenhance-
ment in the arterial phase accompanied by portal and/or late phases washout).
The nodules were classified according to their size in 3 cm and 43 cm. We re-
evaluated all 249 HCCs CEUS studies using the ACR CEUS LI-RADSv 2016
algorithm.
Results: After CEUS examination a conclusive diagnosis of HCC was obtained in
190/249 cases (76.3%). Arterial phase hyperenhancement pattern was present in
227/249 cases (91.2%), isoenhancement in the arterial phase was oberved in 17/
249 cases (6.8%) and hypoenhacement in 5/249 cases (2%). In the portal phase
washout was observed in 111/249 cases (44.6%); in 121/249 (48.6%) patients the
nodules were isoenhancing and in 17/249 (6.8%) the arterial hyperenhancing
pattern was maintained. In the late phase washout was observed in 197/249
(79.1%) cases. The nodules 3 cm were diagnostic conclusive on CEUS in
63.7% (72/113), while nodules 43 cm had a conclusive result in 86% of cases
(117/136), p5 .0001. CEUS examination was conclusive for HCC in 76.3% of
the cases (190/249), while using the ACR CEUS LI-RADSv 2016 algorithm in
72.2% of all HCCs (180/249), p¼ 0.35.
Conclusion: In our study, CEUS arterial hyperenhancement is the most common
pattern observed in HCC(91.2% of cases), followed by washout in the late phase
(79.1% of cases). The size of the nodule modifies CEUS sensitivity for the diag-
nosis of HCC p5 .0001.
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Introduction: Contrast-Enhanced Ultrasound (CEUS) is an imaging method that
can be used to discriminate between hepatocellular carcinoma (HCC) and other
focal liver lesions.
Aims & Methods: This study aimed to test the latest approved version of a
contrast-enhanced ultrasound algorithm (ACR CEUS LI-RADSv 2016) for
detecting hepatocellular carcinoma (HCC), in a real-life cohort of high-risk
patients. We re-evaluated the CEUS studies of 298 focal liver lesions in patients
at high-risk for HCC (liver cirrhosis of any etiology, chronic hepatitis B or C,
with severe fibrosis, current or prior HCC) using the ACR CEUS LI-RADSv
2016 algorithm. CEUS LI-RADS categories used for the diagnosis of HCC were:
CEUS LR-5 (definitely HCC), CEUS LR-5V (HCC with macrovascular inva-
sion), CEUS LR-Tr (treated HCC). Contrast-enhanced CT, contrast-enhanced
MRI or histology were used as reference methods to evaluate the CEUS LI-
RADS classification of the 298 lesions.
Results: According to reference method, the 298 lesions were classified as follows:
211 HCCs, 60 non-HCC-non-malignant lesions (fatty infiltration, hemangiomas,
simple cysts, regenerative nodules) and 27 non-HCC malignant lesions (liver
metastases, cholangiocarcinoma, indeterminate). The diagnostic accuracy of
ACR CEUS LI-RADSv 2016 for the diagnosis of hepatocellular carcinoma
was 74.4%. Sensitivity, specificity, positive predictive value (PPV) and negative
predictive value (NPV) were 65.4%, 96.5%, 97.8% and 53.5%, respectively.
When we used CEUS alone, a conclusive diagnosis of HCC was obtained in
69.6% of the cases (147/211),while using the algorithm in 65.4% of all HCCs
(138/211), p¼ 0.35.
Conclusion: In our study 65.4% of all HCCs (138/211) were correctly diagnosed
using ACR CEUS LI-RADSv 2016 algorithm, showing good sensitivity, excel-
lent specificity and PPV for the diagnosis of HCC.
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Introduction: Hepatocellular carcinoma (HCC) is the 5th most common cancer
worldwide and the 3rd leading cause of cancer-related mortality. In Egypt, HCC
is the 2nd most common cancer in men and the 6th most common cancer in
women. Egypt has the highest prevalence of HCV worldwide and has rising rates
of HCC. HCC is a disease with fast infiltrating growth and poor prognosis. This
bad prognosis is due to the lack of an effective method for early diagnosis. So, it
is necessary to find a specific & sensitive marker for early diagnosis of HCC and
for monitoring of treatment response.
Aims & Methods: The aim of this work is to assess prognostic value of serum
DKK1 in predicting treatment response, complication and survival in HCC
patients.This study included 60 Patients divided into two groups. Group A:
consisted of 30 patients with liver cirrhosis. Group B: consisted of 30 patients
with HCC. Group B patients underwent either radiofrequency ablation or etha-
nol injection. Clinical assessment, routine laboratory evaluation, CT studies and
measurement of serum alpha-fetoprotein (AFP) and DKK1 were performed to
all patients and repeated to group B patients 1 and 3 months after treatment.
Results: DKK1 significantly can be used for HCC diagnosis even in HCC with
inconclusive AFP. The optimum cut off value of DKK1 for diagnosis of HCC
was 4.3 ng/mL (AUC 0.89, sensitivity 66.7% and specificity 96.6%) (P5 0.001).
Serum DKK1 level significantly decreases after HCC treatment with either radio-
frequency ablation or ethanol injection (P5 0.001).
Conclusion: DKK1 has a promising prognostic value and can be used for follow-
up of HCC patients before and after treatment.
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Introduction: Fibroblast growth factor (FGF), vascular endothelial growth
factor, and hepatocyte growth factor play a critical role in the pathogenesis of
hepatocellular carcinoma (HCC).
Aims & Methods: We determined the association of single nucleotide polymorph-
isms (SNPs) in growth factor signaling–related genes with the development and
progression of tumors and overall survival in patients with hepatitis B virus
(HBV)-associated HCC. We assessed nine SNPs in the FGF1, FGF2, FGF recep-
tor (FGFR)-2, Flt-1, and c-MET genes in 245 HCC patients and 483 chronic
HBV carriers without HCC.
Results: None of the SNPs was associated with the risk of HCC development in
chronic HBV carriers. The FGF2 rs308379 A allele was significantly associated
with small tumor size, early tumor stage, and less vascular invasion. The Flt-1
rs4771249 C allele was associated with low alpha-fetoprotein levels. Kaplan-
Meier analysis showed that the patients with the FGF2 rs308447 TT genotype
had lower survival rates than the patients with the CC or CT genotype
(P¼ 0.016) and that the FGF2 rs308379 A allele carriers had shorter survival
rates than those of patients with the TT genotype (P¼ 0.020). The FGFR2
rs1219648 CC genotype was significantly associated with increased survival
rates (P¼ 0.047). Multivariate Cox proportional analysis revealed that the
FGF2 rs308379 A allele (hazard ratio¼ 1.663, P¼ 0.004) and advanced tumor
stage (hazard ratio¼ 3.430, P5 0.001) were independent prognostic factors for
overall survival rates in patients with HCC.
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Conclusion: These observations suggest that the SNPs of the FGF2 and FGFR2
genes can be potential prognostic indicators in patients with HBV-associated
HCC.
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Introduction: Extrahepatic HCC metastasis are associated with a poor prognosis.
Nevertheless there are some effective therapies available.
Aims & Methods: The aim of this study was to assess the main sites of extra-
hepatic metastasis in hepatocellular carcinoma (HCC) patients and to evaluate
the clinical evolution and treatment. This was a retrospective single-center study
in which patients with HCC confirmed extrahepatic metastasis between January
2010 and December 2016 were evaluated.
Results: We evaluated 51 consecutive patients, 80% male, with a mean age of
64 11 years at the time of metastasis. In 41% of the patients the metastasis were
present at the time of HCC diagnosis. In patients with subsequent metastasis, the
median time until its development was 9 months (IQR 5–16). The diagnosis of
metastasis was incidental in 51% of the patients. Computed tomography (CT)
was the main diagnostic method (86%) and in 18% of the cases histological
confirmation was obtained. Nineteen patients underwent thoracic CT and five
performed bone scintigraphy prior to metastasis. A total of 70 metastatic sites
were identified, the more frequent were lung (33%) and bone (14%). The MELD
score at the time of metastasis was higher than the MELD score at the HCC
diagnosis (p¼ 0.009). Metastasis detection implied changes in HCC therapy in all
patients, 41% started sorafenib and 55% were referred for supportive therapy.
Seven patients performed metastasis targeted treatment, namely 3 patients under-
went radiotherapy. The median overall survival (OS) after metastasis was 4.0
months (95%CI 2.1–5.8 months) and the mortality rate was 81% at 12
months. Patients who underwent metastasis targeted treatment presented a
longer OS than those who did not (median 18.5 vs 3.1 months; p¼ 0.002). In
multivariate analysis, MELD score at the time of metastasis (p¼ 0.004) and
metastasis treatment (p¼ 0.005) were independently associated with OS
estimation.
Conclusion: A systematic HCC staging, with thoracic CT and bone scintigraphy,
may provide an earlier metastasis detection and enable a targeted treatment with
a consequent improvement in survival in this difficult-to-treat population.
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Introduction: According to the Barcelona Clinic Liver Cancer (BCLC) staging
system, intermediate stage contains very heterogeneous hepatocellular carcinoma
(HCC) patients. Recently, subclassification of intermediate stage on the basis of
Milano criteria and up to 7 criteria is proposed. In this study, the effectiveness of
drug-eluting bead-transarterial chemo-embolization (DEB-TACE) in intermedi-
ate stage was investigated.
Aims & Methods: 120 patients (M: F¼ 90:30; median age¼ 76; Child A: B:
C¼ 72:44:4; BCLC stage A: B: C: D¼ 6:85:23:6) with unresectable HCC who
received DEB TACE in our hospital were studied. The objective radiological
response was classified according to the modified Response Evaluation Criteria
in Solid Tumors (mRECIST) v.1.1 by using dynamic CT at one or two months
after therapy. Adverse events were evaluated using NCI CTCAE v. 4.03.
According to Bolondi’s subclassification, the patients of BCLC B stage were
divided into four groups (B1: 24, B2: 31, B3: 19, B4: 10). The response rate
and tumor factor associated response in these patients group were examined.
Results: The overall response rate and disease control rate in intermediate stage
were 36% and 89%, respectively. Considering the subclassification, the response
rate in B1 group (61%) was significantly higher than that of B2þB3 group
(29%). Although B2þB3 group was constituted by the patients who did not
satisfy the up to 7 criteria, only in the patients with less than 7 tumors, the
response rate (60%) was similar to that of B1 group. Tumor factors associated
response and found to be significant on univariate analysis were simple gross
classification (simple nodular type) and number of tumor. Tumor diameter was
not associated with the response.
Conclusion: For the treatment of intermediate stage of HCC, although DEB-
TACE is considered to be most effective in B1 group, it is suggested that
DEB-TACE is also effective in the patients with less than 7 tumors in B2þB3
group. In cases with more than 7 tumors, as the response rate is considered to be
extremely low, sorafenib and arterial infusion therapy are recommended in
B2þB3 group.
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Introduction: In the last few years many HCV patients with previous diagnosis of
hepatocellular carcinoma (HCC) have been treated with direct antiviral agents
(DAAs) for HCV infection. However there are conflicting data on HCC recur-
rence rate after DAAs therapy.
Aims & Methods: Aim of this study was to prospectively evaluate the rate of
HCC recurrence following sustained virological response (SVR) by DAAs. From
April 2015 to September 2016 we consecutively enrolled HCV infected patients
previously treated for HCC at Liver Unit of Cardarelli Hospital. All patients had
a free-disease survival from HCC of at least 6 months before starting antiviral
therapy. The efficacy of HCC therapy was evaluated according to mRecist cri-
teria at CT or MRI. Radiological evaluation was carried out within 30 days from
the start of therapy. All patients underwent DAAs therapy, selected on an indi-
vidual basis according to the recommendation issued by the Italian association of
the study of the liver.
Results: A total of 71 patients were enrolled. Among them, 42 patients had
available data on SVR status and were considered for the analysis. There were
21 males (58.3%) and 15 females. The median age of the patients was 73 years
(range:52–85). The median follow-up was 12 months after the beginning of treat-
ment (range: 6–18 months). Genotype distribution was as follows: 36 patients
infected with genotype 1 (85.7%), 5 with genotype 2 and 1 patients with genotype
3. SVR was achieved in 38/42 patients (90.5%). HCC recurrence was observed in
11/38 patients with SVR (28.9%). The median time for recurrence was 9 months
from the start of therapy with a range of 1–13 months; with 2 patients who
showed recurrence during therapy. Among the patients who did not achieve
SVR, 1/4 showed HCC recurrence after 10 months from end of treatment.
Conclusion: Treatment with DAAs are highly effective with a SVR of about 90%
even in patients with advanced liver disease. Nonetheless, in patients with pre-
vious history of HCC, the eradication of HCV did not reduce the risk of short
and medium-term recurrence.
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Introduction: Primary liver cancer is the sixth most common cancer in the world,
after cancers of the lung, breast, colorectal, prostate and gastric[1]. However, the
extremely poor prognosis for primary liver cancer makes it the second leading
cause of cancer-related death globally (745,000 deaths, 9.1% of the total
death)[2]. Histologically, the majority of primary liver cancer is either
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hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC),
while combined hepatocellular carcinoma and cholangiocarcinoma is less
common[3]. Though these treatments have shown modest improvement in overall
survival in early stage disease, the 5-year relative survival for distant metastasis
patients is still low (3.1%). As we all know, primary liver cancer preferentially
metastasize to the portal vein and extrahepatic metastasis include lungs, bones,
brain, lymph nodes, and adrenal glands[4–6]. To date, few detailed studies
explored extrahepatic metastasis profiles due to rare data of liver cancer metas-
tasis. Patterns of extrahepatic metastasis still need further clarification. Besides, it
is unclear whether different metastatic sites would be translated into distinct
clinical outcomes.
Aims & Methods: The objective of this study was to further evaluate extrahepatic
metastatic patterns of different histological subtypes and assessed effects of extra-
hepatic metastasis on survival of advanced disease. Methods: Based on the
Surveillance, Epidemiology and End Results (SEER) database, we identified
eligible population diagnosed with primary liver cancer. We adopted Chi-squared
test to compared metastasis distribution among different histological types.
Overall survival (OS) and cancer-specific survival (CSS) were compared between
subgroups with different extrahepatic metastasises.
Results: We finally identified 8677 patients who were diagnosed with primary
liver cancer from 2010 to 2012 and 1836 patients were in distant metastasis
stages. Intrahepatic cholangiocarcinoma was more invasive and had a higher
percentage of metastasis compared with hepatocellular carcinoma. Lung was
the most common metastatic site and brain was least common site for both
hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Extrahepatic
metastasis was an independent prognostic factor for liver cancer patients.
Patients with brain metastasis had the worst prognosis, compared with other
metastasis in OS and CSS analysis.
Conclusion: Different histological subtypes of liver cancer had different metasta-
sis patterns. There were profound differences in risk of mortality among distant
extrahepatic metastatic sites. Results from our studies would provide some infor-
mation for follow-up strategies and future studies.
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Introduction: BCLC-C stage hepatocellular carcinoma (HCC) includes a wide
spectrum of tumor and patients’ characteristics. Refining prognosis according
to prognostic factors may allow the selection of those subjects who could benefit
of curative tratments.
Aims & Methods: The aim of this study was to investigate the prognostic
factors for survival of BCLC-C stage HCC patients in a real-life setting.
Consecutive caucasian cirrhotic patients with BCLC-C stage HCC were
included in the analysis. Pre-treatment (Child-Pugh score, performance
status (PS), number and maximum size of lesions, vascular invasion, metas-
tases, the combination of vascular invasion and extrahepatic spread, alfafeto-
protein (AFP) levels, NIACE score) and post-treatment (the number of
treatments after the progression to BCLC-C stage and disease control (DC)
considering stableþ partialþ complete response as the best treatment
outcome) variables were considered as prognostic factors. The analysis was
adjusted for sex and age.
Results: 116 patients were included in the analysis. After a median follow-up of
22.9mo (95%CI 17.3–38.1), the cumulative median survival of the overall popu-
lation was 13.4mo (95%CI 10.6–17). At the univariate analysis, tumor size,
vascular invasion with or without extrahepatic spread, and AFP4 200 as pre-
treatment factors and DC as post-treatment variable were associated with survi-
val. Multivariable cox regression revealed that the only independent predictors of
mortality were AFP4 200 (HR 2.2, 95%CI 1.27–3.8, p¼ 0.004) and DC (HR
0.222, 95%CI 0.12–0.4, p¼50.0001). However, the influence of these factors
was not homogeneous during time. Indeed, in the early and intermediate period
AFP4 200 was an independent predictor of worse outcome (at 6mo: HR 16.602,
95%CI 1.97–139.5, p¼ 0.009; at 1 yr HR 3.069, 95%CI 1.07–8.76, p¼ 0.036). As
expected, in the multivariable post-treatment prognostic model DC was asso-
ciated with a better mid- and long-term survival (at 1 yr: HR 0.245, 95%CI
0.06–0.87, p¼ 0.030; at 2 yrs: HR 0.356, 95%CI 0.12–1.03; p¼ 0.05; at 3 yrs:
HR 0.094, 95%CI 0.02–0.29, p¼50.0001).
Conclusion: In patients with BCLC C HCC, AFP4 200 ng/mL is a strong prog-
nostic factor in the early and intermediate period, while DC is associated with
long-term patients’ survival.
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Introduction:Non-cirrhotic intrahepatic portal hypertension is defined as a portal
hypertension (PH) without cirrhosis in liver biopsy and without an obstruction of
the portal and the hepatic veins.
Aims & Methods: This is a retrospective study conducted on the last 19 years in
‘‘Medecine C’’ department at Ibn Sina hospital in Rabat. 33 non-cirrhotic
patients with intrahepatic portal hypertension were considered. We analyzed
medical data of all patients with hypertension portal without cirrhosis in liver
biopsy and without an obstruction of the portal and the hepatic veins.
Results: 33 patients were included in this study, 22 were women. Mean age was 34
years old (18–70). The PH has been revealed by a digestive bleeding in 10 cases
(30%) and ascitis in 7 cases (21.2%). Clinical examination found a splenomegaly
in (75.7%). Abdominal ultrasonography combined with Doppler showed signs of
PH in all patients and confirmed the absence of obstacle on or above the liver.
Upper gastrointestinal endoscopy found esophageal varices in 26 cases (78.7%).
Transparietal liver biopsy was performed in 29 cases (87.9%).Various etiologies
were identified; in 21.2% (7 cases), intrahepatic PH was due to liver tumors and
in 11.7% (n¼ 4), the etiology was hepatic tuberculosis. Etiological investigations
retained: 3 cases (9%) of primary biliary cirrhosis in pre cirrhotic stage, 6 cases
(18.18) of hepatic portal sclerosis, 4 cases (12.12%) of hepatic sarcoidosis, 2 cases
(6%) with hematological malignancies, 2 cases (6%) of polycystic liver, one case
(2.9%) hepatic angiomatosos liver, a case chronic hepatitis B, a case of Gaucher
disease and one case secondary to hamartoma of the liver. Treatment was indi-
cated according the etiology of PH and its severity (beta blockers, ligation).
Conclusion: Non-cirrhotic intrahepatic portal hypertension is mostly asympto-
matic, related to a heterogeneous group of diseases with a good prognosis
excepted solid and hematological malignancies.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1382 CONSERVATIVE MANAGEMENT OF EXTERNAL BILIARY
FISTULAS COMPLICATING SURGERY OF HYDATID CYST OF THE
LIVER
O. Baraket, K. Ayed, W. Triki, M. A. Lahmidi, A. Itami, I. Abbassi,
S. Bouchoucha
Generla Surgery. Hopital Habibi Bouiguetfa Bizert, Faculty of Medicine of Tunis.
University Tunis ElMANAR, Bizerte/Tunisia
Contact E-mail Address: oubaraket@gmail.com
Introduction: Surgical treatment is nowadays the only curative treatment of hyda-
tid cyst of the liver. Surgical approach exposes to many complications especially
biliairy fistulas. Many modalities are described for the treatment of these
complications.
Aims & Methods: A retrospective study including 250 patients who underwent a
surgical treatment for a hydatid cyst of the liver between 2007 and 2015. The aim
of this study is to evaluate the place of conservative management and his benefits
in biliairy fistulas.
Results: Conservative surgical treatment oh hydatid cyst was done in 180 cases
and radical surgery in 70 cases. A complication occurs in 66 cases. An external
biliary fistula occurs in 45 cases (18%). Management of all this biliary fistulas
was conservative and prolonged drainage of the residual cavity and elevation of
the drainage. No major ionic and electrolytic troubles were observed. The fistula
healed in 44 of patients with a median time of 4 weeks [range, 1–7]. In one case
endoscopic treatment was necessary to heal fistulas. The median hospital stay
was 15 days [range 12–60] when biliary fistulas occurred compared to 8 days [6–
15] when there is no biliary complications.
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Conclusion: External biliary fistulas are a common complication after surgical
treatment of hydatid cyst of the liver. Conservative management of this compli-
cation is safe and very useful when we respect the indications.
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Introduction: Portal vein thrombosis (PVT) is defined as a partial or complete
occlusion of portal vein and/or its tributaries by a thrombus. It exposes to portal
hypertension (PHT) by infrahepatic occlusion and consequently to upper diges-
tive hemorrhage, usually due to rupture of gastro esophageal varices.
Aims & Methods: The aim of this study is to specify the evolution of esophageal
varices and thus risk of rebleeding in patients with PHT by PVT unrelated to
cirrhosis. It is a retrospective study from January 2010 to February 2017, includ-
ing 101 patients followed for PHT by PVT without liver disease in the depart-
ment of hepatogastroenterology (medicine C) at Ibn Sina University hospitaf of
Morroco. PVT was diagnosed by abdominal doppler ultrasonography in all
patients.
Results: The mean age of patients was 36 15 years with extremes ranging from
11 years to 70 years. The sex ratio M/F was 0.42. Five percent of patients had a
splenectomy for undocumented reasons before the diagnosis of PHT. Concerning
the reasons of hospitalization, 10.9% (n¼ 11) were hospitalized for melena,
60.4% (n¼ 61) for hematemesis and melena and 28.7% (n¼ 29) for non-specific
abdominal pain. Clinical examination was normal in 10.9% (n¼ 11), showed an
ascites in 11.9% (n¼ 12), and signs of PHT such as splenomegaly and collateral
abdominal venous circulation in 95.1% (n¼ 96). Complete blood count showed
that 16.8% (n¼ 17) had thrombocytopenia, 12.9% (n¼ 13) had bicytopenia, and
42.6% (n¼ 43) had pancytopenia. In all patients, upper GI endoscopy was per-
formed. Hypertensive gastropathy was found in 30.7% (n¼ 31), grade I esopha-
geal varices (OV) in 5.9% (n¼ 6), grade II in 30.7% (n¼ 31), grade III in 48.5%
(n¼ 49) and gastric varices were noted in 13.9% (n¼ 14). These varices were with
red spots in 18.8% (n¼ 19). All patients had abdominal doppler ultrasonography
showing a PVT in 60,3% (n¼ 61), this was partial in 33.6% (n¼ 34), complete in
11.9% (n¼ 12) and extended to the splenic vein in 14.9% (n¼ 15). Portal caver-
noma was found in 39.6% (n¼ 40). All patients performed an etiologic assess-
ment of thrombosis, myeloproliferative syndrome was found in 8.9% (n¼ 9),
deficiency in inhibitors of coagulation in 31.7% (n¼ 32), celiac disease in 4,9%
(n¼ 5), neoplastic leasions in 2.9% (n¼ 3), no etiology was found in 51.4%
(n¼ 52). Endoscopic variceal Ligation (EVL) was performed in 70.3%
(n¼ 71), the mean number of ligation sessions was 3 and eradication of oeso-
phageal varices was noted in 69.3% (n¼ 70). All patients received anticoagulant
therapy except those having portal cavernoma with no obvious cause and 42.6%
of patients (n¼ 43) received beta-blockers for secondary prophylaxis. During
follow up, 5.9% (n¼ 6) of patients have not been seen at consultation and no
rebleeding was noted in 89.1% (n¼ 90). Concerning portal thrombosis, it dis-
solved in 49.5% (n¼ 50) and stabilized in 10,8% (n¼ 11).
Conclusion: The evolution of esophageal varices in non-cirrhotic portal hyperten-
sion due to PVT seems to be better than in cirrhotic portal hypertension. Indeed
89.1% of patients in this study didn’t rebleed after eradication of esophageal
varices.
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Introduction: Incomplete stones clearance after endoscopic management of diffi-
cult biliary stones poses the risk of complications such as cholangitis.
Confirmation of complete stones clearance is normally confirmed fluoroscopi-
cally with obvious risk of false negative/false positive results, leading to possible
under/overtreatment. Direct peroral cholangioscopy (POC) refers to the use of
nonspecific endoscopes for the direct visualization of the common bile duct
(CBD).
Aims & Methods: We aimed to evaluate the feasibility and safety of POC to
confirm CBD complete clearance after endoscopic treatment of difficult biliary
stones. From 1st June 2016 to 30 March 2017 all consecutive patients treated
with Dilated assisted stone extraction(DASE) for difficult biliary stones at our
institution, underwent POC to verify CBD stones complete clearance. Ultraslim
(5.9mm diameter) or Slim (8.5mm diameter) endoscopes (FujiFilm EG 530NW
or EG 530FP) or standard gastroscope (9.9mm diameter) (Olympus GIF-
HQ190), under CO2 insufflation, were used by the peroral route for intubating
all accessible bile ducts. Technical success rate, procedural time, outcome and
safety of POC were assessed. All adverse events were recorded.
Results: POC was performed in 26 patients (17F/9M mean age 74.6 years 11.9)
under propofol sedation (23 patients) or deep sedation (3 patients). Mean CBD
size was 15mm 3.65; mean stone diameter (13.5mm 1.70); mean balloon
dilation (13.5mm 2.12). Intubation of the papilla and distal biliary duct was
successful in 26 (100%) cases (guide-wire assistance in 17 cases, 65.4%). Hepatic
hilum was reached in 13/26 (50%) patients with a complete CBD evaluation.
Mean investigation time was 6.3 1.5min (range of 5–9 minutes). POC showed
persistent large amount of sludge in 2(7.7%) cases, completely suctioned through
the endoscope, and stones in 4 (15.4%) cases with subsequent endoscopic stones
removal. In the remaining patients, POC confirmed complete duct clearance. No
adverse events occurred.
Conclusion: CBD complete clearance confirmation using POC is a feasible, quick
and safe procedure that can help on clinical decision making (for example obviat-
ing the need for possible plastic stent or naso-biliary drainage placement) without
substantial increase of time or costs. Our experience, however, is preliminary and
was specifically aimed to assess the feasibility of the procedure, which could
represent the first step for the development of a possible new indication in the
setting of difficult biliary stone management.
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Introduction: Percutaneous cholecystostomy (PCT) has been an alternative treat-
ment of acute calculous cholecystitis (ACC) for the patients unsuitable for early
cholecystectomy. Lithotomy with percutaneous transhepatic cholangioscopy
(PTCS) after PCT track maturation is particularly considered for those patients
with gallbladder (GB) stones who are poor surgical candidate. We examined the
long-term outcomes of 171 patients with ACC treated by PTCS.
Aims & Methods: This study was a retrospective observational study of 171
consecutive patients who treated with PTCS for ACC in the period from 1 Jan
2005 to 31 Dec 2015. Outcome measures included the success rates, adverse
events, recurrence rate and mortality. All data were collected from patients’
medical records.
Results: PTCS achieved complete clearance of GB stones in 157 patients (91.8%).
The complication rate of of PTCS was 3.5% (6/171). The adverse events included
GB perforation (n¼ 3, 1.8%), hemorrhage (n¼ 2, 1.2%), disruption of the per-
cutaneous transhepatic biliary drainage fistula (n¼ 1, 0.6%), and all of which
resolved with conservative treatment. The overall recurrence rate of gallstone
diseases was 11.5% during the follow up period. The incidence of recurrent
gallstone diseases was significantly higher in those with completely removed
GB stones than in those without complete clearance (10.2%, 16/157 vs 21.4%,
3/14; p5 0.05). The frequency of recurrence of gallstone disease in patients with
contrast passage to the duodenum on cholangiography after PTCS was lower
than that in patients without contrast passage.
Conclusion: Gallbladder stone removal with PTCS would be recommanded as an
effective and safe treatment modality for the patients with acute cholecystitis who
are unsuitable for surgery.
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Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) with
sphincterotomy is a well-established standard method for treating bile duct
stones (BDS). After cannulation of the common bile duct (CBD), a guidewire
is placed into the CBD and a sphincterotomy is performed. Subsequently, stone
extraction using a balloon or basket catheter is performed. Because of this multi-
step process, endoscopic treatment for BDS always comes with a risk of losing
CBD cannulation. A combination catheter that combines a sphincterotome and a
retrieval balloon in a single instrument can eliminate one step in the process of
bile duct (BD) clearance and may be able to accomplish BD clearance by using
only single device. Additionally, a newly developed 0.025 inch guidewire that is,
at once, rigid and flexible enables us to inject contrast agent through the Y-
connector smoother. Therefore, the combination catheter with a Y-connector
and a 0.025 inch guidewire may become a single device that can facilitate com-
plete BDS clearance. Despite its utility, the success rate of bile duct cannulation
and cost benefit requires further analysis.
Aims & Methods: We aimed to evaluate the therapeutic efficacy of a combined
catheter as a single device required for BDS clearance. From January 2016 to
July 2016, 11 consecutive patients with BDSs 10mm in size were enrolled in this
study (Stonetome group). In all cases, the combined catheter (Stonetome) was
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used for initial bile duct cannulation. Subsequently, sphincterotomy and stone
extraction were performed using the combined catheter. The success rate of
performing the combined procedure, procedure-related time, adverse events,
and the cost of devices were compared with those in 10 patients with
BDSs 10mm in size who had undergone endoscopic stone clearance from
April 2015 to December 2015 as historical control.
Results: The success rate of selective cannulation and stone clearance did not
differ significantly (Stonetome group: 90.9% and 100% vs control group: 100%
and 100%, respectively). The median time after bile duct cannulation to complete
stone clearance and total procedure time in the Stonetome group were signifi-
cantly shorter than those in the control group (401.5 s versus 982.5 s, 645.5 s
versus 1380s, respectively). In the Stonetome group, delayed bleeding occurred
in 1 patient. In the control group, bile duct injury caused by the guidewire
occurred in 1 patient. The costs of the used devices did not differ significantly
(Stonetome group: $678 versus control group: $669).
Conclusion: The combined catheter has the same selective cannulation ability as a
conventional catheter and a similar capacity to remove BDSs as common retrie-
val balloon. Therefore, the combined catheter can reduce the procedure time to
remove BDSs.
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Introduction: The American Society for Gastrointestinal Endoscopy (ASGE)
emitted, in 2010, guidelines for the clinical orientation of patients with suspected
choledocholithiasis (CL), suggesting the direct refereral to endoscopic retrograde
cholangiography (ERC) in certain groups. However, the ERC is an invasive
exam and some studies demonstrated that a significant amount of patients clas-
sified with very strong risk of CL did not have alterations in ERC.
Aims & Methods: The aim of this work was to assess the accuracy of the ASGE
guidelines in portuguese population.This is a retrospective study that included
212 patients (52.8% female sex; 47.2% male sex; mean age 73.9 (14.6 years)
admitted to the hospital from 2014 to 2016.
Results: Of the 212 patients, 28 (13.2%) had intermediate risk of CL and 184
(86.8%) had high risk, according to the ASGE criteria. These patients were
submitted to the following exams/interventions: ERC (154 patients); magnetic
resonance cholangiography (50 patients) and endoscopic ultrasound (8 patients).
In patients initially classified with high risk of CL, this was confirmed in 119
(64.7%). The same was seen in 10 (35.7%) of the patients with intermediate risk.
The ASGE criteria, when applied to this population, demonstrated an accuracy
of 64.3% (21.7% sensitivity; 92.3% specificity) in the high-risk group, and an
accuracy of 35.5% (78.3% sensitivity; 7.8% specificity) in the intermediate-risk
group. Of the patients with intermediate probability, 12 (42.8%) underwent
ERC, and CL was found only in 4 of these patients. The presence of cholangitis,
a common bile duct 4 6mm, a common bile duct stone visualized on transab-
dominal US and a total bilirubin 44mg/dL were strong predictors of CL. The
overall ERC complication rate was 13% (20 patients), of whom 8 had no CL.
Conclusion: The ASGE guidelines showed a limited diagnostic accuracy in the
identification of patients who actually require ERC, conditioning a significant
number of unnecessary procedures with subsequent complications associated
with it. It is urgent to rethink the orientation of these patients, with greater
use of less invasive diagnostic techniques such as magnetic resonance cholangio-
graphy and endoscopic ultrasound.
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Introduction: Laparoscopic choledochotomy as a method of extracting common
bile duct stones is a technique with many advantages. One problem, however, is
bile leakage along the T-tube. To some extent the leakage may be reduced if the
incision is sutured around the T-tube, but this technique has some disadvantages.
The aim of this study was to investigate whether application of fibrin glue around
the tube results in less leakage than suturing.
Aims & Methods: Between 2012 and 2016 a total of 1347 cholecystomies were
performed in Enköping Hospital. From this group, 42 patients were included in
the study and randomized to suturing or fibrin glue for closing the cholangiot-
omy around the T tube. Postoperative cholangiography was performed after 7–
10 days after surgery. The amount of flow in the abdominal drain and the level of
in the fluid bilirubin was measured daily. In case the flow ceased, the abdominal
drain was extracted three days after surgery.
Results: No significant difference between the groups was seen regarding the flow
of the abdominal drain or the T-drain for the first three days or operation time
Conclusion: Discussion Fibrin glue may be an option to seal cholangiotomy
around the T-tube, but studies with greater statistical power are needed to con-
firm this.
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Introduction: Rapid weight loss after bariatric surgery (BS) has been associated
with the formation of gallstones, and subsequent acute cholecystitis and cholan-
gitis (AC). However, the complex post-surgical anatomy limits the possibility of
performing an ERCP as part of AC treatment. Therefore, the aim of this study
was to assess the impact of bariatric surgery on mortality and resource utilization
among patients with AC using a national database.
Aims & Methods: This was a case-control study using the National Inpatient
Sample 2013, the largest publically available inpatient database in the United
States. All patients with an ICD-9 CM code for a principal diagnosis of AC were
included. There were no exclusion criteria. Patients with a past history of BS were
identified using the appropriate ICD-9CM codes. The primary outcome was all
cause mortality. The secondary outcome was resource utilization: use of ERCP,
cholecystectomy, length of hospital stay (LOS), total hospitalization charges and
costs. Multivariate regression analyses were used to adjust for the following
confounders: Age, sex, race, income in patients’ zip code, Charlson
Comorbidity Index, hospital region, location, size and teaching status.
Results: A total of 274,775 patients with AC were included in the study, of which
4,240 (1.7%) had undergone BS. The mean patient age was 51 years and 48%
were female. After adjusting for confounders, patients with and without history
of bariatric surgery had similar adjusted odds of mortality (adjusted Odds Ratio
(aOR): 1.37, 95% CI: 0.51–3.65, p¼ 0.52). As far as resource utilization, patients
with bariatric surgery had lower adjusted odds of ERCP (aOR: 0.28, 95% CI:
0.09–0.83, p¼ 0.02), but higher odds of cholecystectomy (aOR: 3.18, 95% CI:
1.00–10.05, p¼ 0.04). Both patient groups had similar adjusted length of stay
(adjusted mean difference: 1.19 days, 95% CI: 0.09–0.83, p¼ 0.16) total hospi-
talization costs (adjusted mean difference: $2237, 95% CI: -$2308 - $6782,
p¼ 0.49), and total hospitalization charges (adjusted mean difference: $7477,
95% CI: -$9595–$24549, p¼ 0.39)
Conclusion: Bariatric surgery has no impact on inpatient all-cause mortality
among patients who develop acute cholangitis, despite its association gallstone
acute pancreatitis and limited ERCP performance. In addition, bariatric surgery
does not affect resource utilization in this patient population as measured by
length of stay and total hospitalization costs and charges.
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Introduction: Prevalence of gallbladder polyps in the Netherlands is 943 per
100,000 cholecystectomies. Histopathologically these gallbladder polyps can be
divided in neoplastic polyps (with malignant potential) and nonneoplastic polyps
(without malignant potential). Although cholecystectomy is only indicated for
neoplastic polyps, 47% of polyps after cholecystectomy are nonneoplastic.
Further information on the pathological characteristics and subsequent clinical
and radiological features could be useful to predict neoplastic or nonneoplastic
nature of the gallbladder polyp before surgery.
Aims & Methods: To assess pathological characteristics of neoplastic and non-
neoplastic gallbladder polyps and identify preoperative clinical and radiological
predictors for neoplastic and nonneoplastic polyps. Data of the Dutch Pathology
Registry was used. In this search 2081 histopathologically proven gallbladder
polyps (or (focal) wall thickening 45mm) were identified in patients of 18
years undergoing primary cholecystectomy between 2003 and 2013. Of these
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polyps 56.3% was neoplastic (adenoma, dysplasia, carcinoma or other malignan-
cies) and 43.7% nonneoplastic (all other types of polyp). Age and sex of the
patient, number of polyps, size of the polyp, coincidence with gallstones and
presentation as protruding polyp or wall thickening were extracted from the
excerpts. Additional clinical and radiological information was collected from
patients’ medical records at three hospital in the Netherlands (n¼ 178). The
following clinical and radiological predictors were considered: age, gender, eth-
nicity, BMI, medical history (PSC, Hepatitis, metabolic syndrome, gallbladder
disease, Salmonella typhi or Helicobacter pylori infection), family history of gall-
bladder diseases, presence of abdominal symptoms and radiological features
(size, number, shape, surface and echogenicity of the polyp). Associations
between possible predictors and gallbladder polyps were assed using univariate
and multivariate logistic regression analysis.
Results: Patients with neoplastic polyps were found to be significantly older than
patients with nonneoplastic polyps (mean age 65.0 vs 54.2 years, p5 0.001).
Neoplastic polyps were significantly larger (mean size 18.1mm (SD 17.9) vs
7.5mm (SD 5.9), p5 0.001), more frequently presented as wall thickening
(29.2% vs 15.6%, p5 0.001) or as a single polyp (88.3% vs 68.0%,
p5 0.001). Gallstones were more frequently found in gallbladders with neoplas-
tic polyps (50.1% vs 40.4%, p 0.001). No preoperative clinical features were
predictive for neoplastic or nonneoplastic polyps. Presence of a single polyp on
ultrasound was a predictor for neoplastic polyps (OR 6.00 (95%CI 1.32–27.31)).
Size and type of polyp were often not mentioned in ultrasound report, or differ-
ent from histopathological confirmation.
Conclusion: Except for age, no clinical characteristics for neoplastic polyps were
identified in this cohort. Although pathological characteristics of neoplastic and
nonneoplastic polyps are confirmed, identification of these characteristics on
preoperative radiological investigations is poor.
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Introduction: Metformin has evidence of antineoplastic activity in some cancer
cells.
Aims & Methods: This study was performed to demonstrate in the bile duct
cancer cells whether metformin inhibits the proliferation of cancer cells by indu-
cing apoptosis and affects the expression of gene-related proteins involved in
cancer growth, and to identify how metformin affect molecular mechanisms
involved in the inhibition of cancer cell growth. Human extrahepatic bile duct
cancer cells were cultured. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assays were performed to determine the effect of metformin on
cell proliferation. Apoptosis was measured by a cell death detection enzyme-
linked immunosorbent assay and caspase-3 activity assay. Various protein
expressions with or without specific SiRNA transfection were measured by
Western blot analysis. The migratory activity of the cancer cells was evaluated
by wound healing assay.
Results: 1) Metformin suppressed cell proliferation in bile duct cancer cells by
inducing apoptosis. 2) Metformin inhibited mammalian target of rapamycin
(mTOR) by activation of pAMPKThr172 - tuberous sclerosis complex 2
(TSC2) pathway, and hyperglycemia impaired metformin-induced
AMPKThr172 activation and enhanced phosphorylation of AMPKser485. 3)
Metformin blocked inhibitory effect of insulin-like growth factor 1 receptor
(IGF-1R), insulin receptor substrate 1 (IRS-1) and AKt pathway on TSC2,
and hyperglycemia impaired metformin-induced inhibition of IGF-1R-IRS-1-
AKt pathway. 4) Metformin modulated invasiveness of bile duct cancer cells,
and the effect was impaired by hyperglycemia.
Conclusion: This study shows that metformin has antineoplastic effect in bile duct
cancer, and the effect of metformin is attenuated in the hyperglycemic environ-
ment. In addition, AMPK and IGF-1R play a key role in the proliferation of bile
duct cancer cells, thus they are expected to be important targets for future devel-
opment of chemotherapy agents.
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Introduction: Molecular pathology of gall bladder anomalies and progression to
carcinoma is still obscure and understudied; but is critically relevant to India
which harbors the highest number of cases globally, and to ethnically distinct
northeast India (NEI) where the cases have been increasing alarmingly.
Aims & Methods: Evaluate the associative role of genetic alteration(s) and pro-
moter hypermethylation of key BER pathway genes in the predisposition to gall
bladder diseases and progression to gall bladder carcinomas (GBC) in the ethni-
cally distinct NEI population. Whole blood and surgically ressected tissue sam-
ples were collected from clinically and histopathologically confirmed cases of
GBC (adenocarcinomas, N¼ 49) along with non-neoplastic control sections,
cholelithiasis (CL, N¼ 78) and cholecystitis (CS, N¼ 56); along with blood
from voluntary controls (N¼ 122) with informed consent. The BER pathway
genes polymorphisms were screened by PCR-RFLP using DNA samples of the
enrolled cases and controls. Differential mRNA expression profile of BER short
and long patch pathway genes was studied by RT-PCR. Difference in protein
expression was studied by immunofluorescence microscopy. Estimation of oxi-
dative stress in DNA was done using 8-OH-dG EIA kit. The difference in per-
centage promoter methylation of BER pathway genes was analyzed using RT-
PCR based HRM method.
Results: The genetic alterations in hOGG1 and XRCC1 gene were highly pre-
valent in both controls and gall bladder disease cases in NEI population, and was
associated with susceptibility and severity of gall bladder anomalies compared to
controls; most significantly for XRCC1codon280 polymorphism in GBC cases
compared to controls [OR¼ 1.986,p¼ 0.047]. Differential mRNA expression
profile clearly showed a sharp down-regulation in hOGG1, APE1, polb and
PARP1 expression in GBC, CL and CS cases compared to controls; and in
GBC compared to CL and CS cases. The mRNA expression XRCC1, a compo-
nent of both short and long patch pathway, was down-regulated in majority of
the GBC, CS and CL cases compared to controls; and in GBC cases compared to
CS cases. The protein also showed down-regulation of hOGG1 and XRCC1 in
GBC cases compared to controls. The oxidative stress marker 8-oxo-dG estima-
tion showed significantly increased levels in CL, CS and GBC cases DNA com-
pared to controls, the highest being in GBC cases. The higher 8-OH-dG levels in
GBC correlated significantly with the variant hOGG1 genotype (p5 0.001). The
percent methylation of both XRCC1 and hOGG1 in cases and controls was
between 0–30%. Hyper-methylation of XRCC1 and hOGG1 promoter was
noticeable in GBC cases compared to controls.
Conclusion: The data indicates an important role of oxidative stress in the patho-
genesis of gall bladder diseases and progression to GBC in NEI population;
which inturn is due to genetic, expression and epigenetic deregulations in the
key genes of the BER short and long patch pathway. The data also suggests
the prognostic significance of BER pathway parameters, as well as potential
therapeutic targets for the disease, and hence holds clinical relevance.
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Introduction: Gallbladder cancer (GBCa) is often diagnosed at advanced stage
resulting poor prognosis, because the patients with early GBCa has not showed
any symptoms and the tissue cannot be obtained easily with anatomical reason.
To overcome the weakness of the current methods for the diagnosis of GBCa, we
focus on the possibility of ‘‘liquid biopsy’’ with bile juice on the concept of non-
invasive diagnostic method as circulating tumor DNA in blood. To achieve good
treatment effect in future, so called ‘‘precision medicine’’ approach based on the
character of the each tumor is mandatory.
Aims & Methods: Thirty patients with GBCa were enrolled in this study. Bile
juice obtained from 24 of 30 patients was analyzed for mutations of 50 oncogenes
(Cancer panel; Haloplex, Agilent Technology) by next generation sequencing
(NGS; Illumina, San Diego, CA, USA). Tumor tissues from 20 of 30 patients
were analyzed as well as bile juice. Each sample was obtained prior to the
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treatment. As negative controls, 19 non-GBCa bile juice and 33 non-GBCa tissue
samples were analyzed for mutations of 50 oncogenes in the same way.
Results: The median (range) age was 77 (44–90) years and the male/female ratio
was 0.43 (9/21). Six, six, six, and twelve patients were diagnosed as stage I, II, III,
and stage IV, respectively. We set cut-off value at 5% for rare mutation rate
based on the results of healthy samples to avoid false positive. Eleven of 20 (55%)
tumor tissue samples were positive for mutation. TP53, MET, SMAD4,
CTNNB1 and AR were detected in 7/20 (35.0%), 1/20 (5.0%), 1/20 (5.0%), 1/
20 (5.0%) and 1/20 (5.0%) respectively. In this study, 14 of 30 (46.7%) patients
had both tumor tissue samples and bile juice samples. Eight of 14 (57.1%) tumor
tissue samples were positive for mutation. In these eight patients, 7 (87.5%) bile
juice samples had the same mutation (TP53, ERBB2/3 were detected in 6/8
(75%), 1/8 (12.5%), respectively). On the other hand, bile juice samples of
other 6 patients without tumor tissue mutation had no mutation. With regard
to only bile juice, 14 of 24 (58.3%) bile juice samples with GBCa were positive for
mutations. TP53 mutation, ERBB2/3, KRAS were detected in 11/24 (45.8%), 2/
24 (8.3%), 1/24 (4.2%), respectively. Bile juice analysis for mutations indicated
that sensitivity, specificity, positive predictive value (PPV) and negative predict
value (NPV) were 58.3%, 100%, 100% and 65.5%, respectively. None of nega-
tive control samples had any mutations.
Conclusion:Mutations in tumor could be detected in bile juice using NGS. Liquid
biopsy with bile juice may help us to diagnose GBCa because of high PPV
(100%). It may allow us to make new genetic diagnosis of GBCa.
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Introduction: Intraductal radiofrequency ablation (RFA) is a new endoscopic
ablative technique with direct effect to local tumor have been developed to
improve the duration of self-expandable metal stents (SEMS) in the unresectable
malignant biliary obstruction. However, there is the concern for the complication
such as bile duct perforation or bleeding because the ideal power setting of
intraductal RFA has not been clearly revealed still.
Aims & Methods: Therefore, we aimed to investigate the effects of ablative injury
after in vivo intraductal RFA according to the time variation using a novel RFA
catheter (ELRA, STARmed, Goyang, Korea). This novel catheter is a bipolar
device and has a temperature sensor within the distal tip, therefore it has a
characteristic of target temperature controlled mode. Nine female pigs were
divided into three groups according to RFA time variation (60, 90 and 120
seconds) with the same power setting (10 watts) and RFA target temperature
(80C). All pigs underwent endoscopic retrograde cholangiography (ERC) and
intraductal RFA. Additional cholangiogram was taken immediately after RFA
and then a plastic stent was inserted. All the pigs were humanely sacrificed 24
hours after the intraductal RFA. Necropsy was performed and the common bile
duct was excised for histologic analysis.
Results: The ERC and application of the intraductal RFA was successful in
100%, and post-RFA cholangiogram did not show the contrast leakage.
Median depth of microscopic ablation was significantly different between three
groups according to the ablation time (60 vs 90 vs 120 seconds¼ 1.90 (1.17–2.23)
vs. 2.44 (2.31–2.60) vs. 2.52 (2.47–2.64) mm, p¼ 0.018). There was also a linear
relationship between ablation time and microscopic ablation depth (r2¼ 0.552,
p¼ 0.002). However, there were no statistical differences in macroscopic ablation
length and microscopic ablation length. In addition, focal ablation injuries of
adjacent liver were found in five out of nine pigs (2 of 3 pigs in 60 seconds, 1 of 3
in 90 seconds, 2 of 3 in 120 seconds).
Conclusion: Intraductal RFA using a novel RFA catheter successfully ablated the
normal bile duct wall without serious complications in vivo swine model. The
optimal time of intraductal RFA was presumed between 90 and 120 seconds at
the power setting 10 watts and target temperature of 80C. However, focal
ablation injury was found in even short ablation time in which microscopic
ablation depth was superficial. Further studies are needed to validate the optimal
power setting of RFA in a swine model and then human clinical studies are also
warranted.
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Introduction: While many studies have attempted to define the risk factors for
neoplastic potential of gallbladder polyp, precise adaption of the risk factors
individually in an real treatment strategy of gallbladder polyp remains elusive.
Estimating the probability for neoplastic potential of gallbladder polyp using a
combination of several risk factors before surgical resection would be useful in
patient consultation.
Aims & Methods: This study was designed to provide the statistical predictive
model for neoplastic potential of gallbladder polyps. We collected data of
patients confirmed as GBP through cholecystectomy at Samsung Medical
Center between January 1997 and March 2015. Those with a definite evidence
for malignancy, such as adjacent organ invasion, metastasis on preoperative
imaging studies, polyp larger than 15mm, and absence of proper preoperative
ultrasonography imaging, were excluded. A total of 1976 patients were enrolled.
To make and validate the predictive model, we divided the cohort into the
modeling group (n¼ 979) and validation group (n¼ 997). Clinical information,
ultrasonographic findings, and blood tests were retrospectively analyzed. A pre-
diction model for the probability of neoplasia was fitted from the training set
using the logistic regression method equipped with backward elimination with
significance level for removal of P5 .05 for variable selection. The performance
of a fitted prediction model was evaluated by the area under the curve (AUC) of
a receiver operating characteristic (ROC) curve. A cutoff value of the fitted risk
score was chosen by the Youden Index.
Results: Clinical factors of older age, single lesion, sessile shape, and polyp size
showed statistical significance of neoplastic potential of GBP in the modeling
group. A predictive model* for neoplastic potential of GBP was constructed
utilizing the statistical outcome of the modeling group. Statistical validation
was performed with the validation group to determine the optimal clinical sensi-
tivity and specificity of the predictive model. Optimal cut-off value for neoplastic
probability was 7.4%. *Probability of Neoplastic GB polyp¼ e(ps)/1þ e(ps) where
e¼ 2.7182 is the base of the natural logarithm and PS (predictive score) ¼
-7.3633þ 0.0374 [Age]þ 0.6667 [Number]þ 1.5784 [Sessile]þ 0.2189
[Size].
Conclusion: The predictive model for neoplastic potential of GBP may support
clinical decision before cholecystectomy.
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Introduction: Photodynamic therapy (PDT) provide clinical benefit for patients
with unresectable biliary malignancy. In this study, we evaluate the efficacies of
controlled PDT for unresectable primary and secondary high-grade hilar cholan-
giocarcinoma (CC).
Aims & Methods: In cases of high-grade unresectable hilar CC (Bisthmus type III
or IV) and gallbladder (GB) cancer invasion to hilar portion (Group A), we
performed controlled PDT. Controlled PDT means malignant stricture dilatation
by using balloon catheter up to 10mm through percutaneous transhepatic cho-
langioscopy (PTCS) before PDT. And then applied appropriate laser light source
by using straight angled cylindrical diffuser. Finally, gemcitabine-based che-
motherapy was done for 6 cycles. We compared to transpaillary approach with
non-straight cylindrical diffuser using PDT with gemcitabine-based chemother-
apy in similar patients (Group B) in terms of clinical parameters and developing
complications.
Results: Between July 2010 and June 2015, 26 cases(31) of high grade unresect-
able hilar CC (Bisthmus type III or IV), 5 cases of GB cancer with hilar invasion
were enrolled for Group A, 23 cases(26) of high-grade unresectable hilar CC
(Bisthmus type III or IV), 3 cases of GB cancer with hilar invasion were enrolled
for Group B. On three months later, serum bilirubin levels decreased from
7.3 5.2 to 2.4 1.8mg/dL in group A, 6.9 5.5 to 5.2 3.7mg/dL in group
B (p5 0.05). PDT-induced cholangitis is developed in Group A (3/31, 9.6%) and
B (7/26, 26.9%) within seven days (p5 0.001). Progression free survival is super-
ior Group A to Group B that of 14.8 months vs. 8.9 months (P5 0.05).
Conclusion: Controlled PDT with straight applying cylindrical diffuser promise
efficacy for clinical parameters and progression free survival compared with
transpaillary PDT in unresectable high-grade hilar CC and GB cancer.
Additionally, diminished post-PDT cholangitis within 7 days affect improving
long term progression free survival.
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Introduction: IAC is a major manifestation of IgG4-related disease (IgG4-RD), a
multi-organ inflammatory disorder of unknown cause. IAC may present with
jaundice, abdominal pain and weight loss; immunosuppression is the preferred
treatment. Since the disease presentation may closely mimic that of malignancies
of the pancreatobiliary tract and accurate diagnostic tests have only recently been
developed, misdiagnosis and unnecessary surgery are common as has been con-
sistently reported in literature.
Aims & Methods: Our aim is to assess the incidence of Immunoglobulin G4-
associated cholangitis (IAC) in patients resected for presumed perihilar cholan-
giocarcinoma (PHC). All patients that underwent resection for presumed PHC at
our institution between 1984 and 2015 were included. Benign histological speci-
mens were re-evaluated by a pathologist and scored according to the interna-
tional pathological consensus criteria for IgG4-RD. Patients with benign disease
who were still alive were re-evaluated to assess IgG4 serum levels and IgG4/IgG
RNA ratio to detect activity of IAC.
Results: Between 1984 and 2015, 321 patients underwent liver and bile duct
resection for presumed PHC. Of all patients 15% (47/321) were found to have
benign disease on histological examination. 45% (21/47) of patients with benign
disease had evidence of IAC after surgery based on histological criteria (n¼ 17)
or laboratory parameters (n¼ 4). The remaining specimens showed unclassified
sclerosing inflammation. Out of 12 patients with benign disease that were re-
evaluated, 9 had ongoing active IgG4-RD requiring immunosuppressive
treatment.
Conclusion: Benign biliary disorders mimicking PHC have led to a considerable
number of liver and bile duct resections during the last three decades. There was
evidence of IAC in 45% of these patients. When left untreated, IgG4-RD can
remain active years after surgery. Novel accurate diagnostic tests for IAC might
reduce misdiagnosis and unnecessary surgery.
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Introduction: Digital cholangioscopy provides higher-resolution imaging of the
pancreatobiliary tract compared to the 1st fiberoptic generation. The impact of a
new single-operator digital cholangioscope (d-SOC) in diagnosis and treatment
of pancreatobiliary diseases has not been intensely assessed.
Aims & Methods: The aim of this retrospective analysis of prospective case series
from 8 centers from the Czech (n¼ 7) and Slovak (n¼ 1) Republics was to assess
(1) diagnostic yield of d-SOC visual diagnosis and biopsies in patients with
undetermined biliary strictures; (2) the efficacy of d-SOC directed treatment of
difficult lithiasis and (3) to analyze procedure related adverse events (AEs). The
main outcomes were (1) sensitivity and specificity for visual diagnosis with/with-
out biopsies (2) achievement of a complete duct clearance in patients with diffi-
cult lithiasis (3) procedure-related AEs.
Results: A total of 150 patients underwent 166 d-SOC procedures (165 cholan-
gioscopies and 1 pancreatoscopy); 81 (48.8%) for diagnostic intents (with biopsy
in 66/81 patients (81.5%), and 85 (51.2%) for therapeutic intents (1 patient had
pancreaticolithiasis). The most frequent indication for diagnostic d-SOC was
undetermined stenosis (n¼ 59). Reliable views of a target lesion were obtained
in all patients. The sensitivity, specificity and diagnostic accuracy of d-SOC for
visual diagnosis of malignant lesion was 88.9% (95%CI, 70.8–97.7), 81.2%
(65.6–92.3) and 84.6% (73.5–92.4). The mean number of biopsies obtained per
patient was 4 (range 1–13) and the specimen was adequate for histopathological
analysis in 95.5% of patients (63/66). The sensitivity, specificity and diagnostic
accuracy of d-SOC guided biopsies for malignancy were 78.3% (95%CI, 56.3–
92.5), 96.4% (81.6–99.9) and 83.3% (70.7–92.1). The diagnostic accuracy of
visual inspection was not statistically influenced by the presence of biliary stent
(Yates’ p-0.9). Of 63 patients attended for d-SOC-guided stone therapy, a com-
plete intraductal clearance was achieved in one session in 37 and in two sessions
in further 10 patients, respectively and the overall success rate was 77%. A total
of 11 patients (11/166; 6.6%) experienced an adverse event (cholangitis n¼ 6,
pancreatitis n¼ 3, perforation n¼ 2), one patient with severe cholangitis died.
The incidence of cholangitis was higher among patients who had received pro-
phylactic antibiotics (n¼ 5) compared to those who had not received it (n¼ 1).
Conclusion: Our, so far the largest case series analyzing outcomes and safety of a
new generation of d-SOC shows that (1) It provides high diagnostic yield in
patients with undetermined biliary stenosis; (2) The SOC directed biopsies have
a high diagnostic accuracy; (3) d-SOC guided stone lithotripsy is effective in three
quarters of patients and (4) Severe adverse events may occur and prophylactic
antibiotics may not be effective in preventing post-d-SOC cholangitis.
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Introduction: Intrahepatic cholangiocarcinoma (ICC) is famous for its poor prog-
nosis. Deepen the knowledge of the mechanism of ICC contributes to improving
the treatment. Osteopontin (OPN) is believed to promote tumorigenesis and
metastasis in many kinds of cancers, while its role in ICC is controversial.
Aims & Methods: This study aims to investigate the prognostic value and biolo-
gical function of OPN in ICC. Human Transcriptome Array 2.0 (HTA 2.0) were
used to find out ICC-specific genes. Quantitative PCR was used to investigate the
relationship between SPP1 and overall survival (OS) in 85 patients.
Immunohistochemistry was used for detecting the prognostic value of OPN, as
well as the correlation between OPN and clinicopathological characteristics.
Stably transfected ICC cell lines which express either higher or lower level of
OPN were conducted by lentivirus. Cell-IQ, the live cell imaging and analysis
system, was used for proliferation assay. Wound healing assay and Transwell
assay was taken to investigate the ability of migration and invasion among
transfected cell lines. PCR array was taken to screen the potential oncogenes
regulated by OPN.
Results: SPP1 is the most highly expressed genes in ICC with fold change of 43.35
according to HTA 2.0. ICC cell lines express higher level of SPP1 and OPN than
normal live cell line (P5 0.01). SPP1 is higher in tumor than adjacent tissues.
Patients with higher expression of SPP1/OPN in ICC has better OS than those
with low expression (P5 0.01). Both SPP1 and OPN are independent prognostic
factor. Higher expression of OPN correlates with better differentiation of ICC
and less lymph node metastasis. Compared with negative controlled (NC) cells,
ICC cell lines expressing more OPN showed accelerated proliferation rate, stron-
ger ability of migration and invasion. Likewise, ICC cells lines expressing less
OPN than NC cells proliferated slower, their capability of migration and inva-
sion was inhibited as well. MMP1, MMP10 and CXCR4 were down regulated in
OPN high expression cells and up regulated in OPN low expression cells.
Conclusion: High expression of OPN in ICC tumor tissues indicates less aggres-
sive behavior of ICC and better overall survival for patients after resection. OPN
is an advantage prognostic factor in ICC. OPN might function as an inhibitory
factor of MMP1, MMP10 and CXCR4 to weaken the capability of migration
and invasion in ICC cell lines.
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Introduction: Adenoma of the major duodenal papilla is clinically important
because this lesion is premalignant and should be resected completely.
Endoscopic papillectomy of ampullary adenomas is a promising alternative to
surgical resection, however acute and delayed pancratitis represent a major com-
plication of this procedure.
Aims & Methods: We evaluated the clinical importance of pancreatic duct drai-
nage after endoscopic papillectomy in order to prevent early (acute pancreatitis)
and late (pancreatic duct orifice stenosis) complications of this procedure. Our
single-centre, retrospective study with a minimal follow-up of 1 year, includes 19
patients who underwent endoscopic ampullectomy between 2012 and 2016.
Careful preoperative evaluation was performed by EUS (100% of patients)
and CT/MRI (94%). After a collective evaluation between the surgeon and the
endoscopist, patients were candidate for endoscopic ampullectomy. Outcome
parameters included ampulloma characteristics, bioptical accuracy as well as
safety, efficacy, recurrence rate, and survival.
Results: Endoscopic resection was successful in 15 patients (79%). Histological
review of the resected specimens revealed non specific changes (10.5%), low or
medium-grade dysplasia (52.6%), high-grade dysplasia (15.8%) and carcinoma
(21%). Bioptic accuracy was 68.4%. In 4 cases histologic specimen revealed an
invasive carcinoma: 2 patients underwent pancreaticoduodenectomy and two
were treated conservatively with placement of biliary and pancreatic stents,
due to the high preoperative risk. After complete endoscopic resection (15
patients), pancreatic stents were placed in 10 cases (66%). In five cases the
positioning of pancreatic stents was not possible due to anatomical difficulties:
2 developed mild pancreatitis after papillectomy; 1 patient developed, as late
complication, a stenosis of the pancreatic orifice: the patient died of severe
necrotic pancreatitis two years later. Hemorrage was observed in 2 patients, all
with pancreatic stents. Recurrence occurred in 2 patients (10.5%), both were
retreated by snare papillectomy and diathermal ablation (APC).
Conclusion: Pancreatic stent placement after endoscopic ampullectomy is man-
datory to prevent acute and delayed pancreatic complications. Preoperative strat-
egy should be accurate by MRI, EUS and ERCP, in order to define the anatomy
of the pancreatic duct aiming to improve the success rate of pancreatic stent
placement after papillectomy.
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Introduction: Cholangiocarcinoma is a neoplasm arising from the intra- or extra-
hepatic bile duct linning epithelium. Cholangiocarcinom are presents less than
2% of human malignancies, however, it is the second common primary hepatic
malignancy. Till date, many carcinogens have already been identified and the
relevant information with regard to these agents is available. One example is the
potentially harmful presence of heavy metals that can cause serious health pro-
blems. People may be exposed to heavy metals over the course of their lifetime.
The heavy metals in drinking-water pose the greatest threat to public health in
this regard. Nile River water is seriously contaminated with heavy metals, pesti-
cides, and hydrocarbons as a result of increasing discharge of untreated industrial
wastes and agricultural irrigation wastewater. Several reports on Dakahlia
Province show high levels of heavy metal and organocholorine pesticides in the
soil and water in this region. High concentrations of heavy metals, including
cadmium, are among the pollutants in the water. Plants and fish grown in this
water are also contaminated with heavy metals, which can in turn accumulate in
humans and animals that feed on these contaminated foods. The serum cadmium
levels of residents of Dakahlia Province are almost 10-fold higher than those of
residents from cadmium-polluted areas in Cairo and 32 times higher than refer-
ence levels for healthy populations in the United States.
Aims & Methods: We aimed to assess serum levels of Heavy metals namely Zink
(Zn), lead (Pb), Cobalt (Co), Cadmium (Cd),Chromium (Cr) and Iron (Fe) as a
markers of exposure in cholagiocarcinoma patients and healthy control subjects
from the same region in Egypt and its correlation with differentiation of cholan-
giocarcinoma and tumour marker CA 19-9. This study included 45 patients with
cholangiocarcinoma (diagnosed after radiological &histopathological examina-
tion) and 20 healthy control subject attending Mansoura Surgical
Gastroenterology centre. All patients and control were permanent residents of
North Delta region and the patients were recruited before receiving chemother-
apy or radiotherapy. There were no restrictions based on age, sex, or tumor stage.
The serum samples were analyzed for concentrations of zinc, lead, cobalt, cad-
mium, iron and chromium by the acid digestion method followed by using
atomic absorption spectrometry. ‘‘Buck Scientific Accusys 214 atomic absorption
spectrophotometer’’. The results are reported in mg/L. in addition to CA 19-9
was assayed by IMMULITE 2000 XPi immunoassay system supplied by
Siemens Healthcare (GmbH Henkestr.Erlangen Germany) using its commercial
kits.
Results: The serum levels of Zn, Pb, Co, Cd and Fe were significantly higher in
patients having cholangiocarcinoma more than control subjects (P5 0.001).
Progressive increase in the median values of serum levels of lead (Pb) was
found in well differentiated to moderately differentiated to undifferentiated
tumours. (P5 0.05). When correlation was made between the heavy metals
and CA-19-9 and the survival of the patients, it was found that Cd only has a
positive correlation with CA19-9 and negative correlation with the survival of the
patients (P5 0.5, (P5 0.01) respectively.
Cholangiocarcinoma control Significance test
Sex (N&%):
Male Female
22 (48.9%) 23 (51.1%) 22 (48.9%) 23 (51.1%) x2¼ 0.44, P¼ 0.5
Age (mean SD 54.2 7.9 52.5 8.99 t¼ 0.8, P¼ 0.4
Median (Min-Max) Median (Min-Max)
Zn 0.341(0.02–0.92) 0.106(0.002–0.55) Z¼ 3.05,P¼ 0.002
Pb 1.16(0.067–2.98) 0.353(0.019–0.932) Z¼ 4.79,P5 0.001
Co 4.304(0.224–14.1) 0.3255(0.03–2.834) Z¼ 5.88,P5 0.001
Cd 0.211(0.0–0.951) 0.0091(0.002–0.11) Z¼ 5.53,P5 0.001
Fe 1.991(0.662–5.774) 0.9565(0.0231–2.652) Z¼ 3.89,P5 0.001
Cr 0.7063(0.0–2.03) 0.452(0.0663–1.0619) Z¼ 1.91,P¼ 0.057
Conclusion: The results from this study suggest that cholangiocarcinoma in the
Nile Delta region is significantly associated with high serum levels of heavy
metals especially Cadmium and lead.
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Introduction: Early surgery is the standard treatment in patients with resectable
periampullary or pancreatic head cancer with jaundice. However, early surgery is
not always feasible and PBD could be a necesary for patient with jaundice at
diagnosis or for those undergoing neoadjuvant treatment. Most studies consid-
ered plastic stents for PBD, although SEMS are currently considered superior. A
recent RCTS showed that fully covered SEMS are associated with better out-
comes compared to plastic stent.
Aims & Methods: Aim compare the rate of endoscopic reintervention (Stent
failure of PBD) before surgery and post operative outcome of metal vs plastic.
We conducted a bibliographic search using PUBMED, EMBASE including ran-
domized and non randomized trials. OR using the Manthel-Haenszel method
was used for dichotomous variables. Weighted mean differences (WMD) were
used as the summary statistic for quantitative analysis of continuous variables,
Quantitative synthesis was performed using Review Manager version 5.0.
United European Gastroenterology Journal 5(5S) A649
Primary outcome was the rate of endoscopic reintervention before surgery.
Secondary outcomes were rate of overall complications, 30 days surgical post-
operative complications, hospital readmission, overall pancreatic fistula, overall
biliary anastomotic leak, overal postoperative mortality. Clinical heterogeneity
was assessed by I2 value. where a value exceeding 50% was indicative of hetero-
geneity. A random effect model was used in case of heterogeneity.
Results: Three RCTs and five non RCTs were selected including 909 patients. Of
these, 300 patients (33%) were treated with SEMS and 609 (67%) with plastic
stents. The rate of endoscopic reinterventions after PBD was significantly lower
in the metal stent (3.4%) than in the plastic (14.8%) group (p4 0.0001). The rate
of post operative pancreatic fistula was significantly lower in the metal stent
group as well (5.1% vs 11.8%, p5 0.04)(OR 0.23 95%CI0.06–0.96). The overall
pancreatic anastomotic leak was significantly lower in the metal stent group (OR
0.44 95%CI 0.20–0.96)(p¼ 0.04).The rate of postoperative surgical complica-
tions, hospital readmission, overall biliary anastomotic fistula and postoperative
mortality did not differ between the two groups.
Conclusion: Metal stents are more effective than plastic and should be preferred
for PBD in patients with resectable periampullary or pancreatic head tumor
when early surgery without PBD is not feasible. However, more RCTS are
needed before a firm conclusion could be made.
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Introduction: There is considerable controversy as to whether temporary relief of
biliary obstruction prior to major definitive surgery (pre-operative biliary drai-
nage) is of any benefit to the patient. A Cochrane meta-analysis revealed a major
morbidity with no difference in mortality in the group subjected to PBD.
However, the clinical status of patients was heterogeneous between studies.
Aims & Methods: We aimed to investigate the benefits and harms of pre-opera-
tive biliary drainage versus no pre-operative biliary drainage (direct surgery) in
patients with obstructive jaundice. A computerized medical literature search was
performed by using MEDLINE, EMBASE, Cochrane Library, from 1980 to
June 2016 aimed at identifying RCTS comparing PBD versus direct surgery.
Data from RCTS related to safety and effectiveness of PBD versus no PBD
were extracted by two independent reviewers. Risk ratio or mean differences
were calculated with 95 per cent confidence intervals. Clinical heterogeneity
was assessed by I2 value. where a value exceeding 50% was indicative of hetero-
geneity. A random effect model was used in case of heterogeneity. Outcomes
were mortality and morbidity.
Results: Nine trials including 734 patients with malignant or benign obstructive
jaundice comparing PBD (375 patients) with no PBD (359) were included in this
review. There was no significant difference in mortality (risk ratio 0.89, 95%CI
067 to 118; P¼ 042) between the two groups. Complications were higher in the
PBD group (RR 1.41; 95%CI 1.09–1.81 p¼ 0.008). Overall serious morbidity
was higher in the PBD group than in the direct surgery group (RR 1.66 95%CI
1.28–2.16 p¼ 0.0002). There was no significant difference in length of hospital
stay between the two groups: mean difference 4.55 (95% CI 1.51 to 10.61) days
(P¼ 014).
Conclusion: There is currently not sufficient evidence to support or refute the
routine pre-operative biliary drainage for patients with obstructive jaundice.
PBD in patients undergoing surgery for obstructive jaundice is associated with
similar mortality but increased serious morbidity compared with no PBD.
Therefore, PBD should not be used routinely. Further RCTs are needed.
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Introduction:Dietary fat consumption affects the human body fat composition. It
has been described that unsaturated fatty acids, enriched in human pancreatic
necrosis collections, worsen acute pancreatitis (AP) [1]. Preliminary reports ana-
lyzing indirect data have also suggested that patients with AP from world regions
with a high unsaturated fat intake have a worse outcomes at lower body mass
index [2]. We have also described that oleic acid (an unsaturated fat acid) chlor-
ohydrins are associated to worse outcomes [3]. The Mediterranean regions have a
higher unsaturated fatty acid intake.
Aims & Methods: We aimed to compare the incidence of necrotizing AP, persis-
tent organ failure (POF) and mortality among patients with AP from centers
located in the Mediterranean region (group M) and patients from centers in other
regions (group C). This was a retrospective analysis of a prospective multicenter
(23), nation-wide cohort of patients with AP: the ATLANTIS database. Group
M included patients from Spanish autonomous regions in contact with the
Mediterranean Sea. Group C included all other autonomous regions.
Necrotizing AP and POF were defined according to the revised Atlanta classifi-
cation. Chi2 was used for univariate analysis. Multivariate analysis was per-
formed by means of binary logistic regression, including in the model: sex,
body mass index4 30, alcoholic etiology and Charlson score (it includes age
and comorbidity) 3.
Results: We analyzed 1655 patients, 854 (52%) from group M (12 centers) and
801 (48%) from group C (11 centers), 984 (60%) with biliary etiology, 891 (54%)
males. The incidence of necrotizing AP was 281 (17%) patients, persistent organ
failure: 113 (7%), mortality 70 (4%). The proportion of patients with necrotizing
AP was higher in group M: 178 (21%) vs 103 (13%), p5 0.001. POF was also
more frequent in group M: 74 (9%) vs 39 (5%), p¼ 0.002. Finally, mortality was
higher in group M: 49 (6%) vs 21 (3%), p¼ 0.002. In multivariate analysis, group
M was independently associated to necrotizing AP [adjusted OR (aOR) 1.7 (1.3–
2.3), p5 0.001], to POF [aOR 2 (1.3–3.1), p¼ 0.001] and mortality [aOR 2.6
(1.5–4.5), p¼ 0.001].
Conclusion: Patients from the Mediterranean regions of Spain have a higher
incidence of necrotizing AP, POF and mortality. We hypothesize that this dis-
balance is associated to a higher diet unsaturated fat intake.
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Introduction: Exocrine pancreatic insufficiency and exocrine function alterations
are characteristics of pancreatitis. They are frequent in diabetes mellitus (DM)
patients with a prevalence up to 50%. Although reduced levels of insulin may
explain many of the proposed mechanisms of pancreatic dysfunction following
DM, the same phenotype is also detected in insulin-independent DM. This high-
lights the concept that additional factors are likely to contribute to the patho-
physiology of acinar cells. We recently discovered that 1-deoxy-sphingolipids (1-
deoxySLs), the levels of which increase in DM and metabolic syndrome are
cytotoxic for beta cells1. Our preliminary results showed that 1-deoxySLs are
also cytotoxic for acinar cells in vitro. Furthermore, the high level of 1-
deoxySLs in diabetic animal model aggravated acinar cell damage whereas low-
ering levels of 1-deoxySLs improved cell deterioration.
Aims & Methods: In this research, we investigate molecular and cellular factors
that contribute to compromise acinar cell functionality in the context of DM.
Based on the endocrine and exocrine pancreas crosstalk, we hypothesize that
elevated 1-dSeoxyLs levels affect directly the pancreatic exocrine compartment
by compromising pancreatic acinar cells in DM, thus increasing its predisposition
to develop exocrine pancreatic diseases. in vivo mouse models with STZ-induced
diabetes and cerulein-induced pancreatitis were used in this study. Reduction of
1-deoxySLs synthesis was achieved by oral L-serine supplementation. Disease
severity was assessed with biochemical and immunohistochemical methods.
Molecular mechanisms of 1-deoxySL-dependent toxicity were evaluated in vitro
on AR42J pancreatic acinar cells and primary acinar cells.
A650 United European Gastroenterology Journal 5(5S)
Results: DM induction resulted in increased 1-deoxySL levels but also atrophy
and fibrosis of pancreatic parenchyma. Reduction of 1-deoxySL synthesis by oral
L-serine supplementation ameliorated the damage of the exocrine pancreatic
tissue, without restoring insulin production in beta cells. This suggests that ele-
vated 1-deoxySLs rather than insulin deficiency contribute to the exocrine
damage in DM. In vitro studies showed that treatment with 1-deoxysphinganine,
one of the early products of 1-deoxySLs synthesis at low concentration reduced
replication and promoted cytotoxicity in pancreatic acinar cells. In addition, this
1-deoxySL-mediated cytotoxicity was associated with mitochondrial dysfunction
and endoplasmic reticulum stress.
Conclusion: Our work revealed that 1-deoxySLs are cytotoxic for exocrine pan-
creatic cells, suggesting a role for these lipids in the exocrine dysfunctions follow-
ing DM. Oral L-serine supplementation could be a therapeutic treatment for
ameliorating exocrine pancreatic diseases in diabetic patients.
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Introduction: Splanchnic venous thrombosis (SVT) is a common vascular com-
plication of acute pancreatitis (AP). There is paucity of data on its frequency, risk
factors, outcome and natural history. Coagulation abnormality has been impli-
cated but not proven as a cause of SVT in AP.
Aims & Methods:We aimed to prospectively study the frequency, risk factors and
extent of SVT in patients with AP as well as role of trombophilia in causation of
SVT. Patients with AP presenting to our centre between January 2015 and June
2016 were prospectively evaluated with contrast enhanced computerized tomo-
graphy (CECT) abdomen for presence of SVT. These patients were subjected to
detail analysis of coagulation parameters. Outcome was assessed in terms of
presence or absence of necrosis, severity, organ failure, need for intervention
and mortality. None of the patients with SVT were given anticoagulation.
Follow-up ultrasound Doppler was performed to look for the status of SVT.
Results: Ninety-six patients with AP (73 males, mean age 31.85 13.34 years)
were evaluated of which 26 (27.1%) had SVT. Single vessel, two vessels and three
vessels were involved in 19 (73.1%), 3(11.5%) and 4(15.4%) patients respectively.
Splenic vein, portal vein and superior mesenteric vein involvement were seen in
22(84.6%), 11(42.3%) and 4(15.3%) patients respectively. Necrotizing pancrea-
titis, CTSI4 6 and Modified CTSI4 6 were found in significantly higher
number of patients with SVT than those without SVT (96.2% vs 78.6%,
76.9% vs 47.1%, and 92.3% vs 67.1%, respectively). Coagulation analysis was
performed in 42 patients (18 with and 24 without SVT). Protein C, protein S and
AT III deficiency were found in 10(23.8%), 14(33.3%) and 13(31.0%) patients
respectively. b2GPI and lupus anticoagulant were positive in 2 (4.8%) and
5(11.9%) patients respectively. Anticardiolipin antibody was negative in all the
patients. Factor V Leiden mutation analysis was done in 33 patients (14 with
SVT and 19 without SVT) of which 2 (6.1%) were positive. There was no corre-
lation between abnormal coagulation results and outcome of AP. Coagulation
abnormality did not differ significantly between the patients with and without
SVT. On follow-up, Doppler study done in 7 patients with SVT, spontaneous
resolution of SVT occurred in 5 (71.4%) within 1 year. None of the patients had
varices on follow-up.
Conclusion: SVT in AP is more common in patient with necrotizing pancreatitis
and higher CTSI and MCTSI indices suggesting that local inflammation plays a
major role in its causation. Thrombophilia in some form is seen in one third of
the patients with AP but does not increase the risk of AP.
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Introduction: Infected pancreatic necrosis (IPN) is associated to significant mor-
bidity and mortality. Current management of IPN is based on a step-up
approach, based on minimally invasive procedures. Our group has recently
published a protocol of local infusion of antibiotics for the treatment of IPN
(Pancreatology 2016;16:719–25).
Aims & Methods: We aim at analysing the efficacy of this step-up approach for
the treatment of IPN in clinical practice. This was a retrospective single-centre
study of patients admitted with acute pancreatitis (AP) between January 2015
and December 2016. The cases with the diagnosis of pancreatic necrosis (NP) and
IPN (defined by positive culture of necrosis and clinical, analytical, and/or radi-
ological data of infection) were identified and evaluated. IPN was treated follow-
ing a step-up approach defined by 1. intravenous antibiotherapy, 2. Endoscopic
ultrasound (EUS) guided transgastric drainage plus local antibiotherapy, 3.
endoscopic necrosectomy. Number of patients responding to each therapeutic
step was assessed.
Results: 694 cases of AP were included (mean age 79.5 18.3, 355 male). CT scan
was performed only if clinically indicated. 67 patients (9.6%) had acute necrotiz-
ing pancreatitis (ANP), and 21 of them IPN (31% of ANP). IPN patients were
treated with intravenous antibiotics (imipenem [n¼ 15] and meropenem [n¼ 6]),
with good response in 8 (38% of IPN). The remaining 13 cases underwent a EUS
guided transmural drainage plus local infusion of antibiotics. Only 3 patients
needed endoscopic necrosectomy (14% of all IPN). Overall mortality was
1.5% (11 cases), 6 with edematous pancreatitis (0.96%) and 5 with ANP
(7.4% of ANP). Only one patient with IPN died (4.8% of IPN).
Conclusion: By using a step-up approach, nearly two out of three patients with
IPN require transgastric drainage. By associating local antibiotherapy through
nasocystic catheter to the drainage, only 14% cases with IPN require endoscopic
necrosectomy. With this background, comparative studies are needed to evaluate
the impact of local antibiotherapy for IPN.
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Introduction: We aimed to compare the efficiency of plastic and metal stents for
symptomatic pancreatic fluid collection drainage and analyze other main asso-
ciated factors that affect the outcome of drainage therapy.
Aims & Methods: Rates of technical and clinical success, procedure-related side
effects (hemorrhage, stent migration, and cyst rupture), re-interventions, and
duration of hospital stay.
Results: There were 52 patients, 40 who underwent plastic stent placement and 12
who underwent lumen-apposing metal stent placement. The total rate of techni-
cal success was 100%. The total rate of clinical success was 100%. The total rate
of adverse events was 7.7% (4/52). On multiple logistic regression analysis, the
use of plastic stents (P5 0.05, Exp B¼ 12.168) and presence of a large cyst
(P5 0.05, Exp B¼ 1.036) were shown to significantly increase the risk of re-
intervention. On multivariate linear regression analysis, etiology of pseudocyst
(P5 0.05, B¼ -8.427; 9.785; 5.514) was associated with prolonged hospital
stent, while stent type was not shown be a factor (P4 0.05).
Conclusion: Both plastic and lumen-apposing metal stents are proven to be highly
efficient in pancreatic fluid collection drainage. The lumen-apposing metal stent
is superior in preventing complications such as migration and cyst leakage and
reducing the rate of re-intervention. Large cyst size is associated with an
increased risk of re-intervention and prolonged hospital stay.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1410 EARLY ACHIEVABLE SEVERITY (EASY) INDEX FOR
SIMPLE AND ACCURATE EXPEDITE RISK STRATIFICATION IN
ACUTE PANCREATITIS
B. Kui
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Introduction: Acute pancreatitis (AP) is one of the most common diseases of
the gastrointestinal tract associated with significant morbidity and mortality.
The assessment of severity is crucial in the management of the disease. The
pathomechanism of AP is not well understood, it has no specific therapy.
Current methods of risk stratification in AP have a limited value, as they
provide little additional information thus may delay appropriate management.
Early recognition of severe disease may prevent serious adverse events and
improve patient management as well as overall clinical outcome. The EASY
trial is an observational, multicenter, prospective cohort study for establishing
a simple, easy and accurate clinical scoring system for early prognostication of
acute pancreatitis.
Aims & Methods:We aimed to create a new scoring system, which can predict the
severity of AP in early phase of disease. Evaluation of simple attainable potential
prognostic parameters obtained at admission (or not later than 6–12 hours after-
wards) from patients diagnosed with AP will be performed to assess their poten-
tial correlation with the disease severity. Approximately 1200 (900þ 300) patients
from multiple centers will be enrolled into this trial using the Registry. This is an
observational prospective cohort study (in which the care or services that patients
receive will not be altered); therefore it has a relatively low-risk. The study has an
ethical approval by the National Hungarian Ethical Authority (ETT TUKEB).
Study management will strictly follow the Ethical Guidelines for Observational
Studies.
Results: 600 patients were enrolled in the EASY study from different interna-
tional centers so far. In early phase of AP vomiting, loss of weight, fever, abdom-
inal tenderness, elevated serum creatinine and lactate dehydrogenase level were
more common findings in severe AP, as opposed to the mild and moderate
groups.
Conclusion: EASY score may be an easy and accurate system to evaluate the early
severity of AP. Although some parameters have shown correlation with the
severity of AP in early phase of the disease, we have to include more patients
to have reliable results.
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Introduction: Infected walled-off pancreatic necrosis (WON) is treated with anti-
biotics. In order to exert its antibacterial effects in WON, systemically adminis-
tered antibiotics need to overcome a number of limiting steps. First, antibiotics
need to cross the capillary endothelium. Thereafter, antibiotics must diffuse
across the interstitial space and finally, the capsule surrounding the WON
must be crossed. Therefore, the penetration of the intravenously administered
antibiotics into WON can be questioned. Using local antibiotics should theore-
tically increase the antibiotic concentrations in the necrotic tissue and the
efficacy.
Aims & Methods: The aim was to evaluate the efficacy of local instillation of
antibiotics into walled-off pancreatic necrosis. Between 2012 and 2016 we
evaluated all patients treated with endoscopic transmural drainage and
necrosectomy (EDTN) and concomitant local instillation of antibiotics.
We added antibiotics (either gentamicin, vancomycin, or amphotericin B)
to the irrigation fluid according to the microbiological findings. The anti-
microbial efficacies of local and systemic antibiotics were evaluated using
uni- and multivariate logistic regression analyses and Kruskal-Wallis test by
stratification of the isolates in sensitive versus not sensitive/antibiotics not
given.
Results: Ninety-one patients were included. At the first drainage 81 (86%)
patients had infected and 10 sterile WON. A total of 139 isolates were found
at the first drainage. Most patients were infected with enterococci (44%) or other
gram-positive cocci. More than a quarter of the infected patients had fungal
species cultured. The infected patients often had polymicrobial infections
(56%). At the second culture 152 isolated were found. Neither local nor systemic
antibiotics were associated with the eradication of microbes between first and
second culture. Between second and third culture, the use of local antibiotics was
associated with the eradication of microbes (OR¼ 2.54, P¼ 0.01), but not sys-
temic antibiotics (P¼ 0.33) (Table). Between first and second culture 12 patients
with fungal infections were treated with local amphotericine B. In all 12 patients
the fungus was eradicated. After second culture 20 patients were treated local
amphotericine B and in 17 (85%) patients the fungus was eliminated at the third
culture.
Univariate Multivariate Kruskal-Wallis Test
OR (95% CI) P-value OR (95% CI) P-value Chi2 P-value
Culture 1 -4 2
Local Antibiotics 1.52 (0.73–3.17) 0.261 1.54 (0.74–3.21) 0.249 1.26 0.261
Systemic Antibiotics 1.28 (0.64–2.59) 0.487 1.31 (0.64–2.65) 0.458 0.48 0.488
Culture 2 -4 3
Local Antibiotics 2.54 (1.25–5.18) 0.010 2.71 (1.31–5.59) 0.007 6.76 0.009
Systemic Antibiotics 0.72 (0.38–1.38) 0.327 0.64 (0.33–1.25) 0.195 0.96 0.328
Conclusion: Our data suggest a better efficacy of local antibiotics in the treatment
of infected WON compared to systemic antibiotics. The local instillation of
antibiotics may be a promising alternative or supplement to systemic adminis-
tration. Particularly the use of local instillation of amphotericin B appears to be
effective in the treatment fungal infections.
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Introduction: Pancreatitis is a disease of protean manifestations. In its more
severe form, involvement of any organ is possible. Cardiovascular and respira-
tory failure are possible and feared complications.
Aims & Methods: The aim of this study was to evaluate the effect of chronic
ischemic heart disease and chronic obstructive pulmonary disease (COPD) in the
outcome of acute pancreatitis (AP), in our population. Retrospective cohort
study that included all patients admitted with AP from January 2003 to
December 2016, in a tertiary referral centre. Demographic and clinical variables
were analyzed by logistic regression (SPSS v23). Clinical outcomes included
organ failure (OF), persistent OF (448 h), intensive care unit (ICU) admission
and mortality.
Results: A total of 553 patients with AP were included, 58.4% male, median age
80 (18–98) years. Most common etiologies included gallstones (38.9%) and alco-
hol (27.3%). Twenty-three percent (n¼ 129) developed OF (in 43% persistent)
and 26.8% (n¼ 148) were admitted in UCI. Mortality rate was 5.6% (n¼ 31).
Fifty-six patients (10.1%) had previous history of coronary disease and 5.1%
(n¼ 28) had been diagnosed with COPD. The presence of coronary disease and
CODP were not associated with higher Ranson’s score (3), p¼ 0.076 and
p¼ 0.959, respectively. No association was found between previous history of
coronary disease and the development of OF (p¼ 0.525), persistent OF
(p¼ 0.287), need for ICU admission (p¼ 0.115) and mortality (p¼ 0.262).
There was also no association found between previous history of CODP and
the development of OF (p¼ 0.803), persistent OF (p¼ 0.588), need for ICU
admission (p¼ 0.514) and mortality (p¼ 0.720). At multivariate analysis (cor-
recting for age and gender) coronary disease and CODP were not independent
predictors of worse outcome in AP.
Conclusion: In our population, previous history of coronary disease and CODP
were not predictors of worse outcome in AP.
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Introduction: Predicting severe pancreatitis is important for early aggressive man-
agement of patients with acute pancreatitis (AP). Despite the established role of
type-2 diabetes mellitus (DM) in the risk of AP, the impact of DM on the clinical
outcome in AP has not been fully elucidated.
Aims & Methods: Retrospective study including hospital admissions between
January 2003 and December 2016 in a single tertiary referral center. Clinical
outcomes included organ failure (OF), persistente OF (448 h) admission to
intensive care unit (ICU) and mortality. Variables were analysed by logistic
regression (SPSS v23.0). The objective of this study was to assess the risk of
mortality and severity in AP among patients with type-2 DM.
Results: A total of 553 patients (58.4% male) with AP were included, median age
80 (18–98) years. Most common etiologies included gallstones (38.9%) and alco-
hol (27.3%). Twenty three percent developed OF (in 43% persistent) and 5.6%
(n¼ 31) were deceased. There were 127 AP patients (23.0%) with type-2
DM.Type-2 DM were not associated with higher Ransońs score. There was an
association between DM and development of OF (OR 31.7, CI95% 18.8–53.7,
p5 0.001), persistente OF (OR 45.1, CI95% 18.7–108.9, p5 0.001), ICU admis-
sion (OR 12.3, CI95% 7.8–19.4, p5 0.001) and mortality (OR 17.1, CI95% 6.8–
42.8.4, p5 0.001). At multivariate analysis DM was an independent predictor of
OF development and ICU admission.
Conclusion: In our population, Type-2 DM was associated with severity and
increased mortality in patients with AP. Our Endings provide evidence of the
potential role of DM in the management of severe AP.
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Introduction: Acute pancreatitis (AP) is an uncommon but potentially devastat-
ing condition that may occur in patients with organ transplantation. Reported
incidence ranges from 1.5 to 8% in patients undergoing liver transplantation with
significant mortality.
Aims & Methods: The aim of our study was to assess the incidence, potential risk
factors and outcome of AP following liver transplantation in our center. We
performed a retrospective analysis of medical records of all adult patients who
underwent liver transplantation in our center between September 1996 and
November 2014. The diagnosis of AP was defined by combination of clinical
manifestation, finding on imaging methods (CT, USG) and elevation of serum
amylase and lipase.
Results: Nine hundred and sixty-seven orthotopic liver transplantations were
performed in 578 males and 389 females (mean age 51 years, range 18–74). AP
occurred in 18 patients (1.9%, 16 males, 2 females) and resulted in death in 5
patients (28%). According to timing of AP we recognized two clinical presenta-
tion–early AP (5 1 month after liver transplantation) and late (41 month).
Four patients (22%) developed early AP, which was severe necrotizing with
MODS in all cases and resulted in death in 3 of them (75%). Two of them
were transplanted for fulminant hepatic failure, one for end-stage liver disease
due to chronic hepatitis B infection and one for polycystic liver disease. Two
patients were treated by surgical necrectomy and died, the third deceased patient
was treated conservatively. In the only surviving patient, a successful EUS-
guided drainage of walled of pancreatic necrosis and repeated endoscopic
necrectomy were performed. We were unable to identify surgical or other factors
responsible for development of AP. Late AP occurred in 14 patients (78%) with a
median delay of 31 months after liver transplant (range 2–176). In 12 patients AP
was mild with no mortality and the following etiologies were represented: 4 post-
ERCP, 2 alcoholic, 1 biliary (CBD stones), 1 drug-induced (azathioprine), 1
obstructive (pancreatic cancer); in 3 patients the etiology was unknown. One
patient developed a pseudocyst. Two patients with late acute pancreatitis had a
severe necrotizing form and both died. One patient with cirrhosis of the liver
graft due to chronic rejection had post-ERCP pancreatitis which was compli-
cated by retroperitoneal hemorrhage and graft failure. The other patient with
necrotizing pancreatitis of unknown etiology developed MODS and eventually
died. Male patients (p¼ 0.01) and patients transplanted for liver cirrhosis result-
ing from chronic hepatitis B were at a significantly higher risk of AP development
(p¼ 0.03).
Conclusion: The incidence of AP after liver transplant in our center is low. In it
necrotizing form which is more frequent early after liver transplant, it carries a
significant risk of mortality exceeding 80%. Male patients and those transplanted
for end stage liver disease resulting from chronic hepatitis B are more likely to
develop post-liver transplantation pancreatitis.
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Introduction: Biliary sludge (BS) may be one of the factors, related to develop-
ment of chronic pancreatitis (CP) via sphincter of Oddi dysfunction. As it was
demonstrated by Okazaki K et al. in 1988, patients with biliary sludge have
higher sphincter of Oddi (SO) pressure and contraction frequency vs. controls.
Aims & Methods: To assess the frequency of CP signs in patients with BS and to
investigate the state of major duodenal papilla (MDP) in patients with idiopathic
CP with BS by endoscopic ultrasound (EUS); to evaluate whether antispasmo-
dics can be effective in pain relief at CP, that developed on the background of
gallbladder sludge. Protocols of computer tomography, endoscopic and transab-
dominal ultrasound studies of over 6000 patients of gastroenterological tertiary
clinic were examined. Those who had signs of BS were selected to evaluate the
presence of at least ‘‘mild CP’’ according to the modified Cambridge classifica-
tion. Exclusion criteria were: established etiology of CP and signs of pancreatic
neoplasm. Patients, who received ursodeoxycholic acid and drugs that affect
smooth muscle contractility for less then 3 month prior to the study were
excluded. Thirty consecutive patients (15m, 15 f, mean age SD: 52.8 15.3),
who had both BS and CP were summoned for physical examination, quality of
life assessment, US-cholecystography and endoscopic pancreatobiliary ultra-
sound with elastography, calculation of MPD surface area
SMDP¼ (hMDPwMDP)/(2*1.27) and state of MDP before and after 3 weeks of
hymecromone monotherapy 400mg tid.
Results: Signs of CP were revealed in 6.3% of BS cases. CP was most common in
those who had ointment-like bile (33.3%) vs. patients with heterogeneous bile
with clots –7.7% and hypoechoic particles–1.7% (chi-square 38.21, p5 0.00001).
Mean SMDP was 14.9 5.2 mm
2 (95%CI 10.9–18.9). SMDP was below the normal
range (20–25 mm2) in 78% of patents. SMDP had positive correlation to the
volume of evacuated bile according to US-cholecystography (rs¼ 0.683,
p¼ 0.042) and gallbladder contractility coefficient (rs¼ 0.817, p¼ 0.007). All
patients with higher density of MDP at US-elastography had SMDP lower than
the normal range and were attributed to ‘‘fibrosis’’ group. Only 38% of patients
with CP and BS had normal MDP at EUS. Periampullary diverticula were found
in 13% of the cases, papillary edema — in 38%, fibrosis — in 13%. MDP
changes were associated with higher AP level and larger MPD diameter.
Hymecromone monotherapy resulted in significant improvement in abdominal
pain score (t¼ 7.92, p¼ 0.000) and ‘‘bodily pain’’ score of SF-36 questionnaire
(t¼ -3.709 p¼ 0.001). Dynamics of ‘‘bodily pain’’ score by SF-36 demonstrated
significant negative correlation to the post-treatment level of abdominal pain
(rs¼ -0.395, p¼ 0.037) Post-treatment pain level had significant negative correla-
tion to the MDP size (rS¼ -0.867, p¼ 0.002), though no correlation of pre-treat-
ment pain level to MDP features was found, i.e. patients with less MDP size
(most of them had decreased elasticity of papilla of Vater, that was considered as
indirect marker of fibrosis) had lower hymecromone efficacy.
Conclusion: BS may cause MDP changes, resulting in development of obstructive
CP. Intensity of pain in biliary CP may be related to sphincter of Oddi dysfunc-
tion. Efficacy of antispasmodic therapy in these patents could be predicted by the
features of MDP at pancreatobiliary EUS.
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Introduction: Pancreatic exocrine insufficiency is a late complication of chronic
pancreatitis; its clinical onset is characterized by steatorrhea and weight loss,
borborygmi, flatulence, abdominalpain and malnutrition. Exocrine and endo-
crine pancreatic function decreases differently in various diseases (autoimmune,
paraduodenal, genetic, idiopathic). It has been observed that there has been a
recovery of exocrine pancreatic function in autoimmune pancreatitis. In the
literature there are no studies analysing the exocrine pancreatic function over
time. The fecal elastase test is a good test procedure to evaluate the exocrine
pancreatic function
Aims & Methods: The objective of the retrospective study was to re-evaluate a
series of patients with chronic pancreatitis with the aim to evaluate the pancreatic
exocrine function over time, in particular, by comparing the exocrine pancreatic
function in subgroups of patients with different types chronic pancreatitis
Pancreatic exocrine function was estimated through fecal elastase in 143 patients
with at least 2 values each (classified into normal, mild and severe exocrine
pancreatic insufficiency), the first one taken at the diagnosis of chronic pancrea-
titis. Patients undergoing surgical pancreatic resection before the second value of
fecal elastase were excluded. Etiology was classified in: biliary pancreatitis/seque-
lae of necrotizing pancreatitis (15), autoimmune (69), paraduodenal (15), genetic
(17) and idiopathic (27).
Results: The results show a high frequency of severe exocrine pancreatic insuffi-
ciency in the moment of diagnosis of chronic pancreatitis (38%) and it appears
stable over the following 5 years. Autoimmune and paraduodenal pancreatitis
are correlated with severe exocrine pancreatic insufficiency at diagnosis in a high
percentage of cases (51% and 40%), biliary/outcomes of necrotizing pancreatitis
and idiopathic pancreatitis in an intermediate (33% and 26%), while genetic in a
low percentage (12%).
Conclusion: The exocrine pancreatic function in patients with autoimmune pan-
creatitis improved in the first five years of the disease, probably due to the
efficacy of steroid/immunosuppressive therapy. Pancreatic endocrine function
was less compromised at diagnosis, but showed a progressive deterioration in
the first five years. Endocrine and exocrine insufficiency were strictly correlated.
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Introduction: The ‘‘painless’’ chronic pancreatitis (CP) represents a specific subset
of CP characterized by the lack of pancreatic pain. So far, scarcity of data has
been reported in the literature about this matter and what differentiates this
group of patients from those with chronic pancreatitis associated with pancreatic
pain.
Aims & Methods: The aim of the present study is to characterize ‘‘painless’’ CP
from the epidemiologic, clinical, radiological, functional, and follow-up stand-
point, through a comparison with other forms of chronic pancreatitis presenting
with pancreatic pain. The Institutional Database of the Gastroenterology Unit of
the Verona University was queried, and all chronic pancreatitis cases were
retrieved. Patients were clustered based on the presence of ‘‘pancreatic-specific
pain’’ into ‘‘painless’’ and ‘‘pain-associated’’ CP. A retrospective case-control
analysis was carried out.
Results: Of 678 patients included from March 2006 to March 2016, 436 were
considered eligible for the present study. Of these, 368 (84%) were affected by
pain-associated CP, while 68 (16%) had ‘‘painless’’ CP. ‘‘Painless’’ patients were
older (median age of 58.5 10.8 y/o vs. 42.5 15.3 y/o; p5 0.001), less fre-
quently presenting with a history of alcohol consumption (35% vs. 55%;
p5 0.001), more frequently diabetics (18% vs. 1%; p5 0.001), presenting with
steatorrhea (16% vs. 2%; p5 0.001), and asymptomatic (63% vs. 2%;
p5 0.001) compared to pain-associated controls. From the radiological stand-
point, painless cases were more likely presenting with calcifications at imaging
than controls (90% vs. 68%; p5 0.001). Moreover, in most of painless cases, the
CP cause remained unknown (56%). After a median follow-up of 2.6 2.3 years,
the incidence of diabetes was higher in the painless cases than in controls (48%
vs. 30%; p5 0.006).
Conclusion: The present study represents the first definition of "painless" CP so
far reported in the literature. The "painless" CP is a distinct entity from the
epidemiologic, clinical, and radiological standpoint when compared to other
forms of CP characterized by the presence of pancreas-specific pain.
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Introduction: Recently, EUS-guided pancreatic duct drainage with transmural
stenting (EUS-PD) has been used for patients with painful obstructive pancrea-
titis in whom endoscopic retrograde pancreatography (ERP) has failed.
Although the feasibility and safety of EUS-PD with a fully covered self-expand-
able metal stent (FCSEMS) has been assessed, little is known about the long-term
outcomes of EUS-PD with a fully covered self-expandable metal stent
(FCSEMS). Removability of an FCSEMS in long-term use and higher cost are
the main concerns of EUS-PD with an FCSEMS compared with EUS-PD with a
plastic stent.
Aims & Methods: The aim of this study is to evaluate the procedural and long-
term outcomes of EUS-PD with an FCSEMS for patients with painful obstruc-
tive pancreatitis who failed ERP. Forty-one consecutive patients with painful
obstructive pancreatitis underwent EUS-PD with an FCSEMS after failed
ERP. Permanent FCSEMS placement without scheduled stent exchange was
considered in malignant MPD strictures or complete MPD obstruction in
benign pancreatic stricture. Technical and clinical success, adverse events, and
stent patency were assessed. An endoscopic examination and CT scan was per-
formed every 6 months to assess stent patency in benign stricture.
Results: 15 patients had malignant MPD obstruction and 26 patients had benign
stricture. EUS-PD was successful in all 41 patients (technical success rate, 100%),
and symptoms improved in all patients (clinical success rate, 100%). EUS-guided
pancreaticogastrostomy (n¼ 39) and pancreaticojejunostomy (n¼ 2) were per-
formed. Pain scores improved significantly after FCSEMS placement (P¼ .01).
Early mild-grade adverse events occurred in 5 patients (12.2%) with self-limited
abdominal pain, which resolved with conservative treatment. Late adverse events
developed in eight patients (22.2%), including distal stent fracture (n¼ 6), stent
occlusion (n¼ 2). These patients were successfully treated endoscopically. No
other adverse events related to FCSEMS, including stent migration, pancreatic
sepsis, and stent-induced ductal stricture were observed during follow-up periods.
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Overall mean stent patency duration was 412 days (range 14–1081) during mean
follow-up periods (427 days). Median stent patency in malignant stricture was 95
days (range 14–297). Mean stent patency in benign stricture was 525 days (range
121–1081). No patients with malignant strictures required FCSEMS revision or
exchange during follow-up periods. FCSEMS removal and exchange was suc-
cessful in all benign strictures with stent dysfunction. At the end of the follow-up,
two patients (5.6%) showed resolution of stricture after definite stent removal.
Conclusion: EUS-PD with an FCSEMS showed excellent long-term outcomes for
patients who failed conventional ERP in both malignant and benign painful
obstructive pancreatitis. Endoscopic FCSEMS removal and exchange could be
successful in patients with benign strictures until 3-year placement of an
FCSEMS. Prospective randomized trial comparing EUS-PD with FCSEMSs
and plastic stents may be warranted for painful obstructive pancreatitis after
failed ERP.
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Introduction: Fundamental aspects in the treatment of pancreatic exocrine insuf-
ficiency (PEI) include pancreatic enzyme replacement therapy (PERT).
Monitoring the symptoms of maldigestion as well as the nutritional markers is
essential.
Aims & Methods: To follow-up patients with PEI receiving PERT and to provide
normal nutritional status by optimizing the suboptimal PERT if necessary. Study
enrolled 142 patients (88 males, mean age 52 years): 82 patients had chronic
pancreatitis (CP), 30- acute pancreatitis (AP), 30- pancreatic cancer/pancreatic
resection. 58 patients were re-monitored 6 months after adjusting suboptimal
therapy. Alcohol abuse was most common aetiology. Nutritional status was
evaluated by prealbumin and retinol binding protein (RBP) via immunonephe-
lometry, fat-soluble vitamins A, D, E via HPLC and LC-MS/MS; magnesium
(Mg) and hemoglobin (Hb). We evaluated in addition albumin; cRP; BMI.
Imaging morphological data were assessed by Cambridge classification for CT/
MRCP (grade I-IV) and cardiovascular risk (CVR)- by apolipoproteins (apo) A-
I, B and lipid profile. Statistical analysis was performed via SPSS v22.
Results: Protein malnutrition with prealbumin (mean: 0.208 0.105 g/L) and
RBP (mean: 0.0389 0.0258g/L) below reference limits was observed in 67 and
47 of all patients, respectively. We found correlation between prealbumin and
RBP with other nutritional parameters (Hb, Mg, albumin, p5 0.01), lipid profile
and apolipoproteins in patients with CP (p5 0.05) and negative relationship to
CRP (p5 0.001) in AP. Prealbumin and RBP related to age, morphological
changes and BMI in CP, p5 0.05. Mean values of vitamin A, D, E were
527.68 321.12mg/L, 39.74 24.36 nmol/L, 8.07 6.01mg/L. Vitamin A, D, E
insufficiencies were present in 21.95; 94.49 and 40.96% of all evaluated patients,
respectively. Moreover 33.86% had vitamin D deficiency (525 nmol/L). We
found lowest vitamin levels in patients with pancreatic cancer/pancreatic resec-
tion and correlation with structural changes worsening, p5 0.05. Within all
patients we observed suboptimal PERT with nutritional deficiencies despite an
adequate clinical response (prealbumin, RBP, vitamin A, vitamin D and vitamin
E deficiencies in 44.82, 36.73, 11.43, 92.86 and 48.57% of all asymptomatic
patients, respectively). During second follow-up (6 months after PERT optimiza-
tion), we demonstrated clinical improvement with a significant increase in BMI
(p5 0.0001) and nutritional markers, p5 0.01. CVR was increased in 62% of
patients. Dyslipidemia was more severe in men and in CP, p5 0.05. Optimal
non-HDL levels were present in 33.59% (mean non-HDL levels:
5.23 2.25mmol/L). Moderate and high heart attack risk according Apo B/
Apo A-I ratio was observed in 34.35% and 45.04% of all patients. In addition,
33 patients suffered from diabetes mellitus.
Conclusion: Proper follow-up and correction of suboptimal PERT as well as
CVR screening could reduce the risk of severe malnutrition complications and
associated morbidity and mortality by ensuring optimal therapeutic results and
better quality of life.
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Introduction: The mRNA binding protein HuR is involved in the post-transcrip-
tional regulation of cytoprotective molecules, such as COX-2, HO-1 and inhibi-
tors of apoptosis proteins (IAP1, IAP2, XIAP, SURVIVIN), and might be
related to poor prognosis in numerous cancer types. However, the association
of HuR, COX-2, HO-1 and IAPs family, and their impact on chemoresistance
and carcinogenesis in PDAC still remain unclear.
Aims & Methods: The aim of our study is to assess the relevance and correlation
of the IAP regulation by mRNA stabilizing protein HuR and HO-1 and/or COX-
2 signaling pathway, and to determine the association with clinicopathological
parameters and prognosis of PDAC. Data of 32 patients after pancreatodeduo-
denectomy for PDAC between 2011–2016 were analyzed. Patient’s mRNA
expression levels of HuR, COX-2, HO-1, IAP1, IAP2, Survivin and XIAP in
PDAC were compared with normal pancreatic tissue obtained from organ
donors. Additionally, the correlations among HuR, COX-2, HO-1, IAP1,
IAP2, Survivin and XIAP, as well as their respective correlations with clinico-
pathological parameters were analyzed. The Kaplan-Meier method and log-rank
tests were used for univariate analysis. Cox proportional hazard model was
applied to indentify prognostic factors that were independently associated with
survival.
Results: H0–1, COX-2, HuR, IAP1, IAP2 mRNA expression were accordingly 3-
fold, 8.8-fold, 1.5-fold, 4.8-fold and 5-fold higher, while XIAP and Survivin
mRNA expression were 3.8-fold and 3.4-fold lower when compared to normal
pancreatic tissue. Expression of HuR was positively associated with COX-2, H0–
1, IAP1, IAP2, XIAP. High expression levels of HuR were significantly corre-
lated with higher G stage and microvascular invasion, while high levels of XIAP
were negatively associated with microvascular and perineural invasion.
Univariate analysis revealed that high expression of HuR, lymph-node metas-
tases, tumor differentiation and perineural invasion were significantly associated
with overall survival (0S) of PDAC patients. In multivariate analysis, high levels
of HuR, lymph-node metastases, tumor differentiation and perineural invasion
were independently correlated with lower OS in patients with PDAC.
Conclusion: Our results suggested that upregulation of HuR in PDAC patients
were significantly related with poor outcome. Even though, significant correla-
tion with IAP proteins in PDAC was noticed, more data is needed to analyze the
mechanism underlying HuR and IAPs interaction.
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Introduction: Hypoxia-induced reprogramming of cell energy metabolism and
changes in glycosylation are hallmarks of cancer promoting the induction of
an invasive and treatment-resistant phenotype, triggering metastases at an
early stage of tumor development.1 We examined the impact of hypoxia on O-
GalNAc glycosylation in human HEK293, PDAC cell lines and clinical speci-
mens and its link to cancer cell signalling.
Aims & Methods: We profiled the expression of 88 glycosylation related genes by
qPCR in HEK293 cells subjected to hypoxia either induced by 1% O2 or 200mM
CoCl2 identifying key O-GalNAc glycosyltransferases downregulated.
Functional assays and glycoprotein analysis displayed a pronounced rate of O-
GalNAc modified cytosolic proteins derived from hypoxia-treated cells and
PDAC specimens. Glycosidase assays could validate specificity of detection
method used. Aberrant glycotype could be induced by HIF pathway activator
United European Gastroenterology Journal 5(5S) A655
ML 228 and inhibited using Echinomycin. PTK and STK analysis of cell lysates
displayed correlation between phosphorylation and O-glycosylation in hypoxic
samples.
Results: Mechanistically we could show, that hypoxia-induced decreased levels of
C1GALT1C1 results in reduced T-Synthase activity with subsequent expression
of truncated O-glycans (Tn antigen). Differential O-GalNAc glycosylation is
inducible using HIF pathway activator ML228 under normoxia and the effect
is reversed using 5 mM Echinomycin under hypoxia underscoring the role of
HIF1a regulated transcription. Interestingly, the pattern of Tn antigen modified
proteins derived from hypoxic samples differs significantly from engineered
COSMC-deficient cells, displaying O-GalNAc moieties in addition to O-
GlcNAc in cytosolic protein fractions. Further, we could show PI3K/AKT/
MAPK signalling is depending on the state of cellular O-glycosylation providing
a new rationale for the correlation of PDAC Tn antigen glycotype and cancer cell
properties.2
Conclusion: Our findings point to a novel crosstalk of O-GalNAc and O-
GlcNAcylation under hypoxia extending the knowledge base of differential O-
GalNAc glycosylation in pancreatic cancer.
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Introduction: Pancreatic cancer is one of the more common malignant tumors in
digestive system. The 5-year survival rate is less than about 6% of pancreatic
cancer. Pancreatic cancer with poor prognosis and survival rate is low, due to the
early clinical symptom is not easy to find, have a high transfer possible, and the
operation difficulty, radiotherapy and chemotherapy is not sensitive. Radical
surgical resection is the only opportunity to pancreatic cancer patients get
longer survival. Therefore, a deeper understanding of the molecular mechanism
of pancreatic cancer occurs, explore new effective treatment is imminent.
Aims & Methods: Pancreatic cancer is a highly malignant tumor and fourth
leading cause of cancer-related death in the world. The median survival after
diagnosis is 2–8 months, and approximately 3–6% of all patients with pancreatic
cancer survive 5 years after diagnosis. This is mostly due to the fact that it is
diagnosed at a stage when it is either locally advanced or has already metasta-
sized to the distant organs. Hence, there is a paramount need to understand the
molecular mechanisms underlying its initiation, progression and therapy. The
recent discovery of microRNAs (miRNAs) has revealed a novel mechanism of
gene regulation and provided new ways for cancer research. MicroRNAs are
small, non-coding RNA molecules, which regulate the gene expression at post-
transcription level. It is widely reported that miRNAs can act as oncogene or
tumor suppressor gene. MiR-195 has been recognized as a tumor suppressor gene
that is down-regulated in several types of cancer such as HCC, breast cancer,
bladder cancer and gastric cancer. In PC, the role of miR-195 remains unclear.
The purpose of this experiment was to explore the regulation role of miR-195 in
PC development process. We measured miR-195 expression in three pancreatic
cancer cells (PANC-1 KSW-1990 KPANC 03.27) by qRT - PCR, and HPDE cells
were used as a control. We performed study of miR-195 by transfecting Panc-1
cells with miR-195 mimic. We used miRNA qRT - PCR to study the transfection
efficiency of miR-195 mimic. The biology behaviors of Panc-1 cells transfected
with miR-195 and negative control were analysed by CCK-8 proliferation assay,
cell cycle, cell migration and invasion assay. We performed Real-Time PCR and
western blot to detect the expression of CDK4 KCyclin E1 in Panc-1 cells which
were transfected with miR-195 mimic and negative control.
Results: We found that miR-195 was decreased in three pancreatic cancer cells
(PANC-1 KSW-1990 KPANC-03.27).We also found that over-expression of miR-
195 could suppress the proliferation, migration, invasion and cell cycle of Panc-1
cells. That means the malignancy potential of Panc-1 cells is inhibited by miR-
195. Over-expression of miR-195 could down regulate the expression of
CDK4 KCyclin E1 in Panc-1 cells.
Conclusion: The expression of miR-195 was down regulated in pancreatic cancer
cells. Over expression of miR-195 suppressed cell proliferation, cell cycle, migra-
tion and invasion of Panc-1 cells by down regulated the expression of CDK4 and
CyclinE1. Moreover, this finding suggests a potential novel strategy for thera-
peutic interventions of this disease.
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Introduction: Pancreatic cancer (PDAC) is one of the most lethal diseases world-
wide, still exhibiting almost equal mortality as incidence rates. In spite of strong
efforts in clinical and basic research, the molecular mechanisms responsible for
this unusual aggressive phenotype still remain not completely understood and
insufficient diagnostic and therapeutic tools still substantiate its ranking as the
4th-leading cause of cancer-associated deaths in western countries. This devastat-
ing prognosis is partially due to frequent occurrence of intrinsic or acquired
chemoresistance in PDAC specimens against the nucleoside analogue gemcita-
bine which is still the standard for chemotherapeutic treatment of locally
advanced and metastatic PDAC. In principle, cancer cells are well known for
their ability to divide uncontrollably and it was initially thought that high glucose
consumption is the main energy-source for proliferating tumor cells, but a large
body of evidence suggest that most of the cell mass that makes up new cells
resulted from amino-acid metabolism.
Aims & Methods: The aim of this study was the identification of new biomarkers
for chemoresistant pancreatic cancer. A secretome survey of chemoresistant
PDAC cells was performed using SILAC-based mass-spectrometric analyses.
Relative differences in protein-concentrations among samples were investigated
and led to the identification of previously unknown proteins. The impact of
RNAi-mediated knockdown of selected genes in proliferating PDAC cells were
analyzed using MTT-viability assays. Gene- and protein-expression analyses
were performed using Real-Time-PCR and immunohistochemistry using
patient-derived PDAC samples.
Results: SILAC-based identification of the Tryptophan degrading enzyme
Kynureninase (KYNU) in chemoresistant PDAC cells revealed an overexpressed
and secreted form of the KYNU protein, compared to the chemosensitive coun-
terpart. We further identified various stress-related external stimuli
(Gemcitabine, IFNg, Hypoxia) as main inductors of KYNU expression/secre-
tion. A RNAi-mediated KYNU knockdown approach was linked to substan-
tially lower proliferation of chemoresistant and aggressive PDAC cells. Global
expression analyses using a tissue-microarray of PDAC patient samples (n¼ 368)
revealed that high KYNU expression is significantly correlated with a worse
outcome in PDAC patients.
Conclusion: The tryptophan degradation pathway member KYNU is overex-
pressed in a subset of PDAC patients and is linked to substantially increased
cancer cell proliferation. Abundant KYNU expression in PDAC patients is
linked with a worse clinical outcome. We found that KYNU is a new secreted
biomarker of chemoresistant PDAC cells.
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Introduction: The progression of pancreatic ductal adenocarcinoma (PDAC) is
promoted by its highly abundant tumor stroma. As one of the main components
of the tumor stroma human pancreatic stellate cells (hPSCs), precursor cells of
pancreatic tumor stromal myofibroblasts (CAFs), support PDAC progression by
enhancing tumor cell growth, invasion and metastasis [1]. The collagen binding
transmembrane receptor integrin 11 (ITGA11) is known to be overexpressed by
myofibroblasts [2].
Aims & Methods: The aim of the presented study was to investigate the expres-
sion of ITGA11 in human PDAC and to study the role of ITGA11 in CAF
regulation. ITGA11 expression was evaluated using immunostaining on human
PDAC sections and various other organs. The relation between ITGA11 levels,
CAF activation markers and tumor growth was studied in a stroma rich co-
injection model in mice. The biological role of ITGA11 in CAF differentiation
was studied in hPSCs and hPSCs activated with TGF-b or conditioned medium
from Panc-1 endothelial tumor cells using qPCR, immunostaining, western blot,
wound healing, collagen contraction and cell growth assays.
Results: In this study we have for the first time stained ITGA11 in human PDAC
specimens. We found that ITGA11 was highly expressed in stromal myofibro-
blasts of PDAC patients, as shown by co-localization with the myofibroblasts
marker alpha smooth muscle actin (-SMA). Interestingly, there was no expres-
sion in healthy human pancreas and various other tissues from human organs.
Furthermore, we induced subcutaneous tumors in mice by injecting Panc-1 or
Panc-1þhPSCs and found that ITGA11 was significantly overexpressed in
stroma-rich Panc-1þhPSC tumors. The quantitative gene and protein expression
of ITGA11 in subcutaneous tumors, positively correlated with the expression of
the CAF markers -SMA, Col1a1 and PDGFbR. Activation of hPSCs with
TGF-b or conditioned medium from Panc-1 resulted in the significant upregula-
tion of ITGA11 and -SMA. Stable ITGA11 knockdown, mediated by shRNA,
significantly inhibited hPSC differentiation, migration potential, contractility
and cell growth.
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Conclusion: In conclusion, this study introduces ITGA11 to be highly and spe-
cifically expressed in the tumor stroma of human PDAC and explores its role in
the regulation of the phenotype of pancreatic tumor stromal myofibroblasts.
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Introduction: The dismal prognosis of pancreatic ductal adenocarcinoma (PDAC)
is mainly due to chemoresistance linked to the tumor microenvironment. Recent
developments in therapeutic ultrasound(US), particularly US-induced cavitation,
could help overcome chemoresistance by breaking microenvironmental barriers
and increase cytotoxic drug availability. Three-dimensional (3D) culture in the
form of spheroids is a useful model for reproducing multicellular resistance and
analyzing the effects of cavitation.
Aims & Methods: The objective of this work was to study the effects of acoustic
cavitation on a model of PDAC spheroids and to investigate possible potentia-
tion of chemotherapy by US. CAPAN-2 PDAC cell line-derived spheroids were
cultured as previously described by Ivascu et al. Four conditions, i.e. control,
400 nM-gemcitabine-based chemotherapy (CT) alone, US alone, CT-US combi-
nation (n¼ 12 spheroids per condition), were studied. Experiments were carried
out to optimize US settings, in order to observe the occurrence of controlled
acoustic cavitation. Comparisons between groups were based on proliferation
and growth. Proliferation was evaluated 24 hours after treatment(s) by
Uptiblue. Growth was assessed by diameter measurement on light microscopy
at day 7 and day 10.
Results: Compared to the control group, cell proliferation was decreased in
spheroids treated with CT (p5 0.0001), but not with US alone. Proliferation
was also further impaired in spheroids treated with CT-US combination com-
pared to those treated with CT alone (p5 0.0001), but this synergistic effect of
US and CT did not impact growth of spheroid, meaning that spheroid diameter
did not decrease after US-CT compared to CT alone.
Conclusion: This study shows the feasibility of applying an ultrasonic treatment
(acoustic cavitation) in a three-dimensional culture model of PDAC. The com-
bination of CT and ultrasonic cavitation synergistically reduced cell prolifera-
tion. Further analysis of the cytotoxic effects of acoustic cavitation on PDAC
spheroids is in progress.
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Introduction: Intraductal papillary-mucinous neoplasm (IPMN) are a heteroge-
neous group of pancreatic tumors mucin-producing with uncertain biologic beha-
vior. We know, nowadays, that they can be also considered as a precursor of
pancreatic carcinoma (PAC), one out of these lesions will develop into a malig-
nancy of different types. There are no established guidelines for pathologic diag-
nosis/reporting of IPMN.
Aims & Methods: The aim of this study was to analyze the IPMN subtypes
distribution related with clinicopathological, histologic and immunohistochem-
ical and identify which one is more related to development of malignancy. This
prospective study reports a 3-year-follow up, with consecutive patients, where we
analyzed the clinical findings, radiological aspects, and morphologic features in
patient’s suspects of IPMN or PAC undergoing to pancreatic surgery. The
lesions were classified based on morphological and immunohistochemically
defined by the current WHO criteria.
Results: We analyzed 28 patients (16 women), mean age 66 y-old (range 50–83).
15 (53%) patients were asymptomatic, and 13 (47%) showed abdominal pain (8),
chest pain (4), and recurrent acute pancreatitis (1). 10 patients were submitted to
subtotal pancreatectomy, 9 to duodenopancreatectomy, 7 to gastroduodenopan-
creactectomy, 2 subtotal pancreatectomy and splenectomy. The neoplasm was
located in head, body and tail, and entire pancreas in 18, 9, and 1, respectively. 14
patients (50%) had involvement of the main pancreaticþbranch ducts (mixed
type), 7 (25%) had only the main pancreatic duct involved, 6 (21.5%) had only
the branch-duct involved, and 1 (3.5%) had not informed. The mean size of the
lesion was 3.3 cm 6.1 (1–11 cm). Morphologic features showed multi-loculated
(23) solid-cystic (4) and solid (1). The immunohistochemically expressed MUC1,
MUC5AC, and MUC2 in 18 (64%), 17 (61%), and 11 (39%), respectively. The
hispathotologic patterns founded was gastric-type (9), Intestinal-type (3), pan-
creatobiliary-type (9), mixed-type [6 (Pb-tþ I-t (4), and Pb-tþG-t (2)), and onco-
cytic-type (1) (table 1). The IPMN with a low-grade, and high-grade dysplasia
and invasive carcinoma was found in 18 (64.2%), 6 (21.5%) and 4 (14.2%),
respectively. We observed that the all pancreatic intraepithelial neoplasia
(PanIN) founded was related to Pb-t 13 (46%). The invasive PAC was presented
in 4 patients (14,2%) with the follow subtypes (Pb-t (2), and Pb-tþ I (1)), and
colloid PAC [I-t (1)] (table 2). Was found a synchronic neoplasia in 2 patients
(colon adenocarcinoma, and NET).
Conclusion: IPMN of the pancreas is a common cystic lesion located more fre-
quent on both duct (mixed-type). showing more aggressive behaver than others
pattern. Pb-t was the most common lesion and were more connecting to invasive
PAC and HGD, as well as connected with PanIN. MUC stains are helpful for the
diagnosis and papillary histological subtyping. Prospective studies are needed to
confirm these findings.
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Introduction: Because of the progression of systemic chemotherapies (CT) for
locally-advanced pancreas cancer (LA-PC), chemoradiotherapy(CRT) was
selected for limited case. However, very long survival cases were reported in
CRT and detection of prognostic factors were warranted. In this analysis, we
analyzed the LA-PC cases received CRT compared with CT.
Aims & Methods: Gemcitabine (GEM) and S-1 combination chemoradiotherapy
(GS-CRT) was performed according to our previous Phase 1 trial (Journal of
Japan Pancreas Society 2010). Till March 2016, 30 LA-PC cases received GS-
CRT, and the selection criteria were LA-PC with 1) pathological diagnosis, 2)
large vessels (CA, SMA, CHA, PV, SMV) invasion, 3) allochronic and concur-
rency without multiple primary cancer, 4) unexecuted antitumor therapy. The
chemotherapy in CRT administration of GEM (200mg/m2) once a week for 6
weeks, administration of S-1 (80mg/m2) for 2 weeks a week withdrawal was done
twice. Radiation was performed 1.8Gy in power of 10 MeV in a week 5-day
period for 5.5 weeks, and total dose was 50.4Gy (Total 28 times). As after
treatment, GEM 1000mg/m2 was continued until PD. The patients of CT
group were also recruited by the same criteria. One of the regimens among
GEM alone, S-1 alone and GEMþS-1 was selected for the primary treatment,
and total 26 cases were implemented in more than 2 courses.
Results: Baseline characteristics in CRT and CT group were median age (62, 72.5:
p¼ 0.004), male (20, 12: ns) and tumor location Ph/Pb (17/13, 16/10; ns), respec-
tively. Efficacy were disease control rate(DCR) in 3 months after treatment
(90%, 57.7%: p¼ 0.01), response rate (RR) (26.7%,0%: p¼ 0.005) and conver-
sion surgery (10%, 0%: ns). There were significant differences in progression free
survival (PFS) (8 months, 5 months: p¼ 0.002) and overall survival (OS) (13M,
9M: p¼ 0.0165), respectively. The cases who survived for 18 months and longer
were significantly (p¼ 0.0495) more in CRT (43.3%) than CT group (19.2%).
Grade 3/4 adverse events in CRT group were 13 cases of neutropenia (G4:3
cases) and one case of gastrointestinal symptom, and those in CT group, neu-
tropenia was 11 cases (G4:4 case), interstitial pneumonia (IP) aggravation was
one case.
Conclusion: For LA-PC, GS-CRT showed better local tumor control and longer
survival, and was considered as good candidate of neo-adjuvant therapy. More
long survival cases in CRT than CT was other benefit for LA-PC. We should
think about good selection criteria of CRT and improve the survival of LA-PC.
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Introduction: High-intensity focused ultrasound (HIFU) is expected as new
advanced therapy for unresectable pancreatic cancer (PC). HIFU therapy with
chemotherapy is being promoted as new method to control local advance by
ablation tumor, and mainly achieve relief of pain caused by PC.
Aims & Methods: We have evaluated the therapeutic effect of HIFU therapy in
locally advanced and metastatic PC. We treated PC patients by HIFU as
optional local therapy as well as systemic chemo/chemo-radiotherapy, with
whom an agreement was obtained in adequate IC, from the end of 2008 in our
hospital. This study took approval of member of ethic society of our hospital.
HIFU device used is FEP-BY02 (Yuande Bio-Medical Engineering Co.LTD.,
China). The subjects were 140 PC patients, i.e. 69 cases in stage III, 71 cases in
stage IV. Performance status (PS) was PS:0; 79, PS:1; 58, and PS:2; 3 cases. Mean
age was 62.3 10.6 years, The details of therapy before HIFU treatment
(overlap) was chemo-radiotherapy in 34, chemotherapy in 92, arterial infusion
chemotherapy in 5, immunotherapy in 8, operation in 17, and BSC in 7 cases.
Results: All tumors were visualized by HIFU monitor system. Tumor location
was head in 38, uncus in 19, body in 59, body tail in 6, tail in 2, and others
(recurrence) in 16 cases. Treatment data was followed; mean tumor size before
and after therapy was 33.5 10.7 and 33.7 11.5mm, mean treatment sessions:
2.3 0.7 times, mean total treatment time: 105 65.6min, mean total number of
irradiation: 1967.8 1106 shots. The effects of HIFU therapy were the following;
the rate of complete tumor ablation was 87.9%, the rate of symptom relief effect
was 69.4%, the effectiveness of primary lesion was CR:0, PR:21, SD:85, PD:34
cases, primary disease control rate (DCR) more than SD was 75.7%. The therapy
after HIFU treatment was operation in 8, chemotherapy in 116, immunothera-
pies in 4, and best supportive care (BSC) in 14 cases. MST after diagnosis in
HIFU with chemotherapy and chemotherapy alone (38 patients in our hospital)
was 1028.3 vs 366.6 days, respectively (p5 0.001). MST after HIFU therapy was
606.1 days. Combination therapy of HIFU with chemotherapy was better result
than common chemotherapy alone.
Conclusion: This study suggested that HIFU therapy has the potential of new
method of combination therapy for PC.
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Introduction: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis
with an overall 5-year survival rate 56%. Surgically resected patients, although
undergoing a possibly curative treatment, have nevertheless a 5-year survival
525%. In fact, it has been recently suggested that patients with a tumor of
more than 2 cm might harbor micrometastases at diagnosis. In this view, given
the availability of new highly effective chemotherapy regimens that might be
employed in the neoadjuvant setting, the correct evaluation of the T stage of
pancreatic cancer plays a key role. The new proposed AJCC Staging System for
Pancreatic Adenocarcinoma TNM (8th edition), in fact, differs from the 7th edi-
tion mostly for the evaluation of the T, giving high importance to the diameter of
the lesion. This reclassification has already been shown to predict survival differ-
ences more efficiently compared to previous editions. In this context, an efficient
preoperative evaluation of the T is of high importance as it might shift the
therapeutic decision from upfront surgery to neoadjuvant chemotherapy, that
could be preferred in tumors being 42 cm (T2). Few studies compared the accu-
racy of CT scan and EUS in evaluating the dimension of the tumor with hetero-
geneous results and often dated machines, and no study adopted the new TNM
system to evaluate the preoperative staging defined by CT and EUS.
Aims & Methods: The aim was to evaluate the accuracy of CT scan and EUS,
alone and in combination, in establishing the T stage of surgically resected
PDAC as defined by the new upcoming TNM 8th edition and to establish the
sensitivity and specificity of the two imaging modalities in discriminating T1
stage from more advanced T stages. We conducted a retrospective study on a
cohort of surgically resected histologically-confirmed PDAC patients at a pan-
creatic cancer referral center between 2015–2017, who were prospectively
included in a dedicated database. Inclusion criteria: a) having both preoperative
EUS and CT scan with pancreatic phase evaluation at the centre; b) CT and EUS
were performed, at the latest, 30 days apart from each other and from surgical
resection; c) no neoadjuvant chemo or radiotherapy was performed. The evalua-
tion of the T by both imaging modalities was compared to the final pathology T
re-established based on the new TNM 8th edition, in order to calculate specificity
and sensitivity. T-test was used for comparison of continuous variables, Fisher’s
test was used for comparison of categorical variables.
Results: Among the 184 PDAC patients surgically resected between 2015 and
2017 at our center, 30 met inclusion criteria. Of these, 19 (63.3%) were males,
with mean age at resection being 67.8 9.5 years. The tumor was located in the
head in 23/30 (76.7%) patients. Mean diameter of the tumor at pathology was
24.9 10.8mm, mean diameter at EUS was 24.0 8.6mm (p¼ 0.74), and mean
diameter at CT was 25.9 10.9mm (p¼ 0.73). In 4/30 (13.3%) cases CT scan was
not able to detect the lesion; mean diameter of undetected lesions was
21.2 2.9mm. Accuracy in T assessment was 60% (18/30) for both EUS and
CT scan; when considering detection of T2 lesion in any of the two imaging
modalities the accuracy increased to 80% (24/30). The sensitivity and specificity
in discriminating T1 lesions from T2 lesions was respectively 64.7% and 76.9%
for EUS and 76.5% and 72.7% for CT.
Conclusion: This is the first study evaluating the accuracy of CT and EUS ima-
ging modalities in establishing the T in the setting of the new TNM 8th edition. In
our study, CT scan and EUS have both a relatively low accuracy in determining
the correct T stage for pancreatic cancer when used alone, while the accuracy
raises significantly when used in combination. CT scan was not able to detect up
to 13.3% of lesions. EUS resulted having a lower sensitivity but higher specificity
in discriminating T1 lesions from T2 lesions compared to CT scan. These
preliminary results suggest how EUS, often adopted only as a means to obtain
a cytological specimen, has a key role in determining the T stage, and that the
two imaging modalities should be used in combination to better assess the proper
therapeutic management as neoadjuvant chemotherapy or upfront surgical
resection.
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Introduction: Pancreatic adenocarcinoma is associated with a 5–6% survival at 5
years and a poor quality of life. In Romania there are few information about the
prognostic influence of known risk factors for pancreatic cancer.
Aims & Methods: The aim of this study is to evaluate the association between risk
factors and the occurrence of pancreatic adenocarcinoma and patients’ survival,
which may constitute a theoretical basis for screening. We performed a prospec-
tive, multicentric study of patients with suspected pancreatic tumors detected in
abdominal ultrasound or CT examination, during January 2015-December 2016,
in which were analyzed risk factors and possible association with survival
adjusted statistically according to tumor stage (Chi square test, ANOVA, log-
rank test).
Results: There were 279 patients with pancreatic adenocarcinoma included in the
study. Male patients were 58% from all patients, and the mean age was 63.5
years. Smoking, new-onset diabetes and history of chronic pancreatitis are risk
factors for pancreatic adenocarcinoma (p5 0.05). At 12 months of follow-up,
almost one-third of patients with pancreatic adenocarcinoma died (median
survival¼ 5 months). It was demonstrated a statistically significant association
adjusted for tumor stage between the presence of new-onset diabetes and survi-
val: 5 months vs 3 months with a HR¼ 3. Other risk factors (alcohol, obesity,
sex, genetics, coffee intake, some infections and abdominal surgery, history of
chronic pancreatitis) had no prognostic role.
Conclusion: In our study, the risk factors for pancreatic cancer were smoking,
history of chronic pancreatitis and new-onset diabetes, but the only prognostic
factor was diabetes.
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Portugal
2Pathology Department - Centre De Diagnòstic Biomèdic (CDB), Hospital Clı́nic
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Introduction: According to the 2012 International guidelines on the management
of intraductal papillary mucinous neoplasms (IPMN), main-duct IPMN patients
with main pancreatic duct (MPD) diameter of 10mm should have surgical
resection, whereas surgery is not always mandatory in those with MDP diameter
between 5 and 9mm.
Aims & Methods: The aim of the study was to analyze the prevalence of malig-
nancy (high grade dysplasia or invasive carcinoma) in resected IPMN with MPD
diameter between 5 and 9mm and to identify predictive factors of malignancy.
Retrospective analysis of patients with surgically resected IPMN between 2001
and 2016. Demographics, clinical presentation, imaging and histological features
were compared between patients with preoperative evidence of MPD diameter
between 5–9mm (Group A) and 10mm (Group B). Malignancy was defined as
high-grade dysplasia or invasive carcinoma.
Results: From 122 patients with IPMN submitted to surgery, 66 with MD- or
mixed-IPMN entered the final analysis. Mean age was 66 12 years and 48
(72.7%) patients were men. Group A comprised 47 patients and Group B 19.
Abdominal pain was present in 23 (34.8%) patients, jaundice in 19 (28.8%),
diabetes in 18 (27.3%), pancreatitis in 15 (22.7%) and weight loss in 12
(18.2%), with no statistical differences between study groups. The most
common location of the MD-IPMN was the head of pancreas (60.6%), and it
was multifocal in 34.8% of the patients. The prevalence of no dysplasia, low-
grade dysplasia, high-grade dysplasia and invasive carcinoma was 10.6%, 42.6%,
8.5% and 38.3% in group A and 10.5%, 10.5%, 21.1% and 57.9% in Group B
patients. The overall malignancy rate was 46.8% in group A and 79% in group
B. Jaundice (p¼ 0.017), weight loss (p¼ 0.035), and complete involvement of
MPD at pathological analysis (p¼ 0.018) were significantly more common in
patients with malignancy.
Conclusion: Almost half of resected IPMN with MPD diameter between 5–9mm
harbor histologically proven malignancy. In these patients, particularly in those
with jaundice and weight loss, surgery rather than follow-up should be
recommended.
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Introduction: Pancreatic cancer has poor prognosis despite of improvements in
multimodal treatments. As aging of the population advances, it is expected that
elderly pancreatic cancer patients increase.
Aims & Methods: The aim of this study was to investigate the clinical significance
of chemotherapy for patients with unresectable pancreatic cancer. At our hospi-
tal, 96 patients were diagnosed as having unresectable pancreatic cancer between
January 2010 and December 2016. In this study, we defined elderly patients as
those older than 75 years. We retrospectively examined the safety and efficacy of
chemotherapy in patients with unresectable pancreatic cancer. We analyzed and
compared survival periods and adverse events between young and aged patients.
Results: Twenty-seven patients were older than 75 years (group A), and 59 were
younger than 74 years (group B). We treated 6/10/0/2/5/4 patients in group A
with GEM/S-1/modified FOLFIRINOX (mFOLFIRINOX)/GEMþnabPTX/
best supportive care (BSC)/others, respectively. On the other hand, we treated
12/14/4/11/5/13 patients in group B with GEM/S-1/mFOLFIRINOX/
GEMþnabPTX/BSC/others, respectively. Severe adverse events (more severe
than grade 3 according to CTCAE v4.0) occurred in 18.2% of the patients in
group A and in 33.3% of the patients in group B. No significant difference was
found between the two groups. The median survival time of the patients who
were receiving chemotherapies was 197.0 days in group A and 291.0 days in
group B. No significant differences were also found between the two groups.
The median survival time of the patients who underwent chemotherapy in
group A (332.0 days) was significantly longer than that of patients who under-
went BSC (71.0 days).
Conclusion: Conclusions: Chemotherapy could be safe and effective for patients
older than 75 years who have unresectable pancreatic cancer.
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Introduction: Endoscopic ultrasound-guided biopsy (EUS-biopsy) is considered a
reliable, safe, and effective technique for obtaining samples from pancreatic
masses with a very high sensitivity and specificity (ranged to 85%-92% and
96–98%, respectively)[1–3]. A new EUS needle (SharkCore FNB needle,
Medtronic, Dublin, Ireland) was introduced in order to improve the tissue
acquisition.
Aims & Methods: The aim of the present study was to evaluate the presence of a
histological sample using Shark Core Needles. This study was an observational
multicenter prospective non-randomized clinical trial (NCT02946840). All con-
secutive patients referred for EUS examination and sampling of solid pancreatic
masses underwent EUS-guided biopsy with 25 G Shark Core needles. This needle
has an innovative tip geometry with a cutting surface designed to acquire cohe-
sive units of tissue and to minimize tissue fracturing. Three passes were per-
formed in every mass. At every pass, a macroscopic on-site quality evaluation
(MOSE) was done by endoscopist. If a ‘‘worm-like’’ material was observed at
gross visual assessment, it was placed into formalin. If only liquid material was
obtained, it was smeared between 2 glass slides, fixed with ethanol, and stained
with a Papanicolaou-stain for cytological analysis. Endoscopists recorded macro-
scopic features of the specimens. Pathologists described macroscopic, micro-
scopic features, immunohistochemical studies. The primary outcome was the
procurement rates of histologic core. Pathologists defined core all histological
samples with architecturally intact histology, measuring at least 5mm in greatest
axis. All the other specimens (55mm) were defined as micro-fragments. The
final diagnosis was based on surgical resection, and clinical/radiological follow
up. The secondary outcomes were diagnostic accuracy and procedure-related
adverse events.
Results: Study population included 82 patients, enrolled in three centres, between
August 2016 and April 2017, with a mean age of 64.0 (SD 13.7, range 21–84) and
57.3% female gender. The mean size of the lesions was 27.6mm (SD 12.2) and
the location was the body and tail in 27 patients (32.9%), neck in 11 (13.4%),
head and uncinated process in 44 (53.7%). Three needle passages were performed
in all but 3 patients who experienced mild bleeding precluding more than one
needle passage. At MOSE, endoscopists described presence of ‘‘worm-like’’ mate-
rial in 192 biopsy samples over 242 (79.3%). In 8 patients only cytological speci-
mens were obtained after 3 needle passes (9.8%). Six cases of mild self-limited
bleeding were observed (7.3%). The pathologists described the presence of a core
in 80 samples (41.7%), in the other cases, after the specimen preparation, a
micro-fragmentation was observed, that didn’t affect the histological evaluation.
A final histological diagnosis was reached in 73 patients (90%): 50 pancreatic
adenocarcinoma, 16 NET, 5 chronic pancreatitis, 2 pancreatic metastasis from
other organs.
Conclusion: The new biopsy needle showed a good overall adequacy and a good
rate of histological specimens (both core and micro-fragments) during EUS-
guided tissue acquisition of pancreatic masses, with a minimum number of
passes and no major complications. This ability could allow to avoid the use
of rapid on-site evaluation and to perform immunohistochemical, molecular and
genetic studies on histological samples.
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Introduction: EUS FNA is accepted as the primary modality for tissue diagnosis
of solid pancreatic lesions. The presence of on-site cytopathology for immediate
evaluation during endoscopic ultrasound-guided fine needle aspiration (EUS
FNA) has previously been shown to improve performance characteristics. Due
to service pressures EUS FNA is also undertaken in the absence of in-room
cytopathology assistance. This is a review of current practice.
Aims & Methods: We retrospectively assessed 700 consecutive EUS-FNA proce-
dures from January 2011 to January 2016. 459 (65.5%) solid pancreatic lesions
were included in the final analysis after excluding 230 for biliary strictures, hepa-
tic lesions, lymph nodes, gastric, oesophageal lesions, pancreatic cysts and 11 for
insufficient information.
Results: In 399 (86.9%) cases on-site cytopathology support was available, while
the remaining was unsupported. There were 228 males (57.1%) in the supported
and 29 (48.3%) in the unsupported group. Mean age was 64.6 (SD: 11.4) and 67.4
(SD: 11.9) respectively. The mean number of passes in the two groups were 2.8
(SD: 1.12) and 1.9 (SD: 1.0) (P5 0.0001). A conclusive diagnosis (malignant,
benign, NET, GIST) was made in 84% (67%, 12%, 5%, 0%) of the supported
group and in 38% (23%, 10%, 3%, 2%) of the unsupported (P5 0.0001). The
mean follow up for the entire cohort was 14.2 months (SD:14.1) and mean
survival of in patients diagnosed with malignancy was 10.9 months (SD: 8.7).
Overall performance characteristics of EUS FNA were Sensitivity: 90.8%
Specificity: 86.9% PPV: 91.8% NPV: 85.4%
Conclusion: This review confirms high performance characteristics of EUS FNA.
The presence of on-site cytopathologist significantly increases the diagnostic
yield.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Pancreatic cystic lesions are a common finding in clinical practice.
Classification of cysts as mucinous or non-mucinous cysts, using EUS-FNA with
cystic fluid analysis for cytology and CEA became widely used in clinical workup
of patients with suspicious pancreatic cysts. Molecular analysis (KRAS and
GNAS mutation) is not yet recommended in clinical practice.
Aims & Methods: We aimed to etermine if mutation in GNAS and KRAS in
addition to CEA level and cytology of cystic fluid obtained by EUS-FNA can
help in pancreatic cyst classification and decision making. Evaluation of methy-
lation of the GNAS complex locus was performed for cyst classification.
Between 2008–14, 266 EUS were performed for pancreatic cyst evaluation in a
single center. We determined the mutational status of GNAS (exons 8 and 9) and
KRAS (exons 2 and 3) genes by Sanger sequencing in 52 patients, in cystic fluid
obtained by EUS-FNA after cytology and CEA analysis. In operated patients,
cysts were also analyzed for methylation of the GNAS complex locus.
Results: Mainly female (67%), mean age of 59 15 years (29–91). Cysts located
in head (42%), body (39%), tail (17%) and multiple (2%), with a mean size of
3.9 2.3 cm (.8–10), and 60% 43 cm. Cyst types (as after EUS-FNAþCEA/
cytology): 15 serous cystadenomas (SCAs), 9 pseudocysts, 8 intraductal papillary
mucinous neoplasms (IPMNs), 2 mucinous cystic neoplasms (MCNs), 4 adeno-
carcinomas (ADC), 1 solid pseudopapillary neoplasm (SPN), 1 lymphangioma,
12 non-defined. CEA4 192 ng/ml in 33% of patients and cytology with benign
cells in 12 (23%), suspicious/malignant in 8 (15%), 1 NET (2%) and 31(60%)
acellular samples. Surgery in 11 (21%) patients (surgical specimens: 2SCA,
3MCN, 4IPMN, 1 retention cyst and 1 ADC), chemotherapy/palliation in 6
(12%), endoscopic drainage in 1 (2%) and 34 (64%) on f-up. KRAS Mutation
in19% (9) and in GNAS in 4%(2) of cyst aspirates. By cyst type, GNAS was
mutated in 1 IPMN and 1 ADC. KRAS was mutated in 6 patients on fup (2
IPMNs, 3 ADC, 1 pseudocyst- a unilocular 2 cm cyst with CEA¼ 125) and in 3
who had surgery (2 IPMNs and 1 MCN). Sensitivity and specificity of
CEA4 192þ cytology and KRAS/GNAS mutations for the classification of
mucinous and non-mucinous (table 1-1st part) and malignant and non-malignant
(table 1-2nd part) are presented in operated cysts.
Diagnosis of neoplastic mucinous cysts Sensitivity Specificity
CEA4 192þ citology 100% 67%
KRAS/GNAS mutation 42% 100%
Diagnosis of malignant cysts
CEA4 192þ citology 100% 33%
KRAS/GNAS mutation 50% 75%
In the surgery group, methylation of the GNAS complex locus was found in 1/2
ADC, 1/3 IPMNs (the malignant IPMN has GNAs mutation and no methylation
of the GNAS complex), 1/3 MCNs, 0/2 SCA and 0/1 retention cyst.
Conclusion: Sanger sequencing of KRAS and GNAS genes is highly specific for
the diagnosis of mucinous neoplastic cysts of the pancreas and may be useful in
selected patients. The specificity of Sanger sequencing of KRAS and GNAS
genes for the diagnosis of malignant cystic lesions decreases but is higher than
CEA/cytology analysis. Methylation in GNAS complex locus was found in
malignant cysts but data are preliminary and need further evaluation. More
fluid markers are needed to improve pancreatic cyst classification.
All other authors have declared no conflicts of interest.
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Introduction: Promising method, which helps to distinguish between chronic
pancreatitis and cancer, is point mutations of the proto-oncogene KRAS test.
This method is not established in routine clinical practice yet.
Aims & Methods: Determination of the sensitivity of the KRAS assay using
various kinds of samples of patients with pancreatic mass and testing the effect
of the presence of KRAS mutations on the prognosis of survival. 147 patients
underwent EUS-FNA examination of pancreatic mass, accompanied by blood
sampling with subsequent separation of plasma for the detection of circulating
tumor DNA. Part of biopsy sample was left native in a stabilizing solution and
part as cytological smear. Samples (native aspirates, cytological smears, plasma)
were examined for the presence of KRAS mutation by heteroduplex analysis,
denaturing capillary electrophoresis.
Results: Among 147 patients with pancreatic masses, 118x were diagnosed as
cancer, 26x chronic pancreatitis, 3x neuroendocrine tumor. In total 147 native
aspirates, 118 cytological smears and 94 plasma samples were examined. The
highest sensitivity of KRAS mutation was reached in the group of pancreatic
cancer patients using cytology, in which 90% of KRAS mutation was detected
(106/118 of the samples). When using the native cellular aspirates, mutation was
detected in 78% (92/118 samples), and examination of plasma was positive in
27% (24/90 samples).In four patients with chronic pancreatitis KRAS mutations
was detected, although none has been cytologically confirmed as a cancer. Two
of these four patients were confirmed in the course of the disease as a cancer, one
patient died because of alcoholic delirium and the last one was indicated for
surgery recently.
Conclusion: Examination of KRAS mutations can be performed in all patients
undergoing EUS-FNA, with the cytology being the most reliable type of sample
for genetic tests. KRAS examination would be reasonable to introduce into
routine clinical practice in a group of patients with unclear differential diagnosis
of chronic pancreatitis, especially in those with suspicion of cancer in inflamma-
tory terrain. Financial suport by The Ministry of Defence and Armed Forces of
the Czech Republic MO 1012.
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Introduction: Self-expanding metal stents (SEMS) are increasingly preferred to
plastic stents (PS) for pre-operative drainage and palliation of biliary obstruction
secondary to a stricture in the head of pancreas (HOP). Their use has increased
over the last 5–6 years. Endoscopic ultrasound (EUS) with fine needle aspiration
or biopsy (FNA or FNB) is commonly utilised to make a tissue diagnosis and to
aid in staging in those with borderline resectable tumours. Stents may reduce
diagnostic performance of FNA/FNB by reducing the visible mass to puncture.
There have been 2 studies that assessed the impact of stenting on EUS-FNA
performance, one1 found no difference in yield and sensitivity among patients
with or without stents and between SEMS and plastic. Whilst a more recent
study2 found accuracy was significantly reduced by the presence of a stent.
Aims & Methods: The aim was to assess whether stents (SEMS or PS) impair
diagnostic performance of EUS tissue acquisition, in a retrospective study of all
patients with HOP mass undergoing EUS biopsy between January 2010 and June
2016. Stenting information was obtained from the EUS report and images.
Biopsies reported as malignant were considered as such, all other reports were
considered benign. A definitive diagnosis of cancer was based on positive pathol-
ogy or follow up with signs of progression. A benign diagnosis required negative
pathology, stable imaging and symptoms for a year or more. Patients with cystic
lesions were excluded.
Results: A total of 1861 patients had EUS FNA/FNB of which 731 were for HOP
lesions, mean age 65 yrs (410 F), with tissue sensitivity of 72% for all types of
needles used. Tissue accuracy was significantly different between the 3 groups
(p¼ 0.0001); SEMS 67%, PS 71% and 83% in the unstented group. The differ-
ence in accuracy was significant between the unstented group versus SEMS
(p¼ 0.0002) and PS (p¼ 0.003) and not significant between PS and SEMS.
Stepwise multi-variable analysis revealed significant difference for accurate
tissue diagnosis favouring size needle 25G (OR 1.7 [95%CI 1.1–2.7] and
tumour size (OR 1.04 [1.02–1.07]) and negative affected by presence of stent
SEMS (OR 0.3 [0.2–0.6]) or PS (OR 0.5 [0.3–0.9]). Other needle sizes (19G or
22G), number of passes or types of needle did not significantly affect tissue
accuracy.
Conclusion: Our results show a significant adverse impact of both SEMS and PS
on tissue accuracy via EUS FNA/FNB. The effect is greatest with SEMS. These
results suggest that where possible EUS and biopsy if required should be per-
formed before stent placement.
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Introduction: Solid-pseudopapillary neoplasm (SPN) is a rare condition, first
described by Frantz in 1959. It occurs mostly in young women, and surgical
resection is recommended. Its local recurrence rate is less than 10% and usually
occurs within 4 years after surgery. Before such a surgery, especially in young
people, EUS-FNA (Endoscopic ultrasonography with fine needle aspiration) is
discussed to confirm diagnosis but rarely performed due to suspected needle tract
inoculation by neoplastic cells. The aim of our large multicenter study was to
assess the short- and long-term safety of preoperative EUS-FNA in SPN.
Aims & Methods: This study is a multicenter retrospective register of all SPN
diagnosed in the last decade in 14 European expert centers (GRAPHE task
force). Inclusion criterion was realization of preoperative EUS-FNA followed
by surgical resection. Patient and tumor characteristics were collected, as the
EUS-FNA technique (number of passes, needle size, trans-gastric or trans-duo-
denal access). Immediate or late complications of EUS-FNA and recurrence of
SPN were then recorded.
Results: During the period study, 49 patients (41 women/8 men) with preopera-
tive EUS-FNA for SPN were recorded. Mean age of patients was 37 15yo.
Tumor location was mostly cephalic (21/36, 59%), but also corporeal in 25%
(9/36), caudal in 25% (9/36), isthmic in 11% (4/36) and in uncus in 5% (2/36).
Mean tumor size measured on EUS was 40 22mm. Needle used was a 25G in
3% (1/37), 22G in 76% (28/37), 20G in 8% (3/37) and 19G in 13.5% (5/37).
Trans-duodenal EUS-FNA was performed in 56% (24/43) and trans-gastric in
44% (19/43). Mean number of needle passes was 2.2 0.7. EUS-FNA allowed
certain preoperative diagnosis of SPN in 74% of cases (35/47), probable diag-
nosis in 6% (3/47), negative in 4% (2/47) and wrong in 6% (3/47). No acute
complication of EUS-FNA was reported. With a mean follow-up of 36 36
months, only one local recurrence was noted. In this 74 years old man case, a
19G needle was used (2 trans-gastric passes), and recurrence occurred after 84
months.
Conclusion: In this large multicenter retrospective series, a systematic preopera-
tive EUS-FNA did not seem to modify the SPN recurrence rate. Therefore this
study allows to validate this attitude as a possible alternative. The data for the
series are incomplete at the date of submission of the abstract. The final data will be
completed on the day of presentation.
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Introduction: Pancreatic neuroendocrine tumours (PNETs) are relatively rare,
i.e., 1 per 100,000 individuals per annum, and account for only 1–2 percent
of all pancreatic tumours. They are separated into 2 major categories: 1) well-
differentiated (WD-NETs) which have round to oval nuclei, coarsely stippled
chromatin and finely granular cytoplasm and 2) poorly-differentiated (PD-
NETs) which have a diffuse architecture with an irregular nucleus and less cyto-
plasmic granularity. WD-NETs tend to have an indolent course (survival 67%
at 5 years) but 50% have metastasised at the time of diagnosis. PD-NETs are
high-grade cancers with an aggressive course resembling NETs arising in lung.
WD-NETs contain neurosecretory granules which stain for synaptophysin and/
or chromogranin. Endoscopic ultrasonography guided fine-needle aspiration
biopsy (EUS-FNA) can provide a non-operative cytological diagnosis of
PNETs when the pathologist is provided with a good specimen such as the
pellet of cells obtained through SurePath (SP).
Aims & Methods: EUS-FNA samples of pancreatic tumours were collected into a
SurePath vial and slides prepared from the cellular pellet. The slides were stained
for synaptophysin and Ki67 by immunohistochemistry (IHC) and examined by 2
independent senior cytopathologists.
Results: Sixteen (16) patients with a mean age 65 (8 male) were identified by EUS
with a suspected PNET. The mean tumour size was 16.2mm þ/ 4.2mm. All
had the morphology of a PNET and stained positive for synaptophysin.
Conclusion: SP prepared cytology slides from solid pancreatic tumours provides
enough diagnostic material for IHC staining for synaptophysin and Ki67 without
the need for a formal excision biopsy. Morphology of SP slides is often diagnostic
but a positive stain for synaptophysin makes the diagnosis irrefutable. The
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mitotic index derived from Ki67 staining helps identify WD-NETs which can be
monitored and PD-NETs which need aggressive treatment.
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Introduction: Pancreatic neuroendocrine neoplasms (PNEN) are highly angio-
genic tumors which–despite of various targeted options including mTOR and
VEGF inhibition–frequently develop secondary drug resistance. IGF2BṔs
(IGF2 mRNA-binding proteins) represent a family of canonical RNA-binding
proteins (RBP) comprised of three members (IGF2BP1–3) which have been
described to promote stem and/or progenitor cell maintenance with reported
expression and oncogenic roles in aggressive cancers. IGF2BṔs show a differen-
tial expression pattern in various solid tumors including pancreatic neuroendo-
crine tumors.
Aims & Methods: We aimed to characterize the role of IGF2BṔs in progression
and resistance of pancreatic neuroendocrine neoplasms. We used three different
siRNA-pools (IGF2BP1/2/3) to inhibit the different IFG2BP’s in pancreatic
neuroendocrine BON1 tumor cells. Cellular effects where investigated by
Western blot analyses, flow cytometry, clonogenic survival, cell viability and
migration assays.
Results: In the pancreatic neuroendocrine tumor cell line BON1, knock-down of
IGF2BP1 resulted in a significant reduction of cell viability. Cell cycle analysis by
FACS showed a decreased S phase progression paralleled by a reduction in the
proliferation marker PCNA and a markedly reduced MEK/ERK activation. In
contrast, Akt signaling was unaffected. Moreover, knock-down of IGF2BP1
significantly reduced clonogenic growth as assessed by colony formation assays
and led to decreased cell migration as determined by scratch assays. Interestingly,
knock-down of IGF2BP1 was insufficient to induce apoptosis, as assessed by
PARP and caspase-3 cleavage as well as annexin-V FACS. Rather, si-IGF2BP1
increased the expression of both the anti-apoptotic and pro-survival factor BCL-
2 and the cell cycle inhibitor CDKN1B. In contrast to IGF2BP1, knock-down of
IGF2BP3 rather induced cell viability, whereas IGF2BP2 modulation had no
impact on cell viability and cell cycle progression indicating opposing effects of
the three IGF2BṔs on PNEN progression. These in vitro findings were paralleled
by distinct expression patterns of IGF2BPs in human and murine PNEN tissues.
Elucidation of IGF2BP-modulated RNÁs in PNEN cells is ongoing.
Conclusion: In summary, our data suggest that IGF2BP1 promotes tumor pro-
gression by enhancing cell cycle progression and clonogenic growth, whereas
IGF2BP2 and -3 exert no tumor-promoting role in PNEN.
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Introduction: Intraductal papillary mucinous neoplasms (IPMNs) and neuroen-
docrine tumors (NETs) of the pancreas are rare tumors. Up to now 15 patients
with association of endocrine and exocrine neoplasms of the pancreas have been
reported in the literature, but this association is not expected to be frequent. The
aim of this study is to describe a series of nine patients with IPMN and con-
comitant NET of the pancreas followed in our center and to look for any
common findings between them that could help early recognition and further
comprehension of this association.
Aims & Methods: Among all the patients who were followed in our clinic for
IPMN or NET, we identified 9 with both diseases, diagnosed on imaging or after
biopsies requested for uncertain results of previous investigations. We collected
data about the patients (age, sex, symptoms, past and current medical history,
blood chemistry, type of imaging) and about the lesions (classification, dimen-
sion, localization, imaging features, fine-needle aspiration (FNA) biopsies results
and histology).
Results: All patients (4 men and 5 women), except one were asymptomatic.
Average age at diagnosis was 61 years. All IPMN were branch duct, localized
in the head (n¼ 4) and in body-tail (n¼ 5), with a medium diameter of the cysts
of 12mm (range 8mm-16mm). All NETs underwent endoscopic ultrasound
examination with FNA; 8 were non functional G1 with a Ki67 of 1%, positive
for Chromogranine A and Neuronospecific Enolase staining. One NET was a
symptomatic insulinoma located at the tail (Ki67 of 2%, 20mm diameter) and
underwent distal spleno-pancreasectomy. Among NETs, 6 were in the head and 3
at body-tail, with a medium diameter of 11mm (range 6m–15mm). In 4 patients,
the first diagnosis was IPMN, followed by identification of NET with second
level imaging. In 5 patients, who underwent magnetic resonance imaging for
NET, a concomitant IPMN was found.
Conclusion: Our study describes 9 cases of endocrine-exocrine pancreatic neo-
plasms association. In the 15 cases reported by literature one out of the two
lesions, had a malignant behavior. In our records, except in one patient, both
IPMN and NET in all patients behave in an indolent fashion. All the IPMN were
branch type and all the NET, except one, were G1; mainly patients are asympto-
matic and a hormone production symptom was observed in only one case. We
found neither sex or age predisposition, nor predominant localization or
common pathologic background in the patients. No other concomitant neoplas-
tic diseases were found. Although the frequency of association between NET and
IPMN is not too large and no diagnostic hallmark were found, it is still to be
proven that this association is fortuitous. Further studies in the future are
required.
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Introduction: The chemopreventive effect of aspirin (ASA) and other NSAIDs
have been observed in the setting of colorectal cancer, showing a reduction in the
incidence and mortality. However, the impact of aspirin use on clinical outcome
of patients with gastro-entero- pancreatic neoplasms (GEP NEN) has not yet
been evaluated.
Aims & Methods: Aim of the study was to retrospectively evaluate the clinical
outcome of GEP NEN patients treated with ASA at three different European
referral Centres for NENs. All the GEP NENs patients followed up in three
European Centres (Fondazione IRCCS Ca’ Granda Ospedale Policlinico
Milano, Italy; Fondazione IRCCS Istituto Tumori Milano. Italy; Mater
Misericordiae University Hospital, Dublin, Ireland), from January 2005 and
September 2016, were retrospectively enrolled. The possible association between
ASA and disease grading, staging, primary site, overall OS and PFS were eval-
uated. At the time of enrolment, clinical data and biochemical parameters were
collected for every patient. Chromogranin A (CgA) and specific circulating pep-
tides were evaluated. Morphological and functional imaging (computed tomo-
graphy, magnetic resonance and Gallium 68PET) were performed to follow up
the patients at each Centre.
Results: In the 253 patients included (121 M, median age 64 yrs), the primary
neuroendocrine tumor was located at the stomach (#35), pancreas (#82), small
bowel (#80), appendix (27), colon (#19) or unknown (#7). Grading was G1 in 154
patients, G2 in 64, G3 in 5 and not available in 28. TNM staging was I in 99
patients, II in 16, III in 32 and IV in 86. No clear impact on OS or PFS was
observed in patients taking ASA compared to those not taking it. Interestingly, in
pNEN an inverse relation was observed between Ki67 and ASA assumption
(r¼ -0.35, p¼ 0.008). In small bowel NEN an inverse relation was observed
between positive lymphnodes at surgery and ASA assumptions (r¼ -0.3,
p¼ 0.02). As expected, the intake of ASA was related with the older age of the
patients.
Conclusion: According to present data, ASA therapy seems not to have a direct
clinical impact on disease progression or survival of NENs, even if it is associated
with lower Ki-67 values and less node involvement. Further studies are needed to
confirm this observation.
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Introduction: Von Hippel-Lindau disease (VHL) is a rare heritable genetic syn-
drome that may affect different systems and organs: pancreatic manifestations of
the disease are frequent during lifetime of the patients. The key feature is the
presence of simple cysts, but serous cystadenomas (SCAs) or neuroendocrine
tumors (NETs) can be frequently found as well. The aim of this study is to
describe pancreatic manifestations in patients with VHL, considering the pecu-
liarity and rarity of this disease.
Aims & Methods: All patients who referred to the established multi-disciplinary
team in our center (Molinette Hospital - Turin) for management and follow-up of
VHL disease were included in the study: we then considered the ones with pan-
creatic involvement (simple cysts, SCAs or pNETs). We collected data about the
patients (demographics and medical history), about the lesions (imaging features,
hystological and cytological analysis) and about the management.
Results: We enrolled a total of 24 patients, 18 of which (75%) had a pancreatic
involvement. Multiple simple pancreatic cysts were found in 13 patients, SCAs
were found in 2 patients and NETs in 7 patients. The mean age of the patients
with pancreatic lesions was 42 (min 25 - max 75), 11 were males and 7 females
(1.6:1 M:F). Simple cysts affected 13 patients, are always multiple (ranging from
12 to 80mm) mostly in the head. 3 patients underwent surgery for symptomatic
disease. All pNETs were well differentiated (G1, Ki67 52%); 7 were located in
the head and 2 in the tail (2 patients had multiple tumors). 5 out of the 7 pNET
patients underwent surgery. The two SCAs were multiple (max 65mm), mostly
affecting the head in 1 case and the tail in the other. No surgery was performed.
Conclusion: 75% of our VHL patients showed pancreatic involvement, mostly in
males compared to females. 72% of patients with pancreatic lesions suffered
from simple cysts, 39% from NETs and 11% from SCAs. To note that all
NETs were G1 and behaved in a benign fashion. Surgery was performed only
in patients with NETs in the pancreatic head and in patients with symptomatic
cystic disease. The mean age of incidence of VHL-related pancreatic lesions was
lower than in sporadic cases, thus confirming literature data. Although all lesions
in our patients were benign or stable, constant monitoring is needed.
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Introduction: Neuroendocrine tumours (NET) consist of a diverse group of neo-
plasms that derive from diffuse neuroendocrine cells throughout the body.
Commonly found in gastrointestinal (GI) duct and lung, they also arise in the
pancreas. The relationship between tumour size and metastasis rate is poorly
recognized in patients with pancreatic neuroendocrine tumours (PNETs). The
impact of tumour size on prognosis was controversial in previous investigations.
Aims & Methods: The aim of this study is to evaluate the prognostic impact of
tumour size on survival outcomes and its correlation with risk of metastasis in a
large PNETs cohort, including all stages. Methods: PNETs cases diagnosed from
1988 to 2013 were retrieved from the Surveillance, Epidemiology, and End
Results (SEER) database. Clinicopathologic features were retrospectively ana-
lyzed. Survival was calculated by the Kaplan-Meier method. Multivariable Cox
regression models with hazard ratios (HRs) were constructed to analyze survival
outcomes and risk factors. Cubic spline analysis was used to assess relationship
between tumor size and probability of metastasis.
Results: A total of 5424 patients were identified. There were 1226 patients
(22.6%) with tumour size of 2 cm or less. The probability of metastasis increased
in a non-linear fashion with increasing tumours size. Univariate analysis showed
that tumour size was significantly correlated with survival (P50.001), no matter
surgery was performed or not. However, subgroup analysis suggested this asso-
ciation to be linear for patients with localized and regional tumours (P50.001),
but stochastic in patients with distant stages (P¼ 0.703). On multivariate analy-
sis, tumour size was an indicator for metastasis (HR¼ 1.010, 95% CI: 1.008–
1.013, P50.001) and size 20mm was an independent prognostic factor for
good survival (HR¼ 1.211, 95% CI: 1.048–1.399, P¼ 0.009 for size of 21–
40mm; HR¼ 1.282, 95% CI: 1.116–1.474, P50.001 for size440mm). For
tumours 20mm, surgical treatment was associated with significantly improved
survival compared with those patients who did not undergo operation
(P50.001).
Conclusion: Tumour size affects the probability of metastasis. Its prognostic
impact on survival is restricted to patients with localized and regional disease.
For patients with tumour size 20mm, surgical treatment should be considered
preferably.
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Introduction: Multiple Endocrine Neoplasia type-1 (MEN-1) occurs usually spor-
adically but because it is an autosomal dominant disorder it may affect other
family members too. The combination of parathyroid tumors, pancreatic islet cell
tumors, and anterior pituitary tumors is characteristic of MEN-1 although it may
be accompanied by a substantial number of non-endocrine tumors. The muta-
tions of the MEN-1 result in the alteration of MENIN production which is a
protein encoded by this gene and is responsible for tumor-supression under
normal circumstances. Herein we present the largest MEN-1 family in Turkey
to the best of our knowledge and a newly discovered mutation in MEN-1 that
effects this family.
Aims & Methods: The family inherited the specific MEN-1 mutation is originally
Ş ebinkarahisar, Giresun and most of the members have moved to Istanbul and
Yalova. Consanguineous marriages have been practiced within the family.
Family mapping was structured and contained fifty-five members. Among
them, eleven patients underwent biochemical, radiologic and if necessary endo-
sonographic evaluation along with the genetic testing. Additionally, we learnt
that 2 members of the family had died of pancreatic malignancy. Diagnostic
criteria for familial MEN-1 syndrome include; 1- the presence of at least one
MEN-1 associated tumor that are from parathyroid, pituitary, or GEP tract
origins, 2- at least one first-degree relative with one or more of these endocrine
tumors and/or 3-positive genetic testing for abnormal MEN-1 mutation. For our
index case, DNA sequencing of the MEN-1 gene performed using Sanger sequen-
cing technique at ABI 3500 sytem. For the other family members only the tar-
geted mutation analysis is performed.
Results: Among the family members we had peripheral blood DNA from 9 and
we used the tumour tissue DNA from 1 patient. MENIN gene is analyzed with
Sanger sequencing. Our index case was ZK who had hypophysis adenoma, para-
thyroidectomy and pancreatic neuroendocrine tumour and had whipple opera-
tion. A three nucleotide deletion p.ser560argfs*3(c.1680_1683 del TGAG)
mutation causing a frameshift was detected. Seven out of ten who were analysed
tested positive for the mutation. Genetic counseling and information about pre-
implantation genetic diagnosis (PGD) was given to all patients who are tested
positive for the mutation. All 7 patients had p.ser560argfs*3(c.1680_1683 del
TGAG) three nucleotide deletion same with that of index case. Out of 15
patients, MEN-1 diagnosis was confirmed in 11. Tumours detected at patients
with MEN-1 diagnosis were; nonfunctional pancretic neuroendocrine tumour at
three, parathyroid adenoma/hyperplasia at 6 patients and hypophysis adenoma
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at 4 patients. The mean age of our MEN-1 patients were 51 and the age at
diagnosis was 41.8. The mean plasma calcium level was 11.46mg/dl and there
was no history of renal calculus at any of them.
Conclusion: The family presented here is the one which had the largest number of
affected individuals with genetic and clinical properties of MEN-1 at Turkey.
Besides the mutation detected here is the novel pathogenic mutation causing loss
of function that is described for the first time. Also at MEN-1 families, counsel-
ing to prevent the neoplasia development and to prevent the new family member
to be effected with PGD has a pivotal importance. We could point out that
awareness is the most important caution for prevention.
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Introduction: Several inflammatory response materials could be used for predic-
tion of prognosis in cancer patients. The neutrophil lymphocyte ratio (NLR),
platelet lymphocyte ratio (PLR), thrombocytosis (the platelets number
4400*103/mm3) have been introduced for prognostic scoring system in various
cancers.
Aims & Methods: The objective of this study was to determine whether the NLR,
the PLR or thrombocytosis could predict the clinical outcomes in G1-G2 neu-
roendocrine tumors. We performed a retrospective review of 31 patients with
neuroendocrine tumors with ki 67 below 20% diagnosed in Fundeni Clinical
Institute between 2011–2017. Data about site of the primary tumor, presence
of metastasis, NLR, PLR, thrombocytosis (platelet count4 400) and survival
were collected and analysed.
Results: The patients characteristics were: primary tumor location was: 61.29%
pancreas, 22.58% gastrointestinal tract, 16.13% unknown, 61.29% had hepatic
metastasis, 6.45% had locally advanced tumor. The primary tumor was resected
in 35.48% patients. The overall 2-year survival rate was 77.42%. The Ki 67 index
(p5 0.04), PLR (cut off 4300) p5 0.01 have statistical significant impact on
survival in univariate analysis and on multivariate analysis (P5 0.05). Other
factors like ki 67 index, metastatic disease, thrombocytosis and NLR have an
impact on survival statistical significant on multivariate analysis.
Conclusion: This study demonstrates the prognostic role of different variables like
Ki 67 index, PLR and PLT value, thrombocytosis and metastasis. This factors
may be integrated in different scoring systems for prognosis that could guide
clinicians for a better management in patients with neuroendocrine tumors.
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Introduction: Neuroendocrine pancreatic tumors represent the second prevalent
entity of malignant tumours of the pancreas and show an overall mortality of
about 60%. At the moment surgical resection is the only option of potentially
curative therapy, as with the currently available chemo- and radiotherapeutic
approaches an inhibition of tumor growth but no regression of the tumor can
be achieved. Therefore for about 80% of pNET patients no curative therapy can
be offered. To obtain the identification of novel potential target genes for the
development of new therapeutic strategies, primary tissues from pNET patients
were analyzed. Amongst others Plac8 (Placenta-specific 8) was identified, which
is a small protein of unknown function, showing different forms of cellular
localisation depending on the cell type analyzed, indicating at its ability to fulfill
a variety of physiological functions.
Aims & Methods: In the course of this study, the function of Plac8 in neuroendo-
crine pancreatic tumors is to be unveiled to evaluate its value as a potential target
for pNET therapy. Therefore primary tumor tissue of about 100 pNET patients
were analyzed for Plac8 expression by quantitative realtime PCR and immuno-
histochemistry. Furthermore established pNET cell lines from human origin
where transfected with siRNAs against Plac8 and there proliferative activity
and viability where analyzed by BrdU and MTT assay. Changes in these impor-
tant characteristics of tumor cells were further examined by westernblot analyzes
of key regulators of apoptosis and cell growth.
Results: Plac8 is highly expressed in primary human pNET tissues on RNA- as
well as on protein level. Functional in vitro analyses show that the siRNA-
mediated knockdown of Plac8 not only in human but also in rat cell lines
leads to significantly reduced proliferative activity and reduced cell growth.
These effects come along with indicative changes in the expression of central
regulators of cell cycle while apoptotic pathways seem not to be affected.
Conclusion: Overexpression of Plac8 in neuroendocrine tumors of the pancreas
promotes the proliferative phenotype of the tumor cells while the inhibition of
Plac8 inhibits cell growth and metabolism. Therefore in the future Plac8 could
represent a very interesting target molecule for the treatment of pNETs.
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Introduction: Since the majority of laryngopharyngeal carcinomas are detected at
an advanced stage, most cases are treated with concurrent chemotherapy and
radiation therapy. The key to improving the prognosis and quality of life is early
detection of the primary cancer and treatment using minimally invasive surgery.
We previously reported the good oncologic outcomes with ELPS (Endoscopic
laryngo-pharyngeal surgery) for superficial laryngo-pharyngeal carcinoma.
However there is no clinical evidence for an additional treatment nor prognosis
about the cases conducted endoscopic resection which were diagnosed to be
surficial carcinoma with lympho-vascular invasion histopathologically.
Aims & Methods: This study aimed to investigate the optimal additional treat-
ment and clinical course for the surficial laryngo-pharyngeal carcinoma with
lympho-vascular invasion. We analyzed clinicopathological data in 9 patients
showed Lympho-vascular invasion receiving ELPS between 2007 and 2014.
Results: Positive lympho-vascular invasion was found in 9 cases. Detected the
tumor depth was SEP in 7 lesions and MP in 2 lesions. Mean alcohol consump-
tion is 9.9 abv units. Average smoking history is 38.9 pack years. 5 cases are low-
activity ALDH2 heterozygotes and have alcohol flushing reaction.
Histopathological findings showed 5 cases with lymphatic invasion (ly1, v0), 2
cases with vascular invasion(ly0, v1), and 2cases with lympho-vascular inva-
sion.(ly1, v1). Two patients underwent an additional chemoradiotherapy without
recurrence. Four patients had cervical lymph node or local recurrence, two of
them were salvage ELPS cases after chemoradiotherapy. One of two salvage
cases also had distant metastasis and was given palliative treatment, and finally
died. The other one underwent surgical salvage and remained alive. One case
with lymphatic and vascular invasion had no adjuvant therapy and remained no
recurrence. And the other 2 cases had no recurrence but died of other cause.
Conclusion: Lympho-vascular invasion is a risk factor for cervical lymph node
metastasis, which has a possibility to a very aggressive disease. In those cases,
chemoradiotherapy as an additional treatment is recommended as far as
possilble.If patients already had prior radiotherapy, close follow-up is essential
to detect recurrence early. In those cases, chemotherapy or additional surgical
resection are also considerable if the general conditions are satisfactory.
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Introduction: The positive lateral margin after endoscopic resection(ER) of early
gastric cancer(EGC), additional surgery or endoscopic submucosal
dissection(ESD) are recommended. However, the additional surgery often diffi-
cult due to advanced age or patient’s comorbid conditions.
Aims & Methods: The aims of this study is to investigate of appropriate manage-
ment in patients with positive lateral margin after ER. We analyzed
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retrospectively 103 patients with positive lateral margin after ER from January
2005 to December 2015, in single tertiary center. Clinicopathological data were
retrieved to assess the local recurrence rate, survival rate, procedure related
adverse events.
Results: Of the 103 patients, 27 patients (26.4%) underwent early re-treatment
within 3months after initial ER(17 patients in re-do ESD, 10 patients in addi-
tional surgery). And 76 patients (73.6%) were observed under close surveillance.
Median duration of follow-up period was 45.7(6–132) months. Recurrence rates
of early re-treatment group(3.7%, n¼ 1/27) was lower than surveillance
group(18.4%, n¼ 14/76; p¼ 0.05). five-year survival rates not significantly dif-
ferent between the two groups, at 100%, 97.4% respectively. In close surveillance
periods, 12 patients were confirmed to local recurrence by follow-up biopsy, then
delayed re-treatment was performed (7 patients in re-do ESD, 5 patients in
surgery, mean time after initial ER¼ 27.5months). Finally, a total of 24 patients
were treated with re-ESD, and 17 patients were treated with additional surgery.
Among these two groups, there were no significant difference in recurrence rates
(8.3% vs. 0%) and five-year survival rates (both 100%). However, adverse events
that related to treatment was more frequent in additional surgical group (2 ileus,
1 umbilical hernia).
Conclusion: The additional treatment should be recommended for patients with
positive lateral margin after initial ER for EGCs. In addition, re-ESD which have
a similar efficacy and a better quality of life, compared to additional surgery is a
favorable option for control of recurrence or residual EGCs.
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Introduction: Bleeding control is one of the most important factors to success
endoscopic submucosal dissection (ESD) in safety. We have reported the endo-
scopic precoagulation technique using soft coagulation mode (S method) is effec-
tive1. This method is useful for the prevention of bleeding when relatively large
vessels penetrating between muscle layers are dissected. However we have
thought that S method is insufficient especially for large vessels such as more
than 2mm, we have to use hemostatic forceps for preventing hemorrhage despite
trying S method. However we found that forced coagulation mode with low high-
frequency power setting (F1-10 method) can exhibit precoagulation function
without bursting vessels. It is suggested that F1-10 method is useful for large
vessel precoagulation.
Aims & Methods: We investigated the deference of hemostatic ability between S
method and F1-10 method in clinical study and ex vivo study. In clinical study we
analyzed retrospectively their hemostatic ability about consecutive six gastric
ESD cases in each groups excluded some cases, which have the risk of affecting
data for example taking anticoagulation drugs. The diameter of treated vessels,
frequency and duration of the compressed vessel, and bleeding frequency after
cutting vessels were noted by the recorded videos. In ex vivo study, to investigate
the coagulation mechanism of those two different power settings was evaluated
the peak voltage, current elapsed time, and electric energy by using the data
recording program (VIO DOKU) and the width and depth of coagulation was
measured on macro- and microscopic levels using porcine tissues.
Results: In clinical study, the total number of vessels processed by endoknife
precoagulation were 49 and 61 vessels in the S and F1-10 methods. The
median vessel diameter was 2mm in the S method and 1.5mm in the F1-10
method. The median frequency of the compressed vessel was twice in both meth-
ods, and the median coagulation time was 9 s and 10 s in the S and F1-10 meth-
ods, respectively. No significant difference was found between the S and F1-10
methods. The bleeding rate after vessel processing was 18.4% (8/49) and 4.8% (3/
62) in the S and F1-10 methods, respectively (P¼ 0.058, odds ratio [OR]: 3.84,
95% confidence interval [CI]: 0.96–15.34). No statistically significant differences
were found; however, the F1-10 method strongly showed a trend in preventing
bleeding after precoagulation compared with the S method (P¼ 0.058). We
further investigated the bleeding rates of the large vessels, defined as 2mm in
diameter. There were 26 and 29 large vessels in the S and F1-10 methods, respec-
tively. The bleeding rates of the large vessels were 26.9% (7/26) and 3.4% (1/29)
in the S and F1-10 methods, respectively, which were significantly different
(P¼ 0.021, OR: 10.32, 95% CI: 1.17–90.78). In ex vivo study, the median peak
voltage was 172 Vp and 560 Vp in the S and F1-10 methods. The median current
elapsed time was 0.22 s and 1.54 s in the S and F1-10 methods. The F1-10 method
could keep the electric current longer than the S method. The mean total elec-
trical energy was 6.34 W and 12.5 W in the S and F1-10 methods. F1-10 method
was able to achieve to give larger electrical energy in the poutine block. And the
width and depth of coagulation in F1-10 method spread wider and deeper in
macro- and microscopic sections.
Conclusion: F1-10 method is suggested to achieve a stronger hemostatic effect
than the S method in clinical procedures and ex vivo models.
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Introduction: Although certification in diagnostic gastroscopy has been estab-
lished in the UK, there is no formal process for quality assurance (QA) in
endotherapy for upper gastrointestinal bleeding (UGIB). Training opportunities
are variable, with 11% of final year UK gastroenterology trainees citing inade-
quate exposure,[1] despite an expectation to independently manage UGIB upon
achieving specialist status. Data on endotherapy exposure during endoscopy
training is limited. We aimed to assess whether trainees are receiving adequate
exposure to endotherapy at the time of gastroscopy certification.
Aims & Methods: Trainees awarded certification in gastroscopy between
September 2009–2016 were identified from the national trainee electronic port-
folio (JETS). Trainee inputs and formative assessments (direct observation of
procedural skills - DOPS) for UGIB therapy, up to their certification date,
were analysed. Only trainees with 4200 procedures were included, which is the
minimum procedural number to allow certification within the UK, thereby
excluding those who had submitted baseline information which may have con-
tained therapeutic data. Exposure rates from medical endoscopists (physician
and surgical trainees) were compared with non-medical endoscopists (NME).
Results: 885 trainee portfolios were analysed (765 medical and 120 NMEs), with
a median procedural count of 276 (IQR 124). The median number of therapeutic
entries and DOPS were 4 (IQR 11), and 1 (IQR 3) respectively. Overall rates for
endotherapy and DOPS were 2.9% and 0.8% per procedure. When stratified by
therapy, the median exposure to each therapy was either 0 or 1, with means
displayed in Table 1. 25.2% of trainees had no exposure to any type of endother-
apy (67.5% of NME and 18.6% of medical endoscopists, p5 0.0001). Of medical
endoscopists awarded certification, 37.1% had not performed band ligation,
50.7% had not placed a clip, and 54% had not used heater probe. NME had
significantly less exposure to each modality of endotherapy considered (overall
odds ratio 0.10, p5 0.0001).
Table 1: Mean procedural counts at the point of UGI certification.
Total
UGIB
Therapy DOPS Argon Banding Clip
Heater
Probe Injection
Medical 346 10.7 2.6 2.1 4.4 1.6 1.6 4.0
Non-medical 323 1.1 0.29 0.3 0.4 0.1 0.1 0.3
p-value 0.143 50.0001
Conclusion: Training on endotherapy prior to certification is limited. The current
UGI certification process does not ensure competency in endotherapy for UGIB.
In response, the JAG QA team have recently released new DOPS forms specific
to UGIB, and are consulting on introducing formal certification in endotherapy
for UGIB.
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Introduction: Barrett’s esophagus (BE) is a known premalignant condition with
risk for progression to esophageal adenocarcinoma. Electronic chromoendo-
scopy with magnification (ECM) is an evolving imaging technology being inves-
tigated as a novel imaging tool to identify dysplasia in BE to assist with higher
yield BE surveillance and improve the diagnostic yield of esophageal biospies for
BE.
Aims & Methods: This is a single-center study to evaluate the efficacy of ECM
(iScan by Pentax) in the detection of BE and dysplasic BE in a screening, average
risk population with BE in Northeast Mexico. We conducted a retrospective
study of 100 consecutive patients (41 males) with known BE (confirmed by
pathology) during surveillance upper endoscopy for dysplasic BE between
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March and September of 2016. All patients underwent EC with iScan. The
esophagus was inspected with a ECM capable endoscope (EG- 2990-Zi) and
deliberate biopsies were taken from tissue identified by ECM that suggested
BE. All biopsies were confirmed by a GI pathologist. Primary endpoint was
the correlation between visual inspection diagnosis of dysplasic BE by ECM
versus pathologic diagnosis of BE as the gold standard.
Table 1: Patient characteristics and outcomes
Characteristics 100
Age (mean) 47.7
Male 41/100
Endoscopic diagnosis: nondysplastic BE 96/100
Endoscopic diagnosis: BE with LGD 4/100
Pathologic diagnosis: nondysplastic BE 94/100
Pathologic diagnosis: BE with LGD 4/100
Pathologic diagnosis: benign gastric mucosa 1/100
Pathologic diagnosis: esophageal ulcer 1/100
Accuracy 98%
Sensitivity 100% [95% CI (96%–100%)]
Specificity 0% [95% CI (0%–84%)]
Positive predictive value 98% [95% CI (93%–99.7%)]
Negative predictive value NA
Results: In our cohort 41% were male, with mean age of 47.7 years. Endoscopic
diagnoses by ECM were divided into nondysplastic BE (96/100) and suspected
dysplastic BE (4/100). On pathology nondysplastic BE was found in 94/100
patients, BE with low-grade dysplasia was found in 4/100 patients. Benign gastric
mucosa with no alterations (1/100), and ulcerated esophagitis (1/100). The overall
accuracy of endoscopic diagnoses using ECM against pathology diagnosis was of
98%, with sensitivity of 100% [95% CI (96%–100%)], and positive predictive
value of 98% [95% CI (93%–99.7%)].
Conclusion: Endoscopic diagnosis of BE by directed biopsies of esophageal tissue
with use of ECM is highly accurate. Future prospective studies are needed to
validate our preliminary findings and assess inter-observer variability.
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Introduction: Barrett’s oesophagus (BO) is the main risk factor for oesophageal
adenocarcinoma (OAC). International guidelines recommend endoscopic surveil-
lance for early detection of dysplasia (DYS) and/or OAC but current biopsy
protocols can miss areas of endoscopically unapparent neoplasia. At present,
advanced diagnostic imaging technologies and specific endoscopist and pathol-
ogist expertise in detecting the subtle phenotypic changes associated with DYS/
OAC are available only in tertiary care referral centres.
Aims & Methods: The aim of this study is to investigate the diagnosis changes
after BO assessment in a tertiary care referral centre. 119 consecutive patients
[male¼ 103, female¼ 16; median age¼ 58 (50;64)] referred to the Veneto
Institute of Oncology (IOV-IRCCS) BO Unit between 01/03/2015 and 01/03/
2017 were considered. Patients were divided in 3 groups according to the admit-
ting diagnosis (AD): BO patients without DYS/OAC or visible lesions (Group 1,
n¼ 82); BO patients with DYS/OAC but no visible lesions (Group 2, n¼ 33); BO
patients with DYS/OAC and visible lesions (Group 3, n¼ 4). All patients under-
went an endoscopy under deep sedation at IOV with HD magnification
endoscopesþNBIþ acetic acid chromoendoscopy. Target biopsies and/or
EMR were obtained in case of endoscopically visible lesions; 4-quadratic biop-
sies/2 cm were obtained otherwise. All the specimens were diagnosed by two
expert GI pathologists, who reached a final diagnosis (FD). In Group 2 patients
where FD was BO without DYS/OAC, previous histology was reviewed by two
expert pathologist.
Results: Results are summarized in Table 1. Group 1 (n¼ 82): FD of DYS/OAC
with visible lesion was reached in 2 out of 82 patients (2.4%), both treated by
EMRþRFA. No one had a FD of DYS/OAC without visible lesions. Group 2
(n¼ 33): FD of DYS/OAC with visible lesions was revealed in 13 out of 33
patients (39,4%): 11 were treated by EMRþRFA, 1 by surgery and 1 chemio/
radiotherapy. In 20 patients the AD was downgraded to uncomplicated BO: in 19
patients (57,6%), a review of previously taken biopsies by expert pathologist
excluded neoplasia. In only one patient no lesion was found but the review of
original histology slides confirmed a low-grade DYS and the patient was treated
by RFA. Group 3 (n¼ 4): DYS/OAC was confirmed in all the 4 patients (2
treated by EMRþRFA, and 2 by surgery).
Conclusion: When upper endoscopy is performed in a BO reference center where
specific facilities and expertises are available (i.e. deep sedation, HD magnifica-
tion endoscopes, chromoendoscopy, expert endoscopist and pathologist) ‘‘invi-
sible’’ DYS is a very rare diagnosis.
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Introduction: Endoscopic full-thickness resection (EFTR) for sub-epithelial
lesions (SETs) of GI tract is less frequently described; possibly due to technical
challenges involved in dissection and need for resultant defect closure. Current
study describes single-center experience of EFTR for treatment of SETs.
Aims & Methods: Prospective database of patients undergoing EFTR for SETs
over 6-years (2011–2017) was abstracted.Patient selection for EFTR–endoscopy,
endoscopic ultrasound (EUS) and CECT. Inclusion criteria - encapsulated
lesions, predominantly endophytic component and absence of features of inva-
sive malignancy. Exclusion criteria–patients unfit for general anesthesia or major
invasive procedure, uncorrectable coagulopathy or high risk features for malig-
nancy. All procedures performed under general anesthesia with endotracheal
intubation. High-definition endoscope (GIF-HQ-190 or CIF-HQ-190, Olympus
Corp., Japan) with distal transparent hood and carbon dioxide insufflation used
in all. After submucosal (SM) elevation by Gelofuscin, mucosal incision and SM
dissection performed to expose SET. Encapsulated SET enucleated maintaining
intact capsule. Adherent and attached muscularis propria (MP) layer fibers
divided. IT or Dual-knifeTM used for dissection and coag-grasper for hemostasis.
Resultant MP layer defect closed endoscopically.
Results: Total N¼ 18(M:F–11:7), mean age-53.6(Range-28–78). Presentation–GI
bleed–7(38%), abdominal pain–4(22%), non ulcer dyspepsia–1, rectal mass–1
and asymptomatic, incidentally diagnosed–6(33%). Layer of origin–MP layer
in all. Location–stomach–13(72%), duodenum–2, rectum–2, proximal jejunum–
1. Mean size of SET–3.3 cm (range 1–7). Mean procedure time–182 mins (60–
345), and mean hospital stay was 4 days. Adverse events–two (11%)–esophageal
laceration during specimen retrieval–1 (closed using endoclips), failure–1 (due to
undetected large exophytic component–surgical resection). Histopathology with
Abstract: P1453
Final Diagnosis (FD)
BO without
DYS/OAC
BO with
DYS/OAC but
no visible lesions
BO with
DYS/OAC and
visible lesions
Admitting Diagnosis (AD) Group 1 BO without DYS/OAC (n¼ 82) 80 0 2
Group 2 BO with DYS/OAC but no visible lesions (n¼ 33) 19 1 13
Group 3 BO with DYS/OAC and visible lesions (n¼ 4) 0 0 4
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IHC–GIST–9(50%),neuroendocrine tumor–3(16%), leiomyoma–1, schwan-
noma–1, neuroma–1, duplication cyst–1, parietal cell hyperplasia–1. Closure –
16/18 (2 defects in distal extra peritoneal rectum left open intentionally for heal-
ing by secondary intention); techniques–through-the-scope (TTS) clips–7, over-
the-scope clip–4, omental patchþ clip–2 (TTS– 1, OTS– 1), endoscopic suturing–
1, endoloopþ clip–1. Mortality–nil. Follow up endoscopy at 4 weeks showed
healing in all 17 patients. Median follow up –2 months.
Conclusion: EFTR is safe and effective for resection of SETs. Pre EFTR EUS and
CECT may be useful to select appropriate candidates. Secure closure of defect is
necessary for intraperitoneal full-thickness defects. Further studies comparing
EFTR and surgery are recommended
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Introduction: In the natural history of chronic liver disease, variceal bleeding
represents a life-threatening complication of portal hypertension, with high risk
of mortality and recurrence. Current guidelines define vasoconstrictive therapy
or endoscopic variceal ligation (EVL) in primary prophylaxis and the combina-
tion of both in secondary prophylaxis.
Aims & Methods:: We aimed to evaluate the efficacy of EVL therapy in both
primary and secondary prophylaxis of variceal bleeding in cirrhosis and to estab-
lish the patient’s clinical outcome. This was a retrospective observational cohort
study of a total of 444 EVL procedures performed in 250 cirrhotic patients, who
were admitted in a gastroenterology department of a tertiary centre, between
2004–2016, to receive EVL as prophylaxis of variceal bleeding. Sessions of liga-
tion were repeated every two to three weeks in order to reach variceal eradica-
tion. The clinical outcome included the recurrence of bleeding (primary
endpoint), the eradication success rate of oesophageal varices, EVL-related com-
plications and overall and bleeding-related mortality.
Results: The mean follow-up period for all 250 cirrhotic patients enrolled in
the study was 73.2 41.0months, with mean age of 63.9 10.8years and a
predominance of male gender (80.4%;n¼ 201). At initial endoscopy, 237
(53.4%) had portal hypertensive gastropathy, being severe in 168 (37.8%%).
EVL was performed as primary prophylaxis in 50.9%(n¼ 226) and secondary
prophylaxis in 49.1%(n¼ 218). Varices were obliterated in 209 (83.6%)
patients with mean number of EVL procedures necessary to eradicate varices
of 1.8 0.95 and a maximum of procedures of 6. Recurrent bleeding occurred
in 11.2%(n¼ 28) of cases with a mean time to re-bleeding occurrence of
8.1 14.2months. Major and significant complications were verified in
8.1%(n¼ 36) of patients. The main complications were bleeding related to
post-banding ulceration (75.0%;n¼ 27) and infection (22.2%;n¼ 8), with
mean time between EVL and complication occurrence of 11.1 11.8days
(minimum:0;maximum:43). Intra-procedure complications occurred in
11(2.5%) patients with no death, despite of two cases of Sengstaken-
Blakemore balloon necessity. The overall mortality was 5.4%(n¼ 24), being
0.4%(n¼ 2) related to variceal bleeding.
Conclusion: EVL seems to be an efficient, safe and relatively simple therapeu-
tic procedure in both primary and secondary prophylaxis of variceal bleeding
in cirrhotic patients. Since the main complications occurs over 1 week after
EVL procedure, the majority of patients can be safety treated in an ambu-
latory setting.
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Introduction: Given diminishment of quality of life caused by surgery in the
stomach and duodenum, a minimally invasive treatment is desirable for gastric
and duodenum submucosal tumors (SMTs).
Aims & Methods: We aimed to assess the value of endoscopic full-thickness
resection (EFTR) technique for gastric and duodenal submucosal tumors
(SMTs) originating from the muscular propria (MP) layer. A total of 276 patients
with single gastric SMTs originating from the MP layer were performed EFTR
between January, 2010 and February, 2014. The tight adhesion of the tumor to
gastric or duodenal serosal layer could be seen in every case from endoscopic
ultrasound (EUS) before the procedure. The SMTs orientated endoscopically
were performed EFTR using a standard ESD technique without laparascopic
assistance under direct endoscopic view. The defect of gastric and duodenal wall
was closed after resection.
Results: A total of 276 patients included 94 males and 182 females. Their median
age was 57.8 years (range, 30–81 years). Among all the 276 SMTs in our study,
165 located in gastric fundus, 96 located in gastric body, 8 located in the antrum,
1 located in the angle of stomach, and 6 located in duodenum. The median lesion
size was 1.7 cm (range 0.7–6.0 cm). The success rate of EFTR was 98.9% (273/
276). EFTR was failed in 3 cases: one case was out of control because of bleeding
into enterocoelia, two cases required conversion into laparoscopic surgery
because of giant lobulations of the tumor outside the cavity. The median opera-
tion time was 65min (range, 14–210min). En bloc resection rate was 98.1% (268/
273), piecemeal resection rate was 1.9% (5/273). The median length of hospital
stays was 4.4 days (range, 1–23 days). Pathological outcomes revealed that the
lesions included 137 (49.7%) gastrointestinal stromal tumors (GISTs), 103
(37.3%) leiomyomas, 13 (4.7%) schwannomas, 8 (2.9%) calcifying fibrous
tumors, 7 (2.5%) glomus tumors, 5 (1.8%) displaced pancreas, and 3 (1.1%)
fibroblastomas. The procedure-related complications were as follows. Different
degrees of epigastric pain occurred in 168 (60.9%) cases, among which 24 (8.7%)
cases required analgesics. Pneumoperitoneum occurred in all the patients and
was treated successfully with peritoneocentesis decompression. Seroperitoneum
occurred in 15 (5.4%) cases. localized peritonitis occurred in 3 (1.1%) cases, and
digestive tract leakage occurred in 1 (0.4%) case. All the cases with above com-
plications recovered spontaneously or after conservative treatments. No massive
bleeding or adominal abscess was found after EFTR. None of the 273 cases
developed procedure-related death. No tumor residual or recurrence was found
during the follow-up period ranging 3–55 months.
Conclusion: EFTR without laparoscopic assistance is minimally invasive, safe,
and effective for treating gastric and duodenal SMTs, which originate from the
MP layer and adhere tightly to the serosa. High en bloc resection rate could be
achieved. However, a larger number of the cases and long-term outcome deserve
further research.
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Introduction: Current standard in the characterization of gastric mucosal changes
is the use of virtual chromoendoscopy with magnification to visualize the pit
pattern and vascular changes. The most recent development in light emitting
technology is the so called Multi Light Illumination, that composes light out
of 4 coloured LED. Blue Light Imaging (BLI) is composed of a continuous
spectrum with peaks at 410 and 450 nm to enhance surface and vascular struc-
tures. Linked Color Imaging (LCI) uses BLI light together with post processing
that reallocates colour tones resulting in a high contrast of different red tones.
Until now only few data exist about the use of BLI and LCI in chronic gastritis
(CG).
Aims & Methods: We aimed to analyse the use of LCI and BLI in detecting and
characterization of chronic gastritis and premalignant conditions of the stomach.
24 consecutive patients were investigated. All patients were investigated under
conscious sedation. In all cases an endoscope equipped with zoom (Fujifilm EG-
760Z) was used. Endoscopic classification was based on the following para-
meters: normal gastric mucosa was defined as mucosa with visible superficial
capillary network (SCN) without any focal lesions; atrophy (AG) was defined
by whitening of the mucosa with visible deeper vascular architecture in white
light, BLI and LCI; intestinal metaplasia (IM) was diagnosed if mucosa had
villous or ridged surface with whitening in LCI or white light or light blue
crest sign in BLI; CG was diagnosed in case of loss of SCN or focal lesions
not matching the definition of other focal lesions or cancer. Biopsies were
sampled according to the updated Sidney classification system and in addition
of every visible focal lesion. After endoscopy a prediction of histology was made
by the endoscopist.
Results: We investigated 24 patients (15 female, 9 male, age 65 yrs (25–87yrs)).
H. pylori was detected by histology or urease test in 7 patients. 3 patients showed
normal gastric mucosa, 13 patients presented IM or AG either in the antrum or
the corpus. According to MAPS criteria 7 patients had extensive disease with
premalignant conditions in both, antrum and corpus. The concordance of endo-
scopic classification and histology was 79.1% (19/24) in the antrum and corpus
each. Despite the inconcordance of histology and endoscopic diagnosis in 5 cases
the intervals for surveillance according to MAPS guidelines would have been
correctly respected with the use of endoscopic assessment in all cases.
Conclusion: LCI and BLI are accurate in detection and characterization of
changes in gastric mucosa with an acceptable concordance to histology. These
new imaging modalities are a step towards precise endoscopic diagnosis of gastric
mucosal changes and have the potential to reduce the number of unnecessary
histologic investigations and offer the possibility for more appropriate endo-
scopic diagnosis.
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Introduction: According to the Japanese Esophageal Society Guidelines, Early
Esophageal Squamous Cell Carcinoma (EESCC) involving the muscularis
mucosa or 5200 mm invasion of the submucosa, and circumferential extent of
42/3 were relative indications (RI) for ESD. Additional treatment (AT, includ-
ing esophagectomy or chemoradiotherapy) may be needed after ESD. But in
aged RI patients, most will refuse AT due to higher rates of debilitating symptom
in China.
Aims & Methods: The aim of this study was conducted to evaluate the long-term
outcomes of aged RI patients without AT after ESD.
Between January 2008 and December 2013, a total of 158 aged EESCC patients
were included in the present retrospective study. Prognosis outcomes were
analyzed.
Results: 89 patients included in absolute indication (AI) group and 69 in RI
group. The baseline characteristics were balanced between two groups. During
the follow-up time (median 56 (1–108) months), short-term adverse events (4.3%
vs 1.1%, p¼ 0.319) and postoperative stricture rate (31.8% vs 21.3%, p¼ 0.134)
were higher in RI group than in AI group. 5-year recurrence-free survival rate
(85.8% vs. 87.2%, p¼ 0.561), metastasis-free survival rate (100% vs. 98.6%,
p¼ 0.437), overall survival rate(96.6% vs 90.0%, p¼ 0.613) and cause-specific
survival rate(98.9% vs 98.5%, p¼ 0.264) for AI group and RI group were
comparable.
Conclusion: Aged RI EESCC patients without AT(esophagectomy or chemora-
diotherapy) showed comparable prognosis outcomes with AI group after ESD.
So follow up may be recommended, substituted for AT in aged RI group.
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Introduction: Suspicion of foreign body (FB) and food impaction (FI) are one of
the most common motives for endoscopic emergency. This retrospective study
reviewed 288 cases of suspicion on FB/FI, by the frequency of endoscopic altera-
tions, predictive factors to presence, types of FB found, and therapeutic
approach.
Aims & Methods: Unicentric retrospective cohort study of endoscopies pre-
formed during one year of gastroenterology emergency setting.
Results: In 2015, 288 endoscopies were performed on suspicion of FB/FI (22% of
total emergency endoscopies, n¼ 1309), of them 69.1%(N¼ 199) were performed
during the night. Patients’ median age was 58 years, and 52.8% were women. The
presence of FB/FI was confirmed in 71.2%(n¼ 205); of them 61,5%(n¼ 126)
were FI. The most frequently found foreign bodies were meat bones
18%(n¼ 37) and fish bones 14.6%(n¼ 30). Most FB/FI were found on the prox-
imal esophagus (56.1%, n¼ 115). Endoscopic removal was performed on 129
cases (63.4%), endoscopic mobilization in 54 (26.3%), and in 22 endoscopic
removal wasn’t achieved (10, where referred of otolaryngology; 2 for surgery
and 10 were deferred to endoscopy with sedation, in operating room).
Endoscopy under sedation was performed in 20 cases (9,7%). About ¼ had
associated comorbidities, the most common were esophageal ring in 22
(10.7%) and benign stenosis in 17(8.3%) patients. Major complications were
rare: 1 perforation (0.3%) and 3 deep esophageal lacerations (1.5%). Age
(455years), presence of comorbidities, and previous episodes were associated
with presence of FB/FI on Endoscopy (Odds Ratio 2.01, 3.39 and 4.63
respectively).
Conclusion: Endoscopy is frequently preformed for suspicion of FB/FI in our
emergency setting. Presence is confirmed in the majority of the cases. Predictive
factors for presence were identified. Most FB/FI were removed with success with
low complication rates. This data favor the endoscopic approach on suspicion of
FB/FI.
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Introduction: Endoscopic submucosal dissection (ESD) has become a standard
therapy for early gastric neoplasia. There is no consensus yet about the number
of experiences required for performing ESD alone.
Aims & Methods: We aimed to investigate the learning curve of ESD performed
by a single beginner endoscopist focusing on developing the performance of
dissection, shortening the procedure time, and preventing complications.
Methods: Records of 120 consecutive ESD procedures performed by a single
beginner endoscopist with an ESD knife from March 2012 to Feburary 2016
were collected. For analysis of the learning curve, total procedures were divided
into four periods, each comprising 30 sequential ESD. The parameters assessed
were the en-bloc resection rate, complete resection rate, procedure time, and
related complications.
Results: In the procedure time according to the number of experiences, the pro-
cedure time decreased from 30 experience. However, there was no statistical
difference from the first (63.5 54.0) to the second quarter (44.5 31.4,
p¼ 0.19), to the third quarter (40.7 27.8, p¼ 0.08), and to the fourth quarter
(40.8 23.1, p¼ 0.09). There was no procedure that exceeded 100 minutes from
the third quarter. There were a total of seven perforations, four of which were in
the first quarter, two in the second, and one in the third. In the procedure time
according to the location of the lesions, upper third lesion (92.0 43.7) showed
longer procedure time than middle (46.6 40.2, p5 0.01) and lower third
(39.5 27.5, p5 0.01) with statistically significant difference. In addition, in
the fibrotic lesions, regardless of size and location, all took a very long time,
more than 100 minutes.
Conclusion: It needs accumulate experience with the help of a professional expert
up to 30 cases, and to the more advanced level, about 90 procedures are needed.
And, the location of the lesion is the important factor in determining the diffi-
culty of the procedure. Therefore, it is best to avoid the upper third lesion as far
as possible until experience 90 cases or at least 30 procedures.
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Introduction: Endoscopic resection for gastric subepithelialtumors(SETs) origi-
nated from the muscularispropria (GSET-PM) has offered less invasive alterna-
tives to surgical resection. The aims of this study were to compare endoscopic
subtumoraldissection(ESD) with surgical resection for the removal of GSET-
PM.
Aims & Methods: This study involved 17 patients with GSET-PM removed by
ESD and 76 patients who underwent curative surgical resection. ESD was
attempted in GSET-PM with well marginated tumors which was below 5 cm
and showed an endoluminal growth pattern according to endoscopic
ultrasound(EUS) finding.
Results: ESD group were more likely to have upper portion (10/17, 58.8%) and
surgery group were more likely to have mid portion (41/76, 53.8%) (p¼ 0.039).
ESD group were smaller median tumor size (25.6mm vs 35.9mm, p¼ 0.037) and
higher endoluminal ratio (58.5 9.1% vs 45.8 15.4%, p¼ 0.002). ESD group
were mostly to have Yamada type III (10/17, 58.8%) and surgery group were
mostly Yamada type I (52/76, 68.4%) (p5 0.001). Complete resection by ESD
was lower than by surgical resection (82.4% vs 100%, p5 0.001). In ESD group,
3 performed surgical resection after ESD (1 incompletely resection and 2 uncon-
trolled bleeding) and 1 showed perforation was completely resected with endo-
scopic closure. In surgery group, complications occurred in 6 patients (1 leakage,
1 stricture, 1 hernia and bowel obstruction, 1 wound infection and 2 worsened
general condition after surgery). Although surgery group were lower in compli-
cation rate than ESD group (p¼ 0.006), severity of complications were higher in
the surgery group and there were no mortalities in the ESD group compared with
2 in the surgery group. There was no statistical difference of recurrence and the
follow-up period between two groups.
Conclusion: Conclusion: ESD can be one of good options for the resection of
endoluminal GSET-PM and could be replace treatment by surgical resection in
Yamada type III with a high endoluminal ratio.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Examination of major duodenal papilla (MDP) by standard for-
ward-viewing is limited and the use of side-viewing endoscope (SVE) is manda-
tory. Cap assisted esophagogastroduodenoscopy (CA-EGD) utilizes a cap fitted
to the tip of the endoscope that can depress the mucosal folds and thus might
improve visualization of MDP. The aim of this study was to compare CA-EGD
to SVE for complete examination of the MDP.
Aims & Methods: Prospective, randomized, blinded, controlled, non-inferiority
crossover study. Subjects scheduled for elective EGD were randomized to
undergo CA-EGD (group A) or SVE (group B) before undergoing a second
examination by the alternate method. Images of the MDP were evaluated,
after image processing, by three blinded multicenter-experts. Our primary out-
come measure was complete examination of the papilla. Secondary outcome
measures were image quality of mucosal pattern, ability to obtain an overview
of the papilla and overall satisfaction of the evaluators. For secondary outcomes,
a score was given from 1 to 10 1¼poor, 10¼ excellent).
Results: A total of 62 patients were randomized and completed the study.
Complete examination of MDP was achieved in 59 patients using CA-EGD
compared to 60 patients using SVE (95 vs. 97%, p¼ 1.0). CA-EGD had mean
scores of 8.7 1.3, 7.1 0.86 and 7.9 1 regarding mucosal pattern, overview
and overall satisfaction, respectively, versus 5.3 1.6 (p5 0.001), 8.3 0.9
(p5 0.001) and 7.6 0.6 with SVE (p¼ 0.01).
Conclusion: CA-EGD is non-inferior to SVE for complete examination of MDP.
CA-EGD had significantly higher scores than SVE regarding the image quality
and overall satisfaction, while SVE had a better overview. CA-EGD is a safe and
effective method for examination of MDP and can replace the SVE for diagnostic
indications.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Hereditary diffuse gastric cancer (HDGC) accounts for 1 to 3% of
all gastric cancer and it can be caused by a germline mutation of the gene CDH1.
Life time risk for gastric cancer is 80% with a mean age at diagnosis of 40 years.
Affected individuals generally present multiple foci of signet ring cell carcinoma
(SRCC) scattered throughout the gastric mucosa, difficulty detected by
endoscopy.
Aims & Methods: The aim of this study was to access the validity of Cambridge
protocol with a high-resolution endoscope in patients with proven pathological
germline mutation of the gene CDH1. A prospective cohort study was performed
between September 2016 and March 2017 in 11 patients with CDH1 mutation.
They perform a base line high-resolution endoscopy (Olympus-GIF-HQ190) with
random biopsies according Cambridge protocol and additional targeted biopsies
of any visible lesion. The total number of biopsies and the total number and
localization of SRCC foci was registered. For those patients submitted to pro-
phylactic gastrectomy, data was compared with surgical specimen histology. To
access the validity of Cambridge protocol with a high resolution endoscope in
patients with proven pathological germline mutation of the gene CDH1.
Results: During the 11 endoscopies a total of 353 biopsies (329 random biopsies
and 24 targeted biopsies; mean of 32.1 biopsies per patient) were performed. Two
patients presented 1 SRCC foci in random biopsies, being that one of them
presented positive histology in 2 targeted biopsies. It was necessary to perform
165 random biopsies to identify a single SRCC foci. It was necessary 12 targeted
biopsies to identify a SRCC foci associated with a visible lesion. Five patients
were submitted to total gastrectomy and every surgical specimens presented
SRCC foci.
Conclusion: Despite the use of high-resolution endoscopes and the high number
of random biopsies, endoscopic evaluation presents many limitations for the
diagnosis of HDGC. According to literature, prophylactic total gastrectomy
remains the first option in patients carrying CDH1 mutation.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Endoscopic clips are used in a variety of clinical situations in GI
endoscopy–for arrest of bleeding or for closure of bowel perforations or chronic
fistulae. Conventional through-the-scope clips often cannot provide optimum
results; and therefore full-thickness (FT) over-the-scope (OTS) clips have been
devised.
Aims & Methods: Current study describes the clinical experience of use of a
recently developed FT OTS clip (PadlockTM, Aponos Medical, USA). Data
from a prospectively maintained database of all patients undergoing the new
FT OTS clip was abstracted. Patient demographics, primary diagnosis, history
of previous endotherapy, endoscopic procedure, indications for FT OTS clip
usage, technical and clinical success and early and delayed adverse events were
recorded. The clip–clip is available in two different sizes for use in upper and
lower endoscopy. It is supplied preloaded on a cartridge that fits on the distal end
of endoscope. The trip-wire travels alongside the endoscope, enabling additional
instruments to be passed through the endoscope channel, and special double-
channel endoscope is not required for its application. Technique of clip applica-
tion–the clip was loaded on the distal end of the endoscope and endoscope
advanced to site of interest. Bowel wall defect or bleeding point was positioned
within the clip and strong suction was applied. Clip was fired by closing the
handle on the delivery system. Suction was slowly released and site was inspected.
Results: Total 21 clips used in 19 patients. M: F–12:7, mean age–57.9 years (range
–24–84 years). Indications for FT OTS clip use–severe GI bleeding–7 (36.8%)
(duodenal ulcer bleed–5, rectal ulcer–1, bleed during ESD for rectal lateral
spreading tumor–1); for closure of bowel perforation during endoscopic resec-
tions–7 (36.8%) (gastric–3, duodenum–2, rectum–2); and closure of chronic
bowel fistulae–5 (26.3%) (esophagus–3, duodenum–1, rectum–1). Previous h/o
endotherapy–3/7 of bleeding patients, primary therapy using OTS clip in remain-
ing 16. Technical success was 100%. Two patients needed two clips each due to
large size of defect. Clinical success–bleeding arrested in 7/7 (100%), bowel per-
foration sealed–7/7 (100%); fistula closure successful–4/5 (80%). In one patient
of chronic duodenal fistula, fistula reopened 12 weeks after initial sealing of
fistula and required surgery. Follow up at 4 weeks revealed no delayed adverse
events in any patient.
Conclusion: The new OTS Clip (PadlockTM, Aponos) is safe and effective for
treatment of severe bleeding and for closure of post ER full-thickness defects and
chronic fistulae. Further studies with larger sample size are recommended.
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Introduction: Endoscopic resection of ampullary adenomas has increased in the
last decade due to the high morbidity with a high mortality in patients under-
going surgical procedures1.
Aims & Methods: This study aims to evaluate the outcome of endoscopic ampul-
lectomy (EA) in a tertiary endoscopy department. We included in the study
patients that underwent EA between January 2014 - April 2017 at the
Regional Institute of Gastroenterololgy and Hepatology Cluj-Napoca,
Romania. All patients had a benign pathological result prior to the EA. Post-
procedural complications such as bleeding, perforation, cholangitis, pancreatitis
and mortality were analyzed. Data about resection type, post EA histhology and
1 year follow-up was also proccessed.
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Results: 19 patients underwent EA, with a mean age of 63.5 17.7 years and a
mean size of the tumor of 17.4 7.8mm. The male to female ratio is 0.7. "En
bloc" resection was done in most cases 15/19 (78.9%). Bleeding occured in 6 cases
(31.6%) and two patients (10.5%) developed acute pancreatitis. One patient died
due to severe bleeding. The average days of hospitalization after endoscopic
ampullectomy were 5.7 with a range from 2 to 25 days. Adenocarcinoma was
described in the final histopathological result in 4/19 cases (21.1%). One year
follow-up noted a reccurence rate of 15.8% (3/19 cases).
Conclusion: In conclusion, endoscpic ampullectomy is a difficult procedure with
an increased risk of complications but performed by experienced endoscopists is
safe and surgical interventions can be avoided.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Per-oral endoscopic myotomy (POEM) has been adopted as a mini-
mally invasive treatment option for achalasia and even spastic oesophageal con-
ditions1. The first case of POEM was performed at the King’s Institute of
Therapeutic Endoscopy (KITE) in 2013. Here we present our initial case series
including the first UK case of diffuse oesophageal spasm (DES).
Aims & Methods: Prospective data was collected for consecutive patients under-
going POEM including demographics, POEM technique, the use of Endoluminal
Functional Lumen Imaging Probe (EndoFLIP) and adverse events. Clinical suc-
cess was defined as a reduction of Eckardt score (ES) to5/¼2 or a reduction in 4
points from baseline. Follow up data at 3 and 12–24 months (m) post-POEM was
analysed using the Wilcoxon signed ranks test to compare pre- and post-POEM
ES and 4sIRP and pre and post-treatment GORD-HRQoL score. Repeated-
measures ANOVA was used for multiple time-point comparisons.
Results: POEM was performed in 51 patients (22F, age 48.6þ/13.5 years).
Further baseline data is presented in table 1. Median gastric and oesophageal
myotomy was 3 cm (2–4) and 10 cm (3–18) respectively with a selective circular
myotomy in all cases and a posterior approach in 11. POEM was clinically
successful in n¼ 48/51 (94%) eligible for review at 3m. Reduction in ES at
3m; 8.5 (5–12) vs 0 (0–6) p5 0.0001 was sustained in 31 patients with median
follow up of 15m (3–36); 8.5 (5–12) vs 2 (0–7) ANOVA p5 0.0001. Reduction in
IRP-4 s was observed 24.05 þ/ 10.47mmHg vs 7.81 þ/ 4.91mmHg
(p¼ 0.001). Revision of POEM was performed in n¼ 3 at 6, 16 and 27m with
clinical success achieved in all cases at 3m review. Pre and post-myotomy
EndoFLIP showed an increase in oesophago-gastric junction diameter from
5.87mm to 11.27mm (p5 0.001) (n¼ 11) and distensibility improved from
1.14mm2/mmHg to 2.87 mm2/mmHg (p¼ 0.008) (n¼ 8). Median post-POEM
GORD-HRQoL score (n¼ 50) was 1 (0–31). 8 patients with scores4 12
improved with medical treatment; 15.5 (13–31) vs 6.5 (1–11, p¼ 0.0078) as did
5 cases of acid reflux identified by 24 hr pH testing in n¼ 19 at time of analysis.
Endoclip displacement was encountered in n¼ 2 and replaced endoscopically
including readmission of 1 patient for delayed mucosal incision site healing
(Clavien-Dindo Grade IIIb). There were no cases of mortality, perforation, infec-
tion/major bleeding.
Table 1: Baseline characteristics
Patient Demographics
Age (mean, SD, range) (years) 48.6 þ/ 13.5 (22–79)
Male (n) (%) 29 (57)
Female (n) (%) 22 (43)
Clinical Data
Duration of disease (mean, SD, range) (years) 4.4 þ/ 4.2 (0.25–25)
Eckardt Score (median, range) 8 (4–12)
Chicago Subcategorisation
Achalasia Type I (n) (%) 4 (8)
Achalasia Type II (n) (%) 42 (82)
Achalasia Type III (n) (%) 2 (4)
DES 1 (2)
Uncategorised (EndoFLIP used) 2 (4)
Non-Sigmoid Oesophagus (n) (%) 45 (88)
Sigmoid Oesophagus (n) (%) 6 (12)
Treatment History
Prior Achalasia Treatment 27 (53%)
Prior Botulinum Toxin Injection; BTX (n) (%) 9 (18)
Prior Pneumatic Dilatation; PD (n) (%) 13 (25)
Prior Heller Myotomy; LHM (n) (%) 9 (18)
(continued)
Table 1 Continued
Patient Demographics
Prior POEM (n) (%) 3 (6)
42 prior treatments (n) (%) 4 (8)
ASA Physical Status Classification
ASA grade I (n) (%) 21 (41)
ASA grade II (n) (%) 22 (43)
ASA grade III (n) (%) 8 (16)
Conclusion: This is the largest UK case series of POEM for achalasia including
the first successful UK POEM procedure for DES. At our institute, POEM was
performed successfully in a potentially more challenging cohort where 52.9% had
prior endoscopic/surgical treatment. Our results are in line with international
consortia and ASGE findings that POEM is a safe and efficacious procedure
for the treatment of achalasia and oesophageal spastic disorders for both short
term and sustained symptomatic benefit.
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Introduction: Endoscopic submucosal dissection (ESD) is increasingly accepted as
a minimally invasive treatment for the patients with early gastrointestinal can-
cers. However, ESD demands high maneuverability technique, and the success of
the operation is dependent of each operator’s skill. We have developed a novel
laser surgery system for ESD to overcome such difficulties of ESD, which is
composed of a CO2 laser source and a disposable flexible hollow fiber probe.
Compared to conventional ESD (C-ESD) using electric surgical knives, ESD
using CO2 laser (L-ESD) method has an advantage of less risk of perforation
and massive thermal damage, because the CO2 laser is strongly absorbed by
water such as saline or sodium hyaluronate. Farther more, the cutting point
can be precisely recognized by another visible guide laser. Due to non-contact
laser irradiation and adequate visualization of treatment area, the laser system
facilitates more precise and safer treatment and provides high quality and stable
dissection. We hypothesized that performing ESD using CO2 laser with a sub-
mucosal laser absorber could be a safer and simpler ESD technique.
Aims & Methods: The aim of this study was to evaluate the feasibility of L-ESD
and the quality of the resected specimen obtained by L-ESD in living porcine
compared with C-ESD. We performed ESD for a total of 14 hypothetical lesions
in three porcine stomachs (L-ESD, 7 lesions; C-ESD 7 lesions) under general
anesthesia. En-bloc resection rate, procedure time, adverse events, and the qual-
ity of the resected specimen were evaluated. To evaluate the smoothness of the
cutting surface in the resected specimens, we compared the length of the resected
side of the submucosa (LRS) with the length of the muscularis mucosa (LMM).
Results: The en-bloc resection rate was 100% in both groups. Although the mean
L-ESD procedure time was 23.3 10.8 minutes, and was significantly longer than
in the C-ESD group (9.4 6.6 minutes; p5 0.05), there was no uncontrollable
bleeding or perforation in either group. The mean ratio of LRS to LMM was
107 3.3% in the L-ESD group, and was significantly lower than that of the C-
ESD group (138 28%) (P5 0.005).
Conclusion: ESD using CO2 laser might be a feasible and effective method for the
treatment of early gastrointestinal cancers.
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Introduction: Acute corrosive ingestion (ACI) is a common and serious medical
problem accounting for a number of hospital admissions. ACI causes significant
mortality and morbidity. These patients are at risk of developing luminal stric-
tures of the upper gastrointestinal tract in the long term. This is more in patients
with high-grade injury.
Aims &Methods: The present study aimed at assessing the long-term outcomes of
high-grade (Zargar’s grade Grade 2A) corrosive-induced injury of upper gas-
trointestinal tract (1). This was a prospective sudy conducted in the Department
of Gastroenterology at Christian Medical College, Vellore. The study period was
between January 2008 to December 2014. All patients were managed by a stan-
dard protocol which included doing a gastroscopy within 24 hours of ACI. In
this study we included patients 15 years with high-grade (Zargar’s grade
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Grade 2A) corrosive-induced injury of upper gastrointestinal tract. Patients in
whom gastroscopy could not be done or who had it done at another hospital
were excluded from the study. The study was approved by the Instituitional
Ethics committee and was funded by a fluid research grant received from
Institutional Review Board at Christian Medical College, Vellore, India. The
data was analysed using SPSS version 17. The parametric continuous variables
were expressed as, meanSD and the non parametric continuous variables were
expressed as median.Comparison between groups was done using Fisher’s exact
test.
Results:During the study period a total of 112 patients presented with ACI. In all
82 patients were included in the study. Amongst them, 53% of the patients were
females and the mean age was 36.5 15.5 years. The intent of corrosive ingestion
was suicidal in 70% and accidental in 30%. In majority (50%) of patients the
nature of corrosive was not known. Nasogastric tube placement was done in
50%, nasojejunal tube placement in 32% and 8% no tube was placed. Surgery
as needed in 19% (tracheostomy or feeding jejunostomy or a definitive surgery).
Amongst the 82 patients who were included in the study, 11 were lost to follow
up. Follow up was done in 71 patients in whom the median follow up period was
31 months (range 2m–72m) during which 12 (16.9%) patients expired (73%
related to ACI). Amongst the 59 patients, that were alive 16(27%) were sympto-
matic, 12(20%) had dysphagia, 5(6%) had regurgitation, 4(5%) had chest pain,
6(7%) had weight loss and 11(18%) patients required diet modification. In all,
43(73%) patients underwent barium study during follow up and strictures were
noted in 21(36%). The site of stricture was esophageal in 11(53%), stomach in
8(38%) and combined esophageal and stomach in 2(9%). Esophageal stricture
was seen in all patients with Grade III B esophageal injury, 27% (6/22) with
Grade III A injury and 19%(5/27) with Grade II B injury. None of the patients
with Grade II A injury developed stricture. Stricture in stomach developed in
25% (2/8) patients with Grade III B injury, 25% (6/24) with Grade III A injury,
10%(1/10) with II B injury and 20% (1/5) with II A injury.
Conclusion: Acute corrosive ingestion is associated with significant morbidity and
mortality.There needs to be stringent control on sale, use and storage of such
chemicals.
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Introduction: Probe-based confocal laser endomicroscopy (pCLE) provides real-
time microscopic visualization with 1000-fold magnification, allowing endoscopic
access to the histological evaluation of gastrointestinal lesions. pCLE may
thereby be helpful in guidance of endoscopic therapy. However, histopathologi-
cal assessment still remains a gold standard for histological diagnosis so far,
while pCLE-based diagnosis has not been generally accepted yet. Therefore,
more studies assessing diagnostic accuracy of pCLE are warranted.
Aims & Methods: The aim of this study was to compare diagnostic accuracy of
pCLE with standard biopsies in the diagnosis of macroscopically visible esopha-
geal and gastric lesions.
A single-center, prospective, controlled and pathologist blinded study. We
enrolled all consecutive patients with a visible esophageal or gastric lesion. All
patients underwent high-resolution endoscopy and the lesion was examined by
pCLE. After pCLE, standard biopsies were taken from the lesion and the speci-
men was sent for standard histolopathological assessment. Final diagnosis was
determined based on assessment of endoscopic or surgical resection specimen (if
possible) or standard biopsies. Some of the patients with an obviously malignant
lesion underwent endoscopic resection immediately after pCLE without standard
biopsies being obtained. Main outcomes of the study were diagnostic accuracy,
sensitivity and specificity of pCLE vs. standard biopsies.
Results: We examined 45 lesions (38 esophageal, 7 gastric) in 41 patients.
Definitive diagnoses revealed 28 malignant lesions (21x adenocarcinoma (AC),
7x squamous carcinoma (SCC)) and 17 benign lesions. In summary, pCLE diag-
nosis was correct in 76% (34/45) and incorrect in 24% (11/45) while diagnosis
based on biopsy was correct in 73% (27/37) and incorrect in 27% (10/37). pCLE
confirmed malignant diagnosis in 81% (22/27) of cases and biopsy in 65% (10/
16) (in 6 patients with a definitive diagnosis of AC and SCC, biopsies showed
low- or high-grade dysplasia or necrotic tissue). Benign diagnosis was accurate in
65% (11/17) of lesions based on pCLE vs. 100% of lesions (17/17) based on
biopsy. Overall sensitivity, specificity, and diagnostic accuracy of biopsies were
67% CI 95 (49–88%), 100% (54–100%) and 83% (68–94); sensitivity, specificity,
and accuracy of pCLE for the correct histological diagnosis were 81% (62–93%),
91% (59–99%) and 84% (70–93), respectively.
Conclusion: pCLE provides satisfactory diagnostic accuracy comparable with
standard biopsies in malignant esophageal and gastric lesions in particular.
Supported by a grant from Ministry of Health of the Czech Republic, No. 16–
27648A. ClinTrial registration: NCT02922049.
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Introduction: Non-variceal upper digestive bleeding (NV-UDB) represents a sig-
nificant cause of hospital admission. In order to stratify patients according to the
risk of the complications (re-bleeding/death), and to predict the need of clinical
intervention and patient’s outcome, several risk scores have been proposed by
international guidelines and implemented in clinical practice.
Aims &Methods: The aim of the study consisted in the analysis of the accuracy of
three risk scoring systems used in non-variceal upper digestive bleeding for asses-
sing patient’s prognosis, previously estimated to be predictive for re-bleeding/
death after gastrointestinal bleeding. We assessed prospectively a batch of 1872
patients admitted in the Gastroenterology Department of Emergency County
Hospital Timisoara in a 12-year period, in which we calculated 3 risk scoring
systems, Rockall, Cedars-Sinai and Baylor, based on clinical and endoscopic
data. We compared their accuracy for assessing patient’s prognosis, expressed
as the need of blood transfusions, number of hospitalization days, re-bleeding,
surgery and death. Discriminative ability was assessed using the area under the
receiver operating characteristic curve (AUROC).
Results: The batch included 1134 (60.6%) male and 738 (39.4%) female, mean
age 62 7.8 years. Regarding the need of blood transfusions, the predictive
ability of the scores is as follows: Rockall AUROC 0.59 CI(0.55–0.62),
sensitivity(Se)¼ 81.7%, specificity(Sp)¼ 35.5%, positive predictive
value(PPV)¼ 28.4%, negative predictive value(NPV)¼ 86.1% (p5 0.0001);
Cedars-Sinai AUROC 0.59 CI(0.55–0.63), Se¼ 72.4%, Sp¼ 41.3%,
PPV¼ 28.5%, NPV¼ 82.3% (p5 0.001); Baylor AUROC 0.56 CI(0.49–0.63),
Se¼ 41.9%, Sp¼ 75.5%, PPV¼ 40.6%, NPV¼ 76.5%. Number of hospitaliza-
tion days: Rockall AUROC 0.66 CI(0.55–0.77), Se¼ 61.5%, Sp¼ 65.2%,
PPV¼ 90%, NPV¼ 25% (p¼ 0.003); Cedars-Sinai AUROC 0.63 CI(0.50–
0.75), Se¼ 53.1%, Sp¼ 73.9%, PPV¼ 89.5%, NPV¼ 27.4%; Baylor AUROC
0.52 CI(0.51–0.73), Se¼ 47.06%, Sp¼ 66.6%, PPV¼ 84.2%, NPV¼ 25%. Re-
bleeding: Rockall AUROC 0.69 CI(0.66–0.73), Se¼ 69.1%, Sp¼ 60.4%,
PPV¼ 14.2%, NPV¼ 92.8% (p5 0.0001); Cedars-Sinai AUROC 0.73
CI(0.69–0.77), Se¼ 84.4%, Sp¼ 49.02%, PPV¼ 13.7%, NPV¼ 97%; Baylor
AUROC 0.54 CI(0.45–0.63), Se¼ 35.1%, Sp¼ 81.2%, PPV¼ 16.2%,
NPV¼ 92.4%. Surgery: Rockall AUROC 0.67 CI(0.61–0.73), Se¼ 71.2%,
Sp¼ 59%, PPV¼ 16%, NPV¼ 98.1%; Cedars-Sinai AUROC 0.72 CI(0.66–
0.78), Se¼ 58%, Sp¼ 77.4%, PPV¼ 9.3%, NPV¼ 97.9%; Baylor AUROC
0.55 CI(0.41–0.68), Se¼ 50%, Sp¼ 66.2%, PPV¼ 5.1%, NPV¼ 97.4%. Death:
Rockall AUROC 0.85 CI(0.81–0.89), Se¼ 84.7%, Sp¼ 76%, PPV¼ 18.2%,
NPV¼ 99.5% (p5 0.0001); Cedars-Sinai AUROC 0.71 CI(0.66–0.76),
Se¼ 83.1%, Sp¼ 48.1%, PPV¼ 10.2%, NPV¼ 97.6%; Baylor AUROC 0.75
CI(0.67–0.83), Se¼ 76.09%, Sp¼ 72.3%, PPV¼ 19.2%, NPV¼ 97.2%. There
were no statistically significant differences encountered in predicting the need
of blood transfusions and surgery between the scores (p4 0.05). Baylor score
was superior vs Rockall in estimating the hospitalization period (p¼ 0.04) and
the risk of re-bleeding (p¼ 0.0009), and Cedars-Sinai proved to be superior to
Baylor score in predicting re-bleeding (p¼ 0.002) and to Rockall score in pre-
dicting death (p¼ 0.006).
Conclusion: On our cohort of patients, Cedars-Sinai score proved to be the best in
predicting the re-bleeding and death in patients with NV-UDB in comparison to
Rockall and Baylor scores.
Disclosure of Interest: All authors have declared no conflicts of interest.
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PROCEDURE EVEN IN CANCER PATIENTS
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Introduction: Dysphagia and malnutrition is a common feature in up to 64% of
patients with head and neck, esophagus and gastro-esophageal cancer, and the
need of radiotherapy or chemotherapy often worsens this symptoms.
Percutaneous endoscopic gastrostomy (PEG) is the preferred route of feeding
and nutritional support in these patients. Although generally considered to be a
safe procedure, it has been arguable that PEG tube placement complications in
cancer patients may be superior when compared to non-cancer patients.
Aims & Methods: The aim of this study was to evaluate the complications rate
after PEG tube placement in cancer patients. We did a single-centre prospective
database including all patients with PEG tube insertion between March 2014 and
June 2016, evaluating the complications during 6 months follow-up.
Results: A total of 265 patients (83% men, mean age 59 years) underwent PEG
tube insertion. 224 patients (84.5%) had head and neck cancers and 33 patients
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(12.5%) had esophageal cancer; 207 patients (78.1%) had stage IV disease. At the
time of PEG tube placement, 138 patients (52%) had grade 3 dysphagia and the
mean body mass index (BMI) was 20.9 Kg/m2. All the patients underwent anti-
biotic prophylaxis previous to the procedure. There was an increase on BMI to
23.8 Kg/m2 at 6 months follow up. Eight patients (3.8%) had immediate com-
plications after the procedure (bleeding from the PEG tract–6; anesthetic com-
plications - 2). The overall complication rate at the first month of follow up was
14.4%, at the third month 20.5% and at the sixth month 11.7%. The overall peri-
PEG infection rate was 14%, and was the main complication at the first month of
follow up. Development of hyper-granulation tissue was the most frequent com-
plication at the third month of follow-up. Buried bumper syndrome occurred in
10 patients (3.7%). None of the patients had tumor seeding at the gastrostomy
site. Overall mortality was 26.4%, none of the deaths attributable to PEG tube
insertion.
Conclusion: PEG placement is a safe and effective technique in cancer patients.
The rate of major complications and tube site infection were similar to the results
found in literature for non-cancer patients.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Probe-based confocal laser endomicroscopy (pCLE) has been devel-
oped to overcome limitations of the current endoscopic sampling techniques.
pCLE allows detailed examination of cellular structures and may examine
larger areas compared to standard biopsy. Patients after endoscopic treatment
of Barrett’s esophagus (BE)-related neoplasia (BORN) should undergo endo-
scopic surveillance with biopsies to detect persistence or recurrence of intestinal
metaplasia (IM) or neoplasia (N).
Aims &Methods: The aim of this prospective study was to evaluate the efficacy of
pCLE (vs. standard biopsies) in detection of persistent/recurrent IM/neoplasia in
patients after endoscopic treatment of BORN. A single-center, prospective, con-
trolled and pathologist-blinded (still ongoing) study in patients undergoing sur-
veillance endoscopy after endoscopic treatment of BORN. pCLE images were
obtained from the neo-Z-line (a few cases including macroscopically visible ton-
gues), the cardia and the esophagus. Thereafter, standard biopsies were taken
and sent for histopathological analysis (4 biopsies from macroscopically normal
neo-Z-line, 2 biopsies from the cardia and the esophagus and targeted biopsies
from visible abnormalities, if present). BE was defined in pCLE as columnar-
lined epithelium with dark mucin in goblet cells, a villiform pattern, and regular-
shaped capillaries in the mucosa. The dysplastic BE was characterized by black
cells with irregular borders and shapes, high dark contrast to the surrounding
tissue, and irregular leaking capillaries in the mucosa.
Results: We examined 29 patients, from these 14 patients (48%) had the initial
diagnosis of low-grade intraepithelial neoplasia (LGIN), 7 patients (24%) had
high-grade intraepithelial neoplasia (HGIN) and 8 patients (28%) had an early
adenocarcinoma (EAC). Persistent/recurrent IM was detected at the level of neo-
Z-line in 10 patients (34.5%) by both standard biopsies and pCLE. pCLE but not
biopsies detected persistent/recurrent IM in 2 patients (6.7%), another 2 patients
had IM present in biopsies but not in pCLE. pCLE diagnosed one patient with
recurrent LGIN in a macroscopic visible tongue arising from neo-Z-line, which
was not confirmed in biopsies. Sensitivity and specificity of pCLE detection of
persistent/recurrent IM was 83.3% (95% CI 51.6–97.9) and 89.47% (95% CI
66.9–98.7), respectively, with positive predictive value 83.3% (95% CI 56.1–95.0)
and negative predictive value 89.5% (95% CI 70.4–96.8). Agreement of pCLE
and histopathological findings was 86%.
Conclusion: pCLE seems to be comparable with standard biopsies in detection of
persistent/recurrent IM after endoscopic treatment of BORN. Nevertheless, these
results need to be confirmed in a larger cohort of patients. Supported by a grant
from Ministry of Health of the Czech Republic, No. 16–27648A.
ClinTrial registration: NCT02922049.
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Introduction: Symptomatic Zenker’s diverticulum (ZD) can be treated by flexible
endoscopic septum division (FESD) as a minimally invasive alternative to sur-
gery or to rigid endoscopic procedure. There is still a lack of standardization of
the FESD as well as data on late outcome are scarcely reported. Moreover,
FESD outcomes are differently reported in available literature and no specific
scores have been yet validated.
Aims & Methods: We aim to report the outcome of all ZD treated by FESD in
our institution by using a new symptoms score. We retrospectively reviewed
consecutive patients with ZD treated by FESD in a single tertiary-care academic
medical center between April 2014 and Feb 2017. All patients were included in a
prospectively maintained database. A dedicated new score was created to obtain
reliable and objective evaluation of outcome of our patients. This score (Milano-
Zenker score, MZ-score) is based on the three main ZD symptoms: dysphagia,
regurgitation and weight loss. The ZD score (maximum score, 9) is the sum of the
symptom scores for dysphagia, regurgitation (for both: 0, absent; 1, occasional;
2, daily; and 3, each meal), and weight loss (0, no weight loss; 1, 55 kg; 2, 5–
10 kg; and 3, 410 kg). The main outcome was clinical success, defined as MZ
score 2 at the latest follow up. Patient’s symptoms were evaluated at 1 month
and at every 6 months after the procedure. Adverse events were recorded and
classified as intraprocedural, postprocedural (514 days), and late (15–30 days).
Results: 100 patients underwent FESD, with a mean age of 70.3 11.2 years
(range 39–95) and prevalence of male gender (66%). Twenty-nine (29%) of trea-
ted ZD were re-intervention: 20(69%) after previous FESD; 8 (27.6%) after
previous surgery; 1 (3.4%) after previous surgery and FESD. Mean initial MZ
score was 4.5 1.8 (range 1–8). Intraprocedural bleeding was observed in 5
patients (5%), with all of successfully treated by clips. No postprocedural/late
bleedings were recorded. One perforation was observed and treated conserva-
tively. The mean follow up period was 14 months (range 3–35). Overall clinical
success was obtained in 78.5% of patients. Mean post treatment ZD score was
1.3 1.5, significantly lower than initial MZ score (p5 0.0001).
Conclusion: FESD represents a safe and effective treatment for symptomatic
patients with Zenker’s diverticulum. Although it needs to be validated, proposed
MZ score could represent a useful tool to monitoring post-procedural symptoms
and guide subsequent management.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Food impaction (FI) and foreign body ingestion (FBI) remain the
most frequent indications for emergency esophagogastroduodenoscopy. The
symptoms in these patients are often nonspecific and their location is not
always related to the endoscopic findings.
Aims &Methods: The aim of this study was to caracterize the symptomatology of
the patients with suspected FI and FBI, to correlate the clinical symptoms with
the endoscopic findings and to assess its management and complications. This
was a restrospective unicenter cohort study including patients with suspected FI
and FBI during three years (2013–2016). Statistic analysis were performed using
IBM SPSS Statistics 22 with p5 0,05 deemed to be statistically significant.
Results: 198 patients were included (90 patients with FI, 70 patients with FBI, 38
patients without endoscopic findings of FI or FBI): 59.1% men, with a mean age
of 60.10 19 years. Patients with FI were predominantly men and were signifi-
cantly older when compared with FBI patients (p5 0.05). Dysphagia was the
most frequent symptom in FI patients, while foreign body perception and ody-
nophagia were more common in FBI. The symptoms in FI group were localized
more frequent in the esophagus (83.3%) and FI was identified by esophagogas-
troduodenoscopy in the distal esophagus in 58.9% of those patients. In compar-
ison, the symptoms in patients with FBI were predominantly localized in
oropharynx (65.7%) and FBI was identified in proximal esophagus in 55.7%
of those patients. There was more correlation between the location of the symp-
toms and the endoscopic findings in patients with FI compared with the patients
with FBI (FI 65.6% VS 47.1%; p5 0.05). In FI patients, the most frequent
esophageal abnormalities were peptic stenosis and Schatzki ring. In FBI patients,
the most common foreign bodies identified were meat (47.1%) and fish bones
(22.9%). Foreign body forceps was the most used device in FBI patients, while
Roth Net was preferred in FI patients. Overall, esophagoduodenoscopy was
effective in the resolution of FI in 100% of the patients and foreign body extrac-
tion was not possible in 4 patients (5.7%). Major complications occurred in 0.5%
(1 perfuration).
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Conclusion: In FI patients, the location of the symptoms has a better correlation
with the endoscopic findings compared with FBI patients. The esophagoduode-
noscopy is safe and effective in patients with FI and FBI.
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Introduction: Apparent aspiration is a notable adverse event during gastrointest-
inal endoscopy under sedation (GIES) [1, 2], but data about the incidence and the
role of inapparent aspiration is scarce. Furthermore, patients undergoing endos-
copies experience respiratory symptoms such as coughing, shortness of breathing,
fever and other respiratory adverse events within 24 hours relatively often in
more than 5% [3]. Since coughing during endoscopy has been attributed to an
increased risk of aspiration-related postprocedural infection [4] respiratory infec-
tions might be underreported. Additionally, patients in advanced age are not
only determined as a high-risk group for GI adverse events following colonos-
copies [5], but are also more likely to develop hospital-acquired pneumonia [2].
Therefore, the aim of the study was to determine the risk of pneumonia, lower
respiratory infection (LRI) and systemic inflammatory activation after GIES.
Aims & Methods: A total of 250 consecutive inpatients who had undergone GIES
during a hospital stay of at least three days were included in a retrospective
cohort study. Age-, gender- and length of hospital stay-matched controls (ratio
1:1) who had not undergone any invasive procedure or sedation served as con-
trols. Laboratory parameters had to be available before and three and/or seven
days after endoscopy. Primary objective was the occurrence of pneumonia in
general and older patients (65 years). Secondary objectives were the develop-
ment of LRI, elevation of inflammatory markers (CRP and WBC), initiation of
antibiotic treatment, pathogen detection and pulmonary infiltration. Statistics
included 2 test, paired t-test, ANOVA, multiple linear regression analysis.
Results: No significant differences for the occurrence of pneumonia (1.6%, GIES
group vs. 0.4%, control group, p¼ .178, 2 test) and LRI (4.8% vs. 2.0%,
p¼ .084) in general, but in the older age group (2.6% vs. 0.0%, p¼ .041, and
7.8% vs. 2.5%, p¼ .034, respectively) were detected. Inflammatory parameters
were significantly increased after GIES, particularly on day three. GIES patients
received antibiotic treatment more frequent while pulmonary infiltration did not
differ.
Conclusion: This data confirms a higher risk of pneumonia due to GIES in the
advanced aged population. In general, patients are more likely to develop inflam-
mation and to receive antibiotic treatment suggesting an increased risk of radi-
ologically non-visible inflammation due to micro-aspiration.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Therapeutic options for gastroparesis or delayed emptying follow-
ing oesophagectomy with gastric transposition are limited. Although commonly
performed, there have been no studies addressing the relative merits of endo-
scopic dilatation of the pylorus, botulinum toxin (Botox) injection or combina-
tion therapy. We assessed the symptomatic response of patients undergoing non-
surgical pyloric intervention at a specialist tertiary centre.
Aims & Methods: 33 patients (13 male; mean age 45, range 17–80) underwent a
total of 51 endoscopic procedures over 2 years. Treatments were either 100 IU
units of Botox injected into 4 quadrants of the pylorus or pneumatic dilation
(PD) incrementally up to 16–20mm (Hercules; Cook Medical). Patients with
gastric malignancy, previous pyloric surgery or no documented follow-up were
excluded. Post-therapeutic responses were assessed at first follow up post-proce-
dure and graded as ‘good’, ‘partial’ or ‘none/poor’. Patients were grouped
according to type of therapy and indication.
Results: There were no immediate or late complications observed. 31 procedures
were performed for gastroparesis with a mean post-procedure follow-up of 11
weeks. Overall, a partial or good response was observed in 81% (25/31). Specific
treatment with Botox alone (18 procedures) or as part of combination therapy
(10 procedures) led to a good or partial response in 86% (24/28) compared to
33% (1/3) who had PD alone (p¼ 0.03). 14 procedures were performed in the
post-surgical group with a mean post-procedure follow-up of 10 weeks. Overall, a
partial or good response was observed in 93% (13/14); treatment with Botox
alone or as part of combination therapy led to a good or partial response in
100% (10/10) compared to 75% (3/4) who had dilatation alone (p¼ 0.1). 6
therapies were performed without a defined indication, 2 patients (33%) had a
partial or good response, both of which had combination therapy.
Conclusion: Pyloric intervention with Botox, PD or combination therapy are safe
and effective treatment options for patients with gastroparesis or delayed gastric
emptying following gastric transposition. Subjective treatment without a clear
indication shows little improvement.
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Introduction: Endoscopic submucosal dissection (ESD) is an established techni-
que for the treatment of gastrointestinal (GI) neoplasia in Japan. The high
uptake and mastery of the procedure there was in part enabled by the high
prevalence of early gastric cancer in Japan. Conventional practice in Japan is
to admit patients for 3 to 5 days after the ESD procedure for monitoring in view
of the risk of serious complications which is between 1–10%. Cost and resource
provision in a publicly-funded Western healthcare setting favours shorter
planned stays following ESD.
Aims & Methods: We aimed to identify the type and site of lesions being treated
in a Western setting as well as the rate, timing and predictors of complications in
order to evaluate current admission practice. An electronic database of all ESD
procedures performed in our academic institution from 2012–2017 was analysed.
Parameters were the number, type, onset and management of complications
following ESD. Significant complications (bleeding and perforation) necessitat-
ing hospital admission were categorised as early (within 24 hours) and delayed
(24 hours to 28 days) post procedure.
Results: A total of 410 ESDs were performed within the time period (225 color-
ectal, 117 oesophageal, 52 gastric and 16 duodenal). There were 21 complica-
tions. ESD for gastric and duodenal lesions had a higher complication rate
(11.5% and 12.5% respectively). The table below stratifies the complications
according to type, location and onset.
Colorectal Oesophageal Gastric Duodenal
Early Bleeding 3/225 1/117 0/52 0/16
Perforation 2/225 0/117 2/52 1/16
Total (early) 5/225 (2.2%) 1/117 (0.9%) 2/52 (3.9%) 1/16 (6.3%)
Delayed Bleeding 5/225 1/117 4/52 1/16
Perforation 1/225 0/117 0/52 0/16
Total (delayed) 6/225 (2.7%) 1/117 (0.9%) 4/52 (7.7%) 1/16 (6.3%)
Grand total of
all complications
11/225 (4.9%) 2/117 (1.8%) 6/52 (11.5%) 2/16 (12.5%)
19 of the 21 total complications (90.5%) were successfully managed endoscopi-
cally. 1 patient underwent an emergency right hemicolectomy for a delayed
colonic perforation and 1 patient had radiological embolisation for a bleed 7
days following a caecal ESD. 72.7% (8/11) of the patients who experienced
delayed bleeding presented 7–10 days following ESD. Of this, 50% occurred
following recommencement of anticoagulants/antiplatelets.
Conclusion: ESD in this Western setting was more commonly performed for
colonic and oesophageal lesions rather than gastric as seen in Japan. The com-
plication rate is modest and almost all were managed successfully with an endo-
scopic approach. They occurred more commonly in gastric and duodenal sites.
This may be related to the technical difficulties of resection or low volume of
procedures performed at these locations. The use of anticoagulants is a risk
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factor for delayed bleeding. Given that the majority of delayed complications
occurred more than 5 days post procedure, a standardised 5 day inpatient stay
would prove futile in our cohort.
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Introduction: The optimal management and the predictive factors of response to
endoscopic dilatation of refractory benign oesophageal strictures remains
controversial.
Aims & Methods: To evaluate the prevalence and factors predicting response to
treatment of benign refractory oesophageal strictures with scheduled endoscopic
dilatations Retrospective analysis of 75 patients submitted to scheduled endo-
scopic dilatation of benign oesophageal strictures between October 2010 and
November 2016. Strictures were classified as refractory when 5 endoscopic
dilations were needed with at least one dilation achieving 15mm of diameter
during the course of management of the oesophageal strictures.
Results: The study sample included 42 (56%) male patients and the mean age was
57 18 years. The dysphagia scale at baseline was: solids (1)–17 (22.7%), semi-
solids (2)–23 (30.7%), liquids (3)–23 (30.7%) and complete (4)–12 (16%). Body
mass index (BMI) at baseline was 22 5 Kg/m2. The aetiology of the benign
strictures was: surgical–31 (41.3%), peptic–15 (20%), caustic–10 (13.3%), radio-
therapy–10 (13.3%) and others–9 (12%). The location of the oesophageal stric-
tures was as follows: proximal third–34 (45.3%), middle third–12 (16%), distal
third–27 (36%) and multiple locations–2 (2.7%). Stricture type: simple–44
(58.7%), complex–31 (41.3%). Patients underwent a median of 4 (1–26) endo-
scopic dilation over a median period of 19 weeks (1–229). Dilations were done
with Savary-Gilliard dilators–35 (46.7%), TTS-balloons–24 (32%) or both–16
(21.3%). The mean diameter of dilation achieved was 15.7 2.2 and a dilatation
diameter of 15mm was achieved in 56 (74.6%) patients. Local injection of
corticosteroid (dexametasone 5mg) was performed at least once in 39 (52%)
patients and in 25% of dilations in 39 (52%) patients. From the study
sample, 25 (33.3%) patients fulfilled criteria of refractory strictures. In this sub-
group, there was a significant association with post-surgical aetiology (p¼ 0.042),
lower baseline BMI (p¼ 0.039), higher rate of local injection of corticosteroids
(p5 0.001) and higher dilation diameter (p5 0.001). Refractory strictures were
significantly associated with the need for local corticoid injection (OR 9.76,
95%CI 0.035–0.46, p¼ 0.02) by binary logistic regression analysis. However,
none of the other factors were found to be independent predictors of response
to therapy.
Conclusion: Surgical aetiology was significantly associated with refractory benign
oesophageal strictures and these patients were significantly more liked to require
local corticosteroid injections during scheduled endoscopic dilatations.
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Introduction: Locally injected corticosteroids have been shown to improve out-
comes in patients undergoing endoscopic dilation of peptic strictures.
Aims & Methods: To evaluate factors predicting early clinical response to endo-
scopic dilation of benign oesophageal strictures. Retrospective analysis of 75
consecutive patients submitted to scheduled endoscopic dilatations between
October 2010 and November 2016. Clinical improvement was defined as dyspha-
gia score 1. IBM SPSS21 was used for statistical analysis.
Results: The study sample involved 42 (56%) male patients and the mean age was
57 18 years. Dysphagia scale at baseline: solids (1)–17 (22.7%), semisolids (2)–
23(30.7%), liquids (3) –23 (30.7%) and complete (4)–12 (16%). Body mass index
at baseline was 22 5 Kg/m2. Stricture aetiology: surgical–31 (41.3%), peptic–15
(20%), caustic–10 (13.3%), post-radiotherapy–10 (13.3%) and others–9 (12%).
Stricture location: proximal–34 (45.3%), medium–12 (16%), distal 27 (36%) and
multiple–2 (2.7%). Stricture type: simple–44 (58.7%), complex–31 (41.3%).
Patients underwent a median of 4 (1–26) endoscopic dilations over a median
period of 19 weeks (1–229). Dilations were performed with Savary-Gilliard dila-
tors–35 (46.7%), TTS-balloons–24 (32%) or both–16 (21.3%). The mean dia-
meter of dilation was 15.7 2.2 and dilatation of 15mm was achieved in 56
(74%) of patients. Local corticosteroid injection (dexametasone 5mg) was per-
formed at least once in 39 (52%) patients and in 25% of dilations also in 39
(52%) patients. The rate of complications was 13.3% (perforation (n¼ 9) and
bleeding (¼ 1)). Surgery was performed in 10 patients (13.3%) (refractory stric-
tures (n¼ 7) and post dilation perforation (n¼ 3)). Improvement of dysphagia
symptoms was only associated with the maximum dilation diameter (p¼ 0.026)
and local injection of corticoids (p5 0.001) as was confirmed by binary logistic
regression wherein both maximum dilation diameter (OR: 4.92, 95%IC 1.05–
2.04, p¼ 0.027) and topical injection of corticosteroids (OR: 7.22, 95%IC
0.021–0.55, p¼ 0.007) were strongly associated with improved dysphagia scores.
Conclusion: In our study sample with multiple aetiologies of benign oesophageal
strictures, only the maximum dilation diameter and local injection of corticoster-
oids were associated with improved clinical outcomes in patients undergoing
endoscopic dilation of benign oesophageal strictures.
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Introduction: In the UK, endoscopy certification is overseen by the Joint
Advisory Group (JAG). Since 2011, e-certification has been awarded for upper
and lower GI endoscopy online via the JAG Electronic Training System (JETS).
We aimed to analyse trends in endoscopy e-certification, and assess for differ-
ences between trainees in gastroenterology (GI), surgical (GS) and non-medical
endoscopists (NME).
Aims & Methods: We prospectively identified trainees awarded certification for
gastroscopy, flexible sigmoidoscopy (FS) and colonoscopy from the JETS data-
base. For each specialty, we collected data on lifetime procedural counts, for-
mative assessments, and key performance indicators (KPIs) at the time of
certification. Comparisons between specialties were analysed using a combina-
tion of chi2, Mann-Whitney and median tests.
Results: Between June 2011-Dec 2016, 2857 applications were awarded certifica-
tion. Numbers of gastroscopy and provisional colonoscopy awarded have been in
steady state since 2013, whilst numbers for sigmoidoscopy and full colonoscopy
continue to increase. Trainees awarded certification comprised mainly of GI
(53.2%), GS (28.5%) and NME (15.8%) trainees. With the exception of FS,
most certifications were awarded to GI trainees (Figure 2). Median procedural
numbers (p5 0.001) and formative DOPS count (p5 0.001) pre-certification
varied for each modality in the order of NME4GI4GS. Caecal intubation
rates (CIR) at full certification were similar between GI (95.6%) and GS (95.6%,
p¼ 0.81), but lower in NME (93.6%, p¼ 0.02 vs. GS, p¼ 0.006 vs. GI), despite
no differences at provisional certification (median CIR 95.6%, p¼ 0.32). Rates of
D2 intubation (median 98.7%) varied across groups (GS4GI4NME,
p¼ 0.002). Certification awarded at first attempt were similar across specialties
(mean 89.4%, p¼ 0.19), but varied for gastroscopy (NME 95.5%, GS 90.1%, GI
89.7%, p¼ 0.01).
Conclusion: Despite variations amongst trainee specialties, endoscopy certifica-
tion is a transparent and robust benchmark for assessing competency, as evi-
denced by trainee KPIs. Further studies are required to study the impact of
recent changes to certification, and if variations in KPIs exist following
certification.
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Introduction: A duodenal papilla tumor is an uncommon neoplasm in the upper
gastrointestinal tract. In the early stage, patients often have no complaints and
the tumors are usually occasional found during gastroduodenoscopy examina-
tion. Endoscopic papillectomy can be achieved with curative resection for benign
adenoma and some early papillary carcinoma. However, some complications are
companied with the procedure, like pancreatitis and bleeding. This retrospective
study is to evaluate therapeutic effect and safety of endoscopic papillectomy on
duodenal papilla tumors.
Aims &Methods: From June 2009 to November 2016, the information of patients
who received endoscopic papillectomy was recorded, which included basic char-
acteristics and clinical outcomes, such as recurrence rate, bleeding, pancreatitis.
Results: 37 patients (totally 40 cases) received endoscopic papillectomy. The
procedure was completed with gastroscope in 32 cases and duodenoscope in 8
case. Endoscopic mucosal resection (EMR), endoscopic piecemeal mucosal resec-
tion (EPMR) and endoscopic submucosal dissection (ESD) was performed in 21,
17 and 2 cases respectively. None of the lesions invaded the submucosal layer.
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Pancreatic stents and biliary stents were inserted in 9 and 12 patients respectively.
In general, 5% (2/40) and 12.5% (5/40) cases had intraoperative and postopera-
tive bleeding respectively. 20% (8/40) cases suffered from pancreatitis, of which
mild, moderate and severe happened in 3, 4 and 1 cases. Six patients had tumor
recurrence. And 3 patients received repeat endoscopic papillectomy, two received
pancreatic-coduodenectomy and one received no other treatments with close
follow-up. Two patients died from failures of treatments for papillary tumors
and one patient died due to other unrelated cause.
Characteristics and adverse events of endoscopic papillary in cases
Sex
Male Female 29 8
Age (years, meanSD) 55.1 10.0
Endoscope type
Gastroscope Duodenoscope 32 8
Resection method
EMR EPMR ESD 21 17 2
Pathological results
LGD, HGD, Tis, Tm, Tsm, Non-tumor 12, 24, 0, 2, 0, 2
Tumor sizes (cm)
Longer diameter, Shorter diameter 2.02 0.88, 1.50 0.69
Biliary Stent
Yes, No 12, 28
Pancreatic stent
Yes, No 9, 31
Hospital stays (days, meanSD) 6.7 13.4
Follow-up time (months, meanSD) 36.6 28
Adverse events
Intraoperative bleeding 5%(2)
Postoperative bleeding 12.5%(5)
Perforation 2.5%(1)
Cholangitis 0
Pancreatitis, Mild, Moderate, Severe 20%(8), 7.5%(3), 10%(4), 2.5%(1)
Recurrence 16.2%(6)
Surgery 7.9%(3)
Mortality 7.9%(3)
EMR, endoscopic mucosal resection; EPMR, endoscopic piecemeal mucosal
resection; ESD, endoscopic submucosal dissection; LGD, low-grade dysplasia;
HGD, high-grade dysplasia; Tis, intraepithelial carcinoma; Tm, intramucosal
carcinoma; Tsm, carcinoma with duodenal submucosal invasion.
Conclusion: Endoscopic papillary is proved to be efficient in treating papilla
tumors without submucosal invasion. However, adverse events like pancreatitis
and bleeding should be taken seriously and managed properly.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: DOPS are validated tools for assessing competence in endoscopy.
Previously, DOPS were scored on a 4-point competence-based scale, with scores
of 3 and 4 signifying competence. In July 2016, the DOPS rating scale changed to
a supervision-based scale that has been shown to be more reliable,[1]with 4 ratings
from maximal supervision, up to competent without supervision. We aimed to
assess whether changes to the rating scale have affected distribution of scores and
hence demonstrate validity.
Aims & Methods: We used the UK trainee endoscopy database (JETS) to collect
DOPS scores for gastroscopy (n¼ 1934), sigmoidoscopy (n¼ 517), colonoscopy
(n¼ 2296) and polypectomy (n¼ 370) in the 6-months before July 2016 (old
DOPS) and after (new DOPS), for trainees at early stages of training (total
procedures5 100). To allow analysis, the new DOPS rating scale was aligned
to a 4-point scale, hence a score of 4 on new DOPS¼ Scores 3 or 4 on old DOPS,
and scores on the new and old DOPS compared using the Mann-Whitney U-test.
Results: 5117 DOPS (77.7% new and 22.3% old) were included for analysis.
Overall, there were variations in distributions of all scores (p5 0.001) between
forms (Figure 1). Compared to new DOPS, scores of 1 were underutilised on old
DOPS (0.6% vs 3.0%, p5 0.001). Frequencies of low scores (pooled scores of
1&2) were similar for gastroscopy (p¼ 0.53) and sigmoidoscopy (p¼ 0.34), but
not for colonoscopy (new 11.9% vs. old 13.9%, p5 0.001) and polypectomy
(new 6.8% vs.19.9%, p5 0.001). Trainees on old DOPS were more likely to
be rated as competent (score 3 or 4) compared to new DOPS (86.4% vs.
55.8%, p5 0.001). On subgroup analysis, this was evident for gastroscopy
(86.3% vs. 49.1%, p5 0.001), colonoscopy (86.1% vs. 58.2%, p5 0.001), sig-
moidoscopy (90.6% vs. 62.0%, p5 0.001), but not polypectomy (80.1% vs.
67.9%, p¼ 0.12).
Conclusion: Endoscopy assessors are applying a greater range of scores using a
new DOPS rating scale based on degree of supervision, in two cohorts of trainees
matched for experience. This indicates better construct validity with the new
rating scale. Further work is underway to determine the reliability of the new
DOPS to inform summative assessment and certification for UK endoscopy
trainees.
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Introduction: Endoscopic resection of duodenal adenomata carries an increased
risk of perforation compared to other locations in the upper or lower GI tract. 1,2
Additionally in endoscopic resection of widespread adenomata (Spigelman III/
IV) at the level of D2/D3 there is an increased risk of secondary perforation due
to auto-digestion of the denuded duodenal wall by pancreatic enzymes and bile
independent of the primary endoscopic resection method. We recently reported
of the successful implantation of a mini-vacuum sponge with extended length of
the suction tube and reduced in volume compared to a standard esophageal
vacuum sponge.3
Aims & Methods: From September 9th, 2015 to March 20th, 2017 endoscopic
resection of wide-spread duodenal or papillary adenomata of 42 cm in D2/D3
was performed in five patients. There was a surgical indication for Whipple’s
resection as primary intervention or in case of failure in all patients. All patients
agreed and gave their informed consent to the procedure.
Results: Five patients with widespread duodenal adenomata were included (2x
papilla, 3x D2/D3 extrapapillary adenomata; 5x tubular; 3x HGIN, 2x LGIN).
The macroscopic mean maximum diameter and perpendicular diameter of the
lesions were 4 2.8 cm (largest 7.5 3.7 cm; smallest 2.2 1.8 cm). In all cases
the implantation of a protective mini-vacuum sponge (EsoVac reduced in volume
to 1.2 1.5 cm (dia, length) with extended suction tube; Braun Corp.,
Melsungen). Continuous suction was applied over several days (125mm Hg;
ActiVAC, KCI Medical, Wiesbaden) depending on the size of the resection area
and healing status (m¼ 10 days, 4–14 days). An endoscopic/radiologic vacuum
sponge exchange was performed every 3–5 days. In 4 cases additional atraumatic
over-the scope-clips (OTSC, Ovesco Tuebingen) were placed during the proce-
dure and in 5/5 cases additional hemoclips were applied to secure the wall and for
hemostasis. In 5/5 cases (100%) an excellent healing could be observed during
follow-up. No patient had to be operated during or following the intervention
(FU 2–14mo.). In all cases the resection was curative with ‘en bloc’ resection,
though in one case the specimen ruptured during retrieval into three parts (4x
HGIN, 1X LGD; 4x R0, 1x Rx). In one case 10 days after resection an acute
bleeding occurred with the need of endoscopic clipping and prophylactic radi-
ologic coiling of the gastroduodenal artery with uneventful course. In a second
case a minor bleeding occurred without necessity of transfusion during ablation
of an OTSC three mo after the primary intervention. All patients were asympto-
matic during follow-up.
Conclusion: The endoscopic resection of large duodenal adenomata in D2/D3 is
feasible and was safe in our collective using the application of a duodenal mini-
vacuum sponge for continuous local drainage of bile and pancreatic juice as
alterative to Whipple’s resection. The results in this first small collective should
be reproduced in a prospective multicentric trial.
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Introduction: Acute perforations are one of the recognized complications of both
diagnostic and therapeutic gastrointestinal endoscopy. For decades, surgical
treatment has been the standard of care, but endoscopic closure has become a
more popular approach, due to feasibility and the reduction of the burden of
surgery, combined with the availability of various endoscopic closure devices.
Aims & Methods: We aimed to assess the technical and clinical success and safety
of endoscopic closure, in total, and for each endoscopic device used in closing
acute perforations in animal models. Medical literature (Cochrane library,
EMBASE, MEDLINE) from 1966 till September 2016 was searched. A systema-
tic review and meta-analysis were performed on studies reporting technical and
clinical success of endoscopic closure of acute perforations, according to
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses)
guidelines.
Results: 46 studies on animal models were identified. 15 studies, including 4
randomized controlled trials, met our inclusion criteria (acute, less than 24
hours, iatrogenic, no fistulas or leaks, clear documentation of the method of
closure, and technical and clinical success and 5 cases or more of endoscopic
closure per study), were analysed. A total of 214 endoscopic closures were
attempted in these studies. The overall technical success rate was 94.8%
(n¼ 201/214, 95% CI: 92%-97.6%), clinical success was 92.3% (n¼ 189/214,
95% CI: 88.8%-95.8%), and complication rate was 4.2% (n¼ 6/214, 95% CI:
1.6%-6.8%). Technical success for endoclip closure was 84.9% (95% CI: 71.4%-
93.6%), and clinical success was 83.2% (95% CI: 69.5%-92.5%), and complica-
tion rate was 2.7% (95% CI: 90.12%-99.88%). For OTSC (Over the scope clip
device), technical success was 97% (95% CI: 88%-99.7%), clinical success was
97% (95% CI: 88%-99.7%), and complication rate was 1.87% (95% CI: 91.2%-
98.8%). The technical success for endosuturing (endoscopic suturing device) was
92.7% (95% CI: 82% to 98%), clinical success was 87% (95% CI: 74.9%
94.8%), complication rate was 1.9% (95% CI: 91.1%- 98.9%).
Conclusion: Our study suggests that endoscopic closure is a suitable treatment
option for acute iatrogenic gastrointestinal perforations with a reasonable tech-
nical and clinical success, and low complication rate. Further confirmation from
prospective studies in human is needed.
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Introduction: Current guidelines recommend that adults age 50 to 75 be screened
for colorectal cancer (CRC). However, CRC incidence rates have increased
among young adults and have decreased among older adults.
Aims & Methods: The aim of this study was to investigate the risk factors of
colorectal polyps in young adults aged 550 years. From January 2016 to
December 2016, we compared the risk factors of colorectal polyp group with
non-polyp group in patients aged 550 years who underwent screening
colonoscopy. The risk factors examined included body mass index (BMI), meta-
bolic syndrome, smoking, alcohol consumption, age and gender.
Results: Of the 1862 patients, prevalence of colorectal polyps and adenomatous
polyps were 13.1% and 7.8%, respectively. Multivariate analysis revealed that
metabolic syndrome (OR, 1.89, 95% CI, 1.13–3.17, P¼ 0.015) was independent
predictor for colorectal polyps. Age over 40 years old (OR, 2.47, 95% CI, 1.48–
4.14) and metabolic syndrome (OR, 1.59, 95% CI, 0.87–3.30) were independent
predictors for adenomatous colorectal polyps.
Conclusion: Metabolic syndrome is risk factor of colorectal polyps in young
adults aged 550 years. Age over 40 years old is additional risk factor of adeno-
matous polyps.
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Introduction: Bowel cleansing has a critical role to increase the quality and effec-
tiveness of colonoscopy. International guidelines recommend the use of split-dose
regimens of PEG solutions. However, the adoption of split dose regimens in
clinical practice remains sub-optimal, in particular in early morning.
Aims & Methods: We aimed to compare the efficacy of bowel preparation using
an asymmetric split-dose regimen (approximately 25% of the dose is given on the
day of the procedure and 75% of the dose is given on the day before) with the
standard split-dose regimen in patients undergoing screening colonoscopy. We
prospectively enrolled consecutive outpatients undergoing screening colono-
scopy. All subjects received a split-dose preparation with a 2L PEG-citrate-
simethicone plus Bisacodyl. Patients were randomly assigned to: group A, asym-
metric split dose regimen (1.5 L of PEGþbisacodyl the day before and 0.5 L 3
hours before colonoscopy); group B, symmetric split dose regimen (1 L of
PEGþbisacodyl the day before and 1 L 4 hours before colonoscopy). Bowel
preparation was evaluated using the Boston Bowel Preparation Scale (BBPS)
score. The primary endpoints were the proportion of adequate bowel cleansing
(BBPS 2 in each segment of the colon). Moreover, all patients filled in a nurse-
administered questionnaire assessing compliance, tolerability and safety of bowel
preparation. The threshold for statistical significance in this study was p¼ 0.05
and a 10% margin was used to demonstrate non-inferiority of asymmetric vs.
symmetric split-dose regimen.
Results: 179 patients were enrolled (mean age 60 8 years, males 56%), 88 in
group A and 91 in group B. Split-dose was taken by 76/88 and by 77/91 patients
in group A and B, respectively (85.2% vs 88.5%, p¼ 0.831). Failure of cecal
intubation occurred in 1 patients for each group. In the ITT analysis, bowel
cleansing was considered adequate in 71/76 (93.4%) and 70/77 (90.9%) patients
respectively in group A and B (p¼ 0.765). BBPS total score was similar in group
A and B (6.9 1.2 vs. 6.9 1.4; p¼ 0.846). No differences were observed regard-
ing adenoma detection rate [32/76 (42.1%) vs 35/77 (45.4%); p¼ 0.745)] and
scores of each colon segment. The full amount of product and adjunctive
fluids were taken by 68/76 (89.4) and 71/77 (92.2%) (p¼ 0.158) in group A
and B, respectively. Tolerability and occurrence of adverse events were similar
in the two groups.
Conclusion: An asymmetric (low morning-dose) split-dose preparation with a low
volume formulation with additional Bisacodyl is not inferior to the standard
split-dose regimen in achieving an adequate bowel cleansing in patients under-
going screening colonoscopy. A lower amount of preparation in the morning
allow to the patients to wake up later; this regimen could be thus preferred by
patients undergoing colonoscopy early in the morning. Further study are needed
to determine the efficacy and tolerability of the asymmetric preparation for
colonoscopy scheduled in early morning.
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Introduction: Colorectal endoscopic submucosal dissection (ESD) is a technique
with remarkably greater difficulty than upper gastrointestinal ESD because of
unstable maneuvers and inherited anatomic variability in the colon. Thus, aiming
at reducing these restrictions, we have used single balloon (SB) overtube to assist
colorectal ESD in cases considered to have difficult operability. In this study, to
evaluate the usefulness of a single balloon overtube to assist colorectal ESD.
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Aims & Methods: The study included 35 patients with 39 colorectal lesions who
underwent the SB guided ESD (group SB). The treatment outcome of the group
was compared with that of another group that consisted of patients with 39
colorectal lesions who underwent ESD without SB (group NSB). The back-
grounds of the patients in group NSB were corrected by using the propensity
score matching method. The application of the combined use of SB was deter-
mined when the circumferential access to the lesion was difficult, and paradoxical
movement was observed.
Results: The characteristics of the lesions in group SB were as follows: proximal,
28 lesions; distal, 11; rectal, 0; mean size of tumors, 37.6 9.8mm; gross findings
of laterally spreading tumor of granular type (LST-G), 11 lesions; non-granular
type (NG) tumors, 28; adenomas, 11; mucosal cancers, 22; and submucosal
cancers, 6. The mean procedure time was significantly shorter in group SB (SB
group vs non-SB group: 67.36min vs 106.00min; p5 0.05). No significant dif-
ferences were found in en bloc resection, complete resection, postoperative bleed-
ing, and perforation rates. No accidental symptom associated with balloon
endoscopy was observed.
Conclusion: Using a single balloon overtube can be expected to improve not only
access to the lesion but also facilitate scope manipulation for colorectal ESD.
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Introduction: Endoscopic Submucosal Dissection (ESD) for colorectal lesions is a
highly skilled technique which over the last few years has been adopted by
Western countries for the management of colorectal neoplasia. There is no con-
sensus in the literature regarding the technique of anaesthesia/sedation method
for ESD. We aim to describe current sedation practices used in ESD in Western
Hospitals.
Aims & Methods: A systematic literature search was performed to identify all
articles describing colorectal ESD procedure performed in Europe, America and
Australia. Electronic databases including PubMed, the Cochrane library and
Embase were searched. Original articles or abstracts for congress in English
were included. A questionnaire was sent to the authors of the identified articles
in order to obtain additional information regarding sedation practice, if this was
not explicitly detailed in the original articles. All articles were examined indepen-
dently for eligibility by two reviewers (S.B. and M.S.). Any Disagreements were
resolved by consulting a third reviewer (A.P.)
Results: This review resulted in 18 eligible original articles, of which (5/18) 27.8%
were prospective studies, (7/18) 38.9% retrospective series and (6/18) 33.3% were
abstracts presented at congresses. The mean number of ESD cases described was
68 (range: 11–302). Most institutions opted to admit patients following the pro-
cedure (15) 83.3%, with just one managing patients on an entirely outpatient
basis. The mean duration of post procedure observation was 2 days (0–4). The
Endoscopy department was the chosen location for colorectal ESD in (12) 66.6%
of institutions and operating room (OR) for (4) 22.2%. In (2) 11.1% institutions
the preference was for OR in selected cases. Deep sedation with propofol or
propofolþmidazolam þ/ fentanyl was used in (8) 44.4% of the institutions.
General anaesthesia was used in (4) 22.2%, while conscious sedation was used in
(3) 16.7%. In (3) 16.7% of institutions deep sedation, conscious sedation or
general anaesthesia was used according to the cases and clinician decision. A
designated anaesthesiologist was in charge of sedation in (7) 38.9% of the insti-
tutions, with either nurse anaesthesiologist or an anaesthesiologist in (5) 27.8%, a
nurse anaesthesiologist alone in (2) 11.1%, the performing endoscopist in (2)
11.1%, endoscopy nurse in (1) 5.5% and a second physician in (1) 5.5% of
institutions.
Conclusion: The sedation strategy used in colorectal ESD in Western world is
heterogeneous. Most institutions opt for deep sedation administered by anaes-
thesiologists within the endoscopy room. By and large, patients are admitted post
procedure for observation. Greater sharing of experience is required to better
understand the optimal method of sedation for this technique within the context
of western practice.
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Introduction: Colonic polyp measurement is an important outcome in current
endoscopic practice. Polyp size estimation is mandatory to determine the surveil-
lance interval after polypectomy and useful to anticipate and prevent complica-
tions in therapeutic procedures, for it has been proven that polyp size is one of
the main risk factor of complications (bleeding, perforation). Nevertheless, a high
degree of subjectivity exists (especially overestimation of polyp size) in polyp size
estimation because of a lack of validated and reproductible measurement meth-
ods. The aim of this study was to compare a computer-aided polyp measurement
(CAPME) to an unassisted visual estimation (UVE) and an endoscopic reference
measurement (ERM).
Aims &Methods: This prospective monocentric study was led between November
2015 and July 2016 in the University-affiliated Hospital of Clermont-Ferrand,
the Blaise Pascal Institut (BPI) and the Image Science For Interventional
Techniques (ISIT) research unit of Clermont-Ferrand (France). Video-endo-
scopic procedures were recorded and secondly used for the CAPME method.
The endoscopic acquisition protocol was standardized with a slow back-and-
forth movement of the endoscope towards the polyp. A photography of each
polyp was taken with an open biopsy forceps placed on the base of the polyp.
ERM was then measured thanks to a simple rule of three knowing the fixed size
of the open biopsy forceps (8 millimetres, mm). UVE was determined on the
same photography without any measurement devices by two different endosco-
pists. All the measurements were realized blinded of the other results. Accuracy
of the CAPME and UVE methods was defined by a variation less than 1mm with
the ERM. We used the Lin concordance correlation coefficient (CCC) to measure
the agreement between the variables.
Results: 33 patients and 78 polyps were included in this study. The mean polyp
size was 5.3mm, with 73.1% (n¼ 57) of polyp less than 5mm. The Lin CCC with
the ERM was 0.972 (95% CI, 0.960–0.983; P5 0.001) for the CAPME method,
and was greater than the UVE Lin CCC (0.830; 95% CI, 0.797–0.863; p5 0.001).
Accurate polyp measurement was obtained for 68 polyps with CAPME method
(87.2%) versus 56 polyps (71.8%) for UVE assessment (p5 0.01). Inaccuracy
was increasing proportionally to polyp size (40.9% of inaccurate polyp measure-
ment for polyps greater than 10mm) and we observed a systematic overestima-
tion of supracentimetric polyps for UVE method. Unlike UVE, CAPME
accuracy was not impacted by polyp size variation in our study (11.1%; 14.7%
and 10.8% for polyps of 410mm; 5–10mm and 55mm respectively).
Conclusion: To our knowledge, this is the first prospective study with significant
data analysing a computer-aided polyp measurement in live colonoscopic proce-
dures. In our study, this methods shows more accuracy than the visual estima-
tion, which is the actual gold standard. The main limitation of this study is the
endoscopic protocol (back-and-forth movement of the endoscope) that increases
the endoscopic procedure. The use of DualFocus might be a solution to over-
come this problem.
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Introduction: Endoscopic Non-Technical Skills (ENTS) are an essential compo-
nent of high-quality endoscopy giving information about performance in a team
context however these are not routinely assessed as part of the key performance
indicators (KPIs) for independently practising colonoscopists. We have devel-
oped a validated 360-degree assessment tool based on assistant ratings for ENTS
(MARS tool) with acceptable inter-rater agreement providing an assessment in
4 key ENTS domains. We compared measured performance in these areas
against existing key performance indicators which measure aspects of insertion
and lesion detection skills.
Aims & Methods: We aimed to add a 360-degree multi-assessor rating scale
(MARS) to provide a global assessment of ENTS skills to the existing KPI
panel correlating the results against existing caecal intubation rate (CIR) and
polyp detection rate (PDR). The validated MARS tool assesses 4 ENTS
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domains–Communication (COMM), Situational Awareness (SITA), Leadership
(LEAD) and Judgement & Decision-making (J&DM). Each MARS domain was
represented by 10 items and is assessed on a 7-point scoring scale - endoscopists
should score 490 in each domain (80–90¼ need for improvement, 580¼ sub-
optimal performance). CIR and PDR measures are routinely calculated for all
colonoscopists using the HICCS Electronic Reporting System with manual vali-
dation of these data. Feedback is presented on a quarterly basis to practitioners–
endoscopists are expected to achieve 90% CIR and 20% PDR. Correlation of
these factors with practitioners ENTS scores were measured using the Pearson
test.
ENTS, CIR and PDR scores by colonoscopist
Operator COMM SITA LEAD T&DM CIR(%) PDR(%)
1 96 99 97 100 95.2 72.5
2 94 94 87 95 83.6 49
3 99 100 97 98 90.8 51
4 100 100 100 99 91.5 47
5 79 73 73 85 91.7 34.5
6 100 99 99 98 87.5 34.5
7 66 59 62 69 67.4 17
8 100 100 98 99 83.8 20
9 74 83 84 86 87.5 31.5
Results: 9 endoscopists with known variability in standard colonoscopy KPIs
consented to an assessment of ENTS using the MARS tool. Their ENTS
scores were correlated with existing KPIs for each colonoscopist (Oct 2016-
Mar 2017). Scatter plots provided an overall positive correlation between
ENTS domains and CIR (COMM 0.58; SITA 0.66; LEAD 0.66; J&DM 0.75)
and PDR (COMM 0.49; SITA 0.55; LEAD 0.50; J&DM 0.60). Three endosco-
pists were identified as having sub-optimal scores in all of the ENTS domains
(operators 5,7,9). Taking into account important KPI thresholds 2 out of 3
(33%) of these endoscopists identified were not meeting CIR targets (c.f. 66%
of ENTS competent group) and one (33%) did not meet PDR targets (c.f. 0% in
ENTS competent group).
Conclusion: The MARS tool is a practical way to measure of ENTS performance
designed as a 360 degree feedback and identifies areas for development within
independently practitioners that are not currently highlighted by standard colo-
noscopy KPI measures. There is some correlation with current KPI feedback
panels but using a specific validated ENTS assessment tool augments current
assessment panels. Both CIR and PDR primarily depend on the colonoscopists’
individual skills rather than the team elements required by polypectomy or EMR
and these more complex tasks may show stronger correlation with MARS ENTS
evaluation.
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Introduction: Colorectal Cancer (CRC) is the third most common cancer diag-
nosed in men and second most common cancer in women, affecting 1,361,000
people worldwide each year. CRC is a slow growing tumour that most commonly
develops from polyps which form in the inner lining of the colon or rectum. The
identification and removal of polyps whilst still in a precancerous state has been
shown to be effective in reducing mortality from CRC. Current clinical practice
relies on white light (WL) colonoscopy for detecting colorectal polyps, but this is
associated with a detection "miss-rate" of up to 26% for small (510mm) polyps
and 2% for large polyps (van Rijn et.al., 2006). Missed lesions (false negative
results) puts patients at an unnecessary risk of late stage detection, when manage-
ment has higher costs and worse clinical outcomes. Recent technological devel-
opments have resulted in more accurate technologies for polyp detection
becoming available. One such technology is the EMI-137 imaging agent
(Edinbugh Molecular Imaging (EMI))) which has demonstrated potential to
enhance the sensitivity of colonoscopy.
Aims & Methods: We aimed to evaluate the potential cost-effectiveness of EMI-
137 compared to standard WL colonoscopy in patients at high risk of colorectal
cancer. A de novo economic model for patients participating in the UK national
bowel cancer screening programme referred for colonoscopy as a result of a
positive faecal occult blood test was developed. The early economic modelling
approach consists of 5 stages: 1) literature review, 2) evidence synthesis, 3) care
pathway analysis, 4) decision analytic modelling, 5) sensitivity analysis and value
of information analysis. The structure of the models has been determined by
current recommended practice. The potential benefits of EMI-137 were identified
via interviews with endoscopists across Europe and communication with the
manufacturer. Early cost-effectiveness and value of information analysis will
be conducted to assess the viability of the EMI imaging technology to enhance
current NHS patient care, and to inform the necessity and direction of future
investments into the research and development of this intervention.
Results: The addition of EMI-137 fluorescent agent to standard WL colonoscopy
results in a lifetime per-patient average additional NHS cost of £426 and an
additional 0.04 QALYs, giving an incremental cost-effectiveness ratio (ICER)
of £11,245 per additional QALY. The cost-effectiveness of EMI-137 was sensitive
to the time horizon of the model. EMI-137 remained within the NICE recom-
mended cost-effectiveness threshold priced at $500 or less. Value of information
analyses revealed that uncertainty in the cost-effectiveness of EMI-137 is primar-
ily driven by uncertainty in the assumption that EMI-137 reduces the risk of
future polyps after polypectomy. The results of this modelling exercise have since
been used to inform the design of Phase II/III clinical studies.
Conclusion: The results of this early economic modelling exercise demonstrated
that EMI-137 has the potential to be cost-effective for patients participating in
the UK National Bowel Cancer Screen Programme. The value of information
analyses have highlighted the key parameters for which further evidence is
required, and this will be used to inform the design of future clinical studies.
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Introduction: Safety and diagnostic accuracy of colonoscopy depend on the qual-
ity of colon cleansing. Several factors have been reported to affect the quality of
bowel cleansing, one of them being hospitalized.
Aims & Methods: We performed a prospective, randomized endoscopist blinded
clinical trial between February 2016 and January 2017 included. Our aim was to
investigate whether the association of a visual educational booklet improves the
level of cleanliness achieved in hospitalized patients who are undergoing a colo-
noscopy. Hospitalized patients 418 years undergoing colonoscopy were
included. Exclusion criteria were: previous colonoscopy in the last 3 years, pre-
vious colectomy, known inflammatory bowel disease, urgent colonoscopy,
dementia or refusal to participate in the study. Both groups received 4L poly-
ethyleneglycol solution. The intervention consisted of a visual educational book-
let (visual cohort). Demographic data, personal history, reason for admission
and for colonoscopy, work shift in which it was performed, and findings at
endoscopy were collected. The Boston Bowel Preparation Scale (BBPS) was
used to assess the bowel preparation. A BBPS score 56 or with at least one
segment 52, was considered a poor preparation.
Results: One hundred and thirty six patients were included, 51.5% were male,
with a mean age of 64.3 17.6 years, and 95.59% of Spanish nationality. The
mean body mass index was 27.3 5.2 kg/m2. Educational attainment was below
school education in 71.05%. Most patients were submitted from the internal
medicine ward (72.1%), and the gastroenterology ward (21.32%). Anemia
(31.62%), abdominal radiographic findings (16.91%), hematochezia/rectal bleed-
ing (15.44%), diarrhea (11.03%), and abdominal pain (8.82%) were the most
frequent indications. Patient́s characteristics, bowel cleasing and endoscopic find-
ings are shown in table 1. The educational booklet did not suppose a difference in
the bowel cleansing attained. Factors that impacted on the level of well and
poorly prepared patients in the bivariable study were: age (62.1 18.7 vs
70.5 14.8; p¼ 0.0193), diabetes mellitus (22.33% vs 42.42%; p¼ 0.024), hyper-
tension (45.63% vs 69.70%; p¼ 0.016), cardiovascular disease 14.5% vs 36.3%;
p¼ 0.006), and colorectal cancer on colonoscopy (99% vs 81.82%; p¼ 0.001). In
the multivariable analysis the only factors associated with a poor bowel cleansing
were cardiovascular disease (OR 3.37 (1.34–8.46); p¼ 0.010), and colorectal
cancer on colonoscopy (OR 3.82 (1.26–11.61); p¼ 0.018).
Table 1: Baseline characteristics, bowel cleansing and endoscopic findings.
PATIENTS N¼ 136 (n)
Standard
management
(n¼ 70)
Educational
booklet
(n¼ 66) p
Age(year)* 66.2 (56.8–78.4) 63.3 (53.0–78.3) 0.54
Sex(Male) 51.43% 51.52% 0.99
BMI(Kg/m2)* 26.9 (24.4–29.7) 26.9 (23.5–29.9) 0.85
Diabetes Mellitus (136) 18 (25.71%) 19 (28.79%) 0.69
Hypercolesterolemia (136) 33 (47.14%) 33 (50%) 0.74
Smoking habit (136) 19 (27.14%) 15 (22.73) 0.55
Alcoholism (135) 8 (11.59%) 4 (21.21%) 0.13
Cardiovascular disease(136) 11 (15.71%) 16 (24.24%) 0.21
Chronic kidney disease(136) 5 (7.14%) 9 (13.64%) 0.21
(continued)
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Table 1 Continued
PATIENTS N¼ 136 (n)
Standard
management
(n¼ 70)
Educational
booklet
(n¼ 66) p
Chronic Obstructive Pulmonary Disease (135) 6 (8.70%) 5 (7.58%) 0.81
Obstructive Sleep Apnea Syndrome (136) 6 (8.57%) 3 (4.55%) 0.34
Cirrosis (136) 2 (2.86%) 2 (3.03%) 0.95
Stroke (135) 8 (11.59%) 8 (12.12%) 0.93
Mild dementia (136) 3 (4.29%) 1 (1.52%) 0.34
Constipation (135) 14 (20%) 9 (13.85%) 0.34
Antidepressants (136) 13 (18.57%) 7 (10.61%) 0.19
Family history of CRC (132) 7 (10.45%) 8 (12.31%) 0.74
ASA score 2 (121) 38 (59.37%) 32 (56.14%) 0.81
Need for diaper during admission (128) 9 (13.64%) 10 (16.13%) 0.69
Apendicectomy (136) 18 (25.71%) 4 (6.06%) 0.002
Umbilical herniorrhaphy(136) 3 (4.29%) 2 (3.03%) 0.70
Hysterectomy (136) 8 (11.43%) 4 (6.06%) 0.27
Caesarean (136) 1 (1.43%) 4 (6.06%) 0.15
Other gynecological surgery (136) 4 (5.71%) 5 (7.58%) 0.66
Other surgery (136) 21 (30%) 19 (28.79%) 0.88
COLONOSCOPIES RESULTS:
Work shift (morning) 58 (82.86%) 59 (89.39%) 0.27
Cecal intubation rates 67 (95.71%) 62 (93.94%) 0.49
BBPS* 7 (6–9) 6(5.7–9) 0.17
BBPS Left Colon* 2(2–3) 2(2–3) 0.37
BBPS Mild Colon* 2(2–3) 2(2–3) 0.10
BBPS Right Colon* 2(2–3) 2(2–3) 0.22
BBPS 5 15 (45.45%) 18 (54.55%) 0.43
Adenoma detection rate 29 (41.43%) 18 (27.27%) 0.40
Advanced Adenomas 9 (12.85%) 5 (7.57%) 0.48
Colonrectal cancer 8 (11.43%) 8 (12.12%) 0.90
Conclusion: The use of a visual educational booklet for the preparation of colo-
noscopies does not provide a significant improvement in hospitalized patients in
our health area. Heart disease and/or colon cancer were predictors of poor pre-
paration for colonoscopy. An optimized preparation should be considered for
this type of patients.
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Introduction: Primary sclerosing cholangitis (PSC) is often associated with auto-
immune diseases, and approximately 70% of PSC patients in Europe/United
States and 32% in Japan also have ulcerative colitis (UC). While the complica-
tion of PSC is confirmed in about 5% of UC patients, the clinical features of UC
associated with PSC differ from those of UC without PSC.
Aims & Methods: We investigated the clinical and colonoscopic features of colitis
associated with PSC. We retrospectively examined the clinical features, including
the clinical course and colonoscopic findings, of 25 colitis patients with PSC
attending our hospital between 2000 and 2016.
Results: The male-female ratio was 12:13 and the age at diagnosis of PSC was
49 15 years. PSC was the initial diagnosis in 12 patients (48%), while colitis was
the first to be diagnosed in 4 patients (16%), and both diseases were found
concurrently in 9 patients (36%). Among the 21 patients with the diagnosis of
PSC first or concurrently, 12 patients (57%) had no symptoms of PSC and the
latter was recognized by screening. There were 12 patients with UC (52%) and 11
patients with nonspecific colitis (48%). Among the 24 patients in whom the
disease extent was assessed, 22 had pancolitis, 1 had left-sided colitis, and 1
had proctitis. Inflammation predominantly affected the right colon in 20/22
patients with pancolitis and also involved the terminal ileum in 9 patients
(48%). The Mayo score for colonoscopic evaluation of UC was 1 in 16 patients
(64%), 2 in 8 patients (32%), and 3 in 1 patient (4%). There were no rectal lesions
in 10 patients (40%). Liver biopsy was performed in 17 patients, and Ludwig’s
stage was Stage I in 1 patient (6%), Stage II in 12 patients (71%), Stage III in 3
patients (18%), Stage IV in 1 patient (6%). Ludwig’s stage did not correlate with
the Mayo score. All patients with PSC and enterocolitis received oral
ursodeoxycholic acid (UDCA), including 13 patients with UDCA only (52%),
2 patients with combination of salazosulfapyridine (SASP) (8%), 5 patients in
combination with 5-aminosalicylic acid (5-ASA) (20%), 2 patients in combina-
tion with prednisolone (PSL) (8%), 1 patient with the combination of
SASPþPSL (4%), and 2 patients with 5-ASAþPSL (8%). The UDCA dose
was 300mg in 2 patients (8%), 600mg in 15 (60%), and 900mg in 8 (32%).
Conclusion: In colitis patients with PSC, there was no clear association between
colonoscopic disease activity and the severity of PSC. There was no sex difference
and the age at diagnosis of PSC showed a bimodal distribution (30 s and 60 s).
Pancolitis was very frequent and predominantly affected the right colon, but
disease activity was low. Rectal lesions were mild or absent. About half of the
patients had inflammation of the terminal ileum.
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Introduction: Endoscopic non-technical skills (ENTS), comprising of communi-
cation and teamwork, situation awareness, leadership and judgement and deci-
sion-making, are recognised indicators of quality endoscopy and patient safety.
Since July 2016, electronic assessment forms (DOPS) for UK trainee endosco-
pists have been updated to include ENTS as an assessable domain. We aimed to
assess the uptake and distribution of ENTS scoring in DOPS and their correla-
tion with other endoscopic skills, across all assessable endoscopic modalities.
Aims & Methods: We identified all DOPS submitted between July 2016 and Feb
2017 from the UK endoscopy trainee database (JETS) and acquired data on
trainees, procedures and scores. We collated scores for each of the 4 assessable
domains (pre-procedural, procedural, post-procedural and ENTs) into overall
outcomes of ‘‘not competent’’ (if any domain items required supervision) or
‘‘competent’’, and compared this to the overall competence rating. Statistical
analysis was performed using chi2 and regression modelling.
Results: 8601 DOPS were prospectively collected, with ENTS assessed in 99.3%.
Competency rates of individual ENTS items are summarised in Table 1. Rates of
overall ENTS competency (defined as all items scoring competent) varied across
procedures (p5 0.001): ERCP 39.8%, EUS 44.1%, gastroscopy 59.6%, colono-
scopy 62.3%, PEG 71.1%, gastrointestinal bleed (71.5%), sigmoidoscopy 72.4%
and polypectomy 73.2%. Scores by individual ENTS components are displayed
in Table 1. Of DOPS awarded overall competency, 5.9% (240/4077) lacked full
competence in ENTS (p¼ 0.10 across modalities). Across trainee specialties and
endoscopic modalities, competence was greatest for ‘‘communication and team-
work’’ (77.1% overall), but least with ‘judgement and decision making’ (68.3%).
Competency in ENTS increased with lifetime procedural count (OR 1.008 per
increase in procedure, p5 0.001), and correlated strongly with other assessable
domains, including overall score (p5 0.001). After adjusting for procedural
count, factors predictive of ENTS competence included trainee seniority (OR
for ST5 level: 1.96, p5 0.0001), surgical trainees (OR 1.21, p¼ 0.014), trainees
performing polypectomy (OR 2.02, p5 0.0001), and higher DOPS count (OR
1.03 per increase in DOPS, p5 0.001).
Table 1: Unadjusted ENTS scores by endoscopic modality.
Communication
and Teamwork
Situational
Awareness Leadership
Judgement
and Decision
Making
Colonoscopy 77% 75% 70% 68%
Dilatation 78% 75% 64% 64%
Polypectomy 82% 83% 81% 77%
ERCP 65% 62% 54% 48%
EUS 71% 71% 47% 59%
Sigmoidoscopy 83% 81% 79% 74%
OGD 73% 70% 67% 64%
PEG 80% 76% 78% 77%
Gastrointestinal Bleed 85% 83% 78% 77%
Conclusion: ENTS is an assessable domain within endoscopy training, with scores
that correlate with other procedure-related skills, demonstrating construct valid-
ity of the ENTS scoring system. Competency of ENTS develop with procedural
count, and vary with trainee seniority and specialty. Longer term data are
required to assess the impact of ENTS on certification.
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Introduction: The development of Endoscopic Non-Technical Skills (ENTS) is
associated with expert performance and high quality endoscopic outcomes.
Whilst ENTS domains have been incorporated into Joint Advisory Group
(JAG) Direct Observation of Procedural Skills (DOPS) forms, used as training
tools, knowledge of ENTS domains amongst independent practitioners varies.
To improve performance in this area of practice requires validated measurement
tools and specific feedback against which improvement can be measured. We
have previously developed a validated 360-degree multi-assessor rating scale
(MARS tool) based on experienced endoscopy assistant ratings for ENTS pro-
viding data on 4 main domains of ENTS–each comprising 10 related but inde-
pendent practice points. Providing an optimised feedback format for this data is
likely to maximise the potential benefits of measruing ENTS performance.
Aims & Methods: We aimed to provide an optimised format for performance
enhancing feedback in the ENTS domains and basis for specific auditable out-
comes and performance indicators. Local colonoscopists gave consent to appli-
cation of the ENTS questionnaire. The validated MARS tool assesses 4 ENTS
domains–Communication (COMM), Situational Awareness (SITA), Leadership
(LEAD) and Judgement & Decision-making (J&DM). Each MARS domain in
the administered questionnaire was represented by 10 items and is assessed on a
7-point scoring scale. We sought to develop 1) a format to illustrate an indivi-
dual’s overall performance in each of the 4 main ENTS domains in comparison
to other operators and 2) a detailed domain breakdown highlighting areas of
underperformance 3) Collate feedback on the presentation formats.
Results: 9 endoscopists consented to an assessment of ENTS using the MARS
tool. The MARS questionnaires were administered during January 2017–relating
to the prior 3 months clinical practice. Acceptable performance thresholds were
set as 490% good-excellent ratings in each domain. Need for improvement was
defined as 80–90% good-excellent ratings (i.e. 10–20% average or poor ratings)
and sub-optimal performance as 80% or less good-excellent ratings (i.e. 420%
average-poor ratings). Good intra- and inter-rater reliability was demonstrated
for these cut-off values during validation of the MARS tool. Scatter plots were
used to present the overall domain ratings for COMM, SITA, LEAD and J&DM
domains allowing comparison with other endoscopists. To provide more detailed
domain-specific feedback to endoscopists an individual report is generated of 4
domain tables summarising the question items and using a ‘traffic-light’ display
to help operators quickly identify those specific skills that require areas for
improvement. All endoscopists reported finding the ENTS feedback helpful
and indicated that it was ’likely’ or ’very likely’ to prompt an alteration in
practice. A suggestion to add an additional column to the summary table indi-
cated where performance level has changed in subsequent audit rounds is being
considered.
Example Feedback table - Situational Awareness Domain for Endoscopist 9
SITA 1 Pre-assessment of potential patient risks GREEN
SITA 2 Recognises problems in a timely fashion GREEN
SITA 3 Aware of working environment, minimises disruptions GREEN
SITA 4 Effectively troubleshoots technical problems that arise RED
SITA 5 Recognises and assesses pathological findings effectively GREEN
SITA 6 Reacts flexibly and effectively to unexpected or
unforeseen circumstances
RED
SITA 7 Aware of patient safety parameters during procedure, responds well AMBER
SITA 8 Considers other opinions and guidance when faced with
an untoward event
AMBER
SITA 9 Predicts well the likely outcome of a situation and plans
for this eventuality
AMBER
SITA 10 Constantly checks patient aiming to minimise procedural discomfort AMBER
Conclusion: The MARS tool is a practical way to measure ENTS performance
alongside other key performance measures as part of a robust quality assurance
system. The benefits of providing overall comparative data has been established
previously in sharing more established key performance indicators. The feedback
format for data derived from the MARS tool has additionally provided detailed
domain-specific ENTS performance ratings that brings to attention areas for
improvement in a clear and understandable way that can be re-tested as part
of an integrated audit cycle.
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P1497 OUTCOMES OF ENDOSCOPIC RESECTION OF COMPLEX
COLORECTAL LESIONS REFERRED TO A TERTIARY
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A. Emmanuel, S. Gulati, M. Burt, B. Hayee, A. Haji
Endoscopy, King’s College Hospital, London/United Kingdom
Contact E-mail Address: aemmanuel@nhs.net
Introduction: Substantial manipulation or sampling of large colorectal lesions
prior to endoscopic resection can have significant effects on the feasibility and
outcomes of endoscopic treatment. Failed attempts at resection and extensive
sampling or tattooing into lesions prior to referral to a specialist centre are
common in western practice. However, there are few data defining the scope of
the problem and the effects on outcomes following endoscopic resection. We
examined the effect of significant prior manipulation on the feasibility and out-
comes of endoscopic resection of complex colorectal neoplasms in a UK tertiary
referral centre.
Aims & Methods: Consecutive patients who underwent endoscopic resection of
colorectal lesions 2 cm were included. All lesions were assessed with magnifica-
tion chromoendoscopy supplemented by colonoscopic ultrasound in selected
cases. A lesion specific approach was used to decide on resection technique.
Patients were grouped according to whether they had previous failed attempts
at resection, heavy manipulation (6 biopsies or tattoo into the lesion), or mini-
mal sampling only (56 biopsies). Outcomes included initial successful endo-
scopic resection, complications, recurrence and the need for surgery.
Results: 426 of 437 lesions were successfully resected (97.5%) using EMR
9n¼ 340 and ESD and Hybrid ESD (n¼ 97). The mean lesion size was 5.5 cm
(þ/ 3.0 cm). 225 (51%) lesions had been subjected to failed attempts at resection
or heavy manipulation prior to referral. In 97 lesions (22%), an average of 1.5
(range 1–5) previous attempts at resection had been made, including 43 attempts
at transanal surgical resection in 25 patients. A further 128 lesions (29%) had
been extensively sampled or tattooed Mean lesion size was 55.6mm þ/30.7mm.
Initial endoscopic resection was deemed successful in 98% of cases after previous
failed attempts, 97% of cases with prior heavy manipulation and 97% of other
cases (p¼ 0.86). En bloc resection was possible in fewer patients with previous
attempts at resection (14%, 31% and 42% respectively, p5 0.001). Complication
rates were higher for patients with prior heavy manipulation compared to those
with failed attempts at resection and minimal sampling (14% versus 5% and 3%,
p5 0.001). Recurrence rates were 24.1%, 14.6% and 12.2% respectively
(p¼ 0.07). 95% of patients without invasive cancer who had prior failed attempts
at resection were free from recurrence and had avoided surgery at last follow up.
Conclusion: Failed prior attempts at resection or heavy manipulation of lesions
reduces the chance of achieving en bloc resection and increases the risk of com-
plications and recurrence. Nevertheless, specialist management in a dedicated
tertiary unit results in safe and successful organ preserving endoscopic treatment
of these extremely challenging lesions in over 95% of cases with few significant
complications.
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OBSERVATION OF MUCOSAL BLOOD FLOW IN THE SMALL AND
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(BLUE LASER IMAGING)?
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Introduction: In recent years, significant advances and innovations have been
made in gastrointestinal endoscopy technology. The special light observation
using a narrow band light source different from conventional white light is one
such innovation. The special light observation with a magnifying procedure has
markedly contributed to improving the diagnosis of lesions in the esophagus,
stomach, and large bowel; it is particularly useful for differentiating between
benign and malignant lesions and evaluating the depth of invasion. The instru-
ments for narrow band imaging (NBI) were developed by Olympus Co., Ltd.,
and those for blue laser imaging (BLI) by Fujifilm Co., Ltd. These systems are
applied to magnifying endoscopy in clinical practice. Studies have examined the
usefulness of magnifying observation with NBI (m-NBI), BLI (m-BLI), and new
and brighter BLI (m-BLI bright) for the diagnosis of neoplastic diseases, espe-
cially for the early detection of gastrointestinal cancers. However, there are
relatively few reports describing the application of these techniques to benign
diseases.
Aims & Methods: This basic study aimed to explore the potential of magnifying
endoscopic observation with special light by evaluating the visualization of
mucosal blood flow in the small and large bowel. The subjects were selected
from among patients who had undergone colonoscopy since April 2016. They
were randomized into three groups: patients undergoing examination with EC-
L600ZP, a high-end instrument manufactured by Fujifilm Co., Ltd. (group F),
CF-HQ290ZI, a high-end instrument manufactured by Olympus Co., Ltd.
(group O1) or PCF-H290ZI manufactured by Olympus Co., Ltd (group O2).
Each group consisted of 25 patients. The visualization of mucosal blood flow
in the small and large bowel by magnifying endoscopic observation with special
light was evaluated and scored as follows: good visualization 2; partial visualiza-
tion 1, and no visualization 0. The water method and tip attachment were used in
all cases.
Results: The respective mean scores for visualization of the small and large bowel
were 2 and 2 in group F, 1.32 and 1.24 in group O1, and 1.48 and 1.40 in group
O2. The visualization scores for both the small and the large bowel were signifi-
cantly higher in group F than in groups O1 and O2. Group O2 had higher scores
than group O1, although the difference was not statistically significant. The
endoscope used in group F has a bright laser light source and maximum optical
magnification levels up to 135 times and maximum electronic magnification
levels up to 270 times. On the other hand, the endoscopes used in groups O1
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and O2 have relatively dark xenon light sources and maximum optical magnifi-
cation levels up to 80 and 110 times, respectively. Therefore, the differences in
visualization of mucosal blood flow in the small and large bowel among the
groups were considered to be attributable to differences in instrument efficiency.
Conclusion: Our results show that magnifying observation with BLI is superior to
that with NBI regarding the observation of mucosal blood flow in the small and
large bowel. We are planning to conduct a study on the clinical application of
magnifying observation with BLI for visualization of mucosal blood flow in the
small and large bowel.
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Introduction: Multiple colorectal adenomas (MCRA) can be defined as an endo-
scopic feature of  10 colorectal adenomas in patients (pts) without APC or
MUTYH germline mutation. At present its clinical features, management and
the presence of extracolonic cancer are not well studied.
Aims & Methods: The aim of the present study is to better define the clinical
characteristcs at diagnosis and during follow-up of MCRA affected patients.
Forty-eight patients (22 Females, 26 Males) with MCRA (10 colorectal adeno-
mas), without deleterious mutations of APC or MUTYH genes, were recruited
for the study. Clinical features at diagnosis and extracolonic manifestations were
recorded. Forty patients underwent annual colonoscopy at our division with a
mean follow-up of 8.1 years (range 1 to 38y). Findings from esophagogastroduo-
denoscopy were also recorded. Eight patients were lost at follow-up.
Results: The mean age at MCRA diagnosis was 50.1 14.6 years (range, 19 to 79
years) and 20 pts (41.6%) had at least a first degree relative affected with color-
ectal neoplasia. Clinical features at diagnosis: the number of polyps ranged
between 10 and 20 in 43.7% of the cases; 21 and 50 in 27.1%; 50 in 29.2%;
22.9% of pts had one or more adenocarcinomas (ADC); 16.6% had a previously
diagnosed extracolonic cancer (breast, endometrial, thyroid, lung, bladder, brain,
larynx). Twenty-five pts (52%) needed surgery, ten underwent a subtotal colect-
omy and fifteen a total colectomy. During follow-up twenty-two (55%) pts
developed recurrent adenomas and two (5%) had one or more ADC in the
retained colorectum; 12,5% of pts developed duodenal adenomas, one had a
duodenal adenocarcinoma; we recorded one case of abdominal wall desmoid.
Conclusion: MCRA patients in the present study had similar clinical character-
istics to MUTYH associated Polyposis (MAP) affected patients. They were gen-
erally diagnosed at a mean age of 450 years, they had more than 20 polyps
(56.3%) at diagnosis, associated with ADC in 22.9% of the cases and required
surgery in the majority of cases (52%). During follow-up, pts also developed
recurrent adenomas. Clinical characteristics and family history in these patients
support the hypothesis that pathogenic alterations in yet unknown genes may be
involved. Next-generation sequencing is a promising technology aimed at this
purpose. However, these patients should undergo a closer surveillance than those
with sporadic adenomas.
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Introduction: A degree of fibrosis on targeted lesion is one of the widely known
factors which affects the results of Endoscopic mucosal resection (EMR) and
Endoscopic submucosal dissection (ESD). Severe fibrosis is associated with com-
plications such as perforation, post-coagulation syndrome and bleeding.
Discovering the factors causing fibrosis of tumor could help sorting patients
who is suitable for endoscopic removal of colon tumor. Generally a biopsy is
performed on a tumor larger than 2 cm in diameter for a diagnose purpose.
Fibrosis can be caused by biopsy performed before resection.
Aims & Methods: We conducted a study to evaluate the relationship between
numbers of biopsies and degree of fibrosis in colon. We retrospectively enrolled
149 lateral spreading tumors (LSTs) from 145 patients who underwent colon
ESD or EMR between January 2005 and May 2016. All LSTs were larger
than 2 cm and conducted en-bloc resection. We included elevated or flat type
LSTs and excluded lesions of the depressive or ulcerative type. Each data is
categorized with prior biopsy status, numbers of biopsies. Degree of fibrosis in
resected tumors by EMR or ESD was classified as 0 (no fibrosis), 1 (few), 2
(moderate), 3 (much) by pathologist. Distribution (focal, scattered, and diffuse)
and depth (mucosa, submucosa, mucosa and submucosa) of fibrosis were also
analyzed.
Results: The mean age of patients was 62.9 11.1 years old. Of the total 149
lesions, preprocedural biopsies were performed in 109 lesions (73.2%) and
biopsy was not performed in 40 lesions (26.8%). The size of lesions was 54.4%
in 20–30mm, 28.2% in 30–40mm, and 17.4% in 440mm and the histologic type
of lesions was 60.4% in adenoma, 20.8% of intramucosal cancer, and 18.8% of
submucosal cancer, respectively. Signs of fibrosis were present on 45.9% (50/109)
of patients with prior biopsy, and 40.0% (16/40) of patients without prior biopsy.
(P¼ 0.326) There was no significant difference in degree (P¼ 0.791), distribution
(P¼ 0.941) and depth (P¼ 0.748) of fibrosis between groups with or without
prior biopsy. In relationship between pathologic results and the presence of
fibrosis, the percentage of adenoma, intramucosal cancer, SM-1(51000mm)
cancer and SM-2(41000mm) cancer with fibrosis were 32.31%, 66.67%, 87.5%
and 90% (P¼0.00). Additionally, the fibrosis rate for tumors 3 cm and 43 cm
were 44.12% and 58.97% (P¼ 0.002). When biopsies were performed two or
more times on a same lesion, it showed significant difference comparing to
patients who only underwent biopsy just once. (OR 4.98, 1.20–20.51, 95% CI,
P¼ 0.026)
Conclusion: Degree, distribution and depth of fibrosis were not associated with
prior biopsy status. However, the more invasive tumor is, the more presence of
fibrosis was found. Moreover, the caution should be needed when performing
multiple biopsies because; multiple biopsies are more likely to cause fibrosis.
Disclosure of Interest: All authors have declared no conflicts of interest.
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P1501 ADVANCED NEOPLASIA YIELD IN PATIENTS
UNDERGOING COLONOSCOPY AFTER SCREENING FLEXIBLE
SIGMOIDOSCOPY: DOES THE DISTAL COLONIC PATHOLOGY
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Introduction: Currently patients undergoing a screening flexible sigmoidoscopy
(Bowel Scope screening) examination at the age of 55 are referred for colono-
scopy if the following polyp criteria are met: polyp41 cm, villous histology, high
grade dysplasia, 3 or more adenomas or 420 hyperplastic polyps (HP).
Aims & Methods: Objective is to assess the proportion of patients who had an
advanced adenoma (size4 1 cm, villous or high grade dysplasia on histology) in
the proximal colon when referred for a colonoscopy after a screening flexible
sigmoidoscopy. A retrospective cross-sectional study of patients who underwent
Bowel Scope screening between July 2013 - July 2016 at St Mark’s Bowel Cancer
Screening (BCS) Centre was performed. Epidemiology, procedural and polyp
data were retrieved from the endoscopy and Bowel Cancer screening database.
Results: 9960 patients had a screening flexible sigmoidoscopy in the time period.
Descending colon was reached in 82% of patients. Advanced adenomas were
detected in 351 (3.2%) patients. 520 (5.2%) patients had a colonoscopy following
screening flexible sigmoidoscopy as per the BCS protocol. Median age was 55
years (male: female ratio 2:1). Caecal intubation was achieved in 98% (510/520)
of cases. At least one adenoma or a sessile serrated adenoma/polyp (SSA/P) was
detected, proximal to the extent of flexible sigmoidoscopy examination, in 45%
(232/520) of patients (Table 1). Presence of advanced adenoma in the distal colon
was an indication for colonoscopy in 351/520 patients (68%). Of these, 52
(14.8%) had a synchronous proximal colonic advanced adenoma and 20
(5.7%) had a synchronous SSA/P. Only 5 (1.4%) patients had an advanced
SSA/P (polyp 41 cm or with dysplasia) in the proximal colon. Presence of
distal advanced adenoma was associated with proximal advanced adenoma
(p¼ 0.0006). However, there was no association between presence of distal
advanced adenoma and proximal SSA/P (P¼ 0.47) or advanced SSA/P (p¼ 0.4).
Table 1: Proximal colonic pathology during colonoscopy
(continued)
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Table 1 Continued
Indication
Number
of patients
Proximal
Advanced
adenoma
Proximal
SSA/P
Proximal
advanced
SSA/P
Indication
Number
of patients
Proximal
Advanced
adenoma
Proximal
SSA/P
Proximal
advanced
SSA/P
Adenoma41 cm 153 14.4% 8.5% 2.6%
Villous features 189 14.3% 3.2% 0.5%
High-grade dysplasia 9 36.4% 8.3% 0%
Others(41 cm non adenomatous
polyp,420 hyperplastic
polyps, 43 adenomas)
169 5.3% 5.8% 1.6%
Conclusion: Distal colonic advanced adenomas are a marker of synchronous
proximal colonic adenomas and sessile serrated polyps. When colonoscopies
were performed for other indications (non-adenomatous polyp 41 cm, multiple
distal HP polyps) the yield in the proximal colon was significantly smaller. These
‘‘soft’’ indications for colonoscopy accounted for a significant additional work-
load that appears unjustified.
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P1502 LEARNING CURVE FOR OPTICAL DIAGNOSIS OF
COLORECTAL POLYPS USING CUMULATIVE SUM ANALYSIS
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Introduction: Optical diagnosis for diminutive and small colorectal polyps is an
attractive option to reduce costs and streamline patient care. The American
Society of Gastrointestinal Endoscopy Preservation and Incorporation of
Valuable Endoscopic Innovations (PIVI) established a 90% diagnostic threshold
for real time endoscopic assessment of the histology of diminutive colorectal
polyps. For adoption of optical diagnosis in clinical practice, colonoscopists
must be trained and show on-going competance. The learning curve for trainees
to achieve the competency has not been fully explored.
Aims & Methods: Aim is to evaluate the minimum number of polyps to achieve
and maintain the optical diagnostic thresholds per PIVI standards using an
upward CUSUM plot. Four trainees without previous experience in optical diag-
nosis at our institution participated in this prospective study. Four weeks before
the commencement of the study they were given a training module on optical
diagnosis (OD). OD was based on NICE and WASP classification.1,2 During the
study period (January 2016-August 2016), each trainee documented the optical
diagnosis of polyps less than 10mm in size. Confidence levels of OD were noted
at the same time. Patient demographics and polyp details (site, size, Paris classi-
fication and histology) were collected prospectively. OD of each polyp was com-
pared against the polyp histology. Polyps without the histological confirmation
were excluded from the analysis. Every trainee had on-going feedback on their
performance.
Results: A total of 708 polyp observations were performed by trainees during the
study period. Total number of adenomas, hyperplastic polyps and sessile serrated
adenomas/polyps (SSA/P) were 364,214 and 52 respectively. Trainees OD per-
formance was plotted on a upward CUUM plot.
Table1: Trainees optical diagnostic performance
Trainee1 Trainee 2 Trainee 3 Trainee 4
Sensitivity 95% 96% 94% 92%
Specificity 91% 87% 83% 91%
Positive Predictive Value 89% 94% 88% 94%
Negative Predictive Value 92% 92% 91% 93%
All 4 trainees achieved sustained accuracy (90% threshold) in OD within 12–58
observations. The number of polyps required to reach the plateau varied between
12 to 58. Every trainee’s confidence level improved over time (from 69% to 89%)
and the effect was augmented by in-vivo feedback and revision of training
module. Table 1 summarises the optical diagnostic performance of all 4 trainees.
Negative predictive value for adenomas were above 90% for all trainees.
Conclusion: The CUSUM scores of all 4 trainees in the study reached the PIVI
standards plateau by the 58th polyp observation. In-vivo feedback and continued
training appears important to maintain the performance. Our preliminary find-
ings could be used as a guide to plan the certification process for implementation
of optical diagnosis.
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P1503 THE CLINICAL VALUE OF ENDOSCOPIC FULL-
THICKNESS RESECTION FOR THE TREATMENT OF
COLORECTAL SUBMUCOSAL TUMORS ORIGINATING FROM THE
MUSCULARIS PROPRIA: A PROSPECTIVE SINGLE-CENTER
STUDY
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Introduction: Given diminishment of quality of life caused by colectomy and
rectectomy, a minimally invasive treatment is desirable for colorectal submucosal
tumors (SMTs).
Aims & Methods: The aim of the current study was to evaluate the clinical
efficacy, safety and feasibility of endoscopic full-thickness resection (EFTR)
for colorectal SMTs originating from the MP layer. A prospective study was
carried out, including a consecutive cohort of 56 patients who underwent
EFTR for colorectal SMTs originating from the MP layer between January
2008 and September 2014 in our center. Among these lesions, 21 located in the
colon, 9 located in the intraperitoneal rectum and 26 located in the extraperito-
neal rectum. The tight adhesion of the lesion to the serosal layer was identified
before EFTR in all cases. EFTR was performed using a standard ESD technique
under direct endoscopic view. The defect of colorectal wall was closed after
resection in all cases. Complete resection rate, complications and lesion recur-
rence were evaluated.
Results: Successful EFTR was performed in 54 (96.4%) patients. The other 2
patients were transferred to suffer laparoscopic right hemi-colectomy and EFTR
combining laparoscopic operation respectively, because the lesions involved the
external organs and were too difficult to get en bloc resection endoscopically. The
en bloc resection rate and complete resection rate were both 96.4% (54/56).
Among 54 cases, 52 of these lesions were performed with EFTR without laparo-
scopic assistance, while 2 needed laparoscopic assistance to get the defect closed
after resection. The median operation time was 45min (range, 20–130min). The
median maximum diameter of resected tumors was 1.5 cm (range, 0.5–5.0 cm).
Accurate histopathologic results were acquired from all the resected lesions,
including 18 leiomyomas, 11 gastrointestinal stromal tumors (GISTs), 8 fibrous
tumors, 5 schwannomas, 11 granulomas, 2 displaced endometrium, and 1 hamar-
toma. Three patients had local peritonitis and two patients developed postopera-
tive bleeding. All of them recovered after receiving conservative treatments. No
single case developed diffuse peritonitis. No lesion residual or recurrence was
found during the follow-up period ranging 2–54 months.
Conclusion: EFTR appears to be a safe, feasible, and effective procedure for
providing accurate histopathologic evaluations, as well as a curative treatment
for colorectal SMTs originating from the MP layer. However, it should be per-
formed by the very experienced endoscopists.
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Introduction: Colonic ESD has been becoming a standard treatment in the world.
However, sometimes it is hard to remove the colon tumor during ESD. When we
find it difficult to detach the colorectal neoplasm in ESD, we have to consider,
the following three points: if we don’t have enough experience and skill, we
should take the training more. If there are lots of vessels and fibrosis in the
submucosal layer, it is necessary to choose adequate tools. And if patients
have complicated colon, suitable endoscope need to be selected. In such cases
we always use DBE.
Aims & Methods: We evaluated the outcomes of colonic ESD by using DBE
(DBE-ESD). Short DBE we used were EC450BI5, EN530BI and EI580BT
(Fujifilm Co., Tokyo, Japan). We’ve performed DBE-ESD on 211 lesions in
184 patients. We analyzed the lesions located in the proximal colon, and the
following items were examined: arrival time, procedure time, rate of negative
margin, perforation rate, length of hospital stay and recurrence rate in the 5th-
year after the ESD.
Results: There were 159 lesions located in the proximal colons. The median
arrival time to the lesion was 7.9min, operation time 51.1min, negative rate of
horizontal margin 99.4%, vertical margin 99.4%, perforation rate 0%, median
length of hospital stay 3.1 days., and recurrence rate in patients with more than 5
year follow-up 0%.
Conclusion: Because the balloons and the overtube retained the scope at stable
position, we were able to get good working space. Therefore, DBE should be one
option for difficult cases in ESD.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Adenoma detection rate (ADR) is a quality indicator of screening
colonoscopy. Monitoring withdrawal time (WT) and use of full-spectrum endo-
scopy (FUSE) have been suggested to increase the ADR since allow an accurate
evaluation of the hidden areas of the colon.
Aims & Methods: We aimed to evaluate whether monitoring of WT alone or in
combination with the use of FUSE would be able to increase the ADR. In a
prospective non-randomized observational study, consecutive outpatients, aged
18–85 yr, undergoing colonoscopy with different indications were enrolled. In
phase 1, endoscopists performed 660 colonoscopies either with standard forward-
viewing endoscope (SFVE) (n¼ 330) or with FUSE (n¼ 330) without a dedicated
WT protocol. In this phase, colonoscopy WTs were measured without the endos-
copists’ knowledge of being monitored. In phase 2, endoscopists were informed
of being monitored and performed further 660 colonoscopies either with SFVE
(n¼ 330) or with FUSE (n¼ 330).
Results: No differences were observed among the four arms in terms of demo-
graphic, clinical features, and indications to colonoscopy. WT was lower in phase
1 arms compared to phase 2 arms (SFVE: 267 96 vs. 387 65, p¼ 0.001;
FUSE: 293 112 vs. 430 93, p¼ 0.001). When endoscopists were aware of
being monitored and used full-spectrum endoscope we observed a higher ADR
[phase 1 SFVE 27.3% (90) phase 1 FUSE 33.0% (109) phase 2 SFVE 33.6%
(111) phase 2 FUSE 41.8% (138); p¼ 0.001] and adenoma per colonoscopy
(APC) [phase 1 SFVE 0.43 0.85 phase 1 FUSE 0.56 1.08 phase 2 SFVE
0.65 1.24 phase 2 FUSE 0.71 1.08; p¼ 0.004]. The detection rate of adenoma
located proximally to the splenic flexure was higher in phase 2 arms (phase 1
SFVE 11.2% vs. phase SFVE 16.4%, p¼ 0.056; phase 1 FUSE: 12.7% vs. phase
2 FUSE 18.9%, p¼ 0.033), whereas adenoma located distally to the splenic
flexure was higher in the FUSE arms compared to SFVE arms, but these differ-
ences were not significant (Phase 1 SVFE 20.0% vs. Phase 1 FUSE 24.8%,
p¼ 0.081; Phase 2 SVFE 21.8% vs. Phase 2 FUSE 27.0%, p¼ 0.147).
Conclusion: Unmonitored endoscopists have a sub-optimal WT, which increases
when they are aware to be monitored. Use of full spectrum scopes combined with
WT monitoring results in increase of adenoma detection rate. In particular,
monitoring WT increases the detection of adenomas in proximal colon, whereas
the use of FUSE seems to increase the detection of adenomas in distal colon.
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Introduction: Colonoscopy with polypectomy is considered the optimal method
of bowel cancer prevention. Despite improvements in colonoscopy training and
technology, it remains as an imperfect tool and the adenoma miss rates vary
between 6–27%.
Aims & Methods: Aim is to determine the presumed miss rate for adenomas and
sessile serrated adenomas/polyps (SSA/Ps) after a complete screening colono-
scopy Methodology A prospective observational study was performed at our
bowel cancer screening centre over 12 months from July 2015. Patients who
underwent a surveillance colonoscopy following an index colonoscopy were
included (one and three-year surveillance). All colonoscopies were performed
by 6 experienced, accredited bowel cancer screening colonoscopists. Polyp char-
acteristics and procedural data were prospectively recorded and collected. Polyp
histology and epidemiology data were retrieved from our endoscopy database. A
polyp was considered as ‘‘missed’’ at the index colonoscopy if at 1 year surveil-
lance it was not adjacent to a scar (a recurrence) or at 3 years if 45mm in size
and not adjacent to a scar.
Results: 241 patients underwent a surveillance colonoscopy (male: female 2:1,
median age 65 years). 90/241(37.3%) patients had a one-year surveillance colo-
noscopy. There was no significant difference in the quality of bowel preparation,
caecal intubation rate and total procedure time between index and surveillance
procedures. Total number of polyps detected during index and surveillance colo-
noscopies were 815 and 469 respectively. The presumed miss rate of polyps,
adenomas, SSA/Ps and advanced adenomas were 37.8%(469/1241),
22.1%(176/798), 41.7%(20/48) and 15.2%(36/236) respectively. More adenomas
were missed in the proximal colon when compared to distal colon (26.64% vs
18.04%, p¼ 0.01). Table 1 illustrates the distribution of missed adenomas in each
segment of colon. Adenoma miss rates per size as follows: 55mm, 6–9mm and
410mm were 24.27 and 8% respectively. Higher number of polyps (43)
detected during index colonoscopy independently correlated with high miss
rates (84.3% vs 72%, p¼ 0.04).
Table 1: Missed polyps at different colonic segments
Location
Adenoma miss
rate (%)
Sessile serrated
adenoma
miss rate (%)
Rectum 9 33
Rectosigmoid junction 19 0
Sigmoid colon 23 50
Descending colon 10 0
Splenic flexure 26 0
Transverse colon 27 30
Hepatic flexure 30 57
Ascending colon 26 50
Caecum 26 0
Conclusion: Our study highlights that there is likely to be a significant miss rate
for adenomas and SSA/Ps even after careful index colonoscopy. Miss rate was
higher when multiple polyps are seen at the index examination. This finding
appears to justify the current BSG (British Society of Gastroenterology) guide-
lines for an early, 1 year colonoscopy when multiple polyps are seen. The pre-
sumed polyp miss rate at 1 & 3 years may be justified as a new quality metric
within screening programmes.
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Introduction: Systemic diseases including several types of cancer have been asso-
ciated with periodontitis, potentially owing to the constant systemic inflamma-
tory state in those patients. Data on a potential association of periodontal disease
and colorectal neoplasia is scarce and conflicting.
Aims & Methods: Data from 25,407 patients undergoing healthy check up asses-
sing periodontal disease according to periodontosis-risk classes (PRC 0–healthy
gingiva, PRC 1 - tatar or plaque, PRC 2 - redness or swelling) and screening
colonoscopy between 2009 and 2012 in Austria were included. Colonoscopy out-
comes were compared between patients with and without signs of periodontal
disease using multivariate models adjusting for age, sex, smoking, alcohol con-
sumption, diabetes and BMI.
Results: In multivariate adjusted models, patients with periodontal disease had
similar odds for the detection of colorectal polyps as those without signs of
periodontal disease [adjOR 1.070; 95% CI: 0.918; 1.247]. Regarding the preva-
lence of adenomas, patients with periodontal disease, likewise, had similar odds
as those with healthy periodontal tissue [adjOR 1.010; 95% CI: 0.840; 1.213].
Similarly, those with periodontal disease had comparable odds for colorectal
adenomas as those without signs of periodontal disease [1.055 (0.785; 1.418)].
In the table below the adenoma detection rate (ADR) and advanced adenoma
detection rate (AADR) divided into the periodontosis-risk classes.
Table 1: ADR (adenoma detection rate) and AADR (advanced adenoma
detection rate) according to the periodontosis-risk classes
PRC 0 PRC 1 PRC 2
Adenoma (ADR) 19,34% 19,56% 20,02%
Advanced adenoma (AADR) 5,42% 6,1% 6,5%
Conclusion: Conclusion: Periodontal disease has no impact on the adenoma and
advanced adenoma detection rates in a large screening colonoscopy cohort.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Patients with colitis carry an increased risk for the development of
dysplasia compared to those without1. The SCENIC consensus statement recom-
mends endoscopic resection of all visible dysplasia2. Due to technical challenges
and limited experience in the West of large colitis associated non-polypoid endo-
scopic resections, such patients are often subjected to colectomy.
The King’s Institute of Therapeutic Endoscopy (KITE) is a tertiary centre for
endoscopic assessment and resection of large/challenging colorectal polyps. Here
we present the largest single-centre case series of large non-polypoid resections
associated with colitis.
Aims & Methods: Adults with confirmed colitis (ulcerative colitis extending
beyond the rectosigmoid junction and crohn’s colitis affecting at least the left
colon) with lesions at least 20mm in size within the colitis segment were included.
Data including demographics, clinical history, lesion characteristics, method of
resection and post-resection surveillance were collected prospectively in patients
from January 2011 to November 2016. Resection techniques included endoscopic
mucosal resection (EMR), endoscopic submucosal dissection (ESD) and hybrid
ESD. Surveillance of resection site with magnification chromoendoscopy (mCE)
was performed at 3 months with pan colonic mCE at 1-year post resection and
annually thereafter.
Results: Thirteen lesions satisfied the inclusion criteria in 13 patients. Patient
demographics and clinical data are presented in table 1. Mean lesion size was
47.3þ/22.4 (20–90) mm. All lesions were non polypoid with distinct margins
and no ulceration. High-frequency mini-probe ultrasound confirmed intramuco-
sal lesions in 5 cases where pit/vascular pattern was distorted due to inflamma-
tion. En bloc resection was achieved in 6 cases. 69% lesions were deeply scarred
of which 66% had experienced prior instrumentation. Resection of a single lesion
was abandoned due to intense fibrosis. Macrosocpic evidence of complete resec-
tion was achieved in all remaining cases. Endoscopic diagnosis of pre-cancerous
lesions of less than 1000mm submucosal invasion was confirmed histopathologi-
cally in 100% of resected lesions. Complete excision was confirmed in all en bloc
resections. A single case of small perforation and another with delayed minor
bleeding were both managed endoscopically. Mortality/hospital admission
within 30 days post resection was 0%. Median follow up was 28 months (12–
35) with no recurrence. Alternative site dysplasia was detected in 2 patients. All
lesions were sub 20mm and resected endoscopically. Two patients were referred
for colectomy due to a concomitant diagnosis of neuroendocrine tumour and the
second with alternate site advanced dysplasia.
Table 1: Baseline characteristics.
Patient Demographics
Age at time of resection (mean, SD, range) (years) 57.31þ/12.7, 30–81
Male (n) (%) 10 (77)
Female (n) (%) 3 (23)
Clinical Data
Duration of disease (mean, SD, range) (years) 19.9, 14,2, 1–50
Disease extent
Splenic Flexure (n) (%) 3 (23)
Pan-colonic/Extensive (n) (%) 10 (77)
Primary Sclerosing Cholangitis 3
IBD Medication
5-ASA* (n) (%) 11 (84)
Azathioprine (n) (%) 2 (15)
Biologics (n) (%) 1 (7)
ASA Physical Status Classification
(continued)
Table 1 Continued
Patient Demographics
ASA grade II (n) (%) 7 (54)
ASA grade III (n) (%) 4 (31)
ASA grade IV (n) (%) 2 (15)
Conclusion: This cohort series demonstrates that endoscopic resection of large
non-polypoid lesions in association with colitis is feasible using an array of
resection methods, safe and has good long term outcomes in a western tertiary
endoscopic centre.
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Introduction: Endoscopic submucosal dissection (ESD) has been widely used in
the minimally invasive treatment of early colorectal mucosa and submucosal
lesions. This technique has made it possible to resect even large mucosal or
submucosal lesions en bloc, and the recurrence rate is lower. However, due to
the thinner colorectal wall and more abundant blood vessels, postoperative com-
plications after ESD is higher in this site. As a result, how to prevent complica-
tions related to ESD for colorectal lesions has raised widespread concern. In
recent years, more and more researchers placed transanal tube for patients
with colorectal cancer resection or intestinal obstruction to promote the early
discharge of the gas and liquid in the intestine. The efficacy of this method to
reduce incidence of complications and to promote recovery of intestinal function
have been verified by a number of studies. Based on this, we applied transanal
tube to some patients with colorectal ESD, hoping to provide new ideas for the
prevention and treatment of complications.
Aims & Methods: We aimed to evaluate transanal tube for prevention of com-
plications in colorectal mucosal lesions after endoscopic submucosal dissection
(ESD). Data of 61 patients with colorectal mucosal lesions undergoing ESD from
January to December 2016 were reviewed. All patients were followed up and we
analyzed the incidence rate of complications after ESD within one month.
Results: The median age of 61 patients was 61(32 83) years. 21 of all lesions
were located at right-half colon, 9 at left-half colon and 31 at rectum. The mean
diameter of the lesions was 3.26 2.27 (0.8–12.0) cm. There were not intraopera-
tive complications including serious bleeding and perforation. Delayed bleeding
on the eighth post-ESD day was detected in 1 (1.6%) patient who was cured by
transfusion. 3(4.9%) patients suffered post-ESD electrocoagulation syndrome
and perforation did not present in all cases. In this group with transanal tube
for decompression, the rates of perforation, delayed bleeding and post-ESD
electrocoagulation syndrome were all lower than others which was
1.4 8.2%,0.5% 9.5% and 12.1% 40.2% respectively in literature reports.
Conclusion: The application of transanal tube in colorectal mucosal lesions after
ESD could effectively reduce the incidences of complications. However, we
should do more research to know whether transanal tube need to be placed
routinely after ESD or not.
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Introduction: Underwater endoscopic mucosal resection (UEMR) is an alterna-
tive to traditional EMR for the resection of colonic polyps. With this technique,
water insufflation is used in place of air or CO2, and submucosal lifting is usually
not required, as water-immersed submucosa cushions itself from the muscularis
propria.[1] Theoretically, this reduces the risk of diathermy-induced injury,[1] and
allows for more complete resection margins.[2]
Aims & Methods: In this prospective dual-centre study, we aim to evaluate the
safety and efficacy of UEMR for clinically significant (410mm) colonic polyps.
Studied outcomes included: 1) completeness of UEMR, 2) intraprocedural and
30-day complication rates, 3) percentage requiring submucosal lift, and 4) rates
and predictors of polyp recurrence. Procedures were performed by two screening
endoscopists accepting tertiary referrals at St. Mark’s Hospital, London, and
Russell’s Hall Hospital, Dudley, UK. Recurrence was defined as the presence
of any polyp tissue at the resection site. Endoscopy records were examined and
correlated with histology. Univariate analyses were performed using Pearson’s
chi2 to identify predictors of measured outcomes.
Results: Between June 2014 and March 2017, and A total of 85 patients (median
age 69.5 years, interquartile range [IQR] 11, 50.6% male) underwent UEMR of
97 colonic polyps (median size 25mm, IQR 25mm, range 10–160mm). 13
(13.4%) were recurrences following previous conventional EMR. Polyps were
predominantly left sided (66%) with flat (63.5%) or sessile (35.4%) morphology.
43.8% of polyps were removed en bloc, whilst argon plasma coagulation (APC)
was used in 13.7%. Histology comprised of: low-grade dysplasia (80.2%), high-
grade dysplasia (12.5%), adenocarcinoma (3.1%) and non-dysplastic sessile ser-
rated lesion (4.2%). Overall, resection at index UEMR was deemed endoscopi-
cally complete in 97.9%. Submucosal lift was required in 27.8% and positively
correlated with polyp size 430mm (OR 3.58, 95% CI 1.37–9.38, p¼ 0.01), but
not morphology (flat vs. sessile, p¼ 0.99). The 30-day complication rate was
4.1% (n¼ 4), consisting of intraprocedural bleeding (n¼ 2, average diameters:
35mm) and delayed rebleeding (n¼ 2; average diameter: 57.5mm), with haemos-
tasis achieved for all cases. No cases of perforation or mortality were identified.
Of the 60.8% (n¼ 59) who attended for repeat endoscopy post-UEMR, the rate
of recurrent or residual polyp was 14.8% (8/54) at 4 months and 13/59 (22.0%)
within 1 year. Significant predictors of post-UEMR recurrence included: piece-
meal vs. en bloc resection (OR 5.50, 95% CI 1.10–27.6, p¼ 0.03) and recurrent
polyp (OR 4.17, 95% CI 1.02–17.05, p¼ 0.04), but not polyp size, site, morphol-
ogy, dysplasia status, use of submucosal lift, APC, patient age, or study centre.
Conclusion: UEMR is a safe alternative to conventional EMR for the manage-
ment of clinically significant colonic polyps. However, our post-UEMR recur-
rence rate of 22.0% appears higher than other studies,[2] but may be skewed by
the tertiary nature of referrals. Although randomised trials are awaited, our data
suggest that those performing UEMR should attempt en bloc resection where
possible, and consider wider resection margins for recurrent polyps.
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Introduction: Water-aided techniques have forged a paradigm shift in endoscopic
diagnosis and therapy. The inauguration (10/22/2014) of the International
WATERS with memberships worldwide attested to participants’ commitment
to advance clinical, educational and research missions. To aid planning of
future work in each of these areas, a descriptive study of water-aided colono-
scopy was performed.
Aims & Methods: The aims of this study were two-folds. Study 1: To assess the
focus of investigations in the past decade. Study 2: To obtain a cross-sectional
snapshot of current clinical practice. Study 1: Studies registered at
Clinicaltrial.gov were searched for using the search term "water colonoscopy".
Study 2: Members of International WATERS voluntarily participated in a
survey. After indicating the proportion of patients with different modes of seda-
tion, respondents selected yes (1) or no (0) responses to each of 16 questions
related to their practice of water-aided colonoscopy.
Results: Study 1: In the past decade, 48 trials of water-aided colonoscopy were
registered at Clinicaltrial.gov. They aimed at evaluation of insertion pain in
unsedated, minimally sedated, or on demand sedation patients; assessment of
efficacy in difficult colonoscopy; study of the impact on adenoma detection;
and underwater mucosal resection or polypectomy. Study 2: Questionnaire
responses are summarized in Table 1. Respondents: n¼ 23. Water-aided colono-
scopy is used in patients sedated with propofol, minimal sedation or on demand
sedation (3–16%); but more commonly in patients with moderate or no sedation
(30–34%). During insertion 95.5% use infusion of water and only 36.4% leave
the air/CO2 pump on. 42.9% and 33.3% record volumes infused and suctioned
upon arrival to the cecum. 52.4% remove almost all infused water during inser-
tion. 71.4% and 59.1% performed polypectomy (520mm and 420mm, respec-
tively) underwater during withdrawal.
Table 1A: % of respondent’s patients
Mean SD
Sedated with propofol 16 30
Receive minimal sedation 11 19
Are unsedated 34 35
Receive on demand sedation 3 5
Receive moderate sedation 30 39
Table 1B: Proportion of
respondents using the
following approaches (%)
Mean
Infuse water during insertion 95.5
withdrawal 36.4
Leave air/CO2 pump on during insertion 36.4
withdrawal 90.0
Keep track of volume of water infused at different insertion locations 19.0
suctioned at different insertion locations 14.3
Keep track of volume of water infused upon arrival to the cecum 42.9
suctioned upon arrival to the cecum 33.3
Keep track of volume of water infused when colonoscopy is finished 33.3
suctioned when colonoscopy is finished 28.6
Perform polypectomy (520mm)
underwater during
insertion 31.8
withdrawal 71.4
Perform polypectomy (420mm)
underwater during
insertion 13.6
withdrawal 59.1
Remove almost all infused water during insertion 52.4
withdrawal 57.1
Conclusion: The variable modes of application amongst respondents who profess
to use water-aided colonoscopy reflect the versatility and strength of the para-
digm-changing approach, which is easily adaptable to meet the diverse needs of
individual colonoscopists. Standardization based on results of randomized con-
trolled trials appears to be prudent to permit further assessment of water-aided
colonoscopy in clinical, educational and research settings.
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Introduction: Endoscopic submucosal dissection (ESD) is a suitable technique
used for the endoscopic management of selected early gastrointestinal neoplasms
(EGN).
Aims & Methods: This is a prospective study of patients with EGN eligible for
ESD in three tertiary hospitals. The main goal was to evaluate initial therapeutic
results and learning curve of ESD. Initial Technical success rates, procedure
speed, en-bloc & R0k resection, R0, speed and complications rates were prospec-
tively evaluated. The results of the learning curve were analyzed by chronological
order of blocs of 50 cases. Perforation was established as any disruption of the
muscular layer, regardless of size or identification of peritoneal fat. Time of
procedure was considered from initial submucosal injection to final detachment
of the specimen.
Results: ESD was attempted in 183 lesions from January 2012 to April 2017.
Majority of procedures were performed at Puerta de Hierro University Hospital
(160/87.4%). Mean age was 67 (SD 10.6) years, with male proportion 55.2%.
Most common location was colorectal (77.8%), followed by gastric (12.8%) and
esophageal (9.4%). Success was observed in 96.2% of patients with en-bloc and
R0 resection of 93.9% and 92.3% respectively. Mean lesion size was 46.5mm
(range 8–130) with a mean speed of 9.01min/cm2 (range 1–209). Perforation was
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the main complication (48 (26.2%) events), requiring surgery in 5 (10.4%) cases.
Perforation was related statistically significant to location (p¼ 0.05) and LST
morphology (p¼ 0.05). Most frequent location of perforation was transverse
colon (OR 88.3; SE 137), followed by descending colon (OR 13.5; SE 19.4)
and splenic flexure (OR 6.3, SE 11.8). Perforation was more common in LST-
NG lesions vs LST-G (OR 14,1 SE¼ 19.3 vs 11.6 SE 15.6). Perforation rates were
not statistically associated with the presence of severe submucosal fibrosis com-
pared to absence of fibrosis (0.8 SE 0.6 vs 1 SE 1;p¼ 0.9). Post-ESD complica-
tions were observed in 15 (8.2%) patients (delayed perforation(7), bleeding(4),
electrocoagulation syndrome(1), severe esophageal stricture(1), haemoperito-
neum(1) and splenic rupture(1)). Six cases (40%) were managed with surgery.
Results from the learning curve progression according to consecutive chronolo-
gical blocs of 50 cases (33 last bloc) are summarized in table 1. Initial success
increased from 94% to 100%; speed of ESD decreased after the first 50 cases
(15.5 cm2/min), up to 6.7 and 6.5 cm2/min in the last 2 blocs. A high perforation
rate in the first period (32%) was reduced to 18–30.3% the following periods.
Endoscopic treatment was successful in most cases of perforation (89.6%).
Surgery was required for severe complications, incomplete ESD and/or perfora-
tion (n, %) (16 cases, 8.7%).
Conclusion: On clinical ESD, high rates of success and en-bloc and R0 resection
can be achieved along the learning curve. Perforation is the most common com-
plication and is still a challenge for Western countries. However, increasing
experience reflects a high success in endoscopic management of perforation.
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Introduction: Despite the advantages of endoscopic submucosal resection (ESD)
demonstrated in large series from the far east, the procedure is not commonly
practiced in the west and its role in standard practice is still debated. Although
limited evidence regarding its efficacy in European practice is emerging, very few
centres in the United Kingdom perform ESD regularly, if at all. We report the
experience of a UK tertiary referral institution using ESD as part of a lesion
specific, pragmatic approach to endoscopic resection in a complex patient cohort.
Aims & Methods: Patients who underwent ESD of colorectal lesions were
included. Lesions were assessed with magnification chromoendoscopy supple-
mented by colonoscopic ultrasound in selected cases. A lesion specific approach
was used to decide on resection technique, which included assessment of mor-
phology, pit pattern, risk of submucosal invasion, and presence of submucosal
fibrosis or scarring. ESD was used where en bloc resection was deemed essential,
or as part of a hybrid procedure to ensure resection of a dominant nodule or
suspicious area of a lesion in one piece, or where fibrosis or scarring would make
standard EMR impossible. A resection was designated a hybrid procedure if
ESD was used to effect submucosal dissection, circumferential incision alone
to assist snare resection was not included.
Results: 116 lesions (mean size 58.8mm) were resected using ESD (n¼ 58) and
hybrid ESD (n¼ 58). 82 (70.7%) had been subjected to prior attempts at resec-
tion (n¼ 58) or extensive sampling. Only 11 lesions had no prior biopsies per-
formed. En bloc resection was achieved in 93.1% where ESD was used alone,
with a recurrence rate of 4.7% after a mean follow up of 12.4 months. There were
6 microperforations treated with either endoscopic clips or antibiotics alone with
no adverse sequelae, and one clinically significant perforation requiring surgery.
However, the resected lesion in this case contained an invasive adenocarcinoma
with deep submucosal invasion–there was no residual tumour in the surgical
resection specimen. Post- procedure bleeding occurred in 6 patients, none of
whom required additional interventional therapy. 71% of cases were successfully
performed as day case procedures. 97% of patients without invasive cancer were
free from recurrence and had avoided surgery at last follow-up.
Conclusion: Colorectal ESD can be used as part of a standard lesion specific
approach in a western referral centre to deliver safe and effective organ conser-
ving treatment to patients with large challenging lesions. Knowledge regarding
lesion assessment and selection in western practice should be improved to reduce
the incidence of prior heavy manipulation and guide appropriate referral.
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Introduction: Little is known about the risk of stenosis and outcomes following
endoscopic resection of lesions in the colorectum which leave extensive mucosal
defects. A limited number of studies suggest significant stenosis rates, although
reports on outcomes and suggested management are conflicting. We determined
the risk of stenosis and outcomes of endoscopic resection of colorectal lesions
leaving mucosal defects 75% of the circumference.
Aims & Methods: Consecutive patients who underwent endoscopic resection of
colorectal lesions 2 cm were included. Resection technique included EMR, ESD
and hybrid techniques involving ESD. Patients were grouped according to cir-
cumferential extent of the mucosal defect after resection. Surveillance colono-
scopy was performed at 3 and 12 months. Clinicopathological characteristics and
outcomes were compared between groups.
Results: 435 colorectal lesions 2 cm were resected using EMR (n¼ 342), ESD
(n¼ 45) or hybrid techniques (n¼ 48). Circumferential extent of the resulting
mucosal defect was 75% in 41 patients. 8 lesions were fully circumferential: 1
caecal lesion and the rest in the recto-sigmoid and rectum. 3 of these circumfer-
ential lesions contained deeply invasive adenocarcinoma and 1 benign lesion
ultimately required surgery. The 41 lesions with a mucosal defect 75% of the
circumference had a mean size of 100.5mm vs 49.0mm for other lesions
(p50.001). These patients had significantly more complications (16.7% vs
4.7%, p50.001), including a higher rate of perforation (8.3% vs 2.3%,
p¼ 0.02), although none required surgery, and a significantly higher rate of
recurrence (44.8% vs 9.2%, p50.001). 79% of patients without cancer were
free from recurrence and had avoided surgery at last follow-up compared to
97% of patients with mucosal defects 575% (p50.001). Stenosis occurred in
7 patients: 4 lesions extensively involving the rectum and recto-sigmoid and 2
lesions involving the sigmoid colon extending to the rectosigmoid. 1 of these
involved a mucosal defect of only 50% of the circumference and 3 were fully
circumferential. 1 patient had a symptomatic anorectal stenosis requiring dilata-
tion under anaesthesia, 1 patient was asymptomatic but underwent early dilata-
tion after the first surveillance endoscopy at 3 months. The remaining patients
were asymptomatic and managed expectantly. In all these latter cases sponta-
neous improvement in the stricture was noted at the subsequent surveillance
colonoscopy.
Conclusion: The majority of patients with these extensive complex lesions can
successfully be treated with endoscopic resection and avoid surgery. However,
these patients have a significantly greater risk of complications and recurrence
and should be managed in a tertiary institution. Although there is a significant
risk of stenosis, it appears that most cases are asymptomatic and spontaneously
improve with expectant management.
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Abstract: P1512
N¼ 183 1–50 51–100 101–150 151–183 Total (n/%)
Colorectal location (n.%) 40/50 (80%) 42/50(84%) 34/50(68%) 25/33(75.7%) 141/183(77%)
Success(n,%) 47/50 (94%) 46/50(92%) 50/50(100%) 33/33(100%) 176/183(96.2%)
En bloc(n,%) 47/50 (94%) 46/50(92%) 50/50(100%) 33/33(100%) 172/183(93.9%)
R0(n,%) 45/50 (90%) 45/50(90%) 48/50(96%) 31/33 (94%) 169/183(92.3%)
Speed (cm2/min) Mean (SD) 7.68 (5.02) 15.5(37.8) 6.7(5.5) 6.5(5.1) 9.01(19.1)
Perforation(n,%) 16/50 (32%) 13/50(26%) 9/50(18%) 10/33(30.3%) 48/183(26.2%)
Surgery due to perforation (n,%) 2/16 (12.5%) 1/13(7.7%) 0/9(0%) 2/10(20%) 5/48(10.4%)
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Introduction: Although it is well recognised that the risk of invasive carcinoma in
apparent benign colorectal neoplastic lesions differs according to morphology,
the incidence of invasive cancer varies between studies and there is limited data
from large western series to inform practice. The importance of appropriate
resection techniques, including the use of ESD, is increasingly recognised in
western practice. It is therefore imperative that the risk of submucosal invasion
is assessed as accurately as possible to prevent inappropriate attempts at resec-
tion. We determined the risk of submucosal invasion and high-grade dysplasia
(HGD) in different morphological sub- types of large colorectal lesions subjected
to endoscopic resection.
Aims & Methods: Colorectal lesions 2 cm subjected to endoscopic resection
were included. Lesions were assessed with magnification chromoendoscopy.
Clinicopathological data recorded included morphological type according to
Paris classification, sub-types of laterally spreading tumours (LST), degree of
dysplasia, presence of submucosal invasion and outcomes following resection.
Results: 435 colorectal lesions 2 cm were resected. Mean lesion size was 55.2mm
(range 20mm–160mm). The frequency of and the incidence of high-grade dys-
plasia and invasive adenocarcinoma in the different morphological sub-types are
shown in Table 1. The incidence of high-grade dysplasia (8.6%) and invasive
adenocarcinoma (1.2%) was very low in LST granular homogenous lesions.
Morphology
Mean
size (mm)
High-grade
dysplasia (%)
Invasive
adenocarcinoma (%)
Is 36.7 2 (33.3) 1 (16.7)
Isp 37.8 21 (27.6) 7 (9.2)
IIa 27.2 5 (10) 0 (0)
IIaþ IIc 35.0 3 (100) 2 (66.6)
LST G H 54.3 15 (8.6) 2 (1.2)
LST G MN 83.3 49 (43.0) (12 (10.0)
LST NG 45.0 4 (36.4) 2 (18.2)
LST G H¼LST granular homogenous LST G MN¼LST granular mixed nod-
ular LST NG¼LST non-granular ESD or hybrid ESD was used to resect 97
lesions. 53% of lesions had been subjected to previous failed attempts at resec-
tion, 6 biopsies or had tattoo injected at their base prior to referral. Of 29
invasive adenocarcinomas, 9 were deemed to be cured by endoscopic resection
(superficial submucosal invasion with no adverse prognostic features). Of the
remaining 20, 5 patients refused surgical resection, 5 were unfit for major surgery
and 10 had surgery. 2 had residual tumour in the surgical resection specimen, 5
had none and 3 had surgery at their referring institution. Only 3 patients with
initially benign lesions developed adenocarcinoma in subsequent lesions–all of
these were early cancers without nodal metastases at surgical resection.
Conclusion: In one of the largest European series reporting the incidence of
invasive carcinoma in different morphological sub-types of colorectal neoplastic
lesions, we confirm that LST granular homogeneous type lesions have a very low
incidence of invasive carcinoma and that care should be taken in the choice of
resection technique for other sub-types of LSTs which more frequently harbour
malignancy. Accurate endoscopic assessment and classification to aid meticulous
lesion selection is essential to this process.
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Introduction: Polypectomy of adenomatous polyps during colonoscopy has been
shown to decrease the incidence of colorectal cancer (CRC). Withdrawal time
during colonoscopy is thought to improve polyp detection. A minimal withdra-
wal time of six minutes is recommended.
Aims & Methods: The aim of this study is to evaluate the role of colonoscopy
withdrawal time in adenomatous polyp detection. It is a retrospective, descriptive
and analytic study collecting all consenting patients who had a colonoscopy in
Mohamed Taher Maamouri Hospital of Nabeul, between January 2016 and
March 2017. Incomplete colonoscopies or those performed in patients having
had segmental colectomy were excluded. We defined two groups of patients: -
G1: withdrawal time 7 minutes - G2: withdrawal time 57 minutes Two para-
meters were evaluated: -Polyp Detection Rate (PDR): the percent of colonosco-
pies with one or more adenomatous polyps detected -Mean Number of polyps
detected per colonoscopy (MNP).
Results: A total of 1059 patients were screened for enrollment;749 total colonos-
copies were studied: 383 men (51.1%) and 366 women (48.9%). Colic preparation
was good (Boston score 46) in 49.4% of patients. Colonoscopy was normal in
434 cases (57.9%). Colonic polyps were detected in 197 patients (26.3%). The
mean number of polyps detected per colonoscopy (MNP) was 2.31 (min: 1, max:
25). The mean polyp diameter was 6.8 millimeters (1 to 50mm). The mean with-
drawal time was 8.2 minutes (4 to 20 minutes). Overall PDR was 26%. G1
included 599 colonoscopies and G2 included 150 colonoscopies. PDR in G1
was 28.04% versus 20% in G2, the difference between the two groups was not
significant (p: 0.7). As for the MNP, it was significantly higher in G1: 2.29 versus
1.86 in G2 (p: 0.049).
Conclusion: In our study, a withdrawal time exceeding seven minutes was sig-
nificantly associated with the number of polyps detected in colonoscopy. Further
studies may be helpful to confirm these results ideally by comparing these para-
meters in the same patients.
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Introduction: Endoscopic resection of large colorectal lesions, especially by pie-
cemeal EMR, carries a significant risk of recurrence. Although several series
examine the outcomes and risk of recurrence following endoscopic resection,
few focus on the outcomes of patients being treated for recurrence after initial
expert resection, and these mostly focus on one technique to deal with recurrence.
We evaluated the outcomes after recurrence of colorectal lesions after apparent
successful endoscopic resection in a specialised UK tertiary institution employing
a range of resection techniques.
Aims & Methods: Consecutive patients who underwent endoscopic resection of
colorectal lesions 2 cm were included. All lesions were assessed with magnifica-
tion chromoendoscopy supplemented by colonoscopic ultrasound in selected
cases. A lesion specific approach was used to decide on resection technique.
Outcomes were evaluated for patients treated for recurrent lesions.
Results: Of 396 colorectal lesions 2 cm initially resected, recurrence occurred in
48 patients. 36% of these patients had already had a mean of 1.6 previous failed
attempts at resection prior to referral to our institution, and 66% had had either
a failed attempt at resection or extensive sampling involving 6 biopsies or tattoo
placed under the lesion. 69% of patients were successfully treated with further
endoscopic resection and avoided surgery. 27 recurrent lesions larger than 20mm
were treated with endoscopic resection, with a mean lesion size of 48.3 þ/
19.1mm. Techniques used were EMR (n¼ 16), ESD (n¼ 2), Hybrid ESD and
EMR (n¼ 9). The remaining lesions52 cm were resected using EMR. A mean of
1.4 þ/ 0.75 procedures were required to achieve successful endoscopic treat-
ment of recurrence. Of 23 patients who were ultimately successfully treated with
endoscopic resection, 15 required a single further endoscopic resection after
recurrence, 8 patients required 2 or more further resections. 8 patients required
surgery, 3 as a result of developing invasive adenocarcinoma with the recurrence.
There were no perforations as a result of endoscopic resection of recurrent lesions
and only 1 patient was readmitted with post-procedural bleeding which was
managed conservatively.
Conclusion: These data demonstrate the challenges of an advanced endoscopic
resection service in much of western practice where patients with recurrent lesions
represent a particularly complex cohort, most of whom have already had exten-
sive prior manipulation or attempts at resection. Familiarity with a range of
resection techniques and appropriate equipment is essential to successfully
treat recurrent lesions in this group with endoscopic resection, which can be
achieved in the majority of patients without significant complications.
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Introduction: Self-expandable metallic stent (SEMS) is widely used to treat malig-
nant colonic obstruction. However, most reports about SEMS insertion have
concentrated on the left colon and very tough to insert SEMS on the right
colon, especially distal ascending colon.
Aims & Methods: This study aimed to (1) investigate the effectiveness of new
insertion technique with SEMS for right-sided colonic obstruction and (2) com-
pare the safety and technical success of SEMS insertion. The data from ten
patients who underwent SEMS with a new technique for malignant obstruction
of ascending colon in our hospital were analyzed retrospectively. Initially, we
tried to insert with the straight type guiding tube and wire for obstructed area of
ascending colon under CO2 insufflation. It defined by difficult cannulation more
than 20 minutes manipulation. For difficult cannulation, we change to curved
type guiding tube (CleverCut2V/CleverCut3V Double and Triple Lumen sphinc-
terotomes). All cased were difficult cannulation and change to curved type.
Cannulation time between straight and curved type guiding tube, technical and
clinical success, complications, and technical difficulties were analyzed. We com-
pared the results between SEMS insertion and decompression tube placement in
right colons and the outcomes of SEMS insertion between right- and left-sided
colonic obstructions.
Results: Cannulation time with a curved type guiding tube decreased of all cases
(20min vs 8.5min). For ascending colons, the technical and clinical success rate
of SEMS insertion with new technique significantly 100% (10/10). There was no
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complitation (0/10). Concerning SEMS insertion, the technical difficulty and
safety of SEMS insertion were similar between right- and left-sided colonic
obstructions.
Conclusion: A new technique of curved type guiding tube with SEMS insertion
for right-sided colon, especially distal ascending colon is significantly more effec-
tive than straight type guiding tube, and this procedure was safer and less tech-
nically challenging than expected. SEMS insertion should be considered for
treating right-sided malignant colonic obstruction.
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Introduction: Endoscopic full-thickness resection (EFTR) in the colon using the
FTRD kit is a recent technique that allows en-bloc resection of colonic lesions
that are poor candidates for resection by endoscopic mucosal resection (EMR). It
does not require the injection of a solution into the submucosa and allows an en-
bloc resection of colonic lesions up to approximately 30mm. We present results
of the initial experience in 3 centers of Catalonia.
Aims & Methods: We retrospectively analyzed the clinical, endoscopic and ana-
tomopathological data of all cases of EFTR performed in 3 centers in Catalonia
using the FTRD kit (Ovesco Endoscopy, Tübingen, Germany) during the period
between June 2015 and January 2017. All patients underwent the procedure
under deep sedation with propofol, all patients were duly informed of the tech-
nique and potential complications derived from the procedure, obtaining written
informed consent prior to the procedure. All EFTR resections in the colon were
performed using the FTRD kit (Ovesco Endoscopy, Tübingen, Germany), grasp-
ing and pulling the lesion inside the cap, deploying the OTSC and resecting the
tissue over the OTSC with the preloaded snare. Clinical assessment was per-
formed before and after procedures with a complete blood test before procedure.
Blood test was not routinely used after procedures. Demographic, clinical, endo-
scopic and histologic data were collected from each patient, and analysed with
STATA software.
Results: 16 endoscopic full-thickness resections of the colon were performed. The
mean age of the patients was 69 years (53–79), with men being 88%. The indica-
tions were recurrent/residual lesions with non lifting sign (75%) and untreated
lesions with non lifting sign (25%). The locations were juxtavalvular (n¼ 2),
hepatic flexure (n¼ 3), transverse colon (n¼ 4), descending colon (n¼ 3),
sigma, stump or anastomosis (n¼ 2). The mean diameter of the resected samples
was 20.8mm (13–33mm). The histology of the lesions was adenoma with low
grade dysplasia (50%), adenoma with high grade dysplasia (25%), sessile serrated
polyp without dysplasia (6%) and three lesions were adenocarcinoma with deep
submucosal invasion (19%). There were no clinically relevant complications or
emergency surgery. 1 patient had mild self-limited hemorrhage, 6 patients had
mild abdominal pain (38%) and 3 patients developed postpolypectomy syndrome
(19%).
Conclusion: Endoscopic full-thickness resection is a safe and feasible technique
for selected cases in colon.
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Introduction: Lynch syndrome (LS) is an autosomal-dominant disease, with
increased risk of colorectal cancer (CRC), hence annual surveillance colonoscopy
is recommended. do not recommend one over the other.
Aims & Methods: We aimed to compare the diagnostic yield (DY) of different
endoscopic modalities for detection of colorectal neoplasia in patients with LS by
performing a meta-analysis of existing literature. We searched Pubmed for pro-
spective studies. For each modality, we performed comparative total per-ade-
noma analysis and sub-analyses for flat lesions and location (right/left colon).
Meta-analysis was performed using pooled rate ratios (RR) with fixed effects
model due to low heterogeneity within the subgroups.
Results: Five studies compared white light endoscopy (WLE) to chromoendo-
scopy. In four studies compared WLE to chromoendoscopy directly (one study
used a "back-to-back" design but lesions were resected only after chromoendo-
scopy and the other study compared two different sets of patients).
Chromoendoscopy (n¼ 75) identified more adenomas in the right colon than
WLE (n¼ 73 patients) RR 3.27 (95%CI 1.83–5.87). Overall detection of adeno-
mas or flat lesions was not statistically different between the two methods.
Conclusion: Chromoendoscopy is superior to WLE for detection of adenomas in
Lynch syndrome, especially flat lesions and adenomas in the right colon.
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Introduction: Endoscopic mucosal resection (EMR) has been shown to be useful
in the removal of large colorectal adenomas. These lesions are often resected by
using a piecemeal technique, which a risk of recurrence in 10% to 30% of cases.
Recently, hot avulsion technique (HA) has shown promising results in the resec-
tion of residual fragments of large colorectal adenomas, with lower recurrence
rate.
Aims & Methods: The aim of this study was to evaluate the efficacy and safety of
HA at index EMR and at EMR local recurrence. We did a retrospective study
based on all the HA performed between June 2015 and February 2017. The
endoscopic characteristics, complications and recurrence rate after the initial
HA were evaluated.
Results: 33 HA were performed among 29 patients (16 men and 13 women) with
an average age of 69 years. The average follow up time was 11 months. HA was
used to remove residual adenomatous tissue at 17 index EMR (mean size of the
lesion 30mm) and to remove recurrent fibrotic adenomatous tissue at EMR scar
in 12 cases (mean size of recurrence tissue 14mm). HA was successful in remov-
ing residual/recurrent adenomatous tissue in all patients. There were no immedi-
ate or long term adverse events. Comparing the two groups, local recurrence after
initial HA occurred in one case at the index EMR group (1/17) and in 2 cases at
the local EMR recurrence group (2/12). The overall recurrence rate in patients
with a minimum 6 months follow up was 15% (3/20).
Conclusion: HA is a safe and effective technique to eradicate both residual tissue
in large colorectal adenomas and recurrent fibrotic adenomatous tissue at EMR
site, with low recurrence rate.
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Introduction: Quality of bowel preparation and adenoma detection rate (ADR)
are routinely assessed in screening colonoscopy. However, data on patient experi-
ence are scarce.
Aims & Methods: This prospective non-interventional study compared bowel
preparation quality according to the Harefield Scale, performance quality mea-
sures and patients satisfaction in screening colonoscopies performed within an
Austrian quality assurance program.
Results: 5000 screening colonoscopies performed by 20 endoscopists were
included in this study. 50.3% of screened individuals were women. Because of
the unequal patient count using CitraFleet (CF, n¼ 261), Picoprep  (PP,
n¼ 2678), Klean-Prep (KP, n¼ 804) and Moviprep (MP, n¼ 1252), PC and
CF were grouped as low volume (LV) purgatives. Age and gender adjusted
success rates and ADR per purgative were 97.0% and 23.3% for LV, 97.5%
and 32.5% for KP and 93.5% and 26.0% for MP. Women had higher success
rates than men (p¼ 0.073) and success rate decreased with patients’ age
(p¼ 0.008). The compliance regarding consummation of the entire volume was
best with LV (89.2%, KP 87.6%, MP 87.3%), which had a significant effect on
success rate p¼ 0.027. 93.5% of patients in the LV group would use the same
purgative again compared to 68.4% in the KP and 73.2% in the MP group.
Conclusion: All investigated purgatives met the required quality standards of
90% rate of adequate bowel preparation according to the current ESGE guide-
lines. Success rates were higher in women and younger patients. Although only
590% of patients consumed the whole volume, the majority of patients would
use the same purgative again.
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Introduction: Adequate bowel preparation is necessary for a successful and com-
plete colonoscopy, Minimum of adequate rate (excellentþ goodþ fair) should be
90% according the actual ESGE guidelines (Kaminski et al, Endoscopy 2017).
The aim of study was, to verify if there is a difference at quality of preparation
between screening and surveillance colonoscopy. It might be that there is an
improvement at surveillance colonoscopy due to better knowledge.
Aims & Methods: 107,614 examinations from 288 endoscopists were analysed
between 2012 and 2017 within the Austrian certificate of screening colonoscopy.
For the calculations six different categories were used: excellent, good, fair, poor,
unsatisfactory, poor only in the right colon. Data are shown as Mean and SD.
Results: 8578 surveillance colonoscopies (43.88% female, mean age 66.67) and
99271 screening colonoscopies (51.04% female, mean age was 62.31) were
included. Within screening colonoscopy 37.59% (SD¼ 31.50) were excellent pre-
pared vs. 34.60% (SD¼ 33.98) within surveillance colonoscopy, good 47.43
(SD¼ 27.28) vs. 45.61% (SD¼ 31.28), fair 11.39% (SD¼ 11.58) vs. 14.39%
(SD¼ 21.69), poor 2.38% (SD¼ 3.06) vs. 3.68% (SD¼ 9.75), unsatisfactory
0.77% (SD¼ 1.20) vs. 0.89% (SD¼ 3.69), poor only in the right colon 0.69%
(SD¼ 1.81) vs. 0.39% (SD¼ 1.22). Calculations revealed no significant differ-
ences among screening and surveillance colonoscopies relating the following
categories: excellent (p¼ 0.4357), good (p¼ 0.5911), unsatisfactory (p¼ 0.6282)
and poor only in the right colon (p¼ 0.1457). Bowel preparation varies signifi-
cantly between screening and surveillance in groups of fair (p¼ 0.0454) and poor
(p¼ 0.0497). Bowel preparation influences the adenoma detection rate (ADR).
Mean ADR in excellent preparation was 22.16% (SD¼ 16.36%), in good
25.41% (SD¼ 17.30%), in fair 24.63% (SD¼ 19.44), in poor 19.94%
(SD¼ 25.57), in unsatisfactory 12.08% (SD¼ 22.77) and in poor only in the
right colon 24.22% (SD¼ 30.89%). Adequate rate in screening colonoscopy
was 96.22% (SD¼ 3.98%) vs. 95.07% (SD¼ 10.45%) in surveillance
colonoscopy. Rates correspond to ESGE guidelines and do not differ signifi-
cantly (p¼ 0.1265).
Conclusion: Data showed distinctions between fair and poor, whereas there were
more fair and more poor prepared patients at the surveillance colonoscopy, than
at the screening colonoscopy. Age of patients at surveillance colonoscopy was
higher, hence patients need improved enlightenment. ADR in excellent, good and
fair bowel preparation was adequate. In poor, unsatisfactory was low and ADR
at poor only in the right colon is high due to low count (N¼ 374).
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Introduction: Bowel preparation influences the adenoma detection rate and is
therefore an important quality parameter in screening colonoscopy. According
to actual ESGE guideline ‘‘Performance measures for lower gastrointestinal
endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality
Improvement Initiative’’, 90% of colonoscopies should have adequate bowel
preparation. The aim of this study was to investigate whether there is a difference
in quality of bowel preparation between private practices and hospitals.
Aims & Methods: Data from screening colonoscopies performed within quality
certificate in Austria (2012 - 2017) provided by 245 endoscopists were evaluated.
The recording of the quality of the bowel preparation was described as one of the
following categories: excellent, good, fair, poor, poor only in the right colon and
unsatisfactory.
Results: From the 125,127 screening colonoscopies included in this study, 72.93%
were performed in private practices, (50.66% female, mean age 60.7) and 27.07%
in hospitals (49.35% female, mean age 60.35). Significant difference was found
between the average values of screening colonoscopies with excellent bowel pre-
paration (38.00% (SD¼ 30.36) in private practices vs. 27.92% (SD¼ 23.11) in
hospitals, p¼ 0.0215), fair (10.68% (SD¼ 10.89) vs. 15.18% (SD¼ 9.93),
p¼ 0.0001) and unsatisfactory (0.66% (SD¼ 0.96%) vs. 1.43% (SD¼ 1.76),
p¼ 0.0003) while there was no statistical significance among the average values
from participants with good bowel preparation quality (47.40% (SD¼ 26.38) in
private practices vs. 51.78% (SD¼ 19.28) in hospitals, p¼ 0.6428), poor (2.57%
(SD¼ 2.93) vs. 2.89 (SD¼ 2.89), p¼ 0.2987) and poor only in the right colon
(0.69 (SD¼ 1.74) vs. 0.80% (SD¼ 1.15, p¼ 0.7721). The mean ADR did not
show any statistical difference between private practices and hospitals (23.98%
(SD¼ 10.89%) vs. 25.80% (SD¼ 12.80%), p¼ 0.7652).
Conclusion: More excellent bowel preparation was found in private practices
while the screening colonoscopies in hospitals showed a higher rate of fair and
unsatisfactory bowel preparation.
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Introduction: Laterally spreading tumors (LSTs) are important precursors of
colorectal carcinoma. They are usually removed by endoscopic mucosal resection
(EMR). However, local residual neoplasia (LRN) may occur during follow-up.
The aim of the study was to evaluate the occurrence of LRN and the risk factors
for its presence.
Aims & Methods: This retrospective study in a high-volume tertiary-referral
center examined patients who had undergone EMR between 2013 and 2015
and who had had at least 1 surveillance colonoscopy after the initial treatment.
LRN was defined histologically as the presence of neoplastic tissue in the post-
EMR site.
Results: 160 laterally spreading tumors were diagnosed in 138 patients (62% men,
mean age 67 years). Mean follow-up interval for surveillance colonoscopy was 6
months. Residual neoplasia at surveillance endoscopy was present following 21%
of colonic EMRs. Single variate analysis showed evidence of an increased risk of
residual neoplasia for LST 20mm (p¼ 0.006), villous adenomas (p¼ 0.001),
piecemeal resection (p¼ 0.011) and G-type morphology (p¼ 0.003). In multi-
variate analysis, only size of the lesion (p¼ 0.080) and villous component
(p¼ 0.043) were found to be a significant risk factor of LRN.
Conclusion: This retrospective study shows that the occurrence of LRN is fre-
quent. Careful colonoscopic surveillance after EMR and the use of new methods
to further reduce residual neoplasia are needed.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Familial adenomatous polyposis (FAP) is an autosomal dominantly
inherited syndrome, associated with a lifetime risk for colorectal cancer close to
100%. Thus prophylactic colectomy is recommended for patients with FAP.
Colectomy with ileorectal anastomosis (IRA) is the surgical option of choice in
the majority of patients, given the complications and morbidity associated with
ileal pouch-anal anastomosis. Therefore, annual endoscopic surveillance is
recommended after surgery to prevent cancer in the rectal remnant (CRR).
Aims & Methods: The aim of this study was to determine the impact of endo-
scopic surveillance on CRR prevention in FAP patients after surgery. We did a
retrospective single center study on findings of follow up endoscopies and deter-
mination of the cumulative risk of adenomas and prevalence of high risk adeno-
mas (HRA) (villous histology, high-grade dysplasia and 10mm) and CRR.
Results: 30 patients submitted to IRA were included (50% women), with a mean
age of 43 years, 2 patients with attenuated phenotype. Nine patients had adeno-
carcinoma in the resected colon. Six patients started chemoprophylaxis after
surgery (sulindac–4; celecoxib -1). The median time to adenoma appearance
was 5 years (95% CI 3.4–6.6) and to HRA/CRR 12 years (95% CI 5.2–18.8),
with a decreased median time to both adenomas and HRA/CRR in patients
under chemoprophylaxis. The cumulative risk of adenomas was 20% at 1 year
after surgery, 34.1% at 3 years and 57.4% at 5 years. During the follow up
period, HRA/CRR developed in 17 patients (56.7%): HRA–12 patients (40%);
intramucosal carcinoma–2 patients (6.7%); invasive adenocarcinoma–3 patients
(10%). None of the patients died with CRR. The cumulative risk of HRA/CRR
was 21.8% at 5 years, 46.1% at 10 years and 66.3% at 15 years. All the patients
with HRA/CRR had rectal involvement prior to surgery (p¼ 0.008) and a higher
number of adenomas resect in the rectal remnant (p¼ 0.017).
Conclusion: The FAP endoscopic surveillance program allowed detection of
HRA/CRR in a high percentage of patients. Based on these results, an intensive
surveillance program should be suggested but endoscopic surveillance intervals
widen in the first 5 years after surgery.
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Introduction: Flexible sigmoidoscopy is increasingly used to examine the left side
of the bowel for diagnostic and surveillance purposes, and is now part of the UK
bowel cancer screening programme. It is crucial to achieve adequate bowel
cleansing in order to optimise the diagnostic yield of the test, and also to mini-
mise the number of repeat procedures. However, the optimum bowel preparation
for this procedure has consistently been debated1,2,3.
Aims & Methods: Both phosphate enema and (PEG-ES) are commonly used for
bowel preparation in flexible sigmoidoscopy at both hospitals participating in
this study. We therefore wanted to compare the outcomes for these two methods.
We retrospectively reviewed all the patients who underwent flexible sigmoido-
scopy from January 2014 to December 2016 using each hospital’s electronic
endoscopy reporting system. We analysed their demographics, type of bowel
preparation used in each case, and the quality of their individually achieved
bowel preparation, subjectively graded as ‘‘Excellent, Adequate or Inadequate’’
by the endoscopist performing the procedure. A chi-squared test was used to
calculate p-values.
Results: In total 6196 patients underwent flexible sigmoidoscopy during the study
period (males 2885 (46.56%), mean age 62.80 years, range 16–101 years). 1247
(20.13%) patients were excluded from further analysis for the following reasons:
No bowel preparation given (n¼ 451), no documentation of the quality of the
bowel preparation (n¼ 657), and non-(PEG-ES) oral preparation used (n¼ 139).
A total of 4949 patients were included in the study, of whom 2103 had (PEG-ES)
(42.49%) (males 986 (46.89%), mean age 60.97 years, range 18–95 years) and
2846 (57.50%) (males 1269 (44.59%), mean age 63.98 years, range 17–101 years)
had phosphate enema. The results are summarised in the table below.
Type of bowel
preparation Excellent Adequate
Total Adequate
and Excellent Inadequate
(PEG-ES) (n¼ 2103) 1126 (53.54%) 770 (36.61%) 1896 (90.16%) 207 (9.84%)
Phosphate enema
(n¼ 2846)
624 (21.93%) 1297 (45.57%) 1921 (67.50%) 925 (32.50%)
Total (n¼ 4949) P5 0.0001
Conclusion: Our large retrospective study showed that oral preparation with
(PEG-ES) gave significantly better results than phosphate enema, which gave
acceptable results in only 67.5% of the patients. As a result of this study,
PEG-ES is now the preferred option at our hospitals, if there is no contraindica-
tion for this.
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Introduction: Endoscopic resection of large colonic lesions (LCLs, 420mm) is
effective and it is associated with an acceptable incidence of incomplete resection
and complications when performed by appropriately trained endoscopists in
resourced centers1,2,3. Scanty data on the management of these lesions outside
referral centers are reported in the literature.
Aims & Methods: Aim of present study is to evaluate the management of endo-
scopic resection of LCLs and intra-procedural complications in a real-life setting.
In a prospective, multicenter, observational study in 20 centers, data from con-
secutive endoscopic resections of LCLs performed over a 6-month period were
collected by a web-database. All patients undergoing LCLs resection were
enrolled at procedure-time and followed-up at 15 days for adverse events and
at 6 months for endoscopic/histological recurrence.
Results: 1452 LCLs (mean size 30.6mm, SD 12.4; 41.4% lateral spreading tumor,
28.1% sessile, and 30.5% pedunculated) removed in 1329 patients (58% males,
mean age 66 11.4 years) were analysed. An endoscopic mucosal resection
(EMR) was performed in 57.9%, snare polypectomy in 34.7%, underwater
EMR in 1.2% and endoscopic submucosal dissection in 6.2% of the lesions.
Of patients with LCLs, 19.4% were on ATT (62.5% aspirin, 12.2% thienopyr-
idines, 4.8% dual antiplatelet, 15.4% vitamin K antagonists [VKAs], 5.1% direct
oral anticoagulants [DOACs]). Aspirin and/or thienopyridines were withheld
before resection in 53.6% and 91.7% of patients, respectively. Overall, intra-
procedural bleeding requiring endoscopic therapy occurred in 8.1% of patients;
28% of them were on ATT, which had always been withheld, but in 48% of
patients on aspirin. At multivariate analysis, intra-procedural bleeding was cor-
related with increasing polyp size (Odds Ratio 1.02 95% Confidence Interval
1.01–1.04), and inversely with execution of pre- and post-resection prophylaxis
maneuvers (Odds Ratio 0.55 95% Confidence Interval 0.37–0.82 and Odds Ratio
0.55 95% Confidence Interval 0.37–0.82 respectively). As concerns
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complications, delayed bleeding occurred in 4.5% of the subjects, whereas per-
foration occurred in 1.5% (0.9% early and 0.6% delayed) of patients, 86.7% of
whom were successfully managed endoscopically. At the moment, 6-months
follow-up is available for 35% of the patients, with a positive endoscopic and/
or histological recurrence documented in 22.8%.
Conclusion: The management of resection of LCLs varies widely. The incidence
of intra-procedural bleeding correlates with polyp size and prophylactic maneu-
vers, and its endoscopic management is successful in most of cases. Overall,
complication rate is marginal and efficacy is good, even in a real-life setting.
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Introduction: The incidence and mortality of colorectal cancer (CRC) can be
decreased trough the removal of precancerous adenomas. Endoscopic removal
of polyps over 2 cm is considered a high-risk procedure both for complications
and malignant transformation.
Aims & Methods: The aim of this study was to evaluate the outcome and com-
plication rate after endoscopic removal of polyps over 2 cm. In this retrospective
study clinical and demographic data of patients undergoing polypectomy due to
colorectal adenoma over 2 cm between 2012 and 2017 were collected. Data on
endoscopic procedures, complications of polypectomy and histological assess-
ments of the removed polyp were obtained.
Results: Data of 100 patients (male/female: 58/42) was analyzed in the study.
Forty-seven of the 106 removed polyps proved to be pedunculated, 21 were
sessile and 34 flat. Six patients had more than one large polyp (42 cm). The
locations of the removed polyps were rectum in 33, sigmoid colon in 38, coecum
in 12 and other parts of the colon in 23 patients. In 65 cases, polyps were excised
with endoscopic mucosa resection (EMR) or hybrid endoscopic submucosa dis-
section (ESD), In 41 cases snare was used to remove the polyps in one or more
pieces. Based on histological findings 54 (50.9%) polyps were shown to be low-
grade adenomas, 34 (32.07%) high-grade adenomas, 1 (0.9%) polyp was hyper-
plastic, and 17 (16.03%) proved to be malignant among which complete endo-
scopic removal was achieved in 9 patients (52.9%). Additional smaller polyps
were found in 39 patients and a synchronous cancer in 7. During polypectomies
91 hemoclips were deployed to close suspected perforation (8 cases) to cease
bleeding (19) or for prevention. Postpolypectomy syndrome developed in 8
cases. Second-look colonoscopy was required in 8 cases due to bleeding within
a mean of 4 days after the first examination. Hemoclip insertion was needed in 5
cases and epinephrine injection in 1 case. The bleeding stopped spontaneously in
2 cases. Blood transfusion was required in 3 patients. Surgical intervention was
not needed in any case.
Conclusion: Malignant transformation was revealed in 16% of the polyps over
the size of 2 cm. Complete endoscopic removal of these polyps was successfully
performed in half of the patients. Endoscopic removal of high-risk polyps is safe
in experienced hand.
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Introduction: The choice of polypectomy technique differs according to regional
preferences and availability. This year, in order to standardize the approach to
this techniques, the European Society of Gastrointestinal Endoscopy (ESGE)
published recommendations for colorectal polypectomy and endoscopic mucosal
resection (EMR).1
Aims & Methods: We aimed to evaluate the recent years evolution of the adher-
ence to the recommendations of colorretal polypectomy and EMR at a tertiary
center. We conducted a unicentric analysis of polypectomy and mucosectomy
techniques performed consecutively between January and June of 2011 and 2016
at a tertiary center. According to the recommendations, the excision of sessile
and flat polyps is considered adequate when performed with cold biopsy forceps
or cold snare for polyps 3mm, cold snare if 4–9mm, cold or hot snare if 10–
19mm and EMR if 20mm. Polypectomy of pedunculated polyps is considered
adequate when performed with a diathermic loop in polyps 520mm, always in
association with any prophylactic therapy when polyp size 20mm.
Results: We included 1721 endoscopic procedures of polypectomy and EMR,
concerning 696 patients (64.5% male; mean age¼ 64.2 11.0 years). 1381
(80.2%) sessile polyps, 153 (8.9%) flat lesions and 187 (20.9%) pedunculated
polyps were identified, with a mean size of 7.9 7.0mm. Regarding sessile and
flat polyps, one of the recommended excision techniques was performed in:
84.6% (n¼ 270) of 3mm polyps (75.7% in 2011 vs. 95.8% in 2016;
p5 0.001); 22.2% (n¼ 109) of 4–5mm polyps (12.5% vs. 36.5%; p5 0.001);
13.4% (n¼ 59) of 6–9mm polyps (5.4% vs. 23.8%; p5 0.001); 100% (n¼ 206)
of 10–19mm polyps; and 100% (n¼ 88) of 20mm lesions. For pedunculated
polyps, the resection technique was adequate in: 99.3% (n¼ 134) of polyps of size
520mm (100% vs. 97.6%; p4 0.05) and in 84.6% (n¼ 44) of those 20mm
(82.6% vs. 86.2%; p4 0.05). Overall, 52.3% (n¼ 900) of endoscopic procedures
of polypectomy or EMR were performed as recommended; 42.7% (n¼ 410) in
2011 vs. 64.5% (n¼ 490) in 2016; p5 0.001.
Conclusion: Even before publication of the european recommendations, there has
already been an increase in the proportion of polypectomies performed ade-
quately in the different groups of lesions. There is still a need to adjust clinical
practice in some subgroups, especially in polyps of size 4–9mm, in order to
strictly comply with the recommendations.
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Introduction: Endoscopic resection of superficial neoplasms at the perineal
rectum is difficult due to pain sensibility, narrowness of the anal canal, presence
of internal rectal plexus, whereas that of at the ileocecal valve (ICV) due to the
variable morphology of the ICV itself and ileal involvement.
Aims & Methods: Aim was to assess the feasibility and outcomes of ESD in these
locations. Prospectively collected database in a single nonacademic center. From
1.2010 to 11.2016, all consecutive patients scheduled to ESD for a superficial
neoplasm in the perineal rectum (distal margin 530mm from the dentate line)
and at the ICV were compared to those in the pelvic rectum and in the cecum and
ascending colon, respectively. ESD was performed with the standard technique.
Follow-up was scheduled at 3 and 6 months within the first year and then yearly.
Biopsies were taken from the scar of the resection site if a residual tissue was
detected.
Results: A total 16 neoplasms at ICV were compared to 110 neoplasms in the
cecum and ascending colon; 30 neoplasms in the perineal rectum were compared
to 58 cases in the pelvic rectum (Table). Features of neoplasms in the perineal and
pelvic rectum were no different as well as neoplasms at the ICV and cecum and
ascending colon. ESD en bloc rates were lower in the perineal rectum and at the
ICV, but no significant differences were found with the respective control groups
(P¼ 0.490 and 0.404, respectively). ESD R0 rate was significantly lower at the
ICV (P¼ 0.021). Adverse events were not different, although 3 perforations
occurred in the cecum and ascending colon. During follow-up (median 36
months; range 24–84): residual tissue was diagnosed at the ICV in 2 (13%)
cases, in the cecum and ascending colon in 2 (2%) cases (P¼ 0.078); in the
perineal rectum in 4 (13%) cases and pelvic rectum in 2 (3%).
IC valve
(n.16)
cecum &
Ascending
(n.110)
perineal
rectum
(n.30)
Pelvic
Rectum
(n.58)
size, mm median (range 44 (20–85) 35 (15–80) 48 (23–180) 35 (12–70)
morphology: LST-G/NG 12/4 81/22 23/3 39/7
scar positive 0 19 8 10
ESD en bloc 12 (75) 91 (83) 22 (73) 48 (83)
ESD R0 7 81 15 41
ESD R1 (HM/VM) 5/0 10/0 6/1 4/1
Conclusion: The ESD of neoplasms at the ICV and perineal rectum is feasible and
effective. The complete resection rate is low due to the challenging anatomy of
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that precludes conducting a mucosal incision far from tumor margins. A careful
endoscopic follow-up is mandatory to detect residual neoplasms.
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Introduction: Colorectal cancer (CRC) is one of the most common malignancies
in developed countries, with associated occlusive disease being relatively
common. Endoscopic placement of self-expandable metallic stent (SEMS) is
the first-line palliative treatment for malignant bowel obstruction.
Aims & Methods: Evaluate the outcome of endoscopic SEMS placement in CRC
obstruction. Retrospective analysis of patients CRC submitted to endoscopic
placement of SEMS from 2009 to 2016 in the Gastroenterology Department of
Centro Hospitalar do Algarve. Statistical analysis was performed with SPSS
version 24.
Results: The study included 23 patients with CRC obstruction, who were sub-
mitted to endoscopic SEMS placement, with a mean age of 75.2 13.47 years.
The stents were placed with a palliative purpose in 69.6% of cases (n¼ 16) and a
transitory procedure before surgery in 30.4% of cases (n¼ 7). Technical and
clinical success was found in 91.3% of the patients, without any recorded
death during the procedure. In patients whose goal was palliative treatment
(75% men and 25% women) they had a mean age of 81.6 9.28 years. In
43.8% of the patients the tumor was located in the rectum, 31.6% in the sigmoid
region and 25% in the recto-sigmoid transition. Being the majority (75%) well
differentiated. There was a need for dilatation in 31.3%, most of the stents were
uncovered (56.3%). 25% of the patients had complications. After stent place-
ment, about 25% of the patients did chemotherapy. There was a 75% mortality
rate (37.5% died by 6 months and 37.5% died by 12 months of follow-up). The
use of chemotherapy after SEMS placement influenced the complications asso-
ciated with the procedure (p5 0.05) but none of the other variables had a sta-
tistically significant influence on early death (up to 6 months).
Conclusion: SMES is an effective and safe palliative option for unresectable
tumors, although the use of chemotherapy after the placement of prostheses
may have an influence on the appearance of complications. Malignant colon
occlusive of the colon can be treated effectively with the use of endoscopic
techniques.
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Introduction: Endoscopic mucosal resection (EMR) has been shown to be a safe
and effective technique for removal of large colorectal adenomas. However, local
adenoma recurrence remains a significant limitation, with prior published data
describing recurrence rates of 10% to 30% post EMR.
Aims & Methods: This study aimed to evaluate the outcomes of EMR for large
colorectal adenomas and identify the risk factors for adenoma recurrence. We did
a retrospective analysis of the colorectal EMR performed between June 2009 and
December 2016. Resected lesions larger than 20mm in diameter with at least 3
months follow up were included. Patients referred for surgery were excluded.
Results: During the study period, 201 colorectal lesions 20mm in size were
removed in 198 patients (118 men and 80 women, mean age 68 years). Mean
lesion size was 35mm and 137 (68.2%) were located in the rectum and left colon.
66 lesions (32.8%) were larger than 40mm in diameter. Piecemeal resection was
performed in 171 lesions (85.1%). Local adenoma recurrence occurred in 44 cases
(21.9%) after a mean time of follow up of 7.6 months, and the majority was
managed with polypectomy or new EMR. The cumulative risk of adenoma
recurrence was 7.5% at 3 months, 15.5% at 6 months and 17.1% at 12
months. In the multivariate analysis, the variables associated with a high risk
of recurrence were lesions 40mm in size (p¼ 0.0001) and intra-procedural
bleeding (p¼ 0.020). The recurrence rate was higher in the patients treated
with argon plasma coagulation (p¼ 0.046).
Conclusion: After EMR of large colorectal adenomas, local recurrence rate was
21.9%. The risk factors for adenoma recurrence include lesions 40mm and
intra-procedural bleeding. Argon plasma coagulation was not associated with
lower recurrence rate.
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Introduction: European colorectal screening guidelines have modified the follow-
up interval times based on baseline colonoscopy findings in recent years. In
addition, the waiting list and individual conditions may modify the real follow-
up times and this could impact in advanced adenoma detection rate in follow-up
and patients outcome.
Aims & Methods: The aim of the present study was to comparatively analyse the
risk of advanced lesions (advanced adenoma, invasive cancer) in high-risk
patients included in a colorectal cancer screening program with different real
follow-up times. One-thousand one-hundred and sixty-six patients (mean age:
60.66 5.86 years, 69.1% men) who underwent a baseline colonoscopy with
3adenomas and/or 10mm between 2007–2012 were included. A Kaplan-
Meier regression and a comparative subgroup analysis by Long-Rank test were
carried out to detect the impact of real times within patients of the same risk. An
adjustment for baseline covariates (high-grade dysplasia, villous component) by
Cox analysis was also performed.
Results: The real follow-up times in 3 adenomas (n¼ 853, 73.16%) and 1ade-
noma 10mm (n¼ 779, 66.81%) were 38.54 11.57 and 38.66 11.68 months.
The risk of advanced lesions were 0.26%, 1.46%, 2.83%, 9.09% and 10.38%
(n¼ 121 advanced lesions) in 12, 24, 36, 48 and 60months respectively. The
most important increase was at 3–4 years (þ0.52%/month). The proportion of
advanced lesions within 1–2 adenomas and 3 adenomas subgroups at 48
months were 5.43% and 10.43% (p5 0.001),with no differences in small adeno-
mas 5410mm (p¼ 0.478).
Conclusion: The risk of advanced lesions in high-risk patients increased signifi-
cantly at 36–60 months after baseline colonoscopy, being more important in 3
adenomas subgroup. There were no differences for 1–3 years interval.
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Introduction: Conventional endoscopic resection, such as snare polypectomy and
endoscopic mucosa resection (EMR) of benign polyps in colon and rectum
reduces colorectal cancer (CRC) incidence and mortality but the role of endo-
scopic resection in the management of patients with early CRC (i.e. submucosal
invasion) remain elusive. Large sessile and flat lesions are difficult to remove en
bloc with EMR, resulting in a high level of tumor recurrence. Thus, endoscopic
resection of large (42 cm) sessile and flat malignant lesion with snare or EMR is
not recommended. Endoscopic submucosal dissection (ESD) results in high en
bloc resection rates of large (z2cm) benign lesions resulting in low numbers of
recurrences. However, there is limited data in the literature on the potential role
of ESD in the treatment of patients with early CRC. In the present study, we
present our results on performing ESD in patients with large sessile and flat
malignant lesion in the colon and rectum in a large European center.
Aims & Methods: Our aim was to investigate the potential role of ESD in treat-
ment of early colorectal cancer. We retrospectively reviewed medical records of
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254 patients that underwent colorectal ESD at the endoscopy unit at Skåne
University Hospital in Malmö, Sweden Jan 2014 to Dec 2016. Indications for
ESD were flat and sessile lesions larger than 20mm in diameter with low or high
graded dysplasia (251 cases). Moreover, three patients with known colorectal
adenocarcinoma underwent ESD due to significant comorbidity excluding sur-
gery. In total, we identified and included 29 cases of histologically verified sub-
mucosal invasive CRC in this study.
Results: This study included 29 patients with median age of 69 years (range 44–89
years). Median tumour size was 40mm, ranging from 20 - 70mm. Tumours were
either flat (Paris classification IIa, 6 cases), sessile (Paris classification 1s, 19
cases) or a combination of flat and sessile (4 cases). Half of the lesions were
located in the rectum and half in the colon. En bloc resection was achieved in
24 cases (83%), piecemeal resection in 4 cases (14%) and ESD was incomplete in
one case. Median time to complete the procedure was 89min (Range 18 to
594min). Macroscopic complete resection was obtained in 26 cases (90%). R0
resection was found in 20 specimen (69%), RX was found in 3 cases (10%) and
R1 was found in 5 cases (17%). Lymphovascular involvement was seen in 6 cases
(21%). Depth of invasion was as follows; Sm1: 15, Sm2: 7, Sm 3: 7. In total four
suspected immediate perforations occurred, three of these were managed con-
servatively (clips, fasting and antibiotics) and in one case, ESD was aborted and
the patient was taken to emergency surgery. Pathological assessment of the
resected sigmoid segment revealed T3N0. No acute significant bleeding occurred
during the procedures. One patient sought emergency care 12 days after the
procedure with rectal bleeding, no colonoscopy was performed to determine
the site of bleeding. Five patients underwent additional surgery since the patho-
logical report stated that the resection was R1. Tumour residue was only found in
one of the five resected specimens. 18 patients have undergone endoscopic follow
up, to this date without any sign of recurrence. Two patients await surgery and
three patients await endoscopic follow up.
Conclusion: We herein present our findings on performing ESD on 29 patients
with early CRC. Our results indicate that colorectal ESD is a safe and effective
treatment in meticulously chosen patients even with malignant lesions. Further
studies with longer follow up is needed.
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Introduction: Large colorectal lesions (420mm) can be removed endoscopically
by endoscopic mucosal resection (EMR), often in a piecemeal fashion resulting in
low en bloc and radical (R0)-resection rates. In this indication, submucosal dis-
section (ESD) allows en bloc resection whatever the size, but still remains tech-
nically difficult and time consuming. A hybrid endoscopic technique has been
developed, called simplified or hybrid dissection. The aim of our study was to
evaluate the results and complications of endoscopic dissection by hybrid tech-
nique compared to classical endoscopic submucosal dissection.
Aims & Methods: Our study was carried out from January 2013 to June 2016
from a prospective database. The 40 lesions removed by hybrid technique were
compared to the control group of 109 ESD. The hybrid dissection procedure was
performed as follow: submucosal injection around the lesion of macromolecules,
circumferential mucosal incision and submucosal dissection using the tip of a
single-strand snare by endo-cut Q mode, central submucosal injection of the
lesion and final resection with the single-strand snare, if possible in en-bloc.
Patient characteristics, tumor location and size, dissection characteristics,
"block" resection rate, R0 resection rate (healthy margins), procedure and hos-
pitalization time, and complications were identified and compared with the so-
called "classical" ESD technique.
Results: Lesions were more frequently located in the colon (vs rectum) in the
hybrid dissection group compared to the ESD group (72.5% versus 28.5%,
p5 0.001). The lesions were type IIc according to Paris classification in 10%
of the hybrid dissection group and 13.1% in the ESD group (p¼ 0.8). The mean
size of the lesions was lower in the hybrid dissection group than in the ESD group
(32.4mm 13mm compared to 54.4mm 26.7mm, p5 0.001). An en bloc
resection was performed in 52.5% and 84.4% in the hybrid dissection and
ESD group, respectively (p5 0.001). The procedure time (including general
anesthesia time) was lower in the hybrid dissection group compared to the
ESD group (103min 62min vs 191min 73min, p5 0.001, respectively).
The hospitalization time was lower in the hybrid dissection group than in the
ESD group (1.1 days 1.13 days vs. 2.8 days 1.8 days, p5 0.001). R0 resection
rates were lower in the hybrid dissection group than in the ESD group (47.5%
and 61% respectively, p5 0.001). Hybrid dissection was performed for adeno-
carcinoma, adenoma with high grade dysplasia and adenoma with low grade
dysplasia in 12.5%, 42.5% and 40%, respectively. The rate of adenocarcinoma
was lower compared to the ESD group (12.5% versus 30.8%, p¼ 0.009). In the
hybrid dissection group, the rate of perforation was lower than the ESD group
(5% versus 20%, p¼ 0.04). There was no significant difference in the rate of
bleeding (1.8% In the hybrid dissection group and 2.5% in the ESD group). In
case of complication, there was no need of surgical treatment in the hybrid
dissection group, but was needed in one patient in the ESD group.
Conclusion:Hybrid dissection is less effective in terms of en bloc resection of large
colorectal tumors. Classical endoscopic submucosal resection should be pre-
ferred, especially in case of suspected adenocarcinoma despite longer procedure
and hospitalisation time.
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Introduction: Since its introduction in 1968, Endoscopic retrograde cholangio-
pancreatography (ERCP) has become a commonly performed endoscopic pro-
cedure used to diagnose and to treat conditions associated to the pancreatobiliary
system. It is nevertheless associated to the highest risk of complications of all
routine endoscopic procedures. It is important to have a thorough understanding
of the potential complications and the adverse events that may be associated to
ERCP procedures so that these may be managed appropriately should they
occur. The aim of this study was to examine the trends in ERCP usage here in
the Veneto Region (Northeastern Italian area) and, in particular, the complica-
tions and mortality rate associated to it.
Aims & Methods: Utilizing an anonymous database of hospital discharge records
referring to the period between 2007 and 2015, a retrospective study was carried
out to examine the complications associated to ERCP. All of the elective hospi-
talizations for gallstones in the bile duct during which the procedure was carried
out within two days of being hospitalized were examined. Hospitalizations for
neoplasms were not considered. The study considered the onset of complications
or death as outcome indicators as well as the patients’ post-procedure status; the
threshold value that was utilized was 2 days and the patients who later underwent
surgery (e.g. cholecystectomy) were excluded from our analysis; the associations
between the type of hospital where the patients were being assisted both with
regard to the type of organization (Hub or Spoke model) and the type of manage-
ment (public/private) were also evaluated.
Results: A total of 3,136 admissions out of total of 14,626 hospital days
(SD:4.6 5.8 days) were identified in a total of 40 hospitals, 6 (15%) of which
private. The sex ratios were overlapping and the mean age, which was equal to
68.3 14.2 (range 6–98 yrs), was higher in the females (69.1 14,9 vs.
67.5 13,5); significant deviations during the period examined were not noted.
A total of 212 complications (6.8%) were registered: these included acute pan-
creatitis (4.5%), cholangitis (1.3%), sepsis (0.4%), acute cholecystitis (0.3%),
cardiopulmonary complications (0.2%), perforations and hemorrhage (0.2%).
The complications that presented, which were significantly higher in the female
sex (7.3% vs. 6.2%; p5 0.05), besides a greater average hospital stay in those
subjects (10.9 13.9 vs. 4.2 4.4 days), the within hospital mortality was 4.1%
(13 cases) and there was a 6.1% of deaths due to complications. As far as the
post-procedure hospital stay was concerned, in 55% of the cases, the discharge of
patients within a two day period was more frequent in those assisted in public
hospitals (OR:1.55;IC95%:1.21–1.89;p5 0.05) in which 90% of the activities
were carried out and no differences linked to their characteristics. The stratifica-
tion of complications according to the type of hospital (range 2–17%) did not
uncover any significant differences during the period examined.
Conclusion: Study findings uncovered that pancreatitis was the most common
post-procedure ERCP complication in the patients studied; the total complica-
tion rate was in line with that reported in the literature. That result and the fact
that no correlation was found between the the type and percent of complications
and the type of hospital can be attributed to the effective regional hospital
organization characterized by a capillary network of specialists capable of per-
forming complex endoscopic procedures throughout the region limiting the need
to transfer patients from one hospital to another.
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Introduction: Risk factors for post-endoscopic retrograde cholangiopancreato-
graphy pancreatitis (PEP) have been widely investigated. Nevertheless, studies
focusing in metabolic conditions especially obesity, dyslipidemia and diabetes
mellitus (DM) are still limited.
Aims & Methods: The aim of our study was to evaluate the effect of these factors
on the frequency of PEP. We retrospectively analyzed all ERCP performed over
a 12 months period [January 2015 - December 2015] and carried out at the
gastroenterology unit of our hospital. All patients were evaluated prospectively
for the frequency of PEP based on the consensus criteria.The patients with
obesity (Body mass index BMI 30 kg/m2), dyslipidemia (triglyceride 42 g/L
or LDL-cholesterol 41.6 g/L) and DM (history of DM or fasting glucose level
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41.26 g/l) were find out before the procedure. The rate of PEP compared sepa-
rately between patients with and without of these metabolic conditions.
Results: Two hundred twenty three procedures were performed during the study
period. The rate of obesity, dyslipidemia and DM was 23.7%, 8.1% and 19.7%
respectively. A PEP occurred in 13 patients with an overall incidence of 5.8%.
The rate of PEP was 3.8% in patients with obesity, 11.1% in patients with
dyslipidemia and 9.1% in patients with DM. Although PEP was more frequent
in dyslipidemia (11.1% vs 5.3%) and DM (9.1% vs 5.3%) groups, results did not
rich a statistical significance (p¼ 0.30, p¼ 0.31 respectively). This could be
explained by the small effective of patients. In the other hand, PEP was less
frequent in the obesity group (3.8% vs 6.9%) but there was no statistical sig-
nificance p¼ 0.28.
Conclusion: In our study, metabolic conditions were not associated with an
increased risk of PEP. It seems to be wise to evaluate the role of these conditions
in larger prospective studies since the expanded prevalence of metabolic syn-
drome in general population.
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Introduction: Hepatic hydatid disease (HHD) is a major endemic health problem
in certain areas of the world such as Tunisia. Intrabiliary rupture of a hepatic
hydatid cyst is a common complication ranging between 3 and 17%.
Furthermore, biliary leakage is the most frequent postoperative complication
following surgery for hydatid cysts of liver. Both conditions require per endo-
scopic biliary drainage.
Aims & Methods: The aim of this study was to assess the results of ERCP in
patients with HHD. We retrospectively analyzed the results and complications of
all ERCP performed for HHD whether before or after surgical treatment over a
10 years period [January 2007 - December 2016] and carried out at the gastro-
enterology unit of our hospital.
Results: Sixty seven procedures were included (mean age 40.4 years [15–82] and
sex ratio male/female 31/36). Of the 67 procedures, 58 (86.5%) were performed in
patients who had undergone previous surgery. The indications of the ERCP were
persistent external biliary fistulae in 77.6%, overcome obstruction or cholangitis
due to residual materials within bile duct in 20.7% and secondary biliary stric-
tures in 1.7%. In patients who had not undergone previous surgery (13.4%), the
indications of the ERCP were cholangitis due to intra-biliary rupture of hydatid
cyst in 44.4% associated with acute pancreatitis in 55.6%. The cannulation of the
papilla was impossible in 6 cases (8.9%) and the endoscopic sphincterotomy (ES)
could not performed. When papilla cannulation was obtained, per endoscopic
cholangiographic findings were: dilation of the biliary tract (21.3%) with filling
defects of varying size and shapes (52.5%), leakage of contrast medium into the
cyst cavity (41%) and distal stenosis (3.3%). ES was then performed in all cases
with satisfactory results. Thus, hydatid membranes (36%) or daughter cysts
(1.6%) encountered in bile ducts have been emptied out in 93.4% by biliary
occlusion balloon and/or Dormia basket. Nevertheless, two patients required
biliary stenting due to stricture of the bile duct and two others required naso-
biliary drainage. One patient presented post ERCP pancreatitis (1.5%).
Conclusion: ERCP is a safe and effective way to manage biliary complications of
HHD. In most patients, ES is the most efficient treatment of postoperative
external biliary fistulas, jaundice and accompanying cholangitis. In some cases,
biliary stenting or nasobiliary drainage may be required.
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Introduction: Endoscopic Regrograde Cholangiopancreatogram (ERCP) is a
complex and invasive procedure. Quality control and monitoring for complica-
tions is an important part of ensuring patient safety. Gastroenterology and
Hepatology unit of the National Hospital of Sri Lanka performs the most
number and variety of ERCP procedures in Sri Lanka. Although facilities are
limited, detailed patient records and logs were maintained since commencement
of ERCP procedures in this unit.
Aims & Methods: A retrospective analysis was carried out on quality indicators
and complications of the ERCP procedures performed in this unit since 2006.
Data from written records were entered into an electronic database and analysis
was done using STATA version 13. Quality indicators and standards published
by the American Society of Gastrointestinal Endoscopy and American College of
Gastroenterology in 2015 were used.
Results: A total of 3780 ERCP procedures were performed. Females consisted of
54% of the patients (n¼ 2041). Mean age in years was 57.6 (SD¼ 8.4). Male
patients were older with a mean age of 61.2 years whereas the mean age of
females was 54.6 years (P5 0.05). Choledocolithiasis was the commonest indica-
tion (85%) and 68% out of these patients had active cholangitis at the time of the
procedure. Chronic pancreatitis, benign and malignant strictures requiring stent-
ing, postoperative bile duct damage the other common indications. Data were
available on 19 out of the 24 quality indicators. A total of 15 quality standards
were met (7/9 pre procedure, 4/5 intra procedure and 4/10 post procedure). Most
prevalent major complications were Post ERCP Pancreatitis (PEP) and post
ERCP Cholangitis (PEC) complicating 2.22% and 4.78% procedures respec-
tively. Mortality was less than 0.1% (n¼ 3). Cardiorespiratory complications
and complications of anesthesia were seen in 16 patients (0.41%) resulting in
one mortality. These were significantly associated with older age and the total
number of medical comorbidities the patients had (p5 0.05). Deficiencies prac-
tices and information gathering were noted mostly in postoperative care and
includes documentation of patient satisfaction rate and long-term complication
rates. After the quality review data on all quality indicators are gathered for
future quality control purposes.
Conclusion: This supports the fact that centers with minimal resources can moni-
tor quality standards and maintain satisfactory patient safety levels. Low num-
bers of postoperative complications were noted in this review. Old age and
having multiple medical comorbidities were associated with a higher complica-
tion risk. Quality checkups help to identify deficiencies in practice as well as
documentation and help to adjust future practices, even in low resource settings.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: EUS-guided pancreatic or biliary rendezvous is a technically
demanding procedure, and the intraductal manipulation of the guidewire remains
the most challenging step. Passing the guidewire through the needle may cause its
fragmentation on the sharp metallic bevel. We have described the method of
using a microcatheter for EUS-guided rendezvous, which allows easier handling
and exchange of the guidewire, while avoiding both the risk of fragmentation and
the need of injection of contrast to achieve a complete ductogram.
Aims & Methods: We aimed to evaluate the early experience of the microcatheter
method in EUS-guided rendezvous procedures in the biliary and pancreatic
tracts. During EUS-guided biliary or pancreatic rendezvous, initial puncture of
the duct of interest was attempted with a 19G needle without stylet and
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previously flushed with contrast. A 0.025’’ guidewire was then inserted through
the needle into the duct and advanced anterogradely to the papilla. If further
manipulation was necessary to entry the duodenum, movements were performed
with caution in order to avoid fragmentation of the guidewire. Whenever the
passage through the papilla was not achieved or the guidewire movements were
hampered by the needle bevel, we performed a microcatheter technique. After
removing the needle, leaving the guidewire in situ, a 3F, 150 cm long microcath-
eter was inserted over the guidewire into the duct. Then, manipulation of the
guidewire, guidewire exchange and contrast injection were performed according
to the discretion of the endoscopist. We reviewed the cases of EUS-guided pan-
creatic or biliary rendezvous performed in our unit using microcatheters from
September 2015 to March 2017. Technical success was considered when the
rendezvous could be completed.
Results: Nine patients with previous unsuccessful manipulation of the guidewire
with the needle during EUS-guided biliary or pancreatic rendezvous underwent a
microcatheter-guided attempt on the same procedure. Pancreatic rendezvous was
attempted in 5 cases (2 chronic pancreatitis, 2 pancreas divisum and 1 pancreatic
cancer) and biliary rendezvous in the other 4 (3 biliary stenosis and 1 ampul-
loma). Technical success was achieved in 7 patients (78%) with the microcatheter
technique. Technical failure occurred in 1 patient with biliary stenosis in whom a
EUS-guided hepaticogastrostomy was performed in the same procedure and in 1
patient with chronic pancreatitis with symptomatic pancreatic duct stenosis.
There were no adverse events after the procedure, irrespective of technical
success.
Conclusion: In our series, using a microcatheter for the indractuctal manipulation
of the guidewire increases the EUS-guided rendezvous technical success without
increasing the complication rate, irrespective of technical success.
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Introduction: Biliary tract complications (BTC) are the leading problem in
patients after orthotope liver transplantation (LT). The present study analysed
the results and predictors of treatment outcomes in patients with biliary stenoses
undergoing endoscopic retrograde cholangiopancreatography (ERCP) and/or
percutaneous transhepatic cholangiodrainage (PTCD) at the University
Medical Centre Hamburg-Eppendorf.
Aims & Methods: All adult patients who received ERCP or PTCD for BTC after
LT between 2009 and 2015 were retrospectively analysed. Remission of BTC was
defined as no need of intervention for at least 12 months. To identify predictors
of endoscopic treatment outcome in patients with biliary stenoses, a multivariate
logistic regression analysis was performed after univariate variable selection.
Laboratory parameters that were significant in the multivariate analysis, were
dichotomised stepwise according to the most informative cut-off predicting out-
come. Furthermore, endoscopic techniques were analysed in both the ERCP- and
PTCD-subgroup.
Results: Of 144 patients with BTC after LT, 116 were diagnosed with biliary
stenoses. Among these, 86 received ERCP, 17 PTCD and 13 both techniques.
Long-term remission was achieved in 55 patients (47% overall; 53% in ERCP
alone and 30% when PTCD was applied). Patients with non-anastomotic stric-
tures (NAS) (odds ratio [OR] 0.25, 95% confidence interval [CI] 0.10–0.57;
p¼ 0.001), requirement of PTCD (OR 0.30, 95% CI 0.10–0.79; p¼ 0.018) and
higher pre-interventional serum-bilirubin levels (OR 0.88, 95% CI 0.76–0.98;
p¼ 0.037) were less likely to achieve remission. The most informative bilirubin
cut-off to predict the outcome was 5mg/dl. This cut-off maintained a significant
association with outcome in the multivariate model (OR 0.30, 95% CI 0.08–0.95;
p¼ 0.049). In the ERCP-subgroup, dilation with a higher maximal balloon-dia-
meter was associated with a favourable outcome (p¼ 0.043).
Conclusion: Both ERCP and PTCD can provide long-term benefit in patients
with BTC after LT. However, patients with NAS and requirement of PTCD had
less favourable outcomes. The pre-interventional bilirubin level could be a valu-
able parameter to identify patients at risk of treatment failure. Larger ERCP
balloon diameters may benefit remission.
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Introduction: Confocal endomicroscopy is an endoscopic imaging technique per-
mitting the microscopic analysis of the digestive mucosa in real time (esophagus,
stomach, duodenum, colon, biliary tract and pancreas) due to injection of fluor-
escein which is an intravenous contrast. The aim of this national observational
study under the guard of SFED is to evaluate the practice of confocal endomi-
croscopy in France, specifically its indication, histologic correlation, therapeutic
benefits depending on the operator and complications.
Aims & Methods: We executed a multicentric observational prospective study
from September 2013 to February 2015. Collection of data was based on a
standardized collection sheet. All operators were trained on performing confocal
endmicroscopy. The intravenous injection of fluorescein was given either in bolus
or in a perfusion method at a dilution of 1 or 10%. Demographic, clinical,
endoscopic and endomicroscopic data were collected. For each act the correla-
tion between the confocal endomicroscpy and histology and the outcome of the
ECM depending on the operator was reported.
Results: In total 399 procedures of confocal endomicroscopy were done on 399
patients (median age was 59 þ/ 14.5, males were 52%) and these were per-
formed in 12 centers. The main indications were: diagnosis and monitoring of
Barrett esophagus 28% (111/399), surveillance of gastritis 4% (16/399), charac-
terization of colorectal polyp and searching for dysplasia in IBD patients 17%
(68/399), undetermined biliary stenosis 11% (42/399), pancreatic cysts 30% (123/
399) and other rare cases (lymph nodes characterization, pancreatic mass, ampul-
loma, GIST, celiac disease, control post mucosectomy of gastric and duodenal
polyps) 10% (39/399). The quality of imaging was good in 83% of cases (331/
399), average in 16% (64/399) and poor in 1% (6/399). The correlation with
histology was measured by using Cohen’s kappa coefficient. The results were
respectively k¼ 0.9, 0.78, 0.82, 0.7, 0.94, 0.93 for Barrett’s esophagus, gastritis,
IBD, colorectal polyps, undetermined biliary stenosis and pancreatic cysts. The
outcome of the procedure according to the operator was beneficial for three main
indications: Barrett’s esophagus (82% especially for targeting biopsies), serous
pancreatic cysts (100% of cases), and undetermined biliary stenosis (90% of cases
and especially for real time therapeutic decision). One major side effect was seen
during the study, which was an anaphylactic choc after a bolus injection of 2.5cc
of fluorescein 10% in a 69y old patient who didn’t have any previous history of
allergies. This patient was hospitalized for surveillance for three days.
Conclusion: In conclusion, confocal endomicroscopy is an in vivo microscopic
imaging technique that is easily performed throughout the digestive tube with a
good histologic correlation especially for barrett’s esophagus, undetermined bili-
ary stenosis and pancreatic cysts. Its importance in the management of patients
remains to be clarified with the advent of new endoscopic magnification
techniques.
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Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) repre-
sents a crucial procedure in the management of biliopancreatic pathology.
However, its performance in patients with surgically modified gastro-enteric-
biliary anatomy (SMGA) is a challenging issue.
Aims & Methods: We aimed to evaluate the efficacy of this advanced endoscopic
technique in patients with SMGA. This was a retrospective observational cohort
study of all patients with surgical modification of biliary/pancreatic access under-
gone ERCP, between 01/2002 and 02/2017. Demographic variables, indications,
the breakdown of surgical procedures and technical success rate were evaluated
as well as potential predictive factors of therapeutic efficacy rate. Compared
patients with successful technique(G1) and therapeutic failure by ERCP
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requiring surgical and/or radiological therapy(G2), regarding recurrence of bilio-
pancreatic pathology, major complications and post-procedure 30-days
mortality.
Results: A total of 153 ERCP procedures were carried out in 103 patients with
SMGA (mean age:75.4 11.3years, men:80.6%). The breakdown of surgical
procedures was: Billroth II-77.7%(n¼ 80); Billroth I-10.7%(n¼ 11); Roux-en-
Y-8.7%(n¼ 9); post-duodenopancreatectomy-2; gastric sleeve-1. The forward-
viewing endoscope was used in 79.8%(n¼ 122), duodenoscope in
19.6%(n¼ 30) and colonoscope in 0.6%(n¼ 1). The success rate was: techni-
cal-62.1%(95/153); therapeutic-93.7%(89/95). The success rate by type of surgi-
cal reconstruction was: gastric sleeve-100%; Billroth I-94.4%; Billroth II-60.5%;
post-duodenopancreatectomy-50%; Roux-en-Y-18.2%. After multivariate ana-
lysis, poor papillary orientation/localization (OR¼ 5.618;p¼ 0.006) was the only
independent predictor of technical failure. On the other hand, high values of total
bilirubin (OR¼ 1.339;p¼ 0.024) and benign etiology of obstructive jaundice
(OR¼ 1.789;p¼ 0.017) were independent predictors of therapeutic success. In
25 patients with no endoscopic technical/therapeutic success, surgical (n¼ 14)
or radiological approach (n¼ 11) was performed. Comparing G1vsG2, there
were no differences in the recurrence rate of biliopancreatic disease
(23.1%vs36.0%;p¼ 0.205) or mortality (9.0%vs8.0%;p¼ 1.000). However, G2
group had a high rate of major complications (12.8%vs36.0%;p¼ 0.016).
Conclusion: The technical and therapeutic success rates of ERCP in patients with
SMGA were 62.1% and 93.7%, respectively (lower in Roux-en-Y). Given the
increased number of patients with SMGA and the high rate of complications
associated with radiological and surgical therapies, it is essential to optimize
ERCP technique rather than conventional endoscopy/duodenoscopy, including
the use of balloon-assisted enteroscopy.
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Introduction: Detection of residual or fragmented stones after lithotripsy for
retained common bile duct stones can be improved by digital, single-operator
cholangioscopy (SOC) by high resolution imaging quality. However, therapeutic
intervention for the removal of residual CBD stones is limited by lack of appro-
priate accessories.
Aims & Methods: We evaluated the role of SOC and newly developed dormia
basket for the evaluation and removal of residual stones after lithotripsy. From
March to October 2016, 34 patients who had undergone lithotripsy for retained
CBD stones with no evidence of filling defects in occluded balloon cholangio-
graphy were included. After balloon cholangiography, the bile duct was evalu-
ated by SOC for the complete evacuation of stones. Detected residual CBD
stones were directly retrieved with newly developed dormia basket inserted into
the working channel of SOC. The incidence of residual stones detected by SOC,
and the success rate of residual stone retrieval under SOC were investigated.
Results: DPOC was successfully performed in all patients. Of these, 11 patients
(32.4%) had residual CBD stones. The residual stones were successfully removed
in 10 patients (90.9%) by dormia basket under SOC. (84.6%) except residual
stones on Lt. hepatic duct. There were no complications associated with SOC or
direct stone removal.
Conclusion: Digital SOC combined with newly developed dormia basket is useful
for the detection and extraction of residual stones after lithotripsy for retained
CBD stones expanding therapeutic intervention of SOC.
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Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) relies on
the use of ionizing radiation in the form of fluoroscopy. Because use of fluoro-
scopy has positive relationship with radiation exposure, it makes a risk of the
development of cancer and other radiation toxicity. The increasing exposure of
patients and endoscopists to radiation is concerning.
Aims & Methods: The aim of our study was to evaluation of predictive factors of
radiation exposure to the patients and endoscopists during endoscopic retrograde
cholangiopancreatography. A cross-sectional retrospective analysis of 892
ERCPs performed at tertiary academic hospital over 48-month period by on
expert endoscopist was conducted. The primary outcomes of interest were the
radiation exposure of patients and endoscopists during procedure as determined
by radiation dose in dose area product (DAP), absorbed dose (AD) and fluoro-
scopy time. And we correlated them with age, sex, body mass index, diagnosis,
duration of procedure, procedure name and procedure complexity.
Results: As a result of analysis of the 892 ERCPs performed during 4 years, the
mean duration of fluoroscopy time was 5.52 mins (95% CI, 5.15–5.93). Mean
radiation duration were as follows: CBD stones (n¼ 511, 5.76 mins); malignant
stenosis of bile duct (n¼ 189, 5.78 mins); pancreatic disease (n¼ 95, 5.28 mins);
benign stenosis of bile duct (n¼ 51, 5.32 mins); and periampullary stenosis
(n¼ 46, 4.89 mins). Multivariate analysis revealed that prolonged duration of
fluoroscopy time was related with specific factors of patient included age, BMI,
diagnosis and procedure complexity (all p5 0.05). Among the parameters, pro-
cedure complexity was the most significant relation with radiation dose. In addi-
tion, the following three procedures made prolonged procedure duration: two
more procedures performed during ERCP and mechanical lithotripsy (all
p5 0.05)
Conclusion: ERCPs are associated with significantly higher radiation exposure to
patients on the specific procedure. The endoscopists should be aware of the
increased dose of radiation required when performing ERCP in patients with
increased BMI, old age, and who need two more ERCP procedure.
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Introduction: To obtain representative information about invasive endoscopic
procedures is a principal goal to monitor efficacy and safety. A web-based,
online central registry can serve this aim allowing structured data collection
and usage of universally accepted terminology.
Aims &Methods:We decided to develop a web-based registry which is easy to use
and captures relevant procedure related information. The primary aim of the
registry is to monitor relevant outcome data of ERCP.
Results: Hungarian experts in ERCP were invited at the initiation of the registry
for discussion and consensus. Detailed data collection form was initially devel-
oped based on internationally recommended quality parameters. The prospective
observational research project was approved by the Scientific and Research
Ethics Committee (Budapest, Hungary). A web-based case report form was
developed after finalisation and tested from January 2017 at our department.
ERCP related data of consecutive patients were collected prospectively after
consenting the patients. The data from the first 100 procedures were analysed
to demonstrate the usability of the registry. Ninety-two patients (51 females, 41
males) were involved in this preliminary evaluation with an average age of 69.2
years (23–93 years). The number of elective and urgent examinations were almost
equal. The indication of ERCP were the following: bile duct disorder based on
laboratory or imaging data was the indication in 45%, obstructive jaundice in
31%, cholangitis in 16%, acute biliary pancreatitis in 5%, pancreatic disorder in
3%. The difficulty of procedures was evaluated: grade 1–22%, grade 2–45%,
grade 3–30%, grade 4–3%. Fifty-nine procedures were performed in patients
with intact papilla of Vater, bile duct access was not successful in one case
(1.7%). Precut procedure was applied in 14 cases (23.3%), all of them resulted
successful biliary access at the same procedure. Immediate complications were
observed in 8 cases (8%), 6 of them (6%) were bleeding. All were successfully
controlled, and none of the patients required blood transfusion or repeated
endoscopy. Mild post-ERCP pancreatitis was developed in one patient (1%).
Cholangitis was observed in 2 cases (2%). Follow up was conducted 30 days
after the ERCP by a telephone call and/or reviewing health care documentations
to observe long term outcome. Four patients (4%) died during this period, but
only 1 death was related to the procedure, caused by unresolved cholangitis.
Conclusion: The ERCP registry is an essential tool for measuring quality indica-
tors. The universal usage will allow benchmarking at individual, institutional and
national level and will help in quality improvement. Efficacy, safety and impact
on different pancreatobiliary disorders will be also measurable.
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Introduction: Double-balloon enteroscopy-assisted endoscopic retrograde cho-
langiopancreatography or DBE-ERCP allows access to the biliary ducts of
patients with surgically altered Upper Gastrointestinal (GI) anatomy. We studied
the feasibility and efficacy of DBE-ERCP at our institution.
Aims & Methods: This is a retrospective study of all patients with surgically
altered GI anatomy who underwent DBE-ERCP at our institution between
February 2011 and March 2017. The primary endpoint was the global success
rate of DBE-ERCP. The secondary endpoints were (1) the success rate of entero-
scopy defined as reaching the desired postsurgical anatomic target, (2) the diag-
nostic success rate defined as successful cannulation of the native papilla or
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anastomosis, and (3) the therapeutic success rate. We used a 2.2m DBE with a
2.8 or 3.2mm of operating channel (EN 450 T5, or EN580T Fujinon inc Saitama
Japan).
Results: A total of 12 patients (sex ratio1/1) with a mean age of 65 [47–82]
underwent 14 DBE-ERCP. 7 patients had Roux-en-Y gastro-jejunostomy with
a bilio-jejunostomy, 4 patients had Roux-en-Y with a native papilla, and 1
patient had a Billroth II gastric bypass. Enteroscopy success rate was 93% (13/
14 procedures). The diagnostic success rate was 85% (11/13 procedures) with 4/5
of native papillae. Therapeutic interventions including sphincterotomy (n¼ 4),
biliary stone extraction (n¼ 4) and biliary dilation (n¼ 2) were needed in 8/11
procedures and their success rate was 100%. The global success rate of DBE-
ERCP was 78% (11/14 procedures). Our results were comparable to those of the
literature (global success rate of 82%). The only complication was one case of
superficial intestinal lacerations without perforation (complication rate 7%).
Conclusion: DBE-ERCP in patients with surgically altered upper GI anatomy is a
safe and efficient procedure with a global success rate of 78%. Using shorter
enteroscopes with wider operating channel in the future might improve the suc-
cess rate of this technique.
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Introduction: Biliary cannulation may be difficult in 10–15% of patients (1) and
needle-knife sphincterotomy is more often used as a rescue treatment. A more
recent technique for difficult cases is transpancreatic sphincterotomy. Both situa-
tions are well known as Post-Ercp pancreatitis risk factor (2). To best of our
knowledge only few studies compared success rate and adverse events in these
techniques (3-.7)
Aims & Methods: We aimed to compare the efficacy and safety of NKS compar-
ing to TPS in difficult biliary cannulation We conducted a bibliographic search
using PUBMED, EMBASE including 2 RCTS and 4 non randomized trials from
January 2000 to December 2016. OR using the Manthel-Haenszel method was
used for dichotomous variables. Quantitative synthesis was performed using
Review Manager version 5.0. Primary outcome was success rate. Secondary out-
comes were rate of overall complications, and pancreatitis. Clinical heterogeneity
was assessed by I2 value, where a value exceeding 50% was indicative of hetero-
geneity. A random effect model was used in case of heterogeneity.
Results: Success rate was higher in NKS group compared to TPS (OR 2.98
95%CI 1.01–8.85, p¼ 0-.05). Complications and risk of pancreatitis were similar
in both group (OR 0.74 95%CI 0.51–1.09 p¼ 0.13; OR 1.09 95%CI 0.68–1.75
p¼ 0.71)
Conclusion: NKS is associated with higher success rate with equal risk of com-
plication and pancreatitis risk compared to TPS. Further and well design RCTs
are needed before a firm conclusion could be made
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Introduction: Transpancreatic Sphincterotomy (TPS) involves wire-guided can-
nulation of the main pancreatic duct (MPD) followed by standard pull-type
sphincterotome cutting towards the main channel. Typically a MPD stent inser-
tion should follow TPS to prevent post-ERCP pancreatitis (PEP). ESGE [1]
recommends that in patients with a small papilla that is difficult to cannulate,
TPS should be considered if unintentional wire guided MPD cannulation occurs.
A previous study had suggested that TPS might be as effective as double guide
wire (DGW) technique in achieving biliary cannulation in difficult cases and has
a lower pancreatitis rate. [1]
Aims & Methods: The aim of this study was to review the practice, complications
and outcomes of TPS in University Hospital of North Tees (district general
hospital in the north-east of UK). All ERCP procedures between January 2014
and October 2016 were reviewed. Endoscopy reports, blood results and discharge
letters were used for data collection.
Results: 1365 ERCP procedures were performed in the study period. Overall
CBD cannulation rate was 91.3%. 105/1365 (7.7%) wire guided TPS procedures
were carried out. Mean age in the TPS group was 67 years (range: 20–91) - 64/105
(61%) male and 41/105 (39%) females. 3 senior consultants and a senior endo-
scopic fellow performed TPS. TPS was used as the initial strategy in the event of
MPD cannulation and without using alternative methods such as DGW.
Choledocholithiasis was the commonest ERCP indication in TPS group (58/
105). Other indications include pancreatic cancer, biliary stricture, cholangiocar-
cinoma and bile leak post cholecystectomy. CBD cannulation was achieved in 96/
105 (90.5%) of cases - 81/105 (77.1%) during the first ERCP and 15/105 (14.2%)
at second ERCP [where CBD cannulation was achieved at second attempt, TPS
had been done at the first ERCP]. In 9/105 patients CBD cannulation was not
achieved. 8/105 (7.6%) had a complication. 6/105 (5.7%) patients had PEP - 5/6
had a prophylactic MPD stent. 1/105 had a post sphincterotomy bleed which was
controlled with endoscopic therapy. 1/105 had a perforation and a subsequent
long hospital stay. There were no procedure-related deaths.
Conclusion: This study demonstrates that TPS is a safe and effective way of
gaining CBD access. Our data suggests that experienced operators in a DGH
setting can safely carry out TPS. Our study is the second largest cohort in the
literature and the largest cohort in the UK. We would suggest early adoption of
TPS if wire access to the pancreatic duct is achieved, this will likely reduce
complication rate as a result of less engagement with the papilla and overall
reduced time at CBD cannulation.
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Introduction: Choledocholithiasis is a relative frequent condition in patients with
gallbladder stones (prevalence of 3–16%). Endoscopic sphincterotomy and stone
extraction is the recommended treatment of bile duct stones. In the case of failed
endoscopic therapy, cholecystectomy combined with bile duct exploration or
intraoperative endoscopic retrograde cholangiopancreatography should be
performed.
Aims & Methods: The main objective of this study was to evaluate the efficacy of
endoscopic extraction methods in patients who presented choledocholithiasis. We
conducted a retrospective single center study over 7 years from Jan 2009 to Dec
2015. Patients with single or multiple bile duct stones submitted to endoscopic
retrograde cholangio-pancreatography (ERCP) were included. We analyzed each
technique by considering the following parameters: mean diameter of the
stone(s), mean diameter of CBD and success rate defined by number of cases
solved endoscopically vs. cases of residual lithiasis/referred to surgery. Every
ERCP was performed using Olympus side-viewing endoscopes. Stone size,
number and CBD diameter were documented on the initial diagnostic cholangio-
gram. Stones were removed using retrieval balloon catheter, Dormia extraction
basket, mechanical lithotriptor and CRETM Balloon Dilator (DASE). In case of
residual lithiasis, a biliary 10Fr/7Fr Amsterdam plastic stent was placed and a
second ERCP was planned within 2–4 weeks. The efficacy endpoint was the
success rate regarding complete clearance of the bile duct. Statistical analysis
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was performed using SPSS version 20.0. A P-value of less than 0.05 was con-
sidered statistically significant.
Results: We included 1976 patients who presented choledocholithiasis and under-
went different endoscopic extraction techniques. Mean diameter of stone(s)
extracted using only the basket (Group A) was 6.8mm with a mean CBD dia-
meter of 11.6mm for patients with complete clearance of the bile duct compared
to 11.8mm (mean stone diameter) with 14.3mm (mean CBD diameter) for
patients solved eventually by surgery (P5 0.001). Only 3.2% of cases had to
be referred to surgery. Stones removed using only a retrieval balloon (Group
B) had a mean diameter of 7.6mm with a mean CBD of 13mm among patients
solved endoscopically, significantly lower than those with residual lithiasis:
15.5mm (mean stone diameter) with 16mm (mean CBD diameter) (P5 0.001).
9% of cases were referred to surgery. The lithotriptor alone (Group 3) was
efficient for a mean stone diameter of 12.3mm with a mean CBD diameter of
13.3mm. By associating the basket with a retrieval balloon (Group 4) we
obtained a 100% success rate of endoscopic removal for a mean stone diameter
of 9.6mm with a mean CBD diameter of 12.9mm. We also analyzed the para-
meters in patients who underwent endoscopic extraction by using a retrieval
balloon combined with balloon dilator (Group 5). The success rate in this
group was 90% for a mean stone diameter of 14.8mm with a mean CBD dia-
meter of 12.4mm. In Group 6 we included cases which required combined tech-
niques (4¼ 3). We observed a mean stone diameter of 9.4mm with a mean CBD
diameter of 13.8mm in patients solved endoscopically, compared to those
referred to surgery who had a mean stone diameter of 14.2mm with a mean
CBD diameter of 14.3mm (P5 0.001). In this group the success rate was
67.2%. Overall, we had a success rate of 91.3% for endoscopic removal of
choledocholithiasis with a mean stone diameter of 7.1mm and a mean CBD
diameter of 12.1mm, compared to 3.8% of cases referred to surgery with a
mean stone diameter of 13.6mm and a mean CBD diameter of 14.3mm
(P5 0.001).
Conclusion: The most successful endoscopic method to remove large stones
15mm was balloon dilator combined with retrieval balloon. Intermmediate
stones 7–15mm can be successfully removed by using retrieval balloon or litho-
triptor or a combination of basket with retrieval balloonballoon dilator. Most
CBD stones 57mm were successfully removed by using basket. In conclusion,
any diameter 47mm will most probably require more elaborate techniques.
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Introduction: Diclofenac and indomethacin are the most studied drugs for pre-
venting post-ERCP pancreatitis (PEP), but their use is controversial.
Aims & Methods: Our aim was to evaluate of all trials published in full text and
studied efficacy of diclofenac or indomethacin prospective controlled with pla-
cebo or non-treatment for the prevention of PEP in adult patients undergoing
ERCP. Systematic search of databases (PubMed, Scopus, Web of Science,
Cochrane) for relevant studies published from inception to 30 June 2016.
Results: Our meta-analysis of 4741 patients from 17 trials showed that diclofenac
or indomethacin significantly decreased the risk ratio (RR) of PEP to 0.60 (95%
confidence interval/CI/0.46–0.78, P¼ 0.0001), number needed to treat (NNT)
was 20, and the reduction of RR of moderate to severe PEP was 0.64 (95% CI
0.43–0.97, P¼ 0.0339). The efficacy of indomethacin compared to diclofenac was
similar (P¼ 0.98). The efficacy of indomethacin or diclofenac did not differ
according to timing (P¼ 0.99) nor between patients with average-risk and
high-risk for PEP (P¼ 0.6923). The effect of non-rectal administration of indo-
methacin or diclofenac was not significant (P¼ 0.1507), but rectal route was very
effective (P¼ 0.0005) with a NNT of 19. The administration of indomethacin or
diclofenac was avoided in patients with renal failure. Substantial adverse events
were not detected.
Conclusion: The use of rectally administered inexpensive and safe diclofenac or
indomethacin before or closely after ERCP is recommended in every patient
(without renal failure) undergoing ERCP.
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Introduction: Rectal diclofenac or indomethacin reduces the risk of pancreatitis
after endoscopic retrograde cholangiopancreatography (ERCP). Most studies of
its efficacy included high-risk cohorts and excluded low-risk patients. We inves-
tigated the potential of rectal diclofenac to prevent post-ERCP pancreatitis
(PEP) in a variety of patients.
Aims & Methods: A cohort of 1534 ERCPs performed at the Hospital Clı́nico of
Valladolid between 2009 and July 2016 was collected. The median age of the
patients was 75 years old (between 12 and 102 years). 54% were male and 45.9%
female. There were 93 procedures in which cannulation of the desired pathway
was not achieved but the papilla had been manipulated so they are patients who
have been included in the study. After may 2012, with a few exceptions, patients
received diclofenac before their procedure. 730 patients did not receive
Diclofenac. PEP was defined by consensus criteria.
Data regarding the factors predisposing to the development of PEP have been
collected both in relation to the technique itself and to patient-related factors.
A comparative study has been made between both groups using Chi square.
Results: The two groups were similar in age, sex, suspicion of Oddi sphincter
dysfunction, recurrent acute pancreatitis, chronic pancreatitis, cannulation time-
10m, use of pre-cut, previous PEP, dilation without sphincterotomy. There were
differences in the number of sphincterotomies in which it was greater in the
Diclofenac group (p.004). There was also a greater number of Wirsung cannula-
tions in the group treated with Diclofenac (p.004). There were a total of 47 PEP
(3.1%), being 78.3% mild acute pancreatitis.
Taken as a whole the patients had no difference in the number of PEP between
the two groups, since in those treated with Diclofenac there was 3.4% and in the
non-treated patients 2.8%.
When taking only patients with de novo sphincterotomy, there was no difference
between the number of PEP between the two groups being 4.4% in those treated
with Diclofenac versus 4% in the untreated patients. In those patients who were
cannulated Wirsung, an incidence of PEP of 8.2% was observed in the group
without Diclofenac, compared with 6.6% in the treated group (p.006). There
were no differences between those treated with Wirsung’s prosthesis and those
not treated in both groups. There was no PEP in patients treated with pancreatic
prosthesis.
There was a higher incidence of PEP in women in both groups and a trend
towards greater number of PEP among those treated with Diclofenac, although
without statistical significance. There was also a greater number of PEP in
patients under 40 years of age treated with Diclofenac compared to those not
treated with 14.3% versus 7.1% (p.024).
No differences were found between the groups treated and not treated with
Diclofenac when crossing with sphincter dysfunction of Oddi, previous PEP,
number and sizes of choledocholithiasis and sizes with the appearance of PEP.
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Conclusion: In this retrospective cohort study of patients undergoing ERCP that
included low-risk patients, rectal diclofenac was not associated with a significant
decrease in the absolute rate of pancreatitis. In our study, diclofenac decreases
the impact of PEP in those patients who are cannulated the pancreas.
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Introduction: The confocal laser endomicroscope (CLE) is of two types, an endo-
scope-based CLE (eCLE), which is integrated in the tip of the endoscope, and a
probe-based CLE (pCLE), which goes through the accessory channel of the
endoscope. The biliary tract, which cannot be reached by using eCLE, is obser-
vable with pCLE by using cholangioscopy. pCLE has the advantage of obtaining
a magnification image that is like taking a biopsy tissue specimen but noninva-
sively, without the interference of bleeding and mucus secretion. However, it is
sometimes difficult because only few gastroenterologists can achieve the required
level of conventional diagnostic accuracy.
Aims & Methods:We developed a computer-aided diagnosis (CAD) system based
on pCLE imaging using deep learning technology. The purpose of this study was
to determine the usefulness of this CAD system for the diagnosis of bile duct
cancer. We prepared the classifier of the extracted features of the bile duct cancer
pCEL images by using the deep learning framework presented by Kyocera com-
munication system Co. Ltd. Japan. The pCLE images by Cellvisio (Mauna Kea
Technologies, France) were obtained through the SpyGlass DS (Boston Scientific
Corporation, USA). They were compared with the pathological examination
results from the surgical specimen and biopsy using SpyBite (Boston Scientific
Corporation, USA). Learning sets were constructed by using 49 images of
normal area and 23 images of cancer lesion. The test sets of the pCLE images
were constructed using 6 images of normal area and 14 images of cancer lesion,
separately from the learning set.
Results: The accuracy, sensitivity for cancer diagnosis, specificity, negative-pre-
dictive value, positive-predictive value of our CAD system by test set were
69.8%, 50%, 100%, 53.8%, and 100%, respectively. The 7 false-negative diag-
noses reduced the sensitivity and negative-predictive value. The images of 6 of the
false-negative diagnoses, indicating a 1.0 probability, did not show signs of
cancer at all. A constant diagnosis was possible while being extremely small
learning sets. The specificity and positive-predictive value were good, and the
pCLE image was thought to have a characteristic suitable for CAD by using deep
learning technology. However, many false-negative diagnoses with a probability
1.0 may have occurred owing to deflection and the lack of learning sets. To
improve precision, a teaching set of adequate quality and quantity is necessary.
Conclusion: Automated diagnosis of bile duct cancer can be achieved by using the
deep learning technology of pCLE imaging. Our CAD system will be improved
with the appropriate learning sets.
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Introduction: The acquisition of core tissue in endoscopic ultrasound-guided
tissue sampling (EUS-TS) is necessary for histologic diagnosis and immunohis-
tochemical staining in the diagnosis of some solid mass lesions. Although recent
studies revealed the superiority of core biopsy needle in the specimen adequacy,
controversy still remains that which EUS-TS techniques would result in better
acquisition of core tissue and diagnostic accuracy.
Aims & Methods: The aim of our study was to evaluate EUS-TS techniques with
a ProCore needle using suction and slow pull suction for solid pancreatic lesions
without an on-site cytopaphologist.Patients who referred to EUS-TS for pan-
creatic mass lesion were enrolled. We performed EUS-guided fine needle biopsy
(EUS-FNB) using a ProCore needle (Cook Medical, Limerick, Ireland) with two
needle passes and applied each pass of different techniques (suction or slow pull
suction) which were randomly allocated. EUS-TS specimens were evaluated by
one experienced cytopathologist who was blinded to applied techniques. The
acquisition of core tissue and diagnostic performances were compared between
two techniques.
Results: From Aug. 2014 to Dec. 2016, 94 patients with pancreatic mass were
enrolled and 12 patients were excluded due to no final diagnosis (n¼ 5), cystic
lesion (n¼ 5) and loss of follow up after EUS-TS (n¼ 2). Finally, 82 patients (48
males; median age, 63 years) with 164 needle passes were included without
technical failure and procedure-related adverse events. The median size of the
lesion was 26mm (range, 11 to 80mm). There were 68 malignant and 14 benign
lesions. Overall core tissue acquisition and diagnostic accuracy was 84.8% (139/
164) and 73.2% (120/164), respectively. There was no significant difference
between suction and slow pull suction in the acquisition of core tissue (85.4%
vs. 84.1%, p¼ 1.000) and diagnostic accuracy (72.0% vs. 74.4%, p¼ 0.860).
Conclusion: Although our study revealed no differences between EUS-TS tech-
niques in the core tissue acquisition and diagnostic accuracy for pancreatic solid
lesions, further prospective study including variable lesions and sizes of needle is
needed to validate for optimal application and sequences of EUS-FNB
techniques.
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Introduction: Gallbladder drainage, performed by EUS-guided positioning of
specially designed fully covered metal stents, may be consiedered a valid
option in patients with cholecystitis unfit for surgery. We describe the first case
series of patients with diagnosis of acute cholecistitis treated conservatively using
a silicone-covered nitinol stent with bilateral anchor flanges (NAGI-stent).
Aims & Methods: Our aim was to evaluate the feasibility and clinical impact of
EUS-guided drainage with NAGI-stent in patients with acute cholecistitis unfit
for surgery. Sixteen consecutive patients (9 males; Mean age: 84 years) with
diagnosis acute cholecystitis according to Tokyo guidelines criteria, not suitable
for surgical approach, were conservative treated and drained with EUS-guided
short flared stents positioning. The procedure was performed in 2 tertiary endo-
scopic centers by 4 experienced endoscopists (4500 EUS/ERCP performed
yearly), by using the NAGI-stent. Each attempt to access the gallbladder was
firstly performed from the transduodenal position and resulted successful in 13
(81%) patients, whilst a transgastric approach was preferred in the remaining 3
patients. Two different approaches were performed for the EUS-guided gallblad-
der puncture: a) a 0.035-inch wire was advanced through a 19G-needle into the
gallbladder and dilation of the access was achieved with a 10 Fr cystoenteros-
tome; b) a 0.035-inch wire was advanced through a 10 Fr cystoenterostome
directly used in order to achieve gallbladder access. At the end of the procedure,
a fully covered metallic stent, 12–16mm of diameter and 20–30mm of length with
bilateral anchor flanges (NAGI-stent) was advanced on the wire by using the
fluoroscopy guide. Technical success, clinical success, adverse events, and long-
term outcome were assessed.
Results: Technical success was achieved in all cases, clinical success was observed
in 15 (94%) patients, whilst in 1 case the procedure failed due to stones impaction
into the stent but it resolved with a new stent positioning. Symptoms relief
occurred in all patients, 1 day after the procedure in 12 (75%) cases and 2
days later in remaining 4 (25%) patients. A bleeding episode occurred in 2
(12.5%) patients, in one case such complication was intra-procedural and it
was successfully stopped during the same endoscopic session, in the other case
it was a delayed adverse events requiring arterial embolization but the patient
died 10 days later. At follow-up, two patients died due to myocardial infarction
at 2 and 6 months, one for acute renal failure after 6 months, two for pancreatic
cancer after 7 months and one for cholangiocarcinoma after 5 months. In the
remaining patients no cholecystitis recurrence or biliary obstruction were
observed at median follow-up of 112 days (range 49–180 days).
Conclusion: Our data showed that EUS-guided gallbladder drainage with NAGI-
stent is feasible and successful in patients with acute cholecystitis unfit for sur-
gery. Since this type of stent is cheaper compared to others, the use of such device
may result more attractive as a further endoscopic option for these selected
patients.
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Introduction: Endoscopic ultrasound guided–fine needle aspiration (EUS-FNA)
is considered the gold standard method for assessment solid pancreatic masses.
The needles for aspiration currently available are 19G, 22G and 25G and there is
no concrete evidence to prove the benefit of one against another.
Aims & Methods: We aimed to compare the efficiency in the diagnosis of solid
pancreatic lesions through the EUS-FNA with 25G and 22G needles. Studies
were analyzed from five databases (Medline, Scopus, Cochrane, LILACS and
CINAHL), without year or language restriction, using an extensive search strat-
egy. Only randomized trials comparing 22G and 25G needles were included. Two
independent reviewers went through the literature search and the results were
analyzed by fixed and random effects. The diagnostic characteristics were calcu-
lated for a 95% confidence interval.
Results: 504 studies were found in the search, of which 21 were read and then
finally 04 randomized studies were selected to be included in the analysis. Thus, a
total of 462 patients were evaluated (233: 25G needle/229: 22G needle). The
sensitivity of the 25G needle was 93% (CI, 89–96%; I2 0.0%), and for the
22G needle was 91% (CI, 85–94%; I2 19.9%). The specificity of the 25G
needle was 87% (CI, 73–96%; I2 41.1%), and for the 22G needle was 83%
(CI, 70–93%; I2 81.1%). The positive likelihood ratio of the 25G needle was
4.57 (CI, 2.08–10.03, I2 0.0%), and for the 22G needle was 4.26 (CI, 0.43–41.88,
I2 94.7%). The post-test probability of the 25G needle in the study population
was 93.85% and for the 22G needle was 91.30%. The area under the sROC curve
of the 25G needle was 0.9705 and for the 22G needle 0.9795, also showing no
statistically significant correlation between them (p¼ 0.497).
Conclusion: Based on randomized studies, this systematic review and meta-ana-
lysis did not demonstrate a significant statistical difference between the 22G and
25G needles used during EUS-FNA in the diagnosis of solid pancreatic lesions.
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Introduction: EUS-guided gallbladder drainage (EGBD) is gaining popularity as
an alternative method for drainage of the gallbladder in patients suffering from
acute cholecystitis that are at high-risk for cholecystectomy. However, the long-
term outcomes and the learning curves of the procedure is uncertain.
Aims & Methods: This was a retrospective review of all patients that received
EGBD in the Prince of Wales Hospital between June 2012 to March 2017. All
procedures were performed or supervised by a single operator. EGBD was per-
formed in patients that are at high-risk for cholecystectomy and suffering from
acute cholecystitis or on long-term cholecystostomy tube drainage. Outcome
parameters included demographics, technical and clinical success, procedural
characteristics, adverse events and follow-up duration.
Results: 50 patients were recruited during the study period. The mean (S.D.) age
was 82.34 (9.3) years old and 22 patients were male. 42 patients were American
Society of Anesthesiologist grading of 3 and the mean (S.D.) age-adjusted
Charlson comorbidity index was 5.96 (1.82). The mean (S.D.) size of the gall-
bladder was 9.94 (9.83) cm. The hospital stay was 6.78 (5.36) days and follow-up
duration was 664.65 (541.58) days. The overall technical success and clinical
success rates were 96% and 86% respectively. Clinical success was not achieved
in 7 patients as they suffered from 30-day mortality. 6 were due to uncontrolled
sepsis and multi-organ failure even after adequate gallbladder drainage. 1 patient
had aspiration pneumonia resulting in death. 15 patients (30%) suffered from 30-
day adverse events with 6 of these being attributable to the procedure. Mal-
deployment of the stent occurred in 6 patients and this was managed by place-
ment of an additional metallic stent to bridge the gallbladder to the gastric or
duodenal lumen. Recurrent cholecystitis occurred in 1 patient (2%) during
follow-up.
When comparing the first 25 procedures to the subsequent 25 procedures, sig-
nificant differences were observed in the procedural time [29.21 (10.65) vs 15.6
(1.66) minutes, P5 0.001), the need of an additional stent [24% vs 0%,
P¼ 0.022] and hospital stay [7.76 (5.13) vs 5.75 (5.50) days, P¼ 0.009]. Whilst
no differences were observed in the technical and clinical success rates and
adverse events.
Conclusion: EGBD is a safe and effective method for achieving gallbladder drai-
nage in patients that are at high-risk for cholecystectomy. Performance of 25
procedures are required to gain competency in the procedure.
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Introduction: Despite advances in radiotherapy for pancreatic cancer, local gas-
trointestinal (GI) toxicity still remains one of the major limitations to effective
dose delivery and further dose escalation due to the close proximity of the GI
wall to the pancreas, particularly in the head region. One potential method to
reduce local GI toxicity would be to increase the physical distance between the
head of the pancreas and the duodenal wall. A novel, injectable hydrogel, synthe-
sized as iodinated polyethylene glycol microparticles, has been FDA-approved
for use as a soft tissue fiducial marker. The hydrogel remains stable for 3 months
and is absorbed by 7 months. To date, there has been no reports on the technical
feasibility of endoscopic ultrasound (EUS)-guided hydrogel injection into the
interface between the head of the pancreas and the duodenal wall to increase
the peri-pancreatic space for the course of radiotherapy.
Aims & Methods: We aimed to evaluate the technical feasibility of EUS-guided
hydrogel injection into the interface between the head of the pancreas and the
duodenal wall in a cadaveric model. Baseline CT was performed on three unfixed
cadaveric specimens. Using a linear EUS scope, the interface between the duo-
denal wall and the head of the pancreas was identified in a cadaveric model. A
19-gauge FNA needle was used to inject the hydrogel into the peri-pancreatic
space with creation of a visible separation between the duodenal wall and the
pancreatic parenchyma. The procedure was repeated along the length of the head
and uncinate of the pancreas. CT was performed post procedure to confirm
location and to measure the distance created between the duodenum and pan-
creas. Gross dissection of the pancreas and duodenum was performed to evaluate
localization of the hydrogel.
Results: All three cadavers underwent successful EUS-guided injection of the
hydrogel. Cadaver 1 received a total injection volume of 9.5cc with creation of
peri-pancreatic space along the head of the pancreas measuring 11.77mm in
maximal diameter. Cadaver 2 received a total injection volume of 27cc with
creation of peri-pancreatic space along the head and uncinate of the pancreas
measuring 13.20mm in maximal diameter. Cadaver 3 received a total injection
volume of 10cc with creation of peri-pancreatic space along the head of the
pancreas measuring 12.89mm in maximal diameter. The hydrogel was clearly
visualized during EUS with hyperechoic echogenicity and on post-procedure CT
images without any artifacts in all cases.
Conclusion: EUS-guided delivery of hydrogel is feasible and results in an increase
in the peri-pancreatic space in a cadaveric model. The hydrogel is clearly visua-
lized on EUS and CT without significant artifacts. Further studies are warranted
to evaluate feasibility, effectiveness and safety in a clinical model.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: There are few published studies about the use of a novel radio-
frequency (RF) system (EUSRA RF needle; VIVA RF generator; STARmed
Co, Ltd; Koyang, Korea), with poor standardization of the procedure in terms
of ablation powers and ablation times, resulting in great heterogeneity of the
results.
Aims & Methods: To standardize the radiofrequency ablation (RFA) procedure
using this new system performing ex-vivo tests on porcine liver in order to find
the best ablation power and ablation time to produce the maximum size of
coagulative necrosis at histological examination. The system consists in a radio-
frequency generator delivering electric energy, a 19 Gauge needle (150 cm in
length with a 10mm monopolar electrode), a peristaltic pump (to perfuse the
needle with chilled saline solution, maximizing the ablation volume without
tissue charring), an isolating plate and a pedal to deliver RFA. Liver samples
were treated at different powers: 10, 20, 30 and 40 Watts (W); each ablation
power was applied for a duration of 1, 3, 5, 7 and 15 minutes, according to
Fibonacci escalation dose scheme, used in phase I studies. We registered macro-
scopically: the size (millimeters) of the global treated area and the size of the
central necrotic core. Microscopically an expert pathologist, blinded about abla-
tion powers and times applied, gave the report of the histological examination
(millimeters of coagulative necrosis and surrounded zone).
Results: The lower ablation power (10W) produced the maximum macroscopic
ablated area. RF ablation time at 10W showed a good linear correlation with
both the sizes of total macroscopic ablated area (R¼ 0.92) and central macro-
scopic ablated area (R¼ 0.89). Histologically the pathologist described two dif-
ferent injured zones by thermal effect: a central small and well-demarcated
coagulative necrotic area around the needle insertion point (A zone) with a
maximum diameter of 4 millimeters and a surrounded larger area of ‘‘diaphani-
zation’’ (B zone), showing mild signs of cellular alterations (cytoplasmic hypo-
chromia) without cellular necrosis. A zone sizes didn’t change among different
ablation times (mean size: 3.25mm) while B zone diameter increased with the
increase RF application at the fixed power of 10W. At the microscopic analysis
the pathologist didn’t see any difference in size of coagulative necrosis among the
different ablation powers (R¼ 0.24).
Conclusion: RFA with this new system is feasible and effective to produce very
small areas of coagulative necrosis (millimeters) well-demarcated in respect to the
surrounding parenchyma and could be useful, in the future, to treat, with multi-
ple passes and higher precision, target lesions with a flexible needle. Moreover,
the system can produce larger zones of mild cellular alterations at lower ablation
powers (10W), increasing with the increase of ablation times, but it needs future
in-vivo animal studies in order to assess the evolution of these zones (evolving
into fibrosis? necrosis? recovering?).
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Introduction: Malignant associated thromboembolic disease (TED) has a com-
plex multifactorial pathogenesis. Tumor cells activate platelets and express pro-
coagulant factores including tissue factor and thrombin; in addition, normal host
tissues may express procoagulant activity in response to the tumor. Thrombotic
risk varies substantially according to cancer location and pancreatic cancer is one
of the leading causes. The clinical spectrum includes migratory superficial throm-
bophlebitis, arterial thrombosis, deep venous thrombosis, portal vein thrombosis
and disseminated intravascular coagulation. We ought to assess the role of endo-
scopic ultrasound (EUS) diagnosing TED in pancreatic cancer patients.
Aims & Methods: We perform a retrospective review of all EUS cases for pan-
creatic cancer in two centers and assess all TED events diagnosed.
Results: In a period of 6 months, a total of 55 EUS for pancreatic neoplasms were
performed in two centers. TED was present in 5 patients (9%): 3 were male and
the mean age was 70 (range, 46–81). In 1 patient the EUS indication was a large
abdominal mass whose origin was not clear, in the remaining 4 the indication was
the pancreatic neoplasm. In all of them was performed EUS with fine-needle
aspiration. EUS identified 4 arterial pulmonary embolism (PE) and 1 inferior
vena caval thrombosis (IVCT) with right atrial extension: 2 (3,6%) had recently
been diagnosed by computed tomography (CT) but 3 (5,4%) were not previously
known. In all these, CT confirmed diagnosis.
Table 1: Demographic, clinical and ultrasonographic characteristics of the
patients.
Gender
(F/M) Age
Neoplasm
location
Cytology
results
Thromboembolic
disease
Thromboembolic
disease
previously
known?
(Yes/No)
CT
confirmation?
(Yes/No)
Case 1F 81 Isthmus Leiomyosarcoma
metastasis
EP Yes Yes
Case 2M 70 Tail Adenocarcinoma EP No Yes
Case 3M 81 Head Not available yet EP No Yes
Case 4F 46 Tale Neuroendocrine
tumor
IVCT Yes Yes
Case 5M 72 Uncinate
process
Adenocarcinoma EP No Yes
Conclusion: To the best of our knowledge, this is the first case series of EUS-
based TED diagnosis in pancreatic cancer patients. This series underlines impor-
tance of a systematic, station approach EUS technique, namely in the mediasti-
num regardless the clinical indication. TED is a common complication of
pancreatic cancer and has major therapeutic and prognostic implications.
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Introduction: Choledocholithiasis is the most common cause of biliary pain, lead-
ing to cholangitis and gallstone pancreatitis. Patients affected by cholelithiasis
presents an incidence of choledocholithiasis ranging from 8% to 20%. When the
suspicion of choledocholithiasis is confirmed, stones should be removed by
ERCP, but this operative measurement is associated with high rates of adverse
events as post-ERCP pancreatitis, bleeding or perforation. A correct diagnosis of
choledocholithiasis, before ERCP, is mandatory to decrease the operative risk
and health care costs. Endoscopic ultrasound (EUS) has a high sensitivity and
specificity in the diagnosis of CBD stones and could substitute other imaging
modalities as CT-scan or MRCP, when indicated.
Aims & Methods: The aim of our study was to assess the role of early EUS (548
hours), in patients undergone US in emergency room for suspected biliary colic.
We retrospectively evaluated all the patients arrived at first aid for suspected
biliary colic (i.e. right upper quadrant pain and/or epigastric region, associated
with an elevation in serum ALT, AST, GGT, ALP, or total bilirubin, but in
absence of amylase or lipase elevation). All patients, irrespective of the finding at
the US, performed an EUS within 48 hours since admission. Data are presented
as proportions with 95%CI and mean standard deviation (SD). Correlation
between categorical variables was evaluated by computing the ‘‘phi’’ coefficient.
We computed the number needed to misdiagnose, i.e. the number of patients who
need to be tested in order for one to be misdiagnosed by the test, as 1/(1-diag-
nostic accuracy). All the analyses were run with R statistical software.
Results: Overall, from January 2016 to December 2016, 88 patients (56% female;
mean age 64 17 years) were admitted to our hospital for suspected biliary colic.
All of these subjects underwent abdominal ultrasound (US) at admission, which
identified gallstones in 47 patients (71%); further, US documented common bile
duct (CBD) stones in 58 (65%) patients, CBD sludge in 4 (5%) subjects, whereas
no choledocholithiasis was found in 26 (30%) patients. At EUS examination
CBD stones were found in 70 (80%) patients. Comparing US to EUS, US
gave false negative results in 16 (18%) cases and false positive findings (i.e.
identifying CBD stones not documented by EUS) in 8 (9%) patients. The two
diagnostic procedures showed little correlation (phi¼ 0.289). The number of
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patients needed to be tested by US in order to provide an incorrect diagnosis was
3.7 (95%CI: 2.6–5.5).
Conclusion: US performed in the emergency room has a low diagnostic perfor-
mance compared to EUS, but remains a first-step-approach in patients with right
upper quadrant pain and/or in epigastric region, associated with an elevation in
liver enzyme. Based on the results of our study, EUS performed within 48 hours
from the admission allows an immediate correct endoscopic treatment with sig-
nificant spare of unnecessary operative procedures, reducing possible related
complications and costs.
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Introduction: Three devices are currently available to perform radiofrequency
ablation (RFA) of biliopancreatic lesions. Data from animal models are scarce.
Aims & Methods: Radiofrequency ablation was performed in four live pigs on the
common bile duct and the liver parenchyma using an endobiliary probe
(endoHBP), on the liver and pancreatic parenchyma using an RFA catheter
through an echoendoscope and biopsy needle (EUS RFA) and using a needle-
shaped RFA catheter (EUSRA) through an echoendoscope. Radiofrequency
ablation time and power were allowed to vary. The animals were sacrificed 2
hours after the procedure. Histopathological assessment of the maximal depth of
thermal lesions was performed on three representative slides for each RFA
impact.
Results: In the common bile duct, the depth of ablation ranged from 215 47
(Power¼ 8W, Time¼ 90 s) to 330 43mm (Power¼ 10W, Time¼ 30 s), suggest-
ing that power is the most important parameter in this location. Conversely,
depth of ablation in the liver parenchyma using the endoHBP probe ranged
from 947 237 mm (Power¼ 10W, Time¼ 30 s) to 1960 20 mm (Power¼ 10w,
Time¼ 180 s), suggesting that time is the most important parameter for RFA in
the liver. The EUS RFA probe in the liver parenchyma showed a tissue necrosis
increasing with the power setting used, ranging from 1903 451 mm
(Power¼ 8W, Time¼ 120 s) to 2457 1047 mm (Power¼ 12W, Time¼ 120 s).
This was not observed in the pancreatic parenchyma, were tissue damage
ranged from 3108 373 (Power¼ 8, Time¼ 120 s) to 2305 78mm
(Power¼ 12, time¼ 120 s). The EUSRA ablation of the liver parenchyma
resulted in tissue damage from 1573 245 mm (Power¼ 30w, Time¼ 11 s) to
1545 120 mm (Power¼ 70W, Time¼ 9 s). In the pancreas, ablation depth
ranged from 3616 475 mm (Power¼ 30 s, Time¼ 15 s) to 3805 446 mm
(Power¼ 70W, Time¼ 11 s).
Conclusion: Power and time of ablation have different effects on the extent of
tissue necrosis in the common bile duct, the hepatic and pancreatic parenchyma,
depending on the type of catheter used to perform RFA. As indications for
hepatobiliopancreatic RFA tend to expand, specific ablation protocols should
be developed for each tumor location and device.
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Introduction: Endoscopic ultrasound (EUS)–guided rendezvous techniques facil-
itate common bile duct (CBD) access during subsequent endoscopic retrograde
cholangio-pacreatography (ERCP) in a single session. Cases of initial ERCP
failure mainly comprise malignant biliary or ampullary infiltration and altered
anatomy of the papilla, the former accounting for the majority of reports in the
literature.
Aims & Methods: We aimed to evaluate the efficacy and safety of EUS-guided
rendezvous in a series of distal CBD obstruction with failed initial ERCP, due to
inaccessible intra-diverticular papilla. Consecutive patients with distal CBD
obstruction, in whom selective biliary cannulation at ERCP was unsuccessful
due to large duodenal diverticula, underwent EUS-guided rendezvous. CBD
puncture was performed via the transduodenal approach and the guide wire
was advanced antegradely across the papilla. The echoendoscope was then
exchanged for a duodenoscope and a sphincterotome was inserted through the
papilla alongside or over the wire, to allow further manipulations.
Results: In a total of 2480 ERCPs performed over a 4-year period, 18 cases were
selected to undergo EUS-guided rendezvous due to the presence of a large ampul-
lary diverticulum. Primary indication for ERCP was CBD stones in 15 patients,
pancreatic head cancer in 2 patients and cholangiocarcinoma in 1 patient. Mean
age of the patients was 77 years (range 62–91) and mean diameter of the CBD
was 16mm (range 8–21). Successful CBD puncture with antegrade passing of the
wire into the duodenum and subsequent ERCP, in the same session, was achieved
in 2/3 (66.6%) cases of malignant obstruction and in 13/15 (86.6%) cases of
lithiasis. Retrograde billiary cannulation during ERCP was performed over the
wire in 6 cases and alongside the wire in 12. The mean procedural time was 80
minutes (range 55–115). A case of inadvertent CBD wall penetration by the
sphincterotome, with contrast extravasation, occurred during an over-the-wire
cannulation. No major complications, i.e perforation (extra-luminal air or bile
leakage), bleeding and pancreatitis occurred. Three cases of amylasemia and
transient fever were noted.
Conclusion: EUS-guided rendezvous is an effective salvage technique for failed
CBD cannulation via standard ERCP, in cases of inaccessible papilla due to large
ampullary diverticula. Along the guide-wire billiary cannulation may prevent
inadvertent CBD wall trauma, compared to the over-the-wire approach.
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Introduction: The preoperative differentiation of the solid pancreatic neoplasms
by endoscopic ultrasound fine needle aspiration (EUS-FNA) remains around
90% and different needles or techniques of sampling has been used for improving
the results. Data about the progress in diagnosis when the contrast harmonic
enhanced EUS- FNA (CH-EUS-FNA) is used are scarced.
Aims & Methods: We aimed to assess the role of contrast-enhanced EUS-FNA
compared to standard EUS-FNA in diagnosing the solid pancreatic neoplasms.
Methods: Patients from one tertiary medical center with visible solid pancreatic
mass on CT scan were included. EUS-FNA(one pass) and CH-EUS-FNA (one
pass) were performed randomly in each patients by using a standard 22G needles,
an Olympus-Aloka equipment and Sonovue as contrast agent. Core histology
was assessed separately for each pass by the same pathologist blinded from the
randomization process. The final diagnosis was based on the results of EUS-
FNA and surgery, or the findings after 9 months’ follow-up.
Results: The final diagnosis of 40 patients included was adenocarcinoma (n¼ 36),
neuroendocrine tumors (n¼ 2), chronic pancreatitis (n¼ 2). The lesions were
located in the head of the pancreas (60%), body (32%) and tail (8%). The
diagnostic sensitivity and specificity based on core histology was 89% and
94% in the CH-EUS-FNA passes and 86% and 91% in the EUS-FNA passes
and the diagnostic value was significantly better in the CH-EUS-FNA group
(p¼ 0.0046, t-test). The visual core size was not significant for the true- positive
diagnosis of malignancy.
Conclusion: In a randomized control trial, CH-EUS-FNA improved significantly
the diagnosis of solid pancreatic neoplasms over standard EUS-FNA. These
techniques are complementary, not competitive, and they can be performed in
the same session, resulting the increasing of the diagnostic rate with a minimum
of passes.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Traditionally, clinical symptoms such as melena were used as strong
predictors for an upper GI bleeding source with primary evaluation with an EGD
(esophagogastroduodenoscopy). Little consideration was given to the small
bowel. It has been known for decades that melena can originate from the nose
to the right colon and hematochezia can originate from the proximal gut to the
rectum. Thus, current endoscopic approaches have limited localization value and
diagnostic yields. We hypothesize capsule endoscopy (VCE) provides better loca-
lization of bleeding when compared to clinical symptoms alone.
Aims & Methods: In this study, we compare the efficacy of localizing the source
of bleed in early VCE versus SOC (standard of care) tests chosen based on
clinical symptoms alone. This was a prospective single center randomized trial
of 73 consecutive patients presenting to the University of Massachusetts Medical
Center with NHGIB (melena, hematochezia/anemia, or guaiac-positive stools/
anemia). Exclusion criteria included presence of pacemaker, dementia, non-
English speaking, hemodynamically significant bleeding. Patients were rando-
mized to SOC arm versus early capsule (EC) deployment. The SC group received
a primary diagnostic procedure based on clinical symptoms that was dictated by
the gastroenterologist on service, who was at liberty to choose the procedure
sequence as they felt appropriate.
Results: Of the 218 patients screened, 73 were included. 2 patients from the initial
included group were excluded (one due to technical capsule failure and one was
transferred from an outside hospital). Baseline characteristics were similar and
depicted in Table 1. The EC group (n¼ 34) had localization of presumed source
of bleeding in 67.6% (n¼ 23) of patients at the time of the first diagnostic
procedure compared to 48.4% (n¼ 16) in the SOC group (p¼ 0.02). Active
bleeding or stigmata of recent bleeding at the time of the first procedure was
seen in 64.7% (n¼ 22) of patients in the EC groups compared to only 30%
(n¼ 11) in the SOC group (p¼ 0.003). However, when melena was the presenting
symptom in the SOC (n¼ 26) group, EGD was the most commonly chosen
primary diagnostic procedure (n¼ 23), but was only diagnostic 52% of the
time. After complete diagnostic evaluation in the SOC group, patients presenting
with melena had lesions located in the esophagus (3.8%), stomach/duodenum
(46.2%), small bowel (11.5%), colon (11.5%), but 27% had no source identified.
EC group had lesions localized to the esophagus (2.9%), stomach/duodenum
(35.2%), small intestine (8.8%), colon (20.5%), and 32.3% did not have lesions
identified. When hematochezia/anemia were the presenting symptom (n¼ 7),
EGD was never diagnostic as a primary procedure, colonoscopy (COLO) had
a 50% diagnostic rate, and VCE was diagnostic 100% of the time.
Conclusion: VCE used as the first test in patients with NHGIB detects active
bleeding significantly more often than the SOC approach, since it examines much
more of the GI tract than EGD and COL alone. Detection of the anatomic site of
bleeding allows for better therapeutic decisions.
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Introduction: Data regarding mucosal healing (MH) of isolated small bowel
Crohn’s Disease (CD) induced by anti-tumor necrosis factor alpha agents are
scarce.
Aims & Methods: 1) To evaluate MH rates by capsule endoscopy (CE) in patients
with symptomatic CD and active isolated small bowel (SB) disease treated with
adalimumab (ADA). 2) To correlate MH with clinical and biological indices of
remission. This was a prospective observational, single center study. CD patients
with isolated (per CE) active (CDAI4 220) SB disease, who were recommended
ADA by their treating physician were consecutively recruited; first CE was per-
formed prior to commencing ADA, and the second -14-week after starting ADA.
All enrollees underwent a patency capsule study to confirm patency. Disease
severity was assessed by the capsule endoscopy Crohn’s Disease activity index
(CECDAI) score. MH was defined as CECDAI score 53.
Results: Out of 31 patients screened, 24 were eligible, and 22 completed the study
(as two patients developed an allergic reaction to ADA and were withdrawn)
Females: 12 (54.5%), median disease duration: 3 years (IQR 1–7), biologic
experienced (Infliximab) -3 patients. After 14 weeks of ADA therapy MH was
detected in 8/22 patients (36.4%), CDAI5 150 in 11/22 patients (50%), normal-
ization of CRP in 7/22 patients (31.8%), and normalization of fecal calprotectin
in 8/22 patients (36.4%). Inflammatory indices significantly decreased within 14
weeks of ADA treatment compared with baseline: median CECDAI 5 (1–16) vs
15 (10–20), p¼ 0.001; median CDAI 150.8 (109.8–211.5) vs 256 (240.5–320.2),
p5 0.001; median CRP 0.14 (0.07–0.5) vs 1.1 (0.2–1.5) mg/dl, p¼ 0.002; median
fecal calprotectin- 83 (80–139) vs 128 (61.5–266.5), mg/gram, p¼ 0. 014. MH
detected by CE did not correlate with normalization of either CDAI 5150,
CRP or fecal calprotectin levels.
Conclusion: ADA induced MH in 36% of CD patients with isolated active SB
disease. MH did not correlate with either clinical or biological remission. Thus,
further evaluation should be performed after 52 weeks of maintenance therapy.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Capsule endoscopy (CE) is widely used to investigate the small
bowel (SB). However, patients with inflammatory bowel disease (IBD) are con-
sidered to be at higher risk for capsule retention. The ESGE recommends using
dedicated cross-sectional imaging to assess SB patency in patients with known
Crohn’s Disease (CD) prior to CE. Evidence suggests that a combination of SB
magnetic resonance imaging (MRI), faecal calprotectin (FC) and CE together
may be more effective in assessing SB inflammation compared to an individual
modality alone. We aimed to assess the effectiveness of this approach.
Aims & Methods: Retrospective, multicentre study; consecutive patients who had
undergone both SB MRI and CE within 6 months of each other were included.
Data collected: patient demographics, indications for CE and MRI, CE and MRI
findings, and FC levels closest to the time of CE. Continuous data is presented as
means standard deviation; comparisons were made using T-test (p5 0.05
taken to be significant).
Results: 82 patients (28M/54F, Mean age 41.4yrs) underwent both CE and SB
MRI at 4 centres in the United Kingdom, Israel and Portugal. Indications
included suspected SB inflammation (n¼ 61), IBD reassessment (n¼ 21).
Overall, there were 3 incomplete CEs, but no case of SB capsule retention. Of
82 SB MRIs, 4 patients had evidence of SB obstruction, 10 had SB thickening
and/or inflammation, 3 had other findings (SB pneumatosis, polyps). 64/82 cases
were normal and 1 study had poor contrast, precluding any conclusion. Of the 4
patients with SB MRI evidence of obstruction, only 1 had strictures seen on CE.
The other 3 patients had insignificant or normal CE findings. Of the 10 patients
with SB thickening and/or inflammation seen on MRI, 6 had corresponding CE
findings; in particular, there were 2 cases with strictures on CE and 4 cases with
mucosal inflammatory changes. 64 patients had normal SB MRI and 35 (54.7%)
had a normal CE. 18/64 (28.1%) patients had mucosal inflammatory changes on
CE; 2 of them had strictures which were eventually traversed by the capsule. 10
patients had other non-inflammatory findings on CE. Of 18 patients with normal
SB MRI but SB inflammation on CE, 9 had a raised FC (FC4 150 mg/g), 5 had
borderline FC levels (50–100 mg/g). None of the patients in this group had normal
FC levels; the mean FC was 637.5 844.4 mg/g. In the group of patients with
both normal SB MRI and CE, 16/35 had raised FC; 7 patients had borderline FC
levels. The overall mean FC for these patients was 266.3 221.9 mg/g. The mean
FC between patients with SB inflammation seen on CE and patients with normal
SB MRI and CE was significantly different (p¼ 0.04).
Conclusion: A significant proportion (28.1%) of patients with normal SB MRI to
investigate possible SB inflammation had CE findings showing SB inflammation,
including 2 patients with strictures. However, no retention occurred in this group.
Raised FC was significantly associated with CE findings despite normal SB MRI.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The interpretation of small bowel capsule endoscopy (SBCE)
requires a high level of concentration. An abnormality may be present on just
a few of the many thousands of images presented for interpretation. It is
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unknown whether fatigue affects the accuracy of SBCE reporting and how many
SBCE studies can be read in one session.
Aims & Methods: Thirty-two participants (16 experienced SBCE readers and 16
novices) were invited to participate in this study. Each participant was asked to
read 6 pre-selected SBCE studies consecutively. These studies were presented in a
random order. All readings took place using the single view mode, readers were
able to choose the frames per second viewed from a range of speeds. Fatigue was
measured subjectively using a Likert scale and objectively using a computer-
based psychomotor vigilance test. These measures were performed at prior to
commencing the study and after every second capsule read. Accuracy in lesion
detection was determined by comparison with a gold standard reading derived
from the non-consecutive readings of two expert capsule readers. Accuracy was
plotted against the order in which SBCE studies were read. The aim of this study
was to determine whether fatigue influences the accuracy of SBCE interpretation
and how many cases can be read before accuracy declines.
Results: In keeping with existing literature, high intra-observer variability
amongst the participants was observed, with experienced readers reaching
kappa values of 0.51 with the gold standard and 0.08 amongst novices. As
progressive SBCE studies were read the mean speed increased for both experts
and novices, with a mean reduction of 10 minutes between the first and the last
study read. This was associated with faster reading speeds selected in progressive
studies read. Where accuracy was analyzed with respect to the reading speed
chosen, a negative correlation between increasing speed and accuracy was
demonstrated, with 31% of lesions detected when read at 6–10 frames per
second, compared to 15% when using the 22–28 speed. There was no significant
change in accuracy with progressive capsule read when the group was analyzed as
a whole. The accuracy of experienced readers declined after just one study read,
from 38% to 27% and plateaued thereafter. Novice readers demonstrated no
significant change across the time points, with a trend towards improvement,
perhaps indicating skills acquisition during the study.
Conclusion: The accuracy of SBCE reporting declines after one study reporting in
a given period of time by expert SBCE readers. The optimal time interval
between study reporting needs to be explored. This does not affect novice readers
perhaps demonstrating skill acquisition.
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Introduction: Rates of incomplete colonoscopies (IC) range from 2–19%, requir-
ing repeat procedures or radiological imaging which can often lead to diagnostic
delays as well as increased inconvenience for the patient. Same-day CCE may
offer a more convenient and cost-effective mode of colonic examination post IC.
Aims & Methods: We aimed to determine the feasibility of same-day CCE post
incomplete colonoscopy. A prospective pilot study was performed. Any patient
without a contraindication to CCE with an IC for reasons other than poor bowel
prep was offered the test following an appropriate recovery time of 1-hour post
IC. Informed consent was obtained from all subjects. Upon ingestion of the
capsule, where feasible,10mg of IV metoclopramide was given to overcome the
antimotility effects of fentanyl given during routine colonoscopy. Standard boos-
ter protocol for CCE was administered. Patient demographics, procedure indica-
tion, sedation levels along with key CCE data including preparation quality,
completion, positivity rates and adverse events were all recorded.
Results: To date, 40 same-day CCE have been completed. The mean age was 57
yrs.(22–83 yrs.) and 65% (26) were female. Indications for OC were; altered
bowel habit 33%(n¼ 13), Iron deficiency anaemia 30%(n¼ 12), Inflammatory
Bowel Disease Assessment 15% (n¼ 6), PR bleeding 5%(n¼ 2), abdominal pain
5% (n¼ 2), polyp surveillance 5% (n¼ 2), positive family history of CRC 5%
(n¼ 2) and abnormal imaging 2% (n¼ 1). OC were incomplete due to excessive
looping 40% (n¼ 16), patient intolerance 30% (n¼ 12) and severe diverticular
disease 30% (n¼ 12). The mean sedation used during OC was 5mg midazolam
(range 3–10mg) and 75mcg of fentanyl (range 50–100mcg). In all 84% (n¼ 34)
of CCE were complete, however full colonic views were obtained in 94% (n¼ 37).
Mean colonic passage time was 222 minutes and overall image quality was
deemed to be excellent in 16% (n¼ 6), good in 31% (n¼ 12), adequate in 44%
(n¼ 18) and poor in 9% (n¼ 4) of participants. Overall findings were normal
25% (n¼ 10), polyps 38% (n¼ 15), inflammation 22% (n¼ 9), diverticular dis-
ease 25% (n¼ 10), angiodysplasia 3% (n¼1). Amongst the patients who had
polyps, 8 required polypectomies and the remaining 7 were put on a surveillance
programmes. Based on the CCE findings, 4 of the IBD patients required treat-
ment escalation. In terms of adverse events one patient reported abdominal pain
during the procedure and one patient retained the capsule due to an inflamma-
tory stricture.
Conclusion: CCE would appear to be feasible in the majority of patients and
significantly detects colonic pathology.
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Introduction: Peritoneal carcinomatosis (PC) is a well-known mechanism of
spread of cancer; it is the second-most frequent cause of death in colorectal
cancer patients. However, the prognosis of PC patients has dramatically
improved in recent years. Nowadays, selected patients benefit from extensive
cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-
HIPEC). 5-year survival rates of up to 50% are reported after CRS-HIPEC.
Despite this survival gain, CRS-HIPEC has a considerable morbidity rate of
49% with a severe complication rate of 21%1. Obviously, it is important for
patients with a limited life expectancy to avoid pointless and costly aggressive
surgical procedures. Hence, recognizing patients with a maximum risk-to-benefit
ratio for the procedure is imperative. To select patients who could benefit from
CRS-HIPEC the Peritoneal Cancer Index (PCI) is used. The PCI combines the
location/size of peritoneal tumours found at surgery at 13 abdominal regions.
Each of the 13 regions is scored for implant size on a scale of 0–3 (0¼no visible
tumor implants; 1¼ implants 50.50 cm; 2¼ 0.50–5.0 cm; 3¼45.0 cm). The PCI
is the sum of the lesion scores from all 13 areas, and thus can vary between 0–39.
The PCI is widely validated and is a quantitative prognostic indicator for long-
term outcome. However, with this surgical staging procedure it is not always
feasible to inspect all relevant intra-abdominal regions due to formation of adhe-
sions and/or tumour. So, there is a desperate need for a non-invasive imaging
tool that could select those patients who will benefit from CRS-HIPEC.
However, currently there is no validated imaging tool that can accurately predict
the PCI.
Aims & Methods: Therefore, the aim of this study was to estimate the PCI
preoperatively with diffusion weighted MRI (DW-MRI) and compare this with
the PCI found at surgery to assess whether DW-MRI can be used to select CRS/
HIPEC candidates. In this ongoing study twenty-four consecutive patients (April
2016–April 2017) with histologically proven peritoneal carcinomatosis from col-
orectal origin were included. Patients were scheduled for exploratory laparoscopy
and/or CRS/HIPEC and underwent preoperative dedicated DW-MRI
(scantime¼ 30min).
Two independent readers prospectively determined the PCI on DW-MRI.
Patients were categorized as low-risk (PCI 0–21) versus high-risk (PCI 22–39);
in our center considered operable versus non-operable. Reference standard was
PCI found at surgery. Furthermore both readers evaluated whether a R1 resec-
tion could be achieved on a 5-point scale combining PCI and other risk factors
for an incomplete surgery, like invasion in hepatic hilum, mesenteric vessels,
extensive pelvic invasion of liver metastases. Sensitivity and specificity of the
test were calculated and receiver-operating characteristic curves (ROC) were
constructed. The area-under-the-curve (AUC) was calculated for each reader.
Quadratic weighted kappa was used to evaluate the interobserver agreement.
Results: At surgery the mean PCI was 13.8 (range 0–34). For reader 1 the mean
PCI was 13.4 (0–29) and for reader 11.9 (0–34). Both readers categorized 23 out
of 24 patients correctly (accuracy 96%) when compared to surgical findings. Both
readers understaged the same patient. The sensitivity and specificity for selecting
patients with a PCI5 22 was for both readers 100% and 75%, respectively. The
interobserver agreement was perfect (k¼ 1.0). The UAC for predicting overall
operability was 0.99 for reader 1 and 0.95 for reader 2.
Conclusion: These data suggest that DW-MRI is a robust and highly accurate
selection tool to noninvasively select colorectal cancer patients who could benefit
from CRS/HIPEC. Interestingly, no overstaging occurred with DWI-MRI; this
means that DWI-MRI did not deprive patients from potential curative surgery.
In addition, due to the lack of large studies concerning this subject, our ‘pilot
study’ is one the largest DW-MRI study in PC literature.
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Introduction: During colonoscopy, clinicians perform visual inspection of the
polyps to predict histology. Kudo’s pit pattern classification is one of the most
commonly used for optical diagnosis. These surface patterns present a contrast
with respect to their neighboring regions and they can be considered as bright
regions in the image that can attract the attention of computational methods.
Aims & Methods: We aimed to assess the accuracy of a new computational
system based on the segmentation and characterization of bright regions as
A704 United European Gastroenterology Journal 5(5S)
cues to obtain an automatic histological classification of colonic polyps. Our
automatic histology prediction system is based on the segmentation of textural
elements from polyp surface and their correlation with Kudo’s pit pattern classi-
fication. Textural elements are identified as bright regions in polyp surface and
there are characterized according to their shape into tubular and circular: a high
presence of tubular patterns is associated to an adenomatous histology whereas
the absence of prominent tubular structures is associated to non-adenomatous.
Taking this into account, we characterized segmented bright regions using a
tubularity metric (Tub) designed to obtain low values for circular shapes and
high values for tubular regions of the same area. We tested our method in high
definition (HD) white light polyp images which were obtained with a colono-
scope Olympus CIF-H190 at Hospital Clinic in Barcelona. Neither conventional
nor virtual chromoendoscopy were used. These images were selected to show as
much variability in polyp appearance as possible. We used the mean of all Tub
values for an image to classify it into two classes: Adenoma and Non-Adenoma.
A ROC curve was constructed to select the optimal threshold value of Tub. Then,
we compared the histology prediction provided by our system and the actual
histology obtained after lesion removal.
Results: 51 polyp images were analyzed: 38 (74.5%) adenoma and 13 (25.5%)
non-adenoma. Mean size of polyps was 14 13 (range 1–40) and had the follow-
ing morphology based on Paris classification: 5 (9.8%) 0-Ip, 27 (52.9%) 0-Is and
19 (37.3%) 0-IIa. Mean Tub values were different for adenoma compared to
Non-adenoma (19.5 6.5 vs 14.1 6.3; p¼ 0.013). An optimal threshold value
of Tub¼ 13.14 to separate adenoma vs. non-adenoma was selected from the
operating point of the ROC curve. With this value, our method was able to
provide an accurate histological diagnosis in 44 out of 51 images (86%) (table)
with a Sensitivity, Specificity, PPV and NPV for the diagnosis of adenoma of
95%, 61%, 88% and 80%, respectively. On the other hand, processing of a single
HD image took 2.7 seconds making feasible its use in the endoscopy room.
Histological Gold standard
Non-adenoma Adenoma total
Automatic prediction Non-adenoma 8 2 10
Adenoma 5 36 41
total 13 38 51
Conclusion: A computer vision system based on bright regions in the image has a
high accuracy for on-line prediction of polyp histology during colonoscopy.
Though the use of shape characterization is promising, the inclusion of other
polyp characteristics (i.e. shape, color, vessels. . .) as well as enlarging the valida-
tion database could improve the robustness of our methodology.
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Introduction: Laterally spreading tumors (LSTs) of the colorectum are classified
into the following two subtypes according to their morphology; granular type
(LST-G), and non-granular type (LST-NG). Meanwhile, CT colonography
(CTC) is a relatively new radiological technique for imaging the entire color-
ectum and its sensitivity for detecting polyps more than 1 cm has been reported to
be greater than 90%. However, the detectability of LST in CTC has not been
fully delineated.
Aims & Methods: The aim of this study was to determine the detectability in CTC
of LSTs focusing on their subtypes. We retrospectively reviewed and matched
data on endoscopic and CTC reports in 33 patients (35 LSTs) who received a
multidetector CT scan using contrast media immediately after total colonoscopy
at the Sendai Medical Center, Japan, between May 2012 and December 2016.
LSTs were classified into the following two categories: LST-Gs (24 lesions) and
LST-NGs (11 lesions).
Results: 35 pathologically proven LSTs were evaluated. Histology included ade-
nomas in 18, intramucosal cancers in 14, and submucosal cancer in 3. The mean
diameter of the LSTs was 24.5mm. Of the 35 LSTs detected on colonoscopy, 30
were observed and matched by CTC (85.7%). 23 out of 24 (95.8%) LST-Gs were
detected, while 7 out of 11 (63.6%) LST-NGs were detected. The detectability of
LST-Gs was significantly higher than that of LST-NGs (p5 0.05). The detect-
ability of adenoma (77.8%; 14/18) was lower than that of intramucosal (92.9%;
13/14) and submucosal (100%; 3/3) cancer. Furthermore, the detectability of
LSTs tended to increase with increasing tumor size.
Conclusion: CTC can effectively detect LST-Gs, while the detection of LST-NGs
is still challenging.
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Introduction: CT colonography (CTC) may be readily used for imaging of the
colon in elderly or poor risk patients with colon polyps and cancer because of its
non-invasiveness and relatively short inspection time. But, the drawbacks to
make a misdiagnosis may be inevitable. Therefore, analysis of misdiagnosis
case is crucial on the new modality for the colon cancer screening examination.
Aims & Methods: We evaluated the misdiagnosed case of large neoplastic lesions
determined by colonoscopy (CS) from JANCT by CTC with radiologist and
gastroenterologist interpretations1). Out of 1257 cases enrolled in JANCT,
1181 cases were actually studied, omitting 76 cases according to the exclusion
criteria. More than 16 DAS CT were used for CTC, respectively. Images were
retrospectively reconstructed by using a 0.5mm section index. The CTC exam-
ination was prepared by PEG-C solution before scanning. CO2 gas as an effer-
vescent agent was then administrated just before scanning. This was used for the
contrast medium. CTC images were analyzed by AZE Virtual Place software.
The CTC and CS were independently analyzed by endoscopist and radiologist in
blind fashion. We investigated misdiagnosed lesions with CTC more than 10mm
detected by CS. We considered the pseudo-negative lesions misdiagnosed with
CTC interpretation (PNL) by radiologist or gastroenterologist and also consid-
ered the true pseudo-negative lesions misdiagnosed with CTC interpretation (true
PNL) by radiologists and gastroenterologists. Because we conceived true PNL
showed the limitation of CTC interpretation instead of PNL involved a human
error.
Results: PNL was diagnosed by CS at 0-Ip (8 cases, 8 lesions), 0-Is (10 cases, 12
lesions) and 0-IIa (17cases, 19 lesions), respectively according to the criteria of
the Paris classification. True PNL was also diagnosed at 0-Ip (1 case, 1 lesion), 0-
Is (5 cases, 6 lesions) and 0-IIa (11 cases, 13 lesions), respectively. True PNL/PNL
ratio was 0-Ip 12.5%, 0-IIa 50% and 0-IIa 68.5%, respectively. There was no
PNL at 0-IIc, Type I, II and III on this study. Most of all true PNL were so called
flat lesion not only 0-IIa lesion.
Conclusion: CTC was proven to be a reasonably useful approach to obtain the
image of colon diseases without any invasiveness to the patient. On CTC inter-
pretation, lower protruded lesion was considered less detectivity than highly
protruded lesion like 0-Ip.
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Introduction: The formation of fibrotic tissue in intestinal wall of Crohn’s Disease
(CD) patients is transmural and mucosal biopsies are unrepresentative of real
intestinal damage. Magnetic Resonance Enterography (MRE) allows a trans-
mural study of the bowel loops. Recently the percentage of gain of contrast
medium has been proved useful to study fibrosis in CD patients. Diffusion
Weighted Imaging (DWI) through the restriction of the apparent diffusion coef-
ficient (ADC) allows an accurate evaluation of disease activity in CD patients
avoiding contrast agents.
Aims & Methods: The aim of this study is to investigate if DWI sequence of MRE
was able to identify intestinal fibrosis in CD patients candidate to surgery, using
the histopathology specimens and percentage of gain as gold-standard. Thirty
ileocolonic CD patients candidates to surgery for stricturing disease were con-
secutively enrolled from October 2010 to November 2015. All patients underwent
MRE before the surgery. The histopathological examination was performed
using an histological score for inflammation (AIS) and fibrosis in the stenotic
segment and in the ileum before the stenosis.
Results: All population had an active disease at MRE. ADC value had a sig-
nificant correlation with fibrosis score (r¼ -0.648; p5 0.0001), AIS (r¼ -0.763;
p5 0.0001) and percentage of gain (r¼ -0.687; p5 0.0001). A strong correlation
emerged between wall thickness and fibrosis score (r¼ 0.671; p5 0.0001). The
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threshold of wall thickness for fibrosis was46.3mm (specificity 100% and sen-
sitivity 69.23% with AUC 0.89). The cut-off of ADC value for fibrosis was
51.1 10–3 mm2 s1 with a sensitivity of 71.79% and specificity of 94.44%
(AUC¼ 0.83).
Conclusion: The DWI sequence with ADC value can identify fibrosis in intestinal
wall of CD patients avoiding the use of contrast medium.
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Introduction: The primary indication for c-Met targeted optical imaging agent
EMI-137 is enhanced endoscopic detection of lesions during colorectal cancer
screening, including flat lesions that are difficult to detect by normal white light
endoscopy. We have evaluated the potential benefit of EMI-137 and analogues
beyond colorectal cancer screening since c-Met is up-regulated in many other
cancers.
Aims & Methods: We have synthesised analogues of EMI-137 where the fluor-
escent reporter was replaced by a radionuclide chelating moiety for PET imaging.
The use of this agent alongside EMI-137 could enable the PET localization of the
lesions prior to surgery guided by fluorescent signals. Through a systematic
analysis of scientific literature databases, and the Human Protein Atlas, we
have identified more than 13 different types of solid cancer that are amenable
to optical imaging for which there is evidence for c-Met as a target. We believe
that imaging of c-Met with EMI-137 in these indications has the potential to
positively impact critical problems in the existing patient care path and reduce
morbidity, mortality, and healthcare costs. We have assessed: 1) the healthcare
problem, the impact on patient care path, and the likelihood of adoption by
clinicians 2) the hardware landscape; whether imaging hardware required is
commercially available or is being developed, and feedback from clinicians in
the US and EU 3) our confidence in c-Met as a valid imaging target to address
the healthcare problem
Results: We have identified a number of promising applications within Digestive
Oncology; gastric cancer, locally-advanced rectal cancer, and bile duct cancer
surgery are all life-threatening indications with urgent healthcare problems that
could be improved by utilising imaging of c-Met with EMI-137. Compatible
imaging systems are commercially available for these indications. There is also
strong evidence for c-Met as a biomarker in stratification in Barrett’s oesophagus
(BO), a potentially precancerous lesion with the risk of progression to oesopha-
geal cancer. Progression rates are low and overall survival rates in BO patients
are similar to the general population. However, due to the poor prognosis of
oesophageal cancer, patients with BO lesions are managed by regular endoscopic
surveillance and biopsy. This means that there is arguably a disproportionate
healthcare burden relative to the level of risk.
Conclusion: Gastric cancer, locally advanced rectal cancer, and bile duct cancer
surgery all have strong evidence for c-Met as a valid target, and the healthcare
problems are clear and widely recognized, with EMI-137 having the potential to
have high impact and improve curative procedures in serious, life-threatening
conditions. An imaging agent that enabled more accurate risk stratification of
BO patients would lead to a change in patient management, with the potential to
remove unnecessary biopsy and to reduce the frequency of surveillance.
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Introduction: Esophageal self-expandable metal stents are currently used as an
alternative for surgical treatment in esophageal neoplasia, benign strictures, fis-
tulas and anastomotic leaks. Migration is a common complication after stent
placement and have higher rates when fully covered stents are employed.
Covered stents prevent tumor ingrowth and can be removed easely, they can
be used in the closure of fistulas and leaks. External fixation of the stent with
Shim’s technique seems to be efficient in preventing stent migration, but has a
high cost and is not always avaliable. Fixation by clipping or sutures has similar
limitations. We developed a homemade technique for external fixation of the
stent using dental floss to prevent stent migration. We present the results of
this technique in a small cohort.
Aims & Methods: The present study enroled sixteen patients with esophageal
malignancies, anastomotic leaks, esophageal fistulas and extrinsecal compres-
sion. The stents used in these patients were five partially covered and ten fully
covered. We developed a homemade technique using dental floss for external
fixation of the stent which prevent stent migration. We pull stripes of dental
floss into the stent mesh and using a method similar to exchange of a nasobiliary
drainage catheter, the dental floss is drawn out through the nose, tied a knot into
it and its loose end is fixed to the patient’s earlobe.
Results: Upper gastrointestinal endoscopy was performed after two weeks and
the proximal uncovered flange of the stent was evaluetad. If it was embeddeding
the esophageal mucosa and did not separate from the esophagus with air insuf-
flation, the external fixation was removed. Otherwise, the fixation was kept for
another 2–4 weeks when a new endoscopic evaluation was performed. Patients
were evaluated 15–30-60 days after stent placement. In cases of migration of the
entire lenghy of the stent into the stomach, the patient received a new stent and
the same fixation method was employed. In cases of stents partially migrated
through the cardia, the same stent was repositioned and fixed with dental floss
stripes as previously described.
Conclusion: According to the results we believe this homemade technique using
dental floss for external fixation of stents is a simple and cheap method that can
be applied and used to prevent stent migration.
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Introduction: The reported incidence of colorectal cancer in Sweden in 2014 was
60–65/100,000 inhabitants and caused 25–30 deaths/100,0001. Of all colorectal
cancer, approximately 15–20% debutes with acute obstructive symptoms.
Conventional acute surgical procedures in these conditions (open surgery) have
been shown to lead to mortality risk up to 20% and morbidity risk of 45–50%,
followed by increased need for intensive care and more infections and stoma
complications2. Self-expanding Metal Stent (SEMS) for relieving malignant
colon obstruction is a treatment option for non-curative cases or for bridging
the patient for later surgery. Studies have shown "clinical success" of SEMS at
90%. An article from 2007 concludes that SEMS in acute colon obstruction has
better results regarding sickness and side effects compared with acute open
surgery3.
Aims & Methods: Our compilation covers the years 2010–16, when 248 SEMS
interventions(53% men, 47% women, age 28–97) were performed at SU/Östra
Hospital. In 78% of cases, the obstruction was located below the left flexure. In
80%, SEMS was made for palliative purposes.
Results: Technically, SEMS succeeded in 98% of cases and had clinical success in
90% of cases(absence in need of emergency surgery). Complications (colony
perforation) occurred in 6% of the cases. Mortality within 30 days was 11%
and within 90 days 22%. For all performed interventions, the difference with
regard to 90-day mortality for the indication was palliative vs. bridging, 29 resp.
3%. Based on the clinical outcomes "success" vs "failure", the 90-day mortality
rate was 19 resp. 55%.
Conclusion: Our interpretation is that SEMS is an effective method of acceptable
safety regarding complications in acute malignant colon obstruction. The method
is suitable for both intended intestinal relief for palliative purposes, as well as
awaiting later curative measure (bridge to surgery).
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Introduction: Tracheoesophageal fistulas are severe complications which com-
monly occur secondary to malignant tumors of the esophagus. Other causes
include mediastinal or respiratory tract tumors, surgery, radiotherapy and
trauma. Without treatment they often lead to pulmonary and gastroenterological
complications, such as pneumonia, acute respiratory distress syndrome and poor
nutrition.The purpose of this study was to asses the efficacy of endoscopic treat-
ment performed in our clinic for esophageal fistulas.
Aims & Methods: We performed a retrospective study on 43 patients admitted in
our clinic between January 2015 and April 2017 for esophageal fistulas.
Results: The average age of the patients included in the study was 54 years old.
The causes leading to the tracheoesophageal fistulas were the following: esopha-
geal malignancy in 18 cases (41.8%), surgery in 8 cases (18,6%), respiratory tract
malignancy in 6 cases (14%), gastric sleeve in 5 cases (14%), radiotherapy in 3
cases (7%) and trauma in 2 cases (4.6%). In every case, the treatment of choice
was placement of fully-covered metallic stents. A number of 16 patients needed
reintervention, with a mean of 2 reinterventions per patient. Regarding recurrent
fistulas, endoclips were used in one case (2.3%), additional stenting in 11 cases
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(25.5%) and repositioning of the stent in 4 cases (9.3%). All cases resulted in
fistula closure without additional surgical intervention.
Conclusion: Fully covered metallic stents offered effective treatment for esopha-
geal fistulas, regardless of the cause. Recurrent fistulas were successfully treated
by additional stents and in rare cases endoclips.
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Introduction: Endoscopic treatment of enteric strictures in patients with Crohn’s
disease (CD) is well established; however, long-term outcome is unknown.
Aims & Methods: All patients with CD, who had undergone endoscopic therapy
of symptomatic strictures at Robert-Bosch-Hospital Stuttgart from 2008–2017,
were included in this retrospective cohort study. A follow-up was available for
131/135 (97%) patients with a mean of 30.1 months (0 to 103).
Results: A total of 452 endoscopic interventions (mean 3.4 per patient, median 2
per patient, range 1–69 treatments) were performed in 135 patients (female
n¼ 67/male n¼ 68, mean age 47.5 years, BMI: 22.8 4.98 kg/m2, duration of
illness: median 25.1 months). In 165 cases, the dominant stricture was located
in the ileocecum, in 105 in the colon, esophagus (90), duodenum (54), upper
intestine (26), lower intestine (11) or stomach (1). In 166 and 286 cases, there
was an anastomotic and non-anastomotic stricture present, respectively.
Treatment consisted of hydrostatic balloon dilatation (n¼ 447); bougienage
(4), and cSEMS (1). Dilatation was performed to a mean of 14mm (SD: 2.4,
range 7 to 24mm). In seven cases complications occurred after endoscopic treat-
ment (bleeding: n¼ 5; infection: n¼ 1; perforation: n¼ 1) which resulted in an
extension of the hospital stay (n¼ 5), antibiotic therapy (1) and surgery (1).
Immediate clinical success was observed in 438 of 452 of cases (96.9%). A
single intervention was performed in 61/135 patients (45.2%), two interventions
in 36 (26.7%), and three or more in 38 (28.1%). In 41 of 135 patients (30.4%),
surgical treatment of the stricture was required in the course of disease.
Conclusion: Endoscopic treatment of symptomatic stricture in CD is safe and
effective. Repetitive dilation is feasible with a significant reduction of clinical
symptoms, and surgery was required in about 30% of patients at long-term
follow-up.
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Introduction: Endoscopic dilation is an effective treatment in oesophageal stric-
tures, but recurrences may require frequent and repeated dilations in the long
term. Several trials have been conducted to determine the efficacy of intralesional
steroid injection in the treatment of benign refactory oesophageal strictures, since
the first pediatric case series was published in 1969. However, a meta-analysis has
not been carried out yet.
Aims &Methods: The aim of the analysis is to summarise the results and establish
evidence in support or against the complementary treatment.
A meta-analysis was performed using the preferred reporting items for systematic
review and meta-analysis protocols (PRISMA-P).Two reviewers conducted a
comprehensive search on databases from inception to February 2016, to identify
trials, comparing the efficacy of dilatation to dilatation combined with intrale-
sional steroid injection. A meta-analysis was conducted on the data using the
random-effects method by DerSimonian and Laird, because of the high level of
the heterogeneity.
Results: There were 45 articles found in Embase, 55 in PubMed, and 6 in the
Cochrane database. Altogether 11 articles were suitable for analyses, after exclu-
sion of duplicate articles, case reports, results from non-human and pediatric
studies. These studies involved 373 patients in total. The periodic dilation
index was comparable in 4 studies, where the pooled result showed, that it
decreased in the intralesional steroid plus dilation group (standardized mean
difference: 0.717, 95% CI: 1.191; 0.242, p-value: 0.003). The total number
of repeat dilatations was comparable in 5 studies, where the standardized mean
difference was 0.465 as compared to the dilation alone group (95% CI: 0,777;
0,153, p-value: 0.004). The dysphagia score was comparable in 5 studies, but in
this case no significant difference could observed between the two groups (stan-
dardized mean difference: 0.274, 95% CI: 1.822; 1.165, p-value: 0.510).
Conclusion: Our meta-analysis showed a significant improvement in the periodic
dilatation index and total number of repeated dilations in the patients treated by
intralesional steroid injection as well. We recommend the use of intralesional
steroid injection for benign refractory oesophageal strictures.
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Introduction: Palliative stenting is now established as a major treatment for dys-
phagia resulting from incurable malignant stricture of the oesophagus. There are
multiple possible complications after oesophageal stent insertion; most of these
present with increasing dysphagia; however pain, bleeding, and reflux are also
common. Although data on rates of various complications are available, there
are no agreed standards to audit performance against, nor any requirement to do
so. As this is a palliative procedure, success in symptom control is paramount; if
this is not being achieved, then the appropriateness of the procedure must be
questioned. As with any invasive procedure, complication rates are affected by
multiple variables: technique, type of stent, length and site of stricture, operator
experience, patient co-morbidities and performance status. As a result of these
variables, stated complication rates also vary. Only one study reported a rate of
dysphagia (29%); migration occurred in 5–15% of cases, tumour ingrowth/over-
growth 5–20%, and food bolus obstruction in 5–15%. Quoted median survival
ranged from 61–104 days, with a 30-day mortality of 20–28%.
Aims & Methods: Our aim was to scrutinisy the efficacy and the safety of our
palliative oesophageal stenting work. A retrospective study of all patients under-
going oesophageal stent insertion at our unit, between 01.01.2012 and 01.04.2016
was undertaken, looking for evidence of complications, repeat interventions, and
for survival statistics after stent insertion. Patients who had undergone stent
insertion for reasons other than oesophageal malignancy were excluded.
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Results: Between 01.01.2012 and 01.04.2016, 152 stents were inserted in 125
patients for dysphagia in palliative oesophageal cancer; 104 patients had stent
inserted once, 16 patients had twice, 4 patients had 3 times and 1 patient had 4
stent insertions. 69.6% were male and the median age at death was 79 years (SD
10.94). The reported histology for the 125 patients revealed, 85 (68%) adenocar-
cinoma, 30 (24%) squamous cell carcinoma, 5 (4%) Lung cancer causing external
compression of the oesophagus, 2 (1.6%) mesothelioma, 1 (0.8%) externally
compressing spindle cell sarcoma, 1 (0.8%) metastatic adenocarcinoma from
the colon, 1 (0.8%) externally compressing signet ring adenocarcinoma. Of
these stent insertions 52 (34.2%) were documented to have on going or recurrent
dysphagia after the procedure, of which the causes were: tumour over- or
ingrowth in 9 (5.9%); stent migration in 15 (9.9%); distal obstruction due to
gastric folds 2 (1.3%), dysfunction of the anti-reflux valve in 3 (2.0%); and food
bolus obstruction in 7 cases (4.6%), stent occlusion of unspecified cause 2 (1.3%)
and stent disintegration in 1 (0.7%) case. In 13 (8.6%) cases cause for dysphagia
was not found or not investigated. 100 (65.8%) stent insertions resulted in com-
plete resolution of the dysphagia. Repeat endoscopy was necessary in 34 (27.2%)
patients, who had 98 repeat gastroscopies in total, to deal with minor complica-
tions of the stent insertion or to investigate dysphagia. In total there were 13
(8.7%) significant complications caused by the stent insertion of which 7 (4.6%)
were bleeding, 2 (1.3%) were tracheo-oesophageal fistula formations, 1 (0.7%)
was delayed perforation, 1 (0.7%) was a too short stent, 1 (0.7%) was a disin-
tegrating stent and 1 (0.7%) was a compression of the bronchi. Median survival
of the 125 patients after stent insertion was 96 days (SD 128) and 30-day mor-
tality was 11.2% (14 patients). It is important to note that with retrospective data
analysis, some data is not available, due to variations in recording at the time and
a reliance on the patient to report symptoms to a clinician. Currently 2 patients
are still alive.
Conclusion: Palliative stenting at this centre continues to be an effective treatment
for patients with dysphagia from oesophageal cancer. On the whole, outcomes
from stenting at this unit compare favourably with published data in terms of
dysphagia, other complications, and mortality. Steps to improve post-procedure
monitoring in the form of a ‘‘stent registry’’ with prospective collection of data by
telephone or face-to-face follow-up could be useful in future service development.
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Introduction: Self-expanding metallic stents (SEMS) is a well-established form of
palliative treatment for dysphagia in esophageal cancer. Progression of the tumor
after stenting with re-stenosis is a serious problem in patients with better prog-
nosis and longer survival.
Aims & Methods: The aim of this study was to assess the timing and probability
of esophageal re-stenosis after stenting by tumor growth. We performed a retro-
spective analysis of patients with advanced esophageal cancer who was under-
went stenting, as a palliative treatment, for the last 5 years in the Yaroslavl
Regional Cancer Hospital. We installed partially covered SEMS of one design
from one manufacturer. The length of stents was 80, 100, 120, 140mm, diameter -
20mm. Patients with follow-up of more than 60 days were included in this study.
Results: Of the 165 patients from the database, 97 patients were selected, whose
follow-up period was more than 2 months. There was a predominantly of male
patients (78.5%), mean age of 72 years. To each patient was inserted a same
partially covered stent, which is 4 cm longer than a tumor stenosis. The stent was
placed 2 cm distal and 2 cm proximal of the stenosis. Of 97 patients, 18 (18.5%)
patients had tumor overgrowth with recurrence of dysphagia. Tumor overgrowth
was verified as malignancy. Tumor localization before stenting: the upper and
middle part of the esophagus - 6 patients, the lower part and the cardia - 12
patients. In 12 cases tumor growth spread out in the proximal direction, in 6
cases–in the distal. Interestingly, the distal tumor overgrowth after stenting was
predominant (66.6%) in cases of localization in middle and upper part of the
esophagus, while the proximal tumor spread (83.3%) was noted in cases of
localization in the lower part of the esophagus or cardia. Period of re-stenosis
was from 2 to 12 months, an average of 5.7 months. The period of re-stenosis in
the upper and middle part of the esophagus is 4 months, while in cases of tumor
localization in the lower part of the esophagus or cardia is 6.1 months. In almost
cases palliation was successfully achieved with re-intervention. Five patients
required several sessions of argon-plasma coagulation an average one time in
3–4 weeks.
Conclusion: The use of SEMS in patients with advanced esophageal cancer, with
an expected long-term survival, is associated with an increased risk of re-stenosis
by tumor overgrowth. Period of re-stenosis was an average of 5.7 months. The
direction of spread tumor after stenting and the time of dysphagia recurrence
could depend from localization of the tumor. This complication is not fatal and
managed by endoscopic methods.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Self-expandable metal stents (SEMS) are often used for palliative
treatment of dysphagia in patients with advanced esophageal cancer, with antici-
pated limited survival. However, due to previous reports of high adverse event
(AE) rates when used long-term, concerns have been raised with the use of SEMS
in patients with survival longer than 3 months.
Aims & Methods: We aimed to the role of esophageal SEMS in patients with
advanced esophageal cancer and expected survival longer than 6 months.
Technical success was defined as successful deployment of the stent in the correct
position. Clinical success was defined as relief of dysphagia 1 week after
placement.
This was a retrospective study of patients with clinical dysphagia and advanced
esophageal cancer who underwent SEMS placement with a stent dwell time of
greater than 6 months. In all patients the indication for stent placement was
dysphagia due to esophageal malignancy.
Results: Forty-two patients were followed for 298 days (183–861 days). At the
end of follow-up the mortality was 93%. The majority of lesions were located at
the proximal/middle esophagus (55%), and were traversable using an ultrathin
gastroscope in 79% of patients; in no patient could a standard upper endoscope
pass. Twenty-nine patients (69%) underwent further therapy (chemotherapy and/
or radiotherapy) with SEMS in situ; however, only 14 began therapy before
development of an AE (4 patients underwent further therapy after AE).
Clinical improvement occurred in all patients, however 59% of patients
(n¼ 25) experienced an AE (15 migrations, 8 overgrowth/ingrowths and 2
stent-induced fistulae). The median stent patency was 236 days (19–513). Two
AEs occurred within 30 days of stenting, 7 occurred between 30–90 days, 7
occurred between 90–180 days, and 9 occurred after 180 days. Endoscopic man-
agement was attempted in every SEMS-related AE (20 patients required a second
SEMS, 2 had successful SEMS repositioning and 1 was treated with argon
plasma; 2 SEMS were removed without the need for further therapy), with a
clinical success of 100%, however, in 7 patients the previously treated AE
recurred (4 in/overgrowths and 3 migrations). Multivariate analysis showed
that strictures traversable with an ultrathin gastroscope were associated with a
higher risk of AEs (OR 11.7, 95% CI [1.2–114.6], p¼ 0.035).
Conclusion: Long-term esophageal stenting in patients with advanced esophageal
cancer is associated with a high prevalence of AEs without an impact on mor-
tality, and most could be managed endoscopically. Strictures traversable only
using an ultrathin gastroscope are a risk factor for AEs.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The incidence of iatrogenic bile duct injury (BDI) remains high
despite increased awareness of the problem with significant impact on patient’s
well-being and even survival despite seemingly adequate therapy. Over the past
years, endoscopic and percutaneous biliary interventions became readily
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available in many centers and have revolutionized the management of iatrogenic
biliary or concomitant vascular injuries.
Aims & Methods: Evaluate the role of intervention radiology procedures to
manage different post-cholecystectomy complications focusing on the novel tech-
niques to improve the final outcome. From June 2014 to June 2016, 30 patients
presenting with post cholecystectomy complications were referred to interven-
tional radiology unit in our university hospital. They were 9 males and 21 females
(age range: 18–66 years). Patients presented with biliary leaks (n¼ 12), benign
biliary strictures with intrahepatic biliary dilatations (n¼ 21), postoperative
hernia (n¼ 2), bleeding related to hepatic artery pseudo-aneurysm (n¼ 1).
Different types of interventional procedures were performed, including:
Percutaneous trans-hepatic drainage (PTD) (n¼ 16), sequential dilatation of
benign stricture with increasing catheter calibers over 6 months followed by
manometric studies before catheter withdrawal (n¼ 6), biliary stenting with plas-
tic stent (n¼ 2), Insertion of pigtail catheter (n¼ 15), preoperative progressive
pneumo-peritoneum for their adhesolysis effect to manage post-operative huge
incisional hernias before their surgical repair (n¼ 1), and selective embolization
of bleeding related hepatic artery pseudo-aneurysm (n¼ 1) using tissue adhesive
(n-Butyl 2 Cyanoacrylate).
Results: All percutaneous procedures were technically successful. No recorded
early or late complications.After manometric studies, all managed cases with
benign strictures did not show any clinical evidence of restenosis during 6
months follow-up. Overall, 14 out of 30 patients (46.7%) were only managed
by different interventional radiology procedures. Second step surgical repair was
needed for 13 patients (43.3%) and endoscopic managed for 3 patients (10%)
with biliary leaks.
Conclusion: Minimally invasive interventions were valuable techniques in the
management of different post-cholecystectomy complications. In fully equipped
centers, expert multidisciplinary teams would achieve high cure rates for iatro-
genic biliary injuries.
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Introduction: Angiography is a diagnostic and therapeutic modality that is widely
available for upper gastrointestinal bleeding but is used less frequently when the
source of bleeding is placed distally to the Treitz angle.
Aims & Methods: To assess the usefulness of angiography in the diagnosis of
colonic and small bowel bleeding and to determine the efficacy and complications
of therapeutic procedures. Retrospective study; we included all patients with
colonic and small bowel bleeding that were submitted to arteriography with or
without embolization, admitted to the gastroenterology department of a tertiary
hospital between February 2006 and November 2016. Statistics: Chi-square/
Fisher exact test, T-student.
Results: Sixty-six patients were evaluated, 63.6% male, mean age¼ 75 years (29–
95). Angiography was done for: bleeding recurrence (36.2%), hemodynamic
instability (33.3%), both (27.3%) or failure to endoscopic hemostasis (3%).
The aetiology after angiographic study was: presumed diverticular (n¼ 28),
angiectasis (n¼ 8), confirmed diverticular (n¼ 6), tumoral (n¼ 5), post-muco-
sectomy/polypectomy (n¼ 4), unclarified (n¼ 12), others (n¼ 3: Dieulafoy,
ileum ulcers, radiation proctitis). Angiography showed additional clinical infor-
mation in 25.8% of patients (n¼ 17). Twenty-three patients (34.8%) underwent
arterial embolization, all with technical success, with bleeding recurrence in 3, of
which only one was submitted to surgery; there were 2 cases of bowel ischemia.
The reasons for deciding not to embolize were: absence of active bleeding
(90.7%) and end-vessel bleeding (9.3%). There were no differences between the
groups in demographic data, comorbidities, mortality, source of bleeding, hae-
moglobin at admission/discharge and creatinine (p4 0.05); Arterial emboliza-
tion was more frequent if hemodynamic instability (p¼ 0.029); The average time
of hospitalization was lower in the group submitted to embolization (8.8 vs 11.5
days, p¼ 0.014). Overall, 11 patients died, due to: re-bleeding/hypovolemic shock
(n¼ 5), exacerbation of comorbidities (n¼ 3), hospital acquired infection (n¼ 2)
or post embolization complication (n¼ 1).
Conclusion: Arteriography was a valid option for the diagnosis of colonic and
small bowel bleeding; allowed therapeutic intervention in more than one third of
patients, with 87% of clinical success and reduction of hospitalization time.
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Introduction: Surgery for radical treatment of oesophageal cancer carries signifi-
cant inherent risk. Objectively Identifying patients that are high risk of complica-
tions is of importance. The aim of this study was to assess the prognostic value of
physical fitness variables determined objectively by cardiopulmonary exercise
testing (CPET) in patients undergoing potentially curative surgery for oesopha-
geal cancer (OC) within an enhanced recovery programme.
Aims & Methods: Consecutive 180 OC patients (106 ACA, 11 SCC, 3HGD)
underwent preoperative CPET with prospective recording of morbidity and sur-
vival. Non-parametric receiver operating characteristic (ROC) curves and logistic
regression were used to assess the relationship between CPET variables and post-
operative morbidity severity score (MSS).
Results: Of 180 patients, 120 were included for analysis (median age 65 yr., 100
male, 75 neoadjuvant therapy); 60 did not proceed to surgery and were excluded.
Postoperative morbidity and mortality occurred in 83 (69%, CD 3 in 27,
22.5%) and 4 (3.3%) patients respectively. ROC curve analysis showed oxygen
uptake (peak V02) gave an area under the ROC of 0.66 (95% CI 0.55 to 0.77,
p¼ 0.009) and optimum cut-off of 17.0ml/kg/min (sensitivity 70%, specificity
53%). Anaerobic Threshold (AT) gave an area under the ROC of 0.62 (95% CI
0.51–0.74, p¼ 0.048) and optimum cut-off of 10.5ml/kg/min (sensitivity 60%,
specificity 44%). Multivariable analysis revealed peak V02 to be the only inde-
pendent factor to predict morbidity severity CD 3 (OR 0.85, 95% CI 0.75–0.97,
p¼ 0.018). Cumulative survival was associated with operative MSS (Chi2 4.892,
DF 1, p¼ 0.027) but not with CPET variables.
Conclusion: CPET is a significant predictor of morbidity after oesophagectomy
with peak V02 the most important factor.
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Introduction: PET/CT has become an integral part of the staging pathway for
potentially curable oesophageal cancer (OC), primarily used to identify occult
distant metastases unseen by conventional radiological modalities. The aim of
this study was to analyze the effect of PET/CT introduction on overall survival
and assess patterns of recurrence after oesophagectomy.
Aims & Methods: Consecutive 496 patients undergoing oesophagectomy for
cancer [median age 63 (31–80) yr., 395 male, 425 ACA, 71 SCC, 325 neoadjuvant
therapy] were studied. Two hundred and twenty-three patients underwent PET/
CT enhanced staging protocols and the primary outcome measure was overall
survival based on intention to treat.
Results: Overall 3-year survival pre-PET/CT was 42.5% compared with 57.8%
post-PET/CT (Chi2 6.571, df 1, p¼ 0.004). On multivariable analysis, pT stage
(HR 1.486 [95% CI 1.27–1.74] p5 0.0001), pN stage (HR 1.116 [95% CI 1.05–
1.20] p¼ 0.001) and PET/CT (HR 0.689 [95% CI 0.53–0.89] p¼ 0.004) were
independently associated with duration of overall survival. Recurrent cancer
was observed in 125 patients (51.4%) pre-PET/CT; compared with 74 patients
post- PET/CT (37.8%, p¼ 0.015), and was less likely to be distal in location after
PET/CT inception (39.5 vs. 27.0%, p¼ 0.006).
Conclusion: PET/CT enhanced staging is an important and independent factor
associated with improved survival in patients undergoing oesophagectomy for
cancer.
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Introduction: Although surgical techniques and perioperative management for
esophageal cancer has been developed, it cannot be still safe to be performed
esophagectomy. Therefore, endoscopic submucosal dissection (ESD) for the
superficial cancer have been increased. We also need to consider the risk of
lymph node metastasis before treatment in each patient and the aim of this
study is to predict lymph node metastasis for superficial esophageal cancer.
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Aims & Methods: Seventy patients who was diagnosed as clinical T1a-MM, T1b-
SM1 or T1b-SM2 and underwent esophagectomy at the Keio University, Tokyo,
Japan between July 2000 and June 2016 were enrolled in this study. Patients who
underwent esophagectomy as additional resections after ESD were included. We
used random forest analysis to predict lymph node metastasis.
Results: There were 62 men and 8 women in this study. The mean age of all
patients was 62.8 8.2 years. The main location of the tumor was in the middle
thoracic esophagus (Upper: Middle: Lower, 13: 39: 18, respectively). 14 patients
had lymph node metastasis in pathological findings; 2 patients (25%) were diag-
nosed as clinical T1a-MM, 2 patients (6.6%) were T1b-SM1 and 10 patients
(31.3%) were T1b-SM2. Random forest technique (2000 trees) resulted in an
estimate of error rate of 25.7%. Lymph node metastasis was most associated
with the factor of pathological T (relative importance 100%) followed by lym-
phatic invasion (96.3%), clinical T (89.7%) and multifocal tumor (72.2%).
Conclusion: Random forest analysis confirmed the predictors for lymph node
metastasis such as pathological T and lymphatic invasion.
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Introduction: Malnutrition is associated with higher rates of operative morbidity
and therefore represent potentially reversible prognostic risk factors. Bioelectrical
Impedance Analysis (BIA) is a non-invasive, easily reproducible and simple
means of accurately measuring body composition.
Aims &Methods: The aim of this study was to assess the prognostic value of body
composition variables determined objectively by bioelectrical impedance analysis
(BIA) in patients undergoing potentially curative surgery for oesophageal (OC)
and gastric cancer (GC) within an enhanced recovery programme (ERP).
Consecutive 168 OG patients [median age 65 (24–86) yr., 131 male, 105 OC,
64 GC, 157 ACA, 8 SCC, 3 Neuroendocrine] underwent preoperative measure-
ments of systemic inflammatory response [SIR, including FBC, CRP, Albumin,
and modified Glasgow Prognostic Score (mGPS)], Patients underwent multi-
frequency (0.5 kHz, 50 kHz and 100 kHz) BIA assessment using a Maltron
Bioscan 920 (Maltron International Ltd, Essex, UK), and Cardio Pulmonary
Exercise (CPX) assessment was performed selectively (70 OC, 27 GC). Primary
outcome measure was Clavien Dindo (CD) morbidity severity score (MSS) of 3.
Results: Oesophagectomy was performed in 106, gastrectomy in 64, and lapar-
otomy only in 25 patients. Postoperative morbidity and mortality occurred in 75
(45%, CD 3 in 35, 21%) and 4 (2%) patients respectively. On univariable
analysis, MSS 3 was associated with anaerobic threshold (p¼ 0.011), CRP
(p¼ 0.001), mGPS (p¼ 0.011), intra-cellular water (ICW, p¼ 0.041), and extra-
cellular water content (p¼ 0.015). Multivariable binary logistic regression
revealed ICW content [LQ vs. UQ CD 3, 5 vs. 39%, OR 1.22 (95% CI 1.06–
1.41) p¼ 0.006] and CRP [LQ vs. UQ CD 3, 7 vs. 37%, OR 1.03 (0.99–1.06)
p¼ 0.076] to be independently associated with MSS.
Conclusion: Seven-fold variability in morbidity severity was observed after OG
cancer surgery and ICW and SIR were the most important prognostic indicators.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Esophagectomy is one the most challenging and burdening opera-
tion for its length and the variety of anatomical districts involved. Nowadays, as
consequence of the improved postoperative mortality, effects of esophagetcomy
are chronic and quality of life (QoL) has become one of the main outcome
measure to evaluate treatment. Coping is the ability of managing stressful situa-
tions such as postoperative conditions. At present, there are no studies focusing
on coping after esophagectomy for esophageal cancer
Aims & Methods: The aim of this study is to describe coping styles and QoL after
esophageal resection. EORTC QLQ-C30 was used to assess QoL while the
COPE-NVI (New Italian Version) was used to measure the coping ability.
They are both self-reported questionnaires, validated in Italian language.
EORTC C30 functional scales are: PF2 (physical functioning), RF (role function-
ing), EF (emotional functioning), CF (cognitive functioning) and SF (social
functioning). COPE-NVI considers five dimensions: Social Support (SS),
Avoidance Strategies (AS), Positive Attitude (PA), Orientation to the Problem
(OP), Transcendent Orientation (TO). Non-parametric statistics was used.
Results: Fifty-one EC patients participated in the study and completed the C30
and COPE-NVI questionnaires. Thirty-two patients completed the question-
naires after surgery. Mean COPE-NVI scales were: SS¼ 22.3 (SD 9.5),
AS¼ 23.2 (SD 4.8), PA¼ 30.8 (SD 7.9), PO¼ 22.5 (SD 8.8), TO¼ 22.1 (SD
5.0). Overall, mean C30-QL2 was 72.9 (SD 16.3). Mean C30 functional scales
were: PF2¼ 80.8 (SD 16.6), RF¼ 85.0 (SD 20.7), EF¼ 81.5 (SD 17.0), CF¼ 87.4
(SD 14.0) and SF¼ 90.0 (SD 14.0). Avoidance Strategies score was negatively
correlated with Social Function (rho¼ -0.60, p¼ 0.004). The remaining correla-
tions between COPE-NVI scales, C30-QL2 and C30 functional scales were sta-
tistically not significant. Nineteen patients completed the questionnaire twice,
with 3–6 months between the two fillings. The mean differences of the COPE-
NVI scales were not statistically significant.
Conclusion: In our series, patients used Positive Attitude to manage everyday life
changing. Whenever avoidance strategies (i.e. emotional indifference or drugs)
were used, social abilities were compromised. Moreover, after surgical interven-
tion coping seemed to be a stable feature. Therefore, in the early follow-up after
surgery multidisciplinary team can identify and the coping features of patients in
order to improve them to prevent QoL worsening.
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Introduction: The tumor micro environment plays a vital role in the growth of
malignancies. Through for example tumor-infiltrating lymphocytes (TILs) it
influences overall and disease free survival of patients in various cancer entities.
There a many studies in the literature that investigate TILs. However, there is
great heterogeneity about how to quantify these cells in the tumor tissue.
Therefore, we present a novel Quantification of the Tumor Stroma (QTS)
Algorithm to reliably and accurately quantify cells of the tumor stroma and to
perform a correlation with survival after resection of patients with hepatocellular
carcinoma and pancreatic cancer.
Aims & Methods: Immunohistochemical staining of CD3 and CD8 antigens in
frozen sections of metastatic colorectal cancer (mCRC) and ovarian cancer
(OvCa) as well as in paraffin sections of hepatocellular carcinoma (HCC) and
pancreatic cancer (PCa) was performed. For each entity 10 slides per antigen
were examined (n¼ 80). In these different entities reliability and accuracy of
computed quantification was tested in order to develop a general algorithm
(Figure): First, reliability of identification of hot spots was investigated using
two blinded observers. Hot spots were defined as regions with the highest density
of TILs. The absolute amounts of cells were compared with the intraclass-corre-
lation coefficient (ICC). Second, accuracy was tested. To examine whether quan-
tification of 1 vs 3 hot spots yields accurate results CD8þ/CD3þ ratio as well as
the absolute cell numbers were compared with the ICC respectively. Third, com-
puted counting methods (1) ZEN 2 software counting (ZC), (2) ImageJ software
with subjective threshold (ISC) and (3) ImageJ with colour deconvolution (IAC)
were compared to a manual counting (gold standard) using a linear regression
analysis. Finally, 60 resected tumor tissues of HCC and 30 of PCa were retrieved.
3 hot spots have been selected for every slide and groups of high/low infiltration
of CD3þ and CD8þ Lymphocytes have been created according to the median
value. Then, statistical correlation with overall survival (OS) and disease free
survival (DFS) was performed.
Comparison of manual counting to the computed methods showed mostly excellent accuracy of
the obtained results using intraclass correlation with reliability analysis (ICC) and coefficient B
with linear regression (B):
mCRC OvCa HCC PCa
ZC ICC¼ 0.926, B¼ 0.868ICC¼ 0.987, B¼ 0.968ICC¼ 0.869, B¼ 0.621ICC¼ 0.601, B¼ 1.280
ISC ICC¼ 0.973, B¼ 0.851ICC¼ 0.992, B¼ 1.030ICC¼ 0.990, B¼ 1.060ICC¼ 0.934, B¼ 0.914
IACICC¼ 0.986, B¼ 0.945ICC¼ 0.990, B¼ 1.060ICC¼ 0.955, B¼ 0.723ICC¼ 0.932, B¼ 1.327
Results: Quantification results from 2 blinded observers for reliable detection of
hot spots were 0.949 in mCRC, 0.843 in OvCa, 0.805 in HCC and 0.957 in PCa.
The ICC for the ratio of CD8/CD3 in 1 hot spot compared to the average from 3
hot spots was consistent in all groups. The absolute cell count in 1 vs 3 hot spots
did differ reaching ICC scores reflecting a poor accuracy. ZC in PCa yielded
inconsistencies. ISC reached excellent results in all groups. IAC reached excellent
reliability in frozen sections and HCC but not in PCa (Table). High infiltration of
CD3þ Lymphocytes correlated significantly with improved DFS in HCC
(p¼ 0.016) and PCa (p¼ 0.001) as well as improved OS in PCa (p¼ 0.046).
High infiltration of CD8þ Lymphocytes correlated significantly with improved
DFS in HCC (p¼ 0.028) and OS in PCa (p¼ 0.006).
Conclusion: In this we introduce a systematized way to count tumor stroma cells
in frozen and paraffin sections. Some rules should be observed: First, subjective
selection of hot spots by 1 observer is accurate. Second, if a ratio is to be
determined, quantification of 1 hot spot is sufficient. If the absolute cell count
is to be determined, quantification of 3 hot spots is recommended. Third,
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computed counting methods achieve mostly excellent accuracy. ISC is accurate
for sections with high background staining. IAC can be used in sections with low
background staining. With the QTS Algorithm quantification of cells in the
tumor stroma is reliable and accurate. Furthermore, clinical correlations after
the us of this algorithm show results according to the literature: High infiltration
of CD3þ and CD8þ Lymphocytes correlates with favorable prognosis in HCC
and PCa. The future use of immunoscoring systems may help to predict prog-
nosis after resection.
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Introduction: Lifestyle-related disease has been recognized as a risk factor for
hepatocellular carcinoma (HCC). On the other hand, there are few reports con-
cerning liver resection (LR) in obese patients.
Aims & Methods: We performed curative LR in 471 patients with HCC between
2001 and 2015. In this study, we defined an obesity as no less than 25 of body
mass index (BMI). We compared clinicopathological findings, operation details,
and surgical outcomes of the obese and non-obese patients. Furthermore, we
assessed the safety and the benefit of laparoscopic partial hepatectomy and left
lateral segmentectomy in the obese patients.
Results: Among 471 patients, 123 patients (26.1%) were defined as obese. Among
them, 20 patients (4.2%) showed no less than 30 of BMI. Diabetes, hypertension,
and hyperlipidemia were significantly more common, and the patients with hepa-
titis virus positive were less in the obese patients group than in the non-obese
patients group (p5 0.05). The two groups showed no differences in the liver
function tests except the indocyanine green retention rate at 15 minutes. There
were no significant differences between the two patients group in the number of
tumors, diameter of tumor, prevalence of cirrhosis, frequency of portal invasion,
the operative procedure, operative duration, blood loss, incidence of postopera-
tive complications, postoperative hospital stay, and in-hospital mortality (3.3%
vs. 1.4%). No significant difference was found in relapse-free survival rate, or
overall survival rate between the two groups, too. Thirteen patients underwent
laparoscopic surgery, and 34 patients had open surgery. The two groups showed
no difference in the background, including BMI. However the operation time
(265min vs. 397.5min) and the postoperative hospital stay (14 days vs. 18 days)
were sinificantly shorter, and the blood loss (50ml vs. 600ml) was less in the
laparoscopic surgery group than in the open surgery group (p5 0.05).
Conclusion: Liver resection in the obese patients with HCC was safe, and laparo-
scopic liver resection might be more useful for reducing the surgical stress and
reducing the hospital stay.
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Introduction: Acute cholecystectomy as treatment of acute cholecystitis is stan-
dard of care. However, many patients are still treated conservatively and undergo
elective surgery. Often 6–12 weeks following the primary admittance is postu-
lated as a good timing for an elective surgery but there are no studies on the
optimal timing for delayed cholecystectomy.
Aims & Methods: The aim of our study was to determine when it is most advan-
tageous to perform an elective cholecystectomy after an episode of acute chole-
cystitis. All patients treated for acute cholecystitis in Sweden during the years of
2006 and 2013 were identified through the Swedish Inpatient Register. This
cohort was cross-linked with the Swedish register for gallstone surgery,
GallRiks where information on surgical outcome was retrieved. The impact of
time from admission to surgery with regards to operative time, percentage of
procedures completed with minimally invasive technique, peri and postoperative
complications and bile duct injury or bile leakage were analysed with logarithmic
transformation of time and multivariate logistic regression adjusting for gender
and age.
Results: During the years 2006 to 2013, 31091 patients were treated for acute
cholecystitis in Sweden. After exclusion of patients that did not perform surgery,
were not registered in GallRiks and patients that were treated with acute chole-
cystectomy 8532 patients were identified that underwent planned surgery. In
multivariate linear regression analysis with adjustment for gender and age the
risk for peri- and postoperative complications, bile duct injuries and bile leakage
and amount procedures not completed with minimally invasive technique
decreases with time from the last hospitalization to surgery. All p-values 50.05.
Conclusion: For those patients undergoing elective cholecystectomy after an
acute cholecystitis the safety increases if surgery is performed later than 30
days after discharge.
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Introduction: We developed a CT-based patient-specific holographic surgical
simulation navigation system of immersive mixed reality (MR).
Aims & Methods: The aim of this study is to identify its benefit of simulating,
analyzing and evaluating operative surgical treatment options in gastrointestinal
and hepato-pancreato-biliary surgery.
We used our original immersive MR application using HoloLens, that is a pair of
MR smartglasses built-in head-mounted display. By reconstructing the patient-
specific 3D surface polygons of each organ out of the patient’s MDCT images,
MR anatomy was displayed on the grasses three-dimensionally during actual
surgery. The HoloLens features an inertial measurement unit which includes
an accelerometer, gyroscope, and a magnetometer for environment understand-
ing sensors, an energy-efficient depth camera, a 2.4-megapixel photographic
video camera, and an ambient light sensor. We performed 10 gastrointestinal
and hepato-pancreato-biliary surgeries.
Results: The accurate surgical anatomy of size, position, and depth of the can-
cers, surrounding organs, and vessels during surgeries could be measured using
build-in dual infrared light sensors. The exact location between surgical devices
and patient’s anatomy could be traced on the pair of MR smartglasses by satellite
tracking. The gesture controlled manipulation by surgeons’ hands with surgical
groves was useful for intraoperative anatomical references of tumors and vascu-
lar position under sterilized environment. It allowed the user to manipulate the
spatial attributes of the virtual and real anatomies, which can enhance spatial
awareness. The use of our systems reduced the length of the operation and
discussion time.
MR navigation assistance could support complex procedures with the help of
pre- and intra-operative imaging with better visualisation of the surgical anatomy
and spatial awareness with visualisation of surgical instruments in relation to
anatomical landmarks.
Conclusion: We report illustrative benefits of the immersive MR in surgical plan-
ning, simulation, education, and image-guided navigation. These could overcome
the limitations of the conventional image-guided surgery.
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Introduction: Post-surgical leaks are the first complication after non-bariatric
oeso-gastric surgery in terms of frequency and morbidity. Anastomotic fistula
change the prognostic of the operated patient increasing the length of stay,
increasing costs, increasing mortality and increasing risks of oncological recur-
rence. Surgery is still a possibility of treatment in particular in case of severe
sepsis but the role of endoscopy has evolved with development of a new arma-
mentarium of endotherapy dedicated to such complications. In cases of post
laparoscopic sleeve gastrectomy leaks, a shift is ongoing between closure or
diversion methods (Ovesco, clips, covered self expandable metal stents
(SEMS)) and internal drainage (double pig tail stents). Two large studies have
just reported a high efficiency and a low complication rate with internal drainage
with double pig tail stents for post sleeve gastrectomy leaks. No data are avail-
able for such an endoscopic internal drainage in fistulas of the upper digestive
tract non-linked to bariatric surgery. Here we report the results of a pilot bi-
centre retrospective study.
Aims & Methods: A retrospective study of all upper digestive tract leaks non
linked to bariatric surgery and treated by double pig-tail stent (DPTS) in two
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tertiary centers has been performed. DPTS are traced by the pharmacies of our
two hospitals and all cases of DPTS were analysed thanks to the database of the
pharmacies of our two hospitals since May 2014 (first DPTS used for non bar-
iatric upper digestive tract fistula) 7 or 10 french DPTS have been used according
to the size of the fistula and the choice of the physician. Technical success was
defined as the possibility to place the DPTS within the fistula. Clinical success
was a composite endpoint combining clinical amelioration of the patient and
healing of the fistula allowing the removal of the DPTS.
Results: 17 patients have been treated by DPTS from May 2014 to March 2017
for an upper digestive tract leaks non linked to bariatric surgery. Fistulas were
linked to a lewis-santy surgery in 8 patients (47%), total gastrectomy in 4
(23.5%), boerhaave syndrome in 2 (11.8%), endoscopic perforation in 2
(11.8%) and aortic surgery in 1 (5.9). An infected collection was present in 16
patients (94%) and 11 (64.7%) suffer from a clinical sepsis. The mean delay
between surgery and the diagnostic of flistula was 10 days and the delay of the
diagnosis of fistula and the endoscopic drainage by DPTS was 16,4 days. DPTS
were used alone in first intention in 11 cases (64.7%), in first intenetion in
combination with a SEMS in 11.7% and in second intention after failure of a
SEMS in 3 (11.7%). All patients had a technical success and 15 patients (88.8%)
had a clinical success. The mean delay for refeeding after DPTS was 17 days. The
mean ablation time of the DPTS was 73 days. 3 patients presented a complication
(1 stenosis, 1 bleeding and 1 migration).
N¼ 17
AGE 55 (25–77)
ETIOLOGY
Lewis Santy 8 (47%)
total gastrectomy 4 (23,5%)
Boerhaave 2 (11,8%)
Endoscopic perforation 2 (11,8%)
Aortic surgery 1 (5,9%)
ASA score 2,3 (1–4)
Associated collection 16 (94%)
Clinical sepsis 11 (64,7%)
Biological sepsis 14 (82,3%)
Delay surgery-diagnosis 10 days
Delay Diagnosis-DPTS 16,4 days
Endoscopic procedure
DPTS alone in first intention 11 (64,7%)
DPTSþSEMS in first intention 2 (11,7%)
DPTS in second intention 4 (23,5%)
Technical success 17 (100%)
Clinical success 15 (88,8%)
Delay for refeeding 17 (4–52)
Delay for ablation of DPTS 73 (36–157)
Complications
Stenosis 1 (5,9%)
Migration 1 (5,9%)
Bleeding 1 (5,9%)
Conclusion: Endoscopic internal drainage using DPTS seems to be an interesting
therapeutic option for upper digestive tract leaks non-linked to bariatric surgery.
DPTS are effective, safe, cheap and could replace SEMS not always well toler-
ated and with a high rate of migration. Prospective multicenter studies are needed
to confirm theses preliminary results.
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Introduction: Abdominal compartment syndrome (ACS) is serious complication
of big number of surgical interventions. According the data of the World Society
of the Abdominal Compartment Syndrome (WSACS), rate of mortality without
treatment is more than 90%, after treatment from 25% to 75% [1]. Patients with
ruptured abdominal aortic aneurysms (rAAA) are the group of high risk regard-
ing this complication. Rate of incidence ACS at these patients is between 8% to
25%[2]. According to data of various authors, from one third to one half of them
have died [3]. One of the main cause of this is the absence of good monitoring of
intraabdominal pressure in this group of patients[4]. Currently, we have one
effective way of treatment for this pathology: decompressive laparotomy[5].
But prophylaxis becomes more important point, if we take to attention mortality
after start the develop of abdominal compartment.
Aims & Methods: We aimed to investigate the impact of implantation polypro-
pylene mesh in abdominal wall on rate of development ACS and it severity for
patients after open repairing of ruptured abdominal aortic aneurysm. Patients
with rAAA (total amount n¼ 87 patients) were operated in standard volume.
Before finish of surgery in study group (n¼ 49, 34 males, 15 females, average age
63 years þ/ 14 years) was performed implantation of polypropylene mesh (‘in-
lay’ type) and was sutured skin and subcutaneous tissue only. In control group
(n¼ 38, 26 males, 12 females, average age 61 years þ/15 years) surgery was
finished by standard way. In all patients had infrarenal type of rAAA. Middle
laparotomy or thoracophrenodiafragmal access was used. After surgery intraab-
dominal pressure was controlled by intravesical method during first seven days
after operation. We fixated rate of complication and mortality in both groups.
We followed-up patients after surgery and controlled far outcomes too. First
mesh implantation was performed at 24 February 2014, last at 03 March 2017.
Results: In study group we fixated 5 cases of ACS (10.2%), including 3 cases of
light ADS (intraabdominal pressure (IAP) 12–15mmHg), 1 case of modrate
ADS (IAP 16–20mmHg), and 1 case of severe ADS (IAP 21–
25mmHg).Decompressive laparotomy was performed in one case with satisfac-
tory result. In general, mortality in study group was 18.4% (9 cases).In control
group we fixated 9 cases of ACS (23,7%), including 3 cases of light ADS
(intraabdominal pressure (IAP) 12–15mmHg), 2 cases of moderate ADS
(IAP 16–20mmHg), and 3 cases of severe ADS (IAP 21–25mmHg) and 1 case
with very severe ADS (IAP more than 25 Hgmm).Decompressive laparotomy
was performed in three cases, satisfactory result was ahcieved in 1 case, in two
cases patients have died from polyorgan insufficiency. In general, mortality in
control group was 28.9% (11 cases). We did not find any specific complication,
related with implantation of polypropylene mesh during all three years of follow-
up.
Conclusion: 1. Impantation of polypropylene mesh is a safe and effective proce-
dure for prophylaxis of ACS for patient with rAAA. 2. Impantation of mesh
allows to avoid ACS for patient with rAAA and related with it complication and
outcomes. 3. It is possible to implantate polypropylene mesh for other deseases,
not only for rAAA, but this point requires further investigations.
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PERITONEAL COLLECTIONS AND ABSCESSES SECONDARY TO
BARIATRIC SURGERY LEAKS: THE PARADIGM SHIFT OF SEEING
PERITONEUM AS AN ORGAN AMENABLE FOR FLEXIBLE
ENDOSCOPES INTERVENTIONS
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Introduction: Peritoneal collections and abscess after Bariatric Surgery (BS) leaks
are dreaded complications. Laparoscopic or open surgery and percutaneous CT
drainage are the current indications. Endoscopic management of pancreatic col-
lections is a rationale for Endoscopic Peroral Drainage (EPOD) approach in
cases of BS leaks with abdominal collections.
Aims & Methods: The aim of this study is to evaluate utility and safety of EPOD
to treat peritoneal collections and abscesses secondary to BS leaks. Methods:
This retrospective study included 65 consecutive patients from 2007 to 2015 at
a single center (40 Sleeve gastrectomy, 25 gastric bypass) after 5 to 21 days from
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surgery. Patients presented heart rate over 120 bpm. Images from CT showed left
sub-phrenic, peri-gastric or free abdominal collections. An Upper GI endoscopy
was performed to localize the leak opening and enter to peritoneal cavity. Either
9.8 or 5.8mm diameter gastroscope were used. In 10 patients with orifices smaller
than 5.8mm balloon dilatation of the leak opening allowed peritoneal access.
The fluid content was suctioned out (100 to 700ml). Sample was taken for
bacterial cultures. The cavity was flushed and suctioned out with sterile saline
solution (200ml to 1000ml). In cases of inadequate location surgical drains
catheters were repositioned or replaced using endoscopic forceps and snares.
Fifteen patients had malfunctioning latex drains. Replacement for drainage
catheters was performed advancing with endoscopes through the leak all the
way down to the skin. Once the tip of the endoscope was outside the peritoneum
the latex drains were removed. Catheters were snared or grasped and pulled back
into the peritoneum leaving the proximal end close to the fistula opening. In 5
patients without surgical drainage systems one laparoscopic port was localized
inside peritoneum and re-opened under endoscopic vision to allow drainage
catheters placement. In 8 patients peritoneal adhesions were endoscopically lib-
eration with endoscopic forceps or knifes to facilitate peritoneal navigation.
Results: Heart rate returned to normal within 24 hours and leukocytosis
improved after 72 hours. In 50% of patients heart rate returned to normal
immediately. Average time for the whole procedure was 45 minutes.
Abdominal catheters were removed between 7 and 18 days once full resolution
of the drainage was achieved. Twenty patients were discharged within the first 24
hours. The rest were discharged between 3 and 8 days. Partially covered SEMS
were placed for 6 to 8 weeks leading to complete closure of leaks. There were no
adverse events related.
Conclusion: EPOD for peritoneal collections and abscesses secondary to BS leaks
is feasible, safe and highly effective.
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Introduction: A diverting loop ileostomy with procedure of intestinal resections
and intestinal anastomosis decreases morbidity from anastomotic leaks and may
even reduce the risk of anastomotic leak as shown in recent studies. Reversal of a
temporary ileostomy is considered a simple surgical procedure presenting with a
low morbidity and mortality rates. However, ileostomy reversal may be asso-
ciated with number of complications requiring reoperation, with anastomotic
leak (AL) being most critical often leading to failure in restoration of digestive
tract continuity.
Aims & Methods: The study aimed at evaluating the results of restoration of
intestinal continuity in patients primarily operated on for colorectal cancer and
inflammatory conditions. We assessed the frequency of failure following the
surgical procedure of diverting loop ileostomy closure. The study was conducted
at a tertiary referral center. 147 adult patients (89 men, mean age 50.5y 16.71y
and 58 women, mean age 49.3y 16.99y;) were enrolled to this study. All
included patients underwent surgical closure of a temporary loop ileostomy at
the Department of General and Colorectal Surgery, Lodz, Poland, between 2004
and 2015. The medical data was collected in a retrospective manner basing on
hospital records. The analyzed parameters included length of hospitalization,
gender, age, BMI, concomitant conditions, American Society of
Anesthesiologists classification score (ASA) and the character of postoperative
complications. Statistical analysis was used to evaluate the correlation between
the variables and postoperative complications.
Results: AL as a postoperative complication with the need to create a new ostomy
occurred in 15 patients (10.2%). Higher values of BMI and older age have been
noted compared to noncomplicated surgeries (27.54 2.36 vs. 23.02 3.98;
p5 0.001; 54.53 12.3 vs. 50.25 15.95; p¼ 0.029 respectively). There was no
significant correlation between patients’ gender and the incidence of AL
(p¼ 0.087). The number of prior surgical procedures and ASA scale positively
correlated with the prevalence of AL (p¼ 0.038; p¼ 0.003 respectively). There
were no significance diference betwenn patient with colorectal cancer and inflam-
matory conditions (p¼ 0.534). The average time interval from prior surgery to
reversal of the stoma and AL occurrence were not related and did not reveal
statistical significance (8.5 4.41vs. 7.24 4.47; p¼ 0.25). Univariate logistic
regression demonstrated that a BMI levels, patients’ age and average time inter-
val from prior surgery to reversal procedure were significantly associated with
failure of restoration of intestinal continuity.
Conclusion: AL as a critical postoperative complication is still a major issue
related with failure of intestinal continutiy restoration in patients undergoing
loop ileostomy clouser. Patients with elevated BMI, older age and shorter aver-
age time interval from prior surgery to reversal procedure present higher risk of
failure in restoration of digestive tract continuity. The incidence rate of AL was
similar in patients operated primarily on for inflammatory conditions and color-
ectal cancer.
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Introduction: The impact of body composition on the outcomes following pan-
creaticoduodenectomy is still unclear.
Aims & Methods: The aim of this study was to analyze the association between
body composition and postoperative complications and 90-day mortality in
patients undergoing biliopancreatic cancer surgery. Retrospective study of
patients with pancreatic, ampullary or bile duct carcinoma that underwent sur-
gery between March 2012 and October 2016. Body composition (skeletal muscle
area, visceral fat area, subcutaneous fat area and muscle radiation attenuation)
was assessed in diagnostic or staging computed tomography (CT), in axial images
at the level of the 3rd lumbar vertebra. Postoperative complications were recorded
according to Clavien-Dindo classification and categorized as minor (grade I–
IIIa) and major (grade IIIb–V).
Results: Fifty-nine patients were analyzed and 11 were excluded due to unavail-
able CT scan at our institution. Forty-eight were included, 28 were men, with a
mean age of 70.9 8.5 years. The incidence of major complications was 25% and
90-day mortality was 8.3%. On simple logistic regression of factors associated
with major complications skeletal muscle area (OR 0.97, 95% CI 0.94–1.00,
P¼ 0.09) and index (OR 0.91, 95% CI 0.81–1.00, P¼ 0.09) showed a trend for
a protective effect. On multiple logistic regression skeletal muscle index was a
protective factor (OR 0.89, 95% CI 0.79–0.99, P¼ 0.05) and longer surgery (OR
1.01, 95% CI 0.99–1.03, P¼ 0.07) was associated with higher incidence of major
complications. The receiver-operator characteristic (ROC) curve showed an
acceptable power of discrimination of major complications using a model with
skeletal muscle index and surgery duration as independent variables (area under
the curve of 0.736). On simple logistic regression surgery duration (OR 1.02, 95%
CI 1.00–1.06, P¼ 0.05), visceral fat area (OR 1.02, 95% CI 1.00–1.04, P¼ 0.02)
and index (OR 1.05, 95% CI 1.01–1.12, P¼ 0.04) were associated with higher 90-
day mortality whereas muscle radiation attenuation had a protective effect (OR
0.88, 95% CI 0.76–0.99, P¼ 0.05).
Conclusion: These results suggest that low values of skeletal muscle and muscle
radiation attenuation, as well as high values of visceral fat and longer surgery are
associated with worse clinical outcomes following biliopancreatic cancer surgery.
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Introduction: Gastroschisis is a ventral body wall defect trough which protrude
mainly large and small intestines. The disease’s clinical course and prognosis
depend on both surgical techniques, severity of the defect, accompanying anoma-
lies and complications.
Aims & Methods: We performed a retrospective study based on the analysis of
patientś records admitted to our hospital Neonatal Intensive Care Unit between
January 2000 and December 2016.The aims of this study were to evaluate defect’s
incidence, management and outcome of patients with gastroschisis in our
institution.
Results: During the period 2000–2016 the overall incidence of gastroschisis in our
NICU was 5.23% (140 cases-all transferred from other units). The average birth
gestational age was 35.5 weeks and the average birth weight was 2270 g. The
abdominal wall defect was identified in antenatal period only in 15.4% of cases.
Also, 23 patients (16.4%) presented other associated anomalies: 12 cases with
atresia or stenosis of various intestinal segments, 6 cases with renal anomalies
and 5 cases with cardiac defects. Surgical techniques performed for abdominal
defect closure were: primary closure in 35 cases (25%), staged closure in 12 cases
(8.57%), Gross technique in 44 cases (31.4%) and manual reduction and closure
(Bianchi procedure) in 49 cases (35%). The average period of digestive pause was
12.9 days and the mean length of stay in NICU was 30.4 days. Patients were also
mechanical ventilated for an average period of 4.6 days. The most frequent
complication was late-onset sepsis (37.8%); also 26 neonates (18.5%) underwent
unplanned reoperation and 7 neonates (5%) remained with short bowel. The
average mortality in our group was 33% but it constantly decreased over the
years (from 84% in 2000 to 11% in 2016). Sepsis, prematurity, low birth weight
and associated defects were identified as major risk factors for the unfavorable
outcome (death).
Conclusion: The management of neonates with gastroschisis depends on several
factors including the status of herniated organs, the size of abdominal cavity, the
presence of other associated congenital anomalies and last but not least on the
resources and experience of the neonatal interdisciplinary team. Significant
changes occurred in the management of gastroschisis in our Unit and as conse-
quence, the outcome of patients with gastroschisis has dramatically improved
during the studied period.
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Introduction: Urinary metabolic profiling has been shown to distinguish patients
with inflammatory bowel disease (IBD) from healthy controls (HC), and also
separate ulcerative colitis (UC) from Crohn’s disease (CD) in Caucasian (Cau)
cohorts (1). Diet and lifestyle also have an effect on metabolic profiles (2), and
these differ in patients from different ethnic backgrounds. Moreover, clinical
phenotype varies between Caucasians and South Asians (SA)(3), however dis-
criminatory metabolites have not been studied in different ethnic populations.
The aim of this study was to compare the urinary metabolic profiles of IBD
patients and healthy controls from Caucasian and South Asian backgrounds.
Aims & Methods: Samples from 405 IBD patients (283 Caucasian and 122 South
Asian) and 137 healthy controls (98 Caucasian and 48 South Asian) were ana-
lysed by H1NMR spectroscopy. Clinical and dietary data were collected.
Orthogonal partial least squares discriminant analysis (OPLSDA) was performed
to examine whether there were differences in metabolic data between Cau and
SA. R2 (variance), Q2 (quality assessment) and p values (validity) for each model
were described.
Results: The phenotype of South Asian Crohn’s disease was not significantly
different to Caucasian Crohn’s disease in this cohort. In the South Asian UC
group there was more pancolitis (p¼ 0.051) and less proctitis (p¼ 0.008). There
were more vegetarians in the South Asian group. OPLSDA was able to separate
patients with IBD from healthy controls, and also UC from Crohn’s disease, in
the Caucasian cohort, but this separation could not be replicated in South Asians
(negative Q2 values).
Conclusion: The separation between Caucasian and South Asian healthy controls
may reflect differing lifestyles including diet. Caucasian IBD patients could be
separated from healthy controls, and Crohn’s disease from UC, replicating pre-
vious studies. South Asian IBD patients could not be separated from healthy
controls which may be due to lower numbers of South Asian patients in this
study, and specifically less Crohn’s disease patients where stronger discriminating
models have been shown in Crohn’s disease in previous studies. In Crohn’s
disease, Caucasians and South Asians could be separated, but Caucasian and
South Asian patients could not be distinguished in the UC cohort, possibly
suggesting the metabolic milieu in Crohn’s disease is stronger and less influenced
by the impact of ethnicity.
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Introduction: Reduced saccharolytic fermentation has been described in patients
with quiescent ulcerative colitis (UC). Such defects may differ across colonic
regions along with acute variations in dietary fibre intake. These aspects deserve
further study.
Aims & Methods: We aimed to define regional colonic fermentation by direct
intestinal pH-transit profiling in patients with quiescent UC following acute
variations in fermentable fiber intake. A randomized, double-blind, crossover
trial was performed. Patients with quiescent UC (Partial Mayo Score 1;
faecal calprotectin 5150 mg/g) and healthy controls who were not taking any
Abstract: P1608
Caucasian (n and %) South Asian (n and %) – –
All IBD 283 122 – –
CD 160 (57%) 42 (34%) – –
CD Disease location* L1: 24. L2: 50, L3: 68 L1: 7, L2: 16, L3: 19 – –
CD Disease behaviour* B1: 144, B2: 12, B3: 12 B1: 26, B2: 7, B3: 4 – –
UC 123 (43%) 80 (66%) – –
UC Disease extent* E1: 29, E2: 32, E3: 45 E1: 6, E2: 26, E3: 48 – –
Controls 98 39 – –
All (Cau and SA) All (Cau and SA) All (Cau and SA) All (Cau and SA)
Separation P values (100 permutation testing) R2 Q2
Controls vs IBDþ Yes p¼ 0.001 0.596 0.627
Controls vs CDþ Yes p¼ 0.001 0.659 0.623
Controls vs UCþ Yes p¼ 0.007 0.798 0.757
CD vs UCþ Yes p¼ 0.001 0.880 0.282
Caucasian Caucasian Caucasian Caucasian
Separation P values (100 permutation testing) R2 Q2
Controls vs CDþ Yes p¼ 0.003 o.634 0.627
Controls vs UCþ Yes p¼ 0.012 0.815 0.769
CD vs UCþ Yes p¼ 0.008 0.882 0.458
SA SA SA SA
Separation P values (100 permutation testing) R2 Q2
Controls vs CDþ Noþþ N/A 0.593 0.214
Controls vs UCþ Noþþ N/A 0.337 0.147
CD vs UCþ Noþþ N/A 0.217 0.071
*Montreal classification
þOPLSDA model examining the differences in urinary metabolic profiles between these cohorts
þþp value cannot be calculated if OPLSDA model has negative Q2 values
OPLSDA models also separated South Asian healthy controls from Caucasians healthy controls, and South Asian Crohn’s disease from Caucasian Crohn’s disease,
but in UC no robust model could be made.
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antibiotics (including sulfasalazine), probiotics or fiber supplements were
recruited. After a 7-day run-in, subjects were fed study meals high (11 g oligo-
saccharides, 2 g resistant starch) or low (51 g) in fermentable fiber over a 12-h
period before ingesting the pH-motility capsule, subjects then crossed over to the
other diet 3 days after passage of the capsule. Endpoints were diet-associated
differences in overall, caecal and distal colonic pH, and colonic transit time
(CTT), taken as time between the ileo-cecal junction and capsule exit. Caecal
pH was defined as the minimum pH following passage through the ileo-cecal
junction whereas maximum pH was arbitrarily used as distal colonic pH.
Results: 15 UC patients (aged 24–72 y; 9 males) and 9 controls (aged 22–69 years,
4 males) were studied. A decrease in overall and distal colonic pH was observed
in controls with high vs low fiber diet (Table 1). In UC patients, a high fermen-
table fiber intake reduced caecal pH but paradoxically tended to increase distal
colonic pH. A significant association was observed for UC extent and changes in
overall (r¼ 0.81; p5 0.001, Spearman’s correlation) and caecal pH (r¼ 0.53;
p¼ 0.04) after a high fermentable fiber diet (Figure 1). No differences in CTT
were observed between diets in either cohorts but subgroup analysis in the UC
cohort showed highly heterogeneous responses to a high fermentable fiber diet.
64% patients had slower CTT whilst 36% had unchanged or faster CTT. In
contrast, majority (63%) of controls had no changes in CTT after a high fiber
diet.
Table 1: Colonic pH and transit responses to acute changes in fermentable fiber
intake
Overall
mean pH
(95% CI)
Mean
cecal pH
(95% CI)
Mean distal
colonic pH
(95% CI)
Median
[IQR]
CTT (h)
UC n¼ 15 Low fiber 6.4 (6.2–6.8) 5.6 (5.3–5.7) 7.9 (7.6–8.2) 17 [9–23]
High fiber 6.3 (6.0–6.5) 5.2 (5.0–5.4) 8.1 (7.6–8.4) 21 [16–39]
p-value 0.20 0.001 0.09 0.13
Healthy n¼ 9 Low fiber 6.9 (6.5–7.2) 5.5 (5.2–5.8) 8.2 (8.0–8.5) 16 [15–37]
High fiber 6.3 (6.0–6.5) 5.2 (4.9–5.5) 7.7 (7.4–8.0) 18 [15–32]
p-value1 0.02 0.15 0.04 0.582
1paired t-test or 2Mann-Whitney test
Conclusion: A high fermentable fiber diet partially increased colonic fermentative
activity in patients with quiescent UC compared to controls. Moreover, contrary
to controls, UC patients exhibited an increase in distal pH and heterogeneous
colonic transit responses after a high fermentable fiber intake. Our findings
suggest that abnormalities in motility and regional defects in the function of
the colonic microbiota exist despite quiescent disease.
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Introduction: Microbial dysbiosis in the gut has been suggested to play an impor-
tant role in the pathogenesis of inflammatory bowel disease (IBD).
Aims & Methods: In this study, we aimed to analyze the fecal microbiota in
Chinese patients with IBD. Fecal samples from 15 patients with Crohn’s disease
(CD), 14 patients with ulcerative colitis (UC) and 13 healthy individuals were
subjected to 16S rDNA sequencing. The V4 hypervariable regions of 16S rDNA
were sequenced by the Illumina MiSeq2500 platform. Quality control and opera-
tional taxonomic units (OTUs) were calculated with QIIME software.
Results: Significant differences in community richness and microbial structure
were observed both in CD and UC compared with normal controls. At the
phylum level, analysis of the microbial compositions revealed that the
Proteobacteria percentages, were significant higher in IBD than in controls.
While at the genus level, we found that the abundance of 8 genera in CD and
23 genera in UC, particular the Escherichia genus, were significantly different
when comparing with controls. We next surveyed the taxonomics composition
distribution between different phases of disease, detecting that the abundance of
the Bacteroidetes was significant decreased in active CD group compared with
inactive CD group. However, the Proteobacteria was only nominally increased in
active CD relative to inactive CD, which did not hold significance after correc-
tion. Furthermore, the relative abundance of the Bacteroidetes, especially the
Bacteroides, was negatively correlated with the calculated Crohn’s disease activ-
ity index (CDAI) scores of patients.
Conclusion: Our findings showed the specific characteristics and dysbiosis of fecal
microbiota within Chinese IBD patients. In addition, the abundance of the
Bacteroidetes was significant lower in active CD group than in inactive CD
group and it was negatively correlated with CDAI, indicating that the
Bacteroidetes could be related with the disease activity.
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Aims & Methods: In the present study, we sought to elucidate the effects of iron
supplementation on hypoxia-mediated responses in the intestinal epithelium. For
this purpose, serum starved Caco-2 monolayers were subjected to normoxia
(21% O2) or hypoxia (0.2% O2) in the presence and absence of ferric ammonium
iron citrate (FAC) and the iron chelator deferoxamine (DFO). Total RNA was
isolated and changes in the expression of tumor necrosis factor (TNF), interleu-
kin (IL)-1b, DMT-1, FPN and ferritin was assessed by real-time quantitative
PCR. Western blot analysis was performed with antibodies against ferritin, p-
NF-B, HIF-1, p-mTOR, p62 and LC3. mRNA synthesis in Caco-2 cells under
hypoxia was blocked using actinomycin D. Chromatin immunoprecipitation
experiments were carried using antibodies against NF-B and primers for pro-
moter binding regions of TNF and IL-1b. Healthy volunteers (n¼ 10) were sub-
jected to hypoxic conditions resembling an altitude of 4,000m above sea level for
3 h using a hypobaric chamber. Serum samples were collected the day prior to
hypoxia, and one day, one week and one month after hypoxia.
Introduction: Environmental hypoxia has been stablished to influence the devel-
opment of inflammatory bowel disease (IBD). Adaptive responses to low oxygen-
tension are mediated through hypoxia inducible factor (HIFs), which are tightly
regulated by oxygen and iron levels through the action of hydroxylases. Dietary
iron is mainly absorbed by duodenal enterocytes through the divalent metal
transporter (DMT)-1. Once iron is inside the enterocytes, it is either sequestered
into ferritin or transported out of the enterocyte into the circulation by ferro-
portin (FPN). Regulation of uptake, storage and export of iron is mediated by
signals reflecting oxygen and intracellular iron levels in enterocytes, and systemic
iron requirements. Central to systemic iron regulation is the liver hormone hep-
cidin, which regulates and is regulated by systemic iron levels. Hepticidin expres-
sion is induced by cytokines and results in anemia of inflammation.
Results: Hypoxia induced the mRNA expression of TNF and IL-1b concomi-
tantly with the iron transporters DMT-1 and FPN in Caco-2 cells under iron-
starving conditions, thereby promoting iron uptake. The iron chelator deferox-
amine (DFO) induced HIF-1 stabilization and TNF mRNA expression under
both normoxic and hypoxic conditions. Conversely, iron supplementation
induced ferritin protein accumulation under normoxic and hypoxic conditions,
and reduced TNF and IL-1b mRNA expression. Interestingly, neither iron che-
lation nor iron supplementation reduced hypoxia-mediated p-NF-B. Iron
induced p-mTOR and blocked autophagy. Iron overload enhanced decay of
TNF, but not IL-1b mRNA. Iron also prevented binding of NF-B to the pro-
moter of TNF and IL-1b. Healthy volunteers presented reduced serum levels of
iron, as well as transferrin saturation. Ferritin levels were unchanged indicating
anemia of inflammation and suggesting enhanced intracellular iron accumulation
in enterocytes following hypoxia.
Conclusion: Our results suggest that hypoxia-mediated iron uptake is crucial to
counteract hypoxia-induced pro-inflammatory gene expression, and identify iron
intracellular uptake and storage as a hypoxia protective mechanism to reduce
mucosal inflammation.
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Introduction: In both forms of inflammatory bowel disease (IBD), Crohn’s dis-
ease (CD) and ulcerative colitis (UC), inflammation of the gut wall is associated
with extracellular tissue acidification. Low extracellular pH stimulates the family
of proton-sensing G-protein coupled receptors (GPCRs); ovarian cancer G-pro-
tein coupled receptor 1 (OGR1), T-cell death-associated gene 8 (TDAG8 or
GPR65) and G-protein coupled receptor 4 (GPR4), which activate second mes-
senger signaling cascades. Recent studies reported a link between IBD and this
family of pH-sensing receptors; in genome-wide association studies (GWAS),
TDAG8 has been identified as an IBD-risk gene. The mechanism behind the
increased risk of developing IBD remains unclear. OGR1 and TDAG8 are
alleged to act in opposition by regulation of the inflammatory response; enhan-
cing or inhibiting inflammatory pathways respectively, however the interplay
between OGR1 and TDAG8 is unclear.
Aims & Methods: In this study we aim to investigate the role of OGR1 in IBD
patients. Expression of OGR1 in surgical specimens from non-IBD (n¼ 5), CD
(n¼ 10) and UC (n¼ 10) patients was determined by immunohistochemistry,
RT-qPCR and Western blotting. Clinical disease activity was assessed by the
Harvey Bradshaw Index (HBI) and the Modified Truelove and Witts activity
index (MTWAI) for CD and UC patients, respectively. Nonparametric
Spearman’s rank correlation analysis was performed.
Results: OGR1 immunostaining of human surgical samples from non-IBD
patients revealed OGR1 expression mainly in lamina propria cells, with weaker
staining in epithelial cells. OGR1 staining in IBD patients was stronger compared
to controls; however, in IBD patients OGR1 is highly expressed in both epithelial
cells and cells in the lamina propria. Further, paired samples taken at the same
time, from non-inflamed and inflamed intestinal tissue from IBD patients showed
stronger OGR1 staining in the inflamed mucosa compared to the non-inflamed
mucosa. Accordingly, mRNA and protein expression of OGR1 was significantly
increased in patients with IBD compared to non-IBD patients. Additionally, a
significant positive correlation was observed between OGR1 expression and the
clinical score in both the non-inflamed (rs 0.7311, p¼ 0.0069) and the inflamed
mucosa (rs 0.7698, p¼ 0.0034).
Conclusion: The expression of OGR1 is significantly increased in patients with
IBD. OGR1 expression correlates with IBD disease activity, suggesting an active
role of OGR1 in IBD pathogenesis. OGR1 appears to be a therapeutic target
among the pH-sensing receptors involved in IBD.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1613 MICROBIAL PROFILING OF NEWLY DIAGNOSED
PATIENTS WITH ULCERATIVE COLITIS DIFFERS WITH
ETHNICITY; RESULTS OF AN INCEPTION COHORT TIME SERIES
ANALYSIS
R. Misra
1, A. Perdones-Montero2, N. S. Ding3, D. Rees4, O. Faiz5, J. Marchesi6,
N. Arebi1
1Gastroenterology, St. Marks Academic Institute, London/United Kingdom
2Centre For Computational Systems Medicine, Imperial College, London/United
Kingdom
3Gastroenterology, St. Vincents Hospital, Melbourne/Australia
4Division Of Women’s Health, Kings College, London/United Kingdom
5Surgical Epidemiology Trials And Outcomes Unit (setoc), St. Marks Academic
Institute, London/United Kingdom
6Imperial College London, London/United Kingdom
Contact E-mail Address: rm399@imperial.ac.uk
Introduction: Ulcerative colitis (UC) phenotype in South Asian (SA) migrants
differs to Caucasians with a predominant pan-colonic extent.1 A separate study
showed different microbial profiles with lower bacterial diversity in the SA
group.2 The significance of these findings is unclear due to small sample size
(n¼ 30) and single time point analysis.
Aims & Methods: We aimed to examine microbial profile of SA and Caucasian
UC patients. Faecal samples were collected from 48 UC patients recruited in a
prospective inception cohort study at diagnosis (time point 1; months 0–3) and 2
further time points over one year (time point 2: months 4–8, time point 3: months
9–12). Patients were stratified by ethnic group (SA, Caucasian, Other), treatment
(none, 5-ASA, Azathioprine and Steroids) and disease duration. Healthy controls
(HC) were recruited locally among the staff at St. Marks Hospital. For 16S
pyrosequencing the hypervariable region (V1) of the 16S rRNA gene was ampli-
fied by PCR. The amplicons were subjected to sequencing using Illumina MiSeq
technology. The sequences were loaded onto the QIIME pipeline. Statistical
analysis was performed using STAMP 2.1.3 software with Welch’s two-sided t-
test for comparing two groups. Microbial richness was calculated based on
Chao1 index. Weighted Unifrac metrics were applied to construct Principle
Coordinate Analysis (PCoA) plots.
Results: Ninety-four faecal samples were collected. Sample collection for all time
points included SA (n¼ 13), Caucasian (n¼ 9), healthy SA (n¼ 11) and healthy
Caucasian (n¼ 12). There was no significant difference in relative abundance of
bacteria between treatment groups (5-ASA, Azathioprine, Steroids, None) and
time points (1 vs 3). Comparing healthy SA and healthy Caucasians, there was
only one significant difference in relative abundance of Clostridiales at the family
level. (Increased in SA group). The Chao1 diversity index showed a trend
towards lower diversity in the SA group compared to Caucasians although
there was no significant difference. There were significant increases in
Bifidobacterium, Rikenellaeceae, Lactobacillus and Streptococcus (Table 1) and
significantly decreased relative abundance in Barnessiellacae, Anaerostipes and
Ruminococcus.
TABLE 1: Summary of Bacterial Taxonomic Findings in South Asians (SA) and
Caucasians with ulcerative colitis. *Increase or decrease in SA relative to
Caucasians
Phylum Change* Family Change* Genus Change*
Actinobacteria Increased Bifidobacteriaceae Increased Bifidobacterium Increased
Increased
Bacteriodetes Decreased Bacteroidales Decreased Barnessiellaceae Decreased
Rikenellaceae Increased
Firmicutes Lactobacillacae Increased Lactobacillus Increased
Streptococcae Increased Streptococcus Increased
Clostridiales Increased Decreased
Lachnospiraceae Decreased Anaerostipes Decreased
Unclassified Decreased
Ruminococcaceae Decreased Ruminococcus Decreased
Veillonellaceae Increased
Proteobacteria Pasteurellaceae Decreased
Conclusion: Increased Bifidobacteria and Lactobacillus in the SA group is con-
sistent with the previous study.2 A possible explanation is the consumption of
fermented foods in the SA group although there was no difference between
healthy SA and Caucasian controls. There is a trend towards lower diversity in
the SA group and reduced Bacterioides which are consistent with the UC dys-
biosis described in the literature. Functional analysis of this unique microbial
profile through metagenomic and metabonomic techniques may explain the dif-
ferent disease behaviour in the SA group.
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Introduction: There is evidence for vitamin D as an immunomodulator in patients
with IBD, but results from clinical trials to date are inconclusive. It is uncertain
whether vitamin D supplementation may affect the intestinal microbiota.
Aims & Methods: This study aimed to assess the effect of vitamin D replacement
in deficient patients with and without ulcerative colitis (UC) on inflammation
and faecal microbiota. Vitamin D was replaced over 8 weeks to patients with
active UC, inactive UC, and non-IBD controls with baseline 25(OH) vitamin
D5 50 nmol/L, and markers of inflammation and stool collected for microbiota
analyses by next generation sequencing.
Results: Eight patients with active UC, 9 with inactive UC and 8 non-IBD con-
trols received 40,000 units of vitamin D weekly over 8 weeks. No demographic
differences were noted across the groups. Mean baseline 25(OH) vitamin D levels
were 34 (range 12–49) nmol/L. Vitamin D supplementation increased mean
25(OH) vitamin D to 111 (range 71–158) nmol/L (P5 0.001), and reduced para-
thyroid hormone levels from mean 4.3 to 3.3 pmol/L (p¼ 0.017). No change in
baseline medications for UC took place in patients with UC, except for one
patient with active UC who ceased his 5-aminosalicylate. Faecal calprotectin
levels reduced from median 275 to 91mg/g (p¼ 0.023) in patients with active
colitis, but did not change in patients with inactive colitis or non-IBD controls.
Similar improvements in albumin, platelet count and symptomatic disease activ-
ity indices were noted. No changes in overall bacterial diversity were noted. There
was a trend towards an increase in abundance of Ruminococcus gnavus post
vitamin D supplementation in active UC patients, but this did not reach statis-
tical significance.
Conclusion: Vitamin D supplementation was associated with reduced intestinal
inflammation in patients with active UC. A randomised controlled trial evaluat-
ing vitamin D in IBD is required, along with further investigation of potential
mechanisms by which vitamin D may alter specific microbial composition.
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Introduction: Attack by commensal microbiota is one component for induction of
inflammatory episodes in ulcerative colitis (UC). In UC, the mucus layer is
intrinsically devoid of phosphatidylcholine (PC) resulting in low hydrophobicity
which facilitates bacterial invasion. Colonic ectophospholipase-carrying bacterial
strains are likely candidates to break the PC mucus barrier. Therefore we aimed
to evaluate the effect of phospholipase A2 (PLA2) inhibitors on inflammation in a
genetic UC mouse model.
Aims & Methods: Attack by commensal microbiota is one component for induc-
tion of inflammatory episodes in ulcerative colitis (UC). In UC, the mucus layer
is intrinsically devoid of phosphatidylcholine (PC) resulting in low hydrophobi-
city which facilitates bacterial invasion. Colonic ectophospholipase-carrying bac-
terial strains are likely candidates to break the PC mucus barrier. Therefore we
aimed to evaluate the effect of phospholipase A2 (PLA2) inhibitors on inflamma-
tion in a genetic UC mouse model.
Results: Luminal UDCA-LPE reduced the PLA2 activity in stool by 36 8%.
Concomitantly no inflammatory phenotype was observed when compared to
kindlin 2(/) mice not treated with UDCA-LPE. The improvement was docu-
mented in regard to stool consistency, calprotectin levels in stool, and macro-
scopic/endoscopic as well as histologic features of the mucosa. The pattern of
colonic microbiota distribution obtained in the UC phenotype mice was reversed
by UDCA-LPE to the control mice pattern.
Conclusion: The inhibition of the bacterial ectophospholipase A2 activity
improves mucosal inflammation in a genetic mouse model of UC. It is assumed
that the remaining mucus PC shield is better preserved when luminal PLA2 is
suppressed.
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4Novartis Institutes for Biomedical Research, Basel/Switzerland
Contact E-mail Address: katharina.baebler@usz.ch
Introduction: Inflammatory bowel diseases (IBDs), Crohn’s disease (CD) and
ulcerative colitis (UC) are typically associated with a decrease in local pH.
Genome-wide association studies (GWAS) identified over 240 non-overlapping
single-nucleotide polymorphisms (SNP) associated with IBD. G-protein-coupled
receptor 65 (GPR65) or T-cell death associated gene 8 (TDAG8) has recently
been reported to be a genetic risk factor for IBD. The T genotype of the lead
GPR65 SNP (rs8005161) within the GPR65 gene confers increased IBD risk. In
response to extracellular acidification, GPR65 activates second messengers:
cAMP, via the Gs signaling pathway, and G12/13/Rho signaling.
Aims & Methods: In this study, we analyzed the functional relevance of SNP
rs8005161 as well as the association of this GRP65 variant with IBD. Discovery:
2064 IBD patients from the Swiss IBD Cohort Study (SIBDCS) were genotyped
for IBD risk SNPs by MALDI-TOFF mass spectrometry. Validation: 1138 indi-
viduals (591 non-IBD, 203 UC, 344 CD) were genotyped for risk SNPs, GPR65
(rs8005161, rs3742704) and GALC (rs1805078), with Taqman SNP Genotyping
Assays. 10 IBD patients of each genotype GPR65 rs8005161 TT, CT and wild
type/CC (WT/CC) from the SIBDCS and 10 non-IBD controls (CC) were
recruited for functional studies. CD14þ cells were isolated from blood samples
and subjected to an extracellular acidic pH shift (pH 6.6 vs. pH 7.6) in functional
assays and tested for cAMP and RhoA GTPase activation.
Results: Sequenced genotype frequency of rare homozygote rs8005161 in the
SIBDCS was 1.17%, minor allele frequency (MAF) - 10.3%. The variant
rs8005161 was more frequent in UC patients (MAF 14.53% vs 10.05% in the
non-IBD group), whereas no statistically significant association with IBD, UC or
CD was found for the other variants (GPR65 rs3742704, GALC rs1805078) by
Taqman genotyping. No significant differences were observed in the cAMP pro-
duction between IBD (WT/CC, CT, TT) and non-IBD (WT/CC) genotype car-
riers upon pH shift from 7.6 to 6.6. A decreased activation of GTPase RhoA was
seen in IBD (WT/CC, CT, TT) patients after an acidic pH shift, but no differ-
ences between rs8005161 TT, CT and CC patients was observed.
Conclusion: The minor T allele of the GPR65 associated SNP rs8005161 was
significantly enriched in UC patients. RhoA signaling was reduced in IBD
patients indicating differential activation of Rho signaling in patients versus
controls. However, no differences in cAMP signaling in IBD TT/CT/CC subjects
compared to healthy CC subjects were observed. Our results suggest impaired
RhoA signaling in IBD patients upon a pH shift, indicating a mechanistic expla-
nation for increased IBD risk with GPR65 polymorphisms.
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Introduction: Macrophages contribute to fibrosis through the release of different
mediators and the pattern of secretion may vary according to their phenotype.
Recent evidences have identified Wnt pathway as an emerging modulator of
fibrosis.
Aims & Methods: The aim of the present study is to analyze the pattern of
expression of macrophage markers and Wnt ligands in surgical resections from
Crohńs disease (CD) patients with different disease behavior. CD patients were
categorized according to Montreal classification (age at diagnosis, location and
behavior). mRNA was isolated form resections of patients presenting an strictur-
ing (B2) or a penetrating (B3) behavior or from patients with colorectal cancer
(control). The expression of macrophage markers (CD206, CD86, iNOs,
Arginase), Wnt ligands (Wnt1, Wnt2, Wnt2b, Wnt3, Wnt3a, Wnt3b, Wnt4,
Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b, Wnt8a, Wnt8b, Wnt9a, Wnt9b, Wnt10a,
Wnt10b and Wnt16) and DKK1 (inhibitor of Wnt signaling) was analyzed by RT-
PCR.
Results: B3-patients seem to present a higher infiltration of macrophages since
increased expression of markers classically used to detect pro-inflammatory
(CD86) and regulatory/pro-resolving/pro-fibrotic phenotypes (CD206, ARG)
was detected in this group. These patients also presented a generalized overex-
pression of Wnt ligands together with augmented DKK1 mRNA levels. B2-
patients showed a more complex situation with ligands that present increased
(Wnt3), reduced (Wnt2B) or unchanged expression in the absence of significant
variations in the levels of macrophage markers (Table). Table. Relative (Gene/b-
actin) mRNA expression (fold induction vs control group) of genes with detect-
able levels. Data are expressed as MeanSEM with n 7 in all groups and
analyzed by ANOVA þ Kewman-Keuls test. (*p5 0.05 vs control; #p5 0.05
vs B2).
Conclusion: Crohn’s disease patients presenting a stricturing (B2) or a penetrating
(B3) behavior undergoing surgical resection differ in the pattern of macrophage
infiltration and Wnt signaling.
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Introduction: M2 macrophages play a key role in injury repair and fibrosis. We
have reported that STAT6-dependent macrophages mediate mucosal repair after
TNBS-induced acute colitis 1 and that, in a chronic model, STAT6-deficient
animals accumulate macrophages expressing the CD16 marker that promote
intestinal fibrosis 2.
Aims & Methods: We aim to analyze whether the expression of the pro-fibrotic
mediator TGFb is related with this macrophage phenotype and the relevance of
these cells in murine intestinal fibrosis. Murine peritoneal macrophages obtained
from both WT or STAT6 (-/-) mice were treated with IL-4 (20 ng/ml), IL-10
(50 ng/ml) or vehicle and the mRNA expression of CD16 and TGFb was ana-
lyzed 72 h later by qPCR. WT or STAT6 (-/-) mice were weekly administered
with TNBs (0.5, 0.5, 0.75, 0.75, 1, and 1mg, intrarectally) or saline and were
sacrificed 7 weeks after the first TNBs administration. The mRNA expression of
CD16, TGFb, Vimentin, Col1a1, -SMA, MMP2 and TIMP1 was evaluated in
murine intestinal mucosa by qPCR. In all cases results were expressed as fold
induction vs vehicle and the correlation between different measurements was
analyzed using Pearson’s correlation coefficient (r).
Results: A positive and significant correlation between CD16 mRNA and TGFb
mRNA was observed in isolated macrophages from WT mice (r¼ 0.637,
P¼ 0.03) and STA6 (-/-) mice (r¼ 0.677, P¼ 0.002) receiving different treat-
ments. In the mucosa of WT and STAT6 mice the expression of TGFb
showed a positive and significant correlation with CD16 mRNA (r¼ 0.601,
P5 0.001), and with the expression of several fibrotic markers (vimentin:
r¼ 0.6537, P5 0.0001; Col1a1: r¼ 0.5101, P¼ 0.0003; -SMA: r¼ 0.4126,
P¼ 0.0048; MMP2: r¼ 0.5729, P5 0.0001; and TIMP1: r¼ 0.3958, P¼ 0.0071).
Conclusion: The expression of TGFb is associated with CD16 positive cells and is
involved in murine intestinal fibrosis.
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Introduction: The intestinal inflammation is reduced by electrical stimulation of
the efferent vagus nerve. Cholinergic output may be a target to minimize tissue
damage in autoimmune disease. Cholinergic neural output can modulate innate
immune responses through stimulation of 7 nicotinic acetylcholine receptors
(7nAChR). GTS-21, a selective 7nAChR agonist, has previously demonstrated
to inhibit the inflammation associated with rheumatoid arthritis (RA). In this
study we investigate whether GTS-21 protects against DSS-induced colitis and its
potential mechanism.
Aims & Methods: Male BABL/c mice (8–10 weeks old, n¼ 32) were randomly
divided into 4 groups: normal control group, DSS-induced group, GTS-21 treat-
ment control group (DSS-induced mice treated with GTS-21), -BGT group
(DSS-induced mice treated with -BGT and GTS-21) (n¼ 8, each group). DSS
group was given final concentration of 3.5% DSS drinking water, the treatment
group was treated with GTS-21 (20mg/kg intraperitoneal injection)per day, -
BGT group was pre-treated with a-BGT (0.1mg/kg/day, intraperitoneal injec-
tion) for 30min prior to GTS-21 injection. and the control group received saline.
Caco2 cells were randomly divided into 4 groups: normal control group, TNF--
induced group, GTS-21 treatment control group, -BGT group. TNF- group of
Caco2 cells were exposed by 25 ng/ml TNF-, GTS-21 group were given 100 ng/
ml GTS-21 for 30min prior to TNF-; -BGT group pre-treated with a-BGT
(50 ng/ml) for 30min prior to GTS-21 injection. BAY 11-2028 (NF-B inhibitor)
group were given 50 ng/ml BAY-11-2028 for 30min prior to TNF-. Disease
activity index, macroscopic scores, and colonic damage were determined. The
intestinal permeability of mice was measured by fluorescein-isothiocyanate-dex-
tran (FITC-Dextran) method. Western blot was used to detect the tight junction
protein and NF-B associated protein expression.
Results: Compared with DSS-induce mice, DAI score decreased and colon length
improved after administration of GTS-21 (9.13 0.74 cm vs 6.85 0.53 cm,
P5 0.01), HAI score decreased (1.25 1.32 vs 10.5 2.64, P5 0.05). The
7nAChR antagonist -BGT can eliminate those protective effects (Figure 1).
2. The intestinal permeability improved after administration of GTS-21 com-
pared with DSS-induced mice (49.52 28.59 ug/ml vs 157.40 32.40 ug/ml
P5 0.05); whereas -BGT can block this protection (115.50 6.10 ug/ml vs
49.52 28.59 ug/ml P5 0.05) (Figure 2 K3). 3.The expressions and distribution
of tight junction protein in DSS-induced mice were enhanced after treatment with
GTS-21 (p5 0.05) (Figure 4 K5). 4. GTS-21 attenuated the NF-B activation
(p5 0.05). a-BGT administration reversed the inhibitory effect of GTS-21
(p5 0.05) (Figure 6). 5 GTS-21 improves the distribution of tight junction pro-
teins in the intestinal epithelial cells induced by TNF-  (Figure 7). 6.GTS-21
reduces nuclear translocation of NF-B in Caco2 cells induced by TNF- 
(Figure 8).
Conclusion: The7 nicotinic acetylcholine receptors agonist GTS-21 can attenu-
ate the intestinal inflammation in DSS-induced mice, which may be due to
improving intestinal mucosal barrier function by enhancing the expression of
tight junction protein.
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Introduction: Intestinal fibrosis is a common complication of IBD and macro-
phages can contribute to fibrosis through the release of different mediators. We
have recently reported that Wnt10b increase the deposition of collagen and
promotes intestinal fibrosis in TNBs-treated mice (P015 ECCO 2017).
Aims & Methods: The aim of the present study is to analyze the pattern of
expression of macrophages and the expression of Wnt10b in human macrophages
from surgical resections from Crohn’s disease (CD) patients with a B2-stricturing
and B3-penetrating behavior according to Montreal classification (age at diag-
nosis, location and behavior) as well as from non-inflamed tissue from cancer
patients. Resections were immediately processed and lamina propria mononuc-
lear cells characterized by flow cytometry. Macrophages were identified within
singlet viable leukocytes as CD45þCD14þCD64þ. The percentage of CD206,
CD16, CD163, CD86 and Wnt10b positive cells was analyzed in macrophages.
Data are expressed as Mean SEM % with n 5 in all groups (P5 0.05* vs
control, Student’s t test).
Results: The percentage of macrophages identified as CD45þCD14þCD64þ
constituted the 0.22 0.03% of total events in the control mucosa while repre-
sented the 1.35 0.40% in the mucosa from CD patients (p5 0.05). A high
proportion of mucosal macrophages expressed CD206 in both, control
(83.3 4.8%) and CD (89.6 3.9%). In these CD206þ cells, an increased expres-
sion of CD16 in CD mucosa was observed (Control: 34.5 6.8%; CD:
59.7 6.4%*) while that of CD163 was similar in both groups (control:
72.8 8.4%; CD: 85.2 7.3%). The analysis of Wnt10b in CD206þ showed a
significantly higher expression in CD patients (56.6 4.2%) than in control
samples (30.1 10.4%). Additionally, CD86þmacrophages were more abundant
in CD mucosa (Control: 8.2 1.1%; CD: 29.3 10.2%*).
Conclusion: The mucosa of CD patients accumulate pro-inflammatory macro-
phages measured as CD86þ cells while those macrophages expressing the M2-
marker CD206 alter their phenotype increasing the expression of both, CD16 and
the profibrotic mediator Wnt10b.
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Introduction: For inflammatory bowel disease (IBD), anaemia is the most fre-
quently observed extra intestinal finding, prevalence of which varies from 6% to
74%. It’s of great importance to determine and treat anaemia as it lowers
patients’ life quality and leads to labour loss. The main causes of anaemia in
IBD are iron deficiency anaemia (IDA) and anaemia of chronic disease (ACD).
In this study, we aim to specify the type and prevalence of anaemia along with a
treatment approach for inflammatory bowel disease (IBD).
Aims & Methods: In this study, we aim to specify the type and prevalence of
anaemia along with a treatment approach for inflammatory bowel disease (IBD).
We conducted a retrospective study on 465 patients, who were diagnosed with
IBD and followed up at our hospital from June 2015 to June 2016 (male: 254,
female: 211, average age: 47 14.4, Crohn disease (CD): 257, Ulcerative Colitis
(UC): 208). According to WHO criteria, anaemia occurs when haemoglobin
value is below 13 g/dL in men and 12 g/dL in women.
Results: In our study, we determined that 50.3% of total 465 patients had anae-
mia, which was more frequent in women then men (64% vs. 39%, p5 0.001).
Anaemia frequency was higher in CH cases (57%) then in UC cases (41%)
(p¼ 0,001). CD involvement were as follows: 54.5% in ileal involvement,
60.4% in colonic involvement and 58.5% in ileocolonic involvement.
Furthermore, 27.5% of UC patients had proctitis (E1) involvement while 41%
of them had involvement in left colitis (E2) and 31.5% had pancolitis involve-
ment. There was no significant relation between anaemia frequency and duration
of disease (p¼ 0.216). We specified the following types of anaemia: IDA only
32.9% (77), ACD only 5.5% (13), IDA and ACD combination 6.8% (16), anae-
mia stemming from B12/folic acid deficiency 6.4% (15), multiple anaemia 17.8%
(41) and anaemia with no etiology 30.7% (72). 50% of patients with anaemia
received treatment; 23% of IDA patients had oral iron intake and 41% of them
had parenteral iron treatment while 53% of patients who were suffering from
megaloblastic anaemia got B12/folic acid treatment.
CD206 ARG CD86 Wnt2 Wnt2B Wnt3 Wnt9A Wnt10B DKK1
CONTROL 1.9 04 1.5 0.3 2.7 0.6 2.3 0.6 1.4 0.2 1.4 0.2 1.3 0.2 1.2 0.3 1.7 0.2
B2 3.1 0.8 1.4 0.4 3.4 0.7 3.3 0.7 0.4 0.1* 2.7 0.6* 2.7 0.6 0.6 0.2 2.1 0.7
B3 7.7 1.6*# 3.2 0.8*# 7.0 1.8*# 5.1 1.2 1.7 0.3# 6.0 1.0*# 3.9 1.7* 2.3 0.4*# 6.1 1.7*#
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Conclusion: We found out that almost half of all IBD patients (50.3%), whom we
followed up, had anaemia, the most frequent reason of which was IDA. Almost
half of these patients received anaemia treatment. We should increase the treat-
ment rate in our IBD patients that have anaemia.
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Introduction: IBD is a chronic disorder of the gastrointestinal tract characterized
by disruption of epithelial barrier function and gut inflammation. Evidence sup-
ports a relevant role of succinate, an intermediate of the tricarboxylic acid cycle1,
in inflammation and the succinate receptor, SUCNR1, has been recently related
with rheumatoid arthritis2.
Aims & Methods: To analyze the role of SUCNR1 in a murine model of colitis
induced by TNBS. WT or SUCNR1/ mice received TNBS (3.5mg/20g mice,
intrarectally) or vehicle (EtOH 40%) and were weighed daily (results are
expressed as percentage vs the weight at day 0) and mice were sacrificed 2 and
4 days after TNBS administration. Colon length and mucosal histology were
evaluated according to Wallace Score (1–10). The mRNA expression levels of
iNOS, Arginase I, COX-2, TNF-, IL-1, IL-6 and IL-10 was analysed by qPCR.
Results: Treatment of mice with TNBS induced a loss of body weight that peaked
2 days after treatment. Subsequently, mice began to recover and, four days after
treatment, body weight reached similar values to those of control animals. In
TNBS-treated SUCNR1-/- mice compared with TNBS-treated WT mice: a) the
loss of body weight was significantly (P5 0.05) attenuated (96.99 0.7% vs
91.78 1.1%); b) the reduction in colon length was prevented (6.6 0.2 vs
5.2 0.2 cm); c) damage score was significantly reduced (3.5 0.2 vs 4.8 0.5)
two days after TNBS treatment. d) The increase in the expression of pro-inflam-
matory molecules was significantly prevented (P5 0.05) (table 1) while no sig-
nificant differences were detected in the expression of COX-2 (Table 1).
Table1: mRNA expression of different molecules detected in the colon of TNBS-
treated mice. Results are expressed as fold induction vs the value obtained in WT
mice.
iNOS ArgI COX-2 TNF IL-1b IL-6 IL-10
WT 2.6 0.6 1.6 0.7 1.1 0.2 2.6 0.6 1.7 0.2 4.2 1.0 0.8 0.1
KO 1.5 0.4 2.8 1.0 1.3 0.3 1.3 0.2 1.2 0.1 1.7 0.3 1.4 0.2
Conclusion: Activation of the succinate receptor SUCNR1 mediates murine coli-
tis. These findings highlight the biological significance of SUCNR1 and open the
door to novel approaches for IBD treatment.
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Introduction: Inflammatory bowel disease (IBD) is a chronic intestinal inflamma-
tory disease with a tendency to recurrence, and intestinal barrier disorders play a
key role in its development. The deficiency of zinc is a clinical manifestation and
can promote the development of IBD. Zinc Transporter Member 7 (ZIP7) is a
gate keeper protein in the intracellular release of zinc in cells. Recent studies
revealed that ZIP7 helps to maintain the intestinal mucosal integrity. In addition,
ZIP7 can regulate endoplasmic reticulum stress.
Aims & Methods: Our aim was to investigate the role of ZIP7 in IBD initiation
and progression. We investigated the expression of ZIP7 in the intestinal mucosa
of IBD patients and in interleukin-10-gene-deEcient (Il10/) mice, and assessed
the relation between ZIP7 and disease activity. ZIP7 upregulated/downregulated
lentivirus was used to infect IEC6 and HIEC cells, then we evaluated the expres-
sion of inflammatory factors, mucosal tight junction proteins (Occludin and ZO-
1), and proteins related with endoplasmic reticulum stress (IRE1, XBP1, TRAF2,
ASKl and p-JNK). In addition, we used siRNA to silence IRE1 and SP600125 to
inhibit the JNK pathway respectively, then evaluated the effect of endoplasmic
reticulum stress on mucosal tight junction proteins.
Results: We found that ZIP7 was downregulated both in the intestinal mucosa of
IBD patients and in Il10/ mice, which was associated with disease activity. In
IEC6 and HIEC cells, the expression of mucosal tight junction proteins was
consistent with the level of ZIP7, but the expression of inflammatory factors
and endoplasmic reticulum stress associated proteins were on the contrary.
After the silence of IRE1 and the inhibition of JNK pathway, the expression
of mucosal tight junction proteins was partly resumed in ZIP7 downregulated
cells.
Conclusion: ZIP7 induces disruption of the intestinal barrier, which was asso-
ciated with activation of endoplasmic reticulum stress in IBD. It is expected to
provide a novel mechanism of IBD and provide a new target for the treatment of
IBD.
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Introduction: The accumulation of immune cells around the enteric neuronal
ganglia of patients affected by Crohn’s disease is predictive of disease recurrence
after post-operative resection. As cells of the enteric nervous system could be
implicated in the formation of these myenteric and submucosal plexitis in chronic
inflammatory digestive diseases, inter-relationship between T cells and enteric
glial cells (EGC) was investigated.
Aims & Methods: To analyse the interactions between immune and enteric neural
cells, EGC isolated from the myenteric plexus of the rat digestive tract were co-
cultured with CFSE-labeled T cells. Impact of T cell activation on neuro-immune
interactions was investigated by treating T cells with anti-CD3/anti-CD28 anti-
bodies. To determine whether inflammatory conditions favored the contacts
between glial and immune cells, EGC were treated with LPS or TNF/IL1 prior
their exposition to T cells. After 2 hours, non-adherent cells were removed and
the T cells interacting with EGC (S100þ) were counted. Immunocytochemistry
were also used to characterize the subpopulations of T cells (CD4þ, CD8þ) that
contact glial cells.
Results: Analyses reveal that non-activated T lymphocytes are capable of inter-
acting with EGC. They also show that activation of T cells with anti-CD3/anti-
CD28 antibodies increases the number of T lymphocytes interacting with EGC.
Interestingly, an increased number of EGC-T cell interactions was observed after
pretreatment of EGC with inflammatory stimuli. This phenomenon was also
noted with activated T cells. Characterization of T cells show that both CD4
and CD8 cells are capable of contact with EGC.
Conclusion: Our present data reveal that EGC interact with T cells. These con-
tacts are favored by T cell activation but also by EGC exposure to inflammatory
cytokines. Further experimentations are required to characterize these neuro-
immune interactions but they suggest that EGC-T cell contact may play a crucial
role in case of inflammatory bowel diseases. This work is supported by the
Association François Aupetit.
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Introduction: Enteric glial cells (EGC) are essential to intestinal epithelial barrier
(IEB) homeostasis. In healthy intestines, EGC reduce IEB permeability and
promote mucosal healing. In inflammatory bowel disease (IBD) such as
Crohn’s Disease (CD) and Ulcerative Colitis (UC), both EGC phenotype and
IEB functions are altered, but putative involvement of EGC in IBD pathogenesis
remains unknown. If the astrocyte reactivity is well studied, the reaction of EGC
to chronic inflammation is not well documented. We investigated whether EGC
impact on IEB permeability was altered in an inflammatory environment and in
EGC from IBD patients.
Aims & Methods: Rat EGC as well as human EGC from control, CD and UC
patients were stimulated with the cytomix TI (TNFalphaþIL1beta; 1 to 100 ng/
ml) or LPS for 2 or 4 days. Reactive EGC phenotype where characterized and
reactive EGC functional impact on IEB permeability was studied (i) in vitro using
human intestinal epithelial cells (IEC) in a non-contact co-culture model, or (ii)
in vivo by grafting the treated rat EGC in colon wall of Sprague Dawley rats.
Results: Rat and human control EGC induced a significant reduction of IEB
paracellular permeability after TI treatment when compared with untreated or
LPS treated EGC. LPS or TI treatment had no significant effects on IEC alone.
In vivo colon wall grafting with control EGC did not modified the permeability
whereas colon wall grafting with EGC preconditioned by TI significantly reduced
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the permeability when compared to control animals. Human EGC from control
or UC patients treated with TI induced a decrease in IEB permeability too, but
EGC from CD patients did not.
Conclusion: This work is not only the first evidence showing that reactive EGC
can have beneficial effects upon IEB permeability, but also shows that EGC from
CD but not UC patients have lost these reactivity. This could define EGC as
active players in CD pathogenesis.
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Introduction: In inflammatory bowel disease (IBD) both intestinal epithelial bar-
rier (IEB) permeability and PTGIS expression are altered. Nevertheless the role
of the lipid mediator PGI2 produced by PTGIS in IEB regulation is unknown.
The present study concerns the control of IEB permeability by PGI2 and its
involvement in the development of colitis.
Aims & Methods: PGI2 production from control or IBD biopsies was established
using high sensitivity liquid chromatography tandem mass spectrometry.
Consequences of flolan PGI2 analogous supplementation were evaluated in a
DSS-induced mice model of colitis, measuring disease activity index (DAI),
inflammation (pro-inflammatory cytokine mRNA) and IEB permeability (sul-
fonic acid flux). Molecular mechanisms involved were assessed by quantification
of junctional and pro-proliferative vs pro-apoptotic protein expression (western
blot and immunostaining). Eventually PGI2 impact on reversing IEB breakdown
was assessed ex vivo measuring permeability of mice or human mucosal explants
treated with staurosporine apopstosis inducer, or permeability of IBD biopsies
both treated or not with flolan.
Results: Biopsies from IBD patients had lower PGI2 production compared to
control patients, and addition of flolan reduced their permeability. In vivo PGI2
supplementation significantly reduced DAI, and inflammation (Interferong
mRNA) as well as reduced IEB permeability. DSS-induced clivage of Caspase
3 is normalized by flolan. Ex vivo, staurosporine-induced permeability of mice or
human mucosal explants is entirely inhibited by flolan.
Conclusion: This study not only presents a role of PGI2 in controlling IEB
permeability through the regulation of apoptosis mechanisms, but also reveals
that increased permeability in IBD patients can be fixed by PGI2
supplementation.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: 7-hydroxy-4-cholesten-3-one (7HCO) is a reliable method to diag-
nose bile acid malabsorption (BAM). Since 7HCO is an intermediate metabolite
in the bile acid synthesis, increased levels reflect bile acid production, which is the
case in BAM.
Aims & Methods: We evaluate retrospectively, prospectively collected clinical
data during the first year after implementation of a new test using ultrahigh
performance liquid chromatography coupled to mass spectrometry to measure
7HCO (see reference). In adult patients with clinical suspicion of BAM, unex-
plained diarrhea and a subgroup with obesity 7HCO was measured. Levels
530 ng/ml are considered as normal values. The decision to treat with cholestyr-
amine was at the discretion of the treating physicians.
Results: We performed 126 7HCO analysis in 112 patients (62% female, mean
age 51þ/16 years) with a mean level of 84þ/ 91 ng/ml. Cholestyramin treat-
ment was more likely initiated in patients with Crohn’s disease (RR 1.8; 95%CI
0.9–3.7) or after ileocecal resection (RR 3.1; 95%CI 1.7–5.7). Diarrhea improved
in 60% of patients with a 7HCO level above 40 ng/ml. Thresholds of 60 or
100 ng/ml do not improve prediction of response to cholestyramin treatment.
7HCO measurement in subgroups
Subgroups Number Mean [ng/ml] SD Range#
Diarrhea 79 94* 96 55 - 4300
No diarrhea 33 59* 71 55 - 4300
Cholestyramin treated 27 167x 105 11 - 4300
Cholestyramin untreated 85 57x 67 55 - 4300
Crohn’s disease (CD) 18 182 105 13 - 4300
Ileocecal resection (IR) 26 197 105 28 - 4300
CDþ IR 13 214 95 41 - 4300
Obese (mean BMI 39.1 kg/m2) 21 62 49 6–244
*p5 0.05; xp5 0.001; #Validation Range 5–300 ng/mL
Conclusion: A 7HCO measurement above 40 ng/ml seems to be associated with a
good response to cholestyramine treatment, which suggests clinical bile acid
malabsorption. However, most patients have higher levels, particularly in
Crohn’s disease after ileocecal resection. These preliminary results warranted
confirmation on a larger scale.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Ulcerative colitis (UC) is a clinical type of inflammatory bowel
diseases. The pathogenesis of UC remains unclear. Nowadays the role of T-help-
ers type 17 (Th17) as well as cytokines they release is discussed in pathogenesis of
autoimmune inflammation in UC.
Aims & Methods: The aim of study is to analyze the serum levels of following
cytokines: interleukin (IL)-17A and F, 21, 22, 23, 10 in UC patients both in the
acute stage of disease and remission.Forty eight UC patients in the acute stage
and twenty patients in remission were included into the study. Serum cytokine
levels were analyzed using multiplex immunoassay for Th17 cytokines (Bio-Rad,
USA). Statistical analysis was performed using STATISTICA 6.0 Software
Package. The control group consisted of 11 healthy volunteers.
Results: Statistically significant increase of IL-17A level (15 pg/ml [12.11;23.38]);
14.68 pg/ml [11.29;17.19] respectively) was observed in patients with UC both in
acute stage and remission compared to controls (7.36 pg/ml [5.18;8.06],
o¼ 0.00007, o¼ 0.00029 respectively). The same trend was observed regarding
IL-21, which median values were higher both in acute stage (156.51 pg/ml
[133.44;233.53]) and remission (144.02 pg/ml [133.44;154.43]) compared to con-
trol group (98.31 pg/ml [89.14;124.86]), and showed statistically significant dif-
ferences (o¼ 0.00077, o¼ 0.0054 respectively). Besides it was revealed that IL-
17F and IL-22 were also higher in acute stage (136.5 pg/ml [68.25;228.185] and
3.76 pg/ml [1.5;5.83], respectively) compared to controls (48.7 pg/ml [38.7;87.6];
and 2.6 pg/ml [1.7;3.2], respectively), however differences were not statistically
significant (o¼ 0.06; o¼ 0.172, respectively). Increase of described cytokines
levels could be a sign of Th17 functional overactivity suggesting autoimmune
type of inflammation.Statistically significant increase of IL-10 in remission
(27.99 pg/ml [17.53;33.55]) compared to controls (4.36 pg/ml [3.26;15.25],
o¼ 0.0046) was found as well. IL-10 was also higher in patients with acute
stage (21.93 [3.61;35.35]) compared to controls, however differences were not
statistically significant (o¼ 0.065). IL-10 as an anti-inflammatory cytokine char-
acterizes the activity of regulatory T-cells which suppress autoimmune inflamma-
tion. In addition, it was revealed that the level of IL-23 which stimulates Th17
differentiation was higher both in acute stage (258.4 pg/ml [55;367.49]) and remis-
sion (244.93 pg/ml [200.26;301.93]) compared to controls (124.3 pg/ml
[107.9;296.04]), however differences were not statistically significant.
Conclusion: Increase of IL-17A, IL-17F, IL-21, IL-22 levels could be a sign of
Th17 functional overactivity suggesting autoimmune type of inflammation. IL-
17A and IL-21 produced by Th17 cells might be considered as markers of active
autoimmune inflammation in UC patients.
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Introduction: The steroid-refractoriness is a common complication of ulcerative
colitis (UC), which appears unpredictably. Several mechanism of action (MoA)
has been implicated in corticosteroid failure. However, there are no conclusive
studies on the molecular functions involved in UC steroid-refractoriness.
Aims & Methods: Therefore, we decided to know in depth the MoA related to the
steroid failure, exploring transcriptomic data from a cohort of patients with UC
treated with glucocorticoids. RNA from rectal biopsies was obtained before and
on the 3rd day of glucocorticoid treatment. Then, whole-genome expression
using microarrays (Illumina, USA) and profiles microRNA by sequencing
(Illumina, USA) were analysed. After quality control, omics data were compared
between phenotypes. The results of these comparisons were integrated into math-
ematical models generated by means of Systems Biology.
Results: These models reproduce the updated molecular interactions on gluco-
corticoids and UC, and integrating our experimental data, we identified a poten-
tial MoA that includes 64 key proteins, 18 of them capable of perfectly classifying
patients with a good response to glucocorticoids and the non-responders. The
biological functions of these proteins have been associated with inflammation
(e.g. RelA), glucocorticoid receptor transcription (e.g. NR3C1 and NCOA3) and
angiogenesis (e.g. VEGF), mainly. But among these 18 proteins, the ANP32e has
never been related to either steroid-refractoriness or ulcerative colitis. ANP32e is
a chaperone linked to H2A-H2A.z exchange (H2A.z is part of the nucleosomes
flanking DNA regions recognized by the glucocorticoid receptor). Additional
WB and immunofluorescence assays confirm differences in the intestinal levels
of ANP32e and in the nuclear localization at baseline, between patients with
different responses to glucocorticoids.
Conclusion: In conclusion, this study has identified a potential new MoA related
with UC steroid-refractoriness involving chromatin remodeling modifications.
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Introduction: The intestine is populated with myriads of bacteria, which form a
complex ecosystem and have tremendous impact on our health. In inflammatory
bowel disease (IBD), shifts in microbiota composition and a reduction in overall
diversity have been described. There are attempts to therapeutically transfer the
microbiota from healthy subjects to persons suffering from intestinal disease.
While in case of Clostridium difficile infections, this approach proves to be
very efficient; the therapeutic value of fecal microbial transfer (FMT) in IBD
is still unclear. In mouse models of intestinal inflammation, the effect of FMT
has been studied poorly and if so, germ-free or antibiotic-treated animals have
been used–models that poorly reflect the situation in human IBD patients. Here,
we addressed how transmission of microbiota from healthy to diseased mice
affects recovery from acute colitis.
Aims & Methods: Acute colitis was induced in 12–14 week old C57B6 mice by
administration of 2% DSS in the drinking water for 7 days. Mice with colitis
were co-housed with healthy mice after removal of DSS. Due to coprophagy, this
results in fast transfer of the microbiota between co-housed mice. To analyse
changes in the composition of microbiota over time, stool samples were taken
every second day and sequenced for the V4 hyper-variable region in the bacterial
16S DNA.
Results: As expected, DSS treatment resulted in severe weight loss, and even 7
days after withdraw of DSS (day 15), histology confirmed severe colitis.
Intestinal inflammation was accompanied by an overall reduction of microbial
diversity (decreased Shannon index, p5 0.01), and a marked shift in the compo-
sition of the microbiota (increased abundance of Verrucomicrobia,
Cyanobacteria and some families of Firmicutes [mainly Clostridiacea], although
overall abundance of Firmicutes was decreased [p5 0.01 for all]). However, on
day 15, these changes were less pronounced, indicating a normalization of the
microbiota composition upon recovery. DSS-treated mice which were co-housed
with healthy littermates after colitis induction, showed faster recovery (earlier
weight gain, reduced histological scores, reduced levels of the infiltration marker
myeloperoxidase (MPO), less pronounced shortening of the colon, p5 0.01 for
all) and an earlier normalization of the microbiota composition.
Conclusion: Our results indicate that co-housing of DSS-treated mice with
healthy mice results in transfer of healthy microbiota to diseased mice, and
promotes recovery from colitis. This indicates that introduction of a ‘‘healthy’’
microbiota might have beneficial effects during intestinal inflammation and
opens the possibility to systematically study the effect of genetic alterations in
donor and/or recipient on the efficacy of FMT.
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Introduction: In Crohn’s Disease (CD), colonic phenotype of the ileum has been
reported in severe lesions, but not in CD ileum with no lesions or with early post-
operative recurrence (1).
Aims & Methods: In a prospective study at 5 years, we aimed to address whether
colonic phenotype of the ileum may represent a subclinical marker of clinical
postoperative recurrence in CD. At this purpose, clinical recurrence was assessed
yearly for 5 years in a cohort of CD patients with colonic phenotype of the ileum
already defined at surgery, 6 and at 12 months after ileo-colonic resection (1). A
cohort of CD patients with clinical and endoscopic recurrence already assessed
and reported at 6 and 12 months after ileo-colonic resection (1), was clinically
followed up for additional 4 years. In the 5 years follow up, indication for
treatments, haematochemical, radiological and/or endoscopic assessments was
given according to current European guidelines (2). Haematochemical assess-
ments included whole blood count, ESR, serum CRP evaluation yearly for 5
years, with possible additional assessments, according to clinical indications.
Clinical recurrence (CDAI4 150) was assessed yearly for 5 years. Colonic phe-
notype of the ileum was already reported at surgery, at 6 and 12 mos, according
to the expression of sulfomucins (colon mucin-type) and sialomucins (small intes-
tine mucin-type) (1). In the present study, correlation between the percentage of
expression of sulfomucins and clinical recurrence was evaluated yearly for 5
years. Statistical analysis: results expressed as median (range), correlations
were assessed by the Spearman correlation test, differences between groups by
the unpaired T test.
Results: After ileo-colonic resection, clinical follow up at 5 years was completed
by 17/19 (89.4%) CD patients enrolled (12 males, age 41 [17–57]). The percentage
of expression of sulfomucins (colon phenotype) as assessed in the ileal surgical
specimens was significantly correlated with the CDAI score at 4 years (r¼ 0.62;
p¼ 0.007) and at 5 years (r¼ 0.6; p¼ 0.010). Differently, in the ileal biopsies at 6
months, colonic phenotype of the ileum, evaluated by the expression of sulfo-
mucins was significantly correlated with the CDAI score at 6 monoths (r¼ 0.68;
p¼ 0.003). The percentage of expression of sulfomucins in the ileal biopsies at 12
months was significantly correlated with the CDAI score at 6 months (r¼ 0.57;
p¼ 0.015) and at 2 years (r¼ 0.53; p¼ 0.02). The ileal expression of sulfomucins
in the surgical specimens at surgery was higher in patients with vs without clinical
postoperative recurrence at 2 years (40 [10–99] vs 5 [0–50; p¼ 0.04)]. The expres-
sion of colon mucin-type in the ileal biopsies at 12 months was higher in patients
with vs without clinical recurrence, both at 12 months (30 [1–40] versus 0 [0–35];
p¼ 0.02) and at 2 years (30 [0–40] verus 0 [0–35]; p¼ 0.029). No correlations were
observed between the percentage of expression of sulfomucins at surgery, at 6 or
at 12 months and the haematochemical parameters considered.
Conclusion: In CD, colonic phenotype of the ileum as assessed by the expression
of ileal sulphomucins, may represent a predictive marker of clinical recurrence
after ileo-colonic resection for CD.
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Introduction: Immunization of a quadrivalent influenza vaccine (A/California/7/
2009(H1N1) pdm09, A/Switzerland/9715293/2013(NIB-88) (H3N2), B/Phuket/
3073/2013, and B/Texas/2/2013) began in the 2015/2016 season. We assessed
the immunogenicity and booster effect of quadrivalent influenza vaccine for
adult inflammatory bowel disease patients treated with immunosuppressive
drugs and/or anti-TNF- agents.
Aims & Methods: Single vaccination group and booster group were randomly
assigned to adult patients with crohn’s disease or ulcerative colitis, and quad-
rivalent influenza vaccine was administered subcutaneously. Serum samples were
collected at 3 points (before vaccination, 4 weeks after vaccination and after the
end of influenza season) in the single group and 4 points in the booster group
(before vaccination, 4 weeks after the first vaccination, 4 weeks after the second
vaccination and after the end of the influenza season). Antibody titer against
each influenza strain was measured by inhibition of hemagglutination.
Results: A total of 132 patients with IBD were randomly assigned to single
vaccination and booster groups. Eighteen patients received immunomodulatory
monotherapy and 20 received anti-TNF-alpha single agent therapy. Nineteen
patients received combination therapy of immunosuppressant and anti-TNF-
agents. No significant difference between the single vaccination group and boos-
ter group was observed (geometric mean titers: H1N1: p¼ 0.81; H3N2: p¼ 0.79;
B/Phuket: p¼ 0.82; B/Texas: p¼ 0.84). In patients treated with infliximab, ser-
oprotection rate (SP%) and seroconversion rate (SC%) tended to be lower in
influenza A strains in patients who maintained blood concentrations (SP%:
H1N1: OR 0.37 (0.11–1.21); H3N2: OR 0.22 (0.07–0.68), SC%: H1 N1: 0.23
(0.06–0.91); H3N2: 0.19 (0.06–0.56)).
Conclusion: Serological response rate to influenza vaccination was low in IBD
patients receiving immunosuppressant therapy, especially infliximab, even with a
quadrivalent influenza vaccine.
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Introduction: The global incidence of inflammatory bowel disease (IBD) is
increasing. Migration may influence disease epidemiology. The UK demo-
graphics are affected by sustained migration from South Asia. The incidence
of UC in South Asians (SA) was previously reported as higher than the
Caucasian population.1,2 These single centre studies were done over 20 years
ago. The current epidemiology of IBD in the multiethnic UK is unknown.
Aims & Methods: We aimed to describe the UK incidence of IBD and distribu-
tion within ethnic groups. Census data (2011) was used for background popula-
tion size, ethnic groups and to identify areas with high SA populations where
Indian and Pakistani were the predominant groups. The incidence was calculated
by using the number of subjects in each ethnic group in the background popula-
tion as the denominator. Adult patients (416 years) with newly diagnosed IBD
(fulfilling Copenhagen diagnostic criteria) were prospective recruited over one
year in 7 catchment areas with high SA population. Data including demographics
ethnic codes and disease phenotype (Montreal classification) was collected onto
the Epicom database. Chi-squared test was used to detect differences in IBD
incidence between ethnic groups. A p value 50.05 was considered significant.
Results: Over 1 year IBD was diagnosed in 351 cases; 219 ulcerative colitis (UC),
107 Crohn’s disease (CD) and 26 Inflammatory bowel disease unclassified.
(IBDU). Collective crude incidence rates were 15.54/100,000 for IBD, 9.69/
100,000 for UC, 4.80/100,000 for CD and 1.01/100,000 IBDU. (Table 1) Crude
IBD incidence rates varied between populations: lowest was 6.81/100,000 in
Pennine, North Manchester and highest 26.11/100,000 in Leicester. Overall inci-
dence of UC was higher than CD (9.69/100,000 vs 4.80/100,000) and was con-
sistent for all populations except Pennine (3.31/100,000 for CD and 2.76/100,000
UC) Of the total number of IBD cases recruited 298/351 were coded as
Caucasian, Indian or Pakistani. IBD, UC and CD incidence was similar between
Pakistani and Caucasian groups. UC incidence was significantly higher in the
Indian population compared to Caucasians and Pakistanis (p5 0.001). Data for
disease phenotype was available for 160/219 patients with UC (24% E1, 42% E2
and 34% E3). There was no significant difference in disease extent between ethnic
groups.
Conclusion: The incidence rates for IBD in seven urban populations in England
are similar to recent data from Western Europe (IBD 18.5/100,000, UC 9.8/100/
000 CD 6.3/100,000 and IBDU 2.4/100,000). Ethnic-adjusted incidence rates
showed that Indians have higher incidence of UC than Caucasians and
Pakistanis with highest observed incidence in Northwest London. These findings
are consistent with previous data suggesting that Indians have a higher predis-
position for UC. Genetic, environmental and dietary factors may be responsible
for differences and further analyses are underway. Better understanding of the
susceptibility of Indians to UC may lead to the underlying cause of UC.
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Abstract: P1633. Table 1: Incidence rates per 100 000 for inflammatory bowel disease, Crohn’s disease, ulcerative colitis and inflammatory bowel disease unclassified
in England for patients aged 16 years or older in 2016/17. CD, Crohn s disease; IBD, inflammatory bowel disease; IBDU, IBD unclassified; UC, ulcerative colitis.
Population
Background population
No. of cases IBD crude CD crude UC crude IBDU crudeCauc Ind Pak
Birmingham, University Hospital 520,986 52,491 92,047 31 13.03 4.46 7.48 1.09
Birmingham, Heart of England NHS Trust 70
Birmingham, Sandwell 18
Leicester 137,910 74,098 5,584 86 26.11 7.59 15.79 2.42
London, Brent and Harrow 170,540 103,417 16,632 78 17.74 3.64 13.42 0.64
North Manchester, Pennine NHS Trust 445,293 3,475 37,565 40 6.81 3.31 2.76 0.92
Wolverhampton 141,044 25,370 2,719 28 14.0 5.0 9.0 0.0
All centres 1,415,773 258,851 154,747 351 15.54 (95% CI, 8.42) 4.80 (95% CI,1.90) 9.69 (95% CI,5.55) 1.01 (95% CI, 0.89)
Incidence by Ethnicity
Caucasian 210 14.83 5.58 8.26 0.99
Indian 62 26.22 5.07 19.45 1.69
Pakistani 26 14.67 5.64 7.33 1.69
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Introduction: Inflammatory bowel diseases (IBD-Crohn’s disease (CD); ulcerative
colitis (UC)) are lifelong inflammatory conditions of the gastrointestinal tract.
IBD-associated colorectal cancer (CRC) accounts for approximately 1–2% of all
cases of CRC. Although data on mortality rates in IBD patients are controver-
sial, CRC has been shown to account for approximately 10–15% of all deaths
among IBD patients. The aim of our nationwide registry was to prospectively
collect IBD-related mortalities and all types of malignancies diagnosed in the
Hungarian IBD population.
Aims & Methods: Data on all death and malignancies developed between 2015
and 2016 in IBD patients were recorded. Each members of the Hungarian Society
of Gastroenterology were prospectively interviewed 3 monthly by personal emails
to report both death and malignancies observed in their patient population.
Demographic and clinical data including previous immunosuppressive and bio-
logical therapy were also collected.
Results: Fifty-five newly diagnosed malignancies were reported (mean age: 49.3
years old, mean disease duration was 16.9 years; male/female ratio was 34/21): 30
CRC (mean age: 52.5 years, mean disease duration: 19.9 years, male/female ratio
was 22/8) one of them had 1 pouch cancer previously colectomized because of
sigmoid tumor, 4 skin, 3 lung, 2 breast, 2 cervix, 2 pancreas, 2 liver, 1 gallbladder,
1 prostate, 1 esophageal, 1 salivary gland, 1 thyroid, 1 central nervous system, 1
tonsil, laryngeal cancer, 1 B-cell lymphoma and 1 retroperitoneal sarcoma
throughout the examined period. Twenty-two of the 30 CRC cases were asso-
ciated with UC, 60% with pancolitis. Twenty of the 30 cases were located on the
rectosigmoid region, 2 had multiple localization. Nineteen deaths were reported
during the examined period. Ten fatal cases were related to IBD (6 males 4
females; 1 CD patient with rectal cancer, 1 patient with pouch cancer, 1 CD
patient with pancreas, 1 CD patient with interstitial pneumonia, 1 UC and 2
CD patients with septic complications, 1 UC patient with meningitis, 1 UC
patient with hemorrhagic shock, 1 CD patient with intestinal perforation). Age
of death was significantly lower in case of IBD-related mortality compared to the
other patients and general population (51.9 vs. 65 vs. 73.4 (data from Central
Statistical Office 2013, Hungary) years, p5 0.05). Immunosuppressive and/or
biological therapy was ever given for 4/10 patients with IBD-related mortality.
Conclusion: The most frequently observed IBD-related malignancy is CRC,
which can be multifocal and mainly involved the distal part of the colorectum
typically in UC patients with pancolitis and chronic activity. Malignancy and
septic complications were the leader causes of IBD-related mortality character-
ized by earlier death than in the rest and in the non-IBD population.
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University, Besançon/France
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Introduction: The increasing incidence of anal canal (AC) carcinomas in men and
women requires better knowledge on Human papillomavirus (HPV) infection at
this site and its risk factors. Higher incidence of AC cancers in Crohn’s disease
(CD) patients is strongly suggested in the literature, without knowledge on HPV
involvement. A gastroenterology population offers the opportunity to study a
mixed and non-sexually at risk selected population and to study anal HPV infec-
tion in CD patients.
Aims & Methods: The aim of the study was to assess AC HPV infection preva-
lence and its risk factors in a gastroenterology population. The ‘Human
PAPILLomavirus ANal infection’ - PAPILLAN- study took place in a French
university hospital gastroenterology unit. Consecutive patients were prospec-
tively recruited at the occasion of a colonoscopy, whatever the indication. On
the colonoscopy day, under general anesthesia, AC smear was sampled with a
dedicated brush for molecular analysis. HPV detection and genotyping was per-
formed with the INNO-LiPA assay. Risk factors for any HPV, and high risk
(HR) HPV infection were assessed by bivariate and multivariate analysis after
logistic regression.
Results: A total of 469 consecutive patients (median age 54 years, 52% women)
had suitable anal samplings for HPV DNA detection. Among them 101 had
inflammatory bowel disease (IBD), 70 had CD. 112 patients had at least one
immunosuppressive treatment for IBD or another condition. Overall 34% of the
population had a detection of any HPV type in AC smears. HR HPV prevalence
was 18%, LR HPV prevalence was 9% and HPV16 prevalence was 7%. Most
prevalent HR HPV types were, by decreasing order: HPV16, HPV51, HPV52 and
HPV39. Among all patients with HPV positive or HR HPV positive samples,
65.6% and 65.9% were women, respectively (p5 0.0001; p¼ 0.0035, compared
to men). Regarding medical history, HR HPV and HPV16 prevalence were sig-
nificantly higher in Crohn’s disease patients (30%, p¼ 0.0051; 14%, p¼ 0.0072,
compared to the rest of the study population). Eleven/12 patients (50%) with
perianal CD had an AC infection with any HPV. Multivariable analysis asso-
ciated female gender and history of sexually transmitted disease with the presence
of any HPV in AC; and female gender, history of sexually transmitted disease,
lifetime and past year number of sexual partners, active smoking and immuno-
suppressive treatment (OR 5.3) with the presence of HR HPV.
Conclusion: We demonstrated that CD patients harbor more frequent AC infec-
tion with HR HPVs and that immunosuppressive treatment is an independent
factor for HR HPV infection at this site. These findings strongly support pro-
phylaxis with vaccination and adequate screening in our patients.
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Introduction: Extended spectrum beta-lactamase producing Enterobacteria
(ESBL-E) are the most frequently found multi-drug resistant bacteria colonizing
the gut of inflammatory bowel disease (IBD) patients.1 Changes in the micro-
biome may act as a trigger in IBD inflammation process.
Aims & Methods: The aim of the study was to analyze whether gut colonization
with ESBL producing Enterobacteria is associated with clinically relevant disease
activity increase in ulcerative colitis (UC) and in Crohn’s disease (CD). All con-
secutive patients with confirmed UC and CD diagnosis, previously hospitalized
in two largest tertiary medical care centres in Riga, Latvia during a 7-year period
(2010–2016) were included in the study, interviewed, rectal swabs were collected,
Enterobacteria were cultured and analyzed for ESBL presence according to
EUCAST guidelines. To clinically evaluate disease activity UC patients were
evaluated according to Mayo score, Montreal classification, adapted Truelove
and Witt’s criteria and CD patients according to Crohn’s disease activity index
(CDAI), suggested by ECCO IBD guidelines (2016).
Results: A total of 101 patients with UC and 47 patients with CD were tested for
gut colonization with ESBL-E. We found that 12 (11.9%) of the UC patients and
5 (10.6%) of the CD patients were colonized with ESBL-E. Statistically signifi-
cant differences were found in all UC clinical disease activity scores between
patients with and without gut colonization with ESBL-E and showed tendency
towards statistical significance in CD. The mean disease activity according to
Mayo score in UC patients without ESBL-E colonization was 3.44 (SD¼ 2.07),
whereas in patients with ESBL-E colonization it was 5.08 (SD¼ 2.84) (p¼ 0.015).
Most of the UC patients without ESBL-E colonization (n¼ 63; 70.8%) were in
clinical remission, whereas half of the patients with ESBL-E colonization (n¼ 6;
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50%) had mild to moderate to severe disease activity, according to Montreal
classification disease severity section (p¼ 0.037). Most of the UC patients with-
out ESBL-E colonization (n¼ 81; 91%) had mild disease activity, whereas half of
the patients with ESBL-E colonization (n¼ 6; 50%) had moderate disease activ-
ity, according to modified Truelove and Witt’s criteria (p5 0.001). Most of the
CD patients without ESBL-E colonization (n¼ 38; 90%) had moderate disease
activity, whereas most of the patients with ESBL-E colonization (n¼ 3; 60%)
had severe disease activity, according to CDAI (p¼ 0.05).
Conclusion: Gut colonization with ESBL-E might increase disease activity in out-
patients with IBD. Such finding could be clinically relevant and help to improve
diagnostic and treatment protocols for IBD patients, because eradication of
ESBL producing bacteria might reduce IBD disease activity.
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Introduction: Smoking has a differential effect on inflammatory bowels diseases
(IBD); deleterious for Crohn’s disease (CD) and protective for ulcerative colitis
(UC). Thickness of the mucus layer, immune system (cytokines production),
microvasculature and intestinal microbiome are potential mechanistic factors
influenced by the nictoine and numerous other substances. It has been hypothes-
tized that smoking cessation is associated with the second peak of diagnosis in
UC patients after 50 years old. Our aim was to confirm this hypothesis using data
on smoking status at IBD diagnosis.
Aims & Methods: Adult IBD patients included in the Swiss IBD cohort from
November 2006 to November 2015 were asked about their smoking status at
diagnosis. We compared the proportion of former smokers in 10-year groups of
UC and CD patients.
Results: 2361 IBD patients (1366 CD, 995 UC) were included in the analysis.
Among them 52% of CD ans 24% of UC patients were smokers at diagnosis
(proportion of smokers in Switzerland (2014): 29%). The higher proportion
(66%) of former smokers at diagnosis was in the 50 to 60 years old group of
UC patients compared to only 26% in CD patients between 40 to 50 years old
(p5 0.001). On a gender basis, the higher proportion of former smokers is
particularly significant high among male 50–60 years old with UC (68%) and
persists among them over 60 years old (52%).
Conclusion: The proportion of former smokers at diagnosis increases dramati-
cally and significantly over years in UC patients compared to CD patients. A
peak was reached over 50 years old suggesting an indirect impact of smoking
cessation on the second peak of diagnosis in ulcerative colitis.
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Introduction: In aetiology of inflammatory bowel disease (IBD) role of micro-
organisms including those from the oral cavity is taken into account. Oral bac-
teria are known for biofilm formation and enamel demineralisation leading to the
formation of caries cavities.
Aims & Methods: The aim of the study was to determine the state of hard teeth
tissues measured by DMFT index in adult patients with ulcerative colitis (UC)
and Crohn’s disease (CD). The study involved 119 UC and CD patients aged
from 18 to 72 (mean 34.45). Disease phenotype at diagnosis was classified
according to the Montreal classification and only the patients who had con-
ducted a complete diagnostic workup of the entire gastrointestinal tract were
included. Following, the data on the occurrence of extraintestinal symptoms,
the incidence of IBD in the family, type of treatment, including surgery, were
also collected. The complete assessment of the hard teeth tissues based on the
DMFT index (decayed, missing, filled teeth) was performed.
Results: The study population was characterized by a high DMFT index with
mean value 19.35. There was a significantly higher number of filled (F) and lower
number of lost teeth (M) among patients who underwent respective surgery.
Noticed incidence of IBD in the family was similar in both groups of patients.
Type of treatment has no significant impact on DMFT index values. There were
no statistically significant differences between UC and CD group in DMFT
index, M and F values. However, it has been found that these groups differ in
D values which averaged 4,5 and 3,2 for CD and UC groups (p5 0.05). The
analysis of both patients’ groups with regard to gender showed statistically sig-
nificant differences in D and F values. The lowest mean D value was noticed in
UC females group (2,8) and the highest in CD males (5,2); average F values were
opposite–11,4 for UC females and 7,8 for CD males. Statistical analysis of
DMFT index among patient from CD and UC groups according to disease
phenotype showed no significant differences in DMFT, D and M in both
groups. Average DMFT varied from 18.14 for L1 to 20.50 for L4 patients in
CD group and from 17.30 for E1 to 20.55 for E2 in UC group. However, sig-
nificant difference in F values was observed in CD patients: L1 and L2 have
lower average F than those with L3 and L4 (6.66, 7.46, 10.25 and 14.00 respec-
tively; p¼ 0.0215). D values were significantly higher for patients with none or
one extraintestinal symptoms (p5 0.05). Results of D values obtained in our
study were higher than for healthy population aged 35–44 in Poland (mean
D 2).
Conclusion: The results of preliminary POLIBD study among two groups of IBD
patients showed similar values in DMFT index and higher average number of
carious teeth in CD patients, especially in men.
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Introduction: Crohn’s disease (CD) is a chronic inflammatory disease that can
affect any section of the gastrointestinal tract. Malnutrition is a common sequel
in these patients and many pathogenic mechanisms could be involved such as
poor dietary intake, altered energy expenditure, nutrient malabsorption and/or
losses.
Aims & Methods: This cross-sectional study aimed to evaluate the resting energy
expenditure (REE) in CD patients, in accordance with clinical status of disease,
compared to a control group.
Methods: All consecutive adult CD women were prospectively enrolled, while a
group of healthy women, matched for age and weight, served as control group
(C). CD women were classified in clinically active disease (CD-A) and clinical
remission (CD-R) according to Crohn’s Disease Activity Index (CDAI) (4150
and 5150, respectively). All subjects underwent REE measure by indirect calori-
metry with a canopy system, while body composition variables, such as fat-free
mass (FFM) and fat mass (FM), were assessed by bio-impedance analysis (BIA).
Results: Finally, forty-two women with CD, 23 with clinically active disease (CD-
A; CDAI¼ 219 53) and 19 in clinical remission (CD-R; CDAI¼ 83 41) were
recruited for the study, while 40 matched-healthy women were enrolled as control
group (C). We found that body weight, FFM and phase angle (PA) differed
among groups; but age, height and FM did not. Post-hoc analysis revealed
that body weight was significantly lower for CD-A in comparison with C (CD-
A: 55.7 9.23 kg vs C: 64.5 6.3 kg; p¼ 0.02). FFM was reduced in women with
CD than C (CD-A: 39.6 4.32 kg and CD-R: 39.5 6.68 kg vs C: 44.4 4.68 kg;
p5 0.01) while PA was lower for CD-A compared to both CD-R and C (CD-A:
5.5 0.6 vs CD-R: 6.0 0.5 and C: 6.1 0.5; p5 0.001). REE did not differ
among groups; nevertheless when it was adjusted for FFM, we observed that
REE/FFM increased for both CD-A and CD-R groups compared to C (CD-A:
35.9 4.17 kcal/kg, CD-R: 35.1 4.96 kcal/kg vs C: 30.2 3.38 kcal/kg;
p5 0.01).
Conclusion: These preliminary results show that REE, when adjusted for FFM, is
increased in women with CD, unrelated to disease activity, compared to healthy
subjects and this could negatively affect the energy balance and contribute to
weight loss.
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Introduction: Primary sclerosing cholangitis (PSC) is a rare and devastating com-
plication of inflammatory bowel disease (IBD). There is no standard for the
screening of primary sclerosing cholangitis (PSC) in patients with IBD.
Magnetic resonance cholangiography (MRC) may replace liver biopsy in this
clinical situation. The main objective of this prospective observational study
was to assess the frequency of MRC-detected liver diseases, including PSC, in
adult IBD patients with liver function abnormalities and to identify clinical and
biological characteristics associated with these findings.
Aims & Methods: From June 1, 2009 to January 31, 2017, 421 patients were
included and screened with MRC: cohort 1 included 206 IBD patients with
liver abnormalities; cohort 2 included 28 IBD patients without liver abnormal-
ities; and cohort 3 included 187 non-IBD patients with liver abnormalities. Two
senior radiologists independently evaluated MRC findings.
Results: MRC abnormalities were observed in 18% of patients in the cohort 1;
3.6% in the cohort 2; and 31% in the cohort 3 (Table 1). Based on MRC, we
found respectively 11.2%, 0%, and 7% of PSC in cohorts 1, 2, and 3. 29.2% of
IBD patients with liver abnormalities had infra-clinical PSC. A history of intest-
inal resection (P¼ .0357), abnormal gamma-glutamyl transferase values
(P¼ .0064), and abnormal alkaline phosphatase values (P¼ 0.021) were signifi-
cantly associated to suspected PSC.
Table 1: MRC abnormalities in cohorts 1, 2 and 3
Results of
MRC Total Normal Ductopenia Doubt PSC Others
Cohort 1 206 150 (72.8%) 28 (13.6%) 9 (4.4%) 23 (11.2%) 0
Cohort 2 28 27 (96.4%) 1 (3.6%) 0 0 0
Cohort 3 187 116 (62.0%) 0 0 13 (7.0%) 58 (31.0%)
Conclusion: Using MRC in patients with IBD, we found a higher prevalence of
PSC than based on clinical symptoms. Systematic screening for PSC using MRC
could be recommended in routine practice for IBD patients.
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Introduction: TCUC is a comprehensive real-time web-based programme for
patients with UC. It monitors multiple parameters via electronic questionnaires:
symptoms, quality of life (QoL), outcomes (eg emergency department visits) and
demographics. Medications are entered and personalised treatment guidance
formulated. This information, graphically displayed on a traffic light system, is
available to the patient and clinical team via the TCUC website, which is housed
on a secure National Health Service server.
Aims & Methods: A prospective, non-randomised 6-month pilot study recruited
patients from the Oxford Inflammatory Bowel Disease service. The aims were to
assess feasibility, usability and adherence. Recruitment rate (number recruited/
expression of interest) and retention rates were calculated. At registration, ques-
tionnaires were scheduled either daily (simple clinical colitis activity index,
SCCAI), fortnightly (QoL, IBD-Control-8, CUCQ-8 and EQ5D-5L), or once
only (outcomes,). Patients then received email prompts linked to scheduled ques-
tionnaires. Monthly home IBDoc faecal calprotectin (FCal) measurements were
incorporated, monthly blood tests collected and flexible sigmoidoscopy per-
formed at entry and after 6 months. Adherence to all questionnaires and samples
was calculated. Usability was assessed via the System Usability Scale (SUS)
(n¼ 59) and qualitative interviews (n¼ 28). SUS broadly classifies usability of
a system from poor (570) to superior (490). A deductive approach was used for
the qualitative coding and analysis.
Results: Sixty-six patients were recruited (recruitment rate 66/240 invitations
delivered, 28%). Of 66 patients, 29 (44%) were male, median age 40.7 yrs
(IQR 17.0, range 18–65), median duration of disease 5.6 years (IQR 10.7,
range 0–30), distribution of disease (E1 18%, E2 38%, E3 33%, unknown
11%), activity of disease at entry (remission 38%, mild 35%, moderate 26%,
severe 1%), tertiary education 58%, biologic use 47%. Retention rate 57/66,
(86%). Main reason for withdrawal (5/9, 55%) was the need for sigmoidoscopy
and monthly blood tests during the trial.
Table 1: Adherence to Questionnaires
Questionnaires
Adherence
over
6 months
First
3 months
Last
3 months
Daily symptom (SCCAI) questionnaire 76% 81% 72%
Fortnightly QoL questionnaires
(IBD-Control 8, CUCQ8 and EQ-5D)
95% 96% 94%
Once only demographic and
outcome questionnaires
100% 100% 100%
Uptake of FCal home testing was 73% (48/66), median tests 4 (IQR 3, range 1–
6). Median SUS score was 92.5 (IQR 15, range 45–100) which corresponds to a
‘superior product’. Qualitative interviews confirmed that TCUC was efficient,
effective, easy to learn and well liked. Improvements suggested included optimi-
sation of the graphical display on smartphones and decreasing the number of
QoL questionnaires from three to one, with a preference for IBD-Control.
Conclusion: Patients with UC will collect digital data in real-time, with good
adherence to symptom, QoL, outcome questionnaires and FCal home testing.
Usability was classified as ‘superior’ but further improvements are possible.
Larger studies are required to determine cost effectiveness.
Disclosure of Interest: A. Walsh: An unrestricted educational grant from Abbvie
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Introduction: Malnutrition and altered body composition can develop in patients
with inflammatory bowel diseases (IBD) for a variety of reasons. Malnutrition
and sarcopenia may worsen disease outcome in chronic disorders, raise the risk
of infections and hospitalisation.
Aims & Methods: We followed 198 IBD outpatients (144 CD and 54 UC) for 3
years to indetify potentional risk factors of unfavourable disease outcome.
Baseline body composition were measured by bioelectrical impedance analysing
(BIA) method to evaluate nutritional status. Penalized logistic regression was
used for the multivariate modelling of the outcome, with two sets of - prespecified
- predictor variables age, sex, CU/CD, BMI, FFMI.
Results: According to our results 19.2% of the patients (n¼ 38) were underweight
(had BMI5 18.5 kg/m2) and 29.8% (n¼ 59) had alarming low fat-free mass
index (FFMI) and were at risk of sarcopenia. Overall 31.5% (n¼ 62) of the
patients needed steroid therapy and 53.5% (n¼ 106) was given anti-TNF.
Almost third of the participant (30.8%, n¼ 61) were hospitalized due to disease
flair or its complication at least once during the follow-up time. The mean period
of hospitalization was 19.14 32.7 days. 20.2% (n¼ 40%) of all participants
have undergone intestinal surgery. Hospitalization was positively associated
with sarcopenia risk: alarming low FFMI was associated with an OR of 1.81
(95% CI: 1.03–3.20, p¼ 0.04060). The risk of operation was higher in patients
with lower BMI: OR¼ 1.55 (95% CI: 1.05–2.29, p¼ 0.02778) for 5 units
decrease; no other association was significant in the models.
Conclusion: Our results suggests that low BMI is a risk factor of surgery in
inflammatory bowel disease patients. Furthermore alarming low FFMI is a pre-
dictor of need of hospitalization and that suggets more serious flares.
Identification of malnutrition and altered body composition has notable impor-
tance in disease outcome among IBD patients.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: The majority of Crohn’s disease (CD) develop stricturing complica-
tions of the disease at some point. The proper selection of patients with potential
benefit of therapy escalation is crucial in order to avoid unnecessary bowel
damage. Rapid contrast uptake in the affected bowel segment at intravenous
contrast-enhanced ultrasound (CEUS) has been shown to correlate with disease
activity but there are no data available on the benefit of CEUS for the thera-
peutic decision making in this clinical setting.
Aims & Methods: The aim of the study was to evaluate the clinical outcomes of
CD patients with stricturing disease managed based on the CEUS findings. CD
patients with stricturing disease were recruited from two IBD centra between
June 2015 and February 2017. Patients with penetrating disease complications
were excluded. CEUS was performed using 2.4mL of intravenous contrast
(SonoVue, Bracco Imaging). Patients having rapid uptake (within 20 second
after injection) were indicated for therapy escalation, patients without uptake
with obstructive symptoms were referred for surgery; patients without uptake
and no obstructive symptoms remained at the stable medication. In patients with
the minimal follow-up of one year clinical and endoscopic remission was
evaluated.
Results: In total, 27 patients were included (10 men; median age 37 yrs, range 23–
67; 22 pts with ileo-coecal localization, 3 pts with multiple small bowel segments
involvement, 2 with colonic disease). Seventeen patients (63%) had rapid uptake
at the CEUS; 13 of these patients had therapy escalation (3 pts intensification or
switch of another biological; 10 pts had therapy step-up to antiTNF or immu-
nosuppression). Remaining three pts improved subsequently on stable therapy
with antiTNF and one patient with longstanding symptomatic colonic stricture
was referred for surgery. Ten patients (37%) had no rapid uptake at the CEUS;
seven out of these patients had symptomatic stricturing disease and were referred
for surgery. Three patients had no symptoms and no therapeutic changes were
made. Twenty-five patients had follow-up longer than 12 months (median 18
months, range 13–23). In the group of patients with rapid uptake, all but two
patients achieved sustained remission after therapy escalation. Two patients initi-
ally responded to therapy but have lost response and eventually needed surgery.
In the group with no rapid uptake, patients without surgery remained in remis-
sion without any changes in the medication. Patients who underwent surgery in
this group had no changes in therapy after surgery and none of these patients had
recurrence at the surveillance colonoscopy at 12 months.
Conclusion: Contrast-enhanced ultrasound might be helpful in guiding the ther-
apeutic decision making between surgery and therapy intensification in patients
with stricturing Crohn‘s disease.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Inflammatory bowel disease (IBD) commonly affects patients
during their reproductive years, making the interaction between fertility, preg-
nancy, and IBD an important issue for both genders. As these are the reproduc-
tive years, patients and physicians often have concerns regarding the interaction
between IBD, medications and surgery used to treat IBD, and reproduction,
pregnancy outcomes, and neonatal outcomes.
Aims & Methods: We aimed to determine IBD patient’s reproductive behaviour
and evaluate the factors that affect fear of family planning. Finally we investi-
gated the correlation of disease activity and pregnancy outcome. 207 patients
from our IBD population (142 with Crohn’s disease, 65 with ulcerative colitis)
were reviewed by personal questionnaires.
Results: In all, 53% of participants were female (the mean age was 31.9 years with
mean duration of disease activity of 10.7 years). 47% of patients were male, (the
mean age was 32.5 years with disease duration of 10.2 years). 62 patients (32
female and 30 male) have children (39 and 42) after diagnosing IBD (mean age of
childbearing was 30 years. 81% of reviewed female and 79% of male patients
plan to have more children, although approximately one-third of patients (33%
of female and 29% of male patients) reported having fewer children than planned
up till now secondary to disease activity, surgical and ongoing medical treat-
ments. The main patient-related reasons for ‘‘voluntary infertility’’ were fear of
congenital abnormality secondary to medications of IBD (68%) and concern
about genetic risk of IBD in child (56%). 50% of male and 75% of female
patients got adequate information and education from conception do delivery.
Pregnancy was planned in 77% of cases, the childbearing and delivery was with-
out any complication. Prematurity and low birth weight occurred in 6–6 cases
(10%-10%). IBD was in remission in most cases, during pregnancy 25% of the
patients had flare. 40% of women could breastfeed their baby after 6 months.
Conclusion: The management of IBD in women during their reproductive years
should include consideration of their family planning decisions, and education
counseling regarding the overall safety of medications and the importance of
medication adherence should occur prior to conception. Disease control prior
to desired conception and throughout pregnancy is the most important factor to
keep in mind when caring for the IBD patients. Educating the patients will help
to achieve successful outcomes both for patients and babies.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Crohn’s disease (CD) is a chronic inflammatory bowel disease
whose diagnostic delay (DD) is highly variable. A delay in diagnosis of MC
may be detrimental to the patient, delaying appropriate therapeutic management.
Factors Influencing SD may be a function of the country’s health system, but
also linked to the particular clinical and evolutionary profile of the disease. The
objective of this study was to measure the DD of CD, to describe its distribution
and evolution over time and to The factors associated with a long DD (4Q3).
Aims & Methods: All patients with certain or probable CD between 2004 and
2016 identified by The department’s inflammatory disease hospital registry was
included. The socio-demographic characteristics collected included: the patient’s
residential area at the time of diagnosis in urban, rural or semi-urban, distance
from the nearest hospital (CH). Clinical symptoms and phenotype of CD to
diagnosis according to the Montreal classification were collected
Results: Among 247 patients with CD; 90 had a median SD of 03 months. A DD
 7 months was considered a diagnostic delay observed in most patients is 157. In
univariate and multivariate analysis at diagnosis, the female sex (54.25%), young
age (37.24%), absence of emaciation (27%), presence of extra-digestive manifes-
tations (25.91%) and Isolated lesions (L1) (34%) and penetrating phenotype (B3)
(22.67%) were associated with anopenial lesions (27.12%). Diagnostic delay.
Socio-demographic characteristics were not associated with delayed diagnosis.
Conclusion: This study shows that most of the patients, 63.56% have a diagnostic
delay significantly associated with the female sex, The young age, the absence of
weight loss and a localization of the disease limited to the hail the penetrating
phenotype of disease. No socioeconomic variables or reflective of access to care
were found to influence.
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Introduction: Tumour necrosis factor alpha antagonist (anti-TNF) has revolu-
tionized the treatment of the inflammatory bowel disease (IBD). Considering
that it plays a central role in immune-mediated modulation, there are some
obvious concerns about safety. There is evidence that it increases the risk of
opportunistic infections such as tuberculosis, particularly latent infection reacti-
vation. Due to global high incidence of tuberculosis and its commonly severity in
immunocompromised patients (extrapulmonary and disseminated pattern), the
exclusion of latent tuberculosis (LT) infection is currently part of the screening
prior to starting biologic therapy. Despite negative screening, the risk of tuber-
culosis infection remains active during the immunomodulation therapy.
However, only a few cases of life-threatening disseminated tuberculosis have
been reported in immunocompromised patients probably related to the increased
use of higher accuracy screening tests, such as interferon-gamma release assays
(IGRA). Negative screening cases with IGRA are not described.
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Aims & Methods: We intend to know the incidence of tuberculosis in IBD
patients under anti-TNF therapy in a single tertiary referral centre, analyzing
the tuberculosis screening methods and demographic characteristics. IBD
patients treated with anti-TNF therapy between January 2000 and December
2016 were retrospectively analyzed.
Results:During this period 166 patients received anti-TNF therapy. Before anti-
TNF treatment, screening for LT was performed through medical history, chest
X-ray, tuberculin skin test (TST) and/or IGRA. Forty-two patients (25%) had
positive screening and received tuberculosis prophylaxis prior anti-TNF ther-
apy. Seven patients (4.2%) developed tuberculosis while under anti-TNF treat-
ment (four women, mean age 44 þ/ 7 years and mean IBD duration 10 þ/ 8
years). Six of them had a negative LT screening (methods: 4 TST and 2 IGRA)
and one patient had positive TST screening, been treated with isoniazid before
starting anti-TNF therapy. During screening three patients were under immu-
nosuppressive and one under corticosteroid therapy. In the IGRA negative
screening patients, the diagnosis of tuberculosis occurred within the first 10
weeks after starting anti-TNF. There were five cases of miliary tuberculosis
and two of pulmonary disease. Despite difficult diagnosis, all patients were trea-
ted successfully, six of whom needed hospitalization.
Conclusion: In our centre the incidence of tuberculosis in IBD patients under
anti-TNF therapy was 4.2% and most of them presenting with a severe disease
pattern. The therapeutic regime of tuberculosis was effective and no mortality
was recorded. All this patient had a previously negative screening, two of them
with IGRA, been considered a high sensitivity and specificity screening method.
Therefore, a surveillance strategy for IBD patients with anti-TNF therapy is
needed.
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Introduction: The MediCrohn study was designed to evaluate the level of agree-
ment between the Harvey Bradshaw Index (HBI) translated into a patient-based
questionnaire completed through a mobile app, and the original HBI question-
naire assessed by the clinician (considered as reference).
Aims & Methods: Patients completed the HBI score through a mobile app
designed for both Android and iPhone devices and thereafter (548 h later),
the questionnaire was completed onsite by the gastroenterologist who was
blinded for the patients’ responses. We assessed agreement between HBI scores
of the clinician and patient on the total sum score and per item. HBI score 55
was considered as inactive disease.
Results: 135 patients participated in the study and completed the HBI trough a
mobile app (mean age: 36 8 years, 58% women). The proportion of agreement
between clinician and patient assessment, both evaluating CD as active or in
remission was 91.1%. Only in 12 cases (11%), the patient classified CD as
active, whereas the physician evaluated it as inactive. No active cases remained
undetected by the patient evaluation. Sensitivity, specificity, positive and negative
predictive values are shown in Table. The highest agreement was seen for the
questions: ‘‘abdominal mass’’ and ‘‘general well-being’’ whereas ‘‘number of
liquid stools per day’’ was the item with the lowest agreement.
Patient Rate
Clinician
Assessment
Clinician
Assessment Total
Active Remission
Active 26 12 38
Remission 0 97 97
Total 26 109 135
Sensitivity (%) Specificity (%) PPV(%) NPV (%) Agreement
100 89 68 100 91.1% CI(95%)
Conclusion: The HBI score self-administered by the patient through a mobile app
resulted in a high percentage of agreement with the gastroenterologist evaluation,
and high negative predictive value for disease activity. Results of the MediCrohn
study encourage the use of this mobile app and gives some hints on its conditions
of use as a support for the involvement of patients in the management of their
disease. Future studies will help to define its precise role in clinical practice.
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Introduction: Histological remission (HR) has become an important treatment
target in ulcerative colitis (UC). However, limited data exist on reliability of
histological scoring in daily practice, when it comes to assess minor histological
abnormalities. We investigated the reproducibility and reliability of UC histolo-
gical scores in colonic biopsies assessed as HR by a general pathologist in daily
practice. Next, we investigated correlations between the initial histological assess-
ment and the expert review by expert gastrointestinal (GI)-pathologists.
Aims & Methods: We performed a retrospective single-centre study in a tertiary
IBD referral centre. Colonic biopsies of UC patients with mucosal healing (MH)
throughout the examined colon were included. All biopsies were re-assessed by
three blinded GI-pathologists using three histological scoring indexes (Geboes
score (GS), Riley score (RS), Harpaz (Gupta) Index (HGI)) and a global visual
scale (GVS). We evaluated inter- and intraobserver variation and correlations
between scores and initial histological assessment using Cronbach’s alpha and
Spearman’s rho analysis.
Results: We included 270 biopsies from 39 UC patients. The interobserver con-
cordance for all histological indexes was substantial to almost perfect (GS 0.84;
RS 0.91, HGI 0.61GVS 0.74). The correlation between the RS and GS was
almost perfect (R¼ 0.86), but no correlation was found between the primary
histological assessment and the GS (0.00), the RS (0.01), the HGI (0.03) and
the GVS (0.04) as scored by expert GI-pathologists.
Conclusion: Available histological scores for UC are reliable with strong mutual
correlations in case of limited histological abnormalities. However, the discre-
pancy between daily practice histological assessment and dedicated GI-patholo-
gists is significant and this may have important implications for the selection
process of a unified histological disease activity score in UC.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Current endoscopic activity scores for Ulcerative Colitis (UC) do
not take into account the extent of mucosal inflammation. Recently, two endo-
scopic scores that combine the assessment of severity and disease extension were
developed, the Modified Mayo Endoscopic Score (MMES)1 and Degree of
Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN)2.
Aims & Methods: We aimed to evaluate the relation of the scores with disease
activity and as predictive factors of clinical relapse. Patients with UC in clinical
remission (partial Mayo score [pMS] 1) who underwent colonoscopy between
January/2010 and December/2013 were included. MMES and DUBLIN scores
were calculated. Analytical and histological activity (defined by Geboes score
3.1 and Nancy score¼ 2–4) as well as predictive factors of relapse and
relapse-free time were evaluated. Relapse was defined as pMS 2, therapy to
induce remission, hospitalization and/or colectomy.
Results: 82 patients were selected, 51.2% (n¼ 42) female, mean age¼ 49.4 13.7
years. MMES ranged between 0–13.8 and DUBLIN between 0–9. MMES and
DUBLIN scores presented good correlation (r¼ 0.945, p5 0.001). MMES was
higher in patients with histological activity defined by Nancy (3.7 4.0 vs.
0.8 1.5; p5 0.001) and Geboes (4.0 4.2 vs. 1.3 2.4; p¼ 0.005). DUBLIN
was also higher in patients with histological activity defined by Nancy
(1.9 2.1 vs. 0.5 0.8; p¼ 0.001) and Geboes (2.0 2.3 vs. 0.7 1.2;
p¼ 0.008). There was no significant correlation between both scores and analy-
tical activity. Relapse occurred in 36.6% (n¼ 30) of patients, with a cumulative
risk of 9.8, 18.4, 25.9, 31.5 and 42.0% at 12, 24, 36, 48 and 60 months, respec-
tively. Mayo Endoscopic Subscore (MES) (p5 0.001), MMES (p5 0.001),
DUBLIN (p5 0.001), Geboes (p¼ 0.03) and Nancy scores (p¼ 0.001) presented
a significant association with relapse. In multivariate analysis, MES (OR¼ 2.32;
p5 0.001), MMES (OR¼ 1.19; p5 0.001) and DUBLIN (OR¼ 1.36; p5 0.001)
were predictive of relapse independently from histology. Areas under the ROC
curve were 0.71 (MES, p5 0.001), 0.75 (MMES, p5 0.001) and 0.74 (DUBLIN,
p¼ 0.001) for prediction of relapse, with MMES significantly higher than MES
by a difference of 0.037 (0.002–0.072); p¼ 0.03.
Conclusion: MMES and DUBLIN scores correlate with each other and with
histological activity and are independent predictors of relapse. MMES was super-
ior to MES in the prediction of relapse.
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Introduction: Magnetic resonance enterography (MRE) is an imaging technique
recomended to determinate and confirm the extension and activity of Crohńs
disease (CD) in the small bowel and discriminate penetrating disease and com-
plications. MRE diagnosis allows to optimize medical treatment in IBD patients.
Aims & Methods: The aim of this study is to evaluate the impact of MRE on
medical decision making in IBD patients and determinate the maintenance of this
new treatment along the time. Consecutive MRE studies performed in patients
with confirmed or suspected Crohn’s disease between January 2011 and August
2014 were included in three tertiary centers. Medical charts were retrospectively
reviewed. MRE indication, demographic and IBD data were collected at time of
MRE. Three months after MRE, medical decision (conservative approach with
maintenance therapy, significant change in medical therapy or surgery) was
assessed. After twelve months of follow-up, the treatment decided after MRE
was reviewed.
Results: A total of 474 MRE studies were performed and indications for MRE
were: assesment of small bowel involvement in 40 (8.3%) patients with indeter-
minate colitis (IC) and 20 (4.2%) with suspected-IBD patients or evaluation of
severity and extension of the disease in 414 (87.5%) CD patients (232 F; mean
age 37 13 years). Only 4 patients with suspected-IBD (4/20;20%) had involve-
ment of small bowel on MRE confirming the CD diagnosis. Twenty-one patients
with IC (21/40;52.5%) changed the diagnosis to CD. In 199/474 (40.5%) MRE
determinated a change on medical decision and 140 (70.3%) patients modified
maintenance treatment because of MRE findings. Of them, 127 (63.8%) under-
went ‘‘set-up’’ treatment by prescribing inmunosupressants (IS) (n¼ 45), anti-
TNF agents (n¼ 22), anti-TNF escalation (n¼ 8), adding IS to anti-TNF
agents (n¼ 9) and changing anti-TNF agents (n¼ 5). In addition, 13 (9.2%)
patients underwent ‘‘top-down’’ therapy due to stop IS (n¼ 7), anti-TNF
(n¼ 3) or anti-TNF de-escalation (n¼ 3). Surgery was indicated on 62 (62/
199;31,1%) patients after MRE. After one year of follow-up, the medical deci-
sion was maintained on 65.4% (288/440) of patients.
Conclusion: RE is a very helpful tool for the medical management of CD patients.
MRE provides major information to optimize treatment in the long-term of
patients with active CD.
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Introduction: Crohn’s disease (CD) is a chronic progressive destructive disease,
resulting in cumulative structural bowel damage, which may predict long-term
disability. The Lémann Index (LI) has been developed to measure CD-related
bowel damage, including bowel surgery, presence of stricturing and penetrating
lesions (Pariente and al, Gastroenterology 2015). The first Inflammatory Bowel
Disease - Disability Index (IBD-DI) has recently been validated (Gower-
Rousseau, Gut 2015).
Aims & Methods: The aim of the present study was (1) to identify factors asso-
ciated with bowel damage and with disability in CD and (2) to evaluate the
correlation between the LI and the IBD-DI. We performed a prospective study
in the tertiary referral center of the Claude Huriez Hospital in Lille, from
September 2016 to November 2016, including all consecutive CD outpatients.
Bowel damage was assessed by the LI calculated according to the published LI
protocol. Abdominal and pelvic Magnetic resonance imaging (MRI)s were
reviewed and red by the same couple of one gastroenterologist and one radiol-
ogist. The IBD-DI was also calculated for all patients. Factors associated with LI
and IBD-DI levels were identified by means of bivariate analyses of variance.
Results: 130 patients were prospectively and consecutively included. Median age
was 34.0 (interquartile range [IQR]: 26.0–46,0) and median disease duration was
10.0 (IQR: 5.0–17.0) years. 65 patients (50%) underwent at least one resection
surgery. The median LI was 10,8 (IQR: 0.6–17.5). Disease duration (p5 0.0001),
cumulated anal location (p5 0,0001) and CD activity (p5 0.0001) were asso-
ciated with higher LI scores. Median IBD-DI was 25,0 (IQR: 14,7–41,1). Female
gender (p¼ 0,02), CD activity (p5 0,0001)) and current anoperineal lesions
assessed by clinical examination and pelvic MRIs (p¼ 0.001) were associated
with higher IBD-DI scores. The correlation coefficient between the LI and the
IBD-DI was 0,12 (0,05, 0,29; p¼ 0,154).
Conclusion: In a large cohort of CD patients from a tertiary referral CD center,
disease duration, anal location and CD activity are associated with bowel
damage assessed by the LI, while female gender, disease activity and current
anoperinal lesions are associated with disability assessed by the IBD-DI.
Correlation between the LI and the IBD-DI was low.
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Introduction: The aetiology of Crohn’s disease (CD) and ulcerative colitis (UC) is
not known. Recent data suggest a different cytokine profile between CD and UC.
Aims & Methods: The aim of this study was to analyse the expression of mRNA
of proinflammatory, regulatory anti-inflammatory cytokines, chemokines and
their ligands (IL-6,-8,-10,-12, IL-23, TNF, CCR1,- 2–5.-9, IL-10,TLR2,-4,-5,
CD 207, 206), and transcription factor FoxP3 in the inflamed and non-inflamed
intestinal biopsy samples of mucosa in IBD patients. We performed a cross-
sectional study. The cohort consisted of 87 consecutive IBD patients (47 CD
and 40 UC) who underwent colonoscopy at the IBD centre of University
Hospital Bratislava. We took biopsies from non-inflamed and if present also
from inflamed mucosa from sigma (CD, UC) and terminal ileum (CD).
mRNA was extracted from mucosal biopsy samples, isolated by a RLT buffer
and reversely transcribed. We normalized the expression of the target genes to the
expression of the house-keeping gene (GAPDH). Finally, we compared the
expression of cytokines in inflamed and non-inflamed mucosa separately for
CD and UC patients.
Results: In UC patients, we observed higher expression of IL-8(p¼ 0.04), IL-23
(p¼ 0.019) TLR2 (p¼ 0.002), CCR1 (p¼ 0.007), CCR2 (p¼ 0.037), CCR5
(p 0.001), CD206 (p¼ 0.011), TNF (p¼ 0.002) and IL-6 (p¼ 0.006) in the
inflamed mucosa from sigma. In CD patients, we observed increased expression
of chemokines of CCR1 (p¼ 0.005) and IL-8 (p 0.001) in the inflamed mucosa
of a terminal ileum and decreased expression of CCL5. Also, in group of patients
with CD we did not observe the difference of the expression of mRNA cytokines
between the inflamed and non-inflamed mucosa of sigma.
Conclusion: There was a significant difference in the mRNA cytokine profiles
between CD and UC patients.
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Introduction: The various methods of disease monitoring for Crohn’s disease
(CD) are available however the quality of those methods differ. High accuracy,
low cost, patients-friendly and also physicians-friendly methods are needed.
Balloon-assisted enteroscopy (BAE) is labour-intensive method. However,
DBE enable a detail inspection and therapeutic capabilities, and could not be
substituted for any other modalities. The surgical intervention is one of the
poorest outcome in the disease history of CD patients. There is little knowledge
whether the monitoring of disease activity and the endoscopic intervention using
BAE contribute the preferable outcome of CD.
Aims & Methods: We conducted a retrospective single-centre cohort study to
elucidate whether the on-demand BAE and Endoscopic balloon dilation (EBD)
therapy leads to the decreasing of surgery rate for the small bowel and better
outcomes for CD patients. Double balloon endoscopy (DBE) examinations were
conducted when the attending physicians of each patients were needed. EBD
therapy was undergone at the stenosis where the endoscope could not pass and
was not contraindication regardless of the presence of symptoms. The 181 exam-
inations of DBE for 55 CD patients since 2004 were enrolled in this study. The
primary endpoint is the comparing the differences of surgical rates between using
endoscopic balloon dilation therapy and not. The secondary endpoints are cumu-
lative non-surgery rate of CD patients using DBE monitoring and EBD therapy
by Kaplan-Meier method.
Results: Subjects were 55 patients, genders were 9 females and 46 males, mean age
was 42 years old (SD, 13.0, median 44 range, 22–77). 50 (28%) antegrade, 131
(72%) retrograde DBE and 58 (32%) EBD therapy were undergone. EBD was
performed in 17 (31%, mean 3.4 times per patient) patients. In 17 patients who
underwent EBD therapy, only one (6%) patient underwent surgery after EBD
and the other 16 (94%) of patients did not undergo surgery during follow-up
periods (mean 1719 days). In 38 patients who did not undergo EBD therapy, 7
(18%) patients underwent surgery during the follow-up periods (mean 1659
days). The surgery rate of EBD group was approximately three times lower
than non-EBD group. Cumulative non-surgery rate of CD patients who were
monitored using DBE in on-demand manner were 85% in 3 years and 82% in
5years. These results may mean that non-EBD group consist of two major sub-
groups that one was the patients who had complex strictures that did not meet
the indication for EBD and the early surgery was needed, and the other was the
patients whose small bowel lesions were mild.
Conclusion: In patients who underwent EBD, the necessity for surgery was smal-
ler. Furthermore, in patients who underwent DBE monitoring, the cumulative
non-surgery rate was relatively higher than historical control. DBE may show the
future necessity for surgery and discriminate the necessity for the strict monitor-
ing from mild or moderate monitoring that leads to better quality of life for CD
patients. The scheduled monitoring using enteroscopy would be a further issue to
clarify.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
Hirai F, Beppu T, Takatsu N, Yano Y, Ninomiya K, Ono Y, Hisabe T, Matsui
T. Long-term outcome of endoscopic balloon dilation for small bowel strictures
in patients with Crohn’s disease. Dig Endosc. 2014 Jul;26(4):545–51. PMID:
24528293.
Sunada K, Shinozaki S, Nagayama M, Yano T, Takezawa T, Ino Y, Sakamoto
H, Miura Y, Hayashi Y, Sato H, Lefor AK, Yamamoto H. Long-term Outcomes
in Patients with Small Intestinal Strictures Secondary to Crohn’s Disease After
Double-balloon Endoscopy-assisted Balloon Dilation. Inflamm Bowel Dis. 2016
Feb;22(2):380–6. PMID: 26535767.
P1654 THE RELATIONSHIP OF NEUTROPHILIC AND
ENDOTHELIAL ACTIVITY MARKERS WITH THE DISEASE
ACTIVITY IN INFLAMMATORY BOWEL DISEASE
S. Boga
1, A.R. Koksal1, H. Alkim1, A. A. Ozagari2, I. Sen1, M. Sahin1,
C. Alkim1
1Gastroenterology, Sisli Hamidiye Etfal Education and Research Hospital,
Istanbul/Turkey
2Pathology, Sisli Hamidiye Etfal Education and Research Hospital, Istanbul/
Turkey
Contact E-mail Address: salihboga@yahoo.com
Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) is a protein that
is secreted by neutrophils in increased amounts in inflammatory disorders and its
level reflects neutrophilic activity. Endoglin is the receptor and modulator of
endothelial TGF-b and it is responsible for the endothelial activation secondary
to inflammation. Although the increase in endoglin expression with the inflam-
mation in the colonic mucosa of mice was shown before, its relationship with the
disease activity in inflammatory bowel disease (IBD) is not searched yet. The
relationship of serum NGAL and serum and colonic endoglin levels in ulcerative
colitis (UC) and Crohn’s disease (CD) patients were investigated in this study.
Aims & Methods: Eighty-six UC, 63 CD, 36 non-IBD (screening, irritable bowel
syndrome) and 52 healthy controls who were followed up in Gastroenterology
Department of Sisli Hamidiye Etfal Education and Research Hospital between
years 2015–2016 were enrolled. Patients were evaluated by endoscopic
(Rachmilewitz index for UC, simple endoscopic score for CD (SES-CD) for
CD) clinical (clinical colitis activity index (CCAI) for UC and CD activity
index (CDAI) for CD), and pathologic activity scores and immuhistochemical
staining.
Results: There were no differences between UC and CD patients in terms of
serum endoglin and NGAL levels. NGAL and endoglin levels were significantly
higher in endoscopically active UC group (n¼ 59) (142.8 68.7 ng/mL and
546.0 148.8 pg/mL) compared to inactive UC (n¼ 27) (119.7 26.3 ng/mL
and 476.9 134.2 pg/mL), to non-IBD (115.8 27.2 ng/mL and
460.6 103.2 pg/mL) and to controls (116.7 31.7 ng/mL and 457.2 114.1 pg/
mL). Although there were limited number of inactive CD patients (n¼ 11), serum
NGAL and endoglin levels were significantly higher in endoscopically active CD
group(n¼ 52) (135.0 28.9 ng/mL and 555.6 133.6 pg/mL) compared to inac-
tive CD (115.2 35.9 ng/mL and 458.7 132.8 pg/mL), to non-IBD and to con-
trols (Figure). Stricturing and fistulizing CD groups had significantly higher
endoglin levels compared to inflammatory CD (p5 0.001 and p¼ 0.001).
NGAL levels were significantly increasing with the increasing disease extention
in UC and CD (p¼ 0.012 and p5 0.001). While the clinical activity subgroups
were evaluated, there were significant difference in UC and CD patients in terms
of endoglin levels but not NGAL levels (Endoglin: p¼ 0.002 p¼ 0.574, NGAL:
p¼ 0.020, p¼ 0.171). Endoglin levels were more strongly correlated with the
pathologic activity scores in both UC and CD groups compared to NGAL
levels (Endoglin: r¼ 0.443, p5 0.001; r¼ 0.453, p5 0.001 NGAL: r¼ 0.274,
p¼ 0.011; r¼ 0.409, p¼ 0.001) The immunohistochemical staining index of endo-
glin showed positive correlation with the immunohistochemical staining of vas-
cular endothelial growth factor (VEGF) (UC r¼ 0.486, p5 0.001; CD r¼ 0.383,
p¼ 0.002). The immunohistochemical staining index of endoglin in the colonic
mucosa was correlated with the serum levels of endoglin in both UC and CD
patients (UC r¼ 0.641, p5 0.001; CD r¼ 0.437, p5 0.001)
Conclusion: The present study highlights signiEcant associations between endo-
glin and NGAL and IBD presence and activity, and demonstrates elevated serum
and colonic endoglin levels in patients with active IBD as a novel finding.
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Introduction: Although thiopurine-induced myelotoxicity and hepatotoxicity
rarely occur during maintenance thiopurine therapy for inflammatory bowel
disease (IBD), current guidelines advise laboratory monitoring every 3 months.
This study was performed to assess the current laboratory monitoring regime in
thiopurine maintenance therapy with regards to consequences of myelotoxicity
and hepatotoxicity.
Aims & Methods: In this multicenter cohort study, we evaluated adult IBD
patients with quiescent disease who were on maintenance thiopurine therapy
between 2000–2016. Data collection started after 12 consecutive months of thio-
purine treatment. The primary outcome was therapy adjustment, i.e. therapy
cessation or dose reduction, due to myelotoxicity (leukocyte count 54.0 10e9/
l, platelet count 5150 10e9/l) and/or hepatotoxicity (alkaline phosphatase (AP),
gamma-glutamyltransferase (-GT), alanine aminotransferase (ALT) and/or
aspartate aminotransferase (AST) above the upper limit of normal (ULN)).
The secondary outcomes were prevalence of myelotoxicity and hepatotoxicity
and additional diagnostic procedures due to this toxicity.
Results: This study included 223 IBD patients (55% female, 64% with Crohn’s
disease, mean age at diagnosis 27.2 years (SD 11,5)). Median follow-up was 3.2
years (IQR 1.9–4.7). The mean monitoring frequency was 3.3 assessments per
treatment year (SD 1.8). Toxicity was observed in 445/2402 laboratory assess-
ments (18.5%) in 120 patients. In total, 20 (0.8%) therapy adjustments were
performed and 25 laboratory assessments (1.0%) led to additional diagnostic
procedures. Myelotoxicity, observed in 244 assessments, led to 11 dose reductions
and in 3 patients therapy was stopped. For hepatotoxicity, observed in 201
assessments, 2 dose reductions were performed and in 4 patients therapy was
stopped. Ninety percent of observed toxicity were mild leukopenia (leukocyte
count 3.0–4.0) or mild hepatotoxicity (52 ULN), primarily in the first years of
treatment. Dose adjustments were more often associated with moderate leuko-
penia (leukocyte count 53.0) than with mild leukopenia (p5 0.01). In total, 2
complications were recorded, 1 patient was hospitalized because of pancytopenia
and received red blood cell transfusion, and 1 patient was treated for a CMV
infection. Both patients presented with symptoms in clinic with preceding normal
laboratory values. No mortality due to thiopurine-induced toxicity was observed.
Conclusion: Although mild toxicity is common during maintenance thiopurine
therapy, adjustments based on laboratory assessments are rare. Therefore, a less
intensive regime to monitor thiopurine-induced toxicity should be considered.
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Introduction: Intestinal fibrosis represents one of the main sources of morbidity
for patients with Crohn’s disease (CD), as its onset is associated with the devel-
opment of CD-related complications which increase the likelihood of hospitali-
zation and surgery1. Ultrasound elasticity imaging (UEI) is a non-invasive
ultrasonographic technique developed to evaluate tissue fibrosis by measuring
tissue strain after application of a force2. We have recently demonstrated that
UEI can reliably detect severe ileal fibrosis in patients with Crohn’s disease3. We
therefore hypothesized that a more severe range of fibrosis might influence the
therapeutic response to anti-tumor necrosis factor (TNF) treatment.
Aims & Methods: The aim of this explorative study was to assess the ability of
UEI to predict therapeutic outcome in active CD patients treated with anti-TNF
antibodies. 30 patients with ileal or ileocolonic CD (20 males, age 38.8 14.5)
initiating anti-TNF treatment were enrolled in the study. All patients completed
the induction phase and underwent scheduled maintenance therapy with anti-
TNF for 16.1 8.5 months. Patients underwent bowel ultrasound and UEI at
baseline and 14 weeks after initiation of anti-TNF. Bowel wall stiffness at UEI
was quantified by calculating the strain ratio (SR) between the bowel wall and
the surrounding mesenteric tissue. Receiver operating characteristic curve analy-
sis was used to identify the best SR cut off able to predict surgery/bowel obstruc-
tion. Transmural healing at 14 weeks was defined as a bowel wall thickness
3mm. Frequency of CD-related surgeries or hospitalizations due to bowel
obstruction was recorded during the follow-up. The data are given as mean
values standard deviation
Results: Five patients (16.6%) underwent surgery or hospitalization for bowel
obstruction during the follow up. Frequency of CD-related surgeries or hospita-
lizations was significantly greater in patients with SR 2 at baseline than in
patients with SR5 2 (p¼ 0.02). A significant reduction in bowel thickness was
observed after 14 weeks of anti-TNF treatment (from 5.8 1.5mm to
5.1 1.7mm, p5 0.005), while SR values remained unaltered (1.5 vs 1.3,
p¼ 0.5). A significant inverse correlation was observed between values of
strain ratio at baseline and thickness variations following anti-TNF therapy
(p¼ 0.007). Eight out of 30 patients (27%) achieved transmural healing at 14
weeks. Baseline SR was significantly lower in patients with transmural healing
than in patients not achieving this endpoint (1.06 0.16 vs 1.67 0.17, p5 0.05).
Conclusion: This explorative study shows that UEI is be able to predict thera-
peutic outcomes, including CD-related surgeries and transmural healing, in
patients with Crohn’s disease treated with anti-TNF therapy.
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Introduction: Ulcerative colitis (UC) generally involves the entire large intestine
extending from the rectum to the ileocecal junction. However, some patients with
moderate or severe UC lack any obvious rectal involvement (known as rectal-
sparing [RS]-UC).
Aims & Methods: In this study, we evaluated the differences in the clinical char-
acteristics and disease course between patients with refractory UC with or with-
out RS. Of the 437 inpatients with refractory UC who achieved remission
between April 2001 and September 2016 (follow-up period: 915 53 days,
meanSD), 57 patients were classified as RS-UC and 340 patients without RS
(standard [S]-UC group). Patients of the two groups were compared for gender,
age at onset, site of involvement, disease duration, pretreatment clinical activity
index (CAI, Lichtiger score), Hb, C-reactive protein (CRP), total dose of pre-
dnisolone (PSL) before the achievement of remission, duration of hospitalization,
endoscopic scores (Mayo and UCEIS), and relapse rates (at 100, 300, 500, and
1000 days post-remission). Patients with RS were defined as those without any
detectable rectal inflammation despite not receiving local treatment, such as
rectal enema/infusion or suppositories. Remission was defined as CAI of 4.
Relapse was defined as the need to restart remission induction therapy, such as
intensive intravenous PSL, initiation of treatment with biological agent, or re-
administration and dose escalation of tacrolimus to achieve a high blood trough
level (10 ng/dl).
Results: RS was observed in 57 (10.4%) patients. There were significant differ-
ences in CRP (RS-UC: 5.1 6.02, S-UC: 2.3 3.4mg/L) and pretreatment endo-
scopic scores (Mayo: RS-UC: 2.7 0.3, S-UC: 2.4 0.5; UCEIS: RS-UC:
6.1 1.3, S-UC: 5.7 1.4) between the two groups (P5 0.05). There was no
significant difference in the relapse rate at 100 days after remission (RS-UC:
18%, S-UC: 15%). However, the two groups showed significant differences in
the relapse rates at 300 days (RS-UC: 38%, S-UC: 17%), 500 days (RS-UC:
57%, S-UC: 48%), and 1000 days (RS-UC: 77%, S-UC: 62%) after remission.
Conclusion: Our results showed that RS is not an uncommon finding among
patients with UC. Based on the higher CRP, endoscopic score, and relapse
rates in the RS group, than the standard UC group, we recommend aggressive
treatment of UC patients with RS.
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Introduction: Ulcerative colitis (UC) associated colorectal cancer risk (CRC) is
related to the age of onset and duration and anatomic extent of the disease. The
risk of malignancy increases with the duration of the disease (1). Current guide-
lines recommend beginning the surveillance colonoscopy after eight to ten years
of disease; random biopsies should be obtained from 4 quadrants of every 10 cm
of the entire colon. In addition, any suspicious areas should be biopsied (2).
Recent endoscopic imaging technologies provide a more detailed visualization
of the superficial microstructure of the mucosa and vascularity. Thus it is possi-
ble to get targeted biopsies. The purpose of this study is; to evaluate the image
patterns of dysplastic changes in ulcerative colitis, and their histopathological
correlation, by using a virtual chromoendoscopy technique, FICE and to inves-
tigate the effectiveness of this technique.
Aims & Methods: The purpose of this study is; to evaluate the image patterns of
dysplastic changes in ulcerative colitis, and their histopathological correlation, by
using a virtual chromoendoscopy technique, FICE and to investigate the effec-
tiveness of this technique. Eighteen follow-up patients of our inflammatory
bowel disease polyclinic, with UC at least 8 years of disease history and who
are in clinical remission are included to this study. Screening colonoscopy was
performed to the patients included in the study. Entire colon and especially
dysplasia suspected areas visualised with standart endoscopy first, and then
with FICE; random and targeted biopsies were taken. Image patterns were com-
pared with histopathologic diagnosis. Normal, colitis and polyps images acquired
by FICE, were evaluated by seven endoscopists and statistical analysis was
performed.
Results: In a total of 18 patients, by evaluating 123 colonic segments, 1831 images
were taken. 1652 image acquired by FICE, and 179 were white light images.
Images taken by FICE separately, from each areas of normal colonic mucosa,
polipoid lesions and colitis. A total 584 biopsies were taken, 492 (84.2%) random
and 92 (15.7%) targeted biopsies. While there were no dysplasia in random
biopsies, low-grade dysplasia was detected in 3 diminutive polyps taken as tar-
geted biopsy. The analysis of the FICE images by voting by seven endoscopists
showed that, the best imaging channels are; 2, 6, 9 for normal mucosa; 3, 7, 9 for
polyps; and 2, 3, 9 for colitis. When all the images are analyzed, channels 2 and 9,
were found to be significantly different from other channels. When the most
rated channels, 2 and 9, were compared to the WLE, the FICE image is better
for evaluation of the mucosal and vascular structure. However, there were no
significant difference between channels 2 and 9.
Conclusion: There were no significant superiority of FICE, in dysplasia screening.
Consistent with the literature, this study showed us that FICE is effective in
detecting diminutive polyps, and evaluating surface patterns without magnifica-
tion. In clinical remission in patients with UC, FICE can have a role in the
assessment of the severity of inflammation. For this purpose, more clinical
trials are needed. Our study is the first study with FICE in UC. Channels 2
and 9 are the best image channels of FICE in UC.
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Introduction: The gut microbiome is thought to be relevant to the pathogenesis of
inflammatory bowel disease (IBD). We aimed to explore associations between
measures of gut microbiota and clinical as well as inflammatory disease activity
in an inception cohort of treatment-naı̈ve IBD patients as well as with inflam-
matory activity in symptomatic non-IBD patients and healthy controls. The term
‘dysbiosis’ expresses alterations in the gut microbial community.
Aims & Methods: Patients were diagnosed according to international criteria,
including endoscopic and histopathologic assessment. Clinical disease activity
in Crohn’s Disease (CD) patients was measured by the Harvey-Bradshaw
index (HBI), and in ulcerative colitis (UC) patients by the Simple Clinical
Colitis Activity Index (SCCAI). Inflammatory activity was assessed by CRP
and faecal calprotectin (FCal), (fCAL ELISA, Bühlmann laboratories AG).
Stool samples were collected within 60 days prior to and 14 days after the
diagnosis, and stored at –80C. Antibiotic treatment within the last two
months was an exclusion criterion. Faecal microbiota profiles were generated
by 16S rRNA analyses, using the GA-mapTM Dysbiosis Test. Dysbiosis was
defined as non, mild or severe (1). Differences in disease activity between levels
of dysbiosis severity were analysed using ANOVA at a significance level of
p5 0.05, and univariate associations between inflammatory activity and log-
transformed microbiota profiles were analysed using ANCOVA. P-values cor-
rected for multiple testing, using Benjamini-Hochberg correction, are presented.
Results: Data on dysbiosis, bacteria profiles, and FCal were available in 57 CD,
80 UC, 12 IBD-U patients and 100 symptomatic non-IBD patients, and 45
healthy controls. CRP was available for 52 CD, 74 UC, 10 IBD-U patients,
and 88 symptomatic non-IBD patients. HBI was available for 50 CD patients,
while SCCAI was available for 77 UC patients. Disease activity: No association
was found between FCal and dysbiosis in UC patients (P¼ 0.08), CD patients
(P¼ 0.22), and healthy controls (P¼ 0.57). However, an association was found
between FCal and dysbiosis in symptomatic non-IBD patients (P¼ 0.04) and in
IBD-U (P¼ 0.005). An association was found between CRP and dysbiosis in CD
patients (P¼ 0.02), while not for UC and symptomatic non-IBD patients. No
association was found between HBI and dysbiosis in CD patients (P¼ 0.23), and
between SCCAI and dysbiosis in UC patients (P¼ 0.32). Microbiota: Increasing
dysbiosis severity in UC, CD and non-IBD patients yielded lower abundance of
Faecalibacterium prausnitzii, and higher abundance of Proteobacteria, a profile
typically observed in gut inflammatory conditions. In addition, the commensal
bacteria Bifidobacterium yielded lower abundance with increased dysbiosis sever-
ity in UC and non-IBD patients, and in combination with elevated levels of FCal
and/or CRP in UC patients. In the healthy controls, increasing dysbiosis severity
yielded higher abundance of Proteobacteria.
Conclusion: In conclusion, a relationship between faecal dysbiosis in sub-groups
of IBD and non-IBD was found, in CD patients also with CRP. Accordingly, gut
bacteria profiles and abundance may potentially be used to differentiate between
severity in UC and CD patients, as a non-invasive tool to monitor disease activity
in IBD.
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Introduction: Crohn’s disease (CD) is a lifelong inflammatory bowel disease.
Evaluating the extent and severity of the disease is critical to determine appro-
priate therapeutic strategies in patients with Crohn’s disease. MR imaging is one
of the most recommended technique for detection of large and small bowel
lesions of CD. The aim of this study is to establish clinical utility of the 5-
point MR enterocolonography (MREC) classification for assessing CD activity
based on endoscopic findings.
Aims & Methods: A total of 120 patients (70 for derivation cohort and 50 for
validation cohort) with CD was enrolled and undergone MREC and ileocolono-
scopy or balloon-assisted enteroscopy (BAE). MREC was evaluated for each
bowel segment; rectum, sigmoid, descending, transverse, ascending colon, term-
inal, proximal ileum, and jejunum, according to the consensus of two observers in
the derivation phase, and independently by three observers in the validation
phase, using a 5-point MREC classification based on a lexicon of MR findings.
The conventional MR score, or MaRIA, was evaluated simultaneously. Areas
under the receiver operating characteristic curves (AUCs) were obtained to assess
the accuracy of discriminating deep ulcers. Inter-observer reproducibility was
assessed using weighted Kappa coefficients.
Results: BAE was performed in 49 (70%) and 37 (74%) patients in the derivation
and validation cohorts. The AUCs of MREC classification were 89.0% in the
derivation phase and 88.5, 81.0, and 77.3% for three observers in the validation
phase. The AUCs of MREC classification were statistically non-inferior to those
of MaRIA (p5 0.001). The cross-validation accuracy was 81.9% in the deriva-
tion and 81.5% in the validation phase. The MREC classification showed good.
Conclusion: For clinical use, radiological reporting systems should be simple and
provide appropriate levels of accuracy and reproducibility. The 5-point MREC
classification meets these requirements, and is useful for evaluating CD activity in
the large to deep small bowel segments.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1661 RISK FACTORS FOR METABOLIC SYNDROME AND ITS
COMPONENTS IN INFLAMMATORY BOWEL DISEASE
K. Efthymakis, M. Serio, M. Fioravante, A. Milano, F. Laterza, A. Bonitatibus,
M. Neri
Department Of Medicine And Ageing Sciences And Center For Excellence On
Ageing And Translational Medicine (cesi-met), "G. D’Annunzio" University and
Foundation, Chieti/Italy
Contact E-mail Address: efkn78@gmail.com
Introduction: Metabolic Syndrome (MetS) is a combination of biochemical and
anthropometric disturbances and a recognized risk factor for cardiovascular
disease. A higher prevalence of this condition has been previously reported in
IBD patients, correlating to age as in the general population.
Aims & Methods: The aim of this study was to assess the effect of individual
disease activity-related putative risk factors for MetS in a group of IBD patients,
as well as any protective effects of treatment on MetS or its components.
Consecutive IBD patients and age- and sex-matched controls were included
during a 1-year period. MetS was diagnosed according to the ‘‘harmonized’’
criteria as the presence of 43 criteria among elevated waist circumference,
blood pressure, blood glucose, serum tryglicerides, or reduced HDL levels. All
subjects underwent colonoscopy; endoscopic disease activity was assessed
according to SES-CD and Mayo endoscopic scores. CRP, fecal calprotectin
(FC), hemoglobin and ferritin levels were also measured.
Results: We enrolled 145 consecutive IBD patients (53 Crohn’s disease and 92
ulcerative colitis; 58 M/87 F; mean age 51 18 ys) and 250 age- and sex-matched
controls. Overall MetS prevalence was 37% in IBD and 21.6% in controls
(OR¼ 2.1, 95%CI:1.32–3.39). Prevalence according to sex or disease type did
not show significant differences. At multivariate analysis, age and BMI4 25
were associated to an increased probability for a positive MetS status both in
IBD (respectively, OR¼ 3.41 and OR¼ 6.0) and controls (respectively,
OR¼ 3.47 and OR¼ 3.74). In patients under 50 years, age (OR¼ 1.24), CRP
(OR¼ 1.9) and FC (OR¼ 1.35) positivity were associated to MetS status, while a
BMI4 25 increased risk at any age (550ys OR¼ 3.8, 450ys OR¼ 1.56).
Endoscopic activity did not associate to MetS status at any age. Interestingly,
anti-TNF treatment was protective in both groups, but reached statistical sig-
nificance only in older subjects (450ys OR¼ 0.08). Regarding individual MetS
components, in the 550ys subgroup, age and CRP positivity associated with an
impaired glycemic (respectively, OR¼ 1.15 and OR¼ 2.28) and lipidemic status
(respectively, OR¼ 1.23 and OR¼ 2.3). In older patients, CRP positivity only
associated to impaired HDL status (OR¼ 5.41). Importantly, anti-TNF treat-
ment favourably associated to HDL status (OR¼ 0.2).
Conclusion: MetS prevalence is increased in IBD compared to healthy controls at
any age. Subjects with increased BMI and/or inflammatory markers are at higher
risk for MetS, while anti-TNF agents appear to be protective. The components
associated to MetS are differently distributed according to age, with the inflam-
matory ones prevailing in subjects550 years and metabolic disturbances in older
patients. These results indicate that, while in the short term appropriate treat-
ments may reduce MetS occurrence and associated risks in subjects450 years, in
younger patients more effective inflammation control measures may prevent
MetS and its related long-term neoplastic and cardiovascular complications.
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Introduction: Patients with acute severe ulcerative colitis (ASUC) have a high risk
of rescue medical therapy or colectomy. Recently, the C-reactive protein (CRP)/
albumin ratio at the 3rd day of treatment, with intravenous corticosteroids, has
been shown to be a predictor of early colectomy in patients with ASUC.
Aims & Methods: To evaluate the accuracy of CRP/albumin ratio on admission,
to predict response to intravenous corticosteroids in patients with ASUC.
Retrospective assessment of systematically hospitalized patients with first episode
of ASUC, who required intravenous corticosteroids. Demographic, clinical,
laboratory and endoscopic variables were evaluated on admission. The response
to intravenous corticosteroids on day 3 was based on Oxford criteria. In unre-
sponsive patients, rescue medical therapy with infliximab or cyclosporine has
been instituted. The accuracy of CRP/albumin ratio in predicting non-response
to intravenous corticosteroids was assessed by the area under the ROC curve
(AUC).
Results: 51 patients were included, 30 (58.8%) of them female, with a mean age
34.3 14.5 years. Twelve patients (23.5%) required medical rescue therapy. No
patient underwent colectomy. The presence of deep ulcers and a shorter evolution
of the disease were associated with a lack of response to intravenous corticoster-
oids, p5 0.001 and p¼ 0.008, respectively. Patients with no response to intrave-
nous corticosteroids had higher CRP admission values and lower albumin values,
compared to patients with response, 111 vs 67.5 (mg/L), p¼ 0.028, 2.8 vs 3.5 (g/
dL), p¼ 0.005, respectively. The CRP/albumin ratio was also higher in unrespon-
sive patients 40.06 vs 22.14, p¼ 0.022, showing a good accuracy for predicting no
response to intravenous corticosteroids with an AUC of 0.746, p¼ 0.01.
Conclusion: A high value of CRP/albumin ratio was significantly associated with
the absence of response to intravenous corticosteroids, at the 3rd day of treat-
ment. This index may allow a better risk stratification on admission, of patients
with acute severe ulcerative colitis.
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Introduction: The MCV flow study confirmed the association MCV 7fl at
week 26–28 of Azathioprine monotherapy (mAza) with favourable outcomes in
a Portuguese IBD population.
Aims & Methods: For this work, our aims were to evaluate the need for step-up
therapy in those under mAza with MCV5 7 and to identify predictors of
combined deep remission outcomes (DeepRem), at the same timepoint, for the
patients who subsequently began combination therapy with Anti-TNF
(AzaExperiencedþAnti-TNF). Evaluation of patients under mAza with
VGM5 7 at key timepoint week 26–28 treatment, included for The MCV
flow study. Demographic characterization and severity of pre-treatment disease
was evaluated (Montreal classification, previous surgery status, Mayo score and
Crohn’s disease activity index [CDAI]). MCV’s association with DeepRem
[Steroid-free clinical remission (CDAI5 150, Mayo5 2) þ mucosal healing
(MH)þC-reactive protein (CRP)5 10] and need for biological therapy at the
key-timepoint was verified. Evaluation of DeepRem and its independent predic-
tors in patients who subsequently started combination therapy. Statistic: Chi-
square test; Binary logistic regression.
Results: A total of 106 IBD patients were evaluated [56.6% women, mean age
39 15.2 years; 58 ad, 14% operated] at week 26–28 of mAza. Identified strong
association between an average VGM 7 (n¼ 70; 66%) with DeepRem
(p5 0.05), while a VGM5 7 was associated with biological therapy need
(p5 0.05). 45 patients were later started with Anti-TNF therapy
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(Azaþ Infliximab 46.7%; AzaþAdalimumab 53.3%) and only 44% achieved
DeepRem at the key-timepoint. A Crohn’s A3L2B3þp phenotype (p¼ 0.045),
steroid therapy in the last year (p¼ 0.009) and VGM5 7 (p¼ 0.036) were
identified as the variables that best explained the difficulty reaching DeepRem.
Conclusion: This study confirms the prognostic value of VGM in our popula-
tion. For mAza patients, VGM 7 was associated with DeepRem and
VGM5 7 was found to be associated with biological therapy need.
However, even after starting Anti-TNF, VGM5 7 was identified as a predictor
of the difficulty reaching DeepRem.
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Introduction: Most inflammatory bowel disease (IBD) patients with clinically
successful treatment seem to have some degree of residual mucosal inflammation.
Elevated fecal calprotectin (FC) concentrations can be found despite clinical
remission and may indicate relapse risk in asymptomatic IBD.
Aims & Methods: The aim of this prospective study was to evaluate whether
elevated FC values can predict short-term clinical and/or endoscopic relapse.
We enrolled 60 IBD patients (30 ulcerative colitis - UC, 30 Crohn’s disaese -
CD) who were in clinical and endoscopic remission. FC was measured using
quantitative immunochromatographic point-of-care test (Quantum Blue
Calprotectin, Bühlmann Laboratories AG, Switzerland). Patients were fol-
lowed-up by FC examination and clinical activity assessment every second
month until relapse or up to 24 months. Ileocolonoscopy was performed at
inclusion and at the time of clinical relapse.
Results: During the follow-up 36 (60%) relapsed and 24 (40%) remained in
remission. The mean time to relapse in all patients was 13.9 (range 2–20)
months. Significant increase in median FC levels was seen 2 months
(p5 0.001) before endoscopic relapse. ROC analysis indicated that a cut-off of
490 mg/g (OR 24, 95% CI¼ 5–117, p5 0.001) in mean FC values 2 months
before relapse could predict relapse in UC patients with 83,3% sensitivity and
82.9% specificity. In CD patients a cut-off of 4155 mg/g (OR 193, 95% CI¼ 22–
1682, p5 0.001) could predict relapse within two months with 91.7% sensitivity
and 94.6% specificity. Constantly normal FC values during the follow-up were
predictive for deep remission.
Conclusion: It seems that FC elevates two months before clinical and/or endo-
scopic relapse. FC is a suitable marker for predicting relapse and building a
follow-up strategy for IBD patients in clinical practice.
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Introduction: Hyperglycemia associated with critical illness - also called stress
hyperglycemia or stress diabetes - has been demonstrated with much higher
prevalence of severe ill patients. It is connected with many factors, including
increased cortizol level, catecholamines uptake, glucagon production, gluconeo-
genesis, insulin resistance and inflammatory markers.It is not considered as an
adaptive responce anymore. Futhermore uncontrolled hyperglycemia is asso-
ciated with poor outcomes and significantly increases mortality rates. That is
why stress hyperglycemia and insulin resistance may be a marker of severe illness.
Aims & Methods: We analysed the data (glycemia, insulin level, HOMA IR level,
C-reactive protein level, HbA1C) of 62 patient aged 18 years and older (20
women and 42 men, 32.26 þ/13.8 years of age) with IBD hospitalized in our
clinic from 2016 to 2017. 16 patient were with Ulcerative Colitis (UC) and 48
patients with Crohn’s Disease.
Results: The analysis of patients with Ulcerative Colitis showed that only one of
the patients had hyperglycemia within the range of 140mg–200mg (the patient
had type 2 DM) but interestingly 37.5% of the patients had fasting hyperglyce-
mia over 100mg. Over 86% of these patient were submitted to our clinic with the
exacerbation of the disease and had abnormal level of C-reactive protein, cal-
protectin (41800) and fasting insulin level over 10 IU/ml. The analysis of the
group of patients with Crohn’s Disease showed different results which may be
connected with different metabolic profile of these patients. Most of the patients
with fasting hyperglycemia (only 12.5%) had elevated C-reactive protein level but
not fasting insulin level - it was within normal range. The highest level of the
fasting insulin (over 10 IU/ml) in this group was observed in 3 patients who had
to undergo immediate surgical treatment - two of them because of the bowel
obstruction and one of them because of the perforation.
Conclusion: In our opinion there is a strong connection beetween fasting glucose,
CRP level and exacerbation of the disease in CU patients but not in case of the
Crohn’s Disease. In this group the elevated fasting insulin may be a marker of
severe illness.
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Introduction: Crohn’s disease (CD) is a progressive, chronic and destructive
inflammatory bowel process which, during its course, can lead to complications
such as strictures and penetrating lesions (fistulas and abscesses), which may
consequently require operative treatment. In some patients, bowel damage is
present at the moment of diagnosis. The aim of the study is to assess the initial
Lemann Index (LI), which comprehensively evaluates the entire gastrointestinal
tract damage in patients with newly diagnosed Crohn’s disease.
Aims & Methods: In 209 patients with clinical suspicions of Crohn’s disease MR
imaging, endoscopic examination and histopathology were performed. In 151
patients with confirmed active/chronic CD the Lemann Index has been calculated
on the basis of radiological and clinical information for initial assessment of
cumulative digestive tissue damage. To create the Lemann Index the gastroin-
testinal tract was divided into 4 organs: upper digestive tract, small bowel, colon/
rectum and anus. Each organ was divided into segments (3 for the upper digestive
tract, 6 for the colon/rectum and 1 for anus). Strictures and penetrating lesions
were assessed at each segment on 4-degree scale (0–3) according to the severity of
lesions.
Results: Based on the findings of the initial radiological examination, active
inflammation process was found in 76 patients and chronic process in 75 patients.
The baseline study demonstrated such complications as strictures in 14 patients,
fistulas in 15 and abscesses in 4 patients. For all patients the LI was calculated.
The obtained values were within the range from 0 to 22.
Conclusion: Over the years, the progression of Crohn’s disease leads to an
increase in the value of Lemann Index, therefore, it seems that the evaluation
of this repetitive parameter already in the first, baseline study and in all following
control MR examinations will allow for a more complete assessment of patients
in terms of progressive bowel damage and modification of the therapeutic
process.
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Introduction: Optical imaging is being increasingly advocated for characterization
of polyps during colonoscopy. The accuracy of these techniques during surveil-
lance colonoscopy in colonic inflammatory bowel disease (IBD-C) is unclear and
with variable results reported. We aimed to perform a systematic review and
meta-analysis of the diagnostic accuracy of optical imaging techniques including
dye based and virtual chromoendoscopy, magnification endoscopy and confocal
laser endomicrosocpy.
Aims & Methods: We searched Medline and Embase for relevant papers. Full
articles or abstracts were eligible when characterization performance of dye-
based chromoendoscopy (DCE), virtual chromoendoscopy (VCE) (narrow-
band imaging [NBI], i-scan, Fujinon intelligent chromoendoscopy [FICE]), mag-
nification endoscopy and confocal laser endomicroscopy (CLE) had been com-
pared with histopathology, as the reference standard. Enough information had to
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be required to obtain a 2x2 contingency table. Pooled analysis was done using a
random-effects model. Sub-group analysis was performed at real-time Kudo pit
pattern based and real-time CLE for characterization of visible lesions.
Heterogeneity was assessed using Chi squared and I2 statistics.
Results: Our search strategy identified 172 studies of which only 20 met the
inclusion criteria. The pooled results are outlined in the table.
Conclusion: Real-time CLE and magnification endoscopy had the best perfor-
mance characteristics. However there was a lot of heterogeneity in the results.
Most CLE and magnification studies were single centre, single expert user which
could explain these results. CLE studies were also affected by attrition bias with
some studies reporting non-interpretable mages in a significant proportion.
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Introduction: The need to stratify patients with Crohn’s disease (CD) according
to the risk of developing complications is essential to delineate therapeutic
approach. A score that evaluates the severity of DC (Siegel et al, Gut 2016)
has recently been developed and published, taking into account intestinal lesions,
disease activity and complications during the course of the disease, ranging from
0 to 100.
Aims & Methods: We aimed to evaluate the performance of the aforementioned
score at the time of diagnosis and its relation to the need for surgery and hospi-
talizations in patients with CD. We performed a retrospective study that included
patients diagnosed with DC in our hospital between 01/2012–12/2015. The score
was calculated at the time of diagnosis and information on the course of the
disease was collected. Statistical analysis was performed in SPSS (v23).
Results: A total of 57 patients (52.6% women) with a mean age of 33.74 15.8
years were included. The median severity score at diagnosis was 16 16.5 ranging
from 4 to 50. Twenty-four patients (40.7%) required surgery and 29 (49.2%)
were hospitalized for reasons associated with the disease. At diagnosis, the
score was higher in A1 patients (26 vs 19.2 and 13.7, p¼ 0.05), with a penetrating
phenotype (25.5 vs. 19 and 12, p¼ 0.02), and in patients requiring surgery during
the course of their disease (21 vs 14, p¼ 0.1). There was a positive correlation
between the score at diagnosis and the number of surgeries during follow-up
(r¼ 0.43; p¼ 0.05). Survival analysis showed a trend towards shorter time for
surgery or hospitalization in patients with a score above the median at diagnosis
(p logrank¼ 0.09).
Conclusion: The new severity score seems to be a promising tool for stratification
and prognosis of patients with CD at diagnosis, and its utility should be validated
in prospective studies.
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Introduction: Microscopic colitis (MC) is a clinical syndrome of severe watery
diarrhoea with few or no endoscopic abnormalities. The incidence of MC is
reportedly similar to that of other inflammatory bowel diseases. The need for
histological confirmation of MC frequently guides reimbursement health policies.
With the advent of high-definition (HD) colonoscopes, the incidence of distinct
endoscopic findings reported in MC has risen. This has the potential to improve
diagnosis times, increase cost-effectiveness of MC management and diminish the
workload and costs of busy modern endoscopy units.
Aims & Methods: Publications on distinct endoscopic findings in MC available
until 31st March 2017 were searched systematically (electronic and manual) in
PubMed. The following search terms/descriptors were used: collagenous
colitis(CC) OR lymphocytic colitis(LC) AND endoscopy, colonoscopy, findings,
macroscopic, erythema, mucosa, vasculature, scars, lacerations, fractures. An
additional search for MC AND perforation was made.
Results: Eighty (n¼ 80) articles, predominantly single case reports (n¼ 45), were
retrieved. Overall, 1,582 (1,159 female; 61.6 14.1 years) patients(pts) with MC
and endoscopic findings were reported. The majority of articles (n¼ 62) were on
CC (756 pts; 77.5% female). We identified 16 papers comprising 779 pts (68.9%
female) with LC and 7 articles describing 47 pts (72.3% female) confirmed to
have MC. The youngest patient was 10 and the oldest 97 years old. Aside from
diarrhoea, symptoms included abdominal pain, weight loss, bloating, flatulence
and oedema. In the study group we found 616 (38.9%) pts with macroscopic
findings. The most common colonoscopic findings were non-ulcerous lesions i.e.
pseudomembranes, a variable degree of vasculature pruning & dwindling, muco-
sal lacerations & abnormalities such as erythema/edema/nodularity, or surface
textural alteration (n¼ 537; 87.2% pts). Isolated linear ulcerations were identi-
fied in 5 pts(0.8%) and in conjunction with non-ulcer lesions in 74 pts(12.0%).
The location of endoscopic findings was not reported in 26 articles. Distinct
endoscopic findings were described in the left (descending, sigmoid, rectum
23/20/10 studies), right (cecum, ascending–7/21 studies) & transverse colon
(14), as well as duodenum (4), and terminal ileum (2). Colonic perforation was
reported in 9 patients (0.57%).
Conclusion: Endoscopic findings are recognized with increased frequency in pts
with MC. This could improve MC diagnosis by prompting a more extensive
biopsy protocol in such cases and an earlier initiation of treatment. Procedure-
related perforation has been reported in this group; therefore, cautious air insuf-
flation is advisable when endoscopic findings are recognised.
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Introduction: It is well recognized that patients with inflammatory bowel disease
(IBD) are at risk for nonalcoholic fatty liver disease (NAFLD). Our aim was to
evaluate the prevalence and to quantify hepatic steatosis in IBD patients using
the controlled attenuation parameter (CAP).
Aims & Methods: We prospectively recruited all IBD patients presenting for a
disease flare or follow-up visit in our clinic, during a 18 month period. Patients
who reported chronic alcohol intake more than 20 g/day and those with coexist-
ing viral hepatitis were excluded from analysis. Clinical characteristics and
laboratory data were recorded. Hepatic steatosis was evaluated by conventional
ultrasound, hepatic steatosis index (HSI) and transient elastography with CAP
(Fibroscan, Echosens, Paris). Significant steatosis (S 1) was defined for a CAP
value over 236 [1], and the cut-off of HSI for detecting NAFLD was set
at 36 [2].
Results: Altogether 62 IBD patients (35 ulcerative colitis, UC and 27 Crohn’s
disease, CD), mean age 45 15 years, 50% female, were included in the analysis.
The two groups (UC, CD) were similar regarding disease activity (remission/
flare–48.5/51.4% in the UC group, 55.6/44.4% in the CD group), BMI (24.1
and 24.4 respectively) or inflammatory markers (ESR 21 and 21.1mm/h, fibrino-
gen 498 and 513mg/dl). UC patients had higher mean cholesterol values (205.9
vs. 176.4mg/dl) and 11% of them were diabetic (compared to none in the CD
group). Mean CAP was higher in CD compared to UC–246 vs. 225 dB/m, while
HSI was similar among the two groups 34.9 4.9 and 34.6 5.4, respectively. US
identified 18/62 (29%) patients with fatty liver, HSI detected 3 more patients (21/
62, 33.9%) and CAP even 2 more (23/62, 37.1%), yielding an extra 8% detection
rate. NAFLD-IBD patients were more likely to have CD phenotype, history of
resection, steroid use and longer disease duration.
Conclusion: In our cohort, about one in three IBD patients had fatty liver disease,
as quantified by CAP. Diagnostic performance of CAP was better than conven-
tional ultrasound and HSI in detecting fatty liver in IBD patients.
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Introduction: Irritable Bowel Syndrome (IBS) is a common gastrointestinal dis-
order that affects around 11% of global population. Despite the high prevalence
of IBS, the cause of this disorder remains unknown and the criteria used to
diagnose IBS are still unclear. In recent years, disturbances in the intestinal
microbiota have been associated to the pathophysiology of IBS. Recently, two
accurate biomarkers: Faecalibacterium prausnitzii (Fpra) and Escherichia coli
(Eco) have been shown to discriminate between Inflammatory Bowel disease
(IBD) and Healthy subjects (H). Therefore, the purpose of this study was to
verify the capability of Fpra and Eco abundances to distinguish among healthy
subjects, IBS, and IBD patients, in order to create a non-invasive system of
diagnostic support for IBS patients.
Aims & Methods: A cohort consisting of 33 H and 14 IBS was enrolled. IBS
patients were separated by subtypes: IBS with constipation (C-IBS), IBS with
diarrhea (D-IBS), and alternate IBS (A-IBS). Rome IV criteria were used to
diagnose IBS patients. Moreover, 29 ulcerative colitis (UC) and 15 Crohn’s dis-
ease (CD) patients were also included. All subjects were recruited by the
Gastroenterology Services of the Hospital Universitari Dr. Josep Trueta
(Girona, Spain) and Hospital Universitari de Bellvitge (Hospitalet del
Llobregat, Spain). Fpra total and Eco abundances were quantified by qPCR.
Results: We found lower abundance values of Fpra in IBS patients when com-
pared with H (P¼ 0.005). In contrast, Eco abundance was higher in IBS patients,
although the differences observed were not significant (P¼ 0.221). When com-
paring among subtypes of IBS (C-IBS, D-IBS, and A-IBS) no significant differ-
ences were observed, although Fpra abundance was lower in C-IBS. We also used
Fpra in combination with Eco as a complementary indicator of dysbiosis (Ratio
Fpra/Eco). This ratio allows a good discrimination between H and IBS
(P¼ 0.041). When it comes to discrimination between IBS and IBD patients,
significant differences were observed in Fpra/Eco ratio between UC and IBS
patients (P¼ 0.008), but not between IBS and CD patients (P¼ 0.775).
Concerning disorders different to IBS, significant differences were also observed
between H and CD (P4 0.001), between H and UC (P¼ 0.037), and between CD
and UC (P¼ 0.027).
Conclusion: Fpra abundance is a good biomarker to discriminate between healthy
subjects and IBS patients. The use of Fpra/Eco ratio allows to distinguish IBS
from H and UC patients. In contrast, none of the used biomarkers was able to
differentiate IBS and CD patients. These results show that IBS and CD patients
share similar dysbiosis parameters opening the need of further study to stablished
any eventual pathogenic link.
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Introduction: Inflammatory bowel disease (IBD) and irritable bowel syndrome
(IBS) may present in a similar manner [1] [2]. Measuring faecal calprotectin
concentration is often recommended to rule out inflammatory bowel disease,
however, there are no tests to positively diagnose irritable bowel syndrome and
invasive tests are still used to rule out other pathologies [3, 4]. There is a chance;
therefore, for novel, non-invasive diseasespecific biomarkers. Volatile organic
compounds (VOCs), originating from physiological metabolic processes in the
human body, are excreted as waste products through stool samples. For this
reason, several biological, non-invasive, simple and low-cost biological markers
of inflammation that are useful in clinical practice for both diagnostic screening
and therapeutic or course response monitoring are being evaluated in recent
years Evolution of the disease. In this sense, stool markers, and especially cal-
protectin, have become of great importance in recent years as screening to select
patients requiring more diagnostic studies and as a marker of activity for ther-
apeutic follow-up [5]. Can the VOCs from stool samples show differences
between ulcerative colitis and Crohn’s disease?
Aims & Methods: Five healthy individuals (control group- CON) and nineteen
patients diagnosed with IBD were selected for the analysis of their stool VOCs.
Healthy participants Healthy control samples (Control) (n¼ 5) were collected
from healthy voluntaries workers in the Digestive Diseases Area and they
reported no illnesses related to the gastrointestinal tract and had not undergone
antibiotic treatment in the 3 months before sampling. Active patients were
defined as a Mayo Clinical score of 3 or more for ulcerative colitis (UC) and a
Harvey Bradshaw clinical index of 4 or more for Crohn’s disease (CD). In both
cases with a calprotectin 4300 micrg/gr or relevant endoscopic lesions. Patients
were classified according Montreal and ECCO criteriai. This preliminary study is
based in a group of CD-UC-CON where was analyzed 10 CD patients, 9 UC
patients and 5 controls with 455 samples. Data from stool samples was obtained
using eNose MOOSY32 [6].
Results: Figure 1 shows the scatter 3D plot with three voltage parameters for the
group CD-UC-CON. These parameters mean the voltage from the eNose’s sig-
nals on saturation slope (vB) and late saturation (cV) and the number of sensor
from the MOOSY32. Table 1 shows the comparative between relative error
absolute and classification.
Table 1: Different algorithms test for matrix classification by WEKA software.
Classification Relative absolute error
MLP Cross 10 92.0% 16.5%
MLP 30%Train+70%Test 94.1% 12.2%
BayesNet Cross 10 89.8% 5.8%
BayesNet 30%Train+70%Test 86.0% 22.1%
J48 Cross 10 89.6% 16.7%
J48 30%Train+70%Test 89.7% 17.1%
Conclusion: In this preliminary research to distinguish between Ulcerative Colitis
and Crohn’s Disease, the best algorithm for patient’s classification was the MLP
with 30% to train and 70% to test. Although the high classifications result it is
hopeful is necessary continue working to understanding how the eNose’s signals
affect to the relative absolute error and improving the algorithms to decrease the
error.
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Introduction: Czech Registry of Inflammatory Bowel Disease (IBD) Patients on
Biological Therapy (CREdIT) was launched in March, 2016 in order to collect
and analyze the data from Czech centers appointed to provide biological therapy
to IBD patients.
Aims & Methods: The objective is to provide information on the CREdIT registry
after its first year of operation. Basic demographic data (sex, age, diagnosis,
Montreal classification or disease extent) were collected together with informa-
tion on disease activity, therapeutic regimen, concomitant medication and
adverse events. Patients who begun biologic therapy prior to enrolment into
the registry as well as those who start their treatment are included, and labeled
as ‘‘retrospective‘‘ and ‘‘prospective’’ cohort, respectively.
Results: Among 30 centers providing biological therapy to patients with Crohńs
disease (CD) and ulcerative colitis (UC) in the Czech Republic, 24 participated as
of the end of March 2017. The centres enrolled 2129 IBD patients (CD, 1595,
74.9%; UC, 505, 23.7%; IBD-U, 29, 1.4%), with median of 63 (range 4–528)
patients per center. Majority belong to the retrospective cohort (65%), the
remaining 35% represent the prospective cohort. According to the latest data
check, patients are treated with infliximab (1273, 59.8%), adalimumab (739,
34.7%), vedolizumab (73, 3.4%), and golimumab (42, 2%). Treatment intensifi-
cation (at any time of therapy) was used in 348 patients (19.1%). Infliximab was
the most frequently used drug in the first line of biological treatment of both
diseases, while adalimumab and vedolizumab were the most used drugs in the
second and third line, respectively. When started with biological therapy, major-
ity of CD patients was on concomitant azathioprine (55.4%), while UC patients
used most frequently mesalazine (72.7%). Among CD and UC patients, the
proportion of patients on concomitant corticosteroids decreased from 42.7%
and 67.9% to 10.2% and 24.5%, respectively. 76 (3.5%) patients experienced
at least one adverse event while on biologic treatment.
Conclusion: The new Czech national registry collects and provides data on IBD
patients treated with biological therapy. Majority of patients enrolled have
Crohńs disease, and the mostly used drug is infliximab. Therapy is effective
with low frequency of adverse events.
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Introduction: In patients with inflammatory bowel diseases (IBDs), comprising
Crohn’s disease (CD) and Ulcerative colitis (UC), a patient-tailored therapy is an
unmet need that requires accurate monitoring of the intestinal disease activity.
We demonstrated recently, that the expression of microRNA (miR)-320a follows
the disease activity in murine colitis models1. In this prospective study we eval-
uated the potential of miR-320a as a biomarker to monitor the disease activity in
IBD patients as well as its potential to distinguish UC/CD from infectious colitis.
Aims & Methods: The miR-320a was measured by qRT-PCR analysis in periph-
eral blood samples from 36 CD und 34 UC patients with acute flare of disease
(n¼ 51) and in remission (n¼ 37) as well as in healthy control patients (n¼ 20)
and in patients with infectious colitis (n¼ 9). Disease activity was assessed clini-
cally applying the Crohn’s disease activity index (CDAI) and the partial Mayo
score (pMayo) for UC patients as well as the simple endoscopic score Crohn‘s
disease (SES-CD) and the endoscopic Mayo score (eMayo) to score endoscopic
disease activity.
Results: Both in CD and in UC patients, miR-320a expression in remission was
significantly increased as compared to healthy controls (49 8/87 17 vs. 17 3;
both p5 0.001) but distinctly lower as in CD/UC patients with acute flare
(1718 488; p¼ 0.006; 531 107, p¼ 0.001). In CD patients with clinical acute
flare (CDAI4 220), miR-320a expression level were significantly increased as
compared to CD patients in clinical remission (CDAI5 150; 2677 637 vs.
57 9; p5 0.001) and showed a strong correlation with endoscopic disease activ-
ity (r2¼ 0. 70). Similarly, in UC patients, miR-320a also revealed a significant
increase in patients with low (pMayo 3–4), moderate (pMayo 5–6) and severe
clinical disease activity (pMayo4 6) as compared to UC patients in remission
(259 47; 281 26; 1090 204 vs.76 13, all p5 0.001). Furthermore, we
detected a significantly enhanced miR-320a expression with increasing endo-
scopic disease activity (eMayo 1: 89 14 vs. eMayo 2: 301 50, p¼ 0.006; vs.
eMayo 3: 775 245; p¼ 0.02). Most importantly, miR-320a expression in CD
and UC patients with acute flare of disease was significantly increased as com-
pared to patients with infectious colitis (53 12, p5 0.001).
Conclusion: The miR-320a expression in peripheral blood from IBD patients
follows the clinical and endoscopic disease activity and may distinguish between
IBD and infectious colitis. Therefore, miR-320a might serve as biomarker to
non-invasively assess the disease activity in IBD patients.
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Introduction: Traditionally in our unit all IBD patients started on anti-TNF
therapy are followed up at 3 months in the clinic and we aim to do a colonoscopy
at 6 months to assess for mucosal healing. Recently we have started using a
relatively new technology, called IBDoc, which allows testing the faecal calpro-
tectin at home using a smart phone application and the results are automatically
updated in our database.
Aims & Methods: We aimed to evaluate the cost effectiveness of using IBDoc faecal
calprotectin post induction of biological agents. The data was collected retrospec-
tively from ourIBDoc data base. All patients that were commenced on anti-TNF
therapy for IBD and trained in using IBDoc at home were included. IBDoc faecal
calprotectin was tested at 3 and 6 month post induction of biological agents.
Results: Total number included in the study was 131 patients. 40% had normal
calprotectin at 3 month saving 53 follow up clinic visits (cost of clinical visit 128
euro), and 75% had a normal faecal calprotectin at 6 months saving 40 routine
colonoscopy (cost of colonoscopy 337 euro). 78 patients had a raised faecal
calprotectin at 3 month, of which 28% had a normal faecal calprotectin at 6
month saving 22 follow-up colonoscopy. In total 53 clinical visits and 62 colo-
noscopies were avoided.
Conclusion: This study demonstrate a significant cost effectiveness of using
IBDoc faecal calprotectin post induction of anti-TNF therapy, as well as redu-
cing the waiting time for both clinic visits and colonoscopies.
Disclosure of Interest: G. El-Safi: Abbvie
All other authors have declared no conflicts of interest.
P1676 DOSE OPTIMISATION OF INFLIXIMAB: COMPARATIVE
STUDY OF A RAPID TEST AND A ESTABLISHED ELISA METHOD
A. Echarri Piudo1, G. Molina1, A. Lopez Insua1, H. Ferreiro-Mazón2,
B. Fernandez Saya2, J. Cid Fernandez3, V. Ollero4
1Gastroenterology, H. arquitecto marcide, Ferrol/Spain
2Inmunology, H. arquitecto marcide, Ferrol/Spain
3Inmunology, Hospital Teresa Herrera, Coruña/Spain
4Gastroenterology, Complejo Hospitalario de Ferrol, Ferrol/Spain
A736 United European Gastroenterology Journal 5(5S)
Contact E-mail Address: ana.echarri.piudo@sergas.es
Introduction: Infliximab (IFX) levels have been associated with clinical and endo-
scopic outcomes in patients with inflammatory bowel disesase (IBD).
Therapeutic drug monitoring (TDM) and a treat-to-target therapeutic approach
may arise as a clinical strategy to optimise infliximab efficacy, safety and cost.
The current IFX assay test and the cut-off levels used in practice, are based on a
high time consuming ELISA procedure, processed in a batch-like method (tec-
nical delay) and requiring high expertise. An easy to use, rapid point-of-care test
would dramatically reduce the turnaround time for results, allowing a faster
decision. The aim of this work is to compare a newly developed point-of-care
diagnostic test (Quantum Blue assay) with the standard ELISA method
(Promonitor assay) determining a correlation factor that permits therapeutic
management in a similar way.
Aims & Methods: A total of 135 serum sample from patients with CD and UC.
IFX concentration in serum samples were determined using a well established
IFX-especific ELISA assay (Promonitor) and the tested assay Quantum Blue.
According to the manufacturer, the lower and upper limits of quantification are:
In the Quantum Blue assay 0.4 mg/ml and 20mg/ml, respectively In the
Promonitor assay 0.035 mg/ml and 14.4mg/ml, respectively. All statistics were
carried out using the statistical programs IBM SPSS statistics 21 and Epidat
version 4.2.
Results: The IFX levels measured by the point-of-care method were higher than
those measured by established ELISA (Promonitor level: mean 4.67, median
3.2 s.d. 4.39 (0.035–14.4)); Quantum Blue level mean 6.31; median 3.7 s.d. 6.27
(0.4–20). The intraclass correlation coefficients were 0.81 (p5 0.001). The stan-
dard ELISA had a high (r¼ 0.89) and significant (p5 0.001) correlation with the
Quantum Blue assay. A Bland-Altman analysis showed a bias of 1.88% con-
firming the overall excellent correlation of the two methods. The results for each
method were stratified according to a commonly accepted therapeutic range (3–
7ug/ml; lower than 3 and higher than 7) with a high agreement. We estimated a
simplified score to convert the ‘‘point-of-care’’ level into ‘‘Promonitor’’ level and
facilitate dose management: "Nivel de Promonitor¼ 0,793þ 0,615*Nivel QB".
Conclusion: Quantum Blue assay is a really useful technique enabling the fast
and friendly quantitative determination of IFX levels to ensure correct dosing in
IBD.
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Introduction: The significance of established risk factors for colorectal cancer in
inflammatory bowel disease remains debated.
Aims & Methods: Our aim was to evaluate how individual disease variables
contribute to the development of colorectal cancer. A population-based inception
cohort of patients with ulcerative colitis patients diagnosed between 1990–1994
have been prospectively followed at one, five, 10 and 20 years after inclusion. In
total we identified 517 patients, 266 (51.5%) were males, aged median 37.4 (min
4, max 88) years at inclusion. The following variables were analyzed: age at
ulcerative colitis diagnosis, gender, presence of low or high grade dysplasia,
use of azathioprine and 5-amino salicylic acid, extent of mucosal inflammation,
first-grade relative with colorectal cancer.
Results: We identified 10 patients diagnosed with colorectal cancer after being
diagnosed with ulcerative colitis. Age at ulcerative colitis diagnosis and low grade
dysplasia were significantly associated with higher risk of CRC (HR¼ 1.06,
95%CI [1.02–1.11], p¼ 0.003 and HR¼ 86.4 95%CI [10.1–740.3], p5 0.001
for age and low grade dysplasia respectively). Patients who were older than 40
years at diagnosis had 4 times higher risk of developing colorectal cancer com-
pared to patients diagnosed with ulcerative colitis at a younger age. HR¼ 4.08,
95%CI [1.02,16.39], p¼ 0.047. Male gender (HR¼ 1.949, use of azathioprine
(HR¼ 2.50), use of 5-amino salicylic acid (HR¼ 2.92) and extent (HR¼ 1.78)
were also associated with higher risk of CRC, however the estimates did not
reach the level of statistical significance. Males diagnosed with UC when older
than 40 years and with extent of inflammation had 8.4% probability of devel-
oping CRC within 20 years after their diagnosis
Conclusion: Our results show that the presence of low grade dysplasia signifi-
cantly increases the risk of colorectal cancer. The study was limited by the sample
size.
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Introduction: Perianal fistulae are a frequent manifestation of inflammatory
bowel disease (IBD) often associated with significant morbidity, which may
precede or appear simultaneously with intestinal disease.1 The approach to
patients with perianal fistulae and no intestinal symptoms is poorly defined,
and it remains to elucidate if there is a subgroup of patients in whom a more
extensive search for IBD is warranted.
Aims & Methods: Unicentric retrospective cohort study including patients eval-
uated between 2012 and 2016 for complex perianal fistulae, defined according to
the American Society of Colon and Rectal Surgeons2. Patients with known IBD,
malignancy or history of pelvic radiation where excluded. Patients in whom the
diagnosis of IBD was established were compared to the others.
Results: 124 patients were included (mean age 48.2 17.8 years; 71.0% men),
with a mean follow-up of 26 months. 18 patients (14.5%) were diagnosed with
IBD, namely Crohn’s disease. The classification of the fistulous tracts was as
follows: intersphicteric (71.8%), transphincteric (38.7%), extrasphincteric
(7.3%), suprasphincteric (5.6%), horseshoe (24.2%) and with an abscess
(44.4%). The majority of patients with IBD presented intestinal symptoms (15/
18), in 8 cases preceding the perianal disease but not motivating investigation in
the past. In 3/18 (16.7%) patients diagnosed with IBD, perianal fistula was the
sole clinical manifestation of the disease. Patients with IBD were younger (30.1 vs
51.4 years, p5 0.001), had a higher incidence of perianal abscesses (88.9% vs
36.8%, p5 0.001), more persistent/recurrent disease (88.9% vs 50.6%, p¼ 0.003)
and a tendency to a higher number of fistulous tracts (38.9% had 5 tracts vs
17.9% in the group without IBD; p¼0.059).
Conclusion: In this cohort of patients with complex perianal fistulae, although in
the majority of cases the diagnosis of IBD was suggested by the presence of
intestinal symptoms, these were absent in 16.7% patients. There should be a
higher suspicion of IBD in young patients and in those who have perianal disease
of greater complexity.
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Introduction: In patients with inflammatory bowel disease (IBD) the addition of
an immunosuppressant (IM) after loss of response to anti-TNF alpha monother-
apy is regarded as an emerging strategy of therapeutic optimization. However,
few clinical data have been reported to date.
Aims & Methods: The aim of this study was to evaluate efficacy and tolerability
of this ‘‘selective’’ combination therapy in patients with IBD. All consecutive
patients with loss of response to anti-TNF alpha monotherapy despite an inten-
sive dose optimization who added an IM from October 2014 to October 2016
were entered in a prospectively maintained database. The steroid-free remission
and the clinical response, this latter defined as a clinical improvement (reduction
of Harvey-Bradshaw Index 3 for Crohn’s disease and of Mayo Partial Score 2
for ulcerative colitis compared with baseline) with a concomitant reduction of
steroid dosage compared with baseline and discontinuation within twelve weeks,
were set as clinical end points.
Results: Among 630 patients treated with biologics during the study period, 46
(33 Crohn’s disease and 13 ulcerative colitis) were included (table 1). A total of 31
patients (67.4%) were treated with an intravenous anti-TNF (infliximab, as
originator product or biosimilar), while 15 (32.6%) with a subcutaneous anti-
TNF agent (10 adalimumab and 5 golimumab). The mean doses of thiopurines
used in combination therapy were below those regarded as therapeutic in IBD,
methotrexate was mostly employed at a dose of 15mg/week, and all patients
treated with mycophenolate mofetil were able to tolerate the target dose of
1500mg/day. The mean duration of follow-up was 12.8 7.3 months. Twenty-
one patients (45.7%) remained on combination therapy at the end of follow-up:
15 (32.6%) maintained a steroid-free remission, and 6 patients (13.0%) achieved
a clinical response. In patients who experienced a treatment success, median
value of C-reactive protein decreased from the baseline to the end of follow-up
(13.2 vs. 3.0, p¼ 0.01; normal values 55mg/L). Adverse events leading to treat-
ment discontinuation were reported in 8 out of 46 patients (17.4%).
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Table 1
Variable N¼ 46
Age (years), meanS.D. 45.6 13.0
Male gender, n (%) 22 (47.8%)
Smokers, n (%) Never Current Ex 40 (87.0%)
4 (8.7%)
2 (4.3%)
Type of Disease, n (%) Crohn’s Disease Ulcerative Colitis 33 (71.7%)
13 (28.3%)
Duration of disease (years), meanS.D. 12.4 8.4
Localization of the disease, n (%) Crohn’s Disease Ileal
Ileocolic Colic Upper gastrointestinal tract1 Perianal
Disease involvement Ulcerative Colitis Proctitis Left-
sided Extensive
10 (30.4%)
18 (54.5%)
3 (9.1%)
2 (6.0%)
6 (18.2%)
0 (0.0%)
6 (46.2%)
7 (53.8%)
Behavior (Crohn’s Disease), n (%) Inflammatory Stricturing
Fistulizing
15 (45.5%)
14 (42.4%)
4 (12.1%)
Previous resections (Crohn’s Disease), n (%) 17 (53.1%)
Disease Activity Crohn’s Disease Harvey-Bradshaw Index
(HBI), meanS.D. Ulcerative Colitis Mayo Partial
score, mean S.D. C-Reactive Protein, mean S.D.
(n.v. 55mg/L)
7.7 3.6
4.1 1.6
16.6 25.6
Endoscopy within six months of combination therapy
initiation (n¼ 26) Crohn’s Disease SES-CD,
meanS.D. Rutgeerts score, 0/1/2/3/4 Ulcerative Colitis
Mayo Endoscopic score, 0/1/2/3
9.9 5.8
0/1/2/0/5
0/0/4/6
Extraintestinal manifestations, n (%) 21 (45.7%)
Concurrent prednisone at baseline, n (%) 20 (43.5%)
Line of anti-TNF therapy, n (%) First Second Third 10 (21.7%)
34 (73.9%)
2 (4.4%)
Experienced to the IM used in combination therapy, n (%) 13 (28.3%)
Time between start of anti-TNF therapy and addition of
IM (months), median (I.Q.I.)
7 (13.5)
Combination therapy, n (%) IFXþAZA IFXþ 6-MP
IFXþMTX IFXþMMF TOTAL IV ADAþAZA
ADAþMTX GOLþAZA GOLþMMF TOTAL SC
11/46 (23.9%)
5/46 (10.9%)
12/46 (26.1%)
3/46 (6.5%)
31/46 (67.4%)
2/46 (4.3%)
8/46 (17.4%)
2/46 (4.3%)
3/46 (6.5%)
15/46 (32.6%)
Conclusion: In patients with IBD the addition of an immunosuppressant is an
effective and safe optimization strategy after loss of response to anti-TNF alpha
monotherapy. Low doses of IM are sufficient to achieve a clinical response in this
setting.
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Introduction: Extra-Intestinal Manifestations (EIM) are frequently (up to 40%)
encountered in patients with Crohn’s Disease (CD). Commonly, their presence is
associated to a more severe degree of luminal disease and lower response to
conventional therapy (i.e. immunosuppressants). Drug trough levels are asso-
ciated with biological drug response, while the role of Anti-drug Antibodies
(AAA) is still debated. Moreover, the predicting factors associated with AAA
development have not been thoroughly studied yet. To the best of our knowl-
edge, there are no studies correlating the presence of EIM and AAA
development.
Aims & Methods: The aim of our prospective study was to identify an association
between the presence of EIM and the development of AAA in CD patients
treated with biological therapy. We prospectively enrolled 60 CD patients (32
males, median age¼ 46y, range¼ 21–72) treated either with adalimumab (ADA n
39, 65%; IFX n 21, 35%) with a median follow-up of 80 (range 14–206) weeks.
Blood samples were drawn at standardized time pointsassessed using an homo-
genous mobility shift assay (HMSA; Prometheus Lab, San Diego, United States).
Results: AAA were detected in 27 (45%) patients and their development has
proved to be more frequent in subjects treated with IFX rather than those in
therapy with ADA (n 14, 66.6% vs 13, 33.3%, P¼ 0.017). EIM were observed in
26 (43.3%) patients, without any significant difference between ADA and IFX
patients (n 17, 51.5% vs n¼ 9, 42.9%, P¼ 1). We found that ADA treated
patients with EIM were more likely to develop AAA (n¼ 9, 52.9% versus
n¼ 4, 18.2%, P¼ 0.039) while no statistically significant association between
EIM and AAA development was observed in IFX treated patients (n¼ 5,
55.5% versus n¼ 9, 75%, P¼ 0.4).
Conclusion:We found that ADA-treated patients with EIM tend to develop more
frequently AAA. Assuming that the presence of AAA reduces the effectiveness of
biological therapy, the presence of EIM may be considered a predictive factor for
loss of response to biological therapy with anti-tumor necrosis factor alpha
drugs.
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Introduction: Patients with microscopic colitis (MC) often present with abdom-
inal pain and diarrhoea1, and small cross-sectional surveys suggest that up to
one-third may meet diagnostic criteria for irritable bowel syndrome (IBS)2.
However, the impact of IBS-type symptoms in patients with MC, in terms of
their effect on psychological health and quality of life has not been assessed.
Aims & Methods: We conducted a cross-sectional survey of individuals with MC.
We analysed demographic data, symptoms that met the Rome III criteria for
IBS, mood (via hospital anxiety and depression scale (HADS)) and somatoform-
type behaviour (via patient health questionnaire-15 (PHQ-15)), and quality of life
(QOL) (via SF-36) in order to examine risk factors for, and impact of, IBS-type
symptoms in patients with MC.
Results: In total, 157 individuals with MC returned completed questionnaires, 53
(36.6%) of whom met the Rome III diagnostic criteria for IBS. The commonest
histological subtype of MC was collagenous colitis (52.9%, n¼ 83), followed by
lymphocytic colitis (38.2%, n¼ 60), and MC-not otherwise specified (8.9%,
n¼ 14). Individuals meeting the Rome III criteria for IBS had significantly
higher levels of anxiety (HADS-anxiety score 8.6 vs. 5.0, P5 0.001), depression
(HADS-depression score 6.1 vs. 3.5, P¼ 0.001), and somatoform-type behaviour
(PHQ-15 score 12.5 vs. 7.9, P5 0.001) compared with individuals who did not.
Individuals meeting the Rome III criteria scored significantly worse on all
domains of the SF-36, except for physical functioning. There were also trends
towards these individuals being younger (65 years vs. 69.2 years, P¼ 0.011) or
taking proton-pump inhibitors (58.5%, n¼ 31 vs. 42.4%, n¼ 39, P¼ 0.062).
Conclusion: More than one-third of individuals with MC met diagnostic criteria
for IBS and these individuals reported higher levels of anxiety, depression, and
somatisation plus impaired quality of life. Management strategies for these symp-
toms are required.
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Introduction: Anaemia is one of the most common extraintestinal manifestations
in inflammatory bowel disease (IBD), with iron deficiency being the most fre-
quent cause.
Aims & Methods: To characterize anemia in a population of patients with IBD
and to evaluate the efficacy of anti-TNF and carrier therapy. We retrospectively
analyzed 169/1166 patients with IBD followed in a tertiary center between 2010–
2016. All the patients received replacement therapy with ferric carboxymaltose,
ferric saccharum or transfusional support. We analyzed the effect of immuno-
suppressive therapy with and without anti-TNF: group 1 and 2 respectively.
Active disease was defined as C-reactive protein (CRP) 0.5mg/dl, faecal cal-
protectin (FC) 50ug/ml or presence of ulcers in colonoscopy. Anaemia was
defined acording to ECCO criteria (iron deficiency anaemia (IDA), anaemia of
chronic disease (ACD) and mixed anaemia (MA). Multifactorial anaemia (MFA)
was diagnosed when there was also vitamin B12 or folate deficiency.
Results: 169 patients were included: 111 with Crohn’s Disease (CD), 54 with
Ulcerative Colitis (UC) and 4 with unclassified IBD. 44.4% were male and the
mean age was 32.2 years (range 7–82). 98.2% had anemia and 1.8% had only
iron deficiency; 3.5% and 18.3% had a deficit of vitamin B12 and folate. The
most common etiologies of anemia found in CD and UC were IDA (54.1% and
46.3%), followed by MFA (19.8% and 24.1%), ACD (15.3% and 24.1%) and
MA (8.1% and 5.6%). Female gender (OR 3.743 95% CI 1.554–9.018,
p¼ 0.003), previous surgery (OR 2.845 95% CI 1.111–7.284, p¼ 0.02) and pene-
trating pattern in CD (OR 8.252 95% CI 1.289–52.919, P¼ 0,026) were predic-
tors of normal hemoglobin (Hb). CRP was associated with highest ferritin values
(294.85 302.00 vs 102.10 127.75, p5 0.001). Hb and CRP had a negative
correlation (p.c-0.176, p¼ 0.022). In UC, CRP and FC normalization was asso-
ciated with higher Hb and transferrin saturation (13.63 1.66 vs 12.47 1.38,
p¼ 0.005 and 51.33 26.50 vs 27.63 9.96, p¼ 0.048). There was no difference
in the parameters evaluated comparing groups 1 and 2. There was also no sig-
nificant difference in the variation of Hb and iron values after treatment with
ferric saccharum or ferric carboxymaltose.
Conclusion: In a population of patients with IBD, iron deficiency was the main
cause of anaemia and the two forms of intravenous iron replacement were
equally effective. In the group of patients with UC, elevated CRP was associated
with anaemia.
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Introduction: Ustekinumab (UST) has been shown to be effective in refractory
Crohn’s disease (CD) in phase III trials. The aim of the present study was to
prospectively evaluate the association between UST trough levels and anti-uste-
kinumab antibodies, with the response and the remission to induction and main-
tenance UST treatment in CD patients.
Aims & Methods: We performed a prospective study including all CD patients
refractory to anti-TNF who received subcutaneous UST from September 2015 to
November 2016 in the tertiary French referral center of Gastroenterology in
Claude Huriez hospital in Lille. During induction patients received 90mg of
SC UST at week 0, 4 and 12. During the maintenance phase patients received
90mg of SC UST every 8 weeks that could be optimized by shortening injection
interval to every 4 weeks in case of loss of response. Clinical response was defined
by a decreased Harvey Bradshaw Index (HBI) by 3 points, clinical remission by
HBI 55, loss of response by new increase of HBI. UST trough levels and anti-
bodies were dosed at 12 weeks, and at a single time-point for patients who had
received more than 3 months of UST. The results of dosage were obtained by
enzyme-Linked ImmunoSorbent Assay technique. We evaluated the correlation
between clinical and biological response and remission to UST, and UST through
levels and antibodies concentrations. Differences between independent groups
were traced with the use of the Mann–Whitney exact test.
Results: Forty-eight patients with active disease received at least three UST injec-
tions and were prospectively included. At time of ustekinumab introduction 77%
of patients received concomitant immunosuppressant and 42% received corticos-
teroids. At the end of the induction phase (week 12) clinical response was
observed in 57% patients. There was no significant difference in mean UST
trough levels in patients who responded to UST induction (median 1160 ng/ml;
IQR: 603–1644) as compared to patients who did not respond (median 1556 ng/
ml; IQR: 494–2758, p¼ 0.24). Forty-three (90%) patients received at least 4
injections of UST, with 12 patients who were optimized at the time of dosages.
Clinical response was observed in 30/43 (70%) patients. Median UST concentra-
tion in clinical responder was 1359 ng/ml (IQR: 554–2068) and 2392 ng/ml in
non-responder (IQR: 1496–3494), with no significant difference between the
two groups of patients (p¼ 0.20). UST antibodies were undetectable for the 48
patients.
Conclusion: We confirmed that UST treatment is effective in the majority of CD
patients refractory to anti-TNF agents. Median trough levels to UST are not
correlated to response and remission to UST induction and maintenance treat-
ment, with no antibodies developed against UST.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1684 ECONOMIC IMPLICATIONS IN INFLAMMATORY BOWEL
DISEASES: RESULTS FROM A RETROSPECTIVE ANALISYS IN AN
ITALIAN CENTRE
A. Massella
1, A. Variola1, R. Tessari2, T. Zuppini2, R. Ravasio3, A. Geccherle1
1Gastroenterology, Ospedale Sacro Cuore, Negrar/Italy
2Pharmacy, Ospedale Sacro Cuore, Negrar/Italy
3Health Publishing & Services, Milano/Italy
Contact E-mail Address: arianna.massella@gmail.com
Introduction: Inflammatory bowel diseases (IBDs) are chronic conditions char-
acterized by elevated costs (both direct and indirect). Over the last years also a
significative healthcare burden associated with IBD has emerged, due to an
increasing use of biological therapies and hospitalization costs. Despite the crea-
tion of local or regional databases in Italy data regarding healthcare expenditure
are lacking.
Aims & Methods: The aim of this study was to evaluate costs comprehensive of
biological treatments and hospitalizations in a series of patients with ulcerative
colitis (UC) and Crohn’s disease (CD) and their correlation with demographic
and clinical variables. Disease severity was evaluated by clinical scores (partial
Mayo score for UC, Harvey Bradshaw Index for CD). We analyzed retrospec-
tively patients treated by biologics referred to our IBD Unit between May 2015
and April 2016 who underwent at least six months follow-up (last visit October
2016). As regards biological therapies costs burdened by our Centre pharmacy
for each drug (Infliximab, Adalimumab, Golimumab, Vedolizumab) and for
single patient were evaluated. About hospitalizations the average costs of hospi-
tal care specific for a department through fares for homogeneous groups of
patients i.e. Diagnosis-Related Group (DRG) were collected. The mean overall
monthly expenditure for each case was then evaluated.
Results: We collected clinical-economical data of 142 patients in biological treat-
ment in the selected period (52 UC, mean age 44.3 years and male 40.4%; 90 CD,
mean age 38.8 years and male 56.7%). About half of CD patients (48.9%) under-
went previous intestinal surgery. The disease severity was higher in UC group vs
CD one. In UC group Infliximab was the most prescribed biologic (51.9%),
followed by Golimumab (29.9%) and Adalimumab (21.2%). While CD patients
were treated with Adalimumab in 54.4% and Infliximab in 45.6%. The average
cost for month of treatment was 1235.41 358.38 E for UC and 1148.92 337.36
E for CD (no statistical differences between the groups). In both groups expen-
diture due to biologics amounts for more than 80%. We analyzed costs in groups
different for sex, age and disease activity (only the last one was associated with
increased costs with R2¼ 0.84 for UC and 0.95 for CD). The cost increases in
patients with more lines of therapy in UC (not in CD) but the difference wasn’t
significative.
Conclusion: In our study the main cost is due to biological therapy but the
subjects enrolled were the most severe in comparison to the whole IBD popula-
tion under conventional therapy. No differences were found between the type of
biologic administered and the way of administration (intravenous or subcuta-
neous) so the therapeutical choice could be driven by clinical reasons and not
only economic ones.
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Introduction: The monitoring of appropriateness, costs, and clinical outcomes of
biological therapy in inflammatory bowel disease (IBD) is a relevant need.
Aims & Methods: We aimed to evaluate all these issues in Sicily through a web-
based network of all prescribing centers. The Sicilian Network for Inflammatory
Bowel Disease (SN-IBD) is composed by a super Hub coordinator centre and
five Hub plus ten Spoke centres. From January 2013, all IBD patients starting a
biological agent (incident cases) or already on treatment (prevalent cases) were
entered in a web based software. Herein we report data of incident cases about
the efficacy of biological therapy after twelve weeks and one year of treatment.
As clinical end-point, we set remission (corresponding to a Mayo Partial Score
52 for UC, and to a Harvey-Bradshaw Index 55 for CD), and response (reduc-
tion of Harvey-Bradshaw Index 3 for CD and Mayo Partial Score 2 for UC
compared with baseline).
Results: From January 2013 to January 2017, 1578 patients were included.
Incident cases were 1151 (808 Crohn’s disease [CD], 335 ulcerative colitis [UC],
8 unclassified colitis). Considering that 22.2% of patients experienced more than
one line of therapy, a total of 1407 treatments were reported. CD: there was a
higher proportion of patients naı̈ve to biologics among those on adalimumab
(ADA) compared with infliximab (IFX) and vedolizumab (VDZ) (89.3% vs.
53.3% vs. 30.6%, p5 0.001). At week 12, there was a higher rate of response/
remission for adalimumab (ADA) compared with infliximab (IFX) and vedoli-
zumab (VDZ) (79.8% vs. 71.8%, p¼ 0.005, and 79.8% vs. 47.2%, p5 0.001,
respectively), and a higher efficacy of IFX compared with VDZ (71.8% vs.
47.2%, p¼ 0.004). The superiority of ADA over IFX remained significant in
naı̈ve patients (81.5% vs. 73.7%, OR 1.581, p¼ 0.026), but not in non-naı̈ve.
At week 52, ADA had a higher rate of response compared to IFX (65.4% vs.
56.0%, p¼ 0.018). However, there was no statistical difference between the two
drugs when patients were stratified in naı̈ve and non-naı̈ve, while ADA was
superior over IFX in patients with ileo-colic disease (68.8% vs. 48.4%, OR
2.282, p¼ 0.001). UC: there was a higher proportion of patients naı̈ve to biolo-
gics among those on IFX compared with GOL and ADA (91.6% vs. 44.1% vs.
55.4%, p5 0.001). At week 12, there was a higher rate of response/remission for
IFX compared with golimumab (GOL) (71.8% vs. 56.6%, p¼ 0.034), but this
difference was lost when patients were stratified in naı̈ve and non-naı̈ve. At week
52, IFX had a higher rate of response/remission compared to GOL (58.2% vs.
38.2%, p¼ 0.039) and ADA (58.2% vs. 33.9%, p¼ 0.002). However, IFX was
superior to GOL in naive patients only (60.2% vs. 26.7%, OR 4.165, p¼ 0.018;
interaction test: p¼ 0.02), but non in non-naı̈ve, and IFX was superior to ADA
in naive patients only (60.2% vs. 37.8%, OR 2.650, p¼ 0.029). For both CD and
UC, no significant difference in efficacy was observed between IFX originator
and biosimilars. Several factors were identified as predictor of response -
independently of the drug employed - at multivariable logistic regression analysis
(table 1).
Table 1
DISEASE–TIME POINT VARIABLE OR p
CD–12 WEEKS Naive to biologics 1.989 50.001
Age (continuous variable) 0.982 50.001
Upper GI tract involvement 0.388 0.002
Perianal disease 0.650 0.029
CD–52 WEEKS Naive to biologics 2.262 50.001
Upper GI tract involvement 0.394 0.005
UC–12 WEEKS Naive to biologics 2.188 50.001
UC–52 WEEKS Naive to biologics 2.338 50.001
Current smoking 1.562 0.007
Conclusion: In one of the largest ‘‘real-life’’ series of IBD patients on biological
therapy reported to date, ADA in CD had a higher success compared to IFX at
both 12 and 52 weeks; however, this results could be influenced by the preference
of ADA as first-line anti-TNF drug in CD. IFX in UC was superior to GOL and
ADA at 52 weeks; once again, this result could be influenced by the preference of
IFX as first-line anti-TNF agent in UC; no difference was found between GOL
and ADA in UC. Being naı̈ve to biologics is a relevant predictor of response in
both CD and UC at any time point. No significant difference in efficacy was
observed between IFX originator and biosimilars.
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Introduction: Microscopic colitis (MC) is a common cause of chronic watery
diarrhoea which is effectively treated with budesonide. However, in rare cases
patients are refractory to budesonide leading to a severely deteriorated quality of
life. Data on treatment options for budesonide refractory MC patients are sparse.
We retrospectively evaluated the outcome of MC patients who have received
biological therapy at our centre
Aims & Methods: All patients with MC treated with biological therapy at the
Department of Gastroenterology, University hospital Linkoping, Sweden were
selected and the outcome recorded. Patients were investigated according to sex,
age, disease subtype, clinical remission (defined as 5 mean 3 and no watery
stools/day/week), clinical response (defined as 50% reduction of mean stool
frequency/day/week), side effects and long-term outcome.
Results: 14 patients (10 women) with mean age at diagnosis of 49 years (range 19–
76), thereof 12 with collagenous colitis and 2 with lymphocytic colitis were inves-
tigated. All 14 patients had received anti-TNF agents (11 adalimumab (ADA), 3
infliximab (IFX). ADA was given as induction treatment (160–80-40mg) and
IFX 5mg/kg at week 0, 2 and 6. Six patients achieved clinical remission. Of
these, 2 patients maintained clinical remission for several years after induction
treatment, 2 patients are on maintenance treatment with 40mg ADA/eow, one
patient on 400mg INF every 8 weeks and one patient had loss of response and
did not gain clinical remission despite the use of a third anti-TNF agent (certo-
lizumab). Four patients had a clinical response but stopped treatment due to side
effects (vomiting, anxiety, fatigue and eczema–all reversible). Four patients had
no effect on anti-TNF despite the fact that 2 patient had even tested both anti-
TNF agents. Of these 4 patients who failed anti-TNF, 3 patients received treat-
ment with vedolizumab (300mg week 0, 2 and 6) without effect. One patient had
further treatment with rituximab (1000mg twice) and another patient tested
ustekinumab (390mg once); both did not achieve any clinical improvement.
Conclusion: Budesonide refractory MC patients can achieve clinical remission or
response on anti-TNF agents. In the cases that failed anti-TNF, further treat-
ment with vedolizumab (n¼ 3), rituximab (n¼ 1) and ustekinumab (n¼ 1) did
not improve the clinical condition. Prospective studies with long duration are
necessary to evaluate the efficacy of various biological treatments in budesonide-
refractory MC.
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Introduction: Recent studies have shown that FODMAPs (Fermentable
Oligosaccharides, Disaccharides, Monosaccharides, and Polyols)-free diet is
effective in subjects with Irritable Bowel Syndrome (IBS). Patients with
Inflammatory Bowel Diseases (IBD), and celiac disease (CD) can experience
functional gastrointestinal symptoms unrelated to inflammation, but data
about the use of low FODMAPs diet in these settings is still scarce.
Aims & Methods: To evaluate the usefulness of a low FODMAPs diet on patients
with IBS, non-active IBD, and CD on strict gluten-free diet (GFD), we per-
formed a dietetic interventional prospective study evaluating the effect of a low
FODMAPs diet on subjects affected by IBS, CD following at least a 1-year-GFD
and IBD who had been experiencing abdominal symptoms without signs of
active inflammation. Each subject was put on a low FODMAPs diet after
being evaluated by filling out questionnaires concerning on quality of life and
symptoms experienced (IBS-SSS and SF-36), and was re-evaluated twice, first
after 1 month and second after 3 months.
Results: 127 subjects were enrolled: 56 with IBS, 30 with IBD and 41 with CD.
The analysis of the IBS-SSS survey showed that abdominal symptoms improved
after 1 month and 3 months of low FODMAPs diet in all subjects, with statis-
tically significant difference within each group at T0 (average score in IBS:
293 137 SD, average score in IBD: 206 86 SD, average score in CD:
222 65 SD, p5 0.001). Furthermore, by analysing the SF-36 questionnaire,
while we did not observe any significant difference between the three groups,
in terms of response to diet (p¼NS), we observed a clinical improvement from
T0 to T3, after the start of the diet, for most of the questionnaire’s domains.
Conclusion: A low FODMAPs diet could be a valid option to counter abdominal
symptoms in patients with IBS, non-active IBD or CD on GFD, and, thus
improve their quality of life and social relations.
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Introduction: Vedolizumab (VDZ) is a new biologic agent approved for the treat-
ment of adult patients with moderately to severely active ulcerative colitis (UC)
and Crohn’s disease (CD).
Aims & Methods: The Sicilian Network for Inflammatory Bowel Disease (SN-
IBD) is a group composed by all Sicilian centres prescribing biologics. These
centres continuously enter in a web based software all real-life data about pre-
scriptions ond outcomes of biological therapy in patients with inflammatory
bowel disease (IBD). Herein we report data on efficacy of VDZ on intestinal
and articular symptoms after 10 and 24 weeks of treatment. As clinical end-point,
we set steroid-free remission (corresponding to a Mayo Partial Score 52 for UC,
and to a Harvey-Bradshaw Index 55 for CD), and clinical response (reduction
of Harvey-Bradshaw Index 3 for CD and Mayo Partial Score 2 for UC
compared with baseline with a concomitant reduction of steroids dosage at
week 10, and complete discontinuation at week 24).
Results: From July 2016 to April 2017, 163 patients (84 with CD and 79 with UC)
were included (table 1). At week 10, a steroid-free remission was obtained in 71
patients (43.6%), while a clinical response in 37 (22.7%). Out of 71 patients
reaching 24 weeks of follow-up, 29 (40.8%) were in steroid-free remission, and
10 (14.1%) had a clinical response. No significant difference in terms of clinical
benefit (rate of remission plus clinical response) among patients with UC and CD
was reported at week 10 (68.4% vs. 64.3%, respectively; p¼ 0.58) and at week 24
(54.3% vs. 55.6%, respectively; p¼ 0.91), and no difference was observed com-
paring naı̈ve and non naı̈ve patients, neither at week 10 (61.5% vs. 67.7%,
respectively; p¼ 0.48) nor at week 24 (30.0% vs. 59.0%, respectively; p¼ 0.11).
At multiple logistic regression analysis, a longer duration of disease (OR 0.961,
p¼ 0.047) and presence of steroid-dependence (OR 0.189, p¼ 0.033) were pre-
dictors of reduced rates of clinical benefit at week 10, while a low serum level of
C-reactive protein at baseline (OR 0.950, p¼ 0.031) was predictor of clinical
benefit at week 24. An improvement of articular symptoms was reported in
39.5% of patients with active spondyloarthritis at baseline at week 10, and in
45.4% of patients at week 24. The only factor associated with articular response
was the coexistence of clinical benefit on intestinal symptoms, both at week 10
(OR 8.471, p¼ 0.05) and week 24 (OR 5.600, p¼ 0.08). Three inductions or flares
of spondyloarthritis during treatment with VDZ were reported.
Table 1
Variable N¼ 163
Age (years), mean S.D. 50.6 16.0
Male gender, n (%) 94 (57.7%)
Smokers, n (%) Never Current Ex 134 (82.2%)
17 (10.4%)
12 (7.4%)
Type of Disease, n (%) Crohn’s Disease Ulcerative
Colitis
84 (51.5%)
79 (48.5%)
Duration of disease (years), meanS.D. 11.7 8.5
Localization of the disease, n (%) Crohn’s Disease
Ileal Ileocolic Colic Upper gastrointestinal tract1
Perianal Disease Ulcerative Colitis Proctitis Left-
sided Extensive
22 (26.2%)
50 (59.5%)
8 (9.5%)
4 (4.8%)
12 (14.3%)
1 (1.3%)
25 (31.6%)
53 (67.1%)
Behavior (Crohn’s Disease), n (%) Inflammatory
Stricturing Fistulizing
36 (42.9%)
42 (50.0%)
6 (7.1%)
Previous resections (Crohn’s Disease), n (%) 51 (60.7%)
Disease Activity Harvey-Bradshaw Index, Crohn’s
Disease - meanS.D. Mayo Partial score,
Ulcerative Colitis - mean S.D. C-Reactive
Protein, meanS.D. (n.v. 55mg/L)
8.3 4.6
3.9 2.4
9.8 15.7
Endoscopy within three months of initiation of
VDZ (n¼) Crohn’s Disease SES-CD, mean 
S.D. Rutgeerts score, 0/1/2/3/4 Ulcerative Colitis
Mayo Endoscopic score, 0/1/2/3
7.6 7.5
1/3/4/5/13
2/4/40/24
Extraintestinal manifestations IBD-associated SpA
Past history (inactive at initiation of VDZ)
Peripheral arthropathy Axial arthropathy Active
at initiation of VDZ Peripheral arthropathy
Axial arthropathy Cutaneous Ocular
7 (4.3%)
0 (0%)
40 (24.5%)
15 (9.2%)
4 (2.5%)
1 (0.6%)
Previous biological treatments Yes No (naı̈ve to
biologics)
124 (76.1%)
39 (23.9%)
Indication for treatment with VDZ Failure of anti-
TNF therapy Contraindications to anti-TNF
therapy
109 (66.9%)
54 (33.1%)
Steroid-dependent, n (%) 144(88.3%)
Systemic steroids at baseline, n (%) 103 (63.2%)
Concurrent therapy with immunosuppressant, n
(%)
13 (8.0%)
Conclusion: In this large cohort of Sicilian IBD patients, VDZ showed good
efficacy after 10 and 24 weeks of treatment, particularly in those with a shorter
duration of disease and a limited inflammatory burden. A subset of patients
reported improvement also on articular symptoms, probably as a consequence
of the concomitant control of gut inflammation.
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Introduction: Combined immune suppression of anti-tumour necrosis factor
(antiTNF) biologicals and thiopurines is superior to respective monotherapies
in remission induction and maintenance of response in inflammatory bowel dis-
ease (IBD). One of the putative mechanism of this clinical benefit is mutually
positive pharmacokinetic effect of thiopurines on antiTNF levels and vice versa.
It has been suggested that for this synergistic effect, reduced dose of thiopurines
might be sufficient but the data supporting this hypothesis are still limited.
Aims & Methods: The aim of the study was to assess the differences of infliximab
trough levels according to the dose of concomitantly used thiopurines. All IBD
patients treated with infliximab (Remicade) in two IBD centra between
November 2015 and April 2017 were eligible. Infliximab trough levels were rou-
tinely measured in all patients with maintenance infliximab therapy using com-
mercially available ELISA kit (Ridascreen, R-Biopharm). All patients in
remission with stable dose regimen of 5mg/kg every 8 weeks at the time of the
first assessment of infliximab trough levels were identified retrospectively from
the medical records. The differences in the proportion of patients with adequate
trough levels (3–12mg/mL) between patients on infliximab monotherapy, reduced
(below 2mg/kg) azathioprine (AZA) dose vs. full (2 to 2.5mg/kg) AZA dose were
analyzed statistically.
Results: Out of a total of 214 IBD patients treated with infliximab, there were 154
in remission at the time of the first assessment of infliximab trough levels. After
excluding patients with previously intensified dose regimen, 125 patients were
further analyzed. Among these 125 pts, 41 pts (33%) were on infliximab mono-
therapy, 58 pts (46%) were using combined immune suppression with a reduced
dose of AZA and 26 (21%) were using the full AZA dose concomitantly with
infliximab. Both groups, patients with infliximab monotherapy as well as patients
using a reduced AZA dose had significantly lower percentage of patients with
therapeutic levels of infliximab compared with the group using the full dose AZA
co-medication (41% vs. 64% vs. 81%; infliximab monotherapy, reduced AZA
dose and full AZA dose, respectively; p5 0.001 for both comparisons, infliximab
monotherapy vs. AZA full dose and reduced AZA dose vs. full AZA dose).
Conclusion: The proportion of patients with adequate infliximab trough levels is
significantly higher in patients with full dose of concomitant azathioprine com-
pared with the patients using a reduced dose of azathioprine. Thus, in order to
maximize the chances for sustained benefit from infliximab maintenance treat-
ment, the combined immune suppression should comprise full dose of
azathioprine.
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Introduction: The primary drugs used for inflammatory bowel disease (IBD)
treatment have some adverse effects and often are ineffective, so the need for
more potent and more reliable medications is clear. A significant role at all the
stages of the inflammatory process is attributed to reactive oxygen species, there-
fore the use of antioxidants is a promising direction of the IBD therapy.
Aims & Methods: Q60 fullerenes are the effective free radicals scavengers [1],
therefore the evaluation of possible protective properties of water-soluble pristine
Q60 fullerenes using the simulation of acute ulcerative colitis (UC) in rats was
aimed to be discovered. The pristine C60 fullerene aqueous colloid solution
(C60FAS; initial concentration 0.15mg/ml) was prepared according to the pro-
tocols developed before [2]. UC was simulated by acetic acid intracolonic instilla-
tion. C60FAS was intraperitoneally or intrarectally applied at dose of 0.5mg/kg
C60 daily for 2 times after UC induction. The colon injury was estimated semi-
quantitatively on macro- and light microscopy levels using 10- and 14- grade
scales respectively, and the grade of total injury (GTI) was calculated, perme-
ability of colon epithelium was estimated by phenol red dye daily excretion. The
states of the colon, liver, pancreas and spleen were assessed by histological
(hematoxylin-eosin staining) and biochemical (plasma blood liver enzymes activ-
ity) methods, quantitative blood indices were calculated and leucograms were
analyzed.
Results: Colon wall edema, hyperemia and hemorrhage on bowel internal sur-
face, ulcers of different size, epithelium desquamation and inflammatory features
manifested by submucosa lymphoid and histiocytic infiltration and extravasation
appeared under UC condition. GTI was equal to 12 (GTIcontrol¼ 0). Rat diurnal
phenol red dye excretion exceeded the control one 6.6 times suggesting the
damage of colon epithelial barrier. Degenerative features of exocrine pancreas
and liver injury were also observed in UC rats. Anemia features manifested by
hemoglobin concentration and red blood cell count decrease, reticulocytes
volume, hematocrit and the platelet count increase could be caused by intestinal
hemorrhages and subsequent erythro- and megakariocytopoiesis following active
release of ‘‘young’’ erythrocytes (reticulocytes) and platelets into the blood. The
last could be confirmed with histological assay (rise of the erythroblastic islets
and megakaryocytes numbers in the spleen). Increase the number of neutrophils
and spleen lymphatic follicles suggested the inflammatory process in the organ-
ism. The application of C60FAS by both ways caused GTI drop down to 6 points,
restored the mucosa epithelial barrier integrity, attenuated the signs of anemia
and normalized the platelet and neutrophils counts, AST and the state of spleen.
In addition, C60FAS intraperitoneally restored the state of the pancreas but
increased liver functional upload (as evidenced by elevated ALT activity),
whereas its rectal application normalized both ALT and AST activities but
didn’t affect the pancreas. Moreover, C60FAS rectally increased monocytes
number, which could be explained by involving the latest in mucosa healing
process.
Conclusion: Q60FAS corrects local and systemic morphofunctional changes, con-
ditioned by the induction of acute UC. The protective properties of Q60 fullerenes
against bowel, hematopoietic system and liver due to its local application are
more expressed compared to their systemic one, but their impact on pancreas is
controversial. Thus, water-soluble pristine C60 fullerenes could be used as effi-
cient therapeutic agents at ulcerative colitis.
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Introduction: Tacrolimus, a calcineurin inhibitor, has been shown to be safe and
effective when used as salvage therapy for steroid-refractory ulcerative colitis
(UC). Its pharmacological effect has been reported to be dependent on trough
level in blood, though little is known regarding predictive factors in relation to
the clinical efficacy of tacrolimus in UC patients.
Aims & Methods: The aim of this study was to identify factors related to predic-
tion of short- and long-time efficacy of tacrolimus for UC. We retrospectively
reviewed the medical records of patients with moderate to severe steroid-refrac-
tory UC who were treated with tacrolimus as induction therapy at Shimane
University Hospital between January 2010 and March 2016. Oral tacrolimus
was administered at a whole-blood trough level of 10–15 ng/mL to induce remis-
sion and then 5–10 ng/mL to maintain remission. Following tacrolimus therapy
for 3 months, patients in clinical remission were given azathioprine for mainte-
nance at an appropriate dosage. Using the Rachmilewitz clinical activity index
(CAI), clinical remission was defined as a score of 4. Predictive factors asso-
ciated with short- and long-term tacrolimus efficacy were analyzed by evaluating
various clinical parameters.
Results: Thirty-six patients received oral tacrolimus for induction, of whom 22
(61.1%) and 27 (75%) experienced clinical remission at 2 and 12 weeks, respec-
tively, after starting therapy. In patients showing short-term efficacy, the clinical
remission rate at 2 weeks was significantly associated with CAI at 12 weeks.
Interestingly, of the 22 patients in clinical remission within 2 weeks, 21
(95.5%) remained in remission at 12 weeks. In contrast, only 6 of 14 (42.9%)
who did not achieve clinical remission at 2 weeks were not in clinical remission at
12 weeks. For evaluating the long-term efficacy of tacrolimus induction therapy,
relapse-free periods were assessed using the Kaplan-Meier method. The relapse-
free rate at 48 weeks was higher in patients who achieved clinical remission within
2 weeks as compared to those without remission at that time point (79.0% vs.
60.0%).
Conclusion: Tacrolimus induction therapy was effective for patients with moder-
ate to severe steroid-refractory UC. Our results clearly indicate that clinical
remission achievement within 2 weeks is useful for predicting both short- and
long-term outcome in UC patients treated with that therapy.
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Introduction: UC is a potentially severe disease that carries an increased risk of
complications and colectomy. Immunosuppressant and biological therapies are
relevant tools for complex patients. The ACCENT study showed that in Crohn’s
disease (CD), scheduled IFX infusions vs. episodic are associated with greater
efficacy. In UC, historical difficulties of economic access had conditioned to our
IBD center, to use IFX in moderate to severe UC as a bridge to thiopurines in pts
6mp/aza naı̈ve. In UC, the mentioned strategy was insufficiently compared with
a regimen of scheduled IFX treatment, that currently we use.
Aims & Methods: Our aim was to compare (retrospectively) in moderate to severe
UC the results of induction with IFX (in thiopurine naı̈ve pts.) continuing with
6mp/aza maintenance vs. similar induction followed by scheduled IFX mainte-
nance strategy.
We included a cohort of moderate to severe UC treated with IFX in an IBD
center (2006 to 2015) comparing results between IFX bridge followed by thio-
purines (re-induction when available for moderate to severe relapse) vs. sched-
uled IFX (induction 0,2,6 wks and 8 wks’ interval infusions maintenance).
Optimization (by frequency of intervals) was allowed in both modalities.
Comparisons: Kaplan Meier/Log rank test: a) Cumulative incidence of colect-
omy, b) survival times relapse free, c) survival times corticosteroid free.
Results: We identified 135 UC patients receiving IFX for moderate to severe UC
(M 60, F 75, Age (meanSD) 35.9 13.2, UC duration 5.8 5.9 yrs, Extent:
extensive 58.5%, Left-sided 41.5%, Activity: severe 78.5%, moderate 21.5%,
mean Mayo score: 10.1 1.8. Primary no responders at week 12 (n 25: 18.
5%) were not considered in maintenance comparisons, which were performed
in 110 out of the 135 pts. (Follow-up 37.5 24.0 months) Groups: IFX bridge
(n¼ 51) and scheduled IFX (n 59), which were not different in extent, and mean
age, UC duration, Mayo score. Cumulative incidence of colectomy was signifi-
cantly lower in the scheduled strategy (HR: 6.8805, 95% CI 1.7207 to 27.5133,
p¼ 0.0349), survival times free of relapse (HR 3.1026, 95% CI 1. 8368 to 5.2405,
p5 0.0001) and free of corticosteroids (HR 2.6057, 95% CI 1.5516 to 4.3757,
p¼ 0.0003). A proportion of UC significantly higher within the re-induced pts
(IFX bridge) required a shift of biological drug compared with the scheduled
strategy (p¼ 0.016, Fisher), despite of similar rates of optimization. Infusion
reactions needing definitive IFX suspension were more frequent as a trend
(p5 0.06) in re-induced pts.
Conclusion: Similarly to was described for CD pts, in the CU, the scheduled IFX
treatment strategy regimen, after a moderate-severe outbreak, seem to be asso-
ciated with better long-term outcome regarding colectomy requirement, relapses,
and need for corticosteroids, compared with a bridge IFX strategy followed by
thiopurines
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Introduction: Arthropathies are the most common extra-intestinal manifestation
(EIM) in patients with inflammatory bowel disease (IBD). Psychological and
behavioural factors, including illness perceptions and coping strategies, perceived
by IBD patients with arthropathies may differ from patients without arthropa-
thies and may change during follow-up. Understanding these differences and
changes over time, creates knowledge for health care professionals about inter-
ventions that may be effective in IBD patients with arthropathies.
Aims & Methods: This longitudinal follow-up study evaluates the differences in
illness perceptions (individual cognitions and emotions about a disease), coping
strategies (behavioral efforts and strategies to deal with a chronic disease) and
illness outcomes between IBD patients with and without arthropathies, and
examines the changes of these variables in IBD patients with arthropathies
after 12 months.
In total, 204 IBD patients with (n¼ 123) and without (n¼ 81) arthropathies
completed questionnaires at baseline and after 1 year follow-up to assess illness
perceptions (Revised Illness Perception Questionnaire), coping strategies (Coping
with Rheumatic Stressors Questionnaire) and illness outcomes including quality
of life (Short Form-36), and activity and work impairment (Work Productivity
Activity Index). Linear regression analyses were used to assess the impact of
arthropathies on illness perceptions, coping and illness outcomes compared
with IBD patients without arthropathies. Mixed model analyses were used to
evaluate the change of these factors in IBD patients with arthropathies over time.
Results: Linear regression models demonstrated that arthropathies in IBD were
associated with the illness perceptions strong ‘illness identity’ (ß 1.15 (95%CI
0.31–1.98), p¼ 0.007), strong ‘cyclical timeline’ (ß 1.33 (95%CI 0.33–2.34),
p¼ 0.010), more ‘consequences’ (ß 2.00 (95%CI 0.60–3.42), p¼ 0.006), stronger
‘emotional representations’ (ß 1.58 (95%CI 0.08–3.08), p¼ 0.039) and a low
‘coherence’ (ß 1.29 (95%CI 2.45-(0.14)), p¼ 0.029). In addition, the
coping strategies increased ‘diverting attention’ (ß 1.34 (95%CI 0.02–2.66),
p¼ 0.047) and increased ‘consideration’ (ß 1.18 (95%CI 0.10–2.27), p¼ 0.033),
as well as the illness outcomes low physical (ß 7.22 (95%CI 9.68-(4.77)),
p5 0.001) and mental (ß 3.10 (95%CI 5.99-(0.23)), p¼ 0.035) health and
increased activity impairment (ß 0.15 (95%CI 0.07–0.23), p5 0.001) were related
with arthropathies in IBD. After 12 months follow-up, lower scores on the illness
perception dimension ‘treatment control’ (p¼ 0.001) and increased scores on the
coping strategy ‘pacing’ (p¼ 0.03) were found in IBD patients with arthropathies
compared with baseline scores.
Conclusion: Suffering from arthropathies in IBD is strongly associated with dif-
ferent illness perceptions, coping strategies and illness outcomes and changes of
these factors over time. As a gastroenterologist, addressing the maladaptive ill-
ness perceptions, coping strategies and related poor illness outcomes in these
patients, may provide an important target for behavioural and physical interven-
tions including cognitive behavioural therapy (CBT) or physical exercise.
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Introduction: CT-P13, the first biosimilar monoclonal antibody to infliximab
(IFX) has previously been confirmed to be efficacious in inducing mucosal heal-
ing in ulcerative colitis (UC) patients.
Aims & Methods: The aim of this study was to evaluate the efficacy of CT-P13
therapy in maintaining mucosal healing in UC. Patients diagnosed with UC, who
were administered CT-P13 from June 2014 at 4 Hungarian and one Czech IBD
Centre were prospectively enrolled. Sigmoideoscopy was performed at week 14
and week 54 to assess mucosal healing. Mucosal healing was defined as Mayo
endoscopic subscore of 0 or 1. Complete mucosal healing was defined as Mayo
endoscopic subscore of 0. CT-P13 trough levels, antibody positivity, serum
inflammatory markers as CRP level, fecal calprotectin at weeks 14 and 54, con-
comitant steroid and azathioprine therapy at the time of induction therapy and at
weeks 14 and 54, previous use of anti TNF drug and the need of dose intensifica-
tion as possible predictive factors for mucosal healing at week 54 were evaluated.
Results: Seventy-five UC patients were included in the study of which 74 patients
completed the induction therapy and 54 patients had already completed the 54-
week treatment period. Mucosal healing was shown in 55.4% of the patients at
week 14 and in 61.7% at week 54 (p¼ 0.33). Complete mucosal healing was
present in 24.3% at week 14, but in 36.2% at week 54. The median values of
CRP (p¼ 0.017), leukocytes (p¼50.001), thrombocytes (p¼50.001), and albu-
min (p¼ 0.002) showed significant difference at baseline and week 54. Mean
trough level of CT-P13 was 5.02 mg/ml and 4.4 mg/ml at week 14 and 54.
Serum antibody positivity was proved in 7.7% and 26.2% of cases at week 14
and 54, respectively. Dose escalation was necessary in one third of patients. None
of the patients need surgery who completed week 54, however 4 subjects who
stopped CT-P13 therapy after induction regimen required colectomy.
Conclusion:Mucosal healing was revealed in two-third of the patients during CT-
P13 maintenance therapy. Our study confirmed the long-term efficacy of CT-P13
therapy on mucosal healing in UC.
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Introduction: Anti-tumor necrosis factor (anti-TNF) agents, infliximab (IFX) and
more recently adalimumab (ADA) and golimumab (GOL), have been shown
effective and safe in the treatment of moderate-to-severe ulcerative colitis
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(UC). Lack of head-to-head RCTs makes the choice among the three anti-TNFs
difficult and indirect comparisons by network metanalyses lead to discrepant
results.
Aims & Methods: Our aim was to compare efficacy of IFX, ADA and GOL in
inducing clinical response and remission in a prospective cohort of patients with
moderate to severe UC. From June 2015 to October 2016, 61 consecutive UC
patients were treated with anti-TNFs: 19 with IFX, 25 with ADA and 17 with
GOL. Disease activity was assessed by Mayo Score. Clinical response and/or
remission were evaluated at week 8 and at week 16. We also recorded: indications
to biologic therapy, previous immunosuppressive or anti-TNF therapy and rate
of anti-TNF discontinuation.
Results: Among the 61 patients,36 were males; mean age was 43,6 15, no sig-
nificant difference was present in baseline characteristics (extent and disease
activity); 39 patients were thiopurine failure; 38 were naıve to anti-TNFs, most
were treated with IFX (p¼ 0.001). ADA and GOL were more often used as a
second-line or third-line. The principal indication for steroid resistance patients
was IFX. No significant difference was observed between IFX and ADA both at
week 8 (response p¼ 0.28; remission p¼ 0.68) and at week 16 (response p¼ 0.5;
remission p¼ 0.97), though there was a trend towards a higher rate of response at
week 8 with IFX (79% vs 64%). IFX and ADA were more effective than GOL at
week 8 (response: IFX vs GOL p¼ 0.020; remission: ADA vs GOL p¼ 0.027). At
week 16 only IFX seems to be more effective than GOL in inducing clinical
response (p¼ 0.048) but not remission. No significant difference among the
three drugs was observed in patients naı̈ve to anti-TNFs. Treatment was discon-
tinued in 2 patient in IFX group and in 6 patients in GOL group and in 6 patients
with ADA because of persistent disease activity.
Conclusion: This single-center study shows that IFX is more effective than GOL
both in the induction (8 weeks) and in the maintenance of response (16 weeks).
ADA is more effective than GOL in inducing remission at 8 weeks but no sig-
nificant difference is observed in the medium-term. However, GOL was used
mainly as a second or third-line. In naı̈ve patients, efficacy among anti-TNFs
is comparable. Our results may help clinicians in the choice of an anti-TNF in
UC: IFX should be preferred in steroid-resistant patients to get a faster response,
ADA and GOL should be the first option in steroid-dependant patients naı̈ve to
anti-TNFs.
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Introduction: Vedolizumab (VDZ), a gut-selective monoclonal anti-4b7-integrin
antibody, is used for treatment of Crohn’s disease (CD) and ulcerative colitis
(UC). Data from large real-world cohorts can further characterise safety events
not fully elucidated in a clinical trial setting, such as the risk of serious infections,
as identified with anti-tumour necrosis factor-alpha (TNF) therapy in the
TREAT1, GISEA2 and ENCORE3 registries.
Aims & Methods: We conducted a systematic review and meta-analysis of real-
world safety outcomes reported for VDZ in UC and CD. MEDLINE-,
Cochrane-, and EMBASE-indexed publications and conference abstracts
(n 10) from May 1, 2014–January 10, 2017 were searched for studies reporting
real-world VDZ safety outcomes. Reports for patients 518 years of age or for
off-label VDZ use were excluded. A meta-analysis was conducted using the
DerSimonian–Laird random effects method to obtain a weighted mean of
adverse event (AE) rates.
Results: Two hundred and eighteen published studies were identified, with 33
reporting safety rates on 2857 VDZ-treated patients (CD: 1532; UC: 829; unspe-
cified/other: 36; three studies [n¼460] did not report individual UC/CD data)
over a VDZ exposure/follow-up period ranging 0.5–18 months (20 studies).
Among included studies, the mean age of patients ranged from 21 to 67 years,
with mean disease duration ranging from 7 to 16 years. Most VDZ-treated
patients (62–100%) had prior exposure to 1 anti-TNF therapy and 6–64%
of VDZ-treated patients were receiving concomitant corticosteroids and immu-
nomodulators. The most common non-infectious AEs were acne or acne-like
lesions (7%; 95% confidence interval [CI] 5–11%), fatigue (6%; 95% CI 3–
15%) and arthralgia (5%; 95% CI 3–10%) (Table 1). The most common infec-
tious AEs were upper respiratory tract infections (6%; 95% CI, 3–11%) and
sinusitis (4%; 95% CI 51–19%) (Table 1). Infusion-related reactions occurred
in 2% (95% CI51–4%) of patients (n¼ 811), and malignancies were reported in
51% of patients (51–4%; 2 studies). Overall, the pooled AE rate reported in
VDZ-treated patients was 21% (95% CI 14–32%); 10% (95% CI 6–16%) for
infections, 8% (95% CI 6–10%) for serious AEs and 7% (95% CI 3–13%) for
serious infections (Table 1).
Table 1: Pooled real-world adverse event rates of vedolizumab in inflammatory
bowel disease
Non-infectious adverse events (2% of patients)
Event n Rate, % 95% Confidence
Interval (CI)
Acne or acne-like lesions 290 7.2 4.8–10.9
Fatigue 569 6.3 2.6–14.6
Arthralgia 1356 5.2 2.7–9.9
Exacerbation of IBD
symptoms
674 4.9 2.1–11.1
Muscle pains 147 4.8 2.3–9.7
Headache 937 4.7 3.0–7.2
Dizziness 222 4.5 1.4–13.6
Cough 185 4.0 0.3–39.7
Other skin and subcuta-
neous-relateda
900 3.7 1.6–8.0
Nausea 623 3.2 1.2–8.5
Paraesthesia 526 2.9 1.0–7.9
Respiratory, thoracic and
mediastinal-relatedb
70 2.9 0.7–10.7
Hives 146 2.1 0.7–6.3
Liver-relatedc 468 2.0 0.1–23.9
Memory impairment 136 2.0 0.4–10.2
Other musculoskeletal and
connective tissue-
relatedd
498 2.0 0.3–12.5
Infectious adverse events (2% of patients)
Event n Rate, % 95% CI
Upper respiratory tract
infection
960 6.0 3.2–10.8
Sinusitis 576 4.2 0.8–19.1
Other respiratory
infectionse
328 3.1 1.7–5.7
Genitourinary tract
infections
409 3.0 1.1–8.0
Flu or flu-like infection 450 2.8 0.8–8.8
Perianal abscess 284 2.5 1.1–5.6
Clostridium difficile 1101 2.1 1.2–3.6
Folliculitis 146 2.1 0.7–6.3
Any adverse events
Event n Rate, % 95% CI
Adverse events 1243 21.3 13.7–31.6
Serious adverse events 832 7.7 6.1–9.7
Infections 906 9.9 6.2–15.5
Serious infections 832 6.7 3.3–13.0
aIncludes paradoxical skin manifestations, acute generalised exanthematous pus-
tulosis, dry skin, erythema nodosum, palmar erythema bIncludes spontaneous
nose bleed cIncludes liver test abnormalities (transient transaminitis), drug-
induced liver injury (not specified) dIncludes severe musculoskeletal syndrome,
exacerbation of pre-existing enteropathic arthritis eIncludes pneumonia, lower
respiratory tract infections, respiratory tract infection (not specified)
Conclusion: Pooled analysis of AE rates across multiple studies support the
favourable, long-term benefit–risk profile of VDZ in real-world clinical practice,
with low rates of infusion-related reactions, serious infections and malignancies
reported, and no identification of new safety signals. These results are consistent
with integrated safety data reported for VDZ in six clinical trials (44000 patient-
years),4 despite the selection of complex patients failing previous immunosup-
pressive or biologic therapies. Limitations of incidental reporting in real-world
studies include potential underestimates of AE rates and the reporting of AEs not
regularly observed in clinical trials;3 for example, due to the variability in co-
medication use and sub-optimal screening of prior infections.
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Introduction: Although many biologics (Bs) have been approved for the treatment
of moderate-to-severe Ulcerative Colitis (UC) in patients who have responded
inadequately to conventional therapy, the selection of Bs is controversial due to
the lack of head-to-head trials. Indirect economic comparisons of these costly
drugs are available from National Healthcare perspectives that are not the Italian
ones.
Aims & Methods: The objective is to evaluate cost-utility of Bs for the treatment
of refractory moderate-to-severe UC both in Italy and in the Lombardy Region.
A Markov model (considering 3 transition states: remission, clinical response,
relapse) was constructed using the software R 3.3.1 markovchain-package to
evaluate incremental cost-utility ratios (ICUR) of adalimumab (ADA), inflixi-
mab (IFX), infliximab biosimilar (IFX-B), golimumab (GOL) and vedolizumab
(VED) treatments of patients over a 10-year time horizon from the perspective of
the Italian (N) and Lombardy Region (R) healthcare system. Clinical parameters
were derived from clinical trials. Costs (actualised by–1,5%) were obtained from
the National database and Regional public tender. Utility was expressed as
QALY (Quality Adjusted Life Years).
Results: Costs per treatment were different from a N and R perspective (ADA
55%; IFX 16.7%; IFX-B 29.6%; GOL 9.6%; VED 10%). Direct
healthcare costs (treatment cost, visits, lab tests, hospital admissions) were cal-
culated over 10 years of treatment per patient: ADA (N: E114,227, R: E68,314,
40.2%), IFX (N: E130,595, R: E103,081, 21%), IFX-B (N: E110,438, R:
E78,852, 28.6%), GOL (N: E118,602, R: E96,922, 18.3%), VED (N:
E113,852, R: E102,932, 9.6%) with associated QALY respectively of 6.68,
6.66, 6.66, 6.70, 7.02. From a N perspective, IFX-B was dominating compared
to all other treatments. The ICUR of VED/IFX-B was E9,483 for 10 years
(willingness to pay E948/QALY). From a R perspective, ADA was dominating
compared to all other treatments. The ICUR of VED/ADA was E101,818 for 10
years (WTP E10,182/QALY).
Conclusion: National and Regional cost-utility analyses produced different
results. As Regional price discounts can occur, local analysis is needed to esti-
mate the economic impact of therapies to ensure optimal choice.
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Introduction: Dysplasia is considered as the precursor of colitis-associated cancer
in the long standing ulcerative colitis (UC). Although endoscopic submucosal
dissection (ESD) has been suggested as an endoscopic resection technique for
non-polypoid dysplasia, only a few studies investigated the feasibility of ESD as a
treatment option of non-polypoid dysplasia.
Aims & Methods: We aimed to investigate the feasibility of ESD for the resection
of visible, non-polypoid dysplasia in UC. From August 2009 to January 2017, 19
UC patients with low grade dysplasia (LGD), high grade dysplasia (HGD) or
early colon cancer were admitted for ESD and their medical records were retro-
spectively reviewed.
Results: Mean age of the 19 patients was 55.5 15.4 years and mean duration
between UC diagnosis and dysplasia detection was 13.7 6.5 years. Nine were
male. Five of 19 patients directly underwent colectomy without ESD trial due to
non-lifting sign (n¼ 4) or surface ulceration (n¼ 1). Of these, preoperative single
HGD (n¼ 3) or ECC (n¼ 1) patients showing non-lifting sign were diagnosed as
invasive cancer and a single preoperative LGD case with non-lifting sign had
multifocal LGDs in the colectomy specimen. As a result, ESD was performed for
14 of 19 patients. Major and minor axes of the lesion was 23.4 9.0mm and
18.1 9.1mm, respectively. The lesions were located at the rectum (n¼ 9), sig-
moid colon (n¼ 2), descending colon (n¼ 1), and transverse colon (n¼ 1). The
gross morphology showed Paris IIa (n¼ 7), IIb (n¼ 4), Is (n¼ 1), and IIbþ Is
(n¼ 2). No lesions contained ulcerations. The borders were distinct in 6 and
vague but endoscopically assumable in 8 cases. Mean UC endoscopic index of
severity scores of the surrounding mucosa was 0.3 0.5. Mean resection time was
54.8 25.7 minutes. En bloc resection and R0 resection rates was 92.9% and
71.4%, respectively. There was no perforation or clinically significant bleeding.
Mean hospitalization period after ESD was 1.14 0.36 days. Final histology of
ESD specimens revealed 1 indefinite for dysplasia (IND), 1 sessile serrated ade-
noma/polyp, 7 LGDs, 3 HGDs, and 1 intramucosal adenocarcinoma.
Synchronous lesions were present in 5 patients. Synchronous dysplasia in 4
patients were removed endoscopically. However, colectomy was done in one
patient having synchronous adenocarcinoma and endoscopically unresectable
dysplasia diagnosed by the surveillance biopsy specimens taken during ESD.
Metachronous or recurrent dysplasia was identified in 2 of 9 patients who under-
went follow-up colonoscopy after ESD (median follow-up period 12.3 months,
range 6.3–38.2 months). One developed metachronous LGD at 18 months after
ESD and the other developed both metachronous and recurrent LGDs at 8
months after ESD.
Conclusion: According to our ESD series for dysplasia, ESD seems to be feasible
for the endoscopic resection of UC-associated dysplasia. However, meticulous
surveillance colonoscopy is mandatory to monitor local recurrence and meta-
chronous dysplasia. Non-lifting sign and surface ulceration are highly suggestive
of invasive colitic cancer.
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Introduction: Biological therapies are effective treatments for inflammatory bowel
disease (IBD) but represent an important economic burden to the healthcare
system. Adherence surveillance is necessary to optimize the efficacy of treatment
and its costs. This issue has been evaluated just in a fewer studies.
Aims & Methods: We aim to describe the adherence to infliximab in patients with
IBD and identify causes and factors associated with poor adherence We identi-
fied all IBD patients treated with infliximab in a single center since 2009.
Fulfillment of the prescribed schedule was assessed for every single infliximab
infusion. For every patient, we grouped infusions in ‘‘courses of treatment’’
defined as the administration of infliximab at the same dose and schedule for a
minimum of six months. Therefore, restarting the treatment after a holiday of
more than 4 months, or changing the interval of doses were considered as a new
course of treatment. We defined ‘‘infusion well administrated’’ when it was done
within seven days before or after the date prescribed.
Results: We included a total of 147 courses of treatment, administered to 100
patients. Seventy-four per cent of courses were Crohn disease patients, and 25%
in ulcerative colitis patients. In 89% of courses combo therapy with immuno-
suppressants was used. The prescribed regimes were: every 8 weeks (76.2%),
every 10 weeks (7.5%), every 6 weeks (8.8%), every 12 weeks (5.4%) or every
4 weeks (2%). The mean duration per course was 23 months (range: 6–103). Only
69 out of 1714 infusions (4%), were not properly administered. The reported
causes for that included: 36 ‘‘unknown’’ (52%), 18 ‘‘change requested by patient’’
(26%), 15 ‘‘due to logistic reasons’’ (15%) and 4 ‘‘other’’ (5.7%). In 107 courses
(73%) all the infusions were well administered; in 143 (97%)480% of infusions
were well administered and only 4 courses (2.7%) had less than 580% of adher-
ence. In more than an half of the infusions the cause could not been identified, for
that reason analysis of predictive factors could not be performed.
Conclusion: The adherence to the scheduled infliximab regime was very high and
it would contribute to maintain the drug efficacy. The reasons for changing the
date of administration should be indicated in the clinical history to identify
associated factors and minimize the lack of adherence.
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Introduction: One-third of all patients with inflammatory bowel diseases (IBD)
do not respond to initial treatment with the anti-TNF-antibody Infliximab. Thus,
predictive markers for response to anti-TNF-treatment are required.
Aims & Methods: The study’s aim was to investigate whether levels of TNF
produced by peripheral blood mononuclear cells (PBMCs) can predict response
to anti-TNF-treatment. Fourteen patients with proven Crohn’s disease (CD) or
ulcerative colitis (UC) without treatment with biologicals in the past six months
were included prior to first Infliximab infusion. Disease activity was measured by
the use of Harvey-Bradshaw-Index (HBI) or partial Mayo Score, C-reactive
protein (CRP) and ultrasound (Limberg Score). TNF-expression of LPS-stimu-
lated PBMCs was measured by ELISA before treatment. Additionally PBMCs’
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intracellular TNF-expression was analysed by flow cytometry. According to a
cut-off of 300 pg/ml, patients were divided into low- and high-TNF-producers.
Primary endpoint was clinical response, secondary endpoints were decrease in
CRP and Limberg Score. Clinical response was defined as a decline in Score of
2 (HBI) or 3 (partial Mayo Score). A HBI 55 or a partial Mayo-Score 52
was defined as remission. Results were analysed using the Fisher’s exact test.
Results: Nine patients reached the endpoint at week 6 and were available for
further analysis (5 patients with CD, 4 patients with UC). The median TNF-
expression was 653.84 pg/ml (49.53–1154.78 pg/ml). TNF was mainly produced
by CD14þ monocytes. Four patients were identified as low-producers and five as
high-producers. All high-producers responded well to the treatment regarding
clinical scoring as compared to only half of the low-producers, but statistical
significance was not reached due to the small number of patients (high: 100% vs.
low: 50% clinical response, p¼ 0.167). However, remission rates after 6 weeks
were significantly higher in high-producers compared to low-producers (high:
80% vs. low: 0% remission; p¼ 0.048). Secondary endpoints showed no signifi-
cant difference in the two groups.
Conclusion: Quantification of TNF-expression in PBMCs and the resulting clas-
sification in low- and high-producers could be a potential predictive marker for
response to anti-TNF-treatment in IBD patients.
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Introduction: Corticosteroids (CS) are often used concominantly with biologics in
treatment of inflammatory bowel disease (IBD). However, their side-effect pro-
file causes significant clinical and economic burden in long-term treatment. In
this study, we investigated the impact of concomitant CS use on vedolizumab
treatment persistence in patients with Crohn’s disease (CD) and ulcerative colitis
(UC).
Aims & Methods: This was a nationwide (Finland), retrospective, non-interven-
tional, multi-center chart review. From 27 centers, we included adult (18 years
of age) IBD patients who received at least one vedolizumab infusion since 2014.
Data were collected from medical charts in a standardized case report form. The
key data collection points were at baseline, week 14 and month 6 of vedolizumab
treatment. The main aim of the study was to analyze vedolizumab treatment
persistence among IBD patients using CS in real-world clinical setting.
Results: 247 patients (CD 108, UC 139) were included. At baseline, 47 (43.5%)
CD and 84 (60.4%) UC patients were using CS. Higher percentage of patients
using CS at baseline discontinued vedolizumab during the 6-month follow-up
compared to CS non-users (CD, 14/47 (29.8%) vs. 13/61 (21.3%); UC, 31/84
(36.9%) vs. 16/55 (29.1%)). CS users had less vedolizumab discontinuations due
to primary inefficacy (p¼ 0.04) and more discontinuations due to adverse events
(p¼ 0.04), than CS non-users. Over half of the patients on CS at baseline and
who persisted on vedolizumab were able to discontinue CS before 6 months
timepoint (CD, 18/33 (54.5%); UC, 37/53 (69.8%)). Among CD patients, CS
users had higher baseline disease activity than non-users. Such difference was not
observed in UC. CS users had shorter disease duration in both CD and UC.
There was no difference in the number of prior TNF-alpha inhibitors between CS
users and non-users.
Conclusion: Use of CS at the time of initiating vedolizumab treatment was more
common in UC than in CD. Vedolizumab treatment persistence was lower in CS
users than in non-users in both CD and UC. The data suggests that CS users
have less vedolizumab discontinuations due to primary inefficacy and more dis-
continuations due to adverse events, than CS non-users. The majority of patients
on CS at baseline who persisted on vedolizumab were steroid-free by 6 months,
potentially relieving the burden of CS-induced side-effects for both patients and
society.
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Introduction: Vedolizumab is an alpha4beta7 integrin antagonist for the treat-
ment of inflammatory bowel disease (IBD). The role of Vedolizumab drug mon-
itoring, based on the assessment of Vedolizumab trough levels (VTL) and anti-
Vedolizumab antibodies (AVA) has not been clarified yet. In this study we
investigated the correlation between VTL and AVA and clinical response.
Aims & Methods: Consecutive IBD patients who started therapy with
Vedolizumab at our centre were prospectively enrolled. Each patient underwent
300mg infusion at weeks 0, 2, 6 and 14; additional doses at week 10 and then
every 4 weeks were given to no-responders at week 6. Clinical activity was eval-
uated at baseline and week 6, 14 and 22 by Harvey Bradshaw Index (HBI) and
partial Mayo score (pMayo). C-reactive protein (CRP) was measured at weeks 6,
14, 22. VTL and AVA were assayed by ELISA (Theradiag, Marne La Vallee,
France) at weeks 6, 10 and 14. Limits of detection for VTL and AVA were 2 ug/
ml and 35 ng/ml, respectively. Clinical response was defined as at least 30%
reduction of activity scores from baseline and remission was defined as
HBI5 5 or pMayo 52. Statistics was performed by Mann Whitney test,
Spearman’s rho, receiver operating characteristic (ROC) curve analysis.
Results: We included 50 patients (mean age 45.5 y; male 56%) with Crohn’s
disease (CD, n¼ 28) and Ulcerative colitis (UC, n¼ 22). 44 (88%) IBD patients
had previous anti-TNF therapy. Baseline median HBI was 8 (5–16) and median
pMayo was 6 (5–7). Median VTL (Interquartile range, IQR) at weeks 6, 10 and
14 were 38.6 (20.3–53.5), 25.4 (13.4–45.6) and 17.7 (10.1–33.7) ug/ml, respec-
tively. VTL measured at week 6 were significantly higher in clinical responders
as compared to non-responders: median (IQR) 50.7 (31.8–56.8) vs 33.1 (19.4–42)
ug/ml, p¼ 0.04. Week 6 VTL were also higher in CRP responders (55mg/l):
median (IQR) 48.1 (32.5–55.8) vs 32.8 (19.7–44.3) ug/ml, p¼ 0.04. Week 6 VTL
were inversely correlated with CRP (rho 0.39, p¼ 0.006). By ROC curve ana-
lysis we identified a cut off value for VTL of 44.3 ug/ml for clinical response at
week 6 (AUC 0.677, sensitivity 61.9%, specificity 79.3%, p¼ 0.02). Week 6 VTL
were significantly higher in patients in clinical remission at their last follow-up
(mean 20 weeks) compared to non-remitters: median (IQR) 55.8 (46–64.1) vs 33.3
(25.9–40.4) ug/ml, p¼ 0.0035. The ROC curve analysis identified a cut off of 44.3
ug/ml (AUC 0.813 sensitivity 88.9%, specificity 73.2%, p¼ 0.0006). Week 14
VTL were also significantly higher in patients in clinical remission at 22 weeks
compared to non-remitters: median (IQR) 38.3 (20.5–49.8) vs 13.4 (8.4–20.6) ug/
ml, p¼ 0.0035. The cut off identified by ROC curve analysis for this outcome was
16.4 ug/ml (AUC 0.820 sensitivity 100% specificity 63%, p¼ 0.0019). AVA were
detected in 2% of patients at week 6, in 5.9% at week 10 and in 4.5% at week 14
and were not correlated with clinical response.
Conclusion: These preliminary data suggest that obtaining a VTL of 44.3 ug/ml
after the first 2 Vedolizumab infusions is correlated with early clinical and bio-
logical (CRP) response and with clinical remission at a mean follow-up of 20
weeks. Week 14 VTL are correlated with clinical remission at week 22 and the
identified cut off is 16.4 ug/ml. Immunogenicity of Vedolizumab is low in these
patients.
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11Gastroenterology And Hepatology, University of Zurich, University Hospital
Zurich, Zurich/Switzerland
12Department Of Gastroenterology, Hepatology & Nutrition, Digestive Diseases
And Surgery Institute, Cleveland Clinic Foundation, Cleveland/United States of
America
Contact E-mail Address: dominik.bettenworth@ukmuenster.de
Introduction: Strictures in Crohn’s disease (CD) may occur in different segments
along the gastrointestinal (GI) tract. In contrast to ileocecal strictures, endo-
scopic balloon dilation (EBD) for CD-associated strictures of the upper gastro-
intestinal (UGI) tract is rarely reported. We therefore performed a combined
efficacy and safety analysis of EBD for UGI CD-associated strictures in this
multi-centre cohort study.
Aims & Methods: Individual patients characteristics were retrieved from electro-
nic case report forms. Upper GI tract was defined as esophagus, stomach and
duodenum up to the ligament of Treitz. Time-to-event analysis was performed to
assess symptom recurrence, re-dilation or surgery. Kaplan-Meier estimates were
used to calculate event rates. For the multivariable Cox regression models, all
variables that were available for at least 85% of subjects were considered for
inclusion and the score method was used to choose the best model with two
factors for each outcome.
Results: A total of 73 CD patients and 127 performed dilation procedures were
included. Stricture locations were: duodenum n¼ 46, stomach n¼ 14; esophagus
n¼ 9; stomach and duodenum n¼ 4. Technical success rate was 94.1% resulting
in clinical efficacy in 88.9% of patients. Major complications, defined as perfora-
tion, bleeding or dilation-related surgery, occurred in 2.9% of all procedures.
During a median follow up period of 36 months, 89.4% of patients underwent re-
dilation and 29.8% required surgical intervention. The multivariable Cox regres-
sion analyses indicated that a younger age at diagnosis was associated with
symptom recurrence (HR 0.82 (0.71, 0.95), p¼ 0.008), mucosal inflammation
with need for re-dilation (HR 2.7 (1.4, 5.2), p¼ 0.003) and use of anti-TNF
with need for surgery (HR 4.8 (1.8, 12.4), p¼ 0.001).
Conclusion: EBD for CD-associated strictures of the upper gastrointestinal tract
has a high rate of short-term technical and clinical success with moderate long-
term efficacy and acceptable complication rates.
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Introduction: Systemic immunosuppressive treatment, such as anti-tumour necro-
sis factor-alpha (TNF) therapy, can reactivate latent hepatitis virus.1
Vedolizumab (VDZ), a humanised monoclonal antibody, blocks gut-specific
lymphocyte trafficking by binding to 4b7 integrin and is approved in moderately
to severely active ulcerative colitis or Crohn’s disease. The gut selectivity of VDZ
may be associated with a lower risk of virus reactivation than anti-TNF agents.
The VDZ European Product Label advises caution regarding VDZ use in
patients with controlled chronic severe infection or a history of recurring
severe infection.2 As VDZ clinical trials excluded patients with chronic viral
hepatitis B or hepatitis C infection, there are no clinical trial data available in
this population.
Aims & Methods: Here, we describe the safety experience of VDZ use in patients
with pre-existing hepatitis B or hepatitis C in the post-marketing setting. Adverse
events (AEs) were identified from the VDZ Global Safety database (data-cut
May 20, 2014 to Nov 19, 2016) and included if patients’ medical history or
concurrent conditions included a Medical Dictionary for Regulatory Activities
(MedDRA) preferred term suggestive of hepatitis B or hepatitis C infection.
Results: In the context of 77.382 patient-years of VDZ exposure and a total of
30.470 AEs in the VDZ database, 51 events (n¼ 13 serious [non-fatal]; n¼ 38
non-serious) occurred in 15 patients with pre-existing viral hepatitis B (n¼ 5,
including 2 chronic cases) or hepatitis C (n¼ 10). Of the 15 patients, six had
ulcerative colitis, seven had Crohn’s disease, and in two the indication was not
reported (NR). Eight patients received prior/concomitant anti-TNF therapy;
NR n¼ 2. Events reported were reflective of the general VDZ safety profile in
patients without viral hepatitis. Liver-related events were reported in two patients
with hepatitis C–one patient who was a smoker reported hepatic neoplasm; the
other reported hepatic mass and had a history of skin cancer, cholecystectomy,
bladder tumour removal and right radical orchiectomy. Both events resulted in
VDZ discontinuation. Of events with a reported outcome, 22/26 (84.6%) were
resolved or resolving at the time of reporting and 4/26 (15.4%) were unresolved;
NR n¼ 25. VDZ treatment was continued in 10/14 (71.4%) patients and discon-
tinued in 4/14 (28.6%); NR n¼ 1.
Conclusion: In the post-marketing setting, there was no evidence of increased risk
of viral reactivations in patients with hepatitis B or hepatitis C receiving VDZ.
Limitations associated with post-marketing safety reporting (e.g. voluntary
nature of reporting and incomplete patient medical history) and currently limited
availability of VDZ in regions with endemic hepatitis B and hepatitis C infection
should be considered when interpreting these results.
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Introduction: The goal of maintenance therapy in Ulcerative Colitis (UC) is to
keep clinical and endoscopic steroid-free remission. 5-aminosalicylate (5-ASA)
represents the first line maintenance therapy1. Non-adherence to 5-ASA is asso-
ciated with an increased risk of disease relapse, colorectal cancer and worsening
of quality of life2–3. Adherence rate has been analysed in several studies with
controversial results4–5.
Aims & Methods: The aim of this study is to quantify the prevalence of adherence
to 5-ASA, to identify risk factors to non-adherence and its correlation with the
course of the disease. Observational, analytical, retrospective, single tertiary
centre, cohort study of all UC patients followed-up in our IBD unit, until
January 2016, with 5-ASA maintenance treatment prescribed by an electronic
management program. Adherence was considered when 80% of the prescribed 5-
ASA was dispense at pharmacy, during one year (2016), assuming that dispensed
5-ASA is equivalent to medication intake. The study analysed, according to the
existence and degree of 5-ASA adherence, UC phenotypic expression (age, sex,
smoking habit, Montreal classification, extraintestinal manifestations, complica-
tions), disease course (moderate-severe relapse rate that require corticosteroid
therapy), 5-ASA properties (dose, administration regime, formulation), con-
sumption of other UC and non-UC chronic drugs. A multivariable logistic
regression was applied to discriminate adherent subjects including the risk factors
of the univariable analysis. A Spearman’s rank coefficient analysis was per-
formed to correlate percentage of adherence with relapse rate.
Results: The study cohort included 433 patients, 55% males with a median age at
the first 5-ASA prescription analysed of 49 years (IQR 39–61). 17% had a
proctitis, 31% a left-side colitis and 52% an extended disease. 30% of patients
suffered from extraintestinal manifestations and 8 from a complication. The
mean dose of 5-ASA taken was 2.6 g/day (range 0.7–4.8) distributed in a daily
dose in 61% of the patients. Adherence prevalence to 5-ASA was 63%. Adherent
group had a higher median age (52 (11) vs 43 (13), p¼ 0.001) and received
more non-UC chronic drugs (OR¼ 2.3, 95CI¼ 1.5–3.4, p¼ 0.001). The indepen-
dent variables, age and intake of other non-UC drugs, included in the multi-
variate analysis reached a predictive capacity of 65% outcomes of adherence.
There was no significant reduction in the risk of moderate-severe flares that
required corticosteroid therapy when comparing both adherent and non-adher-
ent groups and rank correlation showed no relationship between adherence to 5-
ASA and relapse rate (r¼ 0.06; p¼ 0.2). Patients treated with adjuvant mainte-
nance therapy (bitherapy with thiopurines or antiTNF or triple therapy with
both) presented a significant reduction of flares (OR¼ 0.6, 95CI¼ 0.7–0.9,
p¼ 0.019).
Conclusion: Adherence to 5-ASA in our population is low. Older patients that
take other non-UC chronic treatments show higher adherence. With a one year
prescribed and dispensed analysis, non-adherence to 5-ASA is not related with a
higher risk of flares that require corticosteroid therapy. Patients treated with
adjuvant maintenance therapy, show better results throughout the course of
the disease.
Disclosure of Interest: All authors have declared no conflicts of interest.
United European Gastroenterology Journal 5(5S) A747
References
Dignass, A., et al. Second European evidence-based consensus on the diagnosis
and management of ulcerative colitis Part 2: Current management. Journal of
Crohn’s and Colitis, 2012, 6(10), 991–1030.
Kawakami, A., et al. Relationship between non-adherence to aminosalicylate
medication and the risk of clinical relapse among Japanese patients with ulcera-
tive colitis in clinical remission: A prospective cohort study. Journal of
Gastroenterology, 2012. 48(9), 1006–1015.
Kane, S., et al. Medication nonadherence and the outcomes of patients with
quiescent ulcerative colitis. The American Journal of Medicine, 2003. 114(1),
39–43.
Kane, S. V., et al. Prevalence of nonadherence with maintenance mesalamine in
quiescent ulcerative colitis. The American Journal of Gastroenterology, 2001.
96(10), 2929–2933.
Bermejo, F., et al. Factors that modify therapy adherence in patients with inflam-
matory bowel disease. Journal of Crohn’s and Colitis, 2010. 4(4), 422–426.
P1706 DEVELOPMENT AND FEASIBILITY OF A WEB-BASED
REGISTRY FOR MULTICENTRE SURVEILLANCE OF
EFFECTIVENESS AND SAFETY OF NOVEL IBD-DRUGS IN THE
NETHERLANDS
V. B.c. Biemans1, CJ. Van Der Woude2, G. Dijkstra3, A. E. Van Der Meulen - De
Jong4, K.h.n (. De Boer5, C.Y. Ponsioen6, B. Oldenburg7, F. Hoentjen8,
M.J. Pierik9
1Gastroenterology And Hepatology, Radboudumc, Nijmegen/Netherlands
2Dept. Of Gastroenterology, Erasmus Medisch Centrum Dept. of
Gastroenterology, Rotterdam/Netherlands
3UMC Groningen Gastroenterology and Hepatology, Groningen/Netherlands
4Leiden University Medical Center Dept. of Gastroenterology, Leiden/Netherlands
5Gastroenterology And Hepatology, VU University Medical Center, Amsterdam/
Netherlands
6Gastroenterology & Hepatology, AMC Amsterdam Gastroenterology and
Hepatology - Gastroenterology & Hepatology, AMC Amsterdam Gastroe,
Amsterdam/Netherlands
7University Medical Center Utrecht, Utrecht/Netherlands
8Dept Of Gastroenterology And Hepatology, Universitair Medisch Centrum St.
Radboud, Nijmegen/Netherlands
9Dept Of Gastroenterology And Hepatology, Maastrich University Medical Center
Dept. of Gastroenterology, Maastricht/Netherlands
Contact E-mail Address: vince.biemans@radboudumc.nl
Introduction: Randomized controlled trials provide efficacy data of novel IBD
drugs. The majority of patients included in these trials however, especially for
novel biologics, are highly selected patients from referral centres and are included
in a variety of countries with very different health care systems. Inclusion criteria
and follow-up protocols are strict and do not reflect routine care. Long-term
country specific effectiveness and safety data for novel drugs are therefore war-
ranted. Development and implementation of a novel protocol and electronic case
reporting registry for every new compound is however time consuming and
expensive. Therefore, the Initiative on Crohn and Colitis (ICC) aimed to develop
a web-based registry suitable for capturing, managing, and reporting data for all
drugs and all IBD phenotypes in everyday practice in all centres.
Aims & Methods: Here, we aim to test the feasibility of the web-based registry in
patients starting vedolizumab. With a structured iterative process with IBD-spe-
cialist from the ICC, case report forms and lab-evaluation forms were developed
to assess key elements of disease activity, safety and a PROM. Furthermore the
ICC decided on a uniform follow-up protocol reflecting everyday practise. A
web-based registry for capturing, managing and reporting follow-up data of
IBD patients starting a new drug was developed (ICC-case series). The registry
automatically reminds the treating physician or nurse prior to novel follow-up
visits. Feasibility of the ICC-case series was assessed in 6 centres in the
Netherlands in patients who started vedolizumab. To test data extraction and
reporting, the baseline characteristics of the first cases were assessed. The char-
acteristics were compared to baseline characteristics of subjects in the vedolizu-
mab registration studies.
Results: A total of 230 IBD (4 IBD-U) patients starting vedolizumab were
included. All users found the ICC-case series easy to use and received the remin-
der mails for follow-up visits. Baseline characteristics were successfully extracted
and are reported in table 1.
Table 1: Baseline characteristics of ICC cohort and GEMINI trials
Characteristic
ICC
cohort CD
(N¼ 146)
GEMINI
2(1)
(N¼ 1115)
ICC
cohort UC
(N¼ 80)
GEMINI
1(2)
(N¼ 895)
Age - yr 39 13.7 36.1 12.1 43.7 16.5 40.3 13.1
Male - no. (%) 50 (34.2) 520 (46.6) 50 (62.5) 525 (58.7)
Current smoker - no. (%) 38 (25.9) 298 (26.7) 1 (1.3) 55 (6.1)
Disease duration–yr 13.6 12.5 9.0 7.8 8.6 7.8 6.9 6.4
Median CRP - mg/L (IQR) 7 (4–20) 11.5 6 (2–15) -
Median fecal calprotectine -
ug/g (IQR)
881 (287–1800) 686.0 1551 (441–2519) 899 (341–2127)
Disease location CD, n(%)
Ileum only 31 (21.2) 181 (16.2) – –
(continued)
Table 1 Continued
Characteristic
ICC
cohort CD
(N¼ 146)
GEMINI
2(1)
(N¼ 1115)
ICC
cohort UC
(N¼ 80)
GEMINI
1(2)
(N¼ 895)
Colon only 36 (24.7) 316 (28.3) – –
Ileum and colon 56 (38.4) 618 (55.4) – –
Ileum and upper GI 11 (7.5) – – –
Ileum and colon and upper
GI
4 (2.7) – – –
Disease behavior
Inflammatory 89 (61) – – –
Stricturing 35 (24) – – –
Penetrating 12 (8.2) – – –
Perianal fistula 13 (8.9) – – –
Disease location UC, n (%)
Proctitis – – 5 (6.3) 116 (13.0)
Left-sided – – 29 (36.3) 448 (50.1)
Pancolitis – – 37 (46.3) 331 (37.0)
Concomittant medications -
no. (%)
Glucocorticosteroids only 59 (40.4) 381 (34.2) 37 (46.3) 332 (37.1)
Immunosuppressive agents
only
28 (19.2) 181 (16.2) 12 (15) 159 (17.8)
Both immunosuppressive
and
16 (11) – 14 (17.5) 149 (16.6)
Corticosteroid
No glucocorticosteroids or 43 (29.5) 189 (17.0) 17 (21.3) 255 (28.5)
immusuppressive agents
Prior TNF antagonist ther-
apy (%)
1 145 (99.3) 645 (57.8) 69 (86.3) 367 (41.0)
2 114 (78.1) 398 (35.7) 37 (46.3) –
Prior IBD surgery (%) 72 (49.3) 466 (41.8) – –
Perianal surgery (%) 27 (18.5) – – –
IPAA (%) – – 3 (3.8) –
Conclusion: The ICC developed a uniform web-based registry to study post-
marketing safety and effectiveness of novel IBD-drugs. A feasibility study with
230 patients starting vedolizumab showed successful data-capture, managing,
and reporting with the ICC-case series in 6 centres. Table 1 shows clear differ-
ences between baseline characteristics of real-life Dutch patients and patients in
the GEMINI studies underlining the importance of country specific post-market-
ing data.
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Introduction: Azathioprine (AZA) and thiopurine are widely used for induction
and maintenance of remission in patients steroid-resistant or dependent with
inflammatory bowel disease (IBD). The treatment must be withdrawn in 5–
30% of patients due to the occurrence of adverse events.
Aims & Methods: Aim of this study has been to investigate its efficacy and safety
in maintaining steroid-free remission in steroid dependent IBD patients six year
after the institution of treatment. Data from consecutive IBD outpatients
referred in our Institution, between 1985–2015, were reviewed and all patients
treated with AZA were included in this retrospective study. AZA was adminis-
tered at the recommended dose of 2–2.5mg/kg. Blood chemistry was analysed
before administration of the drug, every 10–15 days for the first 3 months and
then every 1–2 months following the institution of treatment.
Results: Out of 2722 consecutive IBD outpatients visited in the index period,
AZA was prescribed to 415 patients, 227 (54.7%) were affected by Crohn’s
disease (CD) and 188 (45.3%) by ulcerative colitis (UC). One hundred and
fifty-eight patients with a follow-up 572 months were excluded from the
study. Two hundred and fifty-seven patients were evaluated, 143 (55.6%) with
CD and 114 (44.4%) with UC. One hundred and forty-two (55.2%) were male
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and 115 (44.8%) female (average age of 35.68 14.22 SD years, range 14–74 y.).
Six year after the institution of treatment, 130 (50.6%) patients still were in
steroid-free remission (85 CD vs 45 UC, 59.5% and 39.5%, respectively,
p¼ 0.0017), 71 (27.6%) had a relapse requiring retreatment with steroids (29
CD vs 42 UC, 20.3% and 36.8%, respectively, p¼ 0.0048), 56 (21.8%) discon-
tinued the treatment due to side effects (29 CD vs 27 UC, 20.2% and 23.7%,
respectively). Loss of response from 1st to 6rd year of follow-up was low,
about 20%.
Conclusion: Six years after the onset of treatment 56% of patients did not require
further steroid courses. After the first year loss of response was low in five
subsequent years. In the present series the maintenance of steroid-free remission
was significantly higher in CD than in UC patients. The occurrence of side effects
leading to the withdrawal of AZA treatment has been low.
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Introduction: Many patients, especially the elderly or those with comorbidities,
are excluded from clinical drug trials and little real-life data exists on the safety
and efficacy of anti-TNF.
Aims & Methods: We aimed to compare the clinical efficacy and safety of anti-
TNF therapy in patients over 60 years in a tertiary IBD centre in London, UK.
We interrogated our IBD biologics database from January 2009 to November
2015 and performed retrospective data analysis until end of follow up in April
2017. Data was collected on demographics, endoscopy, calprotectin, CRP, clin-
ical scores, serious infections, malignancy, drug levels and anti-drug antibodies.
Patients with an age of ‘60’ when starting anti-TNF therapy were identified and
‘560’ comparators were selected at random in a 2:1 ratio. Primary endpoints:
week 14 and week 54 steroid free clinical remission (Harvey Bradshaw Index 55
or Simple Colitis Activity index 53) Secondary endpoint: proportion of patients
remaining on anti-TNF at the end of follow up
Results: See table.
Conclusion: Only a small number of ‘60’ patients started anti-TNF (29 out of
greater than 650). This may reflect our local population or that clinicians favour
non anti-TNF therapies in this older group. Overall there was similar clinical
efficacy at weeks 14 and 54 of anti-TNF therapy between the ‘young’ and ‘old’
groups. There was a higher discontinuation rate after 1 year of therapy in the
older group (p¼0.043). There were more adverse events in the older group (7/29)
including 3 new cancer diagnoses compared with the younger group (3/58). 4
patients had detectable anti-drug antibodies in the older group despite 2 of them
having therapeutic thiopurine suggesting that the elderly may have more
immunogenicity than the young. Further studies with more patients across multi-
ple sites are required to clarify safety and efficacy in the elderly.
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Introduction: Rescue therapy is required for patients with moderate - severe
ulcerative colitis (UC) who have failed to respond to steroids and thiopurines.
Anti-Tumour Necrosis Factor agents (Anti-TNFs) are widely used before con-
sidering a colectomy. Calcineurin inhibitors such as ciclosporin and Tacrolimus
may be considered as alternatives to biologics. There have been some case series
in assessing the use of Tacrolimus in such patients although the United Kingdom
experience is limited. (1, 2)
Aims & Methods: We aimed to review the outcome of patients who received
Tacrolimus as rescue and subsequent maintenance therapy for refractory symp-
toms of UC. This was a retrospective single-centre case review series. All patients
who were refractory to standard medical therapies and being considered for a
colectomy were reviewed by a Gastroenterologist with an interest in
Inflammatory Bowel Disease. Demographic data, indications for treatment, clin-
ical course and outcomes were reviewed from Electronic Patient Records (EPR).
Results: Fourteen patients (F¼ 6; mean age of 54 years) received Tacrolimus. 8
patients (57%) had evidence of pancolitis and six patients (43%) had distal
colitis. All patients had previously received thiopurines and 11 patients
(78.6%) had also received anti-TNFs. Three patients declined Anti-TNF treat-
ment. All patients were steroid-dependent prior to commencing Tacrolimus. One
patient received ciclosporin before the switch. The remaining 13 patients were
initiated on Tacrolimus in the out-patient setting at a starting dose of 0.1mg/kg/
day in 2 divided doses. Patients took Tacrolimus for a mean period of 18.8
months (range: 2 months to 49 months). Eight patients (57%) achieved a ster-
oid-free remission within 6 months. An additional 3 patients (23%) had a clinical
response within 6 months, but required one course of steroids during this time
period. Three patients (23%) failed to respond to Tacrolimus; 1 patient remains
steroid-dependent and does not wish to proceed to surgery, 1 patient was
switched to infliximab and 1 patient proceeded at 10 months to have an elective
sub-total colectomy. Tacrolimus was withdrawn in all 3 non-responders. Of the
11 (78.6%) initial responders, 12-month outcome included withdrawal of
Tacrolimus in 7 patients (63.6%). Reasons for withdrawal included: n¼ 1 renal
impairment; n¼ 1 started on infliximab; n¼ 3 referred for leucapharesis; n¼ 1 re-
started on Azathioprine and n¼ 1 referred for proctocolectomy. Three patients
(21.4%) remain in steroid-free clinical remission with a good quality of life and
Abstract No: P1708
560 years 60 years
Total n¼ 58 n¼ 29
Week 14 steroid free remis-
sion (HBI 55,
SCCAI5 3)
28/41 (68.3%) 8/16 (50%)
Week 54 steroid free remis-
sion (HBI 55,
SCCAI5 3)
24/40 (60%) 8/15 (53.3%)
Remain on anti-TNF at
week 54
46/58 (79.3%) 23/28 (82.1%)
Reasons for stopping anti-
TNF before week 54
7 primary non-response 2 secondary loss of response with
detectable anti-drug antibodies 1 infusion reaction 1
clinical & endoscopic remission
2 primary non-response 2 secondary loss of response with
detectable anti-drug antibodies 1 infusion reaction
Remain on anti-TNF at end
of follow up (April 2017)
38/58 (65.5%) 12/29 (41.4%) p5 0.05
Reasons for stopping bio-
logic during study
period
8 primary non-response 4 secondary loss of response 3 sec-
ondary loss of response with detectable anti-drug anti-
bodies 1 infusion reaction 1 clinical and endoscopic
remission 2 infections (skin and respiratory) 1 stopped
attending
4 primary non-response 2 secondary loss of response 3 sec-
ondary loss of response with detectable anti-drug anti-
bodies 1 infusion reaction 1 clinical and endoscopic
remission 1 infection (ophthalmic) 1 new diagnosis
cancer (colorectal) 1 severe fatigue 1 peripheral neuro-
pathy 1 moved away 1 stopped attending
Length of time on anti-TNF
if stopped (months)
Range: 3–73 Median: 12 Range: 3–63 Median: 18
Anti-drug antibodies
detectable during follow
up
3/58 (5.2%)–3 infliximab weeks 14, 34 and 76 2 no conco-
mitant 1 subtherapeutic TGNs 1 prior exposure to
infliximab
4/29 (13.8%) -3 infliximab, 1 adalimumab weeks 14, 48, 52
and 54 2 concomitant with therapeutic TGNs 2 no con-
comitant 0 prior exposure to anti-TNF
Adverse events throughout
follow up
1 new diagnosis cancer (testicular) 1 infusion reaction 1
infection (dental abscess)
3 new diagnosis cancer (prostate, colorectal & thyroid) 1
spontaneous ileal perforation requiring emergency sur-
gery 1 infusion reaction 2 infections (chest infection and
shingles)
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no adverse effects on maintenance treatment with Tacrolimus. 11 patients
(78.6%) have avoided a colectomy during the first 12-months of follow-up.
Conclusion: Tacrolimus should be considered as an alternative treatment for
patients with refractory UC in the out-patient setting. This is particularly
useful if the patient is unwilling to cosider a colectomy. With close monitoring
and adherence to protocols, it is safe and effective allowing patients an alterna-
tive immunosuppresant which may either avoid the need for a colectomy or, give
some time to adjust to its implications.
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Introduction: Adalimumab (ADA) and golimumab (GOL) are effective in the
induction and maintenance treatment of moderate-to-severe ulcerative colitis
(UC). No comparable data between the 2 drugs are available up to now.
Aims & Methods: We reported the Sicilian Network experience on the compara-
tive efficacy of ADA and GOL in patients (pts) with moderate-to-severe UC.
From June 2015 until April 2017, 197 consecutive pts with moderate to severe
UC were treated with ADA or GOL. The efficacy was evaluated at 8 week and at
the end of the follow up considering ‘‘clinical response’’ (reduction of at least 2
points of Partial Mayo Score with concomitant steroid reduction or discontinua-
tion) and ‘‘clinical remission’’ (Partial Mayo Score 52 without steroids). The
presence of clinical response or clinical remission was defined as ‘‘clinical bene-
fit’’. Endoscopic Mayo Score was evaluated at the end of the follow up in pts who
underwent colonoscopy.
Results: 118 pts were treated with ADA and 79 with GOL for a median
follow up of 40.21 [20.32, 69.14] weeks for ADA and 34.00 [17.43, 54.79]
weeks for GOL (p¼ 0.08). Eighty-eight pts were naı̈ve to anti-TNF (59
ADA, 29 GOL, p¼ 0.09). No difference in Mayo Score value was observed
between the 2 groups at the time of first drug injection (p¼ 0.92). After 8
weeks clinical benefit was achieved in 93/118 (78.8%) pts treated with ADA
and 50/79 (63.3%) pts treated with GOL (p¼ 0.026). Clinical remission was
achieved in 48/118 (40.7%) pts treated with ADA and 20/79 (25.3%) pts
treated with GOL (p¼ 0.038). At the end of the follow up clinical benefit
was achieved in 79/118 (66.9%) pts treated with ADA and 37/79 (46.8%) pts
treated with GOL (p¼ 0.008). Clinical remission was achieved in 50/118
(42.4%) pts treated with ADA and 23/79 (29.1%) pts treated with GOL
(p¼ 0.082). No difference was observed in clinical outcomes at 8 weeks
and at the end of the follow up between naive and non naive pts
(p¼ 0.187). At the end of the follow up the median Endoscopic Mayo
Score was 3.00 [0.00, 5.00] in pts treated with ADA and 4.00 [1.00, 7.00]
in pts treated with GOL (p¼ 0.025). Univariable analysis revealed that
age4 40 years at the time of first drug injection and age5 40 years at the
diagnosis were associated with higher remission rate in pts treated with
ADA respect to pts treated with GOL at 8 weeks and at the end of the
follow up (p¼ 0.034 and p¼ 0.016 respectively). Disease duration 45 years
was associated with a higher remission rate in pts treated with ADA respect
to pts treated with GOL at 8 weeks and at the end of the follow up
(p¼ 0.017).
Conclusion: This is the first study where the comparable efficacy of ADA and
GOL was evaluated. These real life data confirmed the efficacy of subcuta-
neous anti-TNF in the treatment of moderate to severe UC. ADA resulted
to be more effective than GOL in inducing and maintaining clinical benefit.
Larger prospective studies with longer follow up are warranted to confirm this
data.
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Introduction: The efficacy of golimumab for the induction and maintenance of
clinical remission in adult subjects moderately to severely active Ulcerative
Colitis (UC) has been studied in two completed clinical trials.1–2 However,
patients enrolled in clinical trials are not entirely representative of those encoun-
tered in the clinical practice setting. In Italy, golimumab is on the market for
treating UC from March 2015. The aim of our study is to evaluate the durability
and safety of golimumab in the context of real-life clinical practice.
Aims & Methods: An observational, multicenter, retrospective-prospective, phase
IV study, enrolling all patients starting golimumab from March to December
2015, from 21 IG-IBG centers. This study consists of two different parts: 1)
retrospective, regarding data until December 2016 and 2) a prospective one,
still ongoing, that will be concluded at the end of 2017. The co-primary outcomes
were the overall durability of treatment with golimumab, defined as persistence
on golimumab therapy because of sustained clinical benefit, and safety. Results
for the first 54-weeks period are reported.
Results: 121 patients (47% female), with mean age of 45.7 years (SD 14.3) and a
median duration of disease of 8 years, (range 0–28) were included. Sixty-seven
patients (55.4%) had severe endoscopic activity (Mayo 3). Clinical activity was
defined as moderate (Partial Mayo Score (PMS) 5–6) in 55 patients (45.5%) and
severe (PMS 7–9) in 66 patients (54.5%) Previous exposure to anti TNF- was
reported in 52% of patients (38 Infiximab, 4 Adalimumab, 21 both). Steroid-
dependence and refractoriness were reported in 78.5% and 16.5% of patients,
respectively. After 54 weeks, the cumulative persistence on golimumab therapy
was 31%. Seventy-seven patients withdrew from treatment, without significant
difference among anti TNF- naı̈ve vs exposed patients (55.2% vs 71.4%,
p¼ 0.11 Chi-Square test). Among 90% of patients who completed week 8,
48% of patients were still on golimumab therapy at week 54. Thirty patients
(39%) withdrew within the first 14 weeks. Among the remaining patients, at
week 54 the persistence on golimumab therapy was 57.1%. Ten patients
reported an adverse event, but only 6 of them withdrew from treatment.
Four patients reported paradoxical skin lesions, unresponsive to topical thera-
pies. Fifteen patients (12.4) underwent surgery within the first 54 weeks, with
a greater percentage among anti TNF- exposed (20.6% vs 3.4%, p¼ 0.02
Chi-Square test).
Conclusion: This preliminary real-life data study endorses golimumab’s promis-
ing results, showing 57.1% of durability treatment at week 54 in those patients
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who completed first 14 weeks of treatment and confirming it as a safe drug. Anti
TNF- naı̈ve patients were more likely to avoid colectomy.
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Introduction: Ciprofloxacin is one of the most frequently used antibiotics in
hospitalized inflammatory bowel disease (IBD) patients. Also discrepancies
between clinical guidelines and real clinical situations are observed in terms of
antibiotics use in patients with IBD. In the last few years an emerging resistance
to ciprofloxacin, ranging from 43% to 82%, has been described in extended
spectrum beta-lactamase producing bacteria (ESBL-E) colonizing the gut.1,2
Aims & Methods: The objective of this study was to evaluate the gut colonization
with ESBL-E in IBD patients, determine the resistance to ciprofloxacin and
bacterial plasmid genes associated with that. Rectal swabs were collected from
all consecutive patients with confirmed ulcerative colitis (UC) and Crohn’s dis-
ease (CD) hospitalized in two largest tertiary medical care centres in Riga, Latvia
during a 7-year period (2010–2016). Enterobacteria were cultured and analyzed
for ESBL presence according to EUCAST guidelines, resistance to ciprofloxacin
and bacterial plasmid genes CTX-M, TEM and SHV were detected.
Results: A total of 148 patients with confirmed IBD diagnosis were included in
the study–101 (68%) with UC, 47 (32%) with CD. We found that 12 (12%) of the
UC patients and 5 (11%) of the CD patients were colonized with ESBL-E. The
isolated ESBL producing strains from UC patients included Escherichia coli
(n¼ 10), Klebsiella oxytoca (n¼ 1) and Escherichia hermanii (n¼ 1). The isolated
ESBL producing strains from CD patients included only Escherichia coli (n¼ 5).
The isolated bacterial plasmid genes associated with ESBL production in UC
included CTX-M (n¼ 11; 92%), TEM (n¼ 4; 33%), SHV (n¼ 1; 8%), in CD–
CTX-M (n¼ 4; 80%) and TEM (n¼ 3; 60%). In UC 6 (50%) and in CD 1 (20%)
of the isolated ESBL-E were resistant to ciprofloxacin. In 1 case of the cipro-
floxacin resistance CTX-M, TEM and SHV gene combination was observed, in 1
case CTX-M and TEM gene combination was observed, in 4 cases only CTX-M
gene was present and in 1 case only TEM gene was present.
Conclusion: 1. Higher gut colonization rate with ESBL-E in IBD patients, mostly
with E. coli, expressing CTX-M gene was found comparing with the literature. 2.
Higher resistance to ciprofloxacin was found in ESBL-E isolated from UC
patients, comparing to UC patients. 3. CTX-M and TEM genes are associated
with resistance to ciprofloxacin.
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Introduction: Anti-TNFs are well-established in therapeutic management of
Crohn’s disease (CD). Real-life data on their pattern of use in a French clinical
setting are, however, limited to this day.
Aims & Methods: The objective of this study was to examine for characteristics of
CD patients and anti-TNF use in a real-life setting in France through the general
sample of health insurance beneficiaries (EGB database) which includes reimbur-
sement data from a sampled 1/97th of the French population. A cohort of 1280
patients with CD in the EGB database between 01/01/2010 and 31/02/2014 was
retrospectively constituted, of which 189 (14.8%) initiated an anti-TNF treat-
ment (infliximab, adalimumab) during that period and were studied for the
analysis. An additional analysis was performed based on French hospital dis-
charge data (medical information systems program [PMSI]) from 8142 CD
patients to compare results from the EGB database but only support infliximab
use due to its exclusive hospital availability in France (adalimumab can be pre-
scribed in both hospital and retail markets).
Results: 48.7% of anti-TNF treated patients were male and the mean age at the
initiation of an anti-TNF treatment was 38. The mean duration between diag-
nosis (measured through the assignment to an ALD [Long Term Illness]) and
start of anti-TNF treatment was 6 years. Concomitant treatments such as corti-
costeroids and immunosuppressants were prescribed at least once in 63% and
47% of patients respectively. Around 57% of patients initiated a treatment with
infliximab and 43% with adalimumab. Results at 12 months after anti-TNF
initiation are presented in the table below:
Table 1: Anti-TNF use in patients initiating an anti-TNF treatment with at least
12 months of follow-up At 12 months, 13.6% of patients underwent surgery.
Results from the hospital discharge database confirmed some of our observa-
tions. Optimization rate for infliximab 12 months after initiation was similar
(33.1% at 12 months for infliximab). Treatment discontinuation rates were also
within the same range observed and stable over time, with 10% of patients
discontinuing infliximab treatment each year and a discontinuation rate after 12
months of treatment of 27.2%.
Anti-TNF use at 12 months after initiation N Results
Drug survival rate for the first line anti-TNF 108 69.8% [62.3–76.1]
Survival rate for first line adalimumab 47 71.7% [59.9–80.6]
Survival rate for first line infliximab 61 66.3% [55.9–74.8]
Anti-TNF dose optimization rate 85 41.5% [34.5–49.3]
Dose optimization rate for adalimumab 53 33.6% [25.2–43.8]
Dose optimization rate for infliximab 63 38.2% [30.1–47.8]
Switch rate to another anti-TNF 126 17.5% [12.6–24.1]
Switch rate from adalimumab to infliximab 70 13.6% [8.1–22.4]
Switch rate from infliximab to adalimumab 88 14.9% [9.6–23.0]
Anti-TNF treatment discontinuation rate 108 31.4% [25.0–38.9]
Discontinuation rate for adalimumab 47 28.2% [19.4–40.0]
Discontinuation rate for infliximab 61 33.7% [25.2–44.0]
Conclusion: The general sample of health insurance beneficiaries’ database pro-
vides a unique representative sample to analyze and describe real-life usage of
anti-TNF in Crohn’s disease patients in France.
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Introduction: Ano-perineal fistulas (APF) are a common location of Crohn’s
disease (CD). Their treatment is still disappointing. Identifying the predictive
factors of response could guide the practitioner to adapt the anti-TNF  treat-
ment of each patient.
Aims & Methods: We performed a descriptive, longitudinal and retrospective
study over a period of 14 years. We included all patients with a definite diagnosis
of complex APF of CD treated with anti-TNF  with a minimum follow-up of
one year. Patients less than 16 years of age or over 70 years were excluded and
non-observing patients were also excluded. A univariate and multivariate statis-
tical analysis was then carried out using the SPSS software to identify the pre-
dictive factors of response to the treatment.
Results: A total of 49 patients had complex APF treated with anti-TNF . 10%
of the patients had also recto-vaginal fistulas. The mean age was 31 years. The
sex ratio women/men was 1.35. All of the patients had an MRI at diagnosis.
Patients had concomitant antibiotics and seton drainage in all cases. 76% of the
patients recieved azathioprin. After the induction phase, 53% of the patients
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achieved clinical remission, 31% a partial clinical response and 12% a primary
failure. 53% of the patients maintaned a clinical remission after a year of main-
tenance therapy. After a mean time of 13 months, 42% of the patients had a loss
of response. The analytical study found that the absence of recto-colic involve-
ment, CRP negativity and normalization of platelet count under treatment and
achievement of clinical remission after the induction phase were predictive fac-
tors of long term good response to anti-TNF  treatment. Clinical remission after
the induction phase was the only independent predictive factor of long-term
remission under maintenance treatment after multivariate analysis. However,
partial clinical response was predictive of loss of response as well as the presence
of a recto-vaginal fistula and young age at diagnosis.
Conclusion: According to our results, the type of response obtained after the
induction phase seems to be closely related to the subsequent development of
our patients. Prospective studies assessing early therapeutic adaptations could
better evaluate this perspective in the event of a partial clinical response. In
addition, rectal involvement and recto-vaginal fistulas are factors of poor
response for which aggressive and specific treatment is essential.
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Introduction: The management of chronic inflammatory bowel disease (IBD) has
experienced significant advance with the development of biologic therapy.
Infliximab (IFX) was the first monoclonal antibody approved for IBD. The
patent expiry of biologics and their relatively high costs that result in a significant
economic burden on the healthcare system, had led to the development of bio-
similar agents. The biosimilar IFX has been authorised for use in all the indica-
tions as the reference IFX. The demonstration of biosimilar IFX efficacy and
safety equivalence was based on two pivotal clinical trials in rheumatic diseases.
As a result of the extrapolation to IBD, there is growing controversy regarding
the appropriate use of biosimilar IFX. The efficacy and safety of infliximab
reference in inducing and maintaining remission in IBD has been extensively
proven in clinical trials. However, the role of biosimilar IFX, has not been
systematically investigated in clinical practice.
Aims & Methods: We aimed to compare the safety and efficacy in inducing and
maintaining remission in IBD, between the reference IFX group and biosimilar
IFX group. This retrospective, multicenter study was carried out at 4 tertiary
hospitals, from January 2013 to December 2016. The analysis included 2 cohorts
of consecutive IBD patients. One cohort composed of patients who were started
original IFX since 2013. The second cohort included patients who were treated
from the introduction of biosimilar IFX. Adverse events (AEs), demographic,
clinical, endoscopic and laboratory data were collected on all patients. Efficacy
was assessed according to response and remission at 14th, 54th week. For CU,
response was defined as a decrease in partial Mayo score of 2 or more from
baseline and a partial Mayo score of 1 or less was used to remission. For CD,
response was defined as a decrease in Harvey-Bradshaw score of 3 or more from
baseline, and a Harvey-Bradshaw score of 4 or less was used to remission. We
used Student’s t test for independent samples and Chi-square test. Time to with-
drawal due to adverse effects was estimated using Kaplan-Meier survival analy-
sis, and the log rank test was used to test for treatment group differences.
Results: The analysis included 346 consecutive IBD patients, 104 treated with
original IFX and 242 with biosimilar IFX. 103 patients were diagnosed with CU,
238 with CD and 5 with indeterminate colitis. Overall median follow-up was 21
months. Baseline clinical activity scores were not significantly different among
the 2 groups. Frequency of concomitant azathioprine and systemic steroids were
not different among both groups. Patients in biosimilar infliximab group were
more likely to experience previous biologic treatment failure (29.2% versus
20.2% in the original IFX, p¼ 0.0163). There were no significant differences in
patients achieving response and remission at weeks 14 and 54. There were no
significant differences in rate of withdrawals among the 2 groups (37.1% versus
38.8% for biosimilar IFX, p¼ 0.811). There were no significant differences in
cumulative discontinuation rate due to AEs in original IFX and biosimilar IFX
(42.42, (95% CI 39.49–45.34) months versus 44.61 (95% CI 42.66–46.56) months,
log-rank test p¼ 0.292).
Conclusion: Our clinical experience showed similar efficacy and safety profile of
biosimilar IFX compared to original IFX.
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Introduction: Acute severe Colitis (ASC) is a severe complication of inflammatory
bowel disease (IBD), for which there is no consensus definition. Its diagnosis is
based on clinico-biological and/or endoscopic criteria. Low endoscopy is essen-
tial for the positive diagnosis of ASC as well as for the diagnosis of IBD
Aims & Methods: The objective of this study is to describe the endoscopic aspect
of ASC and its interest in therapeutic management in our series of 48 cases it is a
prospective descriptive and analytical study of a series of 48 cases of acute severe
colitis (ASC) collected during a period of 3 years (2014–2016) in the gastroenter-
ology department.
Results: The average age of our patients is 39.8 years with extremes ranging from
14 to 65 years, a female predominance was found with a sex ratio, M/F of 0.77.
The ASC was inaugural in 20 (41.66%), while 28 cases (58.33%) are known to
have IBD, with 24 cases of UC (85.7%). Initial endoscopy was performed in all
patients. The average time to perform endoscopy (from the onset of symptoms)
was 37 days (2 to 75 days). Severe endoscopic aspects were present in 30 patients:
deep ulcer (29 cases), spontaneous bleeding (4 cases), friability (4 cases). Other
endoscopic lesions found were erythema (12 cases), erosions (5 cases), superficial
ulcer (25 cases), pseudo polyps (14 cases), contact bleeding (27 cases). Biopsy was
performed in all patients, histology was in favor of UC in 64.58% cases. CMV
viral inclusions were found in 2.08% of cases. First-line medical treatment is
based mainly on parenteral corticosteroid therapy, has been established in all
patients. A second-line treatment with anti-TNF was introduced in 5 cases
(10.41%) while surgical treatment was indicated in 15 cases (31.25%) of which
12 cases had severe endoscopic colitis. steroid refractory disease was associated
with endoscopic severe colitis (p¼ 0.04). In mono-varied analysis, endoscopic
severe colitis was found in males more than females (53.6 vs 43.3) With a statis-
tically significant difference p¼ 0.020
Conclusion: Endoscopy in ASC occupies an important place to specify the mor-
phological severity and thus make the positive diagnosis, the severe endoscopic
colitis constitutes one of the predictive elements of steroid refractory disease
requiring the use of a second therapeutic pallium.
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Introduction: Response to biological drugs in ulcerative colitis (UC) is variable
with induction response rates of 64.5% (vs 29.3% for placebo), 50.4% (vs 34.6%
for placebo), 51.0% (vs 30.3% for placebo), 47.1% (vs 25.5% for placebo) for
infliximab, adalimumab, golimumab and vedolizumab, respectively. Apart from
prior exposure to anti-tumour necrosis factor (anti-TNF) agents and concurrent
immunomodulatory therapy, predictors of clinical response and remission to
biological drugs have not been identified. We sought to investigate the utility
of baseline faecal calprotectin (FC) and early change in FC in predicting clinical
response and remission to biological therapy in UC.
Aims & Methods: Patients who were commenced on any biological therapy for
UC and had a baseline FC at the time of commencement were included in this
retrospective study. Disease activity was monitored serially by calculation of
Simple Clinical Colitis Activity Index (SCCAI) or by Physician global assessment
(PGA) or by treatment persistence. Clinical response was defined as decrease in
SCCAI 3 or a decrease in PGA score from baseline to follow up. The ability of
FC and fold change in FC to predict response and remission at 6 months was
estimated using Mann-Whitney test.
Results: A total of 94 patients were commenced on biological therapy of who 70
commenced anti-TNF therapy and 24 commenced vedolizumab with a mean age
of 41.8 (SD:þ 18.2). Fifty-one (72%) and 39 (55%) patients commencing anti-
TNF therapy were on concurrent immunomodulators (IM) and steroids respec-
tively compared to 9 (38%) and 16 (67%) patients respectively for vedolizumab.
Sixteen (67%) patients treated with vedolizumab had prior exposure to anti-TNF
agents compared to 4 (6%) in the antiTNF treated group. The 6-month response
among patients treated with vedolizumab and anti-TNF agents was 77.2% and
73.5% respectively. The calprotectin values were similar for responders (428.5
(72, 2100) [n¼ 16]) and non-responders (600 (107, 2100) [n¼ 5]) to vedolizumab
(P¼ 0.56). Similarly, responders (909 (13, 2100) [n¼ 28]) and non-responders
(850 (240, 2100) [n¼ 13]) to antiTNF agents had comparable calprotectin
values at baseline, P¼ 0.93.
Conclusion: In a single-centre series of biologic treated UC patients, baseline FC
did not predict clinical response at 6 months.
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Introduction: The prevalence of Crohn’s disease is important for planning of
health care and allocation of clinical resources. In 2005, a National Patient’s
Registry in Poland was established to collect demographic and clinical data.
To quantify efficacy of medications in real-life treatment during the study
period, data regarding medical treatment were collected from Registry.
Aims & Methods: The aim of the study was assess the efficacy and tolerance of
different medications in reference to demographic data and disease location and
behaviour. 6030 of patients have been enrolled to the Polish National CD
Patient’s Registry, conducted in 95 gastroenterology centers in Poland.
Patient’s phenotype according to: Montreal classification, demographics, smok-
ing, alcohol consumption, extraintestinal manifestation and medical treatment
have been evaluated. The impact of demographic factors on the use of drugs
from different groups (mesalamine, prednisone, azathioprine, methotrexate, anti-
TNF), and medications efficacy and tolerance was assessed. The efficacy assess-
ment was evaluated according to subjective 4-step scale. Similarly treatment
tolerance was assessed according to 2-step scale.
Results: No gender effects were observed on the use or efficacy of individual drug
classes, although greater tolerability of prednisone and azathioprine was
observed in men (respectively 95.56 vs 93.82 and 93.94 vs. 91.65, both
p5 0.05). Smoking did not affect the effectiveness and tolerability of the used
medications. However surprisingly fewer smokers were treated with azathioprine,
methotrexate, and anti-TNF in comparison to non-smokers (38 vs 45%, 0.5 vs
1.55%, 6.5 vs 11%, all p5 0.05) In patient’s declaring casual alcohol use, the
efficacy and tolerability of prednisone was significantly better than in patient’s
declaring abstinence (89 vs 84 and 96 vs 93%; p5 0.05). Referring to the
Montreal classification, efficacy of mesalamine, prednisone and azathioprine
was significantly higher in A1 group with the lowest in A2 patients (A1: 90,
A2:83, A3: 86 for prednisone, p5 0.05) Regarding relation to localization of
the disease, the efficacy of treatment with immunosuppressive agents
(azathioprine and methotrexate) in L3 was significantly lower compared with
L1 and L2, despite of increased use of immunosuppressive drugs in L1 (76 vs
82%, p5 0.05). As predicted, the use of immunosuppressive and anti-TNF drugs
was higher in complicated disease behavior (B2 and B3) than in B1, however
efficacy of infliximab was similar in B1 in comparison to others (B3: 15.5% B1:
7% of infliximab use).
Conclusion: This is the first study comparing efficacy and tolerability of treatment
methods used in ‘‘real-life’’ practice in Poland during last 8 years. Most observa-
tions are in compliance with data from clinical trials. Positive effect of casual
alcohol consumption on efficacy of medications requires further observation.
Interestingly some unexpected relationships, concerning similar efficacy of inflix-
imab in different disease behavior was found. This effect requires also further
observations in regards to more frequent use of anti-TNF drugs in last years.
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Introduction: Vedolizumab (VDZ) is the first gut-specific monoclonal antibody
alternative to anti-tumor necrosis factor alpha therapy in patients with moderate-
to-severe inflammatory bowel disease (IBD). It has been registered since 2016 in
Hungary, but currently the high treatment costs are considerably limiting the
availability of VDZ. All newly initiated VDZ therapy is individualized, it should
be approved by the steering committee of five Hungarian IBD-specialists. This
results in that VDZ therapy is available exclusively for patients in whom con-
ventional treatment was ineffective or contraindicated.
Aims & Methods: The aim of our non-interventional retrospective study was to
assess the efficacy of induction VDZ therapy. 41 patients (16 with Crohn’s dis-
ease (CD) and 25 with ulcerative colitis (UC) received VDZ induction therapy
between September 2016 and April 2017 in Hungary. Efficacy of induction ther-
apy was assessed based on the changes of activity indices on week 14.
Results: 40 of 41 enrolled IBD patients were therapeutic failure or intolerant for
infliximab and/or adalimumab therapy. The mean age was 38.6 years (range 18–
67; median 40) and the average disease duration was 11.7 years (range 1–36;
median 10). In 16 cases moderate and in 25 cases severe disease activity was
observed. Extra intestinal manifestations occurred in 6 patients, and in 6 cases
the IBD was associated with primary sclerosing cholangitis (PSC). Rate of the
therapeutic responders for VDZ induction therapy was 80.49% (N¼ 33).
Complete clinical remission was observed in 19 cases (46.34%) 8 cases
(19.51%) of which were steroid-free remission. In one case VDZ therapy had
to be interrupted due to development of IBD associated colorectal cancer and in
one case due to MCV infection.
Conclusion: Our results suggest that induction VDZ therapy is effective and it is a
safe therapeutic option in anti-tumor necrosis factor alpha failure or intolerant
IBD patients with moderate or severe disease activity.
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Introduction: Tuberculosis (TB) reactivation is of particular concern in patients
with inflammatory bowel disease (IBD) treated with biologic therapies. Screening
for latent tuberculosis infection (LTBI) is indicated prior to initiating treatment.
Despite the reduction of TB reactivation following treatment for LTBI the risk of
reactivation still exists. The efficacy of LTBI treatment in IBD patients receiving
biologic therapy and the timing of biologic therapy initiation has not been exten-
sively studied.
Aims & Methods: In order to evaluate the effectiveness of LTBI treatment in IBD
patients receiving biologic, we conducted a retrospective review of all IBD
patients diagnosed with LTBI following a tuberculin skin test (PPD) or inter-
feron gamma release assay (IGRA) and who received biologic therapy between
January 1996 and August 2016. Data extracted included patient demographics,
TB risk factors, chest x-ray findings, biologic agent used, prior and concomitant
therapies, and LTBI treatment regimen. TB reactivation after completion of
LTBI treatment was the primary outcome of the study. Risk of TB reactivation
was calculated using McGill University’s ‘‘The Online TST/IGRA Interpreter.’’
Results: A total of 35 IBD patients (27 Crohn’s; 8 ulcerative colitis) were included
in the study. Their mean age was 38.3 - 14.4 years and 68.6% were male (Table
1). The median time from diagnosis of IBD to LTBI was 9 years (0–48 years).
Prior IBD therapies included corticosteroids (86%), aminosalicylates (83%),
other immunosuppressants (69%). At least 43% of patients have been previously
exposed to at least 1 biologic agent. The most common LTBI treatment regimen
was isoniazid (INH) for 9 months (n¼ 26, 74%). Biologic therapy used were
infliximab (n¼ 14, 40%), adalimumab (n¼ 10, 29%), vedolizumab (n¼ 7,
20%), and certolizumab pegol (n¼ 4, 11%). Combination therapy with an immu-
nomodulator and a biologic agent was administered in 57% of cases (n¼ 20). All
patients were treated for LTBI and the majority (83%) was treated prior to
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starting biologic therapy. The median time from initiation of LTBI treatment to
biologics was 43 days (4–3653). The mean duration of follow-up was 2.9 3.3
years. The median calculated annual risk of developing active TB without treat-
ment was 0.52% (0.08%-1.3%). Of the cohort studied, only one patient taking
adalimumab monotherapy after completing 6 months of INH therapy developed
reactivation of TB. The estimated TB reactivation rate in our cohort was 0.98
cases per 100 patient-years of follow up.
Table 1: Cohort Characteristics and Estimated Post-treatment Tuberculosis
Reactivation Rate
Mean Age 38.3 (14.4) years
Male Sex 24/35 patients
Type of Inflammatory
Bowel Disease (IBD)
Ulcerative Colitis (23%)
Crohn’s Disease (77%)
Mean Time since IBD
Diagnosis
9 years (range: 0–48)
Type of Biologic Therapy Infliximab (40%) Adalimumab
(29%) Vedikuzumab (20%)
Certolizumab (11%)
Type Latent Tuberculosis
Therapy
Isoniazid (INH) for 9-months
(74%) INH for 6-months
(11%) Rifampin 4-months
(9%) INHþRifampin for 3-
months (3%) Others (3%)
Median time to initiate
biologic therapy
43 days (range: 4–3653)
Mean duration of follow-up 2.9 3.3 years
Mean Pre-treatment Risk of
Development of Active
Tuberculosis
0.52%/year (range: 0.08%-
1.3%/year)
Estimated Post-treatment
Tuberculosis
Reactivation Rate
0.98 cases per 100 patient-years
Conclusion: Treatment for LTBI in patients with IBD treated with biologics is
effective, but does not eliminate the risk of reactivation, which occurred at a rate
of 0.98 cases per 100 patient-years in our cohort. Additional studies with
extended follow-up are warranted to further characterize the efficacy of LTBI
treatment in these patients.
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Introduction: Resection in Crohn’s disease (CD) intends to be a curative surgery,
but sometimes it is not possible to remove completely the lesions of the damaged
gut. The aim of our study was to describe the characteristics and management of
patients with residual disease after surgery (RD) and to compare these with
patients with curative surgery (CS) in post operative CD patients.
Aims &Methods: PRACTICROHN was a retrospective study that included adult
patients from 26 Spanish hospitals who underwent CD-related ileocolonic resec-
tion with ileocolonic or ileorectal anastomosis between January 2007 and
December 2010. Clinical data was retrospectively collected from clinical charts.
RD was defined when lesions were still present after surgical resection.
Postoperative recurrence (POR) was defined by clinical symptoms (diarrhea,
abdominal pain) and endoscopic Rutgeerts score i2, and/or CT or MRI con-
firmation of disease activity. Categorical variables were compared with the 2
test or Fisher’s exact test Kaplan-Meier method was used to assess time to
clinical recurrence and a log-rank test to obtain statistical significance.
Results: Three hundred and sixty-four patients were analyzed (mean age 40 years
[SD 13], 50% men). Of these, 27 (7.5%) had RD after surgery. Median age at
diagnosis was shorter in patients with RD than CS: 23 (IQR 19–34) years vs 29
(IQR 23–40), p¼ 0.02. At the time of resection B1(þp) behavior was more fre-
quent in RD than in CS: 6 (22%) vs 26 (8%), p¼ 0.05; and location was mainly
L1(L4) in CS (190, 57%) and L3(L4) in RD (19.70%),p¼ 0.02. Four (16%)
patients in RD were receiving immunomodulators at the time of surgery vs 132
(41%) of CS, p¼ 0.02. More patients in RD vs CS presented postoperative
complications (12 (44%) vs 87 (26%), p¼ 0.06) as well as hospitalizations the
first year after surgery (10 (37%) vs 42 (12%) p¼ 0.001). No differences in
smoking habit, perianal disease or length of resection were found between the
two groups. More patients were performed an endoscopy within the first year
after surgery in the RD vs CS:16 (59%)vs 122 (36%), p¼ 0.03 but no difference
in prophylactic treatment were found in RD vs CS groups. POR was more
frequent among patients with RD (69% vs. 29%,p¼ 0.001). Median time to
POR was longer in patients who received prophylaxis vs those who didn‘t
received it (698 vs 392 days;p¼ 0.4).81/275 (29%) in the CS presented POR
with median time to POR being longer in patients who received prophylaxis
(no median found vs 1529 days) p¼ 0.04. Table 1.
Table 1
Residual disease patients N Events
Median
time to POR
CI 95%
p-valueLL UL
Prophylaxis Yes 15 8 698 217 — 0.4
No 8 8 392 287 —
Curative surgery patients N Events Median time
to POR
CI 95% p-value
LL UL
Prophylaxis Yes 187 48 — — — 0.04
No 88 33 1529 839 —
Conclusion: Residual disease is a rare situation after intestinal resection in CD.
Patients with residual disease after surgery, are more likely followed-up endos-
copically within the first year. Conversely, similar proactive recurrence preven-
tion was observed compared to curative surgery. In the case of residual disease
although prophylactic treatment is useful, most of the patients will present
POR.RD is a factor of poor prognosis in post-operative CD patients.
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Introduction: Bile acid malabsorption (BAM) is a common cause of diarrhoea in
Crohn’s disease (CD) patients with ileal resection and can lead to complications
such as renal and biliary stone disease. BAM is usually diagnosed by selenium
labelled homotaurocholic acid test (75SeHCAT) but its availability is limited.
Thus, a large proportion of resected CD patients either remain underdiagnosed
or subject to empirical therapy. There is a paucity of studies examining the
correlation between length of ileal resection and severity of BAM which will be
of particular use to clinicians with no recourse to diagnostic testing for BAM.
Aims & Methods: We identified all CD patients with a prior surgical resection
who underwent 75SeHCAT testing at our institute. Testing was based on the
treating clinician’s discretion. The length of resected ileum was recorded from
histopathology report. We conducted a Spearman’s correlation test to check for
correlation between length of resected ileum and percentage retention on
75SeHCAT. Response to treatment with bile salt sequestrant and 75SeHCAT
retention values was tested using Mann-Whitney test.
Results: A total of 97 patients were identified with a mean age of 46.4 (SD 14.5).
The median length of resected ileum was 22.5 cms (range 1.5–95 cms) with a
median of 1 resection (range 1–4). Overall, 90 patients (92.8%) had 75SeHCAT
retention values of 55%, 5 (5.2%) patients between 5–10% and only 2 patients
had values of 415%. There was moderate correlation between 75SeHCAT reten-
tion and length of ileal resection (Spearman’s rho: 0.4041, P5 0.001). Data on
response to treatment was available for 60 patients, of who 41 (42%) responded
and 19 (19%) failed to respond to bile salt sequestrants. The 75SeHCAT retention
values was comparable among responders (median 0.02%, range 0.1–6.6) and
non-responders (median 0.02%, range 0.1–6.6, Mann-Whitney test, P¼ 0.72).
Conclusion: There was moderate correlation between length of ileal resection and
severity of BAM as defined by 75SeHCAT retention values. Response to bile salt
sequestrant therapy was not dependent on 75SeHCAT retention values.
Disclosure of Interest: S. Subramanian: Advice report member for Abbvie,
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Introduction: Irritable Bowel Syndrome (IBS) is associated with alterations along
the brain-gut-microbiota axis. Previous studies have suggested a parallel segrega-
tion of microbial features with psychological burden in IBS (1,2,3).
Aims & Methods: The study aimed at examining microbial correlates of psycho-
logical distress, anxiety, depression and stress perception. 16s rRNA faecal
microbial analyses (Illumina MiSeq, V1-2 amplified from total DNA) in 48
IBS patients (Rome-III criteria, mean age 42 years, 35 female subjects, 25 diar-
rhoea-dominant, 5 constipation-dominant and 18 alternating-type IBS).
Assessment of psychological and clinical variables with validated questionnaires,
microbial analysis via QIIME. Machine learning to predict psychological distress
through a composite model of bacterial features. Correlational analysis and
comparisons in bacterial abundance between subgroups defined by thresholds
in psychological variables.
Results: Thirty-one patients (65%) showed psychological distress, 22 (31%) anxi-
ety, and 10 depression (21%). Psychological distress was uncorrelated with IBS
severity (Spearman’s ¼ 0.05, p¼ 0.736). Microbial beta diversity was signifi-
cantly associated with distress and depression q¼ 0.044 each). A random forest
model using 148 microbial estimators was able to correctly classify patients
regarding presence of psychological distress (AUROC¼ 0.98). Patients exceeding
thresholds of distress, anxiety, depression and stress perception showed signifi-
cantly higher abundances of Proteobacteria (LDA¼ 2.5). Patients with anxiety
were characterized by higher abundances of Bacteroidaceae (LDA¼ 3.0).
Depression correlated inversely with Lachnospiraceae (¼ -0.58, q¼ 0.018), anxi-
ety positively with Anaerotruncus (¼ 0.65, q¼ 0.001).
Conclusion: A microbial signature accurately predicted the presence of psycho-
logical distress. Psychological variables significantly segregated gut microbial
features, underscoring the role of brain-gut-microbiota interaction in IBS.
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Introduction: Saccharomyces boulardii (SB) CNCM I-745 demonstrated clinical
efficacy in the secondary prevention of post-antibiotic Clostridium difficile infec-
tion (CDI), but the mechanism remains unclear. Cholic acid (CA) is a primary
bile acid (BA), synthesized by the liver which triggers the germination of C.
difficile spores in the intestine. Physiologically, the gut microbiota transforms
primary BAs (cholic acid and chenodeoxycholic) into secondary (deoxycholic
and lithocholic). CA loses its germinating properties after transformation and
appears to become protective against CDI. The goals of this work in healthy
volunteers (HV) were to: A) Describe the effect of antibiotics on the quantity of
‘pro-germination’ primary BA including CA in human stools B) Describe
whether SB enhances transformation to ‘protective’ secondary BA in human.
Aims & Methods: This work was an ancillary of a previous study conducted in 4
groups of HV at Beth Israel Deaconess Medical Center and Harvard Medical
School, Boston, Massachusetts. The previous results of this work showed that SB
CNCM I-745 can modulate shifts in the microbiota and reduces diarrhea during
an antibiotic therapy. Group 1 (n¼ 12) received SB CNCM I-745 500mg twice
daily for 14 days. Group 2 (n¼ 12) received Amoxicillin-Clavulanate (AC) (875/
125mg, twice daily) for 7 days. Group 3 (n¼ 12) received AC for 7 days and SB
for 14 days. Group 4 (n¼ 12) did not receive any treatment. Groups 1, 2, 3 had
successive stool samples at D-28, 0, 3, 7, 10, 13, 21. Group 4 had stool samples at
D0, 7 and 21. The fecal concentrations of 28 BAs were measured by HPLC/MS,
and expressed as % of total BA concentration.
Results: AC alone (group 2) significantly reduced the rate of fecal secondary BA
at day 7 compared to control (group 4) (54.8 10.1 vs 83.1 7.4%, p¼ 0.017). In
group 3 (AC plus SB), the decrease in secondary BA rate was significantly less
than for AC (71.23 7.4 versus 54.20 9%, p¼ 0.04), and this difference was
prolonged over time. Similarly, the ACþSB group showed a significantly lower
(and sustained) increase in CA than in the AC alone group.
Conclusion: Antibiotics alter the transformation of BA by microbial enzymes into
the intestine. This increases primary BA while reducing secondary BA in feces.
Cholic Acid rates, a primary BA which facilitates C. difficile spore germination
in vitro, increases in stool during antibiotic therapy. The concomitant adminis-
tration of SB during AC treatment significantly reduces this CA peak. These
results highlight new human data on a potential mechanism for post-antibiotic
CDI: alteration of the microbiota can encourage germination of C. difficile
spores via increased CA concentrations and reduced concentrations of secondary
BAs. The effectiveness of SB in preventing recurrent CDI may be explained, in
part, through modulation of microbiota changes that influence the balance of
pro- and anti-germination BA concentrations
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Introduction: While particular imbalances in the gut microbiota have been linked
to colorectal adenomas and cancers, some specific bacterium have been identified
as a related factor. Recent studies have reported a high abundance of
Fusobacterium nucleatum (F. nucleatum) in colorectal cancer (CRC) subjects com-
pared to normal subjects1,2. F. nucleatum is also known as a pathogenic species of
oral microbiota, but it is not known if F. nucleatum plays a role in other part of
the digestive tract. F. nucleatum may affect metabolic pathways for the carcino-
genesis3. We examined whether there is relationship between F. nucleatumin oral
cavity and CRC.
Aims & Methods: We assessed the abundance of Fusobacterium in CRC, color-
ectal mucosa and saliva. We extracted DNA from mucosal biopsies and mea-
sured bacterial levels by quantitative PCR of the 16S ribosomal RNA gene. We
also investigated the homology of F. nucleatum in oral cavity and CRC.
Results: In 51 CRC cases, Fusobacterium positivity was significantly higher in
CRC compared to controls (p5 0.05). Fusobacterium was more detected in
CRC (12.9%) than in normal tissues(3.9%) respectively. The detection rate of
F. nucleatum was 96% in saliva and 93% in CRC by next-generation sequencer.
A total of 15 patients with CRC were included to check the homology of F.
nucleatum in saliva and CRC. From the 15 patients, 9 were F.nucleatum-positive
in CRC. 8 of 9 from these patients were F.nucleatum-positive in saliva. From
these patients who were F.nucleatum-positive in saliva and CRC, we next looked
for the results of AP-PCR and 6 patients have shown common band patterns.
Conclusion: The results support a link between the abundance of F. nucleatum in
oral cavity and CRC. Our data also indicate that there may be a route from the
oral cavity to the CRC in F. nucleatum positive cases. We are now identifying
DNA sequences, specific for the objective strains.
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Introduction: Human Milk Oligosaccharides (HMOs) are a family of complex
carbohydrates found in high concentrations in human milk and which are now
becoming commercially available. In clinical studies, in both infants and adults,
HMOs powerfully and specifically modulate the gut microbiota by increasing
bifidobacteria and reducing certain pathogenic bacteria (1,2). Also, HMO bac-
terial consumption results in the production of beneficial metabolites such as
short chain fatty acids and the lowering of pH. Hence, the selective growth of
bifidobacteria on HMOs can create an ecological niche that is more colonization
resistant against pathogens. Bifidobacteria may also have a direct impact on
microbial toxins by reducing their level and cytotoxic effect (3). Antibiotics,
especially broad spectrum antibiotics, dramatically impact the microbiota and
its balance, and have been implicated in the pathogenesis of many health condi-
tions including gastrointestinal symptoms such as diarrhoea (4). The most com-
monly cited mechanism for antibiotic-associated diarrhoea is intestinal
overgrowth of the pathogenic bacterium, Clostridium difficile.
Aims & Methods: The aim of this study is to investigate, in in vitro models of C.
difficile infection, (i) the impact of HMOs on the microbial community and
activity (e.g. bacterial metabolites and pH), and (ii) the anti-pathogenic activity
of HMOs against C. difficile, with a focus on preventing recurrence of the infec-
tion. Two in vitro models, each using human faecal microbiota infected with C.
difficile, were used to examine the impact of HMOs on bacterial metabolite
production and C. difficile infection. One model is a 48 hour batch fermentation
while the other is a simulated gut model, run for 3 weeks post infection, which
simulates the infection cycle of C. difficile after antibiotic treatment.
Results: The study revealed that the HMOs increase the level of bifidobacteria,
increase the concentration of beneficial metabolites such as short chain fatty
acids and decrease pH compared to a control with no added HMOs.
Additionally, HMOs reduced the level of C. difficile; in some cases completely
eradiating C. difficile below detection limits. This antimicrobial effect of HMOs
on C. difficile was pH-independent, hence another mechanism is causing the anti-
pathogenic activity of HMOs.
Conclusion: Conclusively, the results show that HMOs can impact C. difficile
infection in an in vitro system, which suggests HMOs as a potential approach
to reduce risk of antibiotic associated diarrhoea and post-antibiotic C. difficile
infection.
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Introduction: It has been reported that the composition of human gut microbiota
changes with aging, body mass index (BMI), diet and other environmental fac-
tors. In particular, the relationship between gut microbiota and obesity has been
underlined frequently because intervention in the microbiota may reduce body
fat. In this study, we investigated the relationship between obesity and composi-
tion of gut microbiota in healthy Japanese population.
Aims & Methods: Participants were 1.082 healthy Japanese adults (410 males, 672
females) who participated in the Iwaki Health Promotion Project in 2014. Faecal
samples were analysed by 16S rRNA gene-targeted sequencing to determine
family composition of gut microbiota. They were classified into obese group
(BMI 25) and normal weight group (BMI5 25) according to Japanese stan-
dard and were stratified into 7 age groups, 19–29, 30–39, 40–49, 50–59, 60–69,
70–79 and 80–90. The family composition of gut microbiota in each age group
was compared between obese and normal group.
Results: There were 235 obese participants, and 847 normal ones. The proportion
of Bacteroidaceae decreased substantially, and Ruminococcaceae increasing
slightly with aging in obese group. The proportion of Bifidobacteriaceae,
Lachnospiraceae and Porphyromonadaceae decreased gradually with aging in
both groups.
Conclusion: Changes in composition of gut microbiota with aging were different
between obese and normal group. Some previous researches observed differences
of composition of gut microbiota between them, but many of the researches did
not take aging into consideration. Our study indicated that different intervention
stratified with age could be needed.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1729 BACTERIOCIN PRODUCTION BY MUCOSAL BACTERIA IN
COLORECTAL NEOPLASIA
D. Kohoutova
1, M. Forstlova2, P. Moravkova1, S. Rejchrt1, D. Smajs3, J. Bures1
12nd Department Of Internal Medicine - Gastroenterology, Charles University,
Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove/
Czech Republic
2Department Of Clinical Microbiology, Charles University, Faculty of Medicine
and University Hospital in Hradec Kralove, Hradec Kralove/Czech Republic
3Department Of Biology, Masaryk University, Faculty of Medicine, Brno/Czech
Republic
Contact E-mail Address: darina.kohoutova@seznam.cz
Introduction:Due to its high incidence, sporadic colorectal cancer (CRC) remains
a huge medical and socioeconomical burden in many countries worldwide includ-
ing the Czech Republic. The exact contribution of large intestinal bacteria to the
pathogenesis of CRC has not been elucidated yet, still the mucosal, not the
luminal, microbiota seem to play the crucial role. Bacteriocins are small proteins,
which are produced by the Enterobacteriaceae bacteria, especially by Escherichia
coli. Bacteriocins are divided into more groups, colicins and microcins are the
most important ones. Bacteriocins possess antibacterial, antineoplastic, proapop-
totic and probiotic effect.
Aims & Methods: The aim of this prospective study was to evaluate bacteriocin
production by mucosal large intestinal bacteria in colorectal neoplasia. We used
an original methodology reported by our group (1). Mucosal biopsies were taken
in the caecum, transverse colon and rectum within the colonoscopy in patients
with non-advanced colorectal adenoma, non-a-A (11 men, 10 women, mean age
63 10), advanced colorectal adenoma, a-A (which was defined as neoplasia
larger than 10mm and/or containing villous component and/or containing
high grade dysplasia; 13 men, 7 women, mean age 65 9), sporadic colorectal
carcinoma, CRC (12 men, 10 women, mean age 70 10) and in the controls
(average risk population with normal findings on colonoscopy and with negative
history of colorectal neoplasia and/or inflammatory bowel disease; 7 men, 13
women, mean age 57 14). After appropriate microbiological culture bacteriocin
production by each strain was investigated by PCR methods.
Results: A total of 249 mucosal biopsies were taken (60 controls, 63 non-a-A, 60
a-A, 66 CRC,) and samples were further investigated. Colicin producing strains
were isolated in 22% (13/60) controls, 59% (37/63) non-a-A, 55% (33/60) a-A
and in 76% (50/66) CRC. Significantly higher production of colicins was
observed in non-a-A, a-A and CRC group when compared to controls,
p5 0.001. Significantly higher production of colicins was confirmed in patients
with CRC compared to patients with a-A, p¼ 0.016. Microcin producing strains
were isolated in 23% (14/60) controls, 56% (35/63) non-a-A, 78% (47/60) a-A
and in 62% (41/66) CRC. Significantly higher production of microcins was
observed in non-a-A compared to controls, p¼ 0.002, in a-A and CRC group
when compared to controls, p5 0.001. Microcins were produced more fre-
quently in patients with a-A compared to those with non-a-A, p¼ 0.008.
Conclusion: Strains isolated from large bowel mucosa in patients with colorectal
neoplasia produce bacteriocins more frequently compared to those with normal
findings on colonoscopy. We presume, that mucosal large intestinal microbiota
with their products including bacteriocins play an important role during the
development of colorectal neoplasia.
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Introduction: The production of bacteriocins is considered as the key metabolic
function of gut microbiota and as the inherent property of probiotic strains.
Bacteriocins and metabolites of probiotic microorganisms (metabiotics) can opti-
mize host-specific physiological functions related to human health.
Aims & Methods: This study aims to: (a) detect the bacteriocin genes of probiotic
strains Lactobacillus helveticusD75 (NCBI Reference Sequence NZ_CP020029.1)
and Lactobacillus helveticus D76 (NCBI Reference Sequence NZ_CP016827.1)
and (b) evaluate in vitro effects of the carboxylic and amino acids mixture iden-
tical to the metabolites of the probiotic Escherichia coli strain M17 (components
of Actoflor-S dietary supplement). The antagonistic activity of Lactobacillus
helveticus D75 and Lactobacillus helveticus D76 strains was estimated by the
deferred antagonism method. The identification of bacteriocin genes was per-
formed by PCR using helveticin J gene primers. Amplified fragments were
sequenced using ABI PRISM 310 Genetic Analyzer and were analyzed using
NCBI/BLASTX.
Results: The identical sequences of 537 bp homologous to gene fragment of
helveticin of Lactobacillus helveticus DPC 4571 (lhv_1632 gene) were detected
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in DNA of both probiotic strains. Sequencing of these fragments showed differ-
ence in three nucleotides compared to the reference DNA of DPC 4571 strain (A
instead of G at position 46, C instead of T at position 249 and A instead of T at
position 537), but all these replacements do not lead to changes in the amino acid
sequence of a bacteriocin. For Lactobacillus acidophilus D76 another bacteriocin
gene fragment of 283 bp was identified (in addition to 537 bp fragment). The
latter had 95% homology with the helveticin J gene of Lactobacillus helveticus
R0052 (R0052_09025 gene). In NCBI/BLASTX database the sequences homo-
logous to the helveticin gene of Lactobacillus helveticus DPC 4571 were found in
11 microorganisms related to Lactobacillus acidophilus, Lactobacillus amylovorus,
Lactobacillus crispatus, Lactobacillus gallinarum, Lactobacillus helveticus and
Lactobacillus kitasatonis. The addition of the carboxylic and amino acids mixture
(Actoflor-S) results in 2-2.5-fold enhanced antimicrobial activity of both tested
probiotic strains against test pathogens Escherichia coli O75 and Salmonella
Enteritidis 209, most likely due to an increase in bacteriocin gene expression.
Conclusion: Study shows that there are at least two bacteriocins in Lactobacillus
helveticus D76 and one bacteriocin in Lactobacillus helveticus D75. Carboxylic
and amino acids mixture identical to the metabolites of the probiotic Escherichia
coli strain M17 probably induces bacteriocin synthesis in probiotic strains
Lactobacillus helveticus D75 and Lactobacillus helveticus D76 and enhances
their antimicrobial activity against test pathogens Escherichia coli O75 and
Salmonella enteritidis 209. However, the true potential of gut microbial metabo-
lites mixture and identified probiotic bacteriocins for human health has yet to be
realized.
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Introduction: Fecal microbiota transplantation (FMT) ihas been shown to be
effective treatemtn for recurrent Clostridium difficile infection. Concern has
been raised about the long-term safety of FMT.
Aims & Methods: The aim of this study was to determinate the long-term safety
of fecal microbiota transplantation (FMT), and its effect on gastrointestinal
symptoms (GI) in Clostridium difficile (CDI) patients. We studied 84 patients
of which 45 received an FMT treatment via colonoscopy and 39 served as con-
trols receiving antibiotic treatment (AB) for the recurrent CDI and followed their
recovery on average of 3.8 yrs. All together 130 patients (55 patients in the FMT
group and 75 patients in the AB group were sent a 45-item questionnaire collect-
ing information about the patient demographics, their physical and mental
health, including allergies, infections, gastroenterological conditions such as
IBD and IBS, diabetes, autoimmune diseases, neurological disorders, mental
wellbeing and malignancies. Response rate for the questionnaire was 64.6%.
Results: There were no differences in the incidence of severe diseases between the
groups including the incidence of IBD, diabetes, diseases of the nervous system,
autoimmune disease, incidence of colon polyps and cancer. Change of weight was
neither different between groups (kg;SD); FMTþ 2.5 (5.6) and ABþ 1.3 (5.6),
p¼ 0.51. The AB treated subjects recorded more frequently that their bowel
function had become worse and more irregular after the treatment
(AB¼ 35.9%, FMT¼ 11.1%, P¼ 0.001) compared to FMT group. 77.8% of
the patients treated with FMT experienced GI symptoms related to IBS whereas
92.3% of antibiotic-treated patients recorded these symptoms (P¼ 0.06). AB
patients experienced more symptoms of the upper intestinal tract than the
FMT-treated patients (AB¼ 51.3%, FMT¼ 31.1, p¼ 0.045. In this cohort
97.6% of the FMT-treated patients and 60% of AB treated patients would
prefer in the future that their initial treatment to be FMT instead of antibiotics.
Conclusion: FMT is a rational, durable, safe, and acceptable treatment option for
patients with recurrent CDI. No severe diseases appeared after FMT and FMT
seem to relieve GI symptoms better than antibiotic treatment. FMT and AB
treated patients would prefer in the future that their initial treatment for recur-
rent CDI to be FMT instead of antibiotics.
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Introduction: Clostridium difficile-associated disease (CDAD) is an infection
caused by Clostridium difficile, gram-positive, anaerobic, spore-forming and
toxin-producing bacteria. Infection is recognized as the leading cause of diarrhea
associated with health care services in the developed countries. In Portugal epi-
demiological data are limited.
Aims & Methods: Characterize Clostridium difficile-associated disease episodes in
a Portuguese Hospital Center. Retrospective analysis of 250 hospitalized patients
with CDAD, in Centro Hospitalar do Algarve, between 2011 and 2015. The data
was obtained from clinical processes and statistical analysis was performed with
SPSS version 23.
Results: The patients were mostly women (52%). The mean incidence of CDAD
was 0.21% and the patients had an associated mortality of 28%. The year with
the highest incidence was 2015 (0.53%) but with a lower associated mortality
rate. CDAD was mostly acquired at the hospital level (75.6%) and the mean
length of hospital stay was 33 days. About 82.4% of the cases were first occur-
rences and the remaining (18.6%) were recurrences of CDAD. The majority of
the population under study performed Proton Pump Inhibitors-IBP (52.8%) and
antibiotic therapy (74.4%) (26.8% made a single antibiotic, and 23.6% 2 or more
distinct antibiotics). Penicillin antibiotic class was the most used, followed by
Cephalosporins (21.5%), Fluoroquinolones (11.4%) and Macrolides (10.1%).
Conclusion: A significant increase in the incidence of CDAD was observed in this
study. This increase may be related to several factors, such as the improvement of
laboratory diagnostic methods, increased antibiotic prescription, hospital con-
tamination with Clostridium difficile spores or with the appearance of new and
more virulent Rybotypes.
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Introduction: Colonic diverticular bleeding is the most common cause of lower
gastrointestinal bleeding. Persistent bleeding or acute massive bleeding of pre-
senting with hemodynamic disorders requires an interventional treatment. The
question of what is the best treatment for acute diverticular bleeding remains
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unanswered. In our institution, we gastroenterologists perform interventional
radiology for. Retrospective study of transarterial embolization (TAE) for colo-
nic diverticular bleeding was performed.
Aims & Methods: The aim of this study is to clarify the efficacy of TAE for
colonic diverticular bleeding. 229 patients were diagnosed as diverticular bleeding
from Jan 2010 to Dec 2016 in our institution. Bleeding stopped spontaneously in
126 patients. 103 patients were performed colonoscopy. Overt bleeding occurred
in 8 patients after colonoscopy, and those were eligible for this study who under-
went TAE. Conservative management or endoscopic procedure were not success-
ful in all the patients. 7 patients were male and 1 was female with a median age of
62.6 years (range 39–85 years). The average opportunity for enhanced CT was
2.1, 7 patients were in shock, and all of 8 the patients were treated with blood
transfusion. Those who were extravasation-positive in enhanced CT underwent
angiogram from vasa recta near the extravasation at least 3 times. In case radio-
paque clips were placed at the bleeding site via colonoscopy to mark emboliza-
tion site, regardless of whether or not active extravasation was identified on
angiogram, coil embolization was performed using 0.010 inch coils in vasa
recta. Technical success rate and complications were evaluated. Technical success
was defined as immediate complete cessation of bleeding confirmed by digital
subtraction angiography showing no further contrast extravasation at the end of
each TAE. Clinical success was defined as no recurrent bleeding in observation
period.
Results: Technical success rate was 88%(7/8), and clinical success was also
88%(7/8). 6 patients were extravasation-positive in enhanced CT, and 5 patients
were extravasation-positive in angiogram. Although 3 patients were extravasa-
tion-negative in angiogram, 2 patients underwent TAE. After TAE, no recur-
rence of bleeding was observed. Severe adverse events such as bowel infraction
did not occur in all cases.
Conclusion: As the microcatheter technique has recently improved further,
adverse events are rare. Therefore superselective coil embolization could be
first choice for diverticular bleeding with extravasation-positive in enhanced CT.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1734 ACCURACY OF THE NASOGASTRIC TUBE AND THE BUN/
CREATININE RATIO FOR DISTINGUISHING BETWEEN UPPER
AND LOWER SOURCES OF GASTROINTESTINAL BLEEDING. A
SYSTEMATIC REVIEW
S. Machlab, E. Martinez-Bauer, P. Garcia-Iglesias, A. Lira, C. Marmol,
G. Llibre, J.P. Da Costa, M. Gallach, L. Melcarne, V. Puig-Divi, F. Junquera,
R. Campo, E. Brullet, X. Calvet
Gastroenterology, Hospital Universitari Parc Tauli, Sabadell/Spain
Contact E-mail Address: stmachlab@tauli.cat
Introduction: The insertion of a nasogastric tube (NGT) and assessment of the
BUN/creatinine ratio were recommended as initial measures to distinguish
between upper and lower gastrointestinal bleeding (American College of
Gastroenterology 2016). As the nasogastric tube is one of the most bothersome
interventions for the patient, we evaluated the evidence supporting these
recommendations.
Aims & Methods: The aim of the study was to identify the diagnostic accuracy
(sensitivity, specificity, positive predictive value, negative predictive value and
likelihood ratios) of the NGT and the BUN/creatinine ratio for distinguishing
between upper and lower sources of gastrointestinal (GI) bleeding.We conducted
a systematic review of the literature in order to identify studies assessing the
diagnostic accuracy of the NGT or BUN/creatinine in patients with melena,
hematochezia or rectorrhagia without hematemesis. The search was performed
in November 2016 in five data bases (Pubmed, Scopus, Web of Science,
Cochrane Plus Library and OpenGrey).
Results: Four studies met the selection criteria (two evaluating the NGT, one
BUN/creat and one both). The two methods had a low sensitivity for detecting
upper GI bleeding source. Both a positive NGT aspiration and BUN/creatinine
ratio above 30 markedly increased the probability of an upper GI source with a
positive likelihood ratio ranging from 2 to 11. Unfortunately, the sensitivity of
both tests for upper GI bleeding was very low (negative likelihood ratios around
0.6).Characteristics and results of the studies selected are shown in table 1.
Conclusion: For patients with gastrointestinal bleeding without hematemesis,
BUN/Creat 30 indicates a high probability of an upper GI source.
Nasogastric tube aspiration provides little additional information and so is not
indicated. Neither test reliably rules out an upper GI source of bleeding.
Therefore, in cases of uncertainty, an upper GI endoscopy will be necessary to
reliably rule out an upper GI source.
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Introduction: The incidence of acute lower gastrointestinal bleeding (LGB) is
increasing in Western countries, but the predictors of its outcome are not well
studied and defined.
Aims & Methods: The aim of this study was to compare the accuracy of Glasgow-
Blachford score (GBS) with three available risk scores (State, Velayos and
Newman) for predicting the need of any clinical intervention (endoscopic ther-
apy, vascular embolization, surgery and need of transfusion) in patients admitted
for acute LGB. Retrospective study from January 2013 to December 2015 in a
university tertiary care hospital. Patients with acute LGB were identified using
the International Classification of Diseases (9th Revision) and Clinical
Modification codes for admission diagnosis. Scores were retrospectively calcu-
lated according to clinical reports data. Area under the receiver operating char-
acteristic curve (AUROC), sensitivity, specificity, positive and negative predictive
values were calculated for four scores. Also the best cut-off of each score was
chosen from using the AUROC curve values.
Results: A total of 298 (51% men) consecutive patients with acute LGB were
identified. Median age was 76.1 years (range 25.4–96.5), 201 (67.4%) of patients
were older than 70 years. Five patients (1.7%) died, 18 (6%) developed recurrent
bleeding, 89 (29.9%) needed transfusion, 30 (12.1%) received endoscopic ther-
apy, and 3 (1%) underwent transcatheter arterial embolization. No patient
required any surgical intervention. AUROC of GBS score was 0.87
(95%CI:0.82–0.91) for the need of transfusion, and 0.82 (95%CI:0.76–0.87) for
the need of any clinical intervention. AUROC for the need of transfusion and
clinical intervention were 0.68 (95%CI:0.61–0.74) and 0.67 (95%CI:0.60–0.73)
for the Strate score, 0.77 (95%CI:0.71–0.83) and 0.74 (95%CI:0.68–0.80) for the
Velayos score and 0.78 (95%CI:0.72–0.85) and 0.74 (95%CI:0.68–0.81) for the
Newman score, respectively. GBS was significantly more accurate than LGB risk
scores for predicting the need of transfusion. Although AUROC of GBS was also
numerically better for predicting the need of any clinical intervention, the differ-
ence was only significant when comparing with the Strate score. All the risk
scores were more accurate for determining the need for transfusion than for
the need of clinical intervention. Sensitivity, specificity and negative and positive
predictive values for each score are shown in table 1.
Table 1: Sensitivity (S), specificity (Sp), Positive (PPV) and negative (NPV)
predictive values of the different socres for detecting the need of trasnsfusion
(TRF) or clinical intervention (CI). *Best cut-off scores for Blachford secore were
6 for transfusion and 4 for clinical intervention. Values are expresed as%.
Score TRF S TRF Sp TRF PPV TRF NPV CI S CI Sp CI PPV CI NPV
Blachford* 80 78 61 90 89 59 50 91
Strate4 1 69 58 41 81 66 58 86 78
Velayos4 0 95 46 41 96 90 46 44 90
Newman4 1 92 40 39 93 89 40 32 88
Conclusion: The GBS was superior to the 3 LGB risk scores for predicting the
need for transfusion and clinical intervention. The GBS may be an useful tool for
risk stratification in acute LGB.
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Table 1: Characteristics and results of the studies
Estudy (year) Design/Period Sample size/Testee
Sensitivity
(%)
Specificity
(%)
Predictive
positive value
(%)
Predictive
negative
value (%)
Negative
Likelihood ratio
Positive
Likelihood ratio
Richards 1990 Retrospective 1981–
1990
126 BUN/creat
(Cut off 36)
37 100 100 53 0.63 þþþþþ
Aljebreen 2004 Retrospective 1999–
2001
520 NGT 68 54 41 78 0.61 1.44
Witting 2006 Retrospective 1997–
2002
325 BUN/creat
(Cut off 30) NGT
39 42 94 91 81 81 70 61 0.65 0.56 6.4 11.1
Kessel 2016 Retrospective 2011–
2014
386 NGT 28 86 99 2 0.84 2
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Introduction: Acute lower gastrointestinal bleeding (ALGIB) occurs in patients
taking anticoagulants either warfarin or non Vitamin K oral anticoagulants
(NOACs). The use of NOACs has been increasing compared with warfarin in
recent years. We investigated patients with ALGIB on anticoagulation therapy
and we analyzed characteristics, management and clinical outcome in patients
treated with NOACs versus warfarin.
Aims & Methods: All patients with ALGIB on anticoagulation therapy treated in
our hospital during a seven year period were evaluated. Characteristics and
clinical outcome were compared between patients on warfarin and patients on
NOACs.
Results: Out of 587 patients with ALGIB, 43 (7.3%) were on NOACs and 68
(11.6%) on warfarin with an age 75.9 9.5 vs 77.1 7.9. The bleeding site was in
the small bowel in 2/43 and 6/68 respectively. Causes of bleeding were not dif-
ferent between two groups except for polyps/neoplasia (8/43 vs 6/68, p¼ 0.003).
Endoscopic hemostasis was more commonly needed in patients on NOACs 17/43
vs 14/68 (p¼ 0.049), while they required less hospitalisation days (6.1 4.2 vs
4.5 3.6, p¼ 0.04). Blood transfusions and need for other interventions (embo-
lization and/or surgery) were not different. Also recurrence of bleeding (4/43 vs
11/68) and mortality (3/43 vs 0/68) were low and not statistically different
between the two groups.
Conclusion: ALGIB in patients on NOACs although presents some differences it
has a similar clinical outcome to patients with ALGIB on warfarin.
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Aims & Methods: We aimed to evaluate the accuracy of the NOBLADS score to
predict severe LGIB and the outcome of patients admitted by LGIB. We per-
formed a retrospective, observational and unicentric study. Including patients
admitted for acute LGIB and submitted to endoscopic evaluation between
January/2015 and March/2016. LGIB was classified as severe if 2 units of
erythrocyte concentrate (UCE) were required and/or if hematocrit drop
420%. Total score ranges from 0–8; when total score is 2, it is considered
high risk for severe LGIB.
Introduction: A new risk score for acute lower gastrointestinal bleeding (LGIB)
has recently been validated, based on 8 admission criteria–nonsteroidal anti-
inflammatory drugs use, absence of diarrhea, absence of abdominal tenderness,
systolic blood pressure 100mmHg, antiplatelet drugs use, albumin level 53 g/
dL, disease score 2 (Charlston comorbidity index) and syncope (NOBLADS).
Results: 173 patients were included (male: 50.3%, mean age: 69 17 years), with
LGIB manifested by hematochezia (91.9%) or melena. Endoscopic evaluation
was performed 1.7 2 days after admission, with the most frequent findings
being diverticular hemorrhage (n¼ 53) and ischemic colitis (n¼ 29); no lesions
were found in 8.3% of cases. Thirty-three patients required intervention (endo-
scopic n¼ 27, radiological n¼ 2, surgical n¼ 4) and 36 (20.8%) repeated endo-
scopic evaluation. 28.9% of patients presented severe LGIB and the NOBLADS
score determined the severity of LGIB with an area under the curve value of
0.92 0.018. Overall, higher score values were associated with a requirement for
transfusion support, intervention and longer hospitalization (p5 0.001 for trend
test). Patients at high risk for severe LGIB (score 2, n¼ 39) presented a sig-
nificantly higher number of transfused UCEs (3.6 vs 0.08, p5 0.001), interven-
tion (38% vs 13%, p5 0.001) and days of hospitalization (12.8 vs 3 days,
p5 0.001).
Conclusion: The NOBLADS score is simple and quick to apply. It predicts with
high accuracy the risk of severe LGIB and allows to identify patients that are
more likely to require transfusional support, intervention and prolonged hospi-
talization. In clinical practice, NOBLADS score may be useful to select on
admission patients who will benefit from hospitalization or from earlier
intervention.
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Introduction: The management of antithrombotic agents during the peri-endo-
scopic period concerns the risks of bleeding and thromboembolism. The Japan
Gastrointestinal Endoscopy Socaiety (JGES) guidelines revised in 2012 empha-
sizes the risk of thromboembolism rather than bleeding. So heparin bridge of
anticoagulants is recommended at high-bleeding-risk procedure such as endo-
scopic mucosal resection (EMR). However heparin bridge in colorectal EMR
raises the bleeding rate to approximately 20%, that is very high-rate incident
compared with the bleeding rate of 0.3–6.1% generally. It is doubtful whether
heparin bridge is appropriate.
Aims & Methods: The aim of this study to clarify the safeness of colorectal EMR
under taking anticoagulants without a heparin bridge in anticoagulated patients.
This is a prospective intervention study in our hospital and other nine multi-
centers (UMIN000021416). The subjects are colorectal polyps resectable by
EMR. Inclusion criteria of patient is good performance status (ECOG) 0–1,
without sever organ failure. Warfarin is continued as usual if PT-INR is less
than 2.6, and direct oral anticoagulants (DOAC) is continued until an evening
of the day before and is discontinued only on the day. Primary endopoint is post-
EMR bleeding required any interventions (major bleeding). Major bleeding is
defined as active bleeding or adherent clot on the resection site by emergent
colonoscopy, or conservative treatment required blood transfusion.
Conservative bleeding with no intervension (minor bleeding), thromboembolism,
and comparison between warfarin and DOAC are clarified as secondary endo-
point. The procedure-related period is defined as up to 30 days after EMR or is
finished for two weeks after hemostasis.
Results: 41 patients (154 lesions) were perfomed EMR from February 2015 to
March 2017. Patients’ characteristics were as follow, the median age was 74 years
(range 61–88) and the average of polyp size was 11.6 (range 5–22) mm in dia-
meter. Anticoagulants were devided into 19 cases of warfarin and 22 cases of
DOAC. The incidence of major bleeding was none in all cases. On the other
hand, minor bleeding which did not require any intervention was recognized at
14.6% (6/41), but there was no case to interrupt anticoagulants. The rate of
minor bleeding is no difference between warfarin and DOAC. There was no
correlation between minor bleeding and PT-INR value in three cases of warfarin.
All three cases of DOAC were medicine once a day. Thromboembolism was not
observed.
Conclusion: In colorectal EMR, we clarify the safeness with continuation of
warfarin and short discontinuation of DOAC on that day, compared with
heparin bridge. We expect to lead to reconsideration of current guideline for
safer treatment.
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Introduction: The current literature is mixed regarding whether first-degree rela-
tives (FDRs) of patients who suffered from colorectal cancer (CRC) at much
earlier age are at substantially increased risk of CRC.
Aims & Methods: The present systematic review and meta-analysis examined the
CRC risk conferred by family history of CRC in FDRs according to their age of
onset. We searched Ovid Medline, EMBASE and grey literature from their
inception to December 2016, and included all screening studies that investigated
the relationship between family history of CRC in FDR and incidence/prevalence
of CRC. Two reviewers independently worked on selection, assessment and data
extraction of eligible articles. A random effects meta-analysis was employed to
pool relative risks (RR) and odds ratios. Subgroup analyses were performed
according to the age of onset of CRC in FDRs of asymptomatic subjects
(540 vs. 40; 550 vs.  50; 560 vs. 60 years). Statistical heterogeneity was
assessed by the I2 statistics. Publication bias was evaluated by an inverted funnel
plot analysis with Begg’s regression model.
Results: Fifty-six case-control and seven cohort studies involving 9.28 million
subjects were included in the analysis. A family history of CRC in FDRs of
asymptomatic subjects conferred a significantly higher risk of CRC
(RR¼ 1.76, 95% CI¼ 1.57–1.97; p5 .001, I2¼ 95.7%). Earlier age of onset of
CRC in FDRs was associated with significantly higher risk of CRC in index
subjects (RR¼ 3.29, 95% C.I. 1.67–6.49 for 540 years vs. RR¼ 1.42, 95%
C.I. 1.24–1.62 for 40 years, p¼ 0.017; RR¼ 2.81, 95% C.I. 1.94–4.07 for
550 years vs. RR¼ 1.47, 95% C.I. 1.28–1.69 for 50 years, p¼ 0.001). The
Begg’s regression test did not identify any publication bias (Kendall’s
tau¼ 0.122, p¼ 0.159).
Conclusion: A family history of CRC in FDRs whose age of onset is earlier than
40 or 50 years conferred a significantly higher risk of CRC to asymptomatic
individuals, implying that age of onset could potentially enhance the discrimina-
tory capability of CRC prediction scores.
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Introduction: Few studies compared the risk of colorectal cancer (CRC) among
individuals with probands who were parents, siblings, and those with two or
more probands.
Aims & Methods: This systematic review and meta-analysis tested the hypothesis
that the risk of CRC conferred by family history of CRC in parents vs. siblings
vs. 2 first-degree relatives (FDRs) was similar. The Ovid Medline, EMBASE
and grey literature were searched from their inception to December 2016, and all
screening studies that examined the association between detection of CRC and
family history of CRC in FDR were included. Two reviewers independently
searched, assessed and extracted data from eligible studies. The relative risks
(RR) and odds ratios were pooled based on a random effects meta-analysis.
We conducted subgroup analyses according to the identity of FDRs affected
(parents vs. siblings vs. 2 FDRs), and examined statistical heterogeneity by
the I2 statistics. Potential publication bias was explored by funnel plot analysis
with Begg’s regression test.
Results: We identified 56 case-control and 7 cohort studies, consisting of 9.28
million subjects who were finally included in the meta-analysis. Asymptomatic
individuals with siblings affected (RR¼ 2.44, 95% CI¼ 1.90–3.13); parents
affected (RR¼ 2.18, 95% CI¼ 1.95–2.45) and 2 FDRs affected (RR¼ 2.68,
95% CI¼ 1.92–3.74) had statistically similar risk of CRC. We did not identify
any publication bias based on the Begg’s regression test (p¼ 0.159).
Conclusion: The risk of CRC was similar among subjects whose siblings; parents
or 2 FDRs were affected by CRC. Information on the identity of the FDRs
affected does not seem to be necessary when the risk of CRC in asymptomatic
individuals is predicted.
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Introduction:Gilbert’s syndrome is considered to be entirely benign. Some studies
have shown a reduced risk for cardiovascular disease (CVD). There is conflicting
data regarding cancer risk among these patients
Aims & Methods: We aimed to evaluate the association of Gilbert syndrome with
CVD and cancer. Clinical and epidemiological data was obtained from consecu-
tive healthy subjects undergoing annual screening at the Integrated Cancer
Prevention Center in Tel Aviv. The annual check-up includes: thorough exam-
ination by specialists in internal medicine, surgery, dermatology/plastic surgery,
OBGYN, urology, oncology, oral surgery, gastroenterology. Blood work (smac
24, blood count, TSH, CRP, PSA), vaginal US, PSA and mammography
(440yrs), LDCT in heavy smokers and all needed imaging when clinically indi-
cated. Peripheral blood DNA was extracted from all subjects. Gilbert syndrome
was determined by clinical criteria (normal liver function tests but to mild eleva-
tion in unconjugated bilirubin 53mg/dl without any hemolysis. In the majority
of the cases the diagnosis was confirmed genetically by the homozygous mutation
(TA)7TAA in the promoter region of UGT1A1 enzyme. Prevalence of CVD and
cancer were compared between subjects with/without Gilbert syndrome.
Mortality data was obtained from the Israeli ministry of health and cancer
incidence from the Israeli registry.
Results: A total of 6258 (49%) men and 6461 (51%) women, mean age
47.0 11.5 years, were included of which 1.019 had clinical gilbert. Gilbert was
significantly more common among men (11.5% versus 4.6% P5 0.001). The rate
of gilbert disease was equal in Sephardic and Ashkenazi Jews. Malignancy and
CVD were diagnosed in 678 (5.3%) and 1.837 (14.4%) subjects respectively. The
prevalence of any CVD was significantly higher in the Gilbert group (OR 1.23
95% CI 1.04–1.46 p¼ 0.017), as well as hypertension (OR 1.37 95% CI 1.12–1.68
p¼ 0.003) and CVA (1.1% versus 0.6% p¼ 0.06). Higher rate of kidney and
bladder cancers (OR 2.64, 1.22–5.70, p¼ 0.019) was also observed in the gilbert
group. In contrast, the prevalence of breast cancer was much lower among
patients with Gilberts (OR 0.36, 0.13–0.97, P¼ 0.034).
Conclusion: In Israel Gilbert syndrome is not that innocent. In a large cohort it
seems to be associated with increased risk of
hypertension, CVD and CVA. Bladder cancer is higher but females are protected
from breast cancer. Further studies
are mandated in order to better understand these findings and determine proper
screening and surveillance practices
in Gilbert disease.
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Introduction: Interval colorectal cancer is largely related to a poor endoscopic
performance (missed lesions, incomplete polyp resection) or different biology in
the development of the polyp (accelerated growth). Thus, quality endoscopic
measures and Lynch syndrome were highly investigated for their association
with interval cancer. However, most reports came from the Western world and
not the Middle East, and differences in ethnicity or environmental factors might
potentially have impact on the biology of tumor progression. In addition,
patient-related factors were less investigated for their association with interval
cancer. The aim of this study was thus to assess tumor and patient characteristics
and predictors of interval cancer in a population from Israel.
Aims & Methods: This retrospective cohort study included all patients that were
diagnosed with colon cancer in our institution between 2005–2014. Cases
included patients with a previous colonoscopy within 1–10 years before the diag-
nosis of cancer, with either negative findings or benign polyps. Only full colo-
noscopies with at fair or good preparation were included. Interval cancer was
defined on an individual basis, when cancer occurred within the recommended
surveillance interval according to accepted guidelines. Cases were further strati-
fied according to time since index colonoscopy (53 years, 3–10 years). "Positive"
controls were cancer patients without previous colonoscopy, and "negative" con-
trols were sex- and age-matched patients with two negative colonoscopies within
the study period who were randomly selected on a 5:1 ratio. Tumor character-
istics (location, staging) and patient-related features (age, gender, positive family
history of colon cancer, aspirin use, diabetes, diverticulosis) were compared
between cases and control groups.
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Results: 845 patients were diagnosed with a colon cancer within the study period,
and 83 cases (9.8%) were found to have interval cancer. Among them, 51 patients
(61.5%) had negative findings at index colonoscopy, while 22 (38.5%) had either
non-advanced adenomas (12%) or advanced adenoma (26.5%). Compared to
"positive" controls with primary cancer (575 patients with full data), patients
with interval cancer were older (84% above 60y vs. 65%, p- 0.03) and had
proximal (cecal to splenic flexure) tumor location (57% vs. 34%, p- 0.0001),
but gender (47% vs. 53% males) and tumor staging (78% vs. 70% in stage 0–
2, p- 0.12) were not different. Compared to "negative" healthy controls (255
patients), cases with interval cancer and negative findings at index colonoscopy
(51 patients) had higher prevalence of diabetes (33% vs. 15%, p- 0.002) but the
same rate of family history, aspirin use and diverticulosis. There were no signifi-
cant differences in all these characteristics between patients with interval cancer
53years and 3–10 years.
Conclusion: Patients with interval cancer tend to be older and have proximal
tumor location than patients with primary colon cancer, and have higher pre-
valence of diabetes. A close surveillance or the use of better endoscopic techni-
ques (e.g. use of NBI, longer retrieval time) should be considered for patients
with these characteristics.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Fecal Immunochemical Testing (FIT) is currently used in most
Canadian provinces to screen for colorectal cancer. Newfoundland and
Labrador has implemented a provincial population based colon cancer screening
program over the past five years. Newfoundland and Labrador selects patients
for colonoscopy if one of two FIT values 100 ng/mL.
Aims & Methods: The goal of this study is to assess the effectiveness of different
FIT cut-offs and number of FIT tests for detecting adenomas and colorectal
cancer.
Results: Data for this study were obtained in a prospective fashion using the
Newfoundland and Labrador Colon Cancer Screening Program. 21,371 patients
enrolled in the study were between the ages of 50–74 and at average risk for colon
cancer between July 1, 2012 and June 30, 2016. 16,152 participants returned their
FIT tests. 1831 were positive on at least one FIT kit and underwent colonoscopy.
The positive FIT values ranged from 100.0 to 54,017. The mean FIT was 942.3
(25th percentile: 145, 50th percentile: 260, 75th percentile: 576). Of the 1831
participants who had a colonoscopy 73 (4.0%) were found to have colorectal
cancer and 1092 (59.6%) were found to have an adenoma. By using only one FIT
test at a cut off of 100, our program would have missed 8.2% of cancers. An
additional 541 colonoscopies were required to detect these cancers. If we strati-
fied patients according to number of FIT tests we found that 83.5% of colon
cancers detected were positive on both FIT kits at a quantitiative cut off of 100. If
a FIT cut off of 200 was used and applied to our patients our program would
have missed 9.6% of cancers based on one of two tests being positive, 24.7% of
cancers is only one FIT kit were supplied to patients and 38.4% of cancers based
on both FIT kits being positive. An additional 1133 colonoscopies were required
to detect the additional cancers by using two FIT kits as opposed to one. There
was a substantial decline in detection of cancer, advanced adenoma and simple
adenoma as FIT cut off was increased and with a reduction in FIT kits complted
from two to one. The positive predictive value for cancer increased as the quan-
titative FIT cutoff was increased but this came at the expense of case detected.
Conclusion: Two FIT tests are more effective than one at screening. Patients with
two FIT positive results are more likely to have: colon cancer, an advanced
adenoma and a simple adenoma. Further triaging of colonoscopy wait lists
could be considered based on quantitative FIT values and number of positive
tests. Provinces and health authorities need to be cautious when determining the
number of FIT kits a participant should complete as well as setting the quanti-
tative cut off. Increasing the FIT cut-off results in a higher probability of colon
cancer or adenoma but there are overall less cancers detected.
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Introduction: Screening of colorectal cancer is focused on the population with
average risk of this disease. Individuals with metabolic syndrome represent a
population with a higher risk of developing colorectal cancer, but they are not
included in colorectal cancer screening standards.
Aims & Methods: To identify the metabolic risk factors associated with colorectal
neoplasia (advanced adenomas and cancers) and evaluated their impact in color-
ectal cancer screening. Prospective, multicenter study was performed from
January 2013 to December 2015 at eight high-quality colonoscopy centers.
Demographic characteristics, anthropometric measurements, metabolic risk fac-
tors, and colonoscopic pathologic findings were assessed in patients with meta-
bolic syndrome (target group) who underwent preventive colonoscopy (FIT
positive or screening colonoscopy). This data was compared with consecutive
patients without metabolic syndrome (control group). All patients meet the
screening population criteria (asymptomatic, without family or personal history
of colorectal neoplasia).
Results: 1500 individuals were enrolled; 726 persons (494 men, 68%) in the target
group (metabolic syndrome) and 774 persons (353 men, 46%) in the control
group (without metabolic syndrome). The significantly higher prevalence of
advanced adenomas was observed in the target group (18%; 95% CI 15–21%)
comparing to the control group (9%; 95% CI 7–11%); OR 1.8; p¼ 0.002.
Similarly, the prevalence of all adenomas was higher in the target group (48%;
95% CI 44–51%) than in the control group (35%, 95% CI 32–38%); however,
the difference was not statistically significant (p¼ 0.179). Individuals with iso-
lated high cardiovascular risk (SCORE 10%) had higher prevalence of both,
non-advanced adenomas (51%, 95% CI 46–56%; p¼ 0.327) and advanced ade-
nomas (22%, 95% CI 18–26%; p¼ 0.049) comparing to the individuals with
isolated DM2. Advanced adenomas were more likely in patients aged 65–75
years.
Conclusion: Colorectal neoplasia is positively associated with metabolic syn-
drome. Cardiovascular risk factors (SCORE 10%) is a stronger risk factor
than the presence of diabetes mellitus type 2. Individuals with SCORE 10%
should be considered as a risk group of colorectal carcinomas, and therefore
colonoscopy as the primary screening method is appropriate. This project has
been supported by the Czech Ministry of Health grant NT 13673 and MO 1012.
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Introduction: Serrated polyps (SPs) have been recognized as precursors of color-
ectal cancer (CRC), accounting for up to 30% of CRCs via the serrated neoplasia
pathway. SPs are classified into hyperplastic polyps (HPs), sessile serrated polyps
(SSPs) with or without dysplasia and traditional serrated adenomas (TSAs).1 The
serrated polyposis syndrome (SPS) is characterised by multiple SPs throughout
the colon.1 It is associated with an increased risk of developing CRC.2 Published
data on prevalence of SPS ranged from 0.03 in the UK to 0.8 in Spain.3
Aims & Methods: The aim of the study was to determine the prevalence of SPS in
average-risk individuals participating in the German CRC screening programme.
We retrospectively analyzed screening colonoscopies performed by 11 gastroen-
terologists in 4 medical practices and 1 tertiary academic hospital between 01/01/
2011 and 14/12/2016. Individuals 550 years, with an increased risk for CRC (i.e.
inflammatory bowel disease, history of CRC, cancer syndromes), and with pre-
vious or incomplete colonoscopy (i.e. procedures not reaching the cecum) were
excluded. SPS diagnostic criteria according to the WHO definition from 2010
were: I) 5 SPs proximal to the sigmoid colon, of which two are 10mm, II) any
number of SPs proximal to the sigmoid colon in an individual who has a first-
degree relative with SPS, or III) 20 SPs of any size distributed through-out the
colon.1
Results: A total of 3089 individuals were analyzed. 47.5% were male, median age
was 62 years (interquartile range 56, 70). Overall adenoma detection rate was
33.9%. Detection rates for SPs, HPs, SSAs and TSAs were 21%, 18%, 4%, and
0.2%. Of all individuals with detected SPs none fullfilled the diagnostic criteria
for SPS. Hence, we determined a prevalence of SPS of 0% in our cohort.
Conclusion: In our study, the prevalence of SPS in average-risk individuals under-
going screening colonoscopy was 0%. Because overall ADR was above the
recommended values for screening colonoscopies, we conclude that this low
prevalence might be attributed to a lack of awareness for SPS rather than to
low-quality procedures. However, we were not able to obtain information about
first-degree relatives with SPS from medical records of individuals with SPs to
check the second diagnostic criterium for SPS. We also included only one colo-
noscopy per individual. It has been shown that prevalence increases when follow-
up colonoscopies are included as well.3 Both facts might have caused an under-
estimation of the true prevalence of SPS in our cohort.
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Introduction: Early onset gastroenterological cancers lacking a positive family
history are an increasingly worrisome entity. On one hand, early onset is the
cornerstone of genetically determined oncological problems, but on the other
negative family history does not support the suspect of familial syndromes.
Aims & Methods: We addressed the contribution of germline mutations to non
familial early onset cancers. Patients with pancreatic, gastric, esophageal, duo-
denal and colorectal cancers were enrolled from 2015 to 2017 at the
Gastrointestinal Personalized Medicine unit. Eligibility criteria were the juvenile
onset and the negativity for clinical criteria of hereditary cancer syndromes. Early
onset colorectal cancer was defined as 545 yrs. For the other cancers, the thresh-
old was defined at 50. Eligible patients provided informed consent. Genes were
sequenced by means of a validated Next Generation Sequencing panel of onco-
logical susceptibility genes and confirmed by means of Sanger sequencing.
Results: Among 12 colorectal cancer patients (7F, 5M), NGS analysis showed: 2
mutations of MSH2 and MSH6 occurring de novo, given the absence of family
history; 3 variants of unknown significance (VUS) (2 MSH2 and 1 MLH1); and 7
were negative. Age-stratification revealed that, among those 35 years (n¼ 4), 1
had MSH2 gene mutation and 3 were negative. In the 36–40 age group (n¼ 3), 1
had a VUS in MLH1 and 2 were negative. In the age group 41–45 (n¼ 5), 1
MSH6 mutation and 2 VUS were found, alongside 2 negative results.
Among the colorectal cancers, 17% of patients had a de novo mutation of Lynch
Syndrome, 25% had a VUS, and 58% were negative.
2 gastric diffuse cancer underwent NGS analysis (40 and 45 yrs, 1M and 1F),
both negative.
Among 2 pancreatic cancer patients (550 yrs, 2 F), one tested negative and the
other had a VUS on PMS2.
NGS analysis performed on 1 esophageal cancer (46 yrs, M) was negative.
1 duodenal cancer (46 yrs, F) has a MSH2 mutation and 2 VUS (MSH6 and
PMS2).
Conclusion: A significant percentage (17%) of early onset colorectal cancers
resulted in Lynch Syndrome even when family history is not suggestive of her-
editary cancer. We reliably infer the determinant role of genetics, even when the
family history does not support the hypothesis. Elsewhere, our results suggest
that the already known susceptibility genes seldom contribute to sporadic early
onset cancers. Other genes and mechanisms may explain the early onset pheno-
type. Our data show that NGS is often non conclusive in early onset GI cancers,
and further development is needed to better classify VUS (25%).
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Introduction: Increasing evidence links the immune microenvironment, micro-
biota and colorectal cancer (CRC). Colibactin-producing-E.coli are more fre-
quently detected on mucosa CRC patients and exhibit procarcinogenic
properties on CRC murine models. Aim of this work was to evaluate the
impact of chronical infection by colibactin-producing E. coli on immune cells
in APCmin/þ mice models.
Aims & Methods: Min mice were per os inoculated with a CRC-colibactin-pro-
ducing E. coli strain (11G5), non pathogenic E. coli (K-12 MG1655) or PBS.
Using optical in vivo imaging (IVIS spectrum), we evaluated oxidative stress
induction with a bioluminescent inflammation probe in Min mice chronically
infected. After 7 weeks, number and volume of polyps were evaluated and colo-
nic samples were histogically analysed. Detection of immune cells was quantified
by immunofluorescent labelling using a specific and innovative algorithm created
with Tissue Studio software. Then, the density and localization of immune cells
were performed in the three colon regions of interest: lymphoid follicle, mucosa
and tumor.
Results: Using optical imaging, we detected a significant increase of luminescent
signal in the gut of the infected group suggesting an increase of oxidative stress
and inflammation. Histological analyses showed no difference about intra-
tumoral immune infiltrate density on 11G5 and K12-infected mice. However,
using our specific algorithm, we observed a significant increase of lymphoid
follicle size in the gut of mice infected with the 11G5 strain compared to mice
feeding with non-pathogenic K12 strain. Interestingly, follicle size was positively
correlated with tumor volume, on the 11G5 infected group suggesting an asso-
ciation between pro-carcinogenic proprieties of this strain and gut immune
response. In addition, we observed an increase of neutrophils (Ly6Gþ cells) on
mucosa and lymphoid follicle of mice infected with 11G5 compared to K12 and
non-infected mice. These results can be linked with our in vivo optical imaging
observations and our results about the increase of neutrophils chemo-attractants
CXCL1 and CCL20 measured by qRT-PCR after infection. Analyses of T cells,
macrophages, B cells and myeloid suppressive cells are in progress.
Conclusion: Here we can observe an increase of lymphoid follicle associated with
tumor volume after colibactin-producing E. coli infection. Our first results sug-
gest that neutrophils can be one of the immune cells implicated in this process.
This work shows a link between immune microenvironment, pathogenic E. coli
and tumor development.
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Introduction: CD24 is a glycosylphosphatidylinositol-linked protein that func-
tions as an adhesion molecule and is overexpressed at an early stage of CRC
(Sagiv et al., 2006). The Wnt/b-catenin signaling pathway plays an important role
in the CRC carcinogenesis process. C57BL6/J mice carrying the ApcMin muta-
tion develop 24.3 3.7 adenomas and several carcinomas in the small intestine
by the age of 16 weeks compared to the 7 1.7 polyps that ApcMin/CD24 -/-
("double KO") mice developed. Mice colonoscopy showed a significant reduction
in the number and size of polyps upon depletion of CD24 alleles. The ApcMin
mice displayed severe splenomegaly (355 68 mg) compared (141 49mg) in
double KO mice similar to WT mice. Hb level in the ApcMin was 3.8 2.5,
significantly lower than in the double KO mice (8.2 0.9) and their WT
littermate.
Aims & Methods: We aimed to study the cellular interactions between CD24 and
b-catenin, and effects of their interaction on intestinal tumorigenesis. CD24-
inducible 293T-Rex cells previously developed in our lab (Shapira et al., 2011)
and SW480 CRC cells stably transfected with CD24 (Naumov et al., 2014) were
used to study this interaction in vitro. Coimmunoprecipitation and immunofluor-
escent staining were used to investigate the interaction between the two
proteins. Far western blotting (WB) analysis was used to confirm this direct
interaction by probing the standard WB membrane with the purified CD24
protein.
Results: In vitro: Western blotting analyses showed that expression of CD24 in
293T-Rex cells induced the activation of b-catenin, while down-regulation of
CD24 in SW480 cells caused a decrease in the level of active b-catenin.
Cytoplasmic/nuclear fractionation showed that more active b-catenin entered
the nucleus in cells that expressed CD24 (clone1) as compared to control cells
(clone 4). In addition, in both cell lines, TOP/FOP luciferase reporter assay
showed a significant increase in Luciferase activity upon CD24 expression induc-
tion. Co-immunoprecipitation studies of CD24 and b-catenin indicated that these
two proteins might be interacting. In addition, In HEK-293T cells and SW480
cells, immunofluorescent staining of CD24 and b-catenin showed that these two
proteins co-localize on the cellular membrane. Furthermore, far western blotting
analysis suggests that a direct interaction between the proteins exist.
Conclusion: 1. CD24 plays a major role in intestinal tumorigenesis. 2. CD24
interacts with the Wnt pathway by
activating b-catenin. 3. CD24 interacts directly with b-catenin 4. Down-regula-
tion of CD24 may be an important aim in
the therapy of CRC.
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Introduction: Cancer stem cells survive as the leading reason to tumor recurrence
after tumor repressive treatments. Therefore, it is worth discovering specific and
efficient inhibitors against cancer stemness for applications in reducing tumor
recurrence. Previously, literature has indicated that YM155 can significantly
reduce the stemness-derived tumorsphere formation of gastric cancer and sup-
press EGFR activity. However, the pharmaceutical mechanism of YM155 is not
completely clear.
Aims & Methods: The aim of this study attempted to investigate the potential
mechanism of YM155 against cancer stemness in EGFR-positive cancers. The
tumorspheres derived from EGFR-mutant HCC827 and EGFR-wild-type
HCT116 and A549 cells expressing higher cancer stemness markers, CD133,
were used as cancer stemness models.
Results:We found that higher EGFR autophosphorylation (Y1068) in HCC827-,
A549-, and HCC116- derived tumorspheres compared to the parental cells, which
induced tumorsphere formation through activating G9a-mediated stemness
property. YM155 was demonstrated to inhibit the tumorsphere formation by
unexpectedly blocking the autophosphorylation of EGFR and EGFR/G9a-
mediated stemness pathway. The chemical and genetic inhibitions of EGFR
and G9a revealed the significant role of EGFR-G9a pathway in maintaining
the cancer stemness property.
Conclusion: In conclusion, this study not only revealed that EGFR triggered the
formation of tumorspheres through elevating the G9a-mediated stemness, but
also demonstrated that YM155 inhibited the formation of tumorspheres by
simultaneously blocking autophosphorylation of EGFR and activity of G9a as
a potent anti-stemness agent against EGFR-positive cancers.
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Introduction: Several studies have demonstrated that the colorectal cancer (CRC)
microenvironment harbors an increased neurite density as compared to healthy
areas. Moreover recent findings indicate that specific stimuli activate neurogen-
esis in the enteric nervous system (ENS), in adult mice. However whether tumor
epithelial cells (TEC) induce neuritogenesis and/or neurogenesis in the ENS
during CRC remains unknown.
Aims & Methods: Human colon specimens from patients with CRC and from
AOM/DSS treated mice were whole-mount dissected in order to isolate the
myenteric and submucosal plexus from healthy area and tumor margin. The
number of enteric neurons per ganglia was compared between healthy area
and tumor margin after anti-Hu immunostaining in both plexus. Human CRC
supernatants, TEC (Caco-2 cells)-conditioned medium or NGF were added to
primary culture of rat enteric nervous system and primary culture of rat enteric
neurons. In fixed primary cultures, the number of enteric neurons per ganglia and
the length of neurites were calculated after anti-Hu and anti-tubulin-III immu-
nostaining respectively. In order to determine the role of NGF in CRC super-
natants and TEC-conditioned medium effects, anti-NGF blocking antibodies
were added to primary cultures.
Results: Immunofluorescence studies on whole-mount dissected ENS plexus
demonstrate that the densities of neuronal bodies were significantly increased
in the margins of both human CRC and murine AOM/DSS-induced dysplasia
compared to healthy areas (n¼ 7 and n¼ 5 respectively; p5 0.05). The increase
in neuronal density was similar in low-grade and high-grade dysplasia as well as
carcinoma (n¼ 5). In vitro human CRC supernatants and TEC-conditioned
medium enhanced the densities of neurites and neuronal cell bodies in primary
cultures of ENS (pcENS) as compared to healthy mucosa supernatants and
control medium, respectively (n¼ 6; p5 0.05). Finally, nerve growth factor
(NGF) induced an increase in the density of neuronal bodies in pcENS (n¼ 4;
p5 0.05), and our preliminary data show that the addition of an anti-NGF
blocking antibody to human CRC supernatant and TEC-conditioned medium
inhibits their impact on neurogenesis and neuritogenesis (n¼ 6; p5 0.05).
Conclusion: Altogether these results indicate that the increased neuronal density
in CRC margin may result from the activation of neurogenesis in the ENS
induced by TEC via a NGF-dependent pathway.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1754 FGF14 IS A FUNCTIONAL TUMOR SUPPRESSOR
THROUGH INHIBTING AMPK/MTOR PATHWAY IN COLORECTAL
CANCER
L. Xu
1, N. Zhang2, L. Huang1, X. Li3, S. Peng1, Z. Zeng1, M. Chen1
1Department Of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen
University, Guangzhou/China
2Sun Yat-sen University, Guangzhou/China
3State Key Laboratory Of Oncology In South China, Sun Yat-sen University
Cancer Center, Guangzhou/China
Contact E-mail Address: lixiaxu320@163.com
Introduction: Promoter hypermethylation-induced epigenetic silencing of tumor
related genes played a key role in the initiation and development of colorectal
cancer (CRC). Using Methylated DNA Immunoprecipitation (MeDIP), we iden-
tified that Fibroblast Growth Factor 14 (FGF14) was preferentially methylated
in CRC.
Aims & Methods: We aimed to investigate the epigenetic regulation and biologi-
cal function of FGF14 in CRC.The expression of FGF14 in 10 CRC cell lines
and 24 pairs of CRC tissues and paired adjacent normal tissues by real-time
PCR. CRC cells were treated with DNA demethylating agent 5-aza-2’-deoxycy-
tidine (5-Aza). The methylation status of FGF14 in CRC cell lines and CRC were
determined by real-time MSP. The biological function of FGF14 in CRC was
interrogated by cell viability assay, colony formation, immunofluorescence and
flow cytometry, as well as in vivo study.
Results: FGF14 was downregulated or silence in all (10/10) CRC cell lines, while
it was readily expressed in normal colonic tissues. The expression of FGF14 was
significantly lower in primary CRCs as compared to their adjacent normal tissues
(P5 0.01). The loss of FGF14 gene expression was restored by treatment with
DNA demethylating agent 5-Aza. Re-expression of FGF14 in CRC cell lines
inhibited colony formation, suppressed cell viability, and induced cell apoptosis
via AMPK/mTOR pathway, accompanied with enhanced protein expression of
cleaved caspase-3, cleaved caspase-7, cleaved caspase-9 and PARP. In xenograft
mouse model, overexpression of FGF14 significantly reduced tumor growth
(P5 0.001).
Conclusion: FGF14, which induces cell apoptosis via AMPK/mTOR pathway, is
a novel tumor suppressor down-regulated by epigenetic inactivation.
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Introduction: A cancer with a number of somatic mutations is defined as ‘‘hyper-
mutator’’, and shows therapeutic features, such as high sensitivity to immune
checkpoint inhibitor. However, to date, analyses of hypermutator have not been
done with a large number of cases.
Aims & Methods: The aim of this study is to analyze the incidences and char-
acteristics of hypermutator in digestive system cancers. We analyzed somatic
mutation of digestive system cancers in 1145 cases (age: 67.4 11.3 yrs.,
M:F¼ 755: 390), those underwent surgery after full informed consent during
2014 to 2015. Genomewide sequencing was performed on 47 inherited cancer-
associated genes and 411 cancer-associated genes using next generation sequencer
(Ion Torrent Proton sequencer and Ion AmpliSeq Exome RDY kit, Thermo
Fisher Scientific). Hypermutator was defined when a tumor having 4500 muta-
tions in the somatic DNA.
Results: The 1145 subjects included 583 colorectal cancers (CRC), 229 gastric
cancers (GC), 103 metastatic liver tumors, 100 hepatocellular carcinomas (HCC),
45 pancreatic cancer, 23 GISTs, 15 esophageal cancers and 14 neuroendocrine
tumors, etc. Hypermutator was recognized in 66 cases (5.8%). Age and gender
were not different by the hypermutation. Hypermutator was recognized in 6.2%
(36 cases) of CRCs, 11.8% (27 cases) of gastric cancers, 2% (2 cases) of HCCs,
and one case of small intestinal cancer. Within the hypermutator group, multiple
cancers developed in 13.9% of CRC patients and 25.9% of GC patients.
Mutation of BRAF was detected in 33.3% (22 cases), that of mismatch repair
genes (either of MLH1, MSH2, MSH6, PMS2) in 13.6%, POLE in 9.1%, and
POLD1 in 4.5%, respectively, in the hypermutator group.
Conclusion: Hypermutator was recognized in 5–10% of digestive system cancers,
predominantly seen in CRCs and GCs. Cases of hypermutator sometimes devel-
ops multiple cancers, associated with a somatic mutation of mismatch repair
genes. Further research must be needed to clarify the characteristic of hypermu-
tator of the digestive organs in the therapeutic aspects.
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Introduction: In the intestinal epithelium, stem cells are located at the bottom of
the crypt and their maintenance and differentiation is essential for sufficient
organ function. Accumulation of mis- or unfolded proteins in the endoplasmic
reticulum, so-called ER-stress, leads to an unfolded protein response (UPR)
which can force an intestinal epithelial stem cell (iESC) into differentiation.
However, the molecular mechanism of this differentiation process upon ER
stress is largely unknown. A prominent feature of the UPR is translation inhibi-
tion via PERK-eIF2a phosphorylation and we have previously shown that the
differentiation upon ER-stress is dependent on PERK-eIF2a phosphorylation1.
Therefore we hypothesize that ER stress influences stem cell differentiation on a
translational level by downregulating key transcription factors (TFs) that serve
an important role in maintaining stem cell fate.
Aims & Methods: Our aim is to identify transcription factors important for stem
cell maintenance using a transcriptomics approach. On thapsigargin treated
LS174T-cells, a cell line with a transcriptional profile resembling intestinal
stem cells, we performed a TF DNA-binding assay (catTFRE) in which TFs
present in cellular lysate are bound to plasmid DNA, co-extracted and quantified
using mass-spectrometry2. We confirmed downregulation using immunoblots in
colorectal cancer cell lines. Additionally, we examined CtBP2 expression in
mouse intestine using in situ hybridization, epithelial FACS sorting and immu-
nohistochemistry. To study CtBP2 function, we transfected a LS174T cell line
with shRNA CtBP2 and analyzed stemcell and differentiation markers.
Results: By using the CatTFRE assay we quantified the binding activity for
41000 transcription factors. Forty-three TFs showed significant downregulated
binding to template DNA upon thapsigargin treatment compared to control. We
confirmed downregulation of eight of these TFs on protein level, suggesting a
loss of binding due to translation inhibition upon ER stress. We identified tran-
scriptional corepressor CtBP2 as the most significantly downregulated protein.
Interestingly, in mouse small intestine, CtBP2 is expressed in the proliferative
compartment where stem cells reside. Additionally, mRNA expression analysis
showed abundance of CtBP2 in iESCs. We next investigated the effect of CtBP2
knockdown on stemness in the LS174T cell line. Three days upon shCtBP2
transfection we showed a significant decrease in mRNA levels of stem cell mar-
kers Lgr5 and Olfm4 compared to control and an increase in differentiation
markers Villin and P21, suggesting induced iESC differentiation.
Conclusion: Using an unbiased transcriptomics approach we identified transcrip-
tion factors that are lost on protein level upon ER stress. Furthermore, our data
suggests that the significant loss of the transcriptional regulator CtBP2 contri-
butes to intestinal epithelial stem cell differentiation.
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Introduction: Location and somatic gene signature of CRCs may impact prog-
nosis and therapy response. A relative specific CRC-related dysbiosis has been
characterized.
Aims & Methods: The aim was to characterize colon microbiota in CRC patients
regarding location, gene markers and outcome. Patients (N¼ 173) signed consent
for whole metagenome (shot gun sequencing on Illumina HiSeq2500) analysis of
stool DNA: 72 CRC (53 sporadic-S, 19 Lynch-L), 87 asymptomatic subjects
(normal colonoscopy), 14 first degree healthy relatives from Lynch families.
"MOCAT" pipeline was used, library sorted (Phred quality score 20
Alientrimmer v0.4.0) after exclusion of535 nt, human genes or phage sequences.
Quality sequences were aligned (REFMG.V13) and most abundant genes con-
structed (MBMA program v0.1). The Shaman program (shaman.c3bi.pasteur.fr)
was used. The number of bacteria was estimated (REFMG program). The linear
model (GLM) was implemented in the DESeq2 R kit. Differences between
Control (N¼ 87) and CRCs (N¼ 69), between L (N¼ 19) and S
CRCs(N¼ 50), and between LCRC (N¼ 19) and Healthy Lynch relatives were
obtained after interaction of age, BMI and gender was considered (GLM model).
The P5 0.1 value was retained after correction (Benjamini and Hochberg). The
specific taxonomic composition of the control and CRC groups was subjected to
random analysis (Caret’s R package) with two optimization parameters (preci-
sion and kappa) in the model.
Results: There was no difference for gender, age (p¼ 0.08) and BMI (p¼ 0.187)
in the L and S CRCs. Significant differences were observed between Normal and
CRCs, C-CRC and L-CRC, L-CRC and first degree relatives based on the
common component (similarity of sequences): 13 species differentiated Normal
and CCRs, two were more prevalent in L-CRCs. The panels of bacteria linked
with location, MSI, Ras mutations, methylation phenotypes and survival were
identified. No significant link was observed with TNM Staging: I (N¼ 17, 2L and
15S), II (N¼ 12, 5L and 7S), III (N¼ 20, 10L, 10S), IV (N¼ 22.1L, 21S). DFS
might be dysbiosis dependent.
Conclusion: CRC dysbiosis is location-dependent. Several bacteria are associated
with Ras mutation, MSI, and methylation status. They may directly or through
therapies impact the prognosis. Microbiota signature should be taken in consid-
eration in trials.
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Introduction: Colorectal serrated lesions (SLs) include hyperplastic polyp (HP),
traditional serrated adenoma (TSA) and sessile serrated adenoma/polyp (SSA/P).
SSA/Ps are well-known precursors of colorectal cancer (CRC) characterized by
BRAF mutation and microsatellite instability (MSI), whereas the molecular
characteristics of TSAs are not fully understood.
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Aims & Methods: We aimed to identify epigenetic alterations associated with the
development of TSAs and to clarify the associations between clinical, patholo-
gical and molecular characteristics in colorectal lesions. The genome-wide DNA
methylation status in TSAs consisting of protruding and flat components was
analyzed using an Infinium HumanMethylation450 BeadChip, and changes in
DNA methylation during the development of TSAs were identified. Methylation
of identified genes and CIMP markers (MINT1, -2, -12, -31, p16 and MLH1) and
BRAF/KRAS mutations were analyzed in 847 colorectal lesions and 61 samples
of normal colonic tissue. Effects of ectopic expression on CRC cell growth in a
prevalently methylated gene in TSAs were assessed in vitro and in vivo.
Results: BeadChip analysis revealed 11 genes in which methylation levels were
progressively increased during development of TSAs. Among them, SMOC1 was
prevalently methylated in TSAs, but was rarely methylated in SSA/Ps
(p5 0.001). RT-PCR revealed that SMOC1 is abundantly expressed in normal
colon and SSA/Ps, but is significantly downregulated in TSAs.
Immunohistochemical analysis showed that SMOC1 was expressed in the epithe-
lium of normal colonic tissues and SSA/Ps, but that expression is significantly
reduced in TSAs. Ectopic expression of SMOC1 suppressed proliferation, colony
formation and in vivo tumor formation by CRC cells. Analysis of colorectal
lesions revealed that SMOC1 is frequently methylated in TSAs and CRCs, and
that SMOC1 methylation is strongly associated with KRAS mutation and
CIMP-low.
Conclusion: Methylation of SMOC1 is associated with TSA development but is
rarely observed in SSA/Ps. Immunohistochemical analysis of SMOC1 may be a
useful marker to discriminate between SSA/Ps and TSAs. Our data suggests
SMOC1 methylation may play a role in the neoplastic pathways arising in TSAs.
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Introduction: The number of individuals partaking in colorectal cancer (CRC)
screening still remains to be low even after the implementation of the Korean
Government’s National Cancer Screening Program for CRC. The aim of this
study is to identify factors associated with partaking in CRC.
Aims & Methods: The Korean National Health and Nutrition Examination
Survey (KNHANES) 2007 2010 datasets were used to develop a CRC screen-
ing participation screening score. 10,527 individuals aged 50 who completed the
survey and not previously diagnosed with CRC were selected. Both logistic
regression (LR) analysis and artificial neural network (ANN) were used to
develop predictive models. Multilayer perception ANN was constructed based
on 16 clinical variables. We then validated the models using the KNHANES 2011
and 2012 (n¼ 5986) datasets and compared them with each other.
Results: Out of 10,527 individuals selected, 57.0% (n¼ 6005) responded
unscreened for CRC. Among various demographic and socioeconomic factors,
following 8 parameters including, age, household income, marital status, educa-
tion level, private health insurance, self-reported depression, self-reported health
status, and residence were found to be independently associated with CRC
screening participation. LR analysis produced screening score (range 0–10.3),
and a cutoff point of 5.5 defined 49% as unscreened for CRC and yielded
area under the curve (AUC) of 0.626. When validated with KNHANES 2011
and 2012 datasets, the AUC of the defined LR model was 0.663, meanwhile the
AUC of ANN based predictive model was 0.743.
Conclusion: The ANN produced better performing model than LR analysis based
model in identifying population with low CRC screening participation. Sensible
approaches should be implemented to encourage partaking in CRC screening in
the identified individuals.
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Introduction: Background: CD24, a mucin-like cell surface molecule, highly
expressed in large variety of solid tumors and hematological malignancies
(HM) (Gastro 2006, Clin Can Res 2007, Can Res 2008). mAb to CD24 were
found to inhibit the growth CD24 cancer cells (Gastro 2009). We have shown
that a simple non-invasive blood test evaluating CD24 levels on PBL had good
sensitivity and specificity for detecting colorectal neoplasia in subjects under-
going screening colonoscopy (Kraus et al., 2009).
Aims & Methods: We aimed to improve a simple, noninvasive blood test that
could reliably identify individuals with different types of cancer.
Blood was taken from patients with various malignancies (CRC, Pancreatic
Cancer (PC), gastric cancer (GC), sarcoma and HM), that was confirmed by
histology. Age, gender and ethnic matched healthy individuals served as controls.
Healthy subjects were indeed very healthy. They underwent a thorough and
extensive workout at the Integrated cancer prevention center at Tel Aviv
Medical Center (Eur J Intern Med. 2013) All samples were collected and pro-
cessed identically. For each sample, 20,000 leukocytes were analyzed by flow
cytometry for the expression of CD24. An initial template file has been generated
using gates within the software to create a hierarchical population tree at the
beginning of the screen. All additional analyses were accomplished after data
acquisition have been completed. The template file include compensation adjust-
ment, which is uniformly applied to all the data collected in order to minimize
fluorescence overlap between detection channels
Results: The novel assay was improved significantly. distinguished healthy from
CRC (Fig.1a) (P5 0.013), PC (Fig.1b) (P5 0.018), biliary tract (P5 6.45E-12),
sarcoma (P5 0.036), multiple myeloma (Fig 2a) (P5 0.4E-08), MDS (P5 0.1)
and Lymphoma (P5 2.1E-07) patients. CD24 expression levels were higher by
up to 25% in cancer cases as compared to normal subjects. The sensitivity and
specificity for CRC were 79.2% and 74.7%, and for PC 70.0% and 75.9%,
respectively.
The positive (PPV) and negative predictive (NPV) values of CD24 for the detec-
tion of CRC was 38% and 94.8%, and for PC 17.1% and 97.3%, respectively.
Specificity and sensitivity for HM were also statistically significant (data not
shown). The CD24 test could not discriminate between patients with cervical,
stomach and lung cancers and healthy subjects.
Conclusion: Conclusions: CD24 expression in PBLs is a promising blood test for
the early detection of CRC, PC and HM.
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Introduction: Colonoscopy is considered the gold standard for prevention and
early detection of colorectal cancer (CRC), however its effectiveness is directly
related to quality of bowel preparation. Two of the quality measures of colono-
scopy, cecal intubation rate and adenoma detection rate, are both associated with
adequate bowel prepation. Data on factors associated with quality of preparation
using Picolax are limited.
Aims & Methods: We aimed to evaluate factors associated with a good bowel
preparation using Picolax (Sodium picosulfate\magnesium citrate) in the Israeli
heterogeneous population. Consecutive outpatients referred for colonoscopy
were prospectively assessed by a nurse practitioner filling out a questionair.
Bowel preparation consisted of Bisacodyl 10mg/d 3 days before colonoscopy
and split dose picolax. Demographics, medical history, Bisacodyl and water
consumption, time of total preparation and time between end of prep to colono-
scopy were evaluated. Quality was assessed using the Boston Bowel Preparation
Score (BBPS). Bowel prep was considered "good" if BBPS was 6 and 2 in each
l segment or "low" if BBPS was 56 or 52 in any colonic segment.
Results: A total of 452 patients were included in the study (M¼ 54%, mean age
56.5 16.3 yrs), 366452 (81%) achieved a ‘‘good’’ bowel preparation, and 86
(19%) were classified as ‘‘not good.’’ No significant difference was observed
between ethnicities and gender in terms of achieving a good bowel preparation
(p¼ 0.77, p¼ 0.054). There was a significant difference among diabetics (n¼ 93,
20.6%) and non-diabetics (n¼ 359, 79.4%) in quality of the bowel prep. While
69.9% of diabetics achieved a good bowel preparation only 83.8% of non dia-
betics achieved a good bowel preparation (p¼ 0.004). In the univariant analysis,
Bisacodyl had no effect on bowel preparation (p¼ 0.83) except in the diabetics,
where those who took an average of 5.3 1.9 (median¼ 6) vs. 4.31 1.5 (med-
ian¼ 4) tablets fared better (p¼ 0.018). Other chronic diseases had no effect on
bowel preparation. Drinking 3–7 vs 8–15 glasses of water achieved good prepara-
tion in 72.7% vs 83.8% of cases, respectively (p¼ 0.01). Time from end of pre-
paration to colonoscopy 58 hrs achieved significantly better prep vs 48 hrs
(p¼ 0.002). In the multivariant model for prediction of quality of bowel prepar-
artion that included the time between sachets of picolax, number of water cups
consumed, diabetes, gender, and age we found that all, excluding age, were good
predictors of bowel preparation. Women had a better chance of achieving an
adequate bowel preparation (OR1.68, p¼ 0.045, 95%CI¼ 1.01–2.79). Patients
without diabetes had a better chance of achieving an adequate bowel preparation
(OR¼ 2.05, p¼ 0.014, 95%CI¼ 1.16–3.63). Patients who had 5–9 hours between
the 2 sachets of picolax had a lower chance of achieving an adequate bowel
preparation as compared to those who had 9 to 24 hours between the 2 sachets
(OR¼ 0.375, p¼ 0.009, 95%CI¼ 0.180–0.785). Lastly, drinking fewer than 8
cups lowers the chance of achieving an adequate bowel preparation
(OR¼ 0.461, p¼ 0.003, 95%CI¼ 0.275–0.775).
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Conclusion: Diabetics require a more intense bowel preparation aided by
Bisacodyl, which does not help others. Time between both doses should exceed
8 hours and preparation should end no later than 8 hours prior to colonoscopy.
Patients should be instructed to drink a minimum of 8 glasses of water with each
dose of picolax.
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Introduction: Colonoscopy is the gold standard method of colorectal cancer and
polyp screening, but polyps are missed during a colonoscopic examination at a
rate that varies from 6% to 27%. Improved adenoma detection rates can be
achieved with optimized endoscopic visualization methods. A recently developed
new Fujinon endoscope system, Eluxeo carries a new function of electronic
chromoendoscopy, Linked Color Imaging (LCI), that enhances the coloring
and contrast of mucous membranes and blood vessels which are difficult to see
with the conventional endoscopes. In our prospective randomized study, we
evaluated the effectiveness of LCI, a new endoscopic visualization technique
that may enhance image quality to improve colonic adenoma detection.
Aims & Methods: Up till now 247 eligible patients, elder than 45 years, admitted
for screening outpatient colonoscopy were randomly enrolled to undergo high-
definition white-light colonoscopy (WLC) or LCI colonoscopy during instrument
withdrawal. The colonoscopic procedures were performed by three experienced
endoscopists with Fujinon 7000 processor and with either the conventional high-
definition Fujinon EC 590Z or a new EC 760Z VS Eluxeo colonoscope. All of the
colonoscopic procedures were made under Propofol deep sedation guided by an
anesthesiologist team. The minimum withdrawal time was defined as more than 6
minutes. All colonoscopies were routinely assisted with pure CO2 insufflation.
The primary outcome parameter of our study was to assess and compare the
polyp and adenoma detection rate with the two endoscopic technology.
Results: A total of 247 patients were randomized (mean age 58.7 years), 101
patients enrolled in the WLC group and 146 patients in the LCI group. No
significant differences have been observed in the patient demographics and colo-
noscope withdrawal time between the two groups. Patients having both color-
ectal polyps and adenomas were detected more frequently in the LCI group than
in the control group: 60.9% and 43.8% versus 55.4% and 33.6% respectively,
however, this was not statistically significant (p¼ 0.32 and 0.16). In contrast, the
total number of adenomas relative to the total number of polyps detected with
LCI withdrawal were significantly higher than with conventional WLC: 105 vs.
159 and 55 vs. 102, respectively (p5 0.0498).
Conclusion: The LCI enhancement of the Fujinon Eluxeo colonoscopy system
was superior to the conventional HD-WLC in detecting patients with colorectal
adenomas, which was mainly due to the ability of the more sensitive detection of
minute (less than 5mm) adenomas.(Study was supported by ECT grant GINOP
2.1.1.-15- 2015-00128.)
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Introduction: Long non-coding RNAs (lncRNAs) play role in colorectal cancer
(CRC) development, however, lncRNA expression profile in CRC and its rela-
tion to the epigenetic regulatory system still remain incomplete.
Aims & Methods: We aimed the perform whole genomic lncRNA expression
profiling and the analysis of underlying functional interactions of aberrantly
expressed lncRNAs. lncRNA expression levels were analyzed on 60 colonic
biopsy samples (20 CRCs, 20 adenomas, 20 normals) by Human
Transcriptome Array (HTA) 2.0. Expression alteration of certain candidates
was verified by qPCR. Furthermore, in silico validation was performed on
HGU133 Plus 2.0 array data and also on TCGA COAD dataset. miRNA targets
of lncRNAs were predicted with the miRCODE algorithm and miRNA expres-
sion was analyzed using miRNA 3.0 Array. Comprehensive lncRNA-mRNA
coexpression pattern analysis was also performed.
Results: According to HTA results in adenomas 12 lncRNAs (e.g. LINC00278)
were upregulated and 6 lncRNAs (e.g. RP11.747D18.1) were downregulated
compared to normals, while in CRCs 1 lncRNA (UCA1) was overexpressed
and 8 lncRNAs (e.g. LINC00350) were underexpressed compared to adenomas
(p5 0.05; -2Fc 2). In CRC samples 8 lncRNAs (e.g. AC123023.1) were
overexpressed and 9 lncRNAs (e.g. RP13–497K6.1) were downregulated
compared to normals. 42% of lncRNAs upregulated in CRC samples showed
elevated expression (p5 0.05) already in adenomas (e.g. overexpressed CCAT1,
downregulated LINC01133). In line with aberrant expression of certain lncRNAs
in tumors, miRNA and mRNA targets’ expression showed systematic altera-
tions, e.g. UCA1 upregulation in CRC samples in parallel with miR-1 down-
regulation accompanied by CMET target mRNA overexpression (p5 0.05).
Conclusion: The defined lncRNA sets (e.g. CCAT1, UCA1) may have a regula-
tory role in adenoma and CRC development and in tumor cell growth pathways.
A subset of CRC-associated lncRNAs showed significant differential expression
in precancerous samples, that raise the possibility to develop potential adenoma-
specific markers and achieve early detection of colon lesions.
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Introduction: Serine protease inhibitors (Serpins) play an important role in the
regulation of enzymes involved in proteolytic cascades. Members of the family
are: alpha1-antitrypsin, alpha1-antichymotrypsin, C1 inhibitor, antithrombin
and neuroserpin. Kallikrein-related peptidases (KLKs) are involved in proteoly-
tic cascades of different tissues. KLK14, acting via PAR-2, represents an auto-
crine/paracrine regulator of colon tumorigenesis and alpha1-antitrypsin is a
natural inhibitor of KLK14. Therefore its role in regulating the proteolytic cas-
cade in colorectal tumorigenesis is of great importance.
Aims & Methods: The aim of this study was to analyze A1-antitrypsin (AAT)
expression in tissue samples at different stages in the process of colon cancer
development. We examined a total of 245 colon samples. Of those, there were 101
colorectal carcinoma tissues, for 70 of which paired normal mucosa was also
examined. A total of 74 colorectal adenomas were examined. Quantitative real
time PCR was used to measure AAT expression. Clinical evaluation of AAT
levels was demonstrated in terms of disease-free survival (DFS) and overall
survival (OS).
Results: Alpha1-antitrypsin expression was found to be significantly associated
with TNM stage (p¼ 0.028). Cox proportional hazard regression model using
univariate analysis revealed that high status alpha1-antitrypsin expression is a
significant factor for disease-free survival (DFS) (p¼ 0.002) and overall survival
(OS) (p¼ 0.026) in patients with colorectal cancer. Kaplan-Meier survival curves
demonstrated that low alpha1-antitrypsin expression is significantly associated
with longer DFS (p¼ 0.001) as well as OS (p¼ 0.021).
Conclusion: Our data suggests that alpha1-antitrypsin expression could be con-
sidered as a potential biomarker of unfavorable prognosis for colorectal cancer.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
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Introduction: Real-time differentiation between neoplastic and non-neoplastic
colorectal lesions may be crucial during colonoscopy. While adenomas are
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neoplastic, and therefore should be resected, hyperplastic polyps never turn
malignant and do not require specific endoscopic therapy. The aim of our pro-
spective, randomized study was to distinguish subcentimetric hyperplastic and
adenomatous polyps based on Fujinon FICE versus Eluxeo BLI electronic chro-
moendoscopic technology with high-definition colonoscopy with and without
optical magnification.
Aims & Methods: In order to create a video and digital picture library of polyps,
patients undergoing screening or diagnostic colonoscopy were considered for
inclusion. Patients with at least one histologically verified 510mm polyp were
included. A short (20 sec) video-clip and at least one still picture of each polyp
without and with 50x optical zoom at standard white-light (WLI), and with
FICE-light or BLI-light were recorded with Fujinon EC 590Z and EC760Z
endoscopes and stored in an anonymized database. Once the video-library was
completed, each of our 5 colonoscopic experts (ML, SZM, OL, DZS, and SZA)
independently and randomly reviewed all of the cases with a standardized elec-
tronic questionnaire. In each cases, all of the observers had to assess the color,
the vascularization and the surface of the polyps, and the pit pattern was also
analyzed according to the Kudo classification. Finally, with the degree of con-
fidence (low/medium/high on VAS), the histological prediction and the final
decision has been clarified on each lesion as neoplastic or non-neoplastic
(hyperplastic).
Results: Up till now 115 polyps were enrolled and recorded into our digital web-
based library, 59 were assigned into the FICE and 56 into the BLI group. All of
the detected 115 polyps were endoscopically removed and histologically analyzed
and this was regarded as gold standard. The overall accuracy with WLI versus
FICE versus BLI technology of the 5 experts without zoom and with 50x times
magnification to differentiate between hyperplastic and adenomatous lesions
were 77.62% and 84.51%, vs. 74.58% and 83.90% vs. 83.93%, and 88.84%,
respectively. There was an excellent correlation between the histopathological
results and our KUDO classification with both FICE and BLI technology.
Both 50x times optical zoom and BLI technology were independently and sig-
nificantly improved our confidence rate that was associated with a more precise
histological prediction as compared to non-zoom, WLI or FICE endoscopic
polyp assessment.
Conclusion: The new electronic chromoendoscopic technology with Eluxeo BLI
significantly improved the reliability of the histology prediction as compared to
FICE technology of Fujinon. High-confidence predictions for the differentiation
of neoplastic and non-neopastic polyps with Eluxeo BLI electronic chromoendo-
scopy provide a potential for real-time endoscopic diagnosis of hyperplastic
polyps to support resect and discharge strategy. (Study was supported by ECT
grant GINOP 2.1.1.-15- 2015-00128)
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Introduction: Colorectal cancer (CRC) is the 4th commonest cancer in the UK
but has an excellent prognosis upon early diagnosis accounting for the develop-
ment of bowel cancer screening. However not all patients are eligible for this.
Furthermore, colorectal investigations have the potential to miss the diagnosis
and lack of appropriate investigation of alarm symptoms may also delayed
diagnosis.
Aims & Methods: We aimed to determine the miss rate of previous investigations
and reviews for colorectal symptoms and iron deficiency anaemia (IDA) over the
preceding 3 years prior to CRC diagnosis at our institution. 215 patients were
identified from the local CRC registry between 1/10/15–30/9/16 and electronic
records reviewed to determine if any review for lower GI symptoms or IDA had
occurred in the preceding 3 years. Missed diagnoses were defined as patients
having prior endoscopic or cross sectional imaging viewing the affected area or
having prior clinic/inpatient review failing to adequately investigate colorectal
alarm symptoms.
Results: Of the 215 patients 37 (17%) were deemed to have undergone possible
delay in their diagnosis causing an average 9.6 and median 5 months delay (1.5–
33 months). Cancers were right sided in 18 patients (49%), Dukes C or above in
76%, with 57% only suitable for palliative therapy. Of the 37 patients with a
delayed diagnosis 22 (59%) were deemed possible missed diagnoses. The remain-
ing 15 delays (41%) were due to patient choice (11%) or delayed clinic review/
investigation (30%); in this latter group the delay was a mean 3.9 months (1.5–7
months). Missed diagnosis occurred at: 1) Endoscopy in 10 (48%); 8 colonosco-
pies (median 18 (4.5–27) months earlier), 2 sigmoidoscopies (1 and 3 months
earlier), 2) Radiology: CTvC missed 2 CRC (15 and 2 months earlier but laparo-
scopy for a presumed benign lesion was planned for the latter); CTAP/CTKUB
missed 8 cases (median 5(2–26) months previously), 3) Clinical assessment:
missed appropriate inpatient/outpatient investigation based on presenting with
colorectal alarm symptoms or IDA occurred in 7 cases (median 3(2–16) months
delay). 2 patients were a miss on both CT and endoscopy and 3 on CT and clinic
review. Delayed follow-up upon re-referral compounded delayed diagnosis in 11
(50%) of the 22 missed cases.
Conclusion: Our data suggest a delay in CRC diagnosis occurred in almost a fifth
of cancer diagnoses. Delayed cancer diagnosis tended to occur in right-sided
lesions and resulted in a median 5-month delay with lesions generally advanced
at diagnosis. In 59% the diagnosis could have been expedited by earlier follow-up
and/or investigation. While miss rates for endoscopic and imaging modalities
were low, 19% of missed cancer diagnosis were due to lack of appropriate
investigations following outpatient or inpatient review for colorectal alarm symp-
toms or IDA; this might be improved by increasing specialist inpatient in-reach
services and senior review of outpatient cases.
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Introduction: Till now, narrow-band imaging (NBI) could make it possible to
analyze the surface microvessels of colorectal lesions for differentiating neo-
plasms from non-neoplasms and for predicting the histropathological diagnosis.
Endocytoscopy (EC) is the next generation of ultramagnification endoscopy that
allow visualization of the glandular structure and cellular atypia. EC has visua-
lized living tumor cells in vivo and obtained an ultra-magnification pathological
image simply by applying the scope to the target mucosa during an endoscopic
examination. However, in order to visualize cell nuclei, dye staining (i.e. methy-
leneblue) is always required. Since dye staining complicates the procedure, new
observation method without use of dye has been strongly desired. On the other
hand, EC with NBI (EC-NBI) allows ultra-magnified microvessel observation
without using any dye solution.
Aims & Methods: The aim of this study was to validate the evidence whether the
observation of surface microvessels using EC-NBI was useful in predicting the
histopathology of colorectal lesions. The study included 438 patients who under-
went complete colonoscopy and endoscopic or surgical treatment between April
2006 and June 2015. A total of 576 lesions (45 Non-neoplastic polyps, 304
adenomas, 71 intramucosal cancer, 21 slightly invasive submucosal cancer
(SMs) and 135 massively invasive submucosal cancer) were retrospectively eval-
uated. We used the Kudo classification for the degree of submucosal invasion
and classified cancers accordingly. SMs cancer without vessel permeation does
not metastasize. In contrast, SMm lesions show a substantial proportion (10%)
of lymph node metastasis. We named the ultra-magnified microvessel findings as
endocytoscopic vascular (ECV) pattern and classified into the following 3
groups: EC-V1, the surface microvessels were very fine obscure; EC-V2, the
surface microvessels were more clearly seen and showed a regular vessel network,
and their caliber and arrangement were uniform; and EC-V3, the surface micro-
vessels were thick, and their caliber and arrangement were non-homogeneous.
Results: The sensitivity, specificity and accuracy of EC-V1 for diagnosis of hyper-
plastic polyp were 88.9%, 98.5% and 97.7%, respectively. As regards the sensi-
tivity, specificity and accuracy of EC-V3 for diagnosis of SMm were 82.2%,
98.0% and 94.3%, respectively.
Conclusion: Endocytoscopic vascular pattern was helpful in predicting the histo-
pathology of colorectal lesions.
Disclosure of Interest: All authors have declared no conflicts of interest.
Reference
1. Kudo S. Endoscopic mucosal resection of flat and depressed types of early
colorectal cancer. Endoscopy. 1993;25(7):455–61. Epub 1993/09/01.
P1768 CONSIDERATION OF RECTAL NEUROENDOCRINE
TUMOR IN OUR HOSPITAL
M. Akita
Internal Medicine, Mitoyo General Hospital, Kanonji City/Japan
Contact E-mail Address: m_akita1976@yahoo.co.jp
Introduction: Although patients with endoscopic treatment indications for rectal
neuroendocrine tumours (NETs) are recommended to undergo endoscopic ther-
apy, those with a tumour diameter of 10mm and up to the deep submucosal
layer. However, no clear guideline has been established on the radical criteria and
additional resection. Prognosis of the disease is also unclear. The validity of the
diagnosis and treatment recommended in the guideline for rectal NETs will be
examined in the cases treated at our hospital.
Aims & Methods: We examined the macroscopic features, pathological features,
treatment methods, and prognosis of 22 patients diagnosed as having a rectal
NET and treated at our hospital between 2007 and May 2016.
Results: The mean age of the patients was 65.2 years (range, 49–88 years); male-
to-female ratio, 15:7; diagnosis opportunity, 21 asymptomatic cases and 1
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symptomatic condition (lumbago); lesion site (Rs/Ra/Rb), 1/2/19 cases; mean
tumour diameter, 8.2mm; presence of biopsy, 14/8 cases; biopsy diagnosis rate,
11/14 (78.5%); presence/absence of endoscopic ultrasonography, 11/11 cases;
and M/SM/MP, 1/19/1 cases. The TNM classification of the cases was as follows:
T1a, 16 cases; T1b, 5 cases; T2, 1 case; N1, 1 case; and M1, 1 case. The treatment
was endoscopic mucosal resection/endoscopic mucosal resection with ligation/
endoscopic mucosal resection/endoscopic submucosal dissection/surgery/drug
therapy in 5/5/7/2/1/1 case. Of 19 endoscopic treatment cases, 15 corresponded
to a tumor diameter of 10mm, with negative resection margin and vascular
invasion as criteria for curative resection, and 3 cases of unknown stump were
recognised. In the EMRL group, all cases were negative. In all the cases except
the case of other-disease death, it elapsed without recurrence. Both surgical cases
showed a positive vascular invasion, and one case was a confirmed N1, but
neither of the patients survived without a relapse. In the case with hepatic and
bone metastases, medication was administered, and the effect was temporarily
effective, but the patient died a year and a half later.
Conclusion: Endoscopic treatments are considered appropriate for rectal NETs
with no evidence of ulcer or depression, no apparent metastasis, and not
410mm in diameter. Among the treatment options, EMRL is considered
useful and well tolerated. However, follow-up observation and case accumulation
seem necessary to determine the long-term prognosis in NET, which may recur
after years of surgery.
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Introduction: Inactivation of TP53 is the most frequent genetic damage in human
cancer. In addition, hyperactivation of the RAS pathway is common in many
human malignancies (Lung (LC)40%, pancreatic (PC)495% and colorectal
cancer (CRC)50%). Despite multiple attempts, targeting these pathways for
the treatment of cancer, for example through the development of RAS pathway
inhibitors has not proven to be effective thus far. Herein, we propose to exploits
the hyperactive RAS pathway and TP53 mutation status of human cancer to
deliver targeted antitumor herapy. We had previously reported that a recombi-
nant adenovirus, carrying a pro-apoptotic gene (PUMA) under the regulation of
RAS-responsive elements (PY4) effectively suppressed the growth of human
cancer cells harboring hyperactive RAS (Giladi et al, 2007). Furthermore, we
had shown, both in vitro and in vivo, that replacing the pro-apoptotic gene with a
bacterial toxin can improve the efficacy of this system (Shapira et al, 2015).
Aims & Methods: We aimed to establish a tight regulated dual system by expres-
sing a toxin under PY4 elements in cancer cells, while sparing normal cells by
expressing the anti-toxin under p53 responsive elements (RGC) specifically in
non-malignant cells. Adenoviral vectors carrying the toxin (PY4-MazF-mcherry)
and the antitoxin (RGC-MazE-GFP) were designed under the regulation of RAS
and p53 responsive elements, respectively. A virus carrying the toxin but lacking
the PY4 serves as a control virus. Those three constructs were cloned into a ‘‘first
generation’’ E1/E3 human type5 adenoviral vector. Virus particles were pro-
duced, their titer was calculated by the End-Point Dilution Assay and their
potency was tested in vitro. Cell death was measured qualitatively by using the
fluorescent microscopy and was quantified by the enzymatic MTT assay.
HCT116þ/þ;Rasmut/p53wt and HCT116-/-;Rasmut/p53 mut CRC cell lines,
as well as, A549;Rasmut/p53wt and H2030 Rasmut/p53wt LC cells were used
for testing the potency and safety of the system
Results: Massive cell death was induced in a dose-dependent manner (60%; 7.5
MOI) in CRC cells harboring mutated Ras after co-infection with the toxin and
the antitoxin viruses. The antidote was able to protect 70% of the cells that
were affected by background low level expression of the toxin construct, due to
promoter leakage [Fig1]. Similar results were obtained in a colony formation
assay and FACS analysis of co-infected LC cells. A549 harboring mutated Ras
showed greater sensitivity (82% early apoptotic cells) compared to H1650 cells
harboring WT Ras (27% early apoptotic cells) [Fig2]. These results indicate
that the antitoxin indeed actively protects cells with WT p53.
Conclusion: Exploiting the activated RAS pathway and mutation in p53 holds
promise for effective and safe therapy that could specifically target tumor cells
while sparing normal tissues.
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Introduction: Lentiviral replication is driven by a molecular motor consisting of
the three viral enzymes: the reverse transcriptase, protease and integrase (IN).
The genomic RNA of the virus is used to produce a copy of viral DNA by reverse
transcription, and the integrase catalyses the covalent insertion of this DNA into
the chromosomes of the infected cells. Integration of the viral DNA –which is
flanked by LTR sequences- proceeds through a combination of cleavage and
ligation resulting in the appearance of double-stranded breaks in the host
genome that eventually leads to apoptosis. CD24 is a heavily glycosylated cell-
surface GPI-anchored protein. We have previously shown that CD24 is an
important player in the multistep process of GI carcinogenesis (Gastro 2006,
Clin Can Res 2007, Can Res 2008) as well as in many other human malignancies
(Cervical, Bladder, Esophageal squamous cell carcinoma, Glioma, Breast etc.).
Aims & Methods: We aimed to develop and specifically direct lentiviruses
towards target cells for effective and selective eradication by stimulation of the
viral integrase. Integrase derived peptides (designated as INS) were synthesized as
well as control peptide. Humanized Anti-CD24 antibody fragment (scFv) was
engineered and fused to the lentivirus envelope. Cell death was measured quali-
tatively by using fluorescent microscopy and was quantified by the enzymatic
MTT assay. Human colorectal, pancreatic, lung and triple negative breast cancer
cells were used for testing the potency of the lentiviral-based system.
Results: INS was able to stimulate the viral Integrase enzyme in test tubes and in
viral infected cells. The anti-CD24 antibody fragment has a high affinity and
specificity toward CD24, allowing targeted precision of viral transduction
(Figure 1). These Lentivirus particles contain DNA molecules with flanked
LTRs allowing their integration into the CD24-expressing target cells DNA
and formation of double-strand breaks due to the action of the particles integrase
whose activity was stimulated by the IN derived peptides. Massive cell death was
induced upon exposure of the infected cells to the INS peptide compared to the
control peptide.
Conclusion: The use of IN derived peptides together with the CD24-targeted
lentitherapy approach suggest a novel strategy to specifically promote death of
CD24-expressing cancer cells.
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Introduction: A specific inhibitor of interleukin enhancer binding factor 3 (ILF3),
YM155, suppresses EGFR phosphorylation and significantly inhibits the forma-
tion of cancer stemness tumorspheres in vitro, suggesting that ILF3 as an onco-
gene participates in the maintaining of cancer stem cell property through
stabilizes EGFR-mediated stemness pathway. Since cancer stemness cell is the
leading reason for tumor recurrence in the tumor repressive treatments, and
EGFR enhances the formation of cancer stemness, it is worthy of investigating
the function of ILF3 for maintaining the cancer stemness property in the EGFR-
positive cancers.
Aims & Methods: The tumorspheres derived from EGFR-wild-type and KRAS-
mutant colorectal HCT116 and lung A549 cells expressing higher cancer stem-
ness markers, CD133, were used as cancer stemness models in this study.
RNAseq was utilized to search for the putative genes involving in the formation
of tumorspheres as the cancer stemness markers. Meanwhile, the differentiating
stemness markers were also compared between ILF3-knockdowned and the con-
trol shLuc cells. Then, the protein level and phosphorylation of EGFR were
investigated in the YM155-treated and ILF3-knockdowned cells for validating
that EGFR was regulated and stabilized by ILF3. The ILF3-knockdowned cells
were also transplanted into SCID mice for evaluating the function of ILF3
in vivo.
Results: We found that higher EGFR autophosphorylation (Y1068) in HCC116-
and A549-derived tumorspheres compared to the parental cells. The results of
RNAseq evaluated that CD133 was a positive stemness marker, whereas
MARCH4 as a negative marker. Knockdown of ILF3 reduced the cell prolifera-
tion in A549 cells in vitro and in vivo, demonstrating that ILF3 was an oncogene
involving in cancer cell survival. Moreover, inhibition of ILF3 by YM155
blocked the autophosphorylation of EGFR and inhibited the EGFR-down-
stream G9a activation, leading to a reduction of stemness property. Moreover,
Knockdown of G9a reduced the CD133 expression and increased MARCH4
expression, revealing that G9a was essential for maintaining for cancer stemness
property in the EGFR-positive cancers.
Conclusion: In conclusion, this study demonstrated that ILF3 played an impor-
tant role maintaining the EGFR-mediated cancer stemness property in HCC116
and A549 EGFR-positive cancer cells. We demonstrated that ILF3 stabilized and
phosphorylated EGFR to enhance the activation of G9a, leading to increasing
CD133 and decrease MARCH4 expressions. Therefore, we suggested that the
ILF3 inhibitor, YM155, was potential for utilization in cancer therapy against
the EGFR-positive cancers.
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Introduction: Although various pharmacological agents have been trialed for
recurrent colorectal adenomas, their comparative effectiveness remains
unknown. We conducted both direct and indirect comparisons of twelve chemo-
preventive agents for recurrent colorectal adenomas.
Aims & Methods:MEDLINE, EMBASE, Scopus, Web of Science, and Cochrane
Central Register of Controlled Trials, and ClinicalTrials.gov were searched up to
May 1, 2016. RCTs were assessed by a random-effects model within a Bayesian
framework. Agents for each outcomes were ranked by surface under the cumu-
lative ranking area (SUCRA). This study is registered with PROSPERO, number
CRD42016041923.
Results: 33 RCTs were eligible, enrolling 44,647 participants treated by twelve
regimens: 9 aspirin and other NSAIDs, 11 antioxidants, 4 dietary supplements, 3
clacium, 4 folic acid, 2 calcium plus antioxidants, 2 aspirin plus folic acid and 1
each metformin, ursodeoxycholic acid (UDCA), aspirin plus calcium with vita-
min D, and difluoromethylornithine (DMFO) plus sulindac. For recurrent color-
ectal adenomas, findings were significantly better for sulindac plus
difluoromethylornithine than other tested agents. Aspirin/NSAIDs was more
effective than placebo in both pairwise (OR, 0.73 [95%CI, 0.59 to 0.90]) and
NMA (OR, 0.75 [95%CrI, 0.57 to 0.98]). Subgroup analysis showed the highest
probability of aspirin (160mg/L) to be the most efficacious agent among all
NSAIDs (SUCRA¼ 71.7%). For safety profiles, the top three ranked agents
were metformin (86.7%), antioxidants (82.0%) and dietary supplements
(65.9%), but none reached statistically significance when compared with placebo.
Aspirin/NSAIDs performed the worst (16.4%) with significantly more serious
adverse events than placebo (pairwise: OR, 1.25 [95%CI 1.14 to 1.38]); NMA
(OR, 1.26[95%CrI 1.12 to 1.44]). Other regimens were not significantly different
to each other in both pairwise and network comparisons, these agents include
antioxidants, dietary supplements, calcium as well as folic acid.
Conclusion: For individuals with presumed increased risk of CRC, moderate-to-
low dose aspirin and sulindac-associated combination therapy are both effective
for recurrent colorectal adenomas. Future studies are required to provide more
precise estimates of the optimal NSAIDs with an effective dose and low adverse
events.We also suggest the further evaluation of NSAIDs-associated combina-
tion regimens and other novel agents (e.g.metformin)in the chemoprevention of
CRC.
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Introduction: The omega-3 polyunsaturated fatty acid eicosapentaenoic acid
(EPA) has anti-colorectal cancer (CRC) activity. Several mechanisms of action
have been described, including lipid mediators metabolism and surface receptor
signalling. Aspirin is a known cyclo-oxygenase (COX) inhibitor with cancer pre-
ventive properties.
Aims & Methods: The aim of this study was to identify possible mediators of
resistance to EPA in CRC cells. Human and mouse CRC cell lines were screened
for their sensitivity to EPA by MTT assay in vitro (n¼ 3). The MC38/MC38r and
CT26 wt/COX2 CRISPR/Cas9 knocked out (COX2ko, gifted by Dr Zelenay,
Manchester, UK) isogenic mouse CRC line pairs were used to further investigate
the molecular basis of resistance to EPA. COX-1/2 protein expression was mea-
sured by western blot in vitro and by immunohistochemistry in vivo. Aspirin was
used at a non-cytotoxic dose of 500mM to provide COX inhibition in combina-
tion studies (n¼ 3). In vivo studies were performed using female CD1-nude mice,
fed diets supplemented with 7%(v/w) control corn oil, 6.1%(v/w) EPA-triglycer-
ide oilþ 0.9%(v/w) control oil, 600 ppm aspirin or a combination of both EPA
and aspirin (n¼ 14) for 4 weeks. After the first 2 weeks, 5x106 MC38 and MC38r
cells were injected as subcutaneous tumours on the right flank, before sacrifice 2
weeks later. Tumour volumes were measured by calipers.
Results: The human and mouse CRC cell lines tested displayed varying levels of
sensitivity to EPA (IC50 range: 36 1 mM to 242 2 mM). HT29 cells were sensi-
tive human CRC cells (IC50¼ 89 1 mM) and CaCo2 cells were the least sensitive
(IC50¼ 228 1 mM). In particular, MC38 mouse CRC cells were the most sensi-
tive to EPA (IC50¼ 36 1 mM) of all cell lines tested, whilst isogenic MC38r cells
were 3.9-fold more resistant (IC50¼ 163 1 mM). We found a strong increase in
COX1 and COX2 protein expression in EPA-resistant MC38r compared to
MC38 cells. Genetically modified CT26 COX2ko cells were used to assess
whether COX2 specifically played a role in EPA resistance. Indeed, CT26
COX2ko cells were 3 times more sensitive to EPA (IC50¼ 78 1 mM) than par-
ental CT26 cells (IC50¼ 242 2 mM, high COX2 expression). Aspirin was then
evaluated as a potential combination treatment with EPA. A decrease in IC50
values for EPA was observed in 8 out 10 CRC cell lines tested (1.1-fold to 4-fold
increase in sensitivity to EPA). Whilst the response of MC38 cells to EPA was
increased 2-fold [IC50 (EPAþ aspirin)¼ 19 1 mM], MC38r cell response was
increased 3.8-fold [IC50 (EPAþ aspirin)¼ 42 1 mM]. Aspirin increased CT26
wt response to EPA [IC50 (EPA)¼ 242 1 mM compared with IC50
(EPAþ aspirin)¼ 99 1 mM] but did not affect the EPA response of CT26
COX2ko cells [IC50 (EPA)¼ 78 1 mM and IC50 (EPAþ aspirin)¼ 84 1 mM].
We measured EPA incorporation in these cells and observed an increased accu-
mulation of EPA in CT26wt cells treated with both EPA and aspirin compared to
EPA alone. A similar pattern of response was measured in vivo. EPA adminis-
tration exerted anti-tumour activity in MC38 subcutaneous tumour-bearing
CD1-nude mice (n¼ 14, 37% decrease in mean tumour volumes, p¼ 0.02),
which was not augmented by combination with aspirin. However, EPA alone
did not significantly impact on tumour volumes in EPA-resistant MC38r tumour
bearing mice whilst the EPA-aspirin combination was associated with a 42%
reduction in tumour volume compared with control (n¼ 14, p¼ 0.003).
Administration of aspirin, alone or in combination with EPA, did not alter
COX1/2 protein expression in tumour tissues.
Conclusion: Human and mouse CRC cells display differential sensitivity to EPA
in vitro. Our data indicate that COX2 mediates resistance to EPA in CRC cells by
a mechanism that likely involves EPA substrate utilisation, thereby reducing
EPA levels. Aspirin combination sensitises CRC cells to EPA in vitro and in
vivo and may be a clinically relevant candidate for prevention and treatment of
CRC in combination therapy.
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Introduction: Colorectal cancer (CRC) is the third most common cancer world-
wide and accounts for 10% of all newly diagnosed cancers1. Although the thera-
pies have dramatically developed, the long-term survival rate of patients with
CRC remains low. In recent years, great efforts have been made to identify
inflammation-related factors for precise prediction of disease prognosis.
Glasgow Prognostic Score (GPS) is such an inflammation-based factor, defined
by the combination of the level of serum C-reactive protein (CRP) and albumin,
which are indicators of systematic inflammatory response and nutritional status
respectively. Growing evidence suggested that GPS was served as an independent
prognostic index in a variety of malignant cancers. For patients with CRC, the
GPS system was also widely studied, but the results were controversial.
Aims & Methods: To investigate the correlation between GPS and prognosis of
patients with CRC to further clarify its clinical significance. A comprehensive
search of Pubmed, Embase, Cochrane library, Web of Science, ChinaInfo and
Chinese National Knowledge Infrastructure was performed to identify eligible
studies, from which the risk of overall survival (OS) and cancer-specific survival
(CSS) were extracted. A random-effect model was adopted to combine hazard
ratio (HR) and 95% confidence interval (CI).Heterogeneity and publication bias
among studies were assessed.
Results: 25 articles with a total of 5660 participants were included. The pooled
results indicated that elevated GPS was associated with poor OS (HR¼ 2.83,
95%CI: 2.00–4.00, P5 0.01) and CSS (HR¼ 1.94, 95%CI: 1.51–2.49,
P5 0.01). This correlation was confirmed both in primary operable and
advanced inoperable patients. Increased GPS was also closely related to
advanced tumour-node-metastasis (TNM) stage (odds ratio [OR]¼ 1.44, 95%
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CI: 1.010–2.065, P5 0.05) and elevated level of serum carcinoembryonic antigen
(OR¼ 2.252, 95% CI: 1.508–3.362, P5 0.01). Subgroup analysis revealed a sig-
nificant association between high GPS and poor survival outcome according to
the factors of sample size, study of region and cut-off value of GPS level.
Conclusion: GPS could serve as a reliable predictive index for patients with CRC.
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Introduction: The implementation of the CRC screening program has generated
an increase in surveillance colonoscopies. However, the intermediate-high risk
group that included advanced lesions (size 10mm, villous component or high
grade dysplasia) or the presence of 3 or more polyps, has a low incidence of
metachronous risk lesions when performing colonoscopy at 3 years according to
the current recommendations. Identifying predictors of metachronous lesions
would provide a better risk stratification and improve the efficiency of surveil-
lance programs.
Aims & Methods: We aimed to identify the cost effectiveness of the first surveil-
lance colonoscopy and the predictive factors of metachronous lesions at 3 years
in individuals with advanced lesions or 3 polyps detected at baseline screening
colonoscopy. This was an analysis of all cases with advanced polyps and/or
multiplicity from CRC screening program population of Barcelona detected at
baseline colonoscopy during the years 2010–2011 and with a performed colono-
scopy after 3 years. Epidemiological and clinical data of all individuals were
collected as well as the morphological data of all polyps. For the statistical
study, a bivariate analysis and logistic regression were performed.
Results: 638 cases were identified, with mean age of 64 years. 342 were men
(66.2%). 23.8% required more than one colonoscopy for the complete removal
all the polyps. A complete surveillance colonoscopy at 3 years was performed in
518 cases (82%) with an average surveillance time of 38 months [15–75]. Mean
fecal hemoglobin was 440 ng/ml. 51.8% suffered from hypertension, 15% from
diabetes mellitus, 46.5% from dyslipidemia and 12.3% from chronic obstructive
pulmonary disease. 45.8% of individuals were overweight (BMI 25) and 34.7%
were obese (BMI 30). Surveillance colonoscopy was normal or with low-risk
polyps in 420 cases (80.1%); and advanced polyps or multiplicity were identified
in 98 cases (18.9%) 73 advanced adenoma in 59 cases (11.4%), 3 adenomas in
62 cases (11.9%), 3 adenomas and/or serrated in 71 cases (13.7%). The pre-
sence of 3 adenomas and/or serrated polyps was the only variable that was
associated with increased risk of the diagnosis of advanced adenomatous or
serrated lesions in surveillance colonoscopy (p5 0.001)
Conclusion: In individuals with advanced polyps and/or multiplicity the incidence
of metachronous risk lesions at 3 years is low. Assessment a quality baseline
colonoscopy with complete removal of all the polyps could allow to increase
the interval of surveillance, maintaining and ensuring the compliance of the
surveillance at 3 years in the cases with multiplicity in the basal colonoscopy
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Introduction: Colorectal Endoscopic Submucosal Dissection (ESD) is recom-
mended for superficial neoplastic lesions at high risk of submucosal invasion.
ESD allows an en-bloc resection but ESD experience is still limited in Western
countries.
Aims & Methods: The aim of this retrospective study was to evaluate technical
and clinical outcomes of colorectal ESD, in a single tertiary European center. We
retrospectively analyzed all consecutive patients treated by ESD for colorectal
lesion at Humanitas Research Hospital (Milan, Italy) from January 2011 to
September 2016. The primary outcomes were technical success, defined as en-
bloc resection and clinical success, defined as curative resection (R0) without
need for surgery. Secondary study outcomes were complication rate and ade-
noma/carcinoma recurrence. Complications were divided in early (24 hours)
and delayed (424 hours) and included bleeding and perforation. Recurrences
were identified as the presence of adenoma or carcinoma at the endoscopic
follow-up performed at 6 months, 1, 3 and 5 years. Data were analyzed by
STATA 14 statistical software.
Results: A total of 185 lesions in 185 patients (M/F 97/59, mean age 67.6 11.5).
Lesions were located in the rectum (64.3%), left colon (9.7%), transverse (11.9%)
and right colon (14%). Mean lesion size was 39.3 16.7mm. Histology revealed
low-grade dysplasia (LGD) in 64 (34.6%), high-grade dysplasia (HGD) in 78
(42.2%) and adenocarcinoma in 42 (22.7%) cases. Only 1 NET (0.5%) was
found. En bloc resection was achieved in 88% of lesions. Clinical success (R0)
was obtained in 84.8% of patients. The remaining 28 patients (15.2%) needed
surgery for unfavorable histology. A total of 12 complications were reported: 10
early complications (8 perforations and 2 bleeding) and 2 delayed complications
(1 bleeding and 1 perforation). All but one adverse events were managed endos-
copically. Surgery was required in the only case of delayed perforation. All
patients untreated with surgery (n¼ 156) underwent follow-up evaluation. In
particular, all patients had 6 months follow up, 97 patients had 1 y follow-up,
26 patients had 3 y follow-up, 9 patients had 5 y follow-up. Adenoma recurrences
were found in 3.8% at 6 months and 2% at 1 year. We did not find any adenoma
recurrence at 3 and 5 years. No cancer recurrence occurred in the follow-up
period.
Conclusion: ESD is a feasible strategy to manage superficial colorectal tumors.
This study demonstrates favorable technical and short-term clinical outcome of
colorectal ESD, but further studies are needed to confirm the long-term efficacy.
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Introduction: The organized non-population based National Colorectal Cancer
(CRC) Screening Program in the Czech Republic has been running since year
2000. In January 2014, the transition to population based setting has been imple-
mented. Currently, the annual immunochemical FOBT (FIT) is offered at the age
50–54, followed by FITþ colonoscopy, if positive. In age of 55, there is a choice
of either FIT biannually or screening colonoscopy in 10 years’ interval.
Aims & Methods: Main aim was to assess the impact of the first 30 months of the
population-based CRC screening program on the target population participation
and colorectal neoplasia detection. The data from National Reference Center
(health insurance companies database) and Preventive Colonoscopies Registry
in years 2013 (non-population based settings) and 2014–2015 (population-based
settings) were evaluated and compared.
Results: In year 2014, there were 1,500,897 individuals (53% of all CRC screening
target population) invited to FIT or colonoscopy, with 17.3% response. It
resulted in the coverage increase by 4.3 percent points in comparison with year
2013 (31.5% in year 2014). This trend continued in year 2015 with the target
population participation at 33.1%. This has influenced the increase of number of
detected adenomas (by 42%) and cancers (by 20%) detection in year 2014. In
year 2015, all the results remained stable (detailed results in the table).
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Year
Colonoscopy
(numbers)
Adenomas
(numbers) Ratio
Cancers
(numbers) Ratio
2013 26 940 10 126 37.6% 867 3.2%
2014 38 128 14 416 37.8% 1 042 2.7%
2015 37 330 14 081 37.7% 969 2.6%
Conclusion: The transition to population-based program resulted in the improve-
ment of target population participation followed by increase in colorectal neo-
plasia detection.
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Introduction: Although endoscopic submucosal dissection (ESD) is a widely
accepted treatment for colorectal neoplasia, little is known about large consecu-
tive studies evaluating long-term outcomes of early cancer and high grade dys-
plasia. We investigated the efficacy and safety of ESD for early cancer and high
grade dysplasia in colorectum and evaluated the long-term outcomes, including
local recurrence and metastasis.
Aims & Methods: We performed a retrospective analysis of data collected from
514 consecutive patients with 520 colorectal early cancer and high-grade dyspla-
sia treated with ESD between January 2007 and December 2013. Histology and
patient data were collected during an average follow-up time of more than 5
years to determine tumor stage and type, resection status, complications,
tumor recurrence, and distant metastasis.
Results: The overall rates of en bloc resection, complete resection, R0 resection,
major complications were 94.4%, 91.3%, 89.2% and 2.1%, respectively. Large
tumors and snare-assisted ESD were independent factors of piecemeal resection.
ESD of colon tumors increased the risk for complications. During the follow-up
period, all patients remained free from metastasis. However, local recurrence
occurred in 4 patients (0.8%); large tumors and piecemeal resection were risk
factors.
Conclusion: ESD is effective and safe for resection of early cancer and high grade
dysplasia in colorectum and long-term outcomes are favorable. ESD is indicated
for the treatment of colorectal early cancer and high grade dysplasia to obtain
curative resection and prevent the local recurrence.
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Introduction: Patients with irritable bowel syndrome (IBS) often have co-existent
mood disorder and psychological illness. Meta-analyses of randomised con-
trolled trials consistently demonstrate that psychological therapies, such as cog-
nitive behavioural therapy (CBT) and hypnotherapy, are effective treatments for
IBS. In the UK the National Institute for Health and Care Excellence (NICE)
recommends considering the use of these in patients with no response to phar-
macological therapies, and for refractory symptoms.
Aims & Methods: We performed a cross-sectional survey to examine willingness
of patients with IBS to engage with psychological therapies. We collected com-
plete symptom data from consecutive, unselected referrals to secondary care seen
in a specialist IBS clinic. All participants completed the validated Rome IV
questionnaire for IBS, the IBS severity scoring system (IBS-SSS), the hospital
anxiety and depression scale (HADS) to assess mood, and the patient health
questionnaire-12 (PHQ-12) to examine somatoform-type behaviour. They also
provided their opinion on possible treatment options, and were asked to rank
medical therapies, dietitian input, psychological therapies, including CBT and
hypnotherapy, and explanation of the condition and/or reassurance in order of
preference.
Results: Among 93 adults with confirmed IBS (74 (79.6%) female, mean age 36.0
years (range 16 to 77 years)), 35 (37.6%) had high levels of anxiety, 22 (23.7%)
had high levels of depression, and 23 (24.7%) had severe levels of somatoform-
type behaviour. Despite this, only 10 (10.8%) of 93 patients ranked psychological
therapies as their first-choice treatment option. In total, 8.8% of patients with
high levels of anxiety ranked psychological therapies as their first-choice treat-
ment option, versus 13.2% without (P¼ 0.64), 9.5% of those with high levels of
depression, versus 12.1% of those without (P¼ 0.91), and 17.4% of patients with
severe somatoform behaviour, versus 9.2% of those without (P¼ 0.26). Those
with severe symptoms according to the IBS-SSS were no more likely to select
psychological therapies as their first-choice treatment option than those with
mild or moderate symptoms (7.7% versus 21.7%, P¼ 0.10).
Conclusion: Despite high levels of psychological comorbidity and NICE recom-
mendations, patients with IBS in a specialist clinic were generally reluctant to
consider psychological therapies such as CBT or hypnotherapy. Those with
anxiety, depression, somatoform-type behaviour, or severe symptoms were no
more willing to consider these therapies than those without.
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Introduction: Symptoms of gastrointestinal dysfunction are among the most
common non-motor complaints in Parkinson’s patients. These may involve mus-
cles from the oropharynx to the anorectum, and the autonomic and enteric
nervous system are often involved, resulting in secondary bowel dysmotility.
Aims & Methods: The objectives of this study were to evaluate a technology
measuring the spectrum of gut dysfunction, the Wireless Motility Capsule
(WMC), in Parkinson’s disease. We also wanted to correlate transit measures
with gastrointestinal symptoms. Fifteen PD patients and 7 controls (table1) were
included. PD severity were scored with the modified Hoehn and Yahr (H&Y)
staging scale. GI symptom burden was identified by Wexner constipation score
and Gastroparesis Cardinal Symptom Index (GCSI). Acidity, motility and tran-
sit data were obtained, as standard, by WMC. All medications affecting pH and
motility, including L-dopa, were discontinued for 5 days before and for the
duration of the WMC study. Were analyzed data about gastric emptying time
(GET), small bowel transit time (SBTT), colonic transit time (CTT) and whole
gut transit time(WGTT).
Results: One patient could not swallow the capsule, and of the 14 patients com-
pleting the study, 8 reported GI symptoms. Compared to non-symptomatic
patients, those with GI symptoms showed significant delayed transit in the sto-
mach, colon and whole gut (table 1). However, small bowel transit did not
significantly differ. GI dysfunction was not correlated with H&Y score in this
small study. GCSI and Wexner constipation scores were correlated, suggesting a
pan-enteric problem in symptomatic individuals. There was a significant correla-
tion between the Wexner constipation score and CTT in all patients (p5 0.01)
but not GCSI and GET (p4 0.10). The results of Wireless Motility Capsule did
not differ between non-symptomatic PD and controls.
Non
symptomatic
PD (n¼ 6)
Symptomatic
PD (n¼ 8) [p value vs
Non symptomatic PD]
Controls (n¼ 7)
[p value vs Non
symptomatic PD]
Sex (M:F) 5:1 6:2 5:2
Age 61.2 10.9 69.6 13.4 [0.2744] 56.8 13.1 [0.0924]
GCSI 3.3 1.5 22.6 9.6 [0.0017] 2.4 1.4 [0.5704]
Wexner 2.2 2.0 14.3 3.2 [0.0003] 2.1 3.0 [0.6428]
GET 2.74 1.05 5.18 0.58 [0.0007] 2.58 1.14 [0.4713]
SBTT 4.08 0.71 4.17 0.34 [0.7193] 4.10 0.40 [0.7294]
CTT 27.44 7.89 57.82 30.61 [0.0426] 28.3 6.90 [0.5156]
Conclusion: We have shown that Parkinson’s patients with gut symptoms have
both upper and lower complaints. Symptomatic PD patients also have markedly
delayed transit times throughout the whole gut compared to asymptomatic PD
patients and controls. Whilst severity of constipation is related to delayed colonic
transit no such relationship is present between gastroparesis symptoms and gas-
tric emptying. The implication is that treating symptomatic Parkinson’s patients
should address the whole gut, whether with prokinetics or dual therapy.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1781 OUTLET DYSFUNCTION IS PREVALENT IN SEVERE
FUNCTIONAL BLOATING: PRELIMINARY REPORT FROM A
MULTICENTER ITALIAN STUDY
P. Iovino1, M.C. Neri2, L. D’Alba3, S. Gallotta1, G. Chiarioni4
1Medicine And Surgery, University of Salerno, Baronissi, SA/Italy
2Istituto Pio Albergo Trivulzio, Milan/Italy
3Gastroenterology And Digestive Endoscopy, Azienda Ospedaliera San Giovanni
Addolorata, Rome/Italy
4Gastroenterology, AOUI Verona - Gastroenterology, AOUI Verona; Verona/IT,
Verona/Italy
Contact E-mail Address: piovino@unisa.it
Introduction: Bloating and abdominal distension are common and bothersome
symptoms and a frequent complaint of patients affected by functional gastro-
intestinal disorders (FGID). Recent studies demonstrated that an impairment in
United European Gastroenterology Journal 5(5S) A771
the handling of gas is a relevant underlining mechanism in FGID patients with
bloating. However, solid data on defecation pattern in these patients are lacking.
Aims & Methods: Our aim is to study the relationship between the defecation
pattern, the severity of bloating and the abdominal girth measurements in FGID
patients consulting for bloating as primary complain with/without visible
abdominal distension unresponsive to diet advise. We performed a prospective,
multi-center study of patients with severe abdominal bloating (VAS score 24 on
a 100-mm scale) as primary complain with/without visible abdominal distension.
Patients were recruited at 4 gastroenterology outpatient clinics in Italy.
Comorbid FGID were grouped according to Rome III criteria. All patients
were prescribed a lactose-free diet supplemented by dietary advice according to
the NICE guidelines for two weeks. A belt around the abdomen at standardized
sites provided assessment of abdominal girth measurements. During the 2-week
run-in period patients completed a daily diary log including abdominal bloating
and pain/discomfort scores (100-mm VAS), Bristol Stool Form and stool fre-
quency. At randomization visit, all patients filled in a questionnaire on adequate
relief of bloating on a Likert scale and a further abdominal bloating 100-mm
VAS. A belt around the abdomen at standardized sites provided assessment of
abdominal girth two hours after a meal. All patients reporting insufficient ade-
quate relief of abdominal bloating at the end of the run-in period underwent a
standardized balloon expulsion test (BET) scored as either successful or failed. A
straining questionnaire was also administered.
Results: 76 patients (66 female, 39.8 12.2 mean age, 6 IBS-D, 6 IBS-M, 30 IBS-
C, 9 IBS-U, 6 FC, 16 FB, 3 FD) completed the 2-week run-in period. A signifi-
cant negative correlation was found between adequate relief and both bloating
and abdominal girth changes (r¼ -.53 and -.52, p5 0.001, respectively). 53/76
(70%) patients reported inadequate relief (worse or no improvement). Among
the non-responders the vast majority (68%) failed the BET. Multiple regression
analysis showed that BET (successful or failed), as dependent variable, was sig-
nificantly related to bloating severity. No relationship was demonstrated for
abdominal girth changes, FGID diagnosis and straining questionnaire.
Conclusion: In this prospective, multicenter trial simple diet advise was of benefit
in approximately 30% of FGID patients consulting for severe bloating. In the
non-responders outlet dysfunction was prevalent and correlated with subjective
bloating perception. The study is ongoing, but our data may support bowel
retraining as potential treatment option for functional bloating.
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Introduction: Faecal Incontinence (FI) is a common and socially disabling con-
dition, more prevalent among females over 50 years old. Detailed anatomical and
physiological assessment of each patient is important to determine the correct
cause of FI and selection the most appropriate therapy. Conventional and High
Resolution (HR) Anorectal Manometry (ARM) is a useful tool to categorize anal
and/or rectal dysfunction in addition to provide physiological assessment of both
anal sphincters and rectum.
Aims & Methods: To evaluate symptoms and anorectal function of patients
affected by FI, we included 358 patients with FI (77% female (F) and 23%
men (M), mean age 63 (range 22–92 year) referring to the outpatient unit of
Digestive Pathophysiology of S. Giovanni-Addolorata Hospital, Rome from
January 2006 to Dicember 2016. Clinical presentation (history, symptom profile
and severity) and anorectal physiological evaluation (digital examination, mano-
metry, rectal sensory testing, balloon evacuation test) were analyzed. The mano-
metric parameters obtained with conventional and HR-ARM were: resting
pressure, squeeze pressure, rectal compliance, rectal sensibility and the anorectal
pattern during the defecatory maneuvers.
Results: 114 out of 358 patients (32%) reported both FI and difficulty evacuating
stools. 1 68 with FI had also urinary incontinence UI (47%). Proctological
surgery (n 122, 34%), pelvic surgery (n 77, 21%) and traumatic anal or vaginal
history (n 144, 40%) were statistically associated with FI (p 0.05). Normal
manometric parameters were found in 16 patients (4%). Manometric alterations
observed were: internal anal sphincter (IAS) dysfunction: 228 (64%); isolated
external anal sphincter (EAS) dysfunction: 274 (76%); combined sphincter dys-
function IAS and EAS: 198 (55%); isolated dyssynergic defecation: 100 (28%);
rectal hypersensitivity: 130 (36%).
Conclusion: In our study, in accordance with the literature, we observed a female
prevalence in FI. FI is significantly associated with UI. This may be expired by
risk factors in common with these clinical conditions. In effect FI is significantly
associated with previous proctological/pelvic surgery and traumatic anal/vaginal
delivery. Furthermore, patients with FI referred difficulty evacuating stools, too.
In fact in patients with dyssynergic-type constipation, the FI may be confused
with an encopresis. Finally we observed these prevalent manometric alterations:
combined dysfunction IAS and EAS, and rectal hypersensitivity. Manometric
findings could help physicians to identify appropriated patients for a biofeedback
therapy.
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Introduction: Bile acid malabsorption (MAB) is a common and frequently under-
investigated cause of chronic diarrhoea. Most of the cases of chronic diarrhoea
after excluding organic disorders are labelled as functional diarrhoea or irritable
bowel syndrome (IBS). The most commonly used diagnostic test is Selenium
homocholic acid taurine (SeHCAT) scan due to its sensitivity, specificity,
safety and low cost. However this test is not frequently used in the algorithm
for the diagnosis of chronic diarrhoea.
Aims & Methods: We aimed to evaluate the usefulness of SeHCAT scan in
evaluating patients with chronic diarrhoea and identify potential risk factors
associated to MAB. We retrospectively reviewed all patients who had
SeHCAT scan between june 2014 and Octuber 2016 in a University Hospital.
BAM was defined as SeHCAT retraction of less than 15%. We collected the
following variables: demographic characteristics, IBS-D Rome III criteria, dura-
tion of diarrhoea (months),stool culture, parasitic investigation of stool speci-
mens, background of comorbid gastrointestinal and other comorbid conditions,
positive HLA-DQ2 and DQ8 haplotype.
Results: 137 patients referred to clinic for chronic diarrhoea underwent SeHCAT
testing over the reviewed period. 42M; 95F, median age 46 y (95% C.I 44.0–50.1),
median BMI 25.34 kg/m2 (95% C.I 24.88–27.00), 70.4% of patients met IBS-D
Rome III criteria, median duration of diarrhoea 48 months (95% C.I 43.10–
59.24). Background of co-morbid gastrointestinal conditions 45.3% (62/136),
other co morbid conditions 55.3% (73/136). History of previous positive stool
culture 1.5% and parasitic investigation of stool specimens 13% (17/131).
Percentage of positive HLA-DQ2 and DQ8 haplotypes were 27.8% (35/126)
and 10.2% (13/127), respectively. SeHCAT test was positive for BMA in
48.9% (67/137): 25.4% (mild 10–15%); 31.3% (moderate 5–10%), and 43.3%
(severe5 5%). Patient characteristics between positive and negative SeHCAT
test were similar (Table 1). Interestingly, patients with SeHCAT test exhibited
longer periods of diarrhoea.
Table 1
Positive
SeHCAT test
Negative
SeHCAT test
Sex (M;F) 30;37 12;58
Age y (median; 95% C.I) 48.00 (44.52–53.4) 40.50 (40.69–49.4)
BMI (median; 95% C.I) 26.84(25.56–28.78) 23.64(23.31–25.98)
Duration of diarrhoea
(months; median; 95%
C.I)
60.00 (43.51–66.95) 24.00 (35.53–58.34)
IBS-D Rome III criteria
(%)
67.2%(45/67) 71.4%(50/70)
Abdominal surgery (%) 34.3%(23/67) 14.3%(10/70)
Cholecystectomy (%) 14.9% (10/67) 0
Gastrointestinal conditions
(%)
41.8%(28/67) 48.6%(34/70)
Other co morbid conditions
(%)
57.1%(36/63) 53.6%(37/69)
(continued)
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Table 1 Continued
Positive
SeHCAT test
Negative
SeHCAT test
HLA-DQ2 Haplotype (%) 23.8%(15/63) 31.7%(20/63),
HLA-DQ8 Haplotype (%) 14.1%(9/64) 6.3%(4/63)
Patients who exhibited MAB (confirmed by SeHCAT test) were treated with
colestyramine, 37.1% (23/67) exhibited partial response, 33.9% (21/67) exhibited
total response, 3.2% (2/67) exhibited no good tolerance, we had no information
in 21%(13/67).
Conclusion: SeHCAT scanning must be considered as a diagnostic tool for the for
the diagnosis of chronic diarrhoea, specially in those patients with long-standing
diarrhoea.
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Introduction: The cause of IBS is uncertain; however, food intolerance shares
many features with this condition. Consumption of FODMAPs has been
shown to induce IBS-type symptoms (Shephard 2008) and clinical trials have
shown that a low FODMAP diet can improve symptoms in this patient group
(Halmos 2014). However, FODMAP intake is not higher in IBS than in health
(Bohn 2013) and it is not proven that the outcome of low FODMAP diet is better
than standard dietary advice in this condition (Bohn 2015). Recent, experimental
research has shown that psychological factors are associated with increased post-
prandial symptoms in IBS patients (Zhu 2013, Van Oudenhove 2016). This study
was designed to assess the relative importance of, and interaction between, psy-
chiatric disease, social stress and diet in the aetiology of IBS in the general
community.
Aims & Methods: This population based study tested the hypothesis that high
FODMAP intake increases the risk of IBS more in individuals with psychiatric
disease and/or life event stress than other members of the community.
Subjects aged 16–74 were randomly selected from five South-Chinese commu-
nities. All subjects completed questionnaires by face-to-face inquiry with inves-
tigators including demographic information, gastrointestinal symptoms (Rome
III), dietary intake (food frequency chart validated in Chinese community), psy-
chiatric disease (HADS), life event stress (LES) and quality of life (SF-8).
Results: From 1999/2115 (94.7%) members of the community that completed
study questionnaires, 117 (5.9%) had IBS by Rome III criteria. The IBS group
ingested less lactose than the "No-IBS" group (P¼ 0.024). Intake of other
FODMAPs was similar in both groups (P¼ 0.346). Compared to the "No-
IBS" group, individuals with IBS had a greater likelihood of depression (OR
1.5 (0.97–2.32); p¼ .05), anxiety (2.84(1.84–4.39), p5 0.001), recent life event
stress (1.5(1.03–2.20); P¼ 0.03) or medical and/or surgical co-morbidity (OR
2.90(1.30–5.45), P5 0.001). The IBS group also had lower quality of life
(P50.001). Joint risk analysis identified high intake of total FODMAP intake
as a risk factors for IBS only in subjects with psychiatric disease and/or life event
stress (table). Similar effects were seen for individual symptoms, in particular
bloating (OR 2.4(1.25–4.60), p5 0.008). Increased risk of IBS was identified
with ingestion of high intake of individual FODMAPs (e.g. fructose, fructans,
lactose) in combination with psychosocial factors, but not with sucrose (control)
in any group.
Table: Joint effects of psychiatric disease, life stress & total FODMAP intake on
relative risk of IBS in community
Psych Disease FODMAP Life Stress IBS No IBS Adjusted* OR p-value
No Low Low 19 (5.1) 356 (94.9) 1.0 –
" " High 23 (6.8) 315 (93.2) 1.2 (0.6–2.4) 0.530
" High Low 14 (3.5) 383 (96.5) 0.6 (0.3–1.3) 0.213
" " High 16 (4.5) 342 (95.5) 0.9 (0.5–1.9) 0.886
Yes Low Low 9 (7.6) 109 (92.4) 1.6 (0.7–3.8) 0.274
" " High 16 (9.5) 152 (90.5) 1.9 (0.9–3.9) 0.094
" High Low 5 (4.9) 97 (95.1) 1.0 (0.4–2.9) 0.932
" " High 15 (10.5) 128 (89.5) 2.3 (1.1–4.8) 0.029
*Adjusted variables: age, sex, marital status, education, job, income, smoking,
drinking, and medical history.
Conclusion: FODMAP intake was similar in IBS and No-IBS groups in the
community (lactose intake was lower in IBS subjects, likely due to avoidance
of dairy products (Long 2017)). However, as expected, IBS patients in the com-
munity had a greater likelihood of psychiatric disease, life event stress and clinical
co-morbidity. Joint effects analysis demonstrated that high FODMAP intake
alone was not associated with abdominal symptoms; however, IBS was more
common in those with a high FODMAP intake and concomitant psychosocial
factors known to increase visceral sensitivity to digestive dysfunction (Zhu
2013).(ClinicalTrials: NCT01286597)
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Introduction: A large proportion of patients with irritable bowel syndrome (IBS)
suffer from anxiety or depression, but the associations with pathophysiological
findings and overall symptom reporting are not clear.
Aims & Methods: We included 772 patients with IBS (Rome III criteria) who
attended a university hospital-based outpatient clinic specialized in functional GI
disorders between 2005 and 2015. The patients underwent examinations to inves-
tigate oro-anal transit time (OATT) and visceral sensitivity (rectal balloon dis-
tension and a lactulose challenge test), and they also completed questionnaires to
assess anxiety and depression (HAD), overall IBS symptoms (IBS-SSS), bowel
habits (BSF), quality of life (IBSQOL), extraintestinal somatic symptoms (PHQ-
12), sense of coherence (SOC), fatigue (MFI), GI-specific anxiety (VSI) and
physical and sexual abuse.
Results: Based on validated HAD cut-off levels (8), anxiety and depression were
present in 55% and 26% of the IBS patients, respectively. More women were
anxious (p5 0.001), but for depression no gender differences were detected
(p¼ 0.76). IBS patients with anxiety or depression were younger (p5 0.001,
p¼ 0.01), and more commonly reported sexual and/or physical abuse
(p5 0.001) than IBS patients without anxiety or depression. The presence of
anxiety or depression did not differ between IBS subgroups based on the pre-
dominant bowel habit (p¼ 0.41, p¼ 0.18). For an overview of comparisons of
data from questionnaires and pathophysiological examinations, see table 1. Both
the presence of anxiety and of depression were associated with reports of more
severe GI and extraintestinal symptoms, GI-specific anxiety, fatigue, and lower
sense of coherence. Regarding pathophysiological examinations, the findings
were more inconsistent. OATT was similar between groups, as was stool form
and frequency. Visceral sensitivity tended to be higher in patients with anxiety,
and depressed patients reported more severe pain during the lactulose challenge
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test. Quality of life (IBSQOL) was reduced for all domains in patients with
anxiety and depression (p5 0.001 for all comparisons).
Table 1: Characterization of IBS patients with anxiety or depression
Variable Anxiety Median P-value Depression Median P-value
IBS-SSS No Yes 283 331 50.001 No Yes 298 330 50.001
VSI No Yes 33 52 50.001 No Yes 39 56 50.001
SOC No Yes 153 124 50.001 No Yes 146 111 50.001
PHQ-12 No Yes 6 9 50.001 No Yes 7 10 50.001
MFI No Yes 14 14 50.001 No Yes 15 19 50.001
OATT (days) No Yes 1.3 1.4 0.67 No Yes 1.3 1.4 0.52
Stool form (BSF) No Yes 4 4 0.93 No Yes 4.0 4.0 0.49
Stool frequency (stools/day) No Yes 1.7 1.7 0.53 No Yes 1.7 1.8 0.36
Lactulose challenge test,
perceived pain (AUC)
No Yes 776 833 0.06 No Yes 705 1710 0.01
Balloon distension, pain
threshold (mmHg)
No Yes 28 24 0.01 No Yes 24 28 0.53
Conclusion: The presence of anxiety and depression seems to clearly potentiate
the already substantial disease burden in IBS patients. However, the association
with other pathophysiological findings is less distinct. This group of patients with
complex and severe symptoms will benefit from a holistic management approach.
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Introduction: Irritable bowel syndrome (IBS) and lactose intolerance may co-exist
and readily cause diagnostic confusion due to similar symptomatology (1,2).
Aims & Methods: This study aim to examine the incidence of lactose intolerance
in healthy controls and in subjects diagnosed with IBS based on Roma III
criteria, as an effort to investigate the association between IBS and lactose intol-
erance. The patient population consisted of individuals between 18 and 80 years
of age who attended between June-December 2013. Patients diagnosed with IBS
based on Roma III criteria comprised the IBS group, and subtypes of IBS.
Control subjects were healthy volunteers over 18 years of age with no IBS-like
symptoms. All participants ingested 25 g of lactose dissolved in 250ml of water
within 5 minutes after 8 hours of fasting, in order to evaluate the lactose intol-
erance via hydrogen breath test (0, 15, 30, 60, 90, and 120 minutes). Additionally,
symptoms arising during the test were assessed.
Results: Of the total 200 participants, 100 (50%) were in IBS and 100 (50.0%)
were in control group. There were 133 females (66.5%), and the mean age was
40.5 12.3 years. Of the total 70 patients (35.0%) with lactose intolerance, 47
(47.0%) were in IBS and 23 (23.0%) were in control groups (p¼ 0.001).
Symptoms related to IBS were more common in participants with lactose intol-
erance in both groups (p¼ 0.001, p¼ 0.001 respectively). A comparison of the
two groups with regard to symptomatology after the test showed the presence of
complaints in 35 (35.0%) patients in IBS group as compared to 24 (24.0%)
subjects among controls (p¼ 0.092). The incidence of lactose intolerance in
patients with IBS subtypes of diarrhea-predominant IBS, constipation-predomi-
nant IBS, mixed IBS, and unspecified IBS were 27 (57.4%), 7 (4.9%), 10 (21.3%),
and 3 (6.4%), respectively, with no significant differences (p¼ 0.161, p¼ 0.124,
p¼ 1.000, and p¼ 0.661 respectively).
Conclusion: A significantly increased frequency of lactose intolerance was found
among IBS patients than in controls. In additional, symptoms associated with
lactose intake occurred at a higher frequency in IBS patient, although the differ-
ence was insignificant.
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Introduction: The population prevalence of Rome IV functional gastrointestinal
disorders (FGIDs) and their cumulative effect on health impairment is unknown.
We sought to address this issue.
Aims & Methods: An Internet-based health survey was completed by 5931 of
6300 general population adults from three English-speaking countries (2100
each from US, Canada, and UK). The survey included questions on demo-
graphics, medication, surgical history, somatisation, quality of life, doctor-diag-
nosed organic GI disease, and criteria for the Rome IV FGIDs. Comparisons
were made between those with Rome IV FGIDs against non-GI and organic GI
disease controls.
Results: The number of subjects having symptoms compatible with a FGID was
2083 (35%) compared to 3421 (57.7%) non-GI and 427 (7.2%) organic GI dis-
ease controls. The most frequently met diagnostic criteria for FGIDs was bowel
disorders (n¼ 1665, 28.1%), followed by gastroduodenal (n¼ 627, 10.6%), anor-
ectal (n¼ 440, 7.4%), oesophageal (n¼ 414, 7%), and gallbladder disorders
(n¼ 10, 0.2%). On average, the 2083 individuals who met FGID criteria qualified
for 1.5 FGID diagnoses, and 742 of them (36%) qualified for FGID diagnoses in
more than one anatomic region. The presence of FGIDs in multiple regions was
associated with increasing somatisation, worse mental and physical quality of
life, greater use of medical therapies, and a higher prevalence of abdominal
surgeries; all p5 0.001, see table. Notably, individuals with FGIDs in multiple
regions had worse somatisation and quality of life scores than organic GI disease
controls.
No
FGID
(healthy)
One
FGID
region
Two
FGID
regions
Three
FGID
regions
Four
FGID
regions
Organic
GI-disease
Number of subjects 3421 1341 493 166 83 427
Mean number of somatic
symptoms
2.8 4.6 5.6 6.3 7.3 4.7
Mean PHQ-12 score 3.3 6 7.5 9.1 10.9 6.3
Mean SF8-MCS QOL 52.1 45.7 42.8 38.6 37.2 47.9
Mean SF8 PCS-QOL 51.9 47.4 44.1 40.2 38.6 43.8
GI-related medication (%) 35% 59% 74% 84% 93% 71%
Abdominal surgery (%) 19% 26% 31% 37% 54% 53%
Conclusion: Roughly a third of the general adult population fulfils diagnostic
criteria for a Rome IV FGID. In a third of this subset multiple GI regions are
involved and this overlap is associated with increased health impairment. Study
Support: The Rome Foundation
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Introduction: Although correlations between features of irritable bowel syndrome
(IBS) have been reported, these were based on between-person rather than
within-person variation. We investigated the longitudinal within-person correla-
tions between features of IBS.
Aims & Methods: We used a longitudinal cohort of 276 IBS patients, who filled
out questionnaires once annually over five years on the following features: gas-
trointestinal (GI) symptom severity (GSRS), quality of life (QOL), GI specific
anxiety (VSI), general anxiety and depression (HADS), coping resources (CRI),
and sense of coherence (KASAM). For each participant, scores were centered on
their own mean, and within-person correlations were computed for all pairs of
features.
Results: Aggregate within-person correlations are shown in figure 1. Within-
person correlations were strong for the triad GI symptom severity, GI specific
anxiety, and QOL (jrj: 0.47 to 0.64). Another set of features was comprised of
general anxiety, depression, coping resources, and sense of coherence (jrj: 0.39 to
0.57). Within-person correlations between the two sets were weak (jrj: 0.00 to
0.37). However, within-person correlations tended towards bimodal distributions
across the population, especially for GI symptom severity and depression (r 0.6
for half of participants, and r –0.4 for the other half).
Conclusion: Here we show that, within individual IBS patients, GI symptom
severity is strongly correlated with GI specific anxiety and QOL, but not with
four other psychological features. The presence of negative within-person corre-
lations in some individuals may imply a lack of relation, but could also signal
long-term causative processes.
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Introduction: Irritable bowel syndrome with constipation (IBS-C) is a chronic
gastrointestinal disorder associated with significant impairment in health-related
quality of life (HRQoL). However, information on the impact of IBS-C symptom
severity on patients’ HRQoL is lacking.
Aims & Methods: This post hoc analysis assessed the burden of IBS-C on HRQoL
according to symptom severity among adult patients meeting the modified Rome
II criteria for IBS based on baseline data from two Phase 3 clinical trials of
linaclotide. HRQoL was evaluated based on the disease-specific Irritable Bowel
Syndrome Quality of Life questionnaire (IBS-QOL) and the EuroQol-5-
Dimension (EQ-5D). The IBS-QOL includes eight subscales (dysphoria, activity
interference, body image, health worry, food avoidance, social reaction, sexual,
relationships), with total and subscale scores calculated on a 0–100 scale and
higher scores indicating better IBS-specific HRQoL. A within-person change of
10 points is considered clinically meaningful. The EQ-5D assesses five dimen-
sions of general health (mobility, self-care, usual activities, pain/discomfort, anxi-
ety/depression), generating an overall index score of between 0 (worst possible
health state) and 1 (best possible health state); a within-person change of 0.05 is
considered meaningful. Symptom severity was assessed during the pre-treatment
period based on the global symptom score (GSS) on a scale of 0–4, where 0¼ no
symptoms and 4¼ very severe symptoms. Data from both trials were pooled and
scores for both instruments were assessed for all patients based on GSS (53 or
3), as well as age (565 or 65 years) and sex.
Results: A total of 1602 IBS-C patients were included for analysis. Compared to
patients with GSS 53, those with GSS 3 had lower HRQoL as indicated by
lower mean IBS-QOL overall and subscale scores, with the greatest differences
seen for body image (15-point difference), dysphoria and health worry (both 13-
point difference) subscales (Table). Patients with GSS 3 also had a lower EQ-
5D index score compared to those with GSS 53 (0.67 vs 0.72) (Table). Women
reported a slightly lower mean total IBS-QOL score compared to men, but had a
notably lower score (14-point difference) on the body image subscale (Table). No
difference in mean EQ-5D score was observed between sexes. IBS-QOL total and
EQ-5D index scores were similar between patients aged 565 and 65 years,
though the younger subgroup generally had lower scores on the IBS-QOL,
including on the food avoidance and sexual subscales (Table).
Table
Pooled Phase 3 trials baseline data
Instrument
Total
Sex Age GSS
IBS-QOL F M 565 65 53 3
n 1595 1437 158 1511 84 92 1503
Total score, mean 61.1 60.8 63.8 60.9 65.0 71.5 60.4
Dysphoria 62.3 62.2 62.8 62.2 64.2 74.6 61.5
Activity interference 68.0 68.2 66.4 68.1 67.1 76.4 67.5
Body image 48.2 46.8 61.0 47.8 55.5 62.0 47.4
Health worry 44.9 44.4 49.3 44.7 49.5 57.3 44.2
Food avoidance 50.1 49.7 54.1 49.6 59.5 59.0 49.6
Social reaction 67.1 66.7 70.0 66.8 71.5 75.5 66.5
Sexual 67.9 67.0 75.5 67.2 80.4 77.8 67.2
Relationships 73.4 73.6 71.6 73.3 75.3 80.6 72.9
EQ-5D
n 1598 1440 158 1513 85 93 1505
Index score, mean 0.68 0.68 0.67 0.68 0.70 0.72 0.67
Conclusion: Among this patient population, IBS-C patients with higher symptom
severity reported greater impairments in HRQoL. These results indicate that
symptom severity may be an important consideration for disease management
and emphasise the need for IBS-C treatments that improve both symptom
burden and HRQoL.
Disclosure of Interest: A. Marciniak: Anne Marciniak is an employee of Allergan
plc and shareholder in Pfizer, Amgen, and Allergan plc.
Y. Mo: Yifan Mo is an employee of Allergan plc.
J. Ma: Julia Ma is an employee of Allergan plc.
J.L. Abel: Jessica L. Abel is an employee of Allergan plc and shareholder in
Allergan plc.
R.T. Carson: Robyn T. Carson is an employee of Allergan plc and shareholder in
Allergan plc.
P1791 HEALTH CARE UTILIZATION FOR ROME IV IRRITABLE
BOWEL SYNDROME; A THREE-COUNTRY SURVEY IN THE
GENERAL POPULATION
N. Jossan1, H. Törnblom1, M. Simrén1, I. Aziz1, O.S. Palsson2,
W.E. Whitehead2, A. Sperber3
1Department Of Internal Medicine And Clinical Nutrition, Institute of Medicine,
Sahlgrenska University hospital, Gothenburg/Sweden
2Dept. Of Medicine, University of North Carolina, Chapel Hill, Chapel Hill, NC/
United States of America/NC
3Ben-gurion University Of The Negev, Faculty of Health Sciences, Beer-Sheva/
Israel
Contact E-mail Address: navkiran.jossan@gu.se
Introduction:No population-based studies have investigated the symptom burden
and healthcare utilization associated with Rome IV defined irritable bowel syn-
drome (IBS).
Aims & Methods: The aim of the current study was to assess these variables in
IBS subjects in the general population. An Internet survey was completed by
6300 individuals distributed equally between United States, United Kingdom and
Canada. Equal sex, age and education distribution across the countries was
ensured by use of quota-based sampling. The survey included questions on demo-
graphics, the Rome IV diagnostic questionnaire, the patient health questionnaire
(PHQ-12), the 8-item Short Form (SF-8) quality of life (QOL) questionnaire,
health care utilization and past gastrointestinal (GI) disease diagnoses by doc-
tors. Respondents with an organic GI disease were excluded from the IBS
population.
Results: From the 6300 individuals who completed the survey, 369 were excluded
due to inconsistent responses, leaving 5931 (49.2% female; mean age 47.4 17.1
years) to be included for analysis (1949 US, 1994 UK, 1,988 Canada). 305 (5.1%)
of these fulfilled Rome IV diagnostic criteria for IBS, after 36 individuals were
excluded due to organic disease. Compared to the non-IBS population, the IBS
population was younger (mean-age 44.7 14.5 years; p¼ 0.004) and predomi-
nantly female (66%; p5 0.001). Apart from reporting more frequent GI
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symptoms, IBS subjects also reported more somatic symptoms; 103 (34%) had
abdominal pain at least 3 times/week, 232 (76%) subjects reported sensation of
bloating at least 3 times/month, and 232 (76%) scored 7 on PHQ-12, indicating
high somatic symptom burden (p5 0.001 for all). They also had poorer self-rated
overall health, more general body pain, and more health-related impairment of
social activities (p5 0.001 for all). See table 1 for details. IBS subjects also
reported more frequent visits to the doctor compared to the non-IBS population,
both for non-GI and GI related problems; 241 (79%) vs. 3133 (56%) reported
visiting a doctor at least once/year for any health issue and 195 (63%) vs. 1144
(20.5%) had seen a doctor for GI problems (p5 0.001 for all). IBS subjects also
reported higher frequency of visits to gastroenterologists, gynaecologists and
surgeons in secondary care; p5 0.001 for all. The use of medication for pain
(both subscribed and over the counter), GI related symptoms, depression and
anxiety was increased amongst subjects with IBS, as was the rate of abdominal
surgery (p5 0.001 for all), appendectomy excluded. See table 1 for details.
IBS,
n¼ 305
n(%)
Not IBS
n¼ 5590
n(%) p-value
GI symptoms
Abdominal pain 43times/week
Bloating43 times a month
103 (33.8)
232 (76.1)
88 (1.6)
849 (15.2)
50.001
50.001
Somatization PHQ-score 7 or
above
323 (76.1) 1381 (24.7) 50.001
Quality Of Life
Overall estimation of health past
4 weeks (SF-8). Very poor/poor
Fair/good Very good/excellent
90 (29.5)
182 (59.7)
33 (10.8)
273 (4.9)
3026 (54.1)
2291 (41.0)
50.001
Bodily pain past 4 weeks (SF-
8)None/very mild Mild/moder-
ate Severe/very severe
41 (13.4)
168 (55.1)
96 (31.5)
3567 (63.8)
1707 (30.5)
316 (5.6)
50.001
Limitation in social activities due
to physical health or emotional
problems past 4 weeks (SF-8)
Not at all Very little/somewhat
Quite a lot/could do no social
acticity
53 (17.4)
144 (47.2)
108 (35.4)
3084 (55.2)
2021 (36.2)
485 (8.7)
50.001
Frequency of doctor visits At
least once/year
241 (79) 3133 (56) 50.001
Medication use
For constipation For diarrhea
Pain, prescribed Pain, over
the counter Gas/bloating
Anti-depressive Anti-anxiety
76 (24.9)
62 (20.3)
122 (40)
114 (37.4)
67 (22.0)
107 (35.1)
92 (30.2)
274 (4.9)
163 (2.9)
775 (13.9)
972 (17.4)
249 (4.5)
669 (12.0)
557 (10.0)
50.001
50.001
50.001
50.001
50.001
50.001
50.001
Surgery
Cholecystectomy
Appendectomy
Hysterectomy Other
abdominal surgery
52 (17.9)
38 (12.5)
31 (10.2)
53 (17.4)
412 (7.4)
553 (9.9)
334 (6.0)
399 (7.1)
50.001
0.18
0.005
50.001
Conclusion: Individuals fulfilling the Rome IV criteria for IBS in the general
population have increased GI and non-GI healthcare utilization in primary
and secondary care, excess non-GI symptom burden and impaired QOL.
[Support: Rome Foundation]
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Introduction: Ischaemic colitis (IC) is the most common vascular disease of the
colon, although its exact pathophysiological mechanisms remain unclarified.1
Aims & Methods: The aim of this study was to evaluate routine coagulation
parameters associated with vitamin K in patients with IC and to compare
them with a group of controls (individuals with known predisposing factors
for IC but without evidence of the disease). This study was carried out in the
context of a study evaluating thrombophilia among IC patients. The present
study used the same study groups as the latter.2 History of malignancy, systemic
inflammation, liver disease-cirrhosis or use of anticoagulants were exclusion cri-
teria for both patients and controls. The control group was using more antihy-
pertensive drugs compared to the patients’ group, while no difference was
observed in any other drug category. Fifty-six cases of IC (admitted from
September 2007 until June 2011 at the tertiary Department of
Gastroenterology in central Greece) and 44 controls (subjects admitted for
upper gastrointestinal bleeding, choledocholithiasis, and colon polyps) with
known predisposing factors but no evidence of IC were evaluated. Coagulation
indices measured were: prothrombin time (PT), activated partial thromboplastin
time (aPTT) and lupus anticoagulant (LA). Venous blood collected from all IC
patients and controls at the second or third day of hospitalization (1–3 days from
the onset of symptoms).
Table 1: Coagulation tests in IC and control groups.
Parameter IC group Controls Normal range Units p value
PT 14.5 [13.7–15.7] 13.1 [12.3–13.9] 9.0–14.0 sec .0005
INR 1.15 [1.09–1.22] 1.02 [0.96–1.07] 0.85–1.15 .0005
aPTT 28.7 [26.7–31.7] 26.4 [24.9–28.6] 25.0–35.0 sec .0005
LA 1.05 [0.97–1.13] 1.04 [1.03–1.10] 0.8–1.22 .948
Results: Significant differences were recorded in the levels of PT (median: 14.5 vs
13.1 sec, p¼ .0005) and aPTT (median: 28.7 vs 26.4 sec, p¼ .0005) between
patients and controls, respectively. Prolongation over the upper limit of
normal of PT (414 sec) was most common in IC patients, 67.9% vs 18.2%
(p¼ .0005) as well as the prolongation of aPTT (435 sec), 12.2% vs 6.2%
(p¼ .469). The presence of LA was characterized as weakly present in 5 of 6
patients with the aPTT prolongation (9.6%, normalized LAC ratio: 1.2–1.5) and
moderately present in 1 patient (1.9%, normalized LAC ratio: 1.5–2.0).
Conclusion: Prolongation of PT and aPTT, possibly indicating a chronic Vitamin
K deficiency state, may be implicated in the pathophysiological mechanisms of
IC.
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Introduction: Ischaemic colitis (IC) encompasses a number of clinical entities
resulting in insufficient blood supply to the colon. The incidence of adverse
outcome in patients with IC remains high.
Aims & Methods: We conducted a multicenter retrospective cohort study includ-
ing consecutive patients with IC diagnosed between January 2013 and December
2016, according to the Modified Brandt and Boley criteria (clinical, colonoscopy,
pathology consistent with IC and negative culture). The following data were
collected: age, sex, clinical symptoms, comorbidities, organ failure, laboratory
(hemoglobin, platelet number, leucocytes, C-reactive protein, creatinine, sodium,
potassium, arterial pH and arterial lactate and LDH), endoscopic and CT find-
ings, surgery and death. Logistic regression was used to study association with
poor outcomes - surgery and overall mortality.
Results: In this study, 349 patients were registered and 193 fulfilled the prede-
termined criteria: 121 (62.7%) were females and mean age was 72-years-old
(IQR: 23–94). At admission a total of 165 (85.5%) patients presented with hema-
tochezia, 112 (58%) with abdominal pain, 82 (42.5%) with diarrhea, 27 (11.9%)
with shock and 7 (3.6%) with occlusion. Twenty three (11%) required surgery.
In-hospital, 30-day and overall follow-upmortality rates (up to 205 weeks) were
7.3%, 6.7% and 14%, respectively. On multivariate analysis, surgery was inde-
pendently associated with shock (OR: 4.8; p¼ 0.011) intestinal occlusion(OR:
3.5; p¼ 0.046), and arterial lactate (OR: 1.3; p¼ 0.012). On univariate analysis,
hemoglobin, hematocrit, C-reactive protein, LDH, the number of risk factors,
arterial pH, and the need of red blood support IQ were significantly (p5 0.05)
associated with in-hospital and 30-day mortality. Creatinine was also associated
with intra-hospital mortality. The variables that correlated independently in the
multivariate analysis with in-hospital mortality were male gender (OR:4.5;
p¼ 0.03), and arterial pH (OR: 0.001; p¼ 0.036) and with 30-day mortality
was the need of red blood cells support (OR: 2.1; p¼ 0.0086).
Conclusion: In our cohort of predominant elderly patients, arterial pH, shock and
lactate were significantly associated with need of surgery. Arterial pH on admis-
sion was also independently associated with in-hospital mortality. Early identi-
fication of these factors can anticipate decision management in this context and
select the best care level for each patient.
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Introduction: Although most cases of colon ischemia (IC) are mild and self-limit-
ing, when severe it implies high mortality rates. We aimed to evaluate the risk
predictive value of the classification of disease severity proposed by American
College of Gastroenterology (ACG) guidelines (2015), created to provide a man-
agement algorithm for these patients and select the level of care.
Aims & Methods: A retrospective multicenter study was conducted on adult
patients with definite CI (clinical, colonoscopic, pathologic and culture criteria),
between 2013 and 2016. Data was collected on clinical presentation, comorbid-
ities, organ failure, management and outcome. Each case was classified according
to ACG guidelines after assessment of the number of risk factors (gender, systolic
blood pressure 590mm Hg, heart rate 4100 beats per min, abdominal pain
without rectal bleeding, BUN4 20mg/dl, Hgb5 12 g/dl, LDH4 350 U/l, serum
sodium 5136 mEq/l (mmol/l), WBC 415 109/cmm). Patients were then clas-
sified as mild (0 risk factors (RF)), moderate (1–3 risk factors), and severe (more
than 3 risk factors or any of the following: peritoneal signs, pneumatosis or
portal venous gas, gangrene on colonoscopic examination and pan-colonic or
isolated right-colon ischemia involvement on imaging by colonoscopy or com-
puted tomography).
Results: 349 cases with the clinical diagnosis of IC were analyzed.193 patients met
the inclusion criteria of definitive diagnosis of CI (62.7% females; mean age 72
years (13). ACG classification of mild, moderate and severe disease was attrib-
uted respectively to 21% of patients (0 intra-hospital deaths), 45% (2 deaths) and
34% (12 deaths). The number of ACG RF was: 40% with 0 RF, 8% with 1, 9%
with 2, 15% with 3, 16% with 4, 8% with 15%, 4% with 6 and 1% with 7. No
patient with 0 or 1 RF died. Only 1 patient with 2 RF died. The remaining 13
deaths were verified with at least 3 RF. The univariate analysis revealed a sta-
tistical correlation between RF and intra-hospital or 30-day mortality as well as
the need for surgery (mean¼ 4.06, sd¼ 1.85). ACG classification presented high
predictive accuracy for in-hospital and 1-month mortality with an AUROC of
0.78 and 0.79 (p5 0.001), respectively. For a cutoff of 2 ACG RF, the sensibility
(SE) for death was 100%, specificity (SP) 52%, with a positive predictive value
(PPV) of 14% and negative predictive value (NPV) of 100%. For 3 ACG RF the
results were: SE 93%, SP 61%, PPV 16% and NPV 99%. 3 or more risk factors
had an odds ratio of 20.2 (confidence interval (CI) 2.59–158) for intra-hospital
mortality and 18.42 for 1-month mortality (CI 2.34–144).
Conclusion: No patient in this cohort with less than 2 ACG RF died, suggesting
that the ACG classification as mild disease may include 0 and 1 risk factor
without changing the prognosis. Short-term mortality risk increases significantly
in patients with at least 3 ACG RF.
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Introduction: Drug pricing and third party payer coverage exert a profound effect
on access to prescription therapies in patients with irritable bowel syndrome with
diarrhea (IBS-D). We performed a cost-effectiveness analysis to assess the trade-
offs associated with treating IBS-D patients with a tricyclic agent (TCA) or
rifaximin.
Aims & Methods: We constructed a decision analytic model evaluating three
treatment strategies for IBS-D in the United States healthcare system: first-line
therapy with TCA-only, first-line rifaximin followed by second-line TCA for
nonresponders, and first-line TCA followed by second-line rifaximin for nonre-
sponders. This model accounted for direct and indirect costs of therapy
(Medicaid NADAC database and Healthcare Blue Book) and work-productivity
loss (published literature and US Bureau of Labor) with a 3% per annum dis-
count rate. Rifaximin was administered in 4-month treatment cycles based on
published clinical experience. Responder and discontinuation rates were derived
from clinical trial data, and validated health utility values were assigned to
terminal health states. Base-case analysis was performed to determine incremen-
tal cost-effectiveness ratios (ICER) for both rifaximin strategies. Threshold ana-
lysis assessed rifaximin pricing at contemporary willingness-to-pay (WTP) levels
per quality adjusted life year (QALY). Appropriate sensitivity analyses were
conducted. Analysis was performed with a 1-year time horizon from societal
and payer perspectives.
Results: Based on the average acquisition cost of rifaximin (USD $29.78/pill),
second-line rifaximin could be cost-effective from a societal perspective (Table 1).
However, at contemporary WTP thresholds neither rifaximin strategy was cost-
effective from a payer perspective despite greater effectiveness than TCA alone.
Dependent on WTP, a 12–62% price reduction (USD $18.46-$26.34/pill) would
enable the first-line TCA followed by second-line rifaximin to be more cost-
effective than a TCA-only strategy (Table 1). An 84–88% price reduction
(USD $3.53-$4.71/pill) would enable first-line rifaximin followed by second-
line TCA to be more cost-effective than TCA-only, though first-line TCA fol-
lowed by second-line rifaximin would remain the more cost-effective strategy.
Our model was robust in tornado analysis and most influenced by rifaximin
treatment interval. Sensitivity analysis on rifaximin retreatment interval suggests
that current pricing may be based on longer retreatment intervals than those
found in clinical literature (Fig 1a). Sensitivity analysis with a lower TCA respon-
der rate could enable first-line rifaximin to be the preferred strategy, albeit at a
reduced price (Fig 1b).
Conclusion: Rifaximin is an effective therapy for IBS but is less cost-effective than
TCA as currently priced. We propose an evidence-based pricing strategy which
would maximize the cost-effectiveness of rifaximin in IBS-D patients.
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Introduction: Colonoscopy has been widely used for diagnostic and therapeutic
purposes. Although the incidence is very low, perforation is one of the most
serious complications. It is important to decide whether to try endoscopic clip-
ping or to perform prompt surgical management.
Aims & Methods: We retrospectively reviewed charts of all patients who experi-
enced colonoscopy-associated perforation in a single center between May 2009
and July 2015, and totally 45 patients were enrolled.
Table: The risk factors surgical treatment in colonoscopy-associated perforation
variable
Surgery group
(N¼ 18)
Conservative group
(N¼ 27) P value
Age(year) 66 67 .688
Sex(M/F) 10/8 14/13 .807
Purpose of colonoscopy .000
Therapeutic 9 27
Diagnostic 9 0
Location of perforation .002
Rectum 2 6
Sigmoid 14 7
Descending 0 1
Transverse 2 3
Ascending 0 10
Endoscopic clipping .007
Yes 8 23
No 10 4
Results: Diagnostic cases in purpose, sigmoid colon in location and non-clipping
status were significantly more common in surgery group than conservative group
(Table). Endoscopic clipping was performed in 31 cases (immediate; 23, delayed;
8), and immediate clipping group had significantly lower rate of operation
(p¼ 0.013) and better clinical outcome (duration of antibiotics: p¼ 0.006, hospi-
tal stay: p¼ 0.001). Among 18 surgical cases, 13 patients had primary closure and
5 patients had complex surgery (2; segmental resection, 3; Hartmann’s proce-
dure). The early (524 hr) surgical management significantly decreased the pos-
sibility of complex surgery (p¼ 0.002), as well as had better clinical outcomes
such as duration of antibiotic use, fasting time and length of hospital stay
(p¼ 0.003, p¼ 0.001, p¼ 0.005, respectively). In therapeutic cases, all five perfo-
rated patients who had surgery within 1 day could be managed by simple primary
closure, but all four patients who had surgery after 1 day required complex
surgery.
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Conclusion: In colonoscopy-associated perforation, immediate endoscopic clip-
ping decreases the possibility of operation and shows better clinical outcomes,
and early surgical approach decreases complex operation rate. Especially, early
operation need be considered in diagnostic perforation regardless of endoscopic
clipping.
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Introduction: Despite diagnostic criteria and effective management options for
functional gastrointestinal disorders (FGID), confidence in managing these dis-
orders in primary care is low, and long waiting lists for specialist care are
common. New models which efficiently transfer specialist-held expertise to pri-
mary care practitioners is needed.
Aims & Methods: We aimed to explore and describe the patient and primary
healthcare provider (PHCP) experience of a novel non-specialist-dependent algo-
rithm-based approach to the diagnosis and management of FGID (ADAM-
FGID). Consecutive patients triaged to the ‘routine waitlist’ of an Australian
public hospital Gastroenterology Department over 2 years, with non-specific
gastrointestinal symptoms (no alarms) were randomised to waitlist control or
the algorithm (2:1). Algorithm patients were screened for organic disease with
an alarms-based questionnaire and panel of routine blood/stool tests. When
patients had clinical alarms or abnormal tests, data were reviewed by a gastro-
enterologist and, if appropriate, prompt gastroenterologist appointment offered.
All others were classified using Rome III criteria. and received a letter explaining
their FGID diagnosis and dietary/psychological management options. Waitlist
control patients were not screened. All participants completed follow-up surveys
at 6, 26 and 52 weeks. Referring doctors of the algorithm group were sent a
feedback survey at study completion.
Results: 89 participants were screened (42 years [SD 14], 62% female). 35 had
clinical alarms warranting gastroenterologist review and 45 were diagnosed with
FGID (9 excluded). At 6 week follow up: 35/36 FGID respondents had read the
diagnostic/management letter, and most (n¼ 25) found it useful (17 useful, 8
partially useful). Few discussed it with their PHCP (n¼ 13), yet most (n¼ 28)
commenced management (n¼ 33 by 12 months). Dietary management options
were preferred over psychological therapies (n¼ 30 vs n¼ 16) (p¼ .001), as were
do-it-yourself options above therapist consultation. 61% (n¼ 22) of patients saw
symptom improvement at 6 weeks, (18/21 at 12 months). 2 did not accept the
diagnosis, and 3 consulted a specialist privately. 19/36 participants had no con-
cerns at 6-week follow-up (19/21 at 12 months). Common concerns included
symptom persistence (6-wk n¼ 10, 12-mth n¼ 10) and fear of missed pathology
(6-wk n¼ 4, 12-mth n¼ 4). Most respondents (74%, 46/62) found the approach
acceptable (FGID group: acceptable 12/36, moderately acceptable 10/36; Screen
Fail Group: acceptable 20/26, moderately acceptable 4/26). Others expressed
dissatisfaction with the healthcare system (n¼ 4), diagnosis (n¼ 3), screening
questionnaire (n¼ 1) and lack of improvement in symptoms (n¼ 1). All respond-
ing PHCPs (23/80; 14 FGID group, 9 screen-fail group) found the approach
acceptable (13 acceptable, 12 moderately acceptable).
Conclusion: An algorithm-based approach to the diagnosis and management of
FGIDS, which does not rely on specialist input is feasible, acceptable and effec-
tive. A larger scale randomised controlled trial of this new clinical pathway for
the diagnosis and management of FGIDs, in primary care is warranted.
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Introduction: Colonoscopy every 5 years, starting at the age of 40 years, is con-
sidered the first-choice screening strategy in first degree relatives (FDR) of
patients with colorectal cancer CRC, as these individuals are considered at
higher risk of developing CRC than average-risk individuals. However, this
practice has a low adherence and remains opportunistic. Recently, it has been
suggested that annual fecal immunochemical testing (FIT) might be a valid alter-
native to colonoscopy in this setting. However, there are scarce data regarding
cost-effectiveness of these strategies from the perspective of healthcare services.
Aims & Methods: This study was aimed to compare the cost-effectiveness of
annual FIT and colonoscopy every 5 years, to reduce CRC mortality, in FDR
of patients with CRC. A Markov model was constructed to simulate the efficacy
and cost of annual FIT (cut-off 10mg Hb/g feces) or colonoscopy every 5 years of
Abstract No: P1796
Table 1: Comparative cost-effectiveness of treatment approaches with and without rifaximin in irritable bowel syndrome with diarrhea (IBS-D)
Strategy
Total cost
(USD/yr)
Total
effectiveness
(QALY gained)
Incremental
cost (USD)
Incremental
effectiveness
(QALY)
ICER
(USD/QALY gain)
Societal perspective
TCA only $4,355 0.017
Rifaximin as first-line for IBS-D $7,608 0.020 $428 þ0.0029 $1,138,254 (dominated*)
Rifaximin as second-line for IBS-D $4,783 0.022 $3,252 þ0.0052 $82,375
Payer perspective
TCA only $728 0.017
Rifaximin as first-line for IBS-D $4,177 0.020 $894 þ0.0029 $1,207,136 (dominated*)
Rifaximin as second-line for IBS-D $1,622 0.022 $3,449 þ0.0052 $171,850
*first-line rifaximin strategy was dominated (less effective and more expensive) than a second-line rifaximin strategy at all price points. ICER¼ incremental cost
effectiveness ratio; QALY¼quality adjusted life year; TCA¼ tricyclic antidepressant; IBS-D¼ irritable bowel syndrome with diarrhea; USD¼US dollar.
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previously unscreened FDR, starting at age 40 years and ending at age 75. A
50% adherence for each strategy was assumed. The model was adjusted to the
incidence of CRC in Spain and real prevalence of advanced adenoma and CRC
in the familial-risk population (http://dx.doi.org/10.1371/journal.-
pmed.1002008.g001). The main outcomes were quality-life-year (QALY) gained
compared with no screening, lifetime burden of colonoscopy, lifetime number of
colonoscopy complications, and the incremental cost-effectiveness ratio (ICER).
We applied a willingness-to-pay threshold of E25,000 per QALY gained. Data
from a prospective EuroQoL survey carried out on 920 Spanish patients at
different disease stages were used for QALY measurement. Sensitivity analysis
was performed to evaluate the robustness of the model.
Results: In a hypothetical cohort of 10,000 asymptomatic FDR, annual FIT and
colonoscopy every 5 years were cost-effective over no screening. Taking no
screening as comparator, ICER for annual FIT and colonoscopy every 5 years
was 1989 and 4472 euros/QALY, respectively. Compared to no screening, annual
FIT and colonoscopy every 5 years reduced CRC mortality by 59% and 81%,
respectively. The annual FIT strategy saved 33% of colonoscopies and was
associated with a lower number of complications compared to colonoscopy
every 5 years. The results were robust in sensitivity analyses.
Conclusion: Assuming a 50% adherence, annual FIT is less costly than colono-
scopy every 5 years for CRC screening and reduces mortality in the familial-risk
population. These data suggest that FDR of patients with CRC could be
included in organized nationwide FIT-based screening programs.
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Introduction: Faecal occult blood test (FOBT) is a non-invasive and easily per-
formed test which has demonstrated to reduce CRC incidence and mortality in
the populations. Faecal calprotectin (FCP) has good evidence for detecting
inflammatory bowel disease but its value in CRC and adenoma detection in
the symptomatic population is less well studied. Most patients with symptoms
have benign pathology but in an effort to detect most cancer or pre-cancerous
lesions, almost all patients undergo colonoscopy.
Aims & Methods: To evaluate and compare the diagnostic accuracy of the com-
bination of FOBT plus FCP versus each test alone in symptomatic patients
referred for diagnostic colonoscopy. A total of 171 patients who completed
colonic investigations and returned stool samples, were prospectively recruited
and included in the final analysis. FOBT was performed by SENTi FIT 270 test
(Sentinel Diagnostics, Milan, Italy) and FCP by the EliA Calprotectin immu-
noassay (Thermo Fisher Scientific, Waltham, United States). Reference cut-off
levels for abnornal test were 117 ng/ml for FOBT and 50 mg/g for FCP respec-
tively. The diagnostic accuracy of FOBT and FCPwere evaluated by a logistic
regresion model. CRC, advanced adenoma, IBD and angiodysplasia were con-
sidered as relevant pathology. Positive and negative predictive values, sensitivity
and specificity were calculated. MedCalc was used for the ROC curve analysis.
Results: 171 patients (42.7% female; median age 62 years, IQR: 51–68) were
included. 37 (21.6%) had relevant colonic pathology. The most frequent indica-
tions for colonoscopy were previous episode of rectal bleeding in 71 (42%)
patients, change of bowel habits in 28 (16%) and anaemia in 22 (13%).
Diagnostic accuracy of FOBT, FCP and combination of both are summarized
in table 1.
PPV: predictive positive value; NPV: predictive negative value
Test Normal test Abnormal test PPV NPV Sensitivity Specificity
FOBT 131 40 55% 89% 59% 89%
FCP 81 90 30% 88% 73% 53%
Combination 114 57 56% 96% 86% 81%
AuROC curves for relevant colonic pathology were 0.777 (95% CI: 0.708–0.837;
P5 0.0001) for FOBT, 0.692 (95% CI: 0.617–0.760; P¼ 0.0005) for FCP and
0.848 (95% CI: 0.785–0.898; P5 0.0001) for combination of both tests respec-
tively. Combination of both test have a significant better diagnostic accuracy
compared to either test alone (P¼ 0.043 vs FOBT and P¼ 0.002 vs FCP) with
a higher NPV. No significant difference was observed between FOBT and FCP
(P¼ 0.221).
Conclusion: Our model based on combination of FOBT and FCP has a better
diagnostic accuracy performance compared to each test alone for the detection of
relevant colonic pathology. Because of high NPV, performing FOBT and FCP in
symptomatic patients before colonoscopy could be a feasible strategy in order to
avoid unnecessary procedures
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Introduction: Procedural sedation is considered an integral part of gastrointest-
inal endoscopy in many countries. The use of sedation does, however, vary
internationally and can present patient safety concerns. It has been questioned
whether trials assessing patient safety in endoscopy can be generalized worldwide
given variations in sedation practice and adverse events rates.
Aims & Methods: We conducted an international survey to examine procedural
sedation practices and the incidence of adverse events (AEs) during procedural
sedation in France, Germany, Italy, UK, and USA. Data collection from provi-
ders (nurses, physicians, and anaesthesiologists) was via online surveys.
Respondents were screened to assure that they had the expertise and experience
to complete the survey. The survey covered topics such as guidelines, sedation
agents, monitoring, patient throughput, and AE incidence, treatment, and out-
comes as defined by World SIVA1. Data analysis took a global approach with
subgroup analysis by location.
Results: 101 providers completed the survey, with 20 responses per country,
excepting the USA with 21. More than 62% of respondents were gastroenterol-
ogists and anaesthesiology nurses. The main sedation agents reported employed
were midazolam (93 respondents), propofol (90), fentanyl (75), ketamine (57),
and meperidine (15). Respondents from France reported higher ketamine and
lower fentanyl use than other countries (p¼ 0.03). Standard of care monitoring
was generally reported to be comprised of pulse oximetry plus blood pressure
and/or heart rate. Capnography use varied by country, and was standard of care
for 46% of respondents (ranging from 15% in Italy to 67% in the US). The most
desired property of a monitoring modality across all countries was one that
‘‘provides an early warning of patient compromise’’. ‘‘Data displays and
alarms relat[ing] to clinical events’’ was ranked second globally and in all coun-
tries apart from Italy. All respondents reported experience with patient safety
issues in the last year, with hypotension the most common (67), followed by mild
desaturation (63), bradycardia (63) and prolonged desaturation (52). AE inci-
dence was influenced by monitoring modalities used. Among German respon-
dents, for example, 7 of 11 who did not use capnography as standard of care
reported severe oxygen desaturation events, compared with versus 0 of 9 who
routinely use it (p¼ 0.005). Providers also differed in their reported adverse event
incidence. Gastroenterologists most commonly reported mild oxygen desatura-
tion to occur, while anaesthesiologists and nurses reported hypotension to be the
most common AE experienced during procedural sedation (Table).
Conclusion: Clinical sedation practices are relatively consistent across countries,
as are the occurrence of adverse events. Pulse oximetry monitoring is almost
universally used during sedation, while capnography use is more variable.
Sedation monitoring that provides an actionable early warning of patient com-
promise remains a priority.
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Introduction: The success of colonoscopy depends on the quality of the bowel
preparation, which is estimated to occur in as many as 25% of colonoscopy
procedures. The MOTUS GI Pure-VuTM System (Tirat Carmel, Israel) is an
FDA cleared device designed to improve visualization in an inadequately pre-
pared colon by facilitating intra-procedural cleaning.
Aims & Methods: This study aims to evaluate the performance of the Pure-Vu
System in cleansing a poorly prepared colon, assess the system’s usability, patient
satisfaction and safety. Forty-seven cases were planned to be enrolled at three
clinical sites, of which 32 had completed the study so far. Pure-Vu was used in
subjects with a partially prepped colon after 2x10 mg Bisacodyl, diet restrictions
(no dried fruit, seeds or nuts) starting 2 days before the procedure and a 24-hour
clear liquid diet prior to the colonoscopy. Study endpoints were: (1) Safety, 2)
Improvement of colon cleansing level as per the Boston Bowel Preparation
Scoring (BBPS) when comparing before and after Pure-Vu use, (3) Pure-Vu
usability via questionnaire and (4) Patients’ satisfaction via questionnaire.
Results: Thirty-two subjects (41% males), aged 31–74 years and with a mean
BMI of 26 3.9. were included in the analysis. Indications for colonoscopy
included family history of CRC (56%) and polyp surveillance (44%). No serious
adverse events were reported. The Pure-Vu significantly increased the number of
subjects with an adequate cleansing level (BBPS4¼ 2 for all 3 colon segments)
from 25%; CI 95% [11%, 43%] at baseline to 100%; CI 95% [89%, 100%] after
Pure-Vu and the cecum was reached and visualized in all study cases (i.e., 100%;
CI 95% [89%, 100%]). Mean post-treatment BBPS score was 8.5 0.8 vs.
3.38 2.3 prior to Pure-Vu use. Physicians were satisfied with the device’s general
use of ease and found it in most cases acceptable to good or excellent to insert
and to angulate the colonoscope. No major difficulties were experienced when
performing polypectomy. Thirty of 32 (94%) patients reported that they would
recommend Pure-Vu to theirs friends and family members who need a colono-
scopy. Thirty (94%) of the patients found the overall bowel preparation as very
tolerable (55%) or acceptable (39%). Seventy-nine percent of patients who had a
previous colonoscopy procedure reported that the Pure-Vu bowel preparation
was more tolerable as compared to their previous colonoscopy preparation and
14% of the patients reported it to be about the same.
Conclusion: The Pure-Vu System was found to be safe and effective in cleaning
inadequately prepared colons to an adequate level for a thorough exam. Based
upon these early results it is expected that the device may play a role in patients
with an inadequately prepared colon which may help to improve the overall
quality of colonoscopy.
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Introduction: Recently, the European Society of Gastrointestinal Endoscopy
(ESGE) published guidelines on key performance measures for colonoscopy
(1). We analyzed feasibility of monitoring these measures and whether the pro-
posed standards were met in the Polish Colonoscopy Screening Program (PCSP).
Aims & Methods: We analyzed database records for 40,644 participants aged 55
to 64 years, who between 2014 and 2015, underwent screening colonoscopy in 24
centers of population-based PCSP. We used the ESGE guideline definitions to
calculate values of all seven key performance measures. We compared key per-
formance measures within the PCSP against proposed standards on the program
and center level. Data on adequacy of bowel preparation was routinely assessed
with the Boston Bowel Preparation Scale, whereas data on patient experience
with the validated Gastronet questionnaire (2). Data on complication rates were
collected from the National Health Fund database and Personal Identification
Number Registry.
Results: Overall, on the program level, all minimum standards for colonoscopy
key performance measures were met. Rate of adequate bowel preparation was
92.1% for the whole program, ranging 80.9–99.2% per individual center, with 7
centers (29.2%) not reaching minimum standard of 90% and 9 centers (37.5%)
reaching the target standard of 95%. Cecal intubation rate was 97.4% (range
93.4–99.4%), with all centers reaching minimum standard of 90% and only one
center not reaching target standard of 95%. Adenoma detection rate was 29.9%
(range 19.1–39.1%), with 7 centers (29.2%) not reaching minimum standard of
25%. Appropriate polypectomy technique was applied in case of 90.9% 6 to
9mm polyps (range 64.3–100%) with only 2 centers not reaching minimum
standard of 80% and 48.2% of 4 to 5mm polyps (range 0–100%) with only 6
centers reaching minimum standard of 80%. Target standard of 90% was
reached in 15 centers for polyps 6 to 9mm in diameter and only 2 centers for
polyps 4 to 5mm in diameter. For the whole program, 7-day hospitalization rate
after screening colonoscopy was 0.3% (122 cases) and 30-day all-cause mortality
was 0.02% (9 cases). Gastronet questionnaire coverage is assumed to be 100%,
however the response rate was 65.3% (range 7.6%-81.8%), with painful colono-
scopy rate of 19.2%. No minimum standard is set, however target standard of
90% of procedures with measured patient’s experience was not met. Appropriate
post-polypectomy surveillance, based on the European guidelines, was proposed
in 95.4% of cases (range 84.9–99.7%). Target standard of 95% was met in 15
centers, the minimum standard is not set.
Conclusion: Monitoring ESGE performance measures for colonoscopy is feasible
in colonoscopy programmatic screening setting. 6 of 7 performance measures
were easy to monitor with PCSP database, however monitoring complications
needs further development to avoid extracting data from external registries.
PCSP meets proposed minimum standards on program level, however some
centers need additional interventions to meet the quality standards. Applying
appropriate polypectomy technique for polyps ranging 4 to 5mm in diameter
Abstract No: P1801
Table: Most commonly reported adverse events by provider
Rank Anaesthesiologist Sedation Nurse Gastroenterologist
1 (Most frequent) Hypotension Hypotension Mild desaturation (short)
2 Bradycardia Bradycardia Bradycardia
3 Tachycardia Tachycardia Tachycardia
4 Mild desaturation (short) Mild desaturation (short) Hypotension
5 Airway obstruction Apnoea (short) Mild desaturation (prolonged)
6 Mild desaturation (prolonged) Mild desaturation (prolonged) Hypertension
7 Apnoea (short) Hypertension Severe desaturation
8 Hypertension Failed sedation Airway obstruction
9 Prolonged apnoea Allergy Allergy
10 Failed sedation Airway obstruction Apnoea (short)
11 Allergy Prolonged apnoea Failed sedation
12 Severe desaturation Severe desaturation Prolonged apnoea
13 Cardiac arrest Cardiovascular collapse Cardiovascular collapse
14 Cardiovascular collapse Cardiac arrest Seizure
15 (Least Frequent) Seizure Seizure Cardiac arrest
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is currently the biggest issue in PCSP and further training is needed to reach
minimum standard for this performance measure.
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Introduction: Treatment of chronic idiopathic constipation is somewhat empiric,
but based on step-wise approach[1]. If first-line conservative treatment (lifestyle
advice and laxatives) do not relieve symptoms sufficiently, secondary approaches
with prokinetic or secretagogue drugs are used before considering hospital-based
care (biofeedback, psychosocial support, transanal irrigation (TAI), surgery).
Nevertheless, patients are often dissatisfied with care[2] and fail to progress to
adequate levels of therapy. The 5-point Failure to Provide Adequate Relief (F-
PAR) scale[3] was developed to facilitate the recognition of when to move from
one step to the next.
Aims & Methods: The aim of this study was to validate F-PAR in a tertiary clinic
setting. We studied 403 consecutive consultations of 331 patients (262 women,
mean age 41) in our specialist clinic. All fulfilled Rome III/IV diagnostic criteria
for chronic constipation. Immediately prior to each face-to-face clinical assess-
ment by one of 2 experienced physicians, participants completed the F-PAR
scale; patients were seen blind to the F-PAR result. Standard clinic assessment
was undertaken to identify efficacy of the current management as the gold
standard.
Results: Of the 403 consultations, clinical assessment identified inadequate relief
with current therapy was identified in 200. Neither duration nor type of treat-
ment were correlated with relief. The table stratifies, by clinical gold standard,
each item of the F-PAR and in the lower panel the total number of F-PAR items
replied to positively.
Table: Positive F-PAR items correlated to clinical assessment of relief
Adequate relief
(Clinical)
n¼ 203
Inadequate
relief (Clinical)
n¼ 200
Bowel frequency inadequate 5 71
Strain most occasions 6 89
Stool hardness 3 21
Onset other symptom 2 57
Current therapy poor tolerable 8 80
0 FPAR replies 187 1
1 FPAR replies 10 41
2 FPAR replies 4 67
3 FPAR replies 2 22
4 FPAR replies 0 8
5 FPAR replies 0 9
Conclusion: Our findings showed that the F-PAR with only five questions can be
considered sufficient to provide clinical evidence of treatment failure. The use of
standardized process to investigate the efficacy of treatment may reduce the time
and improve the quality of managing for the chronic constipation patients.
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Introduction: Transanal irrigation has become a key therapeutic modality in
managing patients with neurological diseases who experience constipation and/
or faecal incontinence. Such neurogenic bowel dysfunction (NBD) complicates
over three quarters of patients with spinal cord injury (SCI) and multiple sclerosis
(MS). Approximately 60% of patients who start TAI continue with long-term
treatment. A common cause of treatment cessation is impaired hand (1). Training
of the patient is a key aspect of TAI therapy and requires patients to be willing to
manage their health themselves: self-efficacy.
Aims & Methods: We wished to study whether use of a novel TAI system,
NavinaTM Smart, which has an electronic pump component allows patients
with impaired levels of hand function to adhere to TAI therapy. We also
wished to identify if there were physiological or psychological correlates of adher-
ence. Twenty-eight consecutive patients (19 SCI and 9 MS; 17 male, mean age 42)
were studied. All patients scored greater than 18 on the Cochin Hand Function
questionnaires were completed to assess anxiety/depression and locus of control
respectively. Anorectal physiology (manometry, sensation and rectal compliance)
was undertaken at baseline. Training in TAI was undertaken by the same experi-
enced nurse, with weekly follow up until a stable regime was established.
Adherence with therapy at 12 weeks was identified.
Results: At 12 weeks, 16/28 (57%) of patients were still using Navina TAI, similar
proportions with SCI (11/19) and MS (5/9). There was no difference in baseline
scores for HAD-anxiety (6.4 2.3 vs 5.9 2.9; p¼ 0.37) and HAD-depression
(8.6 3.9 vs 8.8 4.2; p¼ 0.46) and were similar in both those who were and
were not still using TAI (mean SD respectively). The Rotter score for non-
adherers was significantly greater than adherers (14.2 6.7 vs 10.6 5.9 respec-
tively; p¼ 0.008). There was no difference in any of the anorecyal parameters
between those who did or did not adhere with TAI.
Conclusion: Navina Smart TAI is an effective therapy in 57% of NBD patients
with significant hand dysfunction. Anorectal physiology, anxiety and depression
did not predict likelihood of treatment adherence. An external locus of control,
reflecting a belief that health events occur because of outside forces (such as fate,
chance, or powerful others), is associated with reduced treatment success.
The results suggest that future studies of TAI should consider locus of control
as an important potential predictor of outcome.
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Introduction: The microbiota inhabiting the gastrointestinal (GI) tract plays an
essential role in gut health. Although mucosal biopsies are increasingly used for
microbiota studies, these are subject to variations introduced through sampling
technique and patient preparation. The impact of bowel preparation on the
mucosa-associated microbiota (MAM) is of particular interest given it results
in complete emptying of bowel contents via laxative ingestion. Although bowel
preparation does not appear to induce long term changes to stool microbiota [1],
it can induce short-term changes to the colonic MAM [2]. While improvements in
clearance of the small intestine after bowel preparation have been reported [3],
the impact on the upper GI microbiota is currently unknown. Given patients may
undergo both upper GI endoscopy and colonoscopy consecutively, a subset of
endoscopy patients will have consumed bowel preparation prior to their proce-
dure, representing a potential bias in MAM analyses. Therefore, this study aimed
to assess the impact of bowel preparation on the duodenal MAM.
Aims & Methods: Individuals undergoing upper GI endoscopy, with or without
concurrent colonoscopy, were recruited consecutively with ethical approval.
Individuals underwent upper GI endoscopy following overnight fast (n¼ 58),
or both upper endoscopy and colonoscopy following polyethylene glycol bowel
preparation (n¼ 48). Participants were undergoing screening for iron deficiency
anaemia or GI symptoms with no evidence of mucosal disease/inflammation
(n¼ 88), or with diagnosed Crohn’s disease (n¼ 18). Duodenal biopsies were
obtained and gDNA extracted. Amplicon libraries of the 16S rRNA gene were
sequenced (Illumina MiSeq). Sequencing of reagent controls enabled exclusion of
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non-duodenal sequences. Bioinformatics and statistics were performed in QIIME
and Calypso.
Results: A diverse microbiota was observed in duodenal mucosal samples from
all subjects, following overnight fasting or bowel preparation. Overall the duo-
denal microbiota was dominated by the genus Streptococcus, followed by
Prevotella, Veillonella and Neisseria. Microbial diversity within samples was
not significantly different with and without bowel preparation (Chao1 metric).
Principal coordinates analysis (weighted UniFrac) revealed substantial overlap
between the two groups, and no significant clustering was observed (ADONIS)
based on whether patients had undergone overnight fasting or bowel prepara-
tion. Similar findings were obtained when these analyses were repeated with
exclusion of the Crohn’s disease population.
Conclusion: This study reveals a diverse duodenal MAM is retained following
bowel preparation. The comparison of overnight fasting and bowel preparation
indicates these differences in patient preparation do not substantially alter the
duodenal MAM. Thus patients undergoing concurrent upper GI endoscopy and
colonoscopy can be included in study cohorts investigating the upper GI MAM
without risk of a substantial confounding effect.
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Introduction: Upper gastrointestinal bleeding (UGIB) in patients with cancer
presents a unique and difficult challenge as these patients are at higher risk for
rebleeding and mortality.1 Currently available prognostic scoring systems for
UGIB for the general population have produced variable accuracy in their vali-
dation studies.2 An effective method of stratification for cancer patients to iden-
tify the high-risk group for early hospital-based intervention and death could
enhance the outcomes of this specific population.
Aims & Methods: The primary aim of this study was to compare the Glasgow-
Blatchford score (GBS), Rockall score (RS) and AIMS65 score for predicting
ICU admission, blood transfusion, hemostatic therapy, rebleeding, and in-hos-
pital mortality in cancer patients with UGIB. The secondary aim was to assess
the above cited scores in correctly identifying low-risk patients that can be effec-
tively managed as an outpatient. An IRB-approved, prospective study was con-
ducted at the Cancer Institute of Sao Paulo, Brazil. Consecutive patients with
known cancer admitted with UGIB were enrolled. Pre-endoscopic clinical para-
meters, endoscopic findings pertinent to the scoring systems, hemostasis techni-
ques, and outcomes were collected into a prospective registry. Patients were
followed for at least 30 days or until the day of discharge, whichever was
longer. The low-risk group was defined as those without blood transfusion,
hemostatic therapy (by endoscopy, radiotherapy, angiographic or surgical inter-
vention), rebleeding or mortality in 30 days. Multiple logistic regression with
receiver operating characteristics analysis was done to assess the predictive ability
of each scoring system for the above outcomes.
Results: From April 2015 to May 2016, 394 consecutive patients were screened,
while 259 patients met the inclusion criteria. A total of 243 patients were con-
sidered for the final analysis, after excluding 16 patients due to missing data or
lost to follow up (Table 1). Predicting outcomes: The AIMS65 score (area under
curve [AUC] 0.85) was significantly better for predicting ICU admission than
GBS (AUC 0.79; p¼ 0.04), both the total and clinical RS (AUC 0.71 and 0.66;
p5 0.001 for both). The GBS best predicted the need for blood transfusion
(AUC 0.82, sensitivity 71% and specificity 80% for GBS 12) compared with
the other prognostic scores. All scores performed poorly in predicting the need
for hemostatic therapy and risk of rebleeding. The AIMS65 score best predicted
in-hospital mortality (AUC 0.84) compared to the GBS (AUC 0.75; p¼ 0.004),
both the total and clinical RS (AUC 0.70 and 0.69; p5 0.001 for both). Among
patients with confirmed bleeding at EGD, there was no difference in 30-day
mortality if the etiology of bleeding was tumoral or non-tumoral disease
(38.1% vs 31.9%; p¼ 0.46). Identifing low-risk group: With GBS score of 0 as
the cut-off value, its specificity was 100% with sensitivity of 5.8%. When
GBS 2 was used as cut-off, its specificity was maintained at 100%, while sensi-
tivity was increased to 23.5%. This change increased the proportion of the
patients from 1% to 5% without erroneously discharging high-risk patients. In
comparison, when an AIMS65 value of 0 was chosen as definition for low-risk,
this tool misclassified 20 patients who needed hospital interventions (specificity
of 53% and sensitivity of 89.5%). Finally, head-to-head comparison between
GBS vs. RS, and GBS vs. AIMS65 scoring system revealed GBS to be superior
to both the clinical RS (p5 0.001) and AIMS65 (p¼ 0.001) in correctly identify-
ing low-risk patients.
Table 1: Demographic and Clinical Characteristics
Factor Total (n¼ 243)
Age (years) 60.6 13.6
Female/Male 71 (29.2%)/172 (70.8%)
Outpatient/Inpatient 178 (73.3%)/65 (26.7%)
Cancer in the Upper GI Tract 74 (30.5%)
Cancer Stage:
I or II 17 (7.0%)
III 48 (19.8%)
IV 177 (73.1%)
Hemoblobin 8.1 2.9
Albumin 2.8 0.75
Rebleeding 24 (9.9%)
RBC Transfusion 147 (60.5%)
ICU 107 (44.0%)
Hemostatic Therapy 104 (42.8%)
30-day Mortality 66 (27.2%)
Follow-up time (days) 30.0 [22.0,30.0]
Clinical Rockall 4.6 1.2
Total Rockall 7.0 2.0
AIMS65 1.7 1.2
Glasgow-Blatchford 10.8 4.2
Conclusion: The AIMS65 score was superior to other scoring systems in predict-
ing in-hospital mortality and ICU admission in patients with cancer and UGIB,
whereas the GBS was superior for predicting the need for blood transfusion. All
scores performed poorly in prediction of hemostatic therapy and rebleeding. The
GBS was superior in accurately identifying low-risk patients. Furthermore, the
cut-off 2 in GBS score displays increased sensitivity without compromising
specificity, effectively increasing the number of patients who can be safely man-
aged as an outpatient.
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Introduction: Endoscopists are more frequently performing endoscopic resection
(ER) in patients on antiplatelet or anticoagulant therapy and nowdays patients
have increasingly started taking direct oral anticoagulant (DOAC) therapies,
including direct anti-Xa and thrombin inhibitors. Major guidelines recommend
the cessation of anticoagulants before ER and heparin bridging therapy (HBT)
for high thrombotic risk cases, although these are still controversial. A recent
study has suggested that HBT may be associated with a higher post-endoscopic
resection bleeding (PEB) rate in patients on anticoagulants.
Aims & Methods: This study aimed to evaluate the effect of anticoagulants on
PEB rate. This was a retrospective study based on medical records from three
centers. PEB was defined as bleeding that occurred 6 h to 10 days after ER, which
required endoscopic hemostasis. We reviewed 108 gastric tumors including ade-
noma and early cancer in 97 patients on anticoagulant therapy who underwent
endoscopic submucosal dissection (ESD) in our hospitals between June 2008 and
February 2016. Further, we reviewed 69 colorectal polyps including adenoma
and early cancer in 69 patients on anticoagulant therapy who underwent ER in
our hospitals between October 2013 and September 2016. ER included polypect-
omy, endoscopic mucosal resection (EMR), and ESD. Patients were divided into
two groups: those prescribed warfarin and patients prescribed DOAC. The man-
agement of antithrombotics was based on the Japanese Gastroenterological
Endoscopy Society guidelines published in 2005 and 2012. The anticoagulants
used during the study period were warfarin, dabigatran, rivaroxaban, apixaban,
and edoxaban. Warfarin was discontinued 4–5 days before ER, whereas the
others were stopped 24–48 h prior to the procedure. For patients at a high
thrombotic risk, intravenous unfractionated heparin was administered after ceas-
ing anticoagulants.
Results: Warfarin and DOAC were prescribed to 73 (75%) and 24 (25%)
patients, respectively. Apixaban was administered to 1 (1%), dabigatran to 12
(12%), rivaroxaban to 11 (11%) patients. There were no significant differences
between the DOAC and warfarin groups in terms of clinical characteristics or
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PEB rate. Overall, 57 patients (78%) in the warfarin group underwent HBT. and
were significantly associated with PEB rate compared to the patients who did not
undergo HBT in the warfarin group (36% vs. 0%, p5 0.05). Although there was
no significant difference in the PEB rate between the group that did and did not
undergo HBT in the DOAC group, the PEB rate was higher among rivaroxaban
recipients than dabigatran recipients (45% vs. 0%; p 5 0.05). Multivariate ana-
lysis revealed that HBT, rivaroxaban, and anticoagulants plus antiplatelet ther-
apy were associated with PEB (P5 0.05). Warfarin and DOAC were prescribed
to 72 (57%) and 54 (43%) patients, respectively. Dabigatran was administered to
16 (13%), rivaroxaban to 18 (14%), apixaban to 18 (14%), edoxaban to 2 (1.6%)
patients. Patients underwent polypectomy (n¼ 50), EMR (n¼ 62), or ESD
(n¼ 10). PEB occurred in 5 (4.0%) patients (one polypectomy and four
EMRs. Among them, warfarin was prescribed to one patient (1.4%) who also
underwent HBT. Rivaroxaban and apixaban were prescribed to two patients
(11%) each. PEB rate was higher in the DOAC group than in the warfarin
group (7.4% vs. 1.4%).
Conclusion: Patients on HBT, rivaroxaban, and anticoagulants plus antiplatelet
therapy are at an increased PEB risk after ESD for gastric tumors. In patients
who underwent ER for colorectal polyps, PEB was more common in DOAC than
that in warfarin recipients. That was the difference between ER for colorectal
polyps and ESD for gastric tumors. We suggested that the PEB rate differs
among DOACs because each drug has its own blood concentration and meta-
bolization. Most clinicians have a limited knowledge on PEB during DOAC
therapy because these are relatively new drugs, and because PEB has a low
prevalence. Therefore, comparative data on larger patient series are needed to
address this issue.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1810 ENDOSCOPIC ALLPICATION OF MUCOADHESIVE
POWDER (NEXPOWDER) FOR HEMOSTASIS IN PATIENTS WITH
GASTROINTESTINAL BLEEDING
B.W. Bang
1, K.S. Kwon1, H.K. Kim1, Y.W. Shin1, S.J. Hong2, J. Park1,
J.H. Moon3, J.J. Hwang2
1Division Of Gastroenteroloy, Department Of Internal Medicine, Inha University
School of Medicine, Incheon/Korea, Republic of
2Digestive Disease And Research Institute, SoonChungHyang University School of
Medicine, Bucheon/Korea, Republic of
3Gastroenterology, Digestive Disease Center, SoonChunHyang University School
of Medicine, Bucheon/Korea, Republic of
Contact E-mail Address: bangbyoung@naver.com
Introduction: Although endoscopic hemostasis is usually effective in controlling
gastrointestinal (GI) hemorrhage, some have difficulty in achieving successful
hemostasis depending on the location and severity of hemorrhage.
NEXPOWDER (Next Biomedical, Incheon, South Korea) is a biocompatible
and biodegradable powder and the hemostatic effects are accomplished by phy-
sical barrier when this powder immediately forms mucoadhesive hydrogel after
contacting blood or water. It shows high adhesiveness and persistency of gel on
ulcer base. In addition, new powder delivering device was developed to reduce
catheter clogging during endoscopic application.
Aims & Methods: The aims of this study were to confirm 1) success rate of
hemostasis using NEXPOWDER in acute GI bleeding from post-endoscopic
procedure or various causes, 2) re-bleeding rate on second-look endoscopy at 1 or
3 days after the procedure, 3) persistent rate of hydrogel on ulcer base at follow-
up endoscopy, and 4) clogging rate of catheter during spraying powder. The
NEXPOWDER was delivered by newly developed spraying device through
an 8 Fr catheter. We defined the initial hemostatic success as when the bleeding
disappeared within 10 minutes. A second-look endoscopy was performed in one
and three days after the procedure.
Results: A total of 57 patients were enrolled. The bleeding developed in 46
patients with post-endoscopic resection ulcers (41 ESD induced ulcers and 5
EMR induced ulcers), 8 patients with peptic ulcers and 3 patients with other
causes. 1) Success rates of hemostasis in acute bleeding were 96.5% (55/57) of
NEXPOWDER group. 2) Re-bleeding rates were 5.3% (3/57) of
NEXPOWDER group. 3) Persistent rate of NEXPOWDER on ulcer base
was 70.3% (26/37) 1 day after the procedure, and 38.5% (15/38) 3 days after the
procedure. 4) Clogging rate of spraying catheter was 3.5% (2/57).
Conclusion: The endoscopic application of NEXPOWDER is effective for the
several types of acute GI bleeding. This effective hemostatic action of
NEXPOWDER might be achieved by physical barrier of mucoadhesive and
persistent hydrogel on ulcer base. And new powder delivering device shows low
rate of catheter clogging. In addition, a newly developed powder delivering device
shows low scattering and targeted spraying properties onto bleeding site.
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1. Bustamante-Balén M, Plumé G. Role of hemostatic powders in the endo-
scopic management of gastrointestinal bleeding. World J Gastrointestinal
Pathophysiol 2014;5:284–292
2. Chen YI, Barkun AN. Hemostatic powders in gastrointestinal bleeding: A
systematic review. Gastrointest Endosc Clin A Am 2015;25:535–552
P1811 CLINICAL FEATURES OF DELAYED BLEEDING AFTER
ENDOSCOPIC SUBMUCOSAL DISSECTION FOR GASTRIC
NEOPLASMS IN HIGH-RISK AND LOW-RISK PATIENTS
T. Inoue, Y. Maegawa, S. Ito, T. Shimizu, Y. Yokoyama, S. Tawara, S. Ishii,
Y. Haruna, T. Yakushijin, A. Inoue
Gastroenterology, Osaka General Medical Center, Osaka/Japan
Contact E-mail Address: taktaktakkun@gmail.com
Introduction: Antithrombotic drugs are administered to patients undergoing
endoscopic treatment at high risk for thromboembolism. However, antithrom-
botic drugs have been also known as a cause of delayed bleeding associated with
endoscopic treatment, including endoscopic submucosal dissection (ESD). We
previously reported the clinical features of postpolypectomy bleeding associated
with heparin bridge therapy (1), and then various risk factors of delayed bleeding
after endoscopic treatment have been reported.
Aims & Methods: The aims of the present study are to investigate the risk factors
of delayed bleeding after gastric ESD and to clarify the clinical features of
delayed bleeding in high-risk and low-risk patients. Data of consecutive inpati-
ents who underwent ESD for gastric neoplasms in Osaka General Medical
Center between January 2009 and December 2016 were retrospectively investi-
gated. Independent risk factors of delayed bleeding were analyzed by using a
multivariate analysis by logistic regression model, and three predictors of delayed
bleeding were selected. Patients were categorized into a high-risk group or low-
risk group for bleeding, and the clinical features of post-procedural bleeding in
each group were investigated.
Results: A total of 717 patients with 781 gastric neoplasms were identified. Mean
age was 74.6, and 71.6% was male. With regard to comorbidity, the proportion
of hypertension, diabetes, chronic liver disease, and hemodialysis was 50.2%,
19.2%, 2.7%, and 6.1%, respectively. Total 188 patients have taken oral antith-
rombotic drugs, and of them, 50 patients treated by gastric ESD under heparin
bridge therapy. Two-thirds lesions were located in gastric body and median
tumor size (range) was 15 (3–80) mm. En-bloc resection was achieved in 751
lesions (96.2%), and no uncontrollable bleeding occurred. Forty-nine patients
(6.8%) experienced delayed bleeding after gastric ESD. Hospital stay was sig-
nificantly longer in bleeding cases than in non-bleeding cases [median hospital
stay (range) 11 (3–20) vs. 9 (9–25), p¼ 0.007]. A univariate and multivariate
analysis showed heparin bridge therapy, antiplatelet therapy, and hemodialysis,
and age (755) were the independent risk factors for delayed bleeding. We
defined patients with heparin bridge therapy, antiplatelet therapy, and hemodia-
lysis as a high-risk group for bleeding, and the remainder as a low-risk group.
The incidence of delayed bleeding was significantly higher in the high-risk group
than in the low-risk group (14.3% vs. 3.6%, p5 0.001). Severe bleeding requiring
transfusion and recurrent bleeding were more often in the high-risk group than in
the low-risk group. Median onset (range) of delayed bleeding was POD1 (0–16)
in low-risk group and POD6 (0–15) in high-risk group. No thromboembolism
occurred in each group.
Conclusion: Bleeding high-risk patients with heparin bridge therapy, antiplatelet
therapy, and hemodialysis should be carefully observed after gastric ESD while
early hospital discharge is acceptable for bleeding low-risk patients.
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Introduction: There are few studies of the efficacy of parenteral ferric carboxy-
maltose (FCM) treatment in acute gastrointestinal bleeding (GIB) of different
origins. Few data are available on its use to treat anaemia post-acute
haemorrhage.
Aims & Methods: To determine the efficacy and safety of FCM treatment in
patients with acute GIB not associated with portal hypertension. A retrospective
descriptive 3-year study of patients with acute GIB (anemia with evident bleeding
and/or hemodynamic instability) treated with FCM as part of our hospital’s
habitual clinical practice.
Results: Analysis of 84 patients admitted with acute GIB (69.0% male, mean age
68.0 years [SD 6.9]), with a Charlson index 3 in 67.1% of cases (5 in 31.6%).
15.5% had previously suffered acute GIB due to peptic ulcer. There were 86
hospital admissions for acute GIB; 93.8% were upper GIB (above the angle of
Treitz). The most frequent clinical presentation was melena, in 76.7% of cases.
25.6% presented hemodynamic instability at admission. The mean Glasgow-
Blatchford index score was 10.1 (SD 2.7) and the mean Rockall score post-
endoscopy was 4.2 (SD 1.7). The most common causes of bleeding were:
36.0% duodenal ulcus, 29% gastric ulcus, 9.3% gastritis/erosions, and 7.3%
angiodysplasia of the colon. The mean Hb at admission was 9.0 g/dL (SD 2.2)
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and the mean of the lowest Hb during admission was 7.6 g/dL (SD 1.3). The most
common total dose of FCM administered was 1000mg. During admission, a
mean Hb increase of 0.8 g/dL (SD 2.3) was observed in a mean period of 5.7
days (median: 4.0) after treatment with FCM, with an increase of 4.2 g/dL (SD
2.6) 30 days after acute GIB. After FCM administration, the mean Hb increased
significantly (p5 0.0001) in patients 75 years (2.1 g/dL [SD 1.7]), in patients
with Charlson index 3 (1.9 g/dl [SD 1.6]), and when Hb level during admission
was 510 g/dL (2.0 g/dL [SD 1.7]). No adverse reactions were observed.
Conclusion: In patients with acute GI bleeding the administration of ferric car-
boxymaltose improves Hb levels promptly and safely, especially in patients of
advanced age and with associated comorbidities.
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Introduction: Endoscopic Injection of adhesive agents such as N-Butyl-2-
Cyanoacrylate (NBC) is an accepted option for the management of gastric
varices. Recently the combination of NBC and coils has been used with endo-
scopic ultrasound (EUS) assistance. Nevertheless adhesive properties of the poly-
mer can cause blockage of instrumentation material and damage to endoscopes.
Some adverse events include ulcers, vascular wall necrosis, rebleeding and distal
embolism. Ethylene-vinyl alcohol (EVOH) has been extensively used in interven-
tional radiology to treat cerebral arteriovenous malformations and has the
advantage of being radiopaque.
Aims & Methods: We aimed to demonstrate a novel gastric varices embolization
therapy with EUS-guided injection of a composite non-adhesive endovascular
liquid agent EVOH combined with Dimethylsulfoxide (DMSO) as a primer. Five
cases of EUS-guided Injection under fluoroscopic vision with EVOH is described
in 3 men and 2 women, aged 50–65 years with gastric fundus varices, portal
hypertension, Child-B hepatic cirrhosis and previous episodes of bleeding. The
ecoendoscope was advanced to the gastroesophageal junction. The selected gas-
tric varix was punctured using a 22 Gauge needle. EVOH injected volume ranged
between 1.5 and 3cc. Vascular flow progressive obliteration was real time mon-
itored by EUS. Ceftriaxone was intravenously administered during the proce-
dure. Patients were discharged on the same day. The mean follow-up was 6
months. Endoscopic and radiological control was performed at 1 and 3
months. The average procedure time was 20min.
Results: All patients presented mild epigastric pain during the first 12 hours
effectively managed with oral analgesics The obliteration of variceal flow was
achieved in all patients in a single session. There were no new episodes of bleed-
ing or complications related to the technique.
Conclusion: EUS-guided embolization of gastric varices with EVOH can be con-
sidered as an efficient alternative. The procedure promises effective advantages in
terms of number of sessions required, local or systemic adverse events and endo-
scopes damage. Prospective multicenter study with greater number of cases and
cost evaluation against coils alone or combined with NBC are required.
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Introduction: The increase in life expectancy and the increased use of antiplate-
lets, oral anticoagulants and nonsteroidal anti-inflammatory drugs (NSAIDs)
may account for the increasing frequency of older patients with upper gastro-
intestinal bleeding.
Aims & Methods: The aim of this study was to assess the clinical and endoscopic
aspects, hospital course and mortality rate in the elderly population with peptic
ulcer bleeding. In this prospective study we enrolled all patients diagnosed with
peptic ulcer bleeding, who were hospitalized in a tertiary medical center over a
period of 24 months (January 2015- December 2016). Patients were divided into
two groups, according to their age: patients with age below and over 75 years old.
The following characteristics were analyzed in both groups: antiplatelets, oral
anticoagulants and NSAID’s uses, smoking, alcohol consumption, presence of
comorbidities, (quantified by Charlson score), endoscopic aspect of ulcer
(Forrest IA, IB, IIA, IIB were quantified as high risk endoscopic stigmata,
while Forrest IIC and III were considered as low risk endoscopic stigmata)
and the number of ulcers. We also analyzed comparatively the need of transfu-
sion, hospitalization duration, rebleeding, need for surgery and in-hospital
mortality.
Results: 431 patients have been included in this study. 24.8% of patients were
over 75 years old. The following differences have been observed by comparing
the two groups of patients (over and below 75 years old): female 47.7% vs 25.3%
(p5 0.001); antiplatelets use 40.2% vs 20.1% (p5 0.001); oral anticoagulants
use 20.6% vs 7.7% (p5 0.001); NSAIDs use 25.2% vs 33.6% (p¼ 0.133); smok-
ing 5.6% vs 35.2% (p5 0.001); alcohol consumption 17.8% vs 45.4%
(p5 0.001); one or more comorbidities 77.6% vs 62% (p¼ 0.005); high risk
endoscopic stigmata 61.7% vs 64.4% (p¼ 0.724); multiple ulcers 41.1% vs
31.8% (p¼ 0.099); need for blood transfused 59.8% vs 58% (p¼ 0.832); hospi-
talization duration 8.4 6.1 vs 7.8 6.0 days (p¼ 0.382); rebleeding 10.3% vs
11.4% (p¼ 0.745); need for surgery 2.8% vs 4.6% (p¼ 0.589) and in-hospital
mortality 13.1% vs 6.2% (p¼ 0.021). In most of the cases (88.2%), the cause of
death was other than hemorrhagic shock (92.9% vs 85.0%, p¼ 0.484). Using
multivariate analysis, three out of these factors were identified as representing
independent factors significantly associated with the age over 75 years old: oral
anticoagulants use (OR¼ 2.40, 95%CI:1.24–4.62, p¼ 0.009), antiplatelet use
(OR¼ 2.33, 95%CI:1.43–3.81, p¼ 0.001) and in-hospital mortality (OR¼ 2.09,
95%CI:1.27–4.47, p¼ 0.048).
Conclusion: The use of oral anticoagulants and antiplatelet was significantly
higher in older patients, compared to the younger group. Elderly patients with
peptic ulcer bleeding do not have a different rebleeding, need for surgery, need of
transfusion or hospitalization duration than younger patients. In-hospital mor-
tality was higher in elderly patients due to more frequent association of
comorbidities.
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Introduction: Peptic ulcers are the most frequent cause of upper gastrointestinal
bleeding. In different population based surveys regarding all-cause UGIB, mor-
tality ranges between 3% and 14%.
Aims & Methods: The aim of this study was to assess in-hospital mortality in
patients with peptic ulcer bleeding and to evaluate the risk factors associated with
mortality. In this prospective study we enrolled all patients diagnosed with peptic
ulcer bleeding, who were hospitalized in a tertiary medical center over a period of
24 months (January 2015- December 2016). Patients were divided into two
groups - those who died and those who survived - and the following parameters
were compared: age, signs of hemodynamic instability (hypotension, tachycar-
dia), presence of comorbidities (quantified by Charlson score), endoscopic aspect
of ulcer (Forrest IA, IB, IIA, IIB were quantified as high risk endoscopic stig-
mata, while Forrest IIC and III were considered as low risk endoscopic stigmata),
number of ulcers, Rockall score, Blatchford score, degree of anemia, coagulation
disorders, renal function. We also analyzed comparatively rebleeding, the need of
transfusion and need for surgery.
Results: The study included 431 patients. In-hospital mortality rate was 7.9%.
The following differences have been observed by comparing patients who died
and those who survived: age 475 years 41.2% vs 23.4% (p¼ 0.036); hypotension
17.6% vs 2.3% (p5 0.001); tachycardia 47.1% vs 21.4% (p¼ 0.001); one or
more comorbidities 94.1% vs 63.5% (p¼ 0.001); high risk endoscopic stigmata
79.4% vs 62.2% (p¼ 0.070); multiple ulcers 41.2% vs 33.5% (p¼ 0.473); Rockall
score 5 points 94.1% vs 46.9% (p5 0.001); Blatchford score 10 points 91.2%
vs 66.2% (p¼ 0.005); hemoglobin 59.5 g/dl 70.6% vs 41.1% (p¼ 0.002); INR
2.5 17.6% vs 5.8% (p¼ 0.022); creatinine 1.5mg/dl 38.2% vs 10.8%
(p5 0.001); rebleeding 20.6% vs 10.3% (p¼ 0.123); need for blood transfusion
82.4% vs 56.4% (p¼ 0.006); need for surgery 11.8% vs 3.5% (p¼ 0.063). In most
cases (88.2%), the cause of death was other than hemorrhagic shock. Using
multivariate analysis, three out of these factors were identified as representing
independent factors significantly associated with in-hospital mortality: tachycar-
dia (OR¼ 2.83, 95%CI:1.21–6.58, p¼ 0.016), Rockall score 5 (OR¼ 6.65,
95%CI:1.46–30.16, p¼ 0.014) and creatinine 1.5mg/dl (OR¼ 1.25,
95%CI:1.25–7.73, p¼ 0.014).
Conclusion: In-hospital mortality rates in patients with peptic ulcer bleeding was
7.9%. Tachycardia, Rockall score 5 and creatinine 1.5mg/dl were the inde-
pendent risk factors significantly associated with in-hospital mortality.
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Introduction: There has been significant research recently on the use of blood
transfusions in upper GI bleeding (UGIB) [1] with recent evidence advocating a
restrictive approach to blood transfusions as well as the use of iron therapy[2] for
anaemia post UGIB. Our team conducted a local retrospective analysis on
patients admitted with UGIB over a six month period and analysed the use of
blood transfusions at our trust which consists of two District General Hospitals.
Patient data over a period of up to 12 months post discharge was collected to
monitor their anaemia.
Aims & Methods: Our aim was to monitor the appropriateness of transfusions in
Upper GI Bleeding as well as monitoring the response to iron therapy following
discharge. All inpatients that had an Upper GI endoscopy for UGIB were ana-
lysed. Electronic patient records were obtained from our endoscopy software and
hospital database. Patients were selected over a time period of six months from 1/
6/2015 to 31/12/2015. A Student’s T-Test was used to compare the average
increase in haemoglobin (Hb) for patients discharged with iron therapy against
those who were not.
Results: There were 148 patients, 81 male and 67 female. The mean age was 69.3,
minimum 20 and maximum of 98. The average Hb on admission was 103 g/L
(min¼ 32 g/L, max¼ 178 g/L). 78 out of 148 (52.7%) patients presenting with
UGIB received a blood transfusion. The mean amount of blood received for
those transfused was 3.7 units. 48 out of 78 (61.5%) of blood transfusions
were given when Hb was below 70 g/L. 30 of 78 (38.5%) were transfused
above a Hb of 70 g/L. (36.7%, n¼ 11) of those who were transfused with Hb
above 70 had cardiac risk factors. The mortality rate in those transfused above
Hb of 70 was 13.3% (n¼ 4) vs 10.4% (n¼ 5) 41.5% (n¼ 44) patients who were
anaemic post-UGIB were discharged with iron therapy. The average rise in Hb
was 26.5% for those discharged on iron vs 12.1% for those who did not. There
was a statistically significant rise in Hb for those discharged with iron therapy
(p5 0.005) on follow-up versus those who did not receive it (n¼ 62). The anae-
mia related readmission rates were similar for patients discharged on iron or not
(9.1% n¼ 4 vs 9.7% n¼ 6).
Conclusion: The data obtained supports a restrictive transfusion policy (mortality
rate of 13.3% vs 10.4%). 58.5% of patients who were anaemic on discharge did
not receive any iron therapy. On follow up, there was a statistically significant
rise in Hb level in the group discharged on iron. Our data affirms recent evidence
favouring iron therapy post UGIB. Further education is needed to improve
outcome in patients presented with GI bleed.
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Introduction: Autoimmune gastritis (AIG) is an organ-specific autoimmune dis-
ease of the stomach marked by autoantibodies directed to hydrogen/potassium-
ATPase and intrinsic factor. Gastric emptying of solids is delayed and autonomic
nerve dysfunction is detected in patiens with autoimmune gastritis. This may be a
cause of symptoms and also there is a close relation between autonomic nerve
dysfunction and delayed gastric emptying. As ghrelin and motilin are putative
regulators of gastric emptying and, some autoimmune gastritis patients may have
delayed gastric emptying leading upper gastrointestinal symptoms.
Aims & Methods: The aims of this study were to: (i) compare serum levels of
ghrelin and motilin in patients with delayed to normal gastric emptying and (ii)
investigate whether circulating antimyenteric antibodies, serum levels of ghrelin
and motilin have any effect on autonomic nerve function and gastric emptying.
Forty-one patients with AIG were included into this study. Autoimmune gastritis
was diagnosed depending upon histopathological findings in gastric biopsy speci-
mens. Non-invasive cardiovascular reflex tests were used in order to evaluate
autonomic nervous system function. Sympathetic nerve function was evaluated
with two tests: blood pressure response to standing and handgrip test.
Parasympathetic nerve function was evaluated with three tests: valsalva man-
oeuvre, heart rate response to deep breathing (E/I ratio) and orthostatic blood
pressure testing. Dysfunction was considered to exist if at least two tests were
positive. Gastric emptying time was evaluated by a standard 2-hour scintigraphic
test using a solid meal. A half-time of longer than 110 minutes was chosen in the
present study to further investigate patients with delayed gastric emptying. Serum
ghrelin and motilin levels were tested by ELISA and circulating antimyenteric
antibodies were tested by IFA.
Results: Forty-one patients (27 women), mean age 56.61 11.79 years with AIG
were included into the study. Overall, 22 (53.6%) patients showed delayed GE
and 19 patients showed normal GE (GET ½: 241.19 199 vs 90 19 mins,
p5 0.001). Serum ghrelin and motilin levels of patients with delayed GE were
significantly decreased compared to patients with normal GE, respectively
(67.55 8.81 vs 126.79 25.81 pg/mL, p5 0.001 and 279.59 111.12 vs
500.42 155.95 pg/mL, p5 0.001). In all, 26 (63.4%) patients showed autonomic
nervous system dysfunction and, 15 (36.5%) patients had normal autonomic
nervous system test findings (total autonomic test score: 0.8 0.25 vs
5.65 1.74, p5 0.001). Serum ghrelin and motilin levels of patients with
deranged autonomic nervous system function were significantly decreased com-
pared to patients with normal autonomic nervous system function, respectively
(80.73 28.46 vs 127.79 28.06 pg/mL, p5 0.001 and 316.92 160.47 vs
490.20 141.02 pg/mL, p5 0.001). In multivariate analysis, plasma motilin
level was found as an independent factor that affected serum ghrelin level
(r¼ 0.623, p¼ 0.019). However, serum ghrelin (r¼ 0.623, p¼ 0.019) and gastrin
(r¼ -0.70, p5 0.001) levels were found as independent factors that affected
plasma motilin level. We also investigated the presence of antimyenteric antibo-
dies, however all the patients were negative by means of antimyenteric antibodies
therefore, no further relationship was sought.
Conclusion:Mean fasting serum ghrelin and plasma motilin levels in autoimmune
gastritis patients with delayed GE and deranged autonomic nerve function were
significantly decreased. None of the patients in our study were positive for cir-
culating antimyenteric antibodies. These decreased serum ghrelin and plasma
motilin levels in patients with autoimmune gastritis suggest a potential role for
ghrelin and motilin in explaining the finding of the delayed gastric emptying
observed in an important part ofautoimmune gastritis patients. We believe that
these new observations supply more insight into the pathophysiology of auto-
immune gastritis.
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Introduction: The interaction between gut microbiota and enteroendocrine cells
alterations is believed to play an important role in the pathophysiology of irri-
table bowel syndrome (IBS). The densities of the duodenal enteroendocrine cells
are abnormal in IBS patients, which appears to be caused by a reduced stem cells
density and their differentiation into endocrine cells (1).
Aims & Methods: The aim is to investigate the effects of faecal microbiota trans-
plantation (FMT) on the differentiation of the stem cells into enteroendocrine
cells as detected by neurogenin 3, the stem cells as detected by Musashi 1 and the
enteroendocrine cells in the duodenum of patients with IBS. The study included
16 IBS patients according to Rome III criteria and four patients were excluded.
The remaining patients (n¼ 12, 4 females and 8 males, age range 20–44 years)
were divided according to the cause of IBS into PI-IBS patients (n¼ 6) and
idiopathic IBS (n¼ 6) and received FMT donated from their relatives. The
patients completed the IBS-symptom severity scoring system (IBS-SSS) before
and 3 weeks after FMT. The patients underwent gastroscopies with biopsies
taken from the descending part of the duodenum at baseline and 3 weeks after
FMT. The biopsies were immunostained for neurogenin 3, Musashi 1 and all
types of duodenal enteroendocrine cells, and quantified by computerized image
analysis.
Results: The score of IBS symptoms as assessed by IBS-SSS was significantly
reduced 3 weeks after (240.2 33.6) compared to before (326.6 22.3) receiving
FMT, P¼ 0.0009. The scores of IBS-SSS before and 3 weeks after FMT for PI-
IBS are 300.8 27.8 and 210 41, respectively (P¼ 0.025), and for idiopathic
IBS are 352 34 and 270.3 54, respectively, (P¼ 0.034). The densities of neu-
rogenin 3, Musashi 1 and enteroendocrine cells in the duodenum of IBS patients
before and 3 weeks after receiving FMT are presented in Table 1.
Conclusion: Faecal microbiota transplantation improved the symptoms in IBS
patients, both PI and idiopathic. This improvement was associated with a change
in the enteroendocrine cell density. The changes in the enteroendocrine cell den-
sity does not appear to be caused by changes in the stem cells or their early
progenitors, but rather by changes in the differentiation progeny as detected
by changes in neurogenin 3.
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Introduction: Neuronal plasticity has been reported to develop following noci-
ceptive emotional experience in prefrontal cortex (PFC) and hippocampus. The
N-methyl-D-aspartate receptor (NMDAR) and D-serine, the endogenous co-
agonist of NMDAR1, may mediate the neural plasticity. However, whether the
neural plasticity participates in the mechanism of esophageal visceral hypersen-
sitivity is little known.
Aims & Methods: This study aims to investigate the expression of NMDAR and
the alteration of D-serine after neonatal and adult esophageal acid exposure. All
rats were exposed to esophageal acid or saline at postnatal days 7–15(P7-P15),
and most rats underwent acute acid or saline exposure again at adult time
(P60).All rats were randomly distributed to 5 groups, including P7S, P7H,
P7HþP60H, P7HþP60S, P7SþP60H(P7: postnatal 7–15 days; P60: adult at
postnatal 60 days; H: 0.1N HCL infusion; S: saline control). The tissue harvest
was conducted at P60. We examined the expression of subunits of NMDAR
(including NR1, NR2A, and NR2B), c-fos, and serine racemase in PFC, dorsal
hippocampus(DH) and ventral hippocampus(VH). We also determinated the D-
serine and L-serine in PFC and hippocampus by LC-MS analysis. Statistic com-
parisons were performed by General Linear Model and one way ANOVA in
SPSS.
Results: In PFC, compared with adult saline treatment (AS, including
P7HþP60H and P7SþP60H group) and without adult treatment (A-, including
P7S and P7H group), adult acid exposure (AH) increased the expression of NR1
(P¼ 0.052, P¼ 0.298), NR2B (P¼ 0.035, P¼ 0.045), and serine racemase
(P¼ 0.022, P¼ 0.017) significantly. In ventral hippocampus, compared with
adult treatment absence, adult acid exposure caused increasing expression of
NR2B (P¼ 0.012) and NR1 (P¼ 0.024) significantly. In PFC, the expression of
serine racemase in the P7SþP60H group was obviously higher than that of other
groups (P¼ 0.008). See Table1. In dorsal hippocampus, there was statistical sig-
nificance on the level of c-fos between the P7SþP60H group and other groups
(P¼ 0.008). Table1. In PFC, the LC-MS analysis results that D-serine (AH vs A-
:P¼ 0.000, AS vs A-: P¼ 0.042, AH vs AS: P¼ 0.081) and L-serine(AH vs A-
:P¼ 0.000, AS vs A-: P¼ 0.015, AH vs AS: P¼ 0.082) decreased in the AH and
AS group, comparing with A- group.
The expression of serine racemase in PFC and c-fos in VH
Group
(n¼ 8/group)
PFC Serine Racemase VH c-fos
(meanSD)
P value
(vs P7SþP60H) (meanSD)
P value
(vs P7SþP60H)
P7S 0.139 0.131 0.03 0.035 0.008 0.021
(continued)
Continued
The expression of serine racemase in PFC and c-fos in VH
Group
(n¼ 8/group)
PFC Serine Racemase VH c-fos
(mean SD)
P value
(vs P7SþP60H) (meanSD)
P value
(vs P7SþP60H)
P7H 0.141 0.083 0.034 0.036 0.015 0.026
P7HþP60H 0.166 0.066 0.119 0.035 0.011 0.023
P7HþP60S 0.124 0.031 0.014 0.040 0.015 0.057
P7SþP60H 0.300 0.149 – 0.083 0.060 –
Conclusion: Acute esophageal acid exposure may increase the expression of
NMDAR in PFC and ventral hippocampus. We also found the first acid expo-
sure at adult stage may enhance the expression of serine racemase in PFC and c-
fos in ventral hippocampus, but this phenomenon may be absent in those rats
having the experience of acid exposure in early life. Those long-term and transi-
tional molecular alterations may mediate the development of acid exposure
related esophageal visceral hypersensitivity.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1820 1.8. UPPER GI NERVE- GUT AND MOTILITY:
TRANSMITTERS/SIGNALS/RECEPTORS/ENTERIC NERVOUS
SYSTEM
L. Jia
1, L. Yao1, C. Dong-Yun1, L. Wei-Dong1, X. Jian2
1Department Of Gastroenterology, Guangzhou First People’s Hospital, Guangzhou
Medical University, Guangzhou/China
2Department Of Psychology, Guangzhou Nansha Central Hospital, Guangzhou/
China
Contact E-mail Address: 13925012853@139.com
Introduction:Globus pharyngeus, a sensation of a lump or tightness in the throat,
is a well- defined clinical symptom that is usually long-lasting, difficult to treat,
and has a tendency to recur. More than half of globus patients suffered from
probable psychological disorders, such as anxiety and depression 1.
Antidepressants are used in the treatment of functional gastrointestinal disorders
(FGIDs) and showed a promising efficacy. Our study manifested that low-dose
amitriptyline is well tolerated and effective for general globus pharyngeus
patients 2. Our anterior study had ever speculated that AMT could modify
brain-gut axis function, up-regulating brain-gut peptides, reducing the visceral
sensitivity and regulating the secretory and motor functions of the gastrointest-
inal tract 3, so that gastrointestinal symptoms as well as emotional well-being
could be significantly improved. As we known, serotonin (5-hydroxtryptamine,
5-HT) is an important factor in gut function, playing key role in intestinal peri-
stalsis, secretion, and sensory signaling in the brain-gut axis 4–5. Several studies
have investigated the association between SLC6A4 and functional gastrointest-
inal disorders, including IBS and FD. Besides, the association between various
complex behavioral traits and disorders were also studied, including anxiety,
major depression, suicide, smoking behavior, alcohol dependence. A single
gene (SLC6A4), located on thehuman chromosome 17q11.2. 17q12, is coded
by serotonin transporter (5-HTT). The polymorphism of this gene is character-
ized by the insertion or deletion of the 44-bp sequence and this is related to the
different transcriptional activity of the gene. Allele with 44-bp deletion (short
allele) is characterizedby a three times lower transcriptional activity than allele
with 44-bp insertion (long allele). Compared to other FIGDs, the researches
about globus are rare. The pathogenesis of globus pharyngeus is still unknown.
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Table 1: Densities of stem cells and enteroendocrine cells in the duodenum of total IBS group, PI-IBS and idiopathic IBS patients before and after receiving FMT
Markers/Hormones
Immunoreactive cells densities
*P-value **P-value ***P-value
Total IBS,
before
Total IBS,
after
PI-IBS,
before
PI-IBS,
after
Idiopathic IBS,
before
Idiopathic
IBS, after
Neurogenin 3 222.3 13.8 394.3 30.7 214.2 18.5 430.5 28.9 230.5 21.5 358.2 52.9 0.0006 0.0007 0.1
Musashi 1 5.7 0.4 5 0.5 5.3 0.7 5.2 0.8 6 0.4 4.8 0.7 0.42 0.9 0.2
Chromogranin A 370.3 21 269.8 22 340.8 34 422.7 31 399.8 20.9 316.8 10.2 0.98 0.0006 0.0065
Serotonin 135.1 14.7 142 12.8 100.5 7.1 160.7 16.6 169.7 20.6 123.3 17.3 0.7 0.012 0.034
Somatostatin 58.6 4 66.2 6.3 52.3 2.7 78.5 8.1 64.8 7 53.8 6.8 0.3 0.011 0.017
Cholecystokinin 122.8 6.7 110.7 8.1 113 10.4 126.5 0.5 132.5 7.2 94.8 9 0.2 0.052 0.0006
Secretin 83.8 4.9 86.7 5.9 80.5 8.8 89.7 10.7 87.2 4.8 83.7 5.9 0.5 0.099 0.6
Gastric inhibitory peptide 65.1 3.8 70.3 6.2 60 3 3.7 84 7.1 69.8 6.3 57.2 7 0.5 0.014 0.2
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To the best of our knowledge, our findings are the first to establish an association
between SLC6A4 gene polymorphism and globus.
Aims & Methods: 84 patients diagnosed with globus according to Rome III and
160 healthy controls were genotyped for 5-HTTLPR polymorphism by PCR
amplification and agarose gel electrophoresis. All globus patients were studied
with high-resolution manometry pre-therapy. Globus patients were randomized
into paroxetine group; amitriptyline group for 6-week treatment, and were asked
to complete the following questionnaires pre- and post-therapy: Glasgow
Edinburgh Throat Scale (GETS), Pittsburgh Sleep Quality Index, Hamilton
Rating Scale Anxiety/Depression. Treatment response was defined as a 450%
reduction in GETS scores.
Results: The significant difference was shown in globus performed S/S genotype
with anxiety when compared to without (X2¼ 14.579, P¼ 0.006). The L/S geno-
type was significant difference between high upper esophageal sphincter pressure
(4104mmHg) and non-high upper esophageal sphincter pressure patients
(X2¼ 14.433, P¼ 0.006). There was significant association between the S/S gen-
otype and the response to antidepressants treatment, while patients with sleep
disorders or depression not.
Conclusion: A significant association was observed between S/S genotype of
SLC6A4 polymorphism and globus pharyngeus, suggesting that SLC6A4 is a
potential candidate gene involved in the pathogenesis of globus pharyngeus.
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Introduction: Multiple rapid swallows (MRS) and rapid drink challenge (RDC)
are provocative tests that can enhance the diagnostic value of esophageal HRM.
The discriminatory characteristics of these provocative tests were evaluated in
symptomatic patients referred for esophageal HRM.
Aims & Methods: Consecutive patients presenting for esophageal HRM over a 2-
month period underwent provocative testing with MRS and RDC in addition to
the standard manometric protocol. Integrated relaxation pressure 415mmHg
identified outflow obstruction; those without outflow obstruction were further
analyzed using software tools (IRP, distal contractile integral, DCI; intrabolus
pressure, IBP) for peristaltic reserve (MRS or RDC DCI4 mean DCI from wet
swallows), and obstruction (IBP 430mmHg during MRS or RDC). All patients
completed symptom questionnaires addressing reflux symptoms (GERD-Q), dys-
phagia (Mayo Dysphagia Questionnaire, MDQ) and global symptom severity
(GSS) on a 100mm visual analog scale (VAS). Univariate and multivariate ana-
lyses were performed to evaluate overall yield (proportions with MRS/RDC
findings not seen with the standard HRM protocol) and to assess association
of presenting symptoms with results of MRS and RDC in patients without out-
flow obstruction.
Results: 149 patients (55.4 1.2yr, 68% F) fulfilled inclusion criteria and had no
outflow obstruction on HRM. Of these, 91 (61%) had peristaltic reserve on
MRS, 19 (12.6%) on RDC (p5 0.001), only 10 were concordant. Obstruction
was noted in 16 (9.8%) on MRS, 8 (4.9%) on RDC (p¼ 0.09), and 5 were
concordant; of these, only 2 patients had panesophageal compartmentalization
of pressure, and only 1 had elevated IRP during provocative measures. Within
ineffective esophageal motility, peristaltic reserve was noted in 59.3%. Within
dysphagia presentations, obstruction was noted in 7.7%, and absent peristaltic
reserve in 50%. Thus, the overall yield of MRS was 80.5%, and RDC 19.8%
(p5 0.001). 131 patients had adequate questionnaire data. Findings on provo-
cative tests did not predict presenting symptoms (GERD-Q or MDQ).
Obstruction on RDC predicted higher GSS (odds ratio 5.56, 95% CI 1.04–29.72).
Conclusion: MRS identifies peristaltic reserve better than RDC and has higher
overall clinical value. While both MRS and RDC identify outflow obstruction,
only RDC obstruction predicts higher symptom burden. Neither MRS nor RDC
findings correlate with presenting symptoms.
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Introduction: Achalasia is an uncommon condition of failed lower oesophageal
sphincter relaxation. Data regarding the incidence and prevalence are limited.
The aim of this study was to provide accurate, contempory epidemiological data
utilising two national databases.
Aims & Methods: Hospital Episode Statistics (HES) includes demographic and
diagnostic data for all English hospital admissions. The Health Improvement
Network (THIN) database includes primary care records of 7% of the UK
population, representative of national demographics. Both were searched for
incident cases and THIN for prevalent cases of achalasia.
Results: There were 10,509 and 711 new achalasia subjects in HES and THIN
respectively. The incidence per 100,000 population in HES was 1.99 (95% CI
1.87–2.11) and 1.53 (1.42–1.64) per 100,000 person years in THIN. The preva-
lence measured in THIN was 27.1 (25.4–28.9) per 100,000 population.
Table 1: Annual incidence and prevalence of achalasia
Year
Incidence
rate HES
(per 100,000
population) 95% CI
Incidence rate
THIN
(per 100,000
person years) 95% CI
Prevalence
THIN
(per 100,000
population)
2006 1.733 1.62–1.85 1.409 1.08–1.81 21.14
2007 1.798 1.69–1.92 1.656 1.39–2.08 21.72
2008 1.789 1.68–1.91 1.550 1.21–1.96 22.49
2009 1.853 1.74–1.97 1.696 1.34–2.12 23.16
2010 2.015 1.90–2.14 1.663 1.31–2.09 23.66
2011 1.781 1.67–1.90 1.424 1.09–1.82 24.62
2012 2.032 1.91–2.16 1.549 1.20–1.96 25.23
2013 2.179 2.06–2.31 1.618 1.26–2.05 26.06
2014 2.421 2.29–2.56 1.476 1.12–1.91 26.34
2015 2.236 2.11–2.36 1.342 0.96–1.80 27.10
Conclusion: The incidence of oesophageal achalasia was approximately 15 to 20
per 1 million population. There were approximately 17,500 patients with acha-
lasia in UK. In 2015 the above data represents the largest published epidemio-
logical investigation of achalasia. The variation of findings between the databases
likely results from differences in coding practice and marginally different popula-
tion structures.
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Introduction: Resistance to bolus flow across the lower esophageal sphincter
(LES) is a hallmark of achalasia. Presently the gold standard of diagnosis is by
high-resolution manometry (HRM) demonstration of raised integrated relaxa-
tion pressure (IRP) following ten 5mL water swallows; however, this does not
replicate normal swallowing behavior. It has been demonstrated that the addition
of adjunctive tests improves sensitivity of identifying relevant dysmotility. Such
tests include multiple water swallows (MWS; 200mL water drunk freely) and
solid swallows. In addition, the timed barium esophagram (TBE) measures eso-
phageal emptying. This study describes a cohort of patients who have been
treated as having achalasia based on resistance to flow not exhibited with
single water swallows.
Aims & Methods: Inclusion criteria were all patients between October 2014–2016
with normal mean and median IRP with 5mL water swallows but considered to
have achalasia due to resistance to flow demonstrated by pan-esophageal pres-
surization (PEP) during MWS or solid swallows and/or a persistent column at 5
minutes during TBE. Outcome following treatment was based on the Eckardt
symptom score (ES).
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Results: 14 patients (9 male) fulfilled inclusion criteria. 7 were treatment-naı̈ve
and 7 treatment-experienced (3 myotomy, 4 dilatation). Mean resting LES pres-
sure was 14.6 7.4mmHg. In all patients, mean and median IRP values for ten
5mL water swallows were non-raised (mean 9.1 4.3 and 8.7 4.5mmHg
respectively). Of the 7 treatment-naı̈ve patients, 5 demonstrated PEP on MWS,
3 on solid swallows and 6 had a positive TBE at 5 minutes. In treatment-experi-
enced patients, 5 had PEP on MWS, 1 on solid swallows and all had a positive
TBE. Of the 13 who had resistance to flow on TBE, 10 (77%) also had resistance
demonstrated during MWS and/or solid swallows. Mean height of the 5-minute
column of barium at baseline was 16.5 8.9 cm. 8 patients have (so far) under-
gone therapy based on these findings; one per-oral endoscopic myotomy and 7
pneumatic dilatations. The median baseline ES was 7.5 (IQR 5–8). The median
ES at minimum 3 months (range 3–15 months) following treatment was 1 (IQR
0–2.5; P5 0.01 cf. baseline). Similarly, there was significant improvement in
TBE findings post-therapy (mean 5-minute column height 3.5 4.1 cm;
P¼ 0.04 cf. baseline).
Conclusion: A normal IRP for water swallows does not preclude a diagnosis of
achalasia. The addition of free drinking/solids during HRM or the TBE can
identify pathology that might have been missed with standard 5mL water swal-
lows alone as normal, clinically relevant swallowing behavior is reproduced.
Patients treated based on this algorithm exhibit excellent treatment outcomes,
validating this approach. Further, the close correlation of HRM adjunctive test-
ing with TBE supports its routine inclusion in clinical practice.
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Introduction: In patients with dysphagia, the identification of obstruction at the
OGJ level determines the need for further endoscopic or surgical therapy. Timed
barium oesophagogram (TBO) is regularly used to detect impaired oesophageal
emptying in due to OGJ obstruction in patients with dysphagia and achalasia.
‘‘Volume loading’’ the oesophagus with a 200ml rapid drink challenge (RDC)
has recently been shown to help with the diagnosis of oesophageal motility dis-
orders. We predict that this test can evaluate OGJ emptying at HRM without
need for further TBO study. As such we hypothesised that RDC can predict
pathological barium column at TBO, and associates with symptom severity in
achalasia.
Aims & Methods: 39 patients with untreated dysphagia (mean age 55yr) were
evaluated. All patients underwent HRM with standard protocol plus RDC, fol-
lowed by TBO. In patients with achalasia, symptoms were recorded by Eckhardt
score. Analysis of HRM followed the Chicago Classification v3 algorithm.
During TBO, oesophageal emptying was assessed at min 1, 3 and 5. OGJ
obstruction was diagnosed by persistent barium column at 5 minutes. During
RDC, the mean IRP was measured during the rapid drinking period.
Results: HRM diagnosis was normal or minor peristaltic abnormality (n¼ 5),
achalasia type I (n¼ 3), achalasia type II (n¼ 22), achalasia type III (n¼ 2),
oesophagogastric junction outflow obstruction (n¼ 3), absent contractility
(n¼ 2) and Jackhammer (n¼ 2). ROC curve analysis showed that a mean IRP
during RDC 417mmHg had a sensitivity of 100% and specificity of 87% for an
abnormal TBO. In patients with achalasia, only mean IRP during RDC corre-
lated with Eckhardt score (r¼ 0.42, p¼ 0.03). No standard HRM parameters or
TBO findings correlated with Eckhard score.
Conclusion: 200ml rapid drink challenge during HRM is a useful adjuvant in
assessment of oesophageal motility disorders. It can predict an abnormal TBO
with excellent sensitivity and specificity in patients with dysphagia. In patients
with achalasia, a higher mean IRP during 200ml rapid drink challenge is the only
HRM metric that correlates with worse symptom burden. These findings suggest
that that the rapid drink challenge is a clinically relevant parameter.
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Introduction: The timed barium esophagram (TBE) is an objective measurement
of esophageal emptying used in the assessment of achalasia. Post-therapy reduc-
tion of the maximum height of the residual barium column has been found to
correlate imperfectly with short-term symptomatic outcomes, but carries long-
term prognostic implications. We hypothesize that the surface area (SA) of the
barium column may be more accurate than height; firstly, by incorporating
improvement in esophageal width that often occurs post-therapy, but also by
correcting for artificially higher height values due to esophageal (longitudinal)
contraction occurring during a single image. We aimed to compare the correla-
tion of TBE outcome measures of height and SA with symptom improvement
post-therapy.
Aims & Methods: Inclusion criteria were achalasia patients who underwent ther-
apy between August 2015–6 and had TBE and Eckardt score (ES) performed at
baseline as well as within 6 months post-therapy. With TBE upright single images
were acquired at 1,2 and 5 minutes following ingestion of 100–200mL of low-
density barium sulfate. Barium height was measured between the gastro-esopha-
geal junction and the superior extent of any residual barium column. After
manually defining the column boundaries, software was used to calculate SA
(AGFA IMPAX surface area tool (Figure)). Adequate symptom relief was
defined as reduction in ES to 3. On TBE, metrics of adequate emptying eval-
uated were i) post-therapy column height 55 cm, ii) 450% reduction in column
height from pre to post-therapy and iii) 450% reduction in column SA from pre
to post-therapy. Associations between symptom improvement and TBE measures
of emptying were assessed using Pearson’s correlation (R). Paired t-tests com-
pared TBE measures before and after therapy.
TBE parameter
Cut-off value
for adequate
emptying
Concordance
between adequate TBE &
symptom relief (based
on ES) n/total (%)
Pearson’s
correlation
between TBE &
post-therapy ES R
Post-therapy 5-min barium
column
55 cm 7/18 (39%) 0.05
% Reduction in 5-minute
barium height post-therapy
from baseline
450% 8/18 (44%) 0.20
% Reduction in SA of 5-
min barium post-therapy
from baseline
450% 12/18 (67%) 0.36
Results: 18 patients (9 male; 6 Type I, 11 Type II, 1 Type III) were included. 11
had dilatation and 7 endoscopic myotomy. Reductions with therapy of both
mean 5-minute barium column height (14.7 8.7 to 7.9 6.0 cm; P¼ 0.01) and
SA (52.7 43.5 to 24.5 26.0cm2; P¼ 0.02) were noted. Symptoms also
improved with treatment; median baseline ES of 7 (IQR 5.25–8) improved to 0
(IQR 0–1) post-therapy. Only 2 patients had inadequate symptom relief and are
awaiting further treatment. However there was poor concordance between post-
therapy barium column height and symptomatic relief (i.e. post-therapy column
45 cm despite ES 3 or vice versa), and the correlation (R) between these two
variables was poor (Table). Similar poor concordance was seen when adequate
emptying was defined by 450% reduction in column height, but 450% reduc-
tion in SA paralleled symptom relief most closely.
Conclusion: In TBE performed on achalasia patients post-therapy, reduction in
SA of the residual barium column compared with baseline values parallels symp-
tomatic relief more closely than reduction of column height.
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Introduction: During meal intake, large volumes of gas can be ingested together
with nutrients, and patients with gas-related abdominal symptoms often refer
symptom exacerbation by meals. Previous studies have shown that under fasting
conditions gastric gas is rapidly eliminated from the stomach, either via gas
emptying to the small bowel and colon, or via belching. Nutrients have several
effects on gastric and intestinal motor function that could modulate gas transport
and symptoms.
Aims & Methods: We aimed to determine the effect of gastric nutrients on trans-
port of gastric gas, and its relationship with abdominal symptoms. In 7 healthy
volunteers without gastrointestinal symptoms (4 women and 3 men, age-range
21–25 yrs), a mixture of non-absorbable gases was infused into the stomach, 5-cm
caudal to the lower margin of the LES, at 25mL/min during 60min (Total gas
infused: 1500ml). In each subject two gas infusion tests were performed on
separate days, with simultaneous infusion of nutrients (Nutridrink 1.5 Kcal/ml,
total 315 Kcal) or saline. Belching, by an esophageal multilumen impedance
manometry catheter, rectal gas evacuation, via a rectal tube connected to a
barostat, and epigastric and abdominal symptoms, by specific questionnaires
(from 0–6), were continuously recorded from the start of gas infusion until
30min after gas infusion stopped. (Total recording time: 90min).
Results:During saline infusion, participants evacuated via the rectum virtually all
the infused gas (1613 87ml), with exceptional belching (1.1 0.8 belches) and
mild epigastric perception (score 1.7 0.6 at the end of infusion), that decreased
during the 30min following infusion stop (score 1.1 0.4; p¼ 0.051 vs infusion
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stop). Gastric nutrients reduced significantly rectal gas evacuation
(1220 187ml; p¼ 0.016 vs saline), increased the number of recorded belches
(3.3 1.3 belches; p¼ 0.018 vs saline), and produced greater epigastric perception
(score 2.7 0.6; p¼ 0.030) that decreased during the 30min following infusion
stop (score 1.6 0.7; p¼ 0.042 vs infusion stop). By contrast to epigastric percep-
tion, abdominal perception was only somewhat higher during gas infusion with
nutrients (score 2.6 0.5) than during saline (score 2.1 0.5; p¼ 0.100 vs
nutrients).
Conclusion: Gastric nutrients modulate transit of gastric gas, by reducing gas
propulsion to the distal gut, and enhancing retrograde gas evacuation via
belching.
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Introduction: Peroral endoscopic myotomy (POEM) is a recently developed tech-
nique or the treatment of lower esophageal sphincter achalasia. POEM could be
as efficient as surgical Heller myotomy, while associated with lower morbidity.
Currently, the Eckardt score is the clinical score that is the most widely used to
assess the outcomes after the treatment of achalasia, clinical success being defined
by a score below 4. However, POEM might not equally improve all four para-
meters of the Eckardt score.
Aims &Methods: All consecutive patients undergoing POEM for achalasia at our
institution performed by 3 operators with at least 6 months follow-up were
prospectively included. Demographic, clinical, procedural, manometric and radi-
ological data were collected.
Results: Between March 2013 and July 2016, 62 POEM procedures were per-
formed in 59 patients (Male/female 33/26; Median ageSD¼ 47 17, range
(15–77)). Median (IQR) follow-up time was 8 (3–13) months. Achalasia was
diagnosed for a median (IQR) of 24 (13–62) months, and 42% of the patients
had received a previous treatment, by botulinum toxin injection (8%), pneumo-
dilation (32%), or Heller myotomy (7%). Achalasia subtypes were type I/II/III in
37%/47%/15% of cases. Median Eckardt score and integrated resting pressure
were 7 (6–8) and 24 (19–33) mmHg, respectively. An anterior myotomy was done
in 60% of cases, and a posterior myotomy in 40% of cases. Median myotomy
length was 14 (12–16) cm, and hospital stay was 3 (2–4) days. Severe complica-
tions occurred in 5% of cases (1 pleural effusion requiring drainage, 2 pneumo-
nias with more than 10 days of hospital stay). Success rates were similar between
patients treated by anterior or posterior myotomy (92% vs 92%, p¼ 1), or
between treatment naı̈ve or pretreated patients (88% vs 96%, p¼ 0.32). Six
treatment failures were treated by redo POEM in 3 cases, pneumodilation in 2
cases, and esophagectomy in one case. Median Eckardt score varied from 7 (6–8)
to 1 (0–2) at 3 months and 2 (0–3) at 12 months (p5 0.0001). Dysphagia score
varied from 3 (3–3) to 0 (0–1) and 1 (0–3) (p5 0.0001), while regurgitations
varied from 2 (1–3) to 0 (0–1) and 1 (0–1) (p5 0.0001), chest pain varied from
1 (0–2) to 0 (0–1) and 0 (0–1) (p¼ 0.006), and weight loss from 2 (1–3) to 0 (0–0)
and 0 (0–0) (p5 0.0001). At three months, median (range) drop of the integrated
resting pressure was 16 (12; 22) mmHg. At last follow-up visit, 86% of patients
still had clinical success, and 31% reported gastro-esophageal reflux symptoms.
Conclusion: Our results confirm the efficacy of the POEM as a first line or rescue
treatment for achalasia, with a low complication rate. POEM is most effective on
dysphagia and weight loss, while chest pain and regurgitations tend to persist
after treatment.
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Introduction: Well-proven therapeutic options for the therapy of functional gas-
trointestinal diseases are rare and therefore gain high attention. One of these is
STW 5 (Iberogast), for which more than five decades of therapeutic experience in
more than 73 Mio patients are available. For determining whether its efficacy in
functional dyspepsia proven by meta-analyses is comparable in male and female
as well as patients of different age groups, sub-group analyses were conducted.
Aims & Methods: After meta-analyses of randomized placebo-controlled double
blind trials with STW 5 have proven compliance to modern standards for a proof
of efficacy, now sub-group analyses were conducted. The analyses (ANCOVA)
were based on the original single patient data from the trials, including demo-
grafic data and primary endpoints.
Results: As the primary outcome variable, the validated gastrointestinal symptom
score (GIS) [1], as well as the therapeutic dose (3 20 drops/day) were identical
in all trials, a uniform evaluation was possible. The full analysis set (FAS)
included 557 patients (272 resp. 285 for placebo resp. verum). The mean age
(48 resp. 49 years), the mean body size (in both groups 168.7 cm), the mean
body weight (72.0 resp. 72.2 kg), the BMI (25.35 resp. 25.54), the gender distribu-
tion (67.3 resp. 69.5% females), the duration of the disease at the time of inclu-
sion and the baseline of the GIS (11.6 resp. 11.5 points) were very well
comparable between both groups. For the primary variable GIS the difference
between placebo and verum after 28 days of treatment showed a highly signifi-
cant (p5 0.0001) difference between placebo and verum (6.7 resp. 4.7 points).
The analyses in different age groups (up to 30, 30–40, 40–50, 50–60, above 60)
and in male and female patients did show a comparable efficacy in all these
groups.
Conclusion: These meta-analyses therefore clearly show the efficacy of STW 5
(Iberogast) and its therapeutic usefulness irrespective of age and gender. Given
also the very good tolerability shown by the study data and the pharmacovigi-
lance data, STW 5 is well suitable also in self-medication. Additional insights can
be expected from additional sub group analyses, as e.g. the evaluation of sub-
groups with specific predominant symptoms.
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Introduction: Achalasia is a chronic condition presenting with dysphagia, regur-
gitation, chest pain and/or weight loss. Management options include Heller’s
myotomy, Botox, pneumatic dilatation and Per-Oral Endoscopic Myotomy
(POEM). Treatments carry risks of bleeding and perforation. Conomitant
portal hypertension with varices is very rare and achalasia treatmentin this con-
text has only been described in single case reports.
Aims & Methods: Experience from physicians/surgeons treating these disorders
was sought through the International Manometry Working Group.
Results: 13 patients with portal hypertension from 6 international centres have
been collected; mean age 61 9 years. The median pre- therapy Eckardt score
was 7 (IQR 6–9). 9/13 (69%) patients had a barium swallow and 12/13 (92%) had
oesophageal physiology studies performed. There were 3 Type I, 6 Type II, 2
Type III achalasia and 2 with oesophago-gastric outflow obstruction. Varices
were identified endoscopically in 7 patients, radiologically in 5 and in 1 patient
varices were first noted during surgical myotomy. 2 patients had grade 3 varices,
3 had grade 2 and 3 had grade 1 varices (grading not provided for the rest).
Cirrhosis was due to alcohol in 7 patients, non-alcoholic steatohepatitis in 3,
cryptogenic in 2 and 1 had hepatitis C cirrhosis. 75% were Child-Pugh A and
25% were Child-Pugh B. Patients had diverse treatments for their achalasia. 4
were treated with Botox injections (1 with EUS), 4 had dilation alone, 3 received
a POEM, another had POEM then dilation and 1 patient had Botox followed by
Heller’s myotomy. 3 patients underwent variceal eradication in advance; all had
banding first but in 2 patients superficial eradication was followed by a transju-
gular intrahepatic portosystemic shunt (TIPSS) before endoscopic dilation. All
patients had symptomatic improvement with median Eckardt score post inter-
vention¼ 1 (IQR 0–2) p5 0.0001 compared to baseline. A matched group of 20
patients who underwent treatment for achalasia (all subtypes) but without varices
had similar outcomes (p¼NS). No patients had recorded complications of bleed-
ing or perforation; however both patients who had TIPSS had temporary hepatic
decompensation.
Conclusion: This reports 13 patients from international centres who have had
interventions for achalasia on the background of oesophageal varices. None
had bleeding complications despite only 3 having had variceal eradication.
Symptom response mirrored those who undergo standard achalasia therapy,
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regardless of the severity of varices, treatment modality provided or achalasia
subtype.
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Introduction: Esophageal achalasia is classified into three clinically relevant pat-
terns at High Resolution Manometry (HRM) and according to Chicago
Classification. Currently, it is unclear whether they represent distinct entities or
are part of a disease continuum.
Aims & Methods: The aims of this study were: a) to test the hypothesis that the
three manometric patterns represent different stages in the evolution of esopha-
geal achalasia and b) to investigate whether manometric patterns change after
Laparoscopic Heller-Dor (LHD). We evaluated the patients who had a diagnosis
of achalasia and underwent LHD as first treatment from 1992 to May 2016.
Symptoms were scored using a detailed questionnaire for dysphagia, food-regur-
gitation, and chest pain; barium swallow, endoscopy, and esophageal manometry
(conventional or High Resolution technique) were performed, before and 6
months after surgical treatment. All conventional manometric tracings, before
2010, were reviewed and re-classified according to the manometric-pattern clas-
sification, whereas after 2010 the HRM data were prospectively collected.
Results: Five-hundred and eleven consecutive achalasia patients (M:F¼ 283:228)
represented the study population. Based on their manometric findings, 231
patients (45.2%) were classified as having pattern I, 241 (47.2%) had pattern
II, and 39 (7.6%) had pattern III. Demographic and clinical data showed that
pattern III cases had a shorter duration of symptoms, a more incidence of chest
pain, and a less dilated gullet (p5 0.001). Further, all patients with a sigmoid-
shaped mega-esophagus (radiological grade IV) had pattern I achalasia. One
patient with diagnosis of pattern III achalasia, who refused any treatment
evolved to pattern II at a follow-up manometry performed for a progressive
worsening dysphagia after 36 months. At a median follow-up of 30 months
(IQR 12–56), the outcome of surgery was positive in 479 patients (91.7%). The
only predictor of final outcome was the preoperative manometric pattern
(p5 0.001). All patients (42) whose surgical treatment failed underwent one or
more endoscopic pneumatic dilations using Rigiflex balloons (30, 35 or 40mm).
The overall success rate of the combined treatment (LHD plus endoscopic dila-
tions where necessary) was 98%. All patients with pattern I preoperatively had
the same pattern after LHD, whereas more than 50% of patients with pre-treat-
ment pattern III had patterns I or II after surgery. There were no cases showing
the opposite trend (Table 1). Five patients showed signs of a partial recovery of
peristalsis (all patients had a pattern II before LHD).
Table 1: Changing manometric patterns after LHD. *5 patients had a recovery
of peristalsis
Pattern 1 post Pattern 2 post Pattern 3 post
Pattern 1 pre 159(100%) 0 0
Pattern 2 pre* 65 (29.5%) 149 (67.7%) 0
Pattern 3 pre 7 (24.1%) 8 (27.6%) 8 (48.3%)
Conclusion: The data of this study strongly support the hypothesis/theory that
the different manometric patterns of achalasia could represent different evolutive
stages of the disease - where pattern III is the earlier stage, pattern II an inter-
mediate stage, and pattern I the end stage.
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Introduction: The development of non-invasive methods to detect the presence of
H. pylori, and to estimate the extent and severity of gastritis, have reduced the
need for diagnostic endoscopy in asymptomatic individuals. However, it is not
known whether the use of non-invasive diagnostic methods is effective in dys-
peptic patients.
Aims & Methods: To use a non-invasive blood test with four stomach-specific
biomarkers to assess the prevalence of different stomach conditions: gastroeso-
phageal reflux disease (GERD), H. pylori (HP) infection, chronic atrophic gas-
tritis (CAG), and the efficacy of proton pump inhibitor (PPI) therapy in a
primary care population. A cohort of 2583 dyspeptic patients (male 36%,
mean age 44.0 yrs, range 6–95) was selected in a primary care population and
examined with a panel of biomarkers [Pepsinogen-I (PG-I) and -II (PG-II),
amidated gastrin-17 (G-17), and HP IgG (Biohit, Finland)]. A standard ques-
tionnaire, including upper gastrointestinal symptoms and PPI use, was adminis-
tered. Exclusion criteria were dysphagia, anemia, weight loss and vomiting. CAG
patients underwent to endoscopy and histological examination.
Results: Healthy stomach was found in 21.2% patients. Prevalence of CAG
increased with patient’s age in both sexes as well as the use of PPIs
(p¼ 0.0001). Table 1 shows the serum biomarkers values divided according to
five categories: healthy stomach (H), GER, HP, CAG, and PPIs therapy.
Conclusion: The combination of data on the levels of PG-I, PG-II, G-17 and HP
IgG allow to diagnose different pathological conditions such as HP- and non HP-
related gastritis, the appropriateness of PPI administration, GERD and CAG, a
precancerous condition.
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Introduction: Functional dyspepsia (FD) is one of the most common functional
gastrointestinal disorders characterised by chronic or relapsing symptoms with-
out structural or biochemical abnormalities that can be identified in the routine
clinical setting. Thus, treatment targets symptoms. Very little is known about
prolonged treatment for more than 4 weeks.
Aims & Methods: The aim of the additional data analysis of a previous rando-
mized placebo-controlled trial was to explore post-treatment effects that occurred
after continuation of therapy after a 4-week randomized placebo controlled
treatment with Menthacarin1 with regard to disease-specific symptoms and
QoL in FD patients. After the 4-week randomised placebo-controlled treatment
period, patients were allowed to continue the treatment. The treatment was given
in a double-blind fashion and allocation of treatment followed the initial rando-
misation. 114 adult FD outpatients were initially treated and received twice a day
one enteric-coated Menthacarin capsule or a matched placebo capsule for 4
weeks. Fifty-four of them participated in the optional follow-up phase and
received Menthacarin (34) or placebo (20) for further 8 weeks according to
their original randomization. The results of these 54 patients are reported here.
Outcomes were assessed utilising the validated self-rating Nepean Dyspepsia
Index (NDI). Intra-individual differences between baseline and week 4/week 12
for NDI sub-scores for pain (sum of the NDI items ‘pain or ache in upper
Abstract No: P1831
H GER HP CAG PPI
Patients 548 (21.2%) 784 (30.4%) 353 (13.7%) 138 (5.3%) 760 (29.4%)
Sex (M/F) 162/386 311/473 111/242 43/95 294/466
Age (yrs) 39.6 14.0 40.3 13.0 45.0 13.6 59.1 16.8 c 47.8 15.6d
PG1 (ug/L) 79.1 28.5 72.3 23.9a 92.2 40.8b 12.3 9.7c 167.4 107.7d
PG2 (ug/L) 6.5 3.1 6.3 2.5 a 11.8 9.0b 9.6 10.2c 15.1 11.9d
PG1/PG2 13.1 4.2 12.3 3.9 9.3 3.7b 1.7 1.9c 12.9 5.1
G17 (pmol/L) 2.8 2.4 0.4 0.3a 4.8 8.4b 86.6 99.7c 12.2 16.0d
HP IgG (EIU) 8.9 6.5 9.8 6.8 85.2 34.7b 22.5 23.7c 24.5 34.3d
H vs GER ap¼ 0.0001 H vs Pbp¼ 0.0001, H vs CAG cp¼ 0.0001, H vs PPI dp¼ 0.0001
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abdomen’, ‘discomfort in upper abdomen’, ‘cramps in upper abdomen’ and
‘bloating in upper abdomen’) and discomfort (sum of the NDI items ‘pressure
in upper abdomen’ and ‘fullness after eating or slow digestion’) and for QoL by
NDI total score were compared and descriptively tested by means of Wilcoxon-
Mann-Whitney U-tests.
Results: After the initial 4 weeks, 54/114 patients opted for an extension of
therapy. Interestingly, 34 out of 52 patients had been on active therapy while
only 20 had received placebo. Until week 4, the NDI sub-score for pain had
decreased by 7.5 3.9 points during Menthacarin treatment as compared to
5.0 4.1 points during placebo treatment (p¼ 0.0371). After the follow-up, over-
all reduction for Menthacarin (8.7 4.9 points) was also significantly better as
compared to placebo (5.1 4.9 points, p¼ 0.005). The NDI sub-score for dis-
comfort had decreased until week 4 by 3.5 2.1 points during active therapy as
compared to 1.2 2.1 points during placebo treatment (p¼ 0.0003). For the 12-
week therapy, the score had declined by 3.7 2.5 points and 1.3 2.6 for
Menthacarin and placebo, respectively (p¼ 0.0014). Overall QoL improvement
was better for active medication for 4 and 12 weeks as compared to placebo.
Conclusion: After 4 weeks of randomised double-blind, placebo-controlled treat-
ment with either Menthacarin or placebo, patients who received active medica-
tion are more likely to opt for a continuation of therapy as compared to patients
on placebo. The gain over placebo remained significant even after 12 weeks of
treatment. 1 Menthacarin is a proprietary combination of essential oils of a
specified quality from Mentha piperita L. (90mg Peppermint oil WS 1340)
and Carum carvi (50mg Caraway oil WS 1520)
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Introduction: The introduction of proton pump inhibitors (PPIs) into clinical
practice has revolutionized the management of acid-related diseases. Studies in
primary care and emergency settings suggest that PPIs are frequently inappro-
priately prescribed or used in clinical conditions with little benefit.
Aims & Methods: To evaluate the role of Gastropanel in relation to the appro-
priateness of PPI-therapy prescription. 2583 dyspeptic patients (male 36%, mean
age of 44.0 yrs, range 6–95) with no alarm symptom (i.e., dysphagia, anemia,
weight loss and vomiting) from a primary care population were included in the
study. For each patient a blood sample was collected for serum Pepsinogen I
(PG-I) and II (PG-II), Gastrin 17 (G-17) and IgG HP (Biohit, Oyj, Finland);
moreover, a clinical questionnaire searching for symptoms and presence of HP,
and PPI therapy was filled out. We have evaluated the following serological
profiles: HP infection, chronic atrophic gastritis (CAG), response to PPI therapy.
The results obtained were used to evaluate the appropriateness of PPI-therapy
prescription.
Results: 1015/2583 (39.3%) received PPI therapy up to three months before
serum sampling and were included in the study. Among 1015 patients under
PPI therapy, 294 (29.0%) received half-dose PPIs, 709 (69.8%) full-dose PPIs
and 12 (1.2%) an exceeding-dose PPIs. 38 patients under PPIs therapy (3.7%)
showed a serological status compatible with body CAG (the definitive diagnosis
was confirmed histologically). 68 (6.7%) presented HP infection. Table 1 shows
the values of PG-I and G-17 values according to the response to PPI therapy.
Conclusion: An appropriate prescription of PPI should be preceded by the assess-
ment of gastric functional status. In particular, patients with HP infection should
be eradicated before PPI therapy, while CAG patients should not receive PPI
therapy because they are no responder. Patients who do not respond to PPI
therapy should be further investigated (compliance, diagnosis).
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Introduction: We recently reported that functional dyspepsia patients show
impaired duodenal integrity, associated with low-grade inflammation (Vanheel,
Gut 2014). A potential cause underlying this phenomenon may be the increased
duodenal acid exposure that has been demonstrated in some of these patients.
Aims & Methods: Our aim was to evaluate the effect of duodenal acid perfusion
on duodenal permeability in healthy volunteers and to investigate whether mast
cell activation is required for acid-induced impairment of mucosal integrity. As it
has already been shown that duodenal acid activates duodenogastric reflex path-
ways, we also assessed intragastric pressure (IGP). This study consisted of 2
parts, each including 10 healthy volunteers. 1) An infusion tube was positioned
in the second part of the duodenum and a high resolution manometry probe was
positioned in the stomach to measure IGP. HCl 0.1N or saline was infused in the
duodenum during 30min (5mL/min) in a randomized, double-blind manner.
Duodenal biopsy specimens were obtained after infusion to measure transepithe-
lial electrical resistance (TEER) and paracellular passage (fluorescein-labeled
dextran, 4 kDa) in Ussing chambers. Expression of cell-to-cell adhesion proteins
(claudin 1–4, occludin, zonula occludens 1–3, b-catenin, E-cadherin, desmocollin-
2, desmoglein-2) in biopsies was evaluated by PCR, western blot and/or immu-
nofluorescence. The number of mast cells and eosinophils was counted using
immunohistochemistry for tryptase and eosinophilic major basic protein respec-
tively, and by evaluating the expression of these proteins using PCR and western
blot. 2) The participants were orally treated with placebo or with the mast cell
stabilizer disodiumcromoglycate (DSCG) 200mg qid for 2 weeks. After treat-
ment, the study design was as described above (although only acid perfusion
was performed).
Results: IGP was significantly lower during acid perfusion compared with saline
perfusion (p¼ 0.003). Acidification also resulted in decreased TEER (p¼ 0.005),
increased passage (p¼ 0.007) and lower protein expression of claudin 3
(p¼ 0.0006). No difference in mast cell (p¼ 0.34) and eosinophil (p¼ 0.34)
counts were detected, but an increased protein expression of tryptase
(p¼ 0.0008) was found after acid perfusion. In the placebo and the DSCG
group, acidification induced a similar drop in IGP (p¼ 0.68). There was also
no difference in TEER (p¼ 0.70) and passage (p¼ 0.21) after acid perfusion
between both pretreatments.
Conclusion: Duodenal acid perfusion in healthy volunteers disrupts epithelial
integrity and activates an inhibitory duodenogastric reflex. Although this effect
seems to be independent from mast cell activation, increased duodenal acid
exposure in functional dyspepsia is a potential pathophysiological mechanism
contributing to abnormalities in duodenal and gastric structure and function
observed in patients with functional dyspepsia.
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Introduction: Gastric acid secretion is believed to decrease in the aging stomach,
but the number of elderly patients on proton pump inhibitor (PPI) therapy is
Abstract No: P1833
Therapy Gastric Functionl status Gastric Functionl status
N Half PPI n.,% Full PPI n.,% Excess PPI n.,% PG-I (ug/L) meansþ/DS G-17 (pmol/L)meansþ/DS
All 1015 294 709 12 137.0þ/84.7 11.7þ/21.1
Good response G-174 7 351 83 (23.6) 259 (73.8) 9 (2.6) 194.5þ/121.1 22.1þ/17.9
Low response G-17 1–7 421 141 (33.5) 279 (66.3) 1 (0.2) 127.1þ/8.3 3.1þ/1.76
No response G175 1 205 64 (31.2) 140 (68.3) 1 (0.5) 91.7þ/40.9 0.38þ/0.28
CAG 38 6 (15.8) 31 (68.3) 1 (2.6) 16.6þ/14.8 70.3þ/55.2
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increasing. Pepsinogen I (PGI) 530 mg/L, PGI/PGII 53 and gastrin-17 (G17)
410 pmol/L are non-invasive serological markers surrogate to explore gastric
function, with a negative predictive value for chronic atrophic gastritis (CAG) of
96%.
Aims & Methods: Aim of the study was to evaluate gastric function by means of
serology (PGI, PGII, G-17 and IgG-antibodies against Helicobacter pylori) in
very elderly patients, including centenarians. A total of 379 patients were pro-
spectively enrolled (M¼ 126, F¼ 253, mean age¼ 83.6 8.7, range 70–106).
They were divided in four groups: 132 subjects with an age between 70 and 79
years old (first group), 146 subjects between 80 and 89 (second group), 76 sub-
jects between 90 and 99 (third group) and 25 subjects between 100 and 106
(fourth group). Demographics and drug intake, particularly the PPI intake,
were collected. For all patients, serological markers were determined in fasting
blood by using Gastropanel (Biohit Oyj, Finland; normal values: PGI: 30–
120 mg/L; PGII: 2–15mg/L; PGI/PGII ratio: 43; G17: 1–9 pmol/L; H.p.-IgG:
530 EIU).
Results: In the first group (age 70–79), 18.2% of the subjects showed H. pylori
infection (PGII 410 mg/L, IgG against H.p. 430 EIU), 22.7% had CAG (PGI
530 mg/L and PGI/PGII 53) and 53.8% were under PPI therapy. 16.9% of the
patients on PPI therapy had CAG. In the second group (age 80–89), 32.9% of the
subjects showed H. pylori infection, 8.9% had CAG and 48.6% were under PPI
therapy. 8.5% of the patients on PPI therapy had CAG. In the third group (age
90–99), 22.4% of the subjects showed H. pylori infection, 10.5% had CAG and
48.7% were under PPI therapy. 8.1% of the patients on PPI therapy had CAG.
In the fourth group (age 100–106), 44.0% of the subjects showed H. pylori
infection, 16.0% had CAG and 72.0% were under PPI therapy. 16.7% of the
patients on PPI therapy had CAG.
Conclusion: Acid secretion is preserved in most of the elderly and very elderly
subjects, even in centenarians. Serological markers may be helpful to identify
patients affected by CAG in which the administration of PPI is inappropriate,
especially in the elderly.
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Introduction: Reflux hypersensitivity (RHV) was lately defined as a functional
esophageal disorder by Rome IV workshop. The clinical and psychological char-
acteristics are still unknown.
Aims & Methods: The aim of this study was to assess the reflux and psychological
characteristics of RHV. Patients who underwent 24 h pH-impedance monitoring
were screened from Jan 1st 2011 to Nov 31st 2015. The patients with heartburn or
chest pain 2 days/week for more than 6 months were enrolled. Healthy volun-
teers (HV) were enrolled too. All subjects fulfilled the SCL-90 questionnaire,
underwent gastroscopy to exclude upper gut organic diseases and underwent
HRM test to exclude main motility disorders. The patients with normal esopha-
geal mucosal but overload acid, weakly acid or non-acid reflux were diagnosed as
non-erosive reflux disease (NERD). The patients with normal esophageal muco-
sal and normal reflux but positive symptom index (SI) or symptom association
possibility (SAP) were diagnosed as RHV. And the patients with normal muco-
sal, normal reflux, normal SI or SAP and negative PPI test results were enrolled
in functional heartburn (FH) group. The reflux and psychological characteristics
were compared among NERD, RHV and FH.
Results: Total 231 patients were enrolled. 107 were NERD (48.25 1.18 yrs,
M:F¼ 55:52), 92 were FH (48.30 1.27yrs, M:F¼ 9:83), 32 were RHV
(48.41 2.36yrs, M:F¼ 4:28). 28 HVs (47.21 2.27, M:F¼ 8:20) were enrolled
as controls. NERD presented significantly higher acid exposure time (pH4 4.2)
than those of FH, RHV and HV (6.55 0.71,1.25 0.12,1.90 0.33, 2.95 0.53,
respectively, p5 0.005). The acid reflux and weakly acid reflux were both higher
in NERD than that in FH, RHV and HV (p5 0.001). The total scores of SCL-90
of each group of patients were significantly higher than HV (NERD:HV,
133.15 3.68 vs. 108.61 4.51,p¼ 0.004; FH:HV, 133.15 3.68 vs.
108.61 4.51,p¼ 0.003; RHV:HV, 142.67 8.91vs. 108.61 4.51,p¼ 0.002).
RHV patients presented higher compulsive factor score than FH (1.85 0.16
vs. 1.58 0.06, p¼ 0.047) and HV (1.85 0.16 vs. 1.37 0.09, p¼ 0.004). The
patients of NERD, FH and RHV presented significantly higher depression,
anxiety, hostile factor scores than those of HV (p5 0.05).
Conclusion: NERD, RHV and FH patients showed higher scores than HVs in
total and most factors of SCL-90. Furtherly, RHV patients presented higher
compulsive score than FH, NERD and HVs. The role of senseless thought,
impulse, and act of compulsive behavior in the pathogenesis of RHV needs to
be studied furtherly.
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Introduction: High-Resolution Manometry (HRM) has recently became the gold
standard for the evaluation of esophageal motility. A new classification of eso-
phageal motility disorders (Chicago Classification, v. 3.0) has been developed,
based on the findings from a given hardware and software. Different systems for
HRM and new features of the existing ones have recently been developed.
Aims & Methods: In this study we aimed to evaluate a new solid-state HRM
system and a new 3-D catheter and system for the study of lower esophageal
sphincter (LES). Fifteen healthy volunteers (7m, 8 f, median age 27) underwent
two consecutive Esophageal HRM studies by using two different solid state
systems (ManoScan, Medtronic, Minneapolis, USA and Medica SpA, Italy
with Unisensor AG, Attikon, Switzerland catheter). The studies were performed
in a random order using the standard protocol. Furthermore, a new 3-D catheter
for the study of sphincters was evaluated in 12/15 volunteers.
Results: Table 1 reports the findings obtained with the Medica system compared
to the consolidated Medtronics system. The data of the 3-D evaluation are also
reported. The data are expressed as medians (and 5th-95th percentiles).
Conclusion: Significant differences were recorded in most of the considered para-
meters obtained by the two HRM systems. This is particularly relevant in the
evaluation of the LES relaxation, the cardinal point in the hierarchical approach
of the Chicago Classification, probably due to different analysis used by the two
systems (the lowest residual pressure vs IRP). Furthermore, the differences found
in the measurement of the LES resting pressure and abdominal length may rely
either on the different technology (3-D vs linear transducers) or on the different
algorithms and thresholds used. The latter may probably also apply to the dif-
ferences found with the two systems in the duration of the esophageal contrac-
tions and in the new contractile parameters (i.e.: DCI and DL) introduced by the
Chicago Classification. This study emphasizes the need for a careful validation of
any new system for esophageal manometry. The acquisition of new sets of
normal values, to be used to compare the data measured in patients, is therefore
mandatory. The results of our study may represent the reference normal values
for other esophageal laboratories that are using the HRM systems and devices we
tested here.
Disclosure of Interest: All authors have declared no conflicts of interest.
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LES Resting
pressure
(mmHg)
LES Overall
length (cm)
LES Abdominal
Length (cm)
LES Residual
pressure/IRP
(mmHg)
Amplitude
3–5 cm
(mmHg)
Amplitude
7–9 cm
(mmHg)
Amplitude
11–13 cm
(mmHg)
A. Medica/Unisensor 17.5 (6.5–31.5) 3.7 (2.8–5.3) 1.0 (0–2.3) 0 (0.7–4.5) 111 (56–224) 74 (37–134) 75 (33–112)
B. Medtronics 33.1 (16–56) 4.1 (2.0–5.0) 1.9 (0.1–2.8) 14.1 (3.8–15.9) 94 (61–155) 80.8 (50–154) 67 (40–114)
C. 3-D Medtronics 39.3 (26–60) 4.0 (2.9–5.6) 2.35 (0.6–3.8) 14.2 (1.4–25) _ _ _
p A vs B¼ p B vs C¼ 50.01 50.01 0.94 0.48 0.01 0.06 50.001 0.46 0.9 0.15 0.17
Duration 3–5 cm
(sec)
Duration 7–9 cm
(sec)
Duration 11–13 cm
(sec)
Distal Contractile
Index (DCI) (mmHg*s*cm)
Distal Latency
(DL) (sec)
IntraBolus
Pressure (IBP) (mmHg)
A. Medica/Unisensor 3.1 (1.7–4.6) 1.7 (1.0–3.1) 2.4 (1.4–3.3) 3000 (1167–6200) 8.8 (7.45–12.5) 7.1 (0.2–19)
B. Medtronics 3.7 (2.8–5.1) 3.2 (2.6–4.3) 3.0 (2.4–4.2) 1583 (650–2760) 6.4 (4.7–8.9) 10.4 (8.7–14.95)
p A vs B¼ 0.01 0.002 0.004 50.001 50.001 0.13
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Introduction: Proton Pump Inhibitor-response esophageal eosinophilia (PPI-
REE) is a condition characterised by symptoms of esophageal dysfunction in
the setting of eosinophilic inflammation on esophageal biopsies responding to
a course of 8 weeks of PPI therapy. Recent data collected by using esophageal
high resolution manometry (HRM) documented that patients with PPI-REE
present frequently motility abnormalities, mostly weak peristalsis and hypoten-
sive esopahgogastric junction (EGJ). Data on the effect of PPIs in improving
these motor abnormalities are lacking.
Aims & Methods: We aimed to prospectively compare HRM features of patients
with PPI-REE before and after a course of PPI therapy. Consecutive patients
with symptoms suggestive of EoE underwent upper endoscopy to assess the
presence of at least 15 eos/hpf on oesophageal biopsies at mid/proximal esopha-
gus and, then, were treated with twice-daily PPIs for at least 8 weeks. Thereafter,
patients repeated upper endoscopy and PPI-REE was identified in case of less
than 15 eos/hpf and a 50% decrease from baseline. Patients with PPI-REE
underwent HRM at the time of the diagnosis (off-PPI) and after the course of
PPIs (on-PPI). Patients with achalasia and absent peristalsis were excluded
(Chicago Classification v.3).
Results: Twenty-eight patients [23M/5F; mean age 35] reporting dysphagia
(93%), bolus impaction (68%) and chest pain (25%) were diagnosed with PPI-
REE. After anti-secretory therapy, most of the patients reported complete reso-
lution of esophageal symptoms directly linked to esophageal infiltration
(p5 0.001), namely dysphagia, bolus impaction and chest pain. Compared to
HRM features at baseline, HRM after PPI therapy showed that patients with
PPI-REE had higher median EGJ resting pressure [baseline 11 (1–34) vs. post-
PPI 17 (1–34); p5 0.05], greater mean distal contraction integral [1094 (483–
5281) vs. 2634 (495–6450); p5 0.01], and less frequent panesophageal pressur-
ization [6 (21%) vs. 0 (0%); p¼ 0.02)]. No differences were observed in terms of
distal latency and rate of different EGJ subtypes (p¼ ns). As to the manometric
diagnoses, after PPI therapy patients with PPI-REE showed a reduced rate of
ineffective motility or fragmented peristalsis [16 (57%) vs. 7 (25%), p¼ 0.02] and
increased frequency of normal peristalsis [9 (32%) vs. 18 (64%), p¼ 0.03]. No
differences were observed in terms of frequency of distal esophageal spasm and
outflow obstruction diagnoses (p¼ns).
Conclusion: In most PPI-REE patients, PPI therapy restores the impairment of
esophageal motility as expressed by ineffective or fragmented peristalsis, thus
favouring the return to a normal motility pattern. This finding, paralleled with
symptoms improvement in the same subjects, seems to emphasize the important
role of inflammation linked to the eosinophilic infiltration of the esophageal wall
in inducing motor dysfunction and related symptoms.
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Introduction: In recent years, new guidelines and recommendations have been
published regarding the diagnostic criteria and therapeutic management of eosi-
nophilic esophagitis (EoE).
Aims & Methods: The aim of this study was to assess the diagnostic and ther-
apeutic management of patients diagnosed with EoE in daily clinical Dutch
practice and whether this was according to guidelines and recommendations.
A population-based, retrospective cohort study was conducted using data from
the Dutch national pathology registry (PALGA), medical records, and telephone
interviews of patients diagnosed with EoE in two academic and two non-aca-
demic hospitals in the period 2004–2014. Data regarding demographics, clinical
manifestations, endoscopic results, histologic samples and therapeutic strategies
were collected. Standard statistical analyses were performed to summarize the
patient characteristics.
Initial treatment after diagnosis EoE
Treatment,
n (%)
Total,
n (%)
(n¼ 119)
AC 1,
n (%)
(n¼ 49)
AC 2,
n (%)
(n¼ 27)
Non AC 1,
n (%)
(n¼ 25)
Non AC 2,
n (%)
(n¼ 18)
TCS 36 (30.3) 17 (34.7) 5 (18.5) 11 (44.0) 3 (16.7)
PPI 35 (29.4) 16 (32.7) 8 (29.6) 4 (16.0) 7 (38.9)
PPIþTCS 12 (10.1) 5 (10.2) 1 (3.7) 4 (16.0) 2 (11.1)
Dilation 3 (2.5) 0 2 (7.4) 0 1 (5.6)
Prednisone 2 (1.7) 0 1 (3.7) 1 (4.0) 0
TCSþ dilation 1 (0.8) 1 (2.0) 0 0 0
Diet 0 0 0 0 0
None 24 (20.2) 9 (18.4) 8 (29.6) 4 (16.0) 3 (16.7)
Missing 6 (5.0) 1 (2.0) 2 (7.4) 1 (4.0) 2 (11.1)
Results: In total, 119 patients were diagnosed with EoE and included in this
study. The median age at onset of symptoms was 29 years (IQR, 15–42) and
the median age at diagnosis was 38 years (IQR, 23–51 years), leading to a median
diagnostic delay of 6.5 years (IQR, 2–14 years). The median delay in diagnosis
between first contact in the hospital and diagnosis was 1.0 year (IQR, 2–14
years). The incidence of patients newly diagnosed with EoE increased steadily
over a period of 11 years. Criteria for the microscopic diagnosis of EoE varied
between pathologists in each hospital. Initial treatment included topical corticos-
teroids (30.3%), proton pump inhibitors (PPIs) (29.4%) or a combination of
both (10.1%). A follow-up endoscopy was performed in 40.3% of patients.
During follow-up, treatment included PPIs (76.0%), topical corticosteroids
(59.6%) or a combination of both (45.4%).
Conclusion: Diagnostic and therapeutic discrepancies between daily clinical prac-
tice and recommendations from current and past guidelines were observed.
Remarkably, the diagnostic entity PPI-responsive EoE was only used in one
center, follow-up endoscopy was performed in less than half of patients and all
pathologists used different criteria for the microscopic diagnosis of EoE.
Moreover, varying therapeutic strategies were utilized in the participating cen-
ters. Our results show that apart from developing guidelines, efforts should be
undertaken to implement them in daily clinical practice.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Eosinophilic Esophagitis (EoE) is a chronic immune disease of the
esophagus, which is presented by esophageal dysfunction und histologically char-
acterized by a predominant eosinophilic inflammation. EoE is mainly found in
patients with atopic conditionsHowever, recently an association with IgG4 but
not with IgE has been reported. Gastroesophageal reflux disease (GERD) is the
most important differential diagnosis of EoE. In this study we measured systemic
serum IgG4 and IgE levels of EoE patients before and a after a topic steroid
therapy, correlated them to esophageal IgG4-positive plasma cells and compared
them to GERD patients.
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Aims & Methods: Serum levels of IgG4 and IgE of 19 EoE patients were mea-
sured before and after eight weeks of therapy with budesonide (1mg twice a day).
Biopsies were taken from the esophagus before and after therapy for histological
and immunhistochemical evaluation. 14 patients with GERD without histologi-
cal proof of eosinophilic granulocyte infiltration were taken a as control group.
Serum levels of IgG4 and IgE of 19 EoE patients were measured before and after
eight weeks of therapy with budesonide (1mg twice a day). Biopsies were taken
from the esophagus before and after therapy for histological and immunhisto-
chemical evaluation. 14 patients with GERD without histological proof of eosi-
nophilic granulocyte infiltration were taken a as control group.
Results: Serum IgG4 levels of EoE patients were significantly higher than in
GERD patients (mean: 121.0mg/dL vs. 71.2mg/dL, p¼ 0.034). In contrast, no
significant difference of IgE levels in EoE and GERD patients was observed. In
EoE patients, the number of eosinophilic granulocytes in histology was decreased
at a significant level after topic steroid therapy (mean: 51.9 eosinophiles/high
power field (hpf) vs. 6.4 eosinophiles/hpf p5 0.001). After therapy lower levels
of IgG4-serum-levels could be measured (mean: 121.0mg/dL vs. 104.2mg/dL
p¼ 0.019), whereas IgE levels did not show a significant difference.The esopha-
geal biopsies of EoE patients showed a high number of IgG4-positive plasma
cells (mean expression of 27.4 IgG4-positive plasma cells of 46.4 stromal plasma
cells/hpf).
Conclusion: EoE patients show higher systemic IgG4- but not IgE-serum levels
compared to GERD-patients. These elevated levels normalize under effective
topic steroid therapy. Additionally high local expression of IgG4- positive
plasma cells can be seen in EoE patients. These findings might be further evi-
dence for a possible IgG4-association of EoE.
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Introduction: Measurement of Health-related quality of life (HRQoL) with gen-
eric or specific intruments has been increasingly used in patients suffering from
EoE to support both research and clinical care. Generic instruments aim at
measuring the overall HRQoL of patients across several conditions, being
useful to compare HRQoL across different disease states and for evaluating
health economics outcomes. Disease-specific instruments assess domains specific
to a given disease and are considered more sensitive to changes in the patient’s
health state. An up-to-date systematic review will provide a useful resource for
researchers and EoE specialists to ensure they can select an appropriate HRQoL
measure for patients in their practice in order to identify correctable factors
determining an impaired perception and to improve treatment outcomes.
Aims & Methods: We aim to systematically review the current HRQoL measures
for patients with EoE and to appraise their measurement properties using a
robust evaluation methodology checklist. We also sought to identify disease-
specific determinant factors for HRQoL in children and adults with EoE, and
the effect of investigations and interventions for EoE on HRQoL. A search
strategy was designed to identify and retrieve all documents dealing with the
relationship between HRQoL and EoE in children and adults. This systematic
literature search was performed in 5 major databases (PubMed, EMBASE,
Scopus, PsycInfo and Web of Science) for the period up to March 2017. The
measure properties of each specific EoE instrument identified and their perfor-
mance properties were assessed using the quality properties checklist proposed by
Terwee et al. Levels of the HRQoL measure establishment or use in literature: we
used Cohen’s criteria. Cohort studies, case series and case reports were evaluated
for the risk of bias with the aid of the Joanna Briggs Institute critical appraisal
checklist. A descriptive summary with data tables was produced to summarize
the literature. Quantitative pooling of data was not meaningful so a narrative
synthesis of the data was undertaken.
Results: Of the 596 references identified, data was collected from 34 studies
including a total of 1,842 individual patients. Three disease-specific HRQoL
measures in EoE covering different aspects of patients’ lives and developed in
English were scored positive regarding measurement properties. Respectively, the
PedsQL inventory (including parent and child report forms) and the Peds-QoLä
EoE module were the generic and specific instruments respectively used in chil-
dren, while the SF-36 and EoE-QoL-A were the most used questionnaires in
adults. EoE significantly impairs HRQoL of affected children and adolescents,
which manifests in the normal development of their daily activities, their physical
health and their mental status, with parents generally underestimating the impact
of the disease regarding children declared HRQoL. Regarding determinant fac-
tors, age was not associated with HRQoL. Number and severity of symptoms
negatively correlated with child-reported and Parent proxy-reported PedsQL
score and family impact score. Disease duration was identified as a risk factor
for a low SF-36 score. EoE impacts on a number of domains including frustra-
tion, embarrassment or fear about the disease outcomes. No significant differ-
ences in the overall QoL score were found in adult patients managed with dietary
or pharmacological therapy, with specific treatment modalities having a negligi-
ble influence on overall EoE-specific QoL. Symptoms scores determined exerted
an increased impact on swallowing anxiety and emotional impact subscales.
Female gender negatively influenced QoL scores. Disease activity, as expressed
by endoscopic findings, were also significant determinants of QoL. A higher
educational level was also found to be a strong determinant for a worse QoL.
Emotional impact was the only dimension with a significantly worse score in
patients under dietary restrictions.
Conclusion: HRQoL is a relevant outcome that should be considered in clinical
practice and research of EoE. Further validation studies in several languages and
populations are required to support the use of disease-specific HRQoL measures.
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Introduction: Available treatment options for adult EoE patients include drugs
(proton-pump inhibitors [PPI], swallowed topical corticosteroids [STC]), food
elimination diets, and esophageal dilation. Knowledge about patients’ view
regarding the different therapeutic options is very limited.
Aims & Methods: We aimed to systematically assess adult EoE patients’ satisfac-
tion with different EoE-specific treatment modalities. We first created a ques-
tionnaire that included items that queried general demographic characteristics (7
items), EoE-specific patient history and presence of atopic disease (8 items), past
and present EoE-specific therapy (9 items), concomitant medication use (7 items),
important considerations for choice of therapy (2 items), as well as treatment
satisfaction with various therapies recalled over a period of 12 months (assessed
using the validated ‘‘Treatment Satisfaction Questionnaire for Medication’’
[TSQM], 52 items). The TSQM consists of 14 items falling into 4 scales: effec-
tiveness (3 items), side effects (5 items), convenience (3 items), and overall satis-
faction (3 items). The score for each TSQM scale ranges from 0 (dissatisfied) to
100 (satisfied). In analogy with other conditions, a score above 66.6 and 83.3
identifies patients that are ‘satisfied‘ and ‘very satisfied’ with therapy, respec-
tively. The psychologist-guided focus groups with adult EoE patients were con-
ducted to inform the content and the structure of the questionnaire and ensure
that patient understand the items, instructions, and response options. The ques-
tionnaire was sent to 148 patients in Switzerland. Data were double-entered by
two researchers into an EpiData database (version 3.1, the EpiData Association,
Odense, Denmark). Dataset was then imported into Stata (version 13, College
Station, Texas, USA) for analysis.
Results: Patient response rate was 73.5% (108/147). Mean patient age at inclu-
sion was 46.3 15.9 years, 85/108 (78.8%) of patients were male, and mean
disease duration (from the time of diagnosis to the time of enrollment) was
6.8 5.1 years. In the last 12 months, 11.1%, 48.1%, 10.2%, and 28.7% of
patients reported to have suffered from symptoms of asthma, rhinoconjunctivitis,
eczema, and food allergy, respectively. In the last 12 months, 25.0%, 3.7%,
77.8%, 1.9%, 19.4%, and 13.0% were treated with PPI, STC in the form of a
syrup, STC in the form of a powder, STC in a form of a spray, diet, and
esophageal dilation, respectively (37.0% patients received more than one treat-
ment; 7.4% of patients did not receive any treatment). Patients identified the
following considerations as important for the choice of therapy: the effect of the
treatment on the symptoms (88.9%), the effect of treatment on esophageal
inflammation (75.9%), possible side effects (69.4%), ease of therapy use
(58.3%), recommendation of the physician (50.0%), and compatibility of therapy
with lifestyle (46.3%). When asked about single most important criterion for the
choice of therapy, 48.5%, 33.7%, 11.9%, 3.0% and 2.0% of patients chose the
effect of treatment on symptoms AND esophageal inflammation, the effect of the
treatment on the symptoms, the effect of treatment on esophageal inflammation,
compatibility of therapy with lifestyle, possible side effect, and recommendation
of the physician, respectively, as deciding factor. The TSQM scales scores as well
as average TSQM values for patients on PPI, STC, and diet are shown in Table 1.
Conclusion: Adult EoE patients consider both effect of medication on symptoms
as well as inflammation as most important criteria, when choosing EoE therapy.
EoE patients appear to be ‘satisfied’ with PPI, STC, and dietary therapy and
‘very satisfied’ with STC, if the therapy is taken twice daily.
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Introduction: For technical reasons, the histologic characterization of eosinophi-
lic esophagitis (EoE)-specific alterations is almost exclusively based on those
found in the esophageal epithelium, whereas little is known about subepithelial
abnormalities.
Aims & Methods: In this study, we aimed to systematically assess the nature of
subepithelial histologic alterations, analyze their relationship with epithelial his-
tologic findings, endoscopic features, and symptoms, and evaluate the diagnostic
impact of subepithelial eosinophil counts in patients with an epithelial peak
eosinophil count of 515/hpf. We prospectively included in this cohort study
adult EoE patients who underwent assessment of clinical, endoscopic, and his-
tologic disease activity using scores.
Results: We included 200 EoE patients (mean age 43.5 15.7 years, 74% males)
with a median peak count of 36 intraepithelial eosinophils/hpf [IQR 14–84]. The
following histologic features were identified in the subepithelial layer: eosinophi-
lic infiltration (median peak count of 20 eosinophils/hpf [IQR 10–51]), eosinophil
degranulation (43%), fibrosis (82%), and lymphoid follicles (56%). Peak intrae-
pithelial eosinophil counts were higher, identical, and lower when compared to
the subepithelial layer in 62.5%, 7%, and 30.5% of patients, respectively.
Subepithelial histologic activity correlated with epithelial histologic activity
(rho 0.331, p5 0.001), endoscopic severity (rho 0.208, p¼ 0.003), and symptom
severity (rho 0.179, p¼ 0.011). Forty percent (21/52) of patients with 515 intrae-
pithelial eosinophils/hpf had subepithelial peak counts of 15/hpf.
Conclusion: In one third of patients subepithlial peak eosinophilc counts are
higher than epithelial eosinophil counts. Systematic assessment of subepithelial
eosinophil counts can aid in diagnosing EoE in additional 40% of all patients
with epithelial eosinophils 515/hpf.
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Introduction: The modern understanding of gastroesophageal reflux disease
(GERD) pathogenesis includes cell and molecular mechanisms of associated
esophagus mucosal inflammation and Th1/Th2 immune response imbalance
due to the recurrent exposure to acidic and nonacidic refluxate of gastric con-
tents. Th1 or Th2 immune response is mainly predetermined by innate and
adaptive immune response cells - macrophages. Considering the concept of
M1/M2 macrophage phenotype programming and paradigm of Th1/Th2
immune response M1/M2 macrophage phenotype imbalance is one of the main
cell components of GERD mucosal inflammation.
Aims & Methods: We aimed to assess the influence of refluxate type on macro-
phage phenotype and compare the data with predominated macrophage pheno-
type in systemic circulation in GERD patients. 68 patients with different forms of
GERD and Barrett’s esophagus were included in the study. Macrophage pheno-
type was assessed in vitro by adding acidic and nonacidic refluxates of patients
(n¼ 68) with different pH (4.6–6.6, n¼ 31 (group I); 6.7–7.2, n¼ 28 (group II);
7.3–8.1, n¼ 6 (group III)) to peritoneal macrophages of C57/BL6 mice (n¼ 68)
with the following macrophage culturing in standard conditions (10% FBS,
RPMI1640) for 36 hours. Monocytes were isolated from the patients’ blood
samples and cultured to macrophages (monocyte derived macrophages, MDM)
in standard conditions -RPMI1640 medium, 10% FBS, 37oC, 5% CO2. Pooled
analysis of macrophage and MDM phenotype included assessment of secretory
activity (Th1/Th2 cytokine production in culture medium, Antigenix, USA),
typical M1/M2 surface macrophage CD markers (CD25, CD80 and CD163,
CD206, respectively) performed by flow cytometry (Beckman Coulter FC500).
Results: Analysis of cytokine macrophage production revealed the prevalence of
Th1 and Th1/Th2 bivalent (IL-2, IL-6) cytokines as compared to Th2. The most
significant changes due to the influence of refluxate pH were observed in Th1
cytokine IL-8, TNF and TNFb. Increasing of pH resulted in 2 times-fold, 1.8
times-fold and 3.5 times-fold fall of these cytokines production respectively
(p5 0.05). Th2 cytokine macrophage production increased with increasing pH,
and most significantly changed in IL10: 8.43 3.13 pg/ml in group I
vs.27.7 8.65 pg/ml in group III (p5 0.05). The expression of surface M1/M2
macrophage CD markers significantly varied depending on the acidity of reflux-
ate. Mild-alkaline pH (III group) resulted in increasing expression of M2 markers
CD163/CD206 as compared to M1–CD80/CD25, but changing M1/M2 index of
CD expression still showed the prevalence of M1 phenotype in groups:
2.49 0.15 (II) vs 1.29 0.12 (III) (p5 0.05). Analysis of MDM phenotype
showed the prevalence of M1 phenotype in all groups.
Conclusion: Pooled analysis of GERD patients refluxate type influence on macro-
phage phenotype showed the prevalence of M1 proinflammatory activated
macrophages (Th1) with increased expression of M1 surface markers and pre-
dominantly increased production of Th1 cytokines (IL-8, TNF, TNFb). The
changes were more expressed in macrophages exposed to acid refluxate. The
effect of mild-alkalotic refluxate resulted in definite trend of increasing expres-
sion of CD M2 markers and increased production of Th2 cytokines as compared
to the other refluxate types. Analysis of MDM phenotype showed the prevalence
of M1 phenotype regardless of refluxate pH.
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Introduction: The pathophysiology of heartburn perception in gastro-esophageal
reflux disease (GERD) remains unclear. The degree of reflux-induced epithelial
change seldom predicts symptom severity, as evidenced by the greater symptom
burden seen in non-erosive reflux disease (NERD) compared to patients with
Barrett’s esophagus (BE). Existing models of acid hypersensitivity are inadequate
to explain this discordance.
Aims & Methods: To test the hypothesis that differences in peripheral esophageal
mucosal innervation may be relevant, we studied the distribution of mucosal
nerve fibers in patients with NERD and BE and compared the results with
that of healthy subjects. 13 patients with NERD undergoing reflux testing and
16 patients with BE undergoing endoscopic surveillance were prospectively
recruited. Biopsies were obtained from the proximal and distal esophageal
mucosa in NERD patients and the distalmost squamous epithelium in BE
patients, then examined immunohistochemically for presence and location for
calcitonin gene-related peptide (CGRP)-immunoreactive nerve fiber. The results
were compared with those from 10 healthy volunteers (HV) previously studied by
our group.
Results: The distribution of mucosal CGRP-immunoreactive nerves is equidi-
stant from the distal esophageal lumen in HV and BE (median 25.5 cell layers
to surface [IQR 21.4–28.8] vs 21.5 [16.1–27.5] respectively, p¼ 0.155). Mucosal
innervation is significantly more superficial in NERD both distally (9.5 cell layers
[1.5–13.3], p5 0.0001 vs both BE and HV) and proximally (5.0 [2.5–9.3],
p¼ 0.0098 vs HV).
Conclusion: The acid hypersensitivity seen in NERD may be partially explained
by the increased proximity of mucosal afferents to the esophageal lumen, and
therefore greater exposure to noxious substances in refluxate. Conversely, the
relative acid hyposensitivity in BE may be attributed to the deeper location of
mucosal nerves.
Abstract No: P1842
Table 1: TSQM scales scores for PPI, STC (in powder form), and different diets in adult EoE patients.
TSQM scales
PPI (n¼ 27; median
treatment duration 6
years [3–9]
STC (n¼ 84; median
treatment duration 5
years [2–6]
STC only (n¼ 17; once
daily; median treatment
duration 5 years [3–6]
STC only (n¼ 22; twice
daily; median treatment
duration 3.5 years [1–6]
Diet (n¼ 21; median
treatment duration 2
years [1–4.5]
Effectiveness
Side-effects
Convenience
Overall satisfaction
Average score
66.7 [38.9–77.8] 100
[100–100] 88.9 [77.8–
100] 71.4 [50–85.7] 79.8
[69.4–85.5]
83.3 [66.7–94.4] 100
[100–100] 83.3 [66.7–
100] 78.6 [64.3–92.9]
84.4 [72.8–92.3]
77.8 [61.1–94.4] 100
[100–100] 72.2 [61.1–
100] 78.6 [57.1–92.9]
80.1 [71.3–89.4]
83.3 [72.2–100] 100
[100–100] 75 [61.1–100]
85.7 [64.3–92.9] 83.8
[69.9–94.4]
77.8 [50–88.9] 100 [100–
100] 50 [33.3–66.7] 78.6
[57.1–92.9] 76.6 [59.8–
81.9]
United European Gastroenterology Journal 5(5S) A795
Disclosure of Interest: P. Woodland: Research grant Reckkit Benckiser (Hull
UK)
D. Sifrim: research grant Sandhill Scientific (Denver USA) research grant
Reckkit Benckiser (Hull UK)
All other authors have declared no conflicts of interest.
P1846 BELCHING PATTERNS IN PATIENTS WITH ISOLATED
PATHOLOGICAL UPRIGHT REFLUX AND PATHOLOGICAL
BIPOSITIONAL REFLUX
J.M. Conchillo, J. T.w. Snijkers, J. Santos Fernandez, A. A.m. Masclee
Gastroenterology, Maastricht UMC, Maastricht/Netherlands
Contact E-mail Address: j.conchillo@mumc.nl
Introduction: Belching is a commonly occurring symptom in patients with gastro-
esophageal reflux disease (GERD). Belching may elicit reflux. It is unknown
whether GERD patients with isolated pathological upright reflux (UP) have
belching patterns that are different from GERD patients with pathological bipo-
sitional reflux (BIP).
Aims & Methods: Aim of this study was therefore to examine the belching pat-
terns of UP reflux patients as compared with BIP reflux patients. We included 50
consecutive patients with pathological reflux and typical symptoms who under-
went 24-h pH-impedance monitoring at the Maastricht University Medical
Centre from 2015 to 2017. Patients referred for excessive belching were excluded.
A group of 25 UP reflux patients (10 male, mean age 52.9 years (range 22–77))
and 25 BIP reflux patients (11 male, mean age 47.9 years (range 18–77)) were
enrolled. All 24-h pH-impedance tracings were analysed manually. We classified
belches according to: a) physiological mechanism: supragastric vs. gastric; and b)
their temporal relationship with a liquid reflux episode: isolated belch, preceding
or during a liquid reflux episode. Symptom-association analysis was performed
to assess a relationship between reported symptoms and reflux episodes.
Results: BIP patients showed higher acid reflux time (17.8 2.4% vs. 7.3 0.6%,
p5 0.001) and higher number of total reflux episodes (121 9 vs. 97 8,
p¼ 0.05) than UP patients. Notably, both the proportion of reflux episodes
with belches of any type and the proportion of belches preceding liquid reflux
were higher in UP patients than in BIP patients (51.7 3.6% vs. 32.1 3.7%,
p5 0.001 and 27.3 3.1% vs. 17.8 2.9%, p¼ 0.03, respectively). No difference
was found in the proportion of both supragastric and gastric belches between
groups. During 24-h pH-impedance monitoring UP patients reported more
symptoms (21 6 vs. 12 3, p¼ 0.16) and had more positive symptoms with
belches (60.2 7.1% vs. 39.0 6.6%, p¼ 0.03) than BIP patients. Of the total
number of belches that were detected using 24-h pH-impedance, more belches
were symptomatic in UP patients than in BIP patients (24.4 6.4% vs.
11.1 2.5%, p¼ 0.06).
Conclusion: In our study, GERD patients with isolated pathological upright
reflux had more often (symptomatic) belches than GERD patients with patho-
logical bipositional reflux. Therefore, examination of belching patterns can assist
diagnostic and therapeutic strategic planning in GERD patients who are refrac-
tory to medical therapy.
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Introduction: Gastroesophageal reflux in the recumbent period is related to a
higher risk of developing oesophageal lesions (severe esophagitis or Barrett oeso-
phagus). The only study to date that analysed reflux during daytime naps sug-
gests that it is worse than that which occurs during the night-time sleep. Our
objective was to determine if reflux during naps is more severe than during night-
time sleep.
Aims & Methods: Between February 2015 and November 2016 patients that
underwent ambulatory 24-hour oesophageal pH monitoring at our motility
unit were screened. Those who slept an afternoon nap in the recumbent position
in addition to the regular night-time sleep, and had a pathological acid exposure
(deMeester score 414.72) were included. We excluded those patients with pre-
vious foregut surgery or sleep apnea, those taking sleeping medication and those
who were in recumbent position more than twice during the study. All studies
were done off-therapy. Number of refluxes, number of refluxes per hour, reflux
duration and oesophageal acid exposure (AET) time were compared between the
two recumbent periods. Correlation between AET and meal-to-bed time was
analysed, both for naps and night-time sleep.
Results: A total of 32 patients were selected (59.4% women, mean age
51.31 14.59, median BMI 26.48 (range 21.63–38.71)). Indication was typical
GERD symptoms in 68.8% and atypical symptoms in 32.3%. Oesophageal
manometry revealed normal oesophageal body motility in 65.6%, inefficient
peristalsis in 28.1%, and a median lower oesophageal sphincter pressure of
8mmHg (range 1–24). Median nap duration was shorter than that of the
night-time sleep: 108 mins (range 30–375) vs 454 mins (range 240–593)
(p¼ 0.00). Median meal-to-bed time was also shorter for naps: 30.5 mins
(range 4–185) vs 110.5 mins (range 9–247) (p¼ 0.00). Median number of refluxes
per hour and median recumbent AET were similar in both periods: 1.71 (range 0–
26.5) vs 1.85 (range 0–12.8) (p¼ 0.45) and 1.55 (range 0–61) vs 5.9 (range 0–36.1)
(p¼ 0.57), respectively. 87% of total recumbent reflux took place during the
night. Correlation between AET and meal-to-bed time trended to be significant
for naps (Spearman rho¼ 0.33, p¼ 0.065), and was not significant for night-time
sleep (Spearman rho¼ 0.02, p¼ 0.94). All 5 patients who waited more than an
hour after lunch to lay down had an AET during the nap of less than 1%.
Conclusion: Naps are not associated with a more severe acid reflux than night-
time sleep, what does not support a specific recommendation against taking
daytime naps for GERD patients. Avoiding short meal-to-bed time specifically
for naps could be advisable.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: PPI improve LPR symptoms in many patients. It is implicitly
assumed that this effect is due to reduction of acidic LPR by PPI. Here we
tested this assumption. We evaluated LPR and distal gastroesophageal reflux
by using simultaneous pH/impedance monitoring in laryngopharyngeal segment
and in distal esophagus before and after PPI treatment.
Aims & Methods: Patients referred for suspected LPR were screened and those
with positive reflux finding score (RFS4 7, determined by ENT physician) and/
or positive reflux symptom index (RSI4 13) and at least one acidic LPR episode
during 24 h pH-impedance study were enrolled. The RSI, RFS and dual pH/
impedance study of LPR and distal reflux were completed before and after 3
months therapy with PPI twice a day. Appropriate distance between pH sensors
was chosen based on manometrically determined LES and UES so that the
proximal pH sensor was positioned 1 cm above UES and distal sensor was posi-
tioned 4–6 cm above LES. By definition each LPR event was preceded by reflux
detection in the distal esophagus.
Results: 18 patients (11M/7F, 51 10yrs) completed the study. In this group the
PPI treatment substantially improved the symptoms of LPR. Reflux finding
score (RFS) was decreased by 40% from 9 1 to 5 1 (P5 0.01). Reflux symp-
tom index (RSI) was decreased by 40% from 23 3 to 14 3 (P5 0.01). As
expected distal acidic reflux was dramatically (by 75%) decreased by PPI treat-
ment (P5 0.01). The number of distal acidic reflux episodes was reduced from
17 2 to 3 1 (P5 0.01). Surprisingly, acidic LPR was not decreased by PPI
treatment. The number of LPR with pH5 5.0 was 2 0.5 vs. 3 1, P¼NS, and
the number of LPR episodes with pH5 4.0 was 0.7 0.1 vs. 0.6 0.2, P¼NS).
Surprisingly, the number of acidic LPR episodes with pH¼ 5.0–6.0 was even
increased (14 2 vs. 21 3, P5 0.05) leading to an increase in the overall
number of LPR episodes by approximately 50% from 16 2 to 24 3
(p5 0.05). PPI treatment did not decrease laryngopharyngeal time the pH
was5 6.0 (258 48 s vs. 301 64 s, P¼NS) and did not alter the composition
of laryngopharyngeal reflux (P¼NS).
Conclusion: Proton pump inhibitor treatment does not reduce acidic laryngo-
pharyngeal reflux despite substantially improving symptoms in patients with
objectively established LPR. This suggests that PPI treatment influences some
aspects of pathogenesis of LPR symptoms that are not readily detected by lar-
yngopharyngeal pH/impedance monitoring.
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Introduction: Menthol is widely used as a food flavourant. In general, it is con-
sidered a trigger of gastroesophageal reflux symptoms. It has been assumed that
menthol reduces the tone of the lower esophageal sphincter (LES) as a conse-
quence of direct effect on the smooth muscle of the LES. Evidence has been
provided that menthol sprayed on the gastric mucosa significantly suppresses
gastric peristalsis (1). However, there is no clear evidence of the impact of
menthol on the esophageal peristalsis and LES tone.
Aims & Methods: The aim of the study was to evaluate the effect of the menthol
infusion into the esophagus on the esophageal peristalsis and lower esophageal
sphincter pressure in healthy volunteers. High-resolution manometry and the
parameters of esophageal pressure topography were used to quantitatively eval-
uate the certain components of esophageal motility. 13 healthy volunteers with-
out esophageal symptoms were enrolled. High-resolution manometry catheter
with a thin silicon tube attached were placed transnasally so that the distal end
of the tube was 5 cm above the LES. After a 5min. adaptation period the mea-
surement was performed in the supine position according to the protocol as
follows: after the baseline recording 10 water swallows of 5ml and 3þ 3 water
swallows of 10 and 15ml 15ml. After that a 20min. infusion challenge with 3mM
menthol 8ml/min. was carried out and subsequently the water swallows in order
described above were repeated. HRM tracings were manually analyzed using
ManoScan software and parameters used in the Chicago classification (v3.0)
were evaluated. Integrated relaxation pressure (IRP), nadir LES pressure and
distal contractile integral (DCI) values from 5ml, 10ml and 15ml swallows
were obtained. These were compared before and after the menthol infusion.
Paired parametric tests were used for statistical analysis.
Results: None of the subjects had any motility disorder defined by the Chicago
Classification v3.0. Few volunteers reported only mild cold sensation during
infusion presumed to be of the esophageal origin. The nadir LES pressure
before and after menthol infusion was 7.5 0.8mmHg vs. 7.3 0.7mmHg,
respectively (p4 0.7). IRP of 5ml swallows was 2.8 0.6mmHg
vs.2.1 0.5mmHg showed significance (p¼ 0.01). However, difference of IRP
of 10ml and 15ml swallows was not significant (p4 0.1, p4 0.5, respectively).
Average DCI pressure (5ml swallows) was 737.8 126.2mmHg and
814.2 116.2mmHg before and after menthol infusion, respectively (p4 0.5).
We found no difference in DCI in 10ml and 15ml swallows before and after
menthol infusion. Menthol seemed to have had only a marginal insignificant
effect on IRP and DCI in rapid swallow test
Conclusion: We quantified the effect of menthol on the esophageal function and
LES pressure in healthy volunteers using high resolution manometry. The ana-
lysis of HRM tracings revealed that menthol has no effect on particular para-
meters of the LES pressure and esophageal peristalsis.
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Introduction: Globus is considered to be related to the gastroesophageal reflux
disease/laryngopharyngeal reflux (LPR). However, a substantial part of subjec-
tiveness and self-perception of globic sensation which is impossible to measure
objectively makes this symptom difficult to study. Visceral hypersensitivity and/
or altered functional state of the afferent nerve endings in the hypopharynx
resulting from reflux have been suggested responsible for the development of
globus. We hypothesized differences in the reflux burden and esophageal/phar-
yngeal acid exposure between the patients with LPR symptoms with globus
compared to the patients with LPR symptoms without globus.
Aims & Methods: Patients referred for suspected LPR were screened and those
with positive reflux symptom index (RSI4 13) and at least one acidic LPR
episode during 24 h pH/impedance study were enrolled. We recruited patients
that were at least 30 days without PPI treatment. Appropriate distance between
pH sensors was chosen based on manometrically determined LES and UES so
that the proximal pH sensor was positioned 1 cm above UES and distal sensor
was positioned 4–6 cm above LES. For each LPR event we determined the max-
imum drop of pH on the pH levels 55.5 and 55.0. For these pH levels we
determined pharyngeal acid exposure time calculated as cumulative time of phar-
yngeal reflux below that pH level during 24 h. According to the question 8
(sensations of sticking/lump in the throat) of self-evaluated RSI questionnaire
the patients were divided into globus positive group (tick 4–5 in the RSI) or
globus negative (tick 0–1 in the RSI).
Results: 19 (13M/6F) completed the study. The number of globus positive and
negative patients was 11 and 8, respectively. There were no major differences
between groups. Disregarding the question about globus in the RSI, there was no
significant difference of the RSI between the globus positive and negative group
(25 2 vs. 21 2, respectively, p¼NS). As for the reflux in distal esophagus, we
observed no difference in the acid exposure time between the globus positive and
negative patients (2.2 0.5% vs. 3.9 1.1%, respectively, p¼NS). We therefore
assumed differences in the results from the hypopharyngeal pH sensor. However,
the number of LPR events with pH drop to 55.5 showed no significant differ-
ence between the globus positive and negative patients, either for the number of
LPR events (5[2.5–6.5] vs. 3.5[1.8–6.3], respectively, p¼NS), or for the pharyn-
geal acid exposure time (45 14 s vs. 88 42 s, respectively, p¼NS). We specu-
lated that more acidic LPR events (pH drop to 55) might be of greater
relevance. However, no significant difference was found between the globus
positive and negative patients either in terms of the number of these LPR
events (1[0–2] vs. 1[1–1], respectively, p¼NS), or the pharyngeal acid exposure
time (16 6 s vs. 42 36 s, respectively, p¼NS).
Conclusion: We found no significant difference in the reflux burden in the distal
esophagus/hypopharynx between the groups of symptomatic LPR patients with
and without globus using 24 h dual channel pH/impedance. Other factors, e.g.
visceral hypersensitivity might play a role in the development of globus symp-
toms, even in patients with objectively established LPR.
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C. Miraglia2, A. Bertelè6, V. Corrente7, C. Scarpignato2
1Department Of Medicine And Surgery, University of Parma, Parma/Italy
3Endoscopic Unit, Department Of Surgery, Ulss4, Hospital ULSS4 Alto Vicentino,
Santorso/Italy
4Department Of Surgery, Oncology And Gastroenterology, University of Padua,
Padua/Italy
5Division Of Gastroenterology, Department Of Internal Medicine, University of
Pisa, Pisa/Italy
6Department Of Clinical & Experimental Medicine, Clinical Pharmacology &
Digestive Pathophysiology Unit, University of Parma, Parma/Italy
7University Hospital, Parma (Italy), Parma/Italy
Contact E-mail Address: francesco.dimario@unipr.it
Introduction: Due to a negative feed-back mechanism, gastrin-17 (G17) can be
considered a mirror of acid secretion: the lower G17 values, the higher gastric
acid secretion. Some studies suggest serum G17 low levels as a marker of acid-
related conditions, like Gastroesophageal Reflux Disease (GERD). Aim of the
study was to evaluate the property of low levels of G17 in GERD diagnosis, in
comparison with clinical and instrumental GERD gold-standards (typical symp-
toms, esophagitis at endoscopy, a positive Demeester score at pH-metry).
Aims & Methods: We enrolled 777 consecutive patients (M¼ 369; mean
age¼ 55.3 ys; range¼ 33–76y ys) affected by upper gastrointestinal (GI) troubles,
showing low levels of serum G17 (BioHit Oyj, Finland; mean values: 1–9 pmol/l).
Exclusion criteria included: current Proton Pump Inhibitors, previous history of
surgery, neoplasms, current Helicobacter Pylori infection. Both typical, atypical
and extra esophageal GERD symptoms, according with Montreal Classification
were collected. All patients underwent upper GI endoscopy and esophagitis was
classified according with Los Angeles criteria. In a subgroup of 221 patients
(M¼ 103; mean age¼ 52.5 ys; range¼ 35–69 ys) with Non Erosive Reflux
Disease (NERD) a 24 hours pH-metry was performed using the Demeester
score of 14 to establish a condition of acid reflux.
Results: Typical symptoms (heartburn and/or regurgitation) have been detected
in 547 patients, being in 479 ones heartburn the prevalent symptom and in 68
ones regurgitation. Extra-esophageal symptoms (mainly chronic cough) were
present in 303 patients. At the endoscopical evaluation, 349 subjects showed a
picture of esophagitis with different degrees of severity of Los Angeles score. One
hundred and seventy out 221 patients which underwent 24 h pH-metry showed a
positive Demeester score for acid gastroesophageal reflux. Summarizing, 700 out
of the 777 subjects included in the study showed at least one of the criteria
(clinical, endoscopical or functional) accepted to support the diagnosis of
GERD.
Conclusion: By using low levels of G17 as a non-invasive marker of GERD, in
more than 90% (700 out of 777 pts) the diagnosis of reflux disease was con-
firmed, according with the current clinical or instrumental gold standard criteria,
suggesting the use of this simple method to identify subjects with suspected
GERD almost when typical symptoms are lacking or a NERD picture is find.
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Introduction: Sliding hiatal hernia (HH) is a frequent diagnosis during upper
endoscopy (UE) in patients with GERD-related symptoms. Recently, high reso-
lution manometry (HRM) allowed an accurate evaluation of the esophago-gas-
tric junction (EGJ) and its sub-types (Chicago Classification V3.0; CCv3). Few
data are available comparing the diagnostic accuracy of HRM and UE to detect
HH.
Aims & Methods: The aim of this study was to compare the prevalence of HH
obtained with UE and HRM and to determine the role of this finding by diag-
nosing gastroesophageal reflux disease (GERD) on the basis of impedance and
pH (MII-pH) monitoring. We enrolled consecutive patients with heartburn and
HH diagnosed with UE. After UE, all patients underwent HRM and MII-pH to
investigate GERD. All tests were performed previous a 20-day wash-out from
proton pump inhibitors. Erosive esophagitis (ERD) was diagnosed according to
the Los Angeles Classification, and HH was diagnosed when the separation
between the squamo-columnar junction and the diaphragmatic impression was
greater than 2 cm. Patients with achalasia or major disorders of peristalsis or
previos surgery were excluded. MII-pH monitoring allowed to sub-classify
patients with non-erosive GERD in: NERD (abnormal AET), hypersensitive
esophagus (normal AET, reflux events but positive symptom-reflux association,
HE) and functional heartburn (normal AET, reflux events and negative symp-
tom-reflux association, FH). All patients underwent barium X-ray to measure
HH. Recognition of two rings larger than 2 cm (recumbent position) between
EGJ and diaphragmatic hiatus was necessary to detect HH.
Results: We evaluated 151 patients (94 females) with mean age of 56.2 15.4 yrs.
ERD was diagnosed in 34 patients (22.5%). MII-pH allowed to subgroup
patients in: 48 (31.8%) NERD, 43 (28.5%) HE, and 26 (17.2%) FH. As expected,
MII-pH showed a higher AET in ERD and NERD group (p5 0.001). HRM was
normal in 131/151 (86.8%) and 20/151 (13.2%) had ineffective motility. HH was
confirmed in 83/151 patients (HRM 55% vs UE 100%; p5 0.05) with HRM and
in 88/151 patients (barium 58.3% vs UE 100%; p5 0.05) with barium X-ray.
The mean length of HH during endoscopy (5.4 2.6) was reported greater than
that during HRM (3.9 2.2) and Barium X-ray (4 2.5) (p5 0.05). All details
are reported in Table I.
Table I: Characteristic of the enrolled population stratified for GERD diagnosis
ERD (34) NERD (48) HE (43) FH (26) p
EGJ pressure (mean) 25.86 11.8 30.3 13.2 31.4 12.6 33.1 13.7 0.635
DCI 1001 683 1431 1632 1577 1365 1799 1453 0.042
IRP 11.8 5.1 12.6 7.2 13.1 7.8 11.4 7.1 0.57
DL 6.8 1.6 6.8 1.1 6.6 1.4 6.9 1.5 0.836
AET (%) 7.7 2.9 5.1 2.3 2.7 1.4 1.1 0.9 50.001
Reflux number 77.8 23.7 66.9 31.4 24.6 9.1 17.97.5 50.001
Hiatal hernia (HRM) 33 (97.1%) 34 (70.8%) 16 (37.2%) 0 50.001
Hiatal hernia (X-ray) 34 (100%) 36 (75%) 17 (39.5%) 1 (3.8%) 50.001
Conclusion: HRM and barium X-ray showed similar diagnostic accuracy to
detect HH. Thus, HRM might be considered the test of chioce during pre-surgi-
cal evaluation for laparoscopic antireflux surgery.
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Introduction: In patients with symptoms suggestive of gastroesophageal reflux
disease (GERD) candidate to anti-reflux surgery or in those refractory to antacid
therapy, it is recommended to perform function tests in order to objectively
diagnose GERD. Esophageal manometry is currently considered the gold stan-
dard method to assess esophageal motility. However, it has been shown limited
capability to diagnose GERD. With the advent of high-resolution manometry
(HRM), new metrics have been developed to investigate esophageal motor func-
tion, esophagogastric junction (EGJ) morphology and theirfunction. In particu-
lar, the antireflux barrier function of EGJ can now be assessed evaluating the
contraction integral of the EGJ.
Aims & Methods: Our aim was to assess the differences in terms of HRM char-
acteristics between patients with typical reflux symptoms with GERD and those
with functional heartburn (FH), classified by means of upper GI endoscopy and
impedance-pH (MII-pH) monitoring off-medication. We also aimed to develop a
predictive model for distinguishing FH from GERD by using the prevalence of
these HRM features. Consecutive patients with heartburn and/or regurgitation
and a recent endoscopic assessment were enrolled. All patients underwent HRM
to assess the EGJ and 10 single water swallows to evaluate esophageal peristalsis
and EGJ function and one multirapid swallow (MRS). The tracings were ana-
lyzed according to the Chicago Classification 3.0. EGJ pressure, EGJ contractile
integral (EGJ-CI), EGJ morphology, mean and peak distal contractile integral
(DCI), MRS DCI/mean DCI ratio and motility pattern were measured.
Moreover, all patients underwent MII-pH off-therapy. We measured the esopha-
geal acid exposure time (AET), number of total impedance reflux episodes and
symptom association analysis using both symptom association probability
(SAPþ if 95%) and symptom index (SIþ if 50%). GERD was diagnosed in
case of one or more abnormal parameters at MII-pH. To analyze the differences
between patients with MII-pH positive and negative for GERD, Mann-
Whitney’s U test for continuous variables was used and significance was set at
P5 0.05. A multivariate logistic regression analysis was then carried out to
identify factors independently associated with MII-pH positivity for GERD,
significance settled at P5 0.05. According to Hosmer’s purposeful selection of
covariates, a predictive model based on HRM variables was built by logistic
regression analysis. The model was tested for discriminative performance by
computing the area under ROC curve (AUROC), and calibration was assessed
by Hosmer-Lemeshow goodness-of-fit test.The bootstrap re-sampling method
was used to evaluate the internal validity of the model and to correct for over-
fitting.
Results: Overall, 68 patients (39 F/29 M, median age 42.3) underwent HRM and
MII-pH.HRM findings stratified according to MII-pH positivity for GERD are
provided in Table 1. At univariate analysis, statistically significant differences
were found in EGJ pressure, EGJ-CI, mean DCI and MRS DCI/mean DCI ratio
between GERD and FH. Based on logistic regression analysis and according to
Hosmer’s purposeful selection of covariates, we developed a predictive model
which ultimately encompassed two HRM variables, i.e. DCI MRS/mean DCI
ratio (OR 1.614, 95%CI 0.993–2.895) and EGJ-CI (OR 0.952, 95%CI 0.913–
0.985). The model had a fair discriminative performance (AUROC: 0.798,
95%CI: 0.650–0.894) between MII-pH positivity and negativity for GERD and
was well calibrated according to Hosmer-Lemeshow goodness-of-fit test
(p¼ 0.769). The internal validation of the model by bootstrap method showed
AUROC¼ 0.779. Considering as cut-off the predicted probability of MII-pH for
GERD which maximized sensitivity and specificity (i.e. 67.4%), sensitivity and
specificity of the predictive model in predicting GERD against FH were 80.8%
and 76.2%, respectively.
Table 1
HRM variable
GERD group
(n¼ 47)
No GERD group
(n¼ 21) P value
EGJ resting pressure,
mmHg (median, IQR)
17.6 (16.9) 22.7 (19.1) 0.028
Peak DCI, mmHg * cm *
sec (median, IQR)
991 (1887) 1632 (2160) 0.018
Mean DCI, mmHg * cm *
sec (median, IQR)
590 (1299.5) 1191 (1166) 0.004
DCI MRS, mmHg * cm *
sec (median, IQR)
1039 (1983) 842 (1764) 0.465
DCI MRS/mean DCI,
mmHg * cm * sec
(median, IQR)
1.723 (2.299) 1.113 (1.212) 0.012
EGJ CI, mmHg * cm * sec
(median, IQR)
7 (18) 22 (17.6) 0.004
EGJ morphology (type II
and III vs. type I), n (%)
14 (29.8) 3 (14.3) 0.232^
Conclusion: Our data indicate that HRM can be useful in detecting GERD, with
our predictive model allowing a high level of suspicion for reflux disease. In
particular the role of the EGJ-CI in GERD pathophysiology has been
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emphasized highlighted. Further larger studies considering different GERD phe-
notypes are needed.
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Introduction: Randomized controlled trials report about 30% of GORD patients
complain of bothersome remaining symptoms (heartburn, regurgitation) despite
PPI. The LOPA (Lost Patients) I Study of 333 GORD patients seen in general
practice revealed 46% of patients experienced heartburn or regurgitation symp-
toms at least twice per week despite PPI. A total of 20% were dissatisfied with
their treatment. Few patients had received specific GORD diagnostics or recom-
mended other options (510%).
Aims & Methods: The LOPA II study is a prospective, multicenter, observational
study conducted in 17 general practice clinics. Patients with chronic GORD,
taking PPI therapy for at least 1 year, and not satisfied with their treatment
were asked to complete a questionnaire. Patients were asked the duration of
their PPI therapy, satisfaction with their current condition, frequency of symp-
toms in the last week, whether they had previously received diagnostic evaluation
or surgical consult related to GORD, whether they plan to consult a reflux
specialist for further diagnostics, and reasons for dissatisfaction with their cur-
rent medication treatment. ‘‘Lost Patients’’ were defined as those with a satisfac-
tion score of 1 or 2 on a 5-point Likert scale (1: very dissatisfied; 2: dissatisfied),
GerdQ score at least 8, and have not previously received specialized GORD
diagnostics.
Results: 510 consecutive patient responses were collected within one year.
Patients suffered from GORD an average of 9.6 years and prescribed PPI therapy
for an average duration of 7.9 years. 70% were dissatisfied or very dissatisfied on
their current PPI therapy (score of 1 or 2). 83% reported heartburn or regurgita-
tion at least 2 days in the prior week (53% 4–7 days). 49% reported using
additional medication other than their prescribed PPI at least 2 days per week
(34% 4–7 days). In patients dissatisfied on PPI, most cited insufficient symptom
control (87%) as a reason for dissatisfaction. In addition, 31% cited concern with
long-term use of drugs and 27% the need for daily medication. 92% of patients
had received an upper endoscopy, 12% had a prior pH-metry, 7% manometry,
and 9% received prior surgical consult for GORD. Of patients who never
received surgical consult, 48% were not aware of any surgical anti-reflux meth-
ods, 25% were concerned about possible complications, 18% felt their condition
is not serious enough, 6% were recommended against anti-reflux procedure by
their doctor.
Conclusion: Chronic GORD patients who are dissatisfied with their PPI therapy
are rarely offered specialized GORD diagnostic procedures or treatment alter-
natives. Half of the patients took medication in addition to PPI to control their
reflux. In addition to persistent symptoms, concerns of long-term PPI use and
burden of daily medication play a role in patient dissatisfaction with PPI therapy.
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Introduction: Autoimmune gastritis (AIG) is characterized by corpus-predomi-
nant atrophy with consequent hypo-achlorhydria. In AIG patients dyspepsia is
frequent but acid reflux symptoms not uncommon, with few data available
regarding gastroesophageal reflux disease (GERD) in AIG.
Aims & Methods: Our study was aimed to define the prevalence of reflux symp-
toms in AIG patients, to evaluate the serological, histological and clinical differ-
ences in AIG patients with or without reflux symptoms and to investigate the
physiopathology behind these symptoms. One hundred and fifty AIG outpatients
were evaluated and 87 were included in the study: 29 AIG patients with reflux
symptoms (AIG-R) and 58 without (controls), selected with similar age and
gender distribution. AIG-R underwent a pH-impedance (pH/I) and high resolu-
tion manometry (HRM). Serum biomarkers, EGDS, histology and anamnestic
data were evaluated in both groups. Statistics was performed as indicated.
Results: AIG-R were 19% overall and 28% of them showed endoscopic esopha-
geal lesions, with more frequent hiatal hernia than in controls (p5 0.02). pH/I
diagnosed acid reflux, esophageal hypersensitivity and a normal pattern in 7%,
28% and 66% patients, respectively. The number of non-acid reflux (NAR) was
higher when compared with acid ones (p5 0.0001), moreover NAR and NAR
proximal extension were associated with endoscopic lesions (p5 0.03 and
p5 0.05, respectively). HRM revealed normal pattern in 62% of patients,
minor peristalsis disorders in 24%, and outflow obstruction in 14%.
According to the new Rome IV criteria, 55% of patients presented ‘‘functional
esophageal disorders’’ (Rome IV-IN). No differences were detected in serological
marker and clinical presentation. AIG-R presented lower antrum gastritis
(p5 0.006) and a trend toward lower atrophy stage (p¼ 0.07) when compared
with controls. The two patient with acid GERD were an OLGA 0 with mild
gastrin increase and an OLGA I with short segment Barrett’s esophagus. Lower
OLGA stages, lower corpus atrophy (p5 0.02) and more frequent response to
PPI (p5 0.05) were associated with Roma IV-OUT status.
Conclusion: AIG-R patients are not uncommon despite the hypo-achlorhydria.
Acid reflux is rare in AIG, while motility and ‘‘functional’’ disorders are fre-
quent. Lower corpus atrophy and OLGA stage in Rome IV-OUT patients, with
an at least partly preserved secretion, is likely relevant in the pathogenesis of
symptoms. Treatment should consider use of proton pump inhibitor drugs only
in specific patients.
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Introduction: Gastroesophagel reflux disease (GERD) is a common disorder
commonly overlapping with several functional or allergic/immunological disor-
ders, whose symptoms are related to food intake. Awareness of health care costs
and potential side effects of long-term acid suppression has increased the atten-
tion in non-pharmacologic treatment for alleviating reflux symptoms.
Aims & Methods: The aim of our prospective study was to evaluate the non-
inferiority of a controlled diet compared to antacid compounds in relieving reflux
symptoms in patients suffering from mild GERD. We considered 500 consecutive
patients referred to the Division of Allergy and Clinical Immunology of Azienda-
IST IRCCS San Martino of Genova for gastrointestinal symptoms associated to
food intake. Patients with a clinical and instrumental diagnosis of food allergy,
food intolerance, Irritable Bowel Syndrome (IBS) and Small intestinal Bacterial
Overgrowth (SIBO) were excluded. Patients with a diagnosis of GERD based on
clinical history represented our study population. Basal metabolic rate and cal-
ories need of patients was assessed by means of Harry-Benedict equation cor-
rected for their physical activity. Patients were asked to take antacids for one
month. Subsequently patients discontinued medication consumption and fol-
lowed an elimination diet of food commonly associated to eliciting reflux symp-
toms, based on their calories need. Efficacy of the two treatments was evaluated
by means of a validated symptomatic questionnaire (RDQ administered at base-
line, after antacids course (1 month) and after diet (1 month). A treatment was
considered effective if a 50% improvement in the symptomatic score was
recorded.
Results: After investigations 261 patients out of 500 (52.2%) were excluded
because of IBS (140), celiac disease (6), nickel allergy (25), lactose intolerance
(60), SIBO (10), and allergy to other foods (20). The remaining 239 patients were
diagnosed as affected by mild GERD (median age 47; BMI 24; 132F/107M; no
erosive reflux disease) and were included in our interventional prospective study.
Among them, antacids treatment was effective in 180 cases (75.3%). Symptoms
relief was reported by 220 patients (92.1%) after diet based on calories need. No
differences were noted between responders and not responders in terms of BMI,
age and gender. Diet was more effective than antacids treatment in relieving
reflux symptoms in mild GERD (p5 0.01)
Conclusion: A structured diet regimen, tailored on the metabolic need of the
patients, apperas more effective than antacids alone in relieving reflux symptoms
in patients with mild GERD. Further controlled studies are mandatory to con-
firm these preliminary data.
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Introduction: Safety and efficacy of electrical stimulation of the lower oesopha-
geal sphincter (ES-LOS) using the EndoStim LOS Stimulation System
(Nijmegen, The Netherlands) has been demonstrated in clinical trials up to 45
years. Data on outcomes in routine clinical practice is growing.
Aims & Methods: An ongoing, prospective international multicenter web-based
registry is collecting data in patients with disruptive GORD symptoms, treated
with ES-LOS in clinical practice. Data is collected at baseline and at routine
follow-ups for 5 years. Demographics, adverse events, GORD symptoms,
GORD health related quality of life (GORD-HRQL) scores, use of proton
pump inhibitors (PPIs) and physiological data (oesophageal pH/manometry)
are collected when available.
Results: 180 patients at 13 sites in Europe and Latin America have been enrolled.
Follow-up data up to 2 years is available. Median (IQR) age at the time of
implant was 51 (41–60), 57% were male. All patients were taking prescription
PPI at baseline. At their last follow-up between 6 and 24 months post op, 70%
(84/121) were completely off PPI (p5 0.001). Median (IQR) composite GORD-
HRQL score improved from 23 (17–29) preoperatively to 8 (4–15) at 6 months, 7
(2–12) at 12 months, and 8 (4–15) at 24 months (p5 0.001 at all time points,
n¼ 154, 121, 66, 33 at baseline, M6, M12, M24, respectively). Oesophageal pH
testing post-op was performed by a few sites either as standard of care or in
patients with residual symptoms. Median (IQR)% 24-hour oesophageal acid
exposure improved from 8.2% (4.6–18.4) at baseline to 4.7% (1.4–14.5) at 6
months (p¼ 0.26) and 3.6% (1.0–5.8) at 12 months (p¼ 0.04) (n¼ 120, 39, 10
at baseline, M6, M12, respectively). The proportion of patients with moderate to
severe regurgitation decreased from 64% at baseline to 22.5% after 6 and 13.4%
after 12 months. Extra-oesophageal symptoms (recurrent cough, pneumonitis,
shortness of breath) and sleep disturbances also decreased substantially. Overall,
dysphagia and gas were less common at 12 months than preoperatively. Four
serious adverse events were reported in 3 patients. One myocardial infarction
related sudden death at 11-month post-op, not related to the device or procedure;
1 event of asymptomatic electrode erosion into the oesophagus detected during
routine endoscopy and the device safely removed during laparoscopic fundopli-
cation; and 2 events of gastroparesis in 1 patient requiring hospitalization, pos-
sibly related to the device, were reported.
Conclusion: ES-LOS is safe and effective in treating patients with disruptive
GORD symptoms despite PPI in routine clinical practice. ES-LOS should be
considered a viable treatment option for treating these patients.
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Introduction: PPI therapy remains the mainstay for treatment of gastroesopha-
geal reflux disease (GERD), however laparoscopic fundoplication is recom-
mended in refractory patients. Various endoscopic methods have been
attempted with variable success. Anti-reflux mucosectomy (ARMS) is a recently
introduced endoscopic therapy for refractory GERD.
Aims & Methods: The current study describes initial clinical experience of
ARMS.Data from a prospectively maintained database of consecutive patients
undergoing ARMS for refractory GERD was abstracted. Inclusion criteria–
GERD symptoms 4¼ 1 year, daily PPI usage 4¼ 6 months; absence of
hiatus hernia 43 cm on EGD and normal esophageal body motility on high-
resolution manometry (HRM). Exclusions–hiatus hernia 43 cm, poor or absent
esophageal body motility, poor-risk candidates for anesthesia or invasive proce-
dure. Pre-ARMS evaluation–EGD to assess Hill’s grade of flap valve, esophageal
manometry, 24-hour ambulatory esophageal pH studies, PPI requirement and
GERD-HRQL questionnaire. ARMS performed using cap EMR technique.
Follow up protocol–EGD at 2–4 weeks, GERD-HRQL questionnaire, pH stu-
dies and PPI requirement at 4–6 weeks. Parameters for data analysis - pre-and
post-ARMS GERD-HRQL questionnaire and Deemester scores, Hill’s grading
of gastroesophageal valve on EGD, PPI requirement and procedure-related
adverse events (AE).
Results: N¼ 15, duration–12-months. Mean age–40.8 years (Range 22–69); M:
F–11: 4. HRM–normal esophageal body motility in all. Mean GERD-HRQL
score improved significantly from pre-ARMS–40.4 to post-ARMS–7.6
(p5 0.05). Mean Deemester score decreased from 85.8 pre-ARMS to 5.9 post-
ARMS (p5 0.05). Mean Hill’s valve grade decreased pre-ARMS¼ 2.8; post-
ARMS¼ 1.6 (p5 0.05). Three AE’s–muscle injury–2 (treated by endoclips),
grade I dysphagia–1. At 4 weeks follow up, 11/15 patients (73.3%) had discon-
tinued PPI, 4/11 (36.3%) had 450% reduction in PPI dosage.
Conclusion: Current study shows impressive short-term results for ARMS.
Significant symptom resolution and acid exposure reduction occurred in all
patients. 100% patients could discontinue or reduce PPI usage. AE’s were
minor. Larger randomized studies with longer term follow up are recommended.
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Introduction: To date a large quantity of 5-MR4 receptors were found in esopha-
geal mucosa that indicates on an important role of this neuromediator in patho-
genesis of non-erosive reflux disease (NERD) and gastroesophageal reflux
disease (GERD). Antidepressants seems to be effective, as they have central
analgesic effect, reduce chemical and mechanical sensitivity and have local
effect on gastrointestinal tract.
Aims & Methods: Our aim was to assess the superiority of combined treatment
using proton pump inhibitor (PPI) plus antidepressant by comparison with PPI
for patients with NERD. Methods: In this randomized superiority study adult
patients (18–65 years) with confirmed diagnosis of NERD were eligible to parti-
cipate. Exclusion criteria: the presence of ‘‘red flag’’ signs and other comorbid-
ities that could explain the symptoms. Patients were assessed in clinically and
psychologically. Psychological testing was done using validated short-form ver-
sion of the depression anxiety stress scales (DASS-21) and Toronto alexithymia
scale (TAS). All the patients were randomly divided into two arms: patients of
the first arm received PPI (pantoprasole) 40mg once a day plus escitalopram as
follows: initial dose - 5mg/day for the first two weeks of treatment; depending on
individual response the dose was increased to 10mg/day. The second arm
received only PPI 40mg once a day. Patients were assessed on the 4th and 8th
week of treatment. The superiority was shown if there was more lasting decrease
in heartburn severity, reduced anxiety (A), depression (D) and alexithymia levels.
Results: Of 75 randomized patients 39 were allocated to the first arm and 36 to
the second one. The groups were statistically comparable in age and sex.
Treatment results showed reduction of heartburn severity in both groups on
the 8th week, however more significant in the first group (1group-89.7%,
2group-61.1%, P5 0.001). Also both A and D levels were much lower in the
first group compared to the second one (P5 0.001). Compering the levels alex-
ithymia between two arms on the 8th week after the initiation of treatment we
found that alexithymic type of personality prevailed in patients that received PPI
only (P5 0.001).
Conclusion: The combination of PPI plus antidepressant demonstrates superior-
ity to PPI therapy along, showing more lasting symptoms regression and
improved psychological and emotional condition of patients.
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Introduction: The quality of histologic healing or inflammatory cytokine-related
change in erosive reflux disease (ERD) had been verified in few studies.
Rebamipide is an anti-inflammatory drug promoting gut mucosal healing.
Aims & Methods: We conducted double-blinded comparative study to assess
endoscopic, histologic quality of mucosal healing in ERD, following 4-week
medical treatment with lansoprazole combined with rebamipide or not. The
patients with ERD in modified LA classification grade A-D were enrolled via
four referral institutes, regardless of GERD related symptoms. The enrolled
subjects were randomly allocated to ingest 30mg lansoprazole alone or ingest
lansoprazole 30mg with rebamipide 100mg three times in a day for 4 weeks.
Baseline and follow up endoscopies were performed to assess endoscopic healing
(regressed into minimal change or normal), and to obtain esophageal biopsy
specimens (at 3 o’clock direction, 3 cm proximal area from squamocolumnar
junction). Additional tissue samples were obtained to measure tissue inflamma-
tory cytokines (IL-8, PAF, at 9 o’clock direction, 3 cm proximal area from squa-
mocolumnar junction).
Results: Overall 109 patients were enrolled and randomly allocated to lansopra-
zole group (N¼ 54) or combination group (N¼ 55). Demographic data, smoking
or drinking habits were not significantly different between both groups. The
endoscopic healing rate at 4-week was not different significantly (75.0% vs
78.9%; P¼ 0.686, Difference 3.95%, 95%CI [–15.24, 23.13]). The histologic
changes of basal layer thickness, intraepithelial infiltration of inflammatory
cells (eosinophils, neutrophils) were normalized in subsets of patients regardless
of the fate of endoscopic healing, and were not different in both groups. In
contrast, papillary length, intraepithelial infiltration of T lymphocyte and the
dilated intercellular space (DIS) was normalized significantly in endoscopically
A800 United European Gastroenterology Journal 5(5S)
healed combination group. When both group were pooled in a group (proton
pump inhibitor administration), the papillary length and DIS was significantly
improved in endoscopically healed patients. Tissue level of IL-8, but not Lyso-
PAF, was significantly decreased in lansoprazole alone group.
Conclusion: Adjuvant therapy of rebamipide to lansoprazole failed to reveal
additional esophageal healing effect by endoscopic or histologic evaluation.
Papillary length and DIS was more evident parameter of quality of mucosal
healing in patient of erosive reflux disease treated with proton pump inhibitor.
Long term follow-up data are needed on whether these histologic parameters of
mucosal healing can help predict the prognosis of gastroesophageal reflux
disease.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Radiofrequency ablation (RFA) with or without endoscopic resec-
tion (ER) is an established endoscopic treatment of early Barrett’s esophagus
(BE) related neoplasia (BORN). After successful treatment, follow-up is still
required as recurrences may occur. The aim of this prospective single-center
case series was to assess the long-term efficacy of endoscopic treatment (RFA
with or without ER) for BORN. Main outcomes were complete remission of
neoplasia (CR-N) and intestinal metaplasia (CR-IM) and recurrence of IM (R-
IM) and neoplasia (R-N).
Aims & Methods: A total of 99 consecutive patients with BORN have been
treated since 2009. Of those, 87 patients (75 men, mean age 64, range 22–91)
completed the treatment and were included into this analysis. The patients had
been followed up during 296 patient-years (mean 3.4 years, range 0.5–6). Thirty-
three patients were diagnosed with adenocarcinoma (38%), 24 patients with high-
grade dysplasia (28%) and 30 patients with low-grade dysplasia (34%). Prior to
RFA, ER for visible lesions was performed in 57 patients (66%). Mean length of
the Barrett’s esophagus (BE) was 4.6 cm (range 1–13 cm). After treatment, the
patients have undergone regular endoscopic surveillance with multiple biopsies.
Results: Complete remission of IM (CR-IM) and complete remission of neoplasia
(CR-N) were achieved in 54 patients (54/83 pts, 65.1%; 95% CI 54.3–74.5) and
82 patients (98.8%; 95% CI 92.8–99.9), respectively. All patients who did not
achieve CR-IM had macroscopically normal neo-Z-line without visible abnorm-
alities except one patient where macroscopic eradication of BE was not achieved
due to giant hiatal hernia and who was referred for anti-reflux surgery. During
the follow-up, 18 patients (33.3%, 18/54 pts) experienced a recurrence of IM and
3 patients (3.7%, 3/82 pts) had a recurrence of neoplasia (LGD 2x, HGD 1x). We
did not encounter any patient with a subsquamous neoplasia. All recurrences
occurred at the level of neo-Z-line and 6 patients with recurrent IM had also
macroscopic recurrence of BE. A total of 13 patients underwent endoscopic
retreatment: 7x probe-based re-RFA, 5x escape argon plasma coagulation
(APC) and 1x ER. After retreatment, we achieved 100% CR-N and 54% (7/13
pts) CR-IM. Treatment-related adverse events occurred in 22 patients (25%): 12x
chest pain and 10x stricture. Two patients with a stricture had to undergo surgi-
cal resection - first patient due to perforation during balloon dilatation of a post-
RFA stricture, the second because of refractory post-RFA stricture after 20
sessions of dilatation.
Conclusion: RFA combined with ER for patients with BORN achieves a high
success rate of CR-N with durable results. Recurrence of IM occurs in approxi-
mately one-third of patients and supports continuous endoscopic surveillance
even after complete eradication. Nonetheless, the majority of recurrent IM
occurs within a normally appearing neo-Z-line with questionable clinical
relevance.
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Introduction: Barrett’s Esophagus (BE) is a premalignant condition, in which
prolonged gastroesophageal reflux results in intestinal metaplasia, leading to
an annual risk of adenocarcinoma 0.12%/year1. The current standard of treat-
ment is Endoscopic Resection (ER) of visible nodular lesions and
Radiofrequency Ablation (RFA) of flat Barrett’s, which has a success rate of
92%2. For refractory cases, wide field ER, cryotherapy and other methods are
used, but may have higher adverse events. We hypothesize that thicker Barrett’s
tissue is less likely to respond to RFA and have developed methods to precisely
measure tissue thickness with Volumetric Laser Endomicroscopy (VLE). These
methods may facilitate future studies, correlating tissue thickness with response
to therapy and prediction of optimal treatment.
Aims & Methods: We performed a nested cohort study from the U.S. VLE
Registry (which comprises 1000 patients) of patients with BE, who had a baseline
VLE scan, followed by RFA ablation and had at least one follow up exam. We
excluded patients who had any ablative therapy prior to baseline VLE. The
primary outcome was the percentage reduction of Prague length after the first
treatment. Secondary outcomes were: 1. complete remission of intestinal meta-
plasia (CRIM) during 12 months after baseline procedure, 2. complete remission
of dysplasia (CRD) during 12 months after baseline procedure, and 3. number of
RFA treatments necessary for complete response of intestinal metaplasia. We
estimated the thickness of BE mucosal layers, by measuring the distance between
the esophageal surface to the deepest edge of the lamina propria. In order to do
so, we developed an algorithm (ImageJ software; imagej.nih.gov/ij/) that auto-
matically adjusts every clockwise image into a high-resolution vertical scan with
enhanced contrast. We used two measurement protocols: subjective, by drawing
a line from the surface to the edge of the lamina propria (LP) and by plotting a
grayscale density plot at the same location, using the sharp drop off in density to
indicate the lamina propria.
Results: We included 92 patients with BE (at least C0M1), who had a baseline
VLE scan, followed by RFA, and had no prior ablative therapy. These patients
were divided in three patient groups: without prior EMR and treated with only
RFA (n¼ 70, mean Prague length(M)¼ 5.399, SEM¼ 0.520), without prior
EMR treated with combined EMR and RFA at baseline(n¼ 3, mean Prague
length(M)¼ 6.67, SEM¼ 1.67), with prior EMR and RFA at baseline (n¼ 19,
mean Prague length (M)¼ 3.816, SEM¼ 0.616). After determination of gastro-
esophageal junction (GEJ) location on VLE, we measured mucosal thickness in 8
segments at 0.5 cm intervals from GEJ to the top of the Barrett’s tissue. The
mean amount of selected cross sections per scan in the first 40 patients was 6.33
(SEM¼ 0.50; n¼ 40). The measurements of thickness, using the subjective and
objective protocol in one patient is shown in Table 1.
Conclusion: We developed an algorithm, that automatically adjusts raw VLE
images in order to recognize superficial layers of the esophageal wall and measure
the thickness of these different layers in Barrett’s tissue. We performed both
subjective and objective methods for thickness calculation. This is the first step
to the production of a biomarker for the prediction of treatment response in
patients with Barrett’s Esophagus. Further research is needed to demonstrate
which of these two measurement protocols can predict the response to RFA
and ER.
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Table 1: The measurements of Barrett’s thickness in one patient, using the two different measurement protocols.
Pt.
Age
(years) SEX BMI
Highest grade
prior biopsy
Prior
Treatment
Prague Length,
circumferential and
maximum extend
in cm
Thickness
subjective measured,
pixels [SEM, number
of measurements]
Thickness
objective measured,
pixels [SEM, number
of measurements]
1 85 Male 25.8 High grade dysplasia None C16M16 317.38 [9.96, 65] 286.85 [8.96, 65]
United European Gastroenterology Journal 5(5S) A801
P1863 SEVEN-YEAR PROSPECTIVE FOLLOW-UP RESULTS OF
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Introduction: Radiofrequency ablation (RFA) of Barrett’s esophagus (BE), with
or without prior endoscopic resection (ER) of focal lesions, results in complete
eradication of intestinal metaplasia (CE-IM) and complete eradication of neo-
plasia (CE-neo) in 93–100% and 96–100%, respectively.
Aims & Methods: The aim of this study was to assess if the excellent results after
successful RFA for BE with high-grade dysplasia (HGD) or early cancer (EC)
are sustained on the long term. We screened all patients treated with RFA, and
ER in case of visible lesions, for BE with histologically proven HGD/EC, who
were previously enrolled in 5 consecutive cohort studies in a tertiary referral
center in the Netherlands. All patients who had reached endoscopic and histo-
logically confirmed CE-neo and CE-IM after RFA were included for evaluation
of long-term follow-up (FU). Primary outcome: recurrence of HGD/EC; recur-
rence of endoscopically visible Barrett’s mucosa. Secondary outcomes: Buried
Barrett’s glands; IM in biopsies obtained distal to a normal appearing neo squa-
mocolumnar junction (neo-SCJ); need for retreatment; sustained CE-IM and
CE-neo at last FU.
Results: 68 patients were included (55 men, median 64 yrs, median BE C5M6). In
53/68 patients ER was performed (worst pathology: low-grade dysplasia (LGD)
(n¼ 3), HGD (n¼ 23), EC (n¼ 27)). Worst pathology pre-RFA (after any ER)
was: non-dysplastic IM (n¼ 9), LGD (n¼ 27), HGD (n¼ 32). Median FU was 85
months (IQR 58–96) with a median of 7 FU endoscopies per patient. Recurrence
of HGD/EC was found in 2 patients (3%): one patient with a T1m2 EAC 3 cm
above the neo-SCJ after 44 months and one patient had a visible lesion at the
neo-SCJ with HGD after 22 months, both were treated successfully with ER.
Recurrence of endoscopically visible Barrett’s mucosa was seen in 22 patients
(32%) after a median of 20 months: small Barrett island (n¼ 10), BE tongue
(1 cm n¼ 9, 2 cm n¼ 1), circumferential BE 2 cm (n¼ 2). In 3 patients
Buried Barrett’s glands were detected (overall 3/448 FU endoscopies, 0.7%).
IM in a normal appearing neo-SCJ was found in 19 patients (28%), and this
was not reproduced in 84%. In 2 patients LGD without IM was found in the neo-
SCJ. Eleven patients required retreatment: APC for small areas of visible
Barrett’s mucosa (n¼ 5), six patients had additional ER (1x T1m2, 1x HGD,
2x LGD, 2x visible Barrett’s islands), RFA for LGD without IM in the neo-SCJ
(n¼ 1). CE-neo and CE-IM (excluding IM in the neo-z-line) at the last FU
endoscopy was seen in 100% and 96% respectively.
Conclusion: With 7-years of follow-up, this study presents the longest published
follow-up data on RFA for BE with HGD/EC to date. Our long-term outcomes
show that after successful RFA recurrence of HGD/EC is rare (3%). Recurrence
of endoscopically visible BE was found in 32% of patients, however it was
confined to small islands or tongues 1 cm in the vast majority of patients.
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Introduction: Barrett’s oesophagus (BE) is the only identifiable pre-cursor condi-
tion for oesophageal adenocarcinoma. Endoscopic surveillance is performed in
BE to detect dysplasia as it likely to be amenable to curative therapy. There is
data to suggest that a diagnosis of BE has a negative impact on the quality of life
of patients. To our knowledge, no guidance exists on the counselling of patients
entered into endoscopic surveillance for BE. The aim of this study was to check
patient understanding of their diagnosis of BE and associated anxiety levels at a
district general hospital.
Aims & Methods: An in-house database was used to identify patients with BE
over a 10-year period (2006–17). A simple, 14-point based questionnaire was
devised and answers obtained via a telephone consultation (Table 1).
Results: 163 patients with BE were identified. In total, 104 patients (70 male, 34
female) were recruited (13 deceased, 38 did not answer, 8 declined). 2 patients had
previously undergone therapy for BE (1 RFA, 1 fundoplication). Results are
displayed in Table 1. Less than a third of patients remembered meeting a clinician
to discuss their diagnosis and the rationale for follow-up. Consequently, only
41% of patients understood their diagnosis and 44% the rationale for surveil-
lance. Although almost all patients (92%) were on a regular proton pump inhi-
bitor, less than half (48%) understood why. Only 11% of patients were aware of
the overall cancer progression risk and even fewer (7%) of the treatment options
that are currently available. Interestingly, half of all patients admitted feeling
anxious about their diagnosis with the majority (82%) admitting that further
counselling would benefit in this regard.
Table 1: A 14-point based questionnaire which was used to check the under-
standing amongst patients with Barrett’s Oesophagus (BE–Barrett’s Oesophagus,
OAC–Oesophageal adenocarcinoma PPI–Proton pump inhibitor).
Yes (%) No (%)
1. Did you receive a letter or see someone in
clinic to discuss your diagnosis and plans for
future follow-up?
32 (31) 72 (69)
2. If yes, did you understand this? 15 (47) 17 (53)
3. Broadly speaking, do you understand what
BE is?
43 (41) 61 (59)
4. Do you understand that chronic acid reflux
into the lower oesophagus is the most likely
cause of BE?
50 (48) 54 (52)
5. Are you on a regular PPI? 96 (92) 8(8)
6. Do you know what the overall risk of pro-
gression to cancer is?
11(11) 93 (89)
7. Are you aware of the term ‘dysplasia’ and
how this helps to risk stratify your condition
and interval length for surveillance endoscopy?
6(6) 98 (94)
8. Do you understand what the rationale for
endoscopic surveillance in BE is?
46 (44) 58 (56)
9. Have you ever been told if you have a short or
long segment of BE and the importance of this?
6(6) 98 (94)
10. Are you aware of any treatment options for
BE?
7 (7) 97 (93)
11. If yes, do you know when this indicated? 4 (57) 3 (43)
12. Does or has anyone in your family suffered
with BE or OAC?
36 (35) 68 (65)
13. Do you feel or have you ever felt anxious
about your diagnosis of BE?
53 (51) 51 (49)
14. Do you think it would be useful for your
understanding or reduce your anxiety if you
either sat down with someone in clinic or
spoke to someone over the phone regarding
your BE?
82 (79) 22 (21)
Conclusion: We have demonstrated that patients with BE have a relatively poor
understanding of their diagnosis and the treatment options that are available to
them. Further efforts need to be made to address this and help empower a group
of patients who are understandably anxious about their diagnosis.
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Introduction: Data on the association between inflammatory and metabolic bio-
markers and Barrett’s esophagus (BE) are scant and conflicting.
Aims & Methods: We aimed to study the association between circulating inflam-
matory biomarkers (interleukin-6 [IL-6], high-resolution C-reactive protein
[hrCRP], intra-cellular adhesion molecule [ICAM], tumor necrosis factor recep-
tor-2 [TNF-R2]) and metabolic biomarkers (leptin, adiponectin, C-peptide, insu-
lin-like growth factor 1 [IGF-1], and insulin-like grow factor binding proteins -1,
-2 and -3 [IGFBP-1, -2 and -3]) with BE. This was a case-control study, nested
within two female-only prospective cohort studies (Nurses’ Health Study 1 and 2)
and one male-only prospective cohort (Health Professional Follow-up Study).
Participants of provided biennial detailed information on demographic, lifestyle,
dietary and medical factors, including endoscopy use. Overall, 80,437 partici-
pants enrolled in these cohorts provided a prediagnostic blood specimen between
1989 and 1995. Among these participants, through 2012, we identified 283 cases
of BE (163 females and 120 males). Two study physicians, blinded to biomarkers
results, reviewed the medical records of patients reporting BE. We matched BE
participants with 626 controls who underwent upper endoscopy during the same
time period and did not have BE (361 females and 265 males) on year of birth,
year of blood collection, month of blood collection, fasting status and ‘‘am or
pm’’ blood draw. We used multivariable conditional logistic regression models,
adjusting for known and putative risk factors for BE, to assess the association
between each biomarker and the risk of BE. We used the lowest quintile as
reference, and assessed linear trend across exposure categories using the
median of each quintile as a continuous variable.
Results: In women, plasma adiponectin was significantly associated with BE
(p-trend¼ 0.01). When compared to the lowest quintile (Q1), the the multivariate
odds ratio (OR) for the highest quintile (Q5) of adiponectin was 0.39 (95%CI
0.17, 0.88). This association was not materially altered after further adjustment
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for leptin. The association did not differ according to subgroups defined by BMI
(p-interaction¼ 0.33) or regular aspirin use (p- interaction¼ 0.82). Among men, we
observed that adiponectin was not associated with BE. However, we observed an
OR of 0.41; 95%CI 0.17, 0.99 comparing extreme quintiles of IGFBP-3
(p-trend¼ 0.11). Among both women and men, we did not observe any other
significant associations between inflammatory or metabolic biomarkers and BE.
Conclusion: There was little evidence that pre-diagnostic inflammatory or meta-
bolic biomarkers are associated with risk of BE. Only adiponectin was associated
with a decreased risk of BE in women but not in men. These findings may serve
to provide input for clinical risk assessment for BE and shed light on potential
mechanisms of its pathogenesis.
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Introduction: Endoscopic mucosal resection (EMR) is an established diagnostic
and treatment tool in the management of Barrett’s oesophagus (BO) with early
neoplasia. However there is not enough clinical evidence on the management of
the patients, in whom the EMR’s histologic assessment identifies early-stage
adenocarcinoma of the oesophagus with incipient submucosal invasion (pT1b
sm1).
Aims &Methods:We have conducted a retrospective analysis using our electronic
database for endoscopic procedures for patients with BO, who underwent EMR
from October 2010 to December 2016. We investigated the size of the EMRs, the
complication rates of the EMRs, the histological features and the resection mar-
gins of the EMR specimens and also the outcomes with the mortality.
Results: A total of 99 patients underwent 134 EMR procedures, and the histology
identified early adenocarcinoma with incipient invasion of the submucosa in 25
patients. 23 (92%) were male, the mean age at the EMR was 71 years (SD: 8.1).
In all 25 EMRs 7 (28%) patients had a single piece, 7 (28%) patients a 2 piece, 7
(28%) patients 3 piece and 4 (16%) patients 4 piece EMR. The median length of
the circumferential and maximum extent of the BO segments were 2 and 5 cm
respectively (interquartile range (IQR) 2–4). We observed 6 (24%) intra-proce-
dural bleedings and 2 (8%) patient needed admissions with post procedural
bleeding and 1 (4%) of them required transfusion. Stricture was endoscopically
detectable but not causing any symptoms in 1 (4%) patient and another patient
(4%) had slight dysphagia post EMR, but did not need dilation. Histology
showed lymphovascular invasion in 6 (24%) patients and vascular invasion in
1 (4%) patient. Of all 25 early adenocarcinomas 7 (28%) were reported as poorly
differentiated, 11 (44%) as moderately differentiated and 3 (12%) as well differ-
entiated. In 4 (16%) cases differentiation was not reported. All resection margins
were reported as being clear from dysplasia or cancer in 7 (28%) cases, radial
resection margins were reported with dysplasia in 3 (12%) cases and with cancer
in 15 (60%) cases, but this included the multiple piece EMRs. The deep margin
was reported as being clear in 18 (72%) cases, with dysplasia in 1 (4%) case and
with cancer in 6 (25%) cases. There were 15 (60%) patients with cancer invasion
on the radial and/or deep margin of the EMR specimen, of these patients 9 (60%)
had oesophagectomy and in the histologic assessment of these specimens, lymph
node involvement was observed in 2 cases (22.2% of all oesophagectomies and
9.5% of all surviving and currently cancer-free patients). There was no residual
cancer in 3 (33.3%) of the surgical specimens. Radical radio-chemotherapy was
given in 1 (6.7%) patient and 5 (33.3%) patients did not have radical treatment
for clinical reasons. There were 10 (40%) patients without cancer invasion of the
EMR resection margins, of these 4 (40%) had oesophagectomy and 1 (10%)
radical radio-chemotherapy. The histologic assessment of these surgical speci-
mens showed residual cancer in 3 (30%) cases and high-grade dysplasia in 1
(10%) case. Of the 25 patients 5 (20%) met the criteria and had radio frequency
ablation of the residual Barrett’s oesophagus. Of the 13 (52%) patients who have
had oesophagectomy 1 (7.7%) patient died of the deterioration precipitated by
the oesophagectomy, and sadly in this case the oesophagectomy specimen did not
show any residual cancer. Of the 12 (48%) patients who have not had oesopha-
gectomy 3 (25%) died since their EMR, 1 (8.3%) of cardiac arrest, 1 (8.3%) of
chronic obstructive pulmonary disease and 1 (8.3%) of advanced oesophageal
cancer, 18 months after the EMR, and the 9 (75%) surviving patient are all
cancer free on follow up investigations, one after radical chemo/radiotherapy.
The median survival of all 21 (84%) patients currently alive is 25 months (range:
2–68 months; SD: 22.2).
Conclusion: In this retrospective analysis we have found that the clinical out-
comes are very difficult to predict for patients with early adenocarcinoma and
incipient invasion of the submucosa. Clinical decision making remains very chal-
lenging and has to be individualised for all patient, until further in depth studies
gives us more useful prognostic factors.
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Results: From July 2015 to March 2017, forty-four patients were included in the
study. Seventeen of the forty-four (38.6%) patients had histological confirmed
cancer of the esophagus. There were sixteen patients who had normal finding and
nine patients with esophagitis. The positive predictive value for malignancy
(ECA 4 and 5) was 89.5%; the negative predictive value was 100%. Sensitivity
was 100% and specificity was 92.6%. Similar findings were noted with IPCL on
magnifying NBI. The positive predictive value for malignancy (IPCL 4 and 5)
was 89.5%; negative predictive value was 100%. Sensitivity and specificity were
also similar at 100% and specificity 92.6% respectively. To compare the diag-
nostic accurary of endocystoscopy and magnifying NBI, the McNemar test was
performed. The McNemar chi-squared statistic is NaN, and the McNemar chi-
squared statistics with Yates correction of 0.5 is infinity, meaning that the two
tests have the same diagnostic accurary.
Conclusion: Endocystoscopy had a high positive predictive value and sensitivity
for esophageal malignancy. Its diagnostic accuracy was comparable to magnify-
ing NBI. It may be helpful as an adjunct for better characterization of esophageal
lesions. However, further studies on interobserver variability is required.
Introduction: Early detection of esophageal cancers can significantly reduce the
morbidity and improve the prognosis of these patients. A new prototype scope
incorporating the endocystoscopy function into a magnifying endoscope has
been designed. Previously, Inoue et al have published a pilot trial on evaluating
the use of this endocystoscope in various types of benign and malignant pathol-
ogy in the esophagus. An endocytoscopic atypia (ECA) classification was pro-
posed. The sensitivity and specificity of this classification system was evaluated.
Aims & Methods: All consecutive patients who had esophagogastroduodeno-
scopy (EGD) arranged for screening of the esophagus during the period July
2015 to March 2017 were recruited into the study. EGD with narrow band
imaging and endoscocystoscopy were performed in these patients. During the
procedure, the esophageal mucosa was stained with 0.5% methylene blue and
then with crystal violet. The endocystoscopic findings were graded from 1 to 5
according the Inoue et al’s ECA classification. The esophageal mucosa was also
evaluated with narrow band imaging (NBI) and the findings were classified
according to the Intrapapillary capillary loop (IPCL) pattern classification.
These findings were compared against the gold standard of histopathological
diagnosis which was based on the Vienna classification.
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Introduction: Esophageal achalasia is considered to be a high-risk factor for
superficial esophageal cancer. But there are few reports of endoscopic resection
for this cancer, and the outcome is unclear. In our hospital, we have performed
over 1300 Per-Oral Endoscopic Myotomy procedures for esophageal achalasia
and related diseases. In this process, we diagnosed 10 superficial esophageal
cancers in patients with achalasia. We performed endoscopic resection for all
cases and report relatively long-term outcome.
Aims & Methods: We aimed to evaluate clinicopathological findings and out-
comes of endoscopic resection for 10 achalasia-associated superficial esophageal
cancer. This is a case series study at our hospital. Between August 2010 and
February 2017, 10 achalasia patients with superficial esophageal cancer under-
went endoscopic resection. We performed in all cases upper gastrointestinal
endoscopy using lugol’s solution and narrow band imaging, and we included
all patients that had early cancers that were eligible for endoscopic resection in
this series. At 2 and 12 months after treatment, we performed follow-up endo-
scopy in all cases. After this, we performed long-term endoscopic follow-up every
year. In the case that the tumor invasion depth is to the muscularis mucosa(MM)
on histopathology, we performed endoscopic follow-up every 6 months and CT
scan.
Results: There were 6 men and 4 women and their average age was 61.7 years. 8
patients were diagnosed with lesions before POEM. We performed endoscopic
resection (ESD/EMR;9/1) in all cases after POEM. None of the patients had a
severe adverse event. The mean tumor diameter was 30mm (range: 5–80mm).
The pathological diagnosis was 8 SCC, 2 high grade intraepithelial neoplasia.
Out of the SCC cases, 7 were found with superficial lesion with depth of Tis-EP
to T1a-LPM, and 1 with depth of T1a-MM, without lymphatic invasion(ly0) or
venous invasion(v0). Follow-up surveillance mean term was 32 months (range: 1–
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67months). Ectopic lesions were detected in 2 cases, and these patients underwent
endoscopic resection. All patients survived in this term.
Conclusion: Endoscopic resection for achalasia-associated superficial esophageal
cancer invasive to the MM on histopathology is safe and effective, and relatively
long term outcome is good.
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Introduction: ESD is a standard treatment for superficial esophageal cancer in
Japan. Stricture is one of important complication of esophageal ESD, and it
makes quality of life of the patient worse. Usefulness of Triamcinolone (TA)
injection to prevent stricture after semi-circumferential ESD has been reported.
However, usefulness of TA injection after circumferential esophageal ESD is still
unclear.
Aims & Methods: The aim of this study is to clarify the usefulness of triamcino-
lone injection to prevent stricture after circumferential ESD. A total of forty-four
patients treated by circumferential esophageal ESD from 2004 to 2016 in Saku
Central Hospital Advanced Care Center were enrolled to this retrospective study.
The patients treated from 2004 to 2009 were followed up without TA injection
(Non-TA group). And, local injection of TA was performed for the patients after
2009 (TA group). The number of patient in Non-TA and TA group was 16 and
28, respectively. Age of both groups was 65 (30–83) and 61 (42–82) years old. The
length of circumferential resection was 75 (50–10) and 76 (55–111) mm, respec-
tively. There was no significant difference in the background of both groups.
Fifty mg TA was injected into submucosal layer just after ESD, and TA injection
was repeated in two-weeks interval by the ESD ulcer healed. When the length of
circumferential ESD was 50mm or longer, 100mg Triamcinolone was injected
just after ESD, and 50mg TA injection was repeated in two-weeks interval.
Fifteen mm endoscopic balloon dilatation (EBD) was performed when the
scope couldn’t pass the ESD ulcer. The primary endpoint was the number of
balloon dilatation. The secondary endpoints were duration from ESD to ulcer
healing, complications and the difference between Barrett’s esophageal adeno-
carcinoma (EAC) and squamous cell carcinoma (SCC).
Results: 1. Number of EBD in Non-TA and TA group were 20 (13–33) and 5.1
(0–23), respectively (p5 0.01) 2. Duration from ESD to ulcer healing were 10 (3–
23) and 6.9 (1–24) months. respectively. (p¼ 0.47) 3. Complications: Perforation
rate due to EBD was 6.3% (1/16) and 3.6%(1/28). Both patients were treated by
conservative therapy. 4. Difference between EAC and SCC: There were four
EAC and 24 SCC patients in TA group. The number of EBD were 5.3 (5–11)
and 5.4 (3–11), respectively. Duration of ulcer healing were 10 (4–14) and 6.5 (1–
24), respectively. There was no significant difference between two groups.
Conclusion: Triamcinolone injection is safe and effective treatment to prevent
stricture after circumferential ESD, not only for SCC but also for EAC.
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Introduction: Superficial pharyngeal squamous cell carcinoma (SCC) has been
increasing in Japan. And, such SCC could be treated by endoscopic submucosal
dissection (ESD). However, the outcome of pharyngeal ESD is unknown.
Aims & Methods: The aim of this study is to clarify the outcome and prognosis of
pharyngeal SCC treated by ESD. 89 pharyngeal SCC in 68 patients treated by
ESD from Jan. 2006 to Jan. 2017 in Saku Central Hospital Advanced Care
Center were enrolled to this retrospective study. CT and neck US were performed
for the preoperative staging. All ESD were performed using a Hook knife under
general anesthesia with tracheal intubation. Clip with line or forceps was used to
make traction during ESD. Annual endoscopy, CT scan and neck US were
performed as surveillance after ESD, and these examinations were recommended
twice a year for the patients who had subepithelial (SEP) SCC. Male/Female was
67/1. Mean age was 67.1 (40–92). Mean size of tumor and specimen were 12.9 (1–
50) and 26.8 (5–65) mm, respectively.
Results: 1. En bloc resection rate was 100%. 2. Complication: Delayed bleeding
rate was 1.5% (1/68). Re-intubation was needed for the hemostasis. Dysphasia
was shown in 4.4% (3/68). Two patients had mild dysphagia and improved in
two weeks. The remaining one patient had severe dysphagia. The patient had a
big SCC, 50mm in size, and the SCC extend from light piriform sinus to ary-
epiglotic fold. The patient could keep vocal function. However, eating was
impossible for mis-swallowing. 3. Invasion depth: Epithelial (EP) and subepithe-
lial (SEP) SCC were 60% (53/89) and 39% (35/89), respectively. One case was
inflammation. 4. The rate of lymph-duct involvement of EP and SEP were 0%
and 5.7% (2/35), respectively. LNM was found in one of two patients who had
lymph duct involvement, and treated by lymph node dissection. The other patient
was followed up without additional therapy, and free from LNM for one year. 5.
Venous involvement of EP and SEP were 0% and 2.9% (1/35), respectively. The
only patient who had venous involvement was 92 years old, and followed up
without an additional therapy. 6. Local recurrent rate was 0%. 7. LNM rate of
EP and SEP was 0% and 5.7% (2/35), respectively. One of two patients who had
LNM was a 76-year-old male. He had SEP SCC without lymph duct involve-
ment. A cervical LNM was diagnosed 6 months after ESD. Lymph node dissec-
tion and chemo-radio therapy (CRT) was performed for the patient. The patient
died of other disease without recurrence of pharyngeal SCC. The other patient
also had a cervical LNM and treated by lymph node dissectionþCRT. The
patient is alive without recurrence for 10 years after ESD. 8. Prognosis No
patient died of pharyngeal SCC after ESD.
Conclusion: ESD is a safe and useful treatment for superficial pharyngeal SCC.
However, surveillance of LNM is important for the patients who had SEP SCC.
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Introduction: Endoscopic submucosal dissection (ESD) has been widely per-
formed as a minimally invasive treatment for superficial esophageal squamous
cell neoplasms (ESCNs) in Japan and Asian countries. According to the current
guidelines[1], ESD is classified as a high bleeding risk procedure. However, these
guidelines have not been fully validated.
Aims &Methods: The aim of this study was to identify the risk factors of bleeding
associated with esophageal ESD, and to clarify whether antithrombotic agents
increase the risk of bleeding for esophageal ESD. A total of 458 ESCNs in 411
patients who underwent ESD at our hospital from January 2013 to October 2016
were analyzed in this retrospective study. ESD was performed using an IT knife
nano (Olympus, Tokyo, Japan). Hemostatic forceps (Coagrasper; Olympus,
Tokyo, Japan) were used when hemostasis during ESD proved difficult with
the IT knife nano. Longer hemostatic time during ESD was defined as more
than 120 secs required for hemostasis with hemostatic forceps. We analyzed
the relationship between risk factors for longer hemostatic time during ESD
and the following factors using univariate and multivariate analyses: age (575
or 75 years), sex, body mass index (525 or 25), treatment for synchronous
multiple ESCNs, previous radiation therapy, antithrombotic agents, lesion loca-
tion (upper or middle or lower), lesion size (52 cm or 2 cm), lesion circumfer-
ence (53/4 or 3/4), and the endoscopist’s experience of esophageal ESD (540
or 40 procedures).
Results: Twenty-nine ESCNs (6%) were treated by ESD without discontinuation
of antithrombotic agents. Hemostatic forceps were used for 116 lesions (25%),
median forceps use time was 73 secs (range: 8–1200 secs), and the median number
of forceps application during procedures was 2 (range: 1–9 times). Of these, 41
lesions (9%) met our definition for longer hemostatic time. Univariate analysis
revealed that lesion size (2 cm), lesion circumference (3/4), and the endosco-
pist’s experience (40) were significantly associated with longer hemostatic time.
Multivariate logistic regression analysis revealed that a lesion size 2 cm (OR 2.4
[95% CI 1.1–5.1], P¼ 0.02) was an independent risk factor for longer hemostatic
time. Postoperative bleeding occurred 20 days after ESD in one patient (0.2%)
receiving the continuous administration of warfarin and aspirin.
Conclusion: Our results suggest that continuous use of antithrombotic agents
does not increase the risk of bleeding during esophageal ESD, and that post-
operative bleeding was a rare occurrence. Discontinuation of antithrombotic
agents may therefore not be necessary prior to esophageal ESD.
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Introduction: While definitive chemoradiotherapy (CRT) showed high efficacy
for esophageal squamous cell carcinoma (ESCC), approximately 40% of patients
develop local failure, resulting in poor long-term survival1. However, there is no
definitive biomarker which is useful to predict survival outcome after CRT for
ESCC. Several studies have investigated the correlation of expression of CD24,
cytokeratin 4 (CK4), or podoplanin (PDPN) with prognosis of patients with
various malignant tumors who underwent surgical resection2,3. However, it
remains unclear whether the expression of these proteins can predict the outcome
of CRT for patients with ESCC.
Aims & Methods: The aim of this study was to clarify the predictive values of
expression of CD24, CK4, and PDPN for ESCC patients who received CRT.
Among patients with ESCC who received CRT or curative esophagectomy with
extended lymph node dissection (OPE) as an initial treatment between 2005 and
2009 at our institution, cohorts were selected based on the following criteria:
clinical stage II, III (UICC-TNM classification 6th editon), age of 75 years old
or younger, ECOG Performance Status 0–1, and no prior or concurrent other
cancers. The method of immunohistochemistry (IHC) was utilized to examine the
protein expression of CD24, CK4, and PDPN in pretreatment biopsy specimens
of ESCC. The cut-off values for CD24, CK4, and PDPN expression were used
hazard ratio for overall survival (OS). The prognostic factor of CD24, CK4, and
PDPN expression were statistically analyzed. OS was calculated from the date of
CRT or OPE to the date of death or last follow-up, using the Kaplan-Meier
method. The survival predictors identified by univariate analysis was assessed by
multivariate analysis using a Cox’s proportional hazards model.
Results: 148 ESCC patients (CRT group, n¼ 83; OPE group, n¼ 65) were ana-
lyzed. In the CRT group, 40 patients had stage II and 43 patients had stage III,
and the 5-year OS was 52%. In the OPE group, 32 patients had stage II and 33
patients had stage III, and the 5-year OS was 66%. By univariate analysis, there
were no significant clinical variables for OS in differences between the CRT and
OPE group. The cut off value for CD24, CK4, and PDPN expression were 20%,
10%, and 20%, respectively. While the expression equal to the cut off value or
more was defined as strong, the expression less than the cut off value was defined
as weak. The frequency of strong protein expression was 50% for CD24, 12% for
CK4, 65% for PDPN, respectively. In the CRT group, the OS of patients with
strong CD24 expression was significantly better than that of patients with weak
CD24 expression (P¼ 0.015; strong/weak 5-year: OS 65%/43%).On the other
hand, patients with strong CD 24 expression was poorer OS comparing with
patients with weak expression in the OPE group, however there was no signifi-
cant difference (P¼ 0.286; strong/weak 5-year OS: 57%/74%). As for patients
with strong CD24 expression, there was no significant difference between CRT
group and OPE group(p¼ 0.446), however there was significant difference
between CRT and OPE group in patients with weak CD 24 expression
(p¼ 0.009). There were also no significant differences of the OS based on expres-
sion of CK4 or PDPN between the CRT and OPE group, respectively.
Multivariate analyses revealed the strong CD24 expression in the CRT group
(P¼ 0.012; HR¼ 2.787; 95%CI: 1.253–6.200) as an independent variable for
favorable outcome.
Conclusion: CD24 expression was significantly associated with the survival out-
come of patients with ESCC when they were treated with CRT. Furthermore,
weak CD24 expression might be a useful predictive biomarker of poor outcome
for CRT in ESCC patients.
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Introduction: Endoscopic treatment is a standard therapeutic approach for
patients with T1a early esophageal cancer (EEC). In patients with ‘high-risk’
T1a cancer (e.g. advanced grading or invasion to blood/lymphatic vessels) and
in patients with any submucosal (sm) invasion (T1b), surgery is recommended as
a standard of care. However, recent data suggest, that endoscopic treatment
might be curative in selected patients with ‘high-risk’ EEC.
Aims & Methods: The aim of this study was to assess outcomes of endoscopic
treatment in patients with ‘high-risk’ EEC. ‘High-risk’ cancer was defined as any
cancer with sm invasion or mucosal cancer with at least one of the following:
poor differentiation (G3/G4), invasion to blood (Aþ) or lymphatic vessels (Lþ)
and high tumor cell dissociation (TCD3). The main outcome measurement was
tumor-free survival.
A single-center, retrospective analysis of prospectively collected data. Patients
with EEC underwent endoscopic resection (ER) or endoscopic submucosal
dissection (ESD). Based on histopathological staging, patients with ’high-risk’
EEC without contraindications were referred for surgery. Remaining patients
continued in endoscopic treatment consisting of further sessions of ER and/or
radiofrequency ablation if necessary. The patients have been followed up for a
median of 39 months (range 2–156).
Results: A total of 56 patients with ‘high-risk’ EEC underwent endoscopic treat-
ment: 21 patients (41%) had T1a cancer with ‘high-risk’ features and 35 patients
(59%) had T1b cancer with sm invasion (sm1: 15, sm2: 9, sm3: 11); 45 patients
had adenocarcinoma (EAC), 11 patients had squamous carcinoma (SCC); 19
patients were referred for surgery. A total of 37 patients (66%) continued in
endoscopic treatment. Complete local remission (CLR) of neoplasia was
achieved in 35/37 patients (95%). Two patients without CLR continued endo-
scopic therapy with palliative intent. Tumor generalization occurred in 2 patients
(one of them achieved CLR) 24 months after endoscopic treatment (both patients
had sm3 invasion, Aþ, Lþ) and these patients are undergoing oncological treat-
ment. All remaining patients with CLR (n¼ 33) have experienced neither local
relapse nor generalization. One patient had to undergo surgery due to endoscopy
related perforation. Tumor-free survival was 89% (CI 79–99%) in patients trea-
ted endoscopically and endoscopy related mortality was 0% (0/37). Among 19
patients who were referred for esophagectomy, one patient presented with tumor
generalization revealed during the operation. The remaining 18 patients under-
went esophagectomy; local residua of malignancy were present in 5/18 patients
(28%,). Lymph node (LN) metastases have not been detected in any patient
among the 337 examined LNs. Surgery related mortality was 6% (1/18).
Conclusion: Endoscopic treatment provides long-term remission or cure in a
considerable number of patients with ‘high-risk’ EEC and it may thus represent
a valid alternative to surgery. Broadening of indications for radical endoscopic
treatment of early EEC should be reconsidered.
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Introduction: Normally, resided within the submucosal layer of esophagus, each
esophageal submucosal gland will culminate in a single duct. The esophageal
submucosal gland ducts (ESMGDs) can traverse the subepithelial connective
tissue and muscularis mucosa, and deliver the acinar serections to the esophageal
lumen. However, the clinicopathological features of the esophageal submucosal
gland duct involvement (ESMGDI) and its precursor lesion have not been com-
prehensively evaluated so far, and the series study focusing on endoscopic fea-
tures of this lesion has not been reported widely. While since the 1990s, the
esophageal lesions presumed to originate from ESMGDs had been described
constantly in various case reports. Currently, in addition to the gold standard
of histopathology, almost no more useful modality could be applied to this
lesion. In our study, we considered that the ESMGDI had a correlation with
early esophageal cancer, and we noted that the ESMGDI had special features
under the endoscopic ultrasonography (EUS). The typical ultrasonic images of
EUS could help diagnose ESMGDI.
Aims & Methods: In order to investigate the clinical value of EUS for diagnosing
ESMGDI accompanied by early esophageal cancer, which were suggested by
conventional endoscopy or biopsy, this study retrospectively analyzed the con-
secutive patients with early esophageal cancer diagnosed in the Endoscopy
Center at the Affiliated Drum Tower Hospital, Nanjing, China from
September 2009 to November 2016. The clinical data of 519 patients were
included in this study, and all of them had already underwent EUS combined
with Endoscopic Submucosal Dissection(ESD). The EUS preoperative diagnosis
were compared with the results of postoperative pathology from ESD.
Results: According to the pathological results, all patients (371 males and 148
females, with a mean age of 67.5 4.5years) had been diagnosed with early
esophageal cancer with different invasive depth. Out of 519 patients, about 478
patients were not found ESMGDI by both examinations. Besides, postoperative
pathology confirmed that 40 patients were identified with ESMGDI, 34 patients
of which were completely consistent with the preoperative diagnosis of EUS.
Approximately 98.7% (512/519) of ESMGDI were diagnosed exactly by EUS.
Another six cases were estimated as flase negative inaccurately, including two
squamous cell carcinoma and four high-grade intraepithelial neoplasia. One case
was regarded as ESMGDI by EUS while confirmed not by pathology. Therefore,
the EUS values for sensitivity and specificity for the diagnosis of ESMGDI were
85.0% (34/40) and 99.8% (478/479) respectively. Furthermore, the positive pre-
dictive value was 97.1% (34/35), and the negative predictive value was 98.8%
(478/484).
Conclusion: The esophageal submucosal gland duct involvement is a kind of
lesion performed as a hypoechoic sonographic pattern located in the thickened
mucosa. EUS has a satisfactory diagnostic accuracy for ESMGDI as well as
good sensitivity and specificity.
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Introduction: Preoperative Neutrophil to Lymphocyte Ratio (NLR) has been
proposed as a prognostic marker in several solid tumors (Templeton 2014). A
recent retrospective study of 60 patients showed the prognostic relevance of NLR
as a predictor of response in esophageal cancer patients treated with chemora-
diotherapy. The aim of this study is to assess the NLR prognostic strength in a
retrospective series of two high-volume centers.
Aims & Methods: A retrospective review of two prospective esophageal cancer
database was conducted. Neutrophil to lymphocyte ratio was defined as the pre-
chemoradiotherapy serum neutrophil count divided by lymphocyte count. We
dichotomized the NLR data using as cut-off values 2,5 and 3 respectively.
Univariable logistic regressions were performed to determine the effect of NLR
on response after neoadjuvant treatment. Survival curves were constructed with
Kaplan Meier method and compared with the long rank test.
Results: We included 280 patients. The analysis of NLR as predictor of patho-
logic complete response (pCR) showed a OR of 0.963 (95% CI 0.531–1.746,
p¼ 901) and 1.161 (95% CI 0.647–2.081, p¼ 0.617) considering as cut-off
values 2.5 and 3 respectively. In our large series, NLR did not result as a pre-
dictive marker neither in terms of Overall Survival nor in terms of Disease Free
Survival (p¼ 0.997 and p¼ 0.672 respectively).
Conclusion: Our results did not confirm NLR as a significant marker of pCR.
Moreover, the survival analysis did not reveal significant differences using NLR
as pre-treatment prognostic marker. The heterogeneity of treatments, the com-
plexity of the disease, the absence of a validated and pre-defined NLR cut-off
value in the available literature are the main limits to our analysis. Further
studies are needed to assess the clinical relevance of NLR as a predictive
marker of response to neoadjuvant treatment.
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Introduction: Background consumption of non-steroidal-anti-inflammatory-
drugs (NSAID) and Aspirin is high in Denmark and the majority of these
drugs are prescribed in General Practice. Risk factors for complicated ulcer are
well established and include NSAID, Aspirin, age, prior ulcer, Helicobacter
pylori, anticoagulants, selective-serotonin-reuptake-inhibitors (SSRIs),
Adenosine-Di-Phosphate (ADP)-inhibitors and glucocorticoids. Proton Pump
Inhibitors (PPIs) reduce the risk of complication but preventive treatment with
PPI is only given to a third of the people at risk. The mortality from an ulcer
complication is 10% and above.
Aims & Methods: The aim was first in a randomised cluster design to test if a
Computer Decision Support System (CDSS) - based on a risk profile for the
individual patient - reduced the frequency of ulcer complications. Second to
investigate if use of the CDSS changed the prescription pattern in general prac-
tice with regard to prescriptions of NSAID, Aspirin and PPI.
Results: Ninety-six GPs responsible for the treatment of 52,649 patients were
randomised to the CDSS-group and 90 GPs responsible for the treatment of
43,861 patients to the control group. No significant differences were found
between the two patients groups regarding peptic ulcer complications, uncompli-
cated ulcer, gastro-oesophageal reflux or usage of upper gastrointestinal(GI)-
endoscopies. The patients’ risk profile was identical in the two groups. During
the intervention period lasting from April 2013 to September 2014 a significantly
higher prescription rate of NSAID and PPI was found in the CDSS group. In
addition a significantly higher co-prescription of NSAID and PPI was found in
the CDSS group–particularly in high-risk patients. No significant difference was
found in co-prescription of Aspirin and PPI when comparing CDSS-group to the
control-group.
Conclusion: Conclusion A CDSS based on a risk profile for the individual patient
had no impact on the main outcomes ulcer complications, uncomplicated ulcer,
reflux or endoscopies. Usage of CDSS increased the amount of co-prescription of
PPI and NSAID in medium and high-risk groups. A similar pattern was not
found for Aspirin. Triggering and the timing of the CDSS and its implementation
in the Electronical Health Record should be optimized.
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Introduction: Carbon monoxide (CO) is produced endogenously in the body as a
by-product of heme degradation via activity of the enzyme heme oxygenase
(HO)-1. This gaseous mediator with multidirectional biological activity exerts
antiproliferative, anti-inflammatory and immunomodulatory properties. A
newly discovered class of compounds, named CO-releasing molecules
(CORMs), is capable of liberating CO gaseous molecule that can be useful as
pharmacological tool to assess the physiological role of CO under experimental
conditions. CORM-2 was implicated in gastroprotection against formation of
acute gastric lesions but the contribution of CO to the mechanism of gastric
ulcer healing has not been fully elucidated.
Aims & Methods: We determined the effect of daily treatment with vehicle or
CORM-2, on healing of preexisting gastric ulcers induced by serosal application
of acetic acid (ulcer area¼ 28 mm2) in rats. Our second goal was to examine the
mechanism of CO released from its donor by the determination of the CORM-2-
induced alterations in gastric blood flow (GBF) at ulcer margin, the parameters
of oxidative stress and the gastric mucosal expression of pro-inflammatory and
anti-inflammatory factors. Groups of seventy rats with gastric ulcers (A-D)
received daily treatment with A) vehicle (saline), B) CORM-2 in doses from 1
up to 10mg/kg i.g., C) the HO-1 inductor, hemin (5mg/kg i.p.),, D) the HO-1
activity inhibitor, zinc protoporphirin IX (ZnPP IX) (5mg/kg i.p.). After 9 days
of treatment, the ulcer area was measured by planimetry, the gastric blood flow
(GBF) at ulcer margin was determined by Laser Doppler technique, plasma
TNF- and IL-1b levels were monitored by ELISA and IL-1b-, TNF-, HO-1,
HO-2, COX-1, COX-2, iNOS, cNOS mRNAs were analyzed by RT-PCR and
Western blot. Gastric mucosal samples were collected for the assessment of MPO
activity, level of reduced glutathione (GSH) and lipid peroxidation products
(MDAþ 4HNE) by spectrophotometry.
Results: Treatment with CORM-2 significantly reduced the area of gastric ulcers
and significantly raised GBF at ulcer margin. The dose accelerating ulcer healing
by 50% (ID50) and significantly raising GBF was 10mg/kg as compared with
vehicle-control animals. The administration of hemin significantly reduced the
area of gastric ulcers and raised GBF at ulcer margin but the treatment with
ZnPP IX significantly increased the area of gastric ulcers and significantly
decreased the GBF at ulcer margin. The decrease in gastric ulcer healing by
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CORM-2 was accompanied by a significant decrease in plasma levels of IL-1ß
and TNF-alpha comparing to vehicle-control group. The expression of IL-1ß,
TNF-alpha, COX-2 and iNOS mRNA was strongly upregulated in vehicle-trea-
ted gastric mucosa but expression of these factors was significantly attenuated in
CORM-treated animals. The increased mucosal expression of mRNA for HO-1
but not HO-2 was detected in vehicle control group and these effects were ame-
liorated by treatment with CORM-2. The gastric mucosal MPO activity and
themucosal content of MDAþ 4HNE in gastric mucosa were elevated in vehi-
cle-control group and these effects were significantly inhibited by CORM-2.
Conclusion: CO released from its donor CORM-2 accelerates the healing of pre-
existing gastric ulcerations by the mechanism involving an increase in gastric
microcirculation at ulcer margin, the inhibition of inflammatory response as
manifested by the attenuation of enhancing synthesis of the proinflammatory
markers IL-1ß, TNF-alpha, COX-2 and iNOS as well as by antioxidative proper-
ties of CORM-2 releasing CO limiting lipid peroxidation.
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Introduction: There is evidence of proton pump inhibitors (PPIs) misuse in the
community and in the hospitals causing significant direct and indirect costs
burden for the health care system.
Aims & Methods: We aimed to evaluate the frequency of inappropriate PPIs
administration in hospitalized patients, to measure the direct in-hospital costs
of PPIs overuse and to calculate the number of patients exposed to the risk of
upper gastrointestinal (UGI) complications due to medication underuse. This
was a prospective, cross-sectional, prescription-indication drug-utilization,
chart-review study in hospitalized patients with follow-up until discharge, in a
tertiary 500 beds hospital in Athens, Greece. We recorded data of all patients
admitted (intensive care, psychiatric, pediatric, obstetrics and day clinic admis-
sion were excluded) during three consecutive on-call days of the hospital in
March 2017 regarding PPIs utilization before admission, during hospitalization
and at discharge. We thereafter calculated the direct hospital costs of PPIs over-
use and the number of patients at risk of UGI complications due to PPIs under-
use for 1 year period, using a simulation model.
Results: We included data from 470 patients aged 67 19 yrs; 32.5% were pre-
scribed a PPI before admission, 65.9% during hospitalization and 32.8% at
discharge. PPIs overutilization was detected in 15.7%, 41.3% and 12.6% of
the patients before, during and after the admission, while medications under-
utilization was detected in 10.2%, 8.1% and 9.5% of them, respectively.
Admission at internal medicine and orthopedics clinics was associated with the
highest unadjusted ORs (1.68 [95%CI 1.63–1.72] and 1.68 [1.59–1.78]) for PPIs
misuse. 80% of the 193 over treated patients received PPIs iv (80% of them od,
20% bid) while the rest were treated with PPIs per os (90% of them od, 10% bid)
during their 8 days of mean hospitalization length. This accounts for 1480 PPI iv
and 344 PPI per os doses inappropriately given during the observation period.
Taking into account in our simulation model that there are 90 on-call days of our
hospital annually, the cost of each PPI dose is 3.435 and 0.235 euros for iv and
per os preparations and assuming a similar to that of our sample case distribution
for the next 12 months, we calculated the direct hospital costs burden of inap-
propriate PPIs use at 154940 euros per year. Using the same model, 1200 patients
would be at risk of UGI complications annually, due to under prescription of
PPIs at discharge.
Conclusion: Hospitalization does not represent an opportunity for optimization
of PPIs utilization. On the contrary, the frequency of PPIs inappropriate use
during hospitalization is higher than that before admission, causing significant
direct costs for the hospital and exposing patients to the risks of UGI
complications.
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Introduction: Proton pump inhibitor (PPI) usage is associated with an increased
risk of development of fundic gland polyps (FGP). The trend of change in the
prevalence with increasing length of PPI exposure over 5 years is not known.
Theoretical risk of FGP seems to be very low for clinical consequence in
management.
Aims & Methods: To evaluate the relationship between the length of PPI use and
risk of fundic gland polyps. Prospective cohort study in patients referred for
upper gastrointestinal endoscopy between years 2015–2016 was performed. The
length of PPI use was ascertained from direct patient interview and confirmed
with medical records. The use of PPI in history not continuing at the time of
endoscopy was also inquired. FGP were determinated both endoscopically and
histologically. Odds ratios for subsequent intervals of length of PPI use were
calculated. Clinically relevant complications–dysplasia and bleeding from large
polyps were recorded.
Results:During study period 1525 patients (mean age 59.2 years, 53% male) were
included. Only 612 (40%) of patients had no history of any PPI use. Fundic gland
polyps were identified in 170 patients (11%) and only 13 of them (7.6%) were
without PPI use. The prevalence of FGP in subgroups of patients according to
the length of PPI use was: 10.6% of 161 patients using PPI less than 1 year, 9.4%
of 405 (1–4 years of PPI), 25.2% of 230 (5–9 years of PPI), 35.1% of 94 (10–15
years of PPI) and 47.8% of 23 patients using PPI more than 15 years. The
appropriate odds ratios were 5.4 (CI 2.6–11.4), 4.8 (CI 2.5–9.1), 15.5 (CI 8.3–
29.0), 24.9 (CI 12.4–49.9) and 42.2(CI 15.7–113.1) respectively, all with statistical
significance (p5 0.0001). Only 1 case of low grade dysplasia within FGP was
observed in the patient with familiar adenomatous polyposis. Polyps larger than
15mm with signs of bleeding determinated as a cause of sideropenic anemia were
diagnosed in 6 patients.
Conclusion: The prevalence of FGP is permanently growing during prolonged use
of PPI. Complex source of informations regarding history of PPI use identified
quite low proportion of patient with FGP and without prior PPI use. Rather rare
complications like bleeding from FGP might be clinically significant in increasing
number of long term PPI users. The requirement of repetitive endoscopies and
therapeutic interventions may burden gastroenterologists and sources.
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Introduction: Adenomas of the ampulla of Vater are rare. Endoscopic ampullect-
omy has been recognized as a safe and reliable treatment of selective tumors of
the ampulla of Vater and is associated with lower morbidity and mortality rates
than surgical resection. However, the success rates for endoscopic ampullectomy
range from 61 to 92 percent, with recurrence described in up to 33 percent of
patients. Despite the increasing number of studies concerning endoscopic resec-
tion of ampullary tumors, data evaluating endoscopic resection of the more
advanced ampullary adenomas are limited.
Aims & Methods: The aim of our study was to evaluate the technical success,
complications and recurrence of endoscopic resection for treating patients with
ampullary adenomas with intraductal extension (AIE), and patients with lateral
spreading adenomas (LSA). Between January 2002 and November 2016, all
patients referred to the Erasmus Medical Center, Rotterdam, for endoscopic
resection of an ampullary lesion were retrospectively identified. Cases were
selected by using ENDOBASE and we provided a search in the our local
PALGA database. We included patients with a histological diagnosis of ade-
noma. Endoscopic resection was performed by 5 experienced endoscopists.
Endoscopic success was defined as complete excision of the adenoma, irrespective
of the number of attempts, and in the absence of recurrence. All patients under-
went endoscopic follow-up. Early and late complications were registered.
Results: We included 84 patients, 56 patients (67%) had an adenoma confined to
the ampulla (ACA), 17 patients (20%) had a LSA and 11 patients (13%) were
treated for adenomas that demonstrated growth pattern with intraductal exten-
sion. Fifty-five percent of the patients were men and the median age was 65.4
years (range 32–89). The median lesion size was 24.6mm (range 5–80) for
patients with ACA, 34.8mm (range 23–50) for LSA and 16.3mm (range 10–
20) for patients with an AIE (P¼ 0.039). Complications occurred in 26 patients
(30.9%), of which hemorrhage was most seen in 17.9%, followed by perforation
in 5.9% of the patients. Complications were equally divided over these three
groups (P¼ 0.775). The mean follow-up duration was 31.1 months (range 0–
129) for ACA, 23.1 months (range 0–127) for LSA and 11.9 months (range 0–
37) for IEA (P¼ 0.136). Endoscopic resection was curative in 87.5% of patients
with a localized adenoma, 82.3% in patients with a lateral spreading adenoma
and in only 9.1% of patients with an intraductal extended tumor (P5 0.000).
Recurrence occurred in 9 patients (10.7%), 5 of them had a localized adenoma, 3
patients with a lateral spread adenoma and 1 patient with an intraductal
extended adenoma (P¼ 0.875).
Conclusion: Endoscopic ampullectomy is a safe and successful treatment in
patients with an adenoma with or without a lateral spreading growth pattern.
In case of an intraductal extended adenoma endoscopic success rates are signifi-
cantly lower.
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Introduction: There are few reports about the technical difficulty of gastric endo-
scopic submucosal dissection (ESD) which were investigated through the pro-
spective trial.
Aims & Methods: The aim of this study was to evaluate the factors associated
with the technical difficulty of ESD for early gastric cancer (GC) which met
expanded indication criteria using data from JCOG0607. The major inclusion
criteria of JCOG 0607 was as follows: 1) histologically proven intestinal-type
adenocarcinoma; 2) cT1aN0M0; 3) lesion without finding of ulcer (UL negative)
and 42 cm in size, or UL positive and 3 cm in size; 4) age 20–75. ESD were
performed by certiEed endoscopists or under the supervision of certified endos-
copists who had experienced 100 cases or more. The difficult case was defined
that ESD took 120 minutes (min) or longer, and/or developed perforation during
procedure. Multivariate analysis was performed to investigate the clinical factors
associated with technical difficulty of ESD.
Results: Between June 2007 and Oct. 2010, a total of 470 patients (pts) (male/
female: 385/85, median age 65y-o (range: 40–75)) were enrolled from 29 institu-
tions. Tumor location was upper (U) of stomach in 71, middle in 255, and lower
in 144 pts, respectively. The median tumor size was 2.5 cm (range: 0.5–13), and
207 lesions were judged as UL positive whereas the other 263 were assessed as
UL negative. And, 152 of 263 UL negative lesions were 3 cm or less in size, and
the other 111 of them were larger than 3 cm. Median procedure time was 79min
(range: 14–462), and it took 120min or longer in 127 pts. 12 pts developed
perforation during ESD, and the procedure time took 120min or longer in 9
of them. Therefore, 130 pts (27.7%) were classified in difficult case group. The
proportion of difficult case was 23.2% (48/207) in UL positive and 3 cm cases,
18.4% (28/152) in UL negative and 3 cm, and 48.6% (54/111) in UL negative
and 43 cm, respectively. Multivariable showed UL negative and 43 cm (vs. UL
negative and 3 cm, odds ratio, 4.66; 95% confidence interval, 2.59–8.37,
p5 0.0001) was the most significant factor associated with technical difficulty,
and U of stomach, and age 60 were also associated with difficulty.
Conclusion: Lesion larger than 3 cm without finding of ulcer, U of stomach, age
60 were independent factors associated with technical difficulty of ESD for GC
which met expanded indication criteria.
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Introduction: Endoscopic ultrasound with fine-needle aspiration (EUS-FNA) is
commonly used for the diagnosis of various gastrointestinal lesions. Recently, a
novel fine-needle biopsy (FNB) system (SharkCore, Medtronic) was developed to
acquire cohesive units of tissue to increase the diagnostic yield of EUS.
Aims & Methods: Our study objective was to compare the diagnostic yield of
EUS-FNA using a conventional needle vs. EUS-FNB using the novel needle for
gastric submucosal lesions. We conducted a prospective analysis of patients
undergoing diagnostic EUS from November 2014 to October 2015. Each patient
underwent 3 FNA passes followed by 3 FNB passes, without onsite cytologic
evaluation. Data gathered included demographics, size and location of the lesion,
needle size, and complications. Pathology and cytology were reviewed separately
by two blinded, expert gastrointestinal pathologists. Diagnostic yield was defined
as the ratio between the number of significant findings detected by EUS tissue
acquisition and the total number of EUS examinations performed for a given
indication.
Results: During the study period 1487 EUS procedures were performed in our
clinic. Thirty patients with gastric submucosal lesions were enrolled to participate
in the study, 66% were female, mean age was 62 years (range 31–88). Mean lesion
size was 27mm (range 12–60mm). Twenty-two-gauge needles were used in 14
cases (55%) and twenty-five-gauge needles were used in 12 cases (45%). Overall
diagnostic yield for 3 needle passes was higher for FNB vs. FNA for gastric
submucosal lesions (78% [N¼ 20] vs. 44% [N¼ 12], P¼ 0.04). Analyzing each
of the different passes, the diagnostic yield was: 61%, 67% and 78% with the
first, second, and third FNB pass, respectively. In evaluation of tissue quantity
and quality of FNB specimens, the mean tissue length was 7.3 5.2mm, with a
mean lesional tissue proportion between 51 to 75% of the total tissue procured
(determined as the percent of the surface are occupied by lesion over the surface
area of the entire tissue on one slide). No complications occurred during the
study period.
Conclusion: FNB using a novel core needle system is safe and effective for diag-
nosis of gastric submucosal lesions. When performed without on-site cytologic
evaluation, EUS-FNB has a higher diagnostic yield than FNA and may represent
an advance for endoscopic ultrasound guided gastrointestinal biopsies.
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Introduction: Submucosal tumors (SMT) refer to protuberant lesion covered with
intact mucosa, and most of SMT found in stomach are small and asymptomatic.
While a half of these gastric SMTs are considered to be gastrointestinal stromal
tumors (GIST) with malignant potential, especially for those with large dia-
meters[1]. One of the strategies for SMTs5 2 cm is periodical surveillance by
esophagogastroduodenoscopy (EGD) and endoscopic ultrasonography (EUS),
but it involves issues related to the patient’s compliance and stress, cost-effec-
tiveness, and the risk associated with repeated endoscopic procedures and
delayed diagnosis of malignancy [1]. Therefore, it is necessary to remove these
SMTs and endoscopic resection could be considered as an alternative method.
Endoscopic full-thickness resection (EFTR) is a safe and effective endoscopic
method for gastric fundus SMT originating from the muscularis propria (MP)
layer with a high rate of complete resection [2]. Submucosal tunneling endoscopic
resection (STER) is a novel endoscopic technique and has demonstrated to be
safe and effective for the treatment of gastric SMTs [3]. However, little is known
about the comparison between STER and EFTR for treating SMTs in gastric
fundus. In this retrospective study, we aimed to compare both endoscopic tech-
niques for treating gastric fundus SMTs.
Aims & Methods: Both submucosal tunneling endoscopic resection (STER) and
endoscopic full-thickness resection (EFTR) are effective methods for gastric
fundus submucosal tumors (SMTs), however, little is known about the compar-
ison between these two resections. The aim of this study was to compare the
safety and efficacy of STER and EFTR for treating SMTs in gastric fundus. We
retrospectively collected the clinical data about patients with gastric fundus sub-
mucosal tumors who received submucosal tunneling endoscopic resection or
endoscopic full-thickness resection at our hospital from April 2011 to May
2016. Epidemiological data (gender, age), tumor size, procedure-related para-
meters, complications, length of stay, cost and follow-up data were compared.
Results: A total of 43 patients were enrolled, and 15 of them received submucosal
tunneling endoscopic resection, while the other 28 cases received endoscopic full-
thickness resection. There was no significant difference between the two groups in
terms of gender, age, tumor size, en bloc resection rate, operation time, patho-
histological results, hospital stay and cost (p4 0.05). However, patients who
received endoscopic full-thickness resection had a longer suture time and
needed more clips to close the gastric wall defect (p5 0.05). No recurrence
was noted in the submucosal tunneling endoscopic resection and endoscopic
full-thickness resection groups during a mean follow-up of 12.1 and 22.8
months, respectively.
Comparison of clinical characteristics and therapeutic outcomes between STER
and EFTR
STER (n¼ 15) EFTR (n¼ 28) P
Sex, M/F 5/10 13/15 0.407
Age, year 48.4 11.2 53.4 9.7 0.136
Concomitant disease, % 20% (3/15) 21.4% (6/28) 1.000
Tumor size, mm 19.0 8.3 15.3 7.0 0.126
Operation time, min 76.7 38.0 63.3 24.4 0.200
Suture time, sec 296.7 97.0 383.4 104.0 0.011
(continued)
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Comparison of clinical characteristics and therapeutic outcomes between STER
and EFTR
STER (n¼ 15) EFTR (n¼ 28) P
No. of clips for suture 5.8 1.4 7.6 1.6 0.001
Complications, % 6.7% (1/15) 14.3% (4/28) 0.643
En bloc resection, % 6.7% (1/15) 3.6 % (1/28) 1.000
GIST/Leiomyoma/Schwannoma 11/4/0 25/2/1 0.173
Length of stay, d 6.1 1.5 6.2 2.0 0.856
Cost, USD 3260.9 618.3 3237.5 615.8 0.906
Follow-up time, mon 12.1 12.2 22.8 18.4 0.052
Conclusion: The treatment efficacy between submucosal tunneling endoscopic
resection and endoscopic full-thickness resection for treating gastric fundus sub-
mucosal tumors was comparable, but submucosal tunneling endoscopic resection
offers advantages over endoscopic full-thickness resection in terms of shorter
suture time and smaller number of clips needed to close the gastric wall defect.
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Introduction: The progress of diagnosis and treatment for gastrointestinal sub-
epithelial lesions (SELs) have been remarkable by the wide use of Endoscopic
Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) and the development of
Laparoscopy and Endoscopy Cooperative Surgery. EUS-FNA is used widely for
SELs that occur in the digestive tract. There are many reports on gastric SELs,
but there are no studies on a large group of patients focusing on duodenal SELs.
Aims & Methods: The aim of this study was to investigate the usefulness and
safety of EUS-FNA for duodenal SELs, comparing them with gastric SELs.
Cross-sectional study was conducted using 41 patients who underwent EUS-
FNA at teritary medical center in Tokyo between April, 2012 and February,
2017. We divited into 2 groups: 6 patients with duodenal SELs (group D) and
35 patients with gastric SELs (group G), who were diagnosed as SELs located on
the 4th layer by pre-operative EUS and were performed EUS-FNA consecu-
tively. We retrospectively evaluated the patient characteristics and outcome of
the technique on the subjects.
Results: Age (median, [range]); D: 61, [42–63], G: 60, [32–85]; male/female ratio:
D, 1/5, G, 18/17; tumor size (median, [range])(mm): D, 16, [14–45], G, 24, [13–
67]; type of needle (22-gauge/19-gauge): D, 5/1, G, 30/6 (One case was used two
type of needles.); number of needle passes: D, 5, [4–5], G, 4, [3–7]; procedure time
(median, [range])(min): D, 34, [22–52], G, 42, [20–67]; diagnostic yield: D, 100%,
G, 91.4%; complication: D, 0%, G, 2.9%. There were no significant differences
into 2 groups, but the size of duodenal SELs tended to be smaller than gastric
SELs. Histological diagnosis of EUS-FNA using immunohistochemical analysis
showed duodenal SELs were 5 GIST, 1 neurinoma, and gastric SELs were 25
GIST, 4 ectopic pancreas, 3 neurinoma, 3 indeterminate.Two of the indetermi-
nates were followed up by CT, one was SEL like cancer diagnosed by conven-
tional biopsy.
Conclusion: Although five of the six cases of duodenal SELs were small lesions of
less than 20mm, immunohistochemical staining was performed for all the cases,
and diagnosis was made. EUS-FNA for duodenal SELs was as useful and safe as
gastric SELs.
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Introduction: Endoscopic submucosal dissection(ESD) is widely used as a stan-
dard treatment for superficial tumors in the GI tract and its safety has been
established. Opportunities for elderly patients to undergo ESD for early gastric
cancer is increasing due to the continued improvement in life expectancy.
However, short-term and long-term outcome of ESD for elderly patients is still
unclear because of the high frequency of comorbidities and possible increased
risk of complications related to ESD in this population.
Aims & Methods: Therefore, we investigated the safety, efficacy and short-term
outcome of gastric ESD for patients over 80 years old. Additionally, we evalu-
ated the long-term outcome of non-curative resections according to both age
groups. 1056 lesions in 886 patients treated with ESD between January 2011
and December 2015 in our hospital were retrospectively reviewed. They were
classified into two groups; elderly group - older than 80 years old (246 lesions
in 201 patients) and non-elderly group - 79 years old and younger (810 lesions in
685 patients). The patient demographics, lesion characteristics, short-term ESD
outcome, complications (perforation, postoperative bleeding, postoperative delir-
ium, and pneumonia), were examined and compared between the two groups.
Concerning the long-term outcome of non-curative ESD, cases performed
between 2011 and 2013 were assessed.
Results: The median age was 83 years old (range: 80–92) in the elderly group and
70 years old (36–78) in the non-elderly group. The ratio of female patients was
significantly higher in the elderly group (30.9% vs. 17.0%: p5 0.0001).
Comorbidities were significantly higher in the elderly group including heart dis-
ease (24.8% vs. 10.5%: p5 0.0001), lung disease (13.8% vs. 7.4%: p¼ 0.002) and
dementia (3.3% vs. 1.0%: p¼ 0.01). Tumor location was not significantly differ-
ent between the two groups. Median specimen and tumor size were the same in
both groups with no significant difference: 43mm and 15mm, respectively. The
en bloc resection rates (96.3% and 97.8%) and the curative resection rates
(82.5% and 84.6%) were not significantly different. The perforation rates were
not statistically different (2.44% and 3.21%). However, the postoperative bleed-
ing rate (5.28% vs. 2.72%: p¼ 0.05), postoperative delirium (2.0% vs. 0.25%:
p¼ 0.009) and pneumonia (2.0% vs. 0.25%: p¼ 0.009) were significantly higher
in the elderly group. In multivariate analysis, age over 80 was not an independent
risk factor for postoperative bleeding, however it was the independent risk factor
for postoperative delirium and postoperative pneumonia. Nineteen elderly
patients and 54 non-elderly patients with non-curative resections were fol-
lowed-up for 3 years after ESD for the long-term outcome analysis. The percen-
tage of patients who underwent additional surgery after ESD was 26.3% (5/19)
and 51.85% (28/54) respectively (p¼ 0.05). Neither disease specific death nor
progression to advanced gastric cancer was found in each age group. Overall
survival rate 3 years after ESD was 68.4% and 85.2% respectively (p¼ 0.17).
Conclusion: ESD is a safe and effective treatment for early gastric neoplasia even
in patients over 80 years old. However, because postoperative delirium and post-
operative pneumonia were observed more often in the elderly patients, more
careful attention to these conditions during perioperative care may be necessary.
Elderly patients over 80 years, with non-curative resections, underwent less fre-
quent additional surgery without any impact on the disease specific death and
global mortality.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
Akasaka, T., Nishida, T., Tsutsui, S., Michida, T., Yamada, T., Ogiyama, H., . . .
Hayashi, N. (2013). Short-term outcomes of endoscopic submucosal dissection
(esd) for early gastric neoplasm: Multicenter survey by osaka university esd study
group. Gastroenterological Endoscopy, 55(1), 77–83.
Toyokawa, T., Fujita, I., Morikawa, T., Okamoto, A., Miyasaka, R., Watanabe,
K., . . . Tomoda, J. (2011). Clinical outcomes of ESD for early gastric neoplasms
in elderly patients. European Journal of Clinical Investigation, 41(5), 474–478.
P1886 GASTRIC INTESTINAL METAPLASIA OUTCOMES:
RESULTS FROM A 17 YEAR TERTIARY CENTRE UPPER GI
SURVEILLANCE PROGRAMME IN IRELAND
M. Mc Nally1, I. Cretu1, A. O’Connor1
1Trinity Academic Gastroenterology Group, Naas General Hospital, Kildare/
Ireland
Contact E-mail Address: maireadnf@gmail.com
Introduction: Adenocarcinoma of the stomach is the second leading cause of
cancer related death in the world. Gastric intestinal metaplasia (GIM) is an
important intermediate stage in the gastric cancer cascade through a series of
well-defined precursor lesions including nonatrophic gastritis, multifocal
atrophic gastritis, intestinal metaplasia, and dysplasia. The prevalence of GIM
is unclear in many parts of the world and few studies have evaluated the rate of
progression to gastric cancer in patients with GIM. There is a lack of clarity in
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published guidelines regarding appropriate surveillance of patients with GIM
and there is wide disparity in the management of this premalignant condition.
Aims & Methods: This study aimed to analyze surveillance practice and charac-
terize the natural history of this premalignant condition by identifying all
patients with GIM on an upper GI surveillance programme and reviewing
follow up data. This is a retrospective study of patients with GIM who are
currently enrolled in an upper GI surveillance programme. Patients with a history
of GIM identified at any time during an 18 year surveillance period (from 1998 to
2016) were included in the study. Patient characteristics, endoscopy data includ-
ing histology, rates of Helicobacter pylori infection, Barrett’s oesophagus asso-
ciation and outcomes were reviewed.
Results: 160 patients (including those with Barrett’s oesophagus, GIM and family
history of gastric cancer) were enrolled on the surveillance programme. 42
patients with GIM were identified–20 females (47.6%) and 22 males (52.3%).
The mean age at which GIM was first diagnosed was 60.6 years (range from 17.9
to 71.5 years). 15/42 patients (35.7%) had co-existent Barrett’s oesophagus and
Helicobacter pylori was identified in 6/42 (14.3%). The follow-up period ranged
from 0.5 to 17.3 years. 27 patients had repeat gastroscopies following initial
diagnosis. 15 patients are still awaiting a repeat gastroscopy. A large degree of
variability in the number and frequency of follow-up gastroscopies was observed.
The average interval of follow-up gastroscopies was 3.3 years per person. 14/27
patients (51.8%) had no evidence of GIM on most recent gastroscopy, 7/27
patients (26%) had repeat findings of persistent focal GIM, 5/27 patients
(18.5%) progressed to extensive GIM. No cases of dysplasia were recorded but
1 patient (3.7%) developed gastric cancer.
Conclusion: This study suggests a low apparent risk of progression of gastric
intestinal metaplasia in a small western cohort. Further studies may be necessary
to address if the applicability of published surveillance guidelines can be general-
ised to regions with low gastric cancer prevalence.
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Introduction: Previously we reported that direct family history of gastric cancer
(GC) as a risk factor of GC and genetic polymorphisms of TGFB1 (transforming
growth factor-b1) was associated with the development of GC in the first-degree
relative of GC. The aim of this study is to investigate relationship between stage
of gastric cancer and genetic polymorphism of TGFB1 regarding first-degree
relative of GC.
Aims &Methods: From January 2006 to March 2017, 1090 gastric cancer patients
were enrolled at Seoul National University Bundang Hospital in whom stage of
GC was obtained from surgery, endoscopic submucosal dissection (ESD), endo-
scopic mucosal resection (EMR), and computer tomography (CT) and positron
emission tomography (PET)-CT images. 203 patients (18.6%) had direct family
history GC and 887 (81.4%) did not have. Genotype of TGFB1-509 was mea-
sured by the polymerase chain reaction-restriction fragment length polymorph-
ism. Relationship between TGFB polymorphism and stage or GC tissue type was
analyzed.
Results: Proportion of stage 1 & 2 was statistically higher in the group with direct
family history GC (170, 83.7%) than without direct family history (660, 74.4%).
(P¼ 0.005). When GC stage was analyzed regarding direct family history and
TGFB1genetic polymorphism the ratio of gastric cancer stage I to TGFB1509 T
carrier was significantly higher than that of stage II or higher (P¼ 0.008), only in
male. However, this difference was not found in female. In addition no
significant difference was found in GC patients without direct family history.
Lauren classification and TGFB1 genotype did not show any statistically signifi-
cant results even in the group with direct family history.
Conclusion: Family history of GC affects the stage of GC and the genotype of
TGFB1-509 could be underlying mechanism in case of male. Survival analysis is
undergoing.
Table: Differences of gastric cancer stage according to TGFB1-509 polymorph-
ism and family history (Hx) of gastric cancer
TGFB1-509
Stage 1
N (%)
Stage 2
N (%) Total P-value
Family Hx. (þ) Female C/C 18 (78.3) 5 (21.7) 23 0.243
T carrier 27 (64.3) 15 (35.7) 42
Male C/C 20 (52.6) 18 (47.4) 38 0.008
T carrier 76 (76.0) 24 (24.0) 100
Total C/C 38 (62.3) 23 (37.7) 61 0.146
T carrier 103 (72.5) 39 (27.5) 142
Family Hx. () Female C/C 46 (61.3) 29 (38.7) 75 0.781
T carrier 137 (63.1) 80 (36.9) 217
Male C/C 91 (61.9) 56 (38.1) 147 0.568
T carrier 289 (64.5) 159 (35.5) 448
Total C/C 137 (61.7) 85 (38.3) 222 0.529
T carrier 426 (64.1) 239 (35.9) 665
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Introduction: Gastric adenocarcinoma and proximal polyposis of the stomach
(GAPPS) has to been described recently only in a few families worldwide (only
one in Europe so far). Three different point mutations in promoter 1B of the
APC gene were identified as causal (c.-191T4 C, c.-192A4 G, and c.-195A4
C). We diagnosed GAPPS in the second Czech white family (not related to that
one published previously–ref. 1).
Aims & Methods: We diagnosed GAPPS across 3 generations in a new Czech
white family. A genetic analysis of the family was performed.
Results: The Proband (a 43-year-old male) was endoscopically regularly surveyed
from his 34 years of age because of fundic-gland polyposis with predominant
involvement of the gastric fundus and body (with relative sparing of the lesser
curve) and microcytic anaemia. Polyposis slowly progressed with the intestinal
differentiated low-grade dysplasia in polypectomy specimens 10 years after the
diagnosis. As the GAPPS criteria were fulfilled (ref. 2), he and his family under-
went genetic testing and bi-directional Sanger sequencing of promoter 1B
revealed a point mutation (c.-191 T4C). The same type of mutation was
described in his father (63 years old), sister (41 years old), nephew (son of his
sister, 6 years old), uncle (father’s brother, 51 years old) and 2 cousins (uncle’s
daughters, 23 and 27 years old), all have been asymptomatic. No gastric cancer in
the family history was mentioned. The Proband underwent preventive total gas-
trectomy, histology of the surgical specimen confirmed severe involvement of
gastric body with fundic gland polyps, low-grade and focal high-grade dysplasia.
The microcytic anaemia improved rapidly after surgery. The rest of family is
scheduled for gastroscopy. The fundic-gland polyposis of similar distribution
(with significantly lower number of polyps, without any dysplastic changes)
was recently diagnosed in the 23-year-old cousin.
Conclusion: The second European family with GAPPS is presented. The recently
described mutations in promoter 1B of the APC gene does not automatically
mean a faster progression of the disease as suggested earlier. GAPPS can be
presented with various phenotypes with a different course of disease, the preva-
lence can be higher than previously reported. Acknowledgement: The study was
supported by the Research Project PROGRES Q40–15.
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Introduction: ESD is the one of the options of treatment even for lateral spread-
ing (size is over 5 cm) esophageal squamous cell carcinoma (ESCC). Endoscopic
diagnosis is developed by magnified endoscopy, however accuracy of diagnosis
for lateral spreading ESCC is not high. Some patients have to undergo additional
treatment because tumor is invaded to submucosal layer or lymphvascular inva-
sion. On the other hand, wide resection by ESD could cause the delay of addi-
tional treatment because of the treatment for esophageal stricture after ESD.
Thus, treatment strategy for lateral spreading ESCC has to include additional
treatment after ESD. Aim of this study is to evaluate our treatment strategy for
lateral spreading superficial ESCC.
Aims & Methods: From January 2010 to December 2014, 49 cases of lateral
spreading superficial ESCC were resected by surgery or ESD. Diagnosis, treat-
ment methods and outcomes are evaluated. Our indications for additional treat-
ment after ESD are the cases of over pT1b (SM2) or lymphvascular invasion.
Results: In 49 cases of lateral spreading superficial ESCC, 32 cases were treated
by ESD and 17 case were treated by surgery. All lesions of 32 cases are comple-
tely resected by ESD. Average size of tumor treated by ESD is 59.4mm(50–
85mm). Accuracy of estimated depth of invasion by endoscopy for ESD cases
is 65.7%. Four of 32 cases of ESD underwent additional therapy (3 for surgery
and 1 for CRT) because of pT1b (SM2) or lymphvascular invasion, and one case
has lymph-node metastasis. Rate of stricture after ESD is 20.0% for sub-circum-
ference ESD and 77.8% for circumference ESD instead of steroid injection.
Average time and duration for control of esophageal stricture by Baloon
Bougie is 13.5 times and 18 weeks. In 17 surgical cases, all cases are treated by
thoracoscopic esophagectomy. Average size of tumor treated by surgery is
76.5mm (50–130mm). Accuracy of estimated depth of invasion by endoscopy
for surgical cases is 47.1%. Seven cases in 17 (41.2%) have lymph node metas-
tasis. Rate of lymph node metastasis is 42.9% for pT1a-MM, 100% for pT1b-
SM1 and 42.9% for pT1b-SM2. One case died by recurrence after surgery and 48
cases were survived without any recurrences.
Conclusion: Accuracy of estimated depth of invasion by endoscopy for lateral
spreading superficial ESCC is cute low compared to normal superficial ESCC.
Most of strictures after sub-circumference ESD could be prevented by steroid
injection. However control of strictures after circumference ESD is difficult.
Thus, diagnostic ESD should not be performed for circumferencial lesions of
lateral spreading superficial ESCC for the patients who will select CRT for
additional treatment, and CRT should be selected for first treatment of these
cases. Long survival could be obtained by ESD or surgery for the patients of
lateral spreading ESCC by our treatment strategy.
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Introduction: Normally, resided within the submucosal layer of esophagus, each
esophageal submucosal gland will culminate in a single duct. The esophageal
submucosal gland ducts (ESMGDs) can traverse the subepithelial connective
tissue and muscularis mucosa, and deliver the acinar serections to the esophageal
lumen. However, the clinicopathological features of the esophageal submucosal
gland duct involvement (ESMGDI) and its precursor lesion have not been com-
prehensively evaluated so far, and the series study focusing on endoscopic fea-
tures of this lesion has not been reported widely. While since the 1990s, the
esophageal lesions presumed to originate from ESMGDs had been described
constantly in various case reports. Currently, in addition to the gold standard
of histopathology, almost no more useful modality could be applied to this
lesion. In our study, we considered that the ESMGDI had a correlation with
early esophageal cancer, and we noted that the ESMGDI had special features
under the endoscopic ultrasonography (EUS). The typical ultrasonic images of
EUS could help diagnose ESMGDI.
Aims & Methods: In order to investigate the clinical value of EUS for diagnosing
ESMGDI accompanied by early esophageal cancer, which were suggested by
conventional endoscopy or biopsy, this study retrospectively analyzed the con-
secutive patients with early esophageal cancer diagnosed in the Endoscopy
Center at the Affiliated Drum Tower Hospital, Nanjing, China from
September 2009 to November 2016. The clinical data of 519 patients were
included in this study, and all of them had already underwent EUS combined
with Endoscopic Submucosal Dissection (ESD). The EUS preoperative diagnosis
were compared with the results of postoperative pathology from ESD.
Results: According to the pathological results, all patients (371 males and 148
females, with a mean age of 67.5 4.5years) had been diagnosed with early
esophageal cancer with different invasive depth. Out of 519 patients, about 478
patients were not found ESMGDI by both examinations. Besides, postoperative
pathology confirmed that 40 patients were identified with ESMGDI, 34 patients
of which were completely consistent with the preoperative diagnosis of EUS.
Approximately 98.7% (512/519) of ESMGDI were diagnosed exactly by EUS.
Another six cases were estimated as flase negative inaccurately, including two
squamous cell carcinoma and four high-grade intraepithelial neoplasia. One case
was regarded as ESMGDI by EUS while confirmed not by pathology. Therefore,
the EUS values for sensitivity and specificity for the diagnosis of ESMGDI were
85.0% (34/40) and 99.8% (478/479) respectively. Furthermore, the positive pre-
dictive value was 97.1% (34/35), and the negative predictive value was 98.8%
(478/484).
Conclusion: The esophageal submucosal gland duct involvement is a kind of
lesion performed as a hypoechoic sonographic pattern located in the thickened
mucosa. EUS has a satisfactory diagnostic accuracy for ESMGDI as well as
good sensitivity and specificity.
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Introduction: Few major international guidelines consider pepsinogen tests as the
best available non-invasive tests to detect precancerous lesions (in particular, -
corpus atrophy) in the stomach mucosa. Gastrin-17 (G-17) has been suggested as
indirect marker for antral atrophy. Different tests are used in Europe and Asia.
Recommendations from the European Commission expert group consider the
need for additional studies before any screening with biomarkers can be recom-
mended for implementation.
Aims & Methods: Generally healthy 40–65 years aged participants of the
GISTAR pilot study referred for upper endoscopy according to the pilot study
protocol were enrolled. Pepsinogen (Pg) I and II were assessed from plasma
samples by two methods–ELISA (Biohit Plc.) and latex-agglutination (Eiken
Chemical Co.) test systems. G-17 and IgG group antibodies to H.pylori infection
were assessed by Biohit Plc. ELISA test systems. The following cutoff values were
considered characteristic for atrophy: Pg I/II5 3 for ELISA, Pg I/II5 3 and PgI
570 ng/ml for latex-agglutination, and G-1751 pmol/l (in a plasma sample
obtained in fasting condition). Biopsies were sampled and read by two indepen-
dent pathologists according to the updated Sydney system. OLGA and OLGIM
scoring systems were also applied. Cancer, dysplasia, OLGA/OLGIM III-IV
taken together were considered high-risk lesions.
Results: Altogether 1044 subjects (55% females, mean age¼ 52, 67.7% with
positive H. pylori antibodies) were included to the study. The sensitivity and
specificity for detecting moderate to severe atrophy in the corpus for Biohit
ELISA test was 47.2% and 92.3%, but for Eiken latex-agglutination test–
81.1% and 62.1%, respectively. The corresponding values for G-17 to detect
atrophy in the antrum were 29.2% and 58.9%. High-risk lesions were detected
by Biohit ELISA pepsinogen testsystem with 22.8% sensitivity and 91.6% spe-
cificity, but with Eiken latex-agglutination test–with 67.4% and 62.5% sensitivity
and specificity.
Conclusion: Due to the high specificity, pepsinogens (e.g. ELISA) could be poten-
tially used for screening of precancerous lesions if relatively low sensitivity could
be accepted. G-17 does not seem to provide any additional benefit.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction:miRNAs are a group of small non-coding RNAs that dysregulate in
various types of cancers [1–3]. They play a pivotal role in several pathological
processes. Growing evidence show that miRNAs can act as either tumour onco-
genes or suppressors in different types of cancers. Previous studies revealed that
miR-211-5p could suppress melanoma proliferation, migration, and invasion [4].
However, the contrasting result suggested that miR-211-5p was a potential onco-
gene in non-small cell lung cancer by targeting SRCIN [5]. Therefore, the func-
tional role of miR-211-5p is still unclear in the pathogenesis of gastric cancer.
Aims & Methods: We aimed to investigate and characterize the biological roles of
miR-211 in the development of gastric cancer. The expression level of miR-211-
5p was measured in paired primary gastric cancer with corresponding adjacent
gastric mucosa by RT-PCR. Furthermore, we investigate the biological role of
miR-211-5p in proliferation, apoptosis, migration of gastric cancer cell lines
in vitro.
Results: The expression levels of miR-211-5p were significantly decreased in
gastric cancer and low expression of miR-211-5p correlates with poor prognosis
in gastric cancer patients. Ectopic expression of miR-211-5p suppressed prolif-
eration, migration and induced apoptosis in gastric cancer cells in vitro.
Bioinformatics and quantitative analysis revealed that FoxC1 might be a target
of miR-211-5p. Downregulation of FoxC1 inhibited proliferation and migration
of gastric cancer cells and Overexpression of FoxC1 partly abrogated the inhi-
bitory effects of miR-211-5p on gastric cancer cell proliferation and motility.
Conclusion: We demonstrate that miR-211-5p acted as a tumour suppressor by
targeting FoxC1 in gastric cancer and miR-211-5p might be a potential target for
the treatment of gastric cancer.
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Introduction: The dramatic rise in the incidence of gastroesophageal junction
(GEJ) adenocarcinoma in the Western countries, has promoted an incresead
interest about the etiopathogenesis and natural history of GEJ. The cardiac
epithelium (CE), which integrates the morphological spectrum of Barrett’s eso-
phagus, is frequently present in endoscopically normal GEJ in children and
adults. Its congenital versus metaplastic origin still needs to be clarified. The
gastroesophageal neo-junction after esophagectomy seems the ideal model to
study the development of GEJ epithelia, reproducing "in-vivo" its natural
history.
Aims & Methods: The aim of this study was to evaluate the prevalence of meta-
plastic CE in the gastroesophageal neo-junction. Prospective study of patients
undergoing esophagectomy due to esophageal/GEJ neoplasia between
November/2015 and November/2016. Upper gastrointestinal endoscopy
(UGIE) (Olympus, GIF-HQ 190) was performed 3 months after surgery; the
neo-junction was evaluated with white light and Narrow band imaging (NBI);
protocolated biopsies were made (suspected areas of CE, randomized in the
anastomosis if endoscopic absence of CE, 2 cm above and below the anastomo-
sis). Endoscopic CE defined by the presence of circular pattern with NBI in the
anastomosis. Histological evaluation performed by 3 pathologists with gastro-
intestinal expertise. A questionnaire for gastroesophageal reflux (GER) symp-
toms evaluation was applied.
Results: 20 patients were included (9 adenocarcinomas), 19 men, mean age
60 11 years, 9 under proton-pump inhibitor and 10 with RGE symptoms.
UGIE: unable to pass a standard scope in anastomosis due to stenosis: 3/20;
esophagitis: 5/20; columnar epithelium of the esophagus: 1/20. Epithelium sug-
gestive of CE: present in 17/20, suspect in 2/20 and absent in 1/20. Histologically:
CE confirmed in 18/20 patients; additionally identified oxyntocardiac epithelium
in 12/20 and intestinal metaplasia in 2/20. The endoscopic diagnosis of CE
revealed a sensitivity, specificity, positive and negative predictive value of
94.4%, 100%, 100% and 66.7%, respectively.
Conclusion: The identification of metaplastic CE in neo-junctions is a very fre-
quent and early event and its presence corroborates the hypothesis of metaplasia,
to the detriment of a congenital origin. The good endoscopic and histological
correlation observed for CE will allow the definition of endoscopic patterns,
essential for its recognition.
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Introduction: Duodenal adenomas are rare epithelial tumors and represent 25%
of the benign lesions diagnosed in the small bowel. Non-ampullary sporadic
duodenal adenomas (NASDA) are usually asymptomatic and their diagnosis is
mostly incidental. NASDA are benign epithelial tumors with a potential for
malignant transformation via the adenoma–carcinoma sequence; nevertheless
this risk is lower compared to ampullary or duodenal adenomas in the context
of genetic syndromes. Results of Endoscopic Mucosal Resection (EMR) of
NASDA are assessed in a large series after long-term follow-up.
Aims & Methods: Consecutive patients undergoing EMR of NASDA between
May 2002 and December 2016 were identified from an electronic database.
Patients with a genetic polyposis syndrome (FAP or Peutz-Jeghers) and/or ade-
noma of the major or minor duodenal papilla were excluded. Preoperative biopsy
were performed at operator discretion, considering that the majority of the
patients were referred from other centers. In case of doubt for a possible involve-
ment of the ampulla of Vater, duodenoscopy with a side-viewing endoscope was
also performed. EUS was not systematically done before duodenal EMR. Size,
site of the lesion, pre- and post-EMR histology, adverse events, local recurrence
and survival rates were retrospectively analysed. En-bloc resection was preferred,
when possible, for lesions 520mm; bigger lesions were removed piecemeal.
Blended ‘‘endocut’’ current was used in all the cases. All resected specimens
were retrieved for histological examination. CO2 insufflation was routinely
used during duodenal EMR after 2013. Argon plasma coagulation was used to
eradicate residual adenomatous tissue at discretion of the operator. Endoscopic
follow-up was scheduled after 3, 6 and 12 months for the first year, and then
yearly for up to 5 years.
Results: EMR of 75 NASDA was performed in 68 patients (56% en-bloc resec-
tion, 44% piecemeal). The mean size was 14.4mm and 29.9mm for lesions
resected en-bloc and piecemeal, respectively. Histopatological findings were:
low-grade dysplasia (n¼ 27, 36%), high-grade dysplasia (n¼ 34, 45.4%), high-
grade dysplasia with focal adenocarcinoma (n¼ 12, 16%), intramucosal adeno-
carcinoma (n¼ 2, 2.6%). Pre-EMR biopsy tended to downgrade the lesion in
44.4% (16/36). Retroperitoneal perforations occurred in 3/75 (4.0%) procedures
and were treated by surgical (n¼ 2) or percutaneous (n¼ 1) drainage; delayed
bleeding was reported in 13/75 (17.3%) resections and was successfully managed
by endoscopy (n¼ 12) or radiologic embolization (n¼ 1). There was no proce-
dure-related mortality. Follow-up was available in 61/68 patients (89.7%) after a
median time of 59 months (range 3–147) from resection. Residual and recurrent
adenoma were diagnosed in 9 and 6 cases, respectively; all but one were success-
fully retreated endoscopically.
Conclusion: The present series reports the results of duodenal EMR for NASDA
after more than 4-year median follow-up. When biopsies had been performed
before duodenal EMR for NASDA, downstaging of the lesion was recorded
more than 40% cases in our series, suggesting that biopsies are not routinely
necessary before EMR. EMR for NASDA is effective with favorable long-term
outcomes. The main limitation of duodenal EMR is the high incidence of resi-
dual/recurrent adenoma which was 27.3% in our series. Piecemeal EMR was
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associated, in our series, with a higher incidence of residual/recurrent adenoma,
when compared to en-bloc resection. These results are similar to those reported in
the literature. Residual and recurrent duodenal adenomas were successfully
retreated by EMR in all of them but one. Mortality related to NASDA was
absent in our series after a median follow-up of 59 months (range 1–147).
Management of adverse events after EMR for NASDA requires the availability
of interventional radiologists and surgeons with experience in retroperitoneal
surgery. In our experience colorectal adenomas was correlated to NASDA
(33.3%), colonoscopy is considered part of the pre-EMR assessment when
NASDA is diagnosed. A recall system and patient’s compliance to endoscopic
follow-up are mandatory to detect recurrences and their prompt treatment.
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Introduction: Obestatin is a bioactive peptide with a well-defined function on cell
proliferation mediated by the GPR39 receptor. Our data involve this system in
several processes located in the stomach: from pepsinogen secretion in healthy
stomach to malignant proliferation in gastric adenocarcinomas (1). A key step in
obestatin signaling is the transactivation process GPR39-RTK through MMPs
activation. This step could imply a key mechanism by which MMPs regulate
these diseases. Numerous studies have shown that alterations in the expression
and/or mutations in members of the family of receptors EGFR/ErbB are present
in tumours, and these changes may contribute to the progression of cancer. In
this sense, obestatin is added to the group of MMPs regulator factors, which have
been implicated in diverse human diseases, such as inflammatory diseases and
cancer (2,3).
Aims & Methods: The aim of the present study is to elucidate the detailed activa-
tion/regulation mechanism of GPR39-RTK cross-talk triggered by obestatin.
Results: Obestatin triggers phosphorylation of RTKs that belong mainly to the
family of EGFR (EGFR, 126.7 1.1%), insulin (InsulinR, 128.6 1.3%), Trk
(TrkC, 170.9 4.6%), VEGF (VEGFR3, 114.9 3.1%) and the ephrin receptors
(EphA1, 135.8 5.2%), both in AGS and KATO-III cell lines. Furthermore, we
observed an augment in the expression of proteases in lysates and secretomes
after obestatin treatment both in AGS and KATO-III cell lines. The most out-
standing increments were located in the families of: ADAMs (ADAM9,
133.9 0.1%; ADAM8, 406.9 19.6%), CTSs (CTSB, 193.4 3.9%; CTSV,
189.2 4.9%), KLKs (KLK3, 358.4 12.6%; KLK13, 365.1 7.1%) and
MMPs (MMP1, 690.6 10.0%; MMP13, 273.1 0.2%). In human tissues, the
obtained data were heterogeneous. However, it was observed an overexpression
for EphA1 and InsulinR in adenocarcinomas when compared to healthy sto-
mach, while it was observed a decrease for Axl. Regarding the proteases,
ADAMTS13 y PSEN1 were found overexpressed in healthy tissue compared
to gastric adenocarcinomas. Besides, CTSX/Z/P expression augmented with
the differentiation of the tumour.
Conclusion: These data corroborated obestatin involvement in proliferation,
migration and apoptosis and in diverse oncogenic process. Besides, the
GPR39-RTK crosstalk is not only limited to the EGFR, but instead depends
on the existing RTKs present in the tissues, and regulated the expression of
proteases involved in processes and pathways already described for obestatin.
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Introduction: NSAIDs have demonstrated chemopreventive activity against gas-
trointestinal cancers but their toxicity limits their use as prophylactics. They have
now been postulated as possible adjuvants to surgery or chemotherapy in order
to prevent the formation of new lesions and reduce disease progression. Cancer
cells enhance their resistance to the cytotoxic action of antineoplastic drugs by
activating autophagy, which is a catabolic process that degrades superfluous and
damaged organelles in the lysosome. We previously showed that indomethacin
inhibits autophagy in gastric cancer cells by acting at a late stage in this catabolic
process.
Aims & Methods: The aim of this study is to analyze whether indomethacin
modulates lysosomal function and oxaliplatin-induced cell death in these cells.
Gastric AGS cells were treated with increasing concentrations of indomethacin
for 2, 6 and 20 hours. Lysosomal pH was assessed by using Lysotracker Red and
acridine orange fluorescent probes (static cytometry). Cathepsin activity was
determined by using Omnicathepsin fluorescence substrate. In cells treated
with indomethacin for 2 hours LAMP2 immunostaining was also carried out.
In another set of experiments AGS cells were treated with increasing doses of the
antineoplastic drug oxaliplatin and indomethacin. Cell viability was measured by
an MTT assay, the rate of apoptosis/necrosis was analyzed by means of the
Apoptosis Detection Kit, and autophagy by p62 immunoblotting.
Results: Treatment of AGS cells with indomethacin decreased Lysotracker fluor-
escence in AGS cells after 2, 6 and 20 hours. Indomethacin also produces an
acute reduction in lysosome-derived fluorescence of acridine orange after 2 and 6
hours of treatment. In addition, we observed a significant reduction of cathepsin
enzymatic activity in cells treated with indomethacin for 6 or 20 hours.
Furthermore, there was an altered distribution of LAMP2-positive dots from
the perinuclear position observed in control cells to a peripheral position in
cells treated with indomethacin. Taken together, these data suggest that indo-
methacin inhibits the activity of lysosomal acidic enzymes by increasing lysoso-
mal pH. On the other hand, oxaliplatin decreased cell viability in a dose-
dependent manner after 48 hours of treatment, and treatment of cells with indo-
methacin during the last 24 hours further decreased cell viability. In addition,
indomethacin also increased the rate of apoptosis and necrosis in AGS cells
treated with oxaliplatin. Finally, indomethacin blocked the autophagic degrada-
tion of p62 protein induced by oxaliplatin.
Conclusion: Indomethacin inhibits lysosomal function in gastric cancer cells. This
could explain the inhibitory action on autophagy and the resultant increase in
susceptibility to cytotoxic drugs.
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Introduction: Gastric cancer (GC) is the fifth most common cancer and the third
leading cause of cancer death worldwide. Our previous studies have demon-
strated that HoxD10 functioned as a candidate tumor suppressor in GC,
which is silenced through promoter hypermethylation. The diagnostic value of
HoxD10 methylation in the plasma of GC patients was not determined.
Aims & Methods: We aim to evaluate whether HoxD10 promoter methylation in
plasma could serve as noninvasive biomarker of GC. Methylated specific PCR
(MSP) assays were used to measure HoxD10 promoter methylation in plasma of
38 healthy volunteers, 55 patients with gastric intraepithelial neoplasia (GIN),
123 GC patients and 17 GC after surgery patients.
Results: We demonstrated that the rate of HoxD10 methylation was 0% in
healthy controls, 34.55% in GIN, 46.34% in GC and 17.65% in GC after surgery
group, respectively. The methylation rate was significantly higher in GIN or GC
than in the normal control group (p5 0.01).The methylation rate of the post-
treatment group was significantly lower than that in the GC group (p5 0.05). In
GC patients, HoxD10 promoter methylation was correlated to tumor invasion
depth (p5 0.05), while no association was found in sex, age, tumor size, TNM
stage, CEA level and H. pylori infection (p4 0.05).
Conclusion: It demonstrated that the HoxD10 promoter methylation rate in
plasma dissociated DNA was increased with the progression from precancerous
lesions to GC. Combined testing of HoxD10 methylation and CEA may be a
great significant method for the early diagnosis of GC in high-risk populations.
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Introduction: The mechanisms of gastric carcinogenesis, especially of diffuse type
of gastric cancer (GC) are poorly understood. The cancer stem cells (CSC) repre-
sent a particular fraction of cancer cells, considered at the origin of cancer and
responsible for tumor development. The enteric nervous system (ENS) is a newly
recognized component of tumor microenvironment and its role in carcinogenesis
has been recently suggested. In particular, the role of acetylcholine (ACh), a
major neuromediator released by enteric nerves, has been suggested in gastric
carcinogenesis but its effect on gastric CSC remains to be established.
Aims & Methods: Our aim was to study the effect of ACh on gastric cancer cells,
and in particular its capacity to induce the stem cell phenotype, and to study the
mechanisms involved. Adenocarcinoma gastric epithelial cells MKN-45 were first
cultured in adherent conditions in the presence of ACh (0.1–1-10mM), before
being cultured in non- adherent condition in order to favour expansion of CSC
and formation of tumorspheres (T). The effect of ACh on T formation was
evaluated under microscope by quantifying the number and size of T using the
System snapshot file in INCell analyzer 2200/6000. The involvement of different
cholinergic (muscarinic and nicotinic) receptors in ACh- induced responses was
studied by pharmacological approach using selective agonists and antagonists.
The role of nitregic pathway was studied using SNP (NO donor) and L-Name
(nitric oxide synthesis inhibitor). Finally, the effect of ACh on the expression of
CSC and epithelial-mesenchymal transition (EMT) markers was studied by
immunofluorescence, RT-qPCR and flow cytometry. Statistical analysis was
performed by Man-Whitney test, Kruskal-Wallis test, or two-way non-para-
metric ANOVA test using SPSS16.0 F software
Results: ACh at concentrations of 0.1 and 1 mM significantly increased the
number and size of T as compared to control conditions (p5 0.001).
Bethanecol, a selective muscarinic receptor agonist, increased the number and
size of T, while the stimulatory effect of ACh on T was significantly reduced by
selective muscarinic receptor antagonist, atropine. Similarly, DMPP, a selective
nicotinic receptor agonist, increased the number and size of T, while hexametho-
nium, a nicotinic receptor antagonist, significantly inhibited stimulatory effect of
ACh on T (p5 0.001 as compared to ACh-stimulated cells). Interestingly, L-
Name, significantly inhibited the effects of ACh on the number of T. Conversely,
SNP, at 0.1 and 1 mM, increased the number and size of T. Finally, ACh induced
the expression of CSC markers (CD44, ALDH) and EMT markers (Snail, Zeb1
and Vimentin) on gastric cancer cells.
Conclusion: This study shows that ACh induces CSC properties of gastric cancer
cells of diffuse type via activation of muscarinic and nicotinic pathways. It also
shows that Ach effects are, at least in part, mediated by nitregic pathway. These
results suggest that ENS may be a new actor in gastric carcinogenesis.
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Introduction: CpG Island Methylator Phenotype (CIMP) has been identified as a
distinct molecular subtype of gastric cancer, yet associations with survival are
conflicting. A meta-analysis was performed to estimate its potential prognostic
significance.
Aims & Methods: A systematic review of Embase, Medline, PubMed, PubMed
Central and Cochrane databases related to CIMP in gastric was performed and
the primary outcome measure was cumulative 5-year survival.
Results: A total of 967 patients from 10 studies were included, and the median
rate of tumour CIMP-H was 40.9% (range 5.3–62.7%). Pooled analysis sug-
gested that specimens exhibiting CIMP-H were associated with poorer 5-year
survival (OR 1.49, 95% CI 1.11–2.01, p5 0.05). Significant heterogeneity was
observed between studies (I2¼ 88%, p5 0.001). Sub-analysis related to poor
(n¼ 5) or improved outcomes (n¼ 5), revealed that CIMP was associated with
both poor (OR 8.15, 95% CI 4.65–14.28, p5 0.05, study heterogeneity I2¼ 52%,
p¼ 0.08) and improved survival (OR 0.42, 95% CI 0.27–0.65, p5 0.05, study
heterogeneity I2¼ 0%, p¼ 0.960).
Conclusion: There was significant heterogeneity in the gene panels used to iden-
tify CIMP which may explain the survival differences. Consensus regarding
CIMP methodology would be welcome to better facilitate the assessment of its
prognostic value.
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Introduction: The BreathIDHp urea breath test (UBT) system provides several
advantages over other 13C breath analyzers for the detection of Helicobacter
pylori (H. pylori), including: higher accuracy, operator independence and imme-
diacy of results. However, there are occasions when mailing or transporting
saved breath samples may be preferable to real time analysis, especially in centers
requiring a large quantity of automated analyses where continuous sampling
from a single patient can provide a bottle neck preventing multiple other users
from accessing the device.
Aims & Methods: To evaluate the sensitivity and specificity of a new
BreathIDHp Lab System (Exalenz Bioscience Ltd, Modiin, Israel), a 13C-
UBT system using breath sampling bags, for the diagnosis of H. pylori in a
multi-center international clinical study. A total of 257 subjects with evaluable
results for UBT and biopsy [rapid urease testing (RUT) and histology] were
enrolled into two study groups: 189 naı̈ve subjects with unknown H. pylori
status were included in the pre-therapy group, and 68 subjects who had com-
pleted eradication therapy comprised the post–eradication therapy group. To
assess the stability of the breath samples in the breath sample bags, each pair
of breath sample bags was analyzed at a different time point up to 14 days after
collection. Analytical studies were conducted to evaluate the reproducibility and
repeatability of the 13C-UBT results using a cut-off of 5 Delta Over Baseline
(DOB).
Results: Among the pre-therapy subjects evaluated with the composite results
from the two biopsy based methods (RUT and histology/immunohistochemis-
try), 176 results (37 positive, 139 negative) matched those of the UBT resulting in
an overall agreement of 98.3% (95% CI: 95.2%; 99.7%) with a sensitivity of
100% (95% CI: 90.6%; 100.00%) and specificity of 97.9% (95% CI: 94.0%;
99.3%). The overall agreement between the UBT and the biopsy diagnosis in
the post-eradication therapy cohort (55 negative, 13 positive) was 98.5% (95%
CI: 92.1%; 100.0%). The sensitivity of the UBT in this cohort was 92.3% (95%
CI: 66.7%; 98.6%) and its specificity was 100.0% (95% CI: 93.5%; 100.0%). The
overall stability evaluated in samples of 191 (45 positive, 146 negative) subjects
from the pre-therapy cohort was excellent, with positive agreement in 97.8%
[95% CI (88.43, 99.61)]) and negative agreement in 100.0% [95% CI (97.44,
100.0)]. Similarly there was uniformly high overall reproducibility of the test
results over different batches, when analyzed on different days and under differ-
ent storage conditions.
Conclusion: The validation studies of the BreathIDHp Lab System described
above show it is a highly accurate and dependable method for the diagnosis of H.
pylori infection.Based on the current study, BreathIDHp Lab System received
on November 2016 U.S. Food and Drug Administration (FDA) marketing clear-
ance for H. pylori bacterium detection.
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Introduction: Linked color imaging (LCI), a recently developed endoscopic tech-
nique, emphasizes diffuse redness, which is a characteristic of Helicobacter pylori
(Hp) infection. However, the diagnosis of Hp infection does not have objective
indicators; it depends on medical doctors’ experience. Therefore, it is necessary to
construct objective indicators to diagnose Hp infection.
Aims & Methods: The aims of this study are to determine objective indicators for
the presence or absence of Hp infection to support medical doctors’ diagnoses by
constructing an automatic diagnostic system. In the proposed system, first, a
region with a high hue in LCI images is defined as a region of interest (ROI).
Images with a wide ROI and images with a narrow ROI are classified as high and
low hue images, respectively. As a result, LCI images are classified into two types
in which inflammation due to Hp infection presents as red and purple. Then, the
presence or absence of Hp infection is learned by machine learning for each type
of LCI image. The feature values used in the learning process are the ratio of the
ROI, the average and median hue values in high hue images, and the mode
saturation value and the median and variance of the hue in low hue images.
Then, the trained classifiers diagnose the presence or absence of Hp infection
automatically. In this paper, the constructed system was evaluated using 128
images (32 patients) in which endoscopic examination (LCI observation) and
Hp infection diagnosis were performed at Murakami Memorial Hospital of
Asahi University. Furthermore, support vector machines were used as classify
learners for diagnosis.
Results: In the previous system [1], 29 out of 32 cases were automatically diag-
nosed correctly. In contrast, all cases were automatically diagnosed correctly with
the proposed system. This result demonstrates that classifying LCI images into
two types based on color improves the accuracy of this system.
Conclusion: The proposed system can automatically diagnose the presence or
absence of Hp infection with the same precision as medical doctors with sufficient
experience. Therefore, the proposed system can support the diagnosis of medical
doctors with less experience.
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Introduction: -glutamyltranspeptidase (GGT) is a cell surface-associated enzyme
that is not highly expressed in normal cell. However GGT is overexpressed in
various type of human cancers. It is known that Helicobacter pylori (H. pylori)
also produce GGT. Urano et al have developed an enzymatically activatable
fluorescent probe, -glutamyl hydroxymethyl rthodamine green (gGlu-
HMRG), which is nonfluorescent under a neutral pH and normal cellular envir-
onment, but turns to be highly fluorescent upon reaction with GGT1). Aim of this
study is to consider if gGlu-HMRG can be useful for diagnosing infection H.
pylori.
Aims & Methods: In this study, we investigated whether activation of gGlu-
HMRG fluorescence detects a wild-type of H. pylori (WT) and a ggt gene-dis-
rupted mutant of H. pylori (ggt mutant). In addition, we investigated whether
activation of gGlu-HMRG fluorescence was suppressed in H. pylori culture
solution which was co-incubated with an inhibitor of GGT (GGsTop).
Furthermore, we applied gGlu-HMRG to biopsy specimens which were taken
from antrum and corpus of stomach in H. pylori positive patients (n¼ 13) and H.
pylori negative patients (n¼ 14). We then observed the increase of fluorescence
intensity over time (1min, 5min, 10min, 15min). Fluorescence intensity was
quantified by Image J2 software (National Institutes of Health, Rockville,
Maryland)2).
Results: Activation of gGlu-HMRG fluorescence was detected in WT strain, but
was not in ggt mutant strain. Activation of gGlu-HMRG fluorescence was inhib-
ited by GGsTop. There was significant difference of the increase of fluorescence
intensity between H. pylori positive and negative both in antrum corpus of sto-
mach (antrum p¼ 0.0008, corpus p¼ 0.047).
Conclusion:GGT-activated fluorescent probe can be useful forH. pylori infection
diagnosis.
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Introduction: The serum anti-Helicobacter pylori (H. pylori) IgG and serum pep-
sinogen (PG) assays are widely used for gastric cancer screening. An equivocal
serology test finding indicates IgG titer between the positive and negative test
findings.
Aims & Methods: The study aim was to evaluate the long-term, follow-up result
after an equivocal test finding on the serum anti-H. pylori IgG assay. Koreans
above 18 years-old with an equivocal serum anti-H. pylori IgG assay finding were
included. Subjects were excluded if they did not undergo H. pylori serology test,
serum PG assay, and upper gastrointestinal (UGI) endoscopy on the same day at
our center. Annual test findings were followed up using the same methods.
Results: Of the 7,178 subjects who underwent the serum assays and UGI endo-
scopy on the same day, 274 (3.8%) subjects showed an equivocal H. pylori
serology test finding. Of the 98 followed-up subjects, 58 (59.2%) showed sero-
positive finding at the mean follow-up period of 30.6 12.4 months. Subjects
with seroconversion showed a higher initial serum PG I (p¼ 0.023) and PG II
(p¼ 0.036) levels than the subjects without seroconversion.
Conclusion: An equivocal H. pylori serology test finding is not rare (3.8%) in
Korean adults, and 60% of the equivocal subjects show seroconversion within 3
years. Higher seroconversion rates in the subjects with high PG I and PG II levels
suggest that intact gastric secreting ability play a role for the survival ofH. pylori.
Therefore, equivocal subjects with increased serum PG levels should be consid-
ered as a potential seropositive subjects.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Several H. pylori (HP)infection related gastric findings (mucosal
atrophy, metaplastic change, diffuse redness, spotty redness and nodular
change of the antrum etc.) are so important sign of HP infection on endoscopic
examination. On the other hand, we have confused with various newly endo-
scopic findings (patchy redness and map-like redness etc.) were seen on the post-
eradicated stomach. On this time, we have found out a new other ultimate useful
finding showing HP infection related gastritis at gastric cardia (EG junction)
including present and post HP infection. The endoscopic image of gastric
cardia is the first gastric view through the esophagus on each endoscopic
examination.
Aims & Methods: Our aim of this study is to elucidate possibility of judgement
with only this cardiac endoscopic view about presence or absence with HP infec-
tion. We have found out so useful and specific cardiac image (We call Whale
Shark Sign: WSS) closely related to HP infection. We have examined the presence
of WSS on 4, 268 cases that have been able to overviewed on their endoscopic
profiles. We have judged the presence of HP infection with serum HP antibody
titers on each case. The 3,233 cases their serum HP antibody titers were measured
from Jan. 2012 to Oct. 2016. A total of 2,810 patients (HP positive) were
enrolled. Fisher’s exact test was used in all statistical analyses. The judgement
of HP present or past infection was done more than serum HP antibody 3 U/ml
to avoid false negative results.
Results: Mean age of patients was 52.4 years old. In case of WSS positive, all
their serum HP antibody titers showed more than cut-off level (3 U/ml). This
means that the presence of WSS closely related to HP related gastritis. The
positive predictive value (PPV) of WSS was surprisingly high (98%).
According to this high PPV, we can think WSS positive cases are high risk of
gastric carcinoma. This WSS mean that the presence of irregular gastric mucosal
surface pattern and the presence of lymphoid hyperplasia, that showing HP
infectious stomach. Especially presence of lymphoid hyperplasia at gastric
cardia is most important specific sign of HP related gastritis. This lymphoid
hyperplasia at gastric cardia were recognized small round whitish nodules on
white light endoscopy. And this was more emphasized with image-enhanced
endoscopy (Narrow Band Imaging: NBI), it looks like Whale Shark. This WSS
sign is very simple and easy for every gastroenterologist. It is so useful to know
gastric cancer risk at gastric entrance (cardia) with the presence of very easy
simple sign.
Conclusion: We have been able to judge the presence of HP infection with only
cardiac endoscopic images (WSS), we should take care of seeing the presence of
WSS sign. Since this sign is very easy and simple, everyone will be able to judge
the presence of HP infection and gastric cancer risk.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1905 SERUM PEPSINOGEN II AS A NON-INVASIVE MARKER
FOR DIAGNOSIS OF HELICOBACTER PYLORI INFECTION: A
PROSPECTIVE STUDY IN A COHORT OF DYSPEPTIC PATIENTS
F. Di Mario
1, C. Miraglia1, S. Scida1, A. Violi1, M. Franceschi2, G. Baldassarre3,
M. Rugge4, P. Crafa5, A. Tursi6, G. Brandimarte7, L. Franzoni1, N. Dal Bò8,
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Introduction: The diagnosis of Helicobacter pylori (H.p.) infection is currently
made by means of non-invasive (Urea Breath Test or HpSA) or invasive (gastric
biopsy or culture) methods. Serological assessment of H.p. infection by using
levels of IgG is not recommended. Pepsinogen II (PGII) is validated in the
literature as a non-invasive marker of gastric inflammation. Aim of the study
was to assess in a population of dyspeptic patients the clinical availability of PGII
determination in singling out subjects infected by H.p. in comparison with non-
infected ones.
Aims & Methods: A cohort of 880 consecutive dyspeptic patients (F 439; mean
age 55.5 ys; range: 29.83 ys) were enrolled in the study. Exclusion criteria: pre-
vious surgery, previous H.p. eradication therapy, concomitant PPI. In all patients
the diagnosis of H.p. infection was made by means of upper GI endoscopy and at
least one of these two methods: UBT, HpSA. All patients underwent blood
sample for determination of serum levels of PGII (Biohit Oyj; Finland; normal
values: 2–15mg/l). In a group of 670 pts a course of antibiotics (triple, concomi-
tant or sequential therapy) to cure H.p. infection was performed and PGII levels
were assessed at baseline (T0) and after two months (T1) from the end of the
antibiotic therapy. The search for the most appropriate cut-off of PGII in diag-
nosis of H.p. infection was assessed by using the ROC curve method.
Results: 430 out of 860 dyspeptic patients (F 245;mean age 52.3 ys; range 32–69
ys) showed an H.p-related gastritis (group1) in comparison with 430 (F 261;
mean age 57.3 ys; range 38–74 ys) resulted negative for H.p infection (group
2). The mean value of PGII in group 1 was 20.9 6.1 opposite to 7.2 1.7 in
group 2; p50.0001. 415 out of 670 patients treated with antibiotics schedules
were cured from H.p infection, opposite with 255 non-eradicated ones. In the
group of cured patients, the PGII values at T0 were 16.5. in comparison with 8.6
at T1; p50.001.The cut-off for PGII in the diagnosis of H.p infection, by com-
paring the 430 H.p positive pts and the 430 negative ones with method of ROC
curve identified the mean value of 10.6 mg/l, youden index J¼ 0.997.
Conclusion: serum PGII levels seem able to perform diagnosis of H.p infection in
dyspeptic patients, as well as the efficacy of antibiotics treatment for H.p eradi-
cation, being 10.6mg/l the best cut-off in singling out infected from non-infected
subjects.
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Abstract No: P1903. Table: Different characteristics of the subjects with an equivocal H. pylori test finding according to the repeated H. pylori serology test findings
Variables
Seropisitive finding on the
follow-up test (n¼ 58)
Seronegative or equivocal
finding on the follow-up test (n¼ 40) p-value
Age (years-old) 52.1 9.8 54.0 11.2 0.386
Gender (male) 43 (74.1%) 23 (57.5%) 0.084
Follow-up preriod (months) 32.1 13.0 28.6 11.3 0.165
Past H. pylori eradication 6 (10.3%) 10 (25.0%) 0.054
Initial serum pepsinogen I level (ng/ml) 61.2 32.0 48.5 15.6 0.023
Initial serum pepsinogen II level (ng/ml) 12.3 8.6 9.3 3.5 0.036
Initial serum pepsinogen I/II ratio 5.5 1.5 5.5 1.4 0.985
Body mass index (kg/m2) 24.6 3.4 23.8 2.6 0.231
Cigarette smoking Current smoker Past smoker Non-smoker 18 (31.0%) 16 (27.6%) 24 (41.4%) 5 (12.5%) 13 (32.5%) 22 (55.0%) 0.101
Alcohol drinking Heavy drinker* Social drinker Non-drinker 5 (8.6%) 40 (69.0%) 13 (22.4%) 6 (14.3%) 23 (59.5%) 11 (26.2%) 0.451
Upper gastrointestinal symptom 18 (31.0%) 10 (25.0%) 0.516
Recent intake of drug(s) 14 (24.1%) 8 (20.0%) 0.629
Comorbidity Hypertension Diabetes mellitus Others 17 (29.3%) 5 (8.6%) 19 (32.8%) 13 (32.5%) 4 (10.0%) 13 (32.5%) 0.736 0.816 0.979
Statistically significant values are highlighted in bold. Continuous variables are shown as mean value standard deviation using the Student’s t-test. Categorical
variables are shown in frequency (%) using the Chi-square test or Fisher’s exact test. *Criteria for heavy drinking was 15 drinks/week for men and 8 drinks/week
for women. Social drinker was defined as those who drink alcohol, but less than heavy drinkers.
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Introduction: The Urea Breath Test (UBT) is considered the gold standard non-
invasive test for detection of Helicobacter pylori infection in Ireland. In Ireland,
eradication rates for standard clarithromycin-based triple therapy have fallen
below the 80% deemed acceptable for a given treatment. With this in mind, it
is important to optimise management ofH. pylori infection. It has been suggested
that the DOB value is reflective of the amount of bacteria present in the stomach
and could predict whether the infection is eradicated.
Aims & Methods: The aim of this study was to determine whether there is an
association between DOB and eradication of H. pylori infection in an Irish
cohort. Treatment naı̈ve adult patients undergoing UBT were included.
Patients were deemed to be H. pylori positive if a Delta Over Baseline (DOB)
value of 44.0 % was obtained. Positive patients were categorised into low (516
%), intermediate (16–35 %), and high (435 %) DOB groups. A random subset
of positive patients was given clarithromycin-based triple therapy for 7 days. A
follow-up breath test was performed at least 8 weeks post-treatment to confirm
eradication of H. pylori in all patients. The three DOB groups were compared
with respect to age, gender and eradication rates.
Results: Out of 860 of UBTs assessed (mean age 43.5 15.2 years, 39% male),
289 (33.6%) were H. pylori positive (mean age 43.1 14.9 years, 41.9% male). Of
the total positive patients, 91 (31.5%) returned for a follow-up UBT to confirm
eradication of H. pylori. When patients were categorised into low, intermediate
and high UBT groups, there was no significant difference in age and gender
between the three groups (p¼ 0.06 for age, p¼ 0.3 for gender). Eradication
rates in the low, intermediate and high UBT groups were 70.5%, 63.0% and
50.0% respectively (p¼ 0.3). Patients were then categorised according to eradica-
tion status. When eradication was successful, the average DOB value was sig-
nificantly lower, at 20.6 % compared to 29.8% when eradication was
unsuccessful (p¼ 0.03, 95% CI 0.69 to 17.5). 46 (50.5%) patients were given
clarithromycin-based triple therapy for 7 days. When this subset of patients
was categorised into low, intermediate and high UBT groups, eradication rates
were 76.2%, 75% and 70% respectively. When these rates were compared to
respective rates in those whose treatment was not known, no difference was
observed. The subset was also categorised according to eradication status.
When eradication was successful, the average DOB value was lower, at 22.0%
compared to 25.8% when eradication was unsuccessful (p¼ 0.6). Similarly, when
these DOB values were compared to respective values in those whose treatment
was not known, no difference was observed.
Conclusion: As the DOB value increases in the UBT, the eradication rate of H.
pylori decreases, regardless of treatment regimen. When categorised according to
eradication status, the DOB value was significantly lower when eradication was
successful (20.6 % vs 29.8%, p¼ 0.03). The DOB value could be a useful value in
stratifying patients with H. pylori infection; especially as histology and antimi-
crobial resistance information is unavailable in patients undergoing non-invasive
testing for H. pylori infection.
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Introduction: Success or failure of Amoxicillin (AMX) and Clarithromycin
(CAM)-based H. pylori (HP) eradication therapy mainly depends on sensitivity
of CAM for HP. In Japan, we are permitted to prescribe AMX and CAM as
antibiotics of 1st eradication. So far now, several proton pomp inhibitors (PPIs)
have been used in HP eradication therapy, most of reports said that the success
rate of eradication approximately from 70 to 80% on AMX and CAM-based
triple therapy regardless of CAM dose (400 or 800mg/day) in Japan. Recently
the ratio of CAM resistance in Japan comes up to over 30%, we have to over-
come CAM resistance. On the other hand, recently it is considered that the
stability of continuous gastric acid suppression is one of most important factors.
At the point of gastric acid suppression, we expect stronger acid suppressive drug
rather than PPIs. Since Feb. 2015 we have used P-CAB (Potassium-Competitive
Acid Blocker) instead of PPIs in AMX and CAM-based HP eradication therapy
to improve success rate of eradication.
Aims & Methods: The aim of this study is to elucidate effects of CAM dose on
success rate of P-CAB Vonoprazan (VPZ) and one of PPI Rabeprazole (RPZ)
based triple therapy regimens (VAC, RAC).
This study is a multicenter center (7 hospitals), prospective case study from
Jan. 2012 to Oct. 2016. A total of 1,310 patients (HP positive) were
enrolled. Mean age of patients was 52.4 years old. Fisher’s exact test was
used in all statistical analyses. Regimen of VAC (400 or 800) was VPZ
(40mg/day) b.i.d., AMX (1.500mg/day) b.i.d. plus CAM (400 or 800mg/
day) b.i.d. for 7 days. Regimen of RAC (400 or 800) was RPZ (20mg/day)
b.i.d., AMX (1.500mg/day) b.i.d. plus CAM (400 or 800mg/day) b.i.d. for
7 days. The judgement of success or failure on eradication was done with
urea breath test on 3 months later after eradication therapy to avoid false
negative results.
Results: Success rate of VAC 800 showed significantly high (416/428¼ 97.2%,
PPS) rather than VAC 400 (373/423¼ 88.2%, PPS) (p5 0.001). The average
success rate of VAC regimens was 92.7% (789/851, PPS). On the other hand,
success rate of RAC 800 showed high (190/245¼ 77.6%, PPS) rather than RAC
400 (140/198¼ 70.7%, PPS) (p¼ 0.125). The average success rate of RAC regi-
mens was 74.5% (330/443, PPS). The average success rate of VAC regimens
(789/851¼ 92.7%) were significantly high rather than the average success rate
of RAC regimens (330/443¼ 74.5%) (p5 0.001). These results suggest that
using high dose CAM with VPZ (P-CAB) plus AMX regimen might be the
strongest H. pylori eradication triple therapy regimen to overcome CAM
resistance.
Conclusion: High-dose CAM with Vonoprazan (P-CAB) plus AMX triple ther-
apy regimen is the strongest H. pylori eradication therapy even if CAM resis-
tance. We will be able to expect significantly high success rate (more than 97%)
as HP 1st eradication therapy.
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Introduction: Bismuth is a heavy metal which has antimicrobial activity through
regulating iron uptake profile of bacteria. Helicobacter pylori (H. pylori) is also
highly susceptible to bismuth. So the Korean guideline preferably recommends
the regimen contains bismuth for the patients who failed on H. pylori eradication
with the primary regimen consists of proton pump inhibitors, amoxicillin, and
clarithromycin. Rifaximin is one of derivatives of rifamycin with antimicrobial
activity against H. pylori. It can achieve high concentrations within the gastro-
intestinal tract and remains active in acidic environment. So rifaximin has been
studied as a treatment for persistent H. pylori infection. Rifaximin has been
prescribed for replacing the bismuth of the regimen concurrently uses PPI, metro-
nidazole, and tetracycline in Soonchunhyang University Hospital, Seoul for a
while. So we reviewed the clinical outcomes of the 2 different regimens.
Aims & Methods: From May 1st 2003 to October 31st 2015, six thousand and five
hundred ninety-five patients were treated their H. pylori infection in
Soonchunhyang University Hospital, Seoul. And their prescriptions and result
of eradication were retrospectively reviewed on the medical records. The patients
had clarified pre-and post-eradication result, which can be assured by the rapid
urease test or the urea breath test performed within 100 days of eradication were
enrolled. And statistical analyses were performed to the patients who had second-
line treatment to compare the efficacy of the bismuth containing regimen and the
rifaximin containing one.
Results: During the periods over 12 years, two thousand and seven hundred
patients were prescribed the standard triple eradication regimen and 2,109
(78.11%) patients showed the successful treatment result. One hundred twenty-
six of treatment failure group were consecutively treated with second-line regi-
mens. Thirty-five patients were prescribed the bismuth-containing regimen and
34 (97.14%) of them showed successful eradication result. Other 91 patients were
treated with the rifaximin-containing regimen and showed 92.31% of eradication
rates. These treatment success rates are not different significantly in statistics.
(Fishers’ exact test, p-value¼ 0.442)
Conclusion: Alternative rifaximin containing regimen of second-line H. pylori
treatment didn’t showed inferiority on standard bismuth-containing one. This
suggest that the use of rifaximin is possible in the patients who are not suitable to
bismuth use and failed with primary eradication.
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Introduction: Standard triple therapy (STT) has been widely used in Helicobacter
pylori infection, but eradication rate is decreasing because of clarithromycin
resistance. Recently, Levofloxacin-based therapy (LBT) has been evaluated to
overcome the low eradication rate of standard triple therapy and reported era-
dication rated over 80%.
Aims & Methods: We compared the efficacy and safety of STT group and LBT
group for Koreans. Between April 2014 and April 2016, 49 patents in the STT
group (amoxicillin 1 g bid, clarithromycin 500mg bid and esomeprazole 20mg
bid for 10 days) and 48 in the LBT group(levofloxacin 500mg bid, amoxicillin 1 g
United European Gastroenterology Journal 5(5S) A817
bid and esomeprazole 20mg bid for 10 days) were enrolled, prospectively.
H. pylori eradication rate as the primary endpoint and serious adverse effects
as the secondary endpoint were defined.
Results: H. pylori eradication rate as the primary endpoint was higher in the LBT
group than in the STT group, but there was no statisfically significant difference
between the two groups (82.0% vs. 84.8%, P¼ 0.927). Serious adverse effects as
the secondary endpoint tended to be more frequent in the LBT group, but there
was no significant difference (6.1% vs. 15.2%, P¼ 0.267). The overall rates of
adverse effects were not different between two groups.
Conclusion: In comparison of H. pylori eradication rate of our study, LBT was
not significantly higher than STT, but it may be an alternative treatment if STT
eradication rate is lowered in Korea.
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Introduction: In Ireland, Helicobacter pylori infection has become increasingly
resistant to commonly used antibiotics, such as clarithromycin. Concurrently,
eradication rates for standard clarithromycin-based triple therapy have fallen
below the 80% deemed acceptable for a given treatment.
Aims & Methods: The aim of this study was to compare eradication rates of
standard clarithromycin-based triple therapy with those of tailored therapy
based on antimicrobial susceptibility as a first-line treatment for H. pylori infec-
tion. Treatment-naı̈ve adult patients undergoing endoscopy were prospectively
recruited. Biopsies from H. pylori-positive patients (assessed by CLO test) were
processed for sensitivity testing by E-testing and genotyping by the GenoType
HelicoDR assay (Hain). Patients randomly received either clarithromycin-based
standard triple therapy or tailored treatment based on antibiotic sensitivities, for
7/14 days. A follow-up breath test was performed at least 8 weeks post-treatment.
Results: To date 889 patients have undergone endoscopy and 186 (21%) were H.
pylori positive. Infected patients were significantly younger (mean age 53 vs 49
years, p¼ 0.002) and tended to be male (43% vs 53%, p¼ 0.02). Of 186H. pylori-
positive patients, 112 (60%) were treatment naı̈ve. Culture of H. pylori was
successful in 57% (64/112) of samples and primary clarithromycin resistance
was 47% (30/64) by E-test. Genotypic resistance data was available for 93%
(104/112) patients and 55% (61/104) strains were clarithromycin resistant.
Thus far, 99 (88%) treatment naı̈ve patients have been enrolled in the study,
92 (93%) have completed the study. Of these, 45 (46%) have received standard
triple therapy and 54 (54%) have received tailored therapy. In the tailored arm,
25 (46%) patients received standard triple therapy, 14 (26%) received levoflox-
acin-based triple therapy, 12 (22%) received a PPI and combination of antibiotics
based on their sensitivities (e.g. levofloxacin, clarithromycin, rifampicin, tetracy-
cline or metronidazole), and 3 (6%) bismuth quadruple therapy. The eradication
efficacy of tailored therapy by intention-to-treat analysis was higher at 74% (40/
54) compared to 67% (n¼ 30/45) for standard therapy (p¼ 0.5). The eradication
efficacy by per-protocol analysis was also higher, at 82% (40/49) for tailored
versus 70% (30/43) for standard therapy (p¼ 0.2). Patients in each arm were
further categorised by clarithromycin resistance status, phenotypically by E-
test or genotypically by GenoType HelicoDR when culture was unsuccessful.
Of note, in clarithromycin resistant patients, tailored therapy achieved a better
eradication rate per protocol analysis than standard triple therapy (83% vs 57%
per protocol, p¼ 0.09).
The eradication rates of standard triple therapy and tailored therapy according to clarithro-
mycin resistance status
Standard Arm (n¼ 45) Tailored Arm (n¼ 54)
Resistant
strains
(n¼ 22)
Sensitive
Strains
(n¼ 23)
Resistant
strains
(n¼ 26)
Sensitive
Strains
(n¼ 28)
Eradication
Rate
ITT analysis 12/22¼ 55% 18/23¼ 78% 19/26¼ 73% 21/28¼ 75%
PP analysis 12/21¼ 57% 18/22¼ 82% 19/23¼ 83% 21/26¼ 81%
Conclusion: In those who are sensitive to clarithromycin, standard clarithromy-
cin-based triple therapy achieves an acceptable eradication rate of approximately
81%. However, a high primary clarithromycin resistance rate was observed in
this study (47%). In those who are resistant to clarithromycin, prescribing a
regimen based antibiotic susceptibilities increases eradication rates to 83%, com-
pared to those treated with standard triple therapy (57%, p¼ 0.09).
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Introduction: Due to increasing prevalence of antibiotic-resistant Helicobacter
pylori, the number of patients who require rescue treatment (after 1 or more
failed eradication attempts) is increasing. The Irish Helicobacter pylori
Working Group consensus for the diagnosis and treatment of H. pylori infection
in adult patients in Ireland recommendeds that second-line and subsequent treat-
ments depend on the first-line treatment and should not be the same treatment.
First-line treatment for H. pylori is not standardised in Ireland, therefore it’s
difficult to recommend a specific rescue treatment. Prescribing a tailored regimen
based on antibiotic sensitivities upon first eradication failure may be most
effective.
Aims & Methods: The aim of this study was to examine the efficacy of a tailored
regimen based on antimicrobial susceptibility as a rescue treatment for H. pylori
infection. Patients previously treated for H. pylori and undergoing endoscopy
were prospectively recruited. Biopsies from H. pylori-positive patients (CLO test)
were processed for sensitivity testing by E-testing and genotyping by the
GenoType HelicoDR assay (Hain). Patients received treatment based on anti-
biotic sensitivities, for 7/14 days. A follow-up breath test was performed 8 weeks
post-treatment.
Results: Of 889 gastroscopies done between April 2013- February 2017, 186
(20.9%) were H. pylori positive. Of these, 74 (39.8%) were previously treated:
39 (52.7%) received one prior treatment and 35 (47.3%) received 41. Thus far,
55 patients have agreed to participate and been eligible for the study; 44 (80%)
patients have completed the study. 27 (49%) patients have received levofloxacin
triple therapy; 14 (26%) a PPI and 2 antibiotics based on their sensitivities; 10
(18%) bismuth quadruple and 4 (7%) clarithromycin triple therapy. The efficacy
of tailored treatment by intention-to-treat and per protocol analysis was poor, at
47.3% (26/55) and 59.1% (26/44) respectively. Patients who received one pre-
vious treatment were significantly more likely to achieve eradication than those
who received 41 previous treatment (76.2% vs 43.5%, p¼ 0.04).
Conclusion: Rescue eradication rates are disappointing. Eradication rates in
patients who received more than one previous treatment were significantly
lower than those who had just one previous treatment (43.5% vs 76.2%,
p¼ 0.04). This emphasizes the importance of eradicating H. pylori infection the
first time round, before more virulent or antimicrobial resistant strains are
selected for.
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Introduction: Helicobacter pylori (Hp) successful eradication has been considered
since it contributes to several gastrointestinal disorders. Sequential therapy has
been used widely as the first approach in Hp eradication therapy (HpET).
However, its fails in 10–45%. The addition of probiotics has been considered
because of potential benefit in the improvement of efficacy and reduction of side
effects during HpET.
Aims & Methods: We aimed to evaluate the effect of probiotics, as adjuvant to
sequential HpET on treatment efficacy, side effects and patient compliance. This
was a prospective study of total of 1159 patients followed in a gastroenterology
outpatient clinic. Selected patients undergone Hp screening for unexplained gas-
trointestinal symptoms or disorders with HpET indication. Compared patients
undergone sequential therapy (10-day treatment of 5 days of pantoprazo-
leþ amoxicilin followed by further 5 days of pantoprazo-
leþ clarithromycinþmetronidazole-G1:n¼ 85) and patients with additional
supplement of Lactobacillus reuteriprotectis therapy 2tablets/day in previous
two weeks and during treatment (G2;n¼ 77), since it was approved for this
indication. Screening Hp test and indication, eradication rate, auto-reported
side effects and patient compliance were evaluated.
Results: Of 265(22.9%) patients underwent screening Hp test, 147(55.5%;147/
265) were positive, being the majority obtained by gastric biopsy
(86.0%;n¼ 228). The mean age was 58.6 15.8years with women predominance
(60.8%;n¼ 161). The main indications for Hp screening were dyspepsia (27.9%),
epigastric pain (24.2%), gastroduodenal peptic ulcerous disease(19.2%) and gas-
troesophageal reflux disease (15.8%). At gastric biopsies, chronic gastritis was
present in 61.5% (n¼ 163), gastric atrophy in 17.0% (n¼ 45) and intestinal
metaplasia in 7.9% (n¼ 21), with Hp mild colonization in most cases
(58.5%;76/130). Eradication rate was significantly higher in patients who had
probiotic supplement (G1–74.1%vsG2–92.2%;p¼ 0.002;OR¼ 4.132). No signif-
icant difference was verified between two groups in relation to side effects (G1–
15.3%vsG2–9.1%;p¼ 0.094) or patient non-compliance (G1–2.4%vsG2–
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0.0%;p¼ 0.106). However, significantly higher rates of diarrhea were noted in
treated group without probiotics (G1–5.9%vs0.0%;p¼ 0.031;OR¼ 1.063). Of
G2 patients, 19(24.5%) performed sequential therapy first, with eradication
rate improvement of 78.9%(15/19). The remaining cases that didn’t respond
were submitted to 14-day of quadruple therapy with
PPIþ amoxicilinþmetronidazoleþ levofloxacin with success.
Conclusion: Co-adjuvant sequential therapy with probiotic Lactobacillus reuteri
protectis, within previous two weeks to final of treatment, is associated with
higher HpET rate, initially or after sequential therapy failure, and lower rate
of diarrhea-associated treatment.
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Introduction: As a country with high incidence of gastric cancer, the elimination
of Helicobacter pylori (HP) is useful strategy for the prevention of gastric cancer
in Japan. And the eradication therapy for HP -infected gastritis was approved as
an insurance indication since 2013, and virtually all HP -infected patients were
subject to eradication. In Japan, triple therapy using proton pump inhibitor
(PPI)/amoxicillin (AMPC)/clarithromycin (CAM) has been used as a regimen
for the primary eradication therapy. Since HP has rapidly acquired the resistant
character against CAM, the eradication rate has gradually been decreasing.
Recently, vonoprazan (VPZ), a novel potassium competitive acid blocker, has
been approved for HP eradication therapy. Recently, higher HP-eradication ratio
by VPZþAMPCþCAM than PPI based triple therapy has been reported.
However, there might be some concern for the use of VPZ; higher serum gastrin,
decrease in the diversity of intestinal microbiota and increase in colitis.
Therefore, PPI-based triple therapy is still used, and additive effect of probiotics
has been reported in these therapy.
Aims & Methods: The aim of this study is to investigate the effect of probiotics,
Clostridium butyricum Miyairi-588 (Miya-BM:MBM) on PPI-based triple ther-
apy comparing the eradication rate and side effect with VPZ-based triple therapy.
From January 2015 to December 2016, patients who received HP primary era-
dication therapy in our hospital were retrospectively evaluated. They were
divided into three groups; 1) patients who received PPIþAMPCþCAM therapy
(PPI group), and 2) patients who received VPZþAMPCþCAM therapy (VPZ
group), 3) patients who received PPIþAMPCþCAMþMBM therapy
(PPIþMBM group), and the eradication rate and side effects were evaluated.
Results: The number of patients enrolled in this study were 468; 150 cases in the
PPI group, 271 cases in the VPZ group and 47 cases in the PPIþMBM group.
Successful rate of HP eradication was 81.7% in the PPI group, 89.8% in the VPZ
group and 89.1% in the PPIþMBM group. The eradication rate in VPZ group
was significantly higher than PPI group. However, the eradication rate of VPZ
group was not significantly higher than that of PPIþMBM group. The rate of
side effect was 14.7% in the PPI group, 10.0% in the VPZ group and 19.1% in
the PPIþMBM group, and there was no significant difference between 3 groups.
Conclusion: The study shows that Clostridium butyricum Miyairi-588 can have
additive effects in PPI-based triple therapy for HP.
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Introduction: The eradication of Helicobacter Pylori remains crucial because of
constantly evolving data. The recent recommendations of Mastricht V stipulate
that the concomitant quadritherapy and the bismuth quadruple therapy are more
efficient than the sequential therapy because of a higher rate of eradication (90%
vs 82%), but with more important side effects. The aim of our study is to
investigate the effects of the Saccharomyces boulardii supplementation to the
sequential therapy on Helicobacter pylori eradication rate and associated therapy
side effects.
Aims & Methods: One hundred ninety nine patients with Helicobacter pylori
infection documented on a histological study of gastric biopsies were enrolled
from May 2013 to May 2016, on a single center, prospective, controlled and
randomized study, performed in the Gastro Enterology II department on the
military hospital of Rabat. Using a permuted block randomization, our patients
were assigned to one of the following groups: a control group receiving the
standard sequential therapy, and an experimental group receiving in addition
of sequential therapy, 500mg of Saccharomyces boulardii (Ultralevures) orally
and daily during the ten days of regimen. All the patients were reviewed in the
end of the therapy to evaluate the adherence to treatment and the incidence and
severity of side effects. The eradication of Helicobacter pylori was evaluated by
13C-urea breath 4 to 6 weeks after the end of the protocol. Statistical analysis
was performed by the software SPSS 20.0. A model of logistic regression was
performed to analyse the effects of Saccharomyces boulardii supplementation on
eradication rate and side effects.
Results: There was no significant difference between the two groups on age
(middle age¼ 44.3þ/13.8years vs 43þ/13.2years), gender (Sex ratio M/
F¼ 1.15 vs 1.05), medical antecedents, smoking, endoscopic and histological
datas. In Intention To Treat ITT and Per Protocol PP analysis, the eradication
rate was significantly higher in the experimental group (86.6% ITT, 87.5% PP),
comparing to the control group (78.2% ITT 74.7% PP), p¼ 0.02. Moreover, the
Saccharomyces boulardii supplementation allowed a significant reduction of the
incidence of overall side effects (RR¼ 0.26, IC 95% [0.14–0.47], p5 0.001), and
the incidence of antibiotic-associated diarrhea (RR¼ 0.07, IC95%[0.028–0.20],
p5 0.001). The incidence of nausea and vomiting, dizziness, asthenia and metal-
lic taste was also lower in the experimental group, although the differences were
not statiscally significant. In the multivariate analysis, the Saccharomyces bou-
lardii supplementation is associated with an optimization of the eradication rate
(RR¼ 2.4, IC95%¼ [0.19–1.09], p¼ 0.02), and with a reduction of the antibiotic-
associated diarrhea AAD (RR¼ 0.07, IC95%¼ [0.02–0.26], p5 0.001).
Conclusion: Our study shows that the Saccharomyces boulardii treatment during
sequential therapy in Helicobacter pylori regimen is associated with a significant
reduction of side effects and particularly the antibiotic-associated diarrhea, and
allows an optimization of the eradication rate of Helicobacter pylori.
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Introduction: Helicobacter pylori (H. pylori) infection, the major cause of peptic
ulcer disease, is a bacterial infection that can lead to inflammation and ulcers in
the lining o the stomach and the upper part of the small intestine. It has been
proved that curative treatment of H. pylori infection markedly reduces relapse of
peptic ulcers, bleeding, and gastric cancer. The decline of Helicobacter pylori (H.
pylori) eradication rates with standard triple therapy resulted in a search for
novel therapies for first-line therapy of H.pylori infection
Aims & Methods: The objective of this study is to compare, in Morocco, an
African country, the efficacy rates of the concomitant versus the sequential H.
pylori eradication therapy. Our prospective randomized study included 164
patients with newly diagnosed H. pylori infection, randomized to receive a 14-
day concomitant or 10-day sequential therapy. Treatment outcome was assessed
by C13-urea breath test at least 4 weeks after therapy. Intention to treat (ITT)
and per protocol (PP) analysis of the eradication rates were performed.
Secondary end points included patient compliance and safety.
Results: The concomitant therapy group achieved statistically significant higher
eradication rates when compared with the sequential treatment group, both in
the ITT and in the PP analysis (86.6% versus 79.9%, p¼0.002, and 90.6% versus
72.1%, p¼0.001, respectively), after adjusting for age, gender, smoking status,
and the presence or not of ulcer and/or non-ulcer dyspepsia. Both groups dis-
played excellent compliance rates (99.5% for the concomitant therapy group and
96.2% for the sequential therapy group, p¼0.067). Regarding treatment safety,
major adverse events that led to the discontinuation of both regimens were few,
with no statistical difference between the two groups (6.2% for the concomitant
therapy group and 3.1% for the sequential therapy group).
Conclusion: Concomitant therapy led to statistically significant higher eradication
rates over sequential therapy. Both therapies showed excellent compliance and an
acceptable safety profile. The 14-day quadruple concomitant scheme should be
the adopted for first-line H. pylori eradication in Morocoo.
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Introduction: The Maastricht V/Florence Consensus Report recommends bis-
muth quadruple or non-bismuth quadruple concomitant therapies as first-line
treatments for H pylori infection, in areas where clarithromycin resistance is high
(415%). Head-to-head studies between both therapies are needed.
Aims & Methods: We aimed to compare compliance, efficacy and adverse effects
of two first-line H pylori eradication therapies in a high clarithromycin resistance
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area, and in clinical practice. A prospective study was performed in a Spanish
center recruiting consecutive naı̈ve adult patients, candidates to H pylori eradica-
tion. Omeprazole 40mg, Clarithromycin 500mg, Amoxicillin 1 g and
Metronidazole 500mg, all drugs b.i.d, for 14 days (OCAM); or Omeprazole
20mg b.i.d and 3-in-1 capsule with Bismuth 140mgþTetracycline
125mgþMetronidazole 125mg, 3 capsules q.i.d, for 10 days (3–1-OBMT)
were prescribed according to physician criteria. Compliance was assessed by
striking the consumed doses in a patient filled template, and adverse effects
using a specific questionnaire with a 1–3 intensity scale. Efficacy was determined
by 13C-urea breath test. A descriptive study and analysis of efficacy by intention
to treat (ITT) were performed. Cases with poor therapeutic compliance (580%)
or no available data were excluded in per-protocol (PP) analysis. Chi2, Student’s
t, and Mann-Whitney U tests with significance level p5 0.05 were applied. The
protocol was approved by the Ethics Committee.
Results: 216 patients (63.43% women; mean age 51.53 -range 19–84 years-) were
included. OCAM were prescribed in 103 and 3–1-OBMT in 113. No differences
in age, sex and functional dyspepsia as indication to eradicate were observed
between groups. Main indications for treatment were functional dyspepsia
(39.35%), gastroduodenal ulcer (19.44%) and non-investigated dyspepsia
(13.89%). Compliance was 580% in 11 patients and unknown in 7. The efficacy
outcome was unavailable in 9 subjects. Compliance 80% was obtained in 96%
with OCAM and in 93.53% with 3–1-OBMT (p¼ 0.64). The ITT rates were
82.52% vs 85.84% (p¼ 0.63), and PP 89.47% vs 96.04% (p¼ 0.13), for
OCAM and 3–1-OBMT respectively. The outcomes of adverse effects (frequency,
number, duration and intensity) are shown in the Table.
Frequency
[%]
Number
[Mean (SD)]
Days
[Mean (SD)]
Maximum
Intensity [%]
None Mild Moderate Intense
OCAM 96.97 4.08 (2.49) 10.07 (4.6) 3.41 20.45 22.73 53.41
OBMT 91.51 3.92 (2.6) 6.02 (3.43) 7.14 19.39 40.82 32.65
p-value 0.17 0.70 50.0001 0.0149
Conclusion: In a high clarithromycin resistance area, 14-days OCAM and 10-days
3–1-OBMT regimens achieve high and similar compliance and efficacy rates, but
3–1-OBMT provides a superior safety profile.
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Introduction: We have detected a large increase of urea breath test (UBT)
requests for Helicobacter pylori (Hp) diagnosis by primary care physicians
(PCP). In this way, most Hp-infected patients are now being managed at primary
care level. However, little is known about outcomes of Hp infection by PCP.
Aims & Methods: 1. To evaluate and compare the eligibility of UBT indications,
treatment regimens and eradication rates between PCP and gastroenterology
specialist (GS). 2. To evaluate the effect of introduction of specific counselling
to PCP in the management profile of Hp infection. First, we prospectively
included 500 consecutive UBT indicated by PCP (250) and GS. Appropriate
UBT indications were considered those included in the 3rd Spanish Consensus
Conference on Helicobacter pylori infection (1). Hp treatment prescribed and
eradication rates were collected retrospectively. Finally, we analyzed another
consecutive 240 UBT and treatment outcomes after the introduction of specific
counselling to PCP (a personal letter with the accepted indications for UBT and
treatment issued by their referent GS). Statistical analysis was performed using
SPSS (version 22.0).
Results: We have analyzed 740 UBT (500 pre-intervention and 240 post-inter-
vention). 66.89% women, mean age of 48.94 16.6 years. Most (68.4%) of pre-
intervention UBT were performed for the initial diagnosis of Hp infection, and
the rest were indicated after previous eradication treatment. Inappropriate indi-
cation of UBT in the pre-intervention cohort was significantly higher in those test
requested by PCP compared to GS (36.4% vs 7.2%; p5 0.001). Also, inap-
propriate treatment regimens were significantly higher in the PCP group (65%
vs 26.4% ; p5 0.0001). Consequently, eradication rates were significantly lower
in PCP compared to GS group (57.1% vs 81.1%; p5 0.001). A significant
increase in the adherence to appropriate treatment regimens (71% vs 35%;
p5 0.0001) and eradication rates (78% vs 57.1%; p5 0.0001) were observed
in the PCP group after the implementation of specific counselling based on
national guidelines.
Conclusion: Hp infection management at primary care level is inappropriate with
very low Hp infection eradication rates. The introduction of a specific counselling
to PCP has significantly improved these outcomes.These data should encourage
the implementation of interventional strategies in order to reduce the actual
increase in antibiotic resistance.
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Introduction: Radiation-induced gastrointestinal syndrome (RIGS) stems from
the clonogenic loss of crypt cells and villi depopulation and results in mucosal
barrier disruption, bacterial invasion, inflammation and sepsis. Valproate (VPA)
is the one of the popular anti-convulsants, recently its Notch signal modulatory
effect has been reported. Notch signal pathway is the essential to maintain
intestinal stem cells and to differentiate to secretory cells such as goblet cells.
Moreover, It has been reported that combination of VPA and CHIR 99021
(GSK3ß inhibitor) has powerful proliferatory effect for instestinal stem cells,
such as Lgr 5þ cells. One of the major difficulties for RIGS studies is the fact
that crypts are not easily accessed and cultured with traditional means. Ex-vivo
culture techniques for single crypt or a stem cell derived enteroid, with essential
features of the in vivo tissue architecture, have been recently developed. Thus, we
have adopted the 3D-cultured enteroids for RIGS ex-vivo model, and proved the
effect of VPA and SCFAs for RIGS.
Aims & Methods: We have adopted the 3D-cultured enteroids for RIGS ex-vivo
model, and proved the effect of VPA and SCFAs for RIGS. To culture enteroid,
ten centimeters segments of jejunum were procured from 9–13 week-old C57BL6
mice. Crypts were isolated by EDTA chelation, suspended in Matrigel and grown
in culture media containing epidermal growth factor, noggin, R-spondin 1. After
1 day in culture, the enteroids were treated (or not) 3mM CHIR 99021 (GSK3ß
inhibitor) and 1mM VPA. On day 3, the enteroids were irradiated as a dose
dependent manner. The evaluation of irradiated enteroids was performed by
measuring MTT assay, budding efficiency of enteroid, and EdU staining. On
post-irradiation Day 2 and Day 7, RT-PCR was performed.
Results: Enteroid from mouse had multiple crypts (‘budding’) with well-differ-
entiated goblet, Paneth cells, þ4 stem cells (quiescence stem cells, BMI1 is
expressed), Lgr5þ stem cells. In the response of radiation, irradiated enteroid
decreased proliferation rate in a dose dependent manner, as measured by MTT
assay and budding efficiency of enteroids. Irradiated enteroids with VPA
þCHIR 99021 could maintain their þ4 stem cells even in 10Gy of irradiation,
lethal dose of mouse intestinal epithelium., and they were able to proliferation.
Combination of VPA þ CHIR 99021 did not have an effect on paneth cells,
enterochromaffin cells and goblet cells.
Conclusion: VPA and CHIR 99021 may ameliorate RIGS in ex-vivo mouse
enteroid, through þ4 reservoir stem cell preservation and stimulatory action
for epithelial proliferation. Considering their clinical application such as safety,
they could be possible strategy for prevention and treatment of RIGS.
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Introduction: Celiac disease (CD) is an important health problem worldwide. It is
characterized by a high prevalence (1%), non specific morbidity, long-term com-
plications and epidemiological progression. However, mass screening is not
recommended. Currently, the strategy of ‘Targeted screening,’ defined as screen-
ing of high-risk groups, is widely practiced and recommended by learned
Societies, in particular, in relatives of CD patients. In the world, targeted screen-
ing studies related to CD showed prevalence ranging from 4.2 to13%.
Aims & Methods: The main aim of our study is to determine the prevalence of
CD in the first degree relatives in Algerian population. This was a descriptive-
transversal study with prospective recruiting. This is a screening of first-degree
relatives of patients known and treated for CD. Relatives are screened by using
antitransglutaminase (TTG) antibodies in the serum. Upper digestive endoscopy
and duodenal biopsy are performed in all sero-positive relatives and graded as
per Marsh modified by Oberhuber classification to confirm the diagnosis. 546
first degree relatives of 107 families are included in our study.
Results: Among the 546 first-degree relatives, we have 18.5% of parents, 57.5%
of siblings and 24% of children; 44 cases have positive anti TTG antibodies. The
prevalence of CD among first-degree relatives is 8.1% with Confident Interval
(CI) at 95% [5.8–10.4]. The prevalence of CD in first-degree relatives with posi-
tive serology and positive duodenal biopsy is 7.3% with CI at 95% [5.2–9.4].
Histo-pathological study of duodenal biopsies of new cases, detected by targeted
screening, shows 5 cases of Marsh I, 5 cases Marsh IIIa, 27 cases Marsh IIIb and
3 cases Marsh IIIc. 44 patients are screened with CD; they are divided as follows:
9% Parents (4 mothers), 11% of children (son 3 and 5 girls) and 72% of siblings
(brothers and 23 sisters 9).The average age of screening cases is 31.8 years with CI
at 95% [27.2 to 36.4] and extremes of [3–71] years. The mean duration of symp-
toms before diagnosis is 3.4 years, with CI at 95% [2.8 to 4.0] years. Among the
44 new cases detected by targeted screening, whereas 11.4% are asymptomatic,
88.6% are symptomatic. This is a classical form in one case and atypical form in
86.4% of cases.
Conclusion: The present work entitled ‘‘Prevalence of celiac disease in relatives’’ is
the first screening study of CD in the first-degree relatives carried out in Algeria.
Among the 546 first-degree relatives, it is showed that 44 patients present positive
serology which corresponds to the prevalence of CD in first degree relatives of
8.1% with CI at 95% [5.8–10.4]. Our investigation supports the idea that the
development of an extensive screening approach is needed to promote early
diagnosis and to prevent complications of CD in first-degree relatives.
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Introduction: Celiac disease affects 1–2% of population, but due to diverse pre-
sentation most patients remain unrecognized. Diagnostic efficiency could be
improved by screening of at-risk groups, but long-term benefits of this approach
are unclear. To shed light to this issue, we compared a variety of celiac disease-
related and other parameters in large cohorts of adult patients diagnosed in
childhood either because of clinical suspicion or by screening.
Aims & Methods: A questionnaire about current health and lifestyle, adherence
to gluten-free diet (GFD) and follow-up of celiac disease was sent to 564 adults
with a childhood diagnosis. Further, the participants fulfilled validated
Gastrointestinal Symptom Rating Scale (GSRS) and Psychological General
Well-Being (PGWB) surveys for symptoms and quality of life. Clinical and his-
tological presentation at diagnosis and other relevant medical data were con-
firmed from patient records. All variables were compared between screen-
detected and clinically detected patients.
Results: Altogether 235 (42%) adults completed the questionnaires. At diagnosis,
screen-detected patients (n¼ 49) were older (11.3 vs 8.8 yr, p¼ 0.016) and had
less symptoms (44% vs 85%, p5 0.001) and poor growth (17% vs 51%,
p5 0.001) than clinically detected patients (n¼ 186). They also had a trend to
have less often total villous atrophy (18% vs 32%, p¼ 0.075) and anemia (18%
vs 32%, p¼ 0.072). The groups did not differ in gender, current age (median 26.5
vs 27.1 yr, p¼ 0.245), time from the diagnosis, self-experienced health or concern
about health, clinical symptoms, strict GFD (74% vs 80%, p¼ 0.161), lifestyle
restrictions caused by GFD, presence of celiac disease-related complications,
physical activity, fertility or GSRS and PGWB scores. However, screen-detected
patients smoked less (4% vs 15%, p¼ 0.037) and had more often celiac disease in
relatives (78% vs 58%, p¼ 0.011).
Conclusion: Diagnostic approach and presentation of celiac disease in childhood
do not seem to affect the long-term health outcomes or attitude towards the
disease in adulthood. Lack of difference in the dietary adherence and lifestyle
restrictions gives further support for active screening and early diagnosis of celiac
disease.
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Introduction: In the UK, 1 in 100 people are affected with coeliac disease. NICE
published quality standards (QS134) for coeliac disease in October 2016 based on
NICE guidelines NG20 (September 2015). This quality standard covers the
recognition, assessment and management of coeliac disease in children, young
people and adults. The quality standard is expected to contribute to improve-
ments in the diagnosis of coeliac disease, growth in children and young people,
health-related quality of life, incidence of osteoporosis, intestinal lymphoma,
vitamin D deficiency, and iron deficiency
Aims & Methods: We audited our departmental practices against NICE quality
standards for coeliac disease. It is a retrospective data analysis of patients, 16
years and above, with positive coeliac serology from April 2016 to September
2016. The main parameters examined were source of referral, value of tissue
transglutaminase (tTG) antibodies, type of referral (new or follow up), timing
of OGD (less than or more than 6 weeks), whether or not seen by dietician, offer
of annual review, and DEXA scan.
Results: Total of 95 cases were examined. The General Practitioner was the main
source of referral for tTG antibody (76%) test followed by gastroenterology
outpatients (OP) (13%), 2% each was shared by surgical OP and inpatient gas-
troenterology services. Other referrers contributed 3% each. 88% (84 out of 95)
positive tTG results was more than 20 U/ml. 53 out of 95 (56%) were new
referrals, 30 (31%) were follow-up and 12 (13%) referrals had no further
record on system. 11 of 53 (21%) new patients had OGD in less than 6 weeks;
30 of 53 (56%) had OGD in more than 6 weeks, 22 of 95 (23%) had no record of
OGD on system. 56 of 95 (59%) patients had dietician review. 26 of 95 (27%)
were offered or had annual review. 42 of 95 (44%) had DEXA scan to assess
bone density.
Conclusion: The incidence and prevalence of coeliac disease in our study are 30.28
per 100,000 persons-years and 8 per 100,000 population respectively.The data
demonstrates that Mid Yorkshire NHS Trust is not providing required service
standards for optimum care of coeliac patients in the Mid Yorkshire region. We
need to keep in mind that some gastroscopies would have been performed in the
primary care sector, the records of which were not available on our system. This
factor could have potentially affected our results. Due to several constraints in
our service provision, time frames stipulated in the NICE guidance are challen-
ging as evidenced by the audit results. Inspite of our unique local access to
endoscopy units in primary care, we are still not able to deliver the required
standards of care. Given the potential disease sequelae of coeliac disease, such
as osteoporosis and lymphoma, it is important that these issues are addressed by
the development of local referral and management pathways to ensure that all
coeliacs are captured, investigated, and followed up appropriately.
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Introduction: In nonresponsive celiac disease (NRCD) the symptoms and duode-
nal damage persists despite a gluten-free diet (GFD). We have previously shown
an association between dysbiotic microbiota and persistent symptoms in treated
CD (1). Furthermore, serum microbial antibodies to Saccharomyces cerevisiae
(ASCA), Pseudomonas fluorescens-associated sequence (I2) and Bacteroides
caccae TonB-linked outer membrane protein (OmpW) were found to be
gluten-sensitive (2) and present already at early stages of CD development (3).
We hypothesized that increased seroreactivity to microbial antibodies is asso-
ciated also with NRCD.
Aims & Methods: Serum ASCA, I2 and OmpW were measured in 20 CD patients
with persistent villous atrophy and mucosal inflammation despite strict GFD and
negative celiac serology (NRCD group). Corresponding GFD responsive
patients served as CD controls (58 samples at diagnosis and 55 on GFD) and
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80 healthy blood donors as non-CD controls. Kruskal-Wallis test was used to
compare antibody titers and Dunn-Bonferroni for post hoc pairwise
comparisons.
Results: At least one serum microbial marker was positive in 80% of NRCD
patients, in 97% of untreated and 87% of treated CD patients and in 44% of
non-CD controls. NRCD patients had the highest frequency of ASCA positivity
(64% vs 52%, 20% and 0%, respectively) and also significantly higher ASCA
IgA (median 14.5 U/ml) and IgG (32.5 U/ml) titers than treated CD patients (7.0
U/ml, 13.0 U/ml) and non-CD controls (4.5 U/ml, 5.8 U/ml). There was no
difference in ASCA between NRCD and untreated CD. The frequencies of I2
(65%) and OmpW (45%) were lower in NRCD than in untreated CD (86%,
59%, respectively), while I2 titers were higher in NRCD (median absorbance
0.76) and untreated (1.0) and treated (0.83) CD than non-CD controls (0.32).
OmpW was elevated in untreated (1.1) and treated (0.94) CD patients compared
with non-CD controls (0.79).
Conclusion: Seropositivity and high titers of ASCA were associated with NRCD
and might thus serve as additional follow-up tool for histological recovery in CD.
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Introduction: High levels of reactive oxygen species (ROS) and impaired antiox-
idant defense systems lead to oxidative stress (OxS) and tissue injury in different
intestinal and extraintestinal conditions, including celiac disease (CD). A possible
effect of gluten ingestion on intracellular oxidative imbalance has been suggested.
Aims & Methods: The first aim of the study was to investigate the effects of OxS
in CD, evaluating the levels of ROS and oxidative damage biomarkers in sera of
naı̈ve patients (N-CD), coeliac patients on a gluten-free diet (GFD) including
responders (CD-GFD) or non-responders (NRCD) to dietary treatment. The
second aim was to look for new serological biomarkers corresponding to mor-
phological/functional alterations detected in biopsies according to Marsh-
Oberhuber classification. Finally, a possible correlation between ROS production
and/or biomarkers of OxS and/or hematological data was investigated. Analysis
were conducted on small intestinal biopsy specimens and peripheral blood sam-
ples of celiac patients (N-CD, CD-GFD and NRCD). The methods included
Electron Paramagnetic Resonance (EPR) technique for ROS detection, High
Performance Liquid Chromatography (HPLC) analysis of erythrocytes glu-
tathione (GSH), enzymatic assays for oxidative damage biomarkers (lipid per-
oxidation measured by thiobarbituric acid-reactive substances (TBARS) method;
protein oxidation, measured by a protein carbonyl (PC) assay kit; total
antioxidant capacity (TAC), measured by an enzymatic kit; nitric oxides meta-
bolites in sera, assessed by the Griess method).
Results: Overall, blood samples and biopsies from 54 patients affected by CD
were collected (44 F; median age 43.98 13.44 years; range 19–80 years; 17 N-
CD, 18 CD-GFD and 19 NRCD). Hemoglobin and haematocrit levels were
significantly lower in NRCD and N-CD than in CD-GFD group (p5 0.05).
In our study, a significantly increased production of ROS, lipid peroxidation
and oxidized protein levels, plasma nitrate concentrations were reported in
NRCD and N-CD compared to CD-GFD. On the contrary, the TAC and
GSH levels were significantly decreased in N-CD and NRCD groups compared
to CD-GFD. Data are summarized in Table 1. A significant direct relationship
between Marsh subtypes and ROS production rate R2¼ 0.19; p5 0.001),
TBARS (R2¼ 0.20; p5 0.001) and PC (R2¼ 0.17; p5 0.001) was found by
Pearson’s product-moment correlation while an inverse correlation between
Marsh subtypes and TAC (R2¼ 0.23; p5 0.001) and GSH (R2¼ 0.34;
p5 0.0001) was identified. In all groups of patients, at higher ROS production
rate levels corresponded to greater plasma TBARS concentrations and lower
erythrocytic GSH levels.
Conclusion: Several defense mechanisms are implied in maintaining the cell integ-
rity and tissue homeostasis. According to our results, the presence of higher levels
of ROS, oxidative damage biomarkers and nitric oxides metabolites in naı̈ve and
non-responders patients suggest an implication of OxS in the functional and
histological damage of CD. In parallel, the antioxidant capacity of celiac patients
with the active form of the disease is significantly reduced. On the contrary, in
patients responding to GFD, the pro-oxidant/antioxidant balance seems to be
greatly recovered.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1924 CIRCULATING EXTRACELLULAR VESICLES, A NOVEL
MECHANISM OF ENDOCRINE CELLULAR CROSS-TALK, ARE
INCREASED IN NEWLY DIAGNOSED CELIAC DISEASE PATIENTS
K. Efthymakis, G. Bologna, P. Lanuti, C. Pipino, A. Milano, F. Laterza,
P. Simeone, A. Bonitatibus, A. Pandolfi, M. Marchisio, S. Miscia, M. Neri
Department Of Medicine And Ageing Sciences And Center For Excellence On
Ageing And Translational Medicine (cesi-met), "G. D’Annunzio" University and
Foundation, Chieti/Italy
Contact E-mail Address: efkn78@gmail.com
Introduction: Extracellular vesicles (EVs) have been recently hypothesized to
represent a major peripheral mechanism of cellular cross-talk. EVs carry surface
receptors and proteins characteristic of their cells of origin and shuttle molecules
(proteins, RNAs, microRNAs) potentially controlling physiological and patho-
logical systemic processes. Recent studies have demonstrated an increased
number of circulating EVs in a variety of conditions characterized by multi-
organ impairment and/or damage such as insulin-resistance, atherosclerosis
and obesity. Celiac disease (CD) is an immune-mediated inflammatory entero-
pathy, elicited by gluten ingestion in genetically susceptible individuals. It is
frequently associated with a variety of systemic conditions both autoimmune
and potentially immune-mediated in nature.
Aims & Methods: The aim of this study was to assess and characterize patterns of
circulating EVs in newly diagnosed CD patients. We enrolled consecutive adult
anti-tTG positive, biopsy proven CD patients. Circulating EVs were identified
untouched on whole blood samples by a no-lyse/no-wash method, combined with
EVs volumetric count (FACSVerse, BD), based on a novel six-colour flow cyto-
metry panel, in order to identify and enumerate both the whole EV compartment
and different EVs subpopulations. Data are expressed as meanSD and statis-
tical differences were evaluated by means of T-test.
Results: We evaluated 12 celiac adults (mean age¼42.9 19.1 vs. 40.8 15.9
years, F/M¼ 4:1) at diagnosis and 12 age- and sex-matched healthy controls.
Histology was considered positive for lesions of grade B1 according to the
Corazza-Villanacci classification. Mean anti-tTG levels at diagnosis were
6.9 3.5 times ULN. Mean number of total circulating EVs was significantly
higher in CD than in controls (59895 72482 vs 14383 10018 EV/microL,
p¼ 0.035). Subgroup analysis showed that EpCAMþEVs, of epithelial origin,
and CD41þ platelet-derived EVs were not significantly different between CD
and controls (894 1004 vs. 548 1237 and 3052 1563 vs. 1734 1810 respec-
tively, p¼ns). On the contrary, CD45þEVs, of leucocyte origin, showed a sig-
nificantly higher number in CD patients vs. controls (460 492 vs. 119 150
p¼ 0.026).
Abstract No: P1923
Data on levels of ROS and oxidative damage biomarkers in sera of naı̈ve patients (N-CD), coeliac patients on a gluten-free diet (GFD) including responders (CD-
GFD) or non-responders (NRCD) to treatment.
N-CD NRCD CD-GFD P value
ROS production (mmol.min1) 0.21 0.03* 0.22 0.04^ 0.17 0.03*^ *^5 0.05
TAC levels (mM) 1.07 0.30* 1.16 0.47^ 1.68 0.54*^ *5 0.01,^5 0.05
GSH levels (mmol.L1) 534.40 37.46* 507.80 81.73^ 634.00 187.80*^ *50.001, ^50.0001
Peroxidized lipid levels (mM) 3.59 0.67* 3.46 0.87^ 2.82 0.47*^ *50.01, ^50.05
Oxidized proteins levels (nmol.mg1 protein) 1.42 0.43* 1.23 0.53^ 0.91 0.20*^ *50.001, ^50.05
Plasma nitrates concentrations (mmol.L-1) 99.74 30.76* 54.61 14.57^ 22.21 6.92*^ *50.001, ^50.01
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Conclusion: Celiac disease patients at diagnosis show higher numbers of circulat-
ing EVs than age- and sex-matched controls. Phenotypical assessment suggests
that this increase is not primarily driven by epithelial or endothelial damage. On
the contrary, the increased numbers of leucocyte-derived EVs, suggest their
potential implication in systemic signaling.
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Introduction: The coeliac disease is an autoimmune enteropathy induced by the
ingested gluten proteins (Corn, barley, rye), that occurs in people who are geneti-
cally predisposed primarily affecting the small intestine inducing atrophic lesions,
which are regressive with a gluten-free diet. The classic form is actually a min-
ority of patients. The extradigestive forms are currently the most found, with
varieted manifestations including reproductive disorders. The aim of our study is
to evaluate the frequency of these disorders in the coeliac disease and their
evolution under gluten-free diet.
Aims & Methods: It’s a single-center, retrospective and descriptive study includ-
ing 241 patients with coeliac disease enrolled within period of 17 years from 1995
to 2016 in the department of Gastroenterology « Medecine C » in Ibn Sina
University Hospital.
Results: About 241 patients suffering from coeliac disease, 58 patients presented
reproductive disorders, either 28.9%. Recruting 53 women and 5 men, with a sex
ratio M/F of 10/6. The mean age was 32.25years ranging from 13 to 59years old.
The diagnosis of coeliac disease was based on: Histology (severe or partial
Villous atrophy with intraepithelial lymphocytosis exceeding 30%), the antien-
domysial antibodies and/or antitransglutaminase antibodies positive. The repro-
ductive disorders were never isolated but always associated with digestive or
extradigestive signs at the time of the diagnosis of coeliac disease. These disorders
were manifested by: retarding puberty in 11 cases (19%), secondary amenorrhea
in 13 cases (22.4%), Metrorrahgia in 12 cases (20.6%), absence of developpement
of secondary sexual caracters in 8 cases (12.5%), spontaneous abortion in 7 cases
(10.9%), menometrorrahgia in 4 cases (13.8%), primary sterility in 5 cases
(8.6%), precocious menopause in 6 cases (10.3%), premature labour and/or
IUGR in 3 cases (5%), primary amenorrhea in 2 cases (3.4%), and intrauterine
Fœtal death IUFD in one case (1.7%). All our patients benefited from a gluten-
free diet. 15 patients were excluded from the study, 2 patients died, and 12
patients are still under follow-up. Of the 29 patients stayed, the evolution of
the reproductive disorders under gluten-free diet was good in 26 cases (90%),
with normalization of the cycles in 15 cases, The cycle was returned in 6 cases,
development of secondary sexual characters in 2 cases, fertility was returned in
one case, one case developed her cycle after primary amenorrhea, and one case
was delivered a baby in term after a repeated premature deliveries. The evolution
was good in 3 cases as regard missed abortion four years after the gluten-free diet
in 1 patient, and amenorrhea continued in 2 cases.
Conclusion: Reproductive disorders related to the coeliac disease were frequent
and variable. In our study, these disorders well responded to the gluten-free diet
in 90% of cases, and these disorders were reversible under gluten-free diet.
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Introduction: Celiac disease (CD) is a chronic imune-mediated enteropathy that
occurs in genetically predisposed individuals. The clinical phenotypes ranges
from classical gastrointestinal manifestations to only atypical signs, thus
making the clinical diagnosis a challenge. The aim of the study was to investigate
the relationship between duodenal histology, specific antibody levels and clinical
presentation in adult CD Romanian patients.
Aims & Methods: Study design: retrospective retrieval of information prospec-
tively entered into a structured database including 81 adult patients diagnosed
with CD hospitalized at the Institute of Gastroenterology and Hepatology, ‘‘St.
Spiridon’’ Hospital, Iasi between January, 2012- December, 2016 admitted with
symptoms of abdominal disturbances (diarrhoea, heartburn, nausea, vomiting,
regurgitation, abdominal pain). Demographic, clinical, serological, and histolo-
gical characteristics of individuals with CD were reviewed.
Results: The study group included 81 adult patients with a female: male ratio of
3:1, 60(71.1%) female patients, mean age 40.02 12.14 years. A total of 48.1%
patients presented with gastrointestinal (GI) complaints and 51.9% of patients
presented mostly with non-GI manifestations, and advanced age of symptom
onset in the latter category (38yrs vs 47yrs). Marh-Oberhuber classification was
used to assess mucosal injury and Marsh 3c lesions were found in 25 (30.9%)
cases. When assessing the serological parameters, IgA anti-tissue transglutami-
nase (IgA-tTG) antibody (61.45 76.458 u/mL vs 162.02 106.179 u/mL,
P¼ 0.001) and IgA anti-gliadine antibodies (IgA-AGA) levels (61.83 69.41u/
mL vs 77.15 71.02 u/mL, P¼ 0.001) correlated with intestinal villous atrophy
(Marsh 3a and 3c) in CD patients by Spearman rank correlation. Among symp-
toms, abdominal distention and diarrhea were associated with abnormal histol-
ogy. Hemoglobin levels were evaluated and anemia was diagnosed in 61.7%
patients among patients with elevated IgA-tTG levels (r¼ -0.316; P¼ 0.004),
IgA-AGA (r¼ -0.301; P¼ 0.006) and Marsh 3b-3c lesions (P¼ 0.0048). Among
biological markers included in the statistical analysis, low iron levels (cut off
30mg/dl), hypocholesterolemia and low protein levels were associated with
Marsh 3 b lesions (P¼ 0.006) and elevated tTG-IgA titers (r¼ -0.384; P¼ 0.001).
Conclusion: IgA-tTG and AGA levels correlate with duodenal villous atrophy in
adult CD patients. An IgA-tTG titer 4160 was nearly always associated with
severe CD histopathology. GI and non-GI symptoms are not reliable predictors
of CD.
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Introduction: Celiac disease is an immunologically-mediated enteropathy that
triggered by the intake of gluten-containing foods in genetically predisposed
individuals. It causes intestinal and extraintestinal problems. Extraintestinal find-
ings are observed in many systems. The prevalence of extraintestinal findings in
the cardiovasculer system of celiac disease is not clearly known and the correla-
tion between them has not been yet obviously explained. There is also no data in
the literature regarding the association of patent foramen ovale (PFO) and celiac
disease, which is 10–25% common in the general population. We performed an
echocardiography study to determine the frequency of accompanying cardiac
findings in our patients with celiac disease. In this article, we aimed to share
the frequency of the PFO detected in celiac patients with high results.
Aims & Methods: Between May-June 2015, 65 patients who applied to the gas-
troenterology clinic of Derince Education and Research Hospital and followed
up with celiac diagnosis were identified. The sociodemographic characteristics,
celiac disease diagnosis duration, symptoms and complaints, accompanying dis-
eases, drug use histories, hemogram and biochemical parameters of these patients
were recorded. The patients underwent saline contrast transthoracic echocardio-
graphy in the cardiology clinic. Patients’ data were recorded. The obtained data
were evaluated with appropriate statistical methods.
Results: Sixty-five celiac patients were included in the study, 21 (32.3%) male and
44 (67.7%) female. The mean age of the patients was 41.5 14.1 years. PFO was
detected in 39 (60%) of the patients. There was no difference in the incidence of
PFO in between male and female patients. (61.9% and 59.1% respectively,
p:0.829). Compared with the frequency of PFO in the general population, the
incidence of PFO in celiac patients was higher. (25% and 60% respectively)
Conclusion: As a result, the incidence of PFO is more prevalent in celiac patients
than in the general population. For this reason, the evaluation and treatment of
the PFO, which may be the cause of cerebrovascular disease in clinical follow-up
of patients, are required. In addition, the high incidence of PFO in celiac patients
suggests that celiac disease is a factor affecting the development of patients from
intrauterine period. Because our patients did not undergo transesophageal echo-
cardiography, this rate may be less than real exist. For this reason, further
evaluation is required with a wider patient group and by transesophageal
echocardiography.
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Introduction: Currently available celiac disease (CD) guidelines recommend sam-
pling of both the bulb and distal duodenum for diagnostics. This has been
reinforced by the recent data on ultra-short CD [1]. However, it has been pre-
viously shown in pediatric CD that bulb specimens are frequently of poor quality
and that morphological injury is common in the duodenal bulb in non-celiac
patients also, and it can lead to false-positive diagnoses [2]. Our aim was to
address the same issue in adult CD, using the same validated morphometric
methods [3].
Aims & Methods: We prospectively recruited cases of clinically recommended
upper GI endoscopy; all patients also had signs and symptoms of CD and
were checked for CD serology (serum tissue transglutaminase 2 antibodies and
endomysial antibodies) and biopsy sampled according with current
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recommendations. Paraffin embedded biopsy samples were assessed for villous
height (VH), crypt depth (CrD) and VH to CrD ratio (VH:CrD). The corre-
sponding frozen duodenal samples were assesed for duodenal IgA deposits tar-
geting transglutaminase 2 (TG2-IgA), density of CD3 (cut-off 37 cells/mm
epithelium) and  T cell receptor bearing intraepithelial lymphocytes/IELs
(cut-off 4.3 cells/mm epithelium). The study was approved by the Local
Ethical Committee.
Results: Altogether 41 patients, mean age 45 14 years, 61% female, were
recruited. Among these, 21 were finally diagnosed as adult CD (mean tTG 156
U/l, median EMA 1:500, and crypt hyperplastic mucosal lesion in distal duode-
num) and the rest 20 were non-CD controls (serum negative and normal on distal
duodenal biopsy). All patients were on a gluten-containing diet. Quality of bulb
biopsy samples was unsatisfactory and unreadable in 67% of CD cases and 50%
of controls, even after reorientations and recuttings. All CD patients had, when
measurable, VH:CrD5 2 in the anatomical bulb (average 0.31, range 0.02–0.61).
On the other hand also non-CD controls had a crypt hyperplastic diseased bulb
mucosa in 80% of patients (average VH:CrD 1.65, range 0.7–4.1), but the injury
was not that severe as in CD (p¼ 0.0006). Inflammation was significantly higher
in CD compared to controls (CD3 81.87 vs. 34.05, p5 0.01;  IELSs 29.12 vs.
6.44, p5 0.01). Bulb IgA deposits were positive in all CD patients and was able
to discriminate CD cases from disease controls.
Conclusion: As reported in children, bulb biopsy samples in adults are frequently
of poor quality and not reliable for accurate histological measurements. Also,
interpretation of results from bulb samples should be done with caution, as non-
CD patients may have mild injury in the bulb lining and could be misinterpreted
as CD. Assessment of bulb TG2-IgA subepithelial deposits is a powerful tool to
confirm CD.
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2Praxis am Mexicoplatz, Berlin/Germany
3Gastroenterologische Praxis, Berlin/Germany
4Praxis am Bayrischen Platz, Berlin/Germany
5Praxis am Hohenzollerndamm, Berlin/Germany
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Introduction: Celiac disease (CD) is a chronic inflammatory disorder triggered by
the ingestion of gluten in genetically susceptible people. The prevalence varies in
between European countries and averages at 1% within whole Europe. It is
anticipated that the number of undetected and therefore untreated cases is
high. Since untreated CD is associated with a high morbidity, further diagnostic
modalities to uncover undiagnosed coeliacs are currently explored. In this setting,
we evaluate SimtomaxTM, a POCT detecting deamidated gliadin peptide anti-
bodies, with the goal to identify patients at need for duodenal biopsies prior to
gastroscopy. Thus, the goal was to establish a test allowing to guide the endos-
copist in his decision to collect duodenal biopsies.
Aims &Methods: Prospective investigator-initiated multi-center study in six adult
gastroscopy and two pediatric gastroscopy centers in Berlin and Brandenburg,
Germany, approved by the local ethical committees. Finger prick blood of
patients registered for gastroscopy and eligible for the study (exclusion: defective
coagulation, established celiac disease or on gluten-free diet) was analyzed by the
POCT (IgA and IgG for deamidated gliadin peptides; SimtomaxTM test, Tillots,
Switzerland). Test results were compared with duodenal histology (Marsh classi-
fication). In POCT-positive individuals transglutaminase-IgA serology was
performed.
Results: Analysis was performed at n¼ 721 adult patients (average age: 48 yrs)
and n¼ 108 pediatric patients (average age: 11 yrs). In the adult cohort 45 POC-
tests were judged as ‘‘positive’’. Within the POCT positives, 6 Marsh III case
were detected. None of the 676 POCT-negative individuals revealed CD.
Therefore, the prevalence of CD in this population was 0.8%. The POCT-speci-
ficity in this group was 94% (95%-CI 92–96%), the sensitivity was 100% (95%-
CI 51–100%). In the pediatric cases 21 POCTs were judged as ‘‘positive’’ with 13
being true-positive. Of the 87 negative POCTs, 68 were true-negative, but 4 were
false-negatives. Thus, the prevalence of CD in the pediatric gastroscopy was
16%. However, sensitivity in this group was only 76% (CI 50–93%) and speci-
ficity 91% (CI 83–96%). Examiners at various centers suggested, that ‘‘faint’’
bands in the POCT analysis might contribute to interpretation failures.
Conclusion: A screening test–like a POCT in CD–needs to perform optimally
especially in sensitivity. In the adult population all CDs were detected by the
POCT. However, the CD prevalence in this group was low. In the pediatric group
the test revealed a critically lower sensitivity, either due to a sensitivity problem
with this serology in the pediatric population or secondary to a suboptimal IgA
band expression of the POCT.
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Introduction: Quality standards in coeliac disease management were recently
published by the National Institute for Health and Care Excellence1. These
specify a new 6-week target for the time from referral to endoscopy, which was
previously covered by the 18-week referral to treatment (RTT) pathway2. They
also state that all newly-diagnosed patients should discuss a gluten-free diet with
a specialist dietitian. We retrospectively evaluated practice in the Oxford
University Hospitals NHS Foundation Trust coeliac clinic against these criteria,
and against national guidelines (duodenal bulb sampling at endoscopy and
screening for nutritional deficiency)3.
Aims & Methods: The medical records of 110 patients referred to our clinic
between September 2015 and September 2016 were examined. The date of refer-
ral and endoscopy were recorded, along with relevant demographic, clinical and
laboratory information. Data were collected and analysed in Microsoft Excel.
Results: Eighty-five patients (68% female, median age 34) were seen with sus-
pected or newly-diagnosed coeliac disease, of whom 76 (89%) were referred with
positive coeliac serology and would be subject to the 6-week target. Six patients
declined or delayed endoscopy, and endoscopy or referral information were not
available for 4 patients. For the remaining 66 patients, median time from referral
to endoscopy was 12 weeks 2 days (SD 37 days), with 59 patients (89%) within 18
weeks, but only 11 patients (17%) within 6 weeks (Figure 1). Duodenal bulb
biopsies were taken at endoscopy in 31 patients (44%). A diagnosis of coeliac
disease was made in 74 (87%) of all patients referred, of whom 67 (90%) were
referred to a specialist dietitian. Haematinics (iron studies, vitamin B12 and
folate) were measured in 67 patients (90%), bone densiometry was measured in
51 patients (69%) and all patients were offered a follow-up appointment in the
coeliac clinic. Iron deficiency was found in 31 patients (45%) of patients tested,
folate deficiency in 12 patients (18%), vitamin B12 deficiency in 5 patients (7%)
and vitamin D deficiency in 23 patients (38%). Osteoporosis was diagnosed in 5
patients (10%) and osteopenia in 10 patients (20%).
Conclusion: Appropriate dietitian referral, specialist follow-up and screening for
nutritional deficiency and bone disease occur within the Oxford coeliac disease
service. Compliance with recommended biopsy protocols was only 44%. Whilst
most referrals met the previous 18-week RTT pathway, few would have met the
new quality standards.
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Introduction: We previously reported that small-bowel capsule endoscopy (CE) is
effective in diagnosing small-bowel lesions with occult obscure gastrointestinal
bleeding (OGIB) (Gastroenterol Res Pract. 2013). However, there is no consensus
regarding the management of occult OGIB patients without bleeding source
lesions.
Aims & Methods: We aimed to consider management of occult OGIB patients
based on the long-term outcomes. A total of 357 consecutive occult OGIB
patients (203 men; mean age: 59.7 years) who underwent CE at Hiroshima
University Hospital before March 2016 and whose entire small-bowel could be
observed and followed-up by CE for at least 12 months, were enrolled. We
examined each patient to confirm the positive CE findings rate, the detection
rate of bleeding source lesions, the details of bleeding source lesions, the overt
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bleeding rate with or without treatment, the rate of anaemia exacerbation (hemo-
globin levels decreased 42.0 g/dL), 5 year overall survival rate (OS), and 5 year
disease specific survival rate (DSS). Occult OGIB was defined as recurrent or
persistent iron deficiency anaemia with or without a positive faecal occult blood
test and no bleeding findings by esophagogastroduodenoscopy and colonoscopy.
Results: Results: The positive CE findings rate was 44% (157/357) and the detec-
tion rate of bleeding source lesions was 27% (98/357). All of the treated bleeding
source lesions (Group A) were as follows: angioectasia 61 patients (Yano-
Yamamoto classification Type 1a 37 patients, Type 1b 24 patients), non-specific
ulcer 10 patients, nonsteroidal anti-inflammatory drugs-indeeded ulcer 8
patients, hemangioma 5 patients, Crohn’s disease 3 patients, primary cancer 2
patients, metastatic cancer 2 patients, gastrointestinal stromal tumour 2 patients,
malignant lymphoma 2 patients, others 3 patients. Lesions that were not
regarded as bleeding source and were followed-up without treatment (Group
B) were as follows: angioectasia 25 patients (Type 1a without oozing 25 patients),
erythema 31 patients, others 3 patients. There were no patients with overt bleed-
ing in Group B. Although 6 patients (10%) had anaemia exacerbation in Group
B, they had angioectasia (Type 1a) that was not a bleeding source lesion. OS in
both Group A and Group B was 90%. DSS in Group A was 99% and in Group
B was 100%. One patient in Group A died of a primary small-bowel cancer.
Conclusion: Conclusion: Long-term outcomes with occult OGIB patients were
good except malignant tumor, because overt bleeding and/or anaemia exacerba-
tion did not occur within the follow-up period. Thus, occult OGIB patients
without bleeding source lesions, including Type 1a angioectasia without
oozing, and erythema, are unnecessary to follow-up with CE in occult OGIB
patients.
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Introduction: Small bowel capsule endoscopy (SBCE) is a very useful method of
investigating iron-deficient anaemia, or occult gastrointestinal (GI) bleeding. It
can help diagnose sources of anaemia or bleeding, such as angiodysplasia, small
bowel Crohn’s disease, polyps, lymphoma, and malignant lesions. There is how-
ever a need to improve the diagnostic yield, particularly where resources and
access to capsule endoscopy are restricted. Faecal immunochemical test (FIT)
has an established role, in investigating large bowel bleeding, and is incorporated
into a number of bowel cancer screening programmes.
Aims & Methods: The aim of our study was to investigate whether FIT could help
predict likelihood of small bowel bleeding or other significant pathology at time
of small bowel capsule endoscopy. This was a prospective pilot study, performed
at our centre from September 2016-April 2017. Indications for enrolment were
patients referred for SBCE with the indication of anaemia or occult GI bleeding.
Baseline patient characteristics were obtained including age, gender, history of
renal disease, transfusion requirements and use of antiplatelet/anti-coagulants.
Patient haemoglobin (Hb) level was checked on the day of SBCE where possible.
Patients were asked to return one completed FIT for further analysis. A cut of
50 ng/ml was chosen, as this is the standard cut-off used, in the Irish National
Bowel Cancer Screening programme.
Results: A total of 40 patients were enrolled, mean age 55.4 years (range 18–77),
64% were female. A total of 27.6% of patients were on anti-platelet agents or
anti-coagulants. 34% of patients had a blood transfusion within the last year.
Mean Hb for the cohort was 12.8 g/dL (range 7.8–15.9 g/dL). The average FIT
reading was 459 ng/ml (range 0–4426 ng/ml). 30% of patients had a FIT level
450 ng/ml. 46% of patients, had positive findings at SBCE. 9/12 (75%) of
patients with a FIT level 450 ng/ml had positive findings at capsule endoscopy
compared to 5/28 (17.8%) for FIT5 50 ng/ml, p value¼ 0.002, 95% C.I. 0.29–
0.86 O.R. 0.16. These included 4/12 (33%) new cases of Crohns, 3/12 (25%)
angiodysplasia, 3/12 (33%) non-IBD enteritis, 1/12 (16.7%) small bowel
tumour, and 1/12 (16.7%) melaena, with no clear source. In addition there was
a good correlation between FIT and Haemoglobin levels. 60% of patients with
FIT4 50 ng/ml were anaemic (Hb5 11.5 g/dL), compared to 17% with
FIT5 50 ng/ml, p value¼ 0.02 95% C.I 0.09–0.76 O.R 0.14. Combining Hb
and FIT levels, was also informative and predictive of small bowel pathology.
83% of patients, who were anaemic and had a FIT4 50 ng/ml had clinically
significant findings at SBCE compared to 21% pick up rate in patients with
normal Hb and FIT levels, p value¼ 0.05 95% C.I 0.22–1.03 O.R. 0.05.
Overall the sensitivity for a FIT4 50 ng/ml for detecting small bowel pathology
was 83% with a specificity of 92%, giving a positive predictive value of 83.3%
(95% C.I. 56%-95%). Antiplatelet usage was not predictive of a positive FIT, as
16.7% of patients with a FIT4 50 ng/ml were on anti-platelet agents, compared
to 83.3% who weren’t.
Conclusion: FIT is useful at predicting clinically significant small bowel pathol-
ogy at the time of capsule endoscopy. It may help better identify and prioritise
patients who would best benefit from referral.
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Introduction: The features of the portal hypertension enteropathy (PHE) vary
from mild mucosal changes to varices with or without bleeding. The prevalence
and the correlation of factors that predict the development of PHE are not fully
understood.
Aims & Methods: Our aim in this study is to examine the prevalence of the
different manifestations portal hypertensive enteropathy and it’s correlation
with the Child-Pugh score (CTP) in cirrhosis using video capsule endoscopy
(VCE). At a single center, we performed a retrospective chart review study of
patients between the age of 18 and 80 with cirrhosis, who had VCE study between
January 2010 and January 2016. Based on the published literature, we divided the
portal hypertensive enteropathy lesions in our study into vascular lesions (arter-
iovenous malformation (AVM), red spots, bleeding or varices) and mucosal
lesions (mild inflammatory changes or severe inflammatory changes which are
a mosaic, congested and friable mucosa).
Results: 100 patients with cirrhosis had a VCE study. The mean age was 62.82
years. Male gender was predominant with a 64%, while the Caucasians repre-
sented 82% of the cohort. The most common etiologies of the cirrhosis were
chronic alcohol abuse followed by chronic hepatitis C virus (HCV) and non-
alcoholic steatohepatitis (NASH)table 1A. The average MELD score was
13.86(0.66). VCE detected small bowel lesions in 71% of the patients while
the features of portal hypertensive enteropathy were found in 65% from the
total cohort. AVMs and Inflammatory changes were the most common findings,
followed by bleeding. 13 patients found to have two or more lesions by VCE.
More than 50% of the lesions were vascular in nature (table1A). The percentage
of the CTP A, CTP B and CTP C was 46%, 42% and 12% respectively. The odds
of finding portal hypertensive enteropathy in decompensated cirrhosis is twice
that in compensated cirrhosis (odd ratio of 2.0) table 1B. 45 patients had negative
EGD exam for any active bleeding, esophageal varices (EV), portal hypertensive
gastropathy(PHG) or gastric varices(GV). 31 of them (69%) had features of
portal hypertension enteropathy in their VCE. table 1B.
Table 1A
Number & (%)
Total number of patients 100
Causes of cirrhosis:
Congestive Hepatopathy 4(4%)
Cryptogenic 8(8%)
HCV 22(22%)
Alcohol 37(37%)
Hemochromatosis 2(2%)
NASH 18(18%)
PSC 2(2%)
PBC 6(6%)
AIH 1(1%)
Age 62.82 2
MELD score 13.86(0.66)
Demographic: Male 64(64%)
Female 36(36%)
Whites 82(82%)
Asian 2(2%)
African-American 1(1%)
Others 15(15%)
Small intestine lesions 71(71%)
Portal hypertensive enteropathy (PHE) 65(65%)
Vascular lesions: AVMs 18(18%)
Varices 1(1%)
Bleeding 15(15%)
Red spot 9(9%)
Inflammatory changes: Mild 18(18%)
Severe 15(15%)
No Portal hypertension enteropathy 35(35%)
Table 1B
Number PHE No PHE O.R P-value
CTP-A 46 26 20 0.5 0.01
CTP-BþC 54 39 15 2.0 0.01
(continued)
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Continued
Number PHE No PHE O.R P-value
Alcohol 37 20 17 0.4 0.04
HCV 22 13 9 0.4 0.02
NASH 18 14 4 2.1 0.1
Cholestatic liver disease(PSCþPBC) 8 6 2 1.6 0.4
Thrombocytopenia 69 48 21 1.8 0.09
Male 64 42 22 1.1 0.7
Female 36 23 13 0.9 0.7
EGDþ (EV, PHG or GV) 55 34 21 0.7 0.5
EGD 45 31 14 1.3 0.5
Conclusion: VCE detected small bowel lesions in 71% in our cohort. There is a
high prevalence of PHE in patients with decompensated cirrhosis. Vascular
lesions are the most common finding in the small bowel of this population.
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Introduction: Small-bowel capsule endoscopy (SBCE) have been useful in mana-
ging obscure gastrointestinal bleeding. We previously reported that the use of
oxicams and diclofenac was associated with an increased risk of nonsteroidal
anti-inflammatory drug (NSAID)-induced small-bowel injury (Aliment
Pharmacol Ther 2014). However, the etiology and temporal development of
drug-associated small-bowel bleeding (SBB) has not been well characterized.
Aims & Methods: The aim of this study is to determine the risk of drugs asso-
ciated with overt SBB using a case-crossover design. The Japanese Association
for Capsule Endoscopy developed a prospectively recorded database of outpa-
tients and inpatients who underwent SBCE at 18 medical centers in Japan, and
data were collected from 1052 patients with obscure gastrointestinal bleeding
(OGIB) between December 2010 and June 2016. This database includes patient
characteristics, drugs used, SBCE findings, and final diagnosis. Drugs used were
identified during a ‘‘case period’’ 4 weeks before the overt SBB, and a ‘‘control
period’’ 24–5 weeks before the overt SBB. Drug adherence was classified into 4
groups: 1) 100%, 2) 50% or higher, 3) lower than 50%, and 4) 0%. Using
conditional logistic regression, odds ratios (ORs) and 95% confidential intervals
(CIs) were estimated using Mantel-Haenszel estimator in discordant cases.
Results: Of 1052 patients with OGIB (male/female: 678/374, age of onset:
68 87), 455 with SBB (male/female: 291/164, age of onset: 70 91) were
enrolled. Final diagnoses were vascular lesions (n¼ 169, 37%), followed by
inflammatory lesions (n¼ 148, 33%), drug injuries (n¼ 64, 14%: NSAID 47,
aspirin 15, both 1, anticancer drug 1), tumors (n¼ 48, 11%: malignant 32,
benign 16), diverticula (n¼ 13, 3%), etc. Data from 133 patients on 346 drugs
which could be identified 24 weeks before overt SBB were analyzed. ORs
(95%Cis) of enteric-coated aspirin (n¼ 51), warfarin (n¼ 27), clopidogrel
(n¼ 24), and loxoprofen (a propionic acid derivative, n¼ 21) were 5.7(1.3–
24.3), 3.7(0.8–16.6), 313406(2.3E-145–4.3Eþ 155), and 18.0(2.3–139.6). Aspirin-
associated SBB was caused by aspirin-induced injuries, angiodysplasias, Meckel’s
diverticula, and polyps. Loxoprofen-associated SBB was caused by mostly lox-
oprofen-induced injuries.
Conclusion: Enteric-coated aspirin, clopidogrel, and loxoprofen were identified as
agents causing overt SBB during a relatively short period after administration.
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Introduction: Video capsule endoscopy (VCE) is the first-line diagnostic modality
for obscure gastrointestinal bleeding (OGIB) investigation and different re-bleed-
ing rates have been published among Western and Eastern studies.
Aims & Methods: Aim of this meta-analysis was to examine the differences in re-
bleeding rates in patients with OGIB after index VCE, as measured in Western
and Eastern studies. A comprehensive literature search in MEDLINE was con-
ducted to identify all studies examining re-bleeding rate after VCE for OGIB.
Meta-analysis assessed the pooled proportion of re-bleeding events after VCE for
OGIB according to study’s origin (Western vs. Eastern) as the primary end point.
Pooled odds ratios for re-bleeding after positive vs. negative index VCE and after
long (424 months) vs. short (524 months) follow-up in the two studies origins,
comprised the secondary endpoints. Study outcomes effect sizes were calculated
using RevMan 5.3 software random effect model and they are presented as
rate[95%CI] or OR[95%CI]. Heterogeneity was measured using the I2 statistics
and publication bias risk was examined with Funnel plots inspection.
Results: Thirty-eight (14 Eastern and 24 Western) studies were included in the
analysis with 5197 patients followed from 6 to 52 months. We detected significant
heterogeneity with no evidence for publication bias in the meta-analyzed studies.
While the overall, pooled rate of re-bleeding after VCE was 25(21–29)%,
I2¼ 93%, similar re-bleeding rates were detected among Eastern and Western
populations [22(16–28)%, I2¼ 93% vs. 28(22–35)%, I2¼ 95%]. The re-bleeding
risk after positive compared to negative VCE index examination was higher
[1.89(1.10–3.24), I2¼ 72%] in Eastern population studies, while a similar differ-
ence was not detected in the Western studies [1.46(0.72–2.94), I2¼ 88%]. When
only studies with short-term follow-up were analyzed, the OR of re-bleeding after
positive vs. negative VCE was 1.23[0.58–2.61], I2¼ 77% and 1.93[0.90–4.13],
I2¼ 71% in Western and Eastern studies, respectively. For studies with long-
term follow-up, no significant difference in the OR of re-bleeding after positive
vs. negative index VCEs was detected either in the East [2.03(0.96–4.29),
I2¼ 71%] or in the West [2.29(0.46–11.37), I2¼ 96%].
Conclusion: Our analysis shows that patients undergoing VCE for OGIB have
similar re-bleeding rates in the East and in the West, regardless of the length of
the follow-up. An increased re-bleeding risk after positive vs. negative index VCE
was noted only in studies originating from the East.
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Introduction: There are very few reports about long-term outcomes in patients
with negative balloon assisted enteroscopy for suspected overt small bowel bleed-
ing (obscure-overt gastrointestinal bleeding).
Aims & Methods: The aim of this study is to evaluate long-term outcomes and
risk factors of re-bleeding after negative double balloon enteroscopy (DBE) for
suspected overt small bowel bleeding. We investigated 297 patients undergoing
DBE for suspected overt small bowel bleeding between December 2004 and April
2016 at Sendai Kousei Hospital. Prospectively collected data were reviewed, and
83 patients (27.9%) showed negative results in the first antegrade and/or retro-
grade DBE. For these patients, letter and telephone interviews were conducted in
April 2017. As a result, a cohort of 64 patients could be followed. The primary
outcome measurement is overt rebleeding and necessity for clinical assessment
after negative DBE.
Results: Rebleeding was observed in 19 of 64 patients (29.7%) with 76 months
follow-up period. The mean period during the first DBE and the first rebleeding
episode were 11.6 months(2day-48months). Three patients showed rebleeding
after more than three years of the first DBE. At the time of rebleeding, emergent
endoscopy including DBE (within less than 48 hours) and/or contrast-enhanced
computed tomography (CECT) was performed in all patients. The bleeding
source was identified in 17 of 19 patients (89.4%). The bleeding source were
duodenum (n¼ 8), jejunoileum (n¼ 7) and colon (n¼ 2), respectively. One
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patient died due to uncontrollable duodenal bleeding. Blood transfusion before
the first DBE was associated with rebleeding (odds ratio 22.5, p¼ 0.0005), but
total enteroscopy rate, use of capsule endoscopy, use of anti-thrombotic agents
and use of NSAIDs were not associated with rebleeding.
Conclusion: Rebleeding after negative DBE for suspected overt small bowel
bleeding is not rare. Blood transfusion before the first DBE may predict rebleed-
ing. Emergent endoscopy including DBE and concomitant CECT use could help
the diagnosis on re-bleeding.
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Introduction: Capsule endoscopy (CE) is a useful and noninvasive modality for
investigation of the small intestine, and currently, it has become the first-line
modality for the diagnosis of obscure gastrointestinal bleeding (OGIB). Use of
antithrombotic agents including antiplatelets and anticoagulants is associated
with gastrointestinal bleeding. Antithrombotic users account for a large portion
of patients with OGIB, and those with OGIB often undergo CE. It should be
noted that some patient with over OGIB discontinue antithrombotic agents at
the time of CE, which may affect endoscopic findings.
Aims & Methods: To examine the effect of discontinuation of antithrombotic
agents on the diagnostic yield of CE, and to assess the predictive factors asso-
ciated with positive CE findings in patients using antithrombotics who develop
overt OGIB. Between March 2004 and December 2015, 130 consecutive patients
(75 male; mean age, 71.9 years) taking antithrombotics who underwent CE for
overt OGIB were enrolled, whereas patients who underwent double-balloon
endoscopy prior to CE were excluded. Findings were considered positive if the
observed lesions could explain the bleeding, while findings including isolated red
spots and a single small polyp were considered negative. The primary endpoint
was the difference in the rate of positive CE findings between patients who
continued and those who discontinued antithrombotic agents. Furthermore, a
propensity score analysis was performed to reduce the effects of selection bias
and potential confounding factors. The secondary endpoint was to assess the
predictive factors for the positive CE findings by using multiple logistic
regression.
Results: Of the 73 patients who continued antithrombotic agents, 36 (49.3%)
patients had positive findings in the small intestine (ulcer/erosion [n¼ 24],
angioectasia [n¼ 7], tumor [n¼ 4], and blood pooling [n¼ 1]), while of the 57
patients who discontinued these agents, 35 (61.4%) patients had positive findings
(ulcer/erosion [n¼ 17], angioectasia [n¼ 11], tumor [n¼ 3], and blood pooling
[n¼ 4]). The rates of positive CE finding did not differ between the two groups.
Even after propensity score matching, discontinuation of antithrombotic agents
did not affect the rate of positive CE finding. In multivariate analysis, the lowest
hemoglobin level before CE examination was an independent predictive factor
associated with positive CE findings. The odds ratio per 1 g/dL increase in the
lowest hemoglobin level was 0.84 (95% confidence interval, 0.71–0.98). However,
other factors, including sex, age, and discontinuation of antithrombotic agents,
were not associated with positive CE findings.
Conclusion: Discontinuation of antithrombotic agents did not affect the diagnos-
tic yield of CE in patients with overt OGIB, and lowest hemoglobin level was
associated with positive CE findings
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Introduction: Long-term use of low-dose aspirine (LDA) is associated with devel-
opment of peptic ulcers, gastrointestinal bleeding, enteropathy. For prevention of
LDA-induced gastroduodenal mucosal injury, proton pomp inhibtor (PPI) are
the first-line therapy according to several guidelines. However, gastric acid sup-
presants, like PPI, do not prevent small intestinal mucosal injury. The latest
clinical trials sjowed that rebamipide stimulates the production of prostaglan-
dines, thereby preventing mucosal injury. This could improve mucosal breaks in
small intestine in patients recieve LDA.
Aims & Methods: We aimed to investigate the protective role and efficacy of
rebamipide for prevention low-dose aspirin-induced small intestinal mucosal
injury and enteropathy. Subjects comprised patients undergoing longlife low-
dose aspirin therapy prescribed by cardiologist. Patients with a high-risk of
gastrointestinal bleeding were excluded. This trial was performed as a rando-
mised open-labelled clinical study with the permission of an institutional
review board. The trial was included 100 patients (50 cases in each group)
received enteric-coated low-dose aspirin 100mg. The Group PPI received LDA
plus pantoprazole 40mg, the Group RBD received plus rebamipide 300mg.
Before starting therapy, we checked the background characteristics of each
patient (H.pylori, use of LDA, NSAID, bismuth, PPI; and endoscopic findings).
Gastroduodenoscopy and capsule endoscopy were performed, and the fecal
occult blood reaction and fecal calprotectin levels were measured before, two
and four weeks after drug administration. After the therapy, we has asked phy-
sicians and patients about medication compliance and side effects. Capsule endo-
scopy was then repeated. The primary endpoint was the change in the number of
mucosal breaks from baseline to 4 weeks. The secondary endpoints were the rates
of side effects.
Results: The fecal calprotectin levels increased significantly in Group PPI, they
did not increase in Group RBD. The mean number of small intestinal mucosal
injuries by capsule endoscopy in Group PPI increased significantly up to 3,9 after
4 weeks of LDA treatment. There was not detected new small intestinal injuries
in Group RBD. Stomach ulcer, bleeding or stenosis were not found in any
subject. There were no significant differences in the presence of fecal occult
blood in both groups. There were no significant side effects in Group RBD.
Conclusion: In conclusion, rebamipide is effective and sufficient for preventing
mucosal injury of the small intestine induced by low-dose aspirin. These results
show the gastroprotective and enteroprotective effects of rebamipide, suggesting
that it may be a good choice in low-dose aspirin users with gastrointestinal
toxicity that is not suppressed by acid suppressants alone.
Disclosure of Interest: All authors have declared no conflicts of interest.
References
1. Watanabe T, Takeuchi T, Handa O, et al. A Multicenter, Randomized,
Double-Blind, Placebo-Controlled Trial of High-Dose Rebamipide
Treatment for Low-Dose Aspirin-Induced Moderate-to-Severe Small
Intestinal Damage. Green J, ed. PLoS ONE. 2015;10(4):e0122330.
doi:10.1371/journal.pone.0122330.
2. Ota K, Takeuchi T, Nouda S, et al. Determination of the adequate dosage of
rebamipide, a gastric mucoprotective drug, to prevent low-dose aspirin-
induced gastrointestinal mucosal injury. Journal of Clinical Biochemistry
and Nutrition. 2016;59(3):231–237. doi:10.3164/jcbn.16-49.
3. Yamamoto T, Isono A, Mishina Y, et al. Gastroduodenal Mucosal Injury in
Patients Taking Low-Dose Aspirin and the Role of Gastric Mucoprotective
Drugs: Possible Effect of Rebamipide. Journal of Clinical Biochemistry and
Nutrition. 2010;47(1):27–31. doi:10.3164/jcbn.09-103.
4. Iwamoto J, Mizokami Y, Saito Y, et al. Small-bowel mucosal injuries in low-
dose aspirin users with obscure gastrointestinal bleeding. World Journal of
Gastroenterology: WJG. 2014;20(36):13133–13138. doi:10.3748/
wjg.v20.i36.13133.
5. Mo C, Sun G, Wang Y-Z, Lu M-L, Yang Y-S. PPI versus Histamine H2
Receptor Antagonists for Prevention of Upper Gastrointestinal Injury
Associated with Low-Dose Aspirin: Systematic Review and Meta-analysis.
Green J, ed. PLoS ONE. 2015;10(7):e0131558. doi:10.1371/
journal.pone.0131558.
P1939 CAPSOCAM SV-1 VERSUS PILLCAM SB 3 IN THE
DETECTION OF OBSCURE GASTROINTESTINAL BLEEDING:
RESULTS OF A PROSPECTIVE RANDOMIZED COMPARATIVE
MULTI-CENTER STUDY
L. L. Zwinger
1, B. Siegmund1, A. Stroux3, A. Adler4, W. Veltzke-Schlieker5,
R. Wentrup1, C. Jürgensen4, B. Wiedenmann4, F. Wiedbrauck7, S. Hollerbach8,
T. Liceni9, C. Bojarski1
1Medizinische Klinik Mit Schwerpunkt Gastroenterologie, Infektiologie,
Rheumatologie, Charité, Berlin/Germany
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Introduction: Capsule endoscopy allows high-quality imaging of the small bowel.
Newer capsule with a panoramic viewing mode is available and might increase
the detection rate of bleeding lesions in patients with obscure gastrointestinal
bleeding. Furthermore, an improved patient acceptance rate is expected.
Aims & Methods: In a randomized prospective comparative multi-center study,
patients with obscure gastrointestinal bleeding were included and examined
either with CapsoCam SV-1 or with PillCam SB 3. Detection of bleeding lesions,
transit and evaluation time and adverse events were evaluated. Physicians were
interviewed about their experience with both capsules and the evaluation soft-
ware. A detailed subject questionnaire analyzed acceptance of each capsule
system. Three months after initial capsule endoscopy follow-up procedures
were documented.
Results: One hundred eighty-one patients with obscure gastrointestinal bleeding
were recruited into the study. After exclusion of 28 patients 153 patients were
randomized and CapsoCam SV-1 (n¼ 78) or PillCam SB 3 (n¼ 75) was admi-
nistered. CapsoCam SV-1 detected more cases of bleeding (31/79, diagnostic
yield 39.7%) compared to PillCam SB 3 (26/75, diagnostic yield 34.6%, n.s.).
Transit time of both capsules was not different. Evaluation time with PillCam SB
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3 was superior to CapsoCam SV-1 (27min. vs. 40min, p¼ 0.01). 95% of the
physicians were satisfied with each capsule system and evaluation software. The
acceptance rate of the patients to retrieve the CapsoCam SV-1 was high. Adverse
events/SAEs were 17.9%/1.3% with CapsoCam SV-1 and 16%/0% with PillCam
SB 3. Re-bleeding rate was 28.75% within 3 months.
Conclusion: Both capsules allow high-quality imaging of the small bowel.
CapsoCam SV-1 detected more lesions, however, relevant bleeding sources
were visualized by both capsules. Physician’s satisfaction was high with both
capsule systems and evaluation software. Patient’s acceptance with CapsoCam
SV-1 was unexpectedly high. SAEs were 0% with PillCam SB 3 and 1.3% with
CapsoCam SV-1.
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Introduction: Chronic mesenteric ischemia (CMI) is the result of insufficient
mucosal perfusion of the gastrointestinal tract, mostly caused by atherosclerotic
stenosis of the mesenteric arteries. Other causes of CMI are vasculitis, median
arcuate ligament syndrome or non-occlusive ischemia (NOMI) due to decreased
cardiac output or hypo-oxygenation. The diagnosis of CMI remains challenging
as chronic abdominal pain is common and mesenteric artery stenoses are fre-
quently observed in the general population but not necessarily related. Harki
et al.(1) designed a score chart to predict the risk of CMI based on a cohort of
CMI suspected patients. This score chart consists of patient characteristics
(female 1 pt, weight loss 1 pt, cardio-vascular disease 1 pt) and radiologic evalua-
tion (50–70% celiac artery (CA) stenosis 1 pt, 470% CA stenosis 4 pts, 50–70%
superior mesenteric artery (SMA) stenosis 1 pt and 470% SMA stenosis 3 pts).
A total score of 0–2 pts predicts an absolute risk of CMI of 0–21%, 3–6 pts a 22–
46% risk and 7 pts a risk of 479%. We aimed to validate this prediction model
in a prospective large multicenter patient cohort.
Aims & Methods: Patients suspected of CMI referred to two Dutch specialized
CMI referral centers were included consecutively from January 2014 to August
2016. After diagnostic work-up of medical history taking, mesenteric CT-angio-
graphy or MR-angiography, and a mucosal ischemia test (visible light spectro-
scopy or tonometry), all patients were discussed in a specialized CMI
multidisciplinary meeting resulting in an expert based consensus diagnosis. All
patients with a CMI consensus diagnosis were planned for treatment (revascu-
larization for occlusive disease and medication for NOMI). A definitive diagnosis
of CMI was made if successful treatment resulted in durable symptom relief. The
score chart to predict the risk of CMI was computed for each patient.
Results: A total of 246 patients were included and consensus diagnosis of CMI
was made in 108 (44%) patients, which resulted in 96 (39%) patients with a
definitive diagnosis of CMI after a positive response therapy. A definitive diag-
nosis of CMI was made in 9% of the patients with low risk, in 40% of the
patients with intermediate risk and in 94% of the patients with high risk of
CMI according to the score chart, respectively. Etiology and vascular lesions
are specified for each risk group in the table. The discriminative ability of the
score chart was strong (C-Statistic 0.87).
Low risk
(0–2 pts)n¼ 91
Intermediate
risk (3–6 pts)
n¼ 107
High risk
(7 pts)
n¼ 48
Diagnosis
Consensus diagnosis CMI 9 (9.9%) 53 (49.5%) 46 (95.8%)
Definitive diagnosis CMI 8 (8.8%) 43 (40.2%) 45 (93.8%)
Vascular lesion
No significant vascular lesion# 73 (80.2%) 20 (18.7%) 0 (0.0%)
Single vessel 17 (18.7%) 69 (64.5%) 5 (10.4%)
CA stenosis 11 (64.7%) 50 (72.5%) 5 (100.0%)
SMA stenosis 0 (0.0%) 18 (26.1%) 0 (0.0%)
IMA stenosis 6 (35.3%) 1 (1.4%) 0 (0.0%)
Multi vessel 1 (1.1%) 18 (16.8%) 43 (89.6%)
CA and SMA stenosis 0 (0.0%) 7 (38.9%) 19 (44.2%)
(continued)
Continued
Low risk
(0–2 pts)n¼ 91
Intermediate
risk (3–6 pts)
n¼ 107
High risk
(7 pts)
n¼ 48
CA and IMA stenosis 0 (0.0%) 3 (16.7%) 1 (2.3%)
SMA and IMA stenosis 0 (0.0%) 7 (38.9%) 1 (2.3%)
CA, SMA and IMA stenosis 1 (1.1%) 1 (5.5%) 22 (51.2%)
Etiology
No sign. vascular lesion#,
no ischemia
68 (74.7%) 19 (17.8%) 0 (0.0%)
Atherosclerosis 7 (7.7%) 53 (49.5%) 42 (87.5%)
MALS 8 (8.8%) 32 (29.9%) 2 (4.2%)
MALS and atherosclerosis 0 (0.0%) 0 (0.0%) 3 (6.3%)
Vasculitis 0 (0.0%) 1 (0.9%) 0 (0.0%)
NOMI 5 (5.5%) 1 (0.9%) 0 (0.0%)
NOMI and atherosclerosis 3 (3.3%) 0 (0.0%) 1 (2.1%)
NOMI and MALS 0 (0.0%) 1 (0.9%) 0 (0.0%)
Conclusion: The score chart for CMI based on patient characteristics and anat-
omy is a reliable tool to discriminate the risk of CMI and useful for clinical
decision-making, for example to adopt a wait-and-see policy in patients with a
low risk and immediate vascular intervention in patients with high risk of CMI.
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Introduction: Isolated stenosis of the celiac artery (CA) or the superior mesenteric
artery (SMA) is frequently detected in patients with abdominal complaints. These
patients may suffer from chronic mesenteric ischemia (CMI) causing nonspecific
abdominal complaints as postprandial pain, nausea or diarrhea. However, the
existence of single artery mesenteric ischemia is a topic of continuous clinical
debate and reports on the effectiveness of single mesenteric artery revasculariza-
tion are scarce. We evaluated the long-term clinical success rates for single CA or
SMA revascularization in patients with gastrointestinal symptoms and confirmed
mucosal ischemia.
Aims & Methods: Data were collected from all 97 consecutive patients with
gastrointestinal symptoms and a single mesenteric artery stenosis referred to
the outpatient clinic of our tertiary care institution for analysis of CMI between
January 2006 and October 2010. All patients underwent a standardized diagnos-
tic work-up for CMI at baseline consisting of medical history taking and physical
examination, imaging of the gastrointestinal arteries with either CT- or MR-
angiography and/or conventional catheter angiography, and a functional test
for detecting mucosal ischemia using either tonometry or visible light spectro-
scopy. All cases were discussed in a multidisciplinary meeting attended by a
vascular surgeon, interventional radiologist and gastroenterologist, all specia-
lized in CMI, leading to an expert based consensus diagnosis. Patients with
consensus diagnosis of CMI underwent surgical or endovascular revasculariza-
tion. The primary outcome was clinical response to revascularization, defined as
relief of presenting symptoms as experienced by the patient.
Results: Consensus diagnosis of CMI was obtained in 62/97 patients and all
consensus patients were revascularized. Isolated CA stenosis was present in 55/
62 patients (89%) (31 vascular disease; 24 median arcuate ligament syndrome,
MALS) and isolated atherosclerotic SMA stenosis in 7 patients. After a mean
follow-up of 5.5 3.0 years, 42/62 patients (68%) experienced sustained symp-
tom relief. Responders to revascularization had a BMI increase during follow-up
in contrast to the non-responders (þ0.43 2.5 versus 1.06 2.4 kg/m2,
p¼ 0.033). Response to revascularization was not related to lesion localization
(CA 67% versus SMA 71%, p¼ 0.825) or lesion etiology (MALS 63% versus
vascular disease 71%, p¼ 0.483). See table.
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CA¼ celiac artery; SMA¼ superior mesenteric artery; MALS¼median arcuate
ligament syndrome
Symptom relief No symptom relief
All patients 42/62 (68%) 20/62 (32%)
Vascular lesion
CA stenosis 37/55 (67%) 18/55 (33%)
SMA stenosis 5/7 (71%) 2/7 (29%)
Etiology
MALS 15/24 (63%) 9/24 (38%)
Vascular disease 27/38 (71%) 11/38 (29%)
Conclusion: Revascularization of the CA or SMA provides long-term symptom
relief in 68% of patients with chronic gastrointestinal symptoms and confirmed
mucosal ischemia due to single mesenteric artery stenosis. This provides the
opportunity to help patients with otherwise unexplained, refractory abdominal
complaints.
Disclosure of Interest: All authors have declared no conflicts of interest.
P1942 UNDERUTILIZATION OF ENDOSCOPIC ARGON PLASMA
COAGULATION FOR TREATMENT OF BLEEDING
GASTROINTESTINAL ANGIODYSPLASIAS: AN INTERNATIONAL
MULTICENTRE COHORT STUDY
K. Grooteman1, M. Matheeuwsen1, G. Holleran2, E. Van Geenen1,
D. Mcnamara2, J.P.h. Drenth1
1Gastroenterology And Hepatology, Radboudumc, Netherlands, Nijmegen/
Netherlands
2Department of Clinical Medicine, Trinity College, Dublin/Ireland
Contact E-mail Address: karinagrooteman@gmail.com
Introduction: Endoscopic argon plasma coagulation (APC) is the first-line treat-
ment in patients with iron deficiency anaemia or overt bleeding resulting from
gastrointestinal angiodysplasias. In the minority of patients active bleeding
angiodysplasias are seen during endoscopy, but in contrast non-bleeding angio-
dysplasias can be an incidental finding. This can make the decision whether to
treat endoscopic detected angiodysplasias with APC difficult.
Aims & Methods: The aim of this study is to investigate the need for repeat
endoscopies with APC in patients with angiodysplasias who were left untreated
during the index endoscopy performed for iron deficiency anaemia or overt
bleeding. We initiated an international, multicentre cohort study to collect clin-
ical, laboratory and endoscopic data from angiodysplasia patients. Cases were
identified through a systematic search in endoscopy reports from 2010–2015 with
follow-up until July 2016. Inclusion criteria was endoscopic detection of angio-
dysplasia in the context of overt bleeding or iron deficiency anaemia. Exclusion
criteria were other vascular anomalies and angiodysplasias as incidental finding.
The primary outcome was repeat endoscopy with APC.
Results: A total of 197 patients with proven angiodysplasia as cause for anaemia
or bleeding were included (mean age¼ 68 years; 58% male). Median follow-up
was 37 months (range 18–57). In 52% of the cases (n¼ 103) APC treatment for
bleeding angiodysplasia(s) was performed at the index endoscopy. Repeat endo-
scopy with APC was necessary in 17 patients (18%) in whom angiodysplasias
were detected but left untreated during the index endoscopy. Median time
between index and repeat endoscopy was 21 weeks. A total of 48 patients
(51%) who received a purely diagnostic index endoscopy were in need of other
treatment modalities (e.g. iron supplementation, blood transfusion, stop antic-
oagulants). Anaemia and/or overt bleeding resolved spontaneously in 24 patients
(26%).
Conclusion: A substantial proportion of patients with clinical symptomatic angio-
dysplasia bleeding do not receive APC at the index endoscopy and continue to be
dependent on iron supplementation, blood transfusion or undergo repeat endo-
scopy with APC.
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Introduction: Digestive manifestations in systemic diseases including vasculitis
and granulomatosis is broad and can affect any segment of the digestive tract
and related organs. The clinical symptoms are not specific and it can be challen-
ging for diagnosis. The other difficulty remains the interference of digestive side
effects of medication used.
Aims & Methods: We aimed to review various digestive manifestations of sys-
temic diseases. This was a retrospective study from Feb 2009 to Sep 2016 in
internal medicine and gastroenterology departments. The exclusion criteria was
incomplete data considering the diagnosis of the systemic disease.
Results: patients were included, sex ratio 0.38 (101F/39 M), mean age at inclu-
sion was 40 years old [13,79]. The following chart summarize the% of digestive
manifestations by disease:
Systemic disease
Number of
cases
Digestive
manifestations (%)
Systemic Lupus erythematosus 49 10.36%
Systemic sclerosis 27 8.33%
Behcet’s disease 27 4.39%
Sjogren syndrome 14 7.37%
Wegener’s granulomatosis 2 21.60%
Antiphospholipid Anti body Syndrome 3 22.58%
Amyloidosis 1 45.16%
Churg-Strauss syndrome 2 20.96%
Dermatomyositis 2 25.80%
Microscopic Polyangiitis 1 0%
Horton’s disease 2 8.06%
Takayasu arteritis 3 3.22%
Cryoglobulinaemic vasculitis 2 0%
Henoch–Schönlein purpura 3 30.10%
Leucocytoclasic vasculatis 2 12.9%
Patients symptoms and clinical findings were: Abdominal pain in 32 cases
(22.9%),Nausea and vomiting in 7 cases (5%), stool modification 15 cases
(10.7%), jaundice in 4 cases (2.9%),dysphagia in cases (7.1%), hepatomegaly
in 4 cases (2.9%), splenomegaly in 8 cases (5.7%), ascitis in 13 cases (9.3%),
digestive bleeding 17 cases (12.1%). Laboratory findings: elevated liver enzymes
18 cases (15.9%), alkaline phosphatase elevation 15 cases (19.2%). Radiological
findings: 17 ascitis (14.4%), 12 digestive thickening (10.16%), 6 hepatomegaly
(5.08%), 14 splenomegaly (11.86%), 2 portal cavernoma (1.6%), 3 portal throm-
bosis (2.5%), 4 esophageal distension (3.4%), acalculous cholecystitis in 2 cases
(1.6%), 2 portal hypertension (1.6%), steatosis in 3 cases (2.5%), 3 hepatic
angioma (2.5%), acute pancreatitis in 2 cases (1.6%), 2 mesenteric ischemia
(1.6%), 1 budd chiari (0.8%), 1 hepatic carcinoma (1.8%). Upper gastrointestinal
Endoscopy findings: hiatus hernia in 3 cases (8.6%), esophagitis in 11 cases
(31.4%), esophageal varices in 2 cases (5.7%), Gastritis in 37 cases, duodenitis
in cases 16 cases, ulcers in 3 cases (8.6%), 4 celiac disease (11.42%). Lower GI
endoscopy: Crohn’s desease in 1 case (8.3%), ulcerative colitis in 1case (8.3%), 1
hyperplastic polyps (8.3%), 2 colitis (16.6%). Eosophagal manometry: motility
disorder in 4 cases. The most used drugs were immunosuppresive drugs, steroids
and hydrochloroquine, all causing digestive side effects mainly abdominal pain.
Conclusion: The digestive involvement is around 10% of cases in the most repre-
sented systemic diseases, the main symptom is abdominal pain probably related
to medication, endoscopic modifications are mainly non specific but we found
some association with celiac disease and IBD. Liver involvement was noticed in
15% of cases.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: An association between obesity and vitamin D deficiency has been
reported in several studies. This may be explained, among other things by the
sequestration of the fat-soluble vitamin D in the adipose tissue. Bariatric surgery,
including Roux-en-Y gastric bypass (RYGB) is an effective treatment for more
extreme cases of obesity, promoting significant weight loss and consequently
reduction in some obesity-related health problems. However, the problem of
vitamin D deficiency doesn’t seem to be solved after RYGB and can even be
exacerbated by the changes in digestion and absorption of this nutrient after the
surgery.
Aims & Methods: The aim of this study was to analyze the prevalence of vitamin
D deficiency (VDD) and vitamin D insufficiency (VDI) in a population of obese
patients, before and after being submitted to RYGB. We included patients
patients selected to undergo RYGB for obesity. We measured anthropometric
values and the levels of 25-hydroxy-vitamin D (25 [OH]D) before and 1 year after
the procedure. VDD was defined as serum 25(OH) D 520 ng/mL and VDI as
serum 25(OH)D concentrations between 20–30 ng/mL. Levels of 25(OH) D
430 ng/mL were considered normal.
Results: We included 39 patients. Thirty-two were females (82.1%) and the mean
age was 43.6 11.3 years. The mean BMI before surgery was 41.6 kg/m2. There
was a significant decrease in BMI after surgery and, on average, the mean total
body weight loss was 34% and the mean excess BMI loss was 90%. Before
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bariatric surgery, 52.3% of patients had VDD and 36.8% had VDI. After sur-
gery, the number of VDD increased to 71.1% (p¼ 0.079). The mean levels of
25(OH) D decreased significantly from 19.8 ng/mL before surgery to 16.6 ng/mL
after surgery (p5 0.05). There was no correlation between the amount of weight
loss and the changes in the levels of 25(OH)D in our study.
Conclusion: There is a high prevalence of vitamin D deficiency in obese patients
eligible for bariatric surgery. The level of deficiency tends to increase after
RYGB. This population of patients should, therefore, be offered an adequate
level of vitamin D supplementation, especially after the procedure.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Bariatric surgery is established as an excellent therapy for obesity.
However, lower degrees of overweight without surgical indication also impact on
patients’ health and quality of life, and the intragastric balloon(IGB) may be a
treatment option.
Aims & Methods: We aimed to assess the efficacy of excess weight treatment with
an IGB in patients with overweight and grade I obesity at EndogastroRio Clinic.
A total of 717 patients were analyzed. A liquid filled IGB was used. The patients
had initial body mass index (BMI) between 27 and 34.9 kg/m2. The level of
significance was set at p5 0.05.
Results: Results 615 patients were women. 131 patients had overweight and 586
had grade I obesity. Mean age was 37.97 years (17–75). Weight loss results and
treatment success rates are shown on table 1. Percent excess weight loss (%EWL)
was higher in overweight group (p5 0.0001) and percent total body weight loss
(%TBWL) was higher in the grade I obesity group (p¼ 0.0009). 96 (73.28%)
overweight patients and 132 (22.52%) grade I obesity patients reached a normal
BMI(525 kg/m2).
Total group
(n¼ 717)
Overweight
(n¼ 131)
Grade I Obesity
(n¼ 586)
Body weight(kg)
Baseline 88.55 10.14 78.90 6.56 90.67 9.56
Final 73.20 10.78 66.73 8.13 74.62 10.73
Reduction 15.35 6.49 12.16 4.76 16.05 6.53
%TBWL 17.36 7.08 15.51 6.11 17.76 7.11
BMI(kg/m2)
Baseline 32.05 2.04 28.73 0.94 32.78 1.38
Final 26.46 2.43 24.26 1.85 26.95 2.51
Reduction 5.59 2.36 4.46 1.86 5.83 2.37
Excess weight (kg)
Baseline 19.77 6.04 10.52 2.7 21.81 4.45
Final 4.42 7.44 1.65 5.09 5.77 2.37
%EWL 83.97 41.89 122.77 57.89 75.36 31.33
%TBWL
510% 106(14.78%) 22(15.27%) 83(14.16%)
10% 611(85.22%) 109(83.21%) 503(85.84%)
%EWL(n;%)
525% 32(4.46%) 2(1.52%) 30(5.12%)
25% 685(95.54%) 129(98.48%) 556(94.88%)
BMI(n;%)
525 kg/m2 213(29.71%) 96 (73.28%) 132(22.52%)
*p5 0.0001 for all comparisons between values at baseline and at the end of the
study. IGB¼ intragastric balloon; BMI¼body mass index; TBWL¼ total body
weight loss; EWL¼ excess weight loss. Success rates (criteria: 10%TBWL or
25%EWL)
Conclusion: Endoscopic treatment of obesity with an IGB shows to be an excel-
lent therapeutic option to non elective patients for bariatric surgery according to
BMI criterion
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Introduction: Intragastric balloons (IGB) are already used worldwide in the treat-
ment of overweight and obesity, with established success. The Spatz3 adjusta-
ble balloon brings the possibility of balloon volume control during all the
treatment, possibly reducing the risk of early removals due to intolerance and
greater weight loss when compared to traditional IGBs.
Aims & Methods: We aimed to analyze the initial 25 months results regarding
weight loss and complications with Spatz3 adjustable intragastric balloon in
Brazil. In this retrospective longitudinal study were included patients submitted
to Spatz3 adjustable IGB treatment between October 2014 to April 2017 in four
private clinics in Brazil. The IGB Spatz3 was filled with a standard volume of
600ml that was downward or upward adjusted when necessary. The patients
presented a minimum body mass index (BMI) of 27 kg/m2. Were analyzed the
complications of Spatz3 treatment and BMI reduction, percent total body
weight loss (%TBWL) and percent excess weight loss (%EWL). Data were ana-
lyzed using descriptive statistic and the Student t test. The level of significance
was set at p5 0.05.
Results: 422 patients underwent implant Spatz3 balloon in the period. The
complications (14.28%) at the present study were: early balloon removal
(6.89%), gastric ulcer (3.94%), spontaneous deflation (1.48%), gas production
inside the balloon (0.98%), gastric perforation (0.23%) and Malory Weiss
Syndrome (0.23%). There was no death at the present study. Twenty-eight
patients underwent downward adjustment due to intolerance (mean volume
reduction: 162.86mL) and all of then kept in the treatment (no early removals).
180 patients have completed the treatment (minimum 9 months of gastric balloon
stay). The BMI decreased from 37.69 to 31.51 kg/m2 (p5 0.0001), body weight
decreased from 107.67 to 90.16 kg (p5 0.0001) and excess weight dimished from
36.79 to 19.27 kg (p5 0.0001). Eighty-six patients underwent upward adjust-
ment. The adjustment resulted in a further mean weight loss of 4.2 kg (9 to
20 kg), the range of upward volume was 281.73 66.58ml (100–420ml) and the
moment of the procedure was 7.06 1.64 months. The group of patients that did
the upward adjustment dońt have a higher %TBWL, %EWL or a a higher BMI
reduction when compared to the group that did not (p¼ 0.4413, p¼ 0.9245,
p¼ 0.2729, respectively).
Total
(n¼ 180)
With adjustment
(n¼ 86)
Without adjustment
(n¼ 94)
Body weight (kg)
Baseline 107.67 23.65 108.66 25.12 106.76 22.3
Final 90.16 22.53 90.41 23.39 89.94 21.83
Reduction 17.51 11.67 18.26 10.99 16.83 12.28
% TBWL 16.22 9.74 16.81 9.09 15.68 10.33
BMI (kg/m2)
Baseline 37.69 6.16 38.26 6.56 37.16 5.77
Final 31.51 6.11 31.55 6.11 31.29 6.14
Reduction 6.18 4.07 6.51 3.91 5.87 4.21
Excess weight (kg)
Baseline 36.79 19.07 38.15 20.15 35.58 18.04
Final 21.79 19.33 19.89 18.45 23.25 19.39
% EWL 56.68 40.12 56.98 34.18 56.41 42.86
%TBWL
510% 52 (28.89%) 19 (22.09%) 33 (35.11%)
10% 128 (71.11%) 67 (77.91%) 61 (64.89%)
% EWL (n;%)
525% 40 (22.22%) 16 (18.6%) 24 (25.53%)
25% 140 (77.78%) 70 81.4%) 70 (74.47%)
BMI (n;%)
23–28 kg/m2 21 (11.67%) 10 (11.63%) 11 (11.7%)
Conclusion: This study shows that Spatz3 IGB treatment is an effective proce-
dure for weight reduction, without mortality but with higher morbidity rates
when compared to tradition IGBs. Even more, the downward adjustment
shows to be effective in preventing the early balloon removal, although the
upward adjustment does not show to be able in providing a greater weight loss.
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from FRACTYL LABS, GI WINDOWS, APOLLO ENDO SURGERY, GI
DYNAMICS, ETHICON ENDO SURGERY, not related to the present study.
All other authors have declared no conflicts of interest.
A830 United European Gastroenterology Journal 5(5S)
P1948 VOMITING FREQUENCY AFTER INTRAGASTRIC
BALLOON PLACEMENT AND INTRAVENOUS HYDRATION
REQUIREMENT
S. Barrichello
1, R.J.F. Fernandez2, E. Usuy3, A. F. Teixeira1, M. Galvao Neto4,
T. F. Souza5, E. Grecco5
1Endoscopy, FMABC, São paulo/Brazil
2Dept. Of Digestive Endoscopy, Endogastro Med Service, Rio de Janeiro/Brazil
3Dept. Of Gastroenterology, Usuy Clinic, Florianopolis/Brazil
4Bariatric Endoscopy, Gastro Obeso Center, São Paulo/Brazil
5Bariatric Endoscopy, Faculdade de Medicina do ABC - Hospital Mário Covas,
São Paulo/Brazil
Contact E-mail Address: sergio.barrichello@healthme.com.br
Introduction: The endoscopic treatment of obesity and over weight with intragas-
tric balloon (IGB), is a safe and effective option. Nausea and Vomiting are the
most commons side effects after IGB implant.
According to A. Scudero Sanches, 71.1% of patients experience nause and 57.9%
had vomiting. Iñaki Imaz et al, in a systematic review with more than 3000
patients showed that nausea and vomiting are the fifth leading cause of early
acessory explantation. The reported symptoms are more common in first 3 days
post implant.
Regarded as one of the major causes of gastric balloon early removal, is impor-
tant to evaluate in daily practice the frequency of patients requiring intravenous
hydration to quell nausea and vomiting during the first day os the accessory use.
Aims & Methods: Evaluation of Frequency of vomiting and number of patients
requiring intravenous hydration (HEV) after gastric balloon placement. This was
a retrospective analysis of medical records of 340 obese and over weight patients
treated with intragastric balloon, between November 2015 to December 2016 in
the bariatric endoscopy division of the Mario Covas Hospital in São Paulo. The
implant was performed by 3 endoscopists with experience in bariatric endoscopy,
all procedure were performed under moderate sedation and anesthetist’s care.
The patients used omeprazole 40mg once a day, and antiemetic drugs (dimenhy-
drinate) 8/8 hours the first 5 days as well. The data recorded were about the
numbers and frequency of vomiting and if there was need for intravenous hydra-
tion during the first three days after intragastric balloon implant
Results: There were 340 patients treated with intragastric balloon betwen 2015
and 2016.
The present study showed 74.41% vomiting until the third day after placement of
the BIG, and it is in accordance with literature. Those 252 patients who had
vomiting, 67.58% presents frequence of 0 to 5 times per day and 32.42% of the
group 5 to 10 times per day. Approximately 9.48% of the patients required
intravenous hydration and there were no early explant.
Conclusion: Gastric balloon causes vomiting in the early days post implant in
74.41% of patients and cause dehydration requiring Intravenous fluid therapy in
7.06% of all patients who underwent implantation of gastric balloon (IGB).
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Introduction: While monitoring weight loss in patients undergoing very low cal-
orie diets (VLCD), regardless of which method used, mostly patients experience
significant weight reduction, but also a significant fat-free mass (FFM) loss. The
fat-free mass loss is associated a decrease in basal metabolic rates, a fact con-
firmed in patients undergoing treatment with intragastric balloon (IGB).
Aims & Methods: Retrospective study was conducted with analysis of medical
records of obese patients treated with intragastric balloon betwem 2013 to 2015
in a supplementary health service. Patients were evaluated at three different
moments: before intragastric balloon placement, 45 days post implant and
after BIG removal (30 days).
Results: We evaluated 29 patients, mean age of 40.07 years (10.35 years), pre-
treatment weight 97.44 kg (16.70 kg), pre BMI 35.51 kg/m2 (4.3 kg/m2) and a
bioimpedance showing a % of fat-free mass (FFM) of 63.15 and 36.84% fat mass
(FM) with a metabolic pretreatment rate of 1893.24 (337.21). Forty five days
after gastric balloon placement, bioimpedance avaluation showed 64.9% of Fat-
Free Mass, 35.1% of Fat Mass and metabolic rate in 1731, associated with a
weight loss of 9.46 kg or 27.37% overweight In the third assessment, there were a
significant improvement in BMI, weight and metabolic rate with p5 0.05. The
final metabolic rate was 1694.67, FFM was 69.7% with 30.3% of FM, a reduc-
tion about 17% of the initial weight with the decrease of 44.29% overweight.
Conclusion: Intragastric balloon was effective as minimally invasive treatment of
obesity and over weight.
Patients’ body mass distribution had a clear improvement, with a significant
increase in the percentage of Fat-Free Mass. A significant reduction of the
basal metabolic rate of 1893.24 to 1694.67 was noted. Endoscopic approach
with gastric balloon provides a significant weight loss and helps patients acquir-
ing healthy habits
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Introduction: Endoscopic methods, especially the intragastric balloon (IGB), have
been shown to be effective for the treatment of excess weight.
Aims & Methods: We aimed to assess the efficacy and complications of excess
weight treatment with a non adjustable IGB.
A liquid-filled IGB with a volume of 600 to 700ml was used. The patients had a
minimum initial body mass index (BMI) of 27 kg/m2 and were followed up by a
multidisciplinary team consisting of a nutritionist, a doctor and a psychologist.
For statistical analysis, the patients were divided into groups according to sex
and degree of excess weight (overweight and grade I, II and III obesity). Data
were analyzed using descriptive statistical methods, the Student t-test, and ana-
lysis of variance followed by the Tukey post-test. The level of significance was set
at p5 0.05.
Results: A total of 5874 patients were analyzed. The incidence of complications
was 7.32% (n¼ 430), as listed below: 299 (5.09%) early IGB removal, 58 (0.98%)
absence of weight loss or weight gain. The incidence of gas production inside the
balloon was 0.20% (n¼ 12) and the incidence of leakage was 0.54% (n¼ 32);
pregnancy was 0.32% (n¼ 19); gastric perforation was 0.06% (n¼ 4); upper
digestive bleeding was 0.05% (n¼ 3); Wernick Korsakoff syndrome due to exces-
sive vomiting was 0.01% (n¼ 1), pancreatitis and esophagus perforation was
0.01% each (n¼ 1). Of the 5444 remaining patients, 4081 (74.9%) were women
and 1363 (25.1%) were men. Mean age was 38.38 years. The patients showed a
significant weight loss, with a significantly lower final BMI (mean:
30.08 5.06 kg/m2) than the initial BMI (mean: 36.94 5.67 kg/m2)
(p5 0.0001). Mean BMI reduction was 6.85 3.06 kg/m2 (range: 0.25–29.79).
Mean percent total body weight loss (TBWL) was 18.42 7.25% and mean
percent excess weight loss (EWL) was 65.66 36.24% (range 3.99–336.14). The
weight loss in kilograms was 19.13 8.86. The treatment success rate
(%EWL4 25) was 93.0%, as follow: overweight was 99.0%, grade I obesity
was 95.83%, grade II obesity 93.65% and grade III obesity was 86.09%.
Percent EWL was higher in the overweight group (OVW) (131.54%EWL), fol-
lowed by grade I obesity (G1O)(76.67%), grade II obesity (G2O) (56.01%) and
grade III obesity (G3O) (45.45%) sequentially (p5 0.0001). Percent EWL was
also higher in women (69.71%EWL) than in men (53.39%EWL) (p5 0.0001).
Results are better shown in table 01.
n¼ 5444
BMI(Kg/m2)
initial 36.94 5.67
final* 30.08 5.06
reduction 6.85 3.06
Body weight
reduction(Kg) 19.13 8.86
%TBWL 18.42 7.25
Excess weight
%EWL (total group) 65.66 36.24
%EWL (OVW) 131.54*
%EWL (G1O) 76.67*
%EWL (G2O) 56.01*
%EWL (G3O) 45.45*
Treatment Success Rate (%EWL4 25)
total group 93.0%
OVW 99.0%
G1O 95.83%
G2O 93.65%
G3O 86.09%
*p5 0.0001 for all comparisons between values at baseline and at the end of the
study. body mass index(BMI); total body weight loss(TBWL); excess weight
loss(EWL); overweight (OVW); grade I obesity (G1O); grade II obesity (G2O);
grade III obesity (G3O)
Conclusion: Endoscopic treatment of excess weight with an IGB has been estab-
lished as an excellent therapeutic option.
United European Gastroenterology Journal 5(5S) A831
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Introduction: Many factors contribute to the development of irritable bowel
syndrome (IBS) including the altered visceral perception, intestinal low-grade
inflammation and psychosocial factors.Recent research has revealed a relation-
ship between intake of FODMAPs (Fermentable Oligosaccharides,
Disaccharides, Monosaccharides, and Polyols) and abdominal complaints. A
diet low in FODMAPs can reduce symptoms in patients with IBS but mechan-
isms were poorly understood.
Aims & Methods: We aim to explore the role of FODMAPs in triggering IBS
symptoms by investigating visceral sensitivity, intestinal inflammation and short
chain fatty acid (SCFA) in stress induced IBS mice model. Fructo-oligosacchar-
ide (FOS) as one of the most frequently exposed FODMAPs in daily life was
used in this study. Mice were subjected to water avoidance stress (WAS condi-
tion; 1 h/day for 10 days) or sham stress (basal condition; 1 h/day for 10 days)
with an oral gavage of saline or saline solution containing FOS (8 g/kg) for 2
weeks. Then visceral sensitivity was measured by abdominal withdrawal reflex
(AWR) in response to colorectal distension (CRD) and histologic analyses were
used to evaluate mucosal inflammation. Immunohistochemistry, reverse tran-
scription, and gas chromatography were used to estimate mucosal mast cell,
levels of cytokines (IL-6, IL-23, TNF-, IL-10, IL-1b) and SCFA, respectively.
Results: Stress induced visceral hyperalgesia and low-grade inflammation in
WAS mice as a model of IBS. In WAS condition, increased visceral sensitivity
and mucosal mast cell (12.3 2.61 vs. 8.33 3.55, P5 0.01) were observed in
FOS-administered mice compared with saline-administered mice. In WAS con-
dition, cytokine expression were mediated by FOS with increased IL-23
(3.17 2.11-fold, P5 0.05) in ileum and IL-1b (2.45 1.55-fold, P5 0.05) in
colon compared with saline. In addition, the average concentrations of acetic
(2.48 0.62 vs. 1.04 0.10, P5 0.01), propionic (0.48 0.09 vs. 0.33 0.0,
P5 0.01), butyric (0.27 0.09 vs. 0.19 0.003, P5 0.05) and total SCFA
(3.61 0.89 vs. 1.79 0.17, P5 0.01) significantly increased in FOS-adminis-
tered mice compared with saline-administered mice in WAS condition. In basal
condition, no difference of visceral sensitivity, intestinal inflammation and SCFA
were observed between mice treated with FOS or saline.
Conclusion: Oral gavage of FOS leads to both an increase in visceral sensitivity
and gut inflammation in stress induced IBS mice. These effects are link with the
production of SCFA in the gut which involved in the regulation of sensitivity and
intestinal immune activation. These findings support the hypothesis that visceral
hypersensitivity and intestinal inflammation aggravated by certain FODMAPs
may be responsible for IBS symptom generation, and indicate an alternative
mechanism of the efficacy of the low-FODMAP diet for IBS patients.
Disclosure of Interest: All authors have declared no conflicts of interest.
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Introduction: Several formulations consisting of live lactic acid bacteria, including
bifidobacteria, are marketed as probiotic products. However, these products are
often poorly defined and insight into their mode of action is lacking. This ham-
pers further application in treating diseases, limits comparative studies, and pre-
vents predicting their efficacy. We have previously addressed this by providing
genomic and functional characterization of single commercial strains
(Kainkainen et al 2009, Douillard et al 2013, Tytgat et al 2016). The multispecies
product VSL#3 is marketed globally for treating colitis ulcerosa, pouchitis, and
irritable bowel syndrome. To provide a rational basis for understanding the
function of VSL#3 and generate a baseline for future studies, the genomes of
all 8 strains that make up this multispecies product were determined and used to
predict their function. The strains were provided by the facility which is currently
producing both the single strains and the blend mix (CSL-SACCO System, Zelo
Buon Persico - Lodi–ITALY).
Aims & Methods: The individual strains of multispecies product VSL#3 were
cultured on MRS-based media and DNA was extracted using established meth-
ods. The DNA was subject to paired-end Illumina sequencing using a HiSeq2000
platform, assembled and annotated as previously described (Douillard et al
2013).
Results: The next generation sequencing provided high quality genomes of all 8
strains that are components of the multispecies product VSL#3. Detailed phylo-
genetic and genomic analysis confirmed the species composition to be as indi-
cated in the VSL#3 product specification and showed the 8 strains of this
multispecies product to belong the species Streptococcus thermophilus,
Lactobacillus acidophilus, Lactobacillus (para)casei, Lactobacillus plantarum,
Lactobacillus helveticus, Bifidobacterium breve and B. animalis subsp. lactis
(this species included two strains). The species L. paracasei and L. casei are
highly related and in need for further official taxonomic resolution. The anno-
tated genes of the assembled genomes were used to identify genes involved in
potential probiotic functions. Full sets of genes for the production of tight adher-
ence pili were observed in the Bifidobacterium spp. and are known to produce
pseudopilins that we recently identified to mediate microbe-host crosstalk, pro-
mote intestinal integrity, and influence host cell development (O’Connell
Motherway et al 2011). Moreover, a series of signaling proteins were identified
in the genomes of the Lactobacillus spp., including surface layer proteins and
sortase-dependent pili proteins that we showed to interact with the mucosal
surfaces and dendritic cells (Konstantinov et al 2008; Kankainen et al 2008;
Tygat et al 2016).
Conclusion: The genomic analysis of the VSL#3 strains confirmed the product
specifications, defined the baseline genetic coding capacity, and predicted a
number of probiotic mechanisms that could explain the efficacy of this multi-
species product.
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Introduction: Disease prevention and high public awareness are fundamental to
reduce morbidity, mortality and health-related costs. Extensive research led to
identification of causes of gastrointestinal (GI) diseases, nevertheless it is still
difficult to get population involved. The goals of our pilot campaign are: (a) to
raise awareness about GI diseases, risk factors, signs, symptoms, in order to
convince people to change behavior and to prompt them with concerns to visit
doctors as early as possible; (b) to facilitate communication between healthcare
providers and population; (c) to determine the knowledge of health personnel
about the appropriate diagnostic investigations. Any information we can share
may also benefit patients and their families, in recognition of the many people
who suffer with the pain and discomfort caused by GI disorders.
Aims & Methods: We organized population-based events, out of health facilities,
during which: (a) giant inflatable anatomical models of GI organs that can be
visited inside, were installed; (b) educational panels and brochures were set and
explained both inside and outside the models; (c) videos illustrating endoscopic
exams and histopathology examinations were projected and discussed; (d) clinical
cases, also mimicking patient encounter, were simulated.
Results: We started an innovative strategy focused on the keywords: multidisci-
plinary team, scientific rigor but simple words, people attraction, curiosity indu-
cing communication, in Parma and neighbouring Cities. Specialists in
Gastroenterology, Anatomic Pathology, Radiology, Surgery, Biochemistry,
Nutrition, together with pre- and post-graduate Students, discussed various
aspects of gastrointestinal diseases. Selected people were examined by ultrasono-
graphy. Municipality and civil society were also involved to ensure organiza-
tional efficiency. The most discussed topics regarded dyspepsia, gastritis,
helicobacter pylori infection, gastroesophageal reflux disease, alcohol abuse, cir-
rhosis, hepatitis, irritable bowel syndrome, intestinal polyp and polyposis, GI
cancer, food allergy and intolerance, optimal nutrition in health and disease.
The event performed in the main square of Parma lasted two full consecutive
days and was attended by about 3,000 people, most of which also filled a ques-
tionnaire. A total of 120 ultrasound examinations were performed. In neighbour-
ing Cities the events were organized for one day; as a consequence, the number of
participants was lower in proportion, but very satisfactory.
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Conclusion: The events were educational and enjoyable for all age groups. The
interactive approach and the environment out of health-care centres facilitated
population to feel comfortable and eager to learn, as well as clinical cases simula-
tion provided a valuable entertaining experience. This strategy of raising public
awareness of GI diseases seems promising, we are refining the model for a
national campaign.
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Introduction: Amino acids are essential metabolites which play a role as protein
constituents. Moreover, amino acids and their metabolites feature in regulation
of anabolic and catabolic metabolism, detoxification processes, and act as neu-
rotransmitters. Concentration of circulating amino acids reflects about dietary
protein intake and can be an indicative of malnutrition. Changes in the amino
acid homeostasis are observed in coeliac disease (CD) [1] due to malabsorption
caused by enteropathy but also because of the treatment with gluten-free diet
(GFD) shown to be low in the important nutrients.
Aims & Methods: A randomized, placebo-controlled interventional trial was
designed to assess the influence of an oligofructose-enriched inulin (OEI) as a
supplement of GFD on plasma profile and urine excretion of amino acids in CD
children strictly following GFD at least 1 year. We randomized 34 children
diagnosed with CD into a group receiving 10 g of OEI daily and a placebo
(maltodextrin) group during a 12-week nutritional intervention. Amino acid
profiles in urine and plasma was analysed via EZ:FaastTM derivatisation
method followed by gas chromatography/mass spectrometry detection.
Results: At the baseline and after supplementation, 22 and 27 amino acids were
identified in plasma and urine, respectively in both groups of children.
Significantly higher levels (p5 0.05) of alanine, serine, asparagine, glutamine,
threonine, phenylalanine, lysine, histidine, -aminoadipic acid, -aminopimelic
acid, hydroxylysine and cystine were determined in urine of OEI group after
intervention as compared to the baseline and placebo group. The analysis of
amino acid profiles in plasma samples showed a significant increase (p5 0.05)
of majority of amino acids in both OEI and placebo groups after intervention.
However, the concentrations of glutamine and glutamic acid were significantly
higher (p5 0.05) in the OEI supplemented group.
Conclusion: Our study showed that supplementation of GFD with OEI impacts
the amino acid homeostasis in CD children. OEI in GFD increased a total
concentration of amino acids in both urine and plasma. Higher excretion of
amino acids in urine accompanied with increased amino acid content in
plasma may indicate the improved absorption or/and stimulated de novo synth-
esis of proteins. Increase in the concentration of glutamine can stimulate recovery
of the intestinal mucosa by itself or by the involvement in the synthesis of citrul-
line known as negatively correlated with intestinal mucosal damage [1], therefore
we can suspect that OEI added to GFD can help in restoring of the intestinal
barrier integrity.
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Introduction: The quality of life and nutritional management after gastrectomy
are major issues for gastric cancer patients, as is oncological surveillance. Weight
loss usually follows gastric resection, with reported losses ranging from 10% to
30% of the preoperative weight.This loss has been attributed to inadequate oral
intake, malabsorption, rapid intestinal transit time, and bacterial overgrowth.
Timely, appropriate nutritional intervention can minimize diet intolerance,
weight loss, and micronutrient deficiencies that often follow surgery.
Aims & Methods: This study investigated long-term trends in hematological and
nutritional parameters after gastrectomy for gastric cancer and evaluated the
influence of the reconstruction type on these trends. The medical records of
558 patients who underwent curative gastrectomy with standard lymph node
dissection for stage I gastric cancer between January 2006 and December 2013
were reviewed. The hematological and nutritional parameters evaluated included
hemoglobin, ferritin, vitamin B12, total protein, albumin, total cholesterol, tri-
glyceride, and calcium. The patients were followed up for 6 months postopera-
tively and then annually until death, cancer recurrence, or follow-up loss.
Results: In the long term, ferritin and triglyceride gradually decreased after gas-
trectomy, while the other parameters decreased slightly or were stable. In the
comparisons according to reconstruction type, the Roux-en-Y group had the
lowest levels of hemoglobin, ferritin, vitamin B12, total protein, albumin, and
total cholesterol beginning 6 months postoperatively compared with the Billroth
I and II groups. However, only ferritin and vitamin B12 had significant differ-
ences in the 5-year cumulative incidences of deficiency according to the recon-
struction type, whereas albumin, triglyceride, total cholesterol and calcium did
not.
Conclusion: Although malabsorption and malnutrition are common in patients
after a gastrectomy, most nutritional parameters were stable or decreased slightly
in the long-term and were not markedly influenced by the reconstruction type or
extent of gastrectomy. Therefore, for more accurate nutritional assessment after
gastrectomy, multidirectional monitoring should be considered rather than
simply measuring biochemical parameters.
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Introduction: Celiac disease is an autoimune enteropathy inducted by the inges-
tion of gluten. the classical form has become a minority. Currently, the most
frequent forms of presentation are extradigestive with various manifestations,
among others, reproductive disorders. The aim of our study is to assess the
frequency of these disorders in celiac disease and their evolution under gluten-
free diet.
Aims & Methods: Descriptive retrospective study of 173 patients with celiac
disease followed in the departement of diseases of the digestive tract medecine
c of the Ibn Sina Hospital in Rabat, over a period of 18 years.
Results: In 173 patient with celiac disease, 58 patients had reproductive disorders.
there are 53 women and 5 men. The average age was 32.25 years; the diagnosis of
celiac disease is based on histology and serology. The reproductive problems were
never isolated but always associated with other digestive signs at the time of
diagnosis of celaic disease. These disorders are represented by: delayed puberty
in 11 cases, secondary amenorrhea in 13 cases, irregular menstrual in 12 cases,
absence of development of secondary sex characteristics in 8 cases, spontaneous
abortions in 7 cases, menometrorrhagia in 4 cases, primary sterility in 5 cases
early menopause in 6 cases, premature delivery in 3 cases primary amenorrhea in
2 cases and intrauterine fetal death in 1 case. All our patients have had a gluten-
free diet. 15 Patients lost to follow-up, 2 patients died, and 12 patients under-
gowing follow-up. The remaining 29 patients, the evolution of reproductive dis-
orders under gluten-free diet was favorable in 26 cases (90%), with the
normalization of cycles in 15 cases, resumption of cycles in 6 cases development
of secondary sex characteristics in 2 cases, fertility resumption in one case, initia-
tion of cycles after primary amenorrhea in one case and delivery of a newborn at
term after premature deliveries in one case. The evolution was unfavorable in 3
cases with the notion of miscarriage 4 years after the start of the gluten-free diet
in one patient and the absence of cycle resumption in 2 cases.
Conclusion: The reproductive disorders associated with celiac disease are frequent
and varied. In our study, these disorders responded very well under a gluten-free
diet conducted in 90% of the case. these disorders are thus reversible under this
diet.
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Introduction: High –fat diet induces depression and anxiety, alters gastrointest-
inal motility in rats but operative mechanisms are not clear. Vagal nerve conducts
physiological information about luminal content to the higher brain centres.
Aims & Methods: Is there any role of vagal afferent nerves on high fat diet
(HFD)-induced alterations in cognitive functions and gut motility? Ten-week
old male Sprague-Dawley rats (n¼ 38) were treated with either perivagal 1%
capsaicin (n¼ 19) or vehicle (10% Tween 80 in oil) (n¼ 19). After 3 weeks of
recovery, rats were pair-fed with chow (fat 2–7%) (n¼ 18) or HFD (% 45 fat)
(n¼ 20) for 5 weeks until decapitation. In between 4th and 5th weeks of HFD
rats were subjected to open field tests (anxiety and depression-like behaviour);
novel object recognition, passive avoidance tests (memory). Food and water
intake were measured after 16 hrs. of food and 24 hrs. of water deprivation.
Weight of faeces for 16 hrs. and transit time with charcoal were measured.
Data was expressed as mean standard deviation, comparison between groups
were done with two- way ANOVA.
Results: VAD increased body weight significantly (p5 0.05) during feeding
period irrespective of fat content of the diet. Fat content and VAD had no
effect on 1 hr food intake after food deprivation. HFD decreased water intake
(p5 0.0075), VAD blunted this effect (p5 0.05). Both HFD and VAD decreased
faeces weight significantly (p5 0.0001 and p5 0.05 respectively) but there was
not any change in intestinal transit. HFD impaired short -term memory
(p5 0.02), whereas VAD compromised spatial learning (p5 0.04). HFD rats
were more anxious in OFT (p5 0.01).
Conclusion: HFD-induced alterations in memory and anxiety were not affected
by VAD but VAD blunted effect of HFD on water intake and faeces weight,
suggesting that their operating mechanisms are different. VAD by itself impaired
spatial memory that requires further investigation.
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Introduction: Total gastrectomy can profoundly influence patients’ nutritional
status and controversy surrounds the various nutritional options available post-
operatively, namely total parenteral nutrition (TPN), or enteral nutrition (EN)
either via the nasojejunal (NJ) or feeding jejunostomy (JEJ) route. The aim of
this review was to determine the optimal nutritional route after total gastrectomy
for cancer.
Aims & Methods: PubMed, MEDLINE and the Cochrane Library (January 1985
to January 2017) were systematically searched for randomized controlled trials
comparing various nutritional routes after total gastrectomy. The primary out-
come measure was overall morbidity.
Results: Six studies involving 353 patients (median age 62 years, 217 males, 170
TPN, 96 NJ, 87 JEJ) who underwent total gastrectomy were analysed. Overall
morbidity was significantly greater in patients after TPN compared with EN
[odds ratio (OR) 1.95, 95% Confidence Interval (CI) 1.16–3.28, p¼ 0.01].
There was a trend towards greater mortality in patients who received TPN com-
pared with EN (OR 1.90, 95%CI 0.64–5.70, p¼ 0.25). When EN was sub ana-
lyzed according to NJ or JEJ, morbidity was significantly greater in patients who
received TPN compared with JEJ (OR 4.59, 95%CI 1.74–12.10, p¼ 0.002) but
not in patients who received NJ feeding (OR 1.23, 95%CI 0.64–2.36, p¼ 0.53).
Conclusion: Enteral nutrition in the form of feeding jejunostomy was associated
with lower morbidity compared with TPN following total gastrectomy for
cancer.
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Introduction: Patients on home parenteral nutrition (HPN) are exposed to a life-
long risk of catheter-related bloodstream infections (CRBSI), which threaten
catheter and patient survival. Both taurolidine 2% and saline 0.9% solution
are used as catheter lock solutions (CLS) to prevent CRBSI. The optimal
agent however, remains unclear. We hypothesized that taurolidine as CLS is
superior to saline in preventing CRBSI in HPN patients.
Aims & Methods: We hypothesized that taurolidine 2% as CLS is superior to
saline 0.9% in preventing CRBSI in HPN patients. This multicenter double
blinded trial randomly assigned HPN patients to use either the CLS taurolidine
2% or saline 0.9% for one year. Primary outcome was the number of CRBSI/
1000 catheter days. Secondary outcomes included time to CRBSI or catheter
removal due to CRBSI, number of catheter removals due to CRBSI, exit-site
infections, catheter occlusions, and (serious) adverse events.
Results: Of 105 randomized patients, 102 were enrolled as modified intention-to-
treat population. With taurolidine, 5 CRBSI occurred during 15318 catheter
days. In the saline arm 18 CRBSI occurred over 12493 catheter days. CRBSI/
1000 catheter days were 0.33 and 1.44 in the taurolidine and saline groups,
respectively (relative risk, 0.23; 95%CI, 0.07 to 0.63; P¼ 0.002). The cumulative
proportion of CRBSI-free patients after one year was 88% in the taurolidine
group and 49% in the saline group (P¼ 0.002). The number of catheter removals
due to CRBSI was two (4%) in the taurolidine group and eight (16%) in the
saline arm (P¼ 0.049). The cumulative proportion of patients without a catheter
removal due to CRBSI was higher in the taurolidine group (P¼ 0.025). Exit-site
infection and catheter occlusion rates were similar in both groups. Except for
occurrence of CRBSI (P¼ 0.002), there was no difference in (serious) adverse
events between groups. Drug-related adverse events were rare and generally mild
to moderate.
Conclusion: Taurolidine 2% decreased the risk for CRBSI by more than four
times in HPN patients compared to saline 0.9%. Given its favorable safety
profile and lack of evidence for altering microbial susceptibility, taurolidine lock-
ing therefore seems a key strategy to prevent CRBSI.
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Introduction: Patients with severe intestinal failure depend on life-long home
parenteral nutrition (HPN) support. Repeated central venous catheter (CVC)
loss due to complications, including mechanical damage, compromises vascular
access. It remains unclear whether repair of damaged CVCs is an effective strat-
egy to extend catheter life, avoid surgical replacement and maintain venous
access.
Aims & Methods: The objective of this study was to characterize patients who
underwent catheter repair and to evaluate effects on catheter survival and
describe complications. This study concerns a retrospective analysis of all cathe-
ter repairs that were performed in HPN patients in the Radboud University
Medical Center between January 2000 and May 2017. Primary endpoint was
the difference in catheter survival in the presence or absence of catheter repair.
To this end, a non-parametric survival analysis was performed. Secondary out-
comes included localization of catheter damage and frequency of repair-related
complications within 1 month after catheter repair.
Results: A total of 50 repairs in 38 CVCs of 32 HPN patients were included in the
analysis. 16 CVCs (32%) were damaged at the distal end, near the screw thread of
the catheter, 25 CVCs (50%) at the junction between the rigid and flexible part of
the catheter, and 9 CVCs (18%) at the flexible part of the catheter. The mean
time to catheter repair after placement was 2.2 years (95% CI¼ 1.55–2.89). The
mean catheter survival after repair was extended by 1.4 years to 3.6 years (95%
CI¼ 2.69–4.46; p¼ 0.01). No repair-related complications occurred within 1
month after catheter repair.
Conclusion: Repair of damaged CVCs significantly extends catheter life in HPN
patients and maintains venous access. Catheter repair is a safe procedure.
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Introduction: Catheter-related complications (CRCs) in home parenteral nutri-
tion (HPN) patients are a threat to both catheter and patient survival.
Taurolidine 2%, an antimicrobial catheter lock solution (CLS), is an effective
agent for the prevention of catheter-related bloodstream infections (CRBSI).
Aims & Methods: The aim of this retrospective study was to evaluate long-term
clinical outcomes of our HPN patient cohort that uses the CLS taurolidine.
Between 2008 and 2016, all adult HPN patients requiring a central venous cathe-
ter (CVC) or port-a-cath (PAC) who used taurolidine as CLS were included.
CRC incidence rates/1000 catheter days were described. Kaplan-Meier analysis
was used to determine the time until a first CRC. Cox proportional hazard
analysis was performed to identify risk factors for a first CRC.
Results: In 221 HPN patients, 658 CVCs (418 Hickmans, 172 PACs, and 28 non-
tunneled CVCs) were inserted, comprising 261252 catheter days. Median survival
for Hickmans, PACs and non-tunneled catheters was 175 (43–544), 310 (61–827)
and 14 (7–19) days, respectively. During eight years of follow-up, 176 CRBSI
occurred and 80 catheter-related occlusions (CRO). CRBSI and CRO rates/1000
catheter days were 0.74 and 0.34, respectively. In 47% and 32% of patients, at
least one CRBSI and CRO occurred, respectively. Median time to a first CRBSI
or CRO was 246 (54–817) and 215 catheter days (5–2070). Numerically, but not
significantly, CRBSI and CRO rates decreased over time. The sole use of intra-
venous fluids was associated with a significantly lower risk for CRBSI (RR 0.32).
Twenty patients reported adverse events (5 grade 1, 13 grade 2 and 2 grade 3)
which were possibly related to the use of taurolidine.
Conclusion: This study describes the largest cohort of HPN patients to date on
long-term taurolidine 2% as CLS. Overall, CRC incidence rates were low when
compared with the literature. We found no evidence for a decreased effect of
taurolidine over time.
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Introduction: Patients with short bowel syndrome (SBS) exhibit substantial dis-
turbances in gut microbiota composition, which implicates significant alterations
of intestinal metabolome.
Aims & Methods: The aim of this study was to perform genetic and metabolomic
analysis of stool samples collected from SBS patients totally dependent on par-
enteral nutrition (TPN). We analysed the stool samples from 8 healthy indivi-
duals and 8 patients with SBS dependent on TPN. Faecal microbiota
composition was assessed by sequencing of variable V3 and V4 regions of 16S
rRNA gene using Illumina MiSeq TM platform. Library preparation, template
preparation and template sequencing was performed according to manufacturer’s
protocols. Obtained data were filtered by quality and length and processed for
alpha and beta diversity analyses using QIIME software package. SCFA profile
was measured using solid phase microextraction (SPME) coupled to gas chro-
matography and high resolution mass spectrometry employing time of flight
mass analyser (Pegasus GC-HRT; LECO, USA). D-lactate content was deter-
mined using Megazyme kit.
Results: Weighted Unifrac analysis revealed significant differences between con-
trol and TPN subjects. In healthy controls, most abundant phylum was
Firmicutes (64.2 7.5%), followed by Bacteroidetes (22.5 9.1%) and
Actinobacteria (8.9 4.5%). Proteobacteria were found only in one control
sample. In TPN group, Firmicutes represented 66.4 29% of microbiota but
Bacteroidetes were absent and Actinobacteria significantly reduced (1.6%).
Proteobacteria were found in all samples (23.6 15%). The most abundant meta-
bolites in control stool samples were short - chain fatty acids (SCFA): acetate,
propionate and butyrate. In the TPN group, lactate predominated significantly,
while SCFA were absent in the intestinal content of these patients.
Conclusion: Long-term dependence on total parenteral nutrition results in dys-
biosis of the intestine residuum characterized by extinction of Bacteroidetes and
appearance of Proteobacteria. This shift was reflected by the changes in the
composition of prevailing metabolites in stool.
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Introduction: Techniques of percutaneous endoscopic gastrostomy (PEG) place-
ment can be divided into two techniques, the pull technique or the introducer
technique. Although the development of the pull technique greatly improved
procedural safety for the gastrostomy placement, the pull technique, in which
the PEG catheter is delivered through the oral cavity and the hypopharynx,
inevitably contaminates the peristomal site. A series of studies directly comparing
the newly developed modified introducer technique using a blunt cannula com-
pared with the conventional pull technique demonstrated that the modified intro-
ducer technique was more preferable regarding procedure related adverse
events.1.2) Meanwhile, use of an overtube while guiding the catheter into the
stomach in pull technique succeeded the reduction of the bacterial implantation.
It is still unclear if the modified introducer technique or the overtube assisted pull
technique would reduce risks of adverse events.
Aims & Methods: In this study, we retrospectively investigated risks of adverse
events associated with the modified introducer technique and the overtube
assisted pull method.Outcomes of patients who underwent the PEG placement
from Jan 2013 to Oct 2016 at Jikei University Hospital were analyzed. The
following data were collected from clinical records: age, gender, technique of
PEG, reasons for PEG, lab tests and prognostic nutritional index (PNI).
Results: During the study period, 236 PEG placements were done in 234 patients.
The average age was 69.3 12.5. The modified introducer technique was applied
in 167 procedures (70.8%) and the overtube assisted technique was applied in 69
procedures (29.2%). The PEG was placed aiming for nutrition supports for
cancer patients in 132 procedures, cerebrovascular accident in 51 procedures,
aspiration pneumonia in 32 procedures, and others such as infection and
disuse atrophy in 21 procedures. Age (the overtube assisted pull technique4 the
modified introducer group), Gender and preoperative serum C-reactive protein
level were significantly different between the two groups (p5 0.05). Overall,
adverse events were observed in 19 (8.1%) procedures, although there was no
procedure related mortality in the both groups. The risks of clinically significant
adverse events were not different between the two groups. There was no signifi-
cant difference in the types and the rate of adverse events between the two
groups. However, severe peristomal bleedings were observed only in the modified
introducer technique group. Four patients required suture placements and 3
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patients required blood transfusion for the peristomal bleeding. In a univariate
analysis, age, the rate of aspiration pneumonia as the reason for the PEG place-
ment were higher in patients encountering adverse events (p5 0.05) (table 1).
Also, serum platelet level, serum albumin and the rate of nutrition supports for
cancer as the reason of the PEG placement was lower in patients encountering
adverse events (p5 0.05). In a multivariate analysis, lower serum platelet level
was solely recognized as a relevant predictive factor for adverse events (p5 0.05).
The types of the technique used were not relevant to risks of adverse events.
Clinical backgrounds of patients with and without adverse events.
with adverse
events (n¼ 19)
without adverse
events (n¼ 217) p
Age (meanSD) 77.4 7.9 68.6 12.6 p5 0.05
Sex (male/female) 13/6 162/55 n.s.
Technique for PEG (intro-
ducer/pull)
13/6 154/63 n.s.
Reasons for PEG (cancer/
cerebrovascular acci-
dent/aspiration pneu-
monia/others)
5/5/6/3 127/46/26/18 p5 0.05
Lab tests (meanSD)
ChE (U/L) 184.9 60.8 214.9 78.9 n.s.
(continued)
Continued
Clinical backgrounds of patients with and without adverse events.
with adverse
events (n¼ 19)
without adverse
events (n¼ 217) p
TP (g/dL) 6.1 0.9 6.4 0.8 n.s.
Alb (g/dL) 2.9 0.6 3.1 0.6 p5 0.05
CRP (mg/dL) 1.5 2.0 2.0 3.3 n.s.
WBC (/mL) 7336.8 3162.1 6696.8 3086.6 n.s.
Hb (g/dL) 10.4 2.2 11.3 1.9 n.s.
Plt (/mL) 20.7 8.4 25.6 8.8 p5 0.05
TLC (/mL) 1400 797.9 1387.6 967.4 n.s.
PNI 35.7 8.5 38.4 8.5 n.s.
Conclusion: There was no significant difference in overall risks of adverse events
between the modified introducer technique group and the overtube assisted pull
technique group. However, the modified introducer technique may be associated
with higher risks of severer adverse events. Especially, special care should be
taken in patients with lower serum platelet level.
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